<SEC-DOCUMENT>0001493152-25-010984.txt : 20250320
<SEC-HEADER>0001493152-25-010984.hdr.sgml : 20250320
<ACCEPTANCE-DATETIME>20250320080036
ACCESSION NUMBER:		0001493152-25-010984
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		121
CONFORMED PERIOD OF REPORT:	20241231
FILED AS OF DATE:		20250320
DATE AS OF CHANGE:		20250320

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Neuraxis, INC
		CENTRAL INDEX KEY:			0001933567
		STANDARD INDUSTRIAL CLASSIFICATION:	ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS [3845]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				455079684
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-41775
		FILM NUMBER:		25754545

	BUSINESS ADDRESS:	
		STREET 1:		11611 N. MERIDIAN ST
		STREET 2:		SUITE 330
		CITY:			CARMEL
		STATE:			IN
		ZIP:			46032
		BUSINESS PHONE:		(812) 689-0791

	MAIL ADDRESS:	
		STREET 1:		11611 N. MERIDIAN ST
		STREET 2:		SUITE 330
		CITY:			CARMEL
		STATE:			IN
		ZIP:			46032
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>form10-k.htm
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:us-types="http://fasb.org/us-types/2024" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:ecd="http://xbrl.sec.gov/ecd/2024" xmlns:country="http://xbrl.sec.gov/country/2024" xmlns:srt="http://fasb.org/srt/2024" xmlns:cyd="http://xbrl.sec.gov/cyd/2024" xmlns:stpr="http://xbrl.sec.gov/stpr/2024" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:NRXS="http://neuraxis.com/20241231">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html"/>
</head>
<!-- Field: Set; Name: xdx; ID: xdx_029_US%2DGAAP%2D2024%2D(with%2DECD%2Dand%2DCYD) -->
<!-- Field: Set; Name: xdx; ID: xdx_03A_NRXS_neuraxis.com_20241231 -->
<!-- Field: Set; Name: xdx; ID: xdx_04C_20240101_20241231 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_05A_edei%2D%2DDocumentFiscalPeriodFocus_FY -->
<!-- Field: Set; Name: xdx; ID: xdx_05B_edei%2D%2DEntityCentralIndexKey_0001933567 -->
<!-- Field: Set; Name: xdx; ID: xdx_076_XDX_form10%2Dk.xdx -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_069_Pure_4_xbrli%2D%2Dpure -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000003" name="dei:AmendmentFlag">false</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000004" name="dei:DocumentFiscalPeriodFocus">FY</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000005" name="dei:EntityCentralIndexKey">0001933567</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="xdx2ixbrl0058" name="dei:AuditorFirmId">89</ix:nonNumeric>
  <ix:nonFraction name="us-gaap:SecurityDeposit" contextRef="AsOf2023-12-31" id="xdx2ixbrl0111" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:CommitmentsAndContingencies" contextRef="AsOf2024-12-31" id="xdx2ixbrl0155" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:CommitmentsAndContingencies" contextRef="AsOf2023-12-31" id="xdx2ixbrl0156" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="AsOf2023-12-31" id="xdx2ixbrl0162" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DerivativeGainLossOnDerivativeNet" contextRef="From2024-01-01to2024-12-31" id="xdx2ixbrl0244" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:GainsLossesOnExtinguishmentOfDebt" contextRef="From2024-01-01to2024-12-31" id="xdx2ixbrl0250" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:PreferredStockDividendsAndOtherAdjustments" contextRef="From2023-01-012023-12-31" id="xdx2ixbrl0266" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_PreferredStockMember_custom_ConvertibleSeriesBPreferredStockMember" id="xdx2ixbrl0295" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2022-12-31_us-gaap_PreferredStockMember_custom_ConvertibleSeriesBPreferredStockMember" id="xdx2ixbrl0305" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="NRXS:StockIssuedDuringPeriodValueCommonStockIssuedUponInitialPublicOffering" contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember_custom_ConvertibleSeriesAPreferredStockMember" id="xdx2ixbrl0309" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="NRXS:StockIssuedDuringPeriodValueCommonStockIssuedUponInitialPublicOffering" contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember_custom_ConvertibleSeriesSeedPreferredStockMember" id="xdx2ixbrl0310" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="NRXS:StockIssuedDuringPeriodValueCommonStockIssuedUponInitialPublicOffering" contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember_custom_ConvertibleSeriesBPreferredStockMember" id="xdx2ixbrl0311" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="NRXS:StockIssuedDuringPeriodValueCommonStockIssuedUponInitialPublicOffering" contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0314" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember_custom_ConvertibleSeriesBPreferredStockMember" id="xdx2ixbrl0321" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0324" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="From2023-01-012023-12-31" id="xdx2ixbrl0325" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfUnits" contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember_custom_ConvertibleSeriesAPreferredStockMember" id="xdx2ixbrl0333" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfUnits" contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember_custom_ConvertibleSeriesSeedPreferredStockMember" id="xdx2ixbrl0334" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfUnits" contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember_custom_ConvertibleSeriesBPreferredStockMember" id="xdx2ixbrl0335" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfUnits" contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0338" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember_custom_ConvertibleSeriesAPreferredStockMember" id="xdx2ixbrl0343" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember_custom_ConvertibleSeriesSeedPreferredStockMember" id="xdx2ixbrl0344" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember_custom_ConvertibleSeriesBPreferredStockMember" id="xdx2ixbrl0345" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0348" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember_custom_ConvertibleSeriesAPreferredStockMember" id="xdx2ixbrl0353" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember_custom_ConvertibleSeriesSeedPreferredStockMember" id="xdx2ixbrl0354" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember_custom_ConvertibleSeriesBPreferredStockMember" id="xdx2ixbrl0355" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0356" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0358" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="NRXS:StockIssuedDuringPeriodValueWarrantsExercised" contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember_custom_ConvertibleSeriesAPreferredStockMember" id="xdx2ixbrl0361" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="NRXS:StockIssuedDuringPeriodValueWarrantsExercised" contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember_custom_ConvertibleSeriesSeedPreferredStockMember" id="xdx2ixbrl0362" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="NRXS:StockIssuedDuringPeriodValueWarrantsExercised" contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember_custom_ConvertibleSeriesBPreferredStockMember" id="xdx2ixbrl0363" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="NRXS:StockIssuedDuringPeriodValueWarrantsExercised" contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0366" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember_custom_ConvertibleSeriesAPreferredStockMember" id="xdx2ixbrl0371" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember_custom_ConvertibleSeriesSeedPreferredStockMember" id="xdx2ixbrl0372" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember_custom_ConvertibleSeriesBPreferredStockMember" id="xdx2ixbrl0373" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0374" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0375" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_us-gaap_PreferredStockMember_custom_ConvertibleSeriesAPreferredStockMember" id="xdx2ixbrl0379" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_us-gaap_PreferredStockMember_custom_ConvertibleSeriesSeedPreferredStockMember" id="xdx2ixbrl0380" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_us-gaap_PreferredStockMember_custom_ConvertibleSeriesBPreferredStockMember" id="xdx2ixbrl0381" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2023-12-31_us-gaap_PreferredStockMember_custom_ConvertibleSeriesAPreferredStockMember" id="xdx2ixbrl0387" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2023-12-31_us-gaap_PreferredStockMember_custom_ConvertibleSeriesSeedPreferredStockMember" id="xdx2ixbrl0389" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2023-12-31_us-gaap_PreferredStockMember_custom_ConvertibleSeriesBPreferredStockMember" id="xdx2ixbrl0391" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_us-gaap_PreferredStockMember_custom_ConvertibleSeriesAPreferredStockMember" id="xdx2ixbrl0395" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_us-gaap_PreferredStockMember_custom_ConvertibleSeriesSeedPreferredStockMember" id="xdx2ixbrl0396" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_us-gaap_PreferredStockMember_custom_ConvertibleSeriesBPreferredStockMember" id="xdx2ixbrl0397" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2023-12-31_us-gaap_PreferredStockMember_custom_ConvertibleSeriesAPreferredStockMember" id="xdx2ixbrl0403" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2023-12-31_us-gaap_PreferredStockMember_custom_ConvertibleSeriesSeedPreferredStockMember" id="xdx2ixbrl0405" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2023-12-31_us-gaap_PreferredStockMember_custom_ConvertibleSeriesBPreferredStockMember" id="xdx2ixbrl0407" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="NRXS:StockIssuedDuringPeriodValueWarrantsExercised" contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember_custom_ConvertibleSeriesAPreferredStockMember" id="xdx2ixbrl0411" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="NRXS:StockIssuedDuringPeriodValueWarrantsExercised" contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember_custom_ConvertibleSeriesSeedPreferredStockMember" id="xdx2ixbrl0412" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="NRXS:StockIssuedDuringPeriodValueWarrantsExercised" contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember_custom_ConvertibleSeriesBPreferredStockMember" id="xdx2ixbrl0413" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="NRXS:StockIssuedDuringPeriodValueWarrantsExercised" contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0416" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember_custom_ConvertibleSeriesAPreferredStockMember" id="xdx2ixbrl0421" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember_custom_ConvertibleSeriesSeedPreferredStockMember" id="xdx2ixbrl0422" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember_custom_ConvertibleSeriesBPreferredStockMember" id="xdx2ixbrl0423" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0424" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0426" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="NRXS:AdditionalPaidInCapitalFromWarrantsIssuedAsDebtDiscount" contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember_custom_ConvertibleSeriesAPreferredStockMember" id="xdx2ixbrl0429" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="NRXS:AdditionalPaidInCapitalFromWarrantsIssuedAsDebtDiscount" contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember_custom_ConvertibleSeriesSeedPreferredStockMember" id="xdx2ixbrl0430" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="NRXS:AdditionalPaidInCapitalFromWarrantsIssuedAsDebtDiscount" contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember_custom_ConvertibleSeriesBPreferredStockMember" id="xdx2ixbrl0431" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="NRXS:AdditionalPaidInCapitalFromWarrantsIssuedAsDebtDiscount" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0432" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="NRXS:AdditionalPaidInCapitalFromWarrantsIssuedAsDebtDiscount" contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0434" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember_custom_ConvertibleSeriesAPreferredStockMember" id="xdx2ixbrl0437" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember_custom_ConvertibleSeriesSeedPreferredStockMember" id="xdx2ixbrl0438" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember_custom_ConvertibleSeriesBPreferredStockMember" id="xdx2ixbrl0439" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0442" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature" contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember_custom_ConvertibleSeriesAPreferredStockMember" id="xdx2ixbrl0447" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature" contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember_custom_ConvertibleSeriesSeedPreferredStockMember" id="xdx2ixbrl0448" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature" contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember_custom_ConvertibleSeriesBPreferredStockMember" id="xdx2ixbrl0449" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0450" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature" contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0452" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember_custom_ConvertibleSeriesAPreferredStockMember" id="xdx2ixbrl0455" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember_custom_ConvertibleSeriesSeedPreferredStockMember" id="xdx2ixbrl0456" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0458" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0460" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="NRXS:StockIssuedDuringPeriodValuePreferredStock" contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember_custom_ConvertibleSeriesAPreferredStockMember" id="xdx2ixbrl0465" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="NRXS:StockIssuedDuringPeriodValuePreferredStock" contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember_custom_ConvertibleSeriesSeedPreferredStockMember" id="xdx2ixbrl0466" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="NRXS:StockIssuedDuringPeriodValuePreferredStock" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0468" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember_custom_ConvertibleSeriesAPreferredStockMember" id="xdx2ixbrl0475" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember_custom_ConvertibleSeriesSeedPreferredStockMember" id="xdx2ixbrl0476" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember_custom_ConvertibleSeriesBPreferredStockMember" id="xdx2ixbrl0477" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0478" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0479" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-12-31_us-gaap_PreferredStockMember_custom_ConvertibleSeriesAPreferredStockMember" id="xdx2ixbrl0483" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-12-31_us-gaap_PreferredStockMember_custom_ConvertibleSeriesSeedPreferredStockMember" id="xdx2ixbrl0484" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2024-12-31_us-gaap_PreferredStockMember_custom_ConvertibleSeriesAPreferredStockMember" id="xdx2ixbrl0491" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2024-12-31_us-gaap_PreferredStockMember_custom_ConvertibleSeriesSeedPreferredStockMember" id="xdx2ixbrl0493" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-12-31_us-gaap_PreferredStockMember_custom_ConvertibleSeriesAPreferredStockMember" id="xdx2ixbrl0499" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-12-31_us-gaap_PreferredStockMember_custom_ConvertibleSeriesSeedPreferredStockMember" id="xdx2ixbrl0500" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2024-12-31_us-gaap_PreferredStockMember_custom_ConvertibleSeriesAPreferredStockMember" id="xdx2ixbrl0507" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2024-12-31_us-gaap_PreferredStockMember_custom_ConvertibleSeriesSeedPreferredStockMember" id="xdx2ixbrl0509" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:InventoryWriteDown" contextRef="From2023-01-012023-12-31" id="xdx2ixbrl0534" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:PaidInKindInterest" contextRef="From2024-01-01to2024-12-31" id="xdx2ixbrl0539" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2023-01-012023-12-31" id="xdx2ixbrl0543" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:GainsLossesOnExtinguishmentOfDebt" contextRef="From2024-01-01to2024-12-31" id="xdx2ixbrl0545" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="NRXS:IssuanceOfWarrantsForNoncashConsideration" contextRef="From2023-01-012023-12-31" id="xdx2ixbrl0552" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DerivativeGainLossOnDerivativeNet" contextRef="From2024-01-01to2024-12-31" id="xdx2ixbrl0557" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:PaymentsToAcquireIntangibleAssets" contextRef="From2024-01-01to2024-12-31" id="xdx2ixbrl0596" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="From2024-01-01to2024-12-31" id="xdx2ixbrl0605" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" contextRef="From2023-01-012023-12-31" id="xdx2ixbrl0609" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="NRXS:DeferredOfferingCostsPaid" contextRef="From2024-01-01to2024-12-31" id="xdx2ixbrl0611" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="NRXS:DeferredOfferingCostsPaid" contextRef="From2023-01-012023-12-31" id="xdx2ixbrl0612" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProceedsFromNotesPayable" contextRef="From2024-01-01to2024-12-31" id="xdx2ixbrl0620" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:IncomeTaxesPaidNet" contextRef="From2023-01-012023-12-31" id="xdx2ixbrl0648" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="NRXS:RecognitionOfRightOfUseAsset" contextRef="From2023-01-012023-12-31" id="xdx2ixbrl0654" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="NRXS:ConversionOfConvertiblePromissoryNotesToSeriesBPreferredStock" contextRef="From2023-01-012023-12-31" id="xdx2ixbrl0657" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="NRXS:FairValueOfWarrantsFromDebtDiscountInConvertibleNotesClassifiedOfAdditionalPaidInCapital" contextRef="From2023-01-012023-12-31" id="xdx2ixbrl0660" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="NRXS:WriteoffOfDebtDiscountOnConvertibleNotesClassifiedAsAdditionalPaidInCapital" contextRef="From2023-01-012023-12-31" id="xdx2ixbrl0663" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NotesIssued1" contextRef="From2023-01-012023-12-31" id="xdx2ixbrl0666" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="NRXS:FairValueOfWarrantLiabilitiesOfWarrantsFromConvertibleNotes" contextRef="From2024-01-01to2024-12-31" id="xdx2ixbrl0668" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="NRXS:FairValueOfDerivativeLiabilitiesOfConversionFeatureFromConvertibleNotes" contextRef="From2024-01-01to2024-12-31" id="xdx2ixbrl0671" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="NRXS:ReclassificationOfWarrantLiabilityToEquity" contextRef="From2024-01-01to2024-12-31" id="xdx2ixbrl0674" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="NRXS:ConversionOfPreferredStockToCommonStock" contextRef="From2024-01-01to2024-12-31" id="xdx2ixbrl0677" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="AsOf2024-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel1Member" id="xdx2ixbrl0827" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="AsOf2024-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel2Member" id="xdx2ixbrl0828" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="AsOf2023-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel1Member" id="xdx2ixbrl0832" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="AsOf2023-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel2Member" id="xdx2ixbrl0833" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DividendsPreferredStock" contextRef="From2023-01-012023-12-31" id="xdx2ixbrl0840" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember47706312" id="xdx2ixbrl0848" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2023-01-012023-12-31_us-gaap_SeriesBPreferredStockMember" id="xdx2ixbrl0854" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DividendsPreferredStock" contextRef="From2023-01-012023-12-31" id="xdx2ixbrl0865" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AccountsReceivableNet" contextRef="AsOf2023-12-31_custom_CustomerAMember_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember" id="xdx2ixbrl0940" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AccountsReceivableNet" contextRef="AsOf2024-12-31_custom_CustomerBMember_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember" id="xdx2ixbrl0944" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AccountsReceivableNet" contextRef="AsOf2024-12-31_custom_CustomerDMember_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember" id="xdx2ixbrl0960" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AccountsReceivableNet" contextRef="AsOf2024-12-31_custom_CustomerEMember_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember" id="xdx2ixbrl0968" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NotesAndLoansReceivableNetCurrent" contextRef="AsOf2024-12-31_us-gaap_RelatedPartyMember" id="xdx2ixbrl1070" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:InterestReceivable" contextRef="AsOf2024-12-31_us-gaap_RelatedPartyMember" id="xdx2ixbrl1072" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="NRXS:InterestIncomeCurrent" contextRef="AsOf2024-12-31_us-gaap_RelatedPartyMember" id="xdx2ixbrl1074" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NotesAndLoansReceivableNetCurrent" contextRef="AsOf2023-12-31_us-gaap_RelatedPartyMember" id="xdx2ixbrl1100" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:InterestReceivable" contextRef="AsOf2023-12-31_us-gaap_RelatedPartyMember" id="xdx2ixbrl1102" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="NRXS:InterestIncomeCurrent" contextRef="AsOf2023-12-31_us-gaap_RelatedPartyMember" id="xdx2ixbrl1104" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:LoansPayable" contextRef="AsOf2024-12-31_custom_OtherConvertiblesMember" id="xdx2ixbrl1112" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:InterestPaid" contextRef="From2024-01-012024-12-31_custom_OtherConvertiblesMember" id="xdx2ixbrl1116" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:LoansPayable" contextRef="AsOf2024-12-31" id="xdx2ixbrl1118" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:InterestPaid" contextRef="From2024-01-01to2024-12-31" id="xdx2ixbrl1122" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:LoansPayable" contextRef="AsOf2023-12-31_custom_ShareHolderOneMember47707859" id="xdx2ixbrl1128" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="NRXS:InterestAndServiceFeeAccrued" contextRef="AsOf2023-12-31_custom_ShareHolderOneMember47707859" id="xdx2ixbrl1130" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:LoansPayable" contextRef="AsOf2023-12-31_custom_ShareHolderTwoMember47707859" id="xdx2ixbrl1138" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="NRXS:InterestAndServiceFeeAccrued" contextRef="AsOf2023-12-31_custom_ShareHolderTwoMember47707859" id="xdx2ixbrl1140" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:LoansPayable" contextRef="AsOf2023-12-31_custom_OtherConvertiblesMember" id="xdx2ixbrl1148" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:InterestPaid" contextRef="From2023-01-012023-12-31_custom_OtherConvertiblesMember" id="xdx2ixbrl1152" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:LoansPayable" contextRef="AsOf2023-12-31" id="xdx2ixbrl1154" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="NRXS:AdvisoryFees" contextRef="AsOf2023-12-31" id="xdx2ixbrl1268" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonNumeric contextRef="AsOf2023-12-31_custom_TwoThousandTwentyTwoConvertibleNotesMember" id="xdx2ixbrl1548" name="us-gaap:WarrantsAndRightsOutstandingTerm">P5Y</ix:nonNumeric>
  <ix:nonNumeric contextRef="AsOf2023-12-31_custom_AdvisoryAgreementMember" id="xdx2ixbrl1553" name="us-gaap:WarrantsAndRightsOutstandingTerm">P5Y</ix:nonNumeric>
  <ix:nonNumeric contextRef="AsOf2023-12-31_custom_UnderwritingAgreementMember" id="xdx2ixbrl1558" name="us-gaap:WarrantsAndRightsOutstandingTerm">P5Y</ix:nonNumeric>
  <ix:nonNumeric contextRef="AsOf2024-12-31_custom_TwoThousandTwentyFourConvertiblePromissoryNotesMember47712359" id="xdx2ixbrl1565" name="us-gaap:WarrantsAndRightsOutstandingTerm">P5Y</ix:nonNumeric>
  <ix:nonNumeric contextRef="AsOf2024-12-31_custom_AdvisoryAgreementsMember" id="xdx2ixbrl1570" name="us-gaap:WarrantsAndRightsOutstandingTerm">P5Y</ix:nonNumeric>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl1607" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember" id="xdx2ixbrl1645" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember" id="xdx2ixbrl1647" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations" contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember" id="xdx2ixbrl1649" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="NRXS:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsWeightedAverageExercisePriceCancelledExpiredNumber" contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember" id="xdx2ixbrl1651" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" contextRef="AsOf2023-12-31_us-gaap_PreferredStockMember" id="xdx2ixbrl1657" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2023-12-31_us-gaap_PreferredStockMember" id="xdx2ixbrl1659" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="AsOf2023-12-31" id="xdx2ixbrl1788" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="AsOf2024-12-31" id="xdx2ixbrl1796" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" contextRef="AsOf2024-12-31" id="xdx2ixbrl1804" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2023-01-012023-12-31" id="xdx2ixbrl1808" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:WarrantsAndRightsOutstanding" contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel1Member" id="xdx2ixbrl1830" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:WarrantsAndRightsOutstanding" contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel2Member" id="xdx2ixbrl1832" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="NRXS:AdditionToWarrantLiabilities" contextRef="From2023-01-012023-12-31_us-gaap_FairValueInputsLevel1Member" id="xdx2ixbrl1836" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="NRXS:AdditionToWarrantLiabilities" contextRef="From2023-01-012023-12-31_us-gaap_FairValueInputsLevel2Member" id="xdx2ixbrl1838" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="NRXS:ReclassifiedToEquity" contextRef="From2023-01-012023-12-31_us-gaap_FairValueInputsLevel1Member" id="xdx2ixbrl1842" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="NRXS:ReclassifiedToEquity" contextRef="From2023-01-012023-12-31_us-gaap_FairValueInputsLevel2Member" id="xdx2ixbrl1844" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="From2023-01-012023-12-31_us-gaap_FairValueInputsLevel1Member" id="xdx2ixbrl1848" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="From2023-01-012023-12-31_us-gaap_FairValueInputsLevel2Member" id="xdx2ixbrl1850" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:WarrantsAndRightsOutstanding" contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel1Member" id="xdx2ixbrl1854" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:WarrantsAndRightsOutstanding" contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel2Member" id="xdx2ixbrl1856" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="From2024-01-012024-12-31_us-gaap_FairValueInputsLevel1Member" id="xdx2ixbrl1860" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="From2024-01-012024-12-31_us-gaap_FairValueInputsLevel2Member" id="xdx2ixbrl1862" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:WarrantsAndRightsOutstanding" contextRef="AsOf2024-12-31_us-gaap_FairValueInputsLevel1Member" id="xdx2ixbrl1866" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:WarrantsAndRightsOutstanding" contextRef="AsOf2024-12-31_us-gaap_FairValueInputsLevel2Member" id="xdx2ixbrl1868" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="NRXS:ChangesInDerivativeLiabilities" contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel1Member" id="xdx2ixbrl1886" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="NRXS:ChangesInDerivativeLiabilities" contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel2Member" id="xdx2ixbrl1888" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="NRXS:AdditionToDerivativeLiabilities" contextRef="From2023-01-012023-12-31_us-gaap_FairValueInputsLevel1Member" id="xdx2ixbrl1892" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="NRXS:AdditionToDerivativeLiabilities" contextRef="From2023-01-012023-12-31_us-gaap_FairValueInputsLevel2Member" id="xdx2ixbrl1894" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:IncreaseDecreaseInDerivativeLiabilities" contextRef="From2023-01-012023-12-31_us-gaap_FairValueInputsLevel1Member" id="xdx2ixbrl1898" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:IncreaseDecreaseInDerivativeLiabilities" contextRef="From2023-01-012023-12-31_us-gaap_FairValueInputsLevel2Member" id="xdx2ixbrl1900" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="NRXS:ExtinguishmentOfDerivativeLiabilities" contextRef="From2023-01-012023-12-31_us-gaap_FairValueInputsLevel1Member" id="xdx2ixbrl1904" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="NRXS:ExtinguishmentOfDerivativeLiabilities" contextRef="From2023-01-012023-12-31_us-gaap_FairValueInputsLevel2Member" id="xdx2ixbrl1906" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="NRXS:ChangesInDerivativeLiabilities" contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel1Member" id="xdx2ixbrl1910" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="NRXS:ChangesInDerivativeLiabilities" contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel2Member" id="xdx2ixbrl1912" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="NRXS:ChangesInDerivativeLiabilities" contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel3Member" id="xdx2ixbrl1914" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DerivativeGainLossOnDerivativeNet" contextRef="From2024-01-012024-12-31_us-gaap_OperatingSegmentsMember" id="xdx2ixbrl1967" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:GainsLossesOnExtinguishmentOfDebt" contextRef="From2024-01-012024-12-31_us-gaap_OperatingSegmentsMember" id="xdx2ixbrl1973" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2023-01-012023-12-31" id="xdx2ixbrl2008" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:CurrentIncomeTaxExpenseBenefit" contextRef="From2024-01-01to2024-12-31" id="xdx2ixbrl2080" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:CurrentIncomeTaxExpenseBenefit" contextRef="From2023-01-012023-12-31" id="xdx2ixbrl2081" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="From2024-01-01to2024-12-31" id="xdx2ixbrl2095" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="From2023-01-012023-12-31" id="xdx2ixbrl2096" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" contextRef="From2024-01-01to2024-12-31" id="xdx2ixbrl2109" unitRef="Pure" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" contextRef="From2023-01-012023-12-31" id="xdx2ixbrl2110" unitRef="Pure" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DeferredTaxLiabilities" contextRef="AsOf2024-12-31" id="xdx2ixbrl2159" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DeferredTaxLiabilities" contextRef="AsOf2023-12-31" id="xdx2ixbrl2160" unitRef="USD" xs:nil="true"></ix:nonFraction>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="nrxs-20241231.xsd" xlink:type="simple"/>
  </ix:references>
 <ix:resources>
    <xbrli:context id="From2024-01-01to2024-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-03-13">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-03-13</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_ConvertibleSeriesBPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">NRXS:ConvertibleSeriesBPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_ConvertibleSeriesBPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">NRXS:ConvertibleSeriesBPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_PreferredStockMember_custom_ConvertibleSeriesAPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">NRXS:ConvertibleSeriesAPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_PreferredStockMember_custom_ConvertibleSeriesSeedPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">NRXS:ConvertibleSeriesSeedPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_PreferredStockMember_custom_ConvertibleSeriesBPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">NRXS:ConvertibleSeriesBPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_PreferredStockMember_custom_ConvertibleSeriesAPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">NRXS:ConvertibleSeriesAPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_PreferredStockMember_custom_ConvertibleSeriesSeedPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">NRXS:ConvertibleSeriesSeedPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_PreferredStockMember_custom_ConvertibleSeriesBPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">NRXS:ConvertibleSeriesBPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_PreferredStockMember_custom_ConvertibleSeriesAPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">NRXS:ConvertibleSeriesAPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_PreferredStockMember_custom_ConvertibleSeriesSeedPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">NRXS:ConvertibleSeriesSeedPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_PreferredStockMember_custom_ConvertibleSeriesBPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">NRXS:ConvertibleSeriesBPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_PreferredStockMember_custom_ConvertibleSeriesAPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">NRXS:ConvertibleSeriesAPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_PreferredStockMember_custom_ConvertibleSeriesSeedPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">NRXS:ConvertibleSeriesSeedPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_PreferredStockMember_custom_ConvertibleSeriesBPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">NRXS:ConvertibleSeriesBPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_PreferredStockMember_custom_ConvertibleSeriesAPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">NRXS:ConvertibleSeriesAPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_PreferredStockMember_custom_ConvertibleSeriesSeedPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">NRXS:ConvertibleSeriesSeedPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_PreferredStockMember_custom_ConvertibleSeriesBPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">NRXS:ConvertibleSeriesBPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-102023-01-10">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-10</xbrli:startDate>
        <xbrli:endDate>2023-01-10</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_ConvertibleSeriesAPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">NRXS:ConvertibleSeriesAPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_ConvertibleSeriesSeedPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">NRXS:ConvertibleSeriesSeedPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-08-092023-08-09_us-gaap_CommonStockMember_custom_AlexanderCapitalLPMember_us-gaap_IPOMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">NRXS:AlexanderCapitalLPMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-08-09</xbrli:startDate>
        <xbrli:endDate>2023-08-09</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-08-09_us-gaap_CommonStockMember_custom_AlexanderCapitalLPMember_us-gaap_IPOMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">NRXS:AlexanderCapitalLPMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-08-09</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-08-092023-08-09_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-08-09</xbrli:startDate>
        <xbrli:endDate>2023-08-09</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-08-15_us-gaap_SeriesBPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-08-15</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-08-152024-08-15_us-gaap_SeriesBPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-08-15</xbrli:startDate>
        <xbrli:endDate>2024-08-15</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-08-152024-08-15_custom_ConvertibleSeriesAPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">NRXS:ConvertibleSeriesAPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-08-15</xbrli:startDate>
        <xbrli:endDate>2024-08-15</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-08-152024-08-15_custom_ConvertibleSeriesSeedPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">NRXS:ConvertibleSeriesSeedPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-08-15</xbrli:startDate>
        <xbrli:endDate>2024-08-15</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-11-11_custom_ConvertibleSeriesBPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">NRXS:ConvertibleSeriesBPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-11-11</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-11-112024-11-11_custom_ConvertibleSeriesBPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">NRXS:ConvertibleSeriesBPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-11-11</xbrli:startDate>
        <xbrli:endDate>2024-11-11</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_TrademarksMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_LicensingAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">NRXS:LicensingAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_GeneralAndAdministrativeExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_GeneralAndAdministrativeExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_MachineryAndEquipmentMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_MachineryAndEquipmentMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_FurnitureAndFixturesMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_FurnitureAndFixturesMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_ComputerEquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_LeaseholdImprovementsMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_LeaseholdImprovementsMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel2Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel2Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_OptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:OptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_OptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:OptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_CommonStockMember47706312">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_CommonStockMember47706312">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_WarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">NRXS:WarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_WarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">NRXS:WarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_SeriesBPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_SeriesBPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_stpr_CA">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_stpr_CA">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_stpr_OH">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:OH</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_stpr_OH">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:OH</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_stpr_IL">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:IL</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_stpr_IL">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:IL</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_stpr_WI">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:WI</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_stpr_WI">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:WI</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_stpr_MA">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:MA</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_stpr_MA">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:MA</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_stpr_FL">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:FL</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_stpr_FL">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:FL</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_AllOtherStatesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">NRXS:AllOtherStatesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_AllOtherStatesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">NRXS:AllOtherStatesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_CustomerAMember_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">NRXS:CustomerAMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_CustomerAMember_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">NRXS:CustomerAMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_CustomerAMember_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">NRXS:CustomerAMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_CustomerAMember_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">NRXS:CustomerAMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_CustomerBMember_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">NRXS:CustomerBMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_CustomerBMember_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">NRXS:CustomerBMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_CustomerBMember_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">NRXS:CustomerBMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_CustomerBMember_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">NRXS:CustomerBMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_CustomerCMember_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">NRXS:CustomerCMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_CustomerCMember_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">NRXS:CustomerCMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_CustomerCMember_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">NRXS:CustomerCMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_CustomerCMember_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">NRXS:CustomerCMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_CustomerDMember_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">NRXS:CustomerDMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_CustomerDMember_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">NRXS:CustomerDMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_CustomerDMember_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">NRXS:CustomerDMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_CustomerDMember_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">NRXS:CustomerDMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_CustomerEMember_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">NRXS:CustomerEMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_CustomerEMember_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">NRXS:CustomerEMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_CustomerEMember_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">NRXS:CustomerEMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_CustomerEMember_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">NRXS:CustomerEMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_CustomerMember_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">NRXS:CustomerMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_CustomerMember_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">NRXS:CustomerMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_CustomerMember_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">NRXS:CustomerMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_CustomerMember_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">NRXS:CustomerMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_CustomerAMember_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">NRXS:CustomerAMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_CustomerAMember_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">NRXS:CustomerAMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_CustomerBMember_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">NRXS:CustomerBMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_CustomerBMember_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">NRXS:CustomerBMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_CustomerCMember_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">NRXS:CustomerCMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_CustomerCMember_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">NRXS:CustomerCMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_CustomerMember_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">NRXS:CustomerMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_CustomerMember_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">NRXS:CustomerMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_ShareholdersOneAndTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">NRXS:ShareholdersOneAndTwoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_RelatedPartyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_MrWatkinsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">NRXS:MrWatkinsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_MrWatkinsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">NRXS:MrWatkinsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_MrSealeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">NRXS:MrSealeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_MrSealeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">NRXS:MrSealeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_MrSealeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">NRXS:MrSealeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_MrSealeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">NRXS:MrSealeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_srt_ChiefFinancialOfficerMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefFinancialOfficerMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_ShareHolderOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">NRXS:ShareHolderOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_ShareHolderTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">NRXS:ShareHolderTwoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_RelatedPartyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_ShareHolderOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">NRXS:ShareHolderOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_ShareHolderTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">NRXS:ShareHolderTwoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_RelatedPartyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_OtherConvertiblesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">NRXS:OtherConvertiblesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_OtherConvertiblesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">NRXS:OtherConvertiblesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_ShareHolderOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">NRXS:ShareHolderOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_ShareHolderOneMember47707859">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">NRXS:ShareHolderOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_ShareHolderTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">NRXS:ShareHolderTwoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_ShareHolderTwoMember47707859">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">NRXS:ShareHolderTwoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_OtherConvertiblesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">NRXS:OtherConvertiblesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_OtherConvertiblesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">NRXS:OtherConvertiblesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_MachineryAndEquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_MachineryAndEquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_FurnitureAndFixturesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_FurnitureAndFixturesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_ComputerEquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_LeaseholdImprovementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_LeaseholdImprovementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_DecemberTwoThousandTwentyFiveMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">NRXS:DecemberTwoThousandTwentyFiveMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_DecemberTwoThousandTwentySixMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">NRXS:DecemberTwoThousandTwentySixMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_DecemberTwoThousandTwentySevenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">NRXS:DecemberTwoThousandTwentySevenMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_DecemberTwoThousandTwentyEightMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">NRXS:DecemberTwoThousandTwentyEightMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_DecemberTwoThousandTwentyNineMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">NRXS:DecemberTwoThousandTwentyNineMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_DecemberTwoThousandTwentyThereafterMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">NRXS:DecemberTwoThousandTwentyThereafterMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_SoftwareImplementationMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">NRXS:SoftwareImplementationMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_SoftwareImplementationMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">NRXS:SoftwareImplementationMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_PatentsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_PatentsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_TrademarksMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_TrademarksMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_LicensesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">NRXS:LicensesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_LicensesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">NRXS:LicensesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-16_custom_ChannelPartnersCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">NRXS:ChannelPartnersCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-16</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-03-162023-03-16_custom_ChannelPartnersCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">NRXS:ChannelPartnersCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-03-16</xbrli:startDate>
        <xbrli:endDate>2023-03-16</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-01-01_custom_ChannelPartnersCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">NRXS:ChannelPartnersCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-01-01</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-09-16_custom_ChannelPartnersCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">NRXS:ChannelPartnersCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-09-16</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-05-24_custom_ChannelPartnersCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">NRXS:ChannelPartnersCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-05-24</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_ChannelPartnersCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">NRXS:ChannelPartnersCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_ChannelPartnersCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">NRXS:ChannelPartnersCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-02-15_custom_ExchangeListingLLCMember_custom_PromissoryNoteMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">NRXS:ExchangeListingLLCMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">NRXS:PromissoryNoteMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-02-15</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-08-312023-08-31_custom_ExchangeListingLLCMember_custom_PromissoryNoteMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">NRXS:ExchangeListingLLCMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">NRXS:PromissoryNoteMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-08-31</xbrli:startDate>
        <xbrli:endDate>2023-08-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-08-09_custom_PromissoryNoteMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">NRXS:PromissoryNoteMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-08-09</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-08-092024-08-09_custom_PromissoryNoteMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">NRXS:PromissoryNoteMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-08-09</xbrli:startDate>
        <xbrli:endDate>2024-08-09</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-11-01_custom_SecondPromissoryNoteMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">NRXS:SecondPromissoryNoteMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-11-01</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-11-012024-11-01_custom_SecondPromissoryNoteMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">NRXS:SecondPromissoryNoteMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-11-01</xbrli:startDate>
        <xbrli:endDate>2024-11-01</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_SecondPromissoryNoteMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">NRXS:SecondPromissoryNoteMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_SecondPromissoryNoteMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">NRXS:SecondPromissoryNoteMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-11-30_custom_TwoThousandTwentyTwoConvertibleNotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">NRXS:TwoThousandTwentyTwoConvertibleNotesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-11-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-11-302022-11-30_custom_TwoThousandTwentyTwoConvertibleNotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">NRXS:TwoThousandTwentyTwoConvertibleNotesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-11-30</xbrli:startDate>
        <xbrli:endDate>2022-11-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-06-032022-11-30_custom_TwoThousandTwentyTwoConvertibleNotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">NRXS:TwoThousandTwentyTwoConvertibleNotesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-06-03</xbrli:startDate>
        <xbrli:endDate>2022-11-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_TwoThousandTwentyTwoConvertibleNotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">NRXS:TwoThousandTwentyTwoConvertibleNotesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-11-30_srt_MinimumMember_custom_TwoThousandTwentyTwoConvertibleNotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">NRXS:TwoThousandTwentyTwoConvertibleNotesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-11-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-11-30_srt_MaximumMember_custom_TwoThousandTwentyTwoConvertibleNotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">NRXS:TwoThousandTwentyTwoConvertibleNotesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-11-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-19_custom_TwoThousandTwentyTwoConvertibleNotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">NRXS:TwoThousandTwentyTwoConvertibleNotesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-19</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-12-192022-12-19_custom_TwoThousandTwentyTwoConvertibleNotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">NRXS:TwoThousandTwentyTwoConvertibleNotesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-12-19</xbrli:startDate>
        <xbrli:endDate>2022-12-19</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_ConvertiblePromissoryNoteMember_custom_AccreditedInvestorsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">NRXS:ConvertiblePromissoryNoteMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">NRXS:AccreditedInvestorsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_AccreditedInvestorsMember_custom_ConvertiblePromissoryNoteMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">NRXS:AccreditedInvestorsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">NRXS:ConvertiblePromissoryNoteMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_ConvertiblePromissoryNoteMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">NRXS:ConvertiblePromissoryNoteMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_TwoThousandTwentyThreeConvertibleNotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">NRXS:TwoThousandTwentyThreeConvertibleNotesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_ConvertiblePromissoryNoteMember_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">NRXS:ConvertiblePromissoryNoteMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_ConvertiblePromissoryNoteMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">NRXS:ConvertiblePromissoryNoteMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_TwoThousandTwentyThreeConvertibleNotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">NRXS:TwoThousandTwentyThreeConvertibleNotesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-08-09_custom_TwoThousandTwentyThreeConvertibleNotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">NRXS:TwoThousandTwentyThreeConvertibleNotesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-08-09</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-08-092023-08-09_custom_TwoThousandTwentyThreeConvertibleNotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">NRXS:TwoThousandTwentyThreeConvertibleNotesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-08-09</xbrli:startDate>
        <xbrli:endDate>2023-08-09</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_SignatureBankMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">NRXS:SignatureBankMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_AlexanderCapitalLPMember_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">NRXS:AlexanderCapitalLPMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_AlexanderCapitalLPMember_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">NRXS:AlexanderCapitalLPMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-08-09_custom_ChannelPartnersCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">NRXS:ChannelPartnersCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-08-09</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-08-092023-08-09_custom_ChannelPartnersCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">NRXS:ChannelPartnersCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-08-09</xbrli:startDate>
        <xbrli:endDate>2023-08-09</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-11-08">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-11-08</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-11-082023-11-08">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-11-08</xbrli:startDate>
        <xbrli:endDate>2023-11-08</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_ConvertiblePromissoryNotesMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">NRXS:ConvertiblePromissoryNotesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_ConvertiblePromissoryNotesMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">NRXS:ConvertiblePromissoryNotesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_ConvertiblePromissoryNotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">NRXS:ConvertiblePromissoryNotesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_ConvertiblePromissoryNotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">NRXS:ConvertiblePromissoryNotesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_TwoThousandTwentyFourConvertiblePromissoryNotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">NRXS:TwoThousandTwentyFourConvertiblePromissoryNotesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_SeriesBPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_SeriesBPreferredStockMember47710687">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-21_custom_TwoThousandTwentyFourConvertiblePromissoryNotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">NRXS:TwoThousandTwentyFourConvertiblePromissoryNotesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-21</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-02-12_custom_TwoThousandTwentyFourConvertiblePromissoryNotesMember_us-gaap_SeriesBPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">NRXS:TwoThousandTwentyFourConvertiblePromissoryNotesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-02-12</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-12_us-gaap_SeriesBPreferredStockMember_custom_TwoThousandTwentyFourConvertiblePromissoryNotesMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">NRXS:TwoThousandTwentyFourConvertiblePromissoryNotesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-12</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-02-12_us-gaap_SeriesBPreferredStockMember_custom_TwoThousandTwentyFourConvertiblePromissoryNotesMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">NRXS:TwoThousandTwentyFourConvertiblePromissoryNotesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-02-12</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-02-12_us-gaap_SeriesBPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-02-12</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-02-122024-02-12_us-gaap_SeriesBPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-02-12</xbrli:startDate>
        <xbrli:endDate>2024-02-12</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-08-152024-08-15_custom_TwoThousandTwentyFourConvertibleNotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">NRXS:TwoThousandTwentyFourConvertibleNotesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-08-15</xbrli:startDate>
        <xbrli:endDate>2024-08-15</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-09-15_custom_TwoThousandTwentyFourConvertiblePromissoryNotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">NRXS:TwoThousandTwentyFourConvertiblePromissoryNotesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-09-15</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-08-15_custom_TwoThousandTwentyFourConvertiblePromissoryNotesMember_us-gaap_SeriesBPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">NRXS:TwoThousandTwentyFourConvertiblePromissoryNotesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-08-15</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-08-152024-08-15_custom_TwoThousandTwentyFourConvertibleNotesMember_us-gaap_SeriesBPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">NRXS:TwoThousandTwentyFourConvertibleNotesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-08-15</xbrli:startDate>
        <xbrli:endDate>2024-08-15</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-08-152024-08-15_custom_TwoThousandTwentyFourConvertiblePromissoryNotesMember_us-gaap_SeriesBPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">NRXS:TwoThousandTwentyFourConvertiblePromissoryNotesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-08-15</xbrli:startDate>
        <xbrli:endDate>2024-08-15</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_TwoThousandTwentyFourConvertiblePromissoryNotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">NRXS:TwoThousandTwentyFourConvertiblePromissoryNotesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-01-01_custom_VersaillesIndianaMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:GeographicDistributionAxis">NRXS:VersaillesIndianaMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-01-01</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-01-01_custom_VersaillesIndianaMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:GeographicDistributionAxis">NRXS:VersaillesIndianaMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-01-01</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-01-01_custom_CarmelIndianaMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:GeographicDistributionAxis">NRXS:CarmelIndianaMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-01-01</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-01-01_custom_CarmelIndianaMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:GeographicDistributionAxis">NRXS:CarmelIndianaMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-01-01</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_ConvertibleSeriesSeedPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">NRXS:ConvertibleSeriesSeedPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_VendorsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">NRXS:VendorsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_VendorsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">NRXS:VendorsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_EmployementAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">NRXS:EmployementAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_TwoThousandTwentyThreeConvertiblePromissoryNotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">NRXS:TwoThousandTwentyThreeConvertiblePromissoryNotesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_TwoThousandTwentyTwoConvertibleNotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">NRXS:TwoThousandTwentyTwoConvertibleNotesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_AdvisoryAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">NRXS:AdvisoryAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_UnderwritingAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">NRXS:UnderwritingAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_TwoThousandTwentyFourConvertiblePromissoryNotesMember47712359">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">NRXS:TwoThousandTwentyFourConvertiblePromissoryNotesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_AdvisoryAgreementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">NRXS:AdvisoryAgreementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_TwoThousandTwentyThreeConvertiblePromissoryNotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">NRXS:TwoThousandTwentyThreeConvertiblePromissoryNotesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_PreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_PreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_PreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_PreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_InvestorWarrantOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">NRXS:InvestorWarrantOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_InvestorWarrantPSAOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">NRXS:InvestorWarrantPSAOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_InvestorWarrantPSAOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">NRXS:InvestorWarrantPSAOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_TwoThousandTwentyTwoConvertibleNotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">NRXS:TwoThousandTwentyTwoConvertibleNotesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_TwoThousandTwentyTwoConvertibleNotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">NRXS:TwoThousandTwentyTwoConvertibleNotesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_TwoThousandTwentyThreeConvertibleNotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">NRXS:TwoThousandTwentyThreeConvertibleNotesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_TwoThousandTwentyThreeConvertibleNotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">NRXS:TwoThousandTwentyThreeConvertibleNotesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_UnderwriterWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">NRXS:UnderwriterWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_AdvisoryAgreementWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">NRXS:AdvisoryAgreementWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_AdvisoryAgreementWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">NRXS:AdvisoryAgreementWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_SeriesAPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_SeriesSeedPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">NRXS:SeriesSeedPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_SeriesAPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-08-15_custom_AmendedTwoThousandTwentyFourConvertibleNotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">NRXS:AmendedTwoThousandTwentyFourConvertibleNotesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-08-15</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-08-152024-08-15_custom_AmendedTwoThousandTwentyFourConvertibleNotesMember_us-gaap_SeriesBPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">NRXS:AmendedTwoThousandTwentyFourConvertibleNotesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-08-15</xbrli:startDate>
        <xbrli:endDate>2024-08-15</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-08-15_custom_AmendedTwoThousandTwentyFourConvertibleNotesMember_us-gaap_SeriesBPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">NRXS:AmendedTwoThousandTwentyFourConvertibleNotesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-08-15</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-11-11_us-gaap_SeriesBPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-11-11</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-11-13_us-gaap_SeriesBPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-11-13</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-11-112024-11-11_us-gaap_SeriesBPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-11-11</xbrli:startDate>
        <xbrli:endDate>2024-11-11</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_PreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_PreferredStockMember47713734">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-10-12_custom_TwentySeventeenStockCompensationPlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">NRXS:TwentySeventeenStockCompensationPlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-10-12</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-09-13_custom_TwentySeventeenStockCompensationPlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">NRXS:TwentySeventeenStockCompensationPlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-09-13</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_srt_ChiefFinancialOfficerMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefFinancialOfficerMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_TwentySeventeenStockCompensationPlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">NRXS:TwentySeventeenStockCompensationPlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_TwentySeventeenStockCompensationPlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">NRXS:TwentySeventeenStockCompensationPlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_MeasurementInputSharePriceMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_MeasurementInputPriceVolatilityMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_MeasurementInputPriceVolatilityMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_MeasurementInputRiskFreeInterestRateMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_MeasurementInputRiskFreeInterestRateMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_MeasurementInputExpectedDividendRateMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_FairValueInputsLevel1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_FairValueInputsLevel2Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_FairValueInputsLevel3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_FairValueInputsLevel1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_FairValueInputsLevel2Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_FairValueInputsLevel3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_FairValueInputsLevel1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_FairValueInputsLevel2Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_FairValueInputsLevel3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_FairValueInputsLevel1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_FairValueInputsLevel2Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_FairValueInputsLevel3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_FairValueInputsLevel1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_FairValueInputsLevel2Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_FairValueInputsLevel3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_MeasurementInputPriceVolatilityMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_OperatingSegmentsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_OperatingSegmentsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-03-182024-03-18_custom_AdvisoryAgreementMember_us-gaap_PrivatePlacementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">NRXS:AdvisoryAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-03-18</xbrli:startDate>
        <xbrli:endDate>2024-03-18</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-03-182024-03-18_custom_AdvisoryAgreementMember_us-gaap_PrivatePlacementMember_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">NRXS:AdvisoryAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-03-18</xbrli:startDate>
        <xbrli:endDate>2024-03-18</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-03-18_custom_AdvisoryAgreementMember_us-gaap_CommonStockMember_us-gaap_PrivatePlacementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">NRXS:AdvisoryAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-03-18</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-03-262025-03-26_srt_ScenarioForecastMember_custom_AdvisoryAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">NRXS:AdvisoryAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-03-26</xbrli:startDate>
        <xbrli:endDate>2025-03-26</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_CommonStockMember_custom_SettlementAgreementMember_us-gaap_SeriesAPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">NRXS:SettlementAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_SeriesAPreferredStockMember_custom_SettlementAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">NRXS:SettlementAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_CommonStockMember_us-gaap_SeriesAPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_SeriesAPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-10-012022-10-01_srt_MinimumMember_custom_ExecutiveEmploymentAgreementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">NRXS:ExecutiveEmploymentAgreementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-10-01</xbrli:startDate>
        <xbrli:endDate>2022-10-01</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-10-012022-10-01_srt_MaximumMember_custom_ExecutiveEmploymentAgreementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">NRXS:ExecutiveEmploymentAgreementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-10-01</xbrli:startDate>
        <xbrli:endDate>2022-10-01</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-10-012022-10-01_custom_ExecutiveEmploymentAgreementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">NRXS:ExecutiveEmploymentAgreementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-10-01</xbrli:startDate>
        <xbrli:endDate>2022-10-01</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_ExecutiveEmploymentAgreementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">NRXS:ExecutiveEmploymentAgreementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_ExecutiveEmploymentAgreementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">NRXS:ExecutiveEmploymentAgreementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-06-30_custom_ExecutiveEmploymentAgreementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">NRXS:ExecutiveEmploymentAgreementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-01-02_custom_ExecutiveEmploymentAgreementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">NRXS:ExecutiveEmploymentAgreementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-01-02</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-01-02_custom_ExecutiveEmploymentAgreementsMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">NRXS:ExecutiveEmploymentAgreementsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-01-02</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-04-30_custom_ExecutiveEmploymentAgreementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">NRXS:ExecutiveEmploymentAgreementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-04-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-04-30_custom_ExecutiveEmploymentAgreementsMember_us-gaap_IPOMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">NRXS:ExecutiveEmploymentAgreementsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-04-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-04-102024-04-10_srt_ChiefOperatingOfficerMember_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefOperatingOfficerMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-04-10</xbrli:startDate>
        <xbrli:endDate>2024-04-10</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-04-102024-04-10_srt_ChiefOperatingOfficerMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefOperatingOfficerMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-04-10</xbrli:startDate>
        <xbrli:endDate>2024-04-10</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_srt_ChiefOperatingOfficerMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefOperatingOfficerMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-02-062019-02-06">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-02-06</xbrli:startDate>
        <xbrli:endDate>2019-02-06</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-07-142022-07-14">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-07-14</xbrli:startDate>
        <xbrli:endDate>2022-07-14</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-01-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-01-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_DomesticCountryMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_TaxYear2037Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">NRXS:TaxYear2037Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_TaxYear2038Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">NRXS:TaxYear2038Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_TaxYear2039Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">NRXS:TaxYear2039Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_TaxYear2040Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">NRXS:TaxYear2040Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_TaxYear2041Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">NRXS:TaxYear2041Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_TaxYearThereafterMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">NRXS:TaxYearThereafterMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_NoExpirationMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">NRXS:NoExpirationMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-032025-01-03_us-gaap_SubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-03</xbrli:startDate>
        <xbrli:endDate>2025-01-03</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-03-062025-03-06_us-gaap_SubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-03-06</xbrli:startDate>
        <xbrli:endDate>2025-03-06</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-172025-01-17_us-gaap_SubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-17</xbrli:startDate>
        <xbrli:endDate>2025-01-17</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-172025-01-17_us-gaap_SubsequentEventMember_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-17</xbrli:startDate>
        <xbrli:endDate>2025-01-17</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-172025-01-17_us-gaap_SubsequentEventMember_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-17</xbrli:startDate>
        <xbrli:endDate>2025-01-17</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
    <xbrli:unit id="Pure">
      <xbrli:measure>xbrli:pure</xbrli:measure>
    </xbrli:unit>
  <ix:relationship fromRefs="Fact001937" toRefs="Footnote001987"/>
  <ix:relationship fromRefs="Fact001938" toRefs="Footnote001987"/>
  <ix:relationship fromRefs="Fact001940" toRefs="Footnote001987"/>
  <ix:relationship fromRefs="Fact001941" toRefs="Footnote001987"/>
  <ix:relationship fromRefs="Fact001943" toRefs="Footnote001987"/>
  <ix:relationship fromRefs="Fact001944" toRefs="Footnote001987"/>
  <ix:relationship fromRefs="Fact001946" toRefs="Footnote001987"/>
  <ix:relationship fromRefs="Fact001947" toRefs="Footnote001987"/>
  <ix:relationship fromRefs="Fact001949" toRefs="Footnote001988"/>
  <ix:relationship fromRefs="Fact001950" toRefs="Footnote001988"/>
  </ix:resources>
 </ix:header>
</div>


<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 4pt solid; font-size: 1pt; border-bottom: Black 1.5pt solid">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b>UNITED
STATES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b>SECURITIES
AND EXCHANGE COMMISSION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 12pt"><b>Washington,
D.C. 20549</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b>FORM
<span id="xdx_902_edei--DocumentType_c20240101__20241231_z2HRplHRWRuc"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000011" name="dei:DocumentType">10-K</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span id="xdx_902_edei--DocumentAnnualReport_c20240101__20241231_zllolFBaGdG2"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" format="ixt:booleantrue" id="Fact000012" name="dei:DocumentAnnualReport">&#9746;</ix:nonNumeric></span>&#160;<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ANNUAL
REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the fiscal year ended: <span id="xdx_905_edei--DocumentPeriodEndDate_c20240101__20241231_z8dQeNOOz2ok"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" format="ixt:datemonthdayyearen" id="Fact000013" name="dei:DocumentPeriodEndDate"><span id="xdx_90F_edei--CurrentFiscalYearEndDate_c20240101__20241231_zDopDVUTpQo"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" format="ixt:datemonthdayen" id="Fact000014" name="dei:CurrentFiscalYearEndDate">December 31</ix:nonNumeric></span>, <span id="xdx_905_edei--DocumentFiscalYearFocus_c20240101__20241231_zDez43RrFjq4"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000015" name="dei:DocumentFiscalYearFocus">2024</ix:nonNumeric></span></ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">or</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span id="xdx_90E_edei--DocumentTransitionReport_c20240101__20241231_zAckho892PSg"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" format="ixt:booleanfalse" id="Fact000016" name="dei:DocumentTransitionReport">&#9744;</ix:nonNumeric></span>&#160;<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">TRANSITION
REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the transition period from _________ to ________</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Commission
File Number: <b><span id="xdx_90B_edei--EntityFileNumber_c20240101__20241231_z4MOBpcVV5U1"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000017" name="dei:EntityFileNumber">001-41775</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b><span style="text-decoration: underline"><span id="xdx_900_edei--EntityRegistrantName_c20240101__20241231_z0rynofW9ztc"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000018" name="dei:EntityRegistrantName">Neuraxis,
Inc.</ix:nonNumeric></span></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Exact
name of registrant as specified in its charter)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 49%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_90C_edei--EntityIncorporationStateCountryCode_c20240101__20241231_z2EJRKTExVCk"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" format="ixt-sec:stateprovnameen" id="Fact000019" name="dei:EntityIncorporationStateCountryCode">Delaware</ix:nonNumeric></span></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; width: 2%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 49%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_903_edei--EntityTaxIdentificationNumber_c20240101__20241231_zqpZyJalgfG2"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000020" name="dei:EntityTaxIdentificationNumber">45-5079684</ix:nonNumeric></span></b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(State
    or other jurisdiction <br/>
    of incorporation)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(I.R.S.
    Employer <br/>
    Identification Number)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 49%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_902_edei--EntityAddressAddressLine1_c20240101__20241231_zKdtJXH9ay5b"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000021" name="dei:EntityAddressAddressLine1">11611
    N Meridian St,</ix:nonNumeric></span> <span id="xdx_908_edei--EntityAddressAddressLine2_c20240101__20241231_zq6KUIkrWwha"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000022" name="dei:EntityAddressAddressLine2">Suite 330</ix:nonNumeric></span> <br/>
    <span id="xdx_908_edei--EntityAddressCityOrTown_c20240101__20241231_ztituOC3Hppa"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000023" name="dei:EntityAddressCityOrTown">Carmel</ix:nonNumeric></span>, <span id="xdx_900_edei--EntityAddressStateOrProvince_c20240101__20241231_zBZRrnmpFrf2"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000024" name="dei:EntityAddressStateOrProvince">IN</ix:nonNumeric></span> <span id="xdx_907_edei--EntityAddressPostalZipCode_c20240101__20241231_zb1VcVoY7L4i"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000025" name="dei:EntityAddressPostalZipCode">46032</ix:nonNumeric></span></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; vertical-align: top; width: 2%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center; width: 49%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_903_edei--CityAreaCode_c20240101__20241231_zTUNGDA9thSc"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000026" name="dei:CityAreaCode">(812)</ix:nonNumeric></span>
    <span id="xdx_905_edei--LocalPhoneNumber_c20240101__20241231_zcHbmtxhas42"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000027" name="dei:LocalPhoneNumber">689-0791</ix:nonNumeric></span></b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Address
    of principal executive offices and zip code)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Registrant&#8217;s
    telephone number, including area code)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Securities
registered pursuant to Section 12(b) of the Act:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 34%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title
    of each class</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; width: 2%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 18%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Trading
    Symbol(s)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; width: 2%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 44%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name
    of each exchange on which registered</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90C_edei--Security12bTitle_c20240101__20241231_z5I5BKZwr2sf"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000028" name="dei:Security12bTitle">Common
    Stock</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90E_edei--TradingSymbol_c20240101__20241231_znEyYOg0HvK9"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000029" name="dei:TradingSymbol">NRXS</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_908_edei--SecurityExchangeName_c20240101__20241231_zIFirDRd9gU1"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" format="ixt-sec:exchnameen" id="Fact000030" name="dei:SecurityExchangeName">NYSE
    American LLC</ix:nonNumeric></span></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Securities
registered pursuant to Section 12(g) of the Act: None</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes&#160;&#9744;&#160;<span id="xdx_905_edei--EntityWellKnownSeasonedIssuer_c20240101__20241231_zdoUhiKl997c"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000031" name="dei:EntityWellKnownSeasonedIssuer">No</ix:nonNumeric></span>&#160;&#9746;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes&#160;&#9744;&#160;<span id="xdx_90B_edei--EntityVoluntaryFilers_c20240101__20241231_zRTawicqutca"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000032" name="dei:EntityVoluntaryFilers">No</ix:nonNumeric></span>&#160;&#9746;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange
Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)
has been subject to such filing requirements for the past 90 days. <span id="xdx_905_edei--EntityCurrentReportingStatus_c20240101__20241231_z4e9A4UiIfJ7"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000033" name="dei:EntityCurrentReportingStatus">Yes</ix:nonNumeric></span>&#160;&#9746;&#160;No&#160;&#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule
405 of Regulation S-T (&#167; 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant
was required to submit such files). <span id="xdx_900_edei--EntityInteractiveDataCurrent_c20240101__20241231_zXEaF863mN89"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000034" name="dei:EntityInteractiveDataCurrent">Yes</ix:nonNumeric></span>&#160;&#9746;&#160;No&#160;&#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company,
or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller
reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 50%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Large
    accelerated filer&#160;&#9744;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 50%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accelerated
filer&#160;&#9744;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_edei--EntityFilerCategory_c20240101__20241231_zKr6vxUvdRpe"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" format="ixt-sec:entityfilercategoryen" id="Fact000035" name="dei:EntityFilerCategory">Non-accelerated
    filer</ix:nonNumeric></span>&#160;&#9746;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Smaller
reporting company&#160;<span id="xdx_908_edei--EntitySmallBusiness_c20240101__20241231_z7muSU77HgK4"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" format="ixt:booleantrue" id="Fact000036" name="dei:EntitySmallBusiness">&#9746;</ix:nonNumeric></span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Emerging
growth company&#160;<span id="xdx_90E_edei--EntityEmergingGrowthCompany_c20240101__20241231_zbFqaFFBsdia"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" format="ixt:booleantrue" id="Fact000037" name="dei:EntityEmergingGrowthCompany">&#9746;</ix:nonNumeric></span></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.&#160;<span id="xdx_904_edei--EntityExTransitionPeriod_c20240101__20241231_zBaa5Yot6ocl"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" format="ixt:booleantrue" id="Fact000038" name="dei:EntityExTransitionPeriod">&#9746;</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness
of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered
public accounting firm that prepared or issued its audit report.&#160;<span id="xdx_908_edei--IcfrAuditorAttestationFlag_c20240101__20241231_zt9MYsP9zOC7"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" format="ixt:booleanfalse" id="Fact000039" name="dei:IcfrAuditorAttestationFlag">&#9744;</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant
included in the filing reflect the correction of an error to previously issued financial statements.&#160;<span id="xdx_902_edei--DocumentFinStmtErrorCorrectionFlag_c20240101__20241231_zbe4Rfo5BfS2"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" format="ixt:booleanfalse" id="Fact000040" name="dei:DocumentFinStmtErrorCorrectionFlag">&#9744;</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation
received by any of the registrant&#8217;s executive officers during the relevant recovery period pursuant to &#167;240.10D-1(b).&#160;&#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes&#160;&#9744;&#160;No&#160;<span id="xdx_906_edei--EntityShellCompany_dbF_c20240101__20241231_zifT7wzXq6j9"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" format="ixt:booleanfalse" id="Fact000041" name="dei:EntityShellCompany">&#9746;</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
aggregate market value of the registrant&#8217;s outstanding common equity held by non-affiliates as of the last business day of the
registrant&#8217;s most recently completed second fiscal quarter, based upon the closing price for the registrant&#8217;s common stock
on that day as reported by the NYSE American, was approximately $<span id="xdx_906_edei--EntityPublicFloat_iI_pn5n6_c20240630_zbQ7XgGo3Jl"><ix:nonFraction name="dei:EntityPublicFloat" contextRef="AsOf2024-06-30" id="Fact000042" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">16.4</ix:nonFraction></span> million.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
registrant had <span id="xdx_905_edei--EntityCommonStockSharesOutstanding_iI_pid_c20250313_zCVqufSfa1hh"><ix:nonFraction name="dei:EntityCommonStockSharesOutstanding" contextRef="AsOf2025-03-13" id="Fact000043" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">7,215,864</ix:nonFraction></span> shares of its common stock, par value $<span id="xdx_904_edei--EntityListingParValuePerShare_pid_c20240101__20241231_zcJLRLK369oe"><ix:nonFraction name="dei:EntityListingParValuePerShare" contextRef="From2024-01-01to2024-12-31" id="Fact000044" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.001</ix:nonFraction></span>, issued and outstanding as of March 13, 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt; border-bottom: Black 4pt solid">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>TABLE
OF CONTENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; vertical-align: top; width: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 1pt; width: 0.1in">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 0.5in; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Page</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#me_001">PART I</a></span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
    1.</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#me_002">Business</a></span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
    1A.</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#me_003">Risk Factors</a></span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">36</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
    1B.</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#ar_001">Unresolved Staff Comments</a></span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">61</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
    1C.</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#ar_002">Cybersecurity</a></span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">61</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
    2.</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#ar_003">Properties</a></span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">62</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
    3</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#ar_004">Legal Proceedings</a></span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">63</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
    4.</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#ar_005">Mine Safety Disclosures</a></span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">64</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#ar_006">PART II</a></span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
    5.</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#ar_007">Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</a></span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">64</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
    6.</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#ar_008">Reserved</a></span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">64</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
    7.</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#ar_009">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">65</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
    7A.</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#ar_010">Quantitative and Qualitative Disclosures About Market Risk</a></span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">69</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
    8.</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#ar_011">Financial Statements and Supplementary Data</a></span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">69</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
    9.</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#ar_012">Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</a></span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">69</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
    9A.</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#ar_013">Controls and Procedures</a></span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">69</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
    9B.</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#ar_014">Other Information</a></span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">70</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
    9C.</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#ar_015">Disclosures Regarding Foreign Jurisdictions that Prevent Inspections</a></span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">70</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#ar_016">PART III</a></span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
    10.</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#ar_017">Directors, Executive Officers and Corporate Governance</a></span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">71</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
    11.</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#ar_018">Executive Compensation</a></span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">76</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
    12.</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#sh_007">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</a></span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">86</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
    13.</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#sh_008">Certain Relationships and Related Transactions, and Director Independence</a></span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">87</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
    14.</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#sh_009">Principal Accounting Fees and Services</a></span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">87</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#sh_010">PART IV</a></span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
    15.</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#sh_011">Exhibits and Financial Statement Schedules</a></span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">88</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
    16</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#sh_019">Form 10-K Summary</a></span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">90</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#D_001">Signatures</a></span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">92</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>FORWARD-LOOKING
STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Annual Report on Form 10-K (&#8220;Annual Report&#8221;) contains forward-looking statements within the meaning of the federal securities
laws. All statements contained in this Annual Report, other than statements of historical fact, including statements regarding our future
operating results and financial position, our business strategy and plans, potential growth or growth prospects, future research and
development, sales and marketing and general and administrative expenses, and our objectives for future operations, are forward-looking
statements. Words such as &#8220;believes,&#8221; &#8220;may,&#8221; &#8220;will,&#8221; &#8220;estimates,&#8221; &#8220;potential,&#8221;
&#8220;continues,&#8221; &#8220;anticipates,&#8221; &#8220;intends,&#8221; &#8220;expects,&#8221; &#8220;could,&#8221; &#8220;would,&#8221;
&#8220;projects,&#8221; &#8220;plans,&#8221; &#8220;targets,&#8221; and variations of such words and similar expressions are intended
to identify forward-looking statements. We have based these forward-looking statements largely on our current expectations and projections
about future events and trends that we believe may affect our financial condition, results of operations, business strategy, short-term
and long-term business operations and objectives, and financial needs. These forward-looking statements are subject to a number of risks,
uncertainties and assumptions, including those described in the &#8220;Risk Factors&#8221; in this Annual Report. Readers are urged to
carefully review and consider the various disclosures made in this Annual Report and in other documents we file from time to time with
the Securities and Exchange Commission (the &#8220;SEC&#8221;) that disclose risks and uncertainties that may affect our business. Moreover,
we operate in a very competitive and rapidly changing environment. New risks emerge from time to time. It is not possible for us to predict
all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors,
may cause actual results to differ materially from those contained in any forward-looking statements we may make. In light of these risks,
uncertainties, and assumptions, the future events and circumstances discussed in this Annual Report may not occur and actual results
could differ materially and adversely from those anticipated or implied in the forward-looking statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">You
should not rely upon forward-looking statements as predictions of future events. The events and circumstances reflected in the forward-looking
statements may not be achieved or occur. Although we believe that the expectations reflected in the forward-looking statements are reasonable,
we cannot guarantee future results, performance, or achievements. In addition, the forward-looking statements in this Annual Report are
made as of the date of this filing, and we do not undertake, and expressly disclaim any duty, to update such statements for any reason
after the date of this Annual Report or to conform statements to actual results or revised expectations, except as required by law.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">You
should read this Annual Report and the documents that we reference herein and have filed with the SEC as exhibits to this Annual Report
with the understanding that our actual future results, performance, and events and circumstances may be materially different from what
we expect.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Annual Report also contains or may contain estimates, projections and other information concerning our industry, our business and the
markets for our products, including data regarding the estimated size of those markets and their projected growth rates. Information
that is based on estimates, forecasts, projections or similar methodologies is inherently subject to uncertainties and actual events
or circumstances may differ materially from events and circumstances reflected in this information. Unless otherwise expressly stated,
we obtained these industry, business, market and other data from reports, research surveys, studies and similar data prepared by third
parties, industry and general publications, government data and similar sources. In some cases, we do not expressly refer to the sources
from which these data are derived.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 3; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="me_001"></span>PART
I</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="me_002"></span>ITEM
1. BUSINESS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Overview</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Neuraxis,
Inc. (&#8220;we&#8221;, &#8220;us&#8221;, the &#8220;Company&#8221; or &#8220;Neuraxis&#8221;) is a medical technology company focused
on developing neuromodulation therapies to address chronic and debilitating conditions in children and adults. We are dedicated to advancing
science with our proprietary IB-Stim therapy, based on our Percutaneous Electrical Nerve Field Stimulation (PENFS) technology, which
was developed internally by the Company. We believe that superior science and evidence-based research, are necessary for adoption by
the medical and scientific community. With one FDA indication (functional abdominal pain associated with IBS in adolescents 8-21 years
old) on the market, additional clinical trials of PENFS in multiple pediatric conditions are underway focused on unmet healthcare needs
in children, see &#8220;<i>Our Pipeline</i>&#8221; for more information.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
first product, IB-Stim, is a PENFS system intended to be used in patients 8-21 years of age with functional abdominal pain associated
with IBS. IB-Stim is a US FDA Class II medical device that has received one regulatory clearance: IB-Stim (DEN180057, 2019), under the
regulation name of &#8220;non-implanted nerve stimulator for functional abdominal pain relief.&#8221;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
second product, Rectal Expulsion Device (&#8220;RED&#8221;), is indicated to evaluate the neuromuscular function of a patient&#8217;s
ability to expel its contents from the rectum and as a qualitative test for rectal hypersensitivity. RED (K242304, 2024) helps identify
patients with rectal hypersensitivity who experience a desire or urge to defecate at lower volumes of distension. RED is intended to
be used in a clinical setting by trained health care providers in adult populations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Our
Mission</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
mission is to provide solutions that create value and provide better and safer patient outcomes. We believe in improving lives and minimizing
suffering; particularly in the pediatric population, where research and therapeutics are usually lacking. The Company already has market
clearance for its IB-Stim &#174; that targets functional abdominal pain associated with IBS, in children, with a total addressable market
of up to 6 million children. Through innovation and research, we are reimagining the future of patient care.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Our
Corporate History</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Neuraxis,
Inc. was established in 2011 and incorporated in the state of Indiana on April 17, 2012, under the name of Innovative Health Solutions,
Inc. The name was changed to Neuraxis, Inc. in March of 2022. Additionally, the Company filed a Certificate of Conversion to become a
Delaware corporation on June 23, 2022. The authorized shares were increased, and a par value established. On September 7, 2021, the Company&#8217;s
board of directors authorized a 4-for-1 stock split. They also increased the number of authorized common stock shares from 2,700,000
to 10,800,000. Furthermore, on September 9, 2021, the board authorized an increase of authorized shares of common stock from 10,800,000
to 13,400,000 in anticipation of a capital offering.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
part of the conversion to a Delaware corporation, the total number of shares of all classes of stock which the Corporation shall have
authority to issue was 101,120,000 shares, consisting of (i) 100,000,000 shares of common stock, par value $0.001 per share, and (ii)
1,120,000 shares of Preferred Stock, par value $0.001 per share (&#8220;Preferred Stock&#8221;), 1,000,000 of which was designated as
&#8220;Series A Preferred Stock&#8221; and 120,000 of which was designated as &#8220;Series Seed Preferred Stock&#8221;.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Furthermore,
on January 10, 2023, the Company&#8217;s board of directors authorized a 1-for-2 reverse stock split. All per share information has been
adjusted for this reverse stock split. The reverse split became effective on January 12, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August 9, 2023, the Company consummated an initial public offering (&#8220;IPO&#8221;), conducted on a firm commitment basis, pursuant
to which it sold 1,098,667
</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of its common stock at a price of $6.00
</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per share, resulting in gross proceeds to the
Company of $6,592,002</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.
Net proceeds to the Company, after deducting underwriting discounts and commissions and other offering expenses paid by the Company,
were $4,110,721</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.
All shares sold in our IPO were registered pursuant to a registration statement on Form S-1 (File No. 333- 269179), as amended, declared
effective by the SEC on August 9, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August 15, 2024, the Company&#8217;s shareholders (i) authorized 5,000,000 shares of preferred stock of which 4,000,000 were designated
at $0.001 par value &#8220;Series B Preferred Stock&#8221; inclusive of cumulative dividends, due and payable quarterly at the Company&#8217;s
discretion either in cash or common stock when declared, at a rate of 8.5% per annum through June 30, 2025, (ii) retired 1,000,000 shares
of Series A Preferred Stock and (iii) retired 120,000 shares of Series Seed Preferred Stock. On November 11, 2024, the holders of a majority of the then-outstanding shares of Series B Preferred
Stock authorized (i) an increase in the number of designated Series B Preferred Stock to 5,000,000 shares and (ii) an extension
of the 8.5% cumulative dividend period to December 31, 2026. The stated value of the Series B Preferred Stock is $2.38 per share. As of March 13, 2025, there are 4,280,939 shares of Series B Preferred
Stock issued and outstanding, which are convertible (based on the stated value of each share and the conversion price both equalling $2.38)
into 4,280,939 shares of common stock, subject to a maximum ownership cap of between 4.99% and 19.99% of the shares outstanding (following
conversion by the holder) set at the discretion of each holder of Series B Preferred Stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
holder of Series B Preferred Stock is entitled to cast the number of votes equal to the number of whole shares of common stock into
which the shares of Series B Preferred Stock held by such holder. Solely for purposes of voting rights, the conversion price is
$3.80 per share. The 4,280,939 shares of Series B Preferred Stock outstanding therefore represent 2,681,208 votes of common stock,
subject to a maximum voting percentage cap of between 4.99% and 19.99% of the votes outstanding (inclusive of all 2,681,208 votes plus the shares
outstanding on the record date for any particular shareholder meeting) set at the discretion of each holder of Series B Preferred
Stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have developed three FDA cleared products, the IB-Stim (DEN180057, 2019), the RED (K242304, 2024), the NSS-2 Bridge (DEN170018, 2017),
and the original 510(K) clearance (K140530, 2014), all of which were developed internally by the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            IB-Stim is a PENFS device that is indicated in patients 8-21 years of age with functional
                                            abdominal pain associated with irritable bowel syndrome. IB-Stim currently is one of two
                                            products marketed and sold by the Company.</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"></p></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">RED
    is indicated to evaluate the neuromuscular function and rectal hypersensitivity in patients with chronic constipation. RED is a point-of-care
    test that helps determine why patients may not respond to conventional laxative therapy and helps identify patients that will respond
    to pelvic floor therapy.</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    NSS-2 Bridge is a percutaneous nerve field stimulator, or PNFS, device indicated for use in the reduction of the symptoms of opioid
    withdrawal. The NSS-2 Bridge device was licensed to Masimo in April 2020, and we received a one-time licensing fee of $250,000 from
    Masimo. Masimo markets and sells this product as its <i>Masimo Bridge</i>, and we will not receive any further licensing payments
    or other revenue from this product.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    original 510(K) device was the electroacupuncture device (&#8220;EAD&#8221;), now called <i>NeuroStim</i>. The EAD is no longer being
    manufactured, sold or distributed but reserved only for research purposes.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 4; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Pediatrics
Industry Overview</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pediatric
providers, as a whole, had expressed concern about the lack of attention given to children with functional abdominal pain disorders (including
IBS) and the limited treatment options available for a population that suffers from significant disabilities. With 20% of the United
States population under age 18, our Company focus is on opportunities in pediatrics industry. The pediatrics industry has multi-billion-dollar
market opportunities. The following points clearly outline the unmet need in children:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Functional
    abdominal pain in children is one of the most common conditions seen by pediatricians and pediatric gastroenterologists.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Children
    with functional abdominal pain report lower quality of life compared with their healthy peers and equal to those with inflammatory
    bowel disease.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Overall,
    40-45% of children with functional abdominal pain disorders continue to have symptoms into adulthood, which impacts quality of life
    and healthcare spending.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
    study published in 2021 demonstrates insufficient evidence for the use of medications in pediatric functional abdominal pain disorders.
    This lack of evidence for drugs has been supported in by the American Academy of Pediatrics and NASPGHAN.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">IB-Stim
    is the only medical therapy that has shown to improve pain, global symptoms, and functional disability in children with FAP and IBS.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">IB-Stim
    is the only currently used medical therapy that is better than placebo in a randomized controlled trial and received FDA clearance
    for pediatric IBS.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: left">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Our
Opportunity</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
years, physicians and qualified healthcare professionals have resorted to the use of off-label medications without proper evidence of
efficacy or safety. This is despite a technical report from the American Academy of Pediatrics and NASPGHAN which found very little evidence
to endorse the use of any drugs in the treatment of FAPDs in children. Medications including tricyclic antidepressants, SSRIs and gabapentinoids
continue to be used off-label despite lack of evidence to support efficacy or safety. Not only have the most commonly used medications
(amitriptyline and citalopram) failed to beat placebo in clinical trials, but new studies also suggest significant risks with the potential
for serious side effects with these drugs. The absence of conclusive data to support treatments based on scientific evidence, and the
fact no drug therapies have been approved by the FDA for the treatment of FAPDs or IBS in children, presents a unique market opportunity
for Neuraxis. Below are the current standard treatments in children with functional abdominal pain and IBS.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><img src="form10-k_001.jpg" alt="" style="width: 580px"/></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 5; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Our
Solutions</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
entered the pediatric market with clinical evidence, key opinion leaders and society endorsement, including a signed letter from the
American Academy of Pediatrics and NASPGHAN supporting our request for insurers to pay for our IB-Stim device. Our IB-Stim&#174; is a
non-drug alternative to reduce functional abdominal pain in patients with IBS. In June 2019, the FDA cleared IB-Stim, a non-surgical,
neuromodulation device for children and adolescents who suffer from IBS, through a de novo process (DEN180057, 2019). The FDA created
a new classification of PENFS for the IB-Stim device. This is based on pre-clinical and clinical studies demonstrating the mechanism
of action and efficacy. Based on this new class of devices, the IB-Stim falls under 21 CFR Part 876, Subpart F &#8211; Therapeutic Devices,
876.5340, Product Code QHH. As a PENFS device, it is non-implantable and provides field stimulation to cranial nerves V, VII, IX and
X in the ear to access the CNS. It stimulates remotely from the source of pain to modulate central pain regions, such as the limbic system,
and relieve functional abdominal pain associated with IBS. Studies have demonstrated long-term benefits in functional disability, psychological
co-morbidities, and pain. For example, the table below is from a recently published study of IB-Stim in a population of patients with
chronic functional abdominal pain. The follow-up was done at 6-12 months post-treatment and shows improvements in validated questionnaires
compared to baseline (API), functional disability index (FDI), pain catastrophizing scale (PCS), Screen for Childhood Anxiety Related
Disorders (SCARED) and the Promis Anxiety.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Santucci
NR, King C, El-Chammas KI, Wongteerasut A, Damrongmanee A, Graham K, Fei L, Sahay R, Jones C, Cunningham NR, Coghill RC. <i>Effect of
percutaneous electrical nerve field stimulation on mechanosensitivity, sleep, and psychological comorbidities in adolescents with functional
abdominal pain disorders.</i> Neurogastroenterol Motil. 2022;34:e14358.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><img src="form10-k_020.jpg" alt=""/></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have only submitted one FDA De Novo request and two 510(k) submissions and plan to submit additional 510(k) premarket notifications from
our pipeline indications in the future.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Compliance
with treatment so far has been outstanding with the four weeks of therapy required to sustain long-term benefits. Compliance has been
an issue with non-pharmacological treatment for children, particularly with some of the psychological approaches such as cognitive behavioral
therapy or guided imagery, which sometimes requires 8-12 weeks of treatment. In fact, 95% of adolescents who used IB-Stim said that they
would recommend this treatment to family and friends. Many children&#8217;s hospitals across the country are already treating children
with IB-Stim successfully since it provides a better alternative for therapy in children with IBS and disability and allows them to treat
them safely and effectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have concentrated our marketing focus on the 260 children&#8217;s hospitals within the United States. To date, we have sold our IB-Stim
product to approximately 77 children&#8217;s hospitals within our target market.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><img src="form10-k_003.jpg" alt="" style="width: 600px"/></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 6; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Competition</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
competitive landscape for therapies includes off-label drugs and drugs with FDA approved only for adults with IBS while there is no FDA
indicated treatments for patients 8-21 years of age with functional abdominal pain associated with IBS and prescriptions often contain
FDA black box labels. Psychological treatments such as cognitive behavioral therapy (CBT) or guided imagery have been shown to be some
of the most effective treatments for these conditions, however, these are limited by access to trained therapists. It also includes devices
that could theoretically be used, but do not have supporting data or FDA clearance for functional bowel disorders or IBS. Digital therapeutics
that offer CBT for IBS have been developed for adults with IBS with limited success in terms of reaching large numbers of patients. Virtual
reality could potentially be used in the future to also deliver CBT to patients with IBS. Our method patents also limit other devices
from targeting IBS through stimulation of cranial nerve branches in the ear.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span><img src="form10-k_021.jpg" alt=""/></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Approved
drugs for Adults with IBS</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Rifaximin:
    an intraluminal antibiotic approved for IBS-diarrhea</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amitiza:
    a drug that stimulates fluid secretion from the intestine, approved for IBS-diarrhea</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Linzess<b>:
    </b>a drug that stimulates fluid secretion from the intestine, approved for IBS-constipation</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Plecanatide:
    a drug that stimulates fluid secretion from the intestine, approved IBS-constipation</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Eluxadoline:
    a schedule IV-controlled substance that is a mixed opioid receptor agonist/antagonist in the intestine approved for IBS-diarrhea</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 7; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Devices</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">gammaCore:
    a transcutaneous, cervical vagal nerve stimulator cleared for cluster and migraine headaches. Recent studies using this device for
    adults with gastroparesis.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Transcranial
    Magnetic Stimulation: Multiple devices cleared to treat major depressive disorder and obsessive-compulsive disorder. To date, no
    known gastrointestinal indications.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Roo
    System and Sparrow therapy system: Transcutaneous auricular stimulation devices-cleared for neonatal and adult opioid withdrawal.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
neurostimulation market is predominantly comprised of surgically implanted, invasive technologies that are not directly competitive with
our technology. Several neurostimulation companies are large, publicly traded companies that have a history in the market, have significantly
easier access to capital and other resources and have an established product pipeline. The combined clinical research and product development
done by the industry, including by us and all our competitors, is uncovering the beneficial effects of neurostimulation which now establishes
neuromodulation as a valid and scientifically supported approach to the treatment of neurological conditions, and accordingly, we expect
for competition in the non-implanted space to grow in the future.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">While
many companies have joined the neuromodulation space, there are no companies targeting the CNS or the brain-gut axis through auricular
nerves for functional bowel disorders or IBS. Currently, the Neuraxis method patents protect access to the brain, particularly the limbic
systems through branches of cranial nerves in the ear.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Our
Competitive Strengths</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe that the following competitive strengths will enable us to compete effectively:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">First
    to market</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Strong
    portfolio of device and method patents</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Large
    Market Opportunities</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Strong
    pediatric pipeline</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Academic
    Society Support</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lower
    capital expenditures in nurse, trainers, and representatives for first line therapy</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Strong
    clinical data carried out in leading academic institutions in the U.S.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Our
Growth Strategies</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">List
    price of our product is $1,195 per device and $4,780 per patient</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Strong
    gross margin</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Direct
    sales force</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Target
    customers are children&#8217;s hospitals and pediatric clinics</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Our
Pipeline</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
IB-Stim device is to be used for the indication of functional abdominal pain associated with IBS and functional nausea in children. The
same underlying technology will be used for the remaining pipeline indications, but we may use a name other than &#8220;IB-Stim&#8221;
for marketing and commercialization purposes.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">With
one FDA indication&#8212;functional abdominal pain associated with IBS in adolescents 8-21 years old&#8212;on the market, additional
clinical trials of PENFS in multiple pediatric conditions are underway focused on unmet healthcare needs in children. These indications
consist of chronic nausea, post-concussion syndrome, chemotherapy-induced nausea and vomiting, cyclic vomiting syndrome.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
chart below shows our status in the FDA review process for IB-Stim and each of the following pediatric indications:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.
<i>Functional dyspepsia</i> (<i>nausea</i>): RCT completed, and data being analyzed. ClinicalTrials.gov Identifier: NCT03675321, <i>Defining
Adolescent Nausea Through Brain-Gut Physiology and Non-Invasive Neurostimulation Response.</i> A randomized, double blind, placebo-controlled
trial to evaluate the efficacy of IB-Stim in children with functional nausea. The primary endpoint was to measure improvements in nausea
using the Nausea Severity Scale after IB-Stim therapy compared to a placebo device. The study enrolled 110 participants and was conducted
at Children&#8217;s Wisconsin/Medical College of Wisconsin.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 8; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.
<i>Post-concussion:</i> RCT currently enrolling patients. ClinicalTrials.gov Identifier: NCT04978571, <i>A Prospective Study
on the Effect of Auricular Percutaneous Electrical Nerve Field Stimulation (PENFS) in Patients with Post-Concussion Syndrome (PCS).</i>
A randomized, double blind, placebo-controlled trial to evaluate the efficacy of IB-Stim in children with post-concussion symptoms. The
primary endpoint will be to measure improvements in validated measures, including the Immediate Post-Concussion Assessment, Post-Concussion
Symptom Scale, and Balance Error Scoring Symptom compared to placebo. The study will enroll 100 participants and is being conducted at
Children&#8217;s Hospital of Orange County.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.
<i>Chemotherapy-induced nausea and vomiting:</i> RCT currently enrolling patients. ClinicalTrials.gov Identifier: NCT05143554, <i>Efficacy
of Auricular Neurostimulation for Children Adolescents and Young Adults with Chemotherapy Induced Nausea and Vomiting.</i> Subject will
be randomized to five days of active vs placebo device during administered chemotherapy known to cause moderate to severe nausea/vomiting.
With the next scheduled identical chemotherapy cycle, each subject will cross over to the other device (active vs placebo). The primary
endpoint will be to measure improvements in validated measures of nausea and vomiting including the Baxter Retching Faces Scale, Rhodes
Index of Nausea, Vomiting and Retching, and also assessment of rescue medication. The study will enroll 50 participants and is being
conducted at Children&#8217;s Wisconsin/Medical College of Wisconsin.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.
<i>Cyclic vomiting syndrome:</i> Pilot study completed, see ClinicalTrials.gov Identifier: NCT03434652. <i>Auricular Neurostimulation
for Children with Cyclic Vomiting Syndrome: A randomized, placebo-controlled trial.</i> RCT anticipated to begin enrolling patients in
the second half of 2023. This will be a double blind, placebo-controlled trial to evaluate efficacy of IB-Stim in pediatric patients
with cyclic vomiting syndrome. The primary endpoint will be to measure decreases in the frequency and severity of cyclic vomiting episodes
compared to a placebo device. The study will include a minimum of 120 patients and the site is yet to be finalized.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
step in the FDA review process differs in duration and cannot be predicted with accuracy. Timing of FDA review and approval, if ever
received, cannot be assured and the process and any approval is within the sole control and discretion of the FDA.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><img src="form10-k_005.jpg" alt=""/></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>


<!-- Field: Page; Sequence: 9; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Products</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
IB-Stim is a percutaneous PENFS system intended to be used in patients 8-21 years of age with functional abdominal pain associated with
IBS. IB-Stim already has market clearance from FDA for functional abdominal pain associated with IBS in children. FDA has classified
the non-implanted nerve stimulator for functional abdominal pain relief as Class II devices.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
IB-Stim is intended to be used for 120 hours per week, using one (1) device per week, for four (4) consecutive weeks, through application
to branches of Cranial Nerves V, VII, IX and X, and the occipital nerves identified by transillumination, as an aid in the reduction
of pain when combined with other therapies for IBS (DEN180057, 2019). In published studies, patients treated with IB-Stim demonstrated
significant improvement in pain, disability and global symptoms with no serious adverse events, and minimal to no side effects, including
localized skin irritation. The following table presents a summary of IB-STIM studies performed to date:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; width: 90%; border-collapse: collapse; margin-right: auto">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; width: 14%; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Author</b></span></td>
    <td style="text-align: center; width: 2%">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; width: 20%; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>DGBI</b></span></td>
    <td style="text-align: center; width: 2%">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom; width: 6%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>N=</b></span></td>
    <td style="text-align: center; width: 2%">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; width: 8%; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Ages</b></span></td>
    <td style="text-align: center; width: 2%">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; width: 8%; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>#
    of devices</b></span></td>
    <td style="text-align: center; width: 2%">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; width: 20%; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Outcomes</b></span></td>
    <td style="text-align: center; width: 2%">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; width: 12%; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Major
    adverse events</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Karento
    et al, 2023</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cyclic
    Vomiting Syndrome</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">30</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-18
    years </span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Abdominal
    pain, nausea, FD</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">None</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Santucci
    et al., 2023</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Functional
    Dyspepsia</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">84</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">11-21</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Abdominal
    pain, nausea, anxiety, disability</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">None</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Bora
    et.al2,.2023</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Irritable
    bowel syndrome</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">20</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">11-18</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">IBS
                                            severity scale,</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Microbiome
    diversity</span></p></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">None</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Kovacic
    et.al.,2017</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">IBS,
    FD, FAP, abdominal migraine</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">115</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">11-18</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Abdominal
    pain, disability, global symptoms.</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Syncope=1
    in sham group</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Castillo
    et.al., 2023</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Irritable
    bowel syndrome</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">27</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">11-18</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Abdominal
    pain, Microbiome Metabolism</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">None</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chogle
    et.al., 2023</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Irritable
    bowel syndrome, functional dyspepsia</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">31</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">11-18</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Quality
    of life, disability, anxiety</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">None</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Krasaelap,
    et.al., 2020</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Irritable
    bowel syndrome</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">51</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">11-18</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Abdominal
    pain, global symptoms, disability </span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">None</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Santucci
    et.al.,2021</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Functional
    abdominal pain</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">20</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">11-19</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Abdominal
    pain, sleep, nausea, anxiety</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">None</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chogle
    et.al., 2023 (Registry)</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Irritable
    bowel syndrome, functional dyspepsia</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">292</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-18</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Abdominal
    pain, nausea, disability </span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">None</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Santucci
    et.al.,2023</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Irritable
    bowel syndrome, functional dyspepsia, FAP</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">11-21</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Abdominal
    pain, nausea, disability</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">None</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
ability of the IB-Stim to produce systemic effects by modulating the central nervous system has been demonstrated in a pre-clinical animal
model of IBS (see Business&#8212;<i>Pre-Clinical Data</i>). In patients with IBS, the largest effect on all pain measures, including
composite pain scores, worst pain, disability and global symptoms, was seen after completing three consecutive weeks of treatment (see
Business&#8212;<i>Clinical Data</i>). A fourth consecutive week of treatment was included in clinical testing; no safety concerns were
identified with this extra consecutive week of treatment. In the trial of 115 subjects, 10 patients reported side-effects and only three
discontinued the study because of side-effects. Of such 10 patients, six experienced ear discomfort (three in the PENFS group, three
in the sham group), three experienced adhesive allergies (one in the PENFS group, 2 in the sham group), and one experienced syncope due
to needle phobia (in the sham group). There were no serious adverse events.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Medical
providers are trained to place the IB-Stim through IB-Stim Training and Certification. Once the provider is trained, the device can be
placed in the outpatient clinic and can be removed by the provider in the clinic or the patient at home. IB-Stim stays on for a total
of five-days to allow delivery of gentle electrical pulses to nerves below the skin that access the central nervous system. A study in
adolescents showed greater improvement in functional abdominal pain and global symptom improvement with every week of treatment (up to
four weeks). At the end of the four-week study, 95% of adolescents stated they would recommend the treatment to family or friends. Safety
of percutaneous electrical nerve field stimulation has also been reported in a separate study of over 1200 adult patients with no serious
adverse events and minimal to no side-effects.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">When
wearing our IB-Stim device and following an easy-to-learn and efficient procedure, patients can still attend school and extracurricular
activities, exercise or play non-contact sports, shower, wear ear buds or headphones, and travel.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
IB-Stim device costs $1,195 per device, and each patient will use four (4) devices. Potential patients with other indications are expected
to use six (6) or more devices per patient.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Technology</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
maladaptive central nervous system can process pain and emotions differently. This often occurs in children following a traumatic event,
viral infections, inflammation or trauma. Changes in brain pathways are known to be involved in the pathophysiology of functional bowel
disorders and IBS. The IB-Stim works by sending gentle electrical impulses into cranial nerve bundles located in the ear. This stimulation
targets brain areas that process pain and helps reduce functional abdominal pain associated with IBS. An animal model of IBS demonstrated
that the firing of neurons in the amygdala could be reduced by more than 50% in just 15 minutes of stimulation with the IB-Stim technology.
A recent human study in adults with pain related to fibromyalgia suggested that the IB-Stim technology exerts its effect by modulating
emotional and executive control centers related to pain processing, see <i>Feasibility of Auricular Field Stimulation in Fibromyalgia:
Evaluation by Functional Magnetic Resonance Imaging, Randomized Trial</i>, Woodbury et.al.<i>,</i> Pain Med. 2021;22:715-726. The field
of art pertains to an electrical stimulation device, including a stimulator containing a generator to deliver electrical pulses with
defined parameters, and a power supply for supplying the electrical energy through four separate needles, and at least one of which is
a needle array.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 10; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><img src="form10-k_006.jpg" alt="" style="width: 600px"/></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Pre-Clinical
Data</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
an animal model of IBS, extracellular, electrophysiologic recordings were performed from neurons in the rat amygdala before and 15
minutes after PENFS treatment. There was a 65% decrease in the spontaneous firing of these neurons after 15 minutes of PENFS. This
dampening of neurons in the CNS likely accounts for the modulation of pain responses in a model of post-inflammatory visceral and
somatic hyperalgesia.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 11; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><img src="form10-k_007.jpg" alt="" style="width: 200px"/></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Clinical
Data</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have over 700 published patients specific to our first FDA indication which is functional abdominal pain associated with irritable bowel
syndrome in patients 8-21 years of age. A published patient is defined as a patient who went through a study, the study was analyzed
and now the study has been published in a peer-reviewed journal.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
randomized, controlled study in children 11-18 year of age used primary endpoint of improvements in abdominal pain. The Pain Frequency-Severity-Duration
(&#8220;PFSD&#8221;) questionnaires was completed at baseline by all subjects and after each week of treatment (weeks 1&#8211;3), as
well as at extended follow-up occurring in the 8&#8211;12 weeks following the end of treatment. The PFSD scale incorporates multiple
aspects of the pain experience and was administered weekly during treatment and at extended follow-up appointments. The PFSD scale validated
for chronic pain in children (aged 8&#8211;18 years). The PFSD was also used to rate weekly worst abdominal pain on a numerical rating
scale (0 for no pain, 10 for worst pain). Patients were followed up for a median of 9.2 weeks from the last week of treatment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the active PENFS group, median worst pain at follow-up remained lower (baseline: 8.0 vs. follow-up: 6.0), whereas there was no difference
at follow-up in the control group (baseline: 7.5 vs. follow-up: 7.0). The between-group differences in worst pain ratings after 3 weeks
of treatment showed that the PENFS group improved to a greater extent, with the control group reporting significantly higher worst pain
(median 7.0) than the PENFS group (median 5.0).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
long-term follow-up, median PFSD composite scores were 12.6 (IQR 3.6&#8211;22.5) in the PENFS group and 16.8 (4.8&#8211;33.6) in the
control group. A comparison of changes in PFSD composite scores (baseline to follow-up) showed that patients in the PENFS group reported
significantly greater improvement in pain (median &#8211;8.4) than those in the control group (median 0.0). This study was published
in the Lancet Gastroenterology Hepatology, (Kovacic K, et.al. Lancet Gastroenterol Hepatol. 2017;2:727-737).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 12; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><img src="form10-k_008.jpg" alt="" style="width: 600px"/></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
secondary endpoint in the same study used the functional disability index (FDI) to assess functional disability in those treated with
PENFS and compared to sham treatment. Those treated with PENFS changed from moderate disability to minimal at the 2&#8211;3-month follow-up
while the sham device group had no change.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><img src="form10-k_009.jpg" alt="" style="width: 550px"/></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
separate published paper looked at 51 pediatric patients with IBS and used the symptoms response scale (SRS) to assess global symptoms
improvement following PENFS treatment compared to sham. Global symptom improvement was assessed with a validated pediatric questionnaire,
Symptom Response Scale (SRS). Symptoms were recorded as better, worse, or no change based on a 15-point scale across individual domains
for both improvement and deterioration of overall symptoms. Findings from several studies that used the SRS have shown that using 7-point
scale response options in disease-specific measures, a change score of 0.5 represents the minimal clinically important difference (Juniper
et.al. J Clin Epidemiol 1994; 47: 81&#8211;87 and Guyatt GH et.al.1987; 42: 773&#8211;78). As previously noted, a minimum change in score
of &#8805; 2 was chosen for this study as a more stringent criterion for global improvement before and after PENFS treatment and to compare
between groups. Patients and providers were blinded in terms of those who received active PENFS or sham. At the end 3 weeks of therapy
using the change of &#8805; 2, 81% of the PENFS group compared with 26% of the sham group (*p&#8804; 0.001, #p=0.002) reported overall symptom
improvement. When applying an even more stringent criteria with a change &#8805; 3 on the SRS, 67% of the PENFS group compared with 22%
of the sham group reported symptoms improvement (p=0.002) (Krasaelap A et.al. Efficacy of Auricular Neurostimulation in Adolescents With
Irritable Bowel Syndrome in a Randomized, Double-Blind Trial. Clin Gastroenterol Hepatol. 2020;18:1987-1994).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 13; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><img src="form10-k_010.jpg" alt="" style="width: 300px"/></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Recently,
the largest, prospective, multicenter registry for any drug or device in pediatric patients with pain associated DGBIs was published.
It evaluated outcomes of pediatric patients (8-18 years) following a 4-week course of IB-Stim in a real-world clinical setting. Overall,
292 patients met Rome IV Diagnostic criteria for any pain associated disorder of the gut-brain interaction (DGBIs). In this cohort, 92%
had failed medication therapy and 61% of patients had failed 4 or more medications when they entered the study. Patients were asked to
fill out several validated pediatric measures, including the abdominal pain index (API) and a validated questionnaire that assesses frequency,
duration, and intensity of abdominal pain episodes. Data were collected weekly for the first 3 weeks and at 3, 6, 9 and 12 months. Compared
to baseline scores, there were significant improvements in the API after 4 weeks of IB-Stim treatment at every time point, including
6 month (p&lt;0.001) and 12 months (p&lt;0.001). Although there were many dropouts by the end of the 12 months, the results were still
significant and sustained. No serious adverse effects were recorded during the entire 12 month follow-up. (Chogle, A. et. al. A multicenter
registry study on percutaneous electrical nerve field stimulation for pediatric disorders of gut-brain interaction. J Pediatr Gastroenterol
Nutr. 2024 Mar 7.).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; width: 65%; border-collapse: collapse; margin-right: auto">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <td colspan="7" style="border-bottom: Black 1pt solid; text-align: center; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Abdominal
    Pain Index (API)</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 30%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Time
    point</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; width: 20%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>n</i></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 24%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Median
    (IQR)</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; width: 20%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>p
    Value</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Baseline</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>288</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2.68(1.84,
    3.58)</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>N/A</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>3
    weeks</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>209</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>1.99
    (1.13, 3.27)</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&lt;0.001</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>3
    months</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>75</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>1.81
    (0.85, 3.20)</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&lt;0.001</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>6
    months</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>60</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>1.70
    (0.93, 2.72)</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&lt;0.001</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>9
    months</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>26</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>1.90
    (1.33, 2.82)</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>0.002</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>12
    months</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>22</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>220(0.41,
    3.21)</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&lt;0.001</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">An
open-label study of 20 patients treated with PENFS in a &#8220;real-world&#8221; clinical setting at Cincinnati Children&#8217;s Hospital
demonstrated that after PENFS, abdominal pain (p &lt; 0.0001), nausea (p=0.001), pain catastrophizing (p = 0.001), functional disability
(p&lt;0.0001), and anxiety (p = 0.03) exhibited significant improvements, and were sustained 6-12 months after treatment (Santucci et.al.
Effect of percutaneous electrical nerve field stimulation on mechanosensitivity, sleep, and psychological comorbidities in adolescents
with functional abdominal pain disorders. Neurogastroenterol Motil. 2022;34:e14358). Validated questionnaires included the abdominal
pain index (API), nausea severity scale (NSS), functional disability index (FDI), as well as psychological measures of catastrophizing
(PCS-C) and anxiety (SCARED). The table below summarizes the results pre, during and post PENFS results at long-term follow-up (Santucci
et.al. Effect of percutaneous electrical nerve field stimulation on mechanosensitivity, sleep, and psychological comorbidities in adolescents
with functional abdominal pain disorders. Neurogastroenterol Motil. 2022;34:e14358).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><img src="form10-k_022.jpg" alt=""/></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
clinically meaningful endpoint is the number needed to treat (NNT) used in treatment for abdominal pain-related functional gastrointestinal
disorders in adolescents. NNT means the number of patients that need to be treated for one patient to get the targeted improvement (&#8805;30%
improvement).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 14; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>PENFS
Reimbursement</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
American Medical Association (AMA) assigned a procedure-specific Category III CPT Code (0720T) to PENFS, which was published on December
30, 2021 and became effective for utilization on July 1, 2022. Category III CPT Codes are temporary codes issued to define and track
the utilization of new procedural technology. To expand patient access to PENFS procedures and IB-Stim technology, we launched our internal
Prior Authorization team under our Guidance &amp; Patient Support function in 2023. This continues to address the Prior Authorization
process barriers for providers and children&#8217;s hospitals and streamlines a patient&#8217;s access to our Patient Advocacy and Financial
Assistance offerings, if needed. In September of 2024, the AMA&#8217;s CPT Editorial Panel accepted addition of Category I CPT Code (placeholder
64X11) for PENFS and deletion of Category III CPT Code 0720T. The finalized Category I CPT Code for PENFS, and associated valuations,
will be announced publicly in Q4 of 2025. The new code will become effective for utilization on January 1, 2026. Sixteen (16) commercial
health insurers, including certain Blue Cross Blue Shield licensees, have instituted formal medical policy coverage for PENFS. The total
membership of these health insurers is approximately 45,000,000 covered lives. An additional health insurer, with approximately 6,000,000
members, will institute formal medical policy coverage for PENFS beginning the second quarter of 2025, bringing the total number of covered
lives to approximately 51,000,000 across seventeen (17) commercial health insurers. Patients who are appropriate clinical candidates
may have policy-covered access to PENFS and IB-Stim technology under their specific health plan. We continue to actively leverage clinical
evidence and peer-reviewed publications to expand patient access to IB-Stim technology. In addition, we anticipate academic medical society
support in the form of a position paper and an update to treatment guidelines to support the use of PENFS as a potential standard of
care.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Marketing</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
market our products through search engine optimization, or SEO, internet channels and to physicians via the academic society. We plan
to extensively ramp-up our marketing efforts to patients and physicians as we gain additional indications.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Patients/Customers</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
current patient base is children 8-21 years of age and suffering from functional abdominal pain. Our customers are primarily children&#8217;s
hospitals who serve these children.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span><img src="form10-k_023.jpg" alt=""/></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Rectal
Expulsion Device (RED)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Rectal Expulsion Device (RED) enables comprehensive constipation care for every gastroenterology practice. The mission is to develop
the best tool for clinical decision making with the physician and patient in mind. RED was designed to be the most efficient, accurate,
and cost-effective diagnostic tool for patients with chronic constipation. The goal is for every Gastroenterologist practice to be able
to safely and confidently perform meaningful anorectal testing without it impacting clinical workflow or requiring a large capital expense.
Eight (8) million patients each year present with constipation. Of those eight million patients, 700,000 patients present to the Emergency
Room.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Clinical
Background</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Constipation
is one of the most encountered gastrointestinal complaints in clinical practice. A recent systematic review reported that the prevalence
of chronic constipation (CC) in North America is between 10-15%. This condition causes significantly reduced quality of life, reduced
work-related productivity and billions of dollars in health expenditures. Clinical practice guidelines recommend empiric treatment of
chronically constipated patients with fiber supplements or laxative therapies. Approximately 40% of patients do not adequately respond
to empiric laxative therapy. In these patients, anorectal physiology testing is essential.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
is a clinical need for an easy-to-use, office-based, point-of-care, anorectal function test that can measure rectal sensitivity and be
used as a rectal expulsion device to assess pelvic floor dysfunction. Current testing methods typically require elaborate volumetric
testing equipment to assess sensation and expulsion, which makes them not practical in the clinical setting. The current standard is
to refer patients to specialized motility centers for evaluation, resulting in sub-optimal number of patients with constipation undergoing
anal-rectal testing. In the current clinical setting, only about 2% of all patients with constipation are referred for anal-rectal testing
and thus, a large number with pelvic floor dysfunction and rectal hypersensitivity are missed and/or fail to get proper treatment. The
design of RED allows for it to be used as a self-inflating expulsion device and as a balloon to assess patients who experience rectal
hypersensitivity. When it is opened to atmospheric pressure, RED safely self inflates and contains a specially selected foam that mimics
the &#8220;feel&#8221; of stool. This provides an alternative to sensation and expulsion testing in the office without affecting clinical
workflow.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

<!-- Field: Page; Sequence: 15; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Rectal
Sensation Testing</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Rectal
sensation is an important metric to guide clinical care, particularly rectal hypersensitivity. For example, a patient that reports an
immediate perceived immediate need to defecate or discomfort (max tolerated) to low volumes of distension would have rectal hypersensitivity.
This diagnosis is important because it would impact how a patient is treated. Rectal hypersensitivity is addressed by pelvic floor physical
therapists who deliver education and re-training to help the patient align the desire to defecate according to the actual volume of stool
contained within the rectal vault. The basis of sensory re-training during physical therapy involves inflating a balloon in the rectum
until urge threshold is reached. With repeated inflations, the patient learns to associate a given sensory intensity with the inflated
volume. Over time, the balloon is inflated with decreasing volumes and the patient is asked to closely monitor and attend to sensations
experienced. Eventually, new sensory thresholds are established. Unfortunately, because of the difficulty in performing hypersensitivity
testing in routine clinical care, only a small percentage of all patients with constipation undergo anorectal testing in the clinical
setting.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
a recent study, 60 adult patients (mean&#177;standard deviation age of 46.4&#177;17.6 years; 93.3% women) that underwent evaluation
with RED and answered the questions were included in the analysis. One patient did not undergo rectal sensation testing due to suspected
anal fissure and overall, 58 patients were included in the analysis.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
outlined in the figure below, 18 of 58 patients, or 31.%, had rectal hypersensitivity on RED when defined on a single yes/no question
of &#8220;do you feel you have to poop right now&#8221; that evaluates the patient perception to defecate.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><img src="form10-k_024.jpg" alt=""/></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
data suggest that approximately 31% of patients with chronic constipation reported urge to defecate with RED baseline distension volume,
thus meeting the London criteria for hypersensitivity.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Balloon
Expulsion Testing</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">RED
can be used as a rectal expulsion device and in a recent prospective trial of 60 adults with functional constipation (defined by Rome
IV criteria), it was demonstrated to be safe in a clinical setting. It can be quickly performed in the left lateral position (i.e., the
patient lying on their left side) immediately after a rectal examination. Further, it proved to be effective for patients who fail a
trial of laxative therapy. In those patients with constipation who failed laxative treatment, RED was able to reliably identify patients
for whom pelvic floor physical therapy was unlikely to provide substantial benefit (i.e, patients who might be more likely to benefit
from intensifying medical therapy). Patients with an abnormal RED in the left lateral position or commode were likely to respond to pelvic
floor therapy (48.8% to 71.4%, respectively). Also, RED showed very high sensitivity (&gt;95%) to broadly detect evacuation disorders
as a simple screening tool as noted in the table below.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><img src="form10-k_014.jpg" alt="" style="width: 670px"/></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

<!-- Field: Page; Sequence: 16; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>RED
Benefits Over Predicates</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prompt
                                            point of care test allows assessment of patients and potentially changes clinical management.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Identifies
                                            those who would benefit from physical therapy or who would require optimization of laxatives
                                            or addition of secretagogues.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Identifies
                                            many patients with rectal hypersensitivity that otherwise would never get tested.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">RED
                                            finds people that are willing to try physical therapy but don&#8217;t need it.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fits
                                            clinical workflow.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
is an urgent need to better identify patients with pelvic floor abnormalities and/or rectal hypersensitivity. Making the right diagnosis
can impact care and ensure that patients are properly assessed and treated. The figure below demonstrates how RED can impact clinical
decision making.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><img src="form10-k_015.jpg" alt="" style="width: 500px"/></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Overall,
RED is a point-of-care device designed to be used in the office. Rectal sensation is an important component of evaluating pelvic floor
function among patients with chronic constipation. Currently, 98% of clinically appropriate patients do not receive anorectal testing.
The study findings demonstrate that RED impacts clinical decision making by identifying patients who would benefit from physical therapy
or who would require optimization of laxatives. It is also sufficient to qualitatively assess for rectal hypersensitivity which was evident
in almost one-third of patients with chronic constipation failing a trial of fiber/laxatives. It is critical to assess rectal sensation
and balloon expulsion in patients with constipation and/or fecal incontinence.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>RED
Safety</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            tube for RED remains open to room air as the patient defecates. The pressure is therefore
                                            never greater than room air.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            predicate device uses manual inflation with a syringe against resistance. The predicate device
                                            is re-capped so that the patient must defecate an air-filled balloon with low compliance.
                                            The resistance with defecating the predicate is therefore greater than RED, because RED is
                                            more compliant than an air-filled balloon. The RED device is therefore safer with regard
                                            to patients with decreased compliance.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
                                            only is RED safer by design, but there have not been any safety events related to compliance
                                            in MAUDE with the predicate in the last 10 years.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#9679;</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">RED
                                            is more compliant than air or water based on balloon compression data as demonstrated in
                                            the graph below.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><img src="form10-k_025.jpg" alt=""/></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>RED
Reimbursement</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">RED
is billable under CPT 91120. The documentation is Rectal Hypersensitivity at 52-60mL: present/absent.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Intellectual
Property</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
intellectual property consists of patents, trademarks, and trade secrets. Our trade secrets consist of product formulas, research, and
development, and unpatentable know-how, all of which we seek to protect, in part, by confidentiality agreements. To protect our intellectual
property, we rely on a combination of laws and regulations, as well as contractual restrictions. Federal trademark law protects our registered
trademarks. We also rely on the protection of laws regarding unregistered copyrights for certain content we create and trade secret laws
to protect our proprietary technology. To further protect our intellectual property, we enter into confidentiality agreements with our
executive officers and directors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 17; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Trademarks</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has seven (7) registered trademarks, and two (2) allowed pending applications for registration:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 8%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Country</b></span></td>
    <td style="padding-bottom: 1pt; width: 1%">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Trademark</b></span></td>
    <td style="padding-bottom: 1pt; width: 1%">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 8%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Reg.
    No.</b></span></td>
    <td style="padding-bottom: 1pt; width: 1%">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Reg.
    Date</b></span></td>
    <td style="padding-bottom: 1pt; width: 1%">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 47%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Class/Goods</b></span></td>
    <td style="padding-bottom: 1pt; width: 1%">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Status</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">US</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NEURO-STIM
    and Design</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5105257</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">20-Dec-2016</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10
    Int. nerve stimulator apparatus</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Registered</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">US</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NSS
    THE NEUROSTIM SYSTEM and Design</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4905470</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">23-Feb-2016</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10
    Int. nerve stimulator apparatus</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Registered</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">US</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NSS</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4852008</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10-Nov-2015</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10
    Int. Medical apparatus, namely, electrical nerve stimulators; medical device, namely, a non- implantable neurological pain management
    generator, with percutaneously-implantable needle arrays; medical system and apparatus consisting of a non-implantable modulating
    frequency generator, providing neuromodulation therapy to cranial and peripheral nerves; medical system and apparatus consisting
    of implantable arrays for transmitting current into auricular and peri-auricular tissue; medical device for peripheral nerve and
    nerve field stimulation; medical system and apparatus consisting of a non-implantable modulating frequency generator and implantable
    needle arrays for transmitting current into auricular and peri-auricular tissue for use in pain management, namely, patient stimulators
    for auricular and peri-auricular peripheral nerve field neuromodulation therapy; medical apparatus, appliances and instruments for
    peripheral nerve field stimulation in cranial and peripheral nerves and occipital nerve branches, for pain control, headache control,
    control of phantom limb pain, stump pain, reflex sympathetic dystrophy (RSD), peripheral neuropathies and other types of sympathetically
    mediated pain</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Registered</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">US</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">IB-STIM</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5926831</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">03-Dec-2019</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10
    Int. medical apparatus, namely, electrical nerve stimulators; medical device, namely, a non- implantable modulating frequency generator,
    providing neuromodulation therapy to cranial and peripheral nerves; medical apparatus consisting of percutaneously implantable arrays
    for transmitting current into auricular and peri-auricular tissue; medical device for peripheral nerve and nerve field stimulation;
    medical device consisting of a non-implantable modulating frequency generator and percutaneously implantable needle arrays for transmitting
    current into auricular and peri-auricular tissue for use in pain management and FGID (functional gastrointestinal disorders), namely,
    patient stimulator for auricular and peri-auricular peripheral nerve field neuromodulation therapy; medical apparatus, for peripheral
    nerve field stimulation in cranial and peripheral nerves and occipital nerve branches, for pain control, FGID, irritable bowel, functional
    dyspepsia, functional abdominal pain, nausea, functional nausea, abdominal migraine, Crohn&#8217;s Disease, visceral hypersensitivity,
    chronic inflammatory bowel disease, changes in FGID co-morbidities, sleep disturbances, psychological disorders, including mood and
    anxiety, satiety and changes in autonomic nervous system and other types of sympathetically mediated pain</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Registered</span></td></tr>
</table>

<p style="margin: 0">&#160;</p>

<p style="margin: 0"></p>

<!-- Field: Page; Sequence: 18; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 8%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">US</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 10%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">IB-STIM
    and Design</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 8%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5926832</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 10%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">03-Dec-2019</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 47%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10
    Int. medical apparatus, namely, electrical nerve stimulators; medical device, namely, a non- implantable modulating frequency generator,
    providing neuromodulation therapy to cranial and peripheral nerves; medical apparatus consisting of percutaneously implantable arrays
    for transmitting current into auricular and peri-auricular tissue; medical device for peripheral nerve and nerve field stimulation;
    medical device consisting of a non-implantable modulating frequency generator and percutaneously implantable needle arrays for transmitting
    current into auricular and peri-auricular tissue for use in pain management and FGID (functional gastrointestinal disorders), namely,
    patient stimulator for auricular and peri-auricular peripheral nerve field neuromodulation therapy; Medical apparatus, for peripheral
    nerve field stimulation in cranial and peripheral nerves and occipital nerve branches, for pain control, FGID, irritable bowel, functional
    dyspepsia, functional abdominal pain, nausea, functional nausea, abdominal migraine, Crohn&#8217;s Disease, visceral hypersensitivity,
    chronic inflammatory bowel disease, changes in FGID co-morbidities, sleep disturbances, psychological disorders, including mood and
    anxiety, satiety and changes in autonomic nervous system and other types of sympathetically mediated pain</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 12%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Registered</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">US</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">IB-STIM
    AURICULAR STIMULATOR</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5978411</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">04-Feb-2020</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10
    Int. medical apparatus, namely, electrical nerve stimulators; Medical device, namely, a non- implantable modulating frequency generator,
    providing neuromodulation therapy to cranial and peripheral nerves; Medical apparatus consisting of percutaneously implantable arrays
    for transmitting current into auricular and peri-auricular tissue; Medical device for peripheral nerve and nerve field stimulation;
    Medical device consisting of a non-implantable modulating frequency generator and percutaneously implantable needle arrays for transmitting
    current into auricular and peri-auricular tissue for use in pain management and FGID (functional gastrointestinal disorders), namely,
    patient stimulator for auricular and peri-auricular peripheral nerve field neuromodulation therapy; Medical apparatus, for peripheral
    nerve field stimulation in cranial and peripheral nerves and occipital nerve branches, for pain control, FGID, irritable bowel, functional
    dyspepsia, functional abdominal pain, nausea, functional nausea, abdominal migraine, Crohn&#8217;s Disease, visceral hypersensitivity,
    chronic inflammatory bowel disease, changes in FGID co-morbidities, sleep disturbances, psychological disorders, including mood and
    anxiety, satiety and changes in autonomic nervous system and other types of sympathetically mediated pain</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Registered</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">US</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">IB-STIM
    AURICULAR STIMULATOR and Design</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5978412</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">04-Feb-2020</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10
    Int. medical apparatus, namely, electrical nerve stimulators; medical device, namely, a non- implantable modulating frequency generator,
    providing neuromodulation therapy to cranial and peripheral nerves; medical apparatus consisting of percutaneously implantable arrays
    for transmitting current into auricular and peri-auricular tissue; medical device for peripheral nerve and nerve field stimulation;
    medical device consisting of a non-implantable modulating frequency generator and percutaneously implantable needle arrays for transmitting
    current into auricular and peri-auricular tissue for use in pain management and FGID (functional gastrointestinal disorders), namely,
    patient stimulator for auricular and peri-auricular peripheral nerve field neuromodulation therapy; medical apparatus, for peripheral
    nerve field stimulation in cranial and peripheral nerves and occipital nerve branches, for pain control, FGID, irritable bowel, functional
    dyspepsia, functional abdominal pain, nausea, functional nausea, abdominal migraine, Crohn&#8217;s Disease, visceral hypersensitivity,
    chronic inflammatory bowel disease, changes in FGID co-morbidities, sleep disturbances, psychological disorders, including mood and
    anxiety, satiety and changes in autonomic nervous system and other types of sympathetically mediated pain</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Registered</span></td></tr>

</table>

<p style="margin: 0">&#160;</p>

<p style="margin: 0"></p>

<!-- Field: Page; Sequence: 19; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="border-bottom: Black 1pt solid; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-align: center"><b>Country</b></td>
    <td style="text-align: center; padding-bottom: 1pt; vertical-align: bottom">&#160;</td>
    <td style="border-bottom: Black 1pt solid; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-align: center"><b>Trademark</b></td>
    <td style="text-align: center; padding-bottom: 1pt; vertical-align: bottom">&#160;</td>
    <td style="border-bottom: Black 1pt solid; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-align: center"><b>App. No.</b></td>
    <td style="text-align: center; padding-bottom: 1pt; vertical-align: bottom">&#160;</td>
    <td style="border-bottom: Black 1pt solid; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-align: center"><b>App. Date</b></td>
    <td style="text-align: center; padding-bottom: 1pt; vertical-align: bottom">&#160;</td>
    <td style="border-bottom: Black 1pt solid; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-align: center"><b>Class/Goods</b></td>
    <td style="text-align: center; padding-bottom: 1pt; vertical-align: bottom">&#160;</td>
    <td style="border-bottom: Black 1pt solid; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-align: center"><b>Status</b></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 8%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">US</span></td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 10%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NEURAXIS</span></td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 8%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">97/327951
    </span></td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 10%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;04-Mar-2022</span></td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 47%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10
    Int. Nerve stimulator apparatus; nerve stimulator apparatus for FGID, irritable bowel, functional dyspepsia, functional abdominal
    pain, nausea, functional nausea, abdominal migraine, Crohn&#8217;s Disease, visceral hypersensitivity, chronic inflammatory bowel
    disease, changes in FGID co- morbidities, sleep disturbances, psychological disorders, including mood, anxiety, and satiety, pain
    control, headache control, control of phantom limb pain, stump pain, reflex sympathetic dystrophy (RSD), peripheral neuropathies
    and other types of sympathetically mediated pain</span></td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 12%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Filed:
    Allowed</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">US</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NEURAXIS
    (STYLIZED)</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;97/356330</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">11-Apr-2022
    </span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10
    Int. Nerve stimulator apparatus; nerve stimulator apparatus for FGID, irritable bowel, functional dyspepsia, functional abdominal
    pain, nausea, functional nausea, abdominal migraine, Crohn&#8217;s Disease, visceral hypersensitivity, chronic inflammatory bowel
    disease, changes in FGID co- morbidities, sleep disturbances, psychological disorders, including mood, anxiety, and satiety, pain
    control, headache control, control of phantom limb pain, stump pain, reflex sympathetic dystrophy (RSD), peripheral neuropathies
    and other types of sympathetically mediated pain</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Filed:
    Allowed</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has no core trademarks that are currently unregistered.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Patents</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has twelve (12) granted patents in the United States and seven (7) applied for patent applications in the United States and one
(1) granted foreign patent and two (2) applied for foreign patent applications.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 8%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Country</b></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 8%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Owner</b></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 8%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Serial
    No.</b></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 8%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Actual
    Filing Date</b></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 8%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Patent
    No.</b></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 8%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Issue
    Date</b></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 8%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Anticipated
    Expiration Date</b></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 19%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Title</b></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 8%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Application
    Status</b></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 8%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Licensing
    Status</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">CA</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Neuraxis,
    Inc.</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3096494</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">25-Apr-2019</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">AURICULAR
    NERVE FIELD STIMULATION DEVICE</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Applied
    for</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">JP</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Neuraxis,
    Inc.</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2021-509961</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">23-Oct-2020</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;7252319</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">27-March-2023
    </span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;25-April-2039</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">AURICULAR
    NERVE FIELD STIMULATION DEVICE</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Granted</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">US</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Neuraxis,
    Inc.</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">17/040766</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">23-Sep-2020</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">11369791</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">28-Jun-2022</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">21-Jun-2039</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">AURICULAR
    NERVE FIELD STIMULATION DEVICE</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Granted</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">US</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Neuraxis,
    Inc.</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">17/715121</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">07-Apr-2022</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">12097371
    </span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;24-Sept-2024</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;04-Jan-2040</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">AURICULAR
    NERVE FIELD STIMULATION DEVICE</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Granted</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">US</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Neuraxis,
    Inc.</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">16/014169</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">21-Jun-2018</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10322062</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">18-Jun-2019</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">14-May-2034</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">AURICULAR
    PERIPHERAL NERVE FIELD STIMULATOR AND METHOD OF OPERATING SAME</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Granted</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Out-licensed</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">US</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Neuraxis,
    Inc.</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">16/408004</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">09-May-2019</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">11077019</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">03-Aug-2021</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">16-July-2034</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">AURICULAR
    PERIPHERAL NERVE FIELD STIMULATOR AND METHOD OF OPERATING SAME</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Granted</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Out-licensed</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">US</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Neuraxis,
    Inc.</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">17/363620</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">30-Jun-2021
    </span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">11654082
    </span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">23-May-2023
    </span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;29-July-2034</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">AURICULAR
    PERIPHERAL NERVE FIELD STIMULATOR AND METHOD OF OPERATING SAME</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Granted</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Out-licensed
    </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">US</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Neuraxis,
    Inc.</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;17/830411</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">02-Jun-2022</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">DEVICE
    AND METHOD FOR ERADICATING PATHOGENS IN NASAL PASSAGES</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Applied
    for</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">US</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Neuraxis,
    Inc.</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">17/589082</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">31-Jan-2022</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">EXTERNAL
    AUDITORY CANAL PHOTOBIOMODULATION AND AUDIO THERAPY DEVICE</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Applied
    for</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
</table>

<p style="margin: 0">&#160;</p>

<p style="margin: 0"></p>

<!-- Field: Page; Sequence: 20; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">US</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Neuraxis,
    Inc.</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;17/861646</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">11-Jul-2022</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">EXTERNAL
    AUDITORY CANAL THERAPY DEVICE</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Applied
    for</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">US</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Neuraxis,
    Inc.</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">17/617364</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">08-Dec-2021</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">EXTERNAL
    AUDITORY CANAL PHOTOBIOMODULATION DEVICE</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Applied
    for</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">US</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Neuraxis,
    Inc.</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">15/488416</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">14-Apr-2017</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10413719</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">17-Sep-2019</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">14-April-2037</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">METHODS
    OF TREATING DISEASE USING AURICULAR PERIPHERAL NERVE FIELD STIMULATION</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Granted</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Out-licensed</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">US</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Neuraxis,
    Inc.</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">16/534159</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">07-Aug-2019</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">11331473</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">17-May-2022</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">14-April-2037</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">METHODS
    OF TREATING DISEASE USING AURICULAR PERIPHERAL NERVE FIELD STIMULATION</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Granted</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">US</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Neuraxis,
    Inc.</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">15/595185</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">15-May-2017</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">9839577</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">12-Dec-2017</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">14-May-2034</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">SYSTEM
    AND METHOD FOR AURICULAR PERIPHERAL NERVE FIELD STIMULATION</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Granted</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Out-licensed</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">US</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Neuraxis,
    Inc.</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">15/811278</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">13-Nov-2017</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10010479</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">03-Jul-2018</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">14-May-2034</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">SYSTEM
    AND METHOD FOR AURICULAR PERIPHERAL NERVE FIELD STIMULATION</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Granted</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Out-licensed</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">US</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Neuraxis,
    Inc.</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">14/277158</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">14-May-2014</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">9662269</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">30-May-2017</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">14-May-2034</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">SYSTEMS
    AND METHODS FOR AURICULAR PERIPHERAL NERVE FIELD STIMULATION</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Granted</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Out-licensed</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">US</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Neuraxis,
    Inc.</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">17/725,761</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">21-Apr-2022</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">11813448</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;14-Nov-2023</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;14-April-2037
    </span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">AURICULAR
    NERVE FIELD STIMULATION DEVICE AND METHODS FOR USING THE SAME</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Granted</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 8%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">US</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 8%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Neuraxis,
    Inc.</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 8%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">18/154,375</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 8%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">13-Jan-2023</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 8%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">12029701</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 8%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">09-July-2024</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 8%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">14-May-2034</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 19%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">AURICULAR
    PERIPHERAL NERVE FIELD STIMULATOR AND METHOD OF OPERATING SAME</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 8%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Granted</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 8%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Out-licensed</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">US</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Neuraxis,
    Inc.</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">18/736,834</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">07-June-2024</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">AURICULAR
    PERIPHERAL NERVE FIELD STIMULATOR AND METHOD OF OPERATING SAME</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Applied
    for</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Out-licensed</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">US</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Neuraxis,
    Inc.</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">18/173,893</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">24-Feb-2023</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">AURICULAR
    NERVE FIELD STIMULATION DEVICE AND METHODS FOR USING THE SAME</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Applied
    for</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">US</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Neuraxis,
    Inc.</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">18/377,968</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">09-Oct-2023</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">AURICULAR
    NERVE FIELD STIMULATION DEVICE AND METHODS FOR USING THE SAME</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Applied
    for</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">CA</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Neuraxis,
    Inc.</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3243826</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">07-Aug-2024</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">AURICULAR
    NERVE FIELD STIMULATION DEVICE AND METHODS FOR USING THE SAME</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Applied
    for</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 21; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>License
Agreements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>TKBMN
Exclusive License Agreement</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 7, 2020, the Company entered into an exclusive license agreement with TKBMN, LLC to obtain an exclusive license under certain patent
rights (the &#8220;Patent Rights&#8221;) owned by TKBMN. Dr. Thomas Carrico, our Chief Regulatory Officer, is the manager of TKBMN. Brian
Carrico, our Chief Executive Officer, and Matt Carrico, our National Sales Director, are members of TKBMN. TKBMN owns the Patent Rights
set forth in the patents listed in the following table (the &#8220;TKBMN Patents&#8221;) by virtue of an assignment from Dr. Carrico,
who is the sole inventor listed on the TKBMN Patents. TKBMN has assigned the auricular portion of the TKBMN Patent Rights to the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Licensed
TKBMN Patents</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 10%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Country</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; vertical-align: top; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 10%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Owner</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; vertical-align: top; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 14%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Application
    No.</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; vertical-align: top; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 10%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Patent
    No.</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; vertical-align: top; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 12%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Issue
    Date</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; vertical-align: top; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 14%"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Anticipated</b></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Expiration</b></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Date*</b></span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; vertical-align: top; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 24%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Title</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">US</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">TKBMN,
    LLC</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">15/981,082</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10,792,500</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">October
    2, 2020</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">October
    18, 2037</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Systems
    and methods for electro-therapy treatment</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">US</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">TKBMN,
    LLC</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">17/014,450</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">11,684,782</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">June
    7, 2023</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">October
    18, 2037</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Systems
    and methods for electro-therapy treatment</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*
If all maintenance fees remain paid</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the exclusive license agreement, TKBMN agreed to grant an exclusive, worldwide, non-transferable, royalty-free license under Patent
Rights, which including three patents applications filed by TKBMN in connection with systems and methods for elector-therapy treatment,
to the Company to develop, market, and sell licensed products, in the field of electro-therapy treatment by stimulation of cranial nerves,
cranial nerve branches, auricular nerves, auricular nerve branches, auricular nerve bundles, and/or auricular anatomical structures in
human patients (the &#8220;Field&#8221;), in consideration of a one-time license fee of $1.00. The Company has the right to grant sublicenses
to the Patents Rights in the Field. The exclusive license agreement expires upon the expiration of the last to expire valid claim within
the Patent Rights and may be terminated by the Company upon 60 days prior written notice. Upon expiration or termination of the exclusive
license agreement, all rights in the Patent Rights will revert to TKBMN. There are no royalties or any other form of committed revenue
to TKBMN or any of its members Under the agreement, the Company has agreed to cover fees and expenses associated with maintenance, prosecution,
and additional associated/continuation patent filings for the TKBMN Patents.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Masimo
License and Collaboration Agreement</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
April 9, 2020, the Company entered into a license and collaboration agreement with Masimo. As consideration, in part, Masimo entered
into a Series A Preferred Stock purchase agreement with the Company. Under the license and collaboration agreement, the Company grants
an exclusive, fully paid-up, royalty-free license to specifically identified patents and trademarks in a limited Field of use. At all
times, the Company remains the owner of all licensed intellectual property rights, and there is a possibility of joint ownership of collaboratively
developed products and methods. The licensed patents are generally directed to a device and the treatment of opioid withdrawal symptoms.
The licensed trademarks are generally directed to the NSS-2 Bridge mark. The license agreement includes a collaboration component to
efficiently develop, obtain regulatory approval, and commercialize products for the limited field of use. The term of the agreement is
in effect until the expiration or lapse of the last intellectual property rights. Masimo paid a one-time fee of $250,000. The license
and collaboration agreement may not be terminated by the Company for any reason, and the sole remedy for any breach or default by Masimo
shall be to seek monetary damages and equitable remedies. The license and collaboration agreement may be terminated by Masimo if there
is material breach by the Company that remain uncured for thirty (30) days or without cause by providing thirty (30) days prior written
notice. See<i>&#8221;&#8212;Our Corporate History</i>&#8221; for more information.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Implications
of Being a Smaller Reporting Company</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are a &#8220;smaller reporting company&#8221; as defined in Rule 10(f)(1) of Regulation S-K. Smaller reporting companies may take advantage
of certain reduced disclosure obligations, including, among other things, providing only two years of audited financial statements. We
will remain a smaller reporting company until the last day of the fiscal year in which (1) the market value of our shares held by non-affiliates
equals or exceeds $250 million as of the prior June 30<sup>th</sup>, or (2) our annual revenues equaled or exceeded $100 million during
such completed fiscal year and the market value of our shares held by non-affiliates equals or exceeds $700 million as of the prior June
30<sup>th</sup>. Such reduced disclosure and corporate governance obligations may make it more challenging for investors to analyze our
results of operations and financial prospects.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
additional information, see &#8220;<i>Risk Factors &#8211; Because the Company is a &#8216;smaller reporting company,&#8217; we may take
advantage of certain scaled disclosures available to us, resulting in holders of our securities receiving less Company information than
they would receive from a public company that is not a smaller reporting company&#8221; and &#8220;As a smaller reporting company,&#8221;
we may at some time in the future choose to exempt our Company from certain corporate governance requirements that could have an adverse
effect on our public stockholders.&#8221;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 22; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Implications
of Being an Emerging Growth Company</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are an &#8220;emerging growth company&#8221; as defined in the JOBS Act. We will remain an emerging growth company until the earlier
of (1) December 31, 2028, (2) the last day of the fiscal year in which we have total annual gross revenue of at least $1.235 billion,
(3) the last day of the fiscal year in which we are deemed to be a &#8220;large accelerated filer&#8221; as defined in Rule 12b-2 under
the Securities Exchange Act of 1934, as amended, or the Exchange Act, which would occur on the date on which we have issued more than
$1.0 billion in non-convertible debt securities during the prior three-year period. An emerging growth company may take advantage of
specified reduced reporting requirements and is relieved of certain other significant requirements that are otherwise generally applicable
to public companies. As an emerging growth company, we may:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">present
    only two years of audited financial statements, plus unaudited condensed financial statements for any interim period, and related
    management&#8217;s discussion and analysis of financial condition and results of operations in this prospectus;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">avail
    ourselves of the exemption from the requirement to obtain an attestation and report from our auditors on the assessment of our internal
    control over financial reporting pursuant to the Sarbanes-Oxley Act of 2002;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">provide
    reduced disclosure about our executive compensation arrangements; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">not
    require stockholder non-binding advisory votes on executive compensation or golden parachute arrangements.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, under the JOBS Act, an emerging growth company can delay the adoption of certain accounting standards until those standards
would otherwise apply to private companies. We have elected not to take advantage of the extended transition period for complying with
new or revised accounting standards provided to emerging growth companies under the JOBS Act.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Government
Regulation</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
products and our operations are subject to extensive regulation by the U.S. Food and Drug Administration, or FDA, and other federal,
state, and local authorities in the United States, as well as comparable authorities in foreign jurisdictions. Our products are subject
to regulation as medical devices in the United States under the Federal Food, Drug, and Cosmetic Act, or FDCA, and its implementing regulations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>United
States Regulation</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
FDA regulates, among other things, the development, design, non-clinical and clinical testing, manufacturing, safety, effectiveness,
labeling, packaging, storage, installation, servicing, recordkeeping, premarket clearance or approval, adverse event reporting, advertising,
promotion, marketing and distribution, and import and export and post-marketing surveillance of medical devices in the United States
to ensure that medical devices distributed domestically are safe and effective for their intended uses and otherwise meet the requirements
of the FDCA.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 23; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>FDA
Premarket Clearance and Approval Requirements</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unless
an exemption applies, each new or significantly modified medical device commercially distributed in the United States requires FDA clearance
of a 510(k) premarket notification. The 510(k) clearance can be resource intensive, expensive, and lengthy.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the FDCA, medical devices are classified into one of three classes&#8212;Class I, Class II or Class III&#8212;depending on the degree
of risk associated with each medical device and the extent of manufacturer and regulatory control needed to ensure its safety and effectiveness.
Class I devices are those for which safety and effectiveness can be assured by adherence to the FDA&#8217;s general controls for medical
devices, which include compliance with the applicable portions of FDA&#8217;s current good manufacturing practices for devices, as reflected
in the Quality System Regulation, or QSR, establishment registration and device listing, reporting of adverse medical events, and truthful
and non-misleading labeling, advertising, and promotional materials. Some Class I devices, also called Class I reserved devices, also
require premarket clearance by the FDA through the 510(k) premarket notification process described below. Most Class I devices are exempt
from the premarket notification requirements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Class
II devices are subject to the FDA&#8217;s general controls, and any other special controls deemed necessary by the FDA to ensure the
safety and effectiveness of the device. These special controls can include performance standards, special labeling requirements, post-market
surveillance, patient registries and FDA guidance documents.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Most
Class II devices are required to submit to the FDA a premarket notification under Section 510(k) of the FDCA requesting permission to
commercially distribute the device. The FDA&#8217;s permission to commercially distribute a device subject to a 510(k) premarket notification
is generally known as 510(k) clearance.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
a new medical device does not qualify for the 510(k) premarket notification process because no predicate device to which it is substantially
equivalent can be identified, the device is automatically classified into Class III. The Food and Drug Administration Modernization Act
of 1997 established a new route to market for low to moderate risk medical devices that are automatically placed into Class III due to
the absence of a predicate device, called the &#8220;Request for Evaluation of Automatic Class III Designation,&#8221; or the de novo
classification process. This process allows a manufacturer whose novel device is automatically classified into Class III to request down-classification
of its medical device into Class I or Class II on the basis that the device presents low or moderate risk. If the manufacturer seeks
reclassification into Class II, the manufacturer must include a draft proposal for special controls that are necessary to provide a reasonable
assurance of the safety and effectiveness of the medical device. The FDA may reject the reclassification petition if it identifies a
legally marketed predicate device that would be appropriate for a 510(k) or that general controls would be inadequate to control the
risks and special controls cannot be developed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Obtaining
FDA marketing authorization, de novo down-classification, or approval for medical devices is expensive and uncertain, and may take several
years, and generally requires significant scientific and clinical data.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Some
pre-amendment devices are unclassified, but are subject to FDA&#8217;s premarket notification and clearance process in order to be commercially
distributed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Investigational
Device Process</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Clinical
trials are sometimes required to support a 510(k) submission. In the United States, absent certain limited exceptions, human clinical
trials intended to support medical device clearance or approval or to determine safety and effectiveness of a device for an investigational
use must be conducted in accordance with the FDA&#8217;s investigational device exemption, or IDE, regulations which govern investigational
device labeling, prohibit promotion of the investigational device, and specify an array of recordkeeping, reporting and monitoring responsibilities
of study sponsors and study investigators. If the device presents a &#8220;significant risk,&#8221; to human health, as defined by the
FDA, the FDA requires the device sponsor to submit an IDE application to the FDA, which must become effective prior to commencing human
clinical trials. The IDE application must be supported by appropriate data, such as animal and laboratory testing results, showing that
it is safe to test the device in humans and that the testing protocol is scientifically sound. The IDE application must be approved in
advance by the FDA for a specified number of subjects. Generally, clinical trials for a significant risk device may begin once the IDE
application is approved by the FDA and the study protocol and informed consent are approved by appropriate institutional review boards
at the clinical trial sites. There can be no assurance that submission of an IDE will result in the ability to commence clinical trials,
and although the FDA&#8217;s approval of an IDE allows clinical testing to go forward for a specified number of subjects, it does not
bind the FDA to accept the results of the trial as sufficient to prove the product&#8217;s safety and effectiveness, even if the trial
meets its intended success criteria.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 24; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
the device under evaluation does not present a significant risk to human health, then the device sponsor is not required to submit an
IDE application to the FDA before initiating human clinical trials, but must still comply with abbreviated IDE requirements when conducting
such trials. A significant risk device is one that presents a potential for serious risk to the health, safety or welfare of a patient
and either is implanted, used in supporting or sustaining human life, substantially important in diagnosing, curing, mitigating or treating
disease or otherwise preventing impairment of human health, or otherwise presents a potential for serious risk to a subject. An IDE application
must be supported by appropriate data, such as animal and laboratory test results, showing that it is safe to test the device in humans
and that the testing protocol is scientifically sound. The IDE will automatically become effective thirty (30) days after receipt by
the FDA unless the FDA notifies the company that the investigation may not begin. If the FDA determines that there are deficiencies or
other concerns with an IDE for which it requires modification, the FDA may permit a clinical trial to proceed under a conditional approval.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Regardless
of the degree of risk presented by the medical device, clinical studies must be approved by, and conducted under the oversight of, an
Institutional Review Board, or IRB, for each clinical site. The IRB is responsible for the initial and continuing review of the IDE,
and may pose additional requirements for the conduct of the study. If an IDE application is approved by the FDA and one or more IRBs,
human clinical trials may begin at a specific number of investigational sites with a specific number of patients, as approved by the
FDA. If the device presents a non-significant risk to the patient, a sponsor may begin the clinical trial after obtaining approval for
the trial by one or more IRBs without separate approval from the FDA, but must still follow abbreviated IDE requirements, such as monitoring
the investigation, ensuring that the investigators obtain informed consent, and labeling and record-keeping requirements. Acceptance
of an IDE application for review does not guarantee that the FDA will allow the IDE to become effective and, if it does become effective,
the FDA may or may not determine that the data derived from the trials support the safety and effectiveness of the device or warrant
the continuation of clinical trials. An IDE supplement must be submitted to, and approved by, the FDA before a sponsor or investigator
may make a change to the investigational plan that may affect its scientific soundness, study plan or the rights, safety or welfare of
human subjects.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
a study, the sponsor is required to comply with the applicable FDA requirements, including, for example, trial monitoring, selecting
clinical investigators and providing them with the investigational plan, ensuring IRB review, adverse event reporting, record keeping
and prohibitions on the promotion of investigational devices or on making safety or effectiveness claims for them. The clinical investigators
in the clinical study are also subject to FDA&#8217;s regulations and must obtain patient informed consent, rigorously follow the investigational
plan and study protocol, control the disposition of the investigational device, and comply with all reporting and recordkeeping requirements.
Additionally, after a trial begins, we, the FDA or the IRB could suspend or terminate a clinical trial at any time for various reasons,
including the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    FDA or other regulatory authorities do not approve a clinical trial protocol or a clinical trial, or place a clinical trial on hold;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Patients
    do not enroll in clinical trials at the rate expected;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Patients
    do not comply with trial protocols;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Patient
    follow-up is not at the rate expected;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Patients
    experience serious adverse events;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Patients
    die during a clinical trial, even though their death may not be related to the products that are part of the trial;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Device
    malfunctions occur with unexpected frequency or potential adverse consequences;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Side
    effects or device malfunctions of similar products already in the market that change the FDA&#8217;s view toward approval of result
    in the imposition of new requirements or testing;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 25; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Institutional
    review boards and third-party clinical investigators may delay or reject the trial protocol;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Third-party
    clinical investigators decline to participate in a trial or do not perform a trial on the anticipated schedule or consistent with
    the clinical trial protocol, investigator agreement, investigational plan, good clinical practices, the IDE regulations, or other
    FDA or IRB requirements;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Third-party
    investigators are disqualified by the FDA;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    or third-party organizations do not perform data collection, monitoring and analysis in a timely or accurate manner or consistent
    with the clinical trial protocol or investigational or statistical plans, or otherwise fail to comply with the IDE regulations governing
    responsibilities, records, and reports of sponsors of clinical investigations;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Third-party
    clinical investigators have significant financial interests related to us or our study such that the FDA deems the study results
    unreliable, or the company or investigators fail to disclose such interests;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Regulatory
    inspections of our clinical trials or manufacturing facilities, which may, among other things, require us to undertake corrective
    action or suspend or terminate our clinical trials;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Changes
    in government regulations or administrative actions;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    interim or final results of the clinical trial are inconclusive or unfavorable as to safety or effectiveness; or</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    FDA concludes that our trial design is unreliable or inadequate to demonstrate safety and effectiveness.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>510(k)
Clearance Process</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the 510(k) process, the manufacturer must submit to the FDA a premarket notification submission demonstrating that the proposed device
is &#8220;substantially equivalent,&#8221; as defined in the FDCA, to a legally marketed predicate device.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
predicate device is a legally marketed device that is not subject to premarket approval, i.e., a device that was legally marketed prior
to May 28, 1976 (pre-amendments device) and for which a PMA is not required, a device that has been reclassified from Class III to Class
II or I, or a device that was found substantially equivalent through the 510(k) process. A device is considered to be substantially equivalent
if, with respect to the predicate device, it has the same intended use and has either (i) the same technological characteristics; or
(ii) different technological characteristics, but the information provided in the 510(k) submission demonstrates that the device does
not raise different questions of safety or effectiveness than the predicate device.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Before
the FDA will accept a 510(k) premarket notification for substantive review, the FDA will first assess whether the submission satisfies
a minimum threshold of acceptability. If the FDA determines that the 510(k) submission lacks necessary information for substantive review,
the FDA will issue a &#8220;Refuse to Accept&#8221; letter which generally outlines the information the FDA believes is necessary to
permit a substantive review and to reach a determination regarding substantial equivalence. An applicant must submit the requested information
before the FDA will proceed with additional review of the submission. If a 510(k) submission is accepted for substantive review, the
Medical Device User Fee Amendments sets a performance goal of 90 days for FDA review of a 510(k) submission, but the review time can
be delayed if FDA raises questions or requests additional information during the review process. As a practical matter, clearance often
takes longer, and clearance is never assured. Thus, as a practical matter, clearance often takes longer than 90 days. Although many 510(k)
premarket notifications are cleared without clinical data, the FDA may require further information, including clinical data, to make
a determination regarding substantial equivalence, which may significantly prolong the review process. If the FDA agrees that the device
is substantially equivalent, it will grant clearance to commercially market the device.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 26; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
the FDA determines that the device is substantially equivalent to a predicate device, it will grant 510(k) clearance to commercially
market the device. If the FDA determines that the device is &#8220;not substantially equivalent&#8221; to a previously cleared device,
the device is automatically designated as a Class III device. The device sponsor must then fulfill more rigorous requirements of the
PMA approval process, or can request a risk-based classification determination for the device in accordance with the &#8220;<i>de novo</i>&#8221;
process, which is a route to market for certain novel medical devices that are low to moderate risk and are not substantially equivalent
to a predicate device.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Medical
devices can only be marketed for the indications for use for which they are cleared or approved. After a device receives 510(k) clearance,
any modification that could significantly affect its safety or effectiveness, or that would constitute a major change or modification
in its intended use, will require a new 510(k) clearance or, depending on the modification, PMA approval or <i>de novo</i> reclassification.
The FDA requires each manufacturer to determine whether the proposed change requires submission of a 510(k), <i>de novo</i> request or
a PMA in the first instance, but the FDA may review this determination to evaluate the regulatory status of the modified product at any
time and may require the manufacturer to cease marketing and/or request the recall of the modified device until 510(k) marketing clearance
or PMA approval is obtained or a <i>de novo</i> request is granted. Also, in these circumstances, the manufacturer may be subject to
significant regulatory fines or penalties.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Over
the last several years, the FDA has proposed reforms to its 510(k) clearance process, and such proposals could include increased requirements
for clinical data and a longer review period, or could make it more difficult for manufacturers to utilize the 510(k) clearance process
for their products. For example, in November 2018, FDA officials announced steps that the FDA intended to take to modernize the premarket
notification pathway under Section 510(k) of the FDCA. Among other things, the FDA announced that it planned to develop proposals to
drive manufacturers utilizing the 510(k) pathway toward the use of newer predicates. These proposals included plans to potentially sunset
certain older devices that were used as predicates under the 510(k) clearance pathway, and to potentially publish a list of devices that
have been cleared on the basis of demonstrated substantial equivalence to predicate devices that are more than 10 years old. These proposals
have not yet been finalized or adopted, although the FDA may work with Congress to implement such proposals through legislation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">More
recently, in September 2019, the FDA issued revised final guidance describing an optional &#8220;safety and performance based&#8221;
premarket review pathway for manufacturers of &#8220;certain, well-understood device types&#8221; to demonstrate substantial equivalence
under the 510(k) clearance pathway by showing that such device meets objective safety and performance criteria established by the FDA,
thereby obviating the need for manufacturers to compare the safety and performance of their medical devices to specific predicate devices
in the clearance process. The FDA has developed and maintains a list device types appropriate for the &#8220;safety and performance based&#8221;
pathway and continues to develop product-specific guidance documents that identify the performance criteria for each such device type,
as well as recommended testing methods, where feasible.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>PMA
Approval Process</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Class
III devices require PMA approval before they can be marketed, although some pre-amendment Class III devices for which FDA has not yet
required a PMA are cleared through the 510(k) process. The PMA process is more demanding than the 510(k) premarket notification process.
In a PMA, the manufacturer must demonstrate that the device is safe and effective for its intended use, and the PMA must be supported
by extensive data, including data from preclinical studies and human clinical trials. The PMA must also contain a full description of
the device and its components, a full description of the methods, facilities, and controls used for manufacturing, and proposed labeling.
Following receipt of a PMA, the FDA conducts an administrative review to determine whether the application is sufficiently complete to
permit a substantive review. If it is not, the agency will refuse to file the PMA. If FDA accepts the application for substantive review,
it has 180 days under the FDCA to complete its review of a filed PMA application, although in practice, the FDA&#8217;s review often
takes significantly longer, and can take up to several years. During this review period, the FDA may request additional information or
clarification of information already provided, and the FDA may issue a major deficiency letter to the applicant, requesting the applicant&#8217;s
response to deficiencies communicated by the FDA. The FDA considers a PMA or PMA supplement to have been voluntarily withdrawn if an
applicant fails to respond to an FDA request for information (e.g., major deficiency letter) within a total of 360 days. Before approving
or denying a PMA application, an advisory panel of experts from outside the FDA may be convened to review and evaluate the application
and provide recommendations to the FDA as to whether the FDA should approve the submission, approve it with specific conditions, or not
approve it. The FDA may or may not accept the panel&#8217;s recommendation. Prior to approval of a PMA, the FDA may conduct inspections
of the clinical trial data and clinical trial sites, as well as conduct inspections of the applicant or its third-party manufacturers&#8217;
or suppliers&#8217; manufacturing facility or facilities to, among other things, ensure compliance with the QSR. PMA applications are
also subject to the payment of user fees, which for fiscal year 2021 includes a standard application fee of $365,657.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 27; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Overall,
    the FDA review of a PMA application generally takes between one and three years, but may take significantly longer. The FDA can delay,
    limit or deny approval of a PMA application for many reasons, including:</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    device may not be shown safe or effective to the FDA&#8217;s satisfaction;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    data from pre-clinical studies and/or clinical trials may be found unreliable or insufficient to support approval;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    manufacturing process or facilities may not meet applicable requirements; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Changes
    in FDA approval policies or adoption of new regulations may require additional data.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
the FDA evaluation of a PMA is favorable, the FDA will issue either an approval letter, or an approvable letter, the latter of which
usually contains a number of conditions that must be met in order to secure final approval of the PMA. When and if those conditions have
been fulfilled to the satisfaction of the FDA, the agency will issue a PMA approval letter authorizing commercial marketing of the device,
subject to the conditions of approval and the limitations established in the approval letter. The FDA may approve a PMA with post-approval
conditions intended to ensure the safety and effectiveness of the device, including, among other things, restrictions on labeling, promotion,
sale and distribution, and collection of long-term follow-up data from patients in the clinical study that supported PMA approval or
requirements to conduct additional clinical studies post-approval. The FDA may condition PMA approval on some form of post-market surveillance
when deemed necessary to protect the public health or to provide additional safety and effectiveness data for the device in a larger
population or for a longer period of use. In such cases, the manufacturer might be required to follow certain patient groups for a number
of years and to make periodic reports to the FDA on the clinical status of those patients. Failure to comply with the conditions of approval
can result in material adverse enforcement action, including withdrawal of the approval. If the FDA&#8217;s evaluation of a PMA application
or manufacturing facilities is not favorable, the FDA will deny approval of the PMA or issue a not approvable letter. The FDA also may
determine that additional tests or clinical trials are necessary, in which case the PMA approval may be delayed for several months or
years while the trials are conducted and data is submitted in an amendment to the PMA, or the PMA is withdrawn and resubmitted when the
data are available. The PMA process can be expensive, uncertain and lengthy and a number of devices for which the FDA approval has been
sought by other companies have never been approved by the FDA for marketing.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain
changes to an approved medical device, such as changes in manufacturing facilities, methods, quality control procedures, sterilization
(if applicable), packaging, expiration date, labeling, device specifications, materials, or design of a device, or other changes which
affect the safety or effectiveness of the device that has been approved through the PMA process require submission of a new PMA or PMA
supplement. PMA supplements often require submission of the same type of information as a PMA, except that the supplement is limited
to information needed to support any changes from the device covered by the original, approved PMA and may not require as extensive clinical
data or the convening of an advisory panel, depending on the nature of the proposed change. Certain other changes to an approved device
require the submission of a new PMA, such as when the design change causes a different intended use, mode of operation, and technical
basis of operation, or when the design change is so significant that a new generation of the device will be developed, and the data that
were submitted with the original PMA are not applicable for the change in demonstrating a reasonable assurance of safety and effectiveness.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 28; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Ongoing
Regulation by the FDA</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Even
after the FDA permits a device to be marketed, numerous and pervasive regulatory requirements continue to apply. These include:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Establishment
    registration and device listing with the FDA;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">QSR
    requirements, which require manufacturers, including third-party manufacturers, to follow stringent design, testing, control, supplier/contractor
    selection, compliant handling, documentation and other quality assurance procedures during all aspects of the design and manufacturing
    process;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Labeling
    regulations, advertising and promotion requirements, restrictions on sale, distribution or sale of a device, each including the FDA
    prohibition against the promotion of products for any uses other than those authorized by the FDA, which are commonly known as &#8220;off-label&#8221;
    uses;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Medical Device Reporting, or MDR, regulations, which require that a manufacturer report to the FDA if a device it markets may have
    caused or contributed to a death or serious injury, or has malfunctioned and the device or a similar device that it markets would
    be likely to cause or contribute to a death or serious injury, if the malfunction were to recur;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Medical
    device correction and removal reporting regulations, which require that manufacturers report to the FDA field corrections or removals
    if undertaken to reduce a risk to health posed by the device or to remedy a violation of the FDCA that may present a risk to health;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Recall
    requirements, including a mandatory recall if there is a reasonable probability that the device would cause serious adverse health
    consequences or death;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 72px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">An
    order of repair, replacement, or refund;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Device
    tracking requirements; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Post-market
    study and surveillance requirements.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">After
a device receives 510(k) clearance, any modification that could significantly affect its safety or effectiveness, or that would constitute
a major change in its intended use, will require a new 510(k). The FDA requires each manufacturer to make this determination initially,
but the FDA can review any such decision and can disagree with a manufacturer&#8217;s determination. If the FDA disagrees with a manufacturer&#8217;s
determination not to seek a new 510(k) clearance, the FDA may retroactively require it to seek 510(k) clearance. The FDA could also require
the manufacturer to cease marketing and distribution and/or recall the modified device until 510(k) clearance is obtained. Also, in these
circumstances, the manufacturer may be subject to significant regulatory fines and penalties.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">FDA
regulations require us to register as a medical device manufacturer with the FDA. Additionally, some states also require medical device
manufacturers and/or distributors doing business within the state to register with the state or apply for a state license, which could
subject our facility to state inspection as well as FDA inspection on a routine basis for compliance with the QSR and any applicable
state requirements. These regulations require that we manufacture our products and maintain related documentation in a prescribed manner
with respect to manufacturing, testing and control activities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Manufacturing
processes for medical devices are required to comply with the applicable portions of the QSR, which cover the methods and the facilities
and controls for the design, manufacture, testing, production, processes, controls, quality assurance, labeling, packaging, distribution,
installation and servicing of finished devices intended for human use. The QSR also requires, among other things, maintenance of a device
master file, device history file, and complaint files. As a manufacturer, we are subject to periodic scheduled or unscheduled inspections
by the FDA. Failure to maintain compliance with the QSR requirements could result in the shutdown of, or restrictions on, manufacturing
operations and the recall or seizure of marketed products, which would have a material adverse effect on our business. The discovery
of previously unknown problems with any of our products, including unanticipated adverse events or adverse events of increasing severity
or frequency, whether resulting from the use of the device within the scope of its clearance or off-label by a physician in the practice
of medicine, could result in restrictions on the device, including the removal of the product from the market or voluntary or mandatory
device recalls.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 29; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
FDA has broad regulatory compliance and enforcement powers. If the FDA determines that a manufacturer has failed to comply with applicable
regulatory requirements, it can take a variety of compliance or enforcement actions, which may result in any of the following sanctions:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Warning
    letters, untitled letters, fines, injunctions, consent decrees and civil penalties;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Recalls,
    withdrawals, or administrative detention or seizure of our products;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating
    restrictions or partial suspension or total shutdown of production;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Refusing
    or delays in processing, clearing, or approving submissions or applications for new products or modifications to existing products;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Suspension
    or withdrawal of 510(k) clearances or PMA approvals that have already been granted;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">FDA
    refusal to issue certification to foreign governments needed to export our products for sale in other countries; or</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Criminal
    prosecution.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
facilities, records and manufacturing processes are subject to periodic unscheduled inspections by the FDA. Failure to comply with the
applicable United States medical device regulatory requirements could result in, among other things, warning letters, untitled letters,
fines, injunctions, consent decrees, civil penalties, unanticipated expenditures, repairs, replacements, refunds, recalls or seizures
of products, operating restrictions, total or partial suspension of production, the FDA&#8217;s refusal to issue certificates to foreign
governments needed to export products for sale in other countries, the FDA&#8217;s refusal to grant future premarket clearances or approvals,
withdrawals or suspensions of current product clearances or approvals and criminal prosecution.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Regulation
of Medical Devices in the European Union</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
European Union, or EU, has adopted specific directives regulating the design, manufacture, clinical investigations, conformity assessment,
labeling and adverse event reporting for medical devices. EU directives must be implemented into the national laws of the EU member states
and national laws may vary from one member state to another.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the EU, there is currently no premarket government review of medical devices. However, the EU requires that all medical devices placed
on the market in the EU must meet the relevant essential requirements laid down in the Council Directive 93/42/EEC, or the Medical Devices
Directive, and the Council Directive 90/385/EEC, or the Active Implantable Medical Devices Directive. The most fundamental essential
requirement is that a medical device must be designed and manufactured in such a way that it will not compromise the clinical condition
or safety of patients, or the safety and health of users and others. In addition, the device must achieve the performances intended by
the manufacturer and be designed, manufactured, and packaged in a suitable manner. The European Commission has adopted various standards
applicable to medical devices. These include standards governing common requirements, such as sterilization and safety of medical electrical
equipment and product standards for certain types of medical devices. There are also harmonized standards relating to design and manufacture.
While not mandatory, compliance with these standards is viewed as the easiest way to satisfy the essential requirements as a practical
matter. Compliance with a standard developed to implement an essential requirement also creates a rebuttable presumption that the device
satisfies that essential requirement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
demonstrate compliance with the essential requirements laid down in Annex I to the Medical Devices Directive, medical device manufacturers
must undergo a conformity assessment procedure, which varies according to the type of medical device and its (risk) classification. Conformity
assessment procedures require an assessment of available clinical evidence, literature data for the product, and post-market experience
in respect of similar products already marketed. Except for low-risk medical devices (Class I non-sterile, non-measuring devices), where
the manufacturer can self-declare the conformity of its products with the essential requirements (except for any parts which relate to
sterility or metrology), a conformity assessment procedure requires the intervention of a Notified Body. Notified Bodies are independent
organizations designated by EU countries to assess the conformity of devices before being placed on the market. A Notified Body would
typically audit and examine a product&#8217;s technical dossiers and the manufacturers&#8217; quality system (which must, in particular,
comply with ISO 13485:2016 related to Medical Devices Quality Management Systems). If satisfied that the relevant product conforms to
the relevant essential requirements, the Notified Body issues a certificate of conformity, which the manufacturer uses as a basis for
its own declaration of conformity. The manufacturer may then apply the CE Mark to the device, which allows the device to be placed on
the market throughout the EU.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 30; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notified
Body certificates of conformity are valid for a fixed duration (which shall not exceed five years). Throughout the term of the certificate,
the manufacturer will be subject to periodic surveillance audits to verify continued compliance with the applicable requirements. In
particular, there will be a new audit by the Notified Body before it will renew the relevant certificate(s).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a general rule, demonstration of conformity of medical devices and their manufacturers with the essential requirements must be based,
among other things, on the evaluation of clinical data supporting the safety and performance of the products during normal conditions
of use. Specifically, a manufacturer must demonstrate that the device achieves its intended performance during normal conditions of use,
that the known and foreseeable risks, and any adverse events, are minimized and acceptable when weighed against the benefits of its intended
performance, and that any claims made about the performance and safety of the device are supported by suitable evidence. All manufacturers
placing medical devices into the market in the EU must comply with the EU medical device vigilance system. Under this system, incidents
must be reported to the relevant authorities of the EU member states, and manufacturers are required to take Field Safety Corrective
Actions, or FSCAs, to reduce a risk of death or serious deterioration in the state of health associated with the use of a medical device
that is already placed on the market. An incident is defined as any malfunction or deterioration in the characteristics and/or performance
of a device, as well as any inadequacy in the labeling or the instructions for use which, directly or indirectly, might lead to or might
have led to the death of a patient or user or of other persons or to a serious deterioration in their state of health. An FSCA may include
the recall, modification, exchange, destruction or retrofitting of the device. FSCAs must be communicated by the manufacturer or its
legal representative to its customers and/or to the end users of the device through Field Safety Notices.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
advertising and promotion of medical devices is subject to some general principles set forth by EU directives. According to the Medical
Devices Directive, only devices that are CE-marked may be marketed and advertised in the EU in accordance with their intended purpose.
Directive 2006/114/EC concerning misleading and comparative advertising and Directive 2005/29/EC on unfair commercial practices, while
not specific to the advertising of medical devices, also apply to the advertising thereof and contain general rules, for example requiring
that advertisements are evidenced, balanced and not misleading. Specific requirements are defined at national level. EU member states
laws related to the advertising and promotion of medical devices, which vary between jurisdictions, may limit or restrict the advertising
and promotion of products to the general public and may impose limitations on promotional activities with healthcare professionals.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Many
EU member states have adopted specific anti-gift statutes that further limit commercial practices for medical devices, in particular
vis-&#224; -vis healthcare professionals and organizations. Additionally, there has been a recent trend of increased regulation of
payments and transfers of value provided to healthcare professionals or entities. In addition, many EU member states have adopted national
&#8220;Sunshine Acts&#8221; which impose reporting and transparency requirements (often on an annual basis), similar to the requirements
in the United States, on medical device manufacturers. Certain countries also mandate implementation of commercial compliance programs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 25, 2017, Regulation 2017/745, or the EU Medical Devices Regulation, entered into force, which repeals and replaces the Medical Devices
Directive and the Active Implantable Medical Devices Directive. Unlike directives, which must be implemented into the national laws of
the EU member states, regulations are directly applicable, without the need for adoption of EU member state laws implementing them, in
all EU member states and are intended to eliminate current differences in the regulation of medical devices among EU member states. The
Medical Devices Regulation, among other things, is intended to establish a uniform, transparent, predictable and sustainable regulatory
framework across the EU for medical devices and ensure a high level of safety and health while supporting innovation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Medical Devices Regulation was originally intended to become applicable three years after publication, but in April 2020 the transition
period was extended by the European Parliament and the Council of the EU by an additional year &#8211; until May 26, 2021. Devices lawfully
placed on the market pursuant to the Medical Devices Directive and the Active Implantable Medical Devices Directive prior to May 26,
2021 may generally continue to be made available on the market or put into service until May 26, 2025. Once applicable, the new regulations
will among other things:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Strengthen
    the rules on placing devices on the market and reinforce surveillance once they are available;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 31; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Establish
    explicit provisions on manufacturers&#8217; responsibilities for the follow-up of the quality, performance and safety of devices
    placed on the market;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Improve
    the traceability of medical devices throughout the supply chain to the end-user or patient through a unique identification number;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Set
    up a central database to provide patients, healthcare professionals and the public with comprehensive information on products available
    in the European Union, or EU; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Strengthen
    the rules for the assessment of certain high-risk devices, which may have to undergo an additional check by experts before they are
    placed on the market.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
aforementioned EU rules are generally applicable in the European Economic Area, or EEA, which consists of the 27 EU member states plus
Norway, Liechtenstein and Iceland. Other countries, such as Switzerland, have entered into Mutual Recognition Agreements and allow the
marketing of medical devices that meet EU requirements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
EU-UK Trade and Cooperation Agreement, or TCA, came into effect on January 1, 2021. The TCA does not specifically refer to medical devices.
However, as a result of Brexit, the Medical Devices Regulation will not be implemented in the UK, and previous legislation that mirrored
the Medical Devices Regulation in the UK law has been revoked. The regulatory regime for medical devices in the UK will continue to be
based on the requirements derived from current EU legislation, and the UK may choose to retain regulatory flexibility or align with the
Medical Devices Regulation going forward. CE markings will continue to be recognized in the UK, and certificates issued by EU recognized
Notified Bodies will be valid in the UK, until June 30, 2023. For medical devices placed on the UK market after this period, the UK Conformity
Assessment, or UKCA, marking will be mandatory. In contrast, UKCA marking and certificates issued by UK Notified Bodies will not be recognized
on the EU market. The TCA does provide for cooperation and exchange of information in the area of product safety and compliance, including
market surveillance, enforcement activities and measures, standardization related activities, exchanges of officials, and coordinated
product recalls (or other similar actions). For medical devices that are locally manufactured but use components from other countries,
the &#8220;rules of origin&#8221; criteria will need to be reviewed. Depending on which countries products will ultimately be sold in,
manufacturers may start seeking alternative sources for components if this would allow them to benefit from no tariffs. The rules for
placing medical devices on the Northern Ireland market will differ from those in the UK.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Healthcare
Fraud and Abuse Laws</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the United States, we are subject to a number of federal and state healthcare regulatory laws that restrict business practices in the
healthcare industry. These laws include, but are not limited to, federal and state anti-kickback, false claims, transparency and other
healthcare fraud and abuse laws.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
U.S. federal Anti-Kickback Statute prohibits, among other things, any person or entity from knowingly and willfully offering, paying,
soliciting, receiving or providing any remuneration, directly or indirectly, overtly or covertly, to induce or in return for purchasing,
leasing, ordering, or arranging for or recommending the purchase, lease, or order of any good, facility, item or service reimbursable,
in whole or in part, under Medicare, Medicaid or other federal healthcare programs. The term &#8220;remuneration&#8221; has been broadly
interpreted to include anything of value, including cash, improper discounts, and free or reduced-price items and services. Among other
things, the Anti-Kickback Statute has been interpreted to apply to arrangements between medical device manufacturers on the one hand
and prescribers and purchasers on the other. Although there are a number of statutory exceptions and regulatory safe harbors protecting
some common activities from prosecution, the exceptions and safe harbors are drawn narrowly. The government can exercise enforcement
discretion in taking action against unprotected activities. Further, a person or entity does not need to have actual knowledge of the
statute or specific intent to violate it in order to have committed a violation. The majority of states also have anti-kickback laws,
which establish similar prohibitions, and in some cases may apply to items or services reimbursed by any third-party payor, including
commercial insurers and self-pay patients.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
federal false claims, including the civil False Claims Act, prohibit, among other things, any person or entity from knowingly presenting,
or causing to be presented, a false, fictitious or fraudulent claim for payment to, or approval by, the federal government, knowingly
making, using, or causing to be made or used a false record or statement material to a false or fraudulent claim to the federal government,
or knowingly making a false statement to avoid, decrease or conceal an obligation to pay money to the U.S. federal government. A claim
includes &#8220;any request or demand&#8221; for money or property presented to the U.S. government. Actions under the civil False Claims
Act may be brought by the Attorney General or as a qui tam action by a private individual in the name of the government. Moreover, a
claim including items or services resulting from a violation of the U.S. federal Anti-Kickback Statute constitutes a false or fraudulent
claim for purposes of the federal civil False Claims Act. In addition, various states have enacted false claim laws analogous to the
federal False Claims Act, although many of these state laws apply where a claim is submitted to any third-party payor and not merely
a federal healthcare program.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 32; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
federal Health Insurance Portability and Accountability Act of 1996 created additional federal criminal statutes that prohibit, among
other actions, knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program, including
private third-party payors, knowingly and willfully embezzling or stealing from a healthcare benefit program, willfully obstructing a
criminal investigation of a healthcare offense, and knowingly and willfully falsifying, concealing or covering up a material fact or
making any materially false, fictitious or fraudulent statement in connection with the delivery of or payment for healthcare benefits,
items or services. Similar to the U.S. federal Anti-Kickback Statute, a person or entity does not need to have actual knowledge of the
statute or specific intent to violate it in order to have committed a violation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
federal Physician Payments Sunshine Act requires certain manufacturers of drugs, devices, biologics and medical supplies for which payment
is available under Medicare, Medicaid or the Children&#8217;s Health Insurance Program, with specific exceptions, to report annually
to CMS, information related to payments or other transfers of value made to physicians (defined to include doctors, dentists, optometrists,
podiatrists and chiropractors), and teaching hospitals, and applicable manufacturers and applicable group purchasing organizations to
report annually to CMS ownership and investment interests held by physicians and their immediate family members. Beginning in 2022, such
obligations will include payments and other transfers of value provided in the previous year to additional healthcare professionals,
including physician assistants, nurse practitioners, clinical nurse specialists, certified nurse anesthetists, anesthesiologist assistants
and certified nurse midwives.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Violations
of fraud and abuse laws, including federal and state anti-kickback and false claims laws, may be punishable by criminal and civil sanctions,
including fines and civil monetary penalties, the possibility of exclusion from federal healthcare programs (including Medicare and Medicaid),
disgorgement and corporate integrity agreements, which impose, among other things, rigorous operational and monitoring requirements on
companies. Similar sanctions and penalties, as well as imprisonment, also can be imposed upon executive officers and employees of such
companies.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Coverage
and Reimbursement</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the United States, our currently cleared products are not separately reimbursed by any third-party payors and if covered, are paid for
as part of the procedure in which the product is used. Outside of the United States, there are many reimbursement programs through private
payors as well as government programs. In some countries, government reimbursement is the predominant program available to patients and
hospitals. Our commercial success depends in part on the extent to which governmental authorities, private health insurers and other
third-party payors provide coverage for and establish adequate reimbursement levels for the procedures in which our products are used.
Failure by physicians, hospitals, ambulatory surgery centers and other users of our products to obtain coverage and adequate reimbursement
from third-party payors for procedures in which our products are used, or adverse changes in government and private third-party payors&#8217;
coverage and reimbursement policies, may adversely impact demand for our products.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
on our experience to date, third-party payors generally reimburse for the procedures in which our products are used if medical necessity
is met and a prior approval is completed with a favorable response. Some payors are moving toward a managed care system and control their
healthcare costs by establishing coverage policies that categorically restrict coverage of certain procedures, or by limiting authorization
for procedures, including elective procedures using our devices. No uniform policy of coverage and reimbursement among payors in the
United States exists and coverage and reimbursement for procedures can differ significantly from payor to payor. Third-party payors are
increasingly auditing and challenging the prices charged for medical products and services with concern for upcoding, miscoding, using
inappropriate modifiers, or billing for inappropriate care settings. Some third-party payors must approve coverage for new or innovative
devices or procedures before they will reimburse healthcare providers who use the products or therapies. Even though a new product may
have been cleared for commercial distribution by the FDA, we may find limited demand for our product unless reimbursement approval can
be obtained and/or maintained from governmental and private third-party payors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 33; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition to uncertainties surrounding coverage policies, there are periodic changes to reimbursement levels. Third-party payors regularly
update reimbursement amounts and also from time to time revise the methodologies used to determine reimbursement amounts. This includes
routine updates to payments to physicians, hospitals and ambulatory surgery centers for procedures during which our products are used.
These updates could directly impact the demand for our products.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe the overall escalating cost of medical products and services being paid for by the government and private health insurance has
led to, and will continue to lead to, increased pressures on the healthcare and medical device industry to reduce the costs of products
and services. Third-party payors are developing increasingly sophisticated methods of controlling healthcare costs through prospective
reimbursement and capitation programs, group purchasing, redesign of benefits, and exploration of more cost-effective methods of delivering
healthcare. In the United States, some insured individuals enroll in managed care programs, which monitor and often require pre-approval
of the services that a member will receive. Some managed care programs pay their providers on a per capita (patient) basis, which puts
the providers at financial risk for the services provided to their patients by paying these providers a predetermined payment per member
per month and, consequently, may limit the willingness of these providers to use our products.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
international markets, reimbursement and healthcare payment systems vary significantly by country, and many countries have instituted
price ceilings on specific product lines and procedures. In the European Union, member states are facing increased pressure to limit
public healthcare spending. There can be no assurance that procedures using our products will be covered for a specific indication, that
our products will be considered cost-effective by third-party payors, that an adequate level of reimbursement will be available or that
the third-party payors&#8217; reimbursement policies will not adversely affect our ability to sell our products profitably. More and
more, local, product specific reimbursement law is applied as an overlay to medical device regulation, which has provided an additional
layer of clearance requirement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Healthcare
Reform</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
United States and some foreign jurisdictions are considering or have enacted a number of legislative and regulatory proposals to change
the healthcare system in ways that could affect our ability to sell our products profitably. Among policy makers and payors in the United
States and elsewhere, there is significant interest in promoting changes in healthcare systems with the stated goals of containing healthcare
costs, improving quality or expanding access. Current and future legislative proposals to further reform healthcare or reduce healthcare
costs may limit coverage of or lower reimbursement for the procedures associated with the use of our products. The cost containment measures
that payors and providers are instituting and the effect of any healthcare reform initiative implemented in the future could impact our
revenue from the sale of our products.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
implementation of the Affordable Care Act (the &#8220;ACA&#8221;) in the United States, for example, has changed healthcare financing
and delivery by both governmental and private insurers substantially, and affected medical device manufacturers significantly. The ACA,
among other things, provided incentives to programs that increase the federal government&#8217;s comparative effectiveness research,
and implemented payment system reforms including a national pilot program on payment bundling to encourage hospitals, physicians and
other providers to improve the coordination, quality and efficiency of certain healthcare services through bundled payment models. Additionally,
the ACA expanded eligibility criteria for Medicaid programs and created a new Patient-Centered Outcomes Research Institute to oversee,
identify priorities in, and conduct comparative clinical effectiveness research, along with funding for such research. Since its enactment,
there have been judicial, executive and political challenges to certain aspects of the ACA. On June 17, 2021, the U.S. Supreme Court
dismissed the most recent judicial challenge to the ACA brought by several states without specifically ruling on the constitutionality
of the ACA. It is unclear how healthcare reform measures of the Biden administration or other efforts, if any, to challenge, repeal or
replace the ACA will impact the law or our business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 34; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, other legislative changes have been proposed and adopted since the ACA was enacted. For example, the Budget Control Act of
2011, among other things, reduced Medicare payments to providers by 2% per fiscal year, effective on April 1, 2013 and, due to subsequent
legislative amendments to the statute, will remain in effect through 2030, with the exception of a temporary suspension from May 1, 2020
through March 31, 2021, unless additional Congressional action is taken. Additionally, the American Taxpayer Relief Act of 2012, among
other things, further reduced Medicare payments to several providers, including hospitals, and increased the statute of limitations period
for the government to recover overpayments to providers from three to five years. The Medicare Access and CHIP Reauthorization Act of
2015 repealed the formula by which Medicare made annual payment adjustments to physicians and replaced the former formula with fixed
annual updates and a new system of incentive payments that began in 2019 that are based on various performance measures and physicians&#8217;
participation in alternative payment models, such as accountable care organizations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
expect additional state and federal healthcare reform measures to be adopted in the future, any of which could limit the amounts that
federal and state governments will pay for healthcare products and services, which could result in reduced demand for our products or
additional pricing pressure.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Data
Privacy and Security Laws</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Numerous
state, federal and foreign laws, including consumer protection laws and regulations, govern the collection, dissemination, use, access
to, confidentiality and security of personal information, including health-related information. In the United States, numerous federal
and state laws and regulations, including data breach notification laws, health information privacy and security laws, including HIPAA,
and federal and state consumer protection laws and regulations (e.g., Section 5 of the FTC Act), that govern the collection, use, disclosure,
and protection of health-related and other personal information could apply to our operations or the operations of our partners. In addition,
certain state and non-U.S. laws, such as the CCPA, the CPRA and the GDPR, govern the privacy and security of personal information, including
health-related information in certain circumstances, some of which are more stringent than HIPAA and many of which differ from each other
in significant ways and may not have the same effect, thus complicating compliance efforts. Failure to comply with these laws, where
applicable, can result in the imposition of significant civil and/or criminal penalties and private litigation. Privacy and security
laws, regulations, and other obligations are constantly evolving, may conflict with each other to complicate compliance efforts, and
can result in investigations, proceedings, or actions that lead to significant civil and/or criminal penalties and restrictions on data
processing.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
Europe, the GDPR went into effect on May 25, 2018 and introduces strict requirements for processing the personal data of European Union
data subjects. Companies that must comply with the GDPR face increased compliance obligations and risk, including more robust regulatory
enforcement of data protection requirements and potential fines for noncompliance of up to &#8364;20 million or 4% of the annual global
revenues of the preceding financial year of the noncompliant company, whichever is greater.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Among
other requirements, the GDPR regulates transfers of personal data subject to the GDPR to third countries that have not been found to
provide adequate protection to such personal data, including the United States, and the efficacy and longevity of current transfer mechanisms
between the EU and the United States remains uncertain. For example, in 2016, the EU and United States agreed to a transfer framework
for data transferred from the EU to the United States, called the Privacy Shield, but the Privacy Shield was invalidated in July 2020
by the Court of Justice of the European Union.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Further,
from January 1, 2021, companies have to comply with the GDPR and also the United Kingdom General Data Protection Regulation, or the UK
GDPR, which, together with the amended UK Data Protection Act 2018, retains the GDPR in UK national law. The UK GDPR mirrors the fines
under the GDPR, i.e., fines up to the greater of &#8364;20 million (&#163;17.5 million) or 4% of global turnover. The relationship between
the United Kingdom and the European Union in relation to certain aspects of data protection law remains unclear, and it is also unclear
how United Kingdom data protection laws and regulations will develop in the medium to longer term, and how data transfers to and from
the United Kingdom will be regulated in the long term. Currently there is a four- to six-month grace period agreed in the EU and United
Kingdom Trade and Cooperation Agreement, ending June 30, 2021 at the latest, while the parties discuss an adequacy decision. The European
Commission published a draft adequacy decision on February 19, 2021. If adopted, the decision will enable data transfers from EU member
states to the United Kingdom for a four-year period, subject to subsequent extensions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 35; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Environmental
Matters</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
on our current operations, environmental protection requirements do not have a significant financial and operational effect on the capital
expenditures, earnings and competitive position of our Company in the current financial year and are not expected to have a significant
effect in the reasonably foreseeable future.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Manufacturing
Services Agreement</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August 21, 2020, the Company entered into a Manufacturing Services Agreement with GMI Corporation (&#8220;GMI&#8221;), dated as of August
21, 2020 (&#8220;MSA&#8221;), for the manufacture and supply of the Company&#8217;s IB-STIM device based upon the Company&#8217;s product
specifications as set forth in the MSA.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company provides the necessary equipment to GMI and retains ownership. GMI bears the risk of loss of and damage to the equipment and
consigned materials. Performance under the MSA is initiated by orders issued by the Company and accepted by GMI.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
initial term of the MSA was 24 months and automatically renews for terms of twelve months unless either party provides a written termination
notice to the other party within 180 days prior to the end of the then-current term.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">GMI
was established in 1990 and manufactures our IB-Stim device in its 69,000 square foot facility that including offices, factory, environmentally
controlled room, warehouse, parts processing, assembly, quality control, of which approximately 1,000 square feet is dedicated to producing
our product, located in Indiana.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">With
controlled, repeatable, monitored production process, GMI has kit production capacity that is sufficient for all our projected needs.
There is a new, dedicated, environmentally controlled build room built in 2022 for our equipment and production. All of our materials
are now maintained in this room.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">GMI
has a quality management system that is ISO 13485:2016 certified, FDA registered, and ITAR registered.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with the MSA, the Company entered into a quality agreement with GMI, dated as of August 24, 2020, for GMI to test product
provided by the Company and perform quality assurance services.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Employees</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2024, we had 21 full-time employees.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="me_003"></span>ITEM
1A. RISK FACTORS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risks
Relating to Our Business and Our Product</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
business and prospects depend entirely on our current products, IB-Stim and RED. Even though we have received FDA clearance for our products,
it will remain subject to ongoing regulatory review. If we are unable to maintain regulatory clearance and commercialize our product
or are significantly delayed or limited in our commercialization efforts, our business and prospects will be materially harmed.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Almost
all of our revenues have been derived from sales and royalties from sales of IB-Stim, and we expect to develop, market, and sell other
neuromodulation therapy devices for the treatment of chronic and debilitating conditions in children. The commercial success of our products
and our ability to generate and maintain revenues from the sale of our products will depend on a number of factors, including:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to develop and obtain additional regulatory clearances and further commercialize our products for additional indications;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to expand into new markets and future indications;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    acceptance of our products by patients and the healthcare community, including physicians and third-party payers (both private and
    governmental), as therapeutically effective and safe;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    accomplishment of various scientific, engineering, clinical, regulatory and other goals, which we sometimes refer to as milestones,
    on our anticipated timeline;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 36; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    relative cost, safety and efficacy of alternative therapies;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to obtain and maintain sufficient coverage or reimbursement by private and governmental third-party payers and to comply
    with applicable health care laws and regulations;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    ability of our third-party manufacturers to manufacture our products in sufficient quantities with acceptable quality;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to provide marketing, distribution and customer support for our products;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    potential presence of competitive products in our active indications;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">results
    of future clinical studies relating to our products or other competitor products for similar indications;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">compliance
    with applicable laws and regulatory requirements;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    maintenance of our existing regulatory clearance; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    consequences of any reportable adverse events involving our products.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, the promotion of our products is limited to approved indications, which vary by geography. The labelling for our device in
the U.S. is limited in certain respects, which may limit the number of patients to whom it is prescribed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
ability to generate future revenues will also depend on achieving regulatory approval of, and eventual commercialization of, our products
for additional indications and in additional geographies, which is not guaranteed. Our near-term prospects are substantially dependent
on our ability to obtain regulatory approvals on the timetable we have anticipated, and thereafter to further successfully commercialize
our products for additional indications. Regulatory changes or actions in areas in which we operate or propose to operate may further
affect our ability to obtain regulatory clearances on our anticipated timetable. If we are not able to receive such approvals, meet other
anticipated milestones, or further commercialize our products, or are significantly delayed or limited in doing so, our business and
prospects will be materially harmed and we may need to reduce expenses by delaying, reducing or curtailing the development of our products
and we may need to raise additional capital to fund our operations, which we may not be able to obtain on favorable terms, if at all.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>To
date, we have not generated any operating profits, and due to our long-term research and development efforts, we have a history of incurring
substantial operating losses.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
were founded in 2011 and have a history of incurring substantial operating losses. We anticipate continuing to incur significant costs
associated with developing and commercializing our products for approved indications including signal development, device hardware and
software development, product sales, marketing, manufacturing, and distribution expenses. We expect our research, development, and clinical
study expenses to increase in connection with our ongoing activities and as additional indications enter clinical development and as
we advance our product development. Our expenses could increase beyond expectations if, for example, we are required by the FDA, or other
regulatory agencies or similar governing bodies, to change manufacturing processes for our products or to perform clinical, nonclinical
or other types of studies in addition to those that we currently anticipate. Our revenues are dependent, in part, upon the size of the
markets in the jurisdictions in which we receive regulatory approval, the accepted price for our products and the ability to obtain reimbursement
at the accepted applicable price. If the number of addressable patients is not as significant as we or our strategic partners and licensees
estimate, the indications approved by regulatory authorities are narrower than we expect or the eligible population for treatment is
narrowed by competition, regulatory approvals, physician choice or treatment guidelines, we may not generate significant revenues. If
we are not able to generate significant revenues, we may never be sustainably profitable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
clinical studies could be delayed or otherwise adversely affected by many factors, including difficulties in enrolling patients.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Clinical
testing can be costly and take many years, and the outcome is uncertain and susceptible to varying interpretations. Moreover, success
in pre-clinical and early clinical studies does not ensure that large-scale studies will be successful or predict final results. Acceptable
results in early studies may not be replicable in later studies. A number of companies in therapeutics industries have suffered significant
setbacks in advanced clinical studies, even after promising results in earlier studies. Negative or inconclusive results or adverse events
or incidents during a clinical study could cause the clinical study to be redone or terminated. In addition, failure to appropriately
construct clinical studies could result in high rates of adverse events or incidents, which could cause a clinical study to be suspended,
redone or terminated. Our failure or the failure of third-party participants in our studies to comply with their obligations to follow
protocols and/or legal requirements may also result in our inability to use the affected data in our submissions to regulatory authorities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 37; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
timely completion of clinical studies depends, among other things, on our ability to enroll a sufficient number of patients who remain
in the study until its conclusion. We may experience difficulties in patient enrollment in our clinical studies for a variety of reasons,
including:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    severity of the disease under investigation;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    limited size and nature of the patient population;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    patient eligibility criteria defined in our protocol and other clinical study protocols;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    nature of the study protocol, including the attractiveness of, or the discomforts and risks associated with, the treatments received
    by enrolled subjects;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">difficulties
    and delays in clinical studies that may occur as a result of the COVID-19 pandemic;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    ability to obtain IRB approval at clinical study locations;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">clinicians&#8217;
    and patients&#8217; perceptions as to the potential advantages, disadvantages and side effects of our products in relation to other
    available therapies, including any new drugs or treatments that may be approved for the indications we are pursuing;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">availability
    of other clinical studies that exclude use of our products;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    possibility or perception that enrolling in a product&#8217;s clinical study may limit the patient&#8217;s ability to enroll in future
    clinical studies for other therapies due to protocol restrictions;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    possibility or perception that our software is not secure enough to maintain patient privacy;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">patient
    referral practices of physicians;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    ability to monitor patients adequately during and after treatment;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    availability of appropriate clinical study investigators, support staff, drugs and other therapeutic supplies and proximity of patients
    to clinical sites;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">physicians&#8217;
    or our ability to obtain and maintain patient consents; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    risk that when we collaborate with a third-party for research of a product in a particular institution, we can expect to relinquish
    some or all of the control over the future success of that study to the third-party.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we have difficulty enrolling and retaining a sufficient number or diversity of patients to conduct our clinical studies as planned, or
encounter other difficulties, we may need to delay, terminate or modify ongoing or planned clinical studies, any of which would have
an adverse effect on our business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
we are unable to develop an adequate sales and marketing organization or contract with third parties to assist us, we may not be able
to successfully commercialize our products for current and future indications.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
achieve commercial success for our products, we must compliantly develop and grow our sales and marketing organization and, as necessary,
enter into sales and distribution relationships with third parties to market and sell our products. Developing and managing a sales and
marketing organization is a difficult, expensive and time consuming process. We may not be able to successfully develop adequate sales
and marketing capabilities to achieve our growth objectives. We compete with other medical device, pharmaceutical and life sciences companies
to recruit, hire, train and retain the sales and marketing personnel that we anticipate we will need, and the nature of our products
may make it more difficult to compete for sales and marketing personnel. In addition, because our current products require, and we anticipate
our future products will require, physician training and education, our sales and marketing organization may need to grow substantially
as we expand our approved indications and markets. As a consequence, our expenses associated with building up and maintaining our sales
force and marketing capabilities may be disproportionate to the revenues we may be able to generate on sales of our products.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we are unable to establish adequate sales and marketing capabilities or successful sales and distribution relationships, we may fail
to realize the full revenue potential of our products for current and future indications, and we may not be able to achieve the necessary
growth in a cost-effective manner or realize a positive return on our investment. In our future sales and distribution agreements with
other companies, we generally may not have control over the resources or degree of effort that any of these third parties may devote
to our products, and if they fail to devote sufficient time and resources to the marketing of our products, or if their performance is
substandard, our revenues may be adversely affected.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 38; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>The
success of our business may be dependent on the actions of our collaborative partners.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
business strategy includes, in part, the consummation of collaborative arrangements with companies who will support the development and
commercialization of our products and technology. We may also enter into clinical collaborations with third parties to test our products
and technology together with other products and technologies.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">When
we collaborate with a third party for commercialization of a product in a particular territory, we can expect to relinquish some or all
of the control over the future success of that product to the third party in that territory. In addition, our collaborative partners
may have the right to terminate applicable agreements, including payment obligations, prior to or upon the expiration of the agreed-upon
terms. We may not be successful in establishing or maintaining collaborative arrangements on acceptable terms or at all, collaborative
partners may terminate funding before completion of projects, our products may not achieve the criteria for milestone payments, our collaborative
arrangements may not result in successful product commercialization, our products may not receive acceptable pricing and we may not derive
any revenue from such arrangements. Additionally, our collaborators may not perform their obligations as expected or in compliance with
study protocols or applicable laws. Acts or omissions by collaborators may disqualify study data for use in regulatory submissions and/or
create liability for us in the jurisdictions in which we operate. Any disagreements with collaborators, including disagreements over
proprietary rights, contract interpretation or the preferred course of commercialization, might cause delays or termination of the commercialization
of products, might lead to additional responsibilities for us with respect to commercializing products, or might result in litigation
or arbitration, any of which would be time-consuming and expensive. To the extent that we are not able to develop and maintain collaborative
arrangements, we would need to devote substantial capital to undertake commercialization activities on our own in order to further expand
our reach, and we may be forced to limit the territories in which we commercialize our products.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may not be successful in achieving market acceptance of our products by healthcare professionals, patients and/or third-party payers
in the timeframes we anticipate, or at all, which could have a material adverse effect on our business, prospects, financial condition
and results of operations.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may not achieve market acceptance of our products for current or future indications within the timeframes we have anticipated, or at
all, for a number of different reasons, including the following factors:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">it
    may be difficult to gain broad acceptance of our products because they are new technologies and involve a novel or derivative mechanism
    of action and, as such, physicians may be reluctant to prescribe our products without prior experience or additional data or training;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">physicians
    may be reluctant to prescribe our products due to their perception that the supporting clinical study designs have limitations, as
    they are, for example, unblinded;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">physicians
    at large academic universities and medical centers may prefer to enroll patients into clinical studies instead of prescribing our
    products;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">it
    may be difficult to gain broad acceptance at community hospitals where the number of patients seeking treatment may be more limited
    than at larger medical centers, and such community hospitals may not be willing to invest in the resources necessary for their physicians
    to become trained to use our products, which could lead to reluctance to prescribe our products;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">patients
    may be reluctant to use our products for various reasons, including a perception that the treatment is untested or difficult to use
    or a perception that our software is not secure;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    products may have side effects and our products cannot be worn in all circumstances; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">each
    patient will use more than one device and therefore, as the duration of the treatment course increases, the overall price will increase
    correspondingly and, when used in combination with other treatments, the overall cost of treatment will be greater than using a single
    type of treatment.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
particular, our products may not achieve market acceptance for current or future indications because of the following additional factors:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">achieving
    patient acceptance could be difficult because not all patients are willing to comply with requirements of treatment with our products,
    and other patients may forego our products for financial, privacy, cosmetic, visibility or mobility reasons;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 39; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">achieving
    patient compliance may be difficult because the recommended use of our products is 120 hours per week for three (3) consecutive weeks,
    and not to exceed four (4) weeks, which to some extent restricts physical mobility because our products cannot be worn in all circumstances,
    and the patient or a caregiver must ensure that it remains continuously operable and this may also impact the pool of patients to
    whom physicians may be willing to prescribe our products;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">there
    may be certain perceived limitations to our study designs or data obtained from our clinical studies;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">efficacy
    may also be limited in instances where patients take a break from the device when experiencing skin rashes, or while bathing or swimming
    (because our products should not be immersed in water); and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">patients
    may decline therapy or prescribers may be unwilling to prescribe our products due to certain adverse events attributable to the device
    reported in clinical studies by patients treated with our products.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, even if we are successful in achieving market acceptance of our products for IBS or other indications, we may be unsuccessful
in achieving market acceptance of our products for other indications.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
may be other factors that are presently unknown to us that also may negatively impact our ability to achieve market acceptance of our
products. If we do not achieve market acceptance of our products in the timeframes we anticipate, or are unable to achieve market acceptance
at all, our business, prospects, financial condition and results of operations could be materially adversely affected.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Failure
to secure and maintain adequate coverage and reimbursement from third-party payers could adversely affect acceptance of our products
and reduce our revenues.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
expect that the majority of our revenues will come from third-party payers, primarily children&#8217;s hospitals, either directly to
us in markets where we provide our products or plan to provide our device candidates to patients or indirectly via payments made to hospitals
or other entities providing our products or which may in the future provide our device candidates to patients.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the U.S., private payers cover the largest segment of the population, with the remainder either uninsured or covered by governmental
payers. The majority of the third-party payers outside the U.S. are government agencies, government sponsored entities or other payers
operating under significant regulatory requirements from national or regional governments.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Third-party
payers may decline to cover and reimburse certain procedures, supplies or services. Additionally, some third-party payers may decline
to cover and reimburse our products for a particular patient even if the payer has a favorable coverage policy addressing our products
or previously approved reimbursement for our products. Additionally, private and government payers may consider the cost of a treatment
in approving coverage or in setting reimbursement for the treatment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Private
and government payers are increasingly challenging the prices charged for medical products and services. Additionally, the containment
of healthcare costs has become a priority of governments. Adoption of additional price controls and cost-containment measures, and adoption
of more restrictive policies in jurisdictions with existing controls and measures, could further limit our revenues and operating results.
If third-party payers do not consider our products or the combination of our products with additional treatments to be cost-justified
under a required cost-testing model, they may not cover our products for their populations or, if they do, the level of reimbursement
may not be sufficient to allow us to sell our products on a profitable basis.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Reimbursement
for the treatment of patients with medical devices is governed by complex mechanisms. These mechanisms vary widely among countries, can
be informal, somewhat unpredictable, and evolve constantly, reflecting the efforts of these countries to reduce public spending on healthcare.
As a result, obtaining and maintaining reimbursement for the treatment of patients with medical devices has become more challenging.
We cannot guarantee that the use of our products will receive reimbursement approvals and cannot guarantee that our existing reimbursement
approvals will be maintained in any country.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
failure to secure or maintain adequate coverage or reimbursement for our products by third-party payers in the U.S. or in the other jurisdictions
in which we market our products could have a material adverse effect on our business, revenues and results of operations and cause our
stock price to decline.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 40; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may not be successful in maintaining reimbursement codes necessary to facilitate accurate and timely billing for our products or physician
services attendant to our products</i>.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Third-party
payers, healthcare systems, government agencies or other groups often issue reimbursement codes to facilitate billing for products and
physician services used in the delivery of healthcare. Our IB-STIM technology specific CAT III CPT Code (0720T) was published on December
30, 2021 and effective on July 1, 2022. In September of 2024, the AMA&#8217;s CPT Editorial Panel accepted addition of Category I CPT
Code (placeholder 64X11) for PENFS and deletion of Category III CPT Code 0720T. The finalized Category I CPT Code for PENFS, and associated
valuations, will be announced publicly in Q4 of 2025. The new code will become effective for utilization on January 1, 2026. RED is billable
under Category I CPT Code 91120. We may not be able to maintain the CPT code for physician services related to our products. Our future
revenues and results may be affected by the absence of CPT codes, as physicians may be less likely to prescribe the therapy when there
is no certainty that adequate reimbursement will be available for the time, effort, skill, practice expense and malpractice costs required
to provide the therapy to patients.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Outside
the U.S., we have not secured codes to describe our products or to document physician services related to the delivery of therapy using
our products. The failure to obtain and maintain these codes could affect the future growth of our business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may depend on single-source suppliers for some of our components. The loss of these suppliers could prevent or delay shipments of our
products, delay our clinical studies or otherwise adversely affect our business.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
certain jurisdictions, we may source some of the components of our products from only a single vendor. If any one of these single-source
suppliers were to fail to continue to provide components to us on a timely basis, or at all, our business and reputation could be harmed.
We will seek and maintain second-source suppliers, but we can provide no assurance that we will secure or maintain such suppliers. We
have developed or are in the process of developing and obtaining regulatory approval for second sources for components in all jurisdictions.
Various steps must be taken before securing these suppliers, including qualifying these suppliers in accordance with regulatory requirements,
but we may never receive such approvals. The risks associated with the failure of our suppliers to comply with strictly enforced regulatory
requirements as described below are exacerbated by our dependence on single-source suppliers.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we experience any deficiency in the quality of, delay in or loss of availability of any components supplied to us by third-party suppliers,
or if we switch suppliers or components, we may face additional regulatory delays and the manufacture and delivery of our products would
be interrupted for an extended period of time, which could materially adversely affect our business, prospects, financial condition and
results of operations. If we are required to obtain prior regulatory approval from the FDA or regulatory authorities or similar governing
bodies in other jurisdictions or to conduct a new conformity assessment procedure for our products, regulatory approval for our products
may not be received on a timely basis, or at all, which would have a material adverse effect on our business, prospects, financial condition
and results of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Quality
control problems with respect to devices and components supplied by third-party suppliers could have a material adverse effect on our
reputation, our clinical studies or the commercialization of our products and, as a result, a material adverse effect on our business,
prospects, financial condition and results of operations</i></b><i>.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
products, which are manufactured by third parties, are highly technical and are required to meet exacting specifications. Any quality
control problems that we experience with respect to the devices and components supplied by third-party suppliers could have a material
adverse effect on our reputation, our attempts to complete our clinical studies, our operating expenses or the commercialization of our
products. The failure of our suppliers to comply with strictly enforced regulatory requirements could expose us to regulatory action,
including warning letters, product recalls, suspension or termination of distribution, product seizures or civil penalties. If we experience
any delay in the receipt or deficiency in the quality of products supplied to us by third-party suppliers, or if we have to switch to
replacement suppliers, we may face additional regulatory delays and the manufacture and delivery of our products would be interrupted
for an extended period of time, which would materially adversely affect our business, prospects, financial condition and results of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 41; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
currently do not own a manufacturing facility and rely on a sole manufacturer for the production of our product</i></b>. <b><i>Any significant
disruption to the sole manufacturer&#8217;s operations or facilities could have a material adverse effect on our business, financial
condition and results of operations</i></b>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
rely on a sole manufacturer for the production of our products. We do not have control over the operations of the facilities of the third-party
manufacturer that we use. A significant disruption to our manufacturer could have a material adverse effect on our business, financial
condition and results of operations. Our reliance on our manufacturer poses a number of risks, including lack of control over the manufacturing
process and ultimately over the quality and timing of delivery of our product. A change in our relationship with our manufacturer could
result in a material adverse effect on our business, financial condition and results of operations. A decision to change manufacturers
would result in longer times for design and production as we secure any necessary licenses or clearances, develop quality control measures,
and implement manufacturing processes.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Continued
testing of our products may not yield successful results and could reveal currently unknown aspects or safety hazards associated with
our products</i></b><i>.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
research and development programs are designed to test the safety and efficacy of our products through extensive pre-clinical and clinical
testing. Even if our ongoing and future pre-clinical and clinical studies are completed as planned, we cannot be certain that their results
will support our claims or that the FDA and other regulatory authorities will agree with our conclusions. Success in pre-clinical studies
and early clinical studies does not ensure that later clinical studies will be successful, and we cannot be sure that the later studies
will replicate the results of prior studies and pre-clinical studies. The clinical study process may fail to demonstrate that our device
candidates are safe and effective for the proposed indicated uses, which could cause us to abandon a device candidate and may delay development
of others. It is also possible that patients enrolled in clinical studies will experience adverse side effects that have not been previously
observed. In addition, our pre-clinical and clinical studies for our device candidates involve a relatively small patient population
and, as a result, these studies may not be indicative of future results.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may experience numerous unforeseen events during, or as a result of, the testing process that could delay or prevent further commercialization
of our products, including the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">pre-clinical
    and clinical testing for our products may not produce the desired effect, may be inconclusive or may not be predictive of safety
    or efficacy results obtained in future clinical studies, following long-term use or in much larger populations;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">unanticipated
    adverse events or other side effects that are not currently known may occur during our clinical studies that may preclude additional
    regulatory approval or result in additional limitations to commercial use if approved; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    data collected from our clinical studies may not reach statistical significance or otherwise not be sufficient to support FDA or
    other regulatory approval.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
unacceptable side effects arise in the development of our products for future indications, we could suspend or terminate our clinical
studies or the FDA or other regulatory authorities could order us to cease clinical studies or deny approval of our device candidates
for any or all targeted indications, narrow the approved indications for use or otherwise require restrictive product labeling or marketing
or require further clinical studies, which may be time-consuming and expensive and may not produce results supporting FDA or other regulatory
approval of our products in a specific indication. Treatment-related side effects could also affect patient recruitment or the ability
of enrolled patients to complete the study or result in potential product liability claims. In addition, these side effects may not be
appropriately recognized or managed by the treating medical staff. We expect to have a need to train medical personnel using our devices
for clinical studies and upon any commercialization of our products for future indications. Inadequate training in recognizing or managing
the potential side effects of our products could result in patient injury or death. Any of these occurrences may harm our business, prospects
and financial condition significantly.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
delay or termination of our clinical studies will delay the filing of submissions for regulatory approvals of our products and ultimately
our ability to commercialize our products and generate revenues. Furthermore, we may abandon our products for indications that we previously
believed to be promising. Any of these events could have a material adverse effect on our business, prospects, financial condition and
results of operations and cause our stock price to decline.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 42; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>As
we expand, we may experience difficulties managing our growth</i></b>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
anticipated growth will place a significant strain on our management and on our operational and financial resources and systems. We could
face challenges inherent in efficiently managing a more complex business with an increased number of employees over large geographic
distances, including the need to implement appropriate systems, policies, benefits and compliance programs. Failure to manage our growth
effectively could materially adversely affect our business. Additionally, our anticipated growth will increase the demands placed on
our third-party suppliers, resulting in an increased need to carefully monitor the available supply of components and services and to
scale up our quality assurance programs. There is no guarantee that our suppliers will be able to support our anticipated growth. Any
failure by us to manage our growth effectively could have an adverse effect on our ability to achieve our development and commercialization
goals.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>The
size and expected growth of our available market has not been established with precision and may be smaller than we estimate.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
data on the available market for our current products and future products is based on a number of internal and third-party research reports,
estimates and assumptions. While we believe that such research, our assumptions and the data underlying our estimates are reasonable,
these assumptions and estimates may not be correct. In addition, the statements in this prospectus relating to, among other things, the
expected growth in the market for our IB-Stim are based on a number of internal and third-party data, estimates and assumptions, and
may prove to be inaccurate. If the actual number of consumers who would benefit from our products, the price at which we can sell future
products or the available market for our products is smaller than we estimate, it could have a material adverse effect on our business,
financial condition and results of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
physicians and patients do not accept our current and future products or if the market for indications for which any product candidate
is approved is smaller than expected, we may be unable to generate significant revenue, if any.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Even
when any of our product candidates obtain regulatory approval, they may not gain market acceptance among physicians, patients, and third-party
payers. Physicians may decide not to recommend our treatments for a variety of reasons including:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">timing
    of market introduction of competitive products;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">demonstration
    of clinical safety and efficacy compared to other products;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">cost-effectiveness;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">limited
    or no coverage by third-party payers;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">convenience
    and ease of administration;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">prevalence
    and severity of adverse side effects;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">restrictions
    in the label of the device;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">other
    potential advantages of alternative treatment methods; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ineffective
    marketing and distribution support of its products.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
any of our product candidates is approved but fails to achieve market acceptance or such market is smaller than anticipated, we may not
be able to generate significant revenue and our business would suffer.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Because
of the specialized nature of our business, the termination of relationships with our key employees, consultants and advisors may prevent
us from successfully operating our business, including developing our products, conducting clinical studies, commercializing our products
and obtaining any necessary financing</i></b><i>.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are highly dependent on the members of our executive team, the loss of whose services may adversely impact the achievement of our objectives.
While we have entered into employment agreements with each of our key executives, any of them could leave our employment at any time.
We do not have &#8220;key person&#8221; insurance on any of our employees. The loss of the services of one or more of our current employees
might impede the achievement of our business objectives.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
competition for qualified personnel in the medical device fields is intense, and we rely heavily on our ability to attract and retain
qualified scientific, technical and managerial personnel. Our future success depends upon our ability to attract, retain and motivate
highly skilled employees. In order to commercialize our products successfully, we will be required to expand our workforce, particularly
in the areas of research and development and clinical studies, sales and marketing and supply chain management. These activities will
require the addition of new personnel and the development of additional expertise by existing management personnel. We face intense competition
for qualified individuals from numerous pharmaceutical, biopharmaceutical and biotechnology companies, as well as academic and other
research institutions. We may not be able to attract and retain these individuals on acceptable terms or at all. Failure to do so could
materially harm our business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 43; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Customer
or third-party complaints or negative reviews or publicity about our company or our products could harm our reputation and brand.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are heavily dependent on customers who use our IB-Stim device to provide good reviews and word-of-mouth recommendations to contribute
to our growth. Customers who are dissatisfied with their experiences with our products or services may post negative reviews. We may
also be the subject of blog, forum or other media postings that include inaccurate statements and/or create negative publicity. In addition,
any negative news regarding similar products may adversely impact our business. Any negative reviews or publicity, whether real or perceived,
disseminated by word-of-mouth, by the general media, by electronic or social networking means or by other methods, could harm our reputation
and brand and could severely diminish consumer confidence in our products.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Adverse
global economic conditions could have a negative effect on our business, results of operations and financial condition and liquidity.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
general slowdown in the global economy, including a recession, or in a particular region or industry, an increase in trade tensions with
U.S. trading partners, inflation or a tightening of the credit markets could negatively impact our business, financial condition and
liquidity. Adverse global economic conditions have from time to time caused or exacerbated significant slowdowns in the industries and
markets in which we operate, which have adversely affected our business and results of operations. Macroeconomic weakness and uncertainty
also make it more difficult for us to accurately forecast revenue, gross profit and expenses, and may make it more difficult to raise
or refinance debt. Sustained uncertainty about, or worsening of, current global economic conditions and further escalation of trade tensions
between the U.S. and its trading partners, could result in a global economic slowdown and long-term changes to global trade. Such events
may also (i) cause our customers and consumers to reduce, delay or forgo spending, (ii) result in customers sourcing products from other
suppliers not subject to such restrictions or tariffs, (iii) lead to the insolvency or consolidation of key suppliers and customers,
and (iv) intensify pricing pressures. Any or all of these factors could negatively affect demand for our products and our business, financial
condition and results of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additionally,
economic conditions in certain regions may also be affected by natural disasters and public health emergencies, such as extreme weather
events, and could have a significant adverse effect on our business, including interruption of our commercial and clinical operations,
supply chain disruption, endangerment of our personnel, fewer patient visits, increased patient drop-out rates, delays in recruitment
of new patients, and other delays or losses of materials and results.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>
A pandemic could materially adversely impact our business</i></b>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
pandemic could disruption and impact our business and clinical studies, which could include:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">delays
    and/or difficulties in onboarding active patients and enrolling patients in our clinical studies;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">delays
    and/or difficulties in clinical site initiation, including difficulties in recruiting clinical site investigators and clinical site
    staff;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">declines
    in prescriptions written due to a perception that our products are difficult to administer remotely or if patients are unwilling
    to travel to treatment sites or receive in-home treatment assistance from us or other caregivers;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reductions
    in third-party reimbursements, which could materially affect our revenue, as most of our patients rely on third-party payers to cover
    the cost of our products and a material number of our patients could lose access to their private health insurance plan if they or
    someone in their family lose their job;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">diversion
    of healthcare resources away from conducting clinical studies, including the diversion of hospitals serving as our clinical study
    sites and hospital staff supporting the conduct of our clinical studies;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 44; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">interruption
    of key clinical study activities, such as clinical study site monitoring, due to limitations on travel imposed or recommended by
    federal or state governments, employers and others;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">staff
    disruptions and turnover internally and at treatment sites and third-party providers who provide support, either directly as a result
    of illness or indirectly as a result of vaccine mandates and other changes in terms of employment;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">delays
    in receiving approval from local regulatory authorities or IRBs to initiate our planned clinical studies;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">delays
    in clinical sites receiving the supplies and materials needed to conduct our clinical studies;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">interruption
    in shipping that may affect the transport of active patient and clinical study materials;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes
    in local regulations as part of a response to a pandemic that may require us to change the ways in which our clinical
    studies are conducted, which may result in unexpected costs, or to discontinue the clinical studies altogether;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">delays
    in necessary interactions with local regulators, ethics committees and other important agencies and contractors due to limitations
    in employee resources or forced furlough of government employees;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">disruption
    of our supply chain as our suppliers and common carriers are unable to meet our requirements to provide us the materials we need
    for clinical study and active patient care needs;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">indirect
    consequences of a pandemic on the economy in general, such as an increase in bankruptcies of our key suppliers, or the
    inability of our third-party payers to meet their obligations reimburse us in a timely fashion or at all;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">postponements
    and cancellations of key conferences and meetings and travel restrictions could interfere with our ability to interact with key thought
    leaders in the field, leading to a disruption in the rate of adoption of our technology;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">access
    restrictions at offices, hospitals, and treatment centers, and stakeholder illness could interfere with the ability of our sales
    force to engage in face-to-face visits with providers, leading to a disruption in the rate of adoption of our technology;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">increases
    in expenditures for technology and other tools necessary to provide patient care in an environment where both patient and care-giver
    travel is restricted and access to in-person interaction is limited;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">refusal
    of the FDA to accept data from clinical studies in affected geographies outside the United States; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">patient
    delays in seeking or receiving treatment, either due to fear of infection or lack of access to treatment and study sites, leading
    to fewer diagnoses of the indications our products are approved to treat or more advanced procession of the disease, which may contraindicate
    the use of our products or disqualify the patient from participating in a given study.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">The extent to which a pandemic may
impact our business and clinical studies will depend on future developments, which are highly uncertain and cannot be predicted with
confidence, such as the ultimate geographic spread of the disease, the duration of the pandemic, travel restrictions and social distancing
guidelines, business closures or business disruptions and the effectiveness of actions taken to contain and treat the disease. The response
to a pandemic may result in permanent changes to the environment in which we operate as described above in ways we are unable to predict.
A pandemic may also have the effect of heightening many of the other risks described herein.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Developing
medical technology entails significant technical, regulatory and business risks</i></b>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may fail to adapt our technology to user requirements or emerging treatment standards. Neuromodulation therapies are not currently considered
standard of care for IBS and may not ever be considered standard of care. Treatment standards may not evolve to incorporate our product.
New industry standards for the development, manufacture and marketing of medical devices may evolve and we may not be able to conform
to the changes, meet new standards in a timely fashion or maintain a competitive position in the market. In particular, regulatory standards
for electrical treatments of medical conditions are evolving. If we face material delays in introducing our products and new technology,
we may fail to attract new customers.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
Company has an evolving business strategy and investors must be willing to accept a substantial degree of uncertainty.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s strategic focus is on the development of developing neuromodulation therapies to address chronic and debilitating conditions
in children. The Company may engage in ongoing discussions with potential licensees, other strategic partners and institutional or private
financing sources, the result of which could add to or alter its current strategic focus, cash needs or ownership structure. Investors
must be willing to accept a substantial degree of uncertainty and must be willing to rely upon the Company&#8217;s board of directors
and management to complete an appropriate business strategy to commercially exploit targeted business opportunities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 45; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may not be able to compete with treatments now being marketed and developed, or which may be developed and marketed in the future by
other companies.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
products will compete with existing and new therapies and treatments for chronic and debilitating conditions in children. We are aware
of a number of companies currently seeking to develop alternative therapies or treatment for such diseases and conditions at least in
part. Numerous pharmaceutical, biotechnology, drug delivery and medical device companies, hospitals, research organizations, individual
scientists, and nonprofit organizations are engaged in the development of alternatives to our technology. Some of these companies have
greater research and development capabilities, experience, manufacturing, marketing, financial, and managerial resources than we do.
Collaborations or mergers between large pharmaceutical or biotechnology companies with competing treatment technologies could enhance
our competitors&#8217; financial, marketing, and other resources. Developments by other medical device companies could make our products
or technologies uncompetitive or obsolete. Accordingly, our competitors may succeed in developing competing technologies, obtaining FDA
clearances and/or approval for products or gaining market acceptance more rapidly than we can.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Due
in part to our limited financial resources, we may fail to select or capitalize on the most scientifically, clinically or commercially
promising or profitable indications or therapeutic areas for our product candidates, and/or we may be unable to pursue the clinical trials
that we would like to pursue.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have limited technical, managerial, and financial resources to determine the indications on which we should focus the development efforts
related to our product candidates. Due to our limited available financial resources, we may have curtailed clinical development programs
and activities that might otherwise have led to more rapid progress of our product candidates through the regulatory and development
processes.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may make incorrect determinations with regard to the indications and clinical trials on which to focus the available resources that we
do have. Furthermore, we cannot assure you that we will be able to retain adequate staffing levels to run our operations and/or to accomplish
all of the objectives that we otherwise would seek to accomplish. Our decisions to allocate our research, management, and financial resources
toward particular indications or therapeutic areas for our product candidates may not lead to the development of viable commercial products
and may divert resources from better opportunities. Similarly, our decisions to delay or terminate product development programs may also
cause us to miss valuable opportunities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
had material weaknesses in our internal control over financing reporting during the years ended December 31, 2024 and 2023, that are
unremediated as of December 31, 2024. If we fail to establish and maintain proper and effective internal control over financial
reporting, our operating results and our ability to operate our business could be harmed.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ensuring
that we have adequate internal financial and accounting controls and procedures in place so that we can produce accurate financial statements
on a timely basis is a costly and time-consuming effort that needs to be re-evaluated frequently. Our internal control over financial
reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation
of financial statements in accordance with generally accepted accounting principles.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 46; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
document, review and improve our internal controls and procedures for compliance with Section 404 of the Sarbanes-Oxley Act, which requires
annual management assessment of the effectiveness of our internal control over financial reporting. To comply with the requirements of
being a public company, the Company has undertaken various actions to implement internal controls and procedures. Testing and maintaining
internal controls can divert our management&#8217;s attention from other matters that are important to the operation of our business.
Additionally, when evaluating internal controls over financial reporting, the Company may identify material weaknesses that it may not
be able to remediate in time to meet the applicable deadline imposed upon us for compliance with the requirements of Section 404 of the
Sarbanes-Oxley Act. If the Company identifies any additional material weaknesses in its internal control over financial reporting or
is unable to remediate the material weakness described above or comply with the requirements of Section 404 of the Sarbanes-Oxley Act
in a timely manner or if the Company&#8217;s independent registered public accounting firm is unable to express an unqualified opinion
as to the effectiveness of our internal control over financial reporting once it is no longer an emerging growth company, or if the Company
is unable to conclude in our quarterly and annual reports that our disclosure controls and procedures are effective, investors may lose
confidence in the accuracy and completeness of the Company&#8217;s financial reports and the market price of our common stock could be
negatively affected, and the Company could become subject to investigations by the stock exchange on which our securities are listed,
the SEC or other regulatory authorities, which could require additional financial and management resources.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, if the Company fails to remediate any identified material weakness, our financial statements could be inaccurate and the Company
could face restricted access to capital markets. Our small size and internal control deficiencies may adversely affect our financial
condition, results of operation and access to capital. <span style="background-color: white">Moreover, our internal control over financial
reporting will not prevent or detect all errors and all fraud. A control system, no matter how well designed and operated, can provide
only reasonable, not absolute, assurance that the control system&#8217;s objectives will be met. Because of the inherent limitations
in all control systems, no evaluation of controls can provide absolute assurance that misstatements due to error or fraud will not occur
or that all control issues and instances of fraud will be detected.</span> If we cannot provide reliable financial reports or prevent
fraud, we may not be able to manage our business as effectively as we would if an effective control environment existed, and our business
and reputation with investors may be harmed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risks
Related to Legal and Regulatory Matters</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Product
liability suits, whether or not meritorious, could be brought against us due to alleged defective devices or for the misuse of our products,
which could result in expensive and time-consuming litigation, payment of substantial damages and/or expenses and an increase in our
insurance rates</i></b><i>.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
our current or future devices are defectively designed or manufactured, contain defective components or are misused, or if someone claims
any of the foregoing, whether or not meritorious, we may become subject to substantial and costly litigation. For example, we may be
sued if our products cause or are perceived to cause injury or are found to be otherwise unsuitable during clinical testing, manufacturing,
marketing or sale. This may occur if our products are misused or damaged, have a sudden failure or malfunction (including with respect
to safety features) or are otherwise impaired due to wear and tear. Even absent a product liability suit, malfunctions of our products
or misuse by physicians or patients would need to be remedied swiftly in order to maintain continuous use and ensure efficacy of our
products.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
product liability claims may include allegations of defects in manufacturing, defects in design, a failure to warn of dangers inherent
in the device, negligence, strict liability or a breach of warranties. Claims could also be asserted under state consumer protection
acts. If we cannot successfully defend ourselves against product liability claims, we may incur substantial liabilities or be required
to limit commercialization of our products. Even successful defense may require significant financial and management resources. Regardless
of the merits or eventual outcome, liability claims may result in:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">decreased
    demand for our products;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">injury
    to our reputation;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">withdrawal
    of clinical study participants and inability to continue clinical studies;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">initiation
    of investigations by regulators;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 47; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">costs
    to prepare for and defend the related litigation;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
    diversion of management&#8217;s time and our resources;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">substantial
    monetary awards to study participants or patients;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">product
    recalls, withdrawals or labeling, marketing or promotional restrictions;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">loss
    of revenues;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">exhaustion
    of any available insurance and our capital resources;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    inability to commercialize any device candidate; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
    decline in our share price.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Product
liability claims could divert management&#8217;s attention from our core business, be expensive to defend and result in sizable damage
awards against us. We may not have sufficient insurance coverage for all claims. Any product liability claims brought against us, with
or without merit, could increase our product liability insurance rates or prevent us from securing continuing coverage, could harm our
reputation in the industry and could reduce revenues. Product liability claims in excess of our insurance coverage would be paid out
of cash reserves, if any, which could have a material adverse effect on our business, prospects, financial condition and results of operations
and cause our stock price to decline. Even if our agreements with our third-party manufacturers and suppliers entitle us to indemnification
against losses, such indemnification may not be available or adequate should any claim arise.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Other
future litigation and regulatory actions could have a material adverse impact on the Company</i></b><i>.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">From
time to time, we may be subject to litigation and other legal and regulatory proceedings relating to our business or investigations or
other actions by governmental agencies. No assurances can be given that the results of these or new matters will be favorable to us.
An adverse resolution of lawsuits, arbitrations, investigations or other proceedings or actions could have a material adverse effect
on our financial condition and results of operations, including as a result of non-monetary remedies. Defending ourselves in these matters
may be time-consuming, expensive and disruptive to normal business operations and may result in significant expense and a diversion of
management&#8217;s time and attention from the operation of our business, which could impede our ability to achieve our business objectives.
Additionally, any amount that we may be required to pay to satisfy a judgment, settlement, fine or penalty may not be covered by insurance.
Subject to the Delaware General Corporation Law, our certificate of incorporation permit us to indemnify any director against any liability,
to purchase and maintain insurance against any liability for any director and to provide any director with funds (whether by loan or
otherwise) to meet expenditures incurred or to be incurred by such director in defending any criminal, regulatory or civil proceedings
or in connection with an application for relief (or to enable any such director to avoid incurring such expenditure). In addition, under
our Articles of Incorporation and bylaws (the &#8220;Bylaws&#8221;) we are obligated to indemnify each of our directors and officers
against certain liabilities and expenses arising from their being a director or officer to the maximum extent permitted by Delaware law.
In the event we are required to make such payments to our directors and officers, there can be no assurance that any of these payments
will not be material.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
are subject to consumer protection laws that regulate our marketing practices and prohibit unfair or deceptive acts or practices. Our
actual or perceived failure to comply with such obligations could harm our business, and changes in such regulations or laws could require
us to modify our products or marketing or advertising efforts.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with the marketing or advertisement of our products, we could be the target of claims relating to false, misleading, deceptive
or otherwise noncompliant advertising or marketing practices, including under the auspices of the FTC and state consumer protection statutes.
If we rely on third parties to provide any marketing and advertising of our products, we could be liable for, or face reputational harm
as a result of, their marketing practices if, for example, they fail to comply with applicable statutory and regulatory requirements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we are found to have breached any consumer protection, advertising, unfair competition or other laws or regulations, we may be subject
to enforcement actions that require us to change our marketing and business practices in a manner that may negatively impact us. This
could also result in litigation, fines, penalties and adverse publicity that could cause reputational harm and loss of customer trust,
which could have a material adverse effect on our business, financial condition and results of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 48; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->48<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
are increasingly dependent on information technology systems and are subject to privacy and security laws. Our products and our systems
and infrastructure face certain risks, including cyber security breaches and data leakage</i></b><i>.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
increasingly rely upon technology systems and infrastructure. Our technology systems, including our products, are potentially vulnerable
to breakdown or other interruption by fire, power loss, system malfunction, unauthorized access and other events. Likewise, data privacy
breaches by employees and others with both permitted and unauthorized access to our products and our systems may pose a risk that protected
patient information (&#8220;PI&#8221;) may be exposed to unauthorized persons or to the public, or may be permanently lost. The increasing
use and evolution of technology, including cloud-based computing, creates additional opportunities for the unintentional dissemination
of information, intentional destruction of confidential information stored in our systems or in non-encrypted portable media or storage
devices. We could also experience a business interruption, information theft of confidential information, or reputational damage from
industrial espionage attacks, malware or other cyber incidents, which may compromise our system infrastructure or lead to data leakage,
either internally or at our third-party service providers or other business partners.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
size and complexity of our computer systems, and scope of our geographic reach, make us potentially vulnerable to information technology
system breakdowns, internal and external malicious intrusion, cyberattacks and computer viruses. Because the techniques used to obtain
unauthorized access, or to sabotage systems, change frequently and generally are not recognized until launched against a target, we may
be unable to anticipate these techniques or to implement adequate preventative measures. If we do not allocate and effectively manage
the resources necessary to build and sustain the proper technology infrastructure or properly manage third-party contractors who perform
data management services on our behalf, then a security breach could subject us to, among other things, transaction errors, business
process inefficiencies, the loss of customers, damage to our reputation, business disruptions or the loss of or damage to intellectual
property. Such security breaches could expose us to a risk of loss of information, litigation, penalties, remediation costs and potentially
significant liability to customers, employees, business partners and regulatory authorities, including, for example, under the Health
Insurance Portability and Accountability Act of 1996 (&#8220;HIPAA&#8221;) in the United States and Regulation 2016/679 on the protection
of natural persons with regard to the processing of personal data and on the free movement of such data under GDPR in the EU. If our
data management systems (including third party data management systems) do not effectively collect, secure, store, process and report
relevant data for the operation of our business, whether due to equipment malfunction or constraints, software deficiencies, or human
error, our ability to effectively plan, forecast and execute our business plan and comply with applicable laws and regulations will be
impaired. Any such impairment could materially and adversely affect our financial condition and results of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">While
we have invested heavily in the protection of data and information technology and in related training, there can be no assurance that
our efforts will prevent significant breakdowns, breaches in our systems or other cyber incidents or ensure compliance with all applicable
security and privacy laws, regulations, and standards, including with respect to third-party service providers that utilize sensitive
personal information, including PI, on our behalf.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
security breach, whether of our products, systems or third-party hosting services we utilize, could disrupt treatments being provided
by our products, disrupt access to our customers&#8217; stored information, such as patient treatment data and health information, and
could lead to the loss of, damage to or public disclosure of such data and information, including patient health information. Such an
event could have serious negative consequences, including possible patient injury, regulatory action, fines, penalties and damages, reduced
demand for our products, an unwillingness of customers to use our products, harm to our reputation and brand and time-consuming and expensive
litigation, any of which could have a material adverse effect on our financial results. We currently carry cyber and privacy liability
insurance with an aggregate limit of $1,000,000, but the amount of insurance coverage that we purchased and may purchase in the future
may be inadequate. In the future, our insurance coverage may be expensive or not be available on acceptable terms or in sufficient amounts,
if at all.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 49; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->49<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may choose to, or may be required to, suspend, repeat or terminate our clinical studies if they are not conducted in accordance with
regulatory requirements, the results are negative or inconclusive or the studies are not well designed</i></b><i>.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Clinical
studies must be conducted in accordance with the FDA&#8217;s cGCPs and the equivalent laws and regulations applicable in other jurisdictions
in which the clinical studies are conducted. The clinical studies are subject to oversight by the FDA, regulatory agencies in other jurisdictions,
ethics committees and institutional review boards at the medical institutions where the clinical studies are conducted. In addition,
clinical studies must be conducted with device candidates produced under the FDA&#8217;s QSR and in accordance with the applicable regulatory
requirements in the other jurisdictions in which the clinical studies are conducted. The conduct of clinical studies may require large
numbers of test patients.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
FDA or regulatory agencies in other jurisdictions might delay or terminate our clinical studies of a device candidate for various reasons,
including:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    device candidate may have unforeseen adverse side effects or may not appear to be more effective than current therapies;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
    may not agree with the FDA, a regulatory authority in another jurisdiction or an ethics committee regarding the protocol for the
    conduct of a clinical study;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">new
    therapies may become the standard of care while we are conducting our clinical studies, which may require us to revise or amend our
    clinical study protocols or terminate a clinical study; or</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">fatalities
    may occur during a clinical study due to medical problems that may or may not be related to clinical study treatments.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Furthermore,
the process of obtaining and maintaining regulatory approvals in the U.S. and other jurisdictions is lengthy, expensive and uncertain.
It can vary substantially, based on the type, complexity and novelty of the product involved. Accordingly, any of our device candidates
could take a significantly longer time than we expect to, or may never, gain regulatory approval, which could have a material adverse
effect on our business, prospects, financial condition and results of operations and cause our stock price to decline.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Legislative
and regulatory changes in the U.S. and in other countries regarding healthcare insurance and government-sponsored reimbursement programs
(such as Medicare in the United States) may adversely affect our business and financial results</i></b>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
rely to a material degree on highly regulated private and government-run health insurance programs for our revenue in most of the countries
in which we operate. The laws and regulations regarding health care programs, both public and private, are driven by public policy considerations
that may be unrelated to the direct provision of patient care, such as lowering costs or requiring or limiting access to healthcare options.
These laws and regulations are very complicated and there are many requirements we must satisfy in order for our products to become and
remain eligible for reimbursement under these programs. In many cases we may have limited negotiating power when negotiating reimbursement
rates for our products.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the future, lawmakers and regulators could also pass additional healthcare laws and implement other regulatory changes at both the national
and local levels. These laws and regulations could potentially affect coverage and reimbursement for our products. However, we cannot
predict the ultimate content, timing or effect of any future healthcare initiatives or the impact any future legislation or regulation
will have on us.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">With
respect to countries outside the U.S., the national competent authorities in the EU member states, the UK, Switzerland, Israel, Japan,
and other jurisdictions are also increasingly active in their goal of reducing public spending on healthcare. We cannot, therefore, guarantee
that the treatment of patients with our products would be reimbursed in any particular country or, if successfully included on reimbursement
lists, whether we will remain on such lists.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
are subject to extensive post-marketing regulation by the FDA and comparable authorities in other jurisdictions, which could impact the
sales and marketing of our products and could cause us to incur significant costs to maintain compliance. In addition, we may become
subject to additional regulation in other jurisdictions if we market and sell our products outside of the U.S</i></b><i>.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
market and sell our products subject to extensive regulation by the FDA and numerous other federal, state and governmental authorities
in other jurisdictions. These regulations are broad and relate to, among other things, the conduct of pre-clinical and clinical studies,
product design, development, manufacturing, labeling, testing, product storage and shipping, premarket clearance and approval, conformity
assessment procedures, premarket clearance and approval of modifications introduced in marketed products, post-market surveillance and
monitoring, reporting of adverse events and incidents, pricing and reimbursement, interactions with healthcare professionals, interactions
with patients, information security, advertising and promotion and product sales and distribution. Although IB-Stim already has market
clearance from FDA for functional abdominal pain associated with IBS in children, we will require additional FDA clearances to market
our products for treating other indications.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 50; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->50<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, before our products can be marketed in the EU, our products must obtain a CE Certificate from a notified body. New intended
uses of CE marked medical devices falling outside the scope of the current CE Certificate require a completely new conformity assessment
before the device can be CE marked and marketed in the EU for the new intended use. The process required to gather necessary information
and draw up documentation in order to obtain CE Certification of a medical device in the EU can be expensive and lengthy and its outcome
can be uncertain. We may make modifications to our products in the future that we believe do not or will not require notifications to
our notified body or new conformity assessments to permit the maintenance of our current CE Certificate. If the competent authorities
of the EU member states or our notified body disagree and require the conduct of a new conformity assessment, the modification of the
existing CE Certificate or the issuance of a new CE Certificate, we may be required to recall or suspend the marketing of the modified
versions of our products.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
Japan, new medical devices or new therapeutic uses of medical devices falling outside the scope of the existing approval by the MHLW
require a new assessment and approval for each such new device or use. Accordingly, we may be required to obtain a new approval from
MHLW before we launch a modified version of our products or the use of our products for additional indications. Approval time frames
from the MHLW vary from simple notifications to review periods of one or more years, depending on the complexity and risk level of the
device. In addition, importation into Japan of medical devices is subject to &#8220;Quality Management System (QMS) Ordinance,&#8221;
which includes the equivalent of &#8220;Good Import&#8221; regulations in the U.S. As with any highly regulated market, significant changes
in the regulatory environment could adversely affect our ability to commercialize our products in Japan.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the U.S. and other jurisdictions, we also are subject to numerous post-marketing regulatory requirements, which include regulations under
the QSR related to the manufacturing of our products, labeling regulations and medical device reporting regulations, which require us
to report to the FDA or comparable regulatory authorities in other jurisdictions and our notified body if our products cause or contributes
to a death or serious injury, or malfunction in a way that would likely cause or contribute to a death or serious injury. In addition,
these regulatory requirements may in the future change in a way that adversely affects us. If we fail to comply with present or future
regulatory requirements that are applicable to us, we may be subject to enforcement action by the FDA or comparable regulatory authorities
in other jurisdictions and notified bodies, which may include any of the following sanctions:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">untitled
    letters, warning letters, fines, injunctions, consent decrees and civil penalties;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">unanticipated
    expenditures to address or defend such actions;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">patient
    notification, or orders for repair, replacement or refunds;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">voluntary
    or mandatory recall, withdrawal or seizure of our current or future devices;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">administrative
    detention by the FDA or other regulatory authority in another jurisdiction of medical devices believed to be adulterated or misbranded;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">operating
    restrictions, suspension or shutdown of production;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">refusal
    or delay of our requests for approval for new intended uses for or modifications to our products or for approval of new devices;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">refusal
    or delay in obtaining CE Certificates for new intended uses for or modifications to our products;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">suspension,
    variation or withdrawal of the CE Certificates granted by our notified body in the EU;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">prohibition
    or restriction of products being placed on the market;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">operating
    restrictions;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">suspension
    or withdrawal of approvals that have already been granted;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">refusal
    to grant export approval for our products or any device candidates; or</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">criminal
    prosecution.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
occurrence of any of these events could have a material adverse effect on our business, prospects, financial condition and results of
operations and cause our stock price to decline.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 51; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->51<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Over
time, we expect to make modifications to our products that are designed to improve efficacy, reduce side effects, enhance the user experience
or for other purposes. Modifications to our products may require approvals, modified or new CE Certificates and analogous regulatory
approvals in other jurisdictions or even require us to cease promoting or to recall the modified versions of our products until such
clearances, approvals or modified or new CE Certificates are obtained, and the FDA, comparable regulatory authorities in other jurisdictions
or our notified body may not agree with our conclusions regarding whether new approvals are required</i></b><i>.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, any substantial change introduced to a medical device or to the quality system certified by our notified body requires a new
conformity assessment of the device and can lead to changes to the CE Certificates or the preparation of a new CE Certificate of Conformity.
Substantial changes may include, among others, the introduction of a new intended use of the device, a change in its design or a change
in the Company&#8217;s suppliers. Responsibility for determination that a modification constitutes a substantial change lies with the
manufacturer of the medical device. We must inform the notified body that conducted the conformity assessment of the products we market
or sell in the EU of any planned substantial changes to our quality system or changes to our products that could, among other things,
affect compliance with the MDR or the devices&#8217; intended use. The notified body will then assess the changes and verify whether
they affect the product&#8217;s conformity with the Essential Requirements laid down in Annex I to the MDD or the conditions for the
use of the device. If the assessment is favorable, the notified body will issue a new CE Certificate or an addendum to the existing CE
Certificate attesting compliance with the Essential Requirements laid down in Annex I to the MDD. There is a risk that the competent
authorities of the EU member states or our notified body may disagree with our assessment of the changes introduced to our products.
The competent authorities of the EU member states or our notified body also may come to a different conclusion than the FDA on any given
product modification.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, medical devices that have obtained a CE Certification under the MDD may in principle continue to be marketed under such CE
Certificate until the CE Certificate expires and at the latest until May 27, 2024, provided that the manufacturer complies with the MDR&#8217;s
additional requirements related to post-marketing surveillance, market surveillance, vigilance, and registration of economic operators
and of devices. However, if such medical devices undergo a significant change in their design or intended use, we would need to obtain
a new CE Certificate under the MDR for these devices.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
the FDA disagrees with us and requires us to submit a new application for then-existing modifications and/or the competent authorities
of the EU member states or our notified body disagree with our assessment of the change introduced in a product, its design or its intended
use, we may be required to cease promoting or to recall the modified product until we obtain approval and/or until a new conformity assessment
has been conducted in relation to the product, as applicable. In addition, we could be subject to significant regulatory fines or other
penalties. Furthermore, our products could be subject to recall if the FDA, comparable regulatory authorities in other jurisdictions,
or our notified body determine, for any reason, that our products are not safe or effective or that appropriate regulatory submissions
were not made. Any recall or requirement that we seek additional approvals or clearances could result in significant delays, fines, increased
costs associated with modification of a product, loss of revenues and potential operating restrictions imposed by the FDA, comparable
foreign regulatory authorities in other jurisdictions, or our notified body. Delays in receipt or failure to receive approvals/certification,
or the failure to comply with any other existing or future regulatory requirements, could reduce our sales, profitability and future
growth prospects.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 52; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->52<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>In
addition to FDA requirements, we will spend considerable time and money complying with other federal, state, local and foreign rules,
regulations and guidance and, if we are unable to fully comply with such rules, regulations and guidance, we could face substantial penalties</i></b><i>.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are subject to extensive regulation by the U.S. federal government and the states and other countries in which we conduct our business.
U.S. federal government healthcare laws apply when we submit a claim on behalf of a U.S. federal healthcare program beneficiary, or when
a customer submits a claim for an item or service that is reimbursed under a U.S. federal government-funded healthcare program, such
as Medicare or Medicaid. The laws that affect our ability to operate our business in addition to the Federal Food, Drug, and Cosmetic
Act and FDA regulations include, but are not limited to, the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    U.S. federal Anti-Kickback Statute, an intent-based federal criminal statute which prohibits knowingly and willfully offering, providing,
    soliciting or receiving remuneration of any kind to induce or reward, or in return for, referrals or the purchase, lease, order or
    recommendation or arranging of any items or services reimbursable by a federal healthcare program;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    Federal Civil False Claims Act, which imposes civil penalties, including through civil whistleblower or &#8220;qui tam&#8221; actions,
    for knowingly submitting or causing the submission of false or fraudulent claims of payment to the federal government, knowingly
    making, using or causing to be made or used a false statement or record material to payment of a false claim or avoiding, decreasing
    or concealing an obligation to pay money to the federal government;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    Federal Criminal False Claims Act, which is similar to the Federal Civil False Claims Act and imposes criminal liability on those
    that make or present a false, fictitious or fraudulent claim to the federal government;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Medicare
    laws and regulations that prescribe requirements for coverage and reimbursement, and laws prohibiting false claims or unduly influencing
    selection of products for reimbursement under Medicare and Medicaid;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">healthcare
    fraud statutes that prohibit false statements and improper claims to any third-party payer;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    Federal Physician Self-Referral Law, commonly known as the Stark law, which, absent an applicable exception, prohibits physicians
    from referring Medicare and Medicaid patients to an entity for the provision of certain designated health services (&#8220;DHS&#8221;),
    if the physician (or a member of the physician&#8217;s immediate family) has an impermissible financial relationship with that entity
    and prohibits the DHS entity from billing for such improperly referred services;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    Federal Beneficiary Anti-Inducement Statute, which prohibits the offering of any remuneration to a beneficiary of Medicare or Medicaid
    that is likely to influence that beneficiary&#8217;s choice of provider or supplier. This can include, but is not limited to, inappropriate
    provision of patient services including financial assistance. Recent government investigations have focused on this particular prohibition.
    There are established exceptions from liability, but we cannot guarantee that all of our practices will fall squarely within those
    exceptions;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    U.S. Foreign Corrupt Practices Act, which can be used to prosecute companies in the U.S. for arrangements with physicians or other
    parties outside the U.S. if the physician or party is a government official of another country and the arrangement violates the law
    of that country;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    Federal Trade Commission Act, the Lanham Act and similar federal and state laws regulating truthfulness in advertising and consumer
    protection; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    Federal Physician Payments Sunshine Act, the French Sunshine Act and similar state and foreign laws, which require periodic reporting
    of payments and other transfers of value made to U.S. and French-licensed physicians, teaching hospitals, and in the U.S., physician
    assistants, nurse practitioners, clinical nurse specialists, certified nurse anesthetists, and certified nurse-midwives.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Similar
laws exist in the EU, individual EU member states and other countries. These laws are complemented by EU or national professional codes
of practices.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">HIPAA
provides data privacy and security provisions for safeguarding medical information. Additionally, states in the U.S. are enacting local
privacy laws (e.g., California). In the EU, the GDPR harmonizes data privacy laws and rules on the processing of personal data, including
patient and employee data, across the EU. The GDPR has a number of strict data protection and security requirements for companies processing
data of EU residents, including when such data is transferred outside of the EU. Additionally, we need to comply with analogous privacy
laws in other jurisdictions in which we operate, such as the Israeli Privacy Protection Law, the Asia Pacific Economic Cooperation Privacy
Framework, and Japan&#8217;s Act on the Protection of Personal Information.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
laws and codes of practices applicable to us are subject to evolving interpretations. Moreover, certain U.S. federal and state laws regarding
healthcare fraud and abuse and certain laws in other jurisdictions regarding interactions with healthcare professionals and patients
are broad and we may be required to restrict certain of our practices to be in compliance with these laws. Healthcare fraud and abuse
laws also are complex and even minor, inadvertent irregularities, or even the perception of impropriety, can potentially give rise to
claims that a statute has been violated.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 53; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->53<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
violation of these laws could have a material adverse effect on our business, prospects, financial condition and results of operations
and cause our stock price to decline. Similarly, if there is a change in law, regulation or administrative or judicial interpretations,
we may have to change our business practices or our existing business practices could be challenged as unlawful, which likewise could
have a material adverse effect on our business, prospects, financial condition and results of operations and cause our stock price to
decline. Fines and penalties for violations of these laws and regulations could include severe criminal and civil penalties, including,
for example, significant monetary damages, exclusion from participation in the federal healthcare programs and permanent disbarment of
key employees. Any penalties, damages, fines, curtailment or restructuring of our operations would adversely affect our ability to operate
our business, our prospects and our financial results. In addition, any action against us for violation of these laws, even if we successfully
defend against it, could cause us to incur significant legal expenses, divert our management&#8217;s attention from the operation of
our business and damage our reputation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, although we believe that we have the required licenses, permits and accreditation to dispense our products in the future, a
regulator could find that we need to obtain additional licenses or permits. We also may be subject to mandatory reaccreditation and other
requirements in order to maintain our billing privileges. Failure to satisfy those requirements could cause us to lose our privileges
to bill governmental and private payers. If we are required to obtain permits or licenses that we do not already possess, we also may
become subject to substantial additional regulation or incur significant expense.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
ensure compliance with Medicare, Medicaid and other regulations, federal and state governmental agencies and their agents, including
MACs, may conduct audits of our operations to support our claims submitted for reimbursement of items furnished to beneficiaries and
health care providers. Depending on the nature of the conduct found in such audits and whether the underlying conduct could be considered
systemic, the resolution of these audits could adversely impact our revenue, financial condition and results of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we, our collaborative partners, our contract manufacturers or our component suppliers fail to comply with the FDA&#8217;s QSR or equivalent
regulations established in other countries, the manufacturing and distribution of our products could be interrupted, and our product
sales and results of operations could suffer.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We,
our collaborative partners, our contract manufacturers and our component suppliers are required to comply with the FDA&#8217;s QSR and
the equivalent quality system requirements imposed by the laws and regulations in other jurisdictions, which are a complex regulatory
framework that covers the procedures and documentation of the design, testing, production, control, quality assurance, labeling, packaging,
sterilization, storage and shipping of our products. We cannot assure you that our facilities or our contract manufacturers&#8217; or
component suppliers&#8217; facilities would pass any future quality system inspection. If our or any of our contract manufacturers&#8217;
or component suppliers&#8217; facilities fails a quality system inspection, the manufacturing or distribution of our products could be
interrupted and our operations disrupted. Failure to take adequate and timely corrective action in response to an adverse quality system
inspection could force a suspension or shutdown of our packaging and labeling operations or the manufacturing operations of our contract
manufacturers, and lead to suspension, variation or withdrawal of our regulatory approvals or a recall of our products. If any of these
events occurs, we may not be able to provide our customers with our products on a timely basis, our reputation could be harmed and we
could lose customers, any or all of which could have a material adverse effect on our business, prospects, financial condition and results
of operations and cause our stock price to decline.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
products may in the future be subject to recalls that could harm our reputation, business and financial results</i></b><i>.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
FDA and similar governmental authorities in other jurisdictions have the authority to require the recall of commercialized products in
the event of material deficiencies or defects in design or manufacture. In the case of the FDA, the authority to require a recall must
be based on an FDA finding that there is a reasonable probability that the device would cause serious injury or death. In addition, governmental
bodies in other jurisdictions have the authority to require the recall of our products in the event of material deficiencies or defects
in design or manufacture. Distributors and manufacturers may, under their own initiative, recall a product if any material deficiency
in a device is found. A government-mandated or voluntary recall by us or one of our manufacturers could occur as a result of component
failures, manufacturing errors, design or labeling defects or other deficiencies and issues. The FDA requires that certain classifications
of recalls be reported to the FDA within ten working days after the recall is initiated. Requirements for the reporting of product recalls
to the competent authorities are imposed in other jurisdictions in which our products are or would be marketed in the future. Companies
are required to maintain certain records of recalls, even if they are not reportable to the FDA or to the competent authorities of other
countries. In the future, we may initiate voluntary recalls involving our products that we determine do not require notification of the
FDA or to other equivalent non-U.S. authorities. If the FDA or the equivalent non-U.S. authorities disagree with our determinations,
they could require us to report those actions as recalls. A future recall announcement could harm our reputation with customers and negatively
affect our sales. In addition, the FDA and the equivalent non-U.S. authorities could take enforcement action if we fail to report the
recalls when they were conducted. Recalls of our products would divert managerial and financial resources and could have a material adverse
effect on our business, prospects, financial condition and results of operations and cause our stock price to decline.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 54; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->54<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
our products cause or contribute to a death or a serious injury, or malfunction in certain ways, we will be subject to medical device
reporting regulations, which can result in voluntary corrective actions or agency enforcement actions</i></b><i>.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the FDA Medical Device Reporting regulations and the equivalent regulations applicable in other jurisdictions in which our products are
or may be marketed in the future, medical device manufacturers are required to report to the FDA and to the equivalent non-U.S. authorities
information that a device has or may have caused or contributed to a death or serious injury or has malfunctioned in a way that would
likely cause or contribute to death or serious injury if the malfunction of the device or one of our similar devices were to recur. If
we fail to report these events to the FDA or to the equivalent authorities in other jurisdictions within the required time frames, or
at all, the FDA or the equivalent authorities in other jurisdictions could take enforcement action against us. Any such adverse event
involving our products also could result in future voluntary corrective actions, such as recalls or customer notifications, or agency
action, such as inspection or enforcement action. Any corrective action, whether voluntary or involuntary, as well as defending ourselves
in a lawsuit, will require the dedication of our time and capital, distract management from operating our business, and may harm our
reputation and financial results.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may be subject to fines, penalties or injunctions if we are determined to be promoting the use of our products for unapproved or off-label
uses</i></b>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Medical
devices may be marketed only for the indications for which they are approved. Our promotional materials and training materials must comply
with FDA regulations and other applicable laws and regulations governing the promotion of our products in the U.S. and other jurisdictions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
the FDA or the competent authorities in other jurisdictions determine that our promotional materials or training constitutes promotion
of an unapproved use, they could request that we modify our training or promotional materials or subject us to regulatory or enforcement
actions, including the issuance of an untitled or warning letter, an injunction, seizure, civil fines and criminal penalties. It is also
possible that authorities in other federal, state or national enforcement in other jurisdictions might take action if they consider our
promotional or training materials to constitute promotion of an unapproved use, which could result in significant fines or penalties
under other statutory authorities, such as laws prohibiting false claims for reimbursement. In that event, our reputation could be damaged
and the commercialization of our products could be impaired.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
are affected by and subject to environmental laws and regulations that could be costly to comply with or that may result in costly liabilities</i></b>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are subject to environmental laws and regulations, including those that impose various environmental controls on the manufacturing, transportation,
storage, use and disposal of hazardous chemicals and other materials used in, and hazardous waste produced by, the manufacturing of our
products. We incur and expect to continue to incur costs to comply with these environmental laws and regulations. Additional or modified
environmental laws and regulations, including those relating to the manufacture, transportation, storage, use and disposal of materials
used to manufacture our products or restricting disposal or transportation of batteries, may be imposed that may result in higher costs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, we cannot predict the effect that additional or modified environmental laws and regulations may have on us, our third-party
suppliers of equipment and our products or our customers.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>The
pediatrics and medical device industries are characterized by patent and other intellectual property litigation and disputes, and any
litigation, dispute or claim against us may cause us to incur substantial costs, could place a significant strain on our financial resources,
divert the attention of management from our business, harm our reputation and require us to remove certain devices from the market</i></b><i>.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Whether
a product infringes a patent or violates other intellectual property rights involves complex legal and factual issues, the determination
of which is often uncertain. Any intellectual property dispute, even a meritless or unsuccessful one, would be time consuming and expensive
to defend and could result in the diversion of our management&#8217;s attention from our business and result in adverse publicity, the
disruption of research and development and marketing efforts, injury to our reputation and loss of revenues. Any of these events could
negatively affect our business, prospects, financial condition and results of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 55; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->55<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Third
parties may assert that our products, the methods employed in the use of our products or other activities infringe on their patents.
Such claims may be made by competitors seeking to obtain a competitive advantage or by other parties, many of whom have significantly
larger intellectual property portfolios than we have. Additionally, in recent years, individuals and groups have begun purchasing intellectual
property assets for the purpose of making claims of infringement and attempting to extract settlements from companies like ours. With
respect to our current products, the risk of infringement claims is exacerbated by the fact that there are numerous issued and pending
patents relating to the treatment of cancer. Because patent applications can take many years to issue, and in many cases remain unpublished
for many months after filing, there may be applications now pending of which we are unaware that may later result in issued patents that
our products may infringe.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
could also be existing patents that one or more components of our products or other device candidates may inadvertently infringe. As
the number of competitors in the market or other device candidates grows, the possibility of inadvertent patent infringement by us or
a patent infringement claim against us increases. To the extent we gain greater market visibility, our risk of being subject to such
claims is also likely to increase. If a third party&#8217;s patent was upheld as valid and enforceable and we were found to be infringing,
we could be prevented from making, using, selling, offering to sell or importing our products or other device candidates, unless we were
able to obtain a license under that patent or to redesign our systems to avoid infringement. A license may not be available at all or
on terms acceptable to us, and we may not be able to redesign our products to avoid any infringement. Modification of our products or
development of device candidates to avoid infringement could require us to conduct additional clinical studies and to revise our filings
with the FDA and other regulatory bodies, which would be time-consuming and expensive. If we are not successful in obtaining a license
or redesigning our devices, we may be unable to make, use, sell, offer to sell or import our devices and our business could suffer. We
may also be required to pay substantial damages and undertake remedial activities, which could cause our business to suffer.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may also be subject to claims alleging that we infringe or violate other intellectual property rights, such as copyrights or trademarks,
may have to defend against allegations that we misappropriated trade secrets, and may face claims based on competing claims of ownership
of our intellectual property. The confidentiality and assignment of inventions agreements that our employees, consultants and other third
parties sign may not in all cases be enforceable or sufficient to protect our intellectual property rights. In addition, we may face
claims from third parties based on competing claims to ownership of our intellectual property.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may employ individuals who were previously employed at other medical device companies, and as such we may be subject to claims that such
employees have inadvertently or otherwise used or disclosed the alleged trade secrets or other proprietary information of their former
employers. Any such litigation, dispute or claim could be costly to defend and could subject us to substantial damages, injunctions or
other remedies, which could have a material adverse effect on our business, prospects, financial condition and results of operations
and cause our stock price to decline.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Changes
in U.S. patent law could diminish the value of patents in general, thereby impairing our ability to protect our devices</i></b><i>.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
is the case with other medical device companies, our success is heavily dependent on our intellectual property rights, and particularly
on our patent rights. Obtaining and enforcing patents in the medical device industry involves both technological and legal complexity,
and is therefore costly, time consuming and inherently uncertain. In addition, the U.S. has recently enacted and is currently implementing
wide-ranging patent reform legislation. Certain U.S. Supreme Court rulings have narrowed the scope of patent protection available in
certain circumstances and weakened the rights of patent owners in certain situations. In addition to increasing uncertainty with regard
to our ability to obtain patents in the future, this combination of events has created uncertainty with respect to the value of patents
once obtained. Depending on decisions by the U.S. Congress, the federal courts and the USPTO, the laws and regulations governing patents
could change in unpredictable ways that could further negatively impact the value of our patents, narrow the scope of available patent
protection or weaken the rights of patent owners.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 56; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->56<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Future
regulatory action remains uncertain.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 20pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
operate in a highly regulated and evolving environment with rigorous regulatory enforcement. Any legal or regulatory action could be
time-consuming and costly. If we or the manufacturers or distributors that supply our products fail to comply with all applicable laws,
standards, and regulations, action by the FDA or other regulatory agencies could result in significant restrictions, including restrictions
on the marketing or use of the products we sell or the withdrawal of the products we sell from the market. Any such restrictions or withdrawals
could materially affect our reputation, business and operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
product candidates will remain subject to ongoing regulatory review even after they receive marketing clearances, and if we fail to comply
with continuing regulations, we could lose these clearances and the sale of any of our approved commercial products could be suspended.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 27pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Even
as we received regulatory clearance to market the IB-Stim, the manufacturing, labeling, packaging, adverse event reporting, storage,
advertising, promotion, and record keeping related to IB-Stim will remain subject to extensive regulatory requirements. If we fail to
comply with the regulatory requirements of the FDA and other applicable domestic and foreign regulatory authorities or discover any previously
unknown problems with any approved product, manufacturer, or manufacturing process, we could be subject to administrative or judicially
imposed sanctions, including:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">restrictions
    on the products, manufacturers, or manufacturing processes;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">warning
    letters;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">civil
    or criminal penalties;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">fines;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">injunctions;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">product
    seizures or detentions;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">pressure
    to initiate voluntary product recalls;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">suspension
    or withdrawal of regulatory clearances and/or approvals; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">refusal
    to approve pending applications for marketing clearances and/or approval of new products or supplements to approved applications.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Intellectual
property litigation and infringement claims could cause us to incur significant expenses or prevent us from selling certain of our products.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
therapeutic medical device and pharmaceutical industries are characterized by extensive intellectual property litigation and, from time
to time, we may become the subject of claims of infringement or misappropriation. Regardless of outcome, such claims are expensive to
defend and divert management and operating personnel from other business issues. A successful claim or claims of patent or other intellectual
property infringement against us could result in payment of significant monetary damages and/or royalty payments or negatively impact
our ability to sell current or future products in the affected category.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
depend extensively on our patents and proprietary technology and the patents, and we must protect those assets in order to preserve our
business.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Although
we expect to seek patent protection for any devices, <i>in silico</i> products (if any), systems, and processes we discover and/or for
any specific use we discover for new or previously known compounds, devices, biologics, products, systems, or processes, any or all of
these may not be subject to effective patent protection. In addition, our issued patents may be declared invalid or our competitors may
find ways to avoid the claims in the patents.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 27pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
success will depend, in part, on our ability to obtain patents, protect our trade secrets and proprietary knowledge and operate without
infringing on the proprietary rights of others. We are the sole assignee of numerous granted United States patents, pending United States
patent applications and international patents. The patent position of pharmaceutical and biotechnology firms like us are generally highly
uncertain and involves complex legal and factual questions, resulting in both an apparent inconsistency regarding the breadth of claims
allowed in United States patents and general uncertainty as to their legal interpretation and enforceability. Accordingly, patent applications
assigned to us may not result in patents being issued, any issued patents assigned to us may not provide us with competitive protection
or may be challenged by others, and the current or future granted patents of others may have an adverse effect on our ability to do business
and achieve profitability.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 57; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->57<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Moreover,
others may independently develop similar products, may duplicate our products, or may design around our patent rights. In addition, as
a result of the assertion of rights by a third-party or otherwise, we may be required to obtain licenses to patents or other proprietary
rights of others in or outside of the United States. Any licenses required under any such patents or proprietary rights may not be made
available on terms acceptable to us, if at all. If we do not obtain such licenses, we could encounter delays in product market introductions
during our attempts to design around such patents or could find that the development, manufacture or sale of products requiring such
licenses is foreclosed. In addition, we could incur substantial costs in defending suits brought against us or in connection with patents
to which we hold licenses or in bringing suit to protect our own patents against infringement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Due
to legal and factual uncertainties regarding the scope and protection afforded by patents and other proprietary rights, we may not have
meaningful protection from competition.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
long-term success will substantially depend upon our ability to protect our proprietary technologies from infringement, misappropriation,
discovery and duplication, and avoid infringing the proprietary rights of others. Our patent rights and the patent rights of biotechnology
and pharmaceutical companies in general, are highly uncertain and include complex legal and factual issues. Because of this, our pending
patent applications may not be granted. These uncertainties also mean that any patents that we own or will obtain in the future could
be subject to challenge, and even if not challenged, may not provide us with meaningful protection from competition. Due to our financial
uncertainties, we may not possess the financial resources necessary to enforce our patents. Patents already issued to us or our pending
applications may become subject to dispute, and any dispute could be resolved against us. Because a substantial number of patents have
been issued in the field of neuromodulation therapy and because patent positions can be highly uncertain and frequently involve complex
legal and factual questions, the breadth of claims obtained in any application or the enforceability of our patents cannot be predicted.
Consequently, we do not know whether any of our pending or future patent applications will result in the issuance of patents or, to the
extent patents have been issued or will be issued, whether these patents will be subject to further proceedings limiting their scope,
will provide significant proprietary protection or competitive advantage, or will be circumvented or invalidated.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Also,
because of these legal and factual uncertainties, and because pending patent applications are held in secrecy for varying periods in
the United States and other countries, even after reasonable investigation, we may not know with certainty whether any products that
we (or a licensee) may develop will infringe upon any patent or other intellectual property right of a third party. We believe that the
patents that we own or have applied for do not infringe any third-party patents; however, we cannot know for certain whether we could
successfully defend our position, if challenged. We may incur substantial costs if we are required to defend our intellectual property
in patent suits brought by third parties. These legal actions could seek damages and seek to enjoin testing, manufacturing and marketing
of the accused product or process. In addition to potential liability for significant damages, we could be required to obtain a license
to continue to manufacture or market the accused product or process.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
the third parties on which we rely for the conduct of our clinical trials and results do not perform our clinical trial activities in
accordance with good clinical practices and related regulatory requirements, we may be unable to obtain regulatory approval for or commercialize
our product candidates.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may use independent clinical investigators and other third-party service providers to conduct and/or oversee the clinical trials of our
product candidates for the foreseeable future.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
FDA requires us and our clinical investigators to comply with regulations and standards, commonly referred to as good clinical practices,
for conducting, recording, and reporting the results of clinical trials to assure that data and reported results are credible and accurate,
and that the trial participants are adequately protected. Our reliance on third parties that we do not control does not relieve us of
these responsibilities and requirements. Third parties may not complete activities on schedule or may not conduct our clinical trials
in accordance with regulatory requirements or the respective trial plans and protocols. The failure of these third parties to carry out
their obligations could delay or prevent the development, approval, and commercialization of our product candidates or result in enforcement
action against us.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 58; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->58<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risks
Related to Our Common Stock</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may not be able to maintain a listing of our common stock on NYSE American.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
common stock is listed on NYSE American. We must meet certain financial and liquidity criteria to maintain such listing. If we violate
NYSE American&#8217;s listing requirements, or if we fail to meet any of NYSE American&#8217;s listing standards, our common stock may
be delisted. In addition, our board of directors may determine that the cost of maintaining our listing on a national securities exchange
outweighs the benefits of such listing. A delisting of our common stock from NYSE American may materially impair our stockholders&#8217;
ability to buy and sell our common stock and could have an adverse effect on the market price of, and the efficiency of the trading market
for, our common stock. The delisting of our common stock could significantly impair our ability to raise capital and the value of your
investment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
do not expect to declare or pay dividends in the foreseeable future.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
do not expect to declare or pay dividends in the foreseeable future, as we anticipate that we will invest future earnings in the development
and growth of our business. Therefore, holders of our common stock will not receive any return on their investment unless they sell their
securities, and holders may be unable to sell their securities on favorable terms or at all.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
securities industry analysts do not publish research reports on us, or publish unfavorable reports on us, then the market price and market
trading volume of our common stock could be negatively affected.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
trading market for our common stock may be influenced in part by any research reports that securities industry analysts publish about
us. We do not currently have and may never obtain research coverage by securities industry analysts. If no securities industry analysts
commence coverage of us, the market price and market trading volume of our common stock could be negatively affected. In the event we
are covered by analysts, and one or more of such analysts downgrade our securities, or otherwise reports on us unfavorably, or discontinues
coverage of us, the market price and market trading volume of our common stock could be negatively affected.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Future
issuances of our common stock or securities convertible into, or exercisable or exchangeable for, our common stock, or the expiration
of lock-up agreements that restrict the issuance of new common stock or the trading of outstanding common stock, could cause the market
price of our common stock to decline and would result in the dilution of your holdings.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Future
issuances of our common stock or securities convertible into, or exercisable or exchangeable for, our common stock, or the expiration
of lock-up agreements that restrict the issuance of new common stock or the trading of outstanding common stock, could cause the market
price of our common stock to decline. We cannot predict the effect, if any, of future issuances of our securities, or the future expirations
of lock-up agreements, on the price of our common stock. In all events, future issuances of our common stock would result in the dilution
of your holdings. In addition, the perception that new issuances of our securities could occur, or the perception that locked-up parties
will sell their securities when the lock-ups expire, could adversely affect the market price of our common stock. In addition to any
adverse effects that may arise upon the expiration of these lock-up agreements, the lock-up provisions in these agreements may be waived,
at any time and without notice. If the restrictions under the lock-up agreements are waived, our common stock may become available for
resale, subject to applicable law, including without notice, which could reduce the market price for our common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 59; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->59<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Future
issuances of debt securities, which would rank senior to our common stock upon our bankruptcy or liquidation, and future issuances of
preferred stock, which could rank senior to our common stock for the purposes of dividends and liquidating distributions, may adversely
affect the level of return you may be able to achieve from an investment in our common stock.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the future, we may attempt to increase our capital resources by offering debt securities. Upon bankruptcy or liquidation, holders of
our debt securities, and lenders with respect to other borrowings we may make, would receive distributions of our available assets prior
to any distributions being made to holders of our common stock. Moreover, if we issue preferred stock, the holders of such preferred
stock could be entitled to preferences over holders of common stock in respect of the payment of dividends and the payment of liquidating
distributions. Because our decision to issue debt or preferred stock in any future offering, or borrow money from lenders, will depend
in part on market conditions and other factors beyond our control, we cannot predict or estimate the amount, timing or nature of any
such future offerings or borrowings. Holders of our common stock must bear the risk that any future offerings we conduct or borrowings
we make may adversely affect the level of return, if any, they may be able to achieve from an investment in our common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
our shares of common stock become subject to the penny stock rules, it would become more difficult to trade our shares.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
SEC has adopted rules that regulate broker-dealer practices in connection with transactions in penny stocks. Penny stocks are generally
equity securities with a price of less than $5.00, other than securities registered on certain national securities exchanges or authorized
for quotation on certain automated quotation systems, provided that current price and volume information with respect to transactions
in such securities is provided by the exchange or system. If we do not retain a listing on NYSE American or another national securities
exchange and if the price of our common stock is less than $5.00, our common stock could be deemed a penny stock. The penny stock rules
require a broker-dealer, before a transaction in a penny stock not otherwise exempt from those rules, to deliver a standardized risk
disclosure document containing specified information. In addition, the penny stock rules require that before effecting any transaction
in a penny stock not otherwise exempt from those rules, a broker-dealer must make a special written determination that the penny stock
is a suitable investment for the purchaser and receive (i) the purchaser&#8217;s written acknowledgment of the receipt of a risk disclosure
statement; (ii) a written agreement to transactions involving penny stocks; and (iii) a signed and dated copy of a written suitability
statement. These disclosure requirements may have the effect of reducing the trading activity in the secondary market for our common
stock, and therefore stockholders may have difficulty selling their shares.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
are subject to ongoing public reporting requirements that are less rigorous than Exchange Act rules for companies that are not emerging
growth companies, and our stockholders could receive less information than they might expect to receive from more mature public companies.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are required to publicly report on an ongoing basis as an &#8220;emerging growth company&#8221; (as defined in the JOBS Act) under the
reporting rules set forth under the Exchange Act. For so long as we remain an emerging growth company, we may take advantage of certain
exemptions from various reporting requirements that are applicable to other Exchange Act reporting companies that are not emerging growth
companies, including but not limited to:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">not
    being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">being
    permitted to comply with reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements;
    and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">being
    exempt from the requirement to hold a non-binding advisory vote on executive compensation and stockholder approval of any golden
    parachute payments not previously approved.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
expect to take advantage of these reporting exemptions until we are no longer an emerging growth company. We would remain an emerging
growth company for up to five years, although if the market value of our common stock that is held by non-affiliates exceeds $700 million
as of any June 30 before that time, we would cease to be an emerging growth company as of the following December 31.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Because
we are subject to ongoing public reporting requirements that are less rigorous than Exchange Act rules for companies that are not emerging
growth companies, our stockholders could receive less information than they might expect to receive from more mature public companies.
We cannot predict if investors will find our common stock less attractive if we elect to rely on these exemptions, or if taking advantage
of these exemptions would result in less active trading or more volatility in the price of our common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 60; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->60<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Because
the Company is a &#8220;smaller reporting company,&#8221; we may take advantage of certain scaled disclosures available to us, resulting
in holders of our securities receiving less Company information than they would receive from a public company that is not a smaller reporting
company.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are a &#8220;smaller reporting company&#8221; as defined in the Exchange Act. As a smaller reporting company, we may take advantage of
certain of the scaled disclosures available to smaller reporting companies and will be able to take advantage of these scaled disclosures
for so long as (i) our common stock held by non-affiliates is less than $250 million measured on the last business day of our second
fiscal quarter, or (ii) our annual revenue is less than $100 million during the most recently completed fiscal year and our common stock
held by non-affiliates is less than $700 million measured on the last business day of our second fiscal quarter. To the extent we take
advantage of any reduced disclosure obligations, it may make it harder for investors to analyze the Company&#8217;s results of operations
and financial prospectus in comparison with other public companies.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a smaller reporting company, we are permitted to comply with scaled-back disclosure obligations in our SEC filings compared to other
issuers, including with respect to disclosure obligations regarding executive compensation in our periodic reports and proxy statements.
We have elected to adopt the accommodations available to smaller reporting companies. Until we cease to be a smaller reporting company,
the scaled-back disclosure in our SEC filings will result in less information about our company being available than for other public
companies.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
investors consider our common stock less attractive as a result of our election to use the scaled-back disclosure permitted for smaller
reporting companies, there may be a less active trading market for our common stock and our share price may be more volatile.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>As
a &#8220;smaller reporting company,&#8221; we may at some time in the future choose to exempt our Company from certain corporate governance
requirements that could have an adverse effect on our public shareholders.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
NYSE American rules, a &#8220;smaller reporting company,&#8221; as defined in Rule 12b-2 under the Exchange Act, is not subject to certain
corporate governance requirements otherwise applicable to companies listed on NYSE American. For example, a smaller reporting company
is exempt from the requirement of having a compensation committee composed solely of directors meeting certain enhanced independence
standards, as long as the compensation committee has at least two members who do meet such standards. Although we have determined not
to avail ourselves of this or other exemptions from NYSE American requirements that are or may be afforded to smaller reporting companies
while we will seek to maintain our shares on NYSE American, in the future we may elect to rely on any or all of these exemptions. By
electing to utilize any such exemptions, our Company may be subject to greater risks of poor corporate governance, poorer management
decision-making processes, and reduced results of operations from problems in our corporate organization. Consequently, if we were to
avail ourselves of these exemptions, our stock price might suffer, and there is no assurance that we would be able to continue to meet
all continuing listing requirements of NYSE American from which we would not be exempt, including minimum stock price requirements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="ar_001"></span>ITEM
1B. UNRESOLVED STAFF COMMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.2in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
applicable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="ar_002"></span>ITEM
1C. CYBERSECURITY</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.2in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_982_ecyd--CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock_iB_c20240101__20241231_gBFCRMPFAIAMT-WZUFCDJS_zEmMgyTvvsJ6" class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" continuedAt="ConU000048-01" escape="true" id="Fact000048" name="cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CYBERSECURITY
RISK MANAGEMENT AND STRATEGY. </b>NeurAxis has developed and implemented a cybersecurity framework intended to assess, identify and manage
risks from threats to the security of our information, systems, products and network using a risk-based approach. The framework is informed
in part by the National Institute of Standards and Technology (NIST) Cybersecurity Framework and International Organization for Standardization
27001 (ISO 27001) Framework, although this does not imply that we meet all technical standards, specifications, or requirements under
the NIST or ISO 27001.</span></ix:nonNumeric></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span id="xdx_C0F_gBFCRMPFAIAMT-WZUFCDJS_zv6PQTrd7BY9"><ix:continuation continuedAt="ConU000048-02" id="ConU000048-01"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span>Our
key cybersecurity processes include the following:</span></span></ix:continuation></span></p>

<div id="xdx_C0E_gBFCRMPFAIAMT-WZUFCDJS_zHhfuL3u0Ali"><ix:continuation continuedAt="ConU000048-03" id="ConU000048-02"><div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risk-based
    controls for information systems and information on NeurAxis&#8217; networks:</b> We seek to maintain an information technology infrastructure
    that implements physical, administrative and technical controls that are calibrated based on risk and designed to protect <span id="xdx_90E_ecyd--CybersecurityRiskManagementProcessesIntegratedFlag_dbT_c20240101__20241231_z5YO9ZFsajK9" class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" format="ixt:booleantrue" id="Fact000049" name="cyd:CybersecurityRiskManagementProcessesIntegratedFlag">the confidentiality,
    integrity and availability of our information systems</ix:nonNumeric></span> and information stored on NeurAxis&#8217; networks, including customer information,
    personal information, PHI/PII, intellectual property and proprietary information. NeurAxis added physical safeguards in the form
    of biometric entry systems to access server rooms and 24/7 surveillance at both NeurAxis locations.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Cybersecurity
    incident policies: </b>We have cybersecurity incident policies, an incident response plan and a dedicated team to respond to cybersecurity
    incidents, including experienced counsel. When a cybersecurity incident occurs or we identify a vulnerability, the dedicated team
    is responsible for leading the initial assessment of priority and severity, including external experts that may also be engaged as
    appropriate. NeurAxis&#8217; response to incidents depends on the severity level and seeks to improve its cybersecurity incident
    response plan. NeurAxis, through experienced cybersecurity and HIPAA/HITECH counsel, has developed a security manual and a privacy
    policy.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 61; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->61<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Training:
    </b>We provide security awareness training to help our employees understand their information protection and cybersecurity responsibilities
    at NeurAxis. We also provide additional role-based training to some employees based on customer requirements, regulatory obligations,
    and industry risks.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Supplier
    risk assessments: </b>We have participated in <span id="xdx_90E_ecyd--CybersecurityRiskManagementThirdPartyEngagedFlag_dbT_c20240101__20241231_zAIa48IUx2j" class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" format="ixt:booleantrue" id="Fact000050" name="cyd:CybersecurityRiskManagementThirdPartyEngagedFlag">several third-party risk assessment processes</ix:nonNumeric></span> that include expectations regarding information
    and cybersecurity. NeurAxis also seeks contractual commitments from key suppliers to appropriately secure and maintain their information
    technology systems and protect NeurAxis information that is processed or stored on their systems. This may or may not include business
    associate agreements, downstream vendor agreements and vendor auditing in some cases.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Third-party
    assessments of NeurAxis: </b>We have third-party cybersecurity companies engaged to assess NeurAxis&#8217; cybersecurity readiness
    and to assist in identifying and remediating risks from cybersecurity threats. NeurAxis has a &#8220;real time&#8221; cybersecurity
    partner that monitors our servers 24/7/365 for any attempted intrusions.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</div></ix:continuation></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span><span id="xdx_C0A_gBFCRMPFAIAMT-WZUFCDJS_zzluHpOf4uz"><ix:continuation id="ConU000048-03">NeurAxis
routinely reviews the Office of Civil Right (OCR) audit requirements to assess any gaps within our cybersecurity, privacy and security
programs. We have not identified risks from known cybersecurity threats, that have materially affected us, including our operations,
business strategy, results of operations, cash flows or financial condition. We face certain ongoing risks from cybersecurity threats,
including active interactions with children&#8217;s hospitals while assisting with insurance prior approvals, that, if realized, are
reasonably likely to materially affect us, including our operations, business strategy, results
of operations, cash flows or financial condition.</ix:continuation></span></span><span style="background-color: white"><span></span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span id="xdx_90D_ecyd--CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock_c20240101__20241231_z1HO26yeGPhl" class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000051" name="cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock">As of the fiscal year ended December 31, 2024, the
Company had <span id="xdx_900_ecyd--CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag_dbF_c20240101__20241231_zgnGEIsUM3yj" class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" format="ixt:booleanfalse" id="Fact000052" name="cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag">not</ix:nonNumeric></span> experienced any material cybersecurity incidents that have had a significant impact on our operations, data integrity,
results of operations, or financial performance.</ix:nonNumeric></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p id="xdx_98A_ecyd--CybersecurityRiskBoardOfDirectorsOversightTextBlock_c20240101__20241231_gBFCRBODOTB-GPL_zSnjCrFbG1Bk" class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" continuedAt="ConU000054-01" escape="true" id="Fact000054" name="cyd:CybersecurityRiskBoardOfDirectorsOversightTextBlock"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CYBERSECURITY
GOVERNANCE. </b>NeurAxis&#8217; Board of Directors is responsible for oversight of cybersecurity risk. The Board receives reporting about
NeurAxis&#8217; practices, programs, notable threats or incidents and other developments related to cybersecurity throughout the year,
including through periodic updates from NeurAxis&#8217; Chief Regulatory Officer/Privacy Officer and VP of IT/Security Officer.</span></ix:nonNumeric></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span><span id="xdx_C0F_gBFCRBODOTB-GPL_zHcudq30OXqi"><ix:continuation id="ConU000054-01">NeurAxis&#8217;
Security Officer reports to NeurAxis&#8217; <span id="xdx_90B_ecyd--CybersecurityRiskRoleOfManagementTextBlock_c20240101__20241231_zVH6Wqj9tsI7" class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000055" name="cyd:CybersecurityRiskRoleOfManagementTextBlock">Chief Regulatory Officer and together, they lead the Company&#8217;s overall cybersecurity
function</ix:nonNumeric></span>. The Security Officer has over 13 years of experience in managing and leading IT or cybersecurity teams and participates in
various cyber security trainings frequently. The Security Officer collaborates with NeurAxis personnel and our outside IT vendors to
identify and analyze cybersecurity risks to NeurAxis, considers industry trends, implement controls, as appropriate and feasible, to
mitigate these risks and enables business leaders to make risk-based business decisions that impact cybersecurity considerations. The
Security Officer meets with senior leadership to review and discuss NeurAxis&#8217; cybersecurity program, including emerging cyber risks,
threats, and industry trends. The Security Officer also supervises efforts to prevent, detect, mitigate, and remediate cybersecurity
risks and incidents through various means, including by collaborating with external security personnel and business stakeholders, and
incorporating threat intelligence and other information obtained from governmental, public, or private sources to strengthen our cybersecurity
technologies and processes.</ix:continuation></span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.2in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="ar_003"></span>ITEM
2. PROPERTIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
corporate headquarters are located in Carmel, Indiana, where we lease office space for employees, pursuant to a lease agreement with
Zeller-Carmel Property, LLC. The term of this lease commenced on January 1, 2024 and is scheduled to end on May 31, 2029. Over the term
of the lease, the monthly base rent is $6,721 with an annual 2.5% escalator. We received a 50% reduction in our monthly rent for the
first 10 months of the lease.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
also lease office space in Versailles, Indiana, pursuant to an agreement that commenced January 1, 2022 for a term of one year with automatic
one year renewal options, unless 60 day notice of vacating is given. The monthly base rent is $1,800 with an annual 4% escalator upon
renewal.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.2in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 62; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->62<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="ar_004"></span>ITEM
3. LEGAL PROCEEDINGS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.2in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">From
time to time, the Company may be involved in litigation relating to claims arising out of operations in the normal course of business.
As of the date of issuance, other than those described below, there were no pending or threatened legal proceedings that could reasonably
be expected to have a material effect on the results of the Company&#8217;s operations. There are also no proceedings in which any of
the Company&#8217;s directors, officers or affiliates is an adverse party to the Company or has a material interest adverse to the Company&#8217;s
interest.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 6, 2019, plaintiff Ritu Bhambhani, M.D., initiated a lawsuit against Innovative Health Solutions, Inc. and others in the United
States District Court for the District of Maryland. Plaintiffs Bhambhani and Sudhir Rao subsequently amended the complaint, with the
Third Amended Complaint (&#8220;Complaint&#8221;) containing the most recent set of allegations. The Complaint asserted claims under
the RICO Act, as well as of fraudulent misrepresentation, intentional misrepresentation by concealment, and civil conspiracy and sought
compensatory damages in excess of $5 million, pre-judgment interest, punitive damages, attorney&#8217;s fees, court costs and designation
of the case as a class action. The Complaint stated that the Company, distributors of the Company&#8217;s product, and medical billing
and coding consultants allegedly made misrepresentations to the plaintiffs that the Company&#8217;s NeuroStim device and related procedures
could be billed to, and reimbursed by, Medicare and other insurance payors as a surgically implantable neurostimulator. Plaintiffs claim
to have suffered damages when Medicare administrative contractors declined to pay plaintiffs for their use of the device.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 11, 2022, the Company filed a motion for summary judgment based upon the plaintiffs not being proper parties to assert claims
against the Company. On June 14, 2022, the Court granted the Company&#8217;s motion for summary judgment and dismissed the Complaint.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
July 14, 2022, plaintiffs Ritu Bhambhani and Sudhir Rao filed a notice of appeal with the Fourth Circuit Court of Appeals. On June 3,
2024, the Fourth Circuit denied the plaintiff&#8217;s appeal and entered judgment against the plaintiffs. On June 25, 2024, the Fourth
Circuit entered its mandate declaring that its judgment against the plaintiffs took effect that day. The plaintiffs did not seek any
further review or appeal of that judgment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Also
on July 14, 2022, plaintiffs Ritu Bhambhani, LLC; Box Hill Surgery Center, LLC; Pain and Spine Specialists of Maryland, LLC; and SimCare
ASC, LLC initiated a lawsuit against the Company and others in the United States District Court for the District of Maryland. The plaintiffs
in this lawsuit are business entities owned or partially owned by the plaintiffs that initiated the litigation described above. The Complaint
asserted claims under the RICO Act, as well as fraudulent misrepresentation, intentional misrepresentation by concealment, and civil
conspiracy and seeks compensatory damages in excess of $75,000, pre-judgment interest, punitive damages, attorney&#8217;s fees, and court
costs. The Complaint states that the Company, distributors of the Company&#8217;s product, and medical billing and coding consultants
allegedly made misrepresentations to the plaintiffs that the Company&#8217;s NeuroStim device and related procedures could be billed
to, and reimbursed by, Medicare and other insurance payors as a surgically implantable neurostimulator. Plaintiffs claim to have suffered
damages when Medicare administrative contractors declined to pay plaintiffs for their use of the device.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
September 28, 2022, the Company filed a motion to dismiss all claims. On May 25, 2023, the Court issued an Order and a Memorandum Opinion
which dismissed the plaintiffs&#8217; claims related to the RICO Act. The remaining claims are still pending, and no trial date has been
set for the case. </span>The Court has vacated its Scheduling Order at the parties&#8217; request so that the parties could try to resolve
the disputes in both cases through an independent third-party mediator. Mediation has not yet resulted in a resolution of the case.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 63; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->63<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">In January 2024, Dr. Arturo Taca served notice to the Company that asserted
an interest in its U.S. Patent No. 10,413,719 valued at $2,000,000 based on his own work in neurostimulation.&#160; The Company denied
both the neurostimulation patent and compensation claims.&#160; The case remains unresolved.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">While it is too early to predict
the ultimate outcome of these matters, we believe the Company has meritorious defenses and intends to defend these matters vigorously.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="ar_005"></span>ITEM
4. MINE SAFETY DISCLOSURES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.2in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
applicable.</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="ar_006"></span>PART
II</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="ar_007"></span>ITEM
5. MARKET FOR REGISTRANT&#8217;S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 12.95pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Market
Information and Holders of Common Stock</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 12.95pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
common stock is listed on the NYSE American, under the symbol &#8220;NRXS&#8221;.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 12.95pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of March 13, 2025, there were approximately 682 record holders of our common stock. The number of record holders does not include beneficial
owners of common stock whose shares are held in the names of banks, brokers, nominees or other fiduciaries and holders of unissued shares
common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
last reported sales price for our Common Stock as reported on the NYSE American on March 13, 2025 was $2.10.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Dividends</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have not declared or paid any cash dividends on our common stock, and we do not anticipate declaring or paying cash dividends for the
foreseeable future. We are not subject to any legal restrictions respecting the payment of dividends, except that we may not pay dividends
if the payment would render us insolvent. Any future determination as to the payment of cash dividends on our common stock will be at
the discretion of our board of directors and will depend on our financial condition, operating results, capital requirements and other
factors that the board of directors considers to be relevant.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Recent
Sales of Unregistered Securities</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 12.95pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
November 14, 2024, the Company entered into security purchase agreements with five accredited investors for the issuance and purchase
of 45,653 shares of the Company&#8217;s Series B Preferred Stock, par value $0.001 per share, for an aggregate purchase price
of $108,664.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 26, 2024, the Company issued 10,000 shares of common stock to an accredited investor for their services in bringing RED to
market.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 3, 2025 and March 6, 2025, the Company granted 360,902 and 373,275 restricted stock units (RSUs), respectively, to certain
employees pursuant to the 2022 NeurAxis, Inc. Omnibus Securities and Incentive Plan, as amended on August 15, 2024. The RSUs
vest annually over a three-year cliff-vesting period and are payable in shares of the Company&#8217;s common stock. The RSUs fully
vest upon (i) death or disability or (ii) change of control. Dividend equivalents accrue on RSUs and are paid upon
vesting.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 17, 2025, the Company issued (i) 39,471 shares of common stock to its independent board members for their service from April
1, 2024 through December 31, 2024 and (ii) 186,166 shares of common stock to an accredited investor upon conversion of 502,647
common stock warrants in a cash less exercise transaction.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="ar_008"></span>ITEM
6. RESERVED</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 64; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->64<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="ar_009"></span>ITEM
7. MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 12.95pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Overview</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are a growth stage company focused on developing neuromodulation therapies to address chronic and debilitating conditions in children.
Our mission is to provide solutions that create value and provide better and safer patient outcomes. Our IB-Stim device is a PENFS system
intended to be used in patients 8-21 years of age with functional abdominal pain associated with IBS. Our device already has market clearance
from FDA for functional abdominal pain associated with IBS in children. Other indications in our pipeline are comprised of functional
nausea in children, post-concussion syndrome in children, and cyclic vomiting syndrome in children.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Since
our inception, we have incurred significant operating losses. Our net loss was $8,241,501 and $14,626,683 for the years ended December
31, 2024 and 2023, respectively. Our auditors have expressed substantial doubt about our ability to continue as a going concern in their
audit opinion. We expect to incur significant expenses and operating losses for the foreseeable future as we continue to pursue widespread
insurance coverage of our IB-Stim and RED devices and seek FDA clearance of our device for other indications. There are a number of milestones
and conditions that we must satisfy before we will be able to generate sufficient revenue to fund our operations, including FDA clearance
of our IB-Stim device to treat future indications.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Factors
Affecting our Business and Results of Operations</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Revenue</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
revenue is derived from the sale of our IB-Stim device to healthcare companies, primarily hospitals and clinics. Sales generally are
not seasonal and only mildly correlated with economic cycles. Our IB-Stim device sells for $1,195 per device, and each child being treated
for functional abdominal pain associated with IBS will use four.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
sales typically are made on a purchase order basis rather than through long-term purchase commitments. We enter into sales agreements
with customers for IB-Stim devices based on purchase orders and standard terms, which vary slightly based on the customer&#8217;s form,
and conditions of sale. Standard payment terms generally are that payment is due within 30 days. Our largest sales were to three customers
representing approximately 40% and 45% of total sales for the years ended December 31, 2024 and 2023, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inflation
did not have a material impact on our operations for any applicable period, and we do not expect inflation to have a material impact
on our operations for the foreseeable future.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Gross
profit and Gross Margin</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Our
management uses gross profit and gross margin to evaluate the efficiency of operations and as a key component to determining the effectiveness
and allocation of resources. We calculate gross profit as net sales less cost of goods sold, and gross margin as gross profit divided
by net sales. Our gross margin has been and will continue to be affected by a variety of factors, primarily the average selling price
of our IB-Stim device, production volume, order flows, change in mix of customers, third-party manufacturing costs related to components
of our IB-Stim device, and cost-reduction strategies. We expect our gross profit to increase for the foreseeable future as our net sales
grows, both through broader insurer acceptance of our IB-Stim device in the near term and approval of our technology for the treatment
of other indications over the longer term. Our gross margin may fluctuate from quarter to quarter due to changes in average selling prices,
particularly as we introduce enhancements to our IB-Stim device and new products to address other indications, and as we adopt new manufacturing
processes and technologies.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Expenses</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have four categories of expenses: cost of goods sold, selling, research and development (&#8220;R&amp;D&#8221;), and general and administrative
(&#8220;G&amp;A&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Costs
of goods sold consist of costs paid for the IB-Stim device to our contract manufacturer along with shipping and handling costs and expired
inventory charges. Expired inventory expense is related to our FDA clearance for our device in the treatment of functional abdominal
pain associated with IBS in children. Specifically, a certain component of our IB-Stim device is cleared for a two-year period after
the date the device is manufactured, and if the device is not sold in such period, we must take the device out of inventory and write
it off. The cost of expired inventory was $25,008 for the year ended December 31, 2023, representing 8.2% of our costs of goods sold.
The Company did not have any expired inventory in the year ended December 31, 2024. We have a fixed-price contract with the manufacturer
of our IB-Stim device to produce the device. We expect production costs to remain relatively constant and only nominal inventory expirations
in the foreseeable future.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 65; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->65<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
core selling expenses primarily consist of commissions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development expense is attributable to our clinical trials and related efforts to have our IB-Stim device cleared by the FDA for
other indications. We expect future R&amp;D expenses for other indications, such as functional nausea, post-concussion syndrome and cyclic
vomiting syndrome in children.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">General
and administrative expense primarily consists of wages and benefits, professional fees including legal and audit, insurance, investor
relations, advertising, facility costs, utilities and travel.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Results
of Operations</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Comparison
of Year Ended December 31, 2024, and Year Ended December 31, 2023</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table presents our statements of operations for the years ended December 31, 2024 and 2023:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center">Years Ended December 31,</td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2024</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2023</td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; font-weight: bold; text-align: left">Net sales</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">2,685,925</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">2,460,049</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Cost of goods sold</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">362,002</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">303,345</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Gross profit</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,323,923</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,156,704</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Selling expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">324,708</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">323,569</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Research and development</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">206,107</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">169,315</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">General and administrative</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">8,949,925</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">8,328,315</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Operating loss</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(7,156,817</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(6,664,495</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">Other (expense) income, net:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Financing charges</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(230,824</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(2,772</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Interest expense, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(174,328</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(476,416</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Change in fair value of warrant liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(941</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">844,854</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Change in fair value of derivative financial instruments</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">198,551</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Amortization of debt discount and issuance costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(126,387</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(4,881,622</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Extinguishment of debt liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(3,649,561</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Other (expense) income, net</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(552,204</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">4,778</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Total other (expense) income, net</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(1,084,684</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(7,962,188</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Net loss</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(8,241,501</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(14,626,683</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 66; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->66<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Net
Sales</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
sales increased $225,876, or 9.2%, from $2,460,049 for the year ended December 31, 2023, to $2,685,925 for the year ended December 31,
2024, primarily due to volume growth from our financial assistance programs that provide discounts to patients without insurance coverage.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Gross
Profit and Gross Margin</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Gross
profit increased $167,219, or 7.8%, from $2,156,704 for the year ended December 31, 2023, to $2,323,923 for the year ended December 31,
2024, due to higher sales volume. Despite the increase in sales volume, the decrease in gross margin from 87.7% for the year ended December
31, 2023, to 86.5% for the year ended December 31, 2024, was due to higher growth in the Company&#8217;s financial assistance programs
that are discounted to patients without insurance coverage compared to the Company&#8217;s undiscounted full reimbursement customers.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Selling
Expenses</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Selling
expenses increased $1,139, or 0.4%, from $323,569 for the year ended December 31, 2023, to $324,708 for the year ended December 31, 2024,
due to higher sales volume.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Research
and Development</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development expenses increased $36,792, or 21.7%, from $169,315 for the year ended December 31, 2023, to $206,107 for the year ended
December 31, 2024, due to costs to bring the RED product to market and higher costs on a medical research project.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>General
and Administrative</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">General
and administrative expenses increased $621,610, or 7.5%, from $8,328,315 for the year ended December 31, 2023, to $8,949,925 for the year
ended December 31, 2024, due to <span style="background-color: white">(i) higher legal, insurance, investor relations, board of directors
and stock exchange listing costs as a publicly held entity that the Company did not incur prior to its 2023 IPO, (ii) incremental headcount
to build out the market access, sales and finance teams, (iii) severance charges related to the Company&#8217;s prior Chief Operating
Officer, (iv) one-time advisory costs, (v) expenses related to the introduction of an annual short-term incentive program
and (vi) higher advertising costs in order to expand market awareness, partially offset by the non-recurrence of 2023 post-IPO consulting
and recruiting services and the payment of incentive bonuses contingent upon the 2023 IPO.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Operating
Loss</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
operating loss increased $492,322, or 7.4%, from $6,664,495 for the year ended December 31, 2023, to $7,156,817 for the year ended December
31, 2024, primarily due to higher general and administrative expenses partially offset by higher sales volume.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 67; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->67<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Other
(Expense) Income</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
expense decreased $6,877,504 or 86.4%, from $7,962,188 for the year ended December 31, 2023, to $1,084,684 for the year ended
December 31, 2024, <span style="background-color: white">due to the full conversion of the convertible notes upon the IPO on August
9, 2023, that eliminated any further debt discount, issuance cost, debt extinguishment and fair value derivative valuation net
charges and lower interest expense and issuance cost amortization from a lower debt burden in 2024, partially offset by financing
charges incurred to settle a 2023 convertible note dispute and other expense to settle certain claims of pre-IPO Series A Preferred
Stock shareholders.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Net
Loss</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
net loss decreased $6,385,182, or 43.7%, from $14,626,683 for the year ended December 31, 2023, to $8,241,501 for the year ended December
31, 2024, primarily due to <span style="background-color: white">(i) higher sales volume, (ii) the elimination of debt discount, issuance
cost and fair value derivative valuation net charges as a result of the conversion of notes upon the 2023 IPO and (iii) lower interest
expense and issuance cost amortization from a lower debt burden in 2024, partially offset by (iv) financing charges incurred to settle
a 2023 convertible note dispute and other expense to settle certain claims of pre-IPO Series A Preferred Stock shareholders and (v) higher
general and administrative expenses due to the absence of 2023 post-IPO consulting and recruiting services and the payment of incentive
bonuses relating to the 2023 IPO.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Liquidity
and Capital Resources</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
had cash on hand of $3,696,870 and $78,560 as of December 31, 2024 and 2023, respectively. We maintained a working capital surplus of
$1,832,858 and negative working capital of $1,643,058 as of December 31, 2024 and 2023, respectively. The increase in working capital
was primarily due to the issuance of $5,000,000 of Convertible Series B Preferred Stock in November 2024 that significantly improved
the Company&#8217;s liquidity position.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have incurred losses since inception and have funded our operations primarily with a combination of sales, debt, and the sale of capital
stock. As of December 31, 2024, we had stockholders&#8217; equity of $2,067,748, short-term outstanding borrowings of $154,152 and no
long-term debt.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
future capital requirements will depend upon many factors, including progress with developing, manufacturing, and marketing our technologies,
the time and costs involved in preparing, filing, prosecuting, maintaining, and enforcing patent claims and other proprietary rights,
our ability to establish collaborative arrangements, marketing activities and competing technological and market developments, including
regulatory changes and overall economic conditions in our target markets. Our ability to generate revenue and achieve profitability requires
us to successfully market and secure purchase orders for our products from customers currently identified in our sales pipeline and to
new customers as well. The primary activity that will drive all customers and revenues is the adoption of insurance coverage by commercial
insurance carriers nationally, so this is a top priority of the Company. These activities, including our planned research and development
efforts, will require significant uses of working capital through the rest of 2025 and beyond. Based on our current operating plans,
we believe that our existing cash at the time of this filing will only be sufficient to meet our anticipated operating needs before the
end of 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additionally,
we will have to meet all the financial disclosure and reporting requirements associated with being a publicly reporting company. Our
management will have to spend additional time on policies and procedures to make sure it is compliant with various regulatory requirements,
especially that of Section 404 of the Sarbanes-Oxley Act. This additional corporate governance time required of management could limit
the amount of time our management has to implement our business plan and may delay our anticipated growth plans.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 68; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->68<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes our cash flows from operating, investing, and financing activities for the years ended December 31, 2024 and
2023:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center">Years Ended December 31,</td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2024</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2023</td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Net cash used in operating activities</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">(6,098,264</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">(6,693,978</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Net cash used in investing activities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(27,776</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(71,781</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Net cash provided by financing activities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">9,744,350</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">6,590,620</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Net increase (decrease) in cash and cash equivalents</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,618,310</td><td style="text-align: left"/><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(175,139</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Cash and cash equivalents at beginning of period</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">78,560</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">253,699</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Cash and cash equivalents at end of period</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">3,696,870</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">78,560</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Operating
Activities</i> &#8211; Net cash used in operating activities declined 595,714, or 8.9% from $6,693,978 for the year ended December
31, 2023, to $6,098,264 for the year ended December 31, 2024, primarily due to more issuances of common stock instead of cash for
certain services in 2024 than in 2023 and lower interest payments in 2024 due to the conversion of debt in the 2023 IPO, partially
offset by payments to past due vendors in 2024 for 2023 services.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Investing
Activities</i> &#8211; Net cash used in investing activities decreased $44,005, or 61.3%, from $71,781 for the year ended December 31,
2023, to $27,776 for the year ended December 31, 2024, primarily due to the purchase of the Company&#8217;s trademark in 2023 that did
not recur in 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Financing
Activities </i>&#8211; Net cash provided by financing activities increased $3,153,730, or 47.9%, from $6,590,620 for the year ended
December 31, 2023, to $9,744,350 for the year ended December 31, 2024, primarily due to principal repayments on notes payable in
2023 that did not recur in 2024 and the Company subsequently raised capital from the IPO in 2023 to retire the notes payable and
issued Convertible Series B Preferred Stock in 2024.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="ar_010"></span>ITEM
7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 12.95pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
applicable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 12.95pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="ar_011"></span>ITEM
8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 12.95pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">See
Index to Financial Statements and Financial Statement Schedules from page F-1 of this annual report on Form 10-K, which are incorporated
herein by reference.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 12.95pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="ar_012"></span>ITEM
9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 12.95pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
applicable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="ar_013"></span>ITEM
9A. CONTROLS AND PROCEDURES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 12.95pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Disclosure
Controls and Procedures</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 12.95pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
maintain &#8220;disclosure controls and procedures,&#8221; as that term is defined in Rule 13a-15(e), promulgated by the SEC pursuant
to the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;). Disclosure controls and procedures include controls
and procedures designed to ensure that information required to be disclosed in our Company&#8217;s reports filed under the Exchange Act
is recorded, processed, summarized and reported within the time periods specified in the SEC&#8217;s rules and forms, and that such information
is accumulated and communicated to our management, including our principal executive officer and principal financial officer to allow
timely decisions regarding required disclosure. Our management, with the participation of our principal executive officer and principal
financial officer, evaluated our Company&#8217;s disclosure controls and procedures as of the end of the period covered by this Form
10-K. Based on this evaluation, our principal executive officer and principal financial officer concluded that as of December 31, 2024,
our disclosure controls and procedures were, is design and operation, not effective.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 69; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->69<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Management&#8217;s
Annual Report on Internal Control Over Financial Reporting</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
management is responsible for establishing and maintaining adequate internal control over financial reporting, as defined in Rule 13a-15(f)
of the Exchange Act. Under the supervision and with the participation of our principal executive officer and principal financial officer
and oversight of the Board of Directors, we conducted an evaluation of the effectiveness of our internal control over financial reporting
based on criteria established in the framework set forth in <i>Internal Control&#8212;Integrated Framework (2013)</i> issued by the Committee
of Sponsoring Organizations of the Treadway Commission.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
management, including our principal executive officer and principal financial officer, recognizes that disclosure controls and procedures
and internal controls over financial reporting, no matter how well designed and operated, can provide only reasonable assurance of achieving
the desired control objectives. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute
assurance that all control issues and instances of fraud, if any, have been detected. Additionally, controls can be circumvented by the
individual acts of some persons, by collusion of two or more people, or by management override of the controls.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">Based on our evaluation, management concluded that our internal control over financial reporting was not effective as of December 31,
2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Material
Weaknesses</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
material weakness is a significant deficiency, or a combination of significant deficiencies, in internal control over financial reporting
such that it is reasonably possible that a material misstatement of the annual or interim financial statements will not be prevented
or detected.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following material weaknesses in our internal control over financial reporting were identified as of December 31, 2024:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ineffective
                                            approval processes governing (i) timely Board of Directors authorization and (ii) segregation of duties
                                            and roles and responsibilities configurations within the Company&#8217;s financial reporting
                                            system; and</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 20.3pt"/><td style="font: 10pt Times New Roman, Times, Serif; width: 18pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inadequate
                                            contract management process to capture all executed agreements prior to the commencement
                                            of services in order to ensure accuracy within the proper accounting period.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 38.3pt; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following material weaknesses in our internal control over financial reporting were previously disclosed in our Annual Report on Form
10-K for the year ended December 31, 2023:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Misapplication
                                            of U.S. GAAP as evidenced by the restatement of our unaudited financial statements as of and
                                            for the three and nine months ended September 30, 2023; and</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ineffective
                                            disclosure controls and procedures a result of (i) lack of segregation of duties, (ii) lack
                                            of internal control structure review and (iii) misapplication of U.S. GAAP.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
order to remediate the identified material weaknesses, management, with the oversight of the Audit Committee of the Board of
Directors, undertook measures to enhance the Company&#8217;s internal control environment, including the (i) hiring of a principal
financial officer and other accounting personnel, (ii) implementation of a documented internal control framework and program, (iii)
documentation and communication of business policies such as a delegation of authority over company transactions and invoice
approvals and (iv) completion of a formal monthly close process including account reconciliations with supporting documentation.
However, management has not fully implemented the remediation steps and expects remediation efforts to continue into fiscal year
2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">While
these remediation efforts are subject to ongoing management evaluation and will require validation and testing of the design and operating
effectiveness of the Company&#8217;s internal controls over a sustained period of financial reporting cycles, management is committed
to maintaining a strong internal control program over financial reporting and will take further actions and implement additional enhancements
or improvements as necessary.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Changes
in Internal Control Over Financial Reporting</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the most recent quarter as discussed above, there were changes to the design and operation of our internal control over financial reporting.
Other than those measures, there were no changes in the Company&#8217;s internal control over financial reporting (as defined in Rules
13a-15(f) and 15d-15(f) of the Exchange Act) during the quarter ended December 31, 2024 that has materially affected, or is reasonably
likely to materially affect, the Company&#8217;s internal control over financial reporting.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Attestation
Report of the Independent Registered Public Accounting Firm</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 12.95pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
independent registered public accounting firm is not required to provide an attestation report on the effectiveness of our internal control
over financial reporting pursuant to Section 404 of the Sarbanes-Oxley Act due to an exemption for &#8220;smaller reporting companies&#8221;
as defined by Rule 12b-2 under the Exchange Act.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 12.95pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="ar_014"></span>ITEM
9B. OTHER INFORMATION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90B_ecustom--NoInsiderTradingFlag_dbT_c20240101__20241231_zltLUMMYAVs" title="No insider trading flag" class="xdx_phnt_RGlzY2xvc3VyZSAtIEluc2lkZXIgVHJhZGluZyBBcnJhbmdlbWVudHMA"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" format="ixt:booleantrue" id="Fact000057" name="NRXS:NoInsiderTradingFlag">Not
applicable</ix:nonNumeric></span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="ar_015"></span>ITEM
9C. DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
applicable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 70; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->70<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="ar_016"></span>PART
III</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="ar_017"></span>ITEM
10. DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table and biographical summaries set forth information, including principal occupation and business experience, about our directors
and executive officers as of March 13, 2025:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; width: 90%; border-collapse: collapse; margin-right: auto">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 30%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Name</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; width: 2%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 8%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Age</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; width: 2%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 58%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Position</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Brian
    Carrico</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">43</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">President,
    Chief Executive Officer, and Director</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Timothy
    Henrichs (1)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">52</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Financial Officer</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr.
    Adrian Miranda</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">55</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Medical Officer, Senior Vice President of Science and Technology</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr.
    Thomas Carrico</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">68</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Regulatory Officer, Compliance Officer and Privacy Officer</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr.
    Christopher Robin Brown</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">71</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Bradley
    Mitch Watkins</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">50</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director
    and Chairman of the Board</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Beth
    Keyser</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">56</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Kristin
    Ferge</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">51</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Gilad
    Aharon</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">51</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
    January 30, 2024, our former Chief Financial Officer John Seale resigned from his position, effective as of the close of business
    on January 30<sup>th</sup>. On the same day, Timothy R. Henrichs resigned as a member of the board of directors, effective February
    2, 2024. On January 26, 2024, the board of directors appointed Mr. Henrichs to serve as the CFO, effective on February 5, 2024.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Brian
Carrico, President, Chief Executive Officer and Director</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Brian
Carrico joined the Company in 2012. During his tenure, Mr. Carrico has held multiple leadership positions of increasing responsibility,
including Vice President of Sales and President before becoming CEO on January 1, 2018. As an early employee in the Company&#8217;s life
cycle, Mr. Carrico was instrumental in setting the strategic agenda for the Company, raising start-up capital, championing new product
development, and bringing the Company&#8217;s technology to market. Prior to joining Neuraxis, Mr. Carrico worked selling in the operating
room at Bard Medical and in the Cath lab at St. Jude Medical. He attended Indiana State University and holds a Bachelor of Science in
Business Marketing.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Timothy
Henrichs, Chief Financial Officer</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Timothy
Henrichs currently serves as the Company&#8217;s Chief Financial Officer since February 5, 2024 and was a director of the Company from
August 9, 2023 to February 2, 2024. Mr. Henrichs&#8217; global leadership experience spans over 20 years and across several industries,
including healthcare, home improvement, retail, software and education. Previously Mr. Henrichs served as the Chief Financial Officer
of Renovo Home Partners since 2022. He also served as the Executive Vice President and Chief Financial Officer of Follett Corporation
from 2008 to 2022 and Global Controller of General Electric Company&#8217;s Healthcare Clinical Systems division responsible for the
manufacture and distribution of medical devices to the ultrasound, patient monitoring and anesthesiology markets from 2005 to 2008 in
addition to leadership positions at Federal Signal Corporation and Ernst &amp; Young LLP. Mr. Henrichs earned his bachelor&#8217;s degree
in accounting from the University of Notre Dame and is a Certified Public Accountant with an inactive license in the State of Illinois.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 71; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->71<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Dr.
Adrian Miranda, Chief Medical Officer, Senior Vice President of Science and Technology</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr.
Adrian Miranda has served as our Chief Medical Officer since 2018 and brings a unique background of research and clinical expertise to
his role. Prior to joining Neuraxis, Dr. Miranda was an Assistant professor at the Medical College of Wisconsin. He is a board-certified
pediatric gastroenterologist. He obtained his undergraduate degree in Biology from San Diego State University and obtained his medical
degree from the Medical College of Wisconsin. He completed his residency and subspecialty training in pediatric gastroenterology at Children&#8217;s
Hospital of Wisconsin.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a physician scientist, he has spent the past 20 years of his career investigating the pathophysiology of visceral and somatic pain, as
well as exploring new therapeutic options. His focus has been on studying the effects of adverse early life events, neuroplasticity and
the development of chronic pain. He has an extensive publication record and has lectured nationally and internationally.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Dr.
<i>Thomas Carrico, Chief Regulatory Officer, Compliance Officer and Privacy Officer</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr.
Thomas Carrico has served as our Chief Regulatory Officer since November 2017. He joined the Company in February 2012 as Director of
Regulatory Affairs. Prior to and during his early years with Neuraxis, he was President &amp; Clinic Director at Spine and Neuromuscular
Associates in Lawrenceburg, Indiana from January 2002 to December 2018. He has over 40 years of experience in the healthcare field and
has been involved in the study and application of techniques and treatments that directly affect the autonomic nervous system, especially
regarding homeostasis and balance of the parasympathetic and the sympathetic nervous system. Dr. Carrico has a history of working with
attorneys while serving on state and national boards, which has positioned him to integrate into regulatory responsibilities at the Company.
Dr. Carrico received his undergraduate education from Indiana University and his Doctorate from Palmer College of Chiropractic.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Dr.
Christopher Robin Brown, Director</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr.
Chirstopher Robin Brown is a co-founder of the Company. He developed clinical protocol, initial practice guidelines, designed and implemented
the practitioner certification program and personally financed the first two years of the Company. After developing the technique of
transillumination to isolate auricular neurovascular bundles, he authored and designed the initial studies establishing neurovascular
and tissue energy transfer theories upon which the devices&#8217; use are based. Dr. Brown is listed as the sole or principal inventor
on all Neuraxis patents and is currently active in further device development working closely with compliance, product design and engineering.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon
graduation from the Indiana University School of Dentistry in 1982, while serving as clinic chief in the United States Army Reserve (USAR)
dental corps at Fort Benjamin Harrison in Indianapolis, Indiana, Dr. Brown started a private practice (current) concentrating in head,
neck, and facial pain developing the first hospital based facial pain clinic in Indiana. He received his master&#8217;s degree in Biomechanical
Trauma in 1996 from Lynn University, one of only 12 dentists in the United States to hold the combination of DDS and MPS degrees. Dr.
Brown has authored several textbook chapters, published peer reviewed articles on the physics of soft tissue trauma, pain, financial
management, was regional editor for a national facial pain management Journal, and has lectured extensively nationally and internationally.
He served on the Board of Directors of the American Academy of Pain Management for 15 years, helping grow the organization from 800 members
to over 5,000. Throughout his tenure, he developed educational tracks, served as Industry liaison, one term as treasurer and one term
as President. He served on the national board of The Alliance of TMD practitioners, serving one term as president.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Throughout
his career, Dr. Brown has been active in the purchasing and management of several destressed clinics and re-structuring them into profitable
enterprises. He has performed extensive volunteer work overseas providing surgical care in the Dominican Republic, local dental clinics
serving the underprivileged, and recently provided dental screenings for the deployment of soldiers in the USAR and National Guard.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 72; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->72<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Bradley
Mitch Watkins, Director and Chairman of the Board</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Bradley
Mitch Watkins has overseen four companies through their early commercialization periods within the medical device sector over the last
20 years. He has directly reported to the CEO or board of directors and operated as the lead for all field operations. Over his 20 years
in a multitude of medical device markets, Mr. Watkins has overseen $410 million in company acquisitions in an array of leadership roles.
He has thrived in early commercialization, recruitment, and strategic company direction. These duties have groomed Mr. Watkins with a
wide array of responsibilities beyond sales, including marketing, clinical study design, manufacturing, R&amp;D, FDA submissions, and
fiscal oversight. Mr. Watkins has been the National Sales Manager of Terumo Interventional Systems since 2015, where he has led multiple
new technology sales teams within the peripheral IV and Electrophysiology markets. Mr. Watkins received his bachelor&#8217;s degree in
behavioral science from the University of Maryland.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Beth
Keyser, Director</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">With
more than 20 years of experience in executive roles in population health, Beth Keyser is skilled at understanding the unique,
complex needs of multiple market segments and devises solutions that meet their specific goals. Ms. Keyser is the President, BCBS of
Indiana at Anthem, Inc. since 2020. From 2018 to 2020, Ms. Keyser served as the President, Create at Brighton Health Plan Solutions.
From 2015 to 2020, Ms. Keyser served as the Senior Vice President, International and Hawaii Markets at Sharecare, Inc. Ms. Keyser
received her master&#8217;s degree in Executive Master of Science, Health Administration, from University of Alabama at
Birmingham.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Kristin
Ferge, Director</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Kristin
Ferge has been President and Chief Financial Officer of Capri Communities and Bridges Home Healthcare, a Wisconsin-based privately held
senior living corporation, since 2016. Prior to joining Capri, Ms. Ferge was an executive for 18 years with Brookdale Senior Living Inc.
or one of its predecessors. Ms. Ferge ended her tenure at Brookdale, a publicly traded senior living company, as Executive Vice President,
Treasurer, and Chief Accounting Officer. Prior to Brookdale, Ms. Ferge was an auditor with KPMG. Ms. Ferge is a certified public accountant.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b><i>Gilad
Aharon, Ph.D.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Dr.
Aharon is a co-founder of and has served as a Portfolio Manager at Rosalind Advisors, Inc., since 2006. Dr. Aharon holds a Ph.D. in Biophysics
and Molecular Biology from the University of Toronto. Prior to co-founding Rosalind Advisors, Dr. Aharon worked as an equity analyst
at Infinium Securities Inc.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Family
Relationships</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Brian
Carrico, our Chief Executive Officer and Director, is the son of Dr. Carrico, our Chief Regulatory Officer. There are no other family
relationships between or among any of our executive officers or other directors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Role
of the Board</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">It
is the paramount duty of the board to oversee our management in the competent and ethical operation of the Company on a day-to-day basis
and to assure that the long-term interests of the stockholders are being served. To satisfy this duty, the directors take a proactive,
focused approach to their positions, and set standards to ensure that we are committed to business success through maintenance of ambitious
standards of responsibility and ethics.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Director
Terms; Qualifications</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
directors are elected for a term of one year and until their successors qualified, nominated, and appointed or elected.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">When
considering whether directors and nominees have the experience, qualifications, attributes and skills to enable the board of directors
to satisfy its oversight responsibilities effectively in light of the Company&#8217;s business and structure, the board of directors
focuses primarily on the industry and transactional experience, and other background, in addition to any unique skills or attributes
associated with a director.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Director
or Officer Involvement in Certain Legal Proceedings</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
are no material proceedings to which any director or officer, or any associate of any such director or officer, is a party that is adverse
to our Company or any of our subsidiaries or has a material interest adverse to our Company or any of our subsidiaries. No director or
executive officer has been a director or executive officer of any business which has filed a bankruptcy petition or had a bankruptcy
petition filed against it during the past ten years. No director or executive officer has been convicted of a criminal offense or is
the subject of a pending criminal proceeding during the past ten years. No director or executive officer has been the subject of any
order, judgment or decree of any court permanently or temporarily enjoining, barring, suspending or otherwise limiting his involvement
in any type of business, securities or banking activities during the past ten years. No director or officer has been found by a court
to have violated a federal or state securities or commodities law during the past ten years.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 73; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->73<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Directors
and Officers Liability Insurance</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company maintains directors&#8217; and officers&#8217; liability insurance insuring its directors and officers against liability for
acts or omissions in their capacities as directors or officers, subject to certain exclusions. Such insurance may also insure the Company
against losses, which it may incur in indemnifying its officers and directors. In addition, officers and directors also have indemnification
rights under applicable laws, and the Company&#8217;s Certificate of Incorporation and Bylaws.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Director
Independence</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
listing rules of NYSE American require that independent directors must comprise a majority of a listed company&#8217;s board of directors.
In addition, the rules of NYSE American require that, subject to specified exceptions, each member of a listed company&#8217;s audit,
compensation, and nominating and governance committees be independent. Audit committee members must also satisfy the independence criteria
set forth in Rule 10A-3 under the Exchange Act. Under the rules of NYSE American, a director will only qualify as an &#8220;independent
director&#8221; if, in the opinion of that company&#8217;s board of directors, that person does not have a relationship that would interfere
with the exercise of independent judgment in carrying out the responsibilities of a director.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
board of directors has undertaken a review of the independence of our directors and considered whether any director has a material relationship
with it that could compromise his or her ability to exercise independent judgment in carrying out his or her responsibilities. Based
upon information requested from and provided by each director concerning his background, employment and affiliations, including family
relationships, the board of directors has determined that three are &#8220;independent&#8221; as that term is defined under the applicable
rules and regulations of the SEC and the listing standards of NYSE American. In making these determinations, our board of directors considered
the current and prior relationships that each non-employee director has with the Company and all other facts and circumstances our board
of directors deemed relevant in determining their independence.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Board
Committees</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2024, the following three standing committees have been established: Audit Committee; Compensation Committee; and
Nominating and Corporate Governance Committee. Each of our independent directors, Bradley Mitch Watkins, Beth Keyser, Kristin Ferge
and Dr. Gil Aharon, serve on certain committees. Our board has adopted written charters for each of these committees. Copies of the
charters are available on our website. Our board may establish other committees as it deems necessary or appropriate from time to
time.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Audit
Committee</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Audit Committee, among other things, is responsible for:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">appointing;
    approving the compensation of; overseeing the work of; and assessing the independence, qualifications, and performance of the independent
    auditor;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing
    the internal audit function, including its independence, plans, and budget;</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">approving,
    in advance, audit and any permissible non-audit services performed by our independent auditor;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing
    our internal controls with the independent auditor, the internal auditor, and management;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing
    the adequacy of our accounting and financial controls as reported by the independent auditor, the internal auditor, and management;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">overseeing
    our financial compliance system; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">overseeing
    our major risk exposures regarding the Company&#8217;s accounting and financial reporting policies, the activities of our internal
    audit function, and information technology.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 74; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->74<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
board of directors has affirmatively determined that each member of the Audit Committee meets the additional independence criteria applicable
to audit committee members under SEC rules and listing standards of NYSE American All members of the Audit Committee are able to read
and understand fundamental financial statements, are familiar with finance and accounting practices and principles and are financially
literate. The board of directors has adopted a written charter setting forth the authority and responsibilities of the Audit Committee.
The board of directors has affirmatively determined that each member of the Audit Committee is financially literate, and that Kristin
Ferge meets the qualifications of an Audit Committee financial expert.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Audit Committee consists of Kristin Ferge, Bradley Mitch Watkins, and Beth Keyser and Ms. Ferge serves as chair of the Audit Committee.
The functioning of the Audit Committee complies with the applicable requirements of the rules and listing standards of NYSE American
and the SEC.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Compensation
Committee</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Compensation Committee is responsible for:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing
    and making recommendations to the Board with respect to the compensation of our officers and directors, including the CEO;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">overseeing
    and administering the Company&#8217;s executive compensation plans, including equity-based awards;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">negotiating
    and overseeing employment agreements with officers and directors; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">overseeing
    how the Company&#8217;s compensation policies and practices may affect the Company&#8217;s risk management practices and/or risk-taking
    incentives.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Compensation Committee consists of Dr. Gil Aharon, Bradley Mitch Watkins, Beth Keyser, and Kristin Ferge, and Dr. Aharon serves as
chair of the Compensation Committee. The board of directors has affirmatively determined that each member of the Compensation
Committee meets the independence criteria applicable to compensation committee members under SEC rules and listing standards of NYSE
American. The Company believes that the composition of the Compensation Committee meets the requirements for independence under, and
the functioning of such Compensation Committee comply with, any applicable requirements of the rules and regulations of listing
standards of NYSE American and the SEC.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Nominating
and Corporate Governance Committee</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Nominating and Corporate Governance Committee, among other things, is responsible for:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing
    and assessing the development of the executive officers and considering and making recommendations to the Board regarding promotion
    and succession issues;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">evaluating
    and reporting to the Board on the performance and effectiveness of the directors, committees and the board of directors as a whole;</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">working
    with the Board to determine the appropriate and desirable mix of characteristics, skills, expertise and experience, including diversity
    considerations, for the full Board and each committee;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">annually
    presenting to the Board a list of individuals recommended to be nominated for election to the board;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing,
    evaluating, and recommending changes to the Company&#8217;s committee charters;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">recommending
    to the Board individuals to be elected to fill vacancies and newly created directorships;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">overseeing
    the Company&#8217;s compliance program, including the Code of Conduct; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">overseeing
    and evaluating how the Company&#8217;s corporate governance and legal and regulatory compliance policies and practices, including
    leadership, structure, and succession planning, that may affect the Company&#8217;s major risk exposures.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Nominating and Corporate Governance Committee consists of Bradley Mitch Watkins, Beth Keyser, and Kristin Ferge and Ms. Keyser serves
as chair of the Nominating and Corporate Governance Committee. The Company&#8217;s board of directors has determined that each member
of the Nominating and Corporate Governance Committee is independent within the meaning of the independent director requirements for independence
under the NYSE American listing standards and SEC rules and regulations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 75; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->75<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Compensation
Committee Interlocks and Insider Participation</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">None
of the Company&#8217;s executive officers serves, or in the past has served, as a member of the board of directors or compensation committee,
or other committee serving an equivalent function, of any entity that has one or more executive officers who serve as members of the
Company&#8217;s board of directors or its compensation committee. None of the members of the Company&#8217;s compensation committee is,
or has ever been, an officer or employee of the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Code
of Business Conduct and Ethics</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s board of directors has adopted a code of business conduct and ethics (&#8220;Code of Conduct&#8221;) applicable to its
employees, directors and officers, in accordance with applicable U.S. federal securities laws and the corporate governance rules of NYSE
American. The Code of Conduct is effective and is publicly available on the Company&#8217;s website. Any substantive amendments or waivers
of the Code of Conduct may be made only by the Company&#8217;s board of directors and will be promptly disclosed as required by applicable
U.S. federal securities laws and the corporate governance rules of NYSE American.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b><span id="ar_018"></span>Item
11. Executive Compensation</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Summary
Compensation Table</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table sets forth information concerning all compensation earned by our Chief Executive Officer and three other persons who
served as executive officers as, at, or during the years ended December 31, 2024 and 2023, and who earned compensation exceeding $100,000
during 2024 and 2023 (the &#8220;Named Executive Officers&#8221;), for services as executive officers for the last two years.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%; margin-left: 0.5in">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-weight: bold">Name and Principal Position</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Year</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Salary ($) (1)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Bonus</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>($) (2)</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> Stock Awards ($) (3)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Benefits</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>($) (4)</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Total</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>($)</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 28%; text-align: left">Brian Carrico</td><td style="width: 2%">&#160;</td>
    <td style="vertical-align: bottom; width: 1%; text-align: center">&#160;</td><td style="vertical-align: bottom; width: 8%; text-align: center">2024</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%; text-align: right">352,973</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%; text-align: right">206,730</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%; text-align: right">&#8212;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%; text-align: right">18,673</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%; text-align: right">578,376</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Chief Executive Officer</td><td>&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td><td style="vertical-align: bottom; text-align: center">2023</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">375,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">441,346</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">23,052</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">839,398</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td><td style="vertical-align: bottom; text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Timothy Henrichs</td><td>&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td><td style="vertical-align: bottom; text-align: center">2024</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">274,077</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">112,239</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">227,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">15,561</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">628,877</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Chief Financial Officer</td><td>&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td><td style="vertical-align: bottom; text-align: center">2023</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td><td style="vertical-align: bottom; text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Dr. Thomas Carrico</td><td>&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td><td style="vertical-align: bottom; text-align: center">2024</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">288,307</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">63,772</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">16,835</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">368,914</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Chief Regulatory Officer</td><td>&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td><td style="vertical-align: bottom; text-align: center">2023</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">278,837</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">116,716</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">15,544</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">411,097</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td><td style="vertical-align: bottom; text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Dr. Adrian Miranda</td><td>&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td><td style="vertical-align: bottom; text-align: center">2024</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">300,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">63,772</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">18,673</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">382,445</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Chief Medical Officer</td><td>&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td><td style="vertical-align: bottom; text-align: center">2023</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">300,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">23,052</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">323,052</td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in">(1)</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Represents
    W-2 Box 1 bi-weekly payments to our executive officers pursuant to their respective employment agreements. Mr. Henrichs began employment
    on February 5, 2024.</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Represents
    bonus earned by our executive officers from the annual incentive plan adopted in 2024 upon achievement of certain targets. Mr. Carrico&#8217;s
    bonus includes $62,222 related to the successful issuance of the 2024 Convertible Notes. Bonuses are expected to be paid in 2025.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
    Mr. Henrichs was granted 100,000 common stock awards as a hiring grant.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Represents
    medical, dental and vision benefits. </span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 76; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->76<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Outstanding
Equity Awards at Fiscal Year-End</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table sets forth information regarding equity awards held by the Named Executive Officers as of December 31, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-weight: bold">Name</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Number of Securities Underlying Unexercised Options, Exercisable (#)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Number of Securities Underlying Unexercised Options, Not Exercisable (#)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Option</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exercise</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Price</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>($)</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Option</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Expiration</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Date</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td>
    </tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left">Brian Carrico</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%; text-align: right">320,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%; text-align: right">&#8212;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%; text-align: right">6.94</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">09/13/29</span></td><td style="width: 1%; text-align: left">&#160;</td>
    </tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Timothy Henrichs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td>
    </tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Dr. Thomas Carrico</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">306,236</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6.94</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">09/13/29</span></td><td style="text-align: left">&#160;</td>
    </tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Dr. Adrian Miranda</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">337,204</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6.94</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">09/13/29</span></td><td style="text-align: left">&#160;</td>
    </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
    option awards were granted under the Innovative Health Solutions, Inc. 2017 Stock Compensation Plan and vested fully upon grant.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Innovative
Health Solutions, Inc. 2017 Stock Compensation Plan, As Amended</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
October 12, 2017, the Company adopted the Innovative Health Solutions, Inc. 2017 Stock Compensation Plan, as amended on September 13,
2019, September 9, 2021, and November 1, 2022 (collectively, the &#8220;2017 Plan&#8221;). The purpose of the 2017 Plan is to grant incentive
stock options, nonqualified stock options, or restricted stock awards to our officers, employees, directors, advisors, and consultants.
The maximum numbers of shares of common stock that may be issued pursuant to awards granted were 1,319,394. Cancelled and forfeited stock
options and stock awards may again become available for grant under the 2017 Plan. As of the date of December 31, 2024, options to purchase
all 1,319,394 shares of common stock have been granted under the 2017 Plan and remain outstanding, and no shares remain available for
issuance under the 2017 Plan. The following summary briefly describes the principal features of the 2017 Plan and is qualified in its
entirety by reference to the full text of the 2017 Plan, which is filed as an exhibit to the registration statement of which this prospectus
forms a part.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Purpose
of the 2017 Plan</i>: The purposes of the 2017 Plan are to encourage ownership of shares by eligible employees and key non-employees
in order to attract and retain such eligible employees in the employ of the Company or an affiliated entity, or to attract such key non-employees
to provide services to the Company or an affiliated entity, and to provide additional incentive for such persons to promote the long-term
success of the Company or an affiliated entity.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Administration
of the Plan</i>: The 2017 Plan is administered by the board of directors, or the committee to which the board of directors delegates
the power to act. Among other things, the administrator has the authority to select persons who will receive awards, determine the types
of awards and the number of shares to be covered by awards, and to establish the terms, conditions, restrictions and other provisions
of awards. The administrator has authority to establish, amend and rescind rules and regulations relating to the 2017 Plan.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Eligible
Recipients</i>: Persons eligible to receive awards under the 2017 Plan are those officers, employees, directors, advisors, and consultants
of the Company or an affiliated entity who are selected by the administrator.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Shares
Available under the 2017 Plan</i>: The maximum number of shares of our common stock that may be delivered to participants under the 2017
Plan is 1,319,394 shares, subject to adjustment for certain corporate changes affecting the shares, such as stock splits. No new grants
will be made under the 2017 Plan, and shares subject to an award under the 2017 Plan for which the award is canceled, forfeited or expires
will become available for grants under the 2022 Plan described below. Shares subject to an award that is settled in cash will not again
be made available for grants under the 2017 Plan.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 77; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->77<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Stock
Options</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">General</span><i>.
</i>Subject to the provisions of the 2017 Plan, the administrator has the authority to determine all grants of stock options, although
there are currently no shares of common stock remaining reserved for grants under the 2017 Plan.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Option
Price</span>. The exercise price for stock options is determined at the time of grant. The exercise price may not be less than the fair
market value on the date of grant. Additionally, incentive stock option grants to any person owning more than 10% of our voting stock
must have an exercise price of not less than 110% of the fair market value on the grant date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Exercise
of Options</span><i>.</i> An option may be exercised only in accordance with the terms and conditions for the option agreement as established
by the administrator at the time of the grant. The option must be exercised by notice to us, accompanied by payment of the exercise price.
Payments may be made in cash or, at the option of the administrator, by actual or constructive delivery of shares of common stock to
the holder of the option based upon the fair market value of the shares on the date of exercise.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Expiration
or Termination</span><i>.</i> Options, if not previously exercised, will expire on the expiration date established by the administrator
at the time of grant. In the case of incentive stock options, such term cannot exceed ten years provided that in the case of holders
of more than 10% of our voting stock, such term cannot exceed five years. Options will terminate before their expiration date only if
the holder&#8217;s service with our Company or an affiliate terminates before the expiration date and the holder is terminated for cause.
The option may remain exercisable until the expiration date of the option after terminations of employment for any reason other than
for cause, including terminations as a result of death, disability or retirement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Incentive
and Non-Qualified Options</span><i>.</i> An incentive stock option is an option that is intended to qualify under certain provisions of
the Internal Revenue Code, for more favorable tax treatment than applies to non-qualified stock options. Any option that does not qualify
as an incentive stock option will be a non-qualified stock option. Under the Code, certain restrictions apply to incentive stock options.
For example, the exercise price for incentive stock options may not be less than the fair market value of the shares on the grant date
and the term of the option may not exceed ten years. In addition, an incentive stock option may not be transferred, other than by will
or the laws of descent and distribution and is exercisable during the holder&#8217;s lifetime only by the holder. In addition, no incentive
stock options may be granted to a holder that is first exercisable in a single year if that option, together with all incentive stock
options previously granted to the holder that also first become exercisable in that year, relate to shares having an aggregate market
value in excess of $100,000, measured at the grant date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Restricted
Stock Awards:</i> Restricted stock awards could have also been granted under the 2017 Plan, although there are currently no shares of
common stock remaining reserved for grants under the 2017 Plan. A restricted stock award is a grant of shares of common stock or of a
right to receive shares in the future.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Other
Material Provisions</i><b>:</b> Awards are evidenced by a written agreement, in such form as may be approved by the administrator. In
the event of various changes to the capitalization of our Company, such as stock splits, stock dividends and similar re-capitalizations,
an appropriate adjustment will be made by the administrator to the number of shares covered by outstanding awards or to the exercise
price of such awards. The administrator is also permitted to include in the written agreement provisions that provide for certain changes
in the award in the event of a change of control of our Company, including acceleration of vesting. Except as otherwise determined by
the administrator at the date of grant, awards will not be transferable, other than by will or the laws of descent and distribution.
Prior to any award distribution, we are permitted to deduct or withhold amounts sufficient to satisfy any employee withholding tax requirements.
Our board of directors also has the authority, at any time, to discontinue the granting of awards. The Plan may be amended by the board
of directors and such amendment shall become effective upon adoption by the board of directors; provided, however, that any amendment
shall be subject to the approval of the stockholders of the Company at or before the next annual meeting of the stockholders of the Company
if such stockholder approval is required by applicable laws. No amendment that would adversely affect any outstanding award made under
the Plan can be made without the consent of the holder of such award.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">No
new grants can be made under the 2017 Plan. The terms and conditions of awards granted under the 2017 Plan prior to the effective date
of the 2022 Plan will not be affected by the adoption or approval of the 2022 Plan, and the 2017 Plan will remain effective with respect
to such awards.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 78; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->78<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Neuraxis,
Inc. 2022 Omnibus Securities and Incentive Plan, As Amended on August 15, 2024</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
November 1, 2022, the Company adopted the Neuraxis, Inc. 2022 Omnibus Securities and Incentive Plan (as amended January 18, 2023, the
&#8220;2022 Plan&#8221;). The purpose of the 2022 Plan is to attract, retain and provide incentives to key management employees and non-employee
directors of, and non-employee consultants to, the Company and its affiliates, and to align the interests of such employees, non-employee
directors and non-employee consultants with those of the Company&#8217;s stockholders. The maximum number of shares of common stock that
may be issued pursuant to awards granted are 300,000. Cancelled and forfeited stock options and stock awards may again become available
for grant under the 2022 Plan. On August 15, 2024, the Company held an annual meeting of stockholders whereby an amendment was approved
such that the maximum number of shares of common stock (including shares of common stock underlying options designated as incentive stock
options) that may be issued under the Plan shall not exceed six hundred thousand (600,000) shares of Common Stock, plus an annual increase
on the first day of each calendar year beginning January 1, 2025 and ending on and including January 1, 2031 equal to the lesser of (i)
five percent (5%) of the shares of common stock outstanding on the final day of the immediately preceding calendar year, and (ii) such smaller
number of shares of common stock as determined by the Board or the Compensation Committee.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of the date of this Form 10-K, 896,028 awards have been granted under the 2022 Plan, and 62,791 shares of common stock
remain available for issuance under the 2022 Plan. The following summary briefly describes the principal features of the 2022 Plan and
is qualified in its entirety by reference to the full text of the 2022 Plan.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Purpose
of the 2022 Plan</i>: The purposes of the 2022 Plan is to benefit the stockholders of the Company, by assisting the Company to attract,
retain and provide incentives to key management employees and non-employee directors of, and non-employee consultants to, the Company
and its affiliates, and to align the interests of such employees, non-employee directors and non-employee consultants with those of the
Company&#8217;s stockholders.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Administration
of the 2022 Plan</i>: The 2022 Plan shall be administered by the board of directors or the committee designated by the board of directors.
Among other things, the administrator has the authority to select persons who will receive awards, determine the time or times when an
award shall be made, what type of award shall be granted, the term of an award, the date or dates on which an award vests (including
acceleration of vesting), the form of any payment to be made pursuant to an award, the terms and conditions of an award (including the
forfeiture of the award (and/or any financial gain) if the holder of the award violates any applicable restrictive covenant thereof),
the restrictions under a restricted stock award and the number of common stock which may be issued under an award, all as applicable.
In addition, subject to the express provisions of the 2022 Plan, the administrator is authorized to construe the 2022 Plan and the respective
award agreements executed thereunder, to prescribe such rules and regulations relating to the 2022 Plan as it may deem advisable to carry
out the intent of the 2022 Plan, to determine the terms, restrictions and provisions of each award, and to make all other determinations
necessary or advisable for administering the 2022 Plan.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Eligible
Recipients</i>: Persons eligible to receive awards under the 2022 Plan will be those officers, employees, directors, advisors, and consultants
of the Company or an affiliated entity who are selected by the administrator.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Shares
Available under the Plan</i>: The maximum number of shares of our common stock that may be delivered to participants under the 2022 Plan
is 958,820 shares, subject to adjustment for certain corporate changes affecting the shares, such as stock splits. Shares subject to
an award under the 2022 Plan for which the award lapses, expires, is canceled, terminated, unexercised or ceases to be exercisable again
become available for grants under the 2022 Plan.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Stock
Options</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>General.
</i>Subject to the provisions of the 2022 Plan, the administrator has the authority to determine all grants of stock options.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Option
Price.</i> The exercise price for stock options is determined at the time of grant. The exercise price may not be less than the fair
market value on the date of grant. Additionally, incentive stock option grants to any person owning more than 10% of our voting stock
must have an exercise price of not less than 110% of the fair market value on the grant date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Exercise
of Options.</i> An option may be exercised only in accordance with the terms and conditions for the option agreement as established by
the administrator at the time of the grant. The option must be exercised by notice to us, accompanied by payment of the exercise price.
Payments may be made in cash or, at the option of the administrator, by actual or constructive delivery of shares of common stock to
the holder of the option based upon the fair market value of the shares on the date of exercise.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 79; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->79<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Expiration
or Termination.</i> Options, if not previously exercised, will expire on the expiration date established by the administrator at the
time of grant. In the case of incentive stock options, such term cannot exceed ten years provided that in the case of holders of more
than 10% of our voting stock, such term cannot exceed five years. Options will terminate before their expiration date if the holder&#8217;s
service with our Company or a subsidiary terminates before the expiration date. The option may remain exercisable for specified periods
after certain terminations of employment, including terminations as a result of death, disability or retirement, with the precise period
during which the option may be exercised to be established by the administrator and reflected in the grant evidencing the award.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Incentive
and Non-Qualified Options.</i> As described elsewhere in this summary, an incentive stock option is an option that is intended to qualify
under certain provisions of the Code, for more favorable tax treatment than applies to non-qualified stock options. Any option that does
not qualify as an incentive stock option will be a non-qualified stock option. Under the Code, certain restrictions apply to incentive
stock options. For example, generally, the exercise price for incentive stock options may not be less than the fair market value of the
shares on the grant date and the term of the option may not exceed ten years. In addition, an incentive stock option may not be transferred,
other than by will or the laws of descent and distribution, and is exercisable during the holder&#8217;s lifetime only by the holder.
In addition, to the extent that the aggregate fair market value of common stock with respect to which incentive stock options are exercisable
for the first time by an individual during any calendar year under all plans of the Company and any parent corporation or subsidiary
corporation thereof which provide for the grant of incentive stock options exceeds $100,000, the portion of such incentive stock options
that exceeds such threshold shall be treated as non-qualified stock options. Incentive stock options shall be granted to employees only.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Restricted
Stock Awards:</i> Restricted stock awards can be granted under the 2022 Plan. A restricted stock award is a grant of shares of common
stock or of a right to receive shares in the future. These awards will be subject to such conditions, restrictions and contingencies
as the administrator shall determine at the date of grant. Those may include requirements for continuous service and/or the achievement
of specified performance goals.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Unrestricted
Stock Awards</i>: Unrestricted stock awards can also be granted under the 2022 Plan. An unrestricted stock award is a grant of shares
of common stock which is not subject to restrictions, in consideration for past services rendered thereby to the Company or an affiliate
or for other valid consideration.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Restricted
Stock Unit Awards</i>: Restricted stock unit awards (&#8220;RSUs&#8221;) can be granted under the 2022 Plan upon the satisfaction of
predetermined individual service related vesting requirements. The holder of a restricted stock unit shall be entitled to receive a cash
payment equal to the fair market value of shares of common stock, for each unit awarded to the holder.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Performance
Stock Unit Awards</i>: Performance stock unit awards can be granted under the 2022 Plan. A holder of performance stock units shall be
entitled to receive a cash payment equal to the dollar value or number of shares of common stock assigned to such units if the holder
and/or the Company satisfy the predetermined performance goals and objectives.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Distribution
Equivalent Rights</i>: Distribution equivalent right awards can be granted under the 2022 Plan. A distribution equivalent right award
entitles the holder to receive bookkeeping credits, cash payments and/or common stock distributions equal in amount to the distributions
that would have been made to the holder had the holder held a specified number of common stock during the period the holder held the
distribution equivalent right.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Stock
Appreciation Right</i>s: Stock appreciation rights can also be granted under the 2022 Plan, which is a right, granted alone or in connection
with a related Option, to receive a payment on the date of exercise. The base value of the stock appreciation right shall be set forth
by the administrator and shall not be less than the fair market value of the common stock at the date of grant for the stock appreciation
right which is not a tandem stock appreciation right. No stock appreciation right shall be exercisable after the expiration of ten (10)
years from the date of its grant. Upon the exercise of some or all of the portion of a stock appreciation right, the holder shall receive
a payment from the Company, in cash or in the form of common stock having an equivalent fair market value or in a combination of both.
If the administrator grants a stock appreciation right which is intended to be a tandem stock appreciation right, the tandem stock appreciation
right shall be granted at the same time as the related option.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 80; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->80<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Other
Material Provisions</i>: Awards are evidenced by a written agreement, in such form as may be approved by the administrator. In the event
of various changes to the capitalization of our Company, such as stock splits, stock dividends and similar re-capitalizations, an appropriate
adjustment will be made by the administrator to the number of shares covered by outstanding awards or to the exercise price of such awards.
The administrator is also permitted to include in the written agreement provisions that provide for certain changes in the award in the
event of a change of control of our Company, including acceleration of vesting. Except as otherwise determined by the administrator at
the date of grant, awards will not be transferable, other than by will or the laws of descent and distribution. Prior to any award distribution,
we are permitted to deduct or withhold amounts sufficient to satisfy any employee withholding tax requirements. Our board of directors
also has the authority, at any time, to discontinue the granting of awards. The 2022 Plan may be amended by the board of directors and
such amendment shall become effective upon adoption by the board of directors; provided, however, that any amendment shall be subject
to the approval of the stockholders of the Company at or before the next annual meeting of the stockholders of the Company if such stockholder
approval is required by applicable laws. No amendment that would adversely affect any outstanding award made under the 2022 Plan can
be made without the consent of the holder of such award. The 2022 Plan shall continue in effect, unless sooner terminated, until the
tenth (10th) anniversary of the date on which it is adopted by the board of directors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Employment
Agreements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Brian
Carrico</i>, our Chief Executive Officer, entered into an employment agreement with the Company, dated August 9, 2022 and amended on
May 4, 2023, which has a five-year initial term and provides for a base salary of $330,000, which shall be increased each year by not
less than 3% per annum. Mr. Carrico also will receive a one-time incentive payment in the amount of $435,577, which amount consists of
accrued and unpaid salary and a bonus to incentivize Mr. Carrico to remain with the Company for future service. Neither the accrued and
unpaid salary nor bonus was the subject of any contract or agreement between Mr. Carrico and the Company prior to the execution of the
employment agreement. The agreement contemplated that the incentive payment would be paid by December 15, 2022, but due to administrative
impracticability, payment was made with a portion of the proceeds from the IPO in August 2023. In addition, Mr. Carrico is entitled to
payment of a deferred bonus in an amount equal to (i) the aggregate of the strike price or exercise price of all 320,000 unexercised
options to purchase stock or shares of the Company held by Mr. Carrico (the &#8220;Aggregate Strike Price&#8221;) plus (ii) a tax gross-up
payment on the Aggregate Strike Price reasonably calculated by the Company at the highest marginal rates so that after payment of all
ordinary income taxes on such Aggregate Strike Price, there remains an amount sufficient to pay such ordinary income taxes. The special
deferred bonus will be paid in substantially equal 20% installments (the &#8220;Annual Deferred Bonus Payment&#8221;) on January 2 on
each of 2024, 2025, 2026, 2027, and 2028 (the &#8220;Scheduled Payment Dates&#8221;), with a condition that on or before each Scheduled
Payment Date, Mr. Carrico shall exercise at least 64,000 of the stock option. None of stock options has been exercised, therefore, no
special deferred bonus has been paid as of the date of this prospectus. Mr. Carrico may exercise any portion of the stock options after
a Scheduled Payment Date; provided, however, an exercise after the applicable Scheduled Payment Date shall result in forfeiture of the
related Annual Deferred Bonus Payment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
the employment agreement is terminated by the Company without cause (as defined in the employment agreement), Mr. Carrico will receive
any accrued compensation (as defined in the employment agreement) and is entitled to severance payments as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
    termination occurs during the initial term, the severance payment shall be the amount equal to the greater of (a) three times Mr.
    Carrico&#8217;s base salary as of the termination date; and (b) three times the total amount of Mr. Carrico&#8217;s bonus payments
    the Company paid Mr. Carrico over the one year prior to the termination date, to be paid in substantially equal monthly installments
    over the course of the three years.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
    termination occurs after the initial term, the severance payment shall be the amount equal to the greater of (a) one and one half
    (1.5) times Mr. Carrico&#8217;s base salary as of the termination date; and (b) one and one half (1.5) times the total amount of
    Mr. Carrico&#8217;s bonus payments the Company paid Mr. Carrico over the one (1) year prior to the termination date, to be paid in
    substantially equal monthly installments over the course of 18 months following the termination date.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
    addition, as part of the severance payment, we agreed to pay Mr. Carrico monthly COBRA premiums for continuation of health coverage
    for 18 months post termination.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 81; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->81<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
the employment agreement is terminated by the Company for cause, Mr. Carrico will forfeit any unpaid Annual Deferred Bonus Payment, but
will receive any unpaid base salary that has been earned at the time of such termination, reimbursement of any expenses properly incurred
prior to the Mr. Carrico&#8217;s termination date; and accrued and unused paid time off (&#8220;PTO&#8221;), if any, in accordance with
the Company&#8217;s PTO policy in effect on Mr. Carrico&#8217;s termination date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr.
Carrico may terminate the employment agreement without good reason upon more than thirty (30) days&#8217; prior written notice or for
good reason without prior written consent, and will receive accrued compensation (as defined in the employment agreement) and the unpaid
balance of the deferred bonus.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the event that Mr. Carrico is terminated without cause, non-forfeited portions of the deferred bonus will be paid in equal installments
over the remaining scheduled payment dates, if vested options as scheduled are exercised before the scheduled payment dates. A deferred
bonus tranche will be forfeited if its corresponding options have expired.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
a change in control (as defined in the employment agreement), full vesting of the Annual Deferred Bonus Payment will occur and be paid
in a single lump sum within 30 days after the change in control. The offering shall not be considered a change in control.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the employment agreement, Mr. Carrico also agreed to (i) not disclose to any unauthorized person or use for his own account any confidential
information without the prior written consent of the Company or the board of directors, (ii) will not, directly or indirectly encourage,
solicit, induce (or attempt to encourage, solicit or induce) any employee or agent of the Company that was employed (or otherwise engaged)
at the time of his separation during his employment and for 24 months after his separation from that employment for any reason; (iii)
will not, directly or indirectly, have any ownership interest in, work for, advise, manage, act as an agent or consultant for, or have
any business connection or business or employment relationship with any entity or person which competes with Company; (iv) will not,
directly or indirectly, have any ownership interest in, work for, advise, manage, act as an agent or consultant for, or have any business
connection or business or employment relationship with any entity or person which competes with the Company during his employment and,
(v) will not, directly or indirectly and in a competitive capacity own, manage, finance, operate, control or participate in ownership,
management, or operation of, act as an agent, consultant, or be employed with, any business engaged in the design, manufacture, marketing,
sale or servicing of any service or product with which Mr. Carrico was involved during his last year of employment with the Company;
or which the Company is developing, producing, marketing, selling or servicing (or plans to develop, produce, market, sale or service)
and about which Mr. Carrico gained any confidential information in the course of his employment with the Company for a period of 24 months
after his separation from the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Timothy
Henrichs</i>, our Chief Financial Officer entered into an employment agreement with the Company, dated January 1, 2025 which has a five-year
initial term and provides for a base salary of $330,000, which shall be increased each year by not less than 3% per annum. Mr. Henrichs
also will receive a one-time hiring grant of 100,000 shares of common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
the employment agreement is terminated by the Company without cause (as defined in the employment agreement), Mr. Henrichs will receive
any accrued compensation (as defined in the employment agreement) and is entitled to severance payments as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
    termination occurs during the initial term, the severance payment shall be the amount equal to the greater of (a) one times Mr. Henrichs&#8217;
    base salary as of the termination date; and (b) one times the total amount of Mr. Henrichs&#8217; bonus payments the Company paid
    Mr. Henrichs over the one year prior to the termination date, to be paid in substantially equal monthly installments over the course
    of one year.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
    termination occurs after the initial term, the severance payment shall be the amount equal to the greater of (a) one and times Mr.
    Henrichs&#8217; base salary as of the termination date; and (b) one times the total amount of Mr. Henrichs&#8217; bonus payments
    the Company paid Mr. Henrichs over the one (1) year prior to the termination date, to be paid in substantially equal monthly installments
    over the course of 12 months following the termination date.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
    addition, as part of the severance payment, we agreed to pay Mr. Henrichs monthly COBRA premiums for continuation of health coverage
    for 18 months post termination.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 82; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->82<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
the employment agreement is terminated by the Company for cause, Mr. Henrichs will forfeit any unpaid Annual Deferred Bonus Payment,
but will receive any unpaid base salary that has been earned at the time of such termination, reimbursement of any expenses properly
incurred prior to the Mr. Henrichs&#8217; termination date; and accrued and unused paid time off (&#8220;PTO&#8221;), if any, in accordance
with the Company&#8217;s PTO policy in effect on Mr. Henrichs&#8217; termination date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr.
Henrichs may terminate the employment agreement without good reason upon more than thirty (30) days&#8217; prior written notice or for
good reason without prior written consent, and will receive accrued compensation (as defined in the employment agreement) and the unpaid
balance of the deferred bonus.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the employment agreement, Mr. Henrichs also agreed to (i) not disclose to any unauthorized person or use for his own account any confidential
information without the prior written consent of the Company or the board of directors, (ii) will not, directly or indirectly encourage,
solicit, induce (or attempt to encourage, solicit or induce) any employee or agent of the Company that was employed (or otherwise engaged)
at the time of his separation during his employment and for 24 months after his separation from that employment for any reason; (iii)
will not, directly or indirectly, have any ownership interest in, work for, advise, manage, act as an agent or consultant for, or have
any business connection or business or employment relationship with any entity or person which competes with Company; (iv) will not,
directly or indirectly, have any ownership interest in, work for, advise, manage, act as an agent or consultant for, or have any business
connection or business or employment relationship with any entity or person which competes with the Company during his employment and,
(v) will not, directly or indirectly and in a competitive capacity own, manage, finance, operate, control or participate in ownership,
management, or operation of, act as an agent, consultant, or be employed with, any business engaged in the design, manufacture, marketing,
sale or servicing of any service or product with which Mr. Henrichs was involved during his last year of employment with the Company;
or which the Company is developing, producing, marketing, selling or servicing (or plans to develop, produce, market, sale or service)
and about which Mr. Henrichs gained any confidential information in the course of his employment with the Company for a period of 24
months after his separation from the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Dr.
Adrian Miranda</i>, our Chief Medical Officer and Senior Vice President of Science and Technology, entered into an employment agreement
with the Company, dated August 17, 2022, which has a two-year initial term and provides for a base salary of $300,000 with annual compensation
increase. In addition, Dr. Miranda shall be entitled to payment of a special deferred bonus in an amount equal to (i) the aggregate of
the strike price or exercise price of all 337,204 unexercised options to purchase stock or shares of the Company held by Dr. Miranda
(the &#8220;Aggregate Strike Price&#8221;) plus (ii) a tax gross-up payment on the Aggregate Strike Price reasonably calculated by the
Company at the highest marginal rates so that after payment of all ordinary income taxes on such Aggregate Strike Price, there remains
an amount sufficient to pay such ordinary income taxes. The deferred bonus will be paid in substantially equal 20% installments (the
&#8220;Annual Deferred Bonus Payment&#8221;) on January 2 on each of 2024, 2025, 2026, 2027, and 2028, with a condition that on or before
each scheduled payment date, Dr. Miranda shall exercise at least 67,441 of the stock options.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 83; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->83<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
the employment agreement is terminated by the Company without cause (as defined in the employment agreement) occurs during the term of
the agreement, Dr. Miranda will receive any accrued compensation (as defined in the employment agreement) and is entitled to certain
amount of severance payments as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
    termination occurs during the initial term, the Company shall provide Dr. Miranda with severance compensation in the form of salary
    continuation at his Base Salary as of the termination date and ending the later of (i) 6 months or (ii) on the expiration date of
    the initial term.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
    termination occurs after the initial term, the severance payment shall be the amount equal to one half (1/2) of Dr. Miranda&#8217;s
    Base Salary as of the termination date.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
    addition, if termination occurs during the initial term, as part of the severance payment, we agreed to pay Dr. Miranda reimbursement
    of his monthly COBRA premiums for continuation of health coverage for 18 months post termination.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
the employment agreement is terminated by the Company for cause, Dr. Miranda will forfeit any unpaid Annual Deferred Bonus Payment, but
will receive any unpaid base salary that has been earned at the time of such termination, reimbursement of any expenses properly incurred
prior to the Dr. Miranda&#8217;s termination date; and (iii) accrued and unused PTO, if any, in accordance with the Company&#8217;s PTO
policy in effect on Dr. Miranda&#8217;s termination date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr.
Miranda may terminate the employment agreement without good reason upon more than thirty (30) days&#8217; prior written notice or for
good reason without prior written consent, and will receive accrued compensation (as defined in the employment agreement) and the unpaid
balance of the special deferred bonus.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the event that Dr. Miranda is terminated without cause, non-forfeited portions of the deferred bonus will be paid in equal installments
over the remaining scheduled payment dates, if vested options as scheduled are exercised before the scheduled payment dates. A deferred
bonus tranche will be forfeited if its corresponding options have expired.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
a change in control (as defined in the employment agreement), full vesting of the Annual Deferred Bonus Payment will occur and be paid
in a single lump sum within 30 days after the change in control. The offering shall not be considered a change in control.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the employment agreement, Dr. Miranda also agreed to (i) not disclose to any unauthorized person or use for his own account any confidential
information without the prior written consent of the Company or the board of directors, (ii) will not, directly or indirectly encourage,
solicit, induce (or attempt to encourage, solicit or induce) any employee or agent of the Company that was employed (or otherwise engaged)
at the time of his separation during his employment and for 24 months after his separation from that employment for any reason; (iii)
will not, directly or indirectly, have any ownership interest in, work for, advise, manage, act as an agent or consultant for, or have
any business connection or business or employment relationship with any entity or person which competes with Company; (iv) not, directly
or indirectly, have any ownership interest in, work for, advise, manage, act as an agent or consultant for, or have any business connection
or business or employment relationship with any entity or person which competes with the Company during his employment and (v) will not,
directly or indirectly and in a competitive capacity own, manage, finance, operate, control or participate in ownership, management,
or operation of, act as an agent, consultant, or be employed with, any business engaged in the design, manufacture, marketing, sale or
servicing of any service or product with which Dr. Miranda was involved during his last year of employment with the Company; or which
the Company is developing, producing, marketing, selling or servicing (or plans to develop, produce, market, sale or service) and about
which Dr. Miranda gained any confidential information in the course of his employment with the Company for a period of 24 months after
his separation from the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 84; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->84<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Dr.
Thomas Carrico</i>, Chief Regulatory Officer, entered into an employment agreement with the Company, dated August 9, 2022 and amended
on May 4, 2023, which has a two-year initial term and provides for a base salary of $275,000 with annual compensation increase. Dr. Carrico
will also receive a one-time incentive payment in the amount of $135,655, which amount includes accrued and unpaid salary and a bonus
to incentivize Dr. Carrico to remain with the Company for future service. Neither the accrued and unpaid salary nor bonus was the subject
of any contract or agreement between Dr. Carrico and the Company prior to the execution of the employment agreement. The agreement contemplated
that the incentive payment would be paid by December 15, 2022, but due to administrative impracticability, payment was made with a portion
of the proceeds from the IPO in August 2023. In addition, Dr. Carrico shall be entitled to payment of a deferred bonus in an amount equal
to (i) the aggregate of the strike price or exercise price of all 306,236 unexercised options to purchase stock or shares of the Company
held by Dr. Carrico (the &#8220;Aggregate Strike Price&#8221;) plus (ii) a tax gross-up payment on the Aggregate Strike Price reasonably
calculated by the Company at the highest marginal rates so that after payment of all ordinary income taxes on such Aggregate Strike Price,
there remains an amount sufficient to pay such ordinary income taxes. The special deferred bonus will be paid in substantially equal
20% installments (the &#8220;Annual Deferred Bonus Payment&#8221;) on January 2 on each of 2024, 2025, 2026, 2027, and 2028 (the &#8220;Scheduled
Payment Dates&#8221;), with a condition that on or before each Scheduled Payment Date, Dr. Carrico shall exercise at least 61,274 of
the stock option. None of stock options has been exercised, therefore, no special deferred bonus has been paid as of the date of this
prospectus. Dr. Carrico may exercise any portion of the stock options after a Scheduled Payment Date; provided, however, an exercise
after the applicable Scheduled Payment Date shall result in forfeiture of the related Annual Deferred Bonus Payment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
the employment agreement is terminated by the Company without cause (as defined in the employment agreement), Dr. Carrico will receive
any accrued compensation (as defined in the employment agreement) and is entitled to certain amount of severance payments as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
    termination occurs during the initial term, the Company shall provide Dr. Carrico with severance compensation in the form of salary
    continuation at his Base Salary as of the termination date and ending the later of (i) 6 months or (ii) on the expiration date of
    the initial term.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
    termination occurs after the initial term, the severance payment shall be the amount equal to one half (1/2) of Dr. Carrico&#8217;s
    Base Salary as of the termination date.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
    addition, if termination occurs during the initial term, as part of the severance payment, we agreed to pay Dr. Carrico reimbursement
    of his Medicare, Medicare Supplement and prescription drug coverage insurance premiums for continuation of health coverage for 18
    months post termination.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
the employment agreement is terminated by the Company for cause, Dr. Carrico will forfeit any unpaid Annual Deferred Bonus Payment, but
will receive any unpaid base salary that has been earned at the time of such termination, reimbursement of any expenses properly incurred
prior to the Dr. Carrico&#8217;s termination date; and (iii) accrued and unused PTO, if any, in accordance with the Company&#8217;s PTO
policy in effect on Dr. Carrico&#8217;s termination date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr.
Carrico may terminate the employment agreement without good reason upon more than thirty (30) days&#8217; prior written notice or for
good reason without prior written consent, and will receive accrued compensation (as defined in the employment agreement) and the unpaid
balance of the special deferred bonus.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the event that Dr. Carrico is terminated without cause after this offering, non-forfeited portions of the deferred bonus will be paid
in equal installments over the remaining scheduled payment dates, if vested options as scheduled are exercised before the scheduled payment
dates. A deferred bonus tranche will be forfeited if its corresponding options have expired.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
a change in control (as defined in the employment agreement), full vesting of the Annual Deferred Bonus Payment will occur and be paid
in a single lump sum within 30 days after the change in control. The offering shall not be considered a change in control.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the employment agreement, Dr. Carrico also agreed to (i) not disclose to any unauthorized person or use for his own account any confidential
information without the prior written consent of the Company or the board of directors, (ii) will not, directly or indirectly encourage,
solicit, induce (or attempt to encourage, solicit or induce) any employee or agent of the Company that was employed (or otherwise engaged)
at the time of his separation during his employment and for 24 months after his separation from that employment for any reason; (iii)
will not, directly or indirectly, have any ownership interest in, work for, advise, manage, act as an agent or consultant for, or have
any business connection or business or employment relationship with any entity or person which competes with Company; (iv) not, directly
or indirectly, have any ownership interest in, work for, advise, manage, act as an agent or consultant for, or have any business connection
or business or employment relationship with any entity or person which competes with the Company during his employment and (v) will not,
directly or indirectly and in a competitive capacity own, manage, finance, operate, control or participate in ownership, management,
or operation of, act as an agent, consultant, or be employed with, any business engaged in the design, manufacture, marketing, sale or
servicing of any service or product with which Dr. Carrico was involved during his last year of employment with the Company; or which
the Company is developing, producing, marketing, selling or servicing (or plans to develop, produce, market, sale or service) and about
which Dr. Carrico gained any confidential information in the course of his employment with the Company for a period of 24 months after
his separation from the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 85; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->85<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Non-Employee
Director Compensation</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table presents the compensation awarded to or earned by or paid to all individuals who served as non-employee directors during
the years ended December 31, 2024 and 2023. We do not provide additional compensation to directors who are our employees for also serving
as a director.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 93%; margin-left: 0.5in">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-weight: bold">Name</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Year</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Fees Earned ($) </td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Stock Awards Earned ($) </td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Total </b></span><b>($)</b></p></td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 32%; text-align: left">Bradley M. Watkins</td><td style="width: 2%">&#160;</td>
    <td style="width: 12%; text-align: center">2024</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right">60,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right">50,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right">110,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: center">2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">23,836</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">19,863</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">43,699</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Beth Keyser</td><td>&#160;</td>
    <td style="text-align: center">2024</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">60,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">50,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">110,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: center">2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">23,836</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">19,863</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">43,699</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Kristin Ferge (1)</td><td>&#160;</td>
    <td style="text-align: center">2024</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">49,151</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">40,959</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">90,110</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: center">2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Timothy Henrichs (2)</td><td>&#160;</td>
    <td style="text-align: center">2024</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,260</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,384</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">9,644</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: center">2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">23,836</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">19,863</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">43,699</td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)
Kristin Ferge was appointed to the board of directors on March 7, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)
On January 30, 2024, Timothy R. Henrichs resigned as a member of the board of directors, effective February 2, 2024 and became the Company&#8217;s
Chief Financial Officer.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="sh_007"></span>ITEM
12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table sets forth certain information known to us with respect to the beneficial ownership of our common stock as of March
13, 2025 based on 7,215,864 shares of common stock outstanding. In addition, holders of Series B Preferred Stock are entitled to an
additional 2,681,208 votes (solely for purposes of voting rights, the conversion price is $3.80 per share). Therefore, the total
votes of the Company&#8217;s currently outstanding securities is 9,897,072 votes, subject to a maximum voting percentage cap of
between 4.99% and 19.99% of the votes outstanding set at the discretion of each holder of Series B Preferred Stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have determined beneficial ownership in accordance with the rules of the Securities and Exchange Commission, and the information is not
necessarily indicative of beneficial ownership for any other purpose. These rules generally attribute beneficial ownership of securities
to persons who possess sole or shared voting power or investment power with respect to those securities as well as any common stock that
the person has the right to acquire within 60 days of March 13, 2025 through the exercise of stock options or other rights. These shares
are deemed to be outstanding and beneficially owned by the person holding those options for the purpose of computing the percentage ownership
of that person, but they are not treated as outstanding for the purpose of computing the percentage ownership of any other person. Unless
otherwise indicated, the persons or entities identified in this table have sole voting and investment power with respect to all shares
shown as beneficially owned by them.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Beneficially Ownership Common Stock</td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Shares</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Percentage</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Percentage of</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Voting
                                            Power</b></p></td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Name of beneficial owner 5% shareholders:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 52%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Masimo Corporation <sup>(1)</sup></span></td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right">821,327</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right">10.9</td><td style="width: 1%; text-align: left">%</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right">8.3</td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Brian P. Hannasch <sup>(2)</sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">770,753</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">10.7</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7.8</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Rosalind Master Fund LP<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <sup>(3) (8)</sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">796,800</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">9.9</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">9.9</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Named executive officers and directors:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Brian Carrico <sup>(4)</sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">340,118</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4.5</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3.4</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Timothy Henrichs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">*</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Adrian Miranda <sup>(5)</sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">337,204</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4.5</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3.4</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Thomas Carrico <sup>(6)</sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">311,236</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4.1</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3.1</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Christopher Robin Brown</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">792,837</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">11.0</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">8.0</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Bradley Mitch Watkins</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">24,737</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">*</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Beth Keyser</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">24,737</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">*</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Kristin Ferge</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">14,340</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">*</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Gil Aharon<sup>(7)</sup></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">105,042</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1.4</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">*</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">All executive officers and directors as a group (nine (9) persons)</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">1,950,251</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">26.4</td><td style="font-weight: bold; text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><b>19.3</b></td><td style="text-align: left"><b>%</b></td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 24pt; text-align: justify; text-indent: -24pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Less
    than 1%.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">(1) The business address
for Masimo Corporation is 52 Discovery, Irvine, California 92618. Shares of common stock beneficially owned consist of (i) 531,548 shares
of common stock and (ii) warrants to purchase 289,779 shares of common stock.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">(2) Shares of common stock
beneficially owned consist of (i) 757,901 shares of common stock and (ii) warrants to purchase 12,852 shares of common stock.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">(3) The business
address for Rosalind Master Fund LP is c/o Rosalind Advisors, Inc., 15 Wellesley Street West, Suite 326, Toronto, ON, Canada M4Y
0G7. Shares of beneficially owned common stock consist of 1,890,756 shares of common stock issuable upon conversion of 1,890,756 shares
of Series B Preferred Stock, subject to an ownership cap of 9.99%, which equals 796,800 shares. 1,890,756 shares of Series B Preferred Stock entitle Rosalind Master Fund LP to 1,184,210 votes, subject to a maximum
percentage of 9.99%, or 988,717 votes.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">(4) Shares of common stock
beneficially owned consist of (i) 20,118 shares of common stock and (ii) 320,000 stock options.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">(5) Shares of common stock
beneficially owned consist of 337,204 stock options.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">(6) Shares of common stock
beneficially owned consist of (i) 5,000 shares of common stock and (ii) 306,236 stock options.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">(7) Shares of common
stock beneficially owned consist of 105,042 shares of common stock issuable upon conversion of 105,042 shares of Series B Preferred
Stock. 105,042 shares of Series B Preferred Stock entitle <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Gil
Aharon to 65,789 votes.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">(8) Mr. Aharon has indirect
ownership over Rosalind Master Fund LP.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>


<!-- Field: Page; Sequence: 86; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->86<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b><span id="sh_008"></span>Item
13. Certain Relationships and Related Transactions and Director Independence</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following includes a summary of transactions since January 1, 2023, to which we have been a party in which the amount involved exceeded
or will exceed the lesser of (i) $120,000 and (ii) one percent (1%) of the average of our total assets at year-end for the prior two
fiscal years, and in which any of our directors, executive officers or, to our knowledge, beneficial owners of more than 5% of our capital
stock or any member of the immediate family of any of the foregoing persons had or will have a direct or indirect material interest,
other than equity and other compensation, termination, change in control and other arrangements, which are described under &#8220;Item
11. Executive Compensation.&#8221; We also describe below certain other transactions with our directors, executive officers and stockholders.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has two demand notes receivable from its two founding shareholders, Christopher Robin Brown and Gary Peterson, related to the
sale of common stock on January 1, 2016. The initial balances of both notes were $506,400, with interest calculated monthly based on
applicable federal rates. No payments have been received on the notes. As of December 31, 2023, the balances of both notes were $506,400.
The entire $1,012,800 balance has been fully reserved as of December 31, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has loans payable to Christopher Robin Brown, one of our founders and a member of our board of directors, related to funding
needs for operations with original principal amounts of $55,000 and $50,000 each bearing interest at 15% per annum. In August 2023, the
Company used a portion of the proceeds from the IPO to repay these loans payable in full, including $37,103 in interest.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr.
Watkins, Director, provided certain sales, marketing and commercialization consulting services to the Company prior to his appointment
to the Board of Directors. For the fiscal years ended December 31, 2024 and 2023, the Company paid Mr. Watkins $0 and $11,083, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">John
Seale, our former Chief Financial Officer, is also the managing partner of a third- party public accounting firm that provides contracted
services to the Company. Mr. Seale, through the third-party firm, has provided accounting services since 2017. For the fiscal years ended
December 31, 2024 and 2023, the Company paid the third-party accounting firm $207,103 and $312,803, respectively, for accounting services.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have adopted a formal policy that our executive officers, directors, holders of more than 5% of any class of our voting securities, and
any member of the immediate family of and any entity affiliated with any of the foregoing persons, are not permitted to enter into a
related party transaction with us without the prior consent of our Audit Committee, or other independent members of our Board of Directors
if it is inappropriate for our audit committee to review such transaction due to a conflict of interest. Any request for us to enter
into a transaction with an executive officer, director, principal shareholder, or any of their immediate family members or affiliates,
in which the amount involved exceeds the lesser of $120,000 or 1% of the average of our total assets at year-end for the last two completed
fiscal years must first be presented to our audit committee for review, consideration and approval. In approving or rejecting any such
proposal, our Audit Committee is to consider the relevant facts and circumstances available and deemed relevant to the audit committee,
including, but not limited to, whether the transaction is on terms no less favorable than terms generally available to an unaffiliated
third party under the same or similar circumstances and the extent of the related party&#8217;s interest in the transaction.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b><span id="sh_009"></span>Item
14. Principal Accounting Fees and Services</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Fees
Billed for Audit and Non-Audit Services</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table presents for each of the last two fiscal years the aggregate fees billed in connection with the audits of our financial
statements and other professional services rendered by our independent registered public accounting firm Rosenberg Rich Baker Berman,
P.A.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Audit Fees (1)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">181,195</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">221,570</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)
<i>Audit Fees</i>. These are fees for professional services for the audit of our annual financial statements, and for the review of the
financial statements included in our filings on Form 10-K and Form 10-Q, and for services that are normally provided in connection with
statutory and regulatory filings or engagements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 87; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->87<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="sh_010"></span>PART
IV</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 12.95pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="sh_011"></span>ITEM
15. EXHIBIT AND FINANCIAL STATEMENT SCHEDULES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 12.95pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.
    Financial Statements</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    financial statements and Report of Independent Registered Public Accounting Firm are listed in the &#8220;Index to Financial Statements
    and Schedules&#8221; on page F-1 and included from F-2 onwards.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.
    Financial Statement Schedules</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
    schedules for which provision is made in the applicable accounting regulations of the Securities and Exchange Commission (the &#8220;Commission&#8221;)
    are either not required under the related instructions, are not applicable (and therefore have been omitted), or the required disclosures
    are contained in the financial statements included herein.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.
    Exhibits (including those incorporated by reference).</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
Exhibits</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exhibit</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 0.75in; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; width: 0.1in; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exhibit
    Description</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1933567/000149315223001110/ex3-1.htm" style="-sec-extract: exhibit">Certificate of Incorporation (incorporated by reference to exhibit 3.1 to Registration Statement on Form S-1, filed on January 10, 2023)</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.2</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1933567/000149315223002577/ex3-2.htm" style="-sec-extract: exhibit">Certificate of Amendment to Certificate of Incorporation (incorporated by reference to exhibit 3.2 to Registration Statement on Form S-1, filed on January 26, 2023)</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">3.3</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1933567/000149315224044538/ex3-1.htm" style="-sec-extract: exhibit">Certificate of Amendment to the Certificate of Incorporation of Neuraxis, Inc., dated August 22, 2024 (incorporated by reference to exhibit 3.1 to Quarterly Report on Form10-Q, filed on November 12, 2024)</a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">3.4</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><a href="https://www.sec.gov/Archives/edgar/data/1933567/000149315224044538/ex3-2.htm" style="-sec-extract: exhibit">Certificate of Designation of Series B Preferred Stock, dated August 22, 2024 (incorporated by reference to exhibit 3.2 to Quarterly Report on Form10-Q, filed on November 12, 2024)</a></p>
</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">3.6</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1933567/000149315224047196/ex3-1.htm" style="-sec-extract: exhibit">Amendment No. 1 to Certificate of Designation of Preferences, Rights and Limitations of Series B Preferred Stock (incorporated by reference to exhibit 3.1 to current report on Form 8-K, furnished to the SEC on November 21, 2024)</a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.7</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1933567/000149315223001110/ex3-3.htm" style="-sec-extract: exhibit">Bylaws (incorporated by reference to exhibit 3.3 to Registration Statement on Form S-1, filed on January 10, 2023)</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex4-1.htm">Description of the Company&#8217;s Securities</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1933567/000149315223001110/ex4-21.htm" style="-sec-extract: exhibit">Second Amendment to Shareholders&#8217; Agreement, dated January 8, 2023 (incorporated by reference to exhibit 4.21 to Registration Statement on Form S-1, filed on January 10, 2023)</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1&#8224;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1933567/000149315223001110/ex10-12.htm" style="-sec-extract: exhibit">Employment Agreement between Neuraxis, Inc. and Brian Carrico, dated as of August 9, 2022 (incorporated by reference to exhibit 10.12 to Registration Statement on Form S-1, filed on January 10, 2023)</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.2&#8224;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1933567/000149315223019787/ex10-13.htm" style="-sec-extract: exhibit">First Amendment to Executive Employment Agreement between Neuraxis, Inc. and Brian Carrico, dated as of May 4, 2023 (incorporated by reference to exhibit 10.13 to Registration Statement on Form S-1, filed on June 1, 2023)</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.3&#8224;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1933567/000149315223001110/ex10-13.htm" style="-sec-extract: exhibit">Employment Agreement between Neuraxis, Inc. and Adrian Miranda, dated as of August 17, 2022 (incorporated by reference to exhibit 10.13 to Registration Statement on Form S-1, filed on January 10, 2023)</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.4&#8224;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1933567/000149315223001110/ex10-14.htm" style="-sec-extract: exhibit">Employment Agreement between Neuraxis, Inc. and Thomas Carrico, dated as of August 9, 2022 (incorporated by reference to exhibit 10.14 to Registration Statement on Form S-1, filed on January 10, 2023)</a></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 88; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->88<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.5&#8224;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1933567/000149315223019787/ex10-16.htm" style="-sec-extract: exhibit">First Amendment to Executive Employment Agreement between Neuraxis, Inc. and Thomas Carrico, dated as of May 4, 2023 (incorporated by reference to exhibit 10.16 to Registration Statement on Form S-1, filed on June 1, 2023)</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.6&#8224;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1933567/000149315223001110/ex10-15.htm" style="-sec-extract: exhibit">Employment Agreement between Neuraxis, Inc. and Dan Clarence, dated as of August 9, 2022 (incorporated by reference to exhibit 10.15 to Registration Statement on Form S-1, filed on January 10, 2023)</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.7&#8224;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1933567/000149315223019787/ex10-18.htm" style="-sec-extract: exhibit">First Amendment to Executive Employment Agreement between Neuraxis, Inc. and Dan Clarence, dated as of May 4, 2023 (incorporated by reference to exhibit 10.18 to Registration Statement on Form S-1, filed on June 1, 2023)</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.8&#8224;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1933567/000149315223001110/ex10-16.htm" style="-sec-extract: exhibit">Employment Agreement between Neuraxis, Inc. and Christopher Robin Brown, dated as of August 9, 2022 (incorporated by reference to exhibit 10.16 to Registration Statement on Form S-1, filed on January 10, 2023)</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.9&#8224;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1933567/000149315223019787/ex10-20.htm" style="-sec-extract: exhibit">First Amendment to Executive Employment Agreement between Neuraxis, Inc. and Christopher Robin Brown, dated as of May 4, 2023 (incorporated by reference to exhibit 10.20 to Registration Statement on Form S-1, filed on June 1, 2023)</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.10&#8224;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1933567/000149315223001110/ex10-17.htm" style="-sec-extract: exhibit">Employment Agreement between Neuraxis, Inc. and Gary Peterson, dated as of August 9, 2022 (incorporated by reference to exhibit 10.17 to Registration Statement on Form S-1, filed on January 10, 2023)</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.11&#8224;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1933567/000149315223019787/ex10-22.htm" style="-sec-extract: exhibit">First Amendment to Executive Employment Agreement between Neuraxis, Inc. and Gary Peterson, dated as of May 4, 2023 (incorporated by reference to exhibit 10.22 to Registration Statement on Form S-1, filed on June 1, 2023)</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.12&#8224;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1933567/000149315223001110/ex10-20.htm" style="-sec-extract: exhibit">Innovative Health Solutions, Inc. 2017 Stock Compensation Plan, as amended (incorporated by reference to exhibit 10.20 to Registration Statement on Form S-1, filed on January 10, 2023)</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.13&#8224;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1933567/000149315223001110/ex10-21.htm" style="-sec-extract: exhibit">Neuraxis, Inc. 2022 Omnibus Securities and Incentive Plan (incorporated by reference to exhibit 10.21 to Registration Statement on Form S-1, filed on January 10, 2023)</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.14&#8224;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1933567/000149315223002577/ex10-26.htm" style="-sec-extract: exhibit">First Amendment to Neuraxis, Inc. 2022 Omnibus Securities and Incentive Plan (incorporated by reference to exhibit 10.26 to Registration Statement on Form S-1, filed on January 26, 2023)</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.15</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1933567/000149315223040826/ex10-1.htm" style="-sec-extract: exhibit">Securities purchase agreement, dated November 9, 2023, between the Company and Flagstaff International, LLC (incorporated by reference to exhibit 10.1 to current report on Form 8-K, furnished to the SEC on November 14, 2023)</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.16</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1933567/000149315223040826/ex10-2.htm" style="-sec-extract: exhibit">Registration rights agreement, dated November 9, 2023, between the Company and Flagstaff International, LLC (incorporated by reference to exhibit 10.2 to current report on Form 8-K, furnished to the SEC on November 14, 2023)</a></span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: center; width: 0.75in"><span style="font-size: 10pt">10.21</span></td>
    <td style="text-align: justify; width: 0.1in">&#160;</td>
    <td style="text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1933567/000149315224006888/ex10-1.htm" style="-sec-extract: exhibit"><span style="font-size: 10pt">Form of Securities Purchase Agreement (incorporated by reference to exhibit 10.1 to current report on Form 8-K, furnished to the SEC on February 15, 2024)</span></a></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: center">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: center"><span style="font-size: 10pt">10.22</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1933567/000149315224006888/ex10-2.htm" style="-sec-extract: exhibit"><span style="font-size: 10pt">Form of Convertible Promissory Note (incorporated by reference to exhibit 10.2 to current report on Form 8-K, furnished to the SEC on February 15, 2024)</span></a></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: center">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: center"><span style="font-size: 10pt">10.23</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1933567/000149315224006888/ex10-3.htm" style="-sec-extract: exhibit"><span style="font-size: 10pt">Form of Registration Rights Agreement (incorporated by reference to exhibit 10.3 to current report on Form 8-K, furnished to the SEC on February 15, 2024)</span></a></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: center">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: center"><span style="font-size: 10pt">10.24</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1933567/000149315224006888/ex10-4.htm" style="-sec-extract: exhibit"><span style="font-size: 10pt">First Amendment to Securities Purchase Agreement, dated February 12, 2024, between the Company and Flagstaff International (incorporated by reference to exhibit 10.4 to current report on Form 8-K, furnished to the SEC on February 15, 2024)</span></a></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: center">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: center"><span style="font-size: 10pt">10.25</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1933567/000149315224011761/ex10-1.htm" style="-sec-extract: exhibit"><span style="font-size: 10pt">Third Amendment to Securities Purchase Agreement, dated March 22, 2024, between the Company and Flagstaff International, LLC&#160; (incorporated by reference to exhibit 10.1 to current report on Form 8-K, furnished to the SEC on March 28, 2024)</span></a></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: center">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: center"><span style="font-size: 10pt">10.26</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1933567/000149315224011761/ex10-2.htm" style="-sec-extract: exhibit"><span style="font-size: 10pt">Form of Convertible Promissory Note issued to Flagstaff International, LLC (incorporated by reference to exhibit 10.2 to current report on Form 8-K, furnished to the SEC on March 28, 2024)</span></a></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: center">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: center"><span style="font-size: 10pt">10.27</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1933567/000149315224021615/ex10-1.htm" style="-sec-extract: exhibit"><span style="font-size: 10pt">Form of Securities Purchase Agreement (incorporated by reference to exhibit 10.1 to current report on Form 8-K, furnished to the SEC on May 28, 2024)</span></a></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: center">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: center"><span style="font-size: 10pt">10.28</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1933567/000149315224021615/ex10-2.htm" style="-sec-extract: exhibit"><span style="font-size: 10pt">Form of Convertible Promissory Note (incorporated by reference to exhibit 10.2 to current report on Form 8-K, furnished to the SEC on May 28, 2024)</span></a></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: center">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: center"><span style="font-size: 10pt">10.29</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1933567/000149315224021615/ex10-3.htm" style="-sec-extract: exhibit"><span style="font-size: 10pt">Form of Registration Rights Agreement (incorporated by reference to exhibit 10.3 to current report on Form 8-K, furnished to the SEC on May 28, 2024)</span></a></td></tr>
</table>

<p style="margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>


<!-- Field: Page; Sequence: 89; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->89<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: center; width: 0.75in"><span style="font-size: 10pt">10.30&#8224;</span></td>
    <td style="text-align: justify; width: 0.1in">&#160;</td>
    <td style="text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1933567/000149315224026362/ex10-1.htm" style="-sec-extract: exhibit"><span style="font-size: 10pt">Form of Unrestricted Stock Award Agreement by and between NeurAxis, Inc. and Grantees dated on July 1, 2024 (incorporated by reference to exhibit 10.1 to current report on Form 8-K, furnished to the SEC on July 5, 2024)</span></a></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: center">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: center"><span style="font-size: 10pt">10.31</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1933567/000149315224041597/ex10-1.htm" style="-sec-extract: exhibit"><span style="font-size: 10pt">Fourth Amendment to Securities Purchase Agreement, dated October 12, 2024, between the Company and Flagstaff International, LLC (incorporated by reference to exhibit 10.1 to current report on Form 8-K, furnished to the SEC on October 18, 2024)</span></a></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: center">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: center"><span style="font-size: 10pt">10.32</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1933567/000149315224041597/ex10-2.htm" style="-sec-extract: exhibit"><span style="font-size: 10pt">Form of Securities Purchase Agreement (incorporated by reference to exhibit 10.2 to current report on Form 8-K, furnished to the SEC on October 18, 2024)</span></a></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: center">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: center"><span style="font-size: 10pt">10.33</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1933567/000149315224041597/ex10-3.htm" style="-sec-extract: exhibit"><span style="font-size: 10pt">Form of Registration Rights Agreement (incorporated by reference to exhibit 10.3 to current report on Form 8-K, furnished to the SEC on October 18, 2024)</span></a></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: center">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: center"><span style="font-size: 10pt">10.34</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1933567/000149315224046285/ex10-1.htm" style="-sec-extract: exhibit"><span style="font-size: 10pt">Form of Securities Purchase Agreement (incorporated by reference to exhibit 10.1 to current report on Form 8-K, furnished to the SEC on November 15, 2024)</span></a></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: center">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: center"><span style="font-size: 10pt">10.35</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1933567/000149315224046285/ex10-2.htm" style="-sec-extract: exhibit"><span style="font-size: 10pt">Form of Registration Rights Agreement (incorporated by reference to exhibit 10.2 to current report on Form 8-K, furnished to the SEC on November 15, 2024)</span></a></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: center">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: center"><span style="font-size: 10pt">19.1*</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt"><a href="ex19-1.htm">Insider Trading Policy</a></span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: center">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 72px; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">21.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 10px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1933567/000149315223001110/ex21-1.htm" style="-sec-extract: exhibit">List of Subsidiaries of Neuraxis, Inc. (incorporated by reference to exhibit 21.1 to Registration Statement on Form S-1, filed on January 10, 2023)</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">23.1*</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex23-1.htm">Consent of Rosenberg Rich Baker Berman, P.A.</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">31.1*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex31-1.htm">Certification of Chief Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act Of 2002</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">31.2*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex31-2.htm">Certification of Chief Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act Of 2002</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">32.1**</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex32-1.htm">Certification of Chief Executive Officer and Chief Financial Officer Pursuant to Section 906 of the Sarbanes-Oxley Act Of 2002</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">97.1</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1933567/000149315224014832/ex97-1.htm" style="-sec-extract: exhibit">NeurAxis, Inc. Compensation Recovery Policy (incorporated by reference to exhibit 97.1 to Annual Report on Form 10-K, filed on April 16, 2024)</a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.INS*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL Instance Document.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.SCH*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL Taxonomy Extension Schema Document.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.CAL*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL Taxonomy Extension Calculation Linkbase Document.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.DEF*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL Taxonomy Extension Definition Linkbase Document.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.LAB*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL Taxonomy Extension Label Linkbase Document.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.PRE*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL Taxonomy Extension Presentation Linkbase Document.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">104*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cover
    Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8224;
Executive compensation plan or arrangement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*
Filed herewith.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">**
Furnished herewith.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="sh_019"></span>ITEM
16. FORM 10-K SUMMARY</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
Applicable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 90; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->90<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="sh_012"></span>Index
to Financial Statements</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>FOR
THE YEARS ENDED DECEMBER 31, 2024 AND 2023</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Page(s)</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#sh_013">Report of Independent Registered Public Accounting Firm</a> (PCAOB Firm ID <span id="xdx_902_edei--AuditorFirmId_c20240101__20241231_zX3tlgdDaPBh"><span style="-sec-ix-hidden: xdx2ixbrl0058">0089</span></span>)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-1</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#sh_014">Balance Sheets as of December 31, 2024 and 2023</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-2</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#sh_015">Statements of Operations for the Years Ended December 31, 2024 and 2023</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-4</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#sh_016">Statements
    of Stockholders&#8217; Equity (Deficit) for the Years Ended December 31, 2024 and 2023</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-5</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#sh_017">Statements of Cash Flows for the Years Ended December 31, 2024 and 2023</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-6</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#sh_018">Notes to Financial Statements</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-7</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 91; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->91<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="sh_013"></span>REPORT
OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
the Board of Directors and<br/>
Stockholders of Neuraxis, Inc.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Opinion
on the Financial Statements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_98F_edei--AuditorOpinionTextBlock_c20240101__20241231_zBZkvba4Sga8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000059" name="dei:AuditorOpinionTextBlock"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have audited the accompanying balance sheets of Neuraxis, Inc. (the Company) as of December 31, 2024 and 2023, and the related
statements of operations, stockholders&#8217; equity (deficit), and cash flows for each of the years in the two-year period ended
December 31, 2024, and the related notes (collectively referred to as the financial statements). In our opinion, the financial
statements present fairly, in all material respects, the financial position of the Company as of December 31, 2024 and 2023, and the
results of its operations and its cash flows for each of the years in the two-year period ended December 31, 2024, in conformity with
accounting principles generally accepted in the United States of America.</span></ix:nonNumeric></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Emphasis
of Matter Regarding Going Concern</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note
2 to the financial statements, the Company is not profitable, has recorded negative cash flows from operations, and will need substantial
capital to support its operations. This raises substantial doubt about the Company&#8217;s ability to continue as a going concern. Management&#8217;s
plans in regard to these matters also are described in Note 2. The financial statements do not include any adjustments that might result
from the outcome of this uncertainty.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Basis
for Opinion</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s
financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board
(United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities
laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain
reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company
is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits,
we are required to obtain an understanding of internal control over financial reporting, but not for the purpose of expressing an opinion
on the effectiveness of the Company&#8217;s internal control over financial reporting. Accordingly, we express no such opinion.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error
or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding
the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant
estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits
provide a reasonable basis for our opinion.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 50%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    <span id="xdx_90B_edei--AuditorName_c20240101__20241231_z89rmLQXQw4g"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000060" name="dei:AuditorName">Rosenberg Rich Baker Berman, P.A.</ix:nonNumeric></span></i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 50%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    have served as the Company&#8217;s auditor since 2022.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_edei--AuditorLocation_c20240101__20241231_zf5l0Ff1kQv3"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000061" name="dei:AuditorLocation">Somerset,
    New Jersey</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March
    20, 2025</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 92; Options: NewSection; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="sh_014"></span>Neuraxis,
Inc. </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Balance
Sheets</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_30B_111_zV14g0trUXU8" summary="xdx: Statement - Balance Sheets" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49A_20241231_zbWeFXZ4l5vj" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, 2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_499_20231231_zAXh3RITd4Yd" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, 2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--AssetsAbstract_iB_zG1ilS2LdYp2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold">Assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--AssetsCurrentAbstract_i01B" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Current Assets:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--CashAndCashEquivalentsAtCarryingValue_i02I_pp0p0_maACza3I_zZ7W2Iehxie8" style="vertical-align: bottom; background-color: White">
    <td style="width: 60%; text-align: left; padding-left: 10pt">Cash and cash equivalents</td><td style="width: 2%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">$</td><td style="width: 16%; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2024-12-31" id="Fact000069" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">3,696,870</ix:nonFraction></td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2023-12-31" id="Fact000070" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">78,560</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--AccountsReceivableNetCurrent_i02I_pp0p0_maACza3I_zyHVj5meskJ9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt">Accounts receivable, net of credit losses of $<span id="xdx_90A_eus-gaap--AllowanceForDoubtfulAccountsReceivable_iI_c20241231_z6VarWq5P1e" title="Accounts receivable, net of credit losses"><ix:nonFraction name="us-gaap:AllowanceForDoubtfulAccountsReceivable" contextRef="AsOf2024-12-31" id="Fact000075" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,000</ix:nonFraction></span> and $<span id="xdx_90D_eus-gaap--AllowanceForDoubtfulAccountsReceivable_iI_c20231231_zLElET8hPSbg" title="Accounts receivable, net of credit losses"><ix:nonFraction name="us-gaap:AllowanceForDoubtfulAccountsReceivable" contextRef="AsOf2023-12-31" id="Fact000077" format="ixt:numdotdecimal" decimals="0" unitRef="USD">11,993</ix:nonFraction></span> as of December 31, 2024 and 2023, respectively</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:AccountsReceivableNetCurrent" contextRef="AsOf2024-12-31" id="Fact000072" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">244,618</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccountsReceivableNetCurrent" contextRef="AsOf2023-12-31" id="Fact000073" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">73,167</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--InventoryNet_i02I_pp0p0_maACza3I_z1zpnQQ5xJFf" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt">Inventories, net of reserves of $<span id="xdx_906_eus-gaap--InventoryRawMaterialsNetOfReserves_iI_c20241231_zUbEm1YwbRt1" title="Inventories, net of reserves"><ix:nonFraction name="us-gaap:InventoryRawMaterialsNetOfReserves" contextRef="AsOf2024-12-31" id="Fact000082" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,454</ix:nonFraction></span> and $<span id="xdx_90C_eus-gaap--InventoryRawMaterialsNetOfReserves_iI_c20231231_zJfupkDFSYd3" title="Inventories, net of reserves"><ix:nonFraction name="us-gaap:InventoryRawMaterialsNetOfReserves" contextRef="AsOf2023-12-31" id="Fact000084" format="ixt:numdotdecimal" decimals="0" unitRef="USD">0</ix:nonFraction></span> as of December 31, 2024 and 2023, respectively</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:InventoryNet" contextRef="AsOf2024-12-31" id="Fact000079" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">44,328</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:InventoryNet" contextRef="AsOf2023-12-31" id="Fact000080" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">21,220</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_i02I_pp0p0_maACza3I_zfK7cRUB4519" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 10pt">Prepaids and other current assets</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="AsOf2024-12-31" id="Fact000086" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">280,367</ix:nonFraction></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="AsOf2023-12-31" id="Fact000087" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">69,663</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--AssetsCurrent_i01TI_mtACza3I_maAzdB1_zQVvAxlfnPk2" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 20pt">Total current assets</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="AsOf2024-12-31" id="Fact000089" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,266,183</ix:nonFraction></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="AsOf2023-12-31" id="Fact000090" format="ixt:numdotdecimal" decimals="0" unitRef="USD">242,610</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--PropertyPlantAndEquipmentGross_i01I_pp0p0_maPPAENzYtf_zJZif0LNP4id" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Property and Equipment, at cost:</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2024-12-31" id="Fact000092" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">464,402</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2023-12-31" id="Fact000093" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">436,626</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_i02NI_pp0p0_di_msPPAENzYtf_zLbcwLSiFtIh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 10pt">Less - accumulated depreciation</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="AsOf2024-12-31" id="Fact000095" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">374,420</ix:nonFraction></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="AsOf2023-12-31" id="Fact000096" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">348,074</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_407_eus-gaap--PropertyPlantAndEquipmentNet_i01TI_mtPPAENzYtf_maAzdB1_zFyNvbJNaQw1" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 20pt">Property and equipment, net</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2024-12-31" id="Fact000098" format="ixt:numdotdecimal" decimals="0" unitRef="USD">89,982</ix:nonFraction></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2023-12-31" id="Fact000099" format="ixt:numdotdecimal" decimals="0" unitRef="USD">88,552</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--OtherAssetsNoncurrentAbstract_i01B" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Other Assets:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--OperatingLeaseRightOfUseAsset_i02I_pp0p0_maAzdB1_zgnrYBJr6gN3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt">Operating lease right of use asset, net</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="AsOf2024-12-31" id="Fact000104" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">284,656</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="AsOf2023-12-31" id="Fact000105" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">70,263</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--FiniteLivedIntangibleAssetsNet_i02I_pp0p0_maAzdB1_zhNDH6HRMxNb" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt">Intangible assets, net</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="AsOf2024-12-31" id="Fact000107" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">96,588</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="AsOf2023-12-31" id="Fact000108" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">108,073</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--SecurityDeposit_i02I_pp0p0_maAzdB1_zgImrLN9XHC6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 10pt">Security deposit</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:SecurityDeposit" contextRef="AsOf2024-12-31" id="Fact000110" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">20,163</ix:nonFraction></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0111">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--Assets_iTI_mtAzdB1_zbcMarvJ2IA2" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1pt">Total Assets</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2024-12-31" id="Fact000113" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,757,572</ix:nonFraction></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2023-12-31" id="Fact000114" format="ixt:numdotdecimal" decimals="0" unitRef="USD">509,498</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Notes
to financial statements are an integral part of these statements.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 93; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Neuraxis,
Inc. </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Balance
Sheets</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, 2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, 2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--LiabilitiesAndStockholdersEquityAbstract_iB" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold">Liabilities</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">&#160;</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">&#160;</td><td style="font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--LiabilitiesCurrentAbstract_i01B" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Current Liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--AccountsPayableCurrent_i02I_pp0p0_maLCznsV_zQcuW64RIlk6" style="vertical-align: bottom; background-color: White">
    <td style="width: 60%; text-align: left; padding-left: 10pt">Accounts payable</td><td style="width: 2%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">$</td><td style="width: 16%; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" contextRef="AsOf2024-12-31" id="Fact000122" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">596,946</ix:nonFraction></td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" contextRef="AsOf2023-12-31" id="Fact000123" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,204,219</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--AccruedLiabilitiesCurrent_i02I_pp0p0_maLCznsV_z1l6SVh3YBMk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt">Accrued expenses</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" contextRef="AsOf2024-12-31" id="Fact000125" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,577,780</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" contextRef="AsOf2023-12-31" id="Fact000126" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">401,088</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--NotesPayableToBankCurrent_i02I_pp0p0_maLCznsV_zGyjjOY8rufa" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt">Notes payable</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:NotesPayableToBankCurrent" contextRef="AsOf2024-12-31" id="Fact000128" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">154,152</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:NotesPayableToBankCurrent" contextRef="AsOf2023-12-31" id="Fact000129" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">148,062</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--OperatingLeaseLiabilityCurrent_i02I_pp0p0_maLCznsV_zyVdxLXRCwik" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt">Current portion of operating lease payable</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="AsOf2024-12-31" id="Fact000131" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">62,754</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="AsOf2023-12-31" id="Fact000132" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">49,127</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--Deposits_i02I_pp0p0_maLCznsV_zmvWaGS0MNl5" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt">Customer deposits</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:Deposits" contextRef="AsOf2024-12-31" id="Fact000134" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">32,527</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:Deposits" contextRef="AsOf2023-12-31" id="Fact000135" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">74,947</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_ecustom--WarrantLiabilities_i02I_pp0p0_maLCznsV_zYmX2aRExt3j" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 10pt">Warrant liabilities</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="NRXS:WarrantLiabilities" contextRef="AsOf2024-12-31" id="Fact000137" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">9,166</ix:nonFraction></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="NRXS:WarrantLiabilities" contextRef="AsOf2023-12-31" id="Fact000138" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">8,225</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--LiabilitiesCurrent_i01TI_mtLCznsV_maLzx77_zyWYWzFItFh8" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 20pt">Total current liabilities</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="AsOf2024-12-31" id="Fact000140" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,433,325</ix:nonFraction></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="AsOf2023-12-31" id="Fact000141" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,885,668</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--LiabilitiesNoncurrentAbstract_i01B" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Non-current Liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--OperatingLeaseLiabilityNoncurrent_i02I_pp0p0_maLNza0y_zTDpPB0BAKga" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 10pt">Operating lease payable, net of current portion</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="AsOf2024-12-31" id="Fact000146" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">256,499</ix:nonFraction></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="AsOf2023-12-31" id="Fact000147" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">27,071</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--LiabilitiesNoncurrent_i01TI_pp0p0_mtLNza0y_maLzx77_zq4L35ycNIo" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 20pt">Total non-current liabilities</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesNoncurrent" contextRef="AsOf2024-12-31" id="Fact000149" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">256,499</ix:nonFraction></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesNoncurrent" contextRef="AsOf2023-12-31" id="Fact000150" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">27,071</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--Liabilities_iTI_pp0p0_mtLzx77_maLASEzf7I_zYld1pEPY9j" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 20pt">Total liabilities</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:Liabilities" contextRef="AsOf2024-12-31" id="Fact000152" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,689,824</ix:nonFraction></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:Liabilities" contextRef="AsOf2023-12-31" id="Fact000153" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,912,739</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">&#160;</td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--CommitmentsAndContingencies_iI_pp0p0_maLASEzf7I_z4RSkvZzsoYl" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Commitments and contingencies (see note 16)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="display: none; font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0155">-</span></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="display: none; font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0156">-</span></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--StockholdersEquityAbstract_i01B" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">Stockholders&#8217; Equity (Deficit)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--PreferredStockValue_i02I_pp0p0_maSEz6Ve_zp8C9V2cuTSb" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt">Convertible Series B Preferred stock, $<span id="xdx_902_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20241231__us-gaap--StatementClassOfStockAxis__custom--ConvertibleSeriesBPreferredStockMember_zw0q8W1SMZD3" title="Preferred stock, par value"><span id="xdx_903_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20231231__us-gaap--StatementClassOfStockAxis__custom--ConvertibleSeriesBPreferredStockMember_zrLPTRvJMHrj" title="Preferred stock, par value"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2024-12-31_custom_ConvertibleSeriesBPreferredStockMember" id="Fact000164" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2023-12-31_custom_ConvertibleSeriesBPreferredStockMember" id="Fact000166" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.01</ix:nonFraction></ix:nonFraction></span></span>
    par value; <span id="xdx_90A_eus-gaap--PreferredStockSharesAuthorized_iI_c20241231__us-gaap--StatementClassOfStockAxis__custom--ConvertibleSeriesBPreferredStockMember_zQ0wBG8TpOU7" title="Preferred stock, shares authorized"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2024-12-31_custom_ConvertibleSeriesBPreferredStockMember" id="Fact000168" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">5,000,000</ix:nonFraction></span>
    and <span id="xdx_90F_eus-gaap--PreferredStockSharesAuthorized_iI_c20231231__us-gaap--StatementClassOfStockAxis__custom--ConvertibleSeriesBPreferredStockMember_z45rN0ySQ4i3" title="Preferred stock, shares authorized"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2023-12-31_custom_ConvertibleSeriesBPreferredStockMember" id="Fact000170" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">0</ix:nonFraction></span> shares authorized, <span id="xdx_902_eus-gaap--PreferredStockSharesIssued_iI_c20241231__us-gaap--StatementClassOfStockAxis__custom--ConvertibleSeriesBPreferredStockMember_ztB864FKhLEf" title="Preferred stock, shares issued"><span id="xdx_903_eus-gaap--PreferredStockSharesOutstanding_iI_c20241231__us-gaap--StatementClassOfStockAxis__custom--ConvertibleSeriesBPreferredStockMember_zjCfM0601oZ4" title="Preferred stock, shares outstanding"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="AsOf2024-12-31_custom_ConvertibleSeriesBPreferredStockMember" id="Fact000172" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2024-12-31_custom_ConvertibleSeriesBPreferredStockMember" id="Fact000174" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">4,280,939</ix:nonFraction></ix:nonFraction></span></span>
    and <span id="xdx_90C_eus-gaap--PreferredStockSharesIssued_iI_c20231231__us-gaap--StatementClassOfStockAxis__custom--ConvertibleSeriesBPreferredStockMember_z6zKiT1YecHa" title="Preferred stock, shares issued"><span id="xdx_90C_eus-gaap--PreferredStockSharesOutstanding_iI_c20231231__us-gaap--StatementClassOfStockAxis__custom--ConvertibleSeriesBPreferredStockMember_z2cE4JnU7zg4" title="Preferred stock, shares outstanding"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="AsOf2023-12-31_custom_ConvertibleSeriesBPreferredStockMember" id="Fact000176" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2023-12-31_custom_ConvertibleSeriesBPreferredStockMember" id="Fact000178" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">0</ix:nonFraction></ix:nonFraction></span></span>
    shares issued and outstanding as of December 31, 2024 and 2023, respectively</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="AsOf2024-12-31" id="Fact000161" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">4,281</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0162">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--CommonStockValue_i02I_pp0p0_maSEz6Ve_z4fcL0TlDnl7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt">Common stock, $<span id="xdx_90D_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20241231_zoL4rJsLiGTh" title="Common stock, par value"><span id="xdx_909_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20231231_zstDs3P80938" title="Common stock, par value"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2024-12-31" id="Fact000183" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2023-12-31" id="Fact000185" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.001</ix:nonFraction></ix:nonFraction></span></span> par value; <span id="xdx_907_eus-gaap--CommonStockSharesAuthorized_iI_c20241231_zFk4WXDYGel3" title="Common stock, shares authorized"><span id="xdx_909_eus-gaap--CommonStockSharesAuthorized_iI_c20231231_zWySEW5e55Za" title="Common stock, shares authorized"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2024-12-31" id="Fact000187" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2023-12-31" id="Fact000189" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">100,000,000</ix:nonFraction></ix:nonFraction></span></span> shares authorized; <span id="xdx_900_eus-gaap--CommonStockSharesIssued_iI_c20241231_z8Bd12cTuk1i" title="Common stock, shares issued"><span id="xdx_90A_eus-gaap--CommonStockSharesOutstanding_iI_c20241231_zuCLateQyNL9" title="Common stock, shares outstanding"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2024-12-31" id="Fact000191" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2024-12-31" id="Fact000193" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">6,990,227</ix:nonFraction></ix:nonFraction></span></span> and <span id="xdx_908_eus-gaap--CommonStockSharesIssued_iI_c20231231_zYTuahIe2NSi" title="Common stock, shares issued"><span id="xdx_908_eus-gaap--CommonStockSharesOutstanding_iI_c20231231_zCnjt3cbzY78" title="Common stock, shares outstanding"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2023-12-31" id="Fact000195" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2023-12-31" id="Fact000197" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">6,508,897</ix:nonFraction></ix:nonFraction></span></span> issued and outstanding as of December 31, 2024 and 2023, respectively</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="AsOf2024-12-31" id="Fact000180" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">6,990</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="AsOf2023-12-31" id="Fact000181" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">6,509</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--AdditionalPaidInCapital_i02I_pp0p0_maSEz6Ve_zQip7xjW9u4c" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt">Additional paid in capital</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:AdditionalPaidInCapital" contextRef="AsOf2024-12-31" id="Fact000199" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">58,856,089</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdditionalPaidInCapital" contextRef="AsOf2023-12-31" id="Fact000200" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">47,148,361</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--RetainedEarningsAccumulatedDeficit_i02I_pp0p0_maSEz6Ve_zv1ELEWuYea4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 10pt">Accumulated deficit</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2024-12-31" id="Fact000202" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">56,799,612</ix:nonFraction></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2023-12-31" id="Fact000203" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">48,558,111</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">&#160;</td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--StockholdersEquity_i02TI_maLASEzf7I_mtSEz6Ve_z5YThgV8nCb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 20pt">Total stockholders&#8217; equity (deficit)</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-12-31" id="Fact000205" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,067,748</ix:nonFraction></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31" id="Fact000206" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,403,241</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--LiabilitiesAndStockholdersEquity_i01TI_pp0p0_mtLASEzf7I_zWkfuUcCbNqk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1pt">Total Liabilities and Stockholders&#8217; Equity (Deficit)</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="AsOf2024-12-31" id="Fact000208" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">4,757,572</ix:nonFraction></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="AsOf2023-12-31" id="Fact000209" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">509,498</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Notes
to financial statements are an integral part of these statements.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 94; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="sh_015"></span>Neuraxis,
Inc. </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Statements
of Operations</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_30A_113_zjm33QkRFls1" summary="xdx: Statement - Statements of Operations" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49E_20240101__20241231_zqeI1TcqcXY9" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49A_20230101__20231231_zxqSmvjbrjH5" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">For the Years Ended December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_maCz7vj_maGPzh9A_zG098HDswEs2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; font-weight: bold; text-align: left">Net sales</td><td style="width: 2%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">$</td><td style="width: 16%; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2024-01-01to2024-12-31" id="Fact000211" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,685,925</ix:nonFraction></td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2023-01-012023-12-31" id="Fact000212" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,460,049</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--CostOfGoodsAndServicesSold_msGPzh9A_zRuGz4qZAuX4" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Cost of goods sold</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:CostOfGoodsAndServicesSold" contextRef="From2024-01-01to2024-12-31" id="Fact000214" format="ixt:numdotdecimal" decimals="0" unitRef="USD">362,002</ix:nonFraction></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:CostOfGoodsAndServicesSold" contextRef="From2023-01-012023-12-31" id="Fact000215" format="ixt:numdotdecimal" decimals="0" unitRef="USD">303,345</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">&#160;</td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--GrossProfit_iT_pp0p0_mtGPzh9A_maOILzmZO_z4wdmhaWpqP9" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">Gross profit</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:GrossProfit" contextRef="From2024-01-01to2024-12-31" id="Fact000217" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,323,923</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:GrossProfit" contextRef="From2023-01-012023-12-31" id="Fact000218" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,156,704</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">&#160;</td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--SellingExpense_i01_pp0p0_msOILzmZO_z6psL8RThb1j" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Selling expenses</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:SellingExpense" contextRef="From2024-01-01to2024-12-31" id="Fact000220" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">324,708</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:SellingExpense" contextRef="From2023-01-012023-12-31" id="Fact000221" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">323,569</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--ResearchAndDevelopmentExpense_i01_pp0p0_msOILzmZO_zfxz26IRKcNa" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Research and development</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2024-01-01to2024-12-31" id="Fact000223" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">206,107</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2023-01-012023-12-31" id="Fact000224" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">169,315</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--GeneralAndAdministrativeExpense_i01_pp0p0_msOILzmZO_zPVx8RqmB1Wd" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">General and administrative</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2024-01-01to2024-12-31" id="Fact000226" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">8,949,925</ix:nonFraction></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2023-01-012023-12-31" id="Fact000227" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">8,328,315</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">&#160;</td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--OperatingIncomeLoss_iT_mtOILzmZO_maNILzGNZ_zuOiPFDGdxm4" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1pt">Operating loss</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2024-01-01to2024-12-31" id="Fact000229" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">7,156,817</ix:nonFraction></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2023-01-012023-12-31" id="Fact000230" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">6,664,495</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">&#160;</td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--NonoperatingIncomeExpenseAbstract_iB" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Other (expense) income:</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">&#160;</td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_ecustom--FinancingCharges_i01N_pp0p0_di_msONIEzShH_zUrirIhc4p48" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt">Financing charges</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">(<ix:nonFraction name="NRXS:FinancingCharges" contextRef="From2024-01-01to2024-12-31" id="Fact000235" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">230,824</ix:nonFraction></td><td style="font-weight: bold; text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="NRXS:FinancingCharges" contextRef="From2023-01-012023-12-31" id="Fact000236" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,772</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40B_eus-gaap--InterestExpense_i01N_pp0p0_di_msONIEzShH_zHYegUNlwJdf" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt">Interest expense</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:InterestExpense" contextRef="From2024-01-01to2024-12-31" id="Fact000238" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">174,328</ix:nonFraction></td><td style="font-weight: bold; text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:InterestExpense" contextRef="From2023-01-012023-12-31" id="Fact000239" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">476,416</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_402_eus-gaap--FairValueAdjustmentOfWarrants_i01N_pp0p0_di_msONIEzShH_zKehtrLDFjdj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt">Change in fair value of warrant liability</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="From2024-01-01to2024-12-31" id="Fact000241" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">941</ix:nonFraction></td><td style="font-weight: bold; text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="From2023-01-012023-12-31" id="Fact000242" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">844,854</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--DerivativeGainLossOnDerivativeNet_i01_pp0p0_maONIEzShH_z7jSGuYTQkOl" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt">Change in fair value of derivative liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0244">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DerivativeGainLossOnDerivativeNet" contextRef="From2023-01-012023-12-31" id="Fact000245" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">198,551</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--AmortizationOfFinancingCostsAndDiscounts_i01N_pp0p0_di_msONIEzShH_zBa3yLqhmzS5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt">Amortization of debt discount and issuance cost</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" contextRef="From2024-01-01to2024-12-31" id="Fact000247" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">126,387</ix:nonFraction></td><td style="font-weight: bold; text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" contextRef="From2023-01-012023-12-31" id="Fact000248" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">4,881,622</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40E_eus-gaap--GainsLossesOnExtinguishmentOfDebt_i01_pp0p0_maONIEzShH_zLlMQ04jryq4" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt">Extinguishment of debt liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0250">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:GainsLossesOnExtinguishmentOfDebt" contextRef="From2023-01-012023-12-31" id="Fact000251" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">3,649,561</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40C_eus-gaap--OtherNonoperatingIncome_i01_pp0p0_maONIEzShH_zeWTk3fRNyu7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt">Other income</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:OtherNonoperatingIncome" contextRef="From2024-01-01to2024-12-31" id="Fact000253" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">33,620</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OtherNonoperatingIncome" contextRef="From2023-01-012023-12-31" id="Fact000254" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">15,133</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--OtherNonoperatingExpense_i01N_pp0p0_di_msONIEzShH_z0kZqqUw484e" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 10pt">Other expense</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:OtherNonoperatingExpense" contextRef="From2024-01-01to2024-12-31" id="Fact000256" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">585,824</ix:nonFraction></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:OtherNonoperatingExpense" contextRef="From2023-01-012023-12-31" id="Fact000257" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">10,355</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_40E_eus-gaap--OtherNonoperatingIncomeExpense_i01T_maNILzGNZ_mtONIEzShH_z2S0TDmd2RO4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 20pt">Total other (expense) income, net</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="From2024-01-01to2024-12-31" id="Fact000259" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,084,684</ix:nonFraction></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="From2023-01-012023-12-31" id="Fact000260" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">7,962,188</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--NetIncomeLoss_iT_mtNILzGNZ_maNILATztS9_z3Avci3ik8hd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Net loss</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">$</td><td style="font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-01-01to2024-12-31" id="Fact000262" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">8,241,501</ix:nonFraction></td><td style="font-weight: bold; text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-12-31" id="Fact000263" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">14,626,683</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_402_eus-gaap--PreferredStockDividendsAndOtherAdjustments_iN_di_msNILATztS9_ziVkJCHnLX98" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt; padding-left: 0.125in">Preferred stock dividends</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:PreferredStockDividendsAndOtherAdjustments" contextRef="From2024-01-01to2024-12-31" id="Fact000265" format="ixt:numdotdecimal" decimals="0" unitRef="USD">211,268</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0266">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_iT_mtNILATztS9_zRdn9olxVnpb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Net loss available to common stockholders</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="From2024-01-01to2024-12-31" id="Fact000268" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">8,452,769</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="From2023-01-012023-12-31" id="Fact000269" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">14,626,683</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--EarningsPerShareAbstract_iB" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Per-share data</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 10pt">Basic and diluted loss per share</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><span id="xdx_90F_eus-gaap--EarningsPerShareBasic_c20240101__20241231_z1xiQGwj5pBj" title="Basic loss per share" class="xdx_phnt_U3RhdGVtZW50IC0gU3RhdGVtZW50cyBvZiBPcGVyYXRpb25zAA__"><span id="xdx_90A_eus-gaap--EarningsPerShareDiluted_c20240101__20241231_zMhxqfyZGO95" title="Diluted loss per share" class="xdx_phnt_U3RhdGVtZW50IC0gU3RhdGVtZW50cyBvZiBPcGVyYXRpb25zAA__">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2024-01-01to2024-12-31" id="Fact000274" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="From2024-01-01to2024-12-31" id="Fact000276" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">1.22</ix:nonFraction></ix:nonFraction></span></span></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_90D_eus-gaap--EarningsPerShareBasic_c20230101__20231231_zKYoAd1qFF9j" title="Basic loss per share" class="xdx_phnt_U3RhdGVtZW50IC0gU3RhdGVtZW50cyBvZiBPcGVyYXRpb25zAA__"><span id="xdx_904_eus-gaap--EarningsPerShareDiluted_c20230101__20231231_z3YxE3bI2Pxg" title="Diluted loss per share" class="xdx_phnt_U3RhdGVtZW50IC0gU3RhdGVtZW50cyBvZiBPcGVyYXRpb25zAA__">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2023-01-012023-12-31" id="Fact000278" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="From2023-01-012023-12-31" id="Fact000280" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">4.50</ix:nonFraction></ix:nonFraction></span></span></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--WeightedAverageNumberOfSharesOutstandingAbstract_iB" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold">Weighted average shares outstanding</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 10pt">Basic and diluted</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><span id="xdx_903_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20240101__20241231_zhhadNs4hBal" title="Basic" class="xdx_phnt_U3RhdGVtZW50IC0gU3RhdGVtZW50cyBvZiBPcGVyYXRpb25zAA__"><span id="xdx_908_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20240101__20241231_zLcIDbf0VcTh" title="Diluted" class="xdx_phnt_U3RhdGVtZW50IC0gU3RhdGVtZW50cyBvZiBPcGVyYXRpb25zAA__"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2024-01-01to2024-12-31" id="Fact000285" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2024-01-01to2024-12-31" id="Fact000287" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">6,918,887</ix:nonFraction></ix:nonFraction></span></span></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_904_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20230101__20231231_zH5uPHHrO4Qd" title="Basic" class="xdx_phnt_U3RhdGVtZW50IC0gU3RhdGVtZW50cyBvZiBPcGVyYXRpb25zAA__"><span id="xdx_900_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20230101__20231231_z604OZA3NPRa" title="Diluted" class="xdx_phnt_U3RhdGVtZW50IC0gU3RhdGVtZW50cyBvZiBPcGVyYXRpb25zAA__"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2023-01-012023-12-31" id="Fact000289" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2023-01-012023-12-31" id="Fact000291" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,252,328</ix:nonFraction></ix:nonFraction></span></span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Notes
to financial statements are an integral part of these statements.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 95; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="sh_016"></span>Neuraxis,
Inc. </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Statements
of Stockholders&#8217; Equity (Deficit)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_305_114_z8xBlK5VLWoe" summary="xdx: Statement - Statements of Stockholders' Equity (Deficit)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Shares</td><td style="text-align: center; padding-bottom: 1pt">&#160;</td><td style="text-align: center; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_4B7_us-gaap--StatementEquityComponentsAxis_us-gaap--PreferredStockMember_us-gaap--StatementClassOfStockAxis_custom--ConvertibleSeriesAPreferredStockMember_zJVVVcAiCZh8" style="border-bottom: Black 1pt solid; text-align: center">Amount</td><td style="text-align: center; padding-bottom: 1pt">&#160;</td><td style="text-align: center; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Shares</td><td style="text-align: center; padding-bottom: 1pt">&#160;</td><td style="text-align: center; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_4BC_us-gaap--StatementEquityComponentsAxis_us-gaap--PreferredStockMember_us-gaap--StatementClassOfStockAxis_custom--ConvertibleSeriesSeedPreferredStockMember_zVZ9eN6H6Ppd" style="border-bottom: Black 1pt solid; text-align: center">Amount</td><td style="text-align: center; padding-bottom: 1pt">&#160;</td><td style="text-align: center; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Shares</td><td style="text-align: center; padding-bottom: 1pt">&#160;</td><td style="text-align: center; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_4BF_us-gaap--StatementEquityComponentsAxis_us-gaap--PreferredStockMember_us-gaap--StatementClassOfStockAxis_custom--ConvertibleSeriesBPreferredStockMember_zlLwmooBhCPa" style="border-bottom: Black 1pt solid; text-align: center">Amount</td><td style="text-align: center; padding-bottom: 1pt">&#160;</td><td style="text-align: center; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Shares</td><td style="text-align: center; padding-bottom: 1pt">&#160;</td><td style="text-align: center; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_4B3_us-gaap--StatementEquityComponentsAxis_us-gaap--CommonStockMember_zyMYIz51xbt3" style="border-bottom: Black 1pt solid; text-align: center">Amount</td><td style="text-align: center; padding-bottom: 1pt">&#160;</td><td style="text-align: center; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_4B2_us-gaap--StatementEquityComponentsAxis_us-gaap--AdditionalPaidInCapitalMember_z4gmhyT8WqNd" style="border-bottom: Black 1pt solid; text-align: center"> Capital</td><td style="text-align: center; padding-bottom: 1pt">&#160;</td><td style="text-align: center; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_4B3_us-gaap--StatementEquityComponentsAxis_us-gaap--RetainedEarningsMember_zTLeeWMMl2Lj" style="border-bottom: Black 1pt solid; text-align: center"> Deficit</td><td style="text-align: center; padding-bottom: 1pt">&#160;</td><td style="text-align: center; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_4BB_zLJQPWt45PLk" style="border-bottom: Black 1pt solid; text-align: center"> (Deficit)</td><td style="text-align: center; padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center">Convertible Series A Preferred Stock</td><td style="text-align: center; padding-bottom: 1pt">&#160;</td><td style="text-align: center; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center">Convertible Series Seed Preferred Stock</td><td style="text-align: center; padding-bottom: 1pt">&#160;</td><td style="text-align: center; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center">Convertible Series B Preferred Stock</td><td style="text-align: center; padding-bottom: 1pt">&#160;</td><td style="text-align: center; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center">Common Stock</td><td style="text-align: center; padding-bottom: 1pt">&#160;</td><td style="text-align: center; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="text-align: center">Additional Paid In</td><td style="text-align: center; padding-bottom: 1pt">&#160;</td><td style="text-align: center; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="text-align: center">Accumulated</td><td style="text-align: center; padding-bottom: 1pt">&#160;</td><td style="text-align: center; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="text-align: center">Stockholder&#8217;s Equity</td><td style="text-align: center; padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Shares</td><td style="text-align: center; padding-bottom: 1pt">&#160;</td><td style="text-align: center; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Amount</td><td style="text-align: center; padding-bottom: 1pt">&#160;</td><td style="text-align: center; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Shares</td><td style="text-align: center; padding-bottom: 1pt">&#160;</td><td style="text-align: center; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Amount</td><td style="text-align: center; padding-bottom: 1pt">&#160;</td><td style="text-align: center; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Shares</td><td style="text-align: center; padding-bottom: 1pt">&#160;</td><td style="text-align: center; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Amount</td><td style="text-align: center; padding-bottom: 1pt">&#160;</td><td style="text-align: center; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Shares</td><td style="text-align: center; padding-bottom: 1pt">&#160;</td><td style="text-align: center; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Amount</td><td style="text-align: center; padding-bottom: 1pt">&#160;</td><td style="text-align: center; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"> Capital</td><td style="text-align: center; padding-bottom: 1pt">&#160;</td><td style="text-align: center; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"> Deficit</td><td style="text-align: center; padding-bottom: 1pt">&#160;</td><td style="text-align: center; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"> (Deficit)</td><td style="text-align: center; padding-bottom: 1pt">&#160;</td></tr>
  <tr id="xdx_43B_c20230101__20231231_eus-gaap--StockholdersEquity_iS_z2lj4JoLyzw6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 45%; font-weight: bold">Balance at January 1, 2023</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--SharesOutstanding_iS_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__custom--ConvertibleSeriesAPreferredStockMember_zk5XnBb1KVjh" title="Balance, shares" style="width: 2%; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2022-12-31_us-gaap_PreferredStockMember_custom_ConvertibleSeriesAPreferredStockMember" id="Fact000301" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">506,637</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 2%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_PreferredStockMember_custom_ConvertibleSeriesAPreferredStockMember" id="Fact000293" format="ixt:numdotdecimal" decimals="0" unitRef="USD">507</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--SharesOutstanding_iS_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__custom--ConvertibleSeriesSeedPreferredStockMember_z6PNoBHerF9d" title="Balance, shares" style="width: 2%; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2022-12-31_us-gaap_PreferredStockMember_custom_ConvertibleSeriesSeedPreferredStockMember" id="Fact000303" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">115,477</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 2%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_PreferredStockMember_custom_ConvertibleSeriesSeedPreferredStockMember" id="Fact000294" format="ixt:numdotdecimal" decimals="0" unitRef="USD">115</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--SharesOutstanding_iS_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__custom--ConvertibleSeriesBPreferredStockMember_zopGmjwzSS23" title="Balance, shares" style="width: 2%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0305">-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 2%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0295">-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--SharesOutstanding_iS_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z4rhThkJpmhk" title="Balance, shares" style="width: 2%; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2022-12-31_us-gaap_CommonStockMember" id="Fact000307" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,963,322</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 2%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_CommonStockMember" id="Fact000296" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,963</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 2%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000297" format="ixt:numdotdecimal" decimals="0" unitRef="USD">28,355,230</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 2%; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_RetainedEarningsMember" id="Fact000298" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">33,931,428</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 2%; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31" id="Fact000299" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">5,573,613</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td></tr>
  <tr id="xdx_403_ecustom--StockIssuedDuringPeriodValueCommonStockIssuedUponInitialPublicOffering_zc9bDw2Cf63e" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Common stock issued upon initial public offering</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0309">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0310">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0311">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_ecustom--StockIssuedDuringPeriodSharesCommonStockIssuedUponInitialPublicOffering_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z43OS4wKLPL6" title="Common stock issued upon initial public offering, shares" style="text-align: right"><ix:nonFraction name="NRXS:StockIssuedDuringPeriodSharesCommonStockIssuedUponInitialPublicOffering" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember" id="Fact000317" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,098,667</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="NRXS:StockIssuedDuringPeriodValueCommonStockIssuedUponInitialPublicOffering" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember" id="Fact000312" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,099</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="NRXS:StockIssuedDuringPeriodValueCommonStockIssuedUponInitialPublicOffering" contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000313" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,109,578</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0314">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="NRXS:StockIssuedDuringPeriodValueCommonStockIssuedUponInitialPublicOffering" contextRef="From2023-01-012023-12-31" id="Fact000315" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,110,677</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_zSJgYLA98gFf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Common stock issued upon preferred stock conversion</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__custom--ConvertibleSeriesAPreferredStockMember_ziOAdWrEETL9" title="Common stock issued upon preferred stock conversion, shares" style="text-align: right">(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember_custom_ConvertibleSeriesAPreferredStockMember" id="Fact000327" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="Shares">506,637</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember_custom_ConvertibleSeriesAPreferredStockMember" id="Fact000319" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">507</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__custom--ConvertibleSeriesSeedPreferredStockMember_zTHr1hD6qxG8" title="Common stock issued upon preferred stock conversion, shares" style="text-align: right">(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember_custom_ConvertibleSeriesSeedPreferredStockMember" id="Fact000329" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="Shares">115,477</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember_custom_ConvertibleSeriesSeedPreferredStockMember" id="Fact000320" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">115</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0321">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zNjvdiCvVIWl" title="Common stock issued upon preferred stock conversion, shares" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember" id="Fact000331" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,244,228</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember" id="Fact000322" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,244</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000323" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">622</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0324">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0325">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--StockIssuedDuringPeriodValueConversionOfUnits_zl1kdkeEofaa" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Common stock issued upon debt conversion</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0333">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0334">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0335">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--StockIssuedDuringPeriodSharesConversionOfUnits_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zSuD7o3Sbonk" title="Common stock issued upon debt conversion, shares" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember" id="Fact000341" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,649,900</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfUnits" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember" id="Fact000336" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,650</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfUnits" contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000337" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9,897,833</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0338">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfUnits" contextRef="From2023-01-012023-12-31" id="Fact000339" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9,899,483</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--StockIssuedDuringPeriodValueNewIssues_zIHMpJS71wAh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Common stock issued from agreements</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0343">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0344">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0345">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zBlTQyKBDTRj" title="Common stock issued from agreements, shares" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember" id="Fact000351" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">425,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember" id="Fact000346" format="ixt:numdotdecimal" decimals="0" unitRef="USD">425</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000347" format="ixt:numdotdecimal" decimals="0" unitRef="USD">749,575</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0348">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2023-01-012023-12-31" id="Fact000349" format="ixt:numdotdecimal" decimals="0" unitRef="USD">750,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--AdjustmentsToAdditionalPaidInCapitalWarrantIssued_zmU5eZr6S5Zg" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Reclassification of warrant liability to equity</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0353">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0354">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0355">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0356">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000357" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,720,997</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0358">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" contextRef="From2023-01-012023-12-31" id="Fact000359" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,720,997</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_ecustom--StockIssuedDuringPeriodValueWarrantsExercised_z7qyHoStGYL9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Warrants exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0361">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0362">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0363">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_ecustom--StockIssuedDuringPeriodSharesWarrantsExercised_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z82YO8OW7Ane" title="Warrants exercised, shares" style="text-align: right"><ix:nonFraction name="NRXS:StockIssuedDuringPeriodSharesWarrantsExercised" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember" id="Fact000369" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">127,780</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="NRXS:StockIssuedDuringPeriodValueWarrantsExercised" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember" id="Fact000364" format="ixt:numdotdecimal" decimals="0" unitRef="USD">128</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="NRXS:StockIssuedDuringPeriodValueWarrantsExercised" contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000365" format="ixt:numdotdecimal" decimals="0" unitRef="USD">315,770</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0366">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="NRXS:StockIssuedDuringPeriodValueWarrantsExercised" contextRef="From2023-01-012023-12-31" id="Fact000367" format="ixt:numdotdecimal" decimals="0" unitRef="USD">315,898</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--NetIncomeLoss_zlTvDw1IkPce" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Net loss</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0371">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0372">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0373">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0374">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0375">-</span></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember" id="Fact000376" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">14,626,683</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-12-31" id="Fact000377" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">14,626,683</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_438_c20240101__20241231_eus-gaap--StockholdersEquity_iS_zOCdvCQwSUv6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold">Balances at December 31, 2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--SharesOutstanding_iS_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__custom--ConvertibleSeriesAPreferredStockMember_zYr9OtmUbef4" title="Balance, shares" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0387">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0379">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--SharesOutstanding_iS_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__custom--ConvertibleSeriesSeedPreferredStockMember_zQuc5PImAvOk" title="Balance, shares" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0389">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0380">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--SharesOutstanding_iS_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__custom--ConvertibleSeriesBPreferredStockMember_zsPTjuL4Psqe" title="Balance, shares" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0391">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0381">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--SharesOutstanding_iS_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z5B7bsEV7y64" title="Balance, shares" style="text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2023-12-31_us-gaap_CommonStockMember" id="Fact000393" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">6,508,897</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_us-gaap_CommonStockMember" id="Fact000382" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,509</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000383" format="ixt:numdotdecimal" decimals="0" unitRef="USD">47,148,361</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_us-gaap_RetainedEarningsMember" id="Fact000384" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">48,558,111</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31" id="Fact000385" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,403,241</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_43C_c20240101__20241231_eus-gaap--StockholdersEquity_iS_zjYAYqpBA4Se" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold">Balance</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--SharesOutstanding_iS_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__custom--ConvertibleSeriesAPreferredStockMember_zAPQ3gwfDWV4" title="Balance, shares" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0403">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0395">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--SharesOutstanding_iS_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__custom--ConvertibleSeriesSeedPreferredStockMember_zoZ4xyROlB8d" title="Balance, shares" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0405">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0396">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--SharesOutstanding_iS_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__custom--ConvertibleSeriesBPreferredStockMember_z6CiVuoFQTV9" title="Balance, shares" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0407">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0397">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--SharesOutstanding_iS_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zOWiTeARve9b" title="Balance, shares" style="text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2023-12-31_us-gaap_CommonStockMember" id="Fact000409" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">6,508,897</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_us-gaap_CommonStockMember" id="Fact000398" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,509</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000399" format="ixt:numdotdecimal" decimals="0" unitRef="USD">47,148,361</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_us-gaap_RetainedEarningsMember" id="Fact000400" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">48,558,111</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31" id="Fact000401" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,403,241</ix:nonFraction></td><td style="text-align: left">)</td></tr>
<tr id="xdx_407_ecustom--StockIssuedDuringPeriodValueWarrantsExercised_zqbxJf4xlGta" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Warrants exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0411">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0412">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0413">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_ecustom--StockIssuedDuringPeriodSharesWarrantsExercised_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zGYLz0sVTfjf" title="Warrants exercised, shares" style="text-align: right"><ix:nonFraction name="NRXS:StockIssuedDuringPeriodSharesWarrantsExercised" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember" id="Fact000419" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">11,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="NRXS:StockIssuedDuringPeriodValueWarrantsExercised" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember" id="Fact000414" format="ixt:numdotdecimal" decimals="0" unitRef="USD">11</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="NRXS:StockIssuedDuringPeriodValueWarrantsExercised" contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000415" format="ixt:numdotdecimal" decimals="0" unitRef="USD">26,169</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0416">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="NRXS:StockIssuedDuringPeriodValueWarrantsExercised" contextRef="From2024-01-01to2024-12-31" id="Fact000417" format="ixt:numdotdecimal" decimals="0" unitRef="USD">26,180</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--AdjustmentsToAdditionalPaidInCapitalWarrantIssued_zMGhtxHxQpec" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Additional paid in capital from warrants issued under advisory agreement</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0421">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0422">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0423">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0424">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000425" format="ixt:numdotdecimal" decimals="0" unitRef="USD">157,745</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0426">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" contextRef="From2024-01-01to2024-12-31" id="Fact000427" format="ixt:numdotdecimal" decimals="0" unitRef="USD">157,745</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_ecustom--AdditionalPaidInCapitalFromWarrantsIssuedAsDebtDiscount_zefOrScPj6Cf" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Additional paid in capital from warrants issued as debt discount</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0429">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0430">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0431">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0432">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="NRXS:AdditionalPaidInCapitalFromWarrantsIssuedAsDebtDiscount" contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000433" format="ixt:numdotdecimal" decimals="0" unitRef="USD">97,465</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0434">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="NRXS:AdditionalPaidInCapitalFromWarrantsIssuedAsDebtDiscount" contextRef="From2024-01-01to2024-12-31" id="Fact000435" format="ixt:numdotdecimal" decimals="0" unitRef="USD">97,465</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--StockIssuedDuringPeriodValueNewIssues_zLQTCV7Br2o6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Common stock issued from agreements</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0437">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0438">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0439">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zQ3RXpxd7vzh" title="Common stock issued from agreements, shares" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember" id="Fact000445" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">470,330</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember" id="Fact000440" format="ixt:numdotdecimal" decimals="0" unitRef="USD">470</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000441" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,407,541</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0442">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2024-01-01to2024-12-31" id="Fact000443" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,408,011</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature_zUTcbUBkwCtd" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Debt discount on mandatory conversion of convertible promissory notes to Series B Preferred Stock</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0447">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0448">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0449">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0450">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature" contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000451" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">165,577</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0452">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature" contextRef="From2024-01-01to2024-12-31" id="Fact000453" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">165,577</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_400_eus-gaap--StockIssuedDuringPeriodValueOther_zRAc5flYZrt6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Conversion of convertible promissory notes to Series B Preferred Stock</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0455">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0456">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--StockIssuedDuringPeriodSharesOther_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__custom--ConvertibleSeriesBPreferredStockMember_zlCSkMmThrrg" title="Conversion of convertible promissory notes to Series B Preferred Stock, shares" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesOther" contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember_custom_ConvertibleSeriesBPreferredStockMember" id="Fact000463" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,073,524</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember_custom_ConvertibleSeriesBPreferredStockMember" id="Fact000457" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,074</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0458">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000459" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,932,929</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0460">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2024-01-01to2024-12-31" id="Fact000461" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,935,003</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_ecustom--StockIssuedDuringPeriodValuePreferredStock_zg8W9E6VLGWb" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Issuance of Series B Preferred Stock</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0465">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0466">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_ecustom--StockIssuedDuringPeriodSharesPreferredStock_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__custom--ConvertibleSeriesBPreferredStockMember_zydcinyNPT8l" title="Issuance of Series B Preferred Stock, shares" style="text-align: right"><ix:nonFraction name="NRXS:StockIssuedDuringPeriodSharesPreferredStock" contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember_custom_ConvertibleSeriesBPreferredStockMember" id="Fact000473" format="ixt:numdotdecimal" decimals="INF" unitRef="USD">2,207,415</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="NRXS:StockIssuedDuringPeriodValuePreferredStock" contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember_custom_ConvertibleSeriesBPreferredStockMember" id="Fact000467" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,207</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0468">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="NRXS:StockIssuedDuringPeriodValuePreferredStock" contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000469" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,251,456</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="NRXS:StockIssuedDuringPeriodValuePreferredStock" contextRef="From2024-01-01to2024-12-31" id="Fact000471" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,253,663</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--NetIncomeLoss_zbhSepylZR5k" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Net loss</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0475">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0476">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0477">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0478">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0479">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember" id="Fact000480" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">8,241,501</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-01-01to2024-12-31" id="Fact000481" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">8,241,501</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_430_c20240101__20241231_eus-gaap--StockholdersEquity_iE_zAKNkUs3tNN2" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; padding-bottom: 2.5pt">Balances at December 31, 2024</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--SharesOutstanding_iE_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__custom--ConvertibleSeriesAPreferredStockMember_z3bwZmKXDwDb" title="Balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0491">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0483">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--SharesOutstanding_iE_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__custom--ConvertibleSeriesSeedPreferredStockMember_zesP3N8JSrJ" title="Balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0493">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0484">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--SharesOutstanding_iE_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__custom--ConvertibleSeriesBPreferredStockMember_zhjMELEKi9dh" title="Balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2024-12-31_us-gaap_PreferredStockMember_custom_ConvertibleSeriesBPreferredStockMember" id="Fact000495" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">4,280,939</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-12-31_us-gaap_PreferredStockMember_custom_ConvertibleSeriesBPreferredStockMember" id="Fact000485" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,281</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--SharesOutstanding_iE_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zxdnPbON2up3" title="Balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2024-12-31_us-gaap_CommonStockMember" id="Fact000497" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">6,990,227</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-12-31_us-gaap_CommonStockMember" id="Fact000486" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,990</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000487" format="ixt:numdotdecimal" decimals="0" unitRef="USD">58,856,089</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-12-31_us-gaap_RetainedEarningsMember" id="Fact000488" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">56,799,612</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-12-31" id="Fact000489" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,067,748</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_43F_c20240101__20241231_eus-gaap--StockholdersEquity_iE_zRwUudyASKs8" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-bottom: 2.5pt">Balance</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--SharesOutstanding_iE_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__custom--ConvertibleSeriesAPreferredStockMember_z6t5DhxYJ1zb" title="Balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0507">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0499">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--SharesOutstanding_iE_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__custom--ConvertibleSeriesSeedPreferredStockMember_z2qMbZG40sI2" title="Balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0509">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0500">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--SharesOutstanding_iE_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__custom--ConvertibleSeriesBPreferredStockMember_z3RdW04vaRB1" title="Balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2024-12-31_us-gaap_PreferredStockMember_custom_ConvertibleSeriesBPreferredStockMember" id="Fact000511" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">4,280,939</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-12-31_us-gaap_PreferredStockMember_custom_ConvertibleSeriesBPreferredStockMember" id="Fact000501" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,281</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--SharesOutstanding_iE_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zqI23k4YbT6a" title="Balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2024-12-31_us-gaap_CommonStockMember" id="Fact000513" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">6,990,227</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-12-31_us-gaap_CommonStockMember" id="Fact000502" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,990</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000503" format="ixt:numdotdecimal" decimals="0" unitRef="USD">58,856,089</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-12-31_us-gaap_RetainedEarningsMember" id="Fact000504" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">56,799,612</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-12-31" id="Fact000505" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,067,748</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Notes
to financial statements are an integral part of these statements.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 96; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="sh_017"></span>Neuraxis,
Inc. </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Statements
of Cash Flows</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_30F_112_zpSCjbYPSMF6" summary="xdx: Statement - Statements of Cash Flows" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_492_20240101__20241231_z8cJLyB6ebr2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_499_20230101__20231231_zr4ZOPZgrG5k" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">For the Years Ended December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--NetCashProvidedByUsedInOperatingActivitiesAbstract_iB" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Cash Flows from Operating Activities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--NetIncomeLoss_i01_pp0p0_maNCPBUz5Ya_zzsDz6zekgVa" style="vertical-align: bottom; background-color: White">
    <td style="width: 60%; text-align: left; padding-left: 10pt">Net Loss</td><td style="width: 2%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">$</td><td style="width: 16%; font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-01-01to2024-12-31" id="Fact000518" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">8,241,501</ix:nonFraction></td><td style="width: 1%; font-weight: bold; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-12-31" id="Fact000519" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">14,626,683</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td></tr>
  <tr id="xdx_403_eus-gaap--AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_i01B" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt">Adjustments to reconcile net loss to net cash used by operating activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--AmortizationOfFinancingCostsAndDiscounts_i02_pp0p0_maNCPBUz5Ya_z5q8HdKUz9pj" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 20pt">Amortization of debt discount and issuance cost</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" contextRef="From2024-01-01to2024-12-31" id="Fact000524" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">126,387</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" contextRef="From2023-01-012023-12-31" id="Fact000525" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">4,881,622</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--DepreciationDepletionAndAmortization_i02_pp0p0_maNCPBUz5Ya_zemH564HZES2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 20pt">Depreciation and amortization</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:DepreciationDepletionAndAmortization" contextRef="From2024-01-01to2024-12-31" id="Fact000527" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">37,831</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DepreciationDepletionAndAmortization" contextRef="From2023-01-012023-12-31" id="Fact000528" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">40,725</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--ProvisionForDoubtfulAccounts_i02_pp0p0_maNCPBUz5Ya_zzQqjVpy1Yle" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 20pt">Provisions for losses on accounts receivable</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:ProvisionForDoubtfulAccounts" contextRef="From2024-01-01to2024-12-31" id="Fact000530" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">7,395</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ProvisionForDoubtfulAccounts" contextRef="From2023-01-012023-12-31" id="Fact000531" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">25,281</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--InventoryWriteDown_i02_pp0p0_maNCPBUz5Ya_zFFW8LqjIrY2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 20pt">Provision for losses on inventory</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:InventoryWriteDown" contextRef="From2024-01-01to2024-12-31" id="Fact000533" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">4,454</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0534">&#8212;</span></td><td style="font-weight: bold; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_ecustom--NoncashLeaseExpense_i02_pp0p0_maNCPBUz5Ya_zuzTTODiJuR" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 20pt">Non-cash lease expense</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction name="NRXS:NoncashLeaseExpense" contextRef="From2024-01-01to2024-12-31" id="Fact000536" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">32,075</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="NRXS:NoncashLeaseExpense" contextRef="From2023-01-012023-12-31" id="Fact000537" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">31,119</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--PaidInKindInterest_i02_pp0p0_maNCPBUz5Ya_zrHQqxi9Bftk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 20pt">Non-cash interest expense</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0539">&#8212;</span></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PaidInKindInterest" contextRef="From2023-01-012023-12-31" id="Fact000540" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">260,777</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--ShareBasedCompensation_i02_pp0p0_maNCPBUz5Ya_zdw0QDW9M0Ed" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 20pt">Stock based compensation</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2024-01-01to2024-12-31" id="Fact000542" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">227,000</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0543">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--GainsLossesOnExtinguishmentOfDebt_i02N_pp0p0_di_msNCPBUz5Ya_zM6jdKUL2oBf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 20pt">Extinguishment of debt liabilities</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0545">&#8212;</span></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:GainsLossesOnExtinguishmentOfDebt" contextRef="From2023-01-012023-12-31" id="Fact000546" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">3,649,561</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_ecustom--IssuanceOfCommonStockForNoncashConsideration_i02_pp0p0_maNCPBUz5Ya_zYvVEmfYIOee" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 20pt">Issuance of common stock for non-cash consideration</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction name="NRXS:IssuanceOfCommonStockForNoncashConsideration" contextRef="From2024-01-01to2024-12-31" id="Fact000548" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,177,187</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="NRXS:IssuanceOfCommonStockForNoncashConsideration" contextRef="From2023-01-012023-12-31" id="Fact000549" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">750,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_ecustom--IssuanceOfWarrantsForNoncashConsideration_i02_pp0p0_maNCPBUz5Ya_zlIq34sDqx74" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 20pt">Fair value of warrants issued for non-cash consideration</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction name="NRXS:IssuanceOfWarrantsForNoncashConsideration" contextRef="From2024-01-01to2024-12-31" id="Fact000551" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">157,745</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0552">&#8212;</span></td><td style="font-weight: bold; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_ecustom--FinancingCharges_i02_pp0p0_maNCPBUz5Ya_zKVfqadrRRd7" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 20pt">Finance charges</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction name="NRXS:FinancingCharges" contextRef="From2024-01-01to2024-12-31" id="Fact000554" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">230,824</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="NRXS:FinancingCharges" contextRef="From2023-01-012023-12-31" id="Fact000555" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,772</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--DerivativeGainLossOnDerivativeNet_i02N_pp0p0_di_msNCPBUz5Ya_zQ3Ci9S2vO55" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 20pt">Change in fair value of derivative liabilities</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0557">&#8212;</span></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:DerivativeGainLossOnDerivativeNet" contextRef="From2023-01-012023-12-31" id="Fact000558" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">198,551</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40D_eus-gaap--FairValueAdjustmentOfWarrants_i02_pp0p0_maNCPBUz5Ya_zBcnMhWuqAvd" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 20pt">Change in fair value of warrant liabilities</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="From2024-01-01to2024-12-31" id="Fact000560" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">941</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="From2023-01-012023-12-31" id="Fact000561" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">844,854</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40B_eus-gaap--IncreaseDecreaseInOperatingCapitalAbstract_i01B" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 20pt">Changes in operating assets and liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--IncreaseDecreaseInAccountsReceivable_i02N_pp0p0_di_msNCPBUz5Ya_zGynuurZkiC8" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 30pt">Accounts receivable</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsReceivable" contextRef="From2024-01-01to2024-12-31" id="Fact000566" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">178,845</ix:nonFraction></td><td style="font-weight: bold; text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsReceivable" contextRef="From2023-01-012023-12-31" id="Fact000567" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">75,951</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--IncreaseDecreaseInInventories_i02N_pp0p0_di_msNCPBUz5Ya_z9yFkuH0zi34" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 30pt">Inventory</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInInventories" contextRef="From2024-01-01to2024-12-31" id="Fact000569" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">32,500</ix:nonFraction></td><td style="font-weight: bold; text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInInventories" contextRef="From2023-01-012023-12-31" id="Fact000570" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">26,913</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_i02N_pp0p0_di_msNCPBUz5Ya_zeqiaiFTeXQ4" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 30pt">Prepaids and other current assets</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="From2024-01-01to2024-12-31" id="Fact000572" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">56,157</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="From2023-01-012023-12-31" id="Fact000573" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">68,937</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_401_eus-gaap--IncreaseDecreaseInAccountsPayable_i02_pp0p0_maNCPBUz5Ya_zs9TOpK3uTo" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 30pt">Accounts payable</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayable" contextRef="From2024-01-01to2024-12-31" id="Fact000575" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">607,273</ix:nonFraction></td><td style="font-weight: bold; text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayable" contextRef="From2023-01-012023-12-31" id="Fact000576" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">387,897</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_404_eus-gaap--IncreaseDecreaseInAccruedLiabilities_i02_pp0p0_maNCPBUz5Ya_z0mk7SXXY06e" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 30pt">Accrued expenses</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccruedLiabilities" contextRef="From2024-01-01to2024-12-31" id="Fact000578" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">949,693</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccruedLiabilities" contextRef="From2023-01-012023-12-31" id="Fact000579" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">294,154</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_400_ecustom--IncreaseDecreaseInCustomerDeposit_i02_pp0p0_maNCPBUz5Ya_zXriUCKvH2P4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 30pt">Customer deposits</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">(<ix:nonFraction name="NRXS:IncreaseDecreaseInCustomerDeposit" contextRef="From2024-01-01to2024-12-31" id="Fact000581" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">42,420</ix:nonFraction></td><td style="font-weight: bold; text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="NRXS:IncreaseDecreaseInCustomerDeposit" contextRef="From2023-01-012023-12-31" id="Fact000582" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">15,773</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--IncreaseDecreaseInOperatingLeaseLiability_i02_pp0p0_maNCPBUz5Ya_zIIQSOt9PSTl" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 30pt">Operating lease liability</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" contextRef="From2024-01-01to2024-12-31" id="Fact000584" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">3,414</ix:nonFraction></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" contextRef="From2023-01-012023-12-31" id="Fact000585" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">33,396</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_40D_eus-gaap--NetCashProvidedByUsedInOperatingActivities_i01T_mtNCPBUz5Ya_maCCERCzWVN_zzFRMKJfkph3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 10pt">Net cash used by operating activities</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2024-01-01to2024-12-31" id="Fact000587" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">6,098,264</ix:nonFraction></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2023-01-012023-12-31" id="Fact000588" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">6,693,978</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--NetCashProvidedByUsedInInvestingActivitiesAbstract_iB" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Cash Flows from Investing Activities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--PaymentsToAcquirePropertyPlantAndEquipment_i01N_pp0p0_di_msNCPBUz1xT_z6V2wKcD3M76" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt">Additions to property and equipment</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="From2024-01-01to2024-12-31" id="Fact000593" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">27,776</ix:nonFraction></td><td style="font-weight: bold; text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="From2023-01-012023-12-31" id="Fact000594" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">30,781</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_409_eus-gaap--PaymentsToAcquireIntangibleAssets_i01N_pp0p0_di_msNCPBUz1xT_zaNenEjUbWDc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 10pt">Additions to intangible assets</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0596">&#8212;</span></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:PaymentsToAcquireIntangibleAssets" contextRef="From2023-01-012023-12-31" id="Fact000597" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">41,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_401_eus-gaap--NetCashProvidedByUsedInInvestingActivities_i01T_mtNCPBUz1xT_maCCERCzWVN_zZebJ4Sw3qai" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 20pt">Net cash used by investing activities</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="From2024-01-01to2024-12-31" id="Fact000599" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">27,776</ix:nonFraction></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="From2023-01-012023-12-31" id="Fact000600" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">71,781</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--NetCashProvidedByUsedInFinancingActivitiesAbstract_iB" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">Cash Flows from Financing Activities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--ProceedsFromIssuanceOfCommonStock_i01_pp0p0_maNCPBUzHnn_zcaq088Bqs86" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt">Proceeds from issuance of common stock, net of issuance costs</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0605">&#8212;</span></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="From2023-01-012023-12-31" id="Fact000606" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">4,847,457</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_i01_pp0p0_maNCPBUzHnn_zRgYN9ustxFh" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt">Proceeds from issuance of Series B preferred stock</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" contextRef="From2024-01-01to2024-12-31" id="Fact000608" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">5,253,663</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0609">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_ecustom--DeferredOfferingCostsPaid_i01N_di_msNCPBUzbVV_msNCPBUzHnn_zpRkYPAPEYTf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt">Deferred offering costs paid</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0611">&#8212;</span></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0612">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--ProceedsFromIssuanceOfWarrants_i01_maNCPBUzbVV_maNCPBUzHnn_zO7hTruDyHC5" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt">Proceeds from exercised warrants</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfWarrants" contextRef="From2024-01-01to2024-12-31" id="Fact000614" format="ixt:numdotdecimal" decimals="0" unitRef="USD">26,180</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfWarrants" contextRef="From2023-01-012023-12-31" id="Fact000615" format="ixt:numdotdecimal" decimals="0" unitRef="USD">209,097</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--RepaymentsOfNotesPayable_iN_di_msCz92t_msNCPBUzHnn_zvmF0vAu6ER5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt">Principal payments on notes payable</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:RepaymentsOfNotesPayable" contextRef="From2024-01-01to2024-12-31" id="Fact000617" format="ixt:numdotdecimal" decimals="0" unitRef="USD">275,994</ix:nonFraction></td><td style="font-weight: bold; text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:RepaymentsOfNotesPayable" contextRef="From2023-01-012023-12-31" id="Fact000618" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,553,765</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40D_eus-gaap--ProceedsFromNotesPayable_i01_pp0p0_maNCPBUzHnn_zGQwslpUk39d" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt">Proceeds from notes payable</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0620">&#8212;</span></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromNotesPayable" contextRef="From2023-01-012023-12-31" id="Fact000621" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">159,831</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--ProceedsFromConvertibleDebt_i01_maCz92t_maNCPBUzHnn_zAPkGTVlH4ek" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt">Proceeds from convertible notes</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromConvertibleDebt" contextRef="From2024-01-01to2024-12-31" id="Fact000623" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,935,003</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromConvertibleDebt" contextRef="From2023-01-012023-12-31" id="Fact000624" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,460,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--PaymentsOfFinancingCosts_i01N_di_msNCPBUzbVV_msNCPBUzHnn_zIT6vCTJaDR2" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 10pt">Financing fees paid</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:PaymentsOfFinancingCosts" contextRef="From2024-01-01to2024-12-31" id="Fact000626" format="ixt:numdotdecimal" decimals="0" unitRef="USD">194,502</ix:nonFraction></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:PaymentsOfFinancingCosts" contextRef="From2023-01-012023-12-31" id="Fact000627" format="ixt:numdotdecimal" decimals="0" unitRef="USD">552,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_40F_eus-gaap--NetCashProvidedByUsedInFinancingActivities_i01T_mtNCPBUzHnn_maCCERCzWVN_zrJen4SQaoJg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 20pt">Net cash provided by financing activities</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="From2024-01-01to2024-12-31" id="Fact000629" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9,744,350</ix:nonFraction></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="From2023-01-012023-12-31" id="Fact000630" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,590,620</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_iT_mtCCERCzWVN_zis9d8XAUQ2d" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Net Increase (Decrease) in Cash and Cash Equivalents</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="From2024-01-01to2024-12-31" id="Fact000632" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,618,310</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="From2023-01-012023-12-31" id="Fact000633" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">175,139</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_iS_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Cash and Cash Equivalents at Beginning of Period</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="AsOf2023-12-31" id="Fact000635" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">78,560</ix:nonFraction></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="AsOf2022-12-31" id="Fact000636" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">253,699</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_iE_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1pt">Cash and Cash Equivalents at End of Period</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="AsOf2024-12-31" id="Fact000638" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">3,696,870</ix:nonFraction></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="AsOf2023-12-31" id="Fact000639" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">78,560</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">&#160;</td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--SupplementalCashFlowInformationAbstract_iB_zd3qG1UBti1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Supplemental Disclosure of Non-Cash Operating Activities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--InterestPaidNet_i01_zMgjQ9pmN4T2" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt">Cash paid for interest</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">$</td><td style="font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:InterestPaidNet" contextRef="From2024-01-01to2024-12-31" id="Fact000644" format="ixt:numdotdecimal" decimals="0" unitRef="USD">33,830</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:InterestPaidNet" contextRef="From2023-01-012023-12-31" id="Fact000645" format="ixt:numdotdecimal" decimals="0" unitRef="USD">214,562</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--IncomeTaxesPaidNet_i01_z4wgwOS62ICk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt">Cash received for income taxes</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:IncomeTaxesPaidNet" contextRef="From2024-01-01to2024-12-31" id="Fact000647" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,164</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0648">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_iB_zT4U23T7qind" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">Supplemental Schedule of Non-Cash Investing and Financing Activities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_ecustom--RecognitionOfRightOfUseAsset_i01_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt">Recognition of right of use asset</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">$</td><td style="font-weight: bold; text-align: right"><ix:nonFraction name="NRXS:RecognitionOfRightOfUseAsset" contextRef="From2024-01-01to2024-12-31" id="Fact000653" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">284,339</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">$</td><td style="font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0654">&#8212;</span></td><td style="font-weight: bold; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_ecustom--ConversionOfConvertiblePromissoryNotesToSeriesBPreferredStock_i01_pp0p0" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt">Conversion of convertible promissory notes to Series B preferred stock</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction name="NRXS:ConversionOfConvertiblePromissoryNotesToSeriesBPreferredStock" contextRef="From2024-01-01to2024-12-31" id="Fact000656" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">4,935,000</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0657">&#8212;</span></td><td style="font-weight: bold; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_ecustom--FairValueOfWarrantsFromDebtDiscountInConvertibleNotesClassifiedOfAdditionalPaidInCapital_i01_ztdMkNBiQm3j" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt">Fair value of warrants from debt discount in convertible notes classified as additional paid in capital</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction name="NRXS:FairValueOfWarrantsFromDebtDiscountInConvertibleNotesClassifiedOfAdditionalPaidInCapital" contextRef="From2024-01-01to2024-12-31" id="Fact000659" format="ixt:numdotdecimal" decimals="0" unitRef="USD">97,465</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0660">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_ecustom--WriteoffOfDebtDiscountOnConvertibleNotesClassifiedAsAdditionalPaidInCapital_i01_zRBmovinSqoj" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt">Write-off of debt discount on convertible notes classified as additional paid in capital</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction name="NRXS:WriteoffOfDebtDiscountOnConvertibleNotesClassifiedAsAdditionalPaidInCapital" contextRef="From2024-01-01to2024-12-31" id="Fact000662" format="ixt:numdotdecimal" decimals="0" unitRef="USD">165,577</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0663">&#8212;</span></td><td style="font-weight: bold; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--NotesIssued1_i01_zY4v3PHmu2xg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt">Issuance of note payable to financing company for insurance premiums</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:NotesIssued1" contextRef="From2024-01-01to2024-12-31" id="Fact000665" format="ixt:numdotdecimal" decimals="0" unitRef="USD">282,086</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0666">&#8212;</span></td><td style="font-weight: bold; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_ecustom--FairValueOfWarrantLiabilitiesOfWarrantsFromConvertibleNotes_i01_zcfPcnXslBA7" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt">Fair value of warrant liabilities of warrants from convertible notes</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0668">&#8212;</span></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="NRXS:FairValueOfWarrantLiabilitiesOfWarrantsFromConvertibleNotes" contextRef="From2023-01-012023-12-31" id="Fact000669" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,446,502</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_ecustom--FairValueOfDerivativeLiabilitiesOfConversionFeatureFromConvertibleNotes_i01_zRtfwWpSCFk7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt">Fair value of derivative liabilities of conversion feature from convertible notes</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0671">&#8212;</span></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="NRXS:FairValueOfDerivativeLiabilitiesOfConversionFeatureFromConvertibleNotes" contextRef="From2023-01-012023-12-31" id="Fact000672" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,375,378</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_ecustom--ReclassificationOfWarrantLiabilityToEquity_i01_zLYrRv5riEs7" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt">Reclassification of warrant liability to equity</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0674">&#8212;</span></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="NRXS:ReclassificationOfWarrantLiabilityToEquity" contextRef="From2023-01-012023-12-31" id="Fact000675" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,720,997</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_ecustom--ConversionOfPreferredStockToCommonStock_i01_zgZMRIBveBLj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt">Conversion of preferred stock to common stock</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0677">&#8212;</span></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="NRXS:ConversionOfPreferredStockToCommonStock" contextRef="From2023-01-012023-12-31" id="Fact000678" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,244</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Notes
to financial statements are an integral part of these statements.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 97; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="sh_018"></span>Neuraxis,
Inc.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Notes
to Financial Statements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000680" name="us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock"><p id="xdx_800_eus-gaap--BusinessDescriptionAndBasisOfPresentationTextBlock_zhNYctRuImhg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>1.
<span id="xdx_82C_zYzIq02BSlKk">Basis of Presentation, Organization and Other Matters</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Neuraxis,
Inc. (&#8220;we,&#8221; &#8220;us,&#8221; the &#8220;Company,&#8221; or &#8220;Neuraxis&#8221;) was established in 2011 and incorporated
in the state of Indiana on April 17, 2012, under the name of Innovative Health Solutions, Inc. In 2022, the name was changed to Neuraxis,
Inc. and the Company filed a Certificate of Conversion to become a Delaware corporation that increased the number of authorized shares
and established a par value.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is headquartered in Carmel, Indiana, and specializes in the development, production, and sale of medical neuromodulation devices.
The Company has developed four FDA cleared products: (i) the IB-STIM (DEN180057, 2019), (ii) the Rectal Expulsion Device (&#8220;RED&#8221;)
(K242304, 2024), (iii) NSS-2 Bridge (DEN170018, 2017) and (iv) the original 510(K) clearance (K140530, 2014).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    IB-STIM is a percutaneous electrical nerve field stimulator (PENFS) device that is indicated in patients 8-21 years of age with functional
    abdominal pain associated with irritable bowel syndrome. The IB-STIM currently is one of two products marketed and sold by the Company.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">RED
is indicated to evaluate the neuromuscular function of a patient&#8217;s ability to expel its contents from the rectum and as a qualitative
test for rectal hypersensitivity patients who experience desire or urge to defecate at lower volumes of distention. RED is intended to
be used in a clinical setting by trained health care providers in adult populations. </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    NSS-2 Bridge is a percutaneous nerve field stimulator (PNFS) device indicated for use in the reduction of the symptoms of opioid
    withdrawal. The NSS-2 Bridge device was licensed to Masimo Corporation in April 2020, and the Company received a one-time licensing
    fee of $250,000 from Masimo. Masimo markets and sells this product as its Masimo Bridge, and the Company will not receive any further
    licensing payments or other revenue from this product.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    original 510(K) device was the EAD, an electroacupuncture device, now called NeuroStim. The EAD is no longer being manufactured,
    sold or distributed but reserved only for research purposes.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 10, 2023, the Company&#8217;s board of directors authorized a <span id="xdx_904_eus-gaap--StockholdersEquityNoteStockSplit_c20230110__20230110_zKlBv0h1ikB4" title="Description of stock split"><ix:nonNumeric contextRef="From2023-01-102023-01-10" id="Fact000682" name="us-gaap:StockholdersEquityNoteStockSplit">1-for-2 reverse stock split</ix:nonNumeric></span>. All per share information has been
adjusted for this reverse stock split. The reverse split became effective on January 12, 2023. All share and per share amounts for the
common stock have been retroactively restated to give effect to the splits.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
part of the conversion to a Delaware corporation, the total number of shares of all classes of stock which the Corporation had authority
to issue was (1) <span id="xdx_907_eus-gaap--CommonStockSharesAuthorized_iI_c20241231_zOnIA2bk1eRl" title="Common stock, shares authorized"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2024-12-31" id="Fact000684" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">100,000,000</ix:nonFraction></span> shares of Common Stock, par value $<span id="xdx_901_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20241231_z0t9slsGFmFb" title="Common stock, par value"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2024-12-31" id="Fact000686" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.001</ix:nonFraction></span> per share (&#8220;Common Stock&#8221;) and (ii) <span id="xdx_904_eus-gaap--PreferredStockSharesAuthorized_iI_c20241231_zwgE6tZAogch" title="Preferred stock, shares authorized"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2024-12-31" id="Fact000688" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,120,000</ix:nonFraction></span> shares
of Preferred Stock, par value $<span id="xdx_906_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20241231_zQd6K0WB8wQg" title="Preferred stock, par value"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2024-12-31" id="Fact000690" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.001</ix:nonFraction></span> per share (&#8220;Preferred Stock&#8221;), <span id="xdx_901_eus-gaap--PreferredStockSharesAuthorized_iI_c20241231__us-gaap--StatementClassOfStockAxis__custom--ConvertibleSeriesAPreferredStockMember_zr5VCINVC3E8" title="Preferred stock, shares authorized"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2024-12-31_custom_ConvertibleSeriesAPreferredStockMember" id="Fact000692" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,000,000</ix:nonFraction></span> shares of which was designated as &#8220;Series
A Preferred Stock&#8221; and <span id="xdx_905_eus-gaap--PreferredStockSharesAuthorized_iI_c20241231__us-gaap--StatementClassOfStockAxis__custom--ConvertibleSeriesSeedPreferredStockMember_zDB5mk60DHTk" title="Preferred stock, shares authorized"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2024-12-31_custom_ConvertibleSeriesSeedPreferredStockMember" id="Fact000694" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">120,000</ix:nonFraction></span> shares of which were designated as &#8220;Series Seed Preferred Stock&#8221; with the rights, preferences,
powers, privileges and restrictions, qualifications and limitations set forth in this Article IV of the Delaware Certificate of Incorporation.
All share amounts have been retroactively restated to give effect to these changes.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August 9, 2023, the Company consummated an initial public offering (&#8220;IPO&#8221;), conducted on a firm commitment basis, pursuant
to which it sold <span id="xdx_901_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20230809__20230809__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--ConsolidatedEntitiesAxis__custom--AlexanderCapitalLPMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zUDH8AN8ek9h" title="Sale of stock, number of shares issued in transaction"><ix:nonFraction name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" contextRef="From2023-08-092023-08-09_us-gaap_CommonStockMember_custom_AlexanderCapitalLPMember_us-gaap_IPOMember" id="Fact000696" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,098,667</ix:nonFraction></span> shares of its common stock at a price of $<span id="xdx_906_eus-gaap--SharesIssuedPricePerShare_iI_c20230809__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--ConsolidatedEntitiesAxis__custom--AlexanderCapitalLPMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zI9u57xXBAj6" title="Shares issued, price per share"><ix:nonFraction name="us-gaap:SharesIssuedPricePerShare" contextRef="AsOf2023-08-09_us-gaap_CommonStockMember_custom_AlexanderCapitalLPMember_us-gaap_IPOMember" id="Fact000698" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">6.00</ix:nonFraction></span> per share, resulting in gross proceeds to the Company of $<span id="xdx_905_eus-gaap--ProceedsFromIssuanceOfCommonStock_c20230809__20230809__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--ConsolidatedEntitiesAxis__custom--AlexanderCapitalLPMember_zczW038XAupi" title="Proceeds from issuance of common stock"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="From2023-08-092023-08-09_us-gaap_CommonStockMember_custom_AlexanderCapitalLPMember_us-gaap_IPOMember" id="Fact000700" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,592,002</ix:nonFraction></span>.
Net proceeds to the Company, after deducting underwriting discounts and commissions and other offering expenses paid by the Company,
were $<span id="xdx_90B_eus-gaap--DeferredOfferingCosts_iI_c20230809__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember__srt--ConsolidatedEntitiesAxis__custom--AlexanderCapitalLPMember_zGLTziJMzVdl" title="Deferred offering costs"><ix:nonFraction name="us-gaap:DeferredOfferingCosts" contextRef="AsOf2023-08-09_us-gaap_CommonStockMember_custom_AlexanderCapitalLPMember_us-gaap_IPOMember" id="Fact000702" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,110,721</ix:nonFraction></span>. All shares sold in our IPO were registered pursuant to a registration statement on Form S-1 (File No. 333- 269179),
as amended, declared effective by the SEC on August 9, 2023. Alexander Capital L.P. (&#8220;Alexander&#8221;) acted as sole book-running
manager for the offering and Spartan Capital Securities, LLC acted as co-manager for the offering. The underwriters did not exercise
their option to purchase up to an additional <span id="xdx_906_ecustom--PurchaseOfAdditionalStockOnNumberOfOptionsNotExercised_c20230809__20230809__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zm8mbjoUdTSh" title="Purchase of additional stockon number of options not exercised"><ix:nonFraction name="NRXS:PurchaseOfAdditionalStockOnNumberOfOptionsNotExercised" contextRef="From2023-08-092023-08-09_us-gaap_CommonStockMember" id="Fact000704" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">164,801</ix:nonFraction></span> shares of common stock. The Company paid the underwriters an underwriting discount
of seven percent (<span id="xdx_90E_ecustom--UnderwritersDiscountPercentage_iI_pid_dp_uPure_c20230809__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember__srt--ConsolidatedEntitiesAxis__custom--AlexanderCapitalLPMember_zfRQJp40dYZa" title="Underwriters discount percentage"><ix:nonFraction name="NRXS:UnderwritersDiscountPercentage" contextRef="AsOf2023-08-09_us-gaap_CommonStockMember_custom_AlexanderCapitalLPMember_us-gaap_IPOMember" id="Fact000706" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">7</ix:nonFraction></span>%) of the amount raised in the offering. In addition, we also paid the underwriters a non-accountable expense allowance
in the amount of <span id="xdx_90F_ecustom--NonaccountableExpenseAllowancePercentage_iI_pid_dp_uPure_c20230809__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember__srt--ConsolidatedEntitiesAxis__custom--AlexanderCapitalLPMember_zPCTDqW6Qvlc" title="Nonaccountable expense allowance percentage"><ix:nonFraction name="NRXS:NonaccountableExpenseAllowancePercentage" contextRef="AsOf2023-08-09_us-gaap_CommonStockMember_custom_AlexanderCapitalLPMember_us-gaap_IPOMember" id="Fact000708" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">1</ix:nonFraction></span>% (such <span id="xdx_909_ecustom--CashFeePercentage_iI_pid_dp_uPure_c20230809__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember__srt--ConsolidatedEntitiesAxis__custom--AlexanderCapitalLPMember_zd5TUoVVCMSf" title="Cash fee percentage"><ix:nonFraction name="NRXS:CashFeePercentage" contextRef="AsOf2023-08-09_us-gaap_CommonStockMember_custom_AlexanderCapitalLPMember_us-gaap_IPOMember" id="Fact000710" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">8</ix:nonFraction></span>% in commissions and fees amounted to a total of $<span id="xdx_907_eus-gaap--ProceedsFromIssuanceInitialPublicOffering_c20230809__20230809__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember__srt--ConsolidatedEntitiesAxis__custom--AlexanderCapitalLPMember_z27GlCZDvRrj" title="Proceeds from issuance initial public offering"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" contextRef="From2023-08-092023-08-09_us-gaap_CommonStockMember_custom_AlexanderCapitalLPMember_us-gaap_IPOMember" id="Fact000712" format="ixt:numdotdecimal" decimals="0" unitRef="USD">527,000</ix:nonFraction></span>) at closing, as well as $<span id="xdx_90B_ecustom--ReimbursementExpenses_c20230809__20230809__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember__srt--ConsolidatedEntitiesAxis__custom--AlexanderCapitalLPMember_zFn36kMnZ0w2" title="Reimbursement expenses"><ix:nonFraction name="NRXS:ReimbursementExpenses" contextRef="From2023-08-092023-08-09_us-gaap_CommonStockMember_custom_AlexanderCapitalLPMember_us-gaap_IPOMember" id="Fact000714" format="ixt:numdotdecimal" decimals="0" unitRef="USD">175,000</ix:nonFraction></span> for the reimbursement
of certain of the underwriters&#8217; expenses. Additionally, as partial consideration for services rendered in connection with the offering,
the Company issued Alexander unregistered warrants to purchase an aggregate of <span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20230809__20230809__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember__srt--ConsolidatedEntitiesAxis__custom--AlexanderCapitalLPMember_zfvPq9OomCPd" title="Warrants to purchase an aggregate common stock, shares"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" contextRef="From2023-08-092023-08-09_us-gaap_CommonStockMember_custom_AlexanderCapitalLPMember_us-gaap_IPOMember" id="Fact000716" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">65,921</ix:nonFraction></span> shares of Company common stock, representing <span id="xdx_90B_eus-gaap--SaleOfStockPercentageOfOwnershipAfterTransaction_pid_dp_c20230809__20230809__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember__srt--ConsolidatedEntitiesAxis__custom--AlexanderCapitalLPMember_zp4fZvG67qzk" title="Sale of stock, percentage of ownership after transaction"><ix:nonFraction name="us-gaap:SaleOfStockPercentageOfOwnershipAfterTransaction" contextRef="From2023-08-092023-08-09_us-gaap_CommonStockMember_custom_AlexanderCapitalLPMember_us-gaap_IPOMember" id="Fact000718" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">6.0</ix:nonFraction></span>%
of the aggregate shares sold in the offering. The warrants had an initial exercise price of $<span id="xdx_901_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20230809__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember__srt--ConsolidatedEntitiesAxis__custom--AlexanderCapitalLPMember_zA7rR49oMrFg" title="Exercise price of warrants"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2023-08-09_us-gaap_CommonStockMember_custom_AlexanderCapitalLPMember_us-gaap_IPOMember" id="Fact000720" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">7.20</ix:nonFraction></span> per share (equal to <span id="xdx_90A_ecustom--OfferingPricePerPercentage_iI_pid_dp_c20230809__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember__srt--ConsolidatedEntitiesAxis__custom--AlexanderCapitalLPMember_z1Pdk2I5dVwf" title="Offering price per percentage"><ix:nonFraction name="NRXS:OfferingPricePerPercentage" contextRef="AsOf2023-08-09_us-gaap_CommonStockMember_custom_AlexanderCapitalLPMember_us-gaap_IPOMember" id="Fact000722" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">120</ix:nonFraction></span>% of the offering
price per share), a term of five years from the commencement of sales in the offering, and are exercisable at any time.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August 15, 2024, the Company&#8217;s shareholders (i) authorized <span id="xdx_906_eus-gaap--PreferredStockSharesAuthorized_iI_c20240815__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zl89IR6FHHAl" title="Preferred stock, shares authorized"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2024-08-15_us-gaap_SeriesBPreferredStockMember" id="Fact000724" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">5,000,000</ix:nonFraction></span> shares of preferred stock of which <span id="xdx_905_eus-gaap--TemporaryEquitySharesAuthorized_iI_pid_c20240815__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zESFK4ND2Is7" title="Temporary equity, shares authorized"><ix:nonFraction name="us-gaap:TemporaryEquitySharesAuthorized" contextRef="AsOf2024-08-15_us-gaap_SeriesBPreferredStockMember" id="Fact000726" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">4,000,000</ix:nonFraction></span> were designated
at $<span id="xdx_90C_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20240815__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zbN3I9AT92J5" title="Preferred stock, par value"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2024-08-15_us-gaap_SeriesBPreferredStockMember" id="Fact000728" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.001</ix:nonFraction></span> par value &#8220;Series B Preferred Stock&#8221; inclusive of cumulative dividends, due and payable quarterly at the Company&#8217;s
discretion either in cash or common stock when declared, <span id="xdx_90E_eus-gaap--PreferredStockDividendPaymentTerms_c20240815__20240815__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zzdDgSZhsJR6" title="Cumulative dividend description"><ix:nonNumeric contextRef="From2024-08-152024-08-15_us-gaap_SeriesBPreferredStockMember" id="Fact000730" name="us-gaap:PreferredStockDividendPaymentTerms">at a rate of 8.5% per annum through June 30, 2025</ix:nonNumeric></span>, (ii) retired <span id="xdx_906_eus-gaap--StockRepurchasedAndRetiredDuringPeriodShares_c20240815__20240815__us-gaap--StatementClassOfStockAxis__custom--ConvertibleSeriesAPreferredStockMember_zhR3u3LaTB8i" title="Stock repurchased and retired during period shares"><ix:nonFraction name="us-gaap:StockRepurchasedAndRetiredDuringPeriodShares" contextRef="From2024-08-152024-08-15_custom_ConvertibleSeriesAPreferredStockMember" id="Fact000732" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,000,000</ix:nonFraction></span> shares
of Series A Preferred Stock and (iii) retired <span id="xdx_907_eus-gaap--StockRepurchasedAndRetiredDuringPeriodShares_c20240815__20240815__us-gaap--StatementClassOfStockAxis__custom--ConvertibleSeriesSeedPreferredStockMember_zcAg2O2sFNZ4" title="Stock repurchased and retired during period shares"><ix:nonFraction name="us-gaap:StockRepurchasedAndRetiredDuringPeriodShares" contextRef="From2024-08-152024-08-15_custom_ConvertibleSeriesSeedPreferredStockMember" id="Fact000734" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">120,000</ix:nonFraction></span> shares of Series Seed Preferred Stock. On November 11, 2024, the Company&#8217;s
shareholders authorized (i) an increase in the number of designated Series B Preferred Stock to <span id="xdx_909_eus-gaap--PreferredStockSharesAuthorized_iI_c20241111__us-gaap--StatementClassOfStockAxis__custom--ConvertibleSeriesBPreferredStockMember_z2SZx3kgdrUa" title="Preferred stock, shares authorized"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2024-11-11_custom_ConvertibleSeriesBPreferredStockMember" id="Fact000736" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">5,000,000</ix:nonFraction></span> shares and (ii) an <span id="xdx_902_eus-gaap--PreferredStockDividendPaymentTerms_c20241111__20241111__us-gaap--StatementClassOfStockAxis__custom--ConvertibleSeriesBPreferredStockMember_zAxo7p68lPQf" title="Cumulative dividend description"><ix:nonNumeric contextRef="From2024-11-112024-11-11_custom_ConvertibleSeriesBPreferredStockMember" id="Fact000738" name="us-gaap:PreferredStockDividendPaymentTerms">extension
of the 8.5% cumulative dividend period to December 31, 2026</ix:nonNumeric></span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<ix:exclude><!-- Field: Page; Sequence: 98; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Neuraxis,
Inc.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Notes
to Financial Statements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000740" name="us-gaap:SignificantAccountingPoliciesTextBlock"><p id="xdx_80F_eus-gaap--SignificantAccountingPoliciesTextBlock_zlJdJYr3Cvnj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2.
<span id="xdx_828_zEQNQ1WBaVd4">Summary of Significant Accounting Policies</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
summary of significant accounting policies of Neuraxis, Inc. is presented to assist in understanding the Company&#8217;s financial statements.
The financial statements and notes are representations of the Company&#8217;s management, who are responsible for their integrity and
objectivity. These accounting policies conform to U.S. generally accepted accounting principles and have been consistently applied in
the preparation of the financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Preparing
the Company&#8217;s financial statements in conformity with accounting principles generally accepted in the United States of America
(&#8220;GAAP&#8221;) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities
and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and
expenses during the reporting period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000742" name="us-gaap:UseOfEstimates"><p id="xdx_843_eus-gaap--UseOfEstimates_zCNBGrFAkxnd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_862_zCQCbX5hehLh">Use
of Estimates and Critical Accounting Estimates and Assumptions</span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the
reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the dates of the financial statements
and the reported amounts of revenues and expenses during the reporting periods.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
significant accounting estimates or assumptions bear the risk of change due to the fact that there are uncertainties attached to these
estimates or assumptions, and certain estimates or assumptions are difficult to measure or value.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management
bases its estimates on historical experience and on various assumptions that are believed to be reasonable in relation to the financial
statements taken as a whole under the circumstances, the results of which form the basis for making judgments about the carrying values
of assets and liabilities that are not readily apparent from other sources.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management
regularly evaluates the key factors and assumptions used to develop the estimates utilizing currently available information, changes
in facts and circumstances, historical experience, and reasonable assumptions. After such evaluations, if deemed appropriate, those estimates
are adjusted accordingly. The Company uses estimates in accounting for, among other items, revenue recognition, allowance for credit
losses, stock-based compensation, income tax provisions, excess and obsolete inventory reserve, and impairment of property and equipment,
and intellectual property. Actual results could differ from those estimates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000744" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock"><p id="xdx_84E_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_ztvqhicgjizf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_86B_zlm33AKL50gf">Cash
and Cash Equivalents</span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company considers all highly liquid debt instruments purchased with a maturity of three months or less to be cash equivalents. The Company
did not hold any cash equivalents as of December 31, 2024 and 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000746" name="us-gaap:TradeAndOtherAccountsReceivablePolicy"><p id="xdx_846_eus-gaap--TradeAndOtherAccountsReceivablePolicy_zfROzNl3ffE" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_866_z8W5SJsnYNZ3">Trade
Accounts Receivable and Allowance for Credit Losses</span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Trade
accounts receivable are stated at the amount management expects to collect from outstanding balances, net of an allowance for credit
losses. Management evaluates many factors when determining the collectability of specific customer accounts, including, but not
limited to, creditworthiness, past transaction and payment history, current economic industry trends and changes in payment terms.
Management used assumptions and judgment based on the best available facts and circumstances to estimate and record an allowance.
The allowance for credit losses was $<span id="xdx_90F_eus-gaap--AllowanceForDoubtfulAccountsReceivable_iI_c20241231_zP8VFScW5y0c" title="Allowance for doubtful accounts"><ix:nonFraction name="us-gaap:AllowanceForDoubtfulAccountsReceivable" contextRef="AsOf2024-12-31" id="Fact000748" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,000</ix:nonFraction></span>
and $<span id="xdx_903_eus-gaap--AllowanceForDoubtfulAccountsReceivable_iI_c20231231_ztE0yvQuOmXa" title="Allowance for doubtful accounts"><ix:nonFraction name="us-gaap:AllowanceForDoubtfulAccountsReceivable" contextRef="AsOf2023-12-31" id="Fact000750" format="ixt:numdotdecimal" decimals="0" unitRef="USD">11,993</ix:nonFraction></span>
as of December 31, 2024 and 2023, respectively. The Company recorded credit losses for the years ended December 31, 2024 and 2023 of
$<span id="xdx_90D_eus-gaap--ProvisionForOtherCreditLosses_c20240101__20241231_z7Ql8mCSpFj8" title="Credit losses"><ix:nonFraction name="us-gaap:ProvisionForOtherCreditLosses" contextRef="From2024-01-01to2024-12-31" id="Fact000752" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,395</ix:nonFraction></span> and $<span id="xdx_904_eus-gaap--ProvisionForOtherCreditLosses_c20230101__20231231_zJyECgcqyDrd" title="Credit losses"><ix:nonFraction name="us-gaap:ProvisionForOtherCreditLosses" contextRef="From2023-01-012023-12-31" id="Fact000754" format="ixt:numdotdecimal" decimals="0" unitRef="USD">25,281</ix:nonFraction></span>,
respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 99; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Neuraxis,
Inc.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Notes
to Financial Statements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000756" name="us-gaap:DepositContractsPolicy"><p id="xdx_845_eus-gaap--DepositContractsPolicy_z0S65AE6qnwc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_86B_zs9KrkyOFyU1">Customer
Deposits</span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Customer
deposits consists of  payments and returned devices from clients in advance of revenue recognition. The Company will recognize
the customer deposits over the next year. As of December 31, 2024, and 2023, the Company had customer deposits of $<span id="xdx_904_eus-gaap--Deposits_iI_c20241231_zSmRjs0DXNzj" title="Customer deposits"><ix:nonFraction name="us-gaap:Deposits" contextRef="AsOf2024-12-31" id="Fact000758" format="ixt:numdotdecimal" decimals="0" unitRef="USD">32,527</ix:nonFraction></span> and $<span id="xdx_902_eus-gaap--Deposits_iI_c20231231_zueWOiNKKjkg" title="Customer deposits"><ix:nonFraction name="us-gaap:Deposits" contextRef="AsOf2023-12-31" id="Fact000760" format="ixt:numdotdecimal" decimals="0" unitRef="USD">74,947</ix:nonFraction></span>,
respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000762" name="us-gaap:InventoryPolicyTextBlock"><p id="xdx_846_eus-gaap--InventoryPolicyTextBlock_zxmZEstGpDWd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_866_zKh9Gova5AU2">Inventories</span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inventories
are valued at the lower of cost or net realizable value. Cost is determined using the weighted average method. The inventory is comprised
of finished medical devices on hand. Certain components within the devices have an expiration date that are removed from current inventory
and expensed at the date of expiration. For the years ended December 31, 2024 and 2023, $<span id="xdx_901_ecustom--InventoryExpenses_iI_c20241231_zZoDkfglZ1Ia" title="Inventory expenses"><ix:nonFraction name="NRXS:InventoryExpenses" contextRef="AsOf2024-12-31" id="Fact000764" format="ixt:numdotdecimal" decimals="0" unitRef="USD">0</ix:nonFraction></span> and $<span id="xdx_900_ecustom--InventoryExpenses_iI_c20231231_zEQ7Zl1KsBUg" title="Inventory expenses"><ix:nonFraction name="NRXS:InventoryExpenses" contextRef="AsOf2023-12-31" id="Fact000766" format="ixt:numdotdecimal" decimals="0" unitRef="USD">25,008</ix:nonFraction></span> were expensed as expired inventory,
respectively. Inventory reserves totaled $<span id="xdx_906_eus-gaap--InventoryRawMaterialsNetOfReserves_iI_c20241231_zgVGVW7KmyZ2" title="Inventory reserves"><ix:nonFraction name="us-gaap:InventoryRawMaterialsNetOfReserves" contextRef="AsOf2024-12-31" id="Fact000768" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,454</ix:nonFraction></span> and $<span id="xdx_90C_eus-gaap--InventoryRawMaterialsNetOfReserves_iI_c20231231_zZjhKB4ngEMj" title="Inventory reserves"><ix:nonFraction name="us-gaap:InventoryRawMaterialsNetOfReserves" contextRef="AsOf2023-12-31" id="Fact000770" format="ixt:numdotdecimal" decimals="0" unitRef="USD">0</ix:nonFraction></span> as of December 31, 2024 and 2023, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000772" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock"><p id="xdx_846_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zWScFqAl6Wg6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_860_zuZEawh0Gg39">Property
and Equipment</span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property
and equipment are recorded at cost less accumulated depreciation. Depreciation is computed using the straight-line method over the estimated
useful lives of the assets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000774" name="NRXS:ScheduleOfPropertyPlantAndEquipmentUsefulLivesTableTextBlock"><p id="xdx_89D_ecustom--ScheduleOfPropertyPlantAndEquipmentUsefulLivesTableTextBlock_zA63jvQhipj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Depreciation
is calculated using the following estimated useful lives:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B1_zS3Vx59ipME8" style="display: none">Schedule of Estimated Useful Lives</span></span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; width: 60%; border-collapse: collapse; margin-right: auto">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; width: 79%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Classification</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; width: 19%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Years</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Machinery
    and Equipment </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_908_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--MachineryAndEquipmentMember__srt--RangeAxis__srt--MinimumMember_zBoCKBqUpo16" title="Property and equipment, estimated useful lives"><ix:nonNumeric contextRef="AsOf2024-12-31_us-gaap_MachineryAndEquipmentMember_srt_MinimumMember" format="ixt-sec:duryear" id="Fact000776" name="us-gaap:PropertyPlantAndEquipmentUsefulLife">7</ix:nonNumeric></span>-<span id="xdx_90B_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--MachineryAndEquipmentMember__srt--RangeAxis__srt--MaximumMember_zs1iIMSzTnZ" title="Property and equipment, estimated useful lives"><ix:nonNumeric contextRef="AsOf2024-12-31_us-gaap_MachineryAndEquipmentMember_srt_MaximumMember" format="ixt-sec:duryear" id="Fact000778" name="us-gaap:PropertyPlantAndEquipmentUsefulLife">10</ix:nonNumeric></span>
    </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Furniture
    and Fixtures</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_906_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember__srt--RangeAxis__srt--MinimumMember_zmPdomKTkuj5" title="Property and equipment, estimated useful lives"><ix:nonNumeric contextRef="AsOf2024-12-31_us-gaap_FurnitureAndFixturesMember_srt_MinimumMember" format="ixt-sec:duryear" id="Fact000780" name="us-gaap:PropertyPlantAndEquipmentUsefulLife">3</ix:nonNumeric></span>-<span id="xdx_90D_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember__srt--RangeAxis__srt--MaximumMember_zMDjRUq42GH8" title="Property and equipment, estimated useful lives"><ix:nonNumeric contextRef="AsOf2024-12-31_us-gaap_FurnitureAndFixturesMember_srt_MaximumMember" format="ixt-sec:duryear" id="Fact000782" name="us-gaap:PropertyPlantAndEquipmentUsefulLife">10</ix:nonNumeric></span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Computer
    Hardware</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_zay71H131WJ9" title="Property and equipment, estimated useful lives"><ix:nonNumeric contextRef="AsOf2024-12-31_us-gaap_ComputerEquipmentMember" format="ixt-sec:duryear" id="Fact000784" name="us-gaap:PropertyPlantAndEquipmentUsefulLife">5</ix:nonNumeric></span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Leasehold
    Improvements</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90F_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember__srt--RangeAxis__srt--MinimumMember_zttmRcV3egyh" title="Property and equipment, estimated useful lives"><ix:nonNumeric contextRef="AsOf2024-12-31_us-gaap_LeaseholdImprovementsMember_srt_MinimumMember" format="ixt-sec:duryear" id="Fact000786" name="us-gaap:PropertyPlantAndEquipmentUsefulLife">10</ix:nonNumeric></span>-<span id="xdx_903_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember__srt--RangeAxis__srt--MaximumMember_zDksIX8dOpz9" title="Property and equipment, estimated useful lives"><ix:nonNumeric contextRef="AsOf2024-12-31_us-gaap_LeaseholdImprovementsMember_srt_MaximumMember" format="ixt-sec:duryear" id="Fact000788" name="us-gaap:PropertyPlantAndEquipmentUsefulLife">20</ix:nonNumeric></span></span></td></tr>
  </table>
</ix:nonNumeric><p id="xdx_8A9_zz9GmOk7OY67" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Depreciation
expense was $<span id="xdx_908_eus-gaap--Depreciation_c20240101__20241231_zCE9MU3CfcB" title="Depreciation expense"><ix:nonFraction name="us-gaap:Depreciation" contextRef="From2024-01-01to2024-12-31" id="Fact000790" format="ixt:numdotdecimal" decimals="0" unitRef="USD">26,346</ix:nonFraction></span> and $<span id="xdx_907_eus-gaap--Depreciation_c20230101__20231231_zg5lb62IyG23" title="Depreciation expense"><ix:nonFraction name="us-gaap:Depreciation" contextRef="From2023-01-012023-12-31" id="Fact000792" format="ixt:numdotdecimal" decimals="0" unitRef="USD">30,240</ix:nonFraction></span> during the years ended December 31, 2024 and 2023, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000794" name="us-gaap:ResearchAndDevelopmentExpensePolicy"><p id="xdx_847_eus-gaap--ResearchAndDevelopmentExpensePolicy_zaqJbGezMLz8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_861_z6QRpnJ2AG38">Research
and Development</span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Costs
for research and development are expensed as incurred. Research and development expenses consist primarily of clinical research studies
and new product development.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000796" name="us-gaap:IntangibleAssetsFiniteLivedPolicy"><p id="xdx_843_eus-gaap--IntangibleAssetsFiniteLivedPolicy_zGVWfgMVm0Lf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_862_zLVPmPO16MM7">Intangible
Assets</span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Intangible
assets consist of software, patents, a trademark and a license. Intangible assets are stated at their historical cost and amortized on
a straight-line basis over their expected useful lives. Capitalized patent costs, net of accumulated amortization, includes legal costs
incurred for patent applications. In accordance with ASC 350, once a patent is granted, we amortize the capitalized patent costs over
the remaining life of the patent using the straight-line method. If the patent is not granted, we write off any capitalized patent costs
at that time.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company purchased a trademark related to the Company&#8217;s name for $<span id="xdx_908_eus-gaap--PaymentsToAcquireIntangibleAssets_c20240101__20241231__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_zPy2rZ9bDnpa" title="Payment to acquire intangible assets"><ix:nonFraction name="us-gaap:PaymentsToAcquireIntangibleAssets" contextRef="From2024-01-012024-12-31_us-gaap_TrademarksMember" id="Fact000798" format="ixt:numdotdecimal" decimals="0" unitRef="USD">50,000</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.
The trademark does not have a determinate life and therefore the cost is not being amortized.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company entered into an option agreement on April 12, 2023 to bring an optionor&#8217;s invention to commercialization via a royalty-bearing
licensing agreement. The agreement required an initial payment of $<span id="xdx_90D_eus-gaap--PaymentsToAcquireIntangibleAssets_c20240101__20241231__us-gaap--TypeOfArrangementAxis__custom--LicensingAgreementMember_zbq2IOfPbfml" title="Payment upon execution"><ix:nonFraction name="us-gaap:PaymentsToAcquireIntangibleAssets" contextRef="From2024-01-012024-12-31_custom_LicensingAgreementMember" id="Fact000800" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,000</ix:nonFraction></span> and was fully amortized in the year ended December 31, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 100; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Neuraxis,
Inc.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Notes
to Financial Statements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
review intangible assets for impairment annually or when events or circumstances indicate that their carrying amount may not be recoverable.
During the years ended December 31, 2024, and 2023, the Company recorded no impairment charges for intangible assets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amortization
expense was $<span id="xdx_902_eus-gaap--AmortizationOfIntangibleAssets_c20240101__20241231_zHntBXDIkQQh" title="Amortization expense"><ix:nonFraction name="us-gaap:AmortizationOfIntangibleAssets" contextRef="From2024-01-01to2024-12-31" id="Fact000802" format="ixt:numdotdecimal" decimals="0" unitRef="USD">11,485</ix:nonFraction></span> and $<span id="xdx_909_eus-gaap--AmortizationOfIntangibleAssets_c20230101__20231231_z6VW5MqTev6c" title="Amortization expense"><ix:nonFraction name="us-gaap:AmortizationOfIntangibleAssets" contextRef="From2023-01-012023-12-31" id="Fact000804" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,485</ix:nonFraction></span> during the years ended December 31, 2024 and 2023, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000806" name="us-gaap:IncomeTaxPolicyTextBlock"><p id="xdx_844_eus-gaap--IncomeTaxPolicyTextBlock_zkgEMdBxd1ml" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_864_zSM75xOhiFEk">Income
Taxes</span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company recognizes deferred tax assets and liabilities for the expected future tax consequences of events that have been included in
the Company&#8217;s financial statements and tax returns. Deferred tax assets and liabilities are determined based upon the differences
between the financial statement carrying amounts, and the tax bases of existing assets and liabilities for the loss and credit carryforwards
using enacted tax rates expected to be in effect in the year in which the differences are expected to reverse. Deferred tax assets are
reduced by a valuation allowance if it is more likely than not that these assets may not be realized. The Company determines whether
a tax position will be sustained upon examination. If it is more likely than not that a position will be sustained, none of the benefit
attributable to the position is recognized. The tax benefit to be recognized for any tax position that meets the more likely than not
recognition threshold is calculated as <span id="xdx_900_eus-gaap--IncomeTaxExaminationLikelihoodOfUnfavorableSettlement_c20240101__20241231_zhScl8zCptK8" title="Income tax examination, likelihood of unfavorable settlement"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000808" name="us-gaap:IncomeTaxExaminationLikelihoodOfUnfavorableSettlement">the largest amount that is more than 50% likely of being realized upon resolution of the contingency</ix:nonNumeric></span>.
The Company accounts for interest and penalties related to uncertain tax positions as part of its provision for income taxes.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management&#8217;s
evaluation of the Company&#8217;s deferred tax assets and liabilities did not have a material effect on the Company&#8217;s financial
statements. Furthermore, <span id="xdx_907_eus-gaap--IncomeTaxExaminationPenaltiesAndInterestAccrued_iI_do_c20241231_ztC0RV1l8oLb" title="Income tax interest or penalties accrued"><span id="xdx_908_eus-gaap--IncomeTaxExaminationPenaltiesAndInterestAccrued_iI_do_c20231231_zhqBNkKSJdb6" title="Income tax interest or penalties accrued"><ix:nonFraction name="us-gaap:IncomeTaxExaminationPenaltiesAndInterestAccrued" contextRef="AsOf2024-12-31" id="Fact000810" format="ixt-sec:numwordsen" decimals="0" unitRef="USD"><ix:nonFraction name="us-gaap:IncomeTaxExaminationPenaltiesAndInterestAccrued" contextRef="AsOf2023-12-31" id="Fact000812" format="ixt-sec:numwordsen" decimals="0" unitRef="USD">no</ix:nonFraction></ix:nonFraction></span></span> interest or penalties have been accrued or charged to expense as of December 31, 2024 and 2023 and for the
years then ended.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000814" name="us-gaap:AdvertisingCostsPolicyTextBlock"><p id="xdx_847_eus-gaap--AdvertisingCostsPolicyTextBlock_zo5yvzL87Rx8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_867_zWUOXu7pc5n5">Advertising
Cost</span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Advertising
costs are expensed as incurred and amounted to $<span id="xdx_90F_eus-gaap--AdvertisingExpense_c20240101__20241231__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zHFN1G5pWFd9" title="Advertising cost"><ix:nonFraction name="us-gaap:AdvertisingExpense" contextRef="From2024-01-012024-12-31_us-gaap_GeneralAndAdministrativeExpenseMember" id="Fact000816" format="ixt:numdotdecimal" decimals="0" unitRef="USD">232,125</ix:nonFraction></span>
and $<span id="xdx_900_eus-gaap--AdvertisingExpense_c20230101__20231231__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zIlntYARjZTf" title="Advertising cost"><ix:nonFraction name="us-gaap:AdvertisingExpense" contextRef="From2023-01-012023-12-31_us-gaap_GeneralAndAdministrativeExpenseMember" id="Fact000818" format="ixt:numdotdecimal" decimals="0" unitRef="USD">192,400</ix:nonFraction></span> for
the years ended December 31, 2024 and 2023, respectively, and are classified as general and administrative expenses in the
statements of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 101; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Neuraxis,
Inc.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Notes
to Financial Statements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000820" name="NRXS:WarrantLiabilityPolicyTextBlock"><p id="xdx_848_ecustom--WarrantLiabilityPolicyTextBlock_zaVIsSf1c53d" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_86D_zrlgX8Mm8yia">Warrant
Liabilities</span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management
evaluates all of the Company&#8217;s financial instruments, including issued warrants to purchase its common stock, to determine if such
instruments are liabilities pursuant to ASC 480 and ASC 815-15. The classification
of derivative financial instruments, including whether such instruments should be recorded as liabilities or as equity, is reassessed
at the end of each reporting period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company utilizes a Black-Scholes option-pricing model to compute the fair value of the derivative and to mark to market the fair value
of the derivative at each balance sheet date. The inputs utilized in the application of the Black-Scholes option-pricing model included
an exercise price, the stock price as of the valuation date, an expected remaining term of each warrant as of the valuation date, estimated
volatility, a dividend yield, and a risk-free rate. The Company records the change in the fair value of the warrant as other income or
expense in the statements of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000822" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock"><p id="xdx_846_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_zuoNDbkmfx99" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_867_zA6yTR80qBQ1">Fair
Value Measurements</span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for financial instruments in accordance with ASC 820, Fair Value Measurements and Disclosures (&#8220;ASC 820&#8221;).
ASC 820 establishes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy
gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and
the lowest priority to unobservable inputs (Level 3 measurements). The three levels of the fair value hierarchy under ASC 820 are described
below:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
1 &#8211; Quoted prices (unadjusted) for identical unrestricted assets or liabilities in active markets that the reporting entity has
the ability to access as of the measurement date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
2 &#8211; Significant other observable inputs other than Level 1 prices such as quoted prices for similar assets or liabilities: quoted
prices in markets that are not active; or financial instruments for which all significant inputs are observable or can be corroborated
by observable market date, either directly or indirectly.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
3 &#8211; Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets
or liabilities. These unobservable inputs reflect that reporting entity&#8217;s own assumptions about assumptions that market participants
would use in pricing the asset or liability. Level 3 assets and liabilities include financial instruments whose value is determined using
pricing models, discounted cash flow methodologies, or similar techniques, as well as instruments for which the determination of fair
value require significant management judgment or estimation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s Level 1 assets/liabilities include cash, accounts receivable, accounts payable, prepaids, and other current assets. Management
believes the estimated fair value of these accounts on December 31, 2024 approximate their carrying value as reflected in the balance
sheets due to the short-term nature of these instruments or the use of market interest rates for debt instruments.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s Level 3 assets/liabilities include warrant liabilities. Inputs to determine fair value are generally unobservable
and typically reflect management&#8217;s estimates of assumptions that market participants would use in pricing the asset or liability.
The fair values are therefore determined using model-based techniques, including option pricing models and discounted cash flow models.
The valuation techniques involve management&#8217;s estimates and judgment based on unobservable inputs. The fair value estimates may
not be indicative of the amounts that would be realized in a market exchange. Additionally, there may be inherent uncertainties or changes
in the underlying assumptions used, which could significantly affect the current or future fair value estimates. Unobservable inputs
used in the models are significant to the fair values of the assets and liabilities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 102; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Neuraxis,
Inc.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Notes
to Financial Statements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000824" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"><p id="xdx_89E_eus-gaap--ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_zSRjCMWMj1w3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table provides a summary of the relevant assets and liabilities that are measured at fair value on a recurring
basis:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B3_z3g9hDaGrTA9" style="display: none">Schedule
of Fair Value of Assets and Liabilities  measured on Recurring Basis</span>&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_4B9_us-gaap--FairValueByMeasurementFrequencyAxis_us-gaap--FairValueMeasurementsRecurringMember_us-gaap--FinancialInstrumentAxis_us-gaap--WarrantMember_zBZgAXCyF1Vk" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_4B0_us-gaap--FairValueByMeasurementFrequencyAxis_us-gaap--FairValueMeasurementsRecurringMember_us-gaap--FairValueByFairValueHierarchyLevelAxis_us-gaap--FairValueInputsLevel1Member_zDB43ntMIDc2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 1</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_4BA_us-gaap--FairValueByMeasurementFrequencyAxis_us-gaap--FairValueMeasurementsRecurringMember_us-gaap--FairValueByFairValueHierarchyLevelAxis_us-gaap--FairValueInputsLevel2Member_z9UbeIrsNMjf" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 2</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_4BC_us-gaap--FairValueByMeasurementFrequencyAxis_us-gaap--FairValueMeasurementsRecurringMember_us-gaap--FairValueByFairValueHierarchyLevelAxis_us-gaap--FairValueInputsLevel3Member_zWqguAEicMAk" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 3</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: center"><b>Valuation Methodology</b></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: center"><b>Unobservable<br/>
Inputs</b></td></tr>
  <tr id="xdx_439_c20241231_eus-gaap--LiabilitiesFairValueDisclosure_iI_z3pBMIl0Qkg3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 23%; text-align: left; padding-bottom: 1pt; padding-left: 0pt">Fair value of warrant  liabilities as of
    December 31, 2024</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 7%; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="AsOf2024-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_WarrantMember" id="Fact000826" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9,166</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 7%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0827">&#8212;</span></td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 7%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0828">&#8212;</span></td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 7%; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="AsOf2024-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel3Member" id="Fact000829" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9,166</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="text-align: center; width: 12%">Black-Scholes model</td>
    <td style="width: 2%">&#160;</td>
    <td style="text-align: center; width: 17%">Project simulated cash flows</td></tr>
  <tr id="xdx_43C_c20231231_eus-gaap--LiabilitiesFairValueDisclosure_iI_z6bHNiK1NE4k" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 0pt">Fair value of warrant  liabilities as of
    December 31, 2023</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="AsOf2023-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_WarrantMember" id="Fact000831" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,225</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0832">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0833">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="AsOf2023-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel3Member" id="Fact000834" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,225</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">Black-Scholes model</td>
    <td>&#160;</td>
    <td style="text-align: center">Project simulated cash flows</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

</ix:nonNumeric><p id="xdx_8AF_zDV1NvmR9hqi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
were no transfers between any of the levels during the years ended December 31, 2024 and 2023. In addition to assets and liabilities
that are recorded at fair value on a recurring basis, the Company&#8217;s assets and liabilities are also subject to recurring fair
value measurements. As of December 31, 2024 and 2023, the Company had no assets that were measured on a recurring basis.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000836" name="us-gaap:EarningsPerSharePolicyTextBlock"><p id="xdx_843_eus-gaap--EarningsPerSharePolicyTextBlock_z3Z5xHrFvPnb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_868_zRILTRgfzVRf">Basic
and Diluted Net Income (Loss) per Share</span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basic
earnings or loss per share (&#8220;EPS&#8221;) is computed by dividing net income (loss), net of preferred stock dividends, by the
weighted average number of common shares outstanding during the period. Diluted EPS is determined using the weighted average number
of common shares outstanding during the period, adjusted for the dilutive effect of common stock equivalents that were outstanding
for the periods presented. In periods when losses are reported, which is the case for December 31, 2024 and 2023 presented in these
financial statements, the weighted average number of common shares outstanding excludes common stock equivalents because their
inclusion would be anti-dilutive. Preferred stock dividends (neither declared nor paid) were $<span id="xdx_90F_eus-gaap--DividendsPreferredStock_c20240101__20241231_zMa5zOaCz0dh" title="Preferred stock dividend"><ix:nonFraction name="us-gaap:DividendsPreferredStock" contextRef="From2024-01-01to2024-12-31" id="Fact000838" format="ixt:numdotdecimal" decimals="0" unitRef="USD">211,268</ix:nonFraction></span>
and $<span id="xdx_906_eus-gaap--DividendsPreferredStock_dxL_c20230101__20231231_zCKOVIyQCu2e" title="Preferred stock dividend::XDX::-"><span style="-sec-ix-hidden: xdx2ixbrl0840">0</span></span>
as of December 31, 2024 and 2023, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 103; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Neuraxis,
Inc.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Notes
to Financial Statements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000842" name="us-gaap:ScheduleOfEarningsPerShareDilutedByCommonClassTextBlock"><p id="xdx_894_eus-gaap--ScheduleOfEarningsPerShareDilutedByCommonClassTextBlock_zQrWqPsSpLsb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company had the following potentially dilutive common stock equivalents at December 31, 2024 and 2023:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BC_zox9NmqQpub9" style="display: none">Schedule of Dilutive Common Stock Equivalents</span>&#160;</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_494_20240101__20241231_zCfMhiwPQpEd" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49E_20230101__20231231_zb3LNMgKs5Qd" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--OptionMember_z2YvJ0OOXEw7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%">Options</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2024-01-012024-12-31_us-gaap_OptionMember" id="Fact000844" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,319,394</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2023-01-012023-12-31_us-gaap_OptionMember" id="Fact000845" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,319,394</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--CommonStockMember_z4IBT9gvKFCb" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Pre-Funded Warrants for Common Stock</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember47706312" id="Fact000847" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">289,779</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0848">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--WarrantsMember_zm2CD0h3eBoj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2024-01-012024-12-31_custom_WarrantsMember" id="Fact000850" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,352,751</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2023-01-012023-12-31_custom_WarrantsMember" id="Fact000851" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,822,358</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--SeriesBPreferredStockMember_zPVzzRS4kdql" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Series B Preferred Stock</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2024-01-012024-12-31_us-gaap_SeriesBPreferredStockMember" id="Fact000853" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">4,280,939</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0854">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_zswUml38NNc9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-bottom: 1pt; padding-left: 10pt">Totals</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2024-01-01to2024-12-31" id="Fact000856" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">8,242,863</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2023-01-012023-12-31" id="Fact000857" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,141,752</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AE_zZkRPjMKhCOg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000859" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"><p id="xdx_89D_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_zX3d573GQcn8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table shows the calculation of the basic and diluted net loss per share and the effect of preferred stock dividends.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BC_zXyehy2Q4OB7" style="display: none">Schedule of Basic and Diluted Net Loss Per Share</span>&#160;</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49E_20240101__20241231_zkLWbBazjZl2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_493_20230101__20231231_zPg30jDzserk" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">For the Years Ended December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Numerator</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--NetIncomeLoss_iT_mtNILzQKI_zp3QgJK7iOg" style="vertical-align: bottom; background-color: White">
    <td style="width: 60%; text-align: left; padding-left: 10pt">Net loss</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-01-01to2024-12-31" id="Fact000861" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">8,241,501</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-12-31" id="Fact000862" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">14,626,683</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td></tr>
  <tr id="xdx_402_eus-gaap--DividendsPreferredStock_iN_di_zqUV04SEGgVl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 10pt">Preferred stock dividends</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:DividendsPreferredStock" contextRef="From2024-01-01to2024-12-31" id="Fact000864" format="ixt:numdotdecimal" decimals="0" unitRef="USD">211,268</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0865">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_zqBPWqst7E72" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Net loss available to common stockholders</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="From2024-01-01to2024-12-31" id="Fact000867" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">8,452,769</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="From2023-01-012023-12-31" id="Fact000868" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">14,626,683</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Denominator</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 20pt">Weighted-average shares of common stock outstanding - basic and diluted</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_903_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20240101__20241231_z6adsR0YsnZ9" title="Weighted average shares of common stock outstanding - basic"><span id="xdx_901_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20240101__20241231_zco5F3MbpLAc" title="Weighted average shares of common stock outstanding - diluted"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2024-01-01to2024-12-31" id="Fact000870" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2024-01-01to2024-12-31" id="Fact000872" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">6,918,887</ix:nonFraction></ix:nonFraction></span></span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_900_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20230101__20231231_zpa3Fn0QmNfb" title="Weighted average shares of common stock outstanding - basic"><span id="xdx_903_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20230101__20231231_zRyq1dOtor4d" title="Weighted average shares of common stock outstanding - diluted"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2023-01-012023-12-31" id="Fact000874" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2023-01-012023-12-31" id="Fact000876" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,252,328</ix:nonFraction></ix:nonFraction></span></span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Basic and diluted net loss per share</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_90E_eus-gaap--EarningsPerShareBasic_c20240101__20241231_zrz21PRWjGCl" title="Basic net loss per share"><span id="xdx_90F_eus-gaap--EarningsPerShareDiluted_c20240101__20241231_zIgmac8dw9Ed" title="Diluted net loss per share">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2024-01-01to2024-12-31" id="Fact000878" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="From2024-01-01to2024-12-31" id="Fact000880" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">1.22</ix:nonFraction></ix:nonFraction></span></span></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_908_eus-gaap--EarningsPerShareBasic_c20230101__20231231_z2hMbWcceUqg" title="Basic net loss per share"><span id="xdx_905_eus-gaap--EarningsPerShareDiluted_c20230101__20231231_z96vWnNsnYxe" title="Diluted net loss per share">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2023-01-012023-12-31" id="Fact000882" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="From2023-01-012023-12-31" id="Fact000884" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">4.50</ix:nonFraction></ix:nonFraction></span></span></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AF_z8OuXYGzkAE7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000886" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy"><p id="xdx_848_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_zuHjXlK84ss5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_862_zfwsy8KpLtyk">Stock-Based
Compensation</span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for all stock-based awards at fair value. The Company recognizes its stock-based compensation expense using the straight-line
method. Compensation cost is not adjusted for estimated forfeitures, but instead is adjusted upon an actual forfeiture.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for the granting of stock options and restricted stock units to employees and non-employees using the fair value method
whereby all awards are measured at fair value on the date of the grant. The fair value of all employee stock options and restricted stock
units is expensed over the requisite service period with a corresponding increase to additional paid-in capital. Upon exercise of stock
options, the consideration paid by the option holder is recorded in additional paid-in capital, while the par value of the shares received
is reclassified from additional paid-in-capital to common stock. Upon vesting of restricted stock units, the par value of the shares
issued are reclassified from additional paid-in-capital to common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock-based
awards to non-employees are measured based on the fair value of the equity instrument issued. Compensation expense for non-employee stock
awards is recognized over the requisite service period following the measurement of the fair value on the grant date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company uses the Black-Scholes option-pricing model to calculate the fair value of stock options. The use of the Black-Scholes option-pricing
model requires management to make assumptions with respect to the expected term of the option, the expected volatility of the common
stock consistent with the expected term of the option, risk-free interest rates, the value of the common stock and expected dividend
yield of the common stock. Changes in these assumptions can materially affect the fair value estimate.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 104; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Neuraxis,
Inc.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Notes
to Financial Statements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000888" name="us-gaap:RevenueRecognitionPolicyTextBlock"><p id="xdx_843_eus-gaap--RevenueRecognitionPolicyTextBlock_zbJsYb6ra5wg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_862_zPNGdCffZD65">Revenue
Recognition</span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
accordance with FASB&#8217;s ASC 606, <i>Revenue from Contracts with Customers</i>, (&#8220;ASC 606&#8221;), the Company recognizes revenue
when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the Company expects
to be entitled in exchange for those goods or services. To determine revenue recognition for arrangements that the Company determines
are within the scope of ASC 606, it performs the following five steps:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">identify
    the contract(s) with a customer&#894;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">identify
    the performance obligations in the contract&#894;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">determine
    the transaction price&#894;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iv)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">allocate
    the transaction price to the performance obligations in the contract&#894; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(v)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">recognize
    revenue when (or as) the entity satisfies a performance obligation.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company applies the five-step model to contracts when it determines that it is probable it will collect substantially all the consideration
it is entitled to in exchange for the goods or services it transfers to the customer. At contract inception, once the contract is determined
to be within the scope of ASC 606, the Company assesses the goods or services promised within each contract and determines those that
are performance obligations and assesses whether each promised good or service is distinct. The Company then recognizes as revenue the
amount of the transaction price, after consideration of variability and constraints, if any, that is allocated to the respective performance
obligation when the performance obligation is satisfied.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company estimates credit losses on accounts receivable by utilizing an aging schedule.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company offers a Patient Assistance Program for patients without insurance coverage for IB-Stim. This program offers potential self-pay
discounts for IB-Stim devices, based upon household income and size.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Also,
the Company offers providers an opt-in program to address adequate insurance claim payments on IB-Stim devices. This program may extend
a rebate or invoice credit where the insurance payment and patient responsibility (i.e., deductible, co-payment, and/or co-insurance
amounts required by the Payer) are less than the acquisition cost of the IB-Stim device. The Company recognizes revenue at such a time
that collection of the amount due is assured.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000890" name="us-gaap:DisaggregationOfRevenueTableTextBlock"><p id="xdx_89B_eus-gaap--DisaggregationOfRevenueTableTextBlock_z51iF5FwY8Ik" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table disaggregates the Company&#8217;s revenue based on the customer&#8217;s location by state for the years ended December
31:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B7_zFnT94CGa2N4" style="display: none">Schedule of Disaggregation of Revenue</span>&#160;</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 60%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 20%">California</td><td style="width: 2%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">$</td><td id="xdx_983_eus-gaap--Revenues_c20240101__20241231__srt--StatementGeographicalAxis__stpr--CA_ztWpMGR6FjK" title="Revenues" style="width: 16%; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2024-01-012024-12-31_stpr_CA" id="Fact000892" format="ixt:numdotdecimal" decimals="0" unitRef="USD">778,209</ix:nonFraction></td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--Revenues_c20230101__20231231__srt--StatementGeographicalAxis__stpr--CA_zhaa1ANY8XF7" title="Revenues" style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2023-01-012023-12-31_stpr_CA" id="Fact000894" format="ixt:numdotdecimal" decimals="0" unitRef="USD">601,235</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Ohio</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--Revenues_c20240101__20241231__srt--StatementGeographicalAxis__stpr--OH_z8HHuDbKCMGd" title="Revenues" style="font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2024-01-012024-12-31_stpr_OH" id="Fact000896" format="ixt:numdotdecimal" decimals="0" unitRef="USD">431,328</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--Revenues_c20230101__20231231__srt--StatementGeographicalAxis__stpr--OH_zzOMNsxW8pak" title="Revenues" style="text-align: right"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2023-01-012023-12-31_stpr_OH" id="Fact000898" format="ixt:numdotdecimal" decimals="0" unitRef="USD">407,632</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Illinois</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--Revenues_c20240101__20241231__srt--StatementGeographicalAxis__stpr--IL_zb6kZssrfWfe" title="Revenues" style="font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2024-01-012024-12-31_stpr_IL" id="Fact000900" format="ixt:numdotdecimal" decimals="0" unitRef="USD">246,217</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--Revenues_c20230101__20231231__srt--StatementGeographicalAxis__stpr--IL_zWDTnM17q319" title="Revenues" style="text-align: right"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2023-01-012023-12-31_stpr_IL" id="Fact000902" format="ixt:numdotdecimal" decimals="0" unitRef="USD">117,963</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Wisconsin</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--Revenues_c20240101__20241231__srt--StatementGeographicalAxis__stpr--WI_z3428iyridQh" title="Revenues" style="font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2024-01-012024-12-31_stpr_WI" id="Fact000904" format="ixt:numdotdecimal" decimals="0" unitRef="USD">157,786</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--Revenues_c20230101__20231231__srt--StatementGeographicalAxis__stpr--WI_zGxpKPV1TjK7" title="Revenues" style="text-align: right"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2023-01-012023-12-31_stpr_WI" id="Fact000906" format="ixt:numdotdecimal" decimals="0" unitRef="USD">292,601</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Massachusetts</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--Revenues_c20240101__20241231__srt--StatementGeographicalAxis__stpr--MA_zasnvjzBkL05" title="Revenues" style="font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2024-01-012024-12-31_stpr_MA" id="Fact000908" format="ixt:numdotdecimal" decimals="0" unitRef="USD">154,407</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--Revenues_c20230101__20231231__srt--StatementGeographicalAxis__stpr--MA_zKTfMKrP2Fwk" title="Revenues" style="text-align: right"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2023-01-012023-12-31_stpr_MA" id="Fact000910" format="ixt:numdotdecimal" decimals="0" unitRef="USD">127,300</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Florida</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--Revenues_c20240101__20241231__srt--StatementGeographicalAxis__stpr--FL_zjSSE7PnWXPh" title="Revenues" style="font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2024-01-012024-12-31_stpr_FL" id="Fact000912" format="ixt:numdotdecimal" decimals="0" unitRef="USD">149,985</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--Revenues_c20230101__20231231__srt--StatementGeographicalAxis__stpr--FL_z0AEkB7FcCsg" title="Revenues" style="text-align: right"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2023-01-012023-12-31_stpr_FL" id="Fact000914" format="ixt:numdotdecimal" decimals="0" unitRef="USD">186,840</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">All other states</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--Revenues_c20240101__20241231__srt--StatementGeographicalAxis__custom--AllOtherStatesMember_zhSbHj7bt2ag" title="Revenues" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2024-01-012024-12-31_custom_AllOtherStatesMember" id="Fact000916" format="ixt:numdotdecimal" decimals="0" unitRef="USD">767,993</ix:nonFraction></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--Revenues_c20230101__20231231__srt--StatementGeographicalAxis__custom--AllOtherStatesMember_zVzeZm5mSkih" title="Revenues" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2023-01-012023-12-31_custom_AllOtherStatesMember" id="Fact000918" format="ixt:numdotdecimal" decimals="0" unitRef="USD">726,478</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">$</td><td id="xdx_988_eus-gaap--Revenues_c20240101__20241231_z8xgf1LC4xKf" title="Revenues" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2024-01-01to2024-12-31" id="Fact000920" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,685,925</ix:nonFraction></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_986_eus-gaap--Revenues_c20230101__20231231_zCiswA2OlDda" title="Revenues" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2023-01-012023-12-31" id="Fact000922" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,460,049</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A0_zvTYoR5sc9Ua" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain
economic factors affect the nature, amount, timing, and uncertainty of the Company&#8217;s revenue and cash flows. All of the Company&#8217;s
products are sold to healthcare customers including hospitals and clinics. Sales to healthcare customers lack seasonality and have a
mild correlation with economic cycles. All of the Company&#8217;s sales are to customers located within the United States. Sales contracts
consist of purchase orders that are short-term (i.e., less than or equal to one year).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 105; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Neuraxis,
Inc.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Notes
to Financial Statements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company typically satisfies its performance obligations for goods at a point in time as they are received at the customer&#8217;s
destination (rather than over time). Goods are shipped by common carrier to customers under FOB destination terms. As such,
ownership of goods in transit is transferred to the customer upon receipt as the Company bears the associated risks (e.g., loss,
damage, delay). Management typically relies on shipping information from common carriers to evaluate when the
customer has obtained control of the goods. Shipping and handling costs are recorded as Cost of Goods Sold in the Statements of
Operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s contracts with customers typically do not involve variable consideration. The information that the Company uses to determine
the transaction price for a contract is similar to the information that the Company&#8217;s management uses in establishing the prices
of goods to be sold.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Orders
may not be cancelled after shipment. Customers may return devices within 10 days of delivery if the goods are found to be defective,
nonconforming, or otherwise do not meet the stated technical specifications. At the option of the customer, the Company shall either:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Refund
    the price paid for any defective or nonconforming products.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Supply
    and deliver to the customer replacement conforming products.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Reimburse
    the customer for the cost of repairing any defective or nonconforming products.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
the time revenue is recognized, the Company estimates expected returns and excludes those amounts from revenue. The Company also
maintains appropriate accounts to reflect the effects of expected returns on the Company&#8217;s financial position and periodically
adjusts those accounts to reflect its actual return experience. Estimated returns totaled</span> $<span id="xdx_908_eus-gaap--ContractWithCustomerLiabilityRevenueRecognized_c20240101__20241231_zBqEO4HnlF7c" title="Estimated returns of revenue"><ix:nonFraction name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" contextRef="From2024-01-01to2024-12-31" id="Fact000924" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,000</ix:nonFraction></span> and $<span id="xdx_90C_eus-gaap--ContractWithCustomerLiabilityRevenueRecognized_c20230101__20231231_zt5BroE5J4dl" title="Estimated returns of revenue"><ix:nonFraction name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" contextRef="From2023-01-012023-12-31" id="Fact000926" format="ixt:numdotdecimal" decimals="0" unitRef="USD">0</ix:nonFraction></span> as of December 31,
2024 and 2023, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Payment
for goods sold by the Company is typically due after an invoice is sent to the customer, within 30 days. The Company does not offer discounts
if the customer pays some or all of an invoiced amount prior to the due date. None of the Company&#8217;s contracts have a significant
financing component.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Medical
devices that the Company contracts to sell and transfer to customers are manufactured by one specific third-party manufacturer located
within the state of Indiana. In no case does the Company act as an agent (i.e., the Company does not provide a service of arranging for
another party to transfer goods to the customer).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 106; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Neuraxis,
Inc.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Notes
to Financial Statements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000928" name="us-gaap:LesseeLeasesPolicyTextBlock"><p id="xdx_846_eus-gaap--LesseeLeasesPolicyTextBlock_zFGApbXnaIf2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_862_zlz6TSsaBUBh">Leases</span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
accordance with Accounting Standards Updated (&#8220;ASU&#8221;) No. 2016-02, <i>Leases (Topic 842)</i> (&#8220;ASU 2016-02&#8221; or
&#8220;ASC 842&#8221;), at the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based
on the unique facts and circumstances present in the arrangement. Leases with a term greater than one year are recognized on the balance
sheet as right-of-use assets and current and non-current lease liabilities, as applicable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating
lease liabilities and their corresponding right-of-use assets are initially recorded based on the present value of lease payments over
the expected remaining lease term. Certain adjustments to the right-of-use asset may be required for items such as incentives received.
The interest rate implicit in lease contracts is typically not readily determinable. As a result, the Company utilizes its incremental
borrowing rate to discount lease payments, which reflects the fixed rate at which the Company could borrow on a collateralized basis
the amount of the lease payments in the same currency, for a similar term, in a similar economic environment. Prospectively, the Company
will adjust the right-of-use assets for straight-line rent expense, or any incentives received and remeasure the lease liability at the
net present value using the same incremental borrowing rate that was in effect as of the lease commencement or transition date. The Company
has elected not to recognize leases with an original term of one year or less on the balance sheet. The Company typically only includes
an initial lease term in its assessment of a lease arrangement. Options to renew a lease are not included in the Company&#8217;s assessment
unless there is reasonable certainty that the Company will renew.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Assumptions
made by the Company at the commencement date are re-evaluated upon occurrence of certain events, including a lease modification. A lease
modification results in a separate contract when the modification grants the lessee an additional right of use not included in the original
lease and when lease payments increase commensurate with the standalone price for the additional right of use. When a lease modification
results in a separate contract, it is accounted for in the same manner as a new lease.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Entities
may elect not to separate lease and non-lease components. The Company has elected to account for lease and non-lease components together
as a single lease component for all underlying assets and allocate all the contract consideration to the lease component only.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 107; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Neuraxis,
Inc.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Notes
to Financial Statements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000930" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"><p id="xdx_84C_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_zBrdlPiMtEtd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_864_z3HRppsuDOqc">Impairment
of Long-Lived Assets</span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Long-lived
assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset group may
not be recoverable. If events or changes in circumstances indicate that the carrying amount of an asset group may not be recoverable,
we compare the carrying amount of the asset group to future undiscounted net cash flows, excluding interest costs, expected to be generated
by the asset group and their ultimate disposition. If the sum of the undiscounted cash flows is less than the carrying value, the impairment
to be recognized is measured by the amount by which the carrying amount of the asset group exceeds the fair value of the asset group.
Assets to be disposed of are reported at the lower of the carrying amount or fair value, less costs to sell.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000932" name="us-gaap:ConcentrationRiskCreditRisk"><p id="xdx_84A_eus-gaap--ConcentrationRiskCreditRisk_znCEHkM7M1r6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_865_zp8VPiZFHkLc">Concentrations
of Credit Risk</span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s business activity consists of the sale of medical neuromodulation devices to doctors, clinics, and hospitals across
the country. Receivables consist of unsecured amounts due from customers. The table below sets forth the Company&#8217;s customers
that accounted for greater than 10% of its net accounts receivable for the years ended December 31, 2024 and 2023,
respectively.</span></p>

<ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000934" name="us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock"><p id="xdx_898_eus-gaap--SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_zUwJC7G3vMd4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span id="xdx_8BF_ziuviCdUkIG6" style="display: none">Schedule of Customer Accounts Receivable</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Percentage
    of Net Accounts</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Percentage
    of Net Accounts</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2024</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Receivable</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2023</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> Receivable</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 36%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Customer
    A</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>$</b></span></td><td id="xdx_98A_eus-gaap--AccountsReceivableNet_iI_c20241231__srt--MajorCustomersAxis__custom--CustomerAMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zGVtJHY4ngni" title="Net accounts receivable" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:AccountsReceivableNet" contextRef="AsOf2024-12-31_custom_CustomerAMember_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember" id="Fact000936" format="ixt:numdotdecimal" decimals="0" unitRef="USD">119,616</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20240101__20241231__srt--MajorCustomersAxis__custom--CustomerAMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_ztfwx0Pn3dvb" title="Risk percentage"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2024-01-012024-12-31_custom_CustomerAMember_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember" id="Fact000938" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">49</ix:nonFraction></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>$</b></span></td><td id="xdx_985_eus-gaap--AccountsReceivableNet_iI_c20231231__srt--MajorCustomersAxis__custom--CustomerAMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zKXzKALlmJz7" title="Net accounts receivable" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0940">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_901_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20231231__srt--MajorCustomersAxis__custom--CustomerAMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_z9o22JCbwIjb" title="Risk percentage"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2023-01-012023-12-31_custom_CustomerAMember_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember" id="Fact000942" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0</ix:nonFraction></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Customer
    B</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98C_eus-gaap--AccountsReceivableNet_iI_c20241231__srt--MajorCustomersAxis__custom--CustomerBMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zR77yBuhHffb" title="Net accounts receivable" style="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0944">-</span></span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_905_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20240101__20241231__srt--MajorCustomersAxis__custom--CustomerBMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_z9SVmlN18mH9" title="Risk percentage"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2024-01-012024-12-31_custom_CustomerBMember_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember" id="Fact000946" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0</ix:nonFraction></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98B_eus-gaap--AccountsReceivableNet_iI_c20231231__srt--MajorCustomersAxis__custom--CustomerBMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zDCakzXb5lvc" title="Net accounts receivable" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:AccountsReceivableNet" contextRef="AsOf2023-12-31_custom_CustomerBMember_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember" id="Fact000948" format="ixt:numdotdecimal" decimals="0" unitRef="USD">23,900</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20231231__srt--MajorCustomersAxis__custom--CustomerBMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zYReW668WMIf" title="Risk percentage"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2023-01-012023-12-31_custom_CustomerBMember_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember" id="Fact000950" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">28</ix:nonFraction></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Customer
    C</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_985_eus-gaap--AccountsReceivableNet_iI_c20241231__srt--MajorCustomersAxis__custom--CustomerCMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zECBJOkoPFzh" title="Net accounts receivable" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:AccountsReceivableNet" contextRef="AsOf2024-12-31_custom_CustomerCMember_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember" id="Fact000952" format="ixt:numdotdecimal" decimals="0" unitRef="USD">22,799</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_907_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20240101__20241231__srt--MajorCustomersAxis__custom--CustomerCMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zCoq7BCeaAUd" title="Risk percentage"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2024-01-012024-12-31_custom_CustomerCMember_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember" id="Fact000954" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">9</ix:nonFraction></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98A_eus-gaap--AccountsReceivableNet_iI_c20231231__srt--MajorCustomersAxis__custom--CustomerCMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zSmayTQpiaTa" title="Net accounts receivable" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:AccountsReceivableNet" contextRef="AsOf2023-12-31_custom_CustomerCMember_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember" id="Fact000956" format="ixt:numdotdecimal" decimals="0" unitRef="USD">14,401</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90D_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20231231__srt--MajorCustomersAxis__custom--CustomerCMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_z058r726xm0j" title="Risk percentage"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2023-01-012023-12-31_custom_CustomerCMember_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember" id="Fact000958" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">17</ix:nonFraction></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Customer
    D</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_989_eus-gaap--AccountsReceivableNet_iI_c20241231__srt--MajorCustomersAxis__custom--CustomerDMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_ziWgXs4rhsT5" title="Net accounts receivable" style="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0960">-</span></span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_905_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20240101__20241231__srt--MajorCustomersAxis__custom--CustomerDMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zSEvYV8lKLbh" title="Risk percentage"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2024-01-012024-12-31_custom_CustomerDMember_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember" id="Fact000962" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0</ix:nonFraction></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_987_eus-gaap--AccountsReceivableNet_iI_c20231231__srt--MajorCustomersAxis__custom--CustomerDMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zgOcWsNkjKF1" title="Net accounts receivable" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:AccountsReceivableNet" contextRef="AsOf2023-12-31_custom_CustomerDMember_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember" id="Fact000964" format="ixt:numdotdecimal" decimals="0" unitRef="USD">23,982</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_909_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20231231__srt--MajorCustomersAxis__custom--CustomerDMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zlZgVpBjp056" title="Risk percentage"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2023-01-012023-12-31_custom_CustomerDMember_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember" id="Fact000966" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">28</ix:nonFraction></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Customer
    E</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98E_eus-gaap--AccountsReceivableNet_iI_c20241231__srt--MajorCustomersAxis__custom--CustomerEMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zl2qNb56zJwh" title="Net accounts receivable" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0968">-</span></span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90F_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20240101__20241231__srt--MajorCustomersAxis__custom--CustomerEMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zqDT0bFj4H1k" title="Risk percentage"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2024-01-012024-12-31_custom_CustomerEMember_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember" id="Fact000970" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0</ix:nonFraction></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98E_eus-gaap--AccountsReceivableNet_iI_c20231231__srt--MajorCustomersAxis__custom--CustomerEMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zwaoP8QxF9Bf" title="Net accounts receivable" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:AccountsReceivableNet" contextRef="AsOf2023-12-31_custom_CustomerEMember_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember" id="Fact000972" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9,599</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_901_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20231231__srt--MajorCustomersAxis__custom--CustomerEMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zyXKzz43jjZf" title="Risk percentage"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2023-01-012023-12-31_custom_CustomerEMember_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember" id="Fact000974" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">11</ix:nonFraction></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>$</b></span></td><td id="xdx_986_eus-gaap--AccountsReceivableNet_iI_c20241231__srt--MajorCustomersAxis__custom--CustomerMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_z1Hroo9j0F5k" title="Net accounts receivable" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:AccountsReceivableNet" contextRef="AsOf2024-12-31_custom_CustomerMember_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember" id="Fact000976" format="ixt:numdotdecimal" decimals="0" unitRef="USD">142,415</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_902_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20240101__20241231__srt--MajorCustomersAxis__custom--CustomerMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zvYJPTm3tgrf" title="Risk percentage"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2024-01-012024-12-31_custom_CustomerMember_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember" id="Fact000978" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">58</ix:nonFraction></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>$</b></span></td><td id="xdx_98E_eus-gaap--AccountsReceivableNet_iI_c20231231__srt--MajorCustomersAxis__custom--CustomerMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_z3M4Bf5OFDta" title="Net accounts receivable" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:AccountsReceivableNet" contextRef="AsOf2023-12-31_custom_CustomerMember_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember" id="Fact000980" format="ixt:numdotdecimal" decimals="0" unitRef="USD">71,882</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_906_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20231231__srt--MajorCustomersAxis__custom--CustomerMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zHYTFLfnmKr" title="Risk percentage"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2023-01-012023-12-31_custom_CustomerMember_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember" id="Fact000982" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">84</ix:nonFraction></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr>
  </table>
</ix:nonNumeric><p id="xdx_8AC_zCXEfpOPYya" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
table below sets forth the Company&#8217;s customers that accounted for greater than 10% of its net sales for the years ended
December 31, 2024 and 2023, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000984" name="us-gaap:ContractWithCustomerAssetAllowanceForCreditLossTableTextBlock"><p id="xdx_896_eus-gaap--ContractWithCustomerAssetAllowanceForCreditLossTableTextBlock_zkkwaR2En4R4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span id="xdx_8BA_z9EQpd6TmZ1d" style="display: none">Schedule of Customers Accounted Revenues</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Percentage of</td><td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Percentage of</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Net Sales</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Net Sales</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 36%; text-align: left">Customer A</td><td style="width: 2%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">$</td><td id="xdx_98B_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20240101__20241231__srt--MajorCustomersAxis__custom--CustomerAMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zhKwbiXDFFs3" title="Revenue" style="width: 12%; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2024-01-012024-12-31_custom_CustomerAMember_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember" id="Fact000986" format="ixt:numdotdecimal" decimals="0" unitRef="USD">521,810</ix:nonFraction></td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right"><span id="xdx_903_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20240101__20241231__srt--MajorCustomersAxis__custom--CustomerAMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zklF9jeBuOtg" title="Risk percentage"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2024-01-012024-12-31_custom_CustomerAMember_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember" id="Fact000988" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">20</ix:nonFraction></span></td><td style="width: 1%; text-align: left">%</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_986_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20230101__20231231__srt--MajorCustomersAxis__custom--CustomerAMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zHFwu8jqdfzh" title="Revenue" style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2023-01-012023-12-31_custom_CustomerAMember_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember" id="Fact000990" format="ixt:numdotdecimal" decimals="0" unitRef="USD">452,680</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right"><span id="xdx_908_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20231231__srt--MajorCustomersAxis__custom--CustomerAMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zUGo6Jpa5fgl" title="Risk percentage"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2023-01-012023-12-31_custom_CustomerAMember_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember" id="Fact000992" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">18</ix:nonFraction></span></td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Customer B</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20240101__20241231__srt--MajorCustomersAxis__custom--CustomerBMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zbvEOGjsePt8" title="Revenue" style="font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2024-01-012024-12-31_custom_CustomerBMember_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember" id="Fact000994" format="ixt:numdotdecimal" decimals="0" unitRef="USD">396,950</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90C_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20240101__20241231__srt--MajorCustomersAxis__custom--CustomerBMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_z6L6EIm7A9m7" title="Risk percentage"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2024-01-012024-12-31_custom_CustomerBMember_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember" id="Fact000996" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">15</ix:nonFraction></span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20230101__20231231__srt--MajorCustomersAxis__custom--CustomerBMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zLhqQLg76db" title="Revenue" style="text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2023-01-012023-12-31_custom_CustomerBMember_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember" id="Fact000998" format="ixt:numdotdecimal" decimals="0" unitRef="USD">382,082</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_909_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20231231__srt--MajorCustomersAxis__custom--CustomerBMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zACbxoOC2pSe" title="Risk percentage"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2023-01-012023-12-31_custom_CustomerBMember_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember" id="Fact001000" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">16</ix:nonFraction></span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Customer C</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20240101__20241231__srt--MajorCustomersAxis__custom--CustomerCMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zswU6SLkue39" title="Revenue" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2024-01-012024-12-31_custom_CustomerCMember_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember" id="Fact001002" format="ixt:numdotdecimal" decimals="0" unitRef="USD">142,270</ix:nonFraction></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_904_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20240101__20241231__srt--MajorCustomersAxis__custom--CustomerCMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_z2crm1yRVs5d" title="Risk percentage"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2024-01-012024-12-31_custom_CustomerCMember_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember" id="Fact001004" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">5</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left">%</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20230101__20231231__srt--MajorCustomersAxis__custom--CustomerCMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zWVmxOqlJMFc" title="Revenue" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2023-01-012023-12-31_custom_CustomerCMember_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember" id="Fact001006" format="ixt:numdotdecimal" decimals="0" unitRef="USD">274,581</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_906_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20231231__srt--MajorCustomersAxis__custom--CustomerCMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zs8Tc7rodGKf" title="Risk percentage"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2023-01-012023-12-31_custom_CustomerCMember_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember" id="Fact001008" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">11</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">$</td><td id="xdx_989_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20240101__20241231__srt--MajorCustomersAxis__custom--CustomerMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zpQ98lLEyvZa" title="Revenue" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2024-01-012024-12-31_custom_CustomerMember_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember" id="Fact001010" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,061,030</ix:nonFraction></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_90E_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20240101__20241231__srt--MajorCustomersAxis__custom--CustomerMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zLqb9DZOwDyh" title="Risk percentage"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2024-01-012024-12-31_custom_CustomerMember_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember" id="Fact001012" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">40</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left">%</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_98E_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20230101__20231231__srt--MajorCustomersAxis__custom--CustomerMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zuCpenm53Myd" title="Revenue" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2023-01-012023-12-31_custom_CustomerMember_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember" id="Fact001014" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,109,343</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_909_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20231231__srt--MajorCustomersAxis__custom--CustomerMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zV0CREuaTTec" title="Risk percentage"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2023-01-012023-12-31_custom_CustomerMember_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember" id="Fact001016" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">45</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left">%</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A8_zQMCLDFvtWn5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">From
time to time, the Company&#8217;s bank balances may exceed the FDIC limit of $<span id="xdx_901_eus-gaap--CashFDICInsuredAmount_iI_c20241231_zo5mHRQzxyD1" title="Cash, FDIC insured amount"><ix:nonFraction name="us-gaap:CashFDICInsuredAmount" contextRef="AsOf2024-12-31" id="Fact001018" format="ixt:numdotdecimal" decimals="0" unitRef="USD">250,000</ix:nonFraction></span>.
As of December 31, 2024 and 2023, the Company had $<span id="xdx_901_eus-gaap--CashUninsuredAmount_iI_c20241231_zJJUkOAzfSya" title="Cash uninsured"><ix:nonFraction name="us-gaap:CashUninsuredAmount" contextRef="AsOf2024-12-31" id="Fact001020" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,263,618</ix:nonFraction></span>
and $<span id="xdx_909_eus-gaap--CashUninsuredAmount_iI_c20231231_zQEDtlFPjsD" title="Cash uninsured"><ix:nonFraction name="us-gaap:CashUninsuredAmount" contextRef="AsOf2023-12-31" id="Fact001022" format="ixt:numdotdecimal" decimals="0" unitRef="USD">0</ix:nonFraction></span> of its cash balance
uninsured, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact001024" name="NRXS:GoingConcernPolicyTextBlock"><p id="xdx_84E_ecustom--GoingConcernPolicyTextBlock_zs8TSICVHdrc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_864_z7ogNBVMc5Kh">Going
Concern</span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have incurred losses since inception and have funded our operations primarily with a combination of sales, debt, and the sale of capital
stock. As of December 31, 2024, we had stockholders&#8217; equity of $<span id="xdx_908_eus-gaap--StockholdersEquity_iI_c20241231_zcrwDhOD4KL9" title="Stockholders' equity"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-12-31" id="Fact001026" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,067,748</ix:nonFraction></span>, short-term outstanding borrowings of $<span id="xdx_901_eus-gaap--ShortTermBorrowings_iI_c20241231_zcj9tEASlJp6" title="Short term borrowings outstanding"><ix:nonFraction name="us-gaap:ShortTermBorrowings" contextRef="AsOf2024-12-31" id="Fact001028" format="ixt:numdotdecimal" decimals="0" unitRef="USD">154,152</ix:nonFraction></span>, cash
of $<span id="xdx_909_eus-gaap--Cash_iI_c20241231_zqeGWmRH93nf" title="Cash"><ix:nonFraction name="us-gaap:Cash" contextRef="AsOf2024-12-31" id="Fact001030" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,696,870</ix:nonFraction></span> and a working capital surplus of $<span id="xdx_907_ecustom--WorkingCapitalDeficit_iI_c20241231_zeQGhPzPxHu3" title="Working capital surplus"><ix:nonFraction name="NRXS:WorkingCapitalDeficit" contextRef="AsOf2024-12-31" id="Fact001032" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,832,858</ix:nonFraction></span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 108; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Neuraxis,
Inc.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Notes
to Financial Statements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
future capital requirements will depend upon many factors, including progress with developing, manufacturing, and marketing our technologies,
the time and costs involved in preparing, filing, prosecuting, maintaining, and enforcing patent claims and other proprietary rights,
our ability to establish collaborative arrangements, marketing activities and competing technological and market developments, including
regulatory changes and overall economic conditions in our target markets. Our ability to generate revenue and achieve profitability requires
us to successfully market and secure purchase orders for our products from customers currently identified in our sales pipeline and to
new customers as well. The primary activity that will drive all customers and revenues is the adoption of insurance coverage by commercial
insurance carriers nationally which is a top priority of the Company. These activities, including our planned research and development
efforts, will require significant uses of working capital through the rest of 2025 and beyond. Based on our current operating plans,
we believe that our existing cash at the time of this filing will only be sufficient to meet our anticipated operating needs before the
end of 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management
evaluates whether there are conditions or events that raise substantial doubt about the Company&#8217;s ability to continue as a going
concern for a period of one year from the date the financial statements are issued.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
date, the Company has experienced operating losses and negative cash flows from operations. Management believes that increased sales
and acceptance of their product by insurance providers will allow the Company to achieve profitability in the future.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">While
the Company believes in the viability of its strategy to further implement its business plan and generate sufficient revenues and in
its ability to raise additional funds by way of a public or private offering of its debt or equity securities, there can be no assurance
that it will be able to do so on reasonable terms, or at all. The ability of the Company to continue as a going concern is dependent
upon its ability to further implement its business plan and generate sufficient revenues and its ability to raise additional funds by
way of a public or private offering. Neither future cash generated from operating activities, nor management&#8217;s contingency plans
to mitigate the risk and extend cash resources through the evaluation period, are considered probable. As a result, substantial doubt
is deemed to exist about the Company&#8217;s ability to continue as a going concern. As we continue to incur losses, our transition to
profitability is dependent upon achieving a level of revenues adequate to support its cost structure. We may never achieve profitability,
and unless and until doing so, we intend to fund future operations through additional dilutive or nondilutive financing. There can be
no assurances, however, that additional funding will be available on terms acceptable to us, if at all.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
financial statements do not include any adjustments related to the recoverability and classification of recorded asset amounts or the
amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact001034" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock"><p id="xdx_84D_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zcEfnqT2G8F2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_862_zHoVgdNJrcdl">Recently
Adopted Accounting Pronouncements</span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
November 2023, the FASB issued Accounting Standards Update (&#8220;ASU&#8221;) 2023-07, <i>Segment Reporting (Topic 280): Improvements
to Reportable Segment Disclosures</i>, which requires disclosure of (i) significant segment expenses, (ii) other segment items and (iii)
the title and position of the Chief Operating Decision Maker (&#8220;CODM&#8221;) on an annual and interim basis. Additionally, ASU 2023-07
requires that a public entity that has a single reportable segment provide all the disclosures required by Topic 280. Public business
entities are required to adopt the standard for fiscal years beginning after December 15, 2023 and interim periods withing fiscal year
beginning after December 15, 2024. Disclosures are required for all prior periods presented in the financial statements. The Company
adopted the disclosure provisions of ASU 2023-07 as of December 31, 2024 as operations are managed through one reportable segment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:exclude><!-- Field: Page; Sequence: 109; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
June 2016, the FASB issued ASU 2016-13, <i>Financial Instruments &#8211; Credit Losses (Topic 326): Measurement of Credit Losses on Financial
Instruments</i>, which requires measurement and recognition of expected credit losses for financial assets held and enhanced disclosures
regarding significant estimates and judgments used in estimating credit losses. In November 2019, the FASB issued ASU 2019-10, Financial
Instruments &#8211; Credit Losses (Topic 326), Derivatives and Hedging (Topic 815) and Leases (Topic 842): Effective Dates, which amended
the effective date of ASU 2016-13. Public business entities meeting the definition of an SEC filer, excluding entities eligible to be
a Smaller Reporting Company (&#8220;SRC&#8221;) as defined by the SEC, are required to adopt the standard for fiscal years beginning
after December 15, 2019, including interim periods within those fiscal years. All other entities are required to adopt the standard for
fiscal years beginning after December 15, 2022, including interim periods within those fiscal years. The Company meets the definition
of an SRC and therefore the standard was adopted as of January 1, 2023. The adoption of this guidance did not have a material impact
on the Company&#8217;s financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact001036" name="NRXS:RecentlyIssuedAccountingPronouncementsPolicyTextBlock"><p id="xdx_840_ecustom--RecentlyIssuedAccountingPronouncementsPolicyTextBlock_zjKjcdN7Te33" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_86A_zxIiHNzeegpc">Recently
Issued Accounting Pronouncements</span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
November 2024, the FASB issued ASU 2024-03, <i>Income Statement&#8212;Reporting Comprehensive Income&#8212;Expense Disaggregation Disclosures
(Subtopic (220-40): Disaggregation of Income Statement Expenses</i>, which requires disclosures that disaggregate, in a tabular presentation,
each relevant expense caption on the face of the income statement that includes inventory purchases, employee compensation, depreciation
and intangible amortization expense. Additional disclosures are also required to provide a qualitative description of the amounts in
an expense caption that are not separately disaggregated quantitatively and the total amount of selling expenses including a definition.
Public business entities are required to adopt the standard for fiscal years beginning after December 15, 2026 and interim periods within
fiscal years beginning after December 15, 2027. Disclosures are required for all prior periods presented in the financial statements.
Although the standard requires enhanced disclosures, the adoption is not expected to have a material impact on the Company&#8217;s financial
statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
December 2023, the FASB issued ASU 2023-09, <i>Income Taxes (Topic 740): Improvements to Income Tax Disclosures</i>, which requires the
enhancement of income tax disclosures to provide better insight into how an entity&#8217;s operations and related tax risks, planning
and opportunities affect its tax rate and prospects for future cash flows. The enhanced disclosures require (i) specific categories in
a tabular rate reconciliation including both amounts and percentages and (ii) additional information for reconciling items and income
tax paid that meet a quantitative threshold. Public business entities are required to adopt the standard for annual periods beginning
after December 15, 2024. All other entities are required to adopt the standard for annual periods beginning after December 15, 2025.
The adoption of the standard is not expected to have a material impact on the Company&#8217;s financial statements.</span></p>

</ix:nonNumeric><p id="xdx_85C_zHvhrIrV3o8d" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:exclude><!-- Field: Page; Sequence: 110; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Neuraxis,
Inc.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Notes
to Financial Statements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact001038" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock"><p id="xdx_80E_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_zw3qdvYP29ce" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>3.
<span id="xdx_823_zxseoGpv3kuf">Related Party Transactions</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has two demand notes receivable from shareholders related to the sale of common stock on January 1, 2016. Both notes&#8217; initial
balances were $<span id="xdx_90D_eus-gaap--NotesAndLoansReceivableGrossCurrent_iI_c20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ShareholdersOneAndTwoMember_zYT7P04QrYh9" title="Loan Receivable"><ix:nonFraction name="us-gaap:NotesAndLoansReceivableGrossCurrent" contextRef="AsOf2024-12-31_custom_ShareholdersOneAndTwoMember" id="Fact001040" format="ixt:numdotdecimal" decimals="0" unitRef="USD">506,400</ix:nonFraction></span>, with interest calculated monthly based on applicable federal rates. No payments have been received on the notes.
Since repayment is not assured, the Company has fully reserved for the entire balance of principal and interest. The current allowance
is $<span id="xdx_90D_ecustom--AllowanceForInterestReceivableCurrent_iI_c20241231_zKAxBF9ZSgWc" title="Allowance for interest receivable current"><ix:nonFraction name="NRXS:AllowanceForInterestReceivableCurrent" contextRef="AsOf2024-12-31" id="Fact001042" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,201,367</ix:nonFraction></span> as of December 31, 2024. The current loan balances are as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact001044" name="us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock"><p id="xdx_89C_eus-gaap--ScheduleOfRelatedPartyTransactionsTableTextBlock_zOv4aX3fMcwj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span><span id="xdx_8B6_zby8DV48UlMe" style="display: none">Schedule of Related Party Transactions</span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Loan</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Interest</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Interest</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-weight: bold">December 31, 2024</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Receivable</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Receivable</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Income</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%">Shareholder 1</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_984_eus-gaap--NotesAndLoansReceivableGrossCurrent_iI_c20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ShareHolderOneMember_zWFF6fDKgOOh" title="Loan Receivable" style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:NotesAndLoansReceivableGrossCurrent" contextRef="AsOf2024-12-31_custom_ShareHolderOneMember" id="Fact001046" format="ixt:numdotdecimal" decimals="0" unitRef="USD">506,400</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--InterestReceivableCurrent_iI_c20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ShareHolderOneMember_zhO2kKTUPrH7" title="Interest Receivable" style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:InterestReceivableCurrent" contextRef="AsOf2024-12-31_custom_ShareHolderOneMember" id="Fact001048" format="ixt:numdotdecimal" decimals="0" unitRef="USD">94,351</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_986_ecustom--InterestIncomeGrossCurrent_iI_c20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ShareHolderOneMember_zGv6Q28DbLFb" title="Interest Income" style="width: 12%; text-align: right"><ix:nonFraction name="NRXS:InterestIncomeGrossCurrent" contextRef="AsOf2024-12-31_custom_ShareHolderOneMember" id="Fact001050" format="ixt:numdotdecimal" decimals="0" unitRef="USD">23,413</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt">Shareholder 2</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--NotesAndLoansReceivableGrossCurrent_iI_c20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ShareHolderTwoMember_zk0nJ4TbCeT6" title="Loan Receivable" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:NotesAndLoansReceivableGrossCurrent" contextRef="AsOf2024-12-31_custom_ShareHolderTwoMember" id="Fact001052" format="ixt:numdotdecimal" decimals="0" unitRef="USD">506,400</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--InterestReceivableCurrent_iI_c20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ShareHolderTwoMember_zvYvtR6VyOQ5" title="Interest Receivable" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:InterestReceivableCurrent" contextRef="AsOf2024-12-31_custom_ShareHolderTwoMember" id="Fact001054" format="ixt:numdotdecimal" decimals="0" unitRef="USD">94,216</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_985_ecustom--InterestIncomeGrossCurrent_iI_c20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ShareHolderTwoMember_zDlrgzmboFb6" title="Interest Income" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="NRXS:InterestIncomeGrossCurrent" contextRef="AsOf2024-12-31_custom_ShareHolderTwoMember" id="Fact001056" format="ixt:numdotdecimal" decimals="0" unitRef="USD">23,413</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt">Principal Balance</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--NotesAndLoansReceivableGrossCurrent_iI_c20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_ztUVY7XqRxSd" title="Loan Receivable" style="text-align: right"><ix:nonFraction name="us-gaap:NotesAndLoansReceivableGrossCurrent" contextRef="AsOf2024-12-31_us-gaap_RelatedPartyMember" id="Fact001058" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,012,800</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--InterestReceivableCurrent_iI_c20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zjTDLXBg8xha" title="Interest Receivable" style="text-align: right"><ix:nonFraction name="us-gaap:InterestReceivableCurrent" contextRef="AsOf2024-12-31_us-gaap_RelatedPartyMember" id="Fact001060" format="ixt:numdotdecimal" decimals="0" unitRef="USD">188,567</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_ecustom--InterestIncomeGrossCurrent_iI_c20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zCgEEzRhYDy" title="Interest Income" style="text-align: right"><ix:nonFraction name="NRXS:InterestIncomeGrossCurrent" contextRef="AsOf2024-12-31_us-gaap_RelatedPartyMember" id="Fact001062" format="ixt:numdotdecimal" decimals="0" unitRef="USD">46,826</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Allowance for Collection Risk</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--AllowanceForNotesAndLoansReceivableCurrent_iNI_di_c20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zfyohD0vh37l" title="Allowance for collection risk, loan receivable" style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:AllowanceForNotesAndLoansReceivableCurrent" contextRef="AsOf2024-12-31_us-gaap_RelatedPartyMember" id="Fact001064" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,012,800</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98D_ecustom--AllowanceForInterestReceivableCurrent_iI_c20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zVYzxHfKGjzl" title="Allowance for collection risk, interest receivable" style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="NRXS:AllowanceForInterestReceivableCurrent" contextRef="AsOf2024-12-31_us-gaap_RelatedPartyMember" id="Fact001066" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">188,567</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_988_ecustom--AllowanceForInterestIncomeCurrent_iNI_di_c20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zzOQmVoFft9" title="Allowance for collection risk, interest income" style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="NRXS:AllowanceForInterestIncomeCurrent" contextRef="AsOf2024-12-31_us-gaap_RelatedPartyMember" id="Fact001068" format="ixt:numdotdecimal" decimals="0" unitRef="USD">46,826</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Net Balance</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_98B_eus-gaap--NotesAndLoansReceivableNetCurrent_iI_c20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zWhNsIQX3dT1" title="Loan Receivable" style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1070">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_989_eus-gaap--InterestReceivable_iI_c20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zYN9wmZutSp4" title="Interest Receivable" style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1072">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_98E_ecustom--InterestIncomeCurrent_iI_c20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zJz5EcU2SFMh" title="Interest Income" style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1074">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Loan</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Interest</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Interest</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-weight: bold">December 31, 2023</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Receivable</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Receivable</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Income</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%">Shareholder 1</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--NotesAndLoansReceivableGrossCurrent_iI_c20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ShareHolderOneMember_zWSabdjGXQL1" title="Loan Receivable" style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:NotesAndLoansReceivableGrossCurrent" contextRef="AsOf2023-12-31_custom_ShareHolderOneMember" id="Fact001076" format="ixt:numdotdecimal" decimals="0" unitRef="USD">506,400</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_988_eus-gaap--InterestReceivableCurrent_iI_c20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ShareHolderOneMember_zDPEXZk6ETm2" title="Interest Receivable" style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:InterestReceivableCurrent" contextRef="AsOf2023-12-31_custom_ShareHolderOneMember" id="Fact001078" format="ixt:numdotdecimal" decimals="0" unitRef="USD">70,938</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_982_ecustom--InterestIncomeGrossCurrent_iI_c20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ShareHolderOneMember_zY8vYDQbfVG3" title="Interest Income" style="width: 12%; text-align: right"><ix:nonFraction name="NRXS:InterestIncomeGrossCurrent" contextRef="AsOf2023-12-31_custom_ShareHolderOneMember" id="Fact001080" format="ixt:numdotdecimal" decimals="0" unitRef="USD">23,867</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt">Shareholder 2</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--NotesAndLoansReceivableGrossCurrent_iI_c20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ShareHolderTwoMember_zeI6ZkI1sNy" title="Loan Receivable" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:NotesAndLoansReceivableGrossCurrent" contextRef="AsOf2023-12-31_custom_ShareHolderTwoMember" id="Fact001082" format="ixt:numdotdecimal" decimals="0" unitRef="USD">506,400</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--InterestReceivableCurrent_iI_c20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ShareHolderTwoMember_zGzV0Q4plaJ9" title="Interest Receivable" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:InterestReceivableCurrent" contextRef="AsOf2023-12-31_custom_ShareHolderTwoMember" id="Fact001084" format="ixt:numdotdecimal" decimals="0" unitRef="USD">70,803</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_981_ecustom--InterestIncomeGrossCurrent_iI_c20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ShareHolderTwoMember_zvRaHSTC4382" title="Interest Income" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="NRXS:InterestIncomeGrossCurrent" contextRef="AsOf2023-12-31_custom_ShareHolderTwoMember" id="Fact001086" format="ixt:numdotdecimal" decimals="0" unitRef="USD">23,867</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt">Principal Balance</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--NotesAndLoansReceivableGrossCurrent_iI_c20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zQi2kWkjffrh" title="Loan Receivable" style="text-align: right"><ix:nonFraction name="us-gaap:NotesAndLoansReceivableGrossCurrent" contextRef="AsOf2023-12-31_us-gaap_RelatedPartyMember" id="Fact001088" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,012,800</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--InterestReceivableCurrent_iI_c20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zKHhhwuk6iJ8" title="Interest Receivable" style="text-align: right"><ix:nonFraction name="us-gaap:InterestReceivableCurrent" contextRef="AsOf2023-12-31_us-gaap_RelatedPartyMember" id="Fact001090" format="ixt:numdotdecimal" decimals="0" unitRef="USD">141,741</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_ecustom--InterestIncomeGrossCurrent_iI_c20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zosHxJYGrgxj" title="Interest Income" style="text-align: right"><ix:nonFraction name="NRXS:InterestIncomeGrossCurrent" contextRef="AsOf2023-12-31_us-gaap_RelatedPartyMember" id="Fact001092" format="ixt:numdotdecimal" decimals="0" unitRef="USD">47,734</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Allowance for Collection Risk</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--AllowanceForNotesAndLoansReceivableCurrent_iNI_di_c20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zfx5avVhZnK4" title="Allowance for collection risk, loan receivable" style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:AllowanceForNotesAndLoansReceivableCurrent" contextRef="AsOf2023-12-31_us-gaap_RelatedPartyMember" id="Fact001094" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,012,800</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98A_ecustom--AllowanceForInterestReceivableCurrent_iI_c20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_z3W1QciT6pS" title="Allowance for collection risk, interest receivable" style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="NRXS:AllowanceForInterestReceivableCurrent" contextRef="AsOf2023-12-31_us-gaap_RelatedPartyMember" id="Fact001096" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">141,741</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98A_ecustom--AllowanceForInterestIncomeCurrent_iNI_di_c20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zIEXyFnrGwx3" title="Allowance for collection risk, interest income" style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="NRXS:AllowanceForInterestIncomeCurrent" contextRef="AsOf2023-12-31_us-gaap_RelatedPartyMember" id="Fact001098" format="ixt:numdotdecimal" decimals="0" unitRef="USD">47,734</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Net Balance</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_98E_eus-gaap--NotesAndLoansReceivableNetCurrent_iI_c20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zhXSahQJ7MP1" title="Loan Receivable" style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1100">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_98E_eus-gaap--InterestReceivable_iI_c20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zuNWYHRuzlIg" title="Interest Receivable" style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1102">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_98D_ecustom--InterestIncomeCurrent_iI_c20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_z4gJ4dE3iUN2" title="Interest Income" style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1104">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A4_zeWOMVKmkwK1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has loans payable to shareholders related to funding needs for operations. The current loan details for all related party loans
are as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact001106" name="NRXS:ScheduleOfRelatedPartyLoansTableTextBlock"><p id="xdx_891_ecustom--ScheduleOfRelatedPartyLoansTableTextBlock_zYPySHBVmcS7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B0_zf8TjuMlvU4c" style="display: none">Schedule of Related Party Loans payable to shareholder</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Interest &amp;</td><td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Interest</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Loan</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Service Fee</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Interest</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-weight: bold">December 31, 2024</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Due Date</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Rate</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Balance</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Accrued</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Paid</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 30%; text-align: left; padding-bottom: 1pt">Other Convertibles</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="width: 12%; text-align: center; padding-bottom: 1pt"><span id="xdx_90D_eus-gaap--DebtInstrumentMaturityDateDescription_c20240101__20241231__us-gaap--DebtInstrumentAxis__custom--OtherConvertiblesMember_ztlLQ0Sr0av9" title="Due date"><ix:nonNumeric contextRef="From2024-01-012024-12-31_custom_OtherConvertiblesMember" id="Fact001108" name="us-gaap:DebtInstrumentMaturityDateDescription">Various</ix:nonNumeric></span></td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; width: 1%; text-align: left">&#160;</td><td style="padding-bottom: 1pt; width: 10%; text-align: center"><span id="xdx_908_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_dp_uPure_c20241231__us-gaap--DebtInstrumentAxis__custom--OtherConvertiblesMember_zqSoAz84D45j" title="Debt instrument percentage"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextRef="AsOf2024-12-31_custom_OtherConvertiblesMember" id="Fact001110" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">5.0</ix:nonFraction></span>%</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--LoansPayable_iI_c20241231__us-gaap--DebtInstrumentAxis__custom--OtherConvertiblesMember_zWABE9Cu0pab" title="Interest payable" style="border-bottom: Black 1pt solid; width: 10%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1112">&#8212;</span></td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">&#160;</td><td id="xdx_983_ecustom--InterestAndServiceFeeAccrued_iI_c20241231__us-gaap--DebtInstrumentAxis__custom--OtherConvertiblesMember_zfhfCYXJY2w2" title="Interest payable" style="border-bottom: Black 1pt solid; width: 10%; text-align: right"><ix:nonFraction name="NRXS:InterestAndServiceFeeAccrued" contextRef="AsOf2024-12-31_custom_OtherConvertiblesMember" id="Fact001114" format="ixt:numdotdecimal" decimals="0" unitRef="USD">66,648</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--InterestPaid_c20240101__20241231__us-gaap--DebtInstrumentAxis__custom--OtherConvertiblesMember_z57rRBACUFUg" title="Interest payable" style="border-bottom: Black 1pt solid; width: 10%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1116">&#8212;</span></td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; font-weight: bold; padding-bottom: 1pt">Total</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_98C_eus-gaap--LoansPayable_iI_c20241231_zPLJkVYOokw9" title="Loan payable" style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1118">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_984_ecustom--InterestAndServiceFeeAccrued_iI_c20241231_zuHlAygaJSw6" title="Interest payable" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="NRXS:InterestAndServiceFeeAccrued" contextRef="AsOf2024-12-31" id="Fact001120" format="ixt:numdotdecimal" decimals="0" unitRef="USD">66,648</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_981_eus-gaap--InterestPaid_c20240101__20241231_z8Wm1dCWuYgg" title="Interest payable" style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1122">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Interest &amp;</td><td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Interest</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Loan</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Service Fee</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Interest</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-weight: bold">December 31, 2023</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Due Date</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Rate</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Balance</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Accrued</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Paid</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 30%">Shareholder 1</td><td style="width: 2%">&#160;</td>
    <td style="width: 12%; text-align: center"><span id="xdx_90B_eus-gaap--DebtInstrumentMaturityDateDescription_c20230101__20231231__us-gaap--DebtInstrumentAxis__custom--ShareHolderOneMember_zD7Nd8CcgBnk" title="Due date"><ix:nonNumeric contextRef="From2023-01-012023-12-31_custom_ShareHolderOneMember" id="Fact001124" name="us-gaap:DebtInstrumentMaturityDateDescription">June, 2019</ix:nonNumeric></span></td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 10%; text-align: center"><span id="xdx_90A_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_dp_uPure_c20231231__us-gaap--DebtInstrumentAxis__custom--ShareHolderOneMember_zLgE9AFgTgab" title="Debt instrument percentage"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextRef="AsOf2023-12-31_custom_ShareHolderOneMember47707859" id="Fact001126" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">15.0</ix:nonFraction></span>%</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_eus-gaap--LoansPayable_iI_c20231231__us-gaap--DebtInstrumentAxis__custom--ShareHolderOneMember_zN3dNK2VXGv6" title="Loan payable" style="width: 10%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1128">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_983_ecustom--InterestAndServiceFeeAccrued_iI_c20231231__us-gaap--DebtInstrumentAxis__custom--ShareHolderOneMember_zFgriPhYsCj9" title="Interest payable" style="width: 10%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1130">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--InterestPaid_c20230101__20231231__us-gaap--DebtInstrumentAxis__custom--ShareHolderOneMember_zQME5pjAHsJ8" title="Interest payable" style="width: 10%; text-align: right"><ix:nonFraction name="us-gaap:InterestPaid" contextRef="From2023-01-012023-12-31_custom_ShareHolderOneMember" id="Fact001132" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,047</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Shareholder 2</td><td>&#160;</td>
    <td style="text-align: center"><span id="xdx_902_eus-gaap--DebtInstrumentMaturityDateDescription_c20230101__20231231__us-gaap--DebtInstrumentAxis__custom--ShareHolderTwoMember_zpH8ZXwFTij3" title="Due date"><ix:nonNumeric contextRef="From2023-01-012023-12-31_custom_ShareHolderTwoMember" id="Fact001134" name="us-gaap:DebtInstrumentMaturityDateDescription">June, 2019</ix:nonNumeric></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center"><span id="xdx_903_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_dp_uPure_c20231231__us-gaap--DebtInstrumentAxis__custom--ShareHolderTwoMember_zf0NRnHbYLxf" title="Debt instrument percentage"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextRef="AsOf2023-12-31_custom_ShareHolderTwoMember47707859" id="Fact001136" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">15.0</ix:nonFraction></span>%</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--LoansPayable_iI_c20231231__us-gaap--DebtInstrumentAxis__custom--ShareHolderTwoMember_zqeyWtHDawre" title="Loan payable" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1138">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_ecustom--InterestAndServiceFeeAccrued_iI_c20231231__us-gaap--DebtInstrumentAxis__custom--ShareHolderTwoMember_zwizrWGlHZB" title="Interest payable" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1140">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--InterestPaid_c20230101__20231231__us-gaap--DebtInstrumentAxis__custom--ShareHolderTwoMember_zqcl1NyjQVI5" title="Interest payable" style="text-align: right"><ix:nonFraction name="us-gaap:InterestPaid" contextRef="From2023-01-012023-12-31_custom_ShareHolderTwoMember" id="Fact001142" format="ixt:numdotdecimal" decimals="0" unitRef="USD">27,056</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Other Convertibles</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1pt"><span id="xdx_90B_eus-gaap--DebtInstrumentMaturityDateDescription_c20230101__20231231__us-gaap--DebtInstrumentAxis__custom--OtherConvertiblesMember_zdURnn0ve00d" title="Due date"><ix:nonNumeric contextRef="From2023-01-012023-12-31_custom_OtherConvertiblesMember" id="Fact001144" name="us-gaap:DebtInstrumentMaturityDateDescription">Various</ix:nonNumeric></span></td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: center"><span id="xdx_90E_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_dp_uPure_c20231231__us-gaap--DebtInstrumentAxis__custom--OtherConvertiblesMember_zHHONbcvNHPk" title="Debt instrument percentage"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextRef="AsOf2023-12-31_custom_OtherConvertiblesMember" id="Fact001146" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">5.0</ix:nonFraction></span>%</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--LoansPayable_iI_c20231231__us-gaap--DebtInstrumentAxis__custom--OtherConvertiblesMember_zsriqlzXJhOg" title="Interest payable" style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1148">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98B_ecustom--InterestAndServiceFeeAccrued_iI_c20231231__us-gaap--DebtInstrumentAxis__custom--OtherConvertiblesMember_zteqJglcLHv9" title="Interest payable" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="NRXS:InterestAndServiceFeeAccrued" contextRef="AsOf2023-12-31_custom_OtherConvertiblesMember" id="Fact001150" format="ixt:numdotdecimal" decimals="0" unitRef="USD">66,648</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--InterestPaid_c20230101__20231231__us-gaap--DebtInstrumentAxis__custom--OtherConvertiblesMember_zdCzgHVG7OMf" title="Interest payable" style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1152">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; font-weight: bold; padding-bottom: 1pt">Total</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_985_eus-gaap--LoansPayable_iI_c20231231_z7ORZjjvl3zc" title="Loan payable" style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1154">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_98E_ecustom--InterestAndServiceFeeAccrued_iI_c20231231_zk4ROeNOQu59" title="Interest payable" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="NRXS:InterestAndServiceFeeAccrued" contextRef="AsOf2023-12-31" id="Fact001156" format="ixt:numdotdecimal" decimals="0" unitRef="USD">66,648</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_982_eus-gaap--InterestPaid_c20230101__20231231_zxw0Nw7EIlJ4" title="Interest payable" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:InterestPaid" contextRef="From2023-01-012023-12-31" id="Fact001158" format="ixt:numdotdecimal" decimals="0" unitRef="USD">37,103</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A2_zFWiTm1MloAl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company was granted an exclusive, worldwide non-transferable, royalty-free license for the auricular portion of certain patents owned
by a limited liability company in which the Company&#8217;s President and Chief Executive Officer and Chief Regulatory, Compliance and
Privacy Officer both maintain an ownership interest. The license allows for the development, marketing and sales of electro-therapy treatments
by stimulation of cranial nerves, cranial nerve branches, auricular nerves, auricular nerve branches, auricular nerve bundles and auricular
anatomical structures in human patient. The exclusive license agreement expires on October 18, 2037, may be terminated by either party
upon 60 days prior written notice and requires the Company to pay costs associated with the maintenance, prosecution and continuation
of patent filings. For the year ended December 31, 2024, the Company paid the limited liability company $<span id="xdx_90A_eus-gaap--RelatedPartyTransactionAmountsOfTransaction_c20240101__20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zYxMPwjCzXU6" title="Limited liability"><ix:nonFraction name="us-gaap:RelatedPartyTransactionAmountsOfTransaction" contextRef="From2024-01-012024-12-31_us-gaap_RelatedPartyMember" id="Fact001160" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,973</ix:nonFraction></span>. No costs were incurred
during the year ended December 31, 2023. No amounts were owed to the limited liability company as of December 31, 2024 and 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr.
Bradley Mitch Watkins, Director, provided certain sales, marketing and commercialization consulting services to the Company prior to
his appointment to the Board of Directors. For the years ended December 31, 2024 and 2023, the Company paid Mr. Watkins $<span id="xdx_900_eus-gaap--RelatedPartyTransactionAmountsOfTransaction_c20240101__20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MrWatkinsMember_zEnDK5sjmQV3" title="Related party transaction amounts"><ix:nonFraction name="us-gaap:RelatedPartyTransactionAmountsOfTransaction" contextRef="From2024-01-012024-12-31_custom_MrWatkinsMember" id="Fact001162" format="ixt:numdotdecimal" decimals="0" unitRef="USD">0</ix:nonFraction></span> and $<span id="xdx_907_eus-gaap--RelatedPartyTransactionAmountsOfTransaction_c20230101__20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MrWatkinsMember_zm5F2kSv1wZc" title="Related party transaction amounts"><ix:nonFraction name="us-gaap:RelatedPartyTransactionAmountsOfTransaction" contextRef="From2023-01-012023-12-31_custom_MrWatkinsMember" id="Fact001164" format="ixt:numdotdecimal" decimals="0" unitRef="USD">11,083</ix:nonFraction></span>,
respectively. No amounts were owed to Mr. Watkins as of December 31, 2024 and 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s former Chief Financial Officer provides certain accounting and tax services on a continuous basis through a
third-party public accounting firm. He is the third-party public accounting firm&#8217;s managing partner and majority shareholder.
Fees paid for services were $<span id="xdx_907_eus-gaap--PaymentsForFees_c20240101__20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MrSealeMember_zMQRtP7A6AP5" title="Fees paid for services"><ix:nonFraction name="us-gaap:PaymentsForFees" contextRef="From2024-01-012024-12-31_custom_MrSealeMember" id="Fact001166" format="ixt:numdotdecimal" decimals="0" unitRef="USD">207,103</ix:nonFraction></span>
and $<span id="xdx_907_eus-gaap--PaymentsForFees_c20230101__20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MrSealeMember_zkxBH472uiVg" title="Fees paid for services"><ix:nonFraction name="us-gaap:PaymentsForFees" contextRef="From2023-01-012023-12-31_custom_MrSealeMember" id="Fact001168" format="ixt:numdotdecimal" decimals="0" unitRef="USD">312,803</ix:nonFraction></span>
for the years ended December 31, 2024 and 2023, respectively. The Company owed the third-party accounting firm for open invoices of
$<span id="xdx_903_eus-gaap--AccountsPayableCurrentAndNoncurrent_iI_c20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MrSealeMember_zTGy1xM9AsP" title="Accounts payable"><ix:nonFraction name="us-gaap:AccountsPayableCurrentAndNoncurrent" contextRef="AsOf2024-12-31_custom_MrSealeMember" id="Fact001170" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,173</ix:nonFraction></span>
and $<span id="xdx_90A_eus-gaap--AccountsPayableCurrentAndNoncurrent_iI_c20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MrSealeMember_z0G24SXdEhAe" title="Accounts payable"><ix:nonFraction name="us-gaap:AccountsPayableCurrentAndNoncurrent" contextRef="AsOf2023-12-31_custom_MrSealeMember" id="Fact001172" format="ixt:numdotdecimal" decimals="0" unitRef="USD">84,279</ix:nonFraction></span>
that are included in accounts payable as of December 31, 2024 and 2023, respectively. On June 28, 2024, the Company also issued <span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20240101__20241231__srt--TitleOfIndividualAxis__srt--ChiefFinancialOfficerMember_zQRfkfn74ZKb" title="Stock issued during period shares issued for services"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" contextRef="From2024-01-012024-12-31_srt_ChiefFinancialOfficerMember" id="Fact001174" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">20,000</ix:nonFraction></span>
common shares with a fair value $<span id="xdx_904_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_c20240101__20241231__srt--TitleOfIndividualAxis__srt--ChiefFinancialOfficerMember_z2a6VJQXiZH8" title="Stock issued during period value  issued for services"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2024-01-012024-12-31_srt_ChiefFinancialOfficerMember" id="Fact001176" format="ixt:numdotdecimal" decimals="0" unitRef="USD">55,600</ix:nonFraction></span>
to the former</span> Chief Financial Officer for services rendered during the IPO process.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 111; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Neuraxis,
Inc.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Notes
to Financial Statements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact001178" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock"><p id="xdx_80F_eus-gaap--PropertyPlantAndEquipmentDisclosureTextBlock_zUFxuIJo0Bz4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>4.
<span id="xdx_82B_zGSUumEulbKl">Property and Equipment</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact001180" name="us-gaap:PropertyPlantAndEquipmentTextBlock"><p id="xdx_898_eus-gaap--PropertyPlantAndEquipmentTextBlock_zZExnw39C8Mb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property
and equipment, net consists of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span id="xdx_8BD_zSpbTDAq6AI2" style="display: none">Schedule of Property And Equipment</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_492_20241231_z1L83aOgT7Ca" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, 2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49A_20231231_zX9lQ20XfjUh" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, 2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--MachineryAndEquipmentMember_zheELRMbM1pg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Machinery and equipment</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2024-12-31_us-gaap_MachineryAndEquipmentMember" id="Fact001182" format="ixt:numdotdecimal" decimals="0" unitRef="USD">282,181</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2023-12-31_us-gaap_MachineryAndEquipmentMember" id="Fact001183" format="ixt:numdotdecimal" decimals="0" unitRef="USD">282,181</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zgoPHiIyxVKh" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Furniture and fixtures</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2024-12-31_us-gaap_FurnitureAndFixturesMember" id="Fact001185" format="ixt:numdotdecimal" decimals="0" unitRef="USD">111,036</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2023-12-31_us-gaap_FurnitureAndFixturesMember" id="Fact001186" format="ixt:numdotdecimal" decimals="0" unitRef="USD">96,768</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_zQoYCrk5twy" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Computer hardware</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2024-12-31_us-gaap_ComputerEquipmentMember" id="Fact001188" format="ixt:numdotdecimal" decimals="0" unitRef="USD">50,121</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2023-12-31_us-gaap_ComputerEquipmentMember" id="Fact001189" format="ixt:numdotdecimal" decimals="0" unitRef="USD">36,613</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zidW0RfYiTCe" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Leasehold improvements</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2024-12-31_us-gaap_LeaseholdImprovementsMember" id="Fact001191" format="ixt:numdotdecimal" decimals="0" unitRef="USD">21,064</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2023-12-31_us-gaap_LeaseholdImprovementsMember" id="Fact001192" format="ixt:numdotdecimal" decimals="0" unitRef="USD">21,064</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--PropertyPlantAndEquipmentGross_iI_maPPAENzDOd_zAkjgdLgKp1c" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Total property and equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2024-12-31" id="Fact001194" format="ixt:numdotdecimal" decimals="0" unitRef="USD">464,402</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2023-12-31" id="Fact001195" format="ixt:numdotdecimal" decimals="0" unitRef="USD">436,626</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_di_msPPAENzDOd_zjVmdbF0MLib" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Less: accumulated depreciation</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="AsOf2024-12-31" id="Fact001197" format="ixt:numdotdecimal" decimals="0" unitRef="USD">374,420</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="AsOf2023-12-31" id="Fact001198" format="ixt:numdotdecimal" decimals="0" unitRef="USD">348,074</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_409_eus-gaap--PropertyPlantAndEquipmentNet_iTI_mtPPAENzDOd_zctvrjFcVVIl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: left; padding-bottom: 1pt">Property and equipment, net</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2024-12-31" id="Fact001200" format="ixt:numdotdecimal" decimals="0" unitRef="USD">89,982</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2023-12-31" id="Fact001201" format="ixt:numdotdecimal" decimals="0" unitRef="USD">88,552</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A8_z94iI4eYJHYa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Depreciation
expense was $<span id="xdx_904_eus-gaap--Depreciation_c20240101__20241231_zsy0uhxgb9Ch" title="Depreciation"><ix:nonFraction name="us-gaap:Depreciation" contextRef="From2024-01-01to2024-12-31" id="Fact001203" format="ixt:numdotdecimal" decimals="0" unitRef="USD">26,346</ix:nonFraction></span></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">and
$<span id="xdx_909_eus-gaap--Depreciation_c20230101__20231231_z1e82Ze8LH4j" title="Depreciation"><ix:nonFraction name="us-gaap:Depreciation" contextRef="From2023-01-012023-12-31" id="Fact001205" format="ixt:numdotdecimal" decimals="0" unitRef="USD">30,240</ix:nonFraction></span></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">for
the years ended December 31, 2024 and 2023, respectively. The Company expects to record future depreciation expense totaling $<span id="xdx_90D_eus-gaap--Depreciation_c20240101__20241231__us-gaap--AwardTypeAxis__custom--DecemberTwoThousandTwentyFiveMember_zkjKxXzQIcy4" title="Depreciation"><ix:nonFraction name="us-gaap:Depreciation" contextRef="From2024-01-012024-12-31_custom_DecemberTwoThousandTwentyFiveMember" id="Fact001207" format="ixt:numdotdecimal" decimals="0" unitRef="USD">13,438</ix:nonFraction></span>,
$<span id="xdx_903_eus-gaap--Depreciation_c20240101__20241231__us-gaap--AwardTypeAxis__custom--DecemberTwoThousandTwentySixMember_z3NxraUtaX4c" title="Depreciation"><ix:nonFraction name="us-gaap:Depreciation" contextRef="From2024-01-012024-12-31_custom_DecemberTwoThousandTwentySixMember" id="Fact001209" format="ixt:numdotdecimal" decimals="0" unitRef="USD">12,344</ix:nonFraction></span>, $<span id="xdx_90B_eus-gaap--Depreciation_c20240101__20241231__us-gaap--AwardTypeAxis__custom--DecemberTwoThousandTwentySevenMember_zYV9ind1ph5d" title="Depreciation"><ix:nonFraction name="us-gaap:Depreciation" contextRef="From2024-01-012024-12-31_custom_DecemberTwoThousandTwentySevenMember" id="Fact001211" format="ixt:numdotdecimal" decimals="0" unitRef="USD">11,977</ix:nonFraction></span>, $<span id="xdx_907_eus-gaap--Depreciation_c20240101__20241231__us-gaap--AwardTypeAxis__custom--DecemberTwoThousandTwentyEightMember_zwE12gHhqe9a" title="Depreciation"><ix:nonFraction name="us-gaap:Depreciation" contextRef="From2024-01-012024-12-31_custom_DecemberTwoThousandTwentyEightMember" id="Fact001213" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9,753</ix:nonFraction></span>, $<span id="xdx_907_eus-gaap--Depreciation_c20240101__20241231__us-gaap--AwardTypeAxis__custom--DecemberTwoThousandTwentyNineMember_ztixW5WddXW8" title="Depreciation"><ix:nonFraction name="us-gaap:Depreciation" contextRef="From2024-01-012024-12-31_custom_DecemberTwoThousandTwentyNineMember" id="Fact001215" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,259</ix:nonFraction></span> and $<span id="xdx_90D_eus-gaap--Depreciation_c20240101__20241231__us-gaap--AwardTypeAxis__custom--DecemberTwoThousandTwentyThereafterMember_zrjbQb1vUUYe" title="Depreciation"><ix:nonFraction name="us-gaap:Depreciation" contextRef="From2024-01-012024-12-31_custom_DecemberTwoThousandTwentyThereafterMember" id="Fact001217" format="ixt:numdotdecimal" decimals="0" unitRef="USD">14,111</ix:nonFraction></span> for the years ending December 31, 2025, 2026, 2027, 2028, 2029 and thereafter, respectively.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact001219" name="us-gaap:IntangibleAssetsDisclosureTextBlock"><p id="xdx_800_eus-gaap--IntangibleAssetsDisclosureTextBlock_zIGckrcXtkNe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>5.
<span id="xdx_82C_zhiyZ8YSnib8">Intangible Assets</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact001221" name="us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"><p id="xdx_89A_eus-gaap--ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_z7HEvAFzd705" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Intangible
assets, net consists of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BF_ztWJTbv4oTL3" style="display: none">Schedule of Intangible Assets</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_493_20241231_zffQXKuWcn2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, 2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_498_20231231_z33gPHqBRVv2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, 2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_hus-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--SoftwareImplementationMember_z91J2gu0Mtek" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Software Implementation</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="AsOf2024-12-31_custom_SoftwareImplementationMember" id="Fact001223" format="ixt:numdotdecimal" decimals="0" unitRef="USD">49,815</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="AsOf2023-12-31_custom_SoftwareImplementationMember" id="Fact001224" format="ixt:numdotdecimal" decimals="0" unitRef="USD">49,815</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_hus-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zf6epMbZTE2h" style="vertical-align: bottom; background-color: White">
    <td>Patents</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="AsOf2024-12-31_us-gaap_PatentsMember" id="Fact001226" format="ixt:numdotdecimal" decimals="0" unitRef="USD">32,463</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="AsOf2023-12-31_us-gaap_PatentsMember" id="Fact001227" format="ixt:numdotdecimal" decimals="0" unitRef="USD">32,463</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_hus-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_z0qGsDlM50x4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Trademark</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="AsOf2024-12-31_us-gaap_TrademarksMember" id="Fact001229" format="ixt:numdotdecimal" decimals="0" unitRef="USD">50,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="AsOf2023-12-31_us-gaap_TrademarksMember" id="Fact001230" format="ixt:numdotdecimal" decimals="0" unitRef="USD">50,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_hus-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LicensesMember_zPayp6miIW38" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt">Licenses</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="AsOf2024-12-31_custom_LicensesMember" id="Fact001232" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,000</ix:nonFraction></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="AsOf2023-12-31_custom_LicensesMember" id="Fact001233" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_maFLIANzh0b_ziGX9bS4QS2a" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Total intangible assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="AsOf2024-12-31" id="Fact001235" format="ixt:numdotdecimal" decimals="0" unitRef="USD">133,278</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="AsOf2023-12-31" id="Fact001236" format="ixt:numdotdecimal" decimals="0" unitRef="USD">133,278</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iNI_di_msFLIANzh0b_zI6Tp7ZxyOE7" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Less: accumulated amortization</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="AsOf2024-12-31" id="Fact001238" format="ixt:numdotdecimal" decimals="0" unitRef="USD">36,690</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="AsOf2023-12-31" id="Fact001239" format="ixt:numdotdecimal" decimals="0" unitRef="USD">25,205</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_40F_eus-gaap--FiniteLivedIntangibleAssetsNet_iTI_mtFLIANzh0b_zP3Z51RAYuo1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: left; padding-bottom: 1pt">Intangible assets, net</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="AsOf2024-12-31" id="Fact001241" format="ixt:numdotdecimal" decimals="0" unitRef="USD">96,588</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="AsOf2023-12-31" id="Fact001242" format="ixt:numdotdecimal" decimals="0" unitRef="USD">108,073</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A1_zVo20MoPcPWd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amortization
expense was $<span id="xdx_907_eus-gaap--AmortizationOfIntangibleAssets_c20240101__20241231_zTMToDTzkRsf" title="Amortization expense"><ix:nonFraction name="us-gaap:AmortizationOfIntangibleAssets" contextRef="From2024-01-01to2024-12-31" id="Fact001244" format="ixt:numdotdecimal" decimals="0" unitRef="USD">11,485</ix:nonFraction></span>
and $<span id="xdx_907_eus-gaap--AmortizationOfIntangibleAssets_c20230101__20231231_zKXNJcVK7yUh" title="Amortization expense"><ix:nonFraction name="us-gaap:AmortizationOfIntangibleAssets" contextRef="From2023-01-012023-12-31" id="Fact001246" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,485</ix:nonFraction></span>
for the years ended December 31, 2024 and 2023, respectively. The Company expect to record future amortization expense totaling $<span id="xdx_90A_eus-gaap--AmortizationOfIntangibleAssets_c20240101__20241231__us-gaap--AwardTypeAxis__custom--DecemberTwoThousandTwentyFiveMember_z3T8gdPSqdxl" title="Amortization expense"><ix:nonFraction name="us-gaap:AmortizationOfIntangibleAssets" contextRef="From2024-01-012024-12-31_custom_DecemberTwoThousandTwentyFiveMember" id="Fact001248" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,485</ix:nonFraction></span>, $<span id="xdx_909_eus-gaap--AmortizationOfIntangibleAssets_c20240101__20241231__us-gaap--AwardTypeAxis__custom--DecemberTwoThousandTwentySixMember_ztSoQDyy8PX5" title="Amortization expense"><ix:nonFraction name="us-gaap:AmortizationOfIntangibleAssets" contextRef="From2024-01-012024-12-31_custom_DecemberTwoThousandTwentySixMember" id="Fact001250" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,485</ix:nonFraction></span>, $<span id="xdx_90F_eus-gaap--AmortizationOfIntangibleAssets_c20240101__20241231__us-gaap--AwardTypeAxis__custom--DecemberTwoThousandTwentySevenMember_z5FuQsYzAjXi" title="Amortization expense"><ix:nonFraction name="us-gaap:AmortizationOfIntangibleAssets" contextRef="From2024-01-012024-12-31_custom_DecemberTwoThousandTwentySevenMember" id="Fact001252" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,485</ix:nonFraction></span>, $<span id="xdx_90F_eus-gaap--AmortizationOfIntangibleAssets_c20240101__20241231__us-gaap--AwardTypeAxis__custom--DecemberTwoThousandTwentyEightMember_zjs5JWJzEcx8" title="Amortization expense"><ix:nonFraction name="us-gaap:AmortizationOfIntangibleAssets" contextRef="From2024-01-012024-12-31_custom_DecemberTwoThousandTwentyEightMember" id="Fact001254" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,760</ix:nonFraction></span>, $<span id="xdx_900_eus-gaap--AmortizationOfIntangibleAssets_c20240101__20241231__us-gaap--AwardTypeAxis__custom--DecemberTwoThousandTwentyNineMember_zruZIP5NfTPj" title="Amortization expense"><ix:nonFraction name="us-gaap:AmortizationOfIntangibleAssets" contextRef="From2024-01-012024-12-31_custom_DecemberTwoThousandTwentyNineMember" id="Fact001256" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,941</ix:nonFraction></span> and $<span id="xdx_90B_eus-gaap--AmortizationOfIntangibleAssets_c20240101__20241231__us-gaap--AwardTypeAxis__custom--DecemberTwoThousandTwentyThereafterMember_zJ6M35G3qjql" title="Amortization expense"><ix:nonFraction name="us-gaap:AmortizationOfIntangibleAssets" contextRef="From2024-01-012024-12-31_custom_DecemberTwoThousandTwentyThereafterMember" id="Fact001258" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,432</ix:nonFraction></span> for the years
ending December 31, 2025, 2026, 2027, 2028, 2029 and thereafter, respectively. The Company&#8217;s trademark does not have a determinate life
and therefore the cost is not being amortized.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact001260" name="us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock"><p id="xdx_804_eus-gaap--AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_zNMRRyCHPx6h" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>6.
<span id="xdx_820_zIWxJtFoBTZ6">Accrued Expenses</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact001262" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock"><p id="xdx_897_eus-gaap--ScheduleOfAccruedLiabilitiesTableTextBlock_zvUb0GeiOnXj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accrued
expenses consisted of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BB_zpdknJa9shG3" style="display: none">Schedule of Accrued Expenses</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_499_20241231_zKsVdgUSQQmk" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, 2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_497_20231231_zTS4WmLwiwVl" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, 2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_401_ecustom--AccruedCompensationAndBenefitsCurrent_iI_maALCz94I_zfW9IkDNsimh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Compensation and benefits</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="NRXS:AccruedCompensationAndBenefitsCurrent" contextRef="AsOf2024-12-31" id="Fact001264" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,261,317</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="NRXS:AccruedCompensationAndBenefitsCurrent" contextRef="AsOf2023-12-31" id="Fact001265" format="ixt:numdotdecimal" decimals="0" unitRef="USD">333,477</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_ecustom--AdvisoryFees_iI_maALCz94I_zmfz7vtKw8Nj" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Advisory fees</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="NRXS:AdvisoryFees" contextRef="AsOf2024-12-31" id="Fact001267" format="ixt:numdotdecimal" decimals="0" unitRef="USD">176,750</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1268">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--InterestPayableCurrent_iI_maALCz94I_znHRDcQk5vL8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Interest</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:InterestPayableCurrent" contextRef="AsOf2024-12-31" id="Fact001270" format="ixt:numdotdecimal" decimals="0" unitRef="USD">66,648</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:InterestPayableCurrent" contextRef="AsOf2023-12-31" id="Fact001271" format="ixt:numdotdecimal" decimals="0" unitRef="USD">66,648</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--AccrualForTaxesOtherThanIncomeTaxesCurrent_iI_maALCz94I_zEo4FtIWXx23" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt">Other</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:AccrualForTaxesOtherThanIncomeTaxesCurrent" contextRef="AsOf2024-12-31" id="Fact001273" format="ixt:numdotdecimal" decimals="0" unitRef="USD">73,065</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:AccrualForTaxesOtherThanIncomeTaxesCurrent" contextRef="AsOf2023-12-31" id="Fact001274" format="ixt:numdotdecimal" decimals="0" unitRef="USD">963</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--AccruedLiabilitiesCurrent_iTI_mtALCz94I_zUvo3TiPrkFi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Total accrued expenses</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" contextRef="AsOf2024-12-31" id="Fact001276" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,577,780</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" contextRef="AsOf2023-12-31" id="Fact001277" format="ixt:numdotdecimal" decimals="0" unitRef="USD">401,088</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AA_zWDzSdN9GyAg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

<ix:exclude><!-- Field: Page; Sequence: 112; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact001279" name="us-gaap:DebtDisclosureTextBlock"><p id="xdx_805_eus-gaap--DebtDisclosureTextBlock_zqDM9DydFvQj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>7.
<span id="xdx_820_zrHP8dXRKMOk">Notes Payable</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Neuraxis,
Inc.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Notes
to Financial Statements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Promissory
Notes</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company borrowed $<span id="xdx_90E_eus-gaap--DebtInstrumentFaceAmount_iI_c20211216__dei--LegalEntityAxis__custom--ChannelPartnersCapitalMember_zEFgcCQS5p66"><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="AsOf2021-12-16_custom_ChannelPartnersCapitalMember" id="Fact001280" format="ixt:numdotdecimal" decimals="0" unitRef="USD">250,000</ix:nonFraction> </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">on
December 16, 2021, from Channel Partners Capital (the &#8220;2021 Promissory Note&#8221;). The 2021 Promissory Note called for 65
weekly payments of $<span id="xdx_90D_eus-gaap--DebtInstrumentPeriodicPayment_pp2d_c20230316__20230316__dei--LegalEntityAxis__custom--ChannelPartnersCapitalMember_zIhJDUCy6u28"><ix:nonFraction name="us-gaap:DebtInstrumentPeriodicPayment" contextRef="From2023-03-162023-03-16_custom_ChannelPartnersCapitalMember" id="Fact001281" format="ixt:numdotdecimal" decimals="2" unitRef="USD">4,923</ix:nonFraction> </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">with
the final payment scheduled for March 16, 2023. The principal outstanding at January 1, 2022 was $<span id="xdx_90B_eus-gaap--LongTermDebtAverageAmountOutstanding_c20220101__20220101__dei--LegalEntityAxis__custom--ChannelPartnersCapitalMember_zu7oEe0sn3j1"><ix:nonFraction name="us-gaap:LongTermDebtAverageAmountOutstanding" contextRef="From2022-01-012022-01-01_custom_ChannelPartnersCapitalMember" id="Fact001282" format="ixt:numdotdecimal" decimals="0" unitRef="USD">244,048</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.
The Company borrowed $<span id="xdx_905_eus-gaap--DebtInstrumentFaceAmount_iI_c20220916__dei--LegalEntityAxis__custom--ChannelPartnersCapitalMember_zDlf2W34cPyf"><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="AsOf2022-09-16_custom_ChannelPartnersCapitalMember" id="Fact001283" format="ixt:numdotdecimal" decimals="0" unitRef="USD">122,000</ix:nonFraction> </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">on
September 16, 2022, to bring the 2021 Promissory Note&#8217;s principal balance back to $<span id="xdx_902_eus-gaap--DebtInstrumentRepurchasedFaceAmount_iI_c20220916__dei--LegalEntityAxis__custom--ChannelPartnersCapitalMember_zu0onMRBFkE1"><ix:nonFraction name="us-gaap:DebtInstrumentRepurchasedFaceAmount" contextRef="AsOf2022-09-16_custom_ChannelPartnersCapitalMember" id="Fact001284" format="ixt:numdotdecimal" decimals="0" unitRef="USD">250,000</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.
After making scheduled payments, the Company borrowed another $<span id="xdx_90F_eus-gaap--DebtInstrumentFaceAmount_iI_c20230524__dei--LegalEntityAxis__custom--ChannelPartnersCapitalMember_zMDaPLFvDHL1"><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="AsOf2023-05-24_custom_ChannelPartnersCapitalMember" id="Fact001285" format="ixt:numdotdecimal" decimals="0" unitRef="USD">107,231</ix:nonFraction> </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">on
May 24, 2023, to bring the 2021 Promissory Note&#8217;s principal balance back to $<span id="xdx_908_eus-gaap--DebtInstrumentRepurchasedFaceAmount_iI_c20230524__dei--LegalEntityAxis__custom--ChannelPartnersCapitalMember_zoT6NPXmc5Ab"><ix:nonFraction name="us-gaap:DebtInstrumentRepurchasedFaceAmount" contextRef="AsOf2023-05-24_custom_ChannelPartnersCapitalMember" id="Fact001286" format="ixt:numdotdecimal" decimals="0" unitRef="USD">250,000</ix:nonFraction> </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">once
again. The terms of the incremental borrowings were the same as the 2021 Promissory Note with the final payment made on August 22,
2024. The principal outstanding as of December 31, 2024 and 2023 was $<span id="xdx_90E_eus-gaap--NotesPayable_iI_c20241231__dei--LegalEntityAxis__custom--ChannelPartnersCapitalMember_z4GkskSuYK4d"><ix:nonFraction name="us-gaap:NotesPayable" contextRef="AsOf2024-12-31_custom_ChannelPartnersCapitalMember" id="Fact001287" format="ixt:numdotdecimal" decimals="0" unitRef="USD">0</ix:nonFraction> </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">and
$<span id="xdx_90A_eus-gaap--NotesPayable_iI_c20231231__dei--LegalEntityAxis__custom--ChannelPartnersCapitalMember_zPcArPDgmb1"><ix:nonFraction name="us-gaap:NotesPayable" contextRef="AsOf2023-12-31_custom_ChannelPartnersCapitalMember" id="Fact001288" format="ixt:numdotdecimal" decimals="0" unitRef="USD">148,062</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">,
respectively, with an effective interest rate of <span id="xdx_902_eus-gaap--DebtInstrumentInterestRateEffectivePercentage_iI_pid_dp_uPure_c20241231__dei--LegalEntityAxis__custom--ChannelPartnersCapitalMember_z0tGbscimUTh" title="Debt instrument interest rate effective percentage"><span id="xdx_908_eus-gaap--DebtInstrumentInterestRateEffectivePercentage_iI_pid_dp_uPure_c20231231__dei--LegalEntityAxis__custom--ChannelPartnersCapitalMember_zNervzHDQ127" title="Debt instrument interest rate effective percentage"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" contextRef="AsOf2024-12-31_custom_ChannelPartnersCapitalMember" id="Fact001290" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" contextRef="AsOf2023-12-31_custom_ChannelPartnersCapitalMember" id="Fact001292" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">55.9</ix:nonFraction></ix:nonFraction></span></span>%. The Company believes that the advancement of additional funds is a minor
modification to the terms of the existing promissory note since the difference in present value of the cash flows under the terms of
the new loan is less than 10% of the present value of the remaining cash flows under the terms of the original loan. As a result,
the modification was accounted for as a modification of debt.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
lender was granted and assigned a continuing security interest in all the Company&#8217;s personal property assets including, but not
limited to, business equipment, inventory, accounts, accounts receivable, intellectual property, chattel paper, instruments, deposit
accounts, commercial tort claims, contract rights, licenses, claims, and general intangibles.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 15, 2023, The Company signed a note with Exchange Listing, LLC in the amount of $<span id="xdx_901_eus-gaap--DebtInstrumentFaceAmount_iI_c20230215__dei--LegalEntityAxis__custom--ExchangeListingLLCMember__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember_zRMlWKPbwri7" title="Promissory note"><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="AsOf2023-02-15_custom_ExchangeListingLLCMember_custom_PromissoryNoteMember" id="Fact001294" format="ixt:numdotdecimal" decimals="0" unitRef="USD">52,600</ix:nonFraction></span> (the &#8220;2023 Promissory Note&#8221;).
The 2023 Promissory Note carried an interest rate of <span id="xdx_90C_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_dp_uPure_c20230215__dei--LegalEntityAxis__custom--ExchangeListingLLCMember__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember_zql6zk4wtE0j" title="Interest rate"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextRef="AsOf2023-02-15_custom_ExchangeListingLLCMember_custom_PromissoryNoteMember" id="Fact001296" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">1</ix:nonFraction></span>% and was to be paid on the earlier of (i) three months or (ii) the Company receiving
financing at the minimum of $<span id="xdx_905_eus-gaap--NotesPayable_iI_c20230215__dei--LegalEntityAxis__custom--ExchangeListingLLCMember__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember_zTzH4vK2X6Kf" title="Promissory note"><ix:nonFraction name="us-gaap:NotesPayable" contextRef="AsOf2023-02-15_custom_ExchangeListingLLCMember_custom_PromissoryNoteMember" id="Fact001298" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,000,000</ix:nonFraction></span>. In August 2023, the Company used proceeds from the IPO to pay the 2023 Promissory Note back in
full, including interest, in the amount of $<span id="xdx_900_eus-gaap--ProceedsFromIssuanceInitialPublicOffering_pp2d_c20230831__20230831__dei--LegalEntityAxis__custom--ExchangeListingLLCMember__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember_zliXyL9i6Hg6" title="Proceeds from issuance of ipo"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" contextRef="From2023-08-312023-08-31_custom_ExchangeListingLLCMember_custom_PromissoryNoteMember" id="Fact001300" format="ixt:numdotdecimal" decimals="2" unitRef="USD">52,858</ix:nonFraction></span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August 9, 2024, the Company entered into a $<span id="xdx_90E_eus-gaap--NotesPayable_iI_c20240809__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember_zSLcTzH4lfH3" title="Promissory note"><ix:nonFraction name="us-gaap:NotesPayable" contextRef="AsOf2024-08-09_custom_PromissoryNoteMember" id="Fact001302" format="ixt:numdotdecimal" decimals="0" unitRef="USD">210,000</ix:nonFraction></span> promissory note to finance the premiums of its annual directors and officers insurance
policy, bearing interest at a rate of&#160;<span id="xdx_903_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20240809__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember_zxUHjNWitNhc" title="Interest rate"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextRef="AsOf2024-08-09_custom_PromissoryNoteMember" id="Fact001304" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">7.40</ix:nonFraction></span>% per annum and maturing on <span id="xdx_90E_eus-gaap--DebtInstrumentMaturityDate_pid_dp_uPure_c20240809__20240809__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember_z2OkaoitC9Bl" title="Maturity date"><ix:nonNumeric contextRef="From2024-08-092024-08-09_custom_PromissoryNoteMember" format="ixt:datemonthdayyearen" id="Fact001306" name="us-gaap:DebtInstrumentMaturityDate">June 9, 2025</ix:nonNumeric></span>. On November 1, 2024, the Company entered into
a second promissory note with a principal balance of $<span id="xdx_90E_eus-gaap--DebtInstrumentFaceAmount_iI_c20241101__us-gaap--DebtInstrumentAxis__custom--SecondPromissoryNoteMember_zVxIbOe4nfM7" title="Face amount"><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="AsOf2024-11-01_custom_SecondPromissoryNoteMember" id="Fact001308" format="ixt:numdotdecimal" decimals="0" unitRef="USD">64,328</ix:nonFraction></span> to finance premiums of its annual business insurance policies, bearing interest
at a rate of <span id="xdx_908_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20241101__us-gaap--DebtInstrumentAxis__custom--SecondPromissoryNoteMember_zT8azvnZtHBk"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextRef="AsOf2024-11-01_custom_SecondPromissoryNoteMember" id="Fact001309" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">7.65</ix:nonFraction></span>% per annum and maturing on <span id="xdx_902_eus-gaap--DebtInstrumentMaturityDate_pid_dp_uPure_c20241101__20241101__us-gaap--DebtInstrumentAxis__custom--SecondPromissoryNoteMember_z3FbP6YiSzJi" title="Maturity date"><ix:nonNumeric contextRef="From2024-11-012024-11-01_custom_SecondPromissoryNoteMember" format="ixt:datemonthdayyearen" id="Fact001311" name="us-gaap:DebtInstrumentMaturityDate">September 1, 2025</ix:nonNumeric></span> (collectively referred to as the &#8220;2024 Promissory Notes&#8221;).
The principal outstanding on 2024 Promissory Notes was $<span id="xdx_90A_eus-gaap--DebtInstrumentFaceAmount_iI_c20241231__us-gaap--DebtInstrumentAxis__custom--SecondPromissoryNoteMember_zKmFOTDHcsNh" title="Outstanding promissory notes"><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="AsOf2024-12-31_custom_SecondPromissoryNoteMember" id="Fact001313" format="ixt:numdotdecimal" decimals="0" unitRef="USD">154,152</ix:nonFraction></span> and $<span id="xdx_904_eus-gaap--DebtInstrumentFaceAmount_iI_c20231231__us-gaap--DebtInstrumentAxis__custom--SecondPromissoryNoteMember_zIKBHYh1IO6j" title="Outstanding promissory notes"><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="AsOf2023-12-31_custom_SecondPromissoryNoteMember" id="Fact001315" format="ixt:numdotdecimal" decimals="0" unitRef="USD">0</ix:nonFraction></span> as of December 31, 2024 and 2023, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">2022
Convertible Notes</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
2022, the Company issued multiple convertible notes with aggregate gross principal amounts totaling $<span id="xdx_908_eus-gaap--DebtInstrumentCarryingAmount_iI_c20221130__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyTwoConvertibleNotesMember_zqQaw6ZIDRqc" title="Debt instrument gross"><ix:nonFraction name="us-gaap:DebtInstrumentCarryingAmount" contextRef="AsOf2022-11-30_custom_TwoThousandTwentyTwoConvertibleNotesMember" id="Fact001317" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,333,333</ix:nonFraction></span>
and net proceeds of $<span id="xdx_906_eus-gaap--ProceedsFromIssuanceOfDebt_c20221130__20221130__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyTwoConvertibleNotesMember_zjgkQLG15Kl7" title="Net proceeds of debt"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfDebt" contextRef="From2022-11-302022-11-30_custom_TwoThousandTwentyTwoConvertibleNotesMember" id="Fact001319" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,870,000</ix:nonFraction></span>
(the &#8220;2022 Convertible Notes&#8221;). The 2022 Convertible Notes consisted of an <span id="xdx_90F_eus-gaap--DebtInstrumentDescriptionOfVariableRateBasis_c20220603__20221130__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyTwoConvertibleNotesMember_zvDbyVtXaXMi" title="Debt instrument description"><ix:nonNumeric contextRef="From2022-06-032022-11-30_custom_TwoThousandTwentyTwoConvertibleNotesMember" id="Fact001321" name="us-gaap:DebtInstrumentDescriptionOfVariableRateBasis">original
issue discount of 10% with an interest rate of the greater of (i) Prime rate plus 8.5% or (ii) 12% resulting in an effective
interest rate of <span id="xdx_90F_eus-gaap--DebtInstrumentInterestRateEffectivePercentage_iI_pid_dp_uPure_c20221231__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyTwoConvertibleNotesMember_zmFpWDLEwHX8" title="Debt instrument interest rate effective percentage"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" contextRef="AsOf2022-12-31_custom_TwoThousandTwentyTwoConvertibleNotesMember" id="Fact001323" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">24.2</ix:nonFraction></span>%.</ix:nonNumeric></span> The 2022 Convertible Notes converted into common shares at the lower of (i) $<span id="xdx_900_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_c20221130__srt--RangeAxis__srt--MinimumMember__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyTwoConvertibleNotesMember_zvQKZ0utCRB1"><ix:nonFraction name="us-gaap:DebtInstrumentConvertibleConversionPrice1" contextRef="AsOf2022-11-30_srt_MinimumMember_custom_TwoThousandTwentyTwoConvertibleNotesMember" id="Fact001324" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">9.44</ix:nonFraction></span>
or (ii) a <span id="xdx_900_ecustom--DebtInstrumentDiscountRate_iI_dp_uPure_c20221130__srt--RangeAxis__srt--MaximumMember__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyTwoConvertibleNotesMember_z50OMeun7FZd"><ix:nonFraction name="NRXS:DebtInstrumentDiscountRate" contextRef="AsOf2022-11-30_srt_MaximumMember_custom_TwoThousandTwentyTwoConvertibleNotesMember" id="Fact001325" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">30</ix:nonFraction></span>%
discount to the price per share of any subsequent offering. The 2022 Convertible Notes matured on the one-year anniversary date from
issuance and contained <span id="xdx_900_ecustom--DebtWarrantConversionDescription_c20221130__20221130__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyTwoConvertibleNotesMember_zeHL1W9gR2jk" title="Debt warrant conversion, description"><ix:nonNumeric contextRef="From2022-11-302022-11-30_custom_TwoThousandTwentyTwoConvertibleNotesMember" id="Fact001327" name="NRXS:DebtWarrantConversionDescription">a
five-year warrant to purchase common stock equal to one hundred percent (100%) of the shares into which the 2022 Convertible Notes
could be converted into at issuance.</ix:nonNumeric> </span>The warrants had an exercise price at the lower of (i) $<span id="xdx_902_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20221130__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyTwoConvertibleNotesMember_zD15DYCBQuc3" title="Exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2022-11-30_custom_TwoThousandTwentyTwoConvertibleNotesMember" id="Fact001329" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">11.80</ix:nonFraction></span>
per share or (ii) a <span id="xdx_908_ecustom--ClassOfWarrantDiscountRate_iI_dp_uPure_c20221130__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyTwoConvertibleNotesMember_zpyyX39zWKL1" title="Class of warrant discount rate"><ix:nonFraction name="NRXS:ClassOfWarrantDiscountRate" contextRef="AsOf2022-11-30_custom_TwoThousandTwentyTwoConvertibleNotesMember" id="Fact001331" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">12.5</ix:nonFraction></span>%
discount to the price per share of any subsequent offering.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
convertible notes signed on December 19, 2022 had aggregate gross principal amounts totaling $<span id="xdx_902_eus-gaap--DebtInstrumentCarryingAmount_iI_c20221219__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyTwoConvertibleNotesMember_zY4AipqPlXjh" title="Debt instrument gross"><ix:nonFraction name="us-gaap:DebtInstrumentCarryingAmount" contextRef="AsOf2022-12-19_custom_TwoThousandTwentyTwoConvertibleNotesMember" id="Fact001333" format="ixt:numdotdecimal" decimals="0" unitRef="USD">222,222</ix:nonFraction></span> and net proceeds of $<span id="xdx_90A_eus-gaap--ProceedsFromIssuanceOfDebt_c20221219__20221219__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyTwoConvertibleNotesMember_zzQRSmAAdBD6" title="Net proceeds of debt"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfDebt" contextRef="From2022-12-192022-12-19_custom_TwoThousandTwentyTwoConvertibleNotesMember" id="Fact001335" format="ixt:numdotdecimal" decimals="0" unitRef="USD">200,000</ix:nonFraction></span> and
consisted of an original issue discount of <span id="xdx_902_ecustom--DebtInstrumentDiscountRate_iI_dp_uPure_c20221219__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyTwoConvertibleNotesMember_z7hWSk50ycQj" title="Debt instrument discount rate"><ix:nonFraction name="NRXS:DebtInstrumentDiscountRate" contextRef="AsOf2022-12-19_custom_TwoThousandTwentyTwoConvertibleNotesMember" id="Fact001337" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">10</ix:nonFraction></span>% of the principal amount with an interest rate of <span id="xdx_901_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_dp_uPure_c20221219__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyTwoConvertibleNotesMember_zOVeh7LRY85" title="Accrued interest"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextRef="AsOf2022-12-19_custom_TwoThousandTwentyTwoConvertibleNotesMember" id="Fact001339" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">12</ix:nonFraction></span>% per annum. The notes matured at the
earlier of (i) twelve (12) months from the issue date or (ii) the date upon which the Company completes a registered public offering
of shares of the Company, which encompasses the closing of the IPO. The notes are convertible into shares of common stock at the higher
of (i) $<span id="xdx_901_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_c20221219__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyTwoConvertibleNotesMember_zPaI12QxapN9" title="Conversion price"><ix:nonFraction name="us-gaap:DebtInstrumentConvertibleConversionPrice1" contextRef="AsOf2022-12-19_custom_TwoThousandTwentyTwoConvertibleNotesMember" id="Fact001341" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">9.44</ix:nonFraction></span> per share or (ii) the price per share of common stock issued pursuant to the next registered public offering of shares of
the Company made prior to the conversion of any portion of the note. Interest accrues on the aggregate principal amount (which includes
original issue discount) and is payable on the maturity date, at the Company&#8217;s election, in cash or in-kind. The holders of the
notes are entitled to piggyback registration rights on any registration statement filed by the Company, other than any registration statement
filed on Form S-4 or Form S-8. The warrants and conversion shares are subject to anti-dilution provisions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
investors of the notes signed on December 19, 2022 above did not convert their notes and, as such the Company used proceeds from the
initial public offering to pay the remaining promissory notes back in full, including interest in the amount of $<span id="xdx_906_eus-gaap--ProceedsFromIssuanceInitialPublicOffering_c20221219__20221219__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyTwoConvertibleNotesMember_zO90UJ5v8AA4" title="Proceeds from issuance of ipo"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" contextRef="From2022-12-192022-12-19_custom_TwoThousandTwentyTwoConvertibleNotesMember" id="Fact001343" format="ixt:numdotdecimal" decimals="0" unitRef="USD">239,104</ix:nonFraction></span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">2023
Convertible Notes</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
2023, the Company conducted multiple closings of a private placement offering to accredited investors for aggregate gross principal
amounts of $<span id="xdx_90E_eus-gaap--DebtInstrumentCarryingAmount_iI_c20231231__us-gaap--DebtInstrumentAxis__custom--ConvertiblePromissoryNoteMember__srt--TitleOfIndividualAxis__custom--AccreditedInvestorsMember_zpDMokGIBjK3" title="Debt instrument gross"><ix:nonFraction name="us-gaap:DebtInstrumentCarryingAmount" contextRef="AsOf2023-12-31_custom_ConvertiblePromissoryNoteMember_custom_AccreditedInvestorsMember" id="Fact001345" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,066,667</ix:nonFraction></span>
and net proceeds of $<span id="xdx_902_eus-gaap--ProceedsFromIssuanceOfDebt_c20230101__20231231__srt--TitleOfIndividualAxis__custom--AccreditedInvestorsMember__us-gaap--DebtInstrumentAxis__custom--ConvertiblePromissoryNoteMember_znCDb3Ms1PEg" title="Net proceeds of debt"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfDebt" contextRef="From2023-01-012023-12-31_custom_AccreditedInvestorsMember_custom_ConvertiblePromissoryNoteMember" id="Fact001347" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,908,000</ix:nonFraction></span>
(the &#8220;2023 Convertible Notes&#8221;). The offering consisted of a convertible promissory note that accrued interest at <span id="xdx_90E_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_dp_uPure_c20231231__us-gaap--DebtInstrumentAxis__custom--ConvertiblePromissoryNoteMember_zUaQiNCsuCb6" title="Debt instrument interest rate"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextRef="AsOf2023-12-31_custom_ConvertiblePromissoryNoteMember" id="Fact001349" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">12</ix:nonFraction></span>%
that could be paid in cash or PIK and had an original issue discount of <span id="xdx_90B_ecustom--DebtInstrumentDiscountRate_iI_pid_dp_uPure_c20231231__us-gaap--DebtInstrumentAxis__custom--ConvertiblePromissoryNoteMember_z9UC19ga76na" title="Debt instrument discount rate"><ix:nonFraction name="NRXS:DebtInstrumentDiscountRate" contextRef="AsOf2023-12-31_custom_ConvertiblePromissoryNoteMember" id="Fact001351" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">10</ix:nonFraction></span>%
resulting in an effective interest rate of <span id="xdx_909_eus-gaap--DebtInstrumentInterestRateEffectivePercentage_iI_pid_dp_uPure_c20231231__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeConvertibleNotesMember_zDQzuqODLQR1" title="Debt instrument interest rate effective percentage"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" contextRef="AsOf2023-12-31_custom_TwoThousandTwentyThreeConvertibleNotesMember" id="Fact001353" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">27.5</ix:nonFraction></span>%. The 2023 Convertible Notes automatically converted into common shares at a <span id="xdx_90C_ecustom--DebtInstrumentDiscountRate_iI_dp_uPure_c20231231__us-gaap--DebtInstrumentAxis__custom--ConvertiblePromissoryNoteMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z5r3vk1LAJxh" title="Discount rate"><ix:nonFraction name="NRXS:DebtInstrumentDiscountRate" contextRef="AsOf2023-12-31_custom_ConvertiblePromissoryNoteMember_us-gaap_CommonStockMember" id="Fact001355" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">30</ix:nonFraction></span>%
discount to the IPO. The 2023 Convertible Notes matured on the sooner of the six-month anniversary date from issuance or a
successful IPO on primary exchange in the U.S. and included <span id="xdx_90B_ecustom--DebtWarrantConversionDescription_c20230101__20231231__us-gaap--DebtInstrumentAxis__custom--ConvertiblePromissoryNoteMember_z3Ni11xEdEwf" title="Debt warrant conversion, description"><ix:nonNumeric contextRef="From2023-01-012023-12-31_custom_ConvertiblePromissoryNoteMember" id="Fact001357" name="NRXS:DebtWarrantConversionDescription">a
five-year warrant to purchase common stock equal to fifty percent (50%) of the shares into which the 2032 Convertible Notes could be
converted into at issuance.</ix:nonNumeric> </span>The warrants had a strike price at a <span id="xdx_903_eus-gaap--DebtInstrumentConvertibleConversionRatio1_dp_uPure_c20230101__20231231__us-gaap--DebtInstrumentAxis__custom--ConvertiblePromissoryNoteMember_zfRoCwQIV1jc" title="Strilke price"><ix:nonFraction name="us-gaap:DebtInstrumentConvertibleConversionRatio1" contextRef="From2023-01-012023-12-31_custom_ConvertiblePromissoryNoteMember" id="Fact001359" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">25</ix:nonFraction></span>%
premium to the conversion price subject to anti-dilution, issuable on a pro rata basis at each funding.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>


<ix:exclude><!-- Field: Page; Sequence: 113; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company used proceeds from the 2023 Convertible Notes to pay a portion of the principal balance of the 2022 Convertible Notes totaling
$<span id="xdx_90C_eus-gaap--NotesPayable_iI_c20231231__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeConvertibleNotesMember_zoEzkqhpEx76"><ix:nonFraction name="us-gaap:NotesPayable" contextRef="AsOf2023-12-31_custom_TwoThousandTwentyThreeConvertibleNotesMember" id="Fact001360" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,650,000</ix:nonFraction></span> which resulted in a $<span id="xdx_908_eus-gaap--GainsLossesOnExtinguishmentOfDebt_c20230101__20231231__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeConvertibleNotesMember_zovuuAZwlnyg" title="Gain on extinguishment of debt liabilities"><ix:nonFraction name="us-gaap:GainsLossesOnExtinguishmentOfDebt" contextRef="From2023-01-012023-12-31_custom_TwoThousandTwentyThreeConvertibleNotesMember" id="Fact001362" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,129,653</ix:nonFraction></span> gain recorded as a benefit to Extinguishment of Debt Liabilities in the Statements of Operations.
Upon partial repayment, the terms of the remaining 2022 Convertible Notes were amended to accrue interest at <span id="xdx_904_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_dp_uPure_c20231231__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeConvertibleNotesMember_zDkNUsQQ8Xh6"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextRef="AsOf2023-12-31_custom_TwoThousandTwentyThreeConvertibleNotesMember" id="Fact001363" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">8</ix:nonFraction></span>% per annum without maturity
or default rights. The remaining principal balance also automatically converted into shares of common stock at a <span id="xdx_903_ecustom--DebtInstrumentDiscountRate_iI_dp_uPure_c20231231__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeConvertibleNotesMember_zIQaTlFHT68b"><ix:nonFraction name="NRXS:DebtInstrumentDiscountRate" contextRef="AsOf2023-12-31_custom_TwoThousandTwentyThreeConvertibleNotesMember" id="Fact001364" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">27.5</ix:nonFraction></span>% discount to the
per share offering price in the Company&#8217;s IPO, or $<span id="xdx_904_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_c20231231__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeConvertibleNotesMember_zU3VLYdijpM1"><ix:nonFraction name="us-gaap:DebtInstrumentConvertibleConversionPrice1" contextRef="AsOf2023-12-31_custom_TwoThousandTwentyThreeConvertibleNotesMember" id="Fact001365" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">4.35</ix:nonFraction></span> per share. After the closing of the IPO on August 9, 2023, the Company
converted some of the remaining balance of the 2022 Convertible Notes and $<span id="xdx_90D_eus-gaap--NotesPayable_iI_c20230809__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeConvertibleNotesMember_zpxhJO0tYrzd"><ix:nonFraction name="us-gaap:NotesPayable" contextRef="AsOf2023-08-09_custom_TwoThousandTwentyThreeConvertibleNotesMember" id="Fact001366" format="ixt:numdotdecimal" decimals="0" unitRef="USD">173,205</ix:nonFraction></span> of accrued interest into <span id="xdx_905_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230809__20230809__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeConvertibleNotesMember_zaVdBFCEvqsa"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2023-08-092023-08-09_custom_TwoThousandTwentyThreeConvertibleNotesMember" id="Fact001367" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">107,509</ix:nonFraction></span> shares of common
stock. The shares were issued at a discounted price of $<span id="xdx_907_eus-gaap--SharesIssuedPricePerShare_iI_c20230809__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeConvertibleNotesMember_zFKBNQfNmFg5"><ix:nonFraction name="us-gaap:SharesIssuedPricePerShare" contextRef="AsOf2023-08-09_custom_TwoThousandTwentyThreeConvertibleNotesMember" id="Fact001368" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">4.35</ix:nonFraction></span> per share resulting in a $<span id="xdx_90B_eus-gaap--GainsLossesOnExtinguishmentOfDebt_c20230809__20230809__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeConvertibleNotesMember_z3wlc7JBI3Z4" title="Extinguishment of debt"><ix:nonFraction name="us-gaap:GainsLossesOnExtinguishmentOfDebt" contextRef="From2023-08-092023-08-09_custom_TwoThousandTwentyThreeConvertibleNotesMember" id="Fact001370" format="ixt:numdotdecimal" decimals="0" unitRef="USD">663,991</ix:nonFraction></span> loss to the Company recorded as a charge
to Extinguishment of Debt Liabilities in the Statements of Operations. As the remaining holders of the 2022 Convertible Notes did not
convert, the Company used proceeds from the IPO to pay the remaining balance in full, including interest in the amount of $<span id="xdx_90E_eus-gaap--ProceedsFromIssuanceInitialPublicOffering_c20230809__20230809__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeConvertibleNotesMember_zLhLTcObjsG2" title="Proceeds from issuance of ipo"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" contextRef="From2023-08-092023-08-09_custom_TwoThousandTwentyThreeConvertibleNotesMember" id="Fact001372" format="ixt:numdotdecimal" decimals="0" unitRef="USD">445,544</ix:nonFraction></span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
facilitators to the 2023 Convertible Notes, Signature Bank received a $<span id="xdx_903_eus-gaap--EscrowDeposit_iI_c20231231__dei--LegalEntityAxis__custom--SignatureBankMember_zoSjuS5jBFCa" title="Escrow deposit"><ix:nonFraction name="us-gaap:EscrowDeposit" contextRef="AsOf2023-12-31_custom_SignatureBankMember" id="Fact001374" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,000</ix:nonFraction></span> escrow fee and Alexander Capital, L.P. received (i) a $<span id="xdx_90B_eus-gaap--ProceedsFromFeesReceived_c20230101__20231231__dei--LegalEntityAxis__custom--AlexanderCapitalLPMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z1ehwztzuPv8" title="Deferred financing fees"><ix:nonFraction name="us-gaap:ProceedsFromFeesReceived" contextRef="From2023-01-012023-12-31_custom_AlexanderCapitalLPMember_us-gaap_WarrantMember" id="Fact001376" format="ixt:numdotdecimal" decimals="0" unitRef="USD">546,000</ix:nonFraction></span>
cash commission representing nine percent (9%) of the proceeds raised in the offering from investors introduced to the Company and (ii)
<span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20231231__dei--LegalEntityAxis__custom--AlexanderCapitalLPMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zFOaTIC7d4T3" title="Number of warrants received"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2023-12-31_custom_AlexanderCapitalLPMember_us-gaap_WarrantMember" id="Fact001378" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">120,235</ix:nonFraction></span> warrants for the purchase of a number of shares of Common Stock equal to 6% of the number of underlying securities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">After
the closing of the IPO on August 9, 2023, the Company converted the 2023 Convertible Notes and $<span id="xdx_90F_eus-gaap--NotesPayable_iI_c20230809__dei--LegalEntityAxis__custom--ChannelPartnersCapitalMember_zwuNrF6R97Ah"><ix:nonFraction name="us-gaap:NotesPayable" contextRef="AsOf2023-08-09_custom_ChannelPartnersCapitalMember" id="Fact001379" format="ixt:numdotdecimal" decimals="0" unitRef="USD">226,391</ix:nonFraction></span> of accrued interest into <span id="xdx_906_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230809__20230809__dei--LegalEntityAxis__custom--ChannelPartnersCapitalMember_zlTXDEX9FLD6"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2023-08-092023-08-09_custom_ChannelPartnersCapitalMember" id="Fact001380" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,498,332</ix:nonFraction></span>
shares of common stock. The shares were issued at a discounted price of $<span id="xdx_908_eus-gaap--SharesIssuedPricePerShare_iI_c20230809__dei--LegalEntityAxis__custom--ChannelPartnersCapitalMember_znT55MEeIB31"><ix:nonFraction name="us-gaap:SharesIssuedPricePerShare" contextRef="AsOf2023-08-09_custom_ChannelPartnersCapitalMember" id="Fact001381" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">4.20</ix:nonFraction></span> per share that resulted in a $<span id="xdx_907_eus-gaap--GainsLossesOnExtinguishmentOfDebt_c20230809__20230809__dei--LegalEntityAxis__custom--ChannelPartnersCapitalMember_zOlt4qwjAyi"><ix:nonFraction name="us-gaap:GainsLossesOnExtinguishmentOfDebt" contextRef="From2023-08-092023-08-09_custom_ChannelPartnersCapitalMember" id="Fact001382" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,115,223</ix:nonFraction></span> loss to the Company
which was recorded as a charge to Extinguishment of Debt Liabilities in the Statements of Operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">2024
Convertible Notes</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
November 8, 2023, the Company entered into a Securities Purchase Agreement (&#8220;SPA&#8221;) with a shareholder for the
issuance&#160;<span id="xdx_90F_eus-gaap--ConvertiblePreferredStockSharesIssuedUponConversion_iI_c20231108_zSpU5amBgfOd"><ix:nonFraction name="us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion" contextRef="AsOf2023-11-08" id="Fact001383" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,260,504</ix:nonFraction></span>&#160;shares
of Series B Convertible Preferred Stock, par value $<span id="xdx_900_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_c20231108_z4JXZysGzjk8"><ix:nonFraction name="us-gaap:DebtInstrumentConvertibleConversionPrice1" contextRef="AsOf2023-11-08" id="Fact001384" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.001</ix:nonFraction></span>&#160;per
share (the &#8220;Series B Preferred Stock&#8221;), for an aggregate purchase price of $<span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20231108__20231108_zganK9PRuxs7"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2023-11-082023-11-08" id="Fact001385" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,000,000</ix:nonFraction></span>&#160;paid
in 15 monthly installments of $<span id="xdx_90F_eus-gaap--DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid_iI_c20231108_zK3TtlgteSQe"><ix:nonFraction name="us-gaap:DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid" contextRef="AsOf2023-11-08" id="Fact001386" format="ixt:numdotdecimal" decimals="0" unitRef="USD">200,000</ix:nonFraction></span>&#160;each,
commencing on the later of January 10, 2024 or a date after stockholder approval of an amendment to the Company&#8217;s Certificate
of Incorporation to authorize the creation of the Series B Preferred Stock. The Series B Preferred Stock was convertible at any time
into shares of common stock of the Company without any further consideration. Following the issuance of the Series B Preferred
Stock, it would rank senior to the common stock with respect to payments upon the liquidation, dissolution and winding up of the
Company. Due to a delay in the stockholder approval, the Company amended the SPA on February 12, 2024 to issue a promissory note,
due and payable on the earlier of 15 months or 12 months if the Series B Preferred Stock has not been authorized, convertible into
Series B Convertible Preferred Stock with identical funding amounts and terms (the &#8220;$<span id="xdx_903_eus-gaap--ConvertibleDebt_iI_c20241231_zgzI8itrNQO5" title="Convertible debt"><ix:nonFraction name="us-gaap:ConvertibleDebt" contextRef="AsOf2024-12-31" id="Fact001388" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,000,000</ix:nonFraction></span>
Convertible Promissory Note&#8221;). The shareholder funded $<span id="xdx_905_eus-gaap--ProceedsFromContributedCapital_c20240101__20241231__us-gaap--DebtInstrumentAxis__custom--ConvertiblePromissoryNotesMember__srt--RangeAxis__srt--MaximumMember_zjteYQfZeOV3" title="Shareholder funded"><ix:nonFraction name="us-gaap:ProceedsFromContributedCapital" contextRef="From2024-01-012024-12-31_custom_ConvertiblePromissoryNotesMember_srt_MaximumMember" id="Fact001390" format="ixt:numdotdecimal" decimals="0" unitRef="USD">800,000</ix:nonFraction></span>
of the $<span id="xdx_900_eus-gaap--ProceedsFromContributedCapital_c20240101__20241231__us-gaap--DebtInstrumentAxis__custom--ConvertiblePromissoryNotesMember__srt--RangeAxis__srt--MinimumMember_zubQQQVByqo4" title="Shareholder funded"><ix:nonFraction name="us-gaap:ProceedsFromContributedCapital" contextRef="From2024-01-012024-12-31_custom_ConvertiblePromissoryNotesMember_srt_MinimumMember" id="Fact001392" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,000,000</ix:nonFraction></span>
commitment in 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company then proceeded to enter into a series of incremental convertible promissory notes with other investors totaling $<span id="xdx_902_eus-gaap--DebtInstrumentAnnualPrincipalPayment_iI_c20241231__us-gaap--DebtInstrumentAxis__custom--ConvertiblePromissoryNotesMember_zqMtxGlPF6ui" title="Total principal amount"><ix:nonFraction name="us-gaap:DebtInstrumentAnnualPrincipalPayment" contextRef="AsOf2024-12-31_custom_ConvertiblePromissoryNotesMember" id="Fact001394" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,135,000</ix:nonFraction></span>&#160;with
terms identical to the $<span id="xdx_907_eus-gaap--ConvertibleDebt_iI_c20241231__us-gaap--DebtInstrumentAxis__custom--ConvertiblePromissoryNotesMember_zcyNEtVNxe14" title="Convertible debt"><ix:nonFraction name="us-gaap:ConvertibleDebt" contextRef="AsOf2024-12-31_custom_ConvertiblePromissoryNotesMember" id="Fact001396" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,000,000</ix:nonFraction></span>&#160;Convertible Promissory Note (collectively referred to as the &#8220;Original 2024 Convertible
Promissory Notes&#8221;) for an aggregate principal amount of $<span id="xdx_90C_eus-gaap--DebtInstrumentPeriodicPayment_c20240101__20241231__us-gaap--DebtInstrumentAxis__custom--ConvertiblePromissoryNotesMember_zTtOsplvGC0b" title="Principal amount due in monthly installments"><ix:nonFraction name="us-gaap:DebtInstrumentPeriodicPayment" contextRef="From2024-01-012024-12-31_custom_ConvertiblePromissoryNotesMember" id="Fact001398" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,935,000</ix:nonFraction></span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<ix:exclude><!-- Field: Page; Sequence: 114; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
2024 Original Convertible Promissory Notes earned interest at&#160;<span id="xdx_907_eus-gaap--DebtConversionOriginalDebtInterestRateOfDebt_dp_uPure_c20240101__20241231__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyFourConvertiblePromissoryNotesMember_zFrMXutDFmci" title="Debt conversion, original debt, interest rate of debt"><ix:nonFraction name="us-gaap:DebtConversionOriginalDebtInterestRateOfDebt" contextRef="From2024-01-012024-12-31_custom_TwoThousandTwentyFourConvertiblePromissoryNotesMember" id="Fact001400" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">8.5</ix:nonFraction></span>% per annum payable quarterly in either cash or common stock at the
election of the Company. At any time following the date of shareholder approval to authorize the creation of Series B Preferred Stock
prior to the maturity date, the investor may elect to convert all or part of the principal into the Company&#8217;s Series B Preferred
Stock at a conversion price per share equal to $<span id="xdx_906_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pid_c20241231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zgG3yQ2gkZ47" title="Preferred stock, par value"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2024-12-31_us-gaap_SeriesBPreferredStockMember" id="Fact001402" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.38</ix:nonFraction></span>. Without limiting the forgoing, all principal amounts outstanding on the maturity
date will automatically convert into the Company&#8217;s Series B Preferred Stock. The Series B Preferred Stock is entitled to cumulative
dividends at<span id="xdx_905_ecustom--CumulativeDividendsPercent_iI_pid_dp_uPure_c20241231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zX9iursTBdyl" title="Cumulative dividends percent">&#160;<ix:nonFraction name="NRXS:CumulativeDividendsPercent" contextRef="AsOf2024-12-31_us-gaap_SeriesBPreferredStockMember" id="Fact001404" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">8.5</ix:nonFraction></span>% per annum (whether or not declared) payable quarterly in either cash or common stock at the $<span id="xdx_903_eus-gaap--CommonStockConvertibleConversionPriceDecrease_pid_c20240101__20241231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zEmJMQVEvfoe" title="Common stock conversion price"><ix:nonFraction name="us-gaap:CommonStockConvertibleConversionPriceDecrease" contextRef="From2024-01-012024-12-31_us-gaap_SeriesBPreferredStockMember47710687" id="Fact001406" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.38</ix:nonFraction></span>&#160;conversion
price at the election of the Company. Upon conversion to Series B Preferred Stock, the investor may elect, at its option at any time,
to convert all or part of the Series B Preferred Stock plus accrued but unpaid dividends into an equivalent amount of common stock at
the $<span id="xdx_907_eus-gaap--CommonStockConvertibleConversionPriceDecrease_pid_c20240101__20241231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zYUMz2kUlIAf" title="Common stock conversion price"><ix:nonFraction name="us-gaap:CommonStockConvertibleConversionPriceDecrease" contextRef="From2024-01-012024-12-31_us-gaap_SeriesBPreferredStockMember47710687" id="Fact001408" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.38</ix:nonFraction></span>&#160;conversion price.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subsequently,
the Company entered into three convertible promissory notes with related institutional accredited investors with terms similar to
the Original 2024 Convertible Promissory Notes (collectively referred to as the &#8220;Amended 2024 Convertible Promissory
Notes&#8221;) for an additional principal amount of $<span id="xdx_904_eus-gaap--ConvertibleDebt_iI_c20241221__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyFourConvertiblePromissoryNotesMember_zxzVGfogPE5"><ix:nonFraction name="us-gaap:ConvertibleDebt" contextRef="AsOf2024-12-21_custom_TwoThousandTwentyFourConvertiblePromissoryNotesMember" id="Fact001409" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,000,000</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.
Certain provisions to the SPA and Certificate of Designation previously issued on February 12, 2024 changed, including (i) the
number of shares of preferred stock to be designated as Series B Preferred Stock was increased &#160;to&#160;<span id="xdx_906_eus-gaap--PreferredStockSharesAuthorized_iI_c20240212__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyFourConvertiblePromissoryNotesMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_z29Cg7GrSyLe"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2024-02-12_custom_TwoThousandTwentyFourConvertiblePromissoryNotesMember_us-gaap_SeriesBPreferredStockMember" id="Fact001410" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">4,000,000</ix:nonFraction> </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares,
(ii) the stated value of the Series B Preferred Stock was changed to $<span id="xdx_907_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pid_c20240212__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyFourConvertiblePromissoryNotesMember_zKe3cDwiWKWa"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2024-02-12_custom_TwoThousandTwentyFourConvertiblePromissoryNotesMember_us-gaap_SeriesBPreferredStockMember" id="Fact001411" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.38</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;per
share, (iii) the right to receive dividends will expire automatically on June 30, 2025, (iv) the liquidation rights will
automatically expire on June 30, 2025, and (v) the number of shares of the common stock that a holder of Series B preferred stock is
entitled to receive shall not exceed the maximum percentage chosen by the holder, which is initially set at between<span id="xdx_90A_ecustom--DebtInstrumentDiscountRate_iI_dp_uPure_c20241212__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyFourConvertiblePromissoryNotesMember__srt--RangeAxis__srt--MinimumMember_zk5Yi6FLQSx4">&#160;<ix:nonFraction name="NRXS:DebtInstrumentDiscountRate" contextRef="AsOf2024-12-12_us-gaap_SeriesBPreferredStockMember_custom_TwoThousandTwentyFourConvertiblePromissoryNotesMember_srt_MinimumMember" id="Fact001412" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">4.99</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%
and&#160;<span id="xdx_906_ecustom--DebtInstrumentDiscountRate_iI_dp_uPure_c20240212__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyFourConvertiblePromissoryNotesMember__srt--RangeAxis__srt--MaximumMember_zCior02h0463"><ix:nonFraction name="NRXS:DebtInstrumentDiscountRate" contextRef="AsOf2024-02-12_us-gaap_SeriesBPreferredStockMember_custom_TwoThousandTwentyFourConvertiblePromissoryNotesMember_srt_MaximumMember" id="Fact001413" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">19.99</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%
until shareholder approval is obtained, of the number of outstanding shares of the common stock at the time of the conversion of the
Series B Preferred Stock shares.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
maturity date was on the earlier of (i) June 21, 2025, (ii) upon written demand occurring on or after March 21, 2025 in the event that
the Series B Preferred Stock has not been duly authorized on or before such date, or (iii) immediately upon the occurrence of an event
of default. Automatic conversion into shares of Series B preferred stock (at a conversion price of $<span id="xdx_901_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pid_c20240212__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_z38FWDM4Q7k2" title="Preferred stock, par value"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2024-02-12_us-gaap_SeriesBPreferredStockMember" id="Fact001415" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.38</ix:nonFraction></span>&#160;per share) would occur
following the date of shareholder approval. In the event the Company failed to obtain shareholder approval before August 15, 2024, rights
existed to convert the outstanding amount into shares of the common stock, at a price per share of $<span id="xdx_907_eus-gaap--CommonStockConvertibleConversionPriceDecrease_pid_c20240212__20240212__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zFq5z6Zgut6d" title="Common stock conversion price"><ix:nonFraction name="us-gaap:CommonStockConvertibleConversionPriceDecrease" contextRef="From2024-02-122024-02-12_us-gaap_SeriesBPreferredStockMember" id="Fact001417" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.38</ix:nonFraction></span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of August 15, 2024, the Company received $<span id="xdx_90E_eus-gaap--DebtInstrumentPeriodicPayment_c20240815__20240815__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyFourConvertibleNotesMember_zXnYu9tKPJV1" title="Principal amount due in monthly installments"><ix:nonFraction name="us-gaap:DebtInstrumentPeriodicPayment" contextRef="From2024-08-152024-08-15_custom_TwoThousandTwentyFourConvertibleNotesMember" id="Fact001419" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,935,000</ix:nonFraction></span>&#160;of
the principal amount of the Amended 2024 Convertible Notes with the remainder due in monthly installments through March of 2025
resulting in an effective interest rate of <span id="xdx_904_eus-gaap--DebtInstrumentInterestRateEffectivePercentage_iI_pid_dp_uPure_c20240915__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyFourConvertiblePromissoryNotesMember_zRmMIGMhojjd" title="Debt instrument interest rate effective percentage"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" contextRef="AsOf2024-09-15_custom_TwoThousandTwentyFourConvertiblePromissoryNotesMember" id="Fact001421" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">12.5</ix:nonFraction></span>%. On August 15, 2024, the Company&#8217;s shareholders authorized&#160;<span id="xdx_903_eus-gaap--PreferredStockSharesAuthorized_iI_c20240815__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyFourConvertiblePromissoryNotesMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zrwbtgBVzqU4" title="Preferred stock, shares authorized"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2024-08-15_custom_TwoThousandTwentyFourConvertiblePromissoryNotesMember_us-gaap_SeriesBPreferredStockMember" id="Fact001423" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">5,000,000</ix:nonFraction></span>&#160;shares
of preferred stock of which&#160;<span id="xdx_909_eus-gaap--TemporaryEquitySharesAuthorized_iI_pid_c20240815__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyFourConvertiblePromissoryNotesMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zWIBgMWt78qi" title="Temporary equity, shares authorized"><ix:nonFraction name="us-gaap:TemporaryEquitySharesAuthorized" contextRef="AsOf2024-08-15_custom_TwoThousandTwentyFourConvertiblePromissoryNotesMember_us-gaap_SeriesBPreferredStockMember" id="Fact001425" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">4,000,000</ix:nonFraction></span>&#160;shares
were designated as $<span id="xdx_902_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20240815__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyFourConvertiblePromissoryNotesMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zFlL4jy3qIjk" title="Common stock, par value"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2024-08-15_custom_TwoThousandTwentyFourConvertiblePromissoryNotesMember_us-gaap_SeriesBPreferredStockMember" id="Fact001427" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.001</ix:nonFraction></span>&#160;par
value Series B preferred stock. Pursuant to the terms of the Amended 2024 Convertible Promissory Notes, the outstanding principal
balance of $<span id="xdx_902_eus-gaap--DebtInstrumentPeriodicPayment_c20240815__20240815__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyFourConvertibleNotesMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zZt5xsKjsRT1" title="Principal amount due in monthly installments"><ix:nonFraction name="us-gaap:DebtInstrumentPeriodicPayment" contextRef="From2024-08-152024-08-15_custom_TwoThousandTwentyFourConvertibleNotesMember_us-gaap_SeriesBPreferredStockMember" id="Fact001429" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,935,000</ix:nonFraction></span>&#160;was
mandatorily converted into <span id="xdx_90B_eus-gaap--ConversionOfStockSharesConverted1_c20240815__20240815__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyFourConvertiblePromissoryNotesMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zZ33ZmUS0hka" title="Number of shares converted"><ix:nonFraction name="us-gaap:ConversionOfStockSharesConverted1" contextRef="From2024-08-152024-08-15_custom_TwoThousandTwentyFourConvertiblePromissoryNotesMember_us-gaap_SeriesBPreferredStockMember" id="Fact001431" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,073,524</ix:nonFraction></span>&#160;Series
B Preferred Shares at a conversion price of $<span id="xdx_907_ecustom--CommonStockConvertibleConversionPrice_pid_c20240815__20240815__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyFourConvertiblePromissoryNotesMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zPYYVSWxi6ve" title="Common stock conversion price"><ix:nonFraction name="NRXS:CommonStockConvertibleConversionPrice" contextRef="From2024-08-152024-08-15_custom_TwoThousandTwentyFourConvertiblePromissoryNotesMember_us-gaap_SeriesBPreferredStockMember" id="Fact001433" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.38</ix:nonFraction></span>.
Upon the mandatory conversion, the unamortized debt discount of $<span id="xdx_902_eus-gaap--UnamortizedDebtIssuanceExpense_iI_c20241231__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyFourConvertiblePromissoryNotesMember_zWlZydP0zQ8i"><ix:nonFraction name="us-gaap:UnamortizedDebtIssuanceExpense" contextRef="AsOf2024-12-31_custom_TwoThousandTwentyFourConvertiblePromissoryNotesMember" id="Fact001434" format="ixt:numdotdecimal" decimals="0" unitRef="USD">165,577</ix:nonFraction></span>
was reclassified to Additional Paid-In-Capital in the Statements of Stockholders&#8217; Equity (Deficit).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interest
expense totaled $<span id="xdx_90D_eus-gaap--InterestExpense_c20240101__20241231_zjJ8eRLATKW8" title="Interest expense"><ix:nonFraction name="us-gaap:InterestExpense" contextRef="From2024-01-01to2024-12-31" id="Fact001436" format="ixt:numdotdecimal" decimals="0" unitRef="USD">174,328</ix:nonFraction></span> and $<span id="xdx_904_eus-gaap--InterestExpense_c20230101__20231231_zgAjaQYk3xmc" title="Interest expense"><ix:nonFraction name="us-gaap:InterestExpense" contextRef="From2023-01-012023-12-31" id="Fact001438" format="ixt:numdotdecimal" decimals="0" unitRef="USD">476,416</ix:nonFraction></span> for the years ended December 31, 2024 and 2023, respectively. The Company&#8217;s accrued interest
total $<span id="xdx_908_eus-gaap--AccruedLiabilitiesCurrentAndNoncurrent_iI_c20241231_zyK2e3l3mMzf"><span id="xdx_902_eus-gaap--AccruedLiabilitiesCurrentAndNoncurrent_iI_c20231231_z78hv9D4gJpc"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrentAndNoncurrent" contextRef="AsOf2024-12-31" id="Fact001439" format="ixt:numdotdecimal" decimals="0" unitRef="USD"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrentAndNoncurrent" contextRef="AsOf2023-12-31" id="Fact001440" format="ixt:numdotdecimal" decimals="0" unitRef="USD">66,648</ix:nonFraction></ix:nonFraction></span></span> as of December 31, 2024 and 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 115; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Neuraxis,
Inc.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Notes
to Financial Statements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact001442" name="us-gaap:LesseeOperatingLeasesTextBlock"><p id="xdx_802_eus-gaap--LesseeOperatingLeasesTextBlock_zDaqugDXqxi6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>8.
<span id="xdx_82C_zWExa9FWg8Q5">Leases</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s leases are comprised of operating leases for office space. At the inception of the lease, the Company determines whether
the lease contract conveys the right to control the use of identified property for a period of time in exchange for consideration. Leases
are classified as operating or finance leases at the commencement date of the lease. Operating leases are recorded as operating lease
right-of-use assets, other current liabilities, and operating lease liabilities in the Balance Sheets. The Company did not have any finance
leases at December 31, 2024 and 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has two leases primarily consisting of office space in Versailles and Carmel, Indiana.&#160;<span id="xdx_90E_eus-gaap--LesseeOperatingLeaseDescription_c20240101__20241231_zzNggvW090B1" title="Operating lease description"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact001444" name="us-gaap:LesseeOperatingLeaseDescription">The lease in Versailles, Indiana
started January 1, 2022 and had a term of one year, with automatic one year renewal options, unless 60 day notice of vacating is given.
The current monthly lease payment for this lease is $<span id="xdx_90B_eus-gaap--OperatingLeasePayments_c20220101__20220101__us-gaap--GeographicDistributionAxis__custom--VersaillesIndianaMember_zXtKFmAmcJGd" title="Operating lease payment"><ix:nonFraction name="us-gaap:OperatingLeasePayments" contextRef="From2022-01-012022-01-01_custom_VersaillesIndianaMember" id="Fact001446" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,800</ix:nonFraction></span>&#160;with a&#160;<span id="xdx_90B_eus-gaap--LesseeOperatingLeaseDiscountRate_iI_dp_uPure_c20220101__us-gaap--GeographicDistributionAxis__custom--VersaillesIndianaMember_zsOtgeDtJ2x2" title="Discount rate"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseDiscountRate" contextRef="AsOf2022-01-01_custom_VersaillesIndianaMember" id="Fact001448" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">4</ix:nonFraction></span>% per annum increase. A new lease in Carmel, Indiana commenced
January 1, 2024. The initial term is five years and five months. The monthly lease payment started at $<span id="xdx_900_eus-gaap--OperatingLeasePayments_c20240101__20240101__us-gaap--GeographicDistributionAxis__custom--CarmelIndianaMember_zEzmFZPahbfg" title="Operating lease payment"><ix:nonFraction name="us-gaap:OperatingLeasePayments" contextRef="From2024-01-012024-01-01_custom_CarmelIndianaMember" id="Fact001450" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,721</ix:nonFraction></span>&#160;with an annual increase
of&#160;<span id="xdx_90E_eus-gaap--LesseeOperatingLeaseDiscountRate_iI_pid_dp_uPure_c20240101__us-gaap--GeographicDistributionAxis__custom--CarmelIndianaMember_zefaptoL8Nvb" title="Operating lease payment rate"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseDiscountRate" contextRef="AsOf2024-01-01_custom_CarmelIndianaMember" id="Fact001452" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">2.5</ix:nonFraction></span>%. As long as the Company is not in default, it is only obligated to pay an amount equal to 50% of the monthly base rent for
months 1-10</ix:nonNumeric></span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating
lease right-of-use assets and liabilities are recognized at the commencement date based on the present value of lease payments over the
lease term. As the implicit interest rate is generally not readily determinable, the Company uses an incremental borrowing rate based
on the information available at the commencement date in determining the present value of lease payments. The incremental borrowing rate
reflects the estimated rate of interest that the Company would pay to borrow on a collateralized basis over a similar economic environment.
Lease expense for the operating lease is recognized on a straight-line basis over the lease term.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Leases
may include renewal options, and the renewal option is included in the lease term if the Company concludes that it is reasonably certain
that the option will be exercised. Certain leases may contain rent escalation clauses, either fixed or adjusted periodically for inflation
of market rates, that are factored into the calculation of lease payments to the extent they are fixed and determinable at lease inception.
The Company also has variable lease payments that do not depend on a rate or index, primarily for items such as common area maintenance
and real estate taxes, which are recorded as expenses when incurred.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the years ended December 31, 2024 and 2023, the Company recognized $<span id="xdx_90B_eus-gaap--OperatingLeaseExpense_c20240101__20241231_zzEan1koYyq8" title="Operating lease expense"><ix:nonFraction name="us-gaap:OperatingLeaseExpense" contextRef="From2024-01-01to2024-12-31" id="Fact001454" format="ixt:numdotdecimal" decimals="0" unitRef="USD">96,177</ix:nonFraction></span> and $<span id="xdx_907_eus-gaap--OperatingLeaseExpense_c20230101__20231231_zTeBySBAQXg2" title="Operating lease expense"><ix:nonFraction name="us-gaap:OperatingLeaseExpense" contextRef="From2023-01-012023-12-31" id="Fact001456" format="ixt:numdotdecimal" decimals="0" unitRef="USD">49,051</ix:nonFraction></span> of operating lease expense, including short-term
lease expense and variable lease costs, which are immaterial.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact001458" name="us-gaap:LeaseCostTableTextBlock"><p id="xdx_89C_eus-gaap--LeaseCostTableTextBlock_zFztbrypnsXg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table presents information related to the Company&#8217;s operating leases:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span id="xdx_8B7_zfHapyJiPMx" style="display: none">Schedule of Operating Leases</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_495_20241231_zcoyBtzitmTd" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, 2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49B_20231231_z7nQi5gKvHf4" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, 2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--OperatingLeaseRightOfUseAsset_iI_z3IUYNRAlpId" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left; padding-bottom: 1pt">Operating lease right-of-use assets</td><td style="width: 2%; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="AsOf2024-12-31" id="Fact001460" format="ixt:numdotdecimal" decimals="0" unitRef="USD">284,656</ix:nonFraction></span></td><td style="width: 1%; padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 16%; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="AsOf2023-12-31" id="Fact001461" format="ixt:numdotdecimal" decimals="0" unitRef="USD">70,263</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--OperatingLeaseLiabilityCurrent_iI_maOLLz38G_zLVvb7Ghl128" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Other current liabilities</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="AsOf2024-12-31" id="Fact001463" format="ixt:numdotdecimal" decimals="0" unitRef="USD">62,754</ix:nonFraction></span></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="AsOf2023-12-31" id="Fact001464" format="ixt:numdotdecimal" decimals="0" unitRef="USD">49,127</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_maOLLz38G_zUI2yxIjMR36" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Operating lease liabilities</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="AsOf2024-12-31" id="Fact001466" format="ixt:numdotdecimal" decimals="0" unitRef="USD">256,499</ix:nonFraction></span></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="AsOf2023-12-31" id="Fact001467" format="ixt:numdotdecimal" decimals="0" unitRef="USD">27,071</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--OperatingLeaseLiability_iTI_mtOLLz38G_zKDhLqa2gJd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt">Total</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:OperatingLeaseLiability" contextRef="AsOf2024-12-31" id="Fact001469" format="ixt:numdotdecimal" decimals="0" unitRef="USD">319,253</ix:nonFraction></span></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiability" contextRef="AsOf2023-12-31" id="Fact001470" format="ixt:numdotdecimal" decimals="0" unitRef="USD">76,198</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Weighted-average remaining lease term (in years)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_907_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20241231_zQIProZFW8bc" title="Weighted average remaining lease term (in years)"><ix:nonNumeric contextRef="AsOf2024-12-31" format="ixt-sec:duryear" id="Fact001472" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1">2.75</ix:nonNumeric></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90B_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20231231_zhbewRy86dwf" title="Weighted average remaining lease term (in years)"><ix:nonNumeric contextRef="AsOf2023-12-31" format="ixt-sec:duryear" id="Fact001474" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1">3.75</ix:nonNumeric></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Weighted-average discount rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_900_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_dp_uPure_c20241231_z5BSj9aa6XE4" title="Weighted average discount rate"><ix:nonFraction name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" contextRef="AsOf2024-12-31" id="Fact001476" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">15.0</ix:nonFraction></span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90B_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_dp_uPure_c20231231_z940P4nqH1Ke" title="Weighted average discount rate"><ix:nonFraction name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" contextRef="AsOf2023-12-31" id="Fact001478" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">15.0</ix:nonFraction></span></td><td style="text-align: left">%</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A1_z7jIB6o5sUmf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact001480" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock"><p id="xdx_89C_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zHwzvxcPJMja" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2024, the maturities of the Company&#8217;s operating lease liabilities were as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B6_zTIR3865vQEf" style="display: none">Schedule of Maturities Operating Lease Liabilities</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
  <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left"/><td id="xdx_49E_20241231_zE69sUSivHee" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_maLOLLPzyNu_zAnUqfeRV5mj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%; text-align: left">2025</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" contextRef="AsOf2024-12-31" id="Fact001482" format="ixt:numdotdecimal" decimals="0" unitRef="USD">105,130</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_maLOLLPzyNu_z8Q5BQvx38Mf" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">2026</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" contextRef="AsOf2024-12-31" id="Fact001484" format="ixt:numdotdecimal" decimals="0" unitRef="USD">108,106</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_maLOLLPzyNu_z1wKRjz18iIb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">2027</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" contextRef="AsOf2024-12-31" id="Fact001486" format="ixt:numdotdecimal" decimals="0" unitRef="USD">86,856</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFour_iI_maLOLLPzyNu_ztch8OL13t4l" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">2028</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" contextRef="AsOf2024-12-31" id="Fact001488" format="ixt:numdotdecimal" decimals="0" unitRef="USD">89,027</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFive_iI_maLOLLPzyNu_z3Yt9rhqjbL" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">2029</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive" contextRef="AsOf2024-12-31" id="Fact001490" format="ixt:numdotdecimal" decimals="0" unitRef="USD">38,025</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_mtLOLLPzyNu_z63kL7uUXONc" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Total lease payments</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" contextRef="AsOf2024-12-31" id="Fact001492" format="ixt:numdotdecimal" decimals="0" unitRef="USD">427,144</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_di_zDr3iSUhUu2l" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Less: imputed interest</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" contextRef="AsOf2024-12-31" id="Fact001494" format="ixt:numdotdecimal" decimals="0" unitRef="USD">107,891</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_401_eus-gaap--OperatingLeaseLiability_iI_zMTx5ZJu3jC8" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Total present value of lease payments</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiability" contextRef="AsOf2024-12-31" id="Fact001496" format="ixt:numdotdecimal" decimals="0" unitRef="USD">319,253</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  </table>
<!-- Field: Split-Segment; Name: 001 -->
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric></ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact001498" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock"><p id="xdx_80B_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zyRGFQBtZSU1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>9.
<span id="xdx_827_zOYBYQ9MVzY8">Common Stock and Warrants</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company authorized <span id="xdx_90E_eus-gaap--CommonStockSharesAuthorized_iI_c20241231_zx0NR2fOdFD9" title="Common stock, shares authorized"><span id="xdx_909_eus-gaap--CommonStockSharesAuthorized_iI_c20231231_z9bAu6A7b1S3" title="Common stock, shares authorized"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2024-12-31" id="Fact001500" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2023-12-31" id="Fact001502" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">100,000,000</ix:nonFraction></ix:nonFraction></span></span> shares of common stock, of which <span id="xdx_907_eus-gaap--CommonStockSharesIssued_iI_c20241231_zWqLP4IufL74" title="Common stock, shares issued"><span id="xdx_90C_eus-gaap--CommonStockSharesOutstanding_iI_c20241231_zw3AtzhhAce4" title="Common stock, shares outstanding"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2024-12-31" id="Fact001504" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2024-12-31" id="Fact001506" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">6,990,227</ix:nonFraction></ix:nonFraction></span></span> and <span id="xdx_90B_eus-gaap--CommonStockSharesIssued_iI_c20231231_zQNWweik0yQc" title="Common stock, shares, issued"><span id="xdx_900_eus-gaap--CommonStockSharesOutstanding_iI_c20231231_zKgmFzJ3Robd" title="Common stock, shares, outstanding"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2023-12-31" id="Fact001508" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2023-12-31" id="Fact001510" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">6,508,897</ix:nonFraction></ix:nonFraction></span></span> shares were issued and outstanding as of December
31, 2024 and 2023, respectively. On January 10, 2023, the Company&#8217;s board of directors authorized a <span id="xdx_909_eus-gaap--StockholdersEquityReverseStockSplit_c20230110__20230110_z3gbNKCeDgo4" title="Reverse stock split"><ix:nonNumeric contextRef="From2023-01-102023-01-10" id="Fact001512" name="us-gaap:StockholdersEquityReverseStockSplit">2-for-1 reverse stock split.</ix:nonNumeric></span>
All share information in these financial statements has been adjusted for this reverse stock split.&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended December 31, 2023, the Company issued (i) <span id="xdx_90E_ecustom--StockIssuedDuringPeriodSharesCommonStockIssuedUponInitialPublicOffering_c20230101__20231231_zX9UpQi4jOn4" title="Common shares, issued upon initial public offering, shares"><ix:nonFraction name="NRXS:StockIssuedDuringPeriodSharesCommonStockIssuedUponInitialPublicOffering" contextRef="From2023-01-012023-12-31" id="Fact001514" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,098,667</ix:nonFraction></span> common shares issued upon the completion of the IPO on August 9, 2023
at a price of $<span id="xdx_909_eus-gaap--SharePrice_iI_c20231231_zYvgEdpVO7C4" title="Common shares, per share"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2023-12-31" id="Fact001516" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">6.00</ix:nonFraction></span> per share resulting in net proceeds of $<span id="xdx_90B_eus-gaap--ProceedsFromIssuanceInitialPublicOffering_c20230101__20231231_zyooScp2GJO8" title="Net proceeds"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" contextRef="From2023-01-012023-12-31" id="Fact001518" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,110,677</ix:nonFraction></span>, (ii) <span id="xdx_907_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_c20230101__20231231_zD5lTo3DroD3" title="Conversion shares"><ix:nonFraction name="us-gaap:DebtConversionConvertedInstrumentSharesIssued1" contextRef="From2023-01-012023-12-31" id="Fact001520" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,244,228</ix:nonFraction></span> common shares upon conversion of <span id="xdx_902_eus-gaap--ConvertiblePreferredStockSharesIssuedUponConversion_iI_c20231231_zMptYG4BMD5f" title="Shares issued upon conversion"><ix:nonFraction name="us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion" contextRef="AsOf2023-12-31" id="Fact001522" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">506,637</ix:nonFraction></span> shares
of Convertible Series A Preferred Stock and <span id="xdx_90B_eus-gaap--ConversionOfStockSharesConverted1_c20230101__20231231__us-gaap--StatementClassOfStockAxis__custom--ConvertibleSeriesSeedPreferredStockMember_zRnID9P3FCBf" title="Stock value converted"><ix:nonFraction name="us-gaap:ConversionOfStockSharesConverted1" contextRef="From2023-01-012023-12-31_custom_ConvertibleSeriesSeedPreferredStockMember" id="Fact001524" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">115,477</ix:nonFraction></span> shares of Convertible Series Seed Preferred Stock, (iii) <span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodSharesConversionOfUnits_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zR4zARwjwVI4" title="Common stock issued upon debt conversion, shares"><span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodSharesConversionOfUnits_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z7Cg7pRur7Nj" title="Common stock issued upon debt conversion, shares"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember" id="Fact001526" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits" contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember" id="Fact001528" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,649,900</ix:nonFraction></ix:nonFraction></span></span> common shares
upon conversion of the 2022 and 2023 Convertible Notes, (iv) <span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20230101__20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--VendorsMember_zmVZK67FzrC8" title="Service for payments"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" contextRef="From2023-01-012023-12-31_custom_VendorsMember" id="Fact001530" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">425,000</ix:nonFraction></span> common shares as payment to vendors for services and (v) <span id="xdx_902_eus-gaap--ConversionOfStockSharesIssued1_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z6oOmHqPdwNc" title="Exercise of warrants"><ix:nonFraction name="us-gaap:ConversionOfStockSharesIssued1" contextRef="From2023-01-012023-12-31_us-gaap_WarrantMember" id="Fact001532" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">127,780</ix:nonFraction></span>
common shares upon the exercise of warrants.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended December 31, 2024, the Company issued (i) <span id="xdx_901_ecustom--StockIssuedDuringPeriodSharesCommonStockIssuedUponInitialPublicOffering_c20240101__20241231_zsxKga9uUwme" title="Common shares, issued upon initial public offering, shares"><ix:nonFraction name="NRXS:StockIssuedDuringPeriodSharesCommonStockIssuedUponInitialPublicOffering" contextRef="From2024-01-01to2024-12-31" id="Fact001534" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">245,955</ix:nonFraction></span> common shares to settle 2022 Convertible Note and Series A Preferred
Stock holder disputes, (ii) <span id="xdx_901_eus-gaap--ConversionOfStockSharesIssued1_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zLweVUlZfsu8" title="Exercise of warrants"><ix:nonFraction name="us-gaap:ConversionOfStockSharesIssued1" contextRef="From2024-01-012024-12-31_us-gaap_WarrantMember" id="Fact001536" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">11,000</ix:nonFraction></span> common shares upon the exercise of warrants, (iii) <span id="xdx_900_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20240101__20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--VendorsMember_zCE1ZtZ3VkJ9" title="Service for payments"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" contextRef="From2024-01-012024-12-31_custom_VendorsMember" id="Fact001538" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">115,145</ix:nonFraction></span> common shares as payment to vendors for
services, (iv) <span id="xdx_904_eus-gaap--ConversionOfStockSharesConverted1_c20240101__20241231_zhgdD00kyqH7" title="Conversion, interest"><ix:nonFraction name="us-gaap:ConversionOfStockSharesConverted1" contextRef="From2024-01-01to2024-12-31" id="Fact001540" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">59,055</ix:nonFraction></span> common shares in lieu of interest on the 2024 Convertible Notes, (v) <span id="xdx_904_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20240101__20241231__us-gaap--TypeOfArrangementAxis__custom--EmployementAgreementMember_zZZUyryZreT9" title="Service for payments"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" contextRef="From2024-01-012024-12-31_custom_EmployementAgreementMember" id="Fact001542" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">25,832</ix:nonFraction></span> shares pursuant to the severance provisions
of an employment agreement and (vi) <span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20240101__20241231_zRr3DNtdTN9a" title="Service for payments"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" contextRef="From2024-01-01to2024-12-31" id="Fact001544" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">24,343</ix:nonFraction></span> common shares for board service.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 116; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Neuraxis,
Inc.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Notes
to Financial Statements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended December 31, 2023, the Company issued (i) <span id="xdx_903_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20231231__us-gaap--TypeOfArrangementAxis__custom--TwoThousandTwentyThreeConvertiblePromissoryNotesMember_zVKjb30hmoFh" title="Number of Warrants"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2023-12-31_custom_TwoThousandTwentyThreeConvertiblePromissoryNotesMember" id="Fact001546" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">505,570</ix:nonFraction></span> <span id="xdx_907_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dxL_c20231231__us-gaap--TypeOfArrangementAxis__custom--TwoThousandTwentyTwoConvertibleNotesMember_zosR6VaCDMLc" title="Warrants, term::XDX::P5Y"><span style="-sec-ix-hidden: xdx2ixbrl1548">five-year</span></span> warrants to purchase common stock equal to fifty percent (50%)
of the shares into which the 2023 Convertible Promissory Notes could be converted at issuance at an exercise price of $<span id="xdx_90D_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20231231__us-gaap--TypeOfArrangementAxis__custom--TwoThousandTwentyThreeConvertiblePromissoryNotesMember_zR4x9Sat3sV3"><ix:nonFraction name="us-gaap:SharesIssuedPricePerShare" contextRef="AsOf2023-12-31_custom_TwoThousandTwentyThreeConvertiblePromissoryNotesMember" id="Fact001549" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">5.25</ix:nonFraction></span> per share,
(ii) <span id="xdx_905_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20231231__us-gaap--TypeOfArrangementAxis__custom--AdvisoryAgreementMember_zVQ7JmajdSq6" title="Number of Warrants"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2023-12-31_custom_AdvisoryAgreementMember" id="Fact001551" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">122,202</ix:nonFraction></span> <span id="xdx_906_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dxL_c20231231__us-gaap--TypeOfArrangementAxis__custom--AdvisoryAgreementMember_zeMxjMDhpCM7" title="Warrants, term::XDX::P5Y"><span style="-sec-ix-hidden: xdx2ixbrl1553">five year</span></span> warrants to purchase common stock pursuant an advisory agreement with a consulting firm upon closing of the Company&#8217;s
IPO at an exercise price of $<span id="xdx_904_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20231231__us-gaap--TypeOfArrangementAxis__custom--AdvisoryAgreementMember_zzJImS8mABYg"><ix:nonFraction name="us-gaap:SharesIssuedPricePerShare" contextRef="AsOf2023-12-31_custom_AdvisoryAgreementMember" id="Fact001554" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">5.25</ix:nonFraction></span> per share and (iii) <span id="xdx_901_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20231231__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementMember_zFd7uBVvCi7" title="Number of Warrants"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2023-12-31_custom_UnderwritingAgreementMember" id="Fact001556" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">186,156</ix:nonFraction></span> <span id="xdx_90C_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dxL_c20231231__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementMember_zLXlqvyUvWO6" title="Warrants, term::XDX::P5Y"><span style="-sec-ix-hidden: xdx2ixbrl1558">five-year</span></span> warrants to purchase common stock pursuant to an underwriting
agreement upon closing of the Company&#8217;s IPO at an exercise price of $<span id="xdx_908_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20231231__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementMember_z32lFDpFX2ed"><ix:nonFraction name="us-gaap:SharesIssuedPricePerShare" contextRef="AsOf2023-12-31_custom_UnderwritingAgreementMember" id="Fact001559" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">5.25</ix:nonFraction></span> per share. Additionally, <span id="xdx_904_ecustom--NumberOfEquivalentOfWarrantsDescription_c20230101__20231231_zZ30RcjUsfNl" title="Number of equivalent of warrants, description"><ix:nonNumeric contextRef="From2023-01-012023-12-31" id="Fact001561" name="NRXS:NumberOfEquivalentOfWarrantsDescription">investors converted (i) 87,856
warrants into an equivalent number of common shares at an exercise price of $2.38 in exchange for $209,097 in cash proceeds and (ii)
40,000 warrants into 39,924 common shares in a cashless exercise transaction.</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended December 31, 2024, the Company issued (i) <span id="xdx_901_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20241231__us-gaap--TypeOfArrangementAxis__custom--TwoThousandTwentyFourConvertiblePromissoryNotesMember_zNMBz3dhtKck" title="Number of Warrants"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2024-12-31_custom_TwoThousandTwentyFourConvertiblePromissoryNotesMember47712359" id="Fact001563" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">38,697</ix:nonFraction></span> <span id="xdx_905_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dxL_c20241231__us-gaap--TypeOfArrangementAxis__custom--TwoThousandTwentyFourConvertiblePromissoryNotesMember_z93VtfAJbd4j" title="Warrants, term::XDX::P5Y"><span style="-sec-ix-hidden: xdx2ixbrl1565">five-year</span></span> warrants to purchase common stock equal to six percent (6%)
of the aggregate number of Original 2024 Convertible Promissory Note common stock equivalents pursuant to an underwriting agreement at
an exercise price of $<span id="xdx_90D_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20241231__us-gaap--TypeOfArrangementAxis__custom--TwoThousandTwentyFourConvertiblePromissoryNotesMember_z0WCE7f0jCYl"><ix:nonFraction name="us-gaap:SharesIssuedPricePerShare" contextRef="AsOf2024-12-31_custom_TwoThousandTwentyFourConvertiblePromissoryNotesMember47712359" id="Fact001566" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.38</ix:nonFraction></span> per share, (ii) <span id="xdx_903_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20241231__us-gaap--TypeOfArrangementAxis__custom--AdvisoryAgreementsMember_zaTjwtuUgC58" title="Number of Warrants"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2024-12-31_custom_AdvisoryAgreementsMember" id="Fact001568" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">68,067</ix:nonFraction></span> <span id="xdx_904_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dxL_c20241231__us-gaap--TypeOfArrangementAxis__custom--AdvisoryAgreementsMember_z6uin94lQ6Ke" title="Warrants, term::XDX::P5Y"><span style="-sec-ix-hidden: xdx2ixbrl1570">five-year</span></span> warrants to purchase common stock pursuant to an advisory agreement at an
exercise price of $<span id="xdx_906_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20241231__us-gaap--TypeOfArrangementAxis__custom--AdvisoryAgreementsMember_zbo3yjrjVAY1"><ix:nonFraction name="us-gaap:SharesIssuedPricePerShare" contextRef="AsOf2024-12-31_custom_AdvisoryAgreementsMember" id="Fact001571" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.38</ix:nonFraction></span> per share. The Common Stock Purchase Warrant Agreements attached to the 2023 Convertible Promissory Notes contained
anti-dilution provisions on both the exercise price and the number of warrants. These anti-dilution features were triggered when the
Company issued the Original 2024 Convertible Promissory Notes that contained a conversion price of $<span id="xdx_907_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20241231__us-gaap--TypeOfArrangementAxis__custom--TwoThousandTwentyFourConvertiblePromissoryNotesMember_zgL4MnU5TVJ8"><ix:nonFraction name="us-gaap:SharesIssuedPricePerShare" contextRef="AsOf2024-12-31_custom_TwoThousandTwentyFourConvertiblePromissoryNotesMember47712359" id="Fact001572" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.38</ix:nonFraction></span> per share as compared to the
$<span id="xdx_900_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20241231__us-gaap--TypeOfArrangementAxis__custom--TwoThousandTwentyThreeConvertiblePromissoryNotesMember_zgoFI7KbFvnb"><ix:nonFraction name="us-gaap:SharesIssuedPricePerShare" contextRef="AsOf2024-12-31_custom_TwoThousandTwentyThreeConvertiblePromissoryNotesMember" id="Fact001573" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">5.25</ix:nonFraction></span> per share exercise price in the 2023 Convertible Promissory Note Common Stock Purchase Warrant Agreements. As a result, the Company
issued <span id="xdx_90B_ecustom--ClassOfWarrantOrRightAdditional_iI_pid_c20241231__us-gaap--TypeOfArrangementAxis__custom--TwoThousandTwentyFourConvertiblePromissoryNotesMember_zw314jkXahv6" title="Number of Warrants, additional"><ix:nonFraction name="NRXS:ClassOfWarrantOrRightAdditional" contextRef="AsOf2024-12-31_custom_TwoThousandTwentyFourConvertiblePromissoryNotesMember47712359" id="Fact001575" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">754,660</ix:nonFraction></span> additional warrants in 2024 to the holders of the 2023 Convertible Promissory Note Common Stock Purchase Warrant Agreements.
Additionally, <span id="xdx_904_ecustom--NumberOfEquivalentOfWarrantsDescription_c20240101__20241231_z4crh28Pft94" title="Number of equivalent of warrants, description"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact001577" name="NRXS:NumberOfEquivalentOfWarrantsDescription">investors converted  11,000 warrants into an equivalent number of common shares at an exercise price of $2.38 in exchange
for $26,180 in cash proceeds.</ix:nonNumeric></span>  The Company also
canceled <span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z7adNtyrgzn3" title="Warrants, canceled"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember" id="Fact001579" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">30,252</ix:nonFraction></span> warrants for no consideration in conjunction with an amendment to an advisory agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember" escape="true" id="Fact001581" name="NRXS:ScheduleOfWarrantActivityForCommonStockTableTextBlock"><p id="xdx_89D_ecustom--ScheduleOfWarrantActivityForCommonStockTableTextBlock_hus-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zLrw0eGMZ8Fh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following is a summary of warrant activity for common stock during the years ended December 31, 2024 and 2023:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span><span id="xdx_8B4_zF19HNxPm3Bk" style="display: none">Schedule of Warrant Activity for Common Stock</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Number of Warrants for Common Stock</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted-Avg. Exercise Price</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted-Avg. Remaining Contractual Life</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; font-weight: bold">Outstanding as of January 1, 2023</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zqCUE1twemab" title="Number of Warrants, Outstanding at beginning of period" style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" contextRef="AsOf2022-12-31_us-gaap_CommonStockMember" id="Fact001583" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">846,507</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zhr3vJ6fezYi" title="Weighted Average Exercise Price, Outstanding at beginning of period" style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2022-12-31_us-gaap_CommonStockMember" id="Fact001585" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">5.06</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z1Jwb8Y6z7F4" title="Weighted Average Remaining Contractual Life - Warrants"><ix:nonNumeric contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember" format="ixt-sec:duryear" id="Fact001587" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">4.72</ix:nonNumeric></span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zvCO7feZJtO3" title="Number of Warrants, Granted" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember" id="Fact001589" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">813,928</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zJhAxuudUgBe" title="Weighted Average Exercise Price, granted" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember" id="Fact001591" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">5.81</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsWeightedAverageRemainingContracualLifeOutstandingNumberGranted_dtY_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zdueqO08qFP" title="Weighted Average Remaining Contractual Life - Warrants Granted"><ix:nonNumeric contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember" format="ixt-sec:duryear" id="Fact001593" name="NRXS:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsWeightedAverageRemainingContracualLifeOutstandingNumberGranted">4.38</ix:nonNumeric></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Converted Prefunded Warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsConvertedPrefundedWarrants_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z1T7to5A8GSd" title="Number of Warrants, Converted Prefunded Warrants" style="text-align: right"><ix:nonFraction name="NRXS:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsConvertedPrefundedWarrants" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember" id="Fact001595" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">289,779</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsConvertedPrefundedWarrantsInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zY56eTAD5bmg" title="Weighted Average Exercise Price, Converted Prefunded Warrants" style="text-align: right"><ix:nonFraction name="NRXS:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsConvertedPrefundedWarrantsInPeriodWeightedAverageExercisePrice" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember" id="Fact001597" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.01</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Cancelled</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zYXpsY5K2eyh" title="Number of Warrants, Granted" style="text-align: right">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember" id="Fact001599" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="Shares">30,252</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsWeightedAverageExercisePriceCancelledExpiredNumber_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zftXG45d9Fcg" title="Weighted Average Exercise Price, Cancelled Expired" style="text-align: right"><ix:nonFraction name="NRXS:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsWeightedAverageExercisePriceCancelledExpiredNumber" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember" id="Fact001601" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2.38</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90B_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsCancelledWeightedAverageRemainingContractualTerm1_dtY_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z3ExdXdKOUI4" title="Weighted Average Remaining Contractual Life - Warrants Cancelled"><ix:nonNumeric contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember" format="ixt-sec:duryear" id="Fact001603" name="NRXS:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsCancelledWeightedAverageRemainingContractualTerm1">4.79</ix:nonNumeric></span></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt">Exercised</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zJwgA5K3QICa" title="Number of Warrants, Exercised" style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember" id="Fact001605" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="Shares">127,856</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_ztaF8wIpjGHb" title="Weighted Average Exercise Price, Excercised" style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1607">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-bottom: 1pt">Outstanding as of December 31, 2023</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zyC3xdrUua51" title="Number of Warrants, Outstanding at beginning of period" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" contextRef="AsOf2023-12-31_us-gaap_CommonStockMember" id="Fact001609" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,822,358</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zk5KvZkRA7S6" title="Weighted Average Exercise Price, Outstanding at beginning of period" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2023-12-31_us-gaap_CommonStockMember" id="Fact001611" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">4.69</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zpHWNBLzvNfe" title="Weighted Average Remaining Contractual Life - Warrants"><ix:nonNumeric contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember" format="ixt-sec:duryear" id="Fact001613" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">3.05</ix:nonNumeric></span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zyDwKGvOqya4" title="Number of Warrants, Granted" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember" id="Fact001615" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">861,424</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zP5e8TEsARIl" title="Weighted Average Exercise Price, granted" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember" id="Fact001617" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.38</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z9qIs9iz7aje" title="Weighted Average Remaining Contractual Life - Warrants Granted"><ix:nonNumeric contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember" format="ixt-sec:duryear" id="Fact001619" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">3.49</ix:nonNumeric></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Cancelled</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_iN_pid_di_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z0JtbrAmw6L9" title="Number of Warrants, Granted" style="text-align: right">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember" id="Fact001621" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">30,252</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsWeightedAverageExercisePriceCancelledExpiredNumber_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z0fBvAhyc7fe" title="Weighted Average Exercise Price, Cancelled Expired" style="text-align: right"><ix:nonFraction name="NRXS:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsWeightedAverageExercisePriceCancelledExpiredNumber" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember" id="Fact001623" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2.38</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90E_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsCancelledWeightedAverageRemainingContractualTerm1_dtY_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zgIGKKCyLomf" title="Weighted Average Remaining Contractual Life - Warrants Cancelled"><ix:nonNumeric contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember" format="ixt-sec:duryear" id="Fact001625" name="NRXS:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsCancelledWeightedAverageRemainingContractualTerm1">4.79</ix:nonNumeric></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt">Exercised</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zfwcoWXVFRFd" title="Number of Warrants, Exercised" style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember" id="Fact001627" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="Shares">11,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zbTO4y9uPVR2" title="Weighted Average Exercise Price, Excercised" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember" id="Fact001629" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.38</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_90A_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisedWeightedAverageRemainingContractualTerm1_dtY_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zcjv1U3Qle25" title="Weighted Average Remaining Contractual Life - Warrants Granted"><ix:nonNumeric contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember" format="ixt-sec:duryear" id="Fact001631" name="NRXS:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisedWeightedAverageRemainingContractualTerm1">3.61</ix:nonNumeric></span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-bottom: 1pt">Outstanding as of December 31, 2024</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zgqcy9ma0rvk" title="Number of Warrants, Outstanding at Ending of period" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" contextRef="AsOf2024-12-31_us-gaap_CommonStockMember" id="Fact001633" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,642,530</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_znzR0pZ73WD1" title="Weighted Average Exercise Price, Outstanding at Ending of period" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2024-12-31_us-gaap_CommonStockMember" id="Fact001635" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.41</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zti3Xue9xa3i" title="Weighted Average Remaining Contractual Life - Warrants"><ix:nonNumeric contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember" format="ixt-sec:duryear" id="Fact001637" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">2.93</ix:nonNumeric></span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A6_zEQVibhbHKD5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 117; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Neuraxis,
Inc.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Notes
to Financial Statements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember" escape="true" id="Fact001639" name="NRXS:ScheduleOfWarrantActivityForPreferredStockTableTextBlock"><p id="xdx_891_ecustom--ScheduleOfWarrantActivityForPreferredStockTableTextBlock_hus-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zNT710L4p2uf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following is a summary of warrant activity for preferred stock during the year ended December 31, 2023:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8BD_zdZp51J3cWs2" style="display: none">Schedule of Warrant Activity for Preferred Stock</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Number of</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Weighted-Avg.</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Warrants for</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Exercise</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Preferred Stock</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Price</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; font-weight: bold; padding-bottom: 1pt">Outstanding as of December 31, 2022</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zfcGzLOG3dr1" title="Number of Warrants, Outstanding at beginning of period" style="border-bottom: Black 1pt solid; width: 16%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" contextRef="AsOf2022-12-31_us-gaap_PreferredStockMember" id="Fact001641" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">144,890</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zN0O4Rsc9wJ" title="Weighted Average Exercise Price, Outstanding at beginning of period" style="border-bottom: Black 1pt solid; width: 16%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2022-12-31_us-gaap_PreferredStockMember" id="Fact001643" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.01</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_z2Va9eQzser" title="Number of Warrants, Granted" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1645">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_uUSDPShares_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zOMOCQMMk1bg" title="Weighted Average Exercise Price, granted" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1647">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Cancelled/Expired</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zF9FzeR5PABe" title="Number of Warrants, Cancelled Expired" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1649">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsWeightedAverageExercisePriceCancelledExpiredNumber_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_z14hGJgeTKV6" title="Weighted Average Exercise Price, Cancelled Expired" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1651">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Converted to Common Stock Warrant</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsCommonStockWarrant_iN_pid_di_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_znHVx7Qc6Qmb" title="Converted to Common Stock Warrant" style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="NRXS:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsCommonStockWarrant" contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember" id="Fact001653" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">144,890</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsWeightedAverageExercisePriceCommonStockWarrant_iN_pid_di_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zxR5E0bIf4hl" title="Weighted Average Exercise Price, Converted to Common Stock Warrant" style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="NRXS:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsWeightedAverageExercisePriceCommonStockWarrant" contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember" id="Fact001655" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">0.01</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-bottom: 1pt">Outstanding as of December 31, 2023</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zMic3aPT4rBb" title="Number of Warrants, Outstanding at Ending of period" style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1657">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_z8VxpLHbvBK4" title="Weighted Average Exercise Price, Outstanding at Ending of period" style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1659">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AC_zyLc5OvCht5e" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
was no preferred stock warrant activity during the year ended December 31, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact001661" name="us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock"><p id="xdx_898_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_z9igFQMpLx0d" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes the Company&#8217;s warrants outstanding and exercisable as of December 31, 2024:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8BC_zvxaUvkopMl5" style="display: none">Schedule of Warrants outstanding and Exercisable</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Number of</td><td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Warrants</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Exercise</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: center">Expiration</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Outstanding</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Price</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Date</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; text-align: left">Investor Warrant</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--InvestorWarrantOneMember_zCwbBa9nn5Ti" title="Number of Warrants" style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2024-12-31_custom_InvestorWarrantOneMember" id="Fact001663" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">12,852</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_980_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--InvestorWarrantOneMember_zzr2tmz9546e" title="Exercise Price" style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2024-12-31_custom_InvestorWarrantOneMember" id="Fact001665" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">8.76</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 18%; text-align: center"><span id="xdx_90E_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--InvestorWarrantOneMember_zYJKbGJUSZKb" title="Expiration Date"><ix:nonNumeric contextRef="AsOf2024-12-31_custom_InvestorWarrantOneMember" format="ixt:datemonthdayyearen" id="Fact001667" name="us-gaap:WarrantsAndRightsOutstandingMaturityDate">September 18, 2028</ix:nonNumeric></span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Investor Warrant</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--InvestorWarrantPSAOneMember_zcLpYDWZaeAl" title="Number of Warrants" style="text-align: right"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2024-12-31_custom_InvestorWarrantPSAOneMember" id="Fact001669" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">289,779</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_987_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--InvestorWarrantPSAOneMember_zmzsgDqFYzq6" title="Exercise Price" style="text-align: right"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2024-12-31_custom_InvestorWarrantPSAOneMember" id="Fact001671" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.01</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center"><span id="xdx_90C_ecustom--WarrantExpirationDateDescription_c20240101__20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--InvestorWarrantPSAOneMember_zhIdSpG22uz" title="Expiration Date"><ix:nonNumeric contextRef="From2024-01-012024-12-31_custom_InvestorWarrantPSAOneMember" id="Fact001673" name="NRXS:WarrantExpirationDateDescription">None</ix:nonNumeric></span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">2022 Convertible Notes</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--TwoThousandTwentyTwoConvertibleNotesMember_zoK0YKQK2Zlc" title="Number of Warrants" style="text-align: right"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2024-12-31_custom_TwoThousandTwentyTwoConvertibleNotesMember" id="Fact001675" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">782,655</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--TwoThousandTwentyTwoConvertibleNotesMember_zvl7qbY1ug3e" title="Exercise Price" style="text-align: right"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2024-12-31_custom_TwoThousandTwentyTwoConvertibleNotesMember" id="Fact001677" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.38</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center"><span id="xdx_90B_ecustom--WarrantExpirationDateDescription_c20240101__20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--TwoThousandTwentyTwoConvertibleNotesMember_zvM5SIXYBBo6" title="Expiration Date"><ix:nonNumeric contextRef="From2024-01-012024-12-31_custom_TwoThousandTwentyTwoConvertibleNotesMember" id="Fact001679" name="NRXS:WarrantExpirationDateDescription">Various in 2027</ix:nonNumeric></span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">2023 Convertible Notes</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--TwoThousandTwentyThreeConvertibleNotesMember_z9Htp0tD3X5g" title="Number of Warrants" style="text-align: right"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2024-12-31_custom_TwoThousandTwentyThreeConvertibleNotesMember" id="Fact001681" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,149,586</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_989_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--TwoThousandTwentyThreeConvertibleNotesMember_zfgkRFQC2Yj5" title="Exercise Price" style="text-align: right"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2024-12-31_custom_TwoThousandTwentyThreeConvertibleNotesMember" id="Fact001683" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.38</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center"><span id="xdx_90E_ecustom--WarrantExpirationDateDescription_c20240101__20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--TwoThousandTwentyThreeConvertibleNotesMember_znoFVfcfoDo7" title="Expiration Date"><ix:nonNumeric contextRef="From2024-01-012024-12-31_custom_TwoThousandTwentyThreeConvertibleNotesMember" id="Fact001685" name="NRXS:WarrantExpirationDateDescription">Various in 2028</ix:nonNumeric></span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Underwriter Warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--UnderwriterWarrantsMember_zZO43U71DrG2" title="Number of Warrants" style="text-align: right"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2024-12-31_custom_UnderwriterWarrantsMember" id="Fact001687" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">331,146</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_980_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--UnderwriterWarrantsMember_zUZ13v9jeyFj" title="Exercise Price" style="text-align: right"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2024-12-31_custom_UnderwriterWarrantsMember" id="Fact001689" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.38</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center"><span id="xdx_903_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--UnderwriterWarrantsMember_zwBgUbqUDd2i" title="Expiration Date"><ix:nonNumeric contextRef="AsOf2024-12-31_custom_UnderwriterWarrantsMember" format="ixt:datemonthdayyearen" id="Fact001691" name="us-gaap:WarrantsAndRightsOutstandingMaturityDate">August 8, 2028</ix:nonNumeric></span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Advisory Agreement Warrants</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--AdvisoryAgreementWarrantsMember_zeWU4i89Vkd2" title="Number of Warrants" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2024-12-31_custom_AdvisoryAgreementWarrantsMember" id="Fact001693" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">76,512</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">$</td><td id="xdx_98F_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--AdvisoryAgreementWarrantsMember_zuEVWVpc4Ix3" title="Exercise Price" style="padding-bottom: 1pt; text-align: right"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2024-12-31_custom_AdvisoryAgreementWarrantsMember" id="Fact001695" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.38</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1pt"><span id="xdx_90E_ecustom--WarrantExpirationDateDescription_c20240101__20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--AdvisoryAgreementWarrantsMember_zns5lNIaieig" title="Expiration Date"><ix:nonNumeric contextRef="From2024-01-012024-12-31_custom_AdvisoryAgreementWarrantsMember" id="Fact001697" name="NRXS:WarrantExpirationDateDescription">Various in 2029</ix:nonNumeric></span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20241231_zCUeLXbdEkB4" title="Number of Warrants" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2024-12-31" id="Fact001699" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,642,530</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td></tr>
  </table>


</ix:nonNumeric><p id="xdx_8AC_zLQMJ8gCt1T4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact001701" name="us-gaap:PreferredStockTextBlock"><p id="xdx_805_eus-gaap--PreferredStockTextBlock_zZYzrZvyML03" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>10.
<span id="xdx_826_zCSBQTL0v5Ba">Preferred Stock</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2023, the Company had&#160;<span id="xdx_907_eus-gaap--PreferredStockSharesAuthorized_iI_c20231231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zp47lXYOLbfj" title="Preferred stock, shares authorized"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2023-12-31_us-gaap_SeriesAPreferredStockMember" id="Fact001703" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,000,000</ix:nonFraction></span>&#160;and&#160;<span id="xdx_905_eus-gaap--PreferredStockSharesAuthorized_iI_c20231231__us-gaap--StatementClassOfStockAxis__custom--SeriesSeedPreferredStockMember_zAWxjg4zLpJi" title="Preferred stock, shares authorized"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2023-12-31_custom_SeriesSeedPreferredStockMember" id="Fact001705" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">120,000</ix:nonFraction></span>&#160;shares authorized as Series A and Series Seed Preferred
Stock, respectively, of which&#160;<span id="xdx_901_eus-gaap--PreferredStockSharesIssued_iI_dc_c20231231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zTdXQaXAUy61" title="Preferred stock, shares issued"><span id="xdx_906_eus-gaap--PreferredStockSharesOutstanding_iI_dc_c20231231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zSodCfpNEsh3" title="Preferred stock, shares outstanding"><span id="xdx_900_eus-gaap--PreferredStockSharesIssued_iI_dc_c20231231__us-gaap--StatementClassOfStockAxis__custom--SeriesSeedPreferredStockMember_zjoOeCO9i7ng" title="Preferred stock, shares issued"><span id="xdx_909_eus-gaap--PreferredStockSharesOutstanding_iI_dc_c20231231__us-gaap--StatementClassOfStockAxis__custom--SeriesSeedPreferredStockMember_ziLCyiFQcgbc" title="Preferred stock, shares outstanding"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="AsOf2023-12-31_us-gaap_SeriesAPreferredStockMember" id="Fact001707" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2023-12-31_us-gaap_SeriesAPreferredStockMember" id="Fact001709" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="AsOf2023-12-31_custom_SeriesSeedPreferredStockMember" id="Fact001711" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2023-12-31_custom_SeriesSeedPreferredStockMember" id="Fact001713" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares">zero</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></span></span></span></span>&#160;shares are issued and outstanding for both classes of preferred stock. The Series A and
Series Seed Preferred Stock (i) voted together with common stock on an as-converted basis, and not as separate classes and (ii) converted
1:1 to common stock at any time at option of holder, subject to adjustments for stock dividends, splits, combinations, and similar events.
The Series A Preferred Stock carried an annual&#160;<span id="xdx_90C_eus-gaap--PreferredStockDividendRatePercentage_dp_uPure_c20230101__20231231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zMQGLxpbUZs8" title="Preferred stock dividend rate percentage"><ix:nonFraction name="us-gaap:PreferredStockDividendRatePercentage" contextRef="From2023-01-012023-12-31_us-gaap_SeriesAPreferredStockMember" id="Fact001715" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">8</ix:nonFraction></span>% cumulative dividend, payable upon any liquidation, dissolution or winding up of
the Company. For any other dividends or distributions, the Series A Preferred Stock participated with common stock on an as-converted
basis. <span id="xdx_90F_ecustom--PreferredStockSharesRetiredDescription_iI_c20231231__us-gaap--StatementClassOfStockAxis__custom--SeriesSeedPreferredStockMember_zoZlUtluCbr8" title="Preferred stock, retired description">The Company&#8217;s&#160;<ix:nonFraction name="NRXS:PreferredStockSharesRetiredDescription" contextRef="AsOf2023-12-31_custom_SeriesSeedPreferredStockMember" id="Fact001717" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,000,000</ix:nonFraction>&#160;shares of Series A Preferred Stock and&#160;120,000&#160;shares of Series Seed Preferred
Stock were retired on August 15, 2024.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August 15, 2024, the Company&#8217;s shareholders authorized&#160;<span id="xdx_90E_eus-gaap--PreferredStockSharesAuthorized_iI_c20240815__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zgA7sLfI2vkj" title="Preferred stock, shares authorized"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2024-08-15_us-gaap_SeriesBPreferredStockMember" id="Fact001719" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">5,000,000</ix:nonFraction></span>&#160;shares of preferred stock of which&#160;<span id="xdx_909_eus-gaap--TemporaryEquitySharesAuthorized_iI_pid_c20240815__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zqZFtyvS61i2" title="Temporary equity, shares authorized"><ix:nonFraction name="us-gaap:TemporaryEquitySharesAuthorized" contextRef="AsOf2024-08-15_us-gaap_SeriesBPreferredStockMember" id="Fact001721" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">4,000,000</ix:nonFraction></span>&#160;shares
were designated as $<span id="xdx_909_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20240815__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zUiJ7TNL8Jr7" title="Preferred stock, par value"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2024-08-15_us-gaap_SeriesBPreferredStockMember" id="Fact001723" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.001</ix:nonFraction></span>&#160;par value Series B Preferred Stock. Series B Preferred Stock shareholders vote with Common Stock shareholders
on an as-converted basis and not as a separate class. Cumulative dividends accrue at&#160;<span id="xdx_906_eus-gaap--PreferredStockDividendRatePercentage_dp_uPure_c20240815__20240815__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zaTB22F8i2Oi" title="Preferred stock dividend rate percentage"><ix:nonFraction name="us-gaap:PreferredStockDividendRatePercentage" contextRef="From2024-08-152024-08-15_us-gaap_SeriesBPreferredStockMember" id="Fact001725" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">8.5</ix:nonFraction></span>% per annum and are due and payable in either
cash for common shares as the Company&#8217;s discretion on a quarterly basis through June 30, 2025. Series B Preferred Stock converts
to common stock on a 1:1 basis, subject to adjustments for stock dividends, splits, combinations and similar events as well as unpaid
dividends thereon, solely at the election of the holder at any time.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white">&#160;</p>


<ix:exclude><!-- Field: Page; Sequence: 118; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the terms of the Amended 2024 Convertible Notes, the principal balance of $<span id="xdx_90C_eus-gaap--DebtInstrumentFaceAmount_iI_c20240815__us-gaap--ShortTermDebtTypeAxis__custom--AmendedTwoThousandTwentyFourConvertibleNotesMember_zYHpg4Zafdq2" title="Borrowed amount"><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="AsOf2024-08-15_custom_AmendedTwoThousandTwentyFourConvertibleNotesMember" id="Fact001727" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,935,000</ix:nonFraction></span> on August 15, 2024 was mandatorily converted
into <span id="xdx_90E_eus-gaap--ConversionOfStockSharesConverted1_c20240815__20240815__us-gaap--ShortTermDebtTypeAxis__custom--AmendedTwoThousandTwentyFourConvertibleNotesMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zIYWn3b9oGh6" title="Shares converted"><ix:nonFraction name="us-gaap:ConversionOfStockSharesConverted1" contextRef="From2024-08-152024-08-15_custom_AmendedTwoThousandTwentyFourConvertibleNotesMember_us-gaap_SeriesBPreferredStockMember" id="Fact001729" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,073,524</ix:nonFraction></span> Series B Preferred Shares at a conversion price of $<span id="xdx_90B_eus-gaap--SharesIssuedPricePerShare_iI_c20240815__us-gaap--ShortTermDebtTypeAxis__custom--AmendedTwoThousandTwentyFourConvertibleNotesMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zjAj2KsuJf55" title="Conversion per shares"><ix:nonFraction name="us-gaap:SharesIssuedPricePerShare" contextRef="AsOf2024-08-15_custom_AmendedTwoThousandTwentyFourConvertibleNotesMember_us-gaap_SeriesBPreferredStockMember" id="Fact001731" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.38</ix:nonFraction></span>. Subsequently, the Company then proceeded to issue <span id="xdx_90A_ecustom--ProceedsFromIssuanceOfStock_c20240815__20240815__us-gaap--ShortTermDebtTypeAxis__custom--AmendedTwoThousandTwentyFourConvertibleNotesMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zCyF4tansIoh" title="Issuance of debt, shares"><ix:nonFraction name="NRXS:ProceedsFromIssuanceOfStock" contextRef="From2024-08-152024-08-15_custom_AmendedTwoThousandTwentyFourConvertibleNotesMember_us-gaap_SeriesBPreferredStockMember" id="Fact001733" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">64,913</ix:nonFraction></span> shares
of Series B Preferred Stock to various investors for $<span id="xdx_90E_eus-gaap--ProceedsFromIssuanceOfDebt_c20240815__20240815__us-gaap--ShortTermDebtTypeAxis__custom--AmendedTwoThousandTwentyFourConvertibleNotesMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zv8WWQCZm0Ug" title="Issuance of debt"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfDebt" contextRef="From2024-08-152024-08-15_custom_AmendedTwoThousandTwentyFourConvertibleNotesMember_us-gaap_SeriesBPreferredStockMember" id="Fact001735" format="ixt:numdotdecimal" decimals="0" unitRef="USD">154,500</ix:nonFraction></span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
November 11, 2024, the Company&#8217;s shareholders authorized (i) an increase in the number of designated Series B Preferred Stock
to <span id="xdx_905_eus-gaap--PreferredStockSharesAuthorized_iI_c20241111__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_z6g2JyMHGWMa" title="Preferred stock, shares authorized"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2024-11-11_us-gaap_SeriesBPreferredStockMember" id="Fact001737" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">5,000,000</ix:nonFraction></span>
shares and (ii) an extension of the <span id="xdx_902_ecustom--CumulativeDividendsPercent_iI_pid_dp_uPure_c20241111__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zf3nOa6DXTx5" title="Cumulative dividends percent"><ix:nonFraction name="NRXS:CumulativeDividendsPercent" contextRef="AsOf2024-11-11_us-gaap_SeriesBPreferredStockMember" id="Fact001739" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">8.5</ix:nonFraction></span>%
per annum cumulative dividend period to December 31, 2026. Subsequently, the Company issued <span id="xdx_900_eus-gaap--SharesIssued_iI_c20241113__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zJ2jGjVeNYii" title="Preferred stock, shares issued"><ix:nonFraction name="us-gaap:SharesIssued" contextRef="AsOf2024-11-13_us-gaap_SeriesBPreferredStockMember" id="Fact001741" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,100,840</ix:nonFraction></span>
shares of Series B Preferred Stock to a dedicated life sciences fund for $<span id="xdx_904_eus-gaap--PreferredStockSharesAuthorized_iI_c20241113__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zmmXdHHuihg6" title="Preferred stock, shares authorized"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2024-11-13_us-gaap_SeriesBPreferredStockMember" id="Fact001743" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">5,000,000</ix:nonFraction></span>
and <span id="xdx_900_ecustom--ProceedsFromIssuanceOfStock_c20241111__20241111__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zZqFfsYMI1ng" title="Issuance of debt, shares"><ix:nonFraction name="NRXS:ProceedsFromIssuanceOfStock" contextRef="From2024-11-112024-11-11_us-gaap_SeriesBPreferredStockMember" id="Fact001745" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">41,662</ix:nonFraction></span> shares of Series B Preferred Stock to various investors for $<span id="xdx_90F_eus-gaap--ProceedsFromIssuanceOfDebt_c20241111__20241111__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zGXcN9H8Pjn6" title="Issuance of debt"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfDebt" contextRef="From2024-11-112024-11-11_us-gaap_SeriesBPreferredStockMember" id="Fact001747" format="ixt:numdotdecimal" decimals="0" unitRef="USD">99,164</ix:nonFraction></span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon
any liquidation, dissolution or winding up of the Company, whether voluntary or involuntary, the Series B Preferred Stock
shareholders maintain priority preference over all other classes of capital stock. A merger or consolidation (other than one in
which stockholders of the Company own a majority by voting power of the outstanding shares of the surviving or acquiring
corporation) and a sale, lease, transfer, exclusive license or other disposition of all or substantially all of the assets of the
Company will be treated as a liquidation event, thereby triggering payment of the liquidation preferences.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2024, there were <span id="xdx_90D_eus-gaap--PreferredStockSharesOutstanding_iI_c20241231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zBbg0B4WYbb8"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2024-12-31_us-gaap_SeriesBPreferredStockMember" id="Fact001748" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">4,280,939</ix:nonFraction> </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares
of Series B Preferred Stock issued and outstanding. As of December 31, 2024 and 2023, there were&#160;<span id="xdx_907_eus-gaap--DividendsPayableCurrentAndNoncurrent_iI_do_c20241231__us-gaap--StatementClassOfStockAxis__us-gaap--PreferredStockMember_z7lAlJ6WX1Jg" title="Dividends declared"><span id="xdx_90F_eus-gaap--DividendsPayableCurrentAndNoncurrent_iI_do_c20231231__us-gaap--StatementClassOfStockAxis__us-gaap--PreferredStockMember_z1oUoRfkOZK3" title="Dividends declared"><ix:nonFraction name="us-gaap:DividendsPayableCurrentAndNoncurrent" contextRef="AsOf2024-12-31_us-gaap_PreferredStockMember" id="Fact001750" format="ixt-sec:numwordsen" decimals="0" unitRef="USD"><ix:nonFraction name="us-gaap:DividendsPayableCurrentAndNoncurrent" contextRef="AsOf2023-12-31_us-gaap_PreferredStockMember47713734" id="Fact001752" format="ixt-sec:numwordsen" decimals="0" unitRef="USD">no</ix:nonFraction></ix:nonFraction></span></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;preferred
stock dividends declared or paid. Series B Preferred Stock undeclared cumulative dividends totaled $<span id="xdx_902_eus-gaap--DividendsPreferredStock_c20240101__20241231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zwgSShbrbgD1" title="Dividends"><ix:nonFraction name="us-gaap:DividendsPreferredStock" contextRef="From2024-01-012024-12-31_us-gaap_SeriesBPreferredStockMember47710687" id="Fact001754" format="ixt:numdotdecimal" decimals="0" unitRef="USD">211,268</ix:nonFraction></span>,
or $<span id="xdx_900_eus-gaap--PreferredStockDividendRatePerDollarAmount_uUSDPShares_c20240101__20241231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zFsHY00Iz4bc" title="Dividends, preferred stock per share"><ix:nonFraction name="us-gaap:PreferredStockDividendRatePerDollarAmount" contextRef="From2024-01-012024-12-31_us-gaap_SeriesBPreferredStockMember47710687" id="Fact001756" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.05</ix:nonFraction></span> per share, as of December 31, 2024. Series B Preferred Stock did not exist during the year ended December 31, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact001758" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"><p id="xdx_806_eus-gaap--DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_z582ETxRitH3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>11.
<span id="xdx_82F_zoqOnkd3y7Th">Stock-Based Compensation</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
October 12, 2017, the Company adopted the 2017 Stock Compensation Plan authorizing the issuance of <span id="xdx_90F_eus-gaap--CommonStockSharesAuthorized_iI_pid_c20171012__us-gaap--PlanNameAxis__custom--TwentySeventeenStockCompensationPlanMember_zfNNVZCieyQ1" title="Common stock, shares authorized"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2017-10-12_custom_TwentySeventeenStockCompensationPlanMember" id="Fact001760" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,435,652</ix:nonFraction></span> shares of common stock.
On September 13, 2019 the Company entered into a Stock Option Cancellation agreement with all holders of these stock options effective
on that date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
plan was then amended on September 13, 2019, to increase the share amount to <span id="xdx_901_eus-gaap--SharesIssued_iI_pid_c20190913__us-gaap--PlanNameAxis__custom--TwentySeventeenStockCompensationPlanMember_zB1TMvrsYdXl" title="Shares issued"><ix:nonFraction name="us-gaap:SharesIssued" contextRef="AsOf2019-09-13_custom_TwentySeventeenStockCompensationPlanMember" id="Fact001762" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,638,788</ix:nonFraction></span>. This plan was enacted to enable the Company to
retain the services of certain key employees, officers, and directors of the Company. The Plan provides for the grant of stock options,
including incentive stock options, or ISOs, and nonqualified stock options, or NSOs and restricted stock, and they were estimated using
the Black-Scholes option-pricing model with the following weighted-average assumptions:</span></p>

<ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact001764" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"><p id="xdx_892_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zG5Qp2V0YQjd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B2_zGOV7bG7BGUc" style="display: none">Schedule of Option-pricing Model with Following Weighted-average Assumptions</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 60%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Assumptions as of December 31, 2023</td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">Fully Vested</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%">Number of Shares</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_c20231231__us-gaap--PlanNameAxis__custom--TwentySeventeenStockCompensationPlanMember_znhL7DOHtJSf" title="Number of Shares" style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" contextRef="AsOf2023-12-31_custom_TwentySeventeenStockCompensationPlanMember" id="Fact001766" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,319,394</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Stock price</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_980_eus-gaap--SharePrice_iI_c20231231__us-gaap--PlanNameAxis__custom--TwentySeventeenStockCompensationPlanMember_z35t4olRGgj2" title="Stock price" style="text-align: right"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2023-12-31_custom_TwentySeventeenStockCompensationPlanMember" id="Fact001768" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.67</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Exercise price</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_c20231231__us-gaap--PlanNameAxis__custom--TwentySeventeenStockCompensationPlanMember_zAUbudleH1La" title="Exercise price" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" contextRef="AsOf2023-12-31_custom_TwentySeventeenStockCompensationPlanMember" id="Fact001770" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">6.94</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Expected term</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230101__20231231__us-gaap--PlanNameAxis__custom--TwentySeventeenStockCompensationPlanMember_z14VKcAWI4G3" title="Expected term"><ix:nonNumeric contextRef="From2023-01-012023-12-31_custom_TwentySeventeenStockCompensationPlanMember" format="ixt-sec:duryear" id="Fact001772" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">5.75</ix:nonNumeric></span> years</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Expected volatility</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20230101__20231231__us-gaap--PlanNameAxis__custom--TwentySeventeenStockCompensationPlanMember_zQeLhyj1Eqy1" title="Expected volatility" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="From2023-01-012023-12-31_custom_TwentySeventeenStockCompensationPlanMember" id="Fact001774" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">31.90</ix:nonFraction></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Risk-free interest rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20230101__20231231__us-gaap--PlanNameAxis__custom--TwentySeventeenStockCompensationPlanMember_zNjBU10Mq145" title="Risk-free interest rate" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="From2023-01-012023-12-31_custom_TwentySeventeenStockCompensationPlanMember" id="Fact001776" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">3.84</ix:nonFraction></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Dividend rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20230101__20231231__us-gaap--PlanNameAxis__custom--TwentySeventeenStockCompensationPlanMember_zUZLFZTEndI5" title="Dividend rate" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="From2023-01-012023-12-31_custom_TwentySeventeenStockCompensationPlanMember" id="Fact001778" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0</ix:nonFraction></td><td style="text-align: left">%</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A1_zrs24MhAL5Ji" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 119; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Neuraxis,
Inc.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Notes
to Financial Statements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact001780" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"><p id="xdx_89E_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zN7Dhk6r2Y0a" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following is a summary of the outstanding stock options as of December 31, 2024 and 2023:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8BB_zZTUR7enWRSi" style="display: none">Schedule of Stock Option Activity</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Number of Options</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted Avg. Remaining Contractual Life (in years)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted Avg. Exercise Price</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Aggregate Intrinsic Value</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 36%; font-weight: bold; padding-bottom: 1pt">Outstanding as of December 31, 2023</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20240101__20241231_zbdgYc0k0tj6" title="Number of Options, Outstanding, Beginning balance" style="border-bottom: Black 1pt solid; width: 12%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2023-12-31" id="Fact001782" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,319,394</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; width: 12%; text-align: right"><span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230101__20231231_z39nUXErIBH7" title="Weighted Average Remaining Contractual Life (in years), Outstanding"><ix:nonNumeric contextRef="From2023-01-012023-12-31" format="ixt-sec:duryear" id="Fact001784" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">5.69</ix:nonNumeric></span></td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_uUSDPShares_c20240101__20241231_zRBnsQjAVTg3" title="Weighted Average Exercise Price, Outstanding, Beginning balance" style="border-bottom: Black 1pt solid; width: 12%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2023-12-31" id="Fact001786" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">6.94</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_c20240101__20241231_zo0CKJ6eWyza" title="Aggregate Intrinsic Value, Outstanding, Beginning balance" style="border-bottom: Black 1pt solid; width: 12%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1788">&#8212;</span></td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; padding-bottom: 1pt">Outstanding as of December 31, 2024</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20240101__20241231_z55EeHnyKinh" title="Number of Options, Outstanding, Ending balance" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2024-12-31" id="Fact001790" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,319,394</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231_zxR1WpQg0Oz2" title="Weighted Average Remaining Contractual Life (in years), Outstanding"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" format="ixt-sec:duryear" id="Fact001792" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">4.69</ix:nonNumeric></span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_uUSDPShares_c20240101__20241231_zvtuUdJvgcr" title="Weighted Average Exercise Price, Outstanding, Ending balance" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2024-12-31" id="Fact001794" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">6.94</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_c20240101__20241231_zwttZBExv1sa" title="Aggregate Intrinsic Value, Outstanding, Ending balance" style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1796">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-bottom: 1pt">Vested and Exercisable as of December 31, 2024</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_iE_pid_c20240101__20241231_zj5LvhhpSMce" title="Number of Options, Vested and Exercisable, Ending balance" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" contextRef="AsOf2024-12-31" id="Fact001798" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,319,394</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_dtY_c20240101__20241231_zg10RHlZAHDg" title="Weighted Average Remaining Contractual Life (in years), Vested and Exercisable"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" format="ixt-sec:duryear" id="Fact001800" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1">4.69</ix:nonNumeric></span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iE_pid_uUSDPShares_c20240101__20241231_zHcu58EvmXoj" title="Weighted Average Exercise Price, Vested and Exercisable, Ending balance" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" contextRef="AsOf2024-12-31" id="Fact001802" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">6.94</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_iE_c20240101__20241231_zURCbanmCr4e" title="Aggregate Intrinsic Value, Vested and Exercisable, Ending balance" style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1804">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AD_zZE9c8ADNSw4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">Total stock-based compensation
expense is classified in the Company&#8217;s statements of operations as general and administrative expense totaling $<span id="xdx_90C_eus-gaap--ShareBasedCompensation_c20240101__20241231_zI8x5UZ9IfJk" title="Share based compensation"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2024-01-01to2024-12-31" id="Fact001806" format="ixt:numdotdecimal" decimals="0" unitRef="USD">227,000</ix:nonFraction></span>
and $<span id="xdx_90E_eus-gaap--ShareBasedCompensation_dxL_c20230101__20231231_zx6I8yThynj1" title="Share based compensation::XDX::-"><span style="-sec-ix-hidden: xdx2ixbrl1808">0</span></span>
for the years ended December 31, 2024 and 2023, respectively. The stock compensation incurred during the year ended December 31,
2024 related to a hiring grant of <span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20240101__20241231__srt--TitleOfIndividualAxis__srt--ChiefFinancialOfficerMember_z4ZqWM8HhEI9" title="Granted"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" contextRef="From2024-01-012024-12-31_srt_ChiefFinancialOfficerMember" id="Fact001810" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">100,000</ix:nonFraction></span> common
shares to the Company&#8217;s Chief Financial Officer at a fair value of $<span id="xdx_902_eus-gaap--SharePrice_iI_c20241231__srt--TitleOfIndividualAxis__srt--ChiefFinancialOfficerMember_zUe2s28C9Eul" title="Share price"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2024-12-31_srt_ChiefFinancialOfficerMember" id="Fact001812" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.27</ix:nonFraction></span> per share.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact001814" name="NRXS:WarrantLiabilitiesDisclosureTextBlock"><p id="xdx_802_ecustom--WarrantLiabilitiesDisclosureTextBlock_zLJ9px8k3Syi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>12.
<span id="xdx_824_z6GXrWDDRILk">Warrant Liabilities</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has evaluated financial instruments arising from warrants that are issued and outstanding as of December 31, 2024 and 2023. The
Company utilizes a Black-Scholes option-pricing model to compute the fair value of the liability and to mark to market the fair value
of the warrant at each balance sheet date. The inputs utilized in the application of the Black-Scholes option-pricing model included
(i) an exercise price of $<span id="xdx_902_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uUSDPShares_c20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember_zrjptfCvcQz8" title="Warrants and rights outstanding, measurement input"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="AsOf2024-12-31_us-gaap_MeasurementInputSharePriceMember" id="Fact001816" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">8.76</ix:nonFraction></span> per share, (ii) an expected remaining term of each warrant based on the remaining contractual maturity
of the each warrant, (iii) estimated volatility ranging from <span id="xdx_901_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__srt--RangeAxis__srt--MinimumMember_zmSn9NaiSFL2" title="Warrants and rights outstanding, measurement input"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="AsOf2024-12-31_us-gaap_MeasurementInputPriceVolatilityMember_srt_MinimumMember" id="Fact001818" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">75.0</ix:nonFraction></span>% to <span id="xdx_902_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__srt--RangeAxis__srt--MaximumMember_zf5dKmajsiZ6" title="Warrants and rights outstanding, measurement input"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="AsOf2024-12-31_us-gaap_MeasurementInputPriceVolatilityMember_srt_MaximumMember" id="Fact001820" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">84.5</ix:nonFraction></span>% based on historical stock prices of comparable companies
with a look back period commensurate with the period to maturity, (iv) a risk-free interest rate ranging from <span id="xdx_90C_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MinimumMember_zQ203NSiNd12" title="Warrants and rights outstanding, measurement input"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="AsOf2024-12-31_us-gaap_MeasurementInputRiskFreeInterestRateMember_srt_MinimumMember" id="Fact001822" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">3.84</ix:nonFraction></span>% to <span id="xdx_90E_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MaximumMember_zThTTGydVYB5" title="Warrants and rights outstanding, measurement input"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="AsOf2024-12-31_us-gaap_MeasurementInputRiskFreeInterestRateMember_srt_MaximumMember" id="Fact001824" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">4.38</ix:nonFraction></span>% based on
the interest rates of U.S. Treasury Notes consistent with the expected remaining contract term and (v) a <span id="xdx_908_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zB9nQtROHcvl" title="Warrants and rights outstanding, measurement input"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="AsOf2024-12-31_us-gaap_MeasurementInputExpectedDividendRateMember" id="Fact001826" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">0</ix:nonFraction></span>% expected dividend yield as
the Company has not paid dividends to date and does not anticipate declaring dividends in the near future.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 120; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Neuraxis,
Inc.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Notes
to Financial Statements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact001828" name="NRXS:ScheduleOfChangesInWarrantLiabilitiesTableTextBlock"><p id="xdx_897_ecustom--ScheduleOfChangesInWarrantLiabilitiesTableTextBlock_zhnajgsOSnk5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following are the changes in the warrant liabilities during the years ended December 31, 2024 and 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8BD_ziPvejQmf2bf" style="display: none">Schedule of Changes in Warrant Liabilities</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 1</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 2</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 3</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; font-weight: bold">Warrant liabilities as of January 1, 2023</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--WarrantsAndRightsOutstanding_iS_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zT88wBP0RRP8" title="Warrant liabilities, Beginning balance" style="width: 12%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1830">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--WarrantsAndRightsOutstanding_iS_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zdwd7tq2Q0bl" title="Warrant liabilities, Beginning balance" style="width: 12%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1832">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_986_eus-gaap--WarrantsAndRightsOutstanding_iS_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zx9tsgBNOnD4" title="Warrant liabilities, Beginning balance" style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstanding" contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel3Member" id="Fact001834" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,234,384</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt">Addition</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_ecustom--AdditionToWarrantLiabilities_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zee6DAMsbl2j" title="Addition" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1836">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_ecustom--AdditionToWarrantLiabilities_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zSD8bz35u2Id" title="Addition" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1838">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_ecustom--AdditionToWarrantLiabilities_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zA7l7yecfaIh" title="Addition" style="text-align: right"><ix:nonFraction name="NRXS:AdditionToWarrantLiabilities" contextRef="From2023-01-012023-12-31_us-gaap_FairValueInputsLevel3Member" id="Fact001840" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,446,502</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Reclassified to equity</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_ecustom--ReclassifiedToEquity_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zvOYF9TMRBFg" title="Reclassified to equity" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1842">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_ecustom--ReclassifiedToEquity_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zw1ZC82J6fde" title="Reclassified to equity" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1844">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_ecustom--ReclassifiedToEquity_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z4zv76UCtXHk" title="Reclassified to equity" style="text-align: right">(<ix:nonFraction name="NRXS:ReclassifiedToEquity" contextRef="From2023-01-012023-12-31_us-gaap_FairValueInputsLevel3Member" id="Fact001846" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">3,827,807</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Changes in fair value of warrant liabilities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--FairValueAdjustmentOfWarrants_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zHU0YUGcnGE5" title="Changes in fair value of warrant liabilities" style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1848">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--FairValueAdjustmentOfWarrants_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zaBHCB3F95se" title="Changes in fair value of warrant liabilities" style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1850">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--FairValueAdjustmentOfWarrants_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zvYO3V51Q4Q8" title="Changes in fair value of warrant liabilities" style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="From2023-01-012023-12-31_us-gaap_FairValueInputsLevel3Member" id="Fact001852" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">844,854</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold">Warrant liabilities as of December 31, 2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--WarrantsAndRightsOutstanding_iS_c20240101__20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zAQCcSYfDdUi" title="Warrant liabilities, Beginning balance" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1854">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--WarrantsAndRightsOutstanding_iS_c20240101__20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zl5xaH5D1Jo8" title="Warrant liabilities, Beginning balance" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1856">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--WarrantsAndRightsOutstanding_iS_c20240101__20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zbrQ6KXGpJW7" title="Warrant liabilities, Beginning balance" style="text-align: right"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstanding" contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel3Member" id="Fact001858" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,225</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Changes in fair value of warrant liabilities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--FairValueAdjustmentOfWarrants_c20240101__20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zf8FawArezfl" title="Changes in fair value of warrant liabilities" style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1860">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--FairValueAdjustmentOfWarrants_c20240101__20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zZrLRI2XKRp8" title="Changes in fair value of warrant liabilities" style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1862">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--FairValueAdjustmentOfWarrants_c20240101__20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zXJzf1PfozVa" title="Changes in fair value of warrant liabilities" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="From2024-01-012024-12-31_us-gaap_FairValueInputsLevel3Member" id="Fact001864" format="ixt:numdotdecimal" decimals="0" unitRef="USD">941</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-bottom: 1pt">Warrant liabilities as of December 31, 2024</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_982_eus-gaap--WarrantsAndRightsOutstanding_iE_c20240101__20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zkMY2pnoFcq3" title="Warrant liabilities, Ending balance" style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1866">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_980_eus-gaap--WarrantsAndRightsOutstanding_iE_c20240101__20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zdADnq4PbFzl" title="Warrant liabilities, Ending balance" style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1868">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_985_eus-gaap--WarrantsAndRightsOutstanding_iE_c20240101__20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zDMfqGcS94G1" title="Warrant liabilities, Ending balance" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstanding" contextRef="AsOf2024-12-31_us-gaap_FairValueInputsLevel3Member" id="Fact001870" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9,166</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AF_zxrrg3ZKTql1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact001872" name="us-gaap:DerivativesAndFairValueTextBlock"><p id="xdx_805_eus-gaap--DerivativesAndFairValueTextBlock_zu2vEO7IMDw7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>13.
<span id="xdx_827_zVORf07c8s3c">Derivative Liabilities</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has evaluated derivatives arising from convertible financial instruments as of December 31, 2024 and 2023. The Company utilized
a Monte Carlo simulation model for commitment shares that have an option to convert at a variable number of shares to compute the fair
value of the derivative and to mark to market the fair value of the derivative at each balance sheet date. The inputs utilized in the
application of the Monte Carlo model included a starting stock price of $<span id="xdx_905_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember_zKzjUyOljpae" title="Derivative liability, measurement input"><ix:nonFraction name="us-gaap:DerivativeLiabilityMeasurementInput" contextRef="AsOf2024-12-31_us-gaap_MeasurementInputSharePriceMember" id="Fact001874" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">7.91</ix:nonFraction></span> per share, (ii) an expected remaining term of each derivative
based on the remaining contractual maturity of the each derivative, (iii) estimated volatility of <span id="xdx_90B_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zkpiEtIGim5e" title="Derivative liability, measurement input"><ix:nonFraction name="us-gaap:DerivativeLiabilityMeasurementInput" contextRef="AsOf2024-12-31_us-gaap_MeasurementInputPriceVolatilityMember" id="Fact001876" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">70.0</ix:nonFraction></span>% based on historical stock prices
of comparable companies with a look back period commensurate with the period to maturity, (iv) a risk-free interest rate ranging from
<span id="xdx_902_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MinimumMember_zfRiq3dgO9ai" title="Derivative liability, measurement input"><ix:nonFraction name="us-gaap:DerivativeLiabilityMeasurementInput" contextRef="AsOf2024-12-31_us-gaap_MeasurementInputRiskFreeInterestRateMember_srt_MinimumMember" id="Fact001878" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">3.46</ix:nonFraction></span>% to <span id="xdx_903_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MaximumMember_zf7y7oyPPPa7" title="Derivative liability, measurement input"><ix:nonFraction name="us-gaap:DerivativeLiabilityMeasurementInput" contextRef="AsOf2024-12-31_us-gaap_MeasurementInputRiskFreeInterestRateMember_srt_MaximumMember" id="Fact001880" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">5.47</ix:nonFraction></span>% based on the interest rates of U.S. Treasury Notes consistent with the expected remaining contract term and (v) a <span id="xdx_901_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zVhPZeP70wph" title="Derivative liability, measurement input"><ix:nonFraction name="us-gaap:DerivativeLiabilityMeasurementInput" contextRef="AsOf2024-12-31_us-gaap_MeasurementInputExpectedDividendRateMember" id="Fact001882" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">0</ix:nonFraction></span>% expected
dividend yield as the Company has not paid dividends to date and does not anticipate declaring dividends in the near future and (vi)
drift.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact001884" name="us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock"><p id="xdx_89F_eus-gaap--ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock_zfXEuYd43pb8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following are the changes in the derivative liabilities during the year ended December 31, 2023:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B4_zD5ZA7TNqMEk" style="display: none">Schedule of Changes in Derivative Liabilities</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 1</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 2</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 3</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; font-weight: bold">Derivative liabilities as of December 31, 2022</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_986_ecustom--ChangesInDerivativeLiabilities_iS_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zP8tnL9A2rg8" title="Derivative liabilities, Beginning balance" style="width: 12%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1886">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_987_ecustom--ChangesInDerivativeLiabilities_iS_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zeqmf28McAp2" title="Derivative liabilities, Beginning balance" style="width: 12%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1888">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_982_ecustom--ChangesInDerivativeLiabilities_iS_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zCuIuUgQiaw2" title="Derivative liabilities, Beginning balance" style="width: 12%; text-align: right"><ix:nonFraction name="NRXS:ChangesInDerivativeLiabilities" contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel3Member" id="Fact001890" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,735,700</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt">Addition</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_ecustom--AdditionToDerivativeLiabilities_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zbSf9gQIUbWc" title="Addition" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1892">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_ecustom--AdditionToDerivativeLiabilities_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zUnRulXJI57e" title="Addition" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1894">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_ecustom--AdditionToDerivativeLiabilities_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z6VRuutgHygf" title="Addition" style="text-align: right"><ix:nonFraction name="NRXS:AdditionToDerivativeLiabilities" contextRef="From2023-01-012023-12-31_us-gaap_FairValueInputsLevel3Member" id="Fact001896" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,375,378</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Changes in fair value of derivative liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--IncreaseDecreaseInDerivativeLiabilities_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zPG3xHL5PHK6" title="Changes in fair value of Derivative liabilities" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1898">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--IncreaseDecreaseInDerivativeLiabilities_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_z7iD4PCJp5qi" title="Changes in fair value of Derivative liabilities" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1900">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--IncreaseDecreaseInDerivativeLiabilities_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z0aCo4QrZhql" title="Changes in fair value of Derivative liabilities" style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInDerivativeLiabilities" contextRef="From2023-01-012023-12-31_us-gaap_FairValueInputsLevel3Member" id="Fact001902" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">198,551</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Extinguishment of derivative liabilities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_986_ecustom--ExtinguishmentOfDerivativeLiabilities_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_z2tptvDslgV6" title="Extinguishment of Derivative liabilities" style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1904">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_988_ecustom--ExtinguishmentOfDerivativeLiabilities_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zG9Bj6nOkTKj" title="Extinguishment of Derivative liabilities" style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1906">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98E_ecustom--ExtinguishmentOfDerivativeLiabilities_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zcshAjGpFsW9" title="Extinguishment of Derivative liabilities" style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="NRXS:ExtinguishmentOfDerivativeLiabilities" contextRef="From2023-01-012023-12-31_us-gaap_FairValueInputsLevel3Member" id="Fact001908" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">3,912,527</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-bottom: 1pt">Derivative liabilities as of December 31, 2023</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_98A_ecustom--ChangesInDerivativeLiabilities_iE_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zpfbG6B2XGSk" title="Derivative liabilities, Ending balance" style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1910">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_983_ecustom--ChangesInDerivativeLiabilities_iE_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zdxl4nMNr2uh" title="Derivative liabilities, Ending balance" style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1912">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_98F_ecustom--ChangesInDerivativeLiabilities_iE_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zHFXPAjluqB6" title="Derivative liabilities, Ending balance" style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1914">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AC_z3wz7LuPHqBe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
were no derivatives identified during the year ended December 31, 2024.</span></p>
<!-- Field: Split-Segment; Name: 002 -->
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 121; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Neuraxis,
Inc.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Notes
to Financial Statements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact001916" name="us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock"><p id="xdx_801_eus-gaap--PensionAndOtherPostretirementBenefitsDisclosureTextBlock_zjerfXftDTjh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>14.
<span id="xdx_82F_z78zqGuKdltg">Retirement Plan</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company sponsors a 401(k)-retirement plan for its employees. Employees are eligible to participate in the elective deferral portion of
the plan after twelve months and 1,000 hours of service. The Company can also make a <span id="xdx_901_eus-gaap--DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_dp_uPure_c20240101__20241231_z2NE3ADGeJXk" title="Employee contribution percentage"><ix:nonFraction name="us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" contextRef="From2024-01-01to2024-12-31" id="Fact001918" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">3</ix:nonFraction></span>% discretionary profit-sharing contribution on
an annual basis to employees with earnings under a certain threshold. Profit sharing expense totaled $<span id="xdx_902_eus-gaap--DefinedContributionPlanAdministrativeExpenses_c20240101__20241231_zOF0Tk3wGnW8" title="Profit sharing contribution expenses"><ix:nonFraction name="us-gaap:DefinedContributionPlanAdministrativeExpenses" contextRef="From2024-01-01to2024-12-31" id="Fact001920" format="ixt:numdotdecimal" decimals="0" unitRef="USD">20,868</ix:nonFraction></span> and $<span id="xdx_903_eus-gaap--DefinedContributionPlanAdministrativeExpenses_c20230101__20231231_zuptPMhsu8b9" title="Profit sharing contribution expenses"><ix:nonFraction name="us-gaap:DefinedContributionPlanAdministrativeExpenses" contextRef="From2023-01-012023-12-31" id="Fact001922" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,980</ix:nonFraction></span> for years ended
December 31, 2024 and 2023, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact001924" name="us-gaap:SegmentReportingDisclosureTextBlock"><p id="xdx_80A_eus-gaap--SegmentReportingDisclosureTextBlock_zzwg7jbYz5R7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>15.
<span id="xdx_820_zr9ex6xRUP24">Segment Information</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company evaluates the following factors to identify its reportable segments: (i) nature of products and services, (ii) type of customer
for the products and services, (iii) sales, production and distribution methods of the products and services and (iv) the nature of the
regulatory environment, if applicable. Based on an evaluation of these factors, management concluded that the Company&#8217;s operations are managed through one reportable segment, IB-STIM, that derives its revenues in the United States from a
PENFS device that is used to treat patients 8-21 years of age with functional abdominal pain associated with irritable bowel syndrome.
IB-STIM currently is the only product marketed and sold by the Company. The accounting policies of the IB-STIM segment are the same as
those described in the Summary of Significant Accounting Policies (see Footnote 2). The CODM regularly evaluates the performance of the
IB-STIM segment for the purpose of allocating resources based on net sales and operating loss, both of which are reported in the Statements
of Operations. The CODM uses net sales to evaluate IB-STIM&#8217;s adoption and utilization by insurance carriers and physicians. As
Neuraxis is an emerging growth company, operating loss is used to monitor the Company&#8217;s cost structure in order to achieve future
segment profitability. Both net sales and operating loss are measured against the budget on a periodic basis to assess achievement toward
annual compensation incentive targets. The Company&#8217;s CODM is its Chief Executive Officer.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact001926" name="us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock"><p id="xdx_89D_eus-gaap--ScheduleOfSegmentReportingInformationBySegmentTextBlock_zxiAZRRNNNX4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following reconciles the reportable segment net sales and operating loss to the Company&#8217;s reported net loss:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B3_zIRrk2PmXsYd">Schedule
of Reconciles the Company&#8217;s Net Sales and Operating Loss</span>&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="display: none; text-align: center">&#160;</td><td style="display: none; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_496_20240101__20241231__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_zQVzSUxLXCS8" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center">2024</td><td style="display: none; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="display: none; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_492_20230101__20231231__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_zS6R7VBfCF2f" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center">2023</td><td style="display: none; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">For the Years Ended December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_maCzEo3_zCN9uWPcUpNh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; width: 60%; font-weight: bold; text-align: left">Net Sales</td><td style="width: 2%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">$</td><td style="width: 16%; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2024-01-012024-12-31_us-gaap_OperatingSegmentsMember" id="Fact001928" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,685,925</ix:nonFraction></td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2023-01-012023-12-31_us-gaap_OperatingSegmentsMember" id="Fact001929" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,460,049</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--CostOfGoodsAndServicesSold_msCzEo3_zdJ2IIL909ld" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Cost of Goods Sold</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:CostOfGoodsAndServicesSold" contextRef="From2024-01-012024-12-31_us-gaap_OperatingSegmentsMember" id="Fact001931" format="ixt:numdotdecimal" decimals="0" unitRef="USD">362,002</ix:nonFraction></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:CostOfGoodsAndServicesSold" contextRef="From2023-01-012023-12-31_us-gaap_OperatingSegmentsMember" id="Fact001932" format="ixt:numdotdecimal" decimals="0" unitRef="USD">303,345</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--GrossProfit_iT_mtCzEo3_maOILz3im_zHXktUBsxMc" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; font-weight: bold; text-align: left">Gross Profit</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:GrossProfit" contextRef="From2024-01-012024-12-31_us-gaap_OperatingSegmentsMember" id="Fact001934" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,323,923</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:GrossProfit" contextRef="From2023-01-012023-12-31_us-gaap_OperatingSegmentsMember" id="Fact001935" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,156,704</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--SellingExpense_i01_msOILz3im_zYmpOrmV48va" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Selling Expenses <span id="xdx_F44_ztbxsniXabr">(a)</span></td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:SellingExpense" contextRef="From2024-01-012024-12-31_us-gaap_OperatingSegmentsMember" id="Fact001937" format="ixt:numdotdecimal" decimals="0" unitRef="USD">324,708</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:SellingExpense" contextRef="From2023-01-012023-12-31_us-gaap_OperatingSegmentsMember" id="Fact001938" format="ixt:numdotdecimal" decimals="0" unitRef="USD">323,569</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--ResearchAndDevelopmentExpense_i01_msOILz3im_zhthLcmgssrj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Research and Development <span id="xdx_F4B_zOI0PHE1bj1j">(a)</span></td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2024-01-012024-12-31_us-gaap_OperatingSegmentsMember" id="Fact001940" format="ixt:numdotdecimal" decimals="0" unitRef="USD">206,107</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2023-01-012023-12-31_us-gaap_OperatingSegmentsMember" id="Fact001941" format="ixt:numdotdecimal" decimals="0" unitRef="USD">169,315</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--LaborAndRelatedExpense_i01_msOILz3im_zF297Hh5Tt95" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Wages and Benefits <span id="xdx_F41_zAwA6AQear57">(a)</span></td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:LaborAndRelatedExpense" contextRef="From2024-01-012024-12-31_us-gaap_OperatingSegmentsMember" id="Fact001943" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,378,952</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:LaborAndRelatedExpense" contextRef="From2023-01-012023-12-31_us-gaap_OperatingSegmentsMember" id="Fact001944" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,367,486</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--ProfessionalAndContractServicesExpense_i01_msOILz3im_zCoI4NrOzSv2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Professional Services <span id="xdx_F4D_z7AiQB8GNFef">(a)</span></td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:ProfessionalAndContractServicesExpense" contextRef="From2024-01-012024-12-31_us-gaap_OperatingSegmentsMember" id="Fact001946" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,945,331</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ProfessionalAndContractServicesExpense" contextRef="From2023-01-012023-12-31_us-gaap_OperatingSegmentsMember" id="Fact001947" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,721,461</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--OtherCostAndExpenseOperating_i01_msOILz3im_zoEc5bAAdv51" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Other Operating Expenses <span id="xdx_F4C_zrk53HU68AZ1">(a)</span> <span id="xdx_F4B_zK9RzMvJ25Ee">(b)</span></td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:OtherCostAndExpenseOperating" contextRef="From2024-01-012024-12-31_us-gaap_OperatingSegmentsMember" id="Fact001949" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,625,642</ix:nonFraction></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherCostAndExpenseOperating" contextRef="From2023-01-012023-12-31_us-gaap_OperatingSegmentsMember" id="Fact001950" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,239,368</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--OperatingIncomeLoss_iT_maCz7fC_mtOILz3im_zxdpcZ5o8Qyf" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1pt">Segment Operating Loss</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2024-01-012024-12-31_us-gaap_OperatingSegmentsMember" id="Fact001952" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">7,156,817</ix:nonFraction></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2023-01-012023-12-31_us-gaap_OperatingSegmentsMember" id="Fact001953" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">6,664,495</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--NonoperatingIncomeExpenseAbstract_iB_zbAcjN2ODiE7" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Other (Expense) Income:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_ecustom--FinancingCharges_i01N_di_msONIEz60J_z2B0GCtuEkt6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: left">Financing charges</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">(<ix:nonFraction name="NRXS:FinancingCharges" contextRef="From2024-01-012024-12-31_us-gaap_OperatingSegmentsMember" id="Fact001958" format="ixt:numdotdecimal" decimals="0" unitRef="USD">230,824</ix:nonFraction></td><td style="font-weight: bold; text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="NRXS:FinancingCharges" contextRef="From2023-01-012023-12-31_us-gaap_OperatingSegmentsMember" id="Fact001959" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,772</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_408_eus-gaap--InterestExpense_i01N_di_msONIEz60J_zztXzQpOihe6" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left">Interest expense</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:InterestExpense" contextRef="From2024-01-012024-12-31_us-gaap_OperatingSegmentsMember" id="Fact001961" format="ixt:numdotdecimal" decimals="0" unitRef="USD">174,328</ix:nonFraction></td><td style="font-weight: bold; text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:InterestExpense" contextRef="From2023-01-012023-12-31_us-gaap_OperatingSegmentsMember" id="Fact001962" format="ixt:numdotdecimal" decimals="0" unitRef="USD">476,416</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40B_eus-gaap--FairValueAdjustmentOfWarrants_i01N_di_msONIEz60J_zNFSq4n7haY6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: left">Change in fair value of warrant liability</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="From2024-01-012024-12-31_us-gaap_OperatingSegmentsMember" id="Fact001964" format="ixt:numdotdecimal" decimals="0" unitRef="USD">941</ix:nonFraction></td><td style="font-weight: bold; text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="From2023-01-012023-12-31_us-gaap_OperatingSegmentsMember" id="Fact001965" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">844,854</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--DerivativeGainLossOnDerivativeNet_i01_maONIEz60J_z1Q0FrtYcXu5" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left">Change in fair value of derivative liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1967">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DerivativeGainLossOnDerivativeNet" contextRef="From2023-01-012023-12-31_us-gaap_OperatingSegmentsMember" id="Fact001968" format="ixt:numdotdecimal" decimals="0" unitRef="USD">198,551</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--AmortizationOfFinancingCostsAndDiscounts_i01N_di_msONIEz60J_ztXLMWhzcoo6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: left">Amortization of debt discount and issuance cost</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" contextRef="From2024-01-012024-12-31_us-gaap_OperatingSegmentsMember" id="Fact001970" format="ixt:numdotdecimal" decimals="0" unitRef="USD">126,387</ix:nonFraction></td><td style="font-weight: bold; text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" contextRef="From2023-01-012023-12-31_us-gaap_OperatingSegmentsMember" id="Fact001971" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,881,622</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_400_eus-gaap--GainsLossesOnExtinguishmentOfDebt_i01_maONIEz60J_zG8IEht4gaie" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left">Extinguishment of debt liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1973">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:GainsLossesOnExtinguishmentOfDebt" contextRef="From2023-01-012023-12-31_us-gaap_OperatingSegmentsMember" id="Fact001974" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">3,649,561</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_404_eus-gaap--OtherNonoperatingIncome_i01_maONIEz60J_zCzqQ1YCpcMj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: left">Other income</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:OtherNonoperatingIncome" contextRef="From2024-01-012024-12-31_us-gaap_OperatingSegmentsMember" id="Fact001976" format="ixt:numdotdecimal" decimals="0" unitRef="USD">33,620</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OtherNonoperatingIncome" contextRef="From2023-01-012023-12-31_us-gaap_OperatingSegmentsMember" id="Fact001977" format="ixt:numdotdecimal" decimals="0" unitRef="USD">15,133</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--OtherNonoperatingExpense_i01N_di_msONIEz60J_zdZ31bllWTOa" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left; padding-bottom: 1pt">Other expense</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:OtherNonoperatingExpense" contextRef="From2024-01-012024-12-31_us-gaap_OperatingSegmentsMember" id="Fact001979" format="ixt:numdotdecimal" decimals="0" unitRef="USD">585,824</ix:nonFraction></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:OtherNonoperatingExpense" contextRef="From2023-01-012023-12-31_us-gaap_OperatingSegmentsMember" id="Fact001980" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,355</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_40B_eus-gaap--OtherNonoperatingIncomeExpense_i01T_maCz7fC_mtONIEz60J_znSMZiHMxXVk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 30pt; text-align: left; padding-bottom: 1pt">Total other (expense) income, net</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="From2024-01-012024-12-31_us-gaap_OperatingSegmentsMember" id="Fact001982" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,084,684</ix:nonFraction></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="From2023-01-012023-12-31_us-gaap_OperatingSegmentsMember" id="Fact001983" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">7,962,188</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--NetIncomeLoss_iT_mtCz7fC_zCVtniRT8qb4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1pt">Net Loss</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-01-012024-12-31_us-gaap_OperatingSegmentsMember" id="Fact001985" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">8,241,501</ix:nonFraction></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-12-31_us-gaap_OperatingSegmentsMember" id="Fact001986" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">14,626,683</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span id="xdx_F0A_zSHbxJTS4XIa" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F1B_zCM34Oh92oT7" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:footnote id="Footnote001987" xml:lang="en-US">The
                                            significant expense categories and amounts align with the segment-level information provided
                                            on a regular basis to the CODM.</ix:footnote></span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"/><td style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_F0D_zmCzF8AwSMi2" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F12_zBTE0DIvtEci" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:footnote id="Footnote001988" xml:lang="en-US">Other
                                            operating expenses include advertising, rent and utilities, insurance, depreciation and
                                            amortization, travel, software subscription fees, board fees and bad debt expense.</ix:footnote></span></td></tr></table>

</ix:nonNumeric><p id="xdx_8A8_zThmupzGkeR1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
segment assets for IB-STIM amounted to $<span id="xdx_909_eus-gaap--Assets_iI_c20241231_zdWgAYvatPX4" title="Assets"><ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2024-12-31" id="Fact001990" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,757,572</ix:nonFraction></span>
and $<span id="xdx_90B_eus-gaap--Assets_iI_c20231231_z0XPgYkRHAof" title="Assets"><ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2023-12-31" id="Fact001992" format="ixt:numdotdecimal" decimals="0" unitRef="USD">509,498</ix:nonFraction></span> as of December 31, 2024 and 2023,
respectively. Total segment capital expenditures for IB-STIM amounted to $<span id="xdx_904_eus-gaap--NetCashProvidedByUsedInInvestingActivities_iN_di_c20240101__20241231_z5UjbH8Wd5ek" title="Net cash used by investing activities"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="From2024-01-01to2024-12-31" id="Fact001994" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">27,776</ix:nonFraction></span>
and $<span id="xdx_905_eus-gaap--NetCashProvidedByUsedInInvestingActivities_iN_di_c20230101__20231231_zy3dON3rH4Rf" title="Net cash used by investing activities"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="From2023-01-012023-12-31" id="Fact001996" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">71,781</ix:nonFraction></span>
for the years ended December 31, 2024 and 2023, respectively. Total segment depreciation and amortization amounted to $<span id="xdx_901_eus-gaap--DepreciationAndAmortization_c20240101__20241231_z4TCnRFV1smd" title="Depreciation and amortization"><ix:nonFraction name="us-gaap:DepreciationAndAmortization" contextRef="From2024-01-01to2024-12-31" id="Fact001998" format="ixt:numdotdecimal" decimals="0" unitRef="USD">37,831</ix:nonFraction></span> and $<span id="xdx_906_eus-gaap--DepreciationAndAmortization_c20230101__20231231_zWCRrQ7y47z9" title="Depreciation and amortization"><ix:nonFraction name="us-gaap:DepreciationAndAmortization" contextRef="From2023-01-012023-12-31" id="Fact002000" format="ixt:numdotdecimal" decimals="0" unitRef="USD">40,725</ix:nonFraction></span> for the years ended December 31, 2024 and 2023, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">Significant segment non-cash charges settled in common stock
include (i) consulting and advisory fees totaling $<span id="xdx_90E_ecustom--ConsultingAndAdvisoryFees_c20240101__20241231_z1JustoTJCo7" title="Consulting and advisory fees"><ix:nonFraction name="NRXS:ConsultingAndAdvisoryFees" contextRef="From2024-01-01to2024-12-31" id="Fact002002" format="ixt:numdotdecimal" decimals="0" unitRef="USD">754,685</ix:nonFraction></span> and $<span id="xdx_90A_ecustom--ConsultingAndAdvisoryFees_c20230101__20231231_z4M3Sf3Wnc1h" title="Consulting and advisory fees"><ix:nonFraction name="NRXS:ConsultingAndAdvisoryFees" contextRef="From2023-01-012023-12-31" id="Fact002004" format="ixt:numdotdecimal" decimals="0" unitRef="USD">750,000</ix:nonFraction></span> for the years ended December 31, 2024 and 2023, respectively,
and (ii) hiring grants totaling $<span id="xdx_907_eus-gaap--ShareBasedCompensation_c20240101__20241231_zXkZInxUm2k4" title="Stock based compensation"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2024-01-01to2024-12-31" id="Fact002006" format="ixt:numdotdecimal" decimals="0" unitRef="USD">227,000</ix:nonFraction></span> and $<span id="xdx_90D_eus-gaap--ShareBasedCompensation_dxL_c20230101__20231231_zkdR0OGsfFM" title="Stock based compensation::XDX::-"><span style="-sec-ix-hidden: xdx2ixbrl2008">0</span></span> for the years ended December 31, 2024 and 2023, respectively.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>


<ix:exclude><!-- Field: Page; Sequence: 122; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact002010" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock"><p id="xdx_802_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_z9MraOrNsOl4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>16</b>.
<b><span id="xdx_82A_ze7exhKFYWQ5">Commitments and Contingencies</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Manufacturing
Services Agreement</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is party to a manufacturing services agreement for the manufacture and supply of the Company&#8217;s IB-STIM device based on
the Company&#8217;s product specifications that automatically renews annually unless either party provides a written termination notice
to the other party within 180 days prior to the end of the then-current term. The Company provides the necessary equipment to the manufacturer
and retains ownership. The manufacturer bears the risk of loss of and damage to the equipment and consigned materials. Performance under
the agreement is initiated by orders issued by the Company and accepted by the manufacturer.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Advisory
Agreement</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
March 18, 2024, the Company terminated its private placement services agreement and entered into an advisory agreement with a financial
advisor for debt, equity and public securities market services for one year. The advisory agreement included a monthly fee of $<span id="xdx_90E_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_c20240318__20240318__us-gaap--TypeOfArrangementAxis__custom--AdvisoryAgreementMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zjfu9PspRz64" title="Monthly advisory fee"><ix:nonFraction name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" contextRef="From2024-03-182024-03-18_custom_AdvisoryAgreementMember_us-gaap_PrivatePlacementMember" id="Fact002012" format="ixt:numdotdecimal" decimals="0" unitRef="USD">30,000</ix:nonFraction></span>
and <span id="xdx_90D_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_c20240318__20240318__us-gaap--TypeOfArrangementAxis__custom--AdvisoryAgreementMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zNXrgHi5fopl" title="Monthly advisory fee"><ix:nonFraction name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" contextRef="From2024-03-182024-03-18_custom_AdvisoryAgreementMember_us-gaap_PrivatePlacementMember_us-gaap_CommonStockMember" id="Fact002014" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,563</ix:nonFraction></span> common stock warrants to be issued monthly at an exercise price of $<span id="xdx_902_eus-gaap--SaleOfStockPricePerShare_iI_pid_c20240318__us-gaap--TypeOfArrangementAxis__custom--AdvisoryAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zxKzUidIR55l" title="Monthly exercise price"><ix:nonFraction name="us-gaap:SaleOfStockPricePerShare" contextRef="AsOf2024-03-18_custom_AdvisoryAgreementMember_us-gaap_CommonStockMember_us-gaap_PrivatePlacementMember" id="Fact002016" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.38</ix:nonFraction></span> with a term of five years. On December 31, 2024, the
Company and the financial advisor terminated the advisory agreement subject to the cancelation of all common stock warrants issued after
July 2024 and the payment for services rendered in three equal installments of $<span id="xdx_900_eus-gaap--IssuanceOfStockAndWarrantsForServicesOrClaims_c20250326__20250326__srt--StatementScenarioAxis__srt--ScenarioForecastMember__us-gaap--TypeOfArrangementAxis__custom--AdvisoryAgreementMember_zGZcEnjrkRab" title="Payment for services"><ix:nonFraction name="us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims" contextRef="From2025-03-262025-03-26_srt_ScenarioForecastMember_custom_AdvisoryAgreementMember" id="Fact002018" format="ixt:numdotdecimal" decimals="0" unitRef="USD">60,000</ix:nonFraction></span> by March 26, 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Settlement
Agreements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company issued <span id="xdx_909_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--SettlementAgreementMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_z87GpsPnaq4j" title="Number of shares new issuance"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember_custom_SettlementAgreementMember_us-gaap_SeriesAPreferredStockMember" id="Fact002020" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">245,955</ix:nonFraction></span> shares of common stock to various pre-IPO 2022 Convertible Note and Series A Preferred Stock holders to settle
certain claims. The Company recorded the fair value of the settlements as $<span id="xdx_902_ecustom--FinanceCharges_c20240101__20241231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember__us-gaap--TypeOfArrangementAxis__custom--SettlementAgreementMember_z3dFFcYQGAWa" title="Finance Charges"><ix:nonFraction name="NRXS:FinanceCharges" contextRef="From2024-01-012024-12-31_us-gaap_SeriesAPreferredStockMember_custom_SettlementAgreementMember" id="Fact002022" format="ixt:numdotdecimal" decimals="0" unitRef="USD">230,824</ix:nonFraction></span> of Finance Charges and $<span id="xdx_902_eus-gaap--OtherExpenses_c20240101__20241231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember__us-gaap--TypeOfArrangementAxis__custom--SettlementAgreementMember_zSpbD2ayjoja" title="Other expense"><ix:nonFraction name="us-gaap:OtherExpenses" contextRef="From2024-01-012024-12-31_us-gaap_SeriesAPreferredStockMember_custom_SettlementAgreementMember" id="Fact002024" format="ixt:numdotdecimal" decimals="0" unitRef="USD">580,250</ix:nonFraction></span> of Other Expense in
the Statements of Operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Furthermore,
the Company authorized the issuance of <span id="xdx_909_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zLY0XIiDMZ6h" title="New issuance, shares"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember_us-gaap_SeriesAPreferredStockMember" id="Fact002026" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,518</ix:nonFraction></span> shares of its common stock to settle remaining claims with one pre-IPO Series A Preferred
Stock shareholder classified as $<span id="xdx_905_eus-gaap--OtherExpenses_c20240101__20241231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zmOQVLFTy9ee" title="Other expenses"><ix:nonFraction name="us-gaap:OtherExpenses" contextRef="From2024-01-012024-12-31_us-gaap_SeriesAPreferredStockMember" id="Fact002028" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,220</ix:nonFraction></span> of Other Expense for the year ended December 31, 2024 in the Statements of Operations and accrued
expenses in the Balance Sheets as of December 31, 2024. These common shares have not yet been issued as of the reporting date as the
Company awaits execution of the settlement agreements by the counterparties.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Executive
Employment Agreements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company, as authorized by the board of directors, entered into employment agreements with nine key employees to provide incentives to
improve shareholder value and to contribute to the growth and financial success of the Company. The agreements had an employment start
date of October 1, 2022, with initial terms from <span id="xdx_904_ecustom--ExecutiveEmploymentAgreementsTerms_dtY_c20221001__20221001__srt--RangeAxis__srt--MinimumMember__us-gaap--TypeOfArrangementAxis__custom--ExecutiveEmploymentAgreementsMember_zAkLqA3S85r6" title="Executive employment agreements renewals"><ix:nonNumeric contextRef="From2022-10-012022-10-01_srt_MinimumMember_custom_ExecutiveEmploymentAgreementsMember" format="ixt-sec:duryear" id="Fact002030" name="NRXS:ExecutiveEmploymentAgreementsTerms">2</ix:nonNumeric></span> to <span id="xdx_90A_ecustom--ExecutiveEmploymentAgreementsTerms_dtY_c20221001__20221001__srt--RangeAxis__srt--MaximumMember__us-gaap--TypeOfArrangementAxis__custom--ExecutiveEmploymentAgreementsMember_z5nCL1ZDLvd2" title="Executive employment agreements renewals"><ix:nonNumeric contextRef="From2022-10-012022-10-01_srt_MaximumMember_custom_ExecutiveEmploymentAgreementsMember" format="ixt-sec:duryear" id="Fact002032" name="NRXS:ExecutiveEmploymentAgreementsTerms">5</ix:nonNumeric></span> years and <span id="xdx_900_ecustom--DescriptionOfExecutiveEmploymentAgreementsRenewals_dtY_c20221001__20221001__us-gaap--TypeOfArrangementAxis__custom--ExecutiveEmploymentAgreementsMember_znpA4eJ42zlb" title="Description of Executive employment agreements renewals"><ix:nonNumeric contextRef="From2022-10-012022-10-01_custom_ExecutiveEmploymentAgreementsMember" id="Fact002034" name="NRXS:DescriptionOfExecutiveEmploymentAgreementsRenewals">optional one-year renewals</ix:nonNumeric></span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
total base salaries for the nine key employees in the agreements are $<span id="xdx_902_eus-gaap--SalariesAndWages_c20240101__20241231__us-gaap--TypeOfArrangementAxis__custom--ExecutiveEmploymentAgreementsMember_zaUJD6RObTX" title="Base salaries for nine key employees"><ix:nonFraction name="us-gaap:SalariesAndWages" contextRef="From2024-01-012024-12-31_custom_ExecutiveEmploymentAgreementsMember" id="Fact002036" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,920,000</ix:nonFraction></span> per year with various provisions for annual increases.
In addition to base salaries, eight of the employees have a provision for a special one-time incentive payment to be paid in a lump sum
after the start date. The total amount of these special incentive payments is $<span id="xdx_909_eus-gaap--IncentiveFeeExpense_c20240101__20241231__us-gaap--TypeOfArrangementAxis__custom--ExecutiveEmploymentAgreementsMember_z4oweevxVPzc" title="Incentive payments"><ix:nonFraction name="us-gaap:IncentiveFeeExpense" contextRef="From2024-01-012024-12-31_custom_ExecutiveEmploymentAgreementsMember" id="Fact002038" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,100,000</ix:nonFraction></span>. The special incentive payment amount includes
any accrued backpay wages for the employee. The amount for backpay of $<span id="xdx_90E_eus-gaap--AccruedLiabilitiesCurrent_iI_c20231231__us-gaap--TypeOfArrangementAxis__custom--ExecutiveEmploymentAgreementsMember_zwz8Yxj2KZZ1" title="Accrued amount for backpay"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" contextRef="AsOf2023-12-31_custom_ExecutiveEmploymentAgreementsMember" id="Fact002040" format="ixt:numdotdecimal" decimals="0" unitRef="USD">417,390</ix:nonFraction></span> was paid in the year ended December 31, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
are seven key employees that have stock options of the Company totaling <span id="xdx_900_eus-gaap--StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan_pid_uShares_c20240101__20240630__us-gaap--TypeOfArrangementAxis__custom--ExecutiveEmploymentAgreementsMember_z30oTuhjpm95" title="Seven key employees stock options"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan" contextRef="From2024-01-012024-06-30_custom_ExecutiveEmploymentAgreementsMember" id="Fact002042" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,238,712</ix:nonFraction></span> shares. These key employees have a provision in their
agreements whereas the Company will pay a special bonus equal to the aggregate of the strike price or exercise price of all their stock
options plus a tax gross-up payment. The special bonus shall be paid in twenty percent (<span id="xdx_900_ecustom--SpecialBonusPercentage_iI_pid_dp_uPure_c20240102__us-gaap--TypeOfArrangementAxis__custom--ExecutiveEmploymentAgreementsMember_zEThdkppPw7j" title="Special bonus percentage"><ix:nonFraction name="NRXS:SpecialBonusPercentage" contextRef="AsOf2024-01-02_custom_ExecutiveEmploymentAgreementsMember" id="Fact002044" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">20</ix:nonFraction></span>%) installments starting January 2, 2024, and
the same date each of the next four years. As a condition of the payment, the key employee must exercise at least <span id="xdx_901_ecustom--KeyEmployeeExercisePercentage_iI_pid_dp_uPure_c20240102__us-gaap--TypeOfArrangementAxis__custom--ExecutiveEmploymentAgreementsMember__srt--RangeAxis__srt--MinimumMember_zyz75b434FS5" title="Key employee exercise percentage"><ix:nonFraction name="NRXS:KeyEmployeeExercisePercentage" contextRef="AsOf2024-01-02_custom_ExecutiveEmploymentAgreementsMember_srt_MinimumMember" id="Fact002046" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">20</ix:nonFraction></span>% of their stated
number of stock options. There are additional provisions to cover termination and change of control events. None of the key employees
exercised any of options as of January 2, 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
April 2023, the Company amended the employee agreements to, among other things, clarify that the special one-time incentive payment and
the deferred bonus are contingent upon the effective date of the planned initial public offering. The amendment also sets forth a process
for executives to exercise the stock options in accordance with the terms of the stock option agreement in effect as of the date of the
employment agreement and to clarify that there is no modification to the stock option agreements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 123; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Neuraxis,
Inc.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Notes
to Financial Statements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company recorded the backpay portion of the incentive bonus notes above. The balance of the incentive bonuses of $<span id="xdx_90C_eus-gaap--AccruedBonusesCurrent_iI_c20230430__us-gaap--TypeOfArrangementAxis__custom--ExecutiveEmploymentAgreementsMember_zuWouEEq34kg" title="Incentive bonus"><ix:nonFraction name="us-gaap:AccruedBonusesCurrent" contextRef="AsOf2023-04-30_custom_ExecutiveEmploymentAgreementsMember" id="Fact002048" format="ixt:numdotdecimal" decimals="0" unitRef="USD">694,056</ix:nonFraction></span> and the special
options bonuses of $<span id="xdx_900_eus-gaap--AccruedBonusesCurrent_iI_c20230430__us-gaap--TypeOfArrangementAxis__custom--ExecutiveEmploymentAgreementsMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_z3lp8dxKDAtf" title="Incentive bonus"><ix:nonFraction name="us-gaap:AccruedBonusesCurrent" contextRef="AsOf2023-04-30_custom_ExecutiveEmploymentAgreementsMember_us-gaap_IPOMember" id="Fact002050" format="ixt:numdotdecimal" decimals="0" unitRef="USD">14,821,830</ix:nonFraction></span> were contingent upon a successful IPO. The incentive bonuses have been paid in full while the special
options bonuses will be recorded when paid.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
April 10, 2024, the Company terminated the employment of the Company&#8217;s Chief Operating Officer. Pursuant to the employment agreement,
the Company made (i) make salary continuation payments for six months during the year ended December 31, 2024, (ii) issued <span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20240410__20240410__srt--TitleOfIndividualAxis__srt--ChiefOperatingOfficerMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zrAsVhH5OgGi" title="Common stock shares issue"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2024-04-102024-04-10_srt_ChiefOperatingOfficerMember_us-gaap_CommonStockMember" id="Fact002052" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">25,832</ix:nonFraction></span> shares
of common stock at a fair value of $<span id="xdx_901_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20240410__20240410__srt--TitleOfIndividualAxis__srt--ChiefOperatingOfficerMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zRHnOyE1Lek4" title="Common stock with a fair value"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2024-04-102024-04-10_srt_ChiefOperatingOfficerMember_us-gaap_CommonStockMember" id="Fact002054" format="ixt:numdotdecimal" decimals="0" unitRef="USD">78,788</ix:nonFraction></span> and (iii) made a $<span id="xdx_903_eus-gaap--PaymentsToAcquireEquitySecuritiesFvNi_c20240410__20240410__srt--TitleOfIndividualAxis__srt--ChiefOperatingOfficerMember_zeNAE0Wt252k" title="One time payment"><ix:nonFraction name="us-gaap:PaymentsToAcquireEquitySecuritiesFvNi" contextRef="From2024-04-102024-04-10_srt_ChiefOperatingOfficerMember" id="Fact002056" format="ixt:numdotdecimal" decimals="0" unitRef="USD">41,980</ix:nonFraction></span> one-time payment in lieu of the exercise of <span id="xdx_905_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20240410__20240410__srt--TitleOfIndividualAxis__srt--ChiefOperatingOfficerMember_za3qfLRP1EBe" title="Stock option, exercise"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="From2024-04-102024-04-10_srt_ChiefOperatingOfficerMember" id="Fact002058" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">13,764</ix:nonFraction></span> stock options
that expired on January 2, 2024. The Company is obligated to provide health care coverage through October 2025 and has accrued for that
obligation totaling $<span id="xdx_908_eus-gaap--AccruedLiabilitiesFairValueDisclosure_iI_c20241231__srt--TitleOfIndividualAxis__srt--ChiefOperatingOfficerMember_zKSSNoKQNmqd" title="Accrued expenses"><ix:nonFraction name="us-gaap:AccruedLiabilitiesFairValueDisclosure" contextRef="AsOf2024-12-31_srt_ChiefOperatingOfficerMember" id="Fact002060" format="ixt:numdotdecimal" decimals="0" unitRef="USD">21,418</ix:nonFraction></span> classified as Accrued Expenses in the Balance Sheets as of December 31, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Litigation</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">From
time to time, the Company may be involved in litigation relating to claims arising out of operations in the normal course of business.
As of the date of issuance, other than those described below, there were no pending or threatened legal proceedings that could reasonably
be expected to have a material effect on the results of the Company&#8217;s operations. There are also no proceedings in which any of
the Company&#8217;s directors, officers or affiliates is an adverse party to the Company or has a material interest adverse to the Company&#8217;s
interest. Legal fees are expensed as incurred.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 6, 2019, plaintiff Ritu Bhambhani, M.D., initiated a lawsuit against Innovative Health Solutions, Inc. and others in the United
States District Court for the District of Maryland. Plaintiffs Bhambhani and Sudhir Rao subsequently amended the complaint, with the
Third Amended Complaint (&#8220;Complaint&#8221;) containing the most recent set of allegations. The Complaint asserted claims under
the RICO Act, as well as of fraudulent misrepresentation, intentional misrepresentation by concealment, and civil conspiracy and sought
compensatory damages in excess of $<span id="xdx_900_eus-gaap--LossContingencyDamagesSoughtValue_pn6n6_c20190206__20190206_zSpe14Of6Bn4" title="Sought compensatory damages"><ix:nonFraction name="us-gaap:LossContingencyDamagesSoughtValue" contextRef="From2019-02-062019-02-06" id="Fact002062" format="ixt:numdotdecimal" decimals="-6" scale="6" unitRef="USD">5</ix:nonFraction></span> million, pre-judgment interest, punitive damages, attorney&#8217;s fees, court costs and designation
of the case as a class action. The Complaint stated that the Company, distributors of the Company&#8217;s product, and medical billing
and coding consultants allegedly made misrepresentations to the plaintiffs that the Company&#8217;s NeuroStim device and related procedures
could be billed to, and reimbursed by, Medicare and other insurance payors as a surgically implantable neurostimulator. Plaintiffs claim
to have suffered damages when Medicare administrative contractors declined to pay plaintiffs for their use of the device.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 11, 2022, the Company filed a motion for summary judgment based upon the plaintiffs not being proper parties to assert claims
against the Company. On June 14, 2022, the Court granted the Company&#8217;s motion for summary judgment and dismissed the Complaint.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
July 14, 2022, plaintiffs Ritu Bhambhani and Sudhir Rao filed a notice of appeal with the Fourth Circuit Court of Appeals. On June 3,
2024, the Fourth Circuit denied the plaintiff&#8217;s appeal and entered judgment against the plaintiffs. On June 25, 2024, the Fourth
Circuit entered its mandate declaring that its judgment against the plaintiffs took effect that day. The plaintiffs did not seek any
further review or appeal of that judgment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Also
on July 14, 2022, plaintiffs Ritu Bhambhani, LLC; Box Hill Surgery Center, LLC; Pain and Spine Specialists of Maryland, LLC; and SimCare
ASC, LLC initiated a lawsuit against the Company and others in the United States District Court for the District of Maryland. The plaintiffs
in this lawsuit are business entities owned or partially owned by the plaintiffs that initiated the litigation described above. The Complaint
asserted claims under the RICO Act, as well as fraudulent misrepresentation, intentional misrepresentation by concealment, and civil
conspiracy and seeks compensatory damages in excess of $<span id="xdx_90E_eus-gaap--LossContingencyDamagesSoughtValue_c20220714__20220714_zh22x5PD1Rth" title="Sought compensatory damages"><ix:nonFraction name="us-gaap:LossContingencyDamagesSoughtValue" contextRef="From2022-07-142022-07-14" id="Fact002064" format="ixt:numdotdecimal" decimals="0" unitRef="USD">75,000</ix:nonFraction></span>, pre-judgment interest, punitive damages, attorney&#8217;s fees, and court
costs. The Complaint states that the Company, distributors of the Company&#8217;s product, and medical billing and coding consultants
allegedly made misrepresentations to the plaintiffs that the Company&#8217;s NeuroStim device and related procedures could be billed
to, and reimbursed by, Medicare and other insurance payors as a surgically implantable neurostimulator. Plaintiffs claim to have suffered
damages when Medicare administrative contractors declined to pay plaintiffs for their use of the device.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
September 28, 2022, the Company filed a motion to dismiss all claims. On May 25, 2023, the Court issued an Order and a Memorandum
Opinion which dismissed the plaintiffs&#8217; claims related to the RICO Act. The remaining claims are still pending, and no trial
date has been set for the case. </span>The Court has vacated its Scheduling Order at the parties&#8217; request so that the parties
could try to resolve the disputes in both cases through an independent third-party mediator. Mediation has not yet resulted in a
resolution of the case.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 124; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Neuraxis,
Inc.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Notes
to Financial Statements</b></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In January 2024, Dr. Arturo Taca served notice to the Company that asserted
an interest in its U.S. Patent No. 10,413,719 valued at $<span id="xdx_904_eus-gaap--FiniteLivedPatentsGross_iI_c20240131_zhTQ8gMuj3Y2" title="Patent value"><ix:nonFraction name="us-gaap:FiniteLivedPatentsGross" contextRef="AsOf2024-01-31" id="Fact002066" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,000,000</ix:nonFraction></span> based on his own work in neurostimulation.&#160; The Company denied
both the neurostimulation patent and compensation claims.&#160; The case remains unresolved.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">While it is too early to predict
the ultimate outcome of these matters, we believe the Company has meritorious defenses and intends to defend these matters vigorously.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact002068" name="NRXS:HealthBenefitPlanDisclosureTextBlock"><p id="xdx_801_ecustom--HealthBenefitPlanDisclosureTextBlock_zOGtIJTwkHU8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>17.
<span id="xdx_827_zpEbH2V3LJbi">Health Benefit Plan</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company participates in a self-funded employer program in conjunction with a group health plan for the benefit of eligible employees.
This plan is a level funded plan, and the services and products include:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
    self-funded employer health benefit plan.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stop
    loss insurance purchased from a stop loss insurance company.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Third
    party administrator to provide administrative services with regard to the plan.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company maintains a stop loss contract that reimburses the Company for claims paid under the plan if they exceed a predetermined level.
The Company makes contributions for health care costs and associated expenses that are expected during the plan year. The amount of contributions
is determined annually based on the Company&#8217;s maximum liability for expected claims, administrative expenses, and premiums for
the stop loss policy. The Company paid premiums of $<span id="xdx_90B_eus-gaap--HealthCareOrganizationStopLossInsurancePremiumExpense_c20240101__20241231_zl9uSPmhw03l" title="Stop loss insurance premium expense"><ix:nonFraction name="us-gaap:HealthCareOrganizationStopLossInsurancePremiumExpense" contextRef="From2024-01-01to2024-12-31" id="Fact002070" format="ixt:numdotdecimal" decimals="0" unitRef="USD">257,642</ix:nonFraction></span> and $<span id="xdx_90E_eus-gaap--HealthCareOrganizationStopLossInsurancePremiumExpense_c20230101__20231231_zenk5ce2Vlr2" title="Stop loss insurance premium expense"><ix:nonFraction name="us-gaap:HealthCareOrganizationStopLossInsurancePremiumExpense" contextRef="From2023-01-012023-12-31" id="Fact002072" format="ixt:numdotdecimal" decimals="0" unitRef="USD">255,715</ix:nonFraction></span> for the years ended December 31, 2024 and 2023, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is responsible for the monthly premiums, as established, and nothing further. The stop loss policy covers the claims if they
exceed the claims funds. After a certain time, and if there is a surplus in the claims fund, the Company may be entitled to receive a
<span id="xdx_90E_ecustom--HealthCareOrganizationStopLossInsurancePremiumPercentage_pid_dp_uPure_c20240101__20241231_zs7tu9UUY2Cg" title="Stop loss insurance premium percentage"><ix:nonFraction name="NRXS:HealthCareOrganizationStopLossInsurancePremiumPercentage" contextRef="From2024-01-01to2024-12-31" id="Fact002074" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">48.5</ix:nonFraction></span>% refund from the fund. This amount is recognized by the Company when received.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact002076" name="us-gaap:IncomeTaxDisclosureTextBlock"><p id="xdx_802_eus-gaap--IncomeTaxDisclosureTextBlock_zqVtiVAgaN9h" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>18.
<span id="xdx_823_zmuUDI73bEIh">Income Taxes</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact002078" name="us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"><p id="xdx_890_eus-gaap--ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_zDb3lcW75Ijk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
income tax provision consists of:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B5_zNP32LdYNA2g">Schedule
of Income Tax Provision</span>&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="display: none">&#160;</td><td style="display: none; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49F_20240101__20241231_zGKRhM3a4gI" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center">2024</td><td style="display: none; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="display: none; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49A_20230101__20231231_zoONEQJVCXxg" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center">2023</td><td style="display: none; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">For the Years Ended December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--CurrentIncomeTaxExpenseBenefit_maDITEBzp9r_zgzdKTwjUnl5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0pt; text-align: left">Total current provision</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">$</td><td style="font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2080">-</span></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2081">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0pt">Deferred:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--DeferredFederalIncomeTaxExpenseBenefit_maDITEBzp9r_z4B2XbNXY3Se" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; width: 60%">Federal</td><td style="width: 2%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 16%; font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" contextRef="From2024-01-01to2024-12-31" id="Fact002083" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,721,242</ix:nonFraction></td><td style="width: 1%; font-weight: bold; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right">(<ix:nonFraction name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" contextRef="From2023-01-012023-12-31" id="Fact002084" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">3,067,056</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td></tr>
  <tr id="xdx_402_eus-gaap--DeferredStateAndLocalIncomeTaxExpenseBenefit_maDITEBzp9r_zfUDQpdKPKFd" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; padding-bottom: 1pt">State</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" contextRef="From2024-01-01to2024-12-31" id="Fact002086" format="ixt:numdotdecimal" decimals="0" unitRef="USD">124,823</ix:nonFraction></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" contextRef="From2023-01-012023-12-31" id="Fact002087" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">154,060</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_408_eus-gaap--DeferredIncomeTaxExpenseBenefit_iT_mtDITEBzp9r_maITEBzTsP_z0FkcE7aj5Sb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0pt; text-align: left">Total deferred benefit</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:DeferredIncomeTaxExpenseBenefit" contextRef="From2024-01-01to2024-12-31" id="Fact002089" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,596,419</ix:nonFraction></td><td style="font-weight: bold; text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:DeferredIncomeTaxExpenseBenefit" contextRef="From2023-01-012023-12-31" id="Fact002090" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">3,221,116</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_405_eus-gaap--IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_maITEBzTsP_zfcx9bJKyV79" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Valuation allowance</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" contextRef="From2024-01-01to2024-12-31" id="Fact002092" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,596,419</ix:nonFraction></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" contextRef="From2023-01-012023-12-31" id="Fact002093" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,221,116</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--IncomeTaxExpenseBenefit_iT_mtITEBzTsP_zIsWExreKkA6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Total income tax provision</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2095">&#8212;</span></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2096">&#8212;</span></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A0_zDSa6BtIEhIa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact002098" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"><p id="xdx_892_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_z1gVIsJ6URf6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
reconciliation of the U.S. federal statutory income tax rate to the effective income tax rate is as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B0_zTBhoPXev1aj" style="display: none">Schedule of Federal Statutory Income Tax Rate and Effective Income Tax Rate</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="display: none">&#160;</td><td style="display: none; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_490_20240101__20241231_zdvSC8iN66j" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center">2024</td><td style="display: none; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="display: none; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49C_20230101__20231231_z0XKOJgDOSWc" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center">2023</td><td style="display: none; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">For the Years Ended December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_uPure_maEIT001_z1qbu3Hil3a6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; width: 60%; text-align: left">Federal statutory income tax rate</td><td style="width: 2%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 16%; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextRef="From2024-01-01to2024-12-31" id="Fact002100" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">21.0</ix:nonFraction></td><td style="width: 1%; font-weight: bold; text-align: left">%</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextRef="From2023-01-012023-12-31" id="Fact002101" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">21.0</ix:nonFraction></td><td style="width: 1%; text-align: left">%</td></tr>
  <tr id="xdx_40A_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_pid_dp_uPure_maEIT001_zIZ8oRAWthS2" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">State tax rate, net of federal benefit</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" contextRef="From2024-01-01to2024-12-31" id="Fact002103" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">5.3</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" contextRef="From2023-01-012023-12-31" id="Fact002104" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">4.9</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_pid_dp_uPure_maEIT001_zZTKo9bs0Sp9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0pt; text-align: left; padding-bottom: 1pt">Change in valuation allowance</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" contextRef="From2024-01-01to2024-12-31" id="Fact002106" format="ixt:numdotdecimal" decimals="INF" scale="-2" sign="-" unitRef="Pure">26.3</ix:nonFraction></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" contextRef="From2023-01-012023-12-31" id="Fact002107" format="ixt:numdotdecimal" decimals="INF" scale="-2" sign="-" unitRef="Pure">25.9</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_40C_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_iT_pid_dp_uPure_mtEIT001_zLvS1c6f5o88" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Effective income tax rate</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2109">&#8212;</span></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">%</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2110">&#8212;</span></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">%</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AF_znd1p4cCyBn1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company did not recognize an income tax provision for the years ended December 31, 2024 and 2023 due to net operating losses reported
in both years.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact002112" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"><p id="xdx_898_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zVope19dWKwe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred
income taxes are provided for temporary differences between the financial and tax bases of the Company&#8217;s assets and liabilities.
The temporary differences that give rise to net deferred tax assets and liabilities were as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B9_zndQqMtgcaHi">Schedule
of Net Deferred Tax Assets and Liabilities</span>&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="display: none">&#160;</td><td style="display: none; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49F_20241231_zhXUsZI3niV4" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center">2024</td><td style="display: none; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="display: none; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_490_20231231_z7C0J1onSSN7" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center">2023</td><td style="display: none; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Deferred tax assets:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_maDTAGzJbV_zNoECr7RCSAh" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; width: 60%; text-align: left">Net operating losses</td><td style="width: 2%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">$</td><td style="width: 16%; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" contextRef="AsOf2024-12-31" id="Fact002114" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,019,218</ix:nonFraction></td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" contextRef="AsOf2023-12-31" id="Fact002115" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,573,406</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_iI_maDTAGzJbV_za6weCmEW96f" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Stock based compensation</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" contextRef="AsOf2024-12-31" id="Fact002117" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,447,339</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" contextRef="AsOf2023-12-31" id="Fact002118" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,366,391</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_ecustom--DeferredTaxAssetsNotesReceivableReserve_iI_maDTAGzJbV_zP9Xtj47KL35" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Notes receivable reserve</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction name="NRXS:DeferredTaxAssetsNotesReceivableReserve" contextRef="AsOf2024-12-31" id="Fact002120" format="ixt:numdotdecimal" decimals="0" unitRef="USD">266,816</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="NRXS:DeferredTaxAssetsNotesReceivableReserve" contextRef="AsOf2023-12-31" id="Fact002121" format="ixt:numdotdecimal" decimals="0" unitRef="USD">251,893</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsOther_iI_maDTAGzJbV_zsPbpUzTJcX4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Accrued compensation</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsOther" contextRef="AsOf2024-12-31" id="Fact002123" format="ixt:numdotdecimal" decimals="0" unitRef="USD">296,297</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsOther" contextRef="AsOf2023-12-31" id="Fact002124" format="ixt:numdotdecimal" decimals="0" unitRef="USD">57,763</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_ecustom--DeferredTaxAssetsAccountsPayable_iI_maDTAGzJbV_zZVAIHIlDJl8" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Accounts payable</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction name="NRXS:DeferredTaxAssetsAccountsPayable" contextRef="AsOf2024-12-31" id="Fact002126" format="ixt:numdotdecimal" decimals="0" unitRef="USD">143,484</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="NRXS:DeferredTaxAssetsAccountsPayable" contextRef="AsOf2023-12-31" id="Fact002127" format="ixt:numdotdecimal" decimals="0" unitRef="USD">257,391</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_ecustom--DeferredTaxAssetsOperatingLeasePayable_iI_maDTAGzJbV_zIk3RIZ85ade" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Operating lease payable</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction name="NRXS:DeferredTaxAssetsOperatingLeasePayable" contextRef="AsOf2024-12-31" id="Fact002129" format="ixt:numdotdecimal" decimals="0" unitRef="USD">84,105</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="NRXS:DeferredTaxAssetsOperatingLeasePayable" contextRef="AsOf2023-12-31" id="Fact002130" format="ixt:numdotdecimal" decimals="0" unitRef="USD">18,951</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--DeferredTaxAssetsOther_iI_maDTAGzJbV_zwDLA3KP1g6i" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; padding-bottom: 1pt">Other</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOther" contextRef="AsOf2024-12-31" id="Fact002132" format="ixt:numdotdecimal" decimals="0" unitRef="USD">206,468</ix:nonFraction></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOther" contextRef="AsOf2023-12-31" id="Fact002133" format="ixt:numdotdecimal" decimals="0" unitRef="USD">175,904</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--DeferredTaxAssetsGross_iTI_mtDTAGzJbV_maDTANz8qu_zSMHce1zy2w4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0pt; text-align: left">Total gross deferred tax assets</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsGross" contextRef="AsOf2024-12-31" id="Fact002135" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,463,727</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsGross" contextRef="AsOf2023-12-31" id="Fact002136" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,701,699</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_di_msDTANz8qu_zAcJuJYdrqti" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0pt; text-align: left; padding-bottom: 1pt">Valuation allowance</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="AsOf2024-12-31" id="Fact002138" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,225,739</ix:nonFraction></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="AsOf2023-12-31" id="Fact002139" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,629,320</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_406_eus-gaap--DeferredTaxAssetsNet_iTI_mtDTANz8qu_msDTLzJxU_zZCRtEmahuWk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0pt; text-align: left; padding-bottom: 1pt">Total deferred tax assets</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsNet" contextRef="AsOf2024-12-31" id="Fact002141" format="ixt:numdotdecimal" decimals="0" unitRef="USD">237,988</ix:nonFraction></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsNet" contextRef="AsOf2023-12-31" id="Fact002142" format="ixt:numdotdecimal" decimals="0" unitRef="USD">72,379</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0pt; text-align: left">Deferred tax liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_ecustom--DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset_iI_maDITLzRLP_zZrYdGsyoYyj" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Operating lease right of use asset</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">$</td><td style="font-weight: bold; text-align: right"><ix:nonFraction name="NRXS:DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset" contextRef="AsOf2024-12-31" id="Fact002144" format="ixt:numdotdecimal" decimals="0" unitRef="USD">74,991</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="NRXS:DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset" contextRef="AsOf2023-12-31" id="Fact002145" format="ixt:numdotdecimal" decimals="0" unitRef="USD">17,475</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--DeferredTaxLiabilitiesPrepaidExpenses_iI_maDITLzRLP_zpaquPF7s5Bg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Prepaid expenses</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxLiabilitiesPrepaidExpenses" contextRef="AsOf2024-12-31" id="Fact002147" format="ixt:numdotdecimal" decimals="0" unitRef="USD">72,560</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxLiabilitiesPrepaidExpenses" contextRef="AsOf2023-12-31" id="Fact002148" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,337</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_ecustom--DeferredTaxLiabilityAccountsReceivable_iI_maDITLzRLP_zjaKtI9Ap3i3" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Accounts receivable</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction name="NRXS:DeferredTaxLiabilityAccountsReceivable" contextRef="AsOf2024-12-31" id="Fact002150" format="ixt:numdotdecimal" decimals="0" unitRef="USD">64,443</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="NRXS:DeferredTaxLiabilityAccountsReceivable" contextRef="AsOf2023-12-31" id="Fact002151" format="ixt:numdotdecimal" decimals="0" unitRef="USD">18,197</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--DeferredTaxLiabilitiesOther_iI_maDITLzRLP_zlQ4mlye7Uv1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; padding-bottom: 1pt">Other</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxLiabilitiesOther" contextRef="AsOf2024-12-31" id="Fact002153" format="ixt:numdotdecimal" decimals="0" unitRef="USD">25,994</ix:nonFraction></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxLiabilitiesOther" contextRef="AsOf2023-12-31" id="Fact002154" format="ixt:numdotdecimal" decimals="0" unitRef="USD">29,370</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--DeferredIncomeTaxLiabilities_iTI_mtDITLzRLP_maDTLzJxU_zHtpCPEkSRbj" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Total deferred tax liabilities</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:DeferredIncomeTaxLiabilities" contextRef="AsOf2024-12-31" id="Fact002156" format="ixt:numdotdecimal" decimals="0" unitRef="USD">237,988</ix:nonFraction></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:DeferredIncomeTaxLiabilities" contextRef="AsOf2023-12-31" id="Fact002157" format="ixt:numdotdecimal" decimals="0" unitRef="USD">72,379</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--DeferredTaxLiabilities_iTI_mtDTLzJxU_zlE7IC9Wb103" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Deferred tax assets, net</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2159">&#8212;</span></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2160">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AA_zScLxdMbkknb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 125; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Neuraxis,
Inc.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Notes
to Financial Statements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management
assessed the realizability of its deferred tax assets and determined that it is more likely than not that the Company will not recognize
the benefits of the net deferred tax assets due to a history of operating losses. As a result, the Company maintained a full valuation
allowance and does not reflect any deferred taxes in its Balance Sheets as of December 31, 2024 and 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 31, 2024, the Company&#8217;s federal and state net operating loss (NOL) carryforwards totaled $<span id="xdx_901_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_iI_c20241231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--DomesticCountryMember_zAJh4uZZVVpk"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" contextRef="AsOf2024-12-31_us-gaap_DomesticCountryMember" id="Fact002161" format="ixt:numdotdecimal" decimals="0" unitRef="USD">36,202,858</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">and $34</span>,748,524 respectively. These NOL carryforwards
may be offset against future taxable income. There is no limitation on the number of years to utilize the federal NOLs. The federal deduction
will be limited to 80% of modified taxable income. The state NOLs are allowed up to <span id="xdx_90E_eus-gaap--EffectiveIncomeTaxRateReconciliationOtherAdjustments_pid_dp_c20240101__20241231_zRpt4R9WCYJd"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" contextRef="From2024-01-01to2024-12-31" id="Fact002162" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">100</ix:nonFraction></span>%
of taxable income and generally can be carried forward no longer than 20 years after the year of the taxable loss.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Federal
and state tax laws impose limitations on the utilization of NOLs and credit carryforwards in the event of an ownership change for tax
purposes, as defined in Section 382 of the Internal Revenue Code. Accordingly, the Company&#8217;s ability to utilize these carryforwards
may be limited as a result of an ownership change. Such an ownership change could result in a limitation in the use of the NOLs in future
years and possibly a reduction of the net operating losses available.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact002164" name="us-gaap:SummaryOfOperatingLossCarryforwardsTextBlock"><p id="xdx_89B_eus-gaap--SummaryOfOperatingLossCarryforwardsTextBlock_z8KsPtHCLbOb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
not used, the state NOL carryforwards will expire as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8BF_zsQ5DJSkDt42" style="display: none">Schedule of State Carryforwards</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 60%; margin-right: auto">
  <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="display: none; text-align: justify">&#160;</td><td style="display: none">&#160;</td>
    <td style="display: none; text-align: left">&#160;</td><td id="xdx_49B_20241231_zIjmiiM9ZDLj" style="display: none; text-align: right">&#160;</td><td style="display: none; text-align: left">&#160;</td></tr>
<tr id="xdx_40F_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_iI_hus-gaap--TaxPeriodAxis__custom--TaxYear2037Member_zjxftYeYpkz4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 78%; text-align: justify">2037</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" contextRef="AsOf2024-12-31_custom_TaxYear2037Member" id="Fact002166" format="ixt:numdotdecimal" decimals="0" unitRef="USD">72,216</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_iI_hus-gaap--TaxPeriodAxis__custom--TaxYear2038Member_zrilnWyMrWh3" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">2038</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" contextRef="AsOf2024-12-31_custom_TaxYear2038Member" id="Fact002168" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,039,986</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_iI_hus-gaap--TaxPeriodAxis__custom--TaxYear2039Member_zYpBSeKjSPo4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">2039</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" contextRef="AsOf2024-12-31_custom_TaxYear2039Member" id="Fact002170" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,033,565</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_iI_hus-gaap--TaxPeriodAxis__custom--TaxYear2040Member_zzAYhiafCmD1" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">2040</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" contextRef="AsOf2024-12-31_custom_TaxYear2040Member" id="Fact002172" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,457,495</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_iI_hus-gaap--TaxPeriodAxis__custom--TaxYear2041Member_zG5919ryuNS6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">2041</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" contextRef="AsOf2024-12-31_custom_TaxYear2041Member" id="Fact002174" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,406,225</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_iI_hus-gaap--TaxPeriodAxis__custom--TaxYearThereafterMember_zwC79DGKyVgc" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Thereafter</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" contextRef="AsOf2024-12-31_custom_TaxYearThereafterMember" id="Fact002176" format="ixt:numdotdecimal" decimals="0" unitRef="USD">24,671,088</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_iI_hus-gaap--TaxPeriodAxis__custom--NoExpirationMember_zia4lqC4qMhe" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt; text-align: justify">No expiration</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" contextRef="AsOf2024-12-31_custom_NoExpirationMember" id="Fact002178" format="ixt:numdotdecimal" decimals="0" unitRef="USD">67,949</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_iI_z9mLazXw2Q1a" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt; text-align: justify">Total state NOL carryforwards</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" contextRef="AsOf2024-12-31" id="Fact002180" format="ixt:numdotdecimal" decimals="0" unitRef="USD">34,748,524</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AD_zSMz5TaeJgIh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company believes it has made adequate provision for all income tax uncertainties. The assessment is subject to change based on the completion
of audits or statute of limitation expirations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
federal and state income tax returns have a three-year statute of limitations once filed with the appropriate jurisdiction. The Company&#8217;s
income tax returns are subject to examination by the federal and state taxing authorities in the United States for the years ended 2021
through 2024 and 2021 through 2024, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 126; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact002182" name="us-gaap:SubsequentEventsTextBlock"><p id="xdx_806_eus-gaap--SubsequentEventsTextBlock_zYQ16dqfOpui" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>19.
<span id="xdx_824_zlexf9AyuLj3">Subsequent Events</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">On January 3, 2025 and March 6, 2025,
the Company granted <span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_c20250103__20250103__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_znHlIcZjDMU3" title="Restricted stock, granted"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" contextRef="From2025-01-032025-01-03_us-gaap_SubsequentEventMember" id="Fact002184" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">360,902</ix:nonFraction>
</span>and <span id="xdx_909_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_c20250306__20250306__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zrRZ7byrH4Xh" title="Restricted stock, granted"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" contextRef="From2025-03-062025-03-06_us-gaap_SubsequentEventMember" id="Fact002186" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">373,275</ix:nonFraction></span> restricted stock units (&#8220;RSUs&#8221;), respectively, pursuant to the Neuraxis, Inc. 2022 Omnibus Securities and Incentive
Plan as amended on August 15, 2024. The RSUs cliff-vest at the end of a three year period and are payable in shares of the Company&#8217;s
common stock. The RSUs fully vest upon (i) death or disability or (ii) change of control. Dividend equivalents accrue on RSUs and are
paid upon vesting; there were no accrued dividends on unvested RSUs as of the report date.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 17, 2025, the Company issued <span id="xdx_906_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20250117__20250117__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zQ5n3hCkO3Oe" title="Issued common shares"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2025-01-172025-01-17_us-gaap_SubsequentEventMember" id="Fact002188" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">39,471</ix:nonFraction> </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">common
shares to its independent board members for their service from April 1, 2024 through December 31, 2024 and an investor converted
<span id="xdx_904_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_c20250117__20250117__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zkPLlHLmw2dk" title="Investor converted warrant"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" contextRef="From2025-01-172025-01-17_us-gaap_SubsequentEventMember_us-gaap_WarrantMember" id="Fact002190" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">502,647</ix:nonFraction></span> warrants into <span id="xdx_909_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_c20250117__20250117__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zHoyPGV7ySJa" title="Investor converted warrants into common shares"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" contextRef="From2025-01-172025-01-17_us-gaap_SubsequentEventMember_us-gaap_CommonStockMember" id="Fact002192" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">186,166</ix:nonFraction></span> common shares in a cashless exercise transaction.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has evaluated subsequent events through the filing of this Annual Report on Form 10-K and determined that there have been no
other events that have occurred that would require adjustments to our disclosures in the financial statements.</span></p>

</ix:nonNumeric><p id="xdx_819_zC07szAoTLQ6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 127; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="D_001"></span>SIGNATURES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed
on its behalf by the undersigned, thereunto duly authorized.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NEURAXIS,
    INC.</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 50%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 5%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 45%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dated:
    March 20, 2025</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    Brian Carrico</i></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Brian
    Carrico</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Executive Officer</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dated:
    March 20, 2025</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    Timothy R. Henrichs</i></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Timothy
    R. Henrichs</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Financial Officer</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the
registrant and in the capacities and on the dates indicated.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom; width: 30%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Signature</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt; vertical-align: bottom; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom; width: 42%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Title</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt; vertical-align: bottom; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt; vertical-align: bottom; width: 24%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Date</b></span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    Brian Carrico</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Executive Officer and Director</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: top">March 20, 2025</td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Brian
    Carrico</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal
    Executive Officer)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    Timothy R. Henrichs</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Financial Officer (Principal</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: top">March 20, 2025</td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Timothy
    R. Henrichs</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial
    Officer and Principal Accounting Officer)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    Christopher Robin Brown</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: top">March 20, 2025</td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Christopher
    Robin Brown</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    Bradley Mitch Watkins</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: top">March 20, 2025</td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Bradley
    Mitch Watkins</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    Beth Keyser</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: top">March 20, 2025</td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Beth
    Keyser</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    Kristin Ferge</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: top">March 20, 2025</td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Kristin
    Ferge</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    Gilad Aharon</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">March 20, 2025</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Gilad
    Aharon</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span>&#160;</p>


<!-- Field: Page; Sequence: 128; Options: NewSection Last; Value: 92 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->92<!-- Field: /Sequence --></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>
</body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.1
<SEQUENCE>2
<FILENAME>ex4-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
4.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>DESCRIPTION
OF THE REGISTRANT&rsquo;S SECURITIES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>General</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of March 13, 2025, Neuraxis, Inc. (the &ldquo;Company&rdquo;) has one class of securities registered under Section 12 of the Securities
Exchange Act of 1934, as amended (the &ldquo;Exchange Act&rdquo;): common stock, par value $0.001 per share.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following description summarizes the most important terms of our common stock. This summary does not purport to be complete and is qualified
in its entirety by the provisions of our certificate of incorporation a copy of which have been incorporated by reference as an exhibit
to the Annual Report on Form 10-K of which this Exhibit 4.1 is a part. For a complete description of our capital stock, you should refer
to our certificate of incorporation and to the applicable provisions of Delaware General Corporation Law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
certificate of incorporation authorizes us to issue up to 105,000,000 shares of capital stock, consisting of 100,000,000 shares of
common stock, par value $0.001 per share, and 5,000,000 shares of &ldquo;blank check&rdquo; preferred stock, all of which were
designated as Series B Preferred Stock, par value $0.001 per share.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
shares of common stock trade on the NYSE American under the symbol &ldquo;NRXS.&rdquo; The outstanding common stock are fully paid and
nonassessable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
holders of common stock are entitled to one vote per share on each matter submitted to a vote at any meeting of stockholders. Shares
of common stock do not carry cumulative voting rights and, therefore, a majority of the shares of outstanding common stock will be able
to elect the entire board of directors and, if they do so, minority stockholders would not be able to elect any persons to the board
of directors. Our bylaws provide that a majority of our issued and outstanding shares constitutes a quorum for stockholders&rsquo; meetings,
except respecting certain matters for which a greater percentage quorum is required by statute or the bylaws.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
common stockholders have no pre-emptive rights to acquire additional shares of common stock or other securities. The common stock is
not subject to redemption and carries no subscription or conversion rights. In the event of our liquidation, the shares of common stock
are entitled to share equally in corporate assets after satisfaction of all liabilities and after the payment of liquidation preferences,
if any, on any outstanding shares of preferred stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Holders
of common stock are entitled to receive such dividends as the board of directors may, from time to time, declare out of funds legally
available for the payment of dividends. We seek growth and expansion of our business through the reinvestment of profits, if any, and
do not anticipate that we will pay dividends in the foreseeable future.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Dividend
Rights</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subject
to preferences that may apply to any shares of Series B preferred stock outstanding at the time, the holders of our common stock are
entitled to receive dividends out of funds legally available if our Board, in its discretion, determines to declare and pay dividends
and then only at the times and in the amounts that our Board may determine. Series B preferred stockholders are entitled to receive cumulative
dividends at a rate of 8.5% per annum through December 31, 2026.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Voting
Rights</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Holders
of our common stock are entitled to one vote for each share held on all matters properly submitted to a vote of stockholders on which
holders of common stock are entitled to vote. We have not provided for cumulative voting
for the election of directors in our Certificate of Incorporation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>No
Pre-emptive or Similar Rights</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
common stock is not entitled to pre-emptive rights, and is not subject to conversion, redemption or sinking fund provisions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Right
to Receive Liquidation Distributions</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we become subject to a liquidation, dissolution or winding-up, the assets legally available for distribution to our stockholders would
be distributable ratably among the holders of our common stock and any participating preferred stock outstanding at that time, subject
to prior satisfaction of all outstanding debt and liabilities and the preferential rights of and the payment of liquidation preferences,
if any, on any outstanding shares of Series B preferred stock. The Series B preferred stock has the right to be paid before any payments
made to the holders of common stock; that right expires on June 30, 2025.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-19.1
<SEQUENCE>3
<FILENAME>ex19-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
19.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>Neuraxis,
Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>POLICY
ON INSIDER TRADING</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Insider Trading Policy (&ldquo;Policy&rdquo;) sets forth the policies of Neuraxis, Inc. (the &ldquo;Company&rdquo;) on trading and causing
the trading of securities while in possession of confidential information.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Purpose</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Board of Directors of the Company has adopted this Policy to provide guidance to the Company&rsquo;s directors, officers, and employees
about trading in the Company&rsquo;s securities and the securities of any publicly traded companies with whom the Company has a business
relationship.</FONT></P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Policy is designed to (i) promote compliance with applicable securities laws in order to preserve the Company&rsquo;s reputation for
integrity and ethical conduct, (ii) provide guidelines for transactions in the securities of the Company, and (iii) provide guidelines
for the handling of confidential information about the Company and any companies with which the Company does business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Scope</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
policy applies to the following &ldquo;Covered Persons&rdquo;: (i) all directors of the Company; (ii) all officers of the Company and
its subsidiaries; and (iii) all sales management of the Company and its subsidiaries.</FONT></P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sections
1 through 3 and Section 5 apply to the following &ldquo;Associated Person(s)&rdquo;: members of your immediate family and persons sharing
your household; it also covers venture capital funds and other entities (such as partnerships, trusts and corporations) that are affiliated
or associated with such person(s). Affiliated means directly or indirectly controlled or controlled by, or under common control with,
such person(s). Associated means (1) a corporation or organization (other than the Company or a majority-owned subsidiary of the Company)
of which such person(s) is an officer or partner or is directly or indirectly the beneficial owner of 10% or more of any class of equity
securities or (2) any trust in which such person(s) has a substantial beneficial interest or as to which such person serves as trustee
or in a similar capacity.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
 <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>1.</B></FONT></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>The
                                            Basic Policy&mdash;No Trading or Causing Trading While in Possession of Material Non-Public
                                            Information</B></FONT></TD></TR></TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
<B> </B>No person associated with the Company may purchase or sell any security, whether or
not issued by the Company, while in possession of material non-public information concerning the security. (The terms &ldquo;material&rdquo;
and non-public&rdquo; are defined in Section 2 below.)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 1; Options: NewSection -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b) No
person associated with the Company who knows of material non-public information may communicate that information to any other person
if he or she has reason to believe that the information may be improperly used in connection with securities trading.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c) Covered
Persons and Associated Persons must &ldquo;preclear&rdquo; all trading in securities of the Company in accordance with the procedures
set forth in Section 4 below.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d) This
Policy applies to all transactions in the Company&rsquo;s equity securities, including common stock and any other type of securities
that the Company may issue, such as preferred stock, notes, bonds, convertible debentures and warrants, and exchange-traded options (including
puts and calls) and other derivative securities. This Policy applies to sales, purchases, gifts, exchanges, pledges, options, hedges,
puts, calls and short sales.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e) This
Policy does not apply to a surrender of shares to the Company or the retention and withholding from delivery to the applicable officer,
director or employee of shares by the Company (i.e., a so-called &ldquo;net settlement&rdquo;) upon vesting of restricted stock in satisfaction
of any tax withholding obligations in a manner permitted by the applicable equity award agreement or the Company plan pursuant to which
the restricted stock was granted.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
 <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2.</B></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>The
                                            Law Against &ldquo;Insider Trading&rdquo;</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">One
of the principal purposes of the federal securities laws is to prohibit so-called insider trading. In recent years this has become a
major focus of the enforcement program of the Securities and Exchange Commission and of criminal prosecutions brought by United States
Attorneys.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Application
                                            to Non-Insiders and to Securities Other Than Securities of the Company</U></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prohibitions
against &ldquo;insider trading&rdquo; apply to trades, tips, and recommendations by any person&mdash;including all persons associated
with the Company &mdash;if the information involved is &ldquo;material&rdquo; and &ldquo;non-public.&rdquo; Thus, for example, the prohibitions
would apply if you trade on the basis of material non-public information you obtain regarding the Company, its borrowers, customers,
suppliers, or other corporations with which the Company has contractual relationships or may be negotiating transactions. For compliance
purposes, you should never trade, tip, or recommend securities (or otherwise cause the purchase or sale of securities) while in possession
of information that you have reason to believe is material and non-public unless you first consult with, and obtain the advance approval
of, the Company&rsquo;s Chief Compliance Officer (the &ldquo;Compliance Officer&rdquo;). The current Compliance Officer referred to herein
is the Chief Financial Officer of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Materiality</U></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Insider
trading restrictions come into play if the information you possess is &ldquo;material.&rdquo; Materiality, however, involves a low threshold.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Information
is generally regarded as &ldquo;material&rdquo; if it has market significance, that is, if its public dissemination is likely to affect
the market price of securities, or if it otherwise is information that a reasonable investor would want to know before making an investment
decision. Information dealing with the following subjects is reasonably likely to be found material in particular situations:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Significant
    changes in the Company&rsquo;s prospects;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Significant
    write-downs in assets or increases in reserves;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Developments
    regarding significant litigation or government agency investigations;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Liquidity
    problems;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Changes
    in earnings estimates or unusual gains or losses in major operation;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Major
    changes in management;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Changes
    in dividends;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Extraordinary
    borrowings;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Award
    or loss of a significant contract;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Changes
    in debt ratings;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Proposals,
    plans, or agreements, even if preliminary in nature, involving mergers, acquisitions, divestitures, recapitalizations, strategic
    alliances, licensing arrangements, or purchases or sales of substantial assets;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Public
    offerings; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pending
    statistical reports (e.g., consumer price index, money supply and retail figures, or interest rate developments).</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Material
information is not limited to historical facts but may also include projections and forecasts. With respect to a future event, such as
a merger, acquisition, or introduction of a new product, the point at which negotiations or product development are determined to be
material is determined by balancing the probability that the event will occur against the magnitude of the effect the event would have
on a company&rsquo;s operations or stock price should it occur. Thus, information concerning an event that would have a large effect
on stock price, such as a merger, may be material even if the possibility that the event will occur is small. When in doubt about whether
particular non-public information is material, exercise caution. Consult the Compliance Officer before making a decision to disclose
such information (other than to persons who need to know it) or to trade in or recommend securities to which that information relates.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Non-Public
                                            Information</U></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Insider
trading prohibitions come into play when you possess information that is material and &ldquo;non-public.&rdquo; The fact that information
has been disclosed to a few members of the public does not make it public for insider trading purposes. To be &ldquo;public&rdquo; the
information must have been disseminated in a manner designed to reach investors generally. Even after public disclosure of information
regarding the Company, you must wait two full business days for the information to be absorbed by public investors before you can treat
the information as public.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-public
information may include:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Information
    available to a select group of analysts or brokers or institutional investors;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Undisclosed
    facts that are the subject of rumors, even if the rumors are widely circulated; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Information
    that has been entrusted to the Company on a confidential basis until a public announcement of the information has been made and enough
    time has elapsed for the market to respond to a public announcement of the information (two full business days).</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
with questions of materiality, when in doubt about whether information is non-public, call the designated Compliance Officer or assume
that the information is &ldquo;non-public&rdquo; and, therefore, treat it as confidential.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
 <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>3.</B></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Severe
                                            Penalties for Violating Insider Trading Laws</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Penalties
for trading on or communicating material non-public information are severe, both for individuals involved in such unlawful conduct and
their employers and supervisors. A person who violates the insider trading laws can be sentenced to a substantial jail term and required
to pay a penalty of several times the amount of profits gained or losses avoided.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Moreover,
Congress has passed insider trading legislation that, in a significant departure from prior law, explicitly empowers the Securities and
Exchange Commission to seek substantial penalties from any person who, at the time of an insider trading violation, &ldquo;directly or
indirectly controlled the person who committed such violation.&rdquo; Such persons may be held liable for up to the greater of $1 million
or three times the amount of the profit gained or loss avoided. Thus, even for violations that result in a small or no profit, the Securities
and Exchange Commission can seek a minimum of $1 million from the Company and various management and supervisory personnel.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Given
the severity of the potential penalties, compliance with the policies set forth in Section 1 of this Statement is absolutely mandatory,
and noncompliance is a ground for dismissal. Exceptions to these policies, if any, may only be granted by the Compliance Officer and
must be provided before any activity contrary to the above policies takes place.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
 <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>4.</B></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Preclearance
                                            of Securities Transactions</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Because
Covered Persons are likely to obtain material non-public information on a regular basis, the Company requires all such persons to preclear
all purchases and sales of the Company&rsquo;s securities in accordance with the following procedures:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subject
                                            to the exemption in part &ldquo;(d)&rdquo; below, no Covered Person may, directly or indirectly,
                                            purchase or sell any security issued by the Company without first obtaining prior approval
                                            from the Compliance Officer. These procedures also apply to transactions by such person&rsquo;s
                                            spouse, other persons living in such person&rsquo;s household and minor children, and to
                                            transactions by entities over which such person exercises control.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            Compliance Officer shall record the date each request is received and the date and time each
                                            request is approved or disapproved. Unless revoked, a grant of permission will normally remain
                                            valid until the close of trading two business days following the day on which it was granted.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Requests
                                            are most likely to be approved for trading that is to occur in the following &ldquo;window
                                            periods&rdquo;:</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i) Commencing
at the close of trading on the second full business day following the date of public disclosure of the financial results for a particular
fiscal quarter or year and continuing until the eleventh business day of the third month of the next fiscal quarter. For example, if
public disclosure occurs on Monday, May 14th, trading requests would likely be approved from Thursday, May 17th through Thursday, June
14th; or</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii) Following
the wide dissemination of information on the status of the Company and current results.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Preclearance
                                            is not required for purchases and sales of securities under a preexisting written plan, contract,
                                            instruction, or arrangement that is adopted pursuant to Securities and Exchange Commission
                                            Rule 10b5-1(c) (17 C.F.R. &sect; 240.10b5-1(c)) and approved in writing by the Compliance
                                            Officer or such other person as the Board of Directors may designate from time to time (the
                                            &ldquo;Authorizing Officer&rdquo;). Generally, Rule 10b5-1(c) trading plans are developed
                                            in consultation with individual counsel and not the responsibility of the Compliance Officer.
                                            For more information about Rule 10b5-1 trading plans, see Section 5 below.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>5.</B></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Rule
                                            10B5-1 Trading Plans, Section 16 and Rule 144</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 13.5pt; text-indent: -13.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>A.</B></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Rule
                                            10b5-1 Trading Plans</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1) <U>Overview</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Rule
10b5-1 will protect directors, officers and employees from insider trading liability under Rule 10b5-1 for transactions under a previously
established contract, plan or instruction to trade in the Company&rsquo;s stock (a &ldquo;Trading Plan&rdquo;) entered into in good faith
and in accordance with the terms of Rule 10b5-1 and all applicable state laws and will be exempt from the trading restrictions set forth
in this Policy. The initiation of, and any modification to, any such Trading Plan will be deemed to be a transaction in the Company&rsquo;s
securities, and such initiation or modification is subject to all limitations and prohibitions relating to transactions in the Company&rsquo;s
securities. Each such Trading Plan, and any modification thereof, must be submitted to and pre-approved by the Compliance Officer, or
such other Authorizing Officer, who may impose such conditions on the implementation and operation of the Trading Plan as the Authorizing
Officer deems necessary or advisable. However, compliance of the Trading Plan to the terms of Rule 10b5-1 and the execution of transactions
pursuant to the Trading Plan are the sole responsibility of the person initiating the Trading Plan, not the Company or the Authorizing
Officer.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Trading
Plans do not exempt individuals from complying with Section 16 short swing profit rules or liability.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Rule
10b5-1 presents an opportunity for insiders to establish arrangements to sell (or purchase) Company stock without the restrictions of
trading windows and black-out periods, even when there is undisclosed material information. A Trading Plan may also help reduce negative
publicity that may result when key executives sell the Company&rsquo;s stock. Rule 10b5-1 only provides an &ldquo;affirmative defense&rdquo;
in the event there is an insider trading lawsuit. It does not prevent someone from bringing a lawsuit.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
director, officer or employee may enter into a Trading Plan only when he or she is not in possession of material, non-public information,
and only during a trading window period outside of the trading black-out period. Although transactions effected under a Trading Plan
will not require further pre-clearance at the time of the trade, any transaction (including the quantity and price) made pursuant to
a Trading Plan of a Section 16 reporting person must be reported to the Company promptly on the day of each trade to permit the Company&rsquo;s
Securities Counsel to assist in the preparation and filing of a required Form 4. Such reporting may be oral or in writing (including
by e-mail) and should include the identity of the reporting person, the type of transaction, the date of the transaction, the number
of shares involved and the purchase or sale price. However, the ultimate responsibility, and liability, for timely filing remains with
the Section 16 reporting person.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company reserves the right from time to time to suspend, discontinue or otherwise prohibit any transaction in the Company&rsquo;s securities,
even pursuant to a previously approved Trading Plan, if the Authorizing Officer or the Board of Directors, in its discretion, determines
that such suspension, discontinuation or other prohibition is in the best interests of the Company. Any Trading Plan submitted for approval
hereunder should explicitly acknowledge the Company&rsquo;s right to prohibit transactions in the Company&rsquo;s securities. Failure
to discontinue purchases and sales as directed shall constitute a violation of the terms of this Section 5 and result in a loss of the
exemption set forth herein.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"></P>

<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Officers,
directors and employees may adopt Trading Plans with brokers that outline a pre-set plan for trading of the Company&rsquo;s stock, including
the exercise of options. Trades pursuant to a Trading Plan generally may occur at any time. However, the Company requires a cooling-off
period of 30 days between the establishment of a Trading Plan and commencement of any transactions under such plan. An individual may
adopt more than one Trading Plan. Please review the following description of how a Trading Plan works.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to Rule 10b5-1, an individual&rsquo;s purchase or sale of securities will not be &ldquo;on the basis of&rdquo; material, non-public information
if:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">First,
                                            before becoming aware of the information, the individual enters into a binding contract to
                                            purchase or sell the securities, provides instructions to another person to sell the securities
                                            or adopts a written plan for trading the securities (i.e., the Trading Plan).</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Second,
                                            the Trading Plan must either:</FONT></TD></TR></TABLE>

<P STYLE="text-align: justify; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 1in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">specify
                                            the amount of securities to be purchased or sold, the price at which the securities are to
                                            be purchased or sold and the date on which the securities are to be purchased or sold;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">include
                                            a written formula or computer program for determining the amount, price and date of the transactions;
                                            or</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">prohibit
                                            the individual from exercising any subsequent influence over the purchase or sale of the
                                            Company&rsquo;s stock under the Trading Plan in question.</FONT></TD></TR></TABLE>

<P STYLE="text-align: justify; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Third,
                                            the purchase or sale must occur pursuant to the Trading Plan and the individual must not
                                            enter into a corresponding hedging transaction or alter or deviate from the Trading Plan.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Revocation
                                            of and Amendments to Trading Plans</U></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Revocation
of Trading Plans should occur only in unusual circumstances. Effectiveness of any revocation or amendment of a Trading Plan will be subject
to the prior review and approval of the Authorizing Officer. Revocation is effected upon written notice to the broker. Once a Trading
Plan has been revoked, the participant should wait at least 30 days before trading outside of a Trading Plan and 180 days before establishing
a new Trading Plan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
person acting in good faith may amend a prior Trading Plan so long as such amendments are made outside of a quarterly trading black-out
period and at a time when the Trading Plan participant does not possess material, non-public information. Plan amendments must not take
effect for at least 30 days after the plan amendments are made.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
certain circumstances, a Trading Plan <I>must </I>be revoked. This may include circumstances such as the announcement of a merger or
the occurrence of an event that would cause the transaction either to violate the law or to have an adverse effect on the Company. The
Authorizing Officer is authorized to notify the broker in such circumstances, thereby insulating the insider in the event of revocation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Discretionary
                                            Plans</U></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Although
non-discretionary Trading Plans are preferred, discretionary Trading Plans, where the discretion or control over trading is transferred
to a broker, are permitted if pre-approved by the Authorizing Officer.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Authorizing Officer of the Company must pre-approve any Trading Plan, arrangement or trading instructions, etc., involving potential
sales or purchases of the Company&rsquo;s stock or option exercises, including but not limited to, blind trusts, discretionary accounts
with banks or brokers, or limit orders. The actual transactions effected pursuant to a pre-approved Trading Plan will not be subject
to further pre-clearance for transactions in the Company&rsquo;s stock once the Trading Plan or other arrangement has been pre-approved.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Reporting
                                            (if Required)</U></FONT></TD></TR></TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
required, an SEC Form 144 will be filled out and filed by the individual/brokerage firm in accordance with the existing rules regarding
Form 144 filings. A footnote at the bottom of the Form 144 should indicate that the trades &ldquo;are in accordance with a Trading Plan
that complies with Rule 10b5-1 and expires <U>_____</U>.&rdquo; For Section 16 reporting persons, Form 4s should be filed before the
end of the second business day following the date that the broker, dealer or plan administrator informs the individual that a transaction
was executed, provided that the date of such notification is not later than the third business day following the trade date. A similar
footnote should be placed at the bottom of the Form 4 as outlined above.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Options</U></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exercises
of options for cash may be executed at any time. &ldquo;Cashless exercise&rdquo; option exercises through a broker are subject to trading
windows. However, the Company will permit same day sales under Trading Plans. If a broker is required to execute a cashless exercise
in accordance with a Trading Plan, then the Company must have exercise forms attached to the Trading Plan that are signed, undated and
with the number of shares to be exercised left blank.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Once
a broker determines that the time is right to exercise the option and dispose of the shares in accordance with the Trading Plan, the
broker will notify the Company in writing and the Authorizing Officer will fill in the number of shares and the date of exercise on the
previously signed exercise form. The insider should not be involved with this part of the exercise.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 8 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(6)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Trades
                                            Outside of a Trading Plan</U></FONT></TD></TR></TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
an open trading window, trades differing from Trading Plan instructions that are already in place are allowed as long as the Trading
Plan continues to be followed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(7)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Public
                                            Announcements</U></FONT></TD></TR></TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company may make a public announcement that Trading Plans are being implemented in accordance with Rule 10b5-1. It will consider in each
case whether a public announcement of a particular Trading Plan should be made. It may also make public announcements or respond to inquiries
from the media as transactions are made under a Trading Plan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(8)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Prohibited
                                            Transactions</U></FONT></TD></TR></TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
transactions prohibited under <U>Section V</U> of this Policy, including among others short sales and hedging transactions, may not be
carried out through a Trading Plan or other arrangement or trading instruction involving potential sales or purchases of the Company&rsquo;s
securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(9)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Limitation
                                            on Liability</U></FONT></TD></TR></TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">None
of the Company, the Compliance Officer, the Authorizing Officer or the Company&rsquo;s other employees will have any liability for any
delay in reviewing, or refusal of, a Trading Plan submitted pursuant to this <U>Section 5</U> or a request for pre-clearance submitted
pursuant to <U>Section 5</U> of this Policy. Notwithstanding any review of a Trading Plan pursuant to this <U>Section 5</U> or pre-clearance
of a transaction pursuant to <U>Section 5</U> of this Policy, none of the Company, the Compliance Officer, the Authorizing Officer or
the Company&rsquo;s other employees assumes any liability for the legality or consequences of such Trading Plan or transaction to the
person engaging in or adopting such Trading Plan or transaction.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">B.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
                                            16: Insider Reporting Requirements, Short-Swing Profits and Short Sales</B><U>&#9;</U></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)
 <U>Reporting Obligations Under Section 16(a): SEC Forms 3, 4 and 5</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
16(a) of the 1934 Act generally requires all officers, directors and 10% stockholders (&ldquo;insiders&rdquo;), within 10 days after
the insider becomes an officer, director or 10% stockholder, to file with the SEC an &ldquo;Initial Statement of Beneficial Ownership
of Securities&rdquo; on SEC Form 3 listing the amount of the Company&rsquo;s stock, options and warrants which the insider beneficially
owns. Following the initial filing on SEC Form 3, changes in beneficial ownership of the Company&rsquo;s stock, options and warrants
must be reported on SEC Form 4, generally within two business days after the date on which such change occurs, or in certain cases on
Form 5, within 45 days after fiscal year end. A Form 4 must be filed even if, as a result of balancing transactions, there has been no
net change in holdings. In certain situations, purchases or sales of Company stock made within six months prior to the filing of a Form
3 must be reported on Form 4. Similarly, certain purchases or sales of Company stock made within six months after an officer or director
ceases to be an insider must be reported on Form 4.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"></P>

<!-- Field: Page; Sequence: 9 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)
 <U>Recovery of Profits Under Section 16(b)</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the purpose of preventing the unfair use of information which may have been obtained by an insider, any profits realized by any officer,
director or 10% stockholder from any &ldquo;purchase&rdquo; and &ldquo;sale&rdquo; of Company stock during a six-month period, so called
&ldquo;short-swing profits,&rdquo; may be recovered by the Company. When such a purchase and sale occurs, good faith is no defense. The
insider is liable even if compelled to sell for personal reasons, and even if the sale takes place after full disclosure and without
the use of any inside information.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
liability of an insider under Section 16(b) of the 1934 Act is only to the Company itself. The Company, however, cannot waive its right
to short swing profits, and any Company stockholder can bring suit in the name of the Company. Reports of ownership filed with the SEC
on Form 3, Form 4 or Form 5 pursuant to Section 16(a) (discussed above) are readily available to the public, and certain attorneys carefully
monitor these reports for potential Section 16(b) violations. In addition, liabilities under Section 16(b) may require separate disclosure
in the Company&rsquo;s annual report to the SEC on Form 10-K or its proxy statement for its annual meeting of stockholders. No suit may
be brought more than two years after the date the profit was realized. However, if the insider fails to file a report of the transaction
under Section 16(a), as required, the two-year limitation period does not begin to run until after the transactions giving rise to the
profit have been disclosed. Failure to report transactions and late filing of reports require separate disclosure in the Company&rsquo;s
proxy statement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Officers
and directors should consult the attached &ldquo;Short-Swing Profit Rule Section 16(b) Checklist&rdquo; attached hereto as &ldquo;Attachment
A&rdquo; in addition to consulting the Compliance Officer prior to engaging in any transactions involving the Company&rsquo;s securities,
including without limitation, the Company&rsquo;s stock, options or warrants.</FONT></P>

<P STYLE="margin-left: 0pt; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)
 <U>Short Sales Prohibited Under Section 16(c)</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
16(c) of the 1934 Act prohibits insiders absolutely from making short sales of the Company&rsquo;s equity securities. Short sales include
sales of stock which the insider does not own at the time of sale, or sales of stock against which the insider does not deliver the shares
within 20 days after the sale. Under certain circumstances, the purchase or sale of put or call options, or the writing of such options,
can result in a violation of Section 16(c). Insiders violating Section 16(c) face criminal liability.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Compliance Officer should be consulted if you have any questions regarding reporting obligations, short-swing profits or short sales
under Section 16.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&nbsp;</P>


<!-- Field: Page; Sequence: 10 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>C.</B></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Rule
                                            144</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Rule
144 provides a safe harbor exemption to the registration requirements of the Securities Act of 1933, as amended, for certain resales
of &ldquo;restricted securities&rdquo; and &ldquo;control securities.&rdquo; &ldquo;Restricted securities&rdquo; are securities acquired
from an issuer, or an affiliate of an issuer, in a transaction or chain of transactions not involving a public offering. &ldquo;Control
securities&rdquo; are <I>any </I>securities owned by directors, executive officers or other &ldquo;affiliates&rdquo; of the issuer, including
stock purchased in the open market and stock received upon exercise of stock options. Sales of Company restricted and control securities
must comply with the requirements of Rule 144, which are summarized below:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Holding
    Period</I></B>. Restricted securities must be held for at least six months before they may be sold in the market.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Current
    Public Information. </I></B>The Company must have filed all SEC-required reports during the last 12 months or such shorter period
    that the Company was required to file such reports.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Volume
    Limitations. </I></B>For affiliates, total sales of Company common stock for any three-month period may not exceed the <I>greater
    </I>of: (i) 1% of the total number of outstanding shares of Company common stock, as reflected in the most recent report or statement
    published by the Company, or (ii) the average weekly reported volume of such shares traded during the four calendar weeks preceding
    the filing of the requisite Form 144.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Method
    of Sale. </I></B>For affiliates, the shares must be sold either in a &ldquo;broker&rsquo;s transaction&rdquo; or in a transaction
    directly with a &ldquo;market maker.&rdquo; A &ldquo;broker&rsquo;s transaction&rdquo; is one in which the broker does no more than
    execute the sale order and receive the usual and customary commission. Neither the broker nor the selling person can solicit or arrange
    for the sale order. In addition, the selling person or Board member must not pay any fee or commission other than to the broker.
    A &ldquo;market maker&rdquo; includes a specialist permitted to act as a dealer, a dealer acting in the position of a block positioner,
    and a dealer who holds himself out as being willing to buy and sell Company common stock for his own account on a regular and continuous
    basis.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Notice
    of Proposed Sale. </I></B>For affiliates, a notice of the sale (a Form 144) may be required to be filed with the SEC at the time
    of the sale. Brokers generally have internal procedures for executing sales under Rule 144 and will assist you in completing the
    Form 144 and in complying with the other requirements of Rule 144.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
you are subject to Rule 144, you must instruct your broker who handles trades in Company securities to follow the brokerage firm&rsquo;s
Rule 144 compliance procedures in connection with all trades.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>6.</B></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Prohibited
                                            Activities</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a) Prohibitions<B>.
</B>Except for limited exceptions described below, the following activities are prohibited under this Policy:</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i) No
Covered Person may purchase, sell, transfer or effectuate any other transaction in Company securities while in possession of material
nonpublic information concerning the Company or its securities. This prohibition includes sales of shares received upon exercise of stock
options or upon vesting of Restricted Stock Units and Awards.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 11 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)
 No Covered Person may &ldquo;tip&rdquo; or disclose material nonpublic information concerning
the Company or its securities to any outside person (including family members, affiliates, analysts, investors, members of the investment
community and news media). Should a Covered Person inadvertently disclose such information to an outsider, the Covered Person must promptly
inform the Compliance Officer regarding this disclosure. The Company will take steps necessary to preserve the confidentiality of the
information, including requiring the outsider to agree in writing to comply with the terms of this Policy and/or sign a confidentiality
agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)
 No Covered Person may purchase Company securities on margin, hold Company securities in a margin
account, or otherwise pledge Company securities as collateral for a loan because, in the event of a margin call or default on the loan,
the broker or lender could sell the shares at a time when the Covered Person is in possession of material nonpublic information, resulting
in liability for insider trading. In addition, pledging of securities by Covered Persons, including margin arrangements, can be perceived
to undermine the alignment of their interests and incentives with the long-term interests of other stockholders.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iv) Short-term
and speculative trading in Company securities, as well as hedging and other derivative transactions involving Company securities, can
create the appearance of impropriety and may become the subject of an SEC investigation, particularly if the trading occurs before a
major Company announcement or is followed by unusual activity or price changes in the Company&rsquo;s stock. These types of transactions
can also result in inadvertent violations of insider trading laws and/or liability for short-swing profits under Section 16(b) of the
Securities Exchange Act of 1934.<SUP>1</SUP> Therefore, it is the Company&rsquo;s policy to prohibit the following activities, even if
you are not in possession of material nonpublic information:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No
    Covered Person may trade in any interest or position relating to the future price of Company securities, such as put or call options
    or other derivatives, or short sale of Company securities.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No
    Covered Person may hedge Company securities. A &ldquo;hedge&rdquo; is a transaction designed to offset or reduce the risk of a decline
    in the market value of an equity security, and can include, but is not limited to, prepaid variable forward contracts, equity swaps,
    collars, and exchange funds.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Covered
    Persons may not trade in securities of the Company on an active basis, including short term speculation.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(v)
 No Covered Person may trade in securities of another company if the Covered Person is in possession
of material nonpublic information about that other company which the Covered Person learned in the course of their work for the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 12 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(vi) &ldquo;Quiet&rdquo;
Periods. The Company&rsquo;s announcement of its quarterly financial results has the potential to have a material effect on the market
for the Company&rsquo;s securities. Therefore, to avoid even the appearance of trading on the basis of material non-public information,
Covered Persons who are subject to the pre-clearance procedure set forth above may not, except as expressly permitted under this Policy,
carry out any transaction in the Company&rsquo;s securities during the period beginning on the 15th day of the last month of each quarter
(March, June, September, December) and ending on the third business day following the release of the Company&rsquo;s earnings for that
quarter.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(vii) Event-Specific
Quiet Periods. The Company reserves the right to close any open window period at any time if the Compliance Officer, or his or her designee,
determines, in his or her sole discretion, that there may be material non-public information with respect to the Company. If the Company
closes an open window, it will not pre- clear any transaction that is not expressly permitted by this Policy during the period that such
open window is closed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company may on occasion issue interim earnings guidance or other potentially material information by means of a press release, Current
Report on Form 8-K, or other means designed to achieve widespread dissemination of the information. Covered Persons should anticipate
that trading will be prohibited while the Company is in the process of assembling the information to be released and until the information
has been released and absorbed by the market.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">From
time to time, an event may occur that is material to the Company and is known by only a few directors, executives, or other employees.
So long as the event remains material and non-public, the persons who are aware of the event, as well as all Designated Persons, may
not trade in the Company&rsquo;s securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
existence of an event-specific quiet period will not be announced, other than to those who are aware of the event giving rise to the
quiet period. If, however, a person whose trades are subject to the pre-clearance requirements set forth above desires to effect a transaction
during an event-specific quiet period, the Compliance Officer may refuse to grant permission to carry out the transaction and will have
no obligation to disclose to the person the reason for the refusal or the reason for the event-specific quiet period. Any person who
becomes aware of the existence of an event-specific quiet period shall not disclose the existence of the quiet period to any other person.
The failure of the Compliance Officer to inform a person that they are subject to an event-specific quiet period will not relieve that
person of the obligation not to trade while aware of material non- public information.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b) Exceptions
to Prohibited Activities. Prohibitions in trading securities under this Policy do not include:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i) The
exercise of vested employee stock options where no Company stock is sold to fund the option exercise.<SUP>1</SUP></FONT></P>

<P STYLE="text-indent: 0.5in; text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii) The
receipt of Company stock upon vesting of Restricted Stock Units and Awards, as well as the withholding of Company stock by the Company
in payment of tax obligations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><SUP>1
</SUP>While vested employee stock options may be exercised at any time under this Policy, the sale of any stock acquired through such
exercise is subject to this Policy.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 13 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii) Company
securities purchased or sold under a Company authorized Rule 10b5-1 Trading Plan (see Section 4(d) above).</FONT></P>

<P STYLE="text-indent: 0.5in; text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iv) Transfers
of Company stock by a Covered Person into a trust for which the Covered Person is a trustee, or from the trust back into the name of
the Covered Person.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
 <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>7.</B></FONT></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Blackout
                                            Periods Applicable to Covered Persons</B></FONT></TD></TR></TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a) No
Trading During Blackout Periods. No Covered Person may trade or effectuate any other transactions in Company securities during regular
blackout periods or during any special blackout periods designated by the Compliance Officer (except for the limited exceptions described
in Section 5(b) above). Remember that even during an open trading window, you may not trade in Company securities if you are in possession
of material nonpublic information concerning the Company or its securities.</FONT></P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b) Regular
Blackout Periods Defined. Subject to obtaining trading pre-approval from the Compliance Officer, Covered Persons may not trade in Company
securities during the period beginning on the 15<SUP>th</SUP> day of the last month of each quarter (March, June, September, December)
and ending on the third business day following the release of the Company&rsquo;s earnings for that quarter. To provide clarity, the
Compliance Officer will notify Covered Persons, in advance of each quarter end, of the date on which the blackout period begins and ends.
Trades made pursuant to an approved 10b5-1 Trading Plan (see Section 4(d) above) are exempted from this restriction.</FONT></P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c) Special
Blackout Periods. From time to time, the Compliance Officer may determine that trading in Company securities is inappropriate during
an otherwise open trading window due to the existence of material nonpublic information. Accordingly, the Compliance Officer may prohibit
trading at any time by announcing a special blackout period. The Compliance Officer will provide notice of any modification of the trading
blackout policy or any additional prohibition on trading during the period when trading is otherwise permitted under this Policy. The
existence of a special blackout period should be considered confidential information and Covered Persons are prohibited from communicating
the existence of a special blackout period to anyone who is not a Covered Person.</FONT></P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d) Hardship
Trading Exceptions. The Compliance Officer may, on a case-by-case basis, authorize trading in Company securities during a trading blackout
period due to financial or other hardship. Any person wanting to rely on this exception must first notify the Compliance Officer in writing
of the circumstance of the hardship and the amount and nature of the proposed trade. Such person will also be required to certify to
the Compliance Officer in writing no earlier than two business days prior to the proposed trade that he or she is not in possession of
material nonpublic information concerning the Company or its securities. Upon authorization from the Compliance Officer, the person may
trade, although such person will be responsible for ensuring that any such trade complies in all other respects with this Policy.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 14 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
 <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>8.</B></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Inquiries</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
you have any questions regarding any of the provisions of this Policy, please contact the Compliance Officer at spope@emulatetx.com.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
 <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>9.</B></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Acknowledgment
                                            and Certification</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
undersigned does hereby acknowledge receipt of the Company&rsquo;s Policy On Insider Trading regarding trading on material non-public
information. The undersigned has read and understands (or has had explained to them by someone who understands) such Policy and agrees
to be governed by such Policy at all times in connection with the purchase and sale of securities and the confidentiality of non-public
information. The undersigned understands that if the undersigned is a Covered Person, the entire policy applies to them. The undersigned
understands that if the undersigned is not a Covered Person, Sections 1 through 3 and Section 5 applies to them.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Signature)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Please
    print name)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title/Relationship
    to the Company</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
    </FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 44%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 49%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 15 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>ATTACHMENT
A</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>SHORT-SWING
PROFIT RULE SECTION 16(B) CHECKLIST</U></FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Note:
ANY combination of PURCHASE AND SALE or SALE AND PURCHASE within six months of each other by an officer, director or 10% stockholder
(or any family member living in the same household or certain affiliated entities) results in a violation of Section 16(b), and the &ldquo;profit&rdquo;
must be recovered by Neuraxis, Inc. (the &ldquo;<B><I>Company</I></B>&rdquo;). It makes no difference how long the shares being sold
have been held or, for officers and directors, that you were an insider for only one of the two matching transactions. The highest priced
sale will be matched with the lowest priced purchase within the six-month period.</FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Sales</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
a sale is to be made by an officer, director or 10% stockholder (or any family member living in the same household or certain affiliated
entities):</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Have
    there been any purchases by the insider (or family members living in the same household or certain affiliated entities) within the
    past six months?</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Have
    there been any option grants or exercises not exempt under Rule 16b-3 within the past six months?</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Are
    any purchases (or non-exempt option exercises) anticipated or required within the next six months?</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Has
    a Form 4 been prepared?</FONT></TD></TR>
  </TABLE>
<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Note:
If a sale is to be made by an affiliate of the Company, has a Form 144 been prepared and has the broker been reminded to sell pursuant
to Rule 144?</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Purchases
and Option Exercises</B></FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
a purchase or option exercise for Company stock is to be made:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Have
    there been any sales by the insider (or family members living in the same household or certain affiliated entities) within the past
    six months?</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Are
    any sales anticipated or required within the next six months (such as tax- related or year-end transactions)?</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Has
    a Form 4 been prepared?</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Before
proceeding with a purchase or sale, consider whether you are aware of material, non-public information which could affect the price of
the Company stock. All transactions in the Company&rsquo;s securities by officers and directors must be <U>pre-cleared </U>by contacting
the Company&rsquo;s Compliance Officer.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 16; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>4
<FILENAME>ex23-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
23.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CONSENT
OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have issued our report dated March 20, 2025, with respect to the financial statements included in the Annual Report of Neuraxis, Inc.
on Form 10-K for the year ended December 31, 2024. We consent to the incorporation by reference of said report in the Registration Statements
of Neuraxis, Inc. on Forms S-3 (File No. 333-283798).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
Rosenberg Rich Baker Berman, P.A.</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Somerset,
New Jersey</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">March
20, 2025</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>5
<FILENAME>ex31-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
31.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CERTIFICATION
OF PRINCIPAL EXECUTIVE OFFICER<BR>
PURSUANT TO SECTION 302<BR>
OF THE SARBANES-OXLEY ACT OF 2002</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I,
Brian Carrico, certify that:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I
    have reviewed this annual report on Form 10-K of Neuraxis, Inc. (the &ldquo;registrant&rdquo;);</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
    on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary
    to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to
    the period covered by this report;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
    on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material
    respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in
    this report;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    registrant&rsquo;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures
    (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange
    Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Designed
    such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision,
    to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others
    within those entities, particularly during the period in which this report is being prepared;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Designed
    such internal controls over financial reporting, or caused such internal control over financial reporting to be designed under our
    supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements
    for external purposes in accordance with generally accepted accounting principles;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Evaluated
    the effectiveness of the registrant&rsquo;s disclosure controls and procedures and presented in this report our conclusions about
    the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation;
    and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Disclosed
    in this report any change in the registrant&rsquo;s internal control over financial reporting that occurred during the registrant&rsquo;s
    most recent fiscal quarter (the registrant&rsquo;s fourth fiscal quarter in the case of an annual report) that has materially affected,
    or is reasonably likely to materially affect, the registrant&rsquo;s internal control over financial reporting; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    registrant&rsquo;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial
    reporting, to the registrant&rsquo;s auditors and the audit committee of the registrant&rsquo;s board of directors (or persons performing
    the equivalent functions):</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
    significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are
    reasonably likely to adversely affect the registrant&rsquo;s ability to record, process, summarize and report financial information;
    and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
    fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&rsquo;s
    internal control over financial reporting.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
    March 20, 2025</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 3%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 47%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Brian Carrico</I></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Brian
    Carrico</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Executive Officer</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>(Principal
    Executive Officer)</I></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>6
<FILENAME>ex31-2.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
31.2</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CERTIFICATION
OF PRINCIPAL EXECUTIVE OFFICER</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>PURSUANT
TO SECTION 302</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>OF
THE SARBANES-OXLEY ACT OF 2002</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I,
Timothy R. Henrichs, certify that:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I
    have reviewed this annual report on Form 10-K of Neuraxis, Inc. (the &ldquo;registrant&rdquo;);</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
    on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary
    to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to
    the period covered by this report;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
    on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material
    respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in
    this report;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    registrant&rsquo;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures
    (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange
    Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Designed
    such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision,
    to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others
    within those entities, particularly during the period in which this report is being prepared;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Designed
    such internal controls over financial reporting, or caused such internal control over financial reporting to be designed under our
    supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements
    for external purposes in accordance with generally accepted accounting principles;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Evaluated
    the effectiveness of the registrant&rsquo;s disclosure controls and procedures and presented in this report our conclusions about
    the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation;
    and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Disclosed
    in this report any change in the registrant&rsquo;s internal control over financial reporting that occurred during the registrant&rsquo;s
    most recent fiscal quarter (the registrant&rsquo;s fourth fiscal quarter in the case of an annual report) that has materially affected,
    or is reasonably likely to materially affect, the registrant&rsquo;s internal control over financial reporting; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    registrant&rsquo;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial
    reporting, to the registrant&rsquo;s auditors and the audit committee of the registrant&rsquo;s board of directors (or persons performing
    the equivalent functions):</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
    significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are
    reasonably likely to adversely affect the registrant&rsquo;s ability to record, process, summarize and report financial information;
    and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
    fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&rsquo;s
    internal control over financial reporting.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
    March 20, 2025</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 3%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 47%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Timothy R. Henrichs</I></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Timothy
    R. Henrichs</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Financial Officer (Principal Financial Officer)</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT>&nbsp;</P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>7
<FILENAME>ex32-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
32.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CERTIFICATION
PURSUANT TO</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SECTION
906 OF THE SARBANES-OXLEY ACT OF 2002</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with the Annual Report on Form 10-K of Neuraxis, Inc. (the &ldquo;Company&rdquo;) for the year ended December 31, 2024, as
filed with the Securities and Exchange Commission on the date hereof (the &ldquo;Report&rdquo;), I, Brian Carrico, Chief Executive Officer
of the Company and I, Timothy R. Henrichs, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted
pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of
    the Company.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 52%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dated:
    March 20, 2025</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 46%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Brian Carrico</I></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Brian
    Carrico</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Executive Officer (Principal Executive Officer)</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dated:
    March 20, 2025</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Timothy R. Henrichs</I></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Timothy
    R. Henrichs</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Financial Officer (Principal Accounting and Financial Officer)</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>The
foregoing certification is being furnished solely to accompany the Report pursuant to 18 U.S.C. &sect; 1350,and is not being filed for
purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and is not to be incorporated by reference into any filing
of the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing. A signed
original of this written statement required by Section 906, or other document authenticating, acknowledging, or otherwise adopting the
signature that appears in typed form within the electronic version of this written statement has been provided to the Company and will
be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>form10-k_001.jpg
<TEXT>
begin 644 form10-k_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" #X G<# 2(  A$! Q$!_\0
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M\G]S<<D\C@'.<$<=\<4KQ&U5[AS]E:TM9;EKN[N2MA9V-N#]KN)QT!*AF8=
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M#YOM5YIL]EJEI@0?V$+"_P!-GCA),K2N0:,/P.WBJN&_UK@E2J.G\2Z->?\
M>T=V3+.E2H4ZW]E/WX1GL[KF7R_X9G](GV*[R L$Y'3]V.">X'O4L,.H(3%#
M;RS7"M]K@M2"&62"%S)?RCO':6_F. >P(^O\M7P@_:(_;>LO@!^U=INAR?&+
MQAXVTK1?"-U%\08OMT]KX?TJZUF3^WKWPOI.LZ;INIV?CJVM5D6^LM#O]4EC
MM\<MWZ+P?\;?VG;GX:?#<_$+XL_&?3OV<-5^-6I:/XH^+/@SP[KUQ\2=+T.[
M\*OG1XQJ&@07C:1/JS&"ZDD$NUWN=MQ* ".N?AZZLY37%47[!N*:E'3E^?\
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M+:VBEU"R$6R RKC:!,8U"R@KQ^\#<#!!SD?%%[_P5Z_X)QSV$L7_  TGX>)
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MO450DNM,C67[':6L2S2F26-+:!$ED!R'E5(U$K X(:0,RDYR"37BOQ(_:-^
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MA-VWCBOE;XJ?MQ_L=?!J>XL_B%^T%\-M,O[(E9K*PU>;7=6CE"L3&19;K=2
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M$$"0@10VMM!$Q#M"(;=59P/E=$$8564G(8*&'8U^4Y_X+9_\$VXIXW/QRNP
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MBIOEOK'EMSO6ZMHTW^'XO^V\9B8RO4]_6RE-VV;VEW=MM=>B/+/LUM_SZV^
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M2&>S,\(GMKV%VB%L^.2T<21JP;DON.,DUU?@WP#XX^(=KXRO? OA;5/%=O\
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M'!'<<'BOZG/^#;(J-$_:CC"J,2:5)PH&6"!0_  W*, 'JO8@5_+8GW)/HO\
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M;3IPIT7#F;<:?V^5\2X#"X2\[.4%:-XQDU>ZERMIM.]W9;N3OT;_ %1_9K\
M>&/ F@?!?Q'X<GUW^V?B-_P2>_:2U_Q3+?ZG?7ECJFNQZSJ%M:)81W%Q)'HV
MD01XENK>R6"W+,[LC,S&MS]E+P]^RS^QU^V5^P#^S!9?LW6'CKXK_$'X+:)\
M7-8_:7?Q%?\ _"2Z3XY^('A?4M1TR3P39VP&G7'A;PY;2S6&H(5:W5PC3!F0
MFOQAT#_@H+\?_"^G>!-)M9O#'V#X>? ;QA^S=H<?]GQ?-\,/&TDUQX@2[ C
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M_$SX37%DVN7OA7Q%X#URQUVREU'PQKOACQA:7":K%J]O//(;P70N99DADB=
M9"RH#7M9]PKQ#F53*<3A,QP_[GV4()0CSJLO=KR<N5.'-"*I)1;YHN3G>T8/
MFRO/,GRS#5,/5:G*I*4I.5I)7;:LY*3TDT[7:5].K7]#WQ1\8?LN_$#XA?\
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M\9S6^F6^DZAK]O+>1VUMIRSBXG28!%A525 53YMX\\.?LA_ G_@L/JME\6?
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MF:J^^TTEKB)D@>%5N3O9&;XR_P""=G[']Y>_M$:IKG[67P5\96'PZ^!_P/\
MB#\>K3X?>,M'OM'M?B7K?@:Q:\TK0I2\ :\L?M:"ZNX2D@EM3M(,>*]3"<>T
M9Y/C\3",?KC<Z<(*4:E^5PY7&R33ESI.ZBUK>T;2.7$9 YU/81;?(E*Z;UYK
M_P"%O;716[::_E,'0FW$)$27*-):2W$&H6L-_&GWS"UW ()G4<J8I\$_<#'
MH<PME3YD0ZE6!",P^Z0YR I.< $!O?O^L<__  52'Q<\/?%;P/\ M1?LV?![
MQY\$OB)X5U+3_AEX:^%?@33?"'BKX*^(D=Y?#>H>'O$NDV$%Y<+I@%K]N@G
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MDYMQ=10RS*KH-[F:X4F*$9 3<<#<P7.XBGJWS8,9CC7IOX,[%?W>TD9RSE2
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M(I(Y0CE22=IP/7CIU[CBO[Q_^"$CBV_X)P_#F15,KCQGXW=X_O,=MWG SGG
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MBL')/]Y/_K5^+-?M%_P0*DD3_@H+9[%Y_P"%5>*N0,'JO>OF/$3_ )(_-O\
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M8*I1J8S%5>>%?#0JN*@KR4M''SL+',S2[M^V=IK@M\Q,AV%S)G.2=B,Q()R
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M!\3"%*O*%'$8?$4%"BZ57#4JU&#4J-.512C6?-*<:KG&4DW%M:::*9I%*D
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MCZR_;@\8_LV>/OVG?B!XF_9*\)ZCX'^!=XMF?#VA:E";8V[1Q*MU'86Y=S#
M[AB%9V*KP6SR?CC4]DNGZB$/ER+:+<Q7 X96W,/LH)X"S* K+WR<8YSHR.TF
M Y+;0R@$] QY''&">O'/-0O%&XGB:,-&PC<H>A:,!D;KU0\CMGG!-8T,#1P>
M7QPDJU2<HPC!3JU95*DE&*BI2JS;E.;44Y2D^:4G*3]Z3,Y8F,\:L7RQ4+J7
M+&,5%+?2*T2ULEK965[)'[]_MA:Q^PSX<\,?L-WW[3?PJ^-'CGQQI/[*O@;6
M]/7P'XKLM T>73+:Z$^G6=V9'.I+<-??+.+=580$$<"M>#]N#6O&'[/G[=W[
M;'AWX/\ PWM_'NB^*O@A\)?A/9^--#M/'O\ PJWP%IE@VC1W5S>W<<MN=5&G
MPJ1*V95G,AD^8FOP9\;_ !9\8_$)O#D?Q"\77WB2Y\'Z$GA;PK!?BR9M-\/Q
M*5M]/M;U@?)M;7.$1G.Q\L",4^P\>^,M(\$Z]\-],\5W]GX$\7ZAIFM>(/"D
M38L=4U#1_FL[B\@BVPWLJ,7>&60/N+EAN!KYZGPO1JMO"U'4DW)W3DM7/GMI
M).R:BGJT^6S3B[/Z6.;5</&+E#F6EKI-*+W24DUK';=7W/Z)9_&/CWX=_%_]
MA?X&_!K]GWP%X\^!/[3/PY\'>)OC7JUU\*['Q&GQ)UWQ\TUQX]FN?%<<+0^#
MM.\+03SW6ELTT0LRD0&1& <[QKX[^(_[)O[&VCZ-^R;\+=%^)'@V+]OCXK>#
MM.UO6O!B?$^WT?09KIH;'PC;+!'<36LLC0MI$NHK$J,SR-O!9:_$KP-^V1^U
M-\+_ (>R_"WP'\;O&7AWP$\%[:6F@6WD3-I>GZC)+-<:?IFJRI)=Z3;,TT@,
M%O/$D08HH" **/PK_;$_:D^".C1>'/A3\8/$O@_0+:_U#6#H%N]I?6CZWK#F
M6[\206UPL\3:S-*WVB2]8&?S07# FN3%</XI62J35I*]Y5%:U[\MII773F5O
MB33]WEZHYS1=O<@M'?1+F;;?O+E=GK:VFRU1^]GQA_9S_9_?4/VFO#>I>"O"
MWA;0O$7QQ_8Y3XA1VFFBV7P!J_CN&SUSQKX?T_4T;_B4V,VH3MINHVB8^SQ'
MR;C#(:RM4U+Q5\6_C;^W=^R_\;/V=?A]X$_9@^!7PJ\:^)?AEK]G\/[3P[/\
M.;CP;:0R_#;6=/\ B+%#$-3M_%%Q;PO&D,LYUDRERH,K"OYWM1^,'Q8U?1_&
MGA[4O'WB"_TOXC>(+?Q7X_M]3U6\DN/&'B>TE\ZVU_4RTK2/J%O,!-:LLJ"V
M.%10!7I?C3]L']J;XD_#^W^$_CGXW>,/$'@$:?;:-J&BW,D$;ZQHVED?V3HV
MN7R+#=ZO:6)C3R!=S2 %=PX %<_]A8JRM6J+2S2G.W2^G-MOTO>VNZ:_M?#Z
M^[3?FX1OYM>[O=/>UT_-\O[]>+/%/BKXS6_P:L_B7X+\,^(?"5C_ ,$KO%?Q
M%T+6)/ Z6BQ^++#3Q:6ZV5X$40W5O;(MW%:HP9#&K,FX5X7XSUCXM?!>Z_93
M_9K_ &6OV9? 'Q9^$/Q6_9A\/^)O$<FL?#^UOXOBOXE\3>'KC4?%/B'4O'LL
M;'PYJOAV<$0/-<126SQHK(2*_&6W_:K_ &D;?P=H/P_/Q:\6OX.\,^'M7\':
M+H8>**'1?"6KJT-_X;L[LDS/I=W$[)+"TSQLI.PJ,8G\)_M??M1>"OA;-\'/
M#?QJ\::1\.+BROM*M=%M9(KF?3]/U(R-J>D:9J3$WVDV-V9'$D%O<QJJN578
MN!6>&R/'1D[*44G*R5U=-MI[]_ON]0>;T:_NQC36G*FHV6UD[I+5?IL?T/?#
M?0])\7?#CP!^S1X%^'_A?X#_ !)U'X-^+;G5/@?\6/@W:^+_ (8_%S4-/L=0
MFM_%N@?''3HGU"PU&R4R,MW/*D+2VD6XX6OY8KZQETW4M:TN=52^TG6-1TZ_
MBCG:ZM8+JSNYK>XBLKI_FGM4EC86TK#+P[2>:^A-$_;._:H\+?#<?"#1/C=X
MOTOX?'2;[1++3+VXBO=5T[3=6,IUC1],ULK)J6G:3J!N)U\J.^C1O.94V@XK
MYO+K!O6;[3]F#X#7+*]\LV<XF9"1)N;+%MSY!#;V))KULJPE; 592QCE"',[
M2;L[<S=U=[6MOJ<N8XB.(II123Y4M/1;NW?I=[ZL9(\0=@!D ]3D$].3@=>N
M>?3TJ-Y&4%D)7Z'L ?IQQ_A2JZW$N65%^9K6X\MO,DC*#(N5CX >0$ XXSD
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M@JH'4E< '!P!WSR^X\:75[;O#::9I<,$EQ%<7;" *US/$Q9'DQC<2_S YP2
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M7(X__5G'%:WA_P -:SXCN9K71[>*>>"&6XF2=@(UB"[E8$X^8#)&<_@*Y\2
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MQRDM?A]X<\,?MN?LPZYXAT[6-1T]K&*+PKX\_P"$EM2NAQZ;X.LFB/B6&*2
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MVK=DG8F (&#U[_YQZ>U?MG_P;^?\I"K$=F^$_BW(]<,!_+BOQ')N"Q*J&7.
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M+BW=W]I4ZWU]I;[['T/ <:?^LN"<9>T4G*\F[N4F[R;;U>JWO<_JPG.QIBH
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MJ9S[O\>-"_::\"_MM_M'_%WX+>#_  =\>_#GBG]D+X6:U\>/V(?B)FZ\:?\
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M^&?Q%&L?Z%>^*O OA'5FCNVUGP,@X)1[E%D=(Y,,V>P_X)\_"+]FOPI^T/\
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MMH^9='\)VKRLZRVEY*L>HZA<*$N[B\GN%FGD3Y:^4B%!(550 D>6C;UB(ZQ
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M3W[FK4<2&-F8@$R2]21D!CS[]0/PZUU7@_1M9UJ^O+/1;>SGEALY)IOM*Q,
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M&C5RG"59Y/E>;5YN56KDN9X'&8FK0PE2:PTZ<H\J:=CAHM>UK3[#[-I^NWT
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M$? *@KRI /.";TEZ=%^'-O;WU@L&NWI-K:3"7,W]AS3_ &I;9L,0NY2OSC#
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MY4?=]!3K.RGU>]6P2Y%I!-$TS7DMO*D+.FYVB1R &WX W@Y.00< 8\_#>'O
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MM3ITN:S/=[&?5-,D\"6GAO3R]KJ&LWDFL206T5Y''/!?/%'--<2 M!%Y9V[
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MG\["_P"M'_;7_P!"%1S?ZW_@/^%2+_K1_P!M?_0A4<W^M_X#_A7]PTOX<?\
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MDO=WOOUZ?YG60R.0588R0/ISG- 4,N\_>_3G';\33'Y8*>@_/C/^>E*S%(V
MQP._MC_"O/E)R3;;;O:[?E'_ #-()-:I/7_(B\QA*%&,9]/J*;*[!NQ_#OP2
M>O?-'_+,3?QA\>V.>WX^M0LQ8Y./\_\ ZJX%4G>7ORW77R-8I*5K+>UO/7_@
M!O)ZXP?0=OQ)Y_SQ33@9/8?Y_EZ4UCA6(Z@9'UX_IFHI9%6/=))'%'_RTDDS
ML10P!+$9(!'&0#@D'%2XU*TK<[24;N5]DFWY?GT/5P]*"Y:CDDK\OLK7YV[6
M=M6W=I+?\ALTA\BX)P7,3"(8&#)CY05 P<GC'?ZU_I._\$D_AG=?";_@G?\
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M>@-Y8C/?J9^..:YJG$O#4G[N:TTK:_O(ZO[^UBEDV<05I9=*[U7N2M^1^7[
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M_P" 1_\ D26.6[8$B5NN.7<GH/\ ;J=)+L#_ (^=G/0N_/3G[_X?A114\O\
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M:$!6V.\3LWF22QE5EF8=/.?:3(/K^=30(D<)BC79%G>8\LX,G.9"TA=PQ/.
MP7/0445G3@JL7[6]2S5N>4I6TOI>7<MV?1?<E^20Y>H^H_G4QX!/H#1173?2
>,?LQ5HKLNW_#W"UOZ_X+'1C>,G]/J?KZ4444 ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>form10-k_020.jpg
<TEXT>
begin 644 form10-k_020.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" &L [8# 2(  A$! Q$!_\0
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M)^"?A]=)XY\?>/?&7AN9(;"YC5=-U35);:U-W=%1';6WE2\S3ND4:[F+!<T
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M#&#]LP(T/) /VH^U6^$/F* X++N.TL%ZX#8)QG&!T/7&#43ZC91E_-N88EC
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@#'U%8D$UQ<LT=NL,>]VE9(LI(6 *_=S
MDC<3]Y?E(XK*74- 'DHFH:?%$X>>2V5HQ#)*_P SNT0^3<2<DXR2>3R<\?\
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M '\7_&C^WM*_Z"=G_P!_%_QK\O?M&K?]!:\_\"&_^*H^T:M_T%KS_P "&_\
MBJ.1=W^'_P B%WW?WL_4+^WM*_Z"=G_W\7_&C^WM*_Z"=G_W\7_&OR]^T:M_
MT%KS_P "&_\ BJ/M&K?]!:\_\"&_^*HY%W?X?_(A=]W][/U"_M[2O^@G9_\
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MA_\ (A=]W][/U"_M[2O^@G9_]_%_QH_M[2O^@G9_]_%_QK\O?M&K?]!:\_\
M AO_ (JC[1JW_06O/_ AO_BJ.1=W^'_R(7?=_>S]0O[>TK_H)V?_ '\7_&C^
MWM*_Z"=G_P!_%_QK\NC>:HI(.KW@(_Z;O]>QI/MVI_\ 08O/^_[_ .-'(N[_
M  _^1"[[O[V?J-_;VE?]!.S_ ._B_P"-']O:5_T$[/\ [^+_ (U^7/V[4_\
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M  _^1"[[O[V?J-_;VE?]!.S_ ._B_P"-']O:5_T$[/\ [^+_ (U^7/V[4_\
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M  _^1"[[O[V?J-_;VE?]!.S_ ._B_P"-']O:5_T$[/\ [^+_ (U^7/V[4_\
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M  _^1"[[O[V?J-_;VE?]!.S_ ._B_P"-']O:5_T$[/\ [^+_ (U^7/V[4_\
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M  _^1"[[O[V?J-_;VE?]!.S_ ._B_P"-']O:5_T$[/\ [^+_ (U^7/V[4_\
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MV_!X\#XE>#03P"=7MR ?IF@#OLS^W_?;_P#Q5&9_;_OM_P#XJN!_X73\(O\
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M -PQYVC&"0">=W(]./7'H>A "BE( 9@,@ C )R1E03SWY)I* "BBB@ HHHH
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M[FW>9G;:<%1(61U.=R, Z="H(&7#= )HKA9(Y%8PE/+D=A*6.$PH8G//S<@
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ME?B1X0_:)_;#\*^&[#XEZ;H^K:?XD^(FOVO@NZOM8T75+L>'M-\%R2Z!%<,
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M52"1D$?IW^S#\$+S]GSP5XA\"ZKJ<FL#4-=FUC3I))/,%N]Y<RS[5.Y@"FY
M<'J,8&<  ^A%SCD8()!&<\@D'D]>GY4M'))+##$_,/0C@_J,_C10 4444  #
M,=JC)()P2!TZ\GO[5!)=6L3I%/=V=M))_JUN[RVM"_3A3<RQACR, $Y[9R,O
ME1'1_,$I5$>;$.?-9H%\U0N%8D%E&[Y2-N>G6ORV_;M\#_%+XJ?M&?LT^"_
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M +V?F!]CNO\ GUO?^_)_QI?LER 2;2\X!_Y8OV'^]U/2OT^_X1W1O^@98_\
M?A/_ (FE7PYHQ(']EV)_[8)_A1S2[O\ KY#6_P!WYGY=^3=?\^=[_P" Y_PH
M%M>,2O\ 9]VZN\3G=&P!>([D8KT!0DD'!(_'C]2O^$<T7_H&67_?D?X4G_"-
M:$6);2K/.!\PB7! Y (ZY!)[?C1S2[O^OD;<L>R^X_+864T-S%=-H8EO()?,
MBU"YL4N=0B3YBT"W<JM,+5B<M;!S$Q",5;:,57TBRF@BL[CPO87=A S26VFW
M>@V5SIMK*Q)::UL9H&MK>;).)8XUD!P=U?JFWAG0NO\ 95F3D$9A4C)/4C&"
M!G)'I2_\(YHO_0,LO^_(_P *7,^[^\$DME8_*N70]-N1"9O"]B9($,22_P!B
M6@F\K "Q&7R=[11J-L2$[8P6"  U.=,A 'EZ,(&,!MI)+;3HH);BV)!-M<RQ
M1J]Q;_*@\F5GCVHHVX45^I3>'M%4X_LVP'UB&?T%-_L#1?\ H':?_P!^O_K4
M*333N]&N_=#/RSL=&L=+E\[2?#EII+,2TJ:7H]K813L1@O<16T,:3.1@%Y S
M' YXJ\;:Y=G<6ETN]RQ5;;:H)P3@ 8 ]@ !7Z??V!HO_ $#M/_[]?_6I/^$?
MT0]=-TX_]L?_ *U:NHNWX)?JQ<J[+[D?F";.Z_Y][OV_T<]>@]/YTW['=?\
M/K>#Z0G_ .*[=L5^H'_"/:)VTS3B>V(1_P#$TG_".Z-_T#+'_OPG_P 342FW
MMI]W^1E-6>G;IIU\C\P/L=U_SZWO_?D_XTHM+K_GTO._/DMGV'#?_J_.OT^_
MX1W1O^@98_\ ?A/_ (FE'AS1B0/[+L/Q@7^@I<TN[_KY"6Z]5^9^8'V2[_Y]
M;S_OQ2)8ZCYCF.SNV26(PNK0L4977;("A)7.WA6QUSQS7ZA_\(UH_P#T"]/_
M ._(_P *<OAK1,_-I5D",8*Q+@YSGC';WI<TN[-N5=E]Q^6QTNZB9))M&%T\
M"%+:XOM/BO;JQ5FW%K&>X5Y+23=E0]NR.(V=00&.8I]/MKI+V&Y\,V,]GJ"*
M+S3I="M)--GE5]_VQ[!X3;&^8A0]YY?GL$C!<A% _4]O#>A\$:79DY[Q+P/P
M'/M1_P (YHO_ $#++_OR/\*?-+NPY8]D?E*V@Z<XL0?"]E_Q+8O)L"-#M UK
M%A0$A(A!C "*%"8P!@59&F0>:)H_#ELEP8VA,L>D6\4DD;YW))(L09@<G[Q-
M?J>?#^A@X.FV(([>4/\ "D/A_0SQ_9UB<]A",_AQUI<TN[^\32L]%L^A^4UE
MX8T_39;"XTSP7I>G7&G0O!#<V.B6%I<S+(KJSWEQ!;I+=RD.2)9V=PV&!! -
M:JVEW@[K*\5BS,1Y;L<L<YR6[YX!Z?S_ %!_X1S0_P#H&6G_ 'Y3_"D_X1S1
M1TTRRQ[P(3G\NG3]:.:7=_>8GY@?8[K_ )];W_OR?\:/L=U_SZWO_?D_XU^G
M_P#PCNC?] RQ_P"_"?\ Q-'_  CNC?\ 0,L?^_"?_$T^:7=_U\@^_P"]GY@?
M8[K_ )];W_OR?\:46=U_SZWOXPM_0U^GW_".Z-_T#+'_ +\)_P#$TH\.:,2!
M_9=C^,"XZ=\+1S2[O^OD"W6^ZZON?F!]DN_^?6\_[\4QH+I3C[)>GCM;G\NE
M?J+_ ,(UH_\ T"]/_P"_(_PIP\-Z-WTNQ'TB'^%'-+N_Z^1O9=E]R/RT:WNF
M4C[+J"'@AHXGC=2"""KIA@>W!Y!([TXV[M=)?2Z0;B]B@>VBN[G3HY[F&WE1
MHY8(IY$,L<,L;LDD:L$=&*L""0?U*_X1S1?^@99?]^1_A1_PCFB_] RR_P"_
M(_PHYI=V'+'LC\JY=%M[FS2PD\+6<UA%=+>1VKZ1:_9UN5+-YH@,1CW;F8D[
M>2:6;0H+JZ-Y-X7L5O&$:"^.CVC7$21[=J1R^3YD:?(H**P4C((P37ZI_P#"
M-:$>6TNSS[1+^O'7_P"M2'PUH*@G^R[,8]8EQZ<\4<TKK5Z-?FO3H'*NR^X_
M+>?2!<2W\S:/9))J4 MKLQ:'9QA[;YP;=0L($<#*[J\:85U=E8$$BJUGH\&D
M0K::9H4&G0*8FV:9H]M81.T2E49DM8HU<@$[BPR[$ELDU^IW_"/:#_T#;#_O
MRO\ A2_\(_H0Z:=8C_MB/\*T]JOY;?C^;8<J[+[C\NO)NW9MUM??O'WMF%@I
M;;MZ<<8'3UP1S3OL=U_SZWO_ 'Y/^-?J$?#^AD$#3;$D]O)4_P Q_G]*9_PC
MNC?] RQ_[\)_\342FV]--/)?D9S5FK::=-#\P/L=U_SZWO\ WY/^-'V.Z_Y]
M;W_OR?\ &OT__P"$=T;_ *!EC_WX3_XFC_A'=&_Z!EC_ -^$_P#B:7-+N_Z^
M1'W_ 'L_,#['=?\ /K>_]^3_ (T?8[K_ )];W_OR?\:_3_\ X1W1O^@98_\
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MIMKIB6%K>?,2W^H)Y))/7GKD_I2?9+KO:WGT\@\_D1^O'M7ZA?\ "-Z/_P!
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MTBN$,Q6TO,SH8Y"86)*G@XST..,C'6OT^7PYHQ/&EV'KS O]%I__  CFD?\
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M^GZG_&C8OI^I_P :#+DEY?>,3J?I_45+2!0.0/U-+0:132L^X4444%!1110
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M#[HF!/7^($  G'U&.0?=L]R*BV?]-5_[Z_\ KT :5%0P#$8&[=RW((/?V_\
MU^M34 %%%% !1110 $X!)Z#DT@(8 @Y![U!-)M! SD=3VR5) )],<GM@8/7A
MB2D1DYSSU'(!)&1COP<C!/.>E %NF&1%)!."/8_7L*K^>?4_]^S_ (TX-N&[
M.<GGC'3CIVZ4 3"1&. <D^Q^O<4^JS':-W(P1@CGD\=.^<X(IOGGU/\ W[/^
M- %NBJ/VG#[=QSC/08 QG.WKP!SR?SXJXC;E!.,]\?Y[C!_'C(P: '4444 %
M%%% !113'&4(W;<X^8\8Y% #Z"0 2>@&3]!579_TU7_OK_Z])(^V/;G."?FX
M(/4X^@XR3Q@'.2,$ M@@@$=",CZ&BJ\,@( YYZ'L#M!(^AY88R"#QZ58H **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH *9(,HXR1\IY!P>G8BGTU_N-_NM_(T ,6-&52R@G:N"
M>2/E X)_/ZUCW4YLI6WO';6O[E!.\C%I9I9!&(=I!P3O0AU)8EB,?**VT^XO
M^ZO\A6)?B=KV&-'N-LX=1M6!K>*2&,RJ\@<&7+G:A*_W0>,4 ?E%\2OVS_BS
MHG[3OB#X2^#[/0];L/#MWX2AN=$M9/M.JBSUC[:;N0 V9D:9UM@(U,@VMD!A
M7?\ B_\ ;\^'\4VH:997FIZ1JOA7R;GQ"C6%O<DVR"**ZT\"6Y&V4WDZ?O.&
M4(5'!P/KC3O@AX TCQMXG^).E^'[*7QGXV72]+\1ZW=P[F6UT]+F%TM#G*7
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MU7Q/'X>$\]T\<EZKWL]U?962>29G:9MGG[5+2?+L  R!0!ROP-^,_P 9M?\
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MRQB,R&,A3(J@L/+<\HP/*\]:M53L+=K6UBMWEEF:)0AEFV>9)M &YM@"\X[
M?0=*N4 %%%% $-P0L+EI!$  3(0"% 8'.#@>W7J:^+=1^./Q/TW]K;0O@Y-X
M?TU?ASK7ANYUB+7[BX:&Z$L-MJ4X"(+4AP39Q\&<##$8QU^T+K;]GEW1^:H7
MF,$ L<C R2 .<'J.GK7S!XQ_9V\'^-OC!HGQ8U[4-7B\9:!X>N-%T9+.<1:4
MEO/;W\1WQX#-(!>3,0V<\8)/0 \#_:+^+?[0G@GXI^&/#/PQN/"_BIO$L-Q>
M6G@Y#$VL/I=DT!FOKATL99[>$17".KJ[AE.XD<9Z;]ESX_\ C3Q[K/CSPA\8
M(;;PI\0/"-VEW<Z"L2+'I6F&WCD5?-,<$ER\Z3Q7 :6%&5)<*2 *]AT_X'>#
MX-:O?$4T0U+Q3=:'<>&!X@\ZX36+#3[FW%I>QVAN)([12B*HA9(RV57+';Q4
M^'OP*\'?#>[\3ZGX?FU"^\3^(YA#>>)M<59;V8M;HB,##'L>*VC5+8!H^?+!
MPW#$ V? _P"T[\+?B-XA\5>&O"WB&"]U;PB;I+^T)C'FO;1ER%=)'89*XX4\
M9[9KXY\+_M>_$[6/BA8ZOK.G>'K'X.ZIX\UCX:Q%+PMK%IJUCK!T9-2GC-DC
MBVBDCDEPUSL=6^8=*]V^#O[+^I?"GQOXH\8Q^([#4&\37\UQ=V<,$*RF*X(#
M E[:,9 +,0&XQW'!L2?L>_"5_'6L>.VM]4&JZI<W=S;6%U.J:5;ZE),\DNK0
M6L4B*)8YF,N_9O<DMASN  /+?'?[0WQE\+_M#?\ "%ZOH=AX7^&VI6L-GX)U
MZ?;<0^*=:N;>&XA-S<S6R&PAV&Z&8'G&85 4AN.I^ 'QV^*GB+XP?$?X6?%2
M'0;2[\*0"^T:32Y5<ZI9O).BXVVMO@J+=F;!;&3SGIWFO?LK?#_Q;X@;7?$M
M[XEU^\M8(HH;-[FV2QL+E+=(H#:<Q3QR^0HF1@Q 4L&.[*UJ_"C]FGP!\&_$
MNI^*-'>^U;Q;J2)]IUC5[AYC#9S,\4< ;>JL-[2JH"L0S \<9 /J2RN&NK6&
MX=%C:5%<HK;PNX XR0IR,]" ?6K55+*.*.$B$ *TDCL!NQYCG<^T,20-Q) '
M [<5;H **** &NVU2V"<= .<GM^O^<UD7=PZ%=TBK,\4IALU /G2K&6B!D(#
M*N\=E/<?73GW"%]K!6P "<D#) [ GD<?4]0.:P[@R0QQ!56  D74LH9W", ,
MQF/=A\YYX7CD< D ^0OA5\:?BOXH_: ^*?PR\:>&=!TGPUX.BT"31+B#5)FU
MG4(];L[FZ$LEF;&%4C@\I%#+<2;PXW 9KRGQ?\6_VF-(_: U/X9^$=1\(:]H
M]IIDFKSKJ*V]@-(MLHD45Y=1:?<RAMTD9W2')WJ/6O>S^S7X 7XJ^(?BSIUU
MK]IXR\2Z?;Z7J]PMT2C6$40AMKN*(L86^S0CY $+J' *YR3:;]G/P%#:>,X9
M(M2?5OB1#%:^(?$EY<R-J2P6[6KQ6-F]K)_H[N+*"X+-&B;-REE+8(!P7[+_
M .T/XS^(.E?%A?BO:Z-IU_\ #+Q1JNDW5_HMQY]O+8V7EA;@(;>TC**?,;<0
M=RCDG&:[_P -_M3?#7QWX.\=^,?!&K'6K;X=6^LOKFFR)'#<SRZ=),G[D1R3
M'8YMY"ARH<$$#.0)?A_^SMX.^%?A3Q9H7@NTFB/C.VU2PUC4;V26=I6OK5[=
M;]U9WD9B\S-GRV;Y0=OIPWP4_9GMO@:OB4W-WH^MZ-XCA>&?3X[>[\^\GN4<
M2+.GDQI^_9W*L0  ?F*YP0#RKX!?M3?%CQ7\0/#/AOX@Z3H,OA_XF>']5\1^
M"[S3;GRKNTAL=7U#3DL;Z**RB7S6.FS$%Y9';>N.235CPC^T3\9)_C1X]^&?
MC33]*\*W^I/>-\(M'UX)IEOJMO!]I:.2;4A;/<.'00[<Q3;L'&,YKUGPI^Q]
M\)O!^NZGKVD6VM+JLL;P6MU-> 1:3%=7 U)[72%:<"W"SRNYW)M.Z09)(J2Y
M_98^&]_K^MZWXCN?$'B?5-?L;BQCU35)1'=:7,(Y@(-#EL?L_P!GEC,XW/<X
MC8; &(#  &7^R;\=OB5\3]1^*/A#XC:=I]KXF\ ^(I=,>33BOV%8S-?+&L,J
MP0&XC*VZ[)7C1G4!L#-?;$$[3G[P0Q2!'4C.\;!D9/?=D@XY[=>/GWX.? 3P
MA\#].U>#P9!JE]/KEQ:37]W?W$4U^S)'-O\ .G$A20Q-*4?)9F8\%@"3] 6Z
M3K,X,82(;2&)Y<[5!Q@GOG/ []@ 0#0HHHH 9(Q5"1U&/U(%$A(C8@X(&1^%
M$@+(P'7C]"#3)F 1U)Y*\#ZG _7BLIM\VC:T6S Q-2N[R&TN)K.S-_<PI)MM
M]Q02-M)0%E5B,@!<X]??'Q_^S7\=O'WCBR^,=Q\6+'1_#T7PY\;7.A12I.$V
MV$6EV&HHTP%O &<"[)#-N8D!2<'(^N+]HO(OH)?,B@N8GBFGBY<._$:IM!VD
MJ2=[#&>"<FOG#PK^RU\/O"%]XYO-)N=8FE\?ZF?$_B"RU2Y,EE+,]K:V$B+Y
M#;AN@LT("M]XC/&14INZU>ZZON@/EJ+]N/QOXUT_XZCX<>&[)M>\"7&K)\-M
M*UZ7[#%X[TCPY]JGU/7;:X6VNI?*GL4AGB6*.6+) W*IR?L'P+\<K>7X%^'_
M (K_ !"N+3P_,VB0:AXCM%92+.\-NLMU;)O6+]W',9$C<JA>-%D*J3M7SP?L
M<?!Z2#Q!/#::KY?BS3[W2]T=Q';S:-IU[!-!+9Z88WB?==PW#0!YO,.5!9P"
M6/8']G;3;#X+?\*8\,^(KRWT1[2>RAFUE()[B*.0MF&5XX')$>X*IY("Y#8Y
M.X&;KO[5?A'5O@?XL^+'PWO++71HD=JEK#+/M5[F[U&UL(_,5!. @DN59SA@
M%!(!Z5Y_\!OC_P#%CQ)K?C[P)\2M*T9_'%AX(T;X@^"[;0YA+9ZIIOB&#5;B
MQTIY5M+9OM4(L$BE(AD?=*"22 *[+X5?LOZ7\-?AGK_PYU_48?$>@:Q'Y=W;
M10*D,J2RQ_,=D,$H>!U65-K85T4D[<TSP)^RIX"^&\<T7A:\UZWN'O3-=ZS=
MW/VC5&TAGS8V-O(6D9;&V3[0L,;*'19#QG- '@OPN_:/^/WC'2?BMHWBBT\/
M>$?BSH,NJ7/A;PAJ0AA6'3;&XFCM!<RO8^9(U_ UM<HTD$C;'.&/?Z=_95^,
M_BCXQ_#;_A(/&$.FZ=XKL=1N=+UC2K"0316\UN0?/C?R("ZR!D4 Q*HRQSQ7
M*6_[(WPLD@\466KWFO7GB#QT;R[NO$LMP8M6MK))FB2&.>#R[>)(XI(TC210
MY6-2V<,:]H^$'PB\&?!KPA;>%?!-NZ6$3/-<7%Y*9KZZ=R4-Q+(CNC,S!5[<
M+R!G@ ]NB)*\G)!Z_50?YD_A3U.1SZL/R8@?H*CA^Z?J/_05IZ]#_O/_ .AM
M0 ZBBB@ KQ+]H;XCZC\*/A/XH\<:39QZAJ.E+I<%G:RL4C:YU75;72XI)&"2
M82&2Z64_(W"'. <U[6SJ@RQP,X_&N*^(7A;0?&?A75O#7B>T:]T/588K>]@7
M[V/-#0RKAE8/!.(YE.>&C#<[3@ _/[PM^U9\3="\&?%]OB3I^@7'BGX?>%_#
MOBW1[O3+K_1=7M_%%MJ=S9V!C2TAB22U&GK',RJ[9F&XL<5YCK?[=OQ/^%ND
M>(/#7C_P_IGB#XJ:EINC:Q\.]&T1@;#5=/\ $.FVNL0&>XBM866:PM[Q+>:,
M6T^Z2-MS9&1]4^&_V2?A-X4T_4O"MFM[?V_B E?$%SJ\MS<75]I66%E:"1&:
M-(K6*2=(%8Q[/,^;VH:3^Q#\'--T^\T[[-J][=//+-:ZUJ4T=SJ6E!BYMXK"
M0LX%G#;N(D0ABJJ@P"M 'T%\#OB-IWQ6\":+XOTC7(M9BO$!NY8H(852;RE\
MRW18F9<0R,5WY#,.H'2O:J\@^$7PX\+_  G\*Z1X1\)V/V'3+*-K>-"2S *2
MY64AF0R%FWEP2IS@-D8'K] !1110 4444 -=MJYXSG W' _/_"O./%_Q4\&>
M Y;6/Q5K5MITE_(L-K"70M)([*J@%F0Y)9>/7..<BO1)UW1L %/?#<#CUP1_
M/\#7 ^(/!'AOQ9);/K_A[3M7>TD$MK<2+,5MY$*L"V)48\A3C#="1DT =?I>
MHP:I9VU]9SBXM;M/-AE  #QNI92,$@8&!P:U*S=/B$-M;Q)'%'%"OE1I K+"
MD<:F-%4/\_  !+#DYZUI4 %%%% !1110 4444 %%%% ",<#CU4?FP!_0TR4E
M5^4X.>OT!/\ ,#/M3F&1_P "4_DP)_2FR@E>!DY/_H+#^9% 'F>I?%WP+H?B
M&+PIK'B/3K37IY$BBL7F19S(ZAU1HR05)4C;P200?7'I"3K(\10DI(FY6 !1
MP5)!#=>/PSW&17G6H_#WPUJ.N+XBU/PWHU]JD$BO;WTGV@7\910 \O[U8"<#
MY=JG*[01G(KN[=I$E57_ '@<D+L7;% JC@#<JM\V2 .<8' H TJ*** "BBB@
M HHHH **** "BBB@ IK_ '&_W6_D:=37^XW^ZW\C0 )]Q?\ =7^0K+N92)[E
M$6/SHK42Q'*^;EMP8*,@XVKQP<GCMQJ)]Q?]U?Y"L:Z8K=S,T05$BMP+CN3+
M(8Y(@<9X3##J06W+C- 'R;XN_:U^%/A#XFK\-O$.J:S::T@T")I!;W+:5%=:
MTDAA^VGR?*CA#(?,DDF1=H)8KSCW35_B-X8L+33[LW\.J6=^%9)=/GC:V122
M/WOEF4 ?+_$1@<< BOAO4OV(I_%_[17C_P"*OB[Q#]M\.:BGAY] T"0>2AU#
M2TO38K)<(QD:!6E"R*0RN" R';@?.6F_L8?M1:KXPU?5KSQG+8^'S=:@-,TR
M+5KZUL8K1;AUMD6VB5(#B)1@^7SU.3G !^P@\4^%[G1]7U&QU72+N'1M.GUR
M]MK"YMYY;:WL89+I_M"0RNR2*MNVX,JGCH,UY98?M%?"V_LO"&KQ:W# OQ#U
M-=$TUYV"1-?P3QVNTEMJH%EN I9CR2#G -?-/P3_ &5/''P_\0:EJM]K,QT?
MQI\.K_P]XH@GUN_ODEUN^LM7M3=Q6]SF*S0M=VW$.P?*2 >W@P_9#^/FM:=I
M_P ,]2;2-'\*^!;OQ'J_@S7XL0W-UJ=W=PW.DPM?):QSJQ:!!O$KLI^8<XH
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M(SASTSC%>VB>*XF1+>[0*L;7 B+JTMO.,'=<1 A]BY;.Y5'.=PR#7P-^S_\
M _QIX)^*WC[Q8-&M?"'@C4+1]-TS1=*N9I7UO[";PP>)9[AX+:1[C4_M$;NA
M,BJ81MD8G(X?X0^'/BYH?[1_C#7?%=QXQD\'ZS)<Z=;M<BY;1]/L)W3]\X>X
M,<2JL:@S*A<<YQN(H ^HH/VL_@Y>?$.X^'\.K3_VU_;)\/&]:)_LG]J+:I>2
M01RE-BL("<CS"<=NM;&H_M&?#BT^+%M\%TDDU3QRT4<C:804BCL79UM[LSLC
M1N7"3$[?[@Y.5KX?N/V6/B_;?%&6WTZS\-2>&]*\9R_$N/6IK>"*_P!1EGL%
MTE8%O$LFG91"H/D"<IE3( 6)QZCX_P#@)\1_B-\9_ OQ%\.^%="\$7>BQ64G
MB'Q@=1G74=6LXGB>2P6W^Q!-JHLRQN)@6,YX&!0!^CULK?:&9I%4HJHUL#D0
MAERJ@C@].,#IG'>M*N9LE9$@Q+YL,*I'YVXL]Q>(@1I&E)W.H8/\C-M ( 7"
MXKI$)*@GKR#[X)&?QQF@!U%%% !1110!7NIH8+:::=RD,4;/(XZJBC)(]Q7S
M[\/_ -H'X??%3Q!XV\'^"=:;5-;^'EVT/B>VFADA-O&/)WG<^ W$P 49SV)X
MKWO4R!9S!EB=&C<,DY"PN".!(Q#;5)P"0#UQ@U^>GPT^&'QK^'OQF^.'C.'P
M5X,BT;QK-#)I\NE,MC+J'[ZS),S6VEQ&0&-"&W-(3\Q- 'KT'[6'P97QGK'@
MD:Q?6%[I%OJEUJ$DMK/&633%=IUM]\:F18PC!=A;/\.,BO3/A3\8? _QJ\++
MXI\$ZA)J6A1:K>Z8EUL9)XK^QNKFTD9@V&7$EO+RR@=.0>1\.^"?A-\>M?\
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MH087I^?8#^0 I0,?F3^9)/ZF@!:*** (93G"#KP?HV1LR?KSCTKCO'OC#0/
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M'CN_U+X<_P#"/_#[P[8:C:>'],2RD.H3:BZR"UU,;8T=T5H/,4K!C;)C?SR
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M(WC1[/+1VL<\<;2J%/F;8'D$S+&H+G"@@ L3C-;]\LC6DZQ1)/(4^2*0@([
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MK@\"O$?$5]\:8?&]M;^&=$\.W'@UYD-U>7+VHU'R?+7S"V^99%;<#M!3)4<
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MQX^(/C#POK6@06,?AR!M0T[R1-;-;VJF&,3.]U,(YP%G;(MS(0>@!!I/9^C
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MZ^P"$3R8#7KQQH4/V@,58%0<8-7K*S@MBZ6RHMLA,4MNB+;0QRY\S=%#'B-
MP(!55 YWGGI^9,W[;'C+P--\49OBIX-C:V\%C?H<FAO]KM)=:NT6YL-*:6"Z
MN%DN4@,R3>6VQ7@D4L,<_9WP&^*H^,'P^T'QJ\L"W>J:>)K[2X5=9-&O?/D
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M"XP5'''3L!0!WJ+M+GCYVW#'I@ ?CU/XT^H+=BR$D]Q\O=.!A3R>WZYZU/0
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MG!_GC'ZU&TJG<BOAMI(;!(Z9R",C^N<XY%<WXLU&ZTG3;B]M@7 C*N!G,9.
M'&.!P<'IQ[<UX'>?$/5[#39+F\US3M(MRS-8W&HW$<"W4_6.!6FFC#;VP-H)
MZXQW ![-XUT&^\2>&M6T6Q>&SFOK2X@D>8;O-2>%H7/R[L*5DSD@<C&1QG\P
M+'_@GAK?@37?AUK?P]U_2(](\.Z#>V/BKPEJ<=W-H_B:6<:@?],A6/*J[72
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MT[:\STU_KW0/HOS%]3_WRW^%'F+ZG_OEO\*^</\ A//$G_/W'_X[_P#%T?\
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M=_\ BZ/^$\\2?\_<?_CO_P 76('T@KH3@YQSGY6]#[5'<RMY>V ,[8("J,#
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M@8Z'/'KP?YG^E?-W_"<^(%^9;R,L.@]>QZL/7.<]NG/"_P#"?^)?^?J+]/\
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M4!./<]_Q]N]1B1&1) ?W<BAT<@A65NAW$8'OGH.3Q4@#-*D(&9) &3D>6P8
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M5IIKE+9KZ[AC8Q1' 0L%8C'RL.&& <=0,@XP%(!&#4P)53(K,KF/DJ2O;/\
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M5C\1/"T&E:?.UKJ.I7HN_MGF NK1PH(@[RDI((WCB>-L#:6!X^&M1_8M\?\
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M&-%^&NA:E#J6N^"M2TZ*Y?Q5J<$MM+'%JTSZC;H;"&6&-K=+BVEC5I)=A).
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M66WQ<_:H^,_@KQ38:!XD\;7%RZ7@U>S2Q:TFT*-3*LQC>ZL8UE"<X%NTKL4
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M@I&[ACUSS@]14:6%LFS:C#RXO(7YWYBV[-K<_/\ +D MDC)(.>:.=_U^OYZ
M>.6_@:;S)DDU*3R;T>=,?L<AM$DF'F/A?,V*RLQ\QLC+ABV#5=?A?*TXWZK#
M=)"6-HZ((C$3@,%3S&Y*E@=IQR>,5[:EG AD*AOWBJK*79DPH"@!"=JY ^;
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MMB<@X.W /H3P#U'3//(]JPWB2",K/$]Y);0RW*28^\4C+B/=AB"^P#C\CP
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MP ?>4<\;*AWY+ $9!!(;E<@@<[2/?\:F!!&0<@]ZRX?,VKYA5GWXRHP-H<!
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M!$5Q(QPJ,44MSCY06&[_ (#FF-J(4L"R'9C>0\95"2 %=@VU&)(PK$$Y'%?
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M2JL2 #I>%?BUX%\=WB6GA#Q=I&M7Y1FDL;.ZC=Q F/->/YMC[.K>6QY8#KU
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M ,\>ON ?)W[3WP-\2_&G2O!]CX<\6'P['X7\267B.XD:**YS>V:7$:3XN(Y
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MFW.^/T A)-L1R02P&0N?E'!"G IH7SMDKI&ID;S!_&5D :,*54Y *G/4@>M
M'YW?![]F_P ;^ /V@?&OQ-UC3K1=,\5K.9M276]6DDC>3SO+=;=U$"$,Z\(P
M'3C((/8:O^R[XV\1?%O3/B3KGQ0N=8L_#MU-=>'-$$%M$]I#),DPMTN8XXYW
M7;#"I#N0^P;\X.?MN*VC*O"T!N [!M[[EC0G&,J2K%>,X&1R1P<U9^RR$J!!
M$L\:A8KJ/=Y**,;5"%B_ X/7I@'!Q0!\$P?LS?%.Z^/=M\8/$OQ;GUO2;"UF
ML=.\&3V%BMIHEK)"5$D<:0*K7(FPXNI%,X$K+YI4FO?_ (/?"#3?A7I-_!),
M-3\0^+M:GUC5]9N6:ZN[IV$#^7+/.6D\I3"2L6XHF\E54LQKW?[(JR27'V,F
MX("S2*PS=+@ J 6VJ. PR <KCTS+%:1QS8\@LJC?'(Q!",V?D&26&,#G&!GO
MV +-FD<<3)&I51-+D$DX8MEL<D!<]%&%4<*  !5JFJ21DKM/<<<^_4]??GZ]
M2Z@ HHHH :_W6X!XS@]..?0\CJ..N*S9""$"RB-9XI(X\[3MD((!YY;DJ5!R
M,]0021I,"58#J01Z=>.^?Y50\@P"WB6$SIO8N^X?NB "K#.TG)'.!G/XF@#\
M\O%'[%^I^,O$WQ2UWQ3XZ\S3/'<VE30Z)'INGQP)<Z%;7=KITMQLBC,J+'=/
MOC=9$FR3*'X-=)\+OV6_$GPQ\*:_IFC>/U:\\27(N9[:^L;.XT83Q0):P;--
MN(9K*UA6"&,&*WMDC=QO92[EC]T+;>8TCS0 E&<QAB/FRW!X[8 P#]#[136B
MF*0S6Z31.,/$ 05 .5(PWJ 3@G'TH ^./AC^S=K'PV\)_$J'4]6M?$GBKQ_)
M=7;"T9M-TY)Y\LGV6TL(8+>S0.>4MK>-"H P1@#AOV4/V>_'OP:?Q[!X@@M-
M,M/%6H7]]'J">(-8U.XAN;B>XE@>.UOU^SPB,W#;8XB(\  CHM??D;W$2[T%
MH(OE"0!9!.%SRIWO@$<GT]"3P7#3HU831PJ\DA#DREF$98Y/ 89 STZX'<T
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M/X?^'] \$Z+ (X/#^DK;>: 6,Z>=-,3)(Q9WF:60LTSLTK* I8J *G\)>/O
M7C*;4[3PIKNF:U+ICI#JD=C=Q3/9SA?D!C5M[;T#,Q0,(R2CE6^6NX7$I0;E
M\V-F5L_*\BE3C&<,1T!P".#CD8'2K6=UW^5T[?Y;:-KH!IQHJ* H(&!W)[>Y
MJ2D&<#/!P,CWQ2U(!1110!$1O=PV<+MQCC&X<CCKG ZUYA\:/AII7Q<^'/B'
MP+J\TMK:ZO':2I=0LR26]YI=Y#JFGS*5=/\ 57MK Y!;:P!5@0<'T_(5W+9
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M,$5M/$BJPDF$A,NX'[2ZKDJ>I&S[Q)"@EACH16R@(4 C!R3CKU)/:@!U%%%
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M;R[,$B1 D22 >4H&0[$XP[8^5<X!(Y .?H :5%9L5X_F>7)L><Y#16[>8D0
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M!%B6,PQY7&0LB*#C+JN0/J<LWWFRQ-3PRS-(N"LT+Y_>J3E0 2 0  ,\=?\
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M*[QJKJX*%E^:O,_CE^TQ\4/"_P"T_;^"_#WB&U'@>RNH-&OKJ"0-%87%]$)
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M6T"ZS>^1<WEK UY!$MS):W,-U!YMOYD3A"RNRE6/Z60R))&&4Y')S@@8R?\
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M?MSVEI]JE@N"KW.YS&[$>9&N<G)Z<<$\3HO[.WPKTA;RX\.^'K2PGO2L$MW
M(59;6.9;AHUV1KD/(C(5#<AL\\Y /SPL_&OQKT;Q'\9KZ+]H72-,^%_@K4KK
M3Y_%?B*WOUMK;5A-=PQZ3%B"&2[8S)'$);2*6%BX(DQ\U?6/P@^-'B?1/V:I
MOBQ\8Y8=<O\ 2)M;FM[K0HY;I=8TB'4+LZ-?0PVYNIE%YIJ6TZK(%=/-VLJL
M-H]@\6?LZ_!OX@>!]8^&^O\ @_3[KPIX@UF+6M4TN 06\\]]'.EPEU(WDLS
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MFO<O _@#PK\.['^P_"NE)IMFZB^D50!NN7"PLS;47Y_*C7&><=30!Z1 L@@
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ME)/S9 P,\]QZ'GK:K%T\21SFU1\PVEO#$Y*<M(N\%5;H-N!NZGZ5M4 %%%%
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MKQ2*L,;F0"-@7.&<;<N..* /FWQC^U5X"\*?%@?!Z.VO==\6P^&;SQ+?FQ6
M:?8647V.1X9'2XC8R 72 ;HBQVGD$FF_L_\ [5?@C]H.Z\:_\(JIM9O!,DL6
MJPZB?)CBL[<1>?<HT+RLZQEV4,PX*\X.<?/WBC]@GPGJWQ-'Q(\-?$#5?#-W
M>6MS_:$,VHVEPY>9XF-D[PPL7M7*M\JL1M4 M47P&_9'\:?!\>(I].\<:&3X
MDL-2T*]MI'(>>SOWF8WLKI*BLW[Q5VY#X7)'>@#ZS^%?[0_@#XR:[XIT[X?W
MZZ[!X<U&]T*XO+>4/92W.G.R3A'9PY(S][RP"K C/0>R6^L6=Z)K2SOK2:_L
MV<3:8LR'[.P/WKDJ6E6/G+<-@D87@@?!/[/_ .R!<_!#Q9?^(1X@\/SZ9'I/
M]F+I6GS-#_:L\*7"OJDHEG8">^,HWM(RN#&N0IS7-?!/X"_$#P;^T1XV^(][
M#':>'=>GG-G;7FM65U;J'D3#^1#>,R <G#*..#C!R >]WO[3VBZ)\;=-^#WB
M/0M=LH=3U.;2-$\6WUM#;Z3>ZO#ILFIRVMH(+AA/:K:H_ERRVZN9@4Q@#'8>
M._VGOAO\//B7X+^%VHG4-1\5^-7@6QBL$MY/)%R\21F[!N(WC4/)DJJ.%PVT
M=,^&'X'?'B]_:,UOXGZ[\1O"^N>"+>W>R\%>&;\!X] A\GS%N( DT96\^U23
MJ9=[+Y#JNW-9>O\ [$'A_7/BSX*^-@\=W^G?$+2;^/6/%EP^H6DVG:O)++#+
M<V.G1)$\MM&ICF"><Y $R@-A20 ?HM ZF1XI84C,4JNAR6RS@MD9'#@G!V\
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M,X/7%7PRGHP.>F"#GOV]N: %HHHH **** ,G5;2WO87@O$+6[+R48+(,\$
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M\':MHMKI/]JRW)NX[21&BFNKUC"H:/,)4(<8H _33_A M"W_ #0W."01\[=
M1UX_(9^;D5*_@+P^LH<07.-@Z2'KD\9P/0YZGVK\WOB+_P %"H=-\1^$IO"V
M@:HWPX75HK?Q5XMOX[=&ECN+.XGAAM(HYY%"LSPD.5C8[#GJ:]!UC_@H%X)T
M#3!'J'A?Q$VN37%M-I%C#%"W]K:)?2Q0V&IL3>!D^T2^>NU=N!'TR: /N%_
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MS&<GY,AE8,<T ?8#^ ?#6(@(;S)8;3YK8)ST.%Z+WR.PQVIW_"O] _YXW/\
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MU)_T>X[9/F$@XZ'.S''Y5&W@;058HEO<E#@\.V<G[V/E&"!SGKSZ<U\*6?\
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M$&FW=_;^(;M(DL)XK>VDF62T=+B0S#Y,N!%@ J5R3B@#V-/ 'AXN62&ZVG:
M#(W48![8XR>![=^BR?#[P\67=#<@9.?WC XZ#^'DD=>,X! !Z5^4>@?\%$/'
ML6HZUX8\=:'HWA7Q /BC-X3\ 7<DERVC^._#']HZG;76H13O$[QZKI)M]/M3
M;1)'"TES+O9MBM71Q?M8_M G4OBQH<]GIX^(>DV%OJO@[X<I' ?/\/O)IT4N
MMZ7<FW\^\GB\VZFD@O9?)$<<AP2JT ?IO_PKWPQ_SPNO^_I_^(_SVJPGP_\
M#P4!8;K';]XWK_N?Y%> _LR_&*_^*'PL;7M4\36OB/Q/I5S=VNMPQQ6UK<VE
MQ#'$0D]M;10PK%%*S^8Z*Q(W=0 *^(_#7_!0/X@/?7G@_P"(FB1^$O$%Y\4M
M9\->%->T^-+C2-;\.V.LZG8JT;WBK_IT,,-FDB"';YC28D8 $@'ZLR^ - ",
M?)NCC!(\QCD9&<#:,_3\^*@7P)X9/,EK=G''+L/QY'8]LCDCWKX_T;]OGX=7
M'CBX\ 7ME?'Q#!J+6%M;6_DO'=0V^E#4KB\=I+A0EQ\LP$(VQ[ #G.*NP?\
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M+Y@R%P"0 .@ /JZ'X>^'UE9VBN=HR2!*W)/ (&.<9!/KVQR ^3P%X9Y_<W?
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M7_:*OM;^ ?C[XQ>#[)M*_L70Y+W0$U7:1<I!>06MUJ$J*UP \$_VB%8L&,[
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M)UU;Q/-J[:-?:%I4NG^$X;:XB_M28V%N7O&P0$9Y-Q=/(DYGP6/< _2>W_9
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M\5/$GB2WNI8]3T^6_2Q^&BS20L8+62*2^2*2WCDVAHVLVPC' R:].7QQX)\
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M1O"G@[P<\<'C'Q7KMV/%GB>T>2VU"ZLK^!I["W:\@*0HSW(2!4G8$,%"8!!
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M.OZ!KWB=+[2=4\(:7_PC>CWND7"6=A/HUU%;0Q:=,DJ33,8K>Q@BF/FJA.2
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M)796,C($ )X!SP<D@DY.".16I10 R,N44R !^<@=!R<8Y/;'>GT44 %%%%
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MF>.&Z#Q1I$VXB3;M .X@\4 ?L':Z%X=2VOK>WTG1!::V_P!GN[6"UMH1=>4
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M\;_'*[^/=_X5T>]UC4/ _AKQ/>Z-KGVZQO8+*#1K.^EM;7[,UPD"2[K2$,!
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ML6$@6?>4"[5("@5VJ6=JL TYHHHK2WME%O:O;63VUFD>1&UFDBE967:,)(N
M<$>M?GOKVH?M7>#_ (*>&?%%QJ-OJ^K6.J+J?B'3[6WF&H7%CJ0NKI[6(-<N
M6-C)<Q6BJ$<L(MZ I\U?'6O?&K]IG7/B##X=^S^+M$N;DVMYX)T@6L\@D G+
MSRW=W%$UJL1@BEQ'(\3 *.Y (!^VE[X6\.:I"MOJ_A[1;[SY+26W:>TMUOI7
MM\E[QHTC5+8!F63%NR(^[YDX"U/<>%?#=W<O/=>%M*NY(Q%%;M-I]C(J)%$J
M+,LA5G41! A*<YR#ZU\$?'?6?VJ= 3X0:I\.;'^U=0\7:+IGAOQ[+.CB3PA<
M7=O96FJZ\@^T0"<PO+/=110B>4"(+M?A0W]F+Q7\=?!/B[Q%X-^-%EXB\76-
MM(T?A_Q>%\NRN+:_*7DKO;2(]PGV>>=[50^TD1JV"F"0#[8U1_AC -5^V'PC
MIRR26EIK<K6&FJ;6_FN$BMEN=UMDR7$[QP(9 3O8#ACD6AI?@74[M;-]/\.Z
MAJ.DVUH6Q:V4UUIMC$G^@W,,K1&2'SH5,D)C91&$!BV+7Y-?M1? #XR>+OCS
M=^#?"]OKMK\+OBGX?MO%/BCQ-9WT#)X;\5>';F]UW2M*2&,M._\ :&H:?IMD
M\L4,L:+<%V=%!9?&O#?AG]M/3+*Q\006>O>%=5\1ZKKO@?Q)J%U(M^++1?"5
MXNC^%]16&VE,L@UBQDENBR"0KM D"$@$ _=/Q%HO@VS8^,=;T;3;F72;6. 7
MFH:?8S7-I;R;$CF6:59)9$4R*-LCLF#C: % ECAT*/2O.^PZ#<V<,4,TEW<V
M-C:VLVE6SF<:H1;PK'&GRR-''&JQ;X?N?,2?QM\:']N3Q)X@\;^']4DO)M%M
M/#5A#X?M[2*1(M?C6PTTO*S-.Z6[F^\P,)O*;*E@-IW'U;X9:!^TEXC_ &/?
M%W@_XCVNJP?$S3UT59-&MYXHKVW\.:;J=O>7NE17[22VLS7EJM[;'R9)/]<>
MF: /TH\.V7PQ\1#4+WPG%X8UF&^:ZAU>73[6TD:=)G.^)Y?)610@+J%4JJ?=
M7Y0*ZP>!O"%SI\6FW7AS2&LE($5J;"WP$$GF;781AW7S,.=Y/8<@5^?W[$GA
M36;3Q5XW\1Z5X1U_P!X#O/#_ (:TS1?"^NSI-<_\)%IVGW-MXGU$;$C"Q7VH
M%)XF*!9%8,CN #7Z4VP<R(Q.=L)C<XP!(&R5 /)P,Y(XSZ=  9Y\*^&R+E3H
MFF&*[MTM9X&LK<V[P1EBD?D&/RE"EB1M0$'D'(%,T_P?X5TITDT[P[HMG)'L
M\N2#3+..1#']QT=80R..N]2&)Y)) -='10!R%WX \%W^I#6+[PSHUWJ8=9/M
MUSI]M-<LZXVEY9(F=]N!@,2!@8 P,7KKPGX9OIVN;S0=)NIW4(\D]A:RLX&=
MI;?$0SH261SET8[E((!'0T4 <JO@?P@MW+?'PYI#W<T$5M)<2V%M-*8(4$<4
M:O+&Y0(@VC:0<=\@8DN?!OA6\U"'5;KP]H]QJ5M$(;>^FTZTDNH$4C!BF>$R
M1N -OFHRR;"4W;#MKIJ* .=E\)>&I9FN&T/3$F=X9))8K*WA>5[>3S86F,4:
M&4QR?.IDW%6Y&*S+WX<^"-1>26[\-:5+<3727DEW]DB6]-PA9E<7BJMRJ@L3
MY:RB/IE, 8[6B@#'GT#1;KRA=Z9978MRC6ZW=M#=+;/'&(EDMEG21;>3RQM,
MD(1B"03S4+>&- :"XM6TNT:UNY[JYN;9HE-O/<7J+'<32P$>4\CJJX8IE" R
M%2 :WJ* .%A^&?@*VMC:0>%=&BMVN(;MD2Q@!>X@#B*1WV;V*AVX+$'/(-=#
M/X=T.Y:W>ZTJQNGM)!+:/=6L-P]LZIY:FW:9',0"< (5 Z@ \ULT4 8-YX7\
M/7\ZW%YHNF7$RN)/,DLK9F9P<AY"8B9&!&09-Q!Y&#BLU_A]X'DENYY/"7AU
MY;Y!'=NVCZ>3.JC #_Z/@D#@-]X G!&37844 8%CX6\.Z;"D%AHVG6D:1O$H
M@M((V\J0$-$72,,T1W']V24!.0H(&)F\/:(]E;Z=)I=C+86HQ!9S6T,UM'T'
M$$B-%D8&"5)!Y!K9HH YB^\%>$M2A$%]X;T2XC7;L#Z99Y0*  J,(0R+QRJD
M*3R1FB3P7X2EMY[23PWHDEM<R)+-;R:99/ \D>SRV,30E $\M"% "Y7.,\UT
M]-=2RD X)QS]"#_2@#YYU;]F'X.:UX\MOB+?^"K"3Q39!!:ZA#<WMI#"L9+(
M$TZUN(M/!!)P?LV>G85[&?!WA=[^/5'T'2WU&.V6T%XUE;M.\"JJK')(T9:5
M55%5?,+;54*,+Q6_MD^[D;3G)_F,9R ?\>0.*D12H()R22?8>P]J .3D\!>"
MY81;R>%M":!9C<>2=+LO*,QQ^\9!"%8\ X8$9&<9S4]WX,\*WUC_ &9=:!I4
MU@LRW$=JUE;B**92&#PH(P(L%5P(]H&,   "NGHH R[/1=)T]62QT^SLPZ)&
MQMK>*!F2-0BAFB16.% ')/KUJ^L,:A JX$9)4 D8)&.<=>#CG(_*I:* "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M4*$SNT=T@7 E2:)WBND[JB-M7+9^7&3@=>#F0P&.5)?WI>WC9II!!DW,+9Q
M,'D*6SCYAA1P.VV45CSGZ9XZ$ XZ9 /%1"VB540!]L;%E!=SR<GDYR1ST/%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
?%%%% !1110 4444 %%%% !1110 4444 %%%% '__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>form10-k_003.jpg
<TEXT>
begin 644 form10-k_003.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $  IT# 2(  A$! Q$!_\0
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M12%9'5CT#*03D9'! /(.0?3F@!E%*002I!!4D$$$$$=00>0?K2<=SCWH_KS
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M^/#TE_Z2SJ:***Z#G"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M^;OVR"R_LB?M1,C,C#]G_P"+15T9D=3_ ,(5K'*NI#*?1E(8=0:^>OA9\"O@
MA<_M2_&K2KGX,_"6YTNQ_9E_8_U*RTRX^&W@V?3K/4M6OOCPFK:C:6,FC-:V
MU_JHL;(:G>01)<Z@ME9K>2S"T@$?T+^V3_R:'^U'_P!F_?%K_P!0K6*X[X2$
M#]K7XYG ./V6OV+\!AD$C4/V@C@CN/7I]:Y*T8RQ%%RBI/W%JK]<1IY=CIIR
M<:%2UUK-Z-K2,:#Z>I[!_P ,Z_L]=_@'\$SZ$_"CP'^G_$@% _9U_9[W _\
M"A?@H#D%3_PJCP%QZ$9T \@\@G(SU!'!\.^(?A&'P=KRV<>J_P#!1?QN-1MW
MU9K[X3>.;WQ%X8TUKF\ND_LAYKB_TAK&Z@\KS8].2":.WL)K,I</NVIZM\%_
M"$444?C4:_\ M3037*:AI)\%?M$^,KR^N;51/#C5F\*.]Y;6\TGD@Z1J@U&2
M3[/+<CR4\TBKB[RY'1@K;VC&Z26]_913Z?:>_7I,[QBY>UGTMK*W73^))_\
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MB,;5P_/#V\ZCJTHU:"KSY^6I)I6JJ-5RQI8+,[4G>:5&E"%.%?%4,15A)X?
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M_P#?+?X5(^67\LON?^0RBG^7)_SS?_OEO\*/+D_YYO\ ]\M_A0'++^67W/\
MR&44_P N3_GF_P#WRW^%'ER?\\W_ .^6_P * Y9?RR^Y_P"0RBG^7)_SS?\
M[Y;_  H\N3_GF_\ WRW^% <LOY9?<_\ (913_+D_YYO_ -\M_A1Y<G_/-_\
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MG;_HC/@3_P %DW_R57NM%%WW_!?Y!]8Q/_/^K_X,D>%?\,P_L[?]$9\">O\
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M344>SA_)#_P"/_R(_K&)O_'J_P#@VK_\M.9_X0WPO_T!K?\ [_7G_P DT?\
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M^6G,_P#"&^%_^@-;_P#?Z\_^2:/^$-\+_P#0&M_^_P!>?_)-=-11[.'\D/\
MP"/_ ,B/ZQB?^?\ 5_\ !M7_ .6G,_\ "&^%_P#H#6__ '^O/_DFC_A#?"__
M $!K?_O]>?\ R37344>SA_)#_P  C_\ (C^LXC_G_6_\&5/_ ):<S_PAOA?_
M * UO_W^O/\ Y)H_X0WPO_T!K?\ [_7G_P DUTU%'LX?R0_\ C_\B'UG$?\
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M_P"_UY_\DUTU%'LX?R0_\ C_ /(B^L8G_H(J_P#@VK_\M.9_X0WPO_T!K?\
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M  A'P4U?Q=H'Q2\0+::JUMX/UCP'#;W'B^QOK<6!OKJ71(;NW>=M-MKV.<2
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MCH<WAZUCTM_#L"ZE&WV:\EG6>Z9+V5Q)<'*R-N0 =UJ?QQ^#FC>'=!\7:O\
M$SPAIGAGQ2EQ)X;UF\U18;77([1Y([J738S&;NY@MY(I$GG2W\F%EVR2*60,
MYX3$PJ.DZ-24E)0_=TZDTY^SA4E"/+3NY1C/WHV4DHRERJ*NR.)H2@JGM81C
M*/.N>=.#Y7.4%)J532,I1M&5W&3<4G=V/4Z*\ZU_XO\ PK\*Z;H^L^(_B%X2
MT;2?$.G/JV@:E>ZQ;+9ZWID;VD<E[I$T;2#48DDO[-'%IYLJFX3,> Y7E_&'
MQ*U'5?!OA#7_ ((SZ3XZ?Q?X[\+^'K?7-.C_ +=\.Z;H$^IM_P )9K.IRVT\
M)M(],TNUNH0T[1/;ZE-:1RQ%G"U,</6;A>G.$9R<54J0G3I)QYN92J3A&$7'
MEDI)R4E).'*Y*PW7I+F2G&<U%2]G"4)U&GR--0C.4[24TXR47%Q][F46F>VT
M5P#?%?X8KXW7X;#QWX:;QXTYMD\)+J*R:W]H%H]^+5[>-61+O[#&]VUM)*DZ
MP*SM&. <OXI^.-5\#)\.GTJUL;D^,/BOX)\!:B+]9F$&D^)9[Z.]NK/R)X"N
MH1"T0VKS&6!"7,D$F1M4</5E4A3Y)0E4CS0]HI0YH\DY\RYHQO'E@]5=:[]V
MZU-0J5%.,HTW:3A*,K2YHPY7RREROFDM^EG:ST]3HKRSXC>-M8\'>)O@UHUA
M:V,]I\1?B.W@[69+Y+AIK335\+Z]K8N--:">%([[[5I<$9:Y2XA\AYE\H.4=
M;6K_ !D^$N@>*H? ^M_$CP;I/B^XFM[>+P[?ZY:0:C]IN_\ CTMIU9O)M+JY
M&#!;7DMO/+N3;&3)&&(X>M*,)0IRG[2%2HE",YR4*<_9RG.,(2E"//I>26Z[
MH3K4E*<93C#DE&#<W&$7*4>91@YRASNS5U&]KGI-%>?>*OBQ\,O VKZ;X?\
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M_P#7/Q-_Z'H5*7PR]%_Z4CKP/^\P])_^DL_JRHHHKP" HHHH **** "BBB@
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MFW)7Y?9YK+HN-/VM6HZM)14'%4XP@HSQ$^10ARJ<;XB2;J3<[:)I<RJ?@O\
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M6D#)7VK^REX&\4^#?$O[8%YXG\-W>@6_C?\ ; ^(_CCP?/>0P1C7O!VK>%_
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M4_C5#X$^%O@[7[&7X;1^,/A5\5ET"VM8WCNO$US$R^&Y]%%SJ'VKQ!;W>GO
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M+WZK7;7R94Z52FTJD)0;5_>B[6NUS<R37+I>^FC6BN2T4459F%%%% !1110
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M6C12LNRU=WHM6K:^NBU\EV*YY_S2^]ATZ4444R0HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K
MX]_:N_UG@/\ ZY^)O_0]"K["KX]_:N_UG@/_ *Y^)O\ T/0J4OAEZ+_TI'7@
M?]YAZ3_])9^^/_!0&21/V+?VADCFN8!>>$M TJY:UN;BTEETW6OB%X,T?6+)
MKBTE@N5MM3TB_OM,OHXI4^TV-Y<VLA:&>16\T^(O[#_A#P)\>?A)\:OV4_@A
M^Q=X)\1?"RP^)^F7.D^/_".J>#[==8\5W_@>?PEXS\,7WPU\,ZK=V?B7P;;^
M&/$&G65S?6<+VVG^*[Z/3KN(3WL<OI/_  4#_P"3,/C[_P!@+P;_ .K4\ U#
M\>_@5X3\=_%/Q'XFU7_@G[\(_P!H"^NOLEO+\3_%OB_X7Z5KFL1V4(@AL+FQ
M\3^%]4UF.'14']G6S7%X\4D,0DMUCB947Y*O%2JU$XN7NT+64I2B^:;3BHPF
MU=I<WNM-73.RA*4*=*TN6+GB%)-TXQFI4J47&7M*M&$KQE+E3GS7NX]3Y \0
M_L">/-6^"WBCX,2?";]@/PA\)O$?Q<TKXX^,M6'B3]H+Q]?>&]>LO$V@ZUXQ
M\3>&6^(GA>;2]$N9_!/A_4_!FGVS:SHOAK0O#%_=:8/LFB&\@E]^\ _#WX$?
M#_\ ;,^$NK_LY>"/AUX$\!_%C]D#XW>++N3X3Z1I.@^%?'MII_Q;_9^N/!'B
M&[B\.I;Z/XA&FZ7XEU8^&]:>*XEM=/U[4$T^Y2SU*99<CXU?"7PI#\(_@]X,
M/["_C;49+7Q5XFL/"?P*^!WC_2])^%^AZ_KTT-W;>%OV@M5\(ZIX8\/W7[/'
MQ-N;==;^)5UJGA?Q7X6TUM M[;7-%O-8U#2+'6?45_M3_AL?]F_^VY_"]QK(
M_8F^/(U>;P.ES'X*DU0?%/\ 9C^WGP?'>.]W'X66Z\U/#\=TQN%TE;02JCAD
M$4Z<(U$E%7YL/K9IKXGR+]U3Y;:\R]YN[YDG=&M2K4G"\JB?,L7[L>11E:$+
MSERUZ[J2]V"4FH0CRJ,%)_O']H444H!)P 23T !)/L .2?85Z%]O/Y*^G7I\
MSR_ZUT_,2O!/BO\ $#XG:'X]^%GPW^%6A_#W4_$'Q%T?XH:W+>_$?4/$]CHU
MC%\.K'PG<P6$#>%H+B\6XUNX\4)"][-#<PZ?':&06=T\GECWO!P258!3AB5(
MP3TSD<9[9Z\^AKR/XD?"&V^(FN>#_$]MXX\=_#[Q-X(L?&6EZ)X@\ W^AV.I
M+IOCRUT:T\16\C:]H.OVL<LB:!IDMA?VUM!?Z=<1--;3C>XK:BZ<:B=51Y>6
M=E*+G&_*^1RA&<)2CSVNDW=)^1G4YG%\C=TX_#*,=.97]^2E%:)[IW/'/"_[
M97@'6= \/:EK?A?QUHVHM;Z;%\3AH^@R^*/"WP9UO4/'FM_#".R\;^*[9K)&
MTZZ\;>&M;MM.U/2-*OW.A6T7B/5+/2]-G22M'XM?M0Z!X/\ A7KGC/PA;7VI
M>(E\+_$+Q+X:TW4]"OI[6\@^$_Q#T#X?^.(+NULKF*[DO%U+6A'H%A:RFXUI
MO*E@VK^Z>X?V1_AM;II^F:#K'CWPWX2&B^"=!\7>"M)\0QS:'\2;#X=Z]>^*
MO#<_C:YU/3]0U^XU,ZWJ&H7?B/6-'UG1[_Q5!=7%EKTM[:OY8S=8_8[\ Z\_
MBB'4O&WQ2ET7Q#H'Q&\.:5X<@\2:;:Z3X%T[XK>-M(^(OC"?P=);Z&NHP:I-
MXNT6TU#2=2UF^UBXT6U!TJP,>GI'"G:GEBJQE:M&//S\CBY)Q4N9TG>>DFW9
M6E).BK2DJO,UA;&<C2=)RY6E)/KHHRORZZ+6RUFY->[9$/B+]K+PKI.K>';J
MZL]:\$^%]*U_XL:5\8K#XB^'+G1O&G@F'P%\(S\4M%EBTVUOKRVD_M[3KO1K
MNREMIM334[34$L(8[355GBM^FM?VF/"GB;X/_&GXG^!M.U*ZU+X,>&_%>J:Y
MX0\41VNEW\.M:'X%D\>:1IFH3Z+J&NV(L-=TN2PECOM,U"]EMXKBX@N(;?4;
M.XM(Z>H?LE?#KQ+I^K6GCK6_'/Q!U/Q+J/C75/%?B'Q'J]@FL^)KOQK\.[7X
M6W!O1HNDZ5IMI'H'@_3].A\.1:386*6.J64>KW O+R6Y>;LM"^!>@Z5\,_'7
MPKU+Q%XA\1Z'\0=(UW0==O[VQ\'^']5BTK7_  Z_A>]AL(_!7A?PSI4%T=/:
M2X;4KG3+O4+C599[^ZN)C((4SG+ *$.55?:1J4N:^D)4N>#J--J\VXNI&#E[
M.;C[*ZUFTTL2G)2E!1<9+16FIN,HPNVGTY)<R37,I73Z_,/PY_;.UWQW:SR+
M#\,+X:/XJN])U77O!\WC2Y\.WFF/^SMXN^-$"Q:1XEMM+\6:=JF@ZUX>B\/Z
M[*(-1TG6+1+S_A'+U[]+I-/]W\-?M1> =:\167A*[L/%]C=_:=+T#5O&\OA6
M\L_A9;>-+[X6V'Q=?PU;>*+R[-R+B7P9=RZG:F?3C%&\/]F7MW#JCPPW$.G?
MLK>"H;ZXUO7O%WQ#\:>);G3;+07\0^)-6T5;R'PUI7P[\9_#+1O#MI::'H.C
M:3::9I6@^/O$]]"\=@VH7.O7RZA?7ETD4=NG2:?^SK\/]/LQIX.MW=DWQ!TC
MXD75M>W\4L-[K>D?"JR^#D-C<*EO&6T6Y\'V$7VRTC99)-3>6[CN(TD$2W5G
METMH58].:G#V=FVFY+FE+F<5>T7'ENW=V2)C'%KW74@V[Z2Y6VK7U:LDV].G
M31;+$^%'[04/Q=^(NL^']$\*>+_#_A"S^%/@_P"(FB:GXX\*7WA?5?$T7B_Q
M-XAT[3-:T-9[VYBO?"FHZ+I-K>V8F@L]9M+F9X]5L[-I8+8?25>%_"?X#:1\
M)]6N=8L_&_Q%\:7)\#^&OAKI,?CG6;'5;?PWX$\%WE_>^'=!T=-/TG2_FL#J
M<L=]K&H-?:SK"QVLNKWUS/!'*/=/\]?\_P#UJY*\J+J+V":IJG!*ZDI2G'G4
MY6E>33O!7TO)/35'12510_>M<UY/1QTU32M&]E:[3;VM?J%>1_&/XE:A\.]#
MT&T\*Z':^+/B9\1/$]IX!^%GA&_OI],TK6/%E]8:CK%WJ?B;5+6"YN](\#>"
M_#6CZWXS\;ZK96]Q?PZ#HL]AI4,VM:GI4,OKA!!((((P"",$9 89!YY5@0>A
M!!'%?&_[2^G^)H/B]^R7XKT?XAW'POTF+QC\4_AA?>,$\)^&?&-KIGBKXM^!
M].M?A]:7VG^+HY='L(_%6L^$KWP38:LXCG77O$^BZ-#(LFN(DG)6DX4Y22=U
MRJRT:YI*+EKUC>]GIO?0ZL/!5*L8/EM:4ES7<).$7*,9*/O.,FDFHOF:NE?F
MT7PUX5TSQUX\^(WPU\3_ +5_QL\7?&GX<Z+X%U7XE:'\,_%LWP6\*^!+3XG6
MNLZQX(E\-^"?"-@;2"TU2RT'5)--/B_Q#\0->^Q6<,FOZA*]XJ3=QHOB#Q]\
M)O'?A/X>_$GQ3<_$CP+\2M0OM ^&?Q1U72M'TCQCH/CFRTN^UZ#X9?%$>'K3
M2O#>NGQ-H.E:Q>^ /'NCZ)H-QJ&J:+?^$_$^DOJMYH>LZK\1_&7]GWQ/H_Q7
MT;X16/B7X@>+Y?\ @H#X9^)?P\_:(^,-E9CPQJ_A[0/!_BCPAXY\3ZZEOX.L
M=/\ #/@HQ? ^Z\5?!CX:-#>66J0WFJ6"6$U]>I>W47;:EX6_:<31OV3_  5\
M:?BMX0A\>:O\=_A -/\ A%\./"6BZYI?_"%_L_RZ=XK\8?$+5OB=KT%IXWOM
M6?PQX1?Q+XQU#2;/2/#NC^(O'V@_#RPAU&&9-5USB56<7).A-3C-)RC-RBVY
M1O"<I3Y7^ZFE)PN^:,I4]$=LJ=.48MXBE*G4IR:C.G[.2M";=:DJ=/GBE6IS
MY(5-/9*'/)RFV_TU^E*.2!ZG'^<\4G7V[XZXSSC]>G&/049QR!DCD?X9]Z]+
M[W?MI>RO\KV5O^">8KW6FO9WW2?XW6J>E[K0\DM/C5X&3P9XD\?>*-2A\$>&
M/"_C_P 6_#J]U#Q!.KK/K/A7QE=^"(VLHM/CNKF\D\0ZO:I_8NEVEO<ZK<?:
M8;<6TD^\#*U#]I?]GW2=/\*ZMJ7Q@\$V6F^-[&]U3PI>S:A<&'6=,TO5XM U
MC44\NT=["QT/7)X=(UZ[U9-/@T'494M=8>RE)4>577[//Q3)O+;3OB;X%M-.
MT#X[:O\ M#?"\7?P]UJ^OM)\9ZOXHU[79M%\=R+XUM[/Q1X6_L[Q5KVCHNC6
M?AO6+6Z;3-;M=0%UIPCG9#^R?--X8\>Z7K'CBVO?$/Q/^&GQM\'^+]9MO#"6
M6G+XI^.7CB'QOX@\0Z'HAU.Z_L[0=+N(8M.L/#DE]/+<6]O'>7VHS7\L\LG=
M[/ WDW6FTW>*@E'W;4DK.=)]5.3FY-N25)4VKU'R\V)25J<6TDGS)>\_><GI
M5;U^%+E6RFVG+E7ONG?&3X5ZO\0[CX2Z5XZT74?B5:?VPMSX.LAJ%QJ43^'H
M+"X\00_:8[%M*>YT.'5--;5[6+49+G3FO[.&ZBBGN(XV\I\2_M%ZYX0^,>H?
M##Q)\'M1T3POI'A.\^)&K?%[5?B9X"T_PKI7PQTS7K3PSJ?C._T.XD'B" VF
MM7D5L/#C+_;%Q'^^MPQ>.-_FGX6?LZ?$ZV_:!^(MW\1O#FL:S\,?&?B/XTW%
MV=5\0M9>'/"OA[Q?JNC:OX>NOA+J'AGX@QZXNO\ CV]\.Z%/\0X;[P-X8FTZ
M"Q>T76+QX?/U?Z)^+/[*^A_$]=6LHO$-QX<T6Z^ MM\$])T];6ZU=]+?2?B;
MX<^)F@Z_<WEYJJ7VKVMM?>&K+2M2TJZO$NM3L9KEVU6&=Q(MRIX&E7A%U?:4
MI48.<VKJ$Y.FW*"A./O1O-^SJ*2M'7F4D3SXF=.4E#V<U5FDN5V<5SQ2?-S*
MWNPM.,E+5M)/5>D6W[1/P,O'\,0VOQ0\,RW7C/5M:T'PMIX;4DU76-:\-RVD
M'B+3(]'ETY-6L;K0)=0T_P#ME-4LK!=+BU"QN+QH;:\MYI,;1?VK/V:O$>H:
M5I6@_&[P#JVHZY>:;8Z/:VFHW;/J,^M726&BR6\CV*0_V=K.HR)IFDZU)+'H
MFI:L3I%EJ,VJ))9IS'PM_9R?P!J/]OWEYX.CUN\\-?$[0]73P=H/B:QTV\O_
M (B77@=O[>:Z\:>,/&OB6YU*TL/!%I87\UYK<G]H6\MM!'':P6$:294W[*\<
MWA*'PN/%D4)B^$/[._PJ^WQZ%$'V? 7XAKX^&K",7:E4\22K]A%@)-NF.6O!
M-<M\C1R9?9_O:[TBE)NGHW)IZ>R2:IKWG91<W=IK6*I/%[\E+K[JYW=*R3O*
M5VV^;[M=TG]=\@D$$$$@@]01P0?0@\$>M?)/[9_Q'UCX8_#'P!JFE?%:#X'V
M?BG]HGX&?#CQ=\59T\%X\&^!?'/BM],\4:A'=?$33-9\%Z9-+:I%:1:IKNF7
M5M9F<NB"=HV'UU-)YLLLN-OF2/)MSG;O8MC(XXSC@5\G_M965GJ-A^S'8:A:
MV][8WG[<W[*-O=6EW!%<VMQ!)XYN@\4]O.DD,L;X&5D1AD XS@CRL3)PP]6:
M=G&FY7C=;6;2:=^C2=]='LV>EAE"6)HJ2O!U=K)WBHU&M)73NDM'S+U/C30;
MOX=Z5\4_B7X]E_X+%:*;/QQX9^%NB6?V;QM^Q0VMB7P'_P )T+S^UX[KX:2:
M'%9G_A*[8Z*^BVEK>R@:E_;<MWY>F>1Z;;_$/X80SP3/_P %BAB*6.5MGC+]
M@\M^[<,0@?X5,FX@?+N5E!(R#TK\_M?^,'QA/[+/Q$^/,7QH_:ZTSQYI,'Q:
MU;3-*\*_\$^/@1XA^!&G2^%?BIXL\+:%I^E>.KG]F?59-6\)VFB:386[:Y<^
M+;Z>YNDEDN=4DG:11Z3\0O$OQ#\+?%7X">"](^.__!0 Z#\2_$_Q/T?Q4=<_
MX)J? 6V\1BQ\(?"_7/%^B?\ "&63?LEVQU'4#K>FVH\00I:Z@;30#>7;Q6:1
M&[7SUB*<4UR5&I6E*]2N[NI)Q_GM:\=-/2VMO5EAIR:ESQ7*G!/V.&5E0IJ;
M=_8K>^FB=]TM66/!7BZ3]F?X;?L_^$/ 7_!37PS\<_&.K_M@_##P9JGPMT#7
M/V9?%&A^+/ W[07[6%S/XPL;.RT?P7%\3AJ%GX*\=7=S?7^F:]!%H^MVU[=:
M2MMX>MK&R@_=M@ S = 2!],\5^!FN^)?$NI:[XD\">(O%?Q7\=Z+X _:N_X)
M'>)?".I_'O\ 9N^'7[/OQ'T/4OB-^U+XBL_%MOIVF>#/A9\,)M7\,:A%X*\/
MM9:C>:=>&*ZAU2TMK_RWG@7]]'^^W^\W\S75A)7]HES*,>1*,I2E9KVL9.\V
MY*[6S\F]=N/,(\OL6^5SG[6<IJ%.'-&3I2@K4XQORIVNU?5I.UAM?,'Q1_:=
MTKX5_$JW\ ZEX%UW6]-M]"^'VO\ B?Q=IGB/PC9_V!;?$[QYJ?P[\*6^G>#]
M8U&R\2^-+M]>TJ:;5K3PO'=7NG:;(MW%9WS@P5]/GD$?Y_I7RU\5/V8M&^)G
MQ#U+XIOJ6G:9XZT[PQ\*[#X8>)9O#UMJ6K_#7Q=\+?'_ (E\=VOBG2;Z2>*X
M>V\0#Q"?#OB#1H'MHM1T2.[M+F:6*\VP^GAWA_:M8EM4^1VM=7E)QLVUJHQM
M>3U:5W%2:Y9>36]KR?NK<W-_Y*KM[JUWLNSL>CW?Q^^"=C=^+[&[^)_A2&Z\
M!+<-XNB-W<L-*^R:W;>&;M8)5M&BUR:T\27MEX>N[?PZ^KW-IKMY::/<PQ:C
M<P6TF):?M*_!N_M8]?LO''A^Y\"S:++J,/C6.]N!!<:G#XW_ .%?-X=L_#3Z
M<OBJ^U)O$ROI2/9Z7.)-6BFTB.&2]C?9\4_$?]A_Q9X<\%>+XOAC?Z=JNJ3>
M,[?6_!NLZ%8:U9_&3PIHGB3XVZ+\5O&QTG6/$'Q'LO MYJ>DG3RNCV>@Z?\
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MBBN\ HHHH **** "BBB@ HHHH *^/?VKO]9X#_ZY^)O_ $/0J^PJ^/?VKO\
M6> _^N?B;_T/0J4OAEZ+_P!*1UX'_>8>D_\ TEG[W?\ !03_ ),O^/W_ & ?
M!O\ ZM3P%7#_ +2MMX2?XP^)VU?]D?\ ;X^+5\R:>7\<_ /Q_K6@_#/45^S
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M2C!1E*T:4)2IK6\E9O6UM*,:T4U5FI_"HZMM)1L[R:3;D]7HE=[*R$K\S_\
M@IE_R+?[,W_9Q%C_ .HCK=?IA7YG_P#!3+_D6_V9O^SB+'_U$=;K.C_%I_XX
M_F=V%_CP_P -7_TQ7/C_ /S_ )_R*_(K_@H!\?+[3M4N?!NE3)_9?@R_TVPM
MK*51+9ZK\3;O3;?Q#=ZYJMM*'MM1T_X6^&[[1I](TVZBGLG\;>*+#4[J*9M!
MAB7]=T"EU#'"D@$^@SR:_FY_:?M?%'BOXTVFB?83'K^O_%GXI65C:^6[J^MZ
MC\5YM L6=2T@F5-*TWPV74!L6Q2,@1D*/U?P\P.'Q>=3K8E0E# X>5>,9Z+F
MY:SE-O>/+3HR2DM(*4Y6;9\5Q5B:U# 1IT>:^(K*FW"R;UCRIM[MSG%)*44W
M%<VES7^#G[,_Q#N?'GA34OC#\,+_ %'0/BQ9W]IX;UWQ-K@EC;Q-KE@VIZ5X
MEUJ#1M?B\3S7,5I!=W]JM^]NJ7+V]Y>0WL=N^GR^S_M3:='X(MM:U_7HHK'X
MP>'YO#D_AWQ)HEAX=\):K:PW=Q/H^J:3XET];*"U^*&C>)K%HK_6&TF758+2
M$_\ $XTS3H;V[6[^X?%OP<L;'_A$=.\2_$3PEK">!=>M/%FL7FG:CX<^#_CO
M3_&FGV21:%>Z?J&G"\TZU\':5)>WCVFE67AUO$?V2ZLK"UU+5%$ZR\_\3_A)
MI'[2/@W5?AWXN^WV?B;X?Z;?^+= \:![N\O_  U<-9WL=O:7]_K5[J=_K^E>
M+;6QLKN:"^B\*7VHVA3Q"-)TA(M.@N?I8\41Q>9X''8N<5@J?[NO'"4L5"-*
MA]9]G1JTJ562]I3J49T(8BE"FG6@Z=2*J7A3CXSR5X?!XG#4*;E7E%3HSKRI
M2G4FZ7-4C-TXMQG&=.<Z,IU&H<LXMQ;<Y4/V"OC8WC#P_P#\(%<E8=/31;KQ
M)X(L!-+,/#JZ3J5OI'CSP%:R3R2SMHWA[5-0T;Q#X/AE=Y+#PIXIMM'$CPZ-
M&5Q_CY\(/'WB;XN_'C5;3X7_ !@\5>'OB-\)_!'@WPMK'PY\=:#X-\/3^(--
ML-2BN;7QY;ZIX@TX:UX=MKVZLOM&GWNF:C;O +^.*WD%QD_)7_!.2YF_X6%X
M659V0GQKXPMA"DA\J2TU#X1:I=:N@&</"UYH/AZ9O62WM')RJFON&XT+X:_%
M+]HKXY>'OVB=8663P6?":?"+P'XD\6:CX1\+Q?#V_P##\%[J/CC1+:UUC18-
M>U>^\1&]M-7U1YKBXTF.T@A"PH5=>+-<-')^*<WKX1.-+^SXXJO3I4JE:O+F
MQN%C?#T:4Z<I256GAIUYRER1HJK*:4JD9+HP59YADN"IUVG/ZW.E3E*<:=)<
MN&K2M6J2C-1CR2KQI6C*4JCA&%XT^67#>*O@I\1O[1\7O\5?@7J?QXUOQ'\*
M_ /AGX9:]X)U_1]'\._"3Q/HW@V+2->TFTL[_6M"/@>*/Q<K^)8?%.@6EW)=
M6*K;QJJ*ELR:-\#OBMHWQI^%7B#7?AMJ7Q.UZ'3_ (6>'_BCX_\ &O\ PC&L
M^"XK+0/"\6F>(_$_P]\4P>(;/QYX7UJS;S+*^\/3Z'J6E^,[Z,ZE<PQ&^21.
MA:*_F^/7PI\.?LW?$;08?#EM^S+X\CT_Q=XAOM7^*.FQ:7I/Q*CBF:RBN-:C
M7Q%JZ:K"-%@O]3U"2+2M.2X2-9Q!;0OX_P"+_B]K_P 3OAWJ/B[7++1=/\1^
M)OV"/BUK^IZIHDFKV4MOJ>C_ !'MM"D&D(-6:SL=/NS:B_96M9K^VN7$4&IK
M;KY+32GF56,%!X)4<3@^6O&4<51Q&'^M1K8:BI8"591PE-TJ$L1*CAL0G4Q=
M*,\1%U+3JW46$A*;?MW.G7<Z3YZ-6G65!QKU''$QA>O/FG&C&K4I.4*%5PHI
M1=ETNB_L^>._#/@RP\(2? [6]6\.>$/V@/$/BKXE>$]"\1Z19V_Q\^'6HW'B
M,^ VT!CKMM_:</@**_TZ34_"6O\ ]BIJ"P^03?%&(TX/V>_'/B+5="AC^&7B
M3P#\%-5_:0\+^*[3X13>)[>._P#!/@2P\!:QI'C+5]0ATG6YX?#VB^,O$$UE
MO\):'J=V]M:M*3! )WV\I\4?C!\1_$OP7^/?A^S\=> ? ?A;X3_"/X<>%'\*
M:_92OX[^(?\ PE'P\\.:E<^)-)\0MK=A=Z5+=27@M/"0TW3M0COKZ&6/46(=
MI%];O/V@OC;H0_:!U?2[7P5JG@7]F[PYX1N(]"FTC5)O%GBQ_$/PWTG4M,LY
M]4M+XV^GZ?HNIW$WB#7=4-I)>WFEPMIMM#;;9+ZG5EGOLY582RQ5ZF(J4I*I
M7QD(J6)^JJA53J1EAGC*^(QM!4I495I86G46&CB50I3IP(++;Q@_KGL8T8N/
M+"BW:E&KSPER-5?84H8>M&I%QIJI)*K[.4YPD_>/V<?AKJ/PMU#X\Z%'X9?P
MEX$U#XQ76M?##1XI8CHZ>%+OPUHJ7%QH%E%=7/\ 9NFS:U%??Z)(MJYG6206
M^QE=OIK#$$A20 2<#H!U)] /4X%?F1=?M._M ^'/AY\0/%&I6OA/6EL?"7P]
M\3^"_$M[IOA+2X%U?Q7XRT?PYJ6A7WAKPE\0/%US>>%YK+4S/X?\37,VGWJR
M6US#?0R721PUN^/_ !/\<8_$?Q"\(^(-8^&WBSQ_\(=!^&?QK^%.K0++\-]!
MLM>\8:MJ_@S4_#NJVFJ>)[?3/%,5A92ZC)X4LO$&KV4.OZN-+AU,AYFAC^<Q
MF0YCC,94Q&+Q& A.HXPG*GB)57/ZO2P.$G5]ZBN;EK5<-];E*I"<)5JTX0FH
ML]6AF>$H4(4J%+%3C'GFE.CRJ$:D\37C3TG%JZA5A0C&+3A3A%R3NS]&:*\&
M_9S^)%Q\3_A]<:SJ'B=?%.LZ/XIU_P +Z[/)X-3P)J.CZIH\MN)=!UK0+;6O
M$&F#5M.291<ZAHNK7>D7Z2PS693#J?>:^6Q6&J83$U\+6252A4=.=N91;2B[
MQYXPERM23BY13E%J7VDW[-"O#$4:=>F[TZL>>#?*W9N6_*VDTTU9-[+S2**/
M_P!7^?\ /IZT?Y_S_4=N]8??]V_IZ=37_AWJM/\ @OMN%%%&.YX'J>GK_+FC
M^OZ[^B3?D&RO_P /]W]+S#_/KD=Q@=<^G>OQ?_:BO+3X<_MIZ+\6O%'CKPKI
MO@/0;SX?:GK_ (4UKQIJFF3:NUKI=U -);2K?3C80MJ'V147;>3ZDL$%SJT6
MUXRD'[9:8=,%QMU:*X>W=<++;2E&@8;B6>)89'N Y*H%5HBA^;<P^4>)_&WX
M?:EK_B[X9_$CX1-X4G\5_#6R^(.FP>&?C!9ZM=^ M7/CS2-.L;;Q+'/X=DFU
M_2/$_A2[TF%[":"&6WU71-2UK0[E[ 7HO%^9XEP$LWPD<#&EBE*GB*&)C5I4
MH3A^[Y[I.=>FF^6;]V5E)VYERZG[KX!^+F*\%.*<WXJPF797G$LVX2SSA2I@
M,QQ57#TXTLVG@I3KN=#"8C$0E3^J6I5,*Z>(IU)JI2JPJ0BS\OIO'EGJGB'7
M/B%HOB*[\2^'/B7<>)/$VO&W\2>$8_AWX+\,>'?V9];^'GPX\+F6PU'4(_'/
MQ(O?&GB22PU?QU:7;Q:J-#T;Q/JDR^)?%FK3:3L^(K#P])X#/Q!LO"'Q2^%?
M@7PUX?\  .G?"3X<?#SQK>>+_'G[0=RF@>)[+XCZ-XEOM+U_QCX>M+:P\2SZ
M%J^O?%U?#P6Q\.Z;>^$M)L-1\:WTJZ=^EG[./P>\&?!+X'^"/A7XFTY/'FOZ
M%!K5]XF\3P0V&B:7K/B/Q-XDU7Q5K4FD>'GL;Z+2-"@U+5YK31]/>>>2WT^U
MM=Q60E%^(?CK^R$WB'QY\=M2\%? 7P;XKO\ XOZ/X.TGX)_$W4_'>F>$K?\
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MO1C<9)*37NR<DGT;C;F2].97]1**F^SW'DFX$$IMQG=/Y;^2 &V$F7;L^_\
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M(W0TZXOK)'-S:0:@;&]^PRW$<:7?V.[,#2"WF*0:OK.DZ!8_VGK>HVFE:?\
M;=-T[[9>RB&W^WZQJ-KI&E6?F-Q]HU'5+ZST^T0\RW5S#$.6HY974>5\SM:-
MM7?:RW=]>G3;5)EUWVWZV?;32_DGNF:=%9L^LZ3;:S8>';C4;2'7M5T[5-7T
MS1Y)0NH7^E:)<:=::QJ%K;D;I;33+G5]+@O)5.(9=0M5;F45I4--6NFKJ^JL
M[7<;V?2ZDNZL[I/0+I_D_)K=/LTFK^J"OS1_X*8 'PY^S*#T_P"&B++_ -1'
M6Z_2ZOS0_P""F)(\-_LRD=?^&B+'_P!1'6ZNC_%I_P")6]3HPO\ &C_AJ_\
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M&2^ 79Y9IYI7DN+J[N));F\NI9KJYFFN)I9&XS0/AC8Z%\7O'OQ>34Y[R_\
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MPO.$Z=>G0_=J-OW<.3FG=-SBY7NVSYM^'_QU\2^%]1^*FD:OH_C?XC^+=?\
MVIOB_P##WX=>$WUF;4AHVB^ ?AWHWCJ7PY#JWD:A;:?;06PU&+2HT@D%S?7\
M/VJ>WTZTGNK;J_'/[2]C?6?B+P1I6DZUX?\ $.N?#3XN7ND:Q::_IS:UX/\
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MHDLDMQ\*/A?=Q)!=?#OP7<01Z=HND)#-X;TJ2)=*\-3BZ\.:=Y;6Q5K+P_<
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M^5)V9S581<U)U7'2,M(QDTJ7-:W-]F3J\LDM]$T]U\'ZQKW[3NHWWP?N]/\
M!'QYT74Y/B/JGBF#5[NZ\82&T\+ZI^U!J$EUX/\ '/A?0==B\%Z/!I7P/-I=
MM?\ Q!_X2."3PW?PZ'X0TZ/4]-EGB@U_X5_$N33-5CUOPK\73X,\*7_PW\;1
MZ)X"NM=TWQ!>3Z-^VA\;O%/BUO"]MX>U#3]5UCQ$OPSUKP[XDATNUN?M4]C+
MHE]9(;^"V"_8GP9_:K^'/Q3\*^ -;U?7?"?@CQ!\4H8-3\$^")O%R:[K5[H6
MJW-S:^&GU*<:-I%MI.OZS-9W]D-!F$D;ZK87=CH>IZ]Y8N&T?B=^T./AGXJ\
M0:$?A7X_\::+X'^'^D?$[X@^*?!]UX6F7PAX0U;5O$NF?;D\+ZIK&G>(_$\^
MFP^$M7U?4[3P[;W=U%ID2FUM[J[(MF[/K&)A/V4<'3HRCS>[&\795(J4:=2H
MU&7+\$%#F:E4<8QNTG@J5"2]HZ\JD9)+17^*%]8PNXMJ/,V[)*"NT[7\V^"%
MS\1[[]H3X@^ ];\0>)KSX9_ F75-4TF_U76+B^O?%TG[0*Z-XT\&^%/%IEFE
MO[G4/@MX7M_$NDQVNKL]U;Q>(?#5VKNT22'Y<\1^"OCWX^^'GQ@\'ZMH_P"T
M5=^+=:^"'Q[TGXVV?B74]7@^'?B_XAWFL6LWP8L?V?$BU4Z>;)K2&]@DC\'0
M:=I$G@V<:+XOBFUVZ"+]]>(_VCOV?_ VF^.-<NO'?ALW7AKPQ/\ $#Q3IFB0
MR3^(M1T;3]*T.9M3M[1+6W?7[R'2M:\,QLL4]Q<V%GJ>CQW_ -BMGBV=CH_Q
MI^$WB#Q!HGA/2/B#X=OO$_B+38M7T'05N+F#4=5L)M*EUV.6QAN[:W66=M&A
MGU?^S_,74AIL,M^UF+:-I1C[?$PE[585P2C2CS*#BE.@E*I)_NTY<[E.NW>*
MA-J7->FHEJE2DE3==-^^]'S>[4FXQ25]+>[2B[WY-+)2;.V\/:3#H.@:)HEO
M+J,\&DZ586$4VKZE>ZQJLJVUM''OU#5M2FN-0U&[)!\Z[O)YKB5AF21CS6Q1
M17FR?-)R;NY-R;WUDW)ZMMNSDU=O6U^IV)65DK)722T5DVE9=K)6"OE7X9^&
MKWXS?M._%'XM>(=.O;KPU^SQXA;]GOX&6<]E-+INB^++KPIH&O\ [0/Q:T]7
MB:W?Q-K%UXJT?X0Z3KL#R7&B^%O!?BS2[26U_P"$M\0V\_U5]?\ /\_Y&OR_
M\!?LB?LT?$;]H/\ :[\,?&#P#K5_\01\9[7XNVVH67Q@^./A"/Q!\)/CGX8T
M;4/#OB2TT3P?\2?#?AQ4TCQOX>^)7@34Y],T6%(=2\+0)J,MU>78N)^3$.HG
M148PG>I)J,Y6BY0IRG"^C3U?NQ:LY1[J+.S#>SY<3*I*<+48KFA%2DHSJQA5
MWE#EC[.W-/F]U3:::DQ[:/JWB']@3]H/X]ZSHNIV_BW]IR36?C+KDE_IMS!?
MV/A*X\;:5X8^#'A&0R+(T.F>"_@]H7A&RT^R6:2UCU"^UO4X6>;6;J:7ZI^*
M6DZE\-_VPO@=\2](L]1L+?X[0^-_V;/B-##9W20ZUJGAGPYXG^-'P/\ $,Z1
MP[9-9\,2^%OBAX1M;^:19#H?CN33OWL5G916_P"45I^Q5^S#=_\ !.+7M:U/
MX9:S9?$OX<^$-;^%_C>*#XX?M#R6ND?$3X2?$P?#3Q/:MH][\48M+199="&I
M6UM)HUO:/8ZI97MG8PVTUKCZ1^.7[ O[)#_'O]EGX;:!\-/$<5UJWQ*^)OQ-
M\50M\=OVCKZ6/X:_"KX7^)])OYS+=?%ZYFTE;SX@_$7X;Z/;ZK:&TNI9[R33
MHKY([BZ@GXDZRY&J=-VAAY0?M)7<Y8B>K7L[MRE.JI)K6,GS::+T)1H<U2+J
MUN55\9&2]@E:FL-#EM^_7NP5.A*$O)2BEHSZH^#VACX&_'SXI?LZ:?;R:7\-
M/%/@^R_:6^"WAGR);>Q\!1:[XOOO!_QR^'_AVW9%BL/!UM\0KCPU\0_#.B6Y
M2S\/S?$SQ#I&F06^CV>GVEK]<5^=?P$^ /P>^&7[:?Q3N_@?X<U/0-#^''[.
MOA?X<_$:74/'7Q(\>0W/Q)^*/CRR^)>E:!!>?$7QIXNDTV_\-_#SP=H6N:Q8
MZ/\ 8?\ 1OB#X>FU'>\MJJ_HI7?AG+V<E.,8\M6I&*C)RBH\Z249-)M)MI:)
M))I:)(\[%\OM8.+E*]"BYRG%0DYN,O>E%2EK**IN[;<FU)ZR9\\_M->#O$GC
MKP)X/T'PJ)H]57XX_!36)=1AT#3/%"Z!I6B^.M/U#5?$EWX?UE)-)U;3]"M(
M7O[ZTU&-[1X(R)5.17Y_:9\/OVD?!L?PC^']A=?%#P!H'A2?Q1HLGB#P'X-\
M5^(M!U7XNS_'WQ%X@\6_$?4O#7@CQ)X:T33? ?Q \):GI>M^&=+\8:9JOPZ\
M/:!JOB7P[IUE9WVE1W,_Z*^*?C3>Z1\0;KX<^#?A9XY^*FL^'])\-Z_X^N/"
M=[X3TNR\$:3XOO+ZV\.Q22>*];T;_A)/$.I6VE:KJ\?AK0FENH-(M([N\N;>
M74-.M[G*T/\ :6^'TGAZS\4>-=3TCX<:-=Z5IE\E_P"(_$FF-&;W6O&_C+P/
MHVAI8PA-7?4-7O?!MY/IDAT\6^JSW+:5IK7=_87:#VZ%3%4J,8QP\*D'::O&
M,ZB]KS-2Y4IR7NZPC*&SDXI.;DO)J4Z-2IS.K.$K)2LW&+5-RDDI.*C=2]V3
M3;;:5FTD?$-GI_[0OC/QG\5K75_ ?Q9TGPE?:[\+=93POXFO/&'B31+3Q?X4
M_:U\+:E/?^%]?\5:M=Z5J%O#\*+:37[MOAYIFA>"[70(K>U6WO\ 4M)EN$]O
M_:G^!GB;XJ_%/1/"&DZ)?77PN_:/\,V/PW_:#U^PD6&T\+Z'\(]>O_B+X/U?
M4V2X@G)\3#4M3\$6<EJ1*7>SAG,MO&L2_2,WQ\^%MNEMJTWC+PQ'X'N_ $/Q
M#M?'Q\2Z2=%N-(N/%UMX*M8+?3!,VNSM=:[=PV$%Y!I[VSZLP\/X&M%;.F7'
M[0OP<:&*+2/B%X7US6-3\+:IXJ\,Z'9Z@\=WXGL]/T+7-?AMM-FFME@%Y?6/
MAS5YH+*9AJ(@T[4+G^SWCLK@*WB<4ZE.K3PJARQE%1C";@I3C"*E)VLJE*=.
MG-+XHRC'VB>K<2HT%"I"592YI1E+WX\UE.7NI)M6FI2IM+>+Z:27P/HN@_&O
M_A&_#OQ'^,G@[X^:8GCOQ3KFB_&/P]\")=3M_BX%^$_P\T#X9_ Z_:3PQJ&G
M:^? WB+Q-I'Q ^(5Q'I=U!9I?^-?#-_KUHFC?VHE=OH/PS^.VOZ'J?B#XO7G
MQ,UWQMI3_L=Z99^&O^$ANW\#2"PU?X?Z_P#%OQ#%X4TR9/#NJ^)K"]L+B3Q9
MXA\N=++4M*U"?13;Q7%Q)=?4^I_'FYM? /P0\8:%\-O$'C+7?CK:^')O#7@?
M1O$/AG2;S3YM=^'=Y\1[F.^\0>)KK2=&>+2=)T^[LS+N@DO[OR!##$DC>5/X
M4_:7^$'B/2O#EYJGB6/X?ZYXAUW6?"7_  A?C]!HGBC1O&7ASQ3_ ,(1KWA;
M6H8'O]+M;^Q\6-#HD-TNJ2Z3J]S>6#:1?7L=];[K>)Q3O46%A>4Y6<(*3BH5
M9Q=.$/>J1I\T)TYR;<:BA&+FG!)GLJ.D'6F[1BY.5E>ZBU*4FE&3<9\^][R>
MCYG;YC^ ?AWXDS_M$Z'XI\?:%\=?^$HTGX>?'C0_BGXD\?3WTWPC/B[7?BCX
M*O\ P?:_!Y+J_N--M]$U#P;I*RV)\+V5CI!T?3[2WU1'\16]]L_1>OGCP]^U
M?^S]X@\/CQ*OQ+T;1-*3Q5XI\&>;XECOM&=-<\'ZY<:#K*2^?;-%;V$=S%%=
MQ:G<S0V*:??Z?/=S6<TYMX_H<C'7^8/Y$9!!Z@@D$<@D5Q8N56<X2JTG2Y8>
MRBI)Z\MY-1O&-HQE5?NKFY8\D;OXGTT%",9*$U.\N=O2]YI1NTM-53BV^K?=
MA7YG_P#!3+_D6_V9O^SB+'_U$=;K],*_,_\ X*9?\BW^S-_V<18_^HCK=94?
MXM/_ !Q_,[L+_'A_AJ_^F*Y\?T44?B/\_P"?\\U[:V7^3?Y)O_+<X'N_5]^[
M[:A13VCE49,<F, YV-T(SG..F.0>A]<4SKSZT6_X&JMIVUM=;I*W7EO:22[O
M3L_^#IZ=_.ST"BBB@ HHHH_SO\^_]?GJ']?I^6@4444?ULNM[]/-_>']?H%%
M%%'6_7N%EV_I!1110 54N+"QNW62ZL[:Y=(VA5YX8Y6$+NDKQ NI(C:6**5E
M& TD4;G)12+=%)I-6:36]FDU?T=U^ TVMFUZ-I_>K,S#HFC';G2=-^1'C7_0
MK<821B\B B/.UW)9QT=CELX&$_L/10"!I&F@%G8A;*W4%Y,>8Y 0 L^U0Y/W
M@J@Y  &I12]G#^2'_@$?_D2O:5'O.?3[<^FWVNA2BTS38(9K>'3[**WN01<V
MZ6L*P7 *E6$\001R[E)5MZME<+]T ",Z1I3>46TVR8P(L<+-;QEHXU9W5%8C
M< KR2..<AW=L[F).C11R0LER1LE9+EC9*][+W=%?6RMKJ+FEOS2OWYG?:V][
M[:;Z];E,:=IZJJK8VBJGD; MM"-GV6,Q6P4A,C[/$3%#@_NHB8DQ&2M1G2=*
M,8B.FV/E!2HC^S1; ID,Q 7;C'G,TO3B1G<8+L3H44<L?Y8_^ Q_^1#GE_-+
M_P "E_\ )%&#3;2VG:X@C2-O)>&.-(XDCA6:;[3=- (XE=&O)PDUT6D;S)(H
MV 3:0S?[)TOC_B767 F49MHN!<RK/< ?+QY\ZK/*1@O,JRD^8H8:%%'+';EC
M9-M>[%ZNS;UB[:I;=EL'-+7WI:Z/WI:K71Z[:O3;5Z&;_8NC[G?^RM.W2.99
M&^QVX:21A(IDD(CS(Y6:92S[B5FF&?WK[I(-,TVVD6:VL+.WF165)8;>..15
M:.*)E5D4$!HH((F&>8X(4/RQ(%O44<D/Y(Z._P ,=UK?;>_4'.;WE)Z-:R;T
M=KK5O1V6GD@HHHJB0HHHH /ZT444?U_7_#!_PWR"BBB@ HHHH ****/Z_1:;
MZNR]7\F?UZ7:2O\ -VZ+S"BDR,X_S_G_ /7TI:/Z_3\'=-.S36J74_K71WU3
M36Z::U]5UT17Q[^U=_K/ ?\ US\3?^AZ%7V%7Q[^U=_K/ ?_ %S\3?\ H>A4
MI?#+T7_I2.O _P"\P])_^DL_JRHHHKP" HHHH ^5_P!J+X>>/OB%H_AN#X;^
M#;'4?&6COKESX/\ B=:_%G4OA-XP^#7BR^LX++3/%>D7>G>'=<?Q7X<F3S?^
M$O\ !TY6U\0VEE9Z;=:=J%O.9+3R6/X$_%7P9XWF\:^%/AO\-?$.N:!^T1IO
MQT77;/Q'I?@*]^+,/B+X0ZU\.O%FBZLD'AB_F\(W?A?Q-KFH^+[%KZ77-/UN
MSU&]L]/BT^_EED;] J*ZJ>+J4Z:IJ,.76Z:D^?FE*34G[124?>:Y8-1;;J.*
MJMR>,J$9R<VY*6EG%Q35DDG;V;BW:,5=IZ*US\N-6_93^+UWHGA*QU3X=?"3
MQSXBD\!?"71#XJUOQ=/$WP+\1?#_ .+>M_$+Q7-\/(KOPY<W^N6GC"SU>V:R
MOK2XT&\?5M*@MO$@FTGR((_>/V<OA?K?AKXK?&[5-524>!_AWXE\0_"?]GZW
MN+6]LY+#P#XJU^/XQ>.?+2\5%N;6U\8>)=/\#:-J=D9+*X\/^ ;"W@E;R9 O
MV?1UQGJ!@'VZX^F?YFJGC\14A.G+DY9I[1:Y6YJ<I13G-)R453=E&\')-OF=
MXCA:4)QE&ZY;63=^;W'#WG97LWSK=<T5M9!1117&=(4444 ?.G[5&A>*M=^$
M</\ PAGA+6O'>N^'?BM\!O'1\(^&WT9?$.M:+X ^-/@7QEXC@T1/$.K:#HMQ
MJ</A_1-1NK2TU#6=.ANY8%MEN5DE0'POP[KV@^&/B-KOQ=L?V$?VR-4^*&O6
M^H:?-X\\7/\ "[QKXATC0M4N5N;_ ,,^#9_%O[3.L6W@#PM=R1VRW?AWP-:^
M'M*OHK.RBU"VNTLX!']_\=P#[&DP/0?D*QE1YIN?.U\-DX4Y\K@I)27-:S:G
M*[W_ #.BGB%"FZ4J;G%N=W&M4I.49\KE"7(FI1O".EE?6[:]U_*!_:%\3?;O
M[4/[$O[6/]IBS_LT:F?"OP &H_V;]H%W_9WV_P#X7W]K_L\W8%V;'SOLOVL?
M:?*\\>97GNIWOAKXC?%3P7\0M<_8G_:U\(?$;3+K0M!M_BWIES\/O -Y:^'H
M-4$MMIGQ#U7X>_M%PW_C?X>:-+<W=Y=>&/%&C>,M/M+*?4QI>AO/>2PS_>.!
MZ#\A1@>@_(4I4I2LI34DI*6M*G=M6U^)6>BU3Z6V&J].+O"@X2Y91NL56>DD
MTTUR6DM?A:<?+J.;[QR5)R<E0 I.>2H 4!2?N@  # P*2BBM_P"NGZ:?=H<W
M]=7^+U?SU'QMLD1\9V,K8SC.TYQ[9QR>M?(VA?L^>.;&TT/PQJWCKPG=^#?!
M_P ;]8^,_A<:;X3UFQ\4M/KGBCQ]XDN]!U[4;GQ+>Z5=10_\)W-9VU[INE:?
M(!IL4TL4AN71/K:BM:5:I2OR-+FY;WBF[PY[2BW?E=JDT]-;W\B94XR:<KZ)
MI6DX[N+>S5]8K[D?!.@?L3P^'O%?@376\0^&_%6G:'X0^ WAKQ18^*M(\8>=
M<:C^S_:M:>&?$7A.ST#QOHWAR"YOL6M\MOXRT7Q6NA:O8P:GI<I+R69]=^*'
MP5^(/C3QCXTUOPC\2-#\%:-\3/A9HGPF\:&Z\'7/B+Q59:'IFL>,KV_U'P9J
M3>(--T;3=8U33/&NHZ;%<ZUHVLP:9<P6VI0VL[)]G;Z9HK1XS$.<:DIJ4HP=
M/WXQE'E<HSOR_#S*48-.W-[D4VS.-"C&+C&%HMWT;3ORR@KM6?P2E&SOI)H^
M"-3_ &+=8UCQEXMUB^^*<\_AB^^'_P 3OASX(TNZM?$M_JWA#PU\0/!>A^#M
M%T)8KOQ6_@V'1/ ,&@03:?\ \([X4T/6?$R7MTWB75KJ\5;F3K[+]G+XE:E\
M<O!/QG\>?%32=?/A"_LM;B\-Z7I7C*PTRPOU^&^K?#_4M"\+:5?>-K[PMI'A
MF\N]6N_%_P#:-[X<U+QO/J=W=:7>>))=*2VCC^R**KZ]B6K.HG[DJ?\ "I:0
MDG%I-JZYHRES-6;;>OO,2PU!.ZA;52^.?Q*UG:^J7)&R;Z?>?E^ P/R[4445
MR:]=S?\ K^M_S"O _C)\'-9\:ZMX4^)OPO\ %5C\.?CS\.+35].\&>,=5TF;
M7O"/B;PGX@FL[OQ-\)/BUX=L[FQU#Q'\,?%-[IFF:H7TF_L/%'@CQ3IVF^,_
M!U]%J-OJ.FZW[Y14SA&<7&2?2S6DDT[IQ?1IZI_FG8J$Y4Y*<7[R35GK&2DG
M&49+[4)1;C*/5=MU^'W[3'C+]H_X>Z1\<UL?V+/VAM=TS]HK1M-3XL> /@?I
M>A?'7PMI/QDT5=#L-/\ CA\&_%_A[5-$U+5/#WQ \,^&--\,?%;P7\0/"'P]
M\56NIZ1X/\=Z?:7=]+XOMKWZ&^%_B/\ :M^+/C+QY\9M/^ 6O?"#XJ?%FTL/
M"6E>,_VBK&QT;P7^S)\"](U&[UGP]X'\'?#*QUJY^(7QN^*6JZMJ=[X[^(US
MJ%G\-OAQJ_CZ72]!D\57G@[P)HJ:O^G6!VX[\<?R_P YYZTN/\?US_/FN2.#
M:J<[Q%9QW4+4EKS.3:FE=.\I-.,4TY2VYKKMECN:E[-86A&334JG/6ES745K
M!RLU:$$XN;34*:ES1BU4\S^$?PI\._!OP9!X0\/WFL:W<W.JZOXH\8>-/$]Q
M!?>,_B-X^\2W(O\ Q;\0/&NIVT%K#?\ B3Q'?A7E6VM[;3='TRUTKPYH5G8:
M!HNE6%MZ91177&,8Q48I*,59):)*]_OZO?6^KT9Q3E*<I2DW*4FG)R=VVK:N
MR2TMI9))))**22^?=<^%WQ*T[XJ>(OB1\*OB)X:\+0?$'2?!FF>/=!\8>";K
MQ?;IJ'@4WMGI'BSPA+8^(_#WV#6[GP[?R:!JFGZRFJZ-=K9:3J2PQ7%C+!>\
M7I/[+ITS5OAYJ+^+XKJ/P%KGPVUOR)-&'_$T?X>?$/XJ^/4A!-VRVIU%_B8M
M@DQ64V4FB"\59#=B.#ZVHKI6)K)<JFHKD5-M0AS2@H.FE*5N:7+3DX1;=XQT
M3LD8.A2;;<;W?-JVTFY*;Y5]F\DI.V[5]VSXDU']D346N] U[1/']A9^)/!>
MIZEXB\(G4_#$VH: OB&7]HC5OCSIH\0:;;:Q8SW^AQ1:Q=>$KNQM+NSN0PA\
M0V-Q;WEK;VXC\2_LO?$WQS\2-"\?>-OB_H^JQ:5%!>?V'IGA[Q9I6DZ1JK>!
M_%_@S4[+PEX=_P"$ZN/"=AHNJ3>+/^$COM5UO0];\;7.HZ>UG_PD,-A>F*W^
MWZ*M8[$QFIJ:<E&4%*4*;DHS:<TI.+DG)J[:L[V;;L0\-1:Y7%\K:;BIR4;J
MUFHWM=6T\SYPU3X,>+K3P1^SWH7@KQ?X=L/$WP!BT"&QU;Q3X:U+6=!\1KI/
MPNU/X973W6D:3K^B:A:/<0:G)K%LL6K,L$T4=K-Y\;.X\&\:?L2^+/%=IX?L
M&^-<]Q9R>);GX@^/[;4=&U^RTW7/B7JGQ<TWXK:_XQ\/>&O#7C#1] MGU2+3
MK;P+8:+XPM_&.D^&_#EI:WVEPMKCWU]>?H114PQ>(IN\)).\W=PIM^_*4Y*_
M+>W/4J22OHY;]"IT*4U:4;[6]Z:7NQC!.U]^2$8?X4D?GS\5/V./B+\1_!NM
M_#>'XS:;H_@74O$?QPU"VT<:%XO@SI_QI\43^,1J?B!?#WCK08/%'BKP/J>I
MZ]I'A^UU1)/ ]YHNL276K^%[O6K:"ZK] ;>+R+>W@R#Y%O;P;@,;O(ACAW8[
M;@F['8FI:*FKB*U:,8U))Q@Y2BN6$;2FUS2]Q*[E97<KMV5K))%0I4Z;DX1L
MY**E[TGI%6BE=VLNB:TUZZA7YG_\%,O^1;_9F_[.(L?_ %$=;K],*_,__@IE
M_P BW^S-_P!G$6/_ *B.MTJ/\6G_ (X_F=F%_CP_PU?_ $Q7/C^OSM_;)_::
M\9>!O$.A_!7X2W"Z?XW\20:9+K/B%4@>^T>+Q!=BRT'1M%-T'MK35-38_:;O
M59HI#I]G+;"U\N:9Y[?]$O\ /^?6OQ8_X*#?#[Q)X7^,.F?%FUCNAX?\5Z=H
M$%IK=LTNW1?%OAB(6XLIKA>;*XGAM[/4])9FC29EN8X"TUM*#^Q>%.6Y3FG%
M^'PV;0PU91P6,KY?A<9'GPN)S.C3OA(5Z<G&->$+U,1]6;?MWA^7EFH.$OSO
MQ QV88#AZO7R^5:GS8K"T<96PTG"O0P-2I..)J4ZD4Y4G*U*E[6.M%5'-N*E
MS+TWPS^Q'^TD_C6+4?%W[0&H:1;):)>W7B?PWXI\7:SXB.I>8%?2+>UU*XTV
M+? $W2ZA/</I[Q;8X;:;)C7]'O MO>Z%8W/A/7OB&WQ USP[':2W^K:M:Z1I
MGB.UTR_AFETV7Q-!I3Q6CO/':W<MMJS6=B;RWAE:8320RW#_  -^RW^U?X>^
M(FAW/@+]H;Q;92>,;/Q#:ZYX<\1^*&M-%TW7H+2>TO\ 2[2:_LDTZPM=9T'5
M+59[>.\,0U2"1':2ZFCGB;[>^'VF//X?\46-WXST;QHNI7^MV2^(]+UB3Q3J
M-M8ZG#=K#INL:_,RQ:C/HL-_]FTVQMH+2TL+.*./RC/<7$C=W'D^)7B:V7\4
MK!X;^S:N&H86679%AL%@L12JU816,P6.A@H2K450=3ZQA_K5/WH4H1PSE&HY
M<G":R)4*6,X?>)K_ %VG7K8A8[-ZN*Q>'JTZ4FZ&*PD\5*-&7MHPC3JK#U%R
M3G4=9\]/E^?X/VI?B+\0]5\1C]GKX%W'Q,\(>%=0N-)OO&VN^*K7PEINM:E9
M\W%KX9M[B!GO-R,KV[23-.\;0SRVL"75NC:NO?M/^*?#FC_ J]U[X/ZGX7UC
MXP^/KKP/J'AKQ-K M]3\-"TN]/LSK5J+.RF;4+6]>^DEL+6_ATRY:&!7E CF
MCFD\-^#_ ,0?&?[(GAF[^"_Q*^#7Q'\3V6F>)]6N_!7C/X<:+%KVD>*-,UB=
M9AY[B6 6UVLJJRH\ANHTG%I=6T36<<DTW[16F^/?CYHG[,M_K/PC\>^#A>_%
M36+?Q3X>C:6]USP_X5O#HEK;>(+[4='C$OA];[3S)/%)?1V5W874$^4VQ12/
MZ3X?R19UAL'+),JI<,.K7A@>(H9W]8Q>:8>.0X_%4Z]6C_:\85ISKTXXFI"G
M@\$\)7I4L#-J=1*IP_VQFCRJOB8YKF%3/.2B\3D\LL5'#8"N\UP5&I0IU7EL
MITHQH3G1IU*F*Q7UFC5J8V,73I<T?J_XS_&N^^$WC[X*^"8O"L6M1_%SQ9+X
M9FU*YU&XTZ30DBO=)M/MEK:I97"ZB[#4S(8)9K=08@@D._<O ^)/VE_%FK_$
M'Q+\-O@'\)I_BUJG@B8V7C/Q+J'B*V\*^$-$U+>\9TN+4)XI?MMW'-#-;NQE
M@62XAN(K>.9())CX#\3?V9]*^&'QJ_9FU;X8:1\1_$>FK\2K.]\6W^K:UKOC
M2ST.QTS6-!EL[NXN;I)H]%MW22[>>=WBCN8X=SDB$5J>$=2\7?L:^./B[IGB
M/X7^.?'WPR^(7B^;QOX6\;_#_3AKUY;7-U+<*='\061>)K6>..[\AA++"_VB
MW-Q:BZM+O=!SX7(.%YY;@:^5T\-G^;2R3%8C"8#'UIY0LVQ<>()X/$5,1A%F
MBG[; 99R3PV"AC\,\7"3Q34Y0C3EMB,WSU8W%TL=/$9/E\<TH4:^+PE..8/
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MT9T,'AJ=6=;$RH8:*<(3Q%2K6J2J2LW%+F^T\<>.>!_$+Q QO$GA[P16\/\
MAJKEN58*EDV-S2&;YABL=@,+*CF&=YGC*&'PN"CCLTK-5*]# 8;#X.A##T^6
MG"<ZD8+7Q[^U=_K/ ?\ US\3?^AZ%7V%G/X@'J#P>AR,@@]B.#VKX]_:N_UG
M@/\ ZY^)O_0]"KZ^7PS6SLM'_B7]=#\MP/\ O,-G>,[6::^%]4VC^K*BBBO
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MTXQTE&+:>M[-K=-ZTJT:KLHR@U%22EU3LWJFU=<RNKZ>MTNYHHHKF-@HHHH
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M(5RIPP5B-K%3PP!)4\'!IM?E!K_Q6^+/PH^(/Q'U[P]_PB'B7QA\7?B_\6=
ML=9\16U_;Z5X?\,?!7P7X5U3PKX$6T\4_&'PAX3BDU!O$MN3>Z1=Z+?V6G:9
MXKUP:/XDO+Y(-*].E_:1^)'P[UCXE^/_ (EZ]X(?X8>#O&'P9N_B#X$L;-[K
MQ;\*?AQ\1OA/X;U'4_%.BZ_8^([N'Q!X?T+X@:W8V]WJ\V@3Z=J]J^M7MC>6
MZB*"TVEEU73DJ4ZCE&+@DVIU)2<%RQA;?FFH+FY$Y63Y>:#E$<73L^:%1-2D
MI72M#E;U<G)*2M&^EW9MZJ,K?HC7YG_\%,O^1;_9F_[.(L?_ %$=;K[S^%VL
M>+_$/PY\$^(?'VF6&B>,?$/AW3]?UW1--CN8K31)]:0ZG::-LO)[FX^UZ5IE
MU8Z?JDDDQ$VJVU]-%%;PO';0_!G_  4R_P"1;_9F_P"SB+'_ -1'6ZY::Y:\
M(MIN-1*Z=T[2:NGU3MH^JL^J/2PCO6IR5[.%1JZL[/#UVKKH]=5NG=/5'Q_6
M5K>A:+XETF^T'Q%I.G:[HFIPFWU#2=6M(;ZPO(2=VR>VN$>-RK /')@21.!)
M$Z. U:M%>Y3G.E.%2E.=.I3E&<*E.4H3A.#O&<)PE&<)Q:3C*,HRBU=-,\^<
M8U(SA4C&<)Q<)PG&,X3@V[QE"<91E%W=XRBTT[--:+Y7/[$_[,1O3?-\+[-V
M,_VC[$^N^)FTHMNW>2VG'6# UKGC[*08=O[LJ8_DKZ0T;1?#_A/1K71]"TO2
M/#7AW2+=UMM/TNSMM+TC3+.(//,Z6UM''##&BB2>XD"%Y"'ED9W+,=BH+JV@
MO+6ZLKE6>VO;:XL[E%)5I+:ZA>WN$5P"49X9'57 RK$, 2,5Z>.SO-\W5"EF
M^;9GF%"E."C#%XW$8I4HMPA.=*%>K./M%24K2Y7.5HQ=36YY^&RO+LO]K/+L
MNP.#J5$W*6'PM*ASRM)Q4W2A&7+SV;2:2NY*#:2/!/#'BGXO_%#2XO&O@K6/
M"/P\\":N\D_@V'7/#&I^+_$_BG0X9[B"V\1:X(?$7A[3]"T[Q"$2]TS2K);S
M4XM,-O<7.H037#P)3U_XK^,/A]K/PAT;XCQ>%+1_&FJ?$'2_$=WX3M_$>L)J
M8\-:##J'A:;PMI@CDUF#5/$%Y-&EUX?^R:Y/ Q:WM;N94:Z6OX%U'QY\'/#&
ME?#37/AMXP\=:;X0@30/!OC/P F@ZE;:[X:MG=-!B\1:5J>N:1?>&M>T[3_(
MT[5)9EN-&NWMEO[?4(Q<&!=&\TKQ]XM\?_ 7QKK/@E/#4/A;5_BM<ZSIZ:]I
MNM7'AS3->\(0Z1X8EU6[M_(@?6=2N!)%=VFAC5+;37)3^T)8]\U?1RI82.-Q
M+KX3)I9)&GF,L!6H5L%'%UZ4<OQT\!:NL75QLZU22P\J\L9A(U*.+E*$:5.2
MHTJGCQJXF6%HNGB,T6:2E@HXNE7I8IX:A4EC,/#%1E16'CA:=*,9UH4%A*ZC
M5PRC5E*I"4JBV[OXU>%[_P '>/M9TC6I?"FJ>!=,BN_$-IX]\(^)+/4/"T5X
M0=/U/6_"1CL-;U'2;Y%F-K+I,TL5T4=8[D3031IK/\3;+0->^*)\5:EIN@>%
MO %A\/[R/5V-U#.Q\7:)=W]Q'/Y;SRWMS/?16UII%A86PNYGG%K%#=W,JUX[
M\9/AOXV\4:[\<+S0= FU&'Q=^SOX=\#^'IEN]/@_M3Q38^-]7U:XTD?:;F%H
M3;Z==0W/VJ[$-EMD:..X:97C74^('P\\::MX@\6>)M#T>#4Y]'\9? 7QYX=T
M&_U"TM+#QP?AQHFJ6?B#P^\TK/%97L#W_GZ-<ZFEO9#7+6PF,IMU>9*PV6\/
MU*$'4Q%&C#&4Z-6U7$X:>(P=2K#+YRI+$2A2;?M(U\/"OB*35"G7J5JL&J%5
MN*V-SB%=\E&K5EAJDX)PI5HTL1&#Q<%4E1A*2:Y(T:SI8>=ZM2C&$)M5::.@
MU3X[:9<Z]\.-"T&UU;3]6\8_$+2?#M[I'CKPGXB\*ZO>>&+S3->N;O7/#]MK
M-OIWVT0W>FZ>CW$9NVLHKM1J-A;R3P[>FTSX^_"[4UG?3?%;S:=9:+?Z_K.L
M+IFMP>'?#NEZ9+>07,GB;7)[&'2]#NWEL9UL=+O[B+4M07R)K2TFCNH'DX?Q
M-=>./B1XK^#=]9?"WQ)X=T3P1\5--\3^)-5\;2:!8ZS8VJZ%XATR?^P].L=8
MU66[M$EO(DUC44GBCNHWL4TZWU%//FMN5T[X+>*)?V6%^&EO9)X;\:G6KKQ?
M/IO]HV]G%J>NV/Q*G\7V]K?ZK:+J=O;OKVG6=C:C4&BO(K"22R>XMVBM9+<5
M/+.'5@\N>,?U#$5,51PU>%+-,+BYX:&+S'%1GBL54I1JNM'#8:E2G3@^5QCB
M'[6JJ*BF1QV<+$XU8>V+H0HU,12G4P5?#1KRH8/#SA0P\*E2$*<Z]>K-5JCY
ME+V-Z5/VO,I>Z>&OBSX/\5:U:>'K+_A(M*U?5;:XO?#]IXJ\*Z]X3_X2BPLX
MHIKN]\,R:Y86<>JQ6T,T<US ACO[>WW7<MBMH///,']HOX4BVM]475M<N/#4
MMW)87GC&V\'^*)?!NAW\>H#2FL_$7B3^RQI^CSKJ!%M*;AS#:,5.H2V2R1&3
MD_#/ANZ\2>-O!&IZ_H'[1I;P;K[^*$O/BAXV\*R^'/#^N0:9=V"-:V^D>?=^
M+9+NWU*ZT[=I@BTXV\LEQ=W(\I+9FV'P_P#%UO\ LH>(OANVA.GC*]\!_$72
MK701<V!>;5]<U+Q%=Z9"+I+C^SA+>_;K6;SY;D(DDH:>6.179,*F6</49TU4
MJ5W*KB\NPTZ7]HX>$,/#%UL52KXN-=PQ,JM.C2I4*_)65*E"I*:G/ZK5HM:Q
MQ^<554Y(45&GA\;B(U'A*KE6EAX4)T</[)J@J=2K5G6I7I^UJ3@HRA#VE.I"
M7HMQ\8?#^G:E?:/JVE>)(-736]>T_1=*T;1-2\6:GXCT+P\VFPW_ (UL;+P_
M97DUIX:2^U)---U?"-1J$$UG%)/<CR:]#T'7-.\2Z19:YI3W+Z?J$;26YO=/
MU#2KL!)9()$N=-U6ULM1LYHIXI8I(;NUAE5D.5P5)\.\=>'#</X"O[[P3\4[
MC7M#\&VVE1_$'X3>(=,L?%WA^YD@L(]2\-W]C=:O9G6='N[BU2_9;JSUO1C>
MPAY((7!NSZ1\+CX\/@;16^)<AD\7LVI?:VE73UU!M-75+P>'VUL:.S:/_P )
M$="_L_\ M_\ LG_B6_VH+@6G[H#/EYC@\NAE]'&8.48577]A5I3QD*DIV>(I
M^TPU&$ZDI4&L-"O*=5T:M&>(]G*%6E*A-=^"Q6,GC*N&Q"<J<:7M(3CAYPY+
MQP\^2M4E"G:HY5YP@DJM.I"B[5*=2%:,NWO+2#4+.\L+I&DM;^TN;*ZC622%
MI+:[@DM[B,2PLDT1>&1U$D3I+'G?&ZN P_+[]L[X;7/AW5/AQJ'A^VAB\'6O
MAA/ OA_0+-;EWT:7P^EYJ\L2^89/-BO[.X>6-S*]S+<6=S)<%W82']2J^;OV
MI-&&J_#K2IK?3-4U?6-,\?>#;G0]/TBWGGO+VYN]2.F:C9Y@CD^SP76BW>HQ
MRW4WE00D1>9,@8@_5^$O$F)X=XXR.K"HGA<3B:^$Q%"HTZ%L9@<1AGB)1G4I
MTX3I>SI)XA3A4I4?:Q4XPG._PWC%PSAN)> L^HRIOZYA<+1QN%K48OZRY8'&
MX?$K#*4*=2I4I5O:U6L+&$U5KQHSY7.$&OC;XA_":/1?@1\&+W1H[S4?%?Q%
ME\"^'=3ELU2;298I_P#A(M?T&%T6'SS?1W'B*.Q$WFGSX=,6W2-&CS)Z#^QM
MX,OM5T&;695DTV3P7\6DUG3+^XT^1DU2T?PCJ?ASQ/H]E=.(=@EDGLA>$-)]
MFN;. 2Q"10!]!:]\,?%6@?"GX5> /#+P^([_ ,#^/? FH3ZW>06MC%H^@>&O
M$%QK-QJ;:>UPYNAIM@$TU;:VEN[JY4F41R%BJZ?[,5MY/PNDG_L_5=-&J^//
MB'K:6NL6<EC<B'4O%%Y+:2P03I'/]DEL1:E))(T9IA. I1%8_H>>^(.)Q?AM
MG^%IXW#XZIB>,<=[+&>U2Q7U/&YSFCP\YX-V>'PM;*9/#T*%6,XJE&<KM>SF
M_P TX?\ #G"X/Q/X?Q5; 8G+Z6'X+P#JX+V3^J/&X'),H^LQAC8QE'$8NCG,
M88C$UZ,U+V[A"_-[2$?&_B+^P!\+O%_Q&\1?%?X;_$[X]_LQ>/\ QW,)_B-J
M_P"SE\1E\"Z5\0[T*R#5_%GA;4M'\0^&[C7<R/+-KECIEAJ-Q-)+/<327,]Q
M//RWP]_9B_9B^%</P-UK35^)DGBG1?VBM>\86WBOQGXTU#Q;XZ\;?&Z;PKXE
M^&>J>(?BSK>J&ZEU6VAT87$%O!8#2[&REN]**P".>Y23]$?IQTKY]U7X7ZQJ
MOBGXBW$K0KX?O="N=1\"XD7S[/QYXB&DW.OWK1D'[/%:ZGX0T"ZAEV(&;5;]
MD5G\R2OP/(,FX:Q.(Q<\W4,,J<:6)I5(U)0]I.5=8>K3HTY.="%>5?$X+'U)
M1HTW+#X#&)S?,U+^A>(LZXGPN'P<<FE4Q3JU*F&KTY4H5(TZ:H^WA5K5$H5I
MT/883'X"G3J5:L88C,\ XQBZ:D>>7'[-_P #_B!\6?B/XUO(O&;>,M>^,?P-
M^)FL"/6Y+?1[CQK^RA86]OX'GT:"WL7C@T33[CQ*UCXITR[NC<ZY?I.L0MX;
M1BD.M_L)_"?4M#M;/PYXC^+'PX\9Z!\8?BQ\</"'Q=^'?BV#0_B?X&\8_&W5
M3JOQ+T_1-8GT;4-+F\&^),K9W7A37]'U;3WM;>SFE,M[9QW1[B?X?^+W\-:'
M;7ZZK-=2^!?$%QXOA\-ZI8VUY<>/_$?C3PSXMOUM;74[R'3=2@BDAUFT9+N\
MCAN]*A?2%OX%O8Y%ATSPMXM2[T"?Q;X!OM:2+2]&L_#-MX:\5MHVF^ KO3]9
MU*:^O-8M9_$_F)<:G8OI.K7D]E>>*A%-!<^&8'>SBAFN/6Q'"/#E=5JV%S/+
MU&,Z]&5)SHRK5IT%.,Z]"K6QN"O]9JX>>*?/.E*AAI4ITJE>O5I8<\G#<9<2
MT)4:&*RG,'.4*%155"O&A05:4)K#XBE1P6-<9X:C6IX-656G7Q=.M&I2H86C
M7Q2Y'X7?L)?!;X37WA;6=%O_ (H>(==\,_&[Q+^T1;>(_''CBZ\4:[KGQ5\9
M?#5/A=XGUSQ%J5S812ZQ;ZQH EOI+']RL&LSO=6TD=H([);'Q._8J\*?$#XE
M^(_BMX3^+?[1'[/_ (T\?Z)I/A[XLS?L_P#Q'_X0*T^+FB>'[=;#0U\:64^B
M:R%UC2M+\W1K+Q7X?;1?$=OITRP0ZDDD22UKVOP^\<BPU*U_LW6+/Q9-HGC>
MP\7^,Y?%\AL/B'>ZXLR:#/I%G%JDTNF?9YW@U&)Y;#1#X96V.F6<ETD@9K_B
MSX9ZO:)K5IX6TC6+O04U'PQJOAK0;/6X[[39=8CT#6M,UXZWI^N>(=,O'TF[
MNY=(:ZDM-:M;VSN577=/BGN+6:*:%P=P]SPPBS[+US585(N%*,(1E34:2K2J
MPS./L_:QQ$I8;GK1E4P<L1+&QPM6$\-._P#7?B-PGC5P_F+=.C*$U4KU/:/V
MCE6^K^PJ95-3E2=&,<4E1E3ABXX:. EBJ52GC(=5X"^"/P]\*^,?C-XQ\,R^
M*-0\1_%O3? '@[XE7.M:[JNM//'\+/ 3> _#9MI]2B-W_:DGAG4S)KFLO=ZA
M+K>K2MJ4\_VL3I7 :K^R+X3/P9^$_P $_ /Q4^//P8T;X*:1_P (]X&\5?"C
MXCMX>\8'0I=-DT>_TCQ5)>Z/JGAWQC97^FRS6[P:YX>N$T^>4WVD_P!GW@\P
M]:WPZU[7]5:7Q?8B736U#QWJD>GVGB34A96UWJOA7P/8>'UM3:WEG<R6]AJ^
MF^(!8BXV_9#C4'MTFNP[>P^$[?5K/PIX8L]>D:77+3P[HMKK,KSK=/+JMOIM
MM#J$CW2$K<N]VDS/<*2)F)D!(;)\O-,BR?!T*3PN-PN.G+DHU:%!1<:2KP6)
MDZ>)IUG.NXXBE/VSY**A4E0475@ZC?K91GV<8VO46*P&*P$:<95:-?$-WK2P
M]3ZI!5<)5PW)1;PU:DZ*YZO/3IXA5(PG&GR\C\&/@_X#^ /PN\&?!SX8Z7-H
MW@7P%I3:3H-C<WDVHWICFO+G4KZ^U'4)_P![>ZEJFJ7M[J>H7)6-)+N[E,,,
M,(CB3TZBBO+A"-.$:<(J-.$8PA"*LHPBE&,4NRBE&*Z))'K5)SJ2G4G)RG-R
MG.;>LIR;E*3;UNY-MM[O4_+_ /X*JKO^#_PO0$ M\2]24$G'+>#M5 )/.!DC
M)QP*_HL\!WNB?MH_\$K_ -COQW^SKXQ\.Z_XW_9*3X)?$34/ U^WVJ:]^(?P
M1^'^K>"O$/PJ\7QV-Y#J/A"[U-M4O[W3-9FMKB.2V@T[4+>UNM*U%+Q/R"_:
M9_9PTK]I?PMX9\+ZMXLU+PC%X9\1S^(X;S3-,M-5EO)9M*N-*-I+#>7%LD4:
MQW+3"5'9BZJA7:2:^8_"?_!.F^\ IXAC\!_M2_%[P/%XNT:7P[XKB\'V[>&8
M_$V@3.DDNC:\FB^)+)=6TR21%9K._%Q"""%10S _H-5<,YYP9PSEN)XD>0YY
MPWG^:9K05;)\;F>!KX?,4L)BL+BH81PG:O@*E>,)T*L9TZDW&I92C4H_!J/$
M&4\7<1YAA\@CG61\19'E^65U#-<-EN-HU\!)XK#8G#RK\ZO2QM/#N4:M-QJ4
MX-P=URU/'_VR/VC-"_:9_;_^ ?C+2-"U'POJ/A:/X1?#[QGX=U&YL[]M$\;:
M!\0]?O=<TFVU/3Y9K+5;6Q75K2$:A;-Y,\HEVA=C(GM_[0O@73-8_::UWQ!X
MX^"GQ!^*WA"[^ -KX=\*MX+\.ZIJ+VOQ&'B34;BP:SURQO=.A\-:I:V<CNNL
MW%VB6(N(G=)!( <?P1_P3-\)>!_&7A'QC:_%SQ+?S>$O$FC>);?3I?"FCVT-
M[-HVH07Z6<T\>IR/#%<M#Y4DL:,Z*Y95+ 9_3AG)+]@[%BH)Q\QR1CO]3R:]
MK/N)^'\KEPSAN%*E7,<#DW#F,R-JL\?E]6E'$8[#XJ,J==+V]TZ4N24+SC2J
M3I3G*:52IXV1\,YYF2XCQ/$\*> QN;<083.8NBL%CJ=5T,'B<+.%6A&:P]N6
MM&34U&,JT(5(045:'Y0Z?K?[8OPI\$:IX/US2_BEXGUZ^_9PTFW^'%UX6T6R
M\7Q>%?BA:^(KR>]7Q-X@\NXSK>D>%&M+.YDU&?4(]1EMUAL+6XG=,R>#A^TU
MX0^,/Q#U32_#WC32_"?Q'\7:1J?B'4M.T!C-XJ\;VOP;TX>$8?%YDMO]%^%T
MGCA9H?%6JZ.B3V6IQI;7$UI:HYK]60Q7H2.<]3U]?K]>U )&<'&>_MW ] >^
M*^=J<9TJU/%PK<,</U7C^66-YZ$Y4:U:E7CB,/7AAYT)TJ53#XB%+$TFU5Y,
M5!XI<N(<:M'WX\'U(3PKAQ'GD(X&5\'RUHJI2A*'LZM.595E5JQJTI5*,[^S
M?L9QH)NA&4*OY^?L]:K^U+XDLOB)8>/=8\4:?K<WPSU&"TM?'?AFZTAO#GQ=
MN#?6]E>^&=:3PIHN@2^'8G>-YM)TR]\36MFEO9:C!J,BR31-I6WA#PY?^%_A
MKH'A#X;>,OA_\3-,\;?"V?X@^([_ , :@/$UH-.U6-O%NKW_ ,0=3TZ^T;Q=
M<3ZB)]2CU==7UR$QRPZL(8DMTA3[QW$@ DD+T!.0,^W3M_G)H+,0 2<#.!V&
M>HP>,'H1C%<5?B>57%5L50RS!X%5*E&M##X*4L/0C4I86MA7&M"%%+%T)*NZ
ML:5:"5.M2I33J>^Y]M'AJ-/"TL/6S'%XUPIUJ,Z^-4<17E3J8NCBXRI5)U.;
M"UHRH1INK2J2<Z4ZT6J3E#D^'_&8^,^L^&/'/@348?&/B#PU'_PL:PLS<:1'
M+=>)H_#WQ5^&[?#S5K^6TLK:'4M57PK>^*$L;ZV@MDU/3[*[O98'GAEF.+XT
MO/C!J.MPZM'#\3+SX@^$M7_:'U*'3H_"$<OP^\.@^"/&.G_"6^\'ZJ='2VU6
M35[=]&BM535-8EU>_O;J'7+:SNH[:&OOK)XY/'3G_#TS1DXQDX[#)X^GI66&
MXAIX:4W3R7*X>TJ3K5/9THTE6Q%:E"CB:U>-/#6J2Q5*G3IUVE&K-4J,7B%1
MHTZ*JMP[*L_>S;,'I"$>>7M'"G2J2J4(TY2Q"G!X><I2H>].$.:HW2E5JSK+
MXWUJX^.FC>+?#6AVWBSQ0^ERZ'\/KW2_$FI^&+_7=/U_Q3?ZS)-\2-+\7VWA
M#PC=VFGVT%EY&G:18:A>^%--T+2;A=2L]4N[RSN&2]H/A[XA>,;?POH?Q+U+
MQOK'AGXA6_Q>MOB%H6I6FG:=IVB6?AKQE:WGPWL[9]-TNQO=-CU?2+3[#<I=
M7MP/%>D3SQW'++*OUUGKCC=C.,C.#D XZ@'IG-&2>I/K^0Q_D]:SEQ!)P@H9
M=E]&K"#B\13H48UN=^VE&K"7U>].<:E2G5C9I0G0IJFX4G*DMH9!&-2<JF8X
M^M2E-25"K5G*E[/]S&5*477:G!TZ<Z4^=/VE*M-34ZMJIX9\"M7\9ZGI'BBW
M\;/XBU+4-(\1M9V?BK6M-OM!T[Q9:S6L=S)?^'/#&K:#X?U;PSI^G32?V3>:
M3/#J>GK?VSS:-K>H64I9/+_VKO\ 6> _^N?B;_T/0J^PB2>I)P,<GL.@_#MZ
M=J^/?VKO]9X#_P"N?B;_ -#T*O'Q^(CB\1B,3&C3PZK.,W1I:4XR4:49.*M'
MEYYQG4<8QC"+J.,=$CZ')</+"K#8>5>IB'2A5C[6K?VDD_:2BF^:?,H1E&"E
M*;G)04I>\V?U&>,O&GA'X=^&M4\9^/?$NB^#O".AQV\NM>)?$5]%IFBZ5%=W
MEOI]K+?W\Y6&VCGOKNUM(WD(4SSQ*2 V0NJ>,O"6B:]X5\*ZSXET73/$WCJ3
M5XO!6@7FH6\.J^*I/#^FC6-<30;0L9-1&DZ45U&_> -'!:,DA?$D8;S']I#X
M?W?Q2^$.M> [718?$4>O>)OAK_:^B7,UO!;ZCX9TSXE^$=6\60S/=R1P-$/#
M-AJTC0EO,G"&&%6FDC1OD?P]\ ?V@I-:\.:]XDDL%\6?"&]\3_!7X-^*SJT%
M\UK\)-"^%OQ1TOPE\6-60GS;?Q%XY\7^)O =OX@TR..XU"TA\%6%S.K0LP3P
M\/A\-5I*=7$QHSYZT)0;27\.*H26CE:57F597M&%I4[2:(J5:L)\L*//&T&I
M*]]6U435[.48VE!KW>:ZFM4?I>89@RH8I [J65"C;F5>K*N,E1W(! [FN8T_
M5_#?BNY\2:?:&VUB?P'XJM] \0P3V$DL>@^+K32]'\26MOF\MA'_ &A::=KN
MCZE;7EFSBW>[C\J=;J.5(OS!\$? CXMZ+X(TNV\6^"?C'XM\/'Q?\-]0^,GP
MAE\4>&M!G\:G2? _C;2=?UOP?J]E\5]5G\5&/QSJGA?Q)XPEU?7_  5#\0X=
M(TR]32%O-.NK>7T_1_@%XYT#Q;JWQ4\)^!]:T;QC>_&72+[3]&UGXFZC/&?@
MXG[,VG^#;KPKXAN[37M0TVZ1O'^GZ?I.M:O'!J'B&>_TRU\4VE[=&SL[P4\)
M0CS)XN#E=JG*/(H\T9M.,N>LG'1.[BI02<6IR<G&$^WJ2:M0:5XN:;=^62ND
MM+73L[=6O+7]!VT.P;4?[1?1K-M7:)8_[0;38&U,VXBFMDC^V&$W9A$%S<6Z
MJ9"GDW$\7W)I%?$L+7P?_;EQH&F:;H*>(= L=%U>?3K+2+:&^TFPG@U31= O
ME,5HBV\:VMGJ^E:>UO();.S2\LXU@M9S'+^9/P>_9P^+FO76DZ-\6O!WB+0_
MAC<_%_PQXOU[P4OBJ[\-Z=#IL7[/OC?PYXLBAL- ^)WC/5KKP]+\5;SPY^ZO
MO$\UYXMN+6R\9:KI%K*\X2]XS^"W[0%_X%T:SU+1?'_BK6=%^&WP*L;#1;;Q
M/I>M:/XB\=> (_C/;ZII'Q.LK[Q[X-O]3\+7\'B'P6NN^(=&\1PZ_;ZTFA>*
MD;6)/#-U:ASP=!2<?KT&]$W=<C;T25ZK32=[[<L=>>2]U"KU&E+ZNUS>2OHM
M;I033MHKO5Z7ZGZ(:K%\,+BV@\.ZS9>";^QU751\.8]$NM,TC5+"?6+>TE\2
M#P3<Z>+6[M+6YM;6V?7&T6^BMTM1'%>-#%)-;M+MW47A'X?:)J&LW5OX<\$^
M'- T::\U34GM=.\/:1I'A_3/M=_--=SI%:VMGI5@T]_>$$K;P23W<B()+B3?
M^?>F? ;XI:!XA\72^"?!EUX#\5^(_P!IFZ^+&J>.+#Q8+WPK>^%_$'P#\4Z#
M81Q-=:W/JVJKX.^*=]"^IV6H>'[::Z$NEZK$NIQVRBQ]6^''PWLHOV=?'O@C
MQ+^SW\0+>;Q!X1T[1OB#\/O$?Q)TO7]9^+/B5O"UGIOC'5O#7B2Y\:ZGI^F-
MJVII<SVNO7VI>%I=<U&.#6);'3IRDBQ4HTDHM8ESCS0A*"G!R7/9N?(Z_)%-
M<R37.N9?O'3A[Y4*M23DG1Y7R2:FU)Q;U=HM1<D]?>O96T2TT^G?!GQ&\"?$
M/3[;5?!'BK2/$MC>/JL=K)82RQSSOH,]G:ZV$T^^AM-2VZ1<ZCIT&H2-9K':
MR:A8B5E%Y;&7MXXY)'5(T9W=BB*H+%F&,@8ZE006_N@@GBOS2T/X-_%K7_%W
MA/Q;\0_"GCGQ+=:5HWQ\^&?PN\;^,]>\,K\5OA[X4\5:/X'N/AAXF^+DOA+Q
M!8Z/K=Y9:YIWCFQDUC1XO$'B7^S;GPQ<>);:\U7[1>V]"?P1\>O%MQ;ZGXU^
M$?Q)D\!Z3HG[+'A?QQ\-$^(OAZ+Q%\3;+X:Z/\5;/XFW6@2Z-XUM+%M-7Q=X
MC\$:[<VNK:[H%W\1='T%1>O$!'9"YX.CS_N\5245%RE>5-VDE4M2BW-<S;A&
M#;C%PJ2U;A[[2KU$KRHSE+HDI--<L6V[)VY7)MI73BHN_,W%?I#H&OZ1XITU
M-8\/WJ:GIDE[K.G)=PQ3QHU]X?U>_P!!UFW"7$4,N[3]7TR_LI6\O8TENTD;
M/"R2/L5^5O@/X5_%+PAXE_9\^$_E>(?!_A[XIV?B3Q+\6_"5WXZOO$FL>!_#
M_P !_C#KGQ,\,"/Q):WES'J-S\1=-\>>%?AUXQU&VOUN=5@MH5O);]4NB?U4
M9BS,QQEF+'  &2<G ' 'L.!TK#%4*=":5.LJT)\\HM)7C!3<(*4E)IN7)-JU
MTXI33Y9QOI1J2J1]Z#C*-HROLWRJ5UU=U):]TU96U;4#VMM+/;74MM;R75D9
MS97,D,;W%F;F/R;DVD[*9;<W,($5P860S1 1R;DXJ>BN;[ON7X::?*VFCNM#
M;_A_FK_YLYG4?!/@O5QI8U?P?X5U4:'?RZKH@U/P[H]__8VJ3SFZN-2TG[79
MS?V=?W%T3<SWEGY-Q-<$SR2-+\]-/@7P0TGB";_A"_"1F\5).GBN?_A&=%,O
MB:*Z6..Z3Q)+]A+:W'=".);@:H;E9RD?F[V5".HKP[]H+1/B!?\ @2T\2?":
MT;5OB?\ #3Q5X?\ B+X*\,R:LNBZ=XUO-$EN++6? VLWL\\%DFE^*O#.K:WI
MKMJ+&SMKY["_;;+:1NNE.+G*--5'34GRIRG-1BV[IM\VB]HJ;;=U=\S3:NXE
M:,924%)Q4I**C&[T5TKK=K3S2MLK'L6E:#I7A_3X]/T'1--T+2H#B+3]'TRV
MTO386*QI^[M+*&"UC9DCC0[(U+(JJ<J% \C\9:K^SW\*I_!4GC:+X7>";Q+_
M %0_#TW_ (?T:UOK"_GGAFUVZ\+I9Z5/=:.KW.IP2ZUJMHEG9I=:C!+J-VLU
MW&S_ "[X!^%WQ;^%/Q;\-^((_"/C7XHV^D?!ZXLO''B/Q!XBT<17WBZ#PI=Z
M_/!\(=2N?',#177CCXCZI?Z'KOA3QUX1M=$TU(H/%>E>*=-L[>VLKCU/]I'P
MY\0-7G\$^*_A3X,^(T7Q@T/0-<A\&>-O"&O^!+;0/#]WKMUX>FU3X=_&'0_%
MFII9^(_AOXB:PM[S7I]+T[5[FQET#[1H%Q8ZW-IEU+U*C!5X1>(YZ=6+?M/:
M1IWG'G474E*;Y8MQ7/)J<_92M&,N:45BZDG3E)4^64))<DE?2\9>[[NM[V7*
ME[R>UN8^LKJUM$,6K7UM:QMI<-Y-!JMY%!&VF6[PYU&2+49PHL;=[> -?R)/
M%$T%ONN&:.'*^->#O%7[/'QJ:*3P1>_##XDMX#GM=3LI-/TC2=5;PM+K,MS<
M6&LZ*;W3@]C;ZQ<6EW<V6N:+MLM2N+::>WO)Y8F>OB+QA^SK\;?'MS\1?#\>
MD>(/#7COQ</VD]/\;?&?4/'<UW\,_B-\/O'WA;7]+^$'@32/"4'B.\U/2[30
M[[4/"=L^GR^%=+_X0VW\):W?V^I:C-XC:*^^\/A9XI\5^)+-8/$OP5UWX0?V
M'X>\.:9'#KFK^"=3AN[Z"WEAU#0O#B>#]4U5F\->'##$FFZKJ']DQZG%>+]C
MT:U\B>E5H4Z5)RAB%6G;_EW4A'EA9)3Y5/FJ0G)U%!0<6DKU:<)RM,A4G.:B
MZ3IP;>LX2G&;MJN:248\K5FG"2D[.+E'4[!? G@5(]?B3P1X.2+Q7]H_X2F-
M/"^AI'XF%VXENQXA1;$+K0N90);@:D+D2RCS'#/\U;6EZ1I&A646FZ'I6F:+
MIL&3#I^D6%IIEC"2%4F*SLHH+:,L$4,4B!.U<]!6A17&Y2=TY2:;3=Y-W:V;
MN]6EHFU=+166ATZ=E]R^[:_RO8****0",0JLS$*JJSLQ.%5$4L[,3P%5068G
M  !)K@?A]\5/AQ\5X;RX^&GC'2/&UMIZ6LMW=:$+V:VCBOEE>SFCN)[.WANH
M;I()9()K1[B)T0OO"E"W;WD;S65[#& TDUE>0QJQPK22VTL:*QR,!G903D8!
MSVK\S?"OPN^*EE\#?@W\/_&/@+X_>.-$\!:IX)B^+/PY\0^._ 5D_B'1-,^'
MOB7P]%H_PPOO"WBK1/M_A'PQXVE\/>(+[P]XCUK2+C5[.ST^[2YO9=.DT^7I
MHT*=2G.4ZOLYJI3C&\XI.+IU*C?+*SG[T(TE:4(J52+E)P4F8U*DX3C&,').
M+;:4F[\RM9J+27*VY74FE%V4G9/]/O*EVE_*DV [2VQMH;=MVDXP#N^7:>=W
MR]>*KSZ=#//9R7-C'+=6<LEQI\D]JDES:3O!);37%B\D9EMY9+:6:VDFMRCO
M;32PLQCD=3^;'_"H/B^_CRYU/3O /C_1/$[>,+S5M ^(E[\5H]5\-^'O@ _P
M9;P]I?P+O=/'BJYFU7Q+:>*V_LNYBDT&ZL9==!^(S>-+NX1)7I6/[.OQ'\&>
M#?!WA^R\*^-O$7@B70/V8-9^.O@&S^)NH7WB'XBZ_P"%](\>Z?\ &33].U/7
M_%<#W6J76JWW@'6_$-K%XCT#2_'%EX=&G+?SL/LMQK]4HVM]<I\[U2M"[T4F
MKJLXQDU+EIVE%SE&7,Z<+2E'MYM:X>=DXWTDM7))64J:?NM*3U=DXOJU']%]
M5\"^$=?A@M=<\%>&==@TW4I-9M;?5_#6E:K%IVL3.TTVK6T-[97"6FJ3RLTT
M]_$L=W-*QDDE9R363+H'PYT_Q2^GR>&?!UKXQ\;6>I:C=1_\(SI::UXILM'F
MT@:E=:E=+IWF:K'9SSZ(THU&X=VE%C)&DKVZ-%^>^H?LU_%;Q/X%N8-8TOQO
MIVJ:#\&_B1#\'M%3XNZVNL_#SQ=KOQKNO$OPZT.\\0:3XE@35_%O@SX;-9:7
M:>)+^[U6ST2,W.@V.JW<49GGW/%?P'^.&C0?%SPM\*(]?T;P>T'Q=@^%]JGQ
M O4E72?%?A_]GFZ_LK3M5U/5;W5M(O?$NK^'?C!I^DZA?2J_A_5=8N]2BN-*
MMM3ANC:PU!2Y?[0CHW&U^6/*Y)^[)56GM%O]VO>O>;Y85:D^VJM*;PTFKWTM
M.3:YKWBX)I:-;O1I6:E8^Z/$\_PT^&UGK7CSQ;%X1\&6JWT-]KWBF_TRQL+F
MYU;54M_#]M<7=Y!9G4M4UK5HYK30K8(+O4]226#3(EG5TAK2\(>*/!OBG2-)
MN? ^LZ'JVCWNB6NL:-%HDL*HWAV6ZN=*LM0MM,58+JUTHWVGWFEP226=O"EY
M8W-BH6>VDB3YOU/P%H%]\!)O#.G? CXP^&-$3Q]8:]X>\ :!\0-#7XN^#+G3
M/$-GJVD?$CPCKVJ>.-5T?1]3\/ZG:IK^E^&(_%=P!&DUN+.07]SITGSK?? S
MXZ>(W\0>,_%G@_5+_P"-?C7]E/7OAUI/Q%M/$/A_1-0T#QAH'CKQQJOAJP\=
M_P#"-ZWIVA:?XI\6_#[5_#6E7NK^#='OO#$'B_\ MF=9-*MU%Y)G"C2G!RGB
M.6<93BG*I!IK]W*-H\\U)14G*H^9<JC&--R4G&%2J3C)*%&Z<.;2$U).\KII
M034FXI1CK=2;FHNU_P!0VRL<DQ5S'%#+<2,B.X6"%6>63"!BRHJ-NV@\C !8
M@5C>'/$&C^+O#VA^+/#EZFJ>'?$NC6/B#0M4ABN(H=1T74[>.ZL-0BBN8H;B
M.&YMY8Y L\,4J;MDD:."H_//QSX*^,'Q'U_Q+XK\7_!?XFZE\,M<^(FMWJ_!
MFW^(_A_1/%]Q;M\!?#'@[P+XMN)]%\;V&BZ9IF@_$/3O$5U>:+#XCEFTR[U?
M3_&?V+4KG3=D5+X(_#GXH^$_BC\%_@[K%SJ-GX/\,_!GX1_'KXC:8GB*[U!_
M#7Q/\%>!9_@A9_#P7UO,UO?:!XHUNQM?'US;P3_V=J&H^"=2O);5X=4_>7]3
MI>SD_K-/VD8*;2LX\L::G.*?M)3]HZCIP4G!4Y-NG"7,VTGB)^T450FH-J*D
MTUK*3C%[)6:3DU>Z6KCK=_IE10.@_P <_P"?KDT5YZO;7?KZ]?QO]QU7N5[N
MTM+^UN+*_M;:^LKR&2VN[*]MXKNTN[:92DUO=6MPDD%Q;S(2DL$T;Q2H2KHR
MDBO"/B#K_P"S%\)=.\+^'_B8_P 'O ND0?VIKWA#1/$?A_0K/2-/6PDMK76]
M>T>P32)=/T6*TDU6SM]4UH16,$37\*7=T!,*]_KYC^*MOXYT+XT>"?B+X:^%
M.M?%C1K/X-?%'P!J&AZ+JO@_3 ^N^*?%GPYUC2++6Y/&&LZ3:0^'M2L/#FK0
MZCJ$$6JFU5 DFG3^>B-O0C&<^24Y1CRSFE&I&ES5(Q7(N>;4%)W:4I=%RW2;
M3SJ-J-XQYG=*W+*?NMNZY8^\U=1=EU2?*['NNH>%/!7BK0A%JWAGPGXH\,7\
ML/B$)J.C:-KWAZ^G>"*>VU]/M-M=Z9=RR6ODS0:NGF-+;&-X[AH2I/->*?AA
M\-_BMX6OH+_1M(U70/&&B>&+2_UWP]'I\;>)/!FD:MIOB?0]#D\1:="\FH^"
M[V>RM'_LZ*\;2[S3+B:*VVPW1<_F]HO[-7QY\.^,/@)X,E\*+/X2\#Z'X#\(
M>,/&GA[7)FT/5_ -]\/_ !Q8_$3PKJU[J/CVPOK#1-"\1ZYI'A30?"OAKX<2
M'7M%TVP\87FN6E];I:VF5H/P'^/7AS3/V5?#O@OX0:SX&'PGTGX&Z?X@UVW\
M1V5W>1:OX=^(4(^.3W5[-\4AI>C>$=6\(VTM[H,6B^#_ !+JGQ!L->NM-U2#
MPY#I%E8Q]D<)1MS4\?!2;E-6E&/)",*O+-)54^>4J<&N6+E'FC*5G&/+S2K3
M?,IX:35K25I2<G)4^9)2A'W$G*WON+UM=MM_L([%V9VQN9BQP !D^B@!5'HJ
M@ #@ "OS-_X*9?\ (M_LS?\ 9Q%C_P"HCK=?IDY4NY3&PLQ7&<;<G;C/.,8Z
M\^M?F;_P4R_Y%O\ 9F_[.(L?_41UNN"C?VM-O=SB_OU71=&NG=:V/5PO\>/^
M&K?U]A7;_,^/Z***]Q;(\][OU?YL**** #^?3/?V_+H,T444=_-W=];MZO>^
M[U]==]0VVT_X&JUWWUW_ #=RCU]^O^>W3M111M:VEMK776_?OK??NV&^^O\
M7_ 7W+L@Z_EC_/?_ ",4444+3;3TVTLEIMT6ZZ+KJ&VVG];]K^=K^8?_ *Z*
M**/U_167GLD@_K77N^M^K;]6WNVP_P _3_/O1111=]W][Z[_ -=M-M T[+[E
MY+:UELMETOOJ%.#,IRI*G&,@XR#U!QU![@]>]-HHLGND]4]4GJG=;I[/7U"[
M6S:]&UNK;II[:;[>KN#CIQCICMZ$?3M2LQ8DL22>Y))_,DGBDHHZWZ_UMV^5
M@_X?\W^;?WL****/Z_%/\TGZI=E8_K^OZ_-W****/\DMELMD]-?G?YATMT[:
MVVMM>VVG_#NX>?\ /6BBBB[[O>^[W[^3T6JML'_#:V>G;5/3163NET2"C]**
M*/Z\_OW_ !_6Y_6[_*]F_-J_F%%%% !1111_PWR0!1110 4444 %%%% !111
M0 4444 %?'O[5W^L\!_]<_$W_H>A5]A5\>_M7?ZSP'_US\3?^AZ%2E\,O1?^
ME(Z\#_O,/2?_ *2S^K*BO'/^&@?A%_T,VL?^&Y^*?_S#T?\ #0'PC_Z&;5__
M  W/Q3_^8BOG?:TO^?M'_P &T?\ Y::_5,5_T"XC_P $5O\ Y4>QT5XY_P -
M ?"+_H9M7]?^2<_%/_YB/TZT?\- ?"/_ *&;5_\ PW/Q3_\ F(H]K27_ "]I
M?^#J7167_+WHMNW3K<^J8O\ Z!L3I:W[BOTT7_+OHCV.BO&_^&@?A%_T,VL?
M^&X^*G;_ +D?_P#7VH_X:!^$7_0S:Q_X;CXJ?_,/1[2EO[6C?_K[1_\ EH?5
M,7_T#8G_ ,$5E^5)=CV2BO&_^&@?A%_T,VL?^&X^*G_S#T?\- _"+_H9M8_\
M-Q\5/_F'H]K2M;VM*R_Z?4O7_G\'U3%_] N(_P#!%;_Y4>R45XW_ ,- _"+_
M *&;6/\ PW'Q4_\ F'H_X:!^$7_0S:Q_X;CXJ?\ S#T>UI:?O:6FW[ZEZ?\
M/[[^_6X?4\5_T"XC_P )ZW9+_GUV27R1['M7=NVC<!MW8&[;G.W=C.W/.W.-
MP!QD9I:\<_X: ^$7_0S:O_X;GXI__,11_P - ?"+_H9M7_\ #<_%/_YB*/:T
MM/WM'31?OJ6B[+][YA]4Q7_0+B/_  16_P#E1['17CG_  T!\(O^AFU?_P -
MS\4__F(H_P"&@/A%_P!#-J__ (;GXI__ #$4>UI?\_:/_@ZE_P#+0^J8O_H%
MQ'_@BM_\J/8Z*\<_X: ^$7_0S:O_ .&Y^*?_ ,Q%)_PT#\(O^AFUC_PW'Q4_
M^8>CVM+_ )^TO_!U+R?_ #]\E]P?5,6O^8;$_P#@BM_\J/9**\;_ .&@?A%_
MT,VL?^&X^*G;_N1__P!?:C_AH'X1?]#-K'_AN/BI_P#,/1[2ETJTO_!U+_Y=
M_P #K:X?5,7_ - V)_\ !%;_ .5?TM-M#V2BO&_^&@?A%_T,VL?^&X^*GT_Z
M$?\ SUZ4?\- _"+_ *&;6/3_ ))Q\5/_ )A_UZ4>UI?\_:/?^+1]/^?H?4\5
M_P! N(_\)ZW_ ,J/9**\<_X: ^$7_0S:O_X;GXI__,11_P - ?"+_H9M7_\
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M,VL?^&X^*G_S#TO_  T!\(O^AFU?_P -S\4__F(H=6GUK4NO_+ZEUW_Y??\
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ME_S]H_\ @VC_ /+0^J8O_H%Q'_@BM_\ *O(]D_S_ )_S_2BO&_\ AH'X1?\
M0S:QZ?\ )./BI_\ ,/\ KTI?^&@?A%_T,VL?^&Y^*?\ \P]#JTGO5I._>M2?
MYU@^J8O;ZMB;;6]A6M;>UO96_ ]CK\S_ /@IE_R+?[,W_9Q%C_ZB.MU]F_\
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MX@?^&Q^)'_S*4;[_ /Z%CX@?^&Q^)'_S*4?6</\ ]!&'_P#"BA_\O#ZGB_\
MH%Q'_@BM_P#*B:BH=]__ -"Q\0/_  V/Q(_^92C??_\ 0L?$#_PV/Q(_^92C
MZSA_^@C#_P#A10_^7A]3Q?\ T"XC_P $5O\ Y4345#OO_P#H6/B!_P"&Q^)'
M_P RE&^__P"A8^('_AL?B1_\RE'UG#_]!&'_ /"BA_\ +P^IXO\ Z!<1_P""
M*W_RHFHJ'??_ /0L?$#_ ,-C\2/_ )E*-]__ -"Q\0/_  V/Q(_^92CZSA_^
M@C#_ /A10_\ EX?4\7_T"XC_ ,$5O_E1-14.^_\ ^A8^('_AL?B1_P#,I1OO
M_P#H6/B!_P"&Q^)'_P RE'UG#_\ 01A__"BA_P#+P^IXO_H%Q'_@BM_\J)J*
MAWW_ /T+'Q _\-C\2/\ YE*-]_\ ]"Q\0/\ PV/Q(_\ F4H^LX?_ *",/_X4
M4/\ Y>'U/%_] N(_\$5O_E1-14.^_P#^A8^('_AL?B1_\RE&^_\ ^A8^('_A
ML?B1_P#,I1]9P_\ T$8?_P **'_R\/J>+_Z!<1_X(K?_ "HFHJ'??_\ 0L?$
M#_PV/Q(_^92C??\ _0L?$#_PV/Q(_P#F4H^LX?\ Z",/_P"%%#_Y>'U/%_\
M0+B/_!%;_P"5$U%0[[__ *%CX@?^&Q^)'_S*4;[_ /Z%CX@?^&Q^)'_S*4?6
M</\ ]!&'_P#"BA_\O#ZGB_\ H%Q'_@BM_P#*B:BH=]__ -"Q\0/_  V/Q(_^
M92C??_\ 0L?$#_PV/Q(_^92CZSA_^@C#_P#A10_^7A]3Q?\ T"XC_P $5O\
MY4345#OO_P#H6/B!_P"&Q^)'_P RE&^__P"A8^('_AL?B1_\RE'UG#_]!&'_
M /"BA_\ +P^IXO\ Z!<1_P""*W_RHFHJ'??_ /0L?$#_ ,-C\2/_ )E*-]__
M -"Q\0/_  V/Q(_^92CZSA_^@C#_ /A10_\ EX?4\7_T"XC_ ,$5O_E1-14.
M^_\ ^A8^('_AL?B1_P#,I1OO_P#H6/B!_P"&Q^)'_P RE'UG#_\ 01A__"BA
M_P#+P^IXO_H%Q'_@BM_\J)J^/?VKO]9X#_ZY^)O_ $/0J^O-]_\ ]"Q\0/\
MPV/Q(_\ F4KYD_:+\'>.?%S^#SX:^'7Q/UL6$>O"\^P_##X@G[*;IM(-N)?.
M\-1<S""8IMW?ZM]V.,J6)P_+)?6*#O9:5Z#ZI]*WD=6"PN)CB(.6'KQ7+/65
*&JE\-MW37<__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>form10-k_021.jpg
<TEXT>
begin 644 form10-k_021.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" 'G [8# 2(  A$! Q$!_\0
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M(XW$[AC])_X@_P ;IM?5<LTT_P"1QA?-?] _D?'?\1!X7?\ S&5__"2IY/\
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MMA&;CX%_LK-O;!$.@_%PE%.XC=GXLGYL =!CGJ!T<O![C>.^&RK_ ,/.$?\
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M&_X.B/VV@\:I\!OV7YE<X+QZ'\5@H]OG^+0(/(Y(QR,=:?\ Q"WB[_GQEO\
MX=<-_P#*3"?B;PE#XL1C^VF68A]_^GWD?W0T5_"ZG_!T5^VSY\L<GP!_9D$<
M2;F*Z)\4MXQ@$?\ )6R&Y)Z#C Z@Y"V__!T5^VA]DFN;SX+?LJ0RJX2*U70?
MB\9FW$;0V?BJR$G./E< 'KZ4?\0MXN_Y\9;_ .';#?\ RD<?$SA.?PXC'N__
M %+,0O\ W,?W0T5_#3+_ ,'/W[;)%LL/P)_9>625%DE\_0OBP$5' 9&0K\6
M1E3G#<CC/49EB_X.=_VUYC/L^#?[)I,*Y,9T/XO"4GY1@ _%8 X+;CC^%2,[
MB!73#PBXTJ*,HX?*K22:OG.$3L_+V%T8R\4^$(2E%XC,KQ;B[93B6KK>S5;5
M>9_<C17\.-S_ ,'./[<5D$EN/@C^RE/!)D@VFA_%UG0  DR!_BOP!D=!T!(R
M.::W_!SY^VG/&$L/@;^R[+='D&71OBFENX&,A<_%F.7<,X.1PP(QGBKGX/\
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MOB,PUV_X2\3UV7\;?4_N9HK^&;_B)]_;>M4']H? K]ED2$X"6VA?%H^G7?\
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MA#QLO^87+?EF^&?_ +@#_7[AO_G_ (SYX"LOSJG]X]%?P??\127[>;VYEA^
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MVA=J9HE& MM%EE*#/095S@*,LQZ XH7PI:VUU)<74^)DMIK2XM<':]S-\J3
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MRIV5KI=-M?-_.YP8C$*3DX-<K>EMMEMVU36GSN<S'IFH7)\QXGM91TCF5H9
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M97[^.XM9+:WE#^81/,0PW$JP+$J"3R!CO[Y(K91=0N;2>YCLHH4D9PUVP4R
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MX&&&0=I&<$'H*?)B/YODK_T]/)G1&IAI*+LGS)/I9IK=^;Z;DPBD%N0=2+N
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M_9Z+<S[I,3WD7F%FR,J"H=LG., =>,U4N;Z9;LW"-<F?YHVM2YFC6-B&>0(
M<%=J@/V##)QTE6+3K6\/G&:2:S5D)=FE5F&<E69B6')S\H/<'&,W;&\M-2:>
M1C!!Y3,=Z#]XP#<C=L4D$C)7(^9<= !2=7F7*[M-VUVMVW?KJ>;)5XSC*3?+
M%W>K6BO?:_?N5(KMFE66"&_C<8W2S6\J6ZGOF1@%&#GDMG!P.<&M%3BVN)K>
M6-7D)DN=SJ$F<DERIR-P;+$'D%3@'BJ]PMY=$O#<M]A3EXLG! ]5R.V,YR#Q
M@Y'(]L&1+.7=#',JF)P,_NVSMW9. =I'4CC.<5U4'L]-%^JU^7X_(OV_G^+Z
M:^7]:>1)9ZRPMYH T* DA3&PWNX8;N%9F((SC@9X)P,$T)A;R26ZZG=3@%L[
M,NI SZ$<+G.<#'N<9JZ'N+)8]*L-%M+JY5O.^V7#A,J,CA_+;YAN!VD]?;DR
M3Q1J=VMZ4KSGE7M[E]JG_9 \O SQ@ 8 'IBN_P!M2I^[.W-YOOJOGO;3R(;K
M5'SQV>GW+6WG]_H37L4ZK]GLWC>W:)6C\M]S[2!@,%/# $;AR3STP16>?#I_
MLP7UY>Q+)'-D032 3,!M)$<;$$L.1@#MZ#G.FNDE8K:W&F6B#*A'U"\61 #C
M#X@(\P+@-C(!(Y)J>&YTCE-1O[69L8A^S7%Q<;9&()9Q,D852N,'.=QP<#-)
MXBA)-65NNG;H[M_E\PA#$\R\W=:^36EM5K;7M>YTMFNGW-EJ$MMYBW(M-D:3
M?*LC;& "A@-Q(Y!7/3(..*X4Z?'Y\$<'V6:;?N>-)8VD4G?N5T7YEP<Y!![C
M)R:ZF"_LK#,BN)XB,88\XVG'4E0.<<#@=3S5&V-E;-<S1&V74)=\J.  P$A#
M8W;2. 1T_B'.!G'!7GA];V\MM[^EOE_P#=1Q&MVV[Z*[NOZUW?8+O08+AG;4
M+Z&T@1 9/+F02<EL J#E1C/.  1SR0#'#I%L\?E6<5I?:6#DS&:-K@;3D$]^
M<, 0!TRPXQ6&;R\FAE@F%O//*^)&.W@<8'W,YY^I()YYIT2W=C:;8KNWMV/\
M.5 R=P )"9QV)/(Y':LX8C#QC&-EI?9+J[]NNVW0REA\1*3;YM;?U_7S=]#L
M;R/5[W*PRZ=%8JN(I6N(EC<@ !$<ML9L#;A<\Y_&K:6U\T,Y-F()[0JHG"D)
M-YA+*R/@;L!0"02/FP,G-46TFXBMK:]\::G:P6$S :?;:21Y:2$93>(Q;8.>
M6X//&,\BP;F>Z1[07S"SL[JR\J56.Z6"0.V)3D$E   "6.>G0YIXJAL[?^2K
M73K^FA$\/7C%MI_)O2[];?Y]BG%;>(EG>Z!:6)9%4A SK%\X 9R/N<D'G''M
MT]'M+^:]NH;.YAC\^S8.]XA'E-L(./,&06&",$YP<@ \5ROB75K.21-"\.3S
M>:\$+7DJ9 9EV$[CN*D';CODL2<C(-23Q)'IMS:VTLT>7*BY8 $*.^?EST&.
M3US@CI750Q5#3X?G_7W_ .6AYU;+L17Z-7_%=.N_]:=>IN;]FU*Y^QK,U^K*
ML2*A>":-5VR,Q *Y4@<D_GVS;RWM9)(YUEN8]7,D>^*)'\E6WK\K;5P <X8Y
M P,G;P*RKJ]LIKIQI^IG[5*H-M+&2BI&0 ZM\P!^?(QSQ\N0:RS_ &I':.8]
M9LS>>8I<RD&3:2 <'8W/50,\D]0.E5,5A^=VM^'9?Y_IL;8?+*]&,=UOH[IK
M5M.ZW_'I?8UYK#4#J#RR7,C.S$O'('%L@YW%<EE& 3C! ]\FLK48+J%R;!DO
M$)!NHXV#^5,21M14YV!-I)/09(P3BI[2XN+8,^HWPF#9R2V0 #]WG@$X(/!P
M1VR!6Q8-H]S%-;V-[#9W\LHD1G)!=!&JDC);&3]!E<CD9K&IB,/*/*TM6OP=
M_P"NYW5/K%.BTY/1QO;JKZ;K[^YC1^'6G^S7\FH0VK+,DT]N;E8Y=J,K.#%]
MXD@\*1R0%)."!TNGV6L65R=2EN2OAD\30W"M&;C<>3$'VB3/!&T'KP3Q3,6-
MF)+>\:WNIRI4S!0Q!QC<./4D]1G@@D\5<,MYJ5I':3WT!L8@!%$6& !TPI&>
M>F0<')S@9(RYJ'9;-_\ !_+74\:O4Q#?5]M?GM=;6VV\^UI]*L+Z-]0LW5;;
MS&:.&=E20  ?=C.TE <E3P!CKW.3?W5K=&&&?%I!;,#),""0B8+,@X+'!5A@
M_-R?3&A:Z2]RHBDOD@M8V,:2(2 @&#M&"I/4].H;&.,'J+;P[I\4,B0R6^HN
MZLIFN""D?^TV0WRC@$#D$\$UWTJ>'E3A+E6L4]E;KY_U]QR5,;*E!-NTDM;V
MU:NW=V>FNZ^9P=G;V$,3&/4KJ[21LQQQ6<LC(I( .U,\#J2>!U!!.:WO-T.-
M6@FO))IFMU; LV=E)!Q&P#<$8P0.0",@9XZ2V\,SB3[2]U906R#81;%5)&,'
M.$3D L !DG@U9@\&V9N9);>]A,,B[RTN?/+L26(Y;@=ANZ9Z=:MTZ"^RMUNE
M_5SSX9ZU5Y.?[+=TM-&M-O/S\SS^XL6GMT%G=J8BQ+6IMY(Y77+851G.>AX7
M('/3IHV>E:?)_94LT5RL[N1.)89!$H0 @RDJ JYX)8XXRO/!ZX^ K=IC<Q:E
M,)HR63#$1@@]\2C*@$$@KG)ZDX%=#8>&WAMW\ZY6X'(())[<[AG)) XP<8&1
MUKLH4\/V2_K_ (?\/(QK9VVW[]_2VF]MVF>>RQW.K7_GO<Q6]C;R&WAA!55
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MN4N6UFJ<YM)*[U25]+MZ%?\ $-,G3;48)-I>;U>[YK+U2V2N?Y[ME_P;Q?\
M!1>1!!J&A>!%BA+/'+%K%F+B1\C9YC-J)5E SP%&">O6B;_@WK_X*,F55&@>
M!O*C^ZW]KVI+ 9QN_P")CCG@$@#GUSBO]"3:66,"(AL%LDG!(/(([GKC/Y<C
M+LG&TQCODXYZ],E3WXP3G'L<5S+Q1XAZU9>G++\^77_AEW%_Q#;*>BI^=[]W
MMKJM-]+K[W_GM#_@WI_X*--.TJ^'/AX 25W'5K;<5_A8G^T@-W][:H&>G'1T
M_P#P;R?\%&VM1;KH_@%E,WF,K:S;'!QC@IJ*DX+9'4<'I7^A"%4<^6<_5O\
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M6B:3:OKN]8[7UTM9'^>/I7_!N=_P43TVZEU :%X DNWB= IUNU,&]D=0=HU
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MH<0M-NM)R3:O.,W9;V7+%=+=[O5-6+_U$RV2T<$KV<8R5F[;MW:V[/3:S/\
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MQ+-N4L3.3VNZ<[Z+RBK'13\.\J@N7FII)RLF[:/YZW];/MW_ ,[FX_X-S/\
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M@#(& 1QQP3P3CT)IP)0DB+!'3KGI[KQ_]?BLI>)W$-]*S^4)6OY76B_X</\
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MYVTU3:U%/&8&GOC4^ONSYK;;^]Y_GV/T#F8J KJS1.&W21X^0\;<X.=K9)&
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MHM->TJ+YR_\ DANSW/\ X_\ X4;..I_\?_G_ "&/7FG>2GO^='DI[_G3YO\
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MI4;MM5:B7:[_ %D)M_W?^^?_ *]&W_=_[Y_^O2\^H_(_XT<^H_(_XTO:5/\
MGS3_ /!G_P!H+V#_ .?M3[W_ /)!@CIM'_ ?_KTW:?48R> HQ3N?4?D?\:.?
M4?D?\:.>I_SYI_\ @S_[0/82_P"?L_Q_^2$Q[J?3*C],$=A^E&W_ '?^^?\
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MO^='//\ Y]P^\T]G'^>?WR_^2#(]7_/_ .O2!O7)],_,/RR.??\ 2E\E/?\
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MG3=/GNO"6FV^A>']%L;EM*E+Z>NHSV:7CBSWL^Z1R??/^",7PX^&OC[X@_\
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MG@>/P]XE\(7FE69TG7[3Q#J6F:1!<FQN?$$=U>D?;+I)3>0.Z#<=G]N?@/\
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M"JFU>U2GS<E3_%#FER.UX\S:LV6M$DM$MDO+1?@5UMHD+,BX9L#/]U01\J8
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MZBH%OKS[4Z2K)&2D?DV?DJ8YBP8EUO,JV5&#,N/W*A<$YX_ED\0?\%X/'GP
M\4?&/P[\3? 5[\4HD_:IA^$?P[UOPW:0OX=\.^'D\!^'_$%[:ZW*=3TZ594>
M;494OPLEBD\D22W"F-PGTEXT_P"#@G]G/PU\7/!WPWL_AOX^\11ZC:_";_A,
M[_2/['U"#PE=?%S5YM$\(2++::V[W5GI^I6]U+XFN+1+^)=/B#VTCL&W ']
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MLQ)8)U)G502L75VPF1U/\_OP$_;\_:>^(_\ P2%^,W[9?C#1M(\*?%KPW?\
MB]O T*LD]M)8Z-\3SX5,-]:V]Y?2[[...ZM64,K,\ DC#1$.WN?B+_@IQX7^
M!/\ P3>_9P_:E^/>[Q1\0/C'X=^'>GZ=I'A2XLP]Q\1_'<L6G:.TT=W?68AT
MJWU6YM3>&>9 D(E!5MI% '[&PW=S<N80)[8E4G662U!C".N]( S. TQ1@901
ME'#IDX-6$O-^Y0\[&3:T3?9P!$A8*-V&P0S9&XCC(!'''\[UI_P<!?L_Z3X5
M\&^*_&'PG^)'A+P;=:1XPM];U?6/[&BM[;XK>'/$4NA6WA>TF37Y$OD\3F'5
M=9TIK4W4*62(D\]I,/(;S'P+_P '&WPB^)>JVWA>S^#OQ/\ "6IWVE>(/">M
MZI?Z=ITT?@KXA1:9>7&@6FHVMGK%[=_9UNI]%NIKB.UN[<07#$S JV #^F=M
M4"<S.MLH-S&QE 0 6T@26XR>""2&11P0220 2;UG/).LA<)A) J.CAQ*A17$
MA  "$EL;1QA<C&2#_,E^QY_P4>_::\5>,/V3+OXN>(])\8:+\??BK^T[\)=6
MM-+M+=8M/N?A]\0-/\+>"-5#E( $6RDFEOD22>7><?9@=J5_31ID+0QRJTKN
M/-.V.3RPT  P4/EC&&;,BY+':X!((P #2HHHH **** "BBB@ HHHH **** "
MI8_N#ZM_Z$:BJ6/[@^K?^A&@!]%%% !37^XW^ZW\C3J:_P!QO]UOY&@"&BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH/\ A^OY
M_G@X]#0 45$'W$!#G)&>_&!G&2>3D8[ =>A-2.I4+\V"0<YQCZ#@]/SZ9]*4
MFHJ[V#T5_)"T5%\__/0?^.__ !--\Q_[DO\ WPO_ ,56?MH=PL^J:]=/U)Z*
M@\Q_[DO_ 'PO_P 51YC?W)?^^%_^*H]M3[_BO\QV_JZ_S)Z*@WL?X)?^^%_^
M*HW_ -Y9/;*+CWQR1W&?PIJK!NR:OK^'I<6O17]&O\R>BJYD4 D+(, ]%7/3
MMT_F*B\[WG^FU/\ XK\.M5S1[K^OD%I?R2_#_-%PD]A_]?Z>F.O?-&>GO^'K
MSCWQTZC\*I^8Q/&[M@2 *>1UR"QP,=>.AQQS4?F3,^1(H56R5'<8Z XS]3C(
MR"21S6%;$1HU*5.49MU?A<4K:MK6\DU:VNEMF%->U=2SY?9/EES=':,M+<U[
M\R7JS0!)ZC'^?U]<].?:EJJ6FR0 .W&XD#/3!ZG/'7OZ=*E438X"G &?O'GK
MCMSSD\ ?RK:<O9SA"2=YQE)-*ZM&UTW??5:6[F<*L9J35_<ERNZ>]VM-]-'J
M2T5'B?\ N+^1_P :,3_W4_#=_7%'.NS^XOF7G]S_ ,B2BH\3=T&?9F _"C;+
M_<_\>:CG7G^'^8R2BH\2_P!S_P >:C;+_<_\>:G&2D[*]TK]/\Q-I*[)**B(
ME SL'7'+L/7O^GU(IN9O^>8_[^&KL^S)YX^?W$QSQQ_G_//X8ZD4'!(!.W/\
M73&.?4=< 8SSGO7G?Q)U?7](\*:A/H,J6>JN;6.RNQ&EP;=Y+J%'8PSJ\3DQ
ML^=R,.<XSTY^T\._$:YMK=KKXF2Q2S2W+O''H6BN/*\N,PQJS6.<Q'?O)P><
M9]#E?9ZASKS/9-@_Y[#\Q_\ %4;!_P ]A^8_^*KR;_A$?'?_ $4V\_\ !#H7
MX_\ +G1_PB/CS_HIMY_X(="_^0Z?)+^5_<'.NS_#_,]"URVDN+!K>.^:WCE=
M4NVAC:6YDM#D3PVFQMT-U(I413@.8R"0C$@#\P?%O_!);]ACQMKOQO\ %OQ%
M^$^G_$KQC^T#J5MKGC/QMXVN1J7C?2KBUT^QT>QFT#4)U2XTZ*U73+-H$BC/
MESQ!U/6OOT>$O'@_YJ;>?AH.A9&>X/V,[3Z,.1VJL? _C-F=V^)%X[NVYF?0
M]"=CP $#-9DB,$;A&/D#DN%#DDG)+^5_<'.O/^OF?FWX3_X(_P#[(W@WP/K7
MPZL8?B9?:-KOBOX*^)KR_P#$7C*Z-[-K_P"SYK.KZY\/H;:YN;97@B;4-=O1
M/(2Z7XVC'[OYN=LO^"*_[$T7B7_A+=:LO'WB0V_Q$7XJCPOK?B2\O/#ECXJM
MM*U+0@MII;Q".$36NJW<SPAC]IF<W8P#7ZEMX-\<,8R_Q+O9/*8N@ET+0I5#
M\8<K)9,&9, Q,<F(Y9""2:/^$-\<;_,_X65>%L<DZ#H)#'/WG'V(!G'17/S*
MO ( HY)?RO[@YUY_U\S\F?A]_P $,?V(O >B>(M ?2/B7XUT/Q+\/+'X=:/I
M/CSQU<ZQ9^$_"%A<:G=:=H7@[1[FU231(_#TNIW5]9"%I#%)(FT*R<_(/CK_
M (-Z_AG;_$_]F]?A/\5OB]X8^%?PFA\0W'BG58?&-[%\4KRZO]5T2[T?1/"G
MC'*76D6,5A:ZA!<Q)9W:131VA<*8@&_H</@3QF>OQ,U)FWK(KMI.CF1&5@V8
MY#:[XP^ L@0@2*-K@KQ3O^%?^,]\LW_"S=3#S2Q7!']D:/L26%7V-&GV0K$"
M')D\M5$APSAF -)QDMXM?)ASKS^X^"?A'_P3,_8G\"W/BWP?X9\(75]+<_"5
M_@EXLT'7-7;4VU+P5/K%SXF:>\#QJUWK+ZW?2WC:KM!:;"[ 0<^9_#C_ ((D
M?L@_"+X1>//@UX6U/XL#PAX_FT%+0?\ ":W;>)?"T7AZ/4(M%TOPWK!MVDT2
MQTU=1FCMD$;1VZI$Q!V8K]%-+^#NMZ-X@\1^([/Q]>MJWBN6*;5[J:QL%:22
M$Q>7]G*VX%G'B%=T-N(HC\Y*L6;/>R^%/'\L;*_CU]KHRDKI&EJP5AAB&6T#
M*V.C###J#FAIK=,.==F?C*__  ;^_L,)\,=+^% N?C)#H=EJTVJ:Q%%X_O1=
M^-#=W]QJ5Q9ZW<_9R=07[7,&E/ =HL[0.!O:G_P0>_8-U;XD6GQ L]*\?Z-_
M8UIH\5EH.C>-+FVTFUO;"[EG@9]&6%VMKO?(BW-VY_?1JB;%$=?KF_@[QI)$
M\3^/92KHL99=-TY)%"E2&CE6T$D;Y7ET8,<MDY.:E/A3QMC \=;22"TB:1I:
M2R,#D-+*MF'E;/.Z1F.><YHL^S^YCYUV?W'YUM_P2*_95?3/"6BS6'BS^P_!
MWA'XX>"]+BG\5/'-!I7QW\:Z/XV\=,7DB!;SM=T6RD0D#&!M( )KR3QS_P $
M-/V4?B)H7PI\$^-->^,OB+PS\*-+TS2-&TG5/'=[=Z9XATO1M=G\2Z4FKSBW
M$8-MJQ1XTF;/E11(  01^NG_  C7CG+Y\=A@X 97T;2G4@#& CV3* W5\#YS
MRV3S43^%?'+X#?$";"L[!1INGJN70QG*BT"D!22JXPC8=0&52"S[/[F+G7:7
MW'5>"M'L?#OA_3] TJWN+/2=%@CTRQL+IFEDL$M%\HVD4K!?-M8 BI;R*NUD
M4,I/)KKJ\KB\,^.H$6./Q\X5$6,%M+TUVVH %W.UH69L ;G)W-R6))J7^P/'
MW_0_'_P4:7_\AT6?9_<PY_)_<>GT'BO,/[ \??\ 0_'_ ,%&E_\ R'7+^,(?
MB7X>T2ZU:T\:B[-KM+Q'2-+W$%U!P!:CC!.3P!QSP:.679_<'/Y,]WZT'BLN
MSN9)[&QNBS.9((3.N I,CQ*78],?.V0%P .@Z"O.?B5K?B'2[#2;#0]3;3-6
MUG5$@BODM+>[%K;F1 P>*XBDC) < ,R$\<YZE-6W*4E*]NAZS@-SO"8XZ\D$
M Y/(XYX_'UHV#_GL/S'_ ,57D47AGQW,TBM\3;QVA$"O_P 2+0AM=[>.1A@6
M0'+,3QD8QSG.9O\ A$O'7_12KS_P1:'_ /(= SU?8/\ GL/S'_Q5&P?\]A^8
M_P#BJ\H_X1+QU_T4J\_\$6A__(='_")>.O\ HI5Y_P""+0__ )#H ]-OK9;B
MSN8#*Y$L+H1%,(7PPYVRY;81US@U\0?M-_L+_L]_M=^+_A#XK^._AO4_B%IG
MP8U>?Q)X6^'FN:H3\.-7UMM*UG19+G7O#4T1M=9O+:QUF]FADD?[T$ "D)7T
MF/"?CH'(^)=X".XT/0__ )#J!O!?C5HDA;XD7ACCD\V,?V)HH*/SDJPM0PR&
M92,X*DJ>"00#\L?$?_!#W]@[Q-J'BK5/#'A#Q)\,+3Q!XH\'^/;.T^&6L77@
MZU\&>*O!FL_V[IVN^$H8HY_[,N]2OXK<ZI<09%U':0K(-J T[4/^")O[&UQ\
M/OASX+AD^+?AU_AMJGC+7-.\9Z#XYOK#QEJ</CKQ3JWBOQ3:>)]?BMC+K%IK
M?B#6KK4KBSD2)I"T;9.S)_5 ^$/'!*'_ (65> 1DE571-$5,''RLBV@5D&!M
M1@57G &32+X.\;K$(?\ A95Z8@SML?1-%=29&+,&#VC;D!8[4;*(,*J@*H !
M^65__P $4OV-YO!OB?P1#:>.K&V\1> ?AQ\-)9[?Q9<1B/2?A=\1+GXI^#[C
M081%OTS5-.\67SZE=7JF5G1!N55&6^DOVC/^"=OP6_:@^%/PB^%7Q'N?'<&J
M_!%/"=_\./B-X5\2W.B?$;1=3\&6UO!9WZ>-(H9G6\OY($N+N1HP\TR[W!Y-
M?6\/@KQI L"I\2+PBV:1X3)HFBRNK2+M<EY+1F8E?ERQ) &!BDE\&>.90BGX
MF:B%CF\]-FDZ1&?,SNRQ2W4NFXG,;Y3!(VXH _+#5O\ @B!^QIJ_P,TCX)MJ
M7QC.B)KM]XDU[Q@GQ N_^$V\7:I>K<6M]+XGUPVIGUK_ $29K$@HA2T@A7)6
M/-,C_P""'7[#.E>-_AAX^\&V?C#PI?\ PW\.^$?!5A#H/BN>VTKQ9IO@AY#I
M%KXQ*QM%J>I%KF9%EN"'::X<[,G%?J>_@GQM(CQ/\2+X12R"4JFC:*FQU"C]
MT4M08E8@&1(]JN2Q<'<Q(G@3Q>DEQ(GQ%NE^TK )(QH>A^0&MV9HI8X?L?EQ
MSAF+-.JB5SM+.2BX /@C]K/_ ()^6W[27QQ^#/Q&7Q+!H_A_P-X%O_A/\1?!
MMWI,NHW/B3X8ZI>-J%[!HVIQW=LEI=K<0Z='YD5M<2>8DC;020/:-._8-_9[
M;]B[2OV$=:\*7&O?L]Z'X&M_!VDZ/K,S7>K?8K74[[5;"^EF9!<QWNF:E<?;
M;"1QNAN88F7) 4_2<G@KQK(VYOB7J&[<K;UT?1U<;5VA0ZVH94(Y9%(5F^9@
M6YIR>#?&\;!U^)=_N  RVC:,^0N2,[K5LX))R>_(H _,[X2?\$@/V5?@19?#
M+3O#L/Q&\3S?"'XL>"_C7X+NO$_CN75;Z'Q=X"^U'PEITEI):K-'I5E%=31)
M#(6C2,*IX"Y^/OC[_P $'OAE\1_VL_"7QB^&_BSQ[X)\!^)_%VN^.OCYJ/A+
MQG-9>.+K6=4\*2^&/LWA36[<FYTO3[BT@L;*^TZVM;DR6[7C,0L[;/WS;P;X
MU<RLWQ'NO,F #RC0M#$W P-LHM!(A X!5A@<"H8_ WC&*0RQ?$>]A8QK$1%H
MVC11E%D\T$Q1VJH9-_64@R%?E+%0!0!^<NE?\$A/V.O#VDZKI.D^'?&.C0^(
M/@K<? _5!%XPDL[K4/!1T6\T6XU9=T <^)=3LK^9M8O@#/)*MLTBJ57/->&_
M^"*W[%GA#XQ6?QD\-:)XK\,ZU#9:)%>^%=!\4267AB^MM"\-P>&+75_$6E+"
M\>LZT]G!%F[S#)^^?Y23FOU"/@GQF7DE?XCW<DDK$EI-#T20KN)+"+?:-Y*O
MGYQ'M#@*K9"@!_\ PAOC7S))?^%CW7F2H(I&_L+0\M&H "'_ $/[HP,#H.>Q
MQ0!^9GQ4_P""-/['GQI^&'P6^$WB6W\?>'],^!S>(CX&U7PMXPGT+7)E\6:?
M::/XFBU=TA>2\EO])LXK822H "Y(!QBN<MO^")G[$5E)H>EV&F_$*.ST<Z;9
MZ5J,GC:X>XOGL(_+6WO[TVP$TL4B)$UJZK)/\[*OR$5^JDO@KQI,YD?XD7AD
M/EX<:)H@=?+?>NUA:!E.>&*D,Z_*Q*\4T^!_&#.6;XC7:[@2%70M#5%<D$S)
M&+/;'/GGSXU67<2V_+$D _&_]DW_ ()[:E\ ?VR?VE_^"A/[0^G^#-,\1^/-
M*T_P?X(\-^&=/ANK#1?"_A]HWM?$NJ:E97D]HOB'4(P=-DEE@M[EXQ&K!@ZJ
M?H+6/^"6G["/QSOOC#\8?B=\,8OB;XE_:=TC2SJ>N^.C)J]]X:L=0CUF708?
M 5U<1H?#5Q9G6;MUFMM[1S1VA*[8BC??'B#X4^)O$FF7NBZM\1+Z\TO4+?[+
M=V3Z1HZPRQ;MV"@M0H8$ AP VX Y&T9=H?PS\7>'=)TG0],\<,FE:)8PZ;IU
MO-IVFS>1:6R+%;C]Y:NS21(@$4AR\9Y1ER30!^9&G?\ !%#]E+1]>\+ZOHWB
M/XQ^&)?#EHNCZQHNG_$*\?3?'MO'&4T]/%MO% HUE].T](;&S\W!@M(8X5PL
M>17E_P""&?[%]Q<&YOX?B5JEE;:U\3-1TK1+CQ=>3:;X5E^+6A6?AKQ$OANU
M\@#3$MK"RA\DJ7$01=H4+7ZN_P#"*^/B$_XKM2Z/O#MI.EL^=I3=O-EOW8)
M.<CUYP(AX0\?B*&$?$&0) 04QING;B5Q@R/]EWR],$REMW\6:AS2=K,#\B?V
MN?\ @D!\)?BK\*/%4'PQT];GXQ:?\"%^"7PYU3QPK:I!!8Z1IVAZ9HDR-<S6
MD6G:C#;>'[%#XBED\J)R[N/WPKF_^"8'_!,;XF_ 7X:_M6:;^U/K-AXAU;]J
M;Q!?ZAXN\/6.JV^I7EK8WWA_3/#L\C^*[2ZGM[^1;73P;:>.&(02B,89HP3^
MSK>$_B \J3-\0&,B)(BL-*TP825E=U(%H,@LJG!X!48II\(>/2LB?\)Z-LK
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MF><8/!8E\M&NZRF[V^##U:D=?\4$>+Q#C*^7Y/C,9AE>M15'D2W]_$4J;_\
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M/0'_ +[/^%'D'T/_ 'V?\* .F_X26+_GC+_W]C_^)H_X26+_ )XR_P#?V/\
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MD]>W_70_AS1Y6/7T^^>HZCH?P]:D#I_^$DC_ .>(_-?\*/\ A)(_^>(_-?\
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M_P#0C452Q_<'U;_T(T /HHHH *:_W&_W6_D:=37^XW^ZW\C0!#1110 4444
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M)_A[=:?:VT6M?VCX9T9O"D4]S->ZG;W2S7-O/%#;!HX4FVN?VD_X)=>%=?\
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M=O9V90Q5)96VDB3> "K@C*K\HR@!!#$$G)YQ@4H+'G>WYC_"ABYD<28#J<,
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MN]"O;[4[_P 0:5>WR:?%J3V[VFH1/-J%W&&FO4$H K\O/C9_P3;_ &M?@-X
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M,?N]2>?KR*QQV<8K,,/##5W35.G451*"@M8PY*:3T:C"-^[DY7FVTC7+L!'
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M)[]Z=ZW_ #]E]_S[=_QU8^7^[#[O^!Y#[5##(9%BNK=8<QZ>[R-/=F.<E93
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MP<<\D=^<D9(G+E]Z<N?57CM;HK/7;?Y;F-&C*E#E?))\TI7MK[SNE=QO=?\
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MC_UW;_T-*Y'R[K^Z/TKL-!1ELP74!_/;D#J-Z]^_]/;D58CH6ZH.^[_V5_\
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M$D8."?SXYY]XFDD>6X_>W6Y95X^U2A<[F'=NAX'MU''->":!SXBT<CIY[>W
M4@?S_7M7O+?\?%U_UVC_ /0S7YEQO%1KX962M)+16^VNB2MM>RL?I_ KYJ&+
ME>]X7[WV7?\ X(K&3(/F7  8X(NI0#S]>@.?;CMS288X_>W7X7<OKC/4]\].
M/YT\]O\ ?_J:5>GY?^@K7SU;545=Z1?KM'R?Y'T*;BJMK752U]]'.71]AFU_
M^>MW_P"!<G^-&U_^>MW_ .!<G^-2TF?3U 'X_P \?T-8\O\ >E]\?_D">>?=
M?^ HKAY"TH4Z@R0;#/*MS,8H4D!P\C _* ,\D8X/.*E*N"0);LE&"R!;N4[
M0&#L.R,"I!Z?,#T-<YXP\3^%_ _A/Q+XK\:ZU'X?\(Z9H]YJ'B74)Y%BB@L;
M*/(=I74B/"ELMD<9QSBI_"_B'2O%^AZ7XIT9I%TW6=(CFL9F^:._@$BK:RQM
MC:PDLXXY%*?> )]<*UW\4EJEK;;_ ,!W>^FMNCV-.:5KJUK?CZ6_#R:OI<V]
MK_\ /6[_ / N3_&C:_\ SUN__ N3_&I:*=O[TOO7_P @9\\^Z_\  40$LO)E
MN^H'_'W+QD'!Z^V0?QZ4B&1)5S+<G<<<W4Q'#@8 R,#+ @=L=.U/F^X/]]/_
M $(4K?ZR+_>'_H<=&S2NW\6[79+^5=[]/.^P.;MK9W5MK;2\K=R2^9]UFIEN
M<[6&#=2[1C)))ZDD'W'X574OOE4RW0(V@XNI>?F/3DX!.#]1S5F^_P!?9_1_
M_0:A'_'Q-]%_K4)ZM=.:VGG=];]4-NUFM/<4EUL[I==U:3^>KOL&U_\ GK=_
M^!<G^-&U_P#GK=_^!<G^-2T5=O[TOO7_ ,@'M)]U_P" HBVO_P ];O\ \"Y/
M\:-K_P#/6[_\"Y/\:EHHM_>E]Z_^0%SS[K_P%$6U_P#GK=_^!<G^-&U_^>MW
M_P"!<G^-2T46_O2^]?\ R <\^Z_\!1%M?_GK=_\ @7+_ (_X_2F,LI((>YSW
MS=RD'G@$%NP' .!GOTJQ11;S;];=[](KM]W;<.>6C=G:_2R=U;5)J^GFBY:N
MQMKX>9<C$*D_Z3+C!E4<<]">3@>F/;*B9]MO();G&3P+F7 R5]\X!..<\YSU
M-:EM_JK[_KA'_P"CA67#_P >\/U/_HQ*&M':^B?X13UM:[NMP3^%^;?XI>;V
M\_\ @R'<23YMW\Q)'^ER=SQW]Q^)Q1M?_GK=_P#@7)_C4M%%O.2]&O\ Y /:
M3[K_ ,!1%M?_ )ZW?_@7)_C1M?\ YZW?_@7)_C4M%%O[TOO7_P @'//NO_ 4
M1;7_ .>MW_X%R?XT;7_YZW?_ (%R?XU+11;^]+[U_P#(!SS[K_P%$6U_^>MW
M_P"!<G^- 5R<>;=\ G_C[DZ#\1^'\C@U+2CI+_N#^3T<O]Z7_DO_ ,@-3E=:
MK=?975I?J-A9A<0+YMUGSHNMW*PYD4#(W8.".F,<#/%=Y(DGVEP+F;J<=,??
M"^IP/IG\\UP,/_'U%_UW@_\ 1PKT*3_CZ;Z_^UJ\G,'=T7U<9?G'LEW_ $/0
MP;;]I?\ N?CS_P"15,,K,Q%S(1D<GK]T'M]>X!]A1Y$W_/P_YFK"?Q?4?^@)
M3Z\X[2IY$W_/P_YFCR)O^?A_S-6Z* *GD3?\_#_F:/(F_P"?A_S-6Z* *GD3
M?\_#_F:0PS $FX?@$]3V_&KE-?[C?[K?R- %;R)L$_:'X..I]5'K_M#]:L!9
M$M@3<RX,C(2.W)'XCICOFI!]Q_\ ?7_V2FR_\>@_Z[O_ .A-0!6,4V.;F7YC
MA1U^Z3D$]>W&.3G';A/(F_Y^'_,_XU:;I%_OR?R>EH J>1-_S\/^9H\B;_GX
M?\S5NB@"IY$W_/P_YFCR)O\ GX?\S5NB@"IY$W_/P_YFCR)O^?A_S-6Z* *O
MV>;:&^T/@XQR>_2FQ"1)X1Y\A+3I& <XR2><YSV[=.O!ZWS_ *I?I'_-:IC_
M (^;3_K]C_\ 0GH EGWFXGD$KD+B(YX.\[3D<YQSG)[YP,5 ;>8$@W#Y!P>3
MUP.G\^_6K$OW[O\ Z^5_]!CJ5_\ 62?[W_LJT 4O(F_Y^'_,T>1-_P _#_F:
MMT4 5/(F_P"?A_S-'D3?\_#_ )FK=% %3R)O^?A_S-'D3?\ /P_YFK=% %3R
M)O\ GX?\S1Y$W_/P_P"9JW10!'*TAL[7][+DL!P>.W7)YSQZ'!.>0*CDAF8J
MWGN R @ G!&!SZCKT/\ ^J67_CSM?]]?Y"IGZ0_]<A_): */D3?\_#_F:/(F
M_P"?A_S-6Z* *GD3?\_#_F:/(F_Y^'_,U;HH J>1-_S\/^9H\B;_ )^'_,U;
MHH J>1-_S\/^9H\B;_GX?\S5NB@"IY$W_/P_YFE$$P(/VA^#GJ>:M44 1;9O
M^>I_,UV.@$_8]K,683MDD?[:\#Z9'7DG-<G75Z#_ ,>Q_P"N[?\ H:4 =+N&
MT)SDM^'WB_7OP/SZT@Z=<\G_  _GU]#QVI&ZI_O'_P! :G4 %%%% !4L?W!]
M6_\ 0C452Q_<'U;_ -"- #Z*** "FO\ <;_=;^1IU-?[C?[K?R- $-%%% !1
M110 51U%UCLYW8H%"$;7 (;=P5"Y&]WSM1 <LY &20*O5C>(HKB?1-4AM)A!
M>2V-S'9RLBN%NWA=+;(96 !G:,%L97.001D535ZM)-V3J15]=+R6NFNGEKH[
M;&=7^%4TO[DM--?=??0_+#P]\%/V0? =O\<?V?-#\=^$;;Q%^TGXH^(.O>(?
M!_B+Q%HW_"?0^)OB)>7,_B4:=97!BU%;2ZN[IETC21;.RHIA224\K\^^!/\
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M[I_*C:WH?Y?SQ^E=GMGW?W+_ ",?8._P?CI]W/\ H:/AU<^(M)5N<3=_HW^
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MILO_ !Z#_KN__H34N?E*X/WL@\8 R&(/?.0<<'MSZ$HQ:+[S,1[9).#[CO0
MC=(O]^3^3TM(W2+_ 'Y/Y/2T %%%% !1110 444?2@!Y_P!4OTC_ )K5,?\
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M?_@ZG9;W\_EWV\HCMVQ_Q[SYY&2"1[G[O!XP<$]#G'2G!>F+>X]L'^7%:O\
MPD.K<*%L>,=84SSZG!XR0/\ Z_%2_P#"0:F>BV/_ 'YC/]*_2G4K7=Z'WS_^
MYOOT/S5*#]/*+?\ 7]>5L8* #F"X!P2.OMR2%).<8&.23Z9R;&Z_9[DC/!&0
M"/Q7_/H*V#X@U8CY$L&]?W,>3ZX.W '3ISGO@XJ/_A(=6! *6.01D>2AST..
M@Z]^.^.U*-3%.3M3]WHN?2UM=?9V=]>US.I&A:_V]+]'VUCZ6^2,O:PY\BX
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MV?)WMTCKKW_+Y6^@AK&K?7]XU9:_:EV*?FQ_\^UQ^3?_ !%'FQ_\^UQ^3?\
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MB@ HHHH *6?_ (]$_P"NK?\ H34E2N!]C4XY\UQSSQEJ (6Z1?[\G\GI:DD
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M,Z:6L5>[^RC\G=9WUDEZS:U6CVML]^PT-L;;M7+9*C)R6'1%#$'+#IR3@#C
M!#MRLJ.J JSXESN4VT3*P%PX8@NC2XB^3G?C(P.&,%EDA0*R31RK=)<G)AA2
M$899>@(8NK!25R,GG!%?*/[5W[1^L?LR>#O WQ";PI-XO\&6_B:+3_B9JEA'
M)(FA^%[\R6L&J3M'',B)9:C<6TTC3.J!4/S*0&''C\33P]%5$K7W^%75WV;L
MGHNCNGLM^W+\'/&UIM-M-*VK:LDMK^EO0^FY=8TNWOK;3IKRV2^O;H6=E9O,
MJ7%W.6V$PPEQ(8U9DWR%?+3<I9P",::,'4[&4E'DC=<.I1XV9'7_ &L.K@$;
M@<95B#7YV_L\:A%^TS^T-X\_:@FU'4Y/@WX:TZX\!_ ^ST^9QIWB>W@673-3
M\:>6#);RS:LMI87^G3P!LF9F663<#7Z(6RM';0>>46Z82&>)<;HE\QOLHDZ-
MYKVVQI,J"7+<9-&"Q<*])2Y=+1L^123;NV^:][**2MRJTGJW>Q&/P<\+746W
M;5-7^[YW]=OF2X;C.,9&>6Z?G3O^ C_OM_\ &EI"<?R_/^5=O/2[*_DDOR_
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MP?R>A;_-?F-;JVEVEIIHVD_S([<*MS!\BG]]#SECC]Z #@GKQGV^O->A2?\
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MPB_+_""Z9 _#CGKQCC' .:\A/NUTUNOR5VNMO*VIZKN]G+T;=UT>K:OLO^&
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MI"I(#Y& W3OU9/Z@_F/HM !1110 5+']P?5O_0C452Q_<'U;_P!"- #Z***
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MWO16GR26O7\S+V$GTCMT;W\]'HO3[B43QG@6$Y^BL<_3YN?H*!<1?\^,Q[\
MYQTX^?\ H?YU6CNX$V,NHPM'"Z) ]K:74+VK.#\[I<(254C;N*E1U/8421-:
MM<.EI,5A@MM-,491+U[AIRPOTFF!MD*F92=PP=AR#D&K7M9J].FYQL_>VU5N
M:Z5W97_'[SV=*.E2HH2_E45*R>SO[N^O0M"]M!D&PF!7[W!.,].Y/<>N>U+]
MNL^/]!EY]O;/KZ<\=N:IB-0LMH!%/+))##J2,KO<N8@ZPRRS*1 \A7S/-DA_
M=EF& H%,DECMWNXYHI599T#P ;I96V*L!LBNY1(6\M7+EE$>_(!!8.2K07-.
ME*,$N9RYT[+35+D5]^C^;&H49-1A5C*;=HQY6K_/GLG9/9?+M>^W6?/^@R\=
M>/7IG)R,^]-^TQ')%C+@DD<$C&3T.X9 Z$CICGFJ;.(?M#7T;6=VHB@U0WH^
MUNSW!=+6"S>Q)B:!W\U9B=Q10"SIE24#B.VE%M;VLMM;IY%NLWF"[,<["6YD
MA8LJ;8[@%%)!*A@">"3G[:%KIRVZQNOD[KIK_5S3ZI-K7EVONE]U[];>OW%Y
M9XR?^/*4<#J#CGZMUZ?GSC(R_P ]/^?)SUZ+Z?CUK.5X_->%7E9U ,BO'(-I
MZ;1.%\B0CGY48L, M\I!,P'J3G)(Y_D,],=N<9P:ZJ34H*2>COTL]&T^K(<)
M0]UM7735[ZVNK=/+3J7C+;;@?L4HY [@'."1C<#VYP,G'&*\[^(]S81KHOF:
M=*X+787(R5PL0QC)&".#@<]AUKL8OOQ\GDC/)_ND^OK7G_Q*SMT/W:Y&>O5(
M0>/7G\?PKV\ACS9KA8WM?VROV2H57W^>_HCQ.(I*&3XR35U^YT[_ .T4K=&<
M2UYIA'_(+D/.3P1SSWS]<C_"H?MFF?\ 0*?\G_\ BJ@  )_P]>W3]0?8]!4
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M#/\ %P?E_5ST<$VU4N[ZP[WVE9Z^A)YD;\M!C'3!P2/7&1@<8')Z$=J,P_\
M/$_F/_BJA3O]1_Z A_G3Z\X[A^8?^>)_,?\ Q5&8?^>)_,?_ !5,HH ?F'_G
MB?S'_P 51F'_ )XG\Q_\53** 'YA_P">)_,?_%4%H0,F$X'/4=N?[U,IK_<;
M_=;^1H D^T6W)\GZG!Z^_-65EMS;JWDC!9L\=OFZ=,D?GTZ\ U,#8_ ^^O;_
M '*23BT&./W[CCCN?Z_ETH E\RWP08<'CIG@9SR1TXZ9 /J!29A_YXG\Q_\
M%5$0,1GN7?)[\;R!^':G4 /S#_SQ/YC_ .*HS#_SQ/YC_P"*IE% #\P_\\3^
M8_\ BJ,P_P#/$_F/_BJ910 _,/\ SQ/YC_XJC="/^6)_,?\ Q5,HH :9]K$+
M:D@' _#\/7)_QI8[@_:+;_1]I^T1@9Y)SD8&>?K@<_7 +R!Y2G SA#T[DC-5
M!_Q\VIY_X_8^Y[,_3T_"@"87&%O?]'QFY7'&<XV#T)SUSQTXZ<B8O$Q),&">
MN"!^&"01CTQCGCCDPR##W6/^?I3^)5"3^IJ5_P#6/_O?^RK0 N8?^>)_,?\
MQ5&8?^>)_,?_ !5,HH ?F'_GB?S'_P 51F'_ )XG\Q_\53** 'YA_P">)_,?
M_%49A_YXG\Q_\53** 'YA_YXG\Q_\51F'_GB?S'_ ,53** "ZG_T2W/D?Q$\
M#@*.X)^O7\CC I1-')C= 1A5([<-W//(P!S_ "Q4<O\ QYVO^^O]*F<#$/'_
M "R'_LM !F'_ )XG\Q_\51F'_GB?S'_Q5,HH ?F'_GB?S'_Q5&8?^>)_,?\
MQ5,HH ?F'_GB?S'_ ,51F'_GB?S'_P 53** 'YA_YXG\Q_\ %49A_P">)_,?
M_%4RB@!^8?\ GB?S'_Q5!:( D0G(!(YSR!D<!L]:910 S[0?^?4_F?\ "NQT
M%]]FI*>7^_;Y>Y^8<_@2.GISR37(UU>@_P#'L?\ KNW_ *&E '3Y'E=?XO\
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M\+:/XNA)LHM:ATFR@O[2T@MP)M2TXPQ;(6GM))-/9%$180L2"K G.\2?LY_
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MKRUU]"<]%_W_ .II5Z?E_P"@K2'^'_?/_H1X_P ^E*O3\O\ T%:^=K?\NO\
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M*;+_ ,>@_P"N[_\ H34[/R,.^]3^L?\ G\#Z4V7_ (]0._G.<=\;CS^H_.@
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M@Q?2'$L>%^;DAQ@<\=<5W$ZV_P!J;$^.3_$!@[B0IXY);''0DC!Q7G<7%Q"
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M&<\^W;ZF&6&(&[ 3K<*,Y/ Q&V>N3R .HX_'+VMX@S+LSM.,EW!)P"3P3ZT
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ME7I^7_H*U\Y6_P"77^%_E$]][5O^OJ_]+E_P!)&95+)]\<I@$G=T! &2<=>
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M]2/_ "(A_H:'\,O\,O\ TD:^SZ_^W)EFBD!!_P#U?A_//7GBEH)7]?B%%%%
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MH  ._ 'K1@>@XZ<=*6@ HHHH 9+_ ,>=K_OK_(5,_2'_ *Y#^2U#+_QYVO\
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MKW_GV/\ WTO_ ,51]FO?^?8_]]+_ /%5']MO/^?F7_OGUZ]J/MMY_P _,O\
MWS_]:ES^;_\  5_F'(NS_P# G_D2?9KW_GV/_?2__%4?9KW_ )]C_P!]+_\
M%5']MO/^?F7_ +Y_^M1]MO/^?F7_ +Y_^M1S^;_\!7^8<B[/_P "?^1)]FO?
M^?8_]]+_ /%4?9KW_GV/_?2__%5']MO/^?F7_OG_ .M1]MO/^?F7_OG_ .M1
MS^;_ / 5_F'(NS_\"?\ D2?9KW_GV/\ WTO_ ,52M;W:X_<-SDD94GH"!PX]
M3SCD8[YJ$WMV>MS*?^ __6I'FNF"XN9#G& 02!QSG&<<YQWP#D#%4I)IZOTL
MD_56;;^[03BET7_;S;7Z)>5W\C4M+6[:WOF%NWS0(&PRX \U>OS#KC\!]21E
MQVEZ([=# VTDGJHZ8(R-WKWY.,GUQHV5Q<I;WW^DR']PF!ACCY_3 Z'CH.<=
M>HS([RZ_<G[5-M+'! ;G/7!Y'\/&><^]#;L[W<7T6Z5NOFD]M+=!QY6U96U?
MGH]=+^=M>_3:U@VM\"1]G)P<=5R<<9/S^GJ.O/M1]FO?^?8_]]+_ /%5&;V[
MW$BYEZGG;S^>/ZT?;;S_ )^9?^^?_K5//YO_ ,!7^8<B[/Y2=ONMH2?9KW_G
MV/\ WTO_ ,51]FO?^?8_]]+_ /%5']MO/^?F7_OG_P"M1]MO/^?F7_OG_P"M
M1S^;_P# 5_F'(NS_ / G_D2?9KW_ )]C_P!]+_\ %4?9KW_GV/\ WTO_ ,54
M?VV\_P"?F7_OG_ZU'VV\_P"?F7_OG_ZU'/YO_P !7^8<B[/_ ,"?^1)]FO?^
M?8_]]+_\52BWO1N_T8_, /O+QC//WN>O3CIUJ+[;>?\ /S+_ -\__6H-[>$?
M\?,I Z_*>/KQT]>V,YXHY_-_^ K_ #'R+L_G+_@$\-I=_:("8& \Z(]4Z"0.
M3]\^^!^IZ5W,G_'TWU_]K5P<%Y=-/"K7#D&:($$'D%QP<8///X_C7>2?\?3?
M4_\ HZO,S"UZ5F_AGNDNL>QWX-)*I;JX];[*7X:C4_B^H_\ 0$I],3^+ZC_T
M!*?7G'8%-(;.4<HW=E/S%<8*?0\G/N<#/-.HH :54DGRU!(_O,V&'1AN!Y'7
MJ.>XIU%% !2$9!'J"/S&*6CIUH .<$<8)!/J",=/K@?2G-$SVP /'F.W;KN)
M]1T (ST&<X.#3?S^N#CZ$] >G'N/6IQ,([=?:20Y[9R05SD<XYQU)X^@!6PX
MV[@,+GH1G<QP21Z?-T&<9YZ<NI?,W*5"D!BHRP(^ZQ;"YQGN" #C Z=TH *;
MAA@HVPA@<@ Y ()4Y[-C!'88'.,TZB@!ACC6:2Y@06]Q*8R\L;NS-Y0(3A\J
M  ?3CH!BI"<DM@ D@D#IG !Q]<9[ 9P.*2B@ HHHH ,L5"_+@ #/.?EQCCWQ
MZU&(_P!] XR2MPLFTG@D%B!VXYQQ@GCZ5)^!QZX./;G&.>W//:A)%26(\,?,
M"@<$Y)Z8SD'CC'OF@")Q)YMRK ?>\X@8&74*,<'H0/J<DYSD4]6+@.PPS\L!
MT!Z$?AC'/-#3$3W#!3PFT ]"<*57C/)&!CKVP,X"1$F-<C!P,C&,'TQ_G/7O
M0 ^@C(/^?Q_"BB@!I!R60+&^T*CKDF,CJRAL@L??IQUI%11ABN92,23%V+2?
M5?NKSS\HR.F2#3Z* "BBB@ HZ444 ,N(KA;2VPJ\,,9[D' '7K@<\D4[,A*B
M0!=J(% YP".03U.", X'X]:+F69K2VP1MW <?-D<#!YSTSG'.< 4 L=I8'_5
MI@G(R,=L^@(]<9QVQ0 M%%% !2$9']#T/L?8]#2T4 1F*-B6>,.^Y'1B[KY;
M1\(55<+\@X7(/0'C%29<[=[ERJ[02 , DMCCKR3C//J3110 4444 %%%% !7
M6Z$N+0-GK.V1_P #4#GVQ^.>U<E77:$1]C R,^>W&>?]8.WXC\Q0!T17*A\]
M&Z8]RG7\<]^F.**7(\O&1G=TR,_ZS/3KT!/T&:2@ HHHH *EC^X/JW_H1J*I
M8_N#ZM_Z$: 'T444 %-?[C?[K?R-.IK_ '&_W6_D: (:*** "BBB@ JAJ)VV
M=SN+*K1.KLK$%8W^21E(PP=8V+*P.Y2 5((!%^J.HRVD5G<37KK':V\9N+B1
M\[(XH,RR2-C^&-4+M[ CKT:TE%\GM+-?NTKN>OP)6=W+X4K/5K1K1Y5ES4:J
M]K["].:]M>WLKQ?[R]U;D^*]U:U[K<_B\'C']MGPAXE_:LMO@MXJ^)7A;1O
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M]JT7_GUF_/\ ^RHYX^?W"]G_ 'OP?^90E=2HPP.&!/T'^!P:5F!DB '0J>V
M"T>#_3\ZNFZT8\+:S9.,<^_/\7I4YGTOS(\VTG5>>!_=QG)R1C!'49SUSR<R
M>JZ7\KWLMQ.%M-_.^VO\N[[Z6_,J:AN/V4 'F,CIG/'3Z_+D=_RJJAVO.S<
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M#]/\*-UK_<'Z?X4 5?,3^\*/,3^\*M;K7^X/T_PHW6I_A'Z?T% %*966.T+
MKAN<\=7S_(5([IYKG<N"L??T!&/KQ_6KEW<VSQ6WR@ OTZ_Q'KTYZ9(YQBFN
M;42/\HQA,#&".#UR.O&>..>,]@"IYB?WA1YB?WA5K=:_W!^G^%&ZU_N#]/\
M"@"KYB?WA1YB?WA5K=:_W!^G^%&ZU_N#]/\ "@"KYB?WA1YB?WA5K=:_W!^G
M^%&ZU_N#]/\ "@"KYB?WA1YB?WA5K=:_W!^G^%&ZU_N#]/\ "@"KYB?WA0)$
M)P&&3P*M;K7^X/T_PH#VHYV#CGMV_"@"OD>H_,5UFBY-F@ )S/(>.>!(#FN>
M\ZV_N+^E=5H3(UN2@ 7SNF/]I/3C^OKB@#93(49!&2V,C'<G^1_GZ4^I).B_
M[W_LK5'0 4444 %2Q_<'U;_T(U%4L?W!]6_]"- #Z*** "FO]QO]UOY&G4U_
MN-_NM_(T 0T444 %%%%  >AQU[53NV=;:9D&]O+;"[MA;<"H^;H.#UP,< ]L
M7.M9VI1&6RN$""0[0P1I9( ^QMY7S8<2+N & #@DXZ9%5!I5(.2O'GBVK7T4
ME?2Z;OM9-7O8RK*3I55%J,G3FHR;249.+LVWHDGK=Z(_F9C_ ."Q7B#X?:Q\
M<]-^*7PIO/B5<> /B?\ M'6M@W@%TT8>'OAM\#=8:*ZU#7_)M-0-Q<VVER++
M>7LQA$SQ22-MS7L=U_P5S\'VGA^]U&__ &>O'UKXL36=$T71?!$EY-)?>(G\
M1>&;/Q/I=U:WYTI5B@FL[V"/=Y$B^9GYCT/MT_[%O["MGXM^*7A274=('CWX
MM)\8Q\0-$'B359M0U#2/C<6/C;2M/C:[:-+VXA,L2PQ/;RK(54%6&1S7[0__
M  3(^%?Q@LO!UKX-N-=\'BT\7>&]1\9SQ^)M=MM7UW0/#OAA/#>F_P!BZA#J
M!O=%GM;&TTZW9-.GL=SVLDA+-([O^@X/$93*FV\/73<;6BZT(KW7?W4N6[>W
M)=KXGK:WR5>CF:3_ -NI-7W]K3O;1WO[3_+3L>>7/_!7?X?17/P[TG3?@EXS
MUGQ5XAF\;K\2- M[Q[:7X1I\,]&L_$GQ!&M7!TR1;YO#GA^ZDU!V\NS^TB!D
M&PY89(_X++?#^WT2]\2ZW\ OB)H.@3)?^)?"NL75U</:^)OACHEV-.\0>/X6
M.DQBVT_2]0FLK>2,R2JWVI6,R@5]>^"_^">O[,_P^UO2/$VB^&-6N]4\+:5X
MY\.W-_K&LZIJ!\2:3\3O#G_")>.YM<>XU&ZDUS4_$&@F2QO;_4Q=7MO'Y5Q;
M3B4 CEOA]_P34_9/^$^D^.-*M/#^L^(=$\=>&_$?A26R^('CSQ/K>G^$/!WB
MZ^BU35?#?A.#6=:U&UTG3+NYM[:?R;);+RI(4"1!02,)ULNE77)@ZS7NV2]K
M=V=FK<ME9N,FWI)-IKGLGSTZ6/4'S8^@ES/65>DETL]:MWU5][ZWL?,/C/\
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MI)\TG&/PG)B$H37)JG+3DVT]Y-+5OK+M;L-\N/TC_+_Z](8X\C"1MU_AY_\
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M#7#*>@)Q[?O O'T &/>O/H?^/J+_ *[P?^CA7H4G_'TWU_\ :U>/CVW[&_\
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MO:WW&T,#CYQ4J4^6G)-Q26BM=/:22UOZ^NAB,TTRBW40V]M;' 5 01LZ$#)
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M3\9>,_!WPV\)>(/'?C_Q-;>'?AYX&L!J.O\ B75H3;01Z4T2W,EP]Y/)&K&
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M]..V,XSCW\'\,[CXCTLE%5&G)CVXP5*MEO?)R.<'GIC!/NL__'Y-_P!?2_\
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M5O)103(D94/+P1\L89B3@ < (BH\7G!5$102!Y \2E"Q4$>8BD\\$ $@?,0
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MPCFN'<G%QJ)IN.D=-&TM>6UW;??S9^RFZ 1&9MBQ^:(@6#H[,2 -D;*'=26
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MM;V:OKV5EI9VO?SMJ7*,J?\ $5NO;3[W_P /H-2U1]Q5RP4;B05Y'L."2/0
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M%OR80Q7S#D2"(@%3AV) )QGY,@YD^X."6Q3WMHXU5F<@.VU.5))R>@&3CIR
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MRBPM>^2[BON'P_\ \%+_ (N:Y^U]X@_9QUCX1:9\/O#&B_$C7/!D/_">P_\
M"-:MXB\/:+JTNG/XVT/Q5K5QIF@ZZ=5M534+'2=*^U:E,S+!%%+)*BGG_'G_
M  6,^'?A'X+ZGXR@\/W7Q&^+5E!JJMX:\+^&]<?P_P"'-&T_XD3^#8=1\9:S
M':W&DZ+"%BA<MJ=[I_F/-!."894#_K4LPXKQ.4X:GA\-@L1RQA[M.G2J-*7+
M!1Y4FEHTI+2ZLES/W7\'7PN'C6YI8VC%<SNW5BMNN_KK;3>R6I^7VG_LA_MV
M>.? O[:GP_\ B/HOQF\2^%=<N_ WBWPE>ZUXNUF'Q'J6I^&/$6J:[XBTVPTN
MVUW^Q[)M2M+6PM;.*R$2JT@(:$\U^F?[;7P4U#XJ_LQ_LE6T?P+^*_BW6_A[
MIG@A+8>%(=.UKQS\,->TKP[-:Q:CJOAC7=:C\+>)X(G+FYAU_P#M=6DF4/"W
M;ZQ^$_\ P4H_9H^*/Q0\'_!:S\:_9?B!XDTT2"-[&[NO#<'C**U:ZUKPG;:]
M;6O]DS:E8QK:+,PU"6.5KN!8T#DAOE+XK?\ !3GXI>"?VT/''[*GA7P3X0TN
MT\$7WA5["[U_P]JWB36+^;7]*34;J[M[O1;R.UM]SS2"TCN8F*JZ_*57-<55
M9U/$4'C\NE'&0H1:ITZ#I)T5*K3C.2Y-'S\RYDG*RC&]G&)UVPW*G3Q=&K"R
MBYPK0FE)*\HW4K*233:Z<ROK9GYL^)/@C_P5)NO#O[+.EVGA?7="\*Z8MM_8
MOA_P?-_P@$F@7D/B:^N)_$7Q*T3P;)I.DOJ\UH8(WT=$U+1A#;V\B0B6XN"?
MHG7?V5?VQ]6'Q>^)OB>Y^*GB;XA6_P 6/@S:>&H+G6[B]\(CP_ID_B >-==M
M/"5[J#Z%YMF7L98;@:4)8A)^[*YKKO$__!:KXJ:/\:-6\"V'[/5WH?@^T^-Q
M^$$'C'Q=IUP]C';Z)H/AGQ7XB\27FK*MEIUO-::?KUU*EH[Q3B*U@7RF9UW_
M '_X?_X*J?L@Z_9_$_5Q\0;]+OX5Q:A-<ZA>:-JDMUXP:-;B29? &GQ:<D^I
MC-J19):0:F\_GP"(2[@&TG0S%5:-=Y5B9QI5(SFH4)S4N5MRA)0A+E5K*3;<
ME)7M;185'A.2<98RC&\7%N56"6O7XMT[7MI?1]4?E)X1^"O_  4$OO&OB>XD
MTWXQ:)\8&GO;WQOX^U3Q1K"?"GQ)X"@T)ET?PWX7T2/69=/T[76NTTP/)9Z!
MI[F5)MUT58LW/>,O!'_!2+XR> _$L5SX4^/GPDBT/X/? WPW:-I^MS)K?B#Q
M=X0U7Q3<>.+M%3Q!,KV^M6=UI<5U-YB3&$$;$QS^J&L?\%9OA.OQ6^ G@/3?
MAY\71IWQ1_M6WU"Y\1^#/$GAR7PI'8Z;JVL2WNI:3K/ARQU/5Y)M/L3>6ZZ<
MG%O/"=AVLQ^@?V5/VZ_@+^V'J7C+3/@?J6O2W7PVE@^WWFJ:#K&E75[IFN27
M-I;:C;MJVGVD1MYQIMP?+\LR1A#O89&<\1F?)"3JY)4@U9Q<L-+E2V;=Z=[M
M)-;J/,E%RY9-/"X.A4DE3Q=.IV4*D7N^C3:MK:R];H_.G0_@]^U'XZ_X(V_%
M'X)?$3PIK%Q\>?$?AGQOHGAGPY?ZOJFO:QX@%_KMS+I5WJUUK-S=2I/%:>0J
MP13FW 8+M*@"N5^*'_!/'XO_  4^ ?B#XH_";QAXP\5?''XEV_PML/C)X:\,
MZ?HG@K6].\ Z%XNTW4==\)>$K#P9#HVGOJMQIDNMVTFMW4L.L31W*(]]M@B*
M?T&BZF>X:59[B*ZB>,6%[B)]/4(H5Y+RU1/,G164!U@9"23CDY$:O):C=;"&
M.2*1C/\ V:AMUU-Y,*UU#]K,WD-&IW!)L_ZL +TQY:S9\R=*E.E3YZDW3=.W
MO25N1WC=0BTI1:]YRW]Q*)ZO]ET[>_4BFTDTYV=KW36JW75::::IM_RQ/^RM
M^VG=>-_@M\8O#/A7XK1P^'M3^*GAOX,^&O&?B34]4\2_"&'Q=KN@7?A+Q'XW
M>^UG47O[73X-)A<+=7VLA428>2V]@W'?#C]GC_@IGXC\#:OHWB*;XP:#9:WX
MZ72?%5C;^+-8BO\ Q%(-46]O/$VB:J-7&IZ7HQT]&LA#9W-@AE$B?91&2S?U
MH%Y'E>X$\T5QO@^SS3[))8V4-NN+CRHQ'(R$@L(T7.3M SRDAG:(XN6$\T8:
MX>)%0+,) ,(-A"JT?SM][.74$$\;QSB,6G/#J<+>]#DYKWN[-<EVE)II;WOH
MM63+*H2C)4\33IS?PS]HERO17OS+I=:_?>U_Y5?%_P"R-^U+:^(=$\3ZKX:^
M+?C&+X=>,/VOO 7@6*_\3:K>3V7A+Q9H'@C2O@GJ%R\FLE]407UIJ[W*Z@]Q
M%,$ G24,12:I\&?^"@\7Q7_9@U*R\!_$S23X#U:S7QOJ-AX@U*'PQK6B7&DW
M N].O_",>L+X9G+7$D&9GTKSLQOF0;Y-_P#5>UU+NMW17#6\4\#;O+9)IY$5
M3?E0AQA@)(8R=\9!W;MW$#,ZLD0:[F@N65+@O)!NMB <W"$QY8%P6"*2VUL'
M'.=WG^$_Z%]U:ZO2E:_9+E;5M]6TV[*R6O/_ &-B?^AG2TV_?QOK_P!O]/.Y
M^<?_  2W^%7CWX._L\^./#'Q#\+:GX4US5/CIXN\3K8ZBL<8>VU'2= A2:W5
M)90D;R6LB*BA4!4[0*_2 8  '3@#O_GZU&7=Y1N20LT2M).[J TA)#JL:@$,
M!R7Q@[@ 20:D''Z_S_SG]*\NK6IXBK4KTZ;I0JSE-4VFN5NREH]=XW3LDT]$
MD>G0HSP]*-*=6-:4;WJ1DI*7,V]U>]MM]"&+[\7U'_H)KR_XO+$=*LVF9T4V
MFI11LK.B/<RVZ+!;.\1$R?:&^53&-V1D8P"/4(OOQ?4?^@FO/OB4"RZ#EOD2
M2>954?O1<PI$UO-$YS&IA8MD.K9R,=\^ID#MFN$=TM:^K:27[FKNWHKNRN[V
MN>+Q3#VF1XV'\WL/PQ%%_IW1^''P?^.WB'P_^S9XC\%>%K_7%^,NE^-/'MMJ
MUN;6XU1=%\.7GCS5[B.]@;6$DCE,=C);R1$[\ A%^3(;-TSXT_%B/7[71_$'
MQ/\ '&E?!W1O%.I:=X ^*MOX/T)_%'Q1U&*UMC8:%>:6U@^FP6#3/&1=K!;S
MN9I%>0JJ@?L.UC:@7$OV2S=UB9;K[1:P/)KJRNLS1&2&.)8#%(00\P 8QCD@
MFN?\6ZQ;>"?!GB;Q8T"7%OX>T*^UFXL4CM#(GD6TLL-HI,)A%PKPX-S"BI\Z
M\DJ:_2>>+E+EDTY65U*T>:5E\2B]4E:G+5/G<6N9RY?QYX2,;*4XV[2WNMEJ
MWI??[]M_QXL?CQ\:O'/Q1?PQ?W7BFT\,ZQ#XAL]:AU/1K?3+G2]7T2^@L=$N
M5_LV/R8KF[MS=W%G!%*;:ZB8R7(62-,0Q?&[XM7GQ,\)^ K;QWXT^']_ILNJ
MWOB6:Z\-:9>Z(VGV.FZ@VBZ=:7MU:7MR]]K&M06-G*)55$@NV9)4?;C[>;]N
M?X P'PGX?U[5-8T_Q5XETS0;AM+LO 7B+50]_P"(M,AU73;&SU/3=&GLWU,0
MR.#/YSPJR3;T&1AFC_MI_"/7_$'BS3;S3[VTF\(^%K7Q1X@\1WOAC4=9TO6]
M,GUR'0H--T^+2M/$]KJ]O=2Q7$WFRGRXXI&D@0[FKI5+$R2G'#U9P;Y8RA"4
MDWS<L=4FE%---ZI>Z](\SC4:-!12>(I1DMTZD5;KU_7I9Z'Q+HW[0G[4.HR:
MP^L7>L:'8:EXFMM(^(]U9Z#9RW'PWTG4KN6)[Z".XMV2<6T/VB3.+D#R%!5N
M,_17A==0U#]C/XR6NO\ B3QWXF&J:C,I\8:' MEXNNO#T>N1?9]>AM(GL8K:
MP@:.TMKB&W6,R)(Y:WD5V8^O6G[:WP5U'Q/JOA71XKW4;#3/#^G>)KSQ5J6E
MRV6D6T&K6[7<%I<W%W8V\,+:8J.F+J;=D,3T85LWO[:'[.FG6][JNK>+=9M6
MTD6U[+]G\':Y;#Q=&T$=FB^'"^D-:>(],MFN$AFET:.]B%Q;DM*'1EI5Z6)I
M1C4E0G"*G%MR@[-QDFH<KLM4G]KF3Y7%-)L3HT&GRXBE)]$JBO;K;76V^JM:
MZ=F?CEXLN_C#HG@ZR7X*65YXAU?3]8\%:K9^._#6H^(;'3/$>G:1KUO?'^VO
M#(>QT2#6;1(7FF2TTH17KF.WNY)H#BOJ*7XC?M >,?C#X0\'>$_&GC'P]H/C
M >#9O%WCBY\,Z)(NCZE/X82]\7V%K;W%M+:;8?$'GVH+6Y,8C"HRC(K]7/ 7
MC7PK\1O#EMXO\#RP7&CW>H3PR?VSH%WI.IVEVB1L]G+:WEO826+0[T8175NC
M2%]J@L0!VHM8C'$TUII[E!=R6UK;V@B:SNVN-PGDE8D2F[)>Y*H3Y8)1@"=M
M2\5-M<L)I^]&Z5[-Q3NURN]FKI2E%>KDD3]6C;XX7T^U_G_E_F<C^SIJ6M:O
MX2^'FI>();R;6;F&Y6_FU""*VNYY+:_O;03RP0CRHC/';I-L0*,. H%?8<__
M !^3?]?2_P#H35X9X;S_ ,)%I"L5++-@E%"1'Y&(\I /D4 @%3D[@S [6%>Y
MS_\ 'Y-_U]+_ .A-7YMQO)RKX:3W;5]+?;MMT>G]:'ZUP#'EPF)C>]H)76J>
MKV?7U)CV_P![^K?7^7YT_/ /J!V/4]/IS[_SS33T'KNX^NX^QI1GY>I&.G'3
M_'D>G0^M?.8ER4:+A%R=FK)7TM'?<^HH14G64I**4Y.[OJTW9?/]'N!*XR[E
M$ 9GD5=Q155F+ <]E/&"2,XSBO&/"W[0?P8\;:0=8\+?$+0]8T>#Q/)X,U?4
M[.60WFF>,8$@G;PU#;SPQPM>2P7-H?\ 2%Q_I8Q+TQ[&[M&DLBF97\F8(T#)
M','>)HT,;.'16#,OWU8$9Z9X_!S4?^"=_P"TCX07PIJ/PEU30;:W\>^,O$/B
M'X\Z!J=S#)#%K\6G7,^@?$#P[(+^!8;VXNK'P[I,EJC74B+9R3/;I$Y9>C#X
M&AB6O;U:=*ZBN:<E'WI736NRBE>[22NNZ3Y\3CL1A;^PH5:RM_R[IN6UK:KR
MW?3M>Y^ZHU&SBCDO9=3TLV=O,8+A7U"T62.60E+:TNL38@U'C9<Q,RQ+.K)&
MQ4<V9+JQACM/^)E8%;QO.M;VXO;-8[B N\06(PRLL@28>01&KN&3!)(:OQCL
MOV+_ (N^*?%WAF'5O ]QX/\   \1>"[WXL6K^,--U&7XJ76BNS>)M9D%EJ,D
MNG0:U<--=):;;>9%N2A4,O'#W_[$_P"TY:>(?#EEIFFM<?#[0X)K;P/X?@\4
M:;;R_#&[/Q!N-<;6!/<Z@6U4W.@27D'E1&X91J.S:'CPO9/+<'"FH+$T)N,/
MBYH-VUC;2;7/>/-+1KE<;6;:.*EG&8UI\L\%B:<>9Q3E1J15M'S7Y=4[[W>S
MZ:G[NN)/-N/.B2T-K&%:*)V=;B1@P5U:0LYRV,;2!VV\'*CVR!A3AOO9*@G/
M7C)(')/'/H*MB@@LK:"6!S<V<.FP+<22*YN# P^T2L%.05P7Z9(R%R3Q9&_=
M(7E\XM([>8%*##,2J 'L@('\N.3Y$L-&C-SC)2WCHU;6S5K>2MY+0].;<J<9
M2;YFXWB]&KIMJWKKW6W<9-]P?[Z?^A"E;_61?[P_]#CI)ON#_?3_ -"%*Q_>
M1#U8?H\=+JO1_H8]%\__ $I'-?$CX?\ @WXE>'U\.>/?#]MKOAX0?:#_ &F[
MVL5E=,[Q_:]*O[)AJ%C>+"=@O+5H;I0&59=O3X?O9/\ @G[J5Q:?";4+7P[=
MW'A;Q4_A2VO9[C69)D\627-K8R^'-=\5NC:WJ)O[A;:SFCU6\N8YEED6X;9)
M)N_1&\98/LX@PAGC6>XEG'G1-(LF/)2)"' ,:#+-E0?J!7XPWGP%_:7U70?V
MHO@3H7PX@T"T^.7[1/C#XI>'OCG?^)_"TMCX0T#5M3LKVVG30$NEUX2PP6K2
M6D2 202 &2)AD5Z.5X>K-U/:8VG23G>,9UX47"$JC7-K/7E@W*R]YI65M+<N
M93I>SCRX"K6DH1YI0H.?,U%7U4=KIN][:W?<_1/4?V<?V<;T7"W'P\\+20^%
M38WOG:7<6EI;Q3):H(+2XN[>:&6ZLUADW-;W;O"YC3?&6"D3W7[//[.EQ?Z5
M>'P/X5N;SPY)"MFUM?6R(]J\BM90ZI;V\XM[\6UT\DJ1W27$"DDC.7Q^0FB_
ML._M.7GP^\1>#)(->TN\34;?2/$=]'XJTI[?QWH\2[9O$,=F+E[V**X2- T:
MLDB"?! *G/I?Q _80^*.EZ/IVK?!>/5=#U"7Q)JMAK.FQ>+M-:UG\!VFD:;+
MIN@V4EQ=M&(;C4Y=90.)9)4>Z8O+A5-=4Z52%>:EF=#V:@N6;Q$8Q<KK1/GU
MT;=KW>KNW<\[#8MQ<DLIQ4M-5]6FVM7K;DV5TMDOD?I;HO[/O[._A?Q#>^(]
M$\#>%='UBZU*:^>XM;RTCB-]<RM<7]Q:*9Q#:RM<!75+((%)Q\N%%3^)M&_9
M\^*WB*_TWQ'9>'?&WC3PY%'X(U#22ME<:CI-D4378;?S9MOV:6+[0EZEW#*M
MS&2KI*I"FORK\ _L-_&[4->^U>/] NE\'V/PO^)T7AKPMJ?BRPOHO"WQ'O[G
M19/"&H!].U!))WE$=_)EI)8K?R]D^TNN>MG_ &0?CWX?^(?Q#\4>!/!^FV[>
M(O&</B.ZUJ_UFUDM/$EA'\/M.\.?8;2R74TNX,7UL\9WX(9#(?EYHY5*2?\
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MWU18- \'^(=9MO#\,D)>QL_$T>F:;=)X<35)%DMO^)X+/R]DADP$<+Q_@/\
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MSM$4WNG75Q87%I-J6CPVJ!;NVU>:6">W\V.>&1'=#RNK^!_V2;?XAVDD^E>
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MVD>*ULK?PQIJZ2+/3];U2^^V:>LZA'!MT0H4RB]*_3H1Q@IMB<%%"J<_P#&
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M%(_^M@_WC_Z%'1*RF,_NW494DC&>#P!SU_ \9X[AA9=\9_>_>&"<<<J3QC\
M>O7ZUFI)M/72Z^;6G4CE:MLW[VE][W[]O1W-"] W69(!Q'G!&<_*W8Y!QL[@
MCGI5-FBFE> 6@E$TL4$X"X*VTK!+B13@'*1EF'3GO4^H,JO9X,G"$Y&.X/;!
MSG!XXQGK\N*@.':0[9I&5U8*@&<JP.05QD@9)R<8+9''%4_B_P"WF[ZZZO3;
MY7V-Y?!%M7M';T2_R/GG]JSXO>./@E\#O%/Q3\$Z1:ZSXP\*QB*RTZ4*+:70
M5?;,\ZK&ZEQLA4NREANZX.3\KZ1_P4=T/5/$/B#2M-^%%Q<?V#++X=LO+O[L
M&\\7V>G1:DU@+%83'%83/>V<3:@F7/F2C9B 9_0#QQX)\(_$GPEK'@;QC82:
MEX9UZWDM-6TF=YHH;V"4@O$TUM)%=QJ2,DP3Q-T^8;>?%?#?['OP(\'ZY+XD
MTGPO;PW\\XNP5N=1E99?+$8D,<MRZ/(%C0;V#,P4')*C'H4ZF$H-SQ$.>$ER
MQ5W=2NI*UK:635M;7EKJ>7B*&)KI1PLG"<7>;6EXVM:]^[5^EK:'S%H_[?7Q
M%UG5+_PQ;_LVZA?Z[;:SX6\/ZK9:9J%_<G2O$WC>&[N- @69;4&^L6^PW?VN
M60)]G9(@(V$AV^QZ?^VGHM_\-/@S\1)O">IQZC\9O$VM>#8?"2FX@/@^]T :
M@]_//*@#H9(M-F=&=(]QD !.<5[U8?!#X5Z5J=[KVF^'1I^IZEJ^CZ]>7D5S
M>F:ZUO0!<KHMZZR7#H)+$75R(415A(F82(XVXYOQ3^S3\%/%GP_L/AAX@\&P
MQ^$M)U*^UC1[*.[U2V-CJFIB47U[;WEK>Q7ZS3B:<.&N&C <JB*,8N6-RMR3
M5&R3BVES*Z5^97:DN5I1=H\LG*-^:S:?,LOS6S3KOR=UUM9;^;UWZ6OM\W?$
M3_@H-X<\#^+-'\.VG@*ZU;2)S+'K'B6^UB_T>+1M/L/+$,FBW4$<O]I^(;I6
MG\^U+0NTL=LKRDR97AA^W3XA^)'PV^(.N_"?PC!X+UOP%H-]\0= G#R7%KXB
M\(:/K<&A:Y'KSRQQK;:U/J%ZLUO:MYSS6YDGWC#$_3\'[&_[/-GIWA"&/PBE
MU:^#TM=.6VFNM5N#+I]DL*6S.TUVTLX1$?,LC-)+GYY'(S7*^*?V*_ $?@/Q
MCX+^$H7P9?\ C:=8IIXWNI4G\,W%TFH:GH"_:OM86"[OXX[M_+195:+:LJ("
MM15^K-<T$US6M?F:C%OJI2VY+K32S4VG)-$X:>,<^2LI-1DXMN^K3:TLO[M_
MGW>GUSX;URT\7:!H&O:')+!9>*/#ECXCLHI5*^3IEQ&\EQ9NI.1+Y<4RE<9*
ML 1GFKNF:'X<TJ[=_#_A[3-)NKQ/M$FJP6D$-S(LP#E6FBCC<N2P8[F.2.<]
M*?8V]KIEEINE:(+2+3]+M+>.W6))O+CA\M+?:AY*Q_(6VY(ZG;R2;-QN8-$5
M<IO8E4!"D]RO(8*<YQG ! ]!7GSY%91DF_+LKM-ZZ[_?=]=/:]FH13_FW3OH
MK7TVZ]O)::%VT198-3CCS&T<0=VSCS6,@R_49;C!/.>>I/&8HW6T2.@?YNN
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M5?&GC[P_J.M:;I\D'V5SI]O:1Z#J=L;V-W=A&C%%,G'OGP@_;"UKXE>-]/\
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MYD8'SXD*(X(D! "$C8#L8_,5+#(M+YT8G5-@%S(99\X.^0A1OW,"4X50 I4
MDX&6Y/\ 67&.ZYI._31+7?;77[]-'K95_86"2;BES)76G5;==?N\S\PO ?\
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M )JD7&-XJ]Y+GC>ZU6YLJLI1]E%J+FG!2:=E>UG=ORZV2T)_LUJ1@ZM<=/\
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M=/V564XV3<7[KNKJUH.VC5]7K?4Z 6/ADE5;Q \;LNY4DADC=N,@*CN&)/0
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MJ]/R_P#05KP:MU[+5OW&K-JUK1TT2?3S/>BW%5;?\_/SG)?H3_9[/_H*W/\
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MY::$C0()?)6Z24B/S&>',L2*0#\\B$JIZY4X(P0<4SRE_P">Y_[X;_XJH(I
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MK_V_;S[]9\377B>UTNRUAM6G:19(KJ2WTB P:B)9;F&:624'>JD]?/P79?\
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M)I/[ UO_ *!6I]_^61_^-]_:OT)V1=[>/\$__52>7%_S[I^1I_\ $3L9_P!
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M*G_[X;_XJC[-JW_0,E_[Y?\ QKZ-V)_=7_OD?X4;$_NK_P!\C_"D\PET5O\
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M_='_ 'U_]:BBCD7>7_@3_P P#:_]T?\ ?7_UJ-K_ -T?]]?_ %J**.1=Y?\
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$0!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>form10-k_005.jpg
<TEXT>
begin 644 form10-k_005.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" (7 [8# 2(  A$! Q$!_\0
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MCX._L&_MH?'6P^!'QA\4? SQIX^^&[?LH6'A&;X@>$-.T'5]:L-&3XE_M1^
M?%=Q:1:9XGT.\AOKWPM81S1WPC0?:(+F*'U;]G#]MSX9?M&^-/''PFD\%_&/
MX"_M ?#G2-/\5>+_ -GO]H_P1;^ /BK#X"UC49]%TCXE>&O[(U[Q?X%^(_PX
MO];M+G0G\9?#7QOXNT;2-<CAT?Q%-HVHZAIMM>^$?\$TD=_$7_!30*C-_P ;
M3_VA\[5+8'_"JOV?NN <<C /!ZX/6L3XZ7%AXJ_X*Y?L!:'X"NK2]\=?"']G
M[]LWQE\?H=*>/^T/#'P-^(^D_"SPI\-M.\:RQ!6AM?&OQDTFRU/P1H^H2&:_
ME\%>*M8TZU\G3+^X'H*E1E56']GRMX55O;^UJ\T9K+5CI3E3:=)TN=.G-+D<
M85:<H34URU>64ZL:<ZWM$U'$2IJFX0Y90^O_ %2,%)?O/:.$E*F_>YJE.<91
MY).5+[S\$_&1?&WQ>^./PB'PJ^-7A$_ ]OAFK?$_QSX D\._!WXO_P#"R_"E
MQXK#? GQTVI74?Q%7P +?_A'/B:8M.TO_A$O%<]OH[_;3+YZ^RU\R_"?]HP?
M%#]I']J[]GO_ (0XZ&?V7[KX$6I\7GQ%_:G_  G'_"[/AO/\0?,'A\:'IY\,
MCPR8?[(VG6M?.M;CJ&_2MOV(_%?@#_@H)^T[^TW<^-M _9$_8FL]:N_AC\5O
MC7\(_B3\6/VC?C9>_!O]GW1_$WPE^+OC3X;66F_#_P 0^'/A1\0_B1\9]>U_
M0O"=GXT\10>$_AUIO@CX>3>);/P3JOQ%U3Q?I.M:=:<_L*LY6C34.7#X>O-R
MJP453J\T(UY3G*,81JU(OW$Y.G)QA&,N>*>OM81BY2GS7KU*,;0?,ZD$INE&
M,%)S<(W?/9*4;R<HJ+9^MZ_>3_?3_P!#%;]?F=\'?VR?B[9_M$>&/V3?VR_@
M!X>^ GQ>^)7AKQ-XK^ _CSX6?%2Z^-'[/_Q\MOA_:V^K?$/PQX4\4ZYX#^%_
MCCP?\3/!VA7<?B6_\!^,/!"#4?"UEJVOZ)XBU"WL)(*ZGXO_ +8'Q4N_C[XA
M_91_8[^"?AKXY?&7X?>%/#/C#XW^,_B?\3+SX1_ /X!:;X\AU"[\ :%XT\6>
M'? OQ1\<>*/B=XTTS3+KQ#H?PV\'^!)GM_"AL_$?BGQ1X6T[5M#DU0>&JJ48
MI1ESTYU8SC4A*DZ5-N-2HZMU3C"G)<E1S<'";C3<'4G3A4:K0Y92;E'DE&$H
MRC*-13J6=."IV<I2J)\U-0YU.*E)2485'3_0<G X]A^9Q7RK\,?VB=4\?_M7
M?M4_LYW/A:PTS2_V=_!W[-OB?2_%4&JW-SJ'BF;X[:7\4+_4;._TF2QAMM)B
M\-M\/[6*RFMKZ^?4EU.=[B.S-K&LWS_X+_:^_:,^&GQM^%OP'_;F^ WPW^&)
M^/>J:AX4^!O[0/P ^+'B#XI_ SQ9\4-.T#6O%S?!CQS!X]^&_P *_&_PK^(V
ML^%_#NN:OX!-]IGB?PE\0CHVJZ/I/B6P\3P6WAZ]J_LY?\I//^"F7_9)O^">
MW_J.?M(T_82A[1S4)P>#Q%6C.$XSA*=*K@Z;<9PLN:FZLHRA))Q<XN4&I4YR
M7M8R4E'FC.%;#1G"<7"<8U?;RUC*_NU(P7+)-I\DDI*49Q7V1\"OC8OQT\/^
M,-?7X3?&WX/CP?\ %'X@?"\Z+\=? $GP[\0>)SX UM]$/Q"\'Z9+J6IG7/A=
MXUV?VO\ #_Q>LMNGB71'2_6QM-WE#VVOE#]G']IT_M ?#?XQ_$!? _\ PB1^
M$O[0G[5/P'&CGQ-_;W_"0']F7XQ^.?A+_P )3_: \/Z/_9(\;'P5_;_]B?8=
M2/AM=2_LO^UM>:S_ +0NOB?X!?M]_ME?MN_"SX??&/\ 9$_8M\!>&OAEXN\
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M>%K.ST*RUNTO]67XFZXWB636=?UVVN6L='.DVNBK#?+J'R-JW_!-^7P3X_\
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MVCZA=7=AJ ;09K*]T'7=+UO19=-U30?%&@ZMINGZYH?B'0;C3=2TC6;*UO\
M3IK:6%<?$]K_ ,$[OV@;;07^&Q_X*P_M]R_!QK,Z:FC2#]F*3XT)IA4#^S_^
M&G)OV>I?C#NP#$?$B:O'X^6 [HO&46HC^T23G1KQE%U?8N&)QE6$ITZDZ=2E
MBZ\:][4U*5.M3E#E:E&4:M.5-*<)4G%YTJ=6A[-^S52^%PE&I&$H1G"IA:+I
M73G:-2G4C-N_-&5.I&3Y90JIQO\ QA^+7[5?QT_:\\<_L?\ [+'Q)\ _L[>&
M/@-\'_A9\5?CW\>?%/PVC^,?Q!U'Q!\<M?\ B!I_PS^&'PF\!:UXB\,^"M$@
MM= ^%GBOQ-XV^(7B]/&T0DU3PYX>T3PA;W$.J:J_R?\ M*^'OVL/@]\?/^"9
M7A[]H#]IGX2_M%_#GQ'_ ,%!/"X\*:]JGP?M?@I\>O#WC;_AG?\ :)TNULY8
M_!/B75?A?\0O!>JZ/K.LV-S?6/@OX8>(/">NW&@6,MQXZM?%GD>'ON_XT_L"
MZ?X^^)GA#X^?!O\ :(^//[,'[17A/X8:7\&M0^+7PXU+P3XV7XJ?#;0KZ[U3
MP_X;^-W@+XS^#?B+X(^),OAS5M6\0ZQH'B>YTC2?&VFZIXCUB9?$\MK<)91^
M.^+_ /@E+H?Q56'QS\<_VJ?VA_C;^TEX?UOX7Z[\*/V@_&L7PGTN[_9YNOAI
M\7/A_P#%Z0?L_P#PB\!_#CP=\&O =UX]UCX:^&M&^(OB/4O!OBCQGXR\.V__
M  C_ (@\3ZEX;']A'?#5L-2GA6ZM.-.G*V(O@YSQ%2;J8F/MX5&Y<L73K8>H
MH*K2=&%&M1]E7JSA*K%>G7J0Q*4)N=6F_8\N(C&E23HT6Z4HI1YI>TIUZ<IN
M%2-9UJ=3FH4H2C2[[XFY_P"'M7[&[L-JO^P?^WTBL>%>0?&W]@!VC1C@.ZI\
M[(N6"?,1M!-9/[8/_)_W_!(K_LLG[7/_ *Q5\7Z^@/VH_P!DJS_:*U?X1?$/
MPO\ %CXA_L__ !X^ >M>*-5^$OQJ^&D'A'6-7T;2_'VC6^@?$3P+XF\'_$/P
MYXM\#>-O 'CK3=.T.;7= UK0_M<&M^&/"VOZ'JVCZGHL4TMAOV54\3>*?V2O
MB5\6?BYX]^)'Q6_9*UGXD^(]#\8)I/P^\&Z=\1]<^*/PU\6?"G7;CQYX4\.^
M$(].MK/3O#'BVZFT*R\%7'A1H-7T_3[O5+G5[?[;8WO-3J4U#".4[2PZQ=.=
M/DDY-5GF4Z=2,E[CC?&0A.+<9Q:;490U6\XU'/$)0O&M'#.,U*-DZ$,)3G":
M=I)OV$IP<5*+6C<963^4?V<Y8-(_X*Y_\%+-(\7RQP>-?%_P,_83\8?"B#4I
M4%_JOP&T#0_C)X3UV;PM#-(T\NAZ!\;9/&<?BA["*.VMM8\1:$-19I[RPS]I
M_MA^(/ACX6_9/_:8\0?&J33U^$6F? /XNS_$N/5#%]AO/!#^ ]=@\1Z;-%-E
M+IM5TR6YTRWL0LDM_<W45E!%-//'$_'_ +3O[%_PX_:9UCX>>/YO%GQ,^"OQ
MW^#\FKM\)?VB?@9XCT_PI\5_ ]EXA^QGQ-X8>77=$\5>#/''@'Q6=.L/^$G^
M'?Q(\'>,?!>KR6=M>2:+%J=M:W\'S[<?\$W-=^+6J^&&_;6_;(^/O[9?P^\%
M^)])\7Z-\!_&'A?X%?"'X%>(_$/AZ_M]9\-ZC\7O!'P-^%O@34/C+!X=U[3]
M+UW2_"OCOQ'J/PY?5-/@N-5\#:J $69JAB:5*-2O+#N&'IX6LH4ISDX4O;P5
M7#.#4/:SI5V^2JZ2AB8\\JDJ,G)5!U:%6<X4E6YJ_P!9IWG&"YVJ,O9U^=.7
MLU4H17M*:J.5";@J:J0C&7R#X>T;QEX:_9R_X-N- ^(4&HV7CO1/BA^SYI'B
MZRU99HM8L=?L?^"7G[4-EJNGZNMP!<#5K&XCELM5$^Z9KZ*Y\YY'+NW[3?':
MVM[WX(?&2SNX8[FUNOA3\0[6Y@E4-%/;S^$-:AFAD3 !CEC9D=>ZL036!\8O
MV?/"'QL\7_L[>-/$^L^*M,U/]FCXTR?'3P1:^'KO1K;3];\52_"?XH?!]M*\
M7Q:IH6KW5YX;'ASXL>(=1%KH=WX>U4:]8:)<'6#IT%_I>I>K^*O#EEXO\+^(
M_"FHSWEMI_BC0-8\.WUQ8/!'?06>MZ=<Z;=3V<ES;W=LEW%!=2/;O<6MS LP
M1I8)D#1O&8UGC:==QCR5:^)S;$.%VXP^OUG6I14VES6YG&3Y4[Q<I*\VD8*E
M]5JX;FES4Z%#*Z+G;WI?4HRA5?)=M75G%<ST:@G[EW^47[._[+_@C]L3_@D#
M^P#\+/'GB#QOX.O;#]E3]BKXE> /B?\ #76[?P[\3/A5\4_AU\+OA]XC\"?$
MCP'KEY8:K8V/B3PYJML&B&HZ5J>G7UA<W^FZA97%I>S*=WP%\8?VU?V5?VA/
M@#^SO^V%XQ^%G[3GPF_:7\0>*?AE\'/VI_ /@.;X)_%/0?B]X4^''B[XN0>"
M_P!H#X16>M^)/A[JEMXX\%>!_&4?A7XB_".[\+Z=#KGA4V'B+X;Z'!K^GWUM
M]#W_ .Q5;6'[+W[/G[,/PI_:/_:4^!-I^S/X;^&/AGX=_%?X7^)_A_:?$C6M
M/^$_P]N/ASX?LOB=9>(OAMXA^&/Q#T#6-+G35?%OA+5?AU!X8U;Q!9:;J]CI
M>CW6DZ2]CQ7PO_80\36'QM^'G[0'[3/[6GQK_:Z\>_!:W\6+\$-)\<^&?@W\
M+OAK\,-9\;Z%<^$_$OCNR\!_!'X>>!+7Q3\1[WPAJ6N>$+3Q/XTU#7[;0O#O
MB+7+;P]HNDWM_)?UVSQ%&IB,94E4C+#5L9CL0J%2A4E4E&N\3*E5H32M0KS<
M\-SMU(1BJ4O;T\1'E.2G0K4\-A*2A+ZQ1PN&H^VA5@H1E3=)3A5B]:U%*-:4
M5R2DW42I2HR<F?H<3C]?T!/]*_)_5_B/^V1^UI^TU^TK\(?V=?C3X&_93^!O
M[)/B[P-\*/%WQ&/PDTGXV?&CXN?&/Q/\+?!_QA\2:?X;L?&^NZ;\/OAM\/?!
M?A+XE>!]+6]U/P=XZU_Q7XE?6IK.ZT?2K2.*7]8:_/#XL?L"7FN?'3QM^TK^
MSA^U'\<_V0?C!\5=)\+:1\8Y/AKI_P */B#\,OBZ?!>EIH'A;Q)XU^%7QL^'
MGQ!\/1>/= \-V]AX9TOQKX2F\+ZJ?#]A;:9JHU6**,IQX>5.-23J\B3HU(TI
M3INK"GB).E[.I4IIWG!05:*TFH3J0JRIU5#ECV5E.4$J=[JI3<XQDH3G17M/
M:0A4>D)2;I2O[O-"$Z:G3<^=_'&K:=^TO\-O^"FW_!.+X??M'?';X0?'NRUG
MPC^VIJ'PQ\;Z%\+[GX+_ !AD^Q_"_P (2>+M!\=^$-+\5>+?A]XGT^"%/#NI
M:9XT\&Q_#[?*EWHVI?#V5K"'Q-=?4GP0)_X>O_\ !08 G!_9,_X)TDC)P2/&
M/[=0!QG&0&.#[GU-9VG?\$NO!:_$GX:?M!>+OV@OCY\4?VJOA[\9? ?Q2?\
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MM;!G!!]&4_DP-=!7/'I^*_S%=#2&%%%% !1110 4444 %%%% !1110 4444
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M;6/"^C:W\1] \+>"_%FI2K\&HIO%=A(/$FO76B>(6=$TF'PG-XBU70-%U?\
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MVW=G*RU=E:[LKNRNKNUE=7:NKFRN]KI7Z7=[*^UW9V5[NSLG9V]WHKQ;P?\
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M;>%]3\%6'C?1-<BNXM1MM4&FO#=S?4G[.?[1>C_M)>'?'WB31OAA\;_A9!X
M^+GCOX/W6F?'3X;:A\,M=\2ZAX"GL8+OQKX/TK4;J[GUOX<Z\]\%\,^)C]D>
M_FL]3L;S3M.U'3+VSAZ<7DN;8&DZ^,P%;#TE%2]I4EA^5P>-JY<IPY,75=6'
MUZA5PZE1C7CS0YW-4)T\15RHYA@L1)0H8BG5FY<O+!5+J7U=8KEFI48>SE]7
M?M.6K[*5DX6]JI45]#45Y/\ '7XN:=\!O@_\1?C)JW@WXC_$+3?AQX7U'Q5>
M^"?A%X1N?'?Q*\2V^FH'?2_!WA.UN+-]9U>8',<,M[8V5O"LU[J-_8Z?;W-W
M#U'P_P#&-O\ $+P%X(\?VN@^*O"]KXX\(>&O&%MX8\<Z#<^%_&WAR#Q-HUEK
M4.@^,?#-XSW?AWQ5I$=ZNG^(="NG:YTC5K>[T^=C+;L3Q>PK?5_K?LW]6>(^
MJJKS4[/$*@L2Z7)[7VMU0:J<_L/96?+[?VG[DZ/:T_:JCS+VKI.LH6E?V2JJ
MBY\W)R655J'*ZBGKS*FX7J+L**0GV)_#_/\ ^NODCQ-^V/\ #SPK^VE\,?V'
M;[PWXXN/B7\5/@GXQ^.>A^*[2T\/MX T_P -^#-=&@WVD:O>3^(K?Q+%K]W<
M1SSV<=EX9OM-\A(_/U*&25DAK#87$XR=2GA:-2O.CAL5C*L::3=/"X*C]8Q=
M>7-*"]G0HIU:C3E)1^&$W[HJU>E0C&=:I&G"56C1C*;:3JXBK&C1IJR?O5:L
MX4X*VLI+5*[7UQ17Y_\ [4O_  4:^#O[+OQ6\(_ -_AO^T1^T+\>O%W@BZ^*
M<?P8_9>^$6H?%SQ_X>^%%EK4_AN?XF^*;%-3T'3-&\)-X@M;O1+.5M5GUC5-
M5MGT_2M'OKN:UBG]OT#]K;X!:]>_LSZ&WCC_ (1[Q;^U_P"$?$/C7]GWP+XQ
MT#Q)X3\<^.='\'>#-+\?^-(7\+:[I-GJOA[6/!WA;6+#4/$NB>)8=)U32Y))
M+.:V-Y!-"G5+)\UAA<+C99?BEA<;"M5PE94U/V]'#T\16KUX4H5:F(^KTZ6$
MQ=5XB>%I8>5/"XJI3Q%6&&Q$J.*Q^"=>MAEB:/M\.Z4:U/F:]E.LZ:I4YS<%
M256;JTDJ*K2K+VU'GI4_;4O:?1LL,4Z&.5%D0]F&>?4'JI'8@@CL:YZ[T:1,
MO:$RKR3"Y =?]QSPXZ_*VU@ ,,Y.*Z7/^<&D)Z<$Y]NGN<_YQFO,NCK.!(*L
M5965U.&1@593Z%3@@_A25\^_LB_M<_#;]M[P7\4/&WP^\+>./"^G_"CX^_%/
M]GG6H/'-IX?L=4OO%7PHU"QL-:UK1QX=\0^)+:3PUJ1U*WETE]0N;+4R%G6^
MTFT9$,OHWQJ^)G@S]G_P#JWQ1^)5WX@M/ 6@7>AP:_K/AKP3XP\=WFA6>N:Y
MIVA?V[J^A>"-$U_6;+POH3ZDNK^+?$TMBNB>%/#5EJGB'7KVPTO3KFX3LK8'
M&X?&?V?7PM6GCN>A3^J2BG6]IB:6&KT(*,9R3G6HXW"3IQ51N2Q%)7C*3A'&
MGB*%6B\13JPG12K-U4WR)4*F(I5FY.*TI5,+B(S=K)T:C7-%)R[RBOC#]B/]
MN'X6?MT_"^/XC?#33/$6D3Z?I^@S>,-)O=.U/5_#'AW6O$,VO_9O"NB?%RPT
MB#X8?$OQ!H]EH<=WXTL?AUXA\0R> KG6='T7Q@NCZS>1V3?9]+'8'&99BZ^
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M/[*'_!,C]O\ _8_N]+_8JT;QAX!_:H6_\8?M8^!(_AKX;\)_!*^7X1:MXO\
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M051TW>,YTZ49ITW43_G#_9Q_8A^%OPN_X*<_L8?\$_?VS)?AG^T]\'OV8_\
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MKRA+2<XT*<DX4ZCG_+[\0?V1/VB_A_\ M[?\$Y_^"??@N[_8<_:*_P"&,/\
M@B!J7COP9J/_  41T#X@?$/]E^'XO#X\0^!OC3XY\ ^$_"D^FZAK/B>T\/\
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MFYW-Q<W*])KF:<)MKD]AHJA_:NE_]!*P_P# RW_^.4?VKI?_ $$K#_P,M_\
MXY2-"_15#^U=+_Z"5A_X&6__ ,<H_M72_P#H)6'_ (&6_P#\<H OT50_M72_
M^@E8?^!EO_\ '*/[5TO_ *"5A_X&6_\ \<H OT50_M72_P#H)6'_ (&6_P#\
M<H_M72_^@E8?^!EO_P#'* +]?SG7?C?PM^S_ /\ !QE\0_%/[1'BO0OA_P"&
MOC[_ ,$^?#?A#]FSQIX\U2UT3PMJM[X;^(?@V[\7_#?0O$>K26^CV?B.35O#
MWBGQ)-H+7L%RT5Y8RE/M/BC1H=3_ *(O[5TO_H)6'_@9;_\ QRO)OB_\&OV>
MOV@_#UMX2^/7PK^#7QM\+6-[_:=CX;^+?@CP3\1]!LM2\EX!J%GI/C#3-8L+
M6_$+O$+V"".Y6)VC$H5B*]W(,VP^55\P6+P];$8/-<ES/),5]5G1IXRC2S&&
M$:Q.$EB(RH.K1K8'#N5*MRTL10GB*$JE-RISCYN:8&ICJ.'C1JQI5L)F& S&
MBZD9SH5*F!K59JCB(4Y1J.E5A7JQ<H-SI5(T:L8SY)1?XL?MF?%[X5?&/_@J
M)_P1!UWX2_$CP/\ $[0M ^.'[>_@O5M>\ ^*-&\6Z'9>+- _9\\&-KOAR75]
M"O+[36UG0WOK:VUFPBN9+C2[YI-/OD@OH+BWB_(RT\1^-/&'P ^#GAB[^*7Q
M3T>/QU_P=4>(O@SK'B'PI\3?&7A?QI9?#_QS8^,?"VNZ!X<\9:+K5IXB\,@:
M1KVH_P!DSZ'J%E<:%J$\>KZ0]GJD$%Y'_8KX=^"7[.7A"V^&UEX2^$?P2\+V
M7P:;77^$%IX=\ ^!-$MOA2_BFWEM/$S_  VM],TFVB\#-XBM)[BVUUO#"Z6=
M7MYYH-0-Q%(ZET7P5_9U@M;"R@^$OP5BL]*^)[?&[2[2+P'X%CMM-^-+RW%P
M_P 7K&!-*$-G\3VGNKF9O']LD?BMIKFXD.K%YI&;ZS+N-\MRS#X'"4,KQN(H
MY=AZ.'P]7%5,ME7DJ&?<39TJM2"PU7#QE-9[AZ4J<(SI<^"?-[>E*G%^)B>'
ML9C*F(K5<7AJ=3%5)5*L*$<9&G'FRK 9=R0E*I&LU%X.4U.4H3M5;C[*I9P_
ME-^(/@_0_P!E&V_X.5?V8_V?[OQ%\-_@7\,_V:_V;/B7\.OAWIOC;Q??Z9X
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M_?Z/_P"*H GHJ#[5;?\ /Q!_W^C_ /BJ* /GS8G]U?\ OD?X4;$_NK_WR/\
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M5_"5@>@_(48 Z #\*K_5O+_Y\5_X.A_\H%_;>+_DH?\ @N?_ ,N/])S]G?\
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M']FZC_SX7O\ X"S_ /QNBZ[K[U_F%GV?W/\ R,_RX_\ GFG_ 'RO^%'EQ_\
M/-/^^5_PK0_LW4?^?"]_\!9__C=']FZC_P ^%[_X"S__ !NBZ[K[U_F%GV?W
M/_(S_+C_ .>:?]\K_A1Y<?\ SS3_ +Y7_"M#^S=1_P"?"]_\!9__ (W1_9NH
M_P#/A>_^ L__ ,;HNNZ^]?YA9]G]S_R,_P N/_GFG_?*_P"%'EQ_\\T_[Y7_
M  K0_LW4?^?"]_\  6?_ .-T?V;J/_/A>_\ @+/_ /&Z+KNOO7^86?9_<_\
M(S_+C_YYI_WRO^%'EQ_\\T_[Y7_"M#^S=1_Y\+W_ ,!9_P#XW1_9NH_\^%[_
M . L_P#\;HNNZ^]?YA9]G]S_ ,C/\N/_ )YI_P!\K_A1Y<?_ #S3_OE?\*T/
M[-U'_GPO?_ 6?_XW1_9NH_\ /A>_^ L__P ;HNNZ^]?YA9]G]S_R,_RX_P#G
MFG_?*_X4>6@Z(@_X"/\ "M#^S=1_Y\+W_P !9_\ XW1_9NH_\^%[_P" L_\
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M>,=,TO0=$TS3_#N@Z-K/AOQ1K^@?V'H.D:9H^F:-J4FG:+8Z=:PVD5MI:?\
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MXH?#+X&?%'Q9\7_AKX0N?#FJZ/\ \(9XK\.>*/'.O^-?&&BP_$'0M;N[/4?
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MC_A7/C7_ * ]M_X4/AG_ .7-?BQ]BM/^?:W_ ._$/_QNC[%:?\^UO_WXA_\
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M1_J9#_H8S_\ "2'_ ,T!_K(_^@./_@^?_P I/VG_ .%<^-?^@/;?^%#X9_\
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M;?\ A0^&?_ES7XL?8K3_ )]K?_OQ#_\ &Z/L5I_S[6__ 'XA_P#C='^ID/\
MH8S_ /"2'_S0'^LC_P"@./\ X/G_ /*3]I_^%<^-?^@/;?\ A0^&?_ES7:ZU
MX-\277@GP#I5O96DNHZ-+XP;4[4:YH"-:#4]9BNK M+)JBP2_:+=6D'V>64Q
M@;9A&Y"U^$?V*T_Y]K?_ +\0_P#QNC[%:?\ /M;_ /?B'_XW1_J9#_H8S_\
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M^$/$6F6SMKF@2B6_OH8$M;<"WU25E,K(P$CJL28)DD0<UQ*_#GQJ% _L>VX
M'_(P^&>P_P"PS7XL_8K3_GVM_P#OQ#_\;H^Q6G_/M;_]^(?_ (W1_J9#_H8S
M_P#"2'_S0'^LC_Z X_\ @^?_ ,I/VG_X5SXU_P"@/;?^%#X9_P#ES1_PKGQK
M_P! >V_\*'PS_P#+FOQ8^Q6G_/M;_P#?B'_XW1]BM/\ GVM_^_$/_P ;H_U,
MA_T,9_\ A)#_ .: _P!9'_T!Q_\ !\__ )2?M/\ \*Y\:_\ 0'MO_"A\,_\
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ME*\*2Y(SBFYN51*,9*,I'YI?V[XJ_P"AZ^)/_ASOB%_\TU']N^*O^AZ^)/\
MX<[XA?\ S35EQ*RQHKG<P4!F]3W/_P"H >@ XI]=GL*%OX-'_P %4O\ Y68N
MK5N_WM1ZO7VE375Z_'UW^9^@7_!-?]J+X[_ G]M']F:P\&_%/XB77@SXN_M
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MCI6N>!-=\))XBCL:C\&_@5I_POTK]JRY^'VNOX*U7X$^#?&<7[/VF?$'78M
MA^,7BW]J7X^_LXV\5W\0+R#4_B1#\#K70?V?M;\?W^E#69/B)+XQ\5>'/AW;
M_$S3M,O4\3Q?-7Q:_:1^*GQC^+7[2'QAU_6Y=.UW]JC5_$-S\5M,M'CU"PO_
M  SK/Q0\(?%S3/ 5M=ZK:S7\/ASPEXJ^'7PY'A^2T>PU&'3_  -HNG27 TU]
M0T^ZS/"'[0?QA\"KH5OX>\76LFC^'?A]K7PGL_"GBGP7\/\ X@^ ]2^&?B#X
MCZQ\8-6\#>+OAY\0/"GBCP+X_P##LWQ4UW4/B':67CSP]XE.D>,$TK7=&DT^
M_P##WAV;25&GB)P52<G3K35*<Z<:D_9T^:$Y8BA%I27Q2IT85N6<X^SG7BTV
MHS'.A"3A%>TIQG5BJCA'GJ1BZ<:%5I\KN^6K5G3]R,E4A1DK-NE]YZOH/P,\
M?> ?@%XY\3_"SQ7;?#WX7?\ !-/XP?%[1/A5X:^+%[IRWOC32/\ @J+\>_ *
MZ7_PL+6O!^O^(H_AQ?:OXVURYO-'N+75?&UEX?SX=MOB-+XFLH?'*^ :MI7[
M.'PUTWX%WOCWX(^*O&Z?M%>$;SXS^(V\&?%?Q+X8N_A+\._$/QN^*/PO\,?#
M[X 0WUCXFMO$_C/PKIGPQO[_ %7QK\;#\3M-\0^)]4A\ /X-T2Z\%ZUXS\9^
M-^+OVF/CGXYLWTSQ)XZBET<> =7^%-GH.B>#/AYX/\.Z)\+M;\4>%_&U_P##
M?POX=\&^$?#^A>$/ B>,/!N@^)M+\)^%-.T70M!UM=:U+0K'3;GQ;XO?79?A
M]^TW\;_A=HGA_0/!?BO0K:T\&:MJ&O?#K4?$GPO^$?Q"\6_"77=5O$U34-:^
M"GCWXB> _%?COX)ZK<:Y%%XG&H?";Q)X,NX/&,4?C2UE@\6QIK2NG1J1;E*\
MHNLZCHK$58*5*57$5:E/VRCS0G.56C>LHRE+V7*G&*BJD2J1<5&+2DJ3@JKH
MP?+.-*E3I35*]G"'+6?LVTOWJFXRG=0^TK7]ECX'?#KXK? []GWXA^'_ !!\
M2?%'Q8_;<^.G['GC?XIZ-X[U'PE9^&?#?PS_ &@_ _P'TKXD_"CP79:?/8IX
MYDG\4:GXL\CXD:OX[\#WEG8:7X=G\(0W-S?>)%Y_X,_L\? C]I:%;[P_X2\0
M?!ZS^&7QLU'P)XWM'^,NG7Y^)OPUL_V8_P!K']I:PN+WQ]\2M#L?"'PT^*TD
M/['_ (I\#ZW\1$T/3/@^H^)N@^+8_A+X9MO .KZ?XN^%]'^+/Q)T"Y^&-YI/
MC#4[6\^#'C.Z^(GPONWATZ\N?"/CB^\1Z#XOO?$MO/?6-S+JNH7?B;POH&LW
M U]M6M9+K38PUOY$]W#</\'_ !?^*7P^5!X%\>>(?"$L7Q*\$?&*"\\/7$.E
MZG:_%#X;V'CC2_ _C2RU:U@35+#5/#NG?$KQW96L-E>0:;=0>)KY=2L;XQ6)
MM)6'Q*IZXANM[-Q]K>:A[;FH*-7V*7)RJG'$?N^7E<JL59N*G3IU:/.W&BE2
MYD_9M1<N5O$RE3]I?F5^?#14D[Q5)\K4;JK[S\?/AW\+-&^&7ACQGX>B^#'@
M+XD-X]F\*:I\,_@Q^U!X:_:7\/>)? =WX8EUG3/B-YNF^-?B)XE\ ZWX:U[2
MKOPQXN37_%;>'?'7_"7^$;SP+X7\)-X5\7QZUX+I?PPUC5? VI_$"'Q7\)K/
M2]+74&F\.ZS\8_AEH?Q'NAII19AI/PQU7Q/:>/-8:YW@Z6FFZ!<MJP5VT\7
MCD*S_$/XN^,?BA'I</BC3OA9ID&D7-_>VL/PQ^ 7P"^!L=Q>ZG':0WMWK2_
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M$K_Y:T?\*I_9P_Z(3'_X=;XE?_+6NBHH_M/,_P#H8X[_ ,*JW_R0?4<%_P!
MF&_\$4O_ )$YW_A5/[.'_1"8_P#PZWQ*_P#EK1_PJG]G#_HA,?\ X=;XE?\
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MC5]+7X').NEZMJ>F+.WQ3^),33KI]]/9B9HQK$@C:40B0QAW"%BH=@-QSO\
MA5/[.'_1"8__  ZWQ*_^6M>@^+/^1L\6?]C3XC_]/5]6!1_:>9_]#''?^%5;
M_P"2#ZC@O^@3#?\ @BE_\B<[_P *I_9P_P"B$Q_^'6^)7_RUH_X53^SA_P!$
M)C_\.M\2O_EK7144?VGF?_0QQW_A56_^2#ZC@O\ H$PW_@BE_P#(G._\*I_9
MP_Z(3'_X=;XE?_+6C_A5/[.'_1"8_P#PZWQ*_P#EK7144?VGF?\ T,<=_P"%
M5;_Y(/J."_Z!,-_X(I?_ ")SO_"J?V</^B$Q_P#AUOB5_P#+6C_A5/[.'_1"
M8_\ PZWQ*_\ EK7144?VGF?_ $,<=_X55O\ Y(/J."_Z!,-_X(I?_(G._P#"
MJ?V</^B$Q_\ AUOB5_\ +6NDU+X%_LVV'AKPIX@7X*"5_$C^(DDM&^)_Q(1+
M/^P]1CL$*3C6W:X^U*YE8-%#Y) 0>8#N#:]#\1?\DY^%W_7?Q_\ ^I!!1_:>
M9_\ 0QQW_A56_P#D@^HX+_H$PW_@BG_\B>-?\*I_9P_Z(3'_ .'6^)7_ ,M:
M/^%4_LX?]$)C_P##K?$K_P"6M=%11_:>9_\ 0QQW_A56_P#D@^HX+_H$PW_@
MBE_\B<[_ ,*I_9P_Z(3'_P"'6^)7_P M:/\ A5/[.'_1"8__  ZWQ*_^6M=%
M11_:>9_]#''?^%5;_P"2#ZC@O^@3#?\ @BE_\B<[_P *I_9P_P"B$Q_^'6^)
M7_RUH_X53^SA_P!$)C_\.M\2O_EK7144?VGF?_0QQW_A56_^2#ZC@O\ H$PW
M_@BE_P#(G._\*I_9P_Z(3'_X=;XE?_+6C_A5/[.'_1"8_P#PZWQ*_P#EK714
M4?VGF?\ T,<=_P"%5;_Y(/J."_Z!,-_X(I?_ "(_PO\  K]FWQ%=ZG;2?!06
M8T[P]K&N*Z?$_P")%P9GTN**1;9E;6X?+6?S,-,&<QXR(WSBN9'PJ_9P(!_X
M43'R ?\ DJWQ*[C_ +"M>S_#3_D*>)?^Q!\6_P#I-;5YRGW%_P!U?Y"C^T\S
M_P"ACCO_  JK?_)!]1P7_0)AO_!%/_Y$Y_\ X53^SA_T0F/_ ,.M\2O_ ):T
M?\*I_9P_Z(3'_P"'6^)7_P M:Z*BC^T\S_Z&.._\*JW_ ,D'U'!?] F&_P#!
M%+_Y$YW_ (53^SA_T0F/_P .M\2O_EK1_P *I_9P_P"B$Q_^'6^)7_RUKHJ*
M/[3S/_H8X[_PJK?_ "0?4<%_T"8;_P $4O\ Y$YW_A5/[.'_ $0F/_PZWQ*_
M^6M'_"J?V</^B$Q_^'6^)7_RUKHJ*/[3S/\ Z&.._P#"JM_\D'U'!?\ 0)AO
M_!%+_P"1.!\;?LR^!_'/@RQ;X/?#NT\#^(8O'VCZ=KOB+4/&_BS7-'T3P8_A
M[Q#J.M:SJR>(-4FM8+.RN+33L&WMC?7%RUM9V\\/VJ3=WFE:-X6\ >$U^'_P
M^AFB\.QNEYKVO7<0AUSQ]KD*8.MZX0 T&G0,,:#H Q;:; (YI8S>%1:Z<>K:
MA#I5UHD5R\6F7UY!?WMM& HN[BVC$=L+AQ\\D$'^MCMR?)-QLN'1Y8;=H<N3
M_5R?[C?^@FJKYICL3A:>$KXBI4I0J3J2YYSG.K.33C[6<I-RC22M2A\$&Y2L
MYM2BJ6!PM&O.O2I0A.48P7+&,8PBDT^2*2474;O4E\4K1C=15GZ1\4?^1FL_
M^Q6\,_\ IN%>=5Z+\4?^1FL_^Q6\,_\ IN%>=5YYUGP)_P %4_#FO>+/^";?
M[;NA>&=)OM=UJ?\ 9V\>ZC;:3IEO)=ZA>6WAVU@\2:L+*TA5I[RXM]&TC4+N
M.SMDENKLV_V>UAFN)(HG_P ^B":*]AAO+*6.\L[N)+FUN[5UGMKFVG42P7%O
M/$6CF@FC99(I8V9)$975BI!K_441WC99(W:.1&#HZ$JR.IRK*P((92 00001
MD5\ ^)O^"5?_  39\8:_JWBCQ#^Q!^SI<ZYKE[/J6K76G> K7PW;WFH73F6[
MO6TGPQ/HNBPW5[.TEU>SVNG0/>7<LUW=--=3332>SE6;++HUH3HRJQJRA-.$
MXQE&48N+3YTTXM/R::ZIZ>9F&7O&RIRC45.5-2B^:+E%J3YNC333]4T^C6O^
M?=Y<G_/-_P#OEO\ "MWPOXE\6^!_$>B>,O _B7Q3X(\9>&;^/5?#7C#P9KVL
M^$_%GAO584>.'5/#_B7P_>:=K>B:E$DLJ17VF7UK=1I)(BRA78'^]C_AT/\
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M&HZ#K_QA_P"+NZYHMY'-IFK_ !4_XN-J%K<^,O\ B=U_=[_PZ'_X)@_]&-_
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M8&K6VH1WX%P&^-OC-\;OB9JGB/7?B7\9?C+\2=<\9>&=*\%>,M;^(?Q1\?\
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M->T.QUG5K/2M0M+?4KV.?T6/]HG]I&'PMXY\"P_M#?M!0^!?BAK7B;Q+\3_
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MT?\ $2!^U3_T;/\ LC_^ G[0?_S]Z/9\3_\ /W#??A__ )6'-DG\E;_RO_\
M)GM'_$-)JW_1^/A/_P 1A\5__/JH_P"(:35O^C\?"?\ XC#XK_\ GU5XO_Q$
M@?M4_P#1L_[(_P#X"?M!_P#S]Z/^(D#]JG_HV?\ 9'_\!/V@_P#Y^]'L^)_^
M?N&^_#__ "L.;)/Y*W_E?_Y,]H_XAI-6_P"C\?"?_B,/BO\ ^?50?^#:/5CU
M_;Q\)_\ B,/BO_Y]5>+_ /$2!^U3_P!&S_LC_P#@)^T'_P#/WH_XB0/VJ?\
MHV?]D?\ \!/V@_\ Y^]'L^)_^?N&^_#_ /RL.;)/Y*W_ )7_ /DSVC_B&DU;
M_H_'PG_XC#XK_P#GU4?\0TFK?]'X^$__ !&'Q7_\^JO%_P#B) _:I_Z-G_9'
M_P# 3]H/_P"?O1_Q$@?M4_\ 1L_[(_\ X"?M!_\ S]Z/9\3_ //W#??A_P#Y
M4'-DG\E;_P K_P#R9[1_Q#2:M_T?CX3_ /$8?%?_ ,^JC_B&DU;_ */Q\)_^
M(P^*_P#Y]5>+_P#$2!^U3_T;/^R/_P" G[0?_P _>C_B) _:I_Z-G_9'_P#
M3]H/_P"?O1[/B?\ Y^X;[\/_ /*PYLD_DK?^5_\ Y,]H_P"(:35O^C\?"?\
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M "L.;)/Y*W_E?_Y,]H_XAI-6_P"C\?"?_B,/BO\ ^?51_P 0TFK?]'X^$_\
MQ&'Q7_\ /JKQ?_B) _:I_P"C9_V1_P#P$_:#_P#G[T?\1('[5/\ T;/^R/\
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MH *]#\1?\DY^%W_7?Q__ .I!!7GE>A^(O^2<_"[_ *[^/_\ U((* //****
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MB-JMT]O8:5\3M*L+>'2_A5\5=5FAM;JVBL?AQ\1[Y/#0\*^*? 'ZY4A 8$$
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M?_,/1_PV%X!_Z(#>_P#AY-4_^8>G_JWG?_0"_P#P?AO_ ):+^V<N_P"@A_\
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M?_#R:I_\P]'_  V%X!_Z(#>_^'DU3_YAZ/\ 5O._^@%_^#\-_P#+0_MG+O\
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MX?\ @==.C\L\2>&?'7B3]D/]E;2_!_[/?@;XDP>'/@)\;] \7?$/5(/%%_\
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M_A7_  Z_^;&OM;R8O^>4?_?"_P"%'DQ?\\H_^^%_PH_UOS#_ *!\%_X#7_\
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M_P *_P"'7_S8U]K>3%_SRC_[X7_"CR8O^>4?_?"_X4?ZWYA_T#X+_P !K_\
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M_FQK[6\F+_GE'_WPO^%'DQ?\\H_^^%_PH_UOS#_H'P7_ (#7_P#EP?ZNX/\
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MC%\/=;\,>'K[X@:SI_BCQ3;^/;S6[/PQI<>BVFJ6_P#AQM_P4_\ ^B*?"O\
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M6I7GB.PLO%FK:=:^&+_^TF>9[B>:XDQYD\LDSX&!OE=G; YP-S' STKY7/\
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M.ZO>;T=HKEE_G\45_H#_ /#E[_@G'_T8MI7_ (<C]KK_ .?I1_PY>_X)Q_\
M1BVE?^'(_:Z_^?I7T'^LN!_Y]XK_ ,!H_P#RX\?^Q,5_S\H?^!5/_E9_G\45
M_H#_ /#E[_@G'_T8MI7_ (<C]KK_ .?I1_PY>_X)Q_\ 1BVE?^'(_:Z_^?I1
M_K+@?^?>*_\  :/_ ,N#^Q,5_P _*'_@53_Y6?Y_%%?Z _\ PY>_X)Q_]&+:
M5_X<C]KK_P"?I1_PY>_X)Q_]&+:5_P"'(_:Z_P#GZ4?ZRX'_ )]XK_P&C_\
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M'_#E[_@G'_T8MI7_ (<C]KK_ .?I1_K+@?\ GWBO_ :/_P N#^Q,5_S\H?\
M@53_ .5G^?Q17^@/_P .7O\ @G'_ -&+:5_X<C]KK_Y^E'_#E[_@G'_T8MI7
M_AR/VNO_ )^E'^LN!_Y]XK_P&C_\N#^Q,5_S\H?^!5/_ )6?Y_%%?Z __#E[
M_@G'_P!&+:5_X<C]KK_Y^E'_  Y>_P""<?\ T8MI7_AR/VNO_GZ4?ZRX'_GW
MBO\ P&C_ /+@_L3%?\_*'_@53_Y6?Y_%%?Z _P#PY>_X)Q_]&+:5_P"'(_:Z
M_P#GZ4?\.7O^"<?_ $8MI7_AR/VNO_GZ4?ZRX'_GWBO_  &C_P#+@_L3%?\
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MZ[484,3B%:5>3E##X:IB6U%337,H<G*Y*=[Z))2?@.K_ +2/[7OA_5M6\/\
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M:G4I2Q%JM24*-2O#XZG/*-*K6IPDHJI:3J>Q;BHV3=U%R7*W\Z_\-3_M3?\
M1T7[2W_B0'Q=_P#FRH_X:G_:F_Z.B_:6_P#$@/B[_P#-E7IGA?X>?#OQW^S3
MIEU\+-#^%?BWXNZ9H=_K?[0^L>._'7Q6T#XS?!:'_A<"Z#HGC7X5?#^R\6^"
M_@Q\0/@5#\.=4^'3>/-0CT3XT?%GPIXBU_XH:[XHT#X=> /#W@WQ7%](_&G]
MEOX/:7XJ^/7[/O@73/@MIWQ0^'7Q%_X5!^SE<>#OVCM:\??M(_'7XLZ=\??"
M7P53X<?&?X6ZKXJU7X::5XA\::%JOBWQ6\7PY\#_  8L_A;XP\-Z?X?U_5_%
M&A+J;7VOM</=1]@N:3LH^QI\SC;#OVBBJ3?(_K-/DMK5C&K4@U"E4Y25.M'F
MO5?N.2D_:U.53C/$0<')S2NGAJCETIWI*HKU87^*;7]IS]K*_N8K/3_VEOVH
M=0O)]P@L['X[?&2\NYS'&\L@@MK;Q=+/,8X8Y)G$<;;(HWD;"*S"N/VJ/VI6
M 9?VH_VE2K $$?M ?%T@@C((/_"9<@CD&OH_XF^&O"GPV^$$O[2OP:O/V?\
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MT=%^TM_XD!\7?_FRKPFBCV5+_GU3_P#!=/\ ^5A[2I_S\J?^#*G_ ,L/=O\
MAJ?]J;_HZ+]I;_Q(#XN__-E1_P -3_M3?]'1?M+?^) ?%W_YLJ\)HI>RI?\
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ML/\ H&G_ .#8_P#R!_J=;X_^>L/_ '^B_P#BZ-\?_/6'_O\ 1?\ Q=?Y8O\
MP@7@7_H2_"?_ (3FC_\ R'1_P@7@7_H2_"?_ (3FC_\ R'1_JQ4_Z#*?_@FI
M_P#)A_;L/^@:?_@V/_R!_J=;X_\ GK#_ -_HO_BZ-\?_ #UA_P"_T7_Q=?Y8
MO_"!>!?^A+\)_P#A.:/_ /(='_"!>!?^A+\)_P#A.:/_ /(='^K%3_H,I_\
M@FI_\F']NP_Z!I_^#8__ "!_J=;X_P#GK#_W^B_^+HWQ_P#/6'_O]%_\77^6
M+_P@7@7_ *$OPG_X3FC_ /R'1_P@7@7_ *$OPG_X3FC_ /R'1_JQ4_Z#*?\
MX)J?_)A_;L/^@:?_ (-C_P#('^IUOC_YZP_]_HO_ (NC?'_SUA_[_1?_ !=?
MY8O_  @7@7_H2_"?_A.:/_\ (='_  @7@7_H2_"?_A.:/_\ (='^K%3_ *#*
M?_@FI_\ )A_;L/\ H&G_ .#8_P#R!_J=;X_^>L/_ '^B_P#BZEB1IV98!Y[(
MC2NL)$S+&F"\C+&681H""[D!5R,D9K_+ _X0+P+_ -"7X3_\)S1__D.M31-
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MX8T"YNO#FE:S\*+#P1J</AN[O/#K7;Z)=W%A+XNDT4C.B2(SQ_ZQ592R>F\
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M>3QI_;/^K^)_L#ZY_:?UC!^R^H6^L^S^L/V_)?3E]E_$_NGX\?\ #^S]NO\
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M7B;_ .=)1S^#O_5'?^ U/_D0_P"-K=^*O_)/\C*_X?V?MU_]"S^RG_X85O\
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MT'_U17P:KX5K]+RW_<,'_P!@U'_T@^(QG^]XK_K_ %?_ $H****[3F"BBB@
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M^C5OVG?_ !'GXQ?_ #%T?\,H_M7?]&K?M._^(\_&+_YBZ/;4?^?M+_P;2_\
MEH>SJ?\ /NI_X+J?_*SP2BO>_P#AE']J[_HU;]IW_P 1Y^,7_P Q='_#*/[5
MW_1JW[3O_B//QB_^8NCVU'_G[2_\&TO_ ):'LZG_ #[J?^"ZG_RL\$HKWO\
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M^Q-_XB1^SS_\[BC_ (8(_8*_Z,3_ &)O_$2/V>?_ )W%'^L\/^@.?_@^G_\
M*@_L*7_03'_P5+_Y,_SE_M5M_P _$'_?Z/\ ^*H^U6W_ #\0?]_H_P#XJO\
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M0OPAX-\3^/M>3PQX.TB77->ET;Q9X@33H;FPLW;1O OA#7O'WBV^\_4KJRM
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M@?V?_P#HOGP,_P##Q?#C_P"::BS[/[G_ )!==U]Z_P SUNBO)/\ AH']G_\
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M)RY7;]W))JZ;:<YJK&Z24>2*3<(3G] _M->!?#6C_M!+X<\%Z7X=^'^@^/\
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M3]TUKHVC6LS377A;X3^%KN6X7P7X*$[R2R--XI\53:CXIU&YNHOM;'/7\/\
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M /D&F44?6\5_T%8K_P *<3_\T!]7P_\ T#T/_!%#_P"4C_L/@/\ Z(M\"/\
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M_#>^#O\ Y2UZ'^M$O^@)?^%#_P#E)Q_V$O\ H)?_ (*7_P F?Y@?_";^"O\
MH<?"G_A1Z-_\FU%)XP\"R@B7Q;X1D!4JP?Q%HK!E8$%6!O<,I!((((()!&*_
MU ?^%5_"O_HEGPR_\-[X._\ E+1_PJOX5_\ 1+/AE_X;WP=_\I:3XG;WP2_\
M*'_\I'_82_Z"7_X*7_R9_E]MXM\!-C/BKP><((A_Q/\ 1/\ 5*05C_X_/N @
M$)]T'G&<$/\ ^$Q\#98_\)=X2!8@L1XBT8%L>I^V\^G/;/J:_P!0'_A5?PK_
M .B6?#+_ ,-[X._^4M'_  JOX5_]$L^&7_AO?!W_ ,I:/]9Y?] 2_P#"E_\
MRH/["7_02_\ P4O_ ),_R^CXJ\ ,26\4^#B6+$DZ_H9)+NDCG_C[X+R1I(Q&
M"9$1R=R*1(/&'@959!XM\)!7)9P/$.BC<QZLW^F\L>,D]?TK_4!_X57\*_\
MHEGPR_\ #>^#O_E+1_PJOX5_]$L^&7_AO?!W_P I:/\ 6>7_ $!+_P *'_\
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MO%7@]FP@RWB#1"2(W\R/)-X=WER$R1ALA'^=0&YJ0>,O! P1XO\ "8()(/\
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MXH/_  <<_MP#K\#?V&?_  V/[2/_ -%Q3^J\2_\ 04O_  HH_P#S*/V^2?\
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MKQ+_ -!2_P#"BC_\RB]ODG_0/+_P35_^:#],_P#B'/\ V'?^BY?ME_\ A0?
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M35_^:#],_P#B'/\ V'?^BY?ME_\ A0? '_YR5'_$.?\ L._]%R_;+_\ "@^
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MHHH ]"T3_DFGQ _[#'@W_P!+IJ\]KT+1/^2:?$#_ +#'@W_TNFKSV@ HHHH
M**** "BBB@ KI/!G_(Y>$?\ L:- _P#3K:US==)X,_Y'+PC_ -C1H'_IUM:
M(O%G_(V>+/\ L:?$?_IZOJP*W_%G_(V>+/\ L:?$?_IZOJP* "BBB@ HHHH
M**** "O0_$7_ "3GX7?]=_'_ /ZD$%>>5Z'XB_Y)S\+O^N_C_P#]2""@#SRB
MBB@ HHHH **** "BBB@#T3X:?\A3Q+_V(/BW_P!)K:O.4^XO^ZO\A7HWPT_Y
M"GB7_L0?%O\ Z36U><I]Q?\ =7^0H =1110 4444 %%%% !3)/\ 5R?[C?\
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M6@7XTC7_ !'X'_9V^!OQ*_:&\8^#-!UMK:]70=;\<^'/A9J?@W2/$7V'4/\
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MC^&_%>C_ +7/BJY_9WUB_P#VAK7X[C0=-B^+XLH/AM;^)/"9U/P=K6G^(&U
M>);2JDJ\I5'2A.$&JBI*4:;DDO92A*5JDN:4_P![2C!M.D_]H?MHI4'$%24:
M:FX3FN1U&I349.]:,HQ;A%1C%>QJ.=G&:3HVIN3K1\;L/V?/$/BKPO\ "WQ-
MX@\1_##X<_#R#]F/4OCQXM\?KHGB-I_#W@./]JGXI_L_:7%XSTWP[H^J:_\
M$?XQ>+/BUIUCX)\$:=X:LI[2?PMJW@0^)M;\)>#?!GCOQ=X5V])_9"7Q%9'Q
MQH'QW^&DGP,/PT^(GQ-'QCUSP]\3M+331\(_''PI\$?$CX9>)OAYH_@[Q1XR
MTKXQ:!-\:_A?KUCX<TB'Q-X)\0Z!\0/!.HZ;\23:ZOJL_A[*T/\ :>LD\,>%
MOASXR^&,>O\ PPMOV<;O]G'QWX<\,^-&\&Z_KNFQ_M5_$']K?PKX^\ >);OP
MEXMT_P"''BWP3X[\8Z3H&E6.L^%?B7X>U/PEH>NZ5K-C<1^-7'ARU?\ [3_A
M_2?A[KWP:^&7PLU'PQ\*K_X6?$[P/IMKXP^(UMXV\?2^.?C'\2?V??'GQ!^+
M?B[Q9I'P\\#:!KE]>Z/^S5\,/AWX?\#^'?!'@O0/#_A;0;"_FU#7/%4GB;7_
M !:2^M>\HQY9.3<%:E."C*5>4_:2E)-U8MT?9**5*<5)SC&\XTVEA_<4I722
M4Y?O(R;2IJ/LU9VA)*K[3F<IPYHJ+DXQE+R'XL_"J#X;Q?#G7M!\9Z=\0_ '
MQ<\$WOCOP!XML]$U;PMJ,VGZ+X^\:_##Q)H7BSPEK)GN?#'BWP_XR\ :]#=Z
M;::MXCT>]T"Z\-^(M(\0W]IKJ0VGD5>F>,OB3-XP\ ?!'P')HD6FQ_!?PKXX
M\+P:K'J3W<GB5?&OQ7\;?%.2^FL6L;5-';3)O&<FA);)=ZH+N+34U)KBU>[:
MPMO,ZZJ:DE)2;=JE11D[7E34_P!W)J-HJ3@];*.L4W%-N^$^5M.*23A!M)MI
M3Y7SI<S;MS)-7<K7:3:M8HHHJR0HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH N:9JFJZ#JNE:_H.K:KH&OZ#JFG:[H.O:%J-YH^N:#KFD7L.HZ1K>B:QI
MT]MJ.D:QI.HVUOJ&EZKI]S;7^G7UO!=VEQ#/#&Z_VT?\$H_^"KFE_MN:7IWP
M'^.^HZ7H'[9>@Z5,^F:DL-GI&A?M4:#H]G)=7_B3PS8VR6NG:1\=-%TZUGU+
MX@_#S3X+:S\<:=;W_P 1?AS91K;^,_"7A+^(NKFF:GJNAZMI.OZ#JVJ:!KV@
M:IIVNZ#KVAZA>:/KN@Z[HU[!J6C:YHFL:=/;:CI&LZ/J5M;:CI6JZ?<VU_IU
M_;07EG<0W$4<B<&89?1S"BZ=1<M2-W1JI+FIR?W<T)67/!NS7O+EG&,CKPF,
MJ82ISQ?-!V52FW:,X_I..O++=;.\6T?Z@2L, @Y!YXYZ_P"?Q]R>75^,?_!*
M+_@JYI?[;>EZ=\"/COJ&EZ%^V3H.ES-IFI+#9Z/HG[4NAZ/9276H>(_#=C:Q
MVVG:3\<M(TVUGU/Q_P" =-@M['QO86U]\0?A_81>1XL\*>&?V:4[N005(X([
M^A![Y_P[YK\]Q.&K8.M*A7CRSCL]XSB[\LX2^U&5M'NG>,E&46CZ^A7IXBG&
MK2ES1>Z^U&2WC)7=I+JNJLTW%IBMT/T/\J[;QW_R$= _[$;P9_Z9H:XENA^A
M_E7RS^UU_P %'?V0OV7?BAX?^%GQI\0?%?3O' ^$WPX\426O@_X7IXLT5='U
MK3KRVTUUUAO%.DEKMWTJ[^T6WV-1 !%B63S#MWR_+,PS;$?5,LP>(Q^*]G.M
M[##4_:5?94^7VE3EYH>[#GAS.^G,M'<QQ^8X#*Z'UK,<70P6']I"E[;$3]G3
M]I4YN2'-RR]Z?)+E5M>5ZJQ]3T5^6_\ P^F_X)U?]#?^T!_X8J/_ .;NC_A]
M-_P3J_Z&_P#: _\ #%1__-W7N?ZC\8?]$UG'_A(__EYXW^N7"G_10Y3_ .%2
M_P#E)^I%%?EO_P /IO\ @G5_T-_[0'_ABH__ )NZ/^'TW_!.K_H;_P!H#_PQ
M4?\ \W='^H_&'_1-9Q_X2/\ ^7A_KEPI_P!%#E/_ (5+_P"4GZD45^6__#Z;
M_@G5_P!#?^T!_P"&*C_^;NC_ (?3?\$ZO^AO_: _\,5'_P#-W1_J/QA_T36<
M?^$C_P#EX?ZY<*?]%#E/_A4O_E)^I%%?EO\ \/IO^"=7_0W_ +0'_ABH_P#Y
MNZ/^'TW_  3J_P"AO_: _P##%1__ #=T?ZC\8?\ 1-9Q_P"$C_\ EX?ZY<*?
M]%#E/_A4O_E)^Q6B?\DT^('_ &&/!O\ Z735Y[7YL67_  7$_P""=5GX:U_P
M[_PDGQ_D&NWFCW9O/^%(1H;7^R)WF$8@_P"$V83"??M+&6+RL9VR9P.>_P"'
MTW_!.K_H;_V@/_#%1_\ S=T?ZC\8?]$UG'_A(_\ Y>'^N7"G_10Y3_X5+_Y2
M?J117Y;_ /#Z;_@G5_T-_P"T!_X8J/\ ^;NC_A]-_P $ZO\ H;_V@/\ PQ4?
M_P W='^H_&'_ $36<?\ A(__ )>'^N7"G_10Y3_X5+_Y2?J117Y;_P##Z;_@
MG5_T-_[0'_ABH_\ YNZ/^'TW_!.K_H;_ -H#_P ,5'_\W='^H_&'_1-9Q_X2
M/_Y>'^N7"G_10Y3_ .%2_P#E)^I%%?EO_P /IO\ @G5_T-_[0'_ABH__ )NZ
M/^'TW_!.K_H;_P!H#_PQ4?\ \W='^H_&'_1-9Q_X2/\ ^7A_KEPI_P!%#E/_
M (5+_P"4GZD5TG@S_D<O"/\ V-&@?^G6UK\D_P#A]-_P3J_Z&_\ : _\,5'_
M /-W6EHW_!;;_@G5I&LZ1J__  E/[0%P=*U2PU(6Y^!L<0G-C=17(A,O_"<2
M&,2^5L,@C<INW;&QM)_J/QA_T36<?^$C_P#EX?ZY<*?]%#E/_A4O_E)^JOBS
M_D;/%G_8T^(__3U?5@5^8^K?\%M/^"=6J:MJVJ?\)3^T!!_:FJ:CJ1@'P-CE
M$!U"\GO#")#XY0R"(S>6)-B;]N[8N=HS_P#A]-_P3J_Z&_\ : _\,5'_ /-W
M1_J/QA_T36<?^$C_ /EX?ZY<*?\ 10Y3_P"%2_\ E)^J=A9S:EJ%AIMNT:W&
MHWUII]NTS,D*SWMQ';1-,Z)(ZQ+)(ID98W94!*HQ !74=.OM(O[O3-3M9;+4
M+&4PW5K, 'C< ,I#*626*5&66">)GAN(7CFADDB='/Y>:/\ \%M?^"=.E:OI
M.JGQ3\?[@:7JFGZEY#? V.-9_L%W#=>2TG_"<2>6)?*\LOY<FP,6\M\;3X!^
MQ7_P6)\)?%GXY?$OX$?M'^*YM/\ !OC?XU_%#4_V2OC_ .,P--NO#OA'QC\1
MO$6M?#_X+_&N22>X6QT!=&U32]*\%>*;BYN#X,NQ%X7UBZFTF.SO&WCP#Q:\
M'C\94R7&X>.7TJ=>='$4)0KXFE*=2-9X2"G4]O/"P@J]:C%>U="4ITHU'3G3
M>,N-^&%B\#A*>;X.O+'5:E"-6A6C.C0JQA"5*.*FXTU1AB92=&C5D_9JLE"I
M*FJD)K]MJ*NZCIU]I%]=:9J=K+9:A92F&ZM9@-\3@!E(92R212QLDT$\3O#<
M021SP2212([4J^./JR2.&:8D0PRS%1EA%&TA4'@%MH. :E^Q7W_/E=_^ \G_
M ,37XL?\%F+?Q)?^"OV<](\*0:]>ZWJ_Q$\:6-AI7AJ+4KK5]6NI/#VA_9[*
MST_20][J%P[%O)MX(II22_EH237X:R?"#]IZ*-YI?A5^T+%#$CR2RR_#_P"*
M4<<<<:EY))'?2 B1H@+L[,%5022 "1_1?A]X T>.>$\MXHK\>Y3P\\RKYE1A
MEN.P%.I6BLNQ\L ZD:M7/\N]M&M./,N3#6IM^R<YR1_*WB=])C$>'7&F:\'X
M?PUSKBA95A\JKU,UR[,JU*A*6:9;3S%4I4*/#6:JC.A"?(_:8J]1+VJA"+L?
MVX_8K[_GQN__  'D_P#B:[WQ-')%\._A>DL;Q.)O'Q*2*4<!M?@895@",@@C
MCD'-?P$VDWCW4+;6+W3YO&E_9>';>.\\0WEE)X@NK7P_9S7D>FQ7>N7$#RPZ
M1;2:C/!81SZB]M%)?316:N;B18S_ %>_\$M;JZN_^"?WPAFO+JXNYC\3?CNI
MFNIYKB4JOB;1\*99WDD(!R0"V!DX%9>*7@'4\-.&H\12XMPN>)YM@,JG@J&4
M5<#.G+'4<77A6G6GFF-4>6GAE*-*5&$JL*L:D)<B4I[^#GTEJ7BYQ9/A>'!&
M,X=Y<ES#.89AB<[IYA"M#+\1A,+.A3H1R;+W+FJXJ4)5HUYQI3HRIRASMQA]
MYT445_/)_40445^6/_!;+XM?%'X#?\$N_P!J?XQ_!;X@>)/A=\3O <?P+N?"
M_C?PE<1VNO:/_P )-^TU\%O >NI9SRI(BKJ'AKQ9K.GSJ5_>0W+QY4.6 !^I
MU%?SK:=^RA\:+W3M.O7_ ."U_P#P4ZC>^T^RO61?A;\#BB&[M8;@JI;XG@D*
M9<#/.!U/4_#/[7/BSQ5\!/!W[17ASX??\%T/^"@7C7]I[X*_L\^(?C[8_!OQ
M!\/_ (5Z=I]SHNCW6F65O%XJ\0:!XXU=?#XN9M8TN>73P7\2II&H6^NV6BWN
MGH[GT:F49G1ASU<%6IP_FG[**;Y93LKU[R?)"<N6*E)J,FHNS..&8X&I+EIX
MFG.7:/.W:\8W=J5DN:45=M*\EKJ?V'T5\8_LH_M7_"/Q)^RS^S3XC^(-]\<_
M$7CW7_@!\'=:\;^(7T7P#</KOB[5/AYX=O?$FL-/+XIM))VU+6)[R\,SVML\
MIF\QX(79HU]]_P"&E?V=?^?7XX_^$_\ #[_YL:T61YQ)*4<NQ3C)*46HT[-2
M2DFOWZT:DFM%OLME+S/+TVGBZ*:;35YZ--IK^$]FFGYH^E?AI_R%/$O_ &(/
MBW_TFMJ\Y3[B_P"ZO\A7&^'_ -K3]GOP]<W]S;Z;\:KEM0T74]$D2?0/ 06.
M'4TCCEG3R_&:DRQ",&,,2A).X$5@C]I7]G0 #[+\<> !_P B_P##[M_W.-/^
MPLY_Z%N*_P# :?\ \O%_:>7_ /071^^?_P J/4J*\N_X:5_9U_Y]?CC_ .$_
M\/O_ )L:/^&E?V=?^?7XX_\ A/\ P^_^;&C^PLY_Z%N*_P# :?\ \O#^T\O_
M .@NC]\__E1ZC17EW_#2O[.O_/K\<?\ PG_A]_\ -C1_PTK^SK_SZ_''_P )
M_P"'W_S8T?V%G/\ T+<5_P" T_\ Y>']IY?_ -!='[Y__*CU&NE\+>%K_P 7
M7FH:=IDD*WUIH]SJMM!.RQI?26]YI]J+!9W98[>:X%\QMI9?W+7$<4$SP1S-
M<0^$_P##2O[.O_/K\<?_  G_ (??_-C63XF_:8^"DW@CXA:'X7L_BX=>\7>!
M=?\ ">FS:UI'@ZSTZSN]6%K);WL]UI7BRXO[<6]Q9PMYMM;7$T8+/'$TBK54
M\@S>=2G"> Q-.$JD(SJ2A!JG&4XQE-I5[M0C*4VENH-=29YK@(PG*.)HSE&,
MI1@G-.<E&3C!/V6CDTHIO9R3/:Y8I;>::VN(9;>YMY9(+BWGC>&>WGB=HY89
MHI KQ2Q2*R21NH9&4JP!%02?ZN3_ '&_]!->;?!3XV6_QCM['P/XYO8+/XNV
M=O%9^&/$UY+%;6GQ.M+:(1V^A:[<.4A@\=6\,:Q:7JDK)%XCBC2TNV6_2*0^
MF744UNUS;7,,MO<V[307%O/&\4T$\):.:&:*0*\<L4BLDD;J'1@58 \5Q8[
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M+E$\N,(\M6523A&E;F?N^[^[Q%1RDFU)J/L%'EIJ=1RJQY8RM9_BCE3QD?\
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MM\1_^#B^_P#CU'_$;L1_T3=#_P .F(_^8P_X@]0_Z*#$?^&ZA_\ -A_G2?\
M"LOB=_T3+XD?^$#XN_\ E-1_PK+XG?\ 1,OB1_X0/B[_ .4U?Z+?_"<^-/\
MH;?$?_@XOO\ X]1_PG/C3_H;?$?_ (.+[_X]1_Q&[$?]$W0_\.F(_P#F,/\
MB#U#_HH,1_X;J'_S8?YTG_"LOB=_T3+XD?\ A ^+O_E-1_PK+XG?]$R^)'_A
M ^+O_E-7^BW_ ,)SXT_Z&WQ'_P"#B^_^/4?\)SXT_P"AM\1_^#B^_P#CU'_$
M;L1_T3=#_P .F(_^8P_X@]0_Z*#$?^&ZA_\ -A_G2?\ "LOB=_T3+XD?^$#X
MN_\ E-1_PK+XG?\ 1,OB1_X0/B[_ .4U?Z2ND>+?%,OP^\;WTOB/6Y+VSU7P
MI%:7;ZG=M<VT=U>2I<QP3&4O$DZ@+*J$"10 V0!7"_\ "<^-/^AM\1_^#B^_
M^/4?\1NQ'_1-T/\ PZ8C_P"8P_X@]0_Z*#$?^&ZA_P#-A_G2?\*R^)W_ $3+
MXD?^$#XN_P#E-1_PK+XG?]$R^)'_ (0/B[_Y35_HM_\ "<^-/^AM\1_^#B^_
M^/4?\)SXT_Z&WQ'_ .#B^_\ CU'_ !&[$?\ 1-T/_#IB/_F,/^(/4/\ HH,1
M_P"&ZA_\V'^=)_PK+XG?]$R^)'_A ^+O_E-1_P *R^)W_1,OB1_X0/B[_P"4
MU?Z+?_"<^-/^AM\1_P#@XOO_ (]1_P )SXT_Z&WQ'_X.+[_X]1_Q&[$?]$W0
M_P##IB/_ )C#_B#U#_HH,1_X;J'_ ,V'^=)_PK+XG?\ 1,OB1_X0/B[_ .4U
M'_"LOB=_T3+XD?\ A ^+O_E-7^BW_P )SXT_Z&WQ'_X.+[_X]1_PG/C3_H;?
M$?\ X.+[_P"/4?\ $;L1_P!$W0_\.F(_^8P_X@]0_P"B@Q'_ (;J'_S8?YTG
M_"LOB=_T3+XD?^$#XN_^4U'_  K+XG?]$R^)'_A ^+O_ )35_HM_\)SXT_Z&
MWQ'_ .#B^_\ CU;_ (3\9>+KKQ7X7MKCQ1K\]M<^(]$M[B";5;R2&>";4K9)
MH98WE*O%+&S1R(P*LC%2""11_P 1NQ'_ $3=#_PZ8C_YC#_B#U#_ **#$?\
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M2VL;6VLK9'_X)A_L^3,EO:0I! C2S3/+(5BC12\CL[XRS$FO-/CC_P $]O\
M@K?^T5\'_B-\"OBK_P %6O@)K'PW^*WA74O!?C72M)_X)O?!3PKJ.H>']614
MO;6T\1>&=3TK7](GD5%V7VE:A:7D# /!,C@,/JY<1X:7UB4L)BZDZE+$4L.J
M^+HU:>$^LTIPJNA%T5)<\IMN4I2J0I?[/2G"C:+\".3UHJE%5\/",)TIU?94
M*D)XCV,XRA[5^T:?+&-DHJ,95/WU2,ZGO*E^R7-$/V5?V9<R)G_AGWX-9^8=
MOAWX=X//Z5] ^?#_ ,]$_P"^A7Z8? /PA/\ !7X%?!7X-W5MX \377PE^$OP
MZ^&5SXE'PV\,68\13^ _"&D>%I==%G=VFI75F-6?2S?_ &6YU'4+B SF.:]N
MI%:>3UG^W?\ J6_ /_AOO!__ ,J*[J?&-&%.G!Y?7;A3IP;6(HV;A"$+J].]
MGR7^=NARSX=J2G.7UJG[TYRM[*IIS3G)+XNBDE\C\=O/A_YZ)_WT*//A_P">
MB?\ ?0K]N_!$VGZS?ZW!J/A7P'/%9^$O$&JVRKX$\*0E+ZPA@>UE)BTE2ZQL
M[$Q,3&^<.K "N,77LJ#_ ,(WX!Y /_)/O!_<?]@BJ_USH?\ 0OK_ /A11_\
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M\7?"?B'X.:-XT\/Z1/J/@?6?C#I?@72O&[R:/8^$KS6=3UWP_9ZE]/\ @O\
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MK-@O^?.(_P#*/_RT/[$Q/_/VA]]7_P"0/\[:BO\ 1)_X=%_L%_\ 2/#X9?\
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M;>._^0CH'_8C>#/_ $S0UQ+=#]#_ "KMO'?_ "$= _[$;P9_Z9H: .*HHHH
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M\\8W%E?^';+Q3+X*T;PSX0\4>$?%S>&O#^IV/A31O$>G^+K#6SJ^G:[^,/\
MPY<_X*FCC_AE/3SCC(_:-_9CP?<?\7:'!^@^@K^]>BO5PV<X["THT*<Z<J<+
MJ"J4U-Q3;?*I<T7RIMM)WM=I.VAP5\MPF(J.K.,U.7Q.$W%2>W,U:7O-))M6
MO975]3^"C_ARY_P5-_Z-2L/_ !(W]F/_ .>W1_PY<_X*F_\ 1J5A_P")&_LQ
M_P#SVZ_O7HK?_6',>^'_ /!/_P!U,?['P7:M_P"#?_M#^"C_ (<N?\%3?^C4
MK#_Q(W]F/_Y[='_#ES_@J;_T:E8?^)&_LQ__ #VZ_O7HH_UAS'OA_P#P3_\
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M+Z:'55>]NS/X[IGBCQ/HNA7_ (9T;Q#K6DZ!JGB'PCXMU#2--U*[L;*[\5>
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M<T35K2'4-'UW0M8T^:XT[6-#UG3KFVU'2-6T^XN+'4;&XANK6:2&16/\C/\
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MH_XAZOB'_P!'D_!/_P -M\3O_B:/[4\&O^??#7_AJQO_ ,R!_9_BS_S\S_\
M\.>"_P#F@^=?^'[/[>'_ #Y_LT_^(_Z'_P#+NC_A^S^WA_SY_LT_^(_Z'_\
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MAJ]WJ;V_BW2K>#Z#\!_\%3]5\*^._P!F7Q/XE_9Z\+>/?"WP2^#=Y\,?BUX
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MYB_\,'_MS[@__##7[9^]5**W_#)O[0.Y48J64-_PKK(5BBEE!PQ5202!3/\
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M/LVK:<]1J5Z%9\T>5IQJ*,M:C<YQ5%N524:GLY5.:4G&$97<[GZT>%;KXC^
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M4:]*HO9I*:4I*7\]O_#C_P )?]'+>)?_  TFD_\ SQ:/^''_ (2_Z.6\2_\
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MM?\ !2C_ ()O^#O^"B7@#P!IEUX_OOA'\5O@_J_B35/A?\28/#2>-](M-/\
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M9W]KC_YP='_#Y/\ X)D_]'K:%_X9W]KC_P"<'7\!E%'^K6"_Y^XK_P #I_\
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M_P""9/\ T>MH7_AG?VN/_G!U_ 911_JU@O\ G[BO_ Z?_P J#^V\5_S[H?\
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M".@?]B-X,_\ 3-#7$MT/T/\ *NV\=_\ (1T#_L1O!G_IFAH XJBBB@ HHHH
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M;_Z36U><I]Q?]U?Y"O1OAI_R%/$O_8@^+?\ TFMJ\Y3[B_[J_P A0 ZBBB@
MHHHH **** "F2?ZN3_<;_P!!-.!!Y%-D_P!7)_N-_P"@F@#TCXH_\C-9_P#8
MK>&?_3<*\ZKT7XH_\C-9_P#8K>&?_3<*\ZH **4 L<*"3UP 3_*G>7)_SS?_
M +Y;_"@!E%/\N3_GF_\ WRW^%'ER?\\W_P"^6_PH 913_+D_YYO_ -\M_A1Y
M<G_/-_\ OEO\* &44_RY/^>;_P#?+?X4>7)_SS?_ +Y;_"@!E%/\N3_GF_\
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M,$E"FGS.,%RN<DHJ"T445J0%%'^?\_E10 4444 %%%% !1110 4444 %%%%
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MU[*]E^,5/%^E3J5*;R"HW3J5:=_[4@K^SJU:=[?4]+^SO;I>UW:[_P!'K_A
M/''_ $*6O?\ @!+1_P (!XX_Z%+7O_ "6O\ .%_X2CQ3_P!#5XH_\*/6O_DZ
MC_A*/%/_ $-7BC_PH]:_^3JT_P"('U/^BFA_X::G_P \"/\ B,5+_HGZG_AU
MA_\ ,9_H]?\ " >./^A2U[_P EH_X0#QQ_T*6O?^ $M?YPO_  E'BG_H:O%'
M_A1ZU_\ )U'_  E'BG_H:O%'_A1ZU_\ )U'_ ! ^I_T4T/\ PTU/_G@'_$8J
M7_1/U/\ PZP_^8S_ $>O^$ \<?\ 0I:]_P" $M'_  @'CC_H4M>_\ ):_P X
M7_A*/%/_ $-7BC_PH]:_^3J/^$H\4_\ 0U>*/_"CUK_Y.H_X@?4_Z*:'_AIJ
M?_/ /^(Q4O\ HGZG_AUA_P#,9_H]?\(!XX_Z%+7O_ "6NYUWP=XLG\"?#NPA
M\.ZO+>Z=-XU:_M4LY&GLQ>ZW#/9FXCQF/[3"#+#G[Z L.!7^:9_PE'BG_H:O
M%'_A1ZU_\G4?\)1XI_Z&KQ1_X4>M?_)U'_$#ZG_130_\--3_ .> ?\1BI?\
M1/U/_#K3_P#F(_T>O^$ \<?]"EKW_@!+1_P@'CC_ *%+7O\ P EK_.%_X2CQ
M3_T-7BC_ ,*/6O\ Y.H_X2CQ3_T-7BC_ ,*/6O\ Y.H_X@?4_P"BFA_X::G_
M ,\ _P"(Q4O^B?J?^'6'_P QG^CU_P (!XX_Z%+7O_ "6C_A /''_0I:]_X
M2U_G"_\ "4>*?^AJ\4?^%'K7_P G4?\ "4>*?^AJ\4?^%'K7_P G4?\ $#ZG
M_130_P##34_^> ?\1BI?]$_4_P##K#_YC/\ 1Z_X0#QQ_P!"EKW_ ( 2T?\
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M4'_SVJ\8HKM^HX+_ *!,-_X(I?\ R!S?6\5_T$U__!U3_P"2/9_^&F/VJ?\
MH[_]LW_Q,;]J#_Y[5'_#3'[5/_1W_P"V;_XF-^U!_P#/:KQBBCZC@O\ H$PW
M_@BE_P#(!];Q7_037_\ !U3_ .2/9_\ AIC]JG_H[_\ ;-_\3&_:@_\ GM4?
M\-,?M4_]'?\ [9O_ (F-^U!_\]JO&**/J."_Z!,-_P""*7_R ?6\5_T$U_\
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MIMAK?B#X6^(I-4M)[RWNOA7\:?A#\:M+@%K<?9;FVU+5_A#XV\:Z;I-VD_\
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M3V.J?$'4[&>73/BI\4]+EE@,,E[\/OA]>GPI_P )%XC\>_K@ %     P .
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M  38_P"B)_%3_P 2-\<__*^C_ASK_P $V/\ HB?Q4_\ $C?'/_ROK]*J*/\
M7/BW_HI<[_\ #A7_ ,@_U1X7_P"B?RC_ ,(J?_R1^:O_  YU_P"";'_1$_BI
M_P")&^.?_E?1_P .=?\ @FQ_T1/XJ?\ B1OCG_Y7U^E5%'^N?%O_ $4N=_\
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M?<7_ '5_D*^3/IS^>;_@J=\7_&'P@_:LNG\'G1R?BC^PU=_!3Q4NLZ:-31_
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M-3_(_@QP?0_D:,'T/Y&O[SO^'+/_  2X_P"C1="_\._^T?\ _/FH_P"'+/\
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MBYR=^5:M15HW;DTY.ZY<1@Z&*<76]I+E5HQC5G"*ON^6.G,]+R=W9)72T?\
M'C_Q#;?M!_\ 1V7[-'_A/?'C_P"=O1_Q#;?M!_\ 1V7[-'_A/?'C_P"=O7]A
MW_"O?'7_ $*>M_\ @(?_ (JC_A7OCK_H4];_ / 0_P#Q5=G^L&9_\_*/_A/3
M_P#DCF_LC!?R5/\ P=/_ "/X\?\ B&V_:#_Z.R_9H_\ ">^/'_SMZ/\ B&V_
M:#_Z.R_9H_\ ">^/'_SMZ_L._P"%>^.O^A3UO_P$/_Q5'_"O?'7_ $*>M_\
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M_P#R0?V1@OY*G_@Z?^1_'C_Q#;?M!_\ 1V7[-'_A/?'C_P"=O1_Q#;?M!_\
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M'3_R/X\?^(;;]H/_ *.R_9H_\)[X\?\ SMZ/^(;;]H/_ *.R_9H_\)[X\?\
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M].N/#GPCL?$UI9:['XL\8:6SCQ]\2-2T[3-7&C7S^ /"=KI>@OXJU3QO^K0
M4!5   P .@'H/:NR_P"%>^.O^A3UO_P$/_Q5'_"O?'7_ $*>M_\ @(?_ (JO
M+Q&(K8JK*M7FZE25M;644MHQBM(QCK:*T5V]9-R?=1HTZ%-4J45&$;V6K;;W
ME*3UE)]6^R2LDDN.HKL?^%>^.O\ H4];_P# 0_\ Q5'_  KWQU_T*>M_^ A_
M^*K$U.-/(/T-=1XKU*RU2\TB:QF,\=KX5\-:9<,8IH?+OM.TV.VO(=L\<;.(
M9E*"5 T,F-T4DB88VO\ A7OCK_H4];_\!#_\51_PKWQU_P!"GK?_ ("'_P"*
MH XZBNQ_X5[XZ_Z%/6__  $/_P 51_PKWQU_T*>M_P#@(?\ XJ@#CJ*['_A7
MOCK_ *%/6_\ P$/_ ,51_P *]\=?]"GK?_@(?_BJ ..HKL?^%>^.O^A3UO\
M\!#_ /%4?\*]\=?]"GK?_@(?_BJ ..HKL?\ A7OCK_H4];_\!#_\51_PKWQU
M_P!"GK?_ ("'_P"*H 32]7T^V\$>+]%GG*:EJNH^&KBPM_(N'$\.G74DMXYG
M2)K>'RD92%GEC>0D")7.<<?78_\ "O?'7_0IZW_X"'_XJC_A7OCK_H4];_\
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M^.O^A3UO_P !#_\ %4 <=178_P#"O?'7_0IZW_X"'_XJC_A7OCK_ *%/6_\
MP$/_ ,50!QU%=C_PKWQU_P!"GK?_ ("'_P"*H_X5[XZ_Z%/6_P#P$/\ \50
MO@C5].T6_P!;GU*<V\5YX1\0Z5;,L%Q<&2_OX8$M("MM%,\8E9&!FD58(\ R
MR(IS7&*"%4'J% /U KLO^%>^.O\ H4];_P# 0_\ Q5'_  KWQU_T*>M_^ A_
M^*H XZBNQ_X5[XZ_Z%/6_P#P$/\ \51_PKWQU_T*>M_^ A_^*H XZBNQ_P"%
M>^.O^A3UO_P$/_Q5'_"O?'7_ $*>M_\ @(?_ (J@#CJ*['_A7OCK_H4];_\
M 0__ !5'_"O?'7_0IZW_ . A_P#BJ ..IK@LC@=2K ?4@@5V?_"O?'7_ $*>
MM_\ @(?_ (JC_A7OCK_H4];_ / 0_P#Q5 #O'FKZ=K>N6U[I=P;FVCT'0[%Y
M&@N+<BZLK,0W,?EW,4,A$<GRB14,4GWHW=<,>,KL?^%>^.O^A3UO_P !#_\
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MO?'7_0IZW_X"'_XJ@#CJ*['_ (5[XZ_Z%/6__ 0__%4?\*]\=?\ 0IZW_P"
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MJ@#CJ*['_A7OCK_H4];_ / 0_P#Q5% 'W_1110 4444 %%%% !1110 4444
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MD^4TZ=2GCO\ 9.6JL?*DYU[0I<ZJMIP37D'_ !$<?"C_ *-D^)/_ (77A/\
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MXJSE9M14HN3BI1<[NE:[M>*DD]&XMV4DOBLVG&-XIR<9J*?)/D]]HKY#\/\
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MJDTG[VWG=I+MNY14;I<SE%1YG**D-J+:;2:3;OV6[](V?,TVHV?,XV9].T4
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M=G@N[&_LIX;JTNH'>&XMY8Y8V9'4G3JFFFTTTTVFFK---IIIZIIIIIZIII[
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MUDDXR<73E&R=*NL1#1-*K&;J*5GNE-M\KO'5IWNV_P R-1_8Q^-FE_"CX]_
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M^,OVN_\ @E7X:\0:##XD\*Z_\;?CAX?\5Z1?Z<VHZ/J'A_7_ (2P:3JNF:S
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MN+>\T_S-+LG^P7=I9RZ?:75GN@/V6XM;">>QMYX/+EALYI;:)UAD=#D+\/\
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M^$K:QU^XT7:N/VO/"5E<S:=J'@3Q]IFLPP3V\>DZE=?#N![GQ+%\:K'X%_\
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M&FBZ!I6LZOX@U>.;3=2\;1>'M,TRPN+>QU&UE\0WLUJD-O<7.C:5J-=_VQ/
M5O+9Z7=^'O$/_"33P61NM!L=;^'<ZV5Y=I\#G$$VOWOC?3/#D-I*?COX=_LW
M6+_4]/TO6%T/78=,N)[^Z\+V'B+ZG?1='DN+&ZDTK3'N=,N;^\TVX>PM6GTZ
M[U1+B/4[JQF:(R6ESJ,=W=)?SV[1RWB7-PEPTBS2ALY?!OA%(G@3PMX<6"2Q
MLM,>%=#TM8GTW31:+I^GO&+78UC8K86*V=H08+5;*T$$<8MX=B4\/9\^'FWK
M[T:SC;2"6C35DE-M6NW)--<K3?)52C:JKI*]X7YG>3;W5M'%*VB2>^A\6>!/
MVY=%UK2?"=MK/@+Q]KWC'6/A=I'Q$UB'X?\ A1;SPU8RW_POG\?II$&J:AXD
MD@BN->O=%\0Z!X6AU*_M+FYU(Z':7D<$>H'4J]A\6?'^[@^$5K\3_ 'A%O$\
MU_XB^#>G:+H=YK_AT-XFTOXH7_PXN)3HE]X=UCQ!;1:PN@^.IK'0;;6VTJ#4
MO%-A;R.P\&ZCIGBC4?=;CPEX5NA$MSX:\/W*P6FH:?"MQHNFS+%8:M9V^G:K
M8Q"2V81VFIZ?:VMCJ%LF(;RSMH+6YCE@ACC6:Q\-^']-6]6QT72[0:CJ-EJ]
M^(+&VC6\U33;'2M+TW4)U6/$EWIVF:'HNGV$[9>RLM(TRUM3%!8VT<3G4PSD
MI0P\XVJJ;A*JYPE#VDI.E;W'&+@X4TT[^ZW=.2DDHU4FG433BTFHVDFXV4D]
M4VI7E9JR]W1I.,OCWPC^W%\/_$5UIMH?#_BR^M-4N]/:W\::#H[S?#N/1O%7
MQ??X9^"-0NO$^KW.EQ6[ZCI4^G^,=562()9:<NJ6EL]YJM@VFTNN?MJ>'%\(
M7_BWPGX,\3ZG8Z=XC\-:<;FZM8]9AUG2'^'5A\:?&]WH&G?#RX\;^(I9-!^&
M%S EAJNK:+I'A&Y\:>(/#&FWGB*VT6ZO]8LOKV;PIX8N#.T_AS09FN=)OM!N
M6ET?3I3<:'J<S7.I:-.7MF,NE:A<NUQ?:=(6L[N=FEN(9)&+5>MM'TFS;?::
M9IUJ^V1-]O96L#;)H;.WE7=%$AVRP:?802+T>&QLXVREM J#J8;F4HX:;LXM
MPG7;C*SNU)QBI+FBE!\J22<YV]HX*-<M1J2=1*_-:48*\;VM9-N/N^\U=N[Y
M(OW%+F^2_$'[97@;1;OQ6T/A[Q7J>F^!I_&VG^(I-/B\*2":X\&^*/AWHFH:
MQI.KW/C2STB?POI^C_$'3O%>J:P))K>RTJ'7-.U&?2/%W@OQ5X6L^]\:?M'>
M&?!_B+Q%X;_X1SQ!K=WX>_X0VQDN+#5O &F6M]XB\>ZQX<TKPYH=I'XH\::#
MJ$<,R>*--OIO%=]8VO@EF6X\.:=XBU+QLL/A:?V>7PCX4F@%M+X9\/26ZV]M
M:+!)HNFR0K:V=^-5L[81/;&,6]KJ@&I6T(41P7X%Y$J7 $E3:CX9\.:Q)=3:
MOH&B:I-?:6^AWLNHZ587TEYHLL_VJ31[I[J"5[C2I+G%P^GRL]HTX$K1%_FJ
M7+#7C:C5LDT[UE>7NP2>B5GS*<FEI[ZCJH18*-76\XWTM:+T]YM[O6\6HZZW
M5WJV?)-M^V?X>UR7PNOA;X<>-;ZV\6:K\,;?2]3US5? N@:=<Z+X_OO@O;:I
MJUMY?BK5M1-YX0B^/7P_BN=(OM-TZ3Q!J]W=V7AZ[O=/M6UE\J3]M#3_ .W/
M ,__  A&OV7A/QG\.-&^),EKJESX&MO%EIX=\57MXGA?5K*-/B,^G:T;G2M,
MO=6O/"&B1ZMXYEBN-,LM$T/5]7?5--TK[1GT+1+MG>ZT?2[IY)1.[7&GVDS/
M,L^GW*RN9(6+R+<:1I-PLC$N)],TZ8$265LT44GAOP],UD\N@Z+*^F_8/[/:
M32[%VL!I4GG:6+-F@)M1ILW[ZP\@Q_8Y?WEOY;<U?M,+S1:PL^5.7,GB)-RB
M[65VDDXJZORK5\R6G*\W#$.+7MHJ7V6J:LM[73;;WCS:KFY6K)2T^0]2_;;\
M#VHT_5+'PGXCU7PM%X'\4^-?%NJV.J>$Y]7\,_V!\./#_P 2;/PW#X:M==N[
MW7O$NHZ=KPTN\TVRGB?0KZV>_P!0?_A'UN]9LNGM/VJ]'U7PQ\0]8TOX?>-[
M'7/ OPBU[XK6OA?QF-%\(ZAXC3P];ZI]O\/VD-QJ=[JUA=6>I65EI^JWU_HL
M<&DIK6C7UY$MMK&BG5?I)?#'AM0=OA[0US?WNJL5TFP7=JFIP:A:ZEJ1Q;C.
MH:C;:OJUO?7AS<7<&J:C#<221WMRLLNF>'M T8DZ1HFCZ46T_3M))TW3+*P)
MTK2%N(])TP_98(B=/TN.ZN8].LS_ *-9)<3K;11":0-'-0Y&E1GSVTFZKM>U
M_>BE9KFNM&G[.R^.\C2,:BFG*:<>=-Q4$KP4E>*E>Z<H)IO^9WMR^Z?-ME^U
MEX-E'C3[=X7\56<G@7X8>+OB=JHM[_P/K$5Y:> -"\&ZYXTT+33I7C"ZN(]4
MTS_A/- L=&OM>M="T#QBK7.N^%=7U7PG]A\07^?J7[8'A31O$/BWPUJWPZ^*
M>FWW@1?#*^+[Z^TKPS:^&]#NM=L/!6KZK;7'BV?Q1'X7N!X/T;Q[HNK>)KVP
MU:[L+'2K37=;-R?#VDOK,OT]:>&/#>GQW4-AX?T2RAOM.L='O8K32;"VCN](
MTNVELM,TJZ2&W1;C3=.LYY[2PL9@]K:6LTMO;Q1PR.A+KPSX=OKN:_O- T6[
MOKAM):>]NM*L+B[F;0+XZEH32W,UN\TAT746>_T@N['3;UVNK/R9R7JN?"\]
M_J]3DT]U5VG?FNVG9I)Q<ERMNSY7=I/FGEK<B7M8N:3][V:L_=25XW_F7-=;
MW:MMR_)5M^W'\,)[CP[%+X3^*-A'XH^)(^'6C7&J>%(M,6[:77/"7A>V\7QV
M]]J<%Y_PADOB7QSX9T2XU<VZG3M0U&&QU&&VU*]T>QU1LW[7HU>PT*Y\(?##
MQ=<W]]??#YM1T#6=6^&%IKC6GCW2M(\2VFC:9;'XG6\#ZVGA7Q+X>UW^WWNI
MOA]"UQJ'A_\ X2FZ\5:;/H0^M!X4\,"83CPYH(F&KSZ^)1HVG"4:]=(L5UK0
MD^S;QJUS$JQ3ZEG[;-&JI).R@ 3CP[H NX;\:'I OK>QMM,M[T:99"[@TVRE
MDGLM.AN?(\^*QLYY99[6T21;>WEEDDBC1G8E<^&25L//G2WE6<H-J*M>*47R
MN2;E:5TFE'9,?+4U_>*SO:T$FDYW6MWK&%HK362YGNT?,6H_M0:?8>.?#8N-
M/^R?";Q!\(_ WCV#Q9=_V-:77]M?$^Z\8WGA6SU.XU/Q?I/_  CNGV'AWX=Z
M\]XKZ#KL>M:QK^DVL6M^'I-%:T\3\SJW[;?A*'POJ6MZ=X$\:V]S<:?J4_@W
M^WKKX<:=IGB2?2++QU<ZU<R7L_Q&MK70=-\-GP%JPU4^*[WPS=:FTMC:>&(]
M8NKQ!']B7&@:%=VWV.ZT72;FT\G3K?[+/IMG-;?9]'N1>Z3!Y$D+1>3I=X!=
MZ=%LV65R!/;+%*-U,F\->';BV^QW&@Z+/:%H6-K-I5A+;%K>_BU6W8P/;M%N
M@U2&'4H3MS%J$4=XFVXC20)SP[O^XFE[RC:J[\KE5E%MJW-42G3C)OEA)4[J
M,92O$4:JE%^TBXKD<HN'Q.*IJ:337+&;C4:7O.+J6NU&S^.[']MCPG8Z?"_B
MCPIXK\V+1_%.H:EKND1>$K3PS%J7A[4_C]:Q:! NK^.EUR*ZU"S_ &<O'MW;
M:K?V-KH,<3Z%+JVHZ+-J5_I^A^SM\>_#\7PBT/XM77A[Q#;6^NR_#^TA\'RW
M?A"/Q78WWQ.\1Z!X:\(VNJS3^*;?PKIIO;CQ-H]_)<7?B6*U&F7(GMY[FX:&
MUF]%\2?#SP3XNT#5?#&O^&],O-%UJTFLM0MH86TV=XK@ZB[R6VHZ6]EJ6GWB
M2ZMJEQ;:AIUW:7]I=:A>W=K<PW-S+*U;PK\,? '@KPS+X.\->%-(T_PW=)"M
M_I<ENVHQ:L\-A9:7]IUN;5'O;K6[Z:QT^SAO-0U>XO;Z^:$3WMQ<3M)*]U)X
M2:;IT*M.7M$^7VO-%T[U'**;2Y':4(QLI:034ES2NHQK+E3J1DE"S;C:7.H0
MBI:?%>49S=VM9M6LD?)G@?\ ;K\%ZMX8T_5?%OA/QKIKZ9\-?AWXU\>>+-,\
M.JWPZTO4_''@/X?>,$TC0]:GUJX;6)'N_B?X-T33K339M5N9[O65F>5M(LY]
M:DZ"\_;,\*:-IGBJ]U/P1X^U"Y\*>(]4\*W^G>'K+PMJ6L3>)E^+6K_"[2?#
M.G^&K+QIJ/B34YY;G3EO[CQ38Z;-X-GC6YLK75X_$\=QX1L?K0>&_#RS27"Z
M#HRW$UCI^F33KI=B)I=.TF9[C2K"640!Y++3+B22?3[1R;>RFD>6VCB=BQ@N
M_"/A2_-V;[PSX>O3?V5UIM\;O1=-N3>Z=?7[ZK?:?=F:V?[197FJ2/J5U:R[
MX+C4'>\FC>X9I"2J81RDUAJL4VGRJO=)<TFTKQNM)**LVDHQT;NV^6JO^7D7
MO]CIT7Q=.]K]%9-6\"E_:I\%0>$?B+XNN?#7C2S3X>2>!X[CP_=VN@Q>*M>7
MXC7-AIGA&70]!BU^>^<:MKM[-X>M8+N.VO+OQ!I6L^'=/MKWQ)I&IZ-:<G:_
MMK_#[4/L,EAX.\>26>NZ3H&K>$M1O)_AQI&G>*(M9T+X4^)+R."_UGXA:?9^
M'VT'2/C-X+?4)?&4_AJVU'4'U#2?#<^MZBNE0:O]8/X<\/26^JV<NA:-)::[
M.MUK=J^EV+6VL72V]K:"YU2 P&/4)Q:V-E;":\6:06]G:PAA%;PJA-X;\.W$
M)MY]!T6> JB>3+I5A)%LC?39(U,3V[1E4DT?2'1=N$?2]-90&L;4Q3S89J:]
MA53DK0:Q#7L[PM=>XW)JI[RNTK>Z^C1RUO=_>0=OBO3^+WDUHI))633MKJFG
MIK\AWG[85CH/@'P1K&J>#=2U[QGXE^ WA'XO7FG:!J'A_2/#Z:IXQ\%^+/$6
M@^'K1O$/B!?%$]OK.J>!?$VGO>Z)H/BD>$M/BL]=\7/8Z,;G4H,V;]MC2O#A
M\2KXT^'7C9IXKNP;P79>![70/&<WB2VGT+X*W&K:/;R:'XKU%[C6_#VM_&;1
MK:[U)K/3/#NK6($GAN\U>=$%[]J_V+HWVC3;K^R=,^U:+:W%EH]S]@M?/TFR
MNX[>&[M-,F\KS+"UNHK2TBN+>U:**:.VMTD1EAC"T'\(>$Y=/_LF7POX=DTK
M[&-._LQ]$TU]/_L\)IT8L?L36QMOL8CTC24%MY7D!-+TY?+Q96PCTE5PDI5)
M?5)QC.=248QKM<D9593A"+LU:G3<:5W&\E%ZK232A62@G53Y8Q4GR:SDJ:C*
M3UTYIISMTO9;6/&!^T9H;_#_ %7XBKX+\9Q:3;>/8?ASH5C?S^"=(U'Q-K\W
MBZ+P-YL$FJ>,+/2O#=A!XD>XL9SXXU/PQJ)>RDAM--N[Z\T>SU3E8?VOO!%Q
MX@D\/P>$O&LTH^(&D?#V&_BN?A])ISWVK>-?'GPWBU:ZFC\=/-I&E?\ ">_#
MS6/#%H-9M['4-;OM3\//X?L=4M[V_DTKZ@NM%T>_TZ[TB^TG3+W2M0\\W^F7
M=A:W&GWQNIFN+HW=E-$]M<FYN'>>X\Z)_.F9I)-SL6-=_#7AU[E[U]!T5[R3
M5+77)+M]*L&N7UNQL5TRSUAYS;^:VJVFF*NG6VH%S=V]BJVD,J6X$=9*>']^
M]"IJWR<M=^ZG%)+5>]*+YFY-6=U[J5T-1K6C^\BY)>\^1).5V[I)NR:LK7NM
M7>]CP#X(_M,:'\7[;PC!J'AJ^\":_P"*_A?X'^)-KI^K:_X5U/2[U?%^FZ??
MW.B^&=4T[5S>^)+CP_)JNG0:I.FBZ?-:#4=*?5;#2I-7TF&^[3QOKOQRL-3\
M90^ O /@OQ!I-A\.3J?@B^USQC=:+>:Y\3SJ,\(\+:O8PZ5=1Z=X:&E""];Q
M MW]H%X6LULS&YNH/2K7PQX;L)VNK'P_HEE<N;4O<6FDZ?;SN;*;4;BS+2Q6
MZ2,;2?5]5GMB6S!-J>H2Q;'O;EI=RE.=-U'*G148/F_=SE*I&+<FUROFC/W8
M\L5S2>TGJY>[48S2M*?,TTU)))M*UT]+--IMV2>MM+)OX:UC]J;QEHGQ!^(7
M@34/"_A"PF\-7W@;PY8:EJ>K:YI>D:7K_BMOV<M-N[Z]UB\T^*R\9Z'I.K_'
MRYDU-/#*Z7=^'X/"?A[3O$D^FW/Q5\/7VD^N>$_B1XZF\;^--(\2S>"=<\,^
M$OA9X*\?Q3_#G2/$VLZUK-WXNU/QWI;6NE1KJFIC5(+:3X;:U-96NGZ=/?ZG
M)KFG:= 4GT>XGUKW6YT31KU;U+O2=,NDU*&[M]16YT^TG6_M[^UMK&_@O5EA
M<74-[96=I9W<4XD2XM;6VMYE>*")%GL]-T[3DBCT^PLK&.&SL].ACL[6"V2+
M3].$JZ?81+!&BQV=B)YQ9VJ 06HFE$"()'S<JM%Q2CAU&7)RRDG=.5J?OQNV
MX-2C4:2YM*BNW*"YI4*BDKU'**:=GHVET;22=[*[LM;V24G;Y:^,?[1^I^!O
M#W@?Q#X5\(ZE,GB/Q3KFDZC8>//#?B[PE<P:?X>\+:OXBN9[HW>G6TGA#1KJ
M73X(-0^(_B:V/@OP9I37WB/Q#OTJPN7CHV/[9OP_U3Q1K7A72O"7C_4KCP[X
MWU7PEK>J06_A.#1[+3-(\1> _#-SX[@N=2\6V$^M>#Y-2^(&E?9'\-VVLZ]=
MP6>J/;:'*\-NES]:WFGV&H)Y=_8V=]'Y=Q%Y=Y;0W*>5=P26MU'MF1U\NYMI
M9;>X3&V:"22&0-&[*:$/ASP];O<RV^@Z-!)>7%U=W<D.EV,3W5U?7,-[>W-R
MZ0*T]Q>7EO!=W4TI>2XNH(9Y6>6-'5*>'4.66'DY)S:DJS6DI0:4GRIR48*I
M&-E'WIQDW:+4B<:K=X5(Q]U*SA=72JWE;FW<I4G;;EIR6\TX_&/@_P#;@\+>
M)=6BBG\)^((=(\1^(O#-IX1>WN_ SZK:>%_$>B? ^:V\0^*+9/'MT'NKG6_C
MOX/2W\*Z!'?>-X-+N93<^%C?06L>K6-#_;?\(>)(M-^S^ ?B%X9DU4^!+NQG
M\4CX=S65SI_C'Q!^SC:%&DT#XE:C]BN(/#_[3WPTUB2[OGAL;%+K6=QO[G0V
MTO4OL2/PQX<A:%XM T2*2VU:ZU^WDBTFPC>WUZ^2[CO=;@9( 8M7O$O[];K4
MD*WEPM]=K+,ZW$P=_P#PCGA[RQ%_86C>4$BC$7]EV/EA(%TQ($">1M"0IHFC
M+$H&(UTC3%0 6%J(J=3"\KMA:G-RI1?UA\L7RR7,X\OO:N+=VD[-VO*T",:B
ME>51.',W915[.::C=]H7CM?F=[V3YODFS_;8\$W,MM;/\.OBK;W5UX7\*^(X
MW?2?#;Z(DOCOQ%I'A_P3HMQXM3Q2?"-EJ'B1-?T;6X+B]UNUTW2=(O94\17N
MCZOI>LZ5IVWHO[0/B#Q'X2^"^IVD'@7P]JGQ5TCQ=XFGU;Q;K9M/"%AIO@VZ
ML&G\.:9?:3J&JVVK>+=>L=3CNM-%EKEWI,&B:)XQ\6VUQKMCX?BTK5OHNW\#
M>"[.W-G:>$/"]K:'1[SPZ;6V\/Z3!;'P_J-S+>:AH1@CM%B.C7]W-+<WNF;?
ML5U<223SPO+(['2NO#^@WUE;:;>Z+I%YI]E<VM[96%UIME<65I>V4WVFRO+6
MUE@>""ZM+D"XMKB*-)8)@)8G1QNI.IAD[PP\TN=/WJO/[J=72SM'53I)J[C+
MV3YFE(2C6L^:I&_+)+ECR^]*%.*=]7[LHU))VNN=63<3Y2TO]L_P+K&H:+86
M7@CX@2C6X[#5EO(I_AW-:Z7X.U/Q!X \.6/B_6A#X_DNM/B^V_$70Y=0\&&V
MD^)NC6R3RZOX(LA=Z-_:F7H_[:.DW/AO0]6USX7>+-)U?5O#V@ZO/IEKXO\
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@B<+_ /1*9#_X*Q__ ,] _M+B#_HI<[_\&X+_ .=I_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>form10-k_006.jpg
<TEXT>
begin 644 form10-k_006.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" +3 T,# 2(  A$! Q$!_\0
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M)!&.BD#IU(_+'&?K6I"I .?6J$/5?H/YBM).A^O]!6%ZBT[:?#V^9?[KS_\
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M_G0:Q_AR]7_Z2>%_&3/F>#R3E?[9M./I,O;IU'Y5^PG@L@^%/#V./^)19?\
MHH?_ %Z_'SXR_>\'_P#89M?_ $>M?L%X)_Y%/P]_V"++_P!%4X?%'Y_D<-;=
M^J_]).IHHHK<P"BBB@ HHHH **** "BBB@ HHHH 0]#]#4.3ZFIZ3 ]!^0H
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M 'VFS* =B3E_T_\ U5\4:%9O\4-/BM/#]F?#FFVQ5Y= N5V:[%M.7:1F D*
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M,E%89 8,&QC.23ZCN![#TKJ;+]G;XJW(#2Z7;VV><2/CMTY8=_6B[_EE_P"
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M^];I?^;3R&TU%3:=FK[._P!WS+QD )''!QUI/-'M_P!]#_"J4UU;PY:8').
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M!Q^GI7\)/_!8+0];N/B?X:\6ZMI^^UT+XK>'I)+D_-%Y<>I(/WAQ@_*/X\\
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MVL=1ED37-4UNZ5R<B\UJ_))8=#FX]\_7'M4_ZQ0_E_%O]#7^P*BU<WV^RO\
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M%!Q@^_H#M0I2Q^M*^NNF_P!UF[>=BLPQ5&A0LDM/R^7:VAU4YBD51>6PCDW
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M2JU)M/F<>5-I>[JF[:VU[K4_OX\2_P#!QE^P3HBR0V>K:UK4D>[9Y%OD,P)
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MV,6G>&H/-)S!)<0;_EZ%B#\NX9&"!UZ=ZAN_B=XEN)1_9MG%:(PRLEO"D<B
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ML0MNA-XR,@VX&!@<CDYW#/3IZUQ.H>*=7Q#_ &/XFT^[C5BMXTBJSJ,D$IM
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M]E=[6U+S$@KCN?\ "G4F <9YQT_R*6N*Z:5NW_!-X[S\Y)_@@HHHH*"BBB@
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M+(1NQCV_#3]GSXP#PSX]@T^240VFL3K;QF4']RVX1[H"<!6)())!Y_"OV?\
MAE_PC@\96&HZY966L.EFMU;R:A#%</$'(VRP[EP)5S\K#H,X]CV-M;6MY/\
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MS-=ZO)]GCR6M #C>?X. ?S]#]><ZLHPV?WO^O2W<G P?,JEM7T>F[3VMU?\
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M;EY7?U\O,Z2ZM7T^YWM%!:QA1NMC#'N;C! ^3U! P>HXK$U.>#4QFQTUK*Y
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M[>0"/>P"N<9 Z<D@#CMSSWYK&2E&+>FB[GEUL9/%8JFHZTTVIMZ.UK[=7?\
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MYQ7\QW[57BK_ (6O_P %(;B73#YUC\)-!OK;4I(\M%'/;0R;5F/*@YX8 CU
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MF/"^W';V[5^R'_!&G_@G??\ [1?Q9C^-OQ'T0P^!/"@2?3C=1>9:3ZK"_F+
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MJ8:W28W44W )/D%0QP1R4SD]/PYK]9/BQX$UQ+R:%X(K6$$^3M0(%56P ,
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MKHP1[Y'"*L:N6D.3U.TX"]3R!FOIPCY]I_B/IV[U\ ?\%$_$S>'_ (%WT<4
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M!R. ,[LCUR< 'U'&ZD$Y/+9YYZ@$8XZ8(]_6I P/0_SJ&%$V9P=Q)+@GD.
M0<' P !@5,% Z#^= "TQ.A^O]!3Z8G0_7^@I2^&2_K^M0Z6_K^M3(U<XTO42
M>@T^\)_"!J_#CX?L&\=_$ C_ *#U]^MP:_<;6?\ D$ZG_P!@Z]_]$/7X:_#S
M_D>OB!_V';W_ -'M7H9:[*IYJ7Y'%7^-+HN3\VSZ"'W/P;^M*DF.I^O'4?\
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M-OX"M_+T]']YT91KBFGK^\E:^V_GMI]Q^=_[&_GZ7XXUS0->TNSU*0ZC,;B
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MW^%6UVZ);?+?L<CXVUCXE?%*\?4_'_B*^U;:J*T=M>W,<!AB 2.(6ZR", (
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M445[Y\T-*JP(95(;A@0"&'H01S^-+@>@_+TZ?E2T4 )@<' R.AP./IZ48'/
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MQCYEZGN0,8(Q[\'%?7NHZ*LL<C1PC:"Q7&.5Y(/X #'%>97.E7+>=$&6-0<
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MH^)/$]M_H[K81.)"3]S.X 9';@9R<_F*^C[KX2:I-<W#A3L7:2@R.P]3U/\
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M)SDU]/V7PX_L^*X9K<,DZG8&C&%8@=!T![\=C7N'PR^';"Q1GME1E"#A ,8
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M^R..ULW6091B%"'> P('IGW[YZ+3[C2K'5=+M-:L+C3[M9+5XV,>U)6GD5L
MD %1C QZ\\U\]4S&LY^SJI*-VDUK=;1U3[6_4^37#F(PU;FI1>DO>O+EL_M6
MO;9WL^O4XSQQHVK>)?CU/::7,;&[M-,TQK.Y1S$8YA#G?N7!4D @G(.>]>@?
M#:]\1V'QGT_3_$E])J$(DEMB[3O,"OEXV NS?+G'&/7M7FWCWQ&$^,WBJXL9
MX[6\L],L$A1&(9D$6 Y[AR,GCCG\:]'^ VBZQXK^(MKJ;DS06RS7LMT26<.%
M.4R?EVC Y^]G X%=:ART*E7[-./MIOM!6UMNWH]#ZW 4965&23J*/,[]8^NS
MVM^9R7Q-TP:;HGQ2N+%5DDU7QA!9H[C<X@$ZY@#$;O) )_=@A.V!UK[B_P""
M'7@M/%O_  5E\!W<<*RS>%O#$#Q6C#$$.(%\R2-<;82F?X<'/K7Q;\8+Q+.T
MUS38BCK+\0/-GD/W_P#7*-H &"HQC).<=,FOU:_X-S]!CUG_ (*;>*-;1/.3
M2?"4C2Q+T(%O'MPX^=2 >0.#Z]<_19U4C3\.\7BYMJAC)8>%"763CB(-WBM8
MK1[GT^22IU,=&%.[G#GYDU9:1:>O=:VV/[4/VS/V[=&_9%U3PSIR^!=9^(FK
M:\?,GTS2YEM[FTM$ !>U\TA)I3&"Y7D\'US7IOPC_;+^!GQ2^&_AGXB3^-M&
M\(V^KW/V.;2?%>K6NFZG9:K(0O\ 9VQIHTF=)/W8(5LGID]?EK]N7]A+Q3^V
M#\8?AA?MXIOO"_P^\-Q0/X@N=*E%GJ36S2,UU'%<*\<@D9044AL@,W)%?G!^
MVE_P2=\>WWQL^$>I_![1=1UO]GOPM!96NJ>$/[9O[>\EUY0%?Q!<36LBW#R^
M<#/OD 1FSD@=/PY-./,M5:_R]-S[.34=_P#/I<_:']I;]O#]GK]EK01XA^(?
MQ)T5]0N/LMOX=\):;>0WFHZ]<:I*D=E.RPO(T439+ Y4*%Y!W9'H?@W]ICX6
M>,M&LM0M_B3X-TG6[G0K'Q-J&CWNJQ(=$T:XC$\PN?,F&+@Q'*AR"&!Q[?BY
M-_P2H\5>(_A_\0;#Q=HEEXI\;?\ "3:%??#[6O$-Q+J-[H&CQ,K0Z6C7#2J8
M[<93S,AP.IR*\?\ %_\ P3A_:I\=Z\W@W2?!VB>!HM*U+3[;Q'XVTO5+\W/B
MSP\XA62R ED%JD-M'&P"Q':0^ .M,:=U===3^B6']HOX))9Z=>GXE^%5TW6+
M@Q>'ICJT9DUJ1 WVB*TWS S.SH1$%SG(QT KS?PK^VQ\#OB%XCU30_!GC6QO
MSX:GF@\6M.Z10:2MN621GG+;01M.27P37X5?MA_\$Z/VH]>\?_ 7PU\"_#^B
MP?#OX>V^E6TNK2:AJ4=Q:ZPB*+N]E6W<1-^\+EB>N[G@\]_H7_!/#]H[3O\
MA._"VA>$]'\,Z9XCAL&\0^(+*\N4N==DR&U *Y<.HG^<DJ2W)..E '[Y:3\?
M/@YK.@:MXGT?XE^&+_PUI$TEEJNHP:K;R1:5<1Y#K/()#C:3EV.['J177^"?
M'G@SXB:2/$?@7Q9I7B[1W8VIU+1[R*[MO-B)+(3"Q174G!X!SP>:_G'^.O[&
MGB']F#X6>)_'>@Z%=W7PUM=#G77OA]I6HZG<2^*M?EM0DDEUEVG4R7 9LP+U
M/!.*^N/^"&7A_P 8:9^S'KVJ^)O .J?#K3_$?BN]U/0] U2:^EDM[6:XF;;$
M=0Q,(PFPC(_B% '[=?,8VVG#8.TGD XXS[56F:X01*"IW$"1R=JCU)SR!Z=3
M5@$@$8&.Y.>![X[5S?BO2]1U[0K[3=(U+^S+R>)DBO$R7B8@X(SW^O _ 4 ;
MKY<H$GB^7&1O!W<CGKV]/IUKS3XNZ(/$GPY\:Z-(25N=#NV4VY1I<QQ2/MP<
MXW8P<\D*:^<(OV;/C#Y[73?'#5X6=V;[,8$*1!F.$W#.X 8QC/:K#?LW?%>4
M7D5U\:-6N(+ZRGM951%CVAXRH)Y7=DDCG( SGCKEBZ<JM%J%I6C:SM%I[OU]
M=V%%JG6A*6BYXRTUT4D]C\+_ ((>)-=\.Z[XSL;O0-8NM$TGQ'<6SQV\2B9[
M9+MED,.T961ER0R@-GU-?J;'XTT74?&'@[0]16];2;[P_'+I^ERI%(]K,T*M
M&;U&!#.IQN+@G(-?C%XM^&?Q,^ W[0?BWP[JGQ1U1M)U?5IIK%[A8PK7,MPQ
MC4JK;6C9SSU8CZXK]%/@S^S'XON8F^)WQ ^+<^GSW=L5TES=Q"WCMY!\KA)I
M?,0A<'"@<?0U\5B)QP\Y4ZMU*3;22<M$G&[:\VC]"H-8JA"M1=Z=)<DW*\6I
M-J223U>BU:6YW?B/3)?"VL:KJOB/4;>[TC6&G\K2X)DB>S3>T<:26Z,$1]H#
M8"C((_#\OOCYH>BZ=\19+RWTN*"PU6QB>RE389))1*7;<PY.$((R>O>OO?QA
M^S2_B$ZE8:;\;YM5FU*<B'489XI9QG)+1QR2%,HWR#C^')[5^0O[37PG^)?P
M\^),>C:G\2[S6=-TVT18)G$9ND&>79$+( 5X.,9/J*\[$)RI2J)>[&UWU^[?
MKL=5%TZS=)O>][K31W_3\5N>LZ%>:E;,EEI.F^:\S)$FU59RSD*H P>2<$#O
MWKUZZ34].U70F?1=1\4WKI''+I=I(J)9.2 3-"IVC8>"2./;-?$?AC2-?@2.
M_L?B;J(N)MJVT3) ICN3_JB"K!@P?&,\_C7U-\+O@AXRMKAM<UGXJ:S::]JX
M$L*I.C1RA^3OWR;D!Y)*8(_$YSPZO;SVOINT_P!/D7-_5D^3IO\ T^MU_2/I
M/2_BO\1OA3K\=U#\*/$6H:1?V9MKVYM\WMG9::XWSW$D($D4<L2NP#D C;ZC
MG.\2_M,_%3XQ6>L>%?@%\$-7LO@_X6@2\^+'CZ_4VM[J5D)2MQ8Z'=(JRQ7<
M,PDEE:&0$Q?*>.*U]2^#GQ8U7X6^+H?#GQRN?#U_;V$\%V)'AN#=J49UCMS<
MO@><2$8H<AL@>M>:?!3Q]XBUOX-7FB_#C6/$ZZ%X.74O"GQ4L8+:);NX\43Q
MR0G4VA 'F6$ZG>LCAAYC8W5<O:<TM-.9[-6WZ:"A7GB/=DK7M?F?RV2.[D@\
M*ZSH7AOQ9\)-.DTWP\KPPWUO>D3ZI=ZQ;LNY)9FW2RN\R$ N3NR">>*]5T'5
M9M3=8->\/W>FW2/O:1X-D)DZYD4JJL<^H/OSU_+WPW8_%GP#I6H^'X=6\5RW
M\'B7[?H+R6L/]C,MW<EH)KAU!(,!=6<)P IR.P^N-,_9U_;&\:Z99>-+GXT6
M5M;2,)!I4,,'ERDC=L=CB0*WW<CGGWKGJ3Q,)PY$FM>:\E=:JUE;7]#HAA:4
M)J3Y?GO]SU^[8_2+P&FGZO<&#[;I>K:Q:JAL]'BNXK:^MH% +,]DKJUP< ,@
M*-\N ,=^J\0Z#8WDDM];1)?V/E_9IXYHUM[VTU)&S+&5PK- $!V\8)'&3S7Y
M/:O^QG^U1X<\>^&/VIO#_CFYO_$_@*]M7UOX>:3=S+9^)]'@">;.D D#R/Y2
M$,IC9-Y-?;P_;.^$GC6>\EUK2O$7A7QO#91+J?AL6R^4;I $F=A$H_>&8,.?
MFP3DGMZM'%KD<:FDFM6E>^E[_AY?,Y,=0G4?[M1<4U]I+1/L_0V-6\-:.;B7
M4+L):VT44@=7A22$85LN=P*Y&"2W48]J^8_$-SX8&JO9V5DU^TQPMY;H/LXS
MQNRHVX[D<G\#5KXE_M-7=_H-SH'A3P1K%Q'<B2.]O[RW>..WLI5*SW"OL! B
MB9WR3P 2:XB+XG^!=$\(Z;;Z+)#?7,D*KJ%Q,NZ2UD*@8A91DXS@;S^%>/6_
MB\_V;I^?W?(RI4IPW2W[KNG^A'XAT>RTVWN;=+0S:E+'F/RURI\Q R*<?Q '
M'7@X!YK@O#O@6\9Y+Z\B^Q:@N7VR*,20[CA(\X._W';-4;CXFRB_FDMXWO=K
M*\5S,K"(*5!&T@9.WCKTJ'4?C;IL:Q+J<T8NT=FC6-B-CA3@8')' XY'?'>M
MJ4X3?O:Q>VC[KT-*T9)-QM=^?>_Y_@>Z:!8^'_#0DUWQ!<P6"VZ-,WVQEVR+
M"ID.P2=&*J0".0>1S7YE_M._MGZ7=^(;W0-%F:33(Y65)A)E47)!VD'Y1C&
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M_P")311F2[705BG7_GE;M" \A8\-@ 9 .0:_,;XBRV^E+XKU2YA7[./%DD#
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MX<\/Z?X]\0?%#Q1J5AIN@0Z7-;^&Q=F%2VH&)DC>,2$$,SXRPP2#["O$M/\
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MR$#((!&.#7V3X*\>_"_XV^"+W5/#>I-'XKMB)+G1990NH6:J"Q5P2)0 <@C
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M]V1]WL>M?O[^S'X%\4_&S]G[X(?!72KZ\TOX>^%=,MM1\>:XKS1#Q%(C(_\
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M_L_6]OJ=Q<_%+PA')IMRL%Q!<:A#%<17<X06ML]N7#LY+, "O!SBOQ-\"?\
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MIHWCC5B<;W#+[GT'_P!8?TH \K^%DIT_]H2P*_NX[MI,L" &95 (]>#W(_'
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M*!M. ,_C7@7Q6U>W^)UAX3^'5Y!;6/B5+ZYN['4;6!5N#>)&3;.Q"[F99=K
M$D^G/-??OP%^+,_Q4^%@\*Z_J+RZS\-A_P (S<6\B>6;Z6S7R#(ZGDDM&3SG
M!]>_6LQE*+IS:ES6U;=U9-:>OS3.[$912J4H8B+G"<8N\8<JA)W6Z:O>RVVU
M/I71-,B\3:#:W$**UQ&@D1K? C,(.8L#CE4P&!YSG'(JOJ^BW=VDD,J%T\D0
MY YC=< DG'0@]1U(KR[POXWO/"6HS:9<.EO9H^V.(MP@<EBN>.!GMCITSBOH
M/1O$>CWX@9+F&62Y(#H2K$!N0<>H)Q^7&:UI.FH\T7=RNU>SZK2]KG!"I5A"
M<)17(KKFL^9+NWJNC5CYU"7.D3S6312219?#$-CH1C!'!]!W[]:\[UN6(W$B
MS(L>[A=V#SQ@Y!'?MBONJ_\ !5A?2BX40D2(25"C+!@0>V=W7'(]>!7E^O?!
MS2]1E,@5HN1[?T'Y]^W>E."GO==5;S(5:BG[\Y+[E9:]UJ?"&N63"2X94RKC
M*;6!!X.2 "<9^G)KP#Q+9RQRS&XC,$9#8=^C''0 ')..<<\<U^G=S\ HYVVV
MEV@8C"B3&0<8YSQP?;^8S\V?%?\ 9T\<:1"^JK;_ -J6<,I:."W3<5(4MYCA
M<_)MXY[_ %KQZN JSJ2DD[*34;;-)Z-^?H:^W?V4G'HWU73;3;[S\U/$6C+Y
MQF\XB)W )P<8+8^[RW/KC!S7S)\5/!7V64ZC8VS2K(26D0*1QD_7TY(XQQGI
M7V-XFBEAO;N.[@^RW4*RJUHXPR[$;G:>F .H[\=J\9NY8FAD>^030%?W0897
M."1C(^GY5Z>%J5<-%*I&*MI'I?ON_N1C6K3E'D45>2=M[WV_)O\ ,^%[G39O
MM,0,#HT:%DD*D;9"=X4?+G/<?ASZ_K_^R!\<-1\+VWAZZ6+-UH-F(VOY& V+
MYR*T8#G=D1Y;C/ ^HKX2U73M.>>.<VT:"9FV@H!PORC!XY/KS@]Z]8^%27#7
M)TNVCXN3L@0'9N=B .F.W7/7MTS3Q-95H\TK*4=59JU_/K;7\!8*I5H58^ZK
MREHI75[I[=^A_0==_M#_  S\;_#?Q;#'>-=:ZFGW#QV5N)2U_<R6KB8GY0!Y
M1+,02,@<9X%<1\"FL!\#5N!.[1+>:E<3H=RF! 68[D;!' YQSW[U\]_ ;2]+
M\*Z?=6UQI\6I:[>HT36KG>Z"=#'OV]25#%N>PS7V/X'\%Q:+\.]7TF=U6ZU9
M]1-M9H /+1]Q.U1R  2.!VSQ65*FI[M_\-9;_,]G$8FA3H\U24O:+>*VTNE9
M;W_X<^'?CS=WGC+P?;WVGP2#3=/UG38K=UX1(X9$6YE5N.K [@.3Z8-?<GPF
MAAGTG1W# (VD6EM;$@D3@Q!I'7N2"N#D9]N<GYU^(G@::3P$/!NE2I"6N[*Y
M3( F\V9EDGR>N-P('UZU]8_"71Y8M.\.:=;1-/<:)9VB2,BE@]TFPE' #=5#
M;AUP.??H47A\90:6C@M7J[6T?XW?0\S%8B=3"05*-XSDMTW;57_'\[GP[_P5
M3\1&6;]GKP3/OA;4=0C:RM2&#7KQ3*0=G0 %1@N!D=.>GY3?M$?$.\T75(?!
M>DVL,_B_4=*,5B\.6N+.W"+'*SLH*Q; 23N8'C@$5^C?_!9KQ9!\.OB=^SYX
MJO[;^U-0U%X[#PYH\*GY-1>18E9(\ DB5@2H'3/I7Y=^(O!>NZ/XCUSXA^*I
M!=>*/$.BWTBZ9-RVD!XB1L0_-'M!&<8Z&OR?C*I36=TI)MKVEI\VVLH[6V5O
ME8_K3PGP]*'#KJ1LZT\.Y0@OA;4)W>R;?,G>VM[]=3]T_P#@A-\&;#P+\*_'
M_C*Y6"_\6>(=5F&H:KM#7165PXM_.(S^[Q@ -MY.*_?FVA*B)5)\N*-DVL06
M=R0=S<8^7'))R<\9K\6?^"'EX]W^S'K+7CB2\/BB\#2]2R"0[4SGG ]?3I7[
M4Q2;=W]X.P'K@$ CGT'-?NW#5*A0R?"RH-OV\(MMVT<DG*UDNW7]#^../OK-
M;C3.98J\73K2Y8JZC;FER_%=[=K7+B)M!P,'''Z__6ZT)N*D-G.,<^N.?7BH
MA,20,GGV%6:]T^4*\<6U@0H!!)9^,L#V'4_7ICH*0P?O?,WR,2X?!;Y% XV!
M<]#G_(Z6:* *BVR1SS3 .S7 "O\ ,2% &",=![<\8J58EA!*!CUR,Y9LG^\>
M<CZU-10!46V5"67S"78NX>5B1N.2HSD;1V7MDBI7C!\L!3M617PA"D,N<$]B
MHXR,Y/%344 53&VS"AU+3[VP0#@GDD_W<=>_XU((]S+(P8.F0 '(4^IVYQST
M.14U% $>PE2"0"Q).WGCTYIP )Y7&WA3[$=1^%.HH **** ,?6_^0;J/_8-O
M?_1+5^-/PG_Y';QY_P!AR]_]'/7[+:W_ ,@W4?\ L&WO_HEJ_&GX3_\ ([>/
M/^PY>_\ HYZ /ID]4^B_SIE//5/HO\Z90 4444 5Z&&8WQC( P>XY['J/PHI
MX4%<%L;SCIG&",_GF@#P7QJ?LGC_ ,%W1.TIK-@6<8#',O=LY_7GUYK]?=.E
M$]EIUP.4FL;5EZ'#>6I+?4GN.?>OQ^^*ZLNM:!>#*BSU;3V!Z9 E&<GJ!S_,
M&OUI\(3B[\*^'9E. VDVDFX'.2(QQU[\\Y.!4SA*<)**N[/JET?<SJ;P_P 2
M^^_^5S^0/_@NUX2;3/VM?!.KF1XAKVCBZ!0E?-$<8^]CA\8 Y_GDU^'OQ,>&
MPMM)NFCE5;@S%9(]P!8@@D$9^<@<D\@5_2/_ ,' '@F>X^*WP"\8)*5MX],O
MM+GC" J22[+([GG(+< @# [5^ WQ9M;#_A56E:@T,7V[3+JX"Q+\PGB8D!Y&
MQN3'=0,=_:OS6NGA\]@IZ.3J15M;N35EIM>]C]3RZ=.?#J3?P.$FFF[64ELM
M]MEW/C[Q$;;4_A-XJ^QK/)=!)5,8))DR&!$O]X# R/Y9KS[]BOP],MRWBGQM
M8VUWI>E7$T,RF(22M;*Y @<MUCQP5.5YQR*]3\!E]>T/Q=H<*1QRSJYA)^9L
MR Y 0C&%XP>F![XKXBU+XF>-?@+>>)?!5Y',+G6[F1])P'42AY"P*J!MQMXX
M/...]?K.4U*:A"A3=\1*-U&W*M5_,]--+=V?A'&T*L%/%4X2=&$[N:6UG>W+
M\71_YGVU^T]X<L_C%IFJOX3^'T_A/3=.AD-AJDD/E:6P3.?)4 1@R#YF5>#G
MD]J^5_V*_BAI?PQ^)2^&_&UO%JMG!++;3:9*H:POD4XCCDM7S'+$&^[E2,G)
M]OT2^"VO>+OV@/A5X,\%V-BUM$C#^T;.93'?71"8EW[E#",MDJ,X(-?G9^UE
M\(7^!?Q#/B5T^PRV,\27*6GSW%K LF8V\M.'9I,@E\'H.>M>PJ]'#TIT\2W&
MK+F48J+DGO972:5]+.]M7>Q\Z_JV98:GFLZBC2@H1BW!J3E%)*\-)*[CVM<^
MV?$/Q ?Q'\1?$L(\/Q:+H-^CMHNG1QK!:1QQC=";:$81,#E2HXZ^IKRC6?!5
MO$EQIE^\=J?%!</<WTJLJ(^<#+GA<< 'V_'%\(>+[GXL^&/#U]X?L9[C7+1(
MDEN[PO:B.   L=OWC,O !X!KTW0O MCK&I7C_$WQ*!]DC/V735E54A(' $V=
M^>QPHX.3FOGI5\70Q*5&',Y2YY.]E[&3T=W9;)WCN>Q0Q%.I#FKR4:<*,94;
M*]^SLKV;MK?WE^!]N?\ ! #XB-HGC'X\_ '^U8W@%[-=:5 9OW,21SN7-I&6
M"H'P6)3L??%?T,_$>.&&V\N']\8 %F0C<!<)P6P ?FRO7@Y]Z_CA_97\9:7^
MRC^VYX-\6_V@VD>%OB!??V0]^T^+$^?-LC>21"68D8/S@ ]2>37]BU_<6UY#
MO\^.]MM:MXM7TB_0@PWUO=1JR%&R1C<W\.#GKV%?@WBY0=3&TL3AZ?[JR5>3
M7+:;V232<KN^J]=C^L_ G.Z6(RZMAL15?,E.%&"3D]%9::V7KMK>QP-C*U_I
MEQ;7=K%LE@EC)>,9.5P$Z'AAP1WST]? ?!BMX?\ &.JZ;M,<,KR&%%^144L>
M$7@ $]A_^KZ!N(K@ 11%T\J4-<QHN=A5LJ!QSO;KGMG!X%>/>.+<Z)KMKXD2
M"0PR8%P"I5$P1SO&20".?\:_$74BI<MW?R3?Y:'].Y;B:?U:IE]635:K=TX6
M;333:][X5^GJ>Q6TD04XE93GYN<8/']>.O\ +%?,_P"U'X?BU_X?ZU @#M)I
MTR;,9.<.03UY[$^Q!X-?1&ERV]]:Z?/;?O3>E-ZYXB#J#NR,[NN>?YUR?Q1T
M/S]$U&S5!+F%XQD9)!4G.,<G!Q@8[?0?08"I[247)ZJW1:VV=]?ZTT/DIT/J
MN.C*#3M/5W[3=]?)Z?U<_E0MM"@T?5]:T]K=!+%?.&"QX/\ K2>>.2"??Z5]
M >%-$2:"-)8PQ8#:6&=OR] ".AZ >O3K71^.?AX='^)6M&:,K;7-XQ+/'L5,
MR%LCCD9]NG4\U[)X1\(1WDT<EN8Q;V\0(<#)?"C.<C Y.,^_U-?5QKQ5%PJR
MM-I\J\K66M^_?J?H="LL92IK1U(TU%+9))::K^O(ZSP1X(TVYBTZ*V61I6DC
M#C'&\D @C'(SQCW^E?>7AKX2R*-(BO(3;VDS1/N"88D[0 ,= ?8XYKRKX<>"
MKEUTR:WCC@D-RF-PRI7</G8@=^"<9_*OUH\$_"ZZ>7PI<ZQ/;W5C*EN'$0!C
M@)*'#MUW=^1VS7C5Z:J2;D_==M59M=M-_P#(^=SK-WE<)<LG&LK<L4KJ[NMU
MIKO]USE?"_P4A6Q6<V\16*V5H%:('?D#).0.=H./\:Y[4_AC!JUGJ5C>D1J=
MT=N6  A/(S%G[A'7Y3P>*^_/$]GI?APQZ;!/$89;9%AE4H#$"@R" =N<9QS[
M=:^=O%#:<L1@BN%!#%VF7;N;D=AD<GCC%8>R4?@E/[I+_@:>?R/SG'8VMFW-
M7Q*?UB+?LMWIK;6UET_K1? "6#^%+N?PAK\)FMKAY$MKBX3S/W>2D;!W'=2I
M[&O%/B'\-)M*9M5T%T\J+,[>60"S E@0%ZC QSG\1C/W5\1]&LO$]F'C@5=0
MM8\1S*!YAV#Y&]R2,_RKY=N6NYHK[2KTL'AC>!%?.9>#ACGT/'''N>36N+I1
MQ%'FI-R45:6C5M$GH]6[_?T[&N1YIB\EJ4Z-2"^K5YVG-M.W.U=-?-_>OE\X
M>'/BYJEGJBZ1>2E!,PA0EVR&3DE#_#P.:^HO"GB&XU1WCN-TD<D2L [%@/E'
M0$X&02<CDY]LU\ _%;P/XDTG4;36-+MIBL%T)6\M6'RLX# [1Z9YSWY]ON'X
M&6TVJ:)IUY-%.\[Q)'.A3(4A0"22-Q/U  KX?$TJBJ\D(MZVE>ZUN]D[>>JT
MM^/Z=FN5X2GEU/&8=PD\115=M<J:G)/_ ('RZGL]EIK*ZN57:,,"1GY3R.2.
M>/\ ZU>E>'L@M'GAF4%<\;=GIZ=>W4=\U!+I;6\<:HN<*O\ #CC ';_/%:6B
MVS1S[O4@D?AT]^PYQWKZK*'&E32G[LU9I6;TT;=_17_X)^08Z=1J<5\7M$O_
M ";?[MC<U.U2: Q2*IA:,@KV&5.#MZ<'&1WKY2UQY/"7C&R:UC*1W-RN]U&W
M(+$X8_XGD5]>R7,3_NY$&U1S[C  !/;C%?/GQ=T='@2\ARC1%G65%!(Q@CG)
M^GOFOIL)7IU9*,&VU9-6:UYO,^4SK"5%1YX13DU?=)ZZZOIK^%CWK3ID?2[6
MY#[FN DS'[Q&\!L9]!V_K6JR(^XD+C"G!Q@ C/ID'^=>0_#'7?[2T*U@ED#R
M0+'&P8EB0HQN*Y/Y8X_GZ;)* ;@QNS,K( A&!RN<#') ^G^ [\92?N^SCI;W
MM;:VN]_G?<TRNU;*Y4)?QTW9=.SLWIHE<KW2QPAI!CY<L< 9ZX/\QUY%<5J%
MU*#),R-(58&-F7<4(. 5/8]_R-=%=_;"%\N/S#(<,I)& W(QQV[9[\=>E@Z;
M_HG[^) S[2PSTXZ@\\=>N/7Z\D7&GB,'3M=3KT^?2_O.4?+IO?\ $ZIQ<\/6
MA>U2CA)JW9)3>CO;O8_*?X^B]USQE<09:)8C/YN\G$BRY"[P>H^;C/ZXK^=K
MX\^"O%-S^T+I_P *-/\ *^S^,=4DU/4KQ 0;.RM!(2/,'W$=?F"D@$K7](OQ
MDBS\3=5M;@".*5XTB()!"1L,8R1DOT/UR.U?FG\;_AQIUC\6M5\?);F&\.C"
MTLG W+'(T#QYCE/S R[MS=,8XZ5_;N05JF"X:P$(4[SJT:?(EJFN6-[M+3W>
M^M[G\/\ $$(U^)L=.4]:5:KS-NS3YI+36[;VT_X;Y"U.6]^!_P (-2\42W4+
M>'+"_OM M+N)A]HN;J,[2RD'YW5@=I[<@5\M_ W]H[7;OQ)<:IH?C#Q3I5R=
M0/E;I)V@(W_*H7=M*@=L$8P:]<_:"\'^,O%7PHT#X>$2PZ<GB"ZU-HXI7\R[
MENI6?S)"<;<9R",]?>N$_9W_ &1/B/HWB'2KR[@F7P\ERD\A=-PD0.K%68XQ
M@#[WL>*ZOJM#$?O*T%"?RO?SLCT,%C\127LZ=Y12TUNGTOO_ ,.EL?KWX"_:
M \=:IX;N+W7M<34WL[4K%+< M-(JQ\,%;E&;C@#C .!W^//%7QBO/%GB._M[
MM'(6]4;F5@I!)R%!&"#CGJ!QW-?3WB/0M&\':#)-:V<<<[IY<MNSG:S;0K..
M,GITZ>_2OC^^TU;W5I9HH(T,LZR*8XP"AYR,#[Q;/?Z\YKVLERFE3YIJUFW)
M/R;;TV[^9\GQ%F=6O)PNI23<;-V5T[6?STT]#U[PMJ<>F>']=UV<(@LQ(]N[
M<8.TJ%0YX')QT_E7S7\%?#][\9/VB?#?@^V2:_BU3QCI]_<JP,R&&.[1FW@Y
M4JHYPP  ':O1_C!K0\'_  P735XN=0#.6W%)"7^4(%'WNH([_P Z^Y?^"%7P
M"O\ QE\<;CXDZ[IDLNG:%#)+:F> -#*Q^8.9F&49#]W;G^1KS>,<1#"9?5I*
MH[2A*6EWW6RMM;_,VX-PE;$8Z$JE.+7.MFMG;7MUT7=']16K:-:>$M ^#WA*
MQ@BM[?3;;0K3R[=%BB62!(P7V*  P/5NO&?0#]U_ ^5\):!&26V:79\GG.Z(
M')/4\<<Y^M?B3\3T0:UX44/]S5[=(B,'RU690%4CLH&!TZ^]?MKX$S_PA_AS
M)W'^R;/YB,$_NE//YU^.X"4:E&M-:KG23V=]6]-^^Y^P9E!T*M&BDHQ<;V](
M]'_6YV8 '0 ?0 ?RI:8'R0,=3CK_ /6I]=1Q!1110 4444 %%%% !1110 44
M44 -8 @Y . 2,CH?45#G ZX'Y"IVZ'Z'^55R 1@TDXJ:YMN5[][KU(DI:2C\
M2V['Q!^V]^S_  _&+X:ZE?:1:1R^+M#M);FPP@:6:"-'>2/(RQ V\#D9&/:O
MY=H]%\5> _$6H>+/".H,/&FBS2V^I^']0W26T*6$C2-)!;.,1OO!^8*,C..U
M?VNO$I9GEP58^0054JT+@;D<="#NQSV.*_!O_@H1^RS<^#?%%_\ &+X=Z*\.
MG7,-S)XBL[: &WGCEA+3297YD)DWG&#QSSQ7RO$>%JN#Q.$BI\D4Y6:CJW9N
MTM79,^PX;SBI&M1R_%/EPU:3C)M\W*DG**LM;722\M'T:Z+]E3]H9?BGX0T/
MQ/=VXU+6K8+I7B*SM9Q$D-PH\IWDC#=$*DY/ Q["OK7QWJ/AM-+A:^U.%+Z\
M(%M%:R":6V5NHN"A9MF"-P;&1GZU_-QX(TOQYI5G=^)O@UXTD\.V-S+.^LZ"
MK@O/=LQ\R.-=P82LX94&T98^M?K;^Q=\3_"6K6=WH'CVWN=6\8RP^1<2:O.Y
M,<C+M9HXF. P)/"_SKYS XNOS*G5BE+LWM\WIZ'TV9X3#N+J497A9M-*[_'K
M9][:&-\=?@3HWCBWNM7TF*QDUNVVSF^T3RK6746$:E3,D6&9D7Y'R.3FOC"/
M0[^R:'0M>LWL[R"X4(9(RMPJPMG>TA&X@J.?7OBOUW\;?!B2PC3Q)X&O[F*=
MW>>6TDD'D,A<MY:Q@X"@<# ]2<5X%K7@^U\>W+:?=Z<MGXJM$9VF:$1PW*D;
M75)" 68$;CR3@Y]JZL;RQBW9W=V[+K9W_P"!W7J<5)4[T5?[,5KOM97OU^X_
M*WP;!_;/QVO]<@+3Q^&6CAM[8DE!.CJ"\8/RH[D??'/)SU-=!\ _B'?>#OBQ
MX]N]75M.T34/$-W+<O(S2PQ2/,Y+L.5#C/)SN^O)KK'\$ZG\)/C7JFD:O:2+
M:^,+>Y.F7R @?;P&\B"/^!B\NU=V01V%<_\ L\>'--UFR^)7AW7FCOO%)\67
MC:A97K[+[2[)9I!YMO'R\P( 'S #'Z_,O$2YW%76O5/>_P"'7RZ'VL*$)8%W
ML]$DTT].7\NOX]#[6A^+7PO\07L6E3*^JO=ZC'#:W\$9MUD:4J!B< ;PK'!
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M]G99 6.-C(4&2"5 .,@ C@BO5OAO\&]3NK46-C!)9>2YF:SFR)I%3AE,38(
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MD'  '?G.>V* +=%1R2%!E4>7VCP2/P)'\_7\7*V[/&.GZ_X4 .HHHH ****
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M^7"2E'X\0G27_;RM9_-M]-OD?EW^U/X>DTOQ?!JT?RQ3I"1-RJLV1N /'3\
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MI[:;/1/IH_,^@S)^TKPFVWRJVKUVM]WW7UTN=.%8$<=QW'^-2T45U'"%%%%
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MWK66Z5M&[:V[6VL?FC:?'W4]+U"VT_XO^#-4\,WW[N$:I%;R+I<C1X59HI(
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MV'^%?Q)\*ZQ;7OB#Q#XV\=1>)-/AN[R27^P_#HN1+%8QLSMY:.C, G&=I]*
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MV;SX2P1.Y>2UOY879B2_EJQ B)X^4<A5Q@#UKYR\:*9O#^I )@K [!1SOP"
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M'U[PI>7\4$]K<D6L\T@!558@1H&P-N!C@DXYQ6,J\**A2E:Z5M4GKMJWJ_\
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MO"UW8Z%?S6-BDBDC1X%D*)'"I!$H8 +N8#'4=!G]L?!NBVEG:V1AB$6$Y4*
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M)K\:/A%_R.OC[_L-W_\ Z-:OV7U[_D$ZE_V#[W_T2:_&CX1?\CKX^_[#=_\
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M(\NQ1(0&P1O8,0.V>,"ON?1-;*QPDW$<5K)@&:5L^?,5R"AYR"#P>,<=^O\
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M /&<'ZUZ;X)\6>&OV@]%EU#0'L[+QEH$<?\ ;6G7<RQRWTMJ/WRC=M97."0
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M_$<^M?1%GJEK>L]E-(3J!7Y+=Q\I/H&)YQTZ>GOCP_Q?I\T&HRBYD\O&X J
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M-)R;7G'[16G:5^RC^R;\2-;L-6>^^(7BRS?3-3\47,H;6+F[U11'<V5G>/\
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M7_X^#_UQ'\A58]/Q7^8JR_\ Q\'_ *XC^0K@E\5/_"OS1U0_BR_KN>&?%O\
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M>6R3QTYSWK]E/V6_!*PW5MJ%U>0V,0CC:-Y&"2J"H.,-SNX(]<YSDU\[>!M
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M6^+CL;KP>=Q^;6[3OQS,.![=:_:#P/D^$?#PR1C2;+W_ .60XK\6?BRV^_\
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MZZ :]%9/]O:+R?[7TS &2?MUOP!U.-_;ZU'_ ,)'X?\ ^@UI?_@=;?\ QRM
M-JBL7_A(_#__ $&M+_\  ZV_^.4?\)'X?_Z#6E_^!UM_\<H V3P"?0&FJ22<
MCCKW]AQ60?$GA\ G^VM+X_Z?K?\ ^.4@\2>'L9&M:5C_ *_K;'O_ ,M!0!MT
MW:23NYQT/3Z]/ZUC_P#"1Z!C/]M:7@]#]NM\'''_ #T]0?YT?\))H''_ !.M
M+R>!_IUN>W_73ZUFZ,^=5/?23OM)+KIVMJ&^CU-H #@45C'Q'H _YC.F=0/^
M/VW[_P#;2C_A(M!_Z#.F?^!MO_\ '*T>N^OJ%DMDE\C8P/0?E1@>@_(5C?\
M"1Z!_P!!K2__  .M_P#XY1_PD?A__H-:7_X'6W_QRE9=E]R V=H]!^5)M7IC
M_/UZUC_\)'X?_P"@UI?_ ('6W_QRE_X2+0?^@SIG_@;;_P#QRIE#F:MI;M=?
MD'GU[FN$4= /\^OK2&*,G)09]:R/^$C\/YQ_;6EY]/MUMG\O,H_X2/03_P Q
MG2\>OVZW_P#B_P"M2J;NKW:ZIN35O1Z#N^[^]FLT,3##1JP.1@C(YX/6D$$(
M"@1J OW1_=]A67_PD6@_]!G3/_ VW_\ CE'_  D6@_\ 09TS_P #;?\ ^.5H
MDELDO1 FT[IM/NFT_P #\POVVOV6/BA\6OC7\(OB3\/A9+;>$)E740^/.:$N
M#,DHSCRG!]!QR37RI\4?V*?VAO$GB?6;K1X=%^SZU$;(//$)(=.CG3]Y+ F<
M*P?!))/MU&/W:GUO26D9[?7-)B+A0[/?0$,J@C 7S.#[CGTS52YUG1Y86MQK
M6GPJ^ 98=0MEDR".0V[^+!R<>AXKXS-^#LNS'$O%UJLG.=1U9IRORMN[23;2
MUVL?<Y%XDYQPIAHX:C2IXBC**4(UHRJ*+V32;:C))W5MW;WET_F,_8/_ ."9
MO[=?[-7[4_Q(\7P_$^PT;P7XLMS+=O%$HBNA(I*1NNTARO;&.F.37[6R?!G]
MK MN@^.]HBYR0EOP1G(&-O\ G'X5]F)J^CF PG7--=&15R]_;M*-ISN+AE)S
MQP??)P>;T6NZ$BX.L:03@<B^M@3UZ@N?7^E?0X#+,/@,-"CAJDZB22:<Y2LD
MDEHOAZIZ6=K^GSN=9UBL_P 8\RQ<(QJUU=\JLWY2;5VHWLDV^5;=3XF'P7_:
MR))3]H"R#C&8C8^9@>N<#KUP>E1Q_!;]K)KA//\ V@K22'<C3VT5B$+Q*ZEQ
MG!P.,<]"?PK[9DUS0F4A-=TR"3.=R7UL1^(+C/Y^OK4#:QH;1[3X@L))#@,R
MZA;1G;G)'#$XR <=Z[N1T_?U?+K9N5G\GI_6QXYYMXM\(>(]<^#_ (J\$7][
M#XB\1ZCX:O\ 3I;J286WVJXN;*:. N2IX$I7 [DXX/7\._V<OV)?CW\)_AA\
M5?"%UHOB#4/''BN#Q#_8+S:B@T+1KJX:0Z=<VC+$ACD@+!HV#G#=:_H,FU71
M))'DDU;0V1XU0AKR#?D'J7$@W8Z@8'/?BGOJNB/ ;<Z]IB(&5D:/48$<;<Y#
M-YA+!LX/L!^ L5)?86O]U?Y;?UU _FM^%G_!.#]I[^ROACJ'QMLY?&?Q2\)W
M/B74-*\8W>KRW,^C27SLVD+;3958[BS7:H.P@'''''(_#O\ X)H?MN6>N?$3
M6O%/B;69YO%OB*22[N&\13MJ-]IS7"F..9B>;=(04VHJ#:/I7]/SZKI,A_Y#
MVDA8Y%> +>P#R\<D,PERQ/7MSVJ2;6-):0S+K>CHXC"1L;^ A2<YR/, ()/0
MC/7Z5HJTFK^S6NNWW[(M5%%6]WK>ZB]?GJ?SZW?_  3%^)UCXFM/&_A&ZU:R
M\4^&]3T^6V1-;N4 CB0F5(PSE#%+( 9 0<\],U\P>-_^">__  42\=?'CQIX
MTNK#2+3P;XK\)ZEHFN6?]JN8-4U'=;)97]U Q*27,<:-L=0N-Q./3^JB/5]'
MC,<LFM:,TP4B>07MO&)6Z*V YV[1QWS[4]M:T5TF0ZWI.)&W*!J$&%/!P1YO
M()R2..<'M3YG+>/+;\?P6PI24K;:=K=?0_$[]I+]CS]H?Q9^S]^S#\/?#=M)
M?67PO-O8>.O!NEZG]ELM7AB9&CFN(H]K2E"6*G<,5\G_ +07[$'[<?C?XC?!
MG4_A!X;7PIX9^'Z10ZV;W5YDO3;20E72Q9G;$D84^4Q#$'M7]+4NI>'I3DZQ
MI<<QVNTT&IPQNS+P.CGC/..:L1Z]I2HD;Z[I#LJG<YOX-S8X&1Y@P?4Y/?@Y
MX"3^<7QI_P $[/V@M.^'7AK5[&+6_$US>:UJFI>-/"=SKEQ)J&JWMQ)&;&YG
M *EU@E5GAVD!5SD$$5B?#S_@G!^U%H7C?5/'VL:5;R:UXKM+&SM=0DU1WO?#
M5E;JP%O;N6Q"(D,:$%6.Y<D]#7])<.J:0LQD.OZ4ZCR  ;Z L#$S&0EC)@[]
MW'&%P.O422:OI#E@-?TD(_VC<IOH"?WVW: ?-XV8/USVH _G>\%_L&_M'6?[
M:7P'^+7BWPG)K=G\/]1D;7O'VI:D]PTELH_=13,Q"-Y2D+]S  &.E/\ ^"E'
M[%_[</[1/[2/A3Q?\(;*+3_!WA?Q#I6KZ?KFG:Q):W2VEC*DDT)V$(7N4!5P
M4(.,<<5_0Y/K&E.&1-;THI(JI(CW\#Q&, AE"AP5=A]Y]V2,?BX:UI"")4UC
M2K>&+:$C34(0H4?>1@7PV[^'^[0!R'PS3Q79^$/".E>++.<:[IGA;3K/6))+
MP21W.H06L<4S2G:-TKNC,7SD'G!QBO5EX &,8 XZXXZ9]JYEM=T'.6UG1LF3
M>2;Z$DK_ '21)][KSSSSCGFXOB3P^W36M*].+ZW[?5Q1RN71NW:_Z$RERV\_
M-+\[#]>_Y!.I?]@^]_\ 1)K\:/A%_P CKX^_[#=__P"C6K]@]8UW0Y]-U&&+
M6=+:4Z?=X07UN20T+<@"0G''8'G K\?/A(8_^$Q\>R1R+,O]N7H#(<H=TSCA
MP2#C'XT_9:.5FK:V?-T]= 52]HZ:Z?9?Y79].#[GX-_6I(ON-]#_ .S56\W
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MVZCM;E5NG,]==;FL,5*$'!1C9MN]W?6VGX;GR/XU\ 6US%+^Z491CPHXSD'
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M&^" T@ PK#ACGZY[Y!/;G'8>$? QUSQ1H>A2;;F""ZCUN_8_-!%9PL$>*4]
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M  @'[0__ $4KQ5_X$S__ !VOZ$$_92^'J@E9[DD8/4@?Y_G[4_\ X9:\ ?\
M/:Y_[[/^-+V-1=?_ "5?HB4J+ZR_KU2/Y[Q\.OVA#R?B#XF<D'YC=3Y;/?AS
MR<=_QIR_#G]HCGROB'XFB/4G[3.V?3C<?>OZ$1^ROX QGS[GD=-Q./IS_GM4
MT?[+7P_CS^^N6R!_$?\ 'O[=.U9.$TWM?TU^^QJIX%)73OU=EO\ <?STM\.?
MVCBK_P#%R?$QX)Q]HG_ ?>_E^6,TD?PY_:.[_$CQ+R 1FXG&?_'^V>WK[5_0
MW_PR]\/^?WESSG'S'_'C/Z=NIH_X9<\ _P!^Z_[[:NFA"3C+F=M=/N^1SUWA
MY2BZ=TDK/3K?_(_GV3X;_M&%0?\ A8_B4Y'7[3<<_P#C]/\ ^%:_M&88GXC^
M)5P.IN;C_P"+]<5_0:O[,G@A5"I+<[0,#@GCZ]Z?_P ,R^!R&$DMR5*GH=I_
M4CCUQD_G6Z@DT[O3T,&H6T;;^1_/+)X _:,3*K\2_$87!SFZFZ8_WQZFH/\
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M%_[2#(I_X6+XE/&3_I$_;G_GIC@"G?\ "M/VC/\ HHWB7_P(F_QK^@-/V</
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M#RC7!7U)R??)#"HIOV8O CIM:2X0$CD9!R.<<L:UC4@Y)3BE%OWG>3LO2_\
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M>O)]!CY$_9UM)_B)^U%IOB'6-Z*NM:GXFA\T^=]HMK*5XX-C9 7S5;>C'(4
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M-U<:_IR0$9 ,J?*,9+<-D8QDY_QK%C^*WPZ8[%\8Z)YAZ*]S&&!]QG(Z>M?
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MRO57Z+7R^7<^H=S#:,G! R/KU_.GTQEVGDYV*#]<9/\ 2G@Y /J,UJ0%%%%
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M*\LIY .022>2<]>M4O@;X5&N:UX!\,SQ>;:>&=,U+XA>+FY*B"*">Y@FE.
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M(OG),;)@8 ( /3OG XKV_P#MBUNM7?27;865!IKS.4C@7@'#'@!E&..>.@H
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M] ,U%*9 I6(Y<\Y8Y ''7TSV_&E9BZE0,%A@'/0G\*\>^*_CU_#/A_5[?3&
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M-0^)/PTU7P7XD/E>(? &H-H]Q#N N-5TNR<QVID5<$I"D:;2H!.!N)JQ\=/
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MMS%(T4YM'4K$V,_,%ZC/3I0!YW=?&?1Y('SK=LTYC8)YDRABP'RE1G&?3/\
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M96D"J&894'"],CUH ^4/V=_@MX_^/NOV_P :_C'YUCX3TD1W?AO0[K*PWL<
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M)TP"<8'T(]<580DYR?3^M9D5W#>1F:T>&ZM[F&*>SEB96CF1E#,Z2@E<8.<
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MR^(]E_8/[9^OR@$0>(-(A>(X !$$!!Z]?O?7IWKT?:1'++@\3G [8W$Y./\
M/X<5O3V?K^AQU_B7H>0^/?\ D:/!P]-7M1CT_?#@]_SK]^? H+>$/#'SC8-'
MM@\> =Y,2XSU/R^GO7X$^.T+^*?"+8.&UFU.1GD^:OU_QK]]_ J%?"?ACI_R
M![;/K_JD]NO%68GP)^VI\*?&/Q*\4^$K:U\3W&@Z%&H6=+)G5S&"Q<L$()R1
MSVXKYPA_9VU?3--=]%\:WEU>V8Q&)Y'+R,O VAFR2?3'X5^A7QO\0V&F>,_#
M5EJ;Q1+>((;<RD"/>X8C.X^H()R1U%>)7C2Q17=T#%%"T[&&>)AM^\<%6'IQ
MT]?I0!\T_#OQOXS\)^+?^$<^(43Z?&T36.FWWFF.?4+?&%N'B8CEL[2,9&.O
M2N]L?!^KZ=XLU'Q!H4F^WN#YTCLI4S;B67D#YRN23Z9K'^)^@)XI\/7NHPF2
M3Q'H,9O;2^Y9C##\_EJ_)&0.@..E7OV>_B;I'CG1([+4+SR=;TXR65Y9RR"-
MT:,E%?:2#^\(/UY[4 <9XZM!J-[;WNOP2R".]C/E(I3?B0957X*^QR,?2OD_
M_@JS^RWX7_:E_8V\6>'$MH9/$.BZ;:W/@P+&IO[6_P!/3[1&\=R!YH#.%7<K
M?CT-???Q)T^+RY;>.#?([MY,Y?*JV<JYY(P, ?\ ZJ\7\2+=WWAK39YFEFM[
M6^CM[^V?(@FME;;(.<+M*CL<<G/0T ?&7_!&?XDZ)\5_V4--\$WVG3Z/\=?@
M?<P^ _B%H<N?[8NM+TF=X!<"U;_2I8'@$<IE*E-I!SBOUZU*$Z,)([N99[EL
M/IDB-N6ULL I!.1_JY%8,I5N<C&*_ /]HRROO^";G[;_ ,&_VW/A_;7I_9Z_
M:(ALO!/Q>TK2MWV+0]?U01V<NLWOE8CC1" Q>3'3.3W_ '#^*?BC0;3P-:^+
M?"^K0ZCX2UK24UG1O$$<BSQWHOK=;I8C*I()@\W!^8D$=N: /D?XP^*OB!\1
MO%<'P]\(3 J\R6FIS6CF1X()6*2N_EY*%5/5L =Z^C_@M^S[X0^"6BA8+2+Q
M!XHUMQ=:GJ&I*KM:2-RZPM*&PPSQ@YR..<UY%^Q]HT6JVWCSXBW]^L^I7.I3
M0V.!\S!G;8 1ST _IQ7VG,))+>.>8$2\$@COC/(]<]3U- %QYXV1A$[;4&&&
M0A7H"& Y4CMTR,8ZU7MK03/YD*;)EY6XE?,2$Y'S,254$=SUY'852\R/S?,E
M(2W2%IKMN@8*"<G/WN!C!X!%?&GQ.^/6O7VI77A7P.WV>T2::VU&[7@^6/E0
MQD<;@^<]Z /L37M:T/2HRNI:II<%T%/F79N8F6)1R7VY)<KU"C).<5\C_M:1
M?LQ_M,_L\_&'X5?%?Q)X6M=$UOP[++I?B[4(K:2\\,^(=*A9["3PS<2_O(;N
MXN$0-':LKY.,9KYOD\':Q>N]_>:]K-]<[O/,LDDLMI9L#D32QDD/$G\:XY'T
MKEK7]G[P]\9?VKOA%\%/&<[:9\.7M5\4:EH( @F\5:C"$F\U20H-M*^X^7W4
M].* /*_^"4W[6?Q"T#]FS7/@_P#$#X3?$OQU<_"34[KPKX&\>V.DS36^M^'K
M6^N(M-U"V>6!Y&66S$(+;FW.#@]*_2.#]K+X;:>UMIOC7PM\1?AM<N5GO=3\
M7:.^GZ8TDJ@8FN7@CCA09+[Y&V%>1TKT+XR?MZ_ _P#8E\9#X.>(_AO8Z7X,
MTZ&ST?0;3PI!:1ZBL$015FNXU42,=Q,C%SO.<ELDFNZ^%_[5W[(W[?6K^*_@
MA:^'5URXMM#AOKRWUBVM9;H6UZOV;]S)L::.2V^\?,<J  0* $TCQSX.\1VE
MG?Z'XCT+4M-NMDFFZE:ZE;26T[G!CQ)&Y1^2-R@GN#76FTBN<37,\$TKD%#;
MW*(K<\;"I .3CIGGCCM^-W@+X+Z=X+^+GQP^!'A+6]=\2VOACQ$^H^&M-TZ5
M_)\/VD=PSM;+*AV*(EPIB4CIC'%?2^D_ 'XZ7&RZTCQ5J>G0D!HH=0OI/W/8
M95GP,'GH/\ #[_:*^MC_ */!??NB$*2;IK<DJ&"*6R&+ @[<]ZQKS0?#_C%Q
MI^L6^F6$Z,TUSJ+64&ZQC@3S;B:=V3,:PPJ79V("@$YZU\[>'_AI^TKX?$1O
M/BCHD\,<RW'D7-X&8..%#%G/H!_GCXD_X*:?M/\ Q[_9S^!\WP@\(7VC:M\9
M?VC=2'@7PO/H0CFUC2X-1A"WFH1^6&FB4VTY4R* .Q.,"@#X7_:5\/ZK_P %
M0/VI_$G['/['NLZM\/\ ]G7X<7"']H+XPP3S+I'B_6K.;9<:)8ZC"PM9!/L>
M&6,2$J#R*_2;X;? OXE_LG?#S2_A]\._A_::I\.?"2+8:3#IL'V>_P!1OX0(
MWUF]$*B2Z1U4R"1BX;(.>3GTO]@?]G#PU^Q7^SOX0^'=UI^IV7CK5+*#Q=\4
MO$<]KYK>)/$&M1K=2K.0F7\N>=][,<C!)P17WC:32!?M-IJS7DFH 2P2O,3:
MV$)&?):'=A5'(VX&=N,<T ?GQIWQ?FM+R.XU4:CHE[(5-V\]K+:A;C(\V+YU
M7*QR94,>JKZ$5]3>%_BO8:W:V\,EY:RNBAHKE'C::0D;66;N4*$GG@MCO7H&
MK^'_  EXI8Q:UH&E:M-)E)KV"WCC21EXWH&7Y67&"<<L">]>,:]^SAX1:\EN
MO"FI:EH>K3)($M_,;[)@C,:(JG (<@Y ^Z>U 'SM^T_X+'ANU@^*?PZU%K>:
M>\BBU6Q$VUKB=Y1NVQJ1N4MD8P<Y].OUY\#()](^&.EZOK,4?]I^(XUF=CC=
M S*K8?NI).,'N<=:_-W]HOPA\?O G@?5K*:UGU[3+>2:_@EM@\LRQ6P:;>H4
M$[PJA@.>1Z5]6_LY?'[2/'GP.\*26]Q'!K_ARUAMM7T6_4)>R2K&JM(8GP_!
M&3D=: /2_P!HW6TT?P*^OS2K'+I]S"BDML<C*X]^0<CU&#7HW@37;C7OAQH6
MJ+"ZVESIB27)D4@2Q,H!PQX8ECGKR>]?+7QUDUKQ9:Z%I+M!<:#J-]!-J3Y!
M"H9$/EL.@\L'9ST Z<5]A106VA^!O#VCZ"%>TATB"(KG";%1,A>V<C&.O6@#
MYNL?'>G^#OB[:VAFBBTVZ96>T>549@SX9@A(SD9YKTOQC\3/#=M<WDC2PBUG
MDF?R9)$4F/:V'"D@[2#U]LYXK\POVUT\9:!KNC^.?#IFM9+2X@A5E!5))//7
M9&S#C8S$*P/4$YJ?PS^S5^T!\>=,T3Q;XM\4R^$=)O@A403.@EMR 7"88;@0
M>.OMU- '@?B+X]^'OA]^U1)KNE7KWNB7-Q$-2T"S'G">1%;&(X@P8MG)XR#Q
MZU]%:C^W)XL:[U"Z'@#6XM,^U#^S+@6%R%BMMK;5.$P,\$<<>G>OJWP1^R7\
M!?@Y!::E<Z-:>._%Y?\ =:KJ444SS7+G+\NI;]RQ*KSP.M?3P\ ^'M4MX(YM
M T2UAFMQ*UK!90R;#D (R["HPI/..GTH _).+]MGXC>*+IM,\'> -7N]6961
M);O3KDIO;A#&3&0<,00!SP/I5WPG^R%^T;XUUL_&/QSXL;2-;U7Y])T,W+PR
MV:-EE66V+!XRH/(*CI7Z8WGA_P ->#[R*_TC3=/M)()$CD==.A0\N Q!$?RD
MCH1SR.<UZ%K_ (TT_2H-+OY8X;D7$.%R0S1DC&><GKD_SH ^(O!OP \>:?J0
MT[Q)XI62Y=@\KO<_*WF\X!9N2!U Z'/U/I^O?LX^#TM]^KWQFU",":UN89 T
MB7*\QM$0<[PP)&"#CUQ6%XP^->B^$/$5E=^(+RV2TU&X?R7$B%QAL!0I.?E/
M'(&<5F#]H'X9:S?WRIXND\^2)HC;O"Q%M&QR9HCC'FJ<!2.0.GI0!Z-\!_VQ
M_$GP6^)5I\&?B[.+OP7>E(?#VOS2;I;,2NL5NEQ*_P!Q0Q4,I88[D<5^T<%W
M#JEA:7VEW$<EK<HEQ!)&RM'/;O@B6-U)#H000PX]Q7\R'QR@\,^.](@DT.=[
MQ[*:.4:V5VW0DC<.F"?F(W@=^ >1Q7ZJ_P#!.KXZ3^./!%QX!\1WTMUXA\*R
M&VLI)R2\FFQ* H4MSM  QCCKB@#])R@+B0L"2JC (/*CG]:LAL\$$9&0><'_
M  ZU1C,ADD\Q=I$LBKTY0?=;CU%7UZ#Z#^5 "T444 %%%% !1110 4444 %%
M%% !1110 4444 9NL?\ (*U+_L'WG_HAJ_%KX7?\CWXY/;_A(;OGM_KV[U^T
M>M?\@G4_^P?>?^B6K\6OA;_R._CO_L8;K_TI:@#Z@DY,F.?D[<]C2 C Y'0=
MQ3^[_P#7(?R-5J )\CU'YBBH** //=\W]YO^^A_C2A7?EBQ/3[P_SWJ7<G]W
M]!3&9L_)@#TY'/X<5[!P7?=_>QCQL!W//<@^M1[&]/U'^-2[V7E\,.F.>OKS
MQ4RE6&0H' /('>E9/=+[@N^[^]E,QENJYZ]_7Z&G11[2 %PN<D9S_7/7%7,#
MT'Y"C '0 ?A19+9+[BX-MZMO3OZ%B+:JY7AQD#J>#UX.1TSUIQ8MU_D!_("J
M^[;SR0.WKVJ5'#C(!'U_'_"F:#IM[C#<@@@CCD'TP/\ Z]8\NGI=,8Y(AY6T
M R G@G/<$$8]#ZUM22J!]T]#Z=0!S_C582LPVC B)^91PQ. #S].*5EV7W(Y
MWN_ZZG&:EI<UI\EL&:WW)D@DX() ))SSG'?\.:NZ9+);J Q8 # /7ICOVZ<'
M]*ZII8%B,31,\9QD'&XMT'MBL^2WBEYB01'IST_\=XST_ T679?<@+,%PK$
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M.B> _&+A ^WPQ?X0]#LM9 H)Z8'U^O)K\SO^"4.LS7%O\;8%MHAN\4:D"=H
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MPDK69NXXF:W.UXF,G^M=B0I . 5[C%?GG\7/#VL^&+?P/\0K"(Q3644-\;E
M=\EI OF,C[1EF9!C)X[=@: /OJST>;3M$73KNV\R2X@8WKD EX&W!D8X& R\
M<>O%?C[\=X/%WP5^->A>+/ FI-IGA?QCK,>E7>FQ/B"WN1( DI9\D>8S$\G
MQZU^J?PC^-6@_%KP%!XAMI1#?-#%:75G.\;SR2 F)V79PH)7.#@@8[U^<_\
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M:UX;U6:234O"WD6,B32!VE01JJO$"=RIE<[3R*^MD5@RAN3&@4M_>W>@Z]J
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M4_AVH _&;]LW]@N7XD:A8?ME?\$_-7L_ _[2_P .K==0O?"MG/%;Z3\6M'A
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MKY#0@R*!\V3D'UX]^.PZ$\5SP<AOE^\.F>GK_*IK4-')Y@*AB3T Z]?3N?\
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M.F2!QUZ^F:_'']GKQ*-7_;A^)6N!7*:3X:UV9)FV_(Q@GV@'H&!QWP*SPO\
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M*YM-]_)W_(^H/!SO_P -'>-"3RVDX;&.03C\./3!KZ?U"*1M+U"&$A1_9LI
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MI1C>21$;)!64K(,#H"01TZ#@9'6K55D*'#0L"DD@=L$X.]=V1_O<'TY'%6:
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M#Q'=WK#^+$\[.#@Y_#G\*Z9?#3_PK\D94O@J_P"-_P#I"-OXA GQ1X2."/\
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M:O?#PUX6\.:K/HJSB%S;)*L<\)?:0,  B13S['D^ONGP^_;S\>_ [3M4.@?
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MO ^WDC#'<!\M?0(*N0". 0QR/X4(=@,<Y*J0/?&:_(3_ (*U_$VYTWX4:?\
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M'.>/3&,#GIGIQ707.A+-$Q.,G\>!_P#7_P \UR5QI4EO*0B'Y>^#GJ1Z?T-
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M;:1/VT?CJ0R>8+6XFZD C#-@9QS@]A_6NV*<_AU]#+!1<:RDU:-V[O\ Q/\
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MGSGW[?3_ !J:J\'?\?Z58K,04444 %%%% !1110 5!-T/T'\ZGJ";H?H/YT
M9\S*%P^U "X)Z-P,@D]<9.>.WZ_!W[9G[=WPF_8G\.Z'K/Q-FN;E-<NA;0BW
MBW,CJ=\C #E"(V49'7&1[?><@0/$64E<NS@XPW X'T(R>A_.OY;O^#CZP+^
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MME4Y64K*A4$-S[8!':I/BG_P6W_8_P#%*:9+I&E7OVZVCPQM8#!%L()(:*-
MA/4J>P ]J_CS%A;Q0-<;X80S;% @3;(QX'7G8>O3IR!R*FMBD,P=X3"I389/
MLX$9)&W*G;R,X';CCC!H?B]QL_\ EYERV5TZ5[;[\^KO_6ADOV2OT9XR<U4X
MQF]7:>-DXW:LURN?*DMU964M=6?T7?M*_P#!4W]G3XL_ ?QSX!\+6NIP>(/$
M-E+8(LOF'R@RMMP2/O;VW!_O 8'& *_/_P#X)^?MY^+?V;_$.F>!?&%S<:G\
M.=?O%LIY+V4R/IT5S+M,OGR,6VB)MBIPJ,-R\GC\TELGC+>48)HY]Q>9452O
M)P6!&X$#ZGH>I(#)85:W$,TQ(6>(QR1LV\-N&T+P.0><9 ].]?-5?$_.*>9T
MI59MUJM52J*F[PYYRO)15^5Q;>C71V\S]QX.^@1X%<"<!<1\ 99E<LQR_B##
M8FM*MF"A6S##XBK";4J<YQE4CR3<6E%M)J]WL?V]^/O$?[-?QC^$_C;0_'7Q
M)\#V?P^^(7AR.PO8]9N[(S6MF\ 9)X()9"'O;4MOC<@-(RA2>:_-S_@E9^Q7
M^U)X_M_BG\.M2^)VIZ-^Q+X2\97P^%.N)-,WB+7-+\^4%M*O%8M#;-!AEBB8
M1Q JJ\ "OY^/"^I>);VT\3:'9>%O$OQ<U*/296AT)+RY$.CVH@8F_)@9E1+9
M"93C! 4X&37].MK^TC^V-^SW^RI^QW!^RA\,IO$_A35?#$MA\1](BL3>7&FZ
ME<PA?M,,Y >1H-V7:3YP4..V/ZHX4S[$9[EE&IB(.G.$81II[R4XJ3:U>B=E
MJ]#_ )LOI4?1WS;Z/7B7C<BKYGA<PR/.JV.QW#F'H2@\1E^"P^)E1JT<7&+O
M&I.I4A*"DHNR=D?3WQV_X(3_  J\4>*#\;?AGXZ\8-\9?#OAV^L?#DOB^[GO
M=(N'DM&6,21,722:=L#<PW!SDX/%?D/\-K_Q1#>^-O@O\7-#O#\2/ ]Y=:7K
M<$8\FSN+2&618+RQA<AE=D0 ;5P00W6OOUOVA?\ @HKX+TW4?'USKNH:C866
MJ>'+N3PK?:5>2WMO#>7-NU]I]A#=1JMU)%&TB[(BZ@# XXKY1_;-\::0/^"@
M^@>)-$MY;#4OB9\--"U/Q!;W._3FA\0S6UN]W;RV$:@0S^8T@W.H&1MR:^JE
M3G'646O6W^9_,S3B[-6?F>@_#_P_J>C6&EZOX=O=3D\.6=VR:OH>M7P9$57_
M 'FU)7RP5,[4Q@XP,U]?O<^&++1[;7-,TDWDMTP9;>&1E@C) (9K=!L&.N"
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ML\4C;Q^[]><>W' S]#VK*7\1?]N_@P,(_,QQSC&<<XR!UQTKSGXY>,[;X?\
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M QS01O#(,='5D*[6X5ASD9^E):V]A;1K:6ME;64$(4);6D,2( ,X 554*,<
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MOR/!7PQ?=?EH8VO_ /('U+_KTD_]!>OQ7^%O_(]^//\ L;=4_P#1JU^U&O\
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M/!QP>*OQADPY/!&, G/MZ#]:Z0.QT6\9)@'YC4X Z$=>_P#^JNIU13<PJL0
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MPL\:Z[XL_8]_:(U7X>Z+XAU/^T[[X<ZW$MQH5A,YRL=KYI91:Q@^6( JIA0
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M38Y(S\TD=Q*$*@J1N #?,!DC!R :_*+]CGP3'K/[1OPWTV%4E/@SPQ%JDL>
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M_P"/]$^&OPRO_BZ/&OCRZ\7:T=-C+^(/#-U<7?VJ;5-&\K]ZMU;-(3"R,&W
M\8%?!7[&'[,'CGXU_MD^ /BRG@OXCZ9\/?AAX771M6U+XG2W42R--;+#<:=8
M+>%MY.&0!5)R>,\5G.;BTDD].]NH'Q=HMQ^T-\<=-^*7[16E^&OB3>?&_3OB
MO+;^%_%]OXGEM_!FA6,6JLJV%]9/<QPB!8$53%*BGD@KV/Z Z;\(?'W[9O[:
MVB^&/VA/B[XIT6+3OV</M/B?P;X(U*6PL+K4].TL-_:%LEO($:Y63:TDB9+D
M<%C7Z/>+?^"2GP_U3XDZCK_A?XK^/_A]\*-;U\>,/%/PJ\.7S1:1KOB R+*_
MVH*RE8)94,FU><.0%.*^N?!7[&WPU\"?&W_A>GAM]0M/$B^"!X%^P3S><D6C
M&V^S+* W/G2 ;G)!R0#U%*,Y-V<5;NG<#^7[X?\ [,NLZW^R?^TM\5=8^-OQ
M+OM:_9M^*DEA\#]5;Q!=-<6FFZ?J[1P:=J\BS%98&0&*>.8Y"CY@#P?H;QC\
M9OB=XI^)^E:W+XTU;1I[K]C:R<6,%V4,NK)9S)+K!(?(<R9EW''!SGO7[E>'
M/V!?A9X6^#_Q5^"EI<7?_"'_ !?\2ZAXH\3(#\_V[4;DW5PRD\C]XV5QCTR*
MX>^_X)H?!^XU:RUE=0U3[7'X'7X:(XR0OAL1>25Y. PC)Z\9Y!)K4#\([[]E
M"?X5?L)_!O\ ;"A^._CZ_P#CVGQ"T#Q!'X@3Q!>&QU2UO_$-Q#)X0O[8R"&2
M$Q1*K)DJ5->S_MM>*_@]\9/B5]G\;:M\7_C+X\M_A+HVLW?PI^&VK76C:?X'
MUB[TF%H=:NI;*58A':S@7#"9@"Q8C)K]O?$W[#WPL\5_LX^'?V:FENCX,\*:
MOI6OZ8[@J_G:5?27*JS9S\TC-P>F1UKYU^)?_!*+X?\ BGXF)\2?A_X_\3_#
MJ\UNSTS1O'<>AS^6?$OARQ@BMGTZYD;DQ(D;21J"N'<C'>HA/F=K6M?\';];
ME2CRJ][Z)[6W5]S\)_AO\3_&7Q5_X)__ ++\/Q.UZ77'\'?M80>'?#;ZK*;C
M5FTNQUKR[2VU6[9F:XO-+C58A*[??3(/>OZG/VI?'.J_#G]D;XF>,]$B=]6T
M7X6RRVC0@R2*)M*6$M'L!)=06(V@G.TCM7R_X8_X)6? +PK\+_#WPLT"^UB;
MPUX>^),/Q'T%;^[:5UU2.Y%S=%B0"_G3AV) .<\$\&OT&\6>$M&\:_#W6/ E
M_$IT;7O#=SX96&1>%=;9[6)SD$8#;""1@[<'K6LH\MM;W\K6U,XRYKZ6LTM[
MWNKGXF?!+]G/3/C!_P $G-5MK>&VU#QIXHM-1^*4&LSH)]13Q3:7$FH1@SX:
M97B6'RP@.<.RXR!CQRR^+,W[:UA^Q7^RQHVM6NL>(/ &H0Z_\>M,/S/:6'AQ
MQ:Z>+R('?'YES:A=DRKQGCO7Z6_\$^_!/CCX&^%_'W[.7C?P_=2:5X*\3ZK)
MX:UIXR;/4/"NI327,:AB"DBQF9T"J<=1C'3K?V;?^"?GP=_9I^/7Q<^/G@^!
MYO&7Q=N9)-0>3A-,T>:5KD10J1M3=<LX*H -I]C4E'R3_P % 9S\)_VK?V&O
M&W@@6VF:[?>(+GP+J%E;+M-[X>,:VT89(P"ZQIA(F*G&T '(S7[:P/)-!%)(
MN#+;*S_[+,,D8/L><\_D:_*CXD?"3QA^T5^WI\/O$&M:))9?"SX#Z=<:AI.L
M-$0NH:_N,\04OPW[XD<#A0!G K]7(6/EJS#!<ECVQN.3GZ9H 0QQ9^93G !Q
MCL *39$.BD'Z _UJSUHH'IV=_7_@$ 5,CZ_W1_0TV3&#CIQ_GFK#=#]#4%#V
M"+Y7>U_+8RIXF=G(59895-M<PN,J\<@VLI4Y#*5)#9ZC(Y[?)^N:5H'PR\=W
M5I9Z-IFA^$O$=C<R2K!$EI#=:O,K&7$BJ$\T*S,H+9!P1S7UXT9+$C.,GH/3
MBN"^(GP_T7XB>'G\/ZW&</*)K"Z"D/8W:J<3(PY&5RN,X/\ /SLQP4,9@<3A
MY)2=2#Y6XIM<OO6M_P!NHQ4'+'X:MS<JIU%)Q2NFG&5U?HOM;/8^:_@K,GA_
M6]7\,:$T-OH%IJ1GT.?5IGEFNX-2)N]36 N"6"WCNL; %0N,''-?:-NZLO3G
M.03S]".WY9'7TK\X=3N]>^$GQ?\ #>E^)E:?PI'!#I6EZX5PC7%TRP01.PX&
M9&4,6^[R<XS7WYH&JM>P-;.BPW=N,(^=T<H!P70]QCZCG(/6OB^'L0J>*KX9
MTE1]A*233;YN73:RY6[*Y[^.BITHSBOLI.S3T>JEYK5:6\^Z75*@9\^O'TQ^
M/L<#W[&I'B#!1Q\IR<]^"/Y\U4A*G!4YZ[CVW\[\=>-V1CL<U?7H/H/Y5^AQ
MDI0C*+4KQBWZM*ZZGB+9>@U5"+C X'8=L=*3<G]W]!4E%4,0$$#' I:** "B
MBB@ HHHH *K/]\?5JLU%L/8C';G_ .M6-6JZ;24;IIZ@(W\/^Z/ZTQCA2>.!
MGDX'4#)/ID\T^1UQSC\<?RY_S@^E96KR@:9<B-@&V  C^([A\O3@$=SP!Q6D
M(U*B2Y+7LM^^UON,YU:4;QE-)]M_UN8?C9%NO"WBR$7C6XDT>[B$B_\ +,R6
MLJ!EQU.2"".A /%?FWI'A>#X4?LF^+=;TN6WO+ZW\1R:IXAUO4E6>_N+(78:
M6-)6#-N&X*H!R!V!SG]&O$.+GPCK5M<O#8LNB7C+*9%.72SF92V2#M# %B,\
M ^@K\BI/B?\ \)#^QWXXT;4H+JXFTSQE?6&H7&B1O);7T(NV""1E! 1\ ,>G
M;UKT\-A:D[]+-*6E[*Z;L^NB\[;/:QPU<73I[-2]'9O_ "U_"Y]=+I>O^-_"
MWPF^+'A/5X-$TBPTH7NKZ?JD4+V\U@D2E+NU67:5DF&6'E@D'&:LZ!XLTO2-
M&\8?%SQSJMC?:7IEO?1Z!->S>=*MT49(([>$@HJ&0= 01@8%>-?#&V^)?Q&^
M''A/1/$]DG@3P]H_A:*/P='YGDKXDM$B BCF&X99T4;@1P3ZUR'[8U]?_#_]
MG;P/X8T'PQ!(NM>(=.LO$<TQ(CLA+,?,N$/1B54D<XRP[D5Z#E*EA\11J0Y8
MR;2K73M'=Z-;.UM'IUZF>78W$5<8Z:I.-.4THSYF[)M:I6\W;75>MC*\.:SX
MC\$? OQQ\7M+U?3)/&?Q(\?,VD.R1F2/39;EA&B@ L%2,@XXP 20#7EO_"U]
M-\*Z]>76C^"K_P".OQ_U[2VMQJ2-)<Z1X&$\(4R1/'OMHF@#;B/,##'2H_B3
MXL\._##]F>Y'B"-V&M/I]A\.$M6+7-KKEX!;M<K$/G\OS)<EBN-O/;CWW]F?
MP'I_P!^"NEV'C=!;>)/B'F_G\4VD7G2JEX@F3?-M9D"I(H(WCGTQQ\OF&?8'
M!Y=B,-&K&51*5FI).5[Z6Z;67^:/TZMEU6A@J6*==U)M7ITW:'*TDVD^9WZ=
M+V^9\;1_LNZIXTN;OQ;\4/'37+Z9'_;VM_#'0KWR=2O+J_9G"/\ 9V+-O*A"
MO+#;@@9KH1X!^%S:OX1OI? >L_#^S\-EB+*[GN9+[5LX,(:1ACRY-I+DL "<
MD\UW%Q9Z)\&OB5=:SK_C&Q/AOQE>22Z3XGN;Q&NGO)/FDLI$+DB.$[ BE< L
M<8Z5X/XZ_:!E^)GQ<E\#>"_$$NIZOH=E<K8Z6+![FSU^6-$:*$E4V?O6V@-O
M^4<YZBOQJEF>8U,36JTZ+J4U)NW,[-7=EL][_A8^AX:X@XL>'K4*+Y<*HRA4
MBI.7-3:U6NFR5M[--GN7CSQ_\%=.U+0/&GC*+Q/X<\)>'[A8WT:^NWCT_5)8
M0/*DAAE91,#(J$"-7!^M8W@%6@^*>H_M#>'M1GO;/X@:3/&UBK^8]CI<496)
M%A0EX5\A$.2JC\Z\V^&_P-UO]I;Q-J6M_MIJW@#P_P##"3;X:^'EE<#3XM8M
MX<F*[DC4Y;<B^80<GG'%?:W@3X<?##P[XCG?X<>*;6'PKXM\.76C:!:ZM*!-
M!<F)H5CM_.QDAAM& ,D8&ZOH<'F>*;BZE/V*NK6J)R3[V=FDMNF_D?29'BJT
M,QE6S!N=-)2G"I1DZ3@W%N+J.,U)N/O-*,W[K3ULE\E?#70Y?VQ/C->> M6T
MR67P'X%N[S5OM-Y&\MFNI3-B':C+Y;2Q2KO ))'4@XS7[D?"/P9J_P /?!FE
M^$=:U/\ MV713<1:??QH$CM=-;:+:RV@\".,;  ,<=A7Y&?L8^&?%_P,^+/C
M[P=K^L"&76?$M[+"MR5/VBTN9M\$D+?Q1LI(C(.#V]:_;&\U*WL+.YD>0&.U
MM8S(W4EI5P@'/);!/\C7W.65J>*HP][EDHJ[;7731=_B;OVLM3XSQ2I/^VX3
MP]*"P^9R5:G.$=5SJ*<K_"XI**BEIJV[:(T(Y"6/<=", C@XX/('O[>_6W$,
M-TQRO\S7)6^OZ?:Z;:ZA/<^1;7#@(DG#/DX^4'N<Y/3(Q780.LRB1?ND*5[Y
M!4%3[<$&O3E3C3DU&:GYK3S5UTO<_-ITIX>I+#SGS^S2M)KE>[35KO9KN]-C
M.U__ ) ^I?\ 7I)_Z"]?BS\*_P#D>_'_ /V-.L?^ABOVEUY@VCZD1VM91^.U
MJ_%KX5_\CWX__P"QIUC_ -#%(1]-'JGT7^=2U$>J?1?YU+0 4444 >5[G_N_
MH:LPDD#/!W?X4Y%#C( Q[CU_.C(1@,=QT QUQ[>E>P>>76_U>?0 C\JJ)(Q8
M@XQD#I[FK!=6C(&?NX_$"JD?WS_O#^9H T)7..@Z-Z_XU!&22"?[P_I4SJ6'
M&.AZ^]1*I3&[USQZ?Y%!<&DW?33]2^BAE(/H3^1JIO.[''7'Z_6IXY4 QSDA
MAT_&H-AW9XZY_7Z4&G-'NBPKLZ'=C@'&!CU']*B7EP3U#8'T_P FEC/RE<')
M'''7K3&<0M\^>N[@9X./I_\ 6[T#-.-RJC&._49Z\4UE#$D\9[# 'X#%5XKJ
M)U&-W?J/Q]34OG)[_E0!+3E16Y.<@\<_C_6FCD ^M3(#L9NP//KT% #@-N,9
MX_.ER?4_F::&#9QGCUI: "@#Y@<D<XX./\GFBGJI.#QP:YP+)P8P&7<,CJ,G
MKCDGMZU1O-#748OW;"-B,XX!Y/3/3T(]_K5^-@, C/7TQW-2)CS-SLRKGD(>
M1_+O[4 >:W-OJ.ASJ&9I8\\G&[ SCZ=._P"?85V.FZK;W<.SSE:X!!\LD!BH
M'4#L0>/KCVSK2112H\4L9</D*S#. 3P2<GK^?YUS%QX8:SF_M2Q?YE'S1EB%
M89S@<'GKV[\=*J#2>O9DR5T[?UJ=!<-'=Q[8U*O$ 'R<@Y('&?SKB]=THR1%
MAC)QR2/;WKJ-/O$O?W;J89!A95==F6&<;03\^#ZXP.?6K>I6*- I)W#O@9)Y
M&3G/I^5:\T>Z,N679_U\SP*>W6!\+G[W.3P#G^N*OVQ"L@7/S#<=WKTXQ]*F
MUJ PRN#T,C8Y[;N/IQV-5+3.Y,^@QZ_C_2NA-2^%W] :<?B37J=+!(R^7C'.
MXGCOBNDTDEIE?^-3\I'KSV_ 5RT;!?*SP IY^O'\ZZK10S3JH5B RDG'R@'U
M.>.HIR:2Y'\;3:CU:M9/T;5C+VD%-7DE\/7L[O\  _'3_@I'XPCU+XZ_#302
M0MEI/AW6KJ_4#81,EK--;R[_ .$B0 C(YY .*^FO^":7A]--^"NH>)IEWWGB
M762;B7^&6!E=D8)@XD.03)N)/(XK\T_VTO%*^(?VCOBE-<S*UMX6T9-*@$9#
M2K/?1M;H(U!^X)''F$'A<G'2OV9_8Y\*GP;^SQX%T610+R73=/U"Y="3"S36
MR.IBDP-^%/S<9#8')KS<3"::O%Z3B]NEU]_R/2IM3I-P:DN5:K5;O<^I+BQ-
MH]VLI8K=HCQ*&/!48';&-IY'<\^U8$T0B8E/O9'7/ ]_R_.NKN99;QHWEP5B
M3:@]P,'/^)_QK&NH3R>,9X'KZGI_D]*]&$E*@HIKFY;67>YP8B,O>T>M_P 8
MV_KLK%*"<&0H00%B5O?) S^&?R_.OSH_X*>^(DA^ 4'AV&X\B;Q9J,6F9S]]
MVN8Q&BCL2Q SWZ5^BRM!$LLDBN0T150BY;*G:<CIM!SCKP ?:OR8_P""G5G)
MJ"_ WPD9?W]WXXTC4)(T?/F6S:A!M0="SX^\H'&#ZUT<\:5+EJ24)-:*3L]E
M:V_W&F%3DDXJZ5KV\G_2]=#SI=!CUGX]?L5?# *77P!\-XO$>H0QG:ZZK,8)
M5D9@"0F"3Y9 SZ\<?MN]N9W$;??>".5R.!YJQE0!UPO8C/;KQ7Y$_L\V@\6_
M\% /&]S(K20?#OP%HFE6<C?ZJ%VLUS$#T4C&6'&"?R_70W:13F/GSPQ&=ORX
M)P!N/Y8QT/->+33CBU.6D=&I=-)-WT\GJ=U24?J\H77/=^[UVW_IF)/;[% .
M=PX8#U''''3%12LJP%6!);!'4=^?\*V;@&0DX .<MG'?^?/Z8J@\2NRA@0 #
MQ@?A@?C7HUYPM"7,N5/5]$VTE]YP4HRBI735T9L,@>&1) ?EC8*!P?NG'UR,
MCMZ5^1?_  4:MGL->^ [R+F)_&FF.5//RF^0Y [$@\'L,=Z_7^XA2-"5ZDJO
M/ RS*!SZ9/-?E)_P4XB"^(O@1;,4!/BO38Q@\"1;E&SG'H./4D ^@Y<SISE0
MYU%N/*M4M.G^3.K+)1C6U:7OK?UM_F+^S[=+J'[7?Q>E!#P#PMIENA!Y$<=K
M&%YY^89&3U/YX^^BGE^:4W9:0AMW.0A&T#TSD\]\?6OSC_96?[1^TQ\;+I2&
M6WTZR@)/#?) @X[X!& >,U^D)=0TF>[#C&>,'D^Y['/I7DTTW&-E>T5M]WYG
MHXF47*6JW?Y6_0?:0)(X\W<4R-P4[6'(/7ZXS_*NQFL9'\*^(Y'0,#:.Q^7&
M$2/<I]>.Y(YSTK#TVV:X<! #EE SP<=< =^ >,X/2O49XT3PYKD;H0ESI,ZQ
MJ!EMZ0MG>">/8_\ UA6WLJEK\CM:_P CSE."J.\DKV^>W^1\1?M&@77[(/AF
M[C7 TOXBZ1)&T?&V234$\P.1U&1P#P.V17[P_ F5;OX1^ +AGW,?#.EKG<,$
M+:Q@<>V2/YU^%/Q?MFU']B/7HH!YEQI7Q!L;QA_<MXM1#$+C.9,=%_(]*_;3
M]F:<W?P*^&LZMD3^&M/D!)P0IMU #_W6R.5R?KDUCSQYN6ZYNQW2O[%M;76O
ME=O_ "_ ]_8 \AOF'3&#SSV[GGI6#K^LIH&A:QKUVDKVNB6%_J5S&B RS06-
MO).QB4'.2J''8X]ZNW$ODHV1/*2CD+;9:0E%+[5/0,VW:#R#G K\K=4_;)^.
MWB+XC_$_X5:I^S;X@TSP);>'?$4%CX_G:6.R:TCLYHS/<2%=@+!BVU<]<CI5
M'*?._A;_ (*V_M"_$^Y\43?!S]BOQO\ $+PGH/B74/#MMXJL3,EK>_89VA^U
M^2&PBL5/R#H5//:OTU^%7[0&HZS\)+7XE_'72=/^ 4XOU34M/\47L-A*(82=
M\!^T.K;GR%4H'8GH#V_G\_X)X?LZ?MP^-_ _Q<U;X+_M2Q?#WP%=?%'7KO1=
M'@CBNI+2ZAU(O=Z;*QB+):,&95EP0Q9P0,5]>_\ !1O7/A_I]W^R]\$_C?'X
MC^-7Q9U21(['P+HE^^C:1XXUB:#;/=ZY>HT$-O86K1>=)*Y;:'!"DY% '[9^
M#OB/X"\>Z5_PD'@;Q+H?B7P_/'<376JZ9=VT^GVPA0'9?S!V$)(WEC(%+*N>
M ,GC-&^,'PE\46OBK2? GBOPEXNU/P<EW=:CH.A:G8F6?4+='E$,D5NP(*3+
MY;LH<;B,Y X_CA^#GQ?^*_P@UW]OCX?>&[G4?AIX3U,V=NW@FS\03:WI7@&S
MOYA;S2:1J*&1O-A0,LF B+NR6]?V@^ '[*O[)_P4\%^ OC/X'^)]YIWQ:\7?
M"/5=;N_"Z^*AJ=QXYU*^TII+F]EL$N)'CG68[\21C:Q/(VMBHJ+O>23Z?U9^
M@'ZN_#OX\Z3J_@C4OB'\3#H7PQMK'4[C197U/7K<:9<-;LZI<&1VV@[,!5&3
MN##MQ3^)'[4GPS\'? OX@_'?PEXHT+XBZ'\/-(N-3U6;PUJ%O?*8;<@R0S"V
M=R/+!^3..<]UK^9_2OB'\-KK]G?P'\//C->>*?'OB[7_ (\:O#I/PYT[59#<
M:QITNJW,D4&IW/GQ"WM</Y;N6(1.QKRGX"ZIXET#QE_P4T^&Y\)VOPM^&^F?
M!*_U#2_A?#XCDUZSTZ**/>MX\CDJEW=AP3&N[Y\KG(Q3E&*5U)-]%?\ X ']
M;G[-/QOT?]HOX,^!OC9H-M-::7X^TO\ M/3=/E)W)&"Z-G(R "C<=L Y->$?
MM#?MMZ)\&/$FO>!]!\/WWC_Q#X:\/2>)O$UOH[,\FAZ1&&>;SQ"'V2H@)#-@
MCTR!7*_\$J)DD_8$_9[GC,,9A\%%K1$;$=O%-/=;,KCB7*DLGH!ZU\@?\$^;
M>R^+7[4G[?5YXM=KV_DUF_\  ,<5\HE?^Q+AGA;R4EW;%978X7 (V@8'-0!^
MG/PB_:?\"_%_]G5/VB]"9[/PM#H&I^(M3LYI09]-30XYGU&PN&;#+/MMY" P
M!!;.,GGX]\%_\%2_!GC'QK\%O!:>"-7L+?XW:GK=AX6U%O-6.YCT<22RRQLP
M 821J,$8!)P#7Y2WWQ4UK]F_P[^TA_P3WDO'TKQ;\3_B1-;?"70X]WVK4_!?
MB.ZC6_:Q/#+&(Y&WI&"H KZ"^/7PXL_@M^TQ_P $FOAEI\-E:+X;T[68M150
MHO1J0T2.>[>4;03EY&#LQSP<YK*FFI:IK??U6UO(N;35D[Z+3_MQ)[^>A^D&
M@_M\^&/$O@;XQ^.-/\)7AA^"'C%O">O?([(BV]\\$]RJ#&THBEF<9ZC/3-?;
MG@#Q]HOQ)\%>&_'OAFXANM%\2:?:WVGHBJWD/,N^99"#]]"2"" 5Q^-?C5_P
M3ST31_&^A?\ !0'P=K"VEWI=_P#$SQQ;ZNN$:(3NE[-!(&(Y$2@.S'&UE[UZ
MM_P1H\6^(/%'[,/BJQUR::9?"'Q+\9^'-":9F:./3-.U.^MK4(S?P^7%'LQQ
MMZ"NB;3M;I?O_7]7ZLP@FG)OJU^"L?KP(41E9!N<+AIL R2J<L4DD RZ!F.%
M)XZ4YHR1*_S!RH'U4'_5X_N#).T=.35F!$2&->.$7.2"<D9/)Z\DX]JD(&Y2
M"H )SR/0X_7%0:%!8(XX]\,4<+R$"411A/,!ZLV!N)]"<]JNJH*!>RD8_#I1
MMRY(88*X SU)R/\ /K3U! P?7_"@!U%%% "-T/T/\JKG@$^@-6&Z'Z'^55SR
M"/4&@:_7]&5FG*;!CDL<^_)Z?Y'M3)I&=Q$@^8@%20" 3G)8=Q@<<CD?G9$2
M%4W#YE.6/7/)/7VS221JS#9E"V!D8_AYZY__ %]_<YE!2DU=*,M.]T]//T)A
MI6A)Z13U;V^&2UZ[M:'SE\9OA[#\1(9M!2X2'5HK*>ZTJ60#8FJ1Q,]@R9'\
M-R(V(#<D'D=OG']G']HG5]6U+4/AEXWTJZTWX@?#F\?3M:N9XGBAURT!,(N+
M2%N&(*[O,1CD$=*^W_%@6UN+/4)(@8X9HD,T>3<^8SKM(0=54\YS]1@\_+7[
M1/A.'P[XC\*_&7P[IL4&H:7>VMIXL,,8BDU2QNF39(ZJ )Y4W#>&;. 22>_P
M.78=1S7%K%_[*ZM23I>T]UU%)NW)OZ]/P/9K2<L-"ROS4]UNI12O?R=U;L[(
M^UK%DDC66%P8I5$Z9'*^< ^&Y^\-W(K35RJKNQG)!(X'&.GY_I^->-^#-?GU
M"V6_MI$DM)XUN! '!GMXY0& EC'* ;A@9(P./?TB&:2YQL8,F#)YBG]V2#M*
M9P#OSU7&,?6OJL%[3#XF6%QBE0<Y2^K*I=.M2O[DH6OS*2LT]--3Q7."LFU%
MVUN_TW6^O3S-\G&".F1D^W^>].JO$X:, @CMP..#V.3GD5+O'H?T_P :])1D
MIU$T[:6]-?PT+2;V3:\A]%,WCT/Z?XTC-D<9&.?3^1]Z'*,?B:06>]F245!E
ML9RV!SGGM3UEC895@W?CFA3@]I(0_(]1^=&<_=()^O;\*IO)N=L;E4 ?,WRJ
M<<'!SS^5,,OEJ7#!@ 2?FQA1R3R1Q51]_2*;:\FOQ:2)<X+>45\U?[KETEP"
M?E. 3WJ+S"%W#&<9,>!P?KGWSG!'TS7#WGQ(\'6$SVUWXBTZ&Y0E6@,Q+ANR
MX (R3P >_'K7GNN?$3Q/=WL=GX,T1K^*<A)-0N%\N")6XWHW(RH.?4>U=M++
M\354INA-1A;WI+E7?=VOM?370\[&9E2PSIP4TW4YMO>M:W;NVEKWOT9Z_JFK
M6.GQ/<:C>6]I#&,DO,H<G!.-F<GG@8&.1C.:\CUGXC7&JI/I?@G3YM7U"1&#
M2RQ,+:& ':\X9L*YC)4@9&>".E3V/PLMK^Y75O$^JW.HWTP62>S:=_LL?<1J
M@P"%#$'@$\=17HC:?H^@Z;,UI;+:6]O 2SV\:K(57GF0<D'J02-QY[<U*MA,
M+95*L.=/:5HQ5FM=7=[=+WM]_G2HXFO_ +1&,E&/O.5^:Z?=W5EKT6FAY/I/
MPRUK4HY)_&'B.[G?4K>2&?3K5S'#'#.AC:(!3@81BI(X.?7I\7:I?>'_  #X
M<^._P0^%/@F77+O3+&^U.:29//M;>Z:&2<RR*ZC+K*%8#J#WK]+=*U2QO-/M
M[VVE1%/!:;&YE4@OCGJ0..W'-?$-A;Z1X,_:(^)CZQK5O#HGQ+T"6>>\C4-!
M9K(B@)<2E1Y$FP,I4D\D=C6,\XIW;A5C4V:46EJI735FGIINWW:Z'3'+:D:2
MK5E*E2W=22?+9Q33OVW=K71\Y?L_?$S6_B+^R1/XL^(:WVB^+? >H-X;MX(&
M:**%;2Z,3&VMU!\II$. 1D*1T-7/VX?$-GJ7[.OPL,3WT=S/=::RVDJM/<:C
MB:$9D; )E9E)$AP5W$#K7*^&+]](\??$SX9>'[9KSX=:QJD.KV%])$3IT%JS
M,]S>R7 !1'9L.5P3CKCDU[+^T[\.[SQ)\$_!S^%]6L-0M=-U2PGMM95XWMK.
MRAF0W42.3L,BXP%SNS@=3QYN(SC%8F-2BZ,X03DHU/LOF5N9;*V[V>K;W=ST
M,+6H4?8SI-3@DFJD4WS6ZZ1NUIT70^$_BC\+-2^)_P 6_@OJFNZP^G>&=#T3
M1S)X!63R(IY8X59;K[*,_OV/S&7&2>3UX_2M/'LVO>$'\&:%X3L=73P]:/H:
MKJ:J+JV+1>6LUOYF&,D8Y!7/W0/I\+_&.*_^"_QM_9]^(>KK>^)_"OB^QTS3
MC>M&VVRG5%ADDN(5^2.%6.8WR=P ..17U5K'C#X<:%XKU62^\16^DZU?.FH>
M$D65X3KEV\2ND,\"H=JL6V?.H/3 P:_'^(<+4A7C6E7<:<I3<_>E9:IJ_:^M
ME^9ZN=9CF6;X7"T<HE.I/#J:KTZ5TTY\JC?F4-^5VMV=[:GY8?%+X%_ U==E
MU?XH?M&ZE;>,;+Q)-;^'_A)J6I/:6MQJ4DRF&WM'D*K&9'8(2.#@>F:^@O"_
MQ.T;X.>9I>A?!+PQI?CS2M':^F\4W>H65W?C3FC5EDBN6;S%EECPZD'  Y&>
MF!^T3\!_A_\ M3ZI!)??!#Q1J?C[3+E-0;6]'CGL1:WUJ2]O>V4T; 3LY"L6
M;&< ]@*^*K+]BQO&/BSQ'#XR\??$KP3X_ELY=!T[P[J.IW!-[I0C,7G"-WY>
M%50+C.-W2L,+G%#+Z<8IPE[7W8STM)M:\MXN[M_P-=3Z;@G,<7E4/99Y6AAH
MSE%.GB)*#FKZ)I3=UW3=FMTUH_L _M0?#/08=2\4?&/7H/',_B^7RK"RT^X2
MXO\ 0)S( +61H&+RH&(C"E1@#GO7H.I^(8/CAJWPZTCPIHDW@K2]*N(+JRNU
MF6UN@P DB)?S%;:X(8J5SD\]Z_(OQK_P3^U[X4^!6^).E>/;V+Q#\,-=EU*^
M\/\ BF\9-/\ $6GI+YH*M,S"25D&0H'4]>,U[_\ !?XR^!_'7@R/XL1:UK\>
MO:3<_P!DW&@Z/<2&QM+R$+"TBA2,1AP2K*IX(["NBMB,57I.M&A*-*U^=17+
M;>]_OU:/Z&R/ 9+G=!5*.-PJFXI+EJ))::62LDE=:*VW=*WZ->.O[7^%WQL\
M':Y\2]8B3PS.;*"T\1B^1)Y+R,HD5K,$)WHFY=P;ELY)K]<==UJT.EZ?<F\C
M$&O2:8-.G;!M[NW$<;HF"<-)*K?*V<GT%?S8>-+'Q#K6B/XC\?0^+?$_A^Z$
M&M>$H;D7%U%9WUS,I =E^:**(1 GA@HYK]:T^*NC>)_@I\#-3MM?LK8:;J^D
M)?VD]P(+B-[.)8OLX60J[;2,,I )'.">*]+)\V<%.'.URQ3A>2OH[25_=35I
M7T2>BT=F>5XA<.4*L^&L/@:E+,<5A<+[/&K"PD_9QM4J*I*#<W!Q]FHS;J.#
M5]4W%'V'K>O:)XM\6Z!X*LC+,+(+)=O9NR16<P53MN"@(QE> <'FOI:WACMX
MDC0\*B+EFR3L4*"<]\#G_&OF#X&Z19V,'B#Q;,8)9_$FK^8EQ(Y$D=IP%,+.
MH.TCD;<CH!Z5]+)()-GEN7#_ '64DC\3VZCUK[K+,<\1.M*K))R47"^E]6K)
M:[)*_P")_.^>8:%#'5(44Y4Z?[KVC=^:<+N=WUDI2DI:O5=D5-<55T?4]IR#
M;2L><\E6S_*OQ<^%?_(]^/\ _L:=8_\ 0Q7[1:P"='U1,_,+6X)R>T<;,W/T
MZ>M?B[\*^/'GCY>Y\2:K,/\ <>3"_CD'([>M>VVE:[2OHO-^1XK:6[2/IH]4
M^B_SJ6HCU3Z+_.I:8N:/=?U\@HHHH#FCW7]?(\WM_N'\/Y56G?;,1_LJ<9XY
MZ_C_ (FEM_N'\/Y5'/W_ .!U[!PEJ)R<CU4_R[^]$?WS_O#^9J&T^]_P$?RJ
M67K^+?S% %CS3[_]]'_"G!BPR?IUS_GK6;%U_%?YFKZ_<;\?Y"@"9/O#\?Y&
MIJR')5LCJ"./7IQ4\4S\?*>3SU[=OQ_K0!KQS)QQ[]N..G]*LR0I/$9, $ K
MCJ1CV]_I7)_:'27D=&]2"?2MF*_!3YL9!QU[# _^M[]>]!T$D,0#8..Y^[[>
MGXU:\H>W_?-4I+Y=O&.""<'L#SWJPFJ+(H0D9 P/QSCG ]!WH 0R$$CGCCJ>
MU68Y?W+YS]X=\]AUZ<>M.:."1<;P21GICK@GGC^=0_9XT8;3U&2,YR>?4GI_
M2@!T#EFP?<\G)Z?RJY61+OBE# 97!&<GC(X].O3BK,5TY!^4\^Y]^_\ GG-
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MWRY.2>,X7GH,<\Z]I-'=3)-<-L$4;N3GH$1FZ#MQ^=?CW_P4 _:XNK#2M2\
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M<4FG;6_4^C(Y%"+\W+<=1WY/!P?QJ7VSS^&17SCX=^*VI _V;XN\,WUM>V9
MEOA&WV=D0X:<X'15!9B#C@X!%=K+\6O! ^8:BQQT:V1W)&/I@\=!U_2NG+XU
M\=2GB8J3C/EM:+TLG?LO_ ;]7Z9PSC#PA&,I).RT=[WV?,]M->KZ:]O6:8[
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MKIHU^!]:'JGT7^=2UF0SB1XSC.0#G/\ GGV_E6G6I7L?ZYO^ %%%% >Q\O\
MR;_@'EBEHR%&,$CJ.?3GTZ5;:"-U).>AZ'N1SVJO-AVRO09Z\=>?>IHY J%6
M^]STY'MU_*O8/.Y5V7W%?)@Y3^\%YYXSCVJPPW#<>N"?Q(S568_*3VW _K4P
MD5EP,_=';U%!G-)/333]6.$:J<C/;OZ59CYRIZ$C]>#_ "J-@5&3[]/:B.50
M><]5[>]! 3HJ,"O7/?D=!4D+DC.%_+W/^%),/, 9>F>_';'\Z9&=@P?T^I^G
MK0 QH@YW%3GV'_UN?QIC1;F&01@ >F>3[<GUK0#HQP!Z=AWIDC(K@$8) Y ]
M2>AH'S2[LJM9[EPA(8GJ3E<=QT':H4TZ6-MRR#/OR/RZ5LJJM&6&0,@<8!')
MZ?7OR*;M']]_T_QH'S2[O^OD8[+>Q9VL#CN0#SV[CCICZU$+^^AE!=8R<#@)
MD 9Z\]_H>E=$1OP%ZCCYN^>G//X_6H&MGSAE4@CU_P#K?UH#FEW?]?(KG6@T
M>V:,$D]5&WH1Z#C_  -21ZO9CK$PY]>?J,C_ #BIH[&.5@"B@X/<^GK^H]Z;
M-I*HI8*G Z \\]\>@H#FEW?]?(T(A#)M:-_O8;!.<$\XZ#\:M;&08RISST/T
MYYXZ5S26DL9RI(.<_C5H2W4*[Y#N53DG.6)R.Q'/''I2Y8]D;&XN\$' QZX/
MTJS'\_7T/3ZX]ZRK:\69.<CUW9&,'MVY/;T[5IQ.@ .X8QZ^N#_*LII)Z::
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MMI>AVW[2^G6<6@^&=0NC9:;IMWK(%UINDS@\V*[FBA2)BJQX4' K^N?XF_\
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MH7NI>36B??7L<-#H>LRD-=:A,"1\XC?:.2,@9SVR!Z>XYK43PM;.?W[S3J0
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M/HU $D77\5_F:DF3/S<\#\..>?KFJT<@[?S],]/I5DMNYXZ8X.?\]: 'PO\
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M@)AK/)59)$3.TKD[01VQ7W+Y0]O^^1_C7XE?'J:_MO\ @KE^RK'HEP$N=3\
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M /.!^F: **.R-A<?>[C/0UK+^\&6]!TXZYS62R,K9([D^_!]/6M."167(/'
MZ'J!S_.@")T59A@X&,\GN![U:0*PPV>XX.,9[_Y]#52XSN#CH,#/_P!;K3HF
M)&>GISTZC^E "B-5/RYX/'.>E3*P P>I/Y=.3^OY4T@KUXZ_I]*K,LCR H!M
M  SG!)!)QC\>M ^679EYN5./\XIT#C)5B,<=\$=3S^&>U, (0EN <CKG&?\
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M8Z?C0!?SMY]/Z\5/%+TQSW_EST_3]*JL<8;T)'YBIXI,8Z?YY(_^O]*RGO\
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MS\KN)%/& >2<=QZ=>U:<<@*#GJ!GCTZ=J +Z,,GD<_S_ *=ZNJ^.F,GL>O\
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M_F?W,_3WSU_NR?\ ?!H\]?[LG_?!K\P1_P %5_@(3CR=4Y]8SC\>*E_X>I?
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MO?T_\AO_ (U^8G_#U+]G8?\ +;4_^_9I/^'K/[//_/74/^_)_P :/:172_\
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MK_P;X5^TR_\ $ATW_6/_ ,NZ^PJ*/P9X5(7_ (D.F]?^?=?6BB@"_'X-\*@
MC0=-!Y/_ ![K]*P7\(>&/M#_ /$CT[J?^7=?]JBB@#4A\&^%C&A.@Z:21_S[
MKZFK7_"%>$_^@!IO_@./\:** #_A"O"?_0 TW_P''^-'_"%>$_\ H :;_P"
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M "[KZBBB@#4_X0OPI_T -,_\!DH_X0OPI_T -,_\!DHHH /^$+\*?] #3/\
MP&2C_A"_"G_0 TS_ ,!DHHH /^$+\*?] #3/_ 9*/^$+\*?] #3/_ 9*** (
MG\%^%,C_ (D&F=/^?9/4TLG@WPJJ$KH.F@Y R+9*** *_P#PB'AC_H!Z=_X#
MK5F/P9X4Y_XD&F=0?^/9.O\ D444 =AH?@'P8R&Z/AO2_M"N464088*.0.&
MX)STS7V7\+=/LK#1_+L[:*W0% %B7:,9Z=SCCUHHJ9;/T?Y%1^)>O^9[(/N?
.@W]:BHHK$V"BBB@#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>form10-k_007.jpg
<TEXT>
begin 644 form10-k_007.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" (0 3,# 2(  A$! Q$!_\0
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M[P].HZ^E&0#@D ]<9&<>M "T4TLJ@EF50.I)  STSD\4H(/(((]0<^_;VYH
M6BBDW+@G<,#J<C ^I[?C0 M%-+H "64!AD$L "/4'/(Y'3UI/,CQN\Q,<G.]
M<8'4YSCCOZ=Z 'T4@((!!!! ((.00>001P01R".M+0 444F1G&1G&<9YQTSC
MKC/>@!:*3(SMR,@9(R,@'H<=<>]+D9(R,CJ.XSTS]: "BBD#*3@,"< X!!.#
MT/'8]CW[4 +13#+$ I,D8#?=)=0&_P!TD\_A3LC&<C'KGC\Z %HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "D/3\5_F*6D/3\5_F* /Y6?CW_RL
M._"7_LE%K_Z/AK^J9>@^@_E7\K/Q[_Y6'?A+_P!DHM?_ $?#7]4R]!]!_*@
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M.WRI"IRW10I.21QS7T[YL?/SKPP0\]'.,+]3D8'O0 XC(Q1@8QU'O[4@=&(
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MPX% 'X=_LC_\% _VC_B!^T/\,OAG?ZV]UH'B:>"*\N999"),E%<DEL$\M_\
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ME^< C"G( _3^O?K4$B$B545E:9,M(.@(^4+]=I(QC%6Z* *069RP *(N(MK
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M?CW_ ,K#OPE_[)1:_P#H^&OZIEZ#Z#^5 "T444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !4;AL?*P  .0
M1G/X\U)4;EA@*N<\$D],\"@#YX_:.\!_$;XI_"SQ!X1^%'CP_#?QE<JQL/%
MC\UK*4QLJR>6?D8!L$AB!P*_DN_;]_9V_P""OW[%'P=E^.MK^WY)XXU4:W;:
M!I[R:/;03Z/8:C<%$ABQA)UC61<,"PXP<&OZX?CY\:_!_P"S9\-]>^+?CA-3
MG\/Z'%F]ATN!KNX.Y68;8(U9G8[& P#@?I_([_P5I_X+??LH?M-_LV1_"GX6
MZ#\4=2\76WB[3=3N-/7PIJ4,26^GW2-*5G,.QP C-L.2<@#T(!]&_!?]@#_@
MKW\;?A=X!^)VH?\ !11;:S\8Z%INJZIX4U#P[::A;7T<JK))OBF22VAE<%@&
M.'3.[C<"?Z5O@%X&\3_#?X3^#O /C;Q+%XM\3>&]-AM-7UF&!;:.ZNPNYG$<
M855#,78!<@ X[+C^=G]F3_@X7_8E^'GP'^%?@_Q'H?Q5D\5Z/HVFZ'+!!X,U
M61(+\HD.R9A"1#&K\,[84 $C'?\ I#^#WQ+\/_&GX>^%OBEX5:X_L3QCID.J
MVD5Y&8)[=)44K#+$P#QR8<%D?YLT >N+T'T'\J6H]ZJH)SP0G0YSTZ>F>]24
M %(>GXK_ #%+2'I^*_S% '\K/Q[_ .5AWX2_]DHM?_1\-?U3+T'T'\J_E9^/
M?_*P[\)?^R46O_H^&OZIEZ#Z#^5 "T444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !3'^XV>NWMZ]OUI]-
M/*@GJ!D?7&: /E/]J33/&E[\*=?D\(^$HO'VJVV9HO!EW91WEEK,<:EV25)3
MC>0"@&,?-7X=^ ?^"A'_  3Z\)ZW/X#_ &I?V3=,^#?Q(TFX>"\EN_AQ%<:1
M<S1R%3,+KR1&%+#<6W.NW)V<&OZ79KP0RE&>1F96$<:CY<]F8CD8/3\:\&^*
M7[-/P!^-EC/9?$OX9>"_%%Y+&PEO+[1K,Z@$?(D/VM(?/+&/=@LY.>=P- 'X
M[>*?V\O^"+.BZ9<Z_-X7\*W^\B1[/PY\/8+F[N+C@HL%O;^6S.7QM*[1GG;7
MIO[*W[=WQ=_::^*^D>%OV?/V?]2\$?LKZ;:+#%XJ\1:3)HEVTJ2[HA;6TP3]
MQ);!7^5<;L#L#7UKX>_X)=_L/>$+VQUC1/@IX7M;^VNDNK:XEL%NQM1MZQ-;
MW$<D)&<?>3/UQQ]R:)H>@:%:QZ7HF@Z;H.G6"QP:?;:79P:?#Y"(%SY%I'"F
M05QEE/4D\DD@'3#=A'!,LJ!(I%!.T-QO?'3@\Y'85;J*+ISWP>P_D!G\<^G2
MI: "D/3\5_F*6D/3\5_F* /Y6?CW_P K#OPE_P"R46O_ */AK^J9>@^@_E7\
MK/Q[_P"5AWX2_P#9*+7_ -'PU_5,O0?0?RH 6BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *;_!_P'^E
M.IO\'_ ?Z4 4 3Y\@"!MR,H.,X<XVY/\(]_ZU^2G_!1__@HWJ'[&D/A_X>_"
MKP"OQ)_:#\9VQO?#/@Q1N^VVN2!,SKDK&),"1BI"*,G&#G]9YG=6"!@JSS")
MF&-Z\;LJ..PP>WXXK^=K_@J]\*?VA?@Y^U'\)_\ @I/\#_ =K\8;3X0^";SP
MCKOP]N8&O))K+4EDM[K4;:RVN7NX(V>6 K&2)5&.: /*?AM_P6C_ &O;SX$:
M]\7?B+^SM:::_@?QO!H?Q$MM,9;V/PM8/=B&YFN!$/ECA0YW';MP>V:_H?\
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MI2S"W2S%EX6@0PR/L\O)C,9WJ2!NZ9&<"OW+^"OB+X?^(_A9X6\0?"JUBM_
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M,>W]&?['7QS7]IS]G3X7_'+^SGTRX\<:!%>WULZ%<7EO_HMQ(H.!L::.3:5
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M[_@EM_R=Q^UW_P!A.'_T>] '[[8'H/RHP/0?E2TR1MJD^X'7% #Z*J>:WO\
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M(_#G[-W@KPAJ/BR_L]-EOHO"UWXOTM'NM,%_';L$>\:>"+8KJ=PP.: /BO\
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M8"?N=OSJ_'WGSNXZD=._<5;J!%<L2=H Q\RYWD@<EN,'/X_IS/0 4AZ?BO\
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MINAZK%?3S2+D#RB"I)R.0%.>YK[PLU)QYN'D *N[(%+% %W%>V<9]Z_Q^_\
M@V]@%Q_P5N_9G@N)KB2U74KV>:W6:1(IL+#M5T5@& R,;NA+8QQ7^P>D3+(S
MDC#,Q &> 2<<GOC&1T!SB@"7H5 X'/ X'3TIU(1R#Z9_44M !1110 4444 %
M%%% !1110 4444 %%%% !1110 4C#<I'J*6F.RJI+G QSC]<=Z ,:^,MI;2O
M#Y:2M(B++)C W,/E'/)(!Y[=^E?A5_P6._:"^"OA72_#/P)U;X&6/[1OQM\>
M*=6\*^#5LTO-0L+!4,8NCC]X+9"/,<<+L],FOW3DCM+TSG=)/Y<94VP)+,"5
M;>BD\.", @9Y([U_/1_P55^#G[1'PG_:@^$/_!1SX!_#N3XI3?";PO=>$M<\
M 6D'VO5;FRU& VTMU]AC)<^7&QV,%.&7=P<T ?"'@K]K?4/$/[--AXD^*W[)
M6F>(='_9\\:V6A7_ (&@TN/^S/"&DP72Q-<WEN@"9@3#;I!Q@'.:_JK_ &=_
MB)X%^+'P9\!?$'X;6T%AX/\ $6@:?=:9I-HJ1VFCK]FC\S3[>) %B2!V*%1P
M2N>O%?Q7_L[_ +5W[7/Q.T']I7]GOP?^QMXVT;Q!^U+XM>WU?Q3XDL+VWT'P
M?;7UR%FN)Y[L1P0>0A+$EOX1G-?V&_L4?!N[_9K_ &:?A5\$M9U6QUSQ!X+T
M"&SU^]TUTEM#JEPQN)HXI4)20(9"@<$@A00=I% 'URG0_7^@I]-4@@$# /..
MGYXIU !2'I^*_P Q2TAZ?BO\Q0!_*S\>_P#E8=^$O_9*+7_T?#7]4R]!]!_*
MOY6?CW_RL._"7_LE%K_Z/AK^J9>@^@_E0 M%%% %.?[TG_7%_P"0K\4?^#A#
M_E%?^T5_V+J?^@K7[7W'5_\ K@]?BG_P<&@'_@EA^T7D9_XIQ.OT6@#_ !Q&
MZ-_UTD_]!J&K( .[(S\\O\A5:@ HHHH *DB^\?\ =;^51U)%]X_[K?RH _>3
M_@VY_P"4N7[-G_7U??\ H-M7^PA7^/?_ ,&W/_*7+]FS_KZOO_0;:O\ 80H
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M="\+Z4 VI:QJ<\=O9VD3$C=)-*R*G'3+CV]_R7_;0_X*Y^%?V;OBU^SK\/?
MGA"S^+GASX]7UE9V?C+P[?"^TO1K2YGB@EGNI[<R1(L:/O+2,I &<Y!KZO\
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MX,T?=97VJI/?H8_MFHQ,)"2JJFQ@=P!STQ7]0=\RRE#;.B^6P>;Y,'8,Y.,
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M_@?^UUX&M$L_!^HZA?VD$^LV*2%_[+M5NIH3'+>86%%B;DR8YZ4 ?G9\</\
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M%RT ?@O_ ,$E_P#DZS_@H)W_ .*^3KSQ]M/'T]!T':OWRC_Y8_\ 7,U^!O\
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M_''7JW^_+_(56JRO5O\ ?E_D*K4 %%%% !4D7WC_ +K?RJ.I(OO'_=;I]/\
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M(DWF0WRDR\E1Y2G*\=>:_I]UG-MXAU>YMW/F/J-V7C;_ %>?/DX^@&!]/6@
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M9Y<_IT]S0!FRQB$/=HX<HI78A[N<$8'7 R<^QJ>-1-:7LC'9*+&7:AX9OD)
M7_ZW4_A541M9OYDA#1/G*?[^.?P.?\FK6H1R.S2V^5A^PN7/I\ISGKQVZ_6@
M#XK_ &2U5/B3^T4+MPDDNL(4$IPYS<?+M4\_3H,^U?8L$TUC"5V/(TDTL84
ML=CG&_'H.YZ#^7QW^S*8[GXH_'L1KYC6^KPAB.2<3@MT[GGCIQ^7VW!)!,JJ
MRXD43>QSGIU]_P#&@#-%KY/^EJ^^0J&\H'+Y/)&/7IQUXQ]/K[]@SS;O]I_P
M"ZQR+.=1MSL"G>5+IDXXX[\_C7R*F^.X^8 (&SQUQT!Y]AS7V7^P3)Y'[5/@
M&[S\IO;=1C_?3KZ9[8_^M0!_;]",6ENIZBW@W<="(UX/H6R<#VJ2$'?G!Q@\
MXXYZ<TV$>9!$?[\,#^A_U?7!Z=JE#;![<>_L/>@">BD!R ?4 _G2T %%%% !
M1110 4444 %%%% !1110 444UC@''7K^&>M  74=QGMSU/IGI1EO[O\ X\*R
MI[D1*96;$2'+,3A5 )Y8C/ '7K2?VA_J=US:(;A=UNLDT4;S+_>B21U=Q]%H
M UQGN,?CFALXX]1QZ\C\JR;F\EMX7>7"A64%@.%). #MR3\W<9'3FK5K<-(A
M\T;&4*3NXX;H3R3SVH _EM^/4(;_ (.&/A*ZY+#X46^0.<XGBQ@>P'-?U-AC
M\@QU"YSGO7\JWQV29O\ @XF^%!-]# J_"6W:.&1MI<>;'R.,'GWS7]4<4C2;
M2X .5 P?O# .X>QR<8Z4 6J*"0!D\ 4SS$_O"@"O<=6_ZX/_ #K\4O\ @X.X
M_P""5_[1A]/#:_R6OVLF(;>5.0(7!([$] ?K7XI?\'!)$W_!*W]HMHB)%/AP
M ,IR"1A3S[,"/J#0!_CCDD;B/^>DG_H-059$;N[1HI9Q)*2HZX ()_ @U6(P
M2#U'!H **** "I80ID =MJX//X''K4521*7=0$+X^8JO4J.3SVXH _2G_@E$
MWE?MI_#S#*#Y-]@D9! B3(X^G6OZ?_$+.NK:C<20[V.H794H#AL7#@$CJ>Q/
M3BOY@_\ @E;+8)^VG\.)6&(!%=*[DD*LACPP8]MV !]/QK^H/Q5-)IGB+4KE
M,75G)?W#"V1=[P(9G.' &!D'/7[M &?!"^HIO:6.-@H58F!R>?F..N0 /4"O
M,/BG\7U^%FA7D=]X6U7Q#-<VSV]BND*=[%U"@-\K<DG@]N<UZO+:C40FHZ,X
M%P%V-;9V@"0'>S X&0/RI4DT[5H?['U6RA74;3Y[:>ZC5HWE&=H!8$'YNW^0
M ?E!^S;\>K_X?^/O'TVL_![QO#_PL'60\%]<*S6]K TH>)Y!Y8P06^<YY7IT
MS7ZIK<1R6NGWT5O*\VH0&X6&(@B 2?,5E R1MZ8X)P<=Z<MQ:6R266J:+:;G
M)6:X-E$ &Q@- X!(&W&"/UP*6(7&G1?;=*4O:!O+*3 956ZE >@ Y';KCCJ
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M<XYSSUS7^GU_Q!Z?L ;+9/\ A-?B)BU5E4_:)-TP;.3<-NS(1DD$\@_2A/\
M@SP_X)^_-N\:?$0GDC_2I!C/U<<#L #Q0!_F"YC](O\ Q_\ QHS'Z1?^/_XU
M_IY/_P &>O\ P3^B5Y)?&_Q!2-.2S7,P 7<!R2W)[<9J7_B#Q_8!E56MO&?C
MUU(!RVH2 D>ORLV/Q H _P PC,?I%_X__C2KL)X:*,X/S9<8[>M?Z?/_ !!X
M?L # ;QA\0 <<XOI2/P.:0_\&>?[ 2E7C\7>/W*.K%7U&6)-H/S,SX;A1\VW
M&& (STH _@T_X)--HA_;2^'[:Y?:;I.CI;WT=S>7\R06RRF,"%MTC*-S-N'7
ML,$ U_3MJ.JV>D:_K5A<ZQX;U"P74KL6U\NLZ>JSP27$IC8"2<. J%5Y/Z5[
M=^V-_P &J_P]^&6N?#.?]D34_'.HC4M?M1XRU8ZE-)<Z78_:@LYMY(MWDCRF
M9EVLVWOR,#]#=._X-2OV7=3\/^'9M:^-/QDCU>73+*75E/B&\G'VZ2WBDN5$
MFY3A)69?G50,8!(&: /QLFO-/LY?M]MK>A"$G)@37=.&X,>HVW&3@9SZ=:DG
MNM"U:,36^J:(ETH_U@UW3<AMWJ+G.<_E7[1'_@T__9*>%H)/C;\9<CA"NN72
M@*>H),O)Y/3.#3;3_@T__9-M%9%^.'QFP_)(UVZ+?GYG'3U_QH _&JTU31KI
M%L+W6- ::U4([OKFFEBPSR2;COQ^ Q3/[7T6PN?(NM7T*33G5H]B:YII(D/"
MM@7'0#DGU[U^S(_X-/\ ]DE7:0?&SXR%W.YF.MW>XGGDGS33F_X-0?V29 5D
M^-?QC8=?^0W=9!]<^90!^*][-H=I,MS8ZSHXMI"6=!KVG=QGH+GISC\:^R/V
M#M4T27]I;P$NC:[X?AU%]0MY9[^\\0::B0+O7=&)'N1@ >A '/3O]P+_ ,&H
M/[)*PF'_ (7=\9BA]=<NR1QT!,IJSI/_  :K_LQ^'KNWOO#_ ,?OC;HU]:S"
M:"_L-?OK>\5P<C,R.21GMG& * /Z>XO&G@\6\$4OC3PB;F.&$717Q%I0W,B!
M6;_C[W8+ X+ <'Z"I&\:^!W(,/C+PEM'WB/$>E'G_@-X1GH.37\YS_\ !N!\
M/7EEF'[7G[1ZR30FW<CQ?J@'EGN 9.''9NO7K52T_P"#;3X=V221P_M@?M*%
M922_F>,]3<\^A\SCJ<4 ?T?CQQX,P,>,/"!';_BH]+Z?^!='_"<>#?\ H</"
M'_A1Z9_\EU_-\?\ @VW\ Y./VP_VD\9./^*RU;IVZ/2?\0V_@+_H\/\ :3_\
M++5O_BZ /Z0O^$X\&_\ 0X>$/_"CTS_Y+H_X3CP;_P!#AX0_\*/3/_DNOYO?
M^(;?P%_T>'^TG_X66K?_ !='_$-OX"_Z/#_:3_\ "RU;_P"+H _I"_X3CP;_
M -#AX0_\*/3/_DNBOYO?^(;?P%_T>'^TG_X66K?_ !=% '].=%%% !1110 4
M444 %1N"<_-@;2,>I-24A&1B@#DHHKL7%X';RPZ.L#GH9#D)CISGN<#OZ5P7
MB3X/?"_QMJ6F:SXR^'_A?Q3KVF/&]MJ/B;3[:\N;9TPWF6;S12E&5Q\A!7&.
MO->O20$L&P3SSZ 9R2".](]C;ROYA+9'OTY)^H_PH R8X(; 0640M8X8D2.P
MM$C"16<*#9&D<:#:$3&U, 8 ':K1)6:,7%OYT[#"W40  !'0G&>.P_.M 6L#
M.LNW+(-H)]/Q&>]/DCR\;  A6R1CH/6@"'RC_<?_ +Z-2*NT8,;GG^^?\15F
MB@"# _YY/_WT?_BJ,#_GD_\ WT?_ (JIZ* *C@YXCE QV8XZGW-(JMN&4EQ[
ML<?C5RB@"'R_9O\ ONH T8F=6+#&Q.7(&]@2H'0$XJ[7/Z^YBTK6IHF#W-OI
M=]=6J#[R3P64[1DX'4N!MSZ=.E $T]QI^V6V:ZL3<$J?L]Q>Q D;AC>F\N!U
MP,=0!GM2&T@S"KQ+E^4$$TN"!U(QC(P?4#'IQG^,3X>^/=>_:%^)GQ^U3XG_
M +:>H_!;Q#\/_$7B=/#>@S:A<PV$L>F37;VT5TJ3QH$/DH%# C/8U^JW_!,G
M]NCQ]J/[.OQ9\8_M#^*(/%?@+X6:M=:9X6^*.C9NW\0QVLACAM6"[G\VX "A
MF8]\Y/- '[XK#"H*1B7"'!_>,<'T))./Q/TIK>4"543-(N#LW9!SP 0WRL#W
M'Z&OR ^$_P#P5V^&GC3XL:%\-_'G@O5OAE9^/)3%X U?7?D?Q@N[RTN+>,B-
M@KX! &YOFK1^./\ P5K^#GPB^*UW\+M+T+4_'<GAJ2%?&MUI.#=>%HKLJMM=
MS189I(HV8,^ "5'!&10!^L22N@DDDN(+&-'V^5%"-N3P/,)48;H,@\=#4Y^6
M:VEDDZY5V#[$W$ KD<*,C! [YX)K\X?CG_P4I^!_P?\  G@/6[BZN_$7CGXD
M6:7G@+X<6:8U3Q7:OM+S^65)00J022#R",=Z\7\4_P#!0?PI\?OV4OC-X@^%
MVL?\(9\5/A_9K/KOAB[E":EHMQ&&#6S $/O0+@849QTH _7W4[B&)"T,Z/<&
M6-_*2<;O)4_O'"!LA57EN,?G5R0"80>6S995<[93]TCKG/?-?@9^RE^TW/K.
MK?"6^\8_$6XFO-4\)ZUK?B6RNYW)FLK*#S;O8KM\S[%PIQGO7<77_!;?X!VC
M&_T[P?X@G\"P^*I_"#>,4@D>QM[VUU#[!))+( 45%<9.6 "XH _<,Q0+MW2.
M-YPN9&Y/^?6C;%&Q5?,=P.4WMG!YS^''3UK\S_VAO^"F/P:^"C^"])T.^A^(
M7CCXF:%:>(O"'A+2I4>:73;B!)1.Y1FV,H8AE(SP<^WL/[(7[;?PG_;!T+7I
M/ >I1KXN\$W8TSQWX:D(%WH&I-_R[2#=N*@@\[0.,F@#[0W#IY,F?3<?\<]/
M:FF,DYV.,\XWGCV_#I4BPY 8L<GG(].W/TJ=1@ 9S@=3WH I^6PY"2?@QS2;
M7_N3?]]&KU% %<#@9C?.!G+'/X\TN!_SR?\ [Z/_ ,54]% $&!_SR?\ [Z/_
M ,51@?\ /)_^^C_\54]% $&!_P \G_[Z/_Q5%3T4 %%%% !1110 4444 %%%
M% !28'H/RI:* # '08HHHH **** "BBB@ HHHH *YWQ&670_$#HNQQI&H!&"
M O*QL+C:B=RQ<*!W[=ZZ*J=RDK;V$:3Q+$V+=O\ EI(3C#9^7;M)'/'K0!_$
MK^RY=_L0^"_B#^U7'^V=X2\16GB;7_&_BB#27DT&[GAU"Q>YO'6"V*PNHDG0
M[4E7G<P(K4^!6H?&[X,_LN?MD>)/V?O@W=Z7^S!JU\;KX=:-XNMKC5);26:<
MF368K"[0.Z!?WJQ[,(.A]?Z^-9_9[^"GB&^_M/7/A+X#U2]:Y^UO<WN@:?<7
M)G=?GE9I+9@\FX_-ECD9(KO(_!7AF+17\+1:#I">%I+9K27PZ-+L4T:6V<!6
MB>S2$0N" !\T9/'KS0!_#5XVV^//C?\ L$^+?!U_XH^+OB?1(M&OO%ME8Z+<
MV>A>#=6FDMII;**=41%A1C(K0MA5VX]Z^E?VP=*^#FD?M"?$_P")>FOXJ^"G
MQYFT#2I;JTO]&N=:\)_$6ZMX83#H_P#9TD9M5EU!T2!'5B0S$@YK^M#2?@=\
M)] 1[70?AQX1T..25;H7.E:/8VUQ%<1L"KI*ENCQG Z(P')SFK?B;X._"_QI
MJ5IK'BGX<^$M?U/3GMWL=0U?1[*[O(IK1E:UE\R2!BRPL R[BW3IP!0!_%%X
MT\!?M%>(O'7[*_[1/[4&FR?#GPS?S7&EV6L:;I<OF>#_  S&2L1@TV-'73Y+
MJ$AMX ()Z9 KZ+^"_P #_"?B7P]^U[\2_@KI_B_5?#VIVTA@\0:BUZ1XR>.6
M027ZV<T:8WR(Z[0.0>.M?UVZ]X#\)^+K)-'\6>%=$\1:9;(IM['5-+L;C3H2
M ,):P21,(E7H,*O'8D&H]$^'/@KPUI,NA>'O!OAK1-'O3Y=_IFFZ;;VMC-$<
MD@00QI&<]P4 W'/)YH _D^^%'A+Q#)\3/@YJ>L>#-6T^UTSX->-X3]GTZ6&%
M[P::RPV\\2KB1IVX^;KV]_=?V<O@P@_X)6_&.SUWX96']IZEX^\7:E9PWNC)
M-J\3/K,TT%Q:JZF:$\*R[/;BOZ5T\$>%;:2WGL_"NA1SV$36UH[6%O\ N[67
M*S11?N_E#KQAL@\9/8S6_@[PU9Z7<Z-9:!IL&DW+M+-I0MHET^665M\DCVX!
MC+%N6XY(Z8H _AOM/V>_'7PX^*GP6^,/Q?UO7-%^%MQHHN1\1)-)FO+GP+$Q
M,:>'X[5E8^4JKMV@ <^YK]C_ /@C'\*?!ND?%O\ :+^)W@GP]KX\/>+]6:2S
M\<WK7.GZ?XP23/\ IPTEU2%)7#!E<<C/%?O7XC^%O@#QCH0\,^*_!GAK6_#\
M>##HMYIMO+IZ%>0?(:((#GN!QZ'-;'AKPAX;\&:5;:)X2\/Z3X<TBW $>G:1
M:0VEM& !C"0H@XQC)']* .G"@+M&< 8')SCIUZTH& !Z>O-+10 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!_
"_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>form10-k_008.jpg
<TEXT>
begin 644 form10-k_008.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $W O@# 2(  A$! Q$!_\0
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M7\_RI?\ AI7XA_\ 1)W_ .^FIZ.^T?O)/^_C^O\ O4[>_P#STD_[^/\ _%4
M1?\ #2OQ#_Z)._\ WTU'_#2OQ#_Z).__ 'TU2[W_ .>DG_?Q_P#XJC>__/23
M_OX__P 50!%_PTK\0_\ HD[_ /?34?\ #2OQ#_Z)._\ WTU2[W_YZ2?]_'_^
M*HWO_P ])/\ OX__ ,50!%_PTK\0_P#HD[_]]-1_PTK\0_\ HD[_ /?35+O?
M_GI)_P!_'_\ BJ-[_P#/23_OX_\ \50!%_PTK\0_^B3O_P!]-1_PTK\0_P#H
MD[_]]-4N]_\ GI)_W\?_ .*HWO\ \])/^_C_ /Q5 $7_  TK\0_^B3O_ -]-
M1_PTK\0_^B3O_P!]-4N]_P#GI)_W\?\ ^*I#,R\%Y#W_ -8__P 6* (_^&E?
MB'_T2=_^^FH_X:5^(?\ T2=_^^FJ03,W >0=_P#6/_\ %FEWO_STD_[^/_\
M%4 1?\-*_$/_ *)._P#WTU'_  TK\0_^B3O_ -]-4N]_^>DG_?Q__BJ-[_\
M/23_ +^/_P#%4 1?\-*_$/\ Z).__?34?\-*_$/_ *)._P#WTU2[W_YZ2?\
M?Q__ (JC>_\ STD_[^/_ /%4 1?\-*_$/_HD[_\ ?34?\-*_$/\ Z).__?35
M+O?_ )Z2?]_'_P#BJ-[_ //23_OX_P#\50!%_P -*_$/_HD[_P#?34?\-*_$
M/_HD[_\ ?35+O?\ YZ2?]_'_ /BJ-[_\])/^_C__ !5 $7_#2OQ#_P"B3O\
M]]-1_P -*_$/_HD[_P#?35+O?_GI)_W\?_XJC>__ #TD_P"_C_\ Q5 $7_#2
MOQ#_ .B3O_WTU'_#2OQ#_P"B3O\ ]]-4N]_^>DG_ '\?_P"*HWO_ ,])/^_C
M_P#Q5 $7_#2OQ#_Z).__ 'TU'_#2OQ#_ .B3O_WTU2[W_P">DG_?Q_\ XJC>
M_P#STD_[^/\ _%4 1?\ #2OQ#_Z)._\ WTU'_#2OQ#_Z).__ 'TU2[W_ .>D
MG_?Q_P#XJC>__/23_OX__P 50!%_PTK\0_\ HD[_ /?34?\ #2OQ#_Z)._\
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M/^_C_P#Q5 $7_#2OQ#_Z).__ 'TU'_#2OQ#_ .B3O_WTU2[W_P">DG_?Q_\
MXJC>_P#STD_[^/\ _%4 1?\ #2OQ#_Z)._\ WTU'_#2OQ#_Z).__ 'TU2[W_
M .>DG_?Q_P#XJC>__/23_OX__P 50!%_PTK\0_\ HD[_ /?34?\ #2OQ#_Z)
M._\ WTU2[W_YZ2?]_'_^*HWO_P ])/\ OX__ ,50!%_PTK\0_P#HD[_]]-1_
MPTK\0_\ HD[_ /?35(977J\AS_TT?_XL4"9FX#R#O_K'_P#BS0!'_P -*_$/
M_HD[_P#?34?\-*_$/_HD[_\ ?35+O?\ YZ2?]_'_ /BJ-[_\])/^_C__ !5
M$7_#2OQ#_P"B3O\ ]]-1_P -*_$/_HD[_P#?35+O?_GI)_W\?_XJC>__ #TD
M_P"_C_\ Q5 $7_#2OQ#_ .B3O_WTU'_#2OQ#_P"B3O\ ]]-4N]_^>DG_ '\?
M_P"*I0TA.!)(,_\ 31_\30!#_P -*_$/_HD[_P#?34?\-*_$/_HD[_\ ?35/
MB7_GM)_W\:F[W_YZ2?\ ?Q__ (J@"+_AI7XA_P#1)W_[Z:C_ (:5^(?_ $2=
M_P#OIJEWO_STD_[^/_\ %4;W_P">DG_?Q_\ XJ@"+_AI7XA_]$G?_OIJ/^&E
M?B'_ -$G?_OIJD+RXXDD!_ZZ/_B:<';!!>0GL?,?^6Z@"'_AI7XA_P#1)W_[
MZ:C_ (:5^(?_ $2=_P#OIJEWO_STD_[^/_\ %4;W_P">DG_?Q_\ XJ@"+_AI
M7XA_]$G?_OIJ/^&E?B'_ -$G?_OIJEWO_P ])/\ OX__ ,51O?\ YZ2?]_'_
M /BJ (O^&E?B'_T2=_\ OIJ/^&E?B'_T2=_^^FJ7>_\ STD_[^/_ /%4;W_Y
MZ2?]_'_^*H B_P"&E?B'_P!$G?\ [Z:C_AI7XA_]$G?_ +Z:I=[_ //23_OX
M_P#\51O?_GI)_P!_'_\ BJ (O^&E?B'_ -$G?_OIJ/\ AI7XA_\ 1)W_ .^F
MJ7>__/23_OX__P 51O?_ )Z2?]_'_P#BJ (O^&E?B'_T2=_^^FH_X:5^(?\
MT2=_^^FJ7>__ #TD_P"_C_\ Q5&]_P#GI)_W\?\ ^*H B_X:5^(?_1)W_P"^
MFH_X:5^(?_1)W_[Z:I=[_P#/23_OX_\ \51O?_GI)_W\?_XJ@"+_ (:5^(?_
M $2=_P#OIJ/^&E?B'_T2=_\ OIJEWO\ \])/^_C_ /Q5&]_^>DG_ '\?_P"*
MH B_X:5^(?\ T2=_^^FH_P"&E?B'_P!$G?\ [Z:I=[_\])/^_C__ !5&]_\
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MG.?T-%+N#*N,\9Z_6DK.2LVEW ****0!1110 4444 %%%% %B*W:=7,95"J
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M4>STZVZ6/VQ2UN#*(WC"ND9,]OO59EE'1(I7(MY%.0>'W8QT-)+;M")"Y4L
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M_"GQ2M-3\96MTC,]SIBRQL\L1'/E! <N/E'KQ7ZLNJ6PD:\:RL+)N4DO;U0
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M(=.6-V81LNIVT9*ABN<,P<;NH)ZC':O,_L_#]G]R/3^OUNT?Q/Y,+K_@EO\
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M .@WX>_\#8__ (JC^T]+_P"@WX>_\#8__BJB4N6VE[@7Z*H?VGI?_0;\/?\
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M 7AFYQ@>PZ5]<.\\"P;+VPDN)XVDALFN+9))R =D:C?O#R<8&W)_&O(/CO\
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M1CFFN3"LS37"QO:HF'G\JVBBD68B:2X9R (3'\T14D%#N'!I0LG\4=NXKO\
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M.Z2?-T+P_'T\O3++'7G,$9SQ_7CH.M<-TKW=M7OIV/44HO9I^C1;P5W#KM.
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M*?']M3T;XSQ6ZQWWB+39=6EEAN;RZ"F>X62TE96/F,02&' -?</B3Q)\=/\
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M->D<HVBDS_LO_P!^W_\ B:,_[+_]^W_^)H 6D8[1G&><4X*S#(20CI_JW_\
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M_P 34@DG\IBLTA4'GY#[9Y([<'CF@#YHF^//B20+_P 65\3*DC;0,L.2,X/
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MFJ1VAO9$,EM]I>&%?*BYED)E*J2BY/)R<\#-1B:5W@EB*LETC-]JM+>*ZC;
MYC,D88#.,$YP,Y'MB#V?H_R9\[?\- >)?^B->+/SII^//BHG(^#?B\!N1\Y'
M!Y&..F*^BM__ $SD_P"_?_V%31F\<^?9R0MY/R/'>;8]I'58MP7( ( (!&*Z
M#G/G ?'WQ/'\K_!OQ;G.?F;)QT[^X-!^/GBAQA?@UXO!'7!*_P Q7T8+Z1"P
MO(72=F+?(@*;#]TJ<8(SD\<]\\T]KAW'^ODVY.T;>1G_ (#GZ]LT ?-W_"^/
M%?\ T1SQ?_W\/^%'_"^/%?\ T1SQ?_W\/^%?1_FO_P ]Y/\ OD__ !-'FO\
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M''Z&H)?COXO4&&V^#/BDV4Z>:R@;2?XC_#PQ./0@C/O7TEYK_P#/:3_OD_\
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MDR1W"!!G<J1@.">!T&>N<]L5*)6R,S2=?[I_^)H ^<O^&@/$O_1&O%GYT?\
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M29;95^QW=O-%*-ZI)#L^5AG!4@!,#/R]N<]*BNB"0S06\DC $F$*%P>F>V[
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MS7P=^U7\>OB#\"_VB?V;C"T1^#7Q,O#X<\8WVY1)8R7T;RP3D8RLJ-;,BD$
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MC&-P6;G@$>/35=N=ZE1VE;XY[6_Q:?<=TG3ARKDAJFW>,=[]VG?3[C];-?\
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M3_#GQIXVO+UK.>]8 $:=J>_[1']C3Y[18)5.=N_-0_L\^/-#^&7A?]OCPEX
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M3Q!^PE\3/%$_C7Q3\5\_%GX4V%Q>7.B/;7#$ZI-+#&S*UI)+YD@>X4X )!W
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MU"S23[4;F[$9,<NU5567/K7Z5:L=._L'63K+QV^C3V$]MK\4NYIEL9499Y)
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MQ$GFR?WOT7_"CS9/[WZ+_A4=%=#W?J_S87?=_>_\SF_&GB/7?#/AC5M;\/\
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M\+"HW[\^VFOGOWZH\RJN1R>^K:Z:;K\RQ_RR@_Z[Q?SJC\,/^3@];_[!4?\
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M6 ,P'F1 !>3C J(NE/X9Q?S?W?TB_JL/Y_\ TK_(]<#2. \A9F<!MSG+,,
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M>1S6M3MYO_TMGV._^M/^\/Z44/\ ZT_[P_I17KT_A7]=CSI[KT_5GC/[2/\
MR1?6?^OBW_\ 1@KQ;2O^0%HG_8,L?_2:.O:?VD?^2+ZS_P!?%O\ ^C!7BVE?
M\@+1/^P98_\ I-'7"NOJ_P!#U33C!:-U W,\;JBY"A6.</DD $$X['WK\S?^
M"I>@)H'PR^'/[3<-LRZU^SAXDT?QCJ&HQN?W.FZ=+()HY43YYH6612VT,HQ\
MWI7Z9*K-%A2 <G!/^>OI7G/QD^&'A7XY_"CQC\'?&\3S>%_'&E3:1KZQ_P"L
METZ<8D1#CY26$9RO( (&*Y,52JRIRE"5D]M;ZZ]+_I<WH_Y_H?RFV'C^[^'G
MBGXK_'Z2^FN(?^"A&GVFFZ%&CRSV]U)JMP(1;V(!*0SRI( (WP2Q((R#7O7A
M_P",/[2/A+63\ /@RWBX0?LMV>@ZM'X%\)VJRV/B2?7#'=WT&N21#RRNUF$A
M?@'C(/%?KQJ'_!-KX :OX-_9T\"74.H1:+^S5JT&M^%+9'_>2S6=R+FP:63C
MS-CHGR,Q [CKCJ_B)^POX<\3?&_3OCIX%\;>)?A#XOE9+3Q9I?A.9(K'QC86
M-N1:R:R.8Y79%7(/0G'7BO#I8;$^]JUKYKY'?.K2@H\Z4FT[;.ROJMV?DKX9
M_;3_ &O/CSX]\1^/? MOXP_X2;P'K=MX2U[X:Z-;Q6_AJ+374VVIM>"3$3SV
M^)$FP"=ZMZUB?L'_ !_^)/Q4_:4^('[+/@;58?A-H?A_XI:KX_\ BG=WBQP7
M'C6^O)Q=SZ'ICKM29["5#;R)"S-\Q! -?J\?^">_@[0?B5-\3?AM\4/&'P\E
MU-HI/&'A[2I-MCXBU.\'F75]<QA2K/<SO)-(P'!D/(J*7_@FQ\%;'6M)\3>&
MM9UCPQXNT3Q==^-+OQEI4S6VJW]Y?727>JVVH31E7N(+B1 J1L64*Q ]*T>&
MQ.GO2>O=O_AO4(5J,N91BHOE;O=+2ZN:G_!175? 7@KX/Z[XR\2?L^K^T?XE
M;0+W1M+T>UB:YN_#230-;C6X!$CF*XMALGFSA\(!VK'_ ."5MK!IG[$O@RWF
MUF?7)[[7-7U73K-IFDG\'+=7;-)X?U".1C,GV.-O)4.  0,8ZU[-^T#<?M:Z
M7&-&_9\T_P %WV@>)M$N/#UU?>(+6VOKZW@U6R^QRZI,9@X6:1M[\X:-AEL9
MYS_V*?V:M1_96^"G_" :YJK>(?&^M:OJ7BGQAJ:S;[**?5+PRO:V29*(D;R?
M*D?W5!XP*]##T:T$G.;:5KKY:_E<XJ[3O9_K]KN?7$@!"QQ\R<%F!^7J,@O]
MT=^,YQCUIE+%L$;1H2;0\2.WW]_/ !^8@GT]/2DKL.8;Y,LK(;1Y9KJ=Q82)
M<LKVL-K,0A55R2$"MR"!L&<X!)K\7?VR/AA\+?'W[47P3^$'[/OA;0T^-/AO
MQG8^/_BAX]\+R;9=,\+6TP^UZ;J-S&1'(S2123-"&W'S,;:_:=!O,R,<6Z6D
MXN# =DP^UH\4;*W!,D;'<-O(P*_,;P3_ ,$P?"OP^^->N?&_PE\;?BAI/BKQ
M#X@FUSQ!:6>K QZHD["0:([7"38LO**AD1E3E@5!J*^WR_\ ;4;K9>B_)&W^
MU!H_PP_;'_9U^-T'B>W\4Z79_ R&?3X9+2>?2(-6U*QMA;IJ861H7N87D!5Y
M5W+E@2>:^4/%/PU\9^(OV(/V4M4\'?#>_P#B7H?@;6K>X\4>&+9FNKN]T>P=
MG,#E-YN?/B5=Q7=C!)/7/ZJ_M'? 72?VC_ACJ/PJU#Q=K'@#1=<M5T_Q'<^%
M6CL[JZT_R2DBW;VT$+W%]--LE>8LV<$<GFOFCX>? +]H3]B;X5Z9X"_8[\8Z
MMX]E@,EE''\1ITU*..WG1XVD@6[WA&57+ ]0!D8Z5Y4Z-><I2IMI7T3NE>_E
M^=NYM!JVK5[N]V=9^R[\;_@_\5?@7\3_ !1\%? 2?"6[\%Z3XHTGQ]X0C#1W
M&F^*-'L)Q;^:S[1"))(QF?B-#G<:_+35=#L[?]BOX.ZI?WEM:V'QE_:HTZ?X
MG:P9R6U;0Y-=EA/AN[U"-MKVUTP9'#/L .6^6OU2_8[_ &4-;^$'@_XNCXIZ
MO9:S\5/C_J>I:IXQT_0]MIHFE#6UD6X$T7RQLZ^:V_RQP<UX9\"OV6KGQ5\,
M?B_^QQ\??"5S8>#='\=7OB/X;>/[*1TM--N+>[EO;"6PZ,)5#QX>,D&3/)YQ
M+P^)_GE][+C4IPOSI2NK+;3O]^QY;::_X#_8U_X*(:]IW@'0KP_"[5O!>C:A
MX@^''A:X,UA:WUQI4*Z9=;X&:%%>)EN'(QYIR>>M</\ \%,-9^'MK9>"(=$_
M9VO[#Q)X_P#$&A^*==_:+-G=QP>"M)GU&V,%E>W*Q@,VV4 JKC(1C7Z/_LN_
ML>> /V<Y?$'BRYUFX^)OCKQ4LL.J>(/B"QU.=-)L]T&EVUH;C<R);6BQPPHO
M(0 8XKP/]IOX6?MJ_M'V?B#X)$^&_#OP&\2W]B9_$;VULQM- L[R%W2U 7[1
M%)''N\I4PV3QC%'U;$_S/[V7]8P_\B^Y'YS_ !=T;P#X-^)7Q[L_VLO"?B?X
MB^$_&7P'\./\#?B9H:W5W8:9JMEI\-S8W]M+ '2!DE,;2J[*YP1USBQXF_:L
MU7Q9^P/\'?V5M'^) T?Q]\0O GB,Z[XKU.[M[+4M+\ :8)EL@9+AUD+26ZB(
MA&\R/)8],U^B?[0WP'_:L\8?#31OV7?A?_P@2? K2])T#09_BIXCL8+OQ,UG
MID4/]H6^GS2*UW%]K0/%&6.. .<"O5+C]@/]G,?!>S\":G\-M(\6>+?#/P\/
MA#PWX^0F+5XM2N[=OM,TK+A_L*W!+RQ@?-$&4 Y%)X;$V?O/JMV"Q&'NO<6Z
MZ+R/C+]FRY_9R\#_ /!,2/Q9XEMM"^*2_#R.\\,:3K]U>IJ$M]XDO8VM(DMU
M1Y);FX%Q@ Q;B,YZ5Y-XG_9VLO@'^P9\./C"NF3:;\6]4^+&B_$> S+*EYI'
MA[6K^)]/TB/<!)]D6VE  &%"]0!FO;O#'_!,74?"/P@^!7P*T77(?"GPU\#_
M !#N?BA\28 99X?%]W+?_:K;3+1"6VPL_P J(XPBD9  S7U+^W!\/_B%\:=?
M^ _P5\'^'+RU^'\GB?2]8\6>(&8&&S\,>&#"@\/B./Y$C01#RV8*) <J32H8
M;$7OS..OI^']?(>(Q&':?NK;MY_I_6I]P:)<S7OAGPGJ%SL-QJ7A;0M2F:,[
MD>2^T^"YD97'#_/(P+ D;@1US5^H;>SATRWMM&M)DET[1+:WTG3 G/DV%I!$
MD,+$$@LG.>>,@=JFKVH)J$4]TM3S&U)MK9ZKT"BBBJ$%075K:W-M/'<SR:>T
MUM=V374>X,T5Z@AA=&'0^877/\&"S$ BIZ<DTL(GBC6"6#4K62QN#> .+9SD
MI+;#DJRYR&P,M6=6$YTY1@[2L];VTMKK^'S+AN_3]3\<O!_P'\&? /\ X*HS
MS^#I/$-_=ZW\))/$WB:[.LK<QW5S#E[O2[6W:5@LTZDLKA<9Z=A7JW[3/QL^
M%/BOX'_$#XO:U^RQKOQ9&C)K?A'PSX8U+3KBZ\007MR9;6758(FB=S]@E07,
M<P7"KEE..:V9/^"<WA:3]HZW_:AMOC1\11XY@O$:;13J,RZ.=$B?;<V21NVP
M0NW B_B7MCI[[^T/=_M5Z:!HW[+'A[P;<:5?:7<:=Y^MV=G="&]UB'[-=ZA-
M&ZLADB1Y)-[*-K'.0<&O+HX?$>SK^\U>+LKM]>BZ]N^NVYJ?FQ^SG9?!SP+_
M ,$X-;^,7Q.T6R\=7VA:[K%GX7\->(YK>YNM&\0Z['*-*\,AMSR>;I<\L<0M
MQRC1X !X'K7[,?C#PY^PK\!?"'A[5/A7XK\1:K\79+WXBZVOA*"[N&\-SZU/
M]LM=.@DB1@X$4@4"(XCQAN:P/#O_  36^(<6@?![P!XA\>V]YX*\-?$V[^+/
MQ9\/QLZV_B7QC)<'4GMT7A&M()MR11@&, ;0,<5^QLBVUDUOIEII>D00:';6
M<6F+<6<%PL5I'@)"NY6!"K@;5/&,$5MAL/B%]II:Z?/:VWE_PP'XV?MO>*O@
M)\5OV?-(U=?@\FJ?'_XRZ]9^$OA3X4O5EA\=Z-JBW@_XJ:\W@2VB68Q+ON-J
M.RDH3D5Z7\6M5^($7[)GB+]C_P -#Q1>?'GPE\(]*UWQ7XHFQ)IVK6@LOM-W
MH=GJ+$Q-J5K;Q-:7%LDAF#,JE02*[/\ :%_X)R>$?V@_CG8_'Z]^,'Q-\#>-
M+*"VM=/7PKJ,5IIEA% 5*?V#9+;F*RNBJ@/*0&(/+$U]J-H/B+PK\/;/1_"+
MVOBWQ_X5T::+3O$OB=+>75_$:Q1X\G7KIHXQ=W3;<3 A@^[ W5A+#XGF?O/=
M]7W9U*OATDG!722V73^F?SX?"7QC\$)_VCOV)M$^%/@GQC\)/&NL>&+OPK\6
MM%UBSO=.TSQ9>I:^5J-[<Q3)&MUF=9IMV'!$H*D9R?2O'TO@?4_^"H'P*\-^
M$?@]=?LY6?@:YU 7/Q C2>RT[XT7J3[6@6$K'YRR,2=[!EZGCK7U_P##[]F'
M]HKQQ\?H/VH?CVO@O3]>\&:)JD7PM\&:-86]G!;ZE=HT#37*Q*BY\I8F7/\
M%D\Y-1:Y^S3^UE^TS\?/A+\1/VC]4\->'_"/[/EY/J'A"V\/PP6M_JKW,Q>&
M.\G@"O.5^7<9&;C(K'ZOB/:O5Z6N];;::_UL85)1E)RBK1:5EMTU_$_52Z9Y
M;F6X>);?[1J%R(8PRL;24*JG(7E$D SOP%^89]ZM+,\4LKW W^;<V<KWB8.V
M)H2D:,@  #N%!(4YZD=325Z^'IU*<6JDN:]K>7E?J85.GS_0****Z#,<B;I$
M.\J$;>P#!2X /R9/')(/K@&OGK]I7X_:=^S%\'_$'Q;O/!_B#QG9:1]HEN=&
MT>WGO=0G>%24M[>VMU>8F1B,.%P!G/ KZ FSY$Q4$RA5,(])-Z $\=,$C\:2
MYM;.XCN[;5;>QU.SE\DMI^IVL=W8B5E"LTL+JZ/'RP8$'C\*'JFENQK=>J_,
M_GR^+7[57[0W[17[)7C;XP:IXG\+>&/AAXIU7P[X:U#X<>')47QAH^DZA>10
M-)X@M86%Y"X@DQ/(Z *<EB.:]H7PS\-?V5OVP?V5M4^"E@\6F:S\%(]5\7>"
M=+O_ +7<:]9OHMM-?:G=0QNVR>25Y)5AD43.7X!ZG]$]1_8Y_9QN-/\ B':Z
M?X!;18_B9IRZ;XD6PEVZ?_:41,L=_:60/EP$,,AD1<' !&*\T_9H_85\ _LW
M>,-5\?#Q3J_Q+\=M9OHWA?7/&LTFHMH6BSY#:79"8ND,-O%B"(<+MC4=J\W$
M8?$._O-[:7]7M>W]>9N?#?AT?"_]KG]MK]HB_P#C%X;OIO!'A7]GZ_O?AOX#
M\673V,&DZO-I%PLOBF"WNF3R9;.3_2(5*AY-@$>37S?^QMH.D_'#XU? ?X(?
M&Z\N/&GPK\#6'Q$C\%V/B/[5!HNORV3N^ERM]I(798DLD,TOR 1@AL,*_7W]
MI?\ 86^&_P"T;XOTOQS'XBU[X:^*H]";PKX@N/",[:=-XE\.2?+>0W;VY12J
MC=%$K$'9C ZUE_$__@G?\'_B)\.?AIX#T'7?%?PZU/X6QKI?ASQ7X7O39>(9
M-'N0HU&XU&]B9'FDO-@+;F+8W ^M<RPV)LO>?WM?ATZ'3&O0C%*4%=))Z+5]
M3\9/"LT^O?'KPA^S7J]^=2^ UG^TEJ$::)/>EM)GN/MS(=!MY@_EPV,*Y0-(
M1%*HVH2<5]0K^S3\+?%OQB_;X_9_TN34;CX'^ M'OO$FD>"O#E]/I^DZ#XE3
M1I[N,I*TB)+Y=VD<FZ$E21GO7Z#:K_P3Y^"6I_ /3O@I;R:CIVHZ3XD?7-'^
M+>ERM!XT&KQN9'U*]O>)WG,F6+ECN/0UC:!_P3S\"^&_@3XQ^$.C_$;QPOB'
MQU=.WC;XD6]_(GC3Q1!-NB<7.I.1(UO%"S!D9^4!&#6;PV)]HM6]%K=Z+7KI
M_D5]8P_\B^Y&A_P3*L+2V_8I^%%L[7"VL$6K6DAN;G[7=-<Z9K%X&6X<,[1*
M+80L)9"$8':#D8K[H!R =JH#G"JXD4#)  =2588 Y4D5\H?LB_LEZ'^Q_P""
M=3\ ^%/''B3QGH=SYMMIZ^*+F2Y6UENW,EQ*@D8A<[F)(P.>IKZPPHX0(J@
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M-="P^(]E)<[]+ONNOE^)7UC#]8+[D?!GQI\)_M ?$3_@I7JFI_"/Q_X;\/\
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MCLZ['4C (QOR0"1G!..2<9_K2-&C.)&7+CHQ)S_.GM\Q#-R1T)[9XH ****
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M<>)M5U"/^R-$@L7"6Y>56,</F@G:RDLW\0!I?6Z7\R^\F=%I=5K_ %]D^UY
M8V2*7_1+ID&ZUN 3-&RG,CR(N"D3*5,1/4YR3C%1&:-I%6WWSQG(,JH50,G,
MN7;@ *#M!Y)%?F?\&O\ @H/96^@_%NT_:0M[?1?&7PJ\1+I6J>)M#LKK5+/Q
M%8J4CW6EQ;12VZ0D$O:/(Z"0^8&QM!/N6M?M'6&I^,? NK^#?&OA&3X&^)/#
MK^)M:U.[EEM]0M].CMC-,-FP$3Q2*$E5<J#D$XS0L72>B:N]M3/V4OYGZW_^
MU/L)1([9CCWQ28,#JZ_-C&Y&/0.>B=!N(SQFG-'-&]L+A#;!YI&O4"&Z>RLC
M_J3*82 L[DJ&!&WT%?,GPD_;/_9C^./CJX^'7PI\5OJ6I/9/=:39WB26\VH/
M;O+%-)8S$>7+%YL+8*L2RXQDY%>/_MR?M ?%/X(7GP5\$_!^]T#P_JGQB\27
MFF>)-<\73_9K2T:QC\TPV\UV4V;NB!BHW<' YJO;?U;_ ((>RE_,_O\ _M3[
MY&&"QPN9[ER0L?E/"%)9@H?S.02 IQD<'.:5_+AR+F>.*9!L>W :1S*3P5=1
MM"8XP03GG)'3Y!M?VEO"7POT_P &> OVE?B7H5G\5/%)0Z(_AMEOK/5Q&OF2
M7,EW:B2-8MAC4NKE??BNE\'?MB?LY^/?$?B[P[I/Q TK2M5\!Z;<ZGXBM]7A
MN;82VMFK%K^"XFB6*=957;$L+MN..,Y%5]=PZ5GRW6CUZK?9FRHNRT>RZOMZ
M=3Z82.Y8HK0B,.W$C."NSU*#YUSU!)QT&.<TY5W71MRZ*@X\TY"$D' #9QUQ
MU%?'W@C]OK]E3QY=^(H/#GCQVUCP^A75X[^SO;>W?1!)Y<FIZ>&@_>0BZ\J#
MS>.9%QQS7M^K_'/X2Z)$+/Q+XJTVPL+_ ,,OXIL9T<QW;:.B>=]I7S=H+X4;
M$!).>!BIEC*#>DHI=KZ>8_8/L_O?^1Z<3(JSAH7$MH2\XR-K0CD/%QDDCGG(
MS4K!4AD9PWFD(T"K@JRN 1NXSD*?FP1@U\M:%^V_^S;XA\"^(OB2GCG[)X5\
M%3+9>);F\C$=S#$7\N(BV&99O/&/**(P;*XX-5?#7[=/[,7C;PCXJ\>>&?B)
M:OX?\$1Q2:Q97]K<VNLW27*N;8Z=:21*93)LP@?!8D8)%3];H_S+[Q>P?9_?
M_P#:GUCY88O'&P,L4<<DN[[GSKN(4CGCIS3$1V$;,-J2.(A(.1YASM 7JP..
MHZ=Z^:OA=^UY\ OB\)[;P;XNW:AI^C7'B36-+U."33=1L]&BW223S1W2Q K;
MJI5BA91S@X-6_BS^T+IWA/\ 9E^(/[1_@&)?$^C^&-"U2/PS"@6X>^U9'$:2
MK!$7:58F5F#H"% <DBE+%4VFHR7-ZA[!^?\ 7R/HF1H46YGE:6RMX72&%[J"
M1C<39Q)L9,*$')4'D^M*8Y7> 6JBXBEC:1I=P0(%!);:W)  +$#)., YK\^?
MV3?C;\4M?^"US^T1\>/B;\/9_A#KNBVVK+)I-Y]LNO"^J/(S/I>HVRJ9;:[B
M(,<L.W.X8&:]<\'?MG_LU?$F;0_^$7\=?:6U36W\-6D)B>SN&O\ YEB?[+*(
MY?L]RW$+!"6R-V!FH6)U^+33^MP]C_5_^ ?4:S0G<K3*KJ"5)C<+)C. @SDD
M]AD]>U2L0B0E@Q>9@H5!N*YQ@L@!9>O0]/RS\R^//VQ?V=_A^=6B\5>.8DO?
M#.HG3)+&PM_/NUNTV^:)54$!;?<#.2<@= <UEZY^V9\ ],M;"VL/B/I;^)/B
M5H'VSP*+-9+[R+QT/[_5(XD?[&JL070 .@!W+GKI];I?S+[P]@_/\?\ Y$^L
MMF//)63%N TF5\MMIZ,JL#N7W!Q^1J%R8RIW"X!032Q0JPDM[=OE6:1FRI4N
M0I &>N*_+2U_X*;>!?A[XW^$OPA^+^JIK%Y\3Y=0FM_%^B6,US':VUG-<1M;
MW?E1ED@C^SNR':7!?YP.*^Y[+]I'X,ZCH'AWQG;>,85\+>,->E\)>%C*(H;Z
M^U:*8P+9W<3L&\J20*\83<X!RR@5F\5=NTE;IUT^\/8_U=_Y'L:LS(6C1[LQ
M_O)_LJ,P@M^,O(#D[E&2W; X%)'(LUTUM;?Z6HB^TB[4&"W\D?>CS*"3,,XP
M#CIQUS\<?MG?&'XP_!\_!OPQ\*[#3K/Q;\6O$$>C&.XDC$=O \B8%Y)GRXVN
M8F#1@-RN[.#@'A/@Q^V=JH\8_$GX$?M6:5IO@#Q[\*]>TJXT5[)EMK/Q)X>U
M)8RMWYTIC>6'YU\PD8S]W(YJXXJ"3YY*_3II][\P]@_/[_\ @'Z#2Y2-V7:7
M1@"N]2,'IG'([>W-6# WG6\640W,RQP(\J;[D%%8F'' (8E?F!'&:\+\>?M*
M? 7X;6WB/4?&GBW3-%BT73[#5;RTF-S)<QVNIQ>;8$+'$R[IU "9."67!KS#
M4_VZ?V8_#T7@_6-:\0:G9:=XPEMYM'U.[TR_6TLQ= 16_P!GD$!!5CM)*Y&2
M?057UNCTDOO7^8>P?G^/_P B?7LACB*).6MF-\;.9F'G-"Q4F-#!%B1C)P=Z
M_(!D'G%"*\D99D-O):RS)>"8C+QK_J);>,89%<9W"7)S@#IS^:?A?_@HWX&^
M+'C#]H7X._#2^M;#Q_\ "VTDN='\:ZQIM]#83J2"!'YUL%D,S$-%*X! ST[^
MQS_MN?!'X9Z'\/M(^+OC*VD^(>N^']/U;Q9)I5M<WT#?:Y'BA,AAC=;9I'C9
MB7*QA,98=*<<52<DDTVW9*^XI4&DWKMW_P" ?94021Q#YJF:4@VZ#@.AQ]XD
MG#<^H%"*2\T4@\B2WR9!(ZG>J]3'C&?;)Y]*^5/B=^VQ^S-\*$TZ/Q7XZM?M
M?B72;?Q!X>DTN&XNUBT6Z91$]XRQL;=\NH+L%B0DEG&./IWPUK&E>,='TOQ?
MH%QIFI^'M;\,VVLZ%JXN'>UU6*YA>401F(,QNE6,B0$! Y&#@$C;VL>R^[_[
M8Q]E+^:7W_\ VI9B6:66%$C>3[7N:WVHR1Q0IR\ES<-F-<@$J !G@5.L,KMN
M6*8V^) ]P(V:*)E_U;-(/E=)#TVX) .*_$SQ/_P4&_:+^'VM>.?B1>:=X0U3
MX0Z#\28?AQ<> 5N!)XA-N;IK8ZC;6L(:Y *#<[%0 3Z<UZW\!?VD?VAOCUXS
M\9>(;#Q1X-T;X6>'-4OY-&\"1:A;Q^*;E--LVO(K*>TE9'"2%67+XW#)&>E8
M/%TD[<RZ]>QO[!^?X_\ R)^JMLKW WI&\D,9:.>1!M,<O\!","Q1OS/8TV#%
MS%)-;^9/MF-NL8B>,^;'EY0\CY15$:L58C&['49K\6/@=_P5&\7_ !,\"?M2
M1^-?#UAX1^+GPA\0:Q)X2T$A;6R\1^';&3RK::U9]HN+E "9 I*;MV">#77>
M#/VL/VB?C/\ $7P?X7\+^,? '@FP/P]T;QAX@M]7E^R'4[N_074EAIZ.JR7-
MR84>*YV JNX["0 :/K='^9?>'L'V?X__ ")^O49$R.Z1.C-D01%UDW%1EC).
MJB-0/3 .>!G(H"2N;98XB3,I,AD81HA''#,,8Z\D^]?E)\"OVE?VG/VE?C=\
M2?#^@>*/ 7@CPC\'=5M]%\1^ [E8;;7]7BW*)?$-G#<;);C3I41W62$,^#DK
M7ZA7?BCPO;Q74USXCT+4K2QL)KNXMAJUK!?BW@C+32K"TRNHC",Q#8;CIGKM
M2Q%&2G>SM;6^VC_/] ]@^S^]_P"1MSH;9&EF9/+!(W1L'48XSN7(8=.1COZ4
MU(IYFB2#RF,T9GCD9ML<H4E39H2?^/PX+CG9MQQGFOCSPE^WO^R=KGBS2OA]
MH?CN-]7U+4;G1[>VO8I?[->]MG;SA'J++]G,<9# LTN[*D 'K76:;^V/^SQX
MA\4>,?A_;^.M(36_![SWDN#-# \=FA:\_LBY9%ANKJVC4R2 .8Q'@[B<BL)8
MNFIV;27KL/V']7?^1]*LXC+)-%(CC_6+E6-J0/\ 5W&!]]CR"N!@?B4&YHI9
MH +M(D9V,!V[ O4OOS@+U)X]N17QY=_\%!?V5G\+W7BNT\9R7:Z?JL.@0V-M
M87DVI>*YY)A!->6*>3Y4\=JX*S2AL!=Q!Z5Z[HW[0?P:\0V&LZS:^+8]-T3P
MS;6.H>*D2.:.:VTN^1'#W",@:-5+A'!&2V0H(H^MT?YE]XO8/S_'_P"1/:$!
MF#F,H/*C$C^8X DX#>7"W ,F.,'//8]XD9WA\S"B0G/E'(('O[C\CVXK\\/
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M[U_D9!1112 **** "BBB@ HHHH **** "BBB@ J.3M^/]*DJ.3M^/]* )_\
MEE!_UWB_G5'X8?\ )P>M_P#8*C_]$FKW_+*#_KO%_.J/PP_Y.#UO_L%1_P#H
MDTZ?QOU_]M)G\/\ 7<^QW_UI_P!X?THH?_6G_>']**]2G\*_KL>9/=>GZL\9
M_:1_Y(OK([BXM\CO_K!VKQK1VB30-&#E7WZ;98V\LG^CQYSZ<Y_I7L_[2'_)
M'=<_Z[6W_HQ*\5T>/.@Z,>!G3;3ZG]PGY#_.*\VOU^?_ *4CJP_3T7Y,^/\
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M;>T.K1HAOH[F%56.!V=7# G[W']0ZO<);7%B9U=-0?SCJ*VZMJUJ3@;$;!9
M,'Y1V''45,+B:,6R-+!=164:Q+/;VEO::G/*K;Q]M?:LDQP0&D<G(^7/->9/
M+6Y2:K54G)NW*NK\M"UBY)6]G':V\O\ ,_F9@D\2_%SXFZ9\,O#'P&G^&'CK
MP[\"KG3-;LIM.CTV7Q3K&E20LT5B$0-?&X:,.K$Y>7:2Q/-:WQ>^&?QV_:S\
M)HOP^^$GC;P9>_!GX<V&F:O+J7GVE_XBU#2Y6BU:QTR L&NHT1&WQ 8(X&>M
M?OC??!_PUK'QHT/XYB>ZTCQGX=L7L;2:V>".P:&0A0MZH(5P6QNW=^.IKV*W
MNKFVN#/+NMM<M+F6[N;O1Q;)8ZG'<DL8IHT(27>&RRD'=@YK>EED'!<U:K>[
MOHE^>H_K<O\ GW'_ ,"E_F?S=>'/V8-.\0_!W2;OP/X!\<3?$;7/%G@G1O&G
MASQ+#-8:)!:^';NU>_O[BR=5BGM9?*?S)65MP)W!LUH?M._L[?%'PU^TWK7Q
M<\"_!R34/A'X.LO 4WB?P%X7@"V_B&;1(5>\$&GP(D=RDLK$$!6R&&X=:_HQ
M5TB=S?6<,[7+^9I]];"VM8+:Y8[LW03 +9Y;=G)[XIH\RT=+N"0"Y0LL4$DE
MO<1DN27?448D21EB3&'! 4C%:?V73_Y_5?\ R47UN7_/N/WR_P S^?+_ (*%
M:RVM>$O@+^T!\%/AVOPD^(?Q.U;2O@YK?PIMK1=+UZZ\,^)I8A?:E-IUL$E>
M&PCF>.>9U C(//%?H'I?[+5U^SQX=\/>,G\7ZSXN\$>$O!,5CJ7P,2%[^PU.
M^O;2*XU*22R):.:2<RRJKD%E88SG-?2&N_LU_#[Q-\;=$^/'BDW6O^)_"EB=
M+T+1+S:?#T$M\HDEUA+,?Z.L]FS%+>15R HYKW1C*LD_V+%M-&T:6K7L8N?,
M*D_:)Q!(&#POE FX$ )C.*4LNA!<T:M1R6UU%K7R7D/ZW+_GW#[Y?YG\Q'BC
M]G?XH_&I/CM>?LM_#OQO\%_@K>-I^M:E\.?$DUY!9ZMK4-X;C6;G1+">1HTS
MAWM[:*(*Y8(!T%>MZ)^RY9>,/V>/'GQ<^%/@CQWH?[2O@>QT76/"6BZ];2:-
M!J.O^'@JRV.FZ8B@7$ET\9?<JC>A+EB:_HGFD200DQ64K*-]U-:6$5FJW"C,
M;O;QHJS!6&2I4AAUJ*,W<ER+RUN;*RODP(M7M=.AAEC(X7S;14"%5X+R,O0%
MCQ6?U63WG*ST^%=?5"^MR_Y]P^^7^9_,/XZ_9+^+VC_#WX"?M!?$+P=XDU"Z
M^(<WB&3X]^%=%234M6T+6M?$5L%FL2#)!-%Y;2Q *<!E((K[-_9N_9?T#P/\
M5KB]\'^ -4U/X>_\*]U:XT?5_'%@T]]8>(-7@9XH$-R&:UN(G?\ U4:J$Q@8
MXK]J#/.MQ+<RVHU"\8E+E[]X&LKN0\&]M+!B8P^?G3:@YZ&I'D=%G$JPW!>(
M,3:6J1NA/_/98UV[QC##@?AFM?[+I_\ /VK_ .2A];E_S[C]\O\ ,_GCTGX-
M?$7X5?$/]EWXC>+_ ('3^,=%\.>)_$_AKQI:0:8FH7MEI_B35KR.UU2:*17%
MN@M[H2Q2;L!%S@8JU\/O@'?^*O\ @HUXK^ ^FWXU/]GSP)#<_$[POJ=GJ+7<
M?A?QIXB0PIIMU%'B&VGTR2595CY*R)@8QFOZ";V![C3)=.:\:&TOK%UE2"*%
MI)995D2&,J^&A:)B2)AALG(/''B'P1_9S\ ? *U\9OX3%\WB[XBZL^N>*/%&
MI7:ZG)\TAEBTZVG9G>!U?YS$& 5/EP*S>#<&XJ<G%:)N*;MZA];E_P ^X??+
M_,_._P#:(^"WQ1^"9^$OB-=9\6_M)V'A?XB_\)!K]M*L\VK:7Y-Z9[>&W=6$
ML=C$D<<"LA(Y QAJ\?\ C'\%_P!H']I;6_BY^V%K7P]ET?4+W4_#&G^%OAY=
MV\D&LR^$M)6 3VZQ(3+,^V$[BW).,YZ5^]0(\F1XI%0WD*VETUS;QR2P,A#?
M;(1(,!Y"@0$]G/>B:^N;EHIHTDTN2U4)'#:RPL+TJ-N][3.T!LDGY<8)]LU'
M+XU$W.I--.RLDE:WF'UN7_/N'WR_S/YY/%?@'XK_ +3VJ>./BC:_"+6-&\*7
MD?P^\'ZEX7U9)!?7%MX7A6&[U&"UD7/V=FCVF3 SD9!S7,_MY> ?CGXR\>Z;
M\-?#7P?UM/A=X*\,^#+_ ,$7VA6<?DSZC;6]C->Z8CQQY-REQYWF1MCCJW:O
MZ.Y)I1YC+9V]C=W6!J\U@]M%ILG3&R-,()2,%^,EL_B]3'8D"U7[3<Q@;&OS
M;S8R P,;2'@#)V\]..E5_9E/_G[5_P#)0^MR_P"?<?OE_F?@#\)? OC7P_XE
M_:#T36/@'K*ZE\8?!6C/X:\01V:PR6DNFVL=I>QR7D4:21S/<8E9&8$[2V<#
MGE/#/@#XC? .W^+FB^._@=?_ !+UWXR_#/3O!7@#5Y;-M;_X1G5KJ:XB5X+B
M9'-M<6:.LK,I7RQR&R:_HF,S217,JX2\E95NI%^S^9'#M.Y;<CE4.<L%XW#.
M#2&>X$<*E([N"-#]C-TEM+=(O'F&!F!*R#^%EY!SBJAEU.$HR56HW%II>[;0
M'BY-6]G'[Y?YGX:_!O\ 9!\=Z%!XVT/Q]X L_%6K+^SXWAG3-1UTK>VT=U/
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M+9VWBCXC)#>:5X0U_P )VH%N]IXC6-DMKR01JS$RK(6.<DYKV?\ X8@^-?\
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M<H3M PH7.!T'? +J=8C#.EA.EJ@VPV^F0P&(E<;\H@((P3NZDY.>:/[+I_\
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MZ/I<D11X(&\P,4VGY3@-7]3:2R">::ZD-[YX!,<<$4<4-OR"N6  C!V@I_\
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M,9M<8QCRY,8],;NGM0?/)#$VI8# 8QR$@>@);('L#BOF/_A37Q3_ .BVZO\
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MB!"X!;IN(!P6QQN//O7S)_PIGXI?]%LU?W_T&#K_ -\T?\*:^*?_ $6W5_\
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MV-O^B[2<D>5)C/KC=C-?,G_"FOBE_P!%MU?_ , 8/_B:/^%-?%/_ *+;J_\
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M\K+Y?./WGTYB;_IU_P"_4G_Q5&)O^G7_ +]2?_%5\Q+\%?B]([R1?&RY-I;
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MLR'R/-:,*-RG_5[^O%?E[H?BSXK_ +</_!2/X\_"JQ^/ES\"/#?[-SQQ^%_
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M4?[5/P"_X)6?%;X@_%""YN_B]\-M4N_#?AWQ!$PU"_;3[X/]FU*?4H@RO+9
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MX:TKPWXOO+LSWGA)/$R1R7>I/*69[6&1Y1=QRLRJHCZCK71?L:_#KQ#\,O\
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M.!6==:#^W<WQ._:?^#</[8&KD?"KX3Z=\5M.UH23B1KR[LEO)8I(BV^.,,2
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M\YYP/%/_  1D_9"\;>()_%OB"Y\6ZSJ&JZ3::%KM]]ODAN_%<MF5,=_K/F.
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M/>_#OPW:Z@9;G1+CP_JD;17MC<!@T5O+&KM&GFE3(?F7(P:\G\.?\$J_V?/
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MI#&EQ/;FWMO,A0/#<3.)BX;[HWY/TS^.>N']4RS^6/W1_P Q^UQ7\S_K^O\
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M"O#GCX?$FTMGD022>([V[EO(C<)*5S 9)IC*IR2,8SUKU#XU_M3^#/@[\?\
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MCU]K7PMKMQXJ\.3R7#@V.K7D<OG*%)RJ,[-NZ#!YXKJ[;_@FU^SS;_#3Q?\
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M<C'&/O8S@]N?6I'DE<-LO8?*P<PA I8<95>."V?\]*RGA%B)>T>NBCTVC?\
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M@HP/#9&*^Z-K%G$B0>4N3 <CENH(Z9YIKF>0I+-(%$0\O'(50O  [8]@03U
MKF^J97_*O7EC_F'M,5W?X?Y_TSXRL_V$/@7;W/QJN3::E-'^THUXGQ4T^:[!
M@DEGB"/<V0W8B+!5*+P ?>N2\?\ _!-_]GOXA? GP1\#=1CUK3XOAD\A^&'B
MC3KTP^-=!:0F)X[?6$97BL?LS/M@$@Q(%8#C-??S6NS#1B.02@2$D]"<#&,C
MTSSVQWII_P!'&\P(S](=O)60_P 1[8"Y&?7MCFL9X7*^:6D=^JCV'[7%=W]Z
M_P _Z^1^=%A_P2O_ &7]%^%6A_"2.'6;VQT_Q9IGC;4/$]]=M<^)]8\1Z;,E
MQ&=9O"S37%NTZ9)<D'/)Z5Z]_P ,5?!F/QO\3O'BVUXWB'XL^!;;X>>+F\W*
M'P[:6XM8?*;=@N(L9VG.?KQ]<8%N%=E\R>]S%(X',:GN>>V._<\T>1[_ *__
M %JZ*%#+(1:Y8N[OLNBMT_,I5JB_BO7IJGI\Y'R'+^Q!\#+[]F>W_8VNM-?_
M (4;:27'VJ!\MJ,]S>2M<F2*7J-LSY5AG:P]J^??AQ_P1Y_8[^'TWBLZCI?B
M#Q;_ &QX>F\&:+-XMU)]3D\+:;>VGV6-_#322/\ 8PD1!?R]H5Q\V!FOT^HW
M(X9'C#-%CR#CDEAN./4!N/ZUK.AEDU;EBK-=$4JR?RU6V_R;U/R,\ ?\$7?V
M4?AQ)8:AX=\5^/K7Q?X=CU'3M UVTU&6'5=+L[F8R3"&X)&^)&D A7)!"_*.
M*[WP3_P2-_8^\+^#OB;X1\0IJ?BW4?C!.M]XB\3>)7-YXKN=2MI&N++4+6^.
M[[(UE,QDQN7S#@#)YK]-3<#RQ&2L-R3S(R9*XZ#/8=!CC/K4%O)Y4X:XDAN)
M&R YB&T$X_(]"!C/U-8_4\KE[O*M59^['MZ[F#S',HSC"A*2BW;1M?UI_3/S
MB\._\$M/@=H?PMF^&?B;Q_\ $CQCX)GUJ+6]-T_Q3JS7\6E3:>P-JEA"7:2/
MRB%, P.@XK=\0?\ !+K]F37M)\?Z+JMGJDEOX_U7PUJ'B*]6Y#2&+1(+4Z8\
M2*3ND!M4\X*"5(^89Q7Z)&>=9V^T26TZ.C;$6(;E)4C(/4$'!'/RD9[8JKQQ
M_P#K_KZ?U_%?V7E7\B^Y?YG5#'8F*7UEM^MWW?JNVY\FZ_\ L-_ ?QCXP;QW
MXKTU]5U6U^&]O\)H]/OR)M-G\)+:BVMIFA((-X( &=@"1)G->=_LT?\ !.KX
M5?LG^+;_ ,2_#KQGX\NM%O+JXNK7P9K&L"X\.V N&+/'86C2'R+<9Q'$!\@
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M[^V%J7PYU[XP07]SJWPLUVSUGP?>0*DMU9QV;I)%H[,5+C2%V*IA)\QU^42
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MN+E9 8;1(3#)! C2";RG9U$@5@*\<^'G_!)SX'_#+P]X^\#:3\3/B#J7P_\
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M_P# :-T7I)_G_@-%EV7W(:;2LFTNR=AHXZ<9ZXXS2YYSQGUP/K2[HO23_/\
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M=E]R_P BE*2V;7HVB,HK!05!"?=! (7Z>E*0""" 0W4'H?KZT_=%Z2?Y_P"
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M/_ Z;_XO_/;H<:Q>*>MK6_DA9=];=?,B#P\;VD]7=^_?R*K26AD,C7^EW+=
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M\P?ENHR.*7_AB'X5_P#0T^+??.H7!^N3OZXQS^/.>'#]B3X5@ ?\)3XOZ?\
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M*_\ H:?%_P#X'3?_ !?\_P"9%3&%>.JB]=?@>[U_5FOM*&W-_P"3(J^=;?\
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M.O%'+B/Y7_X _P#,?-A^_P#Y-_P2MYUM_P!!32?_  *@_P#CGI_A[T>=;?\
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M;?\ 04TG_P "H/\ XY2>=;?]!32/_ N#_P"+]?\ 'VJU_P ,2?"O_H:?%_\
MX'3?_%_Y[]1D_P"&)/A7_P!#3XO_ / Z;C_Q_P#STZ\4<N(_E?\ X Q\V'[_
M /DW_!*WG6W_ $%-)_\  J#_ ..>G^'O1YUM_P!!32/_  +@_P#BZL_\,2?"
MO_H:?%__ ('3?_%_YZ],D'_#$GPK_P"AH\7_ /@=-_\ %_Y_$9.7$?RO_P
M8N;#]_\ R8J^=;?]!32/_ N#_P"+]?\ 'VI?.MO^@II'_@7!_P#%_7_)XL_\
M,2?"O_H:?%__ ('3<_\ C_\ GIUXH_X8D^%?_0T>+_\ P.F_^+_S^!P<N(_E
M?_@#_P Q\V'[_P#DW_!*WG6W_04TC_P+@]?]_P!/UX]Z/.MO^@II/_@5!_\
M'*L_\,2?"O\ Z&GQ?_X'3?\ Q?\ GKTYH_X8D^%?_0T^+_\ P.F_^+_SWZC)
MRXC^5_\ @#%S8?O_ .3%7SK;_H*:1_X%P?\ Q?K_ (^U+YUM_P!!32?_  *@
M_P#CGI_A[U9_X8D^%?\ T-/B_P#\#IN/_'_\].O%'_#$GPK_ .AI\7_^!TW_
M ,7_ )Z],T<N(_E?_@#'S8?O_P"3?\$K>=;?]!32/_ N#_XND\ZV_P"@II'_
M (%P?_%^O^/M5K_AB3X5_P#0T>+_ /P.F_\ B_\ /XC)_P ,2?"O_H:?%_\
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.';=-7;>KW"BBBI-C_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>form10-k_009.jpg
<TEXT>
begin 644 form10-k_009.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $; DT# 2(  A$! Q$!_\0
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 83B.?S;5X]TL*[Y2V?*('78>N<=
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MGK3J@R?4_F:7S0N 02<9SGW-3&HI-I)Z=>GW]P)J*!R ?6BM "BBB@ HHHH
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MEN55I$5U'WGB+ ,J'J,@]>.N!0!K)+'(BR(P9'&589P1G&1D9_2G;U]?T/\
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M4)'$F?NA5Q\HX],4 :-%%% !1110 4444 %4;H9X]<C\UY_^O5ZJDX!;G_/
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M7]!_A7T'L,/_ ,^*7_@,?_D3P'SW_B5-&_M/OZ^0SR3[_F*8\)P.O7U'I_\
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M%!A+XGZ_Y"J,D#_/2OT>_P""6_S?&'4@>@0=/H:_.)/O#\?Y&OT=_P""6O\
MR6+4_P#<'\C7Q'B5_P D5F/_ '$_]-2/M. _^1]A_P#%#_TL_I(;H?H?Y5&G
M4_3^HJ1NA^A_E4:=3]/ZBOX$H_QJW^*7_I3/ZVC\2_Z]1_0NT445U&H4444
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M%=BLL@3_ $KY!@#"\'/3M]?IBOR<_P""H%]X9LO!O@'4'\,^)M=UVU\?Z,+
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M_C]TW_L)V/\ Z4I5+^'7_P"O7_MR)EM\_P!&?[5/_!(;_E'/^S/_ -B+IO\
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M[=OC/Q]X T?P#XD\,^-]-\+:,GBVS77+:XO%MC?Z>'C,EM#NYDFD4E55>3G
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M[OE>MI+FW=E*Z/YSQ7B9FD,96I4D^6,Y1T71.VO;9;;^9_0?_P /3O@Q_P!
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M4 %59OO?Y]!5JJLWWO\ /H* /Y(O^#PS_E'[X/\ ^Q_B_P#14=?Y=U?ZB/\
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MGZ?U%?P'1_C5O\4O_2F?UO'XE_UZC^A=HHHKJ-0HHHH **** "BBB@ HHHH
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M:_[&5?\ T%J_%*@ HHHH **** 'Q_?'T;_T$U_2-_P &MG_*3[P7_P!@:?\
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M^?05:JK-][_/H* /Y(O^#PS_ )1^^#_^Q_B_]%1U_EW5_J(_\'AG_*/WP?\
M]C_%_P"BHZ_R[J "BBB@ HHHH *U](_X_=-_["=C_P"E*5D5KZ1_Q^Z;_P!A
M.Q_]*4JE_#K_ /7K_P!N1,MOG^C/]JG_ ()#?\HY_P!F?_L1=-_]$15^CMY_
MJ)_^N$O_ * U?G%_P2&_Y1S_ +,__8BZ;_Z(BK]';S_43_\ 7"7_ - :N6&V
M6_\ 853_ #B1BO\ <L3_ ->Y?H?R>?M<?\G"^,O^NT__ *&U?.:?ZUO^V?\
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MGL:JH#OZ?QC_ -FH _QO_P#@X0_Y2K?M-?\ 8RK_ .@M7XI5^UO_  <(<_\
M!5;]IK'./$JYQVRK8SZ9]Z_%*@ HHHH **** 'Q_?'T;_P!!-?TC?\&MG_*3
M[P7_ -@:?_T)Z_FYC^^/HW_H)K^D;_@UMX_X*>^"R>!_8TXR>!G+\<]_;K50
M^-_X?\P/]:2;[Y^@KXM_;I*_\*$\3C//E2'&/1"/_K]>_;I7VE-]\_05\4?M
MSDM\"/%.!D"*7D?[F#^H->[P+#GXYR/_ +#:"7G>2^_;SW/G.*JL:638ER3:
M<)+17M[DGKY;+H?RSJ" ?=Y.O/\ RT;N#C_'.>*D0@$Y/;C^O]*:,D8'9I.
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MDD=,#YCS^%9KQWL]QY4<=U#:$$NQ;IW(!/?.<@\]J_',ZO\ \%E,<:?\(/\
MP"4?^S'^549]4_X+-$X6S^$07*DJ+,<C<"W\6<$9Z'ZT ?FA_P '?ZO)_P $
M\O!4D $ENOCV/=),=LPXC PIY).#^G8\_P"8$%AP,$D8'+ 9]^QZ'('/3%?Z
MB'_!4+_@G-_P5-_X*A_"'3OA%\0-6^%WA'2-(U.+4[86%HR0R7"% 92J."69
M5"DAA@="#BOP(?\ X,UOVW&;)^+?PZ8D+DF)\YVC/_+;MT_"@#^.;;%_D?\
MV-&V+_(_^QK^Q?\ X@U?VV_^BM?#K_OU)_\ 'J/^(-7]MO\ Z*U\.O\ OU)_
M\>H _CHVQ?Y'_P!C1MB_R/\ [&O[%_\ B#4_;;/'_"V_AT/^V<@_7SJ7_B#1
M_;;_ .BN?#G_ +YE_P#CU '\<^V+_(_^QK8T]8Q?:-Y(#/\ VC8[D88#-]JC
M('NO8_7WK^P#_B#1_;;_ .BN?#G_ +YE_P#CU6;?_@S;_;=@)GD^+_P\\ZS>
M.:Q2&.0AS$ZR*),S$!MX]^<9!'5N2C2K7_D^?Q=%>[WV6O4#^X?_ (),F[E_
MX)S_ +-/V.W_ +.F'@S3$<1@XG7[.A:4CK\P^7T^45^CMV\48>W"R33_ &4M
M+)@[6W97&<8SN)/K@"OP"_9C^$/_  5W_9>^!WP\^"NB/\(]<TKP)X=AT>WO
M+BS#NWV?Y$W<YR456.>F?>O;X=2_X+'7D9$UC\(("SL6=;)0_ELK!0/F)PIP
M1CD$5ST^7_A,YW%16(C=NZ2WLW9723MMK;H<^*IRJX:M3A\4X.*7?R^>Q^:?
M[8(,7[0_Q"#1,I?4FRP!)')]/\\U\VLP\M<F;&/0YZ]_7'';W]J^L?B=_P $
M[/\ @JG\4O'6K^-]4\2?"FSN-5E,TD:VJ LQYRPR.F:X<_\ !*__ (*B<#_A
M,/A:0.@%JA'\C_GGWK^Q,M\4LCP>597ESQ%&]##TX3E[2%HN,(IJ_-H[I[V=
MGW/Y[S;P_P PQ6;5L4J=3WY2:=I6]YO3W?O^9X=D>LG_ 'RWK]/3Z^O'0KYS
MJ-H\\@=,*1[^A]3W/0?A[A_PZS_X*D?]#1\+?PMH_7\>WZ]Z/^'6?_!4C_H:
M?A;_ . L?OV_+OZUZ7_$7<@_Z"*'_@<.G_;U]3R?^(:9Q?2G5_\  9__ ")X
MB+B0(<>>>3_">>!C''?WS_C5:XDW'_7D>H4]<XX]L<U[S_PZU_X*D@8'BGX6
MXSG_ (]U]!V&,?K44O\ P2T_X*DX&/%'PL'/:W4<?7(]^W7';-/_ (B[D.WU
MFA_X,C_\F8R\-<YN_P!U5W_EG_\ (GAD<C3.D;?:%5V4$[2<#/; Y/ _.OTI
M_P""7QN5^-NMI8VI#+;GS)9E(! 7&1GJ<'G'4U\A'_@EE_P5/8J(_%WPMA?>
MNV;R$^3D9/S$CID?G^/T+\!OV+?^"L?[//BZ_P#$^DZ[\*-::Y@"A3;*<' !
M'RXSSGC].U?(\<>(^2YSP[BL'1Q%&56HIVBIQ;LX-)M*3;5WK\]CVN&>!LXR
MS.\/BJE&I[."BY-QEHU.^[6]E^"/Z;X3-&A,O[SOD').2> /K2_:,\B%SGU'
M/\C7XO2:Q_P6.4$)I_PC XP/L6<'V.>_M]#BA=9_X+($#_B7_"3\;$$_^A5_
M+D%:$FM82JR<7?O=Z:MV>_X=S^B80Y>1OXE3C%KMHKW^?XW/V?:2=CF*&8+C
M!V' SWXRO.,=OQIN^[_YY7'_ 'U_]E7XQ?VQ_P %DCTT_P"$./>Q /\ Z%1_
M:_\ P63_ .@?\(/_  "'_P 73-3]G=]W_P \KC_OK_[*C?=_\\KC_OK_ .RK
M\8O[7_X+)_\ 0/\ A!_X!#_XNC^U_P#@LG_T#_A!_P" 0_\ BZ /V=WW?_/*
MX_[Z_P#LJ-]W_P \KC_OK_[*OQB_M?\ X+)_] _X0?\ @$/_ (NC^U_^"R?_
M $#_ (0?^ 0_^+H _9W?=_\ /*X_[Z_^RHWW?_/*X_[Z_P#LJ_&+^U_^"R?_
M $#_ (0?^ 0_^+H_M?\ X+)_] _X0?\ @$/_ (N@#]G=]W_SRN/^^O\ [*C?
M=_\ /*X_[Z_^RK\8O[7_ ."R?_0/^$'_ (!#_P"+H_M?_@LG_P! _P"$'_@$
M/_BZ /V=WW?_ #RN/^^O_LJ-]W_SRN/^^O\ [*OQB_M?_@LG_P! _P"$'_@$
M/_BZ/[7_ ."R?_0/^$'_ (!#_P"+H _9F66\C1B+9I&<&--YRZ.1PV,D[!D<
M^HJOI]O=VF%O;QY[C=)-%'SL(92!&QQP.V.QY[5^-<FK?\%EBO[O3?@]NZ>8
M;,9 X.W&XC'<'L2:G@U7_@L=]FG#6/P?:=EC3<UF-Z;W"EX_FX9<Y&,X'.,4
M ?YMO_!PJI'_  5>_:=DDC6VDGU^Q,D41RC Q2$EQS\QP#Z=#CBOQ2VQ?Y'_
M -C7]X7[:?\ P;!?\% /VU/VC/B!^T-XL^)'PXTG7?'%W#=:C;)$XW2HC%3Q
M*@.Q7VG"D#CIDY^5/^(-7]MO_HK7PZ_[]2?_ !Z@#^.C;%_D?_8T;8O\C_[&
MO[&/^(-']MO_ **Y\.?^^9?_ (]1_P 0:/[;?_17/AS_ -\R_P#QZ@#^.?;%
M_D?_ &-&V+_(_P#L:_L8_P"(-']MO_HKGPY_[YE_^/4?\0:/[;?_ $5SX<_]
M\R__ !Z@#^.N)(#(@?=MSSM7)]L#'KC/M7]&W_!L'Y$7_!3/P29)V:,6[!4&
M2S$DG))],[2?]GM7W O_  9J?MNHRNGQ=^'*LI!!"2$CL>LX'3/^!Z5]T?L
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MS(68L?.!)R1Y;=_\]..WX>Z#_@EG_P %1QT\9?"X'U^RIV_#UY^M!_X);_\
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M)'^[FO@;]N[]L2X_9#\-^ ]0TOPXOBK7_B+XE7POHVFSR".-;PJ&$\\DAVI
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M]SJ,'  W$Y ZBO<--G=PD4;/.L9='E/0%7(.\'D'(Q^53SP[?C_]N/GEY?\
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M*),G?,Q'; 7_  %>&6OQ[^$5]HJ>(--^)'AZ_P!)DU)M&6ZAOXG!U<-Y8TX
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MYQTZ&NLT+P[I7@G1(-$T'0K72=#TB!(;.VTZ"*"21$PJ%A&HR0>IP2>.3P*
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MI<=TBS"[:.0;SAD&T$9X.W@X]L9!IPMS;Q6\5C +:V")&UO&B1Q0(@RI55
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M50RR',B,1DJY/)93D9ZXQ7XR77QMO=)_;=\4^$?%_@*)_BUX<_9QE\:W.O:
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M>*J#3S$8?LCK B2[I(@"4>(]4 [$GGG(R?84 ?QE?\$N_P#@V-\>_L$_M>>
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M+[)L[<JR?"Y-A5"C43E*T91L]$M5TM^I^ _BW]AW]M?P-^TI^T3\0OV>=?\
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EBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>form10-k_010.jpg
<TEXT>
begin 644 form10-k_010.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" '2 ;(# 2(  A$! Q$!_\0
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M'/2]/L(K6$:_=F,(JHJ*)R-BJ@"HN.,*!Q7ZI.TMJ^.6!.,9+'.<X^G;_.*
M-RBHH7,D:N1@GMZ>Q^E2T %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4Q5VGKQZ8QU_&GT4 1-$"&V81F(RP R0#G&
M?<<?3CI4;VZR8+K&S1MNA8K]QN['GDG_ !]:LT4 0-$QW,"GF[0%<J3MR &
M&> ?QJC>6R0:5J21_+OLKQF/J[02?-Z\>F:U:I:E_P @Z_\ ^O*Z_P#1$E '
MY7?L"A&^*_QZR9#)%XBNHMV[@AI\$@=CW'I7ZK.(UP&3=M 7.>3QU/3GBORH
M_8#_ .2L_M ?]C/<_P#I0:_5:;J?J/Y4 2H.N.!TQ^7/8?I4E,3H?K_04^@
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M; )QD@<X!X&: /R[_8)^S1?%S]H"-(XXH9?$UQY$4:A53]_G  QW]/:OU52
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M_P"O^M.H ^2?VZT0?L??M(,$4%OA9XE+$ 98K9-M)]2.Q[5_A[?$T!?B)XW
M&!_PE&M<#I_Q_P Y_J?SK_<-_;J0M^Q]^T<!CGX5^)^OM9'V/K7^'K\4$*_$
M;QR#CY?%&LYQ[W\V,<4 <'10.2!ZT'@D>E !1110!(G&2.NV3_T$?XU_I,_\
M&9("?LP?&8( HD\6%I O&]A*H#-ZD D GH*_S9DZ'_=D_P#017^DU_P9E_\
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M=_\ 8T:O_P"ETU?[A7[<W_)G_P"T;_V2OQ1_Z0U_AZ_%/_DH_CO_ +&C5_\
MTNFH X!>H^H_G0W4_4_SH7J/J/YT-U/U/\Z $HHHH D3H?\ =D_]!%?Z37_!
MF7_R;#\8_P#L:C_Z-6O\V5.A_P!V3_T$5_I-?\&9?_)L/QC_ .QJ/_HU: /[
M6J*** "BBB@ HHHH **** "BBB@ HHHH **** *T\C1J[JK.0!A >3G X^F<
M_A4<<Y/[HO"TQ!)C$Z>8H/\ L@$\<_3%+>^8MI>/$0L@M;@Q-_=D$+;&_!@#
M7^63_P %=O\ @KI^WK\#OV[OB9X%^'/QS\0^%O#_ (:UBZM8+"RED:'8)R
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M8\\_.  !P>G?U[U^JT0Q@9SA0,^N,<_C0!<4$#GU_P *=110!\H_MS?\F?\
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M@ HHHH **** *U[_ ,>=W_U[3_\ HIZ_QH?^"[7_ "DH^.G_ &,-Q_Z.>O\
M9>O?^/.[_P"O:?\ ]%/7^-#_ ,%VO^4E'QT_[&&X_P#1ST ?CE+_ *U_]XU'
M4DO^M?\ WC4= !1110 J]1]1_.OZ[O\ @SY_Y/\ _%W_ &)EW_Z!<5_(BO4?
M4?SK^N[_ (,^?^3_ /Q=_P!B9=_^@7% '^H0.GXM_,TM(.GXM_,TM !1110
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M?WI.._[[KD_C7ZK2<@'UV_\ H-?C7_P2_P#B?I?Q5\7?'+6M,T6]T9FU^?\
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M-1T %%%% "KU'U'\Z_KN_P"#/G_D_P#\7?\ 8F7?_H%Q7\B*]1]1_.OZ[_\
M@SX _P"&_O&!]/!EUC_OFXH _P!0<=/Q;^9I:;N ZGN?7U-&Y3W_ $/^% #J
M*0DXX&3_ )ZTS]X&R?NXY''Y_E[T 245&9.5 !Y.#QTY'O4E !1110 4444
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MSQBO:4BB()CW;CDG.<9SSU''-9UXDRVFH^9MV_V=>A2.N?)<D$>PQ0!^77[
MRV\'Q/\ COIMG8V=G;'Q'<,%LH5@01K/P JJ,#CH/T'(_5F4!%4(.@5>N#M
MXY[Y[^O>ORG_ &!O^2O?'3_L.7?_ */-?JQ+T'_ ?_0: )XR2O/!!/\ C[^M
M/IB=#]?Z"GT ?*/[<W_)G_[1O_9*_%'_ *0U_AZ_%/\ Y*/X[_[&C5__ $NF
MK_<*_;F_Y,__ &C?^R5^*/\ TAK_  ]?BG_R4?QW_P!C1J__ *734 < O4?4
M?SH;J?J?YT+U'U'\Z&ZGZG^= "4444 2)T/^[)_Z"*_TFO\ @S+_ .38?C'_
M -C4?_1JU_FRIT/^[)_Z"*_TFO\ @S+_ .38?C'_ -C4?_1JT ?VM4U?XO\
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M?^CGK_9>O?\ CSN_^O:?_P!%/7^-#_P7:_Y24?'3_L8;C_T<] 'XY2_ZU_\
M>-1U)+_K7_WC4= !1110 J]1]1_.OZ[O^#/G_D__ ,7?]B9=_P#H%Q7\B*]1
M]1_.OZ[_ /@SX _X;^\8'T\&76/^^;B@#_4!:/<<\]^X]3ZT@AP1UZCN*G'3
M\6_F:6@!FP>I_3_"J\D&Z0'!P ,$ 9SGU[=:MT4 ,1=H]^/TZ4^BB@ HHHH
M**** "BBB@ HHHH **** "BBB@!&W8.W!/;.<?I6>;%7D^TR;FF R IQSG@=
M@/?Z^W.C10!F&T)F^V.I:3&SR%/RA,D9ZX+8P3G(]/9-34#2M1^0*O\ 9UX
MN,'YK=\@@<=16I6?JW_(+U'_ *\;O_T0] 'Y:?L(.K_%3XVQQJ83'KUXCL O
MWVFPHXY^]]?TK]4C\@ 8Y( !/J<=?QZU^57[!G_)6/CM_P!C-/\ ^E)K]59N
MI^H_E0!*@.2>V,?CQ4E,3H?K_04^@#Y1_;F_Y,__ &C?^R5^*/\ TAK_  ]?
MBG_R4?QW_P!C1J__ *735_N%?MS?\F?_ +1O_9*_%'_I#7^'K\4_^2C^._\
ML:-7_P#2Z:@#@%ZCZC^=#=3]3_.A>H^H_G0W4_4_SH 2BBB@"1.A_P!V3_T$
M5_I-?\&9?_)L/QC_ .QJ/_HU:_S94Z'_ '9/_017^DU_P9E_\FP_&/\ [&H_
M^C5H _M:HHHH **** "BBB@ HHHH **** "BBB@ HHHH K7O_'G=_P#7M/\
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M !&)'0G;Q],VA_2@?\%+8!G/P ^(YSUSM/\ .T/'MTH _3@DPPAH)8A"H 3
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MP,\Y/KT_S^$_U:_]=%_]"%?Z"?\ P99_\B[^T'_U^Q?^RT ?W=Q^%?#" %=
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M*** +"?ZM?\ KHO_ *$*_P!!/_@RS_Y%W]H/_K]B_P#9:_S[$_U:_P#71?\
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M&O\ #U^*?_)1_'?_ &-&K_\ I=-0!P"]1]1_.ANI^I_G0O4?4?SH;J?J?YT
M)1110!83_5K_ -=%_P#0A7^@G_P99_\ (N_M!_\ 7[%_[+7^?8G^K7_KHO\
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M]Z /U2T?_D$Z7_V#K+_TFBK1K,THLNE:7PI TZR#'/I;Q#CV]*T2WL3[@9%
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M@/ZH* / _P#AXS^SU_S_ &L_^"Z;_P"-T?\ #QG]GK_G^UG_ ,%TW_QNO?\
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M<QB1EF0<(PS@CKG//I_&/XR^ '_!1;]L?]H_]GW4O&/P,N/A-\>/@KXOT_\
MX6-\:[TL^G^.?"%A>K]M@MW)\D--9*I4JQ)/2O[*])TU;#3[?29)PTUOIVG*
M2,LLD]O $N) >0 [\XR.N: .HB"NH90JY)XVJ3Z9_&I@O'(!/T'^ JM:1[$'
M(R1Z^F.?I5H$'I0 QX]ZLN=H92O &0",'!]:K1V4<4+11G#,#F5E#,3[Y_E5
MVB@"*%&C0*S!R.I"A<^^!4I&01ZC%%% $7DKZO\ ]]M_C1Y*^K_]]M_C4M%
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M 9?&X8Y[]/6HXK)8HW7!)8>H)ZYX/7' XJZH(SEBV3D9[>W4TXY[''/YCTH
MAAB\L>X&!]./?^F:FHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
/ **** "BBB@ HHHH __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>form10-k_022.jpg
<TEXT>
begin 644 form10-k_022.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" &_ [8# 2(  A$! Q$!_\0
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M<Q",2DG:5W@;3OVXSRF-^<?P[<]L9H GHJJU[ HA)+XG?9&1&YRVUF^; ^0
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MX])FBD6"UN7TZ5;62>2%GC(:,AR6^:-)^&W[6?P[\&Z1\/O#_ACQK>)K>G?
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M/S7#7-['):O;"0"ZF-V6CO)+IF$3F*W^:,6 BCC$4JN"THD4H, D ZNBBB@
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M>&+A;(IK.EH8+CSL7,K%@@5U*2F,X?<6W#KP!T;-?G)Y,'_/&#_OXE'DP?\
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MS*Q.T8)/4GECD7=_A_D'._+^OF?HXGC+PK)"C66O::MO,N#%>2'$498DI;E
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M]_?_ *U?E[Y,'_/&#_OXE'DP?\\8/^_B4<B[O\/\@YWV7X_YGZA?\+ \'?\
M0?L/^_O_ -:C_A8'@[_H/V'_ ']_^M7Y>^3!_P \8/\ OXE'DP?\\8/^_B4<
MB[O\/\@YWV7X_P"9^H7_  L#P=_T'[#_ +^__6H_X6!X._Z#]A_W]_\ K5^7
MODP?\\8/^_B4>3!_SQ@_[^)1R+N_P_R#G?9?C_F?J%_PL#P=_P!!^P_[^_\
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M_B4<B[O\/\@YWV7X_P"9^H7_  L#P=_T'[#_ +^__6H_X6!X._Z#]A_W]_\
MK5^7ODP?\\8/^_B4>3!_SQ@_[^)1R+N_P_R#G?9?C_F?J%_PL#P=_P!!^P_[
M^_\ UJ/^%@>#O^@_8?\ ?W_ZU?E[Y,'_ #Q@_P"_B4>3!_SQ@_[^)1R+N_P_
MR#G?9?C_ )GZA?\ "P/!W_0?L/\ O[_]:C_A8'@[_H/V'_?W_P"M7Y>^3!_S
MQ@_[^)1Y,'_/&#_OXE'(N[_#_(.=]E^/^9^H7_"P/!W_ $'[#_O[_P#6H_X6
M!X._Z#]A_P!_?_K5^7ODP?\ /&#_ +^)1Y,'_/&#_OXE'(N[_#_(.=]E^/\
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MY,'_ #Q@_P"_B4>3!_SQ@_[^)1R+N_P_R#G?9?C_ )GZA?\ "P/!W_0?L/\
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M_(.=]E^/^9^H7_"P/!W_ $'[#_O[_P#6H_X6!X._Z#]A_P!_?_K5^7ODP?\
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ME$*QL96CDE5 #S'&I=V)QA<*"<$\XP,GBJ)(_+3^Z*/+3^Z*56+()%5BA1Y
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M&LK>"U22=+6[\-^(I)Y(R[.PED@T?RF9W;=(JL 7)*J!T .2_8M\9_$SQ_\
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M[HIS$JKN5.V.*2=SUVQ1,$D; R259@"HR3G@9XI5#.0JJ23MP#Q][&.O0G/
M/;)],@6?9_<,\M/[HIHQB==D6 BG/EIDG@]<=SD^QP1TJPD<DC2*BC=$EP\B
MEU4A;5-\Y 8@ML7D!<ENB@FJJ,'69U.5:)&4],AE!!P>1P>] C[]^ "*/ EJ
MX4 M*V<  ?=0]!C'45[E7B'P!_Y$*S_ZZM_Z+BKV^L9_$_E^1M#;^O(****D
MH*^-/VDC#)K/AF*9F6>S@GEAE QO9IY<(,_[V#SG/;I7V77QC^TG$9-8\.Q1
MKY0B#RO>OE@JF5RR?-N4CGC/3CI0!\@W_C+PAH^HV^F:_P"*_"^DZK,@D71-
M9N;*.YO&N7>"!;5;BYB99C,/OK'(Q  QTKK5MGC1;1H+Z'49D%Y;0R2M)I<]
MI(%DB=)?+6(1LC+M^8@(0.F37XZ_M"?LY_%CXZ?MH^.(?#]M)H7@*3X>^&;N
M+QQ<ZE?(=+O=&\2:MJL__"/6/ER64VH7\,,5G)&9;;;'(A$F3@>.ZS\:/VUK
M+Q!X\\&^#+;Q^F@:3HQ\%^%=6UKPY97&HVU[90W&G+XAMOM+W1NX)&BBNDCG
MG,6,#:%8BMH?"OG^9C/XG_70_>DVEPX\DQ3AD)<JDF4!.<A %Z9)VD'D'/3F
MD:.\<@V[W4$[AH4 =V:5<#S4!" _+$6)'<9SWK\.?C'\5_VT/ ?C;PWX)\"I
M\1O&$6BZ)X<A\;^*!X3TI+?4-4UG0;/5))(8HYGBA%E+>?9G6!8P6@;>O)S4
MT/QO_P % ?#NIVFH-K/C'Q)J>E1.YT+4O!>AZ?IUS<:@C6JB2^M4EN(S")$=
M%2$AWC"N!N)%!'XE_70_<EV.%OH5FAL[?.D2S74XAC^US8B89D4+G?&>,G]1
M4JPW;S/ ;:Y 2(.K+(Q0@!"K!@I!4YRI[C!&,YK\ M0UK]M'XB_"OXB)XR\5
M>/--FTSXBZ->W.BV7AK3=(N]%L(;[59-:CT6XL)(;C60Z)$$-\\.WRHPNWS6
M%=%HWQ3_ &[VU[XCZ<NL^)TC\.>"]*7P3H$WA?2_^)F[V^B1Q:@VH&-KJ6X6
M"69KB!C)&93("Q*@D-C]V[>"9E+!VBD9VC03R [R &*J#CYL8)P3QW[F7<^1
M;7("2G(#J<%A[$=200>.HY]S^1'PL\1_M4>$_CG\&/"?COQ7XI^)_A7QIX3B
MUWQ==6WA;2=-A\)Z[+_:AFLYI['R6Q&MK:KB1E+>8,@9Y_76YB+O/<V\DK0V
M-[M,]XBPMY"R,&C*(9!N"* 6!W9YSG. QG\3^7Y$(Z?3('T!P*6D!!&1C!)(
MP<C!)(P>XP:6@D**** "BBB@ HHHH **** "D/0_0].OX4M(<X..>,4&L/A^
M;.>N_%W@JRUQ?#>M>,?#FE:C>3V]K?:%'=6D-W;"X@\^"[DQ=!HFD3R@S&('
M,V#R<GH5.H&VMX+B"2 6_P#H<MK,Y*1R(2XNU8A5S(CJF2N?EZD8K^?/]MSP
M/\4M;_:P^)ESX7T'Q]=VFL:!H7_"(+I%M+;6OBB_M+70TGMTOK6ZCGTPPS0W
M,0ELQYCI#O89<K7=R?'+]LV_^('Q+TG1+3QGHOARP\,PM'/J/ARROAH_B+3D
M:>ZT^TFO//>\,MM##%NG977SB_# $A9^Z+HT2>7^X\EAS-O10#C'WLD=^YZ<
M9 .!D:?XB\/:G<?9],\2Z%JNJ O>P+IEQ;2&**R8V,\;F*XE(DCG.R0$9$@(
M(W"OP\NOC#^W#X@U;X9V%N/$/AGP[K>@:'>:B)/"^F7+^(=1:UM9+Y9;BXA,
MNF->32'"6;@0B0^4 $ K@O 6E_M8>#M/L%\':#XT\,76N0^,K:[\1W>BVVL/
M9277C"]NF80ZD\L863:7A(V[8RJA57 H _H69&$I1H[H7'EB6-[EV%G+:,Q5
M!:ET",XD#LVQV8*0<#)(:4,IVSVF%)'SKC'89R%Z9 YSVY]OPY\5_$W]OW2!
M\.]#:Z\5VFBV7B]M!?Q.O@W1+R;7;"."UFDM[F"9/+M(8UFDD6YA<RDL4)PJ
MFOVUT"2_3P[HD6MQS_;)] LKB[NKG_1Y6U![6)YG:&,M&G[YF)1<("0% XH,
M9_$_E^1J !1M'125'T4D#]!2TU,;%P=PVCGUXZ_C3J"0HHHH *#T/7IVZ_A[
MT4'H>W% $BLEMY$C0Z;>->0RV1B8QXB623S SY)P04RV0,M["N"NM!^%5U)J
M5SKGA_P#<2VFJKIVOZA?Q:;>2'6F,(M+60E@R3//+;( S;F9U4+GFNZBDQ.T
M9MDF5%%]J"A%0IIR 0R1HZ+NC>222*02J5D'*AL9-?@_^TE\!?V@-=_:/^(_
MPT^']SXNL_A7XQM3^T%9^)K#4-0E3^WO#4LFLV/A99FES"NL77A.STUH(Y-J
MKJ!94+9R ?M=!X(^%EU=ZK;Q>!/ U[>:= LNJQV^BV<C6UXRR-:6C[-Q4S2)
M)&JG#$K@+P:CE\$_#2TLS-<_#WP=:?9 ;V\EE\/VR".R7*R!B0.%=USG&!U'
M.*_!KP[J'[=/A/PCX(^(5O;>*O!&M?'/Q=JVM>.;6:P77W\,?V'?6MUX1TI;
M;5U>.&VE_M.\@GD18VF2$&192N%]8\0>-OVY_$WQ$\=>%O$S:U8Z'/X'M[71
M] L= T]-)UR>YL],N)9)/$200ZI9SWEQYD[);(WD-(T,9V*N0#]C8/!'PQNK
M"'7;#P'\/KK3[]3<:3=2Z'8F".SN!]GDF9RQ550"1B0PP!UP<B&S\#?"?4_W
M&D>#_AGKPLFWSZCI^CZ=<V[7&GMAK%Y(9)5W(X,90OGL5&37Y]?L&7GQ>O?@
MKXW\$_M'6/B'PKJ7AWP_<:1::&5E==-\.NS_ &>YTK5YG@U#4+^YN)KF M<!
M'C0(ZS%@H7I?^";=M'HO@+XM>#8-.\=Z?'HOQH\;:CIVJ>./M,DNK>'K_P 1
MWLNF0VMW=ZA?7'D"SA58V1E)61<$DC !]U'P#\-6)8_#KP"I8EBO_"/V0PQY
M(Q[$D4G_  @'PU_Z)WX!_P#!!95V1.YF(" %FQ\H;C/&&[\=_6DP?1/^^!0!
MQW_" ?#7_HG?@'_P065'_" ?#7_HG?@'_P $%E78X/HG_? HP?1/^^!0!QQ^
M'_PV/3X=^ ??_BG[(_Y[TG_"OOAN.3\// 1 Y/\ Q3UE798SU"'T_=K2%1@_
M+&/?RUXH-H?#\V<<WPZ^&12.VN_AYX"2>R;SY94\.VGSI(2\:,0?[DBXY]!T
M-5O^$1^%\.HW%A<>#_AO;W\-LE_>V3:+I\<]IHHD(FO)$,FY(U2.<ERBKB-O
MFPN:[)I!);ZT\L:H?]'+ADW%ECC51MR RKC' X]LU^4O_!0GX??&]OB=\/O'
M/P+T_7M>3XM6\GPI\<MH]_?1Q^'/#>HP74+:O]D@;[/"\+ZE*WG*J2KY61(-
MJF@H_2JT\)_!Z>6-=.\(?#[4);@7UQH$<.D6#_VEHUWM9+J+:S>9&EOY3[EW
M+M8<KD&M"W^''PWCFLY3\.O"!C)<HC>'[;%T06\S;N&'\M]R' .-GKP/Y\M!
M\"?MG_#.U^($VAVOC1)?V=)])^%7PW\1W1NM1.O>&H6O=$U_6VL+QY;75"MG
MIEC<BZNQ-)&9"R.A=B?:M2^+O[>T7_"F86UO6[;PS+I^HK?^+8_!NB27%UJM
MUJ4LJVTUD]J+=!%"\T 99-Q\L-@,2  ?LM:>#/A-J@NO[(\%>"M2"7,\?G1:
M':20P7D<2N]A<LF]45%VG8S* '("\C-&#PK\%;R_^R6_A/X22Z[8+9FYTK0]
M(TE]5\XY^V0O!;S/.'M&0JP,8*$_,,]?R^_8RN_VBO"/QQ^('A7XGZ+XMT?X
M.ZOXHU?Q#X9N?L[7TVL:E_8\)99+J[DCFLX)!:H4M[>=HA(6 C&X@Z'P1?P]
MXK_;L\5Z_HW@OXF?#31O#_\ PD46HS:A/J.I:5XL\1ZE)()KVV&I:I+#:QSW
M<#R06UM&D$"SA(D50*#&?Q/Y?D?J,W@'X:EF/_"NO 8RQXD\/V:R#GHX(!#C
M^+(!SG/--_X0#X:_]$[\ _\ @@LJ[-SN=R ,%W/SQKOY8\N,G#GJPR<-D9--
MP?1/^^!02<=_P@'PU_Z)WX!_\$%E1_P@'PU_Z)WX!_\ !!95V.#Z)_WP*,'T
M3_O@4 <=_P (!\-?^B=^ ?\ P065'_" ?#7_ *)WX!_\$%E78X/HG_? HP?1
M/^^!0!QW_" ?#7_HG?@'_P $%E3D^'WPPWB23X?> T$8;:!X?LR':13'@X(X
M7<'Y]![UU^#Z)_WP*,J%<2>6D; (\QB5O*:1A'$<'NTC!1@@^G." J/Q+^NY
MP \*_"6"2ZL[KP-\,(M0CBD2YANM&TV*2UT1T9)]799'#+%;VX>X,K8154L6
M !:IHO!_PGGNETFS\,?#R^;4[$_V/]GT>PE%S8QNB3ZA#LD<21V\X$'F*6 +
MA"PSBOS5_P""@_PV^,5Q\1/A=K?P>CUJ1/BU!=_ ;XD76G7MZ+?P_P"'O$WV
M+PP/$7D1N8;*6TM;^]NUO85CG5H?,63<%-?%OAKPC^VI\-].^(-[H^F^+UU?
MX'1#X8?#G7KAKG5!J/@O7A%KVN>+Y[*],EMJ#Z?K%M'8PO=+,WES!?-16VD-
MC^@I? ?@";SH8?AUX-5S*8I;A_#UJ$8Q[6>568 $[01DMT R1@BJ5CX.^$VK
M+>7&D^!_!5];VDMWIUP;?0K60)J&GL8K]&*[@'$I ;/(X!^8G'XPI\4?V\9-
M>\ Z)J^O>(+?P'K6BI=6_C&W\'Z*KZ_=3/=02Q:F%@1=+W*BJK6CRE6"G .:
M]<_8:NOVCO#OQ4^(G@OXMZ/XET3P3<>*/'6K^$I3 UYI?B6XU.^FEBGN-9NF
MCOK&.<"W?RK99(H1*PC7 &0QG\3^7Y'Z>Z9X7^#>L7<FF:;X=^%M[K-N,R6,
M>C:8\\>W@QR()VD#H2%<%<J>H&<U?/@#X;NOFO\ #KP"KB1H70>'K-0&5=Q.
M,XYR 2!C/'O7YE? /PS?M^VOK/B/P9X2\=^'O 8T+Q#)J]KXQOM2-A<>)[;6
M[2WFO-/GN+Z^D:SD9;QK9-L4<D,B,84V@#]828S/<LLG[UYRTEN(4-O$-B -
M%.<22,2I5@RXQALDT$G(?\(!\-?^B=^ ?_!!94?\(!\-?^B=^ ?_  065=C@
M^B?]\"C!]$_[X% ''?\ " ?#7_HG?@'_ ,$%E1_P@'PU_P"B=^ ?_!!95V.#
MZ)_WP*,'T3_O@4 <=_P@'PU_Z)WX!_\ !!94'X?_  V/W?AWX!]_^*?LS]/Z
MUV.#Z)_WP*,9ZJA]/D7_ .O_ )[B@<?B7K_F<:?A]\-P"?\ A7G@+C_J7K*J
M<WA/X/VXU&V_X13X70:GI%@QU6"]T?3(7L](N72XDU-Q+*I2.%WAA,A"JOF
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M:K]1=L7_ #S_ /('_P!E1MB_YY_^0/\ [*CG?9?C_F+D7=_A_D?EU_8.N_\
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MDT746CG7RKB,6<^%50%5C\OS9V@Y4D\@8QG"0Z%KMG^]M]%U59+=Y%M5%F9
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MMC(HC;RXY&FV%GB+*VPC/ZA[8O\ GG_Y _\ LJ-L7_//_P @?_94<\O+[O\
M@E'Y:QZ%X@DMH53P]<6TXMT$UM=:8LNFQSK*QVVD<<!GB@\O:0-P;>6)'.:L
MRZ-XEFBAC&F7T"Q[S/;III%K(TP'FF!OLYN4Y4\M(.V.U?J#MB_YY_\ D#_[
M*C;%_P \_P#R!_\ 94<[[(EP3=[L_+NXT7Q),L;KI-Z98E-JHFTT(3;.P=\2
M6MO&[+N51F1B[$ G+%C4LVBZ[(^!HU^J*%VK'9W 3=C!89C9^AQ\Q( &.N:_
M3_;%_P \_P#R!_\ 94;8O^>?_D#_ .RHYWV7XBY%W?X'Y=?V#KO_ $!]1_\
M .Y_^-4?V#KO_0'U'_P#N?\ XU7ZB[8O^>?_ ) _^RHVQ?\ //\ \@?_ &5'
M.^R_'_,.1=W^'^1^77]@Z[_T!]1_\ [G_P"-4?V#KO\ T!]1_P# .Y_^-5^H
MNV+_ )Y_^0/_ +*C;%_SS_\ ('_V5'.^R_'_ ##D7=_A_D?EU_8.N_\ 0'U'
M_P  [G_XU1_8.N_] ?4?_ .Y_P#C5?J+MB_YY_\ D#_[*C;%_P \_P#R!_\
M94<[\OZ^8U!)IZZ'Y=?V#KAX.CZCSQ_QYW/_ ,:IL?A[7%V3+INLC?'+_:L$
MUDLCW]HLFT6%D[6Y%O/*NR5)6>-5$;!Y 2 ?U'VQ?\\__('_ -E1MB_YY_\
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M:K]1=L7_ #S_ /('_P!E1MB_YY_^0/\ [*CG?9?C_F'(N[_#_(_+K^P==_Z
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M4>DQYS\_EK;K+; 1M <%B5&[Y=N=M?J)MB_YY_\ D#_[*C;%_P \_P#R!_\
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MWP6^&_P_UN^N+F9+36?%_@WPYJ>E:B]VBZ<%-I)?WLA>4QM(R2$O'NXK]/\
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M_P#:_P"^F_QJ:B@"'R(_]K_OIO\ &CR(_P#:_P"^F_QJ:B@"'R(_]K_OIO\
M&CR(_P#:_P"^F_QJ:B@"'R(_]K_OIO\ &CR(_P#:_P"^F_QJ:B@"'R(_]K_O
MIO\ &CR(_P#:_P"^F_QJ:B@"'R(_]K_OIO\ &CR(_P#:_P"^F_QJ:B@"'R(_
M]K_OIO\ &CR(_P#:_P"^F_QJ:B@"'R(_]K_OIO\ &CR(_P#:_P"^F_QJ:B@"
M'R(_]K_OIO\ &CR(_P#:_P"^F_QJ:B@"'R(_]K_OIO\ &CR(_P#:_P"^F_QJ
M:B@"'R(_]K_OIO\ &CR(_P#:_P"^F_QJ:B@"'R(_]K_OIO\ &CR(_P#:_P"^
MF_QJ:B@"'R(_]K_OIO\ &CR(_P#:_P"^F_QJ:B@"'R(_]K_OIO\ &CR(_P#:
M_P"^F_QJ:B@"'R(_]K_OIO\ &CR(_P#:_P"^F_QJ:B@"'R(_]K_OIO\ &CR(
M_P#:_P"^F_QJ:B@"'R(_]K_OIO\ &CR(_P#:_P"^F_QJ:B@"'R(_]K_OIO\
M&CR(_P#:_P"^F_QJ:B@"'R(_]K_OIO\ &CR(_P#:_P"^F_QJ:B@"'R(_]K_O
MIO\ &CR(_P#:_P"^F_QJ:B@"'R(_]K_OIO\ &CR(_P#:_P"^F_QJ:B@"'R(_
M]K_OIO\ &CR(_P#:_P"^F_QJ:B@"'R(_]K_OIO\ &CR(_P#:_P"^F_QJ:B@"
M'R(_]K_OIO\ &CR(_P#:_P"^F_QJ:B@"'R(_]K_OIO\ &CR(_P#:_P"^F_QJ
M:B@"'R(_]K_OIO\ &CR(_P#:_P"^F_QJ:B@"'R(_]K_OIO\ &CR(_P#:_P"^
MF_QJ:B@"'R(_]K_OIO\ &CR(_P#:_P"^F_QJ:B@"'R(_]K_OIO\ &CR(_P#:
M_P"^F_QJ:B@"'R(_]K_OIO\ &CR(_P#:_P"^F_QJ:B@"'R(_]K_OIO\ &CR(
M_P#:_P"^F_QJ:B@"'R(_]K_OIO\ &CR(_P#:_P"^F_QJ:B@"'R(_]K_OIO\
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MOX;:=8"RL5^-/C35O%NOZ:^KG7%\%S65UH]A96+/!(AU!;FY6&))YF.X!0V
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M7^P/\2]#^&6AZ#ITMG_PF^CZQX?O+?69;Z^:TCO=,D9KS6'C^W[W6ZEVW#1
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MU.:X^WW$VVZ1WAFM62-DD5#LC3/TIHUP]S(\ID1D>W1DY^>4"1E\]0% 6%@
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M]"N]5DMH(M&TO6M2LEU'3]'U34XYQ/!=7NGD7D2+&VV-=H8*,'3\;_M-^"/
M_P 2_#WP=FT[6-<\:>([*/5;2RT>TMKU;+2WDN$>]UTW-Q!Y4:+97,JF-;DN
M$0%>?E^6?'7[(?Q6UOXA>+M+\/:EX/'PM^(OC30OB#J4^I6NHOXI\*WV@:'_
M &+)H]G=I<11O'JMP9-3=TBN I<QK-$/W9Z?XN?L[?$CXL^)?AIK,O@_X?:)
MXM\.V>A+=_%*TCUJ/5?#R:)K,M]<:-I43:K)YL6IV"&UF-Q8WB@:C.1*@P4#
M33E>JOOTOH_OU_I'TE\*_P!H3X:_&#Q)\0_"_@K4XM7F^&.I#2_$ODYEMK6_
MN9[Z">*_AEQ'$(I-.F79'&ZJ-P'"C/T]"5:&)DV;#&A7R^$VE1MV# PN,;1@
M8'&!7P[\#?A9\6/"'QG^-_BCQ98>$=/\$^-KO1+[P\?#EI=6VL&32+C6Y[J3
M6_/N9X+@ZG]NMR_V:%&S'(3C*X^Y(R#'&0  44@ $  J"  >0 .@/(Z4$CZ*
M** "BBB@ KYHM_V@O 9^.6H? :[UJ+_A/8O#TWBNXTE(U^Q6>G6TMG:Q0B?
MEEENDOK>X=70A'9E1L* ?I>O@OXA_"#XQW/[57A'XQ^$;7P7:>#/#7@W4O#M
M_#-:WK:SK=SJ.I6.H>=>2I<A&C@6&2%0 AP$SG ) .L^)G[4GPL^%7C;3? _
MC.]U&WU2[TV'49=0@A6?PMHEO/<SVUK::K=33(PDENHP"YMII$$T9##"XN_#
M/]H[P%\6/%^K^#O#$\K:OHUO++-#=A(H;BWG$A?4/"DD<TC7]A*L+2K)=K:M
M%"86C12S!?G_ .+OP>_:&^+7Q*\-P3Z)\/W^#%MH]S+K&EWUG?'6[GQA<1WT
M$>JO<)?JIL[(/I]S;0A0PN[8EE=6VGG?V</V2/B!\'/BYK_B_4IM$>S_ +&O
M;+685BOGF\;K+#+':7/FK,8K:YM/WDB(OV52UU@Q,!M4 _2M[I"]J+6X1Y(9
M8VNOWF+JX2.,IY,<()&Y.!)N*?,K'<01GYQUO]JKX0V?Q(N?@VVMWMKXIDOH
M8;O5K6&*71X=91TF;0FNY)LIJ4D"0F:U$>R."ZBD1RSG'S'\/_ OQJL/VGO%
MGC#6K+XWOX%\0WEC"+'7/$7@:[\.2Z;;:?;6GV?[+IUHFH1640@"6RK)'<B%
M(Q/(\V]RGBK]D_XPQ>//$6C^&KOPE/\ "KQ#\1+CXP6>H:Q:WDOB+2?$)TO3
M-/B\,SSV\\1ETH'0;.:)8(6<7%[*\MR8SM4 ^L/%7[2G@3PM\5=-^$&N1ZS>
M^+=:LK74&CTFSM_[,\-V,HW0RZOJ'VB"]@%TK/A(XIP!;R!1Q\VM\%_VA/!7
MQUD\8#X7ZJFOP?#SQ"_A+Q/+=[K>2UU.3SY0(D0.)4C2W94DDVM(H#,"3FOF
M+XI_ /XJ_%7Q]X"\5S>&O!GA+Q#HM]X,UCQ)\2M#34HO%(T_PY<+=3^'-)%Y
MJ-U8DW$9GM]USIMPOS('?')]-_9C^&WQ8^'OC_XXZQXUL?"]KX?\;>(=+U;1
MAHL$EO<WR:?I@TZ.[U FXDA.H3H6EOC$D4;W+2F.-$*@ 'VCID<\*K%-*UU^
MZWBZ*(@.9"/)!3ABG4DC/)!K6K.LY,R2(L;I'C>A)PA!(X522PP2>3U_*M&@
M IC]!]?Z&GTUP2  ._M03+X7\OS$7HOU/\FK!FB;%PB1?O4830O-(T<;N%.#
MYBEFP 2#Q@8 '2MX @ $="?USZ?7^><=\*>VB>&..=FFABG,N7RY?<7;8?)
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MX.L=/T9'72-5FNI+V"26ZUB.Y\SR9;:1%: A3@DU^QT?W$X*_(O! !' X('
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M^C2&<F74$BMOMD\KVB3&"YVF9U55K]>2\P,RD[3Y9:-NH4G.#R.<<8!)[@T
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M',MK'%:VAE3_ $B&&ZBAD@LU?(E>46X6-[F6$%!]C("%HV90 QKX/\9_M?\
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MOL1$V*/4CX>T:[D2]N=,L)-6NS<1_P!J/:0O<N7A9+C?*48L\MN7C(C^4*<
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ML%'&\G("GG.^A4HA3A2JE>"/E(&.#R.,<'D=ZH!U%%% !1110 4444 %%%%
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M=J;^$YN+3SX'C$T"'"M(I8,NYEVD A@<5L50U%BEL[[U14&]V;J$0AF*]>0
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MD3! )"@C*L123=DTV^B=WWV0--*[32[M-+[WZK[T>7W'[#OAJ\^'?BKPA/\
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MXH_O1_\ ?$?_ ,31_P +#\4?WH_^^(__ (F@#Z*HKYU_X6'XH_O1_P#?$?\
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M_A:YU#3K_3=6O?\ 7>6RW,C64DTJBW#^4&9B#D9G[,/[-?C[X,6OQ3U?5?\
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M]SZ3HKYU_P"%A^*/[T?_ 'Q'_P#$T?\ "P_%']Z/_OB/_P")K(D^BJ*^=?\
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MS3ZNMY?Z3>7S16XFM=L3ADC*U]1GQMXB9RY2W+$@DF*/DJNQ6/R9+*ORJQY
MR 0"15.V\4:S9K<I!&@%TQ:8NQD<A@ 8U=P7CA '$2$1@EF"[F)+A2Y9Q>NC
M;V?9K5W\^M^A,ZO-&4;K7_-/31=3R#]F?X%>+?ACK/BS7/%]OX:T/2O&,GAZ
M'P_\,O#+VA\'^'1H#7_GZS9_9&^P#5=4^WV\DHBMXI9)+:,%V8#;]X@   <
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M\=?$7Q2L_'VH^(M%UCPE!I]_#>M(^N7NJ)?WEY)&]PUU+/'$B30&-VC8%@0
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MY8I._P!K2R6[OOO]UNYA.7-)OO;^M3Z#'0<8X''I[?A4L??\/ZU\]CQ]XH
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MV89@Z@$ON(.<GZ(?QQX@>,Q9"1E2I6,+&0I.2 4(*^Q'0<"E;QUX@90KI!*
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M8\'S6D&JI_8FH6NL6T"R7UC?VZK<W%BD&6@ZR'##J <=U<^>O'W[2?C#PO\
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M']>OM1N;NRB\-VFOZI%:;(?L8*3>5&TN'F!<^4I8\FN \4?M'^*] _:3\/\
MPFO= L]"\'7FE^';R3Q1JSS16.NZAKNCV.J?V5H<ZI*)C"+R:.1I?(D$MLP&
M0"3[W\;/@_IWQY\'P^"M?\9^-?#>AV=YI.NA?"E[I-K''J.A2_:K.*:>^T^]
MB>8S#:%1MV>"%) KBO%W[-.A^-]5\)W?BKXB?$C6M$\'1Z?=67AN;4=!;15\
M0Z99K9Z3JMZJ:4E[<7R6!E&ZVNE@3S7!C#8  /&OBI^U?XX\&^-_B!8>%/"O
MA;5O 'PHUW0_#?C?6]9U/4K/Q*VL:_JFGZ39_P!D:=:P2Z?<:8+C5[$BXEGA
MFR9PT>U$%=K\*OBS\:/$OQ_\8_#GQ)HWA/4_ /ASP]!X@U#Q5X-O[R_G\/-J
M45U/I&D:LEY:6D$>IM]FD@OH$:;R)8F"NPY.EK?[(?@SQ'XFM/$NI^._'LLF
MIFTU'Q3HC7FD_P!B^-?$&FW(O+'6_$%O_98N9S#);6"11P3V\BR6,+$8!W>M
M_#[X3^%?AK8^*4\+P3#4?%OB?5O%NOWVK$3WW]M:M>27U[-IIMUB$=A9W$LC
M6-M<I-)%$55RYR: +.E?&?X5:_XXU;P#I'B[2+S7/#AMUU6""X9Y/.O;:&\A
MANU*CR95CG5"L2D9&<YR3X/\0/CQ\2_ /QW\%?#S4_!?A^'PEXZUI] TB:XU
M*^7Q3)<P6[7LE\MBD9T[^RY( L:2M="?S$G'E !&+?!?[*]]X7^,WB'XPW6M
M?#R5O$DZSZAIUEH^OV>LA88XH8I!)>7)MY)YX84FN'6-HS-([1A%(%=7K_[+
MWA'Q3\1K?QYK'C+QQ#';7=QK>E> [&]T]?!.G:P]H;<:[#!<:?+JJZJB1Q!W
M74C;M%:P*D)?=N /,?BC^U/XX\)_$#QWI?A;P%HVK> OAIKGA[PYXVU>[U&^
MBU^SU/Q#>ZC96SZ+8PAK.]M4ETZY:1KF:*0(L>V-MS+6U\(_C'\7?%/[0&L?
M#;Q%8> KWP/IG@LZ_/XBT35-4GNK'7-5.D:AX=\/7B/80VZ7USH>HSW<T8=@
MDEK(J.P7=6]JG[(7@#7?%T?C/6O%WC6^2]NM%UK7O#EE>:?#X?\ %_B'1)I+
MO1M7UVWFT\W4MY9W<T\\9BN;=%:XE+1L-H'M'PS^%OASX26WB<>&[C5KJX\9
M:[;ZUJ-_J#VTPDU*UMIK.S$;Q6Z-';Z;9S/8*CX)1%VLRC) /1$1]A(\Z6*.
M1H'NV55CDN -[1QX.6"QLI#%1@CG)XI]$D2(T!0&/R8%M)5 8QW,P=YS?!CE
M-[K((-H8-B/)7&** "BBB@!#T/T-?-'QP^-?C/X6_$;X)^$=(^'RZMX2^)/B
M>#PYXK\77MS/!J/AB[NQ=2V<%A:0.;.[^U6=N;I3<LK #:"!D5],?I7AWQ;^
M ^F_&2_^'UW?>+M>\*6_@OQ/;^*+?2]#FM[6P_M>S6Z@M]1U#[?:W,LY,-Q-
MN2WF#9EX'!P >0^#/VA?%7B#]IS6_@UXHTB#P7HEK<76G>$_MQ<:UXU@L[)K
M\ZOI\3K);F9\2QS0+/'"D%L\B9D.&SM=_:<UC1/VCKCX<>(8]#\$_#/2[:TC
M_P"$P\2S7-K_ &]JLK2)?:9IYB@N(7U"RD2-!"3'$TEPBLY'(]/G_9OTO7?'
MS>-M;^(7Q OM8L6N9_"GFWVBQV/A*Z-H]O+>:5<_V4@CENK<R6TPN+BX5X)6
M2-5D(-/\0_LV>&?&GB;0/$GQ%\;>/_'&DZ38Z:+/P)XLN='G\ 7>LQ(OVO5(
M(K#2K+4VO=4G2.4R'53$&5&9%5CN .(_9V_:FC^/_P 2_BWX8M=%MM \&^#;
MU8_ WB.2>1KWQ;]@MXK?4X9[9VDAAMWU+[28YH<R&.*,X7<5'O?ASXN_#KQ/
MXQUSP)HOB.QU+Q'X8?/B"RCDQ)8SS!8H+!  -X\QHG1V 9I)2K84"N2\'?LY
M?"'X;_$'Q-X^^'W@[2O#OB+Q?I@TF^MIH[F30])M5@MH6N+>*"42HQ-K$Y)G
M=G:1SC!->:_#']E"Z^'GQ4U;XI7.N> []_$"/)KMG8:9KUMJMS')(\<"PW%U
M<_9?.$GEAI7$D9C4(/F4D #==^/GQ)\(_M$^"?A%XB\'^$8?#'CVZU&PT>[&
ML:H?&T<EC):QF]?2U@&D"V87D<@)NR^ 08QCGD/'/[5OQ#T3QKXWA\+^!/#V
MJ?#OP!XOT;P)KNI7FIW\7B2&ZU;2I;]M<6PC1K)K2RGM7M91]HQ^_1A$<9'J
M>J_LJ>&M:\=CQK>_$#Q_;II-_J>HZ+H0O=,31_#^JZU)&ZO8--I9N/M*RV\0
M#_:I(084;:% W9=]^QU\-M8\8#QIJ&M^);E+O4K+Q'XN\.75Y9W'AKQ%K.B6
M;:1INNWEO:V@NCJ-K92O%@W*1LTLK^4PY !3^#GQ8^,'C/XQ_$#P!XHTWPG/
MH'@W1].NY-?\)WMY?6:>(KR]B$WAXRW5G;%OLVD7%K?.[#S1).RY,:J1]@R(
M@GCC!\D?+O'WMW;OR.A!SC)QV%>=?#CX8>'_ (1:=J]EX?EN+V\\2ZK+XG\0
M:YJ$L-UJVI:C<PP6 ^U7%JD=NZ1VMI:QQK'$A58U#$L&SZ2% 1)9$$SN"4Y4
M$Y&1QG/?/.#W/2@"'N0#D D ^H!(!XR.0,\''I12#OQCD_*.BG/(')X!]\>G
M%+0 4444 ,W1F:")YA&TK,%09,LH52TGDKC:S0QAIF#,HVJ>3R*^$-2_:I\?
M1_$R>TL/ FD#X/:1\3]/^%5_XGGO[M?%E_K-_K8T(ZM;:6H;3!I5O,/M,DAN
M$E$+9\EFPH^](I)K>XCNK>YO+6XMEE:)[5HEC8/$R21W2RH[/')&71!%AED*
MEB5R*^3=6_9!^'?B'QO?>-AKWC/1;34M5_X3M_!D-[IZ>#6\=VMR=5M_%-S;
M-8O>MK,>ILEY"8[X0"X7YK=E^0AK!I+5KKU//O&7[6/B[2/'?B=-!\&:)?\
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M]/\ BC\-/$5OX3E\,Z5J%[<>&]<U;Q#>SZ3HLJZG.(]02SL+ZV,ET\<".89
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MI.GVNHK*[F61K5BMJ6FD7;A0I\]\3?L>?&;6?$_AC5['6_#VEG1/!MWH>O\
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MMV__  G,GB>:>VN+CP[;RV]PFFZ)<VUA>W$%SJEQ$VGW;PR6CBSN)-LS'Y*
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M]M=VTRQ7.4\MH)%68N V\;AR.#D?)7Q%_9,^*?Q,^*[_ !9U;4O",-YJVO\
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MI*9Y':4 %%%% !44DGEE<$@GK@GC&,9'0C)Z$=\=Q4M1M&C'+#)_S_@.GH*
M.-^)GC_PU\+O"%_XO\53RQ:;:M"@CM+=KN_N9Y9HHH+>QLHR);RX>:6,>4AW
M%6) P!GR[0OVF_A?XF^'FO\ Q.F?6])T7P=?P67B+2=5T&?3?$T>IO*\=M:Q
M^'9G%W*]S<1O%'&,&1_D4%L"M#]HOX3ZG\9?AZ/#6D:O9:/K>FZSHVO:)>7S
M.L/]H:5JUC?PVSHL4Z2P7C6GV6]\R-REK/+)&IE50?F2\_9<^,OB3PU\1-.\
M7:UX+T;QM\2_B /&^K)HMS=OX=L-1T'56UGPIHUA))IL4G]C7%_//:ZA.;9)
M_L9#[)&^4!M#X?FSUX_ML_!@>'WU-X/'4]_9:W8V5AX%/A?4)?B)(^JVL]_;
MWT7AO<=5M].>)?-M[E8C$(98&1@KKE;C]L_X-V5IX0U73A\1-4TOQ<;::;Q1
M;6>IO:^&KR[OY-+&G>(M14,BK&R(QTRZEA$+SK+C)&? )/V4/CFOC6U^.=QK
M?P[M?CKX>UWPK+;^#/M-W_P@<N@^&M";1(4M]5723JM_?ZI;PV=\]O>6OV9)
MGGBAD$2("D'[)OQ^T]/AWX.CD\ ZW\)]-NU\8>,;?4[NYT?6=3\4/J5Q._V=
M-)TY8YM*MXX[+R(I+F,//"YDMP&9F E\+_KJ?I@#:&R,T95X;R_NO(UFPP+;
M4K-2A"W*1$JI,;Y;?(Y&X@D#JC;!Y@3&P1+MQTQAL8_#'X8[8H$B;DF:(V,D
M=NT<=DL:C1TDD39(8DY.#QAC$&P%((/1#]U\[<^4N=ARG1_N'J5SD@GDYYQ0
M8GT3\/?^0%'_ +Q_DM=Y7!_#W_D!1_[Q_DM=Y6,OB?K_ )&T=OZ[(****DH*
M\-^*G_']I/\ O-_Z&*]RKPWXJ?\ ']I/^\W_ *&* /+5!);]W&09[I6F<$_9
MP\ 7>J@\LV=J\-@\[::D+K!B5K6XLI;"?3Y[C7@Z+!;R1I&TJ7,;VD5FJJ,J
MUPV"!D;B&)?SY-SB6.+]]-@OC)D\I3#LSCGS0N>> 2>U?'G[:=UXGC^'WA4:
M==>+O^$7/BSPB/C,?"PO?MH\%"<C6/[,-FQ<2_83=9V@C<4R.E4I-*RM]P'U
ME#/IL4,3Q:GH!MK)#]EEN-6L7T$A',96UG6\&ZY!W?NS<NQ968(0.)I)M,_<
M6UY>:?'>7JIJ$3W.JV<;W"+(#"L-J9XY1 )(2Q=H_D!9Y'VC*_D5\=+?X5-\
M,_ 6I_ 3Q=X[O?#&BZQ#J]WX%UE;YU\;O#+=QFPB\127!7PU>QF5EE T[47D
ME@D<J"YV\7K_ (QUG3_B5:^,++3O&OBF[\=> =5L]-\ WRW\\WPMFCTK5S+)
M+J<B2G489(V\NUNOL&FJ9R @)7 N$N:<5*UF[.VEM'U=^PFKJW<_:Z6XLD'G
MW#V(M[V7RQ-!*$C;5(&*P0VL[RM%<O+*\@B:!I%<@%21@TT7^DM(L5U=Z=?:
ME>SK9:I8:=J5I'?/;B)I(G:REGDO(1$L4*2RR((V;.W =*_+?Q5JWQ+C_9T_
M9VA2^U.V\2W]_KHL+4_:!<Q:_I\FAKX,&I'<KB.YGEN/-$BC=M.,XKR?1O&V
MA^'M(\.C0=&^)WBCXM>*],\2V/CC6)-9U-?$?A_5XM9NHPT<1L[B\CT[R[=1
M:?OHH_LK0;#L*5T\M/75[OJNGK;[R>2/G]__  #]J(&\SRKAI9II" (GA .D
M6UBC,1;J0K.;T_.LL[3M$Z,B(H89-E0X+QJ5*ZC(98V*D)!# 28XC(1M2.=9
M,%V(7"\D 5^:>J_%7XP_"K]FC]GG4O#5R]Q>:C?V^D>.DUY9/$.J74<ER/*$
M>FRM%-)>"6>/SLL9#$/FX'''ZY^U5^TF_B/QOX)\+^'(AXA\$Z+_ ,))J>K:
MOX:>WTR;0/$5M<7OAVTM_#\A*3W%O:V<R2H+O(8J"$W<\]27+)J-FM+7U>WD
MPY%Y_P!?(_5E%1+QX;CSN)H;59DDC662XEA\Z.%I95,$EOY>0'C7"D*C2!L[
MFL5FW(T-CYL%VT0M;C>+6.>V5)E<P"5+F=G.P,T,C1@?,0 ":_&S6/VM?VM/
M NEZMXE\5'PWJ?A^V6RTB5(OAPJR:0=2LXM1;5E4W\A M0K6XPL>T.%WC.#S
M^J?M#?M)^,X?!>KZ9XPL5\(Z?XIAU.Y\2V7P\>TN-9>3[.EOX>EO8]68V<5W
M,([9I6DF65+EHC <X,<[\OQ_S!02=[O0_;%;B2T$L@$(GUF1TG>Q1AI=M=2G
MYH_(F,MV^7D*OY<QQM&X8Q4,OFP17=N9-UG%:F:.$03SRK=+*BFYC2(,[*"S
M*O!V;B'.Y2#^4]Y^UC^T7*?$%SX?L+:YO+G7-:TF?2'^&\MLOPZU@W<D&CW$
M8-V__"36US,9'9T33$E2T!SB7Y,RQ_:7_;!TB1+R[.F:A:2V4^CZ/&/ 3: _
MVR9_MM[=7.N&]N?M2M=Q702T\E?*1DB\PF(ECG?E]W_!+/UL:596NK6ZN ]T
MS+=7L5G<VQ^QRJ%*VKP O+'(2BA20,&0;L@$4TJ6\MUCCT\CRYXI;,,)YF(W
MRKJ)D:59KD';LDC5(U9G)R#D?G1^R1\2]:^)WQ6UWQ#JUW>_VI?> =$O?&>E
MW$4VFVUCXD?6]1BN?(T9V<1J;9+5?MF1YH'E[0%S7Z./GSKX'_5[2+;[N",$
M#;GL1M_'/&<8TB[I-_UJ9RFTVM/Z^8YE,BN);A"3&R*0A#B0R"02L>A<*"A(
MP,'& ",/1Y/.>:*X:T=M^=X#!D*;5B3:N5VG+9)((8^O$:9V)GKM7/UP,TZF
M2YMJSL5E5HH(X8U^>2X,L\YZ@%@Q;\06_$$?6R/;IR!CH0#@$=.".11102%%
M%%!2DTK*Q&I7$96*.-55D3>&:[@B+;I(D=7$.9I,RH6C;:#AN227'R456V!D
MBCQ')+\TT40.?LD^W"R(6R08T7!<$N "*=6-XCTVYUCP]X@TJPU$Z/J6HZ'J
MMGIVK#.--N[BPN(8[XXDB.;5G2=/WB'<@VLI^8)NR;[?\ ?,Y:.UF:D$UK,W
MVLW.E7%S$"\TFE7D+36-MR;6&X5KB<12:8@*F.1 S,I51D$4R&[LY;*2YL+O
M29XXI7MIM0T6?[5.ZR,TDBW)2>Y6WF5\JZR)& RG"A2,?C_^SYX0^)UBWQH\
M.^(?&6OZ5%K6AZU\/?!?C*Y^UN?$'CC3[:\TG5O&>U[J,Q6L>I26VH6Y%U,&
M2<XNN Y]K_8;TGXB^$=!^+7CGQJ4T_PG>ZHFBZ3H?B'7SITNH:AHEH-,OM:C
M-W$?*@UB_P!.N=1!6&08O ?,D!+MGSOLOQ_S*Y%W?X'Z.B1+0&.UBNK.,@00
M",AIKHIF3-XTB2))#*S;%6!8G5MSN=A!J(&VCNYXH18Q2I!:WU[&LGG7$<Z(
M7\M5CE=;?R&+*OFH!W!(!!^.OV;OVEO'/Q=\<?$3PKXET'PAX?M=&\2:CIFB
MW-AXRL_$MX-*CLK<Q72V<=A9/9.TDDRI.KOOD7RP3@5Y=\)/%WA_P%^UU\?H
M-1\:>--=T1?#&C-]B\007LFAQWQM]6;4%L#<W4MOL$O ,2C*A#CCC2+NKL.1
M=W^!^CQSOVB87%[#+'J,<-M+$=4FM3"$DMKA&WJMN7E\S=Y2;@L9+D=8%%M&
M$CMP7\]3?-(K#R83*3$;/8V95EB,>]F)\M@X"C(8U^>?PRU>VTK]NOQ]!:>-
M?B%K6E:G\-8[S28-0CU(^'K:ZO/^$<G6WM3+=/:J(8I98H]@7"J=H"Y _0I/
M)WN;8(;=G9EEX\V1V )#<9VXYQG&ZF)P23>NA-11109A1110 4TL R+@EI&V
MH #RQ( &>@R2!S3J?$%,F7.U%7>SC.8RIW(R\C)+@ \CC\B#2NTC.;4]+6[6
MP;5M'6_>>2V6Q.K6 O3<1,$:'[(9_M'FESM1/+W2,"$!(J8M;PF5)IH#<)8S
M3"UN+A P=)T3<J&16("L20/N'Y6XK\]_$_@SPG?_ +64?C*"+Q1IWAKX765O
MXM\=ZRDES]BU7Q)JP^WZ!:6<81(Y$@NK&\2Y42RE0X4A>-WSYX/^)?Q?\5?$
MSXO3^-;N[L+?XFZ/K>E:=JJ136D/P.T2UOX;33?$$6@E]MY/J5A96VI-(EUI
M#2-J;/YK;BSAIR+NS]C8;RVO9KJ2PU+2+F"&62)FT^YANU63RD*6TCV\THCE
M#LI*,4=0P+ 9Y<C/<7$J%(8KNSMK*4K^\4/M1S<'=(X1BI52P!/WLXZ5^>O[
M$6K77A7X;?$?1/\ 2/$>B>#-5N9-+^)&OQMILWC_ %1$M3-J4EC<FY;3K:2(
MH@G.H7P8Q%=W!QZ1^S)^T1XP^-VL^,-)\5:'X0T8>'->\60VTVE^)K+5[^\T
MZ"\D33F:PBL[:0;H8057>X4MM4GH<Y3:;2MH4E96/L47$;23S)<V:7,=MYTU
MEITT9D@;=&B$1R/*;>>6-EE9)<&0,TD:B/!IG[NQDGA\^SOY8$$D\-E*LD]Q
M#<$1BWO9?->&*Y@8M.8_W,@4)E &4'\Y?@1XP\.?#W]I/]K#3M0\7>-/%.D:
M?XC\):E9GQ-#>M9V\]YX,T0S:?HWVN>>(6MM->3)LM\*KPXV@KQM_LRZEIFB
M?M2_M2>'(_%?C7Q5H=Y-IWB&PBUV.^_L+3[V^N+6WFBT*:XGGMBHA@172W"
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M5WC"LI+<DENGVU_"RU\[BL^S^Y_Y'&_\*WUG_GXB_3_XW1_PK?6?^?B+]/\
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M!_\ A6^L_P#/Q%^G_P ;H_X5OK/_ #\1?I_\;KWC8WJ?_'?\*-C>I_\ '?\
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M:(N..O\ ]KKWC8WJ?_'?\*-C>I_\=_PJ_:/M'[Y_Y&5OZL_\CP?_ (5OK/\
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M (ZO^%'DC^]_XZO^% 'S^?A5<.YFELM%GG*JJW%SIMC<W42@ ;(;F>T>:$'
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M43RPA9=K)\[O(VQF#E=[EFV[@#C/:IHK6"!@T2!,1B(*I(0(K%@ F=H.222
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MSYC ( 2N2V,$\'*GD"W$C0PVMO>.GESRFX074%L1@7)B*JX01Y?)8#('S=J
M/SH\2?LR_M$_%?XQ:]K'Q9UWP,G@"?1[/P_X#O/!6G:AIOBCP/8RV-A+KMY'
M<WUY=02:M-K<-\^GW*VTD4.EW7V>5&FR]>T?LD?LIW7[,>N?$.UM?&M]XE\,
M^)9XKO1]-OES+I;>9$7<S);012-(L9#;2SY)+8&VOK<7D8N_L[7T;70A0-IT
M=R#=-&%4+<+$"7!D!#G"G[W&<UL:<%0.D:W0C^]_I0;>'. 0-XW;0,8YP.<\
MT :=%%% !1110!2,+^4 @"R!R=SD-W;GCJ.0<=?8]*^//VK_ (*_%#XP0_#:
MT\#W/A*"T\->-;/Q!XD_M^QN;BXN].L9+:YMH-+E@N(3!<FZM@9V<E7@/E\$
MFOM"B@#\Z=-_8VUG0_CMJ_QUT^;PS:WEP6ET+PII5K>V^B:5K'B-GD\5^*)X
M;F>2276Y;A;:\$L5SY+3Q$^1(K!1Y=\/?V$?B%X$^(_B/QW)?^!=<N;C1/$F
MEW4U_IVI23^/(O$NNKK[V7B%/M:0&UL6<6""**RD,5K$1(>6;]9Z* /@;X%_
MLY^.OA+X(^)R7RZ9:ZAXRU6[U/1?!'PZ<Z/X>\/0-!;>3:Z6-;N+WR+AY8'#
MR/>20A9 ,+@UQ/[(OP2^+OPW\2>/YO'&B?$2SL_$NLZ]JEE<>)O&WA#7]/A;
MQ%=W-S,(+31WDN8OL/F((@XP!@+N :OTOHH _.WP[^SM\>K'XTZ]\8-6UKX=
M)KJ>'=1\,:<N@Z3JEGI'B2SN=4L[O3+SQ':W%[+<27NG:;:0:=.UL]K'--$T
MR1E65JY'6_V2_C9\6?BUXVUCXT:SX"F\$:G;+I/A+4/!FG:GIGBSPW91$SOJ
M-C=7=[<VJ:G>-/-97,TEK*KV86,1#&\_J!10!\5_LN?LLZU^S;IOBS1I/'-_
MX]T[4->_M+PS-KHC?4M)TLW%U)+I\TL%M90RW,L,EO$THB*%XMY.UCC[24DJ
MI*[25!*\':2.5R..#QQQ3J* "BBB@"%(S&Y(!(8<G(ZDY)QV^@Z_A7R/^UY\
M&?'?QE\(^%]$\ 'PU;W^E^-/#_B'4)_$=K-<H+/1-7TW5,6'V>>!X;N0V)17
M)91N&Y<$U]?44%1DXR4ENN^VS7EW[GY/Z;^P_P#$BT^-]_\ %!KSP/'=S^*M
M1\?'Q-'8ZG_PDEU?WVH'5;7P\\C7CVPL[*8&VF8VRK*KDQS$#?6AJO[(7QVU
MWQ9J]@?%?A33/AEXV\66/CC7[5[&ZF\3:)J.DZ9/HQTS2K^.9X%M]5:>356+
M07'EL0AE4@1U^J%%!I[>>]H_=Z^?G]^W4_++]G']B?XA_!GXL?\ "P-1U;PM
M<"+3;R/4-1TZUOHO$'BJ:>.ZBCCU6>:Y>S6>,2QRQR06UM%YBJ6! 8&;PM\$
M_C39?M6:O\4;KP[\4K;PMJ?D6[7=WX_\"W6GFWL7E%O$=*MY&O!8LDC 1+$+
M@1_*S!L5^H]%!G.3G)R=KO>VB/SR^,O[-_QH^)GQ>\'>)K?6O UOX2\)^*-/
M\3>'I[S3=1D\2^'FM+":WN;0W4-TEO.MW>W$]WF.VD8*RH77! I?%SX+?M4?
M%#Q_\/9M1U/X37'PP\,0V-SX@\.SZ+K']IZ[XAM[V=Y+Z>Z_M-8&TF.T73Y+
M*T*BZBU&WEFD=XF1!^C5%!)\J?"'X!Z_X,\>?$CXF>*_$D.N^)O&T]OINEP"
M$C3_  OX6TE[]=)T[2$=//A<VU^T5T7ED$GV># &PY^J(U*1HA.XJBJ6]2
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MR=IPM?5E% &;9V?DR^>ZXE^SK;C;]T1K(TBKSDDAF)R"!C&1FM*BB@ HHHH
M*P3]GD!LY$,JS>9OCD'F)G>0"TL8"!1P=I<,%P"-P-;U8,D90- )!:6FYGR3
MB29V9F90<KQN)X.>G SQ0!\:ZS\&OB[+^TQJWQ7AF^'UYX)U3X=2^";G2$TZ
M]C\27B&?4KB&![UKQ;;R6DO$^U[XP)+;S4C*RD,/,?AK^RU\1O#VJ?$6_CG\
M!>"].\=VFG^%;SPCX0TO6K'3]"T*Q^V6LNO:0+N\NE/B>XMKQIYKL2SVINX8
MI#;!/D;]"I;M8W3SU@MB5;RT6=4O)8PK%I FT2?NU+2-P=H5F) !Q5M=7TV[
M=8[35;74I(%,,+6UZDMU'%)A9IIDC9Y&\E0&:1L C<<C)- 'Q7^SW^Q7<?LY
M_$7XB>)O#GQ U75/!GB:QA.C^''EB363J3V5L=2NM6OIK9+6XENM16ZEMV7:
M(8ID23!4FO.?@C\%/C1X/_:(\=^/?$VB?%*+PUXPO9+L0ZGX\\$:AX=:TVJD
M&G7VEV3-J,L-M-"-0C%JR-YC*&9B&6OTRLK[2=2!AL;RRO\ R28II+>XCFDC
MD5BKK+Y98B17R&#=#D-CD5)>1B1?LH)$020FX7.^U 5V+AAUR!@G<IY..U '
MYZ^/?V=OC7XU^-&C>/[[6/AE:Z+X!GU77? -]9:3J]OJ\EU?M!.NF:WYM^PN
MK=38V<3F"WAW!I"LA!#+<^(_P;_:,^(WQ7\ :OK=_P#"RZ^%7A2U&M77@V+1
M=775-1\9EH'M]:N+N34&MWBMH9]0AACR'6.XC!SL8G[A=F^T6=MOLKI)X+:3
M3G>:,7=U'8@'4&CB(=Y!&CQ%PI/WAN/(K4DEM(IQ:?:8(KJ0;\R3H+M5;# )
M$Q#LJAMH4<8V^@P >"?"/X-ZAX4\:_$/XH>)9]&UGQKXVNH;>QN+2RNK<:#X
M5MDM'M/#<8N7)\FWOXKJ]4Q,8RUT0&)#5]$>3=)RR"8W(V3["%$:GC(W'/&3
MTSC'0FEL&#2N%%RZB(?Z1/O =M_*H''( P=P)!SCMDZM "*H5549PH &>3@#
M I:** "BBB@#G]>5V6S$4*O,TSHD\B/)%;H\96<ND7[PF2 O'&RD!)&5F.T$
M5^<.N_LD_%A?%]_IF@^+?"\/PFO/BQ8_&RUT^XL+M_%UOXJT[71XCCTZ:^63
M[.^D3721P>4D D6!7#3 D$?IG>8V!<SJ6) , 8L.,DG;@XXXYP#SR0!6&LUN
M9_(1HO.9=OG2W %Z&(P?W)'F$=P-P&<CKR I2:[?T[GYL>,_V._BCXX\3>*;
M+5O$G@U_AG\3O$^D>*/B!92Z7JO_  DEC<:-I$FD6UKX?OEG%I!;SPR_:)Q-
M'<,TX4JR#*5RMQ^P=\6?%6@^'? 'C#Q[X.NO!_PEA2X^$E]INF:A%K-U<07<
MUW;CQC<&5H=1<22O'(;2"U'D"-1A@S5^IKZA&DMMIYN(&U"XD9)=/GN56Z>W
M5F4SK$P+X*[#G&/F RPX,^GZC9&6YM[9[=H[:0POLF6:1+C".R.B@; $92 >
MO&!SR YMJS2_KYGYEK^P9XY^*J>,/$GQG\=#PYXL\1:9H>@0:3\-E.G>%-GA
M'[:-&UZ_L]174[B>]N7OWGG"W&TF/:T2@XK[)_9S^#&M_!7X7:/\.-?\1#Q:
M=$O+^YLM46-X71;F^N[F/>LB)F0K<C=M0(&W  # KZ%5I-Q<\*PXS^!P1VX!
MY'3]*L@Y /J ?SH)*%C#- -DIWY3)E/+%MV-I/7 7OWP"3FM"BB@ J.1 X!Y
MRIW 9X)'8_X]OID&2B@"%D#Q!7CW   CC(P.H]_;(/XBORCO/V*_B)\0-?\
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MBBB@ HHHH **** .'U9H4L;YM0N/L-I)#<6VH2*#$4C??(EQ#)"/-66.% H
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M!H Z&BFLX09;.,XX&?T%.ZT %%%% !15!-3M'DAC5WWS^9Y8,;@?NW,;EB5
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M4@D T:*IVU_:W:R-"YVQSR6Y,B/%NDC;:VSS OF)G[LB91@058@U<H ****
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M,$B1R*V5;<Y4(54X+HS.%#KE"X9<[E(H T**I2ZC902K!+.B2NR*B,<-(SG
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MUU3XC6.F7NN:)/"?$>D^%;J.&^L-"EN3 9-1U.!HDTZ"V:25GD58MQYK[O\
M">OZ=XI\.:7XCT*.>"SO;&RN;9;J,QRFUGMHI;?SD;!$GDLGF*<['# ]-Q^*
M?'?[$/P^\5>&-$\#VUQJ!\-6_P 6++XQ_8IYYCB6WUHZ[>Z3:WC3M>0V=^SB
M&?3XY8K2=%6.:)D4 ??FGZ5866F6&G6MNMO9V=K:P6\$>8Q'';P)%$IV$$E4
M4 Y)R1DDGF@"U"$\UG(99FB7S ?ND$D@CMG/4@=\9.,"W30H!W <X"Y]A3J
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M/.<U\W_$7]E;X(>/=7T_Q)K_ (-LQJUCJ.HZD^I6)FM+N:XU33VTRX,\MM/
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M8Y=*N6MI(Y?(DF=3&R,I+#G!SQQ7/?#C]G;PS\+M%\8:;X4U20:_XU:>2_\
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MJRZUJJ2N9F:X%SJ(>X9IVE,>1'$4C 6@#ZWM"KS&97.9(1NCX W!\&0@'[S
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M%5AJ6OWEK<>(-=%W*]QK5C8P/::?IUWOG9'AM;!XK-,C>T<*LQW%B?K'X9>
MM#^&OAG1/!GA>RFTSP[X;TE-+T^RD)D!Q<S7,MPT\LDMQ-)++/(2TKL0I !
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M[['^-<[XBB,L$:Q!8IW2[@M[F&[\J:UEN+:2%;F*%5+7+P%Q((@\9RN=PZ@
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MGC^[%_WV/\: )]Z?WE_[Z'^-&]/[R_\ ?0_QJ#C^[%_WV/\ &CC^[%_WV/\
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M_4O"WBJ._EU'2HX/&-[?7^K6=QH^@0327.H7ITO3[",V<;*QBDCM(&6"/A%
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MT$:3XGU;PA:RWFF:C!<WVL:3?26%XME!)9K-<VL5PBXU"!)+*1)$ECF:-PQ
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M\7ZRS;DF"BST[*;'5HV5C%D?,/F (W*=C94L#\O^*?VNCX:^/VI_!E?!$_\
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M,:)I @.?*",HA#'RQ&"<59_#5_8HQE\7:JWV6W>:15M[)S)&LJ1H&)CRI"N
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M,T+PC??&FUG^%WBK7IFMX_"DD\6K17+@SM%$+[2UNK-@(H@&83[58E3M8;:
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MM-T"^T^:WDO]0\2Z-H.JW6OZ%.DTFH&2#4K;6)S+<2!;B26V@CB=E4!A,/\
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MV@OY?AOXFC\*Z3?6N@^-+U19"[T+6M0TJ76;>W2#^TQ-/;&WA91);),X!3
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MEQ/;:EIVG>)=2TS7=%U!'M/W7B2WCDTF#28/(DL)[EYUFNT148@'V_\ %O\
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MGA.R^$^O>(TT"7Q;:MXFN(].MYO$2?#9HE\7:B\5IJ*62R1)<V\X$:J&:<@
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MU-9^&F@-)>Z98Z1)';Q&.6'2K&%[>VM8V\U@R10.8WV[L@ D]-W.ZO\ LG?
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M\*:PFA3MX6T&7P=K=A<Z]%'XZ\3ZQJ&G.W_";:#$T#:E?00-JD#JMNTD<?\
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
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>form10-k_023.jpg
<TEXT>
begin 644 form10-k_023.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" 'P [8# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MI8729(6! CCG$18Q&3=N4R%57:=W2OYC_P#@E?\ 'CXX_%#]IS_@I1X=\?\
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MI!#OUQ&0?GP#SC@'(/ S5DW*!@FU\EBOW3@ #=N)[+C//J,=<X +%%4TO8I
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M7(Y-I=$^:*-?9PLE>5TDEJUHO22^77NR%B#DYW$#@9ZC/U/8YZ'/8@XII7/
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M?@3XG_M@?\%,?VL] ^%_BO\ :$\;_L[Z7K_[*D'CKQ%X<T$6D6J'5=&\(>$
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MD$_@#@_Y^IJ +"G  _??>^8#ACTZ\GYCG']:;(\<* *5&UBF20 %(+8[\9.
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M$_".N>$[KQOX&@^,ZZ5XQ>2?7K*.TO-,@9@-""WUVEO'YZ18FW(N/R<\-?\
M!0?]HCX5_LL7OA3]F?P7J?[-'@J?X^>/XY_&>AZ'?7_AV^TJ"7P^^GR>$K/P
M]%IB>&-%OR&CLPUS<6\\$@@C>38V=%3IU$N7%<K2N]5K?Y*]OGT!4I_\_%_7
MR[']YS6=S,MT++4+E9?,2=48F-Y(%<N8XF*J#+.J[0!N,#',RCC$;VTHF"?V
MOJ<9N5B6VMRL\DMO.1B87$B1;)$1R!E  !G+=Z_CQTC]K']OOXY67ANRL?C[
MJ/@ >$?@1\2/B&OB>VT;7X9/&&H>"_ YUVTA-O#JT%P=1U6>T"/+(\K7LTX"
MH2,'S'QU_P %0?\ @H9JWQG^ >@)X\O? 7ARW\+?!J\CN!X=UNX3XD7.N:#I
M-UXS34I+>_A$=U)>DH8+T22QO=2)(C.'I_5H_P#08]^__ V'[*7\Z_'^OD?V
MS1Z7>R)*\E_JEFL+JGF2S&03\-ODC5$W+&"/XN<%>>363J^KZ%X;OM'LM:\4
MC3;S7KZ#3- @U+5K6V;7-2G21X[*RBG:-YIF$<@6) S$QL0, X_D0@_;&_;*
MG\/?M:?'WXG_ +2OBWP?X6\ Z]X8\$>"? >B>&?%^HR1W'B/P_J%VVM16NF:
MC)FPMKG2RUY=);K;V+W"QSS([#=\[?LM?M7?M#?M2>*?V7K?X[^*/%GBR^^%
MG[9/@6UT;Q;(NJ:&)]"U71_%VM07MY#J;7,L]E;1W5O;S2&5(TE5(W9&PE#P
MT?\ H,?W_AJ@]E/^=?BC^R[XE_&WX5?!U3;?$CXA:'X&.I/&=+M/$OB#2["]
MUY'8(\^F0W4\$ABCF62-F6-P&C?!]/5/#LVD>*-,MM<\.^)H-;T>ZM473]3T
M'6K'4]/N;=_G2Z6[L9+B!TWL8R%DW JP;&./Y;_^"O'PG^(G[1/_  48_9K\
M$_#KP;\/?B1?6WP/U%+ZP^*&GZ9KG@_PY!/XFN(?[1M[W5)[;2;37(VN4G@@
M6Y6^\F5Y$C907KX8^-7CS]N?_@EW9?L__L:>"?C4=(T%?#EKXMO/&^F:!K'B
M#3M6U^\\0:E;MX%@N]*U;RK/34M%CE2.2YDMER3M.13C1IQ:E+%<RL[Q;3U>
MVRZ>76PXTW?6::MM?[GV/[:O$,FF>#]%N]6\4^+$TG1[>6V,NL7^I6]E8QM=
M7,5M;V[R7,B*LDMQ)'$'+!-TBDCJ:J^&?$GA;QDVI#PQXFL]>DTZZ>QNK;2M
M:L+Z2SN(9 LQFGMI987 W8 3GY3R217\/?[;7[9'[3_QU\+^,_!/QO\ BSK7
MPSU71-)^$MUX7^$GA7P;XEDTGXAM+\3-&BO+_P#M'3+J32I7^PK-=WD4D4TL
M-M:&28K&58=1-^V+\4?@'^S_ /%K2_"OB#5/A!XUU;XB>(M.\(>)_#'@K7[S
M[8=,GL)X&U#4M$:);:*_W"&&6YN(TE:1E5F8%3K;#V_C*_1^?33K]Z+Y%_,O
MO7^9_;7J4UC:WJ:.GB6UL]<N(;B6UTN[OK=;^6.UC\RYGBLG=+BZA@3$C_9X
MVPGS$X*FL34O$.C:1JGAO1]1\50VNI^(XKN/3=.GN4AO-4N+8PH]Q9Q2%76W
MA>13)&RL["15W \M_!YX9_:T_:O^(?Q#^!?[0GCOXY^-= \<>%/A%\9]'T?[
M;H?B>YT?7_%/AOP)"MN]_IRW,>3K-^(5M?/FS=/(5B>5@<?;6B?%G]L3PIX0
M_9(^/?C3Q^GQW^*?CC0?C/XKL;&70-5L8_!-WI-SH5YH_A^73=3O[Z>".Z:Y
M^S*@:W25;7")@!1E*A"3YHXOE3MHGIM9JS6BNK_JR)4Y7TFK?U?\3^OCQ+K6
MA>#=(U36_%7B4Z!I>A&W;5-5U.YCM+ )-$TVV*2X6.-GV(V KL25) P#6_8P
M0:EI]O?Z=J\]Y::E9I<6=Y')O@D@N$2:&6-%4M(CQ.C!D+!@1ACD5_%1XC_;
M!^*WQ%_9K^)FI:W^T5KGQO\ B-XDUO7I]?\ @/XL^'7C,:!X$DTV^U6V>RM]
M7UF[FT)%LMPBLHX$3S(5!@RBFN3^*7_!3_\ :M\+_M,?"G2?@Y\5/%,OA71I
M?ACX-\5?#R3P7XMT;PYHEIJ?@72[^^>UM;F>&QN[:WN(&1KVT0P(\NW=N;YE
M]6C_ -!C^]?Y"]G/_GXOQ/[A;;3[F2&)9[Z>2W:?_1[B(E!)$JL'4HP+!A*&
M&XX4 ?B-*+0;J>-9GU'4(G<$LD=PI1<$@;2H(P0 >"><\U_)G^R#^TO^V[=_
M'C]DSQ[XQ^.>L^.OAW\<?B??>#-=^%]SI.O6%OH%DTGB:X^V3M?ZE/:6<"G1
MXT6>2TCCS<*H<[\'^NJ#]U!&'Q;XC#&-G5A&I/>0,J,.<[@ .>O!J)4$ML6W
MZ3BOSBP]G+_GXOZ^1B?\(W-_%J>I,/0S@C]5-+_PC<G_ $$-0_[^K_\ $5T*
MMN&5E# KNR""-IZ-Q)T]^E-,BA/,,RB/.-Y("YXXSYF,\CCW%3['_J*E_P"#
M(?\ R(O9R_Y^1_$P/^$;D_Z"&H?]_5_^(IK>&Y-K?\3#4!P>?.7C_P <KI!N
M(!#Y! 8$#@@\@Y\S&"*1B0.9, @GMD@=2/WAR!GG XS1['_J*E_X,A_\B-4Y
M7_B1]-3F6\/3L8R=6OOW>-O[\=O7CGU[=?3BG-X?D9&62_O9?,D60MYP."@*
MC'RG .<X[D=,"MT-'Q^^Y(+#'<#&6'S<@<9/0<4;E89292 I8DLHPH."QRX
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M%!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M(/WB88 KR*_,6?\ :,_:1.GP1^"O$>O7OB[QAX/\:7/C'2+WPZ((O!6M-J4
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M<DO+K]J/3_M[[N_0]-HKS,>/+Z2.Y":,J7$#VBA;FY:"%Q<HSN1*8B/W6 "
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MYX[+3K^RO1,]Q+)=7+B>:W>U8O))N,Q!X)(^2/%J?M,_$CX;7OPJ\(_ [0O
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M3BK_ +R:YK<S;CI)1U2T=O4H4<XK1;J5<%?5JV$H+6VVDW_AVZ:K5VX/3?\
M@H+\$/$G@[PMXETJ?;XJUJWT6YE\%W]N5N-"CUO4H]*^WWC1H;=6;>R1_P"D
MR#S8U! 7)KJO&7[5GP+MU\7>'7FTKQ)XAT#4+"&_\/,&EOM4NO[16&V>!93'
M 9[*Y3[3*JR)"%4;0P#+7SWX5_X)\:EHWP^\>>"_$?C;1]0\9>,)-%&C:Y;6
MMVAT31-!UVRU^SLUE:U54=WM)[<XW9\WG &:\BC_ ."8OQ+F\>0^,]:^)_@R
MUD?Q)J&IQM:V6O'4Y=.GD1]/MK^9H6M9;R)@1*\8$3,V4Z&MZ%#ARI"3EFKI
MRIM<LJ4I)M[NZIU'S15FES:77,GK$YG#.:-636'PV-NK<E+#4XRI]Y2Y(U&T
M_ALTK-WNW='Z?ZY\?_A_\/\ PQX3\1^,KZWT2/7](LYX]&DC8W-C:2VT4DDR
MPVT<L82"*8M>E2RK&OR9YQY1X3_:^T;XF?'74?A5X&T276?!7A_PS9^*-6^)
M0V)H=C'<Z>FH16EN%FCO/M"(9$;S;$)YD?#, "<SXR_LT^,?B#9> ;[P'XLT
MO3O%O@?PSK/@_4+GQ!;W<NB:A8:IID&CZB_V:WB^U-<F"*1K1SM5)6#M@;JJ
M?L_?L?W7P6O_ !MK%YK^BW]QXT\.Z9IEXEM#?"&.6PTZ6TNV59$63RB\K,%5
MBVTX(W#%<,Z>2U(-3S5*34K155J2][EWC5<FE%MW:3=]4KNVRQF=J3BLHBK6
M7\!=5>]G0LF];6Z=T=;J7[<_[-^GZK>>'V^(6GW>HZ<UW;7,!M[KR6CBE,=S
M.YALAO2VD 29T9B&;!R2*[*3]K7]GH>*=%\)R_$/0X]8U"RCFL@)W,<@N5CG
MCLF;RS(AE219 AVD!.H8D5\P6/[ 5O::S:WZ:QX?>Z'A;XAZ3&DEK>?V=,/&
MFMP:M%<S[H1(;BQ55A0[P1N<*A%?/.D?\$J(M,\76>NOK_A;5]&FU%O$FK:Q
M>0:V==L+RQ,EE':Z0=L2)$(G)0202(/+0YZ5TTL#PLFH_P!MXA6@]L36:O;>
MWM;75M8MW?PN.R-;9[57/*6"I\]I>REA*'-3OO3;<HMN-VFW&+OK9;+ZW\1_
MMU_":\^(EE\*=$2+Q1IDUA+?:_KL\(.FPZ<EY]DE22680K-"ERT:YB6494#J
M&QZ!IW[3'[-NEZCK'AO0_$FA^&VTF-;N]73=.GA234,QYM1+'8-;3*T3*<M(
MQ+'[P )KXUC_ ."=GQ"U./2=%\1?$SPC_P (+X4\*:EX6\+/I5EK$6NW<&HZ
M_)KYN->N);<H\L,UQ/!&RK%\B0@ \EMV]_87^.4_@Y_AIH?Q9\$Z5X5AG6YT
MG4(=,UL>*M1MU* 0ZQ=M:/:M;,5DW)&D4O"X(!!KHJX/A;V+A'.\5!RG3DU#
M%XJ*=Y:/F]HES-6NK^ZW9K1,QJPSJC%U53PF+<794J>%H1E9WO+W54ERPMS/
MW;.^MCWW7?V^/@;I>H^$8M$N7\27OBCQ!JVA3S62"1O#M_8:2]^;>[P8Q$7(
M6(;1)@RC( R:]7TG]L/X(7ESINB:GXUTZWUV6)I+J(^?Y&G7$<1>2RN[@0&!
M+E&C:/8LI7S"H4\YK\^O"?\ P37^(_@6W$^D>.?!*Z[JGCG7/%6J%+/67\/"
M'5=(@L+M'ADC-XEZ8(9/(9'$2W#0LW&\59LO^">_CH:3XC\"V'C_ ,,W7PR\
M6^*)?$VO7UU::M_PDVE:Z;JWO3IUE<+"L"637-K:P>68W(B>7+Y.:U_LOA54
ME-9S7G)4Y-.KB:U1<L4UM4GK:SM#=WTC)6O@L9GRVRB*][I12]Y[+2A;7MW\
MS],_AO\ M,_"/XJ>)=;\)^$?$MOJ6N:$XCO+5!*"Q#2(Q@=XD20 PN6,;'''
M."!7O#W422>68Y#^[:1V&W$>T9VGG.3TZ'&.>V?@KX+?LH0?#'QGX2UNWN]+
MW>$K#5[>X32[>[AFOX[NTCM[2;4'N45;B8F,L=I&UR<CD"ONI-Z1!74$W/FR
MS.<92(D$@\]E8JO3)['BODLT> P]:?U*5;$T$ERU(5*BA-M*_+;F7NRNFDVV
MU=V=T>YA/KU;#PJ8APPU:3EST'%)PM*2C=>X_>BE*_*MTM;HTU:-E#8.& 8>
MP(!Y^:D9U'W=W7'&#C]<]1GGCBA055/+4,FT;>!C;@;3QSTQ^O&:)"S(O SN
MR1GCN!ST/7'&3G\:\BGB%5335:BGHZM2I4Y*:_FES\L;*VMY):K7OT*G6;2=
M=6;LWRK1?^!^70C\W_:D_+_ZU'F_[4GY?_6I@#$ [%Y_VC2X8_P+Z_>-:\D/
M^AI0_P# J?\ \N-/J[_Z"(_A_P#)#O-Z<N1GD$'I[8'7T[>M.\Y,YVMTP<@G
M/&/;G'\ZCPW]Q>F?O'I2?-D#8O/3YC@_C[41A",E-9I0NE;65-JWI[:W7^M"
ME1DM%B(?<O\ Y,D\V,<B,@\\X/<8I?-7@!6&.^,9]SD?ESQFH@&)QL7_ +Z/
M\NO_ .L4N&_N+Q_M$U51*JK2S3#KM9TU_P"Y]1^RE_T$0^Y?_)CFD8G*E@..
M,CV^G^/YTGF/_>--^;^X/S;_  H^;^X/S;_"H5*RLLUH6]*3_P#<X_8_]/*/
M_@,?_DAXD8$Y+'CY>0!GMD?Y^M6Q'*1G<,]0><<X[?B?T'8$T<-_<'X%C^/H
M<5K#@#Z"MZ,%%S?UJEBW+EORJ#Y+7[3J6YK_ -UOEZF-6E&\6YJ6]O9^[;;?
ME;OY7\[%&X0*BM*Z<-D9!P3Z# ^@Y]^>0*YWQ/&DVF2 J2!?6WW,;B/M<)[G
M&1G'4<<=>:ZFYW>7D*K8(R#CCD<C)'09_P ,XKG/$"7+:9,L4L4?^G6I!8D$
M_P"E0GDYQG@=>/Z;.*?2WI9?H*,5%63?S=SI;8*L$04,%$:A0WW@ .,X[_YR
M>M.F#M&RQX#,,9;H 0<_Y_F.*2 .L,0D8,X10S*<@L!R0>X_$_4U+5#*XCD#
M0\KL6,JZD=6( R..AY'7G/.:\[F\%ZC]NN[BVNK6*">0R1Q,90R%AELA4V\M
MGHW?/7KZ910)Q4M'?>^CL>4MX'UMX51]1M!*DX*,C3A?L^"6C8^7N),A!  '
M?D<Y6/P3K8:=/M]G#"U@((?),QD%SYXE,DF^,C88\H=N3G'&,&O5:*AP3^U4
M7I.2_(2C%?93]4G^:/)XO VM1S)*M_:Q,-WF>6\[>:61D9V\Q3M8@C.S"\'"
MC)!>/!6OAB1JMN!]GCB7!DR&0L0Q_='(&[.>N1C!!./5:*VI35+X:6'DWO*K
M0I5)OSE.<7*3[MMO1=C3FM;W8:;>Y'_+\SRP^#?$I,2?VY$+?9FZB"+BZGP3
MND/V8L%+XW!".,X':A?!GB V]PDNIVKR.P>WC 98;=X26M]KB!9BA8CS0Q/"
MC8.U>IT4JDH5=9T,*_3#45^40YO[L/\ P"/^1Y9_PA>O+)!(NI6I-U-:OK4;
M--LEBMOD$=J1'N&Z-G!WE1R!2_\ "'>(E-[)'JUNCLVS3XP7$45LP)=)OW6[
M<7PWRYR,Y8&O4J*:E%1Y?8X;EVM]6H[:Z7Y;]?N#G?:&G]V)Y;-X+UYVC\G5
M+>V41@.8@V1+G)E57B(SG.,YX8@^M,B\'^)D#E]3LGN6!0WY,WVIHR""K#RO
M*'MM7MCIG/JM%<U_93;II4MO=IKDA=]>2"4;OJ[-O2^R!S<H\KC"U[_!%/[T
MCRRW\$ZS97-N]M>V;VJQ/%>03M,WGET<&1,(=CY93]Y1@#.>,5E\#Z]%90Z?
M'J%FP@U"6YMI96G,EM;F.-8XHR(SE@T9W!PPP<@D]?6\=>2,_3Z=P?\ /X48
MYR23CIG''Y 5$YUZLH\\IV4EJFUI?RUO;^K7"$O9IJ,8)--.\(O1[VNM/D>8
MMX2\3)=K<Q:M:2B2,I<+.AS\P8.8PL&#PW&\X.T;ASFJ;>!O$BV]U&FNQ222
M2E[4RJ4%NI8D*#%!NPH( !)^48X[^MT5LH)?:J/UJ2?YL.;^[#:WP1_R_$\R
M7P=KZS6[/K27-O%'!NMI46-!,%3SW1H(49E:12R>822,9P215)O ^OBW"QZE
M:+<&299&+3F,VTTCN47Y"=P4HO*X&#@XQ7K5%$H\UO?JQMTIU)P3\VHM7?9[
MI: I6^S#YPB_T/,9?!FLO>+*FIP+:PM#<6\&'#&ZBA$0,I\H@Q$ER<9;D#'I
M7'@WQ.(8B=6LGN'E,]RC!S;13;BHDM!Y&[/E!5/F <ENV#7JU%82PL);UL5_
MX4U=?Q_X <W]V'_@$?\ (\ND\&Z].TB/J5K!#%$K69@,HD-UO D-SF+'E&(L
MH"$MNQV&3$/!6NLT4TMWI\EPL[*<R72QI9J%,8CV1#,Y?>'++MV[0K>GJU%;
M^RH_\^,/_P""*7_R <[[0_\  (_Y'E2^"M<9;AI+NPCG2YFDL7@>ZVB&;"LE
MSO3))0 ?(",GKWI/^$'UI_(W7ME!Y#Q/B S'>0P:;<73H^T =LGD8Z>K4545
M&%_9PITV]&Z<(TVUV;@HW76SZZAS?W8?^ 1_R/+[CP=X@N([P_VO##-<03P1
M"+<$B#JR0SY\DGSX%(9#@KOSV(PB^"]<BN=+GM]3MH(]-AVS6Z[VCU6<E&::
M]WPLP^96 \HIP[<8P!ZC142IJ7Q2F_\ M^7>X<W]V'_@$?\ (\L3P1K4"7+0
M:E;?:4NEN=->3S2L9*EI$G58ONB5F$94,2@7=R#26W@K7K602QZG:L]VQN-4
M,IF)>[VF(&VQ&<1& ("&VD,#\O0UZI16B4$DO8X=V5KRH4I2>EKRDXMR?5MN
M[=VV[AS-?9A_X!!_FCRW_A"M>^SQHNKQ0RVI*VK0&15\L]?-W1']Y\S@%1@#
M'/)Q(O@K5U8(NKB.%K589G0!IY)5+-O.^$HH+%<LN'*@@DYQ7IU%.\/^?.'7
MG'#THO[U&Y,DIKEE&-KIZ12U3NMD>3CP5XA%K)&-1LA/$(OL;[IRN[?^_DN"
M8R=Y0#;L!!;[P"U8'@O6X[F&6'58O)^S?Z7 X8+/>,H\R0!(C^[>3GJK8'0<
M9]0HH]W_ )]TO_!5/_Y$S]E3_D7W+_(\H;P5XA4N\.HV(994:"!FN%ME1R3=
M%@L>\NW&P].N2.#4[^!M2DF"&_@6RFC"W07S#<(^%#FV+(5 )W$%V!/ .,#'
MJ%%1.*FDGHELHI12]$E97ZV6KU>I:2BDDK)=/Q,73]*_LZQM;.(J3;N6+]W7
M<S<GCYCGYL<9)Q6G%&R,[-CYSGCGL!_3^7I4]%.*4(N,=GOWWOOZC"BBBF 4
M444 %9NIAO*C(N'MT63=*T8)9D"ME1@$_>P3@$XR,5I5FZM>0V%E+<SF$+&,
MJ;B1(80QX!>61ECC )!R[ $@*"&8$ 'XW_M[_ 'QI+XWT3]HW3O$NK7<'A+1
MK:"^L-.FF^W^"634II+?7?#2*&>V6ZN+F#3;N-([F8V<]TS!(V,BZ_P^\%:+
M^W/X%7Q'XROKOP/\9? >K7/@O6?$WA6XBMKK5=.MK6 F^CN4CO%ELKUKZ>#.
M^0,3)AR>*]/_ &QOVD-%^'7AV_\ @_87FGZE\4_'^D)=W5U=/&EGHOAQKLK)
MJ<UK*^[9<O92Z=;Z0+B.[2YECN\2(P1N8_8AT31_@K\.?$7Q*\;WJ^$?#'C*
M[;_A%;3Q#J=O:7H\(1^1<Z7J-Q9W307$=_<7AN(I[-X8[N"%$EFC6,J2 <QJ
MG[*OPZ_99\/:C\6?&&IZU\2+KP09O^%=>&?$=U%>:5;^(9U$%M>_9GMH>%G-
MF\SM*ORQ AE^\/!?V9OA7\3OVAOVA-._:,USQ9K=M-H,EQ<ZGXO2YD2*>\U-
MF:#X;:+$0TP\->%YXFTRZA59H)M/O%2"ZVYD/WC^T1JW@/\ :6^"'BK1?A;X
MQTWQ?XKT-!KEKHNE:S9R7]ZMBRWE_8VUM%/)-.TEO:M&$BC<@N/D(//SI^PC
M^T;HOA6S7X+^+$M/#-Y>F>[\*W-Y;&U@M?$=R"VL^&;S39/+F76--N!96EQ+
M(T3ZK<.$@A5T*  _8O24ECM L_\ K_-E,Q# HTI;YVA ),<+-DQ1L2\:;58Y
M!K3K(T-)$T^+SF+S.SR2R%N'E<AG=(^6MT9LE+9R7@7".2P)K7H **** "BB
MB@!"<8XSG_.?\^M'4>G/\CW_ "[&F2=OQ_I2DD*2/4C/IEL?_JZ\]1C-<KO.
MM*#^%;^BC%NWGKTZ@8]W*#!(S32)$'8 0Y6Y+Y("H<$[=V1G:1C !ZD5#>7$
M4*;[2Y5!C9)+*DKL, [Y40>8< _,NT=^A%?"W_!1+]IGQ!^R[\"M7\;^&-+G
MU'Q'<&6SL+B&WDFAL&</&ES,45MGEY5@3)&<J2"""1_.%\+?^"N7[67@+6!K
MWBCQ5;?$F+7XKI[+1G,CVNDO-(K0QSO-?W,$ @#!"7\M1M.0H%>[A<B]O36(
MAR/ENU&3G=VTM'E6J;OO9VU[(FH^6$GK=1NK?*WY_P##']D$.IL[,&GA;:2<
M?99[=0!_?EF"QX'0G<%S]*P]?^(G@WPK9&]\1^+?#&CPKN,TE_KFE6BQJ,Y*
M^==QEL <A<DDXZC%?SX^!OBS^W/^VLL,MO\ M!_"/X$>&[D 2:3INMZ1<:Y<
M0R?PE-,\66EQ%(REL[[4MDX*YR*^B_#/_!)73/&5TNI?'#X]>._BK'=XENK
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MFO8UI\\$TI13]M[KM=\R4MN5)7YEZ&$PV.A!J=9I[:R?Q6WMV;OY;'Q=<_\
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M66I7EZ\\TQ\V8QP2*R>;L2.39E@ =G';'@YY+AZ7U;^P</4H->U^M>T4O?\
MX:I6YI2VM4=E;=-W/7RJEC*7MUBY3E?V?L^;FTMS\UKR?5K;Y]#U*&=;D2+'
M.LGDCRI5<-D2@AF)9L*< CTP<8.,UB>)Q;?V7-YJ3$?;;8D1 Y8_:XCD$*V
M>.O?IVQ.NL:/!')NEB1A$LTZHJERS, )"Z@@D\ C&?7&,5EZUK-I=6 BL]0B
MCDN+J!X=\3$.JS1.3NW *0H;T)SC ) KP#USN;/;]EM]@94\I-H<Y<+M& QP
M,G'7@59J"V+-;PLSB1C&I+@$!SCE@#R >V>U3T %%%% !1110 4444 %%%%
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MC/A#XH^";[SV*I!'XATFPOVD(!*_8A=O.=PP V,L<@'C ]H0VUZT,MM<P7<
M=9$F>-;]=JD-NCN"2$.,%7!(7J.037Y>_$3_ ()%?LU:S<3ZAX!O_$_PKU:5
M 4N_#VMZKF.?+,)HHH;^S$8)(&Q"%&#@CH/GZY_87_;Q^!3&[_9]_:8U'Q?I
M\#"X32_'N;\311'>+4'5K_4F E!,0*K]T@JK8Q36'H322?+S>[=Z6YM+W?92
MN[=%ZB^L5;J_ETZ?G^1^\J1@D&*3(!SPP(/()[\9Z9[Y![&G%E<D=P,<YSSC
MGGW].AR.QK\&K7]LW_@HK\"Y4@^,7[-)\?:3&W^E:[X1%RH2(??D6WTW0A&Q
M"G(!EYQU //N/@G_ (+#?L]:A*FG_$;1O&?PSUTM''+:Z_H5S;6JOR)R+N\F
MM\QPN K/Y8"D_-CO-7(L335Z515(J_+*G.+6CZ^];_P%M/9G3[57Z77F[?D?
MKIM],?DOI]/7]/SJ;>J@#H  .HXXZ9)[5\Z^ OVJ/@!\3[.*[\&?%7P;J3RJ
MK"U36[#[6"PX5X5G=P0>",9SP<=O:(=6^UHMS9X:!L<7)^S@@KD/&<-O1Q\R
MMT(((!%<+PF,@VJCGV47&S7GHK.ZMJK^:0_:K3X?OM^GYG1>:GK^H_QH\U/7
M]1_C6$^I,A#,(E0C!9Y=D.><^7*1B1^.$&#@$CM217DMR3+;O(4'(C:$!&SC
MA9L]#U'&.,=0:7U>O_>_!?G;^NG0/;1\OO\ ^ =$#D9'0\BBJ(N) D),>TLH
M+@9*@G(P#C.!U!^@P.*M\DHP/RX)(]<@;>_^-:)-))[I6?JM'^1HG=)]TG]X
M^BBBF,**** "BBB@ HHHH *H1HL<DCR'B0E0#_"!G P#V!(XY!_2_5(J\N[]
MWMPQ(8N>I)Y QTX!QTSSZ$@&8FFZ<B7"-:6[B=R[>:B;6.3SE@1DY.!VQFJ_
M]E:688X#8:=B-RQ4+ >#N[8ST8$=!GVXK88MD*ZJX[;5#8(X.!T/7D]!^>&!
M$#%O*.2,']RGM_A0!0&FZ8!./L.G_OF#<+#\P 5>NT=@#S^A%!TW2W\@?8-/
MQ"2<%(>."",XQR"?SYYZZ!1"03$>/^F*_K[>W2D"(I)$3<]?W*_7 ]![>P]*
M *_]FZ1_T#[#_P @4?V;I'_0/L/_ "!5K"_\\C_WY6C"_P#/(_\ ?E: *O\
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M&V'"G+$?P^I' /2M38G_ #Q_\@)1M0$GRCD]?W*T 9\NGZ<Y<I96!#Q+&<+
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M /D&O=,#^\O_ 'RM&!_>7_OE:/:YG_S^?_@<_P#(/J-+LON/"_\ AGCX&?\
M1#_A?_X2'A__ .0:/^&>/@9_T0_X7_\ A(>'_P#Y!KW3 _O+_P!\K1@?WE_[
MY6CVN9_\_G_X'/\ R#ZC2[+[CPO_ (9X^!G_ $0_X7_^$AX?_P#D&C_AGCX&
M?]$/^%__ (2'A_\ ^0:]TP/[R_\ ?*T8']Y?^^5H]KF?_/Y_^!S_ ,@^HTNR
M^X\+_P"&>/@9_P!$/^%__A(>'_\ Y!H_X9X^!G_1#_A?_P"$AX?_ /D&O=,#
M^\O_ 'RM&!_>7_OE:/:YG_S^?_@<_P#(/J-+LON/"_\ AGCX&?\ 1#_A?_X2
M'A__ .0:/^&>/@9_T0_X7_\ A(>'_P#Y!KW3 _O+_P!\K1@?WE_[Y6CVN9_\
M_G_X'/\ R#ZC2[+[CPO_ (9X^!G_ $0_X7_^$AX?_P#D&C_AGCX&?]$/^%__
M (2'A_\ ^0:]TP/[R_\ ?*T8']Y?^^5H]KF?_/Y_^!S_ ,@^HTNR^X\+_P"&
M>/@9_P!$/^%__A(>'_\ Y!I?^&=_@8>GP/\ A=QQ_P BCX>'OS_H/7GC/7\.
M/<\#^\O_ 'RM1N2#@,H& <[5YY/3Z8IJIF;VKO\ \#G_ ),<<'2B[V779'B'
M_#.WP-_Z(=\,/_"0\/\ _P @T?\ #.WP-_Z(;\,/_"0\/_\ R!7MNX_WU_[Y
M2C<?[Z_]\I1SYK_S_?\ X'/_ .1-/JM+L>(G]GOX"Q_)/\%/A=#YI5%+>$/#
MY)9CM  ^P@@G(QCDYXP<&O&?CA\!/@IIOP4^(M]8_"+X8VVHZ3X7\075K,/"
M>@*T86&60;2+1=N2 3@C'7)P<_9\D*7)194601NLJG !#QG>IXY^\.G&>,\&
MO&_VA(4D^!WQ65HXP&\!^)"^Q54[EM) .1^(Z$$'/6C YCBX8Z="K.<I4Y0D
MY<\VF^6+UUCI:?*TU;;1V1EB(JG2Y8[+;3O=[].NJU^\_/W_ ((\E/\ AFC5
MD2..*-?&'B!5CB4+$BKK.JA$B5<*L2!0L:@8"8   K]=D4!P<=(P,Y_W3C']
M?UK\A?\ @CLH7]FK5\9Q_P )CX@ !]!K.KX_SDU^OR]_HN/RYQ^F:WS+]YBX
M5)+7F@^_V'K]VGS(PKM3:\_S2'T445F= 4444 %5[J[MK*%[B[GCMX$QOEE8
M*BY.!ECP,D@?6K%>(_M%3_$6V^#_ (VN/@]8:7J?Q8BT><_#RQUJ6>+3+CQ&
MS1I"MXUO!<R&);9KF3'V>8;D4F,XR #V-K^R6=+9KJ$7$AQ'"7'F.<;N%ZGY
M>>G2IFGA7;ND0;CM7)QEN.!ZGGI7\@/_  1=\0_M>6'_  5#_;G^'_[6/Q'@
M\9_$&TTJ/6+GPZFL7\_AOPS=7&M:-:/9:- ;.QCMW6VW !;2)=LK $9%?UK6
M^G01M'8S32-:E4DMK)F^:)F8GREFSYS!#AMSN6()#9 H UO^$@T03RVQU6Q%
MQ!(8IH3<1B2.0=4=2V58>AJY)?6<4?FR7,*1DQ .7&TF8XBP>A\P\)CJ<XZ&
MO\W#X[_$[X7^(?\ @H#_ ,%4="_:R_:?_:(\#W_@;QAXGM/V?O#_ ,+;MI-+
MT^^BUO7X=&L[J$ZQI.S[5+%8VP!BNB3D<DY/Z0_LB?\ !7#X_P#[#?\ P31^
M UQ\?-)UOXE_'_XY?&3Q7\.OV?M,^*BMI,5Y\.]$U/PQI^A:]XAN]*9-0$K:
M3K]E=JZPWWSB1BYQN< _MQDN[:%#)+-'&@C>8LS8 BC&7<G^ZHY)H2[MI/N3
M(_\ J\;3G/G+OBQ_OI\R^W-?RJ>#/^"_+ZU^R=^U/\3_ !=\#?#=K\<OV6_&
M/A#1O&GP[T77?$MSX;\4CQ0_BI_#E]H.I7EU!J<RSP^&KI]6A\NSAB>ZA6..
M=.%XKQ]_P7Z_:M^!'[.?PU^//QR_8MT;X<'XVZ[HVG?"FVU'4O$X\,6VCZGY
MJIJ/BS4/M,FH66G3 V<_GV<=]+'!(S1*N-A /ZWY;VT@C::>XBBB52[22.$1
M54X9BS8  /!/;O2_:[;9')YT>R8@1-NXD)!("GOD D8]#7\>/[6W_!33Q]^T
M1_P2H^)'QA^,?PW7X67GAGXC:#I]M?\ PB\3^(9](U*+4-*U>^M;B/5KS4-,
MUA+1H%C,RD(F\ ^42!GLOVB/^"_/CW]G3XC^ /V8?A?\#O"_BCQAIWPG\,:U
M/XB^)FM>(M'L]9N[NUTGR5\'7&D2WBZM)]DOD,LFIQ6KFZBN$+E%!D /ZW!=
M6Q8*)XRS)Y@&X9,?(W#U P<^F#40U*P(B87<&)G,<1\P?O)%&61/5@.2HY K
M^-S_ (**?\%$OVZQ\>O^"=-K\'/AU<^&?"?QAFM]>\<>%;2ZN'CUS7OLWB<7
MVB273?:;I;:WTO3XM3B2VNHB[P+YB;'?=TGQA_X.-O%'PO\ C#X^\.>"_@9X
M7\1?#7X*:YI'A#XYZCXDU37K/QZOBB^U:TTC6/[ T739I=%*VD&H6ERI:[L?
MNR;DQU /[!9+F"+(DE12,%MS 8!Z$_4\#WH%S;MLVS1GS"RIAA\Y3&X+ZXR,
MX]1SFOY=/C#_ ,%UOBQ)\=1\!?V/?V5Y_BS97/[/7A_]H32=9U:ZU5-5A\-W
MEEKVL7EK?06FHW$",NG>'YPAR^7<[I.C#\[OVV_^"RG[67QW_91_8S^.G[.W
MPMO?AKJGQ!_:9_X5Q\3-!2[OA<_\)1X+\5^!K:#PY:B::]/EZ_JFKW6ER(9(
M':-]N W S=-.3;;=[::=.E][,#^YB:\@ACDE>6)8H@3-([82, 9RYZ 8R23P
M ,UG1ZYI%S/):PZC8R7$$:33013H9HXI$#QNZ A@CJ0ZGG(P:^#OCWXP\?2_
M\$Z_BCXU\2Z==^&OB,/V:_$.M:W812207_AWQ,_@>:[E$3HR.)]-O_.7+-D-
M%DY*U_GC>#/BCIT_[,GPV\?_  )_::_:Q\;?M]7GQVN+9? ]GY6I^#KG2(/$
M^K1+::F]QK<K_P!FPHFGP2E=,=XXB=J\XJ^6/\J^Y?Y ?ZFCW=I&',EQ&HC0
M22%G.$0@$.3G &"#GMUIQU"Q@DMK66Z@CN;O)MH'E599PQ9@8E/+Y R"/SK^
M4[]KC_@LU^U3^P]X2\%6_B?]FOPUXGM_#_PF\/>-/B-KOCO6M=T>:\N[31M&
M6^MM%BT"207-TTE](YBO8[:,RQL)#@ FQ\1_V]?"'Q__ &K/^"4'Q0A\.>)8
M],_: \)ZCJD.GV.MZSIUEI.HVFK^*XVM]5L;#68;6YB0Z3*D+3QW<C0/$7R3
MA9E!25OA\TE^J _JJGOK6%',UQ'&(V"2,\BJ$?@[6]R,8!SG(..]!GA'E9F4
M"<D0DE<2D#)"<<X'7TK^.:__ .#B/]J*+X>>-/C_ */^Q=I;?L]_"?XPQ_##
MXC_$A=5\07$]S;NME;Q7%E;37CV!F\W5+"1BSP$"-L'G:?ZP/A+XQMOB3\/O
M!OCFQMI8-.\:^&[+Q' 7R38->(S^6 SN4V[ IPQ)!QUX$QI<JLIRWOK;T\[[
M#]WK%/S?_#'I]Q&9RY@G:.1"8S(D,<P5EP64A_EW X)&.,GI@52:VO)$V2&2
M\(&Y&ES8[2,G&+<G=Z8.,>_;7TUE:TCPXE8#$D@&"[X&6.."3P>,\8Y/6K]7
M:5K*<MM'9.SMHUYK?Y":BTURJS35O5-=O,Y":SD>#9<6CRI(N)+9X$U&'OG(
MN0X(/(.5YZ8QP/(/&W[.'PB^)$/D>,?A9X.UN"5)$>631;#3KQ%E(W[9K*T2
M4LW4L9 RD$ALXKZ.HIPEB8)+ZU5:6RY81_\ 24OT.?ZO'^:7W+]6S\C_ !S_
M ,$@?V<]<O)=3\#W_C+X77TS.Y;PQK.KR1(YY!6*35[>- "%( 4#C&,"O#I_
MV$_V[/@HYO?@'^TK?^(K2V=G31_'*VE\9XD;]U KW\&L2#*A5^7&.F3S7[PT
M5U0Q]>E))J-;F5FJB>B5KM.-K-IW>^RT#ZO'^:6BMI;^OZZ'X)S?MA_\%&?@
M@D<'QD_9BA\<Z);2>0_B7PT+^9[F6/YWDCM8-'L[0!HE+ K(HS@ !>GK'@/_
M (+!?L^:U+%I?Q1T+Q7\(M;BPES#XJT[^R=.CE_C"W,NH%C&K9R?*' SCM7Z
M]ZTEJ\,2W;6HA,AREW!%<02G:1L9)HY5!().X+G (R,\^'>.?V>?@E\2X77Q
M=\-/">M"3),UOIL$<YR3R3"EN<\Y)S[@J0*[*>+I3UGAZ<6N9WIRG%V[O5?+
M5M]EN"PZT]^7SM]W_!^\C^''[4_P#^)EC8S^$_BAX+U:.^MXI[*&TUJ">>2*
M3'EDC/!/IN))[G(KZ M;N"Y59K:>*6WD)=)8W5D<-R-I';D'/3.>F.?R9^(?
M_!(;]FOQ3<SZKX'O?&GPGUJXD>Y%YX1U34)/)N&^; L;[6'LH$5QGR88%C4$
MA5]?G^^_8<_;U^!UR+SX"?M/GQ7;6!Q8Z#XWDM/MUS;/E94,,.@:BA9(1R3.
M""<J2<9RG1P4[NGB*JFVW*,X0Y4W=N,;2NTF[)MMVUEU9/MIQ]WEC9:)W>RT
MU\W:^A^^/F( 26  ZGL/J:;Y\.T-YBE22 0<@D=<?2OP<3]K_P#X*,? _;#\
M9OV;SXZT.Q %WXC\/?;Y7GB0_/,L:)ID)W!=ZC:!CVX'J?@7_@L)\ =7D33_
M (GZ)XT^%VI%C#=6OB32K:ST.T=6*!UO8[^XO6#G)</&,'H 1BN6=&45[CYW
M?Y<NNO>^WDBJ=:\K32C&S=UWZ=>JUV_4_9)I$4;F8*/4D>F0?Q%(TT2J&9U"
MGH<]:^9OAO\ M/\ P$^)]B+WP+\3_"&KPLF_R;74Y),E@<)/]HC5D'.&V9QV
M&!D^X6>J6UXJ7%NMO?VTG*3Z;/\ :$&>AP\H!&"22 >O8#!R]G6_D7X_YFWM
M*7\YU/G1;@F]=Q7>%S@[<XW?3/ /<TQ;FW=S&LT;.IP5# D?7%<_,PB0S2:A
M(D3MCYXH0\6?^67 )*]\EL@GDCM:*B79$/,56"L+D)&"Y!R-S9! QCIGKC'3
M&49OVDH3BX\KLVEUM?9O;].I+GK[MFNC[_<;7F)_>%.!!Z'-5&.,@ Y(X.XX
MSD@9YSQUI\#9++G. O;CVP>_'N?>I>)H^TC14GSR;23MK9-_DF.,FWLK=?ZO
MW+-49I(BDDDJRHL0)<<KD ]>J]<<$<D=*O5GS(Q2X6W(#8PP<Y3[K#'.[@],
M=/H2<[%GF<GQ=\'K-+%'=23PPR/"]S:A90)HF*O$6:08*NK*P'<<YYPG_"W?
M!_\ S\W_ /WXB_\ CM4_A?96XT74)+JQTQRVLZD"YABD;<;ZY)SNBP.<Y/7)
M (Z5Z5]FTO\ Y\-,Y_Z=;?\ ^-4>NW]7)?/]F-UWUW//S\8/!H.#<Z@#_P!>
MZ?\ QRD'Q@\&'_EZU#_P'3_XY7HRV.E%018Z;S_TZ0'D<'_E@>X]:7[#I?\
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MMK]^FI]O#XN^#R PN-1(8!E(MXSD'H1B3H>H]L&C_A;O@_\ Y^-1_P# 9/\
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MYCCG4[[BXFL%^RWUI"H18() "FI3%T'FO"B!\1N[GS"!&<8"NNZ _CZ\,_\
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MVFVYD\&6&G:7+I)F(L3/LU.*XB$KL%4)@5] ?#__ ((U_&KPKXF_X)S:U?\
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M'N$W>6^T9ESD\D=:_JTNM/L]3M;RVU+39+Z*[A>QF@NE@D62WD7+%5  "@]
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M!OVY/@!^UYJ?[3?C#]JS]E+X$^*-5UWXU?#:[^'/Q2\'>/I+2Q?3;6UT[2M
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MBNKAQ"7C9!)++&<JHVK'*45NA'S*,\G@YX(J_;;YHM[OAM[KA0I&%<@=5SG
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M6_BW6G\0:-I]UJ%I875SB4QPZM/YHT[1)$2P=WDU&..4B-02QA/ -=/XO_9
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M%)/@?'I/CSQ 8[F5?#&ESZQ8BWBE+Z_IUM<VVGS/:C[.Y;RKZ?[,V0QW1$
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MO='\/>/;O7-<U^&_L(9(M-\/:M/<?:[-=/C2>1Q':W(PGES2JJQH5?I7R/\
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MQMKW_!3/6;?QG:^%=/\ A7'?66E78T7QEJR^+=$2;2M;> O%=:+$8C+<6]O
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MXM>!9N4UA<#(<M%(NP@@<@KSR<?RS0!Z317GO_"TO!'_ $&HOH58'\CS3?\
MA:O@;_H-P_\ ?+?X4 >B45YW_P +5\"_]!N'_OAN?8<=3VIG_"V/ O\ T&4_
M[]2?X4 >CT5YR/BOX&/364]/]4_]12_\+6\#_P#083_OV] 'HM%>=?\ "UO
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M[_@HKXS\/_$KQIX#TB711X*F+Z'I!T2[M(-6AO#%#(\EWJUL3/8WJS),%MI
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MX4X4U1_@MPTM9ZK;R2TN83EB7_#JQ@O.,G^4E_70;#CRDQR-O'TR<#\.E2T
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M2O%J<=5K_DRE.C9<]:-.5O>@X3DXOLW'1]'==S+_ + \._\ 0(TO_P $=O\
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MU]FO[OX"&"99,B.)Q(N9G8X8R+PN !T"Y&<\G&<C)%X<  ]<#/Y>^35+S/\
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M>2/[+/#I)MT@>21(&"I&1D>/OV;OC)J/ASQ5>:9X \8>&8?[)\)*FE:+=7\
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M<&ZSRP@Q(8NI/F 9V<#N?\:?&C-(J(TBNQ_UD2H[J<$DHD@V,<<[6^7L??\
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MN;ET<8N+DG=.*<GH^SO4,3DZDE[6">JZ+I?O^B\CZW63=,\"QR&549PFWYI
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MIH_B;Q'IVE>(KS59Y-/T(*]PQL)(T*3G9%-!%&-LS F9 "AS@<UW_P#PTO\
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M - %76Z#_>3_ -#6J6E_\@ZR_P"O:+_T 5=;H/\ >3_T-: .)\8_\BAXA_[
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MUM%^/WQLN?AUX'M[;5? /_"MO#WQ&T3QHL<\9O++Q4NJ#[&EO,8KR)I(=-5
M)[1!NG"DY!QWGQV_:]^ O[-VK:3H7Q+U%TU:_C6[L]/TFSU.\NXM,E$<CS7B
M6UK=".*S@82322;(U168,0I(KZ_Q;A\YQ2P> H59U*%-RHU\/"I#EA5;<J-&
MK3Y8M7?-:2?*^5MK0V^H<*1H*6/S'$Q@[JG+#XF<9*5FY.;I55)KEM9-OWM;
M;GX<6/\ P29_:VO?@A<^%KCQ]IT%JOBVRU&R\)O<Z@L#Z?;7ES+*)9(;7SV@
MM(C$DC"<R!6^4DDXZOQE_P $L/VCY? VGZ+IUQX,\>77BGX:>-/AY/!K]]K[
MZ3X5O?$5Q:166JV/DQQW)NK"*W9H_/$T).2R-P:]4^/7_!:B#X>_$3Q%H'PJ
M\)6WB[P;X>\(QZOI6KII>L2F;5]>TS^T+"VN64Q(;=9XS%,%C1MOW'SAA]G^
M,OVZ[[P?\'/@A\2)K#PK=^,/B9KWA73O%6AV\LI@\-:;XB0S?;6TO[:-4$L5
MMLD(59<EF81MD+7O8C,>.XT87RC*ESZ*V!PJE'W7.TG&C[MN6UW*SE:*U:OP
M4</P&ZDO^%?-)6YK)X[%M-WLE[U?5:KO;?:S/*OVP/V.?V@OBS^S#\&?@9\.
M==T4GPCIVD:1XYFE\Q;25+.S>&XBCDBM3<QPJ0BJR[)"JC))R3\#V?\ P2I_
M:OTG6_@YJWAW7K.TUWPQ-;G6?$>G7M]<.+:'4+F9DDBU&.6*-# R1YBMU;&/
MF&23^EOQ:_X*C?L^>%_"?Q4C\ ZA%?\ Q!^'OAN/Q#K6ARV.JQ6VIP"VLY+F
M:PEDMH(I%BENT@\I;EIBV<(2#C:\'?\ !47]F:X^'>H?$/QEXH'A;5]/CLUU
M/PB=-UFVO8O.M8)F,=O/I[R7@/F*^;)YS@DX.TX\.6)XHK4)T<3D5*"<ZCE4
M6"@FW4J5)SFI*@K1YZDY1<9-*'+&.D4SKJ?V9&<?JV*G[!<JI.55N4J225-S
MESMRDX*/,WK*5WJ[GZ3V]I/##:V\S!9H["UMOM<'S16H@@0RP$L"<2S)(3N#
M,#/P0, ,=S);"3R8X%>*)HXXV8A8R_&[<20Q()(R>V*^"O _[=7@OXL?&;X9
M_#;X3RKK7P_^)7@I/%=SKXBG@DLI'U#5K40M;W:6]XI8Z5&O%HV/,SQ@U]\W
M"P")C;PO!$Z1LJ.ZN?OXS\K-L!QPC88<Y%?"XS 8BCBW7K1E35I1]GK&*<M(
M^Z[:KE>Z;/I\%]5=!.E5YZCY;>]S-QWD_B>SMLO6PSX,]?%O_8PW_P#Z-%>X
MUX=\&>OBW_L8;_\ ]&BO<:S.HBD^^GTD_P#0:\-_:!_Y(C\5?^Q \2?^D;5[
ME)]]/I)_Z#7AO[0/_)$?BK_V('B3_P!(VK3#_P 27K^L3GQ/\/\ [>7Y,_/?
M_@CQ_P FU:O_ -CCX@_]/&KU^O2_ZP?]<A_Z%7Y"_P#!'C_DVK5_^QQ\0?\
MIXU>OUZ7_6#_ *Y#_P!"IXO^-'T7Y!A?@EZ?HB6BBBLCH"BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH *IW'^KN/]U?_ $!JN53N/]7<?[J_
M^@-0!YG\(_\ D":A_P!AC4O_ $MN*]8KR?X1_P#($U#_ +#&I?\ I;<5ZQ0
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MVJ3:+IU_-X8U.0ZG>B]N[$W!AT:YTZ.:U"^8Q1"K3 XC^9QD'T&#]B7X+P^
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M!*MJ&BD!E=I9 ""F1A<5HH<':WS#%IIVLJ;:O97LUB;-6M[WPNS29SWSOI'
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M'X8M/+CCCEF6X1[E5 N0//=<K*.0?E'/4=.:BI351).3C9\R:WNDU;=::O\
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M _5;CP/X \8:IX;T75Y-?TZR;6[FR6P:^73M%GLQ>W"VEI>QW4L$"2MY);.
M":XL5B>),15I)4\%#$QJJI1G3Q$(SC64VJ7+&G0O*<&HN-I1O=2YE*4HK?#4
M>&J$9Q53-'.47&+>%J.-VO=N_K:LFVN;W6DDU9V3=#QK_P $>?"=]\#?AU\'
M?#OQ6U#P_!X6^UZAKOBV9+J75M32\M+2.>9;B*SW_:"MH\@9XF*LPRO8_?7P
M%^!_B?X5>%].\*:M\1+WQW\/?#_A7P_X9T&#6S<&YM/[*L39'496N(8!)'J(
M2*5E2(.R1$$9; ^ +3_@L'H_B/0?#-UX2^#FL^)(->\,ZIXCO;JZU6TT^/38
M]*TE]5U:RCT>^L4NV06Z,EN$^2-FR PR#U/A#_@K=\-?%5SX5\(-\/=7LO$W
MBU/#TUIHEWJ,%_(NAWK1&XO!;Q62F6'3+699TMU&ZV7*L1G(\S$Y3QCB:RQ&
M)JXAU5*ZLINSU2=VUWW6NZUZVH9+_-CNO_,/-/;3_E_WO=/\M3I_A=_P32M/
MA]\5K?XCW7Q:U'6]+TGQ/XX\5Z#IIM[L6NC3>--=&OW:V"26)59M-G");-$S
MA6C4#S,$GQ%/^"-&G:GXL\:^)_%WQK\3>)3XLL?&.E^&YUOS'>:'/XPU-M42
MYO/.LMSP:?-B-%C1&$2J "<&I_CO_P %+M6\'_M#^#=-^"]G<_$3X<6'P^^(
M?B/X@>#Y;:?PS<6$W@F/3#>76EW>L*EO.EJ'O6GBMK:=KEA'Y; X5MGQ-_P5
MZ^'VD>-/ 6DV_P /M3?2?'E[X?$^HZ;J=OJLMC=W5O"LFEW;V-G(UL&EDE5O
M.\M#Y.2 ,"O8PE/Q J<KPU+'UH4HJG*=&A6G*-GSQIRE%75W[W+=7U=M;F-7
M#\/U&G4>.O&ZBEAIM6;UU=?>ZM:R=GH^AHZ?_P $GKO5M3U37?BA\<;_ ,4:
M[<:MHVI)<P?:F&C0^'M$C\/Z9:VB_9I6P]A#!-,8_,!GW,"A(0367_!)70KF
MQM_"WBKXMZUXB\*:8\]M8:=#%>6]S:QS&6_C<O/I^QA'<2B0A$)/3&00<7PG
M_P %D_A5K.K_ !DN-2^'FM>%K'X=:'=ZU#;WQ:QO=4M+ V<,R:>T]A"VH^=<
M3;Q/:I-''DQ,"_-1Z#_P64\+^,O!HN/#WPG\76_Q4\1>(IO"_A'PWK-PV@V-
M_=C2)M3AOAK6J:;;:68A;02-L\XLY7:K!B >VOA?$2I3BHX3-HJ*5HK"5XQB
ME;2RM%))6TT2V3,O99)&_*\;OUP\KM7_ .O[U=W^9K67_!)JPUNUT^]^(_QG
MU;Q1X@L(M.L?!.M7,5Y%)8:%I.K)J\,&I0S6*RR3.\=U;D!(<K-'A=IR4^+_
M /P27C^*4_C+4_#WQOU;P;9^./''B'QGK.BQPWT<-Q>ZWIEE8RP1V\=B"EM$
MMI')$&!42*Q$A(XZW]F+]MCQIJ/['WQ>_:2^+MA'K?B#P7X^N[6V\/K/&)?L
MK6>B006D$DCSH8HKF_9QL!C9E9P,MN'EWA[_ (+*:3XOT32FT?X0:UJ7CC4?
M$_B7P7_9TFKVEM]DO?"FB0Z]?W0N)K(1&UDL[AH[>-2 )48AW+!6\F..XXJ8
MZ5>C@,,X4YNG.5^62<6FXNG]3:5E**E[S5VVGK9;U\OX;J2C)5<RV6^'JK5J
MWN_[9K9J5KV=M&MST7X7?\$]_&/[.::=XB^"WQ5O]4\7#PK\.OAYJDNI"Z5(
M]/\ !^J327\T8DBLCY<MK?S@@.^5!X(&#ZY^TI^PEJ?[07C+0OB)I7Q2F\!>
M-=/\(:IX+\=76G+=7&G>(O#>KZ6NE:D56SAN?+U"*Q-XZM+,S)+*#Y.<K7S;
M-_P5\T[4V\.6WA3X+ZWJ.N16<C>++0ZY90II%O86_GZ]<S^99!;H_8UG^SR1
M$J)(PX\SI6EIG_!7?PM)J/B;5/#?P<U]_AYX<T?37U+5[6_ABM[GQ%XKCN8M
M#TNXMQIY>)[K4(/L]UJ,H-LP;S6VHI-5BL/QWC\3&O3P%2FX1=ZF$INI5<9S
M<>2:I4J#C%NTH7E)2=K1Y]]X0X9PM-Q=+'8KGM'EK8>7)!J[YTY5JMKZ1;LF
MD[-M+7M;7_@EIX(T;2M>T[1OBCJ=I9:UI'A2TM)#:7TDUQ-X;TR2RG>Z=+ X
MCU!Y5D<,$)5B&(SQZ5\4O^":WPC^(-MX8UK0;R7P?XXTFZ\)7DOBXSILGB\)
MZ<FG3O#:QP_:4EN&C25<J<G.%YP/ [K_ (*Y6.B^!/&,^I?":_LOB3X271[^
M;P3<>(-/1&T/Q/!=7^D7D&J?9%L;Y);"!93';F1[;<(Y-K,N;OA?_@K/H?Q"
MM_AT/ WP9NO$^L^*+'6-7\4:3?\ B32M*@\/Z;X>U"*PU1[#4=1M8[2XFWRB
M00VKO(Y# (S"KK9=X@3@HK#YU=7;7U3$Q3TZ^]JK[7V,*+X;C4YI99-+>_L$
MVNG5/I:]K:*WD>;Q_P#!&33-0UOQ#>:E\>?%7B)M:T+4],M[/4%U 1M/>ZA%
M=I.YFTN-3#;F,Q!6;)!4*6 S6YKO_!&VW\::=?W7CWXZZCX@^)MJ8AX3\2HE
M['I/AS[/!%;PQ20RV;R2-':JZ#R90<L<  9.-\./^"F'Q,TCXZ^,?!'Q+\*W
M>J> /$WQ5\)>!_"OBG3;^&S'@6#7O#BZBUG?%Q<LY29)&\Y/LT<H7>JD-D_N
M.D3J&EGQ#:R1V_EPH \=[>SV\=Q%= )D)&;9]C.V5:4$LV2%I8_B'C?*,/1P
M^94<LITH8:-.+C5H5,6U"$8)XFG/!QJ4Z\=/;4G4G*-634JLK'5A\LRW,ZLG
MA/;TXJH[0J0E24%=-0C^\::2T6B6B]U:H_-_]GW_ ()X:'\#?'WP[^(^E>.;
M[6]7\">#U\.:C->>>MG=.FH:E<LR1R6T)4/_ &@,*7)/S$DFOT;DV&.:0(J&
M0I(XCQM+EADK@L0#CH?H *L$G;/%N8P32":2W./)WA1PJ@ *OR@C&3DGG/2.
M1(]F45461W#(@VJ-D9<8'5?F'(SR*^%Q&:U\SJRG5BHW;;LDE=-M)6C%6NW:
MR5U9][_28? X3 J-*G.I+$*-K--TU&RY[R]I*TNRY==5I8;\&>OBT]CXAO\
M_P!&K7N->)?!A0;7Q--_')XDU)6/;"NA&!V.2<U[;6)U$4GWT^DG_H->&_M
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MQ@\-MXFM=!?2)1#;:[-97VEC45U6WLWA%V]K'YBPM<)$8UD)CWACBO0/CO\
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M=VNH6\)OH](4K'<!WM)74(!O64X<@Y/Z'>(_ GP&UW03I6MZ#X5FTZ/6]/\
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MUS3F+; P>*9'5RI&?V)@TCX)6-JUK;:)X76U;3;_ $\P1:7IJI_9]XRM=Z8
MD8'EWA53Y0 638,*V.,.7P%^SXFK7'BFXT+PH^IM#;K-<?V9IADE2UMX8+9
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M$T81P>!@IT.>Q.<_E[#P+Q!HFN^"M9N-7\/0MJ.C:C(&N;".,O\ 91A1*ZJ
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M&DDKX^C=0=._,^9Q:2;YGAU[S25Y_$^Z;;?%_9V'Z1MK=Z)W\M>ESY1^,?[
M/[.7QK\1:7XBU[1=>\(ZOIVF:QI<,W@#5Y_"\=_I/BSR9/$MCJ?]EPJ)UO3!
M&CK.3N&\,')KSZ\_X);_ +)VL>)]$\5-X8\6:+>>'8[.?1=(T3Q7<:=I,TNA
M10VD5]K%M;VRV]]?7!B6=S.HEE::9LY=L_=P\8^%QS_:\G)!/[E<]?>8X_+B
MG?\ "8^%_P#H+2?A$@_]JUQ?VIQ;ADH5^))9=>/N4Z,H-58Q:3J2<Z<6Y0<8
MP3NWRMJ^KN?V7AI:N,;+IRKS?1/OY+8^&M)_X)B_LG0:OXN\1WWAWQ/K<_C3
MP_>>&&A\1:]<:M;66FW<]O-=C3[*[MV729/M=JKQR1<D$RCB3)M1_P#!-#]F
MFW\#P?#IH_&DL4FO'Q/INL7WB*]U+Q'H5VMF^FB+1?%#1BYT6$6Q=4A@*A1*
MX"DM7VW_ ,)CX6_Z"TG_ 'Z3_P".T#QCX6Z#5I.?^F*?TDJO[?XG3?\ QF=5
MWLK25!JZ7*M.7KU[O7<%E.%_DA;MR_EHK/MVO;8^9-(_8?\ @EHGP0U']G&S
MMO$T?PU\02/J>NW#:[<R>*;J['D@.?$'EB[:4R65JQ.UB1C/:OC?QA_P2%^$
M\]U\-]%^%^L^,/#/@W0=?U?Q5XRO7\47EOXTOY]4TE;"Y6U\29AOM]Q';0Q2
MQJKL\;2(V5DK]83XQ\+D[O[7DR,]85)[_P#3;G\N>M+_ ,)CX8_Z"\@SZP*/
MRS+C_/-:4<9QK%MK'T-6V[N.O-JW;ZN]7IJMNEK(/[.P_P#+V>RZ>JT/RZUS
M_@E?\+-2^-7A/QAI5WXNT+X6:#X*M-!^Q:1XIO-.UW5M2BM+N#4Y_%1@$=UK
MXO8YH$E-Y%BX_?99BQKZ9\/?L.? #P_X>\:>#+#PGJ%EX2\>Z5;V^K69U W4
M^K2:-#='3+NUF%NK>';RR>[DFLG*RR1S,IB^>(D_59\8^%S_ ,Q>3U_U"_@,
MB49QGIUS1_PF/A?_ *"\G_?E1G''.)A_]?\ *M<1F/%M.%-8C/U@$FU"<%&3
MJM132DZE"%W3TJ0EK*,_>33LQK+,/+3E6BZI)=NEK>BTZ,^"'_X)=_LKZGX-
MM_"VN6'C^Z+:E:WU]XDO?%VHZAXKNM.L9&:R\/RZU);F^?3;2U9K&*W9C"EN
M!&$"<&^O_!,/]EVPTSPII&D:-XST.T\%:E,L%QHOC"\L-1O=*UV\.J:C!=W=
MO;K+>1M*$6:&3()PCC*XK[H_X3'PQ_T%Y/\ OT/_ (]1_P )CX8'_,7D_P"_
M*_I^^_(#\*Y?[8XF_P"BUK=7JZ76_P#=Z7]VWPNUM@_L?#]8P];13_+OZ?E;
MYFE_88_9ZC@O;=--UJ9=4\7:%XLO);FZGGGDUG0=*;2-+F>1XB?W=B5261A\
MS@DD$XK["*NTHEMI&'V2UM]+FLYL^1%:011+'<6;-A))@J1H6B&[EQV(KEO^
M$R\,9_Y"\O88\@'ICOYOMZFC_A,O#0(\O5SO'W=\";,]MQ,I&/T/0\5RX['8
M_'QC3Q.(EBIQCRRQ$GK6DDE*HNB55KG]VRUO8>$P2P52<HI)2G*2^<FT_N?G
M\M3IP5+=0">@ST/;C^G<CT."3,!&"WRB,RNY/1$\H@.QZ*F>,GC/ Z<\Q+XP
M\-",O)J3R-@'$%O&3QT *2<'C@ YZ<<UD3WNK>.Q!H?AB*Y@TSSR^H:U+$\3
M%3L\RTW]U5%W8\SG?]T C/+1IJG!IJT].^VNG7I;S]3KDN:JJG927WV_ROY'
M??!IE33?$$CG;')XDU)XY&X21':,(Z,<!E<D!2,ANU>VUR.B:-9:%8VNCV\*
MM:0K$TMR<_O)U'WB<$9+JIQN)''.#SUU:%$4GWT^DG_H->&_M _\D1^*O_8@
M>)/_ $C:O<I/OI])/_0:\-_:!_Y(C\5?^Q \2?\ I&U:8?\ B2]?UB<^)_A_
M]O+\F?GO_P $>/\ DVK5_P#L<?$'_IXU>OUZ7_6#_KD/_0J_(7_@CQ_R;5J_
M_8X^(/\ T\:O7Z]+_K!_UR'_ *%3Q?\ &CZ+\@POP2]/T1+11161T!1110 4
M444 %%)N7&<C'KD8_.C(YY'&,\CC/3/U[4 +11D>HHH **** "BBB@ HHHH
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M0_P[_P! FQ_\!8A_[+7345?)'KS/MS3G*WIS2DE\D@3M>VE]_P"M3F?^$/\
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MM9[[,PQ"<H66KYMO1/\ S1^>W_!'C_DVK5_^QQ\0?^GC5Z_7I?\ 6#_KD/\
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MG6*=M39K=Q<O/:V[E2N^%17WIIR[;6(;5C^5<P(<K 0H_<@ D )TXQTZ 8
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M@?\ \&FF?_-+1_PA_P#P6 _Z#/@?_P &FF?_ #2T_P"R(_\ 0;2_\#0<]?\
MDE^)^Y&\^B_]^V_QHWGT7_OVW^-?AL?"'_!8 8_XG/@;G_J*:;_3Q(:;_P (
MC_P6 _Z#/@;_ ,&NG?\ S1T?V1#_ *#:7_@5_P! YZ_\DC]R]Y]%_P"_;?XT
M;SZ+_P!^V_QK\-/^$1_X+ ?]!GP-_P"#73O_ )HZ7_A$_P#@L I^76/ [=O^
M0GIW'OQXC)_$=OK@G]D0_P"@VE_X$'/7_DD?N5O/HO\ W[;_ !HWGT7_ +]M
M_C7X:?\ "*?\%@O^@IX&_P#!GI__ ,T5)_PB_P#P6!'']J>!>/\ J(Z=_/\
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M[8&@:GXL^!OQ6\-Z/;2/J&K^$]94^4I+&.RTV[ECC;'+"X)*;>^> <\_SB?
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M6_A#]DG1?#&M^(]:\3:Y:Z5?>+(+B"^TNUGGO;>VDMO,@@)C>T>9T96D."N
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MO^'NGC3_ *,Z^,7YW?\ \SU']@U.E2'_ (,A_P#(A[6/=?\ DW^1^WK@%DW
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MJ2Q_X]R2O\0!);)&1P*_);P#\2/#?[&W[2OQI^'7QGN=/\"^!/C5XMO?B7X
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MZ?:);61= #]IC2)G2+S5Q&4#$H%W9P0#V>FA/(9TQF65Y'*RB8%V/S$,.F<
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M_G]6_P# PO\ U9?Y&?\ 99/^F?\ WPO^-'V63_IG_P!\+_C6A11R2_Y_5O\
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M_B*/[#LO^@1IW_?F#_XBNCHHM/\ Y_5?_ @^KT_/\/\ (YS^P[+_ *!&G?\
M?F#_ .(H_L.R_P"@1IW_ 'Y@_P#B*Z.BBT_^?U7_ ,"#ZO3\_P /\CG/[#LO
M^@1IW_?F#_XBC^P[+_H$:=_WY@_^(KHZ*+3_ .?U7_P(/J]/S_#_ ".<_L.R
M_P"@1IW_ 'Y@_P#B*/[#LO\ H$:=_P!^8/\ XBNCHHM/_G]5_P# @^KT_/\
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MRW3/J,8N(5MT6(G<Q\P#D@<<?S5_\$9OC5^UQ^VGXC_:F_;Q\*:3J?B3QO\
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M_B/5XM+M9]3GNY]#T[38Y[G4+V>TA6T6"/+O)/<2$>5"J@DR@95>2">*[<D
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M'Q+\+S:%>>)-$MXUFO9[9-0O6FS!'/:!Q%"P4W"_.IVU_/O^T#\-$_8MO?\
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MZD@ $$YP=N.Q[_3-2EF/&X]^P[_4?E689_WD8@PRF(RJ[D;' )38HSG=G)(
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M>)6O[/\ \'XY?'MW'\,_#$,WQ5L9;'XFW$=GB;7K;R5M3!?$.#*DEN N/E!
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ML=4TVWAO!J44UI>W%FWV>1;@*HD 8%6*X!-=!H_[)_PYM?A-K7PBFU#Q%?\
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M,\'?#-=8^(GA2\\3:=\4[5[NS2TL+WP@PBU4V=Q)=Q0%&GAO?+*7-V&V@C>
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MFJQ7D%]X<MKRTTNUT34X+:"/3[VPFTUQ=K''*KL8)Y@3N3G:<8-?/VI_L"?
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M.-<MM*3^U?$R>(=^O:O"&!FCU/6AIA6]MEE*11V9Q)]GBAQE(LGJK3_@G_\
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MO-1:]R*BDX\KYFV83#8V&'5Y-_O)O\?O5NJW;WV1YKI7[4OB/P;^S;XW\?\
MB30YO%'C'P#XWB\'6^AK/!';:S?7EUHMM!<%IY!$"IUE'<23JP2'=\O!KB]6
M_P""A7B_0-:LOAWJ/PS:X^+1\3:K87NE07%G)9Z?INC6,.HZI(DR7+P%ET^.
M]"%+Q]TB#:CGY3T7Q$_9FM=/_99\4_"#Q!\0M(\*^*_&_BJR\5ZGXFU_Q5I6
MBSSZBFIZ/-<7'A[6-0O+:WL;F*QTI5\D27$X$;'&) !ZI\,/V5_V=M)_X1OQ
M19>)=3^(7B:SOM6E'C&[\5V'B'5-=U'4=*%CJ4%S>6\+R:C:K:2%_D8I'YKS
M.Q0DC2EC.%)^UG6HUK<\W33HIOV:<'2UC5ARJ*]HG!QE*[3<I)J*F;S!2481
MY6[)3YI>ZW=7LXN]G9[K:SL>+WG_  4:O/"T5GXH^(O@)]%\#>+=0U_0/AEJ
M5O-;2W5WKFC6\<A@OHK:6YFBCE:[L8R\MM:(-[$R@!MM7QE_P4/\0?"KPOHT
MOQ&^&3:#XO\ &;"\\!+IMS9ZE#?VE]Y3K<7%IIES?7"27<<]LP21H'D<G";A
MM'T$O["7P-N]6U/5=;D\5^(;22?5M1T;PKKVL)KO@_PI?:O"T5Y?:!IL=DD%
MA>*BPF-HIF>-[: E6V 'D?$?["_P+AT6TTWQ3K_Q U9%O=.NK'QIJWC*"V\2
M>#I5F5]'LO"NI7E@);*S$FV.WL+=)'CBABB!R *A8WA"Z<L-523;M&E):)WA
MH\1=-)-5+J49IK2-A>SSBW^]2UWTCN[WZWL^FGK<^>O%'_!1CQA\1/ 6KW'P
M"\!3:CJFA:->Q_$2[U.6#1)=%OX+=A<75I;:O/I=U*MJ\5V^V%;ILHH4EL$^
MO>&OV[K-?@[X7\9^)?#33Z[+XAT+PG?(+ZS59I]0BN [ N[ AFM#N^?#9&,D
M5UVN?L%? V:UL]4N_$?CGPM#I5I/;:GJ=OXMAT^T\:VFJJKB;Q2YLE77+R:*
M,Y+O'([7%P-F9"!)>_\ !/K]G^34]/\ $#7?CZYTK3)=*OK7PE'KX;P?>:E;
MVZ&PU*#2/[/:+[=Y>]OM(E9MT\Q_Y:$#>&8\&QAK@J]2,9JI_"DG?5M<RJN7
M*^9IJ]MNMB?9YBI)UJ[E*UHW_ENKZ7ULU>_=;ZGS/XB_X*>:OX?\/^&]3USP
M+J&DWOQ#_M?5_"L5E;R7CS>'/#^LW7AV]=OL7VG#->6@*AO+)7D(1S7Z@_!'
MXIZ1\9_AGX.^)>E0WEE8^-K7^T[2SO8I(+NR6WEFT^9+J*6**6!FGM)9 DJ*
M0CJP4J<GY\\9?L/?!?Q%X<\(>'KQ_&V@67P^@O+#P[K6B:ZL>N0V&MZA/KU[
MITD\-A)+';O?W;LJM$BJJ+U&"?I;P1X-TOP!X<T;P9H$<PTK0;1;:R%[J=M+
MJ^J%I7G,EW-MB9G/G,S!H5)V@]:^8SC.^%:L8QI498::G-65*\>2\E%MSJ\]
M[*DY):J7-JXI\WJT*&/T:7,N[;3>NNT=$]?+U:/;@, #K@ ?D/Q_G2TBYVKG
MKM&?KBEKSO0]@**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M *9(K, %(4@Y!*[L<'M]<?E3Z* *XA8Y\QE=L?*P7:5/&,8]/;\,5^='[:OQ
M>^*'P[U#P9X6\ >(-/\ A[;>+[C77U/XA:GX>;Q':V(T/1KC6?LKV@GL]K7;
M6JVJR&[!1IU;!V;6_1^OSE_;NT3X0>)-!\-Z#\6_%FMZ!%K?B&31O#&G:,D_
M]I:AJFH)!:W+VP@O+6=HFM9P"8U9-JMD%<UW9?4I4L0IU<''')1?+2E%2497
M5JBNI6E%7MHT[V:L<&8+%NE#ZFGS\[Y[?R<O71Z<W2U[]3\QK_\ X*"?M+:I
M>^$?#^F:WI=K81:9H>JQ>+IO#XAB\=ZA<RGS]&L@TZ"T-MY,<C$37/GK>+$$
M4@%H-%_:9_:9\*^'_B_XRTSQ[:V?BK6_%EC+J/A[Q/H4C0Z'I*ZI>RW T(7U
MW$K&>VGFCC^QQKCR(L;EVX_6OX<_L]? 'P'X \-?#Z/3O#OB6W^&JVUU%?\
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M-[%H^GVE@DDY8-N)M8("^7&[)Q@[B*Z6"S^S@+&H50Q8@N[G+ @G<Y+'L<<
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MGEM;B^MHWM$22WAEB7R7<X*3QEMQ.X^BL?FE.GBIQPT5]8E.HM&^7G=TI?\
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MFI)4ZMI7C9:M-QL_>]VUWI*Z,J.3TH5.><FU=.R;O>]W>]D[GY,^-?@S\7?
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M,TFR-\*W0_TZRZ983[_.MHI/,*L^X$[BC;T)R>=C ,O8$<4[[!9Y5C;QDKD
ME>@(P1CI@@8(QCVKV,/Q_G]'%U<0\/E;A4YDXJ&(YK2BXVLURKW79VM=W;UU
M?#+)XM>[-+1K6_G:]EKZ?B?S=C]E_P#:6N-%M_"=YX'U>3XGW4OPUO?#?Q6L
M]5U1-,M?#&AQR/XSL6A.I(JO>VLMHA']F$GRP,J I/UK^SW^ROX\^%_CCX9>
M)?L$_P#:#IXZE\>W=SJ.I21:O<MK5I)HLKI)<E 8+3[1&OR1 AR=I!!K]CQI
M]D)A<"WC$X0HL@!W*C#!5>< $ < 4/I]F\9B>WC:-L[E(/.>IR"",]\$9/)K
MFQ/%V85G/DPF!C&IS<Z:KW?-'D:6K45R[*/*KW>[;>F'RF%*"C4FY276.WEN
ME^1_-[\6OV</VF_&/Q[N]8L/ASK-I8GQ;'>1ZGIVJZE%#)I8:7+D'4PFQ@8V
MVB/;GIQBOJO]@7X0?'GX5^-O']AXQ\+ZCIOP]O[6X&C>(M7N)Y/$TVIO<V4C
M1PQ"YFT\QX%XJ,T6XHB;R26-?LU]CM0 /(CP%VCCG:,8&?O<;1CFF?V?9GR_
M]'3]S)YT?4;),,-XP1DX9ASD')SDUEC>(I9CAJ>'Q6#H1=)-0G0YEI*"C*ZE
M)7?NPY=;+WFT]$9PRJM2KNK3JPY6[N,N?H[K9-7U=V_)*VK.=T9KN68FYA\A
M! /)^T*([Z15=<O*L(^S;20067#DGCY<BNA(08).0>IS@#\!ZG(YYX]JM+%&
MH"JH 48&.P)SC/4\\\F@QH1@J,>G-?'PP\H8F56,DJ;;:AK?5MZZ6V:6_0]N
M\E344US)6;\[=-&]]?N%3&Q<'(QD'V//_P!:G4@ ' &   !Z 9Q_.EKK&ME?
M?KZ]?Q"BBB@ HHHH **** "BBB@ HHHH CE(502<#(Y/XU!OCQ]X8_3BK3*K
M## $>_\ /ZU%Y$7]VL*E)SE=-+1+6]^NNUNI#4G*Z:MIIKO^0##*,<GKQZ'Z
MD#GCGK3E3;@YZ9/( Z^N.*<JA>@Q_G_.:=UJ8X=73G9M.+5KO6+NGK;7[];E
M:I=+V$R!W [\GUY[T9'J/S%&T>@_G_.C ]!^0KI%[_\ =_$,KZC\Q3<+C&X$
M>F1_0 _K3L#T'Y"C ]!^0J)0C/62O96Z[7OW_,/?_N_B(74<9!/IZTS<H_A4
M_G_5?ZT\JIQD#CI[4;%]/Y_XUE*G4O\ NYJ*\V]?-V6X]>MOQ(P5P2#DY_Q!
MS@GL?4&@$'.0!@ Y!(QR!ZX^A/?K4FQ1G@<]:-J^@_'G^=9_5YW5I1MU6M_/
MI]WR\QZD 8L.@'_ ?USQU_SQQ5A?NCZ"D**>JCBG  # X KIA3C#5+5JS?X^
MOWDKFYFW;EZ)7NM>M_(****LH**** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@"JRC<WS8)8X_[ZSCWY_6FG* GDXP01C/I[],]
MQT_"K6Q2<X&?7O040C!4$>AR14.$7>RM_7Y$1]IKS.+7S_R6OSMN4_.;_;QT
MZKU]^/\ ]1JRC!D!8X)SU.#P2!]>G;C.3UH\F/.=@_S[?K]:>%4    #H.PY
MSTZ=^M0J2;]Y)QMMKO\ <M+>93OTM?S#Y?7_ ,>/^-'R_P![_P >/^-+@>@_
M(48'H/R%5[*G_(OQ_P Q>_\ W?Q&Y4$<\8]SSD_7U.?J*7>OK^A_PI2H/;I^
M'\J38OI^I_QK-T%=V=DW=+MY![_]W\0WKZ_H?\*3>H)R<9QV./Y=?Z8]*78O
MI^I_QHV*>HS^="HM-.][?\-V&N:^MK>5[B>8G]X4>8G]X4>6G]T4>6G]T57L
MW_=_KY#&.X(&T@\C/MD$?SQ_];J&<^H_(_XU-Y:?W11Y:?W15*E3>LE=]UVZ
M=4)\W3EMYWN0\^H_(_XT#AE+$8Y!XXY'?D]P*F\M/[HH\M/[HINE36L5[R^%
MM*R?1[O9^0>\]U&W6RUMY"JRM]TC@#IVIV1ZBFA57H ,TI /^?T/J/8TXJ25
MI6?5/?UZ=]AO^[Y;_CL+1115 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %?-7Q=^!-M\3O%W@WQ0^J2:;-X/FUUX
M8EP8;HZSHUSI+ET,4F7C2X+ALCE0!G&*^E:RI<F609( 8X !QCZD?R_,]I>,
MJ8*4*E./,Y-P>B=E9RO9NW3K?Y/4RJX.GC8J%1M1@^?1I7=N6VS[]+'XU^,?
M^"6USJ'C.+Q5H7C8NNHQZ-::Y;:FDDSBTT"[>^C6P,,<20F\,LL/SK)M^4L
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
L !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>form10-k_024.jpg
<TEXT>
begin 644 form10-k_024.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" '7 E@# 2(  A$! Q$!_\0
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#/
MU75=.T/3[K5=6O(+#3K&)I[N\N7$<%O"@RTDLC8"H.Y/%>>>$_C9\)_'=_)I
M?A#X@>&-=U*.0Q?8K+4X'N)) A<K#$[(]Q\H+$VXDPJEC@ D>)_M[,R?LC?&
MYU=DV^$I=^UWC9XC=VPEB4ISNE0M&!P"6PQ"DFOP?^'^H?"SXQWW[$GPI^!?
MPA\3_!3XZZ=:>'/$FM_%75-+M/!]OJ&A:-X?:VUF;3;O3KV3_A)EUV7+#[6G
MVB6.X\QU #4 ?TG^,?C1\+?A]J":3XU\<^'_  [J<D(N$L=1O4ANF@.TB80
M-((CO4*[*%;(()S5Z/XK_#F7PC-X]3QCH7_"&VY=9_$;WJ1Z7&R.8F1KA\#>
M) 4V %BW %?AS^T9K_@7PM_P4R\8ZAX]^ WB#]HZTO\ ]GW2M&7P[H>@Z1XC
MN=#NUD\'78UK^R]9N[.QL$=+:2,SVLBS%[S:JA97%>\?MDVW@O7?V#=$@\,_
M#&?X7^%_$_CSPI+<_#J_T?3M(N;-;K6HIKNTU/3+"66R22=\M.J2R!@Q#,=Q
M! /U(\(_%[X8^.[A;/PCXZ\-:_>/&94M+#4[9[QXQ@ETM"ZW#(H9<LL94YZU
MW]W=VUA:SWMY-';6EM$\]Q/,P2."&-=SR2,>%5 "6)(P,^E?C-^VQ^S%\*OA
M7^S[IW[2WP<T.U^#GQ<^%$'AKQ+I7B'P4_\ PC;ZFDWV:VN]$UN#27M[;4=/
MN#>;WM)TFA9HD)C)5<?H'XQ\4:EXK_9*U[Q;J$41U77OA#<ZI=HT8A@-W?Z*
MSRD1JH5(3)(SH H'EE2 ,B@#Z+T;6M*\0Z;::QHE_:ZII=]$)K._LYDGMKF(
M])(I$)5E/K]/6N1N_BK\/['XB:;\)KGQ+8Q_$76-%NO$6F^%66Y^WW>B6+*M
MWJ,;B VH@MRPW[[A7_NH:_)CX>?M!>/O@Q^QS^R/\.O@_H&C:Q\7_C+>6/@G
MP;%KLLD6@Z-;QS6\6HZ_J3PV]Y(\.G+?6SB(6EP)-YWQ@#G%\*-\<=-_X*8_
M#<_M!1^#M2USPQ^SKXQU"/Q?X)$L%GJ&ERRQ->Q7EO/IVD"&XM'A8B&*&6!E
MG!\P!<4 ?N$,\ ]<<GMGC^?:ES_/'Z9_S^=?A7K'_!1?XMZMX,U_]H/P?XJ^
M$D/@'POK=RMI\&M034I?''B[PU82 WLL5Y!X=O&MO$3^3)%8Z?:ZM]F=Y1YE
MQ&V"/H7XB_M9?'OQ7\;O@]\'OV?M&\)6Z_%WX1/\19M9\:I<PR>$C]AFNE:6
MUCTW43<NSQS0BWF1TS -P <D 'ZFNZ1HSR,J(@+.[D*JJ!DLS$@*H'))( ')
M.*Y?Q/XV\+>#-!E\4>)]<L-(\/V\D$4^JW,H:T26[F2WMD\V(2!C+.ZQJ5R-
MQP>^/R/U7]H?]I'XC?LY_ME_"[Q)=^%_"OQU^!7A[Q-8:UXIT:.1-"UKPQ-H
MDLLVM:6?[.@FL-4:T:_6U\JPM5BGMDD26-R)%XWP'\1/B]\/?^";FB^.OC1#
MX%^+6GS7_A:U\-Z9J^F0:E$^EW?B1H#<>)8[_3 MSJ=O="26VN)#=NA\EO,0
M@;0#]8OBI^T-\(/@MI>B:O\ $?QG9>'[3Q-*D?AY!9ZEJ=[K!>*&7-A8:5:7
MEY.L<4\<\KB$)'"Q9F4*2.T\,?$?P3XRNI+'PUXALM4OH=.L=6GLHO.CO+:P
MU*&&XLI[FVGBBEM_.BN(6$<JK*N_#HI!%?B3^TGI/QP\4?MZ_L27OA75_!%C
MI[^!-6UGP+IFJ:7%);:-%>>$$_X2B/4+4Z3<0R.^F_:++2D(F2W9()$\AE!3
MZJT?]H[3OAO\:_VS+SQ%X(\-6MI\%/ &A>([_P 2:%I=A8^(/&%XFBZ1/=Z?
M>WR6]O+,CW\AAT^.>=DC3R2%3:J  _4*BOP_T?\ X* ?%_2(_AG\4?$WBWX8
M>(_!GQ/\8>'-$N/A5X:L[^7Q;X-T?Q7>V]II4WVP>'K>2_N[=;NVN-4%SJ)B
M@WS^7),D29]Q\3?M0_&KQ-^U%XG^#/A;Q/\ #WX1:5X,3PW=Z=8_$F$V^I?$
MFQUNRM-0GNO#UY/I-[9R):Q7#6GE07L,RW;(KQ*02 #].=;US2/#>F7>M:[J
M-KI6DV$7G7E_>RI!;6\994#RRN0JC>RH,]6=0.2*XOP=\8OA=X_NFL?!OCKP
MYXBO55G^QZ=J,,MV8U W2);EEFDB'7S$0IR.>]?)?_!2)[MOV(_BN;LQ^8=%
M\/2:H\39A:.+7]%FOO+90 T4H5RH506CRBCYBM?EKH5G\(OBQX]_8>7]BCP7
MK&E_$3PO-X2\2_%[Q[X,T*^\*:-8^!]/T%K3Q%I?B:^EBTJ/5YKO5KBQ=;5X
M[N"4+YA)V D _I(J%[B"*2.*2>&.64D11O(BR2E1DB-"0SD8.0H.,5^3/[3W
M[2?[2_P*O_&/C6/XB? E/"WAC7+"72?A?+=K=>+M?\,3WR6<D=S=1Z'<3Z=K
MDD4T-S';&]2(L'03[%)'C_[1/BS]I;QQ^UG^Q-XH^&'C31/"WAWQ[X1OM<\/
M>'=;BDCM5O-0M-/NM4M_$T5G87L=\L<4OEZ>'-VT;EW3R6)8@'[1Q^-O"DWB
MNX\#Q:Y8R>+;331K%SH*R$ZA#IC-$JWCQ[<"%C-$%.[)WCCKCJ:_../XR_\
M"(_MA>,/#/BKPIX3:X\(_L\0>,_%?CS2M&L8_%U[+;1Z5/>V,>H"T@NKG1-[
M+]FMIKM(8V2("!"O'Q[>?\%'?B]+X/N?V@=$\1?"_4?ATGB>*ST[X016][)X
M]O\ PN;UK::Y>XBT*0IK8CV2"S@U5[<.S()PHR0#]WO_ *_Z5&\L<49EED2*
M-1EWD=410.I9V(4 >I('>ORL^*'[4G[1GBG]I;PE^SW^S[IWA72[;Q]\%M'^
M*2>+?&T!W^%8[YKXSB2R73M1^V3RI'&(;:XC:!6ADPRAN?%OB)^T9\?_ (M?
ML9_M<^'-3O=#\'?&3X%WVJ>'?%/B+0,KI6LZ!'IMY*]]H<RV4-S9:G.P'V?R
M[*Q\IH\K,-Y! /V]CECEC62-T='&5=&#HP]58<,.#R..*?7XZ^'?C=^T?^S_
M /L*^"OB-XOUCP]XQUG7)/ F@^&M>BTZXN-/\'Z)XBU!;"?Q'XV,.E->W2Z;
M'+]JO)TM=2"1P2&0Y.#]Y?LP>)OB'XN\#RZYX]^(/P]^))N[I)M(USX=O$VF
MQVDMK;2BSNTCT_3FBO(I'E9XYHO-5)$#8& H!],4?Y_.OS'U7]LSQQX#UG]L
M/PMXZL-''B/X*^'O^$I^&%GI\6X>)-+U#2I3HJ70:VMVDN[O7+>:S,:+."J@
MAR6"#ROP?_P4-\>^,/V7?A%XZL="TVU^-WQ*^+GA_P"&USX:GME6VT[[5XHT
M^/7+F2S\IID%GX7U$7PE:S'[P,Y.!OH _673O&/AG5]<UWPSIFMV%WKWAKR!
MKNF0R[KG2S<Q13P_:T(&SS(IXG') 5U)(SBL[QY\1_!GPS\'ZKX^\;:]::)X
M1T14DU76YO-FM;.*2X6U#O\ 9(YY& F=8R$1CNX(!K\N_$OQ1\9>)M;_ ."@
M7A'P1H_A/P3X[^'_ (!\X>/K/2+2#4->DB\(:9=:O/JMW!9?:I[NWMWN+?3I
MV,DL1@M65H"B,GSM;+\;#_P29\<ZE\7_ !1HGC#0[SP-;7OA&>QBEOO$$LI\
M4K)+!XB>\LK=;HSWGFQK(;JZ:.%XE!P@"@'[XZ)K6F>(]'TO7]%NDOM(UK3[
M/5=+O8U=8[S3]0MX[NSNHUE5)!'<6TT<J!T5PK@,JMD"+7_$.B>%=)N]=\1:
MG9Z/I%@@EO-1OYDM[6WC+*@:65R%4%V51D\E@*_''X??M)?M5? 73_V0$^,N
MC> [_P"%GQHTWPIX'LM&\*JZ^(?!2CPU:2:%J-W)+I6GQW$=W9I:?:8S>SI!
M--(L2NJ*3]$?\%89HHOV&OC )TEFA,7AEI;:)0SWD4/BW0II+4'*X^TI&80-
MZ[RX1OE8D 'VGX-^,?PO^(%W)8>#?'/AWQ#>QH)6L].U"*2Y$>U3YBPL4ED0
MA@0Z(RX/IDUZ9_6OYK?@]J?PX^,?[2'[(&B? #X5ZU^S[X\^&_AOPWXL^*.L
M:OI%OX-'BWPHGA=;>;2K.STJYN+;Q.+R:^LKGS+I0Z&'<^UHSGZ\\;_MS?%?
MQ7XQ^+S?#+QE\*OASX0^#FM7F@6VF>.4N[SQ/X_U?1EOEUJ.**VT+6;>QT]9
M],N+>VN(;R"9S=6[/&K_ #( ?LM3))8X4:2:2.*-1EGD=411ZLS$*!TY)[U^
M46K?MW?$+X@_#C]FC2_@WX:TW2?C9^T<]S]AC\6131^%_#^G:#:VZ^)=:D9K
M6\O);6._O;)-,\S3F%Q#,6D"%>>#_;:N/VU-$_8N^)4'C#QEX$T3Q'INMZ1:
M3>+_  :;N";6?"MQ+<F1K>,:)IYTO48YXM/$IMEC!5IE60XY /V:5T=5=&5E
M<!E92"&!Y!!'!'TKG/&'B_P]X"\-:UXQ\6:G#HWAOP[83:GK6J7"RO!86, !
MEN95@CEF*IQD1QLQ)X!P<?!ND:S^T_X8_9J^'M_=?$[X0:)XFETS1I+SQAXD
ME2'38]!^QP^6]O;76C.-1UB2*2-IXS 1O V2R%V)^7[G]I[QG\:/V=?V[OA'
M\1M0\)>)/$_P8\&#?XV\*(\/AOQ+HOB-]4M[,_9_L&GK%=VK:)</<1160CVW
M4/[R3@* ?LGX0\7>'O'?AC1?&7A34HM7\-^(;"+4]'U2%9$AO;";=Y5Q&LR1
MRJKA20'16 ZBIM'\4>'O$$NHPZ+K%AJ<ND7+6>IQV=Q'.]C=*,M;W*H28IE'
M5& 8>E?,W[#)W?L>_ 9?X4^'6GQKQT1'NE4<8'"@ 8]*_+S]F?\ :=O?@C\7
M_P!K7PS:?!#XH?$B.]^-.I7,VK^ =+T[4;9-\,8:&9K_ %?30LP4[44*VY]V
M6X.X _=O1O%/AWQ#/J-MHFL6&IW&D7)L]4AL[B.>2PNU +6UTJ,3#,H(+1N
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MB]:>++#7+2"PO))] N+;1[]I[2*2Y^PVXC,\2QB7;:,58L<.%"M^CX&.G^>
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MK:C;^(7%@]A-_;+7$,UREE)-=1/!,R"%HQC=]N_$;]B#Q=X9G_9V\9_"/2_
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M^H,TFG->H0H5FE$8GQN&U02&P".E\=_#_P :ZW^P=X_\&?M-:?X0\(:AX%\
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M\UTC"YS\I+,!NXSCT.>@-?%,_P 4O&U^C1MJHM5D=C(+*+[,&9AN)^5BP'H
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ I,C]0/Q.,?S%
M,EE2%=SLJ@D*NY@NYV.%C7)&Z1SPBCEFX%>8>+?B=X?\,K/]IO-]U;E5CLD"
MHTD[H/W<@=R\J(6*RHBHT3JRL20, 'I\DT<6WS'5"Y*H&8*7<*6V)G[S$*2%
M&2<' KSGQ#\2_#FC12QRW;O=PLHDLH%+W:GRRP6900ULOF!5:5DD4IG@;P1\
MT>(/BMXI\0.[>8+&PD7$5M;;HXI=RXCF%ZQE%E*(R5>%HYS*Q:561=JUYS'(
M51S)/>M,S^8WGXEC.YB3_I/RB?)+<"//\73D 'M.O_&7Q1=9;2([+3;<QO%+
M:M%)+EG!+727 EB*L2S.(MIP"%9B0S'RJZU/4]38/JFJZKJKN-RS17K:=# N
M WEO:R+=&Y$8( _>H"H. !TRYY28SQP%&!G/KC'7 &"3CD\9(& 6V\F$P=IX
M7 8X/&.@YX!)&#P 0,@ J "2&W,;S)&4CCD*&6:!?)N'QN"%RPEW%5W<J$Y)
MP/NBI)((_*D:1I'*#,?G/Y[Y4\$%5C52,9'7GC!&&,2,S,Y0DCY>C*!R3DC/
M4'/!YQP&] YR^ULYQM.?G0_*!S^."<<]_K0 0#MC'SL,=L;#@=N,?I1+"K89
MB<$DE>A&=Q&.#R,$D$@@$XZG*0LN<Y_B8_@(\'K[\4R>3#=0!G!*\MU.<]>6
MQQC&!S_$  "RD"[&!))(4MD#&<,<CTP0PW8 (.<<A34\A,.5)!",1N[@@\=,
M9QC.">O'%3I-B)C@@;5!*@=,RC!''.0 <8XQ@#D"DTN1)DG !XXXPN XZ8*Y
MVE?XB!R<XH ZS2HV,^I,.G_"':Z.O8Z?<8)X';'0^N >*_D8\6C_ (K3QO\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1137=8QN=E5
M?[S$ ?B3@#OQGG''I0 ZL'7_ !#IOAZTDN]0N[:U1$9E:YD$4<CA24@5VPIF
MG<+%$F2[/(I56Y!XOQO\2M&\+V=S"ETD^KM 9(=,"2&^59&,<,DML5,L<#2
M[I'14:'YD9?E)^4?%&OZ[XEOI)=2N$>&UM+:>&UANXFLK7[3(H9+>UD:6>65
MEDVREVD,9+E!&%!0 ]+\6_&2]U8SV>C0WNEZ=);&)9G 759+H[QN-H\/G0V>
M3@S$ ;/WJ,N1CQ"XF:6>%IV:64J#(\A+EY<*S%MP8Y+X.>N&'7!PV"W$;RL@
MV>: I4,S!-P'S*SEV# ?, &(P/NDC BN(G6Y@ Z[%SG(W#:-I) QSC: P[MG
M@D@ NB0%91A<#8,=0 05PH((/.0K<AB>!CF@2 QL"%P#]S@Y)(RH)'&X\@8&
M[Y@-P.1%Y3XD8C ."1V4A6XSCD(2,;<]!T^\&B&0(ZD #CD$X#;D*]L?+@G"
MG)W=NH 'SR9B/W>!CIDDCOD@8)STQD<DDXQ4ELZ^6.%'RCL"!N4!E)Z[B3D<
M8)P!SE:K3Q2>2<@G)/)!)&."0,$@9.!G'(W9P2:FMX76-2"#^Z!Z''W%R3@8
M^7^[R3O88YH D695=\JO)'RY48"@@ XR"1GG'3Y<\C 62=?+DPJYV-_%_LGT
M4G]..M5XHY7=SA0<+D-D$YS@GD^A/U9L\]))()2CY*@;6R<DX&#G@@Y^F#Z=
M#B@!D<N,'C'H>2G ..Q;/R@,,A< ?,I-3.XPN5#'H0<<D<+\Q&"0"!V!X[D
M4(XIB_E@?*,C)SNQUQN! P?EQS@=&.0*MRPN0JK@# VY''&?0 =,9&/X0/0
M G208C (P0V[  X&S!P,Y!7"X&< [C@@UGB0>;-D+A48!<C #)_%QA>0,XZ,
M">F2+8C?,>T8R'"\' 4A>G'..2",\GH2=M9_EMYLYX4>6S?4F/.6'R]L'U!.
M& !- '4Z5(#/J7 _Y$_71@KQ_P >-QU.>6(QSCAO8"OY&_%ISXU\<'&/^*EU
MWCKP-3N\=A]?QK^N'2XG\[4R5^8>#]>!'( !L;C(Y^4 #MZ>^"?Y&_%0(\9^
M-P<Y'B;7P<G)_P"0I>=^: ,>/JWT7^;5+44?5OHO\VJ6@ HHHH **** "DV@
M]1GV/3OSCIDYP3UQQ2T4 )@>@_(>W^ _(>E,8#!R  <@<=/3.#TR #ZY/.W&
M9*0C((]01^= &AX9UWQ'X-\0:=XH\&ZQJWAOQ'HKJ^GW_A>YEBOM&"R)(?-C
M!FBOHRT*,RM$V0@ .6Q7[G_L>_\ !7.XTU]+\"?M)H)].8Q:?I_Q&L<W-RK9
M98AKUK#$=I+O'YTKRPBW4O(^00!^#*Q$11Q.?-$3%XG=G62-L@@;T*EQGM)O
M''3G%2.I<,AVA91LFVJ ;B,'*I*",#:"_P Z!7)8EB<Y4 _O?\*^,/#?C?1+
M#Q'X4U>QUW1=2MXKJSU#3KB.ZMY89DWH0\+.H?&=R$[E(((R,5TH.0#ZC-?Q
M=_LM_MK_ !;_ &6=5A_L?4+OQ5X,DN(FU3P?JMU//%<0H5\M-&+3I%9ZA;'<
M^FO,DUJEQQ<VTT3%&_JH_9K_ &K?A7^T[X.LO$_@'68!>@"'6_#&HW,4/B+0
M[L #RKRRD2"XE5W8+'/';1Q2$Y0 '% 'TY1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !114<DL<0)D944!B68A0 H!/7!Z'/% "3/Y
M44DGRGRT9\.XC4[1G#.WRJ/]IN!U/2O#/B1\4X-%=-'T>2.;4KJ1(9)V3S[6
MPBQDWD;Q-B>97<I$@+()(]TB/&<5F_%+XFOIQN]#T.[2/45MBD]X@\Y(?/W"
M&S%N5822W!79/=8,%E%(LKF/8S'YSQ+L\R=_M-VWS,Y(;82H=E!Z??)  [@@
M=@ "A<WMY>ZA-->7MS<RS3NM]?2^6^HWD)R4#NJ+'&O5(UBCC*PJ,Y<,])-/
M*89 ]O:E(G6*S==XNH8PRY+N9!'(Q!;^$[=YP1U"QQY9V'+%R)"/O!N, #.,
ME< \@J1SP!5B:']PXVCEXSC. /G& O7CC).>?3!% %&":7 P&P<G)*XP3@D
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MXV\%ZQ>:3XI\)W,=W!J.ER$R3_.LB6MX%#Q:OII4[+A DQACDE0M'BOZKOV
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MH S0C"X8#=RPR"V!D!N >F-HY/7("GU62X5@HY(PZ$@,P!!;/)) X )!Y!Y
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MG.1C()5A@*3CIG.#BK$TD87>.H ;!]QU&W)^?OP<\CKC$:RJ&1>"64.Q//+
M X (Y R%R<CGD#!( Q(R9F4%B,#"Y8GAN%![M@E203C.XXVU-.AV'##[I4E6
M.UAP,D#A@#D-C!Y&,Y6GQR1&=TSG@;F.">,@D\D!B/E)P,Y/3(RLDR/YH.T;
M 2 ,#GG:G.!DG.>A;;@\#@ IQQ@8XQP ,\Y!S\[XZ#)^50021D4LJ= 3QQRN
M[H!V7H .AX')'X3PR*"#AB5Y/&=QP5W=,@C(!ZA<A0?4N)45XP&X?YB>,J>
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MX'=@^QR*L":2:.%YQ^_\A!,O!(=6D^4CU"A>./I0I(Y((X(QP3@@@8[9STY
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MC]G+-\YC7>P"9$>[/RY)SVOQ!\02^)_$M[+ [2Z=HMK(D$;3,$@U#Y5:^M%
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MX/\ PDNO9!]?[4O/<\>G7C% &1'U;Z+_ #:I:BCZM]%_FU2T %%%% !1110
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MP0AP,8X)YW#( 3W(DRJ[2Z@@KP&QT;G ''W<8(.#M'-2K<$0,^%"_,-_/#$
ML.#G )]#C[W\(Q4FB,>9!SN!)_B (!YZ\$Y ;J",$8'6ZL68_LW5@,\^KJ<_
M-UR0<9*Y!XP30!22?Y^.2S J=HP<@J&Z8  RK ]P2/6K,TKK$59=K$(^WC)"
ML&. ,;N!E<G(  '.!4,<6V8G_GD=F >3@!B ,X^^Q )^ZN02<G-F=+<B.:=D
M2*"6WD+2+O4$2I)'N7#9RZ@'&, \]#@ K0S2%@JJ2PC,H7"Y\M!EF( R,!<C
M)W<]\BH;B9&DBG&XQ1C#MM8E25Q@*!G&1W&22,#FORD_;=^*/_!3N^^-NG?
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M]RQND\%:-/,8M6^(>O1VYFNK:QT^:73_ ")1:R(PNSF1&QG]%_A?H/CKPO\
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M.37T1>_%_P"%FGZ%HWBJ]\<^&+;P]XANH[/1M8EU&%;/4[J8[8X;27D2R.V
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M+,,MSP  0"P-PN9# L9D69[BUCB6!Q&[222QI&IDP?+C9V DDP^V-V;!VD
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MOV=OB;^T+>7'P<:+37T[3-7%AJ_C3^U+W1[,RF*/3Y&O["2.>")$*/&VW!&
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M#"@L<@!%!Z$G!)7)8C(Z'!.0&B#BY*G,SY 1L;F.UN0,8;JHQZ<Y/ ,C3-L
M8$XP<D9Z*1D$'WR1C( XXRU(LO\ I9.<')^\-I!SC/\ O$,!@9.,,HY(H DG
MM@3$ >8X(Q+@?<8LV=V3D #_ &<@ YY%01PKE7#D@_=., G'3)QD^N#[$C!J
MQ))AKH 9 MQ\I.,'][WP<C)Z\$Y)R:JP2_Z/!U.?,4 @$'+*O')Y[;B!W)
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M,#'- %F$QM 6;YF"@9.<GA\D=, $9PP! 7D\@4]81YEP_P NY Q0YYZG!#9
MXVC&/11_>Q5MTD2U8E3]S+=,G[W][NQ91ZY!!P0,HJ7 :4\GS1M7C&PG@MG/
M([XQV/'3 !<G@):,A@#-;Q^9QG=\S<MDGG!SQU!Y&.C;>U =4+ HH9E4#HQ.
M<@<8P<-@')XR"<@-D\]2BC?Q$@)5<@D%LY)QR,@?0#M309LY;?P">5Z8[@#/
M/..G0D]J )Y[9#D-LP,C;C.<@9P,$MVR ,C<03C $WD+Y?F'!;RR-V26Q@E0
M#R. !@=NN3P3ERM*2<[LY+$A2, XP#DYZYSGO@#H:L@7 C)R%Z$=\'*MQGD
M ;,XQN'4@T .CAQ/P0"S;>"><C)). PS@X89.2,=21)<PI#'GY0"\9902-^9
M "2"1D]#D9QC' ZYR),)">0".#SR5#$X^7!!^4@]<@G'&XSW(G"@MRH:/@ D
MX\Q0N5[=">@)YXPH% $R+"9)T*J8TB#1CJ%9@23D GYB2 >1Q\P[TQX@YC8L
M"0%QDD8!7 VD@G!Y SR$VXXQ3$603W.%.##P .3E!D#C!R2.O0CIUJM,)04Y
M)&5)Q[JI).>,D$ GH2#QG)H U(X %RH7YACD'D8R 0,$ # Q_L@9.>6FW6)6
M;Y=I(WX4\[B <GGJ<-COM[C-552X95(YXY^5N#TZ@C)( )]_;!+C'<]Q@ @D
MX;C!SGDXXQWXH ?,(O+("]0&R>A  YZG*DGGU^7G)S4MO K(C#!P@*9;MA1@
M<$#:-V1CODKS@4YON!51L'YL[>@4@=#GD9&,\$Y&#R*?"LZHHW9^7T)YR#D=
M\8&#D]3VR 0"V(%,A;Y=PVL#SG@]<#IG"XYP<' P>&S0A8IBVW:RLSX!^8XX
M![D#.1W! ZU5"7)+8YR%)X;TX&!@#'/K[4DL=QY4FX84HP/## X.<G('L?48
MR#B@"6V\LX4J&QM& 3SGIMSTS@ DY"Y  ^7%+<6Z,V2!A3A-QV[ ?FXSN&>>
M0>3C/0$FO &7JISCDX.>@' !Z,<EN>A!R#BFSB9BV#C@$=3@#YOF.3V.." .
MQ( H OI&-KOD;L*0<CJ ^<\ 8 [CH/F!.<54\A5,KY!(#CIEB "#COQSD9QM
MX/1J(UF,3=_?G)7.<$]F(P#E0!QP3P*>RX&X-T(< 8/7CH3QZ = .O!% '6Z
M.L*3:HD:@(_A#7"ZJ<JY%E.Q8C\,D=\ $9XK^1WQ=C_A-?'&.G_"3:][?\Q.
M[[=>3D_CVK^MS258SZEQQ_PB&N 9SDL+"XP5!YZCK@8X!QTK^2#Q5G_A,_&^
M>O\ PD^OCGVU2\_3T_2@#'CZM]%_FU2U%'U;Z+_-JEH **** "BBB@ HHHH
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MUA\NS"KM'^AP%C[E'!S\HY/IG(P.HQEES&WDV?(QA>.N!LZ]^1R0O&3SALT
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MYRM&ZC.SDGOSM( )7/;((8# PW<;CPIJZL?[T@[2%13M& ,[!D@Y/. .2.[
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MD(S#//.6&3G.0>>#D9(!Y7Y@!L<Y'\ "@;<LN%(&<9+( <#YAW.#@G=3I;@
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MQ[3J=X5(VDJ,H02 >#GZ4 <_'U/49VCD'GACQ^!!S^'6I:** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** (Y%9U*(VUFP >, C+<DX'(7
M'7O[BH)2(P)6(+VUSILJ,O\ $!GY@PZ@<9(. #D9P,V3@$>YQ['(Q@_GGMT&
M<XP:,G_'M)[QV/MV7U]>@'7/% ']R'[*]^VI_L\_"*^=][7'@C17W[@P<"U0
M*5(P&4+M&1_%D=J^@*^7?V,)?/\ V8?@H1P(/ FD0'..HMX2.W((SSZ_I]14
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M\M1L=2!ALGDDD_0] !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MT: $HI&"#!5R26 P6SU#=C[D<G([ =,+0 4444 %%%% !1110 4444 %%%%
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MG[+7QXD^(7BSP1HL>J7'A75+-;.[\2I;0W']HG3(Q<32;]\.Z-(%5=L@QM(
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MI!;[5/',(U9U&41;;]X$X#JJG@C !_1B@4#"@  XP !@=0,#MSD?7MFG444
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M\CMC-.!R ?:JJN9H \\T;W%QO2,6I#)+I\9VR0SA2X@NEPZ[@$=25SC) LH
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MX0TV9AY-K&D]N)!=2P*K3N99)5>9UWJ%VK^R*@*   H'  Z 9]O7K0 M%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M_G_(/Y'TI:@5S(\K!E:/($0"JI1=I1E;:/F;<O+$DXZ'=R9Z "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **,]O\_Y_P#K^E)D?Y_SZ\?7B@!:
M*0D#_/Z_3WZ4-G!QZ'Z]#T]Z  $'\.O?!QD@^GU. >W0XA9L&)8E0.[N))L@
MD0\<#GG"Y X(YP -JFE=]TZVZ0&ZE#K';0!)?/$CD[1;QV2R3WQ8CI*DBY*@
MCKG](?V3/^":/Q>_:%D@\4>-K>_^'WPW=HY;F>_M/*UGQ-9D,6@T*,Q@V@9%
MV>>\UE(3(FUR5^4 ^+/A!\'OB#\=?&%IX.^&.B7FIW6H72V%QJ=[:SRZ'8K+
MA;B74)(8W\BVBC??)-Y8$:<Y7.:_J._8F_X)V_#;]F&Q;Q+KMA9^+/BOJ$4:
MZIK^H0PWMCI)C*S0+X7@GA$.E/%)\WVZPAM;ESD-*2 %^L?@3^SK\+_V?O"E
MAX8^'WANTTV.WLX;6XU1XB=7U..)1\VI73RRR32LY;S-TCB1=JN6"@#W@
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MIG. ,]^OOWH 6BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MW.2,X^N* )Z*Y.Q\<^%M1L#J5IK%G+;"&]N!B>+S&@TY6>\E6,ON*0(I9ST
MR3T.-G2M7L-:TZTU;3)TNK"]0RVUPA!66,.\9=2"1C>C+G..#0!IT53L[^SU
M" 7-C<P74#-(J302QRQNT;M'(JNC,I*.C(XSE'5E8 @U;R#R"#]#[X_Q_*@!
M:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *:_3_@2?^AK3
MJ:W0?[R?^AK0 [I1110 4444 %%%% !1110 U>K_ .\/_0%I(^A_WY/_ $8]
M*O5_]X?^@+21_=/^_)_Z,:@!]%%% !1110 4444 %%%% !1110 4444 >$?M
M+>'?B'XJ^"GC_0_A5?7NG>/M0\.ZE;^&;RRU"/3I(-5DM9%M',\B,"/-*C:&
M0@D-DA2*^%_^"<_P=_:\^&MWXUD_:<\1ZKKMI?&W_P"$5DO]<BU6>$Q^4UVL
MOE,VR.8B14W!5QD*22,?J_30BJ  . " ,G@$@D?3@ >@XH _#7XR?#WQYX'U
M7X]?&#P=H.KZS9>-_'>C>$O&?A32=/OA-K6FWDEAINF>)$MEEG>==,N+LS74
ML,2(MO9EI615R/08/$'Q&_X3WPU:'Q!\3-#^*>FZOX%TWPK\.;%+G_A"KWP'
M'H&A#4[^]@%N4>#['_:3/<O<*([R,Q/N>,@_L(;6V*NC6\#)(VZ13$A61LYW
M.I!#'/(SG':F"QLQ.+K[+;?:501K<>1%YZ1J,+&LVSS @[+NP.PH _-7]I3P
M/XB\1_'^PUK2]4\;^'+G0/A!K^MV>I>#&F@2X\0Z2E]J&FZ3>W8AG2:&:ZMX
M%:RVK)<Q?*KJ'!'EFK?$7XXVNO\ ASX9SZ[JT\WQ%\!+\3_[9EG-GJ&@Q^&O
M"(76M*D5@[6L=SJ\4MQ)%*REI22BG//[!&&)CN:-&/S#+(K'#+M(R03@J2".
MA!QTXKB+[X:^#=3\1S^*[_1K:YUN?0;OPT+N1$)@T>^0QW=I  H,:SH2KX;'
M)( )S0!^,_P^^)/QAU72(-0^$_C3XC^-?$5_X5UNY^(@\0PW,^B^'"NJ!--E
MT??'$KW%I8&)85BFS/;[I%QQCK= M/C<_P &[>WTKXV^)]63QC\3?".GWM]X
M<TVZL_$/AVPGMYV\1V4US)=W;1Q7ERLK2,846U9U4AV0[OU^\)^"_#7@C1;3
M0/#6E6FF:990M;P0PP1*1$QSL=U16D'0?.3D  YP*W(M-T^!/+ALK2*/>)-D
M=M!&GF DB3:D:C?DD[\;LD\\T ?E'JVM?%KX=?$3XJ>%_!7B3QK\2)/^$*U&
M#P3Y\TDP\!3V$]K!(GB.S$3OK,]];R375G?J^G*5MF*QN9 8^)\*P?'.\^".
MJ2V?QI\8>*;OQ'KOAZROH=#T>YT[7/ ^H727#ZS;_;'N;TM;LR,H001BW$>"
MS;P1^RRV5HLLLR6UNDTP EE2")99 .TD@0.XQQAB:9'I]C"KK#9VL2R/YCK%
M;PQJ\@+'>ZHBAGRQRS98Y/- 'Y#^-+KXD^#/#LN@KXV\>:CHOP\^,=]9Z=X<
MN+R2+Q7\1_#]O/>11:'%XB$+HDC[8S&?[.N?M 1@(^I%>XL]:\0:[\%/'GCH
M?$+PCIFC?&CQ%93Z<[7-G%IUCJLUBVD6GB "VC^TPO\ 8Y%-])'$CE6.Q=Y4
M_L$]E:2_ZVUMI"7,A+P1,?,/\8+(?GQQN^]ZDT][:WD"B2"&0*P=0\2.%=?N
MN RG#+_"PP1V- 'Y W_BS]H7P?J)U;PW'XEUBW^*WC76_ T>E6<$HM_#M]"U
MB^EZ[&B*XMXKM;Z?[3?/MC86D;$@)5KQGX.\01?%?PQ?^+-;\?KHO@CXD:7I
M3^)-.>XM[62:]-L]M->>7"Z7B3R0W"23M((HUA R,@-^N@M;<>6!!"/*?S(_
MW2?NY#UDCR#L<\Y9<,?7BDDM;648DMX)!YBS8DAC<>:F=DI#*073)VN?F7/!
M!H _-OX8>*OB5K?[1MU\#;OQ#XEDT'X675[XTU;Q%-.93XBT_P 101G0]$U"
M;RQ')%:R:;/A5?<JW+Y49&[]*P,#&2?<\G\ZY#1O GAG0?$/B#Q5INFPP:]X
MGEBDUC42 UQ=B ,(8V; (BB#N$3D+GCCBNPH *\F\<Z;XRU&[T!O#&H0:?%!
MJ%U+=QRQX,EBMO&0DQ,\6X&9964'. S #))KUFFLJLI5@"#VH ^,/VR_#FK>
M)_@?#X=TNT$VI3>,/ R+"UA-J=J)$\0Z-)+>36,,L,DUK9R,][*AF4>5$^7"
MDE?SVET?XS_#'X;ZAX%L+V[^'U[<?%*8?$+Q/I6B7AT=-*O=+,NFZO96JWA%
MEITD$MG'<8O)42[\W>^[Y1^ZS11. 'C1P&# .JL P.00"" 0>0<9SSUYJ">R
MM9UF66VMIEN,"=)H8I$F"@!1*KHPDQA<;PV !C% 'Y&:=-XG_P"$E\!>"/B[
M\7OB)K'AQ/"-W-\//%/@2TNM(TKQMX@O=0"16&KR#^TQ+/IUI,+6)'N$+I;>
M=A5/'*:3JI^&_P"S]XD\+1WGQAU3Q)=?&/X@Z?K=Y#K%QIEQX+>2^\0ZIHUU
M?W<NFW2'2[PPV82,^4)I[F)4D7> W[.MI]BPA#65H1; "VS;0G[-C@&#*'RL
M #&S;C IC:;I["=386;K<DO<*UM 5G?(.Z93&5E8GJT@9N!SQ0!^;'[*\_CK
MQ)\2? _BOQO:ZY<ZP?@U=Z;=:UJEI/";J2TU;1X+1KJ9P!))<6L(G#X4S9:;
M;N<Y\3\4^!OC#<^%_BG=6-RMMX2_X:#GN[WP6/#MY+J>HV4GB'5!/J%MJ*ZB
MA6W:61+V)TLF780PR.#^SL=O!%M,4,492,1*4C1-L8QB-=JC"# PHPH[ 4>1
M!M9?)BVN=SKY:;7;.[<PVX8[N<D$YYZT ?CMXZ^*7Q<TW7?BK\%-)\3ZK!=?
M#7PI/\4K#Q/%<;9H]!U._M;?3M GGP4,UK:7F8( XD0PO\NX&O+?#_Q ^,^I
M>#_$&H?![QY\2O%'A&\\(^'KGQSXM\765[<GP_XDNK20ZV^AQLEH[(DGG-+'
M'(WEA4&_ &?V8N_A-X#OK[Q;J5WH5M/?^-[*#3?$-U(B&:[L+<[H[,2! ZP;
M\.8R6!*J!A1BNMT7PYHGA[1K/0-'TRRLM)L;*#3K>RAMHE@%I;1"&*%XPH61
M1&,'>#N)8GJ: /RM\!^'_BMK5]\#/"MS\9?%WB'P/JFI:]JVM:GX3MY]*-_;
M1_V?);:1K-])-J!Q;&25>?+$@\Y0JD_+S&K>.OC1H5E\<_"?@O7O&7C+Q)#J
M=E>6/CQH[B;0_"WAZ6XU&.\T-]&V%H]7L$@B,DYU &Z\X%+>,1$M^Q,-E:6R
M1QVUK;01Q<QK##%$L?*_<6-%5,@'.T#.!GJ32I8V<0E6.TMD6=F:<+!$HG9B
M2QE"H!(23R7W$]R3S0!^..E^&OB[XH;P-X.M/C=XX\6>#O$R?$/7K;7_  ';
M7&C3Z=_9,'AK[%H>J:B\NI(\WFW=VL!9("Y$NQ6V$5?M?&_Q;AU_X,:IX@U;
MQYXEU75%D\,OX&L3/I.IQ W7V&/Q5JK20WBZK96,92\U*);>V#Q1M_I$8<,/
MU]BL+.WP+:SM8 FXIY4$400O]_8(T4+N*IOQC?CYB<"E^P66^.7[);>9#GRI
M/L\)>,,<D1OLW(#@<(5' !R!B@#\8(-.\16'C?P1\0/$]WXXTC5%\$_$2PT+
M2FCN+?1->\5Z/;:G>V&FWMH(]B27#75I&BN2;HR!$*@&NXN=<^.FCZUX!^$V
MD7'BI;7XY:?8WT>O6L,PMO JV6J7'_"16AN0ABTQ)]-\MH%F>/=*S;><U^L\
MEC:2^6)+2UD$+;XA)!"XC=B [('1MC%0!N3:3T)P!B3[-;YC/D0YASY)\I,Q
M;@ WEG;E-P'S;<9[T ?B]X9N_%/P)^"7B3QKX3\2^/KK5_A;\1]87QKX1\0W
MEQ(+R'5KB.SBM;998D>YBO1(;VT\D.IEND9=V.?U&^!$?B&3X9>&M6\4ZAJ%
M_K'B.RC\1W U)R\]G!K:_P!HV>G 87RULK2Y@@*=5:-@0IR!V?BWP)X7\;Z/
M/H/B+2X+S2[J^L=2NK81QQK<W>G7$5U:27!"'SO+FAC8^8&)"@9P!CJ+:VAL
M[:WM+>-8K>U@BMH(E&%CA@C6**-1V5$55 [ "@">BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "FMT'^\G_ *&M%% #J*** "BBB@ HHHH
M**** &KU?_>'_H"TD?W3_OR?^C&HHH ?1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
/ 4444 %%%% !1110!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>form10-k_014.jpg
<TEXT>
begin 644 form10-k_014.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $L Q4# 2(  A$! Q$!_\0
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M_P /+/\ @GW_ -'F?LW_ /AVO!__ ,M* /MZBOB'_AY9_P $^_\ H\S]F_\
M\.UX/_\ EI1_P\L_X)]_]'F?LW_^':\'_P#RTH ^WJ*^(?\ AY9_P3[_ .CS
M/V;_ /P[7@__ .6E'_#RS_@GW_T>9^S?_P"':\'_ /RTH ^WJ*^(?^'EG_!/
MO_H\S]F__P .UX/_ /EI1_P\L_X)]_\ 1YG[-_\ X=KP?_\ +2@#[>HKXA_X
M>6?\$^_^CS/V;_\ P[7@_P#^6E'_  \L_P""??\ T>9^S?\ ^':\'_\ RTH
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M_P /+/\ @GW_ -'F?LW_ /AVO!__ ,M* /MZBOB'_AY9_P $^_\ H\S]F_\
M\.UX/_\ EI1_P\L_X)]_]'F?LW_^':\'_P#RTH ^WJ*^(?\ AY9_P3[_ .CS
M/V;_ /P[7@__ .6E'_#RS_@GW_T>9^S?_P"':\'_ /RTH ^WJ*^(?^'EG_!/
MO_H\S]F__P .UX/_ /EI1_P\L_X)]_\ 1YG[-_\ X=KP?_\ +2@#[>HKXA_X
M>6?\$^_^CS/V;_\ P[7@_P#^6E'_  \L_P""??\ T>9^S?\ ^':\'_\ RTH
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M /RTH ^WJ*^(?^'EG_!/O_H\S]F__P .UX/_ /EI1_P\L_X)]_\ 1YG[-_\
MX=KP?_\ +2@#[>HKXA_X>6?\$^_^CS/V;_\ P[7@_P#^6E'_  \L_P""??\
MT>9^S?\ ^':\'_\ RTH ^WJ*^(?^'EG_  3[_P"CS/V;_P#P[7@__P"6E'_#
MRS_@GW_T>9^S?_X=KP?_ /+2@#[>HKXA_P"'EG_!/O\ Z/,_9O\ _#M>#_\
MY:4?\/+/^"??_1YG[-__ (=KP?\ _+2@#[>HKXA_X>6?\$^_^CS/V;__  [7
M@_\ ^6E'_#RS_@GW_P!'F?LW_P#AVO!__P M* /MZBOB'_AY9_P3[_Z/,_9O
M_P##M>#_ /Y:4?\ #RS_ ()]_P#1YG[-_P#X=KP?_P#+2@#[>HKXA_X>6?\
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M7_\ EG7[-T4 ?C)_Q#V_\$<O^C%?A!_X"ZO_ /+.C_B'M_X(Y?\ 1BOP@_\
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M_P#+.C_B'M_X(Y?]&*_"#_P%U?\ ^6=?LW10!^,G_$/;_P $<O\ HQ7X0?\
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M !#V_P#!'/\ Z,5^$'_@+J__ ,LZ/^(>W_@CE_T8K\(/_ 75_P#Y9U]#>/\
M]HOXIZ!_P4M^ /[,^F:AI$?PD\??LX?%CXD>)M.ETF&76KCQ5X3\1:%IVBW%
MIK!;S;6RBM+^Y6XLU0K.Y5R05&/FG_@H%^W)\1OV??%GQH\.?"[XE66G^+O
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M2L[Q49*WO*:DJ+BJ;C=5)OVT$J4.:JW>U.RN<+_Q#V_\$<O^C%?A!_X"ZO\
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M"E'BG1_B1X\N?C9\13;^$/!/Q7_:U32/"?A3X;VEV_BOX3_!/P?HGB?3WO\
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MIIM-,%*,E>+35VKKNFXM>JDG%JR::::304444B@HHHH **** "BBB@ HHHH
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M0A)+GO',J]!0H^SDG&I6Q2I4X0KS@ZKJU)3PDZ7.D9R;FIII>S]E"=1:I<^
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M7X@\5:?IOC_XGP>)+KP'X9G,IU#Q);^$+&+4_$DMBJ1NA32;&>*YNC(Z;8Y
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MH.GF*W\1ZU%)I'@71]2EOIK+5?&=^!%X9TZYFOU83I$:_1+3?A5\,M'T*_\
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M;W7B:&5)X?$-S"UH8YM;BGC2:/5)%:^25$D6<.JD8'C3X)_![XCZ9K^C>/\
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M^=O %='XT^ OP1^(UQX2N_'_ ,(OAOXSNO ;PR^"I_$W@SP_K<OA0VP06ZZ
M^H:?.VEQ0^5&8H+/RH5:*-EC#1H5T=Y.]VFZ\JSY7:4:L\+&C/$1G;GE7IUE
M*O0A)^SIRJ5-'%TE2B.C7NQDHT732EJI4UC)8BG0<7[BHRI-8:M-+GJ4XTT]
M8S=3^/GX_?%F_P#CG^R]_P % O'_ .VO^V#XR^#_ .TA\,/ W@[PK\-/@YX4
M\8WW@SP'JO@G6?!_AO4M,\1:%\*;ZWAN/B9IOQCU:[NWO[^2QNI]-W-;?Z%]
MF*U^]G[6?Q7^+WP5_P""2Y^(GP3EU#1?&VB_ 7X0POXFT32Y-7U7P!X7U:R\
M(:5XR\=:3I"13/=W_@[PO?:QK=K$L$IMWL1<^6WV>OT5\7_L_? OX@>*=*\;
M^.O@[\,O&/C#1+!M*TGQ+XH\#^&]=UO3],?[VGVVHZEI]Q<1V8ZI;"0PQ'<8
MT4L<]UKUYX2\+>%M0N/$MQH&A>#-+TMK?4Y-8:QL/#MAHRQ"U>&]^U^7IT&F
MB!A;M%,%MO*81%=C;:5>U2A5IQ5.DZE7#U'!<RH2^KQJ0E[3EG&O?'^U;QBI
M5J<82KUXX545*A[(IQ<<3A:K<JGL(8B&MI56\0\.XQIWC*GRX1T$\-[2G4G/
MDHO$.JXUE6_D0^/'QBU7X%Q_$OX:_L/_ +<'Q=^-/PP\;_LM>$?B+\3OB3>?
M$B7XK:E\$OB;JGQ%\)Z-X1\:Z!XT9+F/PQKWQ,L=4U9+SP(\H6,6R7*V%K%%
M@_K%^Q?I/BOX%_M^?&_]G.R^,?Q9^)7PVU3]F7X1?&TZ=\6O%E]XVO\ 2?B-
MK^KWNC>)=7T'4]14S:7I^NQ0I=76AP/]AMKL!K6*-5 /ZC^!O@%^S[X+\-ZM
MHWP[^$'PJ\-^$_&=Y;^(M<TWPOX*\,Z?HGB:]+K>6>JZC:Z?IT=GJKK(4N;&
M>=)1$2);;RS@TZ/XC?L_VGQ)U'0(?%_POM_BQ FC^&-5T^+4_#L?C:)+U'O-
M"\/7RJXU91.BR7.G:5.?F4-+!;XRU:N:NXP352<ZJGS<KJ2H2H8B,<(E&*2I
M83$5J4J+4(RY,/3YWSNDJ>4X2G12]HE&$*-JBO;VL,1@ZD\7*7-?VN+H8:M3
MK>\X<V)FX*WMG4_F8_X*(?#SP'H7[<W_  4A\8:AX_\ %^F>.O%7_!+"WO\
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M\2/B_9>%=9\+^&OB;*+NWU*3QGX(D_X2*\\*O=78T>>1;AHK>.01U?\ VAO
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MP<U*VKG0CA[3=XTN3,I8Y8BFE%?O7&7LZ<='2FY3G5K0:IGTE1110:A1110
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MOCSPYKOA'P#J-[HL^B-:P'4_ >KWBVUT6(@=)HX@Y_>+X=?\$VOV(?A7HOQ
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M96US]I/P9X0^&OP;_8G_ &UO%_B+]E^X\?\ Q%^$WB*#QW^RQKWPV\;^//\
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MS'9>%](BC;R6M;.(JX$8DE*KBO&_^"K?Q1\2?M4_L1?&'X2?&;]F/XQ_L_\
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M0L84PDVGC6_^T$YW#%NV8MG!^?&[/'0Y_I,HH _G(_LK_@Z _P"AK_X)H?\
M@C\?_P#Q=']E?\'0'_0U_P#!-#_P1^/_ /XNOZ-Z* /YR/[*_P"#H#_H:_\
M@FA_X(_'_P#\71_97_!T!_T-?_!-#_P1^/\ _P"+K^C>B@#^<C^RO^#H#_H:
M_P#@FA_X(_'_ /\ %T?V5_P= ?\ 0U_\$T/_  1^/_\ XNOZ-Z* /YR/[*_X
M.@/^AK_X)H?^"/Q__P#%T?V5_P '0'_0U_\ !-#_ ,$?C_\ ^+K^C>B@#^<C
M^RO^#H#_ *&O_@FA_P""/Q__ /%T?V5_P= ?]#7_ ,$T/_!'X_\ _BZ_HWHH
M_K^OZ_$.M_\ AON/YR/[*_X.@/\ H:_^":'_ ((_'_\ \71_97_!T!_T-?\
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M7_!T!_T-?_!-#_P1^/\ _P"+K^C>B@#^<C^RO^#H#_H:_P#@FA_X(_'_ /\
M%TV32_\ @Z"6.1T\4?\ !-&6149DB&B^/4,C@?+&'9BJ;SQN;A>I/:OZ.:*
M/YK;)?\ @Z8N;E8;R7_@FGIMN0Q:\,?C*[V%1\JB"%M[&0_Q<!>XK;_LK_@Z
M _Z&O_@FA_X(_'__ ,77]&]% '\Y']E?\'0'_0U_\$T/_!'X_P#_ (NC^RO^
M#H#_ *&O_@FA_P""/Q__ /%U_1O10!_.1_97_!T!_P!#7_P30_\ !'X__P#B
MZ/[*_P"#H#_H:_\ @FA_X(_'_P#\77]&]% '\Y']E?\ !T!_T-?_  30_P#!
M'X__ /BZ/[*_X.@/^AK_ .":'_@C\?\ _P 77]&]%'J!_.1_97_!T!_T-?\
MP30_\$?C_P#^+H_LK_@Z _Z&O_@FA_X(_'__ ,77]&]% '\Y']E?\'0'_0U_
M\$T/_!'X_P#_ (NC^RO^#H#_ *&O_@FA_P""/Q__ /%U_1O11_7F!_.1_97_
M  = ?]#7_P $T/\ P1^/_P#XNC^RO^#H#_H:_P#@FA_X(_'_ /\ %U_1O10!
M_.1_97_!T!_T-?\ P30_\$?C_P#^+H_LK_@Z _Z&O_@FA_X(_'__ ,77]&]%
M '\UVH1_\'2]K<&*QN/^":>JP;%;[4(?&5D"Y^]&(9V\S"_WCP<^U:T.F?\
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M>&&T+[.;DZN-9\_[!]@6(%VG,P1,%6(8$#RCP]^UO^S1XJ^''B#XO>'?C?\
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M)NE_ WP%>>"?$NCZQK'Q$L_@OJFC7UOI&C?#OQ/;C^R](T+X1V=A;:A\1XI
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M\-:H%BTKX6FP$6H1>'-6MH]<T"]G8W4MU"E@MPP=5;YK^&?[1OQAL/"GQ/\
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MBO\ M!:BNCI<7^I7US:PW6@^$8_[3O\ 1OML]_>7,M]<2 \W\9/&7[&WQ_\
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ML+.QT;Q-)KMY$EGIT-]JB>)+V%=7MI%AES73>)/A[XV^'0\=:GIOC'POXI^
M?PK^._P7^'OC[XAZQ\/KO0OA!KWQ,\!:0/"_AS6_%G@[26D;Q/\ #SX)Z?!9
MW?C75@[67BOXC75N99'MK'-?UE1Z3X?T:?5M<ATO2--N[Y3<ZSJMM86EK=WR
M6Z$^;J-W#"D]T8HPWSSR2%%SM(KYNL_VGOV2K_P_96]G\0_AW<>$_$LVB06:
M+;0_\([K5UXQ\1WGAO1[=%:Q&G7MWK7B:SO; 0D232WT4C3J"=YN,JEZ$8S3
MK4J;<K;U:]?&8&2FXQ7-&G?"^RP\(VDL36IS3<Z%*$G.TG6E**5*<GRI)+V5
M&EAL>ZB4I.TIVQ;J5I3;@L+1J1:C&M5G'PK0_P!H7]H/XC?\$W?$?Q]\&^";
M>']H";X/>.=7\&Z%I^EW:Z?KOB+0QK=CX?U_1-%OP+Q=-U^#3[3Q!H^FW(:4
MPWEO !(K(&_GW^%/[1W[32_#_P =ZAX1_:6\5^(_&.J?#3X8>*_!_A'POXF\
M=_%CQ#J?[;NI>)(XM"^'GB2Y\0>&-(TSP-X4\:R/?Z-\1?AT)FL=%T6UDU-)
M[9;:-V_LB@B@MH(8((HK>WABCAB@B1(888U54CBBB552.-5 1(T55"@*J] /
MG?4/C?\ LS^"/$?B?PG=>*/ >@^)/#NNV'_"7:5:Z=;P7FDZ_JVA7GB.PN];
M6QL,6]Y=Z!9WFHQZA=,&:UCD)N-QVF9N'ML35<YTX5J,8QY90A4H1I7E5JTY
M.,Z,)>]]9<G2E3HXFG0J-2PU+V-2::DZ-*FJ<*TJ56<VIJI.E4]K[E*G4491
MK2A!\N'5JL9U:%6O!M5ZJJ4_YJE_:3UWQ1K'[%W@W]K_ /:T^/WP''CJ[_:K
M'[9VEZ5J&K>!/^$<^/7A*RTBYLOAA#J^E:9<3>'?ACX/>22;X?:GI3SV&NV2
M6C27[/>21KXWXK_:D_;1\0:-\/=.^)'QJ\4_#CX8Z3\-_'>N?LM?&'QAXK\9
M?"_Q#\;=1T7X@3Z7X&\;^);#PWX:U6Y^(/B@>&8]/:#P-JT&FCQ%87/]IF!Y
M+QY!_5:OP>_9^^//C/X4_M0VMGIWC6_T+P;XCL? /B&WE6[\,:MX7^(%O8?V
MI=W.ESP-::L;N'3[5K*\NXS+;A7,7$C ^_WOASPYJ<-A#J.A:)J$&CRQS:5%
M>Z98W<6ESVX$<,NGI/!(MC+ %"126XC>(*%0J% %>]%^_%4:D<17G.A23A1I
M7JQ]E*FJCG55;"TH<F#C4J.GAZ<G1KQQ4U[449IWY7[6#HTXPJU7&=2;=.?M
M8R=-0IRI8B<E+%-04Z\HPJ4'AXWIO^87X)_&OQC\1?B;&W[6?[4/[1?PT_;7
MN_C/H7PV\)?L\?";1=9M_!_B7X2:KX7M%T_5K/X=W6EMIA\(^,["YO?$_B+X
MA7U[%J'A348MJRP7%O';GXQ\(^,_B%\&/V=OV>?@MX,^+_CCP=\"V^)O[8 ^
M-?C/QU\3O'G@+4_#/Q[\->-M6N/ GPVU3Q]IWAW4]9TNQ73)$\3Z3X>6W32O
M%5\P47DOG>6?[36T/0I-5B\0OHVDOKD-LUI!K3:?9OJT5F_+6T.I&(W:6SYY
MA2<1,3RI->?^#_$?P=^+^C>(I/"$W@WQOH>D>--9\.>)TMM.L+^PMO'7ABY6
MTUJQU."XM#$VMZ3=;(KB62-YX7"XDP :32DY6]V]*G&I3A[L.6EC)UX327OQ
M4JU66(J7ER_7U2E2Y*$/J[(M05I-R3F_9RFTYQG+"^RDHN2Y6XTX>PI>ZY+
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M_A45AKIT^UUK2(%N;YI^ ?ZQOB!\$/AK\4/%GPP\;>-O#Z:SXB^#NOZGXF\
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MP8_X6EX0U=/ '@/7;KX2>,1XAU*_CBLHY+>:.=DMP;N0VUGK,UH+ORXP4/\
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M6I;FCG&I-%%.8YYS'7];UU:Z7<A(+VVL;@32),D%U#;R^=-;@,DJQS*V^6
M%7 +1@9RH'%@BU:0H1 TQ42[,1F78/D$FWERH.5#XQ_"#GBHJTU5P]:C+E3K
M1JPE*$%&"5;#>PJ*%.\E3A%/DA2A+DAA84<-)25*-5U2JNC.,X\S48<D5*;<
MU;$1K0E*I9<\E*//SRBI3Q#E73C*4H+^1RS\"?M,?LO? [X(1_LX:_\ M'76
MM_%;]@SQ#K?Q=T_4)==\17'AVZ\.>)O#;WVJ^"?#]] ;+PC\0?#/@_4_$,'A
MC1M/CMY[R&WC5;:6X@W,[5/B!XDTV3QSH?[,?Q1_:N\1_P#!.*;5?V?3^T+\
M3-0C\=ZM\0O!M_K5Y=K\1[;X<ZYKVGQ^-%L=2M/[.?XKMI%M-'X:GFNO[/$8
M&T?UPI]G=F5/(,D(",J["\(=0VQ@,-&&7!VG 9<'!!JI#::1;VEQ;6UMIT%B
M&G%U!##;16N]\FY$\*((=TFYC/YB[GW$N#G-=%2K[2M5K.,6IUI552J>_2=)
MUU5A@Z]_>JX*DFY0AS0G]8Y*KK3IQ=&?/&*5&%*+DFJ5.E*K"T*BJQI>SJ8N
MC9.-/'56HQ]HXR@J#J4E14I*K'^3S1?'GB"3Q9X1\,^*_B7^TQ!_P2<C_:(^
M(&G>#OBO+)X_MO&6HWEEX%L;SP?X<U[Q;#8_\+"_X4I;^.SJ:^%]<N[='U/4
M(8+2ZF, 7/Z"?\$L;?QSH'_!/;]H74/A18_$'4/%-S\9_P!JW7O@Y>?%K1+[
M1O'/BUI]6OIO >MZ]8ZK;VUU<S:O-'9M:7=U"IU*W6VFER97-?M^UCHYL$LI
M+333I96*.*S>"V.GE"R&!$MV7[,07V&)53&[85&[!J^D<<:A8T2-0!A44*H&
M,#"KA1@# QVX%8RAST*]!U*BE5PRPWUA-+$2M5A6]OB)\O[S$TW!4:,H*E"G
MAHTX2A4JP=>H[)U</6<:=J.)6*5"UZ"M3JTG1HP;3IT:JJ.I7YI5)U,0ZDE*
MG":I4_XS=<CUGXM? WQ=X!^''C?]K3XF>*?B+^R!\8]1_P""@OA/QVOCN&#P
M[\3M-%E-X;ATN/4[*&VT#QNWB_\ M#2-(\.^#6FLM4\(1P231NA+5_57^R3X
M)T_X=?LP_ #P3IT>LPV?AWX1> -/B@U^YN;S6;<IX9TV26VU*>Z5;AKJWGDE
MA>.95>(((MJF/ ^@(K"Q@>XD@L[6&2\<27<D5O#&]U(%VB2Y=4#3N%^4/*7;
M'&<5:      '  & !Z #I6EW^]248*O*C.<(+EIQ]@\7[.E2CO'#4(XN5/"4
MIRG.C3YHNI4<VTI4W*=*3DW[%5XQ<WSSJ.NL*IUJT]%+$U7AE*O4C"$:K]FU
M"'L[26BBB@T"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /
MYV/V[Q\4;;]M3Q]-X;'BH>(+[P#^RG'\*SX56X?6CX3MOC@#\8(M/%L&G&D;
M'LG\5B+Y?[,(:Y(AY'RA\"M3_:>\+?MJVGCOXM>//'&@_%+P3\<?CGXE_: T
MRR\*?%K6[;6_V<=%T_5]1T32M5DNI?\ A4T/@FT\/P:9>>"+SPU"=9_M4&!5
MDG>0C]XOVE/VDOV0?@5\9OA_J/QFNY;?XM>&? /C/QEH.K:/HFIZOJ'A'X;F
M:RT?Q1JVOW&FY73_  [?WTUG9QI>)(+F^4&WBWJT@^R(-3\)^+]*@B6XTS4K
M/Q5X>AU%-/FDB6YU+P[JUL'CDFL79;MK*YM[GRWWQ^7F1HB03BLZ/-3IT9TW
M&<J3QE.$Y+FI>UG5Q-6-N5Z_Q90QD;3]K"C**E3:<H56E"I&=&I'EA5^K59N
M#Y*KIQH8?#5(J33T2I1J82=X>QKU:=1QFHQC5^./V@KH_M;_ +#/B/QG\!/$
MWB[2+CQK\.['XH?"G7]&&I>'/$MQ>:+):>*]!M1:%8-0M9=8;3!I=Q83HK21
MWLD,J$-BOPP^"U__ ,% /B]\2M#N+O3OCIX7M?VM;36/VR(;'Q,VK:;HWP5U
MSX.>%M4\&^'?@5>M+MAT2'QQXPM](\12:#)L@U&-S/,AA+5_5)HZ>'=)MHO#
MFA-I%A;:!9VUJNB:;):0IH]FL0%I"UC P^Q0>4O[D-'$I093(K7BN+>=I5@N
M(9FA<QSK#*DK12$!MDH1F,<FT@A7PV"" 11*$%4Q,J4JL*5>,E2ASISHQ=/$
M4U4A42LZJD\%65567MLOI\MHUL1&41DU3I1FJ<I4Y<TFX/EFW*A4=.<;^]#E
M6+IN#LW3QU6_\.C*'\6GPBUW]IWPGX)^*'C/4;OX^>,O%4?[/'B33_VL_AMX
M"L/C'H/BW4?B'JWC*SLQXGUSQ?XO%SI.A^*/"GG7\K#X46<DFI>#8YXM/C7,
M+UF^&/"?[7'CK4]9^&7[*VJZ[HNNZ-^U3\,?&O[.GC'QYX'^*NI_"+X=:7KO
MP:UFS\6>(_#=Q\1C<>))K:YUU7L9M5U"XCLK;Q)<I?FUCA78W]J5M?Z5=?:C
M97FG7(AN&M;UK:XMIA#=1A4>VNC$[&.Z0%5:";$BJ "HX%6;:6TGB62SDMY8
M!NB1[9HY(AY;%716B)4;'4JR@X5@01FM(S5Y>ZDG15-1I7A&$7)5H^R^)QI4
MZJYL-&3;ITZE:C&I.E5?*._+RZ2?/-\U9*I*?-!TI.MI!3K2IR<*TE&/M)1H
MSE3C.C&_XE#QQJUA_P $9?CAJ^@Z=\9/A;\3?!/P4^+>D^-!\0-5U=_BGI7Q
M9\/VVJV_B_7;/Q)J;B74&U#7$N-5\*ZQ9.NGRV=UIHLECCBV#\C9K[XT:A\)
MK;4/^";M[^TXVEZA^R7X&OOVRM3^*9^(]Y+=^*+N^\,W%UK'A;_A)G?5+SXM
M76@-XHF\12> 'VS^'BC6BK.837]?OQ"^'WA#XJ>"/%'PY\>Z+;>(?!GC/1[S
M0/$NAW9D6VU72;^+R;JSG:)XY=DL9*L4=6QT-;7A_P /Z/X6T+1_#6@V4>GZ
M+H&E:?HNDV,18QVFF:59PV%A:H79F9;>TMX8%+LS%$ )-2^:57%5I*"EB%A[
M4X1Y:+=/#8FC5I58;RP=2I7C46$@X+EI4(.K_L]-L@O9PP].+E*-&>(DY3FY
M5+5:^%JTIJ=O>Q5.%"</K4TWS5:LU3O7JQ/Y(O@M\&_BM\5?%?PO\+>'_$GQ
M#U;X'ZY\:_'6E_#G7=%\.?%72-+^"^LZY\"]4LM2\1^%O$WQ-DE\<0Z?)XH>
MRN;R>[>.PM-:^T6]@S!\5[%X9U+]MSXF>!-/^+OB/3_C=X8^(7PO^,'[/7['
MND^$[R+6+:S\3:A\*-?U1OB9\;;C30K17WA3Q]K,NCB3Q'*AAN=&AF\R7R@^
M?ZDD1(U"QHJ*,X5%"J,G)P  !D\G ZTI .<CKP?U'\B15R=VFKI)PFDGJJL*
M^%FJRG:_M?JU'$8*,FG:EB5.2G5PU"<1W=+V=HZQQ$&WS-.GB*.*A*ERMV5/
MV]7#8MI-?OL-)0Y(8FM%_P Z_P#P3NE\.R?'#X=+K^G_ +8L_P"V<(_BTW[7
M5_XDN_%UO\&K74CK5\MI'XP@\2!O"%_IP/V"+X5IX%$;PV&UYF="^/Z)QD=.
M>O7_ (%].O'\Z01HK,ZHBL^-[!0&?:,+N(&6VC@9)P.!3_\ /^?SHNW3HP:4
M72ARM0]VG=N'NTJ>OLJ45#W*?--IRFW-N0G&]6K4N_WLN;5WGO4=YST]I/\
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M11PC7-R. _:<E)J7\.FZ]6=1V7)+ZHO?YG%J'L*6&K5FY7C[&IB>91YE./\
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M9*]F]XSA)=XSC):-"T444QA1110 4444 %%%% !1110 4444 %%%% !1110
M4444 ?SQ?\%(OV4;_P =?M2_%7XO^%O@GXG\7:_??L':[X0M/%FB6NJWT5_X
MF7XG:&UIX9@MXKL6-QJSZ&EQ/'9&V+26BR3??&ZOCJW^%7QWB\56OA_2_AE^
MT'9_\%/U_:5T37?!/QRN(?%*_!S1_P!G*&QL4L8=1\0K?'P)#\)K#P6D^@:G
MX$FLCK!\5!6:![@&0?U5>/\ XC^#/ACX=U/Q/XUU_3=$T[3-+U;5BM[?6EM=
MW\&BV$^IWT&EVMQ/#+J-ZEI!(Z6EJ))G^4!<L,Y'PL^+W@3XP_#+PC\6_!6L
M0W'@OQMHVGZ[HE_?&*QD-IJ:(UK'>0S2 VEVQ=(GMIF$R2L(R"V!6=%*G"$(
M-N.'<7)P;C4A[7&8O%P<*D+^PE6JU:E"K**YJ^$57#2Y?;2DU5ESZ2TE44HQ
MYES1J<F&H8>2J0:_?1I4H1JTXR:5*O[.NF_8Q2_E>\)_#/XMX\+Z=\(OA+^U
M#X3_ &S=!\+_ +2H_;S^(OB1?%\/AKQ_9:QX=\11Z/%9:]J6H3^&_&MWKWB"
M;1K[X0P>$8(YM"LHHT(MUBD#?K_\+_V;/B5\&O\ @E9K/P^_9VB\9Z+^TCXK
M^ 4^NRZMXU\1:GJOQ$U3XOZWX4A?6+K5-:U^[NI+3Q1-.9[#3B#!::9?BS,<
M<8A9S^IMKXP\)7\VM06/BCP[>7'AEG3Q'#::UIUQ+X?>.,RR)K4<-P[Z45B5
MI'%\L!6-6<C )$VC^)_#/B&VM+S0?$.A:Y9ZA'/-876CZM8:E;7T-NVRXDM)
MK.XGBNHX7^2=X6=8G^5RK#%*<%4P=?"W</;T(4YU*;Y>2G%32A0@KQI85S2J
MQH1?LU559\\N=J%*;CB:6(:B_88BI5C3G>2G4E)3_?R=I5:\8RE3=6:]I[%T
M8<BY$Y?R Z]\%O%WCGP?X@\._L9?"+]K[X1> -1^ OPS\#_M80Z^?'?AKQ-X
MH^.,WQ1\+?:+[PW+K^I7.HZG\2M%TY/$UYXQ\=>&WATF;0;N-3(^Z%!_6A\(
MOA?X.^#'PX\*?#3P#I<^C^%/"FEQ6&EV5UJ%_JEVJDR2W$][J6IW%U?7U[=7
M,DES=W5S/))+<2NWRJ54=/=>,O!^GO90WWBOPW92ZC>)IVGQ7>NZ9;R7VH.2
MJ6%E'-=(]U>,R,JVL >=F5@(R015E_$OAR+6D\-R:_HD?B*2R?48M!?5+%-9
M?3H^)+]-+-P+UK*,@A[I8# G0R UNZCE"<=O;5Y5IN+=FU&M45&"VCAL,Z]2
M6&PZ;CA:,E%-Q?.8*DHRI<TI/V%+V45-WDTY4:?MJKLN?$UE0IQQ.(DE+$U?
M>:4O<>Y17+WOC?P7IL,USJ/B_P +V%O;7EKI]Q/>:_I-K#!?WX!L;&:6>[1(
MKR\!!M;:1EFN 08D8&N33XP>$/\ A,_$O@ZYENM/3PIX4TOQAJGBW4EM[+P3
M_9>JW=Q9Q1P>))KA+%[NVDMG>\A9HUMXVC9Y/GP(NOP;\K**F[O9>ZU)7:;6
MJ4EJ]E=WLGITL[_%R[;OWO=>FCT;3NEZI17BUG\?/AU??%;1OA!;ZLLOB7Q1
MX'G^(7A&^@:"Z\/^+/#UE>K8:I)H&LVTTMKJ-SI<SQ27L$#,T5O-'<<QDFO:
M:$[I/I+FM=-7Y)RIR6J6L9QE"2:34DT^C:NKVZI1=KJ]IQ4XO=Z2BU*+ZI^J
M11113&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% 'C?[05EXDU/X$_&73O"9D'B:_^%_CVTT 0EA,=8N/#.IPZ>L)7YO,:ZDB
M6/:<[RN.17\QGA_QSHOB_P"$?P _9J;X8_$CX<?!/Q?^SU\&;/\ ::^/'PU^
M!FO?$'QU\<[[1=6EM[SX$>&_$>CV5W:>%;#0=9MK\>/?$.L+)J%C;WLUKI=M
M&[/.W]:Q4$$$9!&"#R"/0@_KZUR/@WP#X/\ A[IEWHO@O0+#PYI%YJ^J:]/I
MNFQF&R.JZW=->ZK>16^YHX&O;N22XF2%8XS-)(ZHI=B8A'EJRG*TH2>&E*F]
MIRPTZ\HPD_\ GT_;*K*GK"M6H4%7C4HP<&2NX1C%RC.+KJ,XRLXQQ%.C"4XZ
M/][%T>2G4MST:=>O*@Z==PJ1_F+\:^%?&_@K0_BM^Q_9_L__ !:U#QQKG[>7
MA7]IGP)XMT?P3?WW@9_@!X;O- \;6_CB7QT$>UM=4\/Z)X>;P;+H=S.OB'^V
M)8K&"V:)W ]B^-O[)O[9?Q$_9C;Q5X6\ ?#;QJ/C)=_&K]HK]HCX2_$?5M?\
M.^*/%/CKQ!I5S;_!3PM&FEV5W#JFE> ?#D&FL/"U^8(;O78H8W^6,*?Z0 H'
M;T[GL,#ZD#OUHQG]>Y[_ .?P[4I0E.A.E*4G.I&A!U6^9VP^%IX*FW3:Y&YX
M?"X&6(NK5L5A(8A*+:A&X3]G7IUHPA&,)U:BIQ3BN:MB'BJG+.+4H*%:KBEA
MU%OV-#$2H^\HN4OP#\6? #XF>*?V2?\ @E?KWC[X":1)^T+\*_C/^S:/%4WA
MO0UUS7OAEX3TR+4UUXIKEW9PZKH^D6]I]A;Q! CI;07$C0-N1%KW/_@MW?II
M_P"Q]X1%Y'X^O="O_P!IK]GO3?%.B?#'5;_2?&WB3PO>>.+9-<\/Z+-IMQ:W
MUP^IV)EBN-/MYDEOK7S[= 6=17[%8_S_ )_S^0K@_'_PQ\!?%+3=(T?X@^%]
M,\5:9H/B;0O&6CV6J1O+#8>*/#-VM_H.M6X5XRE]I=XJW%K)NPD@R0P)%;U)
MNK.\HP499FLQG!QYX+GKY?5K4O9R=IQFL"[\[O5E5E[5M;94UR4X0NVZ>"K8
M.$D^2=I4<?3I3YTKP]E+&1Y>16IQIKV:3L?RH>./"NJ6]UXUL/A?^SM\:[7_
M ()Z^._CEX/B\&^'OB'H/Q9O/#7@+QOI?@^_M_'?BJ\^#6DZG#\1=?\  'BG
MQ"]GIVBZ9=WMIX>3Q3#-JT\:P9)X7X#_  *^) M/@-\1_'WP,^/EW\8="_9)
M_;@^ W@[QQJOA?Q=8>)/!OCNW\1ZCJ7PPT*]MWU&X?PU87O@Z=8/!-Q>S74#
M*T%B+N2ZC!']DF!Z#\OP_EQ2_P"?\_E6+A>G4IWE[]'V*J-WK17L,3A^=5&K
M^U5/%UJ<*B2<:"I8>7/"G=VI6E"7+'W9NHZ=E[*3]KA:W*X._P"[E4P="K4I
MMN,Z[JUER3G9?QNZS\&OVR;OXSV?_"='XJ:9\8KB']GJ_P#V:?$FE?#3Q_XN
M\8^'?ASHO@'28?%6A:3X]M-?L_A]X1@AUV/6H?B3I'C'3I]2O6N#<![AW@"^
MRZ-^POX_/P8^"%U_PJ;XO:O\3/CA\*OVT_"/[2[>(-?\57UUXNAU33->O_AW
MX?\ &\-]JC6UEI[ZS%9-X)@CCMQ:;XK>W?R9 #_5[28'_P"OG^=.M"->G7IR
M2C[=UE*25VHUI8^4HVE=2]HL='ZQS:8F>&HU*B3NATYRIU:=6]W3<)15W%.=
M-8!4Y/EM_!>!;P_6A'$UX0=FF?QF>*_A)JWA?PA^R5J_PM^!G[0MWX@\*?L[
M?!GPEX ^ 'COP'\3]/\ #+>-O"?BV/\ X3!/@S\1/">M1:A\%OBHFJ1W4GB>
M\\?6MUX=UW15AGBD-B[1U^\O_!-Z75-3\;_MV>)8[>6S\%:_^U)>S>&+,W"7
MEG::_9>!_#5G\1+:TNH1]FO7M/%J3V5_?VP,%Y?VMS,I+E@/U-=%=&C8$JRE
M2 S*<$8.&4A@<=P01V-<AX%^'_@SX:>'H/"G@/P[IOACP];W>H7Z:7I</DVY
MO]5O9M1U*]E)+R37=]?7,]U=7$KO)-+*S,Q& -74E*6(E)+]]/%U%[TGRSQN
M*H8BK'6[=./L7*//*<G4E&SA3IJ,L?9I0IP@HI06%IOFC&7[O"4Z\*<E:W+5
M;K*$I045[-5.92G5O'L:***@T.?\5P:C<^&/$4&C,8]7GT+58=*D#;"FHRV,
MZ6;AN-I2X\H[L\ >U?S;^#/@B_Q&_P""<_[%%WI7PJMO'?QM^$/[6_@NU\5Z
MO;>'+75O&_@'5-+^.6M7'Q*U ZE+"VIZ/"B.;W6IDFC$EE)')*'21&K^FBN-
M\)_#[P9X&F\33^$?#VG^'Y/&/B*[\6^)1IL;01:MXDU!(8[_ %FXA#&-;V]6
MWA^U21+&)60.P+EF,4X\E;VV[C+ 58)7353+\SI9A!-JSY*JA.E-Q:G'F4H.
M[E95%ST71V4EC82?1T\=E>)RVHFMI2IJO"M3C).$G!QFMF?!GPH^%]Q\</CY
M^UC\9_BYX#%]X0G@3]F[X7^%O&FC17>G:S\.O"<9U#QCK:Z1J4,D-SI?C/QA
M>/Y$LD6R\LM)C(!0BOD/X+_LR3W?_!'OXK?!'QW\!8+K6=-T?]I67P1\)_$7
M@RQNI[*^F\0^,Y_ Y\.^'+J!X+6=HYK*?PXUI'&T8EMV@*D\_O#@?Y_IZ?A1
M64Z'/0JT.9QC5P=#"2:Z.C7JXKVZ3WJ2Q.(KU4W?V;FE3:<$S:G6E2J1J)*3
MAB_K44[I)*C3PZH:;4_84J5.5K.HHR<T^=H_/Y;+Q-X1_P""98T^_BU+PIXI
M\.?L:O9W=M<F33=7T#6M+^$7DS02L&$MCJ&G7<+(6#![:XCR""F:_G&^#.F^
M(/\ A2/P4\;_ +(7[/\ ^U?J6OVO['/B-/VV8];UKQUX<D^+I\1:5ID/AA8?
M%>J7US)XP\:1:F-5\1Z=JO@;?J*^$E?3X;B-Y%C7^R#Q%X=T3Q;H.L^&/$FF
MVVL>'_$.F7VC:WI5ZK/::EI6IVTEG?V-R@92\%U:RR02J&4E'8 C.:J^$/"'
MAOP%X7\/^"O!^D6F@^%?"NDV.A>'M$L59++2M(TVW2TL-/M(V9BEO:VT<<,*
M%FVHH&3UK:LI5Z^-KR:B\5RR2BK\LN?'2J0G*3O/#U%C+5:#LJWLX2E.,J<&
M33E&G0PU%1YO8U:DVY-)<KIX*--TTE:%:G+".=*KK[!SER1DISB_XQM'^ .I
M^,-+^)MGK7P ^*WB[X(^"OVB_P!A?XY>"/"WA[X7?%#PGX2L]%T_4/[&^,/B
M'X?>%O%.M7GB?5]1TV[-N?&5U<S0WNI/#-JZ64:;F/H?QU^$_P"U+J.M07?Q
M/T/XD/\ L[77C;]JZ#P#I'B+X>?$SXG7>C_$S7O&<$_PP\00>'O!&NZ7K>CW
M\OA;R(_AMX@U>6?0-)NX98Y8X6\QC_8UTHJIOF7*DE&Z=DW=Z.$I2M;FJQI*
MG"A6?OT94:,ES*$8K**Y9*6C:C*-VE>S=*:C%M/EINI"<JM-+EJJO6B^7VDF
M_P"46W_9&^/>I?#7]H7XM_$3PU^T'XS_ &EOAOK'[(/_  HWQIK.J>(=/\3V
M<>ECPW%XTU7POX=TK53HT.H-I4M_9>-B([O[3%%-%>M(\;$\%X^_9@T7P'X/
M_:&\*1_"?XX?#'['_P %#O'/Q/\ %$ME\,/&_P 3/@;\2?#7BSP=%/X'NOBQ
MX;\/:U:^*O%GP\OKR>]CM-7\&7!N?#'B?RIM1@950C^O>BHE&[DT[<W1)>[^
M_IXEN-DDG.M352HFI0J34)3@^2*5+1)-<UFWKL_W<Z,8M:KEIT:DZ5*UI4J<
MI1A)<TF_YY/^"?O_  LS4OVG?V7O^$A^'6O?"G5_!W[$'CG1_BGX&UC7]8\0
MWFF:;>?%F(_"6\U2^U^2;7[6TU[2[>ZUCPSH/B.:76M$T:1;*X/[EF/]#(X]
M.,XYQQ\P /7IC_)!KC=%^'?@KP]XJ\6>.-&\.:=8>+O'/]E+XL\0Q1$ZIK<6
MAVTEGI$%W<NSL;;3[>66.UMX_+BC$KML+L6KL\#T]OY_XGGKS6U2HZJA=*+B
MJKDDVTY5L37Q$FKZ_P#+U)[*4W5DHP4H1CG&'*Y6:Y;4HQ:BHRY:5&%.\VK\
MTM)1C)^\J4*$).4HSE):***@T"BBB@ HHHH **** "BBB@ HHHH ***3/L3^
M7]2* %HI,GT/Z?XT9/H?T_QH 6BDR?0_I_C1D^A_3_&@#^>#_@HW\(/$&L_M
M%?&CQ+\7/V8OC)^U1\.OB)^R=J/PZ_9CL_A98WFNVGPR^+ABU<^(++4[.WU7
M3(_!^M^*[FYTB[TSQU,)XH;6RFL'DC&Y#\P_ WX$?%G0?BG^SO\ L+ZCI/B7
M2/A]\8?@Q\(_VM_CQX1MO%DL?B;X2^,?@EX<C\/ZQ\,=3DM[R2701\3O%C>'
M+N&X#164]_I5[+MD"2Y_J\_X"?T]O?V'Y#TKSGP_\(?AEX6\?>,OBGX>\#Z!
MI7Q&^(5MI-GXU\:6UD@\0^([+0HFAT>RU'49'>=[/3T=OLUI&T=NCDR&,R?/
M6="#HI13<D^;GDW\:A]?KX:,Z5O95'''8ZEB:M6:]I..6X&BK1]MSE6]5/I*
MT5!W^%M8.C5G"?\ $I_['A*M&G2IM4U/,,95>OLN3^3/P?\ LR?&!-.^.OP^
MTC]G#]K&\\":W\+/%MA\1?'<_AZT^'W[3'A35HOB(OB'3/"FC>)X_$,O@G]J
M6&]<374>HW=I8ZE=^&(!ICW:F<Q5NVEE\=_V:?V?+O\ :;\-?"74_ 'B?X,?
MM#OX5^#&EZAHVI?!WQ!^TUX0^/'AFQ^'.O\ VKX(ZAK>J6/A37/"_BC4-+UZ
M"PT0BUU:32-1U6TM85\US_7KC_9)[<D'T]6]AGU[UYSXW^$/PR^)6L^!O$'C
M[P/H/BW6/AGK[>*O 5[KEFE\_A;Q(UNUJ-;TJ.5S!#J,<#LD-TT3R09+PF-_
MFJHQM&G!W<%#"T:DHS<*CHT:L?:N+2:YY8.6*P5!/W*=/&U9UO;5*=&<')\T
MISY:=W4Q->$7'F@JM:E/DC*^JIK%_5\55DKSE+"TX4O90G5C+^<'QA_P36\5
M:7I?[46FZA\+/'_Q0\1^"/V//@1I/P+\976LZO<7&J?&BUU76/%GCW6/ X_M
M2,6?C:+Q)>1R76JHL5U]E2.T$GV=FBKQ-OV6OVR+[]I/5KOQUI'QYN?C/J'Q
M5T+XB^%OB;X5^&^FW>B#X71_#2"Q3PWJ/QMO=?C72-#M9Q<Z%XD^'JZ,US>Z
MM)Y]NLDC"<_UXY_V3^G^-&?8_F/\:'&\FU[L73G!0C[L:?//'SYZ45[M.I_M
ME.C*23Y\+A*.&G>G*0E=1M)N<W.,Y5).\YVIX&FXU'O.F_JE6LH-I0Q.+JUX
MVG"!_)+8_LP>&OV:](_9"N_CI\!?'?Q1\%>)?@)\<-4^*_PA'BPZU\2H/VC=
M2U.XN[+XJ^+O#NN>)+&?4=$T[PF6T#3/$=M<2V_P^$UO>K!"JK*?%/@K\.?C
M[J?[,_PR\5VO[/OQ-^*_P7\5?"/X&:+?I<7'B#XCQ^%-,T/XT^.M3U#5(/"-
MGK=E<?%?4/"^ER:9#J.EW%V--U:T>*YNGNK6%5K^M;XS?LW? K]H:UT>T^-'
MPO\ "_Q"C\/RW$NBR:[9LUWI@O$$5_!:7]I/:WT=GJ,*B#4;$7!LKZ$".Z@E
M4 #U;P]X>T+PEH>D^&?"^BZ=X?\ #NA:?:Z5HNB:1:6]AI>EZ;91+!:6-C96
MRQP6UM;PHL<442*B(H %6I-NO.2C>=6BZ=*,;4(T*6)EB53J15N=N,EA8R5J
ME/#PIPIU%3ITZ:-G3Y;NU'$1JU)-^U]K6H.@JE*2^#ED_K#3O2J5FY5*3J2G
M4E_+9^PC\/\ XO\ A7XV?L@?#/Q+X2^)'@GQ3X'_ &B?VQOB/'I7Q!T*V\,Z
MI!^SIXJT6UA\,W5EX>T^_P!1LO#?A+5]9N((-)T".Z\C3KQ&M$7S4<#^JDJV
M#UZG\MS_ -"/;'XUSD?@WPK%XKG\=)X>TP>,;G1XO#\WB0VL3:NVAP7+7D6E
M"\;,J6*W3M<?9HRL;3'S&5F (Z;.?X3^G^-)WE3I0DVY4_:.4G)MR<G0A%W>
MM_8X6@Y])5I5YQ2A.,5FX?O:M2ZM/EY8I<JBN:O4DDEIRJKB:L::WC1A2C)N
M2DQ:*3)]#^G^-&3Z']/\:#06BDR?0_I_C1D^A_3_ !H 6BDR?0_I_C1D^A_3
M_&@!:*3)]#^G^-&3Z']/\: %HI,GT/Z?XT9/H?T_QH 6BDR?0_I_C1D^A_3_
M !H 6BDR?0_I_C1D^A_3_&@!:*3)]#^G^-&3Z']/\: %HI,GT/Z?XT9/H?T_
MQH 6BDR?0_I_C1D^A_3_ !H 6BDR?0_I_C1D^A_3_&@!:*3)]#^G^-&3Z']/
M\: %HI,GT/Z?XT9/H?T_QH 6BDR?0_I_C1D^A_3_ !H 6BDR?0_I_C1D^A_3
M_&@!:*3)]#^G^-&3Z']/\: %HI,GT/Z?XT9/H?T_QH 6BDR?0_I_C1D^A_3_
M !H 6BDR?0_I_C1D^A_3_&@!:*3)]#^G^-&3Z']/\: %HI,GT/Z?XT9/H?T_
MQH 6BDR?0_I_C1D^A_3_ !H 6BDR?0_I_C1D^A_3_&@!:*3)]#^G^-&3Z']/
M\: %HI,GT/Z?XT9/H?T_QH 6BDR?0_I_C1D^A_3_ !H 6BDR?0_I_C1D^A_3
M_&@!:*3)]#^G^-&3Z']/\: %HI,GT/Z?XT9/H?T_QH 6BDR?0_I_C1D^A_3_
M !H 6BDR?0_I_C1D^A_3_&@!:*3)]#^G^-&3Z']/\: %HI,GT/Z?XT9/H?T_
MQH 6BDR?0_I_C1D^A_3_ !H 6BDR?0_I_C1D^A_3_&@!:*3)]#^G^-&3Z']/
M\: %HI,GT/Z?XT9/H?T_QH 6BDR?0_I_C1D^A_3_ !H 6BDR?0_I_C1D^A_3
M_&@!:*3)]#^G^-&3Z']/\: %HI,GT/Z?XT9/H?T_QH 6BBB@ HHHH **** "
MBHVEC1XXW=5DEW>6AX9]@!8 'J0"">GTX-24 %%%5H[RTFN+BTANK:6ZM/*-
MU;1SQ/<6PF4M";B%7,D(E0%XO,5?,4$KD"@"S10?\XQ_6B@ HHH_G[]_\_IZ
M4 %%4=3U/3=&T^\U;5[^STO2]/MY;N_U'4+F&SL;.UA4O+<75U</'!!#&H+/
M)*ZHHY)K*/B_PHMOHUV_B;08K;Q$D,F@33:O80IK:7"*\!THS7"?;_.1T:/[
M+YI=64J"&!H Z.BBLK5==T30TADUK6-+TA+AI4MWU._M;!+AX()+J=(&NI8A
M*\-M#+<2)&69(8I)6 1&8 &K14%K=6U];6]Y9W$-W:7<,5S:W5O*DUO<6\Z+
M)#/!-&6CEBEC97CD1F1T8,I((-3_ .?_ -?I_GZ4 %%9MOK.CW=O>W=IJNFW
M-KIMQ=6NHW-O?6TUO875B ;VVO9HY6CM9[,$&ZAG:.2W!S*J"L5/'G@>1K)(
M_&7A61]2,*Z<D?B#29&OC<RM#;BS5+MC<^?,CQ0^2'\V5&C3<ZD  ZRBL[4]
M8TG18H)]7U.PTJ"ZO+;3K:;4+N"SCN-0O9/*L[*&2XDC26[NI/W=O;H6EF?Y
M8U8\5HT %%8+>*?#"6-]JC^(]"33-,NIK#4=1;5]/6PL+VW<1W%G>WC7 M[6
MZ@D(CFMYY$EC<A70,0*U[6ZMKVWAN[*X@N[2YC6:WNK6:.XMYXG 9)89HF>.
M6-U.4>-F5AR"1B@">BBB@ HH_P _Y_S_ %HH **/I^?:LG4]>T/1&M%UG6M)
MTAK^<6UBNIZC9V#7EPQ 6WM!=31&YG8L (H=TA+ !22,@&M16?J>K:7HMF^H
M:QJ6GZ581O#')>ZE>6]C:))<2K!;H]S<R1PJ\\\D<,*EPTDCJB!G8*6ZCK&D
MZ0+-M5U33],74+V#3; W]W;V@O=1NB1;6-H9Y$%Q=W!5A#;1;YI2#Y:'!H T
MJ*K7EY::?;37M_=6UE9VT9EN;N\GBMK:WB7[TDT\S)%%&O&7D=5&>367I?BC
MPUKDOD:)XAT/6)_LD>H>3I>K6&H2_8)96ACO0EI/,QM))D>*.XQY+RHT:N64
M@ &[115>[N[6PMIKR^N;>SM+:-I;BZNYH[>V@B7[TDT\S)%%&O=Y'51W- %B
MBL2R\2^'=2?3X].U_1=0?5;:XO-+6RU2QNFU*TLW2.[NK 6\\AN[>VDD2.XF
MMQ)%"[JLC*S ';_S_G_/_P!< **SK?6-)N]0O])M=3L+C5-+2VDU/38+N"6^
MT]+Q&DM'O;5)&GMEND5GMVF1!,JLT98 D+J>K:7HUJ;[6-2L-)LA+# ;S4KR
MWL;43W$JPV\)GNI(H1+/,Z10QE]\LC*B*6(! -"BN8O_ !MX,TN\ET[4_%WA
MC3M0@4//8W^OZ59WD*&,RAY;:XNXYHU,0,@9T ,8+@[1FMZTO+74+6WOK"ZM
M[VRNX8[FUN[2:.YMKJWF4/%/;W$+M%-%*C*\<L;LCJ0RD@@T 6:*/\__ *^G
M^?T#Q0 44?Y_S_G^>:/\B@ HJA=ZIIMA/8VM]J-C9W.J7#6NFV]U=V]O/J-T
MD3S/;6$4TB/=W"PH\K0P*\BQ*TA4*":JQ>(O#]QJTV@P:[HTVN6Z&2XT6+5+
M*35H(P QDFTY)VO(D"D$L\*J 0<X- &S111^.?\ /^1^% !115&[U33;":QM
MK[4+&RN-4N39Z;!=W<%O-J%V(GF-K8Q32(]W<"&.24PP+)((HWD*[58@ O45
MBWOB3P[IMV]AJ.O:-87T=E+J3V5[JEC:W::= "9[]K:>=)ELX0K&6Z*>1& =
M[C%/TC7]"\00S3Z%K6E:U!;RB">;2M0M-0BAF:-)5BEDM)9421HI$D5&(+(Z
ML 58&@#7HK.T[5]*UA+J32=3L-32RO;C3;Q["[M[M+74+1@MU8W+6[R""[MF
M(6>WD*RQ$@2("12W>KZ5I]SI]G?ZGI]E=ZM.]KI=K=WEO;7.I7,<9EDM["":
M1);R:.)3*\5NDCK&"[*%&: -"BLJ/7=$EU670HM9TJ36X(1<3Z/'J-H^JPVY
MQB>73EF-W'"<C$KPA#D?-R,ZOX_Y_P .G]2: "BBDS_GUX[=!0 M%%9>JZYH
MFA0QW&N:QI>C6\TRV\,^JZA::=#+.Y 2".6[FA1YG) 6-6+L2 %.10!J44BL
M& 92&5@&5E((8$ @@C(((.00<$8QG-+_ )]J "BC]** "BLJ#7=$NM3NM%MM
M8TJXUBQC66]TF#4+274[.)]I22ZL(YFNK>-PR['EB16W#!.16E)(D,<DLKI'
M%$C222.P5(T12SN[L0JHJ@LS$@* 23B@!]%4-,U33=:L;;5-'U"RU73;Q/,M
M-0TZYAO+*ZC#,ADM[FW>2&9 ZLI:-V7<I7.00+DDL<,<DTSI%%%&\LLLCJD<
M4<:EG>1V(5$1069V(55!+$ 4 /HK#_X2?PV-%C\2'Q!H8\.S1)-#KQU:P&C2
MPR.8TECU0SBQ>)W&Q)%G*L_R@D\5KPS0W,45Q;S1SP31I+#-#(DL,L3@,DD4
MB%DD1U(975BK*05)!S0!+12%@H+,0JJ"68D  #DDDX  '))X%<R_C;P;'H^H
M^(&\5^'/["TAWCU365UO37TS3I8V"217U\ERUM:RH[*ABFD20.RIMW, 0#IZ
M*YK3_&7A+5I;Z#3/$VA:A-ICV,6HQVFJV4[V$VIQK-I\-X(YF^SS7L3H]M#+
MLEF5E*(=PSO+<V[SRVR7$+7,"(\UNLL;3PI+GRGEB#%XUDVL8V=0K[3M)P:
M)Z*S]/U;2M6%V=+U*PU(6%Y-I]\;"\M[P6=_;X\^RNC;R2"WNX-R^=;2[)HM
MR[T7(SH?Y_3M_GUH **@DN;>&2"*6>&*6Y9DMXY94CDG95+LD*,0TK*HW,J
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M9:7^G74%Y97,>XH9+>ZMI)8)DWJR[HW8!E*YR#0!=HHHH **** "BO$?CO\
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MAHWC#5-?E@\8ZMXB\$7;Z7K&LZ?X<CLWLAX:;6(IM/M&FOEU&80/=-!''A*
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M(OWTZ":WN8'>*5HWACFBW 'G'[(GQ@_:@\=>"/VG?%WQ$L?$WBN[^!5UXI^
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MPI:>+=1\"SWUAK']ASWJR7%SH\.IV%Q:-JJ6HBF\IWM5F&TD _)WPO\ %_\
M;MUOXGV'P_N-=^, _: \-> ?@QK]WX#?0-.3X/P?$'6O$.KI\7U\8:K'#A?
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M%VN6FA?#-;/P-JUT?BS)=Z_)X7.H?#E4YU_2;378I+*\OF%I' BBZ(-LZR4
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M>SPK#:Q:/IS:M#+<7%O(;0/)*J-MC8 X)?!O[3NO_P#!/32OA]\/F\87>O\
M_"C[72=<N_B%K.K6WQ_U'QCI>JPIXL\.I>3QPV8DU;2[;4].TS5I+J.YD6>
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M&-E)*)M%OM1\06KZ-81A+I9KMD+/' _G4 ?!'AC3OV];"$ZW;#XE^&U\"_\
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M!D?#'XW_ +='PN_9[M?!"^%?%'@_5M)^)5IX;MYKKPU>:O;>$?@-J%[XJO\
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M>_L_$OAG2_%7C73=8T;P3=^$M"C37YH]%\%7-I%X@O[*[%S<*+U0F_?CY?\
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MCS:)'XN\4Z78_P#"0_%;Q'81Z9#IMJ-,N_BII&FZ3<P68CC799^'UTJUETJ
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M5?F<8PS<<L,##'D8'/%*JJBA45449PJ@*HR23@  #)))]223R:=10 5&(H@
MHCC"JQ=5"* KG)+@8P&)))8<\GGDU)10 @502P4!FP&8  L%SM!/4XR<9Z9.
M.M(R(ZE7575A@JRAE(]"""".!P13J*  # P.@X%,\M-K)L3:^[>NT;7W_?W+
MC#;LG=D'=GG-/HH :$0*JA%"IC8NT;4V_=VC&%VCA<8VC@8%(T<;;MR(VY0K
M;E#;E4DA3D'(!)(!X!)-/HH :$0,7"J&8!68 ;BJYV@G&2!DX!X&33J** &"
M*)=NV.,;"Q7"*-I;[Q7 ^4MD[B,$YYS3Z**  @$$$ @C!!Y!!Z@CN#2
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M<[6*@LN[KM)&1G S@C..:&1'P616(# %E!(##:V"1D;E)!QU'!XIU% ''?\
M"O? H\*7/@8>$?#R^#;T7 N_#"Z5:+H=T+J[-]<BXTU8A;3"XO&-S,)(V\V8
MEWR:ZR&&&VABM[>*."""*.&"&)%CBAAB4)%%&B@*D<:*$1% 55 "@ 8J6B@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ,#IVHHH
MH ,?Y_S_ )Z>@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH *.E%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
F%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>form10-k_015.jpg
<TEXT>
begin 644 form10-k_015.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" #, ?L# 2(  A$! Q$!_\0
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MGQ6T-[K.I:QKU^EUK.K:A?7'UI0 4444 %%%% !1110 4444 %%%% !1110
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M7:?LV> /V8?B]^T/\4-&\'W7@Z;Q]\6/&&D?$#X:_"+X=_#5+7QAX3U+^RM
MNO%_Q-\.0'4=#\5>#KI[_7EUC6-=AT+PG>:/KX!^O5%?DG>_\%(_B_IGQ3\(
M_LV7?['DD_[4&O\ Q<L?AYJ_@#3OCYX8D^'FA>$=4^"^N_'6R^*-O\5;[P5I
M\VL:.GA/PIXJT.^\.KX&L/$4/C/13IEK;7VBZAI_B&?WGXD?ME>,= _:#\9?
M!+X6?L_ZI\7-+^"7AGX0^-/VC/&:?$7PSX&N? /AOXTZYXFT[PU_P@WAGQ'9
M-%\3-9T/0/!OB7QWXPL)_$7@NTT_PWIUO8Z)J?B+Q7JEIX> !]YT5^,6L_\
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M9@_8:_X*&P^+/A2GBKX'_'71/A!X>_X*0_\ !,G]IWP]X1^)WBM+N+X>>'O
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MS3J/P\\2^*-.T'P]XH\+?M _%;2?B5JG[4>KVNI#P+<W>L?#.U^%NH>,]?\
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MFR@N[Z[UK7_$>O:SJ^IZCK$TD?U710 4444 ?-G[,G[6?P3_ &O/#WQ+\4?
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M>-O^" WP@^&OB_6/B]_P3*_:,^/7_!,;XN:E<2ZE<Z5\$O$,WC+]F_Q-J1A
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MAFC)VNJMD4 =S1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M5\":#!X>T7X=>.;FWO/&'@'X'EK74=#D^*/C_3OB#XS\/RZ7H'A2ZCU3Z_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M&N[>.6?3;Z6PO=+;4=+NB!<Z9J0T[4M0LH]1T^6VOH;:]NHHKA$GD# 'R_\
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M_P#L9_!'7/CQH_[0'BG1'\4>(_!]]J^O?#7PEJMGX?@^'OPV\:^*H],7QO\
M$GP]X9TC0],&J_$KQG/HVEW6K>./&EYXIU[3KBR1_#-WH)FN_M/U;110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?-_P"S
M7^R9\!OV1M$^)GA[X">!K'P-I7Q=^,_Q#^/GCNWLSO\ [6^)'Q.U./4_$NHJ
MQ53;V$?D6FG:+I46+/1M(LK/3K-$@A /TA110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0!^7?_!9WQ5\;_!?_!-C]I7Q'\ -1\>Z)XTL=(\%1^(?$?PJ@O+CXG^%OA!>
M_$CPA8_'/Q1\/DTV*;4H_%GA[X/7/C;5M*O-,ADU/39;5M2TX+>VD#I_/!XS
M_:A^%/['7Q$_:5^+/_!%CXP:G\3OV>_A7_P2S^)WQG^/4.H?$/XG?M _L\^'
MOVBM$\;> X?V=M?U74_B/XEUT6/QP\8>&[WQU%XU\)Z7XBTK7-3\/6Z:MXFT
M6&_MQ<5_;'7SY\<?V7/@E^T)\!OBM^S7\0?!MI%\)/C5X?U3PU\0M!\(.W@J
MYUC3M:,3:E+'JGAL6%[::C<M#&7U&"1;MBOS2G)H _DF^+/_  4B_;+^*U_X
M)\/:5^W-\+;KX.?"S_@H?_P3*G\1?MC_  <^$USX)^&-SH7[3&A>-/$?C_\
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M!T6"**YL;V**'2[&*.*\TR"*VTV[C1(%5+G3K:W@M[&=0);2"&**W>..-%4
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
D* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>form10-k_025.jpg
<TEXT>
begin 644 form10-k_025.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" 'M [8# 2(  A$! Q$!_\0
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M>&[AECB2R*$J05 8L/2?V&/VJ/VZ/C;=6GQ+^*D7P1U_X':[X.O/%5DG@/5
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M:2@\?6VH:W\>_"FLW>E^#M>TFS\0"X>ZO4L]&M))#>6<4C_/*ZGSD!8C)/Z
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M_P"/?_%4?V1<?]!B?_Q[_P"*H Z>BN8_LBX_Z#$__CW_ ,51_9%Q_P!!B?\
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M?]Y<?,.V1ZT 2T444 %%%% !1110 4A&01DC(QD<$?0]C[TM% '*>(B5M=,
M)YU2T^\<GBY0\GOS_G/-=77)^(_^/72_^PI:?^E"5UE !1110 4444 %%%%
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MW&_W6_D:X.U_Y*%=?]BVW_I=9T =]1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 C=#]#_ "KF])_X_M;_ .N__M"*ND;H?H?Y5S>D
M_P#']K?_ %W_ /:$5 &^GWU_ZXK_ #%35"GWU_ZXK_,5-0 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110!#<?ZB;_KF_P#Z":Y_0O\ D&V'
M_7&?^5;]R<02^Z,/_'3U].E<]H+%M)TN559EEMY'4J,X60?*7/ 7C)_#KWH
MZBBJK7<:C*I+(=R*5CC+LN\D990?E52#N)Z8R,CFI5F#&,;)!YB[@2N O?#G
M.%8Y&!U/:@"6BH&G"MM\N4\H-P3*_.2.N>BXRYQ\H()ZTD=S%)YA5LK&Q1G_
M ("PQD*>^ <G P.?2@"Q1110 4444 %%%% !1110!G237)=X4,:CR/,6Y9"8
MBYE9#'@-DD*!T;.3GGM^.G[97P=_:0^-OQ;U_6/ ?AC3I/#/PA\,:1>^$[G4
M1(E_J7B^VOK'7GGT?,T0DD:":6RD*(^Z$21<,"P_94Q%RA8  ;MT?\+')*DD
M>APWL>E5HX+E@6E,09FD(VQ@% 49(R3G+L%(#!AUSTH _$B'P'^U%XS\:Z=J
ME]I'CCP/9^,?'GP[U#QM?:-)]CO8[#3/ACHUIJJR7DMG*D=G+X@MI1$C0DJ'
M52[MDM^TFFV4FFZ?%8&YN;M+!+6UM[O4I!<7DZF*)7DNYHTA2:4DGYECCP0#
MM'.=!;68,I+R,T>5W[U"2@H=K21["?D8@* P(P&#8&!8\I@NUE$GR;LDD9F#
M%AG'1<X.<\'UP, %H#  /4 #C./PR2?S)/O2TBEBH+ !L#< <@'N >XI: "B
MBB@#G_$/_(*U#_=A_P#0EJ]H_P#R#++_ *]XO_0%JCXA_P"05J'^[#_Z$M7M
M'_Y!EE_U[Q?^@+0!I4444 %%%% !1110!5>5AY@!4!!_K2#M1B1A6&><#&<'
M)[#/%? O[7/[67B_X"^-/ASX5T?PYHMKI/C*34/[1\>>++_[+X<TI+"2Q06,
MJ%8@UQJ NY&M[@WB+ +60/#*9/D^^I86^8Q@,'SNC8D*S==Q/;H.QYQTKY,_
M::_9?O\ ]HRSCT&[^(6J>'?"5[:2:=X@\-6UI#<66KV,YA:3S'8K-%<Q&'%M
M/#)'Y8EEW!RZE0#EK_\ ;E_9Z\-^/-3^&_B'Q=)8>--&\/:AJVKVJVYN]/FC
MTV&.6[%EJ(98=7EC$@,(@CA^_@J<EASVF?\ !1;]F/5M0_LVU\5:W;7=S>6B
MPQ2>'KF*#[/J;R0V>IW#O*0(;B2VN$CE!5#Y#@9(^7Q-_P#@DQ\.%\;ZAXLM
M/&NN6T<UOK5MIUL<SO9VGB&.VBU&T:21]TJJEE 8')4)EOE.6%>LZG_P3_\
M =U:WB'6;G$O@/PKX,8PVD<,L1\(7FNWECJ$<P+'[1=2:U*L[[<[88R=V M
M$GCC]OGX'6VG>--*\&^)FE\;V.E^(8]!35=+FM])O]:\-PVDMUHR2F= \Z_V
MA:EMK;B)1@ \U-\/?V_/@^\7PM\)_$'Q1HVF_%GX@Z/HDFH:#HH:ZM[+5M9N
MIK*RM98_.=K17EC(59'<GYQNXS7S=\(O^";&K:A?:]>?%7QMJRZ7#XJ\8S^&
M_"NG7,-Y:PZ7XBBTB)-6?51;1,MZZZ8JR6;0N4VJ?-.[ ]?TO_@F3\.]&^)_
MA#XF:1X@O;>_\-PZ"+RQU"W_ +1^W3^';V>^L)8[KS(!$3)<RB3]V<C:.H-
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MU6)I)&+J"#C>H^:OJS2=5T_6K1KG3M2L-3M1.HA>Q972VD0*QAN&5VR\;'+
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M)803Y<97<<.@*EY#G>ZL0%#;1I4 1B-0 !D    = !P ..PI=@]3^G^%/HH
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M?0/@U_PC'B_Q ;=EVQ:CXIU*ZMTM[@E64N5T)=BE5D&23G=\O]%OCKQEX?\
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M_P#F/7'EP\9].>GK6M&?WJ\#_62\]^%'_P"KZ5EZK_R%=%^E_P#^BX*TX_\
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M+P/I2%0J8&0,\!NHQ@$?F">_7ZT]0-J_+C"C /)7CISW'2G4 %%%% !1110
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M0+I?!=_X]^+WB\D"[\+>%;>)&MM/1C/%&@UI6G";HY&;[(<>E?CS^R_\!O\
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M\(?"7P9I/@3P)H=GH/A70[?[-I>F01IN#;V=[R]EXDN+J=B?,=V+&,(G15P
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M* "BBB@#D_$?_'KI?_84M/\ TH2NLKD_$?\ QZZ7_P!A2T_]*$KK* "BBB@
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M1M QCV- 'D?P]^"W@+X<!)](TA)=6EC O=:E\R\N+N;JT[B9Y=C.<9 1-IZ
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M?^!5Q_\ ':Z*B@#G?^$7TO\ NW'_ (%7'_QVC_A%]+_NW'_@5<?_ !VNBHH
MYW_A%]+_ +MQ_P"!5Q_\=H_X1?2_[MQ_X%7'_P =KHJ* .=_X1?2_P"[<?\
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M)KRV\0?$+5=/EN/%/BK4;FXN?$GC?Q#+$<:/X>:>7[4SRRND");+$-\J[\4
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M *XK_,5-4*??7_KBO\Q4U !1110 4444 %%%% !1110 4444 %%%% !1110
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MO3T)**2I4E1E6P67CH2,@D=\$C/0GK3J "BBB@ HHHH **** "BBB@ HHHH
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MX0T&S\.>'-,L?(L=$L+2VM+;2A'&J")4MP$9Y0OSLN_<8P2QX-:^@JHTZP(
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M@(_:'P/\.?!?PU\/Z9X6\#>&-'\(>']*@AMK>PTC3[2PB,<"!8U:.UC57V@
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M_"@#&^U^(/\ GQT[_P "9_\ XU1]K\0?\^.G?^!,_P#\:K9V2?W8_P#OE?\
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M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '/:K_R%=%^E_\
M^BX*TX_]<O\ UTF_]!%9FJ_\A71?I?\ _HN"M./_ %R_]=)O_010!>HHHH *
M*** "BBB@ HHHH :_P!QO]UOY&N#M?\ DH5U_P!BVW_I=9UWC_<;_=;^1K@[
M7_DH5U_V+;?^EUG0!WU%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% "-T/T/\JYO2?^/[6_^N__ +0BKI&Z'Z'^5<WI/_']K?\ UW_]
MH14 ;Z??7_KBO\Q4U0I]]?\ KBO\Q4U !1110 444A( )/  ))]AUH 6H))B
MLGE*N6\HR!F.$X;&&(!QZD]AS3S-$K*I< N-RYR 1@G.<8'3N17EGQ<^+/@S
MX0>"-<\<>--8L]-T32K>1G:Z:1#/.J[4M8E2-Y)'F8A5*H5#'E@ : .A\;^-
MO#_@+PW>>+O%>I6NCZ%H]N][J.IW$J+:VR(I4@L[*7=F8)$ IW.1G:,D?SO?
MM,_M7_$C]O+QQ;?L^_LQV5Z? \\YCUO4I!.G]I*7S->WA@5X[>Q0YN(XQ-,)
MT1$D$8D;;@?$GXN?M!_\%-O'Z?#WX0V^H^$?@YI3L;T7:21:-J*Q7*6)N]7G
M#.KV;6\DLUM'Y<TGVLVK&) &=?V9^ G[/GP5_8O^%IE>?1M..AZ:DWC+QQJB
M)%=/,4"SPF?8TQT]9'(MEC,C&,1@PJ!\H!Q'[&_[$/PZ_9@\,Z=<W^FZ;K?Q
M,GLFN?$/B&YMX1;:>W#R&V:17^S!551]]3C*G SGYY_;/_X*5:=\/]>O?@E^
MSI8W'Q!^-U__ ,2V!M-!N]/T2YO!Q<SQVRW NH("V)6D\DV[X5%< FOG3X^?
MMR_%W]KSXGZC^R;^QG#+I-A,%E\3_%?3DG^PKHN^..ZEAO#'"RJXE6/9$I?>
MV"O<=KX*^&GP%_X)OV,=PAE^-_[7GC8P6UKI47_$W\07FJ7T9N!<P>;F.ST]
M)"LEPT]S"WW L4AH QOA3^SA\-_V:M+@_:L_;C\6CQW\??$ME+J.D>%]4CCN
MTBUBZ9+^UL_#&GW$\TT\B2!H@#;VIC'"C@"O6/!OPO\ CE^WOXFL?'/QS6_^
M'?[,]M,KZ%\++<7%O>>+;6T<?V?<ZD6^RIIT1989WBCM[Q7 ,9.U@P]=^"O[
M'?C#XI>/+;]HC]L1H_$WQ#MG2Y\%_#])O-\,> $E=;B%DMF!B-];(BVTACA4
M%LG>>I_4&.T>)%"QQ%HTCCBC7Y(((E4!4@4 X"[0H&T C&2: ,3PGX'\-^!O
M#NC^$_"VF6VD^'M"A2#3=-@B00V\<:;$"!0JJ0O<+R23T.*ZT*%SC/))Y[9[
M#V]!2T4 %%%(65>I SZ_Y_R>.I% "U6FN5B98^/,8$J&) .,<$@-@G.02.@)
MYQ4^]/E.Y1N^[D@9^@.":^?OC[^T;\)?V=O"&H>+OB=XQL?#=F8)&M(7+3:A
M?26ZX,%I91@S2N[.BK@ '=]X#F@#VO4-02WMGDD,4=NBL;NZEDV001*I\UM^
M#EU. JL%1N<R+CGXF^,_[>O[-/[-7AVUN?B'X_TT:HM@+JV\-Z1-#J6O7B3;
M@%@L8)22<H$7+#YG&>F#^:^K?MQ?M'?MH:/K^B_!3POI/P3^"FJQ7FD7?Q2\
M<R/9ZQK=@YV/+X?T]89IXY;I$,L5P6C$( !)\SGX@\8>-OV)OV5U\,ZG#X";
MXT_'O1M%M[*[U?Q?,WB/4=9O(6_>RZ3921W48C^T'<GF7$&-RX  PH!^A/@S
MP!KG[</Q3_X:4_:GT[4_!G[-'A0P77P7^%'B@""QUZ=FEE?4]=LYI/(#$BR9
M8VMYUD&074 M7L_Q-^.^DZ%K&L? ?]COP9X8T#QIK%DDHU_P]9:? D4,B&&4
MQQZ:G[G[-F,Q/Y@;)?Y$(&?AC1-;_:*_:KL='U[XH>)[CX,_"F_ODL]+\$:<
MMQ-X^U+1G6(PRVVG6@-E:P2[C$C/J4;C:PV*,5]^?L^?LS?\(5INJ7?P5\)V
M?P^N+JSE@3XE^,+>/5/&6H3 J;N\\Z13<0QWA:-X;=)V2)X2=S9H \L\#?\
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M'<:]>V]Q%H/ANUNHWN;N[\F0P"6WR7=#*H64%#U*8(R2 =)^T5^TG\/OV<?
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M\5O \>DKX,U+X?\ BGQ1I.@OX/CA>Y\976G7;PQ7^N6TRX5([1Y+AVA:,#9
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M_P#B: )O[3M/^?JV_P"_C?\ Q-']IVG_ #]6W_?QO_B:A_L;3O\ GP@_,?\
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MI#9VOQZ^*]AX4UC7;-QH?PA\$&?5O%.MS1 %[*Z,/E?8GEW(B3O%)YGS'RU
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M_P"_C?\ Q-']IVG_ #]6W_?QO_B:A_L;3O\ GP@_,?\ Q-']C:=_SX0?F/\
MXF@";^T[3_GZMO\ OXW_ ,31_:=I_P _5M_W\;_XFH?[&T[_ )\(/S'_ ,31
M_8VG?\^$'YC_ .)H F_M.T_Y^K;_ +^-_P#$T?VG:?\ /U;?]_&_^)J'^QM.
M_P"?"#\Q_P#$T?V-IW_/A!^8_P#B: )O[3M/^?JV_P"_C?\ Q-']J6>Y0;F
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M%%% !1110!SVJ_\ (5T7Z7__ *+@K3C_ -:O_72;_P!!%9FJ_P#(5T7Z7_\
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M]5\>>)M7U)7\7:W=:=*U_*6D&9WUIFN=UM)P1*(54J3@*,8_1?P/^S-XCN3
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M=8L\F:V8VAD-C&JM,6,9Y6@#Z,^*O[5?[''[(7@?0M$TB#PYK,N@V1TWPIX
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M/Z%_R#;#_KC/_*@#IJ*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MC'_PD_\ PCZ3*DAU=+R\\T32_OI25LX?+C91MR :^?\ 1?VF?V-OV;WM-/\
M@1X/T'2?&.R?PS/J%I:S>,?'^H?V:KP2WVH@W.]IY1$7>_CMHH=WS^44RM?$
M_C/_ (*!_M0?M0^-=8\'_L_>!/%'BC2;6WO] U"\NH)=5O;172=+F5KO3X;.
MTT?RY)'8+=6MPUNHPQ;;0!^G"7?['/[&FNZK\6_$_P 2-4_:&^-EAHHM+#Q?
MXHO;;5?LLK8PVGZ?#;D1WD+EO,"N[>3O4!#\Z_._Q+_X*F_%OXN:LGAGP3IV
MHLFO26UC9>&?"6CWSZUJ,ITZ._M;JZ\*PR3:B\%WMCA?4(YH;:-)?.:,)\I_
M/;2_@;<_#S7;[0?CY\9=&\*W%Q>Z5JEYX,\+2I\0OBKKL?B,6=E>^'X[:TFC
M73H5COIKL2/IDDL4B[0V17ZU?"_X!?&[XB:+:>'_ -COX V7[*OA$RVVD7GQ
MX^(UM+J'Q'\3)IUDOE^(!H>IBV>Q&H+;J@,,:QK%*%QD[R ?/6C?L/\ [4_Q
M:M-1^*GQ[^)NG_LZ_"TVRZS/HGC?5;>YU73Q92J;_5+;3)KK2[NV\W3H)7CA
MF$PB)4$L!BO2/AMXO_X)M?L]:AI'A?X%_#K7/VU_C/&FH:[X>\16=G<>)S;^
M)IENA<V5D=)LY+;3K26>2>[>*X%RT4;-F1L;A]WZ/_P2K_X2S0/#=]^V!^TC
M\3/C3=^"M8N=9O+6W\0V/ASPC)92"5YK6_TJVTTW$]E)#*R31-?#,1(!7!-=
M/J?[4_[ G[%%E)\,?@UX8\,>(_'=I>-/I/PX^'&A_P!J^(]0U:_A9K1_MS2Z
MA>6K&VN%2X=@\6/,=47<, 'G?A#X*_\ !0G]K&ZBU?XX>/X?V6/A) ]GJ^A_
M#WX9K"/$;V-[I1MQI6NW[SSPV;VT=TPGM?[-ADANHP&(*8%B3P9_P3C_ .">
M^F2>,?$6J:=\1/BI9R:O=V=QJ][#XR^(%_JUSJ$K7,4&F6R!X9YS+.C-]C;9
MN.5P":YBY\-?\%0?VTEU3^U=<T?]D7X0ZU&;C1[:*V:Z\>S64MRCQ6-Y-)-"
MEM*UH6N)";%625-F.Q^V/V</^"<OP"^ -CIFL:GI7_"T?B-&[SZM\1?%S7&L
M:A>7]ZQ^V2BWGE^Q0BXEEESBW(4/E0I 4 'R))\;OVY_VUO PT[]G_X8#]G7
MX;^)+T6EK\5->NAIWB(^'$E*L]CI5U#8>6SQQ"-,QL-S8V$D"O<?A9_P2U^!
MFC-_PDW[1%[?_M*>-KJ&QM[SQ+\3KV.XM+*]M(5AC_L6W@BM418E3R5S)+QD
M$L2"/U;LM(TS38(+33["ULK6V7;!;6L2P00KZ1Q1A8U!YR N#^=71#$ P$:X
M9@S C(+ 8!P<@$#T% 'GG@OX?^#/A]HUIX>\'>&]&\/:/9QB.TT^PM8X85CB
M 5)-R8WE0, D\[LDY/S=R \?^LF0+D (B  #/'<_0\]@<C%6$MX8]VR,#<Q9
MNIRQ))/).,DDX&![5($1>B@<Y]<'VST]L=* '4444 %%%% !1110!#<?ZB;_
M *YO_P"@FN?T+_D&V'_7&?\ E707'^HF_P"N;_\ H)KG]"_Y!MA_UQG_ )4
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MY'B?_GKIG_@.W_QZCR/$_P#SUTS_ ,!V_P#CU '1_:(/^>T?_?8_QH^T0?\
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MG@U6E\7^)$M]L<0U:T@:749[F\4*@MOLZ2.[2  D84 Z7Q'^T1X<_9^TZ_\
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M^F?V8?V(/VAOC%\1=)\3>'/A)=:'H?A6SM](MO&/QSTJ2.*_ET^,W]CK^DZ
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MU;\?M5U;P]^R3^R_XBU'1KZU@N_#_P 5/'FEZMX:T]DEN/*DN(++48[$:@8
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M/4>1XG_YZZ9_X#M_\>H Z/[1!_SVC_[['^-'VB#_ )[1_P#?8_QKG/(\3_\
M/73/_ =O_CU'D>)_^>NF?^ [?_'J .C^T0?\]H_^^Q_C1]H@_P">T?\ WV/\
M:YSR/$__ #UTS_P';_X]1Y'B?_GKIG_@.W_QZ@#H_M$'_/:/_OL?XT?:(/\
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MU'D>)_\ GKIG_@.W_P >H Z/[1!_SVC_ .^Q_C1]H@_Y[1_]]C_&N<\CQ/\
M\]=,_P# =O\ X]1Y'B?_ )ZZ9_X#M_\ 'J .C^T0?\]H_P#OL?XT?:(/^>T?
M_?8_QKG/(\3_ //73/\ P';_ ./4>1XG_P">NF?^ [?_ !Z@#H_M$'_/:/\
M[['^-'VB#_GM'_WV/\:YSR/$_P#SUTS_ ,!V_P#CU'D>)_\ GKIG_@.W_P >
MH Z/[1!_SVC_ .^Q_C1]H@_Y[1_]]C_&N<\CQ/\ \]=,_P# =O\ X]1Y'B?_
M )ZZ9_X#M_\ 'J .C^T0?\]H_P#OL?XT?:(/^>T?_?8_QKG/(\3_ //73/\
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MMME!Z@''(^OU[4WRTQC:._/?DY.#VY.>./:@"K!]R<8D&W*G>NP$A/\ EFH
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M7BZ32-;MO$GQ.NI=4\6Z-/:7$ANYK;3+6/1K&TN9L"2*WU'3+A5B6+,; DL
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MDGU/)YH :BJ#N'S$J/WA/+#@\CMV)X')SWJ6FA%5BP')[^@SG ]!T_(>E.H
M**** "BBB@ HHHH **** "BBB@ HHHH **** (;C_43?]<W_ /037/Z%_P @
MVP_ZXS_RKH+C_43?]<W_ /037/Z%_P @VP_ZXS_RH Z:BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@#G_$/_(*U#_=A_\ 0EJ]H_\
MR#++_KWB_P#0%JCXA_Y!6H?[L/\ Z$M7M'_Y!EE_U[Q?^@+0!I4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 <GXC_ ./72_\ L*6G
M_I0E=97)^(_^/72_^PI:?^E"5UE !1110 4444 %%%% !1110 4444 %%%%
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MW ,I8N22[@*I ! 4!<\9)Z5;J%/OK_UQ7^8J:@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@"&X_U$W_7-_P#T$US^A?\ (-L/^N,_\JZ"
MX_U$W_7-_P#T$US^A?\ (-L/^N,_\J .FHHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH Y_Q#_R"M0_W8?_ $):O:/_ ,@RR_Z]XO\
MT!:H^(?^05J'^[#_ .A+5[1_^099?]>\7_H"T :5%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% ')^(_P#CUTO_ +"EI_Z4)765R?B/
M_CUTO_L*6G_I0E=90 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** .?\ $/\
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M;3$K&3+-T.W &=Q%;^CW)O-+L]1"R(;^SL[MEP,QO<I'*\6#\[!2QVEP0$&
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M_P"0J/\ A8OA/_G[O?\ P2:C_P#(5 '?[T_O+_WT/\:-Z?WE_P"^A_C7 ?\
M"Q?"?_/W>_\ @DU'_P"0J/\ A8OA/_G[O?\ P2:C_P#(5 '?[T_O+_WT/\:-
MZ?WE_P"^A_C7 ?\ "Q?"?_/W>_\ @DU'_P"0J/\ A8OA/_G[O?\ P2:C_P#(
M5 '?[T_O+_WT/\:-Z?WE_P"^A_C7 ?\ "Q?"?_/W>_\ @DU'_P"0J/\ A8OA
M/_G[O?\ P2:C_P#(5 '?[T_O+_WT/\:-Z?WE_P"^A_C7 ?\ "Q?"?_/W>_\
M@DU'_P"0J/\ A8OA/_G[O?\ P2:C_P#(5 '?[T_O+_WT/\:-Z?WE_P"^A_C7
M ?\ "Q?"?_/W>_\ @DU'_P"0J/\ A8OA/_G[O?\ P2:C_P#(5 '?[T_O+_WT
M/\:-Z?WE_P"^A_C7 ?\ "Q?"?_/W>_\ @DU'_P"0J/\ A8OA/_G[O?\ P2:C
M_P#(5 '?[T_O+_WT/\:-Z?WE_P"^A_C7 ?\ "Q?"?_/W>_\ @DU'_P"0J/\
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MZ@XP2HLB0#D8)P"#QFF_\+&\)<_Z;>?+][_B2ZAQSCG_ $/CF@#T#>G]Y?\
MOH?XT;T_O+_WT/\ &N!_X6'X4VJWVJ^VM]UO[$U+#=>A^Q8/0\4'XA^%!UN[
MX?71-2'3K_RY4 =]O3^\O_?0_P :-Z?WE_[Z'^-<%_PL+PJ>ES?_ /@CU+_Y
M"IO_  L7PGS_ *9>Y'4?V+J/'_DGWZT =_O3^\O_ 'T/\:-Z?WE_[Z'^-<!_
MPL7PG_S]WO\ X)-1_P#D*C_A8OA/_G[O?_!)J/\ \A4 ;OB"0-I.HD%/NQ=9
M$QU!YY]N!U.>G!K1TDJNFV0++_Q[Q=&4_P "GJ#[UYUK?Q \+OIU] ES=/*5
MA:.$:/J#2NI*G<L7V3<P/4D+QT-7K#X@>%TL;)7N+Q'^SQAD71=1)#!1N!'V
M,E2"<%3@C'2@#TC>G]Y?^^A_C1O3^\O_ 'T/\:\_'Q&\)$D"\O"1U T74<CZ
M_P"ATO\ PL7PG_S]WO\ X)-1_P#D*@#O]Z?WE_[Z'^-&]/[R_P#?0_QK@/\
MA8OA/_G[O?\ P2:C_P#(5'_"Q?"?_/W>_P#@DU'_ .0J ._WI_>7_OH?XT;T
M_O+_ -]#_&N _P"%B^$_^?N]_P#!)J/_ ,A4?\+%\)_\_=[_ ."34?\ Y"H
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MK>S9+FZ)CU"V<A=&U!F 2=#D#[)Q@8)/MBMK_A8WA)MV-0O#M/SXTK4#M/\
MM8M>/QH [_>O=E![@L./;K1O3^\O_?0_QK@/^%B>$_\ G\O?K_8NHG/?.?L9
MS[$<$4?\+%\)_P#/W>_^"34?_D*@#O\ >G]Y?^^A_C1O3^\O_?0_QK@/^%B^
M$_\ G[O?_!)J/_R%1_PL7PG_ ,_=[_X)-1_^0J ._P!Z?WE_[Z'^-&]/[R_]
M]#_&N _X6+X3_P"?N]_\$FH__(5'_"Q?"?\ S]WO_@DU'_Y"H [_ 'I_>7_O
MH?XT;T_O+_WT/\:X#_A8OA/_ )^[W_P2:C_\A4?\+%\)_P#/W>_^"34?_D*@
M#O\ >G]Y?^^A_C1O3^\O_?0_QK@/^%B^$_\ G[O?_!)J/_R%1_PL7PG_ ,_=
M[_X)-1_^0J ._P!Z?WE_[Z'^-&]/[R_]]#_&N _X6+X3_P"?N]_\$FH__(5'
M_"Q?"?\ S]WO_@DU'_Y"H [_ 'I_>7_OH?XT;T_O+_WT/\:X#_A8OA/_ )^[
MW_P2:C_\A4?\+%\)_P#/W>_^"34?_D*@#O\ >G]Y?^^A_C1O3^\O_?0_QK@/
M^%B^$_\ G[O?_!)J/_R%1_PL7PG_ ,_=[_X)-1_^0J ._P!Z?WE_[Z'^-&]/
M[R_]]#_&N _X6+X3_P"?N]_\$FH__(5'_"Q?"?\ S]WO_@DU'_Y"H [_ 'I_
M>7_OH?XT;T_O+_WT/\:X#_A8OA/_ )^[W_P2:C_\A4#XB^$R,B\O2/4:+J)_
M]LO\X- &]JS'^U=%*+O_ ./X':R\92$ \GGH<@<UKA?+FC#,-S-(RCGG<IR,
M],@*2>W&,Y(KS^/Q3HNNZ[I,&FM?3M$EX7F%C=01Q%UC"K*LL*;<[20S *>Q
M)SCT" 9.'(D=79E<8(5&7:"/3/S+ZD@Y)YH N4444 %%%% !1110!%(<%?8,
M?IRO/X FOD'Q=^Q[\'_%_P 2Y/B?K=GK$VI76IZ?JNJ>&X-6NM-\.>)]?T=+
M=='U;5].AN+:&\N]+CL[$1-(AS]CCSNR:^P656QD9QG')&,_0TQH(F^\@;#!
ME+#<48*%RA.2IV@ XY- &9;F(VT>U1%;PQ*D:Q?*%-NGE-"B@[G";6C .[(
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M!3^QVG_/M:?]^D_PH^QVG_/M:?\ ?I/\*N8'H/R%&!Z#\A0!3^QVG_/M:?\
M?I/\*/L=I_S[6G_?I/\ "KF!Z#\A1@>@_(4 4_L=I_S[6G_?I/\ "C[':?\
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M@'CL,#/Y\YJ3 ]!^0H I_8[3_GVM/^_2?X4?8[3_ )]K3_OTG^%7,#T'Y"C
M]!^0H I_8[3_ )]K3_OTG^%'V.T_Y]K3_OTG^%7,#T'Y"C ]!^0H I_8[3_G
MVM/^_2?X4?8[3_GVM/\ OTG^%7,#T'Y"C ]!^0H I_8[3_GVM/\ OTG^%'V.
MT_Y]K3_OTG^%7,#T'Y"C ]!^0H I_8[3_GVM/^_2?X4?8[3_ )]K3_OTG^%7
M,#T'Y"C ]!^0H I_8[3_ )]K3_OTG^%'V.T_Y]K3_OTG^%7,#T'Y"C ]!^0H
M I_8[3_GVM/^_2?X4?8[3_GVM/\ OTG^%7,#T'Y"C ]!^0H I_8[3_GVM/\
MOTG^%'V.T_Y]K3_OTG^%7,#T'Y"C ]!^0H I_8[3_GVM/^_2?X57^S6^T(84
MW]2$M$"D@@XSY6%[8SCECZC&H54@C Y]A7/:IYITV]CGO(+".+<\M[=2F!4L
MU4F6>:4,BP KG#DQHNUMQ!&2 71#$K%[:.*!U:/SA"D"EX\G(D=!QD9R"V0.
M ,TMLY-T !+#']GCV1,@97(:?.9-I(*X!P7'/0$'G\I=*@^+?Q"F^,'_  K'
MQKXAO/AYI_C#0K?0KK6]8T2PO-7O;&YN9O&EAX;OQ-;32:;<:;)I<5E/>R%!
M.\I@EW!V7[=_9B^(6E_$7X:Z5K&B66OV=K93W?A_4+;Q+,\VJVVKZ5++]L:2
MX9I(KN&;S(3%-;RRH0>'."  ?2-%%% !1110 4A( R>G^?2EIC[\?N\;L_Q=
M,=Z %WKZ_H?\*-Z^OZ'_  J'_2?^F?ZT?Z3_ -,_UH 9<(T@4QRA2I7Y64E&
M7.'##!)RA( Z9P3[>7VOP>\#6WBR3QLF@:8FOO++.LR))Y4=P[[1>)&5"K=/
M;[DED5 6>20[B&)/J?\ I/\ TS_6C_2?^F?ZT 1E9#C]X@P9"3ANKA\$<8&-
MPR/KSQS/&0J(K-EE4 GDY('J1G\Z9_I/_3/]:/\ 2?\ IG^M $V]?7]#_A1O
M7U_0_P"%0_Z3_P!,_P!:/])_Z9_K0!-O7U_0_P"%&]?7]#_A4/\ I/\ TS_6
MC_2?^F?ZT 3;U]?T/^%&]?7]#_A4/^D_],_UH_TG_IG^M $V]?7]#_A1O7U_
M0_X5#_I/_3/]:/\ 2?\ IG^M $V]?7]#_A1O7U_0_P"%0_Z3_P!,_P!:/])_
MZ9_K0!-O7U_0_P"%&]?7]#_A4/\ I/\ TS_6C_2?^F?ZT 3;U]?T/^%&]?7]
M#_A4/^D_],_UH_TG_IG^M $V]?7]#_A1O7U_0_X5#_I/_3/]:/\ 2?\ IG^M
M $V]?7]#_A2,_!VD;L<9R!GMG )Q^%1?Z3_TS_6C_2?^F?ZT 5;FT%TD]O-(
M#:7%N8GB&Y65F#*2KJ P&".=P.<GTKS[PU\)?!?A/6M3\1:/IPBUW5;46EQJ
MUQ<7=]=)#YDK^3;+>22QV<(,KDQVPC5V=BX[GTO_ $G_ *9_K1_I/_3/]: &
MPQK$>"H4(J*B*57CDN5 "AV8DG Y&.:L;U]?T/\ A4/^D_\ 3/\ 6C_2?^F?
MZT 3;U]?T/\ A1O7U_0_X5#_ *3_ -,_UH_TG_IG^M $V]?7]#_A1O7U_0_X
M5#_I/_3/]:/])_Z9_K0!-O7U_0_X4;U]?T/^%0_Z3_TS_6C_ $G_ *9_K0!-
MO7U_0_X4;U]?T/\ A4/^D_\ 3/\ 6C_2?^F?ZT 3;U]?T/\ A1O7U_0_X5#_
M *3_ -,_UH_TG_IG^M $V]?7]#_A1O7U_0_X5#_I/_3/]:/])_Z9_K0!-O7U
M_0_X4;U]?T/^%0_Z3_TS_6C_ $G_ *9_K0!-O7U_0_X4;U]?T/\ A4/^D_\
M3/\ 6C_2?^F?ZT 3;U]?T/\ A59XR\N_S1Y90J\9C&2>-OS[2V,[B<$8SP#D
MFG_Z3_TS_6C_ $G_ *9_K0!Y-\0_@OX'^*8T=_&VF-JDGAZ\34=&BCU#4K6V
M@U"WXM+Z2*VFA62:!6E4*Z/&WF-GIFBT^"7PZM?$B^+H_#]FNO17;7EM=9ED
MB@N#L*W8M9";9KQ"N5N&B\P$Y#CH/6?])_Z9_K1_I/\ TS_6@"4,H &>@ Z$
M=/8#CZ4N]?7]#_A4/^D_],_UH_TG_IG^M $V]?7]#_A1N4]_T/\ A4/^D_\
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M4;U]?T/^%0_Z3_TS_6C_ $G_ *9_K0!-O7U_0_X4;U]?T/\ A4/^D_\ 3/\
M6C_2?^F?ZT 3;U]?T/\ A4,R)-M!*$*V_:\8D4NO,388$*T;X=6 R& QBC_2
M?^F?ZT?Z3_TS_6@#PO1OV<?A3X?UGQ-KVF:$\>H^-FOG\8F>_P!0N;3Q&U_
M]O(+_3[BXELB(HW_ '!2!3"R(T>UE##LO!?PR\)_#ZWN[3PEIEMI<-]/%/=2
M1^8UPQB6)5A$C;F\A4B15C+!5QPO->A?Z3_TS_6C_2?^F?ZT 2@J!C/KVQW]
MACCI^%+O7U_0_P"%0_Z3_P!,_P!:/])_Z9_K0!-O7U_0_P"%&]?7]#_A4/\
MI/\ TS_6C_2?^F?ZT 3;U]?T/^%&]?7]#_A4/^D_],_UH_TG_IG^M $V]?7]
M#_A1O7U_0_X5#_I/_3/]:/\ 2?\ IG^M $V]?7]#_A1O7U_0_P"%0_Z3_P!,
M_P!:/])_Z9_K0!-O7U_0_P"%&]?7]#_A4/\ I/\ TS_6C_2?^F?ZT 3;U]?T
M/^%&]?7]#_A4/^D_],_UH_TG_IG^M $V]?7]#_A1O7U_0_X5#_I/_3/]:/\
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-** "BBB@ HHHH __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>24
<FILENAME>nrxs-20241231.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.25b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: 96Mps7xRiXgen8uDanwsWaiAybP9z5Z8yekhvWB+bQn63y4gjmow4Cg1mwxmccMG -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:us-types="http://fasb.org/us-types/2024" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:ecd="http://xbrl.sec.gov/ecd/2024" xmlns:country="http://xbrl.sec.gov/country/2024" xmlns:srt="http://fasb.org/srt/2024" xmlns:cyd="http://xbrl.sec.gov/cyd/2024" xmlns:stpr="http://xbrl.sec.gov/stpr/2024" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:NRXS="http://neuraxis.com/20241231" elementFormDefault="qualified" targetNamespace="http://neuraxis.com/20241231">
    <annotation>
      <appinfo>
        <link:roleType roleURI="http://neuraxis.com/role/Cover" id="Cover">
          <link:definition>00000001 - Document - Cover</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://neuraxis.com/role/BalanceSheets" id="BalanceSheets">
          <link:definition>00000002 - Statement - Balance Sheets</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://neuraxis.com/role/BalanceSheetsParenthetical" id="BalanceSheetsParenthetical">
          <link:definition>00000003 - Statement - Balance Sheets (Parenthetical)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://neuraxis.com/role/StatementsOfOperations" id="StatementsOfOperations">
          <link:definition>00000004 - Statement - Statements of Operations</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://neuraxis.com/role/StatementsOfStockholdersEquityDeficit" id="StatementsOfStockholdersEquityDeficit">
          <link:definition>00000005 - Statement - Statements of Stockholders' Equity (Deficit)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://neuraxis.com/role/StatementsOfCashFlows" id="StatementsOfCashFlows">
          <link:definition>00000006 - Statement - Statements of Cash Flows</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://neuraxis.com/role/BasisOfPresentationOrganizationAndOtherMatters" id="BasisOfPresentationOrganizationAndOtherMatters">
          <link:definition>999014 - Disclosure - Basis of Presentation, Organization and Other Matters</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://neuraxis.com/role/SummaryOfSignificantAccountingPolicies" id="SummaryOfSignificantAccountingPolicies">
          <link:definition>999015 - Disclosure - Summary of Significant Accounting Policies</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://neuraxis.com/role/RelatedPartyTransactions" id="RelatedPartyTransactions">
          <link:definition>999016 - Disclosure - Related Party Transactions</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://neuraxis.com/role/PropertyAndEquipment" id="PropertyAndEquipment">
          <link:definition>999017 - Disclosure - Property and Equipment</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://neuraxis.com/role/IntangibleAssets" id="IntangibleAssets">
          <link:definition>999018 - Disclosure - Intangible Assets</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://neuraxis.com/role/AccruedExpenses" id="AccruedExpenses">
          <link:definition>999019 - Disclosure - Accrued Expenses</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://neuraxis.com/role/NotesPayable" id="NotesPayable">
          <link:definition>999020 - Disclosure - Notes Payable</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://neuraxis.com/role/Leases" id="Leases">
          <link:definition>999021 - Disclosure - Leases</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://neuraxis.com/role/CommonStockAndWarrants" id="CommonStockAndWarrants">
          <link:definition>999022 - Disclosure - Common Stock and Warrants</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://neuraxis.com/role/PreferredStock" id="PreferredStock">
          <link:definition>999023 - Disclosure - Preferred Stock</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://neuraxis.com/role/Stock-basedCompensation" id="Stock-basedCompensation">
          <link:definition>999024 - Disclosure - Stock-Based Compensation</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://neuraxis.com/role/WarrantLiabilities" id="WarrantLiabilities">
          <link:definition>999025 - Disclosure - Warrant Liabilities</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://neuraxis.com/role/DerivativeLiabilities" id="DerivativeLiabilities">
          <link:definition>999026 - Disclosure - Derivative Liabilities</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://neuraxis.com/role/RetirementPlan" id="RetirementPlan">
          <link:definition>999027 - Disclosure - Retirement Plan</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://neuraxis.com/role/SegmentInformation" id="SegmentInformation">
          <link:definition>999028 - Disclosure - Segment Information</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://neuraxis.com/role/CommitmentsAndContingencies" id="CommitmentsAndContingencies">
          <link:definition>999029 - Disclosure - Commitments and Contingencies</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://neuraxis.com/role/HealthBenefitPlan" id="HealthBenefitPlan">
          <link:definition>999030 - Disclosure - Health Benefit Plan</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://neuraxis.com/role/IncomeTaxes" id="IncomeTaxes">
          <link:definition>999031 - Disclosure - Income Taxes</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://neuraxis.com/role/SubsequentEvents" id="SubsequentEvents">
          <link:definition>999032 - Disclosure - Subsequent Events</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://neuraxis.com/role/SummaryOfSignificantAccountingPoliciesPolicies" id="SummaryOfSignificantAccountingPoliciesPolicies">
          <link:definition>999033 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://neuraxis.com/role/SummaryOfSignificantAccountingPoliciesTables" id="SummaryOfSignificantAccountingPoliciesTables">
          <link:definition>999034 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://neuraxis.com/role/RelatedPartyTransactionsTables" id="RelatedPartyTransactionsTables">
          <link:definition>999035 - Disclosure - Related Party Transactions (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://neuraxis.com/role/PropertyAndEquipmentTables" id="PropertyAndEquipmentTables">
          <link:definition>999036 - Disclosure - Property and Equipment (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://neuraxis.com/role/IntangibleAssetsTables" id="IntangibleAssetsTables">
          <link:definition>999037 - Disclosure - Intangible Assets (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://neuraxis.com/role/AccruedExpensesTables" id="AccruedExpensesTables">
          <link:definition>999038 - Disclosure - Accrued Expenses (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://neuraxis.com/role/LeasesTables" id="LeasesTables">
          <link:definition>999039 - Disclosure - Leases (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://neuraxis.com/role/CommonStockAndWarrantsTables" id="CommonStockAndWarrantsTables">
          <link:definition>999040 - Disclosure - Common Stock and Warrants (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://neuraxis.com/role/Stock-basedCompensationTables" id="Stock-basedCompensationTables">
          <link:definition>999041 - Disclosure - Stock-Based Compensation (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://neuraxis.com/role/WarrantLiabilitiesTables" id="WarrantLiabilitiesTables">
          <link:definition>999042 - Disclosure - Warrant Liabilities (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://neuraxis.com/role/DerivativeLiabilitiesTables" id="DerivativeLiabilitiesTables">
          <link:definition>999043 - Disclosure - Derivative Liabilities (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://neuraxis.com/role/SegmentInformationTables" id="SegmentInformationTables">
          <link:definition>999044 - Disclosure - Segment Information (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://neuraxis.com/role/IncomeTaxesTables" id="IncomeTaxesTables">
          <link:definition>999045 - Disclosure - Income Taxes (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://neuraxis.com/role/BasisOfPresentationOrganizationAndOtherMattersDetailsNarrative" id="BasisOfPresentationOrganizationAndOtherMattersDetailsNarrative">
          <link:definition>999046 - Disclosure - Basis of Presentation, Organization and Other Matters (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://neuraxis.com/role/ScheduleOfEstimatedUsefulLivesDetails" id="ScheduleOfEstimatedUsefulLivesDetails">
          <link:definition>999047 - Disclosure - Schedule of Estimated Useful Lives (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://neuraxis.com/role/ScheduleOfFairValueOfAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails" id="ScheduleOfFairValueOfAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails">
          <link:definition>999048 - Disclosure - Schedule of Fair Value of Assets and Liabilities measured on Recurring Basis (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://neuraxis.com/role/ScheduleOfDilutiveCommonStockEquivalentsDetails" id="ScheduleOfDilutiveCommonStockEquivalentsDetails">
          <link:definition>999049 - Disclosure - Schedule of Dilutive Common Stock Equivalents (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://neuraxis.com/role/ScheduleOfBasicAndDilutedNetLossPerShareDetails" id="ScheduleOfBasicAndDilutedNetLossPerShareDetails">
          <link:definition>999050 - Disclosure - Schedule of Basic and Diluted Net Loss Per Share (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://neuraxis.com/role/ScheduleOfDisaggregationOfRevenueDetails" id="ScheduleOfDisaggregationOfRevenueDetails">
          <link:definition>999051 - Disclosure - Schedule of Disaggregation of Revenue (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://neuraxis.com/role/ScheduleOfCustomerAccountsReceivableDetails" id="ScheduleOfCustomerAccountsReceivableDetails">
          <link:definition>999052 - Disclosure - Schedule of Customer Accounts Receivable (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://neuraxis.com/role/ScheduleOfCustomersAccountedRevenuesDetails" id="ScheduleOfCustomersAccountedRevenuesDetails">
          <link:definition>999053 - Disclosure - Schedule of Customers Accounted Revenues (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://neuraxis.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" id="SummaryOfSignificantAccountingPoliciesDetailsNarrative">
          <link:definition>999054 - Disclosure - Summary of Significant Accounting Policies (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://neuraxis.com/role/ScheduleOfRelatedPartyTransactionsDetails" id="ScheduleOfRelatedPartyTransactionsDetails">
          <link:definition>999055 - Disclosure - Schedule of Related Party Transactions (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://neuraxis.com/role/ScheduleOfRelatedPartyLoansPayableToShareholderDetails" id="ScheduleOfRelatedPartyLoansPayableToShareholderDetails">
          <link:definition>999056 - Disclosure - Schedule of Related Party Loans payable to shareholder (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://neuraxis.com/role/RelatedPartyTransactionsDetailsNarrative" id="RelatedPartyTransactionsDetailsNarrative">
          <link:definition>999057 - Disclosure - Related Party Transactions (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://neuraxis.com/role/ScheduleOfPropertyAndEquipmentDetails" id="ScheduleOfPropertyAndEquipmentDetails">
          <link:definition>999058 - Disclosure - Schedule of Property And Equipment (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://neuraxis.com/role/PropertyAndEquipmentDetailsNarrative" id="PropertyAndEquipmentDetailsNarrative">
          <link:definition>999059 - Disclosure - Property and Equipment (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://neuraxis.com/role/ScheduleOfIntangibleAssetsDetails" id="ScheduleOfIntangibleAssetsDetails">
          <link:definition>999060 - Disclosure - Schedule of Intangible Assets (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://neuraxis.com/role/IntangibleAssetsDetailsNarrative" id="IntangibleAssetsDetailsNarrative">
          <link:definition>999061 - Disclosure - Intangible Assets (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://neuraxis.com/role/ScheduleOfAccruedExpensesDetails" id="ScheduleOfAccruedExpensesDetails">
          <link:definition>999062 - Disclosure - Schedule of Accrued Expenses (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://neuraxis.com/role/NotesPayableDetailsNarrative" id="NotesPayableDetailsNarrative">
          <link:definition>999063 - Disclosure - Notes Payable (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://neuraxis.com/role/ScheduleOfOperatingLeasesDetails" id="ScheduleOfOperatingLeasesDetails">
          <link:definition>999064 - Disclosure - Schedule of Operating Leases (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://neuraxis.com/role/ScheduleOfMaturitiesOperatingLeaseLiabilitiesDetails" id="ScheduleOfMaturitiesOperatingLeaseLiabilitiesDetails">
          <link:definition>999065 - Disclosure - Schedule of Maturities Operating Lease Liabilities (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://neuraxis.com/role/LeasesDetailsNarrative" id="LeasesDetailsNarrative">
          <link:definition>999066 - Disclosure - Leases (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://neuraxis.com/role/ScheduleOfWarrantActivityForCommonStockDetails" id="ScheduleOfWarrantActivityForCommonStockDetails">
          <link:definition>999067 - Disclosure - Schedule of Warrant Activity for Common Stock (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://neuraxis.com/role/ScheduleOfWarrantActivityForPreferredStockDetails" id="ScheduleOfWarrantActivityForPreferredStockDetails">
          <link:definition>999068 - Disclosure - Schedule of Warrant Activity for Preferred Stock (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://neuraxis.com/role/ScheduleOfWarrantsOutstandingAndExercisableDetails" id="ScheduleOfWarrantsOutstandingAndExercisableDetails">
          <link:definition>999069 - Disclosure - Schedule of Warrants outstanding and Exercisable (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://neuraxis.com/role/CommonStockAndWarrantsDetailsNarrative" id="CommonStockAndWarrantsDetailsNarrative">
          <link:definition>999070 - Disclosure - Common Stock and Warrants (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://neuraxis.com/role/PreferredStockDetailsNarrative" id="PreferredStockDetailsNarrative">
          <link:definition>999071 - Disclosure - Preferred Stock (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://neuraxis.com/role/ScheduleOfOption-pricingModelWithFollowingWeighted-averageAssumptionsDetails" id="ScheduleOfOption-pricingModelWithFollowingWeighted-averageAssumptionsDetails">
          <link:definition>999072 - Disclosure - Schedule of Option-pricing Model with Following Weighted-average Assumptions (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://neuraxis.com/role/ScheduleOfStockOptionActivityDetails" id="ScheduleOfStockOptionActivityDetails">
          <link:definition>999073 - Disclosure - Schedule of Stock Option Activity (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://neuraxis.com/role/Stock-basedCompensationDetailsNarrative" id="Stock-basedCompensationDetailsNarrative">
          <link:definition>999074 - Disclosure - Stock-Based Compensation (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://neuraxis.com/role/ScheduleOfChangesInWarrantLiabilitiesDetails" id="ScheduleOfChangesInWarrantLiabilitiesDetails">
          <link:definition>999075 - Disclosure - Schedule of Changes in Warrant Liabilities (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://neuraxis.com/role/WarrantLiabilitiesDetailsNarrative" id="WarrantLiabilitiesDetailsNarrative">
          <link:definition>999076 - Disclosure - Warrant Liabilities (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://neuraxis.com/role/ScheduleOfChangesInDerivativeLiabilitiesDetails" id="ScheduleOfChangesInDerivativeLiabilitiesDetails">
          <link:definition>999077 - Disclosure - Schedule of Changes in Derivative Liabilities (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://neuraxis.com/role/DerivativeLiabilitiesDetailsNarrative" id="DerivativeLiabilitiesDetailsNarrative">
          <link:definition>999078 - Disclosure - Derivative Liabilities (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://neuraxis.com/role/RetirementPlanDetailsNarrative" id="RetirementPlanDetailsNarrative">
          <link:definition>999079 - Disclosure - Retirement Plan (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://neuraxis.com/role/ScheduleOfReconcilesCompanysNetSalesAndOperatingLossDetails" id="ScheduleOfReconcilesCompanysNetSalesAndOperatingLossDetails">
          <link:definition>999080 - Disclosure - Schedule of Reconciles the Company&#8217;s Net Sales and Operating Loss (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://neuraxis.com/role/SegmentInformationDetailsNarrative" id="SegmentInformationDetailsNarrative">
          <link:definition>999081 - Disclosure - Segment Information (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://neuraxis.com/role/CommitmentsAndContingenciesDetailsNarrative" id="CommitmentsAndContingenciesDetailsNarrative">
          <link:definition>999082 - Disclosure - Commitments and Contingencies (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://neuraxis.com/role/HealthBenefitPlanDetailsNarrative" id="HealthBenefitPlanDetailsNarrative">
          <link:definition>999083 - Disclosure - Health Benefit Plan (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://neuraxis.com/role/ScheduleOfIncomeTaxProvisionDetails" id="ScheduleOfIncomeTaxProvisionDetails">
          <link:definition>999084 - Disclosure - Schedule of Income Tax Provision (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://neuraxis.com/role/ScheduleOfFederalStatutoryIncomeTaxRateAndEffectiveIncomeTaxRateDetails" id="ScheduleOfFederalStatutoryIncomeTaxRateAndEffectiveIncomeTaxRateDetails">
          <link:definition>999085 - Disclosure - Schedule of Federal Statutory Income Tax Rate and Effective Income Tax Rate (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://neuraxis.com/role/ScheduleOfNetDeferredTaxAssetsAndLiabilitiesDetails" id="ScheduleOfNetDeferredTaxAssetsAndLiabilitiesDetails">
          <link:definition>999086 - Disclosure - Schedule of Net Deferred Tax Assets and Liabilities (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://neuraxis.com/role/ScheduleOfStateCarryforwardsDetails" id="ScheduleOfStateCarryforwardsDetails">
          <link:definition>999087 - Disclosure - Schedule of State Carryforwards (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://neuraxis.com/role/IncomeTaxesDetailsNarrative" id="IncomeTaxesDetailsNarrative">
          <link:definition>999088 - Disclosure - Income Taxes (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://neuraxis.com/role/SubsequentEventsDetailsNarrative" id="SubsequentEventsDetailsNarrative">
          <link:definition>999089 - Disclosure - Subsequent Events (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:linkbaseRef xlink:type="simple" xlink:href="nrxs-20241231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="nrxs-20241231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="nrxs-20241231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Calculation Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="nrxs-20241231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Definition Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2024" schemaLocation="https://xbrl.sec.gov/dei/2024/dei-2024.xsd" />
    <import namespace="http://fasb.org/us-gaap/2024" schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd" />
    <import namespace="http://fasb.org/us-types/2024" schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd" />
    <import namespace="http://xbrl.sec.gov/ecd/2024" schemaLocation="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2024" schemaLocation="https://xbrl.sec.gov/country/2024/country-2024.xsd" />
    <import namespace="http://fasb.org/srt/2024" schemaLocation="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd" />
    <import namespace="http://xbrl.sec.gov/cyd/2024" schemaLocation="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd" />
    <import namespace="http://xbrl.sec.gov/stpr/2024" schemaLocation="https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd" />
    <element id="NRXS_ConvertibleSeriesBPreferredStockMember" name="ConvertibleSeriesBPreferredStockMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="NRXS_ConvertibleSeriesAPreferredStockMember" name="ConvertibleSeriesAPreferredStockMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="NRXS_ConvertibleSeriesSeedPreferredStockMember" name="ConvertibleSeriesSeedPreferredStockMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="NRXS_AlexanderCapitalLPMember" name="AlexanderCapitalLPMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="NRXS_LicensingAgreementMember" name="LicensingAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="NRXS_WarrantsMember" name="WarrantsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="NRXS_AllOtherStatesMember" name="AllOtherStatesMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="NRXS_CustomerAMember" name="CustomerAMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="NRXS_CustomerBMember" name="CustomerBMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="NRXS_CustomerCMember" name="CustomerCMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="NRXS_CustomerDMember" name="CustomerDMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="NRXS_CustomerEMember" name="CustomerEMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="NRXS_CustomerMember" name="CustomerMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="NRXS_ShareholdersOneAndTwoMember" name="ShareholdersOneAndTwoMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="NRXS_MrWatkinsMember" name="MrWatkinsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="NRXS_MrSealeMember" name="MrSealeMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="NRXS_ShareHolderOneMember" name="ShareHolderOneMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="NRXS_ShareHolderTwoMember" name="ShareHolderTwoMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="NRXS_OtherConvertiblesMember" name="OtherConvertiblesMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="NRXS_DecemberTwoThousandTwentyFiveMember" name="DecemberTwoThousandTwentyFiveMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="NRXS_DecemberTwoThousandTwentySixMember" name="DecemberTwoThousandTwentySixMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="NRXS_DecemberTwoThousandTwentySevenMember" name="DecemberTwoThousandTwentySevenMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="NRXS_DecemberTwoThousandTwentyEightMember" name="DecemberTwoThousandTwentyEightMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="NRXS_DecemberTwoThousandTwentyNineMember" name="DecemberTwoThousandTwentyNineMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="NRXS_DecemberTwoThousandTwentyThereafterMember" name="DecemberTwoThousandTwentyThereafterMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="NRXS_SoftwareImplementationMember" name="SoftwareImplementationMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="NRXS_LicensesMember" name="LicensesMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="NRXS_ChannelPartnersCapitalMember" name="ChannelPartnersCapitalMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="NRXS_ExchangeListingLLCMember" name="ExchangeListingLLCMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="NRXS_PromissoryNoteMember" name="PromissoryNoteMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="NRXS_SecondPromissoryNoteMember" name="SecondPromissoryNoteMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="NRXS_TwoThousandTwentyTwoConvertibleNotesMember" name="TwoThousandTwentyTwoConvertibleNotesMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="NRXS_ConvertiblePromissoryNoteMember" name="ConvertiblePromissoryNoteMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="NRXS_AccreditedInvestorsMember" name="AccreditedInvestorsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="NRXS_TwoThousandTwentyThreeConvertibleNotesMember" name="TwoThousandTwentyThreeConvertibleNotesMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="NRXS_SignatureBankMember" name="SignatureBankMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="NRXS_ConvertiblePromissoryNotesMember" name="ConvertiblePromissoryNotesMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="NRXS_TwoThousandTwentyFourConvertiblePromissoryNotesMember" name="TwoThousandTwentyFourConvertiblePromissoryNotesMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="NRXS_TwoThousandTwentyFourConvertibleNotesMember" name="TwoThousandTwentyFourConvertibleNotesMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="NRXS_VersaillesIndianaMember" name="VersaillesIndianaMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="NRXS_CarmelIndianaMember" name="CarmelIndianaMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="NRXS_VendorsMember" name="VendorsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="NRXS_EmployementAgreementMember" name="EmployementAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="NRXS_TwoThousandTwentyThreeConvertiblePromissoryNotesMember" name="TwoThousandTwentyThreeConvertiblePromissoryNotesMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="NRXS_AdvisoryAgreementMember" name="AdvisoryAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="NRXS_UnderwritingAgreementMember" name="UnderwritingAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="NRXS_AdvisoryAgreementsMember" name="AdvisoryAgreementsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="NRXS_InvestorWarrantOneMember" name="InvestorWarrantOneMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="NRXS_InvestorWarrantPSAOneMember" name="InvestorWarrantPSAOneMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="NRXS_UnderwriterWarrantsMember" name="UnderwriterWarrantsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="NRXS_AdvisoryAgreementWarrantsMember" name="AdvisoryAgreementWarrantsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="NRXS_SeriesSeedPreferredStockMember" name="SeriesSeedPreferredStockMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="NRXS_AmendedTwoThousandTwentyFourConvertibleNotesMember" name="AmendedTwoThousandTwentyFourConvertibleNotesMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="NRXS_TwentySeventeenStockCompensationPlanMember" name="TwentySeventeenStockCompensationPlanMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="NRXS_SettlementAgreementMember" name="SettlementAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="NRXS_ExecutiveEmploymentAgreementsMember" name="ExecutiveEmploymentAgreementsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="NRXS_TaxYear2037Member" name="TaxYear2037Member" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="NRXS_TaxYear2038Member" name="TaxYear2038Member" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="NRXS_TaxYear2039Member" name="TaxYear2039Member" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="NRXS_TaxYear2040Member" name="TaxYear2040Member" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="NRXS_TaxYear2041Member" name="TaxYear2041Member" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="NRXS_TaxYearThereafterMember" name="TaxYearThereafterMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="NRXS_NoExpirationMember" name="NoExpirationMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="NRXS_WarrantLiabilities" name="WarrantLiabilities" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="NRXS_FinancingCharges" name="FinancingCharges" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="NRXS_StockIssuedDuringPeriodValueCommonStockIssuedUponInitialPublicOffering" name="StockIssuedDuringPeriodValueCommonStockIssuedUponInitialPublicOffering" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="NRXS_StockIssuedDuringPeriodSharesCommonStockIssuedUponInitialPublicOffering" name="StockIssuedDuringPeriodSharesCommonStockIssuedUponInitialPublicOffering" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="NRXS_StockIssuedDuringPeriodValueWarrantsExercised" name="StockIssuedDuringPeriodValueWarrantsExercised" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="NRXS_StockIssuedDuringPeriodSharesWarrantsExercised" name="StockIssuedDuringPeriodSharesWarrantsExercised" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="NRXS_AdditionalPaidInCapitalFromWarrantsIssuedAsDebtDiscount" name="AdditionalPaidInCapitalFromWarrantsIssuedAsDebtDiscount" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="NRXS_StockIssuedDuringPeriodValuePreferredStock" name="StockIssuedDuringPeriodValuePreferredStock" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="NRXS_StockIssuedDuringPeriodSharesPreferredStock" name="StockIssuedDuringPeriodSharesPreferredStock" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="NRXS_NoncashLeaseExpense" name="NoncashLeaseExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="NRXS_IssuanceOfCommonStockForNoncashConsideration" name="IssuanceOfCommonStockForNoncashConsideration" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="NRXS_IssuanceOfWarrantsForNoncashConsideration" name="IssuanceOfWarrantsForNoncashConsideration" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="NRXS_IncreaseDecreaseInCustomerDeposit" name="IncreaseDecreaseInCustomerDeposit" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="NRXS_DeferredOfferingCostsPaid" name="DeferredOfferingCostsPaid" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="NRXS_RecognitionOfRightOfUseAsset" name="RecognitionOfRightOfUseAsset" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="NRXS_ConversionOfConvertiblePromissoryNotesToSeriesBPreferredStock" name="ConversionOfConvertiblePromissoryNotesToSeriesBPreferredStock" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="NRXS_FairValueOfWarrantsFromDebtDiscountInConvertibleNotesClassifiedOfAdditionalPaidInCapital" name="FairValueOfWarrantsFromDebtDiscountInConvertibleNotesClassifiedOfAdditionalPaidInCapital" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="NRXS_WriteoffOfDebtDiscountOnConvertibleNotesClassifiedAsAdditionalPaidInCapital" name="WriteoffOfDebtDiscountOnConvertibleNotesClassifiedAsAdditionalPaidInCapital" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="NRXS_FairValueOfWarrantLiabilitiesOfWarrantsFromConvertibleNotes" name="FairValueOfWarrantLiabilitiesOfWarrantsFromConvertibleNotes" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="NRXS_FairValueOfDerivativeLiabilitiesOfConversionFeatureFromConvertibleNotes" name="FairValueOfDerivativeLiabilitiesOfConversionFeatureFromConvertibleNotes" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="NRXS_ReclassificationOfWarrantLiabilityToEquity" name="ReclassificationOfWarrantLiabilityToEquity" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="NRXS_ConversionOfPreferredStockToCommonStock" name="ConversionOfPreferredStockToCommonStock" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="NRXS_NoInsiderTradingFlag" name="NoInsiderTradingFlag" nillable="true" xbrli:periodType="duration" type="xbrli:booleanItemType" substitutionGroup="xbrli:item" />
    <element id="NRXS_DisclosureLeasesAbstract" name="DisclosureLeasesAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="NRXS_DisclosureWarrantLiabilitiesAbstract" name="DisclosureWarrantLiabilitiesAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="NRXS_WarrantLiabilitiesDisclosureTextBlock" name="WarrantLiabilitiesDisclosureTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="NRXS_DisclosureDerivativeLiabilitiesAbstract" name="DisclosureDerivativeLiabilitiesAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="NRXS_DisclosureHealthBenefitPlanAbstract" name="DisclosureHealthBenefitPlanAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="NRXS_HealthBenefitPlanDisclosureTextBlock" name="HealthBenefitPlanDisclosureTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="NRXS_WarrantLiabilityPolicyTextBlock" name="WarrantLiabilityPolicyTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="NRXS_GoingConcernPolicyTextBlock" name="GoingConcernPolicyTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="NRXS_RecentlyIssuedAccountingPronouncementsPolicyTextBlock" name="RecentlyIssuedAccountingPronouncementsPolicyTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="NRXS_ScheduleOfPropertyPlantAndEquipmentUsefulLivesTableTextBlock" name="ScheduleOfPropertyPlantAndEquipmentUsefulLivesTableTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="NRXS_ScheduleOfRelatedPartyLoansTableTextBlock" name="ScheduleOfRelatedPartyLoansTableTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="NRXS_ScheduleOfWarrantActivityForCommonStockTableTextBlock" name="ScheduleOfWarrantActivityForCommonStockTableTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="NRXS_ScheduleOfWarrantActivityForPreferredStockTableTextBlock" name="ScheduleOfWarrantActivityForPreferredStockTableTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="NRXS_ScheduleOfChangesInWarrantLiabilitiesTableTextBlock" name="ScheduleOfChangesInWarrantLiabilitiesTableTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="NRXS_PurchaseOfAdditionalStockOnNumberOfOptionsNotExercised" name="PurchaseOfAdditionalStockOnNumberOfOptionsNotExercised" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="NRXS_UnderwritersDiscountPercentage" name="UnderwritersDiscountPercentage" nillable="true" xbrli:periodType="instant" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="NRXS_NonaccountableExpenseAllowancePercentage" name="NonaccountableExpenseAllowancePercentage" nillable="true" xbrli:periodType="instant" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="NRXS_CashFeePercentage" name="CashFeePercentage" nillable="true" xbrli:periodType="instant" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="NRXS_ReimbursementExpenses" name="ReimbursementExpenses" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="NRXS_OfferingPricePerPercentage" name="OfferingPricePerPercentage" nillable="true" xbrli:periodType="instant" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="NRXS_InventoryExpenses" name="InventoryExpenses" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="NRXS_WorkingCapitalDeficit" name="WorkingCapitalDeficit" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="NRXS_InterestIncomeGrossCurrent" name="InterestIncomeGrossCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="NRXS_AllowanceForInterestReceivableCurrent" name="AllowanceForInterestReceivableCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="NRXS_AllowanceForInterestIncomeCurrent" name="AllowanceForInterestIncomeCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="NRXS_InterestIncomeCurrent" name="InterestIncomeCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="NRXS_InterestAndServiceFeeAccrued" name="InterestAndServiceFeeAccrued" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="NRXS_AccruedCompensationAndBenefitsCurrent" name="AccruedCompensationAndBenefitsCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="NRXS_AdvisoryFees" name="AdvisoryFees" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="NRXS_DebtInstrumentDiscountRate" name="DebtInstrumentDiscountRate" nillable="true" xbrli:periodType="instant" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="NRXS_DebtWarrantConversionDescription" name="DebtWarrantConversionDescription" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="NRXS_ClassOfWarrantDiscountRate" name="ClassOfWarrantDiscountRate" nillable="true" xbrli:periodType="instant" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="NRXS_CumulativeDividendsPercent" name="CumulativeDividendsPercent" nillable="true" xbrli:periodType="instant" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="NRXS_CommonStockConvertibleConversionPrice" name="CommonStockConvertibleConversionPrice" nillable="true" xbrli:periodType="duration" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="NRXS_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsWeightedAverageRemainingContracualLifeOutstandingNumberGranted" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsWeightedAverageRemainingContracualLifeOutstandingNumberGranted" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="NRXS_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsConvertedPrefundedWarrants" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsConvertedPrefundedWarrants" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="NRXS_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsConvertedPrefundedWarrantsInPeriodWeightedAverageExercisePrice" name="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsConvertedPrefundedWarrantsInPeriodWeightedAverageExercisePrice" nillable="true" xbrli:periodType="duration" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="NRXS_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsWeightedAverageExercisePriceCancelledExpiredNumber" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsWeightedAverageExercisePriceCancelledExpiredNumber" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="NRXS_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsCancelledWeightedAverageRemainingContractualTerm1" name="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsCancelledWeightedAverageRemainingContractualTerm1" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="NRXS_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisedWeightedAverageRemainingContractualTerm1" name="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisedWeightedAverageRemainingContractualTerm1" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="NRXS_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsCommonStockWarrant" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsCommonStockWarrant" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="NRXS_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsWeightedAverageExercisePriceCommonStockWarrant" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsWeightedAverageExercisePriceCommonStockWarrant" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="NRXS_WarrantExpirationDateDescription" name="WarrantExpirationDateDescription" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="NRXS_NumberOfEquivalentOfWarrantsDescription" name="NumberOfEquivalentOfWarrantsDescription" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="NRXS_ClassOfWarrantOrRightAdditional" name="ClassOfWarrantOrRightAdditional" nillable="true" xbrli:periodType="instant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="NRXS_PreferredStockSharesRetiredDescription" name="PreferredStockSharesRetiredDescription" nillable="true" xbrli:periodType="instant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="NRXS_ProceedsFromIssuanceOfStock" name="ProceedsFromIssuanceOfStock" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="NRXS_AdditionToWarrantLiabilities" name="AdditionToWarrantLiabilities" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="NRXS_ReclassifiedToEquity" name="ReclassifiedToEquity" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="NRXS_ChangesInDerivativeLiabilities" name="ChangesInDerivativeLiabilities" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="NRXS_AdditionToDerivativeLiabilities" name="AdditionToDerivativeLiabilities" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="NRXS_ExtinguishmentOfDerivativeLiabilities" name="ExtinguishmentOfDerivativeLiabilities" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="NRXS_ConsultingAndAdvisoryFees" name="ConsultingAndAdvisoryFees" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="NRXS_FinanceCharges" name="FinanceCharges" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="NRXS_ExecutiveEmploymentAgreementsTerms" name="ExecutiveEmploymentAgreementsTerms" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="NRXS_DescriptionOfExecutiveEmploymentAgreementsRenewals" name="DescriptionOfExecutiveEmploymentAgreementsRenewals" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="NRXS_SpecialBonusPercentage" name="SpecialBonusPercentage" nillable="true" xbrli:periodType="instant" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="NRXS_KeyEmployeeExercisePercentage" name="KeyEmployeeExercisePercentage" nillable="true" xbrli:periodType="instant" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="NRXS_HealthCareOrganizationStopLossInsurancePremiumPercentage" name="HealthCareOrganizationStopLossInsurancePremiumPercentage" nillable="true" xbrli:periodType="duration" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="NRXS_DeferredTaxAssetsNotesReceivableReserve" name="DeferredTaxAssetsNotesReceivableReserve" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="NRXS_DeferredTaxAssetsAccountsPayable" name="DeferredTaxAssetsAccountsPayable" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="NRXS_DeferredTaxAssetsOperatingLeasePayable" name="DeferredTaxAssetsOperatingLeasePayable" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="NRXS_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset" name="DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="NRXS_DeferredTaxLiabilityAccountsReceivable" name="DeferredTaxLiabilityAccountsReceivable" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="NRXS_OfferingCostsPaid" name="OfferingCostsPaid" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="NRXS_TrademarkAgreementMember" name="TrademarkAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="NRXS_InitialPaymentMember" name="InitialPaymentMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="NRXS_SecondAndFinalPaymentMember" name="SecondAndFinalPaymentMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="NRXS_CustomerOneMember" name="CustomerOneMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="NRXS_CustomerTwoMember" name="CustomerTwoMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="NRXS_CustomerThreeMember" name="CustomerThreeMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="NRXS_CustomerFourMember" name="CustomerFourMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="NRXS_IncreaseDecreaseInWarrantLiability" name="IncreaseDecreaseInWarrantLiability" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="NRXS_ShareLiabilitiesCurrent" name="ShareLiabilitiesCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="NRXS_NoncashInterestExpense" name="NoncashInterestExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="NRXS_OfferingCostsInAdvanceOfSaleOfCommonStock" name="OfferingCostsInAdvanceOfSaleOfCommonStock" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="NRXS_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedNumber" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedNumber" nillable="true" xbrli:periodType="instant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="NRXS_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedWeightedAverageGrantDateFairValue" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedWeightedAverageGrantDateFairValue" nillable="true" xbrli:periodType="instant" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="NRXS_ScheduleOfInauguralGrantOfRestrictedStockUnitsTableTextBlock" name="ScheduleOfInauguralGrantOfRestrictedStockUnitsTableTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="NRXS_ShareBasedCompensationPlansMember" name="ShareBasedCompensationPlansMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="NRXS_StockIssuedDuringPeriodValueChangeInFairValueOfWarrantLiabilityUponInitialPublicOffering" name="StockIssuedDuringPeriodValueChangeInFairValueOfWarrantLiabilityUponInitialPublicOffering" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>25
<FILENAME>nrxs-20241231_cal.xml
<DESCRIPTION>XBRL CALCULATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.25b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://neuraxis.com/role/Cover" xlink:href="nrxs-20241231.xsd#Cover" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/BalanceSheets" xlink:href="nrxs-20241231.xsd#BalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/BalanceSheetsParenthetical" xlink:href="nrxs-20241231.xsd#BalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/StatementsOfOperations" xlink:href="nrxs-20241231.xsd#StatementsOfOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/StatementsOfStockholdersEquityDeficit" xlink:href="nrxs-20241231.xsd#StatementsOfStockholdersEquityDeficit" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/StatementsOfCashFlows" xlink:href="nrxs-20241231.xsd#StatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#CybersecurityRiskManagementAndStrategyDisclosure" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#MaterialCybersecurityIncidentDisclosure" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/BasisOfPresentationOrganizationAndOtherMatters" xlink:href="nrxs-20241231.xsd#BasisOfPresentationOrganizationAndOtherMatters" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="nrxs-20241231.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/RelatedPartyTransactions" xlink:href="nrxs-20241231.xsd#RelatedPartyTransactions" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/PropertyAndEquipment" xlink:href="nrxs-20241231.xsd#PropertyAndEquipment" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/IntangibleAssets" xlink:href="nrxs-20241231.xsd#IntangibleAssets" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/AccruedExpenses" xlink:href="nrxs-20241231.xsd#AccruedExpenses" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/NotesPayable" xlink:href="nrxs-20241231.xsd#NotesPayable" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/Leases" xlink:href="nrxs-20241231.xsd#Leases" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/CommonStockAndWarrants" xlink:href="nrxs-20241231.xsd#CommonStockAndWarrants" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/PreferredStock" xlink:href="nrxs-20241231.xsd#PreferredStock" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/Stock-basedCompensation" xlink:href="nrxs-20241231.xsd#Stock-basedCompensation" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/WarrantLiabilities" xlink:href="nrxs-20241231.xsd#WarrantLiabilities" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/DerivativeLiabilities" xlink:href="nrxs-20241231.xsd#DerivativeLiabilities" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/RetirementPlan" xlink:href="nrxs-20241231.xsd#RetirementPlan" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/SegmentInformation" xlink:href="nrxs-20241231.xsd#SegmentInformation" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/CommitmentsAndContingencies" xlink:href="nrxs-20241231.xsd#CommitmentsAndContingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/HealthBenefitPlan" xlink:href="nrxs-20241231.xsd#HealthBenefitPlan" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/IncomeTaxes" xlink:href="nrxs-20241231.xsd#IncomeTaxes" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/SubsequentEvents" xlink:href="nrxs-20241231.xsd#SubsequentEvents" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="nrxs-20241231.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:href="nrxs-20241231.xsd#SummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/RelatedPartyTransactionsTables" xlink:href="nrxs-20241231.xsd#RelatedPartyTransactionsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/PropertyAndEquipmentTables" xlink:href="nrxs-20241231.xsd#PropertyAndEquipmentTables" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/IntangibleAssetsTables" xlink:href="nrxs-20241231.xsd#IntangibleAssetsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/AccruedExpensesTables" xlink:href="nrxs-20241231.xsd#AccruedExpensesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/LeasesTables" xlink:href="nrxs-20241231.xsd#LeasesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/CommonStockAndWarrantsTables" xlink:href="nrxs-20241231.xsd#CommonStockAndWarrantsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/Stock-basedCompensationTables" xlink:href="nrxs-20241231.xsd#Stock-basedCompensationTables" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/WarrantLiabilitiesTables" xlink:href="nrxs-20241231.xsd#WarrantLiabilitiesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/DerivativeLiabilitiesTables" xlink:href="nrxs-20241231.xsd#DerivativeLiabilitiesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/SegmentInformationTables" xlink:href="nrxs-20241231.xsd#SegmentInformationTables" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/IncomeTaxesTables" xlink:href="nrxs-20241231.xsd#IncomeTaxesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/BasisOfPresentationOrganizationAndOtherMattersDetailsNarrative" xlink:href="nrxs-20241231.xsd#BasisOfPresentationOrganizationAndOtherMattersDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/ScheduleOfEstimatedUsefulLivesDetails" xlink:href="nrxs-20241231.xsd#ScheduleOfEstimatedUsefulLivesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/ScheduleOfFairValueOfAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails" xlink:href="nrxs-20241231.xsd#ScheduleOfFairValueOfAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/ScheduleOfDilutiveCommonStockEquivalentsDetails" xlink:href="nrxs-20241231.xsd#ScheduleOfDilutiveCommonStockEquivalentsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/ScheduleOfBasicAndDilutedNetLossPerShareDetails" xlink:href="nrxs-20241231.xsd#ScheduleOfBasicAndDilutedNetLossPerShareDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/ScheduleOfDisaggregationOfRevenueDetails" xlink:href="nrxs-20241231.xsd#ScheduleOfDisaggregationOfRevenueDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/ScheduleOfCustomerAccountsReceivableDetails" xlink:href="nrxs-20241231.xsd#ScheduleOfCustomerAccountsReceivableDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/ScheduleOfCustomersAccountedRevenuesDetails" xlink:href="nrxs-20241231.xsd#ScheduleOfCustomersAccountedRevenuesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:href="nrxs-20241231.xsd#SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/ScheduleOfRelatedPartyTransactionsDetails" xlink:href="nrxs-20241231.xsd#ScheduleOfRelatedPartyTransactionsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/ScheduleOfRelatedPartyLoansPayableToShareholderDetails" xlink:href="nrxs-20241231.xsd#ScheduleOfRelatedPartyLoansPayableToShareholderDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:href="nrxs-20241231.xsd#RelatedPartyTransactionsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/ScheduleOfPropertyAndEquipmentDetails" xlink:href="nrxs-20241231.xsd#ScheduleOfPropertyAndEquipmentDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/PropertyAndEquipmentDetailsNarrative" xlink:href="nrxs-20241231.xsd#PropertyAndEquipmentDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/ScheduleOfIntangibleAssetsDetails" xlink:href="nrxs-20241231.xsd#ScheduleOfIntangibleAssetsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/IntangibleAssetsDetailsNarrative" xlink:href="nrxs-20241231.xsd#IntangibleAssetsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/ScheduleOfAccruedExpensesDetails" xlink:href="nrxs-20241231.xsd#ScheduleOfAccruedExpensesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/NotesPayableDetailsNarrative" xlink:href="nrxs-20241231.xsd#NotesPayableDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/ScheduleOfOperatingLeasesDetails" xlink:href="nrxs-20241231.xsd#ScheduleOfOperatingLeasesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/ScheduleOfMaturitiesOperatingLeaseLiabilitiesDetails" xlink:href="nrxs-20241231.xsd#ScheduleOfMaturitiesOperatingLeaseLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/LeasesDetailsNarrative" xlink:href="nrxs-20241231.xsd#LeasesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/ScheduleOfWarrantActivityForCommonStockDetails" xlink:href="nrxs-20241231.xsd#ScheduleOfWarrantActivityForCommonStockDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/ScheduleOfWarrantActivityForPreferredStockDetails" xlink:href="nrxs-20241231.xsd#ScheduleOfWarrantActivityForPreferredStockDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/ScheduleOfWarrantsOutstandingAndExercisableDetails" xlink:href="nrxs-20241231.xsd#ScheduleOfWarrantsOutstandingAndExercisableDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/CommonStockAndWarrantsDetailsNarrative" xlink:href="nrxs-20241231.xsd#CommonStockAndWarrantsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/PreferredStockDetailsNarrative" xlink:href="nrxs-20241231.xsd#PreferredStockDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/ScheduleOfOption-pricingModelWithFollowingWeighted-averageAssumptionsDetails" xlink:href="nrxs-20241231.xsd#ScheduleOfOption-pricingModelWithFollowingWeighted-averageAssumptionsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/ScheduleOfStockOptionActivityDetails" xlink:href="nrxs-20241231.xsd#ScheduleOfStockOptionActivityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/Stock-basedCompensationDetailsNarrative" xlink:href="nrxs-20241231.xsd#Stock-basedCompensationDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/ScheduleOfChangesInWarrantLiabilitiesDetails" xlink:href="nrxs-20241231.xsd#ScheduleOfChangesInWarrantLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/WarrantLiabilitiesDetailsNarrative" xlink:href="nrxs-20241231.xsd#WarrantLiabilitiesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/ScheduleOfChangesInDerivativeLiabilitiesDetails" xlink:href="nrxs-20241231.xsd#ScheduleOfChangesInDerivativeLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/DerivativeLiabilitiesDetailsNarrative" xlink:href="nrxs-20241231.xsd#DerivativeLiabilitiesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/RetirementPlanDetailsNarrative" xlink:href="nrxs-20241231.xsd#RetirementPlanDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/ScheduleOfReconcilesCompanysNetSalesAndOperatingLossDetails" xlink:href="nrxs-20241231.xsd#ScheduleOfReconcilesCompanysNetSalesAndOperatingLossDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/SegmentInformationDetailsNarrative" xlink:href="nrxs-20241231.xsd#SegmentInformationDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:href="nrxs-20241231.xsd#CommitmentsAndContingenciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/HealthBenefitPlanDetailsNarrative" xlink:href="nrxs-20241231.xsd#HealthBenefitPlanDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/ScheduleOfIncomeTaxProvisionDetails" xlink:href="nrxs-20241231.xsd#ScheduleOfIncomeTaxProvisionDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/ScheduleOfFederalStatutoryIncomeTaxRateAndEffectiveIncomeTaxRateDetails" xlink:href="nrxs-20241231.xsd#ScheduleOfFederalStatutoryIncomeTaxRateAndEffectiveIncomeTaxRateDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/ScheduleOfNetDeferredTaxAssetsAndLiabilitiesDetails" xlink:href="nrxs-20241231.xsd#ScheduleOfNetDeferredTaxAssetsAndLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/ScheduleOfStateCarryforwardsDetails" xlink:href="nrxs-20241231.xsd#ScheduleOfStateCarryforwardsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/IncomeTaxesDetailsNarrative" xlink:href="nrxs-20241231.xsd#IncomeTaxesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/SubsequentEventsDetailsNarrative" xlink:href="nrxs-20241231.xsd#SubsequentEventsDetailsNarrative" xlink:type="simple" />
    <link:calculationLink xlink:type="extended" xlink:role="http://neuraxis.com/role/Cover" xlink:title="00000001 - Document - Cover" />
    <link:calculationLink xlink:type="extended" xlink:role="http://neuraxis.com/role/BalanceSheets" xlink:title="00000002 - Statement - Balance Sheets">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaapAccountsReceivableNetCurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapAccountsReceivableNetCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaapInventoryNet" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapInventoryNet" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaapPropertyPlantAndEquipmentGross" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:to="loc_us-gaapPropertyPlantAndEquipmentGross" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:to="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapAssetsCurrent" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsNet" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsNet" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SecurityDeposit" xlink:label="loc_us-gaapSecurityDeposit" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapSecurityDeposit" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapAccountsPayableCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapAccruedLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NotesPayableToBankCurrent" xlink:label="loc_us-gaapNotesPayableToBankCurrent" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapNotesPayableToBankCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityCurrent" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapOperatingLeaseLiabilityCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Deposits" xlink:label="loc_us-gaapDeposits" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapDeposits" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_WarrantLiabilities" xlink:label="loc_NRXSWarrantLiabilities" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_NRXSWarrantLiabilities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="loc_us-gaapLiabilitiesNoncurrent" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityNoncurrent" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesNoncurrent" xlink:to="loc_us-gaapOperatingLeaseLiabilityNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapLiabilitiesNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaapPreferredStockValue" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapPreferredStockValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaapAdditionalPaidInCapital" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapAdditionalPaidInCapital" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapLiabilities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaapCommitmentsAndContingencies" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapCommitmentsAndContingencies" xlink:type="arc" weight="1" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://neuraxis.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - Balance Sheets (Parenthetical)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://neuraxis.com/role/StatementsOfOperations" xlink:title="00000004 - Statement - Statements of Operations">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GrossProfit" xlink:label="loc_us-gaapGrossProfit" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapGrossProfit" xlink:to="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="loc_us-gaapCostOfGoodsAndServicesSold" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapGrossProfit" xlink:to="loc_us-gaapCostOfGoodsAndServicesSold" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingIncomeLoss" xlink:to="loc_us-gaapGrossProfit" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingExpense" xlink:label="loc_us-gaapSellingExpense" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingIncomeLoss" xlink:to="loc_us-gaapSellingExpense" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingIncomeLoss" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingIncomeLoss" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaapOtherNonoperatingIncomeExpense" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_FinancingCharges" xlink:label="loc_NRXSFinancingCharges" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherNonoperatingIncomeExpense" xlink:to="loc_NRXSFinancingCharges" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaapInterestExpense" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherNonoperatingIncomeExpense" xlink:to="loc_us-gaapInterestExpense" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaapFairValueAdjustmentOfWarrants" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherNonoperatingIncomeExpense" xlink:to="loc_us-gaapFairValueAdjustmentOfWarrants" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeGainLossOnDerivativeNet" xlink:label="loc_us-gaapDerivativeGainLossOnDerivativeNet" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherNonoperatingIncomeExpense" xlink:to="loc_us-gaapDerivativeGainLossOnDerivativeNet" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="loc_us-gaapAmortizationOfFinancingCostsAndDiscounts" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherNonoperatingIncomeExpense" xlink:to="loc_us-gaapAmortizationOfFinancingCostsAndDiscounts" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherNonoperatingIncomeExpense" xlink:to="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncome" xlink:label="loc_us-gaapOtherNonoperatingIncome" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherNonoperatingIncomeExpense" xlink:to="loc_us-gaapOtherNonoperatingIncome" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingExpense" xlink:label="loc_us-gaapOtherNonoperatingExpense" />
      <link:calculationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherNonoperatingIncomeExpense" xlink:to="loc_us-gaapOtherNonoperatingExpense" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapOtherNonoperatingIncomeExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockDividendsAndOtherAdjustments" xlink:label="loc_us-gaapPreferredStockDividendsAndOtherAdjustments" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="loc_us-gaapPreferredStockDividendsAndOtherAdjustments" xlink:type="arc" weight="-1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://neuraxis.com/role/StatementsOfStockholdersEquityDeficit" xlink:title="00000005 - Statement - Statements of Stockholders&apos; Equity (Deficit)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://neuraxis.com/role/StatementsOfCashFlows" xlink:title="00000006 - Statement - Statements of Cash Flows">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="loc_us-gaapAmortizationOfFinancingCostsAndDiscounts" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapAmortizationOfFinancingCostsAndDiscounts" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaapDepreciationDepletionAndAmortization" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapDepreciationDepletionAndAmortization" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProvisionForDoubtfulAccounts" xlink:label="loc_us-gaapProvisionForDoubtfulAccounts" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapProvisionForDoubtfulAccounts" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryWriteDown" xlink:label="loc_us-gaapInventoryWriteDown" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapInventoryWriteDown" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_NoncashLeaseExpense" xlink:label="loc_NRXSNoncashLeaseExpense" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_NRXSNoncashLeaseExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaidInKindInterest" xlink:label="loc_us-gaapPaidInKindInterest" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapPaidInKindInterest" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:calculationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" />
      <link:calculationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_IssuanceOfCommonStockForNoncashConsideration" xlink:label="loc_NRXSIssuanceOfCommonStockForNoncashConsideration" />
      <link:calculationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_NRXSIssuanceOfCommonStockForNoncashConsideration" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_IssuanceOfWarrantsForNoncashConsideration" xlink:label="loc_NRXSIssuanceOfWarrantsForNoncashConsideration" />
      <link:calculationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_NRXSIssuanceOfWarrantsForNoncashConsideration" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_FinancingCharges" xlink:label="loc_NRXSFinancingCharges" />
      <link:calculationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_NRXSFinancingCharges" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeGainLossOnDerivativeNet" xlink:label="loc_us-gaapDerivativeGainLossOnDerivativeNet" />
      <link:calculationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapDerivativeGainLossOnDerivativeNet" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaapFairValueAdjustmentOfWarrants" />
      <link:calculationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapFairValueAdjustmentOfWarrants" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsReceivable" />
      <link:calculationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsReceivable" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaapIncreaseDecreaseInInventories" />
      <link:calculationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInInventories" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaapIncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
      <link:calculationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayable" />
      <link:calculationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayable" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInAccruedLiabilities" />
      <link:calculationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInAccruedLiabilities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_IncreaseDecreaseInCustomerDeposit" xlink:label="loc_NRXSIncreaseDecreaseInCustomerDeposit" />
      <link:calculationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_NRXSIncreaseDecreaseInCustomerDeposit" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="loc_us-gaapIncreaseDecreaseInOperatingLeaseLiability" />
      <link:calculationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInOperatingLeaseLiability" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="loc_us-gaapPaymentsToAcquireIntangibleAssets" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaapPaymentsToAcquireIntangibleAssets" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfPreferredStockAndPreferenceStock" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_DeferredOfferingCostsPaid" xlink:label="loc_NRXSDeferredOfferingCostsPaid" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_NRXSDeferredOfferingCostsPaid" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="loc_us-gaapProceedsFromIssuanceOfWarrants" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromIssuanceOfWarrants" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfNotesPayable" xlink:label="loc_us-gaapRepaymentsOfNotesPayable" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapRepaymentsOfNotesPayable" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromNotesPayable" xlink:label="loc_us-gaapProceedsFromNotesPayable" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromNotesPayable" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="loc_us-gaapProceedsFromConvertibleDebt" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromConvertibleDebt" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfFinancingCosts" xlink:label="loc_us-gaapPaymentsOfFinancingCosts" />
      <link:calculationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapPaymentsOfFinancingCosts" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:type="arc" weight="1" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" xlink:title="00000012 - Disclosure - Cybersecurity Risk Management and Strategy Disclosure" />
    <link:calculationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure" xlink:title="00000013 - Disclosure - Material Cybersecurity Incident Disclosure" />
    <link:calculationLink xlink:type="extended" xlink:role="http://neuraxis.com/role/BasisOfPresentationOrganizationAndOtherMatters" xlink:title="999014 - Disclosure - Basis of Presentation, Organization and Other Matters" />
    <link:calculationLink xlink:type="extended" xlink:role="http://neuraxis.com/role/SummaryOfSignificantAccountingPolicies" xlink:title="999015 - Disclosure - Summary of Significant Accounting Policies" />
    <link:calculationLink xlink:type="extended" xlink:role="http://neuraxis.com/role/RelatedPartyTransactions" xlink:title="999016 - Disclosure - Related Party Transactions" />
    <link:calculationLink xlink:type="extended" xlink:role="http://neuraxis.com/role/PropertyAndEquipment" xlink:title="999017 - Disclosure - Property and Equipment" />
    <link:calculationLink xlink:type="extended" xlink:role="http://neuraxis.com/role/IntangibleAssets" xlink:title="999018 - Disclosure - Intangible Assets" />
    <link:calculationLink xlink:type="extended" xlink:role="http://neuraxis.com/role/AccruedExpenses" xlink:title="999019 - Disclosure - Accrued Expenses" />
    <link:calculationLink xlink:type="extended" xlink:role="http://neuraxis.com/role/NotesPayable" xlink:title="999020 - Disclosure - Notes Payable" />
    <link:calculationLink xlink:type="extended" xlink:role="http://neuraxis.com/role/Leases" xlink:title="999021 - Disclosure - Leases" />
    <link:calculationLink xlink:type="extended" xlink:role="http://neuraxis.com/role/CommonStockAndWarrants" xlink:title="999022 - Disclosure - Common Stock and Warrants" />
    <link:calculationLink xlink:type="extended" xlink:role="http://neuraxis.com/role/PreferredStock" xlink:title="999023 - Disclosure - Preferred Stock" />
    <link:calculationLink xlink:type="extended" xlink:role="http://neuraxis.com/role/Stock-basedCompensation" xlink:title="999024 - Disclosure - Stock-Based Compensation" />
    <link:calculationLink xlink:type="extended" xlink:role="http://neuraxis.com/role/WarrantLiabilities" xlink:title="999025 - Disclosure - Warrant Liabilities" />
    <link:calculationLink xlink:type="extended" xlink:role="http://neuraxis.com/role/DerivativeLiabilities" xlink:title="999026 - Disclosure - Derivative Liabilities" />
    <link:calculationLink xlink:type="extended" xlink:role="http://neuraxis.com/role/RetirementPlan" xlink:title="999027 - Disclosure - Retirement Plan" />
    <link:calculationLink xlink:type="extended" xlink:role="http://neuraxis.com/role/SegmentInformation" xlink:title="999028 - Disclosure - Segment Information" />
    <link:calculationLink xlink:type="extended" xlink:role="http://neuraxis.com/role/CommitmentsAndContingencies" xlink:title="999029 - Disclosure - Commitments and Contingencies" />
    <link:calculationLink xlink:type="extended" xlink:role="http://neuraxis.com/role/HealthBenefitPlan" xlink:title="999030 - Disclosure - Health Benefit Plan" />
    <link:calculationLink xlink:type="extended" xlink:role="http://neuraxis.com/role/IncomeTaxes" xlink:title="999031 - Disclosure - Income Taxes" />
    <link:calculationLink xlink:type="extended" xlink:role="http://neuraxis.com/role/SubsequentEvents" xlink:title="999032 - Disclosure - Subsequent Events" />
    <link:calculationLink xlink:type="extended" xlink:role="http://neuraxis.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:title="999033 - Disclosure - Summary of Significant Accounting Policies (Policies)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://neuraxis.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:title="999034 - Disclosure - Summary of Significant Accounting Policies (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://neuraxis.com/role/RelatedPartyTransactionsTables" xlink:title="999035 - Disclosure - Related Party Transactions (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://neuraxis.com/role/PropertyAndEquipmentTables" xlink:title="999036 - Disclosure - Property and Equipment (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://neuraxis.com/role/IntangibleAssetsTables" xlink:title="999037 - Disclosure - Intangible Assets (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://neuraxis.com/role/AccruedExpensesTables" xlink:title="999038 - Disclosure - Accrued Expenses (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://neuraxis.com/role/LeasesTables" xlink:title="999039 - Disclosure - Leases (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://neuraxis.com/role/CommonStockAndWarrantsTables" xlink:title="999040 - Disclosure - Common Stock and Warrants (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://neuraxis.com/role/Stock-basedCompensationTables" xlink:title="999041 - Disclosure - Stock-Based Compensation (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://neuraxis.com/role/WarrantLiabilitiesTables" xlink:title="999042 - Disclosure - Warrant Liabilities (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://neuraxis.com/role/DerivativeLiabilitiesTables" xlink:title="999043 - Disclosure - Derivative Liabilities (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://neuraxis.com/role/SegmentInformationTables" xlink:title="999044 - Disclosure - Segment Information (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://neuraxis.com/role/IncomeTaxesTables" xlink:title="999045 - Disclosure - Income Taxes (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://neuraxis.com/role/BasisOfPresentationOrganizationAndOtherMattersDetailsNarrative" xlink:title="999046 - Disclosure - Basis of Presentation, Organization and Other Matters (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://neuraxis.com/role/ScheduleOfEstimatedUsefulLivesDetails" xlink:title="999047 - Disclosure - Schedule of Estimated Useful Lives (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://neuraxis.com/role/ScheduleOfFairValueOfAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails" xlink:title="999048 - Disclosure - Schedule of Fair Value of Assets and Liabilities measured on Recurring Basis (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://neuraxis.com/role/ScheduleOfDilutiveCommonStockEquivalentsDetails" xlink:title="999049 - Disclosure - Schedule of Dilutive Common Stock Equivalents (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://neuraxis.com/role/ScheduleOfBasicAndDilutedNetLossPerShareDetails" xlink:title="999050 - Disclosure - Schedule of Basic and Diluted Net Loss Per Share (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://neuraxis.com/role/ScheduleOfDisaggregationOfRevenueDetails" xlink:title="999051 - Disclosure - Schedule of Disaggregation of Revenue (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://neuraxis.com/role/ScheduleOfCustomerAccountsReceivableDetails" xlink:title="999052 - Disclosure - Schedule of Customer Accounts Receivable (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://neuraxis.com/role/ScheduleOfCustomersAccountedRevenuesDetails" xlink:title="999053 - Disclosure - Schedule of Customers Accounted Revenues (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://neuraxis.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="999054 - Disclosure - Summary of Significant Accounting Policies (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://neuraxis.com/role/ScheduleOfRelatedPartyTransactionsDetails" xlink:title="999055 - Disclosure - Schedule of Related Party Transactions (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://neuraxis.com/role/ScheduleOfRelatedPartyLoansPayableToShareholderDetails" xlink:title="999056 - Disclosure - Schedule of Related Party Loans payable to shareholder (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://neuraxis.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:title="999057 - Disclosure - Related Party Transactions (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://neuraxis.com/role/ScheduleOfPropertyAndEquipmentDetails" xlink:title="999058 - Disclosure - Schedule of Property And Equipment (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaapPropertyPlantAndEquipmentGross" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:to="loc_us-gaapPropertyPlantAndEquipmentGross" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:to="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" weight="-1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://neuraxis.com/role/PropertyAndEquipmentDetailsNarrative" xlink:title="999059 - Disclosure - Property and Equipment (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://neuraxis.com/role/ScheduleOfIntangibleAssetsDetails" xlink:title="999060 - Disclosure - Schedule of Intangible Assets (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsNet" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsGross" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsNet" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsGross" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAccumulatedAmortization" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsNet" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="arc" weight="-1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://neuraxis.com/role/IntangibleAssetsDetailsNarrative" xlink:title="999061 - Disclosure - Intangible Assets (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://neuraxis.com/role/ScheduleOfAccruedExpensesDetails" xlink:title="999062 - Disclosure - Schedule of Accrued Expenses (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrent" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_AccruedCompensationAndBenefitsCurrent" xlink:label="loc_NRXSAccruedCompensationAndBenefitsCurrent" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAccruedLiabilitiesCurrent" xlink:to="loc_NRXSAccruedCompensationAndBenefitsCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_AdvisoryFees" xlink:label="loc_NRXSAdvisoryFees" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAccruedLiabilitiesCurrent" xlink:to="loc_NRXSAdvisoryFees" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestPayableCurrent" xlink:label="loc_us-gaapInterestPayableCurrent" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAccruedLiabilitiesCurrent" xlink:to="loc_us-gaapInterestPayableCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent" xlink:label="loc_us-gaapAccrualForTaxesOtherThanIncomeTaxesCurrent" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAccruedLiabilitiesCurrent" xlink:to="loc_us-gaapAccrualForTaxesOtherThanIncomeTaxesCurrent" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://neuraxis.com/role/NotesPayableDetailsNarrative" xlink:title="999063 - Disclosure - Notes Payable (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://neuraxis.com/role/ScheduleOfOperatingLeasesDetails" xlink:title="999064 - Disclosure - Schedule of Operating Leases (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaapOperatingLeaseLiability" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityCurrent" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingLeaseLiability" xlink:to="loc_us-gaapOperatingLeaseLiabilityCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityNoncurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingLeaseLiability" xlink:to="loc_us-gaapOperatingLeaseLiabilityNoncurrent" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://neuraxis.com/role/ScheduleOfMaturitiesOperatingLeaseLiabilitiesDetails" xlink:title="999065 - Disclosure - Schedule of Maturities Operating Lease Liabilities (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearThree" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearFour" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearFive" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://neuraxis.com/role/LeasesDetailsNarrative" xlink:title="999066 - Disclosure - Leases (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://neuraxis.com/role/ScheduleOfWarrantActivityForCommonStockDetails" xlink:title="999067 - Disclosure - Schedule of Warrant Activity for Common Stock (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://neuraxis.com/role/ScheduleOfWarrantActivityForPreferredStockDetails" xlink:title="999068 - Disclosure - Schedule of Warrant Activity for Preferred Stock (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://neuraxis.com/role/ScheduleOfWarrantsOutstandingAndExercisableDetails" xlink:title="999069 - Disclosure - Schedule of Warrants outstanding and Exercisable (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://neuraxis.com/role/CommonStockAndWarrantsDetailsNarrative" xlink:title="999070 - Disclosure - Common Stock and Warrants (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://neuraxis.com/role/PreferredStockDetailsNarrative" xlink:title="999071 - Disclosure - Preferred Stock (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://neuraxis.com/role/ScheduleOfOption-pricingModelWithFollowingWeighted-averageAssumptionsDetails" xlink:title="999072 - Disclosure - Schedule of Option-pricing Model with Following Weighted-average Assumptions (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://neuraxis.com/role/ScheduleOfStockOptionActivityDetails" xlink:title="999073 - Disclosure - Schedule of Stock Option Activity (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://neuraxis.com/role/Stock-basedCompensationDetailsNarrative" xlink:title="999074 - Disclosure - Stock-Based Compensation (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://neuraxis.com/role/ScheduleOfChangesInWarrantLiabilitiesDetails" xlink:title="999075 - Disclosure - Schedule of Changes in Warrant Liabilities (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://neuraxis.com/role/WarrantLiabilitiesDetailsNarrative" xlink:title="999076 - Disclosure - Warrant Liabilities (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://neuraxis.com/role/ScheduleOfChangesInDerivativeLiabilitiesDetails" xlink:title="999077 - Disclosure - Schedule of Changes in Derivative Liabilities (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://neuraxis.com/role/DerivativeLiabilitiesDetailsNarrative" xlink:title="999078 - Disclosure - Derivative Liabilities (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://neuraxis.com/role/RetirementPlanDetailsNarrative" xlink:title="999079 - Disclosure - Retirement Plan (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://neuraxis.com/role/ScheduleOfReconcilesCompanysNetSalesAndOperatingLossDetails" xlink:title="999080 - Disclosure - Schedule of Reconciles the Company&#8217;s Net Sales and Operating Loss (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GrossProfit" xlink:label="loc_us-gaapGrossProfit" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapGrossProfit" xlink:to="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="loc_us-gaapCostOfGoodsAndServicesSold" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapGrossProfit" xlink:to="loc_us-gaapCostOfGoodsAndServicesSold" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingIncomeLoss" xlink:to="loc_us-gaapGrossProfit" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingExpense" xlink:label="loc_us-gaapSellingExpense" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingIncomeLoss" xlink:to="loc_us-gaapSellingExpense" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingIncomeLoss" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LaborAndRelatedExpense" xlink:label="loc_us-gaapLaborAndRelatedExpense" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingIncomeLoss" xlink:to="loc_us-gaapLaborAndRelatedExpense" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfessionalAndContractServicesExpense" xlink:label="loc_us-gaapProfessionalAndContractServicesExpense" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingIncomeLoss" xlink:to="loc_us-gaapProfessionalAndContractServicesExpense" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCostAndExpenseOperating" xlink:label="loc_us-gaapOtherCostAndExpenseOperating" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingIncomeLoss" xlink:to="loc_us-gaapOtherCostAndExpenseOperating" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaapOtherNonoperatingIncomeExpense" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_FinancingCharges" xlink:label="loc_NRXSFinancingCharges" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherNonoperatingIncomeExpense" xlink:to="loc_NRXSFinancingCharges" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaapInterestExpense" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherNonoperatingIncomeExpense" xlink:to="loc_us-gaapInterestExpense" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaapFairValueAdjustmentOfWarrants" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherNonoperatingIncomeExpense" xlink:to="loc_us-gaapFairValueAdjustmentOfWarrants" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeGainLossOnDerivativeNet" xlink:label="loc_us-gaapDerivativeGainLossOnDerivativeNet" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherNonoperatingIncomeExpense" xlink:to="loc_us-gaapDerivativeGainLossOnDerivativeNet" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="loc_us-gaapAmortizationOfFinancingCostsAndDiscounts" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherNonoperatingIncomeExpense" xlink:to="loc_us-gaapAmortizationOfFinancingCostsAndDiscounts" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherNonoperatingIncomeExpense" xlink:to="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncome" xlink:label="loc_us-gaapOtherNonoperatingIncome" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherNonoperatingIncomeExpense" xlink:to="loc_us-gaapOtherNonoperatingIncome" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingExpense" xlink:label="loc_us-gaapOtherNonoperatingExpense" />
      <link:calculationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherNonoperatingIncomeExpense" xlink:to="loc_us-gaapOtherNonoperatingExpense" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapOtherNonoperatingIncomeExpense" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://neuraxis.com/role/SegmentInformationDetailsNarrative" xlink:title="999081 - Disclosure - Segment Information (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://neuraxis.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="999082 - Disclosure - Commitments and Contingencies (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://neuraxis.com/role/HealthBenefitPlanDetailsNarrative" xlink:title="999083 - Disclosure - Health Benefit Plan (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://neuraxis.com/role/ScheduleOfIncomeTaxProvisionDetails" xlink:title="999084 - Disclosure - Schedule of Income Tax Provision (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="loc_us-gaapDeferredIncomeTaxExpenseBenefit" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="loc_us-gaapCurrentIncomeTaxExpenseBenefit" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredIncomeTaxExpenseBenefit" xlink:to="loc_us-gaapCurrentIncomeTaxExpenseBenefit" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:label="loc_us-gaapDeferredFederalIncomeTaxExpenseBenefit" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredIncomeTaxExpenseBenefit" xlink:to="loc_us-gaapDeferredFederalIncomeTaxExpenseBenefit" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:label="loc_us-gaapDeferredStateAndLocalIncomeTaxExpenseBenefit" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredIncomeTaxExpenseBenefit" xlink:to="loc_us-gaapDeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaapIncomeTaxExpenseBenefit" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeTaxExpenseBenefit" xlink:to="loc_us-gaapDeferredIncomeTaxExpenseBenefit" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapIncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeTaxExpenseBenefit" xlink:to="loc_us-gaapIncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://neuraxis.com/role/ScheduleOfFederalStatutoryIncomeTaxRateAndEffectiveIncomeTaxRateDetails" xlink:title="999085 - Disclosure - Schedule of Federal Statutory Income Tax Rate and Effective Income Tax Rate (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://neuraxis.com/role/ScheduleOfNetDeferredTaxAssetsAndLiabilitiesDetails" xlink:title="999086 - Disclosure - Schedule of Net Deferred Tax Assets and Liabilities (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaapDeferredTaxAssetsGross" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwards" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsGross" xlink:to="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwards" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" xlink:label="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsGross" xlink:to="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_DeferredTaxAssetsNotesReceivableReserve" xlink:label="loc_NRXSDeferredTaxAssetsNotesReceivableReserve" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsGross" xlink:to="loc_NRXSDeferredTaxAssetsNotesReceivableReserve" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsOther" xlink:label="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsOther" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsGross" xlink:to="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsOther" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_DeferredTaxAssetsAccountsPayable" xlink:label="loc_NRXSDeferredTaxAssetsAccountsPayable" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsGross" xlink:to="loc_NRXSDeferredTaxAssetsAccountsPayable" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_DeferredTaxAssetsOperatingLeasePayable" xlink:label="loc_NRXSDeferredTaxAssetsOperatingLeasePayable" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsGross" xlink:to="loc_NRXSDeferredTaxAssetsOperatingLeasePayable" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="loc_us-gaapDeferredTaxAssetsOther" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsGross" xlink:to="loc_us-gaapDeferredTaxAssetsOther" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="loc_us-gaapDeferredTaxAssetsNet" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsNet" xlink:to="loc_us-gaapDeferredTaxAssetsGross" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapDeferredTaxAssetsValuationAllowance" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsNet" xlink:to="loc_us-gaapDeferredTaxAssetsValuationAllowance" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="loc_us-gaapDeferredIncomeTaxLiabilities" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset" xlink:label="loc_NRXSDeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredIncomeTaxLiabilities" xlink:to="loc_NRXSDeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesPrepaidExpenses" xlink:label="loc_us-gaapDeferredTaxLiabilitiesPrepaidExpenses" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredIncomeTaxLiabilities" xlink:to="loc_us-gaapDeferredTaxLiabilitiesPrepaidExpenses" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_DeferredTaxLiabilityAccountsReceivable" xlink:label="loc_NRXSDeferredTaxLiabilityAccountsReceivable" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredIncomeTaxLiabilities" xlink:to="loc_NRXSDeferredTaxLiabilityAccountsReceivable" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesOther" xlink:label="loc_us-gaapDeferredTaxLiabilitiesOther" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredIncomeTaxLiabilities" xlink:to="loc_us-gaapDeferredTaxLiabilitiesOther" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="loc_us-gaapDeferredTaxLiabilities" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxLiabilities" xlink:to="loc_us-gaapDeferredTaxAssetsNet" xlink:type="arc" weight="-1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxLiabilities" xlink:to="loc_us-gaapDeferredIncomeTaxLiabilities" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://neuraxis.com/role/ScheduleOfStateCarryforwardsDetails" xlink:title="999087 - Disclosure - Schedule of State Carryforwards (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://neuraxis.com/role/IncomeTaxesDetailsNarrative" xlink:title="999088 - Disclosure - Income Taxes (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://neuraxis.com/role/SubsequentEventsDetailsNarrative" xlink:title="999089 - Disclosure - Subsequent Events (Details Narrative)" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>26
<FILENAME>nrxs-20241231_def.xml
<DESCRIPTION>XBRL DEFINITION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.25b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://neuraxis.com/role/Cover" xlink:href="nrxs-20241231.xsd#Cover" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/BalanceSheets" xlink:href="nrxs-20241231.xsd#BalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/BalanceSheetsParenthetical" xlink:href="nrxs-20241231.xsd#BalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/StatementsOfOperations" xlink:href="nrxs-20241231.xsd#StatementsOfOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/StatementsOfStockholdersEquityDeficit" xlink:href="nrxs-20241231.xsd#StatementsOfStockholdersEquityDeficit" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/StatementsOfCashFlows" xlink:href="nrxs-20241231.xsd#StatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#CybersecurityRiskManagementAndStrategyDisclosure" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#MaterialCybersecurityIncidentDisclosure" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/BasisOfPresentationOrganizationAndOtherMatters" xlink:href="nrxs-20241231.xsd#BasisOfPresentationOrganizationAndOtherMatters" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="nrxs-20241231.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/RelatedPartyTransactions" xlink:href="nrxs-20241231.xsd#RelatedPartyTransactions" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/PropertyAndEquipment" xlink:href="nrxs-20241231.xsd#PropertyAndEquipment" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/IntangibleAssets" xlink:href="nrxs-20241231.xsd#IntangibleAssets" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/AccruedExpenses" xlink:href="nrxs-20241231.xsd#AccruedExpenses" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/NotesPayable" xlink:href="nrxs-20241231.xsd#NotesPayable" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/Leases" xlink:href="nrxs-20241231.xsd#Leases" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/CommonStockAndWarrants" xlink:href="nrxs-20241231.xsd#CommonStockAndWarrants" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/PreferredStock" xlink:href="nrxs-20241231.xsd#PreferredStock" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/Stock-basedCompensation" xlink:href="nrxs-20241231.xsd#Stock-basedCompensation" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/WarrantLiabilities" xlink:href="nrxs-20241231.xsd#WarrantLiabilities" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/DerivativeLiabilities" xlink:href="nrxs-20241231.xsd#DerivativeLiabilities" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/RetirementPlan" xlink:href="nrxs-20241231.xsd#RetirementPlan" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/SegmentInformation" xlink:href="nrxs-20241231.xsd#SegmentInformation" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/CommitmentsAndContingencies" xlink:href="nrxs-20241231.xsd#CommitmentsAndContingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/HealthBenefitPlan" xlink:href="nrxs-20241231.xsd#HealthBenefitPlan" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/IncomeTaxes" xlink:href="nrxs-20241231.xsd#IncomeTaxes" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/SubsequentEvents" xlink:href="nrxs-20241231.xsd#SubsequentEvents" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="nrxs-20241231.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:href="nrxs-20241231.xsd#SummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/RelatedPartyTransactionsTables" xlink:href="nrxs-20241231.xsd#RelatedPartyTransactionsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/PropertyAndEquipmentTables" xlink:href="nrxs-20241231.xsd#PropertyAndEquipmentTables" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/IntangibleAssetsTables" xlink:href="nrxs-20241231.xsd#IntangibleAssetsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/AccruedExpensesTables" xlink:href="nrxs-20241231.xsd#AccruedExpensesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/LeasesTables" xlink:href="nrxs-20241231.xsd#LeasesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/CommonStockAndWarrantsTables" xlink:href="nrxs-20241231.xsd#CommonStockAndWarrantsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/Stock-basedCompensationTables" xlink:href="nrxs-20241231.xsd#Stock-basedCompensationTables" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/WarrantLiabilitiesTables" xlink:href="nrxs-20241231.xsd#WarrantLiabilitiesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/DerivativeLiabilitiesTables" xlink:href="nrxs-20241231.xsd#DerivativeLiabilitiesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/SegmentInformationTables" xlink:href="nrxs-20241231.xsd#SegmentInformationTables" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/IncomeTaxesTables" xlink:href="nrxs-20241231.xsd#IncomeTaxesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/BasisOfPresentationOrganizationAndOtherMattersDetailsNarrative" xlink:href="nrxs-20241231.xsd#BasisOfPresentationOrganizationAndOtherMattersDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/ScheduleOfEstimatedUsefulLivesDetails" xlink:href="nrxs-20241231.xsd#ScheduleOfEstimatedUsefulLivesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/ScheduleOfFairValueOfAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails" xlink:href="nrxs-20241231.xsd#ScheduleOfFairValueOfAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/ScheduleOfDilutiveCommonStockEquivalentsDetails" xlink:href="nrxs-20241231.xsd#ScheduleOfDilutiveCommonStockEquivalentsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/ScheduleOfBasicAndDilutedNetLossPerShareDetails" xlink:href="nrxs-20241231.xsd#ScheduleOfBasicAndDilutedNetLossPerShareDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/ScheduleOfDisaggregationOfRevenueDetails" xlink:href="nrxs-20241231.xsd#ScheduleOfDisaggregationOfRevenueDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/ScheduleOfCustomerAccountsReceivableDetails" xlink:href="nrxs-20241231.xsd#ScheduleOfCustomerAccountsReceivableDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/ScheduleOfCustomersAccountedRevenuesDetails" xlink:href="nrxs-20241231.xsd#ScheduleOfCustomersAccountedRevenuesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:href="nrxs-20241231.xsd#SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/ScheduleOfRelatedPartyTransactionsDetails" xlink:href="nrxs-20241231.xsd#ScheduleOfRelatedPartyTransactionsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/ScheduleOfRelatedPartyLoansPayableToShareholderDetails" xlink:href="nrxs-20241231.xsd#ScheduleOfRelatedPartyLoansPayableToShareholderDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:href="nrxs-20241231.xsd#RelatedPartyTransactionsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/ScheduleOfPropertyAndEquipmentDetails" xlink:href="nrxs-20241231.xsd#ScheduleOfPropertyAndEquipmentDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/PropertyAndEquipmentDetailsNarrative" xlink:href="nrxs-20241231.xsd#PropertyAndEquipmentDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/ScheduleOfIntangibleAssetsDetails" xlink:href="nrxs-20241231.xsd#ScheduleOfIntangibleAssetsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/IntangibleAssetsDetailsNarrative" xlink:href="nrxs-20241231.xsd#IntangibleAssetsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/ScheduleOfAccruedExpensesDetails" xlink:href="nrxs-20241231.xsd#ScheduleOfAccruedExpensesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/NotesPayableDetailsNarrative" xlink:href="nrxs-20241231.xsd#NotesPayableDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/ScheduleOfOperatingLeasesDetails" xlink:href="nrxs-20241231.xsd#ScheduleOfOperatingLeasesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/ScheduleOfMaturitiesOperatingLeaseLiabilitiesDetails" xlink:href="nrxs-20241231.xsd#ScheduleOfMaturitiesOperatingLeaseLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/LeasesDetailsNarrative" xlink:href="nrxs-20241231.xsd#LeasesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/ScheduleOfWarrantActivityForCommonStockDetails" xlink:href="nrxs-20241231.xsd#ScheduleOfWarrantActivityForCommonStockDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/ScheduleOfWarrantActivityForPreferredStockDetails" xlink:href="nrxs-20241231.xsd#ScheduleOfWarrantActivityForPreferredStockDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/ScheduleOfWarrantsOutstandingAndExercisableDetails" xlink:href="nrxs-20241231.xsd#ScheduleOfWarrantsOutstandingAndExercisableDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/CommonStockAndWarrantsDetailsNarrative" xlink:href="nrxs-20241231.xsd#CommonStockAndWarrantsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/PreferredStockDetailsNarrative" xlink:href="nrxs-20241231.xsd#PreferredStockDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/ScheduleOfOption-pricingModelWithFollowingWeighted-averageAssumptionsDetails" xlink:href="nrxs-20241231.xsd#ScheduleOfOption-pricingModelWithFollowingWeighted-averageAssumptionsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/ScheduleOfStockOptionActivityDetails" xlink:href="nrxs-20241231.xsd#ScheduleOfStockOptionActivityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/Stock-basedCompensationDetailsNarrative" xlink:href="nrxs-20241231.xsd#Stock-basedCompensationDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/ScheduleOfChangesInWarrantLiabilitiesDetails" xlink:href="nrxs-20241231.xsd#ScheduleOfChangesInWarrantLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/WarrantLiabilitiesDetailsNarrative" xlink:href="nrxs-20241231.xsd#WarrantLiabilitiesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/ScheduleOfChangesInDerivativeLiabilitiesDetails" xlink:href="nrxs-20241231.xsd#ScheduleOfChangesInDerivativeLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/DerivativeLiabilitiesDetailsNarrative" xlink:href="nrxs-20241231.xsd#DerivativeLiabilitiesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/RetirementPlanDetailsNarrative" xlink:href="nrxs-20241231.xsd#RetirementPlanDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/ScheduleOfReconcilesCompanysNetSalesAndOperatingLossDetails" xlink:href="nrxs-20241231.xsd#ScheduleOfReconcilesCompanysNetSalesAndOperatingLossDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/SegmentInformationDetailsNarrative" xlink:href="nrxs-20241231.xsd#SegmentInformationDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:href="nrxs-20241231.xsd#CommitmentsAndContingenciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/HealthBenefitPlanDetailsNarrative" xlink:href="nrxs-20241231.xsd#HealthBenefitPlanDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/ScheduleOfIncomeTaxProvisionDetails" xlink:href="nrxs-20241231.xsd#ScheduleOfIncomeTaxProvisionDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/ScheduleOfFederalStatutoryIncomeTaxRateAndEffectiveIncomeTaxRateDetails" xlink:href="nrxs-20241231.xsd#ScheduleOfFederalStatutoryIncomeTaxRateAndEffectiveIncomeTaxRateDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/ScheduleOfNetDeferredTaxAssetsAndLiabilitiesDetails" xlink:href="nrxs-20241231.xsd#ScheduleOfNetDeferredTaxAssetsAndLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/ScheduleOfStateCarryforwardsDetails" xlink:href="nrxs-20241231.xsd#ScheduleOfStateCarryforwardsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/IncomeTaxesDetailsNarrative" xlink:href="nrxs-20241231.xsd#IncomeTaxesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/SubsequentEventsDetailsNarrative" xlink:href="nrxs-20241231.xsd#SubsequentEventsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/PvpDisclosureWithAdditionalMeasures" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#PvpDisclosureWithAdditionalMeasures" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/PvpTable" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#PvpTable" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/PvpAdjustmentsToCompensation" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#PvpAdjustmentsToCompensation" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/TabularListsByExecutiveCategory" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#TabularListsByExecutiveCategory" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/TabularListMeasures" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#TabularListMeasures" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/PvpMeasures" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#PvpMeasures" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/PvpExecutiveCategoriesOnly" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#PvpExecutiveCategoriesOnly" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/PvpAdjustmentsOnly" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#PvpAdjustmentsOnly" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/IndividualsOnly" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#IndividualsOnly" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/AwardTypeOnly" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#AwardTypeOnly" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/TradingArrangementsOnly" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#TradingArrangmentsOnly" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/ForgoneRecoveries" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ForgoneRecoveries" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/OutstandingRecoveries" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#OutstandingRecoveries" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/AwardsCloseToMnpiDisc" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#AwardsCloseToMnpiDisc" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangementsByInd" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#InsiderTradingArrangemenstByInd" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/Defaults" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#Defaults" xlink:type="simple" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll" arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" />
    <link:definitionLink xlink:type="extended" xlink:role="http://neuraxis.com/role/Cover" xlink:title="00000001 - Document - Cover" />
    <link:definitionLink xlink:type="extended" xlink:role="http://neuraxis.com/role/BalanceSheets" xlink:title="00000002 - Statement - Balance Sheets" />
    <link:definitionLink xlink:type="extended" xlink:role="http://neuraxis.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - Balance Sheets (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_ConvertibleSeriesBPreferredStockMember" xlink:label="loc_NRXSConvertibleSeriesBPreferredStockMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_NRXSConvertibleSeriesBPreferredStockMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:label="loc_us-gaapAllowanceForDoubtfulAccountsReceivable_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAllowanceForDoubtfulAccountsReceivable_50" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryRawMaterialsNetOfReserves" xlink:label="loc_us-gaapInventoryRawMaterialsNetOfReserves_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapInventoryRawMaterialsNetOfReserves_50" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare_50" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesAuthorized_50" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaapPreferredStockSharesIssued_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesIssued_50" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaapPreferredStockSharesOutstanding_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesOutstanding_50" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare_50" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesAuthorized_50" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesIssued_50" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesOutstanding_50" xlink:type="arc" order="9" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://neuraxis.com/role/StatementsOfOperations" xlink:title="00000004 - Statement - Statements of Operations" />
    <link:definitionLink xlink:type="extended" xlink:role="http://neuraxis.com/role/StatementsOfStockholdersEquityDeficit" xlink:title="00000005 - Statement - Statements of Stockholders&apos; Equity (Deficit)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockMember" xlink:label="loc_us-gaapPreferredStockMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapPreferredStockMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapRetainedEarningsMember_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_ConvertibleSeriesAPreferredStockMember" xlink:label="loc_NRXSConvertibleSeriesAPreferredStockMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_NRXSConvertibleSeriesAPreferredStockMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_ConvertibleSeriesSeedPreferredStockMember" xlink:label="loc_NRXSConvertibleSeriesSeedPreferredStockMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_NRXSConvertibleSeriesSeedPreferredStockMember_10" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_ConvertibleSeriesBPreferredStockMember" xlink:label="loc_NRXSConvertibleSeriesBPreferredStockMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_NRXSConvertibleSeriesBPreferredStockMember_20" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity_80" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding_80" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_StockIssuedDuringPeriodValueCommonStockIssuedUponInitialPublicOffering" xlink:label="loc_NRXSStockIssuedDuringPeriodValueCommonStockIssuedUponInitialPublicOffering_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_NRXSStockIssuedDuringPeriodValueCommonStockIssuedUponInitialPublicOffering_80" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_StockIssuedDuringPeriodSharesCommonStockIssuedUponInitialPublicOffering" xlink:label="loc_NRXSStockIssuedDuringPeriodSharesCommonStockIssuedUponInitialPublicOffering_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_NRXSStockIssuedDuringPeriodSharesCommonStockIssuedUponInitialPublicOffering_80" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueConversionOfConvertibleSecurities_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueConversionOfConvertibleSecurities_80" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_80" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfUnits" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueConversionOfUnits_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueConversionOfUnits_80" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfUnits_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfUnits_80" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_80" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_80" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalWarrantIssued_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalWarrantIssued_80" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_StockIssuedDuringPeriodValueWarrantsExercised" xlink:label="loc_NRXSStockIssuedDuringPeriodValueWarrantsExercised_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_NRXSStockIssuedDuringPeriodValueWarrantsExercised_80" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:label="loc_NRXSStockIssuedDuringPeriodSharesWarrantsExercised_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_NRXSStockIssuedDuringPeriodSharesWarrantsExercised_80" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLoss_80" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_AdditionalPaidInCapitalFromWarrantsIssuedAsDebtDiscount" xlink:label="loc_NRXSAdditionalPaidInCapitalFromWarrantsIssuedAsDebtDiscount_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_NRXSAdditionalPaidInCapitalFromWarrantsIssuedAsDebtDiscount_80" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature_80" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueOther_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueOther_80" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesOther_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesOther_80" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_StockIssuedDuringPeriodValuePreferredStock" xlink:label="loc_NRXSStockIssuedDuringPeriodValuePreferredStock_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_NRXSStockIssuedDuringPeriodValuePreferredStock_80" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_StockIssuedDuringPeriodSharesPreferredStock" xlink:label="loc_NRXSStockIssuedDuringPeriodSharesPreferredStock_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_NRXSStockIssuedDuringPeriodSharesPreferredStock_80" xlink:type="arc" order="20" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://neuraxis.com/role/StatementsOfCashFlows" xlink:title="00000006 - Statement - Statements of Cash Flows" />
    <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" xlink:title="00000012 - Disclosure - Cybersecurity Risk Management and Strategy Disclosure" />
    <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure" xlink:title="00000013 - Disclosure - Material Cybersecurity Incident Disclosure" />
    <link:definitionLink xlink:type="extended" xlink:role="http://neuraxis.com/role/BasisOfPresentationOrganizationAndOtherMatters" xlink:title="999014 - Disclosure - Basis of Presentation, Organization and Other Matters" />
    <link:definitionLink xlink:type="extended" xlink:role="http://neuraxis.com/role/SummaryOfSignificantAccountingPolicies" xlink:title="999015 - Disclosure - Summary of Significant Accounting Policies" />
    <link:definitionLink xlink:type="extended" xlink:role="http://neuraxis.com/role/RelatedPartyTransactions" xlink:title="999016 - Disclosure - Related Party Transactions" />
    <link:definitionLink xlink:type="extended" xlink:role="http://neuraxis.com/role/PropertyAndEquipment" xlink:title="999017 - Disclosure - Property and Equipment" />
    <link:definitionLink xlink:type="extended" xlink:role="http://neuraxis.com/role/IntangibleAssets" xlink:title="999018 - Disclosure - Intangible Assets" />
    <link:definitionLink xlink:type="extended" xlink:role="http://neuraxis.com/role/AccruedExpenses" xlink:title="999019 - Disclosure - Accrued Expenses" />
    <link:definitionLink xlink:type="extended" xlink:role="http://neuraxis.com/role/NotesPayable" xlink:title="999020 - Disclosure - Notes Payable" />
    <link:definitionLink xlink:type="extended" xlink:role="http://neuraxis.com/role/Leases" xlink:title="999021 - Disclosure - Leases" />
    <link:definitionLink xlink:type="extended" xlink:role="http://neuraxis.com/role/CommonStockAndWarrants" xlink:title="999022 - Disclosure - Common Stock and Warrants" />
    <link:definitionLink xlink:type="extended" xlink:role="http://neuraxis.com/role/PreferredStock" xlink:title="999023 - Disclosure - Preferred Stock" />
    <link:definitionLink xlink:type="extended" xlink:role="http://neuraxis.com/role/Stock-basedCompensation" xlink:title="999024 - Disclosure - Stock-Based Compensation" />
    <link:definitionLink xlink:type="extended" xlink:role="http://neuraxis.com/role/WarrantLiabilities" xlink:title="999025 - Disclosure - Warrant Liabilities" />
    <link:definitionLink xlink:type="extended" xlink:role="http://neuraxis.com/role/DerivativeLiabilities" xlink:title="999026 - Disclosure - Derivative Liabilities" />
    <link:definitionLink xlink:type="extended" xlink:role="http://neuraxis.com/role/RetirementPlan" xlink:title="999027 - Disclosure - Retirement Plan" />
    <link:definitionLink xlink:type="extended" xlink:role="http://neuraxis.com/role/SegmentInformation" xlink:title="999028 - Disclosure - Segment Information" />
    <link:definitionLink xlink:type="extended" xlink:role="http://neuraxis.com/role/CommitmentsAndContingencies" xlink:title="999029 - Disclosure - Commitments and Contingencies" />
    <link:definitionLink xlink:type="extended" xlink:role="http://neuraxis.com/role/HealthBenefitPlan" xlink:title="999030 - Disclosure - Health Benefit Plan" />
    <link:definitionLink xlink:type="extended" xlink:role="http://neuraxis.com/role/IncomeTaxes" xlink:title="999031 - Disclosure - Income Taxes" />
    <link:definitionLink xlink:type="extended" xlink:role="http://neuraxis.com/role/SubsequentEvents" xlink:title="999032 - Disclosure - Subsequent Events" />
    <link:definitionLink xlink:type="extended" xlink:role="http://neuraxis.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:title="999033 - Disclosure - Summary of Significant Accounting Policies (Policies)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://neuraxis.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:title="999034 - Disclosure - Summary of Significant Accounting Policies (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://neuraxis.com/role/RelatedPartyTransactionsTables" xlink:title="999035 - Disclosure - Related Party Transactions (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://neuraxis.com/role/PropertyAndEquipmentTables" xlink:title="999036 - Disclosure - Property and Equipment (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://neuraxis.com/role/IntangibleAssetsTables" xlink:title="999037 - Disclosure - Intangible Assets (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://neuraxis.com/role/AccruedExpensesTables" xlink:title="999038 - Disclosure - Accrued Expenses (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://neuraxis.com/role/LeasesTables" xlink:title="999039 - Disclosure - Leases (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://neuraxis.com/role/CommonStockAndWarrantsTables" xlink:title="999040 - Disclosure - Common Stock and Warrants (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockMember" xlink:label="loc_us-gaapPreferredStockMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapPreferredStockMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_ScheduleOfWarrantActivityForCommonStockTableTextBlock" xlink:label="loc_NRXSScheduleOfWarrantActivityForCommonStockTableTextBlock_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_NRXSScheduleOfWarrantActivityForCommonStockTableTextBlock_40" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_ScheduleOfWarrantActivityForPreferredStockTableTextBlock" xlink:label="loc_NRXSScheduleOfWarrantActivityForPreferredStockTableTextBlock_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_NRXSScheduleOfWarrantActivityForPreferredStockTableTextBlock_40" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="loc_us-gaapScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_40" xlink:type="arc" order="2" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://neuraxis.com/role/Stock-basedCompensationTables" xlink:title="999041 - Disclosure - Stock-Based Compensation (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://neuraxis.com/role/WarrantLiabilitiesTables" xlink:title="999042 - Disclosure - Warrant Liabilities (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://neuraxis.com/role/DerivativeLiabilitiesTables" xlink:title="999043 - Disclosure - Derivative Liabilities (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://neuraxis.com/role/SegmentInformationTables" xlink:title="999044 - Disclosure - Segment Information (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://neuraxis.com/role/IncomeTaxesTables" xlink:title="999045 - Disclosure - Income Taxes (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://neuraxis.com/role/BasisOfPresentationOrganizationAndOtherMattersDetailsNarrative" xlink:title="999046 - Disclosure - Basis of Presentation, Organization and Other Matters (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_ConvertibleSeriesAPreferredStockMember" xlink:label="loc_NRXSConvertibleSeriesAPreferredStockMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_NRXSConvertibleSeriesAPreferredStockMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_ConvertibleSeriesSeedPreferredStockMember" xlink:label="loc_NRXSConvertibleSeriesSeedPreferredStockMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_NRXSConvertibleSeriesSeedPreferredStockMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="loc_us-gaapSeriesBPreferredStockMember_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesBPreferredStockMember_70" xlink:type="arc" order="71" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_ConvertibleSeriesBPreferredStockMember" xlink:label="loc_NRXSConvertibleSeriesBPreferredStockMember_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_NRXSConvertibleSeriesBPreferredStockMember_110" xlink:type="arc" order="111" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="loc_srtConsolidatedEntitiesAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtConsolidatedEntitiesAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="loc_srtConsolidatedEntitiesDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtConsolidatedEntitiesAxis" xlink:to="loc_srtConsolidatedEntitiesDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="loc_srtConsolidatedEntitiesDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtConsolidatedEntitiesAxis" xlink:to="loc_srtConsolidatedEntitiesDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_AlexanderCapitalLPMember" xlink:label="loc_NRXSAlexanderCapitalLPMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtConsolidatedEntitiesDomain" xlink:to="loc_NRXSAlexanderCapitalLPMember_40" xlink:type="arc" order="42" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaapSubsidiarySaleOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IPOMember" xlink:label="loc_us-gaapIPOMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_us-gaapIPOMember_40" xlink:type="arc" order="43" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteStockSplit" xlink:label="loc_us-gaapStockholdersEquityNoteStockSplit_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquityNoteStockSplit_140" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesAuthorized_140" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare_140" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesAuthorized_140" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare_140" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction_140" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaapSharesIssuedPricePerShare_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesIssuedPricePerShare_140" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock_140" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredOfferingCosts" xlink:label="loc_us-gaapDeferredOfferingCosts_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDeferredOfferingCosts_140" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_PurchaseOfAdditionalStockOnNumberOfOptionsNotExercised" xlink:label="loc_NRXSPurchaseOfAdditionalStockOnNumberOfOptionsNotExercised_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_NRXSPurchaseOfAdditionalStockOnNumberOfOptionsNotExercised_140" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_UnderwritersDiscountPercentage" xlink:label="loc_NRXSUnderwritersDiscountPercentage_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_NRXSUnderwritersDiscountPercentage_140" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_NonaccountableExpenseAllowancePercentage" xlink:label="loc_NRXSNonaccountableExpenseAllowancePercentage_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_NRXSNonaccountableExpenseAllowancePercentage_140" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_CashFeePercentage" xlink:label="loc_NRXSCashFeePercentage_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_NRXSCashFeePercentage_140" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="loc_us-gaapProceedsFromIssuanceInitialPublicOffering_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceInitialPublicOffering_140" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_ReimbursementExpenses" xlink:label="loc_NRXSReimbursementExpenses_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_NRXSReimbursementExpenses_140" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_140" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction" xlink:label="loc_us-gaapSaleOfStockPercentageOfOwnershipAfterTransaction_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSaleOfStockPercentageOfOwnershipAfterTransaction_140" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_140" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_OfferingPricePerPercentage" xlink:label="loc_NRXSOfferingPricePerPercentage_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_NRXSOfferingPricePerPercentage_140" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:label="loc_us-gaapTemporaryEquitySharesAuthorized_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapTemporaryEquitySharesAuthorized_140" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockDividendPaymentTerms" xlink:label="loc_us-gaapPreferredStockDividendPaymentTerms_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockDividendPaymentTerms_140" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:label="loc_us-gaapStockRepurchasedAndRetiredDuringPeriodShares_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockRepurchasedAndRetiredDuringPeriodShares_140" xlink:type="arc" order="21" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://neuraxis.com/role/ScheduleOfEstimatedUsefulLivesDetails" xlink:title="999047 - Disclosure - Schedule of Estimated Useful Lives (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaapPropertyPlantAndEquipmentLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MachineryAndEquipmentMember" xlink:label="loc_us-gaapMachineryAndEquipmentMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapMachineryAndEquipmentMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaapFurnitureAndFixturesMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapFurnitureAndFixturesMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComputerEquipmentMember" xlink:label="loc_us-gaapComputerEquipmentMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapComputerEquipmentMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaapLeaseholdImprovementsMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapLeaseholdImprovementsMember_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_10" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaapPropertyPlantAndEquipmentUsefulLife_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentUsefulLife_80" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://neuraxis.com/role/ScheduleOfFairValueOfAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails" xlink:title="999048 - Disclosure - Schedule of Fair Value of Assets and Liabilities measured on Recurring Basis (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaapFairValueByMeasurementFrequencyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="loc_us-gaapFairValueByMeasurementFrequencyAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaapFairValueMeasurementFrequencyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFairValueByMeasurementFrequencyAxis" xlink:to="loc_us-gaapFairValueMeasurementFrequencyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaapFairValueMeasurementFrequencyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFairValueByMeasurementFrequencyAxis" xlink:to="loc_us-gaapFairValueMeasurementFrequencyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaapFairValueMeasurementsRecurringMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueMeasurementFrequencyDomain" xlink:to="loc_us-gaapFairValueMeasurementsRecurringMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaapFinancialInstrumentAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="loc_us-gaapFinancialInstrumentAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFinancialInstrumentAxis" xlink:to="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFinancialInstrumentAxis" xlink:to="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="loc_us-gaapWarrantMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaapFairValueInputsLevel1Member_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel1Member_10" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaapFairValueInputsLevel2Member_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel2Member_20" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaapFairValueInputsLevel3Member_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel3Member_30" xlink:type="arc" order="32" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="loc_us-gaapLiabilitiesFairValueDisclosure_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="loc_us-gaapLiabilitiesFairValueDisclosure_90" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://neuraxis.com/role/ScheduleOfDilutiveCommonStockEquivalentsDetails" xlink:title="999049 - Disclosure - Schedule of Dilutive Common Stock Equivalents (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OptionMember" xlink:label="loc_us-gaapOptionMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_us-gaapOptionMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_us-gaapCommonStockMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_WarrantsMember" xlink:label="loc_NRXSWarrantsMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_NRXSWarrantsMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="loc_us-gaapSeriesBPreferredStockMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_us-gaapSeriesBPreferredStockMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_110" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://neuraxis.com/role/ScheduleOfBasicAndDilutedNetLossPerShareDetails" xlink:title="999050 - Disclosure - Schedule of Basic and Diluted Net Loss Per Share (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://neuraxis.com/role/ScheduleOfDisaggregationOfRevenueDetails" xlink:title="999051 - Disclosure - Schedule of Disaggregation of Revenue (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srtStatementGeographicalAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtStatementGeographicalAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srtSegmentGeographicalDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtStatementGeographicalAxis" xlink:to="loc_srtSegmentGeographicalDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srtSegmentGeographicalDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtStatementGeographicalAxis" xlink:to="loc_srtSegmentGeographicalDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd#stpr_CA" xlink:label="loc_stprCA_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_stprCA_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd#stpr_OH" xlink:label="loc_stprOH_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_stprOH_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd#stpr_IL" xlink:label="loc_stprIL_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_stprIL_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd#stpr_WI" xlink:label="loc_stprWI_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_stprWI_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd#stpr_MA" xlink:label="loc_stprMA_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_stprMA_80" xlink:type="arc" order="81" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd#stpr_FL" xlink:label="loc_stprFL_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_stprFL_100" xlink:type="arc" order="101" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_AllOtherStatesMember" xlink:label="loc_NRXSAllOtherStatesMember_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_NRXSAllOtherStatesMember_120" xlink:type="arc" order="121" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Revenues" xlink:label="loc_us-gaapRevenues_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapRevenues_170" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://neuraxis.com/role/ScheduleOfCustomerAccountsReceivableDetails" xlink:title="999052 - Disclosure - Schedule of Customer Accounts Receivable (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProductInformationLineItems" xlink:label="loc_us-gaapProductInformationLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfProductInformationTable" xlink:label="loc_us-gaapScheduleOfProductInformationTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapScheduleOfProductInformationTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MajorCustomersAxis" xlink:label="loc_srtMajorCustomersAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfProductInformationTable" xlink:to="loc_srtMajorCustomersAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srtNameOfMajorCustomerDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtMajorCustomersAxis" xlink:to="loc_srtNameOfMajorCustomerDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srtNameOfMajorCustomerDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtMajorCustomersAxis" xlink:to="loc_srtNameOfMajorCustomerDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_CustomerAMember" xlink:label="loc_NRXSCustomerAMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtNameOfMajorCustomerDomain" xlink:to="loc_NRXSCustomerAMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_CustomerBMember" xlink:label="loc_NRXSCustomerBMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtNameOfMajorCustomerDomain" xlink:to="loc_NRXSCustomerBMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_CustomerCMember" xlink:label="loc_NRXSCustomerCMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtNameOfMajorCustomerDomain" xlink:to="loc_NRXSCustomerCMember_80" xlink:type="arc" order="81" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_CustomerDMember" xlink:label="loc_NRXSCustomerDMember_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtNameOfMajorCustomerDomain" xlink:to="loc_NRXSCustomerDMember_120" xlink:type="arc" order="121" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_CustomerEMember" xlink:label="loc_NRXSCustomerEMember_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtNameOfMajorCustomerDomain" xlink:to="loc_NRXSCustomerEMember_160" xlink:type="arc" order="161" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_CustomerMember" xlink:label="loc_NRXSCustomerMember_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtNameOfMajorCustomerDomain" xlink:to="loc_NRXSCustomerMember_200" xlink:type="arc" order="201" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="loc_us-gaapConcentrationRiskByBenchmarkAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfProductInformationTable" xlink:to="loc_us-gaapConcentrationRiskByBenchmarkAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaapConcentrationRiskBenchmarkDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapConcentrationRiskByBenchmarkAxis" xlink:to="loc_us-gaapConcentrationRiskBenchmarkDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaapConcentrationRiskBenchmarkDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapConcentrationRiskByBenchmarkAxis" xlink:to="loc_us-gaapConcentrationRiskBenchmarkDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableMember" xlink:label="loc_us-gaapAccountsReceivableMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapConcentrationRiskBenchmarkDomain" xlink:to="loc_us-gaapAccountsReceivableMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="loc_us-gaapConcentrationRiskByTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfProductInformationTable" xlink:to="loc_us-gaapConcentrationRiskByTypeAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaapConcentrationRiskTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapConcentrationRiskByTypeAxis" xlink:to="loc_us-gaapConcentrationRiskTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaapConcentrationRiskTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapConcentrationRiskByTypeAxis" xlink:to="loc_us-gaapConcentrationRiskTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="loc_us-gaapCustomerConcentrationRiskMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapConcentrationRiskTypeDomain" xlink:to="loc_us-gaapCustomerConcentrationRiskMember_0" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNet" xlink:label="loc_us-gaapAccountsReceivableNet_250" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapAccountsReceivableNet_250" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="loc_us-gaapConcentrationRiskPercentage1_250" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapConcentrationRiskPercentage1_250" xlink:type="arc" order="1" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://neuraxis.com/role/ScheduleOfCustomersAccountedRevenuesDetails" xlink:title="999053 - Disclosure - Schedule of Customers Accounted Revenues (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProductInformationLineItems" xlink:label="loc_us-gaapProductInformationLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfProductInformationTable" xlink:label="loc_us-gaapScheduleOfProductInformationTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapScheduleOfProductInformationTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MajorCustomersAxis" xlink:label="loc_srtMajorCustomersAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfProductInformationTable" xlink:to="loc_srtMajorCustomersAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srtNameOfMajorCustomerDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtMajorCustomersAxis" xlink:to="loc_srtNameOfMajorCustomerDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srtNameOfMajorCustomerDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtMajorCustomersAxis" xlink:to="loc_srtNameOfMajorCustomerDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_CustomerAMember" xlink:label="loc_NRXSCustomerAMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtNameOfMajorCustomerDomain" xlink:to="loc_NRXSCustomerAMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_CustomerBMember" xlink:label="loc_NRXSCustomerBMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtNameOfMajorCustomerDomain" xlink:to="loc_NRXSCustomerBMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_CustomerCMember" xlink:label="loc_NRXSCustomerCMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtNameOfMajorCustomerDomain" xlink:to="loc_NRXSCustomerCMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_CustomerMember" xlink:label="loc_NRXSCustomerMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtNameOfMajorCustomerDomain" xlink:to="loc_NRXSCustomerMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="loc_us-gaapConcentrationRiskByBenchmarkAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfProductInformationTable" xlink:to="loc_us-gaapConcentrationRiskByBenchmarkAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaapConcentrationRiskBenchmarkDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapConcentrationRiskByBenchmarkAxis" xlink:to="loc_us-gaapConcentrationRiskBenchmarkDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaapConcentrationRiskBenchmarkDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapConcentrationRiskByBenchmarkAxis" xlink:to="loc_us-gaapConcentrationRiskBenchmarkDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SalesRevenueNetMember" xlink:label="loc_us-gaapSalesRevenueNetMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapConcentrationRiskBenchmarkDomain" xlink:to="loc_us-gaapSalesRevenueNetMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="loc_us-gaapConcentrationRiskByTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfProductInformationTable" xlink:to="loc_us-gaapConcentrationRiskByTypeAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaapConcentrationRiskTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapConcentrationRiskByTypeAxis" xlink:to="loc_us-gaapConcentrationRiskTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaapConcentrationRiskTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapConcentrationRiskByTypeAxis" xlink:to="loc_us-gaapConcentrationRiskTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="loc_us-gaapCustomerConcentrationRiskMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapConcentrationRiskTypeDomain" xlink:to="loc_us-gaapCustomerConcentrationRiskMember_0" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax_90" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="loc_us-gaapConcentrationRiskPercentage1_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapConcentrationRiskPercentage1_90" xlink:type="arc" order="1" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://neuraxis.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="999054 - Disclosure - Summary of Significant Accounting Policies (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:label="loc_us-gaapIndefiniteLivedIntangibleAssetsByMajorClassLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaapScheduleOfIndefiniteLivedIntangibleAssetsTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapIndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:to="loc_us-gaapScheduleOfIndefiniteLivedIntangibleAssetsTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaapIndefiniteLivedIntangibleAssetsByMajorClassAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfIndefiniteLivedIntangibleAssetsTable" xlink:to="loc_us-gaapIndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapIndefiniteLivedIntangibleAssetsMajorClassNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapIndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapIndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapIndefiniteLivedIntangibleAssetsMajorClassNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapIndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapIndefiniteLivedIntangibleAssetsMajorClassNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TrademarksMember" xlink:label="loc_us-gaapTrademarksMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_us-gaapTrademarksMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfIndefiniteLivedIntangibleAssetsTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_LicensingAgreementMember" xlink:label="loc_NRXSLicensingAgreementMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_NRXSLicensingAgreementMember_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaapIncomeStatementLocationAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfIndefiniteLivedIntangibleAssetsTable" xlink:to="loc_us-gaapIncomeStatementLocationAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaapGeneralAndAdministrativeExpenseMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapGeneralAndAdministrativeExpenseMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:label="loc_us-gaapAllowanceForDoubtfulAccountsReceivable_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:to="loc_us-gaapAllowanceForDoubtfulAccountsReceivable_90" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProvisionForOtherCreditLosses" xlink:label="loc_us-gaapProvisionForOtherCreditLosses_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:to="loc_us-gaapProvisionForOtherCreditLosses_90" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Deposits" xlink:label="loc_us-gaapDeposits_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:to="loc_us-gaapDeposits_90" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_InventoryExpenses" xlink:label="loc_NRXSInventoryExpenses_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:to="loc_NRXSInventoryExpenses_90" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryRawMaterialsNetOfReserves" xlink:label="loc_us-gaapInventoryRawMaterialsNetOfReserves_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:to="loc_us-gaapInventoryRawMaterialsNetOfReserves_90" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaapDepreciation_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:to="loc_us-gaapDepreciation_90" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="loc_us-gaapPaymentsToAcquireIntangibleAssets_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:to="loc_us-gaapPaymentsToAcquireIntangibleAssets_90" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaapAmortizationOfIntangibleAssets_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:to="loc_us-gaapAmortizationOfIntangibleAssets_90" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExaminationLikelihoodOfUnfavorableSettlement" xlink:label="loc_us-gaapIncomeTaxExaminationLikelihoodOfUnfavorableSettlement_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:to="loc_us-gaapIncomeTaxExaminationLikelihoodOfUnfavorableSettlement_90" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued" xlink:label="loc_us-gaapIncomeTaxExaminationPenaltiesAndInterestAccrued_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:to="loc_us-gaapIncomeTaxExaminationPenaltiesAndInterestAccrued_90" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdvertisingExpense" xlink:label="loc_us-gaapAdvertisingExpense_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:to="loc_us-gaapAdvertisingExpense_90" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DividendsPreferredStock" xlink:label="loc_us-gaapDividendsPreferredStock_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:to="loc_us-gaapDividendsPreferredStock_90" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:label="loc_us-gaapContractWithCustomerLiabilityRevenueRecognized_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:to="loc_us-gaapContractWithCustomerLiabilityRevenueRecognized_90" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashFDICInsuredAmount" xlink:label="loc_us-gaapCashFDICInsuredAmount_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:to="loc_us-gaapCashFDICInsuredAmount_90" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashUninsuredAmount" xlink:label="loc_us-gaapCashUninsuredAmount_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:to="loc_us-gaapCashUninsuredAmount_90" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:to="loc_us-gaapStockholdersEquity_90" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermBorrowings" xlink:label="loc_us-gaapShortTermBorrowings_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:to="loc_us-gaapShortTermBorrowings_90" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Cash" xlink:label="loc_us-gaapCash_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:to="loc_us-gaapCash_90" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_WorkingCapitalDeficit" xlink:label="loc_NRXSWorkingCapitalDeficit_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:to="loc_NRXSWorkingCapitalDeficit_90" xlink:type="arc" order="18" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://neuraxis.com/role/ScheduleOfRelatedPartyTransactionsDetails" xlink:title="999055 - Disclosure - Schedule of Related Party Transactions (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaapRelatedPartyTransactionLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_ShareHolderOneMember" xlink:label="loc_NRXSShareHolderOneMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_NRXSShareHolderOneMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_ShareHolderTwoMember" xlink:label="loc_NRXSShareHolderTwoMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_NRXSShareHolderTwoMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyMember" xlink:label="loc_us-gaapRelatedPartyMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_us-gaapRelatedPartyMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NotesAndLoansReceivableGrossCurrent" xlink:label="loc_us-gaapNotesAndLoansReceivableGrossCurrent_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapNotesAndLoansReceivableGrossCurrent_70" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestReceivableCurrent" xlink:label="loc_us-gaapInterestReceivableCurrent_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapInterestReceivableCurrent_70" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_InterestIncomeGrossCurrent" xlink:label="loc_NRXSInterestIncomeGrossCurrent_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_NRXSInterestIncomeGrossCurrent_70" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllowanceForNotesAndLoansReceivableCurrent" xlink:label="loc_us-gaapAllowanceForNotesAndLoansReceivableCurrent_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapAllowanceForNotesAndLoansReceivableCurrent_70" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_AllowanceForInterestReceivableCurrent" xlink:label="loc_NRXSAllowanceForInterestReceivableCurrent_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_NRXSAllowanceForInterestReceivableCurrent_70" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_AllowanceForInterestIncomeCurrent" xlink:label="loc_NRXSAllowanceForInterestIncomeCurrent_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_NRXSAllowanceForInterestIncomeCurrent_70" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NotesAndLoansReceivableNetCurrent" xlink:label="loc_us-gaapNotesAndLoansReceivableNetCurrent_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapNotesAndLoansReceivableNetCurrent_70" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestReceivable" xlink:label="loc_us-gaapInterestReceivable_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapInterestReceivable_70" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_InterestIncomeCurrent" xlink:label="loc_NRXSInterestIncomeCurrent_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_NRXSInterestIncomeCurrent_70" xlink:type="arc" order="8" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://neuraxis.com/role/ScheduleOfRelatedPartyLoansPayableToShareholderDetails" xlink:title="999056 - Disclosure - Schedule of Related Party Loans payable to shareholder (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermDebtLineItems" xlink:label="loc_us-gaapShortTermDebtLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShortTermDebtTable" xlink:label="loc_us-gaapScheduleOfShortTermDebtTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapScheduleOfShortTermDebtTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaapDebtInstrumentAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_us-gaapDebtInstrumentAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaapDebtInstrumentNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapDebtInstrumentAxis" xlink:to="loc_us-gaapDebtInstrumentNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaapDebtInstrumentNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapDebtInstrumentAxis" xlink:to="loc_us-gaapDebtInstrumentNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_OtherConvertiblesMember" xlink:label="loc_NRXSOtherConvertiblesMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_NRXSOtherConvertiblesMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_ShareHolderOneMember" xlink:label="loc_NRXSShareHolderOneMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_NRXSShareHolderOneMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_ShareHolderTwoMember" xlink:label="loc_NRXSShareHolderTwoMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_NRXSShareHolderTwoMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentMaturityDateDescription" xlink:label="loc_us-gaapDebtInstrumentMaturityDateDescription_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentMaturityDateDescription_130" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaapDebtInstrumentInterestRateStatedPercentage_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentInterestRateStatedPercentage_130" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LoansPayable" xlink:label="loc_us-gaapLoansPayable_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapLoansPayable_130" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_InterestAndServiceFeeAccrued" xlink:label="loc_NRXSInterestAndServiceFeeAccrued_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_NRXSInterestAndServiceFeeAccrued_130" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestPaid" xlink:label="loc_us-gaapInterestPaid_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapInterestPaid_130" xlink:type="arc" order="4" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://neuraxis.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:title="999057 - Disclosure - Related Party Transactions (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaapRelatedPartyTransactionLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_ShareholdersOneAndTwoMember" xlink:label="loc_NRXSShareholdersOneAndTwoMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_NRXSShareholdersOneAndTwoMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyMember" xlink:label="loc_us-gaapRelatedPartyMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_us-gaapRelatedPartyMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_MrWatkinsMember" xlink:label="loc_NRXSMrWatkinsMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_NRXSMrWatkinsMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_MrSealeMember" xlink:label="loc_NRXSMrSealeMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_NRXSMrSealeMember_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_srtTitleOfIndividualAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ChiefFinancialOfficerMember" xlink:label="loc_srtChiefFinancialOfficerMember_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_srtChiefFinancialOfficerMember_90" xlink:type="arc" order="91" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NotesAndLoansReceivableGrossCurrent" xlink:label="loc_us-gaapNotesAndLoansReceivableGrossCurrent_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapNotesAndLoansReceivableGrossCurrent_110" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_AllowanceForInterestReceivableCurrent" xlink:label="loc_NRXSAllowanceForInterestReceivableCurrent_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_NRXSAllowanceForInterestReceivableCurrent_110" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:label="loc_us-gaapRelatedPartyTransactionAmountsOfTransaction_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapRelatedPartyTransactionAmountsOfTransaction_110" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForFees" xlink:label="loc_us-gaapPaymentsForFees_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapPaymentsForFees_110" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrentAndNoncurrent" xlink:label="loc_us-gaapAccountsPayableCurrentAndNoncurrent_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapAccountsPayableCurrentAndNoncurrent_110" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices_110" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueIssuedForServices_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueIssuedForServices_110" xlink:type="arc" order="6" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://neuraxis.com/role/ScheduleOfPropertyAndEquipmentDetails" xlink:title="999058 - Disclosure - Schedule of Property And Equipment (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaapPropertyPlantAndEquipmentLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MachineryAndEquipmentMember" xlink:label="loc_us-gaapMachineryAndEquipmentMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapMachineryAndEquipmentMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaapFurnitureAndFixturesMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapFurnitureAndFixturesMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComputerEquipmentMember" xlink:label="loc_us-gaapComputerEquipmentMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapComputerEquipmentMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaapLeaseholdImprovementsMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapLeaseholdImprovementsMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaapPropertyPlantAndEquipmentGross_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentGross_110" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_110" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet_110" xlink:type="arc" order="2" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://neuraxis.com/role/PropertyAndEquipmentDetailsNarrative" xlink:title="999059 - Disclosure - Property and Equipment (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_DecemberTwoThousandTwentyFiveMember" xlink:label="loc_NRXSDecemberTwoThousandTwentyFiveMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_NRXSDecemberTwoThousandTwentyFiveMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_DecemberTwoThousandTwentySixMember" xlink:label="loc_NRXSDecemberTwoThousandTwentySixMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_NRXSDecemberTwoThousandTwentySixMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_DecemberTwoThousandTwentySevenMember" xlink:label="loc_NRXSDecemberTwoThousandTwentySevenMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_NRXSDecemberTwoThousandTwentySevenMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_DecemberTwoThousandTwentyEightMember" xlink:label="loc_NRXSDecemberTwoThousandTwentyEightMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_NRXSDecemberTwoThousandTwentyEightMember_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_DecemberTwoThousandTwentyNineMember" xlink:label="loc_NRXSDecemberTwoThousandTwentyNineMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_NRXSDecemberTwoThousandTwentyNineMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_DecemberTwoThousandTwentyThereafterMember" xlink:label="loc_NRXSDecemberTwoThousandTwentyThereafterMember_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_NRXSDecemberTwoThousandTwentyThereafterMember_70" xlink:type="arc" order="71" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaapDepreciation_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapDepreciation_90" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://neuraxis.com/role/ScheduleOfIntangibleAssetsDetails" xlink:title="999060 - Disclosure - Schedule of Intangible Assets (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_SoftwareImplementationMember" xlink:label="loc_NRXSSoftwareImplementationMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_NRXSSoftwareImplementationMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PatentsMember" xlink:label="loc_us-gaapPatentsMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_us-gaapPatentsMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TrademarksMember" xlink:label="loc_us-gaapTrademarksMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_us-gaapTrademarksMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_LicensesMember" xlink:label="loc_NRXSLicensesMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_NRXSLicensesMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsGross_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsGross_110" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAccumulatedAmortization_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAccumulatedAmortization_110" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsNet_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsNet_110" xlink:type="arc" order="2" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://neuraxis.com/role/IntangibleAssetsDetailsNarrative" xlink:title="999061 - Disclosure - Intangible Assets (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_DecemberTwoThousandTwentyFiveMember" xlink:label="loc_NRXSDecemberTwoThousandTwentyFiveMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_NRXSDecemberTwoThousandTwentyFiveMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_DecemberTwoThousandTwentySixMember" xlink:label="loc_NRXSDecemberTwoThousandTwentySixMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_NRXSDecemberTwoThousandTwentySixMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_DecemberTwoThousandTwentySevenMember" xlink:label="loc_NRXSDecemberTwoThousandTwentySevenMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_NRXSDecemberTwoThousandTwentySevenMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_DecemberTwoThousandTwentyEightMember" xlink:label="loc_NRXSDecemberTwoThousandTwentyEightMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_NRXSDecemberTwoThousandTwentyEightMember_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_DecemberTwoThousandTwentyNineMember" xlink:label="loc_NRXSDecemberTwoThousandTwentyNineMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_NRXSDecemberTwoThousandTwentyNineMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_DecemberTwoThousandTwentyThereafterMember" xlink:label="loc_NRXSDecemberTwoThousandTwentyThereafterMember_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_NRXSDecemberTwoThousandTwentyThereafterMember_70" xlink:type="arc" order="71" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaapAmortizationOfIntangibleAssets_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapAmortizationOfIntangibleAssets_90" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://neuraxis.com/role/ScheduleOfAccruedExpensesDetails" xlink:title="999062 - Disclosure - Schedule of Accrued Expenses (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://neuraxis.com/role/NotesPayableDetailsNarrative" xlink:title="999063 - Disclosure - Notes Payable (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiLegalEntityAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_ChannelPartnersCapitalMember" xlink:label="loc_NRXSChannelPartnersCapitalMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_NRXSChannelPartnersCapitalMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_ExchangeListingLLCMember" xlink:label="loc_NRXSExchangeListingLLCMember_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_NRXSExchangeListingLLCMember_70" xlink:type="arc" order="71" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_SignatureBankMember" xlink:label="loc_NRXSSignatureBankMember_320" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_NRXSSignatureBankMember_320" xlink:type="arc" order="321" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_AlexanderCapitalLPMember" xlink:label="loc_NRXSAlexanderCapitalLPMember_330" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_NRXSAlexanderCapitalLPMember_330" xlink:type="arc" order="331" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaapDebtInstrumentAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapDebtInstrumentAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaapDebtInstrumentNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapDebtInstrumentAxis" xlink:to="loc_us-gaapDebtInstrumentNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaapDebtInstrumentNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapDebtInstrumentAxis" xlink:to="loc_us-gaapDebtInstrumentNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_PromissoryNoteMember" xlink:label="loc_NRXSPromissoryNoteMember_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_NRXSPromissoryNoteMember_70" xlink:type="arc" order="72" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_SecondPromissoryNoteMember" xlink:label="loc_NRXSSecondPromissoryNoteMember_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_NRXSSecondPromissoryNoteMember_110" xlink:type="arc" order="111" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_TwoThousandTwentyTwoConvertibleNotesMember" xlink:label="loc_NRXSTwoThousandTwentyTwoConvertibleNotesMember_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_NRXSTwoThousandTwentyTwoConvertibleNotesMember_150" xlink:type="arc" order="151" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_ConvertiblePromissoryNoteMember" xlink:label="loc_NRXSConvertiblePromissoryNoteMember_230" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_NRXSConvertiblePromissoryNoteMember_230" xlink:type="arc" order="231" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_TwoThousandTwentyThreeConvertibleNotesMember" xlink:label="loc_NRXSTwoThousandTwentyThreeConvertibleNotesMember_260" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_NRXSTwoThousandTwentyThreeConvertibleNotesMember_260" xlink:type="arc" order="261" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_ConvertiblePromissoryNotesMember" xlink:label="loc_NRXSConvertiblePromissoryNotesMember_400" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_NRXSConvertiblePromissoryNotesMember_400" xlink:type="arc" order="401" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_TwoThousandTwentyFourConvertiblePromissoryNotesMember" xlink:label="loc_NRXSTwoThousandTwentyFourConvertiblePromissoryNotesMember_440" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_NRXSTwoThousandTwentyFourConvertiblePromissoryNotesMember_440" xlink:type="arc" order="441" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_TwoThousandTwentyFourConvertibleNotesMember" xlink:label="loc_NRXSTwoThousandTwentyFourConvertibleNotesMember_530" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_NRXSTwoThousandTwentyFourConvertibleNotesMember_530" xlink:type="arc" order="531" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember_190" xlink:type="arc" order="191" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_200" xlink:type="arc" order="201" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtTitleOfIndividualAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_AccreditedInvestorsMember" xlink:label="loc_NRXSAccreditedInvestorsMember_230" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_NRXSAccreditedInvestorsMember_230" xlink:type="arc" order="232" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_270" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_270" xlink:type="arc" order="272" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember_330" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapWarrantMember_330" xlink:type="arc" order="332" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="loc_us-gaapSeriesBPreferredStockMember_450" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesBPreferredStockMember_450" xlink:type="arc" order="451" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaapDebtInstrumentFaceAmount_630" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDebtInstrumentFaceAmount_630" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentPeriodicPayment" xlink:label="loc_us-gaapDebtInstrumentPeriodicPayment_630" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDebtInstrumentPeriodicPayment_630" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtAverageAmountOutstanding" xlink:label="loc_us-gaapLongTermDebtAverageAmountOutstanding_630" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLongTermDebtAverageAmountOutstanding_630" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentRepurchasedFaceAmount" xlink:label="loc_us-gaapDebtInstrumentRepurchasedFaceAmount_630" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDebtInstrumentRepurchasedFaceAmount_630" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NotesPayable" xlink:label="loc_us-gaapNotesPayable_630" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNotesPayable_630" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="loc_us-gaapDebtInstrumentInterestRateEffectivePercentage_630" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDebtInstrumentInterestRateEffectivePercentage_630" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaapDebtInstrumentInterestRateStatedPercentage_630" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDebtInstrumentInterestRateStatedPercentage_630" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="loc_us-gaapProceedsFromIssuanceInitialPublicOffering_630" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceInitialPublicOffering_630" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="loc_us-gaapDebtInstrumentMaturityDate_630" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDebtInstrumentMaturityDate_630" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="loc_us-gaapDebtInstrumentCarryingAmount_630" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDebtInstrumentCarryingAmount_630" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfDebt" xlink:label="loc_us-gaapProceedsFromIssuanceOfDebt_630" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfDebt_630" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentDescriptionOfVariableRateBasis" xlink:label="loc_us-gaapDebtInstrumentDescriptionOfVariableRateBasis_630" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDebtInstrumentDescriptionOfVariableRateBasis_630" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="loc_us-gaapDebtInstrumentConvertibleConversionPrice1_630" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDebtInstrumentConvertibleConversionPrice1_630" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_DebtInstrumentDiscountRate" xlink:label="loc_NRXSDebtInstrumentDiscountRate_630" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_NRXSDebtInstrumentDiscountRate_630" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_DebtWarrantConversionDescription" xlink:label="loc_NRXSDebtWarrantConversionDescription_630" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_NRXSDebtWarrantConversionDescription_630" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_630" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_630" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_ClassOfWarrantDiscountRate" xlink:label="loc_NRXSClassOfWarrantDiscountRate_630" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_NRXSClassOfWarrantDiscountRate_630" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:label="loc_us-gaapDebtInstrumentConvertibleConversionRatio1_630" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDebtInstrumentConvertibleConversionRatio1_630" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaapGainsLossesOnExtinguishmentOfDebt_630" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapGainsLossesOnExtinguishmentOfDebt_630" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_630" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_630" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaapSharesIssuedPricePerShare_630" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesIssuedPricePerShare_630" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EscrowDeposit" xlink:label="loc_us-gaapEscrowDeposit_630" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapEscrowDeposit_630" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromFeesReceived" xlink:label="loc_us-gaapProceedsFromFeesReceived_630" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapProceedsFromFeesReceived_630" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_630" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_630" xlink:type="arc" order="23" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="loc_us-gaapConvertiblePreferredStockSharesIssuedUponConversion_630" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapConvertiblePreferredStockSharesIssuedUponConversion_630" xlink:type="arc" order="24" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_630" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_630" xlink:type="arc" order="25" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid" xlink:label="loc_us-gaapDebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid_630" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid_630" xlink:type="arc" order="26" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleDebt" xlink:label="loc_us-gaapConvertibleDebt_630" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapConvertibleDebt_630" xlink:type="arc" order="27" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromContributedCapital" xlink:label="loc_us-gaapProceedsFromContributedCapital_630" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapProceedsFromContributedCapital_630" xlink:type="arc" order="28" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAnnualPrincipalPayment" xlink:label="loc_us-gaapDebtInstrumentAnnualPrincipalPayment_630" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDebtInstrumentAnnualPrincipalPayment_630" xlink:type="arc" order="29" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtConversionOriginalDebtInterestRateOfDebt" xlink:label="loc_us-gaapDebtConversionOriginalDebtInterestRateOfDebt_630" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDebtConversionOriginalDebtInterestRateOfDebt_630" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare_630" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare_630" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_CumulativeDividendsPercent" xlink:label="loc_NRXSCumulativeDividendsPercent_630" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_NRXSCumulativeDividendsPercent_630" xlink:type="arc" order="32" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockConvertibleConversionPriceDecrease" xlink:label="loc_us-gaapCommonStockConvertibleConversionPriceDecrease_630" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockConvertibleConversionPriceDecrease_630" xlink:type="arc" order="33" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized_630" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesAuthorized_630" xlink:type="arc" order="34" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:label="loc_us-gaapTemporaryEquitySharesAuthorized_630" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapTemporaryEquitySharesAuthorized_630" xlink:type="arc" order="35" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare_630" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare_630" xlink:type="arc" order="36" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="loc_us-gaapConversionOfStockSharesConverted1_630" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapConversionOfStockSharesConverted1_630" xlink:type="arc" order="37" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_CommonStockConvertibleConversionPrice" xlink:label="loc_NRXSCommonStockConvertibleConversionPrice_630" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_NRXSCommonStockConvertibleConversionPrice_630" xlink:type="arc" order="38" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnamortizedDebtIssuanceExpense" xlink:label="loc_us-gaapUnamortizedDebtIssuanceExpense_630" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapUnamortizedDebtIssuanceExpense_630" xlink:type="arc" order="39" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaapInterestExpense_630" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapInterestExpense_630" xlink:type="arc" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrentAndNoncurrent_630" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAccruedLiabilitiesCurrentAndNoncurrent_630" xlink:type="arc" order="41" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://neuraxis.com/role/ScheduleOfOperatingLeasesDetails" xlink:title="999064 - Disclosure - Schedule of Operating Leases (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://neuraxis.com/role/ScheduleOfMaturitiesOperatingLeaseLiabilitiesDetails" xlink:title="999065 - Disclosure - Schedule of Maturities Operating Lease Liabilities (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://neuraxis.com/role/LeasesDetailsNarrative" xlink:title="999066 - Disclosure - Leases (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeographicDistributionAxis" xlink:label="loc_us-gaapGeographicDistributionAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapGeographicDistributionAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeographicDistributionDomain" xlink:label="loc_us-gaapGeographicDistributionDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapGeographicDistributionAxis" xlink:to="loc_us-gaapGeographicDistributionDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeographicDistributionDomain" xlink:label="loc_us-gaapGeographicDistributionDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapGeographicDistributionAxis" xlink:to="loc_us-gaapGeographicDistributionDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_VersaillesIndianaMember" xlink:label="loc_NRXSVersaillesIndianaMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapGeographicDistributionDomain" xlink:to="loc_NRXSVersaillesIndianaMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_CarmelIndianaMember" xlink:label="loc_NRXSCarmelIndianaMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapGeographicDistributionDomain" xlink:to="loc_NRXSCarmelIndianaMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseDescription" xlink:label="loc_us-gaapLesseeOperatingLeaseDescription_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLesseeOperatingLeaseDescription_70" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeasePayments" xlink:label="loc_us-gaapOperatingLeasePayments_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOperatingLeasePayments_70" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseDiscountRate" xlink:label="loc_us-gaapLesseeOperatingLeaseDiscountRate_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLesseeOperatingLeaseDiscountRate_70" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseExpense" xlink:label="loc_us-gaapOperatingLeaseExpense_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOperatingLeaseExpense_70" xlink:type="arc" order="3" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://neuraxis.com/role/ScheduleOfWarrantActivityForCommonStockDetails" xlink:title="999067 - Disclosure - Schedule of Warrant Activity for Common Stock (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_70" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_70" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_70" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_70" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_70" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsWeightedAverageRemainingContracualLifeOutstandingNumberGranted" xlink:label="loc_NRXSShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsWeightedAverageRemainingContracualLifeOutstandingNumberGranted_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_NRXSShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsWeightedAverageRemainingContracualLifeOutstandingNumberGranted_70" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsConvertedPrefundedWarrants" xlink:label="loc_NRXSShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsConvertedPrefundedWarrants_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_NRXSShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsConvertedPrefundedWarrants_70" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsConvertedPrefundedWarrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_NRXSShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsConvertedPrefundedWarrantsInPeriodWeightedAverageExercisePrice_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_NRXSShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsConvertedPrefundedWarrantsInPeriodWeightedAverageExercisePrice_70" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_70" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsWeightedAverageExercisePriceCancelledExpiredNumber" xlink:label="loc_NRXSShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsWeightedAverageExercisePriceCancelledExpiredNumber_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_NRXSShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsWeightedAverageExercisePriceCancelledExpiredNumber_70" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsCancelledWeightedAverageRemainingContractualTerm1" xlink:label="loc_NRXSSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsCancelledWeightedAverageRemainingContractualTerm1_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_NRXSSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsCancelledWeightedAverageRemainingContractualTerm1_70" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_70" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_70" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_70" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisedWeightedAverageRemainingContractualTerm1" xlink:label="loc_NRXSSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisedWeightedAverageRemainingContractualTerm1_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_NRXSSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisedWeightedAverageRemainingContractualTerm1_70" xlink:type="arc" order="15" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://neuraxis.com/role/ScheduleOfWarrantActivityForPreferredStockDetails" xlink:title="999068 - Disclosure - Schedule of Warrant Activity for Preferred Stock (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockMember" xlink:label="loc_us-gaapPreferredStockMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapPreferredStockMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_40" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_40" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_40" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_40" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_40" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsWeightedAverageExercisePriceCancelledExpiredNumber" xlink:label="loc_NRXSShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsWeightedAverageExercisePriceCancelledExpiredNumber_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_NRXSShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsWeightedAverageExercisePriceCancelledExpiredNumber_40" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsCommonStockWarrant" xlink:label="loc_NRXSShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsCommonStockWarrant_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_NRXSShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsCommonStockWarrant_40" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsWeightedAverageExercisePriceCommonStockWarrant" xlink:label="loc_NRXSShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsWeightedAverageExercisePriceCommonStockWarrant_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_NRXSShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsWeightedAverageExercisePriceCommonStockWarrant_40" xlink:type="arc" order="7" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://neuraxis.com/role/ScheduleOfWarrantsOutstandingAndExercisableDetails" xlink:title="999069 - Disclosure - Schedule of Warrants outstanding and Exercisable (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="loc_us-gaapClassOfWarrantOrRightLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="loc_us-gaapClassOfWarrantOrRightTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapClassOfWarrantOrRightTable" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_InvestorWarrantOneMember" xlink:label="loc_NRXSInvestorWarrantOneMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_NRXSInvestorWarrantOneMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_InvestorWarrantPSAOneMember" xlink:label="loc_NRXSInvestorWarrantPSAOneMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_NRXSInvestorWarrantPSAOneMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_TwoThousandTwentyTwoConvertibleNotesMember" xlink:label="loc_NRXSTwoThousandTwentyTwoConvertibleNotesMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_NRXSTwoThousandTwentyTwoConvertibleNotesMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_TwoThousandTwentyThreeConvertibleNotesMember" xlink:label="loc_NRXSTwoThousandTwentyThreeConvertibleNotesMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_NRXSTwoThousandTwentyThreeConvertibleNotesMember_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_UnderwriterWarrantsMember" xlink:label="loc_NRXSUnderwriterWarrantsMember_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_NRXSUnderwriterWarrantsMember_70" xlink:type="arc" order="71" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_AdvisoryAgreementWarrantsMember" xlink:label="loc_NRXSAdvisoryAgreementWarrantsMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_NRXSAdvisoryAgreementWarrantsMember_80" xlink:type="arc" order="81" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaapClassOfWarrantOrRightOutstanding_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightOutstanding_120" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_120" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:label="loc_us-gaapWarrantsAndRightsOutstandingMaturityDate_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstandingMaturityDate_120" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_WarrantExpirationDateDescription" xlink:label="loc_NRXSWarrantExpirationDateDescription_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_NRXSWarrantExpirationDateDescription_120" xlink:type="arc" order="3" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://neuraxis.com/role/CommonStockAndWarrantsDetailsNarrative" xlink:title="999070 - Disclosure - Common Stock and Warrants (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaapClassOfStockLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaapScheduleOfStockByClassTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapScheduleOfStockByClassTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_ConvertibleSeriesSeedPreferredStockMember" xlink:label="loc_NRXSConvertibleSeriesSeedPreferredStockMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_NRXSConvertibleSeriesSeedPreferredStockMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapWarrantMember_80" xlink:type="arc" order="81" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_VendorsMember" xlink:label="loc_NRXSVendorsMember_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_NRXSVendorsMember_70" xlink:type="arc" order="71" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_EmployementAgreementMember" xlink:label="loc_NRXSEmployementAgreementMember_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_NRXSEmployementAgreementMember_120" xlink:type="arc" order="121" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_TwoThousandTwentyThreeConvertiblePromissoryNotesMember" xlink:label="loc_NRXSTwoThousandTwentyThreeConvertiblePromissoryNotesMember_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_NRXSTwoThousandTwentyThreeConvertiblePromissoryNotesMember_130" xlink:type="arc" order="131" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_TwoThousandTwentyTwoConvertibleNotesMember" xlink:label="loc_NRXSTwoThousandTwentyTwoConvertibleNotesMember_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_NRXSTwoThousandTwentyTwoConvertibleNotesMember_140" xlink:type="arc" order="141" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_AdvisoryAgreementMember" xlink:label="loc_NRXSAdvisoryAgreementMember_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_NRXSAdvisoryAgreementMember_150" xlink:type="arc" order="151" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_UnderwritingAgreementMember" xlink:label="loc_NRXSUnderwritingAgreementMember_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_NRXSUnderwritingAgreementMember_160" xlink:type="arc" order="161" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_TwoThousandTwentyFourConvertiblePromissoryNotesMember" xlink:label="loc_NRXSTwoThousandTwentyFourConvertiblePromissoryNotesMember_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_NRXSTwoThousandTwentyFourConvertiblePromissoryNotesMember_170" xlink:type="arc" order="171" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_AdvisoryAgreementsMember" xlink:label="loc_NRXSAdvisoryAgreementsMember_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_NRXSAdvisoryAgreementsMember_180" xlink:type="arc" order="181" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapCommonStockSharesAuthorized_220" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapCommonStockSharesIssued_220" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapCommonStockSharesOutstanding_220" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="loc_us-gaapStockholdersEquityReverseStockSplit_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapStockholdersEquityReverseStockSplit_220" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_StockIssuedDuringPeriodSharesCommonStockIssuedUponInitialPublicOffering" xlink:label="loc_NRXSStockIssuedDuringPeriodSharesCommonStockIssuedUponInitialPublicOffering_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_NRXSStockIssuedDuringPeriodSharesCommonStockIssuedUponInitialPublicOffering_220" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaapSharePrice_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapSharePrice_220" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="loc_us-gaapProceedsFromIssuanceInitialPublicOffering_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceInitialPublicOffering_220" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="loc_us-gaapDebtConversionConvertedInstrumentSharesIssued1_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapDebtConversionConvertedInstrumentSharesIssued1_220" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="loc_us-gaapConvertiblePreferredStockSharesIssuedUponConversion_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapConvertiblePreferredStockSharesIssuedUponConversion_220" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="loc_us-gaapConversionOfStockSharesConverted1_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapConversionOfStockSharesConverted1_220" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfUnits_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfUnits_220" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices_220" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConversionOfStockSharesIssued1" xlink:label="loc_us-gaapConversionOfStockSharesIssued1_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapConversionOfStockSharesIssued1_220" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaapClassOfWarrantOrRightOutstanding_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightOutstanding_220" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="loc_us-gaapWarrantsAndRightsOutstandingTerm_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstandingTerm_220" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaapSharesIssuedPricePerShare_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapSharesIssuedPricePerShare_220" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_NumberOfEquivalentOfWarrantsDescription" xlink:label="loc_NRXSNumberOfEquivalentOfWarrantsDescription_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_NRXSNumberOfEquivalentOfWarrantsDescription_220" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_ClassOfWarrantOrRightAdditional" xlink:label="loc_NRXSClassOfWarrantOrRightAdditional_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_NRXSClassOfWarrantOrRightAdditional_220" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_220" xlink:type="arc" order="18" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://neuraxis.com/role/PreferredStockDetailsNarrative" xlink:title="999071 - Disclosure - Preferred Stock (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaapClassOfStockLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaapScheduleOfStockByClassTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapScheduleOfStockByClassTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaapSeriesAPreferredStockMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesAPreferredStockMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_SeriesSeedPreferredStockMember" xlink:label="loc_NRXSSeriesSeedPreferredStockMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_NRXSSeriesSeedPreferredStockMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="loc_us-gaapSeriesBPreferredStockMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesBPreferredStockMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockMember" xlink:label="loc_us-gaapPreferredStockMember_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapPreferredStockMember_120" xlink:type="arc" order="121" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="loc_us-gaapShortTermDebtTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapShortTermDebtTypeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaapShortTermDebtTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapShortTermDebtTypeAxis" xlink:to="loc_us-gaapShortTermDebtTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaapShortTermDebtTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShortTermDebtTypeAxis" xlink:to="loc_us-gaapShortTermDebtTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_AmendedTwoThousandTwentyFourConvertibleNotesMember" xlink:label="loc_NRXSAmendedTwoThousandTwentyFourConvertibleNotesMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtTypeDomain" xlink:to="loc_NRXSAmendedTwoThousandTwentyFourConvertibleNotesMember_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPreferredStockSharesAuthorized_160" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaapPreferredStockSharesIssued_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPreferredStockSharesIssued_160" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaapPreferredStockSharesOutstanding_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPreferredStockSharesOutstanding_160" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockDividendRatePercentage" xlink:label="loc_us-gaapPreferredStockDividendRatePercentage_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPreferredStockDividendRatePercentage_160" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_PreferredStockSharesRetiredDescription" xlink:label="loc_NRXSPreferredStockSharesRetiredDescription_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_NRXSPreferredStockSharesRetiredDescription_160" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:label="loc_us-gaapTemporaryEquitySharesAuthorized_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapTemporaryEquitySharesAuthorized_160" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare_160" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaapDebtInstrumentFaceAmount_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapDebtInstrumentFaceAmount_160" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="loc_us-gaapConversionOfStockSharesConverted1_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapConversionOfStockSharesConverted1_160" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaapSharesIssuedPricePerShare_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapSharesIssuedPricePerShare_160" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_ProceedsFromIssuanceOfStock" xlink:label="loc_NRXSProceedsFromIssuanceOfStock_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_NRXSProceedsFromIssuanceOfStock_160" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfDebt" xlink:label="loc_us-gaapProceedsFromIssuanceOfDebt_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfDebt_160" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_CumulativeDividendsPercent" xlink:label="loc_NRXSCumulativeDividendsPercent_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_NRXSCumulativeDividendsPercent_160" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaapSharesIssued_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapSharesIssued_160" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DividendsPayableCurrentAndNoncurrent" xlink:label="loc_us-gaapDividendsPayableCurrentAndNoncurrent_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapDividendsPayableCurrentAndNoncurrent_160" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DividendsPreferredStock" xlink:label="loc_us-gaapDividendsPreferredStock_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapDividendsPreferredStock_160" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockDividendRatePerDollarAmount" xlink:label="loc_us-gaapPreferredStockDividendRatePerDollarAmount_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPreferredStockDividendRatePerDollarAmount_160" xlink:type="arc" order="16" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://neuraxis.com/role/ScheduleOfOption-pricingModelWithFollowingWeighted-averageAssumptionsDetails" xlink:title="999072 - Disclosure - Schedule of Option-pricing Model with Following Weighted-average Assumptions (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapPlanNameAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_TwentySeventeenStockCompensationPlanMember" xlink:label="loc_NRXSTwentySeventeenStockCompensationPlanMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_NRXSTwentySeventeenStockCompensationPlanMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_30" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaapSharePrice_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharePrice_30" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_30" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_30" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_30" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_30" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_30" xlink:type="arc" order="6" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://neuraxis.com/role/ScheduleOfStockOptionActivityDetails" xlink:title="999073 - Disclosure - Schedule of Stock Option Activity (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://neuraxis.com/role/Stock-basedCompensationDetailsNarrative" xlink:title="999074 - Disclosure - Stock-Based Compensation (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapPlanNameAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_TwentySeventeenStockCompensationPlanMember" xlink:label="loc_NRXSTwentySeventeenStockCompensationPlanMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_NRXSTwentySeventeenStockCompensationPlanMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_srtTitleOfIndividualAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ChiefFinancialOfficerMember" xlink:label="loc_srtChiefFinancialOfficerMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_srtChiefFinancialOfficerMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapCommonStockSharesAuthorized_70" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaapSharesIssued_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharesIssued_70" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensation_70" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_70" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaapSharePrice_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharePrice_70" xlink:type="arc" order="4" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://neuraxis.com/role/ScheduleOfChangesInWarrantLiabilitiesDetails" xlink:title="999075 - Disclosure - Schedule of Changes in Warrant Liabilities (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_PlatformOperatorCryptoAssetLineItems" xlink:label="loc_srtPlatformOperatorCryptoAssetLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_PlatformOperatorCryptoAssetTable" xlink:label="loc_srtPlatformOperatorCryptoAssetTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_srtPlatformOperatorCryptoAssetLineItems" xlink:to="loc_srtPlatformOperatorCryptoAssetTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_srtPlatformOperatorCryptoAssetTable" xlink:to="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaapFairValueInputsLevel1Member_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel1Member_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaapFairValueInputsLevel2Member_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel2Member_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaapFairValueInputsLevel3Member_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel3Member_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="loc_us-gaapWarrantsAndRightsOutstanding_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtPlatformOperatorCryptoAssetLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstanding_160" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_AdditionToWarrantLiabilities" xlink:label="loc_NRXSAdditionToWarrantLiabilities_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtPlatformOperatorCryptoAssetLineItems" xlink:to="loc_NRXSAdditionToWarrantLiabilities_160" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_ReclassifiedToEquity" xlink:label="loc_NRXSReclassifiedToEquity_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtPlatformOperatorCryptoAssetLineItems" xlink:to="loc_NRXSReclassifiedToEquity_160" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaapFairValueAdjustmentOfWarrants_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtPlatformOperatorCryptoAssetLineItems" xlink:to="loc_us-gaapFairValueAdjustmentOfWarrants_160" xlink:type="arc" order="3" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://neuraxis.com/role/WarrantLiabilitiesDetailsNarrative" xlink:title="999076 - Disclosure - Warrant Liabilities (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="loc_us-gaapMeasurementInputTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="loc_us-gaapMeasurementInputTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaapMeasurementInputTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapMeasurementInputTypeAxis" xlink:to="loc_us-gaapMeasurementInputTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaapMeasurementInputTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapMeasurementInputTypeAxis" xlink:to="loc_us-gaapMeasurementInputTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputSharePriceMember" xlink:label="loc_us-gaapMeasurementInputSharePriceMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputSharePriceMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="loc_us-gaapMeasurementInputPriceVolatilityMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputPriceVolatilityMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="loc_us-gaapMeasurementInputRiskFreeInterestRateMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputRiskFreeInterestRateMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputExpectedDividendRateMember" xlink:label="loc_us-gaapMeasurementInputExpectedDividendRateMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputExpectedDividendRateMember_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember_10" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_20" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:label="loc_us-gaapWarrantsAndRightsOutstandingMeasurementInput_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstandingMeasurementInput_70" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://neuraxis.com/role/ScheduleOfChangesInDerivativeLiabilitiesDetails" xlink:title="999077 - Disclosure - Schedule of Changes in Derivative Liabilities (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_PlatformOperatorCryptoAssetLineItems" xlink:label="loc_srtPlatformOperatorCryptoAssetLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_PlatformOperatorCryptoAssetTable" xlink:label="loc_srtPlatformOperatorCryptoAssetTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_srtPlatformOperatorCryptoAssetLineItems" xlink:to="loc_srtPlatformOperatorCryptoAssetTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_srtPlatformOperatorCryptoAssetTable" xlink:to="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaapFairValueInputsLevel1Member_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel1Member_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaapFairValueInputsLevel2Member_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel2Member_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaapFairValueInputsLevel3Member_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel3Member_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_ChangesInDerivativeLiabilities" xlink:label="loc_NRXSChangesInDerivativeLiabilities_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtPlatformOperatorCryptoAssetLineItems" xlink:to="loc_NRXSChangesInDerivativeLiabilities_100" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_AdditionToDerivativeLiabilities" xlink:label="loc_NRXSAdditionToDerivativeLiabilities_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtPlatformOperatorCryptoAssetLineItems" xlink:to="loc_NRXSAdditionToDerivativeLiabilities_100" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInDerivativeLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInDerivativeLiabilities_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtPlatformOperatorCryptoAssetLineItems" xlink:to="loc_us-gaapIncreaseDecreaseInDerivativeLiabilities_100" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_ExtinguishmentOfDerivativeLiabilities" xlink:label="loc_NRXSExtinguishmentOfDerivativeLiabilities_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtPlatformOperatorCryptoAssetLineItems" xlink:to="loc_NRXSExtinguishmentOfDerivativeLiabilities_100" xlink:type="arc" order="3" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://neuraxis.com/role/DerivativeLiabilitiesDetailsNarrative" xlink:title="999078 - Disclosure - Derivative Liabilities (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="loc_us-gaapMeasurementInputTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="loc_us-gaapMeasurementInputTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaapMeasurementInputTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapMeasurementInputTypeAxis" xlink:to="loc_us-gaapMeasurementInputTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaapMeasurementInputTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapMeasurementInputTypeAxis" xlink:to="loc_us-gaapMeasurementInputTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputSharePriceMember" xlink:label="loc_us-gaapMeasurementInputSharePriceMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputSharePriceMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="loc_us-gaapMeasurementInputPriceVolatilityMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputPriceVolatilityMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="loc_us-gaapMeasurementInputRiskFreeInterestRateMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputRiskFreeInterestRateMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputExpectedDividendRateMember" xlink:label="loc_us-gaapMeasurementInputExpectedDividendRateMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputExpectedDividendRateMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember_20" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_30" xlink:type="arc" order="32" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeLiabilityMeasurementInput" xlink:label="loc_us-gaapDerivativeLiabilityMeasurementInput_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="loc_us-gaapDerivativeLiabilityMeasurementInput_60" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://neuraxis.com/role/RetirementPlanDetailsNarrative" xlink:title="999079 - Disclosure - Retirement Plan (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://neuraxis.com/role/ScheduleOfReconcilesCompanysNetSalesAndOperatingLossDetails" xlink:title="999080 - Disclosure - Schedule of Reconciles the Company&#8217;s Net Sales and Operating Loss (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingInformationLineItems" xlink:label="loc_us-gaapSegmentReportingInformationLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:label="loc_us-gaapScheduleOfSegmentReportingInformationBySegmentTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_us-gaapScheduleOfSegmentReportingInformationBySegmentTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidationItemsAxis" xlink:label="loc_srtConsolidationItemsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="loc_srtConsolidationItemsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidationItemsDomain" xlink:label="loc_srtConsolidationItemsDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtConsolidationItemsAxis" xlink:to="loc_srtConsolidationItemsDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidationItemsDomain" xlink:label="loc_srtConsolidationItemsDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtConsolidationItemsAxis" xlink:to="loc_srtConsolidationItemsDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingSegmentsMember" xlink:label="loc_us-gaapOperatingSegmentsMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtConsolidationItemsDomain" xlink:to="loc_us-gaapOperatingSegmentsMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax_30" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="loc_us-gaapCostOfGoodsAndServicesSold_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_us-gaapCostOfGoodsAndServicesSold_30" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GrossProfit" xlink:label="loc_us-gaapGrossProfit_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_us-gaapGrossProfit_30" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingExpense" xlink:label="loc_us-gaapSellingExpense_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_us-gaapSellingExpense_30" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_us-gaapResearchAndDevelopmentExpense_30" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LaborAndRelatedExpense" xlink:label="loc_us-gaapLaborAndRelatedExpense_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_us-gaapLaborAndRelatedExpense_30" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfessionalAndContractServicesExpense" xlink:label="loc_us-gaapProfessionalAndContractServicesExpense_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_us-gaapProfessionalAndContractServicesExpense_30" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCostAndExpenseOperating" xlink:label="loc_us-gaapOtherCostAndExpenseOperating_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_us-gaapOtherCostAndExpenseOperating_30" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_us-gaapOperatingIncomeLoss_30" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaapNonoperatingIncomeExpenseAbstract_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_us-gaapNonoperatingIncomeExpenseAbstract_30" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_FinancingCharges" xlink:label="loc_NRXSFinancingCharges_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract_30" xlink:to="loc_NRXSFinancingCharges_30" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaapInterestExpense_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract_30" xlink:to="loc_us-gaapInterestExpense_30" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaapFairValueAdjustmentOfWarrants_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract_30" xlink:to="loc_us-gaapFairValueAdjustmentOfWarrants_30" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeGainLossOnDerivativeNet" xlink:label="loc_us-gaapDerivativeGainLossOnDerivativeNet_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract_30" xlink:to="loc_us-gaapDerivativeGainLossOnDerivativeNet_30" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="loc_us-gaapAmortizationOfFinancingCostsAndDiscounts_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract_30" xlink:to="loc_us-gaapAmortizationOfFinancingCostsAndDiscounts_30" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaapGainsLossesOnExtinguishmentOfDebt_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract_30" xlink:to="loc_us-gaapGainsLossesOnExtinguishmentOfDebt_30" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncome" xlink:label="loc_us-gaapOtherNonoperatingIncome_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract_30" xlink:to="loc_us-gaapOtherNonoperatingIncome_30" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingExpense" xlink:label="loc_us-gaapOtherNonoperatingExpense_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract_30" xlink:to="loc_us-gaapOtherNonoperatingExpense_30" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaapOtherNonoperatingIncomeExpense_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract_30" xlink:to="loc_us-gaapOtherNonoperatingIncomeExpense_30" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_us-gaapNetIncomeLoss_30" xlink:type="arc" order="19" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://neuraxis.com/role/SegmentInformationDetailsNarrative" xlink:title="999081 - Disclosure - Segment Information (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://neuraxis.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="999082 - Disclosure - Commitments and Contingencies (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_AdvisoryAgreementMember" xlink:label="loc_NRXSAdvisoryAgreementMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_NRXSAdvisoryAgreementMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_SettlementAgreementMember" xlink:label="loc_NRXSSettlementAgreementMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_NRXSSettlementAgreementMember_40" xlink:type="arc" order="42" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_ExecutiveEmploymentAgreementsMember" xlink:label="loc_NRXSExecutiveEmploymentAgreementsMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_NRXSExecutiveEmploymentAgreementsMember_80" xlink:type="arc" order="82" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaapSubsidiarySaleOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrivatePlacementMember" xlink:label="loc_us-gaapPrivatePlacementMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_us-gaapPrivatePlacementMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IPOMember" xlink:label="loc_us-gaapIPOMember_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_us-gaapIPOMember_170" xlink:type="arc" order="172" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_10" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementScenarioAxis" xlink:label="loc_srtStatementScenarioAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtStatementScenarioAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srtScenarioUnspecifiedDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtStatementScenarioAxis" xlink:to="loc_srtScenarioUnspecifiedDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srtScenarioUnspecifiedDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtStatementScenarioAxis" xlink:to="loc_srtScenarioUnspecifiedDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioForecastMember" xlink:label="loc_srtScenarioForecastMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtScenarioUnspecifiedDomain" xlink:to="loc_srtScenarioForecastMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaapSeriesAPreferredStockMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesAPreferredStockMember_40" xlink:type="arc" order="43" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember_80" xlink:type="arc" order="81" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_90" xlink:type="arc" order="91" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtTitleOfIndividualAxis" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ChiefOperatingOfficerMember" xlink:label="loc_srtChiefOperatingOfficerMember_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_srtChiefOperatingOfficerMember_180" xlink:type="arc" order="181" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="loc_us-gaapSaleOfStockConsiderationReceivedOnTransaction_250" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSaleOfStockConsiderationReceivedOnTransaction_250" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaapSaleOfStockPricePerShare_250" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSaleOfStockPricePerShare_250" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:label="loc_us-gaapIssuanceOfStockAndWarrantsForServicesOrClaims_250" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapIssuanceOfStockAndWarrantsForServicesOrClaims_250" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_250" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_250" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_FinanceCharges" xlink:label="loc_NRXSFinanceCharges_250" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_NRXSFinanceCharges_250" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherExpenses" xlink:label="loc_us-gaapOtherExpenses_250" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOtherExpenses_250" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_ExecutiveEmploymentAgreementsTerms" xlink:label="loc_NRXSExecutiveEmploymentAgreementsTerms_250" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_NRXSExecutiveEmploymentAgreementsTerms_250" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_DescriptionOfExecutiveEmploymentAgreementsRenewals" xlink:label="loc_NRXSDescriptionOfExecutiveEmploymentAgreementsRenewals_250" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_NRXSDescriptionOfExecutiveEmploymentAgreementsRenewals_250" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SalariesAndWages" xlink:label="loc_us-gaapSalariesAndWages_250" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSalariesAndWages_250" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncentiveFeeExpense" xlink:label="loc_us-gaapIncentiveFeeExpense_250" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapIncentiveFeeExpense_250" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrent_250" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAccruedLiabilitiesCurrent_250" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan_250" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan_250" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_SpecialBonusPercentage" xlink:label="loc_NRXSSpecialBonusPercentage_250" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_NRXSSpecialBonusPercentage_250" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_KeyEmployeeExercisePercentage" xlink:label="loc_NRXSKeyEmployeeExercisePercentage_250" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_NRXSKeyEmployeeExercisePercentage_250" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedBonusesCurrent" xlink:label="loc_us-gaapAccruedBonusesCurrent_250" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAccruedBonusesCurrent_250" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_250" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_250" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireEquitySecuritiesFvNi" xlink:label="loc_us-gaapPaymentsToAcquireEquitySecuritiesFvNi_250" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPaymentsToAcquireEquitySecuritiesFvNi_250" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_250" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_250" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesFairValueDisclosure" xlink:label="loc_us-gaapAccruedLiabilitiesFairValueDisclosure_250" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAccruedLiabilitiesFairValueDisclosure_250" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingencyDamagesSoughtValue" xlink:label="loc_us-gaapLossContingencyDamagesSoughtValue_250" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLossContingencyDamagesSoughtValue_250" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedPatentsGross" xlink:label="loc_us-gaapFiniteLivedPatentsGross_250" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapFiniteLivedPatentsGross_250" xlink:type="arc" order="20" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://neuraxis.com/role/HealthBenefitPlanDetailsNarrative" xlink:title="999083 - Disclosure - Health Benefit Plan (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://neuraxis.com/role/ScheduleOfIncomeTaxProvisionDetails" xlink:title="999084 - Disclosure - Schedule of Income Tax Provision (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://neuraxis.com/role/ScheduleOfFederalStatutoryIncomeTaxRateAndEffectiveIncomeTaxRateDetails" xlink:title="999085 - Disclosure - Schedule of Federal Statutory Income Tax Rate and Effective Income Tax Rate (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://neuraxis.com/role/ScheduleOfNetDeferredTaxAssetsAndLiabilitiesDetails" xlink:title="999086 - Disclosure - Schedule of Net Deferred Tax Assets and Liabilities (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://neuraxis.com/role/ScheduleOfStateCarryforwardsDetails" xlink:title="999087 - Disclosure - Schedule of State Carryforwards (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="loc_us-gaapOperatingLossCarryforwardsLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="loc_us-gaapOperatingLossCarryforwardsTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapOperatingLossCarryforwardsTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxPeriodAxis" xlink:label="loc_us-gaapTaxPeriodAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapOperatingLossCarryforwardsTable" xlink:to="loc_us-gaapTaxPeriodAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxPeriodDomain" xlink:label="loc_us-gaapTaxPeriodDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTaxPeriodAxis" xlink:to="loc_us-gaapTaxPeriodDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxPeriodDomain" xlink:label="loc_us-gaapTaxPeriodDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTaxPeriodAxis" xlink:to="loc_us-gaapTaxPeriodDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_TaxYear2037Member" xlink:label="loc_NRXSTaxYear2037Member_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapTaxPeriodDomain" xlink:to="loc_NRXSTaxYear2037Member_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_TaxYear2038Member" xlink:label="loc_NRXSTaxYear2038Member_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapTaxPeriodDomain" xlink:to="loc_NRXSTaxYear2038Member_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_TaxYear2039Member" xlink:label="loc_NRXSTaxYear2039Member_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapTaxPeriodDomain" xlink:to="loc_NRXSTaxYear2039Member_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_TaxYear2040Member" xlink:label="loc_NRXSTaxYear2040Member_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapTaxPeriodDomain" xlink:to="loc_NRXSTaxYear2040Member_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_TaxYear2041Member" xlink:label="loc_NRXSTaxYear2041Member_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapTaxPeriodDomain" xlink:to="loc_NRXSTaxYear2041Member_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_TaxYearThereafterMember" xlink:label="loc_NRXSTaxYearThereafterMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapTaxPeriodDomain" xlink:to="loc_NRXSTaxYearThereafterMember_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_NoExpirationMember" xlink:label="loc_NRXSNoExpirationMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapTaxPeriodDomain" xlink:to="loc_NRXSNoExpirationMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:label="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_90" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://neuraxis.com/role/IncomeTaxesDetailsNarrative" xlink:title="999088 - Disclosure - Income Taxes (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaapIncomeTaxAuthorityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationTable" xlink:to="loc_us-gaapIncomeTaxAuthorityAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaapIncomeTaxAuthorityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapIncomeTaxAuthorityAxis" xlink:to="loc_us-gaapIncomeTaxAuthorityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaapIncomeTaxAuthorityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapIncomeTaxAuthorityAxis" xlink:to="loc_us-gaapIncomeTaxAuthorityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DomesticCountryMember" xlink:label="loc_us-gaapDomesticCountryMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeTaxAuthorityDomain" xlink:to="loc_us-gaapDomesticCountryMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:label="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" xlink:to="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_30" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationOtherAdjustments_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationOtherAdjustments_30" xlink:type="arc" order="1" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://neuraxis.com/role/SubsequentEventsDetailsNarrative" xlink:title="999089 - Disclosure - Subsequent Events (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaapSubsequentEventLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaapSubsequentEventTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapSubsequentEventTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapWarrantMember_30" xlink:type="arc" order="32" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_40" xlink:type="arc" order="42" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardGross_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardGross_60" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_60" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_60" xlink:type="arc" order="2" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/PvpExecutiveCategoriesOnly" />
    <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/PvpAdjustmentsOnly" />
    <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/IndividualsOnly" />
    <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/AwardTypeOnly">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_DecemberTwoThousandTwentyFiveMember" xlink:label="loc_NRXSDecemberTwoThousandTwentyFiveMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_NRXSDecemberTwoThousandTwentyFiveMember" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_DecemberTwoThousandTwentySixMember" xlink:label="loc_NRXSDecemberTwoThousandTwentySixMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_NRXSDecemberTwoThousandTwentySixMember" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_DecemberTwoThousandTwentySevenMember" xlink:label="loc_NRXSDecemberTwoThousandTwentySevenMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_NRXSDecemberTwoThousandTwentySevenMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_DecemberTwoThousandTwentyEightMember" xlink:label="loc_NRXSDecemberTwoThousandTwentyEightMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_NRXSDecemberTwoThousandTwentyEightMember" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_DecemberTwoThousandTwentyNineMember" xlink:label="loc_NRXSDecemberTwoThousandTwentyNineMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_NRXSDecemberTwoThousandTwentyNineMember" xlink:type="arc" order="40" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_DecemberTwoThousandTwentyThereafterMember" xlink:label="loc_NRXSDecemberTwoThousandTwentyThereafterMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_NRXSDecemberTwoThousandTwentyThereafterMember" xlink:type="arc" order="50" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/TradingArrangementsOnly" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>27
<FILENAME>nrxs-20241231_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.25b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xml:lang="en-US">Class of Stock [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_ConvertibleSeriesBPreferredStockMember" xlink:label="NRXS_ConvertibleSeriesBPreferredStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_ConvertibleSeriesBPreferredStockMember" xlink:to="NRXS_ConvertibleSeriesBPreferredStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NRXS_ConvertibleSeriesBPreferredStockMember_lbl" xml:lang="en-US">Convertible Series B Preferred Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US">Equity Components [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockMember" xlink:label="us-gaap_PreferredStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockMember" xlink:to="us-gaap_PreferredStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockMember_lbl" xml:lang="en-US">Preferred Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_ConvertibleSeriesAPreferredStockMember" xlink:label="NRXS_ConvertibleSeriesAPreferredStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_ConvertibleSeriesAPreferredStockMember" xlink:to="NRXS_ConvertibleSeriesAPreferredStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NRXS_ConvertibleSeriesAPreferredStockMember_lbl" xml:lang="en-US">Convertible Series A Preferred stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_ConvertibleSeriesSeedPreferredStockMember" xlink:label="NRXS_ConvertibleSeriesSeedPreferredStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_ConvertibleSeriesSeedPreferredStockMember" xlink:to="NRXS_ConvertibleSeriesSeedPreferredStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NRXS_ConvertibleSeriesSeedPreferredStockMember_lbl" xml:lang="en-US">Convertible Series Seed Preferred Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US">Common Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US">Retained Earnings [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="srt_ConsolidatedEntitiesAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ConsolidatedEntitiesAxis" xlink:to="srt_ConsolidatedEntitiesAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ConsolidatedEntitiesAxis_lbl" xml:lang="en-US">Consolidated Entities [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_AlexanderCapitalLPMember" xlink:label="NRXS_AlexanderCapitalLPMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_AlexanderCapitalLPMember" xlink:to="NRXS_AlexanderCapitalLPMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NRXS_AlexanderCapitalLPMember_lbl" xml:lang="en-US">Alexander Capital LP [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xml:lang="en-US">Sale of Stock [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IPOMember" xlink:to="us-gaap_IPOMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IPOMember_lbl" xml:lang="en-US">IPO [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="us-gaap_SeriesBPreferredStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesBPreferredStockMember" xlink:to="us-gaap_SeriesBPreferredStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SeriesBPreferredStockMember_lbl" xml:lang="en-US">Series B Preferred Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xml:lang="en-US">Indefinite-Lived Intangible Assets [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TrademarksMember" xlink:label="us-gaap_TrademarksMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TrademarksMember" xlink:to="us-gaap_TrademarksMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TrademarksMember_lbl" xml:lang="en-US">Trademarks [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_LicensingAgreementMember" xlink:label="NRXS_LicensingAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_LicensingAgreementMember" xlink:to="NRXS_LicensingAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NRXS_LicensingAgreementMember_lbl" xml:lang="en-US">Licensing Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xml:lang="en-US">Statement of Income Location, Balance [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MachineryAndEquipmentMember" xlink:label="us-gaap_MachineryAndEquipmentMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MachineryAndEquipmentMember" xlink:to="us-gaap_MachineryAndEquipmentMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MachineryAndEquipmentMember_lbl" xml:lang="en-US">Machinery and Equipment [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeAxis_lbl" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MinimumMember_lbl" xml:lang="en-US">Minimum [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MaximumMember_lbl" xml:lang="en-US">Maximum [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FurnitureAndFixturesMember" xlink:to="us-gaap_FurnitureAndFixturesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xml:lang="en-US">Furniture and Fixtures [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComputerEquipmentMember" xlink:to="us-gaap_ComputerEquipmentMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComputerEquipmentMember_lbl" xml:lang="en-US">Computer Equipment [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsMember" xlink:to="us-gaap_LeaseholdImprovementsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xml:lang="en-US">Leasehold Improvements [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsRecurringMember" xlink:to="us-gaap_FairValueMeasurementsRecurringMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xml:lang="en-US">Fair Value, Recurring [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_FinancialInstrumentAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinancialInstrumentAxis_lbl" xml:lang="en-US">Financial Instrument [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantMember_lbl" xml:lang="en-US">Warrant [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel2Member" xlink:to="us-gaap_FairValueInputsLevel2Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel3Member" xlink:to="us-gaap_FairValueInputsLevel3Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OptionMember" xlink:label="us-gaap_OptionMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OptionMember" xlink:to="us-gaap_OptionMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OptionMember_lbl" xml:lang="en-US">Options Held [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_WarrantsMember" xlink:label="NRXS_WarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_WarrantsMember" xlink:to="NRXS_WarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NRXS_WarrantsMember_lbl" xml:lang="en-US">Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_StatementGeographicalAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_StatementGeographicalAxis_lbl" xml:lang="en-US">Geographical [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd#stpr_CA" xlink:label="stpr_CA" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="stpr_CA" xlink:to="stpr_CA_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="stpr_CA_lbl" xml:lang="en-US">CALIFORNIA</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd#stpr_OH" xlink:label="stpr_OH" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="stpr_OH" xlink:to="stpr_OH_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="stpr_OH_lbl" xml:lang="en-US">OHIO</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd#stpr_IL" xlink:label="stpr_IL" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="stpr_IL" xlink:to="stpr_IL_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="stpr_IL_lbl" xml:lang="en-US">ILLINOIS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd#stpr_WI" xlink:label="stpr_WI" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="stpr_WI" xlink:to="stpr_WI_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="stpr_WI_lbl" xml:lang="en-US">WISCONSIN</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd#stpr_MA" xlink:label="stpr_MA" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="stpr_MA" xlink:to="stpr_MA_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="stpr_MA_lbl" xml:lang="en-US">MASSACHUSETTS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd#stpr_FL" xlink:label="stpr_FL" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="stpr_FL" xlink:to="stpr_FL_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="stpr_FL_lbl" xml:lang="en-US">FLORIDA</link:label>
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_AllOtherStatesMember" xlink:label="NRXS_AllOtherStatesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_AllOtherStatesMember" xlink:to="NRXS_AllOtherStatesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NRXS_AllOtherStatesMember_lbl" xml:lang="en-US">All other States [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MajorCustomersAxis" xlink:label="srt_MajorCustomersAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MajorCustomersAxis" xlink:to="srt_MajorCustomersAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MajorCustomersAxis_lbl" xml:lang="en-US">Customer [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_CustomerAMember" xlink:label="NRXS_CustomerAMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_CustomerAMember" xlink:to="NRXS_CustomerAMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NRXS_CustomerAMember_lbl" xml:lang="en-US">Customer A [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis_lbl" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableMember" xlink:label="us-gaap_AccountsReceivableMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableMember" xlink:to="us-gaap_AccountsReceivableMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsReceivableMember_lbl" xml:lang="en-US">Accounts Receivable [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="us-gaap_ConcentrationRiskByTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskByTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskByTypeAxis_lbl" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="us-gaap_CustomerConcentrationRiskMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CustomerConcentrationRiskMember" xlink:to="us-gaap_CustomerConcentrationRiskMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CustomerConcentrationRiskMember_lbl" xml:lang="en-US">Customer Concentration Risk [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_CustomerBMember" xlink:label="NRXS_CustomerBMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_CustomerBMember" xlink:to="NRXS_CustomerBMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NRXS_CustomerBMember_lbl" xml:lang="en-US">Customer B [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_CustomerCMember" xlink:label="NRXS_CustomerCMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_CustomerCMember" xlink:to="NRXS_CustomerCMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NRXS_CustomerCMember_lbl" xml:lang="en-US">Customer C [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_CustomerDMember" xlink:label="NRXS_CustomerDMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_CustomerDMember" xlink:to="NRXS_CustomerDMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NRXS_CustomerDMember_lbl" xml:lang="en-US">Customer D [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_CustomerEMember" xlink:label="NRXS_CustomerEMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_CustomerEMember" xlink:to="NRXS_CustomerEMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NRXS_CustomerEMember_lbl" xml:lang="en-US">Customer E [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_CustomerMember" xlink:label="NRXS_CustomerMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_CustomerMember" xlink:to="NRXS_CustomerMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NRXS_CustomerMember_lbl" xml:lang="en-US">Customer [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SalesRevenueNetMember" xlink:label="us-gaap_SalesRevenueNetMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SalesRevenueNetMember" xlink:to="us-gaap_SalesRevenueNetMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SalesRevenueNetMember_lbl" xml:lang="en-US">Revenue Benchmark [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xml:lang="en-US">Related and Nonrelated Parties [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_ShareholdersOneAndTwoMember" xlink:label="NRXS_ShareholdersOneAndTwoMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_ShareholdersOneAndTwoMember" xlink:to="NRXS_ShareholdersOneAndTwoMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NRXS_ShareholdersOneAndTwoMember_lbl" xml:lang="en-US">Shareholders 1 and 2 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyMember" xlink:label="us-gaap_RelatedPartyMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyMember" xlink:to="us-gaap_RelatedPartyMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyMember_lbl" xml:lang="en-US">Related Party [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_MrWatkinsMember" xlink:label="NRXS_MrWatkinsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_MrWatkinsMember" xlink:to="NRXS_MrWatkinsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NRXS_MrWatkinsMember_lbl" xml:lang="en-US">Mr. Watkins [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_MrSealeMember" xlink:label="NRXS_MrSealeMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_MrSealeMember" xlink:to="NRXS_MrSealeMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NRXS_MrSealeMember_lbl" xml:lang="en-US">Mr Seale [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_TitleOfIndividualAxis_lbl" xml:lang="en-US">Title and Position [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ChiefFinancialOfficerMember" xlink:label="srt_ChiefFinancialOfficerMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ChiefFinancialOfficerMember" xlink:to="srt_ChiefFinancialOfficerMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ChiefFinancialOfficerMember_lbl" xml:lang="en-US">Chief Financial Officer [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_ShareHolderOneMember" xlink:label="NRXS_ShareHolderOneMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_ShareHolderOneMember" xlink:to="NRXS_ShareHolderOneMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NRXS_ShareHolderOneMember_lbl" xml:lang="en-US">Shareholder 1 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_ShareHolderTwoMember" xlink:label="NRXS_ShareHolderTwoMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_ShareHolderTwoMember" xlink:to="NRXS_ShareHolderTwoMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NRXS_ShareHolderTwoMember_lbl" xml:lang="en-US">Shareholder 2 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentAxis_lbl" xml:lang="en-US">Debt Instrument [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_OtherConvertiblesMember" xlink:label="NRXS_OtherConvertiblesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_OtherConvertiblesMember" xlink:to="NRXS_OtherConvertiblesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NRXS_OtherConvertiblesMember_lbl" xml:lang="en-US">Other Convertibles [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AwardTypeAxis_lbl" xml:lang="en-US">Award Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_DecemberTwoThousandTwentyFiveMember" xlink:label="NRXS_DecemberTwoThousandTwentyFiveMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_DecemberTwoThousandTwentyFiveMember" xlink:to="NRXS_DecemberTwoThousandTwentyFiveMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NRXS_DecemberTwoThousandTwentyFiveMember_lbl" xml:lang="en-US">December Two Thousand Twenty Five [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_DecemberTwoThousandTwentySixMember" xlink:label="NRXS_DecemberTwoThousandTwentySixMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_DecemberTwoThousandTwentySixMember" xlink:to="NRXS_DecemberTwoThousandTwentySixMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NRXS_DecemberTwoThousandTwentySixMember_lbl" xml:lang="en-US">December Two Thousand Twenty Six [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_DecemberTwoThousandTwentySevenMember" xlink:label="NRXS_DecemberTwoThousandTwentySevenMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_DecemberTwoThousandTwentySevenMember" xlink:to="NRXS_DecemberTwoThousandTwentySevenMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NRXS_DecemberTwoThousandTwentySevenMember_lbl" xml:lang="en-US">December Two Thousand Twenty Seven [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_DecemberTwoThousandTwentyEightMember" xlink:label="NRXS_DecemberTwoThousandTwentyEightMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_DecemberTwoThousandTwentyEightMember" xlink:to="NRXS_DecemberTwoThousandTwentyEightMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NRXS_DecemberTwoThousandTwentyEightMember_lbl" xml:lang="en-US">December Two Thousand Twenty Eight [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_DecemberTwoThousandTwentyNineMember" xlink:label="NRXS_DecemberTwoThousandTwentyNineMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_DecemberTwoThousandTwentyNineMember" xlink:to="NRXS_DecemberTwoThousandTwentyNineMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NRXS_DecemberTwoThousandTwentyNineMember_lbl" xml:lang="en-US">December Two Thousand Twenty Nine [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_DecemberTwoThousandTwentyThereafterMember" xlink:label="NRXS_DecemberTwoThousandTwentyThereafterMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_DecemberTwoThousandTwentyThereafterMember" xlink:to="NRXS_DecemberTwoThousandTwentyThereafterMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NRXS_DecemberTwoThousandTwentyThereafterMember_lbl" xml:lang="en-US">December Two Thousand Twenty Thereafter [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_SoftwareImplementationMember" xlink:label="NRXS_SoftwareImplementationMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_SoftwareImplementationMember" xlink:to="NRXS_SoftwareImplementationMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NRXS_SoftwareImplementationMember_lbl" xml:lang="en-US">Software Implementation [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PatentsMember" xlink:label="us-gaap_PatentsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PatentsMember" xlink:to="us-gaap_PatentsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PatentsMember_lbl" xml:lang="en-US">Patents [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_LicensesMember" xlink:label="NRXS_LicensesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_LicensesMember" xlink:to="NRXS_LicensesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NRXS_LicensesMember_lbl" xml:lang="en-US">Licenses [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LegalEntityAxis" xlink:to="dei_LegalEntityAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LegalEntityAxis_lbl" xml:lang="en-US">Legal Entity [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_ChannelPartnersCapitalMember" xlink:label="NRXS_ChannelPartnersCapitalMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_ChannelPartnersCapitalMember" xlink:to="NRXS_ChannelPartnersCapitalMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NRXS_ChannelPartnersCapitalMember_lbl" xml:lang="en-US">Channel Partners Capital [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_ExchangeListingLLCMember" xlink:label="NRXS_ExchangeListingLLCMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_ExchangeListingLLCMember" xlink:to="NRXS_ExchangeListingLLCMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NRXS_ExchangeListingLLCMember_lbl" xml:lang="en-US">Exchange Listing LLC [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_PromissoryNoteMember" xlink:label="NRXS_PromissoryNoteMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_PromissoryNoteMember" xlink:to="NRXS_PromissoryNoteMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NRXS_PromissoryNoteMember_lbl" xml:lang="en-US">Promissory Note [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_SecondPromissoryNoteMember" xlink:label="NRXS_SecondPromissoryNoteMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_SecondPromissoryNoteMember" xlink:to="NRXS_SecondPromissoryNoteMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NRXS_SecondPromissoryNoteMember_lbl" xml:lang="en-US">Second Promissory Note [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_TwoThousandTwentyTwoConvertibleNotesMember" xlink:label="NRXS_TwoThousandTwentyTwoConvertibleNotesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_TwoThousandTwentyTwoConvertibleNotesMember" xlink:to="NRXS_TwoThousandTwentyTwoConvertibleNotesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NRXS_TwoThousandTwentyTwoConvertibleNotesMember_lbl" xml:lang="en-US">2022 Convertible Notes [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_ConvertiblePromissoryNoteMember" xlink:label="NRXS_ConvertiblePromissoryNoteMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_ConvertiblePromissoryNoteMember" xlink:to="NRXS_ConvertiblePromissoryNoteMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NRXS_ConvertiblePromissoryNoteMember_lbl" xml:lang="en-US">Convertible Promissory Note [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_AccreditedInvestorsMember" xlink:label="NRXS_AccreditedInvestorsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_AccreditedInvestorsMember" xlink:to="NRXS_AccreditedInvestorsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NRXS_AccreditedInvestorsMember_lbl" xml:lang="en-US">Accredited Investors [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_TwoThousandTwentyThreeConvertibleNotesMember" xlink:label="NRXS_TwoThousandTwentyThreeConvertibleNotesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_TwoThousandTwentyThreeConvertibleNotesMember" xlink:to="NRXS_TwoThousandTwentyThreeConvertibleNotesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NRXS_TwoThousandTwentyThreeConvertibleNotesMember_lbl" xml:lang="en-US">2023 Convertible Notes [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_SignatureBankMember" xlink:label="NRXS_SignatureBankMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_SignatureBankMember" xlink:to="NRXS_SignatureBankMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NRXS_SignatureBankMember_lbl" xml:lang="en-US">Signature Bank [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_ConvertiblePromissoryNotesMember" xlink:label="NRXS_ConvertiblePromissoryNotesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_ConvertiblePromissoryNotesMember" xlink:to="NRXS_ConvertiblePromissoryNotesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NRXS_ConvertiblePromissoryNotesMember_lbl" xml:lang="en-US">Convertible Promissory Notes [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_TwoThousandTwentyFourConvertiblePromissoryNotesMember" xlink:label="NRXS_TwoThousandTwentyFourConvertiblePromissoryNotesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_TwoThousandTwentyFourConvertiblePromissoryNotesMember" xlink:to="NRXS_TwoThousandTwentyFourConvertiblePromissoryNotesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NRXS_TwoThousandTwentyFourConvertiblePromissoryNotesMember_lbl" xml:lang="en-US">2024 Convertible Promissory Notes [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_TwoThousandTwentyFourConvertibleNotesMember" xlink:label="NRXS_TwoThousandTwentyFourConvertibleNotesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_TwoThousandTwentyFourConvertibleNotesMember" xlink:to="NRXS_TwoThousandTwentyFourConvertibleNotesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NRXS_TwoThousandTwentyFourConvertibleNotesMember_lbl" xml:lang="en-US">2024 Convertible Notes [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeographicDistributionAxis" xlink:label="us-gaap_GeographicDistributionAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeographicDistributionAxis" xlink:to="us-gaap_GeographicDistributionAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeographicDistributionAxis_lbl" xml:lang="en-US">Geographic Distribution [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_VersaillesIndianaMember" xlink:label="NRXS_VersaillesIndianaMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_VersaillesIndianaMember" xlink:to="NRXS_VersaillesIndianaMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NRXS_VersaillesIndianaMember_lbl" xml:lang="en-US">Versailles Indiana [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_CarmelIndianaMember" xlink:label="NRXS_CarmelIndianaMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_CarmelIndianaMember" xlink:to="NRXS_CarmelIndianaMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NRXS_CarmelIndianaMember_lbl" xml:lang="en-US">Carmel Indiana [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_VendorsMember" xlink:label="NRXS_VendorsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_VendorsMember" xlink:to="NRXS_VendorsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NRXS_VendorsMember_lbl" xml:lang="en-US">Vendors [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_EmployementAgreementMember" xlink:label="NRXS_EmployementAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_EmployementAgreementMember" xlink:to="NRXS_EmployementAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NRXS_EmployementAgreementMember_lbl" xml:lang="en-US">Employement Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_TwoThousandTwentyThreeConvertiblePromissoryNotesMember" xlink:label="NRXS_TwoThousandTwentyThreeConvertiblePromissoryNotesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_TwoThousandTwentyThreeConvertiblePromissoryNotesMember" xlink:to="NRXS_TwoThousandTwentyThreeConvertiblePromissoryNotesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NRXS_TwoThousandTwentyThreeConvertiblePromissoryNotesMember_lbl" xml:lang="en-US">2023 Convertible Promissory Notes [Membe]</link:label>
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_AdvisoryAgreementMember" xlink:label="NRXS_AdvisoryAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_AdvisoryAgreementMember" xlink:to="NRXS_AdvisoryAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NRXS_AdvisoryAgreementMember_lbl" xml:lang="en-US">Advisory Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_UnderwritingAgreementMember" xlink:label="NRXS_UnderwritingAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_UnderwritingAgreementMember" xlink:to="NRXS_UnderwritingAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NRXS_UnderwritingAgreementMember_lbl" xml:lang="en-US">Underwriting Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_AdvisoryAgreementsMember" xlink:label="NRXS_AdvisoryAgreementsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_AdvisoryAgreementsMember" xlink:to="NRXS_AdvisoryAgreementsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NRXS_AdvisoryAgreementsMember_lbl" xml:lang="en-US">Advisory Agreements [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_lbl" xml:lang="en-US">Class of Warrant or Right [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_InvestorWarrantOneMember" xlink:label="NRXS_InvestorWarrantOneMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_InvestorWarrantOneMember" xlink:to="NRXS_InvestorWarrantOneMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NRXS_InvestorWarrantOneMember_lbl" xml:lang="en-US">Investor Warrant W-01 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_InvestorWarrantPSAOneMember" xlink:label="NRXS_InvestorWarrantPSAOneMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_InvestorWarrantPSAOneMember" xlink:to="NRXS_InvestorWarrantPSAOneMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NRXS_InvestorWarrantPSAOneMember_lbl" xml:lang="en-US">Investor Warrant PSA-01 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_UnderwriterWarrantsMember" xlink:label="NRXS_UnderwriterWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_UnderwriterWarrantsMember" xlink:to="NRXS_UnderwriterWarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NRXS_UnderwriterWarrantsMember_lbl" xml:lang="en-US">Underwriter Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_AdvisoryAgreementWarrantsMember" xlink:label="NRXS_AdvisoryAgreementWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_AdvisoryAgreementWarrantsMember" xlink:to="NRXS_AdvisoryAgreementWarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NRXS_AdvisoryAgreementWarrantsMember_lbl" xml:lang="en-US">Advisory Agreement Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="us-gaap_SeriesAPreferredStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesAPreferredStockMember" xlink:to="us-gaap_SeriesAPreferredStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SeriesAPreferredStockMember_lbl" xml:lang="en-US">Series A Preferred Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_SeriesSeedPreferredStockMember" xlink:label="NRXS_SeriesSeedPreferredStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_SeriesSeedPreferredStockMember" xlink:to="NRXS_SeriesSeedPreferredStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NRXS_SeriesSeedPreferredStockMember_lbl" xml:lang="en-US">Series Seed Preferred Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="us-gaap_ShortTermDebtTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ShortTermDebtTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermDebtTypeAxis_lbl" xml:lang="en-US">Short-Term Debt, Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_AmendedTwoThousandTwentyFourConvertibleNotesMember" xlink:label="NRXS_AmendedTwoThousandTwentyFourConvertibleNotesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_AmendedTwoThousandTwentyFourConvertibleNotesMember" xlink:to="NRXS_AmendedTwoThousandTwentyFourConvertibleNotesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NRXS_AmendedTwoThousandTwentyFourConvertibleNotesMember_lbl" xml:lang="en-US">Amended 2024 Convertible Notes [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameAxis_lbl" xml:lang="en-US">Plan Name [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_TwentySeventeenStockCompensationPlanMember" xlink:label="NRXS_TwentySeventeenStockCompensationPlanMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_TwentySeventeenStockCompensationPlanMember" xlink:to="NRXS_TwentySeventeenStockCompensationPlanMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NRXS_TwentySeventeenStockCompensationPlanMember_lbl" xml:lang="en-US">2017 Stock Compensation Plan [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputTypeAxis_lbl" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputSharePriceMember" xlink:label="us-gaap_MeasurementInputSharePriceMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputSharePriceMember" xlink:to="us-gaap_MeasurementInputSharePriceMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputSharePriceMember_lbl" xml:lang="en-US">Measurement Input, Share Price [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputPriceVolatilityMember" xlink:to="us-gaap_MeasurementInputPriceVolatilityMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember_lbl" xml:lang="en-US">Measurement Input, Price Volatility [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:to="us-gaap_MeasurementInputRiskFreeInterestRateMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember_lbl" xml:lang="en-US">Measurement Input, Risk Free Interest Rate [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputExpectedDividendRateMember" xlink:label="us-gaap_MeasurementInputExpectedDividendRateMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputExpectedDividendRateMember" xlink:to="us-gaap_MeasurementInputExpectedDividendRateMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputExpectedDividendRateMember_lbl" xml:lang="en-US">Measurement Input, Expected Dividend Rate [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidationItemsAxis" xlink:label="srt_ConsolidationItemsAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ConsolidationItemsAxis" xlink:to="srt_ConsolidationItemsAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ConsolidationItemsAxis_lbl" xml:lang="en-US">Consolidation Items [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingSegmentsMember" xlink:label="us-gaap_OperatingSegmentsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingSegmentsMember" xlink:to="us-gaap_OperatingSegmentsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingSegmentsMember_lbl" xml:lang="en-US">Operating Segments [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrivatePlacementMember" xlink:to="us-gaap_PrivatePlacementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrivatePlacementMember_lbl" xml:lang="en-US">Private Placement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_StatementScenarioAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_StatementScenarioAxis_lbl" xml:lang="en-US">Scenario [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioForecastMember" xlink:label="srt_ScenarioForecastMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScenarioForecastMember" xlink:to="srt_ScenarioForecastMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ScenarioForecastMember_lbl" xml:lang="en-US">Forecast [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_SettlementAgreementMember" xlink:label="NRXS_SettlementAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_SettlementAgreementMember" xlink:to="NRXS_SettlementAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NRXS_SettlementAgreementMember_lbl" xml:lang="en-US">Settlement Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_ExecutiveEmploymentAgreementsMember" xlink:label="NRXS_ExecutiveEmploymentAgreementsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_ExecutiveEmploymentAgreementsMember" xlink:to="NRXS_ExecutiveEmploymentAgreementsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NRXS_ExecutiveEmploymentAgreementsMember_lbl" xml:lang="en-US">Executive Employment Agreements [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ChiefOperatingOfficerMember" xlink:label="srt_ChiefOperatingOfficerMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ChiefOperatingOfficerMember" xlink:to="srt_ChiefOperatingOfficerMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ChiefOperatingOfficerMember_lbl" xml:lang="en-US">Chief Operating Officer [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xml:lang="en-US">Income Tax Jurisdiction [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DomesticCountryMember" xlink:to="us-gaap_DomesticCountryMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DomesticCountryMember_lbl" xml:lang="en-US">Domestic Tax Jurisdiction [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxPeriodAxis" xlink:label="us-gaap_TaxPeriodAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxPeriodAxis" xlink:to="us-gaap_TaxPeriodAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TaxPeriodAxis_lbl" xml:lang="en-US">Tax Period [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_TaxYear2037Member" xlink:label="NRXS_TaxYear2037Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_TaxYear2037Member" xlink:to="NRXS_TaxYear2037Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NRXS_TaxYear2037Member_lbl" xml:lang="en-US">Tax Year 2037 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_TaxYear2038Member" xlink:label="NRXS_TaxYear2038Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_TaxYear2038Member" xlink:to="NRXS_TaxYear2038Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NRXS_TaxYear2038Member_lbl" xml:lang="en-US">Tax Year 2038 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_TaxYear2039Member" xlink:label="NRXS_TaxYear2039Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_TaxYear2039Member" xlink:to="NRXS_TaxYear2039Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NRXS_TaxYear2039Member_lbl" xml:lang="en-US">Tax Year 2039 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_TaxYear2040Member" xlink:label="NRXS_TaxYear2040Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_TaxYear2040Member" xlink:to="NRXS_TaxYear2040Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NRXS_TaxYear2040Member_lbl" xml:lang="en-US">Tax Year 2040 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_TaxYear2041Member" xlink:label="NRXS_TaxYear2041Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_TaxYear2041Member" xlink:to="NRXS_TaxYear2041Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NRXS_TaxYear2041Member_lbl" xml:lang="en-US">Tax Year 2041 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_TaxYearThereafterMember" xlink:label="NRXS_TaxYearThereafterMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_TaxYearThereafterMember" xlink:to="NRXS_TaxYearThereafterMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NRXS_TaxYearThereafterMember_lbl" xml:lang="en-US">Tax Year Thereafter [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_NoExpirationMember" xlink:label="NRXS_NoExpirationMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_NoExpirationMember" xlink:to="NRXS_NoExpirationMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NRXS_NoExpirationMember_lbl" xml:lang="en-US">No Expiration [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventMember_lbl" xml:lang="en-US">Subsequent Event [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_IcfrAuditorAttestationFlag" xlink:to="dei_IcfrAuditorAttestationFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_IcfrAuditorAttestationFlag_lbl" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFinStmtErrorCorrectionFlag" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFinStmtErrorCorrectionFlag" xlink:to="dei_DocumentFinStmtErrorCorrectionFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag_lbl" xml:lang="en-US">Document Financial Statement Error Correction [Flag]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityListingParValuePerShare" xlink:label="dei_EntityListingParValuePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityListingParValuePerShare" xlink:to="dei_EntityListingParValuePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityListingParValuePerShare_lbl" xml:lang="en-US">Entity Listing, Par Value Per Share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorFirmId" xlink:to="dei_AuditorFirmId_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorFirmId_lbl" xml:lang="en-US">Auditor Firm ID</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorOpinionTextBlock" xlink:label="dei_AuditorOpinionTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorOpinionTextBlock" xlink:to="dei_AuditorOpinionTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorOpinionTextBlock_lbl" xml:lang="en-US">Auditor Opinion [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorName" xlink:label="dei_AuditorName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorName" xlink:to="dei_AuditorName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorName_lbl" xml:lang="en-US">Auditor Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorLocation" xlink:to="dei_AuditorLocation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorLocation_lbl" xml:lang="en-US">Auditor Location</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">Current Assets:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash and cash equivalents</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNetCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xml:lang="en-US">Accounts receivable, net of credit losses of $5,000 and $11,993 as of December 31, 2024 and 2023, respectively</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryNet_lbl" xml:lang="en-US">Inventories, net of reserves of $4,454 and $0 as of December 31, 2024 and 2023, respectively</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US">Prepaids and other current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">Total current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xml:lang="en-US">Property and Equipment, at cost:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xml:lang="en-US">Less - accumulated depreciation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US">Property and equipment, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrentAbstract" xlink:label="us-gaap_OtherAssetsNoncurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrentAbstract" xlink:to="us-gaap_OtherAssetsNoncurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAssetsNoncurrentAbstract_lbl" xml:lang="en-US">Other Assets:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US">Operating lease right of use asset, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xml:lang="en-US">Intangible assets, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SecurityDeposit" xlink:label="us-gaap_SecurityDeposit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SecurityDeposit" xlink:to="us-gaap_SecurityDeposit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SecurityDeposit_lbl" xml:lang="en-US">Security deposit</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">Total Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US">Liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Current Liabilities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US">Accounts payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Accrued expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NotesPayableToBankCurrent" xlink:label="us-gaap_NotesPayableToBankCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesPayableToBankCurrent" xlink:to="us-gaap_NotesPayableToBankCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NotesPayableToBankCurrent_lbl" xml:lang="en-US">Notes payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US">Current portion of operating lease payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Deposits" xlink:label="us-gaap_Deposits" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Deposits" xlink:to="us-gaap_Deposits_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Deposits_lbl" xml:lang="en-US">Customer deposits</link:label>
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_WarrantLiabilities" xlink:label="NRXS_WarrantLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_WarrantLiabilities" xlink:to="NRXS_WarrantLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NRXS_WarrantLiabilities_lbl" xml:lang="en-US">Warrant liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">Total current liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_LiabilitiesNoncurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract_lbl" xml:lang="en-US">Non-current Liabilities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xml:lang="en-US">Operating lease payable, net of current portion</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="us-gaap_LiabilitiesNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrent" xlink:to="us-gaap_LiabilitiesNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesNoncurrent_lbl" xml:lang="en-US">Total non-current liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US">Total liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US">Commitments and contingencies (see note 16)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US">Stockholders&#8217; Equity (Deficit)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US">Convertible Series B Preferred stock, $0.01 par value; 5,000,000 and 0 shares authorized, 4,280,939 and 0 shares issued and outstanding as of December 31, 2024 and 2023, respectively</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US">Common stock, $0.001 par value; 100,000,000 shares authorized; 6,990,227 and 6,508,897 issued and outstanding as of December 31, 2024 and 2023, respectively</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US">Additional paid in capital</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US">Accumulated deficit</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Total stockholders&#8217; equity (deficit)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">Total Liabilities and Stockholders&#8217; Equity (Deficit)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US">Statement [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Statement [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:to="us-gaap_AllowanceForDoubtfulAccountsReceivable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivable_lbl" xml:lang="en-US">Accounts receivable, net of credit losses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryRawMaterialsNetOfReserves" xlink:label="us-gaap_InventoryRawMaterialsNetOfReserves" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryRawMaterialsNetOfReserves" xlink:to="us-gaap_InventoryRawMaterialsNetOfReserves_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryRawMaterialsNetOfReserves_lbl" xml:lang="en-US">Inventories, net of reserves</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Preferred stock, par value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US">Preferred stock, shares authorized</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US">Preferred stock, shares issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US">Preferred stock, shares outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Common stock, par value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Common stock, shares authorized</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US">Common stock, shares issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US">Common stock, shares outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US">Income Statement [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xml:lang="en-US">Net sales</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="us-gaap_CostOfGoodsAndServicesSold" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfGoodsAndServicesSold" xlink:to="us-gaap_CostOfGoodsAndServicesSold_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostOfGoodsAndServicesSold_lbl" xml:lang="en-US">Cost of goods sold</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GrossProfit" xlink:label="us-gaap_GrossProfit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GrossProfit" xlink:to="us-gaap_GrossProfit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_GrossProfit_lbl" xml:lang="en-US">Gross profit</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingExpense" xlink:label="us-gaap_SellingExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingExpense" xlink:to="us-gaap_SellingExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SellingExpense_lbl" xml:lang="en-US">Selling expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research and development</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US">General and administrative</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">Operating loss</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xml:lang="en-US">Other (expense) income:</link:label>
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_FinancingCharges" xlink:label="NRXS_FinancingCharges" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_FinancingCharges" xlink:to="NRXS_FinancingCharges_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="NRXS_FinancingCharges_lbl" xml:lang="en-US">Financing charges</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpense" xlink:to="us-gaap_InterestExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_InterestExpense_lbl" xml:lang="en-US">Interest expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAdjustmentOfWarrants" xlink:to="us-gaap_FairValueAdjustmentOfWarrants_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_lbl" xml:lang="en-US">Change in fair value of warrant liability</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeGainLossOnDerivativeNet" xlink:label="us-gaap_DerivativeGainLossOnDerivativeNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeGainLossOnDerivativeNet" xlink:to="us-gaap_DerivativeGainLossOnDerivativeNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeGainLossOnDerivativeNet_lbl" xml:lang="en-US">Change in fair value of derivative liability</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:to="us-gaap_AmortizationOfFinancingCostsAndDiscounts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts_lbl" xml:lang="en-US">Amortization of debt discount and issuance cost</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl" xml:lang="en-US">Extinguishment of debt liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncome" xlink:label="us-gaap_OtherNonoperatingIncome" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncome" xlink:to="us-gaap_OtherNonoperatingIncome_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNonoperatingIncome_lbl" xml:lang="en-US">Other income</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingExpense" xlink:label="us-gaap_OtherNonoperatingExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingExpense" xlink:to="us-gaap_OtherNonoperatingExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_OtherNonoperatingExpense_lbl" xml:lang="en-US">Other expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xml:lang="en-US">Total other (expense) income, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net loss</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockDividendsAndOtherAdjustments" xlink:label="us-gaap_PreferredStockDividendsAndOtherAdjustments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockDividendsAndOtherAdjustments" xlink:to="us-gaap_PreferredStockDividendsAndOtherAdjustments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PreferredStockDividendsAndOtherAdjustments_lbl" xml:lang="en-US">Preferred stock dividends</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xml:lang="en-US">Net loss available to common stockholders</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xml:lang="en-US">Per-share data</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US">Basic loss per share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US">Diluted loss per share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl" xml:lang="en-US">Weighted average shares outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US">Basic</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US">Diluted</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquity_2_lbl" xml:lang="en-US">Balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US">Balance, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_StockIssuedDuringPeriodValueCommonStockIssuedUponInitialPublicOffering" xlink:label="NRXS_StockIssuedDuringPeriodValueCommonStockIssuedUponInitialPublicOffering" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_StockIssuedDuringPeriodValueCommonStockIssuedUponInitialPublicOffering" xlink:to="NRXS_StockIssuedDuringPeriodValueCommonStockIssuedUponInitialPublicOffering_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NRXS_StockIssuedDuringPeriodValueCommonStockIssuedUponInitialPublicOffering_lbl" xml:lang="en-US">Common stock issued upon initial public offering</link:label>
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_StockIssuedDuringPeriodSharesCommonStockIssuedUponInitialPublicOffering" xlink:label="NRXS_StockIssuedDuringPeriodSharesCommonStockIssuedUponInitialPublicOffering" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_StockIssuedDuringPeriodSharesCommonStockIssuedUponInitialPublicOffering" xlink:to="NRXS_StockIssuedDuringPeriodSharesCommonStockIssuedUponInitialPublicOffering_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NRXS_StockIssuedDuringPeriodSharesCommonStockIssuedUponInitialPublicOffering_lbl" xml:lang="en-US">Common stock issued upon initial public offering, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xml:lang="en-US">Common stock issued upon preferred stock conversion</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xml:lang="en-US">Common stock issued upon preferred stock conversion, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfUnits" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfUnits" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueConversionOfUnits" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfUnits_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfUnits_lbl" xml:lang="en-US">Common stock issued upon debt conversion</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits_lbl" xml:lang="en-US">Common stock issued upon debt conversion, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US">Common stock issued from agreements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US">Common stock issued from agreements, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_lbl" xml:lang="en-US">Additional paid in capital from warrants issued under advisory agreement</link:label>
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_StockIssuedDuringPeriodValueWarrantsExercised" xlink:label="NRXS_StockIssuedDuringPeriodValueWarrantsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_StockIssuedDuringPeriodValueWarrantsExercised" xlink:to="NRXS_StockIssuedDuringPeriodValueWarrantsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NRXS_StockIssuedDuringPeriodValueWarrantsExercised_lbl" xml:lang="en-US">Warrants exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:label="NRXS_StockIssuedDuringPeriodSharesWarrantsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:to="NRXS_StockIssuedDuringPeriodSharesWarrantsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NRXS_StockIssuedDuringPeriodSharesWarrantsExercised_lbl" xml:lang="en-US">Warrants exercised, shares</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_2_lbl" xml:lang="en-US">Net loss</link:label>
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_AdditionalPaidInCapitalFromWarrantsIssuedAsDebtDiscount" xlink:label="NRXS_AdditionalPaidInCapitalFromWarrantsIssuedAsDebtDiscount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_AdditionalPaidInCapitalFromWarrantsIssuedAsDebtDiscount" xlink:to="NRXS_AdditionalPaidInCapitalFromWarrantsIssuedAsDebtDiscount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NRXS_AdditionalPaidInCapitalFromWarrantsIssuedAsDebtDiscount_lbl" xml:lang="en-US">Additional paid in capital from warrants issued as debt discount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature_lbl" xml:lang="en-US">Debt discount on mandatory conversion of convertible promissory notes to Series B Preferred Stock</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueOther" xlink:to="us-gaap_StockIssuedDuringPeriodValueOther_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther_lbl" xml:lang="en-US">Conversion of convertible promissory notes to Series B Preferred Stock</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:to="us-gaap_StockIssuedDuringPeriodSharesOther_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther_lbl" xml:lang="en-US">Conversion of convertible promissory notes to Series B Preferred Stock, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_StockIssuedDuringPeriodValuePreferredStock" xlink:label="NRXS_StockIssuedDuringPeriodValuePreferredStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_StockIssuedDuringPeriodValuePreferredStock" xlink:to="NRXS_StockIssuedDuringPeriodValuePreferredStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NRXS_StockIssuedDuringPeriodValuePreferredStock_lbl" xml:lang="en-US">Issuance of Series B Preferred Stock</link:label>
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_StockIssuedDuringPeriodSharesPreferredStock" xlink:label="NRXS_StockIssuedDuringPeriodSharesPreferredStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_StockIssuedDuringPeriodSharesPreferredStock" xlink:to="NRXS_StockIssuedDuringPeriodSharesPreferredStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NRXS_StockIssuedDuringPeriodSharesPreferredStock_lbl" xml:lang="en-US">Issuance of Series B Preferred Stock, shares</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquity_3_lbl" xml:lang="en-US">Balance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharesOutstanding_2_lbl" xml:lang="en-US">Balance, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Cash Flows from Operating Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetIncomeLoss_3_lbl" xml:lang="en-US">Net Loss</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments to reconcile net loss to net cash used by operating activities:</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:to="us-gaap_AmortizationOfFinancingCostsAndDiscounts_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts_2_lbl" xml:lang="en-US">Amortization of debt discount and issuance cost</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationDepletionAndAmortization" xlink:to="us-gaap_DepreciationDepletionAndAmortization_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xml:lang="en-US">Depreciation and amortization</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProvisionForDoubtfulAccounts" xlink:label="us-gaap_ProvisionForDoubtfulAccounts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProvisionForDoubtfulAccounts" xlink:to="us-gaap_ProvisionForDoubtfulAccounts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProvisionForDoubtfulAccounts_lbl" xml:lang="en-US">Provisions for losses on accounts receivable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryWriteDown" xlink:label="us-gaap_InventoryWriteDown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryWriteDown" xlink:to="us-gaap_InventoryWriteDown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryWriteDown_lbl" xml:lang="en-US">Provision for losses on inventory</link:label>
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_NoncashLeaseExpense" xlink:label="NRXS_NoncashLeaseExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_NoncashLeaseExpense" xlink:to="NRXS_NoncashLeaseExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NRXS_NoncashLeaseExpense_lbl" xml:lang="en-US">Non-cash lease expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaidInKindInterest" xlink:label="us-gaap_PaidInKindInterest" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaidInKindInterest" xlink:to="us-gaap_PaidInKindInterest_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaidInKindInterest_lbl" xml:lang="en-US">Non-cash interest expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US">Stock based compensation</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_2_lbl" xml:lang="en-US">Extinguishment of debt liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_IssuanceOfCommonStockForNoncashConsideration" xlink:label="NRXS_IssuanceOfCommonStockForNoncashConsideration" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_IssuanceOfCommonStockForNoncashConsideration" xlink:to="NRXS_IssuanceOfCommonStockForNoncashConsideration_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NRXS_IssuanceOfCommonStockForNoncashConsideration_lbl" xml:lang="en-US">Issuance of common stock for non-cash consideration</link:label>
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_IssuanceOfWarrantsForNoncashConsideration" xlink:label="NRXS_IssuanceOfWarrantsForNoncashConsideration" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_IssuanceOfWarrantsForNoncashConsideration" xlink:to="NRXS_IssuanceOfWarrantsForNoncashConsideration_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NRXS_IssuanceOfWarrantsForNoncashConsideration_lbl" xml:lang="en-US">Fair value of warrants issued for non-cash consideration</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_FinancingCharges" xlink:to="NRXS_FinancingCharges_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NRXS_FinancingCharges_2_lbl" xml:lang="en-US">Finance charges</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeGainLossOnDerivativeNet" xlink:to="us-gaap_DerivativeGainLossOnDerivativeNet_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DerivativeGainLossOnDerivativeNet_2_lbl" xml:lang="en-US">Change in fair value of derivative liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAdjustmentOfWarrants" xlink:to="us-gaap_FairValueAdjustmentOfWarrants_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_2_lbl" xml:lang="en-US">Change in fair value of warrant liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xml:lang="en-US">Accounts receivable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="us-gaap_IncreaseDecreaseInInventories" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInInventories" xlink:to="us-gaap_IncreaseDecreaseInInventories_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInInventories_lbl" xml:lang="en-US">Inventory</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xml:lang="en-US">Prepaids and other current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xml:lang="en-US">Accounts payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xml:lang="en-US">Accrued expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_IncreaseDecreaseInCustomerDeposit" xlink:label="NRXS_IncreaseDecreaseInCustomerDeposit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_IncreaseDecreaseInCustomerDeposit" xlink:to="NRXS_IncreaseDecreaseInCustomerDeposit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="NRXS_IncreaseDecreaseInCustomerDeposit_lbl" xml:lang="en-US">Customer deposits</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl" xml:lang="en-US">Operating lease liability</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Net cash used by operating activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US">Cash Flows from Investing Activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US">Additions to property and equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireIntangibleAssets" xlink:to="us-gaap_PaymentsToAcquireIntangibleAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets_lbl" xml:lang="en-US">Additions to intangible assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US">Net cash used by investing activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US">Cash Flows from Financing Activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US">Proceeds from issuance of common stock, net of issuance costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:to="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_lbl" xml:lang="en-US">Proceeds from issuance of Series B preferred stock</link:label>
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_DeferredOfferingCostsPaid" xlink:label="NRXS_DeferredOfferingCostsPaid" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_DeferredOfferingCostsPaid" xlink:to="NRXS_DeferredOfferingCostsPaid_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="NRXS_DeferredOfferingCostsPaid_lbl" xml:lang="en-US">Deferred offering costs paid</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfWarrants" xlink:to="us-gaap_ProceedsFromIssuanceOfWarrants_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants_lbl" xml:lang="en-US">Proceeds from exercised warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfNotesPayable" xlink:label="us-gaap_RepaymentsOfNotesPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfNotesPayable" xlink:to="us-gaap_RepaymentsOfNotesPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_RepaymentsOfNotesPayable_lbl" xml:lang="en-US">Principal payments on notes payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromNotesPayable" xlink:label="us-gaap_ProceedsFromNotesPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromNotesPayable" xlink:to="us-gaap_ProceedsFromNotesPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromNotesPayable_lbl" xml:lang="en-US">Proceeds from notes payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="us-gaap_ProceedsFromConvertibleDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromConvertibleDebt" xlink:to="us-gaap_ProceedsFromConvertibleDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromConvertibleDebt_lbl" xml:lang="en-US">Proceeds from convertible notes</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfFinancingCosts" xlink:label="us-gaap_PaymentsOfFinancingCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfFinancingCosts" xlink:to="us-gaap_PaymentsOfFinancingCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsOfFinancingCosts_lbl" xml:lang="en-US">Financing fees paid</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Net cash provided by financing activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xml:lang="en-US">Net Increase (Decrease) in Cash and Cash Equivalents</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xml:lang="en-US">Cash and Cash Equivalents at Beginning of Period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_2_lbl" xml:lang="en-US">Cash and Cash Equivalents at End of Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US">Supplemental Disclosure of Non-Cash Operating Activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaidNet" xlink:to="us-gaap_InterestPaidNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPaidNet_lbl" xml:lang="en-US">Cash paid for interest</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxesPaidNet" xlink:label="us-gaap_IncomeTaxesPaidNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxesPaidNet" xlink:to="us-gaap_IncomeTaxesPaidNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxesPaidNet_lbl" xml:lang="en-US">Cash received for income taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xml:lang="en-US">Supplemental Schedule of Non-Cash Investing and Financing Activities</link:label>
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_RecognitionOfRightOfUseAsset" xlink:label="NRXS_RecognitionOfRightOfUseAsset" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_RecognitionOfRightOfUseAsset" xlink:to="NRXS_RecognitionOfRightOfUseAsset_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NRXS_RecognitionOfRightOfUseAsset_lbl" xml:lang="en-US">Recognition of right of use asset</link:label>
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_ConversionOfConvertiblePromissoryNotesToSeriesBPreferredStock" xlink:label="NRXS_ConversionOfConvertiblePromissoryNotesToSeriesBPreferredStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_ConversionOfConvertiblePromissoryNotesToSeriesBPreferredStock" xlink:to="NRXS_ConversionOfConvertiblePromissoryNotesToSeriesBPreferredStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NRXS_ConversionOfConvertiblePromissoryNotesToSeriesBPreferredStock_lbl" xml:lang="en-US">Conversion of convertible promissory notes to Series B preferred stock</link:label>
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_FairValueOfWarrantsFromDebtDiscountInConvertibleNotesClassifiedOfAdditionalPaidInCapital" xlink:label="NRXS_FairValueOfWarrantsFromDebtDiscountInConvertibleNotesClassifiedOfAdditionalPaidInCapital" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_FairValueOfWarrantsFromDebtDiscountInConvertibleNotesClassifiedOfAdditionalPaidInCapital" xlink:to="NRXS_FairValueOfWarrantsFromDebtDiscountInConvertibleNotesClassifiedOfAdditionalPaidInCapital_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NRXS_FairValueOfWarrantsFromDebtDiscountInConvertibleNotesClassifiedOfAdditionalPaidInCapital_lbl" xml:lang="en-US">Fair value of warrants from debt discount in convertible notes classified as additional paid in capital</link:label>
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_WriteoffOfDebtDiscountOnConvertibleNotesClassifiedAsAdditionalPaidInCapital" xlink:label="NRXS_WriteoffOfDebtDiscountOnConvertibleNotesClassifiedAsAdditionalPaidInCapital" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_WriteoffOfDebtDiscountOnConvertibleNotesClassifiedAsAdditionalPaidInCapital" xlink:to="NRXS_WriteoffOfDebtDiscountOnConvertibleNotesClassifiedAsAdditionalPaidInCapital_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NRXS_WriteoffOfDebtDiscountOnConvertibleNotesClassifiedAsAdditionalPaidInCapital_lbl" xml:lang="en-US">Write-off of debt discount on convertible notes classified as additional paid in capital</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NotesIssued1" xlink:label="us-gaap_NotesIssued1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesIssued1" xlink:to="us-gaap_NotesIssued1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NotesIssued1_lbl" xml:lang="en-US">Issuance of note payable to financing company for insurance premiums</link:label>
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_FairValueOfWarrantLiabilitiesOfWarrantsFromConvertibleNotes" xlink:label="NRXS_FairValueOfWarrantLiabilitiesOfWarrantsFromConvertibleNotes" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_FairValueOfWarrantLiabilitiesOfWarrantsFromConvertibleNotes" xlink:to="NRXS_FairValueOfWarrantLiabilitiesOfWarrantsFromConvertibleNotes_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NRXS_FairValueOfWarrantLiabilitiesOfWarrantsFromConvertibleNotes_lbl" xml:lang="en-US">Fair value of warrant liabilities of warrants from convertible notes</link:label>
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_FairValueOfDerivativeLiabilitiesOfConversionFeatureFromConvertibleNotes" xlink:label="NRXS_FairValueOfDerivativeLiabilitiesOfConversionFeatureFromConvertibleNotes" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_FairValueOfDerivativeLiabilitiesOfConversionFeatureFromConvertibleNotes" xlink:to="NRXS_FairValueOfDerivativeLiabilitiesOfConversionFeatureFromConvertibleNotes_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NRXS_FairValueOfDerivativeLiabilitiesOfConversionFeatureFromConvertibleNotes_lbl" xml:lang="en-US">Fair value of derivative liabilities of conversion feature from convertible notes</link:label>
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_ReclassificationOfWarrantLiabilityToEquity" xlink:label="NRXS_ReclassificationOfWarrantLiabilityToEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_ReclassificationOfWarrantLiabilityToEquity" xlink:to="NRXS_ReclassificationOfWarrantLiabilityToEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NRXS_ReclassificationOfWarrantLiabilityToEquity_lbl" xml:lang="en-US">Reclassification of warrant liability to equity</link:label>
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_ConversionOfPreferredStockToCommonStock" xlink:label="NRXS_ConversionOfPreferredStockToCommonStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_ConversionOfPreferredStockToCommonStock" xlink:to="NRXS_ConversionOfPreferredStockToCommonStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NRXS_ConversionOfPreferredStockToCommonStock_lbl" xml:lang="en-US">Conversion of preferred stock to common stock</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PvpTable" xlink:label="ecd_PvpTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PvpTable" xlink:to="ecd_PvpTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PvpTable_lbl" xml:lang="en-US">Pay vs Performance Disclosure [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ExecutiveCategoryAxis" xlink:label="ecd_ExecutiveCategoryAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ExecutiveCategoryAxis" xlink:to="ecd_ExecutiveCategoryAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ExecutiveCategoryAxis_lbl" xml:lang="en-US">Executive Category [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_IndividualAxis" xlink:label="ecd_IndividualAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_IndividualAxis" xlink:to="ecd_IndividualAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_IndividualAxis_lbl" xml:lang="en-US">Individual [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToCompAxis" xlink:label="ecd_AdjToCompAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AdjToCompAxis" xlink:to="ecd_AdjToCompAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AdjToCompAxis_lbl" xml:lang="en-US">Adjustment to Compensation [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MeasureAxis" xlink:label="ecd_MeasureAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_MeasureAxis" xlink:to="ecd_MeasureAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_MeasureAxis_lbl" xml:lang="en-US">Measure [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PvpTableTextBlock" xlink:label="ecd_PvpTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PvpTableTextBlock" xlink:to="ecd_PvpTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PvpTableTextBlock_lbl" xml:lang="en-US">Pay vs Performance Disclosure, Table</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CoSelectedMeasureName" xlink:label="ecd_CoSelectedMeasureName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_CoSelectedMeasureName" xlink:to="ecd_CoSelectedMeasureName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_CoSelectedMeasureName_lbl" xml:lang="en-US">Company Selected Measure Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NamedExecutiveOfficersFnTextBlock" xlink:label="ecd_NamedExecutiveOfficersFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_NamedExecutiveOfficersFnTextBlock" xlink:to="ecd_NamedExecutiveOfficersFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_NamedExecutiveOfficersFnTextBlock_lbl" xml:lang="en-US">Named Executive Officers, Footnote</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeerGroupIssuersFnTextBlock" xlink:label="ecd_PeerGroupIssuersFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PeerGroupIssuersFnTextBlock" xlink:to="ecd_PeerGroupIssuersFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PeerGroupIssuersFnTextBlock_lbl" xml:lang="en-US">Peer Group Issuers, Footnote</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ChangedPeerGroupFnTextBlock" xlink:label="ecd_ChangedPeerGroupFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ChangedPeerGroupFnTextBlock" xlink:to="ecd_ChangedPeerGroupFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ChangedPeerGroupFnTextBlock_lbl" xml:lang="en-US">Changed Peer Group, Footnote</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoTotalCompAmt" xlink:label="ecd_PeoTotalCompAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PeoTotalCompAmt" xlink:to="ecd_PeoTotalCompAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PeoTotalCompAmt_lbl" xml:lang="en-US">PEO Total Compensation Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoActuallyPaidCompAmt" xlink:label="ecd_PeoActuallyPaidCompAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PeoActuallyPaidCompAmt" xlink:to="ecd_PeoActuallyPaidCompAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PeoActuallyPaidCompAmt_lbl" xml:lang="en-US">PEO Actually Paid Compensation Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToPeoCompFnTextBlock" xlink:label="ecd_AdjToPeoCompFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AdjToPeoCompFnTextBlock" xlink:to="ecd_AdjToPeoCompFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AdjToPeoCompFnTextBlock_lbl" xml:lang="en-US">Adjustment To PEO Compensation, Footnote</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonPeoNeoAvgTotalCompAmt" xlink:label="ecd_NonPeoNeoAvgTotalCompAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_NonPeoNeoAvgTotalCompAmt" xlink:to="ecd_NonPeoNeoAvgTotalCompAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_NonPeoNeoAvgTotalCompAmt_lbl" xml:lang="en-US">Non-PEO NEO Average Total Compensation Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:label="ecd_NonPeoNeoAvgCompActuallyPaidAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:to="ecd_NonPeoNeoAvgCompActuallyPaidAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_NonPeoNeoAvgCompActuallyPaidAmt_lbl" xml:lang="en-US">Non-PEO NEO Average Compensation Actually Paid Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:label="ecd_AdjToNonPeoNeoCompFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:to="ecd_AdjToNonPeoNeoCompFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AdjToNonPeoNeoCompFnTextBlock_lbl" xml:lang="en-US">Adjustment to Non-PEO NEO Compensation Footnote</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:label="ecd_EquityValuationAssumptionDifferenceFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:to="ecd_EquityValuationAssumptionDifferenceFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_EquityValuationAssumptionDifferenceFnTextBlock_lbl" xml:lang="en-US">Equity Valuation Assumption Difference, Footnote</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:label="ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:to="ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock_lbl" xml:lang="en-US">Compensation Actually Paid vs. Total Shareholder Return</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:label="ecd_CompActuallyPaidVsNetIncomeTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:to="ecd_CompActuallyPaidVsNetIncomeTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_CompActuallyPaidVsNetIncomeTextBlock_lbl" xml:lang="en-US">Compensation Actually Paid vs. Net Income</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:label="ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:to="ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock_lbl" xml:lang="en-US">Compensation Actually Paid vs. Company Selected Measure</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:label="ecd_TotalShareholderRtnVsPeerGroupTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:to="ecd_TotalShareholderRtnVsPeerGroupTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TotalShareholderRtnVsPeerGroupTextBlock_lbl" xml:lang="en-US">Total Shareholder Return Vs Peer Group</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:label="ecd_CompActuallyPaidVsOtherMeasureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:to="ecd_CompActuallyPaidVsOtherMeasureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_CompActuallyPaidVsOtherMeasureTextBlock_lbl" xml:lang="en-US">Compensation Actually Paid vs. Other Measure</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TabularListTableTextBlock" xlink:label="ecd_TabularListTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TabularListTableTextBlock" xlink:to="ecd_TabularListTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TabularListTableTextBlock_lbl" xml:lang="en-US">Tabular List, Table</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TotalShareholderRtnAmt" xlink:label="ecd_TotalShareholderRtnAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TotalShareholderRtnAmt" xlink:to="ecd_TotalShareholderRtnAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TotalShareholderRtnAmt_lbl" xml:lang="en-US">Total Shareholder Return Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeerGroupTotalShareholderRtnAmt" xlink:label="ecd_PeerGroupTotalShareholderRtnAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PeerGroupTotalShareholderRtnAmt" xlink:to="ecd_PeerGroupTotalShareholderRtnAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PeerGroupTotalShareholderRtnAmt_lbl" xml:lang="en-US">Peer Group Total Shareholder Return Amount</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetIncomeLoss_4_lbl" xml:lang="en-US">Net Income (Loss)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CoSelectedMeasureAmt" xlink:label="ecd_CoSelectedMeasureAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_CoSelectedMeasureAmt" xlink:to="ecd_CoSelectedMeasureAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_CoSelectedMeasureAmt_lbl" xml:lang="en-US">Company Selected Measure Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OtherPerfMeasureAmt" xlink:label="ecd_OtherPerfMeasureAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_OtherPerfMeasureAmt" xlink:to="ecd_OtherPerfMeasureAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_OtherPerfMeasureAmt_lbl" xml:lang="en-US">Other Performance Measure, Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToCompAmt" xlink:label="ecd_AdjToCompAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AdjToCompAmt" xlink:to="ecd_AdjToCompAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AdjToCompAmt_lbl" xml:lang="en-US">Adjustment to Compensation, Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoName" xlink:label="ecd_PeoName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PeoName" xlink:to="ecd_PeoName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PeoName_lbl" xml:lang="en-US">PEO Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MeasureName" xlink:label="ecd_MeasureName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_MeasureName" xlink:to="ecd_MeasureName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_MeasureName_lbl" xml:lang="en-US">Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonGaapMeasureDescriptionTextBlock" xlink:label="ecd_NonGaapMeasureDescriptionTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_NonGaapMeasureDescriptionTextBlock" xlink:to="ecd_NonGaapMeasureDescriptionTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_NonGaapMeasureDescriptionTextBlock_lbl" xml:lang="en-US">Non-GAAP Measure Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Additional402vDisclosureTextBlock" xlink:label="ecd_Additional402vDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_Additional402vDisclosureTextBlock" xlink:to="ecd_Additional402vDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_Additional402vDisclosureTextBlock_lbl" xml:lang="en-US">Additional 402(v) Disclosure</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PnsnBnftsAdjFnTextBlock" xlink:label="ecd_PnsnBnftsAdjFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PnsnBnftsAdjFnTextBlock" xlink:to="ecd_PnsnBnftsAdjFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PnsnBnftsAdjFnTextBlock_lbl" xml:lang="en-US">Pension Benefits Adjustments, Footnote</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ErrCompRecoveryTable" xlink:label="ecd_ErrCompRecoveryTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ErrCompRecoveryTable" xlink:to="ecd_ErrCompRecoveryTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ErrCompRecoveryTable_lbl" xml:lang="en-US">Erroneously Awarded Compensation Recovery [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDateAxis" xlink:label="ecd_RestatementDateAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_RestatementDateAxis" xlink:to="ecd_RestatementDateAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_RestatementDateAxis_lbl" xml:lang="en-US">Restatement Determination Date [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDeterminationDate" xlink:label="ecd_RestatementDeterminationDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_RestatementDeterminationDate" xlink:to="ecd_RestatementDeterminationDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_RestatementDeterminationDate_lbl" xml:lang="en-US">Restatement Determination Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtErrCompAmt" xlink:label="ecd_AggtErrCompAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AggtErrCompAmt" xlink:to="ecd_AggtErrCompAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AggtErrCompAmt_lbl" xml:lang="en-US">Aggregate Erroneous Compensation Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ErrCompAnalysisTextBlock" xlink:label="ecd_ErrCompAnalysisTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ErrCompAnalysisTextBlock" xlink:to="ecd_ErrCompAnalysisTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ErrCompAnalysisTextBlock_lbl" xml:lang="en-US">Erroneous Compensation Analysis</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:label="ecd_StkPrcOrTsrEstimationMethodTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:to="ecd_StkPrcOrTsrEstimationMethodTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_StkPrcOrTsrEstimationMethodTextBlock_lbl" xml:lang="en-US">Stock Price or TSR Estimation Method</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingAggtErrCompAmt" xlink:label="ecd_OutstandingAggtErrCompAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_OutstandingAggtErrCompAmt" xlink:to="ecd_OutstandingAggtErrCompAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_OutstandingAggtErrCompAmt_lbl" xml:lang="en-US">Outstanding Aggregate Erroneous Compensation Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:label="ecd_AggtErrCompNotYetDeterminedTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:to="ecd_AggtErrCompNotYetDeterminedTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AggtErrCompNotYetDeterminedTextBlock_lbl" xml:lang="en-US">Aggregate Erroneous Compensation Not Yet Determined</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryIndName" xlink:label="ecd_ForgoneRecoveryIndName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ForgoneRecoveryIndName" xlink:to="ecd_ForgoneRecoveryIndName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ecd_ForgoneRecoveryIndName_lbl" xml:lang="en-US">Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:label="ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:to="ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt_lbl" xml:lang="en-US">Forgone Recovery due to Expense of Enforcement, Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:label="ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:to="ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt_lbl" xml:lang="en-US">Forgone Recovery due to Violation of Home Country Law, Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:label="ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:to="ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt_lbl" xml:lang="en-US">Forgone Recovery due to Disqualification of Tax Benefits, Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:label="ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:to="ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock_lbl" xml:lang="en-US">Forgone Recovery, Explanation of Impracticability</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingRecoveryIndName" xlink:label="ecd_OutstandingRecoveryIndName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_OutstandingRecoveryIndName" xlink:to="ecd_OutstandingRecoveryIndName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ecd_OutstandingRecoveryIndName_lbl" xml:lang="en-US">Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingRecoveryCompAmt" xlink:label="ecd_OutstandingRecoveryCompAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_OutstandingRecoveryCompAmt" xlink:to="ecd_OutstandingRecoveryCompAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_OutstandingRecoveryCompAmt_lbl" xml:lang="en-US">Compensation Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:label="ecd_RestatementDoesNotRequireRecoveryTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:to="ecd_RestatementDoesNotRequireRecoveryTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_RestatementDoesNotRequireRecoveryTextBlock_lbl" xml:lang="en-US">Restatement does not require Recovery</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscTable" xlink:label="ecd_AwardsCloseToMnpiDiscTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardsCloseToMnpiDiscTable" xlink:to="ecd_AwardsCloseToMnpiDiscTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardsCloseToMnpiDiscTable_lbl" xml:lang="en-US">Awards Close in Time to MNPI Disclosures [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMnpiDiscTextBlock" xlink:label="ecd_AwardTmgMnpiDiscTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardTmgMnpiDiscTextBlock" xlink:to="ecd_AwardTmgMnpiDiscTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardTmgMnpiDiscTextBlock_lbl" xml:lang="en-US">Award Timing MNPI Disclosure</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMethodTextBlock" xlink:label="ecd_AwardTmgMethodTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardTmgMethodTextBlock" xlink:to="ecd_AwardTmgMethodTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardTmgMethodTextBlock_lbl" xml:lang="en-US">Award Timing Method</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgPredtrmndFlag" xlink:label="ecd_AwardTmgPredtrmndFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardTmgPredtrmndFlag" xlink:to="ecd_AwardTmgPredtrmndFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardTmgPredtrmndFlag_lbl" xml:lang="en-US">Award Timing Predetermined</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMnpiCnsdrdFlag" xlink:label="ecd_AwardTmgMnpiCnsdrdFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardTmgMnpiCnsdrdFlag" xlink:to="ecd_AwardTmgMnpiCnsdrdFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardTmgMnpiCnsdrdFlag_lbl" xml:lang="en-US">Award Timing MNPI Considered</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:label="ecd_AwardTmgHowMnpiCnsdrdTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:to="ecd_AwardTmgHowMnpiCnsdrdTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardTmgHowMnpiCnsdrdTextBlock_lbl" xml:lang="en-US">Award Timing, How MNPI Considered</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MnpiDiscTimedForCompValFlag" xlink:label="ecd_MnpiDiscTimedForCompValFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_MnpiDiscTimedForCompValFlag" xlink:to="ecd_MnpiDiscTimedForCompValFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_MnpiDiscTimedForCompValFlag_lbl" xml:lang="en-US">MNPI Disclosure Timed for Compensation Value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:label="ecd_AwardsCloseToMnpiDiscTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:to="ecd_AwardsCloseToMnpiDiscTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardsCloseToMnpiDiscTableTextBlock_lbl" xml:lang="en-US">Awards Close in Time to MNPI Disclosures, Table</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscIndName" xlink:label="ecd_AwardsCloseToMnpiDiscIndName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardsCloseToMnpiDiscIndName" xlink:to="ecd_AwardsCloseToMnpiDiscIndName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ecd_AwardsCloseToMnpiDiscIndName_lbl" xml:lang="en-US">Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardUndrlygSecuritiesAmt" xlink:label="ecd_AwardUndrlygSecuritiesAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardUndrlygSecuritiesAmt" xlink:to="ecd_AwardUndrlygSecuritiesAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardUndrlygSecuritiesAmt_lbl" xml:lang="en-US">Underlying Securities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardExrcPrice" xlink:label="ecd_AwardExrcPrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardExrcPrice" xlink:to="ecd_AwardExrcPrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardExrcPrice_lbl" xml:lang="en-US">Exercise Price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardGrantDateFairValue" xlink:label="ecd_AwardGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardGrantDateFairValue" xlink:to="ecd_AwardGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardGrantDateFairValue_lbl" xml:lang="en-US">Fair Value as of Grant Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_UndrlygSecurityMktPriceChngPct" xlink:label="ecd_UndrlygSecurityMktPriceChngPct" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_UndrlygSecurityMktPriceChngPct" xlink:to="ecd_UndrlygSecurityMktPriceChngPct_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_UndrlygSecurityMktPriceChngPct_lbl" xml:lang="en-US">Underlying Security Market Price Change</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTradingArrLineItems" xlink:label="ecd_InsiderTradingArrLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_InsiderTradingArrLineItems" xlink:to="ecd_InsiderTradingArrLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_InsiderTradingArrLineItems_lbl" xml:lang="en-US">Insider Trading Arrangements [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MtrlTermsOfTrdArrTextBlock" xlink:label="ecd_MtrlTermsOfTrdArrTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_MtrlTermsOfTrdArrTextBlock" xlink:to="ecd_MtrlTermsOfTrdArrTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_MtrlTermsOfTrdArrTextBlock_lbl" xml:lang="en-US">Material Terms of Trading Arrangement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrIndName" xlink:label="ecd_TrdArrIndName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TrdArrIndName" xlink:to="ecd_TrdArrIndName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ecd_TrdArrIndName_lbl" xml:lang="en-US">Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrIndTitle" xlink:label="ecd_TrdArrIndTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TrdArrIndTitle" xlink:to="ecd_TrdArrIndTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TrdArrIndTitle_lbl" xml:lang="en-US">Title</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Rule10b51ArrAdoptedFlag" xlink:label="ecd_Rule10b51ArrAdoptedFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_Rule10b51ArrAdoptedFlag" xlink:to="ecd_Rule10b51ArrAdoptedFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_Rule10b51ArrAdoptedFlag_lbl" xml:lang="en-US">Rule 10b5-1 Arrangement Adopted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonRule10b51ArrAdoptedFlag" xlink:label="ecd_NonRule10b51ArrAdoptedFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_NonRule10b51ArrAdoptedFlag" xlink:to="ecd_NonRule10b51ArrAdoptedFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_NonRule10b51ArrAdoptedFlag_lbl" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Adopted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrAdoptionDate" xlink:label="ecd_TrdArrAdoptionDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TrdArrAdoptionDate" xlink:to="ecd_TrdArrAdoptionDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TrdArrAdoptionDate_lbl" xml:lang="en-US">Adoption Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Rule10b51ArrTrmntdFlag" xlink:label="ecd_Rule10b51ArrTrmntdFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_Rule10b51ArrTrmntdFlag" xlink:to="ecd_Rule10b51ArrTrmntdFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_Rule10b51ArrTrmntdFlag_lbl" xml:lang="en-US">Rule 10b5-1 Arrangement Terminated</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonRule10b51ArrTrmntdFlag" xlink:label="ecd_NonRule10b51ArrTrmntdFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_NonRule10b51ArrTrmntdFlag" xlink:to="ecd_NonRule10b51ArrTrmntdFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_NonRule10b51ArrTrmntdFlag_lbl" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Terminated</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrTerminationDate" xlink:label="ecd_TrdArrTerminationDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TrdArrTerminationDate" xlink:to="ecd_TrdArrTerminationDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TrdArrTerminationDate_lbl" xml:lang="en-US">Termination Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrExpirationDate" xlink:label="ecd_TrdArrExpirationDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TrdArrExpirationDate" xlink:to="ecd_TrdArrExpirationDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TrdArrExpirationDate_lbl" xml:lang="en-US">Expiration Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrDuration" xlink:label="ecd_TrdArrDuration" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TrdArrDuration" xlink:to="ecd_TrdArrDuration_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TrdArrDuration_lbl" xml:lang="en-US">Arrangement Duration</link:label>
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_NoInsiderTradingFlag" xlink:label="NRXS_NoInsiderTradingFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_NoInsiderTradingFlag" xlink:to="NRXS_NoInsiderTradingFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NRXS_NoInsiderTradingFlag_lbl" xml:lang="en-US">No insider trading flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTradingPoliciesProcLineItems" xlink:label="ecd_InsiderTradingPoliciesProcLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_InsiderTradingPoliciesProcLineItems" xlink:to="ecd_InsiderTradingPoliciesProcLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_InsiderTradingPoliciesProcLineItems_lbl" xml:lang="en-US">Insider Trading Policies and Procedures [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:label="ecd_InsiderTrdPoliciesProcAdoptedFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:to="ecd_InsiderTrdPoliciesProcAdoptedFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_InsiderTrdPoliciesProcAdoptedFlag_lbl" xml:lang="en-US">Insider Trading Policies and Procedures Adopted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:label="ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:to="ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock_lbl" xml:lang="en-US">Insider Trading Policies and Procedures Not Adopted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:to="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract_lbl" xml:lang="en-US">Cybersecurity Risk Management, Strategy, and Governance [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:label="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock_lbl" xml:lang="en-US">Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementProcessesIntegratedFlag" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementProcessesIntegratedFlag" xlink:to="cyd_CybersecurityRiskManagementProcessesIntegratedFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedFlag_lbl" xml:lang="en-US">Cybersecurity Risk Management Processes Integrated [Flag]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock" xlink:to="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock_lbl" xml:lang="en-US">Cybersecurity Risk Management Processes Integrated [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementThirdPartyEngagedFlag" xlink:label="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag" xlink:to="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag_lbl" xml:lang="en-US">Cybersecurity Risk Management Third Party Engaged [Flag]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" xlink:label="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" xlink:to="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag_lbl" xml:lang="en-US">Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" xlink:to="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag_lbl" xml:lang="en-US">Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" xlink:to="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock_lbl" xml:lang="en-US">Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:label="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock_lbl" xml:lang="en-US">Cybersecurity Risk Board of Directors Oversight [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:label="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:to="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_lbl" xml:lang="en-US">Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:label="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:to="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_lbl" xml:lang="en-US">Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskRoleOfManagementTextBlock" xlink:label="cyd_CybersecurityRiskRoleOfManagementTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskRoleOfManagementTextBlock" xlink:to="cyd_CybersecurityRiskRoleOfManagementTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskRoleOfManagementTextBlock_lbl" xml:lang="en-US">Cybersecurity Risk Role of Management [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag_lbl" xml:lang="en-US">Cybersecurity Risk Management Positions or Committees Responsible [Flag]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock_lbl" xml:lang="en-US">Cybersecurity Risk Management Positions or Committees Responsible [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_MaterialCybersecurityIncidentAbstract" xlink:label="cyd_MaterialCybersecurityIncidentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_MaterialCybersecurityIncidentAbstract" xlink:to="cyd_MaterialCybersecurityIncidentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_MaterialCybersecurityIncidentAbstract_lbl" xml:lang="en-US">Material Cybersecurity Incident [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_MaterialCybersecurityIncidentNatureTextBlock" xlink:label="cyd_MaterialCybersecurityIncidentNatureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_MaterialCybersecurityIncidentNatureTextBlock" xlink:to="cyd_MaterialCybersecurityIncidentNatureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_MaterialCybersecurityIncidentNatureTextBlock_lbl" xml:lang="en-US">Material Cybersecurity Incident Nature [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_MaterialCybersecurityIncidentScopeTextBlock" xlink:label="cyd_MaterialCybersecurityIncidentScopeTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_MaterialCybersecurityIncidentScopeTextBlock" xlink:to="cyd_MaterialCybersecurityIncidentScopeTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_MaterialCybersecurityIncidentScopeTextBlock_lbl" xml:lang="en-US">Material Cybersecurity Incident Scope [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_MaterialCybersecurityIncidentTimingTextBlock" xlink:label="cyd_MaterialCybersecurityIncidentTimingTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_MaterialCybersecurityIncidentTimingTextBlock" xlink:to="cyd_MaterialCybersecurityIncidentTimingTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_MaterialCybersecurityIncidentTimingTextBlock_lbl" xml:lang="en-US">Material Cybersecurity Incident Timing [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_MaterialCybersecurityIncidentMaterialImpactOrReasonablyLikelyMaterialImpactTextBlock" xlink:label="cyd_MaterialCybersecurityIncidentMaterialImpactOrReasonablyLikelyMaterialImpactTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_MaterialCybersecurityIncidentMaterialImpactOrReasonablyLikelyMaterialImpactTextBlock" xlink:to="cyd_MaterialCybersecurityIncidentMaterialImpactOrReasonablyLikelyMaterialImpactTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_MaterialCybersecurityIncidentMaterialImpactOrReasonablyLikelyMaterialImpactTextBlock_lbl" xml:lang="en-US">Material Cybersecurity Incident Material Impact or Reasonably Likely Material Impact [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_MaterialCybersecurityIncidentInformationNotAvailableOrUndeterminedTextBlock" xlink:label="cyd_MaterialCybersecurityIncidentInformationNotAvailableOrUndeterminedTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_MaterialCybersecurityIncidentInformationNotAvailableOrUndeterminedTextBlock" xlink:to="cyd_MaterialCybersecurityIncidentInformationNotAvailableOrUndeterminedTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_MaterialCybersecurityIncidentInformationNotAvailableOrUndeterminedTextBlock_lbl" xml:lang="en-US">Material Cybersecurity Incident Information Not Available or Undetermined [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:to="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_lbl" xml:lang="en-US">Basis of Presentation, Organization and Other Matters</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US">Summary of Significant Accounting Policies</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_lbl" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xml:lang="en-US">Related Party Transactions</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xml:lang="en-US">Property and Equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_lbl" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:to="us-gaap_IntangibleAssetsDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock_lbl" xml:lang="en-US">Intangible Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_PayablesAndAccrualsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PayablesAndAccrualsAbstract_lbl" xml:lang="en-US">Payables and Accruals [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:to="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_lbl" xml:lang="en-US">Accrued Expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDisclosureAbstract_lbl" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="us-gaap_DebtDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureTextBlock" xlink:to="us-gaap_DebtDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl" xml:lang="en-US">Notes Payable</link:label>
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_DisclosureLeasesAbstract" xlink:label="NRXS_DisclosureLeasesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_DisclosureLeasesAbstract" xlink:to="NRXS_DisclosureLeasesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NRXS_DisclosureLeasesAbstract_lbl" xml:lang="en-US">Leases</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xml:lang="en-US">Leases</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_EquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityAbstract_lbl" xml:lang="en-US">Equity [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US">Common Stock and Warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockTextBlock" xlink:label="us-gaap_PreferredStockTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockTextBlock" xlink:to="us-gaap_PreferredStockTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockTextBlock_lbl" xml:lang="en-US">Preferred Stock</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xml:lang="en-US">Share-Based Payment Arrangement [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xml:lang="en-US">Stock-Based Compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_DisclosureWarrantLiabilitiesAbstract" xlink:label="NRXS_DisclosureWarrantLiabilitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_DisclosureWarrantLiabilitiesAbstract" xlink:to="NRXS_DisclosureWarrantLiabilitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NRXS_DisclosureWarrantLiabilitiesAbstract_lbl" xml:lang="en-US">Warrant Liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_WarrantLiabilitiesDisclosureTextBlock" xlink:label="NRXS_WarrantLiabilitiesDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_WarrantLiabilitiesDisclosureTextBlock" xlink:to="NRXS_WarrantLiabilitiesDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="NRXS_WarrantLiabilitiesDisclosureTextBlock_lbl" xml:lang="en-US">Warrant Liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_DisclosureDerivativeLiabilitiesAbstract" xlink:label="NRXS_DisclosureDerivativeLiabilitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_DisclosureDerivativeLiabilitiesAbstract" xlink:to="NRXS_DisclosureDerivativeLiabilitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NRXS_DisclosureDerivativeLiabilitiesAbstract_lbl" xml:lang="en-US">Derivative Liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativesAndFairValueTextBlock" xlink:label="us-gaap_DerivativesAndFairValueTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativesAndFairValueTextBlock" xlink:to="us-gaap_DerivativesAndFairValueTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DerivativesAndFairValueTextBlock_lbl" xml:lang="en-US">Derivative Liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_CompensationAndRetirementDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract_lbl" xml:lang="en-US">Retirement Benefits [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:to="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_lbl" xml:lang="en-US">Retirement Plan</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract" xlink:label="us-gaap_SegmentReportingAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_SegmentReportingAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingAbstract_lbl" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingDisclosureTextBlock" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingDisclosureTextBlock" xlink:to="us-gaap_SegmentReportingDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock_lbl" xml:lang="en-US">Segment Information</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US">Commitments and Contingencies</link:label>
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_DisclosureHealthBenefitPlanAbstract" xlink:label="NRXS_DisclosureHealthBenefitPlanAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_DisclosureHealthBenefitPlanAbstract" xlink:to="NRXS_DisclosureHealthBenefitPlanAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NRXS_DisclosureHealthBenefitPlanAbstract_lbl" xml:lang="en-US">Health Benefit Plan</link:label>
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_HealthBenefitPlanDisclosureTextBlock" xlink:label="NRXS_HealthBenefitPlanDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_HealthBenefitPlanDisclosureTextBlock" xlink:to="NRXS_HealthBenefitPlanDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="NRXS_HealthBenefitPlanDisclosureTextBlock_lbl" xml:lang="en-US">Health Benefit Plan</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US">Income Taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US">Subsequent Events</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US">Use of Estimates and Critical Accounting Estimates and Assumptions</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xml:lang="en-US">Cash and Cash Equivalents</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:label="us-gaap_TradeAndOtherAccountsReceivablePolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:to="us-gaap_TradeAndOtherAccountsReceivablePolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TradeAndOtherAccountsReceivablePolicy_lbl" xml:lang="en-US">Trade Accounts Receivable and Allowance for Credit Losses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepositContractsPolicy" xlink:label="us-gaap_DepositContractsPolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepositContractsPolicy" xlink:to="us-gaap_DepositContractsPolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepositContractsPolicy_lbl" xml:lang="en-US">Customer Deposits</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryPolicyTextBlock" xlink:label="us-gaap_InventoryPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryPolicyTextBlock" xlink:to="us-gaap_InventoryPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryPolicyTextBlock_lbl" xml:lang="en-US">Inventories</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xml:lang="en-US">Property and Equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xml:lang="en-US">Research and Development</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:label="us-gaap_IntangibleAssetsFiniteLivedPolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:to="us-gaap_IntangibleAssetsFiniteLivedPolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IntangibleAssetsFiniteLivedPolicy_lbl" xml:lang="en-US">Intangible Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xml:lang="en-US">Income Taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdvertisingCostsPolicyTextBlock" xlink:label="us-gaap_AdvertisingCostsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdvertisingCostsPolicyTextBlock" xlink:to="us-gaap_AdvertisingCostsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdvertisingCostsPolicyTextBlock_lbl" xml:lang="en-US">Advertising Cost</link:label>
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_WarrantLiabilityPolicyTextBlock" xlink:label="NRXS_WarrantLiabilityPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_WarrantLiabilityPolicyTextBlock" xlink:to="NRXS_WarrantLiabilityPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="NRXS_WarrantLiabilityPolicyTextBlock_lbl" xml:lang="en-US">Warrant Liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xml:lang="en-US">Fair Value Measurements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US">Basic and Diluted Net Income (Loss) per Share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xml:lang="en-US">Stock-Based Compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xml:lang="en-US">Revenue Recognition</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xml:lang="en-US">Leases</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xml:lang="en-US">Impairment of Long-Lived Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xml:lang="en-US">Concentrations of Credit Risk</link:label>
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_GoingConcernPolicyTextBlock" xlink:label="NRXS_GoingConcernPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_GoingConcernPolicyTextBlock" xlink:to="NRXS_GoingConcernPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NRXS_GoingConcernPolicyTextBlock_lbl" xml:lang="en-US">Going Concern</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US">Recently Adopted Accounting Pronouncements</link:label>
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_RecentlyIssuedAccountingPronouncementsPolicyTextBlock" xlink:label="NRXS_RecentlyIssuedAccountingPronouncementsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_RecentlyIssuedAccountingPronouncementsPolicyTextBlock" xlink:to="NRXS_RecentlyIssuedAccountingPronouncementsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NRXS_RecentlyIssuedAccountingPronouncementsPolicyTextBlock_lbl" xml:lang="en-US">Recently Issued Accounting Pronouncements</link:label>
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_ScheduleOfPropertyPlantAndEquipmentUsefulLivesTableTextBlock" xlink:label="NRXS_ScheduleOfPropertyPlantAndEquipmentUsefulLivesTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_ScheduleOfPropertyPlantAndEquipmentUsefulLivesTableTextBlock" xlink:to="NRXS_ScheduleOfPropertyPlantAndEquipmentUsefulLivesTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NRXS_ScheduleOfPropertyPlantAndEquipmentUsefulLivesTableTextBlock_lbl" xml:lang="en-US">Schedule of Estimated Useful Lives</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl" xml:lang="en-US">Schedule of Fair Value of Assets and Liabilities measured on Recurring Basis</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTextBlock" xlink:to="us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTextBlock_lbl" xml:lang="en-US">Schedule of Dilutive Common Stock Equivalents</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xml:lang="en-US">Schedule of Basic and Diluted Net Loss Per Share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:label="us-gaap_DisaggregationOfRevenueTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:to="us-gaap_DisaggregationOfRevenueTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisaggregationOfRevenueTableTextBlock_lbl" xml:lang="en-US">Schedule of Disaggregation of Revenue</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:label="us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:to="us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_lbl" xml:lang="en-US">Schedule of Customer Accounts Receivable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerAssetAllowanceForCreditLossTableTextBlock" xlink:label="us-gaap_ContractWithCustomerAssetAllowanceForCreditLossTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerAssetAllowanceForCreditLossTableTextBlock" xlink:to="us-gaap_ContractWithCustomerAssetAllowanceForCreditLossTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ContractWithCustomerAssetAllowanceForCreditLossTableTextBlock_lbl" xml:lang="en-US">Schedule of Customers Accounted Revenues</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_lbl" xml:lang="en-US">Schedule of Related Party Transactions</link:label>
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_ScheduleOfRelatedPartyLoansTableTextBlock" xlink:label="NRXS_ScheduleOfRelatedPartyLoansTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_ScheduleOfRelatedPartyLoansTableTextBlock" xlink:to="NRXS_ScheduleOfRelatedPartyLoansTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NRXS_ScheduleOfRelatedPartyLoansTableTextBlock_lbl" xml:lang="en-US">Schedule of Related Party Loans payable to shareholder</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xml:lang="en-US">Schedule of Property And Equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_lbl" xml:lang="en-US">Schedule of Intangible Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xml:lang="en-US">Schedule of Accrued Expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="us-gaap_LeaseCostTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCostTableTextBlock" xlink:to="us-gaap_LeaseCostTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseCostTableTextBlock_lbl" xml:lang="en-US">Schedule of Operating Leases</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xml:lang="en-US">Schedule of Maturities Operating Lease Liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_lbl" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_lbl" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_ScheduleOfWarrantActivityForCommonStockTableTextBlock" xlink:label="NRXS_ScheduleOfWarrantActivityForCommonStockTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_ScheduleOfWarrantActivityForCommonStockTableTextBlock" xlink:to="NRXS_ScheduleOfWarrantActivityForCommonStockTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NRXS_ScheduleOfWarrantActivityForCommonStockTableTextBlock_lbl" xml:lang="en-US">Schedule of Warrant Activity for Common Stock</link:label>
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_ScheduleOfWarrantActivityForPreferredStockTableTextBlock" xlink:label="NRXS_ScheduleOfWarrantActivityForPreferredStockTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_ScheduleOfWarrantActivityForPreferredStockTableTextBlock" xlink:to="NRXS_ScheduleOfWarrantActivityForPreferredStockTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NRXS_ScheduleOfWarrantActivityForPreferredStockTableTextBlock_lbl" xml:lang="en-US">Schedule of Warrant Activity for Preferred Stock</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl" xml:lang="en-US">Schedule of Warrants outstanding and Exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US">Schedule of Option-pricing Model with Following Weighted-average Assumptions</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US">Schedule of Stock Option Activity</link:label>
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_ScheduleOfChangesInWarrantLiabilitiesTableTextBlock" xlink:label="NRXS_ScheduleOfChangesInWarrantLiabilitiesTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_ScheduleOfChangesInWarrantLiabilitiesTableTextBlock" xlink:to="NRXS_ScheduleOfChangesInWarrantLiabilitiesTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NRXS_ScheduleOfChangesInWarrantLiabilitiesTableTextBlock_lbl" xml:lang="en-US">Schedule of Changes in Warrant Liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" xlink:label="us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" xlink:to="us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock_lbl" xml:lang="en-US">Schedule of Changes in Derivative Liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_lbl" xml:lang="en-US">Schedule of Reconciles the Company&#8217;s Net Sales and Operating Loss</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" xml:lang="en-US">Schedule of Income Tax Provision</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xml:lang="en-US">Schedule of Federal Statutory Income Tax Rate and Effective Income Tax Rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xml:lang="en-US">Schedule of Net Deferred Tax Assets and Liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock" xlink:label="us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock" xlink:to="us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock_lbl" xml:lang="en-US">Schedule of State Carryforwards</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteStockSplit" xlink:label="us-gaap_StockholdersEquityNoteStockSplit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteStockSplit" xlink:to="us-gaap_StockholdersEquityNoteStockSplit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteStockSplit_lbl" xml:lang="en-US">Description of stock split</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl" xml:lang="en-US">Sale of stock, number of shares issued in transaction</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssuedPricePerShare" xlink:to="us-gaap_SharesIssuedPricePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xml:lang="en-US">Shares issued, price per share</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_2_lbl" xml:lang="en-US">Proceeds from issuance of common stock</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredOfferingCosts" xlink:label="us-gaap_DeferredOfferingCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredOfferingCosts" xlink:to="us-gaap_DeferredOfferingCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredOfferingCosts_lbl" xml:lang="en-US">Deferred offering costs</link:label>
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_PurchaseOfAdditionalStockOnNumberOfOptionsNotExercised" xlink:label="NRXS_PurchaseOfAdditionalStockOnNumberOfOptionsNotExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_PurchaseOfAdditionalStockOnNumberOfOptionsNotExercised" xlink:to="NRXS_PurchaseOfAdditionalStockOnNumberOfOptionsNotExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NRXS_PurchaseOfAdditionalStockOnNumberOfOptionsNotExercised_lbl" xml:lang="en-US">Purchase of additional stockon number of options not exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_UnderwritersDiscountPercentage" xlink:label="NRXS_UnderwritersDiscountPercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_UnderwritersDiscountPercentage" xlink:to="NRXS_UnderwritersDiscountPercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NRXS_UnderwritersDiscountPercentage_lbl" xml:lang="en-US">Underwriters discount percentage</link:label>
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_NonaccountableExpenseAllowancePercentage" xlink:label="NRXS_NonaccountableExpenseAllowancePercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_NonaccountableExpenseAllowancePercentage" xlink:to="NRXS_NonaccountableExpenseAllowancePercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NRXS_NonaccountableExpenseAllowancePercentage_lbl" xml:lang="en-US">Nonaccountable expense allowance percentage</link:label>
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_CashFeePercentage" xlink:label="NRXS_CashFeePercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_CashFeePercentage" xlink:to="NRXS_CashFeePercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NRXS_CashFeePercentage_lbl" xml:lang="en-US">Cash fee percentage</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xml:lang="en-US">Proceeds from issuance initial public offering</link:label>
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_ReimbursementExpenses" xlink:label="NRXS_ReimbursementExpenses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_ReimbursementExpenses" xlink:to="NRXS_ReimbursementExpenses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NRXS_ReimbursementExpenses_lbl" xml:lang="en-US">Reimbursement expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_lbl" xml:lang="en-US">Warrants to purchase an aggregate common stock, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction" xlink:label="us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction" xlink:to="us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction_lbl" xml:lang="en-US">Sale of stock, percentage of ownership after transaction</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xml:lang="en-US">Exercise price of warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_OfferingPricePerPercentage" xlink:label="NRXS_OfferingPricePerPercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_OfferingPricePerPercentage" xlink:to="NRXS_OfferingPricePerPercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NRXS_OfferingPricePerPercentage_lbl" xml:lang="en-US">Offering price per percentage</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:label="us-gaap_TemporaryEquitySharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquitySharesAuthorized" xlink:to="us-gaap_TemporaryEquitySharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquitySharesAuthorized_lbl" xml:lang="en-US">Temporary equity, shares authorized</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockDividendPaymentTerms" xlink:label="us-gaap_PreferredStockDividendPaymentTerms" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockDividendPaymentTerms" xlink:to="us-gaap_PreferredStockDividendPaymentTerms_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockDividendPaymentTerms_lbl" xml:lang="en-US">Cumulative dividend description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:label="us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:to="us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_lbl" xml:lang="en-US">Stock repurchased and retired during period shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xml:lang="en-US">Property and equipment, estimated useful lives</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="us-gaap_LiabilitiesFairValueDisclosure" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesFairValueDisclosure" xlink:to="us-gaap_LiabilitiesFairValueDisclosure_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesFairValueDisclosure_lbl" xml:lang="en-US">Fair value of warrant liabilities as of December 31, 2023</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xml:lang="en-US">Antidilutive Security, Excluded EPS Calculation [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US">Totals</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DividendsPreferredStock" xlink:label="us-gaap_DividendsPreferredStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DividendsPreferredStock" xlink:to="us-gaap_DividendsPreferredStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DividendsPreferredStock_lbl" xml:lang="en-US">Preferred stock dividends</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_2_lbl" xml:lang="en-US">Net loss available to common stockholders</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_2_lbl" xml:lang="en-US">Weighted average shares of common stock outstanding - basic</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_2_lbl" xml:lang="en-US">Weighted average shares of common stock outstanding - diluted</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EarningsPerShareBasic_2_lbl" xml:lang="en-US">Basic net loss per share</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EarningsPerShareDiluted_2_lbl" xml:lang="en-US">Diluted net loss per share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_Revenues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Revenues_lbl" xml:lang="en-US">Revenues</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfProductInformationTable" xlink:label="us-gaap_ScheduleOfProductInformationTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfProductInformationTable" xlink:to="us-gaap_ScheduleOfProductInformationTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfProductInformationTable_lbl" xml:lang="en-US">Nature of Operation, Product Information, Concentration of Risk [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProductInformationLineItems" xlink:label="us-gaap_ProductInformationLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProductInformationLineItems" xlink:to="us-gaap_ProductInformationLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProductInformationLineItems_lbl" xml:lang="en-US">Product Information [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNet" xlink:label="us-gaap_AccountsReceivableNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNet" xlink:to="us-gaap_AccountsReceivableNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsReceivableNet_lbl" xml:lang="en-US">Net accounts receivable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="us-gaap_ConcentrationRiskPercentage1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskPercentage1" xlink:to="us-gaap_ConcentrationRiskPercentage1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskPercentage1_lbl" xml:lang="en-US">Risk percentage</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_2_lbl" xml:lang="en-US">Revenue</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable" xlink:label="us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable" xlink:to="us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_lbl" xml:lang="en-US">Intangible Asset, Indefinite-Lived [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_lbl" xml:lang="en-US">Indefinite-Lived Intangible Assets [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:to="us-gaap_AllowanceForDoubtfulAccountsReceivable_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivable_2_lbl" xml:lang="en-US">Allowance for doubtful accounts</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProvisionForOtherCreditLosses" xlink:label="us-gaap_ProvisionForOtherCreditLosses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProvisionForOtherCreditLosses" xlink:to="us-gaap_ProvisionForOtherCreditLosses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProvisionForOtherCreditLosses_lbl" xml:lang="en-US">Credit losses</link:label>
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_InventoryExpenses" xlink:label="NRXS_InventoryExpenses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_InventoryExpenses" xlink:to="NRXS_InventoryExpenses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NRXS_InventoryExpenses_lbl" xml:lang="en-US">Inventory expenses</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryRawMaterialsNetOfReserves" xlink:to="us-gaap_InventoryRawMaterialsNetOfReserves_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_InventoryRawMaterialsNetOfReserves_2_lbl" xml:lang="en-US">Inventory reserves</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Depreciation_lbl" xml:lang="en-US">Depreciation expense</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireIntangibleAssets" xlink:to="us-gaap_PaymentsToAcquireIntangibleAssets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets_2_lbl" xml:lang="en-US">Payment upon execution</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="us-gaap_AmortizationOfIntangibleAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfIntangibleAssets" xlink:to="us-gaap_AmortizationOfIntangibleAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AmortizationOfIntangibleAssets_lbl" xml:lang="en-US">Amortization expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExaminationLikelihoodOfUnfavorableSettlement" xlink:label="us-gaap_IncomeTaxExaminationLikelihoodOfUnfavorableSettlement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExaminationLikelihoodOfUnfavorableSettlement" xlink:to="us-gaap_IncomeTaxExaminationLikelihoodOfUnfavorableSettlement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxExaminationLikelihoodOfUnfavorableSettlement_lbl" xml:lang="en-US">Income tax examination, likelihood of unfavorable settlement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued" xlink:label="us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued" xlink:to="us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued_lbl" xml:lang="en-US">Income tax interest or penalties accrued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdvertisingExpense" xlink:label="us-gaap_AdvertisingExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdvertisingExpense" xlink:to="us-gaap_AdvertisingExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdvertisingExpense_lbl" xml:lang="en-US">Advertising cost</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DividendsPreferredStock" xlink:to="us-gaap_DividendsPreferredStock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DividendsPreferredStock_2_lbl" xml:lang="en-US">Preferred stock dividend</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:label="us-gaap_ContractWithCustomerLiabilityRevenueRecognized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:to="us-gaap_ContractWithCustomerLiabilityRevenueRecognized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ContractWithCustomerLiabilityRevenueRecognized_lbl" xml:lang="en-US">Estimated returns of revenue</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashFDICInsuredAmount" xlink:label="us-gaap_CashFDICInsuredAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFDICInsuredAmount" xlink:to="us-gaap_CashFDICInsuredAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashFDICInsuredAmount_lbl" xml:lang="en-US">Cash, FDIC insured amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashUninsuredAmount" xlink:label="us-gaap_CashUninsuredAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashUninsuredAmount" xlink:to="us-gaap_CashUninsuredAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashUninsuredAmount_lbl" xml:lang="en-US">Cash uninsured</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_4_lbl" xml:lang="en-US">Stockholders' equity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermBorrowings" xlink:label="us-gaap_ShortTermBorrowings" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermBorrowings" xlink:to="us-gaap_ShortTermBorrowings_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermBorrowings_lbl" xml:lang="en-US">Short term borrowings outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Cash" xlink:label="us-gaap_Cash" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Cash" xlink:to="us-gaap_Cash_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Cash_lbl" xml:lang="en-US">Cash</link:label>
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_WorkingCapitalDeficit" xlink:label="NRXS_WorkingCapitalDeficit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_WorkingCapitalDeficit" xlink:to="NRXS_WorkingCapitalDeficit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NRXS_WorkingCapitalDeficit_lbl" xml:lang="en-US">Working capital surplus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xml:lang="en-US">Related Party Transaction [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionLineItems_lbl" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NotesAndLoansReceivableGrossCurrent" xlink:label="us-gaap_NotesAndLoansReceivableGrossCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesAndLoansReceivableGrossCurrent" xlink:to="us-gaap_NotesAndLoansReceivableGrossCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NotesAndLoansReceivableGrossCurrent_lbl" xml:lang="en-US">Loan Receivable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestReceivableCurrent" xlink:label="us-gaap_InterestReceivableCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestReceivableCurrent" xlink:to="us-gaap_InterestReceivableCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestReceivableCurrent_lbl" xml:lang="en-US">Interest Receivable</link:label>
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_InterestIncomeGrossCurrent" xlink:label="NRXS_InterestIncomeGrossCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_InterestIncomeGrossCurrent" xlink:to="NRXS_InterestIncomeGrossCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NRXS_InterestIncomeGrossCurrent_lbl" xml:lang="en-US">Interest Income</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllowanceForNotesAndLoansReceivableCurrent" xlink:label="us-gaap_AllowanceForNotesAndLoansReceivableCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllowanceForNotesAndLoansReceivableCurrent" xlink:to="us-gaap_AllowanceForNotesAndLoansReceivableCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_AllowanceForNotesAndLoansReceivableCurrent_lbl" xml:lang="en-US">Allowance for collection risk, loan receivable</link:label>
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_AllowanceForInterestReceivableCurrent" xlink:label="NRXS_AllowanceForInterestReceivableCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_AllowanceForInterestReceivableCurrent" xlink:to="NRXS_AllowanceForInterestReceivableCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NRXS_AllowanceForInterestReceivableCurrent_lbl" xml:lang="en-US">Allowance for collection risk, interest receivable</link:label>
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_AllowanceForInterestIncomeCurrent" xlink:label="NRXS_AllowanceForInterestIncomeCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_AllowanceForInterestIncomeCurrent" xlink:to="NRXS_AllowanceForInterestIncomeCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="NRXS_AllowanceForInterestIncomeCurrent_lbl" xml:lang="en-US">Allowance for collection risk, interest income</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NotesAndLoansReceivableNetCurrent" xlink:label="us-gaap_NotesAndLoansReceivableNetCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesAndLoansReceivableNetCurrent" xlink:to="us-gaap_NotesAndLoansReceivableNetCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NotesAndLoansReceivableNetCurrent_lbl" xml:lang="en-US">Loan Receivable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestReceivable" xlink:label="us-gaap_InterestReceivable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestReceivable" xlink:to="us-gaap_InterestReceivable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_InterestReceivable_lbl" xml:lang="en-US">Interest Receivable</link:label>
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_InterestIncomeCurrent" xlink:label="NRXS_InterestIncomeCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_InterestIncomeCurrent" xlink:to="NRXS_InterestIncomeCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="NRXS_InterestIncomeCurrent_lbl" xml:lang="en-US">Interest Income</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShortTermDebtTable" xlink:label="us-gaap_ScheduleOfShortTermDebtTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShortTermDebtTable" xlink:to="us-gaap_ScheduleOfShortTermDebtTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShortTermDebtTable_lbl" xml:lang="en-US">Short-Term Debt [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermDebtLineItems" xlink:label="us-gaap_ShortTermDebtLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermDebtLineItems" xlink:to="us-gaap_ShortTermDebtLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermDebtLineItems_lbl" xml:lang="en-US">Short-Term Debt [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentMaturityDateDescription" xlink:label="us-gaap_DebtInstrumentMaturityDateDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentMaturityDateDescription" xlink:to="us-gaap_DebtInstrumentMaturityDateDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentMaturityDateDescription_lbl" xml:lang="en-US">Due date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xml:lang="en-US">Debt instrument percentage</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LoansPayable" xlink:label="us-gaap_LoansPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LoansPayable" xlink:to="us-gaap_LoansPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LoansPayable_lbl" xml:lang="en-US">Loan payable</link:label>
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_InterestAndServiceFeeAccrued" xlink:label="NRXS_InterestAndServiceFeeAccrued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_InterestAndServiceFeeAccrued" xlink:to="NRXS_InterestAndServiceFeeAccrued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NRXS_InterestAndServiceFeeAccrued_lbl" xml:lang="en-US">Interest payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestPaid" xlink:label="us-gaap_InterestPaid" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaid" xlink:to="us-gaap_InterestPaid_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_InterestPaid_lbl" xml:lang="en-US">Interest payable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_AllowanceForInterestReceivableCurrent" xlink:to="NRXS_AllowanceForInterestReceivableCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="NRXS_AllowanceForInterestReceivableCurrent_2_lbl" xml:lang="en-US">Allowance for interest receivable current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:label="us-gaap_RelatedPartyTransactionAmountsOfTransaction" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:to="us-gaap_RelatedPartyTransactionAmountsOfTransaction_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionAmountsOfTransaction_lbl" xml:lang="en-US">Related party transaction amounts</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForFees" xlink:label="us-gaap_PaymentsForFees" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForFees" xlink:to="us-gaap_PaymentsForFees_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsForFees_lbl" xml:lang="en-US">Fees paid for services</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrentAndNoncurrent" xlink:label="us-gaap_AccountsPayableCurrentAndNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrentAndNoncurrent" xlink:to="us-gaap_AccountsPayableCurrentAndNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AccountsPayableCurrentAndNoncurrent_lbl" xml:lang="en-US">Accounts payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl" xml:lang="en-US">Stock issued during period shares issued for services</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_lbl" xml:lang="en-US">Stock issued during period value issued for services</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_2_lbl" xml:lang="en-US">Total property and equipment</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_2_lbl" xml:lang="en-US">Less: accumulated depreciation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_Depreciation_2_lbl" xml:lang="en-US">Depreciation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_lbl" xml:lang="en-US">Intangible Asset, Finite-Lived [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems_lbl" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross_lbl" xml:lang="en-US">Total intangible assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl" xml:lang="en-US">Less: accumulated amortization</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_2_lbl" xml:lang="en-US">Intangible assets, net</link:label>
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_AccruedCompensationAndBenefitsCurrent" xlink:label="NRXS_AccruedCompensationAndBenefitsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_AccruedCompensationAndBenefitsCurrent" xlink:to="NRXS_AccruedCompensationAndBenefitsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NRXS_AccruedCompensationAndBenefitsCurrent_lbl" xml:lang="en-US">Compensation and benefits</link:label>
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_AdvisoryFees" xlink:label="NRXS_AdvisoryFees" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_AdvisoryFees" xlink:to="NRXS_AdvisoryFees_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NRXS_AdvisoryFees_lbl" xml:lang="en-US">Advisory fees</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestPayableCurrent" xlink:label="us-gaap_InterestPayableCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPayableCurrent" xlink:to="us-gaap_InterestPayableCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPayableCurrent_lbl" xml:lang="en-US">Interest</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent" xlink:label="us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent" xlink:to="us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent_lbl" xml:lang="en-US">Other</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AccruedLiabilitiesCurrent_2_lbl" xml:lang="en-US">Total accrued expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFaceAmount" xlink:to="us-gaap_DebtInstrumentFaceAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentFaceAmount_lbl" xml:lang="en-US">Outstanding promissory notes</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentPeriodicPayment" xlink:label="us-gaap_DebtInstrumentPeriodicPayment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentPeriodicPayment" xlink:to="us-gaap_DebtInstrumentPeriodicPayment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentPeriodicPayment_lbl" xml:lang="en-US">Principal amount due in monthly installments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtAverageAmountOutstanding" xlink:label="us-gaap_LongTermDebtAverageAmountOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtAverageAmountOutstanding" xlink:to="us-gaap_LongTermDebtAverageAmountOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebtAverageAmountOutstanding_lbl" xml:lang="en-US">Long-Term Debt, Average Amount Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentRepurchasedFaceAmount" xlink:label="us-gaap_DebtInstrumentRepurchasedFaceAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentRepurchasedFaceAmount" xlink:to="us-gaap_DebtInstrumentRepurchasedFaceAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentRepurchasedFaceAmount_lbl" xml:lang="en-US">Debt Instrument, Repurchased Face Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NotesPayable" xlink:label="us-gaap_NotesPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesPayable" xlink:to="us-gaap_NotesPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NotesPayable_lbl" xml:lang="en-US">Promissory note</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:to="us-gaap_DebtInstrumentInterestRateEffectivePercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage_lbl" xml:lang="en-US">Debt instrument interest rate effective percentage</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_2_lbl" xml:lang="en-US">Debt instrument interest rate</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_2_lbl" xml:lang="en-US">Proceeds from issuance of ipo</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="us-gaap_DebtInstrumentMaturityDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentMaturityDate" xlink:to="us-gaap_DebtInstrumentMaturityDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentMaturityDate_lbl" xml:lang="en-US">Maturity date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="us-gaap_DebtInstrumentCarryingAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentCarryingAmount" xlink:to="us-gaap_DebtInstrumentCarryingAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentCarryingAmount_lbl" xml:lang="en-US">Debt instrument gross</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfDebt" xlink:label="us-gaap_ProceedsFromIssuanceOfDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfDebt" xlink:to="us-gaap_ProceedsFromIssuanceOfDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfDebt_lbl" xml:lang="en-US">Net proceeds of debt</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentDescriptionOfVariableRateBasis" xlink:label="us-gaap_DebtInstrumentDescriptionOfVariableRateBasis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentDescriptionOfVariableRateBasis" xlink:to="us-gaap_DebtInstrumentDescriptionOfVariableRateBasis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentDescriptionOfVariableRateBasis_lbl" xml:lang="en-US">Debt instrument description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:to="us-gaap_DebtInstrumentConvertibleConversionPrice1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1_lbl" xml:lang="en-US">Conversion price</link:label>
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_DebtInstrumentDiscountRate" xlink:label="NRXS_DebtInstrumentDiscountRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_DebtInstrumentDiscountRate" xlink:to="NRXS_DebtInstrumentDiscountRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NRXS_DebtInstrumentDiscountRate_lbl" xml:lang="en-US">Discount rate</link:label>
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_DebtWarrantConversionDescription" xlink:label="NRXS_DebtWarrantConversionDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_DebtWarrantConversionDescription" xlink:to="NRXS_DebtWarrantConversionDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NRXS_DebtWarrantConversionDescription_lbl" xml:lang="en-US">Debt warrant conversion, description</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_2_lbl" xml:lang="en-US">Exercise price</link:label>
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_ClassOfWarrantDiscountRate" xlink:label="NRXS_ClassOfWarrantDiscountRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_ClassOfWarrantDiscountRate" xlink:to="NRXS_ClassOfWarrantDiscountRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NRXS_ClassOfWarrantDiscountRate_lbl" xml:lang="en-US">Class of warrant discount rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:label="us-gaap_DebtInstrumentConvertibleConversionRatio1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:to="us-gaap_DebtInstrumentConvertibleConversionRatio1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentConvertibleConversionRatio1_lbl" xml:lang="en-US">Strilke price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_3_lbl" xml:lang="en-US">Extinguishment of debt</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_2_lbl" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssuedPricePerShare" xlink:to="us-gaap_SharesIssuedPricePerShare_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharesIssuedPricePerShare_2_lbl" xml:lang="en-US">Shares Issued, Price Per Share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EscrowDeposit" xlink:label="us-gaap_EscrowDeposit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EscrowDeposit" xlink:to="us-gaap_EscrowDeposit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EscrowDeposit_lbl" xml:lang="en-US">Escrow deposit</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromFeesReceived" xlink:label="us-gaap_ProceedsFromFeesReceived" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromFeesReceived" xlink:to="us-gaap_ProceedsFromFeesReceived_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromFeesReceived_lbl" xml:lang="en-US">Deferred financing fees</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xml:lang="en-US">Number of warrants received</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_lbl" xml:lang="en-US">Convertible Preferred Stock, Shares Issued upon Conversion</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_2_lbl" xml:lang="en-US">Stock Issued During Period, Value, New Issues</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid" xlink:label="us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid" xlink:to="us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid_lbl" xml:lang="en-US">Debt Instrument, Periodic Payment Terms, Balloon Payment to be Paid</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleDebt" xlink:label="us-gaap_ConvertibleDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleDebt" xlink:to="us-gaap_ConvertibleDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertibleDebt_lbl" xml:lang="en-US">Convertible debt</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromContributedCapital" xlink:label="us-gaap_ProceedsFromContributedCapital" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromContributedCapital" xlink:to="us-gaap_ProceedsFromContributedCapital_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromContributedCapital_lbl" xml:lang="en-US">Shareholder funded</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAnnualPrincipalPayment" xlink:label="us-gaap_DebtInstrumentAnnualPrincipalPayment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentAnnualPrincipalPayment" xlink:to="us-gaap_DebtInstrumentAnnualPrincipalPayment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentAnnualPrincipalPayment_lbl" xml:lang="en-US">Total principal amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtConversionOriginalDebtInterestRateOfDebt" xlink:label="us-gaap_DebtConversionOriginalDebtInterestRateOfDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtConversionOriginalDebtInterestRateOfDebt" xlink:to="us-gaap_DebtConversionOriginalDebtInterestRateOfDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtConversionOriginalDebtInterestRateOfDebt_lbl" xml:lang="en-US">Debt conversion, original debt, interest rate of debt</link:label>
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_CumulativeDividendsPercent" xlink:label="NRXS_CumulativeDividendsPercent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_CumulativeDividendsPercent" xlink:to="NRXS_CumulativeDividendsPercent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NRXS_CumulativeDividendsPercent_lbl" xml:lang="en-US">Cumulative dividends percent</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockConvertibleConversionPriceDecrease" xlink:label="us-gaap_CommonStockConvertibleConversionPriceDecrease" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockConvertibleConversionPriceDecrease" xlink:to="us-gaap_CommonStockConvertibleConversionPriceDecrease_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockConvertibleConversionPriceDecrease_lbl" xml:lang="en-US">Common stock conversion price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="us-gaap_ConversionOfStockSharesConverted1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockSharesConverted1" xlink:to="us-gaap_ConversionOfStockSharesConverted1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConversionOfStockSharesConverted1_lbl" xml:lang="en-US">Number of shares converted</link:label>
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_CommonStockConvertibleConversionPrice" xlink:label="NRXS_CommonStockConvertibleConversionPrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_CommonStockConvertibleConversionPrice" xlink:to="NRXS_CommonStockConvertibleConversionPrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="NRXS_CommonStockConvertibleConversionPrice_lbl" xml:lang="en-US">Common stock conversion price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnamortizedDebtIssuanceExpense" xlink:label="us-gaap_UnamortizedDebtIssuanceExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnamortizedDebtIssuanceExpense" xlink:to="us-gaap_UnamortizedDebtIssuanceExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UnamortizedDebtIssuanceExpense_lbl" xml:lang="en-US">Unamortized Debt Issuance Expense</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpense" xlink:to="us-gaap_InterestExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestExpense_2_lbl" xml:lang="en-US">Interest expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent_lbl" xml:lang="en-US">Accrued Liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_DisclosureLeasesAbstract" xlink:to="NRXS_DisclosureLeasesAbstract_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="NRXS_DisclosureLeasesAbstract_2_lbl" xml:lang="en-US">Schedule Of Operating Leases</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_2_lbl" xml:lang="en-US">Operating lease right-of-use assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_2_lbl" xml:lang="en-US">Other current liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_2_lbl" xml:lang="en-US">Operating lease liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xml:lang="en-US">Total</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xml:lang="en-US">Weighted average remaining lease term (in years)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xml:lang="en-US">Weighted average discount rate</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_DisclosureLeasesAbstract" xlink:to="NRXS_DisclosureLeasesAbstract_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="NRXS_DisclosureLeasesAbstract_3_lbl" xml:lang="en-US">Schedule Of Maturities Operating Lease Liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xml:lang="en-US">2025</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xml:lang="en-US">2026</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xml:lang="en-US">2027</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xml:lang="en-US">2028</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl" xml:lang="en-US">2029</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xml:lang="en-US">Total lease payments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xml:lang="en-US">Less: imputed interest</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiability_2_lbl" xml:lang="en-US">Total present value of lease payments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseDescription" xlink:label="us-gaap_LesseeOperatingLeaseDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseDescription" xlink:to="us-gaap_LesseeOperatingLeaseDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseDescription_lbl" xml:lang="en-US">Operating lease description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasePayments" xlink:to="us-gaap_OperatingLeasePayments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasePayments_lbl" xml:lang="en-US">Operating lease payment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseDiscountRate" xlink:label="us-gaap_LesseeOperatingLeaseDiscountRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseDiscountRate" xlink:to="us-gaap_LesseeOperatingLeaseDiscountRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseDiscountRate_lbl" xml:lang="en-US">Operating lease payment rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseExpense" xlink:label="us-gaap_OperatingLeaseExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseExpense" xlink:to="us-gaap_OperatingLeaseExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseExpense_lbl" xml:lang="en-US">Operating lease expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_lbl" xml:lang="en-US">Number of Warrants, Outstanding at beginning of period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Outstanding at beginning of period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US">Weighted Average Remaining Contractual Life - Warrants</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_2_lbl" xml:lang="en-US">Number of Warrants, Granted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, granted</link:label>
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsWeightedAverageRemainingContracualLifeOutstandingNumberGranted" xlink:label="NRXS_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsWeightedAverageRemainingContracualLifeOutstandingNumberGranted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsWeightedAverageRemainingContracualLifeOutstandingNumberGranted" xlink:to="NRXS_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsWeightedAverageRemainingContracualLifeOutstandingNumberGranted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NRXS_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsWeightedAverageRemainingContracualLifeOutstandingNumberGranted_lbl" xml:lang="en-US">Weighted Average Remaining Contractual Life - Warrants Granted</link:label>
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsConvertedPrefundedWarrants" xlink:label="NRXS_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsConvertedPrefundedWarrants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsConvertedPrefundedWarrants" xlink:to="NRXS_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsConvertedPrefundedWarrants_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NRXS_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsConvertedPrefundedWarrants_lbl" xml:lang="en-US">Number of Warrants, Converted Prefunded Warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsConvertedPrefundedWarrantsInPeriodWeightedAverageExercisePrice" xlink:label="NRXS_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsConvertedPrefundedWarrantsInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsConvertedPrefundedWarrantsInPeriodWeightedAverageExercisePrice" xlink:to="NRXS_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsConvertedPrefundedWarrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NRXS_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsConvertedPrefundedWarrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Converted Prefunded Warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_lbl" xml:lang="en-US">Number of Warrants, Granted</link:label>
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsWeightedAverageExercisePriceCancelledExpiredNumber" xlink:label="NRXS_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsWeightedAverageExercisePriceCancelledExpiredNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsWeightedAverageExercisePriceCancelledExpiredNumber" xlink:to="NRXS_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsWeightedAverageExercisePriceCancelledExpiredNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NRXS_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsWeightedAverageExercisePriceCancelledExpiredNumber_lbl" xml:lang="en-US">Weighted Average Exercise Price, Cancelled Expired</link:label>
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsCancelledWeightedAverageRemainingContractualTerm1" xlink:label="NRXS_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsCancelledWeightedAverageRemainingContractualTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsCancelledWeightedAverageRemainingContractualTerm1" xlink:to="NRXS_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsCancelledWeightedAverageRemainingContractualTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NRXS_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsCancelledWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US">Weighted Average Remaining Contractual Life - Warrants Cancelled</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_lbl" xml:lang="en-US">Number of Warrants, Exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Excercised</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US">Weighted Average Remaining Contractual Life - Warrants Granted</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_2_lbl" xml:lang="en-US">Number of Warrants, Granted</link:label>
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisedWeightedAverageRemainingContractualTerm1" xlink:label="NRXS_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisedWeightedAverageRemainingContractualTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisedWeightedAverageRemainingContractualTerm1" xlink:to="NRXS_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisedWeightedAverageRemainingContractualTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="NRXS_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisedWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US">Weighted Average Remaining Contractual Life - Warrants Granted</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_2_lbl" xml:lang="en-US">Number of Warrants, Outstanding at Ending of period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Weighted Average Exercise Price, Outstanding at Ending of period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_3_lbl" xml:lang="en-US">Number of Warrants, Cancelled Expired</link:label>
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsCommonStockWarrant" xlink:label="NRXS_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsCommonStockWarrant" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsCommonStockWarrant" xlink:to="NRXS_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsCommonStockWarrant_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="NRXS_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsCommonStockWarrant_lbl" xml:lang="en-US">Converted to Common Stock Warrant</link:label>
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsWeightedAverageExercisePriceCommonStockWarrant" xlink:label="NRXS_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsWeightedAverageExercisePriceCommonStockWarrant" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsWeightedAverageExercisePriceCommonStockWarrant" xlink:to="NRXS_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsWeightedAverageExercisePriceCommonStockWarrant_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="NRXS_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsWeightedAverageExercisePriceCommonStockWarrant_lbl" xml:lang="en-US">Weighted Average Exercise Price, Converted to Common Stock Warrant</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="us-gaap_ClassOfWarrantOrRightTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_ClassOfWarrantOrRightTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightTable_lbl" xml:lang="en-US">Class of Warrant or Right [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems_lbl" xml:lang="en-US">Class of Warrant or Right [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xml:lang="en-US">Number of Warrants</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_3_lbl" xml:lang="en-US">Exercise Price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:label="us-gaap_WarrantsAndRightsOutstandingMaturityDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:to="us-gaap_WarrantsAndRightsOutstandingMaturityDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_WarrantsAndRightsOutstandingMaturityDate_lbl" xml:lang="en-US">Expiration Date</link:label>
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_WarrantExpirationDateDescription" xlink:label="NRXS_WarrantExpirationDateDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_WarrantExpirationDateDescription" xlink:to="NRXS_WarrantExpirationDateDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="NRXS_WarrantExpirationDateDescription_lbl" xml:lang="en-US">Expiration Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ScheduleOfStockByClassTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfStockByClassTable_lbl" xml:lang="en-US">Stock, Class of Stock [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfStockLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xml:lang="en-US">Class of Stock [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockSharesIssued_2_lbl" xml:lang="en-US">Common stock, shares, issued</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockSharesOutstanding_2_lbl" xml:lang="en-US">Common stock, shares, outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="us-gaap_StockholdersEquityReverseStockSplit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityReverseStockSplit" xlink:to="us-gaap_StockholdersEquityReverseStockSplit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityReverseStockSplit_lbl" xml:lang="en-US">Reverse stock split</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_StockIssuedDuringPeriodSharesCommonStockIssuedUponInitialPublicOffering" xlink:to="NRXS_StockIssuedDuringPeriodSharesCommonStockIssuedUponInitialPublicOffering_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="NRXS_StockIssuedDuringPeriodSharesCommonStockIssuedUponInitialPublicOffering_2_lbl" xml:lang="en-US">Common shares, issued upon initial public offering, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharePrice" xlink:to="us-gaap_SharePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharePrice_lbl" xml:lang="en-US">Common shares, per share</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_3_lbl" xml:lang="en-US">Net proceeds</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="us-gaap_DebtConversionConvertedInstrumentSharesIssued1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:to="us-gaap_DebtConversionConvertedInstrumentSharesIssued1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtConversionConvertedInstrumentSharesIssued1_lbl" xml:lang="en-US">Conversion shares</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_2_lbl" xml:lang="en-US">Shares issued upon conversion</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockSharesConverted1" xlink:to="us-gaap_ConversionOfStockSharesConverted1_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ConversionOfStockSharesConverted1_2_lbl" xml:lang="en-US">Conversion, interest</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_2_lbl" xml:lang="en-US">Service for payments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConversionOfStockSharesIssued1" xlink:label="us-gaap_ConversionOfStockSharesIssued1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockSharesIssued1" xlink:to="us-gaap_ConversionOfStockSharesIssued1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConversionOfStockSharesIssued1_lbl" xml:lang="en-US">Exercise of warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstandingTerm" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm_lbl" xml:lang="en-US">Warrants, term</link:label>
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_NumberOfEquivalentOfWarrantsDescription" xlink:label="NRXS_NumberOfEquivalentOfWarrantsDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_NumberOfEquivalentOfWarrantsDescription" xlink:to="NRXS_NumberOfEquivalentOfWarrantsDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NRXS_NumberOfEquivalentOfWarrantsDescription_lbl" xml:lang="en-US">Number of equivalent of warrants, description</link:label>
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_ClassOfWarrantOrRightAdditional" xlink:label="NRXS_ClassOfWarrantOrRightAdditional" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_ClassOfWarrantOrRightAdditional" xlink:to="NRXS_ClassOfWarrantOrRightAdditional_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NRXS_ClassOfWarrantOrRightAdditional_lbl" xml:lang="en-US">Number of Warrants, additional</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_4_lbl" xml:lang="en-US">Warrants, canceled</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockDividendRatePercentage" xlink:label="us-gaap_PreferredStockDividendRatePercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockDividendRatePercentage" xlink:to="us-gaap_PreferredStockDividendRatePercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockDividendRatePercentage_lbl" xml:lang="en-US">Preferred stock dividend rate percentage</link:label>
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_PreferredStockSharesRetiredDescription" xlink:label="NRXS_PreferredStockSharesRetiredDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_PreferredStockSharesRetiredDescription" xlink:to="NRXS_PreferredStockSharesRetiredDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NRXS_PreferredStockSharesRetiredDescription_lbl" xml:lang="en-US">Preferred stock, retired description</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFaceAmount" xlink:to="us-gaap_DebtInstrumentFaceAmount_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DebtInstrumentFaceAmount_2_lbl" xml:lang="en-US">Borrowed amount</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockSharesConverted1" xlink:to="us-gaap_ConversionOfStockSharesConverted1_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConversionOfStockSharesConverted1_3_lbl" xml:lang="en-US">Shares converted</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssuedPricePerShare" xlink:to="us-gaap_SharesIssuedPricePerShare_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharesIssuedPricePerShare_3_lbl" xml:lang="en-US">Conversion per shares</link:label>
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_ProceedsFromIssuanceOfStock" xlink:label="NRXS_ProceedsFromIssuanceOfStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_ProceedsFromIssuanceOfStock" xlink:to="NRXS_ProceedsFromIssuanceOfStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NRXS_ProceedsFromIssuanceOfStock_lbl" xml:lang="en-US">Issuance of debt, shares</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfDebt" xlink:to="us-gaap_ProceedsFromIssuanceOfDebt_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfDebt_2_lbl" xml:lang="en-US">Issuance of debt</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssued" xlink:label="us-gaap_SharesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssued" xlink:to="us-gaap_SharesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharesIssued_lbl" xml:lang="en-US">Preferred stock, shares issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DividendsPayableCurrentAndNoncurrent" xlink:label="us-gaap_DividendsPayableCurrentAndNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DividendsPayableCurrentAndNoncurrent" xlink:to="us-gaap_DividendsPayableCurrentAndNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DividendsPayableCurrentAndNoncurrent_lbl" xml:lang="en-US">Dividends declared</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DividendsPreferredStock" xlink:to="us-gaap_DividendsPreferredStock_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DividendsPreferredStock_3_lbl" xml:lang="en-US">Dividends</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockDividendRatePerDollarAmount" xlink:label="us-gaap_PreferredStockDividendRatePerDollarAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockDividendRatePerDollarAmount" xlink:to="us-gaap_PreferredStockDividendRatePerDollarAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockDividendRatePerDollarAmount_lbl" xml:lang="en-US">Dividends, preferred stock per share</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_3_lbl" xml:lang="en-US">Number of Shares</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharePrice" xlink:to="us-gaap_SharePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharePrice_2_lbl" xml:lang="en-US">Stock price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_lbl" xml:lang="en-US">Exercise price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US">Expected term</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xml:lang="en-US">Expected volatility</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xml:lang="en-US">Risk-free interest rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US">Dividend rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US">Number of Options, Outstanding, Beginning balance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_2_lbl" xml:lang="en-US">Weighted Average Remaining Contractual Life (in years), Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xml:lang="en-US">Aggregate Intrinsic Value, Outstanding, Beginning balance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2_lbl" xml:lang="en-US">Number of Options, Outstanding, Ending balance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2_lbl" xml:lang="en-US">Aggregate Intrinsic Value, Outstanding, Ending balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_lbl" xml:lang="en-US">Number of Options, Vested and Exercisable, Ending balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US">Weighted Average Remaining Contractual Life (in years), Vested and Exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Vested and Exercisable, Ending balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_lbl" xml:lang="en-US">Aggregate Intrinsic Value, Vested and Exercisable, Ending balance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssued" xlink:to="us-gaap_SharesIssued_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesIssued_2_lbl" xml:lang="en-US">Shares issued</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensation_2_lbl" xml:lang="en-US">Share based compensation</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_3_lbl" xml:lang="en-US">Granted</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharePrice" xlink:to="us-gaap_SharePrice_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharePrice_3_lbl" xml:lang="en-US">Share price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_PlatformOperatorCryptoAssetTable" xlink:label="srt_PlatformOperatorCryptoAssetTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_PlatformOperatorCryptoAssetTable" xlink:to="srt_PlatformOperatorCryptoAssetTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_PlatformOperatorCryptoAssetTable_lbl" xml:lang="en-US">Platform Operator, Crypto Asset [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_PlatformOperatorCryptoAssetLineItems" xlink:label="srt_PlatformOperatorCryptoAssetLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_PlatformOperatorCryptoAssetLineItems" xlink:to="srt_PlatformOperatorCryptoAssetLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_PlatformOperatorCryptoAssetLineItems_lbl" xml:lang="en-US">Platform Operator, Crypto Asset [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="us-gaap_WarrantsAndRightsOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstanding" xlink:to="us-gaap_WarrantsAndRightsOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_WarrantsAndRightsOutstanding_lbl" xml:lang="en-US">Warrant liabilities, Beginning balance</link:label>
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_AdditionToWarrantLiabilities" xlink:label="NRXS_AdditionToWarrantLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_AdditionToWarrantLiabilities" xlink:to="NRXS_AdditionToWarrantLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NRXS_AdditionToWarrantLiabilities_lbl" xml:lang="en-US">Addition</link:label>
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_ReclassifiedToEquity" xlink:label="NRXS_ReclassifiedToEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_ReclassifiedToEquity" xlink:to="NRXS_ReclassifiedToEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NRXS_ReclassifiedToEquity_lbl" xml:lang="en-US">Reclassified to equity</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAdjustmentOfWarrants" xlink:to="us-gaap_FairValueAdjustmentOfWarrants_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_3_lbl" xml:lang="en-US">Changes in fair value of warrant liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstanding" xlink:to="us-gaap_WarrantsAndRightsOutstanding_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_WarrantsAndRightsOutstanding_2_lbl" xml:lang="en-US">Warrant liabilities, Ending balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_lbl" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_lbl" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:label="us-gaap_WarrantsAndRightsOutstandingMeasurementInput" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:to="us-gaap_WarrantsAndRightsOutstandingMeasurementInput_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantsAndRightsOutstandingMeasurementInput_lbl" xml:lang="en-US">Warrants and rights outstanding, measurement input</link:label>
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_ChangesInDerivativeLiabilities" xlink:label="NRXS_ChangesInDerivativeLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_ChangesInDerivativeLiabilities" xlink:to="NRXS_ChangesInDerivativeLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="NRXS_ChangesInDerivativeLiabilities_lbl" xml:lang="en-US">Derivative liabilities, Beginning balance</link:label>
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_AdditionToDerivativeLiabilities" xlink:label="NRXS_AdditionToDerivativeLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_AdditionToDerivativeLiabilities" xlink:to="NRXS_AdditionToDerivativeLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="NRXS_AdditionToDerivativeLiabilities_lbl" xml:lang="en-US">Addition</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInDerivativeLiabilities" xlink:label="us-gaap_IncreaseDecreaseInDerivativeLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDerivativeLiabilities" xlink:to="us-gaap_IncreaseDecreaseInDerivativeLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInDerivativeLiabilities_lbl" xml:lang="en-US">Changes in fair value of Derivative liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_ExtinguishmentOfDerivativeLiabilities" xlink:label="NRXS_ExtinguishmentOfDerivativeLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_ExtinguishmentOfDerivativeLiabilities" xlink:to="NRXS_ExtinguishmentOfDerivativeLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NRXS_ExtinguishmentOfDerivativeLiabilities_lbl" xml:lang="en-US">Extinguishment of Derivative liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_ChangesInDerivativeLiabilities" xlink:to="NRXS_ChangesInDerivativeLiabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="NRXS_ChangesInDerivativeLiabilities_2_lbl" xml:lang="en-US">Derivative liabilities, Ending balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeLiabilityMeasurementInput" xlink:label="us-gaap_DerivativeLiabilityMeasurementInput" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeLiabilityMeasurementInput" xlink:to="us-gaap_DerivativeLiabilityMeasurementInput_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeLiabilityMeasurementInput_lbl" xml:lang="en-US">Derivative liability, measurement input</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:label="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:to="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_lbl" xml:lang="en-US">Employee contribution percentage</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedContributionPlanAdministrativeExpenses" xlink:label="us-gaap_DefinedContributionPlanAdministrativeExpenses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanAdministrativeExpenses" xlink:to="us-gaap_DefinedContributionPlanAdministrativeExpenses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedContributionPlanAdministrativeExpenses_lbl" xml:lang="en-US">Profit sharing contribution expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_lbl" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingInformationLineItems" xlink:label="us-gaap_SegmentReportingInformationLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_SegmentReportingInformationLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingInformationLineItems_lbl" xml:lang="en-US">Segment Reporting Information [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_3_lbl" xml:lang="en-US">Net Sales</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfGoodsAndServicesSold" xlink:to="us-gaap_CostOfGoodsAndServicesSold_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CostOfGoodsAndServicesSold_2_lbl" xml:lang="en-US">Cost of Goods Sold</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingExpense" xlink:to="us-gaap_SellingExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SellingExpense_2_lbl" xml:lang="en-US">Selling Expenses</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpense_2_lbl" xml:lang="en-US">Research and Development</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LaborAndRelatedExpense" xlink:label="us-gaap_LaborAndRelatedExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LaborAndRelatedExpense" xlink:to="us-gaap_LaborAndRelatedExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LaborAndRelatedExpense_lbl" xml:lang="en-US">Wages and Benefits</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfessionalAndContractServicesExpense" xlink:label="us-gaap_ProfessionalAndContractServicesExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfessionalAndContractServicesExpense" xlink:to="us-gaap_ProfessionalAndContractServicesExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProfessionalAndContractServicesExpense_lbl" xml:lang="en-US">Professional Services</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCostAndExpenseOperating" xlink:label="us-gaap_OtherCostAndExpenseOperating" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCostAndExpenseOperating" xlink:to="us-gaap_OtherCostAndExpenseOperating_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherCostAndExpenseOperating_lbl" xml:lang="en-US">Other Operating Expenses</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_2_lbl" xml:lang="en-US">Other (Expense) Income:</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_Assets_2_lbl" xml:lang="en-US">Assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_2_lbl" xml:lang="en-US">Net cash used by investing activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationAndAmortization" xlink:label="us-gaap_DepreciationAndAmortization" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationAndAmortization" xlink:to="us-gaap_DepreciationAndAmortization_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DepreciationAndAmortization_lbl" xml:lang="en-US">Depreciation and amortization</link:label>
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_ConsultingAndAdvisoryFees" xlink:label="NRXS_ConsultingAndAdvisoryFees" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_ConsultingAndAdvisoryFees" xlink:to="NRXS_ConsultingAndAdvisoryFees_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NRXS_ConsultingAndAdvisoryFees_lbl" xml:lang="en-US">Consulting and advisory fees</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl" xml:lang="en-US">Monthly advisory fee</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockPricePerShare" xlink:to="us-gaap_SaleOfStockPricePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl" xml:lang="en-US">Monthly exercise price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:label="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:to="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_lbl" xml:lang="en-US">Payment for services</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_3_lbl" xml:lang="en-US">Common stock shares issue</link:label>
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_FinanceCharges" xlink:label="NRXS_FinanceCharges" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_FinanceCharges" xlink:to="NRXS_FinanceCharges_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NRXS_FinanceCharges_lbl" xml:lang="en-US">Finance Charges</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherExpenses" xlink:label="us-gaap_OtherExpenses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherExpenses" xlink:to="us-gaap_OtherExpenses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherExpenses_lbl" xml:lang="en-US">Other expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_ExecutiveEmploymentAgreementsTerms" xlink:label="NRXS_ExecutiveEmploymentAgreementsTerms" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_ExecutiveEmploymentAgreementsTerms" xlink:to="NRXS_ExecutiveEmploymentAgreementsTerms_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NRXS_ExecutiveEmploymentAgreementsTerms_lbl" xml:lang="en-US">Executive employment agreements renewals</link:label>
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_DescriptionOfExecutiveEmploymentAgreementsRenewals" xlink:label="NRXS_DescriptionOfExecutiveEmploymentAgreementsRenewals" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_DescriptionOfExecutiveEmploymentAgreementsRenewals" xlink:to="NRXS_DescriptionOfExecutiveEmploymentAgreementsRenewals_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NRXS_DescriptionOfExecutiveEmploymentAgreementsRenewals_lbl" xml:lang="en-US">Description of Executive employment agreements renewals</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SalariesAndWages" xlink:label="us-gaap_SalariesAndWages" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SalariesAndWages" xlink:to="us-gaap_SalariesAndWages_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SalariesAndWages_lbl" xml:lang="en-US">Base salaries for nine key employees</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncentiveFeeExpense" xlink:label="us-gaap_IncentiveFeeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncentiveFeeExpense" xlink:to="us-gaap_IncentiveFeeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncentiveFeeExpense_lbl" xml:lang="en-US">Incentive payments</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AccruedLiabilitiesCurrent_3_lbl" xml:lang="en-US">Accrued amount for backpay</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan_lbl" xml:lang="en-US">Seven key employees stock options</link:label>
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_SpecialBonusPercentage" xlink:label="NRXS_SpecialBonusPercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_SpecialBonusPercentage" xlink:to="NRXS_SpecialBonusPercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NRXS_SpecialBonusPercentage_lbl" xml:lang="en-US">Special bonus percentage</link:label>
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_KeyEmployeeExercisePercentage" xlink:label="NRXS_KeyEmployeeExercisePercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_KeyEmployeeExercisePercentage" xlink:to="NRXS_KeyEmployeeExercisePercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NRXS_KeyEmployeeExercisePercentage_lbl" xml:lang="en-US">Key employee exercise percentage</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedBonusesCurrent" xlink:label="us-gaap_AccruedBonusesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedBonusesCurrent" xlink:to="us-gaap_AccruedBonusesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedBonusesCurrent_lbl" xml:lang="en-US">Incentive bonus</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_3_lbl" xml:lang="en-US">Common stock with a fair value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireEquitySecuritiesFvNi" xlink:label="us-gaap_PaymentsToAcquireEquitySecuritiesFvNi" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireEquitySecuritiesFvNi" xlink:to="us-gaap_PaymentsToAcquireEquitySecuritiesFvNi_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquireEquitySecuritiesFvNi_lbl" xml:lang="en-US">One time payment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US">Stock option, exercise</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesFairValueDisclosure" xlink:label="us-gaap_AccruedLiabilitiesFairValueDisclosure" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesFairValueDisclosure" xlink:to="us-gaap_AccruedLiabilitiesFairValueDisclosure_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AccruedLiabilitiesFairValueDisclosure_lbl" xml:lang="en-US">Accrued expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingencyDamagesSoughtValue" xlink:label="us-gaap_LossContingencyDamagesSoughtValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingencyDamagesSoughtValue" xlink:to="us-gaap_LossContingencyDamagesSoughtValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LossContingencyDamagesSoughtValue_lbl" xml:lang="en-US">Sought compensatory damages</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedPatentsGross" xlink:label="us-gaap_FiniteLivedPatentsGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedPatentsGross" xlink:to="us-gaap_FiniteLivedPatentsGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedPatentsGross_lbl" xml:lang="en-US">Patent value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_HealthCareOrganizationStopLossInsurancePremiumExpense" xlink:label="us-gaap_HealthCareOrganizationStopLossInsurancePremiumExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_HealthCareOrganizationStopLossInsurancePremiumExpense" xlink:to="us-gaap_HealthCareOrganizationStopLossInsurancePremiumExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_HealthCareOrganizationStopLossInsurancePremiumExpense_lbl" xml:lang="en-US">Stop loss insurance premium expense</link:label>
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_HealthCareOrganizationStopLossInsurancePremiumPercentage" xlink:label="NRXS_HealthCareOrganizationStopLossInsurancePremiumPercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_HealthCareOrganizationStopLossInsurancePremiumPercentage" xlink:to="NRXS_HealthCareOrganizationStopLossInsurancePremiumPercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NRXS_HealthCareOrganizationStopLossInsurancePremiumPercentage_lbl" xml:lang="en-US">Stop loss insurance premium percentage</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Total current provision</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Federal</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_lbl" xml:lang="en-US">State</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Total deferred benefit</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Valuation allowance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Total income tax provision</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US">Federal statutory income tax rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xml:lang="en-US">State tax rate, net of federal benefit</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Change in valuation allowance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xml:lang="en-US">Effective income tax rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xml:lang="en-US">Net operating losses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_lbl" xml:lang="en-US">Stock based compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_DeferredTaxAssetsNotesReceivableReserve" xlink:label="NRXS_DeferredTaxAssetsNotesReceivableReserve" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_DeferredTaxAssetsNotesReceivableReserve" xlink:to="NRXS_DeferredTaxAssetsNotesReceivableReserve_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NRXS_DeferredTaxAssetsNotesReceivableReserve_lbl" xml:lang="en-US">Notes receivable reserve</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsOther" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsOther" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsOther" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsOther_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsOther_lbl" xml:lang="en-US">Accrued compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_DeferredTaxAssetsAccountsPayable" xlink:label="NRXS_DeferredTaxAssetsAccountsPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_DeferredTaxAssetsAccountsPayable" xlink:to="NRXS_DeferredTaxAssetsAccountsPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="NRXS_DeferredTaxAssetsAccountsPayable_lbl" xml:lang="en-US">Accounts payable</link:label>
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_DeferredTaxAssetsOperatingLeasePayable" xlink:label="NRXS_DeferredTaxAssetsOperatingLeasePayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_DeferredTaxAssetsOperatingLeasePayable" xlink:to="NRXS_DeferredTaxAssetsOperatingLeasePayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NRXS_DeferredTaxAssetsOperatingLeasePayable_lbl" xml:lang="en-US">Operating lease payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOther" xlink:to="us-gaap_DeferredTaxAssetsOther_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeferredTaxAssetsOther_lbl" xml:lang="en-US">Other</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xml:lang="en-US">Total gross deferred tax assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Valuation allowance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xml:lang="en-US">Total deferred tax assets</link:label>
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset" xlink:label="NRXS_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset" xlink:to="NRXS_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NRXS_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US">Operating lease right of use asset</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesPrepaidExpenses" xlink:label="us-gaap_DeferredTaxLiabilitiesPrepaidExpenses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesPrepaidExpenses" xlink:to="us-gaap_DeferredTaxLiabilitiesPrepaidExpenses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxLiabilitiesPrepaidExpenses_lbl" xml:lang="en-US">Prepaid expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_DeferredTaxLiabilityAccountsReceivable" xlink:label="NRXS_DeferredTaxLiabilityAccountsReceivable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_DeferredTaxLiabilityAccountsReceivable" xlink:to="NRXS_DeferredTaxLiabilityAccountsReceivable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NRXS_DeferredTaxLiabilityAccountsReceivable_lbl" xml:lang="en-US">Accounts receivable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesOther" xlink:label="us-gaap_DeferredTaxLiabilitiesOther" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesOther" xlink:to="us-gaap_DeferredTaxLiabilitiesOther_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeferredTaxLiabilitiesOther_lbl" xml:lang="en-US">Other</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="us-gaap_DeferredIncomeTaxLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="us-gaap_DeferredIncomeTaxLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_lbl" xml:lang="en-US">Total deferred tax liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="us-gaap_DeferredTaxLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilities" xlink:to="us-gaap_DeferredTaxLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxLiabilities_lbl" xml:lang="en-US">Deferred tax assets, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="us-gaap_OperatingLossCarryforwardsTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_OperatingLossCarryforwardsTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwardsTable_lbl" xml:lang="en-US">Operating Loss Carryforwards [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_OperatingLossCarryforwardsLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems_lbl" xml:lang="en-US">Operating Loss Carryforwards [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_lbl" xml:lang="en-US">Total state NOL carryforwards</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTable_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_2_lbl" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards, State and Local</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Other Adjustments, Percent</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTable_lbl" xml:lang="en-US">Subsequent Event [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventLineItems_lbl" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_lbl" xml:lang="en-US">Restricted stock, granted</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_2_lbl" xml:lang="en-US">Investor converted warrants into common shares</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_WarrantLiabilities" xlink:to="NRXS_WarrantLiabilities_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NRXS_WarrantLiabilities_doc" xml:lang="en-US">Warrant liabilities.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_ConvertibleSeriesBPreferredStockMember" xlink:to="NRXS_ConvertibleSeriesBPreferredStockMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NRXS_ConvertibleSeriesBPreferredStockMember_doc" xml:lang="en-US">Convertible Series B Preferred Stock [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_FinancingCharges" xlink:to="NRXS_FinancingCharges_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NRXS_FinancingCharges_doc" xml:lang="en-US">Financing charges.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_ConvertibleSeriesAPreferredStockMember" xlink:to="NRXS_ConvertibleSeriesAPreferredStockMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NRXS_ConvertibleSeriesAPreferredStockMember_doc" xml:lang="en-US">Convertible Series A Preferred stock [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_ConvertibleSeriesSeedPreferredStockMember" xlink:to="NRXS_ConvertibleSeriesSeedPreferredStockMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NRXS_ConvertibleSeriesSeedPreferredStockMember_doc" xml:lang="en-US">Convertible Series Seed Preferred Stock [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_StockIssuedDuringPeriodValueCommonStockIssuedUponInitialPublicOffering" xlink:to="NRXS_StockIssuedDuringPeriodValueCommonStockIssuedUponInitialPublicOffering_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NRXS_StockIssuedDuringPeriodValueCommonStockIssuedUponInitialPublicOffering_doc" xml:lang="en-US">Stock issued during period value common stock issued upon initial public offering.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_StockIssuedDuringPeriodValueWarrantsExercised" xlink:to="NRXS_StockIssuedDuringPeriodValueWarrantsExercised_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NRXS_StockIssuedDuringPeriodValueWarrantsExercised_doc" xml:lang="en-US">Stock issued during period value warrants exercised.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_AdditionalPaidInCapitalFromWarrantsIssuedAsDebtDiscount" xlink:to="NRXS_AdditionalPaidInCapitalFromWarrantsIssuedAsDebtDiscount_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NRXS_AdditionalPaidInCapitalFromWarrantsIssuedAsDebtDiscount_doc" xml:lang="en-US">Additional paid in capital from warrants issued as debt discount.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_StockIssuedDuringPeriodValuePreferredStock" xlink:to="NRXS_StockIssuedDuringPeriodValuePreferredStock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NRXS_StockIssuedDuringPeriodValuePreferredStock_doc" xml:lang="en-US">Stock issued during period value preferred stock</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_NoncashLeaseExpense" xlink:to="NRXS_NoncashLeaseExpense_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NRXS_NoncashLeaseExpense_doc" xml:lang="en-US">Noncash lease expense.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_IssuanceOfCommonStockForNoncashConsideration" xlink:to="NRXS_IssuanceOfCommonStockForNoncashConsideration_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NRXS_IssuanceOfCommonStockForNoncashConsideration_doc" xml:lang="en-US">Issuance of common stock for noncash consideration.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_IssuanceOfWarrantsForNoncashConsideration" xlink:to="NRXS_IssuanceOfWarrantsForNoncashConsideration_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NRXS_IssuanceOfWarrantsForNoncashConsideration_doc" xml:lang="en-US">Issuance of warrants for non-cash consideration.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_FinanceCharges" xlink:to="NRXS_FinanceCharges_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NRXS_FinanceCharges_doc" xml:lang="en-US">Finance charges.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_IncreaseDecreaseInCustomerDeposit" xlink:to="NRXS_IncreaseDecreaseInCustomerDeposit_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NRXS_IncreaseDecreaseInCustomerDeposit_doc" xml:lang="en-US">Increase decrease in customer deposit.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_RecognitionOfRightOfUseAsset" xlink:to="NRXS_RecognitionOfRightOfUseAsset_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NRXS_RecognitionOfRightOfUseAsset_doc" xml:lang="en-US">Recognition of right of use asset.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_ConversionOfConvertiblePromissoryNotesToSeriesBPreferredStock" xlink:to="NRXS_ConversionOfConvertiblePromissoryNotesToSeriesBPreferredStock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NRXS_ConversionOfConvertiblePromissoryNotesToSeriesBPreferredStock_doc" xml:lang="en-US">Conversion of convertible promissory notes to series B preferred stock.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_FairValueOfWarrantLiabilitiesOfWarrantsFromConvertibleNotes" xlink:to="NRXS_FairValueOfWarrantLiabilitiesOfWarrantsFromConvertibleNotes_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NRXS_FairValueOfWarrantLiabilitiesOfWarrantsFromConvertibleNotes_doc" xml:lang="en-US">Fair value of warrant liabilities of warrants from convertible notes.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_FairValueOfDerivativeLiabilitiesOfConversionFeatureFromConvertibleNotes" xlink:to="NRXS_FairValueOfDerivativeLiabilitiesOfConversionFeatureFromConvertibleNotes_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NRXS_FairValueOfDerivativeLiabilitiesOfConversionFeatureFromConvertibleNotes_doc" xml:lang="en-US">Fair value of derivative liabilities of conversion feature from convertible notes.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_ReclassificationOfWarrantLiabilityToEquity" xlink:to="NRXS_ReclassificationOfWarrantLiabilityToEquity_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NRXS_ReclassificationOfWarrantLiabilityToEquity_doc" xml:lang="en-US">Reclassification of warrant liability to equity.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_ConversionOfPreferredStockToCommonStock" xlink:to="NRXS_ConversionOfPreferredStockToCommonStock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NRXS_ConversionOfPreferredStockToCommonStock_doc" xml:lang="en-US">Conversion of preferred stock to common stock.</link:label>
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_OfferingCostsPaid" xlink:label="NRXS_OfferingCostsPaid" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_OfferingCostsPaid" xlink:to="NRXS_OfferingCostsPaid_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NRXS_OfferingCostsPaid_doc" xml:lang="en-US">Offering costs paid</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_FairValueOfWarrantsFromDebtDiscountInConvertibleNotesClassifiedOfAdditionalPaidInCapital" xlink:to="NRXS_FairValueOfWarrantsFromDebtDiscountInConvertibleNotesClassifiedOfAdditionalPaidInCapital_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NRXS_FairValueOfWarrantsFromDebtDiscountInConvertibleNotesClassifiedOfAdditionalPaidInCapital_doc" xml:lang="en-US">Fair value of warrants from debt discount in convertible notes classified of additional paid in capital.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_WriteoffOfDebtDiscountOnConvertibleNotesClassifiedAsAdditionalPaidInCapital" xlink:to="NRXS_WriteoffOfDebtDiscountOnConvertibleNotesClassifiedAsAdditionalPaidInCapital_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NRXS_WriteoffOfDebtDiscountOnConvertibleNotesClassifiedAsAdditionalPaidInCapital_doc" xml:lang="en-US">Writeoff of debt discount on convertible notes classified as additional paid in capital</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_DeferredOfferingCostsPaid" xlink:to="NRXS_DeferredOfferingCostsPaid_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NRXS_DeferredOfferingCostsPaid_doc" xml:lang="en-US">Deferred offering costs paid.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_AlexanderCapitalLPMember" xlink:to="NRXS_AlexanderCapitalLPMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NRXS_AlexanderCapitalLPMember_doc" xml:lang="en-US">Alexander Capital LP [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_PurchaseOfAdditionalStockOnNumberOfOptionsNotExercised" xlink:to="NRXS_PurchaseOfAdditionalStockOnNumberOfOptionsNotExercised_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NRXS_PurchaseOfAdditionalStockOnNumberOfOptionsNotExercised_doc" xml:lang="en-US">Purchase of additional stock on number of options not exercised.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_UnderwritersDiscountPercentage" xlink:to="NRXS_UnderwritersDiscountPercentage_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NRXS_UnderwritersDiscountPercentage_doc" xml:lang="en-US">Underwriters discount percentage.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_NonaccountableExpenseAllowancePercentage" xlink:to="NRXS_NonaccountableExpenseAllowancePercentage_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NRXS_NonaccountableExpenseAllowancePercentage_doc" xml:lang="en-US">Nonaccountable expense allowance percentage.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_CashFeePercentage" xlink:to="NRXS_CashFeePercentage_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NRXS_CashFeePercentage_doc" xml:lang="en-US">Cash fee percentage.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_ReimbursementExpenses" xlink:to="NRXS_ReimbursementExpenses_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NRXS_ReimbursementExpenses_doc" xml:lang="en-US">Reimbursement expenses.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_OfferingPricePerPercentage" xlink:to="NRXS_OfferingPricePerPercentage_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NRXS_OfferingPricePerPercentage_doc" xml:lang="en-US">Offering price per percentage.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_InventoryExpenses" xlink:to="NRXS_InventoryExpenses_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NRXS_InventoryExpenses_doc" xml:lang="en-US">Inventory expenses.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_ScheduleOfPropertyPlantAndEquipmentUsefulLivesTableTextBlock" xlink:to="NRXS_ScheduleOfPropertyPlantAndEquipmentUsefulLivesTableTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NRXS_ScheduleOfPropertyPlantAndEquipmentUsefulLivesTableTextBlock_doc" xml:lang="en-US">Schedule of Property Plant And Equipment Useful Lives [Table Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_TrademarkAgreementMember" xlink:label="NRXS_TrademarkAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_TrademarkAgreementMember" xlink:to="NRXS_TrademarkAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NRXS_TrademarkAgreementMember_doc" xml:lang="en-US">Trademark Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_InitialPaymentMember" xlink:label="NRXS_InitialPaymentMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_InitialPaymentMember" xlink:to="NRXS_InitialPaymentMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NRXS_InitialPaymentMember_doc" xml:lang="en-US">Initial Payment [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_SecondAndFinalPaymentMember" xlink:label="NRXS_SecondAndFinalPaymentMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_SecondAndFinalPaymentMember" xlink:to="NRXS_SecondAndFinalPaymentMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NRXS_SecondAndFinalPaymentMember_doc" xml:lang="en-US">Second and Final Payment [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_LicensingAgreementMember" xlink:to="NRXS_LicensingAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NRXS_LicensingAgreementMember_doc" xml:lang="en-US">Licensing Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_WarrantLiabilityPolicyTextBlock" xlink:to="NRXS_WarrantLiabilityPolicyTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NRXS_WarrantLiabilityPolicyTextBlock_doc" xml:lang="en-US">Warrant Liability [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_ChannelPartnersCapitalMember" xlink:to="NRXS_ChannelPartnersCapitalMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NRXS_ChannelPartnersCapitalMember_doc" xml:lang="en-US">Channel Partners Capital [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_WarrantsMember" xlink:to="NRXS_WarrantsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NRXS_WarrantsMember_doc" xml:lang="en-US">Warrants [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_AllOtherStatesMember" xlink:to="NRXS_AllOtherStatesMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NRXS_AllOtherStatesMember_doc" xml:lang="en-US">All other States [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_CustomerMember" xlink:to="NRXS_CustomerMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NRXS_CustomerMember_doc" xml:lang="en-US">Customer [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_CustomerOneMember" xlink:label="NRXS_CustomerOneMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_CustomerOneMember" xlink:to="NRXS_CustomerOneMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NRXS_CustomerOneMember_doc" xml:lang="en-US">Customer One [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_CustomerTwoMember" xlink:label="NRXS_CustomerTwoMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_CustomerTwoMember" xlink:to="NRXS_CustomerTwoMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NRXS_CustomerTwoMember_doc" xml:lang="en-US">Customer Two [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_CustomerThreeMember" xlink:label="NRXS_CustomerThreeMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_CustomerThreeMember" xlink:to="NRXS_CustomerThreeMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NRXS_CustomerThreeMember_doc" xml:lang="en-US">Customer Three [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_CustomerFourMember" xlink:label="NRXS_CustomerFourMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_CustomerFourMember" xlink:to="NRXS_CustomerFourMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NRXS_CustomerFourMember_doc" xml:lang="en-US">Customer Four [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_GoingConcernPolicyTextBlock" xlink:to="NRXS_GoingConcernPolicyTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NRXS_GoingConcernPolicyTextBlock_doc" xml:lang="en-US">Going Concern [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_WorkingCapitalDeficit" xlink:to="NRXS_WorkingCapitalDeficit_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NRXS_WorkingCapitalDeficit_doc" xml:lang="en-US">Working capital deficit.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_RecentlyIssuedAccountingPronouncementsPolicyTextBlock" xlink:to="NRXS_RecentlyIssuedAccountingPronouncementsPolicyTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NRXS_RecentlyIssuedAccountingPronouncementsPolicyTextBlock_doc" xml:lang="en-US">Recently Issued Accounting Pronouncements [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_ShareholdersOneAndTwoMember" xlink:to="NRXS_ShareholdersOneAndTwoMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NRXS_ShareholdersOneAndTwoMember_doc" xml:lang="en-US">Shareholders 1 and 2 [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_AllowanceForInterestReceivableCurrent" xlink:to="NRXS_AllowanceForInterestReceivableCurrent_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NRXS_AllowanceForInterestReceivableCurrent_doc" xml:lang="en-US">Allowance for interest receivable current.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_ShareHolderOneMember" xlink:to="NRXS_ShareHolderOneMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NRXS_ShareHolderOneMember_doc" xml:lang="en-US">Shareholder 1 [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_ShareHolderTwoMember" xlink:to="NRXS_ShareHolderTwoMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NRXS_ShareHolderTwoMember_doc" xml:lang="en-US">Shareholder 2 [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_InterestIncomeGrossCurrent" xlink:to="NRXS_InterestIncomeGrossCurrent_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NRXS_InterestIncomeGrossCurrent_doc" xml:lang="en-US">Interest income gross current.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_AllowanceForInterestIncomeCurrent" xlink:to="NRXS_AllowanceForInterestIncomeCurrent_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NRXS_AllowanceForInterestIncomeCurrent_doc" xml:lang="en-US">Allowance for interest income current.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_InterestIncomeCurrent" xlink:to="NRXS_InterestIncomeCurrent_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NRXS_InterestIncomeCurrent_doc" xml:lang="en-US">Interest income current.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_ScheduleOfRelatedPartyLoansTableTextBlock" xlink:to="NRXS_ScheduleOfRelatedPartyLoansTableTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NRXS_ScheduleOfRelatedPartyLoansTableTextBlock_doc" xml:lang="en-US">Schedule Of Related Party Loans [Table Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_OtherConvertiblesMember" xlink:to="NRXS_OtherConvertiblesMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NRXS_OtherConvertiblesMember_doc" xml:lang="en-US">Other Convertibles [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_InterestAndServiceFeeAccrued" xlink:to="NRXS_InterestAndServiceFeeAccrued_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NRXS_InterestAndServiceFeeAccrued_doc" xml:lang="en-US">Interest and service fee accrued.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_MrWatkinsMember" xlink:to="NRXS_MrWatkinsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NRXS_MrWatkinsMember_doc" xml:lang="en-US">Mr. Watkins [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_MrSealeMember" xlink:to="NRXS_MrSealeMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NRXS_MrSealeMember_doc" xml:lang="en-US">Mr Seale [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_AccruedCompensationAndBenefitsCurrent" xlink:to="NRXS_AccruedCompensationAndBenefitsCurrent_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NRXS_AccruedCompensationAndBenefitsCurrent_doc" xml:lang="en-US">Accrued compensation and benefits current.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_AdvisoryFees" xlink:to="NRXS_AdvisoryFees_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NRXS_AdvisoryFees_doc" xml:lang="en-US">Advisory fees</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_ExchangeListingLLCMember" xlink:to="NRXS_ExchangeListingLLCMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NRXS_ExchangeListingLLCMember_doc" xml:lang="en-US">Exchange Listing LLC [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_PromissoryNoteMember" xlink:to="NRXS_PromissoryNoteMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NRXS_PromissoryNoteMember_doc" xml:lang="en-US">Promissory Note [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_SecondPromissoryNoteMember" xlink:to="NRXS_SecondPromissoryNoteMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NRXS_SecondPromissoryNoteMember_doc" xml:lang="en-US">Second Promissory Note [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_TwoThousandTwentyTwoConvertibleNotesMember" xlink:to="NRXS_TwoThousandTwentyTwoConvertibleNotesMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NRXS_TwoThousandTwentyTwoConvertibleNotesMember_doc" xml:lang="en-US">2022 Convertible Notes [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_DebtInstrumentDiscountRate" xlink:to="NRXS_DebtInstrumentDiscountRate_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NRXS_DebtInstrumentDiscountRate_doc" xml:lang="en-US">Debt instrument discount rate.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_DebtWarrantConversionDescription" xlink:to="NRXS_DebtWarrantConversionDescription_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NRXS_DebtWarrantConversionDescription_doc" xml:lang="en-US">Debt warrant conversion description.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_ClassOfWarrantDiscountRate" xlink:to="NRXS_ClassOfWarrantDiscountRate_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NRXS_ClassOfWarrantDiscountRate_doc" xml:lang="en-US">Class of warrant discount rate.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_ConvertiblePromissoryNoteMember" xlink:to="NRXS_ConvertiblePromissoryNoteMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NRXS_ConvertiblePromissoryNoteMember_doc" xml:lang="en-US">Convertible Promissory Note [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_AccreditedInvestorsMember" xlink:to="NRXS_AccreditedInvestorsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NRXS_AccreditedInvestorsMember_doc" xml:lang="en-US">Accredited Investors [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_TwoThousandTwentyThreeConvertibleNotesMember" xlink:to="NRXS_TwoThousandTwentyThreeConvertibleNotesMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NRXS_TwoThousandTwentyThreeConvertibleNotesMember_doc" xml:lang="en-US">2023 Convertible Notes [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_SignatureBankMember" xlink:to="NRXS_SignatureBankMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NRXS_SignatureBankMember_doc" xml:lang="en-US">Signature Bank [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_StockIssuedDuringPeriodSharesCommonStockIssuedUponInitialPublicOffering" xlink:to="NRXS_StockIssuedDuringPeriodSharesCommonStockIssuedUponInitialPublicOffering_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NRXS_StockIssuedDuringPeriodSharesCommonStockIssuedUponInitialPublicOffering_doc" xml:lang="en-US">Stock issued during period shares common stock issued upon initial public offering</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_ConvertiblePromissoryNotesMember" xlink:to="NRXS_ConvertiblePromissoryNotesMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NRXS_ConvertiblePromissoryNotesMember_doc" xml:lang="en-US">Convertible Promissory Notes [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_TwoThousandTwentyFourConvertiblePromissoryNotesMember" xlink:to="NRXS_TwoThousandTwentyFourConvertiblePromissoryNotesMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NRXS_TwoThousandTwentyFourConvertiblePromissoryNotesMember_doc" xml:lang="en-US">2024 Convertible Promissory Notes [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_CumulativeDividendsPercent" xlink:to="NRXS_CumulativeDividendsPercent_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NRXS_CumulativeDividendsPercent_doc" xml:lang="en-US">Percentage of cumulative dividends.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_TwoThousandTwentyFourConvertibleNotesMember" xlink:to="NRXS_TwoThousandTwentyFourConvertibleNotesMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NRXS_TwoThousandTwentyFourConvertibleNotesMember_doc" xml:lang="en-US">2024 Convertible Notes [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_CommonStockConvertibleConversionPrice" xlink:to="NRXS_CommonStockConvertibleConversionPrice_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NRXS_CommonStockConvertibleConversionPrice_doc" xml:lang="en-US">Common stock convertible conversion price.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_VersaillesIndianaMember" xlink:to="NRXS_VersaillesIndianaMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NRXS_VersaillesIndianaMember_doc" xml:lang="en-US">Versailles Indiana [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_CarmelIndianaMember" xlink:to="NRXS_CarmelIndianaMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NRXS_CarmelIndianaMember_doc" xml:lang="en-US">Carmel Indiana [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_VendorsMember" xlink:to="NRXS_VendorsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NRXS_VendorsMember_doc" xml:lang="en-US">Vendors [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsConvertedPrefundedWarrants" xlink:to="NRXS_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsConvertedPrefundedWarrants_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NRXS_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsConvertedPrefundedWarrants_doc" xml:lang="en-US">Share based compensation arrangement by share based payment award non option equity instruments converted prefunded warrants.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsWeightedAverageExercisePriceCancelledExpiredNumber" xlink:to="NRXS_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsWeightedAverageExercisePriceCancelledExpiredNumber_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NRXS_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsWeightedAverageExercisePriceCancelledExpiredNumber_doc" xml:lang="en-US">Share based compensation arrangement by share based payment award non options weighted average exercise price cancelled expired number.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsConvertedPrefundedWarrantsInPeriodWeightedAverageExercisePrice" xlink:to="NRXS_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsConvertedPrefundedWarrantsInPeriodWeightedAverageExercisePrice_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NRXS_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsConvertedPrefundedWarrantsInPeriodWeightedAverageExercisePrice_doc" xml:lang="en-US">Share based compensation arrangements by share based payment award options converted prefunded warrants in period weighted average exercise price.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsWeightedAverageRemainingContracualLifeOutstandingNumberGranted" xlink:to="NRXS_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsWeightedAverageRemainingContracualLifeOutstandingNumberGranted_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NRXS_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsWeightedAverageRemainingContracualLifeOutstandingNumberGranted_doc" xml:lang="en-US">Share based compensation arrangement by share based payment award non options weighted average remaining contracual life outstanding number granted.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_ExecutiveEmploymentAgreementsTerms" xlink:to="NRXS_ExecutiveEmploymentAgreementsTerms_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NRXS_ExecutiveEmploymentAgreementsTerms_doc" xml:lang="en-US">Executive employment agreements terms.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_ExecutiveEmploymentAgreementsMember" xlink:to="NRXS_ExecutiveEmploymentAgreementsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NRXS_ExecutiveEmploymentAgreementsMember_doc" xml:lang="en-US">Executive Employment Agreements [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_DescriptionOfExecutiveEmploymentAgreementsRenewals" xlink:to="NRXS_DescriptionOfExecutiveEmploymentAgreementsRenewals_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NRXS_DescriptionOfExecutiveEmploymentAgreementsRenewals_doc" xml:lang="en-US">Description of executive employment agreements renewals.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_SpecialBonusPercentage" xlink:to="NRXS_SpecialBonusPercentage_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NRXS_SpecialBonusPercentage_doc" xml:lang="en-US">Special bonus percentage.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_KeyEmployeeExercisePercentage" xlink:to="NRXS_KeyEmployeeExercisePercentage_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NRXS_KeyEmployeeExercisePercentage_doc" xml:lang="en-US">Key employee exercise percentage.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_ScheduleOfWarrantActivityForPreferredStockTableTextBlock" xlink:to="NRXS_ScheduleOfWarrantActivityForPreferredStockTableTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NRXS_ScheduleOfWarrantActivityForPreferredStockTableTextBlock_doc" xml:lang="en-US">Schedule of warrant activity for preferred stock [Table Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_HealthBenefitPlanDisclosureTextBlock" xlink:to="NRXS_HealthBenefitPlanDisclosureTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NRXS_HealthBenefitPlanDisclosureTextBlock_doc" xml:lang="en-US">Health benefit plan disclosure [Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_HealthCareOrganizationStopLossInsurancePremiumPercentage" xlink:to="NRXS_HealthCareOrganizationStopLossInsurancePremiumPercentage_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NRXS_HealthCareOrganizationStopLossInsurancePremiumPercentage_doc" xml:lang="en-US">Health care organization stop loss insurance premium percentage.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsCommonStockWarrant" xlink:to="NRXS_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsCommonStockWarrant_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NRXS_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsCommonStockWarrant_doc" xml:lang="en-US">Share based compensation arrangement by share based payment award non option equity instruments common stock warrant.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsWeightedAverageExercisePriceCommonStockWarrant" xlink:to="NRXS_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsWeightedAverageExercisePriceCommonStockWarrant_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NRXS_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsWeightedAverageExercisePriceCommonStockWarrant_doc" xml:lang="en-US">Share based compensation arrangement by share based payment award non options weighted average exercise price common stock warrant.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_InvestorWarrantOneMember" xlink:to="NRXS_InvestorWarrantOneMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NRXS_InvestorWarrantOneMember_doc" xml:lang="en-US">Investor Warrant W-01 [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_InvestorWarrantPSAOneMember" xlink:to="NRXS_InvestorWarrantPSAOneMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NRXS_InvestorWarrantPSAOneMember_doc" xml:lang="en-US">Investor Warrant PSA-01 [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_WarrantExpirationDateDescription" xlink:to="NRXS_WarrantExpirationDateDescription_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NRXS_WarrantExpirationDateDescription_doc" xml:lang="en-US">Warrant expiration date description.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_UnderwriterWarrantsMember" xlink:to="NRXS_UnderwriterWarrantsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NRXS_UnderwriterWarrantsMember_doc" xml:lang="en-US">Underwriter Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_IncreaseDecreaseInWarrantLiability" xlink:label="NRXS_IncreaseDecreaseInWarrantLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_IncreaseDecreaseInWarrantLiability" xlink:to="NRXS_IncreaseDecreaseInWarrantLiability_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NRXS_IncreaseDecreaseInWarrantLiability_doc" xml:lang="en-US">Reduced warrant liability.</link:label>
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_ShareLiabilitiesCurrent" xlink:label="NRXS_ShareLiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_ShareLiabilitiesCurrent" xlink:to="NRXS_ShareLiabilitiesCurrent_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NRXS_ShareLiabilitiesCurrent_doc" xml:lang="en-US">Share liabilities current.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_TwentySeventeenStockCompensationPlanMember" xlink:to="NRXS_TwentySeventeenStockCompensationPlanMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NRXS_TwentySeventeenStockCompensationPlanMember_doc" xml:lang="en-US">2017 Stock Compensation Plan [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_NoncashInterestExpense" xlink:label="NRXS_NoncashInterestExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_NoncashInterestExpense" xlink:to="NRXS_NoncashInterestExpense_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NRXS_NoncashInterestExpense_doc" xml:lang="en-US">Noncash interest expense.</link:label>
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_OfferingCostsInAdvanceOfSaleOfCommonStock" xlink:label="NRXS_OfferingCostsInAdvanceOfSaleOfCommonStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_OfferingCostsInAdvanceOfSaleOfCommonStock" xlink:to="NRXS_OfferingCostsInAdvanceOfSaleOfCommonStock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NRXS_OfferingCostsInAdvanceOfSaleOfCommonStock_doc" xml:lang="en-US">Offering costs in advance of sale of common stock.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_AdditionToWarrantLiabilities" xlink:to="NRXS_AdditionToWarrantLiabilities_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NRXS_AdditionToWarrantLiabilities_doc" xml:lang="en-US">Addition to warrant liabilities.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_ReclassifiedToEquity" xlink:to="NRXS_ReclassifiedToEquity_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NRXS_ReclassifiedToEquity_doc" xml:lang="en-US">Reclassified to equity.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_ScheduleOfChangesInWarrantLiabilitiesTableTextBlock" xlink:to="NRXS_ScheduleOfChangesInWarrantLiabilitiesTableTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NRXS_ScheduleOfChangesInWarrantLiabilitiesTableTextBlock_doc" xml:lang="en-US">Schedule of Changes in Warrant Liabilities [Table Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_AdditionToDerivativeLiabilities" xlink:to="NRXS_AdditionToDerivativeLiabilities_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NRXS_AdditionToDerivativeLiabilities_doc" xml:lang="en-US">Addition to derivative liabilities.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_ExtinguishmentOfDerivativeLiabilities" xlink:to="NRXS_ExtinguishmentOfDerivativeLiabilities_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NRXS_ExtinguishmentOfDerivativeLiabilities_doc" xml:lang="en-US">Extinguishment of derivative liabilities.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_SettlementAgreementMember" xlink:to="NRXS_SettlementAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NRXS_SettlementAgreementMember_doc" xml:lang="en-US">Settlement Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_ProceedsFromIssuanceOfStock" xlink:to="NRXS_ProceedsFromIssuanceOfStock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NRXS_ProceedsFromIssuanceOfStock_doc" xml:lang="en-US">Proceeds from issuance of stock.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_CustomerAMember" xlink:to="NRXS_CustomerAMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NRXS_CustomerAMember_doc" xml:lang="en-US">Customer A [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_CustomerBMember" xlink:to="NRXS_CustomerBMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NRXS_CustomerBMember_doc" xml:lang="en-US">Customer B [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_CustomerCMember" xlink:to="NRXS_CustomerCMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NRXS_CustomerCMember_doc" xml:lang="en-US">Customer C [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_EmployementAgreementMember" xlink:to="NRXS_EmployementAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NRXS_EmployementAgreementMember_doc" xml:lang="en-US">Employement Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_TwoThousandTwentyThreeConvertiblePromissoryNotesMember" xlink:to="NRXS_TwoThousandTwentyThreeConvertiblePromissoryNotesMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NRXS_TwoThousandTwentyThreeConvertiblePromissoryNotesMember_doc" xml:lang="en-US">2023 Convertible Promissory Notes [Membe]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_AdvisoryAgreementMember" xlink:to="NRXS_AdvisoryAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NRXS_AdvisoryAgreementMember_doc" xml:lang="en-US">Advisory Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_UnderwritingAgreementMember" xlink:to="NRXS_UnderwritingAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NRXS_UnderwritingAgreementMember_doc" xml:lang="en-US">Underwriting Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsCancelledWeightedAverageRemainingContractualTerm1" xlink:to="NRXS_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsCancelledWeightedAverageRemainingContractualTerm1_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NRXS_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsCancelledWeightedAverageRemainingContractualTerm1_doc" xml:lang="en-US">Share based compensation arrangement by sharebased payment award options cancelled weighted average remaining contractual term 1.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisedWeightedAverageRemainingContractualTerm1" xlink:to="NRXS_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisedWeightedAverageRemainingContractualTerm1_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NRXS_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisedWeightedAverageRemainingContractualTerm1_doc" xml:lang="en-US">Sharebased compensation arrangement by sharebased payment award options exercised weighted average remaining contractual term 1.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_ScheduleOfWarrantActivityForCommonStockTableTextBlock" xlink:to="NRXS_ScheduleOfWarrantActivityForCommonStockTableTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NRXS_ScheduleOfWarrantActivityForCommonStockTableTextBlock_doc" xml:lang="en-US">Schedule of Warrant Activity for Common Stock [Table Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_AdvisoryAgreementWarrantsMember" xlink:to="NRXS_AdvisoryAgreementWarrantsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NRXS_AdvisoryAgreementWarrantsMember_doc" xml:lang="en-US">Advisory Agreement Warrants [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_SeriesSeedPreferredStockMember" xlink:to="NRXS_SeriesSeedPreferredStockMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NRXS_SeriesSeedPreferredStockMember_doc" xml:lang="en-US">Series Seed Preferred Stock [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset" xlink:to="NRXS_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NRXS_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset_doc" xml:lang="en-US">Deferred tax liabilities operating lease right of use asset.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_DeferredTaxLiabilityAccountsReceivable" xlink:to="NRXS_DeferredTaxLiabilityAccountsReceivable_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NRXS_DeferredTaxLiabilityAccountsReceivable_doc" xml:lang="en-US">Deferred tax liability accounts receivable.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_DeferredTaxAssetsOperatingLeasePayable" xlink:to="NRXS_DeferredTaxAssetsOperatingLeasePayable_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NRXS_DeferredTaxAssetsOperatingLeasePayable_doc" xml:lang="en-US">Deferred tax assets operating lease payable.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_DeferredTaxAssetsAccountsPayable" xlink:to="NRXS_DeferredTaxAssetsAccountsPayable_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NRXS_DeferredTaxAssetsAccountsPayable_doc" xml:lang="en-US">Deferred tax assets accounts payable.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_DeferredTaxAssetsNotesReceivableReserve" xlink:to="NRXS_DeferredTaxAssetsNotesReceivableReserve_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NRXS_DeferredTaxAssetsNotesReceivableReserve_doc" xml:lang="en-US">Deferred tax assets notes receivable reserve.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_PreferredStockSharesRetiredDescription" xlink:to="NRXS_PreferredStockSharesRetiredDescription_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NRXS_PreferredStockSharesRetiredDescription_doc" xml:lang="en-US">Preferred stock shares retired description.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_TaxYear2041Member" xlink:to="NRXS_TaxYear2041Member_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NRXS_TaxYear2041Member_doc" xml:lang="en-US">Tax Year 2041 [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_TaxYear2040Member" xlink:to="NRXS_TaxYear2040Member_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NRXS_TaxYear2040Member_doc" xml:lang="en-US">Tax Year 2040 [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_TaxYear2039Member" xlink:to="NRXS_TaxYear2039Member_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NRXS_TaxYear2039Member_doc" xml:lang="en-US">Tax Year 2039 [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_TaxYear2038Member" xlink:to="NRXS_TaxYear2038Member_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NRXS_TaxYear2038Member_doc" xml:lang="en-US">Tax Year 2038 [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_TaxYear2037Member" xlink:to="NRXS_TaxYear2037Member_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NRXS_TaxYear2037Member_doc" xml:lang="en-US">Tax Year 2037 [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_TaxYearThereafterMember" xlink:to="NRXS_TaxYearThereafterMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NRXS_TaxYearThereafterMember_doc" xml:lang="en-US">Tax Year Thereafter [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_NoExpirationMember" xlink:to="NRXS_NoExpirationMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NRXS_NoExpirationMember_doc" xml:lang="en-US">No Expiration [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_NumberOfEquivalentOfWarrantsDescription" xlink:to="NRXS_NumberOfEquivalentOfWarrantsDescription_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NRXS_NumberOfEquivalentOfWarrantsDescription_doc" xml:lang="en-US">Number of equivalent of warrants description.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_AdvisoryAgreementsMember" xlink:to="NRXS_AdvisoryAgreementsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NRXS_AdvisoryAgreementsMember_doc" xml:lang="en-US">Advisory Agreements [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_ClassOfWarrantOrRightAdditional" xlink:to="NRXS_ClassOfWarrantOrRightAdditional_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NRXS_ClassOfWarrantOrRightAdditional_doc" xml:lang="en-US">Class of warrant or right additional.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_AmendedTwoThousandTwentyFourConvertibleNotesMember" xlink:to="NRXS_AmendedTwoThousandTwentyFourConvertibleNotesMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NRXS_AmendedTwoThousandTwentyFourConvertibleNotesMember_doc" xml:lang="en-US">Amended 2024 Convertible Notes [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_WarrantLiabilitiesDisclosureTextBlock" xlink:to="NRXS_WarrantLiabilitiesDisclosureTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NRXS_WarrantLiabilitiesDisclosureTextBlock_doc" xml:lang="en-US">Warrant Liabilities Disclosure [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedNumber" xlink:label="NRXS_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedNumber" xlink:to="NRXS_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedNumber_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NRXS_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedNumber_doc" xml:lang="en-US">Share based compensation arrangement by share based payment award equity instruments otherthan options vested number.</link:label>
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedWeightedAverageGrantDateFairValue" xlink:label="NRXS_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedWeightedAverageGrantDateFairValue" xlink:to="NRXS_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedWeightedAverageGrantDateFairValue_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NRXS_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedWeightedAverageGrantDateFairValue_doc" xml:lang="en-US">Share based compensation arrangement by share based payment award equity instruments other than options vested weighted average grant date fair value.</link:label>
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_ScheduleOfInauguralGrantOfRestrictedStockUnitsTableTextBlock" xlink:label="NRXS_ScheduleOfInauguralGrantOfRestrictedStockUnitsTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_ScheduleOfInauguralGrantOfRestrictedStockUnitsTableTextBlock" xlink:to="NRXS_ScheduleOfInauguralGrantOfRestrictedStockUnitsTableTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NRXS_ScheduleOfInauguralGrantOfRestrictedStockUnitsTableTextBlock_doc" xml:lang="en-US">Schedule Of Inaugural Grant Of Restricted Stock Units [Table Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_ShareBasedCompensationPlansMember" xlink:label="NRXS_ShareBasedCompensationPlansMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_ShareBasedCompensationPlansMember" xlink:to="NRXS_ShareBasedCompensationPlansMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NRXS_ShareBasedCompensationPlansMember_doc" xml:lang="en-US">Share Based Compensation Plans [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_NoInsiderTradingFlag" xlink:to="NRXS_NoInsiderTradingFlag_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NRXS_NoInsiderTradingFlag_doc" xml:lang="en-US">No insider trading flag.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_ChangesInDerivativeLiabilities" xlink:to="NRXS_ChangesInDerivativeLiabilities_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NRXS_ChangesInDerivativeLiabilities_doc" xml:lang="en-US">Changes in derivative liabilities.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_SoftwareImplementationMember" xlink:to="NRXS_SoftwareImplementationMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NRXS_SoftwareImplementationMember_doc" xml:lang="en-US">Software Implementation [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_LicensesMember" xlink:to="NRXS_LicensesMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NRXS_LicensesMember_doc" xml:lang="en-US">Licenses [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:to="NRXS_StockIssuedDuringPeriodSharesWarrantsExercised_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NRXS_StockIssuedDuringPeriodSharesWarrantsExercised_doc" xml:lang="en-US">Stock issued during period shares warrants exercised.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_StockIssuedDuringPeriodSharesPreferredStock" xlink:to="NRXS_StockIssuedDuringPeriodSharesPreferredStock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NRXS_StockIssuedDuringPeriodSharesPreferredStock_doc" xml:lang="en-US">Stock issued during period shares preferred stock.</link:label>
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_StockIssuedDuringPeriodValueChangeInFairValueOfWarrantLiabilityUponInitialPublicOffering" xlink:label="NRXS_StockIssuedDuringPeriodValueChangeInFairValueOfWarrantLiabilityUponInitialPublicOffering" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_StockIssuedDuringPeriodValueChangeInFairValueOfWarrantLiabilityUponInitialPublicOffering" xlink:to="NRXS_StockIssuedDuringPeriodValueChangeInFairValueOfWarrantLiabilityUponInitialPublicOffering_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NRXS_StockIssuedDuringPeriodValueChangeInFairValueOfWarrantLiabilityUponInitialPublicOffering_doc" xml:lang="en-US">Stock issued during period value change in fair value of warrant liability upon initial public offering.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_CustomerDMember" xlink:to="NRXS_CustomerDMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NRXS_CustomerDMember_doc" xml:lang="en-US">Customer D [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_CustomerEMember" xlink:to="NRXS_CustomerEMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NRXS_CustomerEMember_doc" xml:lang="en-US">Customer E [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_DecemberTwoThousandTwentyFiveMember" xlink:to="NRXS_DecemberTwoThousandTwentyFiveMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NRXS_DecemberTwoThousandTwentyFiveMember_doc" xml:lang="en-US">December Two Thousand Twenty Five [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_DecemberTwoThousandTwentySixMember" xlink:to="NRXS_DecemberTwoThousandTwentySixMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NRXS_DecemberTwoThousandTwentySixMember_doc" xml:lang="en-US">December Two Thousand Twenty Six [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_DecemberTwoThousandTwentySevenMember" xlink:to="NRXS_DecemberTwoThousandTwentySevenMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NRXS_DecemberTwoThousandTwentySevenMember_doc" xml:lang="en-US">December Two Thousand Twenty Seven [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_DecemberTwoThousandTwentyEightMember" xlink:to="NRXS_DecemberTwoThousandTwentyEightMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NRXS_DecemberTwoThousandTwentyEightMember_doc" xml:lang="en-US">December Two Thousand Twenty Eight [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_DecemberTwoThousandTwentyNineMember" xlink:to="NRXS_DecemberTwoThousandTwentyNineMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NRXS_DecemberTwoThousandTwentyNineMember_doc" xml:lang="en-US">December Two Thousand Twenty Nine [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_DecemberTwoThousandTwentyThereafterMember" xlink:to="NRXS_DecemberTwoThousandTwentyThereafterMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NRXS_DecemberTwoThousandTwentyThereafterMember_doc" xml:lang="en-US">December Two Thousand Twenty Thereafter [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_ConsultingAndAdvisoryFees" xlink:to="NRXS_ConsultingAndAdvisoryFees_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NRXS_ConsultingAndAdvisoryFees_doc" xml:lang="en-US">Consulting and advisory fees.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_2_lbl" xml:lang="en-US">Assets, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_3_lbl" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_2_lbl" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_3_lbl" xml:lang="en-US">Assets [Default Label]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_2_lbl" xml:lang="en-US">Liabilities, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrent" xlink:to="us-gaap_LiabilitiesNoncurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesNoncurrent_2_lbl" xml:lang="en-US">Liabilities, Noncurrent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_2_lbl" xml:lang="en-US">Liabilities [Default Label]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_2_lbl" xml:lang="en-US">Liabilities and Equity</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GrossProfit" xlink:to="us-gaap_GrossProfit_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GrossProfit_2_lbl" xml:lang="en-US">Gross Profit</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_2_lbl" xml:lang="en-US">Operating Income (Loss)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingExpense" xlink:to="us-gaap_OtherNonoperatingExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNonoperatingExpense_2_lbl" xml:lang="en-US">Other Nonoperating Expense</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_2_lbl" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockDividendsAndOtherAdjustments" xlink:to="us-gaap_PreferredStockDividendsAndOtherAdjustments_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockDividendsAndOtherAdjustments_2_lbl" xml:lang="en-US">Preferred Stock Dividends and Other Adjustments</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesOutstanding_3_lbl" xml:lang="en-US">Shares, Outstanding</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_2_lbl" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInInventories" xlink:to="us-gaap_IncreaseDecreaseInInventories_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInInventories_2_lbl" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_2_lbl" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_2_lbl" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_2_lbl" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_IncreaseDecreaseInCustomerDeposit" xlink:to="NRXS_IncreaseDecreaseInCustomerDeposit_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NRXS_IncreaseDecreaseInCustomerDeposit_3_lbl" xml:lang="en-US">IncreaseDecreaseInCustomerDeposit</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_2_lbl" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_3_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_DeferredOfferingCostsPaid" xlink:to="NRXS_DeferredOfferingCostsPaid_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NRXS_DeferredOfferingCostsPaid_3_lbl" xml:lang="en-US">DeferredOfferingCostsPaid</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfNotesPayable" xlink:to="us-gaap_RepaymentsOfNotesPayable_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RepaymentsOfNotesPayable_2_lbl" xml:lang="en-US">Repayments of Notes Payable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfFinancingCosts" xlink:to="us-gaap_PaymentsOfFinancingCosts_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsOfFinancingCosts_2_lbl" xml:lang="en-US">Payments of Financing Costs</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_2_lbl" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_3_lbl" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ForgoneRecoveryIndName" xlink:to="ecd_ForgoneRecoveryIndName_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ForgoneRecoveryIndName_2_lbl" xml:lang="en-US">Forgone Recovery, Individual Name</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_OutstandingRecoveryIndName" xlink:to="ecd_OutstandingRecoveryIndName_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_OutstandingRecoveryIndName_2_lbl" xml:lang="en-US">Outstanding Recovery, Individual Name</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardsCloseToMnpiDiscIndName" xlink:to="ecd_AwardsCloseToMnpiDiscIndName_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardsCloseToMnpiDiscIndName_2_lbl" xml:lang="en-US">Awards Close in Time to MNPI Disclosures, Individual Name</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TrdArrIndName" xlink:to="ecd_TrdArrIndName_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TrdArrIndName_2_lbl" xml:lang="en-US">Trading Arrangement, Individual Name</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_2_lbl" xml:lang="en-US">Lessee, Operating Leases [Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_WarrantLiabilitiesDisclosureTextBlock" xlink:to="NRXS_WarrantLiabilitiesDisclosureTextBlock_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NRXS_WarrantLiabilitiesDisclosureTextBlock_3_lbl" xml:lang="en-US">Warrant Liabilities Disclosure [Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativesAndFairValueTextBlock" xlink:to="us-gaap_DerivativesAndFairValueTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativesAndFairValueTextBlock_2_lbl" xml:lang="en-US">Derivatives and Fair Value [Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_HealthBenefitPlanDisclosureTextBlock" xlink:to="NRXS_HealthBenefitPlanDisclosureTextBlock_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NRXS_HealthBenefitPlanDisclosureTextBlock_3_lbl" xml:lang="en-US">HealthBenefitPlanDisclosureTextBlock</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_2_lbl" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:to="us-gaap_IntangibleAssetsFiniteLivedPolicy_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IntangibleAssetsFiniteLivedPolicy_2_lbl" xml:lang="en-US">Intangible Assets, Finite-Lived, Policy [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_2_lbl" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_WarrantLiabilityPolicyTextBlock" xlink:to="NRXS_WarrantLiabilityPolicyTextBlock_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NRXS_WarrantLiabilityPolicyTextBlock_3_lbl" xml:lang="en-US">Warrant Liability [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_2_lbl" xml:lang="en-US">Share-Based Payment Arrangement [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_2_lbl" xml:lang="en-US">Lessee, Leases [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllowanceForNotesAndLoansReceivableCurrent" xlink:to="us-gaap_AllowanceForNotesAndLoansReceivableCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllowanceForNotesAndLoansReceivableCurrent_2_lbl" xml:lang="en-US">Financing Receivable, Allowance for Credit Loss, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_AllowanceForInterestIncomeCurrent" xlink:to="NRXS_AllowanceForInterestIncomeCurrent_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NRXS_AllowanceForInterestIncomeCurrent_3_lbl" xml:lang="en-US">AllowanceForInterestIncomeCurrent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesAndLoansReceivableNetCurrent" xlink:to="us-gaap_NotesAndLoansReceivableNetCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NotesAndLoansReceivableNetCurrent_2_lbl" xml:lang="en-US">Financing Receivable, after Allowance for Credit Loss, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestReceivable" xlink:to="us-gaap_InterestReceivable_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestReceivable_2_lbl" xml:lang="en-US">Interest Receivable [Default Label]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_InterestIncomeCurrent" xlink:to="NRXS_InterestIncomeCurrent_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NRXS_InterestIncomeCurrent_3_lbl" xml:lang="en-US">Interest income current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaid" xlink:to="us-gaap_InterestPaid_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPaid_2_lbl" xml:lang="en-US">Interest Paid, Including Capitalized Interest, Operating and Investing Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrentAndNoncurrent" xlink:to="us-gaap_AccountsPayableCurrentAndNoncurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableCurrentAndNoncurrent_2_lbl" xml:lang="en-US">Accounts Payable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_2_lbl" xml:lang="en-US">Finite-Lived Intangible Assets, Accumulated Amortization</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_CommonStockConvertibleConversionPrice" xlink:to="NRXS_CommonStockConvertibleConversionPrice_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NRXS_CommonStockConvertibleConversionPrice_3_lbl" xml:lang="en-US">Common stock convertible conversion price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_2_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_2_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_2_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisedWeightedAverageRemainingContractualTerm1" xlink:to="NRXS_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisedWeightedAverageRemainingContractualTerm1_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NRXS_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisedWeightedAverageRemainingContractualTerm1_3_lbl" xml:lang="en-US">SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisedWeightedAverageRemainingContractualTerm1</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsCommonStockWarrant" xlink:to="NRXS_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsCommonStockWarrant_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NRXS_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsCommonStockWarrant_3_lbl" xml:lang="en-US">ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsCommonStockWarrant</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsWeightedAverageExercisePriceCommonStockWarrant" xlink:to="NRXS_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsWeightedAverageExercisePriceCommonStockWarrant_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NRXS_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsWeightedAverageExercisePriceCommonStockWarrant_3_lbl" xml:lang="en-US">ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsWeightedAverageExercisePriceCommonStockWarrant</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:to="us-gaap_WarrantsAndRightsOutstandingMaturityDate_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantsAndRightsOutstandingMaturityDate_2_lbl" xml:lang="en-US">Warrants and Rights Outstanding, Maturity Date</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_WarrantExpirationDateDescription" xlink:to="NRXS_WarrantExpirationDateDescription_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NRXS_WarrantExpirationDateDescription_3_lbl" xml:lang="en-US">WarrantExpirationDateDescription</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_3_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_2_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_2_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstanding" xlink:to="us-gaap_WarrantsAndRightsOutstanding_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantsAndRightsOutstanding_3_lbl" xml:lang="en-US">Warrants and Rights Outstanding</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_ChangesInDerivativeLiabilities" xlink:to="NRXS_ChangesInDerivativeLiabilities_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NRXS_ChangesInDerivativeLiabilities_4_lbl" xml:lang="en-US">ChangesInDerivativeLiabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_AdditionToDerivativeLiabilities" xlink:to="NRXS_AdditionToDerivativeLiabilities_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NRXS_AdditionToDerivativeLiabilities_3_lbl" xml:lang="en-US">Addition to derivative liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationAndAmortization" xlink:to="us-gaap_DepreciationAndAmortization_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepreciationAndAmortization_2_lbl" xml:lang="en-US">Depreciation, Depletion and Amortization, Nonproduction</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesFairValueDisclosure" xlink:to="us-gaap_AccruedLiabilitiesFairValueDisclosure_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedLiabilitiesFairValueDisclosure_2_lbl" xml:lang="en-US">Accrued Liabilities, Fair Value Disclosure</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_2_lbl" xml:lang="en-US">Deferred Income Tax Expense (Benefit)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxExpenseBenefit_2_lbl" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_2_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_2_lbl" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_DeferredTaxAssetsAccountsPayable" xlink:to="NRXS_DeferredTaxAssetsAccountsPayable_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NRXS_DeferredTaxAssetsAccountsPayable_3_lbl" xml:lang="en-US">DeferredTaxAssetsAccountsPayable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOther" xlink:to="us-gaap_DeferredTaxAssetsOther_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOther_2_lbl" xml:lang="en-US">Deferred Tax Assets, Other</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsGross_2_lbl" xml:lang="en-US">Deferred Tax Assets, Gross</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_2_lbl" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsNet_2_lbl" xml:lang="en-US">Deferred Tax Assets, Net of Valuation Allowance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesOther" xlink:to="us-gaap_DeferredTaxLiabilitiesOther_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxLiabilitiesOther_2_lbl" xml:lang="en-US">Deferred Tax Liabilities, Other</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="us-gaap_DeferredIncomeTaxLiabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_2_lbl" xml:lang="en-US">Deferred Tax Liabilities, Gross</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilities" xlink:to="us-gaap_DeferredTaxLiabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxLiabilities_2_lbl" xml:lang="en-US">Deferred Tax Liabilities, Net</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>28
<FILENAME>nrxs-20241231_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.25b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://neuraxis.com/role/Cover" xlink:href="nrxs-20241231.xsd#Cover" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/BalanceSheets" xlink:href="nrxs-20241231.xsd#BalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/BalanceSheetsParenthetical" xlink:href="nrxs-20241231.xsd#BalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/StatementsOfOperations" xlink:href="nrxs-20241231.xsd#StatementsOfOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/StatementsOfStockholdersEquityDeficit" xlink:href="nrxs-20241231.xsd#StatementsOfStockholdersEquityDeficit" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/StatementsOfCashFlows" xlink:href="nrxs-20241231.xsd#StatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#CybersecurityRiskManagementAndStrategyDisclosure" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#MaterialCybersecurityIncidentDisclosure" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/BasisOfPresentationOrganizationAndOtherMatters" xlink:href="nrxs-20241231.xsd#BasisOfPresentationOrganizationAndOtherMatters" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="nrxs-20241231.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/RelatedPartyTransactions" xlink:href="nrxs-20241231.xsd#RelatedPartyTransactions" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/PropertyAndEquipment" xlink:href="nrxs-20241231.xsd#PropertyAndEquipment" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/IntangibleAssets" xlink:href="nrxs-20241231.xsd#IntangibleAssets" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/AccruedExpenses" xlink:href="nrxs-20241231.xsd#AccruedExpenses" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/NotesPayable" xlink:href="nrxs-20241231.xsd#NotesPayable" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/Leases" xlink:href="nrxs-20241231.xsd#Leases" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/CommonStockAndWarrants" xlink:href="nrxs-20241231.xsd#CommonStockAndWarrants" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/PreferredStock" xlink:href="nrxs-20241231.xsd#PreferredStock" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/Stock-basedCompensation" xlink:href="nrxs-20241231.xsd#Stock-basedCompensation" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/WarrantLiabilities" xlink:href="nrxs-20241231.xsd#WarrantLiabilities" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/DerivativeLiabilities" xlink:href="nrxs-20241231.xsd#DerivativeLiabilities" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/RetirementPlan" xlink:href="nrxs-20241231.xsd#RetirementPlan" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/SegmentInformation" xlink:href="nrxs-20241231.xsd#SegmentInformation" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/CommitmentsAndContingencies" xlink:href="nrxs-20241231.xsd#CommitmentsAndContingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/HealthBenefitPlan" xlink:href="nrxs-20241231.xsd#HealthBenefitPlan" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/IncomeTaxes" xlink:href="nrxs-20241231.xsd#IncomeTaxes" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/SubsequentEvents" xlink:href="nrxs-20241231.xsd#SubsequentEvents" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="nrxs-20241231.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:href="nrxs-20241231.xsd#SummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/RelatedPartyTransactionsTables" xlink:href="nrxs-20241231.xsd#RelatedPartyTransactionsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/PropertyAndEquipmentTables" xlink:href="nrxs-20241231.xsd#PropertyAndEquipmentTables" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/IntangibleAssetsTables" xlink:href="nrxs-20241231.xsd#IntangibleAssetsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/AccruedExpensesTables" xlink:href="nrxs-20241231.xsd#AccruedExpensesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/LeasesTables" xlink:href="nrxs-20241231.xsd#LeasesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/CommonStockAndWarrantsTables" xlink:href="nrxs-20241231.xsd#CommonStockAndWarrantsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/Stock-basedCompensationTables" xlink:href="nrxs-20241231.xsd#Stock-basedCompensationTables" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/WarrantLiabilitiesTables" xlink:href="nrxs-20241231.xsd#WarrantLiabilitiesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/DerivativeLiabilitiesTables" xlink:href="nrxs-20241231.xsd#DerivativeLiabilitiesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/SegmentInformationTables" xlink:href="nrxs-20241231.xsd#SegmentInformationTables" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/IncomeTaxesTables" xlink:href="nrxs-20241231.xsd#IncomeTaxesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/BasisOfPresentationOrganizationAndOtherMattersDetailsNarrative" xlink:href="nrxs-20241231.xsd#BasisOfPresentationOrganizationAndOtherMattersDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/ScheduleOfEstimatedUsefulLivesDetails" xlink:href="nrxs-20241231.xsd#ScheduleOfEstimatedUsefulLivesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/ScheduleOfFairValueOfAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails" xlink:href="nrxs-20241231.xsd#ScheduleOfFairValueOfAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/ScheduleOfDilutiveCommonStockEquivalentsDetails" xlink:href="nrxs-20241231.xsd#ScheduleOfDilutiveCommonStockEquivalentsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/ScheduleOfBasicAndDilutedNetLossPerShareDetails" xlink:href="nrxs-20241231.xsd#ScheduleOfBasicAndDilutedNetLossPerShareDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/ScheduleOfDisaggregationOfRevenueDetails" xlink:href="nrxs-20241231.xsd#ScheduleOfDisaggregationOfRevenueDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/ScheduleOfCustomerAccountsReceivableDetails" xlink:href="nrxs-20241231.xsd#ScheduleOfCustomerAccountsReceivableDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/ScheduleOfCustomersAccountedRevenuesDetails" xlink:href="nrxs-20241231.xsd#ScheduleOfCustomersAccountedRevenuesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:href="nrxs-20241231.xsd#SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/ScheduleOfRelatedPartyTransactionsDetails" xlink:href="nrxs-20241231.xsd#ScheduleOfRelatedPartyTransactionsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/ScheduleOfRelatedPartyLoansPayableToShareholderDetails" xlink:href="nrxs-20241231.xsd#ScheduleOfRelatedPartyLoansPayableToShareholderDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:href="nrxs-20241231.xsd#RelatedPartyTransactionsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/ScheduleOfPropertyAndEquipmentDetails" xlink:href="nrxs-20241231.xsd#ScheduleOfPropertyAndEquipmentDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/PropertyAndEquipmentDetailsNarrative" xlink:href="nrxs-20241231.xsd#PropertyAndEquipmentDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/ScheduleOfIntangibleAssetsDetails" xlink:href="nrxs-20241231.xsd#ScheduleOfIntangibleAssetsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/IntangibleAssetsDetailsNarrative" xlink:href="nrxs-20241231.xsd#IntangibleAssetsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/ScheduleOfAccruedExpensesDetails" xlink:href="nrxs-20241231.xsd#ScheduleOfAccruedExpensesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/NotesPayableDetailsNarrative" xlink:href="nrxs-20241231.xsd#NotesPayableDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/ScheduleOfOperatingLeasesDetails" xlink:href="nrxs-20241231.xsd#ScheduleOfOperatingLeasesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/ScheduleOfMaturitiesOperatingLeaseLiabilitiesDetails" xlink:href="nrxs-20241231.xsd#ScheduleOfMaturitiesOperatingLeaseLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/LeasesDetailsNarrative" xlink:href="nrxs-20241231.xsd#LeasesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/ScheduleOfWarrantActivityForCommonStockDetails" xlink:href="nrxs-20241231.xsd#ScheduleOfWarrantActivityForCommonStockDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/ScheduleOfWarrantActivityForPreferredStockDetails" xlink:href="nrxs-20241231.xsd#ScheduleOfWarrantActivityForPreferredStockDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/ScheduleOfWarrantsOutstandingAndExercisableDetails" xlink:href="nrxs-20241231.xsd#ScheduleOfWarrantsOutstandingAndExercisableDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/CommonStockAndWarrantsDetailsNarrative" xlink:href="nrxs-20241231.xsd#CommonStockAndWarrantsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/PreferredStockDetailsNarrative" xlink:href="nrxs-20241231.xsd#PreferredStockDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/ScheduleOfOption-pricingModelWithFollowingWeighted-averageAssumptionsDetails" xlink:href="nrxs-20241231.xsd#ScheduleOfOption-pricingModelWithFollowingWeighted-averageAssumptionsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/ScheduleOfStockOptionActivityDetails" xlink:href="nrxs-20241231.xsd#ScheduleOfStockOptionActivityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/Stock-basedCompensationDetailsNarrative" xlink:href="nrxs-20241231.xsd#Stock-basedCompensationDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/ScheduleOfChangesInWarrantLiabilitiesDetails" xlink:href="nrxs-20241231.xsd#ScheduleOfChangesInWarrantLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/WarrantLiabilitiesDetailsNarrative" xlink:href="nrxs-20241231.xsd#WarrantLiabilitiesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/ScheduleOfChangesInDerivativeLiabilitiesDetails" xlink:href="nrxs-20241231.xsd#ScheduleOfChangesInDerivativeLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/DerivativeLiabilitiesDetailsNarrative" xlink:href="nrxs-20241231.xsd#DerivativeLiabilitiesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/RetirementPlanDetailsNarrative" xlink:href="nrxs-20241231.xsd#RetirementPlanDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/ScheduleOfReconcilesCompanysNetSalesAndOperatingLossDetails" xlink:href="nrxs-20241231.xsd#ScheduleOfReconcilesCompanysNetSalesAndOperatingLossDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/SegmentInformationDetailsNarrative" xlink:href="nrxs-20241231.xsd#SegmentInformationDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:href="nrxs-20241231.xsd#CommitmentsAndContingenciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/HealthBenefitPlanDetailsNarrative" xlink:href="nrxs-20241231.xsd#HealthBenefitPlanDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/ScheduleOfIncomeTaxProvisionDetails" xlink:href="nrxs-20241231.xsd#ScheduleOfIncomeTaxProvisionDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/ScheduleOfFederalStatutoryIncomeTaxRateAndEffectiveIncomeTaxRateDetails" xlink:href="nrxs-20241231.xsd#ScheduleOfFederalStatutoryIncomeTaxRateAndEffectiveIncomeTaxRateDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/ScheduleOfNetDeferredTaxAssetsAndLiabilitiesDetails" xlink:href="nrxs-20241231.xsd#ScheduleOfNetDeferredTaxAssetsAndLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/ScheduleOfStateCarryforwardsDetails" xlink:href="nrxs-20241231.xsd#ScheduleOfStateCarryforwardsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/IncomeTaxesDetailsNarrative" xlink:href="nrxs-20241231.xsd#IncomeTaxesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/SubsequentEventsDetailsNarrative" xlink:href="nrxs-20241231.xsd#SubsequentEventsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/PvpDisclosure" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#PvpDisclosure" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ErrCompDisclosure" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#AwardTimingDisclosure" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#InsiderTradingArrangements" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#InsiderTradingPoliciesProc" xlink:type="simple" />
    <link:presentationLink xlink:type="extended" xlink:role="http://neuraxis.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="loc_deiIcfrAuditorAttestationFlag" />
      <link:presentationArc order="580" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiIcfrAuditorAttestationFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFinStmtErrorCorrectionFlag" xlink:label="loc_deiDocumentFinStmtErrorCorrectionFlag" />
      <link:presentationArc order="590" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFinStmtErrorCorrectionFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityListingParValuePerShare" xlink:label="loc_deiEntityListingParValuePerShare" />
      <link:presentationArc order="600" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityListingParValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorFirmId" xlink:label="loc_deiAuditorFirmId" />
      <link:presentationArc order="610" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditorFirmId" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorOpinionTextBlock" xlink:label="loc_deiAuditorOpinionTextBlock" />
      <link:presentationArc order="620" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditorOpinionTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorName" xlink:label="loc_deiAuditorName" />
      <link:presentationArc order="630" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditorName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorLocation" xlink:label="loc_deiAuditorLocation" />
      <link:presentationArc order="640" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditorLocation" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://neuraxis.com/role/BalanceSheets" xlink:title="00000002 - Statement - Balance Sheets">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaapAssetsAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapAssetsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaapAssetsCurrentAbstract" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapAssetsCurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaapAccountsReceivableNetCurrent" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapAccountsReceivableNetCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaapInventoryNet" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapInventoryNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapAssetsCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaapPropertyPlantAndEquipmentGross" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrentAbstract" xlink:label="loc_us-gaapOtherAssetsNoncurrentAbstract" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapOtherAssetsNoncurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherAssetsNoncurrentAbstract" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsNet" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherAssetsNoncurrentAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SecurityDeposit" xlink:label="loc_us-gaapSecurityDeposit" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherAssetsNoncurrentAbstract" xlink:to="loc_us-gaapSecurityDeposit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaapLiabilitiesCurrentAbstract" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilitiesCurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapAccountsPayableCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrent" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapAccruedLiabilitiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NotesPayableToBankCurrent" xlink:label="loc_us-gaapNotesPayableToBankCurrent" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapNotesPayableToBankCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityCurrent" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapOperatingLeaseLiabilityCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Deposits" xlink:label="loc_us-gaapDeposits" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapDeposits" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_WarrantLiabilities" xlink:label="loc_NRXSWarrantLiabilities" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_NRXSWarrantLiabilities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="loc_us-gaapLiabilitiesNoncurrentAbstract" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilitiesNoncurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityNoncurrent" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesNoncurrentAbstract" xlink:to="loc_us-gaapOperatingLeaseLiabilityNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="loc_us-gaapLiabilitiesNoncurrent" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilitiesNoncurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaapCommitmentsAndContingencies" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommitmentsAndContingencies" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaapStockholdersEquityAbstract" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapStockholdersEquityAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaapPreferredStockValue" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapPreferredStockValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaapAdditionalPaidInCapital" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapAdditionalPaidInCapital" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://neuraxis.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - Balance Sheets (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_ConvertibleSeriesBPreferredStockMember" xlink:label="loc_NRXSConvertibleSeriesBPreferredStockMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_NRXSConvertibleSeriesBPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:label="loc_us-gaapAllowanceForDoubtfulAccountsReceivable" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAllowanceForDoubtfulAccountsReceivable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryRawMaterialsNetOfReserves" xlink:label="loc_us-gaapInventoryRawMaterialsNetOfReserves" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapInventoryRawMaterialsNetOfReserves" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaapPreferredStockSharesIssued" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaapPreferredStockSharesOutstanding" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesOutstanding" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://neuraxis.com/role/StatementsOfOperations" xlink:title="00000004 - Statement - Statements of Operations">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaapIncomeStatementAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="loc_us-gaapCostOfGoodsAndServicesSold" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapCostOfGoodsAndServicesSold" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GrossProfit" xlink:label="loc_us-gaapGrossProfit" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapGrossProfit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingExpense" xlink:label="loc_us-gaapSellingExpense" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapSellingExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaapNonoperatingIncomeExpenseAbstract" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_FinancingCharges" xlink:label="loc_NRXSFinancingCharges" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_NRXSFinancingCharges" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaapInterestExpense" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapInterestExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaapFairValueAdjustmentOfWarrants" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapFairValueAdjustmentOfWarrants" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeGainLossOnDerivativeNet" xlink:label="loc_us-gaapDerivativeGainLossOnDerivativeNet" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapDerivativeGainLossOnDerivativeNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="loc_us-gaapAmortizationOfFinancingCostsAndDiscounts" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapAmortizationOfFinancingCostsAndDiscounts" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncome" xlink:label="loc_us-gaapOtherNonoperatingIncome" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapOtherNonoperatingIncome" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingExpense" xlink:label="loc_us-gaapOtherNonoperatingExpense" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapOtherNonoperatingExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaapOtherNonoperatingIncomeExpense" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapOtherNonoperatingIncomeExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockDividendsAndOtherAdjustments" xlink:label="loc_us-gaapPreferredStockDividendsAndOtherAdjustments" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapPreferredStockDividendsAndOtherAdjustments" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaapEarningsPerShareAbstract" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapEarningsPerShareAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaapEarningsPerShareBasic" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapEarningsPerShareBasic" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaapEarningsPerShareDiluted" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapEarningsPerShareDiluted" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="loc_us-gaapWeightedAverageNumberOfSharesOutstandingAbstract" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapWeightedAverageNumberOfSharesOutstandingAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaapWeightedAverageNumberOfDilutedSharesOutstanding" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapWeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://neuraxis.com/role/StatementsOfStockholdersEquityDeficit" xlink:title="00000005 - Statement - Statements of Stockholders&apos; Equity (Deficit)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaapStatementOfStockholdersEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfStockholdersEquityAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="70" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockMember" xlink:label="loc_us-gaapPreferredStockMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapRetainedEarningsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="70" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_ConvertibleSeriesAPreferredStockMember" xlink:label="loc_NRXSConvertibleSeriesAPreferredStockMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_NRXSConvertibleSeriesAPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_ConvertibleSeriesSeedPreferredStockMember" xlink:label="loc_NRXSConvertibleSeriesSeedPreferredStockMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_NRXSConvertibleSeriesSeedPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_ConvertibleSeriesBPreferredStockMember" xlink:label="loc_NRXSConvertibleSeriesBPreferredStockMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_NRXSConvertibleSeriesBPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_StockIssuedDuringPeriodValueCommonStockIssuedUponInitialPublicOffering" xlink:label="loc_NRXSStockIssuedDuringPeriodValueCommonStockIssuedUponInitialPublicOffering" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_NRXSStockIssuedDuringPeriodValueCommonStockIssuedUponInitialPublicOffering" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_StockIssuedDuringPeriodSharesCommonStockIssuedUponInitialPublicOffering" xlink:label="loc_NRXSStockIssuedDuringPeriodSharesCommonStockIssuedUponInitialPublicOffering" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_NRXSStockIssuedDuringPeriodSharesCommonStockIssuedUponInitialPublicOffering" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueConversionOfConvertibleSecurities" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfUnits" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueConversionOfUnits" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueConversionOfUnits" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfUnits" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfUnits" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalWarrantIssued" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_StockIssuedDuringPeriodValueWarrantsExercised" xlink:label="loc_NRXSStockIssuedDuringPeriodValueWarrantsExercised" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_NRXSStockIssuedDuringPeriodValueWarrantsExercised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:label="loc_NRXSStockIssuedDuringPeriodSharesWarrantsExercised" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_NRXSStockIssuedDuringPeriodSharesWarrantsExercised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_AdditionalPaidInCapitalFromWarrantsIssuedAsDebtDiscount" xlink:label="loc_NRXSAdditionalPaidInCapitalFromWarrantsIssuedAsDebtDiscount" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_NRXSAdditionalPaidInCapitalFromWarrantsIssuedAsDebtDiscount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueOther" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueOther" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesOther" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesOther" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_StockIssuedDuringPeriodValuePreferredStock" xlink:label="loc_NRXSStockIssuedDuringPeriodValuePreferredStock" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_NRXSStockIssuedDuringPeriodValuePreferredStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_StockIssuedDuringPeriodSharesPreferredStock" xlink:label="loc_NRXSStockIssuedDuringPeriodSharesPreferredStock" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_NRXSStockIssuedDuringPeriodSharesPreferredStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding_2" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://neuraxis.com/role/StatementsOfCashFlows" xlink:title="00000006 - Statement - Statements of Cash Flows">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaapStatementOfCashFlowsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="loc_us-gaapAmortizationOfFinancingCostsAndDiscounts" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapAmortizationOfFinancingCostsAndDiscounts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaapDepreciationDepletionAndAmortization" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapDepreciationDepletionAndAmortization" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProvisionForDoubtfulAccounts" xlink:label="loc_us-gaapProvisionForDoubtfulAccounts" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapProvisionForDoubtfulAccounts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryWriteDown" xlink:label="loc_us-gaapInventoryWriteDown" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapInventoryWriteDown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_NoncashLeaseExpense" xlink:label="loc_NRXSNoncashLeaseExpense" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_NRXSNoncashLeaseExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaidInKindInterest" xlink:label="loc_us-gaapPaidInKindInterest" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapPaidInKindInterest" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_IssuanceOfCommonStockForNoncashConsideration" xlink:label="loc_NRXSIssuanceOfCommonStockForNoncashConsideration" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_NRXSIssuanceOfCommonStockForNoncashConsideration" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_IssuanceOfWarrantsForNoncashConsideration" xlink:label="loc_NRXSIssuanceOfWarrantsForNoncashConsideration" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_NRXSIssuanceOfWarrantsForNoncashConsideration" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_FinancingCharges" xlink:label="loc_NRXSFinancingCharges" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_NRXSFinancingCharges" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeGainLossOnDerivativeNet" xlink:label="loc_us-gaapDerivativeGainLossOnDerivativeNet" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapDerivativeGainLossOnDerivativeNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaapFairValueAdjustmentOfWarrants" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapFairValueAdjustmentOfWarrants" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsReceivable" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsReceivable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaapIncreaseDecreaseInInventories" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInInventories" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaapIncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayable" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInAccruedLiabilities" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInAccruedLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_IncreaseDecreaseInCustomerDeposit" xlink:label="loc_NRXSIncreaseDecreaseInCustomerDeposit" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_NRXSIncreaseDecreaseInCustomerDeposit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="loc_us-gaapIncreaseDecreaseInOperatingLeaseLiability" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOperatingLeaseLiability" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="loc_us-gaapPaymentsToAcquireIntangibleAssets" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_us-gaapPaymentsToAcquireIntangibleAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfPreferredStockAndPreferenceStock" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_DeferredOfferingCostsPaid" xlink:label="loc_NRXSDeferredOfferingCostsPaid" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_NRXSDeferredOfferingCostsPaid" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="loc_us-gaapProceedsFromIssuanceOfWarrants" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromIssuanceOfWarrants" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfNotesPayable" xlink:label="loc_us-gaapRepaymentsOfNotesPayable" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapRepaymentsOfNotesPayable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromNotesPayable" xlink:label="loc_us-gaapProceedsFromNotesPayable" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapProceedsFromNotesPayable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="loc_us-gaapProceedsFromConvertibleDebt" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapProceedsFromConvertibleDebt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfFinancingCosts" xlink:label="loc_us-gaapPaymentsOfFinancingCosts" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapPaymentsOfFinancingCosts" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_2" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaapSupplementalCashFlowInformationAbstract" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestPaidNet" xlink:label="loc_us-gaapInterestPaidNet" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:to="loc_us-gaapInterestPaidNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxesPaidNet" xlink:label="loc_us-gaapIncomeTaxesPaidNet" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:to="loc_us-gaapIncomeTaxesPaidNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_RecognitionOfRightOfUseAsset" xlink:label="loc_NRXSRecognitionOfRightOfUseAsset" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="loc_NRXSRecognitionOfRightOfUseAsset" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_ConversionOfConvertiblePromissoryNotesToSeriesBPreferredStock" xlink:label="loc_NRXSConversionOfConvertiblePromissoryNotesToSeriesBPreferredStock" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="loc_NRXSConversionOfConvertiblePromissoryNotesToSeriesBPreferredStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_FairValueOfWarrantsFromDebtDiscountInConvertibleNotesClassifiedOfAdditionalPaidInCapital" xlink:label="loc_NRXSFairValueOfWarrantsFromDebtDiscountInConvertibleNotesClassifiedOfAdditionalPaidInCapital" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="loc_NRXSFairValueOfWarrantsFromDebtDiscountInConvertibleNotesClassifiedOfAdditionalPaidInCapital" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_WriteoffOfDebtDiscountOnConvertibleNotesClassifiedAsAdditionalPaidInCapital" xlink:label="loc_NRXSWriteoffOfDebtDiscountOnConvertibleNotesClassifiedAsAdditionalPaidInCapital" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="loc_NRXSWriteoffOfDebtDiscountOnConvertibleNotesClassifiedAsAdditionalPaidInCapital" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NotesIssued1" xlink:label="loc_us-gaapNotesIssued1" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="loc_us-gaapNotesIssued1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_FairValueOfWarrantLiabilitiesOfWarrantsFromConvertibleNotes" xlink:label="loc_NRXSFairValueOfWarrantLiabilitiesOfWarrantsFromConvertibleNotes" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="loc_NRXSFairValueOfWarrantLiabilitiesOfWarrantsFromConvertibleNotes" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_FairValueOfDerivativeLiabilitiesOfConversionFeatureFromConvertibleNotes" xlink:label="loc_NRXSFairValueOfDerivativeLiabilitiesOfConversionFeatureFromConvertibleNotes" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="loc_NRXSFairValueOfDerivativeLiabilitiesOfConversionFeatureFromConvertibleNotes" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_ReclassificationOfWarrantLiabilityToEquity" xlink:label="loc_NRXSReclassificationOfWarrantLiabilityToEquity" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="loc_NRXSReclassificationOfWarrantLiabilityToEquity" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_ConversionOfPreferredStockToCommonStock" xlink:label="loc_NRXSConversionOfPreferredStockToCommonStock" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="loc_NRXSConversionOfPreferredStockToCommonStock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/PvpDisclosure" xlink:title="995410 - Disclosure - Pay vs Performance Disclosure">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PayVsPerformanceDisclosureLineItems" xlink:label="loc_ecdPayVsPerformanceDisclosureLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PvpTable" xlink:label="loc_ecdPvpTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPayVsPerformanceDisclosureLineItems" xlink:to="loc_ecdPvpTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ExecutiveCategoryAxis" xlink:label="loc_ecdExecutiveCategoryAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTable" xlink:to="loc_ecdExecutiveCategoryAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllExecutiveCategoriesMember" xlink:label="loc_ecdAllExecutiveCategoriesMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdExecutiveCategoryAxis" xlink:to="loc_ecdAllExecutiveCategoriesMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_IndividualAxis" xlink:label="loc_ecdIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTable" xlink:to="loc_ecdIndividualAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllIndividualsMember" xlink:label="loc_ecdAllIndividualsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdIndividualAxis" xlink:to="loc_ecdAllIndividualsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToCompAxis" xlink:label="loc_ecdAdjToCompAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTable" xlink:to="loc_ecdAdjToCompAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllAdjToCompMember" xlink:label="loc_ecdAllAdjToCompMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAdjToCompAxis" xlink:to="loc_ecdAllAdjToCompMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MeasureAxis" xlink:label="loc_ecdMeasureAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTable" xlink:to="loc_ecdMeasureAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PvpTableTextBlock" xlink:label="loc_ecdPvpTableTextBlock" />
      <link:presentationArc order="2000" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPayVsPerformanceDisclosureLineItems" xlink:to="loc_ecdPvpTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CoSelectedMeasureName" xlink:label="loc_ecdCoSelectedMeasureName" />
      <link:presentationArc order="2010" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTableTextBlock" xlink:to="loc_ecdCoSelectedMeasureName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NamedExecutiveOfficersFnTextBlock" xlink:label="loc_ecdNamedExecutiveOfficersFnTextBlock" />
      <link:presentationArc order="2020" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdCoSelectedMeasureName" xlink:to="loc_ecdNamedExecutiveOfficersFnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeerGroupIssuersFnTextBlock" xlink:label="loc_ecdPeerGroupIssuersFnTextBlock" />
      <link:presentationArc order="2030" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdCoSelectedMeasureName" xlink:to="loc_ecdPeerGroupIssuersFnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ChangedPeerGroupFnTextBlock" xlink:label="loc_ecdChangedPeerGroupFnTextBlock" />
      <link:presentationArc order="2040" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdCoSelectedMeasureName" xlink:to="loc_ecdChangedPeerGroupFnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoTotalCompAmt" xlink:label="loc_ecdPeoTotalCompAmt" />
      <link:presentationArc order="2050" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdCoSelectedMeasureName" xlink:to="loc_ecdPeoTotalCompAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoActuallyPaidCompAmt" xlink:label="loc_ecdPeoActuallyPaidCompAmt" />
      <link:presentationArc order="2060" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdCoSelectedMeasureName" xlink:to="loc_ecdPeoActuallyPaidCompAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToPeoCompFnTextBlock" xlink:label="loc_ecdAdjToPeoCompFnTextBlock" />
      <link:presentationArc order="2070" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdCoSelectedMeasureName" xlink:to="loc_ecdAdjToPeoCompFnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonPeoNeoAvgTotalCompAmt" xlink:label="loc_ecdNonPeoNeoAvgTotalCompAmt" />
      <link:presentationArc order="2080" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTableTextBlock" xlink:to="loc_ecdNonPeoNeoAvgTotalCompAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:label="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" />
      <link:presentationArc order="2090" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTableTextBlock" xlink:to="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:label="loc_ecdAdjToNonPeoNeoCompFnTextBlock" />
      <link:presentationArc order="2100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdAdjToNonPeoNeoCompFnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:label="loc_ecdEquityValuationAssumptionDifferenceFnTextBlock" />
      <link:presentationArc order="2110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdEquityValuationAssumptionDifferenceFnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:label="loc_ecdCompActuallyPaidVsTotalShareholderRtnTextBlock" />
      <link:presentationArc order="2120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdCompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:label="loc_ecdCompActuallyPaidVsNetIncomeTextBlock" />
      <link:presentationArc order="2130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdCompActuallyPaidVsNetIncomeTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:label="loc_ecdCompActuallyPaidVsCoSelectedMeasureTextBlock" />
      <link:presentationArc order="2140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdCompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:label="loc_ecdTotalShareholderRtnVsPeerGroupTextBlock" />
      <link:presentationArc order="2150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdTotalShareholderRtnVsPeerGroupTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:label="loc_ecdCompActuallyPaidVsOtherMeasureTextBlock" />
      <link:presentationArc order="2160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdCompActuallyPaidVsOtherMeasureTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TabularListTableTextBlock" xlink:label="loc_ecdTabularListTableTextBlock" />
      <link:presentationArc order="2170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdTabularListTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TotalShareholderRtnAmt" xlink:label="loc_ecdTotalShareholderRtnAmt" />
      <link:presentationArc order="2180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdTotalShareholderRtnAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeerGroupTotalShareholderRtnAmt" xlink:label="loc_ecdPeerGroupTotalShareholderRtnAmt" />
      <link:presentationArc order="2190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdPeerGroupTotalShareholderRtnAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="2200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTableTextBlock" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CoSelectedMeasureAmt" xlink:label="loc_ecdCoSelectedMeasureAmt" />
      <link:presentationArc order="2210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_ecdCoSelectedMeasureAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OtherPerfMeasureAmt" xlink:label="loc_ecdOtherPerfMeasureAmt" />
      <link:presentationArc order="2220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_ecdOtherPerfMeasureAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToCompAmt" xlink:label="loc_ecdAdjToCompAmt" />
      <link:presentationArc order="2230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_ecdAdjToCompAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoName" xlink:label="loc_ecdPeoName" />
      <link:presentationArc order="2240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_ecdPeoName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MeasureName" xlink:label="loc_ecdMeasureName" />
      <link:presentationArc order="2250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPayVsPerformanceDisclosureLineItems" xlink:to="loc_ecdMeasureName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonGaapMeasureDescriptionTextBlock" xlink:label="loc_ecdNonGaapMeasureDescriptionTextBlock" />
      <link:presentationArc order="2260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdMeasureName" xlink:to="loc_ecdNonGaapMeasureDescriptionTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Additional402vDisclosureTextBlock" xlink:label="loc_ecdAdditional402vDisclosureTextBlock" />
      <link:presentationArc order="2270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPayVsPerformanceDisclosureLineItems" xlink:to="loc_ecdAdditional402vDisclosureTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PnsnBnftsAdjFnTextBlock" xlink:label="loc_ecdPnsnBnftsAdjFnTextBlock" />
      <link:presentationArc order="2280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPayVsPerformanceDisclosureLineItems" xlink:to="loc_ecdPnsnBnftsAdjFnTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" xlink:title="995440 - Disclosure - Recovery of Erroneously Awarded Compensation">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RecoveryOfErrCompDisclosureLineItems" xlink:label="loc_ecdRecoveryOfErrCompDisclosureLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ErrCompRecoveryTable" xlink:label="loc_ecdErrCompRecoveryTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdRecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecdErrCompRecoveryTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDateAxis" xlink:label="loc_ecdRestatementDateAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdErrCompRecoveryTable" xlink:to="loc_ecdRestatementDateAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_IndividualAxis" xlink:label="loc_ecdIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdErrCompRecoveryTable" xlink:to="loc_ecdIndividualAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllIndividualsMember" xlink:label="loc_ecdAllIndividualsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdIndividualAxis" xlink:to="loc_ecdAllIndividualsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDeterminationDate" xlink:label="loc_ecdRestatementDeterminationDate" />
      <link:presentationArc order="2000" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdRecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecdRestatementDeterminationDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtErrCompAmt" xlink:label="loc_ecdAggtErrCompAmt" />
      <link:presentationArc order="2010" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdRestatementDeterminationDate" xlink:to="loc_ecdAggtErrCompAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ErrCompAnalysisTextBlock" xlink:label="loc_ecdErrCompAnalysisTextBlock" />
      <link:presentationArc order="2020" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAggtErrCompAmt" xlink:to="loc_ecdErrCompAnalysisTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:label="loc_ecdStkPrcOrTsrEstimationMethodTextBlock" />
      <link:presentationArc order="2030" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAggtErrCompAmt" xlink:to="loc_ecdStkPrcOrTsrEstimationMethodTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingAggtErrCompAmt" xlink:label="loc_ecdOutstandingAggtErrCompAmt" />
      <link:presentationArc order="2040" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAggtErrCompAmt" xlink:to="loc_ecdOutstandingAggtErrCompAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:label="loc_ecdAggtErrCompNotYetDeterminedTextBlock" />
      <link:presentationArc order="2050" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAggtErrCompAmt" xlink:to="loc_ecdAggtErrCompNotYetDeterminedTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryIndName" xlink:label="loc_ecdForgoneRecoveryIndName" />
      <link:presentationArc order="2060" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAggtErrCompAmt" xlink:to="loc_ecdForgoneRecoveryIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:label="loc_ecdForgoneRecoveryDueToExpenseOfEnforcementAmt" />
      <link:presentationArc order="2070" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAggtErrCompAmt" xlink:to="loc_ecdForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:label="loc_ecdForgoneRecoveryDueToViolationOfHomeCountryLawAmt" />
      <link:presentationArc order="2080" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdRestatementDeterminationDate" xlink:to="loc_ecdForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:label="loc_ecdForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" />
      <link:presentationArc order="2090" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdRestatementDeterminationDate" xlink:to="loc_ecdForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:label="loc_ecdForgoneRecoveryExplanationOfImpracticabilityTextBlock" />
      <link:presentationArc order="2100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:to="loc_ecdForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingRecoveryIndName" xlink:label="loc_ecdOutstandingRecoveryIndName" />
      <link:presentationArc order="2110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:to="loc_ecdOutstandingRecoveryIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingRecoveryCompAmt" xlink:label="loc_ecdOutstandingRecoveryCompAmt" />
      <link:presentationArc order="2120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:to="loc_ecdOutstandingRecoveryCompAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:label="loc_ecdRestatementDoesNotRequireRecoveryTextBlock" />
      <link:presentationArc order="2130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:to="loc_ecdRestatementDoesNotRequireRecoveryTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" xlink:title="995443 - Disclosure - Award Timing Disclosure">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgDiscLineItems" xlink:label="loc_ecdAwardTmgDiscLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscTable" xlink:label="loc_ecdAwardsCloseToMnpiDiscTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardsCloseToMnpiDiscTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_IndividualAxis" xlink:label="loc_ecdIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardsCloseToMnpiDiscTable" xlink:to="loc_ecdIndividualAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllIndividualsMember" xlink:label="loc_ecdAllIndividualsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdIndividualAxis" xlink:to="loc_ecdAllIndividualsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardsCloseToMnpiDiscTable" xlink:to="loc_us-gaapAwardTypeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMnpiDiscTextBlock" xlink:label="loc_ecdAwardTmgMnpiDiscTextBlock" />
      <link:presentationArc order="2000" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardTmgMnpiDiscTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMethodTextBlock" xlink:label="loc_ecdAwardTmgMethodTextBlock" />
      <link:presentationArc order="2010" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardTmgMethodTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgPredtrmndFlag" xlink:label="loc_ecdAwardTmgPredtrmndFlag" />
      <link:presentationArc order="2020" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardTmgPredtrmndFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMnpiCnsdrdFlag" xlink:label="loc_ecdAwardTmgMnpiCnsdrdFlag" />
      <link:presentationArc order="2030" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardTmgMnpiCnsdrdFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:label="loc_ecdAwardTmgHowMnpiCnsdrdTextBlock" />
      <link:presentationArc order="2040" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardTmgHowMnpiCnsdrdTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MnpiDiscTimedForCompValFlag" xlink:label="loc_ecdMnpiDiscTimedForCompValFlag" />
      <link:presentationArc order="2050" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdMnpiDiscTimedForCompValFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:label="loc_ecdAwardsCloseToMnpiDiscTableTextBlock" />
      <link:presentationArc order="2060" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardsCloseToMnpiDiscTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscIndName" xlink:label="loc_ecdAwardsCloseToMnpiDiscIndName" />
      <link:presentationArc order="2070" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardsCloseToMnpiDiscIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardUndrlygSecuritiesAmt" xlink:label="loc_ecdAwardUndrlygSecuritiesAmt" />
      <link:presentationArc order="2080" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardUndrlygSecuritiesAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardExrcPrice" xlink:label="loc_ecdAwardExrcPrice" />
      <link:presentationArc order="2090" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardExrcPrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardGrantDateFairValue" xlink:label="loc_ecdAwardGrantDateFairValue" />
      <link:presentationArc order="2100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardGrantDateFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_UndrlygSecurityMktPriceChngPct" xlink:label="loc_ecdUndrlygSecurityMktPriceChngPct" />
      <link:presentationArc order="2110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdUndrlygSecurityMktPriceChngPct" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:title="995445 - Disclosure - Insider Trading Arrangements">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTradingArrLineItems" xlink:label="loc_ecdInsiderTradingArrLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MtrlTermsOfTrdArrTextBlock" xlink:label="loc_ecdMtrlTermsOfTrdArrTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdMtrlTermsOfTrdArrTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrIndName" xlink:label="loc_ecdTrdArrIndName" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdTrdArrIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrIndTitle" xlink:label="loc_ecdTrdArrIndTitle" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdTrdArrIndTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Rule10b51ArrAdoptedFlag" xlink:label="loc_ecdRule10b51ArrAdoptedFlag" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdRule10b51ArrAdoptedFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonRule10b51ArrAdoptedFlag" xlink:label="loc_ecdNonRule10b51ArrAdoptedFlag" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdNonRule10b51ArrAdoptedFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrAdoptionDate" xlink:label="loc_ecdTrdArrAdoptionDate" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdTrdArrAdoptionDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Rule10b51ArrTrmntdFlag" xlink:label="loc_ecdRule10b51ArrTrmntdFlag" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdRule10b51ArrTrmntdFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonRule10b51ArrTrmntdFlag" xlink:label="loc_ecdNonRule10b51ArrTrmntdFlag" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdNonRule10b51ArrTrmntdFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrTerminationDate" xlink:label="loc_ecdTrdArrTerminationDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdTrdArrTerminationDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrExpirationDate" xlink:label="loc_ecdTrdArrExpirationDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdTrdArrExpirationDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrDuration" xlink:label="loc_ecdTrdArrDuration" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdTrdArrDuration" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_NoInsiderTradingFlag" xlink:label="loc_NRXSNoInsiderTradingFlag" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_NRXSNoInsiderTradingFlag" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" xlink:title="995447 - Disclosure - Insider Trading Policies and Procedures">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTradingPoliciesProcLineItems" xlink:label="loc_ecdInsiderTradingPoliciesProcLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:label="loc_ecdInsiderTrdPoliciesProcAdoptedFlag" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingPoliciesProcLineItems" xlink:to="loc_ecdInsiderTrdPoliciesProcAdoptedFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:label="loc_ecdInsiderTrdPoliciesProcNotAdoptedTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingPoliciesProcLineItems" xlink:to="loc_ecdInsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" xlink:title="00000012 - Disclosure - Cybersecurity Risk Management and Strategy Disclosure">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:label="loc_cydCybersecurityRiskManagementStrategyAndGovernanceAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:label="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:to="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementProcessesIntegratedFlag" xlink:label="loc_cydCybersecurityRiskManagementProcessesIntegratedFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="loc_cydCybersecurityRiskManagementProcessesIntegratedFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock" xlink:label="loc_cydCybersecurityRiskManagementProcessesIntegratedTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="loc_cydCybersecurityRiskManagementProcessesIntegratedTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementThirdPartyEngagedFlag" xlink:label="loc_cydCybersecurityRiskManagementThirdPartyEngagedFlag" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="loc_cydCybersecurityRiskManagementThirdPartyEngagedFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" xlink:label="loc_cydCybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="loc_cydCybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" xlink:label="loc_cydCybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="loc_cydCybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" xlink:label="loc_cydCybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="loc_cydCybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:label="loc_cydCybersecurityRiskBoardOfDirectorsOversightTextBlock" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="loc_cydCybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:label="loc_cydCybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="loc_cydCybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:label="loc_cydCybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="loc_cydCybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskRoleOfManagementTextBlock" xlink:label="loc_cydCybersecurityRiskRoleOfManagementTextBlock" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="loc_cydCybersecurityRiskRoleOfManagementTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" xlink:label="loc_cydCybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="loc_cydCybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" xlink:label="loc_cydCybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="loc_cydCybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure" xlink:title="00000013 - Disclosure - Material Cybersecurity Incident Disclosure">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_MaterialCybersecurityIncidentAbstract" xlink:label="loc_cydMaterialCybersecurityIncidentAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_MaterialCybersecurityIncidentNatureTextBlock" xlink:label="loc_cydMaterialCybersecurityIncidentNatureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydMaterialCybersecurityIncidentAbstract" xlink:to="loc_cydMaterialCybersecurityIncidentNatureTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_MaterialCybersecurityIncidentScopeTextBlock" xlink:label="loc_cydMaterialCybersecurityIncidentScopeTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydMaterialCybersecurityIncidentAbstract" xlink:to="loc_cydMaterialCybersecurityIncidentScopeTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_MaterialCybersecurityIncidentTimingTextBlock" xlink:label="loc_cydMaterialCybersecurityIncidentTimingTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydMaterialCybersecurityIncidentAbstract" xlink:to="loc_cydMaterialCybersecurityIncidentTimingTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_MaterialCybersecurityIncidentMaterialImpactOrReasonablyLikelyMaterialImpactTextBlock" xlink:label="loc_cydMaterialCybersecurityIncidentMaterialImpactOrReasonablyLikelyMaterialImpactTextBlock" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydMaterialCybersecurityIncidentAbstract" xlink:to="loc_cydMaterialCybersecurityIncidentMaterialImpactOrReasonablyLikelyMaterialImpactTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_MaterialCybersecurityIncidentInformationNotAvailableOrUndeterminedTextBlock" xlink:label="loc_cydMaterialCybersecurityIncidentInformationNotAvailableOrUndeterminedTextBlock" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydMaterialCybersecurityIncidentAbstract" xlink:to="loc_cydMaterialCybersecurityIncidentInformationNotAvailableOrUndeterminedTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://neuraxis.com/role/BasisOfPresentationOrganizationAndOtherMatters" xlink:title="999014 - Disclosure - Basis of Presentation, Organization and Other Matters">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:label="loc_us-gaapBusinessDescriptionAndBasisOfPresentationTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapBusinessDescriptionAndBasisOfPresentationTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://neuraxis.com/role/SummaryOfSignificantAccountingPolicies" xlink:title="999015 - Disclosure - Summary of Significant Accounting Policies">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaapSignificantAccountingPoliciesTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapSignificantAccountingPoliciesTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://neuraxis.com/role/RelatedPartyTransactions" xlink:title="999016 - Disclosure - Related Party Transactions">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaapRelatedPartyTransactionsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="loc_us-gaapRelatedPartyTransactionsDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsAbstract" xlink:to="loc_us-gaapRelatedPartyTransactionsDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://neuraxis.com/role/PropertyAndEquipment" xlink:title="999017 - Disclosure - Property and Equipment">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaapPropertyPlantAndEquipmentAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="loc_us-gaapPropertyPlantAndEquipmentDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://neuraxis.com/role/IntangibleAssets" xlink:title="999018 - Disclosure - Intangible Assets">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:label="loc_us-gaapIntangibleAssetsDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapIntangibleAssetsDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://neuraxis.com/role/AccruedExpenses" xlink:title="999019 - Disclosure - Accrued Expenses">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaapPayablesAndAccrualsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:label="loc_us-gaapAccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapAccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://neuraxis.com/role/NotesPayable" xlink:title="999020 - Disclosure - Notes Payable">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaapDebtDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="loc_us-gaapDebtDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapDebtDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://neuraxis.com/role/Leases" xlink:title="999021 - Disclosure - Leases">
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_DisclosureLeasesAbstract" xlink:label="loc_NRXSDisclosureLeasesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="loc_us-gaapLesseeOperatingLeasesTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_NRXSDisclosureLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeasesTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://neuraxis.com/role/CommonStockAndWarrants" xlink:title="999022 - Disclosure - Common Stock and Warrants">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaapStockholdersEquityNoteDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapStockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://neuraxis.com/role/PreferredStock" xlink:title="999023 - Disclosure - Preferred Stock">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockTextBlock" xlink:label="loc_us-gaapPreferredStockTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapPreferredStockTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://neuraxis.com/role/Stock-basedCompensation" xlink:title="999024 - Disclosure - Stock-Based Compensation">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://neuraxis.com/role/WarrantLiabilities" xlink:title="999025 - Disclosure - Warrant Liabilities">
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_DisclosureWarrantLiabilitiesAbstract" xlink:label="loc_NRXSDisclosureWarrantLiabilitiesAbstract" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_WarrantLiabilitiesDisclosureTextBlock" xlink:label="loc_NRXSWarrantLiabilitiesDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_NRXSDisclosureWarrantLiabilitiesAbstract" xlink:to="loc_NRXSWarrantLiabilitiesDisclosureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://neuraxis.com/role/DerivativeLiabilities" xlink:title="999026 - Disclosure - Derivative Liabilities">
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_DisclosureDerivativeLiabilitiesAbstract" xlink:label="loc_NRXSDisclosureDerivativeLiabilitiesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativesAndFairValueTextBlock" xlink:label="loc_us-gaapDerivativesAndFairValueTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_NRXSDisclosureDerivativeLiabilitiesAbstract" xlink:to="loc_us-gaapDerivativesAndFairValueTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://neuraxis.com/role/RetirementPlan" xlink:title="999027 - Disclosure - Retirement Plan">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="loc_us-gaapCompensationAndRetirementDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:label="loc_us-gaapPensionAndOtherPostretirementBenefitsDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCompensationAndRetirementDisclosureAbstract" xlink:to="loc_us-gaapPensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://neuraxis.com/role/SegmentInformation" xlink:title="999028 - Disclosure - Segment Information">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract" xlink:label="loc_us-gaapSegmentReportingAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingDisclosureTextBlock" xlink:label="loc_us-gaapSegmentReportingDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingAbstract" xlink:to="loc_us-gaapSegmentReportingDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://neuraxis.com/role/CommitmentsAndContingencies" xlink:title="999029 - Disclosure - Commitments and Contingencies">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapCommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://neuraxis.com/role/HealthBenefitPlan" xlink:title="999030 - Disclosure - Health Benefit Plan">
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_DisclosureHealthBenefitPlanAbstract" xlink:label="loc_NRXSDisclosureHealthBenefitPlanAbstract" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_HealthBenefitPlanDisclosureTextBlock" xlink:label="loc_NRXSHealthBenefitPlanDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_NRXSDisclosureHealthBenefitPlanAbstract" xlink:to="loc_NRXSHealthBenefitPlanDisclosureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://neuraxis.com/role/IncomeTaxes" xlink:title="999031 - Disclosure - Income Taxes">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaapIncomeTaxDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://neuraxis.com/role/SubsequentEvents" xlink:title="999032 - Disclosure - Subsequent Events">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaapSubsequentEventsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaapSubsequentEventsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventsAbstract" xlink:to="loc_us-gaapSubsequentEventsTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://neuraxis.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:title="999033 - Disclosure - Summary of Significant Accounting Policies (Policies)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaapUseOfEstimates" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapUseOfEstimates" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="loc_us-gaapCashAndCashEquivalentsPolicyTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:label="loc_us-gaapTradeAndOtherAccountsReceivablePolicy" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapTradeAndOtherAccountsReceivablePolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepositContractsPolicy" xlink:label="loc_us-gaapDepositContractsPolicy" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapDepositContractsPolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryPolicyTextBlock" xlink:label="loc_us-gaapInventoryPolicyTextBlock" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapInventoryPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="loc_us-gaapPropertyPlantAndEquipmentPolicyTextBlock" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="loc_us-gaapResearchAndDevelopmentExpensePolicy" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapResearchAndDevelopmentExpensePolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:label="loc_us-gaapIntangibleAssetsFiniteLivedPolicy" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapIntangibleAssetsFiniteLivedPolicy" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_us-gaapIncomeTaxPolicyTextBlock" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapIncomeTaxPolicyTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdvertisingCostsPolicyTextBlock" xlink:label="loc_us-gaapAdvertisingCostsPolicyTextBlock" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapAdvertisingCostsPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_WarrantLiabilityPolicyTextBlock" xlink:label="loc_NRXSWarrantLiabilityPolicyTextBlock" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_NRXSWarrantLiabilityPolicyTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="loc_us-gaapFairValueMeasurementPolicyPolicyTextBlock" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapFairValueMeasurementPolicyPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaapEarningsPerSharePolicyTextBlock" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapEarningsPerSharePolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="loc_us-gaapShareBasedCompensationOptionAndIncentivePlansPolicy" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="loc_us-gaapRevenueRecognitionPolicyTextBlock" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapRevenueRecognitionPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="loc_us-gaapLesseeLeasesPolicyTextBlock" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapLesseeLeasesPolicyTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="loc_us-gaapImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="loc_us-gaapConcentrationRiskCreditRisk" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapConcentrationRiskCreditRisk" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_GoingConcernPolicyTextBlock" xlink:label="loc_NRXSGoingConcernPolicyTextBlock" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_NRXSGoingConcernPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaapNewAccountingPronouncementsPolicyPolicyTextBlock" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapNewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_RecentlyIssuedAccountingPronouncementsPolicyTextBlock" xlink:label="loc_NRXSRecentlyIssuedAccountingPronouncementsPolicyTextBlock" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_NRXSRecentlyIssuedAccountingPronouncementsPolicyTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://neuraxis.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:title="999034 - Disclosure - Summary of Significant Accounting Policies (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_ScheduleOfPropertyPlantAndEquipmentUsefulLivesTableTextBlock" xlink:label="loc_NRXSScheduleOfPropertyPlantAndEquipmentUsefulLivesTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_NRXSScheduleOfPropertyPlantAndEquipmentUsefulLivesTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="loc_us-gaapScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTextBlock" xlink:label="loc_us-gaapScheduleOfEarningsPerShareDilutedByCommonClassTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapScheduleOfEarningsPerShareDilutedByCommonClassTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="loc_us-gaapScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:label="loc_us-gaapDisaggregationOfRevenueTableTextBlock" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapDisaggregationOfRevenueTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:label="loc_us-gaapSchedulesOfConcentrationOfRiskByRiskFactorTextBlock" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapSchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerAssetAllowanceForCreditLossTableTextBlock" xlink:label="loc_us-gaapContractWithCustomerAssetAllowanceForCreditLossTableTextBlock" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapContractWithCustomerAssetAllowanceForCreditLossTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://neuraxis.com/role/RelatedPartyTransactionsTables" xlink:title="999035 - Disclosure - Related Party Transactions (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaapRelatedPartyTransactionsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:label="loc_us-gaapScheduleOfRelatedPartyTransactionsTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsAbstract" xlink:to="loc_us-gaapScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_ScheduleOfRelatedPartyLoansTableTextBlock" xlink:label="loc_NRXSScheduleOfRelatedPartyLoansTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsAbstract" xlink:to="loc_NRXSScheduleOfRelatedPartyLoansTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://neuraxis.com/role/PropertyAndEquipmentTables" xlink:title="999036 - Disclosure - Property and Equipment (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaapPropertyPlantAndEquipmentAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://neuraxis.com/role/IntangibleAssetsTables" xlink:title="999037 - Disclosure - Intangible Assets (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:label="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://neuraxis.com/role/AccruedExpensesTables" xlink:title="999038 - Disclosure - Accrued Expenses (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaapPayablesAndAccrualsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="loc_us-gaapScheduleOfAccruedLiabilitiesTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://neuraxis.com/role/LeasesTables" xlink:title="999039 - Disclosure - Leases (Tables)">
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_DisclosureLeasesAbstract" xlink:label="loc_NRXSDisclosureLeasesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="loc_us-gaapLeaseCostTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_NRXSDisclosureLeasesAbstract" xlink:to="loc_us-gaapLeaseCostTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityMaturityTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_NRXSDisclosureLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://neuraxis.com/role/CommonStockAndWarrantsTables" xlink:title="999040 - Disclosure - Common Stock and Warrants (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockMember" xlink:label="loc_us-gaapPreferredStockMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_ScheduleOfWarrantActivityForCommonStockTableTextBlock" xlink:label="loc_NRXSScheduleOfWarrantActivityForCommonStockTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_NRXSScheduleOfWarrantActivityForCommonStockTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_ScheduleOfWarrantActivityForPreferredStockTableTextBlock" xlink:label="loc_NRXSScheduleOfWarrantActivityForPreferredStockTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_NRXSScheduleOfWarrantActivityForPreferredStockTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="loc_us-gaapScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://neuraxis.com/role/Stock-basedCompensationTables" xlink:title="999041 - Disclosure - Stock-Based Compensation (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://neuraxis.com/role/WarrantLiabilitiesTables" xlink:title="999042 - Disclosure - Warrant Liabilities (Tables)">
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_DisclosureWarrantLiabilitiesAbstract" xlink:label="loc_NRXSDisclosureWarrantLiabilitiesAbstract" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_ScheduleOfChangesInWarrantLiabilitiesTableTextBlock" xlink:label="loc_NRXSScheduleOfChangesInWarrantLiabilitiesTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_NRXSDisclosureWarrantLiabilitiesAbstract" xlink:to="loc_NRXSScheduleOfChangesInWarrantLiabilitiesTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://neuraxis.com/role/DerivativeLiabilitiesTables" xlink:title="999043 - Disclosure - Derivative Liabilities (Tables)">
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_DisclosureDerivativeLiabilitiesAbstract" xlink:label="loc_NRXSDisclosureDerivativeLiabilitiesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" xlink:label="loc_us-gaapScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_NRXSDisclosureDerivativeLiabilitiesAbstract" xlink:to="loc_us-gaapScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://neuraxis.com/role/SegmentInformationTables" xlink:title="999044 - Disclosure - Segment Information (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract" xlink:label="loc_us-gaapSegmentReportingAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:label="loc_us-gaapScheduleOfSegmentReportingInformationBySegmentTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingAbstract" xlink:to="loc_us-gaapScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://neuraxis.com/role/IncomeTaxesTables" xlink:title="999045 - Disclosure - Income Taxes (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="loc_us-gaapScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="loc_us-gaapScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="loc_us-gaapScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock" xlink:label="loc_us-gaapSummaryOfOperatingLossCarryforwardsTextBlock" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapSummaryOfOperatingLossCarryforwardsTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://neuraxis.com/role/BasisOfPresentationOrganizationAndOtherMattersDetailsNarrative" xlink:title="999046 - Disclosure - Basis of Presentation, Organization and Other Matters (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_ConvertibleSeriesAPreferredStockMember" xlink:label="loc_NRXSConvertibleSeriesAPreferredStockMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_NRXSConvertibleSeriesAPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_ConvertibleSeriesSeedPreferredStockMember" xlink:label="loc_NRXSConvertibleSeriesSeedPreferredStockMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_NRXSConvertibleSeriesSeedPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="loc_us-gaapSeriesBPreferredStockMember" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesBPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_ConvertibleSeriesBPreferredStockMember" xlink:label="loc_NRXSConvertibleSeriesBPreferredStockMember" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_NRXSConvertibleSeriesBPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="loc_srtConsolidatedEntitiesAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtConsolidatedEntitiesAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="loc_srtConsolidatedEntitiesDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtConsolidatedEntitiesAxis" xlink:to="loc_srtConsolidatedEntitiesDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_AlexanderCapitalLPMember" xlink:label="loc_NRXSAlexanderCapitalLPMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtConsolidatedEntitiesDomain" xlink:to="loc_NRXSAlexanderCapitalLPMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaapSubsidiarySaleOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IPOMember" xlink:label="loc_us-gaapIPOMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_us-gaapIPOMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteStockSplit" xlink:label="loc_us-gaapStockholdersEquityNoteStockSplit" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquityNoteStockSplit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaapSharesIssuedPricePerShare" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesIssuedPricePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredOfferingCosts" xlink:label="loc_us-gaapDeferredOfferingCosts" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDeferredOfferingCosts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_PurchaseOfAdditionalStockOnNumberOfOptionsNotExercised" xlink:label="loc_NRXSPurchaseOfAdditionalStockOnNumberOfOptionsNotExercised" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_NRXSPurchaseOfAdditionalStockOnNumberOfOptionsNotExercised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_UnderwritersDiscountPercentage" xlink:label="loc_NRXSUnderwritersDiscountPercentage" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_NRXSUnderwritersDiscountPercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_NonaccountableExpenseAllowancePercentage" xlink:label="loc_NRXSNonaccountableExpenseAllowancePercentage" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_NRXSNonaccountableExpenseAllowancePercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_CashFeePercentage" xlink:label="loc_NRXSCashFeePercentage" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_NRXSCashFeePercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="loc_us-gaapProceedsFromIssuanceInitialPublicOffering" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceInitialPublicOffering" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_ReimbursementExpenses" xlink:label="loc_NRXSReimbursementExpenses" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_NRXSReimbursementExpenses" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction" xlink:label="loc_us-gaapSaleOfStockPercentageOfOwnershipAfterTransaction" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSaleOfStockPercentageOfOwnershipAfterTransaction" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_OfferingPricePerPercentage" xlink:label="loc_NRXSOfferingPricePerPercentage" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_NRXSOfferingPricePerPercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:label="loc_us-gaapTemporaryEquitySharesAuthorized" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapTemporaryEquitySharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockDividendPaymentTerms" xlink:label="loc_us-gaapPreferredStockDividendPaymentTerms" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockDividendPaymentTerms" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:label="loc_us-gaapStockRepurchasedAndRetiredDuringPeriodShares" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockRepurchasedAndRetiredDuringPeriodShares" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://neuraxis.com/role/ScheduleOfEstimatedUsefulLivesDetails" xlink:title="999047 - Disclosure - Schedule of Estimated Useful Lives (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaapPropertyPlantAndEquipmentLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MachineryAndEquipmentMember" xlink:label="loc_us-gaapMachineryAndEquipmentMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapMachineryAndEquipmentMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaapFurnitureAndFixturesMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapFurnitureAndFixturesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComputerEquipmentMember" xlink:label="loc_us-gaapComputerEquipmentMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapComputerEquipmentMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaapLeaseholdImprovementsMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapLeaseholdImprovementsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_srtRangeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaapPropertyPlantAndEquipmentUsefulLife" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentUsefulLife" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://neuraxis.com/role/ScheduleOfFairValueOfAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails" xlink:title="999048 - Disclosure - Schedule of Fair Value of Assets and Liabilities measured on Recurring Basis (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaapFairValueByMeasurementFrequencyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="loc_us-gaapFairValueByMeasurementFrequencyAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaapFairValueMeasurementFrequencyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueByMeasurementFrequencyAxis" xlink:to="loc_us-gaapFairValueMeasurementFrequencyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaapFairValueMeasurementsRecurringMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueMeasurementFrequencyDomain" xlink:to="loc_us-gaapFairValueMeasurementsRecurringMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaapFinancialInstrumentAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="loc_us-gaapFinancialInstrumentAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFinancialInstrumentAxis" xlink:to="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="loc_us-gaapWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaapFairValueInputsLevel1Member" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel1Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaapFairValueInputsLevel2Member" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel2Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaapFairValueInputsLevel3Member" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel3Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="loc_us-gaapLiabilitiesFairValueDisclosure" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="loc_us-gaapLiabilitiesFairValueDisclosure" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://neuraxis.com/role/ScheduleOfDilutiveCommonStockEquivalentsDetails" xlink:title="999049 - Disclosure - Schedule of Dilutive Common Stock Equivalents (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OptionMember" xlink:label="loc_us-gaapOptionMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_us-gaapOptionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_WarrantsMember" xlink:label="loc_NRXSWarrantsMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_NRXSWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="loc_us-gaapSeriesBPreferredStockMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_us-gaapSeriesBPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://neuraxis.com/role/ScheduleOfBasicAndDilutedNetLossPerShareDetails" xlink:title="999050 - Disclosure - Schedule of Basic and Diluted Net Loss Per Share (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DividendsPreferredStock" xlink:label="loc_us-gaapDividendsPreferredStock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapDividendsPreferredStock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaapWeightedAverageNumberOfDilutedSharesOutstanding" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapWeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaapEarningsPerShareBasic" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapEarningsPerShareBasic" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaapEarningsPerShareDiluted" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapEarningsPerShareDiluted" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://neuraxis.com/role/ScheduleOfDisaggregationOfRevenueDetails" xlink:title="999051 - Disclosure - Schedule of Disaggregation of Revenue (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srtStatementGeographicalAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtStatementGeographicalAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srtSegmentGeographicalDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtStatementGeographicalAxis" xlink:to="loc_srtSegmentGeographicalDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd#stpr_CA" xlink:label="loc_stprCA" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_stprCA" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd#stpr_OH" xlink:label="loc_stprOH" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_stprOH" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd#stpr_IL" xlink:label="loc_stprIL" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_stprIL" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd#stpr_WI" xlink:label="loc_stprWI" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_stprWI" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd#stpr_MA" xlink:label="loc_stprMA" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_stprMA" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd#stpr_FL" xlink:label="loc_stprFL" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_stprFL" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_AllOtherStatesMember" xlink:label="loc_NRXSAllOtherStatesMember" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_NRXSAllOtherStatesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Revenues" xlink:label="loc_us-gaapRevenues" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapRevenues" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://neuraxis.com/role/ScheduleOfCustomerAccountsReceivableDetails" xlink:title="999052 - Disclosure - Schedule of Customer Accounts Receivable (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfProductInformationTable" xlink:label="loc_us-gaapScheduleOfProductInformationTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapScheduleOfProductInformationTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProductInformationLineItems" xlink:label="loc_us-gaapProductInformationLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfProductInformationTable" xlink:to="loc_us-gaapProductInformationLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MajorCustomersAxis" xlink:label="loc_srtMajorCustomersAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfProductInformationTable" xlink:to="loc_srtMajorCustomersAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srtNameOfMajorCustomerDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtMajorCustomersAxis" xlink:to="loc_srtNameOfMajorCustomerDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_CustomerAMember" xlink:label="loc_NRXSCustomerAMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtNameOfMajorCustomerDomain" xlink:to="loc_NRXSCustomerAMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_CustomerBMember" xlink:label="loc_NRXSCustomerBMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtNameOfMajorCustomerDomain" xlink:to="loc_NRXSCustomerBMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_CustomerCMember" xlink:label="loc_NRXSCustomerCMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtNameOfMajorCustomerDomain" xlink:to="loc_NRXSCustomerCMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_CustomerDMember" xlink:label="loc_NRXSCustomerDMember" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtNameOfMajorCustomerDomain" xlink:to="loc_NRXSCustomerDMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_CustomerEMember" xlink:label="loc_NRXSCustomerEMember" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtNameOfMajorCustomerDomain" xlink:to="loc_NRXSCustomerEMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_CustomerMember" xlink:label="loc_NRXSCustomerMember" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtNameOfMajorCustomerDomain" xlink:to="loc_NRXSCustomerMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="loc_us-gaapConcentrationRiskByBenchmarkAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfProductInformationTable" xlink:to="loc_us-gaapConcentrationRiskByBenchmarkAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaapConcentrationRiskBenchmarkDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskByBenchmarkAxis" xlink:to="loc_us-gaapConcentrationRiskBenchmarkDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableMember" xlink:label="loc_us-gaapAccountsReceivableMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskBenchmarkDomain" xlink:to="loc_us-gaapAccountsReceivableMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="loc_us-gaapConcentrationRiskByTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfProductInformationTable" xlink:to="loc_us-gaapConcentrationRiskByTypeAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaapConcentrationRiskTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskByTypeAxis" xlink:to="loc_us-gaapConcentrationRiskTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="loc_us-gaapCustomerConcentrationRiskMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskTypeDomain" xlink:to="loc_us-gaapCustomerConcentrationRiskMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNet" xlink:label="loc_us-gaapAccountsReceivableNet" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapAccountsReceivableNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="loc_us-gaapConcentrationRiskPercentage1" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapConcentrationRiskPercentage1" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://neuraxis.com/role/ScheduleOfCustomersAccountedRevenuesDetails" xlink:title="999053 - Disclosure - Schedule of Customers Accounted Revenues (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfProductInformationTable" xlink:label="loc_us-gaapScheduleOfProductInformationTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapScheduleOfProductInformationTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProductInformationLineItems" xlink:label="loc_us-gaapProductInformationLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfProductInformationTable" xlink:to="loc_us-gaapProductInformationLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MajorCustomersAxis" xlink:label="loc_srtMajorCustomersAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfProductInformationTable" xlink:to="loc_srtMajorCustomersAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srtNameOfMajorCustomerDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtMajorCustomersAxis" xlink:to="loc_srtNameOfMajorCustomerDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_CustomerAMember" xlink:label="loc_NRXSCustomerAMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtNameOfMajorCustomerDomain" xlink:to="loc_NRXSCustomerAMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_CustomerBMember" xlink:label="loc_NRXSCustomerBMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtNameOfMajorCustomerDomain" xlink:to="loc_NRXSCustomerBMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_CustomerCMember" xlink:label="loc_NRXSCustomerCMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtNameOfMajorCustomerDomain" xlink:to="loc_NRXSCustomerCMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_CustomerMember" xlink:label="loc_NRXSCustomerMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtNameOfMajorCustomerDomain" xlink:to="loc_NRXSCustomerMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="loc_us-gaapConcentrationRiskByBenchmarkAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfProductInformationTable" xlink:to="loc_us-gaapConcentrationRiskByBenchmarkAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaapConcentrationRiskBenchmarkDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskByBenchmarkAxis" xlink:to="loc_us-gaapConcentrationRiskBenchmarkDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SalesRevenueNetMember" xlink:label="loc_us-gaapSalesRevenueNetMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskBenchmarkDomain" xlink:to="loc_us-gaapSalesRevenueNetMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="loc_us-gaapConcentrationRiskByTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfProductInformationTable" xlink:to="loc_us-gaapConcentrationRiskByTypeAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaapConcentrationRiskTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskByTypeAxis" xlink:to="loc_us-gaapConcentrationRiskTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="loc_us-gaapCustomerConcentrationRiskMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskTypeDomain" xlink:to="loc_us-gaapCustomerConcentrationRiskMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="loc_us-gaapConcentrationRiskPercentage1" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapConcentrationRiskPercentage1" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://neuraxis.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="999054 - Disclosure - Summary of Significant Accounting Policies (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaapScheduleOfIndefiniteLivedIntangibleAssetsTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapScheduleOfIndefiniteLivedIntangibleAssetsTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:label="loc_us-gaapIndefiniteLivedIntangibleAssetsByMajorClassLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfIndefiniteLivedIntangibleAssetsTable" xlink:to="loc_us-gaapIndefiniteLivedIntangibleAssetsByMajorClassLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaapIndefiniteLivedIntangibleAssetsByMajorClassAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfIndefiniteLivedIntangibleAssetsTable" xlink:to="loc_us-gaapIndefiniteLivedIntangibleAssetsByMajorClassAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapIndefiniteLivedIntangibleAssetsMajorClassNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapIndefiniteLivedIntangibleAssetsMajorClassNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TrademarksMember" xlink:label="loc_us-gaapTrademarksMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_us-gaapTrademarksMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfIndefiniteLivedIntangibleAssetsTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_LicensingAgreementMember" xlink:label="loc_NRXSLicensingAgreementMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_NRXSLicensingAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaapIncomeStatementLocationAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfIndefiniteLivedIntangibleAssetsTable" xlink:to="loc_us-gaapIncomeStatementLocationAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaapGeneralAndAdministrativeExpenseMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapGeneralAndAdministrativeExpenseMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:label="loc_us-gaapAllowanceForDoubtfulAccountsReceivable" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:to="loc_us-gaapAllowanceForDoubtfulAccountsReceivable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProvisionForOtherCreditLosses" xlink:label="loc_us-gaapProvisionForOtherCreditLosses" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:to="loc_us-gaapProvisionForOtherCreditLosses" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Deposits" xlink:label="loc_us-gaapDeposits" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:to="loc_us-gaapDeposits" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_InventoryExpenses" xlink:label="loc_NRXSInventoryExpenses" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:to="loc_NRXSInventoryExpenses" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryRawMaterialsNetOfReserves" xlink:label="loc_us-gaapInventoryRawMaterialsNetOfReserves" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:to="loc_us-gaapInventoryRawMaterialsNetOfReserves" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaapDepreciation" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:to="loc_us-gaapDepreciation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="loc_us-gaapPaymentsToAcquireIntangibleAssets" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:to="loc_us-gaapPaymentsToAcquireIntangibleAssets" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaapAmortizationOfIntangibleAssets" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:to="loc_us-gaapAmortizationOfIntangibleAssets" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExaminationLikelihoodOfUnfavorableSettlement" xlink:label="loc_us-gaapIncomeTaxExaminationLikelihoodOfUnfavorableSettlement" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:to="loc_us-gaapIncomeTaxExaminationLikelihoodOfUnfavorableSettlement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued" xlink:label="loc_us-gaapIncomeTaxExaminationPenaltiesAndInterestAccrued" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:to="loc_us-gaapIncomeTaxExaminationPenaltiesAndInterestAccrued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdvertisingExpense" xlink:label="loc_us-gaapAdvertisingExpense" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:to="loc_us-gaapAdvertisingExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DividendsPreferredStock" xlink:label="loc_us-gaapDividendsPreferredStock" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:to="loc_us-gaapDividendsPreferredStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:label="loc_us-gaapContractWithCustomerLiabilityRevenueRecognized" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:to="loc_us-gaapContractWithCustomerLiabilityRevenueRecognized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashFDICInsuredAmount" xlink:label="loc_us-gaapCashFDICInsuredAmount" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:to="loc_us-gaapCashFDICInsuredAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashUninsuredAmount" xlink:label="loc_us-gaapCashUninsuredAmount" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:to="loc_us-gaapCashUninsuredAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermBorrowings" xlink:label="loc_us-gaapShortTermBorrowings" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:to="loc_us-gaapShortTermBorrowings" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Cash" xlink:label="loc_us-gaapCash" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:to="loc_us-gaapCash" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_WorkingCapitalDeficit" xlink:label="loc_NRXSWorkingCapitalDeficit" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:to="loc_NRXSWorkingCapitalDeficit" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://neuraxis.com/role/ScheduleOfRelatedPartyTransactionsDetails" xlink:title="999055 - Disclosure - Schedule of Related Party Transactions (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaapRelatedPartyTransactionsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsAbstract" xlink:to="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaapRelatedPartyTransactionLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapRelatedPartyTransactionLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_ShareHolderOneMember" xlink:label="loc_NRXSShareHolderOneMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_NRXSShareHolderOneMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_ShareHolderTwoMember" xlink:label="loc_NRXSShareHolderTwoMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_NRXSShareHolderTwoMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyMember" xlink:label="loc_us-gaapRelatedPartyMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_us-gaapRelatedPartyMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NotesAndLoansReceivableGrossCurrent" xlink:label="loc_us-gaapNotesAndLoansReceivableGrossCurrent" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapNotesAndLoansReceivableGrossCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestReceivableCurrent" xlink:label="loc_us-gaapInterestReceivableCurrent" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapInterestReceivableCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_InterestIncomeGrossCurrent" xlink:label="loc_NRXSInterestIncomeGrossCurrent" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_NRXSInterestIncomeGrossCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllowanceForNotesAndLoansReceivableCurrent" xlink:label="loc_us-gaapAllowanceForNotesAndLoansReceivableCurrent" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapAllowanceForNotesAndLoansReceivableCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_AllowanceForInterestReceivableCurrent" xlink:label="loc_NRXSAllowanceForInterestReceivableCurrent" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_NRXSAllowanceForInterestReceivableCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_AllowanceForInterestIncomeCurrent" xlink:label="loc_NRXSAllowanceForInterestIncomeCurrent" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_NRXSAllowanceForInterestIncomeCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NotesAndLoansReceivableNetCurrent" xlink:label="loc_us-gaapNotesAndLoansReceivableNetCurrent" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapNotesAndLoansReceivableNetCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestReceivable" xlink:label="loc_us-gaapInterestReceivable" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapInterestReceivable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_InterestIncomeCurrent" xlink:label="loc_NRXSInterestIncomeCurrent" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_NRXSInterestIncomeCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://neuraxis.com/role/ScheduleOfRelatedPartyLoansPayableToShareholderDetails" xlink:title="999056 - Disclosure - Schedule of Related Party Loans payable to shareholder (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaapRelatedPartyTransactionsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShortTermDebtTable" xlink:label="loc_us-gaapScheduleOfShortTermDebtTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsAbstract" xlink:to="loc_us-gaapScheduleOfShortTermDebtTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermDebtLineItems" xlink:label="loc_us-gaapShortTermDebtLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_us-gaapShortTermDebtLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaapDebtInstrumentAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_us-gaapDebtInstrumentAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaapDebtInstrumentNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentAxis" xlink:to="loc_us-gaapDebtInstrumentNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_OtherConvertiblesMember" xlink:label="loc_NRXSOtherConvertiblesMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_NRXSOtherConvertiblesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_ShareHolderOneMember" xlink:label="loc_NRXSShareHolderOneMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_NRXSShareHolderOneMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_ShareHolderTwoMember" xlink:label="loc_NRXSShareHolderTwoMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_NRXSShareHolderTwoMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentMaturityDateDescription" xlink:label="loc_us-gaapDebtInstrumentMaturityDateDescription" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentMaturityDateDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaapDebtInstrumentInterestRateStatedPercentage" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentInterestRateStatedPercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LoansPayable" xlink:label="loc_us-gaapLoansPayable" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapLoansPayable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_InterestAndServiceFeeAccrued" xlink:label="loc_NRXSInterestAndServiceFeeAccrued" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_NRXSInterestAndServiceFeeAccrued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestPaid" xlink:label="loc_us-gaapInterestPaid" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapInterestPaid" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://neuraxis.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:title="999057 - Disclosure - Related Party Transactions (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaapRelatedPartyTransactionsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsAbstract" xlink:to="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaapRelatedPartyTransactionLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapRelatedPartyTransactionLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_ShareholdersOneAndTwoMember" xlink:label="loc_NRXSShareholdersOneAndTwoMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_NRXSShareholdersOneAndTwoMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyMember" xlink:label="loc_us-gaapRelatedPartyMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_us-gaapRelatedPartyMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_MrWatkinsMember" xlink:label="loc_NRXSMrWatkinsMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_NRXSMrWatkinsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_MrSealeMember" xlink:label="loc_NRXSMrSealeMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_NRXSMrSealeMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_srtTitleOfIndividualAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ChiefFinancialOfficerMember" xlink:label="loc_srtChiefFinancialOfficerMember" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_srtChiefFinancialOfficerMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NotesAndLoansReceivableGrossCurrent" xlink:label="loc_us-gaapNotesAndLoansReceivableGrossCurrent" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapNotesAndLoansReceivableGrossCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_AllowanceForInterestReceivableCurrent" xlink:label="loc_NRXSAllowanceForInterestReceivableCurrent" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_NRXSAllowanceForInterestReceivableCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:label="loc_us-gaapRelatedPartyTransactionAmountsOfTransaction" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapRelatedPartyTransactionAmountsOfTransaction" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForFees" xlink:label="loc_us-gaapPaymentsForFees" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapPaymentsForFees" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrentAndNoncurrent" xlink:label="loc_us-gaapAccountsPayableCurrentAndNoncurrent" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapAccountsPayableCurrentAndNoncurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueIssuedForServices" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueIssuedForServices" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://neuraxis.com/role/ScheduleOfPropertyAndEquipmentDetails" xlink:title="999058 - Disclosure - Schedule of Property And Equipment (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaapPropertyPlantAndEquipmentAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:to="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaapPropertyPlantAndEquipmentLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MachineryAndEquipmentMember" xlink:label="loc_us-gaapMachineryAndEquipmentMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapMachineryAndEquipmentMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaapFurnitureAndFixturesMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapFurnitureAndFixturesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComputerEquipmentMember" xlink:label="loc_us-gaapComputerEquipmentMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapComputerEquipmentMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaapLeaseholdImprovementsMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapLeaseholdImprovementsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaapPropertyPlantAndEquipmentGross" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentGross" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://neuraxis.com/role/PropertyAndEquipmentDetailsNarrative" xlink:title="999059 - Disclosure - Property and Equipment (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaapPropertyPlantAndEquipmentAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_DecemberTwoThousandTwentyFiveMember" xlink:label="loc_NRXSDecemberTwoThousandTwentyFiveMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_NRXSDecemberTwoThousandTwentyFiveMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_DecemberTwoThousandTwentySixMember" xlink:label="loc_NRXSDecemberTwoThousandTwentySixMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_NRXSDecemberTwoThousandTwentySixMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_DecemberTwoThousandTwentySevenMember" xlink:label="loc_NRXSDecemberTwoThousandTwentySevenMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_NRXSDecemberTwoThousandTwentySevenMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_DecemberTwoThousandTwentyEightMember" xlink:label="loc_NRXSDecemberTwoThousandTwentyEightMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_NRXSDecemberTwoThousandTwentyEightMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_DecemberTwoThousandTwentyNineMember" xlink:label="loc_NRXSDecemberTwoThousandTwentyNineMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_NRXSDecemberTwoThousandTwentyNineMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_DecemberTwoThousandTwentyThereafterMember" xlink:label="loc_NRXSDecemberTwoThousandTwentyThereafterMember" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_NRXSDecemberTwoThousandTwentyThereafterMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaapDepreciation" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapDepreciation" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://neuraxis.com/role/ScheduleOfIntangibleAssetsDetails" xlink:title="999060 - Disclosure - Schedule of Intangible Assets (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_SoftwareImplementationMember" xlink:label="loc_NRXSSoftwareImplementationMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_NRXSSoftwareImplementationMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PatentsMember" xlink:label="loc_us-gaapPatentsMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_us-gaapPatentsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TrademarksMember" xlink:label="loc_us-gaapTrademarksMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_us-gaapTrademarksMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_LicensesMember" xlink:label="loc_NRXSLicensesMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_NRXSLicensesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsGross" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAccumulatedAmortization" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsNet" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://neuraxis.com/role/IntangibleAssetsDetailsNarrative" xlink:title="999061 - Disclosure - Intangible Assets (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_DecemberTwoThousandTwentyFiveMember" xlink:label="loc_NRXSDecemberTwoThousandTwentyFiveMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_NRXSDecemberTwoThousandTwentyFiveMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_DecemberTwoThousandTwentySixMember" xlink:label="loc_NRXSDecemberTwoThousandTwentySixMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_NRXSDecemberTwoThousandTwentySixMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_DecemberTwoThousandTwentySevenMember" xlink:label="loc_NRXSDecemberTwoThousandTwentySevenMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_NRXSDecemberTwoThousandTwentySevenMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_DecemberTwoThousandTwentyEightMember" xlink:label="loc_NRXSDecemberTwoThousandTwentyEightMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_NRXSDecemberTwoThousandTwentyEightMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_DecemberTwoThousandTwentyNineMember" xlink:label="loc_NRXSDecemberTwoThousandTwentyNineMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_NRXSDecemberTwoThousandTwentyNineMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_DecemberTwoThousandTwentyThereafterMember" xlink:label="loc_NRXSDecemberTwoThousandTwentyThereafterMember" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_NRXSDecemberTwoThousandTwentyThereafterMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaapAmortizationOfIntangibleAssets" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapAmortizationOfIntangibleAssets" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://neuraxis.com/role/ScheduleOfAccruedExpensesDetails" xlink:title="999062 - Disclosure - Schedule of Accrued Expenses (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaapPayablesAndAccrualsAbstract" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_AccruedCompensationAndBenefitsCurrent" xlink:label="loc_NRXSAccruedCompensationAndBenefitsCurrent" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_NRXSAccruedCompensationAndBenefitsCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_AdvisoryFees" xlink:label="loc_NRXSAdvisoryFees" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_NRXSAdvisoryFees" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestPayableCurrent" xlink:label="loc_us-gaapInterestPayableCurrent" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapInterestPayableCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent" xlink:label="loc_us-gaapAccrualForTaxesOtherThanIncomeTaxesCurrent" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapAccrualForTaxesOtherThanIncomeTaxesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrent" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapAccruedLiabilitiesCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://neuraxis.com/role/NotesPayableDetailsNarrative" xlink:title="999063 - Disclosure - Notes Payable (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaapDebtDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiLegalEntityAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_ChannelPartnersCapitalMember" xlink:label="loc_NRXSChannelPartnersCapitalMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_NRXSChannelPartnersCapitalMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_ExchangeListingLLCMember" xlink:label="loc_NRXSExchangeListingLLCMember" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_NRXSExchangeListingLLCMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_SignatureBankMember" xlink:label="loc_NRXSSignatureBankMember" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_NRXSSignatureBankMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_AlexanderCapitalLPMember" xlink:label="loc_NRXSAlexanderCapitalLPMember" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_NRXSAlexanderCapitalLPMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaapDebtInstrumentAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapDebtInstrumentAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaapDebtInstrumentNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentAxis" xlink:to="loc_us-gaapDebtInstrumentNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_PromissoryNoteMember" xlink:label="loc_NRXSPromissoryNoteMember" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_NRXSPromissoryNoteMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_SecondPromissoryNoteMember" xlink:label="loc_NRXSSecondPromissoryNoteMember" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_NRXSSecondPromissoryNoteMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_TwoThousandTwentyTwoConvertibleNotesMember" xlink:label="loc_NRXSTwoThousandTwentyTwoConvertibleNotesMember" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_NRXSTwoThousandTwentyTwoConvertibleNotesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_ConvertiblePromissoryNoteMember" xlink:label="loc_NRXSConvertiblePromissoryNoteMember" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_NRXSConvertiblePromissoryNoteMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_TwoThousandTwentyThreeConvertibleNotesMember" xlink:label="loc_NRXSTwoThousandTwentyThreeConvertibleNotesMember" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_NRXSTwoThousandTwentyThreeConvertibleNotesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_ConvertiblePromissoryNotesMember" xlink:label="loc_NRXSConvertiblePromissoryNotesMember" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_NRXSConvertiblePromissoryNotesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_TwoThousandTwentyFourConvertiblePromissoryNotesMember" xlink:label="loc_NRXSTwoThousandTwentyFourConvertiblePromissoryNotesMember" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_NRXSTwoThousandTwentyFourConvertiblePromissoryNotesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_TwoThousandTwentyFourConvertibleNotesMember" xlink:label="loc_NRXSTwoThousandTwentyFourConvertibleNotesMember" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_NRXSTwoThousandTwentyFourConvertibleNotesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtRangeAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtTitleOfIndividualAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_AccreditedInvestorsMember" xlink:label="loc_NRXSAccreditedInvestorsMember" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_NRXSAccreditedInvestorsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="50" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="60" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="loc_us-gaapSeriesBPreferredStockMember" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesBPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaapDebtInstrumentFaceAmount" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDebtInstrumentFaceAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentPeriodicPayment" xlink:label="loc_us-gaapDebtInstrumentPeriodicPayment" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDebtInstrumentPeriodicPayment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtAverageAmountOutstanding" xlink:label="loc_us-gaapLongTermDebtAverageAmountOutstanding" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLongTermDebtAverageAmountOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentRepurchasedFaceAmount" xlink:label="loc_us-gaapDebtInstrumentRepurchasedFaceAmount" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDebtInstrumentRepurchasedFaceAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NotesPayable" xlink:label="loc_us-gaapNotesPayable" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNotesPayable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="loc_us-gaapDebtInstrumentInterestRateEffectivePercentage" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDebtInstrumentInterestRateEffectivePercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaapDebtInstrumentInterestRateStatedPercentage" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDebtInstrumentInterestRateStatedPercentage" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="loc_us-gaapProceedsFromIssuanceInitialPublicOffering" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceInitialPublicOffering" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="loc_us-gaapDebtInstrumentMaturityDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDebtInstrumentMaturityDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="loc_us-gaapDebtInstrumentCarryingAmount" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDebtInstrumentCarryingAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfDebt" xlink:label="loc_us-gaapProceedsFromIssuanceOfDebt" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfDebt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentDescriptionOfVariableRateBasis" xlink:label="loc_us-gaapDebtInstrumentDescriptionOfVariableRateBasis" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDebtInstrumentDescriptionOfVariableRateBasis" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="loc_us-gaapDebtInstrumentConvertibleConversionPrice1" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDebtInstrumentConvertibleConversionPrice1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_DebtInstrumentDiscountRate" xlink:label="loc_NRXSDebtInstrumentDiscountRate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_NRXSDebtInstrumentDiscountRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_DebtWarrantConversionDescription" xlink:label="loc_NRXSDebtWarrantConversionDescription" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_NRXSDebtWarrantConversionDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_ClassOfWarrantDiscountRate" xlink:label="loc_NRXSClassOfWarrantDiscountRate" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_NRXSClassOfWarrantDiscountRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:label="loc_us-gaapDebtInstrumentConvertibleConversionRatio1" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDebtInstrumentConvertibleConversionRatio1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaapSharesIssuedPricePerShare" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesIssuedPricePerShare" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EscrowDeposit" xlink:label="loc_us-gaapEscrowDeposit" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapEscrowDeposit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromFeesReceived" xlink:label="loc_us-gaapProceedsFromFeesReceived" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapProceedsFromFeesReceived" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="loc_us-gaapConvertiblePreferredStockSharesIssuedUponConversion" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapConvertiblePreferredStockSharesIssuedUponConversion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid" xlink:label="loc_us-gaapDebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleDebt" xlink:label="loc_us-gaapConvertibleDebt" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapConvertibleDebt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromContributedCapital" xlink:label="loc_us-gaapProceedsFromContributedCapital" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapProceedsFromContributedCapital" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAnnualPrincipalPayment" xlink:label="loc_us-gaapDebtInstrumentAnnualPrincipalPayment" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDebtInstrumentAnnualPrincipalPayment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtConversionOriginalDebtInterestRateOfDebt" xlink:label="loc_us-gaapDebtConversionOriginalDebtInterestRateOfDebt" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDebtConversionOriginalDebtInterestRateOfDebt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_CumulativeDividendsPercent" xlink:label="loc_NRXSCumulativeDividendsPercent" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_NRXSCumulativeDividendsPercent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockConvertibleConversionPriceDecrease" xlink:label="loc_us-gaapCommonStockConvertibleConversionPriceDecrease" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockConvertibleConversionPriceDecrease" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:label="loc_us-gaapTemporaryEquitySharesAuthorized" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapTemporaryEquitySharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="loc_us-gaapConversionOfStockSharesConverted1" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapConversionOfStockSharesConverted1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_CommonStockConvertibleConversionPrice" xlink:label="loc_NRXSCommonStockConvertibleConversionPrice" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_NRXSCommonStockConvertibleConversionPrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnamortizedDebtIssuanceExpense" xlink:label="loc_us-gaapUnamortizedDebtIssuanceExpense" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapUnamortizedDebtIssuanceExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaapInterestExpense" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapInterestExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrentAndNoncurrent" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAccruedLiabilitiesCurrentAndNoncurrent" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://neuraxis.com/role/ScheduleOfOperatingLeasesDetails" xlink:title="999064 - Disclosure - Schedule of Operating Leases (Details)">
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_DisclosureLeasesAbstract" xlink:label="loc_NRXSDisclosureLeasesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_NRXSDisclosureLeasesAbstract" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityCurrent" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_NRXSDisclosureLeasesAbstract" xlink:to="loc_us-gaapOperatingLeaseLiabilityCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityNoncurrent" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_NRXSDisclosureLeasesAbstract" xlink:to="loc_us-gaapOperatingLeaseLiabilityNoncurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaapOperatingLeaseLiability" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_NRXSDisclosureLeasesAbstract" xlink:to="loc_us-gaapOperatingLeaseLiability" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="loc_us-gaapOperatingLeaseWeightedAverageRemainingLeaseTerm1" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_NRXSDisclosureLeasesAbstract" xlink:to="loc_us-gaapOperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="loc_us-gaapOperatingLeaseWeightedAverageDiscountRatePercent" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_NRXSDisclosureLeasesAbstract" xlink:to="loc_us-gaapOperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://neuraxis.com/role/ScheduleOfMaturitiesOperatingLeaseLiabilitiesDetails" xlink:title="999065 - Disclosure - Schedule of Maturities Operating Lease Liabilities (Details)">
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_DisclosureLeasesAbstract" xlink:label="loc_NRXSDisclosureLeasesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_NRXSDisclosureLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_NRXSDisclosureLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearThree" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_NRXSDisclosureLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearFour" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_NRXSDisclosureLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearFive" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_NRXSDisclosureLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_NRXSDisclosureLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_NRXSDisclosureLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaapOperatingLeaseLiability" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_NRXSDisclosureLeasesAbstract" xlink:to="loc_us-gaapOperatingLeaseLiability" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://neuraxis.com/role/LeasesDetailsNarrative" xlink:title="999066 - Disclosure - Leases (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_DisclosureLeasesAbstract" xlink:label="loc_NRXSDisclosureLeasesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_NRXSDisclosureLeasesAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeographicDistributionAxis" xlink:label="loc_us-gaapGeographicDistributionAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapGeographicDistributionAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeographicDistributionDomain" xlink:label="loc_us-gaapGeographicDistributionDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGeographicDistributionAxis" xlink:to="loc_us-gaapGeographicDistributionDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_VersaillesIndianaMember" xlink:label="loc_NRXSVersaillesIndianaMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGeographicDistributionDomain" xlink:to="loc_NRXSVersaillesIndianaMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_CarmelIndianaMember" xlink:label="loc_NRXSCarmelIndianaMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGeographicDistributionDomain" xlink:to="loc_NRXSCarmelIndianaMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseDescription" xlink:label="loc_us-gaapLesseeOperatingLeaseDescription" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLesseeOperatingLeaseDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeasePayments" xlink:label="loc_us-gaapOperatingLeasePayments" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOperatingLeasePayments" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseDiscountRate" xlink:label="loc_us-gaapLesseeOperatingLeaseDiscountRate" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLesseeOperatingLeaseDiscountRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseExpense" xlink:label="loc_us-gaapOperatingLeaseExpense" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOperatingLeaseExpense" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://neuraxis.com/role/ScheduleOfWarrantActivityForCommonStockDetails" xlink:title="999067 - Disclosure - Schedule of Warrant Activity for Common Stock (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsWeightedAverageRemainingContracualLifeOutstandingNumberGranted" xlink:label="loc_NRXSShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsWeightedAverageRemainingContracualLifeOutstandingNumberGranted" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_NRXSShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsWeightedAverageRemainingContracualLifeOutstandingNumberGranted" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsConvertedPrefundedWarrants" xlink:label="loc_NRXSShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsConvertedPrefundedWarrants" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_NRXSShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsConvertedPrefundedWarrants" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsConvertedPrefundedWarrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_NRXSShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsConvertedPrefundedWarrantsInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_NRXSShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsConvertedPrefundedWarrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsWeightedAverageExercisePriceCancelledExpiredNumber" xlink:label="loc_NRXSShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsWeightedAverageExercisePriceCancelledExpiredNumber" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_NRXSShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsWeightedAverageExercisePriceCancelledExpiredNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsCancelledWeightedAverageRemainingContractualTerm1" xlink:label="loc_NRXSSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsCancelledWeightedAverageRemainingContractualTerm1" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_NRXSSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsCancelledWeightedAverageRemainingContractualTerm1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_2" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisedWeightedAverageRemainingContractualTerm1" xlink:label="loc_NRXSSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisedWeightedAverageRemainingContractualTerm1" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_NRXSSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisedWeightedAverageRemainingContractualTerm1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_2" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://neuraxis.com/role/ScheduleOfWarrantActivityForPreferredStockDetails" xlink:title="999068 - Disclosure - Schedule of Warrant Activity for Preferred Stock (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockMember" xlink:label="loc_us-gaapPreferredStockMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsWeightedAverageExercisePriceCancelledExpiredNumber" xlink:label="loc_NRXSShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsWeightedAverageExercisePriceCancelledExpiredNumber" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_NRXSShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsWeightedAverageExercisePriceCancelledExpiredNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsCommonStockWarrant" xlink:label="loc_NRXSShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsCommonStockWarrant" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_NRXSShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsCommonStockWarrant" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsWeightedAverageExercisePriceCommonStockWarrant" xlink:label="loc_NRXSShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsWeightedAverageExercisePriceCommonStockWarrant" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_NRXSShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsWeightedAverageExercisePriceCommonStockWarrant" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_2" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://neuraxis.com/role/ScheduleOfWarrantsOutstandingAndExercisableDetails" xlink:title="999069 - Disclosure - Schedule of Warrants outstanding and Exercisable (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="loc_us-gaapClassOfWarrantOrRightTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapClassOfWarrantOrRightTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="loc_us-gaapClassOfWarrantOrRightLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightTable" xlink:to="loc_us-gaapClassOfWarrantOrRightLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightTable" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_InvestorWarrantOneMember" xlink:label="loc_NRXSInvestorWarrantOneMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_NRXSInvestorWarrantOneMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_InvestorWarrantPSAOneMember" xlink:label="loc_NRXSInvestorWarrantPSAOneMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_NRXSInvestorWarrantPSAOneMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_TwoThousandTwentyTwoConvertibleNotesMember" xlink:label="loc_NRXSTwoThousandTwentyTwoConvertibleNotesMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_NRXSTwoThousandTwentyTwoConvertibleNotesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_TwoThousandTwentyThreeConvertibleNotesMember" xlink:label="loc_NRXSTwoThousandTwentyThreeConvertibleNotesMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_NRXSTwoThousandTwentyThreeConvertibleNotesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_UnderwriterWarrantsMember" xlink:label="loc_NRXSUnderwriterWarrantsMember" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_NRXSUnderwriterWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_AdvisoryAgreementWarrantsMember" xlink:label="loc_NRXSAdvisoryAgreementWarrantsMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_NRXSAdvisoryAgreementWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaapClassOfWarrantOrRightOutstanding" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:label="loc_us-gaapWarrantsAndRightsOutstandingMaturityDate" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstandingMaturityDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_WarrantExpirationDateDescription" xlink:label="loc_NRXSWarrantExpirationDateDescription" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_NRXSWarrantExpirationDateDescription" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://neuraxis.com/role/CommonStockAndWarrantsDetailsNarrative" xlink:title="999070 - Disclosure - Common Stock and Warrants (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaapScheduleOfStockByClassTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapScheduleOfStockByClassTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaapClassOfStockLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapClassOfStockLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_ConvertibleSeriesSeedPreferredStockMember" xlink:label="loc_NRXSConvertibleSeriesSeedPreferredStockMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_NRXSConvertibleSeriesSeedPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_VendorsMember" xlink:label="loc_NRXSVendorsMember" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_NRXSVendorsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_EmployementAgreementMember" xlink:label="loc_NRXSEmployementAgreementMember" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_NRXSEmployementAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_TwoThousandTwentyThreeConvertiblePromissoryNotesMember" xlink:label="loc_NRXSTwoThousandTwentyThreeConvertiblePromissoryNotesMember" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_NRXSTwoThousandTwentyThreeConvertiblePromissoryNotesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_TwoThousandTwentyTwoConvertibleNotesMember" xlink:label="loc_NRXSTwoThousandTwentyTwoConvertibleNotesMember" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_NRXSTwoThousandTwentyTwoConvertibleNotesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_AdvisoryAgreementMember" xlink:label="loc_NRXSAdvisoryAgreementMember" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_NRXSAdvisoryAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_UnderwritingAgreementMember" xlink:label="loc_NRXSUnderwritingAgreementMember" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_NRXSUnderwritingAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_TwoThousandTwentyFourConvertiblePromissoryNotesMember" xlink:label="loc_NRXSTwoThousandTwentyFourConvertiblePromissoryNotesMember" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_NRXSTwoThousandTwentyFourConvertiblePromissoryNotesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_AdvisoryAgreementsMember" xlink:label="loc_NRXSAdvisoryAgreementsMember" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_NRXSAdvisoryAgreementsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapCommonStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapCommonStockSharesIssued" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapCommonStockSharesOutstanding" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="loc_us-gaapStockholdersEquityReverseStockSplit" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapStockholdersEquityReverseStockSplit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_StockIssuedDuringPeriodSharesCommonStockIssuedUponInitialPublicOffering" xlink:label="loc_NRXSStockIssuedDuringPeriodSharesCommonStockIssuedUponInitialPublicOffering" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_NRXSStockIssuedDuringPeriodSharesCommonStockIssuedUponInitialPublicOffering" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaapSharePrice" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapSharePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="loc_us-gaapProceedsFromIssuanceInitialPublicOffering" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceInitialPublicOffering" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="loc_us-gaapDebtConversionConvertedInstrumentSharesIssued1" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapDebtConversionConvertedInstrumentSharesIssued1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="loc_us-gaapConvertiblePreferredStockSharesIssuedUponConversion" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapConvertiblePreferredStockSharesIssuedUponConversion" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="loc_us-gaapConversionOfStockSharesConverted1" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapConversionOfStockSharesConverted1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfUnits" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfUnits" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConversionOfStockSharesIssued1" xlink:label="loc_us-gaapConversionOfStockSharesIssued1" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapConversionOfStockSharesIssued1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaapClassOfWarrantOrRightOutstanding" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="loc_us-gaapWarrantsAndRightsOutstandingTerm" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstandingTerm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaapSharesIssuedPricePerShare" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapSharesIssuedPricePerShare" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_NumberOfEquivalentOfWarrantsDescription" xlink:label="loc_NRXSNumberOfEquivalentOfWarrantsDescription" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_NRXSNumberOfEquivalentOfWarrantsDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_ClassOfWarrantOrRightAdditional" xlink:label="loc_NRXSClassOfWarrantOrRightAdditional" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_NRXSClassOfWarrantOrRightAdditional" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://neuraxis.com/role/PreferredStockDetailsNarrative" xlink:title="999071 - Disclosure - Preferred Stock (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaapScheduleOfStockByClassTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapScheduleOfStockByClassTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaapClassOfStockLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapClassOfStockLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaapSeriesAPreferredStockMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesAPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_SeriesSeedPreferredStockMember" xlink:label="loc_NRXSSeriesSeedPreferredStockMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_NRXSSeriesSeedPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="loc_us-gaapSeriesBPreferredStockMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesBPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockMember" xlink:label="loc_us-gaapPreferredStockMember" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="loc_us-gaapShortTermDebtTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapShortTermDebtTypeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaapShortTermDebtTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtTypeAxis" xlink:to="loc_us-gaapShortTermDebtTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_AmendedTwoThousandTwentyFourConvertibleNotesMember" xlink:label="loc_NRXSAmendedTwoThousandTwentyFourConvertibleNotesMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtTypeDomain" xlink:to="loc_NRXSAmendedTwoThousandTwentyFourConvertibleNotesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPreferredStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaapPreferredStockSharesIssued" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPreferredStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaapPreferredStockSharesOutstanding" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPreferredStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockDividendRatePercentage" xlink:label="loc_us-gaapPreferredStockDividendRatePercentage" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPreferredStockDividendRatePercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_PreferredStockSharesRetiredDescription" xlink:label="loc_NRXSPreferredStockSharesRetiredDescription" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_NRXSPreferredStockSharesRetiredDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:label="loc_us-gaapTemporaryEquitySharesAuthorized" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapTemporaryEquitySharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaapDebtInstrumentFaceAmount" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapDebtInstrumentFaceAmount" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="loc_us-gaapConversionOfStockSharesConverted1" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapConversionOfStockSharesConverted1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaapSharesIssuedPricePerShare" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapSharesIssuedPricePerShare" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_ProceedsFromIssuanceOfStock" xlink:label="loc_NRXSProceedsFromIssuanceOfStock" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_NRXSProceedsFromIssuanceOfStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfDebt" xlink:label="loc_us-gaapProceedsFromIssuanceOfDebt" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfDebt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_CumulativeDividendsPercent" xlink:label="loc_NRXSCumulativeDividendsPercent" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_NRXSCumulativeDividendsPercent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaapSharesIssued" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapSharesIssued" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DividendsPayableCurrentAndNoncurrent" xlink:label="loc_us-gaapDividendsPayableCurrentAndNoncurrent" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapDividendsPayableCurrentAndNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DividendsPreferredStock" xlink:label="loc_us-gaapDividendsPreferredStock" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapDividendsPreferredStock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockDividendRatePerDollarAmount" xlink:label="loc_us-gaapPreferredStockDividendRatePerDollarAmount" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPreferredStockDividendRatePerDollarAmount" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://neuraxis.com/role/ScheduleOfOption-pricingModelWithFollowingWeighted-averageAssumptionsDetails" xlink:title="999072 - Disclosure - Schedule of Option-pricing Model with Following Weighted-average Assumptions (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapPlanNameAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_TwentySeventeenStockCompensationPlanMember" xlink:label="loc_NRXSTwentySeventeenStockCompensationPlanMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_NRXSTwentySeventeenStockCompensationPlanMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaapSharePrice" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://neuraxis.com/role/ScheduleOfStockOptionActivityDetails" xlink:title="999073 - Disclosure - Schedule of Stock Option Activity (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://neuraxis.com/role/Stock-basedCompensationDetailsNarrative" xlink:title="999074 - Disclosure - Stock-Based Compensation (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapPlanNameAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_TwentySeventeenStockCompensationPlanMember" xlink:label="loc_NRXSTwentySeventeenStockCompensationPlanMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_NRXSTwentySeventeenStockCompensationPlanMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_srtTitleOfIndividualAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ChiefFinancialOfficerMember" xlink:label="loc_srtChiefFinancialOfficerMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_srtChiefFinancialOfficerMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapCommonStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaapSharesIssued" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaapSharePrice" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://neuraxis.com/role/ScheduleOfChangesInWarrantLiabilitiesDetails" xlink:title="999075 - Disclosure - Schedule of Changes in Warrant Liabilities (Details)">
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_DisclosureWarrantLiabilitiesAbstract" xlink:label="loc_NRXSDisclosureWarrantLiabilitiesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_PlatformOperatorCryptoAssetTable" xlink:label="loc_srtPlatformOperatorCryptoAssetTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_NRXSDisclosureWarrantLiabilitiesAbstract" xlink:to="loc_srtPlatformOperatorCryptoAssetTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_PlatformOperatorCryptoAssetLineItems" xlink:label="loc_srtPlatformOperatorCryptoAssetLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtPlatformOperatorCryptoAssetTable" xlink:to="loc_srtPlatformOperatorCryptoAssetLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtPlatformOperatorCryptoAssetTable" xlink:to="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaapFairValueInputsLevel1Member" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel1Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaapFairValueInputsLevel2Member" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel2Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaapFairValueInputsLevel3Member" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel3Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="loc_us-gaapWarrantsAndRightsOutstanding" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtPlatformOperatorCryptoAssetLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstanding" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_AdditionToWarrantLiabilities" xlink:label="loc_NRXSAdditionToWarrantLiabilities" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtPlatformOperatorCryptoAssetLineItems" xlink:to="loc_NRXSAdditionToWarrantLiabilities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_ReclassifiedToEquity" xlink:label="loc_NRXSReclassifiedToEquity" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtPlatformOperatorCryptoAssetLineItems" xlink:to="loc_NRXSReclassifiedToEquity" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaapFairValueAdjustmentOfWarrants" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtPlatformOperatorCryptoAssetLineItems" xlink:to="loc_us-gaapFairValueAdjustmentOfWarrants" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="loc_us-gaapWarrantsAndRightsOutstanding_2" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtPlatformOperatorCryptoAssetLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstanding_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://neuraxis.com/role/WarrantLiabilitiesDetailsNarrative" xlink:title="999076 - Disclosure - Warrant Liabilities (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_DisclosureWarrantLiabilitiesAbstract" xlink:label="loc_NRXSDisclosureWarrantLiabilitiesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_NRXSDisclosureWarrantLiabilitiesAbstract" xlink:to="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="loc_us-gaapMeasurementInputTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="loc_us-gaapMeasurementInputTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaapMeasurementInputTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeAxis" xlink:to="loc_us-gaapMeasurementInputTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputSharePriceMember" xlink:label="loc_us-gaapMeasurementInputSharePriceMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputSharePriceMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="loc_us-gaapMeasurementInputPriceVolatilityMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputPriceVolatilityMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="loc_us-gaapMeasurementInputRiskFreeInterestRateMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputRiskFreeInterestRateMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputExpectedDividendRateMember" xlink:label="loc_us-gaapMeasurementInputExpectedDividendRateMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputExpectedDividendRateMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="loc_srtRangeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:label="loc_us-gaapWarrantsAndRightsOutstandingMeasurementInput" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstandingMeasurementInput" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://neuraxis.com/role/ScheduleOfChangesInDerivativeLiabilitiesDetails" xlink:title="999077 - Disclosure - Schedule of Changes in Derivative Liabilities (Details)">
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_DisclosureDerivativeLiabilitiesAbstract" xlink:label="loc_NRXSDisclosureDerivativeLiabilitiesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_PlatformOperatorCryptoAssetTable" xlink:label="loc_srtPlatformOperatorCryptoAssetTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_NRXSDisclosureDerivativeLiabilitiesAbstract" xlink:to="loc_srtPlatformOperatorCryptoAssetTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_PlatformOperatorCryptoAssetLineItems" xlink:label="loc_srtPlatformOperatorCryptoAssetLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtPlatformOperatorCryptoAssetTable" xlink:to="loc_srtPlatformOperatorCryptoAssetLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtPlatformOperatorCryptoAssetTable" xlink:to="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaapFairValueInputsLevel1Member" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel1Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaapFairValueInputsLevel2Member" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel2Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaapFairValueInputsLevel3Member" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel3Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_ChangesInDerivativeLiabilities" xlink:label="loc_NRXSChangesInDerivativeLiabilities" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtPlatformOperatorCryptoAssetLineItems" xlink:to="loc_NRXSChangesInDerivativeLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_AdditionToDerivativeLiabilities" xlink:label="loc_NRXSAdditionToDerivativeLiabilities" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtPlatformOperatorCryptoAssetLineItems" xlink:to="loc_NRXSAdditionToDerivativeLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInDerivativeLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInDerivativeLiabilities" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtPlatformOperatorCryptoAssetLineItems" xlink:to="loc_us-gaapIncreaseDecreaseInDerivativeLiabilities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_ExtinguishmentOfDerivativeLiabilities" xlink:label="loc_NRXSExtinguishmentOfDerivativeLiabilities" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtPlatformOperatorCryptoAssetLineItems" xlink:to="loc_NRXSExtinguishmentOfDerivativeLiabilities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_ChangesInDerivativeLiabilities" xlink:label="loc_NRXSChangesInDerivativeLiabilities_2" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtPlatformOperatorCryptoAssetLineItems" xlink:to="loc_NRXSChangesInDerivativeLiabilities_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://neuraxis.com/role/DerivativeLiabilitiesDetailsNarrative" xlink:title="999078 - Disclosure - Derivative Liabilities (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_DisclosureDerivativeLiabilitiesAbstract" xlink:label="loc_NRXSDisclosureDerivativeLiabilitiesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_NRXSDisclosureDerivativeLiabilitiesAbstract" xlink:to="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="loc_us-gaapMeasurementInputTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="loc_us-gaapMeasurementInputTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaapMeasurementInputTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeAxis" xlink:to="loc_us-gaapMeasurementInputTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputSharePriceMember" xlink:label="loc_us-gaapMeasurementInputSharePriceMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputSharePriceMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="loc_us-gaapMeasurementInputPriceVolatilityMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputPriceVolatilityMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="loc_us-gaapMeasurementInputRiskFreeInterestRateMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputRiskFreeInterestRateMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputExpectedDividendRateMember" xlink:label="loc_us-gaapMeasurementInputExpectedDividendRateMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputExpectedDividendRateMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="loc_srtRangeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeLiabilityMeasurementInput" xlink:label="loc_us-gaapDerivativeLiabilityMeasurementInput" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="loc_us-gaapDerivativeLiabilityMeasurementInput" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://neuraxis.com/role/RetirementPlanDetailsNarrative" xlink:title="999079 - Disclosure - Retirement Plan (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="loc_us-gaapCompensationAndRetirementDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:label="loc_us-gaapDefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCompensationAndRetirementDisclosureAbstract" xlink:to="loc_us-gaapDefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedContributionPlanAdministrativeExpenses" xlink:label="loc_us-gaapDefinedContributionPlanAdministrativeExpenses" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCompensationAndRetirementDisclosureAbstract" xlink:to="loc_us-gaapDefinedContributionPlanAdministrativeExpenses" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://neuraxis.com/role/ScheduleOfReconcilesCompanysNetSalesAndOperatingLossDetails" xlink:title="999080 - Disclosure - Schedule of Reconciles the Company&#8217;s Net Sales and Operating Loss (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract" xlink:label="loc_us-gaapSegmentReportingAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:label="loc_us-gaapScheduleOfSegmentReportingInformationBySegmentTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingAbstract" xlink:to="loc_us-gaapScheduleOfSegmentReportingInformationBySegmentTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingInformationLineItems" xlink:label="loc_us-gaapSegmentReportingInformationLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="loc_us-gaapSegmentReportingInformationLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidationItemsAxis" xlink:label="loc_srtConsolidationItemsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="loc_srtConsolidationItemsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidationItemsDomain" xlink:label="loc_srtConsolidationItemsDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtConsolidationItemsAxis" xlink:to="loc_srtConsolidationItemsDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingSegmentsMember" xlink:label="loc_us-gaapOperatingSegmentsMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtConsolidationItemsDomain" xlink:to="loc_us-gaapOperatingSegmentsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="loc_us-gaapCostOfGoodsAndServicesSold" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_us-gaapCostOfGoodsAndServicesSold" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GrossProfit" xlink:label="loc_us-gaapGrossProfit" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_us-gaapGrossProfit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingExpense" xlink:label="loc_us-gaapSellingExpense" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_us-gaapSellingExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LaborAndRelatedExpense" xlink:label="loc_us-gaapLaborAndRelatedExpense" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_us-gaapLaborAndRelatedExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfessionalAndContractServicesExpense" xlink:label="loc_us-gaapProfessionalAndContractServicesExpense" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_us-gaapProfessionalAndContractServicesExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCostAndExpenseOperating" xlink:label="loc_us-gaapOtherCostAndExpenseOperating" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_us-gaapOtherCostAndExpenseOperating" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaapNonoperatingIncomeExpenseAbstract" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_FinancingCharges" xlink:label="loc_NRXSFinancingCharges" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_NRXSFinancingCharges" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaapInterestExpense" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapInterestExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaapFairValueAdjustmentOfWarrants" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapFairValueAdjustmentOfWarrants" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeGainLossOnDerivativeNet" xlink:label="loc_us-gaapDerivativeGainLossOnDerivativeNet" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapDerivativeGainLossOnDerivativeNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="loc_us-gaapAmortizationOfFinancingCostsAndDiscounts" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapAmortizationOfFinancingCostsAndDiscounts" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncome" xlink:label="loc_us-gaapOtherNonoperatingIncome" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapOtherNonoperatingIncome" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingExpense" xlink:label="loc_us-gaapOtherNonoperatingExpense" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapOtherNonoperatingExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaapOtherNonoperatingIncomeExpense" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapOtherNonoperatingIncomeExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://neuraxis.com/role/SegmentInformationDetailsNarrative" xlink:title="999081 - Disclosure - Segment Information (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract" xlink:label="loc_us-gaapSegmentReportingAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingAbstract" xlink:to="loc_us-gaapAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationAndAmortization" xlink:label="loc_us-gaapDepreciationAndAmortization" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingAbstract" xlink:to="loc_us-gaapDepreciationAndAmortization" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_ConsultingAndAdvisoryFees" xlink:label="loc_NRXSConsultingAndAdvisoryFees" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingAbstract" xlink:to="loc_NRXSConsultingAndAdvisoryFees" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingAbstract" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://neuraxis.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="999082 - Disclosure - Commitments and Contingencies (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_AdvisoryAgreementMember" xlink:label="loc_NRXSAdvisoryAgreementMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_NRXSAdvisoryAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_SettlementAgreementMember" xlink:label="loc_NRXSSettlementAgreementMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_NRXSSettlementAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_ExecutiveEmploymentAgreementsMember" xlink:label="loc_NRXSExecutiveEmploymentAgreementsMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_NRXSExecutiveEmploymentAgreementsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaapSubsidiarySaleOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrivatePlacementMember" xlink:label="loc_us-gaapPrivatePlacementMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_us-gaapPrivatePlacementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IPOMember" xlink:label="loc_us-gaapIPOMember" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_us-gaapIPOMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementScenarioAxis" xlink:label="loc_srtStatementScenarioAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtStatementScenarioAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srtScenarioUnspecifiedDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtStatementScenarioAxis" xlink:to="loc_srtScenarioUnspecifiedDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioForecastMember" xlink:label="loc_srtScenarioForecastMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtScenarioUnspecifiedDomain" xlink:to="loc_srtScenarioForecastMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="50" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaapSeriesAPreferredStockMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesAPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtRangeAxis" order="60" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtTitleOfIndividualAxis" order="70" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ChiefOperatingOfficerMember" xlink:label="loc_srtChiefOperatingOfficerMember" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_srtChiefOperatingOfficerMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="loc_us-gaapSaleOfStockConsiderationReceivedOnTransaction" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSaleOfStockConsiderationReceivedOnTransaction" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaapSaleOfStockPricePerShare" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSaleOfStockPricePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:label="loc_us-gaapIssuanceOfStockAndWarrantsForServicesOrClaims" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapIssuanceOfStockAndWarrantsForServicesOrClaims" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_FinanceCharges" xlink:label="loc_NRXSFinanceCharges" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_NRXSFinanceCharges" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherExpenses" xlink:label="loc_us-gaapOtherExpenses" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOtherExpenses" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_ExecutiveEmploymentAgreementsTerms" xlink:label="loc_NRXSExecutiveEmploymentAgreementsTerms" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_NRXSExecutiveEmploymentAgreementsTerms" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_DescriptionOfExecutiveEmploymentAgreementsRenewals" xlink:label="loc_NRXSDescriptionOfExecutiveEmploymentAgreementsRenewals" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_NRXSDescriptionOfExecutiveEmploymentAgreementsRenewals" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SalariesAndWages" xlink:label="loc_us-gaapSalariesAndWages" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSalariesAndWages" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncentiveFeeExpense" xlink:label="loc_us-gaapIncentiveFeeExpense" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapIncentiveFeeExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrent" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAccruedLiabilitiesCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_SpecialBonusPercentage" xlink:label="loc_NRXSSpecialBonusPercentage" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_NRXSSpecialBonusPercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_KeyEmployeeExercisePercentage" xlink:label="loc_NRXSKeyEmployeeExercisePercentage" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_NRXSKeyEmployeeExercisePercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedBonusesCurrent" xlink:label="loc_us-gaapAccruedBonusesCurrent" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAccruedBonusesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireEquitySecuritiesFvNi" xlink:label="loc_us-gaapPaymentsToAcquireEquitySecuritiesFvNi" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPaymentsToAcquireEquitySecuritiesFvNi" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesFairValueDisclosure" xlink:label="loc_us-gaapAccruedLiabilitiesFairValueDisclosure" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAccruedLiabilitiesFairValueDisclosure" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingencyDamagesSoughtValue" xlink:label="loc_us-gaapLossContingencyDamagesSoughtValue" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLossContingencyDamagesSoughtValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedPatentsGross" xlink:label="loc_us-gaapFiniteLivedPatentsGross" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapFiniteLivedPatentsGross" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://neuraxis.com/role/HealthBenefitPlanDetailsNarrative" xlink:title="999083 - Disclosure - Health Benefit Plan (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_DisclosureHealthBenefitPlanAbstract" xlink:label="loc_NRXSDisclosureHealthBenefitPlanAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_HealthCareOrganizationStopLossInsurancePremiumExpense" xlink:label="loc_us-gaapHealthCareOrganizationStopLossInsurancePremiumExpense" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_NRXSDisclosureHealthBenefitPlanAbstract" xlink:to="loc_us-gaapHealthCareOrganizationStopLossInsurancePremiumExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_HealthCareOrganizationStopLossInsurancePremiumPercentage" xlink:label="loc_NRXSHealthCareOrganizationStopLossInsurancePremiumPercentage" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_NRXSDisclosureHealthBenefitPlanAbstract" xlink:to="loc_NRXSHealthCareOrganizationStopLossInsurancePremiumPercentage" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://neuraxis.com/role/ScheduleOfIncomeTaxProvisionDetails" xlink:title="999084 - Disclosure - Schedule of Income Tax Provision (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="loc_us-gaapCurrentIncomeTaxExpenseBenefit" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapCurrentIncomeTaxExpenseBenefit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:label="loc_us-gaapDeferredFederalIncomeTaxExpenseBenefit" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredFederalIncomeTaxExpenseBenefit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:label="loc_us-gaapDeferredStateAndLocalIncomeTaxExpenseBenefit" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="loc_us-gaapDeferredIncomeTaxExpenseBenefit" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredIncomeTaxExpenseBenefit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapIncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaapIncomeTaxExpenseBenefit" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxExpenseBenefit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://neuraxis.com/role/ScheduleOfFederalStatutoryIncomeTaxRateAndEffectiveIncomeTaxRateDetails" xlink:title="999085 - Disclosure - Schedule of Federal Statutory Income Tax Rate and Effective Income Tax Rate (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://neuraxis.com/role/ScheduleOfNetDeferredTaxAssetsAndLiabilitiesDetails" xlink:title="999086 - Disclosure - Schedule of Net Deferred Tax Assets and Liabilities (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwards" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwards" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" xlink:label="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_DeferredTaxAssetsNotesReceivableReserve" xlink:label="loc_NRXSDeferredTaxAssetsNotesReceivableReserve" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_NRXSDeferredTaxAssetsNotesReceivableReserve" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsOther" xlink:label="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsOther" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsOther" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_DeferredTaxAssetsAccountsPayable" xlink:label="loc_NRXSDeferredTaxAssetsAccountsPayable" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_NRXSDeferredTaxAssetsAccountsPayable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_DeferredTaxAssetsOperatingLeasePayable" xlink:label="loc_NRXSDeferredTaxAssetsOperatingLeasePayable" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_NRXSDeferredTaxAssetsOperatingLeasePayable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="loc_us-gaapDeferredTaxAssetsOther" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsOther" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaapDeferredTaxAssetsGross" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsGross" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapDeferredTaxAssetsValuationAllowance" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsValuationAllowance" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="loc_us-gaapDeferredTaxAssetsNet" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset" xlink:label="loc_NRXSDeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_NRXSDeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesPrepaidExpenses" xlink:label="loc_us-gaapDeferredTaxLiabilitiesPrepaidExpenses" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxLiabilitiesPrepaidExpenses" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_DeferredTaxLiabilityAccountsReceivable" xlink:label="loc_NRXSDeferredTaxLiabilityAccountsReceivable" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_NRXSDeferredTaxLiabilityAccountsReceivable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesOther" xlink:label="loc_us-gaapDeferredTaxLiabilitiesOther" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxLiabilitiesOther" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="loc_us-gaapDeferredIncomeTaxLiabilities" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredIncomeTaxLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="loc_us-gaapDeferredTaxLiabilities" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://neuraxis.com/role/ScheduleOfStateCarryforwardsDetails" xlink:title="999087 - Disclosure - Schedule of State Carryforwards (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="loc_us-gaapOperatingLossCarryforwardsTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapOperatingLossCarryforwardsTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="loc_us-gaapOperatingLossCarryforwardsLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingLossCarryforwardsTable" xlink:to="loc_us-gaapOperatingLossCarryforwardsLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxPeriodAxis" xlink:label="loc_us-gaapTaxPeriodAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingLossCarryforwardsTable" xlink:to="loc_us-gaapTaxPeriodAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxPeriodDomain" xlink:label="loc_us-gaapTaxPeriodDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTaxPeriodAxis" xlink:to="loc_us-gaapTaxPeriodDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_TaxYear2037Member" xlink:label="loc_NRXSTaxYear2037Member" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTaxPeriodDomain" xlink:to="loc_NRXSTaxYear2037Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_TaxYear2038Member" xlink:label="loc_NRXSTaxYear2038Member" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTaxPeriodDomain" xlink:to="loc_NRXSTaxYear2038Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_TaxYear2039Member" xlink:label="loc_NRXSTaxYear2039Member" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTaxPeriodDomain" xlink:to="loc_NRXSTaxYear2039Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_TaxYear2040Member" xlink:label="loc_NRXSTaxYear2040Member" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTaxPeriodDomain" xlink:to="loc_NRXSTaxYear2040Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_TaxYear2041Member" xlink:label="loc_NRXSTaxYear2041Member" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTaxPeriodDomain" xlink:to="loc_NRXSTaxYear2041Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_TaxYearThereafterMember" xlink:label="loc_NRXSTaxYearThereafterMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTaxPeriodDomain" xlink:to="loc_NRXSTaxYearThereafterMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20241231.xsd#NRXS_NoExpirationMember" xlink:label="loc_NRXSNoExpirationMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTaxPeriodDomain" xlink:to="loc_NRXSNoExpirationMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:label="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://neuraxis.com/role/IncomeTaxesDetailsNarrative" xlink:title="999088 - Disclosure - Income Taxes (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationTable" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaapIncomeTaxAuthorityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationTable" xlink:to="loc_us-gaapIncomeTaxAuthorityAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaapIncomeTaxAuthorityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxAuthorityAxis" xlink:to="loc_us-gaapIncomeTaxAuthorityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DomesticCountryMember" xlink:label="loc_us-gaapDomesticCountryMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxAuthorityDomain" xlink:to="loc_us-gaapDomesticCountryMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:label="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" xlink:to="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationOtherAdjustments" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://neuraxis.com/role/SubsequentEventsDetailsNarrative" xlink:title="999089 - Disclosure - Subsequent Events (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaapSubsequentEventsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaapSubsequentEventTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventsAbstract" xlink:to="loc_us-gaapSubsequentEventTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaapSubsequentEventLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapSubsequentEventLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardGross" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Mar. 13, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-41775<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Neuraxis,
Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001933567<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">45-5079684<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">11611
    N Meridian St,<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 330<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Carmel<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">IN<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">46032<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(812)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">689-0791<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common
    Stock<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">NRXS<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSEAMER<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Elected Not To Use the Extended Transition Period</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,215,864<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFinStmtErrorCorrectionFlag', window );">Document Financial Statement Error Correction [Flag]</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityListingParValuePerShare', window );">Entity Listing, Par Value Per Share</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">89<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorOpinionTextBlock', window );">Auditor Opinion [Text Block]</a></td>
<td class="text"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have audited the accompanying balance sheets of Neuraxis, Inc. (the Company) as of December 31, 2024 and 2023, and the related
statements of operations, stockholders&#8217; equity (deficit), and cash flows for each of the years in the two-year period ended
December 31, 2024, and the related notes (collectively referred to as the financial statements). In our opinion, the financial
statements present fairly, in all material respects, the financial position of the Company as of December 31, 2024 and 2023, and the
results of its operations and its cash flows for each of the years in the two-year period ended December 31, 2024, in conformity with
accounting principles generally accepted in the United States of America.</span><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">Rosenberg Rich Baker Berman, P.A.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">Somerset,
    New Jersey<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorOpinionTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X<br> -Number 210<br> -Section 2<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorOpinionTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFinStmtErrorCorrectionFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates whether any of the financial statement period in the filing include a restatement due to error correction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection w<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFinStmtErrorCorrectionFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityListingParValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The par value per share of security quoted in same currency as Trading currency. Example: '0.01'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityListingParValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheets - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 3,696,870<span></span>
</td>
<td class="nump">$ 78,560<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net of credit losses of $5,000 and $11,993 as of December 31, 2024 and 2023, respectively</a></td>
<td class="nump">244,618<span></span>
</td>
<td class="nump">73,167<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventories, net of reserves of $4,454 and $0 as of December 31, 2024 and 2023, respectively</a></td>
<td class="nump">44,328<span></span>
</td>
<td class="nump">21,220<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaids and other current assets</a></td>
<td class="nump">280,367<span></span>
</td>
<td class="nump">69,663<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">4,266,183<span></span>
</td>
<td class="nump">242,610<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and Equipment, at cost:</a></td>
<td class="nump">464,402<span></span>
</td>
<td class="nump">436,626<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less - accumulated depreciation</a></td>
<td class="num">(374,420)<span></span>
</td>
<td class="num">(348,074)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">89,982<span></span>
</td>
<td class="nump">88,552<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrentAbstract', window );"><strong>Other Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right of use asset, net</a></td>
<td class="nump">284,656<span></span>
</td>
<td class="nump">70,263<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Intangible assets, net</a></td>
<td class="nump">96,588<span></span>
</td>
<td class="nump">108,073<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SecurityDeposit', window );">Security deposit</a></td>
<td class="nump">20,163<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total Assets</a></td>
<td class="nump">4,757,572<span></span>
</td>
<td class="nump">509,498<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">596,946<span></span>
</td>
<td class="nump">1,204,219<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">1,577,780<span></span>
</td>
<td class="nump">401,088<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayableToBankCurrent', window );">Notes payable</a></td>
<td class="nump">154,152<span></span>
</td>
<td class="nump">148,062<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current portion of operating lease payable</a></td>
<td class="nump">62,754<span></span>
</td>
<td class="nump">49,127<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Deposits', window );">Customer deposits</a></td>
<td class="nump">32,527<span></span>
</td>
<td class="nump">74,947<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NRXS_WarrantLiabilities', window );">Warrant liabilities</a></td>
<td class="nump">9,166<span></span>
</td>
<td class="nump">8,225<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">2,433,325<span></span>
</td>
<td class="nump">1,885,668<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrentAbstract', window );"><strong>Non-current Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease payable, net of current portion</a></td>
<td class="nump">256,499<span></span>
</td>
<td class="nump">27,071<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrent', window );">Total non-current liabilities</a></td>
<td class="nump">256,499<span></span>
</td>
<td class="nump">27,071<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">2,689,824<span></span>
</td>
<td class="nump">1,912,739<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (see note 16)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; Equity (Deficit)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Convertible Series B Preferred stock, $0.01 par value; 5,000,000 and 0 shares authorized, 4,280,939 and 0 shares issued and outstanding as of December 31, 2024 and 2023, respectively</a></td>
<td class="nump">4,281<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.001 par value; 100,000,000 shares authorized; 6,990,227 and 6,508,897 issued and outstanding as of December 31, 2024 and 2023, respectively</a></td>
<td class="nump">6,990<span></span>
</td>
<td class="nump">6,509<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid in capital</a></td>
<td class="nump">58,856,089<span></span>
</td>
<td class="nump">47,148,361<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(56,799,612)<span></span>
</td>
<td class="num">(48,558,111)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity (deficit)</a></td>
<td class="nump">2,067,748<span></span>
</td>
<td class="num">(1,403,241)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total Liabilities and Stockholders&#8217; Equity (Deficit)</a></td>
<td class="nump">$ 4,757,572<span></span>
</td>
<td class="nump">$ 509,498<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_NRXS_WarrantLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrant liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">NRXS_WarrantLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>NRXS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481990/310-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 12: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 30: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Deposits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate of all deposit liabilities held by the entity, including foreign and domestic, interest and noninterest bearing; may include demand deposits, saving deposits, Negotiable Order of Withdrawal (NOW) and time deposits among others.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Deposits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483154/926-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 21: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayableToBankCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Current portion of the total carrying amount as of the balance sheet date due within one year or the operating cycle, if longer, on all notes payable to banks paid on an installment with long term maturities. This can include the amount of any loans from the applicant firm. This does not, however, include any mortgage balances.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayableToBankCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SecurityDeposit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of an asset, typically cash, provided to a counterparty to provide certain assurance of performance by the entity pursuant to the terms of a written or oral agreement, such as a lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SecurityDeposit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheets (Parenthetical) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Nov. 11, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivable', window );">Accounts receivable, net of credit losses</a></td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,993<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryRawMaterialsNetOfReserves', window );">Inventories, net of reserves</a></td>
<td class="nump">$ 4,454<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">1,120,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">6,990,227<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,508,897<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">6,990,227<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,508,897<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=NRXS_ConvertibleSeriesBPreferredStockMember', window );">Convertible Series B Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="nump">4,280,939<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">4,280,939<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479344/326-20-45-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481962/310-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479319/326-20-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479319/326-20-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterialsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480581/330-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterialsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=NRXS_ConvertibleSeriesBPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=NRXS_ConvertibleSeriesBPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Statements of Operations - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net sales</a></td>
<td class="nump">$ 2,685,925<span></span>
</td>
<td class="nump">$ 2,460,049<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of goods sold</a></td>
<td class="nump">362,002<span></span>
</td>
<td class="nump">303,345<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross profit</a></td>
<td class="nump">2,323,923<span></span>
</td>
<td class="nump">2,156,704<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingExpense', window );">Selling expenses</a></td>
<td class="nump">324,708<span></span>
</td>
<td class="nump">323,569<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">206,107<span></span>
</td>
<td class="nump">169,315<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">8,949,925<span></span>
</td>
<td class="nump">8,328,315<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating loss</a></td>
<td class="num">(7,156,817)<span></span>
</td>
<td class="num">(6,664,495)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other (expense) income:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NRXS_FinancingCharges', window );">Financing charges</a></td>
<td class="num">(230,824)<span></span>
</td>
<td class="num">(2,772)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(174,328)<span></span>
</td>
<td class="num">(476,416)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Change in fair value of warrant liability</a></td>
<td class="num">(941)<span></span>
</td>
<td class="nump">844,854<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeGainLossOnDerivativeNet', window );">Change in fair value of derivative liability</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">198,551<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts', window );">Amortization of debt discount and issuance cost</a></td>
<td class="num">(126,387)<span></span>
</td>
<td class="num">(4,881,622)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Extinguishment of debt liabilities</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(3,649,561)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncome', window );">Other income</a></td>
<td class="nump">33,620<span></span>
</td>
<td class="nump">15,133<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingExpense', window );">Other expense</a></td>
<td class="num">(585,824)<span></span>
</td>
<td class="num">(10,355)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Total other (expense) income, net</a></td>
<td class="num">(1,084,684)<span></span>
</td>
<td class="num">(7,962,188)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(8,241,501)<span></span>
</td>
<td class="num">(14,626,683)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockDividendsAndOtherAdjustments', window );">Preferred stock dividends</a></td>
<td class="num">(211,268)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss available to common stockholders</a></td>
<td class="num">$ (8,452,769)<span></span>
</td>
<td class="num">$ (14,626,683)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Per-share data</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic loss per share</a></td>
<td class="num">$ (1.22)<span></span>
</td>
<td class="num">$ (4.50)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted loss per share</a></td>
<td class="num">$ (1.22)<span></span>
</td>
<td class="num">$ (4.50)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Weighted average shares outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic</a></td>
<td class="nump">6,918,887<span></span>
</td>
<td class="nump">3,252,328<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted</a></td>
<td class="nump">6,918,887<span></span>
</td>
<td class="nump">3,252,328<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_NRXS_FinancingCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Financing charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">NRXS_FinancingCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>NRXS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69F<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCostsAndDiscounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeGainLossOnDerivativeNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the fair value of derivatives recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeGainLossOnDerivativeNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 13<br> -SubTopic 10<br> -Topic 480<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481766/480-10-25-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481303/470-50-40-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481303/470-50-40-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrossProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrossProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense classified as operating and nonoperating. Includes, but is not limited to, cost of borrowing accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-24<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483013/835-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 6.B)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-5<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockDividendsAndOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate value of preferred stock dividends and other adjustments necessary to derive net income apportioned to common stockholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 6.B)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-5<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-11<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockDividendsAndOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expenses recognized in the period that are directly related to the selling and distribution of products or services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Statements of Stockholders' Equity (Deficit) - USD ($)<br></strong></div></th>
<th class="th">
<div>Preferred Stock [Member] </div>
<div>Convertible Series A Preferred stock [Member]</div>
</th>
<th class="th">
<div>Preferred Stock [Member] </div>
<div>Convertible Series Seed Preferred Stock [Member]</div>
</th>
<th class="th">
<div>Preferred Stock [Member] </div>
<div>Convertible Series B Preferred Stock [Member]</div>
</th>
<th class="th"><div>Common Stock [Member]</div></th>
<th class="th"><div>Additional Paid-in Capital [Member]</div></th>
<th class="th"><div>Retained Earnings [Member]</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2022</a></td>
<td class="nump">$ 507<span></span>
</td>
<td class="nump">$ 115<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 1,963<span></span>
</td>
<td class="nump">$ 28,355,230<span></span>
</td>
<td class="num">$ (33,931,428)<span></span>
</td>
<td class="num">$ (5,573,613)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Dec. 31, 2022</a></td>
<td class="nump">506,637<span></span>
</td>
<td class="nump">115,477<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,963,322<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NRXS_StockIssuedDuringPeriodValueCommonStockIssuedUponInitialPublicOffering', window );">Common stock issued upon initial public offering</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 1,099<span></span>
</td>
<td class="nump">4,109,578<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 4,110,677<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NRXS_StockIssuedDuringPeriodSharesCommonStockIssuedUponInitialPublicOffering', window );">Common stock issued upon initial public offering, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,098,667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,098,667<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Common stock issued upon preferred stock conversion</a></td>
<td class="num">$ (507)<span></span>
</td>
<td class="num">$ (115)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 1,244<span></span>
</td>
<td class="num">(622)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Common stock issued upon preferred stock conversion, shares</a></td>
<td class="num">(506,637)<span></span>
</td>
<td class="num">(115,477)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,244,228<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfUnits', window );">Common stock issued upon debt conversion</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 1,650<span></span>
</td>
<td class="nump">9,897,833<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">9,899,483<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits', window );">Common stock issued upon debt conversion, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,649,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Common stock issued from agreements</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 425<span></span>
</td>
<td class="nump">749,575<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">750,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Common stock issued from agreements, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">425,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued', window );">Additional paid in capital from warrants issued under advisory agreement</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">3,720,997<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">3,720,997<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NRXS_StockIssuedDuringPeriodValueWarrantsExercised', window );">Warrants exercised</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 128<span></span>
</td>
<td class="nump">315,770<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">315,898<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NRXS_StockIssuedDuringPeriodSharesWarrantsExercised', window );">Warrants exercised, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">127,780<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(14,626,683)<span></span>
</td>
<td class="num">(14,626,683)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2023</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 6,509<span></span>
</td>
<td class="nump">47,148,361<span></span>
</td>
<td class="num">(48,558,111)<span></span>
</td>
<td class="num">$ (1,403,241)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Dec. 31, 2023</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">6,508,897<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NRXS_StockIssuedDuringPeriodSharesCommonStockIssuedUponInitialPublicOffering', window );">Common stock issued upon initial public offering, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">245,955<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Common stock issued from agreements</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 470<span></span>
</td>
<td class="nump">1,407,541<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 1,408,011<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Common stock issued from agreements, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">470,330<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued', window );">Additional paid in capital from warrants issued under advisory agreement</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">157,745<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">157,745<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NRXS_StockIssuedDuringPeriodValueWarrantsExercised', window );">Warrants exercised</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 11<span></span>
</td>
<td class="nump">26,169<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">26,180<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NRXS_StockIssuedDuringPeriodSharesWarrantsExercised', window );">Warrants exercised, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(8,241,501)<span></span>
</td>
<td class="num">(8,241,501)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NRXS_AdditionalPaidInCapitalFromWarrantsIssuedAsDebtDiscount', window );">Additional paid in capital from warrants issued as debt discount</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">97,465<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">97,465<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature', window );">Debt discount on mandatory conversion of convertible promissory notes to Series B Preferred Stock</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(165,577)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(165,577)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueOther', window );">Conversion of convertible promissory notes to Series B Preferred Stock</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 2,074<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">4,932,929<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">4,935,003<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesOther', window );">Conversion of convertible promissory notes to Series B Preferred Stock, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,073,524<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NRXS_StockIssuedDuringPeriodValuePreferredStock', window );">Issuance of Series B Preferred Stock</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 2,207<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">5,251,456<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,253,663<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NRXS_StockIssuedDuringPeriodSharesPreferredStock', window );">Issuance of Series B Preferred Stock, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,207,415<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2024</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 4,281<span></span>
</td>
<td class="nump">$ 6,990<span></span>
</td>
<td class="nump">$ 58,856,089<span></span>
</td>
<td class="num">$ (56,799,612)<span></span>
</td>
<td class="nump">$ 2,067,748<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Dec. 31, 2024</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">4,280,939<span></span>
</td>
<td class="nump">6,990,227<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_NRXS_AdditionalPaidInCapitalFromWarrantsIssuedAsDebtDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additional paid in capital from warrants issued as debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">NRXS_AdditionalPaidInCapitalFromWarrantsIssuedAsDebtDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>NRXS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_NRXS_StockIssuedDuringPeriodSharesCommonStockIssuedUponInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period shares common stock issued upon initial public offering</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">NRXS_StockIssuedDuringPeriodSharesCommonStockIssuedUponInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>NRXS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_NRXS_StockIssuedDuringPeriodSharesPreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period shares preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">NRXS_StockIssuedDuringPeriodSharesPreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>NRXS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_NRXS_StockIssuedDuringPeriodSharesWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period shares warrants exercised.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">NRXS_StockIssuedDuringPeriodSharesWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>NRXS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_NRXS_StockIssuedDuringPeriodValueCommonStockIssuedUponInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period value common stock issued upon initial public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">NRXS_StockIssuedDuringPeriodValueCommonStockIssuedUponInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>NRXS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_NRXS_StockIssuedDuringPeriodValuePreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period value preferred stock</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">NRXS_StockIssuedDuringPeriodValuePreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>NRXS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_NRXS_StockIssuedDuringPeriodValueWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period value warrants exercised.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">NRXS_StockIssuedDuringPeriodValueWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>NRXS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in additional paid in capital (APIC) resulting from recognition of deferred taxes for convertible debt with a beneficial conversion feature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 51<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-51<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 25<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481284/470-20-25-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued during the period upon the conversion of units. An example of a convertible unit is an umbrella partnership real estate investment trust unit (UPREIT unit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued attributable to transactions classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The gross value of stock issued during the period upon the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued during the period upon the conversion of units. An example of a convertible unit is an umbrella partnership real estate investment trust unit (UPREIT unit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of shares of stock issued attributable to transactions classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Statements of Cash Flows - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash Flows from Operating Activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Loss</a></td>
<td class="num">$ (8,241,501)<span></span>
</td>
<td class="num">$ (14,626,683)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used by operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts', window );">Amortization of debt discount and issuance cost</a></td>
<td class="nump">126,387<span></span>
</td>
<td class="nump">4,881,622<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">37,831<span></span>
</td>
<td class="nump">40,725<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProvisionForDoubtfulAccounts', window );">Provisions for losses on accounts receivable</a></td>
<td class="nump">7,395<span></span>
</td>
<td class="nump">25,281<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryWriteDown', window );">Provision for losses on inventory</a></td>
<td class="nump">4,454<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NRXS_NoncashLeaseExpense', window );">Non-cash lease expense</a></td>
<td class="nump">32,075<span></span>
</td>
<td class="nump">31,119<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaidInKindInterest', window );">Non-cash interest expense</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">260,777<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock based compensation</a></td>
<td class="nump">227,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Extinguishment of debt liabilities</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">3,649,561<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NRXS_IssuanceOfCommonStockForNoncashConsideration', window );">Issuance of common stock for non-cash consideration</a></td>
<td class="nump">1,177,187<span></span>
</td>
<td class="nump">750,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NRXS_IssuanceOfWarrantsForNoncashConsideration', window );">Fair value of warrants issued for non-cash consideration</a></td>
<td class="nump">157,745<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NRXS_FinancingCharges', window );">Finance charges</a></td>
<td class="nump">230,824<span></span>
</td>
<td class="nump">2,772<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeGainLossOnDerivativeNet', window );">Change in fair value of derivative liabilities</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(198,551)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Change in fair value of warrant liabilities</a></td>
<td class="nump">941<span></span>
</td>
<td class="num">(844,854)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="num">(178,845)<span></span>
</td>
<td class="nump">75,951<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventory</a></td>
<td class="num">(32,500)<span></span>
</td>
<td class="nump">26,913<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaids and other current assets</a></td>
<td class="nump">56,157<span></span>
</td>
<td class="num">(68,937)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="num">(607,273)<span></span>
</td>
<td class="num">(387,897)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued expenses</a></td>
<td class="nump">949,693<span></span>
</td>
<td class="num">(294,154)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NRXS_IncreaseDecreaseInCustomerDeposit', window );">Customer deposits</a></td>
<td class="num">(42,420)<span></span>
</td>
<td class="nump">15,773<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability', window );">Operating lease liability</a></td>
<td class="num">(3,414)<span></span>
</td>
<td class="num">(33,396)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used by operating activities</a></td>
<td class="num">(6,098,264)<span></span>
</td>
<td class="num">(6,693,978)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash Flows from Investing Activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Additions to property and equipment</a></td>
<td class="num">(27,776)<span></span>
</td>
<td class="num">(30,781)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireIntangibleAssets', window );">Additions to intangible assets</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(41,000)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used by investing activities</a></td>
<td class="num">(27,776)<span></span>
</td>
<td class="num">(71,781)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash Flows from Financing Activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock, net of issuance costs</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">4,847,457<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock', window );">Proceeds from issuance of Series B preferred stock</a></td>
<td class="nump">5,253,663<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NRXS_DeferredOfferingCostsPaid', window );">Deferred offering costs paid</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfWarrants', window );">Proceeds from exercised warrants</a></td>
<td class="nump">26,180<span></span>
</td>
<td class="nump">209,097<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfNotesPayable', window );">Principal payments on notes payable</a></td>
<td class="num">(275,994)<span></span>
</td>
<td class="num">(3,553,765)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromNotesPayable', window );">Proceeds from notes payable</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">159,831<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromConvertibleDebt', window );">Proceeds from convertible notes</a></td>
<td class="nump">4,935,003<span></span>
</td>
<td class="nump">5,460,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfFinancingCosts', window );">Financing fees paid</a></td>
<td class="num">(194,502)<span></span>
</td>
<td class="num">(552,000)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">9,744,350<span></span>
</td>
<td class="nump">6,590,620<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net Increase (Decrease) in Cash and Cash Equivalents</a></td>
<td class="nump">3,618,310<span></span>
</td>
<td class="num">(175,139)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash and Cash Equivalents at Beginning of Period</a></td>
<td class="nump">78,560<span></span>
</td>
<td class="nump">253,699<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash and Cash Equivalents at End of Period</a></td>
<td class="nump">3,696,870<span></span>
</td>
<td class="nump">78,560<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental Disclosure of Non-Cash Operating Activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Cash paid for interest</a></td>
<td class="nump">33,830<span></span>
</td>
<td class="nump">214,562<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaidNet', window );">Cash received for income taxes</a></td>
<td class="nump">10,164<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Supplemental Schedule of Non-Cash Investing and Financing Activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NRXS_RecognitionOfRightOfUseAsset', window );">Recognition of right of use asset</a></td>
<td class="nump">284,339<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NRXS_ConversionOfConvertiblePromissoryNotesToSeriesBPreferredStock', window );">Conversion of convertible promissory notes to Series B preferred stock</a></td>
<td class="nump">4,935,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NRXS_FairValueOfWarrantsFromDebtDiscountInConvertibleNotesClassifiedOfAdditionalPaidInCapital', window );">Fair value of warrants from debt discount in convertible notes classified as additional paid in capital</a></td>
<td class="nump">97,465<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NRXS_WriteoffOfDebtDiscountOnConvertibleNotesClassifiedAsAdditionalPaidInCapital', window );">Write-off of debt discount on convertible notes classified as additional paid in capital</a></td>
<td class="nump">165,577<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesIssued1', window );">Issuance of note payable to financing company for insurance premiums</a></td>
<td class="nump">282,086<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NRXS_FairValueOfWarrantLiabilitiesOfWarrantsFromConvertibleNotes', window );">Fair value of warrant liabilities of warrants from convertible notes</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">2,446,502<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NRXS_FairValueOfDerivativeLiabilitiesOfConversionFeatureFromConvertibleNotes', window );">Fair value of derivative liabilities of conversion feature from convertible notes</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">2,375,378<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NRXS_ReclassificationOfWarrantLiabilityToEquity', window );">Reclassification of warrant liability to equity</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">3,720,997<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NRXS_ConversionOfPreferredStockToCommonStock', window );">Conversion of preferred stock to common stock</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 1,244<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_NRXS_ConversionOfConvertiblePromissoryNotesToSeriesBPreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Conversion of convertible promissory notes to series B preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">NRXS_ConversionOfConvertiblePromissoryNotesToSeriesBPreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>NRXS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_NRXS_ConversionOfPreferredStockToCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Conversion of preferred stock to common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">NRXS_ConversionOfPreferredStockToCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>NRXS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_NRXS_DeferredOfferingCostsPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred offering costs paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">NRXS_DeferredOfferingCostsPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>NRXS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_NRXS_FairValueOfDerivativeLiabilitiesOfConversionFeatureFromConvertibleNotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of derivative liabilities of conversion feature from convertible notes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">NRXS_FairValueOfDerivativeLiabilitiesOfConversionFeatureFromConvertibleNotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>NRXS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_NRXS_FairValueOfWarrantLiabilitiesOfWarrantsFromConvertibleNotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of warrant liabilities of warrants from convertible notes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">NRXS_FairValueOfWarrantLiabilitiesOfWarrantsFromConvertibleNotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>NRXS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_NRXS_FairValueOfWarrantsFromDebtDiscountInConvertibleNotesClassifiedOfAdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of warrants from debt discount in convertible notes classified of additional paid in capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">NRXS_FairValueOfWarrantsFromDebtDiscountInConvertibleNotesClassifiedOfAdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>NRXS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_NRXS_FinancingCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Financing charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">NRXS_FinancingCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>NRXS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_NRXS_IncreaseDecreaseInCustomerDeposit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase decrease in customer deposit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">NRXS_IncreaseDecreaseInCustomerDeposit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>NRXS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_NRXS_IssuanceOfCommonStockForNoncashConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance of common stock for noncash consideration.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">NRXS_IssuanceOfCommonStockForNoncashConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>NRXS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_NRXS_IssuanceOfWarrantsForNoncashConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance of warrants for non-cash consideration.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">NRXS_IssuanceOfWarrantsForNoncashConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>NRXS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_NRXS_NoncashLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Noncash lease expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">NRXS_NoncashLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>NRXS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_NRXS_ReclassificationOfWarrantLiabilityToEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reclassification of warrant liability to equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">NRXS_ReclassificationOfWarrantLiabilityToEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>NRXS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_NRXS_RecognitionOfRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Recognition of right of use asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">NRXS_RecognitionOfRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>NRXS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_NRXS_WriteoffOfDebtDiscountOnConvertibleNotesClassifiedAsAdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Writeoff of debt discount on convertible notes classified as additional paid in capital</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">NRXS_WriteoffOfDebtDiscountOnConvertibleNotesClassifiedAsAdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>NRXS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69F<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCostsAndDiscounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeGainLossOnDerivativeNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the fair value of derivatives recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeGainLossOnDerivativeNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 13<br> -SubTopic 10<br> -Topic 480<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481766/480-10-25-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481303/470-50-40-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481303/470-50-40-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after refund, of cash paid to foreign, federal, state, and local jurisdictions as income tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 23<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-22<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -SubTopic 20<br> -Topic 842<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWriteDown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483080/330-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWriteDown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fair value of notes issued in noncash investing and financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaidInKindInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Interest paid other than in cash for example by issuing additional debt securities. As a noncash item, it is added to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaidInKindInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for loan and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from issuance of capital stock which provides for a specific dividend that is paid to the shareholders before any dividends to common stockholders and which takes precedence over common stockholders in the event of liquidation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a borrowing supported by a written promise to pay an obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProvisionForDoubtfulAccounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (reversal of expense) for expected credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479319/326-20-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProvisionForDoubtfulAccounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for a borrowing supported by a written promise to pay an obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pay vs Performance Disclosure - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure [Table]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="num">$ (8,241,501)<span></span>
</td>
<td class="num">$ (14,626,683)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_PvpTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_PvpTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Arrangements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_InsiderTradingArrLineItems', window );"><strong>Insider Trading Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NRXS_NoInsiderTradingFlag', window );">No insider trading flag</a></td>
<td class="text">true<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_NRXS_NoInsiderTradingFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>No insider trading flag.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">NRXS_NoInsiderTradingFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>NRXS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_InsiderTradingArrLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_InsiderTradingArrLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cybersecurity Risk Management and Strategy Disclosure<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract', window );"><strong>Cybersecurity Risk Management, Strategy, and Governance [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock', window );">Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]</a></td>
<td class="text"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CYBERSECURITY
RISK MANAGEMENT AND STRATEGY. </b>NeurAxis has developed and implemented a cybersecurity framework intended to assess, identify and manage
risks from threats to the security of our information, systems, products and network using a risk-based approach. The framework is informed
in part by the National Institute of Standards and Technology (NIST) Cybersecurity Framework and International Organization for Standardization
27001 (ISO 27001) Framework, although this does not imply that we meet all technical standards, specifications, or requirements under
the NIST or ISO 27001.</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span>Our
key cybersecurity processes include the following:</span></span><div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risk-based
    controls for information systems and information on NeurAxis&#8217; networks:</b> We seek to maintain an information technology infrastructure
    that implements physical, administrative and technical controls that are calibrated based on risk and designed to protect <span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_90E_ecyd--CybersecurityRiskManagementProcessesIntegratedFlag_dbT_c20240101__20241231_z5YO9ZFsajK9">the confidentiality,
    integrity and availability of our information systems</span> and information stored on NeurAxis&#8217; networks, including customer information,
    personal information, PHI/PII, intellectual property and proprietary information. NeurAxis added physical safeguards in the form
    of biometric entry systems to access server rooms and 24/7 surveillance at both NeurAxis locations.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Cybersecurity
    incident policies: </b>We have cybersecurity incident policies, an incident response plan and a dedicated team to respond to cybersecurity
    incidents, including experienced counsel. When a cybersecurity incident occurs or we identify a vulnerability, the dedicated team
    is responsible for leading the initial assessment of priority and severity, including external experts that may also be engaged as
    appropriate. NeurAxis&#8217; response to incidents depends on the severity level and seeks to improve its cybersecurity incident
    response plan. NeurAxis, through experienced cybersecurity and HIPAA/HITECH counsel, has developed a security manual and a privacy
    policy.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>



    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">61</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Training:
    </b>We provide security awareness training to help our employees understand their information protection and cybersecurity responsibilities
    at NeurAxis. We also provide additional role-based training to some employees based on customer requirements, regulatory obligations,
    and industry risks.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Supplier
    risk assessments: </b>We have participated in <span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_90E_ecyd--CybersecurityRiskManagementThirdPartyEngagedFlag_dbT_c20240101__20241231_zAIa48IUx2j">several third-party risk assessment processes</span> that include expectations regarding information
    and cybersecurity. NeurAxis also seeks contractual commitments from key suppliers to appropriately secure and maintain their information
    technology systems and protect NeurAxis information that is processed or stored on their systems. This may or may not include business
    associate agreements, downstream vendor agreements and vendor auditing in some cases.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Third-party
    assessments of NeurAxis: </b>We have third-party cybersecurity companies engaged to assess NeurAxis&#8217; cybersecurity readiness
    and to assist in identifying and remediating risks from cybersecurity threats. NeurAxis has a &#8220;real time&#8221; cybersecurity
    partner that monitors our servers 24/7/365 for any attempted intrusions.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</div>NeurAxis
routinely reviews the Office of Civil Right (OCR) audit requirements to assess any gaps within our cybersecurity, privacy and security
programs. We have not identified risks from known cybersecurity threats, that have materially affected us, including our operations,
business strategy, results of operations, cash flows or financial condition. We face certain ongoing risks from cybersecurity threats,
including active interactions with children&#8217;s hospitals while assisting with insurance prior approvals, that, if realized, are
reasonably likely to materially affect us, including our operations, business strategy, results
of operations, cash flows or financial condition.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementProcessesIntegratedFlag', window );">Cybersecurity Risk Management Processes Integrated [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementThirdPartyEngagedFlag', window );">Cybersecurity Risk Management Third Party Engaged [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag', window );">Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock', window );">Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Text Block]</a></td>
<td class="text">As of the fiscal year ended December 31, 2024, the
Company had <span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_900_ecyd--CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag_dbF_c20240101__20241231_zgnGEIsUM3yj">not</span> experienced any material cybersecurity incidents that have had a significant impact on our operations, data integrity,
results of operations, or financial performance.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock', window );">Cybersecurity Risk Board of Directors Oversight [Text Block]</a></td>
<td class="text"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CYBERSECURITY
GOVERNANCE. </b>NeurAxis&#8217; Board of Directors is responsible for oversight of cybersecurity risk. The Board receives reporting about
NeurAxis&#8217; practices, programs, notable threats or incidents and other developments related to cybersecurity throughout the year,
including through periodic updates from NeurAxis&#8217; Chief Regulatory Officer/Privacy Officer and VP of IT/Security Officer.</span>NeurAxis&#8217;
Security Officer reports to NeurAxis&#8217; <span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_90B_ecyd--CybersecurityRiskRoleOfManagementTextBlock_c20240101__20241231_zVH6Wqj9tsI7">Chief Regulatory Officer and together, they lead the Company&#8217;s overall cybersecurity
function</span>. The Security Officer has over 13 years of experience in managing and leading IT or cybersecurity teams and participates in
various cyber security trainings frequently. The Security Officer collaborates with NeurAxis personnel and our outside IT vendors to
identify and analyze cybersecurity risks to NeurAxis, considers industry trends, implement controls, as appropriate and feasible, to
mitigate these risks and enables business leaders to make risk-based business decisions that impact cybersecurity considerations. The
Security Officer meets with senior leadership to review and discuss NeurAxis&#8217; cybersecurity program, including emerging cyber risks,
threats, and industry trends. The Security Officer also supervises efforts to prevent, detect, mitigate, and remediate cybersecurity
risks and incidents through various means, including by collaborating with external security personnel and business stakeholders, and
incorporating threat intelligence and other information obtained from governmental, public, or private sources to strengthen our cybersecurity
technologies and processes.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskRoleOfManagementTextBlock', window );">Cybersecurity Risk Role of Management [Text Block]</a></td>
<td class="text">Chief Regulatory Officer and together, they lead the Company&#8217;s overall cybersecurity
function<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementProcessesIntegratedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementProcessesIntegratedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementThirdPartyEngagedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph ii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph ii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementThirdPartyEngagedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 2<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 2<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskRoleOfManagementTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskRoleOfManagementTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation, Organization and Other Matters<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock', window );">Basis of Presentation, Organization and Other Matters</a></td>
<td class="text"><p id="xdx_800_eus-gaap--BusinessDescriptionAndBasisOfPresentationTextBlock_zhNYctRuImhg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>1.
<span id="xdx_82C_zYzIq02BSlKk">Basis of Presentation, Organization and Other Matters</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Neuraxis,
Inc. (&#8220;we,&#8221; &#8220;us,&#8221; the &#8220;Company,&#8221; or &#8220;Neuraxis&#8221;) was established in 2011 and incorporated
in the state of Indiana on April 17, 2012, under the name of Innovative Health Solutions, Inc. In 2022, the name was changed to Neuraxis,
Inc. and the Company filed a Certificate of Conversion to become a Delaware corporation that increased the number of authorized shares
and established a par value.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is headquartered in Carmel, Indiana, and specializes in the development, production, and sale of medical neuromodulation devices.
The Company has developed four FDA cleared products: (i) the IB-STIM (DEN180057, 2019), (ii) the Rectal Expulsion Device (&#8220;RED&#8221;)
(K242304, 2024), (iii) NSS-2 Bridge (DEN170018, 2017) and (iv) the original 510(K) clearance (K140530, 2014).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    IB-STIM is a percutaneous electrical nerve field stimulator (PENFS) device that is indicated in patients 8-21 years of age with functional
    abdominal pain associated with irritable bowel syndrome. The IB-STIM currently is one of two products marketed and sold by the Company.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">RED
is indicated to evaluate the neuromuscular function of a patient&#8217;s ability to expel its contents from the rectum and as a qualitative
test for rectal hypersensitivity patients who experience desire or urge to defecate at lower volumes of distention. RED is intended to
be used in a clinical setting by trained health care providers in adult populations. </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    NSS-2 Bridge is a percutaneous nerve field stimulator (PNFS) device indicated for use in the reduction of the symptoms of opioid
    withdrawal. The NSS-2 Bridge device was licensed to Masimo Corporation in April 2020, and the Company received a one-time licensing
    fee of $250,000 from Masimo. Masimo markets and sells this product as its Masimo Bridge, and the Company will not receive any further
    licensing payments or other revenue from this product.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    original 510(K) device was the EAD, an electroacupuncture device, now called NeuroStim. The EAD is no longer being manufactured,
    sold or distributed but reserved only for research purposes.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 10, 2023, the Company&#8217;s board of directors authorized a <span id="xdx_904_eus-gaap--StockholdersEquityNoteStockSplit_c20230110__20230110_zKlBv0h1ikB4" title="Description of stock split">1-for-2 reverse stock split</span>. All per share information has been
adjusted for this reverse stock split. The reverse split became effective on January 12, 2023. All share and per share amounts for the
common stock have been retroactively restated to give effect to the splits.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
part of the conversion to a Delaware corporation, the total number of shares of all classes of stock which the Corporation had authority
to issue was (1) <span id="xdx_907_eus-gaap--CommonStockSharesAuthorized_iI_c20241231_zOnIA2bk1eRl" title="Common stock, shares authorized">100,000,000</span> shares of Common Stock, par value $<span id="xdx_901_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20241231_z0t9slsGFmFb" title="Common stock, par value">0.001</span> per share (&#8220;Common Stock&#8221;) and (ii) <span id="xdx_904_eus-gaap--PreferredStockSharesAuthorized_iI_c20241231_zwgE6tZAogch" title="Preferred stock, shares authorized">1,120,000</span> shares
of Preferred Stock, par value $<span id="xdx_906_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20241231_zQd6K0WB8wQg" title="Preferred stock, par value">0.001</span> per share (&#8220;Preferred Stock&#8221;), <span id="xdx_901_eus-gaap--PreferredStockSharesAuthorized_iI_c20241231__us-gaap--StatementClassOfStockAxis__custom--ConvertibleSeriesAPreferredStockMember_zr5VCINVC3E8" title="Preferred stock, shares authorized">1,000,000</span> shares of which was designated as &#8220;Series
A Preferred Stock&#8221; and <span id="xdx_905_eus-gaap--PreferredStockSharesAuthorized_iI_c20241231__us-gaap--StatementClassOfStockAxis__custom--ConvertibleSeriesSeedPreferredStockMember_zDB5mk60DHTk" title="Preferred stock, shares authorized">120,000</span> shares of which were designated as &#8220;Series Seed Preferred Stock&#8221; with the rights, preferences,
powers, privileges and restrictions, qualifications and limitations set forth in this Article IV of the Delaware Certificate of Incorporation.
All share amounts have been retroactively restated to give effect to these changes.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August 9, 2023, the Company consummated an initial public offering (&#8220;IPO&#8221;), conducted on a firm commitment basis, pursuant
to which it sold <span id="xdx_901_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20230809__20230809__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--ConsolidatedEntitiesAxis__custom--AlexanderCapitalLPMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zUDH8AN8ek9h" title="Sale of stock, number of shares issued in transaction">1,098,667</span> shares of its common stock at a price of $<span id="xdx_906_eus-gaap--SharesIssuedPricePerShare_iI_c20230809__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--ConsolidatedEntitiesAxis__custom--AlexanderCapitalLPMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zI9u57xXBAj6" title="Shares issued, price per share">6.00</span> per share, resulting in gross proceeds to the Company of $<span id="xdx_905_eus-gaap--ProceedsFromIssuanceOfCommonStock_c20230809__20230809__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--ConsolidatedEntitiesAxis__custom--AlexanderCapitalLPMember_zczW038XAupi" title="Proceeds from issuance of common stock">6,592,002</span>.
Net proceeds to the Company, after deducting underwriting discounts and commissions and other offering expenses paid by the Company,
were $<span id="xdx_90B_eus-gaap--DeferredOfferingCosts_iI_c20230809__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember__srt--ConsolidatedEntitiesAxis__custom--AlexanderCapitalLPMember_zGLTziJMzVdl" title="Deferred offering costs">4,110,721</span>. All shares sold in our IPO were registered pursuant to a registration statement on Form S-1 (File No. 333- 269179),
as amended, declared effective by the SEC on August 9, 2023. Alexander Capital L.P. (&#8220;Alexander&#8221;) acted as sole book-running
manager for the offering and Spartan Capital Securities, LLC acted as co-manager for the offering. The underwriters did not exercise
their option to purchase up to an additional <span id="xdx_906_ecustom--PurchaseOfAdditionalStockOnNumberOfOptionsNotExercised_c20230809__20230809__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zm8mbjoUdTSh" title="Purchase of additional stockon number of options not exercised">164,801</span> shares of common stock. The Company paid the underwriters an underwriting discount
of seven percent (<span id="xdx_90E_ecustom--UnderwritersDiscountPercentage_iI_pid_dp_uPure_c20230809__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember__srt--ConsolidatedEntitiesAxis__custom--AlexanderCapitalLPMember_zfRQJp40dYZa" title="Underwriters discount percentage">7</span>%) of the amount raised in the offering. In addition, we also paid the underwriters a non-accountable expense allowance
in the amount of <span id="xdx_90F_ecustom--NonaccountableExpenseAllowancePercentage_iI_pid_dp_uPure_c20230809__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember__srt--ConsolidatedEntitiesAxis__custom--AlexanderCapitalLPMember_zPCTDqW6Qvlc" title="Nonaccountable expense allowance percentage">1</span>% (such <span id="xdx_909_ecustom--CashFeePercentage_iI_pid_dp_uPure_c20230809__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember__srt--ConsolidatedEntitiesAxis__custom--AlexanderCapitalLPMember_zd5TUoVVCMSf" title="Cash fee percentage">8</span>% in commissions and fees amounted to a total of $<span id="xdx_907_eus-gaap--ProceedsFromIssuanceInitialPublicOffering_c20230809__20230809__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember__srt--ConsolidatedEntitiesAxis__custom--AlexanderCapitalLPMember_z27GlCZDvRrj" title="Proceeds from issuance initial public offering">527,000</span>) at closing, as well as $<span id="xdx_90B_ecustom--ReimbursementExpenses_c20230809__20230809__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember__srt--ConsolidatedEntitiesAxis__custom--AlexanderCapitalLPMember_zFn36kMnZ0w2" title="Reimbursement expenses">175,000</span> for the reimbursement
of certain of the underwriters&#8217; expenses. Additionally, as partial consideration for services rendered in connection with the offering,
the Company issued Alexander unregistered warrants to purchase an aggregate of <span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20230809__20230809__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember__srt--ConsolidatedEntitiesAxis__custom--AlexanderCapitalLPMember_zfvPq9OomCPd" title="Warrants to purchase an aggregate common stock, shares">65,921</span> shares of Company common stock, representing <span id="xdx_90B_eus-gaap--SaleOfStockPercentageOfOwnershipAfterTransaction_pid_dp_c20230809__20230809__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember__srt--ConsolidatedEntitiesAxis__custom--AlexanderCapitalLPMember_zp4fZvG67qzk" title="Sale of stock, percentage of ownership after transaction">6.0</span>%
of the aggregate shares sold in the offering. The warrants had an initial exercise price of $<span id="xdx_901_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20230809__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember__srt--ConsolidatedEntitiesAxis__custom--AlexanderCapitalLPMember_zA7rR49oMrFg" title="Exercise price of warrants">7.20</span> per share (equal to <span id="xdx_90A_ecustom--OfferingPricePerPercentage_iI_pid_dp_c20230809__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember__srt--ConsolidatedEntitiesAxis__custom--AlexanderCapitalLPMember_z1Pdk2I5dVwf" title="Offering price per percentage">120</span>% of the offering
price per share), a term of five years from the commencement of sales in the offering, and are exercisable at any time.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August 15, 2024, the Company&#8217;s shareholders (i) authorized <span id="xdx_906_eus-gaap--PreferredStockSharesAuthorized_iI_c20240815__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zl89IR6FHHAl" title="Preferred stock, shares authorized">5,000,000</span> shares of preferred stock of which <span id="xdx_905_eus-gaap--TemporaryEquitySharesAuthorized_iI_pid_c20240815__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zESFK4ND2Is7" title="Temporary equity, shares authorized">4,000,000</span> were designated
at $<span id="xdx_90C_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20240815__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zbN3I9AT92J5" title="Preferred stock, par value">0.001</span> par value &#8220;Series B Preferred Stock&#8221; inclusive of cumulative dividends, due and payable quarterly at the Company&#8217;s
discretion either in cash or common stock when declared, <span id="xdx_90E_eus-gaap--PreferredStockDividendPaymentTerms_c20240815__20240815__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zzdDgSZhsJR6" title="Cumulative dividend description">at a rate of 8.5% per annum through June 30, 2025</span>, (ii) retired <span id="xdx_906_eus-gaap--StockRepurchasedAndRetiredDuringPeriodShares_c20240815__20240815__us-gaap--StatementClassOfStockAxis__custom--ConvertibleSeriesAPreferredStockMember_zhR3u3LaTB8i" title="Stock repurchased and retired during period shares">1,000,000</span> shares
of Series A Preferred Stock and (iii) retired <span id="xdx_907_eus-gaap--StockRepurchasedAndRetiredDuringPeriodShares_c20240815__20240815__us-gaap--StatementClassOfStockAxis__custom--ConvertibleSeriesSeedPreferredStockMember_zcAg2O2sFNZ4" title="Stock repurchased and retired during period shares">120,000</span> shares of Series Seed Preferred Stock. On November 11, 2024, the Company&#8217;s
shareholders authorized (i) an increase in the number of designated Series B Preferred Stock to <span id="xdx_909_eus-gaap--PreferredStockSharesAuthorized_iI_c20241111__us-gaap--StatementClassOfStockAxis__custom--ConvertibleSeriesBPreferredStockMember_z2SZx3kgdrUa" title="Preferred stock, shares authorized">5,000,000</span> shares and (ii) an <span id="xdx_902_eus-gaap--PreferredStockDividendPaymentTerms_c20241111__20241111__us-gaap--StatementClassOfStockAxis__custom--ConvertibleSeriesBPreferredStockMember_zAxo7p68lPQf" title="Cumulative dividend description">extension
of the 8.5% cumulative dividend period to December 31, 2026</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>






<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Neuraxis,
Inc.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Notes
to Financial Statements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/235/tableOfContent<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 275<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/275/tableOfContent<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/205/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text"><p id="xdx_80F_eus-gaap--SignificantAccountingPoliciesTextBlock_zlJdJYr3Cvnj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2.
<span id="xdx_828_zEQNQ1WBaVd4">Summary of Significant Accounting Policies</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
summary of significant accounting policies of Neuraxis, Inc. is presented to assist in understanding the Company&#8217;s financial statements.
The financial statements and notes are representations of the Company&#8217;s management, who are responsible for their integrity and
objectivity. These accounting policies conform to U.S. generally accepted accounting principles and have been consistently applied in
the preparation of the financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Preparing
the Company&#8217;s financial statements in conformity with accounting principles generally accepted in the United States of America
(&#8220;GAAP&#8221;) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities
and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and
expenses during the reporting period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_843_eus-gaap--UseOfEstimates_zCNBGrFAkxnd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_862_zCQCbX5hehLh">Use
of Estimates and Critical Accounting Estimates and Assumptions</span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the
reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the dates of the financial statements
and the reported amounts of revenues and expenses during the reporting periods.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
significant accounting estimates or assumptions bear the risk of change due to the fact that there are uncertainties attached to these
estimates or assumptions, and certain estimates or assumptions are difficult to measure or value.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management
bases its estimates on historical experience and on various assumptions that are believed to be reasonable in relation to the financial
statements taken as a whole under the circumstances, the results of which form the basis for making judgments about the carrying values
of assets and liabilities that are not readily apparent from other sources.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management
regularly evaluates the key factors and assumptions used to develop the estimates utilizing currently available information, changes
in facts and circumstances, historical experience, and reasonable assumptions. After such evaluations, if deemed appropriate, those estimates
are adjusted accordingly. The Company uses estimates in accounting for, among other items, revenue recognition, allowance for credit
losses, stock-based compensation, income tax provisions, excess and obsolete inventory reserve, and impairment of property and equipment,
and intellectual property. Actual results could differ from those estimates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84E_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_ztvqhicgjizf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_86B_zlm33AKL50gf">Cash
and Cash Equivalents</span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company considers all highly liquid debt instruments purchased with a maturity of three months or less to be cash equivalents. The Company
did not hold any cash equivalents as of December 31, 2024 and 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_846_eus-gaap--TradeAndOtherAccountsReceivablePolicy_zfROzNl3ffE" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_866_z8W5SJsnYNZ3">Trade
Accounts Receivable and Allowance for Credit Losses</span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Trade
accounts receivable are stated at the amount management expects to collect from outstanding balances, net of an allowance for credit
losses. Management evaluates many factors when determining the collectability of specific customer accounts, including, but not
limited to, creditworthiness, past transaction and payment history, current economic industry trends and changes in payment terms.
Management used assumptions and judgment based on the best available facts and circumstances to estimate and record an allowance.
The allowance for credit losses was $<span id="xdx_90F_eus-gaap--AllowanceForDoubtfulAccountsReceivable_iI_c20241231_zP8VFScW5y0c" title="Allowance for doubtful accounts">5,000</span>
and $<span id="xdx_903_eus-gaap--AllowanceForDoubtfulAccountsReceivable_iI_c20231231_ztE0yvQuOmXa" title="Allowance for doubtful accounts">11,993</span>
as of December 31, 2024 and 2023, respectively. The Company recorded credit losses for the years ended December 31, 2024 and 2023 of
$<span id="xdx_90D_eus-gaap--ProvisionForOtherCreditLosses_c20240101__20241231_z7Ql8mCSpFj8" title="Credit losses">7,395</span> and $<span id="xdx_904_eus-gaap--ProvisionForOtherCreditLosses_c20230101__20231231_zJyECgcqyDrd" title="Credit losses">25,281</span>,
respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Neuraxis,
Inc.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Notes
to Financial Statements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_845_eus-gaap--DepositContractsPolicy_z0S65AE6qnwc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_86B_zs9KrkyOFyU1">Customer
Deposits</span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Customer
deposits consists of  payments and returned devices from clients in advance of revenue recognition. The Company will recognize
the customer deposits over the next year. As of December 31, 2024, and 2023, the Company had customer deposits of $<span id="xdx_904_eus-gaap--Deposits_iI_c20241231_zSmRjs0DXNzj" title="Customer deposits">32,527</span> and $<span id="xdx_902_eus-gaap--Deposits_iI_c20231231_zueWOiNKKjkg" title="Customer deposits">74,947</span>,
respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_846_eus-gaap--InventoryPolicyTextBlock_zxmZEstGpDWd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_866_zKh9Gova5AU2">Inventories</span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inventories
are valued at the lower of cost or net realizable value. Cost is determined using the weighted average method. The inventory is comprised
of finished medical devices on hand. Certain components within the devices have an expiration date that are removed from current inventory
and expensed at the date of expiration. For the years ended December 31, 2024 and 2023, $<span id="xdx_901_ecustom--InventoryExpenses_iI_c20241231_zZoDkfglZ1Ia" title="Inventory expenses">0</span> and $<span id="xdx_900_ecustom--InventoryExpenses_iI_c20231231_zEQ7Zl1KsBUg" title="Inventory expenses">25,008</span> were expensed as expired inventory,
respectively. Inventory reserves totaled $<span id="xdx_906_eus-gaap--InventoryRawMaterialsNetOfReserves_iI_c20241231_zgVGVW7KmyZ2" title="Inventory reserves">4,454</span> and $<span id="xdx_90C_eus-gaap--InventoryRawMaterialsNetOfReserves_iI_c20231231_zZjhKB4ngEMj" title="Inventory reserves">0</span> as of December 31, 2024 and 2023, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_846_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zWScFqAl6Wg6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_860_zuZEawh0Gg39">Property
and Equipment</span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property
and equipment are recorded at cost less accumulated depreciation. Depreciation is computed using the straight-line method over the estimated
useful lives of the assets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_89D_ecustom--ScheduleOfPropertyPlantAndEquipmentUsefulLivesTableTextBlock_zA63jvQhipj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Depreciation
is calculated using the following estimated useful lives:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B1_zS3Vx59ipME8" style="display: none">Schedule of Estimated Useful Lives</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; width: 60%; border-collapse: collapse; margin-right: auto">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; width: 79%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Classification</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; width: 19%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Years</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Machinery
    and Equipment </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_908_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--MachineryAndEquipmentMember__srt--RangeAxis__srt--MinimumMember_zBoCKBqUpo16" title="Property and equipment, estimated useful lives">7</span>-<span id="xdx_90B_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--MachineryAndEquipmentMember__srt--RangeAxis__srt--MaximumMember_zs1iIMSzTnZ" title="Property and equipment, estimated useful lives">10</span>
    </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Furniture
    and Fixtures</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_906_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember__srt--RangeAxis__srt--MinimumMember_zmPdomKTkuj5" title="Property and equipment, estimated useful lives">3</span>-<span id="xdx_90D_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember__srt--RangeAxis__srt--MaximumMember_zMDjRUq42GH8" title="Property and equipment, estimated useful lives">10</span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Computer
    Hardware</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_zay71H131WJ9" title="Property and equipment, estimated useful lives">5</span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Leasehold
    Improvements</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90F_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember__srt--RangeAxis__srt--MinimumMember_zttmRcV3egyh" title="Property and equipment, estimated useful lives">10</span>-<span id="xdx_903_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember__srt--RangeAxis__srt--MaximumMember_zDksIX8dOpz9" title="Property and equipment, estimated useful lives">20</span></span></td></tr>
  </table>
<p id="xdx_8A9_zz9GmOk7OY67" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Depreciation
expense was $<span id="xdx_908_eus-gaap--Depreciation_c20240101__20241231_zCE9MU3CfcB" title="Depreciation expense">26,346</span> and $<span id="xdx_907_eus-gaap--Depreciation_c20230101__20231231_zg5lb62IyG23" title="Depreciation expense">30,240</span> during the years ended December 31, 2024 and 2023, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_847_eus-gaap--ResearchAndDevelopmentExpensePolicy_zaqJbGezMLz8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_861_z6QRpnJ2AG38">Research
and Development</span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Costs
for research and development are expensed as incurred. Research and development expenses consist primarily of clinical research studies
and new product development.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_843_eus-gaap--IntangibleAssetsFiniteLivedPolicy_zGVWfgMVm0Lf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_862_zLVPmPO16MM7">Intangible
Assets</span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Intangible
assets consist of software, patents, a trademark and a license. Intangible assets are stated at their historical cost and amortized on
a straight-line basis over their expected useful lives. Capitalized patent costs, net of accumulated amortization, includes legal costs
incurred for patent applications. In accordance with ASC 350, once a patent is granted, we amortize the capitalized patent costs over
the remaining life of the patent using the straight-line method. If the patent is not granted, we write off any capitalized patent costs
at that time.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company purchased a trademark related to the Company&#8217;s name for $<span id="xdx_908_eus-gaap--PaymentsToAcquireIntangibleAssets_c20240101__20241231__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_zPy2rZ9bDnpa" title="Payment to acquire intangible assets">50,000</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.
The trademark does not have a determinate life and therefore the cost is not being amortized.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company entered into an option agreement on April 12, 2023 to bring an optionor&#8217;s invention to commercialization via a royalty-bearing
licensing agreement. The agreement required an initial payment of $<span id="xdx_90D_eus-gaap--PaymentsToAcquireIntangibleAssets_c20240101__20241231__us-gaap--TypeOfArrangementAxis__custom--LicensingAgreementMember_zbq2IOfPbfml" title="Payment upon execution">1,000</span> and was fully amortized in the year ended December 31, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Neuraxis,
Inc.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Notes
to Financial Statements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
review intangible assets for impairment annually or when events or circumstances indicate that their carrying amount may not be recoverable.
During the years ended December 31, 2024, and 2023, the Company recorded no impairment charges for intangible assets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amortization
expense was $<span id="xdx_902_eus-gaap--AmortizationOfIntangibleAssets_c20240101__20241231_zHntBXDIkQQh" title="Amortization expense">11,485</span> and $<span id="xdx_909_eus-gaap--AmortizationOfIntangibleAssets_c20230101__20231231_z6VW5MqTev6c" title="Amortization expense">10,485</span> during the years ended December 31, 2024 and 2023, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_844_eus-gaap--IncomeTaxPolicyTextBlock_zkgEMdBxd1ml" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_864_zSM75xOhiFEk">Income
Taxes</span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company recognizes deferred tax assets and liabilities for the expected future tax consequences of events that have been included in
the Company&#8217;s financial statements and tax returns. Deferred tax assets and liabilities are determined based upon the differences
between the financial statement carrying amounts, and the tax bases of existing assets and liabilities for the loss and credit carryforwards
using enacted tax rates expected to be in effect in the year in which the differences are expected to reverse. Deferred tax assets are
reduced by a valuation allowance if it is more likely than not that these assets may not be realized. The Company determines whether
a tax position will be sustained upon examination. If it is more likely than not that a position will be sustained, none of the benefit
attributable to the position is recognized. The tax benefit to be recognized for any tax position that meets the more likely than not
recognition threshold is calculated as <span id="xdx_900_eus-gaap--IncomeTaxExaminationLikelihoodOfUnfavorableSettlement_c20240101__20241231_zhScl8zCptK8" title="Income tax examination, likelihood of unfavorable settlement">the largest amount that is more than 50% likely of being realized upon resolution of the contingency</span>.
The Company accounts for interest and penalties related to uncertain tax positions as part of its provision for income taxes.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management&#8217;s
evaluation of the Company&#8217;s deferred tax assets and liabilities did not have a material effect on the Company&#8217;s financial
statements. Furthermore, <span id="xdx_907_eus-gaap--IncomeTaxExaminationPenaltiesAndInterestAccrued_iI_do_c20241231_ztC0RV1l8oLb" title="Income tax interest or penalties accrued"><span id="xdx_908_eus-gaap--IncomeTaxExaminationPenaltiesAndInterestAccrued_iI_do_c20231231_zhqBNkKSJdb6" title="Income tax interest or penalties accrued">no</span></span> interest or penalties have been accrued or charged to expense as of December 31, 2024 and 2023 and for the
years then ended.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_847_eus-gaap--AdvertisingCostsPolicyTextBlock_zo5yvzL87Rx8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_867_zWUOXu7pc5n5">Advertising
Cost</span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Advertising
costs are expensed as incurred and amounted to $<span id="xdx_90F_eus-gaap--AdvertisingExpense_c20240101__20241231__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zHFN1G5pWFd9" title="Advertising cost">232,125</span>
and $<span id="xdx_900_eus-gaap--AdvertisingExpense_c20230101__20231231__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zIlntYARjZTf" title="Advertising cost">192,400</span> for
the years ended December 31, 2024 and 2023, respectively, and are classified as general and administrative expenses in the
statements of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Neuraxis,
Inc.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Notes
to Financial Statements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_848_ecustom--WarrantLiabilityPolicyTextBlock_zaVIsSf1c53d" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_86D_zrlgX8Mm8yia">Warrant
Liabilities</span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management
evaluates all of the Company&#8217;s financial instruments, including issued warrants to purchase its common stock, to determine if such
instruments are liabilities pursuant to ASC 480 and ASC 815-15. The classification
of derivative financial instruments, including whether such instruments should be recorded as liabilities or as equity, is reassessed
at the end of each reporting period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company utilizes a Black-Scholes option-pricing model to compute the fair value of the derivative and to mark to market the fair value
of the derivative at each balance sheet date. The inputs utilized in the application of the Black-Scholes option-pricing model included
an exercise price, the stock price as of the valuation date, an expected remaining term of each warrant as of the valuation date, estimated
volatility, a dividend yield, and a risk-free rate. The Company records the change in the fair value of the warrant as other income or
expense in the statements of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_846_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_zuoNDbkmfx99" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_867_zA6yTR80qBQ1">Fair
Value Measurements</span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for financial instruments in accordance with ASC 820, Fair Value Measurements and Disclosures (&#8220;ASC 820&#8221;).
ASC 820 establishes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy
gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and
the lowest priority to unobservable inputs (Level 3 measurements). The three levels of the fair value hierarchy under ASC 820 are described
below:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
1 &#8211; Quoted prices (unadjusted) for identical unrestricted assets or liabilities in active markets that the reporting entity has
the ability to access as of the measurement date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
2 &#8211; Significant other observable inputs other than Level 1 prices such as quoted prices for similar assets or liabilities: quoted
prices in markets that are not active; or financial instruments for which all significant inputs are observable or can be corroborated
by observable market date, either directly or indirectly.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
3 &#8211; Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets
or liabilities. These unobservable inputs reflect that reporting entity&#8217;s own assumptions about assumptions that market participants
would use in pricing the asset or liability. Level 3 assets and liabilities include financial instruments whose value is determined using
pricing models, discounted cash flow methodologies, or similar techniques, as well as instruments for which the determination of fair
value require significant management judgment or estimation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s Level 1 assets/liabilities include cash, accounts receivable, accounts payable, prepaids, and other current assets. Management
believes the estimated fair value of these accounts on December 31, 2024 approximate their carrying value as reflected in the balance
sheets due to the short-term nature of these instruments or the use of market interest rates for debt instruments.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s Level 3 assets/liabilities include warrant liabilities. Inputs to determine fair value are generally unobservable
and typically reflect management&#8217;s estimates of assumptions that market participants would use in pricing the asset or liability.
The fair values are therefore determined using model-based techniques, including option pricing models and discounted cash flow models.
The valuation techniques involve management&#8217;s estimates and judgment based on unobservable inputs. The fair value estimates may
not be indicative of the amounts that would be realized in a market exchange. Additionally, there may be inherent uncertainties or changes
in the underlying assumptions used, which could significantly affect the current or future fair value estimates. Unobservable inputs
used in the models are significant to the fair values of the assets and liabilities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Neuraxis,
Inc.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Notes
to Financial Statements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_89E_eus-gaap--ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_zSRjCMWMj1w3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table provides a summary of the relevant assets and liabilities that are measured at fair value on a recurring
basis:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B3_z3g9hDaGrTA9" style="display: none">Schedule
of Fair Value of Assets and Liabilities  measured on Recurring Basis</span>&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_4B9_us-gaap--FairValueByMeasurementFrequencyAxis_us-gaap--FairValueMeasurementsRecurringMember_us-gaap--FinancialInstrumentAxis_us-gaap--WarrantMember_zBZgAXCyF1Vk" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_4B0_us-gaap--FairValueByMeasurementFrequencyAxis_us-gaap--FairValueMeasurementsRecurringMember_us-gaap--FairValueByFairValueHierarchyLevelAxis_us-gaap--FairValueInputsLevel1Member_zDB43ntMIDc2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 1</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_4BA_us-gaap--FairValueByMeasurementFrequencyAxis_us-gaap--FairValueMeasurementsRecurringMember_us-gaap--FairValueByFairValueHierarchyLevelAxis_us-gaap--FairValueInputsLevel2Member_z9UbeIrsNMjf" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 2</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_4BC_us-gaap--FairValueByMeasurementFrequencyAxis_us-gaap--FairValueMeasurementsRecurringMember_us-gaap--FairValueByFairValueHierarchyLevelAxis_us-gaap--FairValueInputsLevel3Member_zWqguAEicMAk" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 3</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: center"><b>Valuation Methodology</b></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: center"><b>Unobservable<br/>
Inputs</b></td></tr>
  <tr id="xdx_439_c20241231_eus-gaap--LiabilitiesFairValueDisclosure_iI_z3pBMIl0Qkg3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 23%; text-align: left; padding-bottom: 1pt; padding-left: 0pt">Fair value of warrant  liabilities as of
    December 31, 2024</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 7%; text-align: right">9,166</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 7%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0827">&#8212;</span></td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 7%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0828">&#8212;</span></td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 7%; text-align: right">9,166</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="text-align: center; width: 12%">Black-Scholes model</td>
    <td style="width: 2%">&#160;</td>
    <td style="text-align: center; width: 17%">Project simulated cash flows</td></tr>
  <tr id="xdx_43C_c20231231_eus-gaap--LiabilitiesFairValueDisclosure_iI_z6bHNiK1NE4k" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 0pt">Fair value of warrant  liabilities as of
    December 31, 2023</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">8,225</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0832">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0833">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">8,225</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">Black-Scholes model</td>
    <td>&#160;</td>
    <td style="text-align: center">Project simulated cash flows</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p id="xdx_8AF_zDV1NvmR9hqi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
were no transfers between any of the levels during the years ended December 31, 2024 and 2023. In addition to assets and liabilities
that are recorded at fair value on a recurring basis, the Company&#8217;s assets and liabilities are also subject to recurring fair
value measurements. As of December 31, 2024 and 2023, the Company had no assets that were measured on a recurring basis.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_843_eus-gaap--EarningsPerSharePolicyTextBlock_z3Z5xHrFvPnb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_868_zRILTRgfzVRf">Basic
and Diluted Net Income (Loss) per Share</span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basic
earnings or loss per share (&#8220;EPS&#8221;) is computed by dividing net income (loss), net of preferred stock dividends, by the
weighted average number of common shares outstanding during the period. Diluted EPS is determined using the weighted average number
of common shares outstanding during the period, adjusted for the dilutive effect of common stock equivalents that were outstanding
for the periods presented. In periods when losses are reported, which is the case for December 31, 2024 and 2023 presented in these
financial statements, the weighted average number of common shares outstanding excludes common stock equivalents because their
inclusion would be anti-dilutive. Preferred stock dividends (neither declared nor paid) were $<span id="xdx_90F_eus-gaap--DividendsPreferredStock_c20240101__20241231_zMa5zOaCz0dh" title="Preferred stock dividend">211,268</span>
and $<span id="xdx_906_eus-gaap--DividendsPreferredStock_dxL_c20230101__20231231_zCKOVIyQCu2e" title="Preferred stock dividend::XDX::-"><span style="-sec-ix-hidden: xdx2ixbrl0840">0</span></span>
as of December 31, 2024 and 2023, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Neuraxis,
Inc.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Notes
to Financial Statements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_894_eus-gaap--ScheduleOfEarningsPerShareDilutedByCommonClassTextBlock_zQrWqPsSpLsb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company had the following potentially dilutive common stock equivalents at December 31, 2024 and 2023:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BC_zox9NmqQpub9" style="display: none">Schedule of Dilutive Common Stock Equivalents</span>&#160;</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_494_20240101__20241231_zCfMhiwPQpEd" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49E_20230101__20231231_zb3LNMgKs5Qd" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--OptionMember_z2YvJ0OOXEw7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%">Options</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right">1,319,394</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right">1,319,394</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--CommonStockMember_z4IBT9gvKFCb" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Pre-Funded Warrants for Common Stock</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">289,779</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0848">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--WarrantsMember_zm2CD0h3eBoj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,352,751</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,822,358</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--SeriesBPreferredStockMember_zPVzzRS4kdql" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Series B Preferred Stock</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">4,280,939</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0854">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_zswUml38NNc9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-bottom: 1pt; padding-left: 10pt">Totals</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">8,242,863</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">3,141,752</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8AE_zZkRPjMKhCOg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_89D_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_zX3d573GQcn8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table shows the calculation of the basic and diluted net loss per share and the effect of preferred stock dividends.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BC_zXyehy2Q4OB7" style="display: none">Schedule of Basic and Diluted Net Loss Per Share</span>&#160;</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49E_20240101__20241231_zkLWbBazjZl2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_493_20230101__20231231_zPg30jDzserk" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">For the Years Ended December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Numerator</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--NetIncomeLoss_iT_mtNILzQKI_zp3QgJK7iOg" style="vertical-align: bottom; background-color: White">
    <td style="width: 60%; text-align: left; padding-left: 10pt">Net loss</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">(8,241,501</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right">(14,626,683</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr id="xdx_402_eus-gaap--DividendsPreferredStock_iN_di_zqUV04SEGgVl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 10pt">Preferred stock dividends</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(211,268</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0865">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_zqBPWqst7E72" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Net loss available to common stockholders</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(8,452,769</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(14,626,683</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Denominator</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 20pt">Weighted-average shares of common stock outstanding - basic and diluted</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_903_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20240101__20241231_z6adsR0YsnZ9" title="Weighted average shares of common stock outstanding - basic"><span id="xdx_901_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20240101__20241231_zco5F3MbpLAc" title="Weighted average shares of common stock outstanding - diluted">6,918,887</span></span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_900_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20230101__20231231_zpa3Fn0QmNfb" title="Weighted average shares of common stock outstanding - basic"><span id="xdx_903_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20230101__20231231_zRyq1dOtor4d" title="Weighted average shares of common stock outstanding - diluted">3,252,328</span></span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Basic and diluted net loss per share</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_90E_eus-gaap--EarningsPerShareBasic_c20240101__20241231_zrz21PRWjGCl" title="Basic net loss per share"><span id="xdx_90F_eus-gaap--EarningsPerShareDiluted_c20240101__20241231_zIgmac8dw9Ed" title="Diluted net loss per share">(1.22</span></span></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_908_eus-gaap--EarningsPerShareBasic_c20230101__20231231_z2hMbWcceUqg" title="Basic net loss per share"><span id="xdx_905_eus-gaap--EarningsPerShareDiluted_c20230101__20231231_z96vWnNsnYxe" title="Diluted net loss per share">(4.50</span></span></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  </table>

<p id="xdx_8AF_z8OuXYGzkAE7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_848_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_zuHjXlK84ss5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_862_zfwsy8KpLtyk">Stock-Based
Compensation</span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for all stock-based awards at fair value. The Company recognizes its stock-based compensation expense using the straight-line
method. Compensation cost is not adjusted for estimated forfeitures, but instead is adjusted upon an actual forfeiture.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for the granting of stock options and restricted stock units to employees and non-employees using the fair value method
whereby all awards are measured at fair value on the date of the grant. The fair value of all employee stock options and restricted stock
units is expensed over the requisite service period with a corresponding increase to additional paid-in capital. Upon exercise of stock
options, the consideration paid by the option holder is recorded in additional paid-in capital, while the par value of the shares received
is reclassified from additional paid-in-capital to common stock. Upon vesting of restricted stock units, the par value of the shares
issued are reclassified from additional paid-in-capital to common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock-based
awards to non-employees are measured based on the fair value of the equity instrument issued. Compensation expense for non-employee stock
awards is recognized over the requisite service period following the measurement of the fair value on the grant date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company uses the Black-Scholes option-pricing model to calculate the fair value of stock options. The use of the Black-Scholes option-pricing
model requires management to make assumptions with respect to the expected term of the option, the expected volatility of the common
stock consistent with the expected term of the option, risk-free interest rates, the value of the common stock and expected dividend
yield of the common stock. Changes in these assumptions can materially affect the fair value estimate.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Neuraxis,
Inc.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Notes
to Financial Statements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_843_eus-gaap--RevenueRecognitionPolicyTextBlock_zbJsYb6ra5wg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_862_zPNGdCffZD65">Revenue
Recognition</span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
accordance with FASB&#8217;s ASC 606, <i>Revenue from Contracts with Customers</i>, (&#8220;ASC 606&#8221;), the Company recognizes revenue
when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the Company expects
to be entitled in exchange for those goods or services. To determine revenue recognition for arrangements that the Company determines
are within the scope of ASC 606, it performs the following five steps:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">identify
    the contract(s) with a customer&#894;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">identify
    the performance obligations in the contract&#894;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">determine
    the transaction price&#894;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iv)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">allocate
    the transaction price to the performance obligations in the contract&#894; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(v)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">recognize
    revenue when (or as) the entity satisfies a performance obligation.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company applies the five-step model to contracts when it determines that it is probable it will collect substantially all the consideration
it is entitled to in exchange for the goods or services it transfers to the customer. At contract inception, once the contract is determined
to be within the scope of ASC 606, the Company assesses the goods or services promised within each contract and determines those that
are performance obligations and assesses whether each promised good or service is distinct. The Company then recognizes as revenue the
amount of the transaction price, after consideration of variability and constraints, if any, that is allocated to the respective performance
obligation when the performance obligation is satisfied.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company estimates credit losses on accounts receivable by utilizing an aging schedule.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company offers a Patient Assistance Program for patients without insurance coverage for IB-Stim. This program offers potential self-pay
discounts for IB-Stim devices, based upon household income and size.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Also,
the Company offers providers an opt-in program to address adequate insurance claim payments on IB-Stim devices. This program may extend
a rebate or invoice credit where the insurance payment and patient responsibility (i.e., deductible, co-payment, and/or co-insurance
amounts required by the Payer) are less than the acquisition cost of the IB-Stim device. The Company recognizes revenue at such a time
that collection of the amount due is assured.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_89B_eus-gaap--DisaggregationOfRevenueTableTextBlock_z51iF5FwY8Ik" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table disaggregates the Company&#8217;s revenue based on the customer&#8217;s location by state for the years ended December
31:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B7_zFnT94CGa2N4" style="display: none">Schedule of Disaggregation of Revenue</span>&#160;</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 60%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 20%">California</td><td style="width: 2%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">$</td><td id="xdx_983_eus-gaap--Revenues_c20240101__20241231__srt--StatementGeographicalAxis__stpr--CA_ztWpMGR6FjK" style="width: 16%; font-weight: bold; text-align: right" title="Revenues">778,209</td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--Revenues_c20230101__20231231__srt--StatementGeographicalAxis__stpr--CA_zhaa1ANY8XF7" style="width: 16%; text-align: right" title="Revenues">601,235</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Ohio</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--Revenues_c20240101__20241231__srt--StatementGeographicalAxis__stpr--OH_z8HHuDbKCMGd" style="font-weight: bold; text-align: right" title="Revenues">431,328</td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--Revenues_c20230101__20231231__srt--StatementGeographicalAxis__stpr--OH_zzOMNsxW8pak" style="text-align: right" title="Revenues">407,632</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Illinois</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--Revenues_c20240101__20241231__srt--StatementGeographicalAxis__stpr--IL_zb6kZssrfWfe" style="font-weight: bold; text-align: right" title="Revenues">246,217</td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--Revenues_c20230101__20231231__srt--StatementGeographicalAxis__stpr--IL_zWDTnM17q319" style="text-align: right" title="Revenues">117,963</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Wisconsin</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--Revenues_c20240101__20241231__srt--StatementGeographicalAxis__stpr--WI_z3428iyridQh" style="font-weight: bold; text-align: right" title="Revenues">157,786</td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--Revenues_c20230101__20231231__srt--StatementGeographicalAxis__stpr--WI_zGxpKPV1TjK7" style="text-align: right" title="Revenues">292,601</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Massachusetts</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--Revenues_c20240101__20241231__srt--StatementGeographicalAxis__stpr--MA_zasnvjzBkL05" style="font-weight: bold; text-align: right" title="Revenues">154,407</td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--Revenues_c20230101__20231231__srt--StatementGeographicalAxis__stpr--MA_zKTfMKrP2Fwk" style="text-align: right" title="Revenues">127,300</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Florida</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--Revenues_c20240101__20241231__srt--StatementGeographicalAxis__stpr--FL_zjSSE7PnWXPh" style="font-weight: bold; text-align: right" title="Revenues">149,985</td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--Revenues_c20230101__20231231__srt--StatementGeographicalAxis__stpr--FL_z0AEkB7FcCsg" style="text-align: right" title="Revenues">186,840</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">All other states</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--Revenues_c20240101__20241231__srt--StatementGeographicalAxis__custom--AllOtherStatesMember_zhSbHj7bt2ag" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right" title="Revenues">767,993</td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--Revenues_c20230101__20231231__srt--StatementGeographicalAxis__custom--AllOtherStatesMember_zVzeZm5mSkih" style="border-bottom: Black 1pt solid; text-align: right" title="Revenues">726,478</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">$</td><td id="xdx_988_eus-gaap--Revenues_c20240101__20241231_z8xgf1LC4xKf" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right" title="Revenues">2,685,925</td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_986_eus-gaap--Revenues_c20230101__20231231_zCiswA2OlDda" style="border-bottom: Black 1pt solid; text-align: right" title="Revenues">2,460,049</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A0_zvTYoR5sc9Ua" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain
economic factors affect the nature, amount, timing, and uncertainty of the Company&#8217;s revenue and cash flows. All of the Company&#8217;s
products are sold to healthcare customers including hospitals and clinics. Sales to healthcare customers lack seasonality and have a
mild correlation with economic cycles. All of the Company&#8217;s sales are to customers located within the United States. Sales contracts
consist of purchase orders that are short-term (i.e., less than or equal to one year).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Neuraxis,
Inc.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Notes
to Financial Statements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company typically satisfies its performance obligations for goods at a point in time as they are received at the customer&#8217;s
destination (rather than over time). Goods are shipped by common carrier to customers under FOB destination terms. As such,
ownership of goods in transit is transferred to the customer upon receipt as the Company bears the associated risks (e.g., loss,
damage, delay). Management typically relies on shipping information from common carriers to evaluate when the
customer has obtained control of the goods. Shipping and handling costs are recorded as Cost of Goods Sold in the Statements of
Operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s contracts with customers typically do not involve variable consideration. The information that the Company uses to determine
the transaction price for a contract is similar to the information that the Company&#8217;s management uses in establishing the prices
of goods to be sold.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Orders
may not be cancelled after shipment. Customers may return devices within 10 days of delivery if the goods are found to be defective,
nonconforming, or otherwise do not meet the stated technical specifications. At the option of the customer, the Company shall either:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Refund
    the price paid for any defective or nonconforming products.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Supply
    and deliver to the customer replacement conforming products.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Reimburse
    the customer for the cost of repairing any defective or nonconforming products.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
the time revenue is recognized, the Company estimates expected returns and excludes those amounts from revenue. The Company also
maintains appropriate accounts to reflect the effects of expected returns on the Company&#8217;s financial position and periodically
adjusts those accounts to reflect its actual return experience. Estimated returns totaled</span> $<span id="xdx_908_eus-gaap--ContractWithCustomerLiabilityRevenueRecognized_c20240101__20241231_zBqEO4HnlF7c" title="Estimated returns of revenue">5,000</span> and $<span id="xdx_90C_eus-gaap--ContractWithCustomerLiabilityRevenueRecognized_c20230101__20231231_zt5BroE5J4dl" title="Estimated returns of revenue">0</span> as of December 31,
2024 and 2023, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Payment
for goods sold by the Company is typically due after an invoice is sent to the customer, within 30 days. The Company does not offer discounts
if the customer pays some or all of an invoiced amount prior to the due date. None of the Company&#8217;s contracts have a significant
financing component.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Medical
devices that the Company contracts to sell and transfer to customers are manufactured by one specific third-party manufacturer located
within the state of Indiana. In no case does the Company act as an agent (i.e., the Company does not provide a service of arranging for
another party to transfer goods to the customer).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Neuraxis,
Inc.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Notes
to Financial Statements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_846_eus-gaap--LesseeLeasesPolicyTextBlock_zFGApbXnaIf2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_862_zlz6TSsaBUBh">Leases</span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
accordance with Accounting Standards Updated (&#8220;ASU&#8221;) No. 2016-02, <i>Leases (Topic 842)</i> (&#8220;ASU 2016-02&#8221; or
&#8220;ASC 842&#8221;), at the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based
on the unique facts and circumstances present in the arrangement. Leases with a term greater than one year are recognized on the balance
sheet as right-of-use assets and current and non-current lease liabilities, as applicable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating
lease liabilities and their corresponding right-of-use assets are initially recorded based on the present value of lease payments over
the expected remaining lease term. Certain adjustments to the right-of-use asset may be required for items such as incentives received.
The interest rate implicit in lease contracts is typically not readily determinable. As a result, the Company utilizes its incremental
borrowing rate to discount lease payments, which reflects the fixed rate at which the Company could borrow on a collateralized basis
the amount of the lease payments in the same currency, for a similar term, in a similar economic environment. Prospectively, the Company
will adjust the right-of-use assets for straight-line rent expense, or any incentives received and remeasure the lease liability at the
net present value using the same incremental borrowing rate that was in effect as of the lease commencement or transition date. The Company
has elected not to recognize leases with an original term of one year or less on the balance sheet. The Company typically only includes
an initial lease term in its assessment of a lease arrangement. Options to renew a lease are not included in the Company&#8217;s assessment
unless there is reasonable certainty that the Company will renew.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Assumptions
made by the Company at the commencement date are re-evaluated upon occurrence of certain events, including a lease modification. A lease
modification results in a separate contract when the modification grants the lessee an additional right of use not included in the original
lease and when lease payments increase commensurate with the standalone price for the additional right of use. When a lease modification
results in a separate contract, it is accounted for in the same manner as a new lease.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Entities
may elect not to separate lease and non-lease components. The Company has elected to account for lease and non-lease components together
as a single lease component for all underlying assets and allocate all the contract consideration to the lease component only.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Neuraxis,
Inc.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Notes
to Financial Statements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84C_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_zBrdlPiMtEtd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_864_z3HRppsuDOqc">Impairment
of Long-Lived Assets</span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Long-lived
assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset group may
not be recoverable. If events or changes in circumstances indicate that the carrying amount of an asset group may not be recoverable,
we compare the carrying amount of the asset group to future undiscounted net cash flows, excluding interest costs, expected to be generated
by the asset group and their ultimate disposition. If the sum of the undiscounted cash flows is less than the carrying value, the impairment
to be recognized is measured by the amount by which the carrying amount of the asset group exceeds the fair value of the asset group.
Assets to be disposed of are reported at the lower of the carrying amount or fair value, less costs to sell.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84A_eus-gaap--ConcentrationRiskCreditRisk_znCEHkM7M1r6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_865_zp8VPiZFHkLc">Concentrations
of Credit Risk</span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s business activity consists of the sale of medical neuromodulation devices to doctors, clinics, and hospitals across
the country. Receivables consist of unsecured amounts due from customers. The table below sets forth the Company&#8217;s customers
that accounted for greater than 10% of its net accounts receivable for the years ended December 31, 2024 and 2023,
respectively.</span></p>

<p id="xdx_898_eus-gaap--SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_zUwJC7G3vMd4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span id="xdx_8BF_ziuviCdUkIG6" style="display: none">Schedule of Customer Accounts Receivable</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Percentage
    of Net Accounts</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Percentage
    of Net Accounts</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2024</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Receivable</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2023</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> Receivable</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 36%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Customer
    A</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>$</b></span></td><td id="xdx_98A_eus-gaap--AccountsReceivableNet_iI_c20241231__srt--MajorCustomersAxis__custom--CustomerAMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zGVtJHY4ngni" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right" title="Net accounts receivable"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">119,616</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20240101__20241231__srt--MajorCustomersAxis__custom--CustomerAMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_ztfwx0Pn3dvb" title="Risk percentage">49</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>$</b></span></td><td id="xdx_985_eus-gaap--AccountsReceivableNet_iI_c20231231__srt--MajorCustomersAxis__custom--CustomerAMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zKXzKALlmJz7" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right" title="Net accounts receivable"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0940">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_901_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20231231__srt--MajorCustomersAxis__custom--CustomerAMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_z9o22JCbwIjb" title="Risk percentage">0</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Customer
    B</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98C_eus-gaap--AccountsReceivableNet_iI_c20241231__srt--MajorCustomersAxis__custom--CustomerBMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zR77yBuhHffb" style="font: bold 10pt Times New Roman, Times, Serif; text-align: right" title="Net accounts receivable"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0944">-</span></span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_905_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20240101__20241231__srt--MajorCustomersAxis__custom--CustomerBMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_z9SVmlN18mH9" title="Risk percentage">0</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98B_eus-gaap--AccountsReceivableNet_iI_c20231231__srt--MajorCustomersAxis__custom--CustomerBMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zDCakzXb5lvc" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Net accounts receivable"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">23,900</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20231231__srt--MajorCustomersAxis__custom--CustomerBMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zYReW668WMIf" title="Risk percentage">28</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Customer
    C</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_985_eus-gaap--AccountsReceivableNet_iI_c20241231__srt--MajorCustomersAxis__custom--CustomerCMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zECBJOkoPFzh" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Net accounts receivable"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">22,799</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_907_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20240101__20241231__srt--MajorCustomersAxis__custom--CustomerCMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zCoq7BCeaAUd" title="Risk percentage">9</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98A_eus-gaap--AccountsReceivableNet_iI_c20231231__srt--MajorCustomersAxis__custom--CustomerCMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zSmayTQpiaTa" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Net accounts receivable"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">14,401</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90D_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20231231__srt--MajorCustomersAxis__custom--CustomerCMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_z058r726xm0j" title="Risk percentage">17</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Customer
    D</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_989_eus-gaap--AccountsReceivableNet_iI_c20241231__srt--MajorCustomersAxis__custom--CustomerDMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_ziWgXs4rhsT5" style="font: bold 10pt Times New Roman, Times, Serif; text-align: right" title="Net accounts receivable"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0960">-</span></span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_905_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20240101__20241231__srt--MajorCustomersAxis__custom--CustomerDMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zSEvYV8lKLbh" title="Risk percentage">0</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_987_eus-gaap--AccountsReceivableNet_iI_c20231231__srt--MajorCustomersAxis__custom--CustomerDMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zgOcWsNkjKF1" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Net accounts receivable"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">23,982</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_909_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20231231__srt--MajorCustomersAxis__custom--CustomerDMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zlZgVpBjp056" title="Risk percentage">28</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Customer
    E</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98E_eus-gaap--AccountsReceivableNet_iI_c20241231__srt--MajorCustomersAxis__custom--CustomerEMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zl2qNb56zJwh" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right" title="Net accounts receivable"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0968">-</span></span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90F_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20240101__20241231__srt--MajorCustomersAxis__custom--CustomerEMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zqDT0bFj4H1k" title="Risk percentage">0</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98E_eus-gaap--AccountsReceivableNet_iI_c20231231__srt--MajorCustomersAxis__custom--CustomerEMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zwaoP8QxF9Bf" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Net accounts receivable"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">9,599</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_901_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20231231__srt--MajorCustomersAxis__custom--CustomerEMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zyXKzz43jjZf" title="Risk percentage">11</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>$</b></span></td><td id="xdx_986_eus-gaap--AccountsReceivableNet_iI_c20241231__srt--MajorCustomersAxis__custom--CustomerMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_z1Hroo9j0F5k" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Net accounts receivable"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">142,415</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_902_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20240101__20241231__srt--MajorCustomersAxis__custom--CustomerMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zvYJPTm3tgrf" title="Risk percentage">58</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>$</b></span></td><td id="xdx_98E_eus-gaap--AccountsReceivableNet_iI_c20231231__srt--MajorCustomersAxis__custom--CustomerMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_z3M4Bf5OFDta" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Net accounts receivable"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">71,882</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_906_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20231231__srt--MajorCustomersAxis__custom--CustomerMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zHYTFLfnmKr" title="Risk percentage">84</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr>
  </table>
<p id="xdx_8AC_zCXEfpOPYya" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
table below sets forth the Company&#8217;s customers that accounted for greater than 10% of its net sales for the years ended
December 31, 2024 and 2023, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_896_eus-gaap--ContractWithCustomerAssetAllowanceForCreditLossTableTextBlock_zkkwaR2En4R4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span id="xdx_8BA_z9EQpd6TmZ1d" style="display: none">Schedule of Customers Accounted Revenues</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Percentage of</td><td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Percentage of</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Net Sales</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Net Sales</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 36%; text-align: left">Customer A</td><td style="width: 2%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">$</td><td id="xdx_98B_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20240101__20241231__srt--MajorCustomersAxis__custom--CustomerAMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zhKwbiXDFFs3" style="width: 12%; font-weight: bold; text-align: right" title="Revenue">521,810</td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right"><span id="xdx_903_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20240101__20241231__srt--MajorCustomersAxis__custom--CustomerAMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zklF9jeBuOtg" title="Risk percentage">20</span></td><td style="width: 1%; text-align: left">%</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_986_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20230101__20231231__srt--MajorCustomersAxis__custom--CustomerAMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zHFwu8jqdfzh" style="width: 12%; text-align: right" title="Revenue">452,680</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right"><span id="xdx_908_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20231231__srt--MajorCustomersAxis__custom--CustomerAMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zUGo6Jpa5fgl" title="Risk percentage">18</span></td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Customer B</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20240101__20241231__srt--MajorCustomersAxis__custom--CustomerBMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zbvEOGjsePt8" style="font-weight: bold; text-align: right" title="Revenue">396,950</td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90C_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20240101__20241231__srt--MajorCustomersAxis__custom--CustomerBMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_z6L6EIm7A9m7" title="Risk percentage">15</span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20230101__20231231__srt--MajorCustomersAxis__custom--CustomerBMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zLhqQLg76db" style="text-align: right" title="Revenue">382,082</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_909_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20231231__srt--MajorCustomersAxis__custom--CustomerBMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zACbxoOC2pSe" title="Risk percentage">16</span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Customer C</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20240101__20241231__srt--MajorCustomersAxis__custom--CustomerCMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zswU6SLkue39" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right" title="Revenue">142,270</td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_904_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20240101__20241231__srt--MajorCustomersAxis__custom--CustomerCMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_z2crm1yRVs5d" title="Risk percentage">5</span></td><td style="padding-bottom: 1pt; text-align: left">%</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20230101__20231231__srt--MajorCustomersAxis__custom--CustomerCMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zWVmxOqlJMFc" style="border-bottom: Black 1pt solid; text-align: right" title="Revenue">274,581</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_906_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20231231__srt--MajorCustomersAxis__custom--CustomerCMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zs8Tc7rodGKf" title="Risk percentage">11</span></td><td style="padding-bottom: 1pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">$</td><td id="xdx_989_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20240101__20241231__srt--MajorCustomersAxis__custom--CustomerMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zpQ98lLEyvZa" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right" title="Revenue">1,061,030</td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_90E_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20240101__20241231__srt--MajorCustomersAxis__custom--CustomerMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zLqb9DZOwDyh" title="Risk percentage">40</span></td><td style="padding-bottom: 1pt; text-align: left">%</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_98E_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20230101__20231231__srt--MajorCustomersAxis__custom--CustomerMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zuCpenm53Myd" style="border-bottom: Black 1pt solid; text-align: right" title="Revenue">1,109,343</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_909_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20231231__srt--MajorCustomersAxis__custom--CustomerMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zV0CREuaTTec" title="Risk percentage">45</span></td><td style="padding-bottom: 1pt; text-align: left">%</td></tr>
  </table>

<p id="xdx_8A8_zQMCLDFvtWn5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">From
time to time, the Company&#8217;s bank balances may exceed the FDIC limit of $<span id="xdx_901_eus-gaap--CashFDICInsuredAmount_iI_c20241231_zo5mHRQzxyD1" title="Cash, FDIC insured amount">250,000</span>.
As of December 31, 2024 and 2023, the Company had $<span id="xdx_901_eus-gaap--CashUninsuredAmount_iI_c20241231_zJJUkOAzfSya" title="Cash uninsured">3,263,618</span>
and $<span id="xdx_909_eus-gaap--CashUninsuredAmount_iI_c20231231_zQEDtlFPjsD" title="Cash uninsured">0</span> of its cash balance
uninsured, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84E_ecustom--GoingConcernPolicyTextBlock_zs8TSICVHdrc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_864_z7ogNBVMc5Kh">Going
Concern</span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have incurred losses since inception and have funded our operations primarily with a combination of sales, debt, and the sale of capital
stock. As of December 31, 2024, we had stockholders&#8217; equity of $<span id="xdx_908_eus-gaap--StockholdersEquity_iI_c20241231_zcrwDhOD4KL9" title="Stockholders' equity">2,067,748</span>, short-term outstanding borrowings of $<span id="xdx_901_eus-gaap--ShortTermBorrowings_iI_c20241231_zcj9tEASlJp6" title="Short term borrowings outstanding">154,152</span>, cash
of $<span id="xdx_909_eus-gaap--Cash_iI_c20241231_zqeGWmRH93nf" title="Cash">3,696,870</span> and a working capital surplus of $<span id="xdx_907_ecustom--WorkingCapitalDeficit_iI_c20241231_zeQGhPzPxHu3" title="Working capital surplus">1,832,858</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Neuraxis,
Inc.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Notes
to Financial Statements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
future capital requirements will depend upon many factors, including progress with developing, manufacturing, and marketing our technologies,
the time and costs involved in preparing, filing, prosecuting, maintaining, and enforcing patent claims and other proprietary rights,
our ability to establish collaborative arrangements, marketing activities and competing technological and market developments, including
regulatory changes and overall economic conditions in our target markets. Our ability to generate revenue and achieve profitability requires
us to successfully market and secure purchase orders for our products from customers currently identified in our sales pipeline and to
new customers as well. The primary activity that will drive all customers and revenues is the adoption of insurance coverage by commercial
insurance carriers nationally which is a top priority of the Company. These activities, including our planned research and development
efforts, will require significant uses of working capital through the rest of 2025 and beyond. Based on our current operating plans,
we believe that our existing cash at the time of this filing will only be sufficient to meet our anticipated operating needs before the
end of 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management
evaluates whether there are conditions or events that raise substantial doubt about the Company&#8217;s ability to continue as a going
concern for a period of one year from the date the financial statements are issued.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
date, the Company has experienced operating losses and negative cash flows from operations. Management believes that increased sales
and acceptance of their product by insurance providers will allow the Company to achieve profitability in the future.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">While
the Company believes in the viability of its strategy to further implement its business plan and generate sufficient revenues and in
its ability to raise additional funds by way of a public or private offering of its debt or equity securities, there can be no assurance
that it will be able to do so on reasonable terms, or at all. The ability of the Company to continue as a going concern is dependent
upon its ability to further implement its business plan and generate sufficient revenues and its ability to raise additional funds by
way of a public or private offering. Neither future cash generated from operating activities, nor management&#8217;s contingency plans
to mitigate the risk and extend cash resources through the evaluation period, are considered probable. As a result, substantial doubt
is deemed to exist about the Company&#8217;s ability to continue as a going concern. As we continue to incur losses, our transition to
profitability is dependent upon achieving a level of revenues adequate to support its cost structure. We may never achieve profitability,
and unless and until doing so, we intend to fund future operations through additional dilutive or nondilutive financing. There can be
no assurances, however, that additional funding will be available on terms acceptable to us, if at all.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
financial statements do not include any adjustments related to the recoverability and classification of recorded asset amounts or the
amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84D_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zcEfnqT2G8F2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_862_zHoVgdNJrcdl">Recently
Adopted Accounting Pronouncements</span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
November 2023, the FASB issued Accounting Standards Update (&#8220;ASU&#8221;) 2023-07, <i>Segment Reporting (Topic 280): Improvements
to Reportable Segment Disclosures</i>, which requires disclosure of (i) significant segment expenses, (ii) other segment items and (iii)
the title and position of the Chief Operating Decision Maker (&#8220;CODM&#8221;) on an annual and interim basis. Additionally, ASU 2023-07
requires that a public entity that has a single reportable segment provide all the disclosures required by Topic 280. Public business
entities are required to adopt the standard for fiscal years beginning after December 15, 2023 and interim periods withing fiscal year
beginning after December 15, 2024. Disclosures are required for all prior periods presented in the financial statements. The Company
adopted the disclosure provisions of ASU 2023-07 as of December 31, 2024 as operations are managed through one reportable segment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
June 2016, the FASB issued ASU 2016-13, <i>Financial Instruments &#8211; Credit Losses (Topic 326): Measurement of Credit Losses on Financial
Instruments</i>, which requires measurement and recognition of expected credit losses for financial assets held and enhanced disclosures
regarding significant estimates and judgments used in estimating credit losses. In November 2019, the FASB issued ASU 2019-10, Financial
Instruments &#8211; Credit Losses (Topic 326), Derivatives and Hedging (Topic 815) and Leases (Topic 842): Effective Dates, which amended
the effective date of ASU 2016-13. Public business entities meeting the definition of an SEC filer, excluding entities eligible to be
a Smaller Reporting Company (&#8220;SRC&#8221;) as defined by the SEC, are required to adopt the standard for fiscal years beginning
after December 15, 2019, including interim periods within those fiscal years. All other entities are required to adopt the standard for
fiscal years beginning after December 15, 2022, including interim periods within those fiscal years. The Company meets the definition
of an SRC and therefore the standard was adopted as of January 1, 2023. The adoption of this guidance did not have a material impact
on the Company&#8217;s financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_840_ecustom--RecentlyIssuedAccountingPronouncementsPolicyTextBlock_zjKjcdN7Te33" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_86A_zxIiHNzeegpc">Recently
Issued Accounting Pronouncements</span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
November 2024, the FASB issued ASU 2024-03, <i>Income Statement&#8212;Reporting Comprehensive Income&#8212;Expense Disaggregation Disclosures
(Subtopic (220-40): Disaggregation of Income Statement Expenses</i>, which requires disclosures that disaggregate, in a tabular presentation,
each relevant expense caption on the face of the income statement that includes inventory purchases, employee compensation, depreciation
and intangible amortization expense. Additional disclosures are also required to provide a qualitative description of the amounts in
an expense caption that are not separately disaggregated quantitatively and the total amount of selling expenses including a definition.
Public business entities are required to adopt the standard for fiscal years beginning after December 15, 2026 and interim periods within
fiscal years beginning after December 15, 2027. Disclosures are required for all prior periods presented in the financial statements.
Although the standard requires enhanced disclosures, the adoption is not expected to have a material impact on the Company&#8217;s financial
statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
December 2023, the FASB issued ASU 2023-09, <i>Income Taxes (Topic 740): Improvements to Income Tax Disclosures</i>, which requires the
enhancement of income tax disclosures to provide better insight into how an entity&#8217;s operations and related tax risks, planning
and opportunities affect its tax rate and prospects for future cash flows. The enhanced disclosures require (i) specific categories in
a tabular rate reconciliation including both amounts and percentages and (ii) additional information for reconciling items and income
tax paid that meet a quantitative threshold. Public business entities are required to adopt the standard for annual periods beginning
after December 15, 2024. All other entities are required to adopt the standard for annual periods beginning after December 15, 2025.
The adoption of the standard is not expected to have a material impact on the Company&#8217;s financial statements.</span></p>

<p id="xdx_85C_zHvhrIrV3o8d" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Neuraxis,
Inc.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Notes
to Financial Statements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/235/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related Party Transactions</a></td>
<td class="text"><p id="xdx_80E_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_zw3qdvYP29ce" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>3.
<span id="xdx_823_zxseoGpv3kuf">Related Party Transactions</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has two demand notes receivable from shareholders related to the sale of common stock on January 1, 2016. Both notes&#8217; initial
balances were $<span id="xdx_90D_eus-gaap--NotesAndLoansReceivableGrossCurrent_iI_c20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ShareholdersOneAndTwoMember_zYT7P04QrYh9" title="Loan Receivable">506,400</span>, with interest calculated monthly based on applicable federal rates. No payments have been received on the notes.
Since repayment is not assured, the Company has fully reserved for the entire balance of principal and interest. The current allowance
is $<span id="xdx_90D_ecustom--AllowanceForInterestReceivableCurrent_iI_c20241231_zKAxBF9ZSgWc" title="Allowance for interest receivable current">1,201,367</span> as of December 31, 2024. The current loan balances are as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_89C_eus-gaap--ScheduleOfRelatedPartyTransactionsTableTextBlock_zOv4aX3fMcwj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span><span id="xdx_8B6_zby8DV48UlMe" style="display: none">Schedule of Related Party Transactions</span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Loan</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Interest</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Interest</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-weight: bold">December 31, 2024</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Receivable</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Receivable</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Income</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%">Shareholder 1</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_984_eus-gaap--NotesAndLoansReceivableGrossCurrent_iI_c20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ShareHolderOneMember_zWFF6fDKgOOh" style="width: 12%; text-align: right" title="Loan Receivable">506,400</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--InterestReceivableCurrent_iI_c20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ShareHolderOneMember_zhO2kKTUPrH7" style="width: 12%; text-align: right" title="Interest Receivable">94,351</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_986_ecustom--InterestIncomeGrossCurrent_iI_c20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ShareHolderOneMember_zGv6Q28DbLFb" style="width: 12%; text-align: right" title="Interest Income">23,413</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt">Shareholder 2</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--NotesAndLoansReceivableGrossCurrent_iI_c20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ShareHolderTwoMember_zk0nJ4TbCeT6" style="border-bottom: Black 1pt solid; text-align: right" title="Loan Receivable">506,400</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--InterestReceivableCurrent_iI_c20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ShareHolderTwoMember_zvYvtR6VyOQ5" style="border-bottom: Black 1pt solid; text-align: right" title="Interest Receivable">94,216</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_985_ecustom--InterestIncomeGrossCurrent_iI_c20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ShareHolderTwoMember_zDlrgzmboFb6" style="border-bottom: Black 1pt solid; text-align: right" title="Interest Income">23,413</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt">Principal Balance</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--NotesAndLoansReceivableGrossCurrent_iI_c20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_ztUVY7XqRxSd" style="text-align: right" title="Loan Receivable">1,012,800</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--InterestReceivableCurrent_iI_c20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zjTDLXBg8xha" style="text-align: right" title="Interest Receivable">188,567</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_ecustom--InterestIncomeGrossCurrent_iI_c20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zCgEEzRhYDy" style="text-align: right" title="Interest Income">46,826</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Allowance for Collection Risk</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--AllowanceForNotesAndLoansReceivableCurrent_iNI_di_c20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zfyohD0vh37l" style="border-bottom: Black 1pt solid; text-align: right" title="Allowance for collection risk, loan receivable">(1,012,800</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98D_ecustom--AllowanceForInterestReceivableCurrent_iI_c20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zVYzxHfKGjzl" style="border-bottom: Black 1pt solid; text-align: right" title="Allowance for collection risk, interest receivable">(188,567</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_988_ecustom--AllowanceForInterestIncomeCurrent_iNI_di_c20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zzOQmVoFft9" style="border-bottom: Black 1pt solid; text-align: right" title="Allowance for collection risk, interest income">(46,826</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Net Balance</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_98B_eus-gaap--NotesAndLoansReceivableNetCurrent_iI_c20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zWhNsIQX3dT1" style="border-bottom: Black 1pt solid; text-align: right" title="Loan Receivable"><span style="-sec-ix-hidden: xdx2ixbrl1070">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_989_eus-gaap--InterestReceivable_iI_c20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zYN9wmZutSp4" style="border-bottom: Black 1pt solid; text-align: right" title="Interest Receivable"><span style="-sec-ix-hidden: xdx2ixbrl1072">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_98E_ecustom--InterestIncomeCurrent_iI_c20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zJz5EcU2SFMh" style="border-bottom: Black 1pt solid; text-align: right" title="Interest Income"><span style="-sec-ix-hidden: xdx2ixbrl1074">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Loan</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Interest</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Interest</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-weight: bold">December 31, 2023</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Receivable</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Receivable</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Income</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%">Shareholder 1</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--NotesAndLoansReceivableGrossCurrent_iI_c20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ShareHolderOneMember_zWSabdjGXQL1" style="width: 12%; text-align: right" title="Loan Receivable">506,400</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_988_eus-gaap--InterestReceivableCurrent_iI_c20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ShareHolderOneMember_zDPEXZk6ETm2" style="width: 12%; text-align: right" title="Interest Receivable">70,938</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_982_ecustom--InterestIncomeGrossCurrent_iI_c20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ShareHolderOneMember_zY8vYDQbfVG3" style="width: 12%; text-align: right" title="Interest Income">23,867</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt">Shareholder 2</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--NotesAndLoansReceivableGrossCurrent_iI_c20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ShareHolderTwoMember_zeI6ZkI1sNy" style="border-bottom: Black 1pt solid; text-align: right" title="Loan Receivable">506,400</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--InterestReceivableCurrent_iI_c20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ShareHolderTwoMember_zGzV0Q4plaJ9" style="border-bottom: Black 1pt solid; text-align: right" title="Interest Receivable">70,803</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_981_ecustom--InterestIncomeGrossCurrent_iI_c20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ShareHolderTwoMember_zvRaHSTC4382" style="border-bottom: Black 1pt solid; text-align: right" title="Interest Income">23,867</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt">Principal Balance</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--NotesAndLoansReceivableGrossCurrent_iI_c20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zQi2kWkjffrh" style="text-align: right" title="Loan Receivable">1,012,800</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--InterestReceivableCurrent_iI_c20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zKHhhwuk6iJ8" style="text-align: right" title="Interest Receivable">141,741</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_ecustom--InterestIncomeGrossCurrent_iI_c20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zosHxJYGrgxj" style="text-align: right" title="Interest Income">47,734</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Allowance for Collection Risk</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--AllowanceForNotesAndLoansReceivableCurrent_iNI_di_c20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zfx5avVhZnK4" style="border-bottom: Black 1pt solid; text-align: right" title="Allowance for collection risk, loan receivable">(1,012,800</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98A_ecustom--AllowanceForInterestReceivableCurrent_iI_c20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_z3W1QciT6pS" style="border-bottom: Black 1pt solid; text-align: right" title="Allowance for collection risk, interest receivable">(141,741</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98A_ecustom--AllowanceForInterestIncomeCurrent_iNI_di_c20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zIEXyFnrGwx3" style="border-bottom: Black 1pt solid; text-align: right" title="Allowance for collection risk, interest income">(47,734</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Net Balance</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_98E_eus-gaap--NotesAndLoansReceivableNetCurrent_iI_c20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zhXSahQJ7MP1" style="border-bottom: Black 1pt solid; text-align: right" title="Loan Receivable"><span style="-sec-ix-hidden: xdx2ixbrl1100">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_98E_eus-gaap--InterestReceivable_iI_c20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zuNWYHRuzlIg" style="border-bottom: Black 1pt solid; text-align: right" title="Interest Receivable"><span style="-sec-ix-hidden: xdx2ixbrl1102">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_98D_ecustom--InterestIncomeCurrent_iI_c20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_z4gJ4dE3iUN2" style="border-bottom: Black 1pt solid; text-align: right" title="Interest Income"><span style="-sec-ix-hidden: xdx2ixbrl1104">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A4_zeWOMVKmkwK1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has loans payable to shareholders related to funding needs for operations. The current loan details for all related party loans
are as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_891_ecustom--ScheduleOfRelatedPartyLoansTableTextBlock_zYPySHBVmcS7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B0_zf8TjuMlvU4c" style="display: none">Schedule of Related Party Loans payable to shareholder</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Interest &amp;</td><td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Interest</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Loan</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Service Fee</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Interest</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-weight: bold">December 31, 2024</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Due Date</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Rate</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Balance</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Accrued</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Paid</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 30%; text-align: left; padding-bottom: 1pt">Other Convertibles</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="width: 12%; text-align: center; padding-bottom: 1pt"><span id="xdx_90D_eus-gaap--DebtInstrumentMaturityDateDescription_c20240101__20241231__us-gaap--DebtInstrumentAxis__custom--OtherConvertiblesMember_ztlLQ0Sr0av9" title="Due date">Various</span></td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; width: 1%; text-align: left">&#160;</td><td style="padding-bottom: 1pt; width: 10%; text-align: center"><span id="xdx_908_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_dp_uPure_c20241231__us-gaap--DebtInstrumentAxis__custom--OtherConvertiblesMember_zqSoAz84D45j" title="Debt instrument percentage">5.0</span>%</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--LoansPayable_iI_c20241231__us-gaap--DebtInstrumentAxis__custom--OtherConvertiblesMember_zWABE9Cu0pab" style="border-bottom: Black 1pt solid; width: 10%; text-align: right" title="Interest payable"><span style="-sec-ix-hidden: xdx2ixbrl1112">&#8212;</span></td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">&#160;</td><td id="xdx_983_ecustom--InterestAndServiceFeeAccrued_iI_c20241231__us-gaap--DebtInstrumentAxis__custom--OtherConvertiblesMember_zfhfCYXJY2w2" style="border-bottom: Black 1pt solid; width: 10%; text-align: right" title="Interest payable">66,648</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--InterestPaid_c20240101__20241231__us-gaap--DebtInstrumentAxis__custom--OtherConvertiblesMember_z57rRBACUFUg" style="border-bottom: Black 1pt solid; width: 10%; text-align: right" title="Interest payable"><span style="-sec-ix-hidden: xdx2ixbrl1116">&#8212;</span></td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; font-weight: bold; padding-bottom: 1pt">Total</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_98C_eus-gaap--LoansPayable_iI_c20241231_zPLJkVYOokw9" style="border-bottom: Black 1pt solid; text-align: right" title="Loan payable"><span style="-sec-ix-hidden: xdx2ixbrl1118">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_984_ecustom--InterestAndServiceFeeAccrued_iI_c20241231_zuHlAygaJSw6" style="border-bottom: Black 1pt solid; text-align: right" title="Interest payable">66,648</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_981_eus-gaap--InterestPaid_c20240101__20241231_z8Wm1dCWuYgg" style="border-bottom: Black 1pt solid; text-align: right" title="Interest payable"><span style="-sec-ix-hidden: xdx2ixbrl1122">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Interest &amp;</td><td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Interest</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Loan</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Service Fee</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Interest</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-weight: bold">December 31, 2023</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Due Date</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Rate</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Balance</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Accrued</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Paid</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 30%">Shareholder 1</td><td style="width: 2%">&#160;</td>
    <td style="width: 12%; text-align: center"><span id="xdx_90B_eus-gaap--DebtInstrumentMaturityDateDescription_c20230101__20231231__us-gaap--DebtInstrumentAxis__custom--ShareHolderOneMember_zD7Nd8CcgBnk" title="Due date">June, 2019</span></td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 10%; text-align: center"><span id="xdx_90A_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_dp_uPure_c20231231__us-gaap--DebtInstrumentAxis__custom--ShareHolderOneMember_zLgE9AFgTgab" title="Debt instrument percentage">15.0</span>%</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_eus-gaap--LoansPayable_iI_c20231231__us-gaap--DebtInstrumentAxis__custom--ShareHolderOneMember_zN3dNK2VXGv6" style="width: 10%; text-align: right" title="Loan payable"><span style="-sec-ix-hidden: xdx2ixbrl1128">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_983_ecustom--InterestAndServiceFeeAccrued_iI_c20231231__us-gaap--DebtInstrumentAxis__custom--ShareHolderOneMember_zFgriPhYsCj9" style="width: 10%; text-align: right" title="Interest payable"><span style="-sec-ix-hidden: xdx2ixbrl1130">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--InterestPaid_c20230101__20231231__us-gaap--DebtInstrumentAxis__custom--ShareHolderOneMember_zQME5pjAHsJ8" style="width: 10%; text-align: right" title="Interest payable">10,047</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Shareholder 2</td><td>&#160;</td>
    <td style="text-align: center"><span id="xdx_902_eus-gaap--DebtInstrumentMaturityDateDescription_c20230101__20231231__us-gaap--DebtInstrumentAxis__custom--ShareHolderTwoMember_zpH8ZXwFTij3" title="Due date">June, 2019</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center"><span id="xdx_903_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_dp_uPure_c20231231__us-gaap--DebtInstrumentAxis__custom--ShareHolderTwoMember_zf0NRnHbYLxf" title="Debt instrument percentage">15.0</span>%</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--LoansPayable_iI_c20231231__us-gaap--DebtInstrumentAxis__custom--ShareHolderTwoMember_zqeyWtHDawre" style="text-align: right" title="Loan payable"><span style="-sec-ix-hidden: xdx2ixbrl1138">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_ecustom--InterestAndServiceFeeAccrued_iI_c20231231__us-gaap--DebtInstrumentAxis__custom--ShareHolderTwoMember_zwizrWGlHZB" style="text-align: right" title="Interest payable"><span style="-sec-ix-hidden: xdx2ixbrl1140">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--InterestPaid_c20230101__20231231__us-gaap--DebtInstrumentAxis__custom--ShareHolderTwoMember_zqcl1NyjQVI5" style="text-align: right" title="Interest payable">27,056</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Other Convertibles</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1pt"><span id="xdx_90B_eus-gaap--DebtInstrumentMaturityDateDescription_c20230101__20231231__us-gaap--DebtInstrumentAxis__custom--OtherConvertiblesMember_zdURnn0ve00d" title="Due date">Various</span></td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: center"><span id="xdx_90E_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_dp_uPure_c20231231__us-gaap--DebtInstrumentAxis__custom--OtherConvertiblesMember_zHHONbcvNHPk" title="Debt instrument percentage">5.0</span>%</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--LoansPayable_iI_c20231231__us-gaap--DebtInstrumentAxis__custom--OtherConvertiblesMember_zsriqlzXJhOg" style="border-bottom: Black 1pt solid; text-align: right" title="Interest payable"><span style="-sec-ix-hidden: xdx2ixbrl1148">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98B_ecustom--InterestAndServiceFeeAccrued_iI_c20231231__us-gaap--DebtInstrumentAxis__custom--OtherConvertiblesMember_zteqJglcLHv9" style="border-bottom: Black 1pt solid; text-align: right" title="Interest payable">66,648</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--InterestPaid_c20230101__20231231__us-gaap--DebtInstrumentAxis__custom--OtherConvertiblesMember_zdCzgHVG7OMf" style="border-bottom: Black 1pt solid; text-align: right" title="Interest payable"><span style="-sec-ix-hidden: xdx2ixbrl1152">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; font-weight: bold; padding-bottom: 1pt">Total</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_985_eus-gaap--LoansPayable_iI_c20231231_z7ORZjjvl3zc" style="border-bottom: Black 1pt solid; text-align: right" title="Loan payable"><span style="-sec-ix-hidden: xdx2ixbrl1154">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_98E_ecustom--InterestAndServiceFeeAccrued_iI_c20231231_zk4ROeNOQu59" style="border-bottom: Black 1pt solid; text-align: right" title="Interest payable">66,648</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_982_eus-gaap--InterestPaid_c20230101__20231231_zxw0Nw7EIlJ4" style="border-bottom: Black 1pt solid; text-align: right" title="Interest payable">37,103</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A2_zFWiTm1MloAl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company was granted an exclusive, worldwide non-transferable, royalty-free license for the auricular portion of certain patents owned
by a limited liability company in which the Company&#8217;s President and Chief Executive Officer and Chief Regulatory, Compliance and
Privacy Officer both maintain an ownership interest. The license allows for the development, marketing and sales of electro-therapy treatments
by stimulation of cranial nerves, cranial nerve branches, auricular nerves, auricular nerve branches, auricular nerve bundles and auricular
anatomical structures in human patient. The exclusive license agreement expires on October 18, 2037, may be terminated by either party
upon 60 days prior written notice and requires the Company to pay costs associated with the maintenance, prosecution and continuation
of patent filings. For the year ended December 31, 2024, the Company paid the limited liability company $<span id="xdx_90A_eus-gaap--RelatedPartyTransactionAmountsOfTransaction_c20240101__20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zYxMPwjCzXU6" title="Limited liability">4,973</span>. No costs were incurred
during the year ended December 31, 2023. No amounts were owed to the limited liability company as of December 31, 2024 and 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr.
Bradley Mitch Watkins, Director, provided certain sales, marketing and commercialization consulting services to the Company prior to
his appointment to the Board of Directors. For the years ended December 31, 2024 and 2023, the Company paid Mr. Watkins $<span id="xdx_900_eus-gaap--RelatedPartyTransactionAmountsOfTransaction_c20240101__20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MrWatkinsMember_zEnDK5sjmQV3" title="Related party transaction amounts">0</span> and $<span id="xdx_907_eus-gaap--RelatedPartyTransactionAmountsOfTransaction_c20230101__20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MrWatkinsMember_zm5F2kSv1wZc" title="Related party transaction amounts">11,083</span>,
respectively. No amounts were owed to Mr. Watkins as of December 31, 2024 and 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s former Chief Financial Officer provides certain accounting and tax services on a continuous basis through a
third-party public accounting firm. He is the third-party public accounting firm&#8217;s managing partner and majority shareholder.
Fees paid for services were $<span id="xdx_907_eus-gaap--PaymentsForFees_c20240101__20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MrSealeMember_zMQRtP7A6AP5" title="Fees paid for services">207,103</span>
and $<span id="xdx_907_eus-gaap--PaymentsForFees_c20230101__20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MrSealeMember_zkxBH472uiVg" title="Fees paid for services">312,803</span>
for the years ended December 31, 2024 and 2023, respectively. The Company owed the third-party accounting firm for open invoices of
$<span id="xdx_903_eus-gaap--AccountsPayableCurrentAndNoncurrent_iI_c20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MrSealeMember_zTGy1xM9AsP" title="Accounts payable">4,173</span>
and $<span id="xdx_90A_eus-gaap--AccountsPayableCurrentAndNoncurrent_iI_c20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MrSealeMember_z0G24SXdEhAe" title="Accounts payable">84,279</span>
that are included in accounts payable as of December 31, 2024 and 2023, respectively. On June 28, 2024, the Company also issued <span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20240101__20241231__srt--TitleOfIndividualAxis__srt--ChiefFinancialOfficerMember_zQRfkfn74ZKb" title="Stock issued during period shares issued for services">20,000</span>
common shares with a fair value $<span id="xdx_904_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_c20240101__20241231__srt--TitleOfIndividualAxis__srt--ChiefFinancialOfficerMember_z2a6VJQXiZH8" title="Stock issued during period value  issued for services">55,600</span>
to the former</span> Chief Financial Officer for services rendered during the IPO process.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Neuraxis,
Inc.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Notes
to Financial Statements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(e))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/850/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-6<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property and Equipment</a></td>
<td class="text"><p id="xdx_80F_eus-gaap--PropertyPlantAndEquipmentDisclosureTextBlock_zUFxuIJo0Bz4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>4.
<span id="xdx_82B_zGSUumEulbKl">Property and Equipment</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_898_eus-gaap--PropertyPlantAndEquipmentTextBlock_zZExnw39C8Mb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property
and equipment, net consists of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span id="xdx_8BD_zSpbTDAq6AI2" style="display: none">Schedule of Property And Equipment</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_492_20241231_z1L83aOgT7Ca" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, 2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49A_20231231_zX9lQ20XfjUh" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, 2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--MachineryAndEquipmentMember_zheELRMbM1pg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Machinery and equipment</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">282,181</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">282,181</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zgoPHiIyxVKh" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Furniture and fixtures</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">111,036</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">96,768</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_zQoYCrk5twy" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Computer hardware</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">50,121</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">36,613</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zidW0RfYiTCe" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Leasehold improvements</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">21,064</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">21,064</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--PropertyPlantAndEquipmentGross_iI_maPPAENzDOd_zAkjgdLgKp1c" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Total property and equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">464,402</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">436,626</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_di_msPPAENzDOd_zjVmdbF0MLib" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Less: accumulated depreciation</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(374,420</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(348,074</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_409_eus-gaap--PropertyPlantAndEquipmentNet_iTI_mtPPAENzDOd_zctvrjFcVVIl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: left; padding-bottom: 1pt">Property and equipment, net</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">89,982</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">88,552</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A8_z94iI4eYJHYa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Depreciation
expense was $<span id="xdx_904_eus-gaap--Depreciation_c20240101__20241231_zsy0uhxgb9Ch" title="Depreciation">26,346</span></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">and
$<span id="xdx_909_eus-gaap--Depreciation_c20230101__20231231_z1e82Ze8LH4j" title="Depreciation">30,240</span></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">for
the years ended December 31, 2024 and 2023, respectively. The Company expects to record future depreciation expense totaling $<span id="xdx_90D_eus-gaap--Depreciation_c20240101__20241231__us-gaap--AwardTypeAxis__custom--DecemberTwoThousandTwentyFiveMember_zkjKxXzQIcy4" title="Depreciation">13,438</span>,
$<span id="xdx_903_eus-gaap--Depreciation_c20240101__20241231__us-gaap--AwardTypeAxis__custom--DecemberTwoThousandTwentySixMember_z3NxraUtaX4c" title="Depreciation">12,344</span>, $<span id="xdx_90B_eus-gaap--Depreciation_c20240101__20241231__us-gaap--AwardTypeAxis__custom--DecemberTwoThousandTwentySevenMember_zYV9ind1ph5d" title="Depreciation">11,977</span>, $<span id="xdx_907_eus-gaap--Depreciation_c20240101__20241231__us-gaap--AwardTypeAxis__custom--DecemberTwoThousandTwentyEightMember_zwE12gHhqe9a" title="Depreciation">9,753</span>, $<span id="xdx_907_eus-gaap--Depreciation_c20240101__20241231__us-gaap--AwardTypeAxis__custom--DecemberTwoThousandTwentyNineMember_ztixW5WddXW8" title="Depreciation">6,259</span> and $<span id="xdx_90D_eus-gaap--Depreciation_c20240101__20241231__us-gaap--AwardTypeAxis__custom--DecemberTwoThousandTwentyThereafterMember_zrjbQb1vUUYe" title="Depreciation">14,111</span> for the years ending December 31, 2025, 2026, 2027, 2028, 2029 and thereafter, respectively.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/360/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsDisclosureTextBlock', window );">Intangible Assets</a></td>
<td class="text"><p id="xdx_800_eus-gaap--IntangibleAssetsDisclosureTextBlock_zIGckrcXtkNe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>5.
<span id="xdx_82C_zhiyZ8YSnib8">Intangible Assets</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_89A_eus-gaap--ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_z7HEvAFzd705" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Intangible
assets, net consists of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BF_ztWJTbv4oTL3" style="display: none">Schedule of Intangible Assets</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_493_20241231_zffQXKuWcn2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, 2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_498_20231231_z33gPHqBRVv2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, 2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_hus-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--SoftwareImplementationMember_z91J2gu0Mtek" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Software Implementation</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">49,815</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">49,815</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_hus-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zf6epMbZTE2h" style="vertical-align: bottom; background-color: White">
    <td>Patents</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">32,463</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">32,463</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_hus-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_z0qGsDlM50x4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Trademark</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">50,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">50,000</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_hus-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LicensesMember_zPayp6miIW38" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt">Licenses</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">1,000</td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">1,000</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_maFLIANzh0b_ziGX9bS4QS2a" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Total intangible assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">133,278</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">133,278</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iNI_di_msFLIANzh0b_zI6Tp7ZxyOE7" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Less: accumulated amortization</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(36,690</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(25,205</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_40F_eus-gaap--FiniteLivedIntangibleAssetsNet_iTI_mtFLIANzh0b_zP3Z51RAYuo1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: left; padding-bottom: 1pt">Intangible assets, net</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">96,588</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">108,073</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A1_zVo20MoPcPWd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amortization
expense was $<span id="xdx_907_eus-gaap--AmortizationOfIntangibleAssets_c20240101__20241231_zTMToDTzkRsf" title="Amortization expense">11,485</span>
and $<span id="xdx_907_eus-gaap--AmortizationOfIntangibleAssets_c20230101__20231231_zKXNJcVK7yUh" title="Amortization expense">10,485</span>
for the years ended December 31, 2024 and 2023, respectively. The Company expect to record future amortization expense totaling $<span id="xdx_90A_eus-gaap--AmortizationOfIntangibleAssets_c20240101__20241231__us-gaap--AwardTypeAxis__custom--DecemberTwoThousandTwentyFiveMember_z3T8gdPSqdxl" title="Amortization expense">10,485</span>, $<span id="xdx_909_eus-gaap--AmortizationOfIntangibleAssets_c20240101__20241231__us-gaap--AwardTypeAxis__custom--DecemberTwoThousandTwentySixMember_ztSoQDyy8PX5" title="Amortization expense">10,485</span>, $<span id="xdx_90F_eus-gaap--AmortizationOfIntangibleAssets_c20240101__20241231__us-gaap--AwardTypeAxis__custom--DecemberTwoThousandTwentySevenMember_z5FuQsYzAjXi" title="Amortization expense">10,485</span>, $<span id="xdx_90F_eus-gaap--AmortizationOfIntangibleAssets_c20240101__20241231__us-gaap--AwardTypeAxis__custom--DecemberTwoThousandTwentyEightMember_zjs5JWJzEcx8" title="Amortization expense">4,760</span>, $<span id="xdx_900_eus-gaap--AmortizationOfIntangibleAssets_c20240101__20241231__us-gaap--AwardTypeAxis__custom--DecemberTwoThousandTwentyNineMember_zruZIP5NfTPj" title="Amortization expense">1,941</span> and $<span id="xdx_90B_eus-gaap--AmortizationOfIntangibleAssets_c20240101__20241231__us-gaap--AwardTypeAxis__custom--DecemberTwoThousandTwentyThereafterMember_zJ6M35G3qjql" title="Amortization expense">8,432</span> for the years
ending December 31, 2025, 2026, 2027, 2028, 2029 and thereafter, respectively. The Company&#8217;s trademark does not have a determinate life
and therefore the cost is not being amortized.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all or part of the information related to intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/350-30/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/985-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock', window );">Accrued Expenses</a></td>
<td class="text"><p id="xdx_804_eus-gaap--AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_zNMRRyCHPx6h" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>6.
<span id="xdx_820_zIWxJtFoBTZ6">Accrued Expenses</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_897_eus-gaap--ScheduleOfAccruedLiabilitiesTableTextBlock_zvUb0GeiOnXj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accrued
expenses consisted of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BB_zpdknJa9shG3" style="display: none">Schedule of Accrued Expenses</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_499_20241231_zKsVdgUSQQmk" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, 2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_497_20231231_zTS4WmLwiwVl" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, 2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_401_ecustom--AccruedCompensationAndBenefitsCurrent_iI_maALCz94I_zfW9IkDNsimh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Compensation and benefits</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">1,261,317</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">333,477</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_ecustom--AdvisoryFees_iI_maALCz94I_zmfz7vtKw8Nj" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Advisory fees</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">176,750</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1268">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--InterestPayableCurrent_iI_maALCz94I_znHRDcQk5vL8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Interest</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">66,648</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">66,648</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--AccrualForTaxesOtherThanIncomeTaxesCurrent_iI_maALCz94I_zEo4FtIWXx23" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt">Other</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">73,065</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">963</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--AccruedLiabilitiesCurrent_iTI_mtALCz94I_zUvo3TiPrkFi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Total accrued expenses</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">1,577,780</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">401,088</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8AA_zWDzSdN9GyAg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 720<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483384/720-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Notes Payable<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Notes Payable</a></td>
<td class="text"><p id="xdx_805_eus-gaap--DebtDisclosureTextBlock_zqDM9DydFvQj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>7.
<span id="xdx_820_zrHP8dXRKMOk">Notes Payable</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Neuraxis,
Inc.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Notes
to Financial Statements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Promissory
Notes</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company borrowed $<span id="xdx_90E_eus-gaap--DebtInstrumentFaceAmount_iI_c20211216__dei--LegalEntityAxis__custom--ChannelPartnersCapitalMember_zEFgcCQS5p66">250,000 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">on
December 16, 2021, from Channel Partners Capital (the &#8220;2021 Promissory Note&#8221;). The 2021 Promissory Note called for 65
weekly payments of $<span id="xdx_90D_eus-gaap--DebtInstrumentPeriodicPayment_pp2d_c20230316__20230316__dei--LegalEntityAxis__custom--ChannelPartnersCapitalMember_zIhJDUCy6u28">4,923 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">with
the final payment scheduled for March 16, 2023. The principal outstanding at January 1, 2022 was $<span id="xdx_90B_eus-gaap--LongTermDebtAverageAmountOutstanding_c20220101__20220101__dei--LegalEntityAxis__custom--ChannelPartnersCapitalMember_zu7oEe0sn3j1">244,048</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.
The Company borrowed $<span id="xdx_905_eus-gaap--DebtInstrumentFaceAmount_iI_c20220916__dei--LegalEntityAxis__custom--ChannelPartnersCapitalMember_zDlf2W34cPyf">122,000 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">on
September 16, 2022, to bring the 2021 Promissory Note&#8217;s principal balance back to $<span id="xdx_902_eus-gaap--DebtInstrumentRepurchasedFaceAmount_iI_c20220916__dei--LegalEntityAxis__custom--ChannelPartnersCapitalMember_zu0onMRBFkE1">250,000</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.
After making scheduled payments, the Company borrowed another $<span id="xdx_90F_eus-gaap--DebtInstrumentFaceAmount_iI_c20230524__dei--LegalEntityAxis__custom--ChannelPartnersCapitalMember_zMDaPLFvDHL1">107,231 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">on
May 24, 2023, to bring the 2021 Promissory Note&#8217;s principal balance back to $<span id="xdx_908_eus-gaap--DebtInstrumentRepurchasedFaceAmount_iI_c20230524__dei--LegalEntityAxis__custom--ChannelPartnersCapitalMember_zoT6NPXmc5Ab">250,000 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">once
again. The terms of the incremental borrowings were the same as the 2021 Promissory Note with the final payment made on August 22,
2024. The principal outstanding as of December 31, 2024 and 2023 was $<span id="xdx_90E_eus-gaap--NotesPayable_iI_c20241231__dei--LegalEntityAxis__custom--ChannelPartnersCapitalMember_z4GkskSuYK4d">0 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">and
$<span id="xdx_90A_eus-gaap--NotesPayable_iI_c20231231__dei--LegalEntityAxis__custom--ChannelPartnersCapitalMember_zPcArPDgmb1">148,062</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">,
respectively, with an effective interest rate of <span id="xdx_902_eus-gaap--DebtInstrumentInterestRateEffectivePercentage_iI_pid_dp_uPure_c20241231__dei--LegalEntityAxis__custom--ChannelPartnersCapitalMember_z0tGbscimUTh" title="Debt instrument interest rate effective percentage"><span id="xdx_908_eus-gaap--DebtInstrumentInterestRateEffectivePercentage_iI_pid_dp_uPure_c20231231__dei--LegalEntityAxis__custom--ChannelPartnersCapitalMember_zNervzHDQ127" title="Debt instrument interest rate effective percentage">55.9</span></span>%. The Company believes that the advancement of additional funds is a minor
modification to the terms of the existing promissory note since the difference in present value of the cash flows under the terms of
the new loan is less than 10% of the present value of the remaining cash flows under the terms of the original loan. As a result,
the modification was accounted for as a modification of debt.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
lender was granted and assigned a continuing security interest in all the Company&#8217;s personal property assets including, but not
limited to, business equipment, inventory, accounts, accounts receivable, intellectual property, chattel paper, instruments, deposit
accounts, commercial tort claims, contract rights, licenses, claims, and general intangibles.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 15, 2023, The Company signed a note with Exchange Listing, LLC in the amount of $<span id="xdx_901_eus-gaap--DebtInstrumentFaceAmount_iI_c20230215__dei--LegalEntityAxis__custom--ExchangeListingLLCMember__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember_zRMlWKPbwri7" title="Promissory note">52,600</span> (the &#8220;2023 Promissory Note&#8221;).
The 2023 Promissory Note carried an interest rate of <span id="xdx_90C_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_dp_uPure_c20230215__dei--LegalEntityAxis__custom--ExchangeListingLLCMember__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember_zql6zk4wtE0j" title="Interest rate">1</span>% and was to be paid on the earlier of (i) three months or (ii) the Company receiving
financing at the minimum of $<span id="xdx_905_eus-gaap--NotesPayable_iI_c20230215__dei--LegalEntityAxis__custom--ExchangeListingLLCMember__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember_zTzH4vK2X6Kf" title="Promissory note">3,000,000</span>. In August 2023, the Company used proceeds from the IPO to pay the 2023 Promissory Note back in
full, including interest, in the amount of $<span id="xdx_900_eus-gaap--ProceedsFromIssuanceInitialPublicOffering_pp2d_c20230831__20230831__dei--LegalEntityAxis__custom--ExchangeListingLLCMember__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember_zliXyL9i6Hg6" title="Proceeds from issuance of ipo">52,858</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August 9, 2024, the Company entered into a $<span id="xdx_90E_eus-gaap--NotesPayable_iI_c20240809__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember_zSLcTzH4lfH3" title="Promissory note">210,000</span> promissory note to finance the premiums of its annual directors and officers insurance
policy, bearing interest at a rate of&#160;<span id="xdx_903_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20240809__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember_zxUHjNWitNhc" title="Interest rate">7.40</span>% per annum and maturing on <span id="xdx_90E_eus-gaap--DebtInstrumentMaturityDate_pid_dp_uPure_c20240809__20240809__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember_z2OkaoitC9Bl" title="Maturity date">June 9, 2025</span>. On November 1, 2024, the Company entered into
a second promissory note with a principal balance of $<span id="xdx_90E_eus-gaap--DebtInstrumentFaceAmount_iI_c20241101__us-gaap--DebtInstrumentAxis__custom--SecondPromissoryNoteMember_zVxIbOe4nfM7" title="Face amount">64,328</span> to finance premiums of its annual business insurance policies, bearing interest
at a rate of <span id="xdx_908_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20241101__us-gaap--DebtInstrumentAxis__custom--SecondPromissoryNoteMember_zT8azvnZtHBk">7.65</span>% per annum and maturing on <span id="xdx_902_eus-gaap--DebtInstrumentMaturityDate_pid_dp_uPure_c20241101__20241101__us-gaap--DebtInstrumentAxis__custom--SecondPromissoryNoteMember_z3FbP6YiSzJi" title="Maturity date">September 1, 2025</span> (collectively referred to as the &#8220;2024 Promissory Notes&#8221;).
The principal outstanding on 2024 Promissory Notes was $<span id="xdx_90A_eus-gaap--DebtInstrumentFaceAmount_iI_c20241231__us-gaap--DebtInstrumentAxis__custom--SecondPromissoryNoteMember_zKmFOTDHcsNh" title="Outstanding promissory notes">154,152</span> and $<span id="xdx_904_eus-gaap--DebtInstrumentFaceAmount_iI_c20231231__us-gaap--DebtInstrumentAxis__custom--SecondPromissoryNoteMember_zIKBHYh1IO6j" title="Outstanding promissory notes">0</span> as of December 31, 2024 and 2023, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">2022
Convertible Notes</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
2022, the Company issued multiple convertible notes with aggregate gross principal amounts totaling $<span id="xdx_908_eus-gaap--DebtInstrumentCarryingAmount_iI_c20221130__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyTwoConvertibleNotesMember_zqQaw6ZIDRqc" title="Debt instrument gross">3,333,333</span>
and net proceeds of $<span id="xdx_906_eus-gaap--ProceedsFromIssuanceOfDebt_c20221130__20221130__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyTwoConvertibleNotesMember_zjgkQLG15Kl7" title="Net proceeds of debt">2,870,000</span>
(the &#8220;2022 Convertible Notes&#8221;). The 2022 Convertible Notes consisted of an <span id="xdx_90F_eus-gaap--DebtInstrumentDescriptionOfVariableRateBasis_c20220603__20221130__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyTwoConvertibleNotesMember_zvDbyVtXaXMi" title="Debt instrument description">original
issue discount of 10% with an interest rate of the greater of (i) Prime rate plus 8.5% or (ii) 12% resulting in an effective
interest rate of <span id="xdx_90F_eus-gaap--DebtInstrumentInterestRateEffectivePercentage_iI_pid_dp_uPure_c20221231__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyTwoConvertibleNotesMember_zmFpWDLEwHX8" title="Debt instrument interest rate effective percentage">24.2</span>%.</span> The 2022 Convertible Notes converted into common shares at the lower of (i) $<span id="xdx_900_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_c20221130__srt--RangeAxis__srt--MinimumMember__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyTwoConvertibleNotesMember_zvQKZ0utCRB1">9.44</span>
or (ii) a <span id="xdx_900_ecustom--DebtInstrumentDiscountRate_iI_dp_uPure_c20221130__srt--RangeAxis__srt--MaximumMember__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyTwoConvertibleNotesMember_z50OMeun7FZd">30</span>%
discount to the price per share of any subsequent offering. The 2022 Convertible Notes matured on the one-year anniversary date from
issuance and contained <span id="xdx_900_ecustom--DebtWarrantConversionDescription_c20221130__20221130__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyTwoConvertibleNotesMember_zeHL1W9gR2jk" title="Debt warrant conversion, description">a
five-year warrant to purchase common stock equal to one hundred percent (100%) of the shares into which the 2022 Convertible Notes
could be converted into at issuance. </span>The warrants had an exercise price at the lower of (i) $<span id="xdx_902_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20221130__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyTwoConvertibleNotesMember_zD15DYCBQuc3" title="Exercise price">11.80</span>
per share or (ii) a <span id="xdx_908_ecustom--ClassOfWarrantDiscountRate_iI_dp_uPure_c20221130__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyTwoConvertibleNotesMember_zpyyX39zWKL1" title="Class of warrant discount rate">12.5</span>%
discount to the price per share of any subsequent offering.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
convertible notes signed on December 19, 2022 had aggregate gross principal amounts totaling $<span id="xdx_902_eus-gaap--DebtInstrumentCarryingAmount_iI_c20221219__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyTwoConvertibleNotesMember_zY4AipqPlXjh" title="Debt instrument gross">222,222</span> and net proceeds of $<span id="xdx_90A_eus-gaap--ProceedsFromIssuanceOfDebt_c20221219__20221219__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyTwoConvertibleNotesMember_zzQRSmAAdBD6" title="Net proceeds of debt">200,000</span> and
consisted of an original issue discount of <span id="xdx_902_ecustom--DebtInstrumentDiscountRate_iI_dp_uPure_c20221219__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyTwoConvertibleNotesMember_z7hWSk50ycQj" title="Debt instrument discount rate">10</span>% of the principal amount with an interest rate of <span id="xdx_901_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_dp_uPure_c20221219__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyTwoConvertibleNotesMember_zOVeh7LRY85" title="Accrued interest">12</span>% per annum. The notes matured at the
earlier of (i) twelve (12) months from the issue date or (ii) the date upon which the Company completes a registered public offering
of shares of the Company, which encompasses the closing of the IPO. The notes are convertible into shares of common stock at the higher
of (i) $<span id="xdx_901_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_c20221219__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyTwoConvertibleNotesMember_zPaI12QxapN9" title="Conversion price">9.44</span> per share or (ii) the price per share of common stock issued pursuant to the next registered public offering of shares of
the Company made prior to the conversion of any portion of the note. Interest accrues on the aggregate principal amount (which includes
original issue discount) and is payable on the maturity date, at the Company&#8217;s election, in cash or in-kind. The holders of the
notes are entitled to piggyback registration rights on any registration statement filed by the Company, other than any registration statement
filed on Form S-4 or Form S-8. The warrants and conversion shares are subject to anti-dilution provisions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
investors of the notes signed on December 19, 2022 above did not convert their notes and, as such the Company used proceeds from the
initial public offering to pay the remaining promissory notes back in full, including interest in the amount of $<span id="xdx_906_eus-gaap--ProceedsFromIssuanceInitialPublicOffering_c20221219__20221219__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyTwoConvertibleNotesMember_zO90UJ5v8AA4" title="Proceeds from issuance of ipo">239,104</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">2023
Convertible Notes</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
2023, the Company conducted multiple closings of a private placement offering to accredited investors for aggregate gross principal
amounts of $<span id="xdx_90E_eus-gaap--DebtInstrumentCarryingAmount_iI_c20231231__us-gaap--DebtInstrumentAxis__custom--ConvertiblePromissoryNoteMember__srt--TitleOfIndividualAxis__custom--AccreditedInvestorsMember_zpDMokGIBjK3" title="Debt instrument gross">6,066,667</span>
and net proceeds of $<span id="xdx_902_eus-gaap--ProceedsFromIssuanceOfDebt_c20230101__20231231__srt--TitleOfIndividualAxis__custom--AccreditedInvestorsMember__us-gaap--DebtInstrumentAxis__custom--ConvertiblePromissoryNoteMember_znCDb3Ms1PEg" title="Net proceeds of debt">4,908,000</span>
(the &#8220;2023 Convertible Notes&#8221;). The offering consisted of a convertible promissory note that accrued interest at <span id="xdx_90E_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_dp_uPure_c20231231__us-gaap--DebtInstrumentAxis__custom--ConvertiblePromissoryNoteMember_zUaQiNCsuCb6" title="Debt instrument interest rate">12</span>%
that could be paid in cash or PIK and had an original issue discount of <span id="xdx_90B_ecustom--DebtInstrumentDiscountRate_iI_pid_dp_uPure_c20231231__us-gaap--DebtInstrumentAxis__custom--ConvertiblePromissoryNoteMember_z9UC19ga76na" title="Debt instrument discount rate">10</span>%
resulting in an effective interest rate of <span id="xdx_909_eus-gaap--DebtInstrumentInterestRateEffectivePercentage_iI_pid_dp_uPure_c20231231__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeConvertibleNotesMember_zDQzuqODLQR1" title="Debt instrument interest rate effective percentage">27.5</span>%. The 2023 Convertible Notes automatically converted into common shares at a <span id="xdx_90C_ecustom--DebtInstrumentDiscountRate_iI_dp_uPure_c20231231__us-gaap--DebtInstrumentAxis__custom--ConvertiblePromissoryNoteMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z5r3vk1LAJxh" title="Discount rate">30</span>%
discount to the IPO. The 2023 Convertible Notes matured on the sooner of the six-month anniversary date from issuance or a
successful IPO on primary exchange in the U.S. and included <span id="xdx_90B_ecustom--DebtWarrantConversionDescription_c20230101__20231231__us-gaap--DebtInstrumentAxis__custom--ConvertiblePromissoryNoteMember_z3Ni11xEdEwf" title="Debt warrant conversion, description">a
five-year warrant to purchase common stock equal to fifty percent (50%) of the shares into which the 2032 Convertible Notes could be
converted into at issuance. </span>The warrants had a strike price at a <span id="xdx_903_eus-gaap--DebtInstrumentConvertibleConversionRatio1_dp_uPure_c20230101__20231231__us-gaap--DebtInstrumentAxis__custom--ConvertiblePromissoryNoteMember_zfRoCwQIV1jc" title="Strilke price">25</span>%
premium to the conversion price subject to anti-dilution, issuable on a pro rata basis at each funding.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company used proceeds from the 2023 Convertible Notes to pay a portion of the principal balance of the 2022 Convertible Notes totaling
$<span id="xdx_90C_eus-gaap--NotesPayable_iI_c20231231__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeConvertibleNotesMember_zoEzkqhpEx76">2,650,000</span> which resulted in a $<span id="xdx_908_eus-gaap--GainsLossesOnExtinguishmentOfDebt_c20230101__20231231__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeConvertibleNotesMember_zovuuAZwlnyg" title="Gain on extinguishment of debt liabilities">1,129,653</span> gain recorded as a benefit to Extinguishment of Debt Liabilities in the Statements of Operations.
Upon partial repayment, the terms of the remaining 2022 Convertible Notes were amended to accrue interest at <span id="xdx_904_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_dp_uPure_c20231231__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeConvertibleNotesMember_zDkNUsQQ8Xh6">8</span>% per annum without maturity
or default rights. The remaining principal balance also automatically converted into shares of common stock at a <span id="xdx_903_ecustom--DebtInstrumentDiscountRate_iI_dp_uPure_c20231231__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeConvertibleNotesMember_zIQaTlFHT68b">27.5</span>% discount to the
per share offering price in the Company&#8217;s IPO, or $<span id="xdx_904_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_c20231231__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeConvertibleNotesMember_zU3VLYdijpM1">4.35</span> per share. After the closing of the IPO on August 9, 2023, the Company
converted some of the remaining balance of the 2022 Convertible Notes and $<span id="xdx_90D_eus-gaap--NotesPayable_iI_c20230809__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeConvertibleNotesMember_zpxhJO0tYrzd">173,205</span> of accrued interest into <span id="xdx_905_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230809__20230809__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeConvertibleNotesMember_zaVdBFCEvqsa">107,509</span> shares of common
stock. The shares were issued at a discounted price of $<span id="xdx_907_eus-gaap--SharesIssuedPricePerShare_iI_c20230809__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeConvertibleNotesMember_zFKBNQfNmFg5">4.35</span> per share resulting in a $<span id="xdx_90B_eus-gaap--GainsLossesOnExtinguishmentOfDebt_c20230809__20230809__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeConvertibleNotesMember_z3wlc7JBI3Z4" title="Extinguishment of debt">663,991</span> loss to the Company recorded as a charge
to Extinguishment of Debt Liabilities in the Statements of Operations. As the remaining holders of the 2022 Convertible Notes did not
convert, the Company used proceeds from the IPO to pay the remaining balance in full, including interest in the amount of $<span id="xdx_90E_eus-gaap--ProceedsFromIssuanceInitialPublicOffering_c20230809__20230809__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeConvertibleNotesMember_zLhLTcObjsG2" title="Proceeds from issuance of ipo">445,544</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
facilitators to the 2023 Convertible Notes, Signature Bank received a $<span id="xdx_903_eus-gaap--EscrowDeposit_iI_c20231231__dei--LegalEntityAxis__custom--SignatureBankMember_zoSjuS5jBFCa" title="Escrow deposit">6,000</span> escrow fee and Alexander Capital, L.P. received (i) a $<span id="xdx_90B_eus-gaap--ProceedsFromFeesReceived_c20230101__20231231__dei--LegalEntityAxis__custom--AlexanderCapitalLPMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z1ehwztzuPv8" title="Deferred financing fees">546,000</span>
cash commission representing nine percent (9%) of the proceeds raised in the offering from investors introduced to the Company and (ii)
<span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20231231__dei--LegalEntityAxis__custom--AlexanderCapitalLPMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zFOaTIC7d4T3" title="Number of warrants received">120,235</span> warrants for the purchase of a number of shares of Common Stock equal to 6% of the number of underlying securities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">After
the closing of the IPO on August 9, 2023, the Company converted the 2023 Convertible Notes and $<span id="xdx_90F_eus-gaap--NotesPayable_iI_c20230809__dei--LegalEntityAxis__custom--ChannelPartnersCapitalMember_zwuNrF6R97Ah">226,391</span> of accrued interest into <span id="xdx_906_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230809__20230809__dei--LegalEntityAxis__custom--ChannelPartnersCapitalMember_zlTXDEX9FLD6">1,498,332</span>
shares of common stock. The shares were issued at a discounted price of $<span id="xdx_908_eus-gaap--SharesIssuedPricePerShare_iI_c20230809__dei--LegalEntityAxis__custom--ChannelPartnersCapitalMember_znT55MEeIB31">4.20</span> per share that resulted in a $<span id="xdx_907_eus-gaap--GainsLossesOnExtinguishmentOfDebt_c20230809__20230809__dei--LegalEntityAxis__custom--ChannelPartnersCapitalMember_zOlt4qwjAyi">4,115,223</span> loss to the Company
which was recorded as a charge to Extinguishment of Debt Liabilities in the Statements of Operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">2024
Convertible Notes</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
November 8, 2023, the Company entered into a Securities Purchase Agreement (&#8220;SPA&#8221;) with a shareholder for the
issuance&#160;<span id="xdx_90F_eus-gaap--ConvertiblePreferredStockSharesIssuedUponConversion_iI_c20231108_zSpU5amBgfOd">1,260,504</span>&#160;shares
of Series B Convertible Preferred Stock, par value $<span id="xdx_900_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_c20231108_z4JXZysGzjk8">0.001</span>&#160;per
share (the &#8220;Series B Preferred Stock&#8221;), for an aggregate purchase price of $<span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20231108__20231108_zganK9PRuxs7">3,000,000</span>&#160;paid
in 15 monthly installments of $<span id="xdx_90F_eus-gaap--DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid_iI_c20231108_zK3TtlgteSQe">200,000</span>&#160;each,
commencing on the later of January 10, 2024 or a date after stockholder approval of an amendment to the Company&#8217;s Certificate
of Incorporation to authorize the creation of the Series B Preferred Stock. The Series B Preferred Stock was convertible at any time
into shares of common stock of the Company without any further consideration. Following the issuance of the Series B Preferred
Stock, it would rank senior to the common stock with respect to payments upon the liquidation, dissolution and winding up of the
Company. Due to a delay in the stockholder approval, the Company amended the SPA on February 12, 2024 to issue a promissory note,
due and payable on the earlier of 15 months or 12 months if the Series B Preferred Stock has not been authorized, convertible into
Series B Convertible Preferred Stock with identical funding amounts and terms (the &#8220;$<span id="xdx_903_eus-gaap--ConvertibleDebt_iI_c20241231_zgzI8itrNQO5" title="Convertible debt">3,000,000</span>
Convertible Promissory Note&#8221;). The shareholder funded $<span id="xdx_905_eus-gaap--ProceedsFromContributedCapital_c20240101__20241231__us-gaap--DebtInstrumentAxis__custom--ConvertiblePromissoryNotesMember__srt--RangeAxis__srt--MaximumMember_zjteYQfZeOV3" title="Shareholder funded">800,000</span>
of the $<span id="xdx_900_eus-gaap--ProceedsFromContributedCapital_c20240101__20241231__us-gaap--DebtInstrumentAxis__custom--ConvertiblePromissoryNotesMember__srt--RangeAxis__srt--MinimumMember_zubQQQVByqo4" title="Shareholder funded">3,000,000</span>
commitment in 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company then proceeded to enter into a series of incremental convertible promissory notes with other investors totaling $<span id="xdx_902_eus-gaap--DebtInstrumentAnnualPrincipalPayment_iI_c20241231__us-gaap--DebtInstrumentAxis__custom--ConvertiblePromissoryNotesMember_zqMtxGlPF6ui" title="Total principal amount">1,135,000</span>&#160;with
terms identical to the $<span id="xdx_907_eus-gaap--ConvertibleDebt_iI_c20241231__us-gaap--DebtInstrumentAxis__custom--ConvertiblePromissoryNotesMember_zcyNEtVNxe14" title="Convertible debt">3,000,000</span>&#160;Convertible Promissory Note (collectively referred to as the &#8220;Original 2024 Convertible
Promissory Notes&#8221;) for an aggregate principal amount of $<span id="xdx_90C_eus-gaap--DebtInstrumentPeriodicPayment_c20240101__20241231__us-gaap--DebtInstrumentAxis__custom--ConvertiblePromissoryNotesMember_zTtOsplvGC0b" title="Principal amount due in monthly installments">1,935,000</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
2024 Original Convertible Promissory Notes earned interest at&#160;<span id="xdx_907_eus-gaap--DebtConversionOriginalDebtInterestRateOfDebt_dp_uPure_c20240101__20241231__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyFourConvertiblePromissoryNotesMember_zFrMXutDFmci" title="Debt conversion, original debt, interest rate of debt">8.5</span>% per annum payable quarterly in either cash or common stock at the
election of the Company. At any time following the date of shareholder approval to authorize the creation of Series B Preferred Stock
prior to the maturity date, the investor may elect to convert all or part of the principal into the Company&#8217;s Series B Preferred
Stock at a conversion price per share equal to $<span id="xdx_906_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pid_c20241231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zgG3yQ2gkZ47" title="Preferred stock, par value">2.38</span>. Without limiting the forgoing, all principal amounts outstanding on the maturity
date will automatically convert into the Company&#8217;s Series B Preferred Stock. The Series B Preferred Stock is entitled to cumulative
dividends at<span id="xdx_905_ecustom--CumulativeDividendsPercent_iI_pid_dp_uPure_c20241231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zX9iursTBdyl" title="Cumulative dividends percent">&#160;8.5</span>% per annum (whether or not declared) payable quarterly in either cash or common stock at the $<span id="xdx_903_eus-gaap--CommonStockConvertibleConversionPriceDecrease_pid_c20240101__20241231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zEmJMQVEvfoe" title="Common stock conversion price">2.38</span>&#160;conversion
price at the election of the Company. Upon conversion to Series B Preferred Stock, the investor may elect, at its option at any time,
to convert all or part of the Series B Preferred Stock plus accrued but unpaid dividends into an equivalent amount of common stock at
the $<span id="xdx_907_eus-gaap--CommonStockConvertibleConversionPriceDecrease_pid_c20240101__20241231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zYUMz2kUlIAf" title="Common stock conversion price">2.38</span>&#160;conversion price.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subsequently,
the Company entered into three convertible promissory notes with related institutional accredited investors with terms similar to
the Original 2024 Convertible Promissory Notes (collectively referred to as the &#8220;Amended 2024 Convertible Promissory
Notes&#8221;) for an additional principal amount of $<span id="xdx_904_eus-gaap--ConvertibleDebt_iI_c20241221__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyFourConvertiblePromissoryNotesMember_zxzVGfogPE5">3,000,000</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.
Certain provisions to the SPA and Certificate of Designation previously issued on February 12, 2024 changed, including (i) the
number of shares of preferred stock to be designated as Series B Preferred Stock was increased &#160;to&#160;<span id="xdx_906_eus-gaap--PreferredStockSharesAuthorized_iI_c20240212__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyFourConvertiblePromissoryNotesMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_z29Cg7GrSyLe">4,000,000 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares,
(ii) the stated value of the Series B Preferred Stock was changed to $<span id="xdx_907_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pid_c20240212__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyFourConvertiblePromissoryNotesMember_zKe3cDwiWKWa">2.38</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;per
share, (iii) the right to receive dividends will expire automatically on June 30, 2025, (iv) the liquidation rights will
automatically expire on June 30, 2025, and (v) the number of shares of the common stock that a holder of Series B preferred stock is
entitled to receive shall not exceed the maximum percentage chosen by the holder, which is initially set at between<span id="xdx_90A_ecustom--DebtInstrumentDiscountRate_iI_dp_uPure_c20241212__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyFourConvertiblePromissoryNotesMember__srt--RangeAxis__srt--MinimumMember_zk5Yi6FLQSx4">&#160;4.99</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%
and&#160;<span id="xdx_906_ecustom--DebtInstrumentDiscountRate_iI_dp_uPure_c20240212__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyFourConvertiblePromissoryNotesMember__srt--RangeAxis__srt--MaximumMember_zCior02h0463">19.99</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%
until shareholder approval is obtained, of the number of outstanding shares of the common stock at the time of the conversion of the
Series B Preferred Stock shares.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
maturity date was on the earlier of (i) June 21, 2025, (ii) upon written demand occurring on or after March 21, 2025 in the event that
the Series B Preferred Stock has not been duly authorized on or before such date, or (iii) immediately upon the occurrence of an event
of default. Automatic conversion into shares of Series B preferred stock (at a conversion price of $<span id="xdx_901_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pid_c20240212__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_z38FWDM4Q7k2" title="Preferred stock, par value">2.38</span>&#160;per share) would occur
following the date of shareholder approval. In the event the Company failed to obtain shareholder approval before August 15, 2024, rights
existed to convert the outstanding amount into shares of the common stock, at a price per share of $<span id="xdx_907_eus-gaap--CommonStockConvertibleConversionPriceDecrease_pid_c20240212__20240212__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zFq5z6Zgut6d" title="Common stock conversion price">2.38</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of August 15, 2024, the Company received $<span id="xdx_90E_eus-gaap--DebtInstrumentPeriodicPayment_c20240815__20240815__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyFourConvertibleNotesMember_zXnYu9tKPJV1" title="Principal amount due in monthly installments">4,935,000</span>&#160;of
the principal amount of the Amended 2024 Convertible Notes with the remainder due in monthly installments through March of 2025
resulting in an effective interest rate of <span id="xdx_904_eus-gaap--DebtInstrumentInterestRateEffectivePercentage_iI_pid_dp_uPure_c20240915__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyFourConvertiblePromissoryNotesMember_zRmMIGMhojjd" title="Debt instrument interest rate effective percentage">12.5</span>%. On August 15, 2024, the Company&#8217;s shareholders authorized&#160;<span id="xdx_903_eus-gaap--PreferredStockSharesAuthorized_iI_c20240815__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyFourConvertiblePromissoryNotesMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zrwbtgBVzqU4" title="Preferred stock, shares authorized">5,000,000</span>&#160;shares
of preferred stock of which&#160;<span id="xdx_909_eus-gaap--TemporaryEquitySharesAuthorized_iI_pid_c20240815__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyFourConvertiblePromissoryNotesMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zWIBgMWt78qi" title="Temporary equity, shares authorized">4,000,000</span>&#160;shares
were designated as $<span id="xdx_902_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20240815__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyFourConvertiblePromissoryNotesMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zFlL4jy3qIjk" title="Common stock, par value">0.001</span>&#160;par
value Series B preferred stock. Pursuant to the terms of the Amended 2024 Convertible Promissory Notes, the outstanding principal
balance of $<span id="xdx_902_eus-gaap--DebtInstrumentPeriodicPayment_c20240815__20240815__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyFourConvertibleNotesMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zZt5xsKjsRT1" title="Principal amount due in monthly installments">4,935,000</span>&#160;was
mandatorily converted into <span id="xdx_90B_eus-gaap--ConversionOfStockSharesConverted1_c20240815__20240815__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyFourConvertiblePromissoryNotesMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zZ33ZmUS0hka" title="Number of shares converted">2,073,524</span>&#160;Series
B Preferred Shares at a conversion price of $<span id="xdx_907_ecustom--CommonStockConvertibleConversionPrice_pid_c20240815__20240815__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyFourConvertiblePromissoryNotesMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zPYYVSWxi6ve" title="Common stock conversion price">2.38</span>.
Upon the mandatory conversion, the unamortized debt discount of $<span id="xdx_902_eus-gaap--UnamortizedDebtIssuanceExpense_iI_c20241231__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyFourConvertiblePromissoryNotesMember_zWlZydP0zQ8i">165,577</span>
was reclassified to Additional Paid-In-Capital in the Statements of Stockholders&#8217; Equity (Deficit).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interest
expense totaled $<span id="xdx_90D_eus-gaap--InterestExpense_c20240101__20241231_zjJ8eRLATKW8" title="Interest expense">174,328</span> and $<span id="xdx_904_eus-gaap--InterestExpense_c20230101__20231231_zgAjaQYk3xmc" title="Interest expense">476,416</span> for the years ended December 31, 2024 and 2023, respectively. The Company&#8217;s accrued interest
total $<span id="xdx_908_eus-gaap--AccruedLiabilitiesCurrentAndNoncurrent_iI_c20241231_zyK2e3l3mMzf"><span id="xdx_902_eus-gaap--AccruedLiabilitiesCurrentAndNoncurrent_iI_c20231231_z78hv9D4gJpc">66,648</span></span> as of December 31, 2024 and 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Neuraxis,
Inc.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Notes
to Financial Statements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 470<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/470/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NRXS_DisclosureLeasesAbstract', window );"><strong>Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Leases</a></td>
<td class="text"><p id="xdx_802_eus-gaap--LesseeOperatingLeasesTextBlock_zDaqugDXqxi6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>8.
<span id="xdx_82C_zWExa9FWg8Q5">Leases</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s leases are comprised of operating leases for office space. At the inception of the lease, the Company determines whether
the lease contract conveys the right to control the use of identified property for a period of time in exchange for consideration. Leases
are classified as operating or finance leases at the commencement date of the lease. Operating leases are recorded as operating lease
right-of-use assets, other current liabilities, and operating lease liabilities in the Balance Sheets. The Company did not have any finance
leases at December 31, 2024 and 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has two leases primarily consisting of office space in Versailles and Carmel, Indiana.&#160;<span id="xdx_90E_eus-gaap--LesseeOperatingLeaseDescription_c20240101__20241231_zzNggvW090B1" title="Operating lease description">The lease in Versailles, Indiana
started January 1, 2022 and had a term of one year, with automatic one year renewal options, unless 60 day notice of vacating is given.
The current monthly lease payment for this lease is $<span id="xdx_90B_eus-gaap--OperatingLeasePayments_c20220101__20220101__us-gaap--GeographicDistributionAxis__custom--VersaillesIndianaMember_zXtKFmAmcJGd" title="Operating lease payment">1,800</span>&#160;with a&#160;<span id="xdx_90B_eus-gaap--LesseeOperatingLeaseDiscountRate_iI_dp_uPure_c20220101__us-gaap--GeographicDistributionAxis__custom--VersaillesIndianaMember_zsOtgeDtJ2x2" title="Discount rate">4</span>% per annum increase. A new lease in Carmel, Indiana commenced
January 1, 2024. The initial term is five years and five months. The monthly lease payment started at $<span id="xdx_900_eus-gaap--OperatingLeasePayments_c20240101__20240101__us-gaap--GeographicDistributionAxis__custom--CarmelIndianaMember_zEzmFZPahbfg" title="Operating lease payment">6,721</span>&#160;with an annual increase
of&#160;<span id="xdx_90E_eus-gaap--LesseeOperatingLeaseDiscountRate_iI_pid_dp_uPure_c20240101__us-gaap--GeographicDistributionAxis__custom--CarmelIndianaMember_zefaptoL8Nvb" title="Operating lease payment rate">2.5</span>%. As long as the Company is not in default, it is only obligated to pay an amount equal to 50% of the monthly base rent for
months 1-10</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating
lease right-of-use assets and liabilities are recognized at the commencement date based on the present value of lease payments over the
lease term. As the implicit interest rate is generally not readily determinable, the Company uses an incremental borrowing rate based
on the information available at the commencement date in determining the present value of lease payments. The incremental borrowing rate
reflects the estimated rate of interest that the Company would pay to borrow on a collateralized basis over a similar economic environment.
Lease expense for the operating lease is recognized on a straight-line basis over the lease term.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Leases
may include renewal options, and the renewal option is included in the lease term if the Company concludes that it is reasonably certain
that the option will be exercised. Certain leases may contain rent escalation clauses, either fixed or adjusted periodically for inflation
of market rates, that are factored into the calculation of lease payments to the extent they are fixed and determinable at lease inception.
The Company also has variable lease payments that do not depend on a rate or index, primarily for items such as common area maintenance
and real estate taxes, which are recorded as expenses when incurred.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the years ended December 31, 2024 and 2023, the Company recognized $<span id="xdx_90B_eus-gaap--OperatingLeaseExpense_c20240101__20241231_zzEan1koYyq8" title="Operating lease expense">96,177</span> and $<span id="xdx_907_eus-gaap--OperatingLeaseExpense_c20230101__20231231_zTeBySBAQXg2" title="Operating lease expense">49,051</span> of operating lease expense, including short-term
lease expense and variable lease costs, which are immaterial.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_89C_eus-gaap--LeaseCostTableTextBlock_zFztbrypnsXg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table presents information related to the Company&#8217;s operating leases:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span id="xdx_8B7_zfHapyJiPMx" style="display: none">Schedule of Operating Leases</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_495_20241231_zcoyBtzitmTd" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, 2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49B_20231231_z7nQi5gKvHf4" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, 2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--OperatingLeaseRightOfUseAsset_iI_z3IUYNRAlpId" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left; padding-bottom: 1pt">Operating lease right-of-use assets</td><td style="width: 2%; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">284,656</span></td><td style="width: 1%; padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 16%; text-align: right">70,263</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--OperatingLeaseLiabilityCurrent_iI_maOLLz38G_zLVvb7Ghl128" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Other current liabilities</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">62,754</span></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">49,127</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_maOLLz38G_zUI2yxIjMR36" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Operating lease liabilities</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">256,499</span></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">27,071</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--OperatingLeaseLiability_iTI_mtOLLz38G_zKDhLqa2gJd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt">Total</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">319,253</span></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">76,198</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Weighted-average remaining lease term (in years)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_907_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20241231_zQIProZFW8bc" title="Weighted average remaining lease term (in years)">2.75</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90B_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20231231_zhbewRy86dwf" title="Weighted average remaining lease term (in years)">3.75</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Weighted-average discount rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_900_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_dp_uPure_c20241231_z5BSj9aa6XE4" title="Weighted average discount rate">15.0</span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90B_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_dp_uPure_c20231231_z940P4nqH1Ke" title="Weighted average discount rate">15.0</span></td><td style="text-align: left">%</td></tr>
  </table>

<p id="xdx_8A1_z7jIB6o5sUmf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_89C_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zHwzvxcPJMja" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2024, the maturities of the Company&#8217;s operating lease liabilities were as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B6_zTIR3865vQEf" style="display: none">Schedule of Maturities Operating Lease Liabilities</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
  <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left"></td><td id="xdx_49E_20241231_zE69sUSivHee" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_maLOLLPzyNu_zAnUqfeRV5mj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%; text-align: left">2025</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">105,130</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_maLOLLPzyNu_z8Q5BQvx38Mf" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">2026</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">108,106</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_maLOLLPzyNu_z1wKRjz18iIb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">2027</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">86,856</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFour_iI_maLOLLPzyNu_ztch8OL13t4l" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">2028</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">89,027</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFive_iI_maLOLLPzyNu_z3Yt9rhqjbL" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">2029</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">38,025</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_mtLOLLPzyNu_z63kL7uUXONc" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Total lease payments</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">427,144</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_di_zDr3iSUhUu2l" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Less: imputed interest</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(107,891</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_401_eus-gaap--OperatingLeaseLiability_iI_zMTx5ZJu3jC8" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Total present value of lease payments</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">319,253</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_NRXS_DisclosureLeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">NRXS_DisclosureLeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>NRXS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/842-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common Stock and Warrants<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Common Stock and Warrants</a></td>
<td class="text"><p id="xdx_80B_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zyRGFQBtZSU1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>9.
<span id="xdx_827_zOYBYQ9MVzY8">Common Stock and Warrants</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company authorized <span id="xdx_90E_eus-gaap--CommonStockSharesAuthorized_iI_c20241231_zx0NR2fOdFD9" title="Common stock, shares authorized"><span id="xdx_909_eus-gaap--CommonStockSharesAuthorized_iI_c20231231_z9bAu6A7b1S3" title="Common stock, shares authorized">100,000,000</span></span> shares of common stock, of which <span id="xdx_907_eus-gaap--CommonStockSharesIssued_iI_c20241231_zWqLP4IufL74" title="Common stock, shares issued"><span id="xdx_90C_eus-gaap--CommonStockSharesOutstanding_iI_c20241231_zw3AtzhhAce4" title="Common stock, shares outstanding">6,990,227</span></span> and <span id="xdx_90B_eus-gaap--CommonStockSharesIssued_iI_c20231231_zQNWweik0yQc" title="Common stock, shares, issued"><span id="xdx_900_eus-gaap--CommonStockSharesOutstanding_iI_c20231231_zKgmFzJ3Robd" title="Common stock, shares, outstanding">6,508,897</span></span> shares were issued and outstanding as of December
31, 2024 and 2023, respectively. On January 10, 2023, the Company&#8217;s board of directors authorized a <span id="xdx_909_eus-gaap--StockholdersEquityReverseStockSplit_c20230110__20230110_z3gbNKCeDgo4" title="Reverse stock split">2-for-1 reverse stock split.</span>
All share information in these financial statements has been adjusted for this reverse stock split.&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended December 31, 2023, the Company issued (i) <span id="xdx_90E_ecustom--StockIssuedDuringPeriodSharesCommonStockIssuedUponInitialPublicOffering_c20230101__20231231_zX9UpQi4jOn4" title="Common shares, issued upon initial public offering, shares">1,098,667</span> common shares issued upon the completion of the IPO on August 9, 2023
at a price of $<span id="xdx_909_eus-gaap--SharePrice_iI_c20231231_zYvgEdpVO7C4" title="Common shares, per share">6.00</span> per share resulting in net proceeds of $<span id="xdx_90B_eus-gaap--ProceedsFromIssuanceInitialPublicOffering_c20230101__20231231_zyooScp2GJO8" title="Net proceeds">4,110,677</span>, (ii) <span id="xdx_907_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_c20230101__20231231_zD5lTo3DroD3" title="Conversion shares">1,244,228</span> common shares upon conversion of <span id="xdx_902_eus-gaap--ConvertiblePreferredStockSharesIssuedUponConversion_iI_c20231231_zMptYG4BMD5f" title="Shares issued upon conversion">506,637</span> shares
of Convertible Series A Preferred Stock and <span id="xdx_90B_eus-gaap--ConversionOfStockSharesConverted1_c20230101__20231231__us-gaap--StatementClassOfStockAxis__custom--ConvertibleSeriesSeedPreferredStockMember_zRnID9P3FCBf" title="Stock value converted">115,477</span> shares of Convertible Series Seed Preferred Stock, (iii) <span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodSharesConversionOfUnits_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zR4zARwjwVI4" title="Common stock issued upon debt conversion, shares"><span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodSharesConversionOfUnits_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z7Cg7pRur7Nj" title="Common stock issued upon debt conversion, shares">1,649,900</span></span> common shares
upon conversion of the 2022 and 2023 Convertible Notes, (iv) <span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20230101__20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--VendorsMember_zmVZK67FzrC8" title="Service for payments">425,000</span> common shares as payment to vendors for services and (v) <span id="xdx_902_eus-gaap--ConversionOfStockSharesIssued1_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z6oOmHqPdwNc" title="Exercise of warrants">127,780</span>
common shares upon the exercise of warrants.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended December 31, 2024, the Company issued (i) <span id="xdx_901_ecustom--StockIssuedDuringPeriodSharesCommonStockIssuedUponInitialPublicOffering_c20240101__20241231_zsxKga9uUwme" title="Common shares, issued upon initial public offering, shares">245,955</span> common shares to settle 2022 Convertible Note and Series A Preferred
Stock holder disputes, (ii) <span id="xdx_901_eus-gaap--ConversionOfStockSharesIssued1_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zLweVUlZfsu8" title="Exercise of warrants">11,000</span> common shares upon the exercise of warrants, (iii) <span id="xdx_900_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20240101__20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--VendorsMember_zCE1ZtZ3VkJ9" title="Service for payments">115,145</span> common shares as payment to vendors for
services, (iv) <span id="xdx_904_eus-gaap--ConversionOfStockSharesConverted1_c20240101__20241231_zhgdD00kyqH7" title="Conversion, interest">59,055</span> common shares in lieu of interest on the 2024 Convertible Notes, (v) <span id="xdx_904_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20240101__20241231__us-gaap--TypeOfArrangementAxis__custom--EmployementAgreementMember_zZZUyryZreT9" title="Service for payments">25,832</span> shares pursuant to the severance provisions
of an employment agreement and (vi) <span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20240101__20241231_zRr3DNtdTN9a" title="Service for payments">24,343</span> common shares for board service.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Neuraxis,
Inc.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Notes
to Financial Statements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended December 31, 2023, the Company issued (i) <span id="xdx_903_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20231231__us-gaap--TypeOfArrangementAxis__custom--TwoThousandTwentyThreeConvertiblePromissoryNotesMember_zVKjb30hmoFh" title="Number of Warrants">505,570</span> <span id="xdx_907_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dxL_c20231231__us-gaap--TypeOfArrangementAxis__custom--TwoThousandTwentyTwoConvertibleNotesMember_zosR6VaCDMLc" title="Warrants, term::XDX::P5Y"><span style="-sec-ix-hidden: xdx2ixbrl1548">five-year</span></span> warrants to purchase common stock equal to fifty percent (50%)
of the shares into which the 2023 Convertible Promissory Notes could be converted at issuance at an exercise price of $<span id="xdx_90D_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20231231__us-gaap--TypeOfArrangementAxis__custom--TwoThousandTwentyThreeConvertiblePromissoryNotesMember_zR4x9Sat3sV3">5.25</span> per share,
(ii) <span id="xdx_905_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20231231__us-gaap--TypeOfArrangementAxis__custom--AdvisoryAgreementMember_zVQ7JmajdSq6" title="Number of Warrants">122,202</span> <span id="xdx_906_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dxL_c20231231__us-gaap--TypeOfArrangementAxis__custom--AdvisoryAgreementMember_zeMxjMDhpCM7" title="Warrants, term::XDX::P5Y"><span style="-sec-ix-hidden: xdx2ixbrl1553">five year</span></span> warrants to purchase common stock pursuant an advisory agreement with a consulting firm upon closing of the Company&#8217;s
IPO at an exercise price of $<span id="xdx_904_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20231231__us-gaap--TypeOfArrangementAxis__custom--AdvisoryAgreementMember_zzJImS8mABYg">5.25</span> per share and (iii) <span id="xdx_901_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20231231__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementMember_zFd7uBVvCi7" title="Number of Warrants">186,156</span> <span id="xdx_90C_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dxL_c20231231__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementMember_zLXlqvyUvWO6" title="Warrants, term::XDX::P5Y"><span style="-sec-ix-hidden: xdx2ixbrl1558">five-year</span></span> warrants to purchase common stock pursuant to an underwriting
agreement upon closing of the Company&#8217;s IPO at an exercise price of $<span id="xdx_908_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20231231__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementMember_z32lFDpFX2ed">5.25</span> per share. Additionally, <span id="xdx_904_ecustom--NumberOfEquivalentOfWarrantsDescription_c20230101__20231231_zZ30RcjUsfNl" title="Number of equivalent of warrants, description">investors converted (i) 87,856
warrants into an equivalent number of common shares at an exercise price of $2.38 in exchange for $209,097 in cash proceeds and (ii)
40,000 warrants into 39,924 common shares in a cashless exercise transaction.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended December 31, 2024, the Company issued (i) <span id="xdx_901_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20241231__us-gaap--TypeOfArrangementAxis__custom--TwoThousandTwentyFourConvertiblePromissoryNotesMember_zNMBz3dhtKck" title="Number of Warrants">38,697</span> <span id="xdx_905_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dxL_c20241231__us-gaap--TypeOfArrangementAxis__custom--TwoThousandTwentyFourConvertiblePromissoryNotesMember_z93VtfAJbd4j" title="Warrants, term::XDX::P5Y"><span style="-sec-ix-hidden: xdx2ixbrl1565">five-year</span></span> warrants to purchase common stock equal to six percent (6%)
of the aggregate number of Original 2024 Convertible Promissory Note common stock equivalents pursuant to an underwriting agreement at
an exercise price of $<span id="xdx_90D_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20241231__us-gaap--TypeOfArrangementAxis__custom--TwoThousandTwentyFourConvertiblePromissoryNotesMember_z0WCE7f0jCYl">2.38</span> per share, (ii) <span id="xdx_903_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20241231__us-gaap--TypeOfArrangementAxis__custom--AdvisoryAgreementsMember_zaTjwtuUgC58" title="Number of Warrants">68,067</span> <span id="xdx_904_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dxL_c20241231__us-gaap--TypeOfArrangementAxis__custom--AdvisoryAgreementsMember_z6uin94lQ6Ke" title="Warrants, term::XDX::P5Y"><span style="-sec-ix-hidden: xdx2ixbrl1570">five-year</span></span> warrants to purchase common stock pursuant to an advisory agreement at an
exercise price of $<span id="xdx_906_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20241231__us-gaap--TypeOfArrangementAxis__custom--AdvisoryAgreementsMember_zbo3yjrjVAY1">2.38</span> per share. The Common Stock Purchase Warrant Agreements attached to the 2023 Convertible Promissory Notes contained
anti-dilution provisions on both the exercise price and the number of warrants. These anti-dilution features were triggered when the
Company issued the Original 2024 Convertible Promissory Notes that contained a conversion price of $<span id="xdx_907_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20241231__us-gaap--TypeOfArrangementAxis__custom--TwoThousandTwentyFourConvertiblePromissoryNotesMember_zgL4MnU5TVJ8">2.38</span> per share as compared to the
$<span id="xdx_900_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20241231__us-gaap--TypeOfArrangementAxis__custom--TwoThousandTwentyThreeConvertiblePromissoryNotesMember_zgoFI7KbFvnb">5.25</span> per share exercise price in the 2023 Convertible Promissory Note Common Stock Purchase Warrant Agreements. As a result, the Company
issued <span id="xdx_90B_ecustom--ClassOfWarrantOrRightAdditional_iI_pid_c20241231__us-gaap--TypeOfArrangementAxis__custom--TwoThousandTwentyFourConvertiblePromissoryNotesMember_zw314jkXahv6" title="Number of Warrants, additional">754,660</span> additional warrants in 2024 to the holders of the 2023 Convertible Promissory Note Common Stock Purchase Warrant Agreements.
Additionally, <span id="xdx_904_ecustom--NumberOfEquivalentOfWarrantsDescription_c20240101__20241231_z4crh28Pft94" title="Number of equivalent of warrants, description">investors converted  11,000 warrants into an equivalent number of common shares at an exercise price of $2.38 in exchange
for $26,180 in cash proceeds.</span>  The Company also
canceled <span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z7adNtyrgzn3" title="Warrants, canceled">30,252</span> warrants for no consideration in conjunction with an amendment to an advisory agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_89D_ecustom--ScheduleOfWarrantActivityForCommonStockTableTextBlock_hus-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zLrw0eGMZ8Fh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following is a summary of warrant activity for common stock during the years ended December 31, 2024 and 2023:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span><span id="xdx_8B4_zF19HNxPm3Bk" style="display: none">Schedule of Warrant Activity for Common Stock</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Number of Warrants for Common Stock</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted-Avg. Exercise Price</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted-Avg. Remaining Contractual Life</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; font-weight: bold">Outstanding as of January 1, 2023</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zqCUE1twemab" style="width: 16%; text-align: right" title="Number of Warrants, Outstanding at beginning of period">846,507</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zhr3vJ6fezYi" style="width: 16%; text-align: right" title="Weighted Average Exercise Price, Outstanding at beginning of period">5.06</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z1Jwb8Y6z7F4" title="Weighted Average Remaining Contractual Life - Warrants">4.72</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zvCO7feZJtO3" style="text-align: right" title="Number of Warrants, Granted">813,928</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zJhAxuudUgBe" style="text-align: right" title="Weighted Average Exercise Price, granted">5.81</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsWeightedAverageRemainingContracualLifeOutstandingNumberGranted_dtY_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zdueqO08qFP" title="Weighted Average Remaining Contractual Life - Warrants Granted">4.38</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Converted Prefunded Warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsConvertedPrefundedWarrants_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z1T7to5A8GSd" style="text-align: right" title="Number of Warrants, Converted Prefunded Warrants">289,779</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsConvertedPrefundedWarrantsInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zY56eTAD5bmg" style="text-align: right" title="Weighted Average Exercise Price, Converted Prefunded Warrants">0.01</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Cancelled</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zYXpsY5K2eyh" style="text-align: right" title="Number of Warrants, Granted">(30,252</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsWeightedAverageExercisePriceCancelledExpiredNumber_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zftXG45d9Fcg" style="text-align: right" title="Weighted Average Exercise Price, Cancelled Expired">2.38</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90B_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsCancelledWeightedAverageRemainingContractualTerm1_dtY_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z3ExdXdKOUI4" title="Weighted Average Remaining Contractual Life - Warrants Cancelled">4.79</span></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt">Exercised</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zJwgA5K3QICa" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Warrants, Exercised">(127,856</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_ztaF8wIpjGHb" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price, Excercised"><span style="-sec-ix-hidden: xdx2ixbrl1607">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-bottom: 1pt">Outstanding as of December 31, 2023</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zyC3xdrUua51" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Warrants, Outstanding at beginning of period">1,822,358</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zk5KvZkRA7S6" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price, Outstanding at beginning of period">4.69</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zpHWNBLzvNfe" title="Weighted Average Remaining Contractual Life - Warrants">3.05</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zyDwKGvOqya4" style="text-align: right" title="Number of Warrants, Granted">861,424</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zP5e8TEsARIl" style="text-align: right" title="Weighted Average Exercise Price, granted">2.38</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z9qIs9iz7aje" title="Weighted Average Remaining Contractual Life - Warrants Granted">3.49</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Cancelled</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_iN_pid_di_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z0JtbrAmw6L9" style="text-align: right" title="Number of Warrants, Granted">(30,252</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsWeightedAverageExercisePriceCancelledExpiredNumber_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z0fBvAhyc7fe" style="text-align: right" title="Weighted Average Exercise Price, Cancelled Expired">2.38</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90E_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsCancelledWeightedAverageRemainingContractualTerm1_dtY_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zgIGKKCyLomf" title="Weighted Average Remaining Contractual Life - Warrants Cancelled">4.79</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt">Exercised</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zfwcoWXVFRFd" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Warrants, Exercised">(11,000</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zbTO4y9uPVR2" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price, Excercised">2.38</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_90A_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisedWeightedAverageRemainingContractualTerm1_dtY_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zcjv1U3Qle25" title="Weighted Average Remaining Contractual Life - Warrants Granted">3.61</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-bottom: 1pt">Outstanding as of December 31, 2024</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zgqcy9ma0rvk" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Warrants, Outstanding at Ending of period">2,642,530</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_znzR0pZ73WD1" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price, Outstanding at Ending of period">2.41</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zti3Xue9xa3i" title="Weighted Average Remaining Contractual Life - Warrants">2.93</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A6_zEQVibhbHKD5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Neuraxis,
Inc.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Notes
to Financial Statements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_891_ecustom--ScheduleOfWarrantActivityForPreferredStockTableTextBlock_hus-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zNT710L4p2uf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following is a summary of warrant activity for preferred stock during the year ended December 31, 2023:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8BD_zdZp51J3cWs2" style="display: none">Schedule of Warrant Activity for Preferred Stock</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Number of</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Weighted-Avg.</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Warrants for</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Exercise</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Preferred Stock</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Price</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; font-weight: bold; padding-bottom: 1pt">Outstanding as of December 31, 2022</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zfcGzLOG3dr1" style="border-bottom: Black 1pt solid; width: 16%; text-align: right" title="Number of Warrants, Outstanding at beginning of period">144,890</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zN0O4Rsc9wJ" style="border-bottom: Black 1pt solid; width: 16%; text-align: right" title="Weighted Average Exercise Price, Outstanding at beginning of period">0.01</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_z2Va9eQzser" style="text-align: right" title="Number of Warrants, Granted"><span style="-sec-ix-hidden: xdx2ixbrl1645">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_uUSDPShares_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zOMOCQMMk1bg" style="text-align: right" title="Weighted Average Exercise Price, granted"><span style="-sec-ix-hidden: xdx2ixbrl1647">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Cancelled/Expired</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zF9FzeR5PABe" style="text-align: right" title="Number of Warrants, Cancelled Expired"><span style="-sec-ix-hidden: xdx2ixbrl1649">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsWeightedAverageExercisePriceCancelledExpiredNumber_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_z14hGJgeTKV6" style="text-align: right" title="Weighted Average Exercise Price, Cancelled Expired"><span style="-sec-ix-hidden: xdx2ixbrl1651">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Converted to Common Stock Warrant</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsCommonStockWarrant_iN_pid_di_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_znHVx7Qc6Qmb" style="border-bottom: Black 1pt solid; text-align: right" title="Converted to Common Stock Warrant">(144,890</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsWeightedAverageExercisePriceCommonStockWarrant_iN_pid_di_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zxR5E0bIf4hl" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price, Converted to Common Stock Warrant">(0.01</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-bottom: 1pt">Outstanding as of December 31, 2023</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zMic3aPT4rBb" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Warrants, Outstanding at Ending of period"><span style="-sec-ix-hidden: xdx2ixbrl1657">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_z8VxpLHbvBK4" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price, Outstanding at Ending of period"><span style="-sec-ix-hidden: xdx2ixbrl1659">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8AC_zyLc5OvCht5e" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
was no preferred stock warrant activity during the year ended December 31, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_898_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_z9igFQMpLx0d" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes the Company&#8217;s warrants outstanding and exercisable as of December 31, 2024:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8BC_zvxaUvkopMl5" style="display: none">Schedule of Warrants outstanding and Exercisable</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Number of</td><td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Warrants</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Exercise</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: center">Expiration</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Outstanding</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Price</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Date</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; text-align: left">Investor Warrant</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--InvestorWarrantOneMember_zCwbBa9nn5Ti" style="width: 16%; text-align: right" title="Number of Warrants">12,852</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_980_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--InvestorWarrantOneMember_zzr2tmz9546e" style="width: 16%; text-align: right" title="Exercise Price">8.76</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 18%; text-align: center"><span id="xdx_90E_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--InvestorWarrantOneMember_zYJKbGJUSZKb" title="Expiration Date">September 18, 2028</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Investor Warrant</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--InvestorWarrantPSAOneMember_zcLpYDWZaeAl" style="text-align: right" title="Number of Warrants">289,779</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_987_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--InvestorWarrantPSAOneMember_zmzsgDqFYzq6" style="text-align: right" title="Exercise Price">0.01</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center"><span id="xdx_90C_ecustom--WarrantExpirationDateDescription_c20240101__20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--InvestorWarrantPSAOneMember_zhIdSpG22uz" title="Expiration Date">None</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">2022 Convertible Notes</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--TwoThousandTwentyTwoConvertibleNotesMember_zoK0YKQK2Zlc" style="text-align: right" title="Number of Warrants">782,655</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--TwoThousandTwentyTwoConvertibleNotesMember_zvl7qbY1ug3e" style="text-align: right" title="Exercise Price">2.38</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center"><span id="xdx_90B_ecustom--WarrantExpirationDateDescription_c20240101__20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--TwoThousandTwentyTwoConvertibleNotesMember_zvM5SIXYBBo6" title="Expiration Date">Various in 2027</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">2023 Convertible Notes</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--TwoThousandTwentyThreeConvertibleNotesMember_z9Htp0tD3X5g" style="text-align: right" title="Number of Warrants">1,149,586</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_989_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--TwoThousandTwentyThreeConvertibleNotesMember_zfgkRFQC2Yj5" style="text-align: right" title="Exercise Price">2.38</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center"><span id="xdx_90E_ecustom--WarrantExpirationDateDescription_c20240101__20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--TwoThousandTwentyThreeConvertibleNotesMember_znoFVfcfoDo7" title="Expiration Date">Various in 2028</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Underwriter Warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--UnderwriterWarrantsMember_zZO43U71DrG2" style="text-align: right" title="Number of Warrants">331,146</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_980_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--UnderwriterWarrantsMember_zUZ13v9jeyFj" style="text-align: right" title="Exercise Price">2.38</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center"><span id="xdx_903_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--UnderwriterWarrantsMember_zwBgUbqUDd2i" title="Expiration Date">August 8, 2028</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Advisory Agreement Warrants</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--AdvisoryAgreementWarrantsMember_zeWU4i89Vkd2" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Warrants">76,512</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">$</td><td id="xdx_98F_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--AdvisoryAgreementWarrantsMember_zuEVWVpc4Ix3" style="padding-bottom: 1pt; text-align: right" title="Exercise Price">2.38</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1pt"><span id="xdx_90E_ecustom--WarrantExpirationDateDescription_c20240101__20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--AdvisoryAgreementWarrantsMember_zns5lNIaieig" title="Expiration Date">Various in 2029</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20241231_zCUeLXbdEkB4" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Warrants">2,642,530</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td></tr>
  </table>


<p id="xdx_8AC_zLQMJ8gCt1T4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480237/815-40-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/505/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-16<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Preferred Stock<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockTextBlock', window );">Preferred Stock</a></td>
<td class="text"><p id="xdx_805_eus-gaap--PreferredStockTextBlock_zZYzrZvyML03" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>10.
<span id="xdx_826_zCSBQTL0v5Ba">Preferred Stock</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2023, the Company had&#160;<span id="xdx_907_eus-gaap--PreferredStockSharesAuthorized_iI_c20231231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zp47lXYOLbfj" title="Preferred stock, shares authorized">1,000,000</span>&#160;and&#160;<span id="xdx_905_eus-gaap--PreferredStockSharesAuthorized_iI_c20231231__us-gaap--StatementClassOfStockAxis__custom--SeriesSeedPreferredStockMember_zAWxjg4zLpJi" title="Preferred stock, shares authorized">120,000</span>&#160;shares authorized as Series A and Series Seed Preferred
Stock, respectively, of which&#160;<span id="xdx_901_eus-gaap--PreferredStockSharesIssued_iI_dc_c20231231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zTdXQaXAUy61" title="Preferred stock, shares issued"><span id="xdx_906_eus-gaap--PreferredStockSharesOutstanding_iI_dc_c20231231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zSodCfpNEsh3" title="Preferred stock, shares outstanding"><span id="xdx_900_eus-gaap--PreferredStockSharesIssued_iI_dc_c20231231__us-gaap--StatementClassOfStockAxis__custom--SeriesSeedPreferredStockMember_zjoOeCO9i7ng" title="Preferred stock, shares issued"><span id="xdx_909_eus-gaap--PreferredStockSharesOutstanding_iI_dc_c20231231__us-gaap--StatementClassOfStockAxis__custom--SeriesSeedPreferredStockMember_ziLCyiFQcgbc" title="Preferred stock, shares outstanding">zero</span></span></span></span>&#160;shares are issued and outstanding for both classes of preferred stock. The Series A and
Series Seed Preferred Stock (i) voted together with common stock on an as-converted basis, and not as separate classes and (ii) converted
1:1 to common stock at any time at option of holder, subject to adjustments for stock dividends, splits, combinations, and similar events.
The Series A Preferred Stock carried an annual&#160;<span id="xdx_90C_eus-gaap--PreferredStockDividendRatePercentage_dp_uPure_c20230101__20231231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zMQGLxpbUZs8" title="Preferred stock dividend rate percentage">8</span>% cumulative dividend, payable upon any liquidation, dissolution or winding up of
the Company. For any other dividends or distributions, the Series A Preferred Stock participated with common stock on an as-converted
basis. <span id="xdx_90F_ecustom--PreferredStockSharesRetiredDescription_iI_c20231231__us-gaap--StatementClassOfStockAxis__custom--SeriesSeedPreferredStockMember_zoZlUtluCbr8" title="Preferred stock, retired description">The Company&#8217;s&#160;1,000,000&#160;shares of Series A Preferred Stock and&#160;120,000&#160;shares of Series Seed Preferred
Stock were retired on August 15, 2024.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August 15, 2024, the Company&#8217;s shareholders authorized&#160;<span id="xdx_90E_eus-gaap--PreferredStockSharesAuthorized_iI_c20240815__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zgA7sLfI2vkj" title="Preferred stock, shares authorized">5,000,000</span>&#160;shares of preferred stock of which&#160;<span id="xdx_909_eus-gaap--TemporaryEquitySharesAuthorized_iI_pid_c20240815__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zqZFtyvS61i2" title="Temporary equity, shares authorized">4,000,000</span>&#160;shares
were designated as $<span id="xdx_909_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20240815__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zUiJ7TNL8Jr7" title="Preferred stock, par value">0.001</span>&#160;par value Series B Preferred Stock. Series B Preferred Stock shareholders vote with Common Stock shareholders
on an as-converted basis and not as a separate class. Cumulative dividends accrue at&#160;<span id="xdx_906_eus-gaap--PreferredStockDividendRatePercentage_dp_uPure_c20240815__20240815__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zaTB22F8i2Oi" title="Preferred stock dividend rate percentage">8.5</span>% per annum and are due and payable in either
cash for common shares as the Company&#8217;s discretion on a quarterly basis through June 30, 2025. Series B Preferred Stock converts
to common stock on a 1:1 basis, subject to adjustments for stock dividends, splits, combinations and similar events as well as unpaid
dividends thereon, solely at the election of the holder at any time.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white">&#160;</p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the terms of the Amended 2024 Convertible Notes, the principal balance of $<span id="xdx_90C_eus-gaap--DebtInstrumentFaceAmount_iI_c20240815__us-gaap--ShortTermDebtTypeAxis__custom--AmendedTwoThousandTwentyFourConvertibleNotesMember_zYHpg4Zafdq2" title="Borrowed amount">4,935,000</span> on August 15, 2024 was mandatorily converted
into <span id="xdx_90E_eus-gaap--ConversionOfStockSharesConverted1_c20240815__20240815__us-gaap--ShortTermDebtTypeAxis__custom--AmendedTwoThousandTwentyFourConvertibleNotesMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zIYWn3b9oGh6" title="Shares converted">2,073,524</span> Series B Preferred Shares at a conversion price of $<span id="xdx_90B_eus-gaap--SharesIssuedPricePerShare_iI_c20240815__us-gaap--ShortTermDebtTypeAxis__custom--AmendedTwoThousandTwentyFourConvertibleNotesMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zjAj2KsuJf55" title="Conversion per shares">2.38</span>. Subsequently, the Company then proceeded to issue <span id="xdx_90A_ecustom--ProceedsFromIssuanceOfStock_c20240815__20240815__us-gaap--ShortTermDebtTypeAxis__custom--AmendedTwoThousandTwentyFourConvertibleNotesMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zCyF4tansIoh" title="Issuance of debt, shares">64,913</span> shares
of Series B Preferred Stock to various investors for $<span id="xdx_90E_eus-gaap--ProceedsFromIssuanceOfDebt_c20240815__20240815__us-gaap--ShortTermDebtTypeAxis__custom--AmendedTwoThousandTwentyFourConvertibleNotesMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zv8WWQCZm0Ug" title="Issuance of debt">154,500</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
November 11, 2024, the Company&#8217;s shareholders authorized (i) an increase in the number of designated Series B Preferred Stock
to <span id="xdx_905_eus-gaap--PreferredStockSharesAuthorized_iI_c20241111__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_z6g2JyMHGWMa" title="Preferred stock, shares authorized">5,000,000</span>
shares and (ii) an extension of the <span id="xdx_902_ecustom--CumulativeDividendsPercent_iI_pid_dp_uPure_c20241111__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zf3nOa6DXTx5" title="Cumulative dividends percent">8.5</span>%
per annum cumulative dividend period to December 31, 2026. Subsequently, the Company issued <span id="xdx_900_eus-gaap--SharesIssued_iI_c20241113__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zJ2jGjVeNYii" title="Preferred stock, shares issued">2,100,840</span>
shares of Series B Preferred Stock to a dedicated life sciences fund for $<span id="xdx_904_eus-gaap--PreferredStockSharesAuthorized_iI_c20241113__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zmmXdHHuihg6" title="Preferred stock, shares authorized">5,000,000</span>
and <span id="xdx_900_ecustom--ProceedsFromIssuanceOfStock_c20241111__20241111__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zZqFfsYMI1ng" title="Issuance of debt, shares">41,662</span> shares of Series B Preferred Stock to various investors for $<span id="xdx_90F_eus-gaap--ProceedsFromIssuanceOfDebt_c20241111__20241111__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zGXcN9H8Pjn6" title="Issuance of debt">99,164</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon
any liquidation, dissolution or winding up of the Company, whether voluntary or involuntary, the Series B Preferred Stock
shareholders maintain priority preference over all other classes of capital stock. A merger or consolidation (other than one in
which stockholders of the Company own a majority by voting power of the outstanding shares of the surviving or acquiring
corporation) and a sale, lease, transfer, exclusive license or other disposition of all or substantially all of the assets of the
Company will be treated as a liquidation event, thereby triggering payment of the liquidation preferences.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2024, there were <span id="xdx_90D_eus-gaap--PreferredStockSharesOutstanding_iI_c20241231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zBbg0B4WYbb8">4,280,939 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares
of Series B Preferred Stock issued and outstanding. As of December 31, 2024 and 2023, there were&#160;<span id="xdx_907_eus-gaap--DividendsPayableCurrentAndNoncurrent_iI_do_c20241231__us-gaap--StatementClassOfStockAxis__us-gaap--PreferredStockMember_z7lAlJ6WX1Jg" title="Dividends declared"><span id="xdx_90F_eus-gaap--DividendsPayableCurrentAndNoncurrent_iI_do_c20231231__us-gaap--StatementClassOfStockAxis__us-gaap--PreferredStockMember_z1oUoRfkOZK3" title="Dividends declared">no</span></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;preferred
stock dividends declared or paid. Series B Preferred Stock undeclared cumulative dividends totaled $<span id="xdx_902_eus-gaap--DividendsPreferredStock_c20240101__20241231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zwgSShbrbgD1" title="Dividends">211,268</span>,
or $<span id="xdx_900_eus-gaap--PreferredStockDividendRatePerDollarAmount_uUSDPShares_c20240101__20241231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zFsHY00Iz4bc" title="Dividends, preferred stock per share">0.05</span> per share, as of December 31, 2024. Series B Preferred Stock did not exist during the year ended December 31, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for terms, amounts, nature of changes, rights and privileges, dividends, and other matters related to preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/505/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-Based Compensation</a></td>
<td class="text"><p id="xdx_806_eus-gaap--DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_z582ETxRitH3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>11.
<span id="xdx_82F_zoqOnkd3y7Th">Stock-Based Compensation</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
October 12, 2017, the Company adopted the 2017 Stock Compensation Plan authorizing the issuance of <span id="xdx_90F_eus-gaap--CommonStockSharesAuthorized_iI_pid_c20171012__us-gaap--PlanNameAxis__custom--TwentySeventeenStockCompensationPlanMember_zfNNVZCieyQ1" title="Common stock, shares authorized">1,435,652</span> shares of common stock.
On September 13, 2019 the Company entered into a Stock Option Cancellation agreement with all holders of these stock options effective
on that date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
plan was then amended on September 13, 2019, to increase the share amount to <span id="xdx_901_eus-gaap--SharesIssued_iI_pid_c20190913__us-gaap--PlanNameAxis__custom--TwentySeventeenStockCompensationPlanMember_zB1TMvrsYdXl" title="Shares issued">2,638,788</span>. This plan was enacted to enable the Company to
retain the services of certain key employees, officers, and directors of the Company. The Plan provides for the grant of stock options,
including incentive stock options, or ISOs, and nonqualified stock options, or NSOs and restricted stock, and they were estimated using
the Black-Scholes option-pricing model with the following weighted-average assumptions:</span></p>

<p id="xdx_892_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zG5Qp2V0YQjd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B2_zGOV7bG7BGUc" style="display: none">Schedule of Option-pricing Model with Following Weighted-average Assumptions</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 60%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Assumptions as of December 31, 2023</td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">Fully Vested</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%">Number of Shares</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_c20231231__us-gaap--PlanNameAxis__custom--TwentySeventeenStockCompensationPlanMember_znhL7DOHtJSf" style="width: 16%; text-align: right" title="Number of Shares">1,319,394</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Stock price</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_980_eus-gaap--SharePrice_iI_c20231231__us-gaap--PlanNameAxis__custom--TwentySeventeenStockCompensationPlanMember_z35t4olRGgj2" style="text-align: right" title="Stock price">2.67</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Exercise price</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_c20231231__us-gaap--PlanNameAxis__custom--TwentySeventeenStockCompensationPlanMember_zAUbudleH1La" style="text-align: right" title="Exercise price">6.94</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Expected term</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230101__20231231__us-gaap--PlanNameAxis__custom--TwentySeventeenStockCompensationPlanMember_z14VKcAWI4G3" title="Expected term">5.75</span> years</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Expected volatility</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20230101__20231231__us-gaap--PlanNameAxis__custom--TwentySeventeenStockCompensationPlanMember_zQeLhyj1Eqy1" style="text-align: right" title="Expected volatility">31.90</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Risk-free interest rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20230101__20231231__us-gaap--PlanNameAxis__custom--TwentySeventeenStockCompensationPlanMember_zNjBU10Mq145" style="text-align: right" title="Risk-free interest rate">3.84</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Dividend rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20230101__20231231__us-gaap--PlanNameAxis__custom--TwentySeventeenStockCompensationPlanMember_zUZLFZTEndI5" style="text-align: right" title="Dividend rate">0</td><td style="text-align: left">%</td></tr>
  </table>

<p id="xdx_8A1_zrs24MhAL5Ji" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Neuraxis,
Inc.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Notes
to Financial Statements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_89E_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zN7Dhk6r2Y0a" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following is a summary of the outstanding stock options as of December 31, 2024 and 2023:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8BB_zZTUR7enWRSi" style="display: none">Schedule of Stock Option Activity</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Number of Options</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted Avg. Remaining Contractual Life (in years)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted Avg. Exercise Price</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Aggregate Intrinsic Value</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 36%; font-weight: bold; padding-bottom: 1pt">Outstanding as of December 31, 2023</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20240101__20241231_zbdgYc0k0tj6" style="border-bottom: Black 1pt solid; width: 12%; text-align: right" title="Number of Options, Outstanding, Beginning balance">1,319,394</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; width: 12%; text-align: right"><span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230101__20231231_z39nUXErIBH7" title="Weighted Average Remaining Contractual Life (in years), Outstanding">5.69</span></td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_uUSDPShares_c20240101__20241231_zRBnsQjAVTg3" style="border-bottom: Black 1pt solid; width: 12%; text-align: right" title="Weighted Average Exercise Price, Outstanding, Beginning balance">6.94</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_c20240101__20241231_zo0CKJ6eWyza" style="border-bottom: Black 1pt solid; width: 12%; text-align: right" title="Aggregate Intrinsic Value, Outstanding, Beginning balance"><span style="-sec-ix-hidden: xdx2ixbrl1788">&#8212;</span></td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; padding-bottom: 1pt">Outstanding as of December 31, 2024</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20240101__20241231_z55EeHnyKinh" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Options, Outstanding, Ending balance">1,319,394</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231_zxR1WpQg0Oz2" title="Weighted Average Remaining Contractual Life (in years), Outstanding">4.69</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_uUSDPShares_c20240101__20241231_zvtuUdJvgcr" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price, Outstanding, Ending balance">6.94</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_c20240101__20241231_zwttZBExv1sa" style="border-bottom: Black 1pt solid; text-align: right" title="Aggregate Intrinsic Value, Outstanding, Ending balance"><span style="-sec-ix-hidden: xdx2ixbrl1796">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-bottom: 1pt">Vested and Exercisable as of December 31, 2024</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_iE_pid_c20240101__20241231_zj5LvhhpSMce" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Options, Vested and Exercisable, Ending balance">1,319,394</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_dtY_c20240101__20241231_zg10RHlZAHDg" title="Weighted Average Remaining Contractual Life (in years), Vested and Exercisable">4.69</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iE_pid_uUSDPShares_c20240101__20241231_zHcu58EvmXoj" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price, Vested and Exercisable, Ending balance">6.94</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_iE_c20240101__20241231_zURCbanmCr4e" style="border-bottom: Black 1pt solid; text-align: right" title="Aggregate Intrinsic Value, Vested and Exercisable, Ending balance"><span style="-sec-ix-hidden: xdx2ixbrl1804">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8AD_zZE9c8ADNSw4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">Total stock-based compensation
expense is classified in the Company&#8217;s statements of operations as general and administrative expense totaling $<span id="xdx_90C_eus-gaap--ShareBasedCompensation_c20240101__20241231_zI8x5UZ9IfJk" title="Share based compensation">227,000</span>
and $<span id="xdx_90E_eus-gaap--ShareBasedCompensation_dxL_c20230101__20231231_zx6I8yThynj1" title="Share based compensation::XDX::-"><span style="-sec-ix-hidden: xdx2ixbrl1808">0</span></span>
for the years ended December 31, 2024 and 2023, respectively. The stock compensation incurred during the year ended December 31,
2024 related to a hiring grant of <span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20240101__20241231__srt--TitleOfIndividualAxis__srt--ChiefFinancialOfficerMember_z4ZqWM8HhEI9" title="Granted">100,000</span> common
shares to the Company&#8217;s Chief Financial Officer at a fair value of $<span id="xdx_902_eus-gaap--SharePrice_iI_c20241231__srt--TitleOfIndividualAxis__srt--ChiefFinancialOfficerMember_zUe2s28C9Eul" title="Share price">2.27</span> per share.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Warrant Liabilities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NRXS_DisclosureWarrantLiabilitiesAbstract', window );"><strong>Warrant Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NRXS_WarrantLiabilitiesDisclosureTextBlock', window );">Warrant Liabilities</a></td>
<td class="text"><p id="xdx_802_ecustom--WarrantLiabilitiesDisclosureTextBlock_zLJ9px8k3Syi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>12.
<span id="xdx_824_z6GXrWDDRILk">Warrant Liabilities</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has evaluated financial instruments arising from warrants that are issued and outstanding as of December 31, 2024 and 2023. The
Company utilizes a Black-Scholes option-pricing model to compute the fair value of the liability and to mark to market the fair value
of the warrant at each balance sheet date. The inputs utilized in the application of the Black-Scholes option-pricing model included
(i) an exercise price of $<span id="xdx_902_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uUSDPShares_c20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember_zrjptfCvcQz8" title="Warrants and rights outstanding, measurement input">8.76</span> per share, (ii) an expected remaining term of each warrant based on the remaining contractual maturity
of the each warrant, (iii) estimated volatility ranging from <span id="xdx_901_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__srt--RangeAxis__srt--MinimumMember_zmSn9NaiSFL2" title="Warrants and rights outstanding, measurement input">75.0</span>% to <span id="xdx_902_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__srt--RangeAxis__srt--MaximumMember_zf5dKmajsiZ6" title="Warrants and rights outstanding, measurement input">84.5</span>% based on historical stock prices of comparable companies
with a look back period commensurate with the period to maturity, (iv) a risk-free interest rate ranging from <span id="xdx_90C_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MinimumMember_zQ203NSiNd12" title="Warrants and rights outstanding, measurement input">3.84</span>% to <span id="xdx_90E_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MaximumMember_zThTTGydVYB5" title="Warrants and rights outstanding, measurement input">4.38</span>% based on
the interest rates of U.S. Treasury Notes consistent with the expected remaining contract term and (v) a <span id="xdx_908_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zB9nQtROHcvl" title="Warrants and rights outstanding, measurement input">0</span>% expected dividend yield as
the Company has not paid dividends to date and does not anticipate declaring dividends in the near future.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Neuraxis,
Inc.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Notes
to Financial Statements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_897_ecustom--ScheduleOfChangesInWarrantLiabilitiesTableTextBlock_zhnajgsOSnk5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following are the changes in the warrant liabilities during the years ended December 31, 2024 and 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8BD_ziPvejQmf2bf" style="display: none">Schedule of Changes in Warrant Liabilities</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 1</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 2</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 3</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; font-weight: bold">Warrant liabilities as of January 1, 2023</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--WarrantsAndRightsOutstanding_iS_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zT88wBP0RRP8" style="width: 12%; text-align: right" title="Warrant liabilities, Beginning balance"><span style="-sec-ix-hidden: xdx2ixbrl1830">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--WarrantsAndRightsOutstanding_iS_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zdwd7tq2Q0bl" style="width: 12%; text-align: right" title="Warrant liabilities, Beginning balance"><span style="-sec-ix-hidden: xdx2ixbrl1832">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_986_eus-gaap--WarrantsAndRightsOutstanding_iS_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zx9tsgBNOnD4" style="width: 12%; text-align: right" title="Warrant liabilities, Beginning balance">2,234,384</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt">Addition</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_ecustom--AdditionToWarrantLiabilities_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zee6DAMsbl2j" style="text-align: right" title="Addition"><span style="-sec-ix-hidden: xdx2ixbrl1836">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_ecustom--AdditionToWarrantLiabilities_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zSD8bz35u2Id" style="text-align: right" title="Addition"><span style="-sec-ix-hidden: xdx2ixbrl1838">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_ecustom--AdditionToWarrantLiabilities_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zA7l7yecfaIh" style="text-align: right" title="Addition">2,446,502</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Reclassified to equity</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_ecustom--ReclassifiedToEquity_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zvOYF9TMRBFg" style="text-align: right" title="Reclassified to equity"><span style="-sec-ix-hidden: xdx2ixbrl1842">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_ecustom--ReclassifiedToEquity_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zw1ZC82J6fde" style="text-align: right" title="Reclassified to equity"><span style="-sec-ix-hidden: xdx2ixbrl1844">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_ecustom--ReclassifiedToEquity_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z4zv76UCtXHk" style="text-align: right" title="Reclassified to equity">(3,827,807</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Changes in fair value of warrant liabilities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--FairValueAdjustmentOfWarrants_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zHU0YUGcnGE5" style="border-bottom: Black 1pt solid; text-align: right" title="Changes in fair value of warrant liabilities"><span style="-sec-ix-hidden: xdx2ixbrl1848">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--FairValueAdjustmentOfWarrants_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zaBHCB3F95se" style="border-bottom: Black 1pt solid; text-align: right" title="Changes in fair value of warrant liabilities"><span style="-sec-ix-hidden: xdx2ixbrl1850">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--FairValueAdjustmentOfWarrants_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zvYO3V51Q4Q8" style="border-bottom: Black 1pt solid; text-align: right" title="Changes in fair value of warrant liabilities">(844,854</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold">Warrant liabilities as of December 31, 2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--WarrantsAndRightsOutstanding_iS_c20240101__20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zAQCcSYfDdUi" style="text-align: right" title="Warrant liabilities, Beginning balance"><span style="-sec-ix-hidden: xdx2ixbrl1854">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--WarrantsAndRightsOutstanding_iS_c20240101__20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zl5xaH5D1Jo8" style="text-align: right" title="Warrant liabilities, Beginning balance"><span style="-sec-ix-hidden: xdx2ixbrl1856">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--WarrantsAndRightsOutstanding_iS_c20240101__20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zbrQ6KXGpJW7" style="text-align: right" title="Warrant liabilities, Beginning balance">8,225</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Changes in fair value of warrant liabilities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--FairValueAdjustmentOfWarrants_c20240101__20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zf8FawArezfl" style="border-bottom: Black 1pt solid; text-align: right" title="Changes in fair value of warrant liabilities"><span style="-sec-ix-hidden: xdx2ixbrl1860">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--FairValueAdjustmentOfWarrants_c20240101__20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zZrLRI2XKRp8" style="border-bottom: Black 1pt solid; text-align: right" title="Changes in fair value of warrant liabilities"><span style="-sec-ix-hidden: xdx2ixbrl1862">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--FairValueAdjustmentOfWarrants_c20240101__20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zXJzf1PfozVa" style="border-bottom: Black 1pt solid; text-align: right" title="Changes in fair value of warrant liabilities">941</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-bottom: 1pt">Warrant liabilities as of December 31, 2024</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_982_eus-gaap--WarrantsAndRightsOutstanding_iE_c20240101__20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zkMY2pnoFcq3" style="border-bottom: Black 1pt solid; text-align: right" title="Warrant liabilities, Ending balance"><span style="-sec-ix-hidden: xdx2ixbrl1866">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_980_eus-gaap--WarrantsAndRightsOutstanding_iE_c20240101__20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zdADnq4PbFzl" style="border-bottom: Black 1pt solid; text-align: right" title="Warrant liabilities, Ending balance"><span style="-sec-ix-hidden: xdx2ixbrl1868">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_985_eus-gaap--WarrantsAndRightsOutstanding_iE_c20240101__20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zDMfqGcS94G1" style="border-bottom: Black 1pt solid; text-align: right" title="Warrant liabilities, Ending balance">9,166</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8AF_zxrrg3ZKTql1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_NRXS_DisclosureWarrantLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">NRXS_DisclosureWarrantLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>NRXS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_NRXS_WarrantLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrant Liabilities Disclosure [Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">NRXS_WarrantLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>NRXS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Derivative Liabilities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NRXS_DisclosureDerivativeLiabilitiesAbstract', window );"><strong>Derivative Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesAndFairValueTextBlock', window );">Derivative Liabilities</a></td>
<td class="text"><p id="xdx_805_eus-gaap--DerivativesAndFairValueTextBlock_zu2vEO7IMDw7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>13.
<span id="xdx_827_zVORf07c8s3c">Derivative Liabilities</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has evaluated derivatives arising from convertible financial instruments as of December 31, 2024 and 2023. The Company utilized
a Monte Carlo simulation model for commitment shares that have an option to convert at a variable number of shares to compute the fair
value of the derivative and to mark to market the fair value of the derivative at each balance sheet date. The inputs utilized in the
application of the Monte Carlo model included a starting stock price of $<span id="xdx_905_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember_zKzjUyOljpae" title="Derivative liability, measurement input">7.91</span> per share, (ii) an expected remaining term of each derivative
based on the remaining contractual maturity of the each derivative, (iii) estimated volatility of <span id="xdx_90B_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zkpiEtIGim5e" title="Derivative liability, measurement input">70.0</span>% based on historical stock prices
of comparable companies with a look back period commensurate with the period to maturity, (iv) a risk-free interest rate ranging from
<span id="xdx_902_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MinimumMember_zfRiq3dgO9ai" title="Derivative liability, measurement input">3.46</span>% to <span id="xdx_903_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MaximumMember_zf7y7oyPPPa7" title="Derivative liability, measurement input">5.47</span>% based on the interest rates of U.S. Treasury Notes consistent with the expected remaining contract term and (v) a <span id="xdx_901_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zVhPZeP70wph" title="Derivative liability, measurement input">0</span>% expected
dividend yield as the Company has not paid dividends to date and does not anticipate declaring dividends in the near future and (vi)
drift.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_89F_eus-gaap--ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock_zfXEuYd43pb8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following are the changes in the derivative liabilities during the year ended December 31, 2023:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B4_zD5ZA7TNqMEk" style="display: none">Schedule of Changes in Derivative Liabilities</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 1</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 2</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 3</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; font-weight: bold">Derivative liabilities as of December 31, 2022</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_986_ecustom--ChangesInDerivativeLiabilities_iS_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zP8tnL9A2rg8" style="width: 12%; text-align: right" title="Derivative liabilities, Beginning balance"><span style="-sec-ix-hidden: xdx2ixbrl1886">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_987_ecustom--ChangesInDerivativeLiabilities_iS_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zeqmf28McAp2" style="width: 12%; text-align: right" title="Derivative liabilities, Beginning balance"><span style="-sec-ix-hidden: xdx2ixbrl1888">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_982_ecustom--ChangesInDerivativeLiabilities_iS_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zCuIuUgQiaw2" style="width: 12%; text-align: right" title="Derivative liabilities, Beginning balance">1,735,700</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt">Addition</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_ecustom--AdditionToDerivativeLiabilities_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zbSf9gQIUbWc" style="text-align: right" title="Addition"><span style="-sec-ix-hidden: xdx2ixbrl1892">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_ecustom--AdditionToDerivativeLiabilities_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zUnRulXJI57e" style="text-align: right" title="Addition"><span style="-sec-ix-hidden: xdx2ixbrl1894">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_ecustom--AdditionToDerivativeLiabilities_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z6VRuutgHygf" style="text-align: right" title="Addition">2,375,378</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Changes in fair value of derivative liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--IncreaseDecreaseInDerivativeLiabilities_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zPG3xHL5PHK6" style="text-align: right" title="Changes in fair value of Derivative liabilities"><span style="-sec-ix-hidden: xdx2ixbrl1898">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--IncreaseDecreaseInDerivativeLiabilities_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_z7iD4PCJp5qi" style="text-align: right" title="Changes in fair value of Derivative liabilities"><span style="-sec-ix-hidden: xdx2ixbrl1900">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--IncreaseDecreaseInDerivativeLiabilities_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z0aCo4QrZhql" style="text-align: right" title="Changes in fair value of Derivative liabilities">(198,551</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Extinguishment of derivative liabilities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_986_ecustom--ExtinguishmentOfDerivativeLiabilities_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_z2tptvDslgV6" style="border-bottom: Black 1pt solid; text-align: right" title="Extinguishment of Derivative liabilities"><span style="-sec-ix-hidden: xdx2ixbrl1904">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_988_ecustom--ExtinguishmentOfDerivativeLiabilities_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zG9Bj6nOkTKj" style="border-bottom: Black 1pt solid; text-align: right" title="Extinguishment of Derivative liabilities"><span style="-sec-ix-hidden: xdx2ixbrl1906">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98E_ecustom--ExtinguishmentOfDerivativeLiabilities_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zcshAjGpFsW9" style="border-bottom: Black 1pt solid; text-align: right" title="Extinguishment of Derivative liabilities">(3,912,527</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-bottom: 1pt">Derivative liabilities as of December 31, 2023</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_98A_ecustom--ChangesInDerivativeLiabilities_iE_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zpfbG6B2XGSk" style="border-bottom: Black 1pt solid; text-align: right" title="Derivative liabilities, Ending balance"><span style="-sec-ix-hidden: xdx2ixbrl1910">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_983_ecustom--ChangesInDerivativeLiabilities_iE_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zdxl4nMNr2uh" style="border-bottom: Black 1pt solid; text-align: right" title="Derivative liabilities, Ending balance"><span style="-sec-ix-hidden: xdx2ixbrl1912">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_98F_ecustom--ChangesInDerivativeLiabilities_iE_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zHFXPAjluqB6" style="border-bottom: Black 1pt solid; text-align: right" title="Derivative liabilities, Ending balance"><span style="-sec-ix-hidden: xdx2ixbrl1914">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8AC_z3wz7LuPHqBe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
were no derivatives identified during the year ended December 31, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Neuraxis,
Inc.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Notes
to Financial Statements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_NRXS_DisclosureDerivativeLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">NRXS_DisclosureDerivativeLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>NRXS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativesAndFairValueTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for derivatives and fair value of assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 815<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/815/tableOfContent<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 820<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/820/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativesAndFairValueTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Retirement Plan<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock', window );">Retirement Plan</a></td>
<td class="text"><p id="xdx_801_eus-gaap--PensionAndOtherPostretirementBenefitsDisclosureTextBlock_zjerfXftDTjh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>14.
<span id="xdx_82F_z78zqGuKdltg">Retirement Plan</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company sponsors a 401(k)-retirement plan for its employees. Employees are eligible to participate in the elective deferral portion of
the plan after twelve months and 1,000 hours of service. The Company can also make a <span id="xdx_901_eus-gaap--DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_dp_uPure_c20240101__20241231_z2NE3ADGeJXk" title="Employee contribution percentage">3</span>% discretionary profit-sharing contribution on
an annual basis to employees with earnings under a certain threshold. Profit sharing expense totaled $<span id="xdx_902_eus-gaap--DefinedContributionPlanAdministrativeExpenses_c20240101__20241231_zOF0Tk3wGnW8" title="Profit sharing contribution expenses">20,868</span> and $<span id="xdx_903_eus-gaap--DefinedContributionPlanAdministrativeExpenses_c20230101__20231231_zuptPMhsu8b9" title="Profit sharing contribution expenses">6,980</span> for years ended
December 31, 2024 and 2023, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for retirement benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 70<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480794/715-70-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480482/715-20-55-17<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (q)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/715/tableOfContent<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (o)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (p)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480126/715-20-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480266/715-60-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">Segment Information</a></td>
<td class="text"><p id="xdx_80A_eus-gaap--SegmentReportingDisclosureTextBlock_zzwg7jbYz5R7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>15.
<span id="xdx_820_zr9ex6xRUP24">Segment Information</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company evaluates the following factors to identify its reportable segments: (i) nature of products and services, (ii) type of customer
for the products and services, (iii) sales, production and distribution methods of the products and services and (iv) the nature of the
regulatory environment, if applicable. Based on an evaluation of these factors, management concluded that the Company&#8217;s operations are managed through one reportable segment, IB-STIM, that derives its revenues in the United States from a
PENFS device that is used to treat patients 8-21 years of age with functional abdominal pain associated with irritable bowel syndrome.
IB-STIM currently is the only product marketed and sold by the Company. The accounting policies of the IB-STIM segment are the same as
those described in the Summary of Significant Accounting Policies (see Footnote 2). The CODM regularly evaluates the performance of the
IB-STIM segment for the purpose of allocating resources based on net sales and operating loss, both of which are reported in the Statements
of Operations. The CODM uses net sales to evaluate IB-STIM&#8217;s adoption and utilization by insurance carriers and physicians. As
Neuraxis is an emerging growth company, operating loss is used to monitor the Company&#8217;s cost structure in order to achieve future
segment profitability. Both net sales and operating loss are measured against the budget on a periodic basis to assess achievement toward
annual compensation incentive targets. The Company&#8217;s CODM is its Chief Executive Officer.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_89D_eus-gaap--ScheduleOfSegmentReportingInformationBySegmentTextBlock_zxiAZRRNNNX4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following reconciles the reportable segment net sales and operating loss to the Company&#8217;s reported net loss:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B3_zIRrk2PmXsYd">Schedule
of Reconciles the Company&#8217;s Net Sales and Operating Loss</span>&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="display: none; text-align: center">&#160;</td><td style="display: none; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_496_20240101__20241231__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_zQVzSUxLXCS8" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center">2024</td><td style="display: none; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="display: none; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_492_20230101__20231231__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_zS6R7VBfCF2f" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center">2023</td><td style="display: none; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">For the Years Ended December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_maCzEo3_zCN9uWPcUpNh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; width: 60%; font-weight: bold; text-align: left">Net Sales</td><td style="width: 2%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">$</td><td style="width: 16%; font-weight: bold; text-align: right">2,685,925</td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">2,460,049</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--CostOfGoodsAndServicesSold_msCzEo3_zdJ2IIL909ld" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Cost of Goods Sold</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">362,002</td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">303,345</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--GrossProfit_iT_mtCzEo3_maOILz3im_zHXktUBsxMc" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; font-weight: bold; text-align: left">Gross Profit</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">2,323,923</td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,156,704</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--SellingExpense_i01_msOILz3im_zYmpOrmV48va" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Selling Expenses <span id="xdx_F44_ztbxsniXabr">(a)</span></td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">324,708</td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">323,569</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--ResearchAndDevelopmentExpense_i01_msOILz3im_zhthLcmgssrj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Research and Development <span id="xdx_F4B_zOI0PHE1bj1j">(a)</span></td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">206,107</td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">169,315</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--LaborAndRelatedExpense_i01_msOILz3im_zF297Hh5Tt95" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Wages and Benefits <span id="xdx_F41_zAwA6AQear57">(a)</span></td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">5,378,952</td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,367,486</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--ProfessionalAndContractServicesExpense_i01_msOILz3im_zCoI4NrOzSv2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Professional Services <span id="xdx_F4D_z7AiQB8GNFef">(a)</span></td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">1,945,331</td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,721,461</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--OtherCostAndExpenseOperating_i01_msOILz3im_zoEc5bAAdv51" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Other Operating Expenses <span id="xdx_F4C_zrk53HU68AZ1">(a)</span> <span id="xdx_F4B_zK9RzMvJ25Ee">(b)</span></td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">1,625,642</td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">1,239,368</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--OperatingIncomeLoss_iT_maCz7fC_mtOILz3im_zxdpcZ5o8Qyf" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1pt">Segment Operating Loss</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">(7,156,817</td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(6,664,495</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--NonoperatingIncomeExpenseAbstract_iB_zbAcjN2ODiE7" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Other (Expense) Income:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_ecustom--FinancingCharges_i01N_di_msONIEz60J_z2B0GCtuEkt6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: left">Financing charges</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">(230,824</td><td style="font-weight: bold; text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(2,772</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_408_eus-gaap--InterestExpense_i01N_di_msONIEz60J_zztXzQpOihe6" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left">Interest expense</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">(174,328</td><td style="font-weight: bold; text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(476,416</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40B_eus-gaap--FairValueAdjustmentOfWarrants_i01N_di_msONIEz60J_zNFSq4n7haY6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: left">Change in fair value of warrant liability</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">(941</td><td style="font-weight: bold; text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">844,854</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--DerivativeGainLossOnDerivativeNet_i01_maONIEz60J_z1Q0FrtYcXu5" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left">Change in fair value of derivative liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1967">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">198,551</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--AmortizationOfFinancingCostsAndDiscounts_i01N_di_msONIEz60J_ztXLMWhzcoo6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: left">Amortization of debt discount and issuance cost</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">(126,387</td><td style="font-weight: bold; text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(4,881,622</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_400_eus-gaap--GainsLossesOnExtinguishmentOfDebt_i01_maONIEz60J_zG8IEht4gaie" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left">Extinguishment of debt liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1973">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(3,649,561</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_404_eus-gaap--OtherNonoperatingIncome_i01_maONIEz60J_zCzqQ1YCpcMj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: left">Other income</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">33,620</td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">15,133</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--OtherNonoperatingExpense_i01N_di_msONIEz60J_zdZ31bllWTOa" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left; padding-bottom: 1pt">Other expense</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">(585,824</td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(10,355</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_40B_eus-gaap--OtherNonoperatingIncomeExpense_i01T_maCz7fC_mtONIEz60J_znSMZiHMxXVk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 30pt; text-align: left; padding-bottom: 1pt">Total other (expense) income, net</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">(1,084,684</td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(7,962,188</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--NetIncomeLoss_iT_mtCz7fC_zCVtniRT8qb4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1pt">Net Loss</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">(8,241,501</td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">(14,626,683</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span id="xdx_F0A_zSHbxJTS4XIa" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F1B_zCM34Oh92oT7" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            significant expense categories and amounts align with the segment-level information provided
                                            on a regular basis to the CODM.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_F0D_zmCzF8AwSMi2" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F12_zBTE0DIvtEci" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
                                            operating expenses include advertising, rent and utilities, insurance, depreciation and
                                            amortization, travel, software subscription fees, board fees and bad debt expense.</span></td></tr></table>

<p id="xdx_8A8_zThmupzGkeR1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
segment assets for IB-STIM amounted to $<span id="xdx_909_eus-gaap--Assets_iI_c20241231_zdWgAYvatPX4" title="Assets">4,757,572</span>
and $<span id="xdx_90B_eus-gaap--Assets_iI_c20231231_z0XPgYkRHAof" title="Assets">509,498</span> as of December 31, 2024 and 2023,
respectively. Total segment capital expenditures for IB-STIM amounted to $<span id="xdx_904_eus-gaap--NetCashProvidedByUsedInInvestingActivities_iN_di_c20240101__20241231_z5UjbH8Wd5ek" title="Net cash used by investing activities">27,776</span>
and $<span id="xdx_905_eus-gaap--NetCashProvidedByUsedInInvestingActivities_iN_di_c20230101__20231231_zy3dON3rH4Rf" title="Net cash used by investing activities">71,781</span>
for the years ended December 31, 2024 and 2023, respectively. Total segment depreciation and amortization amounted to $<span id="xdx_901_eus-gaap--DepreciationAndAmortization_c20240101__20241231_z4TCnRFV1smd" title="Depreciation and amortization">37,831</span> and $<span id="xdx_906_eus-gaap--DepreciationAndAmortization_c20230101__20231231_zWCRrQ7y47z9" title="Depreciation and amortization">40,725</span> for the years ended December 31, 2024 and 2023, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">Significant segment non-cash charges settled in common stock
include (i) consulting and advisory fees totaling $<span id="xdx_90E_ecustom--ConsultingAndAdvisoryFees_c20240101__20241231_z1JustoTJCo7" title="Consulting and advisory fees">754,685</span> and $<span id="xdx_90A_ecustom--ConsultingAndAdvisoryFees_c20230101__20231231_z4M3Sf3Wnc1h" title="Consulting and advisory fees">750,000</span> for the years ended December 31, 2024 and 2023, respectively,
and (ii) hiring grants totaling $<span id="xdx_907_eus-gaap--ShareBasedCompensation_c20240101__20241231_zXkZInxUm2k4" title="Stock based compensation">227,000</span> and $<span id="xdx_90D_eus-gaap--ShareBasedCompensation_dxL_c20230101__20231231_zkdR0OGsfFM" title="Stock based compensation::XDX::-"><span style="-sec-ix-hidden: xdx2ixbrl2008">0</span></span> for the years ended December 31, 2024 and 2023, respectively.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 34<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-34<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26C<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-15<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/280/tableOfContent<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text"><p id="xdx_802_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_z9MraOrNsOl4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>16</b>.
<b><span id="xdx_82A_ze7exhKFYWQ5">Commitments and Contingencies</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Manufacturing
Services Agreement</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is party to a manufacturing services agreement for the manufacture and supply of the Company&#8217;s IB-STIM device based on
the Company&#8217;s product specifications that automatically renews annually unless either party provides a written termination notice
to the other party within 180 days prior to the end of the then-current term. The Company provides the necessary equipment to the manufacturer
and retains ownership. The manufacturer bears the risk of loss of and damage to the equipment and consigned materials. Performance under
the agreement is initiated by orders issued by the Company and accepted by the manufacturer.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Advisory
Agreement</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
March 18, 2024, the Company terminated its private placement services agreement and entered into an advisory agreement with a financial
advisor for debt, equity and public securities market services for one year. The advisory agreement included a monthly fee of $<span id="xdx_90E_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_c20240318__20240318__us-gaap--TypeOfArrangementAxis__custom--AdvisoryAgreementMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zjfu9PspRz64" title="Monthly advisory fee">30,000</span>
and <span id="xdx_90D_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_c20240318__20240318__us-gaap--TypeOfArrangementAxis__custom--AdvisoryAgreementMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zNXrgHi5fopl" title="Monthly advisory fee">7,563</span> common stock warrants to be issued monthly at an exercise price of $<span id="xdx_902_eus-gaap--SaleOfStockPricePerShare_iI_pid_c20240318__us-gaap--TypeOfArrangementAxis__custom--AdvisoryAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zxKzUidIR55l" title="Monthly exercise price">2.38</span> with a term of five years. On December 31, 2024, the
Company and the financial advisor terminated the advisory agreement subject to the cancelation of all common stock warrants issued after
July 2024 and the payment for services rendered in three equal installments of $<span id="xdx_900_eus-gaap--IssuanceOfStockAndWarrantsForServicesOrClaims_c20250326__20250326__srt--StatementScenarioAxis__srt--ScenarioForecastMember__us-gaap--TypeOfArrangementAxis__custom--AdvisoryAgreementMember_zGZcEnjrkRab" title="Payment for services">60,000</span> by March 26, 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Settlement
Agreements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company issued <span id="xdx_909_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--SettlementAgreementMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_z87GpsPnaq4j" title="Number of shares new issuance">245,955</span> shares of common stock to various pre-IPO 2022 Convertible Note and Series A Preferred Stock holders to settle
certain claims. The Company recorded the fair value of the settlements as $<span id="xdx_902_ecustom--FinanceCharges_c20240101__20241231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember__us-gaap--TypeOfArrangementAxis__custom--SettlementAgreementMember_z3dFFcYQGAWa" title="Finance Charges">230,824</span> of Finance Charges and $<span id="xdx_902_eus-gaap--OtherExpenses_c20240101__20241231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember__us-gaap--TypeOfArrangementAxis__custom--SettlementAgreementMember_zSpbD2ayjoja" title="Other expense">580,250</span> of Other Expense in
the Statements of Operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Furthermore,
the Company authorized the issuance of <span id="xdx_909_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zLY0XIiDMZ6h" title="New issuance, shares">1,518</span> shares of its common stock to settle remaining claims with one pre-IPO Series A Preferred
Stock shareholder classified as $<span id="xdx_905_eus-gaap--OtherExpenses_c20240101__20241231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zmOQVLFTy9ee" title="Other expenses">4,220</span> of Other Expense for the year ended December 31, 2024 in the Statements of Operations and accrued
expenses in the Balance Sheets as of December 31, 2024. These common shares have not yet been issued as of the reporting date as the
Company awaits execution of the settlement agreements by the counterparties.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Executive
Employment Agreements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company, as authorized by the board of directors, entered into employment agreements with nine key employees to provide incentives to
improve shareholder value and to contribute to the growth and financial success of the Company. The agreements had an employment start
date of October 1, 2022, with initial terms from <span id="xdx_904_ecustom--ExecutiveEmploymentAgreementsTerms_dtY_c20221001__20221001__srt--RangeAxis__srt--MinimumMember__us-gaap--TypeOfArrangementAxis__custom--ExecutiveEmploymentAgreementsMember_zAkLqA3S85r6" title="Executive employment agreements renewals">2</span> to <span id="xdx_90A_ecustom--ExecutiveEmploymentAgreementsTerms_dtY_c20221001__20221001__srt--RangeAxis__srt--MaximumMember__us-gaap--TypeOfArrangementAxis__custom--ExecutiveEmploymentAgreementsMember_z5nCL1ZDLvd2" title="Executive employment agreements renewals">5</span> years and <span id="xdx_900_ecustom--DescriptionOfExecutiveEmploymentAgreementsRenewals_dtY_c20221001__20221001__us-gaap--TypeOfArrangementAxis__custom--ExecutiveEmploymentAgreementsMember_znpA4eJ42zlb" title="Description of Executive employment agreements renewals">optional one-year renewals</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
total base salaries for the nine key employees in the agreements are $<span id="xdx_902_eus-gaap--SalariesAndWages_c20240101__20241231__us-gaap--TypeOfArrangementAxis__custom--ExecutiveEmploymentAgreementsMember_zaUJD6RObTX" title="Base salaries for nine key employees">1,920,000</span> per year with various provisions for annual increases.
In addition to base salaries, eight of the employees have a provision for a special one-time incentive payment to be paid in a lump sum
after the start date. The total amount of these special incentive payments is $<span id="xdx_909_eus-gaap--IncentiveFeeExpense_c20240101__20241231__us-gaap--TypeOfArrangementAxis__custom--ExecutiveEmploymentAgreementsMember_z4oweevxVPzc" title="Incentive payments">1,100,000</span>. The special incentive payment amount includes
any accrued backpay wages for the employee. The amount for backpay of $<span id="xdx_90E_eus-gaap--AccruedLiabilitiesCurrent_iI_c20231231__us-gaap--TypeOfArrangementAxis__custom--ExecutiveEmploymentAgreementsMember_zwz8Yxj2KZZ1" title="Accrued amount for backpay">417,390</span> was paid in the year ended December 31, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
are seven key employees that have stock options of the Company totaling <span id="xdx_900_eus-gaap--StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan_pid_uShares_c20240101__20240630__us-gaap--TypeOfArrangementAxis__custom--ExecutiveEmploymentAgreementsMember_z30oTuhjpm95" title="Seven key employees stock options">1,238,712</span> shares. These key employees have a provision in their
agreements whereas the Company will pay a special bonus equal to the aggregate of the strike price or exercise price of all their stock
options plus a tax gross-up payment. The special bonus shall be paid in twenty percent (<span id="xdx_900_ecustom--SpecialBonusPercentage_iI_pid_dp_uPure_c20240102__us-gaap--TypeOfArrangementAxis__custom--ExecutiveEmploymentAgreementsMember_zEThdkppPw7j" title="Special bonus percentage">20</span>%) installments starting January 2, 2024, and
the same date each of the next four years. As a condition of the payment, the key employee must exercise at least <span id="xdx_901_ecustom--KeyEmployeeExercisePercentage_iI_pid_dp_uPure_c20240102__us-gaap--TypeOfArrangementAxis__custom--ExecutiveEmploymentAgreementsMember__srt--RangeAxis__srt--MinimumMember_zyz75b434FS5" title="Key employee exercise percentage">20</span>% of their stated
number of stock options. There are additional provisions to cover termination and change of control events. None of the key employees
exercised any of options as of January 2, 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
April 2023, the Company amended the employee agreements to, among other things, clarify that the special one-time incentive payment and
the deferred bonus are contingent upon the effective date of the planned initial public offering. The amendment also sets forth a process
for executives to exercise the stock options in accordance with the terms of the stock option agreement in effect as of the date of the
employment agreement and to clarify that there is no modification to the stock option agreements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Neuraxis,
Inc.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Notes
to Financial Statements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company recorded the backpay portion of the incentive bonus notes above. The balance of the incentive bonuses of $<span id="xdx_90C_eus-gaap--AccruedBonusesCurrent_iI_c20230430__us-gaap--TypeOfArrangementAxis__custom--ExecutiveEmploymentAgreementsMember_zuWouEEq34kg" title="Incentive bonus">694,056</span> and the special
options bonuses of $<span id="xdx_900_eus-gaap--AccruedBonusesCurrent_iI_c20230430__us-gaap--TypeOfArrangementAxis__custom--ExecutiveEmploymentAgreementsMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_z3lp8dxKDAtf" title="Incentive bonus">14,821,830</span> were contingent upon a successful IPO. The incentive bonuses have been paid in full while the special
options bonuses will be recorded when paid.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
April 10, 2024, the Company terminated the employment of the Company&#8217;s Chief Operating Officer. Pursuant to the employment agreement,
the Company made (i) make salary continuation payments for six months during the year ended December 31, 2024, (ii) issued <span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20240410__20240410__srt--TitleOfIndividualAxis__srt--ChiefOperatingOfficerMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zrAsVhH5OgGi" title="Common stock shares issue">25,832</span> shares
of common stock at a fair value of $<span id="xdx_901_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20240410__20240410__srt--TitleOfIndividualAxis__srt--ChiefOperatingOfficerMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zRHnOyE1Lek4" title="Common stock with a fair value">78,788</span> and (iii) made a $<span id="xdx_903_eus-gaap--PaymentsToAcquireEquitySecuritiesFvNi_c20240410__20240410__srt--TitleOfIndividualAxis__srt--ChiefOperatingOfficerMember_zeNAE0Wt252k" title="One time payment">41,980</span> one-time payment in lieu of the exercise of <span id="xdx_905_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20240410__20240410__srt--TitleOfIndividualAxis__srt--ChiefOperatingOfficerMember_za3qfLRP1EBe" title="Stock option, exercise">13,764</span> stock options
that expired on January 2, 2024. The Company is obligated to provide health care coverage through October 2025 and has accrued for that
obligation totaling $<span id="xdx_908_eus-gaap--AccruedLiabilitiesFairValueDisclosure_iI_c20241231__srt--TitleOfIndividualAxis__srt--ChiefOperatingOfficerMember_zKSSNoKQNmqd" title="Accrued expenses">21,418</span> classified as Accrued Expenses in the Balance Sheets as of December 31, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Litigation</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">From
time to time, the Company may be involved in litigation relating to claims arising out of operations in the normal course of business.
As of the date of issuance, other than those described below, there were no pending or threatened legal proceedings that could reasonably
be expected to have a material effect on the results of the Company&#8217;s operations. There are also no proceedings in which any of
the Company&#8217;s directors, officers or affiliates is an adverse party to the Company or has a material interest adverse to the Company&#8217;s
interest. Legal fees are expensed as incurred.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 6, 2019, plaintiff Ritu Bhambhani, M.D., initiated a lawsuit against Innovative Health Solutions, Inc. and others in the United
States District Court for the District of Maryland. Plaintiffs Bhambhani and Sudhir Rao subsequently amended the complaint, with the
Third Amended Complaint (&#8220;Complaint&#8221;) containing the most recent set of allegations. The Complaint asserted claims under
the RICO Act, as well as of fraudulent misrepresentation, intentional misrepresentation by concealment, and civil conspiracy and sought
compensatory damages in excess of $<span id="xdx_900_eus-gaap--LossContingencyDamagesSoughtValue_pn6n6_c20190206__20190206_zSpe14Of6Bn4" title="Sought compensatory damages">5</span> million, pre-judgment interest, punitive damages, attorney&#8217;s fees, court costs and designation
of the case as a class action. The Complaint stated that the Company, distributors of the Company&#8217;s product, and medical billing
and coding consultants allegedly made misrepresentations to the plaintiffs that the Company&#8217;s NeuroStim device and related procedures
could be billed to, and reimbursed by, Medicare and other insurance payors as a surgically implantable neurostimulator. Plaintiffs claim
to have suffered damages when Medicare administrative contractors declined to pay plaintiffs for their use of the device.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 11, 2022, the Company filed a motion for summary judgment based upon the plaintiffs not being proper parties to assert claims
against the Company. On June 14, 2022, the Court granted the Company&#8217;s motion for summary judgment and dismissed the Complaint.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
July 14, 2022, plaintiffs Ritu Bhambhani and Sudhir Rao filed a notice of appeal with the Fourth Circuit Court of Appeals. On June 3,
2024, the Fourth Circuit denied the plaintiff&#8217;s appeal and entered judgment against the plaintiffs. On June 25, 2024, the Fourth
Circuit entered its mandate declaring that its judgment against the plaintiffs took effect that day. The plaintiffs did not seek any
further review or appeal of that judgment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Also
on July 14, 2022, plaintiffs Ritu Bhambhani, LLC; Box Hill Surgery Center, LLC; Pain and Spine Specialists of Maryland, LLC; and SimCare
ASC, LLC initiated a lawsuit against the Company and others in the United States District Court for the District of Maryland. The plaintiffs
in this lawsuit are business entities owned or partially owned by the plaintiffs that initiated the litigation described above. The Complaint
asserted claims under the RICO Act, as well as fraudulent misrepresentation, intentional misrepresentation by concealment, and civil
conspiracy and seeks compensatory damages in excess of $<span id="xdx_90E_eus-gaap--LossContingencyDamagesSoughtValue_c20220714__20220714_zh22x5PD1Rth" title="Sought compensatory damages">75,000</span>, pre-judgment interest, punitive damages, attorney&#8217;s fees, and court
costs. The Complaint states that the Company, distributors of the Company&#8217;s product, and medical billing and coding consultants
allegedly made misrepresentations to the plaintiffs that the Company&#8217;s NeuroStim device and related procedures could be billed
to, and reimbursed by, Medicare and other insurance payors as a surgically implantable neurostimulator. Plaintiffs claim to have suffered
damages when Medicare administrative contractors declined to pay plaintiffs for their use of the device.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
September 28, 2022, the Company filed a motion to dismiss all claims. On May 25, 2023, the Court issued an Order and a Memorandum
Opinion which dismissed the plaintiffs&#8217; claims related to the RICO Act. The remaining claims are still pending, and no trial
date has been set for the case. </span>The Court has vacated its Scheduling Order at the parties&#8217; request so that the parties
could try to resolve the disputes in both cases through an independent third-party mediator. Mediation has not yet resulted in a
resolution of the case.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Neuraxis,
Inc.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Notes
to Financial Statements</b></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In January 2024, Dr. Arturo Taca served notice to the Company that asserted
an interest in its U.S. Patent No. 10,413,719 valued at $<span id="xdx_904_eus-gaap--FiniteLivedPatentsGross_iI_c20240131_zhTQ8gMuj3Y2" title="Patent value">2,000,000</span> based on his own work in neurostimulation.&#160; The Company denied
both the neurostimulation patent and compensation claims.&#160; The case remains unresolved.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">While it is too early to predict
the ultimate outcome of these matters, we believe the Company has meritorious defenses and intends to defend these matters vigorously.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 405<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/405-30/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/450/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478522/954-440-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Health Benefit Plan<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NRXS_DisclosureHealthBenefitPlanAbstract', window );"><strong>Health Benefit Plan</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NRXS_HealthBenefitPlanDisclosureTextBlock', window );">Health Benefit Plan</a></td>
<td class="text"><p id="xdx_801_ecustom--HealthBenefitPlanDisclosureTextBlock_zOGtIJTwkHU8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>17.
<span id="xdx_827_zpEbH2V3LJbi">Health Benefit Plan</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company participates in a self-funded employer program in conjunction with a group health plan for the benefit of eligible employees.
This plan is a level funded plan, and the services and products include:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
    self-funded employer health benefit plan.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stop
    loss insurance purchased from a stop loss insurance company.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Third
    party administrator to provide administrative services with regard to the plan.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company maintains a stop loss contract that reimburses the Company for claims paid under the plan if they exceed a predetermined level.
The Company makes contributions for health care costs and associated expenses that are expected during the plan year. The amount of contributions
is determined annually based on the Company&#8217;s maximum liability for expected claims, administrative expenses, and premiums for
the stop loss policy. The Company paid premiums of $<span id="xdx_90B_eus-gaap--HealthCareOrganizationStopLossInsurancePremiumExpense_c20240101__20241231_zl9uSPmhw03l" title="Stop loss insurance premium expense">257,642</span> and $<span id="xdx_90E_eus-gaap--HealthCareOrganizationStopLossInsurancePremiumExpense_c20230101__20231231_zenk5ce2Vlr2" title="Stop loss insurance premium expense">255,715</span> for the years ended December 31, 2024 and 2023, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is responsible for the monthly premiums, as established, and nothing further. The stop loss policy covers the claims if they
exceed the claims funds. After a certain time, and if there is a surplus in the claims fund, the Company may be entitled to receive a
<span id="xdx_90E_ecustom--HealthCareOrganizationStopLossInsurancePremiumPercentage_pid_dp_uPure_c20240101__20241231_zs7tu9UUY2Cg" title="Stop loss insurance premium percentage">48.5</span>% refund from the fund. This amount is recognized by the Company when received.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_NRXS_DisclosureHealthBenefitPlanAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">NRXS_DisclosureHealthBenefitPlanAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>NRXS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_NRXS_HealthBenefitPlanDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Health benefit plan disclosure [Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">NRXS_HealthBenefitPlanDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>NRXS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text"><p id="xdx_802_eus-gaap--IncomeTaxDisclosureTextBlock_zqVtiVAgaN9h" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>18.
<span id="xdx_823_zmuUDI73bEIh">Income Taxes</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_890_eus-gaap--ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_zDb3lcW75Ijk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
income tax provision consists of:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B5_zNP32LdYNA2g">Schedule
of Income Tax Provision</span>&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="display: none">&#160;</td><td style="display: none; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49F_20240101__20241231_zGKRhM3a4gI" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center">2024</td><td style="display: none; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="display: none; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49A_20230101__20231231_zoONEQJVCXxg" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center">2023</td><td style="display: none; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">For the Years Ended December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--CurrentIncomeTaxExpenseBenefit_maDITEBzp9r_zgzdKTwjUnl5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0pt; text-align: left">Total current provision</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">$</td><td style="font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2080">-</span></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2081">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0pt">Deferred:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--DeferredFederalIncomeTaxExpenseBenefit_maDITEBzp9r_z4B2XbNXY3Se" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; width: 60%">Federal</td><td style="width: 2%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 16%; font-weight: bold; text-align: right">(1,721,242</td><td style="width: 1%; font-weight: bold; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right">(3,067,056</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr id="xdx_402_eus-gaap--DeferredStateAndLocalIncomeTaxExpenseBenefit_maDITEBzp9r_zfUDQpdKPKFd" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; padding-bottom: 1pt">State</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">124,823</td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(154,060</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_408_eus-gaap--DeferredIncomeTaxExpenseBenefit_iT_mtDITEBzp9r_maITEBzTsP_z0FkcE7aj5Sb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0pt; text-align: left">Total deferred benefit</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">(1,596,419</td><td style="font-weight: bold; text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(3,221,116</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_405_eus-gaap--IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_maITEBzTsP_zfcx9bJKyV79" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Valuation allowance</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">1,596,419</td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">3,221,116</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--IncomeTaxExpenseBenefit_iT_mtITEBzTsP_zIsWExreKkA6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Total income tax provision</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2095">&#8212;</span></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2096">&#8212;</span></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A0_zDSa6BtIEhIa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_892_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_z1gVIsJ6URf6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
reconciliation of the U.S. federal statutory income tax rate to the effective income tax rate is as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B0_zTBhoPXev1aj" style="display: none">Schedule of Federal Statutory Income Tax Rate and Effective Income Tax Rate</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="display: none">&#160;</td><td style="display: none; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_490_20240101__20241231_zdvSC8iN66j" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center">2024</td><td style="display: none; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="display: none; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49C_20230101__20231231_z0XKOJgDOSWc" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center">2023</td><td style="display: none; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">For the Years Ended December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_uPure_maEIT001_z1qbu3Hil3a6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; width: 60%; text-align: left">Federal statutory income tax rate</td><td style="width: 2%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 16%; font-weight: bold; text-align: right">21.0</td><td style="width: 1%; font-weight: bold; text-align: left">%</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right">21.0</td><td style="width: 1%; text-align: left">%</td></tr>
  <tr id="xdx_40A_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_pid_dp_uPure_maEIT001_zIZ8oRAWthS2" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">State tax rate, net of federal benefit</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">5.3</td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4.9</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_pid_dp_uPure_maEIT001_zZTKo9bs0Sp9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0pt; text-align: left; padding-bottom: 1pt">Change in valuation allowance</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">(26.3</td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(25.9</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_40C_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_iT_pid_dp_uPure_mtEIT001_zLvS1c6f5o88" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Effective income tax rate</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2109">&#8212;</span></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">%</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2110">&#8212;</span></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">%</td></tr>
  </table>

<p id="xdx_8AF_znd1p4cCyBn1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company did not recognize an income tax provision for the years ended December 31, 2024 and 2023 due to net operating losses reported
in both years.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_898_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zVope19dWKwe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred
income taxes are provided for temporary differences between the financial and tax bases of the Company&#8217;s assets and liabilities.
The temporary differences that give rise to net deferred tax assets and liabilities were as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B9_zndQqMtgcaHi">Schedule
of Net Deferred Tax Assets and Liabilities</span>&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="display: none">&#160;</td><td style="display: none; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49F_20241231_zhXUsZI3niV4" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center">2024</td><td style="display: none; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="display: none; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_490_20231231_z7C0J1onSSN7" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center">2023</td><td style="display: none; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Deferred tax assets:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_maDTAGzJbV_zNoECr7RCSAh" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; width: 60%; text-align: left">Net operating losses</td><td style="width: 2%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">$</td><td style="width: 16%; font-weight: bold; text-align: right">8,019,218</td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">6,573,406</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_iI_maDTAGzJbV_za6weCmEW96f" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Stock based compensation</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">1,447,339</td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,366,391</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_ecustom--DeferredTaxAssetsNotesReceivableReserve_iI_maDTAGzJbV_zP9Xtj47KL35" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Notes receivable reserve</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">266,816</td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">251,893</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsOther_iI_maDTAGzJbV_zsPbpUzTJcX4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Accrued compensation</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">296,297</td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">57,763</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_ecustom--DeferredTaxAssetsAccountsPayable_iI_maDTAGzJbV_zZVAIHIlDJl8" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Accounts payable</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">143,484</td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">257,391</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_ecustom--DeferredTaxAssetsOperatingLeasePayable_iI_maDTAGzJbV_zIk3RIZ85ade" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Operating lease payable</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">84,105</td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">18,951</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--DeferredTaxAssetsOther_iI_maDTAGzJbV_zwDLA3KP1g6i" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; padding-bottom: 1pt">Other</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">206,468</td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">175,904</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--DeferredTaxAssetsGross_iTI_mtDTAGzJbV_maDTANz8qu_zSMHce1zy2w4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0pt; text-align: left">Total gross deferred tax assets</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">10,463,727</td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">8,701,699</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_di_msDTANz8qu_zAcJuJYdrqti" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0pt; text-align: left; padding-bottom: 1pt">Valuation allowance</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">(10,225,739</td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(8,629,320</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_406_eus-gaap--DeferredTaxAssetsNet_iTI_mtDTANz8qu_msDTLzJxU_zZCRtEmahuWk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0pt; text-align: left; padding-bottom: 1pt">Total deferred tax assets</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">237,988</td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">72,379</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0pt; text-align: left">Deferred tax liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_ecustom--DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset_iI_maDITLzRLP_zZrYdGsyoYyj" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Operating lease right of use asset</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">$</td><td style="font-weight: bold; text-align: right">74,991</td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">17,475</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--DeferredTaxLiabilitiesPrepaidExpenses_iI_maDITLzRLP_zpaquPF7s5Bg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Prepaid expenses</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">72,560</td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7,337</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_ecustom--DeferredTaxLiabilityAccountsReceivable_iI_maDITLzRLP_zjaKtI9Ap3i3" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Accounts receivable</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">64,443</td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">18,197</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--DeferredTaxLiabilitiesOther_iI_maDITLzRLP_zlQ4mlye7Uv1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; padding-bottom: 1pt">Other</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">25,994</td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">29,370</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--DeferredIncomeTaxLiabilities_iTI_mtDITLzRLP_maDTLzJxU_zHtpCPEkSRbj" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Total deferred tax liabilities</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">237,988</td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">72,379</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--DeferredTaxLiabilities_iTI_mtDTLzJxU_zlE7IC9Wb103" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Deferred tax assets, net</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2159">&#8212;</span></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2160">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8AA_zScLxdMbkknb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Neuraxis,
Inc.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Notes
to Financial Statements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management
assessed the realizability of its deferred tax assets and determined that it is more likely than not that the Company will not recognize
the benefits of the net deferred tax assets due to a history of operating losses. As a result, the Company maintained a full valuation
allowance and does not reflect any deferred taxes in its Balance Sheets as of December 31, 2024 and 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 31, 2024, the Company&#8217;s federal and state net operating loss (NOL) carryforwards totaled $<span id="xdx_901_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_iI_c20241231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--DomesticCountryMember_zAJh4uZZVVpk">36,202,858
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">and $34</span>,748,524 respectively. These NOL carryforwards
may be offset against future taxable income. There is no limitation on the number of years to utilize the federal NOLs. The federal deduction
will be limited to 80% of modified taxable income. The state NOLs are allowed up to <span id="xdx_90E_eus-gaap--EffectiveIncomeTaxRateReconciliationOtherAdjustments_pid_dp_c20240101__20241231_zRpt4R9WCYJd">100</span>%
of taxable income and generally can be carried forward no longer than 20 years after the year of the taxable loss.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Federal
and state tax laws impose limitations on the utilization of NOLs and credit carryforwards in the event of an ownership change for tax
purposes, as defined in Section 382 of the Internal Revenue Code. Accordingly, the Company&#8217;s ability to utilize these carryforwards
may be limited as a result of an ownership change. Such an ownership change could result in a limitation in the use of the NOLs in future
years and possibly a reduction of the net operating losses available.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_89B_eus-gaap--SummaryOfOperatingLossCarryforwardsTextBlock_z8KsPtHCLbOb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
not used, the state NOL carryforwards will expire as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8BF_zsQ5DJSkDt42" style="display: none">Schedule of State Carryforwards</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 60%; margin-right: auto">
  <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="display: none; text-align: justify">&#160;</td><td style="display: none">&#160;</td>
    <td style="display: none; text-align: left">&#160;</td><td id="xdx_49B_20241231_zIjmiiM9ZDLj" style="display: none; text-align: right">&#160;</td><td style="display: none; text-align: left">&#160;</td></tr>
<tr id="xdx_40F_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_iI_hus-gaap--TaxPeriodAxis__custom--TaxYear2037Member_zjxftYeYpkz4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 78%; text-align: justify">2037</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right">72,216</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_iI_hus-gaap--TaxPeriodAxis__custom--TaxYear2038Member_zrilnWyMrWh3" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">2038</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,039,986</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_iI_hus-gaap--TaxPeriodAxis__custom--TaxYear2039Member_zYpBSeKjSPo4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">2039</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,033,565</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_iI_hus-gaap--TaxPeriodAxis__custom--TaxYear2040Member_zzAYhiafCmD1" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">2040</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,457,495</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_iI_hus-gaap--TaxPeriodAxis__custom--TaxYear2041Member_zG5919ryuNS6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">2041</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,406,225</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_iI_hus-gaap--TaxPeriodAxis__custom--TaxYearThereafterMember_zwC79DGKyVgc" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Thereafter</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">24,671,088</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_iI_hus-gaap--TaxPeriodAxis__custom--NoExpirationMember_zia4lqC4qMhe" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt; text-align: justify">No expiration</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">67,949</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_iI_z9mLazXw2Q1a" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt; text-align: justify">Total state NOL carryforwards</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">34,748,524</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8AD_zSMz5TaeJgIh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company believes it has made adequate provision for all income tax uncertainties. The assessment is subject to change based on the completion
of audits or statute of limitation expirations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
federal and state income tax returns have a three-year statute of limitations once filed with the appropriate jurisdiction. The Company&#8217;s
income tax returns are subject to examination by the federal and state taxing authorities in the United States for the years ended 2021
through 2024 and 2021 through 2024, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12C<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12B<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 270<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477891/740-270-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.5.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/740/tableOfContent<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-14<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-21<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482603/740-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text"><p id="xdx_806_eus-gaap--SubsequentEventsTextBlock_zYQ16dqfOpui" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>19.
<span id="xdx_824_zlexf9AyuLj3">Subsequent Events</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">On January 3, 2025 and March 6, 2025,
the Company granted <span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_c20250103__20250103__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_znHlIcZjDMU3" title="Restricted stock, granted">360,902
</span>and <span id="xdx_909_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_c20250306__20250306__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zrRZ7byrH4Xh" title="Restricted stock, granted">373,275</span> restricted stock units (&#8220;RSUs&#8221;), respectively, pursuant to the Neuraxis, Inc. 2022 Omnibus Securities and Incentive
Plan as amended on August 15, 2024. The RSUs cliff-vest at the end of a three year period and are payable in shares of the Company&#8217;s
common stock. The RSUs fully vest upon (i) death or disability or (ii) change of control. Dividend equivalents accrue on RSUs and are
paid upon vesting; there were no accrued dividends on unvested RSUs as of the report date.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 17, 2025, the Company issued <span id="xdx_906_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20250117__20250117__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zQ5n3hCkO3Oe" title="Issued common shares">39,471 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">common
shares to its independent board members for their service from April 1, 2024 through December 31, 2024 and an investor converted
<span id="xdx_904_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_c20250117__20250117__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zkPLlHLmw2dk" title="Investor converted warrant">502,647</span> warrants into <span id="xdx_909_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_c20250117__20250117__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zHoyPGV7ySJa" title="Investor converted warrants into common shares">186,166</span> common shares in a cashless exercise transaction.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has evaluated subsequent events through the filing of this Annual Report on Form 10-K and determined that there have been no
other events that have occurred that would require adjustments to our disclosures in the financial statements.</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/855/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates and Critical Accounting Estimates and Assumptions</a></td>
<td class="text"><p id="xdx_843_eus-gaap--UseOfEstimates_zCNBGrFAkxnd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_862_zCQCbX5hehLh">Use
of Estimates and Critical Accounting Estimates and Assumptions</span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the
reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the dates of the financial statements
and the reported amounts of revenues and expenses during the reporting periods.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
significant accounting estimates or assumptions bear the risk of change due to the fact that there are uncertainties attached to these
estimates or assumptions, and certain estimates or assumptions are difficult to measure or value.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management
bases its estimates on historical experience and on various assumptions that are believed to be reasonable in relation to the financial
statements taken as a whole under the circumstances, the results of which form the basis for making judgments about the carrying values
of assets and liabilities that are not readily apparent from other sources.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management
regularly evaluates the key factors and assumptions used to develop the estimates utilizing currently available information, changes
in facts and circumstances, historical experience, and reasonable assumptions. After such evaluations, if deemed appropriate, those estimates
are adjusted accordingly. The Company uses estimates in accounting for, among other items, revenue recognition, allowance for credit
losses, stock-based compensation, income tax provisions, excess and obsolete inventory reserve, and impairment of property and equipment,
and intellectual property. Actual results could differ from those estimates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text"><p id="xdx_84E_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_ztvqhicgjizf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_86B_zlm33AKL50gf">Cash
and Cash Equivalents</span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company considers all highly liquid debt instruments purchased with a maturity of three months or less to be cash equivalents. The Company
did not hold any cash equivalents as of December 31, 2024 and 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TradeAndOtherAccountsReceivablePolicy', window );">Trade Accounts Receivable and Allowance for Credit Losses</a></td>
<td class="text"><p id="xdx_846_eus-gaap--TradeAndOtherAccountsReceivablePolicy_zfROzNl3ffE" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_866_z8W5SJsnYNZ3">Trade
Accounts Receivable and Allowance for Credit Losses</span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Trade
accounts receivable are stated at the amount management expects to collect from outstanding balances, net of an allowance for credit
losses. Management evaluates many factors when determining the collectability of specific customer accounts, including, but not
limited to, creditworthiness, past transaction and payment history, current economic industry trends and changes in payment terms.
Management used assumptions and judgment based on the best available facts and circumstances to estimate and record an allowance.
The allowance for credit losses was $<span id="xdx_90F_eus-gaap--AllowanceForDoubtfulAccountsReceivable_iI_c20241231_zP8VFScW5y0c" title="Allowance for doubtful accounts">5,000</span>
and $<span id="xdx_903_eus-gaap--AllowanceForDoubtfulAccountsReceivable_iI_c20231231_ztE0yvQuOmXa" title="Allowance for doubtful accounts">11,993</span>
as of December 31, 2024 and 2023, respectively. The Company recorded credit losses for the years ended December 31, 2024 and 2023 of
$<span id="xdx_90D_eus-gaap--ProvisionForOtherCreditLosses_c20240101__20241231_z7Ql8mCSpFj8" title="Credit losses">7,395</span> and $<span id="xdx_904_eus-gaap--ProvisionForOtherCreditLosses_c20230101__20231231_zJyECgcqyDrd" title="Credit losses">25,281</span>,
respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Neuraxis,
Inc.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Notes
to Financial Statements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepositContractsPolicy', window );">Customer Deposits</a></td>
<td class="text"><p id="xdx_845_eus-gaap--DepositContractsPolicy_z0S65AE6qnwc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_86B_zs9KrkyOFyU1">Customer
Deposits</span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Customer
deposits consists of  payments and returned devices from clients in advance of revenue recognition. The Company will recognize
the customer deposits over the next year. As of December 31, 2024, and 2023, the Company had customer deposits of $<span id="xdx_904_eus-gaap--Deposits_iI_c20241231_zSmRjs0DXNzj" title="Customer deposits">32,527</span> and $<span id="xdx_902_eus-gaap--Deposits_iI_c20231231_zueWOiNKKjkg" title="Customer deposits">74,947</span>,
respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryPolicyTextBlock', window );">Inventories</a></td>
<td class="text"><p id="xdx_846_eus-gaap--InventoryPolicyTextBlock_zxmZEstGpDWd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_866_zKh9Gova5AU2">Inventories</span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inventories
are valued at the lower of cost or net realizable value. Cost is determined using the weighted average method. The inventory is comprised
of finished medical devices on hand. Certain components within the devices have an expiration date that are removed from current inventory
and expensed at the date of expiration. For the years ended December 31, 2024 and 2023, $<span id="xdx_901_ecustom--InventoryExpenses_iI_c20241231_zZoDkfglZ1Ia" title="Inventory expenses">0</span> and $<span id="xdx_900_ecustom--InventoryExpenses_iI_c20231231_zEQ7Zl1KsBUg" title="Inventory expenses">25,008</span> were expensed as expired inventory,
respectively. Inventory reserves totaled $<span id="xdx_906_eus-gaap--InventoryRawMaterialsNetOfReserves_iI_c20241231_zgVGVW7KmyZ2" title="Inventory reserves">4,454</span> and $<span id="xdx_90C_eus-gaap--InventoryRawMaterialsNetOfReserves_iI_c20231231_zZjhKB4ngEMj" title="Inventory reserves">0</span> as of December 31, 2024 and 2023, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment</a></td>
<td class="text"><p id="xdx_846_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zWScFqAl6Wg6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_860_zuZEawh0Gg39">Property
and Equipment</span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property
and equipment are recorded at cost less accumulated depreciation. Depreciation is computed using the straight-line method over the estimated
useful lives of the assets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_89D_ecustom--ScheduleOfPropertyPlantAndEquipmentUsefulLivesTableTextBlock_zA63jvQhipj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Depreciation
is calculated using the following estimated useful lives:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B1_zS3Vx59ipME8" style="display: none">Schedule of Estimated Useful Lives</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; width: 60%; border-collapse: collapse; margin-right: auto">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; width: 79%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Classification</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; width: 19%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Years</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Machinery
    and Equipment </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_908_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--MachineryAndEquipmentMember__srt--RangeAxis__srt--MinimumMember_zBoCKBqUpo16" title="Property and equipment, estimated useful lives">7</span>-<span id="xdx_90B_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--MachineryAndEquipmentMember__srt--RangeAxis__srt--MaximumMember_zs1iIMSzTnZ" title="Property and equipment, estimated useful lives">10</span>
    </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Furniture
    and Fixtures</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_906_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember__srt--RangeAxis__srt--MinimumMember_zmPdomKTkuj5" title="Property and equipment, estimated useful lives">3</span>-<span id="xdx_90D_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember__srt--RangeAxis__srt--MaximumMember_zMDjRUq42GH8" title="Property and equipment, estimated useful lives">10</span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Computer
    Hardware</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_zay71H131WJ9" title="Property and equipment, estimated useful lives">5</span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Leasehold
    Improvements</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90F_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember__srt--RangeAxis__srt--MinimumMember_zttmRcV3egyh" title="Property and equipment, estimated useful lives">10</span>-<span id="xdx_903_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember__srt--RangeAxis__srt--MaximumMember_zDksIX8dOpz9" title="Property and equipment, estimated useful lives">20</span></span></td></tr>
  </table>
<p id="xdx_8A9_zz9GmOk7OY67" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Depreciation
expense was $<span id="xdx_908_eus-gaap--Depreciation_c20240101__20241231_zCE9MU3CfcB" title="Depreciation expense">26,346</span> and $<span id="xdx_907_eus-gaap--Depreciation_c20230101__20231231_zg5lb62IyG23" title="Depreciation expense">30,240</span> during the years ended December 31, 2024 and 2023, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development</a></td>
<td class="text"><p id="xdx_847_eus-gaap--ResearchAndDevelopmentExpensePolicy_zaqJbGezMLz8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_861_z6QRpnJ2AG38">Research
and Development</span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Costs
for research and development are expensed as incurred. Research and development expenses consist primarily of clinical research studies
and new product development.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsFiniteLivedPolicy', window );">Intangible Assets</a></td>
<td class="text"><p id="xdx_843_eus-gaap--IntangibleAssetsFiniteLivedPolicy_zGVWfgMVm0Lf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_862_zLVPmPO16MM7">Intangible
Assets</span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Intangible
assets consist of software, patents, a trademark and a license. Intangible assets are stated at their historical cost and amortized on
a straight-line basis over their expected useful lives. Capitalized patent costs, net of accumulated amortization, includes legal costs
incurred for patent applications. In accordance with ASC 350, once a patent is granted, we amortize the capitalized patent costs over
the remaining life of the patent using the straight-line method. If the patent is not granted, we write off any capitalized patent costs
at that time.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company purchased a trademark related to the Company&#8217;s name for $<span id="xdx_908_eus-gaap--PaymentsToAcquireIntangibleAssets_c20240101__20241231__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_zPy2rZ9bDnpa" title="Payment to acquire intangible assets">50,000</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.
The trademark does not have a determinate life and therefore the cost is not being amortized.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company entered into an option agreement on April 12, 2023 to bring an optionor&#8217;s invention to commercialization via a royalty-bearing
licensing agreement. The agreement required an initial payment of $<span id="xdx_90D_eus-gaap--PaymentsToAcquireIntangibleAssets_c20240101__20241231__us-gaap--TypeOfArrangementAxis__custom--LicensingAgreementMember_zbq2IOfPbfml" title="Payment upon execution">1,000</span> and was fully amortized in the year ended December 31, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Neuraxis,
Inc.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Notes
to Financial Statements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
review intangible assets for impairment annually or when events or circumstances indicate that their carrying amount may not be recoverable.
During the years ended December 31, 2024, and 2023, the Company recorded no impairment charges for intangible assets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amortization
expense was $<span id="xdx_902_eus-gaap--AmortizationOfIntangibleAssets_c20240101__20241231_zHntBXDIkQQh" title="Amortization expense">11,485</span> and $<span id="xdx_909_eus-gaap--AmortizationOfIntangibleAssets_c20230101__20231231_z6VW5MqTev6c" title="Amortization expense">10,485</span> during the years ended December 31, 2024 and 2023, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><p id="xdx_844_eus-gaap--IncomeTaxPolicyTextBlock_zkgEMdBxd1ml" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_864_zSM75xOhiFEk">Income
Taxes</span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company recognizes deferred tax assets and liabilities for the expected future tax consequences of events that have been included in
the Company&#8217;s financial statements and tax returns. Deferred tax assets and liabilities are determined based upon the differences
between the financial statement carrying amounts, and the tax bases of existing assets and liabilities for the loss and credit carryforwards
using enacted tax rates expected to be in effect in the year in which the differences are expected to reverse. Deferred tax assets are
reduced by a valuation allowance if it is more likely than not that these assets may not be realized. The Company determines whether
a tax position will be sustained upon examination. If it is more likely than not that a position will be sustained, none of the benefit
attributable to the position is recognized. The tax benefit to be recognized for any tax position that meets the more likely than not
recognition threshold is calculated as <span id="xdx_900_eus-gaap--IncomeTaxExaminationLikelihoodOfUnfavorableSettlement_c20240101__20241231_zhScl8zCptK8" title="Income tax examination, likelihood of unfavorable settlement">the largest amount that is more than 50% likely of being realized upon resolution of the contingency</span>.
The Company accounts for interest and penalties related to uncertain tax positions as part of its provision for income taxes.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management&#8217;s
evaluation of the Company&#8217;s deferred tax assets and liabilities did not have a material effect on the Company&#8217;s financial
statements. Furthermore, <span id="xdx_907_eus-gaap--IncomeTaxExaminationPenaltiesAndInterestAccrued_iI_do_c20241231_ztC0RV1l8oLb" title="Income tax interest or penalties accrued"><span id="xdx_908_eus-gaap--IncomeTaxExaminationPenaltiesAndInterestAccrued_iI_do_c20231231_zhqBNkKSJdb6" title="Income tax interest or penalties accrued">no</span></span> interest or penalties have been accrued or charged to expense as of December 31, 2024 and 2023 and for the
years then ended.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdvertisingCostsPolicyTextBlock', window );">Advertising Cost</a></td>
<td class="text"><p id="xdx_847_eus-gaap--AdvertisingCostsPolicyTextBlock_zo5yvzL87Rx8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_867_zWUOXu7pc5n5">Advertising
Cost</span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Advertising
costs are expensed as incurred and amounted to $<span id="xdx_90F_eus-gaap--AdvertisingExpense_c20240101__20241231__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zHFN1G5pWFd9" title="Advertising cost">232,125</span>
and $<span id="xdx_900_eus-gaap--AdvertisingExpense_c20230101__20231231__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zIlntYARjZTf" title="Advertising cost">192,400</span> for
the years ended December 31, 2024 and 2023, respectively, and are classified as general and administrative expenses in the
statements of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Neuraxis,
Inc.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Notes
to Financial Statements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NRXS_WarrantLiabilityPolicyTextBlock', window );">Warrant Liabilities</a></td>
<td class="text"><p id="xdx_848_ecustom--WarrantLiabilityPolicyTextBlock_zaVIsSf1c53d" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_86D_zrlgX8Mm8yia">Warrant
Liabilities</span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management
evaluates all of the Company&#8217;s financial instruments, including issued warrants to purchase its common stock, to determine if such
instruments are liabilities pursuant to ASC 480 and ASC 815-15. The classification
of derivative financial instruments, including whether such instruments should be recorded as liabilities or as equity, is reassessed
at the end of each reporting period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company utilizes a Black-Scholes option-pricing model to compute the fair value of the derivative and to mark to market the fair value
of the derivative at each balance sheet date. The inputs utilized in the application of the Black-Scholes option-pricing model included
an exercise price, the stock price as of the valuation date, an expected remaining term of each warrant as of the valuation date, estimated
volatility, a dividend yield, and a risk-free rate. The Company records the change in the fair value of the warrant as other income or
expense in the statements of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><p id="xdx_846_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_zuoNDbkmfx99" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_867_zA6yTR80qBQ1">Fair
Value Measurements</span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for financial instruments in accordance with ASC 820, Fair Value Measurements and Disclosures (&#8220;ASC 820&#8221;).
ASC 820 establishes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy
gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and
the lowest priority to unobservable inputs (Level 3 measurements). The three levels of the fair value hierarchy under ASC 820 are described
below:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
1 &#8211; Quoted prices (unadjusted) for identical unrestricted assets or liabilities in active markets that the reporting entity has
the ability to access as of the measurement date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
2 &#8211; Significant other observable inputs other than Level 1 prices such as quoted prices for similar assets or liabilities: quoted
prices in markets that are not active; or financial instruments for which all significant inputs are observable or can be corroborated
by observable market date, either directly or indirectly.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
3 &#8211; Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets
or liabilities. These unobservable inputs reflect that reporting entity&#8217;s own assumptions about assumptions that market participants
would use in pricing the asset or liability. Level 3 assets and liabilities include financial instruments whose value is determined using
pricing models, discounted cash flow methodologies, or similar techniques, as well as instruments for which the determination of fair
value require significant management judgment or estimation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s Level 1 assets/liabilities include cash, accounts receivable, accounts payable, prepaids, and other current assets. Management
believes the estimated fair value of these accounts on December 31, 2024 approximate their carrying value as reflected in the balance
sheets due to the short-term nature of these instruments or the use of market interest rates for debt instruments.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s Level 3 assets/liabilities include warrant liabilities. Inputs to determine fair value are generally unobservable
and typically reflect management&#8217;s estimates of assumptions that market participants would use in pricing the asset or liability.
The fair values are therefore determined using model-based techniques, including option pricing models and discounted cash flow models.
The valuation techniques involve management&#8217;s estimates and judgment based on unobservable inputs. The fair value estimates may
not be indicative of the amounts that would be realized in a market exchange. Additionally, there may be inherent uncertainties or changes
in the underlying assumptions used, which could significantly affect the current or future fair value estimates. Unobservable inputs
used in the models are significant to the fair values of the assets and liabilities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Neuraxis,
Inc.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Notes
to Financial Statements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_89E_eus-gaap--ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_zSRjCMWMj1w3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table provides a summary of the relevant assets and liabilities that are measured at fair value on a recurring
basis:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B3_z3g9hDaGrTA9" style="display: none">Schedule
of Fair Value of Assets and Liabilities  measured on Recurring Basis</span>&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_4B9_us-gaap--FairValueByMeasurementFrequencyAxis_us-gaap--FairValueMeasurementsRecurringMember_us-gaap--FinancialInstrumentAxis_us-gaap--WarrantMember_zBZgAXCyF1Vk" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_4B0_us-gaap--FairValueByMeasurementFrequencyAxis_us-gaap--FairValueMeasurementsRecurringMember_us-gaap--FairValueByFairValueHierarchyLevelAxis_us-gaap--FairValueInputsLevel1Member_zDB43ntMIDc2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 1</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_4BA_us-gaap--FairValueByMeasurementFrequencyAxis_us-gaap--FairValueMeasurementsRecurringMember_us-gaap--FairValueByFairValueHierarchyLevelAxis_us-gaap--FairValueInputsLevel2Member_z9UbeIrsNMjf" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 2</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_4BC_us-gaap--FairValueByMeasurementFrequencyAxis_us-gaap--FairValueMeasurementsRecurringMember_us-gaap--FairValueByFairValueHierarchyLevelAxis_us-gaap--FairValueInputsLevel3Member_zWqguAEicMAk" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 3</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: center"><b>Valuation Methodology</b></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: center"><b>Unobservable<br/>
Inputs</b></td></tr>
  <tr id="xdx_439_c20241231_eus-gaap--LiabilitiesFairValueDisclosure_iI_z3pBMIl0Qkg3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 23%; text-align: left; padding-bottom: 1pt; padding-left: 0pt">Fair value of warrant  liabilities as of
    December 31, 2024</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 7%; text-align: right">9,166</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 7%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0827">&#8212;</span></td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 7%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0828">&#8212;</span></td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 7%; text-align: right">9,166</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="text-align: center; width: 12%">Black-Scholes model</td>
    <td style="width: 2%">&#160;</td>
    <td style="text-align: center; width: 17%">Project simulated cash flows</td></tr>
  <tr id="xdx_43C_c20231231_eus-gaap--LiabilitiesFairValueDisclosure_iI_z6bHNiK1NE4k" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 0pt">Fair value of warrant  liabilities as of
    December 31, 2023</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">8,225</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0832">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0833">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">8,225</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">Black-Scholes model</td>
    <td>&#160;</td>
    <td style="text-align: center">Project simulated cash flows</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p id="xdx_8AF_zDV1NvmR9hqi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
were no transfers between any of the levels during the years ended December 31, 2024 and 2023. In addition to assets and liabilities
that are recorded at fair value on a recurring basis, the Company&#8217;s assets and liabilities are also subject to recurring fair
value measurements. As of December 31, 2024 and 2023, the Company had no assets that were measured on a recurring basis.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Basic and Diluted Net Income (Loss) per Share</a></td>
<td class="text"><p id="xdx_843_eus-gaap--EarningsPerSharePolicyTextBlock_z3Z5xHrFvPnb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_868_zRILTRgfzVRf">Basic
and Diluted Net Income (Loss) per Share</span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basic
earnings or loss per share (&#8220;EPS&#8221;) is computed by dividing net income (loss), net of preferred stock dividends, by the
weighted average number of common shares outstanding during the period. Diluted EPS is determined using the weighted average number
of common shares outstanding during the period, adjusted for the dilutive effect of common stock equivalents that were outstanding
for the periods presented. In periods when losses are reported, which is the case for December 31, 2024 and 2023 presented in these
financial statements, the weighted average number of common shares outstanding excludes common stock equivalents because their
inclusion would be anti-dilutive. Preferred stock dividends (neither declared nor paid) were $<span id="xdx_90F_eus-gaap--DividendsPreferredStock_c20240101__20241231_zMa5zOaCz0dh" title="Preferred stock dividend">211,268</span>
and $<span id="xdx_906_eus-gaap--DividendsPreferredStock_dxL_c20230101__20231231_zCKOVIyQCu2e" title="Preferred stock dividend::XDX::-"><span style="-sec-ix-hidden: xdx2ixbrl0840">0</span></span>
as of December 31, 2024 and 2023, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Neuraxis,
Inc.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Notes
to Financial Statements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_894_eus-gaap--ScheduleOfEarningsPerShareDilutedByCommonClassTextBlock_zQrWqPsSpLsb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company had the following potentially dilutive common stock equivalents at December 31, 2024 and 2023:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BC_zox9NmqQpub9" style="display: none">Schedule of Dilutive Common Stock Equivalents</span>&#160;</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_494_20240101__20241231_zCfMhiwPQpEd" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49E_20230101__20231231_zb3LNMgKs5Qd" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--OptionMember_z2YvJ0OOXEw7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%">Options</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right">1,319,394</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right">1,319,394</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--CommonStockMember_z4IBT9gvKFCb" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Pre-Funded Warrants for Common Stock</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">289,779</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0848">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--WarrantsMember_zm2CD0h3eBoj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,352,751</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,822,358</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--SeriesBPreferredStockMember_zPVzzRS4kdql" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Series B Preferred Stock</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">4,280,939</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0854">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_zswUml38NNc9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-bottom: 1pt; padding-left: 10pt">Totals</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">8,242,863</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">3,141,752</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8AE_zZkRPjMKhCOg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_89D_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_zX3d573GQcn8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table shows the calculation of the basic and diluted net loss per share and the effect of preferred stock dividends.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BC_zXyehy2Q4OB7" style="display: none">Schedule of Basic and Diluted Net Loss Per Share</span>&#160;</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49E_20240101__20241231_zkLWbBazjZl2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_493_20230101__20231231_zPg30jDzserk" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">For the Years Ended December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Numerator</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--NetIncomeLoss_iT_mtNILzQKI_zp3QgJK7iOg" style="vertical-align: bottom; background-color: White">
    <td style="width: 60%; text-align: left; padding-left: 10pt">Net loss</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">(8,241,501</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right">(14,626,683</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr id="xdx_402_eus-gaap--DividendsPreferredStock_iN_di_zqUV04SEGgVl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 10pt">Preferred stock dividends</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(211,268</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0865">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_zqBPWqst7E72" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Net loss available to common stockholders</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(8,452,769</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(14,626,683</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Denominator</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 20pt">Weighted-average shares of common stock outstanding - basic and diluted</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_903_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20240101__20241231_z6adsR0YsnZ9" title="Weighted average shares of common stock outstanding - basic"><span id="xdx_901_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20240101__20241231_zco5F3MbpLAc" title="Weighted average shares of common stock outstanding - diluted">6,918,887</span></span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_900_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20230101__20231231_zpa3Fn0QmNfb" title="Weighted average shares of common stock outstanding - basic"><span id="xdx_903_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20230101__20231231_zRyq1dOtor4d" title="Weighted average shares of common stock outstanding - diluted">3,252,328</span></span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Basic and diluted net loss per share</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_90E_eus-gaap--EarningsPerShareBasic_c20240101__20241231_zrz21PRWjGCl" title="Basic net loss per share"><span id="xdx_90F_eus-gaap--EarningsPerShareDiluted_c20240101__20241231_zIgmac8dw9Ed" title="Diluted net loss per share">(1.22</span></span></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_908_eus-gaap--EarningsPerShareBasic_c20230101__20231231_z2hMbWcceUqg" title="Basic net loss per share"><span id="xdx_905_eus-gaap--EarningsPerShareDiluted_c20230101__20231231_z96vWnNsnYxe" title="Diluted net loss per share">(4.50</span></span></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  </table>

<p id="xdx_8AF_z8OuXYGzkAE7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-Based Compensation</a></td>
<td class="text"><p id="xdx_848_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_zuHjXlK84ss5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_862_zfwsy8KpLtyk">Stock-Based
Compensation</span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for all stock-based awards at fair value. The Company recognizes its stock-based compensation expense using the straight-line
method. Compensation cost is not adjusted for estimated forfeitures, but instead is adjusted upon an actual forfeiture.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for the granting of stock options and restricted stock units to employees and non-employees using the fair value method
whereby all awards are measured at fair value on the date of the grant. The fair value of all employee stock options and restricted stock
units is expensed over the requisite service period with a corresponding increase to additional paid-in capital. Upon exercise of stock
options, the consideration paid by the option holder is recorded in additional paid-in capital, while the par value of the shares received
is reclassified from additional paid-in-capital to common stock. Upon vesting of restricted stock units, the par value of the shares
issued are reclassified from additional paid-in-capital to common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock-based
awards to non-employees are measured based on the fair value of the equity instrument issued. Compensation expense for non-employee stock
awards is recognized over the requisite service period following the measurement of the fair value on the grant date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company uses the Black-Scholes option-pricing model to calculate the fair value of stock options. The use of the Black-Scholes option-pricing
model requires management to make assumptions with respect to the expected term of the option, the expected volatility of the common
stock consistent with the expected term of the option, risk-free interest rates, the value of the common stock and expected dividend
yield of the common stock. Changes in these assumptions can materially affect the fair value estimate.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Neuraxis,
Inc.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Notes
to Financial Statements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><p id="xdx_843_eus-gaap--RevenueRecognitionPolicyTextBlock_zbJsYb6ra5wg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_862_zPNGdCffZD65">Revenue
Recognition</span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
accordance with FASB&#8217;s ASC 606, <i>Revenue from Contracts with Customers</i>, (&#8220;ASC 606&#8221;), the Company recognizes revenue
when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the Company expects
to be entitled in exchange for those goods or services. To determine revenue recognition for arrangements that the Company determines
are within the scope of ASC 606, it performs the following five steps:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">identify
    the contract(s) with a customer&#894;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">identify
    the performance obligations in the contract&#894;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">determine
    the transaction price&#894;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iv)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">allocate
    the transaction price to the performance obligations in the contract&#894; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(v)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">recognize
    revenue when (or as) the entity satisfies a performance obligation.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company applies the five-step model to contracts when it determines that it is probable it will collect substantially all the consideration
it is entitled to in exchange for the goods or services it transfers to the customer. At contract inception, once the contract is determined
to be within the scope of ASC 606, the Company assesses the goods or services promised within each contract and determines those that
are performance obligations and assesses whether each promised good or service is distinct. The Company then recognizes as revenue the
amount of the transaction price, after consideration of variability and constraints, if any, that is allocated to the respective performance
obligation when the performance obligation is satisfied.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company estimates credit losses on accounts receivable by utilizing an aging schedule.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company offers a Patient Assistance Program for patients without insurance coverage for IB-Stim. This program offers potential self-pay
discounts for IB-Stim devices, based upon household income and size.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Also,
the Company offers providers an opt-in program to address adequate insurance claim payments on IB-Stim devices. This program may extend
a rebate or invoice credit where the insurance payment and patient responsibility (i.e., deductible, co-payment, and/or co-insurance
amounts required by the Payer) are less than the acquisition cost of the IB-Stim device. The Company recognizes revenue at such a time
that collection of the amount due is assured.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_89B_eus-gaap--DisaggregationOfRevenueTableTextBlock_z51iF5FwY8Ik" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table disaggregates the Company&#8217;s revenue based on the customer&#8217;s location by state for the years ended December
31:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B7_zFnT94CGa2N4" style="display: none">Schedule of Disaggregation of Revenue</span>&#160;</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 60%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 20%">California</td><td style="width: 2%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">$</td><td id="xdx_983_eus-gaap--Revenues_c20240101__20241231__srt--StatementGeographicalAxis__stpr--CA_ztWpMGR6FjK" style="width: 16%; font-weight: bold; text-align: right" title="Revenues">778,209</td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--Revenues_c20230101__20231231__srt--StatementGeographicalAxis__stpr--CA_zhaa1ANY8XF7" style="width: 16%; text-align: right" title="Revenues">601,235</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Ohio</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--Revenues_c20240101__20241231__srt--StatementGeographicalAxis__stpr--OH_z8HHuDbKCMGd" style="font-weight: bold; text-align: right" title="Revenues">431,328</td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--Revenues_c20230101__20231231__srt--StatementGeographicalAxis__stpr--OH_zzOMNsxW8pak" style="text-align: right" title="Revenues">407,632</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Illinois</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--Revenues_c20240101__20241231__srt--StatementGeographicalAxis__stpr--IL_zb6kZssrfWfe" style="font-weight: bold; text-align: right" title="Revenues">246,217</td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--Revenues_c20230101__20231231__srt--StatementGeographicalAxis__stpr--IL_zWDTnM17q319" style="text-align: right" title="Revenues">117,963</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Wisconsin</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--Revenues_c20240101__20241231__srt--StatementGeographicalAxis__stpr--WI_z3428iyridQh" style="font-weight: bold; text-align: right" title="Revenues">157,786</td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--Revenues_c20230101__20231231__srt--StatementGeographicalAxis__stpr--WI_zGxpKPV1TjK7" style="text-align: right" title="Revenues">292,601</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Massachusetts</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--Revenues_c20240101__20241231__srt--StatementGeographicalAxis__stpr--MA_zasnvjzBkL05" style="font-weight: bold; text-align: right" title="Revenues">154,407</td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--Revenues_c20230101__20231231__srt--StatementGeographicalAxis__stpr--MA_zKTfMKrP2Fwk" style="text-align: right" title="Revenues">127,300</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Florida</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--Revenues_c20240101__20241231__srt--StatementGeographicalAxis__stpr--FL_zjSSE7PnWXPh" style="font-weight: bold; text-align: right" title="Revenues">149,985</td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--Revenues_c20230101__20231231__srt--StatementGeographicalAxis__stpr--FL_z0AEkB7FcCsg" style="text-align: right" title="Revenues">186,840</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">All other states</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--Revenues_c20240101__20241231__srt--StatementGeographicalAxis__custom--AllOtherStatesMember_zhSbHj7bt2ag" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right" title="Revenues">767,993</td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--Revenues_c20230101__20231231__srt--StatementGeographicalAxis__custom--AllOtherStatesMember_zVzeZm5mSkih" style="border-bottom: Black 1pt solid; text-align: right" title="Revenues">726,478</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">$</td><td id="xdx_988_eus-gaap--Revenues_c20240101__20241231_z8xgf1LC4xKf" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right" title="Revenues">2,685,925</td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_986_eus-gaap--Revenues_c20230101__20231231_zCiswA2OlDda" style="border-bottom: Black 1pt solid; text-align: right" title="Revenues">2,460,049</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A0_zvTYoR5sc9Ua" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain
economic factors affect the nature, amount, timing, and uncertainty of the Company&#8217;s revenue and cash flows. All of the Company&#8217;s
products are sold to healthcare customers including hospitals and clinics. Sales to healthcare customers lack seasonality and have a
mild correlation with economic cycles. All of the Company&#8217;s sales are to customers located within the United States. Sales contracts
consist of purchase orders that are short-term (i.e., less than or equal to one year).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Neuraxis,
Inc.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Notes
to Financial Statements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company typically satisfies its performance obligations for goods at a point in time as they are received at the customer&#8217;s
destination (rather than over time). Goods are shipped by common carrier to customers under FOB destination terms. As such,
ownership of goods in transit is transferred to the customer upon receipt as the Company bears the associated risks (e.g., loss,
damage, delay). Management typically relies on shipping information from common carriers to evaluate when the
customer has obtained control of the goods. Shipping and handling costs are recorded as Cost of Goods Sold in the Statements of
Operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s contracts with customers typically do not involve variable consideration. The information that the Company uses to determine
the transaction price for a contract is similar to the information that the Company&#8217;s management uses in establishing the prices
of goods to be sold.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Orders
may not be cancelled after shipment. Customers may return devices within 10 days of delivery if the goods are found to be defective,
nonconforming, or otherwise do not meet the stated technical specifications. At the option of the customer, the Company shall either:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Refund
    the price paid for any defective or nonconforming products.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Supply
    and deliver to the customer replacement conforming products.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Reimburse
    the customer for the cost of repairing any defective or nonconforming products.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
the time revenue is recognized, the Company estimates expected returns and excludes those amounts from revenue. The Company also
maintains appropriate accounts to reflect the effects of expected returns on the Company&#8217;s financial position and periodically
adjusts those accounts to reflect its actual return experience. Estimated returns totaled</span> $<span id="xdx_908_eus-gaap--ContractWithCustomerLiabilityRevenueRecognized_c20240101__20241231_zBqEO4HnlF7c" title="Estimated returns of revenue">5,000</span> and $<span id="xdx_90C_eus-gaap--ContractWithCustomerLiabilityRevenueRecognized_c20230101__20231231_zt5BroE5J4dl" title="Estimated returns of revenue">0</span> as of December 31,
2024 and 2023, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Payment
for goods sold by the Company is typically due after an invoice is sent to the customer, within 30 days. The Company does not offer discounts
if the customer pays some or all of an invoiced amount prior to the due date. None of the Company&#8217;s contracts have a significant
financing component.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Medical
devices that the Company contracts to sell and transfer to customers are manufactured by one specific third-party manufacturer located
within the state of Indiana. In no case does the Company act as an agent (i.e., the Company does not provide a service of arranging for
another party to transfer goods to the customer).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Neuraxis,
Inc.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Notes
to Financial Statements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><p id="xdx_846_eus-gaap--LesseeLeasesPolicyTextBlock_zFGApbXnaIf2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_862_zlz6TSsaBUBh">Leases</span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
accordance with Accounting Standards Updated (&#8220;ASU&#8221;) No. 2016-02, <i>Leases (Topic 842)</i> (&#8220;ASU 2016-02&#8221; or
&#8220;ASC 842&#8221;), at the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based
on the unique facts and circumstances present in the arrangement. Leases with a term greater than one year are recognized on the balance
sheet as right-of-use assets and current and non-current lease liabilities, as applicable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating
lease liabilities and their corresponding right-of-use assets are initially recorded based on the present value of lease payments over
the expected remaining lease term. Certain adjustments to the right-of-use asset may be required for items such as incentives received.
The interest rate implicit in lease contracts is typically not readily determinable. As a result, the Company utilizes its incremental
borrowing rate to discount lease payments, which reflects the fixed rate at which the Company could borrow on a collateralized basis
the amount of the lease payments in the same currency, for a similar term, in a similar economic environment. Prospectively, the Company
will adjust the right-of-use assets for straight-line rent expense, or any incentives received and remeasure the lease liability at the
net present value using the same incremental borrowing rate that was in effect as of the lease commencement or transition date. The Company
has elected not to recognize leases with an original term of one year or less on the balance sheet. The Company typically only includes
an initial lease term in its assessment of a lease arrangement. Options to renew a lease are not included in the Company&#8217;s assessment
unless there is reasonable certainty that the Company will renew.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Assumptions
made by the Company at the commencement date are re-evaluated upon occurrence of certain events, including a lease modification. A lease
modification results in a separate contract when the modification grants the lessee an additional right of use not included in the original
lease and when lease payments increase commensurate with the standalone price for the additional right of use. When a lease modification
results in a separate contract, it is accounted for in the same manner as a new lease.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Entities
may elect not to separate lease and non-lease components. The Company has elected to account for lease and non-lease components together
as a single lease component for all underlying assets and allocate all the contract consideration to the lease component only.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Neuraxis,
Inc.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Notes
to Financial Statements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Impairment of Long-Lived Assets</a></td>
<td class="text"><p id="xdx_84C_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_zBrdlPiMtEtd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_864_z3HRppsuDOqc">Impairment
of Long-Lived Assets</span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Long-lived
assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset group may
not be recoverable. If events or changes in circumstances indicate that the carrying amount of an asset group may not be recoverable,
we compare the carrying amount of the asset group to future undiscounted net cash flows, excluding interest costs, expected to be generated
by the asset group and their ultimate disposition. If the sum of the undiscounted cash flows is less than the carrying value, the impairment
to be recognized is measured by the amount by which the carrying amount of the asset group exceeds the fair value of the asset group.
Assets to be disposed of are reported at the lower of the carrying amount or fair value, less costs to sell.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentrations of Credit Risk</a></td>
<td class="text"><p id="xdx_84A_eus-gaap--ConcentrationRiskCreditRisk_znCEHkM7M1r6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_865_zp8VPiZFHkLc">Concentrations
of Credit Risk</span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s business activity consists of the sale of medical neuromodulation devices to doctors, clinics, and hospitals across
the country. Receivables consist of unsecured amounts due from customers. The table below sets forth the Company&#8217;s customers
that accounted for greater than 10% of its net accounts receivable for the years ended December 31, 2024 and 2023,
respectively.</span></p>

<p id="xdx_898_eus-gaap--SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_zUwJC7G3vMd4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span id="xdx_8BF_ziuviCdUkIG6" style="display: none">Schedule of Customer Accounts Receivable</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Percentage
    of Net Accounts</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Percentage
    of Net Accounts</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2024</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Receivable</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2023</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> Receivable</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 36%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Customer
    A</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>$</b></span></td><td id="xdx_98A_eus-gaap--AccountsReceivableNet_iI_c20241231__srt--MajorCustomersAxis__custom--CustomerAMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zGVtJHY4ngni" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right" title="Net accounts receivable"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">119,616</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20240101__20241231__srt--MajorCustomersAxis__custom--CustomerAMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_ztfwx0Pn3dvb" title="Risk percentage">49</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>$</b></span></td><td id="xdx_985_eus-gaap--AccountsReceivableNet_iI_c20231231__srt--MajorCustomersAxis__custom--CustomerAMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zKXzKALlmJz7" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right" title="Net accounts receivable"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0940">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_901_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20231231__srt--MajorCustomersAxis__custom--CustomerAMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_z9o22JCbwIjb" title="Risk percentage">0</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Customer
    B</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98C_eus-gaap--AccountsReceivableNet_iI_c20241231__srt--MajorCustomersAxis__custom--CustomerBMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zR77yBuhHffb" style="font: bold 10pt Times New Roman, Times, Serif; text-align: right" title="Net accounts receivable"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0944">-</span></span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_905_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20240101__20241231__srt--MajorCustomersAxis__custom--CustomerBMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_z9SVmlN18mH9" title="Risk percentage">0</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98B_eus-gaap--AccountsReceivableNet_iI_c20231231__srt--MajorCustomersAxis__custom--CustomerBMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zDCakzXb5lvc" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Net accounts receivable"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">23,900</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20231231__srt--MajorCustomersAxis__custom--CustomerBMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zYReW668WMIf" title="Risk percentage">28</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Customer
    C</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_985_eus-gaap--AccountsReceivableNet_iI_c20241231__srt--MajorCustomersAxis__custom--CustomerCMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zECBJOkoPFzh" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Net accounts receivable"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">22,799</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_907_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20240101__20241231__srt--MajorCustomersAxis__custom--CustomerCMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zCoq7BCeaAUd" title="Risk percentage">9</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98A_eus-gaap--AccountsReceivableNet_iI_c20231231__srt--MajorCustomersAxis__custom--CustomerCMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zSmayTQpiaTa" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Net accounts receivable"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">14,401</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90D_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20231231__srt--MajorCustomersAxis__custom--CustomerCMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_z058r726xm0j" title="Risk percentage">17</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Customer
    D</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_989_eus-gaap--AccountsReceivableNet_iI_c20241231__srt--MajorCustomersAxis__custom--CustomerDMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_ziWgXs4rhsT5" style="font: bold 10pt Times New Roman, Times, Serif; text-align: right" title="Net accounts receivable"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0960">-</span></span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_905_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20240101__20241231__srt--MajorCustomersAxis__custom--CustomerDMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zSEvYV8lKLbh" title="Risk percentage">0</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_987_eus-gaap--AccountsReceivableNet_iI_c20231231__srt--MajorCustomersAxis__custom--CustomerDMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zgOcWsNkjKF1" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Net accounts receivable"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">23,982</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_909_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20231231__srt--MajorCustomersAxis__custom--CustomerDMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zlZgVpBjp056" title="Risk percentage">28</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Customer
    E</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98E_eus-gaap--AccountsReceivableNet_iI_c20241231__srt--MajorCustomersAxis__custom--CustomerEMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zl2qNb56zJwh" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right" title="Net accounts receivable"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0968">-</span></span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90F_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20240101__20241231__srt--MajorCustomersAxis__custom--CustomerEMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zqDT0bFj4H1k" title="Risk percentage">0</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98E_eus-gaap--AccountsReceivableNet_iI_c20231231__srt--MajorCustomersAxis__custom--CustomerEMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zwaoP8QxF9Bf" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Net accounts receivable"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">9,599</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_901_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20231231__srt--MajorCustomersAxis__custom--CustomerEMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zyXKzz43jjZf" title="Risk percentage">11</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>$</b></span></td><td id="xdx_986_eus-gaap--AccountsReceivableNet_iI_c20241231__srt--MajorCustomersAxis__custom--CustomerMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_z1Hroo9j0F5k" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Net accounts receivable"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">142,415</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_902_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20240101__20241231__srt--MajorCustomersAxis__custom--CustomerMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zvYJPTm3tgrf" title="Risk percentage">58</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>$</b></span></td><td id="xdx_98E_eus-gaap--AccountsReceivableNet_iI_c20231231__srt--MajorCustomersAxis__custom--CustomerMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_z3M4Bf5OFDta" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Net accounts receivable"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">71,882</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_906_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20231231__srt--MajorCustomersAxis__custom--CustomerMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zHYTFLfnmKr" title="Risk percentage">84</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr>
  </table>
<p id="xdx_8AC_zCXEfpOPYya" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
table below sets forth the Company&#8217;s customers that accounted for greater than 10% of its net sales for the years ended
December 31, 2024 and 2023, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_896_eus-gaap--ContractWithCustomerAssetAllowanceForCreditLossTableTextBlock_zkkwaR2En4R4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span id="xdx_8BA_z9EQpd6TmZ1d" style="display: none">Schedule of Customers Accounted Revenues</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Percentage of</td><td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Percentage of</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Net Sales</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Net Sales</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 36%; text-align: left">Customer A</td><td style="width: 2%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">$</td><td id="xdx_98B_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20240101__20241231__srt--MajorCustomersAxis__custom--CustomerAMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zhKwbiXDFFs3" style="width: 12%; font-weight: bold; text-align: right" title="Revenue">521,810</td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right"><span id="xdx_903_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20240101__20241231__srt--MajorCustomersAxis__custom--CustomerAMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zklF9jeBuOtg" title="Risk percentage">20</span></td><td style="width: 1%; text-align: left">%</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_986_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20230101__20231231__srt--MajorCustomersAxis__custom--CustomerAMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zHFwu8jqdfzh" style="width: 12%; text-align: right" title="Revenue">452,680</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right"><span id="xdx_908_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20231231__srt--MajorCustomersAxis__custom--CustomerAMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zUGo6Jpa5fgl" title="Risk percentage">18</span></td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Customer B</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20240101__20241231__srt--MajorCustomersAxis__custom--CustomerBMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zbvEOGjsePt8" style="font-weight: bold; text-align: right" title="Revenue">396,950</td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90C_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20240101__20241231__srt--MajorCustomersAxis__custom--CustomerBMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_z6L6EIm7A9m7" title="Risk percentage">15</span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20230101__20231231__srt--MajorCustomersAxis__custom--CustomerBMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zLhqQLg76db" style="text-align: right" title="Revenue">382,082</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_909_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20231231__srt--MajorCustomersAxis__custom--CustomerBMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zACbxoOC2pSe" title="Risk percentage">16</span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Customer C</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20240101__20241231__srt--MajorCustomersAxis__custom--CustomerCMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zswU6SLkue39" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right" title="Revenue">142,270</td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_904_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20240101__20241231__srt--MajorCustomersAxis__custom--CustomerCMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_z2crm1yRVs5d" title="Risk percentage">5</span></td><td style="padding-bottom: 1pt; text-align: left">%</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20230101__20231231__srt--MajorCustomersAxis__custom--CustomerCMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zWVmxOqlJMFc" style="border-bottom: Black 1pt solid; text-align: right" title="Revenue">274,581</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_906_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20231231__srt--MajorCustomersAxis__custom--CustomerCMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zs8Tc7rodGKf" title="Risk percentage">11</span></td><td style="padding-bottom: 1pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">$</td><td id="xdx_989_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20240101__20241231__srt--MajorCustomersAxis__custom--CustomerMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zpQ98lLEyvZa" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right" title="Revenue">1,061,030</td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_90E_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20240101__20241231__srt--MajorCustomersAxis__custom--CustomerMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zLqb9DZOwDyh" title="Risk percentage">40</span></td><td style="padding-bottom: 1pt; text-align: left">%</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_98E_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20230101__20231231__srt--MajorCustomersAxis__custom--CustomerMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zuCpenm53Myd" style="border-bottom: Black 1pt solid; text-align: right" title="Revenue">1,109,343</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_909_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20231231__srt--MajorCustomersAxis__custom--CustomerMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zV0CREuaTTec" title="Risk percentage">45</span></td><td style="padding-bottom: 1pt; text-align: left">%</td></tr>
  </table>

<p id="xdx_8A8_zQMCLDFvtWn5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">From
time to time, the Company&#8217;s bank balances may exceed the FDIC limit of $<span id="xdx_901_eus-gaap--CashFDICInsuredAmount_iI_c20241231_zo5mHRQzxyD1" title="Cash, FDIC insured amount">250,000</span>.
As of December 31, 2024 and 2023, the Company had $<span id="xdx_901_eus-gaap--CashUninsuredAmount_iI_c20241231_zJJUkOAzfSya" title="Cash uninsured">3,263,618</span>
and $<span id="xdx_909_eus-gaap--CashUninsuredAmount_iI_c20231231_zQEDtlFPjsD" title="Cash uninsured">0</span> of its cash balance
uninsured, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NRXS_GoingConcernPolicyTextBlock', window );">Going Concern</a></td>
<td class="text"><p id="xdx_84E_ecustom--GoingConcernPolicyTextBlock_zs8TSICVHdrc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_864_z7ogNBVMc5Kh">Going
Concern</span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have incurred losses since inception and have funded our operations primarily with a combination of sales, debt, and the sale of capital
stock. As of December 31, 2024, we had stockholders&#8217; equity of $<span id="xdx_908_eus-gaap--StockholdersEquity_iI_c20241231_zcrwDhOD4KL9" title="Stockholders' equity">2,067,748</span>, short-term outstanding borrowings of $<span id="xdx_901_eus-gaap--ShortTermBorrowings_iI_c20241231_zcj9tEASlJp6" title="Short term borrowings outstanding">154,152</span>, cash
of $<span id="xdx_909_eus-gaap--Cash_iI_c20241231_zqeGWmRH93nf" title="Cash">3,696,870</span> and a working capital surplus of $<span id="xdx_907_ecustom--WorkingCapitalDeficit_iI_c20241231_zeQGhPzPxHu3" title="Working capital surplus">1,832,858</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Neuraxis,
Inc.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Notes
to Financial Statements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
future capital requirements will depend upon many factors, including progress with developing, manufacturing, and marketing our technologies,
the time and costs involved in preparing, filing, prosecuting, maintaining, and enforcing patent claims and other proprietary rights,
our ability to establish collaborative arrangements, marketing activities and competing technological and market developments, including
regulatory changes and overall economic conditions in our target markets. Our ability to generate revenue and achieve profitability requires
us to successfully market and secure purchase orders for our products from customers currently identified in our sales pipeline and to
new customers as well. The primary activity that will drive all customers and revenues is the adoption of insurance coverage by commercial
insurance carriers nationally which is a top priority of the Company. These activities, including our planned research and development
efforts, will require significant uses of working capital through the rest of 2025 and beyond. Based on our current operating plans,
we believe that our existing cash at the time of this filing will only be sufficient to meet our anticipated operating needs before the
end of 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management
evaluates whether there are conditions or events that raise substantial doubt about the Company&#8217;s ability to continue as a going
concern for a period of one year from the date the financial statements are issued.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
date, the Company has experienced operating losses and negative cash flows from operations. Management believes that increased sales
and acceptance of their product by insurance providers will allow the Company to achieve profitability in the future.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">While
the Company believes in the viability of its strategy to further implement its business plan and generate sufficient revenues and in
its ability to raise additional funds by way of a public or private offering of its debt or equity securities, there can be no assurance
that it will be able to do so on reasonable terms, or at all. The ability of the Company to continue as a going concern is dependent
upon its ability to further implement its business plan and generate sufficient revenues and its ability to raise additional funds by
way of a public or private offering. Neither future cash generated from operating activities, nor management&#8217;s contingency plans
to mitigate the risk and extend cash resources through the evaluation period, are considered probable. As a result, substantial doubt
is deemed to exist about the Company&#8217;s ability to continue as a going concern. As we continue to incur losses, our transition to
profitability is dependent upon achieving a level of revenues adequate to support its cost structure. We may never achieve profitability,
and unless and until doing so, we intend to fund future operations through additional dilutive or nondilutive financing. There can be
no assurances, however, that additional funding will be available on terms acceptable to us, if at all.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
financial statements do not include any adjustments related to the recoverability and classification of recorded asset amounts or the
amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently Adopted Accounting Pronouncements</a></td>
<td class="text"><p id="xdx_84D_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zcEfnqT2G8F2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_862_zHoVgdNJrcdl">Recently
Adopted Accounting Pronouncements</span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
November 2023, the FASB issued Accounting Standards Update (&#8220;ASU&#8221;) 2023-07, <i>Segment Reporting (Topic 280): Improvements
to Reportable Segment Disclosures</i>, which requires disclosure of (i) significant segment expenses, (ii) other segment items and (iii)
the title and position of the Chief Operating Decision Maker (&#8220;CODM&#8221;) on an annual and interim basis. Additionally, ASU 2023-07
requires that a public entity that has a single reportable segment provide all the disclosures required by Topic 280. Public business
entities are required to adopt the standard for fiscal years beginning after December 15, 2023 and interim periods withing fiscal year
beginning after December 15, 2024. Disclosures are required for all prior periods presented in the financial statements. The Company
adopted the disclosure provisions of ASU 2023-07 as of December 31, 2024 as operations are managed through one reportable segment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
June 2016, the FASB issued ASU 2016-13, <i>Financial Instruments &#8211; Credit Losses (Topic 326): Measurement of Credit Losses on Financial
Instruments</i>, which requires measurement and recognition of expected credit losses for financial assets held and enhanced disclosures
regarding significant estimates and judgments used in estimating credit losses. In November 2019, the FASB issued ASU 2019-10, Financial
Instruments &#8211; Credit Losses (Topic 326), Derivatives and Hedging (Topic 815) and Leases (Topic 842): Effective Dates, which amended
the effective date of ASU 2016-13. Public business entities meeting the definition of an SEC filer, excluding entities eligible to be
a Smaller Reporting Company (&#8220;SRC&#8221;) as defined by the SEC, are required to adopt the standard for fiscal years beginning
after December 15, 2019, including interim periods within those fiscal years. All other entities are required to adopt the standard for
fiscal years beginning after December 15, 2022, including interim periods within those fiscal years. The Company meets the definition
of an SRC and therefore the standard was adopted as of January 1, 2023. The adoption of this guidance did not have a material impact
on the Company&#8217;s financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NRXS_RecentlyIssuedAccountingPronouncementsPolicyTextBlock', window );">Recently Issued Accounting Pronouncements</a></td>
<td class="text"><p id="xdx_840_ecustom--RecentlyIssuedAccountingPronouncementsPolicyTextBlock_zjKjcdN7Te33" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_86A_zxIiHNzeegpc">Recently
Issued Accounting Pronouncements</span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
November 2024, the FASB issued ASU 2024-03, <i>Income Statement&#8212;Reporting Comprehensive Income&#8212;Expense Disaggregation Disclosures
(Subtopic (220-40): Disaggregation of Income Statement Expenses</i>, which requires disclosures that disaggregate, in a tabular presentation,
each relevant expense caption on the face of the income statement that includes inventory purchases, employee compensation, depreciation
and intangible amortization expense. Additional disclosures are also required to provide a qualitative description of the amounts in
an expense caption that are not separately disaggregated quantitatively and the total amount of selling expenses including a definition.
Public business entities are required to adopt the standard for fiscal years beginning after December 15, 2026 and interim periods within
fiscal years beginning after December 15, 2027. Disclosures are required for all prior periods presented in the financial statements.
Although the standard requires enhanced disclosures, the adoption is not expected to have a material impact on the Company&#8217;s financial
statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
December 2023, the FASB issued ASU 2023-09, <i>Income Taxes (Topic 740): Improvements to Income Tax Disclosures</i>, which requires the
enhancement of income tax disclosures to provide better insight into how an entity&#8217;s operations and related tax risks, planning
and opportunities affect its tax rate and prospects for future cash flows. The enhanced disclosures require (i) specific categories in
a tabular rate reconciliation including both amounts and percentages and (ii) additional information for reconciling items and income
tax paid that meet a quantitative threshold. Public business entities are required to adopt the standard for annual periods beginning
after December 15, 2024. All other entities are required to adopt the standard for annual periods beginning after December 15, 2025.
The adoption of the standard is not expected to have a material impact on the Company&#8217;s financial statements.</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_NRXS_GoingConcernPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Going Concern [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">NRXS_GoingConcernPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>NRXS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_NRXS_RecentlyIssuedAccountingPronouncementsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Recently Issued Accounting Pronouncements [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">NRXS_RecentlyIssuedAccountingPronouncementsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>NRXS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_NRXS_WarrantLiabilityPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrant Liability [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">NRXS_WarrantLiabilityPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>NRXS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdvertisingCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for advertising cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -SubTopic 35<br> -Topic 720<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483406/720-35-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdvertisingCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478898/942-825-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepositContractsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the treatment of funds received from or paid to insureds, insurers and reinsurers on contracts for which the criteria for transferring or assuming insurance risk has not been satisfied by the insurer or reinsurer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 1<br> -SubTopic 825<br> -Topic 944<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477037/944-825-05-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepositContractsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480091/360-10-S99-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 4<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482338/360-10-05-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-20<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-19<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-28<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsFiniteLivedPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/350-30/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483154/926-20-50-5<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 920<br> -SubTopic 350<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478609/920-350-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 920<br> -SubTopic 350<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478609/920-350-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 920<br> -SubTopic 350<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478609/920-350-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsFiniteLivedPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483080/330-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483489/210-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 912<br> -SubTopic 330<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478411/912-330-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/330/tableOfContent<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483080/330-10-50-4<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 6<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 270<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482989/270-10-45-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483044/730-10-05-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.C.Q3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.1.Q5)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.3.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TradeAndOtherAccountsReceivablePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481962/310-10-50-6<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481962/310-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481962/310-10-50-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481569/310-20-50-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481962/310-10-50-15<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481962/310-10-50-11B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TradeAndOtherAccountsReceivablePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-9<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-12<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NRXS_ScheduleOfPropertyPlantAndEquipmentUsefulLivesTableTextBlock', window );">Schedule of Estimated Useful Lives</a></td>
<td class="text"><p id="xdx_89D_ecustom--ScheduleOfPropertyPlantAndEquipmentUsefulLivesTableTextBlock_zA63jvQhipj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Depreciation
is calculated using the following estimated useful lives:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B1_zS3Vx59ipME8" style="display: none">Schedule of Estimated Useful Lives</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; width: 60%; border-collapse: collapse; margin-right: auto">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; width: 79%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Classification</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; width: 19%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Years</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Machinery
    and Equipment </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_908_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--MachineryAndEquipmentMember__srt--RangeAxis__srt--MinimumMember_zBoCKBqUpo16" title="Property and equipment, estimated useful lives">7</span>-<span id="xdx_90B_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--MachineryAndEquipmentMember__srt--RangeAxis__srt--MaximumMember_zs1iIMSzTnZ" title="Property and equipment, estimated useful lives">10</span>
    </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Furniture
    and Fixtures</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_906_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember__srt--RangeAxis__srt--MinimumMember_zmPdomKTkuj5" title="Property and equipment, estimated useful lives">3</span>-<span id="xdx_90D_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember__srt--RangeAxis__srt--MaximumMember_zMDjRUq42GH8" title="Property and equipment, estimated useful lives">10</span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Computer
    Hardware</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_zay71H131WJ9" title="Property and equipment, estimated useful lives">5</span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Leasehold
    Improvements</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90F_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember__srt--RangeAxis__srt--MinimumMember_zttmRcV3egyh" title="Property and equipment, estimated useful lives">10</span>-<span id="xdx_903_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember__srt--RangeAxis__srt--MaximumMember_zDksIX8dOpz9" title="Property and equipment, estimated useful lives">20</span></span></td></tr>
  </table>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Schedule of Fair Value of Assets and Liabilities measured on Recurring Basis</a></td>
<td class="text"><p id="xdx_89E_eus-gaap--ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_zSRjCMWMj1w3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table provides a summary of the relevant assets and liabilities that are measured at fair value on a recurring
basis:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B3_z3g9hDaGrTA9" style="display: none">Schedule
of Fair Value of Assets and Liabilities  measured on Recurring Basis</span>&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_4B9_us-gaap--FairValueByMeasurementFrequencyAxis_us-gaap--FairValueMeasurementsRecurringMember_us-gaap--FinancialInstrumentAxis_us-gaap--WarrantMember_zBZgAXCyF1Vk" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_4B0_us-gaap--FairValueByMeasurementFrequencyAxis_us-gaap--FairValueMeasurementsRecurringMember_us-gaap--FairValueByFairValueHierarchyLevelAxis_us-gaap--FairValueInputsLevel1Member_zDB43ntMIDc2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 1</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_4BA_us-gaap--FairValueByMeasurementFrequencyAxis_us-gaap--FairValueMeasurementsRecurringMember_us-gaap--FairValueByFairValueHierarchyLevelAxis_us-gaap--FairValueInputsLevel2Member_z9UbeIrsNMjf" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 2</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_4BC_us-gaap--FairValueByMeasurementFrequencyAxis_us-gaap--FairValueMeasurementsRecurringMember_us-gaap--FairValueByFairValueHierarchyLevelAxis_us-gaap--FairValueInputsLevel3Member_zWqguAEicMAk" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 3</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: center"><b>Valuation Methodology</b></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: center"><b>Unobservable<br/>
Inputs</b></td></tr>
  <tr id="xdx_439_c20241231_eus-gaap--LiabilitiesFairValueDisclosure_iI_z3pBMIl0Qkg3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 23%; text-align: left; padding-bottom: 1pt; padding-left: 0pt">Fair value of warrant  liabilities as of
    December 31, 2024</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 7%; text-align: right">9,166</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 7%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0827">&#8212;</span></td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 7%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0828">&#8212;</span></td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 7%; text-align: right">9,166</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="text-align: center; width: 12%">Black-Scholes model</td>
    <td style="width: 2%">&#160;</td>
    <td style="text-align: center; width: 17%">Project simulated cash flows</td></tr>
  <tr id="xdx_43C_c20231231_eus-gaap--LiabilitiesFairValueDisclosure_iI_z6bHNiK1NE4k" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 0pt">Fair value of warrant  liabilities as of
    December 31, 2023</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">8,225</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0832">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0833">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">8,225</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">Black-Scholes model</td>
    <td>&#160;</td>
    <td style="text-align: center">Project simulated cash flows</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTextBlock', window );">Schedule of Dilutive Common Stock Equivalents</a></td>
<td class="text"><p id="xdx_894_eus-gaap--ScheduleOfEarningsPerShareDilutedByCommonClassTextBlock_zQrWqPsSpLsb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company had the following potentially dilutive common stock equivalents at December 31, 2024 and 2023:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BC_zox9NmqQpub9" style="display: none">Schedule of Dilutive Common Stock Equivalents</span>&#160;</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_494_20240101__20241231_zCfMhiwPQpEd" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49E_20230101__20231231_zb3LNMgKs5Qd" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--OptionMember_z2YvJ0OOXEw7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%">Options</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right">1,319,394</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right">1,319,394</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--CommonStockMember_z4IBT9gvKFCb" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Pre-Funded Warrants for Common Stock</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">289,779</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0848">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--WarrantsMember_zm2CD0h3eBoj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,352,751</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,822,358</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--SeriesBPreferredStockMember_zPVzzRS4kdql" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Series B Preferred Stock</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">4,280,939</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0854">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_zswUml38NNc9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-bottom: 1pt; padding-left: 10pt">Totals</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">8,242,863</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">3,141,752</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of Basic and Diluted Net Loss Per Share</a></td>
<td class="text"><p id="xdx_89D_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_zX3d573GQcn8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table shows the calculation of the basic and diluted net loss per share and the effect of preferred stock dividends.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BC_zXyehy2Q4OB7" style="display: none">Schedule of Basic and Diluted Net Loss Per Share</span>&#160;</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49E_20240101__20241231_zkLWbBazjZl2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_493_20230101__20231231_zPg30jDzserk" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">For the Years Ended December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Numerator</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--NetIncomeLoss_iT_mtNILzQKI_zp3QgJK7iOg" style="vertical-align: bottom; background-color: White">
    <td style="width: 60%; text-align: left; padding-left: 10pt">Net loss</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">(8,241,501</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right">(14,626,683</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr id="xdx_402_eus-gaap--DividendsPreferredStock_iN_di_zqUV04SEGgVl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 10pt">Preferred stock dividends</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(211,268</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0865">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_zqBPWqst7E72" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Net loss available to common stockholders</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(8,452,769</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(14,626,683</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Denominator</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 20pt">Weighted-average shares of common stock outstanding - basic and diluted</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_903_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20240101__20241231_z6adsR0YsnZ9" title="Weighted average shares of common stock outstanding - basic"><span id="xdx_901_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20240101__20241231_zco5F3MbpLAc" title="Weighted average shares of common stock outstanding - diluted">6,918,887</span></span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_900_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20230101__20231231_zpa3Fn0QmNfb" title="Weighted average shares of common stock outstanding - basic"><span id="xdx_903_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20230101__20231231_zRyq1dOtor4d" title="Weighted average shares of common stock outstanding - diluted">3,252,328</span></span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Basic and diluted net loss per share</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_90E_eus-gaap--EarningsPerShareBasic_c20240101__20241231_zrz21PRWjGCl" title="Basic net loss per share"><span id="xdx_90F_eus-gaap--EarningsPerShareDiluted_c20240101__20241231_zIgmac8dw9Ed" title="Diluted net loss per share">(1.22</span></span></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_908_eus-gaap--EarningsPerShareBasic_c20230101__20231231_z2hMbWcceUqg" title="Basic net loss per share"><span id="xdx_905_eus-gaap--EarningsPerShareDiluted_c20230101__20231231_z96vWnNsnYxe" title="Diluted net loss per share">(4.50</span></span></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueTableTextBlock', window );">Schedule of Disaggregation of Revenue</a></td>
<td class="text"><p id="xdx_89B_eus-gaap--DisaggregationOfRevenueTableTextBlock_z51iF5FwY8Ik" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table disaggregates the Company&#8217;s revenue based on the customer&#8217;s location by state for the years ended December
31:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B7_zFnT94CGa2N4" style="display: none">Schedule of Disaggregation of Revenue</span>&#160;</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 60%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 20%">California</td><td style="width: 2%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">$</td><td id="xdx_983_eus-gaap--Revenues_c20240101__20241231__srt--StatementGeographicalAxis__stpr--CA_ztWpMGR6FjK" style="width: 16%; font-weight: bold; text-align: right" title="Revenues">778,209</td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--Revenues_c20230101__20231231__srt--StatementGeographicalAxis__stpr--CA_zhaa1ANY8XF7" style="width: 16%; text-align: right" title="Revenues">601,235</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Ohio</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--Revenues_c20240101__20241231__srt--StatementGeographicalAxis__stpr--OH_z8HHuDbKCMGd" style="font-weight: bold; text-align: right" title="Revenues">431,328</td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--Revenues_c20230101__20231231__srt--StatementGeographicalAxis__stpr--OH_zzOMNsxW8pak" style="text-align: right" title="Revenues">407,632</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Illinois</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--Revenues_c20240101__20241231__srt--StatementGeographicalAxis__stpr--IL_zb6kZssrfWfe" style="font-weight: bold; text-align: right" title="Revenues">246,217</td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--Revenues_c20230101__20231231__srt--StatementGeographicalAxis__stpr--IL_zWDTnM17q319" style="text-align: right" title="Revenues">117,963</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Wisconsin</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--Revenues_c20240101__20241231__srt--StatementGeographicalAxis__stpr--WI_z3428iyridQh" style="font-weight: bold; text-align: right" title="Revenues">157,786</td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--Revenues_c20230101__20231231__srt--StatementGeographicalAxis__stpr--WI_zGxpKPV1TjK7" style="text-align: right" title="Revenues">292,601</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Massachusetts</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--Revenues_c20240101__20241231__srt--StatementGeographicalAxis__stpr--MA_zasnvjzBkL05" style="font-weight: bold; text-align: right" title="Revenues">154,407</td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--Revenues_c20230101__20231231__srt--StatementGeographicalAxis__stpr--MA_zKTfMKrP2Fwk" style="text-align: right" title="Revenues">127,300</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Florida</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--Revenues_c20240101__20241231__srt--StatementGeographicalAxis__stpr--FL_zjSSE7PnWXPh" style="font-weight: bold; text-align: right" title="Revenues">149,985</td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--Revenues_c20230101__20231231__srt--StatementGeographicalAxis__stpr--FL_z0AEkB7FcCsg" style="text-align: right" title="Revenues">186,840</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">All other states</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--Revenues_c20240101__20241231__srt--StatementGeographicalAxis__custom--AllOtherStatesMember_zhSbHj7bt2ag" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right" title="Revenues">767,993</td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--Revenues_c20230101__20231231__srt--StatementGeographicalAxis__custom--AllOtherStatesMember_zVzeZm5mSkih" style="border-bottom: Black 1pt solid; text-align: right" title="Revenues">726,478</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">$</td><td id="xdx_988_eus-gaap--Revenues_c20240101__20241231_z8xgf1LC4xKf" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right" title="Revenues">2,685,925</td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_986_eus-gaap--Revenues_c20230101__20231231_zCiswA2OlDda" style="border-bottom: Black 1pt solid; text-align: right" title="Revenues">2,460,049</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock', window );">Schedule of Customer Accounts Receivable</a></td>
<td class="text"><p id="xdx_898_eus-gaap--SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_zUwJC7G3vMd4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span id="xdx_8BF_ziuviCdUkIG6" style="display: none">Schedule of Customer Accounts Receivable</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Percentage
    of Net Accounts</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Percentage
    of Net Accounts</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2024</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Receivable</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2023</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> Receivable</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 36%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Customer
    A</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>$</b></span></td><td id="xdx_98A_eus-gaap--AccountsReceivableNet_iI_c20241231__srt--MajorCustomersAxis__custom--CustomerAMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zGVtJHY4ngni" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right" title="Net accounts receivable"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">119,616</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20240101__20241231__srt--MajorCustomersAxis__custom--CustomerAMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_ztfwx0Pn3dvb" title="Risk percentage">49</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>$</b></span></td><td id="xdx_985_eus-gaap--AccountsReceivableNet_iI_c20231231__srt--MajorCustomersAxis__custom--CustomerAMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zKXzKALlmJz7" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right" title="Net accounts receivable"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0940">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_901_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20231231__srt--MajorCustomersAxis__custom--CustomerAMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_z9o22JCbwIjb" title="Risk percentage">0</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Customer
    B</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98C_eus-gaap--AccountsReceivableNet_iI_c20241231__srt--MajorCustomersAxis__custom--CustomerBMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zR77yBuhHffb" style="font: bold 10pt Times New Roman, Times, Serif; text-align: right" title="Net accounts receivable"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0944">-</span></span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_905_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20240101__20241231__srt--MajorCustomersAxis__custom--CustomerBMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_z9SVmlN18mH9" title="Risk percentage">0</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98B_eus-gaap--AccountsReceivableNet_iI_c20231231__srt--MajorCustomersAxis__custom--CustomerBMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zDCakzXb5lvc" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Net accounts receivable"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">23,900</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20231231__srt--MajorCustomersAxis__custom--CustomerBMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zYReW668WMIf" title="Risk percentage">28</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Customer
    C</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_985_eus-gaap--AccountsReceivableNet_iI_c20241231__srt--MajorCustomersAxis__custom--CustomerCMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zECBJOkoPFzh" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Net accounts receivable"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">22,799</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_907_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20240101__20241231__srt--MajorCustomersAxis__custom--CustomerCMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zCoq7BCeaAUd" title="Risk percentage">9</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98A_eus-gaap--AccountsReceivableNet_iI_c20231231__srt--MajorCustomersAxis__custom--CustomerCMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zSmayTQpiaTa" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Net accounts receivable"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">14,401</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90D_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20231231__srt--MajorCustomersAxis__custom--CustomerCMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_z058r726xm0j" title="Risk percentage">17</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Customer
    D</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_989_eus-gaap--AccountsReceivableNet_iI_c20241231__srt--MajorCustomersAxis__custom--CustomerDMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_ziWgXs4rhsT5" style="font: bold 10pt Times New Roman, Times, Serif; text-align: right" title="Net accounts receivable"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0960">-</span></span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_905_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20240101__20241231__srt--MajorCustomersAxis__custom--CustomerDMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zSEvYV8lKLbh" title="Risk percentage">0</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_987_eus-gaap--AccountsReceivableNet_iI_c20231231__srt--MajorCustomersAxis__custom--CustomerDMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zgOcWsNkjKF1" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Net accounts receivable"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">23,982</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_909_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20231231__srt--MajorCustomersAxis__custom--CustomerDMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zlZgVpBjp056" title="Risk percentage">28</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Customer
    E</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98E_eus-gaap--AccountsReceivableNet_iI_c20241231__srt--MajorCustomersAxis__custom--CustomerEMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zl2qNb56zJwh" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right" title="Net accounts receivable"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0968">-</span></span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90F_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20240101__20241231__srt--MajorCustomersAxis__custom--CustomerEMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zqDT0bFj4H1k" title="Risk percentage">0</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98E_eus-gaap--AccountsReceivableNet_iI_c20231231__srt--MajorCustomersAxis__custom--CustomerEMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zwaoP8QxF9Bf" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Net accounts receivable"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">9,599</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_901_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20231231__srt--MajorCustomersAxis__custom--CustomerEMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zyXKzz43jjZf" title="Risk percentage">11</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>$</b></span></td><td id="xdx_986_eus-gaap--AccountsReceivableNet_iI_c20241231__srt--MajorCustomersAxis__custom--CustomerMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_z1Hroo9j0F5k" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Net accounts receivable"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">142,415</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_902_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20240101__20241231__srt--MajorCustomersAxis__custom--CustomerMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zvYJPTm3tgrf" title="Risk percentage">58</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>$</b></span></td><td id="xdx_98E_eus-gaap--AccountsReceivableNet_iI_c20231231__srt--MajorCustomersAxis__custom--CustomerMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_z3M4Bf5OFDta" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Net accounts receivable"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">71,882</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_906_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20231231__srt--MajorCustomersAxis__custom--CustomerMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zHYTFLfnmKr" title="Risk percentage">84</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr>
  </table>
<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetAllowanceForCreditLossTableTextBlock', window );">Schedule of Customers Accounted Revenues</a></td>
<td class="text"><p id="xdx_896_eus-gaap--ContractWithCustomerAssetAllowanceForCreditLossTableTextBlock_zkkwaR2En4R4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span id="xdx_8BA_z9EQpd6TmZ1d" style="display: none">Schedule of Customers Accounted Revenues</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Percentage of</td><td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Percentage of</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Net Sales</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Net Sales</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 36%; text-align: left">Customer A</td><td style="width: 2%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">$</td><td id="xdx_98B_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20240101__20241231__srt--MajorCustomersAxis__custom--CustomerAMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zhKwbiXDFFs3" style="width: 12%; font-weight: bold; text-align: right" title="Revenue">521,810</td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right"><span id="xdx_903_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20240101__20241231__srt--MajorCustomersAxis__custom--CustomerAMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zklF9jeBuOtg" title="Risk percentage">20</span></td><td style="width: 1%; text-align: left">%</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_986_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20230101__20231231__srt--MajorCustomersAxis__custom--CustomerAMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zHFwu8jqdfzh" style="width: 12%; text-align: right" title="Revenue">452,680</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right"><span id="xdx_908_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20231231__srt--MajorCustomersAxis__custom--CustomerAMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zUGo6Jpa5fgl" title="Risk percentage">18</span></td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Customer B</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20240101__20241231__srt--MajorCustomersAxis__custom--CustomerBMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zbvEOGjsePt8" style="font-weight: bold; text-align: right" title="Revenue">396,950</td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90C_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20240101__20241231__srt--MajorCustomersAxis__custom--CustomerBMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_z6L6EIm7A9m7" title="Risk percentage">15</span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20230101__20231231__srt--MajorCustomersAxis__custom--CustomerBMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zLhqQLg76db" style="text-align: right" title="Revenue">382,082</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_909_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20231231__srt--MajorCustomersAxis__custom--CustomerBMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zACbxoOC2pSe" title="Risk percentage">16</span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Customer C</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20240101__20241231__srt--MajorCustomersAxis__custom--CustomerCMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zswU6SLkue39" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right" title="Revenue">142,270</td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_904_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20240101__20241231__srt--MajorCustomersAxis__custom--CustomerCMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_z2crm1yRVs5d" title="Risk percentage">5</span></td><td style="padding-bottom: 1pt; text-align: left">%</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20230101__20231231__srt--MajorCustomersAxis__custom--CustomerCMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zWVmxOqlJMFc" style="border-bottom: Black 1pt solid; text-align: right" title="Revenue">274,581</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_906_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20231231__srt--MajorCustomersAxis__custom--CustomerCMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zs8Tc7rodGKf" title="Risk percentage">11</span></td><td style="padding-bottom: 1pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">$</td><td id="xdx_989_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20240101__20241231__srt--MajorCustomersAxis__custom--CustomerMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zpQ98lLEyvZa" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right" title="Revenue">1,061,030</td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_90E_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20240101__20241231__srt--MajorCustomersAxis__custom--CustomerMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zLqb9DZOwDyh" title="Risk percentage">40</span></td><td style="padding-bottom: 1pt; text-align: left">%</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_98E_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20230101__20231231__srt--MajorCustomersAxis__custom--CustomerMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zuCpenm53Myd" style="border-bottom: Black 1pt solid; text-align: right" title="Revenue">1,109,343</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_909_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20231231__srt--MajorCustomersAxis__custom--CustomerMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zV0CREuaTTec" title="Risk percentage">45</span></td><td style="padding-bottom: 1pt; text-align: left">%</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_NRXS_ScheduleOfPropertyPlantAndEquipmentUsefulLivesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of Property Plant And Equipment Useful Lives [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">NRXS_ScheduleOfPropertyPlantAndEquipmentUsefulLivesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>NRXS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetAllowanceForCreditLossTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allowance for credit loss on right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479319/326-20-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetAllowanceForCreditLossTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the effect of income (loss) on an entity's diluted earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-21<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-20<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-20<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-16<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-21<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock', window );">Schedule of Related Party Transactions</a></td>
<td class="text"><p id="xdx_89C_eus-gaap--ScheduleOfRelatedPartyTransactionsTableTextBlock_zOv4aX3fMcwj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span><span id="xdx_8B6_zby8DV48UlMe" style="display: none">Schedule of Related Party Transactions</span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Loan</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Interest</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Interest</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-weight: bold">December 31, 2024</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Receivable</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Receivable</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Income</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%">Shareholder 1</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_984_eus-gaap--NotesAndLoansReceivableGrossCurrent_iI_c20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ShareHolderOneMember_zWFF6fDKgOOh" style="width: 12%; text-align: right" title="Loan Receivable">506,400</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--InterestReceivableCurrent_iI_c20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ShareHolderOneMember_zhO2kKTUPrH7" style="width: 12%; text-align: right" title="Interest Receivable">94,351</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_986_ecustom--InterestIncomeGrossCurrent_iI_c20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ShareHolderOneMember_zGv6Q28DbLFb" style="width: 12%; text-align: right" title="Interest Income">23,413</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt">Shareholder 2</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--NotesAndLoansReceivableGrossCurrent_iI_c20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ShareHolderTwoMember_zk0nJ4TbCeT6" style="border-bottom: Black 1pt solid; text-align: right" title="Loan Receivable">506,400</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--InterestReceivableCurrent_iI_c20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ShareHolderTwoMember_zvYvtR6VyOQ5" style="border-bottom: Black 1pt solid; text-align: right" title="Interest Receivable">94,216</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_985_ecustom--InterestIncomeGrossCurrent_iI_c20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ShareHolderTwoMember_zDlrgzmboFb6" style="border-bottom: Black 1pt solid; text-align: right" title="Interest Income">23,413</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt">Principal Balance</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--NotesAndLoansReceivableGrossCurrent_iI_c20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_ztUVY7XqRxSd" style="text-align: right" title="Loan Receivable">1,012,800</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--InterestReceivableCurrent_iI_c20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zjTDLXBg8xha" style="text-align: right" title="Interest Receivable">188,567</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_ecustom--InterestIncomeGrossCurrent_iI_c20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zCgEEzRhYDy" style="text-align: right" title="Interest Income">46,826</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Allowance for Collection Risk</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--AllowanceForNotesAndLoansReceivableCurrent_iNI_di_c20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zfyohD0vh37l" style="border-bottom: Black 1pt solid; text-align: right" title="Allowance for collection risk, loan receivable">(1,012,800</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98D_ecustom--AllowanceForInterestReceivableCurrent_iI_c20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zVYzxHfKGjzl" style="border-bottom: Black 1pt solid; text-align: right" title="Allowance for collection risk, interest receivable">(188,567</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_988_ecustom--AllowanceForInterestIncomeCurrent_iNI_di_c20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zzOQmVoFft9" style="border-bottom: Black 1pt solid; text-align: right" title="Allowance for collection risk, interest income">(46,826</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Net Balance</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_98B_eus-gaap--NotesAndLoansReceivableNetCurrent_iI_c20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zWhNsIQX3dT1" style="border-bottom: Black 1pt solid; text-align: right" title="Loan Receivable"><span style="-sec-ix-hidden: xdx2ixbrl1070">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_989_eus-gaap--InterestReceivable_iI_c20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zYN9wmZutSp4" style="border-bottom: Black 1pt solid; text-align: right" title="Interest Receivable"><span style="-sec-ix-hidden: xdx2ixbrl1072">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_98E_ecustom--InterestIncomeCurrent_iI_c20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zJz5EcU2SFMh" style="border-bottom: Black 1pt solid; text-align: right" title="Interest Income"><span style="-sec-ix-hidden: xdx2ixbrl1074">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Loan</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Interest</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Interest</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-weight: bold">December 31, 2023</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Receivable</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Receivable</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Income</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%">Shareholder 1</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--NotesAndLoansReceivableGrossCurrent_iI_c20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ShareHolderOneMember_zWSabdjGXQL1" style="width: 12%; text-align: right" title="Loan Receivable">506,400</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_988_eus-gaap--InterestReceivableCurrent_iI_c20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ShareHolderOneMember_zDPEXZk6ETm2" style="width: 12%; text-align: right" title="Interest Receivable">70,938</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_982_ecustom--InterestIncomeGrossCurrent_iI_c20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ShareHolderOneMember_zY8vYDQbfVG3" style="width: 12%; text-align: right" title="Interest Income">23,867</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt">Shareholder 2</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--NotesAndLoansReceivableGrossCurrent_iI_c20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ShareHolderTwoMember_zeI6ZkI1sNy" style="border-bottom: Black 1pt solid; text-align: right" title="Loan Receivable">506,400</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--InterestReceivableCurrent_iI_c20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ShareHolderTwoMember_zGzV0Q4plaJ9" style="border-bottom: Black 1pt solid; text-align: right" title="Interest Receivable">70,803</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_981_ecustom--InterestIncomeGrossCurrent_iI_c20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ShareHolderTwoMember_zvRaHSTC4382" style="border-bottom: Black 1pt solid; text-align: right" title="Interest Income">23,867</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt">Principal Balance</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--NotesAndLoansReceivableGrossCurrent_iI_c20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zQi2kWkjffrh" style="text-align: right" title="Loan Receivable">1,012,800</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--InterestReceivableCurrent_iI_c20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zKHhhwuk6iJ8" style="text-align: right" title="Interest Receivable">141,741</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_ecustom--InterestIncomeGrossCurrent_iI_c20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zosHxJYGrgxj" style="text-align: right" title="Interest Income">47,734</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Allowance for Collection Risk</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--AllowanceForNotesAndLoansReceivableCurrent_iNI_di_c20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zfx5avVhZnK4" style="border-bottom: Black 1pt solid; text-align: right" title="Allowance for collection risk, loan receivable">(1,012,800</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98A_ecustom--AllowanceForInterestReceivableCurrent_iI_c20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_z3W1QciT6pS" style="border-bottom: Black 1pt solid; text-align: right" title="Allowance for collection risk, interest receivable">(141,741</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98A_ecustom--AllowanceForInterestIncomeCurrent_iNI_di_c20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zIEXyFnrGwx3" style="border-bottom: Black 1pt solid; text-align: right" title="Allowance for collection risk, interest income">(47,734</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Net Balance</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_98E_eus-gaap--NotesAndLoansReceivableNetCurrent_iI_c20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zhXSahQJ7MP1" style="border-bottom: Black 1pt solid; text-align: right" title="Loan Receivable"><span style="-sec-ix-hidden: xdx2ixbrl1100">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_98E_eus-gaap--InterestReceivable_iI_c20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zuNWYHRuzlIg" style="border-bottom: Black 1pt solid; text-align: right" title="Interest Receivable"><span style="-sec-ix-hidden: xdx2ixbrl1102">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_98D_ecustom--InterestIncomeCurrent_iI_c20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_z4gJ4dE3iUN2" style="border-bottom: Black 1pt solid; text-align: right" title="Interest Income"><span style="-sec-ix-hidden: xdx2ixbrl1104">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NRXS_ScheduleOfRelatedPartyLoansTableTextBlock', window );">Schedule of Related Party Loans payable to shareholder</a></td>
<td class="text"><p id="xdx_891_ecustom--ScheduleOfRelatedPartyLoansTableTextBlock_zYPySHBVmcS7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B0_zf8TjuMlvU4c" style="display: none">Schedule of Related Party Loans payable to shareholder</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Interest &amp;</td><td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Interest</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Loan</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Service Fee</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Interest</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-weight: bold">December 31, 2024</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Due Date</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Rate</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Balance</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Accrued</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Paid</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 30%; text-align: left; padding-bottom: 1pt">Other Convertibles</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="width: 12%; text-align: center; padding-bottom: 1pt"><span id="xdx_90D_eus-gaap--DebtInstrumentMaturityDateDescription_c20240101__20241231__us-gaap--DebtInstrumentAxis__custom--OtherConvertiblesMember_ztlLQ0Sr0av9" title="Due date">Various</span></td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; width: 1%; text-align: left">&#160;</td><td style="padding-bottom: 1pt; width: 10%; text-align: center"><span id="xdx_908_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_dp_uPure_c20241231__us-gaap--DebtInstrumentAxis__custom--OtherConvertiblesMember_zqSoAz84D45j" title="Debt instrument percentage">5.0</span>%</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--LoansPayable_iI_c20241231__us-gaap--DebtInstrumentAxis__custom--OtherConvertiblesMember_zWABE9Cu0pab" style="border-bottom: Black 1pt solid; width: 10%; text-align: right" title="Interest payable"><span style="-sec-ix-hidden: xdx2ixbrl1112">&#8212;</span></td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">&#160;</td><td id="xdx_983_ecustom--InterestAndServiceFeeAccrued_iI_c20241231__us-gaap--DebtInstrumentAxis__custom--OtherConvertiblesMember_zfhfCYXJY2w2" style="border-bottom: Black 1pt solid; width: 10%; text-align: right" title="Interest payable">66,648</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--InterestPaid_c20240101__20241231__us-gaap--DebtInstrumentAxis__custom--OtherConvertiblesMember_z57rRBACUFUg" style="border-bottom: Black 1pt solid; width: 10%; text-align: right" title="Interest payable"><span style="-sec-ix-hidden: xdx2ixbrl1116">&#8212;</span></td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; font-weight: bold; padding-bottom: 1pt">Total</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_98C_eus-gaap--LoansPayable_iI_c20241231_zPLJkVYOokw9" style="border-bottom: Black 1pt solid; text-align: right" title="Loan payable"><span style="-sec-ix-hidden: xdx2ixbrl1118">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_984_ecustom--InterestAndServiceFeeAccrued_iI_c20241231_zuHlAygaJSw6" style="border-bottom: Black 1pt solid; text-align: right" title="Interest payable">66,648</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_981_eus-gaap--InterestPaid_c20240101__20241231_z8Wm1dCWuYgg" style="border-bottom: Black 1pt solid; text-align: right" title="Interest payable"><span style="-sec-ix-hidden: xdx2ixbrl1122">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Interest &amp;</td><td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Interest</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Loan</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Service Fee</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Interest</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-weight: bold">December 31, 2023</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Due Date</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Rate</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Balance</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Accrued</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Paid</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 30%">Shareholder 1</td><td style="width: 2%">&#160;</td>
    <td style="width: 12%; text-align: center"><span id="xdx_90B_eus-gaap--DebtInstrumentMaturityDateDescription_c20230101__20231231__us-gaap--DebtInstrumentAxis__custom--ShareHolderOneMember_zD7Nd8CcgBnk" title="Due date">June, 2019</span></td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 10%; text-align: center"><span id="xdx_90A_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_dp_uPure_c20231231__us-gaap--DebtInstrumentAxis__custom--ShareHolderOneMember_zLgE9AFgTgab" title="Debt instrument percentage">15.0</span>%</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_eus-gaap--LoansPayable_iI_c20231231__us-gaap--DebtInstrumentAxis__custom--ShareHolderOneMember_zN3dNK2VXGv6" style="width: 10%; text-align: right" title="Loan payable"><span style="-sec-ix-hidden: xdx2ixbrl1128">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_983_ecustom--InterestAndServiceFeeAccrued_iI_c20231231__us-gaap--DebtInstrumentAxis__custom--ShareHolderOneMember_zFgriPhYsCj9" style="width: 10%; text-align: right" title="Interest payable"><span style="-sec-ix-hidden: xdx2ixbrl1130">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--InterestPaid_c20230101__20231231__us-gaap--DebtInstrumentAxis__custom--ShareHolderOneMember_zQME5pjAHsJ8" style="width: 10%; text-align: right" title="Interest payable">10,047</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Shareholder 2</td><td>&#160;</td>
    <td style="text-align: center"><span id="xdx_902_eus-gaap--DebtInstrumentMaturityDateDescription_c20230101__20231231__us-gaap--DebtInstrumentAxis__custom--ShareHolderTwoMember_zpH8ZXwFTij3" title="Due date">June, 2019</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center"><span id="xdx_903_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_dp_uPure_c20231231__us-gaap--DebtInstrumentAxis__custom--ShareHolderTwoMember_zf0NRnHbYLxf" title="Debt instrument percentage">15.0</span>%</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--LoansPayable_iI_c20231231__us-gaap--DebtInstrumentAxis__custom--ShareHolderTwoMember_zqeyWtHDawre" style="text-align: right" title="Loan payable"><span style="-sec-ix-hidden: xdx2ixbrl1138">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_ecustom--InterestAndServiceFeeAccrued_iI_c20231231__us-gaap--DebtInstrumentAxis__custom--ShareHolderTwoMember_zwizrWGlHZB" style="text-align: right" title="Interest payable"><span style="-sec-ix-hidden: xdx2ixbrl1140">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--InterestPaid_c20230101__20231231__us-gaap--DebtInstrumentAxis__custom--ShareHolderTwoMember_zqcl1NyjQVI5" style="text-align: right" title="Interest payable">27,056</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Other Convertibles</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1pt"><span id="xdx_90B_eus-gaap--DebtInstrumentMaturityDateDescription_c20230101__20231231__us-gaap--DebtInstrumentAxis__custom--OtherConvertiblesMember_zdURnn0ve00d" title="Due date">Various</span></td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: center"><span id="xdx_90E_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_dp_uPure_c20231231__us-gaap--DebtInstrumentAxis__custom--OtherConvertiblesMember_zHHONbcvNHPk" title="Debt instrument percentage">5.0</span>%</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--LoansPayable_iI_c20231231__us-gaap--DebtInstrumentAxis__custom--OtherConvertiblesMember_zsriqlzXJhOg" style="border-bottom: Black 1pt solid; text-align: right" title="Interest payable"><span style="-sec-ix-hidden: xdx2ixbrl1148">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98B_ecustom--InterestAndServiceFeeAccrued_iI_c20231231__us-gaap--DebtInstrumentAxis__custom--OtherConvertiblesMember_zteqJglcLHv9" style="border-bottom: Black 1pt solid; text-align: right" title="Interest payable">66,648</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--InterestPaid_c20230101__20231231__us-gaap--DebtInstrumentAxis__custom--OtherConvertiblesMember_zdCzgHVG7OMf" style="border-bottom: Black 1pt solid; text-align: right" title="Interest payable"><span style="-sec-ix-hidden: xdx2ixbrl1152">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; font-weight: bold; padding-bottom: 1pt">Total</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_985_eus-gaap--LoansPayable_iI_c20231231_z7ORZjjvl3zc" style="border-bottom: Black 1pt solid; text-align: right" title="Loan payable"><span style="-sec-ix-hidden: xdx2ixbrl1154">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_98E_ecustom--InterestAndServiceFeeAccrued_iI_c20231231_zk4ROeNOQu59" style="border-bottom: Black 1pt solid; text-align: right" title="Interest payable">66,648</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_982_eus-gaap--InterestPaid_c20230101__20231231_zxw0Nw7EIlJ4" style="border-bottom: Black 1pt solid; text-align: right" title="Interest payable">37,103</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_NRXS_ScheduleOfRelatedPartyLoansTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule Of Related Party Loans [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">NRXS_ScheduleOfRelatedPartyLoansTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>NRXS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of related party transactions. Examples of related party transactions include, but are not limited to, transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of Property And Equipment</a></td>
<td class="text"><p id="xdx_898_eus-gaap--PropertyPlantAndEquipmentTextBlock_zZExnw39C8Mb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property
and equipment, net consists of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span id="xdx_8BD_zSpbTDAq6AI2" style="display: none">Schedule of Property And Equipment</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_492_20241231_z1L83aOgT7Ca" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, 2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49A_20231231_zX9lQ20XfjUh" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, 2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--MachineryAndEquipmentMember_zheELRMbM1pg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Machinery and equipment</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">282,181</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">282,181</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zgoPHiIyxVKh" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Furniture and fixtures</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">111,036</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">96,768</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_zQoYCrk5twy" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Computer hardware</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">50,121</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">36,613</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zidW0RfYiTCe" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Leasehold improvements</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">21,064</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">21,064</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--PropertyPlantAndEquipmentGross_iI_maPPAENzDOd_zAkjgdLgKp1c" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Total property and equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">464,402</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">436,626</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_di_msPPAENzDOd_zjVmdbF0MLib" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Less: accumulated depreciation</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(374,420</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(348,074</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_409_eus-gaap--PropertyPlantAndEquipmentNet_iTI_mtPPAENzDOd_zctvrjFcVVIl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: left; padding-bottom: 1pt">Property and equipment, net</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">89,982</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">88,552</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock', window );">Schedule of Intangible Assets</a></td>
<td class="text"><p id="xdx_89A_eus-gaap--ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_z7HEvAFzd705" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Intangible
assets, net consists of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BF_ztWJTbv4oTL3" style="display: none">Schedule of Intangible Assets</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_493_20241231_zffQXKuWcn2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, 2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_498_20231231_z33gPHqBRVv2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, 2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_hus-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--SoftwareImplementationMember_z91J2gu0Mtek" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Software Implementation</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">49,815</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">49,815</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_hus-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zf6epMbZTE2h" style="vertical-align: bottom; background-color: White">
    <td>Patents</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">32,463</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">32,463</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_hus-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_z0qGsDlM50x4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Trademark</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">50,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">50,000</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_hus-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LicensesMember_zPayp6miIW38" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt">Licenses</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">1,000</td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">1,000</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_maFLIANzh0b_ziGX9bS4QS2a" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Total intangible assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">133,278</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">133,278</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iNI_di_msFLIANzh0b_zI6Tp7ZxyOE7" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Less: accumulated amortization</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(36,690</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(25,205</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_40F_eus-gaap--FiniteLivedIntangibleAssetsNet_iTI_mtFLIANzh0b_zP3Z51RAYuo1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: left; padding-bottom: 1pt">Intangible assets, net</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">96,588</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">108,073</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of Accrued Expenses</a></td>
<td class="text"><p id="xdx_897_eus-gaap--ScheduleOfAccruedLiabilitiesTableTextBlock_zvUb0GeiOnXj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accrued
expenses consisted of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BB_zpdknJa9shG3" style="display: none">Schedule of Accrued Expenses</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_499_20241231_zKsVdgUSQQmk" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, 2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_497_20231231_zTS4WmLwiwVl" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, 2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_401_ecustom--AccruedCompensationAndBenefitsCurrent_iI_maALCz94I_zfW9IkDNsimh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Compensation and benefits</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">1,261,317</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">333,477</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_ecustom--AdvisoryFees_iI_maALCz94I_zmfz7vtKw8Nj" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Advisory fees</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">176,750</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1268">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--InterestPayableCurrent_iI_maALCz94I_znHRDcQk5vL8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Interest</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">66,648</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">66,648</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--AccrualForTaxesOtherThanIncomeTaxesCurrent_iI_maALCz94I_zEo4FtIWXx23" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt">Other</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">73,065</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">963</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--AccruedLiabilitiesCurrent_iTI_mtALCz94I_zUvo3TiPrkFi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Total accrued expenses</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">1,577,780</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">401,088</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NRXS_DisclosureLeasesAbstract', window );"><strong>Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Schedule of Operating Leases</a></td>
<td class="text"><p id="xdx_89C_eus-gaap--LeaseCostTableTextBlock_zFztbrypnsXg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table presents information related to the Company&#8217;s operating leases:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span id="xdx_8B7_zfHapyJiPMx" style="display: none">Schedule of Operating Leases</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_495_20241231_zcoyBtzitmTd" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, 2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49B_20231231_z7nQi5gKvHf4" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, 2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--OperatingLeaseRightOfUseAsset_iI_z3IUYNRAlpId" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left; padding-bottom: 1pt">Operating lease right-of-use assets</td><td style="width: 2%; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">284,656</span></td><td style="width: 1%; padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 16%; text-align: right">70,263</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--OperatingLeaseLiabilityCurrent_iI_maOLLz38G_zLVvb7Ghl128" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Other current liabilities</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">62,754</span></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">49,127</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_maOLLz38G_zUI2yxIjMR36" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Operating lease liabilities</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">256,499</span></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">27,071</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--OperatingLeaseLiability_iTI_mtOLLz38G_zKDhLqa2gJd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt">Total</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">319,253</span></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">76,198</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Weighted-average remaining lease term (in years)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_907_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20241231_zQIProZFW8bc" title="Weighted average remaining lease term (in years)">2.75</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90B_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20231231_zhbewRy86dwf" title="Weighted average remaining lease term (in years)">3.75</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Weighted-average discount rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_900_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_dp_uPure_c20241231_z5BSj9aa6XE4" title="Weighted average discount rate">15.0</span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90B_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_dp_uPure_c20231231_z940P4nqH1Ke" title="Weighted average discount rate">15.0</span></td><td style="text-align: left">%</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of Maturities Operating Lease Liabilities</a></td>
<td class="text"><p id="xdx_89C_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zHwzvxcPJMja" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2024, the maturities of the Company&#8217;s operating lease liabilities were as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B6_zTIR3865vQEf" style="display: none">Schedule of Maturities Operating Lease Liabilities</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
  <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left"></td><td id="xdx_49E_20241231_zE69sUSivHee" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_maLOLLPzyNu_zAnUqfeRV5mj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%; text-align: left">2025</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">105,130</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_maLOLLPzyNu_z8Q5BQvx38Mf" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">2026</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">108,106</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_maLOLLPzyNu_z1wKRjz18iIb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">2027</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">86,856</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFour_iI_maLOLLPzyNu_ztch8OL13t4l" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">2028</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">89,027</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFive_iI_maLOLLPzyNu_z3Yt9rhqjbL" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">2029</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">38,025</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_mtLOLLPzyNu_z63kL7uUXONc" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Total lease payments</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">427,144</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_di_zDr3iSUhUu2l" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Less: imputed interest</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(107,891</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_401_eus-gaap--OperatingLeaseLiability_iI_zMTx5ZJu3jC8" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Total present value of lease payments</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">319,253</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_NRXS_DisclosureLeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">NRXS_DisclosureLeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>NRXS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common Stock and Warrants (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock', window );">Schedule of Warrants outstanding and Exercisable</a></td>
<td class="text"><p id="xdx_898_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_z9igFQMpLx0d" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes the Company&#8217;s warrants outstanding and exercisable as of December 31, 2024:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8BC_zvxaUvkopMl5" style="display: none">Schedule of Warrants outstanding and Exercisable</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Number of</td><td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Warrants</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Exercise</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: center">Expiration</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Outstanding</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Price</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Date</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; text-align: left">Investor Warrant</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--InvestorWarrantOneMember_zCwbBa9nn5Ti" style="width: 16%; text-align: right" title="Number of Warrants">12,852</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_980_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--InvestorWarrantOneMember_zzr2tmz9546e" style="width: 16%; text-align: right" title="Exercise Price">8.76</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 18%; text-align: center"><span id="xdx_90E_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--InvestorWarrantOneMember_zYJKbGJUSZKb" title="Expiration Date">September 18, 2028</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Investor Warrant</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--InvestorWarrantPSAOneMember_zcLpYDWZaeAl" style="text-align: right" title="Number of Warrants">289,779</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_987_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--InvestorWarrantPSAOneMember_zmzsgDqFYzq6" style="text-align: right" title="Exercise Price">0.01</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center"><span id="xdx_90C_ecustom--WarrantExpirationDateDescription_c20240101__20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--InvestorWarrantPSAOneMember_zhIdSpG22uz" title="Expiration Date">None</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">2022 Convertible Notes</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--TwoThousandTwentyTwoConvertibleNotesMember_zoK0YKQK2Zlc" style="text-align: right" title="Number of Warrants">782,655</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--TwoThousandTwentyTwoConvertibleNotesMember_zvl7qbY1ug3e" style="text-align: right" title="Exercise Price">2.38</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center"><span id="xdx_90B_ecustom--WarrantExpirationDateDescription_c20240101__20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--TwoThousandTwentyTwoConvertibleNotesMember_zvM5SIXYBBo6" title="Expiration Date">Various in 2027</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">2023 Convertible Notes</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--TwoThousandTwentyThreeConvertibleNotesMember_z9Htp0tD3X5g" style="text-align: right" title="Number of Warrants">1,149,586</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_989_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--TwoThousandTwentyThreeConvertibleNotesMember_zfgkRFQC2Yj5" style="text-align: right" title="Exercise Price">2.38</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center"><span id="xdx_90E_ecustom--WarrantExpirationDateDescription_c20240101__20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--TwoThousandTwentyThreeConvertibleNotesMember_znoFVfcfoDo7" title="Expiration Date">Various in 2028</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Underwriter Warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--UnderwriterWarrantsMember_zZO43U71DrG2" style="text-align: right" title="Number of Warrants">331,146</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_980_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--UnderwriterWarrantsMember_zUZ13v9jeyFj" style="text-align: right" title="Exercise Price">2.38</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center"><span id="xdx_903_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--UnderwriterWarrantsMember_zwBgUbqUDd2i" title="Expiration Date">August 8, 2028</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Advisory Agreement Warrants</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--AdvisoryAgreementWarrantsMember_zeWU4i89Vkd2" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Warrants">76,512</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">$</td><td id="xdx_98F_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--AdvisoryAgreementWarrantsMember_zuEVWVpc4Ix3" style="padding-bottom: 1pt; text-align: right" title="Exercise Price">2.38</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1pt"><span id="xdx_90E_ecustom--WarrantExpirationDateDescription_c20240101__20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--AdvisoryAgreementWarrantsMember_zns5lNIaieig" title="Expiration Date">Various in 2029</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20241231_zCUeLXbdEkB4" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Warrants">2,642,530</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td></tr>
  </table>


<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NRXS_ScheduleOfWarrantActivityForCommonStockTableTextBlock', window );">Schedule of Warrant Activity for Common Stock</a></td>
<td class="text"><p id="xdx_89D_ecustom--ScheduleOfWarrantActivityForCommonStockTableTextBlock_hus-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zLrw0eGMZ8Fh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following is a summary of warrant activity for common stock during the years ended December 31, 2024 and 2023:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span><span id="xdx_8B4_zF19HNxPm3Bk" style="display: none">Schedule of Warrant Activity for Common Stock</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Number of Warrants for Common Stock</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted-Avg. Exercise Price</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted-Avg. Remaining Contractual Life</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; font-weight: bold">Outstanding as of January 1, 2023</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zqCUE1twemab" style="width: 16%; text-align: right" title="Number of Warrants, Outstanding at beginning of period">846,507</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zhr3vJ6fezYi" style="width: 16%; text-align: right" title="Weighted Average Exercise Price, Outstanding at beginning of period">5.06</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z1Jwb8Y6z7F4" title="Weighted Average Remaining Contractual Life - Warrants">4.72</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zvCO7feZJtO3" style="text-align: right" title="Number of Warrants, Granted">813,928</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zJhAxuudUgBe" style="text-align: right" title="Weighted Average Exercise Price, granted">5.81</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsWeightedAverageRemainingContracualLifeOutstandingNumberGranted_dtY_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zdueqO08qFP" title="Weighted Average Remaining Contractual Life - Warrants Granted">4.38</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Converted Prefunded Warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsConvertedPrefundedWarrants_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z1T7to5A8GSd" style="text-align: right" title="Number of Warrants, Converted Prefunded Warrants">289,779</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsConvertedPrefundedWarrantsInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zY56eTAD5bmg" style="text-align: right" title="Weighted Average Exercise Price, Converted Prefunded Warrants">0.01</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Cancelled</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zYXpsY5K2eyh" style="text-align: right" title="Number of Warrants, Granted">(30,252</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsWeightedAverageExercisePriceCancelledExpiredNumber_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zftXG45d9Fcg" style="text-align: right" title="Weighted Average Exercise Price, Cancelled Expired">2.38</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90B_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsCancelledWeightedAverageRemainingContractualTerm1_dtY_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z3ExdXdKOUI4" title="Weighted Average Remaining Contractual Life - Warrants Cancelled">4.79</span></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt">Exercised</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zJwgA5K3QICa" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Warrants, Exercised">(127,856</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_ztaF8wIpjGHb" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price, Excercised"><span style="-sec-ix-hidden: xdx2ixbrl1607">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-bottom: 1pt">Outstanding as of December 31, 2023</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zyC3xdrUua51" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Warrants, Outstanding at beginning of period">1,822,358</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zk5KvZkRA7S6" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price, Outstanding at beginning of period">4.69</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zpHWNBLzvNfe" title="Weighted Average Remaining Contractual Life - Warrants">3.05</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zyDwKGvOqya4" style="text-align: right" title="Number of Warrants, Granted">861,424</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zP5e8TEsARIl" style="text-align: right" title="Weighted Average Exercise Price, granted">2.38</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z9qIs9iz7aje" title="Weighted Average Remaining Contractual Life - Warrants Granted">3.49</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Cancelled</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_iN_pid_di_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z0JtbrAmw6L9" style="text-align: right" title="Number of Warrants, Granted">(30,252</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsWeightedAverageExercisePriceCancelledExpiredNumber_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z0fBvAhyc7fe" style="text-align: right" title="Weighted Average Exercise Price, Cancelled Expired">2.38</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90E_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsCancelledWeightedAverageRemainingContractualTerm1_dtY_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zgIGKKCyLomf" title="Weighted Average Remaining Contractual Life - Warrants Cancelled">4.79</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt">Exercised</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zfwcoWXVFRFd" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Warrants, Exercised">(11,000</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zbTO4y9uPVR2" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price, Excercised">2.38</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_90A_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisedWeightedAverageRemainingContractualTerm1_dtY_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zcjv1U3Qle25" title="Weighted Average Remaining Contractual Life - Warrants Granted">3.61</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-bottom: 1pt">Outstanding as of December 31, 2024</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zgqcy9ma0rvk" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Warrants, Outstanding at Ending of period">2,642,530</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_znzR0pZ73WD1" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price, Outstanding at Ending of period">2.41</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zti3Xue9xa3i" title="Weighted Average Remaining Contractual Life - Warrants">2.93</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_PreferredStockMember', window );">Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NRXS_ScheduleOfWarrantActivityForPreferredStockTableTextBlock', window );">Schedule of Warrant Activity for Preferred Stock</a></td>
<td class="text"><p id="xdx_891_ecustom--ScheduleOfWarrantActivityForPreferredStockTableTextBlock_hus-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zNT710L4p2uf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following is a summary of warrant activity for preferred stock during the year ended December 31, 2023:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8BD_zdZp51J3cWs2" style="display: none">Schedule of Warrant Activity for Preferred Stock</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Number of</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Weighted-Avg.</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Warrants for</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Exercise</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Preferred Stock</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Price</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; font-weight: bold; padding-bottom: 1pt">Outstanding as of December 31, 2022</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zfcGzLOG3dr1" style="border-bottom: Black 1pt solid; width: 16%; text-align: right" title="Number of Warrants, Outstanding at beginning of period">144,890</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zN0O4Rsc9wJ" style="border-bottom: Black 1pt solid; width: 16%; text-align: right" title="Weighted Average Exercise Price, Outstanding at beginning of period">0.01</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_z2Va9eQzser" style="text-align: right" title="Number of Warrants, Granted"><span style="-sec-ix-hidden: xdx2ixbrl1645">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_uUSDPShares_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zOMOCQMMk1bg" style="text-align: right" title="Weighted Average Exercise Price, granted"><span style="-sec-ix-hidden: xdx2ixbrl1647">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Cancelled/Expired</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zF9FzeR5PABe" style="text-align: right" title="Number of Warrants, Cancelled Expired"><span style="-sec-ix-hidden: xdx2ixbrl1649">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsWeightedAverageExercisePriceCancelledExpiredNumber_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_z14hGJgeTKV6" style="text-align: right" title="Weighted Average Exercise Price, Cancelled Expired"><span style="-sec-ix-hidden: xdx2ixbrl1651">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Converted to Common Stock Warrant</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsCommonStockWarrant_iN_pid_di_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_znHVx7Qc6Qmb" style="border-bottom: Black 1pt solid; text-align: right" title="Converted to Common Stock Warrant">(144,890</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsWeightedAverageExercisePriceCommonStockWarrant_iN_pid_di_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zxR5E0bIf4hl" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price, Converted to Common Stock Warrant">(0.01</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-bottom: 1pt">Outstanding as of December 31, 2023</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zMic3aPT4rBb" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Warrants, Outstanding at Ending of period"><span style="-sec-ix-hidden: xdx2ixbrl1657">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_z8VxpLHbvBK4" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price, Outstanding at Ending of period"><span style="-sec-ix-hidden: xdx2ixbrl1659">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_NRXS_ScheduleOfWarrantActivityForCommonStockTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of Warrant Activity for Common Stock [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">NRXS_ScheduleOfWarrantActivityForCommonStockTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>NRXS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_NRXS_ScheduleOfWarrantActivityForPreferredStockTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of warrant activity for preferred stock [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">NRXS_ScheduleOfWarrantActivityForPreferredStockTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>NRXS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481674/830-30-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-17<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_PreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_PreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Option-pricing Model with Following Weighted-average Assumptions</a></td>
<td class="text"><p id="xdx_892_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zG5Qp2V0YQjd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B2_zGOV7bG7BGUc" style="display: none">Schedule of Option-pricing Model with Following Weighted-average Assumptions</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 60%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Assumptions as of December 31, 2023</td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">Fully Vested</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%">Number of Shares</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_c20231231__us-gaap--PlanNameAxis__custom--TwentySeventeenStockCompensationPlanMember_znhL7DOHtJSf" style="width: 16%; text-align: right" title="Number of Shares">1,319,394</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Stock price</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_980_eus-gaap--SharePrice_iI_c20231231__us-gaap--PlanNameAxis__custom--TwentySeventeenStockCompensationPlanMember_z35t4olRGgj2" style="text-align: right" title="Stock price">2.67</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Exercise price</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_c20231231__us-gaap--PlanNameAxis__custom--TwentySeventeenStockCompensationPlanMember_zAUbudleH1La" style="text-align: right" title="Exercise price">6.94</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Expected term</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230101__20231231__us-gaap--PlanNameAxis__custom--TwentySeventeenStockCompensationPlanMember_z14VKcAWI4G3" title="Expected term">5.75</span> years</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Expected volatility</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20230101__20231231__us-gaap--PlanNameAxis__custom--TwentySeventeenStockCompensationPlanMember_zQeLhyj1Eqy1" style="text-align: right" title="Expected volatility">31.90</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Risk-free interest rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20230101__20231231__us-gaap--PlanNameAxis__custom--TwentySeventeenStockCompensationPlanMember_zNjBU10Mq145" style="text-align: right" title="Risk-free interest rate">3.84</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Dividend rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20230101__20231231__us-gaap--PlanNameAxis__custom--TwentySeventeenStockCompensationPlanMember_zUZLFZTEndI5" style="text-align: right" title="Dividend rate">0</td><td style="text-align: left">%</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of Stock Option Activity</a></td>
<td class="text"><p id="xdx_89E_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zN7Dhk6r2Y0a" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following is a summary of the outstanding stock options as of December 31, 2024 and 2023:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8BB_zZTUR7enWRSi" style="display: none">Schedule of Stock Option Activity</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Number of Options</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted Avg. Remaining Contractual Life (in years)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted Avg. Exercise Price</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Aggregate Intrinsic Value</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 36%; font-weight: bold; padding-bottom: 1pt">Outstanding as of December 31, 2023</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20240101__20241231_zbdgYc0k0tj6" style="border-bottom: Black 1pt solid; width: 12%; text-align: right" title="Number of Options, Outstanding, Beginning balance">1,319,394</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; width: 12%; text-align: right"><span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230101__20231231_z39nUXErIBH7" title="Weighted Average Remaining Contractual Life (in years), Outstanding">5.69</span></td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_uUSDPShares_c20240101__20241231_zRBnsQjAVTg3" style="border-bottom: Black 1pt solid; width: 12%; text-align: right" title="Weighted Average Exercise Price, Outstanding, Beginning balance">6.94</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_c20240101__20241231_zo0CKJ6eWyza" style="border-bottom: Black 1pt solid; width: 12%; text-align: right" title="Aggregate Intrinsic Value, Outstanding, Beginning balance"><span style="-sec-ix-hidden: xdx2ixbrl1788">&#8212;</span></td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; padding-bottom: 1pt">Outstanding as of December 31, 2024</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20240101__20241231_z55EeHnyKinh" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Options, Outstanding, Ending balance">1,319,394</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231_zxR1WpQg0Oz2" title="Weighted Average Remaining Contractual Life (in years), Outstanding">4.69</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_uUSDPShares_c20240101__20241231_zvtuUdJvgcr" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price, Outstanding, Ending balance">6.94</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_c20240101__20241231_zwttZBExv1sa" style="border-bottom: Black 1pt solid; text-align: right" title="Aggregate Intrinsic Value, Outstanding, Ending balance"><span style="-sec-ix-hidden: xdx2ixbrl1796">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-bottom: 1pt">Vested and Exercisable as of December 31, 2024</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_iE_pid_c20240101__20241231_zj5LvhhpSMce" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Options, Vested and Exercisable, Ending balance">1,319,394</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_dtY_c20240101__20241231_zg10RHlZAHDg" title="Weighted Average Remaining Contractual Life (in years), Vested and Exercisable">4.69</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iE_pid_uUSDPShares_c20240101__20241231_zHcu58EvmXoj" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price, Vested and Exercisable, Ending balance">6.94</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_iE_c20240101__20241231_zURCbanmCr4e" style="border-bottom: Black 1pt solid; text-align: right" title="Aggregate Intrinsic Value, Vested and Exercisable, Ending balance"><span style="-sec-ix-hidden: xdx2ixbrl1804">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (f)(2)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Warrant Liabilities (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NRXS_DisclosureWarrantLiabilitiesAbstract', window );"><strong>Warrant Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NRXS_ScheduleOfChangesInWarrantLiabilitiesTableTextBlock', window );">Schedule of Changes in Warrant Liabilities</a></td>
<td class="text"><p id="xdx_897_ecustom--ScheduleOfChangesInWarrantLiabilitiesTableTextBlock_zhnajgsOSnk5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following are the changes in the warrant liabilities during the years ended December 31, 2024 and 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8BD_ziPvejQmf2bf" style="display: none">Schedule of Changes in Warrant Liabilities</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 1</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 2</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 3</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; font-weight: bold">Warrant liabilities as of January 1, 2023</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--WarrantsAndRightsOutstanding_iS_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zT88wBP0RRP8" style="width: 12%; text-align: right" title="Warrant liabilities, Beginning balance"><span style="-sec-ix-hidden: xdx2ixbrl1830">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--WarrantsAndRightsOutstanding_iS_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zdwd7tq2Q0bl" style="width: 12%; text-align: right" title="Warrant liabilities, Beginning balance"><span style="-sec-ix-hidden: xdx2ixbrl1832">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_986_eus-gaap--WarrantsAndRightsOutstanding_iS_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zx9tsgBNOnD4" style="width: 12%; text-align: right" title="Warrant liabilities, Beginning balance">2,234,384</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt">Addition</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_ecustom--AdditionToWarrantLiabilities_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zee6DAMsbl2j" style="text-align: right" title="Addition"><span style="-sec-ix-hidden: xdx2ixbrl1836">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_ecustom--AdditionToWarrantLiabilities_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zSD8bz35u2Id" style="text-align: right" title="Addition"><span style="-sec-ix-hidden: xdx2ixbrl1838">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_ecustom--AdditionToWarrantLiabilities_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zA7l7yecfaIh" style="text-align: right" title="Addition">2,446,502</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Reclassified to equity</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_ecustom--ReclassifiedToEquity_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zvOYF9TMRBFg" style="text-align: right" title="Reclassified to equity"><span style="-sec-ix-hidden: xdx2ixbrl1842">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_ecustom--ReclassifiedToEquity_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zw1ZC82J6fde" style="text-align: right" title="Reclassified to equity"><span style="-sec-ix-hidden: xdx2ixbrl1844">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_ecustom--ReclassifiedToEquity_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z4zv76UCtXHk" style="text-align: right" title="Reclassified to equity">(3,827,807</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Changes in fair value of warrant liabilities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--FairValueAdjustmentOfWarrants_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zHU0YUGcnGE5" style="border-bottom: Black 1pt solid; text-align: right" title="Changes in fair value of warrant liabilities"><span style="-sec-ix-hidden: xdx2ixbrl1848">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--FairValueAdjustmentOfWarrants_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zaBHCB3F95se" style="border-bottom: Black 1pt solid; text-align: right" title="Changes in fair value of warrant liabilities"><span style="-sec-ix-hidden: xdx2ixbrl1850">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--FairValueAdjustmentOfWarrants_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zvYO3V51Q4Q8" style="border-bottom: Black 1pt solid; text-align: right" title="Changes in fair value of warrant liabilities">(844,854</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold">Warrant liabilities as of December 31, 2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--WarrantsAndRightsOutstanding_iS_c20240101__20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zAQCcSYfDdUi" style="text-align: right" title="Warrant liabilities, Beginning balance"><span style="-sec-ix-hidden: xdx2ixbrl1854">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--WarrantsAndRightsOutstanding_iS_c20240101__20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zl5xaH5D1Jo8" style="text-align: right" title="Warrant liabilities, Beginning balance"><span style="-sec-ix-hidden: xdx2ixbrl1856">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--WarrantsAndRightsOutstanding_iS_c20240101__20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zbrQ6KXGpJW7" style="text-align: right" title="Warrant liabilities, Beginning balance">8,225</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Changes in fair value of warrant liabilities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--FairValueAdjustmentOfWarrants_c20240101__20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zf8FawArezfl" style="border-bottom: Black 1pt solid; text-align: right" title="Changes in fair value of warrant liabilities"><span style="-sec-ix-hidden: xdx2ixbrl1860">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--FairValueAdjustmentOfWarrants_c20240101__20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zZrLRI2XKRp8" style="border-bottom: Black 1pt solid; text-align: right" title="Changes in fair value of warrant liabilities"><span style="-sec-ix-hidden: xdx2ixbrl1862">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--FairValueAdjustmentOfWarrants_c20240101__20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zXJzf1PfozVa" style="border-bottom: Black 1pt solid; text-align: right" title="Changes in fair value of warrant liabilities">941</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-bottom: 1pt">Warrant liabilities as of December 31, 2024</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_982_eus-gaap--WarrantsAndRightsOutstanding_iE_c20240101__20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zkMY2pnoFcq3" style="border-bottom: Black 1pt solid; text-align: right" title="Warrant liabilities, Ending balance"><span style="-sec-ix-hidden: xdx2ixbrl1866">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_980_eus-gaap--WarrantsAndRightsOutstanding_iE_c20240101__20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zdADnq4PbFzl" style="border-bottom: Black 1pt solid; text-align: right" title="Warrant liabilities, Ending balance"><span style="-sec-ix-hidden: xdx2ixbrl1868">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_985_eus-gaap--WarrantsAndRightsOutstanding_iE_c20240101__20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zDMfqGcS94G1" style="border-bottom: Black 1pt solid; text-align: right" title="Warrant liabilities, Ending balance">9,166</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_NRXS_DisclosureWarrantLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">NRXS_DisclosureWarrantLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>NRXS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_NRXS_ScheduleOfChangesInWarrantLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of Changes in Warrant Liabilities [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">NRXS_ScheduleOfChangesInWarrantLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>NRXS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Derivative Liabilities (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NRXS_DisclosureDerivativeLiabilitiesAbstract', window );"><strong>Derivative Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock', window );">Schedule of Changes in Derivative Liabilities</a></td>
<td class="text"><p id="xdx_89F_eus-gaap--ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock_zfXEuYd43pb8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following are the changes in the derivative liabilities during the year ended December 31, 2023:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B4_zD5ZA7TNqMEk" style="display: none">Schedule of Changes in Derivative Liabilities</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 1</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 2</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 3</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; font-weight: bold">Derivative liabilities as of December 31, 2022</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_986_ecustom--ChangesInDerivativeLiabilities_iS_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zP8tnL9A2rg8" style="width: 12%; text-align: right" title="Derivative liabilities, Beginning balance"><span style="-sec-ix-hidden: xdx2ixbrl1886">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_987_ecustom--ChangesInDerivativeLiabilities_iS_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zeqmf28McAp2" style="width: 12%; text-align: right" title="Derivative liabilities, Beginning balance"><span style="-sec-ix-hidden: xdx2ixbrl1888">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_982_ecustom--ChangesInDerivativeLiabilities_iS_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zCuIuUgQiaw2" style="width: 12%; text-align: right" title="Derivative liabilities, Beginning balance">1,735,700</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt">Addition</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_ecustom--AdditionToDerivativeLiabilities_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zbSf9gQIUbWc" style="text-align: right" title="Addition"><span style="-sec-ix-hidden: xdx2ixbrl1892">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_ecustom--AdditionToDerivativeLiabilities_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zUnRulXJI57e" style="text-align: right" title="Addition"><span style="-sec-ix-hidden: xdx2ixbrl1894">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_ecustom--AdditionToDerivativeLiabilities_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z6VRuutgHygf" style="text-align: right" title="Addition">2,375,378</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Changes in fair value of derivative liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--IncreaseDecreaseInDerivativeLiabilities_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zPG3xHL5PHK6" style="text-align: right" title="Changes in fair value of Derivative liabilities"><span style="-sec-ix-hidden: xdx2ixbrl1898">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--IncreaseDecreaseInDerivativeLiabilities_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_z7iD4PCJp5qi" style="text-align: right" title="Changes in fair value of Derivative liabilities"><span style="-sec-ix-hidden: xdx2ixbrl1900">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--IncreaseDecreaseInDerivativeLiabilities_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z0aCo4QrZhql" style="text-align: right" title="Changes in fair value of Derivative liabilities">(198,551</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Extinguishment of derivative liabilities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_986_ecustom--ExtinguishmentOfDerivativeLiabilities_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_z2tptvDslgV6" style="border-bottom: Black 1pt solid; text-align: right" title="Extinguishment of Derivative liabilities"><span style="-sec-ix-hidden: xdx2ixbrl1904">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_988_ecustom--ExtinguishmentOfDerivativeLiabilities_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zG9Bj6nOkTKj" style="border-bottom: Black 1pt solid; text-align: right" title="Extinguishment of Derivative liabilities"><span style="-sec-ix-hidden: xdx2ixbrl1906">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98E_ecustom--ExtinguishmentOfDerivativeLiabilities_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zcshAjGpFsW9" style="border-bottom: Black 1pt solid; text-align: right" title="Extinguishment of Derivative liabilities">(3,912,527</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-bottom: 1pt">Derivative liabilities as of December 31, 2023</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_98A_ecustom--ChangesInDerivativeLiabilities_iE_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zpfbG6B2XGSk" style="border-bottom: Black 1pt solid; text-align: right" title="Derivative liabilities, Ending balance"><span style="-sec-ix-hidden: xdx2ixbrl1910">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_983_ecustom--ChangesInDerivativeLiabilities_iE_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zdxl4nMNr2uh" style="border-bottom: Black 1pt solid; text-align: right" title="Derivative liabilities, Ending balance"><span style="-sec-ix-hidden: xdx2ixbrl1912">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_98F_ecustom--ChangesInDerivativeLiabilities_iE_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zHFXPAjluqB6" style="border-bottom: Black 1pt solid; text-align: right" title="Derivative liabilities, Ending balance"><span style="-sec-ix-hidden: xdx2ixbrl1914">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_NRXS_DisclosureDerivativeLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">NRXS_DisclosureDerivativeLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>NRXS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of derivative liabilities at fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock', window );">Schedule of Reconciles the Company&#8217;s Net Sales and Operating Loss</a></td>
<td class="text"><p id="xdx_89D_eus-gaap--ScheduleOfSegmentReportingInformationBySegmentTextBlock_zxiAZRRNNNX4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following reconciles the reportable segment net sales and operating loss to the Company&#8217;s reported net loss:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B3_zIRrk2PmXsYd">Schedule
of Reconciles the Company&#8217;s Net Sales and Operating Loss</span>&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="display: none; text-align: center">&#160;</td><td style="display: none; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_496_20240101__20241231__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_zQVzSUxLXCS8" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center">2024</td><td style="display: none; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="display: none; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_492_20230101__20231231__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_zS6R7VBfCF2f" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center">2023</td><td style="display: none; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">For the Years Ended December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_maCzEo3_zCN9uWPcUpNh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; width: 60%; font-weight: bold; text-align: left">Net Sales</td><td style="width: 2%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">$</td><td style="width: 16%; font-weight: bold; text-align: right">2,685,925</td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">2,460,049</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--CostOfGoodsAndServicesSold_msCzEo3_zdJ2IIL909ld" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Cost of Goods Sold</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">362,002</td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">303,345</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--GrossProfit_iT_mtCzEo3_maOILz3im_zHXktUBsxMc" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; font-weight: bold; text-align: left">Gross Profit</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">2,323,923</td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,156,704</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--SellingExpense_i01_msOILz3im_zYmpOrmV48va" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Selling Expenses <span id="xdx_F44_ztbxsniXabr">(a)</span></td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">324,708</td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">323,569</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--ResearchAndDevelopmentExpense_i01_msOILz3im_zhthLcmgssrj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Research and Development <span id="xdx_F4B_zOI0PHE1bj1j">(a)</span></td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">206,107</td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">169,315</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--LaborAndRelatedExpense_i01_msOILz3im_zF297Hh5Tt95" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Wages and Benefits <span id="xdx_F41_zAwA6AQear57">(a)</span></td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">5,378,952</td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,367,486</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--ProfessionalAndContractServicesExpense_i01_msOILz3im_zCoI4NrOzSv2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Professional Services <span id="xdx_F4D_z7AiQB8GNFef">(a)</span></td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">1,945,331</td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,721,461</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--OtherCostAndExpenseOperating_i01_msOILz3im_zoEc5bAAdv51" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Other Operating Expenses <span id="xdx_F4C_zrk53HU68AZ1">(a)</span> <span id="xdx_F4B_zK9RzMvJ25Ee">(b)</span></td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">1,625,642</td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">1,239,368</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--OperatingIncomeLoss_iT_maCz7fC_mtOILz3im_zxdpcZ5o8Qyf" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1pt">Segment Operating Loss</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">(7,156,817</td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(6,664,495</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--NonoperatingIncomeExpenseAbstract_iB_zbAcjN2ODiE7" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Other (Expense) Income:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_ecustom--FinancingCharges_i01N_di_msONIEz60J_z2B0GCtuEkt6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: left">Financing charges</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">(230,824</td><td style="font-weight: bold; text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(2,772</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_408_eus-gaap--InterestExpense_i01N_di_msONIEz60J_zztXzQpOihe6" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left">Interest expense</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">(174,328</td><td style="font-weight: bold; text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(476,416</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40B_eus-gaap--FairValueAdjustmentOfWarrants_i01N_di_msONIEz60J_zNFSq4n7haY6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: left">Change in fair value of warrant liability</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">(941</td><td style="font-weight: bold; text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">844,854</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--DerivativeGainLossOnDerivativeNet_i01_maONIEz60J_z1Q0FrtYcXu5" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left">Change in fair value of derivative liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1967">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">198,551</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--AmortizationOfFinancingCostsAndDiscounts_i01N_di_msONIEz60J_ztXLMWhzcoo6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: left">Amortization of debt discount and issuance cost</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">(126,387</td><td style="font-weight: bold; text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(4,881,622</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_400_eus-gaap--GainsLossesOnExtinguishmentOfDebt_i01_maONIEz60J_zG8IEht4gaie" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left">Extinguishment of debt liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1973">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(3,649,561</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_404_eus-gaap--OtherNonoperatingIncome_i01_maONIEz60J_zCzqQ1YCpcMj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: left">Other income</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">33,620</td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">15,133</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--OtherNonoperatingExpense_i01N_di_msONIEz60J_zdZ31bllWTOa" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left; padding-bottom: 1pt">Other expense</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">(585,824</td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(10,355</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_40B_eus-gaap--OtherNonoperatingIncomeExpense_i01T_maCz7fC_mtONIEz60J_znSMZiHMxXVk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 30pt; text-align: left; padding-bottom: 1pt">Total other (expense) income, net</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">(1,084,684</td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(7,962,188</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--NetIncomeLoss_iT_mtCz7fC_zCVtniRT8qb4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1pt">Net Loss</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">(8,241,501</td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">(14,626,683</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span id="xdx_F0A_zSHbxJTS4XIa" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F1B_zCM34Oh92oT7" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            significant expense categories and amounts align with the segment-level information provided
                                            on a regular basis to the CODM.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_F0D_zmCzF8AwSMi2" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F12_zBTE0DIvtEci" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
                                            operating expenses include advertising, rent and utilities, insurance, depreciation and
                                            amortization, travel, software subscription fees, board fees and bad debt expense.</span></td></tr></table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-25<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">Schedule of Income Tax Provision</a></td>
<td class="text"><p id="xdx_890_eus-gaap--ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_zDb3lcW75Ijk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
income tax provision consists of:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B5_zNP32LdYNA2g">Schedule
of Income Tax Provision</span>&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="display: none">&#160;</td><td style="display: none; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49F_20240101__20241231_zGKRhM3a4gI" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center">2024</td><td style="display: none; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="display: none; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49A_20230101__20231231_zoONEQJVCXxg" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center">2023</td><td style="display: none; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">For the Years Ended December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--CurrentIncomeTaxExpenseBenefit_maDITEBzp9r_zgzdKTwjUnl5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0pt; text-align: left">Total current provision</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">$</td><td style="font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2080">-</span></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2081">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0pt">Deferred:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--DeferredFederalIncomeTaxExpenseBenefit_maDITEBzp9r_z4B2XbNXY3Se" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; width: 60%">Federal</td><td style="width: 2%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 16%; font-weight: bold; text-align: right">(1,721,242</td><td style="width: 1%; font-weight: bold; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right">(3,067,056</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr id="xdx_402_eus-gaap--DeferredStateAndLocalIncomeTaxExpenseBenefit_maDITEBzp9r_zfUDQpdKPKFd" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; padding-bottom: 1pt">State</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">124,823</td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(154,060</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_408_eus-gaap--DeferredIncomeTaxExpenseBenefit_iT_mtDITEBzp9r_maITEBzTsP_z0FkcE7aj5Sb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0pt; text-align: left">Total deferred benefit</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">(1,596,419</td><td style="font-weight: bold; text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(3,221,116</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_405_eus-gaap--IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_maITEBzTsP_zfcx9bJKyV79" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Valuation allowance</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">1,596,419</td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">3,221,116</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--IncomeTaxExpenseBenefit_iT_mtITEBzTsP_zIsWExreKkA6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Total income tax provision</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2095">&#8212;</span></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2096">&#8212;</span></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of Federal Statutory Income Tax Rate and Effective Income Tax Rate</a></td>
<td class="text"><p id="xdx_892_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_z1gVIsJ6URf6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
reconciliation of the U.S. federal statutory income tax rate to the effective income tax rate is as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B0_zTBhoPXev1aj" style="display: none">Schedule of Federal Statutory Income Tax Rate and Effective Income Tax Rate</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="display: none">&#160;</td><td style="display: none; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_490_20240101__20241231_zdvSC8iN66j" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center">2024</td><td style="display: none; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="display: none; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49C_20230101__20231231_z0XKOJgDOSWc" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center">2023</td><td style="display: none; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">For the Years Ended December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_uPure_maEIT001_z1qbu3Hil3a6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; width: 60%; text-align: left">Federal statutory income tax rate</td><td style="width: 2%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 16%; font-weight: bold; text-align: right">21.0</td><td style="width: 1%; font-weight: bold; text-align: left">%</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right">21.0</td><td style="width: 1%; text-align: left">%</td></tr>
  <tr id="xdx_40A_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_pid_dp_uPure_maEIT001_zIZ8oRAWthS2" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">State tax rate, net of federal benefit</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">5.3</td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4.9</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_pid_dp_uPure_maEIT001_zZTKo9bs0Sp9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0pt; text-align: left; padding-bottom: 1pt">Change in valuation allowance</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">(26.3</td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(25.9</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_40C_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_iT_pid_dp_uPure_mtEIT001_zLvS1c6f5o88" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Effective income tax rate</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2109">&#8212;</span></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">%</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2110">&#8212;</span></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">%</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of Net Deferred Tax Assets and Liabilities</a></td>
<td class="text"><p id="xdx_898_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zVope19dWKwe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred
income taxes are provided for temporary differences between the financial and tax bases of the Company&#8217;s assets and liabilities.
The temporary differences that give rise to net deferred tax assets and liabilities were as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B9_zndQqMtgcaHi">Schedule
of Net Deferred Tax Assets and Liabilities</span>&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="display: none">&#160;</td><td style="display: none; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49F_20241231_zhXUsZI3niV4" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center">2024</td><td style="display: none; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="display: none; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_490_20231231_z7C0J1onSSN7" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center">2023</td><td style="display: none; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Deferred tax assets:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_maDTAGzJbV_zNoECr7RCSAh" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; width: 60%; text-align: left">Net operating losses</td><td style="width: 2%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">$</td><td style="width: 16%; font-weight: bold; text-align: right">8,019,218</td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">6,573,406</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_iI_maDTAGzJbV_za6weCmEW96f" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Stock based compensation</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">1,447,339</td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,366,391</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_ecustom--DeferredTaxAssetsNotesReceivableReserve_iI_maDTAGzJbV_zP9Xtj47KL35" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Notes receivable reserve</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">266,816</td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">251,893</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsOther_iI_maDTAGzJbV_zsPbpUzTJcX4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Accrued compensation</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">296,297</td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">57,763</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_ecustom--DeferredTaxAssetsAccountsPayable_iI_maDTAGzJbV_zZVAIHIlDJl8" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Accounts payable</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">143,484</td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">257,391</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_ecustom--DeferredTaxAssetsOperatingLeasePayable_iI_maDTAGzJbV_zIk3RIZ85ade" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Operating lease payable</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">84,105</td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">18,951</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--DeferredTaxAssetsOther_iI_maDTAGzJbV_zwDLA3KP1g6i" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; padding-bottom: 1pt">Other</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">206,468</td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">175,904</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--DeferredTaxAssetsGross_iTI_mtDTAGzJbV_maDTANz8qu_zSMHce1zy2w4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0pt; text-align: left">Total gross deferred tax assets</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">10,463,727</td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">8,701,699</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_di_msDTANz8qu_zAcJuJYdrqti" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0pt; text-align: left; padding-bottom: 1pt">Valuation allowance</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">(10,225,739</td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(8,629,320</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_406_eus-gaap--DeferredTaxAssetsNet_iTI_mtDTANz8qu_msDTLzJxU_zZCRtEmahuWk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0pt; text-align: left; padding-bottom: 1pt">Total deferred tax assets</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">237,988</td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">72,379</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0pt; text-align: left">Deferred tax liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_ecustom--DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset_iI_maDITLzRLP_zZrYdGsyoYyj" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Operating lease right of use asset</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">$</td><td style="font-weight: bold; text-align: right">74,991</td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">17,475</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--DeferredTaxLiabilitiesPrepaidExpenses_iI_maDITLzRLP_zpaquPF7s5Bg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Prepaid expenses</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">72,560</td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7,337</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_ecustom--DeferredTaxLiabilityAccountsReceivable_iI_maDITLzRLP_zjaKtI9Ap3i3" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Accounts receivable</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">64,443</td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">18,197</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--DeferredTaxLiabilitiesOther_iI_maDITLzRLP_zlQ4mlye7Uv1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; padding-bottom: 1pt">Other</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">25,994</td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">29,370</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--DeferredIncomeTaxLiabilities_iTI_mtDITLzRLP_maDTLzJxU_zHtpCPEkSRbj" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Total deferred tax liabilities</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">237,988</td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">72,379</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--DeferredTaxLiabilities_iTI_mtDTLzJxU_zlE7IC9Wb103" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Deferred tax assets, net</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2159">&#8212;</span></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2160">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock', window );">Schedule of State Carryforwards</a></td>
<td class="text"><p id="xdx_89B_eus-gaap--SummaryOfOperatingLossCarryforwardsTextBlock_z8KsPtHCLbOb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
not used, the state NOL carryforwards will expire as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8BF_zsQ5DJSkDt42" style="display: none">Schedule of State Carryforwards</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 60%; margin-right: auto">
  <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="display: none; text-align: justify">&#160;</td><td style="display: none">&#160;</td>
    <td style="display: none; text-align: left">&#160;</td><td id="xdx_49B_20241231_zIjmiiM9ZDLj" style="display: none; text-align: right">&#160;</td><td style="display: none; text-align: left">&#160;</td></tr>
<tr id="xdx_40F_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_iI_hus-gaap--TaxPeriodAxis__custom--TaxYear2037Member_zjxftYeYpkz4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 78%; text-align: justify">2037</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right">72,216</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_iI_hus-gaap--TaxPeriodAxis__custom--TaxYear2038Member_zrilnWyMrWh3" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">2038</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,039,986</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_iI_hus-gaap--TaxPeriodAxis__custom--TaxYear2039Member_zYpBSeKjSPo4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">2039</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,033,565</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_iI_hus-gaap--TaxPeriodAxis__custom--TaxYear2040Member_zzAYhiafCmD1" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">2040</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,457,495</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_iI_hus-gaap--TaxPeriodAxis__custom--TaxYear2041Member_zG5919ryuNS6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">2041</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,406,225</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_iI_hus-gaap--TaxPeriodAxis__custom--TaxYearThereafterMember_zwC79DGKyVgc" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Thereafter</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">24,671,088</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_iI_hus-gaap--TaxPeriodAxis__custom--NoExpirationMember_zia4lqC4qMhe" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt; text-align: justify">No expiration</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">67,949</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_iI_z9mLazXw2Q1a" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt; text-align: justify">Total state NOL carryforwards</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">34,748,524</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of pertinent information, such as tax authority, amounts, and expiration dates, of net operating loss carryforwards, including an assessment of the likelihood of utilization.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation, Organization and Other Matters (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Nov. 11, 2024</div></th>
<th class="th"><div>Aug. 15, 2024</div></th>
<th class="th"><div>Aug. 09, 2023</div></th>
<th class="th"><div>Jan. 10, 2023</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Nov. 13, 2024</div></th>
<th class="th"><div>Feb. 12, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplit', window );">Description of stock split</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1-for-2 reverse stock split<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,120,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 4,847,457<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Proceeds from issuance initial public offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,110,677<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NRXS_PurchaseOfAdditionalStockOnNumberOfOptionsNotExercised', window );">Purchase of additional stockon number of options not exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">164,801<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted', window );">Warrants to purchase an aggregate common stock, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">861,424<span></span>
</td>
<td class="nump">813,928<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member] | Alexander Capital LP [Member] | IPO [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of stock, number of shares issued in transaction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,098,667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares issued, price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,592,002<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredOfferingCosts', window );">Deferred offering costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,110,721<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NRXS_UnderwritersDiscountPercentage', window );">Underwriters discount percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NRXS_NonaccountableExpenseAllowancePercentage', window );">Nonaccountable expense allowance percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NRXS_CashFeePercentage', window );">Cash fee percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Proceeds from issuance initial public offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 527,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NRXS_ReimbursementExpenses', window );">Reimbursement expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 175,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted', window );">Warrants to purchase an aggregate common stock, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">65,921<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction', window );">Sale of stock, percentage of ownership after transaction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NRXS_OfferingPricePerPercentage', window );">Offering price per percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">120.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=NRXS_ConvertibleSeriesAPreferredStockMember', window );">Convertible Series A Preferred stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares', window );">Stock repurchased and retired during period shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=NRXS_ConvertibleSeriesSeedPreferredStockMember', window );">Convertible Series Seed Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">120,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares', window );">Stock repurchased and retired during period shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">120,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember', window );">Series B Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.38<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.38<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Temporary equity, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockDividendPaymentTerms', window );">Cumulative dividend description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">at a rate of 8.5% per annum through June 30, 2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=NRXS_ConvertibleSeriesBPreferredStockMember', window );">Convertible Series B Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockDividendPaymentTerms', window );">Cumulative dividend description</a></td>
<td class="text">extension
of the 8.5% cumulative dividend period to December 31, 2026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_NRXS_CashFeePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash fee percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">NRXS_CashFeePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>NRXS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_NRXS_NonaccountableExpenseAllowancePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Nonaccountable expense allowance percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">NRXS_NonaccountableExpenseAllowancePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>NRXS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_NRXS_OfferingPricePerPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Offering price per percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">NRXS_OfferingPricePerPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>NRXS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_NRXS_PurchaseOfAdditionalStockOnNumberOfOptionsNotExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Purchase of additional stock on number of options not exercised.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">NRXS_PurchaseOfAdditionalStockOnNumberOfOptionsNotExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>NRXS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_NRXS_ReimbursementExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reimbursement expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">NRXS_ReimbursementExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>NRXS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_NRXS_UnderwritersDiscountPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Underwriters discount percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">NRXS_UnderwritersDiscountPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>NRXS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredOfferingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Specific incremental costs directly attributable to a proposed or actual offering of securities which are deferred at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.A)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480341/340-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredOfferingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockDividendPaymentTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Specific information regarding dividend payment dates or timing and whether or not dividends are paid on a cumulative basis.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockDividendPaymentTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of subsidiary's or equity investee's stock owned by parent company after stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net number of non-option equity instruments granted to participants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased and retired during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedAndRetiredDuringPeriodShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteStockSplit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of the stock split arrangement. Also provide the retroactive effect given by a stock split that occurs after the balance date but before the release of financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB Topic 4.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteStockSplit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of securities classified as temporary equity that are permitted to be issued by an entity's charter and bylaws. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=NRXS_AlexanderCapitalLPMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=NRXS_AlexanderCapitalLPMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=NRXS_ConvertibleSeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=NRXS_ConvertibleSeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=NRXS_ConvertibleSeriesSeedPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=NRXS_ConvertibleSeriesSeedPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=NRXS_ConvertibleSeriesBPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=NRXS_ConvertibleSeriesBPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Schedule of Estimated Useful Lives (Details)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember', window );">Machinery and Equipment [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment, estimated useful lives</a></td>
<td class="text">7 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember', window );">Machinery and Equipment [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment, estimated useful lives</a></td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and Fixtures [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment, estimated useful lives</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and Fixtures [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment, estimated useful lives</a></td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment, estimated useful lives</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold Improvements [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment, estimated useful lives</a></td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold Improvements [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment, estimated useful lives</a></td>
<td class="text">20 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Schedule of Fair Value of Assets and Liabilities measured on Recurring Basis (Details) - Fair Value, Recurring [Member] - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Inputs, Level 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Fair value of warrant liabilities as of December 31, 2023</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Inputs, Level 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Fair value of warrant liabilities as of December 31, 2023</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Inputs, Level 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Fair value of warrant liabilities as of December 31, 2023</a></td>
<td class="nump">9,166<span></span>
</td>
<td class="nump">8,225<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Fair value of warrant liabilities as of December 31, 2023</a></td>
<td class="nump">$ 9,166<span></span>
</td>
<td class="nump">$ 8,225<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial and nonfinancial obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Dilutive Common Stock Equivalents (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Totals</a></td>
<td class="nump">8,242,863<span></span>
</td>
<td class="nump">3,141,752<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_OptionMember', window );">Options Held [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Totals</a></td>
<td class="nump">1,319,394<span></span>
</td>
<td class="nump">1,319,394<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Totals</a></td>
<td class="nump">289,779<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=NRXS_WarrantsMember', window );">Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Totals</a></td>
<td class="nump">2,352,751<span></span>
</td>
<td class="nump">1,822,358<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_SeriesBPreferredStockMember', window );">Series B Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Totals</a></td>
<td class="nump">4,280,939<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_OptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_OptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=NRXS_WarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=NRXS_WarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_SeriesBPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_SeriesBPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Basic and Diluted Net Loss Per Share (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (8,241,501)<span></span>
</td>
<td class="num">$ (14,626,683)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DividendsPreferredStock', window );">Preferred stock dividends</a></td>
<td class="num">(211,268)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss available to common stockholders</a></td>
<td class="num">$ (8,452,769)<span></span>
</td>
<td class="num">$ (14,626,683)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average shares of common stock outstanding - basic</a></td>
<td class="nump">6,918,887<span></span>
</td>
<td class="nump">3,252,328<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average shares of common stock outstanding - diluted</a></td>
<td class="nump">6,918,887<span></span>
</td>
<td class="nump">3,252,328<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic net loss per share</a></td>
<td class="num">$ (1.22)<span></span>
</td>
<td class="num">$ (4.50)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted net loss per share</a></td>
<td class="num">$ (1.22)<span></span>
</td>
<td class="num">$ (4.50)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsPreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of paid and unpaid preferred stock dividends declared with the form of settlement in cash, stock and payment-in-kind (PIK).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -SubTopic 405<br> -Topic 942<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477787/942-405-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsPreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 6.B)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-5<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Disaggregation of Revenue (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">$ 2,685,925<span></span>
</td>
<td class="nump">$ 2,460,049<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=stpr_CA', window );">CALIFORNIA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">778,209<span></span>
</td>
<td class="nump">601,235<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=stpr_OH', window );">OHIO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">431,328<span></span>
</td>
<td class="nump">407,632<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=stpr_IL', window );">ILLINOIS</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">246,217<span></span>
</td>
<td class="nump">117,963<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=stpr_WI', window );">WISCONSIN</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">157,786<span></span>
</td>
<td class="nump">292,601<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=stpr_MA', window );">MASSACHUSETTS</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">154,407<span></span>
</td>
<td class="nump">127,300<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=stpr_FL', window );">FLORIDA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">149,985<span></span>
</td>
<td class="nump">186,840<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=NRXS_AllOtherStatesMember', window );">All other States [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">$ 767,993<span></span>
</td>
<td class="nump">$ 726,478<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_CA">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_CA</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_OH">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_OH</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_IL">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_IL</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_WI">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_WI</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_MA">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_MA</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_FL">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_FL</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=NRXS_AllOtherStatesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=NRXS_AllOtherStatesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Customer Accounts Receivable (Details) - Accounts Receivable [Member] - Customer Concentration Risk [Member] - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=NRXS_CustomerAMember', window );">Customer A [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNet', window );">Net accounts receivable</a></td>
<td class="nump">$ 119,616<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Risk percentage</a></td>
<td class="nump">49.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=NRXS_CustomerBMember', window );">Customer B [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNet', window );">Net accounts receivable</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 23,900<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Risk percentage</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">28.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=NRXS_CustomerCMember', window );">Customer C [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNet', window );">Net accounts receivable</a></td>
<td class="nump">$ 22,799<span></span>
</td>
<td class="nump">$ 14,401<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Risk percentage</a></td>
<td class="nump">9.00%<span></span>
</td>
<td class="nump">17.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=NRXS_CustomerDMember', window );">Customer D [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNet', window );">Net accounts receivable</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 23,982<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Risk percentage</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">28.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=NRXS_CustomerEMember', window );">Customer E [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNet', window );">Net accounts receivable</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 9,599<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Risk percentage</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">11.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=NRXS_CustomerMember', window );">Customer [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNet', window );">Net accounts receivable</a></td>
<td class="nump">$ 142,415<span></span>
</td>
<td class="nump">$ 71,882<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Risk percentage</a></td>
<td class="nump">58.00%<span></span>
</td>
<td class="nump">84.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 310<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477802/946-310-45-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(5)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 310<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479196/954-310-45-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-21<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-20<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=NRXS_CustomerAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=NRXS_CustomerAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=NRXS_CustomerBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=NRXS_CustomerBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=NRXS_CustomerCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=NRXS_CustomerCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=NRXS_CustomerDMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=NRXS_CustomerDMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=NRXS_CustomerEMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=NRXS_CustomerEMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=NRXS_CustomerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=NRXS_CustomerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Customers Accounted Revenues (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">$ 2,685,925<span></span>
</td>
<td class="nump">$ 2,460,049<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=NRXS_CustomerAMember', window );">Customer A [Member] | Revenue Benchmark [Member] | Customer Concentration Risk [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">$ 521,810<span></span>
</td>
<td class="nump">$ 452,680<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Risk percentage</a></td>
<td class="nump">20.00%<span></span>
</td>
<td class="nump">18.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=NRXS_CustomerBMember', window );">Customer B [Member] | Revenue Benchmark [Member] | Customer Concentration Risk [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">$ 396,950<span></span>
</td>
<td class="nump">$ 382,082<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Risk percentage</a></td>
<td class="nump">15.00%<span></span>
</td>
<td class="nump">16.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=NRXS_CustomerCMember', window );">Customer C [Member] | Revenue Benchmark [Member] | Customer Concentration Risk [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">$ 142,270<span></span>
</td>
<td class="nump">$ 274,581<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Risk percentage</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="nump">11.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=NRXS_CustomerMember', window );">Customer [Member] | Revenue Benchmark [Member] | Customer Concentration Risk [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">$ 1,061,030<span></span>
</td>
<td class="nump">$ 1,109,343<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Risk percentage</a></td>
<td class="nump">40.00%<span></span>
</td>
<td class="nump">45.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-21<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-20<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=NRXS_CustomerAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=NRXS_CustomerAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=NRXS_CustomerBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=NRXS_CustomerBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=NRXS_CustomerCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=NRXS_CustomerCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=NRXS_CustomerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=NRXS_CustomerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems', window );"><strong>Indefinite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivable', window );">Allowance for doubtful accounts</a></td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="nump">$ 11,993<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProvisionForOtherCreditLosses', window );">Credit losses</a></td>
<td class="nump">7,395<span></span>
</td>
<td class="nump">25,281<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Deposits', window );">Customer deposits</a></td>
<td class="nump">32,527<span></span>
</td>
<td class="nump">74,947<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NRXS_InventoryExpenses', window );">Inventory expenses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">25,008<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryRawMaterialsNetOfReserves', window );">Inventory reserves</a></td>
<td class="nump">4,454<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">26,346<span></span>
</td>
<td class="nump">30,240<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireIntangibleAssets', window );">Payment upon execution</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">41,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization expense</a></td>
<td class="nump">$ 11,485<span></span>
</td>
<td class="nump">10,485<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExaminationLikelihoodOfUnfavorableSettlement', window );">Income tax examination, likelihood of unfavorable settlement</a></td>
<td class="text">the largest amount that is more than 50% likely of being realized upon resolution of the contingency<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued', window );">Income tax interest or penalties accrued</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DividendsPreferredStock', window );">Preferred stock dividend</a></td>
<td class="nump">211,268<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Estimated returns of revenue</a></td>
<td class="nump">5,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFDICInsuredAmount', window );">Cash, FDIC insured amount</a></td>
<td class="nump">250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashUninsuredAmount', window );">Cash uninsured</a></td>
<td class="nump">3,263,618<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Stockholders' equity</a></td>
<td class="nump">2,067,748<span></span>
</td>
<td class="num">(1,403,241)<span></span>
</td>
<td class="num">$ (5,573,613)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermBorrowings', window );">Short term borrowings outstanding</a></td>
<td class="nump">154,152<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash</a></td>
<td class="nump">3,696,870<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NRXS_WorkingCapitalDeficit', window );">Working capital surplus</a></td>
<td class="nump">1,832,858<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems', window );"><strong>Indefinite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdvertisingExpense', window );">Advertising cost</a></td>
<td class="nump">232,125<span></span>
</td>
<td class="nump">$ 192,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=NRXS_LicensingAgreementMember', window );">Licensing Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems', window );"><strong>Indefinite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireIntangibleAssets', window );">Payment upon execution</a></td>
<td class="nump">1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksMember', window );">Trademarks [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems', window );"><strong>Indefinite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireIntangibleAssets', window );">Payment upon execution</a></td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_NRXS_InventoryExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Inventory expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">NRXS_InventoryExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>NRXS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_NRXS_WorkingCapitalDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Working capital deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">NRXS_WorkingCapitalDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>NRXS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdvertisingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount charged to advertising expense for the period, which are expenses incurred with the objective of increasing revenue for a specified brand, product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 720<br> -SubTopic 35<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483385/720-35-55-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 720<br> -SubTopic 35<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483406/720-35-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdvertisingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479344/326-20-45-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481962/310-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479319/326-20-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479319/326-20-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Cash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477796/946-210-45-21<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 210<br> -Topic 946<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477796/946-210-45-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Cash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFDICInsuredAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash deposited in financial institutions as of the balance sheet date that is insured by the Federal Deposit Insurance Corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFDICInsuredAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashUninsuredAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash as of the balance sheet date that is not insured by the Federal Deposit Insurance Corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashUninsuredAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Deposits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate of all deposit liabilities held by the entity, including foreign and domestic, interest and noninterest bearing; may include demand deposits, saving deposits, Negotiable Order of Withdrawal (NOW) and time deposits among others.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Deposits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsPreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of paid and unpaid preferred stock dividends declared with the form of settlement in cash, stock and payment-in-kind (PIK).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -SubTopic 405<br> -Topic 942<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477787/942-405-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsPreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExaminationLikelihoodOfUnfavorableSettlement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of the likelihood that an uncertainty in income taxes will not be sustained as a result of the examination by the taxing authority.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExaminationLikelihoodOfUnfavorableSettlement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of estimated penalties and interest accrued as of the balance sheet date arising from income tax examinations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterialsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480581/330-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterialsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProvisionForOtherCreditLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense related to credit loss from transactions other than loan and lease transactions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProvisionForOtherCreditLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reflects the total carrying amount as of the balance sheet date of debt having initial terms less than one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=NRXS_LicensingAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=NRXS_LicensingAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Schedule of Related Party Transactions (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NRXS_AllowanceForInterestReceivableCurrent', window );">Allowance for collection risk, interest receivable</a></td>
<td class="nump">$ 1,201,367<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=NRXS_ShareHolderOneMember', window );">Shareholder 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesAndLoansReceivableGrossCurrent', window );">Loan Receivable</a></td>
<td class="nump">506,400<span></span>
</td>
<td class="nump">$ 506,400<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestReceivableCurrent', window );">Interest Receivable</a></td>
<td class="nump">94,351<span></span>
</td>
<td class="nump">70,938<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NRXS_InterestIncomeGrossCurrent', window );">Interest Income</a></td>
<td class="nump">23,413<span></span>
</td>
<td class="nump">23,867<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=NRXS_ShareHolderTwoMember', window );">Shareholder 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesAndLoansReceivableGrossCurrent', window );">Loan Receivable</a></td>
<td class="nump">506,400<span></span>
</td>
<td class="nump">506,400<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestReceivableCurrent', window );">Interest Receivable</a></td>
<td class="nump">94,216<span></span>
</td>
<td class="nump">70,803<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NRXS_InterestIncomeGrossCurrent', window );">Interest Income</a></td>
<td class="nump">23,413<span></span>
</td>
<td class="nump">23,867<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related Party [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesAndLoansReceivableGrossCurrent', window );">Loan Receivable</a></td>
<td class="nump">1,012,800<span></span>
</td>
<td class="nump">1,012,800<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestReceivableCurrent', window );">Interest Receivable</a></td>
<td class="nump">188,567<span></span>
</td>
<td class="nump">141,741<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NRXS_InterestIncomeGrossCurrent', window );">Interest Income</a></td>
<td class="nump">46,826<span></span>
</td>
<td class="nump">47,734<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllowanceForNotesAndLoansReceivableCurrent', window );">Allowance for collection risk, loan receivable</a></td>
<td class="num">(1,012,800)<span></span>
</td>
<td class="num">(1,012,800)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NRXS_AllowanceForInterestReceivableCurrent', window );">Allowance for collection risk, interest receivable</a></td>
<td class="num">(188,567)<span></span>
</td>
<td class="num">(141,741)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NRXS_AllowanceForInterestIncomeCurrent', window );">Allowance for collection risk, interest income</a></td>
<td class="num">(46,826)<span></span>
</td>
<td class="num">(47,734)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesAndLoansReceivableNetCurrent', window );">Loan Receivable</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestReceivable', window );">Interest Receivable</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NRXS_InterestIncomeCurrent', window );">Interest Income</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_NRXS_AllowanceForInterestIncomeCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Allowance for interest income current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">NRXS_AllowanceForInterestIncomeCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>NRXS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_NRXS_AllowanceForInterestReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Allowance for interest receivable current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">NRXS_AllowanceForInterestReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>NRXS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_NRXS_InterestIncomeCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Interest income current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">NRXS_InterestIncomeCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>NRXS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_NRXS_InterestIncomeGrossCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Interest income gross current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">NRXS_InterestIncomeGrossCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>NRXS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForNotesAndLoansReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on financing receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479344/326-20-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481962/310-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForNotesAndLoansReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of interest earned but not received. Also called accrued interest or accrued interest receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 310<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477802/946-310-45-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of current interest earned but not received. Also called accrued interest or accrued interest receivable. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesAndLoansReceivableGrossCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost, before allowance for credit loss, of financing receivable classified as current. Excludes net investment in lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479344/326-20-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesAndLoansReceivableGrossCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesAndLoansReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost, after allowance for credit loss, of financing receivable classified as current. Excludes net investment in lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481990/310-10-45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesAndLoansReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481990/310-10-45-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=NRXS_ShareHolderOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=NRXS_ShareHolderOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=NRXS_ShareHolderTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=NRXS_ShareHolderTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Related Party Loans payable to shareholder (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LoansPayable', window );">Loan payable</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NRXS_InterestAndServiceFeeAccrued', window );">Interest payable</a></td>
<td class="nump">66,648<span></span>
</td>
<td class="nump">66,648<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaid', window );">Interest payable</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 37,103<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=NRXS_OtherConvertiblesMember', window );">Other Convertibles [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDateDescription', window );">Due date</a></td>
<td class="text">Various<span></span>
</td>
<td class="text">Various<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt instrument percentage</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LoansPayable', window );">Loan payable</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NRXS_InterestAndServiceFeeAccrued', window );">Interest payable</a></td>
<td class="nump">66,648<span></span>
</td>
<td class="nump">66,648<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaid', window );">Interest payable</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=NRXS_ShareHolderOneMember', window );">Shareholder 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDateDescription', window );">Due date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">June, 2019<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt instrument percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LoansPayable', window );">Loan payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NRXS_InterestAndServiceFeeAccrued', window );">Interest payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaid', window );">Interest payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,047<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=NRXS_ShareHolderTwoMember', window );">Shareholder 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDateDescription', window );">Due date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">June, 2019<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt instrument percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LoansPayable', window );">Loan payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NRXS_InterestAndServiceFeeAccrued', window );">Interest payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaid', window );">Interest payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 27,056<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_NRXS_InterestAndServiceFeeAccrued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Interest and service fee accrued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">NRXS_InterestAndServiceFeeAccrued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>NRXS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentMaturityDateDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of the maturity date of the debt instrument including whether the debt matures serially and, if so, a brief description of the serial maturities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentMaturityDateDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, including, but not limited to, capitalized interest and payment to settle zero-coupon bond attributable to accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount; classified as operating and investing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LoansPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, aggregate carrying value as of the balance sheet date of loans payable (with maturities initially due after one year or beyond the operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LoansPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=NRXS_OtherConvertiblesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=NRXS_OtherConvertiblesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=NRXS_ShareHolderOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=NRXS_ShareHolderOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=NRXS_ShareHolderTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=NRXS_ShareHolderTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NRXS_AllowanceForInterestReceivableCurrent', window );">Allowance for interest receivable current</a></td>
<td class="nump">$ 1,201,367<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Stock issued during period shares issued for services</a></td>
<td class="nump">24,343<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=srt_ChiefFinancialOfficerMember', window );">Chief Financial Officer [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Stock issued during period shares issued for services</a></td>
<td class="nump">20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Stock issued during period value issued for services</a></td>
<td class="nump">$ 55,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=NRXS_ShareholdersOneAndTwoMember', window );">Shareholders 1 and 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesAndLoansReceivableGrossCurrent', window );">Loan Receivable</a></td>
<td class="nump">506,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related Party [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesAndLoansReceivableGrossCurrent', window );">Loan Receivable</a></td>
<td class="nump">1,012,800<span></span>
</td>
<td class="nump">$ 1,012,800<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NRXS_AllowanceForInterestReceivableCurrent', window );">Allowance for interest receivable current</a></td>
<td class="num">(188,567)<span></span>
</td>
<td class="num">(141,741)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAmountsOfTransaction', window );">Related party transaction amounts</a></td>
<td class="nump">4,973<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=NRXS_MrWatkinsMember', window );">Mr. Watkins [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAmountsOfTransaction', window );">Related party transaction amounts</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">11,083<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=NRXS_MrSealeMember', window );">Mr Seale [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForFees', window );">Fees paid for services</a></td>
<td class="nump">207,103<span></span>
</td>
<td class="nump">312,803<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrentAndNoncurrent', window );">Accounts payable</a></td>
<td class="nump">$ 4,173<span></span>
</td>
<td class="nump">$ 84,279<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_NRXS_AllowanceForInterestReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Allowance for interest receivable current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">NRXS_AllowanceForInterestReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>NRXS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(15)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesAndLoansReceivableGrossCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost, before allowance for credit loss, of financing receivable classified as current. Excludes net investment in lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479344/326-20-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesAndLoansReceivableGrossCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for fees classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAmountsOfTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of transactions with related party during the financial reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAmountsOfTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481990/310-10-45-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_ChiefFinancialOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_ChiefFinancialOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=NRXS_ShareholdersOneAndTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=NRXS_ShareholdersOneAndTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=NRXS_MrWatkinsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=NRXS_MrWatkinsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=NRXS_MrSealeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=NRXS_MrSealeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Schedule of Property And Equipment (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">$ 464,402<span></span>
</td>
<td class="nump">$ 436,626<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: accumulated depreciation</a></td>
<td class="num">(374,420)<span></span>
</td>
<td class="num">(348,074)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">89,982<span></span>
</td>
<td class="nump">88,552<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember', window );">Machinery and Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">282,181<span></span>
</td>
<td class="nump">282,181<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and Fixtures [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">111,036<span></span>
</td>
<td class="nump">96,768<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">50,121<span></span>
</td>
<td class="nump">36,613<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold Improvements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">$ 21,064<span></span>
</td>
<td class="nump">$ 21,064<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">$ 26,346<span></span>
</td>
<td class="nump">$ 30,240<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=NRXS_DecemberTwoThousandTwentyFiveMember', window );">December Two Thousand Twenty Five [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">13,438<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=NRXS_DecemberTwoThousandTwentySixMember', window );">December Two Thousand Twenty Six [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">12,344<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=NRXS_DecemberTwoThousandTwentySevenMember', window );">December Two Thousand Twenty Seven [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">11,977<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=NRXS_DecemberTwoThousandTwentyEightMember', window );">December Two Thousand Twenty Eight [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">9,753<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=NRXS_DecemberTwoThousandTwentyNineMember', window );">December Two Thousand Twenty Nine [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">6,259<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=NRXS_DecemberTwoThousandTwentyThereafterMember', window );">December Two Thousand Twenty Thereafter [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">$ 14,111<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=NRXS_DecemberTwoThousandTwentyFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=NRXS_DecemberTwoThousandTwentyFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=NRXS_DecemberTwoThousandTwentySixMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=NRXS_DecemberTwoThousandTwentySixMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=NRXS_DecemberTwoThousandTwentySevenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=NRXS_DecemberTwoThousandTwentySevenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=NRXS_DecemberTwoThousandTwentyEightMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=NRXS_DecemberTwoThousandTwentyEightMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=NRXS_DecemberTwoThousandTwentyNineMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=NRXS_DecemberTwoThousandTwentyNineMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=NRXS_DecemberTwoThousandTwentyThereafterMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=NRXS_DecemberTwoThousandTwentyThereafterMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Schedule of Intangible Assets (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Total intangible assets</a></td>
<td class="nump">$ 133,278<span></span>
</td>
<td class="nump">$ 133,278<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Less: accumulated amortization</a></td>
<td class="num">(36,690)<span></span>
</td>
<td class="num">(25,205)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Intangible assets, net</a></td>
<td class="nump">96,588<span></span>
</td>
<td class="nump">108,073<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=NRXS_SoftwareImplementationMember', window );">Software Implementation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Total intangible assets</a></td>
<td class="nump">49,815<span></span>
</td>
<td class="nump">49,815<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember', window );">Patents [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Total intangible assets</a></td>
<td class="nump">32,463<span></span>
</td>
<td class="nump">32,463<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksMember', window );">Trademarks [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Total intangible assets</a></td>
<td class="nump">50,000<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=NRXS_LicensesMember', window );">Licenses [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Total intangible assets</a></td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480265/350-10-S45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480265/350-10-S45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 928<br> -SubTopic 340<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478859/928-340-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483154/926-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483154/926-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=NRXS_SoftwareImplementationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=NRXS_SoftwareImplementationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=NRXS_LicensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=NRXS_LicensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization expense</a></td>
<td class="nump">$ 11,485<span></span>
</td>
<td class="nump">$ 10,485<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=NRXS_DecemberTwoThousandTwentyFiveMember', window );">December Two Thousand Twenty Five [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization expense</a></td>
<td class="nump">10,485<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=NRXS_DecemberTwoThousandTwentySixMember', window );">December Two Thousand Twenty Six [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization expense</a></td>
<td class="nump">10,485<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=NRXS_DecemberTwoThousandTwentySevenMember', window );">December Two Thousand Twenty Seven [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization expense</a></td>
<td class="nump">10,485<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=NRXS_DecemberTwoThousandTwentyEightMember', window );">December Two Thousand Twenty Eight [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization expense</a></td>
<td class="nump">4,760<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=NRXS_DecemberTwoThousandTwentyNineMember', window );">December Two Thousand Twenty Nine [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization expense</a></td>
<td class="nump">1,941<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=NRXS_DecemberTwoThousandTwentyThereafterMember', window );">December Two Thousand Twenty Thereafter [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization expense</a></td>
<td class="nump">$ 8,432<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=NRXS_DecemberTwoThousandTwentyFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=NRXS_DecemberTwoThousandTwentyFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=NRXS_DecemberTwoThousandTwentySixMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=NRXS_DecemberTwoThousandTwentySixMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=NRXS_DecemberTwoThousandTwentySevenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=NRXS_DecemberTwoThousandTwentySevenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=NRXS_DecemberTwoThousandTwentyEightMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=NRXS_DecemberTwoThousandTwentyEightMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=NRXS_DecemberTwoThousandTwentyNineMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=NRXS_DecemberTwoThousandTwentyNineMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=NRXS_DecemberTwoThousandTwentyThereafterMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=NRXS_DecemberTwoThousandTwentyThereafterMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Schedule of Accrued Expenses (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NRXS_AccruedCompensationAndBenefitsCurrent', window );">Compensation and benefits</a></td>
<td class="nump">$ 1,261,317<span></span>
</td>
<td class="nump">$ 333,477<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NRXS_AdvisoryFees', window );">Advisory fees</a></td>
<td class="nump">176,750<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPayableCurrent', window );">Interest</a></td>
<td class="nump">66,648<span></span>
</td>
<td class="nump">66,648<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent', window );">Other</a></td>
<td class="nump">73,065<span></span>
</td>
<td class="nump">963<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Total accrued expenses</a></td>
<td class="nump">$ 1,577,780<span></span>
</td>
<td class="nump">$ 401,088<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_NRXS_AccruedCompensationAndBenefitsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued compensation and benefits current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">NRXS_AccruedCompensationAndBenefitsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>NRXS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_NRXS_AdvisoryFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Advisory fees</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">NRXS_AdvisoryFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>NRXS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for real and property taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 720<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483384/720-30-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 8<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Notes Payable (Details Narrative)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Nov. 11, 2024 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Nov. 01, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Aug. 15, 2024 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Aug. 09, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Feb. 12, 2024 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Nov. 08, 2023 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Aug. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Aug. 09, 2023 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 16, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 19, 2022 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Nov. 30, 2022 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Jan. 01, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Nov. 30, 2022 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 21, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Dec. 12, 2024</div></th>
<th class="th">
<div>Nov. 13, 2024 </div>
<div>shares</div>
</th>
<th class="th"><div>Sep. 15, 2024</div></th>
<th class="th">
<div>May 24, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Feb. 15, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th">
<div>Sep. 16, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 16, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Proceeds from issuance of ipo</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,110,677<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Conversion price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Extinguishment of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">$ (3,649,561)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion', window );">Convertible Preferred Stock, Shares Issued upon Conversion | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,260,504<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">506,637<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Stock Issued During Period, Value, New Issues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,408,011<span></span>
</td>
<td class="nump">$ 750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid', window );">Debt Instrument, Periodic Payment Terms, Balloon Payment to be Paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleDebt', window );">Convertible debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,120,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesConverted1', window );">Number of shares converted | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">59,055<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 174,328<span></span>
</td>
<td class="nump">$ 476,416<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent', window );">Accrued Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 66,648<span></span>
</td>
<td class="nump">$ 66,648<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember', window );">Series B Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfDebt', window );">Net proceeds of debt</a></td>
<td class="nump">$ 99,164<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.38<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.38<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NRXS_CumulativeDividendsPercent', window );">Cumulative dividends percent</a></td>
<td class="nump">8.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockConvertibleConversionPriceDecrease', window );">Common stock conversion price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.38<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.38<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized | shares</a></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Temporary equity, shares authorized | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock Issued During Period, Shares, New Issues | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">470,330<span></span>
</td>
<td class="nump">425,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Stock Issued During Period, Value, New Issues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 470<span></span>
</td>
<td class="nump">$ 425<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=NRXS_PromissoryNoteMember', window );">Promissory Note [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayable', window );">Promissory note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 210,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt instrument interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Maturity date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jun.  09,  2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=NRXS_SecondPromissoryNoteMember', window );">Second Promissory Note [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Outstanding promissory notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 64,328<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">154,152<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt instrument interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.65%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Maturity date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Sep.  01,  2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=NRXS_TwoThousandTwentyTwoConvertibleNotesMember', window );">2022 Convertible Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Debt instrument interest rate effective percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt instrument interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Proceeds from issuance of ipo</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 239,104<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Debt instrument gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">222,222<span></span>
</td>
<td class="nump">$ 3,333,333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,333,333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfDebt', window );">Net proceeds of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="nump">$ 2,870,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentDescriptionOfVariableRateBasis', window );">Debt instrument description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">original
issue discount of 10% with an interest rate of the greater of (i) Prime rate plus 8.5% or (ii) 12% resulting in an effective
interest rate of 24.2%.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Conversion price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9.44<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NRXS_DebtInstrumentDiscountRate', window );">Discount rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NRXS_DebtWarrantConversionDescription', window );">Debt warrant conversion, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">a
five-year warrant to purchase common stock equal to one hundred percent (100%) of the shares into which the 2022 Convertible Notes
could be converted into at issuance.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11.80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11.80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NRXS_ClassOfWarrantDiscountRate', window );">Class of warrant discount rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=NRXS_TwoThousandTwentyTwoConvertibleNotesMember', window );">2022 Convertible Notes [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Conversion price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9.44<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9.44<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=NRXS_TwoThousandTwentyTwoConvertibleNotesMember', window );">2022 Convertible Notes [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NRXS_DebtInstrumentDiscountRate', window );">Discount rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=NRXS_ConvertiblePromissoryNoteMember', window );">Convertible Promissory Note [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt instrument interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NRXS_DebtInstrumentDiscountRate', window );">Discount rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NRXS_DebtWarrantConversionDescription', window );">Debt warrant conversion, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">a
five-year warrant to purchase common stock equal to fifty percent (50%) of the shares into which the 2032 Convertible Notes could be
converted into at issuance.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionRatio1', window );">Strilke price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=NRXS_ConvertiblePromissoryNoteMember', window );">Convertible Promissory Note [Member] | Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NRXS_DebtInstrumentDiscountRate', window );">Discount rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=NRXS_ConvertiblePromissoryNoteMember', window );">Convertible Promissory Note [Member] | Accredited Investors [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Debt instrument gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,066,667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfDebt', window );">Net proceeds of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,908,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=NRXS_TwoThousandTwentyThreeConvertibleNotesMember', window );">2023 Convertible Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayable', window );">Promissory note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 173,205<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,650,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Debt instrument interest rate effective percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt instrument interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Proceeds from issuance of ipo</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">445,544<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Conversion price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.35<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NRXS_DebtInstrumentDiscountRate', window );">Discount rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Extinguishment of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 663,991<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,129,653<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock Issued During Period, Shares, New Issues | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">107,509<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares Issued, Price Per Share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.35<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=NRXS_ConvertiblePromissoryNotesMember', window );">Convertible Promissory Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentPeriodicPayment', window );">Principal amount due in monthly installments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,935,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleDebt', window );">Convertible debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAnnualPrincipalPayment', window );">Total principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,135,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=NRXS_ConvertiblePromissoryNotesMember', window );">Convertible Promissory Notes [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromContributedCapital', window );">Shareholder funded</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=NRXS_ConvertiblePromissoryNotesMember', window );">Convertible Promissory Notes [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromContributedCapital', window );">Shareholder funded</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=NRXS_TwoThousandTwentyFourConvertiblePromissoryNotesMember', window );">2024 Convertible Promissory Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Debt instrument interest rate effective percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleDebt', window );">Convertible debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionOriginalDebtInterestRateOfDebt', window );">Debt conversion, original debt, interest rate of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnamortizedDebtIssuanceExpense', window );">Unamortized Debt Issuance Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 165,577<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=NRXS_TwoThousandTwentyFourConvertiblePromissoryNotesMember', window );">2024 Convertible Promissory Notes [Member] | Series B Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.38<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Temporary equity, shares authorized | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesConverted1', window );">Number of shares converted | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,073,524<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NRXS_CommonStockConvertibleConversionPrice', window );">Common stock conversion price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.38<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=NRXS_TwoThousandTwentyFourConvertiblePromissoryNotesMember', window );">2024 Convertible Promissory Notes [Member] | Minimum [Member] | Series B Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NRXS_DebtInstrumentDiscountRate', window );">Discount rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.99%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=NRXS_TwoThousandTwentyFourConvertiblePromissoryNotesMember', window );">2024 Convertible Promissory Notes [Member] | Maximum [Member] | Series B Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NRXS_DebtInstrumentDiscountRate', window );">Discount rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19.99%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=NRXS_TwoThousandTwentyFourConvertibleNotesMember', window );">2024 Convertible Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentPeriodicPayment', window );">Principal amount due in monthly installments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,935,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=NRXS_TwoThousandTwentyFourConvertibleNotesMember', window );">2024 Convertible Notes [Member] | Series B Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentPeriodicPayment', window );">Principal amount due in monthly installments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,935,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=NRXS_ChannelPartnersCapitalMember', window );">Channel Partners Capital [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Outstanding promissory notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 107,231<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 122,000<span></span>
</td>
<td class="nump">$ 250,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentPeriodicPayment', window );">Principal amount due in monthly installments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,923<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtAverageAmountOutstanding', window );">Long-Term Debt, Average Amount Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 244,048<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRepurchasedFaceAmount', window );">Debt Instrument, Repurchased Face Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayable', window );">Promissory note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 226,391<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 148,062<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Debt instrument interest rate effective percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">55.90%<span></span>
</td>
<td class="nump">55.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Extinguishment of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,115,223<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock Issued During Period, Shares, New Issues | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,498,332<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares Issued, Price Per Share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=NRXS_ExchangeListingLLCMember', window );">Exchange Listing LLC [Member] | Promissory Note [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Outstanding promissory notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 52,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayable', window );">Promissory note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt instrument interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Proceeds from issuance of ipo</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 52,858<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=NRXS_SignatureBankMember', window );">Signature Bank [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EscrowDeposit', window );">Escrow deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=NRXS_AlexanderCapitalLPMember', window );">Alexander Capital LP [Member] | Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromFeesReceived', window );">Deferred financing fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 546,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of warrants received | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">120,235<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_NRXS_ClassOfWarrantDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class of warrant discount rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">NRXS_ClassOfWarrantDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>NRXS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_NRXS_CommonStockConvertibleConversionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common stock convertible conversion price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">NRXS_CommonStockConvertibleConversionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>NRXS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_NRXS_CumulativeDividendsPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of cumulative dividends.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">NRXS_CumulativeDividendsPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>NRXS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_NRXS_DebtInstrumentDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt instrument discount rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">NRXS_DebtInstrumentDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>NRXS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_NRXS_DebtWarrantConversionDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt warrant conversion description.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">NRXS_DebtWarrantConversionDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>NRXS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockConvertibleConversionPriceDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share decrease in conversion price of convertible common stock. Excludes change due to standard antidilution provision.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockConvertibleConversionPriceDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockSharesConverted1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockSharesConverted1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, carrying amount of debt identified as being convertible into another form of financial instrument (typically the entity's common stock) as of the balance sheet date, which originally required full repayment more than twelve months after issuance or greater than the normal operating cycle of the company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for each share of convertible preferred stock that is converted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionOriginalDebtInterestRateOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The rate of interest that was being paid on the original debt issue that is being converted in the noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionOriginalDebtInterestRateOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAnnualPrincipalPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of annual principal payment for debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAnnualPrincipalPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionPrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The price per share of the conversion feature embedded in the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionPrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of debt instrument into equity with equity shares divided by debt principal amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-7<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentDescriptionOfVariableRateBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of reference rate used for variable rate of debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentDescriptionOfVariableRateBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateEffectivePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentPeriodicPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the required periodic payments including both interest and principal payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477734/942-470-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentPeriodicPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of payment greater than the preceding installment payments to be paid at final maturity date of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRepurchasedFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of the original debt instrument that was repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRepurchasedFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EscrowDeposit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The designation of funds furnished by a borrower to a lender to assure future payments of the borrower's real estate taxes and insurance obligations with respect to a mortgaged property. Escrow deposits may be made for a variety of other purposes such as earnest money and contingent payments. This element excludes replacement reserves which are an escrow separately provided for within the US GAAP taxonomy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478522/954-440-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EscrowDeposit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481303/470-50-40-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481303/470-50-40-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense classified as operating and nonoperating. Includes, but is not limited to, cost of borrowing accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-24<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483013/835-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtAverageAmountOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Average amount outstanding of long-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Regulation S-K (SK)<br> -Number 229<br> -Section 1402<br> -Paragraph a<br> -Publisher SEC<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Regulation S-K (SK)<br> -Number 229<br> -Section 1402<br> -Paragraph b<br> -Subparagraph (1)<br> -Publisher SEC<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtAverageAmountOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromContributedCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received by a corporation from a shareholder during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromContributedCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromFeesReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received for fees during the current period. This element excludes cash proceeds from license fees.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromFeesReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of securities classified as temporary equity that are permitted to be issued by an entity's charter and bylaws. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnamortizedDebtIssuanceExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The remaining balance of debt issuance expenses that were capitalized and are being amortized against income over the lives of the respective bond issues. This does not include the amounts capitalized as part of the cost of the utility plant or asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnamortizedDebtIssuanceExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=NRXS_PromissoryNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=NRXS_PromissoryNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=NRXS_SecondPromissoryNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=NRXS_SecondPromissoryNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=NRXS_TwoThousandTwentyTwoConvertibleNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=NRXS_TwoThousandTwentyTwoConvertibleNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=NRXS_ConvertiblePromissoryNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=NRXS_ConvertiblePromissoryNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=NRXS_AccreditedInvestorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=NRXS_AccreditedInvestorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=NRXS_TwoThousandTwentyThreeConvertibleNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=NRXS_TwoThousandTwentyThreeConvertibleNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=NRXS_ConvertiblePromissoryNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=NRXS_ConvertiblePromissoryNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=NRXS_TwoThousandTwentyFourConvertiblePromissoryNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=NRXS_TwoThousandTwentyFourConvertiblePromissoryNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=NRXS_TwoThousandTwentyFourConvertibleNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=NRXS_TwoThousandTwentyFourConvertibleNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=NRXS_ChannelPartnersCapitalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=NRXS_ChannelPartnersCapitalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=NRXS_ExchangeListingLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=NRXS_ExchangeListingLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=NRXS_SignatureBankMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=NRXS_SignatureBankMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=NRXS_AlexanderCapitalLPMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=NRXS_AlexanderCapitalLPMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Schedule of Operating Leases (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NRXS_DisclosureLeasesAbstract', window );"><strong>Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">$ 284,656<span></span>
</td>
<td class="nump">$ 70,263<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Other current liabilities</a></td>
<td class="nump">62,754<span></span>
</td>
<td class="nump">49,127<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities</a></td>
<td class="nump">256,499<span></span>
</td>
<td class="nump">27,071<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total</a></td>
<td class="nump">$ 319,253<span></span>
</td>
<td class="nump">$ 76,198<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted average remaining lease term (in years)</a></td>
<td class="text">2 years 9 months<span></span>
</td>
<td class="text">3 years 9 months<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted average discount rate</a></td>
<td class="nump">15.00%<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_NRXS_DisclosureLeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">NRXS_DisclosureLeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>NRXS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Schedule of Maturities Operating Lease Liabilities (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NRXS_DisclosureLeasesAbstract', window );"><strong>Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2025</a></td>
<td class="nump">$ 105,130<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2026</a></td>
<td class="nump">108,106<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2027</a></td>
<td class="nump">86,856<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2028</a></td>
<td class="nump">89,027<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive', window );">2029</a></td>
<td class="nump">38,025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total lease payments</a></td>
<td class="nump">427,144<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: imputed interest</a></td>
<td class="num">(107,891)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total present value of lease payments</a></td>
<td class="nump">$ 319,253<span></span>
</td>
<td class="nump">$ 76,198<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_NRXS_DisclosureLeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">NRXS_DisclosureLeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>NRXS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 01, 2024</div></th>
<th class="th"><div>Jan. 01, 2022</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseDescription', window );">Operating lease description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The lease in Versailles, Indiana
started January 1, 2022 and had a term of one year, with automatic one year renewal options, unless 60 day notice of vacating is given.
The current monthly lease payment for this lease is $1,800&#160;with a&#160;4% per annum increase. A new lease in Carmel, Indiana commenced
January 1, 2024. The initial term is five years and five months. The monthly lease payment started at $6,721&#160;with an annual increase
of&#160;2.5%. As long as the Company is not in default, it is only obligated to pay an amount equal to 50% of the monthly base rent for
months 1-10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Operating lease expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 96,177<span></span>
</td>
<td class="nump">$ 49,051<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeographicDistributionAxis=NRXS_VersaillesIndianaMember', window );">Versailles Indiana [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Operating lease payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseDiscountRate', window );">Operating lease payment rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeographicDistributionAxis=NRXS_CarmelIndianaMember', window );">Carmel Indiana [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Operating lease payment</a></td>
<td class="nump">$ 6,721<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseDiscountRate', window );">Operating lease payment rate</a></td>
<td class="nump">2.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of lessee's operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Discount rate used by lessee to determine present value of operating lease payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating lease expense. Excludes sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-5<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeographicDistributionAxis=NRXS_VersaillesIndianaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeographicDistributionAxis=NRXS_VersaillesIndianaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeographicDistributionAxis=NRXS_CarmelIndianaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeographicDistributionAxis=NRXS_CarmelIndianaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Warrant Activity for Common Stock (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Outstanding at beginning of period</a></td>
<td class="nump">$ 6.94<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Life - Warrants</a></td>
<td class="text">4 years 8 months 8 days<span></span>
</td>
<td class="text">5 years 8 months 8 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Outstanding at Ending of period</a></td>
<td class="nump">$ 6.94<span></span>
</td>
<td class="nump">$ 6.94<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Number of Warrants, Outstanding at beginning of period</a></td>
<td class="nump">1,822,358<span></span>
</td>
<td class="nump">846,507<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Outstanding at beginning of period</a></td>
<td class="nump">$ 4.69<span></span>
</td>
<td class="nump">$ 5.06<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Life - Warrants</a></td>
<td class="text">2 years 11 months 4 days<span></span>
</td>
<td class="text">3 years 18 days<span></span>
</td>
<td class="text">4 years 8 months 19 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted', window );">Number of Warrants, Granted</a></td>
<td class="nump">861,424<span></span>
</td>
<td class="nump">813,928<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, granted</a></td>
<td class="nump">$ 2.38<span></span>
</td>
<td class="nump">$ 5.81<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NRXS_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsWeightedAverageRemainingContracualLifeOutstandingNumberGranted', window );">Weighted Average Remaining Contractual Life - Warrants Granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years 4 months 17 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NRXS_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsConvertedPrefundedWarrants', window );">Number of Warrants, Converted Prefunded Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">289,779<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NRXS_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsConvertedPrefundedWarrantsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Converted Prefunded Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations', window );">Number of Warrants, Granted</a></td>
<td class="nump">30,252<span></span>
</td>
<td class="num">(30,252)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NRXS_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsWeightedAverageExercisePriceCancelledExpiredNumber', window );">Weighted Average Exercise Price, Cancelled Expired</a></td>
<td class="nump">2.38<span></span>
</td>
<td class="nump">2.38<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NRXS_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsCancelledWeightedAverageRemainingContractualTerm1', window );">Weighted Average Remaining Contractual Life - Warrants Cancelled</a></td>
<td class="text">4 years 9 months 14 days<span></span>
</td>
<td class="text">4 years 9 months 14 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised', window );">Number of Warrants, Exercised</a></td>
<td class="num">(11,000)<span></span>
</td>
<td class="num">(127,856)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Excercised</a></td>
<td class="nump">$ 2.38<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted Average Remaining Contractual Life - Warrants Granted</a></td>
<td class="text">3 years 5 months 26 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations', window );">Number of Warrants, Granted</a></td>
<td class="num">(30,252)<span></span>
</td>
<td class="nump">30,252<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NRXS_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisedWeightedAverageRemainingContractualTerm1', window );">Weighted Average Remaining Contractual Life - Warrants Granted</a></td>
<td class="text">3 years 7 months 9 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Number of Warrants, Outstanding at Ending of period</a></td>
<td class="nump">2,642,530<span></span>
</td>
<td class="nump">1,822,358<span></span>
</td>
<td class="nump">846,507<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Outstanding at Ending of period</a></td>
<td class="nump">$ 2.41<span></span>
</td>
<td class="nump">$ 4.69<span></span>
</td>
<td class="nump">$ 5.06<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_NRXS_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsConvertedPrefundedWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award non option equity instruments converted prefunded warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">NRXS_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsConvertedPrefundedWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>NRXS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_NRXS_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsWeightedAverageExercisePriceCancelledExpiredNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award non options weighted average exercise price cancelled expired number.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">NRXS_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsWeightedAverageExercisePriceCancelledExpiredNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>NRXS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_NRXS_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsWeightedAverageRemainingContracualLifeOutstandingNumberGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award non options weighted average remaining contracual life outstanding number granted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">NRXS_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsWeightedAverageRemainingContracualLifeOutstandingNumberGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>NRXS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_NRXS_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsConvertedPrefundedWarrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangements by share based payment award options converted prefunded warrants in period weighted average exercise price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">NRXS_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsConvertedPrefundedWarrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>NRXS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_NRXS_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsCancelledWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by sharebased payment award options cancelled weighted average remaining contractual term 1.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">NRXS_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsCancelledWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>NRXS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_NRXS_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisedWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sharebased compensation arrangement by sharebased payment award options exercised weighted average remaining contractual term 1.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">NRXS_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisedWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>NRXS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481674/830-30-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-17<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of non-option equity instruments exercised by participants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares under non-option equity instrument agreements that were either cancelled or expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net number of non-option equity instruments granted to participants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of equity instruments other than options outstanding, including both vested and non-vested instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Warrant Activity for Preferred Stock (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Outstanding at beginning of period</a></td>
<td class="nump">$ 6.94<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Outstanding at Ending of period</a></td>
<td class="nump">$ 6.94<span></span>
</td>
<td class="nump">$ 6.94<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_PreferredStockMember', window );">Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Number of Warrants, Outstanding at beginning of period</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">144,890<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Outstanding at beginning of period</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted', window );">Number of Warrants, Granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations', window );">Number of Warrants, Cancelled Expired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NRXS_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsWeightedAverageExercisePriceCancelledExpiredNumber', window );">Weighted Average Exercise Price, Cancelled Expired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NRXS_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsCommonStockWarrant', window );">Converted to Common Stock Warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(144,890)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NRXS_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsWeightedAverageExercisePriceCommonStockWarrant', window );">Weighted Average Exercise Price, Converted to Common Stock Warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(0.01)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Number of Warrants, Outstanding at Ending of period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Outstanding at Ending of period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_NRXS_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsCommonStockWarrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award non option equity instruments common stock warrant.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">NRXS_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsCommonStockWarrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>NRXS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_NRXS_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsWeightedAverageExercisePriceCancelledExpiredNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award non options weighted average exercise price cancelled expired number.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">NRXS_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsWeightedAverageExercisePriceCancelledExpiredNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>NRXS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_NRXS_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsWeightedAverageExercisePriceCommonStockWarrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award non options weighted average exercise price common stock warrant.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">NRXS_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsWeightedAverageExercisePriceCommonStockWarrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>NRXS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481674/830-30-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-17<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares under non-option equity instrument agreements that were either cancelled or expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net number of non-option equity instruments granted to participants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of equity instruments other than options outstanding, including both vested and non-vested instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_PreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_PreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Warrants outstanding and Exercisable (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2024 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of Warrants</a></td>
<td class="nump">2,642,530<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=NRXS_InvestorWarrantOneMember', window );">Investor Warrant W-01 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of Warrants</a></td>
<td class="nump">12,852<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price | $ / shares</a></td>
<td class="nump">$ 8.76<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMaturityDate', window );">Expiration Date</a></td>
<td class="text">Sep. 18,  2028<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=NRXS_InvestorWarrantPSAOneMember', window );">Investor Warrant PSA-01 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of Warrants</a></td>
<td class="nump">289,779<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price | $ / shares</a></td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NRXS_WarrantExpirationDateDescription', window );">Expiration Date</a></td>
<td class="text">None<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=NRXS_TwoThousandTwentyTwoConvertibleNotesMember', window );">2022 Convertible Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of Warrants</a></td>
<td class="nump">782,655<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price | $ / shares</a></td>
<td class="nump">$ 2.38<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NRXS_WarrantExpirationDateDescription', window );">Expiration Date</a></td>
<td class="text">Various in 2027<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=NRXS_TwoThousandTwentyThreeConvertibleNotesMember', window );">2023 Convertible Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of Warrants</a></td>
<td class="nump">1,149,586<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price | $ / shares</a></td>
<td class="nump">$ 2.38<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NRXS_WarrantExpirationDateDescription', window );">Expiration Date</a></td>
<td class="text">Various in 2028<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=NRXS_UnderwriterWarrantsMember', window );">Underwriter Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of Warrants</a></td>
<td class="nump">331,146<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price | $ / shares</a></td>
<td class="nump">$ 2.38<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMaturityDate', window );">Expiration Date</a></td>
<td class="text">Aug.  08,  2028<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=NRXS_AdvisoryAgreementWarrantsMember', window );">Advisory Agreement Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of Warrants</a></td>
<td class="nump">76,512<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price | $ / shares</a></td>
<td class="nump">$ 2.38<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NRXS_WarrantExpirationDateDescription', window );">Expiration Date</a></td>
<td class="text">Various in 2029<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_NRXS_WarrantExpirationDateDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrant expiration date description.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">NRXS_WarrantExpirationDateDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>NRXS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expiration date of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=NRXS_InvestorWarrantOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=NRXS_InvestorWarrantOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=NRXS_InvestorWarrantPSAOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=NRXS_InvestorWarrantPSAOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=NRXS_TwoThousandTwentyTwoConvertibleNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=NRXS_TwoThousandTwentyTwoConvertibleNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=NRXS_TwoThousandTwentyThreeConvertibleNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=NRXS_TwoThousandTwentyThreeConvertibleNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=NRXS_UnderwriterWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=NRXS_UnderwriterWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=NRXS_AdvisoryAgreementWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=NRXS_AdvisoryAgreementWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common Stock and Warrants (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jan. 10, 2023</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Nov. 08, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares, issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,990,227<span></span>
</td>
<td class="nump">6,508,897<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares, outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,990,227<span></span>
</td>
<td class="nump">6,508,897<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityReverseStockSplit', window );">Reverse stock split</a></td>
<td class="text">2-for-1 reverse stock split.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NRXS_StockIssuedDuringPeriodSharesCommonStockIssuedUponInitialPublicOffering', window );">Common shares, issued upon initial public offering, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">245,955<span></span>
</td>
<td class="nump">1,098,667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Common shares, per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Net proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,110,677<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Conversion shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,244,228<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion', window );">Shares issued upon conversion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">506,637<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,260,504<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesConverted1', window );">Conversion, interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">59,055<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Service for payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,343<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,642,530<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NRXS_NumberOfEquivalentOfWarrantsDescription', window );">Number of equivalent of warrants, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">investors converted  11,000 warrants into an equivalent number of common shares at an exercise price of $2.38 in exchange
for $26,180 in cash proceeds.<span></span>
</td>
<td class="text">investors converted (i) 87,856
warrants into an equivalent number of common shares at an exercise price of $2.38 in exchange for $209,097 in cash proceeds and (ii)
40,000 warrants into 39,924 common shares in a cashless exercise transaction.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=NRXS_EmployementAgreementMember', window );">Employement Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Service for payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,832<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=NRXS_TwoThousandTwentyThreeConvertiblePromissoryNotesMember', window );">2023 Convertible Promissory Notes [Membe]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">505,570<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares Issued, Price Per Share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.25<span></span>
</td>
<td class="nump">$ 5.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=NRXS_TwoThousandTwentyTwoConvertibleNotesMember', window );">2022 Convertible Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrants, term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=NRXS_AdvisoryAgreementMember', window );">Advisory Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">122,202<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrants, term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares Issued, Price Per Share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=NRXS_UnderwritingAgreementMember', window );">Underwriting Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">186,156<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrants, term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares Issued, Price Per Share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=NRXS_TwoThousandTwentyFourConvertiblePromissoryNotesMember', window );">2024 Convertible Promissory Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38,697<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrants, term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares Issued, Price Per Share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.38<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NRXS_ClassOfWarrantOrRightAdditional', window );">Number of Warrants, additional</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">754,660<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=NRXS_AdvisoryAgreementsMember', window );">Advisory Agreements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">68,067<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrants, term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares Issued, Price Per Share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.38<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=NRXS_VendorsMember', window );">Vendors [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Service for payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">115,145<span></span>
</td>
<td class="nump">425,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NRXS_StockIssuedDuringPeriodSharesCommonStockIssuedUponInitialPublicOffering', window );">Common shares, issued upon initial public offering, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,098,667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits', window );">Common stock issued upon debt conversion, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,649,900<span></span>
</td>
<td class="nump">1,649,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations', window );">Warrants, canceled</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,252<span></span>
</td>
<td class="num">(30,252)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember', window );">Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesIssued1', window );">Exercise of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,000<span></span>
</td>
<td class="nump">127,780<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=NRXS_ConvertibleSeriesSeedPreferredStockMember', window );">Convertible Series Seed Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesConverted1', window );">Conversion, interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">115,477<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_NRXS_ClassOfWarrantOrRightAdditional">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class of warrant or right additional.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">NRXS_ClassOfWarrantOrRightAdditional</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>NRXS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_NRXS_NumberOfEquivalentOfWarrantsDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of equivalent of warrants description.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">NRXS_NumberOfEquivalentOfWarrantsDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>NRXS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_NRXS_StockIssuedDuringPeriodSharesCommonStockIssuedUponInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period shares common stock issued upon initial public offering</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">NRXS_StockIssuedDuringPeriodSharesCommonStockIssuedUponInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>NRXS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483014/272-10-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482987/272-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockSharesConverted1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockSharesConverted1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockSharesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of new shares issued in the conversion of stock in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockSharesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for each share of convertible preferred stock that is converted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentSharesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares under non-option equity instrument agreements that were either cancelled or expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued during the period upon the conversion of units. An example of a convertible unit is an umbrella partnership real estate investment trust unit (UPREIT unit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityReverseStockSplit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB Topic 4.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityReverseStockSplit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=NRXS_EmployementAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=NRXS_EmployementAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=NRXS_TwoThousandTwentyThreeConvertiblePromissoryNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=NRXS_TwoThousandTwentyThreeConvertiblePromissoryNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=NRXS_TwoThousandTwentyTwoConvertibleNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=NRXS_TwoThousandTwentyTwoConvertibleNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=NRXS_AdvisoryAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=NRXS_AdvisoryAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=NRXS_UnderwritingAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=NRXS_UnderwritingAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=NRXS_TwoThousandTwentyFourConvertiblePromissoryNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=NRXS_TwoThousandTwentyFourConvertiblePromissoryNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=NRXS_AdvisoryAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=NRXS_AdvisoryAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=NRXS_VendorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=NRXS_VendorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=NRXS_ConvertibleSeriesSeedPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=NRXS_ConvertibleSeriesSeedPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Preferred Stock (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Nov. 11, 2024</div></th>
<th class="th"><div>Aug. 15, 2024</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Nov. 13, 2024</div></th>
<th class="th"><div>Feb. 12, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,120,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesConverted1', window );">Shares converted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">59,055<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DividendsPreferredStock', window );">Dividends</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 211,268<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=NRXS_AmendedTwoThousandTwentyFourConvertibleNotesMember', window );">Amended 2024 Convertible Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Borrowed amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,935,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockDividendRatePercentage', window );">Preferred stock dividend rate percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=NRXS_SeriesSeedPreferredStockMember', window );">Series Seed Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">120,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NRXS_PreferredStockSharesRetiredDescription', window );">Preferred stock, retired description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember', window );">Series B Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,280,939<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockDividendRatePercentage', window );">Preferred stock dividend rate percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Temporary equity, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 2.38<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.38<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NRXS_ProceedsFromIssuanceOfStock', window );">Issuance of debt, shares</a></td>
<td class="nump">41,662<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfDebt', window );">Issuance of debt</a></td>
<td class="nump">$ 99,164<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NRXS_CumulativeDividendsPercent', window );">Cumulative dividends percent</a></td>
<td class="nump">8.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,100,840<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DividendsPreferredStock', window );">Dividends</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 211,268<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockDividendRatePerDollarAmount', window );">Dividends, preferred stock per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.05<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember', window );">Series B Preferred Stock [Member] | Amended 2024 Convertible Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesConverted1', window );">Shares converted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,073,524<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Conversion per shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.38<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NRXS_ProceedsFromIssuanceOfStock', window );">Issuance of debt, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">64,913<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfDebt', window );">Issuance of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 154,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_PreferredStockMember', window );">Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DividendsPayableCurrentAndNoncurrent', window );">Dividends declared</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_NRXS_CumulativeDividendsPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of cumulative dividends.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">NRXS_CumulativeDividendsPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>NRXS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_NRXS_PreferredStockSharesRetiredDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Preferred stock shares retired description.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">NRXS_PreferredStockSharesRetiredDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>NRXS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_NRXS_ProceedsFromIssuanceOfStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from issuance of stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">NRXS_ProceedsFromIssuanceOfStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>NRXS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483014/272-10-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482987/272-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockSharesConverted1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockSharesConverted1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsPayableCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of dividends declared but unpaid on equity securities issued by the entity and outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 405<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478790/946-405-45-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(15)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsPayableCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsPreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of paid and unpaid preferred stock dividends declared with the form of settlement in cash, stock and payment-in-kind (PIK).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -SubTopic 405<br> -Topic 942<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477787/942-405-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsPreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockDividendRatePerDollarAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount per share used to calculated dividend payments on preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockDividendRatePerDollarAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockDividendRatePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage rate used to calculate dividend payments on preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.12-12A(Column A)(Footnote 3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column A)(Footnote 4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column A)(Footnote 3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A)(Footnote 3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockDividendRatePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of securities classified as temporary equity that are permitted to be issued by an entity's charter and bylaws. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTypeAxis=NRXS_AmendedTwoThousandTwentyFourConvertibleNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTypeAxis=NRXS_AmendedTwoThousandTwentyFourConvertibleNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=NRXS_SeriesSeedPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=NRXS_SeriesSeedPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_PreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_PreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Option-pricing Model with Following Weighted-average Assumptions (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2023 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Stock price</a></td>
<td class="nump">$ 6.00<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=NRXS_TwentySeventeenStockCompensationPlanMember', window );">2017 Stock Compensation Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Number of Shares | shares</a></td>
<td class="nump">1,319,394<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Stock price</a></td>
<td class="nump">$ 2.67<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice', window );">Exercise price</a></td>
<td class="nump">$ 6.94<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term</a></td>
<td class="text">5 years 9 months<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">31.90%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">3.84%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend rate</a></td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Agreed-upon price for the exchange of the underlying asset relating to the share-based payment award.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of equity instruments other than options outstanding, including both vested and non-vested instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=NRXS_TwentySeventeenStockCompensationPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=NRXS_TwentySeventeenStockCompensationPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Stock Option Activity (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Options, Outstanding, Beginning balance</a></td>
<td class="nump">1,319,394<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Life (in years), Outstanding</a></td>
<td class="text">4 years 8 months 8 days<span></span>
</td>
<td class="text">5 years 8 months 8 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Outstanding at beginning of period</a></td>
<td class="nump">$ 6.94<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value, Outstanding, Beginning balance</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Options, Outstanding, Ending balance</a></td>
<td class="nump">1,319,394<span></span>
</td>
<td class="nump">1,319,394<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Outstanding at Ending of period</a></td>
<td class="nump">$ 6.94<span></span>
</td>
<td class="nump">$ 6.94<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value, Outstanding, Ending balance</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber', window );">Number of Options, Vested and Exercisable, Ending balance</a></td>
<td class="nump">1,319,394<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted Average Remaining Contractual Life (in years), Vested and Exercisable</a></td>
<td class="text">4 years 8 months 8 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Vested and Exercisable, Ending balance</a></td>
<td class="nump">$ 6.94<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue', window );">Aggregate Intrinsic Value, Vested and Exercisable, Ending balance</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Sep. 13, 2019</div></th>
<th class="th"><div>Oct. 12, 2017</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">100,000,000<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share based compensation</a></td>
<td class="nump">$ 227,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=srt_ChiefFinancialOfficerMember', window );">Chief Financial Officer [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted', window );">Granted</a></td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price</a></td>
<td class="nump">$ 2.27<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=NRXS_TwentySeventeenStockCompensationPlanMember', window );">2017 Stock Compensation Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,435,652<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,638,788<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.67<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net number of non-option equity instruments granted to participants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_ChiefFinancialOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_ChiefFinancialOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=NRXS_TwentySeventeenStockCompensationPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=NRXS_TwentySeventeenStockCompensationPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>100
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Changes in Warrant Liabilities (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_PlatformOperatorCryptoAssetLineItems', window );"><strong>Platform Operator, Crypto Asset [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Changes in fair value of warrant liabilities</a></td>
<td class="nump">$ 941<span></span>
</td>
<td class="num">$ (844,854)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Fair Value, Inputs, Level 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_PlatformOperatorCryptoAssetLineItems', window );"><strong>Platform Operator, Crypto Asset [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Warrant liabilities, Beginning balance</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NRXS_AdditionToWarrantLiabilities', window );">Addition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NRXS_ReclassifiedToEquity', window );">Reclassified to equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Changes in fair value of warrant liabilities</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Warrant liabilities, Ending balance</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Fair Value, Inputs, Level 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_PlatformOperatorCryptoAssetLineItems', window );"><strong>Platform Operator, Crypto Asset [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Warrant liabilities, Beginning balance</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NRXS_AdditionToWarrantLiabilities', window );">Addition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NRXS_ReclassifiedToEquity', window );">Reclassified to equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Changes in fair value of warrant liabilities</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Warrant liabilities, Ending balance</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Fair Value, Inputs, Level 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_PlatformOperatorCryptoAssetLineItems', window );"><strong>Platform Operator, Crypto Asset [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Warrant liabilities, Beginning balance</a></td>
<td class="nump">8,225<span></span>
</td>
<td class="nump">2,234,384<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NRXS_AdditionToWarrantLiabilities', window );">Addition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,446,502<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NRXS_ReclassifiedToEquity', window );">Reclassified to equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,827,807)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Changes in fair value of warrant liabilities</a></td>
<td class="nump">941<span></span>
</td>
<td class="num">(844,854)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Warrant liabilities, Ending balance</a></td>
<td class="nump">$ 9,166<span></span>
</td>
<td class="nump">$ 8,225<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_NRXS_AdditionToWarrantLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Addition to warrant liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">NRXS_AdditionToWarrantLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>NRXS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_NRXS_ReclassifiedToEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reclassified to equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">NRXS_ReclassifiedToEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>NRXS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_PlatformOperatorCryptoAssetLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.FF.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476188/405-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_PlatformOperatorCryptoAssetLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 13<br> -SubTopic 10<br> -Topic 480<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481766/480-10-25-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>101
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Warrant Liabilities (Details Narrative)<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputSharePriceMember', window );">Measurement Input, Share Price [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and rights outstanding, measurement input</a></td>
<td class="nump">8.76<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember', window );">Measurement Input, Price Volatility [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and rights outstanding, measurement input</a></td>
<td class="nump">75.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember', window );">Measurement Input, Price Volatility [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and rights outstanding, measurement input</a></td>
<td class="nump">84.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember', window );">Measurement Input, Risk Free Interest Rate [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and rights outstanding, measurement input</a></td>
<td class="nump">3.84<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember', window );">Measurement Input, Risk Free Interest Rate [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and rights outstanding, measurement input</a></td>
<td class="nump">4.38<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember', window );">Measurement Input, Expected Dividend Rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and rights outstanding, measurement input</a></td>
<td class="nump">0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 103<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-103<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputSharePriceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputSharePriceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>102
<FILENAME>R73.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Changes in Derivative Liabilities (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Fair Value, Inputs, Level 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_PlatformOperatorCryptoAssetLineItems', window );"><strong>Platform Operator, Crypto Asset [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NRXS_ChangesInDerivativeLiabilities', window );">Derivative liabilities, Beginning balance</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NRXS_AdditionToDerivativeLiabilities', window );">Addition</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDerivativeLiabilities', window );">Changes in fair value of Derivative liabilities</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NRXS_ExtinguishmentOfDerivativeLiabilities', window );">Extinguishment of Derivative liabilities</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NRXS_ChangesInDerivativeLiabilities', window );">Derivative liabilities, Ending balance</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Fair Value, Inputs, Level 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_PlatformOperatorCryptoAssetLineItems', window );"><strong>Platform Operator, Crypto Asset [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NRXS_ChangesInDerivativeLiabilities', window );">Derivative liabilities, Beginning balance</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NRXS_AdditionToDerivativeLiabilities', window );">Addition</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDerivativeLiabilities', window );">Changes in fair value of Derivative liabilities</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NRXS_ExtinguishmentOfDerivativeLiabilities', window );">Extinguishment of Derivative liabilities</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NRXS_ChangesInDerivativeLiabilities', window );">Derivative liabilities, Ending balance</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Fair Value, Inputs, Level 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_PlatformOperatorCryptoAssetLineItems', window );"><strong>Platform Operator, Crypto Asset [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NRXS_ChangesInDerivativeLiabilities', window );">Derivative liabilities, Beginning balance</a></td>
<td class="nump">1,735,700<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NRXS_AdditionToDerivativeLiabilities', window );">Addition</a></td>
<td class="nump">2,375,378<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDerivativeLiabilities', window );">Changes in fair value of Derivative liabilities</a></td>
<td class="num">(198,551)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NRXS_ExtinguishmentOfDerivativeLiabilities', window );">Extinguishment of Derivative liabilities</a></td>
<td class="num">(3,912,527)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NRXS_ChangesInDerivativeLiabilities', window );">Derivative liabilities, Ending balance</a></td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_NRXS_AdditionToDerivativeLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Addition to derivative liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">NRXS_AdditionToDerivativeLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>NRXS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_NRXS_ChangesInDerivativeLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Changes in derivative liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">NRXS_ChangesInDerivativeLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>NRXS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_NRXS_ExtinguishmentOfDerivativeLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Extinguishment of derivative liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">NRXS_ExtinguishmentOfDerivativeLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>NRXS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_PlatformOperatorCryptoAssetLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.FF.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476188/405-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_PlatformOperatorCryptoAssetLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDerivativeLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the period in the carrying value of derivative instruments reported as liabilities that are due to be disposed of within one year (or the normal operating cycle, if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDerivativeLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>103
<FILENAME>R74.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Derivative Liabilities (Details Narrative)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputSharePriceMember', window );">Measurement Input, Share Price [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Derivative liability, measurement input</a></td>
<td class="nump">7.91<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember', window );">Measurement Input, Price Volatility [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Derivative liability, measurement input</a></td>
<td class="nump">70.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember', window );">Measurement Input, Risk Free Interest Rate [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Derivative liability, measurement input</a></td>
<td class="nump">3.46<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember', window );">Measurement Input, Risk Free Interest Rate [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Derivative liability, measurement input</a></td>
<td class="nump">5.47<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember', window );">Measurement Input, Expected Dividend Rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Derivative liability, measurement input</a></td>
<td class="nump">0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilityMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure derivative liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilityMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 103<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-103<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputSharePriceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputSharePriceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>104
<FILENAME>R75.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Retirement Plan (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent', window );">Employee contribution percentage</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanAdministrativeExpenses', window );">Profit sharing contribution expenses</a></td>
<td class="nump">$ 20,868<span></span>
</td>
<td class="nump">$ 6,980<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanAdministrativeExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of administrative expense incurred by defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanAdministrativeExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum percentage of employee gross pay the employee may contribute to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>105
<FILENAME>R76.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Schedule of Reconciles the Company&#8217;s Net Sales and Operating Loss (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net Sales</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 2,685,925<span></span>
</td>
<td class="nump">$ 2,460,049<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of Goods Sold</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">362,002<span></span>
</td>
<td class="nump">303,345<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross profit</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2,323,923<span></span>
</td>
<td class="nump">2,156,704<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingExpense', window );">Selling Expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">324,708<span></span>
</td>
<td class="nump">323,569<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and Development</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">206,107<span></span>
</td>
<td class="nump">169,315<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(7,156,817)<span></span>
</td>
<td class="num">(6,664,495)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other (Expense) Income:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NRXS_FinancingCharges', window );">Financing charges</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(230,824)<span></span>
</td>
<td class="num">(2,772)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(174,328)<span></span>
</td>
<td class="num">(476,416)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Change in fair value of warrant liability</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(941)<span></span>
</td>
<td class="nump">844,854<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeGainLossOnDerivativeNet', window );">Change in fair value of derivative liability</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="nump">198,551<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts', window );">Amortization of debt discount and issuance cost</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(126,387)<span></span>
</td>
<td class="num">(4,881,622)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Extinguishment of debt liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="num">(3,649,561)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncome', window );">Other income</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">33,620<span></span>
</td>
<td class="nump">15,133<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingExpense', window );">Other expense</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(585,824)<span></span>
</td>
<td class="num">(10,355)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Total other (expense) income, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(1,084,684)<span></span>
</td>
<td class="num">(7,962,188)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(8,241,501)<span></span>
</td>
<td class="num">(14,626,683)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net Sales</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2,685,925<span></span>
</td>
<td class="nump">2,460,049<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of Goods Sold</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">362,002<span></span>
</td>
<td class="nump">303,345<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross profit</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2,323,923<span></span>
</td>
<td class="nump">2,156,704<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingExpense', window );">Selling Expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">324,708<span></span>
</td>
<td class="nump">323,569<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and Development</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">206,107<span></span>
</td>
<td class="nump">169,315<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LaborAndRelatedExpense', window );">Wages and Benefits</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">5,378,952<span></span>
</td>
<td class="nump">4,367,486<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfessionalAndContractServicesExpense', window );">Professional Services</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">1,945,331<span></span>
</td>
<td class="nump">2,721,461<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCostAndExpenseOperating', window );">Other Operating Expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">1,625,642<span></span>
</td>
<td class="nump">1,239,368<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(7,156,817)<span></span>
</td>
<td class="num">(6,664,495)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other (Expense) Income:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NRXS_FinancingCharges', window );">Financing charges</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(230,824)<span></span>
</td>
<td class="num">(2,772)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(174,328)<span></span>
</td>
<td class="num">(476,416)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Change in fair value of warrant liability</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(941)<span></span>
</td>
<td class="nump">844,854<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeGainLossOnDerivativeNet', window );">Change in fair value of derivative liability</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="nump">198,551<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts', window );">Amortization of debt discount and issuance cost</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(126,387)<span></span>
</td>
<td class="num">(4,881,622)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Extinguishment of debt liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="num">(3,649,561)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncome', window );">Other income</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">33,620<span></span>
</td>
<td class="nump">15,133<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingExpense', window );">Other expense</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(585,824)<span></span>
</td>
<td class="num">(10,355)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Total other (expense) income, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(1,084,684)<span></span>
</td>
<td class="num">(7,962,188)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (8,241,501)<span></span>
</td>
<td class="num">$ (14,626,683)<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">The
                                            significant expense categories and amounts align with the segment-level information provided
                                            on a regular basis to the CODM.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top">Other
                                            operating expenses include advertising, rent and utilities, insurance, depreciation and
                                            amortization, travel, software subscription fees, board fees and bad debt expense.</td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_NRXS_FinancingCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Financing charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">NRXS_FinancingCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>NRXS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69F<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCostsAndDiscounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeGainLossOnDerivativeNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the fair value of derivatives recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeGainLossOnDerivativeNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 13<br> -SubTopic 10<br> -Topic 480<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481766/480-10-25-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481303/470-50-40-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481303/470-50-40-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrossProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrossProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense classified as operating and nonoperating. Includes, but is not limited to, cost of borrowing accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-24<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483013/835-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LaborAndRelatedExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for salary, wage, profit sharing; incentive and equity-based compensation; and other employee benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LaborAndRelatedExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCostAndExpenseOperating">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total amount of other operating cost and expense items that are associated with the entity's normal revenue producing operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(7)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCostAndExpenseOperating</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfessionalAndContractServicesExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Professional and contract service expense includes cost reimbursements for support services related to contracted projects, outsourced management, technical and staff support.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfessionalAndContractServicesExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expenses recognized in the period that are directly related to the selling and distribution of products or services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>106
<FILENAME>R77.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Assets</a></td>
<td class="nump">$ 4,757,572<span></span>
</td>
<td class="nump">$ 509,498<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used by investing activities</a></td>
<td class="nump">27,776<span></span>
</td>
<td class="nump">71,781<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">37,831<span></span>
</td>
<td class="nump">40,725<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NRXS_ConsultingAndAdvisoryFees', window );">Consulting and advisory fees</a></td>
<td class="nump">754,685<span></span>
</td>
<td class="nump">750,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock based compensation</a></td>
<td class="nump">$ 227,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_NRXS_ConsultingAndAdvisoryFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Consulting and advisory fees.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">NRXS_ConsultingAndAdvisoryFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>NRXS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 12: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 30: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>107
<FILENAME>R78.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 26, 2025</div></th>
<th class="th"><div>Apr. 10, 2024</div></th>
<th class="th"><div>Mar. 18, 2024</div></th>
<th class="th"><div>Nov. 08, 2023</div></th>
<th class="th"><div>Oct. 01, 2022</div></th>
<th class="th"><div>Jul. 14, 2022</div></th>
<th class="th"><div>Feb. 06, 2019</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Jan. 31, 2024</div></th>
<th class="th"><div>Jan. 02, 2024</div></th>
<th class="th"><div>Apr. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued amount for backpay</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,577,780<span></span>
</td>
<td class="nump">$ 401,088<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Common stock with a fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,408,011<span></span>
</td>
<td class="nump">$ 750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyDamagesSoughtValue', window );">Sought compensatory damages</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75,000<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedPatentsGross', window );">Patent value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=srt_ChiefOperatingOfficerMember', window );">Chief Operating Officer [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireEquitySecuritiesFvNi', window );">One time payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 41,980<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Stock option, exercise</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,764<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesFairValueDisclosure', window );">Accrued expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,418<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherExpenses', window );">Other expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,220<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Common stock shares issue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">470,330<span></span>
</td>
<td class="nump">425,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Common stock with a fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 470<span></span>
</td>
<td class="nump">$ 425<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member] | Chief Operating Officer [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Common stock shares issue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,832<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Common stock with a fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 78,788<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member] | Series A Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Common stock shares issue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,518<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=NRXS_AdvisoryAgreementMember', window );">Advisory Agreement [Member] | Forecast [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims', window );">Payment for services</a></td>
<td class="nump">$ 60,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=NRXS_AdvisoryAgreementMember', window );">Advisory Agreement [Member] | Private Placement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Monthly advisory fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=NRXS_AdvisoryAgreementMember', window );">Advisory Agreement [Member] | Private Placement [Member] | Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Monthly advisory fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,563<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Monthly exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.38<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=NRXS_SettlementAgreementMember', window );">Settlement Agreement [Member] | Series A Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NRXS_FinanceCharges', window );">Finance Charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 230,824<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherExpenses', window );">Other expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 580,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=NRXS_SettlementAgreementMember', window );">Settlement Agreement [Member] | Common Stock [Member] | Series A Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Common stock shares issue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">245,955<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=NRXS_ExecutiveEmploymentAgreementsMember', window );">Executive Employment Agreements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NRXS_DescriptionOfExecutiveEmploymentAgreementsRenewals', window );">Description of Executive employment agreements renewals</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">optional one-year renewals<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SalariesAndWages', window );">Base salaries for nine key employees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,920,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncentiveFeeExpense', window );">Incentive payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued amount for backpay</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 417,390<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan', window );">Seven key employees stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,238,712<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NRXS_SpecialBonusPercentage', window );">Special bonus percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedBonusesCurrent', window );">Incentive bonus</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 694,056<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=NRXS_ExecutiveEmploymentAgreementsMember', window );">Executive Employment Agreements [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NRXS_ExecutiveEmploymentAgreementsTerms', window );">Executive employment agreements renewals</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NRXS_KeyEmployeeExercisePercentage', window );">Key employee exercise percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=NRXS_ExecutiveEmploymentAgreementsMember', window );">Executive Employment Agreements [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NRXS_ExecutiveEmploymentAgreementsTerms', window );">Executive employment agreements renewals</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=NRXS_ExecutiveEmploymentAgreementsMember', window );">Executive Employment Agreements [Member] | IPO [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedBonusesCurrent', window );">Incentive bonus</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,821,830<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_NRXS_DescriptionOfExecutiveEmploymentAgreementsRenewals">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of executive employment agreements renewals.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">NRXS_DescriptionOfExecutiveEmploymentAgreementsRenewals</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>NRXS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_NRXS_ExecutiveEmploymentAgreementsTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Executive employment agreements terms.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">NRXS_ExecutiveEmploymentAgreementsTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>NRXS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_NRXS_FinanceCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Finance charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">NRXS_FinanceCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>NRXS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_NRXS_KeyEmployeeExercisePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Key employee exercise percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">NRXS_KeyEmployeeExercisePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>NRXS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_NRXS_SpecialBonusPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Special bonus percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">NRXS_SpecialBonusPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>NRXS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedBonusesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for incentive compensation awarded to employees and directors or earned by them based on the terms of one or more relevant arrangements. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedBonusesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of accrued expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2E<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedPatentsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross carrying amount before accumulated amortization as of the balance sheet date of the costs pertaining to the exclusive legal rights granted to the owner of the patent to exploit an invention or a process for a period of time specified by law. Such costs may have been expended to directly apply and receive patent rights, or to acquire such rights.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedPatentsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncentiveFeeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for incentive fee based on performance under arrangement to manage operations, including, but not limited to, investment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncentiveFeeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of share-based compensation granted to nonemployees as payment for services rendered or acknowledged claims.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyDamagesSoughtValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The value (monetary amount) of the award the plaintiff seeks in the legal matter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyDamagesSoughtValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireEquitySecuritiesFvNi">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to acquire investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as investing activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-19<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 321<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479567/321-10-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireEquitySecuritiesFvNi</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalariesAndWages">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for salary and wage arising from service rendered by nonofficer employee. Excludes allocated cost, labor-related nonsalary expense, and direct and overhead labor cost included in cost of good and service sold.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SalariesAndWages</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of capital stock issued (purchased by employees) in connection with an employee stock ownership plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 40<br> -Section 25<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480637/718-40-25-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_ChiefOperatingOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_ChiefOperatingOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=NRXS_AdvisoryAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=NRXS_AdvisoryAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=srt_ScenarioForecastMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=NRXS_SettlementAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=NRXS_SettlementAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=NRXS_ExecutiveEmploymentAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=NRXS_ExecutiveEmploymentAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>108
<FILENAME>R79.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Health Benefit Plan (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NRXS_DisclosureHealthBenefitPlanAbstract', window );"><strong>Health Benefit Plan</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HealthCareOrganizationStopLossInsurancePremiumExpense', window );">Stop loss insurance premium expense</a></td>
<td class="nump">$ 257,642<span></span>
</td>
<td class="nump">$ 255,715<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NRXS_HealthCareOrganizationStopLossInsurancePremiumPercentage', window );">Stop loss insurance premium percentage</a></td>
<td class="nump">48.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_NRXS_DisclosureHealthBenefitPlanAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">NRXS_DisclosureHealthBenefitPlanAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>NRXS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_NRXS_HealthCareOrganizationStopLossInsurancePremiumPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Health care organization stop loss insurance premium percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">NRXS_HealthCareOrganizationStopLossInsurancePremiumPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>NRXS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HealthCareOrganizationStopLossInsurancePremiumExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stop-loss insurance premiums recognized as expense. In stop-loss insurance, prepaid health care providers or associated entities transfer portions of their financial risks to other companies. A provider typically contracts to recover health care costs in excess of stated amounts during the contract periods.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 720<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478258/954-720-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 720<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478461/954-720-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HealthCareOrganizationStopLossInsurancePremiumExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>109
<FILENAME>R80.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Income Tax Provision (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefit', window );">Total current provision</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit', window );">Federal</a></td>
<td class="num">(1,721,242)<span></span>
</td>
<td class="num">(3,067,056)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit', window );">State</a></td>
<td class="nump">124,823<span></span>
</td>
<td class="num">(154,060)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Total deferred benefit</a></td>
<td class="num">(1,596,419)<span></span>
</td>
<td class="num">(3,221,116)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="nump">1,596,419<span></span>
</td>
<td class="nump">3,221,116<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Total income tax provision</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFederalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(6)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>110
<FILENAME>R81.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Federal Statutory Income Tax Rate and Effective Income Tax Rate (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Federal statutory income tax rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State tax rate, net of federal benefit</a></td>
<td class="nump">5.30%<span></span>
</td>
<td class="nump">4.90%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="num">(26.30%)<span></span>
</td>
<td class="num">(25.90%)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective income tax rate</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.1.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(6)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>111
<FILENAME>R82.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Schedule of Net Deferred Tax Assets and Liabilities (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating losses</a></td>
<td class="nump">$ 8,019,218<span></span>
</td>
<td class="nump">$ 6,573,406<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits', window );">Stock based compensation</a></td>
<td class="nump">1,447,339<span></span>
</td>
<td class="nump">1,366,391<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NRXS_DeferredTaxAssetsNotesReceivableReserve', window );">Notes receivable reserve</a></td>
<td class="nump">266,816<span></span>
</td>
<td class="nump">251,893<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsOther', window );">Accrued compensation</a></td>
<td class="nump">296,297<span></span>
</td>
<td class="nump">57,763<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NRXS_DeferredTaxAssetsAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">143,484<span></span>
</td>
<td class="nump">257,391<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NRXS_DeferredTaxAssetsOperatingLeasePayable', window );">Operating lease payable</a></td>
<td class="nump">84,105<span></span>
</td>
<td class="nump">18,951<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Other</a></td>
<td class="nump">206,468<span></span>
</td>
<td class="nump">175,904<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Total gross deferred tax assets</a></td>
<td class="nump">10,463,727<span></span>
</td>
<td class="nump">8,701,699<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(10,225,739)<span></span>
</td>
<td class="num">(8,629,320)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Total deferred tax assets</a></td>
<td class="nump">237,988<span></span>
</td>
<td class="nump">72,379<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NRXS_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset', window );">Operating lease right of use asset</a></td>
<td class="nump">74,991<span></span>
</td>
<td class="nump">17,475<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses', window );">Prepaid expenses</a></td>
<td class="nump">72,560<span></span>
</td>
<td class="nump">7,337<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NRXS_DeferredTaxLiabilityAccountsReceivable', window );">Accounts receivable</a></td>
<td class="nump">64,443<span></span>
</td>
<td class="nump">18,197<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesOther', window );">Other</a></td>
<td class="nump">25,994<span></span>
</td>
<td class="nump">29,370<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilities', window );">Total deferred tax liabilities</a></td>
<td class="nump">237,988<span></span>
</td>
<td class="nump">72,379<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilities', window );">Deferred tax assets, net</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_NRXS_DeferredTaxAssetsAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets accounts payable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">NRXS_DeferredTaxAssetsAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>NRXS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_NRXS_DeferredTaxAssetsNotesReceivableReserve">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets notes receivable reserve.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">NRXS_DeferredTaxAssetsNotesReceivableReserve</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>NRXS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_NRXS_DeferredTaxAssetsOperatingLeasePayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets operating lease payable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">NRXS_DeferredTaxAssetsOperatingLeasePayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>NRXS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_NRXS_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax liabilities operating lease right of use asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">NRXS_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>NRXS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_NRXS_DeferredTaxLiabilityAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax liability accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">NRXS_DeferredTaxLiabilityAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>NRXS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from compensation and benefits costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences from compensation and benefits, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax consequences attributable to taxable temporary differences derived from prepaid expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesPrepaidExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>112
<FILENAME>R83.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Schedule of State Carryforwards (Details)<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal', window );">Total state NOL carryforwards</a></td>
<td class="nump">$ 34,748,524<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxPeriodAxis=NRXS_TaxYear2037Member', window );">Tax Year 2037 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal', window );">Total state NOL carryforwards</a></td>
<td class="nump">72,216<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxPeriodAxis=NRXS_TaxYear2038Member', window );">Tax Year 2038 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal', window );">Total state NOL carryforwards</a></td>
<td class="nump">1,039,986<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxPeriodAxis=NRXS_TaxYear2039Member', window );">Tax Year 2039 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal', window );">Total state NOL carryforwards</a></td>
<td class="nump">2,033,565<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxPeriodAxis=NRXS_TaxYear2040Member', window );">Tax Year 2040 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal', window );">Total state NOL carryforwards</a></td>
<td class="nump">4,457,495<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxPeriodAxis=NRXS_TaxYear2041Member', window );">Tax Year 2041 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal', window );">Total state NOL carryforwards</a></td>
<td class="nump">2,406,225<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxPeriodAxis=NRXS_TaxYearThereafterMember', window );">Tax Year Thereafter [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal', window );">Total state NOL carryforwards</a></td>
<td class="nump">24,671,088<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxPeriodAxis=NRXS_NoExpirationMember', window );">No Expiration [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal', window );">Total state NOL carryforwards</a></td>
<td class="nump">$ 67,949<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible state and local operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwardsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwardsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxPeriodAxis=NRXS_TaxYear2037Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxPeriodAxis=NRXS_TaxYear2037Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxPeriodAxis=NRXS_TaxYear2038Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxPeriodAxis=NRXS_TaxYear2038Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxPeriodAxis=NRXS_TaxYear2039Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxPeriodAxis=NRXS_TaxYear2039Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxPeriodAxis=NRXS_TaxYear2040Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxPeriodAxis=NRXS_TaxYear2040Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxPeriodAxis=NRXS_TaxYear2041Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxPeriodAxis=NRXS_TaxYear2041Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxPeriodAxis=NRXS_TaxYearThereafterMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxPeriodAxis=NRXS_TaxYearThereafterMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxPeriodAxis=NRXS_NoExpirationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxPeriodAxis=NRXS_NoExpirationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>113
<FILENAME>R84.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Details Narrative)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationLineItems', window );"><strong>Effective Income Tax Rate Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal', window );">Deferred Tax Assets, Operating Loss Carryforwards, State and Local</a></td>
<td class="nump">$ 34,748,524<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments', window );">Effective Income Tax Rate Reconciliation, Other Adjustments, Percent</a></td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Domestic Tax Jurisdiction [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationLineItems', window );"><strong>Effective Income Tax Rate Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal', window );">Deferred Tax Assets, Operating Loss Carryforwards, State and Local</a></td>
<td class="nump">$ 36,202,858<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible state and local operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>114
<FILENAME>R85.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events (Details Narrative) - shares<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 06, 2025</div></th>
<th class="th"><div>Jan. 17, 2025</div></th>
<th class="th"><div>Jan. 03, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Common stock issued from agreements, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">470,330<span></span>
</td>
<td class="nump">425,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Investor converted warrants into common shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,244,228<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Restricted stock, granted</a></td>
<td class="nump">373,275<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">360,902<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Common stock issued from agreements, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39,471<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Investor converted warrants into common shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">502,647<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Investor converted warrants into common shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">186,166<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481674/830-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>115
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0    (  Q =%I&QTU(E0   ,T    0    9&]C4')O<',O87!P+GAM
M;$W/30O", P&X+]2=K>9BAZD#D0]BIZ\SRYUA;8I;83Z[^T$/VYY><@;HBZ)
M(B:VF$7Q+N1M,S+'#4#6(_H^R\JABJ'D>ZXQW8&,L1H/I!\> \.B;=> A3$,
M.,SBM[#IU"Y&9W7/ED)WLCI1)L/B6#0ZL2<?J]P<"A#G>B4^BQ-+.9<K!?^+
M4\L54Y[FRF_\9 6_![H74$L#!!0    (  Q =%I2%&Y(\0   "L"   1
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M0O!])23G4E1OL^L/OYNP[ZT[N']FO/IF?!54#?RZ"_4)4$L#!!0    (  Q
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M#P8=HD\W5^C-P6^G$PO>G<TD:SQ=K#W1 4]7*CM"C(P1Q91[AE_N/YSM#I\
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MI!5I$E;IMZ65Y7T.DM>4EV&DK(<@%5'2+=P>,X(A 8:0MB)-PBI]HZ .YI
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M)ND$%7S!-J7Y*!]_X[N$8ALOEZ5N_J+'UC8"XWRCC:QVSH"@$G7[GSWM)N+
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M)BORBZ)$BVQ3M/R] 9J8H1]8R^LI/\@HJ\NB?&A,K-3,^K/B8Q&[S;GZ#Z<
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M8DBA>HEC/<VK<S=NQB+\ZSZV\BW3M15+.%0V-%R\O:)$C^TQ&J@Z7Y('A;;
M_;2Q+PIHYV#W*Z7P:+@#YC<J_P-02P,$%     @ #$!T6N ,VJ=)!   I0P
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MW2J?/5Y%?%7HVH?0X#C N+4:J2<[?J4T1I*R!%OIC:B8W:H"J0W"&C*2M\;
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MT )\7VO [Q[(P?!_&J=_ 5!+ P04    "  ,0'1:?*2,(% I  #3>P  &0
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M&$_2Z>S<_'I7U,E\-D% ()F/+].+V=2\+\EUK@D(T_E%2B=-)I/+].IB9OX
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M-2Y#Z@^#^AN&JQ_>I+/DQS,U%%,-Q3GT_W=19R%>)EA>!,]/Y,D2,&^)0))
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MM&M1V02Z+Z0T!\<^T&_O^1]02P,$%     @ #$!T6CR&-TJ)"@  ,AH  !D
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M%BGDCWLE486T <^W-<SW7TC!\#/1U7\!4$L#!!0    (  Q =%K9[] IT@8
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MCDLVET8 ^],*Z6M?C('^VG[^#U!+ P04    "  ,0'1:K_\8KJ4$  "/"@
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ML')=%(U/<.LE$>\#OT'7EV>_ 5!+ P04    "  ,0'1:KL_?3B,(  !I$0
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MERTQ!0HI*"SOZG6;3H?O1ZWY1356/FF7)M<5NLA?C%>.RO#[+NGN/13ZG-Q
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MYD!J9 K8#S]RG)<-#B#'1LG%9Y!O*UW:$8HD*<81+[@,%8*(@:;D-")^2_\
M\QC <]:##F'R1G^)K85:$PM04BMZ'-D2RA34V$D'8E\6NP0FJR=P%./%!#:5
M74?6IFBD'O3_&&>?$VR'I-X%H\#<S&%,-979TP4>VFYT1D6.&O:#3?B@,)L
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ML-SU2$!JQC7;M&2SOH\8'3.@=W/2/HKA)]K,FY*]/JG^9O7_"^Z;'[H4A?.
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MX%F !O#!MUG#.>GFG[;9>JN1 >@O<+2LQE^1RO$B_]FF#[Q%L@(%S"LF577
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MI& ZI@.\:96D9F&(NAIU*0B70+V<42-X258*B>I L=ZYCI%"YNJ['<VWHY^
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M-4!0)OX"UO8-F[;!D_S@"RI'NI2R(TI.H^"K-Q1C.K/7D1&"M3LB@S:@>*Z
M]_9AQ9&[$=PP:\*"5"Z@))-I7Y4K#C\W7#YJ&[CK=H5FLCB(:!><J%;%2] !
M<JZ3P#I>"<9[ZZA$_Q_3@RR-T0(,PH2"7TL%(WW;..C1+# B+ZBM)$1U-U:B
MN#(U:).LU^6>0\:69L,@FU1_U6= !+SL,CNF $^54-A?=N9^J@"?9<T- -1H
M>HY49'@(;VMKV6AAMQL"$L!!1Z0R['73M:<;O-7 J*:,'U,8AJ:D4E;DX0E1
M1R#H<#!(UU*"IW%LC"V/H)KNLB#[FPOQJ$\FTK;^UC*.ZW01W8*^?X #Y7'
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M-W#2.AGJ#([GQXX8"T<2NWX'' ."IG,BDV.[_.#Z3"G)BAE2/!;(@A7VXE"
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MC_O>[9EW8*A90Q^ X4]5^*D;0,T<Q5]($*1,7/R]\]*#S 38<D#4T%3)H$J
M& I!1(;J0[JE(%$7R#%<[WDL$*3(@Q&$<=K&^'0QE64E.5*?=Q1)RO2#,M)_
MX"9]V%'#>(@D^R46KI7_@;P"VZ<P%4^X1[*C+<# Q5P75II3K)LL8N$NMX='
M 18N.-:5.9Y=K@FYE+M129QNB.^&EH&G'V2H#/5DX%3V0$[P4ZY4J]O18NO:
M;?HF3.XQE7330J)$CQ='/O^_,ZIB/XHQ'A[%^+8SJOWGLGBX^IGD]/EY@<,K
MGIDQY;91?=OP)SE5_ 3&#H\7L_3D(45NP!E%X1@Q7Y;PF8EB)_/$9'HV&3(/
M5=GNPTZJ<,(8S@_Z_]NQ9Z99I)Z81A([E^YT(8G@N96 6J1+"NC4-ZRA-O6!
M\$C<:@[4B0$F0PZ/9DEQ^Y]T*1]OYJU7$ _<00E[6H_8S0P$,6]![0 5M+UD
M]5'VJ-N#R2:*)P%U,CDI"[J6+*2,)/C-6V5?@$'\H@,CPRO.-#KSDR,[^U(B
M4'1RD[)W%7Y5R]&,Y%XXJF O":-S*%/<T,&.E-A/!(V')X+>E62329 3H9'1
M]>^S^F,OMW_#=-#N)JJ[26]<=86V'8_\E1;T< XXZQ%.F]DISP6(RA*4E*T.
M=PX]6.\EI9,BFY#AK%&0JUF#]5M+ 0T@OSJ,@NG^G<&E+9BS:ZX"E<!3:JMT
M7!C CO6B1#G.:-#61FXZGH"/6KB"'DZD=-3F ^CTQB88)N._(A1HW16FZ4W-
M#^4<>UJCE*\J0(43)B3=U/>>KSQ0[TR%5YH\4!,AEIN[I\[_B3.9P1<G4,-)
ML*H;_WY+XQ*7T7PRU[.E_BO\>J7'^J_^B5?\@88S+,=C'2_"/][I.(YNEDN-
MKTXP?3G1DYOPB=?!ZXOXZ/6?Y(_+Z!K6F$S@;P#.+(YFDVM]O2!P;B;1 EY<
MS. WI.!ON6_]E??-N;R>&^[IC?3-;Y^_X=K>$, @2><ZN&%\M/,;WR/>+"<)
MZ1K=K\H3#@YAC0%1/%0:T8:]!O/%6$]"A.M7>KJ<1\MK^/P:'ILNXF@,R(7+
M#QZZHRN(;\8:GXEO9M'U8N)N)QK/X;_I6,]XHTDT&2^CZ6P*6\(';X!%%86@
MT>""?_L;$U=)\=%]F8:47*#TIX??O'Y[I^D++'A&:BP#9J=1/)\"J2Z&1[''
M?JIG/#S5\^\E#XS#O'9O/>+P^_U"F!95LB@.:Z40J1L+)P4_=4;S&FUAF,]%
M;[A7J&RK8-)2,-G:U9WO5L&D":+8B(86^$&85G1+6;222M*S7Z4 1@\V6(5M
M*W)AMN"9KP-(X":ZF2VH8F%R'</%S(&L%D Q0(/3.%H [WZ52?U;6RFQGFP-
MM\2T9-('>J^IV>,P+/(YPV]0"7U,*N)!?49HDL'>E(WR86!7S\!]]U2?WLJX
M#SL'Q&=2N'ZL;MQ @92G(Z"C1"MMLIS^A:U19S6R&^=!W%X&$S84%+=#F;$L
MJ0Y&;G"ZQ#38E4[^(4"!< 5S?EQFD$-9-,:&!J?Y6$,=!<<2I6[CG=2BTO"
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MIX%_-Q!FV*5TWU#-'B 0(,P7'-SZX)DH]I@8Q/3[RO>(Z3M\O>)*@M!&<HA
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M'&Y W #K<PU=93]!!<.7L8O_ 5!+ P04    "  ,0'1:P;U9$H$#   Q"@
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M9DD_!=3.@?972MG=Q"48?C/SOU!+ P04    "  ,0'1:1MM% -,"   U!@
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M09;P=E#'N)Y$.\YU!SO _?QS28+3ABI145,AE)*3<FNQ&L,I/@,:%C9+5/W
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M:>B"<>:&;G14]@#MKZ0T.\<F&/XCS/\'4$L#!!0    (  Q =%K"UN3E[@0
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MV#\:>*#:?MPZ1BZ:'CB3QG;4QBSM$X;*!=CU0DJS=ER![E&<_ %02P,$%
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M4=5VM%C;A\Q":'P6V>8*WZ$@C0&.%P)K4-<Q"_0OV_D_4$L#!!0    (  Q
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M7-E@=B<;K"IFB_-K7A(NLD6\)NQ)<G'*"3.GZJQBJ!-6TIJU;M-?@";UH;0
M2@NA-(JBZ2JN?##;[(-YY<E?I0.FI/M2]LVM.H5Z8%":6](N:S*=7#3]!&A*
M'TH+H+002J,HFJ[2R@6SS2[8EYV-4/FT)R8/H.87E.:6-*U#M0Z5"G6^H+0
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M-)4I8P]Z<QX.#4M'!!0"J2&P>BQA!)1J)!7'GQS4*.[4CN7U!OTL(Z_(3+&
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MI-H5OIY2UQO)DFS0FS*IQL9LN5"3/7!MH,YGC,G-1L^.Q7\%_C]02P,$%
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MR*#A;??/OIP/XLHASEYQH&<'>NN0ON*0G!T2)[1CYF0MF6'%3,D34=8:T>S
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M0/Z_IE0<;]3+P.KE[^)_4$L#!!0    (  Q =%K8'T%J5@0  )D9   9
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M]PO0/(S4!_*1?%TNR/MW'R:N-OE857>=7_LFNS9[X]J4D3N1Z$"1/Q(?_+J
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M(M6BD9AQ2?\1O0]4T<WPO T>YX[G=:PMNA5AMFM;;C5=MZ#KUM*]VR[H&4I
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M"[I.Y!>V_01%0RV--V>),'_1-E_;Z7EHOA:2I46PJB"-L_R3/A9$[ 3@]I$
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MU0I4*RFM_3&B*2#;/!2]QZG?-F]1L\V;V8D[TH7:V9\>2$U!-175-%334<U
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MGUEC"Z60D0U3-WSW%5H_@>%+.)/U%>V:6']BH60C%2]:L%90T+*YDX<V#SV
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MNF9 VE_4;']5%\Q),_LKXYN$DZL\VXDY>I;_))^S4@Q639>L;:MF]E0QH;0
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MAJ*IDDB#QSNUL5)G\V-3QVKF3-8$NO8'2@NA-(:BJ?I*_\>CR([5@YH_4%H
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M-P^D:]Z4V;Y^@-I-5I;9KGYYSZ,MSZL$XOO;+"N?WE0%'!\+>/E_4$L#!!0
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MN?55ZVKZ.%?3CAHJ!/_0(YWZ"]?K* &:-(#2.)0F4#13":VKZ7^[JVE'#%;
MH4?J3OS)P==3T*P!E,:A-(&BF1)H;4W_U'64[R^3LZ,&2P%J=4)I 93&H32!
MHIF":2U0'[K-I@_U/Z$T!J4%4!J'T@2*9FIF;[?-$TU2W<LL8SW6Z-]>$^J6
M0FG,/W1+#_;6?/<0#FV30-'JHH[W=FU.9/Y<;<A=SA>WJ:KW0]Z]6F_ZS=S+
MH-H;N_/ZK7MY6VV!/6XQ]4[B'\/\.4H+$LLGC70N9I,1R>O-N>LG*MM4>T,_
M9DIE2?5P+<.5S,L#]/M/6:;>GI0)=ENDW_P-4$L#!!0    (  Q =%H;2=I4
M4@,  !$*   9    >&PO=V]R:W-H965T<R]S:&5E=#8X+GAM;,5676_;-A3]
M*Q?:4&S 8GTELIW: NRDQ0HLG1%CZT/1!UJZMHA(HD;2=@SLQ_>24F2UD[5A
MP] 72:1X[CGW@[R<'85\4AFBAN<B+]7<R;2N;EU7)1D63(U$A27]V0I9,$U#
MN7-5)9&E%E3D;N!YD5LP7CKQS,ZM9#P3>YWS$E<2U+XHF#PM,1?'N>,[+Q./
M?)=I,^'&LXKM<(WZMVHE:>2V5E)>8*FX*$'B=NXL_-NE'QJ 7?$[QZ/J?(-Q
M92/$DQF\2^>.9Q1ACHDV)AB]#GB'>6XLD8X_&J-.RVF W>\7ZV^M\^3,ABF\
M$_D'GNIL[DP<2''+]KE^%,>?L7'HQMA+1*[L$X[-6L^!9*^T*!HP*2AX6;_9
M<Q.(#B ,+@""!A!8W36157G/-(MG4AQ!FM5DS7Q85RV:Q/'29&6M)?WEA-/Q
MFM*<[G,$L85?*Q.HJTKRA)<[>! I&CDZ@[<BI_29R0_634ROV $EI0T6BA)J
M@0I^N$?->*Y^G+F:M!D&-VET+&L=P04=?D!\I<X4O"E33+\TX))3K6?!BV?+
M8-#B/28C"/V?(/""$+X'%U3&)*KF-< 0MK$++4-X*7;&T-62:B*%.U'01E',
MEMI"2E;ND(I7P^8$W74K=K+3BR.3*7S\A4S".XV%^M07LYK_NI_?;-A;5;$$
MYP[M2(7R@$[\ZCL_\EX/>'?=>G<]9#U>:Y$\@2D&[)-6@R<6;+;^(8YF[J&'
M[Z;ENQGD"SQ_##7I%\%<Y:R$CP]8;%#V!FG0[+\,4M2*CKYQ"43_@W?CUKOQ
M8$K>[TW0S=&PKK?.G[V;IQ9:FXHZ!>&'_C2<7O>7Q:35,/DO95B#IQW68!2-
M^RFG+>5TD/+-,\J$*[S,.OT+:S2ZY*COG8]B[V]X*^I55"$:9=%[A [C;^"$
M3"J80F&/TH$*\#O]P?]GH@XBI]+.N3[U2FO:C-^)B3>B K@0E.#,'PSR/W+U
M=+65B,!+B@LJ#9+IWJPTEK[2X(632YDY'_3^X$D;W_,#3[%,+U/7>).@,_57
MK&ZG2Q<H=_8NHB 1^U+7#;N=;>\[B[K+GY?7EZ4')G><&FZ.6X)ZHS&=@;*^
M?]0#+2K;\S="TPW"?F9T9T-I%M#_K1#Z96 (VEM@_!E02P,$%     @ #$!T
M6A)E #*Y P  \0\  !D   !X;"]W;W)K<VAE971S+W-H965T-CDN>&ULM5==
M;^(X%/TK5]G5J)4Z#4DHA0Y$ MK1C+2S@XJF\[#:!Y-<@M7$9FT'RK\?.X$
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MU1OR"9!RD[L\87@O=W$WF#&<R\,$P1@1<0/_?HLQ>SH1 >J?&OR?4$L#!!0
M   (  Q =%J[8;L,7@0  %L9   9    >&PO=V]R:W-H965T<R]S:&5E=#<Q
M+GAM;+59;6_B.!#^*U;N=-J5:!,[(5 .D%IZJZO4ZJI6N_VPV@^&#&!M$K.V
M@>V_/^>E"2G!NX'P!6+'\V2>\3CS:#+<<O%=+@$4^AF%L1Q92Z56 ]N6LR5$
M5%[R%<3ZSIR+B"H]% M;K@30(#6*0ILXCF]'E,76>)C./8KQD*]5R&)X%$BN
MHXB*UQL(^79D8>MMXHDMEBJ9L,?#%5W ,ZC/JT>A1W:!$K (8LEXC 3,1]8U
M'DQ(-S%(5WQAL)4[URBA,N7\>S*X"T:6DW@$(<Q4 D'UWP8F$(8)DO;C1PYJ
M%<],#'>OW] _I>0UF2F5,.'A"PO4<F3U+13 G*Y#]<2W_T).*'5PQD.9_J)M
MMM9W+31;2\6CW%A[$+$X^Z<_\T#L&&#_@ ')#<A[ ^^ @9L;N"G1S+.4UBU5
M=#P4?(M$LEJC)1=I;%)KS8;%R38^*Z'O,FVGQL\Z+X)U"(C/T61)XP5(Q&+T
M0H6@L4+WC$Y9R!33TQ]N05$6RH_H GU^OD4?_OPXM)7V(4&R9_GS;K+GD0//
MPP0]\%@M)?HG#B"H MC:^8(!>6-P0XR(MS"[1"[N(.(0K\:AR>^;NP9WW"*@
M;HKG'L![#*E*3A?Z;P6"*BXZ:")>5XJC:RGUL?QZKPW0G8)(?JL+7X;NU:,G
MAWH@5W0&(TN?6@EB ];XKS^P[_Q=1[TEL$H@O"(0G@E]O)--<\H$VM!PG:;9
M-L^ML,RMND!DZ/T4/7D9;<97'A[:FUU^^VLN^I[7[WK%NHKKW<+UKM'U3XF_
M7Q)_.^@N7JV5[*![V$"(,/KZ -$41.W>&5&;[EU+8)4 ^$4 _+,FL=]F(%H"
MJP2B5P2B9\R$E_U<[: ;6+ X9O%"%Y"0QC.H"X$1M]YK5,?^=)P*\7Y!O&\D
M?AT$+*FS==2,EDUW]P@P$[^K@M^5D=\3S$(J)9LS")#.:_BQ9NJUCJT1IRG;
M(\!,;+%3EGGGK&]C,WR#?&X!J!J"':6#FY]EK4)^<9#-J$V8GPY494Y*YN3(
M>D:,]<P,VS3WVT*K!J'49?B\P@RWJLS:0JL&H]1FV"S.CJ]K9N FQ^%TH"KY
M4MUAL[PSU3:S:>-=/@+-R+$4<-@HBQK4-S-08\9'H!D9ETH-FZ7:R16N+<76
M E U!*5FPV;1=FR%.UV#Y<Q;%G.X5'/8+.<.5SC77.%:57=MH57[(*7&(\Y9
M*QPY0IH=#D9;:-5@E&J/'*'V?JO"Y<#^3E>A3TCW7>NA9A4AKN?V#_0>2*G6
MB%FMF<J3V;3Q%I%]#I[G=QUR@$,IMHA1OS0H/V:@QHS</487;I_T^D[O *52
M,I'S]K-R^%W7]AM:-8N,'2U2BAYB%CU'UH8<M=*&P[[_WNW]594CD_EL[[2I
M(Q"+M'LOT8RO8Y7U>XO9[ O!#1Y,TD;ZN_EK/+A.^^5V"9-]=GB@0I]PB4*8
M:TCGLJ<=$UDG/QLHODJ;X5.N%(_2RR70 $2R0-^?<Z[>!LD#BN\IX_\!4$L#
M!!0    (  Q =%H]$V7Q70,  %X0   9    >&PO=V]R:W-H965T<R]S:&5E
M=#<R+GAM;,58T6[:,!3]%2N;IDVJ2)Q @ XBK>VJ52H3HEO[4.W!)!>PFL2I
M[0"5]O&S$YJD [(507D!._8]]]R;DQQ,;\'X@Y@!2+2,PECTC9F4R:EI"G\&
M$1$-ED"L5B:,1T2J*9^:(N% @BPH"DW;LEPS(C0VO%YV;<B]'DME2&,8<B32
M*"+\Z0Q"MN@;V'B^,*+3F=073*^7D"G<@/R9#+F:F05*0".(!64QXC#I&U_P
MZ1GNZH!LQRV%A:B,D2YES-B#GEP%?</2C" $7VH(HK[F< YAJ)$4C\<5J%'D
MU('5\3/Z95:\*F9,!)RS\(X&<M8W.@8*8$+24([8XANL"FII/)^%(OM$BWQO
M6V7T4R%9M I6\XC&^3=9KAI1";!;6P+L58"=\<X392POB"1>C[,%XGJW0M.#
MK-0L6I&CL;XK-Y*K5:KBI'='.">Q1->4C&E()06!/EZ )#04Z+M>U%W[U#.E
M2J9#3'\%?)8#VUN +\!O( >?(-NRF^@],I&8$0[B)9*IZ!:<[8*SG4$WMT /
M@(B4@]*&1%=QDLH3=*.QT9!3']#] *(Q\%^;.-<"ZR?@5"3$A[ZA)"Z S\'P
M/KS#KO6YAK93T'8R=&<+[4M".;HE80IHK0*!2!QDBR03ZP_P9S%]3-7=N+]6
M..A*0B0VEN0<H*1F45*S]DZLU).SY_H!$$@]^D*J.8VG)RBJ%$IUH9LJR'/@
M7$GZ-3+W.HVVVS/G&ZBU"FJMUXHDE\<M"U6/E=2?"J6@WVA 8QJE4:UX:A/N
MV&FW*,<]AGC< Y34+DIJOX%X\AQN13OMUF;E= I>G;TJARS_J9S:A#NVN5N4
MTSV&<KH'* E;I6M9;Z"=51+L5-\\S<86_>"*I^+7*FA$Q0.ZY*!:&DM0+9%H
M1"2\]A54GWC7MI?&B^UC: D?PI9QZ<NXUB/W)29GW<:<1J>Y14REQ>)ZC]U1
M3/_Q5JI/O&O;2X/&K:.(Z1 VC4N?QK6>N2\QN>MB:C:<SA8QE9:+ZSUW@YB^
M+A-U0H( 7= Y#4"Q?J&EC>QJD^S:XM*?<><HPCF$2^/2IG&M9>Y+.-VUWT/6
M7Z(Q*Z=%??(>$#ZEL4 A3%2,U6BK!XCGA]E\(EF2'2#'3*KC:#:< 0F ZPUJ
M?<*8?)[H,VGQEX+W!U!+ P04    "  ,0'1:;+8,O*<#  "T$0  &0   'AL
M+W=O<FMS:&5E=',O<VAE970W,RYX;6RUF/]OFS@8QO\5BYU.FY0KV)0D[261
MFF;3*K6Z:M5V/TSW@P-O@C6#F6V2[K^?#128E+@7UOZ2\.U]W@]@/X_,;"_D
M-Y4":/28\5S-O53KXM+W59Q"1M69*" W9S9"9E2;7;GU52&!)E51QGT2!&,_
MHRSW%K/JV+U<S$2I.<OA7B)59AF5/Y; Q7[N8>_IP">V3;4]X"]F!=W" ^C/
MQ;TT>WZKDK ,<L5$CB1LYMX5OER2T!945WQAL%>];61O92W$-[MSD\R]P!(!
MAUA;"6K^=G -G%LEP_&]$?7:GK:PO_VD_J&Z>7,S:ZK@6O!_6:+3N3?U4 (;
M6G+]2>P_0G-#D=6+!5?5+]K7UT9C#\6ETB)KB@U!QO+ZGSXV#Z)70,B1 M(4
MD(J[;E11KJBFBYD4>R3MU4;-;E2W6E4;.);;M_*@I3G+3)U>/)C7G)0<D-B@
MZY3F6U"(Y6@%DNVH?6#HEM$UXTPS<^;M"C1E7+V;^=HTMQ)^W#1:UHW(D4:8
MH#N1ZU2A]WD"R:\"OJ%NT<D3^I(X%5<0GZ$0CQ )2(@^/ZS0VS_>.73#]I&$
ME>[Y$=T/E$GTA?(21N@F+TJM1N@6=L 11E_O(%N#_._0_3M5[>RZ5 6-8>Z9
MZ:- [L!;_/D&CX._'<SG+?-YI1X>8;[G5-LIBOXI0%(MY A=RQ^%%NA**3.W
MO]Z: G2C(5,'V<]?@3UJV2/G\^Z--=Z-M1%:PI;E.<NW9MIQFL=P"-PI?1@<
M.9C'+?/8R7R5),RZRB$D9^7I2),6:>)$ZLW>C1W!.SN"[;0^_'P/D3L;G$X^
M;<FG3O+WC]J\Y9*IU-B]/@W9J7PZ\D6+?#%HS!IO>V; .G5/!\9!9_3!0%LC
M3EMSRP[T!MS+)_RJSM;(OS ^Z?#)ZYF;6WO 8.DB$+LST.5O[M(!5%W(86<.
MO83%N3L,@.]2#KMC[G=<SBT]@+K+.>P.NN%&YQ8>P-P%(78GX7&G"]U.-R#_
MGK>*+@7Q]'6=;D 6/H_?)2(>%HG_S^EJ[7&E;5>2NP6>A-$D"&;^[M :H8L]
MXHX]EY,UI?VN))Q$X61ZI&N76L09*R_A5$V'/MQ?^&(:1?@(7)=)Q)U)O^-$
MC?0O5.$%)A&9','J,H>X,V>XU;B%3[ :O[>0SD!NJ\\%"L6BS'6]IFZ/MI\D
MKNJ%>'=Y_3WCCDHS[A7BL#&EP=G$6+BL/Q'4.UH4U;)\+;19Y%>;*= $I+W
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M/%_W-)^]M%>ZICF, KR5&M0&@NS5B[@?O3]E]C^1'5GOMM:[Y]BSFZKF\A&
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MH?X- -<&ZOV",;GOZ G:_Q?I;U!+ P04    "  ,0'1:NCFIK)X-  #&QP
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MI2Y P'6 ^KY@3.XZ>H+F2I7\ 5!+ P04    "  ,0'1:'.33]=<"  !+"
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MV9S1FALM3O4Q9RNT.335ET=SKF72&ICW>V'V9.V-/3EU)^75/U!+ P04
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MX*2__X9#[T^+<;\S[MO4TT]<L1S)NLOO/URBY=#Y(;.-7%S+F<?K)O5I1..
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M@:U F GZ^IIS=3<P^_SN-4WZ U!+ P04    "  ,0'1:?J7MC,,"  "T!P
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M!64-<#^5TNPG-D#U4$?? 5!+ P04    "  ,0'1:XE&LU4H$   "'P  &0
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M&G$$<P >,"2.[7MPYWT4K=Y3T?J_E\/?4$L#!!0    (  Q =%J7BKL<P
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MM.=?\24QEK[X_>P\[<8V;\R.U_MS=(=E'CY;'I??\>\S?JG_SCX$I \)Z:.
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M8U!R;W!S+V-O<F4N>&UL4$L! A0#%     @ #$!T6IE<G",0!@  G"<  !,
M             ( !XP$  'AL+W1H96UE+W1H96UE,2YX;6Q02P$"% ,4
M"  ,0'1:.3#BZY$)  "V.0  &               @($D"   >&PO=V]R:W-H
M965T<R]S:&5E=#$N>&UL4$L! A0#%     @ #$!T6I?# PL(!P  )1X  !@
M             ("!ZQ$  'AL+W=O<FMS:&5E=',O<VAE970R+GAM;%!+ 0(4
M Q0    (  Q =%J^!<31K@,  "(1   8              " @2D9  !X;"]W
M;W)K<VAE971S+W-H965T,RYX;6Q02P$"% ,4    "  ,0'1:Y:3I8-4%  "9
M%P  &               @($-'0  >&PO=V]R:W-H965T<R]S:&5E=#0N>&UL
M4$L! A0#%     @ #$!T6ARMAM3-"   34D  !@              ("!&",
M 'AL+W=O<FMS:&5E=',O<VAE970U+GAM;%!+ 0(4 Q0    (  Q =%H&BKP4
M#@H  'XQ   8              " @1LL  !X;"]W;W)K<VAE971S+W-H965T
M-BYX;6Q02P$"% ,4    "  ,0'1:Q#LO^$X"  "B!0  &
M@(%?-@  >&PO=V]R:W-H965T<R]S:&5E=#<N>&UL4$L! A0#%     @ #$!T
M6D[K+^D+ @  KP0  !@              ("!XS@  'AL+W=O<FMS:&5E=',O
M<VAE970X+GAM;%!+ 0(4 Q0    (  Q =%K@#-JG200  *4,   8
M      " @20[  !X;"]W;W)K<VAE971S+W-H965T.2YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    (  Q =%H0!9<1\0(  (4&   9              "
M@<M[  !X;"]W;W)K<VAE971S+W-H965T,30N>&UL4$L! A0#%     @ #$!T
M6LB;[Z.A @  R04  !D              ("!\WX  'AL+W=O<FMS:&5E=',O
M<VAE970Q-2YX;6Q02P$"% ,4    "  ,0'1:/(8W2HD*   R&@  &0
M        @('+@0  >&PO=V]R:W-H965T<R]S:&5E=#$V+GAM;%!+ 0(4 Q0
M   (  Q =%K9[] IT@8  '$0   9              " @8N,  !X;"]W;W)K
M<VAE971S+W-H965T,3<N>&UL4$L! A0#%     @ #$!T6E@C+,WJ!0  P@\
M !D              ("!E),  'AL+W=O<FMS:&5E=',O<VAE970Q."YX;6Q0
M2P$"% ,4    "  ,0'1:K_\8KJ4$  "/"@  &0              @(&UF0
M>&PO=V]R:W-H965T<R]S:&5E=#$Y+GAM;%!+ 0(4 Q0    (  Q =%I*-I07
M000  '<)   9              " @9&>  !X;"]W;W)K<VAE971S+W-H965T
M,C N>&UL4$L! A0#%     @ #$!T6K.YDB.Z P  $@D  !D
M ("!":,  'AL+W=O<FMS:&5E=',O<VAE970R,2YX;6Q02P$"% ,4    "  ,
M0'1:TM[QY\D#   J"0  &0              @('ZI@  >&PO=V]R:W-H965T
M<R]S:&5E=#(R+GAM;%!+ 0(4 Q0    (  Q =%JJC#A5C@(  *,%   9
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M970R-RYX;6Q02P$"% ,4    "  ,0'1:]_;8AB$#  "K!@  &0
M    @(%,S@  >&PO=V]R:W-H965T<R]S:&5E=#(X+GAM;%!+ 0(4 Q0    (
M  Q =%IL^!XB:BH  -R$   9              " @:31  !X;"]W;W)K<VAE
M971S+W-H965T,CDN>&UL4$L! A0#%     @ #$!T6JCK\ITX!P  )1,  !D
M             ("!1?P  'AL+W=O<FMS:&5E=',O<VAE970S,"YX;6Q02P$"
M% ,4    "  ,0'1:P;U9$H$#   Q"@  &0              @(&T P$ >&PO
M=V]R:W-H965T<R]S:&5E=#,Q+GAM;%!+ 0(4 Q0    (  Q =%KN!J]S[ (
M '(&   9              " @6P' 0!X;"]W;W)K<VAE971S+W-H965T,S(N
M>&UL4$L! A0#%     @ #$!T6D;;10#3 @  -08  !D              ("!
MCPH! 'AL+W=O<FMS:&5E=',O<VAE970S,RYX;6Q02P$"% ,4    "  ,0'1:
MG0?VZZ<"  #*!0  &0              @(&9#0$ >&PO=V]R:W-H965T<R]S
M:&5E=#,T+GAM;%!+ 0(4 Q0    (  Q =%HLGTL*9 ,  "\(   9
M      " @7<0 0!X;"]W;W)K<VAE971S+W-H965T,S4N>&UL4$L! A0#%
M  @ #$!T6L+6Y.7N!   LP\  !D              ("!$A0! 'AL+W=O<FMS
M:&5E=',O<VAE970S-BYX;6Q02P$"% ,4    "  ,0'1:"N4(3',#  "<"
M&0              @($W&0$ >&PO=V]R:W-H965T<R]S:&5E=#,W+GAM;%!+
M 0(4 Q0    (  Q =%K,I"&>SP(  " '   9              " @>$< 0!X
M;"]W;W)K<VAE971S+W-H965T,S@N>&UL4$L! A0#%     @ #$!T6IU8RE^K
M @  NP8  !D              ("!YQ\! 'AL+W=O<FMS:&5E=',O<VAE970S
M.2YX;6Q02P$"% ,4    "  ,0'1:L, [@PH%  !O"@  &0
M@(')(@$ >&PO=V]R:W-H965T<R]S:&5E=#0P+GAM;%!+ 0(4 Q0    (  Q
M=%I*K#:*L04  .4.   9              " @0HH 0!X;"]W;W)K<VAE971S
M+W-H965T-#$N>&UL4$L! A0#%     @ #$!T6BU-?0.)"@  $7   !D
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M=#0V+GAM;%!+ 0(4 Q0    (  Q =%H///J*J0,  $T/   9
M  " @?!& 0!X;"]W;W)K<VAE971S+W-H965T-#<N>&UL4$L! A0#%     @
M#$!T6C@GJ#I%!   .A@  !D              ("!T$H! 'AL+W=O<FMS:&5E
M=',O<VAE970T."YX;6Q02P$"% ,4    "  ,0'1:Q+&+D^D#  !L$P  &0
M            @(%,3P$ >&PO=V]R:W-H965T<R]S:&5E=#0Y+GAM;%!+ 0(4
M Q0    (  Q =%KM+'"KI08  +HC   9              " @6Q3 0!X;"]W
M;W)K<VAE971S+W-H965T-3 N>&UL4$L! A0#%     @ #$!T6N;^BC42!
M"!8  !D              ("!2%H! 'AL+W=O<FMS:&5E=',O<VAE970U,2YX
M;6Q02P$"% ,4    "  ,0'1:V!]!:E8$  "9&0  &0              @(&1
M7@$ >&PO=V]R:W-H965T<R]S:&5E=#4R+GAM;%!+ 0(4 Q0    (  Q =%I;
M:AG6A 0  *X7   9              " @1YC 0!X;"]W;W)K<VAE971S+W-H
M965T-3,N>&UL4$L! A0#%     @ #$!T6E);73RB P  2Q$  !D
M     ("!V6<! 'AL+W=O<FMS:&5E=',O<VAE970U-"YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    (  Q =%HG+TX]=RP  --W P 9              "
M@;AZ 0!X;"]W;W)K<VAE971S+W-H965T-3DN>&UL4$L! A0#%     @ #$!T
M6EM@+TW7 @  ?P@  !D              ("!9J<! 'AL+W=O<FMS:&5E=',O
M<VAE970V,"YX;6Q02P$"% ,4    "  ,0'1:$[SSF. "  !-"@  &0
M        @(%TJ@$ >&PO=V]R:W-H965T<R]S:&5E=#8Q+GAM;%!+ 0(4 Q0
M   (  Q =%I,U]@O=00  *L2   9              " @8NM 0!X;"]W;W)K
M<VAE971S+W-H965T-C(N>&UL4$L! A0#%     @ #$!T6K#9&[N/!0  &R$
M !D              ("!-[(! 'AL+W=O<FMS:&5E=',O<VAE970V,RYX;6Q0
M2P$"% ,4    "  ,0'1:;-OD>N0#  #L$@  &0              @(']MP$
M>&PO=V]R:W-H965T<R]S:&5E=#8T+GAM;%!+ 0(4 Q0    (  Q =%JBRZB0
M4@0  -46   9              " @1B\ 0!X;"]W;W)K<VAE971S+W-H965T
M-C4N>&UL4$L! A0#%     @ #$!T6AJLOY3-"@  (G   !D
M ("!H< ! 'AL+W=O<FMS:&5E=',O<VAE970V-BYX;6Q02P$"% ,4    "  ,
M0'1:(R7)CH<(   N70  &0              @(&ERP$ >&PO=V]R:W-H965T
M<R]S:&5E=#8W+GAM;%!+ 0(4 Q0    (  Q =%H;2=I44@,  !$*   9
M          " @6/4 0!X;"]W;W)K<VAE971S+W-H965T-C@N>&UL4$L! A0#
M%     @ #$!T6A)E #*Y P  \0\  !D              ("![-<! 'AL+W=O
M<FMS:&5E=',O<VAE970V.2YX;6Q02P$"% ,4    "  ,0'1:G/HTIR,$  !V
M&   &0              @('<VP$ >&PO=V]R:W-H965T<R]S:&5E=#<P+GAM
M;%!+ 0(4 Q0    (  Q =%J[8;L,7@0  %L9   9              " @3;@
M 0!X;"]W;W)K<VAE971S+W-H965T-S$N>&UL4$L! A0#%     @ #$!T6CT3
M9?%= P  7A   !D              ("!R^0! 'AL+W=O<FMS:&5E=',O<VAE
M970W,BYX;6Q02P$"% ,4    "  ,0'1:;+8,O*<#  "T$0  &0
M    @(%?Z $ >&PO=V]R:W-H965T<R]S:&5E=#<S+GAM;%!+ 0(4 Q0    (
M  Q =%H3T5V?&0,  ,8-   9              " @3WL 0!X;"]W;W)K<VAE
M971S+W-H965T-S0N>&UL4$L! A0#%     @ #$!T6CVK/*V$ @  @@8  !D
M             ("!C>\! 'AL+W=O<FMS:&5E=',O<VAE970W-2YX;6Q02P$"
M% ,4    "  ,0'1:GW\'\<D'  #B)   &0              @(%(\@$ >&PO
M=V]R:W-H965T<R]S:&5E=#<V+GAM;%!+ 0(4 Q0    (  Q =%KAXTW0_@(
M &L(   9              " @4CZ 0!X;"]W;W)K<VAE971S+W-H965T-S<N
M>&UL4$L! A0#%     @ #$!T6KHYJ:R>#0  QL<  !D              ("!
M??T! 'AL+W=O<FMS:&5E=',O<VAE970W."YX;6Q02P$"% ,4    "  ,0'1:
MP!&E7G("  "$!@  &0              @(%2"P( >&PO=V]R:W-H965T<R]S
M:&5E=#<Y+GAM;%!+ 0(4 Q0    (  Q =%K](FD*^P(  %X)   9
M      " @?L- @!X;"]W;W)K<VAE971S+W-H965T.# N>&UL4$L! A0#%
M  @ #$!T6ASDT_77 @  2P@  !D              ("!+1$" 'AL+W=O<FMS
M:&5E=',O<VAE970X,2YX;6Q02P$"% ,4    "  ,0'1:5@7K6B\$   U#P
M&0              @($[% ( >&PO=V]R:W-H965T<R]S:&5E=#@R+GAM;%!+
M 0(4 Q0    (  Q =%I'K47]: ,  +(1   9              " @:$8 @!X
M;"]W;W)K<VAE971S+W-H965T.#,N>&UL4$L! A0#%     @ #$!T6GZE[8S#
M @  M <  !D              ("!0!P" 'AL+W=O<FMS:&5E=',O<VAE970X
M-"YX;6Q02P$"% ,4    "  ,0'1:XE&LU4H$   "'P  &0
M@($Z'P( >&PO=V]R:W-H965T<R]S:&5E=#@U+GAM;%!+ 0(4 Q0    (  Q
M=%IMO^EG10,  ,H4   -              "  ;LC @!X;"]S='EL97,N>&UL
M4$L! A0#%     @ #$!T6I>*NQS     $P(   L              ( !*R<"
M %]R96QS+RYR96QS4$L! A0#%     @ #$!T6CEKGPVH!@  MC<   \
M         ( !%"@" 'AL+W=O<FMB;V]K+GAM;%!+ 0(4 Q0    (  Q =%H@
M%;X0A (  "8R   :              "  >DN @!X;"]?<F5L<R]W;W)K8F]O
M:RYX;6PN<F5L<U!+ 0(4 Q0    (  Q =%J);LQ^*P(  +LP   3
M      "  :4Q @!;0V]N=&5N=%]4>7!E<UTN>&UL4$L%!@    != %T @AD
'  $T @    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>116
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>117
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>119
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>335</ContextCount>
  <ElementCount>450</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>118</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>4</UnitCount>
  <MyReports>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neuraxis.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>00000002 - Statement - Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neuraxis.com/role/BalanceSheets</Role>
      <ShortName>Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>00000003 - Statement - Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neuraxis.com/role/BalanceSheetsParenthetical</Role>
      <ShortName>Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>00000004 - Statement - Statements of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neuraxis.com/role/StatementsOfOperations</Role>
      <ShortName>Statements of Operations</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>00000005 - Statement - Statements of Stockholders' Equity (Deficit)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neuraxis.com/role/StatementsOfStockholdersEquityDeficit</Role>
      <ShortName>Statements of Stockholders' Equity (Deficit)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>00000006 - Statement - Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neuraxis.com/role/StatementsOfCashFlows</Role>
      <ShortName>Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>995410 - Disclosure - Pay vs Performance Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/PvpDisclosure</Role>
      <ShortName>Pay vs Performance Disclosure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>995445 - Disclosure - Insider Trading Arrangements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements</Role>
      <ShortName>Insider Trading Arrangements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>995550 - Disclosure - Cybersecurity Risk Management and Strategy Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure</Role>
      <ShortName>Cybersecurity Risk Management and Strategy Disclosure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>999014 - Disclosure - Basis of Presentation, Organization and Other Matters</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neuraxis.com/role/BasisOfPresentationOrganizationAndOtherMatters</Role>
      <ShortName>Basis of Presentation, Organization and Other Matters</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>999015 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neuraxis.com/role/SummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>999016 - Disclosure - Related Party Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neuraxis.com/role/RelatedPartyTransactions</Role>
      <ShortName>Related Party Transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>999017 - Disclosure - Property and Equipment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neuraxis.com/role/PropertyAndEquipment</Role>
      <ShortName>Property and Equipment</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>999018 - Disclosure - Intangible Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neuraxis.com/role/IntangibleAssets</Role>
      <ShortName>Intangible Assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>999019 - Disclosure - Accrued Expenses</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neuraxis.com/role/AccruedExpenses</Role>
      <ShortName>Accrued Expenses</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>999020 - Disclosure - Notes Payable</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://neuraxis.com/role/NotesPayable</Role>
      <ShortName>Notes Payable</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>999021 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neuraxis.com/role/Leases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>999022 - Disclosure - Common Stock and Warrants</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neuraxis.com/role/CommonStockAndWarrants</Role>
      <ShortName>Common Stock and Warrants</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>999023 - Disclosure - Preferred Stock</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neuraxis.com/role/PreferredStock</Role>
      <ShortName>Preferred Stock</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>999024 - Disclosure - Stock-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neuraxis.com/role/Stock-basedCompensation</Role>
      <ShortName>Stock-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>999025 - Disclosure - Warrant Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neuraxis.com/role/WarrantLiabilities</Role>
      <ShortName>Warrant Liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>999026 - Disclosure - Derivative Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neuraxis.com/role/DerivativeLiabilities</Role>
      <ShortName>Derivative Liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>999027 - Disclosure - Retirement Plan</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neuraxis.com/role/RetirementPlan</Role>
      <ShortName>Retirement Plan</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>999028 - Disclosure - Segment Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neuraxis.com/role/SegmentInformation</Role>
      <ShortName>Segment Information</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>999029 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neuraxis.com/role/CommitmentsAndContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>999030 - Disclosure - Health Benefit Plan</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neuraxis.com/role/HealthBenefitPlan</Role>
      <ShortName>Health Benefit Plan</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>999031 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neuraxis.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>999032 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neuraxis.com/role/SubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>999033 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neuraxis.com/role/SummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://neuraxis.com/role/SummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>999034 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neuraxis.com/role/SummaryOfSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://neuraxis.com/role/SummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>999035 - Disclosure - Related Party Transactions (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neuraxis.com/role/RelatedPartyTransactionsTables</Role>
      <ShortName>Related Party Transactions (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://neuraxis.com/role/RelatedPartyTransactions</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>999036 - Disclosure - Property and Equipment (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neuraxis.com/role/PropertyAndEquipmentTables</Role>
      <ShortName>Property and Equipment (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://neuraxis.com/role/PropertyAndEquipment</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>999037 - Disclosure - Intangible Assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neuraxis.com/role/IntangibleAssetsTables</Role>
      <ShortName>Intangible Assets (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://neuraxis.com/role/IntangibleAssets</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>999038 - Disclosure - Accrued Expenses (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neuraxis.com/role/AccruedExpensesTables</Role>
      <ShortName>Accrued Expenses (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://neuraxis.com/role/AccruedExpenses</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>999039 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neuraxis.com/role/LeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://neuraxis.com/role/Leases</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>999040 - Disclosure - Common Stock and Warrants (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neuraxis.com/role/CommonStockAndWarrantsTables</Role>
      <ShortName>Common Stock and Warrants (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://neuraxis.com/role/CommonStockAndWarrants</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>999041 - Disclosure - Stock-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neuraxis.com/role/Stock-basedCompensationTables</Role>
      <ShortName>Stock-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://neuraxis.com/role/Stock-basedCompensation</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>999042 - Disclosure - Warrant Liabilities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neuraxis.com/role/WarrantLiabilitiesTables</Role>
      <ShortName>Warrant Liabilities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://neuraxis.com/role/WarrantLiabilities</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>999043 - Disclosure - Derivative Liabilities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neuraxis.com/role/DerivativeLiabilitiesTables</Role>
      <ShortName>Derivative Liabilities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://neuraxis.com/role/DerivativeLiabilities</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>999044 - Disclosure - Segment Information (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neuraxis.com/role/SegmentInformationTables</Role>
      <ShortName>Segment Information (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://neuraxis.com/role/SegmentInformation</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>999045 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neuraxis.com/role/IncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://neuraxis.com/role/IncomeTaxes</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>999046 - Disclosure - Basis of Presentation, Organization and Other Matters (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neuraxis.com/role/BasisOfPresentationOrganizationAndOtherMattersDetailsNarrative</Role>
      <ShortName>Basis of Presentation, Organization and Other Matters (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://neuraxis.com/role/BasisOfPresentationOrganizationAndOtherMatters</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>999047 - Disclosure - Schedule of Estimated Useful Lives (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neuraxis.com/role/ScheduleOfEstimatedUsefulLivesDetails</Role>
      <ShortName>Schedule of Estimated Useful Lives (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>999048 - Disclosure - Schedule of Fair Value of Assets and Liabilities measured on Recurring Basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neuraxis.com/role/ScheduleOfFairValueOfAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails</Role>
      <ShortName>Schedule of Fair Value of Assets and Liabilities measured on Recurring Basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>999049 - Disclosure - Schedule of Dilutive Common Stock Equivalents (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neuraxis.com/role/ScheduleOfDilutiveCommonStockEquivalentsDetails</Role>
      <ShortName>Schedule of Dilutive Common Stock Equivalents (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>999050 - Disclosure - Schedule of Basic and Diluted Net Loss Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neuraxis.com/role/ScheduleOfBasicAndDilutedNetLossPerShareDetails</Role>
      <ShortName>Schedule of Basic and Diluted Net Loss Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>999051 - Disclosure - Schedule of Disaggregation of Revenue (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neuraxis.com/role/ScheduleOfDisaggregationOfRevenueDetails</Role>
      <ShortName>Schedule of Disaggregation of Revenue (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>999052 - Disclosure - Schedule of Customer Accounts Receivable (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neuraxis.com/role/ScheduleOfCustomerAccountsReceivableDetails</Role>
      <ShortName>Schedule of Customer Accounts Receivable (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>999053 - Disclosure - Schedule of Customers Accounted Revenues (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neuraxis.com/role/ScheduleOfCustomersAccountedRevenuesDetails</Role>
      <ShortName>Schedule of Customers Accounted Revenues (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>999054 - Disclosure - Summary of Significant Accounting Policies (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neuraxis.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative</Role>
      <ShortName>Summary of Significant Accounting Policies (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://neuraxis.com/role/SummaryOfSignificantAccountingPoliciesTables</ParentRole>
      <Position>50</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>999055 - Disclosure - Schedule of Related Party Transactions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neuraxis.com/role/ScheduleOfRelatedPartyTransactionsDetails</Role>
      <ShortName>Schedule of Related Party Transactions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>999056 - Disclosure - Schedule of Related Party Loans payable to shareholder (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neuraxis.com/role/ScheduleOfRelatedPartyLoansPayableToShareholderDetails</Role>
      <ShortName>Schedule of Related Party Loans payable to shareholder (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>999057 - Disclosure - Related Party Transactions (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neuraxis.com/role/RelatedPartyTransactionsDetailsNarrative</Role>
      <ShortName>Related Party Transactions (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://neuraxis.com/role/RelatedPartyTransactionsTables</ParentRole>
      <Position>53</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>999058 - Disclosure - Schedule of Property And Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neuraxis.com/role/ScheduleOfPropertyAndEquipmentDetails</Role>
      <ShortName>Schedule of Property And Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>999059 - Disclosure - Property and Equipment (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neuraxis.com/role/PropertyAndEquipmentDetailsNarrative</Role>
      <ShortName>Property and Equipment (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://neuraxis.com/role/PropertyAndEquipmentTables</ParentRole>
      <Position>55</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>999060 - Disclosure - Schedule of Intangible Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neuraxis.com/role/ScheduleOfIntangibleAssetsDetails</Role>
      <ShortName>Schedule of Intangible Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>999061 - Disclosure - Intangible Assets (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neuraxis.com/role/IntangibleAssetsDetailsNarrative</Role>
      <ShortName>Intangible Assets (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://neuraxis.com/role/IntangibleAssetsTables</ParentRole>
      <Position>57</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>999062 - Disclosure - Schedule of Accrued Expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neuraxis.com/role/ScheduleOfAccruedExpensesDetails</Role>
      <ShortName>Schedule of Accrued Expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>999063 - Disclosure - Notes Payable (Details Narrative)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://neuraxis.com/role/NotesPayableDetailsNarrative</Role>
      <ShortName>Notes Payable (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://neuraxis.com/role/NotesPayable</ParentRole>
      <Position>59</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>999064 - Disclosure - Schedule of Operating Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neuraxis.com/role/ScheduleOfOperatingLeasesDetails</Role>
      <ShortName>Schedule of Operating Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>999065 - Disclosure - Schedule of Maturities Operating Lease Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neuraxis.com/role/ScheduleOfMaturitiesOperatingLeaseLiabilitiesDetails</Role>
      <ShortName>Schedule of Maturities Operating Lease Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>999066 - Disclosure - Leases (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neuraxis.com/role/LeasesDetailsNarrative</Role>
      <ShortName>Leases (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://neuraxis.com/role/LeasesTables</ParentRole>
      <Position>62</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>999067 - Disclosure - Schedule of Warrant Activity for Common Stock (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neuraxis.com/role/ScheduleOfWarrantActivityForCommonStockDetails</Role>
      <ShortName>Schedule of Warrant Activity for Common Stock (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>999068 - Disclosure - Schedule of Warrant Activity for Preferred Stock (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neuraxis.com/role/ScheduleOfWarrantActivityForPreferredStockDetails</Role>
      <ShortName>Schedule of Warrant Activity for Preferred Stock (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>64</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>999069 - Disclosure - Schedule of Warrants outstanding and Exercisable (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neuraxis.com/role/ScheduleOfWarrantsOutstandingAndExercisableDetails</Role>
      <ShortName>Schedule of Warrants outstanding and Exercisable (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>65</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>999070 - Disclosure - Common Stock and Warrants (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neuraxis.com/role/CommonStockAndWarrantsDetailsNarrative</Role>
      <ShortName>Common Stock and Warrants (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://neuraxis.com/role/CommonStockAndWarrantsTables</ParentRole>
      <Position>66</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>999071 - Disclosure - Preferred Stock (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neuraxis.com/role/PreferredStockDetailsNarrative</Role>
      <ShortName>Preferred Stock (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://neuraxis.com/role/PreferredStock</ParentRole>
      <Position>67</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>999072 - Disclosure - Schedule of Option-pricing Model with Following Weighted-average Assumptions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neuraxis.com/role/ScheduleOfOption-pricingModelWithFollowingWeighted-averageAssumptionsDetails</Role>
      <ShortName>Schedule of Option-pricing Model with Following Weighted-average Assumptions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>68</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>999073 - Disclosure - Schedule of Stock Option Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neuraxis.com/role/ScheduleOfStockOptionActivityDetails</Role>
      <ShortName>Schedule of Stock Option Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>69</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>999074 - Disclosure - Stock-Based Compensation (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neuraxis.com/role/Stock-basedCompensationDetailsNarrative</Role>
      <ShortName>Stock-Based Compensation (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://neuraxis.com/role/Stock-basedCompensationTables</ParentRole>
      <Position>70</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>999075 - Disclosure - Schedule of Changes in Warrant Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neuraxis.com/role/ScheduleOfChangesInWarrantLiabilitiesDetails</Role>
      <ShortName>Schedule of Changes in Warrant Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>71</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>999076 - Disclosure - Warrant Liabilities (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neuraxis.com/role/WarrantLiabilitiesDetailsNarrative</Role>
      <ShortName>Warrant Liabilities (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://neuraxis.com/role/WarrantLiabilitiesTables</ParentRole>
      <Position>72</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R73.htm</HtmlFileName>
      <LongName>999077 - Disclosure - Schedule of Changes in Derivative Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neuraxis.com/role/ScheduleOfChangesInDerivativeLiabilitiesDetails</Role>
      <ShortName>Schedule of Changes in Derivative Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>73</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R74.htm</HtmlFileName>
      <LongName>999078 - Disclosure - Derivative Liabilities (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neuraxis.com/role/DerivativeLiabilitiesDetailsNarrative</Role>
      <ShortName>Derivative Liabilities (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://neuraxis.com/role/DerivativeLiabilitiesTables</ParentRole>
      <Position>74</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R75.htm</HtmlFileName>
      <LongName>999079 - Disclosure - Retirement Plan (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neuraxis.com/role/RetirementPlanDetailsNarrative</Role>
      <ShortName>Retirement Plan (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://neuraxis.com/role/RetirementPlan</ParentRole>
      <Position>75</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R76.htm</HtmlFileName>
      <LongName>999080 - Disclosure - Schedule of Reconciles the Company???s Net Sales and Operating Loss (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neuraxis.com/role/ScheduleOfReconcilesCompanysNetSalesAndOperatingLossDetails</Role>
      <ShortName>Schedule of Reconciles the Company???s Net Sales and Operating Loss (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>76</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R77.htm</HtmlFileName>
      <LongName>999081 - Disclosure - Segment Information (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neuraxis.com/role/SegmentInformationDetailsNarrative</Role>
      <ShortName>Segment Information (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://neuraxis.com/role/SegmentInformationTables</ParentRole>
      <Position>77</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R78.htm</HtmlFileName>
      <LongName>999082 - Disclosure - Commitments and Contingencies (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neuraxis.com/role/CommitmentsAndContingenciesDetailsNarrative</Role>
      <ShortName>Commitments and Contingencies (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://neuraxis.com/role/CommitmentsAndContingencies</ParentRole>
      <Position>78</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R79.htm</HtmlFileName>
      <LongName>999083 - Disclosure - Health Benefit Plan (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neuraxis.com/role/HealthBenefitPlanDetailsNarrative</Role>
      <ShortName>Health Benefit Plan (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://neuraxis.com/role/HealthBenefitPlan</ParentRole>
      <Position>79</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R80.htm</HtmlFileName>
      <LongName>999084 - Disclosure - Schedule of Income Tax Provision (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neuraxis.com/role/ScheduleOfIncomeTaxProvisionDetails</Role>
      <ShortName>Schedule of Income Tax Provision (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>80</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R81.htm</HtmlFileName>
      <LongName>999085 - Disclosure - Schedule of Federal Statutory Income Tax Rate and Effective Income Tax Rate (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neuraxis.com/role/ScheduleOfFederalStatutoryIncomeTaxRateAndEffectiveIncomeTaxRateDetails</Role>
      <ShortName>Schedule of Federal Statutory Income Tax Rate and Effective Income Tax Rate (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>81</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R82.htm</HtmlFileName>
      <LongName>999086 - Disclosure - Schedule of Net Deferred Tax Assets and Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neuraxis.com/role/ScheduleOfNetDeferredTaxAssetsAndLiabilitiesDetails</Role>
      <ShortName>Schedule of Net Deferred Tax Assets and Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>82</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R83.htm</HtmlFileName>
      <LongName>999087 - Disclosure - Schedule of State Carryforwards (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neuraxis.com/role/ScheduleOfStateCarryforwardsDetails</Role>
      <ShortName>Schedule of State Carryforwards (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>83</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R84.htm</HtmlFileName>
      <LongName>999088 - Disclosure - Income Taxes (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neuraxis.com/role/IncomeTaxesDetailsNarrative</Role>
      <ShortName>Income Taxes (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://neuraxis.com/role/IncomeTaxesTables</ParentRole>
      <Position>84</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R85.htm</HtmlFileName>
      <LongName>999089 - Disclosure - Subsequent Events (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neuraxis.com/role/SubsequentEventsDetailsNarrative</Role>
      <ShortName>Subsequent Events (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://neuraxis.com/role/SubsequentEvents</ParentRole>
      <Position>85</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-K" isDefinitelyFs="true" isUsgaap="true" original="form10-k.htm">form10-k.htm</File>
    <File>nrxs-20241231.xsd</File>
    <File>nrxs-20241231_cal.xml</File>
    <File>nrxs-20241231_def.xml</File>
    <File>nrxs-20241231_lab.xml</File>
    <File>nrxs-20241231_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>form10-k_001.jpg</File>
    <File>form10-k_003.jpg</File>
    <File>form10-k_005.jpg</File>
    <File>form10-k_006.jpg</File>
    <File>form10-k_007.jpg</File>
    <File>form10-k_008.jpg</File>
    <File>form10-k_009.jpg</File>
    <File>form10-k_010.jpg</File>
    <File>form10-k_014.jpg</File>
    <File>form10-k_015.jpg</File>
    <File>form10-k_020.jpg</File>
    <File>form10-k_021.jpg</File>
    <File>form10-k_022.jpg</File>
    <File>form10-k_023.jpg</File>
    <File>form10-k_024.jpg</File>
    <File>form10-k_025.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="1021">http://fasb.org/us-gaap/2024</BaseTaxonomy>
    <BaseTaxonomy items="7">http://xbrl.sec.gov/cyd/2024</BaseTaxonomy>
    <BaseTaxonomy items="41">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>122
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "form10-k.htm": {
   "nsprefix": "NRXS",
   "nsuri": "http://neuraxis.com/20241231",
   "dts": {
    "inline": {
     "local": [
      "form10-k.htm"
     ]
    },
    "schema": {
     "local": [
      "nrxs-20241231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd",
      "https://xbrl.sec.gov/country/2024/country-2024.xsd",
      "https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd",
      "https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd",
      "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "nrxs-20241231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "nrxs-20241231_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "nrxs-20241231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "nrxs-20241231_pre.xml"
     ]
    }
   },
   "keyStandard": 367,
   "keyCustom": 83,
   "axisStandard": 33,
   "axisCustom": 0,
   "memberStandard": 43,
   "memberCustom": 63,
   "hidden": {
    "total": 201,
    "http://neuraxis.com/20241231": 50,
    "http://fasb.org/us-gaap/2024": 147,
    "http://xbrl.sec.gov/dei/2024": 4
   },
   "contextCount": 335,
   "entityCount": 1,
   "segmentCount": 118,
   "elementCount": 819,
   "unitCount": 4,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2024": 1021,
    "http://xbrl.sec.gov/dei/2024": 41,
    "http://xbrl.sec.gov/cyd/2024": 7
   },
   "report": {
    "R1": {
     "role": "http://neuraxis.com/role/Cover",
     "longName": "00000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://neuraxis.com/role/BalanceSheets",
     "longName": "00000002 - Statement - Balance Sheets",
     "shortName": "Balance Sheets",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "2",
     "firstAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R3": {
     "role": "http://neuraxis.com/role/BalanceSheetsParenthetical",
     "longName": "00000003 - Statement - Balance Sheets (Parenthetical)",
     "shortName": "Balance Sheets (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:AllowanceForDoubtfulAccountsReceivable",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-12-31_custom_ConvertibleSeriesBPreferredStockMember",
      "name": "us-gaap:PreferredStockSharesIssued",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R4": {
     "role": "http://neuraxis.com/role/StatementsOfOperations",
     "longName": "00000004 - Statement - Statements of Operations",
     "shortName": "Statements of Operations",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:GeneralAndAdministrativeExpense",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R5": {
     "role": "http://neuraxis.com/role/StatementsOfStockholdersEquityDeficit",
     "longName": "00000005 - Statement - Statements of Stockholders' Equity (Deficit)",
     "shortName": "Statements of Stockholders' Equity (Deficit)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "AsOf2022-12-31_us-gaap_PreferredStockMember_custom_ConvertibleSeriesAPreferredStockMember",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2022-12-31_us-gaap_PreferredStockMember_custom_ConvertibleSeriesAPreferredStockMember",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R6": {
     "role": "http://neuraxis.com/role/StatementsOfCashFlows",
     "longName": "00000006 - Statement - Statements of Cash Flows",
     "shortName": "Statements of Cash Flows",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R7": {
     "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure",
     "longName": "995410 - Disclosure - Pay vs Performance Disclosure",
     "shortName": "Pay vs Performance Disclosure",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "7",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R8": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
     "longName": "995445 - Disclosure - Insider Trading Arrangements",
     "shortName": "Insider Trading Arrangements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "8",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "NRXS:NoInsiderTradingFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "NRXS:NoInsiderTradingFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R9": {
     "role": "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure",
     "longName": "995550 - Disclosure - Cybersecurity Risk Management and Strategy Disclosure",
     "shortName": "Cybersecurity Risk Management and Strategy Disclosure",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://neuraxis.com/role/BasisOfPresentationOrganizationAndOtherMatters",
     "longName": "999014 - Disclosure - Basis of Presentation, Organization and Other Matters",
     "shortName": "Basis of Presentation, Organization and Other Matters",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://neuraxis.com/role/SummaryOfSignificantAccountingPolicies",
     "longName": "999015 - Disclosure - Summary of Significant Accounting Policies",
     "shortName": "Summary of Significant Accounting Policies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://neuraxis.com/role/RelatedPartyTransactions",
     "longName": "999016 - Disclosure - Related Party Transactions",
     "shortName": "Related Party Transactions",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://neuraxis.com/role/PropertyAndEquipment",
     "longName": "999017 - Disclosure - Property and Equipment",
     "shortName": "Property and Equipment",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://neuraxis.com/role/IntangibleAssets",
     "longName": "999018 - Disclosure - Intangible Assets",
     "shortName": "Intangible Assets",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:IntangibleAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:IntangibleAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://neuraxis.com/role/AccruedExpenses",
     "longName": "999019 - Disclosure - Accrued Expenses",
     "shortName": "Accrued Expenses",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://neuraxis.com/role/NotesPayable",
     "longName": "999020 - Disclosure - Notes Payable",
     "shortName": "Notes Payable",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://neuraxis.com/role/Leases",
     "longName": "999021 - Disclosure - Leases",
     "shortName": "Leases",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://neuraxis.com/role/CommonStockAndWarrants",
     "longName": "999022 - Disclosure - Common Stock and Warrants",
     "shortName": "Common Stock and Warrants",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://neuraxis.com/role/PreferredStock",
     "longName": "999023 - Disclosure - Preferred Stock",
     "shortName": "Preferred Stock",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "19",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:PreferredStockTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:PreferredStockTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://neuraxis.com/role/Stock-basedCompensation",
     "longName": "999024 - Disclosure - Stock-Based Compensation",
     "shortName": "Stock-Based Compensation",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "20",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://neuraxis.com/role/WarrantLiabilities",
     "longName": "999025 - Disclosure - Warrant Liabilities",
     "shortName": "Warrant Liabilities",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "21",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "NRXS:WarrantLiabilitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "NRXS:WarrantLiabilitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://neuraxis.com/role/DerivativeLiabilities",
     "longName": "999026 - Disclosure - Derivative Liabilities",
     "shortName": "Derivative Liabilities",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "22",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:DerivativesAndFairValueTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:DerivativesAndFairValueTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://neuraxis.com/role/RetirementPlan",
     "longName": "999027 - Disclosure - Retirement Plan",
     "shortName": "Retirement Plan",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "23",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://neuraxis.com/role/SegmentInformation",
     "longName": "999028 - Disclosure - Segment Information",
     "shortName": "Segment Information",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "24",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://neuraxis.com/role/CommitmentsAndContingencies",
     "longName": "999029 - Disclosure - Commitments and Contingencies",
     "shortName": "Commitments and Contingencies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "25",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://neuraxis.com/role/HealthBenefitPlan",
     "longName": "999030 - Disclosure - Health Benefit Plan",
     "shortName": "Health Benefit Plan",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "26",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "NRXS:HealthBenefitPlanDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "NRXS:HealthBenefitPlanDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://neuraxis.com/role/IncomeTaxes",
     "longName": "999031 - Disclosure - Income Taxes",
     "shortName": "Income Taxes",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "27",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://neuraxis.com/role/SubsequentEvents",
     "longName": "999032 - Disclosure - Subsequent Events",
     "shortName": "Subsequent Events",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "28",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://neuraxis.com/role/SummaryOfSignificantAccountingPoliciesPolicies",
     "longName": "999033 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "29",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:UseOfEstimates",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:UseOfEstimates",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://neuraxis.com/role/SummaryOfSignificantAccountingPoliciesTables",
     "longName": "999034 - Disclosure - Summary of Significant Accounting Policies (Tables)",
     "shortName": "Summary of Significant Accounting Policies (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "30",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "NRXS:ScheduleOfPropertyPlantAndEquipmentUsefulLivesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "NRXS:ScheduleOfPropertyPlantAndEquipmentUsefulLivesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R31": {
     "role": "http://neuraxis.com/role/RelatedPartyTransactionsTables",
     "longName": "999035 - Disclosure - Related Party Transactions (Tables)",
     "shortName": "Related Party Transactions (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "31",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R32": {
     "role": "http://neuraxis.com/role/PropertyAndEquipmentTables",
     "longName": "999036 - Disclosure - Property and Equipment (Tables)",
     "shortName": "Property and Equipment (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "32",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R33": {
     "role": "http://neuraxis.com/role/IntangibleAssetsTables",
     "longName": "999037 - Disclosure - Intangible Assets (Tables)",
     "shortName": "Intangible Assets (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "33",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R34": {
     "role": "http://neuraxis.com/role/AccruedExpensesTables",
     "longName": "999038 - Disclosure - Accrued Expenses (Tables)",
     "shortName": "Accrued Expenses (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "34",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R35": {
     "role": "http://neuraxis.com/role/LeasesTables",
     "longName": "999039 - Disclosure - Leases (Tables)",
     "shortName": "Leases (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "35",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R36": {
     "role": "http://neuraxis.com/role/CommonStockAndWarrantsTables",
     "longName": "999040 - Disclosure - Common Stock and Warrants (Tables)",
     "shortName": "Common Stock and Warrants (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "36",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R37": {
     "role": "http://neuraxis.com/role/Stock-basedCompensationTables",
     "longName": "999041 - Disclosure - Stock-Based Compensation (Tables)",
     "shortName": "Stock-Based Compensation (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "37",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R38": {
     "role": "http://neuraxis.com/role/WarrantLiabilitiesTables",
     "longName": "999042 - Disclosure - Warrant Liabilities (Tables)",
     "shortName": "Warrant Liabilities (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "38",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "NRXS:ScheduleOfChangesInWarrantLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "NRXS:WarrantLiabilitiesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "NRXS:ScheduleOfChangesInWarrantLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "NRXS:WarrantLiabilitiesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R39": {
     "role": "http://neuraxis.com/role/DerivativeLiabilitiesTables",
     "longName": "999043 - Disclosure - Derivative Liabilities (Tables)",
     "shortName": "Derivative Liabilities (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "39",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:DerivativesAndFairValueTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:DerivativesAndFairValueTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R40": {
     "role": "http://neuraxis.com/role/SegmentInformationTables",
     "longName": "999044 - Disclosure - Segment Information (Tables)",
     "shortName": "Segment Information (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "40",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R41": {
     "role": "http://neuraxis.com/role/IncomeTaxesTables",
     "longName": "999045 - Disclosure - Income Taxes (Tables)",
     "shortName": "Income Taxes (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "41",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R42": {
     "role": "http://neuraxis.com/role/BasisOfPresentationOrganizationAndOtherMattersDetailsNarrative",
     "longName": "999046 - Disclosure - Basis of Presentation, Organization and Other Matters (Details Narrative)",
     "shortName": "Basis of Presentation, Organization and Other Matters (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "42",
     "firstAnchor": {
      "contextRef": "From2023-01-102023-01-10",
      "name": "us-gaap:StockholdersEquityNoteStockSplit",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-102023-01-10",
      "name": "us-gaap:StockholdersEquityNoteStockSplit",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R43": {
     "role": "http://neuraxis.com/role/ScheduleOfEstimatedUsefulLivesDetails",
     "longName": "999047 - Disclosure - Schedule of Estimated Useful Lives (Details)",
     "shortName": "Schedule of Estimated Useful Lives (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "43",
     "firstAnchor": {
      "contextRef": "AsOf2024-12-31_us-gaap_MachineryAndEquipmentMember_srt_MinimumMember",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "NRXS:ScheduleOfPropertyPlantAndEquipmentUsefulLivesTableTextBlock",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-12-31_us-gaap_MachineryAndEquipmentMember_srt_MinimumMember",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "NRXS:ScheduleOfPropertyPlantAndEquipmentUsefulLivesTableTextBlock",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R44": {
     "role": "http://neuraxis.com/role/ScheduleOfFairValueOfAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails",
     "longName": "999048 - Disclosure - Schedule of Fair Value of Assets and Liabilities measured on Recurring Basis (Details)",
     "shortName": "Schedule of Fair Value of Assets and Liabilities measured on Recurring Basis (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "44",
     "firstAnchor": {
      "contextRef": "AsOf2024-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel3Member",
      "name": "us-gaap:LiabilitiesFairValueDisclosure",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "us-gaap:FairValueMeasurementPolicyPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel3Member",
      "name": "us-gaap:LiabilitiesFairValueDisclosure",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "us-gaap:FairValueMeasurementPolicyPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R45": {
     "role": "http://neuraxis.com/role/ScheduleOfDilutiveCommonStockEquivalentsDetails",
     "longName": "999049 - Disclosure - Schedule of Dilutive Common Stock Equivalents (Details)",
     "shortName": "Schedule of Dilutive Common Stock Equivalents (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "45",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEarningsPerShareDilutedByCommonClassTextBlock",
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEarningsPerShareDilutedByCommonClassTextBlock",
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R46": {
     "role": "http://neuraxis.com/role/ScheduleOfBasicAndDilutedNetLossPerShareDetails",
     "longName": "999050 - Disclosure - Schedule of Basic and Diluted Net Loss Per Share (Details)",
     "shortName": "Schedule of Basic and Diluted Net Loss Per Share (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "46",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R47": {
     "role": "http://neuraxis.com/role/ScheduleOfDisaggregationOfRevenueDetails",
     "longName": "999051 - Disclosure - Schedule of Disaggregation of Revenue (Details)",
     "shortName": "Schedule of Disaggregation of Revenue (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "47",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:Revenues",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "us-gaap:RevenueRecognitionPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:Revenues",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "us-gaap:RevenueRecognitionPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R48": {
     "role": "http://neuraxis.com/role/ScheduleOfCustomerAccountsReceivableDetails",
     "longName": "999052 - Disclosure - Schedule of Customer Accounts Receivable (Details)",
     "shortName": "Schedule of Customer Accounts Receivable (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "48",
     "firstAnchor": {
      "contextRef": "AsOf2024-12-31_custom_CustomerAMember_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember",
      "name": "us-gaap:AccountsReceivableNet",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
       "us-gaap:ConcentrationRiskCreditRisk",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-12-31_custom_CustomerAMember_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember",
      "name": "us-gaap:AccountsReceivableNet",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
       "us-gaap:ConcentrationRiskCreditRisk",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R49": {
     "role": "http://neuraxis.com/role/ScheduleOfCustomersAccountedRevenuesDetails",
     "longName": "999053 - Disclosure - Schedule of Customers Accounted Revenues (Details)",
     "shortName": "Schedule of Customers Accounted Revenues (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "49",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-012024-12-31_custom_CustomerAMember_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ContractWithCustomerAssetAllowanceForCreditLossTableTextBlock",
       "us-gaap:ConcentrationRiskCreditRisk",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R50": {
     "role": "http://neuraxis.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative",
     "longName": "999054 - Disclosure - Summary of Significant Accounting Policies (Details Narrative)",
     "shortName": "Summary of Significant Accounting Policies (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "50",
     "firstAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:AllowanceForDoubtfulAccountsReceivable",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:ProvisionForOtherCreditLosses",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:TradeAndOtherAccountsReceivablePolicy",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R51": {
     "role": "http://neuraxis.com/role/ScheduleOfRelatedPartyTransactionsDetails",
     "longName": "999055 - Disclosure - Schedule of Related Party Transactions (Details)",
     "shortName": "Schedule of Related Party Transactions (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "51",
     "firstAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "NRXS:AllowanceForInterestReceivableCurrent",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-12-31_custom_ShareHolderOneMember",
      "name": "us-gaap:NotesAndLoansReceivableGrossCurrent",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R52": {
     "role": "http://neuraxis.com/role/ScheduleOfRelatedPartyLoansPayableToShareholderDetails",
     "longName": "999056 - Disclosure - Schedule of Related Party Loans payable to shareholder (Details)",
     "shortName": "Schedule of Related Party Loans payable to shareholder (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "52",
     "firstAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "NRXS:InterestAndServiceFeeAccrued",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "NRXS:ScheduleOfRelatedPartyLoansTableTextBlock",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "NRXS:InterestAndServiceFeeAccrued",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "NRXS:ScheduleOfRelatedPartyLoansTableTextBlock",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R53": {
     "role": "http://neuraxis.com/role/RelatedPartyTransactionsDetailsNarrative",
     "longName": "999057 - Disclosure - Related Party Transactions (Details Narrative)",
     "shortName": "Related Party Transactions (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "53",
     "firstAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "NRXS:AllowanceForInterestReceivableCurrent",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-012024-12-31_srt_ChiefFinancialOfficerMember",
      "name": "us-gaap:StockIssuedDuringPeriodSharesIssuedForServices",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R54": {
     "role": "http://neuraxis.com/role/ScheduleOfPropertyAndEquipmentDetails",
     "longName": "999058 - Disclosure - Schedule of Property And Equipment (Details)",
     "shortName": "Schedule of Property And Equipment (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "54",
     "firstAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-12-31_us-gaap_MachineryAndEquipmentMember",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R55": {
     "role": "http://neuraxis.com/role/PropertyAndEquipmentDetailsNarrative",
     "longName": "999059 - Disclosure - Property and Equipment (Details Narrative)",
     "shortName": "Property and Equipment (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "55",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:Depreciation",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-012024-12-31_custom_DecemberTwoThousandTwentyFiveMember",
      "name": "us-gaap:Depreciation",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R56": {
     "role": "http://neuraxis.com/role/ScheduleOfIntangibleAssetsDetails",
     "longName": "999060 - Disclosure - Schedule of Intangible Assets (Details)",
     "shortName": "Schedule of Intangible Assets (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "56",
     "firstAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R57": {
     "role": "http://neuraxis.com/role/IntangibleAssetsDetailsNarrative",
     "longName": "999061 - Disclosure - Intangible Assets (Details Narrative)",
     "shortName": "Intangible Assets (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "57",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:AmortizationOfIntangibleAssets",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:IntangibleAssetsFiniteLivedPolicy",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-012024-12-31_custom_DecemberTwoThousandTwentyFiveMember",
      "name": "us-gaap:AmortizationOfIntangibleAssets",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R58": {
     "role": "http://neuraxis.com/role/ScheduleOfAccruedExpensesDetails",
     "longName": "999062 - Disclosure - Schedule of Accrued Expenses (Details)",
     "shortName": "Schedule of Accrued Expenses (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "58",
     "firstAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "NRXS:AccruedCompensationAndBenefitsCurrent",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "NRXS:AccruedCompensationAndBenefitsCurrent",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R59": {
     "role": "http://neuraxis.com/role/NotesPayableDetailsNarrative",
     "longName": "999063 - Disclosure - Notes Payable (Details Narrative)",
     "shortName": "Notes Payable (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "59",
     "firstAnchor": {
      "contextRef": "From2023-01-012023-12-31",
      "name": "us-gaap:ProceedsFromIssuanceInitialPublicOffering",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2023-11-08",
      "name": "us-gaap:DebtInstrumentConvertibleConversionPrice1",
      "unitRef": "USDPShares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:DebtDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R60": {
     "role": "http://neuraxis.com/role/ScheduleOfOperatingLeasesDetails",
     "longName": "999064 - Disclosure - Schedule of Operating Leases (Details)",
     "shortName": "Schedule of Operating Leases (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "60",
     "firstAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R61": {
     "role": "http://neuraxis.com/role/ScheduleOfMaturitiesOperatingLeaseLiabilitiesDetails",
     "longName": "999065 - Disclosure - Schedule of Maturities Operating Lease Liabilities (Details)",
     "shortName": "Schedule of Maturities Operating Lease Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "61",
     "firstAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R62": {
     "role": "http://neuraxis.com/role/LeasesDetailsNarrative",
     "longName": "999066 - Disclosure - Leases (Details Narrative)",
     "shortName": "Leases (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "62",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:LesseeOperatingLeaseDescription",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:LesseeOperatingLeaseDescription",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R63": {
     "role": "http://neuraxis.com/role/ScheduleOfWarrantActivityForCommonStockDetails",
     "longName": "999067 - Disclosure - Schedule of Warrant Activity for Common Stock (Details)",
     "shortName": "Schedule of Warrant Activity for Common Stock (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "63",
     "firstAnchor": {
      "contextRef": "AsOf2023-12-31",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
      "unitRef": "USDPShares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-012024-12-31_us-gaap_CommonStockMember",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "NRXS:ScheduleOfWarrantActivityForCommonStockTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R64": {
     "role": "http://neuraxis.com/role/ScheduleOfWarrantActivityForPreferredStockDetails",
     "longName": "999068 - Disclosure - Schedule of Warrant Activity for Preferred Stock (Details)",
     "shortName": "Schedule of Warrant Activity for Preferred Stock (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "64",
     "firstAnchor": {
      "contextRef": "AsOf2023-12-31",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
      "unitRef": "USDPShares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2022-12-31_us-gaap_PreferredStockMember",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "NRXS:ScheduleOfWarrantActivityForPreferredStockTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R65": {
     "role": "http://neuraxis.com/role/ScheduleOfWarrantsOutstandingAndExercisableDetails",
     "longName": "999069 - Disclosure - Schedule of Warrants outstanding and Exercisable (Details)",
     "shortName": "Schedule of Warrants outstanding and Exercisable (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "65",
     "firstAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:ClassOfWarrantOrRightOutstanding",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-12-31_custom_InvestorWarrantOneMember",
      "name": "us-gaap:ClassOfWarrantOrRightOutstanding",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R66": {
     "role": "http://neuraxis.com/role/CommonStockAndWarrantsDetailsNarrative",
     "longName": "999070 - Disclosure - Common Stock and Warrants (Details Narrative)",
     "shortName": "Common Stock and Warrants (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "66",
     "firstAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:CommonStockSharesAuthorized",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-102023-01-10",
      "name": "us-gaap:StockholdersEquityReverseStockSplit",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R67": {
     "role": "http://neuraxis.com/role/PreferredStockDetailsNarrative",
     "longName": "999071 - Disclosure - Preferred Stock (Details Narrative)",
     "shortName": "Preferred Stock (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "67",
     "firstAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:PreferredStockSharesAuthorized",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-08-15_custom_AmendedTwoThousandTwentyFourConvertibleNotesMember",
      "name": "us-gaap:DebtInstrumentFaceAmount",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:PreferredStockTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R68": {
     "role": "http://neuraxis.com/role/ScheduleOfOption-pricingModelWithFollowingWeighted-averageAssumptionsDetails",
     "longName": "999072 - Disclosure - Schedule of Option-pricing Model with Following Weighted-average Assumptions (Details)",
     "shortName": "Schedule of Option-pricing Model with Following Weighted-average Assumptions (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "68",
     "firstAnchor": {
      "contextRef": "AsOf2023-12-31",
      "name": "us-gaap:SharePrice",
      "unitRef": "USDPShares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2023-12-31_custom_TwentySeventeenStockCompensationPlanMember",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R69": {
     "role": "http://neuraxis.com/role/ScheduleOfStockOptionActivityDetails",
     "longName": "999073 - Disclosure - Schedule of Stock Option Activity (Details)",
     "shortName": "Schedule of Stock Option Activity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "69",
     "firstAnchor": {
      "contextRef": "AsOf2023-12-31",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R70": {
     "role": "http://neuraxis.com/role/Stock-basedCompensationDetailsNarrative",
     "longName": "999074 - Disclosure - Stock-Based Compensation (Details Narrative)",
     "shortName": "Stock-Based Compensation (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "70",
     "firstAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:CommonStockSharesAuthorized",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-012024-12-31_srt_ChiefFinancialOfficerMember",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R71": {
     "role": "http://neuraxis.com/role/ScheduleOfChangesInWarrantLiabilitiesDetails",
     "longName": "999075 - Disclosure - Schedule of Changes in Warrant Liabilities (Details)",
     "shortName": "Schedule of Changes in Warrant Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "71",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:FairValueAdjustmentOfWarrants",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2022-12-31_us-gaap_FairValueInputsLevel3Member",
      "name": "us-gaap:WarrantsAndRightsOutstanding",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "NRXS:ScheduleOfChangesInWarrantLiabilitiesTableTextBlock",
       "NRXS:WarrantLiabilitiesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R72": {
     "role": "http://neuraxis.com/role/WarrantLiabilitiesDetailsNarrative",
     "longName": "999076 - Disclosure - Warrant Liabilities (Details Narrative)",
     "shortName": "Warrant Liabilities (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "72",
     "firstAnchor": {
      "contextRef": "AsOf2024-12-31_us-gaap_MeasurementInputSharePriceMember",
      "name": "us-gaap:WarrantsAndRightsOutstandingMeasurementInput",
      "unitRef": "USDPShares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "p",
       "NRXS:WarrantLiabilitiesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-12-31_us-gaap_MeasurementInputSharePriceMember",
      "name": "us-gaap:WarrantsAndRightsOutstandingMeasurementInput",
      "unitRef": "USDPShares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "p",
       "NRXS:WarrantLiabilitiesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R73": {
     "role": "http://neuraxis.com/role/ScheduleOfChangesInDerivativeLiabilitiesDetails",
     "longName": "999077 - Disclosure - Schedule of Changes in Derivative Liabilities (Details)",
     "shortName": "Schedule of Changes in Derivative Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "73",
     "firstAnchor": {
      "contextRef": "AsOf2022-12-31_us-gaap_FairValueInputsLevel3Member",
      "name": "NRXS:ChangesInDerivativeLiabilities",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock",
       "us-gaap:DerivativesAndFairValueTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2022-12-31_us-gaap_FairValueInputsLevel3Member",
      "name": "NRXS:ChangesInDerivativeLiabilities",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock",
       "us-gaap:DerivativesAndFairValueTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R74": {
     "role": "http://neuraxis.com/role/DerivativeLiabilitiesDetailsNarrative",
     "longName": "999078 - Disclosure - Derivative Liabilities (Details Narrative)",
     "shortName": "Derivative Liabilities (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "74",
     "firstAnchor": {
      "contextRef": "AsOf2024-12-31_us-gaap_MeasurementInputSharePriceMember",
      "name": "us-gaap:DerivativeLiabilityMeasurementInput",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:DerivativesAndFairValueTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-12-31_us-gaap_MeasurementInputSharePriceMember",
      "name": "us-gaap:DerivativeLiabilityMeasurementInput",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:DerivativesAndFairValueTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R75": {
     "role": "http://neuraxis.com/role/RetirementPlanDetailsNarrative",
     "longName": "999079 - Disclosure - Retirement Plan (Details Narrative)",
     "shortName": "Retirement Plan (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "75",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R76": {
     "role": "http://neuraxis.com/role/ScheduleOfReconcilesCompanysNetSalesAndOperatingLossDetails",
     "longName": "999080 - Disclosure - Schedule of Reconciles the Company\u2019s Net Sales and Operating Loss (Details)",
     "shortName": "Schedule of Reconciles the Company\u2019s Net Sales and Operating Loss (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "76",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-012024-12-31_us-gaap_OperatingSegmentsMember",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R77": {
     "role": "http://neuraxis.com/role/SegmentInformationDetailsNarrative",
     "longName": "999081 - Disclosure - Segment Information (Details Narrative)",
     "shortName": "Segment Information (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "77",
     "firstAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:Assets",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:DepreciationAndAmortization",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R78": {
     "role": "http://neuraxis.com/role/CommitmentsAndContingenciesDetailsNarrative",
     "longName": "999082 - Disclosure - Commitments and Contingencies (Details Narrative)",
     "shortName": "Commitments and Contingencies (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "78",
     "firstAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:AccruedLiabilitiesCurrent",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2022-07-142022-07-14",
      "name": "us-gaap:LossContingencyDamagesSoughtValue",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R79": {
     "role": "http://neuraxis.com/role/HealthBenefitPlanDetailsNarrative",
     "longName": "999083 - Disclosure - Health Benefit Plan (Details Narrative)",
     "shortName": "Health Benefit Plan (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "79",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:HealthCareOrganizationStopLossInsurancePremiumExpense",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "p",
       "NRXS:HealthBenefitPlanDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:HealthCareOrganizationStopLossInsurancePremiumExpense",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "p",
       "NRXS:HealthBenefitPlanDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R80": {
     "role": "http://neuraxis.com/role/ScheduleOfIncomeTaxProvisionDetails",
     "longName": "999084 - Disclosure - Schedule of Income Tax Provision (Details)",
     "shortName": "Schedule of Income Tax Provision (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "80",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:DeferredFederalIncomeTaxExpenseBenefit",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:DeferredFederalIncomeTaxExpenseBenefit",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R81": {
     "role": "http://neuraxis.com/role/ScheduleOfFederalStatutoryIncomeTaxRateAndEffectiveIncomeTaxRateDetails",
     "longName": "999085 - Disclosure - Schedule of Federal Statutory Income Tax Rate and Effective Income Tax Rate (Details)",
     "shortName": "Schedule of Federal Statutory Income Tax Rate and Effective Income Tax Rate (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "81",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R82": {
     "role": "http://neuraxis.com/role/ScheduleOfNetDeferredTaxAssetsAndLiabilitiesDetails",
     "longName": "999086 - Disclosure - Schedule of Net Deferred Tax Assets and Liabilities (Details)",
     "shortName": "Schedule of Net Deferred Tax Assets and Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "82",
     "firstAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R83": {
     "role": "http://neuraxis.com/role/ScheduleOfStateCarryforwardsDetails",
     "longName": "999087 - Disclosure - Schedule of State Carryforwards (Details)",
     "shortName": "Schedule of State Carryforwards (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "83",
     "firstAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:SummaryOfOperatingLossCarryforwardsTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-12-31_custom_TaxYear2037Member",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:SummaryOfOperatingLossCarryforwardsTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R84": {
     "role": "http://neuraxis.com/role/IncomeTaxesDetailsNarrative",
     "longName": "999088 - Disclosure - Income Taxes (Details Narrative)",
     "shortName": "Income Taxes (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "84",
     "firstAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:SummaryOfOperatingLossCarryforwardsTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R85": {
     "role": "http://neuraxis.com/role/SubsequentEventsDetailsNarrative",
     "longName": "999089 - Disclosure - Subsequent Events (Details Narrative)",
     "shortName": "Subsequent Events (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "85",
     "firstAnchor": {
      "contextRef": "From2024-01-012024-12-31_us-gaap_CommonStockMember",
      "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-03-062025-03-06_us-gaap_SubsequentEventMember",
      "name": "us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "us-gaap:SubsequentEventsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    }
   },
   "tag": {
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
     "presentation": [
      "http://neuraxis.com/role/AccruedExpenses"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Expenses",
        "documentation": "The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period."
       }
      }
     },
     "auth_ref": [
      "r498"
     ]
    },
    "us-gaap_AccountsPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://neuraxis.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://neuraxis.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts payable",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r64",
      "r898"
     ]
    },
    "us-gaap_AccountsPayableCurrentAndNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsPayableCurrentAndNoncurrent",
     "crdr": "credit",
     "presentation": [
      "http://neuraxis.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Accounts payable",
        "label": "Accounts Payable",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business."
       }
      }
     },
     "auth_ref": [
      "r135",
      "r1188"
     ]
    },
    "us-gaap_AccountsReceivableMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsReceivableMember",
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfCustomerAccountsReceivableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Receivable [Member]",
        "documentation": "Due from customers or clients for goods or services that have been delivered or sold."
       }
      }
     },
     "auth_ref": [
      "r827"
     ]
    },
    "us-gaap_AccountsReceivableNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsReceivableNet",
     "crdr": "debit",
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfCustomerAccountsReceivableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net accounts receivable",
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business."
       }
      }
     },
     "auth_ref": [
      "r758",
      "r826",
      "r915",
      "r1192",
      "r1193"
     ]
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsReceivableNetCurrent",
     "crdr": "debit",
     "calculation": {
      "http://neuraxis.com/role/BalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://neuraxis.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts receivable, net of credit losses of $5,000 and $11,993 as of December 31, 2024 and 2023, respectively",
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current."
       }
      }
     },
     "auth_ref": [
      "r1082"
     ]
    },
    "NRXS_AccreditedInvestorsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://neuraxis.com/20241231",
     "localname": "AccreditedInvestorsMember",
     "presentation": [
      "http://neuraxis.com/role/NotesPayableDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accredited Investors [Member]",
        "documentation": "Accredited Investors [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccrualForTaxesOtherThanIncomeTaxesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://neuraxis.com/role/ScheduleOfAccruedExpensesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfAccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for real and property taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r66",
      "r850",
      "r1149"
     ]
    },
    "us-gaap_AccruedBonusesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccruedBonusesCurrent",
     "crdr": "credit",
     "presentation": [
      "http://neuraxis.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Incentive bonus",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for incentive compensation awarded to employees and directors or earned by them based on the terms of one or more relevant arrangements. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r66"
     ]
    },
    "NRXS_AccruedCompensationAndBenefitsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://neuraxis.com/20241231",
     "localname": "AccruedCompensationAndBenefitsCurrent",
     "crdr": "credit",
     "calculation": {
      "http://neuraxis.com/role/ScheduleOfAccruedExpensesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfAccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation and benefits",
        "documentation": "Accrued compensation and benefits current."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://neuraxis.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      },
      "http://neuraxis.com/role/ScheduleOfAccruedExpensesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://neuraxis.com/role/BalanceSheets",
      "http://neuraxis.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://neuraxis.com/role/ScheduleOfAccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued expenses",
        "totalLabel": "Total accrued expenses",
        "verboseLabel": "Accrued amount for backpay",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r66"
     ]
    },
    "us-gaap_AccruedLiabilitiesCurrentAndNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccruedLiabilitiesCurrentAndNoncurrent",
     "crdr": "credit",
     "presentation": [
      "http://neuraxis.com/role/NotesPayableDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Liabilities",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities."
       }
      }
     },
     "auth_ref": [
      "r135"
     ]
    },
    "us-gaap_AccruedLiabilitiesFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccruedLiabilitiesFairValueDisclosure",
     "crdr": "credit",
     "presentation": [
      "http://neuraxis.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Accrued expenses",
        "label": "Accrued Liabilities, Fair Value Disclosure",
        "documentation": "Fair value portion of accrued expenses."
       }
      }
     },
     "auth_ref": [
      "r66",
      "r1163",
      "r1164",
      "r1168"
     ]
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://neuraxis.com/role/BalanceSheets": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0,
       "order": 2.0
      },
      "http://neuraxis.com/role/ScheduleOfPropertyAndEquipmentDetails": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://neuraxis.com/role/BalanceSheets",
      "http://neuraxis.com/role/ScheduleOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less - accumulated depreciation",
        "negatedTerseLabel": "Less: accumulated depreciation",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services."
       }
      }
     },
     "auth_ref": [
      "r41",
      "r190",
      "r693"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedOtherComprehensiveIncomeLossLineItems",
     "presentation": [
      "http://neuraxis.com/role/CommonStockAndWarrantsTables",
      "http://neuraxis.com/role/ScheduleOfWarrantActivityForCommonStockDetails",
      "http://neuraxis.com/role/ScheduleOfWarrantActivityForPreferredStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated Other Comprehensive Income (Loss) [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r205",
      "r206",
      "r573",
      "r574",
      "r575",
      "r576",
      "r577",
      "r578"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedOtherComprehensiveIncomeLossTable",
     "presentation": [
      "http://neuraxis.com/role/CommonStockAndWarrantsTables",
      "http://neuraxis.com/role/ScheduleOfWarrantActivityForCommonStockDetails",
      "http://neuraxis.com/role/ScheduleOfWarrantActivityForPreferredStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated Other Comprehensive Income (Loss) [Table]",
        "documentation": "Disclosure of information about components of accumulated other comprehensive income (loss)."
       }
      }
     },
     "auth_ref": [
      "r205",
      "r206",
      "r573",
      "r574",
      "r575",
      "r576",
      "r577",
      "r578"
     ]
    },
    "NRXS_AdditionToDerivativeLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://neuraxis.com/20241231",
     "localname": "AdditionToDerivativeLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfChangesInDerivativeLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Addition",
        "documentation": "Addition to derivative liabilities.",
        "label": "Addition to derivative liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "NRXS_AdditionToWarrantLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://neuraxis.com/20241231",
     "localname": "AdditionToWarrantLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfChangesInWarrantLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Addition",
        "documentation": "Addition to warrant liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_Additional402vDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Additional402vDisclosureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional 402(v) Disclosure"
       }
      }
     },
     "auth_ref": [
      "r984"
     ]
    },
    "us-gaap_AdditionalPaidInCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdditionalPaidInCapital",
     "crdr": "credit",
     "calculation": {
      "http://neuraxis.com/role/BalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://neuraxis.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional paid in capital",
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock."
       }
      }
     },
     "auth_ref": [
      "r80",
      "r898",
      "r1224"
     ]
    },
    "NRXS_AdditionalPaidInCapitalFromWarrantsIssuedAsDebtDiscount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://neuraxis.com/20241231",
     "localname": "AdditionalPaidInCapitalFromWarrantsIssuedAsDebtDiscount",
     "crdr": "credit",
     "presentation": [
      "http://neuraxis.com/role/StatementsOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional paid in capital from warrants issued as debt discount",
        "documentation": "Additional paid in capital from warrants issued as debt discount."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://neuraxis.com/role/StatementsOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Paid-in Capital [Member]",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r723",
      "r1067",
      "r1068",
      "r1069",
      "r1071",
      "r1161",
      "r1226"
     ]
    },
    "ecd_AdjToCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation, Amount"
       }
      }
     },
     "auth_ref": [
      "r990"
     ]
    },
    "ecd_AdjToCompAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToCompAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation [Axis]"
       }
      }
     },
     "auth_ref": [
      "r990"
     ]
    },
    "ecd_AdjToNonPeoNeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToNonPeoNeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Non-PEO NEO Compensation Footnote"
       }
      }
     },
     "auth_ref": [
      "r990"
     ]
    },
    "ecd_AdjToPeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToPeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment To PEO Compensation, Footnote"
       }
      }
     },
     "auth_ref": [
      "r990"
     ]
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature",
     "crdr": "credit",
     "presentation": [
      "http://neuraxis.com/role/StatementsOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt discount on mandatory conversion of convertible promissory notes to Series B Preferred Stock",
        "documentation": "Amount of increase (decrease) in additional paid in capital (APIC) resulting from recognition of deferred taxes for convertible debt with a beneficial conversion feature."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r116",
      "r527"
     ]
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToAdditionalPaidInCapitalWarrantIssued",
     "crdr": "credit",
     "presentation": [
      "http://neuraxis.com/role/StatementsOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional paid in capital from warrants issued under advisory agreement",
        "documentation": "Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r42",
      "r116"
     ]
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://neuraxis.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to reconcile net loss to net cash used by operating activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdvertisingCostsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdvertisingCostsPolicyTextBlock",
     "presentation": [
      "http://neuraxis.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Advertising Cost",
        "documentation": "Disclosure of accounting policy for advertising cost."
       }
      }
     },
     "auth_ref": [
      "r152"
     ]
    },
    "us-gaap_AdvertisingExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdvertisingExpense",
     "crdr": "debit",
     "presentation": [
      "http://neuraxis.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Advertising cost",
        "documentation": "Amount charged to advertising expense for the period, which are expenses incurred with the objective of increasing revenue for a specified brand, product or product line."
       }
      }
     },
     "auth_ref": [
      "r499",
      "r883"
     ]
    },
    "NRXS_AdvisoryAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://neuraxis.com/20241231",
     "localname": "AdvisoryAgreementMember",
     "presentation": [
      "http://neuraxis.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://neuraxis.com/role/CommonStockAndWarrantsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Advisory Agreement [Member]",
        "documentation": "Advisory Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "NRXS_AdvisoryAgreementWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://neuraxis.com/20241231",
     "localname": "AdvisoryAgreementWarrantsMember",
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfWarrantsOutstandingAndExercisableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Advisory Agreement Warrants [Member]",
        "documentation": "Advisory Agreement Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "NRXS_AdvisoryAgreementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://neuraxis.com/20241231",
     "localname": "AdvisoryAgreementsMember",
     "presentation": [
      "http://neuraxis.com/role/CommonStockAndWarrantsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Advisory Agreements [Member]",
        "documentation": "Advisory Agreements [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "NRXS_AdvisoryFees": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://neuraxis.com/20241231",
     "localname": "AdvisoryFees",
     "crdr": "credit",
     "calculation": {
      "http://neuraxis.com/role/ScheduleOfAccruedExpensesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfAccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Advisory fees",
        "documentation": "Advisory fees"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r951",
      "r962",
      "r976",
      "r1002"
     ]
    },
    "ecd_AggtErrCompNotYetDeterminedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtErrCompNotYetDeterminedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Not Yet Determined"
       }
      }
     },
     "auth_ref": [
      "r954",
      "r965",
      "r979",
      "r1005"
     ]
    },
    "NRXS_AlexanderCapitalLPMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://neuraxis.com/20241231",
     "localname": "AlexanderCapitalLPMember",
     "presentation": [
      "http://neuraxis.com/role/BasisOfPresentationOrganizationAndOtherMattersDetailsNarrative",
      "http://neuraxis.com/role/NotesPayableDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Alexander Capital LP [Member]",
        "documentation": "Alexander Capital LP [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AllAdjToCompMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllAdjToCompMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "auth_ref": [
      "r990"
     ]
    },
    "ecd_AllExecutiveCategoriesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllExecutiveCategoriesMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "auth_ref": [
      "r997"
     ]
    },
    "ecd_AllIndividualsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllIndividualsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "auth_ref": [
      "r955",
      "r966",
      "r980",
      "r997",
      "r1006",
      "r1010",
      "r1018"
     ]
    },
    "NRXS_AllOtherStatesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://neuraxis.com/20241231",
     "localname": "AllOtherStatesMember",
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfDisaggregationOfRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All other States [Member]",
        "documentation": "All other States [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AllowanceForDoubtfulAccountsReceivable",
     "crdr": "credit",
     "presentation": [
      "http://neuraxis.com/role/BalanceSheetsParenthetical",
      "http://neuraxis.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts receivable, net of credit losses",
        "verboseLabel": "Allowance for doubtful accounts",
        "documentation": "Amount of allowance for credit loss on accounts receivable."
       }
      }
     },
     "auth_ref": [
      "r198",
      "r289",
      "r323",
      "r326",
      "r328",
      "r1193"
     ]
    },
    "NRXS_AllowanceForInterestIncomeCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://neuraxis.com/20241231",
     "localname": "AllowanceForInterestIncomeCurrent",
     "crdr": "credit",
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfRelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Allowance for collection risk, interest income",
        "documentation": "Allowance for interest income current.",
        "label": "AllowanceForInterestIncomeCurrent"
       }
      }
     },
     "auth_ref": []
    },
    "NRXS_AllowanceForInterestReceivableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://neuraxis.com/20241231",
     "localname": "AllowanceForInterestReceivableCurrent",
     "crdr": "credit",
     "presentation": [
      "http://neuraxis.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://neuraxis.com/role/ScheduleOfRelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Allowance for collection risk, interest receivable",
        "verboseLabel": "Allowance for interest receivable current",
        "documentation": "Allowance for interest receivable current."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AllowanceForNotesAndLoansReceivableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AllowanceForNotesAndLoansReceivableCurrent",
     "crdr": "credit",
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfRelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Allowance for collection risk, loan receivable",
        "label": "Financing Receivable, Allowance for Credit Loss, Current",
        "documentation": "Amount of allowance for credit loss on financing receivable, classified as current."
       }
      }
     },
     "auth_ref": [
      "r198",
      "r289",
      "r323"
     ]
    },
    "NRXS_AmendedTwoThousandTwentyFourConvertibleNotesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://neuraxis.com/20241231",
     "localname": "AmendedTwoThousandTwentyFourConvertibleNotesMember",
     "presentation": [
      "http://neuraxis.com/role/PreferredStockDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amended 2024 Convertible Notes [Member]",
        "documentation": "Amended 2024 Convertible Notes [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentDescription",
     "presentation": [
      "http://neuraxis.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Description",
        "documentation": "Description of changes contained within amended document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://neuraxis.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AmortizationOfFinancingCostsAndDiscounts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AmortizationOfFinancingCostsAndDiscounts",
     "crdr": "debit",
     "calculation": {
      "http://neuraxis.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 2.0
      },
      "http://neuraxis.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": -1.0,
       "order": 5.0
      },
      "http://neuraxis.com/role/ScheduleOfReconcilesCompanysNetSalesAndOperatingLossDetails": {
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfReconcilesCompanysNetSalesAndOperatingLossDetails",
      "http://neuraxis.com/role/StatementsOfCashFlows",
      "http://neuraxis.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Amortization of debt discount and issuance cost",
        "label": "Amortization of debt discount and issuance cost",
        "documentation": "Amount of amortization expense attributable to debt discount (premium) and debt issuance costs."
       }
      }
     },
     "auth_ref": [
      "r407",
      "r873",
      "r874",
      "r1060",
      "r1172"
     ]
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AmortizationOfIntangibleAssets",
     "crdr": "debit",
     "presentation": [
      "http://neuraxis.com/role/IntangibleAssetsDetailsNarrative",
      "http://neuraxis.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amortization expense",
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r342",
      "r349",
      "r869"
     ]
    },
    "dei_AnnualInformationForm": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AnnualInformationForm",
     "presentation": [
      "http://neuraxis.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual Information Form",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form."
       }
      }
     },
     "auth_ref": [
      "r958"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfDilutiveCommonStockEquivalentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Totals",
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r253"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfDilutiveCommonStockEquivalentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities [Axis]",
        "documentation": "Information by type of antidilutive security."
       }
      }
     },
     "auth_ref": [
      "r27"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfDilutiveCommonStockEquivalentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesNameDomain",
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfDilutiveCommonStockEquivalentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r27"
     ]
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "presentation": [
      "http://neuraxis.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://neuraxis.com/role/CommonStockAndWarrantsDetailsNarrative",
      "http://neuraxis.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r543"
     ]
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://neuraxis.com/role/BalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://neuraxis.com/role/BalanceSheets",
      "http://neuraxis.com/role/SegmentInformationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total Assets",
        "verboseLabel": "Assets",
        "label": "Assets [Default Label]",
        "documentation": "Amount of asset recognized for present right to economic benefit."
       }
      }
     },
     "auth_ref": [
      "r131",
      "r144",
      "r192",
      "r223",
      "r256",
      "r264",
      "r276",
      "r280",
      "r320",
      "r374",
      "r375",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r383",
      "r384",
      "r544",
      "r546",
      "r572",
      "r683",
      "r763",
      "r861",
      "r862",
      "r898",
      "r923",
      "r1116",
      "r1117",
      "r1179"
     ]
    },
    "us-gaap_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://neuraxis.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://neuraxis.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://neuraxis.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current assets",
        "label": "Assets, Current",
        "documentation": "Amount of asset recognized for present right to economic benefit, classified as current."
       }
      }
     },
     "auth_ref": [
      "r185",
      "r201",
      "r223",
      "r320",
      "r374",
      "r375",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r383",
      "r384",
      "r544",
      "r546",
      "r572",
      "r898",
      "r1116",
      "r1117",
      "r1179"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://neuraxis.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Assets:"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AuditedAnnualFinancialStatements": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditedAnnualFinancialStatements",
     "presentation": [
      "http://neuraxis.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Audited Annual Financial Statements",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements."
       }
      }
     },
     "auth_ref": [
      "r958"
     ]
    },
    "dei_AuditorFirmId": {
     "xbrltype": "nonemptySequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorFirmId",
     "presentation": [
      "http://neuraxis.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Firm ID",
        "documentation": "PCAOB issued Audit Firm Identifier"
       }
      }
     },
     "auth_ref": [
      "r935",
      "r937",
      "r958"
     ]
    },
    "dei_AuditorLocation": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorLocation",
     "presentation": [
      "http://neuraxis.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location"
       }
      }
     },
     "auth_ref": [
      "r935",
      "r937",
      "r958"
     ]
    },
    "dei_AuditorName": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorName",
     "presentation": [
      "http://neuraxis.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name"
       }
      }
     },
     "auth_ref": [
      "r935",
      "r937",
      "r958"
     ]
    },
    "dei_AuditorOpinionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorOpinionTextBlock",
     "presentation": [
      "http://neuraxis.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Opinion [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1032"
     ]
    },
    "ecd_AwardExrcPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardExrcPrice",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise Price"
       }
      }
     },
     "auth_ref": [
      "r1013"
     ]
    },
    "ecd_AwardGrantDateFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardGrantDateFairValue",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value as of Grant Date"
       }
      }
     },
     "auth_ref": [
      "r1014"
     ]
    },
    "ecd_AwardTmgDiscLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgDiscLineItems",
     "auth_ref": [
      "r1009"
     ]
    },
    "ecd_AwardTmgHowMnpiCnsdrdTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgHowMnpiCnsdrdTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing, How MNPI Considered"
       }
      }
     },
     "auth_ref": [
      "r1009"
     ]
    },
    "ecd_AwardTmgMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Method"
       }
      }
     },
     "auth_ref": [
      "r1009"
     ]
    },
    "ecd_AwardTmgMnpiCnsdrdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMnpiCnsdrdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Considered"
       }
      }
     },
     "auth_ref": [
      "r1009"
     ]
    },
    "ecd_AwardTmgMnpiDiscTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMnpiDiscTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Disclosure"
       }
      }
     },
     "auth_ref": [
      "r1009"
     ]
    },
    "ecd_AwardTmgPredtrmndFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgPredtrmndFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Predetermined"
       }
      }
     },
     "auth_ref": [
      "r1009"
     ]
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://neuraxis.com/role/IntangibleAssetsDetailsNarrative",
      "http://neuraxis.com/role/PropertyAndEquipmentDetailsNarrative",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Type [Axis]",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r461",
      "r462",
      "r463",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489"
     ]
    },
    "ecd_AwardUndrlygSecuritiesAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardUndrlygSecuritiesAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Underlying Securities"
       }
      }
     },
     "auth_ref": [
      "r1012"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Name",
        "label": "Awards Close in Time to MNPI Disclosures, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r1011"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures [Table]"
       }
      }
     },
     "auth_ref": [
      "r1010"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures, Table"
       }
      }
     },
     "auth_ref": [
      "r1010"
     ]
    },
    "us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessDescriptionAndBasisOfPresentationTextBlock",
     "presentation": [
      "http://neuraxis.com/role/BasisOfPresentationOrganizationAndOtherMatters"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Basis of Presentation, Organization and Other Matters",
        "documentation": "The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)."
       }
      }
     },
     "auth_ref": [
      "r62",
      "r100",
      "r101"
     ]
    },
    "stpr_CA": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/stpr/2024",
     "localname": "CA",
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfDisaggregationOfRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "CALIFORNIA"
       }
      }
     },
     "auth_ref": []
    },
    "NRXS_CarmelIndianaMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://neuraxis.com/20241231",
     "localname": "CarmelIndianaMember",
     "presentation": [
      "http://neuraxis.com/role/LeasesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Carmel Indiana [Member]",
        "documentation": "Carmel Indiana [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Cash": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Cash",
     "crdr": "debit",
     "presentation": [
      "http://neuraxis.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r150",
      "r686",
      "r734",
      "r757",
      "r898",
      "r923",
      "r1050"
     ]
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "calculation": {
      "http://neuraxis.com/role/BalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://neuraxis.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and cash equivalents",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r19",
      "r188",
      "r847"
     ]
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "presentation": [
      "http://neuraxis.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents",
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value."
       }
      }
     },
     "auth_ref": [
      "r20"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
     "crdr": "debit",
     "presentation": [
      "http://neuraxis.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Cash and Cash Equivalents at Beginning of Period",
        "periodEndLabel": "Cash and Cash Equivalents at End of Period",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations",
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r19",
      "r96",
      "r219"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://neuraxis.com/role/StatementsOfCashFlows": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://neuraxis.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net Increase (Decrease) in Cash and Cash Equivalents",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r96"
     ]
    },
    "us-gaap_CashFDICInsuredAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashFDICInsuredAmount",
     "crdr": "debit",
     "presentation": [
      "http://neuraxis.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash, FDIC insured amount",
        "documentation": "The amount of cash deposited in financial institutions as of the balance sheet date that is insured by the Federal Deposit Insurance Corporation."
       }
      }
     },
     "auth_ref": []
    },
    "NRXS_CashFeePercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://neuraxis.com/20241231",
     "localname": "CashFeePercentage",
     "presentation": [
      "http://neuraxis.com/role/BasisOfPresentationOrganizationAndOtherMattersDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash fee percentage",
        "documentation": "Cash fee percentage."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "presentation": [
      "http://neuraxis.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Schedule of Non-Cash Investing and Financing Activities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashUninsuredAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashUninsuredAmount",
     "crdr": "debit",
     "presentation": [
      "http://neuraxis.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash uninsured",
        "documentation": "The amount of cash as of the balance sheet date that is not insured by the Federal Deposit Insurance Corporation."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ChangedPeerGroupFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ChangedPeerGroupFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changed Peer Group, Footnote"
       }
      }
     },
     "auth_ref": [
      "r988"
     ]
    },
    "NRXS_ChangesInDerivativeLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://neuraxis.com/20241231",
     "localname": "ChangesInDerivativeLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfChangesInDerivativeLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Derivative liabilities, Beginning balance",
        "periodEndLabel": "Derivative liabilities, Ending balance",
        "documentation": "Changes in derivative liabilities.",
        "label": "ChangesInDerivativeLiabilities"
       }
      }
     },
     "auth_ref": []
    },
    "NRXS_ChannelPartnersCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://neuraxis.com/20241231",
     "localname": "ChannelPartnersCapitalMember",
     "presentation": [
      "http://neuraxis.com/role/NotesPayableDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Channel Partners Capital [Member]",
        "documentation": "Channel Partners Capital [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_ChiefFinancialOfficerMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ChiefFinancialOfficerMember",
     "presentation": [
      "http://neuraxis.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://neuraxis.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Chief Financial Officer [Member]"
       }
      }
     },
     "auth_ref": [
      "r1081"
     ]
    },
    "srt_ChiefOperatingOfficerMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ChiefOperatingOfficerMember",
     "presentation": [
      "http://neuraxis.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Chief Operating Officer [Member]"
       }
      }
     },
     "auth_ref": [
      "r1081",
      "r1177"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CityAreaCode",
     "presentation": [
      "http://neuraxis.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfStockDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfStockDomain",
     "presentation": [
      "http://neuraxis.com/role/BalanceSheetsParenthetical",
      "http://neuraxis.com/role/BasisOfPresentationOrganizationAndOtherMattersDetailsNarrative",
      "http://neuraxis.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://neuraxis.com/role/CommonStockAndWarrantsDetailsNarrative",
      "http://neuraxis.com/role/NotesPayableDetailsNarrative",
      "http://neuraxis.com/role/PreferredStockDetailsNarrative",
      "http://neuraxis.com/role/StatementsOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock."
       }
      }
     },
     "auth_ref": [
      "r163",
      "r194",
      "r195",
      "r196",
      "r223",
      "r246",
      "r247",
      "r250",
      "r252",
      "r258",
      "r259",
      "r320",
      "r374",
      "r377",
      "r378",
      "r379",
      "r383",
      "r384",
      "r415",
      "r416",
      "r419",
      "r422",
      "r430",
      "r572",
      "r714",
      "r715",
      "r716",
      "r717",
      "r723",
      "r724",
      "r725",
      "r726",
      "r727",
      "r728",
      "r729",
      "r730",
      "r731",
      "r732",
      "r733",
      "r735",
      "r749",
      "r772",
      "r795",
      "r819",
      "r820",
      "r821",
      "r822",
      "r823",
      "r1037",
      "r1062",
      "r1073"
     ]
    },
    "us-gaap_ClassOfStockLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfStockLineItems",
     "presentation": [
      "http://neuraxis.com/role/CommonStockAndWarrantsDetailsNarrative",
      "http://neuraxis.com/role/PreferredStockDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r194",
      "r195",
      "r196",
      "r258",
      "r415",
      "r416",
      "r417",
      "r419",
      "r422",
      "r428",
      "r430",
      "r714",
      "r715",
      "r716",
      "r717",
      "r875",
      "r1037",
      "r1062"
     ]
    },
    "NRXS_ClassOfWarrantDiscountRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://neuraxis.com/20241231",
     "localname": "ClassOfWarrantDiscountRate",
     "presentation": [
      "http://neuraxis.com/role/NotesPayableDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of warrant discount rate",
        "documentation": "Class of warrant discount rate."
       }
      }
     },
     "auth_ref": []
    },
    "NRXS_ClassOfWarrantOrRightAdditional": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://neuraxis.com/20241231",
     "localname": "ClassOfWarrantOrRightAdditional",
     "presentation": [
      "http://neuraxis.com/role/CommonStockAndWarrantsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of Warrants, additional",
        "documentation": "Class of warrant or right additional."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightAxis",
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfWarrantsOutstandingAndExercisableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right [Axis]",
        "documentation": "Information by type of warrant or right issued."
       }
      }
     },
     "auth_ref": [
      "r51"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightDomain",
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfWarrantsOutstandingAndExercisableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "presentation": [
      "http://neuraxis.com/role/BasisOfPresentationOrganizationAndOtherMattersDetailsNarrative",
      "http://neuraxis.com/role/NotesPayableDetailsNarrative",
      "http://neuraxis.com/role/ScheduleOfWarrantsOutstandingAndExercisableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise price of warrants",
        "verboseLabel": "Exercise price",
        "terseLabel": "Exercise Price",
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": [
      "r431"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightLineItems",
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfWarrantsOutstandingAndExercisableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "presentation": [
      "http://neuraxis.com/role/NotesPayableDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of warrants received",
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares."
       }
      }
     },
     "auth_ref": [
      "r431"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightOutstanding",
     "presentation": [
      "http://neuraxis.com/role/CommonStockAndWarrantsDetailsNarrative",
      "http://neuraxis.com/role/ScheduleOfWarrantsOutstandingAndExercisableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of Warrants",
        "documentation": "Number of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightTable",
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfWarrantsOutstandingAndExercisableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right [Table]",
        "documentation": "Disclosure of information about warrant or right issued that give holder right to purchase security from issuer at specific price within certain time frame."
       }
      }
     },
     "auth_ref": [
      "r51"
     ]
    },
    "ecd_CoSelectedMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CoSelectedMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Amount"
       }
      }
     },
     "auth_ref": [
      "r989"
     ]
    },
    "ecd_CoSelectedMeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CoSelectedMeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Name"
       }
      }
     },
     "auth_ref": [
      "r989"
     ]
    },
    "us-gaap_CommitmentsAndContingencies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingencies",
     "crdr": "credit",
     "calculation": {
      "http://neuraxis.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://neuraxis.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and contingencies (see note 16)",
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur."
       }
      }
     },
     "auth_ref": [
      "r73",
      "r137",
      "r685",
      "r748"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "presentation": [
      "http://neuraxis.com/role/CommitmentsAndContingencies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies",
        "documentation": "The entire disclosure for commitments and contingencies."
       }
      }
     },
     "auth_ref": [
      "r108",
      "r366",
      "r367",
      "r828",
      "r1106",
      "r1111"
     ]
    },
    "NRXS_CommonStockConvertibleConversionPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://neuraxis.com/20241231",
     "localname": "CommonStockConvertibleConversionPrice",
     "presentation": [
      "http://neuraxis.com/role/NotesPayableDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Common stock conversion price",
        "documentation": "Common stock convertible conversion price.",
        "label": "Common stock convertible conversion price"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockConvertibleConversionPriceDecrease": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockConvertibleConversionPriceDecrease",
     "presentation": [
      "http://neuraxis.com/role/NotesPayableDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock conversion price",
        "documentation": "Per share decrease in conversion price of convertible common stock. Excludes change due to standard antidilution provision."
       }
      }
     },
     "auth_ref": [
      "r431"
     ]
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockMember",
     "presentation": [
      "http://neuraxis.com/role/BasisOfPresentationOrganizationAndOtherMattersDetailsNarrative",
      "http://neuraxis.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://neuraxis.com/role/CommonStockAndWarrantsDetailsNarrative",
      "http://neuraxis.com/role/CommonStockAndWarrantsTables",
      "http://neuraxis.com/role/NotesPayableDetailsNarrative",
      "http://neuraxis.com/role/ScheduleOfDilutiveCommonStockEquivalentsDetails",
      "http://neuraxis.com/role/ScheduleOfWarrantActivityForCommonStockDetails",
      "http://neuraxis.com/role/StatementsOfStockholdersEquityDeficit",
      "http://neuraxis.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock [Member]",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r912",
      "r913",
      "r914",
      "r916",
      "r917",
      "r918",
      "r919",
      "r1067",
      "r1068",
      "r1071",
      "r1161",
      "r1223",
      "r1226"
     ]
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://neuraxis.com/role/BalanceSheetsParenthetical",
      "http://neuraxis.com/role/BasisOfPresentationOrganizationAndOtherMattersDetailsNarrative",
      "http://neuraxis.com/role/NotesPayableDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, par value",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r79"
     ]
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://neuraxis.com/role/BalanceSheetsParenthetical",
      "http://neuraxis.com/role/BasisOfPresentationOrganizationAndOtherMattersDetailsNarrative",
      "http://neuraxis.com/role/CommonStockAndWarrantsDetailsNarrative",
      "http://neuraxis.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, shares authorized",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r79",
      "r749"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://neuraxis.com/role/BalanceSheetsParenthetical",
      "http://neuraxis.com/role/CommonStockAndWarrantsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, shares issued",
        "verboseLabel": "Common stock, shares, issued",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r79"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://neuraxis.com/role/BalanceSheetsParenthetical",
      "http://neuraxis.com/role/CommonStockAndWarrantsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, shares outstanding",
        "verboseLabel": "Common stock, shares, outstanding",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r79",
      "r749",
      "r769",
      "r1226",
      "r1227"
     ]
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "calculation": {
      "http://neuraxis.com/role/BalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://neuraxis.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, $0.001 par value; 100,000,000 shares authorized; 6,990,227 and 6,508,897 issued and outstanding as of December 31, 2024 and 2023, respectively",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r79",
      "r688",
      "r898"
     ]
    },
    "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Company Selected Measure"
       }
      }
     },
     "auth_ref": [
      "r994"
     ]
    },
    "ecd_CompActuallyPaidVsNetIncomeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsNetIncomeTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Net Income"
       }
      }
     },
     "auth_ref": [
      "r993"
     ]
    },
    "ecd_CompActuallyPaidVsOtherMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsOtherMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Other Measure"
       }
      }
     },
     "auth_ref": [
      "r995"
     ]
    },
    "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Total Shareholder Return"
       }
      }
     },
     "auth_ref": [
      "r992"
     ]
    },
    "us-gaap_CompensationAndRetirementDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CompensationAndRetirementDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Retirement Benefits [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ComputerEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ComputerEquipmentMember",
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfEstimatedUsefulLivesDetails",
      "http://neuraxis.com/role/ScheduleOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Computer Equipment [Member]",
        "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskBenchmarkDomain",
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfCustomerAccountsReceivableDetails",
      "http://neuraxis.com/role/ScheduleOfCustomersAccountedRevenuesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage."
       }
      }
     },
     "auth_ref": [
      "r31",
      "r32",
      "r55",
      "r56",
      "r287",
      "r827"
     ]
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfCustomerAccountsReceivableDetails",
      "http://neuraxis.com/role/ScheduleOfCustomersAccountedRevenuesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk Benchmark [Axis]",
        "documentation": "Information by benchmark of concentration risk."
       }
      }
     },
     "auth_ref": [
      "r31",
      "r32",
      "r55",
      "r56",
      "r287",
      "r711",
      "r827"
     ]
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskByTypeAxis",
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfCustomerAccountsReceivableDetails",
      "http://neuraxis.com/role/ScheduleOfCustomersAccountedRevenuesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk Type [Axis]",
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender."
       }
      }
     },
     "auth_ref": [
      "r31",
      "r32",
      "r55",
      "r56",
      "r287",
      "r827",
      "r1041"
     ]
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskCreditRisk",
     "presentation": [
      "http://neuraxis.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentrations of Credit Risk",
        "documentation": "Disclosure of accounting policy for credit risk."
       }
      }
     },
     "auth_ref": [
      "r60",
      "r155"
     ]
    },
    "us-gaap_ConcentrationRiskPercentage1": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskPercentage1",
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfCustomerAccountsReceivableDetails",
      "http://neuraxis.com/role/ScheduleOfCustomersAccountedRevenuesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Risk percentage",
        "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division."
       }
      }
     },
     "auth_ref": [
      "r31",
      "r32",
      "r55",
      "r56",
      "r287"
     ]
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskTypeDomain",
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfCustomerAccountsReceivableDetails",
      "http://neuraxis.com/role/ScheduleOfCustomersAccountedRevenuesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration."
       }
      }
     },
     "auth_ref": [
      "r31",
      "r32",
      "r55",
      "r56",
      "r287",
      "r827"
     ]
    },
    "srt_ConsolidatedEntitiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ConsolidatedEntitiesAxis",
     "presentation": [
      "http://neuraxis.com/role/BasisOfPresentationOrganizationAndOtherMattersDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidated Entities [Axis]"
       }
      }
     },
     "auth_ref": [
      "r227",
      "r544",
      "r545",
      "r546",
      "r547",
      "r605",
      "r835",
      "r1115",
      "r1118",
      "r1119"
     ]
    },
    "srt_ConsolidatedEntitiesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ConsolidatedEntitiesDomain",
     "presentation": [
      "http://neuraxis.com/role/BasisOfPresentationOrganizationAndOtherMattersDetailsNarrative"
     ],
     "auth_ref": [
      "r227",
      "r544",
      "r545",
      "r546",
      "r547",
      "r605",
      "r835",
      "r1115",
      "r1118",
      "r1119"
     ]
    },
    "srt_ConsolidationItemsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ConsolidationItemsAxis",
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfReconcilesCompanysNetSalesAndOperatingLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidation Items [Axis]"
       }
      }
     },
     "auth_ref": [
      "r142",
      "r227",
      "r256",
      "r266",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r280",
      "r281",
      "r282",
      "r374",
      "r375",
      "r376",
      "r377",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r861",
      "r862",
      "r1116",
      "r1117"
     ]
    },
    "srt_ConsolidationItemsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ConsolidationItemsDomain",
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfReconcilesCompanysNetSalesAndOperatingLossDetails"
     ],
     "auth_ref": [
      "r142",
      "r227",
      "r256",
      "r266",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r280",
      "r281",
      "r282",
      "r374",
      "r375",
      "r376",
      "r377",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r861",
      "r862",
      "r1116",
      "r1117"
     ]
    },
    "NRXS_ConsultingAndAdvisoryFees": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://neuraxis.com/20241231",
     "localname": "ConsultingAndAdvisoryFees",
     "crdr": "debit",
     "presentation": [
      "http://neuraxis.com/role/SegmentInformationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consulting and advisory fees",
        "documentation": "Consulting and advisory fees."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ContractWithCustomerAssetAllowanceForCreditLossTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ContractWithCustomerAssetAllowanceForCreditLossTableTextBlock",
     "presentation": [
      "http://neuraxis.com/role/SummaryOfSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Customers Accounted Revenues",
        "documentation": "Tabular disclosure of allowance for credit loss on right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time."
       }
      }
     },
     "auth_ref": [
      "r1092"
     ]
    },
    "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ContractWithCustomerLiabilityRevenueRecognized",
     "crdr": "credit",
     "presentation": [
      "http://neuraxis.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Estimated returns of revenue",
        "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due."
       }
      }
     },
     "auth_ref": [
      "r435"
     ]
    },
    "NRXS_ConversionOfConvertiblePromissoryNotesToSeriesBPreferredStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://neuraxis.com/20241231",
     "localname": "ConversionOfConvertiblePromissoryNotesToSeriesBPreferredStock",
     "crdr": "debit",
     "presentation": [
      "http://neuraxis.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Conversion of convertible promissory notes to Series B preferred stock",
        "documentation": "Conversion of convertible promissory notes to series B preferred stock."
       }
      }
     },
     "auth_ref": []
    },
    "NRXS_ConversionOfPreferredStockToCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://neuraxis.com/20241231",
     "localname": "ConversionOfPreferredStockToCommonStock",
     "crdr": "credit",
     "presentation": [
      "http://neuraxis.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Conversion of preferred stock to common stock",
        "documentation": "Conversion of preferred stock to common stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConversionOfStockSharesConverted1": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConversionOfStockSharesConverted1",
     "presentation": [
      "http://neuraxis.com/role/CommonStockAndWarrantsDetailsNarrative",
      "http://neuraxis.com/role/NotesPayableDetailsNarrative",
      "http://neuraxis.com/role/PreferredStockDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of shares converted",
        "verboseLabel": "Conversion, interest",
        "terseLabel": "Shares converted",
        "documentation": "The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period."
       }
      }
     },
     "auth_ref": [
      "r22",
      "r23",
      "r24"
     ]
    },
    "us-gaap_ConversionOfStockSharesIssued1": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConversionOfStockSharesIssued1",
     "presentation": [
      "http://neuraxis.com/role/CommonStockAndWarrantsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise of warrants",
        "documentation": "The number of new shares issued in the conversion of stock in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period."
       }
      }
     },
     "auth_ref": [
      "r22",
      "r23",
      "r24"
     ]
    },
    "us-gaap_ConvertibleDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConvertibleDebt",
     "crdr": "credit",
     "presentation": [
      "http://neuraxis.com/role/NotesPayableDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible debt",
        "documentation": "Including the current and noncurrent portions, carrying amount of debt identified as being convertible into another form of financial instrument (typically the entity's common stock) as of the balance sheet date, which originally required full repayment more than twelve months after issuance or greater than the normal operating cycle of the company."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r136",
      "r1190"
     ]
    },
    "us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConvertiblePreferredStockSharesIssuedUponConversion",
     "presentation": [
      "http://neuraxis.com/role/CommonStockAndWarrantsDetailsNarrative",
      "http://neuraxis.com/role/NotesPayableDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Preferred Stock, Shares Issued upon Conversion",
        "verboseLabel": "Shares issued upon conversion",
        "documentation": "Number of shares issued for each share of convertible preferred stock that is converted."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r47",
      "r78",
      "r114",
      "r425"
     ]
    },
    "NRXS_ConvertiblePromissoryNoteMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://neuraxis.com/20241231",
     "localname": "ConvertiblePromissoryNoteMember",
     "presentation": [
      "http://neuraxis.com/role/NotesPayableDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Promissory Note [Member]",
        "documentation": "Convertible Promissory Note [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "NRXS_ConvertiblePromissoryNotesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://neuraxis.com/20241231",
     "localname": "ConvertiblePromissoryNotesMember",
     "presentation": [
      "http://neuraxis.com/role/NotesPayableDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Promissory Notes [Member]",
        "documentation": "Convertible Promissory Notes [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "NRXS_ConvertibleSeriesAPreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://neuraxis.com/20241231",
     "localname": "ConvertibleSeriesAPreferredStockMember",
     "presentation": [
      "http://neuraxis.com/role/BasisOfPresentationOrganizationAndOtherMattersDetailsNarrative",
      "http://neuraxis.com/role/StatementsOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Series A Preferred stock [Member]",
        "documentation": "Convertible Series A Preferred stock [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "NRXS_ConvertibleSeriesBPreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://neuraxis.com/20241231",
     "localname": "ConvertibleSeriesBPreferredStockMember",
     "presentation": [
      "http://neuraxis.com/role/BalanceSheetsParenthetical",
      "http://neuraxis.com/role/BasisOfPresentationOrganizationAndOtherMattersDetailsNarrative",
      "http://neuraxis.com/role/StatementsOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Series B Preferred Stock [Member]",
        "documentation": "Convertible Series B Preferred Stock [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "NRXS_ConvertibleSeriesSeedPreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://neuraxis.com/20241231",
     "localname": "ConvertibleSeriesSeedPreferredStockMember",
     "presentation": [
      "http://neuraxis.com/role/BasisOfPresentationOrganizationAndOtherMattersDetailsNarrative",
      "http://neuraxis.com/role/CommonStockAndWarrantsDetailsNarrative",
      "http://neuraxis.com/role/StatementsOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Series Seed Preferred Stock [Member]",
        "documentation": "Convertible Series Seed Preferred Stock [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CostOfGoodsAndServicesSold",
     "crdr": "debit",
     "calculation": {
      "http://neuraxis.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_GrossProfit",
       "weight": -1.0,
       "order": 2.0
      },
      "http://neuraxis.com/role/ScheduleOfReconcilesCompanysNetSalesAndOperatingLossDetails": {
       "parentTag": "us-gaap_GrossProfit",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfReconcilesCompanysNetSalesAndOperatingLossDetails",
      "http://neuraxis.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cost of goods sold",
        "verboseLabel": "Cost of Goods Sold",
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities."
       }
      }
     },
     "auth_ref": [
      "r86",
      "r87",
      "r645"
     ]
    },
    "dei_CountryRegion": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CountryRegion",
     "presentation": [
      "http://neuraxis.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Country Region",
        "documentation": "Region code of country"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "NRXS_CumulativeDividendsPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://neuraxis.com/20241231",
     "localname": "CumulativeDividendsPercent",
     "presentation": [
      "http://neuraxis.com/role/NotesPayableDetailsNarrative",
      "http://neuraxis.com/role/PreferredStockDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cumulative dividends percent",
        "documentation": "Percentage of cumulative dividends."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://neuraxis.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CurrentIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://neuraxis.com/role/ScheduleOfIncomeTaxProvisionDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfIncomeTaxProvisionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total current provision",
        "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r526",
      "r1065"
     ]
    },
    "NRXS_CustomerAMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://neuraxis.com/20241231",
     "localname": "CustomerAMember",
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfCustomerAccountsReceivableDetails",
      "http://neuraxis.com/role/ScheduleOfCustomersAccountedRevenuesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer A [Member]",
        "documentation": "Customer A [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "NRXS_CustomerBMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://neuraxis.com/20241231",
     "localname": "CustomerBMember",
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfCustomerAccountsReceivableDetails",
      "http://neuraxis.com/role/ScheduleOfCustomersAccountedRevenuesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer B [Member]",
        "documentation": "Customer B [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "NRXS_CustomerCMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://neuraxis.com/20241231",
     "localname": "CustomerCMember",
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfCustomerAccountsReceivableDetails",
      "http://neuraxis.com/role/ScheduleOfCustomersAccountedRevenuesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer C [Member]",
        "documentation": "Customer C [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CustomerConcentrationRiskMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CustomerConcentrationRiskMember",
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfCustomerAccountsReceivableDetails",
      "http://neuraxis.com/role/ScheduleOfCustomersAccountedRevenuesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer Concentration Risk [Member]",
        "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer."
       }
      }
     },
     "auth_ref": [
      "r102",
      "r287"
     ]
    },
    "NRXS_CustomerDMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://neuraxis.com/20241231",
     "localname": "CustomerDMember",
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfCustomerAccountsReceivableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer D [Member]",
        "documentation": "Customer D [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "NRXS_CustomerEMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://neuraxis.com/20241231",
     "localname": "CustomerEMember",
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfCustomerAccountsReceivableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer E [Member]",
        "documentation": "Customer E [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "NRXS_CustomerMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://neuraxis.com/20241231",
     "localname": "CustomerMember",
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfCustomerAccountsReceivableDetails",
      "http://neuraxis.com/role/ScheduleOfCustomersAccountedRevenuesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Member]",
        "documentation": "Customer [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r945",
      "r1028"
     ]
    },
    "cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskBoardOfDirectorsOversightTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Board of Directors Oversight [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r945",
      "r1028"
     ]
    },
    "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Positions or Committees Responsible [Flag]"
       }
      }
     },
     "auth_ref": [
      "r947",
      "r1030"
     ]
    },
    "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Positions or Committees Responsible [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r947",
      "r1030"
     ]
    },
    "cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r940",
      "r1023"
     ]
    },
    "cyd_CybersecurityRiskManagementProcessesIntegratedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementProcessesIntegratedFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Processes Integrated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r941",
      "r1024"
     ]
    },
    "cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementProcessesIntegratedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Processes Integrated [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r941",
      "r1024"
     ]
    },
    "cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementStrategyAndGovernanceAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management, Strategy, and Governance [Abstract]"
       }
      }
     },
     "auth_ref": [
      "r939",
      "r1022"
     ]
    },
    "cyd_CybersecurityRiskManagementThirdPartyEngagedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementThirdPartyEngagedFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Third Party Engaged [Flag]"
       }
      }
     },
     "auth_ref": [
      "r942",
      "r1025"
     ]
    },
    "cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]"
       }
      }
     },
     "auth_ref": [
      "r944",
      "r1027"
     ]
    },
    "cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r944",
      "r1027"
     ]
    },
    "cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r945",
      "r1028"
     ]
    },
    "cyd_CybersecurityRiskRoleOfManagementTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskRoleOfManagementTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Role of Management [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r946",
      "r1029"
     ]
    },
    "cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]"
       }
      }
     },
     "auth_ref": [
      "r943",
      "r1026"
     ]
    },
    "us-gaap_DebtConversionConvertedInstrumentSharesIssued1": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtConversionConvertedInstrumentSharesIssued1",
     "presentation": [
      "http://neuraxis.com/role/CommonStockAndWarrantsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Conversion shares",
        "documentation": "The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or payments in the period."
       }
      }
     },
     "auth_ref": [
      "r22",
      "r24"
     ]
    },
    "us-gaap_DebtConversionOriginalDebtInterestRateOfDebt": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtConversionOriginalDebtInterestRateOfDebt",
     "presentation": [
      "http://neuraxis.com/role/NotesPayableDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt conversion, original debt, interest rate of debt",
        "documentation": "The rate of interest that was being paid on the original debt issue that is being converted in the noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period."
       }
      }
     },
     "auth_ref": [
      "r22",
      "r24"
     ]
    },
    "us-gaap_DebtDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtDisclosureTextBlock",
     "presentation": [
      "http://neuraxis.com/role/NotesPayable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Notes Payable",
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants."
       }
      }
     },
     "auth_ref": [
      "r109",
      "r221",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r372",
      "r373",
      "r385",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r401",
      "r408",
      "r409",
      "r411",
      "r581"
     ]
    },
    "us-gaap_DebtInstrumentAnnualPrincipalPayment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentAnnualPrincipalPayment",
     "crdr": "debit",
     "presentation": [
      "http://neuraxis.com/role/NotesPayableDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total principal amount",
        "documentation": "Amount of annual principal payment for debt instrument."
       }
      }
     },
     "auth_ref": [
      "r15"
     ]
    },
    "us-gaap_DebtInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentAxis",
     "presentation": [
      "http://neuraxis.com/role/NotesPayableDetailsNarrative",
      "http://neuraxis.com/role/ScheduleOfRelatedPartyLoansPayableToShareholderDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument [Axis]",
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r65",
      "r66",
      "r133",
      "r136",
      "r227",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r392",
      "r397",
      "r398",
      "r399",
      "r400",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r870",
      "r871",
      "r872",
      "r873",
      "r874",
      "r895",
      "r1063",
      "r1107",
      "r1108",
      "r1109",
      "r1171",
      "r1173"
     ]
    },
    "us-gaap_DebtInstrumentCarryingAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentCarryingAmount",
     "crdr": "credit",
     "presentation": [
      "http://neuraxis.com/role/NotesPayableDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt instrument gross",
        "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r136",
      "r412"
     ]
    },
    "us-gaap_DebtInstrumentConvertibleConversionPrice1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentConvertibleConversionPrice1",
     "presentation": [
      "http://neuraxis.com/role/NotesPayableDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Conversion price",
        "documentation": "The price per share of the conversion feature embedded in the debt instrument."
       }
      }
     },
     "auth_ref": [
      "r110",
      "r388"
     ]
    },
    "us-gaap_DebtInstrumentConvertibleConversionRatio1": {
     "xbrltype": "pureItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentConvertibleConversionRatio1",
     "presentation": [
      "http://neuraxis.com/role/NotesPayableDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Strilke price",
        "documentation": "Ratio applied to the conversion of debt instrument into equity with equity shares divided by debt principal amount."
       }
      }
     },
     "auth_ref": [
      "r47",
      "r70",
      "r114",
      "r115",
      "r388"
     ]
    },
    "us-gaap_DebtInstrumentDescriptionOfVariableRateBasis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentDescriptionOfVariableRateBasis",
     "presentation": [
      "http://neuraxis.com/role/NotesPayableDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt instrument description",
        "documentation": "Description of reference rate used for variable rate of debt instrument."
       }
      }
     },
     "auth_ref": []
    },
    "NRXS_DebtInstrumentDiscountRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://neuraxis.com/20241231",
     "localname": "DebtInstrumentDiscountRate",
     "presentation": [
      "http://neuraxis.com/role/NotesPayableDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Discount rate",
        "documentation": "Debt instrument discount rate."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentFaceAmount",
     "crdr": "credit",
     "presentation": [
      "http://neuraxis.com/role/NotesPayableDetailsNarrative",
      "http://neuraxis.com/role/PreferredStockDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding promissory notes",
        "verboseLabel": "Borrowed amount",
        "documentation": "Face (par) amount of debt instrument at time of issuance."
       }
      }
     },
     "auth_ref": [
      "r386",
      "r581",
      "r582",
      "r871",
      "r872",
      "r895"
     ]
    },
    "us-gaap_DebtInstrumentInterestRateEffectivePercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentInterestRateEffectivePercentage",
     "presentation": [
      "http://neuraxis.com/role/NotesPayableDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt instrument interest rate effective percentage",
        "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium."
       }
      }
     },
     "auth_ref": [
      "r68",
      "r413",
      "r581",
      "r582",
      "r895"
     ]
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "presentation": [
      "http://neuraxis.com/role/NotesPayableDetailsNarrative",
      "http://neuraxis.com/role/ScheduleOfRelatedPartyLoansPayableToShareholderDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt instrument percentage",
        "verboseLabel": "Debt instrument interest rate",
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement."
       }
      }
     },
     "auth_ref": [
      "r68",
      "r387"
     ]
    },
    "us-gaap_DebtInstrumentMaturityDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentMaturityDate",
     "presentation": [
      "http://neuraxis.com/role/NotesPayableDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maturity date",
        "documentation": "Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": [
      "r193",
      "r870",
      "r1166",
      "r1167"
     ]
    },
    "us-gaap_DebtInstrumentMaturityDateDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentMaturityDateDescription",
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfRelatedPartyLoansPayableToShareholderDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Due date",
        "documentation": "Description of the maturity date of the debt instrument including whether the debt matures serially and, if so, a brief description of the serial maturities."
       }
      }
     },
     "auth_ref": [
      "r69"
     ]
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentNameDomain",
     "presentation": [
      "http://neuraxis.com/role/NotesPayableDetailsNarrative",
      "http://neuraxis.com/role/ScheduleOfRelatedPartyLoansPayableToShareholderDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r227",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r392",
      "r397",
      "r398",
      "r399",
      "r400",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r870",
      "r871",
      "r872",
      "r873",
      "r874",
      "r895",
      "r1063",
      "r1107",
      "r1108",
      "r1109",
      "r1171",
      "r1173"
     ]
    },
    "us-gaap_DebtInstrumentPeriodicPayment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentPeriodicPayment",
     "crdr": "debit",
     "presentation": [
      "http://neuraxis.com/role/NotesPayableDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Principal amount due in monthly installments",
        "documentation": "Amount of the required periodic payments including both interest and principal payments."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r59"
     ]
    },
    "us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid",
     "crdr": "credit",
     "presentation": [
      "http://neuraxis.com/role/NotesPayableDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Periodic Payment Terms, Balloon Payment to be Paid",
        "documentation": "Amount of payment greater than the preceding installment payments to be paid at final maturity date of debt."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentRepurchasedFaceAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentRepurchasedFaceAmount",
     "crdr": "debit",
     "presentation": [
      "http://neuraxis.com/role/NotesPayableDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Repurchased Face Amount",
        "documentation": "Face (par) amount of the original debt instrument that was repurchased."
       }
      }
     },
     "auth_ref": []
    },
    "NRXS_DebtWarrantConversionDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://neuraxis.com/20241231",
     "localname": "DebtWarrantConversionDescription",
     "presentation": [
      "http://neuraxis.com/role/NotesPayableDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt warrant conversion, description",
        "documentation": "Debt warrant conversion description."
       }
      }
     },
     "auth_ref": []
    },
    "NRXS_DecemberTwoThousandTwentyEightMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://neuraxis.com/20241231",
     "localname": "DecemberTwoThousandTwentyEightMember",
     "presentation": [
      "http://neuraxis.com/role/IntangibleAssetsDetailsNarrative",
      "http://neuraxis.com/role/PropertyAndEquipmentDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "December Two Thousand Twenty Eight [Member]",
        "documentation": "December Two Thousand Twenty Eight [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "NRXS_DecemberTwoThousandTwentyFiveMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://neuraxis.com/20241231",
     "localname": "DecemberTwoThousandTwentyFiveMember",
     "presentation": [
      "http://neuraxis.com/role/IntangibleAssetsDetailsNarrative",
      "http://neuraxis.com/role/PropertyAndEquipmentDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "December Two Thousand Twenty Five [Member]",
        "documentation": "December Two Thousand Twenty Five [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "NRXS_DecemberTwoThousandTwentyNineMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://neuraxis.com/20241231",
     "localname": "DecemberTwoThousandTwentyNineMember",
     "presentation": [
      "http://neuraxis.com/role/IntangibleAssetsDetailsNarrative",
      "http://neuraxis.com/role/PropertyAndEquipmentDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "December Two Thousand Twenty Nine [Member]",
        "documentation": "December Two Thousand Twenty Nine [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "NRXS_DecemberTwoThousandTwentySevenMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://neuraxis.com/20241231",
     "localname": "DecemberTwoThousandTwentySevenMember",
     "presentation": [
      "http://neuraxis.com/role/IntangibleAssetsDetailsNarrative",
      "http://neuraxis.com/role/PropertyAndEquipmentDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "December Two Thousand Twenty Seven [Member]",
        "documentation": "December Two Thousand Twenty Seven [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "NRXS_DecemberTwoThousandTwentySixMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://neuraxis.com/20241231",
     "localname": "DecemberTwoThousandTwentySixMember",
     "presentation": [
      "http://neuraxis.com/role/IntangibleAssetsDetailsNarrative",
      "http://neuraxis.com/role/PropertyAndEquipmentDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "December Two Thousand Twenty Six [Member]",
        "documentation": "December Two Thousand Twenty Six [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "NRXS_DecemberTwoThousandTwentyThereafterMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://neuraxis.com/20241231",
     "localname": "DecemberTwoThousandTwentyThereafterMember",
     "presentation": [
      "http://neuraxis.com/role/IntangibleAssetsDetailsNarrative",
      "http://neuraxis.com/role/PropertyAndEquipmentDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "December Two Thousand Twenty Thereafter [Member]",
        "documentation": "December Two Thousand Twenty Thereafter [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredFederalIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredFederalIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://neuraxis.com/role/ScheduleOfIncomeTaxProvisionDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfIncomeTaxProvisionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Federal",
        "documentation": "Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r1065",
      "r1158",
      "r1159"
     ]
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://neuraxis.com/role/ScheduleOfIncomeTaxProvisionDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfIncomeTaxProvisionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total deferred benefit",
        "label": "Deferred Income Tax Expense (Benefit)",
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r161",
      "r1065"
     ]
    },
    "us-gaap_DeferredIncomeTaxLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredIncomeTaxLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://neuraxis.com/role/ScheduleOfNetDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxLiabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfNetDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total deferred tax liabilities",
        "label": "Deferred Tax Liabilities, Gross",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences."
       }
      }
     },
     "auth_ref": [
      "r74",
      "r75",
      "r134",
      "r517"
     ]
    },
    "us-gaap_DeferredOfferingCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredOfferingCosts",
     "crdr": "debit",
     "presentation": [
      "http://neuraxis.com/role/BasisOfPresentationOrganizationAndOtherMattersDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred offering costs",
        "documentation": "Specific incremental costs directly attributable to a proposed or actual offering of securities which are deferred at the end of the reporting period."
       }
      }
     },
     "auth_ref": [
      "r1093"
     ]
    },
    "NRXS_DeferredOfferingCostsPaid": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://neuraxis.com/20241231",
     "localname": "DeferredOfferingCostsPaid",
     "crdr": "credit",
     "calculation": {
      "http://neuraxis.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://neuraxis.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Deferred offering costs paid",
        "documentation": "Deferred offering costs paid.",
        "label": "DeferredOfferingCostsPaid"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredStateAndLocalIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://neuraxis.com/role/ScheduleOfIncomeTaxProvisionDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfIncomeTaxProvisionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "State",
        "documentation": "Amount of deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r1065",
      "r1158",
      "r1159"
     ]
    },
    "NRXS_DeferredTaxAssetsAccountsPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://neuraxis.com/20241231",
     "localname": "DeferredTaxAssetsAccountsPayable",
     "crdr": "debit",
     "calculation": {
      "http://neuraxis.com/role/ScheduleOfNetDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfNetDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Accounts payable",
        "documentation": "Deferred tax assets accounts payable.",
        "label": "DeferredTaxAssetsAccountsPayable"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsGross",
     "crdr": "debit",
     "calculation": {
      "http://neuraxis.com/role/ScheduleOfNetDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfNetDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total gross deferred tax assets",
        "label": "Deferred Tax Assets, Gross",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r518"
     ]
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsNet",
     "crdr": "debit",
     "calculation": {
      "http://neuraxis.com/role/ScheduleOfNetDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxLiabilities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfNetDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total deferred tax assets",
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r1154"
     ]
    },
    "NRXS_DeferredTaxAssetsNotesReceivableReserve": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://neuraxis.com/20241231",
     "localname": "DeferredTaxAssetsNotesReceivableReserve",
     "crdr": "debit",
     "calculation": {
      "http://neuraxis.com/role/ScheduleOfNetDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfNetDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Notes receivable reserve",
        "documentation": "Deferred tax assets notes receivable reserve."
       }
      }
     },
     "auth_ref": []
    },
    "NRXS_DeferredTaxAssetsOperatingLeasePayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://neuraxis.com/20241231",
     "localname": "DeferredTaxAssetsOperatingLeasePayable",
     "crdr": "debit",
     "calculation": {
      "http://neuraxis.com/role/ScheduleOfNetDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfNetDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating lease payable",
        "documentation": "Deferred tax assets operating lease payable."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "crdr": "debit",
     "calculation": {
      "http://neuraxis.com/role/ScheduleOfNetDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfNetDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net operating losses",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards."
       }
      }
     },
     "auth_ref": [
      "r1156"
     ]
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal",
     "crdr": "debit",
     "presentation": [
      "http://neuraxis.com/role/IncomeTaxesDetailsNarrative",
      "http://neuraxis.com/role/ScheduleOfStateCarryforwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total state NOL carryforwards",
        "verboseLabel": "Deferred Tax Assets, Operating Loss Carryforwards, State and Local",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible state and local operating loss carryforwards."
       }
      }
     },
     "auth_ref": [
      "r1156"
     ]
    },
    "us-gaap_DeferredTaxAssetsOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsOther",
     "crdr": "debit",
     "calculation": {
      "http://neuraxis.com/role/ScheduleOfNetDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfNetDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Other",
        "label": "Deferred Tax Assets, Other",
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other."
       }
      }
     },
     "auth_ref": [
      "r1156"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits",
     "crdr": "debit",
     "calculation": {
      "http://neuraxis.com/role/ScheduleOfNetDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfNetDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Stock based compensation",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from compensation and benefits costs."
       }
      }
     },
     "auth_ref": [
      "r1156"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsOther",
     "crdr": "debit",
     "calculation": {
      "http://neuraxis.com/role/ScheduleOfNetDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfNetDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued compensation",
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences from compensation and benefits, classified as other."
       }
      }
     },
     "auth_ref": [
      "r1156"
     ]
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsValuationAllowance",
     "crdr": "credit",
     "calculation": {
      "http://neuraxis.com/role/ScheduleOfNetDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfNetDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Valuation allowance",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized."
       }
      }
     },
     "auth_ref": [
      "r519"
     ]
    },
    "us-gaap_DeferredTaxLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://neuraxis.com/role/ScheduleOfNetDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfNetDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Deferred tax assets, net",
        "label": "Deferred Tax Liabilities, Net",
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting."
       }
      }
     },
     "auth_ref": [
      "r1154"
     ]
    },
    "NRXS_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://neuraxis.com/20241231",
     "localname": "DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset",
     "crdr": "credit",
     "calculation": {
      "http://neuraxis.com/role/ScheduleOfNetDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfNetDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating lease right of use asset",
        "documentation": "Deferred tax liabilities operating lease right of use asset."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxLiabilitiesOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxLiabilitiesOther",
     "crdr": "credit",
     "calculation": {
      "http://neuraxis.com/role/ScheduleOfNetDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfNetDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Other",
        "label": "Deferred Tax Liabilities, Other",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences classified as other."
       }
      }
     },
     "auth_ref": [
      "r1156"
     ]
    },
    "us-gaap_DeferredTaxLiabilitiesPrepaidExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxLiabilitiesPrepaidExpenses",
     "crdr": "credit",
     "calculation": {
      "http://neuraxis.com/role/ScheduleOfNetDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfNetDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid expenses",
        "documentation": "Amount of deferred tax consequences attributable to taxable temporary differences derived from prepaid expenses."
       }
      }
     },
     "auth_ref": [
      "r1156"
     ]
    },
    "NRXS_DeferredTaxLiabilityAccountsReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://neuraxis.com/20241231",
     "localname": "DeferredTaxLiabilityAccountsReceivable",
     "crdr": "credit",
     "calculation": {
      "http://neuraxis.com/role/ScheduleOfNetDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfNetDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts receivable",
        "documentation": "Deferred tax liability accounts receivable."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DefinedContributionPlanAdministrativeExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DefinedContributionPlanAdministrativeExpenses",
     "crdr": "debit",
     "presentation": [
      "http://neuraxis.com/role/RetirementPlanDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Profit sharing contribution expenses",
        "documentation": "Amount of administrative expense incurred by defined contribution plan."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent",
     "presentation": [
      "http://neuraxis.com/role/RetirementPlanDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee contribution percentage",
        "documentation": "Maximum percentage of employee gross pay the employee may contribute to a defined contribution plan."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DepositContractsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DepositContractsPolicy",
     "presentation": [
      "http://neuraxis.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer Deposits",
        "documentation": "Disclosure of accounting policy for the treatment of funds received from or paid to insureds, insurers and reinsurers on contracts for which the criteria for transferring or assuming insurance risk has not been satisfied by the insurer or reinsurer."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "us-gaap_Deposits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Deposits",
     "crdr": "credit",
     "calculation": {
      "http://neuraxis.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://neuraxis.com/role/BalanceSheets",
      "http://neuraxis.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer deposits",
        "documentation": "The aggregate of all deposit liabilities held by the entity, including foreign and domestic, interest and noninterest bearing; may include demand deposits, saving deposits, Negotiable Order of Withdrawal (NOW) and time deposits among others."
       }
      }
     },
     "auth_ref": [
      "r132"
     ]
    },
    "us-gaap_Depreciation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Depreciation",
     "crdr": "debit",
     "presentation": [
      "http://neuraxis.com/role/PropertyAndEquipmentDetailsNarrative",
      "http://neuraxis.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Depreciation expense",
        "verboseLabel": "Depreciation",
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r40"
     ]
    },
    "us-gaap_DepreciationAndAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DepreciationAndAmortization",
     "crdr": "debit",
     "presentation": [
      "http://neuraxis.com/role/SegmentInformationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Depreciation and amortization",
        "label": "Depreciation, Depletion and Amortization, Nonproduction",
        "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r40"
     ]
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DepreciationDepletionAndAmortization",
     "crdr": "debit",
     "calculation": {
      "http://neuraxis.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://neuraxis.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Depreciation and amortization",
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r256",
      "r268",
      "r280",
      "r861",
      "r862"
     ]
    },
    "us-gaap_DerivativeGainLossOnDerivativeNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DerivativeGainLossOnDerivativeNet",
     "crdr": "credit",
     "calculation": {
      "http://neuraxis.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 4.0
      },
      "http://neuraxis.com/role/ScheduleOfReconcilesCompanysNetSalesAndOperatingLossDetails": {
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 4.0
      },
      "http://neuraxis.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 13.0
      }
     },
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfReconcilesCompanysNetSalesAndOperatingLossDetails",
      "http://neuraxis.com/role/StatementsOfCashFlows",
      "http://neuraxis.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in fair value of derivative liability",
        "negatedLabel": "Change in fair value of derivative liabilities",
        "documentation": "Amount of increase (decrease) in the fair value of derivatives recognized in the income statement."
       }
      }
     },
     "auth_ref": [
      "r1160"
     ]
    },
    "us-gaap_DerivativeLiabilityMeasurementInput": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DerivativeLiabilityMeasurementInput",
     "presentation": [
      "http://neuraxis.com/role/DerivativeLiabilitiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative liability, measurement input",
        "documentation": "Value of input used to measure derivative liability."
       }
      }
     },
     "auth_ref": [
      "r562",
      "r563",
      "r564"
     ]
    },
    "us-gaap_DerivativesAndFairValueTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DerivativesAndFairValueTextBlock",
     "presentation": [
      "http://neuraxis.com/role/DerivativeLiabilities"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Derivative Liabilities",
        "label": "Derivatives and Fair Value [Text Block]",
        "documentation": "The entire disclosure for derivatives and fair value of assets and liabilities."
       }
      }
     },
     "auth_ref": [
      "r126",
      "r128"
     ]
    },
    "NRXS_DescriptionOfExecutiveEmploymentAgreementsRenewals": {
     "xbrltype": "stringItemType",
     "nsuri": "http://neuraxis.com/20241231",
     "localname": "DescriptionOfExecutiveEmploymentAgreementsRenewals",
     "presentation": [
      "http://neuraxis.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Description of Executive employment agreements renewals",
        "documentation": "Description of executive employment agreements renewals."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisaggregationOfRevenueTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisaggregationOfRevenueTableTextBlock",
     "presentation": [
      "http://neuraxis.com/role/SummaryOfSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Disaggregation of Revenue",
        "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor."
       }
      }
     },
     "auth_ref": [
      "r1122"
     ]
    },
    "NRXS_DisclosureDerivativeLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://neuraxis.com/20241231",
     "localname": "DisclosureDerivativeLiabilitiesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative Liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "NRXS_DisclosureHealthBenefitPlanAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://neuraxis.com/20241231",
     "localname": "DisclosureHealthBenefitPlanAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Health Benefit Plan"
       }
      }
     },
     "auth_ref": []
    },
    "NRXS_DisclosureLeasesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://neuraxis.com/20241231",
     "localname": "DisclosureLeasesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases",
        "verboseLabel": "Schedule Of Operating Leases",
        "terseLabel": "Schedule Of Maturities Operating Lease Liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "presentation": [
      "http://neuraxis.com/role/Stock-basedCompensation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock-Based Compensation",
        "documentation": "The entire disclosure for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r457",
      "r460",
      "r490",
      "r491",
      "r492",
      "r882"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "NRXS_DisclosureWarrantLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://neuraxis.com/20241231",
     "localname": "DisclosureWarrantLiabilitiesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant Liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DividendsPayableCurrentAndNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DividendsPayableCurrentAndNoncurrent",
     "crdr": "credit",
     "presentation": [
      "http://neuraxis.com/role/PreferredStockDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dividends declared",
        "documentation": "Carrying value as of the balance sheet date of dividends declared but unpaid on equity securities issued by the entity and outstanding."
       }
      }
     },
     "auth_ref": [
      "r66",
      "r72",
      "r135",
      "r920",
      "r1188"
     ]
    },
    "us-gaap_DividendsPreferredStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DividendsPreferredStock",
     "crdr": "debit",
     "presentation": [
      "http://neuraxis.com/role/PreferredStockDetailsNarrative",
      "http://neuraxis.com/role/ScheduleOfBasicAndDilutedNetLossPerShareDetails",
      "http://neuraxis.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Preferred stock dividends",
        "label": "Preferred stock dividend",
        "verboseLabel": "Dividends",
        "documentation": "Amount of paid and unpaid preferred stock dividends declared with the form of settlement in cash, stock and payment-in-kind (PIK)."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r116"
     ]
    },
    "dei_DocumentAccountingStandard": {
     "xbrltype": "accountingStandardItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentAccountingStandard",
     "presentation": [
      "http://neuraxis.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Accounting Standard",
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'."
       }
      }
     },
     "auth_ref": [
      "r937"
     ]
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://neuraxis.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r935",
      "r937",
      "r958"
     ]
    },
    "dei_DocumentFinStmtErrorCorrectionFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFinStmtErrorCorrectionFlag",
     "presentation": [
      "http://neuraxis.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Financial Statement Error Correction [Flag]",
        "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction."
       }
      }
     },
     "auth_ref": [
      "r935",
      "r937",
      "r958",
      "r998"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://neuraxis.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://neuraxis.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://neuraxis.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodStartDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodStartDate",
     "presentation": [
      "http://neuraxis.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period Start Date",
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://neuraxis.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r936"
     ]
    },
    "dei_DocumentRegistrationStatement": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentRegistrationStatement",
     "presentation": [
      "http://neuraxis.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Registration Statement",
        "documentation": "Boolean flag that is true only for a form used as a registration statement."
       }
      }
     },
     "auth_ref": [
      "r924"
     ]
    },
    "dei_DocumentShellCompanyEventDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentShellCompanyEventDate",
     "presentation": [
      "http://neuraxis.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Event Date",
        "documentation": "Date of event requiring a shell company report."
       }
      }
     },
     "auth_ref": [
      "r937"
     ]
    },
    "dei_DocumentShellCompanyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentShellCompanyReport",
     "presentation": [
      "http://neuraxis.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Report",
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r937"
     ]
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://neuraxis.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r983"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://neuraxis.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://neuraxis.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Documents Incorporated by Reference [Text Block]",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r927"
     ]
    },
    "us-gaap_DomesticCountryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DomesticCountryMember",
     "presentation": [
      "http://neuraxis.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Domestic Tax Jurisdiction [Member]",
        "documentation": "Designated federal jurisdiction entitled to levy and collect income tax in country of domicile. Includes, but is not limited to, national jurisdiction for non-U.S. jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r506"
     ]
    },
    "us-gaap_EarningsPerShareAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareAbstract",
     "presentation": [
      "http://neuraxis.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Per-share data"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfBasicAndDilutedNetLossPerShareDetails",
      "http://neuraxis.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Basic loss per share",
        "verboseLabel": "Basic net loss per share",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r209",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r243",
      "r246",
      "r250",
      "r251",
      "r252",
      "r255",
      "r539",
      "r542",
      "r557",
      "r558",
      "r679",
      "r698",
      "r855"
     ]
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfBasicAndDilutedNetLossPerShareDetails",
      "http://neuraxis.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Diluted loss per share",
        "verboseLabel": "Diluted net loss per share",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r209",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r246",
      "r250",
      "r251",
      "r252",
      "r255",
      "r539",
      "r542",
      "r557",
      "r558",
      "r679",
      "r698",
      "r855"
     ]
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerSharePolicyTextBlock",
     "presentation": [
      "http://neuraxis.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Basic and Diluted Net Income (Loss) per Share",
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements."
       }
      }
     },
     "auth_ref": [
      "r27",
      "r28",
      "r254"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "calculation": {
      "http://neuraxis.com/role/ScheduleOfFederalStatutoryIncomeTaxRateAndEffectiveIncomeTaxRateDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfFederalStatutoryIncomeTaxRateAndEffectiveIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Effective income tax rate",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r506",
      "r884"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "calculation": {
      "http://neuraxis.com/role/ScheduleOfFederalStatutoryIncomeTaxRateAndEffectiveIncomeTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfFederalStatutoryIncomeTaxRateAndEffectiveIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Federal statutory income tax rate",
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss)."
       }
      }
     },
     "auth_ref": [
      "r224",
      "r506",
      "r530",
      "r884"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "calculation": {
      "http://neuraxis.com/role/ScheduleOfFederalStatutoryIncomeTaxRateAndEffectiveIncomeTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfFederalStatutoryIncomeTaxRateAndEffectiveIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in valuation allowance",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r510",
      "r884",
      "r1066",
      "r1150"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationLineItems",
     "presentation": [
      "http://neuraxis.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r506",
      "r507",
      "r884"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationOtherAdjustments",
     "presentation": [
      "http://neuraxis.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments."
       }
      }
     },
     "auth_ref": [
      "r884",
      "r1066",
      "r1150",
      "r1151"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
     "calculation": {
      "http://neuraxis.com/role/ScheduleOfFederalStatutoryIncomeTaxRateAndEffectiveIncomeTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfFederalStatutoryIncomeTaxRateAndEffectiveIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "State tax rate, net of federal benefit",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit)."
       }
      }
     },
     "auth_ref": [
      "r509",
      "r884",
      "r1066",
      "r1150"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationTable",
     "presentation": [
      "http://neuraxis.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation [Table]",
        "documentation": "Disclosure of information about income tax rate reconciliation between amount of reported income tax expense (benefit) attributable to continuing operation to amount of income tax expense(benefit) that would result from applying statutory federal (national) tax rate to pretax income (loss) from continuing operation."
       }
      }
     },
     "auth_ref": [
      "r506",
      "r507",
      "r884"
     ]
    },
    "NRXS_EmployementAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://neuraxis.com/20241231",
     "localname": "EmployementAgreementMember",
     "presentation": [
      "http://neuraxis.com/role/CommonStockAndWarrantsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employement Agreement [Member]",
        "documentation": "Employement Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://neuraxis.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://neuraxis.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine3": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine3",
     "presentation": [
      "http://neuraxis.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Three",
        "documentation": "Address Line 3 such as an Office Park"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://neuraxis.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCountry": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCountry",
     "presentation": [
      "http://neuraxis.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Country",
        "documentation": "ISO 3166-1 alpha-2 country code."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://neuraxis.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://neuraxis.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "presentation": [
      "http://neuraxis.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Bankruptcy Proceedings, Reporting Current",
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element."
       }
      }
     },
     "auth_ref": [
      "r930"
     ]
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://neuraxis.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r926"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://neuraxis.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://neuraxis.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityDomain",
     "presentation": [
      "http://neuraxis.com/role/NotesPayableDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://neuraxis.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r926"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://neuraxis.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Elected Not To Use the Extended Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r1035"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://neuraxis.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://neuraxis.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r926"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://neuraxis.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://neuraxis.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r1031"
     ]
    },
    "dei_EntityListingParValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityListingParValuePerShare",
     "presentation": [
      "http://neuraxis.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Listing, Par Value Per Share",
        "documentation": "The par value per share of security quoted in same currency as Trading currency. Example: '0.01'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityPrimarySicNumber": {
     "xbrltype": "sicNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityPrimarySicNumber",
     "presentation": [
      "http://neuraxis.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Primary SIC Number",
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity."
       }
      }
     },
     "auth_ref": [
      "r958"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://neuraxis.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://neuraxis.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r926"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://neuraxis.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r926"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://neuraxis.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r926"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://neuraxis.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r926"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://neuraxis.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://neuraxis.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r1033"
     ]
    },
    "us-gaap_EquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://neuraxis.com/role/BasisOfPresentationOrganizationAndOtherMattersDetailsNarrative",
      "http://neuraxis.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://neuraxis.com/role/CommonStockAndWarrantsDetailsNarrative",
      "http://neuraxis.com/role/CommonStockAndWarrantsTables",
      "http://neuraxis.com/role/NotesPayableDetailsNarrative",
      "http://neuraxis.com/role/ScheduleOfWarrantActivityForCommonStockDetails",
      "http://neuraxis.com/role/ScheduleOfWarrantActivityForPreferredStockDetails",
      "http://neuraxis.com/role/StatementsOfStockholdersEquityDeficit",
      "http://neuraxis.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r183",
      "r205",
      "r206",
      "r207",
      "r228",
      "r229",
      "r230",
      "r232",
      "r237",
      "r239",
      "r241",
      "r257",
      "r321",
      "r322",
      "r356",
      "r432",
      "r528",
      "r529",
      "r536",
      "r537",
      "r538",
      "r540",
      "r541",
      "r542",
      "r548",
      "r549",
      "r550",
      "r551",
      "r552",
      "r553",
      "r556",
      "r573",
      "r574",
      "r575",
      "r576",
      "r577",
      "r578",
      "r583",
      "r585",
      "r596",
      "r696",
      "r705",
      "r706",
      "r707",
      "r723",
      "r795"
     ]
    },
    "ecd_EquityValuationAssumptionDifferenceFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EquityValuationAssumptionDifferenceFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Valuation Assumption Difference, Footnote"
       }
      }
     },
     "auth_ref": [
      "r991"
     ]
    },
    "ecd_ErrCompAnalysisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ErrCompAnalysisTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneous Compensation Analysis"
       }
      }
     },
     "auth_ref": [
      "r951",
      "r962",
      "r976",
      "r1002"
     ]
    },
    "ecd_ErrCompRecoveryTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ErrCompRecoveryTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneously Awarded Compensation Recovery [Table]"
       }
      }
     },
     "auth_ref": [
      "r948",
      "r959",
      "r973",
      "r999"
     ]
    },
    "us-gaap_EscrowDeposit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EscrowDeposit",
     "crdr": "debit",
     "presentation": [
      "http://neuraxis.com/role/NotesPayableDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Escrow deposit",
        "documentation": "The designation of funds furnished by a borrower to a lender to assure future payments of the borrower's real estate taxes and insurance obligations with respect to a mortgaged property. Escrow deposits may be made for a variety of other purposes such as earnest money and contingent payments. This element excludes replacement reserves which are an escrow separately provided for within the US GAAP taxonomy."
       }
      }
     },
     "auth_ref": [
      "r130",
      "r829"
     ]
    },
    "NRXS_ExchangeListingLLCMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://neuraxis.com/20241231",
     "localname": "ExchangeListingLLCMember",
     "presentation": [
      "http://neuraxis.com/role/NotesPayableDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exchange Listing LLC [Member]",
        "documentation": "Exchange Listing LLC [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ExecutiveCategoryAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ExecutiveCategoryAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Executive Category [Axis]"
       }
      }
     },
     "auth_ref": [
      "r997"
     ]
    },
    "NRXS_ExecutiveEmploymentAgreementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://neuraxis.com/20241231",
     "localname": "ExecutiveEmploymentAgreementsMember",
     "presentation": [
      "http://neuraxis.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Executive Employment Agreements [Member]",
        "documentation": "Executive Employment Agreements [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "NRXS_ExecutiveEmploymentAgreementsTerms": {
     "xbrltype": "durationItemType",
     "nsuri": "http://neuraxis.com/20241231",
     "localname": "ExecutiveEmploymentAgreementsTerms",
     "presentation": [
      "http://neuraxis.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Executive employment agreements renewals",
        "documentation": "Executive employment agreements terms."
       }
      }
     },
     "auth_ref": []
    },
    "dei_Extension": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Extension",
     "presentation": [
      "http://neuraxis.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Extension",
        "documentation": "Extension number for local phone number."
       }
      }
     },
     "auth_ref": []
    },
    "NRXS_ExtinguishmentOfDerivativeLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://neuraxis.com/20241231",
     "localname": "ExtinguishmentOfDerivativeLiabilities",
     "crdr": "debit",
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfChangesInDerivativeLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Extinguishment of Derivative liabilities",
        "documentation": "Extinguishment of derivative liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "stpr_FL": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/stpr/2024",
     "localname": "FL",
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfDisaggregationOfRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "FLORIDA"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueAdjustmentOfWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAdjustmentOfWarrants",
     "crdr": "debit",
     "calculation": {
      "http://neuraxis.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": -1.0,
       "order": 3.0
      },
      "http://neuraxis.com/role/ScheduleOfReconcilesCompanysNetSalesAndOperatingLossDetails": {
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": -1.0,
       "order": 3.0
      },
      "http://neuraxis.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 14.0
      }
     },
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfChangesInWarrantLiabilitiesDetails",
      "http://neuraxis.com/role/ScheduleOfReconcilesCompanysNetSalesAndOperatingLossDetails",
      "http://neuraxis.com/role/StatementsOfCashFlows",
      "http://neuraxis.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Change in fair value of warrant liability",
        "label": "Change in fair value of warrant liabilities",
        "verboseLabel": "Changes in fair value of warrant liabilities",
        "documentation": "Amount of expense (income) related to adjustment to fair value of warrant liability."
       }
      }
     },
     "auth_ref": [
      "r2",
      "r8"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfFairValueOfAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r560",
      "r561",
      "r568",
      "r885"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfFairValueOfAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r560",
      "r561",
      "r568",
      "r885"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems",
     "presentation": [
      "http://neuraxis.com/role/DerivativeLiabilitiesDetailsNarrative",
      "http://neuraxis.com/role/WarrantLiabilitiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r562",
      "r563",
      "r564",
      "r888"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable",
     "presentation": [
      "http://neuraxis.com/role/DerivativeLiabilitiesDetailsNarrative",
      "http://neuraxis.com/role/WarrantLiabilitiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Table]",
        "documentation": "Disclosure of information about input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r562",
      "r563",
      "r564",
      "r888"
     ]
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfChangesInDerivativeLiabilitiesDetails",
      "http://neuraxis.com/role/ScheduleOfChangesInWarrantLiabilitiesDetails",
      "http://neuraxis.com/role/ScheduleOfFairValueOfAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient."
       }
      }
     },
     "auth_ref": [
      "r399",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r559",
      "r561",
      "r562",
      "r563",
      "r564",
      "r567",
      "r568",
      "r570",
      "r612",
      "r613",
      "r614",
      "r871",
      "r872",
      "r878",
      "r879",
      "r880",
      "r885",
      "r888"
     ]
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueByMeasurementFrequencyAxis",
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfFairValueOfAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Frequency [Axis]",
        "documentation": "Information by measurement frequency."
       }
      }
     },
     "auth_ref": [
      "r560",
      "r561",
      "r562",
      "r564",
      "r885",
      "r1166",
      "r1169"
     ]
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueInputsLevel1Member",
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfChangesInDerivativeLiabilitiesDetails",
      "http://neuraxis.com/role/ScheduleOfChangesInWarrantLiabilitiesDetails",
      "http://neuraxis.com/role/ScheduleOfFairValueOfAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date."
       }
      }
     },
     "auth_ref": [
      "r399",
      "r439",
      "r444",
      "r561",
      "r568",
      "r612",
      "r878",
      "r879",
      "r880",
      "r885"
     ]
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueInputsLevel2Member",
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfChangesInDerivativeLiabilitiesDetails",
      "http://neuraxis.com/role/ScheduleOfChangesInWarrantLiabilitiesDetails",
      "http://neuraxis.com/role/ScheduleOfFairValueOfAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets."
       }
      }
     },
     "auth_ref": [
      "r399",
      "r439",
      "r444",
      "r561",
      "r562",
      "r568",
      "r613",
      "r871",
      "r872",
      "r878",
      "r879",
      "r880",
      "r885"
     ]
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueInputsLevel3Member",
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfChangesInDerivativeLiabilitiesDetails",
      "http://neuraxis.com/role/ScheduleOfChangesInWarrantLiabilitiesDetails",
      "http://neuraxis.com/role/ScheduleOfFairValueOfAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r399",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r561",
      "r562",
      "r563",
      "r564",
      "r568",
      "r614",
      "r871",
      "r872",
      "r878",
      "r879",
      "r880",
      "r885",
      "r888"
     ]
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementFrequencyDomain",
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfFairValueOfAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement frequency."
       }
      }
     },
     "auth_ref": [
      "r560",
      "r561",
      "r562",
      "r564",
      "r885",
      "r1166",
      "r1169"
     ]
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "presentation": [
      "http://neuraxis.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Measurements",
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfChangesInDerivativeLiabilitiesDetails",
      "http://neuraxis.com/role/ScheduleOfChangesInWarrantLiabilitiesDetails",
      "http://neuraxis.com/role/ScheduleOfFairValueOfAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value."
       }
      }
     },
     "auth_ref": [
      "r399",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r559",
      "r561",
      "r562",
      "r563",
      "r564",
      "r567",
      "r568",
      "r570",
      "r612",
      "r613",
      "r614",
      "r871",
      "r872",
      "r878",
      "r879",
      "r880",
      "r885",
      "r888"
     ]
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementsRecurringMember",
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfFairValueOfAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Recurring [Member]",
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value."
       }
      }
     },
     "auth_ref": [
      "r885",
      "r1163",
      "r1164",
      "r1165",
      "r1166",
      "r1167",
      "r1169"
     ]
    },
    "NRXS_FairValueOfDerivativeLiabilitiesOfConversionFeatureFromConvertibleNotes": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://neuraxis.com/20241231",
     "localname": "FairValueOfDerivativeLiabilitiesOfConversionFeatureFromConvertibleNotes",
     "crdr": "debit",
     "presentation": [
      "http://neuraxis.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair value of derivative liabilities of conversion feature from convertible notes",
        "documentation": "Fair value of derivative liabilities of conversion feature from convertible notes."
       }
      }
     },
     "auth_ref": []
    },
    "NRXS_FairValueOfWarrantLiabilitiesOfWarrantsFromConvertibleNotes": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://neuraxis.com/20241231",
     "localname": "FairValueOfWarrantLiabilitiesOfWarrantsFromConvertibleNotes",
     "crdr": "debit",
     "presentation": [
      "http://neuraxis.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair value of warrant liabilities of warrants from convertible notes",
        "documentation": "Fair value of warrant liabilities of warrants from convertible notes."
       }
      }
     },
     "auth_ref": []
    },
    "NRXS_FairValueOfWarrantsFromDebtDiscountInConvertibleNotesClassifiedOfAdditionalPaidInCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://neuraxis.com/20241231",
     "localname": "FairValueOfWarrantsFromDebtDiscountInConvertibleNotesClassifiedOfAdditionalPaidInCapital",
     "crdr": "credit",
     "presentation": [
      "http://neuraxis.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair value of warrants from debt discount in convertible notes classified as additional paid in capital",
        "documentation": "Fair value of warrants from debt discount in convertible notes classified of additional paid in capital."
       }
      }
     },
     "auth_ref": []
    },
    "NRXS_FinanceCharges": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://neuraxis.com/20241231",
     "localname": "FinanceCharges",
     "crdr": "debit",
     "presentation": [
      "http://neuraxis.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Charges",
        "documentation": "Finance charges."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FinancialInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinancialInstrumentAxis",
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfFairValueOfAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Instrument [Axis]",
        "documentation": "Information by type of financial instrument."
       }
      }
     },
     "auth_ref": [
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r324",
      "r325",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r410",
      "r428",
      "r554",
      "r571",
      "r609",
      "r610",
      "r611",
      "r612",
      "r613",
      "r614",
      "r615",
      "r616",
      "r617",
      "r618",
      "r619",
      "r620",
      "r621",
      "r622",
      "r623",
      "r625",
      "r626",
      "r627",
      "r628",
      "r629",
      "r630",
      "r631",
      "r632",
      "r633",
      "r634",
      "r635",
      "r636",
      "r637",
      "r638",
      "r639",
      "r697",
      "r868",
      "r885",
      "r886",
      "r888",
      "r889",
      "r890",
      "r891",
      "r892",
      "r893",
      "r894",
      "r899",
      "r1043",
      "r1044",
      "r1045",
      "r1046",
      "r1047",
      "r1048",
      "r1049",
      "r1086",
      "r1087",
      "r1088",
      "r1089",
      "r1162",
      "r1165",
      "r1166",
      "r1167",
      "r1168",
      "r1169"
     ]
    },
    "NRXS_FinancingCharges": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://neuraxis.com/20241231",
     "localname": "FinancingCharges",
     "crdr": "debit",
     "calculation": {
      "http://neuraxis.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": -1.0,
       "order": 1.0
      },
      "http://neuraxis.com/role/ScheduleOfReconcilesCompanysNetSalesAndOperatingLossDetails": {
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": -1.0,
       "order": 1.0
      },
      "http://neuraxis.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfReconcilesCompanysNetSalesAndOperatingLossDetails",
      "http://neuraxis.com/role/StatementsOfCashFlows",
      "http://neuraxis.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Financing charges",
        "label": "Finance charges",
        "documentation": "Financing charges."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "crdr": "credit",
     "calculation": {
      "http://neuraxis.com/role/ScheduleOfIntangibleAssetsDetails": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less: accumulated amortization",
        "label": "Finite-Lived Intangible Assets, Accumulated Amortization",
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r191",
      "r339",
      "r348",
      "r869"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "documentation": "Information by major type or class of finite-lived intangible assets."
       }
      }
     },
     "auth_ref": [
      "r341",
      "r343",
      "r344",
      "r345",
      "r347",
      "r348",
      "r351",
      "r352",
      "r646",
      "r647",
      "r844"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsGross",
     "crdr": "debit",
     "calculation": {
      "http://neuraxis.com/role/ScheduleOfIntangibleAssetsDetails": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total intangible assets",
        "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r339",
      "r348",
      "r647",
      "r869"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsLineItems",
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Assets [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r341",
      "r348",
      "r351",
      "r352",
      "r354",
      "r646",
      "r844",
      "r869"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company."
       }
      }
     },
     "auth_ref": [
      "r341",
      "r343",
      "r344",
      "r345",
      "r347",
      "r348",
      "r351",
      "r352",
      "r844"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsNet",
     "crdr": "debit",
     "calculation": {
      "http://neuraxis.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 4.0
      },
      "http://neuraxis.com/role/ScheduleOfIntangibleAssetsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://neuraxis.com/role/BalanceSheets",
      "http://neuraxis.com/role/ScheduleOfIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Intangible assets, net",
        "totalLabel": "Intangible assets, net",
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r646",
      "r1102"
     ]
    },
    "us-gaap_FiniteLivedPatentsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedPatentsGross",
     "crdr": "debit",
     "presentation": [
      "http://neuraxis.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Patent value",
        "documentation": "Gross carrying amount before accumulated amortization as of the balance sheet date of the costs pertaining to the exclusive legal rights granted to the owner of the patent to exploit an invention or a process for a period of time specified by law. Such costs may have been expended to directly apply and receive patent rights, or to acquire such rights."
       }
      }
     },
     "auth_ref": [
      "r1051",
      "r1102"
     ]
    },
    "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount"
       }
      }
     },
     "auth_ref": [
      "r955",
      "r966",
      "r980",
      "r1006"
     ]
    },
    "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Expense of Enforcement, Amount"
       }
      }
     },
     "auth_ref": [
      "r955",
      "r966",
      "r980",
      "r1006"
     ]
    },
    "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Violation of Home Country Law, Amount"
       }
      }
     },
     "auth_ref": [
      "r955",
      "r966",
      "r980",
      "r1006"
     ]
    },
    "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery, Explanation of Impracticability"
       }
      }
     },
     "auth_ref": [
      "r955",
      "r966",
      "r980",
      "r1006"
     ]
    },
    "ecd_ForgoneRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Name",
        "label": "Forgone Recovery, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r955",
      "r966",
      "r980",
      "r1006"
     ]
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FurnitureAndFixturesMember",
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfEstimatedUsefulLivesDetails",
      "http://neuraxis.com/role/ScheduleOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Furniture and Fixtures [Member]",
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GainsLossesOnExtinguishmentOfDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GainsLossesOnExtinguishmentOfDebt",
     "crdr": "credit",
     "calculation": {
      "http://neuraxis.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 6.0
      },
      "http://neuraxis.com/role/ScheduleOfReconcilesCompanysNetSalesAndOperatingLossDetails": {
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 6.0
      },
      "http://neuraxis.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://neuraxis.com/role/NotesPayableDetailsNarrative",
      "http://neuraxis.com/role/ScheduleOfReconcilesCompanysNetSalesAndOperatingLossDetails",
      "http://neuraxis.com/role/StatementsOfCashFlows",
      "http://neuraxis.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Extinguishment of debt liabilities",
        "negatedLabel": "Extinguishment of debt liabilities",
        "verboseLabel": "Extinguishment of debt",
        "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r43",
      "r44"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://neuraxis.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://neuraxis.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General and administrative",
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line."
       }
      }
     },
     "auth_ref": [
      "r91",
      "r774"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GeneralAndAdministrativeExpenseMember",
     "presentation": [
      "http://neuraxis.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General and Administrative Expense [Member]",
        "documentation": "Primary financial statement caption encompassing general and administrative expense."
       }
      }
     },
     "auth_ref": [
      "r91"
     ]
    },
    "us-gaap_GeographicDistributionAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GeographicDistributionAxis",
     "presentation": [
      "http://neuraxis.com/role/LeasesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographic Distribution [Axis]",
        "documentation": "Information by geographic distribution of business activity identified as either domestic or foreign. Excludes names of countries, states and provinces, and cities."
       }
      }
     },
     "auth_ref": [
      "r164",
      "r166",
      "r167",
      "r168",
      "r169",
      "r170",
      "r171",
      "r172",
      "r173",
      "r174",
      "r175",
      "r176",
      "r177",
      "r178",
      "r179",
      "r180",
      "r181",
      "r182",
      "r680",
      "r681",
      "r867"
     ]
    },
    "us-gaap_GeographicDistributionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GeographicDistributionDomain",
     "presentation": [
      "http://neuraxis.com/role/LeasesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Allocation of business activity identified as domestic or foreign. Excludes names of countries, states and provinces, and cities."
       }
      }
     },
     "auth_ref": [
      "r164",
      "r166",
      "r167",
      "r168",
      "r169",
      "r170",
      "r171",
      "r172",
      "r173",
      "r174",
      "r175",
      "r176",
      "r177",
      "r178",
      "r179",
      "r180",
      "r181",
      "r182",
      "r680",
      "r681"
     ]
    },
    "NRXS_GoingConcernPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://neuraxis.com/20241231",
     "localname": "GoingConcernPolicyTextBlock",
     "presentation": [
      "http://neuraxis.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Going Concern",
        "documentation": "Going Concern [Policy Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill and Intangible Assets Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GrossProfit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GrossProfit",
     "crdr": "credit",
     "calculation": {
      "http://neuraxis.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      },
      "http://neuraxis.com/role/ScheduleOfReconcilesCompanysNetSalesAndOperatingLossDetails": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfReconcilesCompanysNetSalesAndOperatingLossDetails",
      "http://neuraxis.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Gross profit",
        "label": "Gross Profit",
        "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity."
       }
      }
     },
     "auth_ref": [
      "r85",
      "r88",
      "r143",
      "r223",
      "r320",
      "r374",
      "r375",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r383",
      "r384",
      "r572",
      "r857",
      "r861",
      "r1076",
      "r1077",
      "r1078",
      "r1079",
      "r1080",
      "r1116"
     ]
    },
    "NRXS_HealthBenefitPlanDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://neuraxis.com/20241231",
     "localname": "HealthBenefitPlanDisclosureTextBlock",
     "presentation": [
      "http://neuraxis.com/role/HealthBenefitPlan"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Health Benefit Plan",
        "documentation": "Health benefit plan disclosure [Text Block]",
        "label": "HealthBenefitPlanDisclosureTextBlock"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_HealthCareOrganizationStopLossInsurancePremiumExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "HealthCareOrganizationStopLossInsurancePremiumExpense",
     "crdr": "debit",
     "presentation": [
      "http://neuraxis.com/role/HealthBenefitPlanDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stop loss insurance premium expense",
        "documentation": "Stop-loss insurance premiums recognized as expense. In stop-loss insurance, prepaid health care providers or associated entities transfer portions of their financial risks to other companies. A provider typically contracts to recover health care costs in excess of stated amounts during the contract periods."
       }
      }
     },
     "auth_ref": [
      "r61",
      "r830"
     ]
    },
    "NRXS_HealthCareOrganizationStopLossInsurancePremiumPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://neuraxis.com/20241231",
     "localname": "HealthCareOrganizationStopLossInsurancePremiumPercentage",
     "presentation": [
      "http://neuraxis.com/role/HealthBenefitPlanDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stop loss insurance premium percentage",
        "documentation": "Health care organization stop loss insurance premium percentage."
       }
      }
     },
     "auth_ref": []
    },
    "stpr_IL": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/stpr/2024",
     "localname": "IL",
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfDisaggregationOfRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ILLINOIS"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IPOMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IPOMember",
     "presentation": [
      "http://neuraxis.com/role/BasisOfPresentationOrganizationAndOtherMattersDetailsNarrative",
      "http://neuraxis.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "IPO [Member]",
        "documentation": "First sale of stock by a private company to the public."
       }
      }
     },
     "auth_ref": []
    },
    "dei_IcfrAuditorAttestationFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "IcfrAuditorAttestationFlag",
     "presentation": [
      "http://neuraxis.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "auth_ref": [
      "r935",
      "r937",
      "r958"
     ]
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
     "presentation": [
      "http://neuraxis.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Impairment of Long-Lived Assets",
        "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r107"
     ]
    },
    "us-gaap_IncentiveFeeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncentiveFeeExpense",
     "crdr": "debit",
     "presentation": [
      "http://neuraxis.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Incentive payments",
        "documentation": "Amount of expense for incentive fee based on performance under arrangement to manage operations, including, but not limited to, investment."
       }
      }
     },
     "auth_ref": [
      "r57",
      "r1225"
     ]
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementLocationAxis",
     "presentation": [
      "http://neuraxis.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Income Location, Balance [Axis]",
        "documentation": "Information by location in statement of income where disaggregated amount has been reported."
       }
      }
     },
     "auth_ref": [
      "r357",
      "r364",
      "r365",
      "r565",
      "r566",
      "r569",
      "r702",
      "r704",
      "r779",
      "r844",
      "r887",
      "r1195"
     ]
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementLocationDomain",
     "presentation": [
      "http://neuraxis.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in statement of income where disaggregated amount has been reported."
       }
      }
     },
     "auth_ref": [
      "r364",
      "r365",
      "r565",
      "r566",
      "r569",
      "r702",
      "r704",
      "r779",
      "r844",
      "r887",
      "r1195"
     ]
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxAuthorityAxis",
     "presentation": [
      "http://neuraxis.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Jurisdiction [Axis]",
        "documentation": "Information by income tax jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r218",
      "r506",
      "r507",
      "r514",
      "r523",
      "r884",
      "r1155"
     ]
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxAuthorityDomain",
     "presentation": [
      "http://neuraxis.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income tax jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r218",
      "r506",
      "r507",
      "r514",
      "r523",
      "r884",
      "r1155"
     ]
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxDisclosureTextBlock",
     "presentation": [
      "http://neuraxis.com/role/IncomeTaxes"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Taxes",
        "documentation": "The entire disclosure for income tax."
       }
      }
     },
     "auth_ref": [
      "r224",
      "r502",
      "r506",
      "r511",
      "r512",
      "r513",
      "r515",
      "r521",
      "r531",
      "r533",
      "r534",
      "r535",
      "r719",
      "r884"
     ]
    },
    "us-gaap_IncomeTaxExaminationLikelihoodOfUnfavorableSettlement": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxExaminationLikelihoodOfUnfavorableSettlement",
     "presentation": [
      "http://neuraxis.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income tax examination, likelihood of unfavorable settlement",
        "documentation": "Description of the likelihood that an uncertainty in income taxes will not be sustained as a result of the examination by the taxing authority."
       }
      }
     },
     "auth_ref": [
      "r1153"
     ]
    },
    "us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxExaminationPenaltiesAndInterestAccrued",
     "crdr": "credit",
     "presentation": [
      "http://neuraxis.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income tax interest or penalties accrued",
        "documentation": "The amount of estimated penalties and interest accrued as of the balance sheet date arising from income tax examinations."
       }
      }
     },
     "auth_ref": [
      "r1152"
     ]
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://neuraxis.com/role/ScheduleOfIncomeTaxProvisionDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfIncomeTaxProvisionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total income tax provision",
        "label": "Income Tax Expense (Benefit)",
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r149",
      "r162",
      "r240",
      "r241",
      "r256",
      "r269",
      "r280",
      "r505",
      "r506",
      "r532",
      "r700",
      "r884"
     ]
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxPolicyTextBlock",
     "presentation": [
      "http://neuraxis.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Income Taxes",
        "label": "Income Tax, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements."
       }
      }
     },
     "auth_ref": [
      "r204",
      "r503",
      "r504",
      "r515",
      "r516",
      "r520",
      "r525",
      "r713"
     ]
    },
    "us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "crdr": "debit",
     "calculation": {
      "http://neuraxis.com/role/ScheduleOfIncomeTaxProvisionDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfIncomeTaxProvisionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Valuation allowance",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r510",
      "r884",
      "r1150"
     ]
    },
    "us-gaap_IncomeTaxesPaidNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxesPaidNet",
     "crdr": "credit",
     "presentation": [
      "http://neuraxis.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash received for income taxes",
        "documentation": "Amount, after refund, of cash paid to foreign, federal, state, and local jurisdictions as income tax."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r218",
      "r522",
      "r523"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInAccountsPayable",
     "crdr": "debit",
     "calculation": {
      "http://neuraxis.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 18.0
      }
     },
     "presentation": [
      "http://neuraxis.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Accounts payable",
        "label": "Increase (Decrease) in Accounts Payable",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "crdr": "credit",
     "calculation": {
      "http://neuraxis.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 15.0
      }
     },
     "presentation": [
      "http://neuraxis.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Accounts receivable",
        "label": "Increase (Decrease) in Accounts Receivable",
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://neuraxis.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 19.0
      }
     },
     "presentation": [
      "http://neuraxis.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Accrued expenses",
        "label": "Increase (Decrease) in Accrued Liabilities",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "NRXS_IncreaseDecreaseInCustomerDeposit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://neuraxis.com/20241231",
     "localname": "IncreaseDecreaseInCustomerDeposit",
     "crdr": "debit",
     "calculation": {
      "http://neuraxis.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 20.0
      }
     },
     "presentation": [
      "http://neuraxis.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Customer deposits",
        "documentation": "Increase decrease in customer deposit.",
        "label": "IncreaseDecreaseInCustomerDeposit"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInDerivativeLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInDerivativeLiabilities",
     "crdr": "debit",
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfChangesInDerivativeLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changes in fair value of Derivative liabilities",
        "documentation": "The increase (decrease) during the period in the carrying value of derivative instruments reported as liabilities that are due to be disposed of within one year (or the normal operating cycle, if longer)."
       }
      }
     },
     "auth_ref": [
      "r1059"
     ]
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInInventories",
     "crdr": "credit",
     "calculation": {
      "http://neuraxis.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 16.0
      }
     },
     "presentation": [
      "http://neuraxis.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Inventory",
        "label": "Increase (Decrease) in Inventories",
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "presentation": [
      "http://neuraxis.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changes in operating assets and liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOperatingLeaseLiability",
     "crdr": "debit",
     "calculation": {
      "http://neuraxis.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 21.0
      }
     },
     "presentation": [
      "http://neuraxis.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating lease liability",
        "documentation": "Amount of increase (decrease) in obligation for operating lease."
       }
      }
     },
     "auth_ref": [
      "r1042",
      "r1059"
     ]
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "crdr": "credit",
     "calculation": {
      "http://neuraxis.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 17.0
      }
     },
     "presentation": [
      "http://neuraxis.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Prepaids and other current assets",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IndefiniteLivedIntangibleAssetsByMajorClassAxis",
     "presentation": [
      "http://neuraxis.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Indefinite-Lived Intangible Assets [Axis]",
        "documentation": "Information by type or class of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit."
       }
      }
     },
     "auth_ref": [
      "r341",
      "r346",
      "r350",
      "r869"
     ]
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IndefiniteLivedIntangibleAssetsByMajorClassLineItems",
     "presentation": [
      "http://neuraxis.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Indefinite-Lived Intangible Assets [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r341",
      "r350",
      "r354",
      "r869"
     ]
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IndefiniteLivedIntangibleAssetsMajorClassNameDomain",
     "presentation": [
      "http://neuraxis.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of indefinite-lived intangible asset (for example, trade names, etc. but not all-inclusive), excluding goodwill. A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of the company."
       }
      }
     },
     "auth_ref": [
      "r341",
      "r346",
      "r350",
      "r869"
     ]
    },
    "ecd_IndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "IndividualAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Individual [Axis]"
       }
      }
     },
     "auth_ref": [
      "r955",
      "r966",
      "r980",
      "r997",
      "r1006",
      "r1010",
      "r1018"
     ]
    },
    "ecd_InsiderTradingArrLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTradingArrLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Arrangements [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r1016"
     ]
    },
    "ecd_InsiderTradingPoliciesProcLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTradingPoliciesProcLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r938",
      "r1021"
     ]
    },
    "ecd_InsiderTrdPoliciesProcAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTrdPoliciesProcAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Adopted"
       }
      }
     },
     "auth_ref": [
      "r938",
      "r1021"
     ]
    },
    "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Not Adopted"
       }
      }
     },
     "auth_ref": [
      "r938",
      "r1021"
     ]
    },
    "us-gaap_IntangibleAssetsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IntangibleAssetsDisclosureTextBlock",
     "presentation": [
      "http://neuraxis.com/role/IntangibleAssets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Intangible Assets",
        "documentation": "The entire disclosure for all or part of the information related to intangible assets."
       }
      }
     },
     "auth_ref": [
      "r340",
      "r353",
      "r355",
      "r843",
      "r844"
     ]
    },
    "us-gaap_IntangibleAssetsFiniteLivedPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IntangibleAssetsFiniteLivedPolicy",
     "presentation": [
      "http://neuraxis.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Intangible Assets",
        "label": "Intangible Assets, Finite-Lived, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets."
       }
      }
     },
     "auth_ref": [
      "r642",
      "r643",
      "r644",
      "r646",
      "r852",
      "r1094"
     ]
    },
    "NRXS_InterestAndServiceFeeAccrued": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://neuraxis.com/20241231",
     "localname": "InterestAndServiceFeeAccrued",
     "crdr": "credit",
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfRelatedPartyLoansPayableToShareholderDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest payable",
        "documentation": "Interest and service fee accrued."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InterestExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestExpense",
     "crdr": "debit",
     "calculation": {
      "http://neuraxis.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": -1.0,
       "order": 2.0
      },
      "http://neuraxis.com/role/ScheduleOfReconcilesCompanysNetSalesAndOperatingLossDetails": {
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://neuraxis.com/role/NotesPayableDetailsNarrative",
      "http://neuraxis.com/role/ScheduleOfReconcilesCompanysNetSalesAndOperatingLossDetails",
      "http://neuraxis.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Interest expense",
        "label": "Interest expense",
        "documentation": "Amount of interest expense classified as operating and nonoperating. Includes, but is not limited to, cost of borrowing accounted for as interest expense."
       }
      }
     },
     "auth_ref": [
      "r256",
      "r264",
      "r267",
      "r270",
      "r280",
      "r580",
      "r861",
      "r862"
     ]
    },
    "NRXS_InterestIncomeCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://neuraxis.com/20241231",
     "localname": "InterestIncomeCurrent",
     "crdr": "debit",
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfRelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Interest Income",
        "documentation": "Interest income current.",
        "label": "Interest income current"
       }
      }
     },
     "auth_ref": []
    },
    "NRXS_InterestIncomeGrossCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://neuraxis.com/20241231",
     "localname": "InterestIncomeGrossCurrent",
     "crdr": "debit",
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfRelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest Income",
        "documentation": "Interest income gross current."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InterestPaid": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestPaid",
     "crdr": "credit",
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfRelatedPartyLoansPayableToShareholderDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Interest payable",
        "label": "Interest Paid, Including Capitalized Interest, Operating and Investing Activities",
        "documentation": "Amount of cash paid for interest, including, but not limited to, capitalized interest and payment to settle zero-coupon bond attributable to accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount; classified as operating and investing activities."
       }
      }
     },
     "auth_ref": [
      "r1061"
     ]
    },
    "us-gaap_InterestPaidNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestPaidNet",
     "crdr": "credit",
     "presentation": [
      "http://neuraxis.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash paid for interest",
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount."
       }
      }
     },
     "auth_ref": [
      "r213",
      "r216",
      "r217"
     ]
    },
    "us-gaap_InterestPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://neuraxis.com/role/ScheduleOfAccruedExpensesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfAccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest",
        "documentation": "Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r66"
     ]
    },
    "us-gaap_InterestReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestReceivable",
     "crdr": "debit",
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfRelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Interest Receivable",
        "label": "Interest Receivable [Default Label]",
        "documentation": "Carrying amount as of the balance sheet date of interest earned but not received. Also called accrued interest or accrued interest receivable."
       }
      }
     },
     "auth_ref": [
      "r1055",
      "r1228"
     ]
    },
    "us-gaap_InterestReceivableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestReceivableCurrent",
     "crdr": "debit",
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfRelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest Receivable",
        "documentation": "Carrying amount as of the balance sheet date of current interest earned but not received. Also called accrued interest or accrued interest receivable. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r1055"
     ]
    },
    "NRXS_InventoryExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://neuraxis.com/20241231",
     "localname": "InventoryExpenses",
     "crdr": "debit",
     "presentation": [
      "http://neuraxis.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory expenses",
        "documentation": "Inventory expenses."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InventoryNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InventoryNet",
     "crdr": "debit",
     "calculation": {
      "http://neuraxis.com/role/BalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://neuraxis.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventories, net of reserves of $4,454 and $0 as of December 31, 2024 and 2023, respectively",
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r200",
      "r848",
      "r898"
     ]
    },
    "us-gaap_InventoryPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InventoryPolicyTextBlock",
     "presentation": [
      "http://neuraxis.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventories",
        "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost."
       }
      }
     },
     "auth_ref": [
      "r151",
      "r187",
      "r199",
      "r335",
      "r336",
      "r338",
      "r641",
      "r853"
     ]
    },
    "us-gaap_InventoryRawMaterialsNetOfReserves": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InventoryRawMaterialsNetOfReserves",
     "crdr": "debit",
     "presentation": [
      "http://neuraxis.com/role/BalanceSheetsParenthetical",
      "http://neuraxis.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventories, net of reserves",
        "verboseLabel": "Inventory reserves",
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process."
       }
      }
     },
     "auth_ref": [
      "r104",
      "r851"
     ]
    },
    "us-gaap_InventoryWriteDown": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InventoryWriteDown",
     "crdr": "debit",
     "calculation": {
      "http://neuraxis.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://neuraxis.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Provision for losses on inventory",
        "documentation": "Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels."
       }
      }
     },
     "auth_ref": [
      "r337"
     ]
    },
    "NRXS_InvestorWarrantOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://neuraxis.com/20241231",
     "localname": "InvestorWarrantOneMember",
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfWarrantsOutstandingAndExercisableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investor Warrant W-01 [Member]",
        "documentation": "Investor Warrant W-01 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "NRXS_InvestorWarrantPSAOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://neuraxis.com/20241231",
     "localname": "InvestorWarrantPSAOneMember",
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfWarrantsOutstandingAndExercisableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investor Warrant PSA-01 [Member]",
        "documentation": "Investor Warrant PSA-01 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "NRXS_IssuanceOfCommonStockForNoncashConsideration": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://neuraxis.com/20241231",
     "localname": "IssuanceOfCommonStockForNoncashConsideration",
     "crdr": "debit",
     "calculation": {
      "http://neuraxis.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://neuraxis.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of common stock for non-cash consideration",
        "documentation": "Issuance of common stock for noncash consideration."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IssuanceOfStockAndWarrantsForServicesOrClaims",
     "crdr": "debit",
     "presentation": [
      "http://neuraxis.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payment for services",
        "documentation": "Fair value of share-based compensation granted to nonemployees as payment for services rendered or acknowledged claims."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "NRXS_IssuanceOfWarrantsForNoncashConsideration": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://neuraxis.com/20241231",
     "localname": "IssuanceOfWarrantsForNoncashConsideration",
     "crdr": "debit",
     "calculation": {
      "http://neuraxis.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://neuraxis.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair value of warrants issued for non-cash consideration",
        "documentation": "Issuance of warrants for non-cash consideration."
       }
      }
     },
     "auth_ref": []
    },
    "NRXS_KeyEmployeeExercisePercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://neuraxis.com/20241231",
     "localname": "KeyEmployeeExercisePercentage",
     "presentation": [
      "http://neuraxis.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Key employee exercise percentage",
        "documentation": "Key employee exercise percentage."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LaborAndRelatedExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LaborAndRelatedExpense",
     "crdr": "debit",
     "calculation": {
      "http://neuraxis.com/role/ScheduleOfReconcilesCompanysNetSalesAndOperatingLossDetails": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfReconcilesCompanysNetSalesAndOperatingLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Wages and Benefits",
        "documentation": "Amount of expense for salary, wage, profit sharing; incentive and equity-based compensation; and other employee benefit."
       }
      }
     },
     "auth_ref": [
      "r1057"
     ]
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeaseCostTableTextBlock",
     "presentation": [
      "http://neuraxis.com/role/LeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Operating Leases",
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income."
       }
      }
     },
     "auth_ref": [
      "r1175"
     ]
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeaseholdImprovementsMember",
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfEstimatedUsefulLivesDetails",
      "http://neuraxis.com/role/ScheduleOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leasehold Improvements [Member]",
        "documentation": "Additions or improvements to assets held under a lease arrangement."
       }
      }
     },
     "auth_ref": [
      "r106",
      "r595"
     ]
    },
    "dei_LegalEntityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LegalEntityAxis",
     "presentation": [
      "http://neuraxis.com/role/NotesPayableDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Legal Entity [Axis]",
        "documentation": "The set of legal entities associated with a report."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeLeasesPolicyTextBlock",
     "presentation": [
      "http://neuraxis.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Leases",
        "label": "Lessee, Leases [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee."
       }
      }
     },
     "auth_ref": [
      "r589"
     ]
    },
    "us-gaap_LesseeOperatingLeaseDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseDescription",
     "presentation": [
      "http://neuraxis.com/role/LeasesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating lease description",
        "documentation": "Description of lessee's operating lease."
       }
      }
     },
     "auth_ref": [
      "r590"
     ]
    },
    "us-gaap_LesseeOperatingLeaseDiscountRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseDiscountRate",
     "presentation": [
      "http://neuraxis.com/role/LeasesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating lease payment rate",
        "documentation": "Discount rate used by lessee to determine present value of operating lease payments."
       }
      }
     },
     "auth_ref": [
      "r896"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "presentation": [
      "http://neuraxis.com/role/LeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Maturities Operating Lease Liabilities",
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position."
       }
      }
     },
     "auth_ref": [
      "r1176"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "crdr": "credit",
     "calculation": {
      "http://neuraxis.com/role/ScheduleOfMaturitiesOperatingLeaseLiabilitiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfMaturitiesOperatingLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total lease payments",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease."
       }
      }
     },
     "auth_ref": [
      "r594"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "crdr": "credit",
     "calculation": {
      "http://neuraxis.com/role/ScheduleOfMaturitiesOperatingLeaseLiabilitiesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfMaturitiesOperatingLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2025",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r594"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive",
     "crdr": "credit",
     "calculation": {
      "http://neuraxis.com/role/ScheduleOfMaturitiesOperatingLeaseLiabilitiesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfMaturitiesOperatingLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2029",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r594"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "crdr": "credit",
     "calculation": {
      "http://neuraxis.com/role/ScheduleOfMaturitiesOperatingLeaseLiabilitiesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfMaturitiesOperatingLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2028",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r594"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "crdr": "credit",
     "calculation": {
      "http://neuraxis.com/role/ScheduleOfMaturitiesOperatingLeaseLiabilitiesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfMaturitiesOperatingLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2027",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r594"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "crdr": "credit",
     "calculation": {
      "http://neuraxis.com/role/ScheduleOfMaturitiesOperatingLeaseLiabilitiesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfMaturitiesOperatingLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2026",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r594"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "crdr": "credit",
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfMaturitiesOperatingLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less: imputed interest",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease."
       }
      }
     },
     "auth_ref": [
      "r594"
     ]
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeasesTextBlock",
     "presentation": [
      "http://neuraxis.com/role/Leases"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Leases",
        "label": "Lessee, Operating Leases [Text Block]",
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r584"
     ]
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Liabilities",
     "crdr": "credit",
     "calculation": {
      "http://neuraxis.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://neuraxis.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities",
        "label": "Liabilities [Default Label]",
        "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r65",
      "r66",
      "r67",
      "r71",
      "r72",
      "r73",
      "r76",
      "r223",
      "r320",
      "r374",
      "r375",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r383",
      "r384",
      "r545",
      "r546",
      "r547",
      "r572",
      "r747",
      "r856",
      "r923",
      "r1116",
      "r1179",
      "r1180"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://neuraxis.com/role/BalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://neuraxis.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total Liabilities and Stockholders\u2019 Equity (Deficit)",
        "label": "Liabilities and Equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r84",
      "r138",
      "r690",
      "r898",
      "r1064",
      "r1090",
      "r1170"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "presentation": [
      "http://neuraxis.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://neuraxis.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://neuraxis.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current liabilities",
        "label": "Liabilities, Current",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r67",
      "r186",
      "r223",
      "r320",
      "r374",
      "r375",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r383",
      "r384",
      "r545",
      "r546",
      "r547",
      "r572",
      "r898",
      "r1116",
      "r1179",
      "r1180"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://neuraxis.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesFairValueDisclosure",
     "crdr": "credit",
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfFairValueOfAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair value of warrant liabilities as of December 31, 2023",
        "documentation": "Fair value of financial and nonfinancial obligations."
       }
      }
     },
     "auth_ref": [
      "r561",
      "r1163"
     ]
    },
    "us-gaap_LiabilitiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://neuraxis.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://neuraxis.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total non-current liabilities",
        "label": "Liabilities, Noncurrent",
        "documentation": "Amount of obligation due after one year or beyond the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r71",
      "r72",
      "r73",
      "r76",
      "r223",
      "r320",
      "r374",
      "r375",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r383",
      "r384",
      "r545",
      "r546",
      "r547",
      "r572",
      "r1116",
      "r1179",
      "r1180"
     ]
    },
    "us-gaap_LiabilitiesNoncurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesNoncurrentAbstract",
     "presentation": [
      "http://neuraxis.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-current Liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "NRXS_LicensesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://neuraxis.com/20241231",
     "localname": "LicensesMember",
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Licenses [Member]",
        "documentation": "Licenses [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "NRXS_LicensingAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://neuraxis.com/20241231",
     "localname": "LicensingAgreementMember",
     "presentation": [
      "http://neuraxis.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Licensing Agreement [Member]",
        "documentation": "Licensing Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LoansPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LoansPayable",
     "crdr": "credit",
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfRelatedPartyLoansPayableToShareholderDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loan payable",
        "documentation": "Including the current and noncurrent portions, aggregate carrying value as of the balance sheet date of loans payable (with maturities initially due after one year or beyond the operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r136",
      "r1190"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://neuraxis.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LongTermDebtAverageAmountOutstanding": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongTermDebtAverageAmountOutstanding",
     "crdr": "credit",
     "presentation": [
      "http://neuraxis.com/role/NotesPayableDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Term Debt, Average Amount Outstanding",
        "documentation": "Average amount outstanding of long-term debt."
       }
      }
     },
     "auth_ref": [
      "r163",
      "r165",
      "r780"
     ]
    },
    "us-gaap_LossContingencyDamagesSoughtValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LossContingencyDamagesSoughtValue",
     "crdr": "debit",
     "presentation": [
      "http://neuraxis.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sought compensatory damages",
        "documentation": "The value (monetary amount) of the award the plaintiff seeks in the legal matter."
       }
      }
     },
     "auth_ref": [
      "r1112",
      "r1113",
      "r1114"
     ]
    },
    "stpr_MA": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/stpr/2024",
     "localname": "MA",
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfDisaggregationOfRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "MASSACHUSETTS"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MachineryAndEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MachineryAndEquipmentMember",
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfEstimatedUsefulLivesDetails",
      "http://neuraxis.com/role/ScheduleOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Machinery and Equipment [Member]",
        "documentation": "Tangible personal property used to produce goods and services, including, but is not limited to, tools, dies and molds, computer and office equipment."
       }
      }
     },
     "auth_ref": []
    },
    "srt_MajorCustomersAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MajorCustomersAxis",
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfCustomerAccountsReceivableDetails",
      "http://neuraxis.com/role/ScheduleOfCustomersAccountedRevenuesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Axis]"
       }
      }
     },
     "auth_ref": [
      "r287",
      "r877",
      "r908",
      "r911",
      "r1122",
      "r1194",
      "r1196",
      "r1197",
      "r1198",
      "r1199",
      "r1200",
      "r1201",
      "r1202",
      "r1203",
      "r1204",
      "r1205",
      "r1206",
      "r1207",
      "r1208",
      "r1209",
      "r1210",
      "r1211",
      "r1212",
      "r1213",
      "r1214",
      "r1215",
      "r1216",
      "r1217",
      "r1218",
      "r1219",
      "r1220",
      "r1221",
      "r1222"
     ]
    },
    "cyd_MaterialCybersecurityIncidentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "MaterialCybersecurityIncidentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Cybersecurity Incident [Abstract]"
       }
      }
     },
     "auth_ref": [
      "r969",
      "r970"
     ]
    },
    "cyd_MaterialCybersecurityIncidentInformationNotAvailableOrUndeterminedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "MaterialCybersecurityIncidentInformationNotAvailableOrUndeterminedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Cybersecurity Incident Information Not Available or Undetermined [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r969",
      "r971"
     ]
    },
    "cyd_MaterialCybersecurityIncidentMaterialImpactOrReasonablyLikelyMaterialImpactTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "MaterialCybersecurityIncidentMaterialImpactOrReasonablyLikelyMaterialImpactTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Cybersecurity Incident Material Impact or Reasonably Likely Material Impact [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r969",
      "r972"
     ]
    },
    "cyd_MaterialCybersecurityIncidentNatureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "MaterialCybersecurityIncidentNatureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Cybersecurity Incident Nature [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r969",
      "r972"
     ]
    },
    "cyd_MaterialCybersecurityIncidentScopeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "MaterialCybersecurityIncidentScopeTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Cybersecurity Incident Scope [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r969",
      "r972"
     ]
    },
    "cyd_MaterialCybersecurityIncidentTimingTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "MaterialCybersecurityIncidentTimingTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Cybersecurity Incident Timing [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r969",
      "r972"
     ]
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MaximumMember",
     "presentation": [
      "http://neuraxis.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://neuraxis.com/role/DerivativeLiabilitiesDetailsNarrative",
      "http://neuraxis.com/role/NotesPayableDetailsNarrative",
      "http://neuraxis.com/role/ScheduleOfEstimatedUsefulLivesDetails",
      "http://neuraxis.com/role/WarrantLiabilitiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]"
       }
      }
     },
     "auth_ref": [
      "r368",
      "r369",
      "r370",
      "r371",
      "r455",
      "r497",
      "r564",
      "r640",
      "r701",
      "r703",
      "r710",
      "r739",
      "r740",
      "r803",
      "r806",
      "r810",
      "r811",
      "r816",
      "r841",
      "r842",
      "r866",
      "r875",
      "r881",
      "r888",
      "r889",
      "r893",
      "r894",
      "r909",
      "r1120",
      "r1181",
      "r1182",
      "r1183",
      "r1184",
      "r1185",
      "r1186"
     ]
    },
    "ecd_MeasureAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MeasureAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measure [Axis]"
       }
      }
     },
     "auth_ref": [
      "r989"
     ]
    },
    "ecd_MeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Name"
       }
      }
     },
     "auth_ref": [
      "r989"
     ]
    },
    "us-gaap_MeasurementInputExpectedDividendRateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MeasurementInputExpectedDividendRateMember",
     "presentation": [
      "http://neuraxis.com/role/DerivativeLiabilitiesDetailsNarrative",
      "http://neuraxis.com/role/WarrantLiabilitiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input, Expected Dividend Rate [Member]",
        "documentation": "Measurement input using expected dividend rate to be paid to holder of share per year."
       }
      }
     },
     "auth_ref": [
      "r1165",
      "r1166",
      "r1167"
     ]
    },
    "us-gaap_MeasurementInputPriceVolatilityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MeasurementInputPriceVolatilityMember",
     "presentation": [
      "http://neuraxis.com/role/DerivativeLiabilitiesDetailsNarrative",
      "http://neuraxis.com/role/WarrantLiabilitiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input, Price Volatility [Member]",
        "documentation": "Measurement input using rate at which price of security will increase (decrease) for given set of returns."
       }
      }
     },
     "auth_ref": [
      "r888",
      "r1165",
      "r1166",
      "r1167"
     ]
    },
    "us-gaap_MeasurementInputRiskFreeInterestRateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MeasurementInputRiskFreeInterestRateMember",
     "presentation": [
      "http://neuraxis.com/role/DerivativeLiabilitiesDetailsNarrative",
      "http://neuraxis.com/role/WarrantLiabilitiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input, Risk Free Interest Rate [Member]",
        "documentation": "Measurement input using interest rate on instrument with zero risk of financial loss."
       }
      }
     },
     "auth_ref": [
      "r1165",
      "r1166",
      "r1167"
     ]
    },
    "us-gaap_MeasurementInputSharePriceMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MeasurementInputSharePriceMember",
     "presentation": [
      "http://neuraxis.com/role/DerivativeLiabilitiesDetailsNarrative",
      "http://neuraxis.com/role/WarrantLiabilitiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input, Share Price [Member]",
        "documentation": "Measurement input using share price of saleable stock."
       }
      }
     },
     "auth_ref": [
      "r1165",
      "r1166",
      "r1167"
     ]
    },
    "us-gaap_MeasurementInputTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MeasurementInputTypeAxis",
     "presentation": [
      "http://neuraxis.com/role/DerivativeLiabilitiesDetailsNarrative",
      "http://neuraxis.com/role/WarrantLiabilitiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input Type [Axis]",
        "documentation": "Information by type of measurement input used to determine value of asset and liability."
       }
      }
     },
     "auth_ref": [
      "r562",
      "r563",
      "r564",
      "r888"
     ]
    },
    "us-gaap_MeasurementInputTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MeasurementInputTypeDomain",
     "presentation": [
      "http://neuraxis.com/role/DerivativeLiabilitiesDetailsNarrative",
      "http://neuraxis.com/role/WarrantLiabilitiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input used to determine value of asset and liability."
       }
      }
     },
     "auth_ref": [
      "r562",
      "r563",
      "r564",
      "r888"
     ]
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MinimumMember",
     "presentation": [
      "http://neuraxis.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://neuraxis.com/role/DerivativeLiabilitiesDetailsNarrative",
      "http://neuraxis.com/role/NotesPayableDetailsNarrative",
      "http://neuraxis.com/role/ScheduleOfEstimatedUsefulLivesDetails",
      "http://neuraxis.com/role/WarrantLiabilitiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]"
       }
      }
     },
     "auth_ref": [
      "r368",
      "r369",
      "r370",
      "r371",
      "r455",
      "r497",
      "r564",
      "r640",
      "r701",
      "r703",
      "r710",
      "r739",
      "r740",
      "r803",
      "r806",
      "r810",
      "r811",
      "r816",
      "r841",
      "r842",
      "r866",
      "r875",
      "r881",
      "r888",
      "r889",
      "r893",
      "r909",
      "r1120",
      "r1181",
      "r1182",
      "r1183",
      "r1184",
      "r1185",
      "r1186"
     ]
    },
    "ecd_MnpiDiscTimedForCompValFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MnpiDiscTimedForCompValFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "MNPI Disclosure Timed for Compensation Value"
       }
      }
     },
     "auth_ref": [
      "r1009"
     ]
    },
    "NRXS_MrSealeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://neuraxis.com/20241231",
     "localname": "MrSealeMember",
     "presentation": [
      "http://neuraxis.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Mr Seale [Member]",
        "documentation": "Mr Seale [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "NRXS_MrWatkinsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://neuraxis.com/20241231",
     "localname": "MrWatkinsMember",
     "presentation": [
      "http://neuraxis.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Mr. Watkins [Member]",
        "documentation": "Mr. Watkins [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_MtrlTermsOfTrdArrTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MtrlTermsOfTrdArrTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Terms of Trading Arrangement"
       }
      }
     },
     "auth_ref": [
      "r1017"
     ]
    },
    "srt_NameOfMajorCustomerDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "NameOfMajorCustomerDomain",
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfCustomerAccountsReceivableDetails",
      "http://neuraxis.com/role/ScheduleOfCustomersAccountedRevenuesDetails"
     ],
     "auth_ref": [
      "r287",
      "r877",
      "r908",
      "r911",
      "r1122",
      "r1194",
      "r1196",
      "r1197",
      "r1198",
      "r1199",
      "r1200",
      "r1201",
      "r1202",
      "r1203",
      "r1204",
      "r1205",
      "r1206",
      "r1207",
      "r1208",
      "r1209",
      "r1210",
      "r1211",
      "r1212",
      "r1213",
      "r1214",
      "r1215",
      "r1216",
      "r1217",
      "r1218",
      "r1219",
      "r1220",
      "r1221",
      "r1222"
     ]
    },
    "ecd_NamedExecutiveOfficersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NamedExecutiveOfficersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Named Executive Officers, Footnote"
       }
      }
     },
     "auth_ref": [
      "r990"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://neuraxis.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://neuraxis.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash provided by financing activities",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r215"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://neuraxis.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Flows from Financing Activities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://neuraxis.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://neuraxis.com/role/SegmentInformationDetailsNarrative",
      "http://neuraxis.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash used by investing activities",
        "negatedLabel": "Net cash used by investing activities",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r215"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://neuraxis.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Flows from Investing Activities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://neuraxis.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://neuraxis.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash used by operating activities",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities."
       }
      }
     },
     "auth_ref": [
      "r96",
      "r97",
      "r99"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://neuraxis.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Flows from Operating Activities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://neuraxis.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic",
       "weight": 1.0,
       "order": 1.0
      },
      "http://neuraxis.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 1.0
      },
      "http://neuraxis.com/role/ScheduleOfReconcilesCompanysNetSalesAndOperatingLossDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfBasicAndDilutedNetLossPerShareDetails",
      "http://neuraxis.com/role/ScheduleOfReconcilesCompanysNetSalesAndOperatingLossDetails",
      "http://neuraxis.com/role/StatementsOfCashFlows",
      "http://neuraxis.com/role/StatementsOfOperations",
      "http://neuraxis.com/role/StatementsOfStockholdersEquityDeficit",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net loss",
        "label": "Net loss",
        "verboseLabel": "Net Loss",
        "terseLabel": "Net Income (Loss)",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r89",
      "r99",
      "r140",
      "r184",
      "r202",
      "r203",
      "r207",
      "r223",
      "r231",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r240",
      "r241",
      "r248",
      "r320",
      "r374",
      "r375",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r383",
      "r384",
      "r539",
      "r542",
      "r558",
      "r572",
      "r695",
      "r771",
      "r793",
      "r794",
      "r921",
      "r1116"
     ]
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasic",
     "crdr": "credit",
     "calculation": {
      "http://neuraxis.com/role/StatementsOfOperations": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfBasicAndDilutedNetLossPerShareDetails",
      "http://neuraxis.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net loss available to common stockholders",
        "label": "Net loss available to common stockholders",
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders."
       }
      }
     },
     "auth_ref": [
      "r212",
      "r233",
      "r234",
      "r235",
      "r236",
      "r243",
      "r244",
      "r249",
      "r252",
      "r542"
     ]
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://neuraxis.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Recently Adopted Accounting Pronouncements",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "NRXS_NoExpirationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://neuraxis.com/20241231",
     "localname": "NoExpirationMember",
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfStateCarryforwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Expiration [Member]",
        "documentation": "No Expiration [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "NRXS_NoInsiderTradingFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://neuraxis.com/20241231",
     "localname": "NoInsiderTradingFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No insider trading flag",
        "documentation": "No insider trading flag."
       }
      }
     },
     "auth_ref": []
    },
    "dei_NoTradingSymbolFlag": {
     "xbrltype": "trueItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "NoTradingSymbolFlag",
     "presentation": [
      "http://neuraxis.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Trading Symbol Flag",
        "documentation": "Boolean flag that is true only for a security having no trading symbol."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NonGaapMeasureDescriptionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonGaapMeasureDescriptionTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-GAAP Measure Description"
       }
      }
     },
     "auth_ref": [
      "r989"
     ]
    },
    "ecd_NonPeoNeoAvgCompActuallyPaidAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoAvgCompActuallyPaidAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Compensation Actually Paid Amount"
       }
      }
     },
     "auth_ref": [
      "r987"
     ]
    },
    "ecd_NonPeoNeoAvgTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoAvgTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r986"
     ]
    },
    "ecd_NonRule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonRule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r1017"
     ]
    },
    "ecd_NonRule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonRule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r1017"
     ]
    },
    "NRXS_NonaccountableExpenseAllowancePercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://neuraxis.com/20241231",
     "localname": "NonaccountableExpenseAllowancePercentage",
     "presentation": [
      "http://neuraxis.com/role/BasisOfPresentationOrganizationAndOtherMattersDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nonaccountable expense allowance percentage",
        "documentation": "Nonaccountable expense allowance percentage."
       }
      }
     },
     "auth_ref": []
    },
    "NRXS_NoncashLeaseExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://neuraxis.com/20241231",
     "localname": "NoncashLeaseExpense",
     "crdr": "debit",
     "calculation": {
      "http://neuraxis.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://neuraxis.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-cash lease expense",
        "documentation": "Noncash lease expense."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NonoperatingIncomeExpenseAbstract",
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfReconcilesCompanysNetSalesAndOperatingLossDetails",
      "http://neuraxis.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other (expense) income:",
        "verboseLabel": "Other (Expense) Income:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NotesAndLoansReceivableGrossCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NotesAndLoansReceivableGrossCurrent",
     "crdr": "debit",
     "presentation": [
      "http://neuraxis.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://neuraxis.com/role/ScheduleOfRelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loan Receivable",
        "documentation": "Amortized cost, before allowance for credit loss, of financing receivable classified as current. Excludes net investment in lease."
       }
      }
     },
     "auth_ref": [
      "r197",
      "r849",
      "r1091"
     ]
    },
    "us-gaap_NotesAndLoansReceivableNetCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NotesAndLoansReceivableNetCurrent",
     "crdr": "debit",
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfRelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Loan Receivable",
        "label": "Financing Receivable, after Allowance for Credit Loss, Current",
        "documentation": "Amortized cost, after allowance for credit loss, of financing receivable classified as current. Excludes net investment in lease."
       }
      }
     },
     "auth_ref": [
      "r678",
      "r1082"
     ]
    },
    "us-gaap_NotesIssued1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NotesIssued1",
     "crdr": "credit",
     "presentation": [
      "http://neuraxis.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of note payable to financing company for insurance premiums",
        "documentation": "The fair value of notes issued in noncash investing and financing activities."
       }
      }
     },
     "auth_ref": [
      "r22",
      "r23",
      "r24"
     ]
    },
    "us-gaap_NotesPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NotesPayable",
     "crdr": "credit",
     "presentation": [
      "http://neuraxis.com/role/NotesPayableDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Promissory note",
        "documentation": "Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r136",
      "r1190",
      "r1191"
     ]
    },
    "us-gaap_NotesPayableToBankCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NotesPayableToBankCurrent",
     "crdr": "credit",
     "calculation": {
      "http://neuraxis.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://neuraxis.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Notes payable",
        "documentation": "Current portion of the total carrying amount as of the balance sheet date due within one year or the operating cycle, if longer, on all notes payable to banks paid on an installment with long term maturities. This can include the amount of any loans from the applicant firm. This does not, however, include any mortgage balances."
       }
      }
     },
     "auth_ref": [
      "r63",
      "r66"
     ]
    },
    "NRXS_NumberOfEquivalentOfWarrantsDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://neuraxis.com/20241231",
     "localname": "NumberOfEquivalentOfWarrantsDescription",
     "presentation": [
      "http://neuraxis.com/role/CommonStockAndWarrantsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of equivalent of warrants, description",
        "documentation": "Number of equivalent of warrants description."
       }
      }
     },
     "auth_ref": []
    },
    "stpr_OH": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/stpr/2024",
     "localname": "OH",
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfDisaggregationOfRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "OHIO"
       }
      }
     },
     "auth_ref": []
    },
    "NRXS_OfferingPricePerPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://neuraxis.com/20241231",
     "localname": "OfferingPricePerPercentage",
     "presentation": [
      "http://neuraxis.com/role/BasisOfPresentationOrganizationAndOtherMattersDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offering price per percentage",
        "documentation": "Offering price per percentage."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://neuraxis.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      },
      "http://neuraxis.com/role/ScheduleOfReconcilesCompanysNetSalesAndOperatingLossDetails": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfReconcilesCompanysNetSalesAndOperatingLossDetails",
      "http://neuraxis.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Operating loss",
        "label": "Operating Income (Loss)",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r143",
      "r857",
      "r1076",
      "r1077",
      "r1078",
      "r1079",
      "r1080"
     ]
    },
    "us-gaap_OperatingLeaseExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseExpense",
     "crdr": "debit",
     "presentation": [
      "http://neuraxis.com/role/LeasesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating lease expense",
        "documentation": "Amount of operating lease expense. Excludes sublease income."
       }
      }
     },
     "auth_ref": [
      "r1174"
     ]
    },
    "us-gaap_OperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiability",
     "crdr": "credit",
     "calculation": {
      "http://neuraxis.com/role/ScheduleOfOperatingLeasesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfMaturitiesOperatingLeaseLiabilitiesDetails",
      "http://neuraxis.com/role/ScheduleOfOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total",
        "label": "Total present value of lease payments",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease."
       }
      }
     },
     "auth_ref": [
      "r587"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://neuraxis.com/role/ScheduleOfOperatingLeasesDetails": {
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0,
       "order": 1.0
      },
      "http://neuraxis.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://neuraxis.com/role/BalanceSheets",
      "http://neuraxis.com/role/ScheduleOfOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current portion of operating lease payable",
        "verboseLabel": "Other current liabilities",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r587"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://neuraxis.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0,
       "order": 1.0
      },
      "http://neuraxis.com/role/ScheduleOfOperatingLeasesDetails": {
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://neuraxis.com/role/BalanceSheets",
      "http://neuraxis.com/role/ScheduleOfOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating lease payable, net of current portion",
        "verboseLabel": "Operating lease liabilities",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r587"
     ]
    },
    "us-gaap_OperatingLeasePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeasePayments",
     "crdr": "credit",
     "presentation": [
      "http://neuraxis.com/role/LeasesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating lease payment",
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use."
       }
      }
     },
     "auth_ref": [
      "r588",
      "r591"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseRightOfUseAsset",
     "crdr": "debit",
     "calculation": {
      "http://neuraxis.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://neuraxis.com/role/BalanceSheets",
      "http://neuraxis.com/role/ScheduleOfOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating lease right of use asset, net",
        "verboseLabel": "Operating lease right-of-use assets",
        "documentation": "Amount of lessee's right to use underlying asset under operating lease."
       }
      }
     },
     "auth_ref": [
      "r586"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average discount rate",
        "documentation": "Weighted average discount rate for operating lease calculated at point in time."
       }
      }
     },
     "auth_ref": [
      "r593",
      "r897"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average remaining lease term (in years)",
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r592",
      "r897"
     ]
    },
    "us-gaap_OperatingLossCarryforwardsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLossCarryforwardsLineItems",
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfStateCarryforwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Loss Carryforwards [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r524"
     ]
    },
    "us-gaap_OperatingLossCarryforwardsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLossCarryforwardsTable",
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfStateCarryforwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Loss Carryforwards [Table]",
        "documentation": "Disclosure of information about operating loss carryforward. Includes, but is not limited to, tax authority, amount and expiration date of operating loss carryforward, and likelihood of utilization."
       }
      }
     },
     "auth_ref": [
      "r524"
     ]
    },
    "us-gaap_OperatingSegmentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingSegmentsMember",
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfReconcilesCompanysNetSalesAndOperatingLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Segments [Member]",
        "documentation": "Identifies components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity."
       }
      }
     },
     "auth_ref": [
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r281",
      "r861",
      "r862"
     ]
    },
    "us-gaap_OptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OptionMember",
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfDilutiveCommonStockEquivalentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Options Held [Member]",
        "documentation": "Contracts conveying rights, but not obligations, to buy or sell a specific commodity, or financial or equity instrument, at a specified price during a specified period (an American option) or at a specified date (a European option) which were purchased or otherwise acquired, excluding options written (for which a premium was received)."
       }
      }
     },
     "auth_ref": [
      "r127",
      "r759",
      "r764",
      "r783",
      "r789",
      "r813",
      "r814",
      "r815",
      "r912",
      "r913"
     ]
    },
    "us-gaap_OtherAssetsNoncurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherAssetsNoncurrentAbstract",
     "presentation": [
      "http://neuraxis.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Assets:"
       }
      }
     },
     "auth_ref": []
    },
    "NRXS_OtherConvertiblesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://neuraxis.com/20241231",
     "localname": "OtherConvertiblesMember",
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfRelatedPartyLoansPayableToShareholderDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Convertibles [Member]",
        "documentation": "Other Convertibles [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherCostAndExpenseOperating": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherCostAndExpenseOperating",
     "crdr": "debit",
     "calculation": {
      "http://neuraxis.com/role/ScheduleOfReconcilesCompanysNetSalesAndOperatingLossDetails": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfReconcilesCompanysNetSalesAndOperatingLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Operating Expenses",
        "documentation": "The total amount of other operating cost and expense items that are associated with the entity's normal revenue producing operation."
       }
      }
     },
     "auth_ref": [
      "r90",
      "r699",
      "r861"
     ]
    },
    "us-gaap_OtherExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherExpenses",
     "crdr": "debit",
     "presentation": [
      "http://neuraxis.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other expenses",
        "documentation": "Amount of expense classified as other."
       }
      }
     },
     "auth_ref": [
      "r91",
      "r92"
     ]
    },
    "us-gaap_OtherNonoperatingExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherNonoperatingExpense",
     "crdr": "debit",
     "calculation": {
      "http://neuraxis.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": -1.0,
       "order": 8.0
      },
      "http://neuraxis.com/role/ScheduleOfReconcilesCompanysNetSalesAndOperatingLossDetails": {
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": -1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfReconcilesCompanysNetSalesAndOperatingLossDetails",
      "http://neuraxis.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Other expense",
        "label": "Other Nonoperating Expense",
        "documentation": "Amount of expense related to nonoperating activities, classified as other."
       }
      }
     },
     "auth_ref": [
      "r93"
     ]
    },
    "us-gaap_OtherNonoperatingIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherNonoperatingIncome",
     "crdr": "credit",
     "calculation": {
      "http://neuraxis.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 7.0
      },
      "http://neuraxis.com/role/ScheduleOfReconcilesCompanysNetSalesAndOperatingLossDetails": {
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfReconcilesCompanysNetSalesAndOperatingLossDetails",
      "http://neuraxis.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other income",
        "documentation": "Amount of income related to nonoperating activities, classified as other."
       }
      }
     },
     "auth_ref": [
      "r211"
     ]
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherNonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://neuraxis.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 2.0
      },
      "http://neuraxis.com/role/ScheduleOfReconcilesCompanysNetSalesAndOperatingLossDetails": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfReconcilesCompanysNetSalesAndOperatingLossDetails",
      "http://neuraxis.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total other (expense) income, net",
        "label": "Other Nonoperating Income (Expense)",
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other."
       }
      }
     },
     "auth_ref": [
      "r93"
     ]
    },
    "ecd_OtherPerfMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OtherPerfMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Performance Measure, Amount"
       }
      }
     },
     "auth_ref": [
      "r989"
     ]
    },
    "dei_OtherReportingStandardItemNumber": {
     "xbrltype": "otherReportingStandardItemNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "OtherReportingStandardItemNumber",
     "presentation": [
      "http://neuraxis.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Reporting Standard Item Number",
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS."
       }
      }
     },
     "auth_ref": [
      "r937"
     ]
    },
    "ecd_OutstandingAggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingAggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r953",
      "r964",
      "r978",
      "r1004"
     ]
    },
    "ecd_OutstandingRecoveryCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingRecoveryCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r956",
      "r967",
      "r981",
      "r1007"
     ]
    },
    "ecd_OutstandingRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Name",
        "label": "Outstanding Recovery, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r956",
      "r967",
      "r981",
      "r1007"
     ]
    },
    "us-gaap_PaidInKindInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaidInKindInterest",
     "crdr": "debit",
     "calculation": {
      "http://neuraxis.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://neuraxis.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-cash interest expense",
        "documentation": "Interest paid other than in cash for example by issuing additional debt securities. As a noncash item, it is added to net income when calculating cash provided by or used in operations using the indirect method."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "us-gaap_PatentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PatentsMember",
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Patents [Member]",
        "documentation": "Exclusive legal right granted by the government to the owner of the patent to exploit an invention or a process for a period of time specified by law."
       }
      }
     },
     "auth_ref": [
      "r125",
      "r1095",
      "r1096",
      "r1097",
      "r1098",
      "r1100",
      "r1102",
      "r1104",
      "r1105"
     ]
    },
    "ecd_PayVsPerformanceDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PayVsPerformanceDisclosureLineItems",
     "auth_ref": [
      "r985"
     ]
    },
    "us-gaap_PayablesAndAccrualsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PayablesAndAccrualsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Payables and Accruals [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsForFees": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsForFees",
     "crdr": "credit",
     "presentation": [
      "http://neuraxis.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fees paid for services",
        "documentation": "Amount of cash outflow for fees classified as other."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_PaymentsOfFinancingCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsOfFinancingCosts",
     "crdr": "credit",
     "calculation": {
      "http://neuraxis.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://neuraxis.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Financing fees paid",
        "label": "Payments of Financing Costs",
        "documentation": "The cash outflow for loan and debt issuance costs."
       }
      }
     },
     "auth_ref": [
      "r18"
     ]
    },
    "us-gaap_PaymentsToAcquireEquitySecuritiesFvNi": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsToAcquireEquitySecuritiesFvNi",
     "crdr": "credit",
     "presentation": [
      "http://neuraxis.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "One time payment",
        "documentation": "Amount of cash outflow to acquire investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as investing activity."
       }
      }
     },
     "auth_ref": [
      "r148",
      "r214"
     ]
    },
    "us-gaap_PaymentsToAcquireIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsToAcquireIntangibleAssets",
     "crdr": "credit",
     "calculation": {
      "http://neuraxis.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://neuraxis.com/role/StatementsOfCashFlows",
      "http://neuraxis.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Additions to intangible assets",
        "label": "Payment upon execution",
        "documentation": "The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill."
       }
      }
     },
     "auth_ref": [
      "r94"
     ]
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://neuraxis.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://neuraxis.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Additions to property and equipment",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets."
       }
      }
     },
     "auth_ref": [
      "r94"
     ]
    },
    "ecd_PeerGroupIssuersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeerGroupIssuersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Issuers, Footnote"
       }
      }
     },
     "auth_ref": [
      "r988"
     ]
    },
    "ecd_PeerGroupTotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeerGroupTotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r988"
     ]
    },
    "us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
     "presentation": [
      "http://neuraxis.com/role/RetirementPlan"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retirement Plan",
        "documentation": "The entire disclosure for retirement benefits."
       }
      }
     },
     "auth_ref": [
      "r436",
      "r437",
      "r438",
      "r444",
      "r445",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r880"
     ]
    },
    "ecd_PeoActuallyPaidCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoActuallyPaidCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Actually Paid Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r987"
     ]
    },
    "ecd_PeoName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Name"
       }
      }
     },
     "auth_ref": [
      "r990"
     ]
    },
    "ecd_PeoTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r986"
     ]
    },
    "us-gaap_PlanNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PlanNameAxis",
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfOption-pricingModelWithFollowingWeighted-averageAssumptionsDetails",
      "http://neuraxis.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Name [Axis]",
        "documentation": "Information by plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1123",
      "r1124",
      "r1125",
      "r1126",
      "r1127",
      "r1128",
      "r1129",
      "r1130",
      "r1131",
      "r1132",
      "r1133",
      "r1134",
      "r1135",
      "r1136",
      "r1137",
      "r1138",
      "r1139",
      "r1140",
      "r1141",
      "r1142",
      "r1143",
      "r1144",
      "r1145",
      "r1146",
      "r1147",
      "r1148"
     ]
    },
    "us-gaap_PlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PlanNameDomain",
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfOption-pricingModelWithFollowingWeighted-averageAssumptionsDetails",
      "http://neuraxis.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1123",
      "r1124",
      "r1125",
      "r1126",
      "r1127",
      "r1128",
      "r1129",
      "r1130",
      "r1131",
      "r1132",
      "r1133",
      "r1134",
      "r1135",
      "r1136",
      "r1137",
      "r1138",
      "r1139",
      "r1140",
      "r1141",
      "r1142",
      "r1143",
      "r1144",
      "r1145",
      "r1146",
      "r1147",
      "r1148"
     ]
    },
    "srt_PlatformOperatorCryptoAssetLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "PlatformOperatorCryptoAssetLineItems",
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfChangesInDerivativeLiabilitiesDetails",
      "http://neuraxis.com/role/ScheduleOfChangesInWarrantLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Platform Operator, Crypto Asset [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r358"
     ]
    },
    "srt_PlatformOperatorCryptoAssetTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "PlatformOperatorCryptoAssetTable",
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfChangesInDerivativeLiabilitiesDetails",
      "http://neuraxis.com/role/ScheduleOfChangesInWarrantLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Platform Operator, Crypto Asset [Table]"
       }
      }
     },
     "auth_ref": [
      "r358"
     ]
    },
    "ecd_PnsnBnftsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PnsnBnftsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension Benefits Adjustments, Footnote"
       }
      }
     },
     "auth_ref": [
      "r987"
     ]
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://neuraxis.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r931"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://neuraxis.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r933"
     ]
    },
    "us-gaap_PreferredStockDividendPaymentTerms": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockDividendPaymentTerms",
     "presentation": [
      "http://neuraxis.com/role/BasisOfPresentationOrganizationAndOtherMattersDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cumulative dividend description",
        "documentation": "Specific information regarding dividend payment dates or timing and whether or not dividends are paid on a cumulative basis."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r47",
      "r78"
     ]
    },
    "us-gaap_PreferredStockDividendRatePerDollarAmount": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockDividendRatePerDollarAmount",
     "presentation": [
      "http://neuraxis.com/role/PreferredStockDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dividends, preferred stock per share",
        "documentation": "The amount per share used to calculated dividend payments on preferred stock."
       }
      }
     },
     "auth_ref": [
      "r416"
     ]
    },
    "us-gaap_PreferredStockDividendRatePercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockDividendRatePercentage",
     "presentation": [
      "http://neuraxis.com/role/PreferredStockDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock dividend rate percentage",
        "documentation": "The percentage rate used to calculate dividend payments on preferred stock."
       }
      }
     },
     "auth_ref": [
      "r416",
      "r804",
      "r807",
      "r809",
      "r817"
     ]
    },
    "us-gaap_PreferredStockDividendsAndOtherAdjustments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockDividendsAndOtherAdjustments",
     "crdr": "debit",
     "calculation": {
      "http://neuraxis.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://neuraxis.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Preferred stock dividends",
        "label": "Preferred Stock Dividends and Other Adjustments",
        "documentation": "The aggregate value of preferred stock dividends and other adjustments necessary to derive net income apportioned to common stockholders."
       }
      }
     },
     "auth_ref": [
      "r25",
      "r1036",
      "r1075"
     ]
    },
    "us-gaap_PreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockMember",
     "presentation": [
      "http://neuraxis.com/role/CommonStockAndWarrantsTables",
      "http://neuraxis.com/role/PreferredStockDetailsNarrative",
      "http://neuraxis.com/role/ScheduleOfWarrantActivityForPreferredStockDetails",
      "http://neuraxis.com/role/StatementsOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock [Member]",
        "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company."
       }
      }
     },
     "auth_ref": [
      "r912",
      "r913",
      "r916",
      "r917",
      "r918",
      "r919",
      "r1223",
      "r1226"
     ]
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockParOrStatedValuePerShare",
     "presentation": [
      "http://neuraxis.com/role/BalanceSheetsParenthetical",
      "http://neuraxis.com/role/BasisOfPresentationOrganizationAndOtherMattersDetailsNarrative",
      "http://neuraxis.com/role/NotesPayableDetailsNarrative",
      "http://neuraxis.com/role/PreferredStockDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock, par value",
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer."
       }
      }
     },
     "auth_ref": [
      "r78",
      "r415"
     ]
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockSharesAuthorized",
     "presentation": [
      "http://neuraxis.com/role/BalanceSheetsParenthetical",
      "http://neuraxis.com/role/BasisOfPresentationOrganizationAndOtherMattersDetailsNarrative",
      "http://neuraxis.com/role/NotesPayableDetailsNarrative",
      "http://neuraxis.com/role/PreferredStockDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock, shares authorized",
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r78",
      "r749"
     ]
    },
    "us-gaap_PreferredStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockSharesIssued",
     "presentation": [
      "http://neuraxis.com/role/BalanceSheetsParenthetical",
      "http://neuraxis.com/role/PreferredStockDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock, shares issued",
        "documentation": "Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt."
       }
      }
     },
     "auth_ref": [
      "r78",
      "r415"
     ]
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockSharesOutstanding",
     "presentation": [
      "http://neuraxis.com/role/BalanceSheetsParenthetical",
      "http://neuraxis.com/role/PreferredStockDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock, shares outstanding",
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased."
       }
      }
     },
     "auth_ref": [
      "r78",
      "r749",
      "r769",
      "r1226",
      "r1227"
     ]
    },
    "NRXS_PreferredStockSharesRetiredDescription": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://neuraxis.com/20241231",
     "localname": "PreferredStockSharesRetiredDescription",
     "presentation": [
      "http://neuraxis.com/role/PreferredStockDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock, retired description",
        "documentation": "Preferred stock shares retired description."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PreferredStockTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockTextBlock",
     "presentation": [
      "http://neuraxis.com/role/PreferredStock"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock",
        "documentation": "The entire disclosure for terms, amounts, nature of changes, rights and privileges, dividends, and other matters related to preferred stock."
       }
      }
     },
     "auth_ref": [
      "r112"
     ]
    },
    "us-gaap_PreferredStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockValue",
     "crdr": "credit",
     "calculation": {
      "http://neuraxis.com/role/BalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://neuraxis.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Series B Preferred stock, $0.01 par value; 5,000,000 and 0 shares authorized, 4,280,939 and 0 shares issued and outstanding as of December 31, 2024 and 2023, respectively",
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r78",
      "r687",
      "r898"
     ]
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://neuraxis.com/role/BalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://neuraxis.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaids and other current assets",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r1056"
     ]
    },
    "us-gaap_PrivatePlacementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PrivatePlacementMember",
     "presentation": [
      "http://neuraxis.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Private Placement [Member]",
        "documentation": "A private placement is a direct offering of securities to a limited number of sophisticated investors such as insurance companies, pension funds, mezzanine funds, stock funds and trusts."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromContributedCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromContributedCapital",
     "crdr": "debit",
     "presentation": [
      "http://neuraxis.com/role/NotesPayableDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shareholder funded",
        "documentation": "The cash inflow associated with the amount received by a corporation from a shareholder during the period."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_ProceedsFromConvertibleDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromConvertibleDebt",
     "crdr": "debit",
     "calculation": {
      "http://neuraxis.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://neuraxis.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from convertible notes",
        "documentation": "The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder."
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "us-gaap_ProceedsFromFeesReceived": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromFeesReceived",
     "crdr": "debit",
     "presentation": [
      "http://neuraxis.com/role/NotesPayableDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred financing fees",
        "documentation": "Cash received for fees during the current period. This element excludes cash proceeds from license fees."
       }
      }
     },
     "auth_ref": [
      "r98"
     ]
    },
    "us-gaap_ProceedsFromIssuanceInitialPublicOffering": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromIssuanceInitialPublicOffering",
     "crdr": "debit",
     "presentation": [
      "http://neuraxis.com/role/BasisOfPresentationOrganizationAndOtherMattersDetailsNarrative",
      "http://neuraxis.com/role/CommonStockAndWarrantsDetailsNarrative",
      "http://neuraxis.com/role/NotesPayableDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from issuance initial public offering",
        "verboseLabel": "Proceeds from issuance of ipo",
        "terseLabel": "Net proceeds",
        "documentation": "The cash inflow associated with the amount received from entity's first offering of stock to the public."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "crdr": "debit",
     "calculation": {
      "http://neuraxis.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://neuraxis.com/role/BasisOfPresentationOrganizationAndOtherMattersDetailsNarrative",
      "http://neuraxis.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from issuance of common stock, net of issuance costs",
        "verboseLabel": "Proceeds from issuance of common stock",
        "documentation": "The cash inflow from the additional capital contribution to the entity."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromIssuanceOfDebt",
     "crdr": "debit",
     "presentation": [
      "http://neuraxis.com/role/NotesPayableDetailsNarrative",
      "http://neuraxis.com/role/PreferredStockDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net proceeds of debt",
        "verboseLabel": "Issuance of debt",
        "documentation": "The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt."
       }
      }
     },
     "auth_ref": [
      "r1058"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromIssuanceOfPreferredStockAndPreferenceStock",
     "crdr": "debit",
     "calculation": {
      "http://neuraxis.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://neuraxis.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from issuance of Series B preferred stock",
        "documentation": "Proceeds from issuance of capital stock which provides for a specific dividend that is paid to the shareholders before any dividends to common stockholders and which takes precedence over common stockholders in the event of liquidation."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "NRXS_ProceedsFromIssuanceOfStock": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://neuraxis.com/20241231",
     "localname": "ProceedsFromIssuanceOfStock",
     "presentation": [
      "http://neuraxis.com/role/PreferredStockDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of debt, shares",
        "documentation": "Proceeds from issuance of stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromIssuanceOfWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromIssuanceOfWarrants",
     "crdr": "debit",
     "calculation": {
      "http://neuraxis.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://neuraxis.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from exercised warrants",
        "documentation": "The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt)."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_ProceedsFromNotesPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromNotesPayable",
     "crdr": "debit",
     "calculation": {
      "http://neuraxis.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://neuraxis.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from notes payable",
        "documentation": "The cash inflow from a borrowing supported by a written promise to pay an obligation."
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "us-gaap_ProductInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProductInformationLineItems",
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfCustomerAccountsReceivableDetails",
      "http://neuraxis.com/role/ScheduleOfCustomersAccountedRevenuesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product Information [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProfessionalAndContractServicesExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProfessionalAndContractServicesExpense",
     "crdr": "debit",
     "calculation": {
      "http://neuraxis.com/role/ScheduleOfReconcilesCompanysNetSalesAndOperatingLossDetails": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfReconcilesCompanysNetSalesAndOperatingLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Professional Services",
        "documentation": "Professional and contract service expense includes cost reimbursements for support services related to contracted projects, outsourced management, technical and staff support."
       }
      }
     },
     "auth_ref": []
    },
    "NRXS_PromissoryNoteMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://neuraxis.com/20241231",
     "localname": "PromissoryNoteMember",
     "presentation": [
      "http://neuraxis.com/role/NotesPayableDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Promissory Note [Member]",
        "documentation": "Promissory Note [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfEstimatedUsefulLivesDetails",
      "http://neuraxis.com/role/ScheduleOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Lived Tangible Asset [Axis]",
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r595"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "presentation": [
      "http://neuraxis.com/role/PropertyAndEquipment"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property and Equipment",
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r105",
      "r156",
      "r159",
      "r160"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentGross",
     "crdr": "debit",
     "calculation": {
      "http://neuraxis.com/role/BalanceSheets": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0,
       "order": 1.0
      },
      "http://neuraxis.com/role/ScheduleOfPropertyAndEquipmentDetails": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://neuraxis.com/role/BalanceSheets",
      "http://neuraxis.com/role/ScheduleOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property and Equipment, at cost:",
        "verboseLabel": "Total property and equipment",
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r106",
      "r189",
      "r694"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentLineItems",
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfEstimatedUsefulLivesDetails",
      "http://neuraxis.com/role/ScheduleOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r595"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentNet",
     "crdr": "debit",
     "calculation": {
      "http://neuraxis.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 2.0
      },
      "http://neuraxis.com/role/ScheduleOfPropertyAndEquipmentDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://neuraxis.com/role/BalanceSheets",
      "http://neuraxis.com/role/ScheduleOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Property and equipment, net",
        "label": "Property, Plant and Equipment, Net",
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r595",
      "r682",
      "r694",
      "r898"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "presentation": [
      "http://neuraxis.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Property and Equipment",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r156",
      "r159",
      "r692"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "presentation": [
      "http://neuraxis.com/role/PropertyAndEquipmentTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Property And Equipment",
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfEstimatedUsefulLivesDetails",
      "http://neuraxis.com/role/ScheduleOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software."
       }
      }
     },
     "auth_ref": [
      "r106",
      "r595"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfEstimatedUsefulLivesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property and equipment, estimated useful lives",
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProvisionForDoubtfulAccounts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProvisionForDoubtfulAccounts",
     "crdr": "debit",
     "calculation": {
      "http://neuraxis.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://neuraxis.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Provisions for losses on accounts receivable",
        "documentation": "Amount of expense (reversal of expense) for expected credit loss on accounts receivable."
       }
      }
     },
     "auth_ref": [
      "r210",
      "r327"
     ]
    },
    "us-gaap_ProvisionForOtherCreditLosses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProvisionForOtherCreditLosses",
     "crdr": "debit",
     "presentation": [
      "http://neuraxis.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Credit losses",
        "documentation": "Amount of expense related to credit loss from transactions other than loan and lease transactions."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r139"
     ]
    },
    "NRXS_PurchaseOfAdditionalStockOnNumberOfOptionsNotExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://neuraxis.com/20241231",
     "localname": "PurchaseOfAdditionalStockOnNumberOfOptionsNotExercised",
     "presentation": [
      "http://neuraxis.com/role/BasisOfPresentationOrganizationAndOtherMattersDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Purchase of additional stockon number of options not exercised",
        "documentation": "Purchase of additional stock on number of options not exercised."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PvpTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PvpTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Table]"
       }
      }
     },
     "auth_ref": [
      "r985"
     ]
    },
    "ecd_PvpTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PvpTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure, Table"
       }
      }
     },
     "auth_ref": [
      "r985"
     ]
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RangeAxis",
     "presentation": [
      "http://neuraxis.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://neuraxis.com/role/DerivativeLiabilitiesDetailsNarrative",
      "http://neuraxis.com/role/NotesPayableDetailsNarrative",
      "http://neuraxis.com/role/ScheduleOfEstimatedUsefulLivesDetails",
      "http://neuraxis.com/role/WarrantLiabilitiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r368",
      "r369",
      "r370",
      "r371",
      "r437",
      "r455",
      "r486",
      "r487",
      "r488",
      "r497",
      "r564",
      "r615",
      "r624",
      "r640",
      "r701",
      "r703",
      "r710",
      "r739",
      "r740",
      "r803",
      "r806",
      "r810",
      "r811",
      "r816",
      "r841",
      "r842",
      "r866",
      "r875",
      "r881",
      "r888",
      "r889",
      "r893",
      "r894",
      "r909",
      "r914",
      "r1110",
      "r1120",
      "r1166",
      "r1182",
      "r1183",
      "r1184",
      "r1185",
      "r1186"
     ]
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RangeMember",
     "presentation": [
      "http://neuraxis.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://neuraxis.com/role/DerivativeLiabilitiesDetailsNarrative",
      "http://neuraxis.com/role/NotesPayableDetailsNarrative",
      "http://neuraxis.com/role/ScheduleOfEstimatedUsefulLivesDetails",
      "http://neuraxis.com/role/WarrantLiabilitiesDetailsNarrative"
     ],
     "auth_ref": [
      "r368",
      "r369",
      "r370",
      "r371",
      "r437",
      "r455",
      "r486",
      "r487",
      "r488",
      "r497",
      "r564",
      "r615",
      "r624",
      "r640",
      "r701",
      "r703",
      "r710",
      "r739",
      "r740",
      "r803",
      "r806",
      "r810",
      "r811",
      "r816",
      "r841",
      "r842",
      "r866",
      "r875",
      "r881",
      "r888",
      "r889",
      "r893",
      "r894",
      "r909",
      "r914",
      "r1110",
      "r1120",
      "r1166",
      "r1182",
      "r1183",
      "r1184",
      "r1185",
      "r1186"
     ]
    },
    "NRXS_RecentlyIssuedAccountingPronouncementsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://neuraxis.com/20241231",
     "localname": "RecentlyIssuedAccountingPronouncementsPolicyTextBlock",
     "presentation": [
      "http://neuraxis.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Recently Issued Accounting Pronouncements",
        "documentation": "Recently Issued Accounting Pronouncements [Policy Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "NRXS_ReclassificationOfWarrantLiabilityToEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://neuraxis.com/20241231",
     "localname": "ReclassificationOfWarrantLiabilityToEquity",
     "crdr": "credit",
     "presentation": [
      "http://neuraxis.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Reclassification of warrant liability to equity",
        "documentation": "Reclassification of warrant liability to equity."
       }
      }
     },
     "auth_ref": []
    },
    "NRXS_ReclassifiedToEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://neuraxis.com/20241231",
     "localname": "ReclassifiedToEquity",
     "crdr": "credit",
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfChangesInWarrantLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Reclassified to equity",
        "documentation": "Reclassified to equity."
       }
      }
     },
     "auth_ref": []
    },
    "NRXS_RecognitionOfRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://neuraxis.com/20241231",
     "localname": "RecognitionOfRightOfUseAsset",
     "crdr": "debit",
     "presentation": [
      "http://neuraxis.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Recognition of right of use asset",
        "documentation": "Recognition of right of use asset."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_RecoveryOfErrCompDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RecoveryOfErrCompDisclosureLineItems",
     "auth_ref": [
      "r948",
      "r959",
      "r973",
      "r999"
     ]
    },
    "NRXS_ReimbursementExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://neuraxis.com/20241231",
     "localname": "ReimbursementExpenses",
     "crdr": "credit",
     "presentation": [
      "http://neuraxis.com/role/BasisOfPresentationOrganizationAndOtherMattersDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Reimbursement expenses",
        "documentation": "Reimbursement expenses."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyDomain",
     "presentation": [
      "http://neuraxis.com/role/CommonStockAndWarrantsDetailsNarrative",
      "http://neuraxis.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://neuraxis.com/role/ScheduleOfRelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest."
       }
      }
     },
     "auth_ref": [
      "r288",
      "r446",
      "r600",
      "r601",
      "r684",
      "r691",
      "r742",
      "r743",
      "r744",
      "r745",
      "r746",
      "r768",
      "r770",
      "r802"
     ]
    },
    "us-gaap_RelatedPartyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyMember",
     "presentation": [
      "http://neuraxis.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://neuraxis.com/role/ScheduleOfRelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party [Member]",
        "documentation": "Party related to reporting entity. Includes, but is not limited to, affiliate, entity for which investment is accounted for by equity method, trust for benefit of employees, and principal owner, management, and members of immediate family."
       }
      }
     },
     "auth_ref": [
      "r225",
      "r226",
      "r600",
      "r601",
      "r602",
      "r603",
      "r684",
      "r691",
      "r742",
      "r743",
      "r744",
      "r745",
      "r746",
      "r768",
      "r770",
      "r802"
     ]
    },
    "us-gaap_RelatedPartyTransactionAmountsOfTransaction": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionAmountsOfTransaction",
     "crdr": "debit",
     "presentation": [
      "http://neuraxis.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related party transaction amounts",
        "documentation": "Amount of transactions with related party during the financial reporting period."
       }
      }
     },
     "auth_ref": [
      "r58",
      "r600"
     ]
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionLineItems",
     "presentation": [
      "http://neuraxis.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://neuraxis.com/role/ScheduleOfRelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transaction [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r288",
      "r775",
      "r776",
      "r779"
     ]
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "presentation": [
      "http://neuraxis.com/role/CommonStockAndWarrantsDetailsNarrative",
      "http://neuraxis.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://neuraxis.com/role/ScheduleOfRelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related and Nonrelated Parties [Axis]",
        "documentation": "Information by related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest."
       }
      }
     },
     "auth_ref": [
      "r288",
      "r446",
      "r600",
      "r601",
      "r684",
      "r691",
      "r742",
      "r743",
      "r744",
      "r745",
      "r746",
      "r768",
      "r770",
      "r802",
      "r1178"
     ]
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "presentation": [
      "http://neuraxis.com/role/RelatedPartyTransactions"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions",
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates."
       }
      }
     },
     "auth_ref": [
      "r597",
      "r598",
      "r599",
      "r601",
      "r604",
      "r720",
      "r721",
      "r722",
      "r777",
      "r778",
      "r779",
      "r799",
      "r801"
     ]
    },
    "us-gaap_RepaymentsOfNotesPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RepaymentsOfNotesPayable",
     "crdr": "credit",
     "calculation": {
      "http://neuraxis.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://neuraxis.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Principal payments on notes payable",
        "label": "Repayments of Notes Payable",
        "documentation": "The cash outflow for a borrowing supported by a written promise to pay an obligation."
       }
      }
     },
     "auth_ref": [
      "r95"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://neuraxis.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 3.0
      },
      "http://neuraxis.com/role/ScheduleOfReconcilesCompanysNetSalesAndOperatingLossDetails": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfReconcilesCompanysNetSalesAndOperatingLossDetails",
      "http://neuraxis.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and development",
        "verboseLabel": "Research and Development",
        "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity."
       }
      }
     },
     "auth_ref": [
      "r501",
      "r844",
      "r861",
      "r1187"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "presentation": [
      "http://neuraxis.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development",
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process."
       }
      }
     },
     "auth_ref": [
      "r500"
     ]
    },
    "ecd_RestatementDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDateAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date [Axis]"
       }
      }
     },
     "auth_ref": [
      "r949",
      "r960",
      "r974",
      "r1000"
     ]
    },
    "ecd_RestatementDeterminationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDeterminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date"
       }
      }
     },
     "auth_ref": [
      "r950",
      "r961",
      "r975",
      "r1001"
     ]
    },
    "ecd_RestatementDoesNotRequireRecoveryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDoesNotRequireRecoveryTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement does not require Recovery"
       }
      }
     },
     "auth_ref": [
      "r957",
      "r968",
      "r982",
      "r1008"
     ]
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://neuraxis.com/role/BalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://neuraxis.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated deficit",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r81",
      "r116",
      "r689",
      "r708",
      "r709",
      "r718",
      "r750",
      "r898"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://neuraxis.com/role/StatementsOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retained Earnings [Member]",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r183",
      "r228",
      "r229",
      "r230",
      "r232",
      "r237",
      "r239",
      "r241",
      "r321",
      "r322",
      "r356",
      "r528",
      "r529",
      "r536",
      "r537",
      "r538",
      "r540",
      "r541",
      "r542",
      "r548",
      "r550",
      "r551",
      "r553",
      "r556",
      "r583",
      "r585",
      "r705",
      "r707",
      "r723",
      "r1226"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "crdr": "credit",
     "calculation": {
      "http://neuraxis.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_GrossProfit",
       "weight": 1.0,
       "order": 1.0
      },
      "http://neuraxis.com/role/ScheduleOfReconcilesCompanysNetSalesAndOperatingLossDetails": {
       "parentTag": "us-gaap_GrossProfit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfCustomersAccountedRevenuesDetails",
      "http://neuraxis.com/role/ScheduleOfReconcilesCompanysNetSalesAndOperatingLossDetails",
      "http://neuraxis.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net sales",
        "verboseLabel": "Revenue",
        "terseLabel": "Net Sales",
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise."
       }
      }
     },
     "auth_ref": [
      "r141",
      "r142",
      "r256",
      "r265",
      "r266",
      "r274",
      "r280",
      "r283",
      "r285",
      "r287",
      "r433",
      "r434",
      "r645"
     ]
    },
    "us-gaap_RevenueRecognitionPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenueRecognitionPolicyTextBlock",
     "presentation": [
      "http://neuraxis.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue Recognition",
        "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources."
       }
      }
     },
     "auth_ref": [
      "r773",
      "r845",
      "r854"
     ]
    },
    "us-gaap_Revenues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Revenues",
     "crdr": "credit",
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfDisaggregationOfRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenues",
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss)."
       }
      }
     },
     "auth_ref": [
      "r141",
      "r142",
      "r208",
      "r223",
      "r256",
      "r265",
      "r266",
      "r274",
      "r280",
      "r283",
      "r285",
      "r287",
      "r320",
      "r374",
      "r375",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r383",
      "r384",
      "r572",
      "r681",
      "r861",
      "r1116"
     ]
    },
    "ecd_Rule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Rule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r1017"
     ]
    },
    "ecd_Rule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Rule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r1017"
     ]
    },
    "us-gaap_SalariesAndWages": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SalariesAndWages",
     "crdr": "debit",
     "presentation": [
      "http://neuraxis.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Base salaries for nine key employees",
        "documentation": "Amount of expense for salary and wage arising from service rendered by nonofficer employee. Excludes allocated cost, labor-related nonsalary expense, and direct and overhead labor cost included in cost of good and service sold."
       }
      }
     },
     "auth_ref": [
      "r1057"
     ]
    },
    "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleOfStockConsiderationReceivedOnTransaction",
     "crdr": "debit",
     "presentation": [
      "http://neuraxis.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Monthly advisory fee",
        "documentation": "Cash received on stock transaction after deduction of issuance costs."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleOfStockNameOfTransactionDomain",
     "presentation": [
      "http://neuraxis.com/role/BasisOfPresentationOrganizationAndOtherMattersDetailsNarrative",
      "http://neuraxis.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "presentation": [
      "http://neuraxis.com/role/BasisOfPresentationOrganizationAndOtherMattersDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of stock, number of shares issued in transaction",
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleOfStockPercentageOfOwnershipAfterTransaction",
     "presentation": [
      "http://neuraxis.com/role/BasisOfPresentationOrganizationAndOtherMattersDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of stock, percentage of ownership after transaction",
        "documentation": "Percentage of subsidiary's or equity investee's stock owned by parent company after stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleOfStockPricePerShare",
     "presentation": [
      "http://neuraxis.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Monthly exercise price",
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SalesRevenueNetMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SalesRevenueNetMember",
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfCustomersAccountedRevenuesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue Benchmark [Member]",
        "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation."
       }
      }
     },
     "auth_ref": [
      "r287",
      "r1040"
     ]
    },
    "srt_ScenarioForecastMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ScenarioForecastMember",
     "presentation": [
      "http://neuraxis.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forecast [Member]"
       }
      }
     },
     "auth_ref": [
      "r456",
      "r1070"
     ]
    },
    "srt_ScenarioUnspecifiedDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ScenarioUnspecifiedDomain",
     "presentation": [
      "http://neuraxis.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "auth_ref": [
      "r242",
      "r456",
      "r1038",
      "r1070"
     ]
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "presentation": [
      "http://neuraxis.com/role/AccruedExpensesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Accrued Expenses",
        "documentation": "Tabular disclosure of the components of accrued liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfDilutiveCommonStockEquivalentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Security, Excluded EPS Calculation [Table]",
        "documentation": "Disclosure of information about security that could potentially dilute basic earnings per share (EPS) in future that was not included in calculation of diluted EPS."
       }
      }
     },
     "auth_ref": [
      "r27"
     ]
    },
    "NRXS_ScheduleOfChangesInWarrantLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://neuraxis.com/20241231",
     "localname": "ScheduleOfChangesInWarrantLiabilitiesTableTextBlock",
     "presentation": [
      "http://neuraxis.com/role/WarrantLiabilitiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Changes in Warrant Liabilities",
        "documentation": "Schedule of Changes in Warrant Liabilities [Table Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
     "presentation": [
      "http://neuraxis.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Income Tax Provision",
        "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years."
       }
      }
     },
     "auth_ref": [
      "r1157"
     ]
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "presentation": [
      "http://neuraxis.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Net Deferred Tax Assets and Liabilities",
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r1154"
     ]
    },
    "us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock",
     "presentation": [
      "http://neuraxis.com/role/DerivativeLiabilitiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Changes in Derivative Liabilities",
        "documentation": "Tabular disclosure of derivative liabilities at fair value."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "presentation": [
      "http://neuraxis.com/role/SummaryOfSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Basic and Diluted Net Loss Per Share",
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r1074"
     ]
    },
    "us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEarningsPerShareDilutedByCommonClassTextBlock",
     "presentation": [
      "http://neuraxis.com/role/SummaryOfSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Dilutive Common Stock Equivalents",
        "documentation": "Tabular disclosure of the effect of income (loss) on an entity's diluted earnings per share."
       }
      }
     },
     "auth_ref": [
      "r26",
      "r29",
      "r1072"
     ]
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "presentation": [
      "http://neuraxis.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Federal Statutory Income Tax Rate and Effective Income Tax Rate",
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r508",
      "r884",
      "r1150"
     ]
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "presentation": [
      "http://neuraxis.com/role/SummaryOfSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Fair Value of Assets and Liabilities measured on Recurring Basis",
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)."
       }
      }
     },
     "auth_ref": [
      "r1163",
      "r1164"
     ]
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable",
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Intangible Asset, Finite-Lived [Table]",
        "documentation": "Disclosure of information about finite-lived intangible asset. Excludes indefinite-lived intangible asset."
       }
      }
     },
     "auth_ref": [
      "r341",
      "r348",
      "r351",
      "r352",
      "r354",
      "r646",
      "r844",
      "r869"
     ]
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
     "presentation": [
      "http://neuraxis.com/role/IntangibleAssetsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Intangible Assets",
        "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment."
       }
      }
     },
     "auth_ref": [
      "r869",
      "r1101"
     ]
    },
    "us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfIndefiniteLivedIntangibleAssetsTable",
     "presentation": [
      "http://neuraxis.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Intangible Asset, Indefinite-Lived [Table]",
        "documentation": "Disclosure of information about indefinite-lived intangible asset. Excludes finite-lived intangible asset."
       }
      }
     },
     "auth_ref": [
      "r341",
      "r350",
      "r354",
      "r869"
     ]
    },
    "us-gaap_ScheduleOfProductInformationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfProductInformationTable",
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfCustomerAccountsReceivableDetails",
      "http://neuraxis.com/role/ScheduleOfCustomersAccountedRevenuesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nature of Operation, Product Information, Concentration of Risk [Table]",
        "documentation": "Disclosure of information about concentration risk of product within nature of operation."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfEstimatedUsefulLivesDetails",
      "http://neuraxis.com/role/ScheduleOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Table]",
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r595"
     ]
    },
    "NRXS_ScheduleOfPropertyPlantAndEquipmentUsefulLivesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://neuraxis.com/20241231",
     "localname": "ScheduleOfPropertyPlantAndEquipmentUsefulLivesTableTextBlock",
     "presentation": [
      "http://neuraxis.com/role/SummaryOfSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Estimated Useful Lives",
        "documentation": "Schedule of Property Plant And Equipment Useful Lives [Table Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "NRXS_ScheduleOfRelatedPartyLoansTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://neuraxis.com/20241231",
     "localname": "ScheduleOfRelatedPartyLoansTableTextBlock",
     "presentation": [
      "http://neuraxis.com/role/RelatedPartyTransactionsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Related Party Loans payable to shareholder",
        "documentation": "Schedule Of Related Party Loans [Table Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
     "presentation": [
      "http://neuraxis.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://neuraxis.com/role/ScheduleOfRelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transaction [Table]",
        "documentation": "Disclosure of information about related party transaction."
       }
      }
     },
     "auth_ref": [
      "r57",
      "r58",
      "r775",
      "r776",
      "r779"
     ]
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfRelatedPartyTransactionsTableTextBlock",
     "presentation": [
      "http://neuraxis.com/role/RelatedPartyTransactionsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Related Party Transactions",
        "documentation": "Tabular disclosure of related party transactions. Examples of related party transactions include, but are not limited to, transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners and (d) affiliates."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTable",
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfReconcilesCompanysNetSalesAndOperatingLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Segment Reporting Information, by Segment [Table]",
        "documentation": "Disclosure of information about profit (loss) and total assets by reportable segment."
       }
      }
     },
     "auth_ref": [
      "r37",
      "r38",
      "r39"
     ]
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock",
     "presentation": [
      "http://neuraxis.com/role/SegmentInformationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Reconciles the Company\u2019s Net Sales and Operating Loss",
        "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss."
       }
      }
     },
     "auth_ref": [
      "r37",
      "r38",
      "r39"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "presentation": [
      "http://neuraxis.com/role/IntangibleAssetsDetailsNarrative",
      "http://neuraxis.com/role/PropertyAndEquipmentDetailsNarrative",
      "http://neuraxis.com/role/ScheduleOfOption-pricingModelWithFollowingWeighted-averageAssumptionsDetails",
      "http://neuraxis.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "documentation": "Disclosure of information about share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r458",
      "r459",
      "r461",
      "r462",
      "r463",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "presentation": [
      "http://neuraxis.com/role/Stock-basedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Stock Option Activity",
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r14",
      "r118"
     ]
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "presentation": [
      "http://neuraxis.com/role/Stock-basedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Option-pricing Model with Following Weighted-average Assumptions",
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions."
       }
      }
     },
     "auth_ref": [
      "r124"
     ]
    },
    "us-gaap_ScheduleOfShortTermDebtTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShortTermDebtTable",
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfRelatedPartyLoansPayableToShareholderDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Short-Term Debt [Table]",
        "documentation": "Disclosure of information about short-term debt arrangement. Includes, but is not limited to, description of arrangement, lender, repayment term, weighted-average interest rate, borrowed amount, and description and amount of refinancing of short-term obligation when obligation is excluded from current liability."
       }
      }
     },
     "auth_ref": [
      "r65"
     ]
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfStockByClassTable",
     "presentation": [
      "http://neuraxis.com/role/CommonStockAndWarrantsDetailsNarrative",
      "http://neuraxis.com/role/PreferredStockDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock, Class of Stock [Table]",
        "documentation": "Disclosure of information about stock by class. Includes, but is not limited to, common, convertible, and preferred stocks."
       }
      }
     },
     "auth_ref": [
      "r45",
      "r46",
      "r47",
      "r48",
      "r49",
      "r50",
      "r111",
      "r113",
      "r115",
      "r116",
      "r194",
      "r195",
      "r196",
      "r258",
      "r415",
      "r416",
      "r417",
      "r419",
      "r422",
      "r428",
      "r430",
      "r714",
      "r715",
      "r716",
      "r717",
      "r875",
      "r1037",
      "r1062"
     ]
    },
    "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
     "presentation": [
      "http://neuraxis.com/role/CommonStockAndWarrantsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Warrants outstanding and Exercisable",
        "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable."
       }
      }
     },
     "auth_ref": [
      "r51"
     ]
    },
    "NRXS_ScheduleOfWarrantActivityForCommonStockTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://neuraxis.com/20241231",
     "localname": "ScheduleOfWarrantActivityForCommonStockTableTextBlock",
     "presentation": [
      "http://neuraxis.com/role/CommonStockAndWarrantsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Warrant Activity for Common Stock",
        "documentation": "Schedule of Warrant Activity for Common Stock [Table Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "NRXS_ScheduleOfWarrantActivityForPreferredStockTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://neuraxis.com/20241231",
     "localname": "ScheduleOfWarrantActivityForPreferredStockTableTextBlock",
     "presentation": [
      "http://neuraxis.com/role/CommonStockAndWarrantsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Warrant Activity for Preferred Stock",
        "documentation": "Schedule of warrant activity for preferred stock [Table Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
     "presentation": [
      "http://neuraxis.com/role/SummaryOfSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Customer Accounts Receivable",
        "documentation": "Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark."
       }
      }
     },
     "auth_ref": [
      "r30",
      "r31",
      "r32",
      "r33",
      "r55",
      "r129"
     ]
    },
    "NRXS_SecondPromissoryNoteMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://neuraxis.com/20241231",
     "localname": "SecondPromissoryNoteMember",
     "presentation": [
      "http://neuraxis.com/role/NotesPayableDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Second Promissory Note [Member]",
        "documentation": "Second Promissory Note [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12bTitle",
     "presentation": [
      "http://neuraxis.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r925"
     ]
    },
    "dei_Security12gTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12gTitle",
     "presentation": [
      "http://neuraxis.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(g) Security",
        "documentation": "Title of a 12(g) registered security."
       }
      }
     },
     "auth_ref": [
      "r929"
     ]
    },
    "us-gaap_SecurityDeposit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SecurityDeposit",
     "crdr": "debit",
     "calculation": {
      "http://neuraxis.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://neuraxis.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security deposit",
        "documentation": "The amount of an asset, typically cash, provided to a counterparty to provide certain assurance of performance by the entity pursuant to the terms of a written or oral agreement, such as a lease."
       }
      }
     },
     "auth_ref": [
      "r1052"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://neuraxis.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r928"
     ]
    },
    "dei_SecurityReportingObligation": {
     "xbrltype": "securityReportingObligationItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityReportingObligation",
     "presentation": [
      "http://neuraxis.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Reporting Obligation",
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r934"
     ]
    },
    "srt_SegmentGeographicalDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "SegmentGeographicalDomain",
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfDisaggregationOfRevenueDetails"
     ],
     "auth_ref": [
      "r285",
      "r286",
      "r648",
      "r649",
      "r650",
      "r651",
      "r652",
      "r653",
      "r654",
      "r655",
      "r656",
      "r657",
      "r658",
      "r659",
      "r660",
      "r661",
      "r662",
      "r663",
      "r664",
      "r665",
      "r666",
      "r667",
      "r668",
      "r669",
      "r670",
      "r671",
      "r672",
      "r673",
      "r674",
      "r675",
      "r676",
      "r677",
      "r736",
      "r737",
      "r738",
      "r805",
      "r808",
      "r812",
      "r818",
      "r825",
      "r831",
      "r832",
      "r833",
      "r834",
      "r836",
      "r837",
      "r838",
      "r839",
      "r840",
      "r846",
      "r876",
      "r900",
      "r901",
      "r902",
      "r903",
      "r904",
      "r905",
      "r906",
      "r907",
      "r910",
      "r914",
      "r1122",
      "r1194",
      "r1196",
      "r1197",
      "r1198",
      "r1199",
      "r1200",
      "r1201",
      "r1202",
      "r1203",
      "r1204",
      "r1205",
      "r1206",
      "r1207",
      "r1208",
      "r1209",
      "r1210",
      "r1211",
      "r1212",
      "r1213",
      "r1214",
      "r1215",
      "r1216",
      "r1217",
      "r1218",
      "r1219",
      "r1220",
      "r1221",
      "r1222"
     ]
    },
    "us-gaap_SegmentReportingAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SegmentReportingDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingDisclosureTextBlock",
     "presentation": [
      "http://neuraxis.com/role/SegmentInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Information",
        "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments."
       }
      }
     },
     "auth_ref": [
      "r144",
      "r256",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r271",
      "r272",
      "r273",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r287",
      "r858",
      "r859",
      "r860",
      "r861",
      "r863",
      "r864",
      "r865"
     ]
    },
    "us-gaap_SegmentReportingInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingInformationLineItems",
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfReconcilesCompanysNetSalesAndOperatingLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting Information [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SellingExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SellingExpense",
     "crdr": "debit",
     "calculation": {
      "http://neuraxis.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 2.0
      },
      "http://neuraxis.com/role/ScheduleOfReconcilesCompanysNetSalesAndOperatingLossDetails": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfReconcilesCompanysNetSalesAndOperatingLossDetails",
      "http://neuraxis.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Selling expenses",
        "verboseLabel": "Selling Expenses",
        "documentation": "Expenses recognized in the period that are directly related to the selling and distribution of products or services."
       }
      }
     },
     "auth_ref": [
      "r91"
     ]
    },
    "us-gaap_SeriesAPreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SeriesAPreferredStockMember",
     "presentation": [
      "http://neuraxis.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://neuraxis.com/role/PreferredStockDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series A Preferred Stock [Member]",
        "documentation": "Series A preferred stock."
       }
      }
     },
     "auth_ref": [
      "r1053",
      "r1054",
      "r1121"
     ]
    },
    "us-gaap_SeriesBPreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SeriesBPreferredStockMember",
     "presentation": [
      "http://neuraxis.com/role/BasisOfPresentationOrganizationAndOtherMattersDetailsNarrative",
      "http://neuraxis.com/role/NotesPayableDetailsNarrative",
      "http://neuraxis.com/role/PreferredStockDetailsNarrative",
      "http://neuraxis.com/role/ScheduleOfDilutiveCommonStockEquivalentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series B Preferred Stock [Member]",
        "documentation": "Series B preferred stock."
       }
      }
     },
     "auth_ref": [
      "r1053",
      "r1054",
      "r1121"
     ]
    },
    "NRXS_SeriesSeedPreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://neuraxis.com/20241231",
     "localname": "SeriesSeedPreferredStockMember",
     "presentation": [
      "http://neuraxis.com/role/PreferredStockDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series Seed Preferred Stock [Member]",
        "documentation": "Series Seed Preferred Stock [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "NRXS_SettlementAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://neuraxis.com/20241231",
     "localname": "SettlementAgreementMember",
     "presentation": [
      "http://neuraxis.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Settlement Agreement [Member]",
        "documentation": "Settlement Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "calculation": {
      "http://neuraxis.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://neuraxis.com/role/SegmentInformationDetailsNarrative",
      "http://neuraxis.com/role/StatementsOfCashFlows",
      "http://neuraxis.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock based compensation",
        "verboseLabel": "Share based compensation",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice",
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfOption-pricingModelWithFollowingWeighted-averageAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise price",
        "documentation": "Agreed-upon price for the exchange of the underlying asset relating to the share-based payment award."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfOption-pricingModelWithFollowingWeighted-averageAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dividend rate",
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term."
       }
      }
     },
     "auth_ref": [
      "r487"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfOption-pricingModelWithFollowingWeighted-averageAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expected volatility",
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": [
      "r486"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfOption-pricingModelWithFollowingWeighted-averageAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Risk-free interest rate",
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": [
      "r488"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "presentation": [
      "http://neuraxis.com/role/IntangibleAssetsDetailsNarrative",
      "http://neuraxis.com/role/PropertyAndEquipmentDetailsNarrative",
      "http://neuraxis.com/role/ScheduleOfOption-pricingModelWithFollowingWeighted-averageAssumptionsDetails",
      "http://neuraxis.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r458",
      "r459",
      "r461",
      "r462",
      "r463",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489"
     ]
    },
    "NRXS_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsCommonStockWarrant": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://neuraxis.com/20241231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsCommonStockWarrant",
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfWarrantActivityForPreferredStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Converted to Common Stock Warrant",
        "documentation": "Share based compensation arrangement by share based payment award non option equity instruments common stock warrant.",
        "label": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsCommonStockWarrant"
       }
      }
     },
     "auth_ref": []
    },
    "NRXS_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsConvertedPrefundedWarrants": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://neuraxis.com/20241231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsConvertedPrefundedWarrants",
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfWarrantActivityForCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of Warrants, Converted Prefunded Warrants",
        "documentation": "Share based compensation arrangement by share based payment award non option equity instruments converted prefunded warrants."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised",
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfWarrantActivityForCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of Warrants, Exercised",
        "documentation": "Number of non-option equity instruments exercised by participants."
       }
      }
     },
     "auth_ref": [
      "r12"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations",
     "presentation": [
      "http://neuraxis.com/role/CommonStockAndWarrantsDetailsNarrative",
      "http://neuraxis.com/role/ScheduleOfWarrantActivityForCommonStockDetails",
      "http://neuraxis.com/role/ScheduleOfWarrantActivityForPreferredStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of Warrants, Granted",
        "negatedLabel": "Number of Warrants, Granted",
        "verboseLabel": "Number of Warrants, Cancelled Expired",
        "terseLabel": "Warrants, canceled",
        "documentation": "Number of shares under non-option equity instrument agreements that were either cancelled or expired."
       }
      }
     },
     "auth_ref": [
      "r121",
      "r122"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted",
     "presentation": [
      "http://neuraxis.com/role/BasisOfPresentationOrganizationAndOtherMattersDetailsNarrative",
      "http://neuraxis.com/role/ScheduleOfWarrantActivityForCommonStockDetails",
      "http://neuraxis.com/role/ScheduleOfWarrantActivityForPreferredStockDetails",
      "http://neuraxis.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants to purchase an aggregate common stock, shares",
        "verboseLabel": "Number of Warrants, Granted",
        "terseLabel": "Granted",
        "documentation": "Net number of non-option equity instruments granted to participants."
       }
      }
     },
     "auth_ref": [
      "r11"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber",
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfOption-pricingModelWithFollowingWeighted-averageAssumptionsDetails",
      "http://neuraxis.com/role/ScheduleOfWarrantActivityForCommonStockDetails",
      "http://neuraxis.com/role/ScheduleOfWarrantActivityForPreferredStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Number of Warrants, Outstanding at beginning of period",
        "periodEndLabel": "Number of Warrants, Outstanding at Ending of period",
        "label": "Number of Shares",
        "documentation": "Number of equity instruments other than options outstanding, including both vested and non-vested instruments."
       }
      }
     },
     "auth_ref": [
      "r119",
      "r120"
     ]
    },
    "NRXS_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsWeightedAverageExercisePriceCancelledExpiredNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://neuraxis.com/20241231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsWeightedAverageExercisePriceCancelledExpiredNumber",
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfWarrantActivityForCommonStockDetails",
      "http://neuraxis.com/role/ScheduleOfWarrantActivityForPreferredStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Exercise Price, Cancelled Expired",
        "documentation": "Share based compensation arrangement by share based payment award non options weighted average exercise price cancelled expired number."
       }
      }
     },
     "auth_ref": []
    },
    "NRXS_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsWeightedAverageExercisePriceCommonStockWarrant": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://neuraxis.com/20241231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsWeightedAverageExercisePriceCommonStockWarrant",
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfWarrantActivityForPreferredStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Weighted Average Exercise Price, Converted to Common Stock Warrant",
        "documentation": "Share based compensation arrangement by share based payment award non options weighted average exercise price common stock warrant.",
        "label": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsWeightedAverageExercisePriceCommonStockWarrant"
       }
      }
     },
     "auth_ref": []
    },
    "NRXS_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsWeightedAverageRemainingContracualLifeOutstandingNumberGranted": {
     "xbrltype": "durationItemType",
     "nsuri": "http://neuraxis.com/20241231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsWeightedAverageRemainingContracualLifeOutstandingNumberGranted",
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfWarrantActivityForCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Remaining Contractual Life - Warrants Granted",
        "documentation": "Share based compensation arrangement by share based payment award non options weighted average remaining contracual life outstanding number granted."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Aggregate Intrinsic Value, Outstanding, Beginning balance",
        "periodEndLabel": "Aggregate Intrinsic Value, Outstanding, Ending balance",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value",
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding."
       }
      }
     },
     "auth_ref": [
      "r52"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Number of Options, Outstanding, Beginning balance",
        "periodEndLabel": "Number of Options, Outstanding, Ending balance",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "documentation": "Number of options outstanding, including both vested and non-vested options."
       }
      }
     },
     "auth_ref": [
      "r465",
      "r466"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfStockOptionActivityDetails",
      "http://neuraxis.com/role/ScheduleOfWarrantActivityForCommonStockDetails",
      "http://neuraxis.com/role/ScheduleOfWarrantActivityForPreferredStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Weighted Average Exercise Price, Outstanding at beginning of period",
        "periodEndLabel": "Weighted Average Exercise Price, Outstanding at Ending of period",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r465",
      "r466"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Aggregate Intrinsic Value, Vested and Exercisable, Ending balance",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value",
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r482"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber",
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Number of Options, Vested and Exercisable, Ending balance",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number",
        "documentation": "Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r482"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice",
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Weighted Average Exercise Price, Vested and Exercisable, Ending balance",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price",
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r482"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://neuraxis.com/role/IntangibleAssetsDetailsNarrative",
      "http://neuraxis.com/role/PropertyAndEquipmentDetailsNarrative",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r461",
      "r462",
      "r463",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489"
     ]
    },
    "NRXS_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsConvertedPrefundedWarrantsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://neuraxis.com/20241231",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsConvertedPrefundedWarrantsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfWarrantActivityForCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Exercise Price, Converted Prefunded Warrants",
        "documentation": "Share based compensation arrangements by share based payment award options converted prefunded warrants in period weighted average exercise price."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfWarrantActivityForCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Exercise Price, Excercised",
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares."
       }
      }
     },
     "auth_ref": [
      "r470"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfWarrantActivityForCommonStockDetails",
      "http://neuraxis.com/role/ScheduleOfWarrantActivityForPreferredStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Exercise Price, granted",
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options."
       }
      }
     },
     "auth_ref": [
      "r469"
     ]
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "presentation": [
      "http://neuraxis.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Stock-Based Compensation",
        "label": "Share-Based Payment Arrangement [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost."
       }
      }
     },
     "auth_ref": [
      "r457",
      "r464",
      "r483",
      "r484",
      "r485",
      "r486",
      "r489",
      "r493",
      "r494",
      "r495",
      "r496"
     ]
    },
    "NRXS_ShareHolderOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://neuraxis.com/20241231",
     "localname": "ShareHolderOneMember",
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfRelatedPartyLoansPayableToShareholderDetails",
      "http://neuraxis.com/role/ScheduleOfRelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shareholder 1 [Member]",
        "documentation": "Shareholder 1 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "NRXS_ShareHolderTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://neuraxis.com/20241231",
     "localname": "ShareHolderTwoMember",
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfRelatedPartyLoansPayableToShareholderDetails",
      "http://neuraxis.com/role/ScheduleOfRelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shareholder 2 [Member]",
        "documentation": "Shareholder 2 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharePrice",
     "presentation": [
      "http://neuraxis.com/role/CommonStockAndWarrantsDetailsNarrative",
      "http://neuraxis.com/role/ScheduleOfOption-pricingModelWithFollowingWeighted-averageAssumptionsDetails",
      "http://neuraxis.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common shares, per share",
        "verboseLabel": "Stock price",
        "terseLabel": "Share price",
        "documentation": "Price of a single share of a number of saleable stocks of a company."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfOption-pricingModelWithFollowingWeighted-averageAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expected term",
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r485"
     ]
    },
    "NRXS_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsCancelledWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://neuraxis.com/20241231",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsCancelledWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfWarrantActivityForCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Remaining Contractual Life - Warrants Cancelled",
        "documentation": "Share based compensation arrangement by sharebased payment award options cancelled weighted average remaining contractual term 1."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfWarrantActivityForCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Weighted Average Remaining Contractual Life - Warrants Granted",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r52"
     ]
    },
    "NRXS_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisedWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://neuraxis.com/20241231",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisedWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfWarrantActivityForCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Weighted Average Remaining Contractual Life - Warrants Granted",
        "documentation": "Sharebased compensation arrangement by sharebased payment award options exercised weighted average remaining contractual term 1.",
        "label": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisedWeightedAverageRemainingContractualTerm1"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfStockOptionActivityDetails",
      "http://neuraxis.com/role/ScheduleOfWarrantActivityForCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Remaining Contractual Life - Warrants",
        "verboseLabel": "Weighted Average Remaining Contractual Life (in years), Outstanding",
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r123"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Remaining Contractual Life (in years), Vested and Exercisable",
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r482"
     ]
    },
    "NRXS_ShareholdersOneAndTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://neuraxis.com/20241231",
     "localname": "ShareholdersOneAndTwoMember",
     "presentation": [
      "http://neuraxis.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shareholders 1 and 2 [Member]",
        "documentation": "Shareholders 1 and 2 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharesIssued",
     "presentation": [
      "http://neuraxis.com/role/PreferredStockDetailsNarrative",
      "http://neuraxis.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Preferred stock, shares issued",
        "label": "Shares issued",
        "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "us-gaap_SharesIssuedPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharesIssuedPricePerShare",
     "presentation": [
      "http://neuraxis.com/role/BasisOfPresentationOrganizationAndOtherMattersDetailsNarrative",
      "http://neuraxis.com/role/CommonStockAndWarrantsDetailsNarrative",
      "http://neuraxis.com/role/NotesPayableDetailsNarrative",
      "http://neuraxis.com/role/PreferredStockDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares issued, price per share",
        "verboseLabel": "Shares Issued, Price Per Share",
        "terseLabel": "Conversion per shares",
        "documentation": "Per share or per unit amount of equity securities issued."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharesOutstanding",
     "presentation": [
      "http://neuraxis.com/role/StatementsOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Balance, shares",
        "periodEndLabel": "Balance, shares",
        "label": "Shares, Outstanding",
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShortTermBorrowings": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShortTermBorrowings",
     "crdr": "credit",
     "presentation": [
      "http://neuraxis.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Short term borrowings outstanding",
        "documentation": "Reflects the total carrying amount as of the balance sheet date of debt having initial terms less than one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r64",
      "r133",
      "r898",
      "r1189"
     ]
    },
    "us-gaap_ShortTermDebtLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShortTermDebtLineItems",
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfRelatedPartyLoansPayableToShareholderDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Short-Term Debt [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShortTermDebtTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShortTermDebtTypeAxis",
     "presentation": [
      "http://neuraxis.com/role/PreferredStockDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Short-Term Debt, Type [Axis]",
        "documentation": "Information by type of short-term debt arrangement."
       }
      }
     },
     "auth_ref": [
      "r65",
      "r1107",
      "r1108",
      "r1109"
     ]
    },
    "us-gaap_ShortTermDebtTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShortTermDebtTypeDomain",
     "presentation": [
      "http://neuraxis.com/role/PreferredStockDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of short-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing."
       }
      }
     },
     "auth_ref": [
      "r64",
      "r1107",
      "r1108",
      "r1109"
     ]
    },
    "NRXS_SignatureBankMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://neuraxis.com/20241231",
     "localname": "SignatureBankMember",
     "presentation": [
      "http://neuraxis.com/role/NotesPayableDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Signature Bank [Member]",
        "documentation": "Signature Bank [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://neuraxis.com/role/SummaryOfSignificantAccountingPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Summary of Significant Accounting Policies",
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r100",
      "r220"
     ]
    },
    "NRXS_SoftwareImplementationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://neuraxis.com/20241231",
     "localname": "SoftwareImplementationMember",
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Software Implementation [Member]",
        "documentation": "Software Implementation [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://neuraxis.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r932"
     ]
    },
    "NRXS_SpecialBonusPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://neuraxis.com/20241231",
     "localname": "SpecialBonusPercentage",
     "presentation": [
      "http://neuraxis.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Special bonus percentage",
        "documentation": "Special bonus percentage."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementClassOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementClassOfStockAxis",
     "presentation": [
      "http://neuraxis.com/role/BalanceSheetsParenthetical",
      "http://neuraxis.com/role/BasisOfPresentationOrganizationAndOtherMattersDetailsNarrative",
      "http://neuraxis.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://neuraxis.com/role/CommonStockAndWarrantsDetailsNarrative",
      "http://neuraxis.com/role/NotesPayableDetailsNarrative",
      "http://neuraxis.com/role/PreferredStockDetailsNarrative",
      "http://neuraxis.com/role/StatementsOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Axis]",
        "documentation": "Information by the different classes of stock of the entity."
       }
      }
     },
     "auth_ref": [
      "r163",
      "r194",
      "r195",
      "r196",
      "r223",
      "r246",
      "r247",
      "r250",
      "r252",
      "r258",
      "r259",
      "r320",
      "r374",
      "r377",
      "r378",
      "r379",
      "r383",
      "r384",
      "r415",
      "r416",
      "r419",
      "r422",
      "r430",
      "r572",
      "r714",
      "r715",
      "r716",
      "r717",
      "r723",
      "r724",
      "r725",
      "r726",
      "r727",
      "r728",
      "r729",
      "r730",
      "r731",
      "r732",
      "r733",
      "r735",
      "r749",
      "r772",
      "r795",
      "r819",
      "r820",
      "r821",
      "r822",
      "r823",
      "r1037",
      "r1062",
      "r1073"
     ]
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://neuraxis.com/role/BasisOfPresentationOrganizationAndOtherMattersDetailsNarrative",
      "http://neuraxis.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://neuraxis.com/role/CommonStockAndWarrantsDetailsNarrative",
      "http://neuraxis.com/role/CommonStockAndWarrantsTables",
      "http://neuraxis.com/role/NotesPayableDetailsNarrative",
      "http://neuraxis.com/role/ScheduleOfWarrantActivityForCommonStockDetails",
      "http://neuraxis.com/role/ScheduleOfWarrantActivityForPreferredStockDetails",
      "http://neuraxis.com/role/StatementsOfStockholdersEquityDeficit",
      "http://neuraxis.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r79",
      "r82",
      "r83",
      "r183",
      "r205",
      "r206",
      "r207",
      "r228",
      "r229",
      "r230",
      "r232",
      "r237",
      "r239",
      "r241",
      "r257",
      "r321",
      "r322",
      "r356",
      "r432",
      "r528",
      "r529",
      "r536",
      "r537",
      "r538",
      "r540",
      "r541",
      "r542",
      "r548",
      "r549",
      "r550",
      "r551",
      "r552",
      "r553",
      "r556",
      "r573",
      "r574",
      "r575",
      "r576",
      "r577",
      "r578",
      "r583",
      "r585",
      "r596",
      "r696",
      "r705",
      "r706",
      "r707",
      "r723",
      "r795"
     ]
    },
    "srt_StatementGeographicalAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "StatementGeographicalAxis",
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfDisaggregationOfRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]"
       }
      }
     },
     "auth_ref": [
      "r285",
      "r286",
      "r648",
      "r649",
      "r650",
      "r651",
      "r652",
      "r653",
      "r654",
      "r655",
      "r656",
      "r657",
      "r658",
      "r659",
      "r660",
      "r661",
      "r662",
      "r663",
      "r664",
      "r665",
      "r666",
      "r667",
      "r668",
      "r669",
      "r670",
      "r671",
      "r672",
      "r673",
      "r674",
      "r675",
      "r676",
      "r677",
      "r736",
      "r737",
      "r738",
      "r805",
      "r808",
      "r812",
      "r818",
      "r825",
      "r831",
      "r832",
      "r833",
      "r834",
      "r836",
      "r837",
      "r838",
      "r839",
      "r840",
      "r846",
      "r876",
      "r900",
      "r901",
      "r902",
      "r903",
      "r904",
      "r905",
      "r906",
      "r907",
      "r910",
      "r914",
      "r1122",
      "r1194",
      "r1196",
      "r1197",
      "r1198",
      "r1199",
      "r1200",
      "r1201",
      "r1202",
      "r1203",
      "r1204",
      "r1205",
      "r1206",
      "r1207",
      "r1208",
      "r1209",
      "r1210",
      "r1211",
      "r1212",
      "r1213",
      "r1214",
      "r1215",
      "r1216",
      "r1217",
      "r1218",
      "r1219",
      "r1220",
      "r1221",
      "r1222"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementLineItems",
     "presentation": [
      "http://neuraxis.com/role/BalanceSheetsParenthetical",
      "http://neuraxis.com/role/BasisOfPresentationOrganizationAndOtherMattersDetailsNarrative",
      "http://neuraxis.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://neuraxis.com/role/LeasesDetailsNarrative",
      "http://neuraxis.com/role/NotesPayableDetailsNarrative",
      "http://neuraxis.com/role/ScheduleOfDisaggregationOfRevenueDetails",
      "http://neuraxis.com/role/StatementsOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r228",
      "r229",
      "r230",
      "r257",
      "r585",
      "r645",
      "r712",
      "r735",
      "r741",
      "r742",
      "r743",
      "r744",
      "r745",
      "r746",
      "r749",
      "r752",
      "r753",
      "r754",
      "r755",
      "r756",
      "r759",
      "r760",
      "r761",
      "r762",
      "r764",
      "r765",
      "r766",
      "r767",
      "r768",
      "r770",
      "r773",
      "r774",
      "r781",
      "r782",
      "r783",
      "r784",
      "r785",
      "r786",
      "r787",
      "r788",
      "r789",
      "r790",
      "r791",
      "r792",
      "r795",
      "r915"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfStockholdersEquityAbstract",
     "auth_ref": []
    },
    "srt_StatementScenarioAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "StatementScenarioAxis",
     "presentation": [
      "http://neuraxis.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Axis]"
       }
      }
     },
     "auth_ref": [
      "r242",
      "r456",
      "r1038",
      "r1039",
      "r1070"
     ]
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementTable",
     "presentation": [
      "http://neuraxis.com/role/BalanceSheetsParenthetical",
      "http://neuraxis.com/role/BasisOfPresentationOrganizationAndOtherMattersDetailsNarrative",
      "http://neuraxis.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://neuraxis.com/role/LeasesDetailsNarrative",
      "http://neuraxis.com/role/NotesPayableDetailsNarrative",
      "http://neuraxis.com/role/ScheduleOfDisaggregationOfRevenueDetails",
      "http://neuraxis.com/role/StatementsOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Table]",
        "documentation": "Disclosure of information about statement of comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity."
       }
      }
     },
     "auth_ref": [
      "r228",
      "r229",
      "r230",
      "r257",
      "r288",
      "r585",
      "r645",
      "r712",
      "r735",
      "r741",
      "r742",
      "r743",
      "r744",
      "r745",
      "r746",
      "r749",
      "r752",
      "r753",
      "r754",
      "r755",
      "r756",
      "r759",
      "r760",
      "r761",
      "r762",
      "r764",
      "r765",
      "r766",
      "r767",
      "r768",
      "r770",
      "r773",
      "r774",
      "r781",
      "r782",
      "r783",
      "r784",
      "r785",
      "r786",
      "r787",
      "r788",
      "r789",
      "r790",
      "r791",
      "r792",
      "r795",
      "r915"
     ]
    },
    "ecd_StkPrcOrTsrEstimationMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "StkPrcOrTsrEstimationMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Price or TSR Estimation Method"
       }
      }
     },
     "auth_ref": [
      "r952",
      "r963",
      "r977",
      "r1003"
     ]
    },
    "NRXS_StockIssuedDuringPeriodSharesCommonStockIssuedUponInitialPublicOffering": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://neuraxis.com/20241231",
     "localname": "StockIssuedDuringPeriodSharesCommonStockIssuedUponInitialPublicOffering",
     "presentation": [
      "http://neuraxis.com/role/CommonStockAndWarrantsDetailsNarrative",
      "http://neuraxis.com/role/StatementsOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock issued upon initial public offering, shares",
        "verboseLabel": "Common shares, issued upon initial public offering, shares",
        "documentation": "Stock issued during period shares common stock issued upon initial public offering"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities",
     "presentation": [
      "http://neuraxis.com/role/StatementsOfStockholdersEquityDeficit",
      "http://neuraxis.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock issued upon preferred stock conversion, shares",
        "verboseLabel": "Investor converted warrants into common shares",
        "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r47",
      "r79",
      "r82",
      "r116",
      "r402"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesConversionOfUnits",
     "presentation": [
      "http://neuraxis.com/role/CommonStockAndWarrantsDetailsNarrative",
      "http://neuraxis.com/role/StatementsOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock issued upon debt conversion, shares",
        "documentation": "The number of shares issued during the period upon the conversion of units. An example of a convertible unit is an umbrella partnership real estate investment trust unit (UPREIT unit)."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r47",
      "r78",
      "r79",
      "r116"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan",
     "presentation": [
      "http://neuraxis.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Seven key employees stock options",
        "documentation": "Number of shares of capital stock issued (purchased by employees) in connection with an employee stock ownership plan."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r53",
      "r78",
      "r79",
      "r116"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesIssuedForServices": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesIssuedForServices",
     "presentation": [
      "http://neuraxis.com/role/CommonStockAndWarrantsDetailsNarrative",
      "http://neuraxis.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock issued during period shares issued for services",
        "verboseLabel": "Service for payments",
        "documentation": "Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://neuraxis.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://neuraxis.com/role/NotesPayableDetailsNarrative",
      "http://neuraxis.com/role/StatementsOfStockholdersEquityDeficit",
      "http://neuraxis.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock issued from agreements, shares",
        "verboseLabel": "Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Common stock shares issue",
        "documentation": "Number of new stock issued during the period."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r78",
      "r79",
      "r116",
      "r714",
      "r795",
      "r820"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesOther": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesOther",
     "presentation": [
      "http://neuraxis.com/role/StatementsOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Conversion of convertible promissory notes to Series B Preferred Stock, shares",
        "documentation": "Number of shares of stock issued attributable to transactions classified as other."
       }
      }
     },
     "auth_ref": []
    },
    "NRXS_StockIssuedDuringPeriodSharesPreferredStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://neuraxis.com/20241231",
     "localname": "StockIssuedDuringPeriodSharesPreferredStock",
     "crdr": "credit",
     "presentation": [
      "http://neuraxis.com/role/StatementsOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of Series B Preferred Stock, shares",
        "documentation": "Stock issued during period shares preferred stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardGross",
     "presentation": [
      "http://neuraxis.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted stock, granted",
        "documentation": "Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r116"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "presentation": [
      "http://neuraxis.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock option, exercise",
        "documentation": "Number of share options (or share units) exercised during the current period."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r78",
      "r79",
      "r116",
      "r470"
     ]
    },
    "NRXS_StockIssuedDuringPeriodSharesWarrantsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://neuraxis.com/20241231",
     "localname": "StockIssuedDuringPeriodSharesWarrantsExercised",
     "presentation": [
      "http://neuraxis.com/role/StatementsOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants exercised, shares",
        "documentation": "Stock issued during period shares warrants exercised."
       }
      }
     },
     "auth_ref": []
    },
    "NRXS_StockIssuedDuringPeriodValueCommonStockIssuedUponInitialPublicOffering": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://neuraxis.com/20241231",
     "localname": "StockIssuedDuringPeriodValueCommonStockIssuedUponInitialPublicOffering",
     "crdr": "credit",
     "presentation": [
      "http://neuraxis.com/role/StatementsOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock issued upon initial public offering",
        "documentation": "Stock issued during period value common stock issued upon initial public offering."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities",
     "crdr": "credit",
     "presentation": [
      "http://neuraxis.com/role/StatementsOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock issued upon preferred stock conversion",
        "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r79",
      "r82",
      "r83",
      "r116"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueConversionOfUnits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueConversionOfUnits",
     "crdr": "credit",
     "presentation": [
      "http://neuraxis.com/role/StatementsOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock issued upon debt conversion",
        "documentation": "Value of stock issued during the period upon the conversion of units. An example of a convertible unit is an umbrella partnership real estate investment trust unit (UPREIT unit)."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r79",
      "r82",
      "r83",
      "r116"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueIssuedForServices": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueIssuedForServices",
     "crdr": "credit",
     "presentation": [
      "http://neuraxis.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock issued during period value issued for services",
        "documentation": "Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "crdr": "credit",
     "presentation": [
      "http://neuraxis.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://neuraxis.com/role/NotesPayableDetailsNarrative",
      "http://neuraxis.com/role/StatementsOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock issued from agreements",
        "verboseLabel": "Stock Issued During Period, Value, New Issues",
        "terseLabel": "Common stock with a fair value",
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r78",
      "r79",
      "r116",
      "r723",
      "r795",
      "r820",
      "r922"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueOther",
     "crdr": "credit",
     "presentation": [
      "http://neuraxis.com/role/StatementsOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Conversion of convertible promissory notes to Series B Preferred Stock",
        "documentation": "Value of shares of stock issued attributable to transactions classified as other."
       }
      }
     },
     "auth_ref": []
    },
    "NRXS_StockIssuedDuringPeriodValuePreferredStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://neuraxis.com/20241231",
     "localname": "StockIssuedDuringPeriodValuePreferredStock",
     "crdr": "credit",
     "presentation": [
      "http://neuraxis.com/role/StatementsOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of Series B Preferred Stock",
        "documentation": "Stock issued during period value preferred stock"
       }
      }
     },
     "auth_ref": []
    },
    "NRXS_StockIssuedDuringPeriodValueWarrantsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://neuraxis.com/20241231",
     "localname": "StockIssuedDuringPeriodValueWarrantsExercised",
     "crdr": "credit",
     "presentation": [
      "http://neuraxis.com/role/StatementsOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants exercised",
        "documentation": "Stock issued during period value warrants exercised."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockRepurchasedAndRetiredDuringPeriodShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockRepurchasedAndRetiredDuringPeriodShares",
     "presentation": [
      "http://neuraxis.com/role/BasisOfPresentationOrganizationAndOtherMattersDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock repurchased and retired during period shares",
        "documentation": "Number of shares that have been repurchased and retired during the period."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r78",
      "r79",
      "r116"
     ]
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://neuraxis.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://neuraxis.com/role/BalanceSheets",
      "http://neuraxis.com/role/StatementsOfStockholdersEquityDeficit",
      "http://neuraxis.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total stockholders\u2019 equity (deficit)",
        "periodStartLabel": "Balance",
        "periodEndLabel": "Balance",
        "label": "Stockholders' equity",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r79",
      "r82",
      "r83",
      "r103",
      "r751",
      "r769",
      "r796",
      "r797",
      "r898",
      "r923",
      "r1064",
      "r1090",
      "r1170",
      "r1226"
     ]
    },
    "us-gaap_StockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityAbstract",
     "presentation": [
      "http://neuraxis.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders\u2019 Equity (Deficit)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "presentation": [
      "http://neuraxis.com/role/CommonStockAndWarrants"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock and Warrants",
        "documentation": "The entire disclosure for equity."
       }
      }
     },
     "auth_ref": [
      "r112",
      "r222",
      "r414",
      "r416",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r426",
      "r427",
      "r429",
      "r432",
      "r555",
      "r798",
      "r800",
      "r824"
     ]
    },
    "us-gaap_StockholdersEquityNoteStockSplit": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityNoteStockSplit",
     "presentation": [
      "http://neuraxis.com/role/BasisOfPresentationOrganizationAndOtherMattersDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Description of stock split",
        "documentation": "Description of the stock split arrangement. Also provide the retroactive effect given by a stock split that occurs after the balance date but before the release of financial statements."
       }
      }
     },
     "auth_ref": [
      "r117"
     ]
    },
    "us-gaap_StockholdersEquityReverseStockSplit": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityReverseStockSplit",
     "presentation": [
      "http://neuraxis.com/role/CommonStockAndWarrantsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Reverse stock split",
        "documentation": "Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements."
       }
      }
     },
     "auth_ref": [
      "r117"
     ]
    },
    "us-gaap_SubsequentEventLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventLineItems",
     "presentation": [
      "http://neuraxis.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Line Items]",
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event."
       }
      }
     },
     "auth_ref": [
      "r579",
      "r607"
     ]
    },
    "us-gaap_SubsequentEventMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventMember",
     "presentation": [
      "http://neuraxis.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Member]",
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r579",
      "r607"
     ]
    },
    "us-gaap_SubsequentEventTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventTable",
     "presentation": [
      "http://neuraxis.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Table]",
        "documentation": "Disclosure of information about significant event or transaction occurring between statement of financial position date and date when financial statements were issued."
       }
      }
     },
     "auth_ref": [
      "r579",
      "r607"
     ]
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventTypeAxis",
     "presentation": [
      "http://neuraxis.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type [Axis]",
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r579",
      "r607"
     ]
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventTypeDomain",
     "presentation": [
      "http://neuraxis.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r579",
      "r607"
     ]
    },
    "us-gaap_SubsequentEventsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventsTextBlock",
     "presentation": [
      "http://neuraxis.com/role/SubsequentEvents"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events",
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business."
       }
      }
     },
     "auth_ref": [
      "r606",
      "r608"
     ]
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsidiarySaleOfStockAxis",
     "presentation": [
      "http://neuraxis.com/role/BasisOfPresentationOrganizationAndOtherMattersDetailsNarrative",
      "http://neuraxis.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock [Axis]",
        "documentation": "Information by type of sale of the entity's stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SummaryOfOperatingLossCarryforwardsTextBlock",
     "presentation": [
      "http://neuraxis.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of State Carryforwards",
        "documentation": "Tabular disclosure of pertinent information, such as tax authority, amounts, and expiration dates, of net operating loss carryforwards, including an assessment of the likelihood of utilization."
       }
      }
     },
     "auth_ref": [
      "r1155"
     ]
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SupplementalCashFlowInformationAbstract",
     "presentation": [
      "http://neuraxis.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Disclosure of Non-Cash Operating Activities"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TabularListTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TabularListTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tabular List, Table"
       }
      }
     },
     "auth_ref": [
      "r996"
     ]
    },
    "us-gaap_TaxPeriodAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TaxPeriodAxis",
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfStateCarryforwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Period [Axis]",
        "documentation": "Information by period subject to enacted tax law."
       }
      }
     },
     "auth_ref": [
      "r1153"
     ]
    },
    "us-gaap_TaxPeriodDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TaxPeriodDomain",
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfStateCarryforwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identified tax period."
       }
      }
     },
     "auth_ref": [
      "r1153"
     ]
    },
    "NRXS_TaxYear2037Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://neuraxis.com/20241231",
     "localname": "TaxYear2037Member",
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfStateCarryforwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Year 2037 [Member]",
        "documentation": "Tax Year 2037 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "NRXS_TaxYear2038Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://neuraxis.com/20241231",
     "localname": "TaxYear2038Member",
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfStateCarryforwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Year 2038 [Member]",
        "documentation": "Tax Year 2038 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "NRXS_TaxYear2039Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://neuraxis.com/20241231",
     "localname": "TaxYear2039Member",
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfStateCarryforwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Year 2039 [Member]",
        "documentation": "Tax Year 2039 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "NRXS_TaxYear2040Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://neuraxis.com/20241231",
     "localname": "TaxYear2040Member",
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfStateCarryforwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Year 2040 [Member]",
        "documentation": "Tax Year 2040 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "NRXS_TaxYear2041Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://neuraxis.com/20241231",
     "localname": "TaxYear2041Member",
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfStateCarryforwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Year 2041 [Member]",
        "documentation": "Tax Year 2041 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "NRXS_TaxYearThereafterMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://neuraxis.com/20241231",
     "localname": "TaxYearThereafterMember",
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfStateCarryforwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Year Thereafter [Member]",
        "documentation": "Tax Year Thereafter [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TemporaryEquitySharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TemporaryEquitySharesAuthorized",
     "presentation": [
      "http://neuraxis.com/role/BasisOfPresentationOrganizationAndOtherMattersDetailsNarrative",
      "http://neuraxis.com/role/NotesPayableDetailsNarrative",
      "http://neuraxis.com/role/PreferredStockDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Temporary equity, shares authorized",
        "documentation": "The maximum number of securities classified as temporary equity that are permitted to be issued by an entity's charter and bylaws. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer."
       }
      }
     },
     "auth_ref": [
      "r77"
     ]
    },
    "srt_TitleOfIndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "TitleOfIndividualAxis",
     "presentation": [
      "http://neuraxis.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://neuraxis.com/role/NotesPayableDetailsNarrative",
      "http://neuraxis.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://neuraxis.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title and Position [Axis]"
       }
      }
     },
     "auth_ref": [
      "r1081",
      "r1177"
     ]
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "presentation": [
      "http://neuraxis.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://neuraxis.com/role/NotesPayableDetailsNarrative",
      "http://neuraxis.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://neuraxis.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "auth_ref": []
    },
    "ecd_TotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r988"
     ]
    },
    "ecd_TotalShareholderRtnVsPeerGroupTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TotalShareholderRtnVsPeerGroupTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Vs Peer Group"
       }
      }
     },
     "auth_ref": [
      "r995"
     ]
    },
    "us-gaap_TradeAndOtherAccountsReceivablePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TradeAndOtherAccountsReceivablePolicy",
     "presentation": [
      "http://neuraxis.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trade Accounts Receivable and Allowance for Credit Losses",
        "documentation": "Disclosure of accounting policy for accounts receivable."
       }
      }
     },
     "auth_ref": [
      "r145",
      "r146",
      "r147",
      "r1083",
      "r1084",
      "r1085"
     ]
    },
    "us-gaap_TrademarksMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TrademarksMember",
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfIntangibleAssetsDetails",
      "http://neuraxis.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trademarks [Member]",
        "documentation": "Rights acquired through registration of a trademark to gain or protect exclusive use of a business name, symbol or other device or style."
       }
      }
     },
     "auth_ref": [
      "r54",
      "r869",
      "r1095",
      "r1096",
      "r1097",
      "r1098",
      "r1099",
      "r1100",
      "r1102",
      "r1103",
      "r1104",
      "r1105"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "TradingSymbol",
     "presentation": [
      "http://neuraxis.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfFairValueOfAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms."
       }
      }
     },
     "auth_ref": [
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r410",
      "r428",
      "r554",
      "r571",
      "r609",
      "r610",
      "r611",
      "r612",
      "r613",
      "r614",
      "r615",
      "r616",
      "r617",
      "r618",
      "r619",
      "r620",
      "r621",
      "r622",
      "r623",
      "r625",
      "r626",
      "r627",
      "r628",
      "r629",
      "r630",
      "r631",
      "r632",
      "r633",
      "r634",
      "r635",
      "r636",
      "r637",
      "r638",
      "r639",
      "r697",
      "r885",
      "r886",
      "r888",
      "r889",
      "r890",
      "r891",
      "r892",
      "r893",
      "r894",
      "r899",
      "r1043",
      "r1044",
      "r1045",
      "r1046",
      "r1047",
      "r1048",
      "r1049",
      "r1086",
      "r1087",
      "r1088",
      "r1089",
      "r1162",
      "r1165",
      "r1166",
      "r1167",
      "r1168",
      "r1169"
     ]
    },
    "ecd_TrdArrAdoptionDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrAdoptionDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adoption Date"
       }
      }
     },
     "auth_ref": [
      "r1019"
     ]
    },
    "ecd_TrdArrDuration": {
     "xbrltype": "durationItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrDuration",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Arrangement Duration"
       }
      }
     },
     "auth_ref": [
      "r1020"
     ]
    },
    "ecd_TrdArrExpirationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrExpirationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expiration Date"
       }
      }
     },
     "auth_ref": [
      "r1020"
     ]
    },
    "ecd_TrdArrIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Name",
        "label": "Trading Arrangement, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r1018"
     ]
    },
    "ecd_TrdArrIndTitle": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrIndTitle",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title"
       }
      }
     },
     "auth_ref": [
      "r1018"
     ]
    },
    "ecd_TrdArrTerminationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrTerminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Termination Date"
       }
      }
     },
     "auth_ref": [
      "r1019"
     ]
    },
    "NRXS_TwentySeventeenStockCompensationPlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://neuraxis.com/20241231",
     "localname": "TwentySeventeenStockCompensationPlanMember",
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfOption-pricingModelWithFollowingWeighted-averageAssumptionsDetails",
      "http://neuraxis.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2017 Stock Compensation Plan [Member]",
        "documentation": "2017 Stock Compensation Plan [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "NRXS_TwoThousandTwentyFourConvertibleNotesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://neuraxis.com/20241231",
     "localname": "TwoThousandTwentyFourConvertibleNotesMember",
     "presentation": [
      "http://neuraxis.com/role/NotesPayableDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2024 Convertible Notes [Member]",
        "documentation": "2024 Convertible Notes [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "NRXS_TwoThousandTwentyFourConvertiblePromissoryNotesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://neuraxis.com/20241231",
     "localname": "TwoThousandTwentyFourConvertiblePromissoryNotesMember",
     "presentation": [
      "http://neuraxis.com/role/CommonStockAndWarrantsDetailsNarrative",
      "http://neuraxis.com/role/NotesPayableDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2024 Convertible Promissory Notes [Member]",
        "documentation": "2024 Convertible Promissory Notes [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "NRXS_TwoThousandTwentyThreeConvertibleNotesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://neuraxis.com/20241231",
     "localname": "TwoThousandTwentyThreeConvertibleNotesMember",
     "presentation": [
      "http://neuraxis.com/role/NotesPayableDetailsNarrative",
      "http://neuraxis.com/role/ScheduleOfWarrantsOutstandingAndExercisableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2023 Convertible Notes [Member]",
        "documentation": "2023 Convertible Notes [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "NRXS_TwoThousandTwentyThreeConvertiblePromissoryNotesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://neuraxis.com/20241231",
     "localname": "TwoThousandTwentyThreeConvertiblePromissoryNotesMember",
     "presentation": [
      "http://neuraxis.com/role/CommonStockAndWarrantsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2023 Convertible Promissory Notes [Membe]",
        "documentation": "2023 Convertible Promissory Notes [Membe]"
       }
      }
     },
     "auth_ref": []
    },
    "NRXS_TwoThousandTwentyTwoConvertibleNotesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://neuraxis.com/20241231",
     "localname": "TwoThousandTwentyTwoConvertibleNotesMember",
     "presentation": [
      "http://neuraxis.com/role/CommonStockAndWarrantsDetailsNarrative",
      "http://neuraxis.com/role/NotesPayableDetailsNarrative",
      "http://neuraxis.com/role/ScheduleOfWarrantsOutstandingAndExercisableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2022 Convertible Notes [Member]",
        "documentation": "2022 Convertible Notes [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TypeOfArrangementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TypeOfArrangementAxis",
     "presentation": [
      "http://neuraxis.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://neuraxis.com/role/CommonStockAndWarrantsDetailsNarrative",
      "http://neuraxis.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r543"
     ]
    },
    "us-gaap_UnamortizedDebtIssuanceExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UnamortizedDebtIssuanceExpense",
     "crdr": "debit",
     "presentation": [
      "http://neuraxis.com/role/NotesPayableDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unamortized Debt Issuance Expense",
        "documentation": "The remaining balance of debt issuance expenses that were capitalized and are being amortized against income over the lives of the respective bond issues. This does not include the amounts capitalized as part of the cost of the utility plant or asset."
       }
      }
     },
     "auth_ref": []
    },
    "NRXS_UnderwriterWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://neuraxis.com/20241231",
     "localname": "UnderwriterWarrantsMember",
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfWarrantsOutstandingAndExercisableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Underwriter Warrants [Member]",
        "documentation": "Underwriter Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "NRXS_UnderwritersDiscountPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://neuraxis.com/20241231",
     "localname": "UnderwritersDiscountPercentage",
     "presentation": [
      "http://neuraxis.com/role/BasisOfPresentationOrganizationAndOtherMattersDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Underwriters discount percentage",
        "documentation": "Underwriters discount percentage."
       }
      }
     },
     "auth_ref": []
    },
    "NRXS_UnderwritingAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://neuraxis.com/20241231",
     "localname": "UnderwritingAgreementMember",
     "presentation": [
      "http://neuraxis.com/role/CommonStockAndWarrantsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Underwriting Agreement [Member]",
        "documentation": "Underwriting Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_UndrlygSecurityMktPriceChngPct": {
     "xbrltype": "pureItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "UndrlygSecurityMktPriceChngPct",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Underlying Security Market Price Change"
       }
      }
     },
     "auth_ref": [
      "r1015"
     ]
    },
    "us-gaap_UseOfEstimates": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UseOfEstimates",
     "presentation": [
      "http://neuraxis.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Use of Estimates and Critical Accounting Estimates and Assumptions",
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles."
       }
      }
     },
     "auth_ref": [
      "r34",
      "r35",
      "r36",
      "r153",
      "r154",
      "r157",
      "r158"
     ]
    },
    "NRXS_VendorsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://neuraxis.com/20241231",
     "localname": "VendorsMember",
     "presentation": [
      "http://neuraxis.com/role/CommonStockAndWarrantsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vendors [Member]",
        "documentation": "Vendors [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "NRXS_VersaillesIndianaMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://neuraxis.com/20241231",
     "localname": "VersaillesIndianaMember",
     "presentation": [
      "http://neuraxis.com/role/LeasesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Versailles Indiana [Member]",
        "documentation": "Versailles Indiana [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "stpr_WI": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/stpr/2024",
     "localname": "WI",
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfDisaggregationOfRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "WISCONSIN"
       }
      }
     },
     "auth_ref": []
    },
    "NRXS_WarrantExpirationDateDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://neuraxis.com/20241231",
     "localname": "WarrantExpirationDateDescription",
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfWarrantsOutstandingAndExercisableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Expiration Date",
        "documentation": "Warrant expiration date description.",
        "label": "WarrantExpirationDateDescription"
       }
      }
     },
     "auth_ref": []
    },
    "NRXS_WarrantLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://neuraxis.com/20241231",
     "localname": "WarrantLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://neuraxis.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://neuraxis.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant liabilities",
        "documentation": "Warrant liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "NRXS_WarrantLiabilitiesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://neuraxis.com/20241231",
     "localname": "WarrantLiabilitiesDisclosureTextBlock",
     "presentation": [
      "http://neuraxis.com/role/WarrantLiabilities"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Warrant Liabilities",
        "documentation": "Warrant Liabilities Disclosure [Text Block]",
        "label": "Warrant Liabilities Disclosure [Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "NRXS_WarrantLiabilityPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://neuraxis.com/20241231",
     "localname": "WarrantLiabilityPolicyTextBlock",
     "presentation": [
      "http://neuraxis.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Warrant Liabilities",
        "documentation": "Warrant Liability [Policy Text Block]",
        "label": "Warrant Liability [Policy Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WarrantMember",
     "presentation": [
      "http://neuraxis.com/role/CommonStockAndWarrantsDetailsNarrative",
      "http://neuraxis.com/role/NotesPayableDetailsNarrative",
      "http://neuraxis.com/role/ScheduleOfFairValueOfAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails",
      "http://neuraxis.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant [Member]",
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount."
       }
      }
     },
     "auth_ref": [
      "r912",
      "r913",
      "r916",
      "r917",
      "r918",
      "r919"
     ]
    },
    "us-gaap_WarrantsAndRightsOutstanding": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WarrantsAndRightsOutstanding",
     "crdr": "credit",
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfChangesInWarrantLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Warrant liabilities, Beginning balance",
        "periodEndLabel": "Warrant liabilities, Ending balance",
        "label": "Warrants and Rights Outstanding",
        "documentation": "Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price."
       }
      }
     },
     "auth_ref": [
      "r1165",
      "r1166",
      "r1167"
     ]
    },
    "us-gaap_WarrantsAndRightsOutstandingMaturityDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WarrantsAndRightsOutstandingMaturityDate",
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfWarrantsOutstandingAndExercisableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Expiration Date",
        "label": "Warrants and Rights Outstanding, Maturity Date",
        "documentation": "Expiration date of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": [
      "r1165",
      "r1166",
      "r1167"
     ]
    },
    "us-gaap_WarrantsAndRightsOutstandingMeasurementInput": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WarrantsAndRightsOutstandingMeasurementInput",
     "presentation": [
      "http://neuraxis.com/role/WarrantLiabilitiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants and rights outstanding, measurement input",
        "documentation": "Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur."
       }
      }
     },
     "auth_ref": [
      "r1165",
      "r1166",
      "r1167"
     ]
    },
    "us-gaap_WarrantsAndRightsOutstandingTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WarrantsAndRightsOutstandingTerm",
     "presentation": [
      "http://neuraxis.com/role/CommonStockAndWarrantsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants, term",
        "documentation": "Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r1165",
      "r1166",
      "r1167"
     ]
    },
    "NRXS_WarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://neuraxis.com/20241231",
     "localname": "WarrantsMember",
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfDilutiveCommonStockEquivalentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants [Member]",
        "documentation": "Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfBasicAndDilutedNetLossPerShareDetails",
      "http://neuraxis.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Diluted",
        "verboseLabel": "Weighted average shares of common stock outstanding - diluted",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r245",
      "r252"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfSharesOutstandingAbstract",
     "presentation": [
      "http://neuraxis.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average shares outstanding"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfBasicAndDilutedNetLossPerShareDetails",
      "http://neuraxis.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Basic",
        "verboseLabel": "Weighted average shares of common stock outstanding - basic",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r243",
      "r252"
     ]
    },
    "NRXS_WorkingCapitalDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://neuraxis.com/20241231",
     "localname": "WorkingCapitalDeficit",
     "crdr": "credit",
     "presentation": [
      "http://neuraxis.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Working capital surplus",
        "documentation": "Working capital deficit."
       }
      }
     },
     "auth_ref": []
    },
    "NRXS_WriteoffOfDebtDiscountOnConvertibleNotesClassifiedAsAdditionalPaidInCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://neuraxis.com/20241231",
     "localname": "WriteoffOfDebtDiscountOnConvertibleNotesClassifiedAsAdditionalPaidInCapital",
     "crdr": "credit",
     "presentation": [
      "http://neuraxis.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Write-off of debt discount on convertible notes classified as additional paid in capital",
        "documentation": "Writeoff of debt discount on convertible notes classified as additional paid in capital"
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://neuraxis.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r1034"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "1",
   "SubTopic": "825",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477037/944-825-05-1"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "4",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482338/360-10-05-4"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "13",
   "SubTopic": "10",
   "Topic": "480",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481766/480-10-25-13"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "SubTopic": "405",
   "Topic": "942",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477787/942-405-45-2"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(g)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-1"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-3"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-4"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-5"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-11"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-16"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-20"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-21"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-4"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-8"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "30",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "20",
   "Section": "25",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481284/470-20-25-2"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "50",
   "Section": "40",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481303/470-50-40-2"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "50",
   "Section": "40",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481303/470-50-40-4"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481142/505-10-45-2"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-10"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-4"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-5"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-8"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-1"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "40",
   "Section": "25",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480637/718-40-25-10"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-14"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-20"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-21"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "850",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "850",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "470",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477734/942-470-50-3"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "825",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478898/942-825-50-1"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "954",
   "SubTopic": "720",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478461/954-720-45-1"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/205/tableOfContent"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r73": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r74": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r75": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r76": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r77": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r78": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r79": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r80": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r81": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r82": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r83": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r84": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r85": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r86": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r87": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(2)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r88": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r89": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r90": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r91": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r92": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r93": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r94": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r95": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r96": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r97": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r98": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r99": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r100": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "235",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/235/tableOfContent"
  },
  "r101": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "275",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/275/tableOfContent"
  },
  "r102": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18"
  },
  "r103": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2"
  },
  "r104": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "330",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.BB)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480581/330-10-S99-2"
  },
  "r105": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/360/tableOfContent"
  },
  "r106": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r107": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.CC)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480091/360-10-S99-2"
  },
  "r108": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "440",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/440/tableOfContent"
  },
  "r109": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "470",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/470/tableOfContent"
  },
  "r110": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-5"
  },
  "r111": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r112": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/505/tableOfContent"
  },
  "r113": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-6"
  },
  "r114": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-6"
  },
  "r115": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-7"
  },
  "r116": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r117": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "4",
   "Subparagraph": "(SAB Topic 4.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-4"
  },
  "r118": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r119": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r120": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r121": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r122": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r123": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r124": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r125": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "38",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-38"
  },
  "r126": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "815",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/815/tableOfContent"
  },
  "r127": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "15",
   "Paragraph": "83",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480647/815-10-15-83"
  },
  "r128": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "820",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/820/tableOfContent"
  },
  "r129": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-21"
  },
  "r130": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r131": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r132": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r133": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r134": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(15)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r135": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(15)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r136": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r137": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r138": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r139": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r140": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r141": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r142": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r143": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r144": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r145": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-11B"
  },
  "r146": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-15"
  },
  "r147": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-6"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "321",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479567/321-10-45-1"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482659/740-20-45-2"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "SubTopic": "210",
   "Topic": "946",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-20"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "270",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482989/270-10-45-6"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "SubTopic": "35",
   "Topic": "720",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483406/720-35-50-1"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-1"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-11"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-12"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-6"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-7"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h))",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "a",
   "Publisher": "SEC"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "a",
   "Subparagraph": "(Instruction 5)",
   "Publisher": "SEC"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(1)",
   "Publisher": "SEC"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(1)(Instruction 5)",
   "Publisher": "SEC"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(2)(Instruction 5)",
   "Publisher": "SEC"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(3)(Instruction 5)",
   "Publisher": "SEC"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(4)(Instruction 5)",
   "Publisher": "SEC"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(5)(Instruction 5)",
   "Publisher": "SEC"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(1)(i)(Instruction 5)",
   "Publisher": "SEC"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(1)(ii)(Instruction 5)",
   "Publisher": "SEC"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(i)(Instruction 5)",
   "Publisher": "SEC"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(ii)(Instruction 5)",
   "Publisher": "SEC"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(iii)(Instruction 5)",
   "Publisher": "SEC"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Subparagraph": "(Instruction 5)",
   "Publisher": "SEC"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1406",
   "Paragraph": "a",
   "Subparagraph": "(1)",
   "Publisher": "SEC"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1406",
   "Paragraph": "a",
   "Subparagraph": "(2)",
   "Publisher": "SEC"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1406",
   "Paragraph": "a",
   "Subparagraph": "(3)",
   "Publisher": "SEC"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1406",
   "Paragraph": "a",
   "Subparagraph": "(4)",
   "Publisher": "SEC"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1406",
   "Paragraph": "a",
   "Subparagraph": "(5)",
   "Publisher": "SEC"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1406",
   "Paragraph": "c",
   "Publisher": "SEC"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483489/210-10-50-1"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-1"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 6.B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-5"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-17"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-19"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2A"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-1"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480530/250-10-S99-5"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-11"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-3"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-1"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-3"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/280/tableOfContent"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-15"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-24"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26B"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26C"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "34",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-34"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-4"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479344/326-20-45-1"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-11"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-14"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-16"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-5"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-4"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-7"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-9"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/330/tableOfContent"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483080/330-10-50-1"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483080/330-10-50-2"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483080/330-10-50-4"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480265/350-10-S45-1"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/350-30/tableOfContent"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-1"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-2"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-4"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.FF.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476188/405-10-S99-1"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-4"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-6"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-16"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-16"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-4"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-8"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/715/tableOfContent"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(n)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(o)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(p)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(q)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(r)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(r)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480126/715-20-S99-2"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480266/715-60-50-3"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "70",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480794/715-70-50-1"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/718/tableOfContent"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-1D"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-3"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.C.Q3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.1.Q5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.3.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "720",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "720",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483384/720-30-45-1"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "720",
   "SubTopic": "35",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483406/720-35-50-1"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483044/730-10-05-1"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/740/tableOfContent"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-25"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-28"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12B"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12C"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-14"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-17"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-19"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-20"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-21"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-22"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-23"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-3"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "51",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-51"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.1.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.5.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 11.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-2"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "270",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477891/740-270-50-1"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482603/740-30-50-2"
  },
  "r536": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r537": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r538": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r539": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r540": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r541": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r542": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r543": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1"
  },
  "r544": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r545": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r546": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r547": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r548": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r549": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r550": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r551": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r552": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r553": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r554": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-5"
  },
  "r555": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-6"
  },
  "r556": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r557": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r558": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r559": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "54B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B"
  },
  "r560": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r561": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r562": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r563": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r564": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r565": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r566": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r567": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
  },
  "r568": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r569": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r570": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r571": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6B"
  },
  "r572": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r573": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17"
  },
  "r574": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r575": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r576": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r577": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r578": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1"
  },
  "r579": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-2"
  },
  "r580": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483013/835-20-50-1"
  },
  "r581": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2"
  },
  "r582": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1"
  },
  "r583": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8"
  },
  "r584": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/842-20/tableOfContent"
  },
  "r585": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "12A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A"
  },
  "r586": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r587": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r588": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-5"
  },
  "r589": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-1"
  },
  "r590": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r591": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r592": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r593": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r594": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6"
  },
  "r595": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A"
  },
  "r596": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r597": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/850/tableOfContent"
  },
  "r598": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r599": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r600": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r601": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r602": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-2"
  },
  "r603": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r604": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-6"
  },
  "r605": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481435/852-10-45-14"
  },
  "r606": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/855/tableOfContent"
  },
  "r607": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r608": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r609": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r610": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r611": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r612": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r613": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r614": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r615": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r616": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r617": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r618": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r619": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r620": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r621": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r622": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481444/860-30-45-1"
  },
  "r623": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7"
  },
  "r624": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7"
  },
  "r625": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r626": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r627": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r628": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(4)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r629": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r630": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r631": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r632": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r633": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r634": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r635": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r636": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r637": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r638": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r639": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r640": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6"
  },
  "r641": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "912",
   "SubTopic": "330",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478411/912-330-50-1"
  },
  "r642": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "920",
   "SubTopic": "350",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478609/920-350-50-1"
  },
  "r643": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "920",
   "SubTopic": "350",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478609/920-350-50-1"
  },
  "r644": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "920",
   "SubTopic": "350",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478609/920-350-50-4"
  },
  "r645": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1"
  },
  "r646": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483154/926-20-50-5"
  },
  "r647": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "928",
   "SubTopic": "340",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478859/928-340-50-1"
  },
  "r648": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478934/932-220-50-1"
  },
  "r649": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18"
  },
  "r650": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18"
  },
  "r651": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18"
  },
  "r652": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-19"
  },
  "r653": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r654": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r655": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r656": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r657": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r658": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r659": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r660": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r661": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r662": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r663": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r664": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r665": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r666": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r667": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r668": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r669": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r670": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r671": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-6"
  },
  "r672": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-7"
  },
  "r673": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8"
  },
  "r674": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8"
  },
  "r675": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8"
  },
  "r676": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "280",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478657/932-280-50-1"
  },
  "r677": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478988/932-323-50-1"
  },
  "r678": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r679": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r680": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r681": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r682": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1"
  },
  "r683": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r684": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r685": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r686": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r687": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r688": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r689": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r690": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r691": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r692": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r693": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r694": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r695": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r696": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r697": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r698": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r699": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(7)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r700": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r701": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r702": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r703": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r704": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-9"
  },
  "r705": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r706": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r707": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r708": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r709": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r710": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.W.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1"
  },
  "r711": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "825",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477351/944-825-50-1B"
  },
  "r712": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r713": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r714": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r715": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r716": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r717": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r718": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11"
  },
  "r719": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-13"
  },
  "r720": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-2"
  },
  "r721": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-5"
  },
  "r722": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-6"
  },
  "r723": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r724": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-2"
  },
  "r725": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "27",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-27"
  },
  "r726": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r727": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r728": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r729": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r730": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r731": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r732": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r733": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r734": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-21"
  },
  "r735": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4"
  },
  "r736": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r737": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-2"
  },
  "r738": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r739": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r740": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r741": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r742": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r743": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r744": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r745": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r746": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r747": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r748": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r749": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r750": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r751": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r752": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r753": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r754": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r755": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r756": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r757": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r758": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(5)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r759": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r760": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r761": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r762": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r763": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r764": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r765": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r766": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r767": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r768": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r769": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r770": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3"
  },
  "r771": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7"
  },
  "r772": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478297/946-220-50-3"
  },
  "r773": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r774": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r775": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r776": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r777": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r778": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r779": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r780": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r781": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r782": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r783": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r784": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r785": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r786": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r787": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r788": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r789": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r790": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r791": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r792": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r793": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r794": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r795": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r796": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r797": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r798": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r799": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r800": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r801": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r802": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r803": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r804": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r805": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r806": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r807": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r808": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r809": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r810": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r811": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r812": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r813": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SX 210.12-13(Column A)(Footnote 3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5"
  },
  "r814": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SX 210.12-13(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5"
  },
  "r815": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SX 210.12-13(Column G)(Footnote 8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5"
  },
  "r816": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r817": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r818": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r819": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-1"
  },
  "r820": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r821": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r822": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r823": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r824": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-6"
  },
  "r825": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column A)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r826": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479196/954-310-45-1"
  },
  "r827": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478785/954-310-50-2"
  },
  "r828": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "440",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478522/954-440-50-1"
  },
  "r829": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "440",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478522/954-440-50-1"
  },
  "r830": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "720",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478258/954-720-50-4"
  },
  "r831": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r832": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r833": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r834": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r835": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column E)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r836": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r837": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r838": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r839": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r840": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r841": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1"
  },
  "r842": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1"
  },
  "r843": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/985-20/tableOfContent"
  },
  "r844": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2"
  },
  "r845": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r846": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(b)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H"
  },
  "r847": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r848": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r849": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r850": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "8",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-8"
  },
  "r851": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r852": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r853": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r854": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r855": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52"
  },
  "r856": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r857": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r858": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r859": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r860": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r861": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "48",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48"
  },
  "r862": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "49",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49"
  },
  "r863": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r864": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r865": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r866": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A"
  },
  "r867": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479294/326-20-55-12"
  },
  "r868": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479081/326-30-55-8"
  },
  "r869": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482640/350-30-55-40"
  },
  "r870": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r871": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69B"
  },
  "r872": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69C"
  },
  "r873": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69E"
  },
  "r874": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69F"
  },
  "r875": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r876": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r877": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r878": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r879": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r880": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17"
  },
  "r881": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8"
  },
  "r882": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r883": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "720",
   "SubTopic": "35",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483385/720-35-55-1"
  },
  "r884": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "231",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-231"
  },
  "r885": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "100",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100"
  },
  "r886": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "101",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-101"
  },
  "r887": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "102",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-102"
  },
  "r888": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "103",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103"
  },
  "r889": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r890": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r891": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r892": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r893": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r894": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r895": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482949/835-30-55-8"
  },
  "r896": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r897": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "53",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479589/842-20-55-53"
  },
  "r898": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10"
  },
  "r899": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481395/860-30-55-4"
  },
  "r900": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-17"
  },
  "r901": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-21"
  },
  "r902": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-29"
  },
  "r903": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-3"
  },
  "r904": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-2"
  },
  "r905": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-4"
  },
  "r906": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-5"
  },
  "r907": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-6"
  },
  "r908": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H"
  },
  "r909": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F"
  },
  "r910": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r911": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r912": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r913": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r914": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1"
  },
  "r915": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r916": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r917": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r918": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r919": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r920": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "405",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478790/946-405-45-2"
  },
  "r921": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10"
  },
  "r922": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11"
  },
  "r923": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12"
  },
  "r924": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12"
  },
  "r925": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r926": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r927": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r928": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r929": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "g"
  },
  "r930": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12, 13, 15d"
  },
  "r931": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r932": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r933": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r934": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "15",
   "Subsection": "d"
  },
  "r935": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r936": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r937": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r938": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16",
   "Subsection": "J",
   "Paragraph": "a"
  },
  "r939": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K"
  },
  "r940": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r941": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r942": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r943": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r944": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "2"
  },
  "r945": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "1"
  },
  "r946": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2"
  },
  "r947": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "i"
  },
  "r948": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1"
  },
  "r949": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r950": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r951": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r952": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r953": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r954": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r955": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r956": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r957": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "2"
  },
  "r958": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r959": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a"
  },
  "r960": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r961": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r962": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r963": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r964": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r965": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r966": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r967": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r968": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "b"
  },
  "r969": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 6-K",
   "Section": "General Instruction",
   "Subsection": "B"
  },
  "r970": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 8-K",
   "Section": "1.05"
  },
  "r971": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 8-K",
   "Section": "1.05",
   "Subsection": "Instruction",
   "Paragraph": "2"
  },
  "r972": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 8-K",
   "Section": "1.05",
   "Subsection": "a"
  },
  "r973": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a"
  },
  "r974": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r975": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r976": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r977": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r978": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r979": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r980": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r981": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r982": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "b"
  },
  "r983": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r984": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v"
  },
  "r985": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "1"
  },
  "r986": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r987": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r988": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iv"
  },
  "r989": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "vi"
  },
  "r990": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "3"
  },
  "r991": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "4"
  },
  "r992": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "i"
  },
  "r993": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "ii"
  },
  "r994": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iii"
  },
  "r995": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iv"
  },
  "r996": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6"
  },
  "r997": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6",
   "Subparagraph": "i"
  },
  "r998": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w"
  },
  "r999": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1"
  },
  "r1000": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r1001": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r1002": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r1003": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r1004": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r1005": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r1006": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r1007": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r1008": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "2"
  },
  "r1009": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "1"
  },
  "r1010": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2"
  },
  "r1011": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "A"
  },
  "r1012": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "C"
  },
  "r1013": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "D"
  },
  "r1014": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "E"
  },
  "r1015": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "F"
  },
  "r1016": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a"
  },
  "r1017": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "1"
  },
  "r1018": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "A"
  },
  "r1019": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "B"
  },
  "r1020": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "C"
  },
  "r1021": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r1022": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106"
  },
  "r1023": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r1024": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r1025": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r1026": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r1027": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "2"
  },
  "r1028": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "1"
  },
  "r1029": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2"
  },
  "r1030": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "i"
  },
  "r1031": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r1032": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-X",
   "Number": "210",
   "Section": "2",
   "Subsection": "2"
  },
  "r1033": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r1034": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  },
  "r1035": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  },
  "r1036": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 6.B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-5"
  },
  "r1037": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-3"
  },
  "r1038": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-10"
  },
  "r1039": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-3"
  },
  "r1040": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18"
  },
  "r1041": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "SubTopic": "825",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477351/944-825-50-1B"
  },
  "r1042": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "SubTopic": "20",
   "Topic": "842",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r1043": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "a",
   "Publisher": "SEC"
  },
  "r1044": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(1)",
   "Publisher": "SEC"
  },
  "r1045": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(2)",
   "Publisher": "SEC"
  },
  "r1046": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(3)",
   "Publisher": "SEC"
  },
  "r1047": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(i)",
   "Publisher": "SEC"
  },
  "r1048": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(ii)",
   "Publisher": "SEC"
  },
  "r1049": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(iii)",
   "Publisher": "SEC"
  },
  "r1050": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r1051": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r1052": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r1053": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r1054": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r1055": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(3)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r1056": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r1057": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r1058": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r1059": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r1060": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r1061": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2"
  },
  "r1062": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r1063": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(f))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r1064": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r1065": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r1066": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r1067": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r1068": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r1069": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r1070": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4"
  },
  "r1071": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r1072": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-3"
  },
  "r1073": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "55",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-55"
  },
  "r1074": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r1075": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r1076": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r1077": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r1078": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r1079": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r1080": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r1081": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r1082": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-2"
  },
  "r1083": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-2"
  },
  "r1084": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-2"
  },
  "r1085": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481569/310-20-50-1"
  },
  "r1086": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-9"
  },
  "r1087": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r1088": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r1089": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r1090": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r1091": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479344/326-20-45-1"
  },
  "r1092": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13"
  },
  "r1093": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480341/340-10-S99-1"
  },
  "r1094": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/350-30/tableOfContent"
  },
  "r1095": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-1"
  },
  "r1096": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r1097": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r1098": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r1099": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r1100": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r1101": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r1102": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r1103": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r1104": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r1105": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r1106": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/405-30/tableOfContent"
  },
  "r1107": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r1108": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r1109": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r1110": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10"
  },
  "r1111": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/450/tableOfContent"
  },
  "r1112": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-1"
  },
  "r1113": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4"
  },
  "r1114": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r1115": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r1116": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r1117": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r1118": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r1119": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r1120": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r1121": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r1122": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5"
  },
  "r1123": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1124": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1125": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1126": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1127": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1128": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1129": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1130": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1131": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1132": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1133": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1134": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1135": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1136": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1137": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1138": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1139": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1140": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1141": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1142": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1143": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1144": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1145": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1146": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1147": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1148": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1149": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "720",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483384/720-30-45-1"
  },
  "r1150": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r1151": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r1152": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15"
  },
  "r1153": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15"
  },
  "r1154": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r1155": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-3"
  },
  "r1156": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-6"
  },
  "r1157": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r1158": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r1159": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r1160": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A"
  },
  "r1161": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r1162": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "54B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B"
  },
  "r1163": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1164": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1165": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1166": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1167": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1168": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
  },
  "r1169": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r1170": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r1171": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2"
  },
  "r1172": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-3"
  },
  "r1173": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1"
  },
  "r1174": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-4"
  },
  "r1175": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r1176": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6"
  },
  "r1177": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-2"
  },
  "r1178": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r1179": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r1180": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r1181": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r1182": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r1183": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r1184": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r1185": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r1186": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r1187": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "912",
   "SubTopic": "730",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1"
  },
  "r1188": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(15)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r1189": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(16)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r1190": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r1191": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r1192": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r1193": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r1194": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479432/944-30-50-2B"
  },
  "r1195": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3"
  },
  "r1196": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r1197": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r1198": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4D"
  },
  "r1199": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4G",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4G"
  },
  "r1200": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1201": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1202": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1203": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1204": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1205": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1206": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1207": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1208": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1209": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1210": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1211": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1212": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1213": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1214": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1215": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1216": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1217": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1218": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1219": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1220": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1221": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r1222": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r1223": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r1224": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r1225": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r1226": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r1227": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r1228": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>123
<FILENAME>0001493152-25-010984-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001493152-25-010984-xbrl.zip
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M? .?:=9KW<XA;(8\*R]&P7/:"O)-\((V]FSIMCXV)@MC5;B=O6?VW=X>Z_%
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MIS&@^)K[[$VBPF_!(:R1 7D=H<Y=1?/+W4*P<]7$P/#LWYSJK(R"^HPKU;Y
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M)DPRHZ4YJ/_06JO/S-$"8DN95/.V(LJ"N-@GAG%A'^3VZHMIYEPOS+G6,L2
MMS:R_UV1MVOB/7O>\I[=FO?L><M[MI:#V?*>X;TVGO<LW##>LSOI%MORI>V
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M\%SJ=Z&J]A4U<EHBW:<D60/&=OUX^L%[91%@_FR7K0YR4>#:V5(F&*843>)
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M!5,%5#;3X^$VD4J]J'J>1?%2V(@"2AX3+EE'BO,BBFT(;KMXQ728(0MOBYO
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M&)C+X5<,@^QV!L2446*IXYAI-Q2[O.A\SKFZW!8 =U. ?!A6NWA5Q_&P%@$
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M]W:/M=U6&SK6YULBW46J.\8##/>YRCYG3_N!VF$=8) 2DTU(D1C"Z_O!0C:
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M/+M&8],(R\+ 0%:/(ZYI*4B; @7##^,)C!WA9JIPM@@=Q$&M%(G+1_P(3>S
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M.<?4;Y+@WJKPL(P3VX^.+$RT8\.1&S=U<D->S$:CN1!#4#C(K*)!7SI0A/^
M29?$#K0[S6K6(?;BB+.\PM7Z(V(=-=),)J>M3&C24B*;Z-WX<\%71)G8O<(7
M7VFR>ZA8@KS3L&&W)7 'F\JMK2@MIIF@P!66)3 =C17_HL3H*EX![D2FF?X9
MF?<*;HM'16R.*OA.4\*/.'"TKG3P49L.OGTZ^&CWT\$;>31W.INR$8F3OVU@
MP\&3E'IIK+-OX&[JH#5W8F5V$3!"0'P:CN-7;5O(:G*VXV5L+"]Z#>8VX0@?
M,D=B=_8E1B+6MT^RB?X_>HS$:+KXW@=C9V<-F%9*WK>4_'4#I>1QB*6\V&B$
MFS6MDD^FB LY6Q)OVD5)"VMDS\N;.9-YIP4NA>HHA">T"5&FL=5'KC%\Z?:-
M#KR2B$49$ZG'^IP&)]*<P@9-O'9;%7O3 I*46K\LCJ_XXT*> V)P8"X$_**
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M3,EMI<X/$#C1RMUQ=/G5U]?'Y^?';W__X_VG\V[G^-63KZ_O*-:\Z P\-.?
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MJEY@%/<.KW@5&6"+E:B+\J"4W:*6^WH=DQ[P\(PWJ/V5JKAY_0102P,$%
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MK YT%6<">DPI[DD'>B''@$335)I_0Q@' ?=0%0LDR0A:*V,!#*TMI0Y7,*G
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MJ"W.T_$\F0K-Q=QF5N[T_0X%^L^D4'8&/IT7-M462(5S:=8KJQW29K5Y,9[
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M$+UH^U>;O>MAO7=] (S] <:-;C;N:E4RGN58H31AX( A^U;_27^#VE$4DO6
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MGUY%']%_M /\1--45JK9]IB,ZPWXDD#V"\YS3*_<^W?PZ57]_P)02P,$%
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MP9EEOM<ZS/^@7>E#]EY[-!\_:)=G].%'K7'\XVOGWXVS7]OM&_@/$@;_>?/
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M9E''4C\WEFYO/NOC**[T(4ME-2PZ\/4@(5RHY2'AF%HL-142BHX$N5#+3UG
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M;C[7BS^NG)2X*R6_*%$@V0E9!+ACR'T?^(E9P"6N8Z//SQIK[)ZY8^T2E7H
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M6JC@7/-@>N%2],VK-U=^GLPO'IDG5>=2YZA,ZARS\'>>PE]XZZ]TYZFX,>-
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M(MO789%M=$><.N[(P19JVJ]87!O];J5TM1VJPX(2Y>6I.4 H/]HYB:%]FBA
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MKLWB40$WH=;$$(\QA0<F#(O.4M /A*THJR4J>X[O@)O@8LQEK$AX"CL<5-=
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M+/FA?L'IG+7(D8RT@$@,7MY<QZ(/?;T!Y8NB,0O*HCLD$<U]2J?LZAXJG:/
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MQSE1.1O#)>$@4!1H9A;]7RJ/6N1Q)[.F4SFIS\KB?A85<U*1N LF*(F!KO/
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M[K_A&3P?YECD8LY8X81"<'M*POSH'W=[_C4<%?TL&)?='LB-&W0*4:Q;.8>
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MOF0AK%47N_Y;5+._A/,%MND*30(BZD/L!<%1O7@^IYY9@I+<N:^S^9W*:(Q
MX1WC+U!AC8MQ-D=HE;\W#[_ GQ-!E24HA0*]P6RCL(LB+@BF!;.\R:HD8CSM
M)J(]4L"DGSPFW+-9%4RT0'0HZ(W\*79(^S,8T<POUG4UNO[E!E4:UYMS"6!V
MHV5='^=@ .R/]%X44J]%OPD(:1^]-*&EK7=*;$1&>.;,GXEDP5XE20ZQ'OT&
M=?%<U!8S'&/3-?DJ ]Y*[.[.ZZ?U4D^JN;)4B%0RY1I>AV \L7D&UFY,BXYS
M172^39PLB:!FIWL8QBF,=DU5!Y3J;U1\:ZAJ[E4I6')^A=9,.8/5P\0"7,L<
MG?>XWMA &GF+4U_E!Q'V7UN21(0Y(Y5UC@ ,.8VQU[:BW/04U$$:J?A''J\.
M-XND?GS\>4USH1_EER,Q!@JI[;AB3#;/A,TTJM<B'+:L0&MCGJ68=B'[$):"
M48KZT!:>,71@ZN>(0J_0_@@H:T%-1"\4HXM :(>JVZ;_>XJ'J$K)XQ5H_I9^
M4.QLCZ><2FNH8 U.HLG.GF5]Y&!O(/:R(3'8QO6+.=FV>,Z!H;CW^E>L76E>
MKXD,-3P%GO(4[*3(WN';Z"+U0NTOQS)%@7_4 _D(G&<U>\4@(2S"</A*.W_0
M+R %(;/2P5'W@)_I#[M'#,M[Y9_L=_=_ (D]%^D+OGV(IVYP/.,&XBHGY*6@
MK('B1K=&535L9*=*7<-&,B"Z7T"F%2 0K#S[*([(LZ7XUW+EA:5MLD><>E%4
MU'$7Q M^SY_$Y'X@8C+9E-8_/+9.RJVD["2C[/ 9."T\$)P)7;$JJR6>(@-0
MK:' [Q\C@UL,0(#V_7[WAX Z_FYRV@&C$7H _5V<P4F9I""*@?? P%R*XF6:
M:1;'")1T4$69O\PJ'_U4] /I38ADS[*%3_TT@;]OE N+SI5JW5S4[C82]POF
M>:-[W"^+/E&#]UV8PP.<JJ?:C770R(-[K@#TY^?IP(!;*7H_80#7B[ [>%%-
MISH.5\_[W&]T6=^(EC(!?K93+&M+:QBZ7[AEG+)E$'@8M '[FQ.(4(S^EJ41
MAO+M9O,K=NM.[LP.,QTU>"1ST8*@.H]::Z<&I]K#P'TMH+DI,H\Z/=59E48/
MR!G2_2G&1V460-(H$TCA7$P*41T9I)2ZT1))%=[%/[6H>!&0JXJ HW;Y58J[
M8DB3J5@-M5\P"F&$ID\\_FR@FD8[Q37TT<>14T*^3+O>B[NB2]X03SM;EBC(
MLE2FH=-[11R)%\;)AZX!JI9J+5F(25(,4GA;Y>@KHLE0/3(UA7H=AEH,F"+3
MH:=7<P-T)[.@.VM\#^I+6-Q ?T %N ,-RZ5(#<$0DAA^7OH$< 6VU-_VD$#X
MVGR]IT_[PO!K59K$GW%-4-?F2#""$M#JI1STD4AARTM:ZZ ^ZSEIY2.$L('E
M8#XC7_$H&4UZMB9+!GQ$-@$O[!H%5*D!&&24<OD%G.ZMNX]0YVP^IW(9HD:
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MN7C>;>( ]3C0QV[7Y292TP$6*%!(*)Z@3&C@?!&99[!R#!@V\*](3,(J(0-
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ML=1VDMH>"7RI2[M()P.6N-0(&A2AS3(&5*30;GH//VEM578S";%H%6CH4UE
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M-H$+R<-8,&@!63K%OU(')?T$,=,UMD$"[@59C>VEJH*[+G[]T[[]:1;Z<NV
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M-IVX\!A*+4@C,^%65?W4PFP6@C<RB7])@I4O9X*5#TBP\N5,L#(3K'S,+!Q
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MP7=%32X.OZ_7?*_N4T8.V]FS#J>2]YU]@DMF%!.=/<"Y%L\MG4O._N%(C!*
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M'V0,T:V"9>A;P/"T@+&0Z[="Q*!['SU+I_!UEE.ZZYV5[?BM\23#%#@@U0)
M%D@T\@3RGL.58?(Y[/K^R86EHV\;V@QZ)44)"_=*3,WOWZ@D##6?]UY<)-DN
M,5VT8BJW%6$4T1 IN$J%Q#=P3W2M9A^11NF<T?:C=9QT[]" .%T8<%16,V71
M13X<L!#G]3(GO YLRA'''0C*S(LYM-AE#A5]JW.<CZ1U)UF] %.@A3+..9NZ
MST3FF^4M[=9R^+5(\$C"=VVL>YZ3QD,HZ'&D\J?[/VJ ?-_$62_;R$L86NCT
M7(7Z[^+YTZ=?_/[9LQ>__^8E7(65EO#V98=-)Y!W[0^%MA6.IS*YUN>_?_XE
M+D43.]2;HF1:,UI\JY(G3PA?I*N^<AD"'@]!T9F*+W_Z;G(I5&DB[/07''%@
M'U0^*)0%8P\4C;SH]']7H"2FIR$Z@F3B;5JUZM8&?V&=DS/)9[B\ :X!^DD*
M3MVH;H>TOAU%?80[077NZA2<PGB4*"<Z?KS[3#<J?<!H^EMT;_R5_,%N[4&1
ML*>*O+<^)DP:WRD[N9/W;W58?D4,2XH%U=LXHM0(85>^0>%)>_R5BI@ 3FQ4
M#I=5P0#'9N.X1%W\:OP[\U[[@>GACMG8K+6C:(PY R#XR;;<<#D?I+6Z_6V&
MEKT5,=*I_6,**C:J.F0W9??D__Z_GC]_\:?%$_KOLV8F*(ZX8#-FJ)0L!G.<
M8#D5S.Y+'E;?PH4(Y%K.TY_(DLD.Q5&W 80U;5%W&W4W$'3R.+"[K(/6V<3P
MF)>D%\+$%&6RA]MY]US;AI.I:O+KH>YVJ/^0=]^I<K)N&;IP QS/#YHF%11A
MHXI<LZ%#A;DL\?_J@=X$5SD^S7TETH<MX7>9'E<)@IV#\;L*P%>+EPKQ"*4S
M/@<$A1'A :.\@C>;*(-%4[MMB_V\MUSBPWU?9]_1"?/\\YP\C6=_R!<!T\P?
M_/X/+S[WL"U:%^."8OAZON!:AX%'F?4G""@>G&T+VH_0W8VA\W72]T/'_51#
M\#9R&SW7T/N 7+/IX#_F@64GQ.++D+K-^?BUM$KME(.2MPY=1*/KRCW]L-3?
MXM1%AOSUR5[$KFKK@@.*SHB*^PH *M%N!(H9:5]T=01$3_;1TZP@I_/&=^/"
M:7;72Y]* Y9=.KH.[ZWL@*6BP!.1?Q[M@CVH0G$'>;O"ZM]A9])DN+7>9!O:
M9MQMT[XE?Z=MM,!/0Y[D265ZK&Y@%O8=!?CB'S*HXP1]R)YSG)HLZ[JY*>;V
MC M]N+N-=G%;P 4HMR4[(XFM+MT*H6D,U]R!.)_+1HL"B@3JG:O]@XL?H"P*
M8BO:,9\_E7(2K%N0L%(<XGO20QLR-6T-^:%HZ3#UB,P8.AQ2D2#\#*X*/1G&
MM&#H"#D<0DW/>_D7V,N?/[ORCTY;S&:@)\VFTGP(8+L!&=#[ &6_:$]&="_Y
M(1U;AK%Q6*/13A4J8XJID.RT1WBEPT7ZD.><A0':B)<_>OC/KQ;?<S([VIEE
M1[Z-M_&,:V*G6]BOQ#;W*\,U9KZY1V%MF_GF?@6:#L2-6^"Y1.H,[@XR4YPG
MT0J4>0;I=B(N:2DLE6D!'YD[?%4 !WX_^DU(OCXJLNO9C.SZ@,BN9S.R:T9V
MS>?U;^;4F\_K?_YY_8VE!'B$[AV\]+*7Y&UG!8Y)B#R:,^COY5+I0WQSAY!&
M/QD.%C(IF#Z_ ]VB+H%PS$S$1C,YUV_>DB[)ZE^A:_;&>1<5BKRN6&I[S6E.
M;M1&@/P4@N4=]V5ZP,43@Z082L7 %IQM(V]BP0B>0/Y5#\CPS;;]F[>72[+M
MURK-2OMOP<YQJXA/P$49)"V%N:@9_,[J(<,2I0S.%6UN.7<[$._<(/G-.[I)
MOX7V/ O2>"R3#"S*V3$+7U^$65W4$CB7A# 7)6UAM0Y[%">D;70$.$&.E"O/
MM'I\HVZ2 5[M'$76RZ,TL/:^K]&2%F<=FYE%[Z.H<11XVWMIJJ57#.(4-CAL
MJ2&['A4SQCOB-ZNF;O:TQUZWKI"=\9OK(!)(FVW7>RSG\S^<5B,/U=!E?VG:
MVX(<[?\JW6K7TQ;=NU(@\*\H6*7_O5I\WX_XV8RZXC7M[G]W+;Z5B[4G9>3O
MAAXHB!_=JMG6;/:+:T@1!PP(-V9B?-G>2_M.^E*%$L($>IF14/C'91\?O?%_
M\].3G_Z\>--RL8@,X67CI0B#C;!-OWE)-KTJ]DYL*D@*_B=%F$#U/;.*&=J$
MZ=N+=4/#B9&4O)!:MU&-[A$72N;YBPHA^F ^2++"KUKWKNSSR;I:7) T8IT3
MA(( >_ZLE 4J<;BH(+FKOQ7#+MN6MH)U=L^-_ 51$PSP*[IN\Q9D!F]V(Z[+
M+;V'R?IZN!(//JW@9=PC9$=.@G&B8XP<N+7P@AE:@99D]$B!/XFNCD-PM6N:
M3K6&54\WR&)7-,-+SU# )A?X/>^8BFVC_&BW14M/_O(;/AI1_9MZ(B8IW0J]
MS>BM)(V*W-ENG 3A-]F8W<#Z]Z2-,;JBE#+_<ZC=XK.G;):?72V^G7@!Z;'.
M,R4%#:Y1<Q>,E)YS^T+$MG$=>.0P:S_]&2M$G]^/S=/Q,$:.-5P+,!'@V_[+
M=\P W7+RL=70H]EI0O./MIXD"]%"!U%T#JM<R!>D(4(P@R$JT"FED["(D+8Q
M]B- V"+12SU$DD)0?B)BIE!;QN<R@0>?:$H39#1,!CD./PCM&WRF-IL-M#NK
MSD1C&=Z.WV0V7&-I_00=)WR$&@Y0M=0^G38.#WFO&MFZ$G8O8!;0)X,9(,<!
MRU)H^D:'-.\FBG+4<MI&@1.&<URU)0NVZIMUAJ)0LC?L*5\SA0<?RW60_5;$
M8<160K^'2"H48"M&YW=-A:61CV3*L2/07+?TDIP3&ZQH# !QW>!'0VMHUNCY
MRHTL"1&;]3[#7D;+;70R!S5:N.C0V:C&K/?@SW:RJ?'^I6&$;;UXU;+/8^N1
M'TS@6":;VG0N+/G9_[C AQ/^U__P"8SLV[88I(GA>HFE]5_%;3=SO5[NPRG#
MY0A2?:K976@VE77(W9J[-[C&P-C.*,,5N2R,^.0=VG>*F*YU!,>7#2*++E'6
M:WK0]FAT@8(<E99! :+A6SA=&>7/6W$^,2KN$7A;KMXNB]5;^@*=0$X;@_,4
MG>[)&.-A;+RI%VSJ&,:\B5W@PR&(^NGJ]94WD6L8QI_5,-CHAYYSLSORL+E-
M?0+LR]1AW /KVRJ4]1>=\/2=2NP(YR"C$.'W.-&".A1'_&\&7,BJ[/DS-(*4
M-]KB*YZ?^)D(1_9#K<[?^?9>4&;JQRO];VZSQO(135J.(,B;J-E+.)##L&,9
M]SRK1,\=3O':!;VJEA;%UNB4N<.+6R%J+Y.NUP#WG./_X>^M95_ T+<-''%5
M/3A"/9=\#^GP5H&!<K\<VHZABFCHN-TUE0T6'3BYI  UN ,AG_Q7N5YXW]#>
M8YI8E^8,=F:8Y<0<NF@RS9OS 2$+#U?'C%G;*.S4UCDC**4GXM?OVVYBV?A5
MT>URA+'(,;7TFCIV]]3+W0!-RU.(M[%^<FCQ^)@.\:=U0M P%(PM,V-C].FD
ME?JACX;LNQKE)6H4:FU\=S7(F&,'\FIRVM?:ON<Z\GF71N5F+S[Z.@8,)@3T
M 6QWVNG$"++HK)#N+)P&PL(G305U(O:,6 6TJLNF94>Y!Z*60A1NGE4^V"@:
MX347"0O(;(TNGUR3FQC:XK9>U#0[S6VE1&D19S-(!]T[-/V K2*$01E>*TVR
MA5J%..+2CFX<%4.MHTZB((I8I!D-/!TG.X?/O%@L(;U7*TX#8D>IW'IK!"&9
M-KGQ2K(6.(9S\^%\4S9,8U@R1%O6HUT1\U?V/#+]'C-2ON$4^5]!!'&T]V2-
M43*2^/#DLR_/)*@);0X1:R3OG-(CRER8M;0^TQIQ$LEX^Y0E$+:$SN\)$DUC
M%Z%ET-*2H>T =(W'IHTCUZ@[J^3&A]965+6AWQQ]Y6T^K"_PX7!8V_Z>>FQA
MYV7&#1:)^9:_\5+(7JY7W&(CMOC+#W'E@>!S$F=K,73:C+]T]D?FT);Q0=UY
MA1Y+)"R;5MQ&"J:QJ6!<<O9*-R<[JI%:"MF[[%[VQ&%'RL.(LCWO.G0RVID]
M&A3W$0AGQ]J&I6I#O-"PMOGVR#FTI:C#V/>FAJR@BXE184;"5.UU.]1+A1OA
M^C=-N<Y%U:>0^S!' +OHBX9VD&UA&FU8M?2VG&_+3]RU<'NPE?((,SVA.SOE
MQ6WZVP!J;"9I05+/CGO.Z_+EQ=5"#?$87F5RT^1FRK<R*.'.E-6!Z\9H%I:,
M1_$$9=>TCEK<]=^UW1UO'GGSOPTEG21[.T:PZ:%]Y(;W<'*VR!4<>'?3KKV]
M)XJ*1_==T[I&DO&9O+:P0J8V6>3JV;>#N4>'@5W[ 2XR*F5DZH/P?$_83Q:9
MO/!%^*J:77EZX8[:DR-B>=^7[.J"3]AH5Y#0L*B+JMGBZ_(B_?YQNCL4YJUP
M_[.,S Q7+\;GU*TX,WH7X?308Y0E/2:.J,#L0#^E15O<X:8^RLGT&.?2W?CZ
MYS.^_@/BZY_/^/H97_^OXQQ*4IJ.#0H!&/+\0]/V!C+E!/6*XW'[Z%J8[I]]
M^>47JE6QCB%&_G@RZ;J45V3D5F;B5A;&BW,N!40A)8)4RZ_0 0(Q#''<Y&\@
M@UM VW'O1#S$TH['^-RPTHV>'W$X9([#R8%TU[ H//_[WXU?KNOI1I%G<-=]
MH^S64GG9X !F?MH242]AE8NNAY18W2E9X[G1X8 GPQ$]=7$9=:2<Y\)_,_K2
M>[-(9="?,W-'F;1/_J:7N\M+#UXK<X34M6AK!G+!M:M*NN]1JH+>EX>3<SI5
M%":?.%]7B]<IJ\G]KM9O,&?PD>XI_S(;Y@^[8X<Z/-KPE5LHIO0),A8&V!QE
M"3>+=3L@B/;PS64)D0SEN_0Y1H;O6\>*I(QTR61EA%R^,\_+S "[LEJWKO8J
M$Z<[?MB5Z'-OY"$5J+2C+*<J/$/DF--'+[][G2<HBH@VS1,O^73S!/L21]SX
MLLUIM_C$N-JB_/&Z6?6\$7-C0B=RLR"4[%O^5W9HUF4A_Q!L!&WB#=?&Z&>?
M*D#(@;:7]K5=TQW*WN,H(KCCB*HU_>.6HM)#E/U/":N@;C&:H87,$*0FZ'*[
M\J I/6SLND\"N8@Q[T!S2?%K- ^!=KG<PR2PR8CY*J22ML.O'"V#6@A( /UY
M+CC)+&0%%"AA$YFP89U]*YX32R-GCR-C!@D$;N&\/P?*S[,01?NG J*Y!.X%
M;[!&JE(+F Q(Q0OVY,_R5[9%6M;\RA4V!$HM_F-1T]SMG!J$_JN3M03!-W^O
M+ (=^5_OR_4M$T5^I%O61[T?_X^=ILSH/55ACO.<]Y2TI<X4Y4CU IJ-.@QU
MV>UX"Z 5ZATTMBG.P72%:7!'-L\*W=&7D#?K@1V-]+AY;4'H)[1TT9Y;#:P/
MR$[D'16ZQ2?A9K;Y\_UL__\T1]%E2[N4\TPQJZ8]-*WDQWJWY:I%X?'1>4)#
M-YWY;4NZ(CM_!JO3N8"8'^VV(@ > 3B;FK6':*>,'3@_9TKE[N<D8G1&2; D
MSTW2N"*.1_8CF-<&.=KAT-06&]PX <C9SDT10M4<G23.>%<,P_A(5\5'O>0%
M0O42D4NQ=;RE_V@%+UC(C)ZZW(>;1D\U0QNI!*\J<C[<.NK=4_!2YY@6V3'@
M_MX*J&P.Y49B8*X_85,M1!PFHVT'7XX$)52<KJPCA3&#VY(?CEK1U>+[H>^
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M>1=\!";="WG_I3%:5AGM4;B>SVX $D;H'"I,.3DAR51"YN;\=48[&V(![9.
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M^5>,1/&R1L)$@6+OR882A_MJ6Y+TZD3O,,W$H%[.98FCET(^AD*%@.1*:X4
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MN[*33MKXAN'Z$F$8Q8\0]R0.*<.\_,FE(>I5]FHSM1UIW.W7YMB/4[JG9<0
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MU..V@AB9K-1/$RGTD<;4MO RJ[%4KQP1P9YS;\SY>%OWDI4_I/3#Z-E:"[B
M>2K8%T>TB\@H:&6)RM]-T99.B!_D9.Q"$#DC6&<$ZXQ@?23\$;>."OIG8_M$
MB8['J $820@'(=D @IAAGS.Z[?ZQAGXFI&;4R$+!>**1#J96&+VA"!;/!O?8
MH[H<@V/)39]K1'PUF\UL-O>.E7'="DPG=[5N@@K?I,;>;%2S43U@+ZII"Q*6
M/.L-XH(22S"3VU7:R3B;TVQ.#^DUH^@^L:8.]/#&P#W1-#W;U6Q7]X[5(]RA
M"(M!:E6 4>Y&V"3XY=F>9GNZ=ZP<M?'H KJ<-J>B[@M 5[!555P_XG1"T.+>
MNW[7K+NY<VZVLP>-M:Q]G,=C])TX0ND341L'#,MF =21Y[+[=;K:YH+'/1UM
M=U<ZXF(7I'$ -NIB7-!I<0.4/ /W64DZ<U0BBV!,ODI6-WT6H9[NJI,)I"^6
M7+K5ICFRQW8NT#Y:@?8KQ_T.F?HLW.2F"J9TVD1,[:&[0NA:DIZ6F!FQ"^15
M;]TQ("1S02149&Z*7:$3KNR:MK-6<[1\9(.*A@7R*8#Z/.U\.I2 J8PTKU)<
M@\JMX ^GK84Q%&[\TRS5SDJ)$!5_4&]G;KK''_S/+HMD'$Q'JS= U9[U@WV7
ME'OG5H/X4:[8BSF;1-/M#B("'C#*?4X>&UON#X5*8NHV&C<*-\N_RL':764>
M)L6P%FXAX?Y9VB1E.:C><^L4G,0KAIO3]6J\<FR@7%ZVWJB](F8J5RB^,[YD
MS]_L:;Y8M"XFG061\?.G?\*5I=N2/WCV)QJ705^;I(+N5^Z)2F28(7RU%I*5
M)NP5!N3P5\CV]&YZS*!3Z=J)&?1'0S25%VJ1%[V<@$;UU4LR"8 11*:O%'T&
M[=0U))RV\&JG^09M.NR! /)6=\YS!S*)\H[,MA0RY3%DN>^A>JPP+FR[6;AK
MQVA].!7Y2*=%8-,,&O-#BU6D[2#1?:&3KN'I>^=Z8[EP0R8(Y)#N*RS9#+*A
ML"Q>U=J:?W=797R4Y5[S<9GJRTC/"__PMFG?LNA)+CHUJZ$"J6.F$UX #"*G
M[AD^SBG&OGS1%97B"U.W7X'SJYV@7JP+@U=]Q\#"\B805)J\H0PE4E>OR<""
M<7C09TJI$/'"<%=/#]Z )?:Z4GB?HBZ0Z'7^[$2/1$UJ$9EGEIHG(&$WY7I
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MSNPD]SGF.UZF]!$*K:0#ZX.O5Z76FBWI $47/=X;&RVK58%U\<1XQ[1^Q<D
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MEKX/+>,]+<T38-%0!%?VN:/)?G6T\H!\EFP__5HF6JXLG_RU6<Y+;5YJ]Y]
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MJ=^OQV$?/8MF$#W"L6P52#N*;2%\2R4R<#J-$GF[C9-WM37>9E"XR*[?GG9
M$JO:"2*@GVW.W,3VZHCXRGS51=V+>X%8]#S7J#)UA5WSJ:JWKG8\7S6P!G(M
MB"*T&2)KF_@=,C+*>!!@6 =J7J%@#7N=\A8HLK9%P3=1/ZH^-V9*EO]&!CP7
M$,UMI9*M+O(Z$I\14R0,J@A =")V91-\:#7"3GX!R8EO!FU9O65^N6@%<6-C
MOS+CC,XE^\*?47\=W>P2<DT7-=0" VOJ8SJ&^P/;ALUV8B).RO%;< UVKRVO
M,P=WL[5O(*8EWP%^W"MB?-^&7N%BG5FD3J"?($X'M9X#?RY7*<SZ4<?=IBE&
MQR8E#A@324@"C\NAO,KK2M$$VQL)>!CVIF766!^WJ<VW<;@[\99KE2HU'RVQ
M6\;S;C2RO''UPQ,!"4"F#Z9$,8'V$(8([R-85LOZ$Z3@$Z;'H;0M'1610%>3
M6.D^4#16-8S]6Z2_I?4,SY@N4"^A%AXK1:>-.TY;LZ?H?G2=-JR<0;(,^1\$
M=\Y5Y3N8+!<Q$>W&^Y7,%MXK+[O,54URZ_9-##-B!S=.K<\$1/$EZOAN=.WO
M615F/^?&3^$;9ALS'N^<<3NGD?*]>O?JH2!KUV(>H 5[E[KW2-QW@D)1+BD0
M%T#1!@.:8V%.Z4SF=]05MUT:ZLBM5RB:G#)\2M+1;*@-2O*'G"XVJFJDI!,8
MK=>"(W)U T:&$&9:V7:Z?5D,0+NCU-R:U0'0XHJ:-QC-((BS,(R//I4--STF
MEJ-%BFB@N>EO;*2LTM8N,BEZP.H+]!7JF,IPE8$'&C;%I0L"0O_ P>)#("W7
MD;L@T6\IVDH-N+SJ>BI+W*R)]ZI=21-I^?RJ2!E*[YGO#;D("LX8 '@DD6!!
M" UHB^9)X_:"H$'H<P@YPYLHQ.@L*Z0F;*,.#K;8DGP.MXP9N-L?_$\<?X\\
M.&4YAQV"S:"2;]D>X!+NV $UO%G%HA'*B8N6F,*!(N,I_X3!BXF$Z#WD5V0K
M#G+H6* 0@=TB.>(DPO"C93\), \-76H$!QKI#>:(*)!Y2AP\D+(!S$6M929<
M'VYV1T0Y+B:ML' H9Q70V+&)&L_QO)F28H.!PMU1,SVK;D+==MD^C*1,1YZ"
MQGYI#3\;2L:\;E&Y0X@W%F%+Y\;-YJ)G2LH!S;>Y;0O05])-J7A7TDZVZE<2
M;$PWX]!P/N_(?P[\^HK.QMV8K@<CINL38KH>C)BN$=,U8KIV%.L8MR72?B:P
M*=.F88O/Y0G(6Y$HA#$$JEFCY%46^S*4XK15"0A:7VE$G.T&B;/DM5@/S4%T
M@;"P!']MPFU&O=@YUY%3,4B39>\D:*#L.O9[P@S,KHQM2VQ--7[+0Y WI-J*
M-1<LFE.6G#C/(BY 65Q?;C5=$!R8&S5;482Q5)JA/C\R5P/@M%V;0[CQ>=+Y
M,+^LJVXEA383XUB6VM!>N6#UT9%]-);%JYDPUU,TBTQQF@_7D5OGV)[WL"V6
M*PVU&($B'(.Y7UMH*09L#D<E#40/H2<.XI_R=A&A?%<"2NRPUC7N'8I&G3?O
M-AXOH\I!'F\<D'J2MJ[.'7:>7P%%%1)H]T$P(1A_,V6*4XYM&FT_<-0:#=TJ
MJ<H4R9_Z('Z2L7>D?ADG2 5?8]:.TBDD#;1(Y$+AD;8= GV'DB\\$.4>QD(D
MFPNT$T0D1U<LS99::.'+/.>B=WX?D>+@T65U'5OFEKFCP,:[=V5ZG=:9"R[!
MF*X]TT_F1.<!UX5@3*[_X/G_BBRF_1G\&RR\5$P3VFJ2.4Y'?]T8VX:XD] <
M41'89DF&5]I%80@CNK-\1DX6+[8E52Z\I8^/&\H7.W)Y7X7FI>=?[WJ"T5/7
MLKLYR2D-Q><!F;/LL&#?:TU<E Y^O1'-R,LI2A^I5$V@>>_I9V9KX"HSE(PV
M@PP:K06TEQUY+*)\)ADF.J#_FBXBIX5H3?PN@OQ8+KWG(!XW[+*.F0S_&DR;
MJT56$.?FE9$@UDV2OB7K3SBX"9K(Q$O*K$VO3AP8UYG+2ZW(H2)Z*.A?5N2(
M<-,?35:P,K%M%/$Z +D!A[2T-7,?)BTHER1/5P88:0&:/42%;\V65::MY]E3
MN$8K$!%G(L8&[L-Z5>6S8'E17:5W\PD+KM*\X(F2'H-U!#/ ^/4-:/BR5>L(
MW!.?T;S'>!",Q%6QZ5#2<MT;S@L*[H8(/V_.(M]!-E]O;H3!UQPL/+-,82ZZ
M;-OC-&TWLYQC>(VK7.J8^-QH(I]09I/9#)ET+MW5Y'P0H;BS)4+A4^YA)KTP
M!Z)_M/[T(UVTB)(D/,<J8A*=2SR2^:[4!3&2RYD9EEH1V4UY]>]DP^$VS!&0
M)\4"R5,EZF.F5^DZ"'0*7RK=D:27SG:4F<ZH%LV:GR&FP961V2&0PAC)FVXO
MV>LON:?%18&#]OC2ELU?9YX[88./'Q![=!"4:;5:2SR2$X"S# =,DT0^<W./
MDY9&X0,-L"7RQNL1.^-;H6U+G6F?*]QQCB"\O(RE!)"C.;#AJVOP52WR523J
M:O!]N*[;;/LY]7C)A88)8VVP>2W18'G%P44SA2BH77IF"$BGE8DXX2!G0<V^
M_*9C@9=(JE?5,HX.L\793IYDP7E(8*XY5Z2W0E73:DAPUP+UZF9%Y6#R]"B7
M)($>UQC6]OG$*:?S&>^<SSW=.%_#KF<A#%QEXZ.S,05#":"-8NT"#Y!=!E2$
M>3KKQ4I*K>'-[HZM3;5"&X$,1;L3>.^'UK4:5T2NKN4TL[R9%@()R%@U]+>_
ML\JTE0DJ&/S:'0ZEYS7<>W2[E&'4?H''SKS@ -1I(R<1XBH'SL\D0+?#.!/C
M S/</SR_+#;_/17]O=ZWG#@_H:X&5&%#H'%Q&8KT6@1EEE/'!#9KN6$E]TQ7
MNNK+K&1L+ 5-)FL!8:KAZ5'6^\>'6)%C=OCV!W]L5K]Q!$D,KKQ!-=->9C\$
M;ODB2Z_,L\V%B(V1U5+>:"4DT@L+>9".6GE$\BL10C4F7CD7QWKL?CQ&XR&#
M@(^URU1/*GAGV7115D5U2=<R-> EZ3)*8R,B$3'S#@OTG ,\4,O)4"(Y+W$5
M'3!>#GN#-X0VUX(K\/AJ:H4H$5+S, G*,MTRQW41,[TVEN$=M!%W+QS3H)88
M=]XPIND@/O&;GUUT*VC]^,1,9HMVB'!.6>67:5U7UW+<-<9^]K9ST+70.OMY
M&5F>H;R>=DN<.^H 7F?&52OE=FJ)V_NQU>;7AS>YD02!(GISY,5R\)YV(EO!
M-W*GM4CBUWX7#*&=#R5!*WF-@4GXA(G@#@C/Q=EN+,648E*SH<?9>/F0UC-B
MBOH$>C0*@P(N;W.D2=M,B9+3BIQ4I3'<&PG&*;GY%.OCJIW?7KQ^\XJON*$(
M2 <BCK#M>-.5@I:CE4,QO@^EGING85M[.7ZA]@[>TNU ,UR6EU!:G&SP99$G
M-RC3()G8)1%?T7F_&PSP< 0#?$(PP,,1##"" ?92<;"M_8R.I<CG%6:ER?G)
MQC,@K%W\^=Y7/LS)?C,*BP<^KI_$.*3?%C-HH%:@6.OA+$:<[5'K0=#%GL@O
M*TJ*>TOOU0URE(#-T"KDG?;9M"=9-) F8--4<P0;3-G2RV'F\W%*O&2%\I&P
MJ'V@LP.1ZX75R:B? :%F/1,;/B@3D3&+]2,5KQMY$-O 95=]HJWTZ-6?^)]'
ME9\-E>+4SA&].G*\S&8S\'G(]SUX90_)[ 5S_ &$Y.%JDVE@)<11;F5"_BJ!
MDOLS^ W":S]Y*'0C!"'Q@H_&HJ\\WB+N\765FV<R.EF95(F^,P.TR8GHM,A2
MZK0@&RCD@O0I Z0 ;),F2_/0!1?(951YJW>U+@5H++D\V/8TL$7"KJYVH)*6
M>?)G5$I[ZT?1H_$HLH,_-<(5$5V.RM7,%T$K YS7); %!.'LR9T+<WH,U"(.
M-_L("8D<QZ^KY(LXMIXWVEB$B]'U1 ";;OPNRU8LNGQ,FC')0+;M*H*---07
MW-]7CG983SK9+%&_E<N6GWF\W\.T&[-JB28I4ZY@,.X!LF3^@>63^7+> .XX
M[2R7WXBZ\ET),FNP?Q= 6/ A6J[=OI/-E@2G=!)2:'.GOVJJ#?*\?6FG:GLO
M6S,.+71LTG+C_/S+'R/Z?_06=5Z9[X7UO;2/?I? 2=OJS'T#-\KSV#[\_@.^
MW3?BDSEW[J.'>WAP]" O_\ I-[[D%SG(QP\?/?Y$H_R#-75@I6*08JDZV.TR
M[%.S30-D3?#"Y.)_$=+X98K??ZN\"3T.C8\I<D:Y&>7FYK$271(KJ'J *VF4
MH5&&;APK,4F-DC)*RHUC]3!*H[R,\G+C6+5U+\8G#'_2@TH*[D<Q&L7H0\0H
MH_:S-$!"FVQT6>JUKAK%:A2K&\?JVLFJ 1WFE88BLQ2=_W-5NZZR?\4GH[B-
MXG9S2&G>-6FA2DQ"RK8@.:A4Y@KGS8Q37_H@IJ49@5^$2,EA+3.I7.C:?\#!
MH, *\F2/$BI[G0V2GCZ#E ,]JK*ANGZ_D"Z@(?.2\%R'R$:75+SB6DJ.2XVK
MA7?V.V+?0NYP% U7RHX:\CI=91WR6CUX-&&O0?263NE[\'7=0)'G<G,?PHV7
M"'["C)*Z@)H_O>K3:;7DWAV:T$*-^S %!O287YY'>.=S0@0S]Q>$KL4-I3!0
MJPWKS!71(E7HE=0$/1(=NZ-M!6+^TE1EF0D(A+.%%K&A75F/_5I<KN31DIX
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M,@AX$A/4HUF&7Y?B8*O*&&5:2:@9%RF26VO^P.S."H*Y'H941.(&B/7-:+
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MZG0&IP'Z-$N7G ;!58PKVCJ<8'>AC*7.N273M.K,$XJ#^"?T!.C[E'8HU'R
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MO%YG3A5N_  MN(7?+P3&[/!U=.R=[)_4674_RGU\#/?*<=TVW,T;^:)4#?[
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MUL=0R0O\A=(B8>R4=JD[MTLU_E21Z61%/Z,$+L*]4C_$T2L8$HU7E5KJ$Y#
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M\&QQRPV=9+1_BD^%V<-PAX.I0K@G<M3B[B5,!JS;Z8N>U(S<J /93L"B/!W
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MAM)#W#U\H;05,,@4S \O4T8#0[ R12I>/R2%THK0!<MO$Q[-4[IM5HJ(+3_
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M$K0K,U%B'BC7H-.^OK.S#U?AC]#@@BM-I2%*MAIO8BL;44-_@*)@>A_UL>*
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MZ?6?@UI">ZY9<0^+_VI,],8E@(Q&NI!J0NXB(EISD^C^%EO"Z)3A\^5;[ E
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M3%7+,B _]@P;[$!AU?R_?_YGJ\?_B1I()^/_)0/0G5F>00.PM0145P*XZDE
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M\]",FQ H!9,SVX,OPW&D0(NQZ)N!8 79ESE3-IS'V1S4&DO20C.6L!ETF1C
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M+N9Z(<G]0NJ;TCO^E]X>TM]^_ID$\G\QN4FW*N?-"MF8%;(EZE4=DTC:@KN
M]&*<]%%OIS>A:W:V>)-LATN9J/!@MLI$Y2F!%-CXN1EI^"L_QEVKB=WJO-:
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M'6F#<GS\Z,@\";;GDTE8Z<5RZ#TB0S,?(NJ]4B\U;CY=S]!1M.04R!;H/LV
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MY1TL#F9:KE&A@_\"S",P,RPULACGEZG^Z'Q[^,+T]Y,VY0" MUA(5KS:LB-
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MF2MWAKL#1QT2J":G[%*8D =HND(Z,>F>8AO!%6(+!CK9T+YZP9P=5#7GS<G
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M.']3BE=]M<]55:5([4TI=@M4B@E0*8N>[*(1!F77D/_\E<HQW%?+(8D= :!
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MN4X623DG-I9?(ALVC5^1F!NS7#L*F1T'AN0X(5'Y?0;Q[(:*YQ$PU0?95A_
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M2)E4,R-0W.#P1!Y5^+1DA2>!W2<^G(B<E?E7![^Z]9^-X7'NQ_VX7#E5.TB
M31)@;VQ/,\?AFG@L$P.^WJED7^=4PJ&#/S]+KSQ9@Z:,SBT^]$0NZ*]Y4"S
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MI0[+!.T93WL]0]<9/ /D(F\\M1P3CJ6"6ZKF<_E06]H!=AF K>X N\64;(9
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M3RH'XGH.#%72U<T'],;AX^Y:[Z[U^D]XZZ_U,DN@O!6)92-.9M852-/'8F,
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MO1Y3&W8?9AK^O_^GFL]5_G'5MJ1(\*L6R&-,QU?4KL,TCSGXDP7#_Z7:'=6
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M?YB\R!?LMP/YIKY'/R#?(.YM9@3Y%L:SS"-U,Q3[U=G=M\+XIF;7'#"^">V
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MMP@8+I$'2?)7T%X-3&<NRDBH@?>0%:@TNG5=?YQ2_/&C\3S.03MN<2OI(C!
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MM1'>Q7WY.JPXLB7IJ!=%%Y^IDCG*P3;(.E7Y3Y3&92*)?^IR<I)DQQ/F3))
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M6UC)A"5^X<] <?RSJ>/U!:Z1MD/N7'=!KR$UZ&MWL,D ES=2)3)DN@\_VX,
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M>M>^ZA6JW9I>['[[Z6[^"[EQ8Q8?C=PHN;+JQVN$,T7]>.QOBX!W3 +4R 6
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MBU:5X<3FI(6-A[ATR%'P"KG.Q$M+%F&(W:YJ*A2T;JP"UV3BB(3]-1;U',
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MOJYK+VM++<[NSUXRO:KU+'I&0>P]3]NMPL7Q =]YX5_^& TQEV6K4!BE)1H
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MOB*4\Y72UT5EZHO*A9F]I)XL+S&Z2BA"Y!7:]OYU6?E'I](=R6HI775$L'>
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M<HI;].BU4%138>LX_L\*%>%4>R)+>HGP1C1?NS9M71X@ZUC%GV)HZI!#<VC
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MQ%$'CI*<Y\YV]W?SGD$$(C<4WW6(+3BQCQ,3#*ZE*.J;2+.4Q\S)NE:'%(,
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M,IDWC5D>RRO]*B_YC,7?TTXT&0,JS'YS1-2&$U:(BT&Y02L=P)V71[2$RS2
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M8UA!0P/UW?W!G8-I8V0]5Y%^Q9+WJ?_9C^&?7(FTQ?'?_P&A0TBN$?%UIT/
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M? 7?!:=IZ 2AX-CF&[++;IB.I,):LQO-Q&V%:/R.7QPP[R8@M\*K=_*.L$O
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M+FIP9Z1Y9U13T?=E:"(B1$2J0$1 E*H@O41!0$"(BM0(J(B42&\!0J+TCH"
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MBXC\4R+7*\_A"]RB=W%BI/] ^Y_(_N^ !?\_(?M?P/XWKAG 10:ZL^(Q< #
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M8LJG_HC_ARTL*YN.>R(34U7L8X:3:A[/ ;%FB"X>R2RA6P80.X$UOVNR5X!
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MSZ$#TFW:X=?L(._S+WC9;CZMX7<V^+M@;[BT/[*Y_!NBL9HB(7D+N;EUW'B
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M9.254IV(\I;O?OUD *F*:C/6O(G0(Z*W519MV<A5>-0V$]'VP,4VA':-I)B
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M.%N5P 'O?S0RZ&,>![RQH+U1F%R]>R?V%*"@>A?#ZV-[!N<4$ T,;8)XX$%
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M9"6D[GW<]*#QG<.$W8K0Y:4B*Y )7(%E=VY]>PL3->H6>JP,F=&2.T:/E[>
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M@QO%ZS9G%6+)DG'U9\ZB"EX1A/)1F*5E9YX)0!5SBL0(VJ'W"-4*MN J[8E
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MO;$\83-RQ&R,C)U]M[+Z!<HI(/._JH<7LE+"?KPY^F!/]L XOZZ-TS4]_)+
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M76SHTY4PMFAN1J7GLS/=KBRP**9O5\LM+IZKOQE]*#NH9/ \C +;K?KO!1G
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MY!F$8["?N,'>N6*@\,,YPZ;5^0(3U'TJ;E]9_-UW(47'%53G?BR0KP!G!V2
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M05>B^%^F5PC:8C^@3$/VWG0'SML[K(/<XU@T<%QL+S45FQ7BEV0EI*Z-;*'
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MF&@XAD$%&7 ,B4?XOA3<.84_%DF/6[Y?]!RV\>V;N*"OWY"L^%MEB9]6W+7
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M8!*&A%#L_.W,+%W_ZX+\Q9)9QO>S7)N:]+>CD/(^+,K$K^T.N'MH<!Q)IY*
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M!F(:M.]W&DX12\W?57N^>^/\K#>C<!N6=FGLU>\;QR;_W7R(PKXJ+/=?NHX
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M1T.VDOOGK4S>$$L:YB67P<E8^MFTP3&VTMT*/K9P/G[X3&=;6Z!U/82,VLO
MU^QY++G9A>NH=.:B)F\U)DCK2+KV/#CQ.+\LV@[_*__!K#+UM1]^/,T-3I^
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MRJ8-_0 ;T5+G(^11F%GR / 1SM5%&&146/AMYY/UU+UKD;R_[T>\[#D9GW&
MP9\?0JCOI;QG^/#%CYS(QT^C\*^__EB'^RL*;@*^A".1#B__O([/'OYG+.?;
M'3]Q7*G]#XPHC%+4 P7;]#(%]?+%XR]2M[4S*4UU0$(-;CQYVX*V2]0Z?<54
MI:FF%V]6XL.$UDZ6MJ>6;I0PU7?H[8.?PK#3*4=<\X'';P&TM6 5G"&JM&T3
M2+8'89%AI1^ /,23[;,)2_'65>_J6P\JMW>BX=8Z="DR"/:&7U^.'(B+O4.<
M,5<W7W#N<H<SZ"),)E8,_6( "*4XS-JHD>IC8XSOS8[N9"?'"_5NC)6UH5@O
MDO,U+$16U-K3.T< ]OY,&MZBNY'EN+<?0/-?Y5>M"=[U2#@@M][YI\NS"_QB
M\<T.Z^%^X+BEWPCHD5WDEJ+]Q4'50Q7"_5Z/@W*T52X6OI7Y)!!1O!I1XY:1
M+L:FP5 )Y6,H815A*,[QT]0\X_1EXP7_LW>N]%(]\.Z:7=INGKUB+X2PWP*\
MY"$NP.63%]C :JS*$9AC!;^XIG!3#-*HL9PTZT.(,>S+7BSBZ1NHJ)7-'J]8
ME71-EIR.<9B,?2%4[?S?1E\F?D)5$;N)]D;$QH,XKU_@6):4[;Z#.&>4:=%1
M&\'Q,=_07'UP8'\!V7"1&YA^_M^EJ)%V&VJMK4J=IG&89Z"YL:F6X+LX3B:#
M.X/7-XW:TV)$68O^KTF: A5 \KL$QW\ 9%P-L63J$Y9")PXRAR/XN(;?6*_*
M*X9=_HH^%L6]:_GI"MM*'75]\'Z\I1K/<94,M/T&'\/\R=VH]&!49][0)\&J
M?7?);*'%.3R@_CH6"<0*LO>*Q<&8;P'NR;2@EU@EI)5=3$'3TN'.=Q"%)H[5
MU[$LY%3%N2\&[LF'H(A?TJ4+(KRVF!>N\9+A]RQR;G?V]]TFM+?3 ;'=5$.<
MIN!VVC?=W9P@;91=7'4WQ6_\ /!^-^E^/GV!\9ST+8 9FVGWGUZI"U/P)Y!T
MH^Q*_$%X0>.^H;FG8V#+EX93]\OJF\'5F1KDKSY)\\='738TAX[ $/$WA!I*
M?E()\Y[!*JUMD?#M;;A0^2+SIQJ^3&(Q3J.,I"OY/*HM^M0*R5^56(ZP4!F0
MTEB5_FS>:ZY$[3ZY5/#DOQ6W4QT!_M..L/W%CEK>H<U; ,26#I/EHV,CW[&\
MXBEZ%<;>8D<.W"B'-;;TG'RZ!=P!3@R8!D2!7I@ZG+B6 @&QB9M'5 ?#<F#V
M#BR,+P[,LWR3BAP.,^D:K!G*;LDFNQ *+BVJ"-"&I+E[TD*&UU'&L"BN38VH
M;B;LDWY,++8( 23 SX,);TJ)!BF25<5_H@,OXK(T.T)%<1(/LKWF<%QE/-V>
MWZ%)#Y(EGI<0TM1MRO,$;:0TQ5A3R38@7:T#A#Y$*C P[+U:%Q=<ETQKK?(C
M?9,XP!+I,RX9VD^YNO1B \Q>(2@C0<-G&_#V(6C&.T/02T>MI&PE+4QV+G%E
MRW2RC :).-$5&7+_IF)[= D3'1US[+CYB?V?V2E@Y0K7<6Y+,&=(+.1Q@ @$
M 3MZAJK#E,P4H3$5;U6_%6$;>QUAFR*HOC&F5P?.E6.^"G-U5H^\DFJH127I
M!V\!*/V3Y?M]805'0F@DQA_+@[;3N"F%N>L1N^<_1AN&G%DWY&Q.]0&Q6IF4
MR)6[*\JT7CN5!%8_6==YT_#S9>J&%@/-!)CO[]G(99:]']AA2);=9)A9CP')
M4*Q\OK-%,@44K# QI#!YJ!6]2_.%D(1VP>A#*X3JQT]4!LEL=!L?[VKU?.WQ
MG!O:+,+F3]>>+631.E#'36VPAJK#TKVF.R*<O:X =<H>6W$=@F7&-+6@*#Y3
M]ZY1W.1+GT1"4 GWR<"<'8O".$ ^%7[A*]E3>+B6Z1&C/Y_2*>-G8*IBWFI6
M>W-C!+??BYN:.O?VT=!QU@'+KL,6@Y7QF2VF#>'W5,/*;()I5"O!5"N^+;Z3
MJ_P&+2KBW_F'Q+^31]$LW#/^\;[<*E1M4_L6 "K?:+E^Z;S6CE*P8>FV;GKR
MHP)*ATBW,H")'&:V-ZTLE%6Y<K?Z?LM[_0ZJ?MD6:K(29M.-]ZZ<]U&^.DO+
MAQ3H]:7&":V&?&UJLA126CXXN^X2#J794P1-'$R(.N[5TXQ.T,2UK1J\'S9\
MM8?]5W><C"=VYQZY!1!@L*$^1G>0"6$0,"CH;'GZ%P(]23C'#*.Z.)_(<7%$
MRW.5(^MN 7902! [ZH6^'HX:LCES7W1-&ET_A::CUXS*+TX:+J\; (5E%Y X
M9FJ_/BB![5+9),]WBMP"4K;LKHD@%=>/BM2DKQ*AXV<OO8HC/5L(A 0'(PET
MQWW,[TWG-YEZ?MS/CNQY+T6LZ9(D*^3)_:6SW*N-P[E%2^A2+N86\-?R3K_$
M&&\!9=]NF/^O)9LCMI0$GF7!3[(WL84.]U%\5@F]!7REZ88>!B(+FNK8&V./
M'B0!$=.@5WO#N)[2?W5 ;N]K9_Z%DWX;.]Q-V79(6QIDF=3L%L -U:V[M,"[
M&; \N==#-=%S?E; A\9#WU7!$P;90E5!&VF3OD)72U4@6JP,\A8 IT9,1>%)
M<**S/Q8ZPY%'SU=>3]=XU:F59.MY\^[!+98CRU-"TM-&(XY;Z\YI%_O>GEZ9
MCSNJZ3XNU&G>&J-EF(GR\]KC3K?R7.;.">.=0I)LY@L6SXO"0F5<_D#&1D2S
MUX[8C(#>_5<SMIO7ZOC)==I;@*-=@BHWEAU=]J)A!N>]Z4^!^<CD]3UK,?G1
M]-F35$:DDXD]LX Z$8#R(.X2@]\J:H#!7S^1YQ20YU9VZ/AO]";X,:$>^"-2
M)E'94?&W3'()_V0"DBE]BY[Q>< .\60NDGO5D;'/)]TAQ] P(<WUSRYJ-HGG
MS9_YVA\K77,'X!;=O1JF1MW%!J@PYC(1/%TY.W1*0NM$R9?ZZLWO2S_Q%^0[
MV<]-7UJ\=4Q_7#SRQ>?5U*]7JQ)#]SC^,2!@OA 7[_B">T"'@H?@$3Q-PTV"
M*A%.KQ$]=7BY2<&&/1NPY6(:;&ZKVX<?'K8W!5EFU^6X'-G31/-^CN1!2JFK
M/]#'EEUS@(#3(%^TW"#L7B?U9L?4QUL S2W@W8HWW*H'3X%]?_7Q"M;7X>DZ
M5%"^BV=K3>_,[NZPKU&(UVC/HAYV>Q?1'^2^ UFLILK^F/YC7167R$<BOPSE
M<T*Z#FO[[<*S?54<4R;';..KKB_P7:Q3 U\(OJ3[L*H_-=U2/QI=95-U=")*
M>J:P[T80@EBE-"'AZ)Y*SV3L9R'7XR.XR@V4N4KYWW:#<#>OC:NI+2N03IG1
M\_KE/HS4$=OK>JV\YL*TNR :H&W#*A/=%#_@^""QZP+S,CY0-=V)4#MO^.V4
M\LD1W[4DCAWK>?T(_PO&T"F&%"*MBP-2'G?JT"?A9%$YGMK&'2V+A<T+(F_;
MX3S-MX"/.D>#N2E2/KS?Y*G>'.E]\I%!^UQ57U:J&G<O=K:$5:TX5[EZ,O\I
M?G<*LJU01W?G'*W!Q<Y6<8N2ZBD4:Y7#'+)]8ORTIQ?'OPD5GF(][D7VJ[@]
MU^IP/#W<BH]8#&:A5R%Y1V%;)%^W>@OXW8\QN9MZ.WB2S^BK"S-4],?UIB0H
M<HIN%<2(;C,GKW);(T3A+,?!3- S^LF6N7,7TU!+(;/U &#(+RN%@9M4B&-=
ME!P,I<,.+T)2#!80N*YQ8K<08D1N8!ZLHG>.OHU]7[MS-.A%B4MB]=ZGX8BN
M[KJ*M3_PFQ\2=V>\%THE%!JI&&PJ5-R;R4!:S+H^S]LODQ^<3^XZ,4I6SLT]
MXJY8N& MFH*WAA5IM@DUY2SL'@6'G\/J=,+!3Z0D?A>GUH/JR7+5JP3':8E0
MY=_H].D!KRHWO #S?)S]GPK\,AQ]>Q_0_/C)@8:2F*BD;[SQM2N[DL-1[0R%
M9>84AO 98^\"+$WSI@QD@5I0Y0L)QKBW,56K2BQ(4Y>6-DDC*]3[A-@I==Y8
M6H73!V8'&I:7:,KX8[S^]RH:I,_X%O ?R!G=@03VUWVD!#EC"SPW8=$%)*!
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M*.G5M<8YGW__6)*4^%2W?3*P &*)!T(V[@PX"Y.#?4S_7I7!]CT1X'[YLR^
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M1#@N5,O0VGU4<O^UU8J.&_"1M:;?2-'^27EQIJ;0K^D1R4.J_\RCN>/ 5;>
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M,XE,9VW)7N>0UXT,9:9%@0=#(>WS2/6J\LHA\*2^G\%%CIG>E08)8OBS,OT
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MM T>73+:Z$^G6=V9'.I+<-??+.+=580$$<"M>#]N#6O&'[/G[=W[;'AWX/\
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MJ3Z#I"7VG:38M>R^-=7LI3+%&QDT^#"KU!!1F;=C!YY[5Y-::E?VMK%;17S
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M6JL873KPG*%3WXMP<H.\)2B^HD\22SFWO+/3-*TVZL9A*SQ!3\FT@JH'4E<
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MDHXJG'F2:CLU?6S:DG=)\KT6U][H(X?)U:TZ<;O5I16OR2O;1OJ[Z[Z_2/\
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MKT!Y%VG:3G((Y'J#ZFJKLQ&222.F>W;^M-&Y0S2,H X &,MR!D<]N]-,BL"
M>3]/KZUG4C&Z]U;=EYFT)S?O.3;6B=]4M[)[I7;T5D('8<@X//8=^/2F$ ]0
M#[\_GUZ]?S]AA&) )'^>:CWMZ_H/\*QE[KM'W5O9:*_>RTN;1][67O-:)RU=
MNUW<>P &0,$=/Y4S>WK^@_PI"Q/!/Z"D! .3T[_YXJ7)R^)M]-6WIVUZ>1;;
M=KZV5E?6R[*^R%+$@@G(/7I3=H/&3SQU/^-*S)M.WKVYS_4U$&8D GJ0.U8U
M$FU=)V6ETGU\Q679?<O\B41JI#%@<<XR#T_"G[X\Y]?4@_UJG*S*< D#ZY[#
MUSZU%O;U_0?X5@VU45M/=6VG5]K!9=E]R+<[)Y,N.NQL8/L?0U_=W_P0M53_
M ,$Y_AN<#/\ PF/C?GZ7*@5_!N[,4<9_A;L/0^U?WD_\$+?^4<WPV_[''QQ_
MZ4K7Y+XVZ\-4;Z_OO_;D?I/ALDLTKR22DJ5DTK-)IW5S]=Z***_DBI\7RC_Z
M2C]^P;;H1;=W>6_JSJ*\,_:7_P"3:OVA/^R0?$?_ -,<E>YUXE^TXBK^S5^T
M'M&/^+0?$;N3_P P.7U/M7;DG_(XRK_%PU_Z73,,R_Y%,?\ LEZG_I+/\TZ(
MQ[$XZS3#O_SV?T.*CFE2-#D+L$ODLC/L^SLV )+N\(,00YX"J" "#CH2)08D
MD  3SYN 3_SV<GH>.._;Z5]&_LF>,/@EX _:*^%/C#]H?PK-XY^"N@>)VNO'
M7AJTCEG;4K)K1I+2.XMHY8C<)'.-P4DA\;&W+D5_I9B,94I9;"5'#QQ#C0@U
M!PC.4FJ,6HQY[+FDXJ*NTN:2NTKR7\5U?]HQ\E%6O.2T 'Q @[][>])/5+SZ
M;6:UO8^=4>%A)L>.5(9%B,L4HFC,CX $J*JN%S_$ N1\P.#@5#*%:X*/YB0V
MTLLI; 65EW'" XV@$'&W!*X!)Q7UQ^W3\1/V=_B?^U#\0/&_[*O@:Z\ _!+5
M!8KH.A31"R,5T(5\]X;=Y)74-)DA&D<+T' %?(.I +9SPX)/V*Y=7!P0S*Y^
M8J0#R<$DD=3C%<5#'5L3EOUS%8=X;'\B<<%*$8VO%/EG3C)P<HW4)N/-'FC+
MEE*-I2J>&_VA823YVVK-N^C:U6BZ:K9V<;V>B^X+/]@CXW:M;>"KFUO/"4MM
MX^^ 7B;]H[2E:]NI5'@#P]*MO?V5_"L)?^VH)$>6QCB.7;Y6+J<5\.PS>5Y:
MS6M_;;4G;-TMQ;SSVVXF.7[-=1VDT0DC"N9-[0\G"A3BOZM_V=-4\3:7XV_8
MWU7P;HJ^(O$MA_P2L^,^K^&]"NXVN[?6+W3)WDB@&D31217B&9 /L]S',)LD
M+&RG!\-^ _A^T_:W\ ?L1^/?VZ_ 'A?PGX^O?VQ-1\':#O\ !]IX(U'XB> 8
M]%NKJ+PSK7AR&VT.._TG3=8BBL8;J2W/VA0@:=XFVGX__6K$8:4U4PM.7)=N
M+C&3WD[.+3<;\ONWMS?9^%L^H6349X1RG--QLDW:ZTT2ZV5M97TMYV/YWM/U
MKQ%X98RZ7J/B#PTVM:-<:>9Y+C4-'/B'0KH*UUIZ%8%FUR%P J20SLL*X\LE
M!SG6.L>(=!NK+7M"GUWP_J".VDZ/KD,M[:W$<M_"3);V^L%%N[F[GM6, @LW
M1V5RDH(//]-'QRU+X>_$#X=_M ^'?&.@>-/$-S\.OC[X#TOPA>ZC\#/#OPST
MGX&ZG:^.=,T2Q\&:!K@_LV;7]#O=/'V1X[::XMKZT(GD1RX:M;Q!\2]7^(?[
M;O[6'PN;X8?"#5-3_9 ^"WB+Q=^S%\*[;X?>'](T^]^)EOX>T8SZGJ]M%9SO
MXJOW$]YJ&FP2/?JTS;(HMNQ1STN)HXB7NY;6U<GS*#23W5E9Z2ELT[)6>NQ4
M<AQ%)1E+%T7%QBTI33LG\ET:34K]M=+?RXWLUU8/YFHQ7]C>PF.65=5L[E+G
M3VD+26]W<6,Z&9IK]W:6"X <%WWN#GBN\5]:*LEU9:AI!GL&NFFU#3;R&:_A
M,N^WGA$D:PD;6#27LRE)<^8@P17])7P%T"Q_:>^&W['?Q+_;4\"^'_#_ ,69
MOVJ->\,^"+C5/"^G_#5_C)H&G>&KB_M_#GB30H;/0"VCZ/KT<=K;2WL+&\VB
M*&8Q/LI$N?VD_CI^S7^W/H7[0WP"\+>&M2\-_''X9^%?A)K>J?#;1OAS-875
MQX[;3H?!5AJR6"-J7@*\T]-.MTO+)S/<V-RSI=9*L.[_ %IPL>5/ XAN\8O6
MVK=F]5K9K2*UE\*U+GDM2FFZ+]K*]Y)VDDWJU'>ZO>SV2M?N_P";BY@N[>RM
MKUK.Z72[B8K9ZG=6=_#I?D!B]ZJ:Q,ALKE;JZ8RPN59R6'E.@*@4F6\BLWU)
MK/55TFV\\MJ[6MX+-+SS<%+B\9&MFFM9#Y3P8)).'+$@U_6UK?A#2_$GAC]N
M7X%>/;O1O&<GPN_9IU.ZU;X<^&?@-I7@WX8?!SQ3X=L+273!X'^(&H6UM?>)
M=2M(465M3%_/!>R.TKQ%2%' _#/3HOBO\%?AE\$/!GA&Q^!OQ#N/V2;^XN/@
MW\4_@[8>*/@O\3_(TFYU%OBW8_&JTL9[G2?%6I):I?6MK<Z^5$[!7B?)%9XC
MB55E:E0A!)*S48II.*:YFM6]5JU>_E9EK*:;LY3M*RYE=:/[2>FZ;:VWW71?
MS:_$+X*_$KX:^$OAAXS\;^'9_#VA?&GPK=>(_ >H&23R-5\.:=?YU22Y@<DV
M\DC%6MHCAV0X7@@#2^'_ ,#/%WQ(\"_%WXFZ?>6.B>"?A)I>CZCKNN7[/&MY
MKFJ:E%9^'_#&@>8Q2[UBZ619FLF$BQ@Y,>*_2#_@I#XX^)_B;]DG_@G39:]"
MEQX&B^#.H6U_JVFZ/I<6F+K_ (>\1WND6FDVOB"VTI774%M+5)[NQ6X N8D5
MY5D=BQ\TN[>6W_X)+_!>/PM>V>G?\+'_ &X+IO'GB-;9_LVC:[I"Q:;X3M;D
MS!FGMO,,5W)!?*]FH5I1 " 1K'.*_P#9E6<J:4U>S33:2O:TN5.]N5O9)NUW
MRW;I97!XFG!59..D;.\E>79*_2+48M-?%:]VDS1/^"4?QYU5- \/7GQ;^!'A
M/XZ>+?#4/B[PQ^S1XH\:BW^+6KVU[9_VM9Z=/I+C[#:7VI6I2[\/VDB'>\VV
M0,,"N$_9V_X)N_$G]I23^Q?#WQC^"O@KXFIXF\1^#KSX-_$?Q9-:?$2TUS05
MG?586LHK?9%8V+6T\DHB41LI)RR%5'ZG^([37OB/^TS\,_@=^VY^Q%XM\4?'
M*2U^'WASPQ^VY^S#KGB'3M8U'3VL8HO"OCS_ (26U*Z''IO@ZR:(^)88I(#'
M'')&2.*^+/V(/A[_ ,*R_P""S=O\.X_%<OQ*N/!WC_XJ^%K+X@W3-)<^)IIO
M#VL3OK.L7CS21O=0HS6T\ZR$SR?O)'9V!'A4,TQ6*PU5N_-&,GSOFE%-)WE=
MM2:5F[:7MU3T]FKEN&PRC)N.JB_AA=W7]V]W9K5VDF[VN>$>+_\ @G/\1=!T
MOXD:GX2^-/P*^+A^#O@77/B%X]TCX7>*Y-5U30?#^@7R:=JL\4%Q!YK7.F74
MBQ/;I*T2QK(Y3 R/%[/]C/XUZE^QQJO[<B6^G1_!'2/&5GX.O=M_]HUE[F!C
MYWB>*Q9WF_LQ)+J&U=LFU\QF!0-S7NG_  3S\:6G@_\ ;_U7P1K'R:!\>KSX
MY? _7+23:UE>P^/6UW1M&MY+=2(Y+BSUEX;E8Y\HY$4C!C@U^K]AX7M_"_Q^
MT7_@C)=ZE9)IFH?LF:Y\(]3-K';II:?&WQ!J[^+[#6-15LP+K4&EV%K'YVX
M&Y"B/FBOG6-PJ@I4Z;<(<S]K'FE[."<92UDFHKW4Y_#%[IMJW-0P&&<I/FM&
M<F]%%)QD[NSL_>O=)]KZMW3_ )Y_BQ\ /'?P=\"_!CX@^.7TR&U_:!\)WGQ
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MI7HC)(T/7"J/IUWA4EM9H7#EV)KY]9)-Q.>6.YE ^6-FY:.,X),<;96,DDE
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M/$VO^#4N-VBZSX@!<C6+FV92/MRL[OYJ,A)/ ].*5/. 9I$ =&PV 2,#ABP
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ME"*2M&+<8J^]DFD6*\5_:B_Y-C_:$_[(_P#$;_TR2U[57BO[4/\ R;%\?_\
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MV-FJ:JU<++D^KM1K8?G2;M?8\27.O&PECOO$GA[42\EI,+72H('9B;C:"[;
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M;2A4C):,0@$[CU]?\_6H&=M^W/R\\8';/?&>PH>1E8@$8^GN:A+$G=GG_/\
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M1BEH[)+=[OYLM4>=<UM_TT[HLJ[ S@'@(H' SR0QYZ]0/PXK^N?_ (-@"?\
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M]!WXJ#>WK^@_PKFK)*4;)+3=>IM"ESIM):.VR_S1+(["-SGHC'H/0U_H*?\
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M>1?W&\R6L?F0)%)<Q1,2(_,V%Q@G!]B!7!F>7^+56KCY3KYS/$5<?EF72JK
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M?0^[-< &-B"./%EX+N?^EZ0I.N[#^F587E'\K2U6*)1K@]G 7*P[7MF?#;1
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M<:AH[ A(U@,A4']UZE5_-."J#M+O3VG_)?NK #M;<[#7P3 ULT9SC]S7<*/
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MT@6$J(!TD":=* @1$)#>042DB6P0I 6B]([T38V4$'JD! 2!2!<0$$(1D)(
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MOKQ%=P%\[]8RL%J(=UAMC=+Z3KA&MAO$HGZ)J$V1$.N!76BEQX:8^^HXCI'
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MM2I([_8>C-C%%.8RMH07>B[1KK0&:H!%@5R +&Z<,P6MM.S]Q(MD!K]1#P]
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ML2Y'#XF5;AVUY;)1&VUK-[8B[@/-#@L@"A&E+@?1(,+\CWC)"'T"K(,*>+[
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M@ M%E)3CG$1,O9'<NTZQR?):%P>U%I4=>H&SC$>XR4I\E$,TM!X2M!>YF,Q
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M,M%-V9J/<$RJ5 H60% & QK'R; UA>Z11&XUQ-<C@B%-NYT.;$10KR>6Z61
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M=RAT>.WHQ0.2%F$ HS%5BB?Y6_OFM,=1."<E8;KH@"=-MI:H#T8&DUO?LYW
MBZ]&-O-#76@H[T*7;<C9Z*\X<>@N\^2FKO5X6!!" *4[L_]Q@<&ZH:)'MQH<
M,#'OXZ$KGT,R5N>B B(4NGAW@FGYWA,)/1 >I0+.>-&<L,9 R]I0).C@6HN[
MV/1R^%0JD'@>>L :B?/FI*C9R8W!#;+L1 6)H4*R_[0BF:@)H2&ZZ0$](@?2
MW"R/,0+71W_7I ( R53 5?G8;JD#J V-!E.R>]X(Z4H[+8Q>R:/)E%::TW)
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MY_HL^.L)#(X^C\?B%Y8<81$J](SEW:L>K[+\OCJM$_L;+^).:[XW^7IP]0;
M]L8NA\E7>;[1Z6_JT2*SWWTU_\B7'N_O/UY]6NPM@JTTS9=*\_/@2P65[31W
M;HS<G"T1\YPN;7E>(K5!.'(P YH>925ZJ'B9C-B/SAJC+9SM:N!#H@9]3+Y.
MG[B(RY/M+'[+2!XZVI:@Y&):8VM/"%S:&GQ*2XFOO>\[\P[N^6=S&V=5PX!O
MLSS28V(P28 ^%G,N.;IZ.449^E.ZX4@RD@/N/]O[\]LY3)P\%>L/IZ@U)9M'
MQXJ1(54+"M4*5YUOQLPL'N-S_3+:'_]B%:W:P"UHV*BN:J+-5%:B37N"G P%
M3'2S.M9Q.QBI?="@)MO\Y(_O 4FNNY\P9CD_DM5 H\ 34SNYA'4L :2??,IN
MB%BG25.<WRMU*_$Q'M/U*.(<]!00WXD1X<.,:HL"+E?8M*V0:XT8?EHV75UR
M)>!0>-W$.."Z^MQU\C4K^5D,PH*6QM"F!U&08GUEX%H@B?/JAOU/]YF=B>$*
MH*O/#V/ >XAMPJT5YQ^N*48QTU(9%O_\]K!GQGG$7TT;MQ*;K"5]I?+]H<]B
MTE2(Y>%'W,(1R,O/MG3!U(2&!MH$1*.OW#\!/951+R>4J4Z&-W7FC_#NH7L-
M^!DV'9,N]#<TC3[Q/USI3L$D&.+1\=@;8?QO6(V[1.<;+=.[..%M[2-0(S9U
M/>A*E/F"L9_(<Z,/V&>[/2BB!FF@CY,5EG,,C^T]UJ\*KS$D;19RG %>UAQ,
MI^ P&\=-A:1D%6#GF$_K"?ZPU<%#Z/DEB3V7=_W5\QHXTXM.8<8"E1_+- GY
M)G*EZY6IJT?"@;!!8)AVWBS:=>@ UM<2(Y7>HJ3T8N.!]4VAU'-":=CSTZ9*
M@G+R[^:7@LU,6D;'<4(_^-H:N-89[AH4=H&LH&/2-%NW;^F;6&&WEI7%S]?4
MBOMRQS@#_<V1Z#C?Y_OEVJ"/7.KOW% M>/-A(M5K-4F?&^Y&JL,C63:/M&?[
M=, <]%VSR=H:M;!/#(73-V3YX8&HU_82B98$+^L#/;5R*]>?N@N-KVG&[,YM
M'CP_MEG.$TOAG6>8J:H161F<P!#/TIU<X&"?D_/*=)U)@EG0K3K)BV+N>UHM
M_2+UB:G^J>E9*B8TX XA_D"-M[\9#_T-'7T'\6I1<3SV[8%Q/0I$,YBWP(:M
MJ^F0RF$3#HZO$7,^07Q\-C2YD+J ?YHNV0P(TW;)+TJH::25@435-E&I7:M<
M*'4VYF4IC7>Z#Q6KFEC([3$. ];04S>F0JCNK> \;Q]$>7*AA^%JC\BGG$ Y
MZRI6.<5[& .WBQ"J&6RN"E>"(DZ<.['S8&J-V=U\8PF260Y&6AA8H3;"__P
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MM_GB9I-7T9^L;55:,RPX6S%5H$PYCQZ$/&)&<*GP]RC>DET3_PQ(3W\>Q;+
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MBTP=WHRI0ZSRM</IY3(SKB?V#=7E!+_#<ZE#\_#F4$E^7"895IJ+?!#1LR3
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MG==A3X,N9=_$IGS-2F;V^K_/3.!RU,\F*XG"A9=?=EZBUKW]KXOP0$_A=9_
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M6J'=^AQ[_/!&DWK:8BQI6\EV5DGW7BVPU#F17=R*:[<=IYY\\%R#;U9NS"O
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MWZ2)Q=)8'L\&BKYB'@YT,\6GGTWBS@ <7=&[3S^BNIWYJ:,9%R<(1-.8J=K
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M5)MQIY3F.!"9K<&.S4$Y5Z9ZO#"SG5"K_+NRBWN.@U!1H^<@J2-.-#!GY*Q
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MS5 %B/]D*#7!<:,71$Y<49+YBC%E&::66M&1 KCNHX;EIE9(H V5/&1I%8K
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M#Q>V/$U02;!'PEO_SITBKO8<\G@A!7P,3P,2S!PZNX,1P8]NZ6[G 2+HR%-
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M3>\!Q'DBTW-ON-=6.QTQ)N$]KKH.@[8T"0=UF9+&4+37NP5!Q.1+N%1^SO/
MQ:TZ]+'UB0AS:>"?/,\5DDP$R)1=[LG9(-9N91<W.=2'3<F]/GAG#'PI:'#U
MB9_&*D-M*WFV+M]6XG3%5YXIRRJ>-.E:19%"7EG<2H->I>#:MV]G.>=*NHD/
M/ F6H#2YA$">9!F-^M8:F@!6Q%=?GY=( _5W7,(JZR>$'_4HK5?1,]8/1 WD
M$!4;U]/Q\([CCG&77@98PI4J6C!9=64O*],?YF=<RM(2%\.I_[8[$TU0UE8
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M-2!K,)8C31?\V3^E(I"/[+_G*NC#'5W_,ZZ%*YDD4'7^AG06S T.77):KSK
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MN4&^>XE/ZTFRX5L?B@)G-<_3*P)O&@CY4948J36U #SE1SG/TV5YI42J(L#
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M"%B:7?1"3UHF?$6BT24[%R\VKY6;;J_K*=W6I?,[CZWG?"_74[K2Q4DWTC^
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M;GKJ@'B% .D_,N!P3XR<OY#]S(3M5:PN*\4_HU]%X[[R:HN8VIB5&J^Q,,C
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MZ_5.J3*^N@3QL!E)S?1\HZ'AP&?OUQ8;W^=EEL[/[D!:%G?-]\X8Z%>K.^D
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MB@@[.2\>'[J0(\)>OY&"=.*F%GF39(=VK?L6;^SM**$W1*Y[&VN]4^$_N'+
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M2>\<&1'7XUU'C3.@"&F>XIIS>1/?8!) 2L%>0N2@Z^\CNR[O0Q:>J>X;.=5
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M*,18%F4SBK- \4)^2=%=N\ I:?0L72.7_-;JG&G\XC@+'2!=3*V.>$,Q!3+
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M2,ZT"5'R#1?/-P^"G6W-#U0C 'R5$H,5G8I2 X5;+!;G@SV,%M]J@:ZJ*[7
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MMNF;BGF1^OT='DSD]7\"4$L#!!0    (  U =%KW205N:D$# "W" P 0
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M3OS_900;MN5%N;NIW?I]_^6-@_&[N8=??-MPM8@UV_TA1R;;\0U3[5,I<O%
MS9%[:48Q:;#%BB>7KPT8FH1:UNWQ_XBQ]I7;;^.\>J5A)187ZGQSO(YR>G1/
MQ9:5VBW4ROG-AOOKU@4'.AI/]5M\'_WU6>L]"_O6J.BATN9!M0W'#T\2]NW6
MWK'W[GG)_T2\'S^W4\GQOQYW2XR30X;S^M$S74=W\+H._G&>DVVL(3FF0'_3
M]@7I+B>PM'CXL_Y;^9%?UH;M5^2GZ8A>:=B/%?VRA]+_Q=A;M#UN&SHO3H-9
M%]:XI/[;CI#K?CL:.GI;C+BIYW_9&$D(=N+!';)12)6:XBWGGCM_KK8]<#N4
MU?=CS8)2G>>J['K.]:KRN24E\=H^5%,J27WTTW,1#1DP4@G'EGZ1TU%RQ"Y+
M8B@CK61[(TCK)<+>X[9Z9'D:@9UP<%<30!D0ZD#^K.6-6(PZ85:H!)Y<YG8>
M TI:_,+,ZI@<X]B$9L7ZMH'#.1O"')XKUHLP0MPO@@6(8.G$IJP!VD-U;!="
M#O\;^+05F&?AH!/5>#M0+Z%3 [</H144(X(E,"%O,(N%?A1Z+"H]:HJJ*3WO
M \X\JK:A!,PNU](#+>W>!\W28,0N/5K ^AR;.;L6#4\0'L3'0D:+8<J!(AAU
MEC-J7,HDJ>%= $02_R*YC\B[0QA3_17+6&H;Z?"OF9/AH+[,"$<Y;HT:A3)U
MWN\EYJ]U'24%".>U3@'1O0A(#\$I98E@,*BIQ_<T4%+/.T28LJO$E7>K?\MG
M8>560JKX^J PI[J!5+_4XMX6PGPQ?30L<GX\).)0\]31;\^_*GR8'U:/8FFK
MAX<_T>PSC%2G&+AO52*-][53 QWQW^L<=50KW%\79H[@CU9Z=HW4;M6Y/:XH
MM_$ZWG_C!3CSC?)&VN4C?<;A^\ML9$X/'' 4P5+$IF&3A(<@;Z%4J@BV4WD6
MOU]LXIZEDA/ 3!/YO;#7Z54CDZ:P_*JM/[6&OHS@A5HW;*L.;'G5XC@W6G6Q
MNC=[K;4IWB7;E!LV1^,*( F>+<3H14MN)$*90#+W,9"4+)_*=^69$\;1<NW6
M@!_[?C[3N_#=T8,@X1D3HS0_X,<>W6GZ(3 ,D=FY?Y5@ B0^GXV)-"_XV$XO
M3HC6G%VS$\%T;_&.$.<:^1(BV+0STQ#R%\I<9*XBM@N'M90%K]M-0TU$L$S&
M"[V^]4013+/S *ZV5\;>A[^_FG\>(#TBG,&?HDT?E*I&/T+I\[5!^92-+%4<
MP2BA::;JQ=CG-YF?)NM+4*D3/<CNAFV.D9,#TV\GGM=-Y3(1#:Y=8S5.RH>7
MIY+1TP*JW]KG=Y9-E<9!=\G.!9E!WX>6V#Z7!S$2=AI..94[I1B2=JI>13HJ
MY%VLU=J3^&4'DW+7TR,1R6LZ^%M_$3X2=^"M>:'0+%?R!49%KQ^[G6_P"JJI
M6<V/\2T, [Y!7[MFVT9[AN'8D("5?!%L7_LI)C85+LM_T !%1>YXU0+X/XFT
MOR'K]*FJ/,QO8Z 7FZ*E#&$ W@!)"1]=:UV&@S,IC_$8M@BFMAJQ?6Q)J 00
M4F-9B+U!]VJ_WW@Q8;(Z1';]_/2P:@YVN'*]9U03KR9(0/LS("-T&AY-].-=
MA*RYS5.TQ2H252LG;.=(78.W<(347.O-1T"S0!I]9O$+G<%T7[O>@#^Y;V[A
MYT3@K]&US8J/%]Y%!"N9CCXN=Z!6<KPS-"J3$G)SG?K8.I8>[KIK'<4&%^?=
M'-Y-%'S)=0F-9!F.%*F^O#9]S*DIRR@G\O@+UT8IG>AA-\3[B4!S3F1:SGUT
MM?03&R>=#VM*]]^MA)=(.F_ 2$%_M\R$F,J<L>/H?J&+8!A:<TM'XU2]?]K*
M('?P^Y'7U/:7KQ]]2EJ965GP^-K2FDG?7Q:5??+OKHP[GN^;&F^???])J/F0
M"Y/^%)TYE6/O8S)=$/S,9-*FJL@KL&+2WJ0@,+0@V_[? P6!Y,%)\03Q07I@
M5:&]^<]>!N!D']%;@H1F%[,>TUZ$<4K!F9Y%ZWZX$GX/2,[JU&A9*[W.W-]Y
M$'?182PJ+JC'"I-*;(8_Q+N'!ZH\8\7)?==89<AX6)M$=YO  ^*_Z,=Y<^\*
M6E#[">.=)N! =R!2%<Q:1'"V 5\O3_)=Q=4WM\[- B[1'J(,>Q:/^3F2+DV@
M='#!/&U?D/B(H,T_39OA&$?J@?D]6 WHC=6$Z=_,<?XEL\SJ%?60YO4$8I?)
M'XQ>+.!\KGI8!-/ "$I_--O]3NRN%9#:%@_<.RXOV2#OU0LMAU]G42"C_+6=
MI9#TRL36 '8WT7]]WKP?"R^=*$%SY/?@9:&L"OY1@-P3<J;_9:]R:3-(Z;?7
M'7(&K+*J+]^FY7?Y&LZ8K&+UKM!>:\576KFZP>>^MR2Z=M":ZX;W/V_VJ[1P
M#IR(;)TDF[0>N.Y65&IJ.N3^U+E./:*>H^C8:UM0Q93SO+@J@KED*.6OGRU/
MR*VAQ1946O0[?LK)0[3S%<$_\"%@+#NK^Q!0QW9/P+SE0K?K0?0 "I;30Y,D
M($2P[B&@<B"M!R\%3@:Y._(O86$R1,@:I?LGE8,0*B"41\/*:?-7.F-XQ_!#
M (F; 5="!\+I;[BQ8CPXO>3/Q;9!"D%X7_PE08T()C7 -QY-^L$__T,RN3^9
M3-J3M>=/XDNSXF"LY0R[.FSBE2"%[[XH#^GK<<[P[#] \^<$?Z!O!)\-6F=F
M]85E$G<+C_ ]!.4$,U^^AH 4253$ZT!OV)BD&:^P'A%L+Q3!M.Y%I\+W;W*(
M%X!B4B;RDF2"4#.P<S?TP#SU#E^QEG]I&HFM6/6*(J-?U%EXF4Q9W(5B?MRK
MVZGL0#'1]G4N*E>SJK],"[>PO!>>X&>,(U.:$VY\-OCAVV%[@@H_5;.C:MGJ
MN%/$W4S&V>S<,#W]ZE>$%LH"9FM2!+NH3,,^8T@2[Y#27Q&IUDGHFXQYQ*)D
M<N=VO"^4QZ0HXBB+Z"R4"MZE#1KGH?GX5Q Q.*P.?Q$82$0Z-^#DF<0G2#AX
MJHNN_(&@0P/@&<B]CQV!YJ?UE*62PU/'UH[$MY'21;!7DGUVM*S.0X)<HA\M
MGJ .?0;SF5N)R%-L^4SA*8@$GOS!A+]%/_0*RSHT9<S?5HJ;["O1!!!]\ .X
M<E9TILGPR=5>2WA/F"2TS[\%*&T"X6EX1V;(&;>Q3].22;65:I7[(R:+/49,
M#QDZY)FQG<KKHAR.DW7>.0YW=8>:?-"TF4RTJKOXU"G4\5/N=?W!DYF7+)]&
M+M;,#3I5DTQ-Y:).U]C86"EKHL?NW3W-A3_KP]<! ]S4:221YTZ81C<5CR8^
M-QE&<*.!Z+5Y5ARB[VI0B[EE<MIMB%/)OTJ;NK.^\>SH]5<3-X!Y/+HY;3 X
M>/7K5+YS\3?M)K/&YPPTA.!V"LI1ZO@0R!N <[] L@"#F0IMU09I*4$:O'-\
M&-3(DD\C2B ]07&[,*6HFG=E'>AB,Y)$,&E^&$!AF34QB7*K!;2']MQG+*(4
M_H*E65WY,DKG!8A46=#JJ.-9$ <QZ,4J+->&MEC"^/6$,&$B2"CE')C2DWS<
MZUI^VN%4 MFV0:XPO.AH:TW;RXS2(T776)]W53K<\YTYZ>3X)8/I+;N_._QN
MD9_[_)#'H)!SN>O>.S/2D>SL7']EKO5;2F8Z.-DC/#X[RS3O9SQF=XE@2H2#
M>(0E8@ +LP'6>[7T4+ 9QF_HO>WP*KN:(/]KD _;AR1NR_)\WY?SY-1(:[O-
M1NK'S_(AE%RT/YP>*1R#RPI/\,]AQ?C=?82P3SA&:L:\#2\G*1+#B-WGB+>Q
M&00+2(SS4ACN0T"8)<A&WL$K"VB"5*[F92@D"K%&XX0\>"ZF8,:=>M!.7IQP
M#OMJO7LTF:$F@MW$O&]YZZL.W6*MPW#FO;-8!6(P(XM@!&'*@TN.ST1J:%KW
M:\E!YYGH9-)VE &T/M"I %B]B8IFG@"S^NCFW>NRT.35\69-/Z8PF461'JY:
M;1EZ[Y);>Z_;A&VK%N@24:<L'=0A'5%IX%*(':#66DG9][N>S;@Q?62L[KS5
MOH@(;@Y%/>AXJ'-DD+V#0H)SV'NRFFU8GNUQ[LML;B;Z?8P1&S,GP6VD"<K+
MH)[%L!3:GM#.7<)Q4E-RKTR8>-VU4/+VK$*,YK*75F4#+MH>)#]"!BZBM;P"
M45HH<^@Z:-3EU4]BP25QV>+X"15GKORQZJ7;S"PV<AHW5L&6($_Q;@IG:,UV
M4'D?^@5Q[2=PT0>28*ZKX+*Z.C4$I2)8$#Q3: )%E.'#IO$:#4%::J!O$X!A
M;G53'M-43#]BF7G)*=1Z.^N)3EVH!PMDH Q?OVCM %H2-RGRIB4=]SLI[B5W
MPS,>''*HJ+6M4%:VI1B5.[J&95^M_Z<C'V%2ZW6-NNY06R:@6KA0]!Z,%,1G
M%%L[%0LJT?Z@@7-3%"*@Z_2@\^=B<_=-VS2(R/46U/.=P6B69!]\CLU>[QH0
M%(MMQ#SVPB0AO5EAR4\[S5Y!.8OR*7"9]I"XAF64/#0*H%FV2UIR[:"8(F&]
M@/X.)N?V,?\N@B(8]@CO2K9ACJI A'[O>O4M=UY\5:7%1';&Q+6QS,NG!T\E
M+ ^;2_^G*&ZNVRVOH+ER?[?MJ02F>N+E*?L^VGVGA/(C;'T'LR\9Y<?\CE2J
MUD]FE.L/.N;>'-0O:SKZ<Y6;+*C :_#,//F:G6!)*JL^%)%)I"*Z$7-O>NR8
M=C[J*_:(?NS^J&7D6>9P6*^$Y\R&Z>/NMEL?;H?<7[4/<?:,?U\72-<E&QS/
M*@W^3A%*-XE@AT6P-2D1+-!%D$#;O'UMMIXPRV@Y(QRD*:']UQ.\,&^)*>*L
M:(_BV2TQ]G,Z52!GYJV19^+R,*L'59GW\*9O)MKU'JBF*-H#+<EX@X: !?-9
MOK68.*01CH/)2>U&P%"/4+)S:C-E,V!3?V:HRD3'*4_^EJKE=+#?H:%_LL-[
M)KM=TJZ-G+"WJGQ@]JDA^TW6L7_\'2]4.MPO=RC1D/=\<V?%O6^B,$27+OBX
M(SN]*:3B0P'J5QE-I_.(D$Y\-;OVANF-R,(V;ZT5 AK=(EB39D,+\PTZ77WK
M+98>VT]3)1PEC/JJ@5:-?G]U@8K]G;(@=HT-U/40]^(UF6<Q+I.8WF<H3>AE
M2%CW+XT5@MYX)%%UV>OL,H4B@@5CZ4-=M)?^/:-R4)T;,) NU,?]8+EG;B 2
MT1($&;Q)4^,4X1 ^ **PTF-Y'^6[.E75*[\5_K7L]B)0W:V)15+&M?06-.0S
M2;MQ9\[-(L_7,D*:XD>^:VG51DZY!+4U^^R.5?]/?<P[*]]^(,;E<W:1,_66
MPZ:VQ05E'9O:#<;9#Z7O,/-V]&Z7[+*BG+H'E'ACXY.QW=<:<[4-)C,QM74_
M9A?E.7W/\0XB6'S,$KI%+Z53"G\.U*V/7L2H0W3>8MC:CU(&W@/*84D"^1EX
M&^:?[:; :$\+ALECJ$+Y[H\OI+$&[+)#+*K:6K,_WO9@>7K_284VQ?+K-+!0
M*-\KIOTODM_68]Y>/]@YVZG,EQ-0-BDI<.IL$M7ML/=JIO9YL&7M!]"R2.DE
M*@;>CW=O!0AY8$Z/ ?%D(586E]]K7C4QR/M,>Z_'_D7X!PV<ITD3)FN8!OQP
M^-O1N3=BA=!_$[C47X]XW(!WA#]"7@<Q?4/,=YN%F:H^I!YSR[)E-J: 2Y1?
M>;E\<G#"KLH'>2QTWEIVR%K!(M8P._/*3GW+J%+GIU&-434.LI/Y;S@W:GI*
M)N,Q!:86?TWF>=I6ZE<Z&3KVV=1,%J-PDSW.1;=4]5=*]0Q,OPURG9*/YF!;
M?-5GDE.19_["I01:+L2;<E1M9Y*263[(9=3A\:2ZZV%Q@CS*<L@1<2_VBJ:C
M!FK?[Z\TBP8^>.\_,/":,SM$HT9S;@$,[C5(07( G6J&TIMB37_C*S.S)/BF
MP*Y<O ]XAD7N@Z>JWH^Q?HA2X". 03OR$(NA"=%\:,GV$T=_>Z7RQT7-;ZWU
MOH'JN_)K5]S0)^;Y=\0+2@U25P.GX"_<UTCE@?6AH6P(P<+.T_KLP(Z_MMG.
M^4"/>T@OB2D$R?>X/[KN10YA4]0'DIVN>9/4VR]RR#H7(O+LK)3*U2?*8YI+
M=UN5Y0C^"7)IJC,,#W?.3G?,.F;[DLS9=Z-^=W_Q9\.7Q6K3OB.%$<4H5]ZL
M@RHWO(@R6.B>;VH9%%K42L144TJ$2"B'6S9&79>YQ#O)UX$,0/-K4^N4Z^"M
M@?[1)X23D"ES72KP!?T"U_W7G1)I2!%L\0 S/W+8PR&Z!?3HQ++F>.6V$ >W
M9R&37XC;"#-P*OE1)YI_5% B@H7(/X3+H@Z\ _FX.CM(%6SA$J N%C&=)(7'
M@(I=G4HSA(/!6$E\^"TV+8&VN]T/6!V8Q<KC$2R&.@ZUO(:T8V+5 WV50<V\
MAJ:JX#:O0/,<AXR5JL7E5ZT<23>%.K3_?H=KN9\#,1\2/BL51"GIK;'-554C
MZM3OWW-VI'IG)Q0=).MW1;P+A,=<=6H+D@O_&HYY%C<:!\+?%H3U(N3P^C30
M+3,0U.L3*H'^3]I/++:N*Y@*(KJ$.Z:1.F700&],5*K@<W\><]A[H$1V<M,[
M[V=(0[M-I=6'CSKA< 64*:5G- V^7:@&3Q#K(&0HP6*58#*NRE+MH<%L6,1$
M$6PWFKD'*!(:6;8,8%1U*P-(\B88Y0=H(!-"7,T><%'?2M=];.51GUZ8R$^'
M)D%%[GRS.$5J^=M;@?6U.D##>\8$.^?-71M'J03221QQ!F\?'1 3.1([?^TF
M0G@0:G%,YEZ=U8$B6*N7)O&[0P@:@;^B>V5D&- 5Y'D:2_DOX,HQ%F5<EL@M
M T<?HHX(>QB[4;KX@V.1:+APYM?7/K0L[B6CFZ'T#>_-9"18SHJ;;;SO<:CG
M@=8?#;Y\<Z">T<O3=&PW$/ORP3QGB29_I%DX)GP??";KI:8QVS4Y2,VKY#,F
M3/IEGHZ70GXK\H:-_D*@U5,-NDN8QS39<E]37DJ>ZZ@OB29_L\:KO%)/Z2M&
M7E>P?L^]V%4].'"RH+JX/((C;<0,HT=PAZ=0>_$.4!S/#+\'LG@NG(0W9_7)
MRP:5H,8("LN$8Q,$+<CN+4TZ\ICO_(69SA/\2*BR;IF^2>M!)#6NYL/%826L
M#'5WG@##GB ]#W0> + )ID-OCGGYG.HB:!/F1;#FT;7,6U5\:\%K$>P6-M$2
MO383=<QRE 4?H,VAV8P,H7G60Q6OSM*02CJ.PEH7!R.%N TEC6O[P6QX]B V
M5&@ ,GH*L]1\H0A[NV(_1^"FV=[VU&+D6:\T.4,9>J>78:5MY&=?6]^1*3^+
M2Z,%Y&^+Z[L=*-]J1B+&758OR-G\0%VN<;F;\*6FKV]D\X"B(U6Q>I:F/RGX
M5*KF29NQ-&**8//:W ^ &,#C*H2C)0<[H& V*8,>S9$ <X1* \E48L+> 19&
M8P&7[ J9@F(V\RBGJU/]LFQ6^K?V$!8F.<;\83V-BK1FPF4A J-?;Z!$%[R=
MSPS;$[R/-L)00 >O0_KY;]>3Z.L<';"<JPH9^0'PMVTF"R90#?"#&<WQ;\!;
M"VJ$</RI<5:(=3_J1 O0-[K&8R+B%\Z"DO'\LR%$EJR_V- DP@E#!OW]1P_(
MK[_S,,W.@_+WU;K3-?2]";4.N;>\ZBT-70,']Q;K<*YAD;=.&_B>R+!@K;A4
M%7[6<5,(,BJX%\EVM<K5<7/(G?J@%Q1DTQ]4]/.8@2V^WCG1:B)_U5X9G.7L
MY]V$3BUFK?U<)#U!R0!<,BA6 6SW%,(^2)$;"JC&1QT[=:D-F@=EV'W<XEM
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MT'L7<5?XMB)8PO-EVEPR+S* ?%'UE\64%<7O"ZWY*X>,6*MG$^<FF<)"P'J
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M..$LKG^5N?Y6_N&"_-1&G/PU*)D5=^IB)XA.-8WS[VU;S=1^2]K3"8?\'=Z
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MKS]6L1?=,_&G7YT,FIV]>2ODCHH6,<FN=?H_61><9ERW=LR^G(A%K[Z )]$
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M@4B"RX11B0KE&0._^,P0&SN.8F.7<KG+F_ &8&SW)2#7$1H'R[BSO4@EH2E
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M":BIJ8B.F(^?OUR^7%&Z'&K-&HB)R7T>$W/MW=2T'2Z81 Q3&*=P?-+,;/3
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MM][#Z[ =[5O8)#AKSM8(Z*#>L=G#H>[RQUWJLY+K3Q:&<_ZQ<2GSQ9R=LST
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M*:P G(%];'P1(_NG*GO#DLU'^8\:GRT//?G?SG;AY1SA2AT9<%.Y;_3D!>S
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M_5Q!J':2([WD Z;V\<E/L4OC@EA)^)DWKL,^-/1HRT%Y5*B B90A[%L4&TJ
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M_3?\%5'5#X5-.+0;B%WR$ICAC4%$XF\C= O\2:@B_MJ4+O!16^<]_D %WAA
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M<K)'PM#3;]_UC_&EFL:ZN*A0)9?2=\.T/X6YS?)BKS4[X]D.WX:Z+X(3S5N
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MLZF5ECA0HXW_X'/F ZS:L<9!C0A]G('3"'UM=M. :(Z)F:ZN;ZN,?TVT@B2
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ME4 \*4Z<8C!]J673DM#?-64V2OX5#^G5=R+8:(=131"=@#3>@J6*Q_;!B\+
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M/&1/C4VQ>PR^OV]RTLN7[61</GRB34\,EG^A!?+38I6$:!T&[9:PFUK056M
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M".,L5;9@!4S/W(%M_Q24?VKPZ.KY_YMWY*LXDR9,-U Q?K6GZ&M@T4*6>^Q
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M3GBB:/_W@\+:,?>W8+42G9CQ=4:N!*!5#JQTY*I&D$[TXX!23Y"21%(7N-=
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M?1:IYU:@^V>F<TQQQ2UK*GK<QE+O$?@@.ML!L[=D(#GV7-%0KJJMKDO*%>0
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MYEG\AWSD309!X/DY=]K7>:(81=GU_2;O7SVY= "SN)\FDD%"E;U.> %8E,#
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MD[DODOWUX9&GN W,37 4/RN.3.  &V9I6RP<>509<C@D44!2M >9C5SJAAE
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M![<.ENAGJL-[^=Z9-,LDTD<[V+D4JOD3NE,.+3Q=S@Q7)L3[\6^9F)B,J_L
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M)$BS.)>A^ XVHT[PV$+Y=DP5?$Z,2FZN]&^XTUL<*$;)X[B\0(4&[ $$T<:
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MT]=LX2^F3::T;8MCPFV+.5F<H@$!)//!@"D_C@D%;^I A 1O2Y, 0OY4"JQ
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M"F\Q/=E.$9]I+0,>U=M'<RTEC_LK2K(R6^TC1XRBFZD'N8Y,:,?R7M3C99H
M\FC$+KG+Q(J&/8A*W>Q26TT2Y?=@MH.IHM%FOZ"1O29>+*CSDS9A[=O+EUBX
MQ?\"(^PAA+S:WL]7]?-0B2[U(RH.AN)E1D=1!<T>XPN6]!UKQLD,K1/\EAT"
MB'YC]<_*+=3<GV+1'\566"OH4LFE'DC$5?UJPHT][%[CA"L4V='VKT'D]*/Z
MDT$SWQD)N]C%T8XYI>H1_7@&)5,WOY!Q6TKR:KK'G:< 13[KZ<M2ZURCJGBL
M$3:KC""U'2\[P Z/3[@^4E5H6WO_CB-0WWA@<%S/Z%F\P^UO'&%BJ/U BA%
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MMFM"GU1?D\7?)?8E7,5S& PIP#A/C+9X)*C^2W;-V#HN+$@ Z<&?I&/_(J>
M+R?!?BZ Y'N%"5D30,;S;P8RD"HZ/[_#>$P2S3)5AOLCF0\BF,7\VFG8*E0(
M^S]L3C33@++W\)^;[98_X( ?!?\K(Q?PD'_"9V$B LC#$0'D>S._8E( F6$+
M*?XOA9NSP'$ [3G<'[:A/(( W;A&0@;7GOQ7?1$:_R#-I 'K+4)ABA<0*YUP
M#@UH25XC'1- 7J)E^%L1 DBFZ$;#$P$$^P7+W94I@&B8J0L@4>=XKX'93"^
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M?MG3SUN&.9Q>"B:W9K7V%>6^G)7W+BP/&-'/\HD<&G0_PB[AX9*/L/\W,^@
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MWU\S4OJDI9ZA/1R!6??V3-'ND>5$VC#>:%M+Q3@IN88F4PPKS._H:W]P,@(
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M2\RL."TT%-ULX846< N06T$7%T9$9C*,K52,!V0"T6H$J7F6\A)*9>[H:I^
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MF- 4#S\_ JF,FQU$JKX-X]I6KBY+BM]17?H (1NM@-IBQ%GVG,7>0HJODZ_
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M?>^E>U[B^V4CA743.L'F19M\I&M+1T@ZT$E@[A*41?Z5/'%&D" ^T09$=#
M"E](= .YW=04A"XZ= IS^ZFVG2XJF4;(Y*/9$;LA3XZ_0S7@^*+CJ*3R<X/E
MRJ:PMNM%@- 1X&DC.1+?;O13E8**1?(.DN*\3X>II,GN9%7XET_H36+X[$;M
M"8R6V! 83&O*E"A&J#F,Y'85!)F/?*OW#]1)_-'LZ(@[T&3[FLI_3A"?B#!L
MIW/TM:"[(.*%U "0P;*8JJ":0.$6\RK?5-MR<#N!U2FU!M')1%]^X%&OCHQ
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MU;3HD;2[?/GJ@$%=?MEDY@7WK."79;E.5NO3@.YI ,Z&_T@:P&Z3'A3?@)!
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MI<2Y3WPFG151M(@N4"#@C)W0$CP;01E"5"$EF7Q%!OL!?<MREYW10_&^8<;
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MK!U]8+0H"5B[;7<$&!<*6+UD%?&Q$3Y6"S+B=_=R,.FV1G_4F1%=]&EVI$,
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M4?A%5/@G5J,\%TJ"^OUL0<@R=6,'@=7#:YSCL#*UVK0RI3NAQ1[$XX+E /!
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M0GTM7*/*FHMKIZQS[8;[:44W#*^;"#%9"*T. T+M.9#+P6;P=HD3A%CX&5H
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M2E^4AHG7 01/'/<  7JU( 2P/W5>J/)PT@*8Z14J5Q4JU#[_V$:-%L">!"/
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MKZE/"&@ ]3Q400R]Q>*3R[DW4E@JRW,SG!G&;BC6&CE&SN!EOR+N38YTDF^
MIA2:>RT!E'Z^28NC?N$9"F HCAVI% R&,EY\HS\*B45-:IIR/.DH22Q1VCB4
M8S?%="[!$;1GD FY1AQ&)S7*P=NE3:$-<(DER(7.]._'%V$-"/)L5'136S/
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MW+T_*-1O5ZV#95O[EO8T]\00$DK"/@=P93<Y $#:@1O ;4BOJ-=3KYN44U!
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M(-._(8 9DU\_W-;3 'W: 3H,N+O*O#V>'V?\_#]Z+.'?C[99W@/B3[AX<H,
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M$.8Z";,9IBFBTFM.*1M@&I01B/2<,,1:T("%(HHMK<Y"M;+;!_);&MM%*6?
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M#H+>1<]9D0;Z)93OO@FWKZK;;=MD9[;@WK2O4+%ZHLE!-5\K6$71UO-A7HT
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MGB7 O'T*>/X"C"VA-G\>^OHX(XWX_H5XIL@I;YZ[ --9C?XQLC0W*L0/NCW
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M2ZOZ^O60_0GO>H>T0D+^2)C6XF+O#?ANE3*D"7KZRIV@CNF>$5IVD[#-4Q"
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M*<MW^-4QNE24/#[+T?71=8&PE7CB0&?N;=QZ")^JE&7T[M'3!=II+EP*7&5
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MBT(G6UF!^@U5MD7S*GL]3R50H\O;Z*F1E7A4+( 4*J)= *J4VU_#*D Y_-M
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M;O$-2 7HKI($-C/+')@(E<"Z?%7&H@QDH<2K&+]G'VY4_$S++'D^PG/<\;1
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MD69V9Z6TOWWJ+!.[A:8P$ 6,ORX^"]TID]-G6R:>;1@BV%8%M0Q,TG:-FQL
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MM"V##+]][!VVO]CL7NR2HE4]DR"+_]_8>P^PIK)V;3B.!1$A(AV$C K2Q%A
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MU6UNT?!J1_8VVHB!9H+&82_[=#?'[IX/=AVYJGI=WA;WM2J]#R?C/*3F $L
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M0]&4!BSO#'.7 #%/)W]CC&'^-!=ZR<7S)5\RH5V:,/UB="O)"!"9P/J=.0V
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M1,97@-DK0+"?KADW\98?0A!#@)#"W;9]?ZCKW%,V5S)563UT-HL\.Y&G<6/
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M:W!J#<Z-R. 1ZJKD(H.W"<,[A_K+J?D_O8>S\@N*I[J^:(?0DHG(B@8P/"%
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M58;2%'QN.'A?O=HOJ>3KH5LG=N1>$O_M%E,'V'^0_PS0A-:?XAQN /9/A)C
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MW >\I5O*JG"&%#&,% 2^@,+TTW-=B"3U'3F5#3S\#5B'/.+AIF D06[YX0U
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M\"]J_UJ;=?<YJ-L-2IO6(;[=)4CB4?_$NTWK1&)3M1B%W4K*"U,'(9-X >H
M%(!41N&>L$[AFO\SQCPGF#SN= XBNXVM70RS!\.S!#1GQV$,[:EUM>BYKP5C
M=,&F)8&JEY/.+ X=N!T3[X]BC PR)A)R?-]8V\7D_+M9G0XY<_D,C70S>C9R
MM\U%& >5U;0ITR9EPN!F%K\=DNK,C;',1R1H8+$;]JJ3DLS8:KL_X<D$"I/Q
MEI50L!"6?0-O6X^_"O ?F6M/1H[9#F/I-I@=N7VL=$0-$-N)_0&W*&@C==+D
M42E*/P;,;68W1]3A4D8W.G)PA(DK.5_XW"86?%#BC*U<8"F-VAPG5B^T>&<V
M(E7&YWW92>M9Q[T&\;9!U%"KH.7&0P%+008^]F=F<UL: U?#]./MXG-&> ;5
M);DN^J,&H;- 97%D+".GZ=7XN/]X=:Z+Y5R>=]=I? )$$K#'K29$S6D2$W4:
MN*M[(RYFHX-/TLK3"-B;HT GLU67)"9;I_'G())94U';;-)ZFT6O4+Z#OU\2
M-/;[R[%B6_ @XMSH6A;<JY'Q8K!JQ6P+IH77^(!W !._YX0S,4+X09SM6ZD>
MZ,"M_1E8?$OX$;(5U%Y4?A?3Y]>I>WAP;=N(2U&37*R8LPHOKK&Q<L@@P"7N
MS)PNX?66X1@C"%.?;TTU/]G[OV_!?='#;QZ4F(!1#H*BF0W]%>OW@$=E56\O
M.LJ_.Y_:IX:P,UOM$>C7H2S;M)T0BYG\P6'O'OK6[Y)?!HWQF 3PQUZA98?G
M-#8)8;[]M^D20A]O!5J2S#&QTX6<U\;U-EA0H8-WRR(N:X6AD51XXX,0)#[R
M.$HXA3.<Y4X=88#4A_B+R$R\@6Z#F^_V*X3NG!8YM=%O1XZT(Z?KQ]55 Q(H
MG3I1G":DO(U?35@39>_JY]&?&- SLPGML+3/+PN(2F&C Y(SJ<CE7>8KCV.K
MVX$X_U\GQM_/K-3V3GJ%?]FX45[Y:0)SHORII1[//5/?X'R72IXO>HX1Z]2S
MW*ROIIKC'>YZ+U/9K<PSZ7:?@3U\,=1H!J8JE?GU71(3C'#RSA2.S2T[",4\
MA9P[*<J$7W"6;Z7'08>'-HK3?!V(P.G450835MA5X[^6G?I@;J+DT3"ROI^E
M<TGDW+\_Y"Q%#>+U<@(..XR-\J1C*(7?W#3&PUI07)0";JA]@WVH[C-TFXY3
M\B4+'5*]1>H5-#1RWZKDN*#-W!P.78UFP_A0<*?Z:*$XEA(,9)8=!GOPSMA=
MS7_BPVT0'^\4NYYU-7UO0W]BS>OSG6^.K@B_.TS3C.S--[!;J%*GQ5<7O7)L
M3LAQK)Y VX.?(R+3"X>CO=^UD)<? ]UV@QA7AH"8440DKR+T.8 O?YH+4S1?
M/2QQSQ7F\SFT,.%HL:#Q%?#7F.2D7D8-W@J0TH5_(?0[A=\02GXWYS>3K"A<
M(X5E69B^F,P5YP'9C!I<]Q6 E04>VG $(L"R9"%;MON'I@RWY+*#8.&C1A.W
MZZ#%0T2KR7(.U'\-R%HICA6PE5VFS]NX"4JUA;JEM7B3,;QC%?X_'R2V@LE?
M@D[NZ\$*,H,M5G)FJ!H&K+O#&%5&;DZFGY.'V^1UFL$IZNH%>_51R2#ZY)V2
M^I6B](Q<WV>,5615"+W$=$<NQ%^^@Z #1=2'\9!DB>TT70:8;[58%2#='O#P
M@^3M43HNP54A1?T99B]K>X7]"O-CFUDS65)VA!(IQE]!T)5<0TUE)M!P41UQ
M7@SZ/"L*J!75-SQ;L+30-0'MJ^BXAWC/K9A;\[J[!VSD=<3-0O(>R0_;E=%\
MDJ\V6JLKIRB\.(@XG:7$U54')ED9":J\,;(>:+@PR'>)$2Q[+0@K2X+.M^E8
MGNJ9KW4]]RD"71]DM)";'F[0:FU1?<XC\Z1.0F7@J<HA9I!22%7TQUL8ZMG<
M6WU&]2'\95^CSZM*TB%=&'B+HM*XJHBWA'KK<!2!,6M_ ^B=5/BVMSJ45HL3
M6[0-2)"R-/>97H6S("K/;^Y"3\%!-U(XTSVH#G)H)YP 4!DV#D'5<P%6 &:E
ME;/ 9XR6PE/9P2;(=NDN<*6Y&A\,44!M 3F=-30]Z=7K"T70\18 G6M$/Q)2
M]G/#Z[+QZ.5@)Y#T\--0O>F9&HCH W"U"C-L3&H7 V#%5T9C3N1B[(QZ7$ZP
MN=5CY?@<[[B =XTSVDU+)67IABX[<A-,&MTB+_?52&UC:2GK73GK\B R5.:Z
M;6\'5\Y[0ENBPHR<H4Z"X9@Q0DUR:HPZ(C&?QA@)D=DV^^53\<Y_-SXRT1W;
MBFT/. 50$M?8RPH4+4E *V"9:8Y*"5 &KP<< Z_$J1;RF\;:-=)[B'NH7&S&
MX8]X;<![624>V<%/09P#_>LS@'/=@] H[!#^\C#=/C\HR'BL'_C:I1 (#%U]
M,X(P"\N9BQ6SCD)A]?Z\CQ,=N<Q;K)[,((.+QX_VG"G**WZ5Z9'#G+B^ABWK
M$21X;'E@[ TL/@V%#CBM>-SW2G<-6$N8=%_O4WM2'N;KD!;M?YP; !M>BI$I
MU>"2.4W%9W#E:=N0.>;XC<;T+9?AM<6)^SC3)>P2-65A<$$>%VXRDWUS_/%P
MJ55U$<9LR*6ZJ,'%H@B]4(2N+JNI+GM;E./A8GY"]JD(;3;D*]O O$+VNF2G
MZG'4W4Y5[O^Z^&BQV.4AZGT/ZA<VO3)"_FSP#^7EEQ7_\>S-Q[Z+2Q_LG[>]
M^TWNT^. /4+XQ#GQ)2"S'RND\^AB#/ /N,*73T5<D)P>H/JS<696Y'23F=VZ
M^\9+P/2I; VUU/L<0<1YTH12"E<(F[15\I?*6QS7?M1A^D? .?ED?_ F4T\S
M 2KQTB3H#^9Y=\31):H;TOV3%0TF8\LU6Q:WSN;L&R080\X![W0>?F#H7#VS
MF%4YVQ0?%2@]T+<CMUL0_&5(S(8N'@^&M8R:[_>6;I&=[W2SEN+'(O\7-6X:
M\NG!QXK).]\:4$3Q[5GG-%RX4@'>C@/D#A@$C_^"77V/]%R[G [E<OB !_9?
M[4X5!VPE88PMESGXXJ9H6'H\1$OA3+BJTO(B[?2/;K\[C+*> [%<I)S$;N@]
M#=CJDAX&1W,.)#['67-Y^FEK@-_*YZ]76*QF[3]/1NFYGM_[^N717P.4G<XS
M]> *^N791@KI'$?VR33.[8_LY9'C'SI$+\[/O9E^^=KX#^76,@7-Q"Y[@Z49
M8SVX>D7\_#\B0J&UUJGR-^___C\:-OP_+?1N&*]0NN_AUB_2,:0ND[AEAW<!
MR=W+\&[4$3Y'.6P4H0!2'JW1#[[%ZT_W'\)I_*H50'DN,1]C*$3H90FR$&']
MC:%C*?Z7G=^(3ML:W_\@[78/2/$KOOO XA=<7:U.:B^H9N"4M'B[ZNC[ZT'G
M7:]/Y%O5='A275TBJ3B' '+BZ9XO$E[FO6\%AU(LD@R[&@U^_VEVWTAF\+YA
MQ^O4U5/O(]R>S.M73!)-Q2@@W++#FC@AWS'8*83K3A&Z$,I0A("LBF/_^OV2
M;):;4+^3G5&(, 7K+'?D#JXMVW;$:211 1(GZUS'IG=B#$H32N)=$FI#Z_V0
MO>3(L_J*F@6I'O1@^T*(U2&2 *-D#W2GF&&,.&5:P.=\:@A"%Q G4WWFM703
MG\ZKWYO?=,VH0%OA+38)A97S<0EM;=FEU)L3[=\K@BU&/W0?#$GT35]Z_SK7
M2JB6F(W-KLW,WDMZ\51SW*[ITX+0L,OP=&TZ_9\*7^;?E?-#5?8'2D_%7_@R
M<V&O^V.F7P]P_05=TV_"ZY[O^*GGT09-,X:X4!O:8(7FZYKA6@_7&/U^6#9"
M4?(+M",'P#F(_=!) 4I%H@?"VK&DG#F"#J"?8>-9 ;'X0N\DJ0+N[E5CFXL
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MZ,VCC)M=K^J9<*GM.3M4*0C>W]TX+5*O;.DH1K^^8D4-*L\9#]/$NR<(C'K
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MVNWM,U=6$EQIKJ.G0<<5[OCN=03;NI9A>P)7 M]-7^BF.S]+<I</<:\)!K%
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M7U+]7436H?.Q?PPT7LJ7C#,T\M^\,OK=0.>$I[N'Q_B7HYD^4N,>7N[4\/"
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M@/_>:,[1TM$S,)YG8KY #:BZ!)RCH:4]1T=+3T]'1ST:2CT.T+'37[XAI<;
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MW+(IJW*\IN,R"$/680^AO=-E]DF<#@5:M-<)X6%O&*1T*0#+3VHNAF8D5RG
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M=<%5E,<D0S$*@7ES^=F(+W!^[X+?7D*C$WZ]"OKI\=+>Q1G [2CT_CF'-=V
MTW,!/-V#"BA84'7U%:,(#KVJGH&VWQH [[J2/VBIT^:54%4UB9O(51@<Z ?#
M788@%OX29RNQ,8D>3\\W*GA')I1+W[N+R!-@D%9QZ/2Y%R**BY-B$#]?Z' H
MVQ%_.0@(MM@PU;VY<DWK&VV80P">-DSUO-R*WY;\>NSO K7KJOQI'RNDS@J#
M)52!E'MO]%V:XLU+%OR)[$J/=4X\>I1A="&W/;""J%/MJN;^5W\8+LA?,^ =
M"'(:2P3?62@C934:HA],YW]2\BSW528X'!%)*@.A4W_-# 7B1R2>KI>G@#]M
M3DY4C;8S>P3'/06V3B^CKB:/"E7&,JYW2CHRCL,@4G<.TWM^[OB*X(1)4(C$
M#+E_O^[<H76R!L/BEW=T?G;9BDZ%M$C;5]3"C[SXS3S#HB&5WS2C57G_\)D3
M2.=$^3$JAV7X1N#]TJL!3@:FLQ?F7";,WS48: 3>Z@*VO ;I:.R\?I)'D!6[
MD;2V6W#>9CXKZR[4#DN(=7YOS]6?5Q2-C;M;H^^IRJ\+[6M6((C#Y&;'8*O2
M[?X@=<RAET@%CF-1-[1L=F9V7N*\XTNW%'M8_/HW0<$%?K&7Z*6D\,IL"<(N
MJGU8:6BSAH8]>LU^58IV;; _D:8K5.Q/H^*9*[3/3F*_)!6+::, UT(N+H.Y
M,1\:Z_V2\S'F-18<Y_R^NW*Z6V:E#GF'MW:&WA=2C639XTVQ-D]XQ*+ASP+Z
MF!.J6;:7:1[ODY!Y0/X4;#EWJR GL7^:0!#G/R8GXR\LP:Y , (B^\W97KS5
M27IC>145-2(,\O8O3>-9O"J]4';KQ4'O/%M6+F&$PBLF][QPOBT[=IPG*"W2
M5ZC@IEJ\W_ 6^UP'3==Z<KD&L*K,259)VQ,_;"PQO2W>P'R>,;%=F>3\X,6,
M@?YTT[;S;?U[WBDA/R8KUH(:Q,3$,*?LXY^"V+Z1?6W5KJ?&)QF0D=4PG>>S
M4;"[7 -L$'W$3$VQ_-G$)FQMM-OM/I=<=F;S  7P_]/X DA&,?([*PU316@H
M&_:'B:UU>_HGOM2P?V*E%Q[),T[6-#GQ:]. &X1A,:[G0@_#8*R,: M1>7?T
M0<ISN=6/@1[Q3LX;LV2!H]$'>X,B)*-MML-?#J&-7.R_NS$S$[G!F_Y[QI_%
M*HEU/.M#)*E^;YU*!V$NWOZJ1D&?)HA![83TZ=4*C\]-W %_#R#QJ=&IK8O'
M#^>^GBID!V+V(&4J3#Q8>$S349P@!?@01D[#3>V_O)_6>..&".RDOT@I,NN/
M3'BB3%*[2M69\&)*7AN4GW<S;^I%RD/\':_CM9J"[SL2ED)5X]8(?)99GO!/
M*SDD/<GWX8_;TLJ::[==O;/^3Y<)J.WA#)GG7.Z',$..'O'*H \*)!DMFQBI
M"F PE9N1AQ97A\DBO"S<>G"2&?J]/NH(J^;D=*W'V_=N')_GS1+;'GL4?[E"
M"V\_JU%!MO:<QNWJD88:A*W/V9\M.^VVVW5R*=;B9R=LE7)3+P_2)2NB&;1M
MZ%X 9:WR0' *F_OXON8.S9E] &1)XJN2U%(M;$ELO^ ;[=N*2L?LUT)W'E5$
MS=Y+2I1'(73PZ)-(4LE]V#N5ZQZ15)-L]8^8]TFH=6>@@X?[KS4%I[-'ER)$
MU23:X\,'O^+0+03^6/*0U!0NPRB3''R!T5:W(^.R1U5M7?RE?I84!L/$]NOG
M]$>D6OI#=NTSAR-#$OTW=X\F2+!%L!Y;?N^;]V-OG2S5VR9=MG8"-XMKS%T'
MS@2^7$1V2$YS&-5/J @%1.Q.##A/^PS'IZ#HRP6E?UG3WB&-7XN^IZW0L]QT
M>7TI)^;KQD1ZD&-5"C[C JUT(#2D%;BAK52J?, :?&CK$5,UR#9CX._DJO0P
MS'D]0;@ZSD?XGP&N]P(=[BIU*/WK^\BPJB8+]50K["I&>.++C6:IKE4'4T&:
M[X]FX^,=8O<=8PM):PM"3:O%1REK=BY;I+/7H9SVD7&&;U\O[2+]=3OS78^/
MRQYT_)RJE*3;R+2M%TZIURAOVV9JT& N90UH^<C?G*<RWHT!TRD)HB^$W@F5
MZ-7C,*\;74S?V;9<XKW.+;[R<59-9$UAT+O?>2: PV0_*7R':+M<[/HG23WY
MR6^A)6[?NH&A.A$1CUK>DY)R@]A,B<_?9K:N^OCU^+N]KGYG6B1@G/#U]R#A
M#_!&7B3+@BMH?D0WA2 9M#O=!(76TS^=B#7^FEM$:FBVA.1691]9+X1>N&K1
MXL'H#!7(/&\C4<-?>W#LVL*_F__/8LV7%!T^T0%O72P%0 6!W^9@VH)6JG\6
M=3!QB_/)-\;\F;YND%K8XIYU%F_QSG6!N^I:P\C-QI=AC]>%@G^SEW5W7W\&
M?RZ_UJR!^[*O,Z.]'_W9[]2(5/+B\))2R\X7SXO)\%IN);YXLEGDQVG78\B*
MQ]MX%Q7G!_W<!S.'1*6DL7[KIUBA^D:K@0@3G8E<9O=LK81;AKK2]G)%APP6
M/"CEAQ9FC!T@MMGN.,]D?)=,?%J75V(HP6'68J6Y[$P5!]8?O6P]>&FZ\X=N
M5;: NSRPH\["G-HUC_ <K HT+SI[N?%0T2UZ=5<8^/6&OS\>*ZW6NI(8FN"S
M-'M6[#;I7CU3@+IO<[>I1N7]J]UL>*A$Y<@Z!O8^!)8_W>U6_$0&8JO5^XXY
MY7L*I_>'1BCO^B3?ROR=G/.C>HU#^4T-C=>[L,2EH'M"DK1*;*5-4)6_T/&3
MS,1O7J%"!^\M:ZBEX=YY5?(E?14XR1NB3E0F(>S'2FXL_*0 ^1=K4XR9GIX^
MHQ/Y-L!8 K9]\<VHMA/I[-^?GP>#V$V<Q15LW;;-[X/YN\X49 N@FHBOZZX6
M9%S)]\ .D#&V(T]O]KB]RK5DU]?]>9/!F4'Z^_I=^D"J\D:Z2+X#L_A:!W<3
M;Z"5'ZC'GC?>+S4WBY;MC7[.Z_?L]M'1-GWP?,)^;*CV\CG"O-L6PQ,OJ9?N
M-"&)JB+)"YE'N@J-BN@=&4/LZ;MB<??75=<"%\=V+XOFUB:]UA>4DZ8Y*Q"A
M%7HP2LNYT<X>G>INM/K% #T]';H92M+[\8O+SLIWK.E[ZDJE!#RX86.7 LB%
M]F$?G$1B![MLSTVC=6M-Z\[N/KD::-@P>Z<P3?^>=&F:X._C38BZ]4 8(N?<
M+'WK]56=U%:3#5AI%>P!C*514[(UF +P.I=C=)<<L=4_ [V6,&(SU0G'"7+:
M5J_^%JUI'K2PMBRF> *EDPM3HR<)6$37'K.E2Z;(.]F9OCZ>S$DSJ3G!3R7+
MP/VZF@$LU'AFD*?[N/1K&[IH_E*JN]Z,7N4>V:E_S?(.HM\\Q;QJQ*"DV<H:
M@LS?#OWM]WM+JG5 4P"N$UW'#[:-7;OV7$C;OWN_>WB_+34"V(QWK)BN&2$\
M4+K7)4-$#BX';MK]^,E=14:OB0@SO='9LJ@>A+;O/K>\8I;AD2'D_@EE.UR>
MW9[G4*U9!;L*NG)TBN7>0>QWS1@G]0[[-ND:.]T-=V#RXNIP'0-HI.E;>?B5
M]6".Y;H\*EY]-Y7LN]X ]I4?Y.4W=W8RR6;(Q7P0Z^X1;/H::CJ]W>7^CI#+
M0Q/1Z8.'^O%:UUDBFKPBXP\4R?[++_D-:-YVFA@UB05K3(KG[582YQ//?)UV
M[<Z-(PSBOT5DK>3%Y<[!VV:,ZX-^0C)/JYIWH)\H0,0E7.RAP;"*4HA"W04!
M^'=<,^;IZ,VVB"$[@^2;HJB^JI9NGHW@+-AC@3>7+6B30CS9:@Y*5P7)3('[
MWMHXLS,]JU=6I",KW]*.)@%^N3E'F 337IY9_#WC%EZ6L!<'VJ@G%L?/?I>K
M,'_F(0[>_,#A9&AZ21N=R(;D+;6.V,?PI@@A_A2>B5;6V/15'5DIA@Q^WG>2
M1(2A&PG9.B')OH)W)*3\4EPLG+^7I-; !L:/P5*5,_M,U\B=WA5SC=77R8P@
M1#Z,"8Q]*LYF78N#+Y5>V9J&GME>6*Z)^9ZR0AP.]-K2 @=X11XDH0>!D](=
M]#(DL1(90P'80ES1H$NVZLX% <$:8[M"K]_-E;FO31G]7<J>+6SA52[W@G0@
M=[Z@BSV6D6W.)<3'3EQ=#?MLRYW9-9'BQK<L14;U?T5,:WT5ZG9_ GZ0B? P
M9E2S@_&9^V(<93T/FC"M>G:]D]LUTY,'RDC&HE[YUX3&I3YM^R\FF=5EQDU?
MYB>37&^+[R%.TL[D7.0RD2T>;Z?S8Q^)[RE=6$)!Q,Y)D<.OZ #G(EMY>/;^
M6M0O DS*05ZC"Z7R%$#9=6UAZD%;#9F-E$5F#_ W,K=.4&PA"YQ3H+WV[H6<
M5 7*4Y_I=BUPGH?GN#/T9J"=M%^B,BF@*V!S!P*+F*1]BZQ?8@XA6,W^UI[!
M@F_UC\&J#F_?0F@O>_&5QZW5^_[0+E64HWI[]ZG76F$TJ"?[7<H/@TU^B.I;
MR*/DN[Q;B$U;5IBFXZ:]L<48R3NK2/&FF9^*@5]S8T5%_S<]-.#E;E3C# US
M<*4 !XQC2,R( 8D>LV^Q%#Z#3@+!#;A<R M=]- )UZ]R:8610W_G'J#YGO01
MCH^Y<-^PHTE\ ?A@T*4M#I#MGM1%W#,6UOFJF9BX8)]Z"M!C^'TDSJ."F)1_
M5:U9@DT-?K@S0S!M=CF#+3PJO.RON<T-"O]Y_EN2PA;8I-_WC6[?GD(@>OV4
M _]?]W"I"^@$DWV,>B0E&Q6HNT$*,FZ)MYF;I_0Y5A4&:W>TQ<YW7Q1R36.D
MC]9XXQFTB"[<,169R(5=?F5E.RJ>G[;SQS-=\)K_;^/ KH?KR7\G-UA3ST1Q
MUPRK*L9V?:V_)/M[L*P[V)_WN1C5]X9!:[#&JV>?3:\!1"L^5_M:6TG5F_@X
M1>7C8; K\:8V&).IF/3'"Y(O!Z_@;OMB^^W7>G8;VB?IP]^M>VJ\1YM)7?5]
MH/"%B[+8*^(TCOP*\>RHYUH4 !/D][4K")ER !;M'*KEB;Z D+</]Q#!F>Y/
M8U@?66]D1K6 .ZK+!8*+T(4M1,SQR<+2>OB.0F3;M,\+%H9[MT)ENEM%^([[
MW6=PWNT3:/97]3Y."GCQH?#1K*B3$V*A< V_W_$H+)68A#H#L^"Z=L;4EMP,
MK]!%NUIRLA]W*>S8FB':]MY;_+C*=E&?9L-1Q4ZEX:/#8>E$6G4T^[OBXC1.
MH#!]/QJE_]6/;';C'5\4C??071T&V%XJ.<@( >LC]IR4G#1X&$@.$6NK</3[
M4&)4J*)!E!;F9M0T@F<@5#D87:U:DCYX\A27)G]NW;BLG#[:X7W[.02CE]+A
MELPH%\&XK)NQ7XS/!Z#Y &:M'%V[W99=-)8A5AN4W(U.9-K$&=?O-A^3'4&
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M ?]=$S7]ZMA@FJU53[B\S*>\.=$[:K%P>L5)Z=)3/H?YBAQ'#2FDTI4B5]'
MA1+":U<^.6D*4/=V524N)5B98.E1=^P(;T5&5XM>EF29L@]22G[/)H"0WYPL
M7>_><&OD7NQ7HJ\:\OE. 8+F[P7PLZI=YW, )Y41,_?!1&X#,A-ZZ;.(!J[P
MOB"-6(*RTF0J(UUNM%"27;!%'YG:3V0&V-Z ;;:J.@[TWG<YQAWWBVR2^%:
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M0WX_^NAL8EHY(2$'$48LX 3Q\PF!9NDW\W61@5M[_K^^C&/\?WI85Y^EB+:
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MB)X6E@;>P W*48D=B.<5^Q/[:/[4F@_LK?LYZ]\5M1EA@N;K2-1T[2K2Y/\
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M?3K35M&NXM5T^^BCGL[RSE2:&2&4 HZ.F05VGGGC\P=),#*[G9N&;<.!NS@
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MG.?!?A9H>A^))-7^#OCV2.U56-SIUU<(K#<OSQF)Y 2N1C[A']:_:[_@LO\
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M08HHHH **** "BBB@ HHHH **** "BBFJQ;.<<8_K4R^%^G^0&=K/_()U/\
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MU%?<'Q&U86D%[K$^6$QDC"$Y"@AL''...I^O%?G'XUU[2SK,UWJ\GV>/):T
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M7/#24*<DT^D[NZU_X8RI9?27OI23>OH[].OW:6.B\0*)].O9HHDM=)R+./1
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M]*!2'CSQP.X_QJQO7U_0_P"%5&E^>+D=%_R?KW]/:I:ZSG)MZ^OZ'_"BH:*
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M2@ED<H/-$TH+2)P. K$@=^QYQG4\'>*WQJT-W8R0ZP[&47"QC;@J2PD.,\=
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MK.K]D<H/(-(3(N1"F&6:<235R-8/Z62)3X.HN 0%WW78*-A8O[+&,\;DK7U
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MVCU/E5IJ]O'*OBKW2P O;:REH-E:#/.J,6U8[?//YF]M"6&/FX1-_%W?:?.
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M0([C^\%76E:EGU&G3I^R^RO%Q$0 ZC5+;>7#GAC:RG=<U\=%J<R$$T1SX.I
MRE+8WO)YJY4D"U!X?<K+1^+$.AIO"'/><08B9_+1)M2? Q '#-<:."4@,;#7
MJQ K,-&M?4Q!VON%OCAYD.?^H#56KS7D)#7.AU,,K;"JA(Q2<3$[3V1V:M<,
M::< :Y"Z/,XDJ[?6F%GR'6*(Z'7=2PFXB[;F@_R9]H,V'WP+PX'<SEN]?V>6
M2BX+?I.#P9TKH^T*6*^W==B"TIV^WBHXY4LG=PZA51KXOSA_%(H;JNVI8<K"
MSPRK5I9_A:='4W>M?+YZ50A:^A2HI-MSK.%;Z>LN8."UI:^L8?8V_GMB/A:D
M+ @R2,R'3^?.:JVHH^/3"X2G!HJ&?DN/UYD-AH3$:8;S3\:@QQBPAT<6Q]N]
M0 YG X06NE*SH_EA4NK&[HF$I3W9@"DJ:!F,:[\%\'<+V3B&?)^>_*1G<0OH
MCE39:JV$* ?IO4>?UPH&>(::X,^F OQ;YH(S,XY)^GZ1<]';..E0;J9:X!30
M]RR+%"]8PZ_5'4I)WXAD.KSCN_YNAQD)+A3%T9)@GC?<I*J\#X[ 6"1D8+@X
M(6J3PCC#=8YK"L2GZ3<' O'RG^V&?G_P],T)&X"AMO%DFVA^PYLRA!MP[A1U
MDY>%;#8(/Z?DZ8-*T)5B.;5*KK72O;DK/M_+:0]\=R:%+[503G-<O9'0'J^,
M<]_)XZJIF:@Z6'V=7  /X7[-X/Y3U7B=,!24W>,RXP-:_=4.ZB+3&!ZT6/)K
M:&AHSC6GY P0ZY%LRC()6K ,[ICT]0:V $3 S'T2"7DKVU5F&B;,5L<)11Q>
M> ::6!Y>@KR O,M^@YF2EW-Y.>M-!_G *JB!OF*=AZ6&D>ZX@4''1?^X.L/L
M_YZY_F\1":E^"+PG@;65.N4Z\*_(E4 U1E'8,U3'T1XE=PGT55N\2)TZD"6?
M.B$&[70I!Y5A$\L^G:-)</\9](RLW@)"_,9[ ;]30!V#I&ZY/0!M^#-/W7MJ
M7/J"86(3J:>QN,E;@$39@XS&LDU>O$EP^27).O5]L,W"ZC;N\=;\UJE1"_(,
M.R,HZ9.T(#G GS8ASJSQ/<4\0BSKQAUKJQRJ3/.Q:E7N@&YCQS?X$_QY^L7/
M=HM/IP0]*;8I!E#M7=!)Q>I1KR@5=K(K@&\7'&@4:3Q>7?EA6M(D#EXU4NF2
M!TGXXOI@2%M(0W5,ZJK<]4Y#NJ6SRB(5'5$'#LL3PIK=F+'@U9 G8OT\796J
M4>P4[-_9@B-C+F4AQI"R*XD##RFK9U]1J1??Y^%GYXT&P-[4W3IX24'SYWMQ
M%;]AO&*JI!UW#:Y7\B",YOBPCC(]VL?'2YP[1<:*D23=B"FA:5137_[JP0&4
M%YMRI%W7!*]MY +]_B;XO.B>4$*,' ]W!/-VUB7;.G_,69M"YX^KDNZ[W5A>
MC]%\4(3WF?),\A J40H@NM,75*;6AVMV2XP%??P0JSNP\RFL5[_\,DPE"B[K
MLF;[7SROF[)[K="?#BT))$%=GY@50SWM3DA1>[*49462D:0GF9'G]_(/!B3?
MV1- -5,0\^]+@T&*,K2%-5%:9%;[[V0HSBD"N0)0U1L3O-,N1T*?_H3;O=*P
ME..KBW/\C1GH!1LCAM&QREG95^WSEKHB;4R!.PVER\GH+J1%B]-Y=D74HSQU
MGU^:#F:32E0S?:3;[,<)\,D]&_)I19YJL-$-Z[8QFB.].-7&O(M-'MIK HJ,
MNC=1\>0$;VB]]27%F:Y;UCIN-SO)_=G/GP2<*+]1?YCW..Q,4 LZ E-JE?<>
MCSI<WA#Y&RG+W:@Q5BI;^3$8&$#Z@:O>K34_97IOX>B?=>)Z?M=PD+98.;S9
MVF)AWJQ?R$B#[OG/L,T/]VH^?4;5LOLR'&$80V\!.@DG;-B-ABR&-#XBZ0T7
MVC2BI"4"FR)>WT?M0;7H_OW+-5T]H)93O<STS/S:MG9;BMET0;/94M4&B3LW
M[V\7WUX_( D\2A(1<2&M_'!:"$ZV8);2KY\UJG<@T.,!UU_S)_S^3^'!V0YB
M^<TYOHWF^,SY0[G7'0*UZ#D%N56=C5_<"/FN:R3I;O1%>9U:6;O'[;J_7:T!
MDQ#.MU[TR9_#8_DCA6:7X?OM;_N=W@!X%#KEF/^U!GAO,[0%5H/+^CRT2\&!
MKS)TZAH=0J3,WQ;DVO(Q;S,_-&,@HH_SEG1>H9:\\U:L_'8_]-GT/<N=T11G
MB[A*:75:[HQAVP*6@WZ#( ^OM[O/W3[NXK7SA)G7>'2*Y?(:+97CH>TVUHG.
MV.!BS=)_K"[Q+!'+TO$;6<]I[5S"-G-7NI;(_BG)F\;CS,<K\6PX$[1F[T E
MK>*(CB5+KKDUR<+JLXY'#TB##IZPO/:-RPMMNP5T>CKE":"AT=4?+5+ D9U7
M:7G")0T*L58,ES3BV^D? -MR4B<9!R''(%4T1^,729:'MX O83VT('GO=!MF
M*Z4_]((O#:WE7")>D_*<2(V=7XDVGI\X%H0/[R*QL%.$3>+D5=,Y55NI="U&
M-XJAJ(Z<<A-'>5W?*-''GW$@-$L:IRM>AS;-TY3"KAXGFB"0""=A4RNL5) C
M.R?CQ'QW3V-OHWD$W>J!\2_#62UREO]"0FP0Q_GK^0>4ZU6,FM-N9XEA[:2_
MX>*[ M:NYTNZ^I-)'<<,E];F148\J'O,IIN.=]W^1S9*&8,F='\G1+UXN641
MF]_#1.=H-%7*$O%A@LYRR)_,8XR?@3FBXK>E0^'TX8T*3(]:DU)>DL/BC6Y6
M3@Z7M6W1"G!D;VM,%PL_=C.?J$;400Q\7#TPF1LIYMZ#Z:A0[86T+QMVR4D!
MMJE[)\'Q>+X5JSEMMS+5PGM?+D\:TW>?B?O*+?7SE[T&)>4;7>OU,!GI*0T/
M4:1:C>[OFFV[L\52W06":@ZFC-Q&S#BD"\L3_S90^M#E6.!:[)%#%Z3D,1(H
M&R!(%I'V,KW<R6<<2EZ(AZVO"W3Y3)2F5YM.+)G:EU[4[J[4X6,#UQ$L/2_C
M?;/LNIQ,G<A;_-V_UW2_0WGD>&7=A&"#UMH,NFWX)B17V,&N]?FDUM_.%H"T
MKX8&'7V[I2?V.R#IQLRC -X\$A5RW#UT8SR4!2N]9U.++I88"R0<M!74H!Q,
M^SRZ'Y=4Z5Z$V"!9!%*VTV#'U@W"[']CV]8LJ^A?I:AYE.XTH'HE9=Y/?_A*
MPU#SP_U9P%HKA8_3AYWI>KCNDJZE0FF*-7#[7P"80DIVJLRFT*I^(P=6/0C3
M]+U1O.*,/<[00& 5CL-697JYJ)84&9LWS^-A\? %W>3'69)/#PL3%*+G'Y]L
MW70?)HN;,RDTLV(2YQTQ/]#!T9"Q.]D@/KO 9J\%Z:T^OM >&<TNJR^ 1.9.
M#;(^\4JA?L4IV-LN"1UJ?S2I3&G]K^I8XQ9@\C>76T^\S]2O-4+N0>':\]ZO
M3][G<,J' 5_@AX,!>"[\R#)@,B&DK&0L 6+M9*M<L.;ZDKPA//-M\G\I1W:*
M.0!-E7A_,$291\_*;_EF9G<E/]"O<5Q1@^22I_1*$X>P-+L,7%4Y"+E6P[%B
MT^X\.$RE_C#L/6=&A95Z&=;1<#:>H0T^2507;<SP'/[K@.@XG7/Z.A_E5-B8
MM3*4"Y=N"A56%UGC'[:48R&M-]Z.J^E@0;F+]08K(.#5<)G>Q 53U%'W =3'
MTE70K.:K54_L?TC*K2.^F-68%.+1A0 [TZ.5D#\!]DMYF65:1@M:E@I/*2)%
M_E;J^//S$_TX] K9 QITF&4:<'V;2/4KB:J@#&Y>;K[K.CU0Q^UTD5/H-T4,
M3!;Q<M8:R"WK,\O+Y?X99='CPTR4"@"<WY=1X"H$D2A< 3I3+'&#]S<"@WZ0
MBC-]U7C6Q,,_@?@&O.<< Y$ZGES'5!>JT.)TD3Y:9SMVEZ5Y0VNF"=*QV X!
MS>$\8K5#D@--W'\D?>Y81\S;8^NLH9W =1;7^BEP-%=SGG'TJ"8OD6U>;HL#
M @ Q7M-*B$511P2\C)"9X*73?I!#OD\MECE%T+I=[74 Y%_3=Y5*[$*)')C.
ME\+@FQRX*I#(36(-^LTC[]K3/\[JRU]3PAJ.PP\G#T9&7&&?YO- :,U5<VSM
MM2V.%"T\]>%P= C#1>=,0_>@>JZWNX4PZ4\E$[>G!-84,^[TGN$+8X/TX*\%
MO=K&ND:U/AZSZ?\":'Y^V[FTS=\$X<G44=DP#NB2LLAQ;9Q>,9BP>W+NZ3NS
M%S^&?GL#;B82^^3CT()7L.CHY.05[V,-HB%2U&!H54@G,TF9SK4H=8T@6<;;
MKZ;'='X-B:YN(*45F\@^[%+V&%NOQ_>-Q8_U58$XO1*?JBIFQ-NY#W-:GEKK
MG(559T L]=D/[MT5-=QNGQIG/VZM'8>+PL%O :$%N-?8<73%';CYC(6QXG-7
ME]1:K5WYHT2E9,Q<MR>$2^,W&\TW;F8S)\$)BH>>J@#DEEO8+0!5&\R%TUP[
MHC/; 5*[2,$HL+::\$G&W<OUAM\MQ_Q?:7U(W]F;V\%/"?,ETB 1@[!_?FN(
M+A4 Y,-?KDX$G>235K75A=@HM_GEU;3W=4V_?,!6,LMOY+BDM4P$QS@@7@8W
M4<$.!Q(]56N"*I'S/O$',_D<.3,-QQJ2F)C[Y&P#A4KM'LP"?U[0Y_CQ$IZX
M=:F@C43GMPV.'=*"CJD[E1E:T%2U_Z4HFL0E+UJ$QHU' U[_H0VM\PHEX-)2
MY@CN-(.*)3+BM%/[+$@BX A2"PMGZE4V(+56HVE#BD4<XU3Z@JA+3=WCETL:
M^K+KF$B+FPP\Y5Z U$RBZ!>7ARL4?^=U>-3!+Y.;!=5#<BA[,'=&.G8+J"O#
MT2-07/LG>9+IP]TTX'S#XYFBH,<PD>K0-04]!:/%DUZZ(3,!5V;7;"W"T/L
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M@\V+T *2C-.G<IT;/TBFV+T6]A.Q_(T1Y\'D^ 4N@G-=A;*8:8A/B9[G@,;
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MT][UH,6UVW9#OL?ERC7;Y14P06J$T&9B__PI59'8[\_J](T8#^[V7GNYKC.
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M0C2.=9MQO51!6_C+NW*NM&[V\8TUZ1+,U!'#VI*TAZ$@L<L17(K4GW!0RCV
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M#*L 5VH%=@2>P"=PPQRO*Q"=]%N(L3.KF;V2DPOP1KQ]$X%R':D396--+($
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MJ>]MWVB[V(;&80? 6O4X;6S*IHF=D3OU@,V4'8N@T2\DF(#MO2-K5OD- 98
M:'0+!=FQQ9%1Y@VS4;_;K&V+7TG<$]9.5!$JB%2\==W;?WOS.K(I#QL\J5_+
M+)W3[%P.LQ0,:&G56L:T']A3^C<QB^Y+5,HT3DD<+EFVML9=Y]R-W^$U8NUO
MY''/T>+%Q+'P@3O"/^YZ7%HE=G24S5&/ *,.[,BHA,N8I!-U%E]<W_%2]5[
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M_L[ -M8TM\59*9-SZSBTDN;'1>?!S!W)YD6K:54<2L^LH76)Q>[-&S^%04%
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MKM(XRW_'B950GS_RXV6C=GDJ=U1+Q4*MTI:H(]A^^H*A38BYRH?8VAN%;9?
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MS?4I[GWXP-WSN%ZK5OY_].QM/RTKA$E+E"9L+%/U+<$F"(YQ+(ML,CY+7Z^
M249!*B7!^SD;H*%;USY6#L\H!*/JHIB9LQ+6;*BVY["(O<'FX7=+V.M12*.
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M ]C61_P4.^%.OCQO\(/%MMK.H>(?#GQ&L],U$NK2RV+WL\L(>(IEE1L.3B0
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M;NK>]A=U?<C/$5.&. VXDXYP<8&2/PQ7R[\(--L?$NNQO>S";=<A@&.['SY
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M;:N\9P>G7K)W[G\SW["%X_AS_@H ]D[!8[SQ)>6$9D(16F^TLOE ,1MY7^(
M CCM7]7&N64+>)M4#L62>W>WB/(5)=F)$#$XP#CG(!)X]OX]/'?B^T_9:_;[
M_P"$@\1QR1:*GCT:Q<SQ':MG;7MX9"KXQ@(IZ''OQS7]2'AG]I#X=_%;^S]:
M\!^(;#5+/4[>%F@$BM)%<2QH=@().6)[G(Q]:_N5*GF,<1BZ=O:0PF$]Y:_$
MJ:>JZOJKZ'\4YE".7YWF^3R35/ 5N:*UBKUJEG:^F\FG;\GKX1X4^',GA_\
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M:.:YMT=O)@5%4D*G!.[;D@#DGWK\J_VQ+*"YUO2_$[6\=Y]K+V5[.BDB4QQ
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M#^Q7\%O"WP_T,_$WPI#XOU[Q)8PSZ[_:!V&TM;V,&WD1;G"^7;QO^[5<D!<
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MH*1LQ(V C@8(SF@#]"8ON ]L9_# J2F)C!(^Z>5^G^&,?E3Z "BBB@ HHHH
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MM"[LX'(Z>V,\U^^O[>?CNU\'?LH1>'KN417/C?4(K!(RVUGA>:-#(H!&\LI
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M_HYZ /I@@93@=%[#UJK+&>>/7VZ]CZ<=*MGJGT7^=-<ANV./K]/RH RS$V>
M<>X.?Y45?\OW_3_Z]% $=(P,D<\:\N%1E7N0,YZX Q]<\]*6IHWCC5B<;W#+
M[GT'_P!8?TH \K^%DIT_]H2P*_NX[MI,L" &95 (]>#W(_' K]6YD:4/&PPL
MMN\)Z %I$.1CUQW[^OK^0VG2/I/QO\+7+/Y:37JQ,1QDRL .OJ/K]#V_7Q9"
MHML#S!-Y0+^@9%YZ^G^ YJ*MG2DG;9Z];O3^NQ#?+.,TWNE;INK?B?P._P#!
M1+3KO0_V[OB?X3TX7$=A<ZU+?* V$>W<*6E." %'S9![<U\/_$O3;-/^$<CB
M>TFN(-5#-;W W1R"&16+. #D$Y!&#GWK]7/^"MFF6GA+]MWQY=+"HGUBTC^R
M2A0'7S(D8X/7/S=NI)K\DOB4UK"OAR>W=[B^=76Y"G=Y<A&23CD,,@GGM7YD
ML/3J9ZU*4X>Y6=XVO>+5EK?1N]_ZM^I49R?#OM4E*3G323O9JS_&VQ^GGPU^
M/VA>,?AM!X-UW3KBVUG28;>QT/3?#6RTM-0$:['GO&^2/[/"H5I_,89!XS7Q
M?^US\<_#7P4\));^']<\-W?Q+U*1UM[#0)4GDT<N&(6_CB#;IE# ,5W?-GN<
MU\M:GXT\0^$OAOXHU#1-;:QO8XI]MY$<S6ZR9#QA@<H'W8SQC&:\$^ GPX^%
M/B&^OO&'Q8\2WFK>([NUEU6(/>M<N-Q8@B%F<J.@.!Q^E?JG#F'@]*D$X6M=
MZR?7>VVU^M_F?BG$6)G0KS<5%M\UD^[NM%==6M[G#?LU2VGQ5^)^L^-/C9J+
M^*M/MM141:9JLKS,MP\O"10DN?O$A!M^4$#MQ]$_MN_!_P %P>%X_%%AX>OO
M K6\*W.@WDMJ8+6ZB6/=''%*%"@$8(5CNY[D<_$OQ"N9OA!\;M(\;^#$F@\$
MWE\FHRV[$BWF6WFW$L!A"6 RPP3U]Z_1O]JC]HA_VP_V<=&TW2[2SL](\,Z5
M:PW%KID2B_DO(D\MKIW0!Q$X7') ^7KP:^H57ZK*=3#4J:YHN,FEK;57NK?\
M/L?%P4)8?V.9U:D:RES4J:?NM\SE%24DVTTXZ;6N?FS\"M)^(&EZ+=?$S4;&
MXN?"BS26\^LMAX67.P-M!+G 7.0G/7FO>-2_:1\'>%+GPEXH\/K]HOK#4XF-
MP?,15=9$#$!PI # @D=\Y[4?L\VGC?PM\.[_ ,"^*[%IO!]Y:RKIJS1'<LTZ
MG[(S.PQD,0?4G@5\4_$KX7>*-#G\0:G*SW^DZ1<274-C;@YC0R%P-JDGY0,]
M!7Q4N%,!F^:8[$XVMB).>%?*^:'Q/VCY%S1ORIOI=^=]_KLNXGSW+,OP='"N
M&'IQQ^E*FIJG*E>G^^DKW]I)+WK:62M8_P!#OX%^*E^)7[/OPK\;V[>7)K'A
M&U,S[\B2?[(C[?4\$$#/M7/^*PIA2YDD!:8&,,%*@R(=NP].1CKCT&>N?CO_
M ()$_%^V^+_[%'@6"WG:6[\'%+*[&XDQQI&(O+)S_ %"$=B"/6OM;QT((O+D
M( MDFV+D#;YC'<3GIWZ]?2OY1XMRC^R<VQU!4(QINM)0J.-IN//*UWHM?3T/
M[TX#S=X[(\#B^:-7$?5K5'>Z5X1OI>ZV=M>][L^>_B7#-:^"O$,VPA_[+N!C
MKB-D8%L9S@ \].O%>8?LEZ##IOA!+V",.][?S2S-P#M,C'=SS@=<=<5]!^,(
M+:_\&>)K>4 O/I<WEY(R$6,D]><>@'&>#Q7BWP =M/T-=,B.!#Y[#' X9L=Q
MV_,GVKY2C!4JG/%7;DG9[=%TMW/V6&-G4X=K+E@V[Z*[TU3LK[VV^9]62W>\
MR!F*A0PR3P ,XR/7TX[<=S7Y7_\ !2F\MI_@5XAL"PD,BS2^8 <J3&R["<>W
M;'4]*_3Y$CNH;)UE5!1 V_=7 0D1)*5!0I#N3I$65KI!I:2[8VD4EI9.::2[
M.Y80$!9869JE<Y=<^O5^[O.^'Y[S?KC.?)MSS<R9\__]9\[,E>60QP?,DO)V
MW(OKFE29]/>LF:!?_(?2#7;T.$T'[S7?\HU+" N<8CGX)8(M[\7=S3\B*+Y\
MO169^/USPM_6D\YY?K7\>O#7K_1VEY)DMZ1M#;CPX7P>3/[:!VV[?N'9G,3\
M.FG?X6GA]J1.=MZEF]2]E/0A<C(]E=SKE'FLGA0S?SVD=Z27OB:_)J.3T"%A
ML'8XQ&AF6S<Q& .;&?]>@P_ZQR;_QN*]X=PG_F8+.,Y4B70Z4W%@A/(P*<//
M-R?J(D&QJS?77M)P"M\_L:*B'!K9ULLU3HZ"QXV/ (&98AAS?<.K1-H6=C)A
M<*C/L!Q=/IT*$UUKM8A)YZQGF2;MEG(UTQO7LY=;<:MLP2I[(PA4]8$B\A!>
M^9IY4S*\6M%G4LELS8L>8:Z MECGJOQCU'BYOSM=QERV'A^ > 1476]T._ED
M?#X0SY0P-3+VAXOLIZXB-=H]+*C2_6HUR]DVV-J@.3DBP%QHIUZ'U[2G4D;0
MA'Z+&6V4$=(Y9B-9!SGU'9$T/SFV)EAN;>Z=QHC1^@9WT@<1)W$7<FOR -%F
MM'M18)ND9N]R:O;W=W3$QS$CA8]/QHZXXL)H] ]WPJ6QX;\@8A&,GH.IQT]#
MBQ45Q>G":-L)\\^=20.$@[].CU89<&VT'WXODEW0I;%PV2D1V VL6!AOH%"X
MU?!^M2#!G7;M7'U@FAJU':"OF*LT3!&=;N12%3I9SH;@34E!SEZG%.T.DZLL
M=[B;_[S3-+XC1#V++3<Q&'>(<2<]]:U3SA=]$J>"72Z99Y+G #O<N2/N6/,H
MW#B*:PAT<G>6?$']"U# ^R1P@%;N?.<F, 1U<$G3W"&#S$&K3GPX+4NU5TZ.
MG2Q0I)8%K"6)TWAO=.5=\B+'[KCFUKMFN9B:6L\*HW43L-C? 5QD;W9R PE$
M%Z4GS02P+_PNQ,JK*E<%]E.KJB3^GM4'9/)&V+7IZ!JX3VIIJY29:3DJ)<U'
M.Z>8%ZCD_>&)JG(\$NQ0"/E1Z?KK=1_E:YR^$9I'@"0BMVG0Y]>-<O&7GN"1
MHZDOXO=8[L)Y1(ZLC<%];EFZ(J1:3UA":#[=Y()HSJOE!S/7VN7YQX*<;KO$
M*';*)X'FNS+20]MOM6/9/X;&BIZN3)[Z[3\"N+AV/Y7I5WS+MNM34-00J/>.
MZ1[M2K,_VC7,TU-,".-=;D7E97F+[912]AWEP4K_'--I>1/K\--U8@$V+_8.
MEB[)-O22,K@_=K9AA;EIN!C8H&[\<^<.,ZF52#],\XK*&EQ02EKL@5TG.1K8
M:K2*"HHIREK:-1Z,>H;^9CO1A;]F*^40O*E8+>F0\J-)&XIAR5-M3?OL\YN)
M4V(]!$#L1N":YQ D&=6O[/@&ZO120+!.>1"2G )7,EFC\>J[>^$'BG4<.@Y[
MXXN%LY/D(C?IYW7_PB>M__:D[D"DW4N96+4WV-_RHN\$VM(4&&[>'!I>F9):
M,:71HK0CE%W;.CHIX6YNVN+5DG(3%!@4'J8>>;C&M@^$W<7+QP_\!/V4LR'?
ME#WE95$:PX%T^[E.05NK0Q>(M#<Q7BLYO%0>N:$_F+#>_^[.IU[I56;%D-LC
M*DIQ04GW"(B7M,>E,U1U4E7IX.+J:#J7*D-P3/=#2#1,CAJSF1>C]?7MX OV
M5W2F4HTE(&DE/APU7OF1\Z-<.:8[;+(1^\R4\0H%Y@>K^IW-2='S@4]>CX +
M2_V:X@1]+GY<4@$G67X##XBD:_8-RL3YNZ24C;?DQV^6W]3C/P8Y+=SDYD:=
MKOVHT]F=CV!W31I2^6RYF8/0 !HJ3FU<Y61!+7;+OY3IW%09327IO UTDVQ6
MU26V5=1?D=Y?-#U<0,D,=93FXA*]4PV5J@OM>Y??^SRU=P2C3/+R3?M4"#GO
MWHWQE,L?!=JEQ([&:%Z\M[J4E >P.%Q15DJRX:!IKV8_\A;[DB$^X>]?ZTU2
M9-P43"=KXD3P/R5#<SG6#&36\E=(D*^^6R/)2PM-<NC&UK]DZ7[L>_U)&6OI
M12$3:_)BJ>K#P!I-'E'4F@DW07+Y;:MB$;79F5N#[:*:88?Q-H@*=>DN3PU)
MK[12>#Z;%;Y.'\'NK3JZO+J\?_7W/FW6P:-+T19K.,/*UV%,1QDU/%TK74C=
M>M)W7DUWL!8_$.MV8'G#%0[T<#MYJ=-G,0G */&]L>[D6*\YDD&>0(S<@$4'
MPG\*%:G(VW+>6R)8?W,N?;*11N_ZU!0$8*"P^U9>SX9_/*!2V%IRC.>F3I\2
MDWQ9E*L,H3=!F6G_S-""J))I?]Q>F3DI.5$7-YXJ/Z<W*M3GCOY)Y602H]@E
MX7D7[0?KSWMQ)X2\M16W_$YB-@+3F^BD83K-?ZD"\#]GL$@V3\MK%"HI)MM:
MFC;)P"#&X\A>][-9 N^([NPEWA2BHHWM8\85C3>$>X4'X[S80ZY>W2?X;/0P
M]7RE=1_OZ0RQXOE.XR1IP1J2Y[X:ZN>Y=\.*HZ!5ML7>9+JY4B7EM&AZ>2<H
M(X#X/CLX'>T:;F);?%S2'#V]W%U.S[[0YRE<'([G9%*FD]/R_JAO,'NM>FFG
MILGGY,C0O<QDEUR<-FG4PGT3U\2HF2F!<>LO?@3 <Z=LS^QZO<.BS$YS;:V#
M[<6=?(+QZA,WZ90U$'T3=:#VX)D1_ '%9?2"5J7OZ09H^:74%2_3[.:_Q)ZY
MQQLXU#<SQFA4DFC^:+1U6X'I/>19G!V&O= R^.L^=*9HJR#1./\(B F\R2OM
M0<H1ADX5 *ONU&8_V6?EZ!LH'PI11H+\9@K2PV@2%'D)GZ-A-]0^1*"->.1)
M1A@OE"N\R.;DVJ+\)/I!O6<MIP=['2UTRQ; ;<B92NML/N<1L\<"QZ@W^4V3
M)#NZ'A5PL;=Z,XVTPT1VA^J A5.^*-.F]Q:W^S\"F,R#-U!-[D8IO[Z0^A;R
M>-D=G317G=]>_KW?B"7#9Q%>!,]$;]UR&9M+78HW<DPK2[<^ F2*I2OZ5E$/
M*5_:$%@OLOR,S0<3"J+9_U\=R?\;D>L6/I9Q6N^4P6!%]Z9( KY)WYHH&2=0
M1%V +%K,\Y?!8H80SPM6^"=/75L]G#08=:UX;NO(7=!:NSN-M:P(*5;H(R
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M!TG>/7F8BUU[U6!J^Y&RQYU822)-.#$5+P1I\.,P$&7^9VK09SUR<3SJ:AA
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MU9[9(\%819S$PI9'@!K[9$#7+TBD9$$MQ#US%[2>$40C51ESWU(SNN&3/-6
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ME+8KF)?+ ]:<]3A9T<RN9,;1EXOL8&CS)(<8$.%&.T^[8;*/VIB7S66[N\H
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M9S N13,LMD^1FT=IR/2,AQ!J7O)1N-Y4V.]-]F,/<MQD&N(X'0T;P.QB7=!
MN(6PM](G1RBN08,/"^Z\V>"RZ_TCUGG:N\61B0=VL:QNF_UF SME&ZQA)B09
M8"4^,U*O59=1GN"NG]DL[ER6X7'X\_B\O?3(L7O4M](\IG!FU='.3SXZ^+7'
MS::UDML+%>1RLQ-- 3G;]!$>V>+I3!N^191,NV/ 6[C<0?!]7"E>*JC&G6_
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M.KFZ4K3YX.VY34*6_,<53;C2@?A"*KSS&.N*VUV%Q,U7-W9!@T,A90VHRJ)
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MH6K'M#Y2-71KHV#S2V9<4/$]"GBIUPMI2];) ^%55F]L6 M<([R%"#A=A;T
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MW^?)ZSU- ) [D1MQK&4.(BX3,7KQ>7;%<_-^;8,7]XF N3]"D[7#A'=17(:
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M%3_&Q(L9\EOI, =>R9ZQ$-2L*A3GJ9OY!O'1+*%#L80CM7?6Z:\PE\[R.V$
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M>2S"*J4OA.LNB1U]:8'<$0:H0'5GR!06RF$1X-_5POO>C&^DW6@P0UKGVJ2
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MZ>DVG.36#F)&*NG9$Z;YZK?1[LZ++=QS-87SH"N#5$#:QDG6].9> ONB8$<
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MGBGX+0N+RD).]6$XV7C1L/95F7F0(<6SE@UZPW3,QM0^L)NOAXNUN?'[(*)
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M\HL"Q>H2\ ?IR=P1MVK&G'5'%Z$OT1B^F]#;)@!NP]2CRXL(BDCZ)FBA464
M@IF_1)4HUQU6];I4OQ!O\9(IM/GE9TZ,[1\??!D@X&_1\2LX%B&PQSO N^C>
MC0)2,$_3YK1JA[OV\\TSJV(^'&AR6]:\O:#]0*U;*QA(>FVETPYBL09Q8,0'
MOBL2%408]$3K^ :NB%V^FI#QQ:]U ,X%'T:2#$$3$+V8YRT4M1\;9_9?%6IY
ME)57+Y0]6[2OM#"1ZQ2VT$,'V+KF/GH +&21&/VO[,DIH)) O<9[\)'BLU22
M,&6+=YV+([&V<MXC!RF1+U=YBGVH1C).^$=D;@6'0=4V\Z1N$I1>>VF 2N+P
MX*@ L0_N0<;!>"13_KORH>Y?,,4PNU037XW6FA=VRB^@31</4%SD(F(4J5RD
M49_UFIES.GFFMP7[!!V]L_R!9'8H6^&F@M\80=%_^Z]>5)C^!HC5YQ3 Y403
M(IMVCI$('T1(;_(*^'6,[F\5X76+9"U[TA(MZ>^JKE0( =@T>ES^ULN?)" 6
MD*#K0?YY%/T#'RB7'P0?_]65?:8,<_ ^$Q(I:C9N8N#QQC<AN.]GB$Z?++>(
M X ^:0SMBKZX+B#^TT#]+ZV?^%2:,LL89W$U.W%(-DGG"9Q^M9GW $NQ@+U)
MLH(MSY4R,/(8W=%06LYIC%*%5ULLXL);N!U;[I/%-C?(NXO6G^"B?@JJLZS=
M!R^,VFR7K.1$G_5S"5U_B9]Z&:K4V[MAE?"1=HXVF/2XCS5,_O/\7X$GAO7*
M6#Z0M7K=?B[K=3(K]1IPD9;YY/7!OV>O^_FE.I[0B> %'4 R7$?>Y6##LXD)
M]5/'F]8RNA9WN/$EWZA)U)@]V8T'PIL1]X\JVQ&516TJ#\ZO!]VNJ8^$V];Y
MY24I\GZ8W3WG)YC0FO#X0/A8->A*2S2]3,<7 :[/V2**/TN*6P=W?LA=%.;&
M@K\ @FR_PZ?G6:5=16R_&Q;L/$ZN2@P)\!'(V(2M)$2CJP]*2EYB7!>;69]G
M:26MO/B[+N%DE3,;SSW6NO)N-_%$ S7BS@GO.070BYT"="M(U=5-0\6)0F;?
MI@;1<GF IF)5V[I]/I,S;PIBH3BHY1^9X"+VQJ)G+]K?Z;X 6&:+C\JY'[C7
M QR GCL+B:> ]PVLH?(GXM//7"5>! ;-%5##N$4R3:5_JPZ^##U[P:X ^U,
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MJ0,K35 []%W^3;<W]I,\7UWK;5N!V4R',0<-)S_ K]$3QX\;&RC5N7YWN^;
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M#!&A50T8:MB^S#%P#K$:B>I"1<SOJ/L1:-V\V!.!4;J]O6:[4X#7D<*E/\'
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MLJ,>1??1*$IR*7EEI&0R8+KY3+WF0& DG;;Q#Q\RW^3(AB-%]006$K/Q:,*
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MCZ?9BC<XD\W;?#%9]R:WI 7$YEMOI(;R&0$[X9QG1!H-'SR#@U, <0U_Z13
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MS+.VM <!Z2?AV^"]AZ9+N/;M0Y"JURG ]C*!EN!\4C .7N8L1DRH[YX"'BG
MI8*D3P&)NQCPP9TYQ.I!+FM1P8;8,7+HNW7X*CCUZG[R"79U5.;!'NAWR/6S
MSEE5)]0@:[1KW1[<TTCX S4X\G'6Y@X""QUSB@UEX>]5\U3&DS@V^9:E;ML
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M4X.W!1)OV-]*,-I,]G<RV00!H.KV+YO'@$_*-D?3>26#KFR" G^[V>#E0_^
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M)E;A9U8?_SNO"'M^<9ME[5KD))[A52P=KAZE$ED&D6"_GJE'\CF]ZJ;-)[_
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M80JHNUS:5PT=^U,!/IL4EO.GV_=XFR4VGUX1LM?U=CA"80EUG:1.S@>RE[Z
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M^I<ZYF?)%'+[?!=GOKE=O>HBU$^#0T1A?T@D4D!_JR#WB9OEV#_JUU0XC+^
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MSX+)U_ZR([&!C+L$8%-&L(=]YNG)ZJX-E"F<\=HLNNXOJ5CMHS@=+!C#?4!
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M34:#!*!P4P[AZJ>3\JY@\R\V[IN4@0%V&F[W;&JRA9_\W(6MC='P_)!50OJ
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M=D-=8NT&>AT)QW+?*969QK_3TU854\"/^W0C..@B+Z^:FI>@C+"I#)2]*,]
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M7$>VPZ;!FO''9TF/3Q\8[0Z?B1>*U?AQ6A?_NP7\XL]5'%X4NY*!IL3V%&]
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MEC*'\PAT]^<@ 4P9)!A(=L;4_VHT2]V@NT[2W^+ B67HO*8R5;A:^:6*+H\
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ML85@#;''Q*5N0W/'5>H0A=JMH$!NG9RD-!.1D6WX[M&I_-94>>\IL%19JTL
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MSK?ON6\SM\Z')S9)?P^W?D6P#?D*JWJXL7B^B%FF6E/-'W 5'/U /'<#D[9
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M1:((VA>/U,"S\1UB=*F?0/?Y]O9=LI27'@^KI-C&CZ+("(C8-HDQ;IV>7'=
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M<(D"J8SFB']I?S=L*M +^:C8]4\ _*3< V(.N90,:O8M,5+F^,*:5I6P!_C
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M96/S?'+M/UR K. MH%7H%N#$'Y?!?I17@=X][TQ:7?;^ZB.;N[J(OVTO,OC
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M5GIT!0-;O06$!STIKQT^DZ=Q2)[1&^@OZ'X Z&7Z(T!8>\[)L+V M+R3[>G
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M^IW7M/RA9Q18@9&(LDBZXIU0EN^G'W=G6EWRE']9+4C?8Q2=.\=DN/B*1.H
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M<5FZ-0.V( 5C-^GOV*^\#CQDYZR-E'MT8AR0E]1!KP$L^\22F/3H&Q-+]P4
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M!OR%6Y]8&X/^[TCIE4EJ]&VV>TN0NS=62A%#S3-+Z+8YCZ,THEQ!!67:91Y
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MU__W05$H[=%>:GL?K]=4A53FDP6UP)U%QPA$T07 NH5:!O>A5"K^7#.0:.#
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M1#>_+.XN= 2'3*])<=_?UKOQ:*$ &BNJ?K-?,&9%YMES@=6J(N?>C1I>' H
M="'_=P$(SWK95RS9ML# !8/YX>) QDDRP2=I@\7JM71/L(CF'*^(+1M>8H%>
M6GZ*X&2,(=;!U>.8^XU9DJ'(AM71'FST<'B_8-AN$JH*[88P74F' (+E8[L"
M/TEE53:5]S"8:[YF8 @W2GN,1?%"9UH:L[K<CN?I5S\H\+OT/*>:8OP#/]KJ
MACZE8.4BNM$$8Q:>V=X*02 S^>IW9_,/\J?%-N534M0CVCV67N$PR2D-WT1#
MNW4LDZ8ON4$8X Y.DQK>MQ67P<6:I26.E'P<-5@P$BZ9,S4Y;<[UP?KM',[
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M.7 *N97-JF+D%\27'2&CB8[Y<-/@R5)P@X Y+E >),(<HE7K.]I/E'U>^,]
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MH6F6*B#MZXY,GWJPS6W>MO##&3I-I&E7OFSN3K,D;*JW42<B_P/6&+7!HBX
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M//-I!;L?$NT&^$!WMA[&OX>I_"OMF-4:N*)&H7V2Y+GO3-+C*K/S4I@2L[L
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MWN"L^@I&RAT:,U*TK5=9#JI"'?'O!L6>"S>)D-U-".I"@1:8ST*SUS3V&:^
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M^$_]#2 62>WD^H]=TU9(G[7TI[5JM;76?'F8.'-F]K%2N*QL3_KH@7X^S0M
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M1$P'IW#:0.AM,S^'0Y7F8,&]G1TJ]^"L2S^F3UG,][I?F41NH$Y7SS+_F=P
MKK]**M%<];!I= O3C/3,-DI?UO=%M/$+M,\ZYPQQ%?J*/9L8;>/QAZ9P"^>]
MH1V&+F!0MO]B9\4=SEW+O)^&!6JD=OODW<G_<RH:>V3?[2D:J\@CG6#[+ $"
M\+!I35E_/2KAH0HPYN_0P!F6$?\"?W'O<UXYX\/?3.]EG$7A#J/J#N^J\I@O
M6.QTT&2_TQ--/7;5^=O*[JMR6SRC7UWHK)!X3P %BH?0*U/OY-6"NX&1E\:Q
M;>PXAI[7V*TXUWJSNC!ADO_"/D5:%/4/CW,6:=;&YX;>EN&X9OJ'<&3HR(@K
M"3_:,QL<5X1]&9Z[.X TP2G+R^V9#^;GN[N92_<OS(LG->MCPT;"7HT#N+\
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MMZE+A<.8-__2AB;&7L:7Z7Y=8\F'5'_'KJ8$I>Q2N4Z6-45<HES7V<\UCQL
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M,C^?F3TZJL;[W@#N4E['*#_T.S>9D@)'-FP9M4Y_:1RGD;FK'2E^X=?%+1)
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M9^%(U- Z!G^!T+1)7*D%@>5S]W!^B!XDQ9LEOQIGT(8SU^7=8=7[HD>29<:
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M:[(+@F,)C'N4NVWD7];$/+&^]?Z8JC)50DL;/=2UN"T6;SL)#T X/)B__\B
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M^+O2/KNLO[\;KLN$-MD>(1R@[\S&6EX<\!0)I[!UQ,^617E1N=9_?TCI2^,
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M>"-?[,_/B40[^>(T<C=D8#3N0/P=*KV%CP+MXN(4#MS,@\'"&?A_4$L#!!0
M   (  U =%K'>\R1JFP  !%X   0    9F]R;3$P+6M?,# W+FIP9\2\9U23
M;;<N^E!#[R*]"$@'*5*D! M-D*9T,"@B(-*EAX0B':D"BDA4.H@1J0H2>A&E
M*D@G!*5# A@").'D_;Z]]UKGC/5^:X^UUA@GC/F#D2?)G'GFO.9UW?.^<_KS
M= G@N&YD:@1045$!;I0_X'06N/K7?_^MQU]O\M]]#ZK3#H"3@9J#2HV&ZAQ
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MM(7UO'4'<*U?S8."/P?&?E_5PJ J(H%HGI@X*EH. ['XK,LK',:TG ,2M8H
MC[5I=M$]3_Z^B'YSS#NUA1C>5//T[8$!?@D),9$DX<!=L^P<5=5+&1@]M3^O
MJ%-E:62U6!@[M&BYXT=Q/_%Z)U;48^:J/=2YDFZ:\U+?Z4^!1[DC:(N!OB"5
MS6+P)8JO;V*8_I5=G<!!?LMZLUOVPI^]8O_EB5DDOM7!%I '#9'DS$14M<>:
M?OR1_5X];I=L)TPPH^3EFZE3P+@;\D/U0/0RL1+P2UJ#YTF0)@AP%0O=.#UO
MAH%>P/TH2,<BQR2%9R@M=(!+8>A'4E-@YFV?_0G\WBD0EP7[!L%:6+(0HGK
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M"S)C9A4-(C-4G>@-+E]KFX1JEL'&+LR[>N,/%?5?8VY(-6)WO3G8R' $OQS
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M 39L0&WOG5I.- 7T//\>]&J(T'W4\CGEQYQI9KD\*,;MS%EJ]@_&3>$?I K
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M984TYD=/L]^JIS:.>@8GR$/2H<I+E@294V#K\S)J1K 7)H%=W9I?0C(\T%=
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MRB=V@D]XD5WO>A?+Y^5Z%!1.KCTJ$8GZ<'!>NVNYK6W^BB8?&?)%(0K%!F/
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M;W2\Z_IV<FSU%NMP4?JXA]?;7&OVVX879"^-VDZDAA[:$UH'FMD\P%52'<=
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MZF 14[+$<3_P&V'E$;^,D<#_@?8W9/\Y8!'_2\C^ ]C_AVL*8*>CH1X>'2<
M!LAEY/-!"^"8.;9Q+9CP*T];&RM9-D':2T.=1_[SG!1@?'@H %W'U.U9INE]
M32$*HEPW\^!6$;_#^BP?QY>3D>=:LPY2)'1.$#(O'\('F]T+I!GI8.90P"_D
MT=C'2O[1BO.PDZL6_$+7FYPSOS.Y6=Z[]I!7V%X2KU-'HB$IZ.[XC9)'<T_5
M1X-8?F8N85*@PSM%%" Z@Q!# :Z_H0#;Q24%;2/' ^#MQ2,*T&HV1P%V1R''
M! I M ;T*, )&3P'.4Z3 J!-#8B7*[O!1^+;%"!4V:25 JP4YO[&4P#">U44
M<2^=3 93 .XKG,@N8Z(N!<@WHP"_QRS^807+;>3AFB2)B"1+)U%7T1:G *@4
M"M!C3@_%C:).48#5=!1I[_L_K'"S&4U^8D0!D" *$%\00@&&C:BR4@#\31K>
MOPH$^LL*/^1_4X"<-"2ZCP(LE/XO0=)54F!8TJ:>#A44SP5:,,$=&HO<,T*3
MCSS F"*$* 48D40>K[V_JJ1*LR3\]W'N@?_U%/%?\&S_'Z3_!^F_'J1HV[N5
MHL.DRTBRK/EYEWFM2-31'TF' (/_&Z3[J\*+3HBJG394H@"F(*(IH/L_%@\2
MAURII4KW[J^SWS*C_A* 2_\QF;W[2P36_^MYT2K\CR+XM9W%.'$F<A.8D/TP
MH(-A2;)J%W3H\Y89^?_K+@Y_U93%7]4.)) %;!= I-.!%* M.^4O"V3]U3!A
M_Z'TL'/_*$W!7^<7_=4P!?\/JNV_ B#=8U.B7LHRB$WBZ@10)?1[H?BOFUW(
MO-K[FW@K]WN:&RT#J41'PDC<H@^78Q*5VFDDR -$CHGO\5.1_'"8Z.)(R49U
M*W![Y-#B.2*=<*W8IR;:36+.+,>3L%*FG)=BR1G]$MWK^I,.?C=QW4*1S_S4
MY_<^Y$99O$=\:_J>\&;7S4@\\<N6W9=[F9J3'XWVV@]*&+;)4 (;%YECXS#U
M(.PA[^<MU)WC8T=\KUOI*Y*[]@X3)N>Y[3L(!CIQ/=A?1R%K?5B05##MVM%Z
M^P9=M4G0YQTZERNJ%X4W>FJ#J+!U\XFSCZ>5QL89U#:FU2I=287(I80-\#X>
M1@$*&(+&G\V[:9Q=(5_-A!Z9Y>ROE/8Y:+15]N^;8 +>[[Y>V;MLN<5>EHC/
M0=TV_FH\5#1#&W^AD$:/R_S?&T-L^93_(_Z;TF'ZZ1IBPXI@Q5@>_D1V^,SK
M)4YC[]>72V]?WGE@)^)^2^)CZO0#^[A ;R6E"-J5M_N5/0H$V88>)"]<>0SI
MHJW4A>;91K"[BV@3(G($\09)FT[I9(DG7I5?OE9E@"_0-TC"6A$FQ*ND>J0[
M!3@)9R85M@AC<I,$^A+)O' =/#IZ$RZ'_V6OCA7Y-=,B:1$D?^==(Z=8;:I7
MP"Y(*CP>O_)ZK$2]8]2[TS+AR?K"% RGK7;O9AZ_0\@(9-N0W"M1FWG.HH"F
MV[?F8K:"G, U7L\V[/NWS_S,? \ME).ZS]35*#<;\>F*5\W:#W@??_%.$K=5
M?UG3F3Y=AY2@ *?:E.!Z!-]C3EU\P3POU@@/.HB*Z59:"Z  _,K\>\V$;3+?
MS_43=&@/#?AY(XG&&,B]$<;$MX?A(G5C1'=">. \Z&?#_.\DI MXFK>; O#9
M+T)26L3R@PJZTV<_*Z. ]>S">OSZJ5D[DX<N#?92$O[,2SY]5^-%7UL^KRMQ
M+LY&-RR.K:P[6]'HN Y:9;CG[TT4D)M /U@:&@TN9MCX9V)NZ?,_[V-5BDA#
MELG[]LN%#S^)5=1DG#@!/GIF_. ,&AL$>^::=V-EM[)3(8("<"(]AG\N'NP2
ME(]%X0Z$=X_P*Q@H%C0/(QC#017HZXQY1>L3*B+^/4D_IE5?>;P?BGT!.QEZ
M268-&9N+LX9$YC(1+:@!H2-' X<]>+G ,=FD +8>6VE('\+3GS9VO,H78.5G
M;8R5UG$^#/_5#*[%V:34Y5:C.B>FMD/:<A5:S-L')(<N3T\=C&TUK",*O<^K
MB[.GAKZ)^)K^+$E*^\2[KY/<,3=>[UR22CZV>]TG?97OJI3S[GD[<5"SA9!F
MG&U'UZ-$V^7Z5Q2 X2&!IE2UR[-AS ?V&!H+YJB#Q7X=M0_V#4)TF05RN#^2
M>J6(UJR0DYNA.1?5%1Y^)ZLSA2#+&PYWQPM>Q:%2=#B"4!C72*(W8X-J9V5<
M$S9A\F=0S^/"-"-OW+#L)=-ZB6/YO@?6/Q,MR6.?J>E/BM0_,.][,4OKS(<L
M8K--;>5*6[:F?'-NY8TTZ8K5.77#X=1SSP/IB16%S]Z_]>OH=_QY4^^5<W=_
M=-"]J;Q[HK\N"?FPOWW&K2Z>'+3T!''2$XJ#PB*R;R DFB(QO,DKWRY#^8WF
MQQ:]32 O@F .>''>%'=O1\9BAP<1-F]4@PW<G+7P\1BP-P=!AK</%4VF)[W6
M.0O7(H#*"+:FA,B%$,-]>IZ-H+FS8]L*>8E7BYB=,N2W7")TZT^/5'WEX"\X
MMI*A &]+?HN2H/P3=.)-S:V\MF7VL%7D=:]"_GC,^(6%9Z7.=@']^@O6L>W"
M*2L0MX& '1O].+,;B4F=G,]ZGG.K[]]5^C;1CJR%$KD$.]$UDIO+N+&#"$(6
M#M6MLH$_<RQC\&EDJW8-\\/;WU3/HMQ;WLNZ"B8QJ&AXL\TN]NYAI0"!A7IL
MMW"5O2G<02L8,@IGNR 9UA)8$&2VT:O#C7-I??#XC<%M7*W)*\W5<]F6K'>D
M;!*53GP.%E/./<BD(T=J/H9.[$5MAB*H"0GT(^7'SR].GV]?L1&?:Z<3^2%)
MDVT4T$VS-YL=%&+$[LZU.6JL%,$[F$#ZY,*?V NA<^09MHB$/FV3I  1KX,D
M#S((5L?&1%X\,@;NC%/MS66%7YH3LW^CX^M=/EC0\3!6X?2OV<ELN\B(CXQT
MK&;K]DB"- 7H&IX,Q* Z($_G0(30153R70D\;QA3 G9+O.Z5]8]*;TOM"5Y5
M*[&7+8T+,VB5Y1GFK\'E-O>S+J.F>6=0Y@<ZR'@*(/;;NC&U "S_9>MY!'Z
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M>6)\4B6K@TFDD<O6")Z*)7S,C[]P,01E>QC%97&%X7_:1MN%A$9A(C%[%$
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MB4EN.YW3)DMXCMQZ\(=DEBA0)4@!JU)/W1&TIU@"[2A;3_G[M,2M+H:4.SB
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M+6?=O=!YR#FYEL O33=7H*OAV_@B-- ,$443^A- )2A>TY6&HDHH]HTG,%2
M4OC@)^\2VQ, N+*Y_OOSWSPN+B[5YSRD'I:NV&1"3L<?25VV,'W[<2EY\P3
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M<YGBG0V^7G8'4GA>'<W0J:&-P+EWSI@IYO(;[HGO^'UKI %KI.A8['12!<H
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MT!H%0C/&81&\[,H\V3!8P/47G0A4KD:=+T3B.]!/,QN)-:;44K-I'H*"4)P
M1T-D/_Q-<7A[&E[NL&]UOM:VJHS654/M?&0!_*,DXO78F_1"G&L[V>Q".(_]
M]Y[Z\JF<]5.@<&UK3YVSJB+O>PM;,I9%*^SK4Q\<#34GZ?&("RD8_=!ACG^+
M#Y7K^\2>-4H(P?/'"4&%\98OQ5U8DWMJ(:/9#$X0(H1ZA=;V"IB98R]D/S]%
M<NVT__(>(_4GZ7:C#L=OS"_79][=NW@Q'OY>P(UUU?T\@Z2?_=S#OF BD>/V
MW4][;P0OQ#J$!LN_DD-V4B&)>Y%D6D[F% $M&OHW2L0K)&9_K",[(O]' T\
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MX,UV],8PB 7=S?H%87 7Z+S  ZGC[F\USS:E<A"O'/EE+$3OJ9FT"9G_@./
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M&#FP=GB'AJ(?@1B;N10_IZ$/98KS$5=(FWOKOF[OTFVJ<A7+6SHN?3]CM"F
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MY;LA]SQ ["WL9'=*5/5\& TM]VG*X0-Y%_/ME:T4^-T\>Y-6$S&UYR%>-=5
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M;AKQ1DVW3M3KI>F,7N#U%DV\Q"7\Q:)OPI.64XKQX=VI:,%:W%X&>_"9;DU
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M7SE^7[O$L@62BOF1T844&9'*#X0\J6F6XUJO&9,62F27^T)USR+>$C=,35Y
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ME9'7"1RJ3"<<PU;KOB+W4[3:2S1IF/L@!^:K&B47ZI$:G =P&R:+(O1Q-!U
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MUI^=\:O\12<LQK4VN9=E3W@]AFY2\9TC P_9%ZA+"W_]J]*#;?]QCYZRW[T
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M*>V(1*U;C:[W\SRD'4OF;&Z<GUEDXE. *2J9F<D3*2F6BZ?9KQ".Q$#<,*$
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M7"+?5TBL?HZ_^6*2\=_!GH)4]=YLM8+DUZ)V.NM_FZOC0AGN?3ZI)YE1\("
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MO7"@=NV>0!L+S6@S[D?1$@8TZ[:!018=BI?KBJ'+RM/=,?*]__=G<&:8/Y^
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MO[EJS\4_*:JD[!VX06WFM+\/DS83JQG]\M+V-I,#>\!)9$*D&>L.&"=XF=T
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M= _/JQM)4,2P]S?A^!%T'0UU[-HWQO\P>S60!$TRI*#;1E[W66/C]4^==4_
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M =,V&ZQ2 <F%^LTSKN^M_8K:?U*[O/^Y!*SR%);A'UU!!$"B=*)>.GV/-_C
M.*7YNR%0=U"7:DRE [O?"ZJS0 5YBP7/(NHS\MGLTU8RINR:+SRYOT.W@;_Z
MK*A^D3Y_9E"V$)YK-"-T(440P;H.BBUNXA!36S,N*A1X:HU.+'_*&NHV1+=T
M5P$8\TH][T@BM3XZ]=S7@2,GGT^3]1CR>0%%H-]9RRC% '7P@J[\A:6."KHQ
MH+>31)%=CWHN*;9V%^O %[BSF!5/?N,6J^:_T@F?$3U*!.KUKA 5<?S30H(Z
MMA<?A3;269'!I[@B[L.F!^YHMPHP*Z2E\)@-4#^RMOM%PB*=T_<^L.!'!U.3
MOXC_+E$MT I(B#M2CR+0/^R=6L0)XO6=#]T:OZI5F#YW<0F:\YI3L*V!L;IP
M2-:_$ D7YDL.?^<3EA)[\9DCV.<+:>[#YI3'PP *@S>1@%^:C'^B#N(N^'XC
M_JMUXPT&X%^AN7BQ>5&>VXL.^QMQ6:*&LV9-$F]?A*IS>[;$\)#FE71^[4V\
M<[\,<#/>DIS\4>'7B2<6U6SIIDYGJ1ZMAC^ZONWTORZ6&WAEZ-#XUSPT]D%U
M8;($<ZH$A?X__8:!^I3SE5=#.HM?;Z7RO7O26[;TJ&B'PSWQ;W[HIV_7G\3O
M8(KTK%SEH^V'Y%ZF!?<E9>:%+>9=:@/M?E\!^"DV-H,F5LCQ3ZYU\UN\.S@<
MU'_6A*17H@ZLA*7IM<UV3M(8U55$Q0@O&$R"5F26RKI)$\5-5[CP=&NN(0C,
M&R=%).FJH^3R?N>-.8))Q6BUH_"83&&6K7?DRH;NIPW7Y6<IY;9OS-O?=S0-
M0##:$S3X+ESZ-,*A[?@:[87;C0HAT*E#KV4#X_I1J'CMF-.6W\<_'U*+'P]^
ME]LN_@%>RR&RSH(= F5QQ<WX7UB)8[2"5+E-\2[(7N!9=C>949/]?/>?+4JE
MM3W&W";^]B\L< U%^+A@TX_JVMV=?[X*X*H)J<M:A"LGR ##=P6X)J%1K1]6
M*/##6">]&8)@(,KIJZX5!8$G!:UD6O6K0N>.8,*3!'X# ,TCIQ/=GD8(T&L5
M+Z 1V<D  P\R<4GC1TN)WXFZO:-EI\W%#9.=]]2^M#3,B+GP?D#7;ISY/3@,
MF:SX)X:ON) A4."G=LO@JGCOXGV%[9PB"X<%F2;.>D/_QLQ 3R?>N]I07A81
MSOY^744/K9 P" D!>!TJKPFBF*CN+F8"%Y8OUT<AKW2S2G?0@@&;%Z-4X]C)
MV='<EKHW;IV>XXL+-SNA+Y=[]_QO02/HSMYPN3)T;M@'$3))-6/%R*HF+W+L
MNO_OCQP(+W"S= !"&S0/9B3P79@M.BA,''I6P"!]OG5.K2]#M146>P6A+*&/
MG.-,AHY=&\S#[G:8M: <+S^T\Q02#"X+$<X0=AC1G-0X[?F<2SM8^,SS?DE2
MP<\7&\8K&^KS=XR9TY>HZ;I1 9=97=8@,N*W(+[9H'O&^(D!"'V0P#Y31C93
M\2:*;5EYI8XVE#':E'<J==4F$?S!LS<DL>'DM.G@?&.5AC@%J@?WVO_]I*&%
M%[_0^:GI7@:[4,][?O3WD\'>9,+,]U$N&H%O'JLPSV )-9M3N.Y)5\?Q)1S]
M\,/V,5DA=#:6:!="X&W NUP!&L\&)A:$UL!]B]=\"4Z%EUYW\ (R+?W^OG0%
ML";H8XU%;HB$ X J1X*#F^YLK39-Y&CII]>"]\+(E." ]RT,^H:D;=>'8BH,
M\#GK6E< -KC6+!P"$_;FI->8YLY;=W[7T@SK?2OQ$.T2TO02LD7S>O/@>%X2
M1X)!'2#*3=_BK3:9X]OMUAF<?DZ$P37<YK)IM[^RAOMG%-(?28[R$+8T\S2/
M+2(N5(,&P'7':!0-X7$+%M*W++J)7I'&-!Q'_<(RL$9NJG>D\)KS:TNIOBFH
M3T%N)XHW/%;$9JM4Q1#M\)>KY;+F<VM!S"N[V>B!"=IKYBQ#O ._@T\J,AN
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M)RF#>V<BJK$<XQ^^W+VG8$V_.A4+#D83R+;*?VLS /35KBU<Z?F WB6.\TU
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M./8RI=Q(/KFF>P\?!!\X'=Z,YVY[>[3:9$>)7.HME-)B7'GX\B184W$GN2]
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M5$3$6J@\B,N3TBE>[YMG*2"*#PWWMSU51]GAN4G\S7_K9>=&1,:AZ 8P43I
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M;ZCM\BXS_WUIGDP/YG*3D-0NV5*@ DTO:''E.U5^D>\ $PVPT:K3RV%#FZT
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M%##9N!VH& /;G<-=:5X#^O3^/?P/A8X'SO\ET5/$PS@9BAP(-^P+0C1[9+\
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MKTR.3YN$K^XC5N.G/!BP3? 29!PR@D9:Q(&\ME(@UVG^B^AXG46R<HR&+DP
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MP$->@<5W?S3U2.?,"$VC;CKUIW;>LU,1E_\P6":;XJ;O/6F@P9ID\=%T*8<
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M"W%:9T*.H[$6;-V.,WA,]MNH^"^"(_\0,YG=V+0&BC)^+U%QI/H;2S;?92W
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MR?YAH 'UZ*X+&<[1SAYQZ,7,0T!M7WS;Z=#,Q9JZZ:T-/0N$0VA\GX$\)DB
M!!):PZ;&SFEE)VC<#9-VTLP^8_+$0>R$:?DN8EQ<9J[%W;[SZ=/HS/S\$/V^
MBSN+D]*6MM9B^T:6:7,9H%,JH0SMBH-JA[(?:+)8\NS^?*LO"0IJF)I?#UA$
M8X$L[E'R&^J[)K(-/%7O#F&*!ETTTS(;J]^*;?SQP8+[N>!?/*?HA..6Q W!
M.!OB3H\[#MJA!/70W4II.T[#+S9B4*?_NS04&M[51<V@!5A&2,D3[XX5R#4V
M3)$XRIM?G>9O=@IYD>:]:QB%9%#^L8"/#P%KTOM;(^>E/317^CFVWFQOMHL;
ME*TS!O"5)^TL-0;K,?8E>Q"PIH93R)1RB _+[!"03F.SUK$CS-0&,':"RF)^
M6IQ61%G[D1%="[Q3BO^V1&C/"&OC:[Q9C3%SMWU)G96"W\5M0ER&G<0[$%\8
M)FR;Y<-,#@+RT)S:PZ,::SPATL^1C@CJ'E::#4JMDVX>+2YW:1ZD:Q\<#>."
M#7S51H4/4MR;!&\WCOAY\Y@[+D<UM^24+MW<RU,U^-NK5O!/K,D)=LWGZ9UZ
M$_,CL*&LTK[A#0&WG_KK26'/[$BB+:(>(5\P$2RX_YOA@!-#&2?-4]J47"I;
MUGUGJT9'T$<. 1WRZ*=;\6Y=MFV2,+ WF-<;*7V%O+3M?%U3IV'IU?[@F?QO
M:G6^?U7""#]:_&CRF(T=/_)$#YN:E:K^)3(T*+Q]UR+O4QY%9!32.L=O4+^H
M#!]Y6\O_FYAF;JZP]0G!QG6CE;N80T#!%P1=[3++F"W_"@>[3=.ZPBM[#1@&
M+!G]'/9;>=&"Y+<X&KO 1<OQ"E,$<OM6G2/W+'QZ23T$_*7^ZCNUX^!P<U;R
ML8F>D,!%;<1I\A9#Z#3U#CFJJB0N^3@RR+TH](T%):L@5Y]RS93@+=%)7G-*
MCA5R\I&XT>7S($P2L\J //7_T.W_:(7K^N+2MAJF_'K?]M?I2S8WLL^C,VZ]
M-M*CP&QZ]6G$JL!*>8<O?\ TGD- O :5Y7T(8.OF$BQ1+X2]=9O,?(B<:Z1#
M&\4G:[,J@))L]GT,91D5I)(1^C/+FVIZN4HLX[&W9^*#]=3NHQ(R&G_ 1Z"+
M&>A:S,8*1:L3*(KB"B/089*A]_X;$LCFT7]AOOP97WF4/KF_JW52+831H[G&
MT?>-8R%++@$%<[M4AGXS,4_K]DE7_D&=LCT*/">M>6467:+\[0]\L,W?=E,:
M-WH(8.>4VB(L!4XV]XL&B4(]I62H9<A6"E<,Y++AI?B>'V6QRL43))1MXS@'
M->J96)X&JK[%YIK+<5N!TRK:G$GX_VR$UL;G((J[7LCS2$/OPD_F$STZ\*ZF
M!@\+KC5I.8<[0^O6]HF04=D%R-,K#]LB[%;CB)>$>@23CE\ U>RV^^6$6?]Z
ME$^E[D(S_5A%_=8_(6M$V4- /BM*02<78F-92JAOK7<Y!%0<Y-UJS9SR^S,[
M2:MD9YX^U..WQFB:*-;W4S 2!]33%HC7>RSD<L+'Z=9WE^RAYUI7L@5C><IW
M -?2U)SAW5N_=1<98#Z&7,@7KY"] EF:%+D.3,9UF4G.98?&SRPY>?$>?W;:
MV7AEB;[BV:XMO,<6;LG7 U>^:G)=.GG=LC/Z[[77+^\&K)L+!)Q4+G(RL5KM
MI<D]&.?LE^B+*BL<?72#VAGF:C-4+!.Q:SRQ?D\T$^G[*0J8SMAG+U6+S0P@
M?JY8/1GZ#4;H1*0#J <L0)OM"5](7_0[]5SM$-"I[:7@K15P)SBP)5NP,O/V
MX.>\:VVJ)_JU$8UZ8>S4R6=F14(IWC:TFNL4>;@/P>PNKINE1-9,#)/+>;OU
MSS3866DZ_Z//IOAOP,E>7?*<F\:!U[4,<N4%7>//R7M-=WA,57AN_B.6W0\Z
MN%[\ZW7-AY&:OKR'*VG77FNO(Y$(0X=*A(+/I0YP:3(D#[>K4J EN;EJ\B-X
M&GO5M@&+P[CB\D) Y'L",Q7=0#'UT62=S0I"JN-Z9V.OQ0F:J1W*:Q?*_;O>
MP"BGK%".[^.U1O7]Z(ZMO&D,>C$'7;N5P#I&0U.#"Z1"S,G@5-2+-GW4E$]9
M>M"(6L^UH16YGM3!3Q28RE%QAS J 7V[FIS C\0-9J_=6%F^**,'J<\QL(?.
M@_-7M 6EN3OZFOA9PF54<]']^Y#6I T6=73X$"#"?L>701XP\=" =A$U6E=?
M-E"P3<R+[)47TJW@8CF:Z+OK_>QIC)3MGG_&FI_"\U,N":D/!%\'[,9W"_Q>
MQ_OU",SL=.'J_-*4_T%%0ZT[L:D%*.393TO)Y6MGIRH3-4I6FYV_"O9^2TEI
MW^(D(;Y&1X_9'IL-+F)>6/?%U5_3OGI<;8*7=MK,P/6EZ7$./CL:; \F9>;Y
M_5Z,5<J+#%NT^S?ZB,CY^H\-_]/>EX=#V;[]WT5)1&1-3'82LD>8Y+&'4-:8
M(DE"]J5A0O9E+$E2IA*2K9!UF.R$A#)9,@RR9\8ZS/8;+<_SU/.\W_<]WN-W
M_/[Z_>,X9N9R7N?U.3_GYSRO>^:^K[%2ET*,?S8MY3I"14E,N/96S]O;I8OK
MDSZBZ# _4Q97"K=RRN@]I/'>)L4P]S&+.\Y-)>=?>9\_*/?0.P!15AHF [YJ
M++YAWH>TP-8S3:"BCEL9XJC AE+7T/P#_6S!@S5E#6>*TNS&Y?5!^W7=9F>?
MA?'<2Z.C9U72EO&6:]/<4(@80=BF3*4WWZB/?MO8+;C[WA%GJR0F%]):4?X=
MZ]A;>B5Q&LJ)5* [%#.P\R2J5>$W")PA;*BJ,?L ?N?ACB':;1 VD@Y>0=N8
MJ354 Y_WV)-DOLV1)!0BUGPN)7/B?,RB)68%?G^P_8TL031_\0E1/K"P>4P1
M-Y920D"U:.[I047(J <\UT1Q1[!["&<9A(U9-PM=UDKTSM+5;P?E<"RRP:6%
MQOW;(<_5V7T05,">K6M.9RP765)+VQNBC;5'MB@04@K>:LF5R !5);_ZDD3$
MRL9!;5R=.5^G)^4_N38,'ZHP]C$VNA/T8+XK>&5>N>S8E=U>;TJE""FT1'I"
MOD<RQB*B0U5P=#1UW@<UQO5C='"MZ>B(TMR79?7O*^Z$Y:2=C^)*^*RQT4G?
M=KI99*:@?4[3GC%59_]42B3=XPY^U;G.&=(Q\>06[:VXE,Z4H]<VMZIYZ7A.
MTCW$+]DV[XDP-_'W&ISOI(0&1U<96:XY&*VYDSM(?3M/I**_3TZCB)-.IV'=
MVPHF^376F>K5/+FOV;+DBD:E3/)]EC8_=:O^>@\_U\RAHX]:7HPTJJ\Z;.&J
M-H0(NW!U6'!"@WB@G592/^0PP5QV=V#X\!70D,4U(X\;W?+6*9GV3ZZ.SB?(
M&RQ!;'3[MN+5]ITU9"'"9%WN=]>=GP$U!8$-[^M)=S(O,'O)&(8'M:NVF:K[
MM:/4C_B&6$B5;UI1Z$#@A>T!U0MMG52@O/+ITBV(.Q7(W2Y?E=W9X6:-YS>#
MV0@OB(V(@PW"@5;-H5)9MA]R<%<?%06%\E76(.^95P6[O[PI+7)F*TE=<N0V
M ^<<HFR9= @SGK]8C&=JA1Q&:CQ?R%8DU&"OUKPTC=$43Y_Y>+QBDT'M3-07
M_0LFK0_#$U@/I,01<]RXO(2TIF7.,@C?F]\WE^U:XI+\K%R?XP]UI#?G&1RP
M!+^DI7&ZQ/.%,^QM?9 3Y?*2G#UF@@(;T)0O)]_1W#,R2KI>H_S@;A^E/S$0
MP:FX5=(8;N 2(SPZ=.!3S,L+$D@@9"&5QF;2(=C&+4(D3KP11.?'LUZL*1ME
M*KASH(3:6O.D_9YG8N))&&M=J[CVQ6[B)79F?<[;DTJ;J[:+S;K"R8;T=]+>
M/V1V$AY0WV@/IC5U>GS=^WK[^9'IR52 ;>EV#>_Z4I(;[X1W@ZLK__;SC6]7
M"X*I 'AA*M37&M8H106<R=P3EM&XU)-^62/\X-8'+HFO60]A[%_WQJ[#V>;*
M15M<;)#'!R[:5<RE7DSVZ9QSJ*<"S!=P5\%\)!,\=L1!)2;T.(%K9&(F/JOG
M+8AEV"[>&IKW.1Q[W,7U72@RQ"O,@W,(VKGLPY'$(%?P-6@IB=RK&"1 !6A=
ME6VMQ+DN0:X:QZ_+9;/% ZN2EL]1<>MS+X*A4]!HV44MG#QQPZ6*G%A20>N]
M(OE<1=N''T,K<S1ZIHJ]K\0YY-SH3;_\J$BC< 83#<+I(3XM3ZR-2:DE96!9
M:5)\(S#8<^^U\L J\Q 34R;7JDJ$<R))L9_6NSDQLNTAU3^Y"/W$6SHPKR(<
MI9>@H ,_.IEJ[7%R?5<UY771K'.:Y71<N3V;81E,VG*$E/6!E(!C(+$%;)@1
MO$2CGDQ@. G;Z%8*/]QLH.* _X#9/7XKH_*:^YTGHL93&D1<@4AO+::5)*EZ
MG"F)765#$X>*:! CZ+5(%A"JS B-:IC ^)8Q49\@;-TCPV'=ZK(/TIY)RV5*
M=[NOM$VOL@"=7U#&QF]66JX4J8BL"HL93C[NO?S>*6'[ ]=*D$54=2I?+-]1
MU1AW^LD5C7T\O1\&P19OI[^N%%] U F,U=U7;Y=/F-S/GAKOW_>:[$I66(UO
M1N&,3,.&04U##;R$K'8JP*[N-)ZY_OQUO8HIWJ0(C7>U<%T\\,+ZC/TS^%O!
MLW1TC[%54"V:3-22,Y66Q-NW90I=7AAX3I*MFFVC8THMIQ2CI-F9+/+4]9]]
M3>8[OQH>?AY^WX5S6\3ED8MGA8&[FIIRBW74M*A^AX86 [W/2DKVIQ=(+RJP
M0&E H/&0H2"KE9U'QGUD]A>3#'&N6@CXO%TR@A!;H (O,6]@/(1&9 "V7FG=
MWA(]48]JNK9&7!$;<,&E#L>[N3Y@WZ<2#O!^VOU'9D\09K&/YN0\X0)1G%!)
M!5I0+$B7R:YBKI5Y[#RZ\4';2QGU4Y=D>,K;+U_K!PF-NK"U,'0 DP^(PSFK
MQP?-RUN%WQY4E.&66U:/%.?I:._IS;V^LBC-9Z!C4UBL6&X;[.JY<*XT%GDK
M#Z6!TI"Q2V_).JQXXC1:KLR.+B;'\4W&'^KA7@EAX5(JOS[/N;!]B?F51M-3
MA-K1+-.>*MBNZ'/ W/+H1U 4:.5F,(8<3A/@/K$2A*Q*=3'?;,-9[-V:\=S/
ML*7/K/\\C=?RGZ?Q@M?QGE0@9T_@QNUXY>C<3L_R):YAC<QLIB3'>ZSE;;WJ
MEZA UWG>_7K"KE_=/H%=M>%W#G^02@QW\^99&5IEN'F:+-6A2-LTLMO3G]AO
M851NWSPM$\73K#M#>#\5\3YE@/,+5@4&KLODMPY!/Z4"_3;XY24R7J49S(*Z
M6F_4HM;;(NTT89GE$[(G*K/4U?QX\-?R@FZL8M5+F;?]LO>;!.'GJI5(HR19
M*A!^-[2O 2"<PM=-3-'4R,\^P+J.D#Z!82*8MH8*6<-CD;(3F$,7>?86! GZ
M3 V-Z"XH=+0<\_J$7F<C6E.ZP(RH&[V1Y5!!0I<;3"9L;ZYKP;6J8,BC/>^B
M?5R%1O64TKMEGO(>]K.\.3^5,$G'B<^/A(TG8EZAHY$:>+KFJKZ%L:.>L8<-
M7=5*<D.DNS<ME^D9]]Q[XN[UA2%\_N,Y>8/4)RO^V7*KA'R'BWUW;*U<3SHL
M05\OD&W;RPU61,5?5,8N]6-2MK:(]@3/C6IR9@5XR&?"M DU_ 5RA)"S\1Q_
M-9JK<++CJ^.'2_V^/=HF5;7U_3=*'5.UZ%-Y'RG+]GSQ[U5**W;;>3Y/"RH>
M5B'>? H^W,2Z>Y8*O))MCE$Z)RL3E5E$F&Q5WO9"*=@C2^ P^O(VH7<LTX[U
MQJ'9A$,41E.<\!M+$--:'GXF">E$!?;#6OS'Q'!V;MN);8^WE7HR(1*9N:I#
M^X\]/WUFG'G:6\IE@]8UA5\*?4<%*MI;[5#QMH.YV-[H84IY[J=K%*7X9GE-
MA,LDD8E9PMB<8Q1M[)N9Y']<)>?@B:!2Y236D]Z>K $"5S"GO,M#S1L2_1<(
MOD:<)OYE<09V.IR;LWT$)2QDQ&>C$6^,6<3@!R8A\>I&XYY#EJ2Y4+X:?'3S
M7.N[G!>$AE/WRERA1M=61(ISQ^S%M.2V'+EX;NS?9MIP)>=H*L]"JMK@$[#A
M0BPB?LV3D:2#C**UCJ$9QM8EZH)8Q-Z* M&'M45&4GKDQ^X&-H(W%&4,G5*E
MUE6P 23VZ U_0K'/>)U[0 M%M%^3/Y"KW7A@K30J&#KPB>"P5)'\M!^[:129
M[ES-IY5ZR5+/,_-^JFWFA"=!5&61UF G.+ 2FI\3X*W9\DA"B ]G;QB4%\MO
M/C^CA\/J5A_\9,=U2,=954B+]_[#YS-QZP+<,2$9LO+3[C)VQ$JTB7W=VB>X
MNT 7K2&=,HW[=AO2:\32+B)'Z(<&U??1"3(6C1A^S2/SDCAAX^SW+QJQY\O@
MBQE&;+N$5J]FVG87B!A4WW8;-XW"X,SA(ZPMV9RXC&8Z;(CNY"2L$<+B%GJ*
MT"H8]O%J'S+6PW=62>4<E K(@V7D^*#Y_MVW@R@9L.N]GR;'EY<B"Z"JZ(83
M6C"?0NAQ](UU!,/8Z0+ICP_]/5)U<LHY910C/[VX+-[MM_7'[00TB.8MA7&5
MJ$+2)/3A32>O/GK:]3PP8I(A"C;!B;^7)IU)Z:SNI[3=2)62,%T^RE885/I%
MGW@?6JU:)!J.Y69@TK[7([%X[X&-;2>FN/: HZ3VV(L,D9 YI:[0"WC?^AK/
MRJK*RK.4$"K@XCEBNC'_7IVW@/+!;+ZVO04319'$R<8N^^%#/'?/-;"A<VI0
M1K+E3SNN6+V^EBSAO"=5(SK"!KR7HD@91K&'<D.U\0VH6UA9 >A>0@$.U6J+
M:7'7NU@;)ET18B+G)>^ZS?7 V;-\KI$*3,>5*"?XO2D=+8V X RIP&T$_3KL
M$.A X$B;+;P9PRF6+Y"#@YG7U68TQ@OD;Z J6!>W0/O.?3;LG%8;CP2N7"W7
MY-G9JVGN(XEK2I>]UQ0B:4. P"K3A@$AG'1;H9_7!%EHX)SKX6N^(PR.0F;(
MIT%M%V7HZ$8RB+(QX'M@ KLLT4Z,8K-S7(DPWH+"V(O';)22"T(Y288X1!,H
M?EBOF<ES:.!-;8+  <)U>N7#[?'.Y43(AN^P#K*4-]LM7T@E,()K;A%\!C:>
M *E@3: (NZ$X-$'00#PF/FLC$4>N+(%"<$1(I5VAL3P30GZ?3)%[E9J@1).7
MC#8CHU # D80<5F<<"DA6+2B6$E&6,]H 5%<2?*P>G!5E R?8=J%2D_%P@6V
MD1O$BWV\3&W=>WEV?URD F6PQ5VXZ UM/#R)UI#(.@RJN^!!V/VF#''JM[!=
MF3*O"_HOP;SJ<>\<F>G/WM9]SN:?L0=^Y>;)=)Z"SM5G=]$*_08RGFW$0^OW
MC<8BH'!K!PS3H,8INVY2/B&">!)ZDOP /%Y"!0"D/:U%@@3FM#0H]"G!. AU
MYGCQ&,':>%/=Y%&Q1)?\'I]X&Q+^\!OU5Z^UM" A522.0V<)Z9/NL FQ.N)Q
MJ&E-A .>J_CI=;6&_-Q1<!1)ZT9_UWZ-^C:,A'23[-<IR\OA0)%L+!7 Z6/"
M8%P4]6%*GX P(1._%],^.'Q'92.MN=24$[F;\0YFZ!XN78K_87=-JES4T8,\
M5U%Z))=<PM/EB1#TG0:>DO2\P$FC/H'FYL.5^<Z,X0<L]^VVN2XGQZ1@KY"W
M)9*J9][RT,?N."?DZK+8L/O7C3GW@"VFD=8Z8O&2?\XM7_0]*A!+ZH&J5.(J
M4#@;6.3@MN>;(5J'2058"0Q-VV-9SYH+C93#\J'GZY#R)S]X"(>DS._B+4OE
M;]1?@+S?7+*Y-4'VV3 A/QUIMMH.K<N9PS"37%VPQ5;&J"0:^2K*@]CY@H3]
M]],37^YZ9Q+\T&K:I(#6\JR3JT)5H6:O"$2B/=02]ZYP$AP5RH*&GL+EF[S/
MB3JZ6=4E],FT0!VL6A/O'73CX@T-[^"02:(LY6T&C)$*7,$<(C$17I78SP^7
MMC*^]L+.-7R4GFYM;:CX.M!:GQE>Y"8FQ+S/OKJ1CN/R"05??$#]!Z>KGQ>7
MI:TNE"#NCPGGKD'&4%\JT%,P!1JEX+1MU>0&BIS=L)^098QC"</!)US>N")M
M2B^2(/W2EM)NV-U-:(6J:$\91\T;&QDL=QQTQ+N.%RUE>T%L:6D(JD ,TUGT
M(SUOT0I<QGAH*>X,* 9T,%46-)^Q;1@X8_!AO/(#Y^,XQGSNE$(>!?I;\HS"
M#$KD@R06 MTX9FAY_!PYFW1( TO2M%X_N7BESB]]VMVNFUO7NND8H^"J#6<X
MRTT3MW%X) :GUWL;L0_III((E<0;836SW'VP&GJMP8C(2X.E(*WZC^O:JNDE
M%2-.S'N%9$1W[7:.4CVINLK%4C1]LL#4BM0_X/!@MG[O*T-Y<T^=F979C"\P
M10$F4QY*MZ8X.0?F*1OU_G-@QL3GF222%RY_TC3:_<'ERWL3B]N54I5&]QF:
MNO!WJ<_<'$G5%ZIEZM@YR-V'PCA4".7$;4:1W&G4;PN5Q'-'K(&XCSD0?,PJ
M!TMMC=R%L,..Y_0.&4P=>REVPD0ACE*&/$7<!:6CJ7JC;"("T'G=2@7"**?F
MN8-[8^]MO%7-2]J>\UYR?F5VV='Z_H/S*>DK!L)Q$R0Z&FE:R ]#!8QQP"RW
M+2:=J#9V\;HF4YQUV+5E42<1+_NR%YG"!H;W+<&R++MNA,7EIJ/K2Q51K5)C
MF\N>!+'2$WF;WMX-2W-OGZ;:C<UW%1?GEL![0",J&_+DYTD('&)C D=3WCO!
MW*W+0V\'[3VQZ#>\GFL3$_Q&?U1J2R^U9D1_%=6_>O^8OG"3L@'/%'K8@8W\
M%&I$](8URB'M\,L;;GV+#4RD\WV.R!#MIEJ-YR_?5_2X-4\]LETUK7PM< &9
MJLY*[%C)-:6_8M6'>EVU*#B.&:8"K94423RD%1P3RF#AS@F/5?1DG+>RO5 :
MX[L.:BC_\"0V;K15+;7L>=NXR;[2QPV,4%:"#?$4Z1@D L3LJ^\+VJ6<XI4S
M.M=UHTW:0:HZP4JE-B89"0^ZR?M SZ73T<CEP4)^6(&>3<WKO!5W"@Q]579I
MWQH)LX7HSLZG GODR$\I,K/WLD\0[$M-+#:<":<" O 4>W5D5R&AZ<,CU="^
MVURNSND)U3=.2/"X5(!I4;@.&LD_0_#!RV+)J%AU':QL.$VW]&@]R06\Q_.C
M-:;[".N#!C<6W<N%U70?%_)T\!E^Q:)NA3+0XJT&<^Z]O0'B]T6Q$JR6@KF7
MV+R\?";C^3X9?TZIKK'9%=4G>**3?E\_(S+?Q>RHY6ZDS\0,B=UG'-8LRQI(
M?#-LVM(;HY;13 5BE%4&56@*5>K'UTDZY<9)2NI1]X]L>C8X^T7*O/C._KH(
M]Z/3ZG7*!:KG<T07GXWDU7K7EQBU]7E\E5Q"6@2448&(&3<_\'ZHS22,("D>
MCKJZ' :NF(G5/.DFH$00QY_(;!#MG-AB/Z#=N"V$*5>:+CHV0B(<W3\5EE+5
MCSJ#NHH:X6[5/$4N_*K./P%."&B0)HB"%CN+".W-: =1MUM,9%/;BO=GRT9'
M'2XB'4/.]$_;=26S3]R]Y%^*;!"&-<J'LD"U"7HXXKA[=!+2?0(<C6)96\WK
M?#9;975PQ.V>L6"JYU*@J'QKD.+M^P:QPGQ\7W'ZTPT2- R%4,Z0F&W0;=]$
M1I(%KB 4-*L0>)V5/5!W9<:HX>-:W7TNID)[O<[D3G6K_<_2S1^7'PEG.9:3
MX?+2$BZ2-K@D/NU6T7%/Z%! 7)R!S6S&;&\S/(;6!;HLE19!^0@7\"HML(/J
M]BY$.3A_8(WF4>AIG-WCC^JG6")*BRPK5R#'PV<6/=EC/I_V\SVN=4RK% T;
M2<-F+#%@60GBK,W@&,PK\5@_5O[*<N>\>0=I?-M]_(%0,-,S-F._YWKN-QT#
MZBHC;MYMK<[,$5GQ<D#AN2F,2CBZ=@P+"81+'6FC2.,";JM+<WW6?K.MT_/!
MUC,^OH=Y];-;7U"BBY^?/UXRY1Y/(TMCF-.#;6ZL^*(KKJL=L5M=DJCA*B"*
M!S>AZ AB/;Y+ IY,R&WWT0U=0>9!4]&(UB.5::3%.37]@'*?<*[">1M*92(X
M%3)E6@F_1@&18DF="PXB2')I@R"EY;!*$V*8"5)%B"^WZE-"Q3B(O?X#C13'
M5M^XFKK!8R%V_F'GD4@9X!0@!3$@2&T\(Z1,P(;B)^%-\&'QC42\0-HD*A+%
M[0??0^##ZMX.7VT54$AWEG*^YC(JHO\LS>MS8[1TTNOMCS@XA1%"E(&R?0P]
M')C66/D@!0]N-K8R'_3M"5WQ'G +V$Z0'[G86:0[=*B]S,7YDU"R0;AU6$36
M)(H@LKG8B@?]@:[0L+6_.FQZD/!E$\O_Y=6!$7Y=_M -4V4M5Z$)Q\K8).F4
M](1+C[I;$I3"WDWU%^4L(MJ=7;H&!ZVJ/U[3R9OD2JNSC$>][2 )X=J7>HDV
MA.@-PTH<.DI3ILL)+VM#SKD1RCE'D4&7G)\?U.2IJ=$W7A]@9"IN>56I.RX_
M4^)6]J$(//Z8*UN6_%*3TY8R.!SQB?*N81=-U%OYU? ESBK;4;E*R0W5Y>Q?
MCP]?*=M=UK*W_TY$V -RTLYO])8WC'&A6>[/;,&Q8N&85C7/!.?JU* K#V8N
M]L\D8?GJ8D5'X[^H263F_''5^,U!M]F1WD_P\<^;\9K2@0,JC,50)YPSZC;2
M ?^VB[[VP.M7Y3&V8OU=?E/D.5%7CLI]9N]=R1FV1%2##MDCFD2,I@"HMU0
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MYFXTL(%U5 L,[;FXE27<F@ </TVH:60=/QLHA918PA)@NM\_(EL8]P)L6\J
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M"JY;4UM8I7#"I.C Z71/?:,4@%/Y/.@&3X0#_ I)BF0# )R9N\_VLK)&_=F
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M"N;.!845V^<S=24UN_Q\VK_;7+8,'7[MLW@H/&&7KIVZ](UPU 5+@VNO'1_
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MK6,.:99D['<57V0RI3,UJG2Z2'3"&I?/*]KIB@&7 I?Y$I2):. 73)O=\MW
M4*>6.)7-EF86F1J3[(RI:/D#<R/&A6<&U_3*:#RFSFW@0Q'C8[;NOR_W>6("
M?_<FE[DTYH-H6_CGXU @_+&+("]DU7%_!O0 OI:_K"J"JU;H"[N2GAAQ3UFO
M9$'L'=LJY^UV[0=4F1FUJ4.ZE#H?$,:"/ =S%B-U/2/]/7$(KI@3W-ZN6692
MK=G#Y-^73*CF?!9/?/J?3V8Y_ZD..X9G%=Q7>?7A9_IJE,F9>P;=W)&+\#=?
MB/\^.H0Q#D3)_L[#>>@"#3_:X 2*.UX4.PZ+.?2P_LY<R2Q%6(A54H:DW,:D
MQ;XO8@AW9^6DO-*/% P[!_$TD%OU<:>*2HTLEFYSKF"@4AKJ;&[_@V&9")<B
MKEJ"A<QR%!<\G[U"C_?K'U'JV.QK@_!!.SV M\#)"#L&XNVOZR1>@EDS=I<>
M?"*AC1##ZL3^3"U/8R5KJNNFR70(H>_YNJ#8"\$U+JAF=*X$\> 6:Z4^UC5'
MW_7U^M#Z8R'>]@%:)>\$YY=F$O3K%P#C<!- ,B11@@4.8XC:6$8T>\\E_&\0
M8RR(N@0AQ6]?>?LJY18E,[WS"@5"S-ZP4F)DN /7+8MK*SJ6>,$%C\X_-Z0G
M 5D(Q3'MK,1EE))SI+Q*?_]DM??D6[V75Q 3?CP(&763E?=O NQ13R>V(\KJ
MZJP]55AM?A3<>DOCRZ>:+5-%V5WL@U/K?5HTWG7]3OIL_9RG98G3>19K"KG8
MJ#;0OS2<1KCFEM+&/77> >$D("<$Q<L"=;;ETAH[H_K\!T1'8CW3E"JW^#.J
M]@V&DZ+MY-8XN.8KQ3W-A1$.ZZ>[GM$8PKH-HKL .+M].G\/%-XLOEJ/9/:X
M&9]X/Y)GU9[&8SU(//@(-:XE<8*>6_+2V<8&/N\ T)$UWC\7GYNSU'++C[#R
MDA_5]7F8_U ^9_,YH<YQT2(V7,,!H$05I2B<\7CBX?A^N45]GMR"BJ'[DT9Y
M^1R_3_VGNL#G55>\,I"<PMRC5'O_>KAGUW 5B:WLA!##256)+TN6X&(=?'6)
ME6)3W- L>L'B6PGK5[_O,M37;UG3*@""=ZCN;P%ESC-40[#IR0IHJ:TUS-P%
M .".GMZJXRD,KYS5NQM] ; )%SB,-Q9,ZL(,6$0,?+6(5I[>U[$:VRXKK/:&
M]*_]<DNM8MYLX72>ZZ>\VDU> 2 8S<T<^[\K_?GJ6W2L7H8OQXOQ&#9K4P=X
M2 @>?P\=7^79Q#NX=';C4E4Z--82:_ _]OJZ^WXJ('SC0^J@WGI*DVQ]9J_+
M@Q=>]M^<G<*'-6-.IP\DW'UN%ZV_P6U+O@ G7 !,9BZO$R5>!4[*FF'G[K)U
MLY!:CQST_5CV1@JOGZ_;WM,H/;O*T?^9>V^>624C!=66QY5H[FZ2E6C]94TU
M:T*I'Y<F5HB=WAO<L86HVZEO2.MX!2KQX?[*[412K4*[<@4FGVI/3>_!FP'O
MCRCVD/LL]4^M)N+Y/;87EJS_>1XZL#Q[P:S.ES'IFG&POR'B]A_MO5D"DV%!
MN^MZZO2NIHK"12#[=;WF2&BAEFB<@V'%@5QVP=NL$+W<DLGRS"3WC9/(E=[)
M(/[4S<VS"T#7!S6:S2@WJI3W9"=D<V<$8U6MNX]V] =+GY'JA?+?OGV_S5*8
M6U[XZ^B_^-A]IL$)\,"?/E8BV00@RZ[##/P,&!<WV7Z(/OU1N0#A[U<@[_"Q
M3>/U/>E^E4U3).L?,*$:@! [7B,:G[(2-Q%PO%%QVA*'JBT,7-=U8KMP7EK$
MTC[.ZEWON<EE?N?#3YUYU5Q9Z>OW?K'S9;50YI->6[SXXH,6>#ZDRZ4CD"U0
MB7%-W[0<$J^^XQZ1((%:'Z3+<]3*&^P<*I7<;E-.\3F9$ODQ/F&^1GI1/&C?
M"X]?O$V,O.1IM#'V M +B[&3);XC4%T"-FEK&J/0\RC),V%?3"@HB4O,_5-(
MVKS6T)"S6TD73T!OX*+$>3[<K5"U[Q-XL%L!*#Y9#:0!Q;E,?HH9:JD)S[7T
M"EQ?H:SK3WAJ4>D,8+)P<#VQ:YWXT-H<9_L J=OB9B%?" UPI3^2'J[/0RL$
MNJ1F)W3:T*=,2#@GZ4JR+7- YKSRIGS+&QXQ]Y3FC>EJ9L]%L9!?O9>2/\KX
MNP;"!>[&N*;L&UXGC?)2MVH0##N!DD2=149\>[*SI_@)-/;,25"?M7K]1VIB
M6N#;DM"JUQI&<TU5]M=!+C!T"%9J*Q'_!6<>NR_A:TZL_$3<V!GW97@X :QP
MQ4C=M!EVNMZ<\"M=%#$>-, FR_]9A8KUW'AA=OUG84-][DV?=U!:1?G$<"?*
M3PO3K]U0)K<?K^#SUN>3\KH]3JMWQJ<R^+2;:W/02A)WXF2?R/;227:,?><P
M8J!&<G  2/K__"]FP@]S\=#M:QCX*Z#8=]1.^_7Y37D0=] N&])/P&I=.76^
M[UGZ@VPK7Z5&0P'M&G[G6UR^&B?5%X KLJ,105A#%LC0$I<J%[8ZI/<F;Y?4
MS3G;S1-@4GK-=K!H(]KQT0W]ZRG<5U([_I I4AUDSEAJ!.?>H$Z#07ES;VV9
M#=QAN]NC>=WAG<X$KRBSS/IBM3W:RN,EAV3$ER^>E@^/9);F^OQ8OC#MD7_U
M%V/@<%4\W$T"D'1)2AYV*@3V#M <(\XUC<0#AG79,1,+")Z/)\\4/CP1;FQ%
MU=\IFI+D'Q_C_D7>/\M0^U7<Y#N"06P#-G.C4WFZ!XD.QPHCBF.*&1K@,4N4
MJK?Q58STQ'2#R1P+[S/39=9XKT9F@1_'0B&#H:D\$^_C8(OI";RTK52$F"XF
MHB?BY%;V49S^F56TA=6<-KW4BHYJAJ"U#F\KK877VBWEFYMR4@SK=C1C?&-R
MMVBG=4?W$YBY5+R5J3]D/GPBRG;]\R^JRD[A-$/R*!#MO^HT;SU[[Q)3A!T^
M?:O%%S_8PPX'J#Y5B[U\Y>3H&211_\M3^0G:NMY(%>LB^HA-7MV"S8L!B, W
M=A3? ']#8I"))"IP7X\]33O#F<S8JQBLE7C.VK.6AE=/]/U6J7M0TXS<:6::
M3;O==^^?/#A4#MKWL]D,,\L.?K$LW#JQO2-)ADO=Y<J8RX@IPG%\*1^X6\TF
MZ.98_ZJ[V]LGD5S<:0<QT/1,B9.CSV>2[*R;-)//F-RN2)JZ -!&&.+KND#7
M=X%R8+K>X%0H0[6;,UX.-2C^\E>D-^57B:<X$Q<7D Q=AYKGOC:)UAU?L:S0
M6SQ;@DU_Y316BFIU.#E\+9PLM;\DRQ4INN 8NQ1KP>TZHM3 16;C@]# ';C+
M;<N/6P;E[4?R<]IJ-JS(2]-U@+E2JHK<':0-E4"I:M5>/J/=]]K&[5_=S5^]
MD_$P2?.3Z,_"UP;4&&[)*T]*AMFYT.?J).?M?Q40$D\6+CWM%U$XB#%6$D(S
M.[MN)9VSH@5=+HB4L=.WN[WJK?NB2?.VK)=_I.Y:XFCK%0(%!GXF:LA.FN"E
M:=4GV&,?\C 1[%\'+M'_&9NWA<?L/LRE^=072JLRV/[P[X^? A\H5IUA&V7>
MCOYWC'WRHS0\CL@7U587I.DM[^J: 82IW*@^<)O2?-T?_"C1&FSE.XOSGC9:
MFND49P(IN3T/%&E&/%(7:',Z"#K[>YI[3';61C0^U"%^7-XEC^#/ZH'03C-V
M+7&>!1ERS("O;NAJ$@,ZBUPP$U_T?J@$<%+\>GZ'\P)@IA66FP9ZP<LR\P?4
MF!NCRHH?QP*Y-IC=3Y#1K9P!-/ESEDD=:,, MF*6KT8RIF\+%RV\SIKOGW,-
M.KLYR-=&OK=\<W. NKKDX43IT[<6K,;494U=K_L$%']5Q0\W_]WNC%;3-VK8
M?V;],?WIQ,CUV"V3+[E&5U$2D]'2GA\8UV[TV%-L@=ST/0]%"YX0I;ZY\UYK
MYR$&B;>&8->WS,2N3CG6ZEDZN36*118,)SBR6K#1AS%Y#JF&GDK8_"%1$1?*
MB&O=BS)C?./M0I;$=(Q+,=8)_#/B>8]X#DJVD^9NSLCU9^I8368-W/US[;G9
M6;2U(5N!L[,C700JF?4KK42Y '-5U6<C17%JBBS$O:2@D8)2>ZMDZVW@X+/Y
MY%5!U$O@:;:2I)YV"H:)0?<#XQNXP[DOCCT9Y JEM3_SP/>FOU;U<UZU7D?A
MY[2ISG0=3>.ZPINP$EPV@SX4NBWB0SV9U'SGA65]@<G2+6XK7".<5T<?@57
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M$525?[P*68;' 86F?"9ZBGA07F6)SO4_ZYK?+J!S,]1E@#0I..[5]MSSP@N
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ME^\7&R8,2?D(QVEFO&R\:\LSFRS9,V]QJQF73Q*[ 'B KA.?V:._'!Y!><Y
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M@C^;4@E0LBR,'E 5S0>=FXO4/.ZZ473OKKCR 9__2^6P,./6S TZ%M<U*A_
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MH2$QLW)J4J/U>VOM;8IV _@)Q1MU-0;%$S_U&_\O)=7_CT%&GT(!,!2D#SH
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M_^*5/DBD\#2LIVSRAHR(37$FM649(YQ>6<<;/MD:ZEI_.Z>$ 4@N@;:WWLP
M/O&:L_VXM[R?ITV!&MJ?T2^8\.KY]Y9HD7!>-J>)4-M?M0EX2/;=(4&-.=+H
MYGP2M8P6R0#F7M*'8-NJ$PQ@41_SV:,974:W@ASC?#,=V/L#=VO/ZD'7 A([
M=&4!>)XD]]_6REPR>D[J8$^BWKUXD?%*0SQ"#\=&*N1XO#9F<+1GGUQ' C?7
MHX#WA*;>TM"T>8O&VL8XPA5LS<B^ Q\_=_E&FQ!H3J_\_49T_&Q;6]P>FAIJ
M]_6KY'0(:TL4D)>F2I"RJ(ZSK48$&&?PSZY?H0V-\+@? [VW9FAZ5R]&Z;N/
MUM:4:T7BR@AO >3@QP@W=Z7)->N1JN/>?<Y987W/TX(?9;7I91EP7+N[HI#Q
M/7'1_+;F?5N_VRHW[ C+S1$4'&_9K5,(5Z]L TF6:_<D3E?C;M,=Z?NH%\F)
ME+/!9K,?IWJFA,GI[6[MV/6+*\[8G,$U"U.^A@[Q@?.R&TYI)W[<\U$T'C1$
M76X5I-B$6Q)]VA$'$#ABKATYN3S_](9)P9JI<]K\LOFXYK?)[Q^/G7F"B74%
MLGS-I"*YR+);77S4"^198N>)7#JO*7'CPGYI-%R\?6D<>S,0\]E9IEH)+[91
M$#S(58(\B>HX'AXV"TN0D"3CRH)C.FN#76]@N;_77KW ?W-\M]99,:6BR#\[
MA@'\PGR]>E5^_5WU5TIUUCY)!U;9*=B7R%,+Q6S2I^H "P-^L)T)9I:?SKJ;
MU@1]"V@F>6J^\@^!WM7*''XT+&#M=7]5DB?S(>XB RC0&F*NLS  ^/\KVRBE
MB$1WS3< W+Q<\R^DK,AD:6)D81?Q@P@1N*M/'%;DU;,64K)]Y;@  [!9+9+K
M:%*?EH@?RUQ"7#)FRR'OFHCK=4Q3'"MD$,U.DISLN$'5@K=/=53T8.+!#&#[
M&%F:8$C<'55T&5&J<U>2^EH"]6Z<<CYOG(I[V%G+/MH4GB-;4+_I$T^5?T[6
M>N<YDZI\J9'^?N04):$HZ?PYV:^6$Q5:<5>RQ@X_FB.&2A@%K'-#4J]R.'"S
M]RWXI165;58\B3KH4B9>R%=J'QV6(7F'R2^+39TMZ@E ;:%%(S\*=N.^,9U*
M4W^6VX67.&]19FTV-0]PW-O<QGRVBE1^840*PFDP /@%:@DM:I?\EC2BS0"Z
MMI<W<+HA\TMK7[ VSK+0;*H.;L>=Z2-_ETQ,=@'J'5J/18"WQZKZ^.7+H07W
M-Y>Z%6*/'% 1O2$)3>T=VDN_#52=&N=RU)"5+56OT/\D;/#E&>^EP]^9! T<
M2A^*7HT.Y7S<]XQGKNE)B/Y5_EC F?.-6."JB1IU CD.%Z(K7*)<MG^56Q8\
M>T!YOPJ" [%PC^_KPEW\B<:!0T6>S.4"<[[H-I>S5SE#S=DV8P("O#'BM8CS
M.UFGK6T,E'\0RO6^CN<%+'TTY3CC]<9,G=M0M46;J)J'JMT5L]WX>*B*@!$/
M[IW&)V@?(;G9D; ]U[84#C  L6N+>S%?@WU,B77*(I-7;UZ[\4'R3/<CXJ^K
MD9Y[;*\S^KU*(QH_UG\N'E'Z<FGY4C6Z7V\F]\BUY)BLT T]\?,<&/X[56\O
MI)S9B:\RM:[:,6"VZ#MGG !] !SV_F%T:V5DN-CCH>'ET*BQH,)][B^@Z$<%
M7/H%.JJ+9F*1$>[_E:X/(N3,0P\=$3OXU 3(C#2[2&  >$LK91GIPT3?$()Z
M#SS'CVX R(T!XL: F%LC\DW%]2?E(VM?47'O-B6PW=YT[(4W]NKQR/FH+#;$
M':Z-;Q6WCXA>&K7CU*]N$0N<W:?>6[:F!\M!O+YX$7V(KMDD&4MB&0T6'KS4
M(;PXC+4^0DB_A-T[B+R&[)A:MZ9K,8"Q 3\&4,**O?+B%[)HUYRY?XB&*BP=
MX7L&$IZ^6>%^5L('AZ===^R&6"TUV,1@2!7SYV;2/\TM')'\F8]5T/F^R#5I
M#'QDD'XB_,((G9NJ1L)WO0V%-7H4L']Z%=22H(3?:3.H,S1DRXMFU=SS]=R]
MBF< TT2SL:>=(JOE1;^F.,,]RMH>A@6]^!"8QT:Q?HD[T+![R%J%-24.XL\N
ME@30FXV^67J(V*7>V952@Y]Q4!W4Z 7IK>T2.88B2%4FIQ*$6ITB_,J_7APQ
M5:,_/B!7V^JQ\3.WGRW +<69RV)\MQ%&#!%<YIXX\PZ5!-6M\L&A=K<)I!>-
M5 DCRL'-F!FW+LG(C#;GU]#&1F,VW3H([6#X21 ,0ZF<9/U9FFV/!"NZZ\G=
MRJJ;3Y_64=SRV8\DUYR7D1Y(R/O!3Q?87OK6ZG?M.GOQFZ3OUAPUW*X.,4#.
MEJ1_L X9,W<<3M:.V1;.J!@@8F=%N.\=XNULE!1S2(C'^!N5;39,$8/7EB5K
MY. 'D5(U.\>(8IPT24DQ,8X8/1C^><;%).X>Z9NQWE3?PDU9TJK.[<J^[.58
MF/-<2-L5^<&^_JD-)V\CH9_83&'L-"E]3/N.)SH.Q5V:6.R8Z*7-:J6?^L+\
ML*3**GO'8@/6 SZ=BR!:HV/A1"LT&QG7BV:GRE8%AQD2\\DCKEZNYT/NQZ?+
M?])3D)8H C@D= "X[6$ODM=^PR$V];F8\?7R$2U;'5\X3L!^K,]\56@I304W
M;V-[Q'"54Z.0Y;_0.J G5XT%/KF]<3^@>\NWB^-9OXTXNVY\$O42>#_BD"-P
M(5U8N#%Q/HXNUAM6\8WMG+:F3N>X-EK%E4^H[WL*;\ 8SR364TW!->>&FTJO
MHONJ'4*CH_<[0;BW<0.3BG+G&J-THD3JDY60G39OB(.5=ZS>=@$N#9DMWK-<
M'YK81N"@)J@CKJVHD<# D#'4:E?N7J"(X+@9SM/0V#9ZBHQIZ_6KV.6I_.CA
M"SD8V.EIV#Y7S?:$4O0.W=B=]I!H9D(ZDT95>&E2-K&8FU,SX,&<SM*UO3WX
MDA*=<>[!A'&[Y+R:;1><> G#UN&=%:Y).C@?5Z_C4372LQZ"XQ"94+G/UR;E
MPJ78?2TA'//![#7%K),!,"-AY("9JMS(4N)V_LO%Z\<?!K[:V7[=6B7[]9IS
MUFFYKVY:3;*E,@4L -*' 70<ITLMP 7"KY'B>ZZ?$FQ(+O>T]5>K[PL\\#@1
M)NV7H;)Z4F%;[5F@5G(U3L8Y<ZQ "S*RB'@P131[JLRY@.9I.[.H*S8L/?Q2
M45L_B+>3PU-D?E!A/=9<)>4NE81XR?+(Z[C_"<V@.>@4M'1)C[?GJU /E^Q6
MN7R%OI@O&P/ [(V40>?0XU7<R-ZINAAF\QLS;HFFW*Q7J[*]9$?3>NM1\8U=
M0X*SLJGM0C#B \^;G&APJC7HI1N8G8.TYHS&Y0B*$20-*4!&8^HSMW7KZ1)8
M?FY,EX]83'INM\B@WQKJM$HWX!MHKB$9.A0L$_H'>#,G]A@O-9C1F%&IJ&(<
M53B+"?D!)AP-/#<[="A#673L0J%J:,8^H" :^_&Q)FS'F0$,&:"*\53A7 9P
MM).43N\I8@!%-I'P^I>0(<<DN4*F_\+&?$RTC&WITOH(Y7F>OGJ'-)7FT6*V
M@UNBGP)"/&B?K-58K$?6B  #.-N,&^G+>CGSF"G^<%2_3!Y!-B8M+*FDDNG4
M]TN-/ R =_Q36GMR".=T&$_O1B'70/J8Z #L$-P=8(7/OF@>]$7]P#::]99>
M_KSW[,P6[#WV&,K!19]T@W 7WQ]Q=RM/XAY:F]JUTXVLS- ,@KX(66RGR3%9
M_<'ZOV1^(=$SED-L[^&-9ZB/&<"** -PQG3#]LXA9I9 N7L!GL8 EMT_,X#-
MYML,P!<S_I0.TMYV*@.HL9U-IQW&$+?(I0S@"*P7M7T*/&+/3@WP/3 :8;3Q
MK!E=3@]4MMB"#<;]0I;N#C&!0 F1"H2O]C. PB0&8((AJRK3+\438+14(P9@
M6(5Z>NSO] (H3ZM_!(Q71&4/W_@YS8-NUO$;8P#:(WK'.(?M6N)\< NHWB=
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M2.^V/_:&E-NC8V8[[$"F/,?$%S4VM;P)4>JI:+0]<;WXDZ(MPN-B?.] _Q9
M?Q]^[$G;XQG,08^]#_T1+Z]ZG,[9FXA,>=JWDBGSH$"?8W=O;_[%1&.<T$^1
MV.ZJ!+34YY+,*S+$M\8XB^R\/-):<K'=[;VV^&=V4^/=;N6(Q1S!T%?YAV;F
M3+1Y6I,&C1YIEPL_8-5I$NI&6M&_[TVM*-TCW>AX8M9QZ;(R67_S,,M\VH$+
MU55OF]&GW2<O_7IOS1\S&* '>\5]6\6 *:+!5$NTW/]U<;:AB/>)+'_]6[(<
M (YMT<)N0K[FL]+W@8F#)[>OG=#52ST0>RQ4+"6  > Q[1^-MJ-(J!6!65B"
MKC0HM4YO=/83I<_6@1KBHNOY])MM([.IWD61%P;FN4Z>,3=7T?C9-C+, +S#
M$ >I!XFP).JUF7R?KE!<XF9+Y8'*_),])O8:A=$&;DW</1T\T5OJPEN%G*AM
MEA0CT@U"D2]\%A5Z68M.>65&0%0,^T.V0$PLQ!,05%XP%"-S2;;=4V+U5:H&
M;S\]KM]E (0]>2E?S.G98LWRN;S -43U]OC8PT>KO>_;XCWVL_<V(C<A?G]B
MMQZP:*H'DZ/_0U%<27N']?;9564 W\[0^Q%)\,TX;"=^%DU]@!)G &.?*AG
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M@V>/LR=_&?=%$W.CWG P3;H3EB;PNTW\]V44C]IU<&MZ2<[@I'7?K"UMJ='
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M407="+=V9CM.0_<M'#<#_XRA!2)H[+9[^T#;R$&M'Z</H;8H@O0!/=CW":0
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M8GN=HI;Y)KA)PCF7\UJ"O;]9Z%YI.P-H.%TY/14U*8'NFMQ/0J3XE ROW6$
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M-SO;TXT+1OJLX$\!,;*U97,;$=UX<#(]_7_PWW#^G0WRU_K_"U!+ P04
M"  -0'1:U0<,BE3R 0":$0( $    &9O<FTQ,"UK7S Q-"YJ<&?LNW=0DVL;
M-QA%14&D=R4JTL6H-$$@1Q00$)#>A*@<A(0#48H$"(F-WH[4(RU20N@1(2 M
M$4(1.(B$)B E04":)"KAT82P.;M?F9WO_6;?;W?_V9TWS#-#YG[FR?V[KNO^
ME<QD[^/> DC,VL+* K1OWS[0;?X?:&\&=/6?=_^/7O\\Y/_I,_;MO06)']YW
M5D!:8-]IT'[Q?0+B^_:Z06 0:-_!_^,&T']Y[=LO<.#@(<'#1X2$^3>0Q$#[
M]PD([#\@</#@@0/\U1C^.NB ^$&)4Q>N'))TN"-X^H'4Q<?/BP\KF]5W2CN.
M,,_HW UY<D1(1E9.7D%%54U=0U-73]_@DJ'1U6OF%I;7K:R=G%U<W=P]/'U_
M][OG'P!'A(:%/XQ 148]?18;%Y^0F)21F96=D_O7B[R2TC)\.:&BLNIU0R.I
MJ?E-2VL7M;NGM^]=_P!M=&Q\8O+CU#2=L?AY:7GER^H:Z]OW']OL'>#GKW]P
M[0,)_#?H_Q*7.!_7_@,'! X(_H-KW_Z(?VX0/W#PU(5#$E<<!.\\D#Q]\?%A
M*;/GQ?6=1Y1U')G2=T-&A&3.Z-)56/] ^]^1_7O GOS?0O;?@/UW7-.@HP+[
M^,T3$ =!03R>>LEKTA#R.G,BM0H5WZU0F)-:_"5'UK.<6(W0Z0N\4[XZ<;ZC
M9VE[\^^:YUXS7E<4AXQI%\L>E.J([3LIX)H$/,8NX"E,^W)0^HP!&WER#S3N
MR41M/2U8>RIG?/S'ELT>2/3L'NA)S!YH9!DSM <"'K:#]T"#UB!.5!(0SU/R
MV ,=X.R!2O_>S=\#,3=1T#U03A:6.@A=P&%_1.(:L+P31,$]T#?:(].Y$O*I
M/5!\#K;3= _TY3OTWAZ(>]E'= ^TA <SOPT#:O.[2OX;\_Q; COY2XTO19LK
MB E8^A*.:4_Y93P\1=D#'9M\N@?Z";?D&C?PCNSL@2Q?< SV0/1I)G8/I*TN
ML+FFQ0 #D?Y<R2U>N@X;N0>BDA;V0#Q/A__@^/\MCHG6UJ:&V*^0<[<;F].5
M_'K^'ND\>KM@/VU@(#GC-\6_0E#++^ Q?A66*^ZSTW-=QROR: S%OYHA+M]/
M1=P<+'(N2$EW@!51Q+'!,$ 5TD,\M(X3)9_FC5,:($G&)Q@VL/K J!-;/7L@
MD:M([!\G?A?OUTMK"8R0=S/WRQ!.*'.5=SL^"64BV6U\.$Z8X;FCS4 T$\LN
MW/VK79(N[%6Y53*R@;GPQ:!^]_7GIP]"529J&8J<57Q6Q3F_EOOG]:O2U-.V
M#1NMKDZ%K/\]@QEQ[FAQ=BDX'EF0#Z_ /[39"%FOZ<#_6'*]E29#T0E>L[Y5
MI3FD/SSJ^9\!^0^._^#X#X[_X/@/CO\7<;A]P!TV-4%+[[[4-;G:/7_ 5 .0
M95#B&VO-&U/M/9BRB;K#$JL3"B6]*H'";;7G& SU<\]NO(Z\>+'%3&Y_F0)H
MNTJ]Y)'0<KL?7?08]PHS-]%8A+%[3@3918:,Z$&/H=(M6V?904[F$]HJ]6,U
MY_2E?47&RVC4DZZ.#N_>&:?E)(&XOX.92"17_!UV*(E[\G-&:%!U9D:(G5VY
M_9G/W_M+>:<V^64VQ([P%_= ;[UA_#J&<PS,09B+V&X3"M,2\NL"[!D8$*[F
M%_-].A#?S#N\M >RT&+R"[(O',OSF-R8E=H'].^!Q-A[H,[CE"\]&#'LPCDB
MOUM&4(;2/*"<NRM'[!+E'ASGE] ?UA!V4W!1C7MUAM_!$'X'I8$K>Z!'K?PB
MG_VR!TJ(QBZDP7[<I1R&,F7=^#TJQ R-_ 9.P;%$^2 &>2EN=$'>_C5^GQK^
ML_?_[/T_>__/WO^_MW>^#/U?;/XJ:@_$3@8(+[&=-A@0[^]?]XK++)F9??,-
M\3WIB4JJHWC:G5S/-RRW9USS8OBT=D_Y*Z\ATNLD&F\I^.RXT/NE6W\Z^R[C
M '79S7Z6(CN&Y=^;?@Q]#LCV(P!M;[%"&"%@>;Y+Z0SS6.$#>I"D-2NW5]A>
M$(COR<7HO&FU:,GQ5K7)=RK]9"[=E%>?:C-\][KD$<WG>/5-5Q>ZXJI_?'>,
M9VD.><-Y2TWUIZ^5=5F!KZP?-JI1(MA9PZ'Z\A^+/NE-Y26_^GM'ED9:,U(O
M?;>V_@7^-RKKQ:\L=K C*KA^#W3P]UU<V/"^0!YT1)>HR*\'M1YM.6)ZF*LY
M:0S!3V']>"/S<B1A^6 ]B#!7IH/<T?":=2BWV#8PXE #8^JK-MK07Z7V0QK;
MK^D>MH#+[]E!QPX@D0%^Q$*?:B4#WF+ <Q:!3MBT8G+Z3.5IX<,),.'M^?U<
M-3*+G(DX54]I'X6<^?M\H$+07"XV]$[=]/)'6[FS IE+(5:&ZF\T^CTLQ"OM
M2 '.^;D0%0.[+'\-*XC_<3L)%]_#C(H6\0B'H$LME9=ZN(Y9*M82Y:6R6F,K
M570Y F<@ZX+N:HN]J.N%K3W0_]AYRW\YL.O+PR#^X-QN]UM(3P#+P_HP(D U
MYRI: 8AA:K&Q0*_Q'2:%?N]%Z3R@TVEJ,(+\:ARTN =2FK&J[#SN=>Z4MQE$
M&)X>63$-9^=>O"+9:P.9HDA2%NHH!]J%&4@)#^ J'=DGF@H5Y<FA_#M]S@/;
MK @Z]FFF!].@$R**_HVFC;Y*7T^7M'T0$8BMAO71.>_".R*LF+NUNU^?EDN&
M5U@J3:08E"1/63NFD;>4DZO_7JO4VWB9+4\)=,K(&9P.-;UI]]7Z/<LAH[F]
MO*SB356P@8OJ;J,$_ABB=FYLH^X^Y=\]=E_ ,M"%.J@ 60D@=BM$/"4KH .
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M[@6Y;#M^' D+8 2,Y:4V9CHL9_F)Y86-&YR9)Z5J]%R=1TBSI%]EJ3A8?"U
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M:X:5#FB]L1I4_>E+GEV^?T3UW&"9'<^NVN]$^DS8BIOL0^:S&+)+)5^V7/9
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MRI26L4V]+9'9@3^O,@QB--\#JT:@-\^URR?TGA/<O3[E-+TI,BS)N?0]*:S
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M%7*8_+:@5YBVUP?75.CH@TNS;\C=L(,(R#@"A5F2D$"*Z)NDS:&/ $V43\V
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MOUDK,;?E^QQ2?@^HE3>%$_4GUA;W<$=Q@B3$E6:;OD<GTHK!#8VMOK$(6WH
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M2B7452OE-RP)*6WI>6WD8:1W8RS%AMC,'WY#K5.(M/ECCZ]]>TGMW(7!(>$
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M&<M1R>,N1W75DA7KW\3>"I+H=/HT)":/?[1?<S4N,"K\+K'2I&0J3T?/+FB
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M+_KAUK=UKV>UV3;1F_X<&;]S'@N?O+N[3OJ*W>C+ZE;86%-JURKQQIW-$7G
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MFW['*6%:(Q?!K1H;%ZD:*:A&1C(=X\"N:]&0AI$.1$ /L7Q-Y&D(I#$@!QF
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MK6GI;._(S";+C[&06,/V86:\-!$"PATF+1/9!NK8\Z[7%H)J(;*D&0_S7'2
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M>4RA0_8T>2PS=$FOQ_0D_ =+"[C!I'KFT5<Q4710'<)G"K:N'2H0)'ZF]&G
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M,85VWBZ%7J2RP8Q?"1I;G.O *Y?,82F>[FAUG'%V_F/UD"G13-?/M=L7C*3
M?WH8V>A\%[BW>'VVLT3V'\[O*_XW5LHPAP]Z71X:+$B<:6OX[T./5!GB)H.O
M"RT I?+AB(K0S2IOA"'C=:E\AD;JSI5QM=.LNBC:_/5Q6XMQ'B,SA=:61ANX
MF;3_@^LN(H.NJ1E=9[(5<1,?7(7N&T:VPB#WUUT^V!<Y8[94Z/Z. JNK\48M
MX4X-:-7#<G<U.;%.YQ7N9(_KY8[5WR:P_?UZC@G2VFN\?AHW&6W[A)$$MFEX
MK:H2;BXPWXO2.=O-^*NE.O>N\7[7^;C^\V;KY?S=RVU!)Z_/M>W\*"[TJR55
MJ*QFG$=^13><3>,H JF+3?%$?;;Q%$<1[JCF$8OJ8$5O\7Z\9_D>\Z[FT:-S
M?F'[5T_N=^OFA0]6O'_4?MO%"_??M 4A;XMV8!%4K#1F\B?B <.^&^?;82_*
MU"VB%=WUGE^OLP$WUOG\XZ.?OVN;OWH.MSBI2B1C!K6#!;P:TD3^K;0:YL<'
M6<"6Q(,8SK&E=D\:]^XK*0=!YVW-U8Q72XKT/]HYAA1@S,*P944^MPEB"]3V
M?*\=C07$T(QO]O[5%-NN)UYIBT7-8E_Z]#=?O#'EMYE]C<*61_S?>:K18]7P
MG6;K.7V_R>'6H;7++&GT@&9\67=\3P?F9Y/POND_K3BJ0.]N!\NPG5/  -%"
MBHM5F'GQ2TRAX:*P?2MF$945\DHXY,.SIL_M]TX\DD,)H(*DQ+1)LQI+C1DE
M-O]UU?:"D BA6WF@5R0_ Z0XU9=M!?PN@0N,F(_O:4@B-(#RX,#0-GX:C\T9
M:,86FF] 6T(B]N2&5(AG9(MYW@$H!AHE_YJV38M)<ID2H\A"2MRY!%3#<M13
M+W,95G$M<GU)&4'?&-V!V02'K%F,A^A4*1;S&/L$&PY[.XZ+::V:0S^"U2)#
M+^T$,WLT51XN2^;G\^=P?XVN=(MXJL/4JF\HQ+BI%TOW+Q3LMZN>8C!=[NM[
M2B1U*U:[@,%T%VN<\L1V^1VU8Z-&:[Y*>SJ G^4H[):G81P.##H=]HNX1>!1
M4W&D_%I B=IC?Q+Q-[!VH ]4=8)$P2"&7F>Q"!![X J(.!Z6<JXB="9,%-@F
MKWI+;]4S,,F<,Z9QL%CCB"I3,>MU>8P_W<I/+^RFOPXFL:RM.><!2H',.;6I
M!ZK7V[)D@KH:\VM?(178E@"44;!H_XIS>M-'HF4*<9/>#J6ATW?;'!91(,#-
M9Y*BYDMK2MB9T'O=]A#VY]6+< _/V.OO9*_W^4ZJ_4H :WV<.4Z)&S[2H[7X
M'Y&'[Q^'1A3P5,F@2*C9=#QK]RRE.\UW6PZ\W=W(+LS0!1J8D8M-'6C@QD_[
ME.*KC+6$D#8'>BKH#X1QL-FHUT9+;8K.RC7/0*1X H6R"LQ[?TE?P^7+0J 2
MQH/5RKR")-B?-ZPJ,WMHFQ9WLS]H!#(OX?3'%IY6>92[Q7\0;?K3\6ZW<OB_
M?LI=!:MC[F1,?*VU0WY:%D;2M"&N2O%C[]TR;+4W)*8^Q]R0^\D7^QG0:U.&
M[6XJ]1(;=' ;^,$*9@HE)K"M8BLW44((6V;&O5<WIG!(N7701;!1]3W/FTOH
M))\K[:"9_8IDYE4C[&6&!?J$"UF[R&1!Y4ZW[-GGAWB=_[Z'<+AYEM+#.]Y"
M6V)[&TJ0W<4B$S^]C6Z@'1)^=;7D]:"%^VK6*U:V0H)O!3_NV%E.SXU1+'JH
M:29ZG?-<'99Q(M!$E1S1VCK""Y'68;:)!-CBWWR= 1*[&8&NZSJ+KU9>'SAG
M6#?FZKUYY$)([NBL$E]?;B"O90^IX;+)R-V(^ANG,CG+N8F:FB*'9-UOWY%F
MW37GAAR?%0M49WMVC1<I?2__TP4/&<]^D#-I>+?<UH$5F2<KM[4B)]IQ7;^#
M/M[Z6EY@)0VM_7ZCMRS'W<;2,;Q*P>V=(M:N,.#TT%#HDA\MLI<Z"UW,Z*A-
MR=75)<HR(NKA$JSDB2.N^U)GO^2*=Q,O,@6G?,5A<([:IJDPCFJ;^8,C(OR"
M-EC0COI"B;(@RXQFQLR;J+3^;Q@&%EL:2371ROK2N$3/1HMQ1.!.K S@)IUT
MQFN=(\-LZN49.<FV( $V2P54H623J_"LKGP;J^#(F)6@8PRY71/,UL+>GK*7
M?6 >=\3EG4]- I^EM8Y<@$1SRFGS\L=BU$9J9%2@D2S77QZXP_:T:4J:H5IK
M9?_39RWP8OJZFDMY(+BSX\7E%;;^)$<4Z.H4#TWB2)C39FO/!N6)Y$7#AC/*
M.BK6?XD\F?>:69CK@[",[G@=5DK\4_YNT=T[I__163FS=?G9;.Q-/M&)Z'ZP
M,=8,!O*HJ=TM=P0WW&N!1]TP$YQ7RJFHC+&1.^UQ[YV^BIQ0\EKA$D_8PL7X
M;YT";=+2%<I"4E83+DI'7/)H/FW[U(4KHZ9!M918$R4VC*'7PY<(:@C8@BT9
M"X&%-=A:Y4!#KV[>_L#" KSA9N/X&-A= K(5T3I_ME^XL3%<JTU%Y4RM'?&P
M'&DT!]_9[9U"21"O#QYQG18RQ1.S%JEG.+TQ.JF^\8:[7UK;=8=7QY40@MJ3
M8P4=+34O5!>4VH W^R7S7S<VU.Z,_>\4[-!3OJ"B<E!@G:6<92D9;M'X2=E6
MTJOD]LMK]99B]PGNUA]DN!ZZA+__=M/9&_Z-<GOZ*D'7"B=E0CYP-0(_I-24
MW3_PH&3\ILOS\^W JK*SL$,2Y#B/;&=)YV\DI(N<A:,31B0I1!N*[2R3%IM(
MUR?C%"=2/AZ65JDH*&<>B]:2]@?K0J5)AY7"#S9OI\JW5NRL6S C2N345QQK
ML/&!#7*T)0+Y!S-TZR=S;0G=BYI-[6W1VSYSQ$68WEJAS]KZ.3!0G??86A^@
M3;J1KL@+;>/!VJ037@C#J>V]0U/:!F0Z_)ANPR7?]IK3YSY)SQZ<@;^BH5-)
MBQ^.N!I,FAG_]>L9.K#<T$/5A:;#:E/ST)?*I@E5H:<0-E.$H0O>T5\W#&O>
M8GIH?!<7@A[L#_SZ\N1_8^N-4]?Q=^.XMP^U*=\,>1,^Q%;-!%)LBZNP2=..
MDVH1!T:Q-QWX"RV:IL?,\D1>:)YZ0'?7S8KC2GE41-N]\&U\1#?KPS?*G>G,
MP:>PX]M_[^L0#(R)( ^SWG3_&%+74JW7:EU2M[55LBC$]O<@=RY96=H_6HGK
MN8^LO3&2?[=CEE_5)F[^CE.WA?VF]( =-U3!5>B#F'XE+CQ<1R,P5X4WQ67S
MXT<E^ON/EKSGR"RX?\*R8U=+G5-,A-OKKP@48("=\:&Z'U/_C4QCDY&>_?AN
M7J,N%(OOQ)TICD;[*]MB_=T=7(381$^L,0%?5Y7C'##7O/??1ET63%3B'DH0
M>,91<S)CGGD74/5M/X[GJGD,)NBBW%#1!%334M&*]E;6Y2W_E[_%G)?/$-P\
M/=0/U72&SL;BY"HC)Y]%"^\]BS;J=_^V"TIVWX3_=#V8JE@]2R*O9S X,."_
MENIN3:,(OF.^-#Q\#_,51^B.JB/%X"2Z1:+_>\ZHB1A3M_7 >',,OM3QRFXB
M!'R_"@CI<L[J]%$?QZE20D\%-4UISOK.]T>5R[ZQ-30X_+"8J1=F^-Q2\L+G
M9>D;DFO%^M7SGA;CL%D],@&G83>E_?N=.%3*=6#V;L/;DF F/K?IJ>VI>,DS
M9O^S_G3J[^<66A7+Z_K]%LZ5G=6>7K/*;S,)V[M..$>]2)\?FP'B<=FQ)4%,
MK 5.3':[_':?YR9C0'#%/SBW<N$7,YQ!M283Q=A" (S)1_^U+46W?VXJ&A&:
M<,2%3TPW?11ZW@?!U<34Z[1/,9%DHGL\C[@$X/9="[SU3->,JCD/U.,AJ?2$
M=XOZBV18'V.J'!K[QRV2,J<)208U6GXQ/\PFGH92"?9=*O;\G#&34Y/$L_"<
M8Y^>>3^-US@-W%S*2&O34:.^JD7*M$5[#Z=7 "#S!,^A&(>$'6-K7GG1D@;=
MBE_]+H?CQ&.V^VE.)CN-XH/-M=_YH:UMMC4'MB/Z:7<_#6%PW0(\!@_N"ANH
MQ86*/Q=\?OH14#+=D6MHTE0+;^SKZB]9GQ(1;VS'0EUU!3P\URFV^#P]$4K<
M]-V6*%WA.BNE3,=;UV7\N%P)LNU9\;^5S CBHVTYW[JXL90G6.T5>WX?[=]U
M.@795UR+)"W$BY3?H,%F:E-.3> U&W[KIVY!53V&R>/9,OZJ.@HNE=J.Z5:=
MY4%"E=8YMS\><>GFFC:@.]U1#T(O<L;R([>5&$=</I-[QR1-$B>JLLT^ T\9
MK%_=Z+,DFA(P]@'SDFW.2*69/M?1#];P(^%?+MF-MX%P<A];LKKS-#?#.[':
M!1('1O"#I;ZM_H.[B&N,VG2VT?L@D !1?AWU!^)TU"):X-M^;QU38&21B"WU
M]5P7U^LB79K-V&J7,0,L ^X'?T18IOPUMN&C0&K6NQ6;/Y=!2>=C$0^3=7Q%
M *W%A2RF+TT Z.JS*MU<X&-<]#:96G)&.R=MB)\?NZ>3_4RW9:KTU(,#JX:6
MF%B?U6MYPI\:EQ4:&*CMFP?*B#O 6#7[*@/58Y] 5 &HBX$$(V^;+E<1UTBD
MTMA2?42&1WU]&_QLX92 -J3: ^*6U5[PMT\/O^ML!%7^JD!:P-;\!TEC/$OT
MCA187CY=+\#(+ )"QJH,1WP:S5&R*P_*41F0__UQ6,? *T][/F"'4J$@I&HG
M#3/P2"^KM+N;<C?=FIUS1=01PQVP2F(+6_8N7&.4L,^E6AZ+2!0CJ_,'J=O8
MIMOD7%:WB2K@7H%P(HVW&0L-QT/\F*3.?;N:XHO,R$3U'(+]!7BX5Y.M0D^D
M>K""QLJ6:3;'Z/"8>*#V4O"U#L,VTB63RPB!IG$.#V?$X]=6G3\SM'M!B8%)
MX\A \X?VO[+_8IY-8I^F\9WW_7;$)4Y(?\"Y5.X+:1I?KU"37Z4Z>GK>-QH@
MC0?T@&9]6;*,4IOW;&]@D%%K>P_L^Q&XM5Y\/0;:^I2.YC.N#X*PH%5&_RM-
M-?_<FL SY',KP[ZN)6L@][N!I@KEYTC2$=>);; W8[#+Y K3ONO54H:X;![H
M'!XZB[NPV6TX<6V]U"GW5P>KS#:6=8LLZ"VQ>4*JKHG[5G?PL#[\NX=5R]OB
MZVX8Q78#C+DSP< '.8X/[+%. QG_>3<'<B 6WD\>QQ=X-3JOG9?$VK^#]F]'
M195+F#N5K:E[D+T(*SK6TE/@-TX<&%B/GD%!V8ZWZ1W80T$@TT!AX%T-9Q8D
M9')Z@RB@2RFN95"[T#PKC*F/PFHJ-,@G_B!^>+AK8X;7J$: 'TQM0NGOIO-2
M+D0H$'!@P;[_B8'I/N(ZM8Z2),HCPIAVV&"&2H_X2 _J G3A"G.ZZQV,A_IZ
MWRV1<# 4\X5SG3%?T\[0HQ-Q9?-6T,A%&]>V<;7'V_*M30?Z3589+!V6BI#+
M$=<M H_DZG9XZ,5S85'0#]F_ \"Y!<F&F9/O_&FUY]?1H<&F?XT>E^6V9UG[
M!&7$AKR-PM?>3+!I_7'^'&OP_7)P\6+_-8008G$J^R'6[L+=M \B=B9#:E**
MU96.[PM_%T*&B7]<2LJRIPS -]Z$/TF/FPUBCU!\-->BFQ1MQ 9U\8[YI4F8
M1*\%>KSHQ JKL)KC@#P/6/9*2S+E?GTQ?0421EX++-9D8K97#@+6D==:IT((
MWK[N#+N:A1,M3+XN6SLU>S?R.VUO/;>)3 J,5/?9T]M.Y+K8/]@;ZSX\_^W8
M!,F@V!UQ+:)[[/DW307!4K1^T\#=>&H=B[ 8I6W3>B*23CT+-^IQ14N:7.D0
MFBHD?]5MH#\-#2Z#%__!V](E+N&9CLLZ% %JZ<>)FLL+GO^KFRC#*,[X" 1P
M^ ^.N 0K^TY1IG*)BJWB]HFA,!NHHOQ$J;?K5JJ1$?:!\K+FKK.C):8/6F$E
M:2M4_B[M?QH?>MJ43WU?B1_G?5ZV^^/2M9,W?_@WY/\S.T.CCV/%G3]-4'4_
M%7[:^_1/*"PBCG'/XRO29C#791YF"DFL& _&NCW-D]T8:,O.R2ZI;#.'^$+[
M_: T:+/<J:6;7Q65X<D8]@OD,/424A[9@ZK'=-8*LB6!MTQHKSBH&R7%&4/7
MC:0@Q8'Z-;>I'8XX<M)$%RC"63%\>T[.NC2\_&']_>9 ?MF86,3O#ZTOMVYO
MK($FUSI"SP%97TCGB%+ S5YI^4EP 'V7#S U([<YT7$/GH9CH9RKB?;/-PV+
MNA=/OYG;L UC+G)="9PX*:*SC!8GGF#S,,^F$:40<*"I<J0,XGM"!TH5_[;O
MOY;D= ,("%[B^;94AV=24[4C;C_^F<'_;= T[T.01_8VZUS-J8\92F8FR5-M
M3N^!F"Y#=)J.L9E^FU'9MVF?RZ2)$MZG@AXZ1:6^7D%_-F[*#)YR39D62_:]
M?G)#XB1V N6676EE@'5,V["J\8AX\E55QS BF^60<\^/F6S5DLWX^9&VX8P[
MKQID;GT!MK254RKGZ%"1U^Y(E!%*RBZC$Y7,XAAP-]EL9==X:T:\$EWA7"AI
M7N'T)\SEIX4P+F9_A^AR^D(.&X/XFXG:(E<BQ]%_V'<62>^:I=)VMU68Q;]8
M:8>Y.QP):+YIW\]I6/JE;E>BZ6&)!E+.([;4$_4'A"@1NNVM8 MEED"G(G/O
M0NIY_IE: &WX=DG+CX+]:=LB/4CAR<<_1R[ 4VWQDWNVOO;O AHF(C:_NM(I
M.PLNM*5<!<=SRY<(+S]=_:_#0TS7DE/SU!'7I[VGU0L>ARF[;IQ_Z\3+A_[Q
M+AE?NOL=.6G\R3?[ANK(!?V9E&'GLBJ+D'ZRH]VE^-G"J&WN9#S&+"0L/EK3
MK4G-0S/A:HY2W^T!DX&G;IF5F:M.0:/94?Z*'CLZ#W"&.@]VRHH,4R*4)U]Q
M@H^X_MY-!M5KI!%U.@X<X- >T_.<,PC%PWS.'_"13M]S)F<!)SOFZ;X> Z30
M G1JB*Z1<IR@A$M:#+U\-]RF=3_-!YKP9QP<%ZC%P>-?O_(TJ5ZW^?286;V^
M=4W_K1:@]J)/@/EK 9[%G:PJSJCI6:0*.QK87)JU%_!&W >:F2(VC:.(&XL:
MB:B&@7F(O?R+#^8!T#+*IH^J2&YT"/KTPH?R]2G->?NP[<-K'H!1I["FO5I>
M?)L>1&W.-A2F5I-<<4/N7\V+/A*)"9/B@67ZZIG"%I>%SZ9%'7&EM%DQ;G8N
MZ#+0"6!7!!\&6.KY%+2?F*#ZDU?/6APWE!%?O=0^^?/6Y]ROA**$MX\9^.D?
M0Z<NYKW6R8HYC?/3[VWDQK1S_OU=&'6,)"YNF-<YEJ[6WU$>7:H/U_N5-8O$
M[Q8*7^+A%AAP<,2D6<F![S@[9R*RO_5F,T8Q6_3MG=%NYZ[>\GES\9_*2C8B
MWE,9/T8.;#G#1'T@ACFX%!IO<@Y.<F'V#-5V'7&E'G&)<&0H *I+ .(CSS#M
MI":[/6L924*<JX8O#!7O]BPH J]0%44J7;K7'QQQ63(J@YJ*/1JZUW[R<,[%
M,@>[4<)(?H#4Y99O_]+^%><BM(7O)5(::*6A$PD@7CBHNQB4UQD=@I-_5[8>
M_0\?:_?TPIP5K2AD5>'Z0M"S^F&@:%7HIW#5@2-RX)C2_:K8*!) 8 P/TB):
MNHLE)XBRE U=/7$+7,UZ4WC@=JE\N9\D&4I))\PYW>L*"-2HF)>LXLZV5/E0
MPAGS;8A%=PSQ+&DDF%P&>$UXX2_WAT?^8@8D5A!2NR+WBYLJ>74IXS.J']+D
M/X1C_S<ZY]D?*O1ON.IV6)*CF59I=$2E8VCQ]?+$LB+<5M!PR#WH@*V'!I^A
M((.1Y5B(<2S-)M9)3#I73L3?:@Y0)@1Y>[?4Q9MXF6>.#<XZ56Y:*_46*G7F
MI^2<T_K]8M(TR#Z-RF<BAR2/4Y#CIL)$56#-G=&T;2^4F-0F40FDVF31;C/*
MTU?6XH.1:NP33(OXTWE=$XSS%^4R7H&?THQ=H:9"=L$/,U5RVBX_].&0C[BD
M$#(,HIH-2^BPS$270[:A4V=N=DCK'E:QS9D7?OA.>RZB4V&VT+\:)MO"2WR\
M L?FX%H]32TZ"ZV'I;18\=F[AG8%#UK8PN:+Z9O[!F2. J>+VO@LE=E TXM#
MRK#UF#\V?$0GVG2840@0E@(IEI46*Z+:$8N7O%]3IKYO6B? RPB<Z<;/[63<
M6A*&(FQ'G&=P_UK4;6!LC,\NRN,61P3A/%V+;-,L-T;A_C.L7U3DXB"<;0S#
M!$67ISV0\KQ+'J=NN8T/_,C+^M<UO#G>UM!..[8PNR!!XJSHP'>'*HO"ZX*%
M*A6%1(Q/-6U;3LQ2* DG#7EPQ34K#8]UL&ZK_/BQ%UYX:^WL0'L.Q(;74;W
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MT*<Y]=1]5SN&)QF6$KU-5L0F_C'6:VZ;6&G4K73!9Y#AESS6'D?F:Q'>9B!
M,NWZTKF94=0E_G7=_%WQA/CR)>?UC#<!CR,+?'-'ZLIEM^85]CL_&>D%=P@$
M?I%/ZW Z'B0ZE@7%J29WL\2?UXB.:MKDFO_J-QK:6+#?< Q8_%E=964,#[,5
M:@OH_@5O5AG/*=<\U$?!J)=2345KMA:DR"R'Y<G=YR&<R\;JWSUET"8'H.-L
M(-Z+6C*''3@ G8/XF+/-F/5T<,\&DF\#CDT(UM%PL@-:^6;)A CL\0V(WVPA
ME9/HWRI^ $IHJN'U5-Q=_[GXT_E$YTGNR0.0N)$72PL= DS'L'26R,NDN=8!
M:>TIK&^F"&:6)()1AZ]39ONNDD2!F)N,KIIEY+-#(Y@9,?PQ.F;?V-K0U,CD
M3@M?,!V^-6Z\%,5')/:7JVUQ"'E#@T&V?4$:>4/Z6<<;G65=[1,4'#($6T_*
M.I<[.)CW''>X^PH$JHVI/XFRWF/J2"R=1D7_NIM.?PZN^QUD2&/*IW(IN1*(
MQ1&HW;K^,SQ;[A7W?.!&3>]R- QS"$YDQU""/%/(0^!8;+?-;K-W3H#E?BPO
MO#K'7M5(5SPMN]2Z5HLGV.%:TY*"87.IARY.XFXE4[330[4<;XT>A6R__=^-
MRB_2<N?<,9QPWT1*<X:^!I&:O&A.?:9,CY(<E"N[8._W^&_19TV7PF\/!H.M
MG,OQ4.7@K=:.H)8_02WSCRW<6^;?0/^\<975LDGSSK*0SW)JSK* ;W4<G@11
M*.]Z4I0K+I6E*(/^/^,8'4G)[%UJ<HR/H;[%B*\)N**5WS9W(),Q.HR@' ^%
MP\YKU47052FN\^*3E;4_NUFN?[,\ GA^+;F\YEJ<^^RT,KOUQ(MUR=,5,X11
MFL%<PTQ(<S&P\6P;9J1;$S!"'>/^@C9-&*-5XJG.ZL'AV%0^XO?HOC]Q.H/>
MB'RRHQ*9,;?@8;KG%G3TSIN2N9(4;%-B#W^LAP+#,Q8=0WL\R;:A_Z7(G/Z>
M9_@ 5[NN=W<@#.FG61H6A(,O#/O@^B(BD4A=7/ASBIEZJ<?U8SZSA]QVJ:-9
M/#BGYT?$NZX6EE2IB-Z)6(V5+XIRWT8]+CG2?/W4_TD<2O,N'3GQH" =$^'D
M@8GVF&"$IL(_.6=$:YXR=) [X40Q&5&U78E>4+%Y%/(GRE><H&#LHA1I0\Y#
MC_172.;JG%)N_>O#N#I0TJ243EK.*\"G&JL$&.L"D4Q;.C6S5UD;)@F843=U
M#\M@+%&];J<#?(QM$4M]4OMXPY=&="7?72N^V,$8:;H[E&TE=TLP#%IE_%]0
MH1; ZA-95 'F&#]W?]&X,SKURE">U-6DBT"S7I)1!!&MP71*;KZ*H,[*3?Y>
M2A86+E9@('M37YP-,-9CY#;-1FL6AK+4%Z]5-[.VXQQXXWDN59_1^@[B_GF,
M4=W2XB@>CI1*+R+FV$)_64CA.G6__X+.9?DYYQX;ECOK<9.W04Z^8 'Z.<WQ
M(EXAF=R?*?_2-:U<%!SP-;=M17FH:5IY,FW#@?#Q74$YC]N/DA_*X[8KX0WG
MZRKJAW+P*NTVJ9%?TQ0V5=H;"<JV<>*828HU=AC2.Y8D([S%N89VG?)C#FS)
M'3[E">X)[,/TJV3(48S FN.B.H0[ C:7OOU[ZO7/\,(8189Q*8-NQ[BZ8=B:
MBK:K6DCW'NMMZ#NO'5I6PZG"=BNRC]%C^/\I&.@K2?TO7(N.3($(&3UA<M$]
M/%,,BRO7J$2!6\RE9.TE/E1DSZ)TE[GW>).EANK)/,K]U+&I>UINPW*$#))-
MUPC>,FIWG"\G?_=[$&=*]ND/:O*'Q[%CO*N]&2[N99IGLT0)'W16%W4!$F.6
MVH5G_+G)Q";_WA*X"^!II<N9((JY?#;G/%C@'6Z$,?&P8-% UF6DN?9GMHKY
M0-Z0Z^,CHYD_JJHM?HW:7P+\I[H:[H9/[><\W-_$ODY_:!>:4TU;",C!\X2%
MY^52"#;303?/$9S.Z2_!_L;HJW3TQ1@)!@SE">M",X1N"@E9]#E@N8'"WBZ=
M3\9R@;HR#0F--%*RM"SR[!5@\GW7)9;O]OLBU?7 ]SKO.->FSGJB_.R?GGYC
M4HG"N$-%VAR2E^/0L<.'#3_VF;'HZ_\2#SGOL=*;QJ(5D',[3[CI XE="FBS
MB4.(,E'_K89,T-WV+0^ YZUIA&_I+[Z@35;\U'C0F>NHLZ3T 7+OX<,FULD"
M/MV)T2%^70MI"66OUKBQ*\$%IN8V@B-RZ F#$PL9GM\,:HZ\RFE4NR5W\V/:
M#3.MKO$VT;2<H-J.'.IK)[GC]E5S7I36:Z=^]=LZ33B[F8J'^S25)N:$2/^6
MQ"F6#JMV-H8XKF!K%4L49=.^0U4VE%2GU&XVWSZ<?3W.,3UN#2FAG8BV&U?^
M:J9CA# S!?6]$%[V.<9'R#$O0(7*3WE#WG4'SODNPT01$+&N2VA'IG%RW9K'
M92"9*="_E_><KR6_?./G8-4!J$>#&CFC5.+(NB^2KW?G_.*)O<;=XS-H,:;K
M;M-^'OL&0^U]P6I"..2IS.OCGKP0?[4U]@D"<'[X-G-GM(T*-&$3HNF>",K#
MZ-94[2!+Z,Q.S/\NZM%&%^TB=VL7I9;:I=6 0D8^]4\J1A+EU[O7'U^&:J0M
MME6A8J@K-13\O)$E<:W]84%=J8]O&/(89X_/6"58_I=O^IT <@A$XR$PT,\Y
M!;CZX0.,92/&M]@VM"(ELFX6@F(U_26_2XYY_ #D.SFSICWOXFL7<NF49FEH
MV4E[-3>8.&@:IZ*L&M*)\^5!+D;6I&?(G/LG]%W]L*-!T3K5-DT([A*NW"_H
MKV"TT3>]2V2E8&80'<TP;M7/#]UR[-!U]OA\XSL.7_X&T%<<1HG(A0.008D,
MYR+[-D.)+3ACY3W;CY7H4EFP9-93G1*;^./V+C*7GK)MEF5.!K2'/VX?1JF9
M)_1O4!/[D+&M;RPU:VA;G@[%DZZ3#S+\L^S#TV36!JV=C)X-\5^[(2<S60^O
M# I?0SINSL]95E'P.?G&#IWY,^-6OT1[^ZQZ;8;TSC_-=0\UUY?W/ !!5K4)
M8+]$W"VLK^H;.PJ#,#055/,X*^?+BL&0;6'ZWXO'7QZ HI** G\2)G'<)]A3
M$VX+LH5N#39Q%R44%%^NJ)B7I:BF0-0/0,LUTA>!^%=H*<"^ %//Y"?+'-?!
M9A2?F, &P(39<JFVV33N1,PI]VO+TZN3ON->;V?"M\[\<G17)?=%=V4C%4LK
M_2-%KKQ_):+S]\@R+$$/*P[QYY^#.$]N']896 8S CD%068*DUFJP'Q??A<X
MX2]&1JFGK5GF_&#58D +,X!"(N]?Z6^0NM)C+,=4#W'W<.F<";G#E)S=X66Z
MTB(/<3K.F'N:'<'4@[_YU'D1KY-;M+/ MGJ4_27@S\R>8U%E]X-D^?S9@J+]
MA7>YN)=:@PJ]DV7'+V09X( -AC69EI'.$.$(>/*M+0F#.X^%,<$PX)&[Q@X+
M#)ISZ_,)HUU--Y [A4/\ZWXG;_Z'^-+E!.?Q&5TY0YGVZG738+L,!>^+?A+]
M1".C0!/K=2<4U#G@;:UZ61F#49]!<"H6$DAV6L)]F$R3%L>=ZLK(A4XK#]DT
M$W=2/@^)/O2\6E"_>4E0)<:@^Q?'[ #4;84^4D5F/<#TEH@;&7C1_W9= 'RZ
M(4UCB1B!A>]Z<'87GXQ('4>B<#N!HI=2&]Z4;96LLQ"BT))B=:_/I\H"R9?S
MDRH$^XKL&9/ 3$4/D)%)O]PXG[!"1L?"ZC%CNY3$+<@3:OT9M!>060=XTEBH
MF7ZU$:<^Q_:%]'*T<=?_= G4I?/^!Z S?,.N*&NSZ8<^O$B)UIUAQ@&(OOW^
M )0FO&A$ L*8(MV<:Y-=0JB, Q#9PW :?8U V1#WC&=;EL-Q'%SEPKKC-TN3
MKDF-^RYUG#'M$M]!IPC?>\91G_Y+Y6UX\(YV> 64P.&'$PC?6!)AFUBI_K(>
M#U\Z">2M!YG*G/OB]OE[?L'T0D*L<8F/=..NR]>&0I?.5I;)_T0,?DIJV7L-
MBYB"BZ8< FP3W]6&Y)8GP?)V<PU_6CN(-P7&2,I/QB$LYQU<2(]#W;KZ/L5;
MM&YCW]@6:>,4W\V-Q\,63$<F=M_^[^W@C,?P7SJ#KXC4&^2Y>YG9FMF$S9@I
M%@;X60$H>H^'(',QG0Y+EM8!O&K^^V?B[&P!%WXYR-5YDMCI G[ZC:EJAE^P
MH,U'9L*F5O,M63[=S]W]XMARK)MLS\,W=-@GGNT,8\&^%Y"ZL9_K^).QO$W(
MTQY :O=N+-VQY%!>9_/^6^P(?A'XL$N6*>N"V/.M*#@]/GRB_\4% 7B'F]SL
M[UO+L'F[71/FG[Y]L]U0!KBOY,3Z >A\$V\1_"/*NF>1)F6\8<M@^7E.&EVK
ML?#B3]09<;J>F[G[+B&QRL-];;OSR^UX>;6=<EYG^WQAIMRY<^"5LA;Z4PGA
M]T$?/]L/#E[P43IF83'T$G=*7_43T8[/40\J5&/&DW=9LB6NYF:+^.74E)6F
M4AF_$5%[0M:;ZISF<-^3CCAP\GA<S: 7?B1*U18'#PB(S"E\B=-T4GW$@6"N
ML!% /E]7(U. +M,'IOB])S4?@-C@[3F_VX!?&0#CG'^B1GU8<I1M;71N]^U*
M8],_*.VU+L6\[5YNFF1[)Q-(&';]^9">(#]4,G4  M1$,L)A_&S[_5BT&A-,
MB^R#)4*.H:.8EC3A%\P0CJ G$ OKG&VJD3GR[ELV'JA<[6$.U\,!*YT+C0&1
ME("HW6JAV$J:V?PB^-#*L9R/BSK QQ+Q3H<R5*$=4VHVI0DBN8 RW1C R$'X
M=K 2*/@)*]X^O450WG[35:(/U-Z"%M'JZJ,=\F4L4/Z#?%UL?_[2&U+O 2AE
MB9M]HV[=T#/-^");&TBF(X^CCM+-LVVF+S &,G^@M2\R'\?7#>#-=$O\(O>?
M-GM<"Y=7_=AUZ\FKE&1*[>NZ3YF*.M[5=U-"*ZHFXP."+Z4$4JQQ\*;UF>P5
MO.J6?8Z/+D%<18?GN=N6ND;TI?H(\3=$%Z]5B9:">*-KZCIP5/B7==-$(^]O
M.>LRH\%/F<?Z#*L8"8DL!S9LOYJM=<B6?YO:]\LS-YN92A:9 ]&>F>PH;.G&
M8PM&#R2Y?2;V'@?\$E&@%@!CY 2V,&[0HKR:@LS-,:;T'7#*4A,GDP:;(].X
M^S/%,)^DP4"1WW)]W"J9=+R3),4V /(UGX;0YSNNR?1S3K1]:F*1CJ /N[U4
M(\D]] %(J%.%CMK2#.^U^)^1QL7Z3</#;O+'0I!\T^0/8M#7=-L9<XUOK:UY
M7\ Y-<?D!@3S@%NB)XDB)QXO.RG1QL31^@S< 2AV("UB^_2:>'Y*YPV1>/89
MRL?=YU_6.?(=*0BY\=\J#QRC=,2HK?_[*_Q#:D*1.[X/80U]634X9/N(8#I9
M-57ME'._I)7XXZ?] $T Y>(M*,<=MQM.N+O[>[^3AF&KF53=L"Z*Z2]XA+^A
M/\A2565/,<*QB^Y*-L,;JA$!#O8*FSYLPA=48-\?3TGT,>8&31XKN<E1J.\I
M 921L1C1=34_FNL357YA9\^1*H"_Y\^>=)$WQ?;+"%Y[ E%"L7F2#R^>,R+X
MA5]_LO$>3MI**]8#E%A7G#<@HM]>[Q,Z3S"4=E^U,E>VZLH#*]F7)C&BP&4%
M8))18CMC]#\B6B>"#A.> R(VPU7BSH^<*:VJL-F\S,-)YBBR+0$L([\G?U$/
MB"=0OB\*CX/#W^I8>;CZ1"#+AXE+KH@\IWS.[=!KN4WYD:_-=#93GO=FO5#P
M$GT@'<L[[V9RHJ_CEKIM;SU26T%,6LS>*.AT\K\^$605T\_+SRZ?K,+]N%FD
MKS=H<K.H;$DS)]=_D3WB@&IW=B,7_ZEB-,1EXUV%Q./-Q@Q&YHNKP[YEN8U4
M5B$8>*AH%.W2D*XU6'!%3,66_!:K 6%8\TMQIA<5]AN,91: /P,>LJW,'RV8
M*_5;3HP_MIDTCT91\<<-43*Q(AZ3G;=\@I:QB1/?D_(N 8Y(GH4[!3MQ:6+W
MSXQX3LVX1?N\]#.N?=+P7GHI_I90;HZ(P,(M1)#0]&AW6)C@.86^@3S=@=6/
M5?*%WFS"MRM!DJ=YFIUB)DJMJO"F+\M6I 1?XL2,[;>5)S/!;6+08..)^LZI
MK-OET=/5>/GJH<LV)/)0=? $U!:]K@G5^I:N:E'3UY(8>8\?O[:]LZ_V:Y;#
M4Z27)KL?"_%W9'BUNUNQ]<JZ,3,Q?3VH *P0@)$1-LSY:MHEF6VO)X]^-CD&
M_IE0_ZF]GRF2^!LI]-UP-IYM@I]?;^=.:JK9%W&9U/QD$83%K3]^,[?D\N4B
M:]S-U4H>.?IHX+BDHQ !BE,QU3#P. ^UJK*8K#&MQMO.8D;Q#;L.ZH6[$0$N
M5^?6H!ZC1(-6-5.K5I'M/JC.A94S*8\<KN%T%W*AX=L+6"W#F4:6+CMXO_S!
M?D&G1-F:# @C 5C2/<E+TJCZP[G,SW:/9-[:+0!^E0(PT[>,H%8R2="L? %1
M? 9PPEF<R42$T*ITS*E3QB,A^+6&.8I5Z$\4Z2GFH@OZ*B-S$TE]<HSJE&:W
M6[K_+T<=,RFMNU^JG0I+;)_.:"[72](T<J]8$S'\D]S_0HJ4I+V=)+Z=U*EG
MG'5Q*N)<C:NI'XKN>MUIKX,!)L.XT(;_[985HCX1YWW"W;UGE9=(!;:O5"VZ
M(*)#3]8&89O 1AN#CC,7&FY.0$<;RC3IK3JS17K6E\<,7K^YLG R?JI_YIC&
MAW]B0<4P,+KG_)$D<]?A"X+]:K@YJ%MV5:F>DH%BJ:-M>G2S_W3E1!9YQ):H
MKDZ8"$Y[-/7Z-Z&?230<YZ(/?5%I/5G5<]XZ/,<W,9UGJMK4<9>14[KS/VO\
MMJ,B#IZ5KUK.@QU&;O'Z,AJ7K0N72^;\G!F[J<L'H(P22:R?U"V..&2W'4AE
MK/9Y&$T8"3%8-+.D[1U/4<#GO:'C"US 8\/MOFN>+M/(B5$EEGRTP[NB/%R5
ME7Z*:/X6) G;".Y!'L=,+C$LQI*PO)V\54"V'2,CF\#6:@7:0KQJ/0/+J8]3
M&2%$HZO\R<'?CO)I:IC$P>1;'5NR!U$;P0.J<I[S+**>=9?J;(NPT\/8D\'$
M>R^K?MNI&G-/U":5V8C7^M><Y3UK?U?.0>)Z&N@HB*3,^[0UXZ7] L'VI3UB
M*,]0OWDS7]Y!]=%'Y4\]=BD3Z:JB:'05>4X>S]IKME_W]MVL# E+HZH8F%:>
M005D( OL:ER6JYUZ1^$Q\-R:9;I#=;X]K<H6-WA:VQW6MPVHX3/"MWF!DEW1
MPTXQPUB>;0.$,0('/)NX&E^Q[[4!-C'$S^M[2PFR#&-<9%#%QB3P6*7YK9'B
MWK,;BFU1E?VSNH_IHS??CF!N G3:=J\$*5$8PJ?$Y-^Z^(0AU8EE6060WH![
MER0W( )&>GXT[#&4IV53YOMVIZ3M3@U<B30PVTO!)B_^X@@));2'L]P#S9\&
M(PLP1S@-71?09X% YJV^DM-&070D?V4C#1S;SL'3D*"%X; 0R6C3^EJ$@']T
M.GE>+@GL2+_S-NM+7Z1D0]WRNM#4N35D)>*-2=#Q@B?9Y ?,03]>ROMQ>.?U
MI&+*Y?@+J*>]06=OQL9?..)LFFJ_86H7X!#HK?3CJLG-,G*UCD1D=J^7N]@8
MK_+;GE2"X_ETYQET81@E?&6HHA3Z\LG^%-7P1]DS>(SZ[8#^XHM64 <YGF#-
MEP0E,%V/&M<%,?3KY<\@5J$Q[_8KC;4X'Y8:(K9FFJO7/#2?HV'8,K1C*GGI
M/-U0:BNNP#>!6$Z9GR?7(G[=S-_5G?CB>5SB:UY[##89TC)%$N/(KN_E9Z)]
MJ&,4Z?G>I:8')<QCW7![&4$=HBF=*IR_O.#./N$52%5Z[9GH(?ZI5LY*S9Z!
M36N*:8N06'!/KSGE^_Q?K+>:GS\.2IE7N=[-TWU66:I5WTV9(M7UX-B1PNSL
M$6WG.=X72).BJL[BB\=GO1<OAJGS#I'EJ4:SR3!9W=!_?HKHC#NT9V5;V*7B
MDG&BMY8K&H2TII%00^6-3()U=:2#BHFI\9!MJ(W9'VL-#K._67QDC%:SV569
M$P@=&<O3-PQ.:PI?'?I:;<H#_LNU7V8,0M].W$7-H$]4H3)W*X!D*NF_' !>
M<#I6/"AB =NW]ZVT!AW$2$SOE(I"5KE6V#05\"?1QNMU_(/9&C@SY"Z+UQ=\
M_^=[]XYTIP%*?APV,#/.,#^>'<*<I'/'@L$0OWI>E"75+1MMQHA,,Q)AD)T8
M&G4EM ?CV@MF5F\9W'W8N'SHG^B2S!VPP* 734K<7%.#XN!?SKTW\--+CDOY
MPV>?_D.#,N4)9\4]<OI!3W.Z0LL\ 83U[0G74[?\8*:O9WYKP,B167,RK]>U
MON^]JVV)CL?EE3^4ZVQP3454I#57-+SY\:7BTG$':'[.BG6Z?+&L<[Q)!6'4
M>$P"*@HOWLQ_G7[:MJ<?*CV1RQ^XN;]V*^NB]50I%&?1]L1#-&H&/D4REL;=
MN:-.5X!'5.U[V]BE&S;[6-C_N?>7!($L9^<;?CT -;0FS#ID(;0[8$DD,74T
MGSPNI?4?#6-%H%+FU/Z_K:[')QWU-Z$/Y *>1]VO5/M=DX%7XMZ(S1OX)8,+
M[3K.T(O'B*.NDC%'&*;I0:]0ECV&)L7QU'WI0>C\VEY0FAI?Y[FO>:&"(EDN
M8A5YCE'WO7\X[_Q/9I:Y5A)0D)<SGX97QEGSV''DIPVUE0DCE?M_6?R(:Y[O
M;*$_9VQM4J%.-JF'N&QP$0/%S+R+7AP5:?Q:6:,:,A[S&J[@*_@>M//CB:'/
MTP%K+BU 6NTGI!=S9IRC@.VVZU)&B=!&4[F3T-Q$3G>T]?/E!0&'*QIY>)]:
MM/54$$?>U5D;>;HGZI,_(^ RW%*2-OW*1?+B49+;(\@8E7.T<ZE7YI01-PV;
M9,P%X&O\:Y0RC:5< UN,A9E\G;_@BW!$EWQ+QJS+Q(\[9U*?5"Y47((^_!'W
M[T#8Z4BMZH^\DD7& ?^&MJIF*+Z<V<X_%UN?\"T%LY&C8*LY\29' :YG;?$.
MK,!3#<ZSM7<3;V^JHKW^G%,(QRF8]&\X#]KE%E@K_=)9ECF"@!R%/#@ ?;[5
MVZ4(^-2A(G?#]XM(R/J,V47C3U@J__2.U)7WQGQ3$1"1->D33&L\-:ZQ<RJX
M4PNWKG=V^$S-KL3VF]2J^IP&W^@UT@,DGQO[_C0;04TR/H^:M-TO1$.8F;O_
MVW\;?@!*'"#G+TI SFE+(>HZKS'"NKMDQIM/;GHW2JN_$S]DG=\+\L2:8QI%
M9+,C+^"DJE-$C> +63,TRF(,(J=B9O*6Y&MHFH5OEHAC^G2R0JS*\>*PVXYY
MK\]ZM3X[+Y=QUCM93E;9OM;&5U!&54'!)_.';%;UJY";<2_]QHRCVL\4&0RI
M6MBC'K87U,//=P:.YBFIER:7X7U/#H6[KMS-(@Q:U#FK/MK[6/.VQS8U32'E
MXX:AMB^OH5:QC&XOM5H_X MB-L5N%?:W93]G&7!@3N[N3FQWB0(01V;^)HN&
M_#SO ?C28 E[LSWN9E0K_&8\3I& MX#TR)Q=_Y>"*&$4 K']\#>+Y*J!F+ G
M56M+WC'#@?6-;B+8=P>@Y7\A9]2-SV,^<JX"3TH!V6WJGX1./=8=-+J141]?
MIST\HBG!?^8 U(-XM.>ZQO#D;[+"N]V^T]+JBW/-\9&%LE_OWVUM>-,4];6Y
ML;DEAG!G%HP\?K>YM_?>R%73E <Y&:>SA$.OC"G6JE:?5JU.RXX_8FHQJ \*
MA<GO*!$#8X(^9I-A_/*KJNF$;Q%A)E%C2P1QA\ 9G,5T6#55S[!9R:'%2S78
ML;-+TD25 =5*\U[SW0 _CK.-4W \A[>MJ2@_$Q"2=E'4'?(53/848<.J4+,T
M? I&"NVVCS="L!X#81P>%?H2%]H8",A"U3L 89$,/2@3K04D]N3M:34;<Y50
M%_#/^G$ZHPW8Q^!-H^LMCYF"^H[,0I(X0*?[I1M%+F]!'/9?>?8<@)J<WL/F
M12R AF4-3SA02@0H,#' @W<+]AXCS9SN6WSA1Y4Y"I1]H5B))+"O+F\EQY3_
M+VBE8'GX%]9SZ13F!/H2<!$/)-X!D-0J[:M(08#>1SH7D34Q'!,20AN3]$R'
M]5+B(O6"U!F*Y:CCQ,#3R4'21P?$JXZ^,[VF9YU@H9#0,Z3RX$6=;]Y5Y_,N
MP6)0G=XL5>ZH.0L[-:U_ZX=<)1W/E@_?%'PP-?%^WQ%1,VE7['KKA$O/Y3]%
MJKF$_= 0@H%UI>HYX@B,8O]TVK9>)SKWU4N#AA*76-B?#*U^F(#IE2RW:GM"
M<R)NDU9N';=J49UL:L9DTCQ%,)\\S@(0JL:Q72P)* ]B79MCG]M/:@(GMX\E
M:Z!#\ NH,.K61_$5?"^PU"L,#T31K>?JR$$X5/NV94:0D\FDJ&A9RGGICNVY
M7]T0*8PQ:LP,0#"Y:4L#Z4Z[$>,<,<QDEPK@?@#B^>4"/*<2S_R4XMHV/P#%
M*9F6#%!^"WNH,XFM"3M.[>V,8$*UJ*:.\A2E,]+Q]6ODAMZF(\9R?C]K_D.N
MN,J]G[(_[Z?_:C>0G6L8?Q.IIF*7_7P0?R,P*%#RT;QK-_*TUM^[Y-,6@G=[
M#4T$_:N?]U\ROLW3>4:_+N5GQ&K*RY=M#3IJ#K:AH8^*_#)?1B#"U'7<[@=0
M'Y:KAE6L*.E!(L55;-)%3;5"<-:"Q&'?8>ZGUC:-Z,9Z&-=WFD1HVIK#2IK7
MT!=2I@R_?[&>^RV:63]8 FVZCS,6Q7Q:$H8LO_3DN>"9,F,LRFQ-J8-[G@8X
MK-O,L$64*ZS5O*R]Y9/&0V^F[.>_\-T2_.+"1G0XV$#A'7B9.[/3I[:;I>U/
M42RAJT0L'<%VF[&%7J&-F>^V4]@N=/!1U!)U.YDCO!X)$<JG"G?0"S4@_0<@
M1OR<2[\B,R.32!RIS*TS:'VV4F8RO^^E@ZLY"U_D4LT4STL^Y?QUX(5X%OY<
M%]=O4<?^DSK?X"7=G@F4L5[(4;;-E)$>$I+:)8XPEITPX@OI,O]] #IS@]9]
M-/"/(29;0K%$&%=U(TBJ-I]SH\W21UYY_4W7>KP'O*$PSDUPS?*Y_RN"#W,N
M+LH["ZCV43*MD%V;)/  *;D"^8W/1L._5(UF9=L^JA>ZYHJ9Y[8\GE,T&1*G
M8O=2L@W'7W,7SY5O-.90EJ)VQ>Z#L?&\503C*EVJF=@TFR\B<QH=<URX9?Q:
M7]_'-X"GK?D6-4''KP!1E*=/<WCP_$/:4?/ZKV5+Y -0RP/<,G9NN =[I//:
MDTKV7<:#1M85O>Y, .YQ=GKRO?2QV>"N\ZA>5*(M*4--^6MK@<&<1G?'O_,N
M&U?@O"3-2W</0 \JCI[4O_#LI)P<=YU9R+IJ!Z_Y;A[K<E#X===AVS>7>OU/
M]4M^/>[9&18O.0,5)AC\LH@Q2;2Z4=5!7;<GG%)16U]P$MR*$+/6BJP:2FMS
M:/,!+]#66.O,%M5T5=MO[O8.:G,=%I2]&Y[ )$!B!NXFS-1R)-9:I56 :<9\
M]Q[_>SXKME85^\X41I6"6N>?]X$RI[<R>UFQ2L^TA^.8^.2'.L>;\[NEA:=G
M(+SKQD(=:9\3TSYLS*"VK?9+XTE;"KA <9'>4SNPY&(% *?7._B;=#1 N$5:
M=U9FUX[1<ZNVY>5,F&B!54P,W+5/\7-S1,SY"0L!4TC]"Z)VV]>$JX6!IU92
M/%O>9Y.1ZL]'_V<3==ZPP2+[(F;B'\.OFIR _GG'J+,:'=!R='+2W.S'XUP1
M*^\?U1Z1^\9S_8-H68405(A@[,R*<+P23O>'U[95*]_<ZE>%?:X.0#_OH;[9
M.^\&Z$]7?9_>%1(R7WC;<S;U979!2)&!W4O\??Q5N]V,T$R=.]9*4NZ(E%SE
M Y"RYUDC.>;JK@^C^,4R?]SBI?^B7ZG6P.1NV'ZVD1?+;./L I#:Q]%D(..#
MFX'_-Z,("/XC_/,+"MFK0B7SU764 1A(,Z( 5A09Z/^F5[PA&!U)$]TA.O44
MBP/YK#O#!Z#CB9 F6%PX,9"V>P!*$D#M?71#7^UX-VND@4.]B0$#SEL,15B2
M);Z/B,J0"-/(_9KE3-9O40_<FSU*\9)]>CQ%SW6H?#@"!!Y!7@ QCOPM"^F/
M<O,FI%H)::\V"5.\UWC2)2A)04Y6YQ*NTOUU4^\6_D'>+(Q<??2%+T@UJP@Z
MK30,0<")#RK;<DJ=1.S.6<<_<6HNC8\W'^ JWURQ;G?P,QS']%%/*MOAH$;C
M*SAHYK6KIG=SC10DK]TQX5421Z7=68.B7D"OQ'V?RA6UPRF(CW,LV6#Z 4AD
M_0U@9K9?9:S F>J2WO^G;!KB_P'BFYGDV(!:A3+_9 2'O]@J \*X>]_9W7J-
M%'*'SR'&"/4]N-FMY=3>>JF&J=;8A/UC^YEC R7'L=UGO3L L3)@%))AZ->#
M3-[+)-> A;]?1GB>#8X0,[*A619![$B?P/1GMYGA>W>R AX_SNZM7'74K7G]
MXCJD_<H<(G2^&Q$1Z*509B1+H:""%A=\D_@;DRZ&_\PS?_9-1N.669-H#SVU
MU,:T[WK-]YKFJ-_S3W<&Z"[VJ<4R0HFKA)&D<M/8>@,E.*:GDRF])"!?MN&-
M5RWNKUC^/K#.3!/2<=S!5?BQV-<B>8*UU<;.5IG TZ*HXAX]<:[Y;\@*_(AA
M<*"2AQUA;% !*M,/[D/R(9;$.3QL7\"7(=(OTYS8#_ZG8&"SC<'JAS3=P5PM
MI!TOJ,MGW;W!5",?LVH9_]$\+Q%D.]\/3V_<R*27<']_/E+JXC)'@37;Z@]R
M2!C1[XZ+8D#(,H3?A7<\L.R0(:(=7D_YY7W;O_=Z(HA8[CJ?3(K1F*B]=^>G
MUP)9\HS]X]?.SI3:FB!?1'#K^:9?M<*,GL918$F[1]M&O>ZZAES"XPOG+8X2
M0=S7N8.YD=#%4-MT\WY5'J+_;$'J'_ORTW<N6JO.[NI'HS*]XM,*B]1UQ,/=
M\'YR_-Y?UH;L0G?M_4S/P <)0W'5#H7S\S2E6_/>>-%^G<"1*9MG;D3_LI38
M1_]M_^'M'1JC+CP1UGU>:#8U;G/$+_3A"D]UK,)<)D_U*26>(XJD=!0:PK(>
M84"ZNXX"053^L[?J$>+(S>%Z-/@3.F)YX2'JV*'V"BKM'X+])"JQ-V]WQA*M
M$<[2:YR*^#QSW6NR5Z"]3[+LUGZ9).A)0M0H1.!+-,O!S]5\NL &*?[*JB_.
MO$JL0=KE6>[P2T7SX>S6@J0;-SN(43%3W^U6XHH,P#YIN+0TJJU>CJI*MVH8
M?*+0X>)VU>++ U#X&IR/1&Q:%;+EWW#F^<R%MYJSYM%Q6Y7 .:K:XW]8-+/#
MV2[ "];=X3*V%L.IS_,<&L8H+J+^8JX/[!8S1=*:,Y,I7(4A+-\UIT_#R_-C
M)P(/#2^<53B?F>B$D4'IU,<9\E7XD",;XB;KOP96Y$@/FV(I 7PQO?"QU*"N
M"QN+VD!B-5M@DJ,(%/.#UMOAZ)OCWOO_8T><'R0B_NB&6@ABL+OA\+QO&2$$
M;1MKG^(P*:SKK&.[^P=S<%!M\/$)^<$34[H__TZZ_C.H.G"YY>\]D- C7E.N
MT%<A]U(=_RT]J]UWNT-++/_>W^.%4:&O5F[197K.H*IJK!S(,^6:]ANFM0K*
M-TQ/.9)C>%($MQ6LS\&R!$LUS;V\S/@4%* Z[K;5WT>O9%ZQ292WK_PRW7".
M> J*RS?**1\;4R; SJZXZP_9/N.8J;-/L>Y@AI>.=9TT8^D?OH*FB)E6INON
M:>:95F8D;$IA%FT20IVO/X,J)".?5 -*Y#^?), GV3<88[$[D+/=U'0)6,9B
MS(<@ND-+'HWOXY8=C3M9>\XHK)3S$2N(#=@^=P#JUJ^<QOI-LFX>6IL<<Y'(
MY.UNW9M>H;#-6H"PND *&J/M*@6=9!EPU%J>!VECQ(L#ZS>9HA)F.STE?H]]
M81<&3YX<ZN#MD;KU\-ZE\00W*?R1?.[CX@2^RN=(1$A04!#^AK=X2,3Q2_,F
M@>]^!M]FE)V,M&A+XWC_>-+[UF DW+YF2\VAEBZ,ASLXJ!;O*UG,.GC%UF.C
MZWBR@N\F:BOM9$#KFM;ZQDN,O'-%;5.S G(-;6MX;Y;5B'N,5FJF9Z<;13B6
MR_C3E57/'&(M%%J+S1X1&2B^D-U7?(XQEL)1X$R>Q78KR>V7&5] +)X!ZM6+
M(2W,O/(HWV57B3%N(,R#^5 7PGA-HD)=@<WU0.J3T!\+,G93%Y]-K/N W#C/
ML-WJ0>RP5]CN:R1_]UM4D\Q>J5M]>A"Q U# 0LSRRFH?\3S+E#F6"G\"WT,>
MV8C>R:A!!D6$Z=9K/PY"1$;P%$$7@BKS%9UT6)@90X/7EBH:VI.XW!3]VD5>
M'WR.>L)QR\>>C6<]O9(=M#J\;#JXZBM"^DM];J=?%[6_6\UUZ5)-O.BQ8U)O
MA=)*QVZ^X[8MRW6[3'[BI=UPOMG9<1=(_LGY)6#5;5.NK'H7GY"N#Q52[9ZM
MVBQRN^8G_K@\V1EW<_85T9JH9)HF85TD7EU.\"QP4+([NVX!?:E(L.-<B?BP
M4Y+J>0SMOBR3**VW3S161.%IX,VGS$R; ]"S9P!L()#^]AYCNW=+V\6*^C;\
M[<Y5Y: F?HG6U,/9J)TN1^[B0]0VPTZ:'<\V_6[IM./$D@>48$ $ZQ(;Q+ N
MDF[D*TG$G$,=@Z7P8;Y]^^72JD(MTK4(:E;YD1LLOKX8I1!/?^% .RE+J33B
M?R7[NN'I#_EGHS-B8$F+2'E'1O\?VQ,4^;:(ZY-O/7.,</.2?D+^H,.#&W3D
M'^Y7QW"(2-94SKV:H;35DYKPD%U^D<TUVPPF^6Z&ICTC!Z\RFF[LWYXK.0^U
M_X*'6ENQA#RTPM"_JC9J58L")L<M!1RH.353:1?%Z^>:3\9<M3B47KZC_[\$
M^?_3X%_UV=V6$0PB!<%DK*@-M%(:[S:(,Q3"5C,6<DV<R8S;ZM(_QGRF8>3*
M]1(A(3W(=I3]BVT\&9AU\2NZE*%FMX_OU& %4%#;M-E,HY!7;%L&;$ F Z.P
M_TI[&,R#AL]L-9/F!DPF=YZ8W9YH=M'$'8#BK?B?!1E!N%Y$+:>.\=V,*-FZ
M>\\A*_+?S$4PQ6XW:__?0ZA] &"KV \Z\I9HLPGH8W2(F+]A2V990'17*54F
MX5N@ADR?> LII'(E_%!*EY:L_/S$/>2???M[HS4UNBEV,TD'<@H@09\IO)W4
M48,(H:*E3+3_5B0'1X#/K,]TT[,"17P[ M4*8THT_@RL?#--^M=:S=!H:FV\
M2$]L*+O?+NYK&R'&9;IW.KW-@]27H_6\:;]6>4C5GA(:[YBC:AH>8)8GA"$Z
M!O-GU>#%1=$ZY@3MW]"< "\E5(SX#F(JI"#-QXF>2>'YSODO,68LB>W'$.A=
MU)S0- ID_!B@)?8484W%\Q.-+$.BR@81M'=<4W"AV+O-^<Y!EQ"1P@)E3<\7
M!T]7W?(FG3;F]3Q4M>O&8#3TTP_-W]L9Q2+-^\0@G<QY60D9 5UBY?>E$Q%C
ML<7"TT82U*6G3D3-S^'FZ! Z[Q.Y7EO_RP]C;=(__KH8UXRU+S!$15JTI)(+
M!!#"PI031<W5WPL>YOU;F?F@X0B"U_D]>?-NE"7KW_%>')>=;#/M;6L1SEGS
MXHO2,,F-TP0UDXM'6J#G_C>@.''2B7SOV1%!Z%D'K<LXU=<XC\OVI:,OO_=-
M]MHY7+11,ZR&G7!Q</28!^.'_6=Z36W$=*QS'A"&[%=&%)?_/OA291^^*L'Z
MM.+<'GQF9'+ @<3X/B33A^_1B-PM8I0\PRBCQFPZ@+]TL) 9RPB5#=L_!!<4
M#YDN'4M;,*-)$^EJ5[5H3\+Z.& 10^M$6B9/U.S/UX"-GWQ!?JQ/L8:QSD>P
M2Y<HHV0KA$Z$N0"^++6 ]A^I==__RP.4$>>,%FLQ5Y]R5->Q)[ND$-';W<0'
M8WW%<HR%@5Z?$)H%L2YB.D:LV?TF[:H:\KP;[F]SAM#G)4IN,R<W8K?<-PKO
MEA0L/K-#K-.H/+M@*B1-^=Z[Z=-^W0%^JD&V"E2U[%"("%)*OM^8M>C,]?WY
M5H&!K+2K4+AC4JZ$%/1-;/R]&V)$.9VH&(*2B9T-#F5Z+M2A?+-+2=Q^O>ZA
M]OUYO#4N0(M@Z."IO#T\7%%BM*1SOQJ*_A1>L8$X83B!5^*9L,ELRO$?M:<;
M:I%H=YG]1*]#LO %J#7?#2/[8?$D ;0 PXZVF$V_P3SF,+U$*\YE^I%W*412
MZLX\Y'Q L,*4Q-W9\W0'1EW#_0W\L%]$9:I"AGX+_X>Y^B[M )E3Q&9^0'%K
M>TN?XE'*4@#$6;M#4QR5DJ0_60M V0\664\$/A!/HBI&3H.--=S]^6C)G29*
M_\@\Y$@KSZ0T_L\*ZTDZVR6#ND7#/S.R8:P.M&NT)J'%Z->D?UUG:B8^ON\:
MY&1!2AUL;RPJ0ZW,J=^O$8QX&*[33#T \7_G"']JPO+YZ]JL[6D^Q2'V-+-]
MSOE(5;[ N9"]O +BYU[D+4XLB@IV7!&\?DH'7. 0XE#Q"I?D'&,7%^7?"N-+
M+G?,=4:J2T%SZ39>%Y;;$'=C:SAC5F]XY\C\UIJVZ6(T^16#-OMF. !OJL0C
M8X2L!97XB59Z(XZUTU=G:P3^R@(:#"2MM<]3B UFM":R+9C\CH!,'3J0.9//
M6'4?1QLPG<PG.+P;AJOOW]D.VS)EXCNMF+H6Z) S)4HITD/??L:T9O1,PEDF
M[V(OH9T:4'ZV^ZV'!B0  SIHUR#TR 3CBV@PT,VZAAEHA\5MR\YHU+*MJM#*
MLSNFP MF"]V*9]P393= ^=BNG]T;6IJP:IJ O.RI;(PER-].O]F?DG(EWH2G
M7$D)!.*"*1TCJH!6Y>JY=V0^/'=2>ES0;M&#4*JNX0%<JH<>DYKWFB5->2XC
M*'D*UM"(1U-*YQ8F=A]G-/3>:/TXB4\J3XDCA+;ZPN:GR=X4*PR+3^&,N7>@
MR0'(\.#0YM;05Y4&^!,MZ]<.0"WJA^-1)FT2,^O$D>]@1I"Z:]S--YR&$3)I
M%Y@7D"<]U][O/P/'(Y9M),A>S=_\;@*<Y'XSZ^B= ]#3)X9,]MIQ_]K1JI2Q
M]$U!KB?EO&^?YE'TQ92./87]M\WR5]G69#E7CKMR:#/_XZ+YQ YH<==0COVU
M(?0D8BAHI.U4_T[ 5,?^9EMS9/&.U.JU:Q4'H*CAD6'^T"+]GZQ2$T%;97;S
MH;&_4OCY_0#T1FCE*P),WN"?-ULNFNT]^<-:>_)A:W0UX,3R35(MN,Z,_1X8
M*?^J3T#4;65:;;E^[A>5>ROYL!6R8LO0^2D"NR&,W)6!/D@\5IK(T4 _^L0.
M15N6N:,\[S*%*C#<#-^BVH)P,_-/X>[GU)NVKO3 9(<-VDA3;B^."7&>8631
M!@S//NRI@*X3P%,J"WP><'41[C\ 04F.EP8U<K^([#J=:[]LR3==M$5\MT#L
MU<SJ-M+ZD,:3LD$,\FIJ:6V.T\L-.GWW]OTP^6(W93FKGP::6TU'1ZU=DKU#
MK;W3W!6_;H&7:.O*I/C)_F5_JFKW&FHP1K!>)"!'057G?&S6"]V5,R;^A+OE
M%LT1RF-\&:BA*U97+3RL*%!&/4_$JR]E;=BB$B[V9:9,-RS1LQ7[GO^IS"DD
M1Z1^2X 5U,?HH#;C$XW4PLI1D>8,4H;152K]D.V3=+%^2:X#9:ZH:)FSA>D^
MT=V*!'7_K*C$8X-=&JB';*[]<J,(ZM(<_-=N&\-ORTRI;_OIH@P#VY.ZQ'6K
MFC,*$306  )-/K&OU*S_NRY,4>C/EGG*_^S5K.)4,^]^](#[)_:M(/'Y^:MN
M/V2F5!S4:^V%W;;D[]>A]'^/H2,JM/K=S&WN_"-TQFQ4\%]HPKK@OZ= _YB+
M29YV, X()0]JKYCJ^T,?HW_AXGJHCZ80[JU"4!ORM'-*:!IAICRM'OKI$7GT
MA0/+?"8]*]W!YF?KB!"\&9JKZO08:DO8GLPU4#&U7Z>N.7PKT7&&_27MYQUJ
M%G8W9;_.6 3^!1#QW"_NDL*,0LYVJ7MP1@Y C2U%C)A^N&(-$?ASM]"N@5G?
MCTWQ/-_,IZ']04-G[4>$93TORH/"'L B(\Z45WVQ4DXYI\06#.Q=.IG)%E2#
M,A*WQ.HXXW9H%<_/-7WB?Q+0*@Q/&R9UG :\1$=&!N(V]NKRE\7L[DI?2M#)
MD#GAL:B&H.T[7BWZH#O[.W+%I .;5W@ ZA*Z%3Z@S@63C%CKBYIEJX(3$VF%
M[ !C\4:(@#PC%'6$;7N'%(0\95+=TBJ=8??QIU'<M%C==&>]MKGY4NM*[8IE
ML;Z^9]8ASW^>SG$-(SB)/.WU*I8MN?+.<*@9JD-7,3"-)7M-GS35#]!2@>6A
MVI/#H!T]J@&P97SB +7!.NUK[BK4GN"$LY''):%>6M8K,G7@',,N+=3P+L%0
MY-D\#9/(,D7%[.8"-HS9W?"93BE:82/3K!>^FLS6@Z1RY@F>* DRYH2YD4@E
MJIC<G1[DRTPY /778[&155'#0@7_S.W)=)><Z0*C-8&GS%3S_;Q.%69)SP%(
MU,B.Y8R. N()%H1;M$&T6CT%1=I]DNT ^-"XW\VD%6CTQ2\E/\@E&B7<;IT5
MYK7$N<C9R\R4IER^)6@[A+OU+V_\P^"[ ]]X/DLD/'ITY:5MO$T:Z-+1S'N&
M_*\&!W (&\/G=6VX4TY[/470T)6"] AN^0+HEQW_\5XG&YOX@'6B"4]H59N@
M1.RKK5/]L:7*$P3I@-!<(7>S KV9LPFR1-53K8;V#JK!$7)6OPY @AY'&+-;
M%C3^>.,KDT923&YZ3J2Q/*-U<[\4\XG"_;3),QT.2_8&RK%,[,U6)C9IE6F6
M\0V[.2;#I[%3 Q,86';NCP<G?GCK)6EQJKX:HX?YF"?- ZSYO=I8Y %8]9PQ
M&1 )>0#Z!Z,-1#<$RISMM$<K^-(S$YUL4/4NG\ S/S8<IHRNZ:5A!A0K[A>O
M#YB1"NPN)BRZ")-J3-(%'O?>7NPK#(C_T@MR><WE_,^10V,YS81>ESM^U/#>
M/Z;7M)S&MB<(HOUGBGP]/G7ZC(A156WQ)VKPEKQ&UYQB+=J\.*__^BI9&=Q?
M_J(V&5:8'G"E["4N2L$V0S8>FO7&)A?Z>^.&=X&-PP(X6FL531JH2XRI!FX-
MR#1[I-/PP#@SD-RE!DBQG/A39,ZAH_A[L<<#L?P>RC_JC4Y4HI&,S)2"52HI
M>46\!M&NU[,529WN(\[!W@RJ\[6-8*U)#1- ,\07-C>"CEDM$:WOQB8>ZS7=
MU*/\%R =][L>LG7SIN?6C<2]Z]YN5M^"%=X$SAC+H2\Q]/I*>!<!,(WK*8(&
MX5UWBG;_AB]W?W%^S"[;E-0Z]1O8GA!)6YB_%1.(O.)Z!RYV&IHEIVC_Q^:6
MH-; ::T*F]NIDC9E\1GZXX_+9$^KEM4/58- ]X[\HWH1-6Y?8-4O"K7)1WEY
M)3>]M+6P&A;8W(XZK)2^J9?K>@'5[W"^3B91M.HAP_D2@1W_)E)[GM14<XZ/
M;8 V5=3,1;DLQ?>$H,WU_YLA#6&N6V$@SR B)61/B@SCWWHR1*(E>3_GC6ZE
MCA?UW>VU 2OGQ )DUXPLZT*2V&G6472OTT\KIM+RTL!V_-)IR'V6ISAJC'ZG
MY#1'%O,13DKO]*&-);62Q-GNM#GLPVO63V;"UG67SGQS1]YF"B=6%"JS!<K6
M;?JH$7G"*=\47U3*L;2+_8G4/%K4>=%[Z2L%"#%;_;)TRT&Y#B^;<_:-5\Y6
M"V8]XL-$HO(Y/$4L <#G[J??6V$TA\_B?5_[FGDA)U&9+N-L2(4)C8OQKB0-
M[5*-@$=LY<>SY:HWON^*ZR7IO C2 ']-Q\4EF15<LI\D*(BU&F;RH0@Z2M8E
MLXC0_A'M%2<1GJEO+Y\4JYU*("@I#^0@ABYU6$W&A? -UD=85SQJM W"1Y[T
M4CIU@Q #U7]Y6]"^\@5@<&UL8.D(9WR)!^U$3P_<30!6F9T'H)["%A(C@5C!
MMCQ4ELPSB,QE@\V=3 & &SZ!ZP!L#DLZ4X(OAJ:7:(3@ZWHG3$"&)ZP%HU\9
MT7>Q3/X^F!#[(B!6S^F%+VW=H'G.ISI,<" 6S%^])6>W.X.PRU9^[\^YH[IX
M$<%(M*5\,5=;P?S=3&CL,MU? >G=F>Z='7TT<,]UEH3<GCLJD\[ C!BV]CHK
M,F?:JIU10G6EGR)JZH\II7;:513!+!@GMGLE8D08S26I$0M2,S\&;N3;6Q8F
M^29?4@A/6D-YTL&;A:S+*#"MGAS$;3]I+(G6W<]D7_2J99OE+G?">-'&XQ'?
MD6S+P'N46J)6^Y1\@FO-S*07HNYYW:OTNX-&(45*^NT1 58_)U^&1""F,MM$
M374:A$(N6=5YUIAX$SK=[K=M]$#SC91A_$,YOJHY:ST\#@(]/>%%2U>*I3-D
M>'6.+VWC#,_O%:9^+=4WQ:MOW&S,_^5>_1GUQXWANYO*$E_@S%$\$R(RG_VW
M(HJ<%[%AVA^ SFVA[8*82S; "VI@9!>C>38ETMT5?8-U!85#V\0L_S_LO5=4
M4UT8+1H+2!&B5*D1Z2!@H2A@4)%NB'0( K\B-8:(M "!*+U'04%I$4((/4J5
M+EU!I(.$FJ B/5'!_4,(E_\\G''/...>M_MV'M9^6WOLO;[YS6_.L=>W]K8+
M)X1_/V_NNJW6!JYVH0,OA)5EBFZ(,9)O,O]K"3X2^45:&N@[M(]+G9.[<Y0>
M=&([;XM%.9!,:RO"AM/:I=;R1=MQ"=E>3X/V(]2V@E0/0"?G+5!%&,KZKSGG
M(@$AR+!GXQZ2/9 O- 8]MJK[MX=PTGLT<FR*?:8:D"J<ZQ_&9-'5IE)0;=,%
MGXA ^(!X[;.[5#R4OA/NN%$I"$%F*\C QQO ?N\N-GK?4HR[+.38ORV30E"_
MP+_.?.*[&A"^T3?=8$_2S4HM$!O-TTWO,E8?B=47ML\[J9G;5BG6F>=@A=;,
M-L_+*<D[\R6ED7*UEW+)L12F.E&>6$SB 1)*6@R7\Z FGNW);HD(PH;=$H2;
M)9/3)V)P!LK'DJ\'N*N\#_5*:D.".E0+V.LN9];<9M;-7@"Z;HYC3ZEI[;7"
M[XRV5V^V01RQ=@FWVJ14D9&2B8AV"N[).PP=$M7.<P[(*'5!2D/QM+\Q8[WB
MI/VHE:S=^ 0'HVIQTG=V;@6]?Y?^TT+M>]7.A;N:S]/-GUT36FTZ/69<0<U\
M$9@0G]V4XXJ0TI4WOOAOU)]/.P^X]IZU9Q]M^RYWZOION"@V'+!:) C@.H4K
M@>9#(Q!#=8O?_=O#I]?1%(HR[*9.1>E?L@J*0-X:K7RY/"'[]%O:E8*Z!:VN
MC^4\.G)7[9+(]I?, J:"9F?^4L2#?"U>/YZ;R)5"O)3G=^R/%;=*E8>#Q=)+
M&\=)>@WK/_>$SZP(D:QS99%.*OX9)*[2WUJ(BJ)5W5>)MW;$55\QMI+_& CZ
M2$M-:NX1CT<JCU1J;4AWV1@6KPGZ_,T<<2$.%,V%A@P/G+1YTQA+^ZVVH*QD
MSTED:J1A96A\X.Y\.:9BPI]412-&9&(HW4!P87;^P[N?V5*Q+0TA8?EODK;D
M6XOL&18R+X<Y;?_)>76_&&6SO)._7+.\_,-':4][PD1A+CT:GM?@/?W[2O;-
M;4E;P9R<J)3[.2_RC%\(F+DTUK\0^87C>3XQ<A<=UR:#T>B%BC/:DUD:=!>(
M,^-O:FTY"MFI&YNZ7]-#A^G^FM!0(X\>^X@/_S'3]%% 7KV@'5-VXQ@OS:#G
M '0,Z\L@ ET?$+G9<2]15<@VL?'[C?7I W=&L3=HK>81JHB1;0NQ#_E?=OHW
MYV*>FQ[QSA?+4E81F!LGBV2_T!@ZO*@9>(YGU, LAY%!BD*C/U)'T_U3QN[6
M!*=4Y3Z8O3MJN1,2XR&/DG17R/GN$Q9Q6)>^H'OX,&WBS&/4(GQ@DT+)Y, I
M]-4J:.\/^62OH1\B<F?=<H*U?W$:/ ,+8,_N%V#Y&+P[MYBX;@TAK%<K$,K$
MV0(S=# UPQ8@E[(>,#DFVKMS7.".M8!: 3),HZN1R$3'Z<L6^2@K,RKK\Y^O
M!/@RI@?+0TE$Q;US<D<R/FQ-X6TVGES.GYWJ%9_:V-N3]U8C.P,Y]*'X6A]]
M$V8J^QA&N\\>K;[7MR!XMCT9UC32(D@&:__N#J[73:XCS5=Z^%%1%3MC%0U*
M]R3>I@JK3*605#(<PWSS9GY8"%Y1\>4F*[K6JZ><(_KH&TG*WIU-.[:3^R([
MB['2M.UE-?W88C5YX8>_KW1GIGB=YW?,GOBK? ]ICRL'(*WLSLAAZ5.3[9X4
M$=8MILF&%+./7I7%V*/E0OD K_*?!B)0R37$ERQ(&MHRAPZ.F;_(V)O#^&D(
M0\"??'R8)VX!C=Y^6E+2H\K%F0JOJ3D,O1Y77>9+?.SVUO2 XS[IT'T#2B\.
M0'647N?P.9/>L*S4;7C,,Y9LS80^7+KA#29]9\<)*D&(VST)F0Y&G!?Y.OX/
M4Y-?YIZ82OM$5K<;57#Q;Q=8'!/PH0W*M"30]@.ZH6),MY0WC>/9$K!#N&=%
M;]S/Z8;*3FV7OY:I&:[-"<K7LVMISKZRW(BK*5#GASX&C/9,(CL,3AR 'I3C
MJ6!:0S<A?O[$_HMS$_IHNC?[++S,@@PXW!FOTK]1>A=3N&?>.#[MIW55"Q:L
MMZ)VK\;,S>H%_FV7RB7/[YI+]H]S8N4WR!OWK&Z2E!UZ?C7;U166#>IJE9E?
MRC]'+(\CK=,4N:;.?Q?WCU7J?_R28WU.1\5.]J0\IO=/1LL+67G[U"O]%XAG
M#$];]?M;9_WN.%3-O+IHCC[P^H+B1@YZSZAA?8^Y"9YA;_7"F*";^BY:Z5T%
M+MZIE9LC</R&_J/?D+AJS!%[)9;Z.\W^X2?(KVV76;S,ADX^'?J))_HZ2SAJ
MR <#;GV70_S: <E+0P(6HMWXI%WU2J95D&<#LPRS.M]U!RVRL@M)W*AWQEK
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MY^Q4=2^-_N,6_)+I8FS>@]>C!GGIFIZV$@F\Z?H'H(YVL381UO5Z9L16-"N
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MIVW]^]Q+[_M.9.]DI#D_+:R$H+[8M=KNFH_<"0&<'76UO+@/0 *$/6F!2O'
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MHNVJD7/>^T_WW.5]7S 89)X@8=W %:(7/'-SW/]TN35LSPV)B'Y39IT.7'W
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M<&Z)XFWVE/%J>%;Q3N!X K=00UC;2_+LRD[(;C[!(Z3<<J?)I7+N>VO=%U*
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MU&<P\3VNPED]392=Y=B6&>_U>\/+[W-ZQ+\7O_.AS9ETMIU.4W9U\>IN\DI
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M%K0MH?,7X<7.BMW-CG_R3IB-_LGP/<MHI<2C"K,=K=V#2GSFD3"%?[6GA@]
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M(7-!B9[*M,"V]:C:]ZU-"IU#C<1GB^E?EF& FQ!K5D/6JU6YMP'7'T53)*;
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M3MA/ZU<2^%*SLT8GIA*N%TB-N9L[QX+MY/ ,M-UCZ)P[H"Y"9*&//9D.@;T
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M5FW,].(U4OE;N>@5,1F_"6,$?3_3W%M#/JW& MVWPWLX4>1-X-?W(I_6QD8
MFUG+L3>VL@6FH@R78>60O]]*MPO594_S]WA'_?>K=A-)J'0&NDHV5-6H;,#W
MK6/4#*5Z.WB)5TH2+?K&70?RFA1O'2T\P>!/C8\^.4<GQ%HZ_MX7_37=RSXK
M^:JL?2..]\%>1D]7$<- :[E9-L::[ YV92%2'-$N<J3^M"LY,"VYC.0NN%[L
MV-@[]K+?N?I G*[%,DP_T",^:8EI._<J:W]C_8@ %_^YJ$DX.W)=U/7G>9*7
M[(&H/<FBBZ&/.+_HGZYRBZ>NIFRA\35#V/T*LWN@L[844U:.RBYXXET[[!%Y
M<&"HUV/\Z=TW\ )2O%*Y5(<F7 %#_0&-4W^-(2H&'!L2\31E\<:^\B2C#E.\
M88SJH *93=7[ZCC#0K*Q>A#Q:%-3?QD]V#,FU_=EWA?QZW66CQ&5(=8::0FG
MO+=R *\7RBUF_(7ELQ[@I3)%%M,<87H,]??"9Y:\F7.IR9MX)10M_L.#Z;WU
M>/^[O_/S#E_^^OEEILW(#SN-_A-E^(ZDQ..@7:J-*(P'S-Z<@Z?EX<6!O;PF
MGPU3&-M6T/??<\)/6PBS,[C)CH]AFZ+?'/EU1@__B+$6*V/&^2TUH,.O;&#%
M@W0!MCZ<OV(,:3!I6I!:04,?9@Y'JIV\+'CK<5-7<.<[Y>5]@9USYZ.96P[7
MOC88_M1 DE$< B30=^4-B J8*<\ #&&;>Q?>K*Q_CIC3,M?(DL^NA?+YYDU\
M*;SHZE32N<[B7;$-?:B<<&'=Y) YN[9P;^>S@*3:M?<>VQ]"D#]0V]U4)J41
M$N,>9T0V=5-#$E(F%'C[R(D=4/0< _X:>9-SC.E3XU7M4>&-I3U-\CC=ZAU_
M-OE+P4O.[LY=/Z]J91M-2==APXTA%P6LV!1*KL*IG(CKI_?[%Z]I?8D;]>G"
M&G-PS,9Z.2]#LD\40^V+PQKA!=8-#6D?W==P'+><,'3.1'UCW9(VT+*YSI1W
M@<(TYQ'[99B>6E0,A_1,9K-5VM6337DBKA%T+ZYTVAQSSV2T<V!GN/-"7ENI
M=U)%ZH/.SH:\^>RLZ+VY )IBU@+Z\Y=APX<Q^GAR)-#4]1:1H;88P$8@C:9=
M_;-0C@0/L"@_>>ZURB-1[J:7="=Y7[?\5V5/VY/&1TJ[IA.*7:#^B@4JDZ(I
MLBJ.?LN4"L.^F*U1(<M(3^";(\3O6C\P#"?5^^I%1+)[!73':](A1'J66\?C
MO3S15149;YR7[5CFX7L\!"Z@ M[=P[RN?<(X^2+6D'#<&WFTCTWP'71TSK$/
MR'+O1>5H27!M]I[]-5\NY'T>">(4?_]R!?=T_H]-F3DI+EUYO ;DS$\%PHJ\
M DAB_V4%6X:E5,M$M,]M(M5AV4Y9+R=8WOHN/*B7?&$_\U*>R[Z(A3NTBL#(
MA,;\<ITOT=G?-U7<<'SZ:HX^W"IW$3)&KHW%SQQ^2I)_/POLA:YK_+ ^+>M&
MZ0@U-,I_&6:FMCQ6%:F)'CDE44-7;7@?%ACI&^ZTN(YX_B>X*SE><_+>(:MI
M.Y51Z]C'8C@@3,$),+\T:#0[/$NUOX6;F_ADHB6O;FP99CY1]9A@M7%HY'1O
M] QQ1JM0[P4.W_9R<%O!J.TBSO#-101P>G9X?C&T2]2H)]?U\D&05B)A).')
MV_->+UW>PE.? )<QUK2S+_OMAIP9^@SXB)#@V)GSJ:U-<.]G-Z'=3_4(.E--
M$?$,*+;0*HW1%(']1P'A3&H-:9^L.].9Z2<*>%X/.3!>^'[TD^P$;3J\&4".
M6'7)>Z^<A-R;Q;(!]^[+6,'Z=2D/J3HFHYJ2[<"06]%@GE!H90X5+9Z,HK*S
MIH>*4=R>_R#WT&I2K8+_*\'/_-7+AH&X?A(:+8%E\>^VC8SHEATC7&V&+25"
MU8N[219R5CMO+=ET ,4R)<4?!?2D-^<0:Z?5B$''L?\]1J(Z8%K*=^$1VNHY
M[-;[^R(-.'?D[YZTV-XZ-BK,@OAJG=>+6+(GH\MJ.\2 IZNMR>=  FE7*(@7
M!#[C*Q#PC^0#G.3?@'#5MN^3UQNOFZ\W/UVETQ;!=,!UW_\\T?SO1_+/_ZW$
M&Z(<4 7V<0W(ORP5J<Q E^ [T19GETI03&+[0HU:J[@/OU*,B^)MX*"JI^:I
MX0[%UN#Z)]+S0-4R[%1;O<=MTLK;*X"W"M$,03&;L0S;@-D2S)<GZ<I8&=P=
MD/:K0&$'TTO6_B+8CI^P#.M0#JJ"Y0>]< 4V [*7/>AKA(-_N3ST,K"H,5QI
M:7X3,T17_IDL1,#&(>M%=ZC['-142<@7)0Q5RQL?3A2TU3XKF"9P$:U @Y+B
M^_Z!78I-9KNS%WL4'7WQ13?'RR;\'7G/XB;5>B"?O@5BR/'I5G9@OF!TG_ Z
MUV&('*P);::3.M1GTUYCDZI-3R?-EXJ*F*FY(WQ95=D=R4"[WNA S?S]MSM_
M8253G-L5(RQ+=7^>> "QT7:I>AP:EOVU=->)<Q"1D<OW0ZQ7Y/+ILM8<4X*9
ME:&Y\0'0@:=_NF5]WXF50;?+MX:85)/AT+Q6F7;F7#!!3LLBCBB(,U0%7C\B
MH?OV&*<7??@9B=H^=%VRJM W<Z.B^+M'L:PV&KUC5<TEU'#%S2__'L+^>DZM
MD[]X@*$=0G+W<?W$S3'+KN$DC5ED4;_H$#%6!+_\II9L._Y\7T2?Y[/(/I]*
MB58#J!L%L#F?4=8Z6WI ,Y51J)(D0O4K=FJG.R_#-MG.I['7JCS6M]@++_WO
MD_6R1S..SFY,J^"50\*0ON&TNI63T/WQZ'>MAZ:303N5,VOFVE/R#G"HI'R8
MQ/*&2F73C!6D2]CD1LUEWL[NX>@!:5,'M2R]%%H9K.[PJW%%46Z;9F-PWGF$
MLA=Q$5:O"X9SKB_#-I.#%P,@H5IG7AX&-F:8J)N2GDR**N38F[7L2G:.UZDL
MN65*PE4IY':J_@4(N\'94>V2\36VO"GS]R;JQ5O6^5M6S70G,UYHT[BFE'Y-
MO658I)?W6<EGA;P[50-=;D> 3W_O/59!"O4$+A5$LRT@N:/2>5#E<[VQ?RK>
M_+)I[UN](LYI9M/*QN;%+5(212H/5:V > I6<K_JQ! *;_1:MFC1JN&XU5!B
M%V5'6V-A9_&^WMB,+\7?1OP'9'<^3[F9\,R/$(R67HIW7#KS\X ,2>>QD>WP
MM.(U )4_LTJ>GSG+4#"_EI00HF4'_>9?4=R@"S6DM\?J./W.7C[Z. FI^E1=
MKW-UVQ$O/<RWST->).;%@6,#=QD."3Y9O"C&2$)'OQR9%EMX,/$,PQL:L:+7
MJ,+ZR5MZ2'"^E?:@ SN1I3<I,:[C])VN0=E[']>S]P#O3YD&IEPO)@0%ACQH
M.?084<78C WKUB:3^] N,D0&%P46:<#%\8_>:,[AL=2!'R-)1D)1PFH /REJ
MZ7A7\99*?&8[UQ!_?S3"/R%IX+'S,<'13"!<<TBD"@Z,-E;% 8N^0YR=M5&8
MU4,<8U%+9:_*,[PR2#(RU3,1R'U6T/CW?,Z-Q\LP0I![]-*CQ(K7J.<G/M^P
M=.$)%IHZ?<0^ BIB&1:>-4LOJ.7)!) 7Z.$-8K,Y>V2(-5%#RS#=,"@Z#*#_
M.HCRR2I@Y#S-W'E6'!R#*R1^P8DBY,UWW$Y\N7_\Y )1V=.CZ1_O*<2+U50M
M&6>(8Z'XR;6-RD_@EE22A!UJB[[8=_ZO#*@=*/EHC \<55[>DO;@AFM4B,5S
MGL'A*Y7;K"NWWSS@<XL!G.S> .V3C8[?5#N3!MG$M1%]'/7Z'K+%LZCKIL56
M]Q?Y]R!J9\OG"OE!RDYVT>EQP5NBR=3YX!.QLQN>Z0:C.(\/S=%S\!I_3N/I
MJ]>/DK& %>_9Q,)]NK%WR93Y5V9\U:29J>27P=B<<X*%I._G'5SNX:;N3>KC
M/DP%7LMZ9W_C9>-W_,:?VL)EF#'V,A+&RJ;H'8[7:%*F^?RM$GRJ4KUAB&+I
M%?^$M#CV-1]X9\>%OE>26M:,)LJ#O03/E.,G;L_O/5%Z>K?S"^<& @:[U$*D
M(* TZ1$1.EHV<O :G_L+=$/&6D\*E7%,76FWF.2# -$31-+(%TJFFG0<%=.&
MI ?$V$+?5BEA*_;W0_,&MP]AZJ"MFKZ7 +.W9RB;2<ERETQJHWJ+"F.>EU'1
M+9O6W>2\ OC$KA"A70 E -&]N0-Q),Z>1)M<'%0>&B[7?5UV=S3HQ,K="W?Z
ME5&05PEYU2 O["5;+Z3_E61W/SKT:;I3'$3+M$WN+"@NK27XE$G>;<SS9!)1
M!SXU[8S>*^YX_C3SGZ=-_V#LH+>+QTE$91CD43E!E!-8\"E'0,/+HIDUUY[4
M-H/6WL!0750H=$]A(4W;6=&)*F:51.EGF=[X_64FZL&L^;!R/13^ZI%&&S2\
MCV>[I')14/])D)I9V(&M%PGTK&5=R7++;=+V$$,P10]TF,18@8TEUZY%;R.%
M=EGM! K*R^(N]CJ\<#=_T6EL=/DQO&4&^\?,?GX@Y",G<0^H0HB;58@>-E4'
MP@E>3&',%N/F;Z.(7]JOR8*C_B'%!H1\L%,>^SLRT:2-^SC=5NN_AD?X0(#>
M@4@W9>C,^:PFB13^V6RJ^;35%M'</)15@BI^4!UA_XRP#S]9@*#)FQM:&KW-
MW)_OCKRNG!\2(:*: KA]&T\=4D&]JC-Q,F(&M2$^1^T&$>2?QF>,9 Q]4KX
MK_7#9UT@1 _HLY"%5:3-,/@%^)M_O""IK*MK]G)+ENJLGCV94IRA__O(\]L
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M20V%/K*9:,/.H** FF*62UB1U;"'6]KT]B7KY#\_'^.LY05V$20^0DW@S&"
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M^&E>9J-"[(/0LF/NI8\5/,3?YS[X&!NK;XS93$6)\ZRW"?O1L&&&3:USD7
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M.CMQE6X0N=-<WBW08F]'3Q NI'%Y],["B]AH<CMG/+?#6DV(A&;>H'?7D:\
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M\H_!\E0)N'T-^1IZ4$0X C!3B-K/(20W#[)=F^AH4P'@20Q]U'I3[/+HS\X
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M-EWH2V5*U1+%(/85L"T%)'Z8MDL4:N#S8K8[(Y3^K(S^@J\QS?=X_/UUW8!
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MU][,C:?J/=N.F!%LP0H*XD3WV_YO6N:_HO!5_'_?$%N?_S]02P,$%     @
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MU5AU6O6DU5M1>OQU5[3):&1B;IEZP:C%L*KL6S.^QK"^_TWYU)41TDBH6R[
MO^I$=KJ\BG8"\J194?*U*],@K/ROA<!VWBVF(><T>%S(,].N+FW,#]U<6SO(
M=8+M *-*%M7O],]4)YGG_(#: 9COQ9% 9N<BRF#.+TY4Y99KT&D9:+L1<@U=
M40L.7EN8'>*!1-)-II5V'8GJ!]= +MX#N'4\S QN2S5%V!$DG_+(%X3X ;[\
MWYUI-A',U=3(*K^*J !P2F)*,XQ@&HT*M.9<SI ;R8C"YM_;->QLQ*+'1.DL
MQ'J;']'Y/SI6KRW8>,GGX;\FUSSJ;4X_D'5V8YB#X]K-TMTZ!WW6_O$;ZN 9
MM("0*=;OP&38[H*+@<QX/S8:UNTH^@%*KPDO/EW-8H=&%EGUD]U:?4:]^F\K
M9Y]/]9P[=W78XZ)I3L[(G;--AH[/F>E:["*JW8^V##[(V5A"=1%]0]M&D8SQ
MFT]3C?JT/WR8NG.::@FZ"VP2#K4.<3Q9U"/0&5-\\9-3T07>A<),JAUU(9F=
M@;>+''9_:&L"4<4EHUV+J"+>"IR+*H;>[H4SC);;7 "V1FKUAS-NU9.-HYBF
M5)U*RC)^.\:8NA%81.FJ3T!GD(1JUP9-OHR4&'_&ZU##X>MRQLT@WZRY'!Z:
M:4LQ$.:_G.;NAL(F;CFSAMOP9?#<(DIOQP +,FH"ORHONL#W@,/Y%3V@A/A2
M%-R1>*V031$"@:ENZT%&5Q Z8RZZ"\K/I&(QG?]6HZ6C_L>BB2MAWY 6N$0V
MYF,3'M17VOBH!K],VTVRPKNI+PP3(C Y"XNH7*<9CJ,<G;J0,:."](&>E&T<
M:]6^R052!\%8,K7P=V,5*.XYW$_UE/H; !,9M U4+]A7/M%7A7-X#H_RN28@
M(3N>APXAVJ3QM;?4:S1WN(9J$[K1E(?1HQ?P/8&M!7CI ;B(V@^1<M7[7E"8
M1_O5CL6C$6+:(]:GQ$O%UQW2J4X.RL!TW!965'Z166^]8V$R;OO3L>B[49:-
MT;_0"N[NS[(]'6*7[1II?]=G^9VG2]Y]GOGQ^=9;?_ZY]\@*>YV]MB0I_19I
M)==Z:GRCB&HI+;3S'J8&R]$6\->@(7WQG,$PY,MPJ&F!"I7Y5YY_D!R431/-
MHJSB&RM>1'!M8[!>K<.&[VJ<"^(]IZ=;F%Y##?X$K_XYF_  3OU _=M-7=-'
M![&SGQ5Q*FM/Q\VVP,>I+PL+T4F.GA'K<_\JF/H,&$38!3R\7I)[6@AD*)R0
MG'7"&V68+''&3(MJ%74')%*;WU/^GO.V/E^&G1E7-DF,\+:2\Q_M.? H]/GB
M:S@)_.I;V]QXU^ET_^SIUH&P+(5;=/*FTW9W.9X'%U&W FAB$G@D-Q1MBQ1Q
M."'RVFLXT.TOC\:,1=12B>9._!A=MHB:F2[ULOE3M-,JO*LG<S@P@.L!CSX+
MVN?Z2Y1%U;/VDC(U&G^OZDWY']M0^K7:3@Q(ZAG1UZZT5/F3:-V8.M^.67%"
M)\T5G&-G-1#6P;Q .%DZBDW'Z_3AG.*="Q.JX?PNC\#.W&MC<57$4Q8%V(SP
M@9B&9:*&/3]U.>%WG[U>O5[3S;Z[B+I$?$]4[M?<GL-F+K!F7H-HV6R[ 2/'
M%-ZMCK6\$7>J/M@IB(""+Z-7P@']CFM.B2>509<?F7]M*&>NKG=O?E?V(EHT
M&?]B2IPV)QR^CSKJ;?Y_8)SDMM8-;&.[.?E,C0N) XK+6#+[\L>\\>%W[_H=
MBJ:F/@(!!YXT-=UR+X@L#<O;W%?X?NM=E--1TDKJCTA^LK5_:E&<FCI;^R'J
M.?U,K2DE6AYX$T>4^F^0"Q91:-P5*7%-=%!^&G5WU23=F(.+)QA,)KI);I\%
MY].<.;Z IP+#3[Q6)>]9JF$%6#1W-EG0BVCVL$05H7T?ZRV;-:28";3+P/PL
MO"WL>!K\D[X<MZ\D*E1OZ!N1T0O3.PM<U-<@AYRXM]8G8@P.P6[)D%T;=PL&
M/4[YALZQ->4-NKXN^'H"7'M;=Y:11P>/H4>^2M^UQ,K\G>6GX18@68\=C\6<
MINY(%P7T<=?!!/[V3POYG71S"KLK,,&"ALZ;E;'2W+K1UC"KS>-2TS/U3Z3E
MG(*/3)EU]_)+180\P@5R-KV>I[!3G:&P "Q#B_F4P#3\QEM"Z9$*LZEALAC/
M$%"82G_I9A@0$_X3F/8W,ZMA!4O$.0=. /JIU),L'S'%_QH]@[F6@P70II-6
MAM_$Z0_*-&DJ3VT;"8U?30GN"!@GI!R FC+C2 94SP$W?^=W/;_#2>[9'#/P
M>)"FD.,-J)R6 ..[JT<!44>RC] 7OO>$DC67;'"JN?_G:F[GY1\LL?-S#0VM
MA1R+A[]Z14=&KPH8;AR&['<JE> &P2IC+ZL75[Q61=4(S*,JK+8^W7P$A8()
MRF@DP0EJ8\UO3FE5G&9>9V??G%\D9YG$.*;>CR\MM/P)E&3AUCX]Y=-\^='9
MHBVB*BH&&(OE>S#R<*'-/<CQK9)"//Q:HAT-@B^J$O:!'V_*HO7[.6Y/(T,Q
M _:#\<DAWQ16'2+_VICCI"&LV]O8HSL;KWCIC\8GAQ_A#<4[%A;%?"ZY'G_]
ME_XSQ&VY_Q1_YQL2[P+C?4[G-<P*W#Z 8$J-U510_?X6PV9(X_WFND*[3=N+
M=QPB__#ZGE_=*[ HQ6Z4LG-8HWCWUJ^K.2_-_*'J\\\;!O?[F\ [L2,B[4H(
M0:Q#!8!**8 ?)2.8TH1T[U-_W@Q3Y0(_[3ZCJ<;;PU'7CZ;G0VQE2I[8WT6F
MJ*YD'=S(K7I"6?;[A^ZE=9-6W#N1.S2M-_!-&O8B2EJ_B*J5S(S)&S5%-'0D
MWEWSBO!S]V2H<+_F/CULCRO5"ZK*>UH7/,IAFN&.EE=)4KGFGX9-Q_:*AR19
MV+#A^NY+T36REE<7?F7_?D7;)@&/S<);5P93,K0K\R& /F*MC!HZE/ +O=V3
M?@%M>>9]U(+VSH[]BZCWDGJ68GVTW=2XX\.SMYPN=(SK.\H>K1;[&11:J'<1
MWV/>SRI7:NX2SM(S)& 5+PQS*]08/EX2DFD/V3:P@OTJX FA5:J)/5VLW0,I
M&YR+$>)>,Y5W_$^SZ6;!7P$O9FV9>H7<]Y;34R@0/=*D#-#\MHBZL(A*%Y,[
ML"/WI)(;6@/JGOZAE1&V^KV*>OZSL4T:,2NSX=C&8<[QZD-A=ZKC9TVC/*KK
MXMYU 0O'HB6?GMY8N?E_9K#;&&8T$;-^XT3'(LJ2)K;J4?@^HQK#,27:/M):
MVCH*05J=I7*8XJW3KH8#9;,(DY,[>:LX1(+"&R OI01WTM>HL57P<$];HB23
MS3GWE%+91EL+4]T4%F+) 9&9/S?FK.[\>+:Z YQ0%,LQ2]5;D<)GJJ/A.V<E
MQK@]JK74.+B.1;'NH*UK[*<2*J=("(EI>S#Z^"U!<)"3_[V9_()W9544=B<I
M;'@N^=VRXDCR54#\;@_7J9+>'M+ -*#N'>"NA7G*DY!;1B['O92Z;IB[BT+D
MXPF/A5P'F&XI5,0>R9$-/Y!&HPVHNUL'N([1!9A;Q0.T]=3 1O_P]D:\<1^V
M>AO5L8+ZXU#<9-5ONLJ";.T5O"&]_0S714V XTM#U!0X.0G*E^LS1/(FH8+4
MKC42?>LV1%BHC;"4>@7R;2<OIZ"E .PNG>NJ@*P!(U:2E&V",8*/"\U.A\"W
MY%X\[C!^RV0LG./5NTU;-\"3/F.:J\^Q(ZT"^>3WO#.0+1/2559!LS,58-))
M"(T(P9449_J:*.3=E9"%WP3?@?0%04ZSJ7,V7K+9-%=#,]E06UW_K$\=,!88
MS+WGH^77[O2[3M%1F7C3\9)Z2[6%0=<OGS#UEK>T%A1'/GXEQ$M1F\@Q:ZG_
M@G/+X*]>\)LP*^I6S1.NF7H35)0+6>Y]"9;Q;B)6)'K!O?-4?(_1)-X"3H.V
MUW>3&D8HS20#^&Y;9.XWNJ)==9X:IOF-%\5+5S[L"V'-C$C1(QG O (->?F
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M-A*WM_GP \!1%6*W7\G,Q("!P>P,FM$0?EL4J78V.YZ<HMU*S_,@S4P#_M8
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M0%K*R,'G[P6:_/(/%"*_R&X(YQ6],HJV5OMGW:#37(A+5C#H1$6K$J.+=)K
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M/7K22U\V#.&V2[T X@Q%H29<^:4VZ>1#A$GT3B^BTK/@FTY5+,4PTP(1R*,
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M@)2RYGS!$=I$1P?K5-J'5S)@^/18Z<0BR%G;_ [#W+:F8L9:I%]C#)-0; 3
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MF'N!=)VFVF40&1N9GIC^+# %,)\&P\HVP$KLB9*0D6KZUSB5\UA8 G.5 I.
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ML1I>333";PV1A5I*#FH-6O&8:Y 3FDKZ<<R,1SWZ1+8+>+PWCZR%IZG:N-_
MIMXIOZ(MY'=(3>:EAF_UT[1#R:=.G0IYTM H;/0M#55'.T?2D[O[W\WL_E1*
M#'7CIFW:_2'%];E'>7C&C4J'VO_QZ?W_HV$^._Q?4$L#!!0    (  U =%K(
MQ//UJUD" "5P @ 0    9F]R;3$P+6M?,#(P+FIP9^R\=5A4W[LVOA&D4^D:
M4I#ND!A *9$0I24DI*25D!A"ND%!$0%)Z>X8.I0&28DAI&$(AR%FYAT_YSWG
M?+XG?M?YO>?]X_WC#->^KKWVWFNMYWZ>>SWK?N;: V8.LPI0/E335 -P<'
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M\^O>61ZU>_]^,V5M@=O8_N-/5\=\-4^3:%EKW5]%_RFHB;_/N;C+B%M&Z'9
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M'"':1X$VAGCS>X0O?P+@K4]N\J=3F_L4D,T8L;?9 M46BLBNI9\V/'$VS!C
M]&>GZ7_E*[R[#._5?EV5?O<*2[3Y/7"QEDF]+UHUTAL6V.J)/WKQ^$S!(VL+
M%\#A+;P[U,6SZ9)"A3J>W28:P&7SE.%,S\0].62C^)"E-*;3=KG5N-F)HTJM
M]]>A?G&]G9MJI.VC';A3.4T+>Q3Z<F5^YU39@XONM$_"LP]RL\[AI;E="EW"
M VO%B38V :675T]V@L8DJJ-2YDWEFM>6/%?X'\R4,3S2/Q"DO'G,J]+A8$#Z
M,([T@GL3R[9.R2WS;!C:'C;6*TP8-($!*#& LVZ<#<SC&#_>&:;@W).Q6789
M45CK4)QG[/"X(H_8-*=1^K&V]['<?=(+:VG KUA>X<HS:$Z1!SX;9ZM(-UE6
M+WSP(:<F#NFC9Q3!Y"<H&.?$"*=DR$TQS_%JRV3E_XT!])"Q\,CN9<ZVAA]M
MSC *LKV77]UN.9?*W?V-P^Q(W]C1I%0S0L5T/[_#BAM?>:WY:Q G>K3[7*\Y
MLG>%F#-0Y6SEV871Y2L/R5%.)7WJ1L+D9,;J^"#]"YX4S::^/KE%B^7P.UDE
M6^N_VH]M$#7(3\=T71V<GXRR>_2OY>"'K5]_.C30TJ49WFM'Q;]OF]D1T'9?
M7%YSMLY/EXO+O.%\MHZ00_Y8AR1DD][NLZ3<YYIH,[%_7;8CC=!?_.YZ)V+,
MH*6^\;.ABJ=M8T-T%]X&F/GU;WODERNPKOP8!B"R[^YM\F!+6V-XE6M^9]!W
M.!?HB0L-"\=;9^@T!Z^-=<9+C>W?TTT(P"E0)BT7)^%?9()(SL_/?^B. GDI
MKA6%^C$H.+".3:#5RZ?H!RF&XGPN/GB=D<I9M\$4)0/H.06/P=T/KIS@.)=4
MBZR1E=7%D?W0,,?N "VX5Z6^3B6^UV^NK1!D(*^(W/78 08(A&( &C5[! ;H
M6,$JD@H"-)U/U\KE745R#-#5W@Z"MW9@SR8TX3YHLH-MW(YA],KY(@8X?OH"
MXG:%[8\L687 ? )8,$!NZNK1-=,BEB$DK:M'*.IL LCJ\G*PW/[_I6DH^H_"
MECJXD')?,<"'=NBC./3'@79-'BRZ$*/OR/>KJ($CVAFVS@W[!(\!*W!2#OF1
M^!5DQ0T#]#W^B((>-6++Q-(P2#R88(C5LA>*']ZYNHO8]UI)496X=D2JR()O
M!S!@@# SR'$.^=6_[XF-'.SU-1L6YJ?5L6O&+K1$WKI;UZHL=N*U0+5*5W'D
MB^#_ESR*N^[3U>$3H U_DWG&6%X->&_)9YL"1[7@1A2VR[4!0_8B^@J"YFL"
M(<U7\"';1;Y*5RR&<[B_Y==/%-]!NK>0:CK'Q])=61;B&(#=V?4S9"S 1P)G
MY5^,%/_GD=S!?Q A_CA"YD]D&G-&/59D$?V\&"!\$>X+5^3VE;C=R6/4R 8J
M=/A/X+ZZYL#"_?C'L]A[\7>1\W /:CKDYU7WE8.]ANTWYX\H90Z]LMK[ ;F?
M_Q%X,D6I:T:WB^)E INY.^VXH@@# !\\>$/GS9,_80M@_LN76&.9S?0(O/XY
MIE__V12#+E \E$"9$TVK&U:=!5YS<]L&5SB"_R$(XP2!_[Y?)P;H/D3*80!5
MGJX5I'1CWC_& /"9_]]>COL7HY\1(9?@KSR#N/YTPT><K2 M0/C8;;G ]Y_:
M9*KMY>=9(?_!7']L?+@1\ CNP"-#8-3 9L.9M2[/JCZ5X"2)=5=PT](QN"M$
M/!127]YB4R%&8#''0D30CNON:*G;=B;_'SF- DUGV06]Y%,DQ5I;CIV-1@?$
MB"9#(#^N;H&6&=NK& Z!H9V]K.95ZU"=O7^_)-ZZQ4,(E :Q@=_?>#TCV.Z'
M$G^$C?D2EM@QNF%0N)N;$FMH\\#(>>MJZME&RAN;]GMM$QU2 0RHJQ&LK=Y=
M %^/::.]I\? NX=QZYRRLOWJ=UH.;O<NLQRKYJ[XFAG6SKY,_UCYLM#D.;%'
M!+["]_,HX':_TKH$3NL_[WW_<DC6UAWT^_:_>8T!B#V!GZ);#OU$0):/IX+,
M[X$OVTK$=S5P/I &$W;R<-DIRY]O9#P$_KQ9^M>1_[BY2O-QBO1K@@Y@)WG4
M_[KC3*3'2@J6Z<HBMT$UI:#0926G=V-"E1IX_.\.]E$9O,PS%MTI*(N.'*X2
MB2H;WF]N CQ;?)E#32YW!8VCA-#T+VR4G52A<ANX* ^EF]0S^^)QF1YG/)>0
MAU*7*1!FB #DLNG ,&?AEV%#1TM VZ!7G-VW(^_*7.ANHC.2# -P;C:BW-U0
M&1V_$U%6& "KWLX8D?RKPJSRC01<?@30^Z>L^;<QP-Z T]4\/A=+AQ_.-;7'
M45PF8[>+Q5*J91!T]F/=;4?)VMH+!\2A26X,O[A>;@PO[D"0#.7RC1^Y%K:O
M0PQTF:*;HH*)UG-X*ND5WU_ MDS->#X&>KBXN-W5"CRGTS,M;0/R!U-TN9R;
MS39'WYQFB8$?*$I'Z0;_MFM)$G@IV,M',#K%])9^S%UG5 3?;XP9(@>%ZY?+
M]5]6ABB2;BO>G'PM]UG= !GI8@=A_?2K9LS1"^+,G+PB\- +MS3Y#D(Y;B/A
M;OELR?5XUI^-;?ML/,HZS5^5]9%&3=V>O'05W[WB)[\6-.7MY;KXXEM9U-XH
M\KNHN'.],JE]V:AQC#Y0_+886GWK)9]67G ^OLS.( W2K?CZ&2H? ]AH=# &
M"-4&>O6EMVRWS=27WUOIN>S_8E=D-O+Z#:+!1[S;[BV'JD('S6>1IFV@G((:
M/8,!ZB$1:++&WFRJ'ERG#N[CD_D="]K)-KGB(86BR%<]>2OL30E,Q7%NLFDG
M=.3)UZ7?0D+,/H :^)NG[^6]=\3C6S3&Y6?F0RV+AX6ZRRB$$YH:PS(D[6/6
MC"(8 !E'O98:*36;KGBTHU0EL(5G!.,(FEMII(L3G#*=?&4+1R26#90O[1@^
M\;5_:F+J0K5&F]1T]<@N:$;(]QO9HD:_:%;+ *(357GM>"RVWF/J&BS/E+OD
M(#KW<WX,-O)(\/?ECH=D?YYKM^]C:?/\(F^F-+ LUSC!0:PZG]NP;=3YH2V'
M*JOI4>HO[6_>E?*W*)0\E;@\M/G2$QB(WR:H#)?3SXL(4MWL#FM6EF'@_$*#
MO+UJN9"'Z(1GLA+!1:?M?L ^F3@'^I@WPV<JE-O$<CXI"\T:N_&)1 :MY3][
MKL2V-7VM??48O6!J&5D>Q+&72.R =2?UIRZI+)Q:.+J !36:2%NN$'?O(\=!
M]WV$_^O7R>4Q'-^(7-J2*.9K):SL?8Y=MKU:\=;I![?]9)A?%WO-+H;M>V3O
M&:-!'=(+ZN'UI5\?2D>=,?F7-AE;S2]KE(S&$7(S&(ML$<R6._6WZK'+Q5SG
M7R:O'..Q8H G,\&@?YLHU!_>9?IR"=I4(O84?<^IH#"J,3"=%-BT]UA;PG#9
MN"5K<GI8(^K9LNEB7;C'YU*)KQH,S.LL?-CZZCOX?!8#W$^!4D%6"VJN'[G%
MHZG"NDTCHU8G<N$2YV)=]D5./J:ZB^O5[;YQ7F9\BY]JQ=0[1'ZI]OH9?-O
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MYF@U&;=Z"IY'CJ5X^;U@I_(X)<K0%?;XEBUHW#1&TI678;[R^X3<&*'^Z_-
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MT2.LN/E]]K5CX#4&4&R$GF]"^Z%Z8!CS^)5CVL>##T] B=39\(3ME3/2:@P
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M %X=WP)F_REMD1!-AZHJ"Z4C:464-ZSSWJ[Q>+0((WXO9:3,4]AI@+$CYX&
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M.\OH ^B(3ICMJ]9O]_@*\7>$>:VC@'766<%W4L>X:# A%GT/58NH[7OOM"9
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MCXG-.!D<DCTI(;0;E[E^)],)^>"[%J>F J#^OUT>O1N:1 6))&J["<CM9TO
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MLG<$M6A_J%=[\[/-(N]Y[3;TH[R5L(7QHXJ*<B%U6W?6.AOLAM^&V8*/VLG
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M^<*"1>3'P&,WPQ=D=W'4W>O:AV7;=0NH.^Q9B5QF1AJ$M_'!J02\7/"S"N[
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M !>!K2UBT9RH0<0"F@Q(I?1U>YFG>MK9L]WRV;=$S8=ML^N,<N)'3/PUN,J
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MSPW&\?S"$]8R..E^<-(?-N0T+LDN#"_\^]6O*R#46E,&3Q@_I<TYO ]ZKG;
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MSX+ ;OC1^-SJN9#MAO%4NO@.VP1THP;8% ?[#]/MAQ^UA*W3[DF-VM8JNU*
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M;"KX)#/LNNKKYS[2P>KK7YK"67G_Z.#B&%5F*/SEWW;(83$RH\,$J+I_P%4
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MPB'D"Q,M\4'!]+*UX1O1N3#.5#%]>):S>^R@8YP&4RI=NIZY%LQE7:E_Y1&
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M<9J=K$Z?YKI>FAYY_H+O:^<V7+HRDQO+TCH\M%^"V;4_@A.Q2B?+,-;5ML'
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MY8L\0V&LG$2*YOSW9\?3)#_HX4#L8&KO;-^_0]_F,3SNX:EH1!_C:J@[A*D
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M)WQ C7TF=:H&#_7"(+W9"C$G<GCXP6))4@\\PY)'54:D\^>^5V2[M#2YK Z
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MX$[)X(40VG8GM@+BLH'G8]\8AQ4"M(;KIUZ,(OZ*NNCXM+:TK\7\O6';A*1
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MY^*7);/L+R4SWU%H\NZZIWOHO8M=Q9W>"U]ZVO3WO8J+DZ-+K-.T9^_TDW/
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M,5N1ZM)YH-5I)U<)5@ AJ5(LQQ7S+5M T3NBQ_H6\QL)*QOKZS;,*LDV)NP
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MP;=HQ1SMA+I8!_4V5U+-8Q10W-]OCB+E]UUN)'<IL/<HOB%PM_HS3(V/.T&
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M-Y*M(0B^873<O[3[JF51RO(E(TC42(RRO;4Y53>;,/5C8O0K8B8LG&<EI(5
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M:<Z"\7+!WQ E6G8VG[%_E$U.Y*(D!*3(/_D?SO/?LD^8KJW!:O?)H(U[Y#!
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M423O5)F;:B+P27(=/:_U)-X 44OV4,4@Y:K9$80*T=1?1+"HX%3GS*R#"GT
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MU?!MAI0P&C<KI0ZD<%%-^5'1X[:VHD'='N3K$_@2W%!'^&7M4QK&=$JJ=F7
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M*6=4^I94<V# =W/8B/;DI;8C8HRL2Q^@A:V"3[<*P;\KN6Y(#0Z,$[F>>O(
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M-]"N.+/Q(*'#$Q7;BZ=SPW5\/S\;/)FT^Q<FEW0+MLV;ZX<!6/%TIZA>Z@>
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M];B!1)Y((K[<\GL!?EK!.7?!X=7(L;!$'[#5L0+N)DPP(D,_ODU8NN3QAL'
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MKW 1'Y.9!B._RDZ^\0)[D7LG7>\]^@>[L]WPV$TF),693"7Z^$^_7!(;&]K
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M)?>T[$]0M,T1YTRZ)L'O1T\2+/XO\+E%?A,.)V!K:(\Z\]?@E,RT//;ZWQ[
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M:9NLRG39SUP@+JUU@4>8SB-@L*<KZ6#:=,-HC;OV/$QBK:J+/SSWXQL;?#W
ML=D[3UG7EN.#=4*YT:<*"8'WTXHQ-85-S+'EJ!QO)SMPM%>^+,M>CV3T]=0,
MN']?D^__L)7TE*<[=N.(9%H&W*3[[!4CIUC7_:&VF?,DU5$@JQ:=X HPA4/F
MO^YBO3WY?/V&;+L[G!8TU$<7'!V7_L\V9HDNPBP*@HLG>'G[D"@[(=":#X^
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M08>);4/Q548S/&W7$6RG$!67'"(L%L8W@P:SZP*MLA-CZMB?0-SY6P*.9H=
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M.H> M^"1]38B&C]CEP^+VW[,J>6* NU#@G2EJ)=H1^3'#6*Y.)PQZ5;<L5B
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M\$-F0L9,I$/!DA]-3N:BJ7>,454#GU>O-6X<\\D/V-RK#MF>]Z>,":%<7?(
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M9"M-<#WYW<F<WL01//[S\[L]I.6A$ KKDT[QN&J6=J4$=30\:!G=;'4]VCP
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M9GSQ9I%M32!UZEV9?(DS4Y4778PL?&GZ">#B@\9P7X\@@1V(YW@@\0?-?-O
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MPMO4=8T*#2]'GBVVB?+1@I?XA ,JU!R4=@H\)[ U7#TVNV1T@).7V'P]/8'
ME[(WYPY<TY"M6,)DW#-VX1$/(#%9\60X*YB/]74\VA- /0D?PL^@V<9R!- 6
MD2K$6B\;ZFF>]M-DD$#L#IL?)UOSOTSN>4$R[M'/GO;K^^'WO<N0LQJ3!#9@
MCAY+XG1]^3.;@'7&I0;"+CL7O+3QJ;=UV/1I*=GRI1DHAA 6;K1?_W,N8GHK
MJD$O15P/*- /Q<U] =LI$"G\_)PE8LY**D[KA?=N]M)JOY.>2:/5JVQ28'J
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M78=%*#)BJLA#JR2.).0M>_SL;!&SHN>Y,W<OM]ASI>EL2'@&*85%7Z-%:YA
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MHSW2?P3$"X?T]&8<)LG(N6FWI#^O%=OFD>L^FSJQT,A,;=9N&!72>X,A;5L
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M::[8.7.9YA4 1K=2(MN> 'L1+C-!^G+((_F^3AJFG-J) -.B#=(F9G%H)IX
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M[!WMYY4&2>+?:KHU+Q\'S>0<*G]DD9+/B786[#W\ZOJ0GN[=$B T>X= (@:
M$AT4R($NTI36".;.]'MS2JJXR#_U#IK)@E-60[D"94#!3Y^9;[2+I B^^>-(
M=P;P)##A[7=2Q8EKQ9"7)I=&@]S$ZYH==BD;TO[,#>'%%A[XA! ^H##8DB[2
M3W(M 85!+ L0?PT4P3AQ)Y*VYSY?^;F]@]7V]1D9Q9,_VZ/+%6*,Z1HFS:(!
MY5:?77C7OJE@07][<7!ZBCVIKN];X("Z;FIG^P<O_DN%[_\\OMZ9J; Y^?>-
M>?&<H7@X*3L5L<YZOZ;)7150AT$LIO<ZB,TJ;@F9]+120<0!%$YRA=4C0J0#
M_*C0/\1-ZV>Q9QT'9NAK67U[SV<,!@#@!9EXK0B!V6U[/Q76"7LH)W]T$)GA
M\P&TFVYG+BJU&XR1?^>]EK*VSA6)F:  2ZA]" Z9_;P(+B@>!TX-(Z8-VL_!
MC-Q\/:^)5PE12X,^/:J_=SO@$XIT.[O3XTNH#\8RGQQ/93C$(U@W^(U;>[^%
MF<S^>X.SY4/O6<V\=RGW\ SQV+W^4T49]T>?T8[+0$7MF0%]$""BHIM4A47.
M6^18+*L3D;GJV7FHQM83;\GFU[?2I7]WLT6G\@]S0B1\[./\4VH0 R9QQTBS
M=Q*#QX('\[FC$*&^8';% DC?+9S5].]%E;Q) YVW671%?G)@%N+.>>H;)LD*
M.4 K^M6?CM7@T^FA=3V["=MB#"[P&KV,A<V<^P]@>:57RQD-,W5,0[@&-U:(
M)GS[*Y<].BYEUI%]3>853P/.-9'P)M"/U UYD<[+^>%7_G7/.#YDY[;>I<L
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M^.XO^G:$_K+%E^R_H1R^9P'>UD9*<II[9*T)?!L:?U'-S85=4V'X_?[=%^U
M=F&G$9<=X27D)K=+S>F70<?]/."NB[5E@XU=<N_!"'=S<8^W;1YU]L+XR[HK
M25\&UNZ(.MEABR C::KO@84PEY.G4*8>!#=]]Q]"7= *=R^V<)QCI9 KTO.
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MUX,MQZ/3UC- 5Y4O5>V.P-48YIC,J9R&TL[F[C. <<O)(-6A9F\BZ'3MYAG
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M[SYM3]#/Z9Z5)HFDER A>(^1/S:=TU.E'M%LL\F=>F" 8_UP^-!<PJK6^NX
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MN4(/9OT%DQ?6(($2-.\YXU#\T"W3#A1JID[F6G#C=)XB=P=+B7[J[-54B$&
M/2!FA^/.>V YIW7<1BT$4OO>.]E1I,%VY$KN"QO3ZG163&G ;YU!NBRYD+HW
MZ03]<EN8BV\<^"JQ]FO)PHJ=HS74V[(]]JH)AY?_PR_V.C1QJXWZ%7::9AK.
MM@IN46JB?1&,E(NDBIA.#6C58,>_9'#V9X.:CTOCM0O&+DPA4P;:$Z5(%<;/
M? 8"^O7C].4-9!!ISC>]6(+<CI,%D2TM)P@U_VRU8ZF"+YW=L0R^186+A_I%
M!GN;#?WN@6\S_GH(A%9>B]0*ZX<W._:.,U(<IB* ]CI5F\6**.+^H6_(!WU?
M?^>*9V9BW,']M1^<_:4BS+,R#%941=*L4)AT@D89Q9(D_A53J:E6!?4=$!9@
M[$A+AQ;^" T;$?-[:%^1_79@6#$E]%V;5E4O]C2AZ1L]SB*9%-\=H=X^17'S
MD T*?^KK6^.C^'6'XU?-#TDQDE1$R#0^+7R#\4=M'3]'WP7@>^HY'].#Q2C2
M;:3:4I+W0#&(A$J&67^VV^01EFZ69#)R"?K]P=-;L"'QK<V+ K=G40QM5X,#
M;M!N?U6X^9HAY-:/3RLKJ8_8AWB[G<<T7@YO0BRDFPFO374Y'!?I8KFOGP$>
M1&;5IY:D"9 CQS7WR$_^>^P.WSL#0,X 4:; -8SII7>*'97=(J#0'^KO$B 5
MILWTU,X:\L')&6!$<1#5*)W>NN@:=0:0-15>GQS"N%0(A:U%ROP:BAB7?:O2
M.1DK9"!%^TJ[QP150E]P]!@/)X@2\9B@,\!K11/V_DJOCOE4I5^RNA--WWB&
M.19'@\,AOA"9LHA9R#5;J59&PTOFW8)<(OS'#KCM7Y@,Z256/[FJD!?5!DZA
MN0/T%N.FEW<<&6%AITF:7*3&_@[W--" >GP\Q=:[VE,=.7\<4>+: :<8*O$&
M:81Y8'+4ULS$)IM>/,%4$7OI,EC7L;X$Z1+8<W(%WC<.K1<;]APF*A<V:B'A
MEK1]!C!2T UV^K,7%:7J>KKT0FRQ/>WN>C;)G1"Y?(F<JQT5Y/N:*F^;>G?*
MFJ)4.0CQ>3EJ[P07OPM L<I-C.GL\FQS%N%5^?7_+N"AU%OI24"<+]-YVXHM
M\[(!)W._W6&VF9E__G-Q<_F:F?_-CAQ1CSJ1V!(I'[>KK-"=P;_GQ'\;+YND
MS76='%7A>-YA^H^U:O,Q?\1?AM-W1U_>G];PG-M)3EC>MC7Z&."601LB,0-X
MY4AS#F^<>+>*I.5IHW,R -)NFGS<G&MM3QE4R?NBT+;G.C#W+(0V<_O.OW\D
M[OP@X<JPLLT#=,W'(G-[MY?#L?T_ FQ+T[_HLB\*!M@Y1[H%A4^F!;!&Z)-O
M$R7Z5Y@IMTD6YX& 1:>#QKDH>@7;F]Z2 @DBN]MNOZZICXA]8!L5A94-#P#
MS:/486UZ34]B(B4(F/0C<[!NR[* \+IQ2SW\=W='3EA[S0=IKKZ$2B!:^5JV
MG8@@48[FKR,CW L.A#TDQU9#+_@R;X$%2 [9;EIH3_0HTM]8^JW*LP77R.J]
M2\"^UUEE>E91@WS\ZX00C)8&SC>)ROG3UA$:WP_F(WXEQT%?EL<1'GV8V&16
MM*+]D=\6;0O@Y>+=RY7RNQC2VN,8>080HJC@3!(C)$DK?7 @.=V&!'O\,:JJ
M;[*_\H\Z+/?+C:FK>=_K+YTP^\!6I#\(.Z\J7PPP.F':C* GH1(C)&""Y%2>
M>$UGG FK%[?R//_L#Y74,N_CFG>$IN/JT0M1BG[?^A3$_'*<G$5!<D/T<]J-
MAX,$ ?QX?%UM]?ZH?F\!M3#0WZW:DS_EIF#+GK71]7;+1;%NZ^]J018")K_H
MWQ\;FC;5:QBF)B0I%\5KJRR#UXM<:A4<KT=\7V'6M"6F=S62X3CM!,5T#G+M
M]C%USX[$A9S[<SS[[]=,XSA,0<0#VY:EGW\MT^*^/B->).J?H&6.OT&F;HCW
M%?9:Y>89NO;A5?:KHFICK HIP5=H)LRL$6ANQWVV<Q[NRM,F?]9NDD+]N?I?
M[<O!24]H0IWSRK9ZLN3\#,TR%#)G4D(MM90.LUKV[.CBPM867F1^'DI.@4UQ
MVZ7X")"* 'X!:M^4"&69ZC(E+YB8W0FF,4W$+B$*1SO?6F-MQ71.=TV6D;Z)
MN&T@^]?6Y>%;O".B^<J2;&'4MS1[V>L$;<R-")4%"F/K2C">:W*[.=S(O$7.
ML&2CX(F)AX_1C]WJ./SI+<YK31==@ER9 7Q39"W27J\V[YO!0VU@^L$2F&[.
MYZ72]9R;_SRQC7'8@N7+A=^AFB>(JV[?$;<?1*5P[I[._^7$W">_UPS[ %VW
MFL;./IOC[.,//D@MM=/8/$Q\M<4UF-&EP\?\5>5VMWU99& K\=Z!(\FQ^UVP
M^;RB-L_&C4&#PGOQQEEN)^!RSDUY+W8O%2;!!/!,W-/4=[\,K7B8TCQHCBL(
M*Q_([@XDX5A\75RQTH22":-8YI(Q5WE)?7%8NKJD@4/PC(7I,DR:PO2N2]AP
M<!9^$:P #</K1_WM%/%XCC>>$MK&M//X+^HR<_Q<&O;VNYYGT*>6<Y/)%:-"
M3Z]V)-E_!JB?/0,D4T!X@7#O@1SU^!28.PZ/:__'70QJM"IOWO3B[K#@/4IE
M#Q03J_H"*,J^U+)?M[#3!V8XS6]&Q+3P%\?7;O)WSZY"M&I?JT,:-X-5@A]"
M$ 2Y[W6BCX0#W$6^6]72 VC_[G"0I_6G-)4JH04+Y;-_(36K:M-T*HX>&91D
M9F,DQ/TYPVY#9M$J&PL4V#6.5C DH[13FQS_ANTP>)T!@+8FA5;-,S@]_E?Y
MGT:#N<H'WTDU&KCZ._L?E$D<WKU^PU8<V7KPXGP.Z;'P;@0;E%ORG4H/52(L
M;++$7J;4-ZP\>>2U6YQW0O_O'ZMW!L>>[G&U7L-/S)%5B)PX5"Q8 %K1C6*C
MN)=N.=PB=:+.VU@2Q;]B_(J"5^CS<C7J[)=;4T<]JIB0N0E%^%?/O'>+>::7
M.JB+8-:YZ^1<7XPCD)P\$$A1G,%,UW(^,)"HGW7/8GC>AHI[A32,MC+D7-1T
M-I??98Z)U)]<N4B5)L/Q^J]?4(*P'Y%&6F;\.&_;/U-J^QN9HV4%WK<,\#?%
M])YK)#NG/0+08JK&?[KWK[#N.X)^4L<=N7AZ'D.WK:R+M]=^X:>G;J2H>'6)
M!(<=,;0]-^_B=KHSKAT,8R:&C_>.QQT#8Y7":JXJ:2EK=;R>FU<^FI')=QS[
M>OVZ")]U*]N"2-I;FIU)#LLW69?Y!E31P'\5E4/KL_&K?< )"UAH;'0M"^&]
MFF#X1T[*+0VU;1:5D[LC18Z+ ",V\#1]@,GA*,!S\K]2_]^=W>RTQ/T,H#VW
M0OYOH>+@#5K=0I]EA1RFH_6"/=]D1[9]DU@'ACG-8!S=U\*'DZ(M\HL_7WM_
M+4P>^51=#<%:BR4RC8?X,XOPV.UL35BZBY>ZODIOM>%HUR;MT0Q+B'"BZ%QH
M(O'IM9IU>-\HQ9T4$%!3!V,8E->T0GC2T-Z$BEZ[F#5O/EGG/+M?&7#2K3OS
M@I!2ZOS]4C?]I4A-.#:8H(893P1SDZBM@=@==O*SK6[ERD]DA-ZL4_*) Q/$
M4,9>K-DL1*,G2[KLA#E C\>#*<62AYXP3,P_ [A7G0'2;6HZ*UVPJ0+FLTUE
MD^QOH3&FWZ::O;_=NA@G\=5,KLW((F^G71#4\QEVZQ01(4X^/T[3]UQ:._03
MD<$XR*WY>_._VW+8RT>=*_3%+,2AM'I3ZM(_CF[UN>[R7$,:HYQL47P4I5E-
M%9+LH+*E\(TO\\VG+CV6Q<)M<?-&+>D6<SO-]UN_-K?O%>LE^LRRO_U$<SM+
M/3(BGZ)-4G10GG@)Y-+WU'KCS:_562+T#:W74%[VF_+Q@G(F[9O=EKFA;KKB
M[#_9N#/ )=AU8*]LO,,5HE3'T1RHM^")#:R@N#3,6_KWHMY8\%'FD5$C*\#2
M-$ A&EIG<1)41Z$NG@$P3UO/ (+_;>8CM:G\P"^(R2D</$U#?:B_=6?F11[&
MB[OO./PC#>4G<"Y2Z4;U2JO-&6"<@*)>M(63OIL0F,"'!UUG@/D9T.30>Z9@
MW=>LCSU400K[.HB"1_'7+UE=D#, $+V'(L0IID14#XAN:QE,,NZ.[T5SM7?(
M^^J(5X9.&MU(NQA\QU66W33I[F]B &!Q(]@FMB3ZONVBM6;W[VSO/ /T&4!2
MD)X/7584W(W9UY:E3L(;UZ/@'N-,""9RXY.9JXU3T@Q3(E/_) 6@/KX%<EP?
MK<T?)Q0K=H4C;^^/ D*T$[1]A"1UB+[1$:+6%#G2N\,HZK4E%EG]F=*6YFMP
MMF^KD[8_/RH)=5]O:OC60>><D-@VM&COVP=<-,&.1W9>\UP!-G^3M% O.MA0
MVD_F:E>W->+L&""=5EK<+=0_[G=IP_.M[H%93C,=>XXM>[2 IB1*A 01T8.%
M?[*&!IH67THRCEA;._VKI')T+>6=^HAIP2!-E*;\[P"3MY1[YT1JB'=,#'5,
MEZ% WC--!KH$?]Z4RSUY<FC!X^@=4UW-S_#N6C3V@=O[O0L$*19 ^&TBST$%
M<9Y 6P<=>4#,083F1'#-('3;9Q:>RJ1D#OO3H\6:Y?-*8^04=E*-+JHQ&H=S
M@A*DW3NI/Z@S4^6SA+);!Q;!UT*2,*^C?6];&.3/)%J_C>:%F%N*4>*)I1B>
M1"20Y-B/N((TQK$(SVSER);8>A3S9FEH,"6[&4+PL[[/VK(@>QWJ#Q>%!!O;
M%HIH?B]?/$4@@TNH4V!Q<DF@F_-I+$[CU=0_JX]STH[C_DK5!QW[;(,1L)8X
M]*14RL-H"YD?GYX0:78<I$ZK*6J8NB1N8<"\IC2NBFM>4U_BM132),3=JT/3
MYD/":U.QR5_(L8;A0,8! LW2&"T7WY65Y#- <W O*KI3G7@N3Q1+X8K@&D<=
MN'^(<,87X]/T9\)+M:5081S/TV])9GZ)S?->7QB121B*(]'D/U#VJ%' /2F6
M)<8>]M:Q,BSJ$,-_+F5ZM<J-^QRODMM,IP<%<W88F(7<6O1^ZM/3]\._U*;C
M?1/5M?M3PP8/C7'=N%$54]+=PBV5Z68$B[6#;S@'KXU$CEC!1)Y!UITV6C'!
M#)HM1SIMKW$&2C#I404V589OW][Q@7M[8TO>S;!1)3X7:XG(83'GC^[6M(!!
M9F3DHXC^9CXGWEBGAU7\E*^BSK$"EG%'49K[@D%UR1&TU-%.(;(T/ET8>MK,
M9&QK1WIW!CA7@E^V'_ZHWS>[=\4L[OG3\ &TRC5Y0C[X3_?@_*MY[HSK[R&/
M9L(S%!\1 EFW\@ZP?%_(YGR) (+H&L9GE?;3AX:X\F>_E/[G3LS@UH,@2;;_
M"E__5+/W'-Q-+Y5SY2@)B*ORQ]:#$9Z1<.4+,9\66#MBOYP!6O][#$"]0N.P
MO695\<[,:84_$5;1Y>(#X'"X-/!W(%C"SG^SO2Y9GY"->4(NEXW$3/ZSK>&A
M<B1J@K13:IS3C!7)Q<L&9I!7PWZ9] 5A7ZVR7X.=/75H-8'UOY'3:QWY-KB%
ME+D!4+/T;(M+;,(*)"Z@3VW$3?]BN\BJY?I:U<D-:*<)"!J]]8 <\V$#SJ2D
MS2V;CB&6/42A;^(*-?*46-2MMA,].)107^H5: ]QJ6_EQ/@!Q\ ^>!,H2@HL
MITO4"C*RCK@N)&S"<09P%A6K#/G8E;,;GN;VYG?<[J;&)V1-E%6FN!CO^COR
M[1-3J"\NO@]TA2))'9A3!+&3E7N,'^&D;7@)Y9W-)ZX6]X2?[*9^\([=':(]
M]"H#^$FNOW,Y4"(IUY,4H?OD+=TOLT$GB^'NCJ1K(^^\T,;2+6C/5PV)?+K?
MOIO(D'[+IU^GE?]79TZ^2:3%T<=VRI-C<*U]LD)_"BCHG*Q.4!J3N\''W$=)
M.*9/U[.3_[J/(KVZ,M_,N)K2+[7HO.U>%VE^.PR^JN_.D5J:\WQ80\_$OSCX
M>8ODNSA;#YGK;U=L#63$<^P*O\+W_?QC[3H-?/+L\'S@#V> @]C<4SII%%$<
M2+T5J?BGFAPD>=.N)]?4\-JJ4,- UR'OU02?RV,*,?-<,/GB%-90IYCBTV_M
M[R_^SYOR$D^;6K_%8I!WY_XBWSHU,!/O #C"!$EV+X5IB7@^?IJ SY@=RXRB
M.+H,>8V]= ?,?&'$U!F _1_J]0HCQ0A_RB@05F-K&'>C:5'->F''M[:6&STU
MZ]RK=S^78R R$U$HT0R[AS$AW^ NP2E@"UD>&S<E#U@4"WG[\D-OY+1FK0S8
MU#37$W]E9ENH/>,Y]'=,C7YB\C8M1H1VOQD,@OK=.!V=$%QG]=."OW9!5/S[
M; D&$"=,/S+5QQ2+O6 OINF)RI#7Y]4:QJ$T!*B,AMB?036/A5E)1E"3WN,7
M;S8[^@[F*F_.UVP[-[1/UF3Z1AMZ"XTLW5H2:O@2%1 PJ&UY#@$?I"+$_G!"
MXW9Z;5;B7E:%J2EIZ3^=<VE--IBJJ2GUW*8UX9K9:S,0E3%,[#Q0^!D9)@E3
M)TX:)-U[)2A/$-?#K*?]N@1^X839Z\*]) >_=]V.6]W?$!6FD%HKC_TW0RU7
M5^)0F \.-^>;$>A0M%&JNK1$5Z?P?+-)3&A<OL^;17+TO&Z\N?>H\_+QLDJ!
MAE;'BW1>ZR?)[\H%1!4IM"=^U GY1;*#L:]1*XDG'J:/"Q=]U$@J1-]S%II:
MV4@-TGIMNJASL?-:QH/ROF=W(4._9DSIMTK((=CGUU1:VMUI?PSF+<5D\]&$
M0;HE^(8&>6FRH+2]/EU2/-8)T;=%@WBWZ?$S@=-"WFO 1=!!)GQA!3-7@2-P
M'T\B0S[;U^9B3L'[?"*HF5(CPSKIJP99P3D:8=Z9R@>)"+%HOXNP<2SB?&Z_
M:9X!&(*,JHQ5'">#4#0KFRM<SR<2W8BO:CZ@-[31#4N%;00QO23OJCFY3QY[
M#*;QO.^!TR;D.TW29P!%%54Q]KW6._H.VE<1A9GFJ$@DN"&>S0[OM'%UZ\V
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MD3, X^&YV/5L4:D(ZK5X(C#.0A[U_*NJVGC>KW'1[9-=5OH7["F44O<3=W)
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M*$J':!<XB'-D^L,_4!K"14:W\!R#$4'A6L6E];_9),/SKF7P)=\6WJ?9]Z:
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M0@+&-[FW+"BUU 27G.;IU8G-AQCN+*^)I:D._!J[@'D6"2;!::!^:@FV]@1
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M6A^178AK))<L_/WH?R^KM,"+9C,RKK=]/:WLT=_9>?=VOP.$+@:!)4X[FTR
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M1DX9\/7S>GY[_H1SWR>NZ_QR+A=VYAJ(]#;]*IRS2L]K"/$3%@O2G;X6 =2
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ML99NN6 \U@I?PLBEQSFE+[^HV9&&P"I5-[^<Y#K' AU2PE5$9F!8UHN^8LR
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MKKMC&_JW+ONS4%A$)^CVCZ>6%E;6"0DF$6/)JX[V0NDHV@O>AT*/DF\U-OR
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MWY8WU)\WGWS5>&4A;ZN03*T>%&(7LM3W?:"_DF" .O9=1K3X3@]?%?$:Z%J
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MK,1*85DZ)5.1PS.;A> \M(;(QE+8RY94_U:AC+<R,<VS;,8M1,'!@(4N=KV
MC#MY==9^YSM:+;.\+O78BUY:/PN$8B+<LY!>12YX^O5^,/7D&5;ODF[ FG7N
M/6I?&S?7(3J1C*T_]9/)<'[OQLIT6Z#-U,$A><MN5=.1Q?$E];2R^+DU0:]D
MUY>QI#_-U3AC=UZVY3 V6F\?S&(=8!I',9'-^^P) "AGH*H$7SL XUQW%E5S
MI=-N *ZKZD%@KT''H$<E4O2-87;Z4W=HL4Y>PC21Y+:+Y!O8I^<]5S5(78:5
MKJ1U>2\6&0@S(4 O>?! $AAYN@(QA<\4[-T KAAE'].__G[,P@@H9K1;-X%!
M \YC"<,0O.<0%SG2K>HWJU-=Z7!9X0-"A!X,H6!=W6SQU/)/>M_4X'G;EJ1T
MS<X(1FTC[E$2($BQ./@GD#+P\;HA(Y2NQU\L8P.*_-!LNC]-PK&,]>1[DK'J
M2DVJ4^T CV3^$:8V,I7U$R!&L,&1]G%1G(;<ANKUYQX6HVQ"E8"^9;OF#NW1
M!;C]QT%.Y[ZL40.2:AF&U%D)/)\< ,(A\)34?[&'T!$U"(_PU!KS1,Y5D7FE
M9_@\U1;<2,L,U=5X>39FU_FDWOL>K0"T;E/!^\NB6^6=,[;&,!O9%,;@J0(*
MPLH&D+T\!W-EL?XK[+0RF X:C<O7THTZZQLKM]H_B')8.^>?W>B0:M[R(\LQ
M.0)0SV+!YXX$J@;07ZW,&JB-VFP)KC N98!*=C%,^3P)8])6<'5&(<^=@16&
M>'I[*P],->F8?7=[0O^+9^'<@*![U=  ?CU:J8?)MS< F\I\ZFYF78CV G'H
M:8*?)0ZR2^G4I[!/_=>G&/-:_9;V,%<S]4!E,$>@"_YG&B:% 9HWS*K5K%+A
M88\G?\.4C@;%5:^PU0FKC@^.?Q=?Q)9>"@U^OWWYF$=FP^3K50W1$:^X_FN(
M@]<(1V:^$'=JDX+BKP@WGE]RMU[K;:%=2WI.5%7S&V5.GQZLBZ-X3](VD5?
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M_Z 0TT!!<.>B=C4/BFQWJO& T)(V](IHL3!>\25K9RY9ZX\S)X5 >^PK=\2
M#M1+,_K3IRMLAKC@.,JL+K%N?'[-"&XT2+:F:H^I/>F'@'1V2+;,.+&6R7;Q
M5HVLIPT#E/H<3=C<M$D,IL%I5&VD4.U*O<A"S:W%V3;'P>7UM%+$"EJ$:3CM
MCEQ^N"\ME[)O*H2P!8(Q#1%<L+.C1*^Q&P!MH-[,T2GXWD$@Q5>*-K= 11^$
M\;LCP7AR9"+::KQK3V*^43Q3"/6S6Q)P.6VX5+-A[8V5A=PW[RSH]G"KWI/R
M>\$@QL/X;1!,9\^OBXC[5KK>3!NDA!XL;*SH.Z('^?M&V<_8IFA,7?.:$?[
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MT89%.'#WHM$Z9PO&S6A(X5>XX*SWBMN1\=[>]<XJZ)W9(7']]U2UV/0K5C[
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M)"Y=:[$R!A$=;764,G!\^ZH#]+)$?E-9>^G32_)1?_&#-%R&ZLR9,N="7XU
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M( E1%B_6O%$G_'H>:5:YRV3.%2U2J\-VIJSV^#UQZV.>;?JL9=UPSM-:YS$
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MGK0^0:7'D90<4V+Z5+H&7%(6_;FA2E_!S^#UBM$%"=.#D_[M<9ZD=,FW]T.
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M7D:+=NRXW_9WC@*"4E"/@X6)DKBCQ%J^D >K8.-5&CQ')R*N.L=;N*W>%H;
MB_C:Z;K5/7*,#R@4VS5+-:@F/.D+!1J+>;DI0&#ZLOEEHZ)]=\_N'KJ]DUJV
MT(;QT8TTPIK4HG@=HY:*EZO5/E Y+?_F9.T FW1-2;]2<!)^+"J-MLF:E[AO
MH0BC^19YJ[=X1[0N\>/<'[]+]>N%0F8D W[5YDZ@).YL>S5.IE1V@37I/*%Z
MV>*Y'\^0]D.VH+'P;JGHEP:^M@N"]=<SA;#SB"+78#J\3(UZB*^SI[??IO[3
M_K_]Z-_&<M]@/O-3J-IL.:GE'OS(SW>K$J-1S&. X/91SC1ONY0JE(O$KH\O
M_BH%>VM5YU'!CU%:I<<*THPG:A1DX ])S"-LV@P9/%!M362&<?R$UC3$_9>9
M8T=3C(%%!W'HD>K]2CL6M2IT8EI:ND$(G_>E#9MKR+<;0-09%PT4/2"YGRN>
M2-3#L"7,S7BK^VU:/):QJ$F@NHLN:[9<*B]QWV/4^Y0L'QXF+,QN\ID0,)A[
M$0L$ 6,4*A)$X(5W"*P3_?-X-,B$T;QL&U'ETRAW5"&;P-.';I%U/CY^XS4.
M"!X-U"04X6X &\"8.J3>9F2"]J2,F_N:03@C#)X)@9SIY07H6<1M.+HD)BE-
M.1EENY7PAYKOU9ZF4+MFD9OI,ZD5H*Y1J&/A/"N5X8GNF?I'M,.4(]^B4B[<
MF'U2'DA\&*["*6MO'$7];Y4=_;<[ZBS)G<H:;8B/G3O=WVY$AHO*2.?E"?_V
M:L6TV<B:-$N$.Z1(MGR6W<PE9)Q[XKN'A;M3?*\9IHZ\D]1[KEGQRH=)]4'M
M0^<40M)@Q5TWM^ ?"_=NZ;5//^Q1=40!2 (>4L]>J5"3W0# UD$I>KB!KB>3
MI7KHA!IAL$;!O-EF\I1Q0*6=[F:.J!B-$OS#7=M%OKF\% KH<_>C,]Z-3I[Y
M'3V+L2"P:?KWJ5SPFZCKR?II7AF4'GNZ,/+[#RW/C"_!NMKKU,EK%$A]/+7E
MU"'\,I]\N)#6'>*=NB^Z?&Y.Z<]N8Y^[,*HZ1@>6S9K\\\@A]1[+]X/;P^V!
M)-,W !"0C6B08DQHK+5!$^@T)VE%Q7N/R*9DNQ]4,,S57LB96*RN\+6$T?HF
MJ],G:TUV?+Y%<GY6N_9@# 0NT=X0*NF&'%PQ+J(7>[(G2/V8:)=ZV1]186%C
MVT4:QK>_,+[V6YPY4.+ L.ENP.!3,IV2I1(3E6QL]VXCIR3$00]^A[ZLS1$*
MT]KQ 3#:A=Q7\L4]/2_\AB\<O-+NSX7$R>B)AZ*POP9N *'ZMXF,J83BZ^N
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M]<^A$P-$9 (X[U*1Q7:FCH>,SOW: FFL.2F1 TC-#WU8;]PMBM1<AZ04TMX
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M]_<?_ RAH;;5S<"3YH8 KO\G/?DS^S]02P,$%     @ #4!T6D_7;;NWO0(
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M!\0X'^^J G,W1/-ZUKR)\S3-.0)GRK:7B/$9_&C4C\!U.9X>$RH<JPRE/+=
M>9T?+)TQ;7TC5.ZNNKN*=8S+K75&4SO'KUB3Q]>ZNP2"J'(C JY4<30I>" B
M;,%X,,CM4CYT.*V;G6P'UX7I&A!/+1U!H*/5@?B-2&NZN G<73LFX8OH+NCJ
M!,&_CE!MK-%2]:[UO9G3/K^SC&W '3^H6?EM\0\PSDFMNBJ4)'3(:OSY,-M
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M3/Q ,KF@N9GIONQZKE<7$\ NKASO*YHEZ 3ESGD7]C0ETV*UI]*:T,$=Y^\
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MN?X0A\@XN?\?X-J?/:<!K]O?D4><-UPWUL.\SNOS%3+)%)R&4N>""()OV\W
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M'!I\X;BZ]I9NP"/]_JZ&F-:C#89BR6S'FZ&'J8$* ?9'/JT^LO(CN?=+#)3
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MB33X*<L"LFB_R4?M[2)2=TB /\C,\)]DH2JV)#),7&PQS.GC9M:13!GLC]7
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M/9AYM/QH<\.9,R110I.GXI-J9,:C.UJ4-%&CB5E>48/ DD#*VLZQN@P7@\B
M=9$#$H NA 0PE2J\:F$]X6R3;CJ#)%+5RY[??M]3^J5?4NOE1ZB'C&V9KQ%K
MZJW?WQP_R3DB'KO>7>ZEH(_$N#:\T!,X<6;>3__[/O]:\H/.5 .AA "/SAV1
MU]NW(,G#]E**0O0*-NG+]P);3[0P!?)'I:LTB\AM:1Q&G9S4DU"F<]B;<('
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M- 63W]]5;Q/CB"6*J5(0[,A,B J?(@&N-&J>&>#)8_7[!?@5PLO10_%K+]9
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M*]*O%[:U?+_WD&@E _D(JO&%8,'P:?@1; CT)BD.)H[/00\FF$)HE9D6SDB
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ML_6R?4S5?C I*M=_QWYNVMC"LGAZG"^ 5YL?Y@GF&53&;';1P/O>)IGQJ9$
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M&%"$$R#D:&XE63O/7\1S<>7H"@F ,"" _O9N_"8O"TH"M$#0"5.1"BHA'[I
M+Z+PF'6C5!+ %](".<7GQWRZIN&MP*FPN@[^#T5GA>Y0F9<>N#TBG?@N4^'>
M^LT*W?#I<W+J_SZUXRX)<0C"X(C/WOFU4B9Z(L]#C[;U_P=\_D^/!*ALL<%\
MG4G.QL3041*@%7[^+83ZP,_%?+>0;'DO"4R'7#^1(,(M]!"$#R0 G<T=%1)
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M\2SF%Q;E]ZHJLE'N#/?SW[7?SS..3DH0\3L6[WOA\-JD:K[)7YZ[T%XC]95
M\NJ/I/*IAQDQ2>[%S\A;W^LD4/*H"M=F;+A-*9D[E$(_1MPS![R)QV0QW#F)
MT0,PLR[!A-NX;/P ZL (_Z"G/9#VZ7N'Z\]^L0AIP]'4=U(LFEP->X3X3_E
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M/29*?"GV%!)A*O5,Z_/^"@_Q$MF[WX"JM+/I[7GC#XHM_!C%2N,@LHYC:E*
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MDLV8,!T:P$NHEB?D$,4T:6=0\/BN*OO*G+V=7>W[>_&/[K8H"C->!#V=I?2
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MMI/K?'DSQA-*%5=SXMJ3!I2X>-1]'L7GL+0YE&$W!_"E=&M9='^0E^#Z+/1
M0#O]0K&F?GR[=C$FBL&NBRN;T:>_0]XK&Y,E+M.;(T2_4D\2\&?8ZX2M)\>\
M:7*TEU;A#)P,Y!"P60U8-KI9E-._*#6W7H(0/W\AY[U[,7N]M_[G\O+7X]B'
MJ.O40=K54(V:5#K\!O!3D8H3<'[*/@]L$'9B="[ ZV$CQ<MED\Y$BR6NC([1
M.J<+RP<7:\9OE<OS,O6;1:9>> 17"#\#.:+?XY@P^%!<!;C#4_ORHU&D(G)4
M@])(\NTXXHJPU?9!T7EFR8RK?)%GT@^R9MO^)S&L4L^^-*O\-M=)@PBB##:)
M(20 :Y*!KKW2 NQ=10+8[9_V6M:$Z9BLWLY4I<2E).PYQ19%_1_=%H;\@0+/
MZOI@C'"D]D53XI>JS_EWLF?^?EBS0894/79)YTIDJKAND(^;4?;BH7^1J,\:
MG62&J<=B_RP</TAE>(S]-)3)GAR72;@P^U0:83IA;!ZP$KT\9,^KPU&//H%6
M) ]5;9YTKJ]95^?@Z@W/0.KCE41(.W:J_E"!Z!UU!GJ><,YS&H%BTZ+Q)X[@
M2UMA(?/,(T@Y^.7VC(#WPAJQ&CM110W@KQO<7&BG4'-H8<S.E;GN,Y#;D]XS
MD'3I_O4_7OF5@'..>_AV?F4%T;ZQX2C]B>W& SO=)VPR,S/PC^WW<I6ZO[LK
M);%<3& F*FSJG4B0M4D'N'88/7(0S*)U=?'1MCC&@=/6=F;.#OI&$>(6!!5K
MK+VYIU%>(S+%D(DV<[ 9</<,>D*2*>]X?;GB1ON:6'AYU3S\L+"XC-&LR:*5
MO1L_;MW%431$^#'<.I(OVY2[K/$KC\$[PT([Q^?A?K(Q]"BNMJ>P1V)_N]59
MK:@N%:&MWFO6H9<G*7&<G"!3CZ@>,>V=W_Y+D8/@HQRJNS:S3X0]<=4!D4@(
MV7:8(K0^+W%:0 XN^EMEL]7TH]PCP\Y*\=% \//GRB?M;N:[PPOGL&)./:S-
M,I4)8QBBI0(@<[&Y5 @A#= NL$QEM!' 71 F>,ZB*9K@B8UYK$7<\VSB!72+
M;#PH0H8'P-8!EFE=1+,O**8R]?8DSW)2KW)B-&/"3#T&D'#=O/H#M\X747"B
M0M89]X^9T]_=,Z]M^)WJU#BJ8I0[ZBTF_^*;U0T37YDD>LWR>AZQUX'@39D3
M$<"70,DC1K<=(@'44^*.]=CW\26B\_=/RN-6?)_@VT+;1N'MK9.S4(%;FB;T
MO<'+78+*Y0U963*7/P^JE/'&G1?0,$]5U>LL"OYB>^?+6+(QW\T4U1?C^AQ
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MX.=U1B9+S']5!=$SZ+=4;/<.@3 AP L)(#@MH2M"2Q'OS3.W'HA^7\&D,_[
MN<C!,ZG'M_#QG"U,N?^%PDKJ2DVR1Y=8K/5#/R%[ F82=GB;&/\%E0\/.GQ%
M/-]8N8QOJG,K*GZ$]7O!MK'%.&RG,5/7_UY*TH7AG#K^\&D-]K)IB22GE@IT
MJ'.\?2A.^J??;+[I_>1V71L53A5UM8[J ,F<WWI-')6:L@\0?\R\:E6]3D</
MH@,=BH>#K<GIJ)9;%=[A.M*G)1CG@3L&P$$)LAM=D1?9;,]BD+[@G8"0="Y
M")&$8G+=N<W=,Y"I6D3/7]I3>Z5?Z]G_6BX/'/QL2$H^:8)127P7:6-1<C.?
MZFF:IV@M<0(F<EYDPH_E//!]!7OX#G D,$FV$!%WQY[P^4"_*_\#1^[3;[N.
M<5F7,HW<'GDF$HT7S#]1!DI/;E &44+*)F J_>"F7 %D%E@BR%J)\C%Y&QE.
MNTQ2V5$)Y>N6PRTG-=/37*S%(Z&_0,R;0I&$@&9<N,-%90B@A^1 :!%Q[Q :
MA;(*[M^L];SS3']_B-"<"4I6V>SY=8T[->J#E)]7KFL6(N!V$W.J2GB^5!<_
MO=[#,%=.>80>M/>%O-?)X$2,F5U5?8@+1XU9:U$N2<DJK-1=<VJWF"U0CAT7
M-.?I3/:@]#E4X<CL_(1\,ML$OK1E)^Z_>^VE2;!%JXB#+^#6+'% ]2F> &G_
MO"/@0=%^Y&!>61M\8ZY$)'[X# 3+DJFM=%MZ(^<4??]71]H1R[3W87\\>.8S
M/F%S#X^]3.8^C:^XC)U:;:V+>'^BCW@(!&<#79V/^8>8(_-/$UH2'WE2.$BF
MG[@*O]GR%&6//*L_$6PG:=@96U@D[(]XG3!0NL<AK'B@P/%$FRQ;#42EF^-0
MK0X2:<@9\1&]*ML8*9V)I3<A-^X8>GU4P-$)>7X%!DX4D-2I__ZG5$<*(43L
M:N=/8.QA6U/ERRNRQ$Q%L&F5BJQ;%\>^Y]6MI"O)E;_^\KR75301[1 VSKIG
MX2]QC*M<2GVD?^-EGGJ=,4NBCGX.MV<E\QM)%<#%!E5IW)<J\=EJ^<7$ZY6F
MM<9-<B)9G-+)#O=9/0RFTN?!#N<2A=CB)6*R)KQJXG:,;B-)_@1[^;9_E)]G
M$%10%19M6^44?9F& WG[PF[GKDQIPRE5+SUUI1[* 3W1G)Z!,\"FLX[N$2EA
M6;QE1.8,')L_BJUPLN-IL<2ONFOU!IR4X_E#;?L2KU:HK.B;-M035&7UIC8>
M]][A-V;KOW,UX% M5N+1@L)_+Q]"M:K<K/.KW9+;SHNR+GY?FS3[T[!J87PJ
M0)_EWX>I9U#PI=.P,Q ^Q>&"SB4D%D+3($?"$EA:L0((%&!&B+N!>P DN#HJ
MO[]9[>[Z/&3=6V-)JVC"<DM4LU6?)_E=9I!,O,^ZREA@S=T\@:/(PLXO7W\:
M$0J>%53G+?9)'%>^MK+"7#,0(3#>"8B7MW3/VS$Z*4<,/![8GU/&!=MC4AUB
MLOB #N+GPQ+JZ-]XX#@0U-0DO@"P9D\!5@NP#AB]NY *,3Y.>2#'M&5_RQM*
MDHMI\.)(@HIO?UD5CGYH;O8)MEY*9KW<W$0W<0;R1DV?@19P$4AU/5)7^S35
MFC4=-9+5.P1O+F"%SX^JO%126?5I_Y'R*>16M/;C^<L560&A;57=0S$JUK/G
MV/\]!VI/5,G,P"(A2AD<Y\!$G0Q:@XH(M2V_4T?3I$-!%<?WWRQ&])+U_!EI
MK%.*7KR\KO'V0GZ+PM01@;O9F[&+@ L#,R,DB8N&=5'\W0V*^4;YT[#EM)G?
MF@7.]:"?;W7^;$GX=EZ7Z>IZU<1RHX_S?$2X!/%C=,!R7N_.QV?B@^LR#U\F
M*'_+[BLZL-%Q_KN<J:IU_LW# NLQ\VCC&UZ[34B7S1FCBK3JRHH *^U0V$C.
M[PQ<7TVJ8U7\@MJWV0&.H?Z>Y33Q&,V9G^?-JM_VTX/PV^72]WV;>275-TU9
M$$3?V8"?4IQ:'Q?,QTDR!:G'XE'472N#],_/*6$#?W<=W0J8"X'@Q<#KF@DP
M&_)Q;R9Q[-J(I?FJ^_1$@^V8G.;CKDG3C#P]E3H3E9FY1G16^N.Z.:XKR[IK
MF21@,;[I$Q:QVJB1$YL@]^9O[<'B>"X6M==E4Z/9RM+@> ;*;4_93MY./AE&
M_3#3NRJ,0F-WJ;!X,,9H(T6ECI#5C6/P':.L5Q045G3OWY]S0WH<(#,]"0+Y
M#&2*24?UE7* *LP2J7M+P8^EOIZ+_C]O=+R"IBCLL<Y4,]Y\Z$-@("T@E.)*
M;4(!6_UCZ3Z-'N]_/9$/]G-$)_(EUS;^@7O?,OQ/]_'P58R@^PV6U83.MUS1
M2C/4@]"4ZF*J$?K4!JDUOE#_&B7&4HN1&J3!X.N^^KIG(&U-7P ?;'A -<[<
M-1.%WNLF4RHJ0*%:>U1+P1&!R5"CQ T*:A E^M?=]PPT<?COG]_.K?,<9O_O
M=A].-5L)-_%OB#HT] @H\]^Y(*J9X-7=;V\9I&] L,=_?:X'"L3Z\]J I*_[
M @<]:VOQ6;A2&QLIT+?H_WVC0F3H.NX?ZX^?CRCX?]64,#>:?3,]$,?$21QE
M R5J^ATSZWUD>\P'BOCO.N$ONB>9+"6:2\C&FG^'LKNC)PFWNXA+P;[HMJQ*
M:=ZOKTQN5GD%:J+NF4=GVCFE?#MX%?C]E"& Z_[L71*T(2<[KOGU_0?JHK1_
M-9Z<1$>Y5]4O?;QH+7:I9'W9EO6#@6AV+Z&L38$IT4:9)OZ\+Y;I=DYFOG'F
MLIG:0*]TK;Y1@<3\VO<16P\NRUBO[8Z.#K^8A-;%J:[\9TDV>CQ/OMLI=:_Z
MQ;9SBT?1E1W?TA(>!&F^2O)P*/^^\.JMOII.*.VOEIU$7(E'Y\7_%B<]C[,R
M.<#=G<4%LX&K=_,BGI2-]+Q6R,K?Z]MQMJQXU[2[Y)@MA@_]T&MT;&W*\ L4
M0L/3W&K@RB9M/@Q-<YG3K"CYI$[#VW--_:^V87,/IW<Q3X?KIONTXE*"K$@V
M3U[NLU*W4O& %Q/L*;D[$G.I)?--X1='BG.EG)B$XQUOR,;;F_7^)%B\I[GE
MD'JK65)MT/>)[5?U%K$T2;%=!_[RT50UWMN&HL(G@[>T@P0HRN:'' ]3<HPS
M4NP7Y2W\QL9&_F[.8U:_;=<AG?7+]=EIQ=JP3J]G9$I:/]^,^H6KLQ.>+7S;
MGB8JD;<K*ML>NG?]F=+N]H,/,Z]BD_O8D]J=5B6^?ZOTV+I968^,*[$<F=_6
MV=JI"MOM^GU2STFHCI\S;K]9\/IU3X]L._KCJAACIE/6JQF>E,[B'JRH@%##
M*G4",Q]T#]!&FX4]V>'X-OS;T^#%A+1[55:&YZY# <][W6Y!%A_8\HA@W6I-
MIWHNW/%#@9^^%%3?6E>QC$><Y9G!@PD!/[&'%1;:-LE>/5X2<^,G.AFJ1W%5
M1U[_ZE,M!^=XIZ[>&A:HCQ?<-1*NHE<7RX*9^YH%ATP9245H]PN$/7O+>:P+
M>B*_N90X:"3LWT%F#OYW,OP$E37K"$DO9O/Y4KNTW#MB-]!H_KMRIC+)Z/64
M^[.G)]62L-D5H-9![J"IZ@PD\F[$*\;PY!%41D9YO<.5AO^E[G4=US0C49>M
M&K$KOI8VYU_2NBX_P6^KB_GUJ"\*""P)Y;XN^&?V0&I/1=K&/#9'K6=]-)O[
M4H_V#D\UYY2FF,7<3G!0RGPG+VVA]XPPPT--+QJ[Z]>^OLU-G/275!=X8(JF
M]SKY;DY'<]M$S./;[)5W%H;W2Q-7WD+>O,.(1C?J23T(U_2YK6@6'?;&HIC9
M'99JNUE@; [UK)*H+0WV;NS]-CCG=*/(\#?7[.!/CN18'P,=8&TD-G:$'U;M
M:GV]E[PCU8' OQ%YCBJF>W>T]\=B6GH@R+(Q?T?=H6YE-M.KLF3_E]XN62/0
MS8PR6-4?>T5&@^Z\3]/]9D;AKNL[S0K+B35O#<5\DMVKTJ_2$7.CX\4F\1KI
M9N$N=$\SJ233-:!?_5SI'Y  PX,PEXP41[&%KZ.I(]$I+M].\J0ZC6P7HH-"
MQ^;6YXL;[?<W,'H3V8]L.GEYN(]5!5ZHN;S@_>@4\3Q .'$ROF+IG6-"GZ7/
MC?:D]GHNL=VN)&ZU^S"0U.!YF)ZYY0IE/W/I#)3A_49G:ZWT^*+MP<ZZ.?02
MVR.).[)>WBN<#U/'U?DLIK$:M%6N7?J(5*W09N61_+;E"H\1B;78;9(QZ=XV
M5$#K1\NG"YMT$"E:D"/(X5NZK'>0S%'55]>F3TZ;216LN65?^D2NY40TGX^1
M.O\>M"I9NS-@G32OSH^<-6J6;]"4^IL;R]98E1S+WJ6FA'<"FZ+CA$'G0/@_
MWY*3C21OSDZ?F.0V;@5OL=GL0W_+9'FGJAO]D,C>@?AKVR0XS03*J:"T5H>W
MQ#T#G)X=CGS^.&G8=B/%3_-8<\+S ZUKIL#+:]@ID>G;I6FF_17/+;KOI)KW
M5:1LWE\V%!-B/I_8P1G[L@8^,!K'8/:#,OLDI;IQ!U=\Y!T4EB]=WVL*LY\[
MPJ$VGOTH?V<XV72_3TD,=4U3\X6O2"S]9:>E&K$1O5AUS7>)1MAT&>[8P"N1
MPD_VWKV%:;%:215+&G.*\SZ,=5DD]D(_%;[V]E+^DU0^W;HI\*T0]--8?KC[
MZ]NXT%[02PZB^@$!\ZR:*37N_I4[W^(*)/1U_.DN[&2&P(IMOQ4FW4QY7NLT
MD_1WIW%L<V9]DN.!:97^;$'8Y8I;/*=HVIJ8TT?>^O0M+4O1B)LO6^.C+\N&
M562YWRA?NL)1[EMVX9RTV+6W(![.%]$?A_/I<AA>FIFO&(DE)37FO:#L30P<
M/5NV:DS=\DY_5C@UHQ[5<"7YTE/Z25J#!LY7O)0KO:]_"3@*KP:P5GUQ6_1L
M33)X2Z?0SW!+5(;^/"US%UU\^Q.+613:S@<B2DV<>84!/N:!/3(2\V5-AT%G
MH"]3\E>"6A5LMX#4K''INU!AV5])%M D9EVS!G##14U='CI&OPXK/ON/][D@
M"MO;BF#9[BM)A=)V;V)ZNI^')MOPK%)Y !&B4*SPBRYY,NAAS=SWS>D"AH+*
MH(?Y ST/R/=7TD4K%_NGRYV+V:!WJZ!]>@#G^+28;'>-2S/VZ"'K[G?0)#/-
MU5>9P9<2<ZS,$_:DU5MZ>'DZE?Z\&CE05Y'@/XD[9B'E,)UVDB.!45EM(0NP
M,RQ5DE/(PBDS<WK?]X6)YKQ)XR3*8>(@^W,@<N!*$D?<-LNVE]?2IZ\1GI'@
M>@/$=?,EUIJ"SD !E]_+34DW*R]LJT8;.;UK^#%^-VE)WTE&:\KA]U=948.V
M%T_R>9_&:5O.R7LAL2(IMN^YV*4)7V=YWG2_85C+C%"_KV^H0L:<@5I,,/C2
M,Q KQADU$]D,9M#AA.<WWT=H !:.A#C'PR_$PU_5Y1XV;4!;^[@0Y_!^(WWQ
MY[[JIM^ACT94/N?6IHUX57A+N_+HU[1>B2R/=>3QW-:ST?B[;^,1,9-4\=FS
M/,!A/']_LRYN>$[7^R9:2[<X.\T@[M[X3VS]0-RVX?T($;5CHR>SBWGWJIT=
MN5E>9]V5N%O[@.]M9E*<[*=^-]!,O?? 45E]-)6 4ZT\WTA$A^BH $>$\?<G
M6F03TFK;&2AB7AZ X,] [ @#XM89* Q#X!E5P<4W"4^0-?$WR]...JH"P_YH
M[T3L+"5WESO,07FO;;Z$:"(XJ>V5G'[S*TR(I-PXS:XP,2"@PUY /$ZHY? (
MA0O?PPM0K3 B%E9%"IUV3[)9MXDHUE)]IJT C?Y[S08FMB:;MM12=\?(]FY1
MVGNYHH8PE,/]=2NV&=FPF>./MR.FS7SD:7P_8*[1X9TG:;LD\Y5FYZ$"0L]^
M=V@@ST";"1%*>I=.]Y_="8GN_\OWI#Y'K5D;D\Z/ A0,HKX"!>XDT2X<XTX3
M&-G[#[<Y01U>G!#3[S&P<2-)-1I/HA0O%+/<RAJ%!]F/;GF=/QA,] 2GPP_-
M;T%[5)/"5%YG73P#A88J@]_/ZQ#1+9 PS.^C=C OV7X< =&I]2;T[&BI?+>=
MT?VI$MX549IN-49VSW?/B$\4_#*HTA<DIW]D;C0_=C5&0O<>R]J+F?M*>BM:
M#_3$RGC'N6(NG.?5Y5],<Y&I5:/;IA7(,/1>2O(63X(OWXUWM7I+(_8@R<Q*
MO4VOH@B_VBM;.[A."?1# PJE;5@VCT"Z)FZ =G$&=QD=8I/0>0:*;A)YXZ=T
ML:U1Z1Y)OPQ?X'=J P&,Z49@KQ:8A&ULOG_R_B%2.<O6<^VN6.)+/Q9 S95P
M$T.\LX#J\(+@,0D[_J7G@:#FQS>'_8(T;67RQA"L),L)VP:BRBC[G9*&![A'
M,W]5XQ;X#5^$D2H.6Z>Y781!*'TL@E/LXYS(S.UXUYHD[3+YM=N1!CWR0^5O
M9-_2U&=]/9>$T[IQ(UV^D"-=_.X3NV-A9W.U + R.5_6.),]24WR^#T)319P
MQ.,8R>* ((D9_!8I7C..E': <4<_AZX%: B%YAL4-25S^/)[<RBM5>^Y\$_P
MI?0P/+/P%<AV+'4#2%3W&B&F-SLDS%\!' H0O!/^I1$4B2NVU;&R_JC+&QJS
MTW%[6I9[:]ZY\"I/J8K15Y=[! ]^SQXC7=I=K_'0_KMD;W2HMRK[)PW^9>5Z
M1*S>C4]7]]Z<4T@I_:B_D+";G/:#.?M'415I@9=MDV<3_=)(WIFNO*$L'.+R
M,$8^1U;@ASGRF<&>RN(.H% =K>(0H:,\BN1!]F*N5)R!>.&AA-(M^@7<6QU9
MDAPNG+OEW_;G$VU@3P\(6"QL]!@?Z4PHS)&,\F^4V4PL3I'_TY#'JG\K[QNJ
M):!R)Z(.M1E 8(G%G:L\P43C^"A";H_5@,\+:D*M(ZTVP268!4&#MG$SM^E4
M['NO+3EYKTI^N&263-7LX;LD4;'!L@\LZR*#1@)][+W5,I>?J[H5\O4(BT%9
MXW0O$7^U/7W?<S&B4V&<.=3?.]@M(_RS_O/216CW/5FQ",N:_B1[O6OI1B*U
M71FQOV]L=8+.5?_X_Q50/.R6J<9B)8_WMNH2I),J[=I0KS!7*<I/,36X#V<@
MJNPAM+_L7=&]\E"LV^KE/13K8Z"H#"5[.,+1SCZ3N+II]K(;[K^[H'GWNUOT
M+P&O&^=NW!HLVK@:?2OZW>&7)OCI(*%[3S')2JT;M/J="6F):K'#>+F?@9YB
M)R>Z()Q:X"+W:5@'[LJZ#>PMDGW6XR_SEX!%$_/U<9>,%0X9V?$J&V.'02Q?
M;4>5-:_%;YI_;^3&AKL$6YNZ)>]O2X8_S>B!:]IHE24N"<<5Z8_$VZI9Q.^N
MHS)F-;7"G4,N1^G5N-U_X\-V!E*<$5UY^.P&Q[MF@3.0"J0<0N;FF]\[M /D
MO$D&>K X5"4ZIDG%$U)^@(G0HM<.S_J\L,,#P.X3#[[L1)U?J2YTFWZ!_CX+
MB?+*J] (WWK?M.L</SYNS=%.S:N3_!2&K<6$:*LL&B" --(&?@HDDV#MX(JL
M4O=7XN.IWCEPF &@3DKO<&#>(LO]L&=R?%(;(L<K\N:IY^<WN3']\7]S&-^B
M='<*<#%]A8^>YWXJGA=<L;C>^0LJTOE";ID!YR9U+WRQ]><WYX^,R8*=.3^Z
M_-BFGJ+/Z47TWKNC<B1FY&=7J'S%IDJ=)NPGX6,Q"HP3.@/A:\!50I\6(3$Z
MD@ G?@!B3S3!M6&G/ML3QV,*&Z//0*TT1< 9Z# )34A_G]=0EV 5(G.BP.I6
MU79O>'YXY\%NZ;:J'8^HI?/IV]-\E!<X#LQ N?;?O38-8$^NT*\SR)&LJ\1@
M= ?4Y!9Z2\9:Y?70S(-AY;Z:;:$6[GY,QB5RS]*LXWG[MW.WP+^YJHL.=WFS
MG(,<JZ#OMQJBY 7P"6(13WISHP*DVJX[KE\[W]1P\B"W4,PI%VF"3OJN'G-!
M?'SOVI19Z(W%HVO<=*L)R\GM8.)C%B$$B&30"6$FFQ Y=SJDD@\+(@G@MD;O
MMM<?,)$(3<(2$1Q)U@WR+.[UU]:P2!7RTG^(N2P>#1,SDFO]."LY_%B9"OPA
M*%<($\*.&- 6!(F@Z) X N-*6[V!>SO["9O!MUGH[1%V8RM#6E=%^MR+Z^>L
MU_ZE-HXV2=140(%T6)1V17Q+-0AUJSHC-VW$MB_I,$EUROE*NUC$M _T].?Z
MDN"?N^%:F<^OW8N1")3&<$P\UZVQB#"2^\/_:D_O?$M 6W$/J/>WBV*UQ_EF
M45$50($*=RJG54A-L@*01ZPFI&^>@8KAGFW0!7#(OS/0UL523[Y8[I7@.VT9
MYV?<0HW>NUK++M:DK=XOJWOO'*(B@EO]Y-.-XL(\/0,!LMY;^82"!KF3NP@4
M$+H(F[YX^.PSP?\,%-.D_<6SA0CW@(3/BS6B.VRLWFJIXHMMY-A; RWKZE:C
MB_SZ>$O.4QK9Q+JQ;[CE09":-=>T&XE0Y9>&>-GGG/9Y'][56C!?]VWUH:5!
M>_B:R%#6^/LRNVI^W%H6M-O%?]!!T'3ST"5F,E"\E,& &FWKXYN %V$.UGP&
M*J]NA["2GY#0G; (S&6R(EXDPZ1B9)YL7CVZ369%>0?Y+MAZ7?./'N](.G@Z
MNI0\D*K(F)EZC,-/D+E5%TY+NTKCSD#G5*C$Y;$.D+_839%>G^<CHM\5;6L)
M?N_ RVFVH1F5<>"-UT?_J!6C]OWJXJ%^HPW?(^^/@@<3'<^?>_L5/*X[^CW^
MD7"6#$I]G) ;+?/MB/_9I6>*M\O(6_*V@:N*G#QS-:-]@1VWRYJ%0R'S#Y]U
MT?TXME$&BW8;MG^R8W3!)+>?@4(6$59UU("YF- D2+Y*DHS%N$+!4TT3"Y%Q
M.ER3T*\&"U@0O/S64*6]8^>137QV 1 Q/+@[( K5=1;Z7+0N4]<;O!$9BQD5
MHA*KT/ SD N6F^PVI,/E!F$BN_^$P^S'&K0)VE8=599_C#SS@)EV"HN0^N_*
MFI@3N\>V:Y:!SWTG<;,J:<SYK"=:PS9UQLW@(<&.V0WI%D6IVXZQ[8+?Y7F?
M/3'J?GD&4LK7A(OMW8/6)XOH#V'K5&+[S6>5%5+[.#ZKSS,'?+WX5%(=M'I<
M1C(@<R=;EI]^.<!.0TU/DQM0K@1_DF4QX0P4.<$77TR@JR&)XR*M8/4D_3S/
MW.KX] ?U(XM#_I>ML]V\('ZM5GZWZ$L3=&ZB6MP@;FA> '>;E$#UWI))P(J@
M$(4X3W!@;<//O:8B3HQ#S?#F-L+"8X>^[J["3SNMUZ\^E]<JQ6[-WH*4R;@K
M<'*IRW^KSQ D+"L6ES4YIEWFDU\.T\^5>LF\\B"QIUU_^\2/,#[/]D3!(^D>
MFY&8+B6U]F:2:%6_GA-VA_9#B^$J<0_?1>;BU@=Z2+;X_,U^).?&:W0%=ZR6
M8S !_)["6YW1(@X\=?T&UP+J!%'6J943;VTV)&B\O,6+TD^6:PUC#?&;Q[84
MA@UJ- 8#J2<2E$G(><IEA ")Y=T^ZC(@PJ2PP+*EY[R J[+SF#X#M<TAM^F5
M&]E; _CLAJUG/)(GUVS("N=/IGX;'BY8\@R 4/>L-.(FH7[1;EO.C:_XC +8
M#)8X[<IO%]?8&\G05BG]HOO0Y)-M8U8D>^DWKD>P+*$G>H63?Y%]]GJTE"7B
MG(1K:Q21YEF.U@J&1>N_Y]C?3&B9D-B['%@PK@E3R5THP0I4&)]JN#_J_30E
MO)2L/22W/[*H$'GX6'5(SN^8;+N(9N;OJ Y]6!%/J@!67WIM7[W!^RM_=Y4
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M+UUJO?,JA1^.[ZH7[P:%G]3\]3Q6 ]Y348$>84@*:(%-IY % )J ;/)S0)&
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MA^'>JJ?+S_?J]!VS?#-D3R"U"5]>HUX=C^.(AJ53%OM8>K?R1_#R$Y:6>5:
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M@'HL* +[T/[Q.="81@HU"$018-\%'F]FT "#A31 (FQ'9Q1&:'[;LL+N3P/
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MYG%YC=_?6F?92KHOXGRN?C)9HYWWG,X3"_R5K S!# 3/!W@5)F9W^8&.AOT
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M:X.F(UN>_NHW[)W%QZ6 YFFF.]2[>>UN!^37<*]6-T]G5N9WSQ<M."@9NC0
M(PUP4F5\B,J2JR-XQ\AJW5BA 02H_$XP%HI>/6:ZJN4#<XRB L[AK4NNL&5-
MQ;#)TZQ7.H '@TUWWCNO8*?,#ZQ/&C2NDH-69F5(?X)$86\L*(^(LA%5-$ $
M<X<*?U8D;CO\D'JC9DP1SN)T>"N\&BQ@<.6AXP%?N2"*4UPEUBNI5'*19&E2
M1/B[,CA5/)BL=+GX=7_OV=D*XPD9E:!#!>=X1Y<,91!'S)=<JY!OWW)&8U0Y
M,Q"2!D4%(S.R"%/8JNT9IO-MQ9R.FHWN4H9+NKB'KV/QL@*:==$^;UA++10
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M0@A&74%\(P&F!.Q!\*CGK5D)M=""Y@!S//;"FNW%T2U3Z2O@0QO^V069H2Y
M@;*I=$@#'ONWY& BZBQ%W9=0T=DL2^3^2=AN>QK 0LITQG7\JB$Q?W=HE@D!
M3VYZWDX^'SHZ'J!N7YS=7-<P@F_0GR_(B132?_QK^HP%EJR?U-D^GQ;>H,0Y
MAHR(JD]")U'/[W09URC=5^TS/?KQU-MP,B^M?J7LPL0O\N9WR+A!=5VV-;UF
M!T8$*+B7"3AVU!M4M^2SZ1OZ$.I+#]5>I80\,1W.*(IDO+ BP/-HP\W2"(]@
MT.#A#_%9;C6;\%*Y4;BVT7R;$*(#O8E,X:NQ*VF9*L^+MU.X&]2:A/;8,?W
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M?Y 2(0D;57:UNNJ6#\*XJ2+]<27B?</LHWD&G:(/Q=R#L@)P4 )=.+;,(6B
MJL(V^ ?8&:K"ZK]SF<R_4V $E4V1,B<$MP:0_HG.%$4?[PJ8H0':)$Y2?)F*
MAO1%DY-YY-95).4M9[J. A@!B?OZ,CT_G3(R(<\7>;6MVOT-CV5?S;L\F\[P
M-?["DSKWK%_NKZ_:LQ]KC2\Q)N^6DF97J_/]E4>B ]G7V&WI1,M* N,&VUN"
M_6B Z%+F#O;(--<(SQ9VJU6>Y)HTO2F2G<GH7IGQ!)6JDG4>'.U?9C8B6;M8
M&YN3^DK[^M-0/].4N ">P.>'\3Z8UE]HE-2/:1LK4HJVI+T[M]4C69F%)C+K
M"Q/&W$>_MJXHHZFF5$YJ=TL-<W@5_#QIVXPDA(/25<N;)#+$)\2@<D+C!=OH
M5#_Q/EX\!<]^QL$8TNT8R6C%O1(P%/%3(+",\[&7>;\PQTDX;"[;:@".JRT/
M$@QX-*0AA(=QD10ZY!VX9V6^@*<P*G%[B3B?Y%;H\ +'RCL;3*->44"*;/B]
M,XXFG][7&7MR.SH^E'"8C %[NZ:D8#PK=*5-HL?)$UV%%]\HYMY$/(FNKO9(
M7.>:X%[;'K6'PC?/DC"M^,?4J<2N+!8UL5XI;K]%9'2 EF*D#+35$FKR!&%,
MOMK8_?0=7=;_"8EH%46YXZ*OEV^."(';XW4]79 %]XO6ZRUJ)J&#@Z+'KYY@
MI9=R/?FW/1)0_95RN0QUOU$[<BH; F0(19;41)1X-AET-D"?5$@6<01="KHE
MVSXX1;Y+"O:P*$A'95W5;SGC$ZS+A"C^4O&CXD?ZIA3Z"?PQ.!^<FKO+HXGJ
M<OU[2#UWJBQH"'3.5:H2'H$V:O_7EE4:WIY,0,5 .BHH(FE8XU$E\(ST?ID<
MMR1?;'Y6=L'TK %;3J,*!_KK6-]#=],_[_LTF:B-!2/83!5_E5=X,]W*RJ0]
M(]/W/XZ6["*=_G*=WVA* ^=/)C;4DQL'U]4F=C?=2DI=^=]"9-Y"P7\&[MF(
M0B-?6EZ ><J+%@_C]6J2J;M!=I2;^0CTF<Q?-I7W"*(Z3S[:"<R/G;XYO57+
M:F;ZY^F'DF!=$2679B>/E387Q;0,CE_IA^F!-K,M7!OUDL"[X9E67W)O#B\4
M81JASI*KA?E9/8=UG-\$P.;+[UX,GNR\4[?/T@K7O.G-*U<KJM"5#R\__7&/
MHO;,F 9 92+)ZY30QR=7:8#R^T?21E+^LG4"K+VPP J2W0YJ]1%?^M*NLEMF
M(8-(R%"P_^:>Z///A@Z@,7^J7:TF^\_EJ!=/#'%ZS89<[T\QAJ$$ 2PO$N1B
MXFZ\1QW9'<KN,'0%@,D/*!($G4XX@'*1"(O $Y8[C*+2Q'^6D)B-ZH(7P,[O
M5E)NN :5^%Q-F% OBOK3#14EZHLZ[$@]_F[5[ LB&".GKE:!!%:39U7&7,5(
M[])(1,;JB??G]?,(S:DR%>6V:)M>A^K#)QA'0O\5LA3*_T[/QZ^WD)?H)4]E
MP$72(%%R'MB.C:(!*G3"H4HPM,*<$?QM@/Z<P^*.'<_QP\7DDCRG8X/^O81[
MR<FN)[\F$X[BAE.A)G(_%X),?4:I+#5D$](][#PP1$-A7K=J C)ECK*"=(+_
M[CM;[*5CHX45"31 7"7&9"DE0:!NJ7F\$BR>^<:-54_,"_T).;$PQ7T_-E^[
M6>56YKGQ+V.KJCV7"HTSEI%$SF<21E-%2ES]6AX)5=@^_.YC%'M4F5X8,.N+
MZ!>QGLS13\('?L6J$E/ D98V;!R6-4B9HDG8[F@)TU(D--?-([A(0;V=7NB<
M=3-9^VS2>^J$).9&5:=^?NV(ZYNJ+-5SD-)SOT1#'"[%VP0NQVBHN[+EDTDU
M;3\MUBY'0 M=+ZX0+*S![9P)O=*A)YUK:-T@81;+',>_@9&V=R^^:&Z!P\Y3
M6X&$)[VNGZRZ$ 2>>?MHD'T#A)ER@:#R(4B"Q$KJNJ&(C0V2)2R';N[%NAJ/
MONWPLVI44<O,RGV7 "[(2633%5:U"7IS;#(OL:% -O$Y;*,! (JN45;LG=<;
M>0JI0_7P#B#0!_24R#8;Y8%@<@0Q*,V<8V=S_#SSVW)#"2: F4J%9D>V\G\Y
M#).(41".FI9M)Z8G26'3NFN-#R:]]%RL>[@6F:^7B.;,C*<[O4^$*VD<*IH8
MS&TE[;VKAY8XU0FG45)/^$C+!V$D@SG9LZ1PE%I*!_"LDYI$F,=ZDQ45R$Y*
M>3".#&JW9S"Z%BVIWYM>G:'#X9KY@GSMLE"FB9MP]KPLQRI5@; <KO%B?H)L
M&X+;5'DXJ5C3I"YFH&X^LKF-^RLB%\:D_NDE5FWAPX71**J6Q_:4R$$VL:".
M_,H9;;\1C1O\9"M.BIZ#\/H(' 2,;#0^/: !&'U@CT;V;%Z.8Y[%2=\<Z('J
M=QP<'@R)448MO[XQ4DIX"P6.+V^LS\]XMT,JD+_9V4A=[#]()>T09JH@R=OZ
MA[>%?7@'6B)DST;!/+I;U?$J_$E5PZ.MBU_S[XAIWUPS@J>]JO,2CGK7V:^^
M=O(])N>+"5E);'Q'O>J[EY&.+)@=WN<&VCW/BSURS$,8''DY]3=!@U*\#KQ>
MLYJ*)54GB,X";L[%?*?D7C_%*,>8D>7V4>^\L'?-$J@M3.:5FSA#<3N@P>WS
MV3WFF(#V<K\+BP$GO&V<\V<-QF+L7BMO+26F-&*@#5B8K,A$X::JR*:YM+Z,
M#WHBN08BS2!]<D!!D<S-ORU@!'<"=@<I+))?RI%W:0"X'0U@@Z$![NN-5>3^
MCPV<_U]LY7S\^7,A(P-*%-_2S#P?CW*;2-QK>3U! Z3,,JQ\9SJ>TM5)$GDQ
MY@+ :Y(8/37B?_]6[;S:5-5];6OJ[L9 AEN6]M;?/6:B4DZN&;8]S:S^$+R[
MRG.$&:P3Q:4[46-AJ=^TZ@9%=H#4^L=Q=;P#(&$$%6DU0+:IWY&%PNW"C?UW
M8X\TZY<U_4R:QUFLHWO?VE<4!.[N+H3$N0WJ]7=]CT[+-JU$+U8C[3VP]<C
MS+3-L6ZS?%<_M[#JRG($,G=_R^&I)6[M@ILW%''X@0H=Q5"NDU^I_Y"A%^\\
MO"LL5 WO/>',BH>W)]*@0\5LL\5Z!RMUJE44YDU'CQ+V)AH@/OOA$[(U;/?0
MD0: \?R[EV+3[?G2SB2!7@OB*HY,R6K8W:5"ZFD:X(]FF>P1V6@[A0:X!LDI
M.E][2J!\T\+N@XW?CA%Q88[5OEFGN/L  SDZKD21\?1O.H'I.269(3?69&5T
ML32 [@U=75MI7:A/Y?CQMGUA=E#4H$IU(=5V\\[>["T0&W898:*#?MX5-.7
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MS3\S7_/L,HD(D)[\#K=R+S5!#M*CPY5/,W5F>&M,**2RSS Z<W":_E8ZUCP
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M8-X/=!K7%?<5]@E,"!<^[K"F-"(2L,F VWQ?^KQ7#-+K[6_:-0E=J2L.#Y!
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M;I_DE_Y-ZF&/=<09S_7^C$1N8# &W4RLW1O AN$\=Z+6X&J^+CYT/]-3D="
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M6R58&)Z7G-5PO] @PA:@34[.H=RDN*RV?R>8F/SK=\I69+<\UYUPT8V6+>'
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M8$44\-?V@3XRD/E3WDY%77751NLIX:EC@_J8$$0!&[6JIDF"0X\4* '_X\*
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MLM0:5%^+^Z#-$+'N-AT8'ICKA6-^@K:'050!QQX;!OVY#"FL.&Q(<_NH[[Q
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M Q,PZI?FLWP)60FJUM&)H?[3FXTJ6NUSL5V";L)?M5NU=\M")+4?>L1DL1.
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MX .-EH?4?BDG)UGL]R=*#US\)F:G3H+[4YHS3T+:_W'2APB8V1 RZ/K8*P1
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MEX$Y=C=]3O4\>6"W6YZKH^3>LE=<+@#-IVU$QG7^]'BS1M"L5>0[5GU;>*9
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M^4C)"Z5:C[\(\ 'N#Q(N$@$UPM61,602$N85 9O@4YNCHO]QP=LR7[*Z%"\
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MMXM^-AT;AX;O)*R40U9!.Q?=_=#@+B"#"N7*$/E3G-,7X%4G%N.,J=?>M$_
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MKWYR!<3FFHZ;Q8G>]K 6G^OM+$P.&2<FT:4WE(Z (&$4N .4'K$B'L%]<8P
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MZ39R0#PVCVZ2N;Z6?"A1=5_=CWDLG^*N6 >S9-@3N9=NZFX>TL./!P!&Y'D
M.CS9E@9E'K*$2]CQ_]1N^=Y_K8*,-0/8_7G_] ;--)6A)(_P\_<T#ZF>^5%-
M\_FQ<VTX59 94R C#APN^I^UG<+T=E4=R9?%8\%U4^U+$2"6UIMX+ESJ\U*<
M2;<:%9JS5:UZPIT^O=!_?<0)LU3\,1]?!-LSM+C'.B-J&Q29],9>XM6EDFV.
ME:6WKN@F8QP,4V#XLR+8#M/4/1O=I5!M7KH8Y$[C>(E_5$6U<%ICT<9L;JC
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M!D@LR)A18R5,OV46'[+=V*2-IE+/%'^MJBN6JK-01\X<VL;7IK:LLE=)IU=
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M9;QIB$Q4 C\(O<(I\YC4WNJ-7->L07\$M<#<98 DYV*^XG-&/?:E,E:?FI+
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MS1H,Y\]D%?1G\?Z5S&?1 '3M$Q:"E@$/-09Z8:#M, H"#XYV[!XC]!V_Z#F
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MJ\*4FE^LZHVTZRV[?\BC]U#HNI;NON+H.!*URW._:TP]?=913%VDX >H]%D
MW/G0_-")_P2F7)W>A+)<9OO AC;8W"P+]C;EPEY'>QLV8=-=T+-F[UB%AH&*
M?M&6Z)A1SZD/;2Y%"A[6]!CCP::F$:W;\(F/Z1RQP%]TA[MSW9$N 1 T9#XB
MQNMCB6;U(AN9CV,'8VIU#5C]F4>Q/>WX,:MBC4I-=.['I \P7F&ZKRO-S!@S
M''7(D3S&-"7?#HXT@(I>V7ZF^RUMM]U4%*.7BSQZ7]A-2F67)>@/N6G$8L12
MWI>,,6G"690*7-96Z3P'/ [@FB^1:,MB1<-#15^8LES_CM2+>9_?_D"DBO%U
MPJMD<9V>GS\[%VMBQ&SXMGX*_WQ!/5W[T]104>XIEU5BZ>ZUA!7C0D,Y]=P#
M%R??]$IWV5=T1]%@L]OD>B7;=V:/[56]6GZX"*0X<%1T?$U7O?$\"F89%4,Y
M3,:1\>RMRZ[$ZFD411,&\?GPBR6?D=,D&<(]]Y#W=6Q0%"5+9;>VR'V$%#W1
M(2[QQ12I-0:6,#IG2IG<5Q,0U@\H0:K*&K4L^-V^HTOM4)RX:C6=H&M4E)OF
M9)=94K\A=B\IUSCV(M4P:^J2958FEFRL\6P![ Q],GV[V;'TBA2#BA:]+ 4E
M/0L9Y\&N98]/&^E-93+\V.J!V"J*.E5/5+8?FK8TMQ1%^B'A<!W::M,TP 0_
M&J#8./(:4C69VCA,[A7?+AHZ8Y/M*.GFZA(K0 >R8&YY;S8TP$]8G9:Z2$[H
MWDQ'';+!R,H4>KHDVZ _6$:UB%A+D]?RKI/Y%:0"8']D=>KM.-RYFLIR.-[/
MG J&)SMAQ.NYEZS#SP'.+03ET_(3F>+A,;.3!_[VPTY*0+=0I?MY2[61R(?/
MH;-JQ7V&%?* RQN:KF[]2B_YF>KEWRY8"'\M^.CL--EQZ0Y#6S*/"##4^2ZG
MN9Z2_;*ZZ*5)Q2KJXKU'C1J<Y?$W.[N9]-*]!S+EF5\VR^/+[^$_-4K-@2@"
MY/%I+U.,,6Q$U:,&;Z:5O54-J]:BL_-6/@/I#950+U4WQG=:>[CY,O:Z77E&
MH=<>AH!!BS^K[@G8F_A_T^CCW>A35_=Z7:FYCH([FX3[1 YEH/BL$C1--U[K
M.TD92@1*:.(I?<;D>+$BC[!A\Z@P;_@O[AB<R:71'6A.-M_PE!V1C$-9]U-1
MITUK/KI88Z3ON_*>]!H5UQ=^DD_8'X!SG8LW-'\]^5K<QJ4M5*7V2;I4\W9K
M;S?H>E#O[ V,2U2C]R(*.;5(%K:*1L4$<2A??CMG1H9-I2H+8L)R*#JF.\EH
MV,TY]O 7C'I.EMP=^4FM8NTOML^9FLAX5BT_M1QA:V4KK*;<M[5E=9WN\?(3
M)@?KY]NM6P_18HGKL_8%5AF<IZ@3(\W>!PY(_UR8:(8E.N-CZ&>QWJ_NPPE.
MLDM#H\T5V\[M ;5X#ES+Z4&XY-[#.+C9_.HYX!%"%H/,F]KY_4K!*+IE6V+5
M9'8(MB=8NW3:< Z $1=]--<YX >Y(,4G.?8A;9&[#'OZ(E4TX2054@. 'FX
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M/(_BU<&GIVLO132$/WC=G)H",U^25V"2OBDLSPRX3,?0_<C=&15?D7,?8,M
M>B.&,DAA_7##%TGH&BYG9QR13%P^![@+$YWO%W,4$Z=9]NTJPZ-4=$9P/?GG
M)!<N**E*<;VW1#R;D@O/$.%CC'=($4C&/JM)@P>5F1;Y^U[SN>$DZ6&0GB2&
MX<>O;-/9[DS*>@G)078_X81.7W^*H)_^,:!,=%N M@PEG_/LE][BZ\B ;M=L
MT2NYA.[A-LEQ#J*DN,V= Q:G\3)C9:)M@A53ZW9$_46=3G1/^#JUU%%N0LQ&
M0MK-H53V4NSG@%Q6Y:>WV$FV8UWEJG>\R20,Z#E ]L:LDESII*<4)X2D)21M
MJ@5%7=ZWT<78]XB[8JU]$C_:W15D:Y>@3>-3 J_XG^X_'.5 9!2[,69M@1E>
M6<5(KK^%Z9R,,^J%&6%5V^2,WJM):#S@?>\X-*Y5!GEV0+AL7"6D7J%>H'$P
M5:9Q+0).!'LIW">Q&KS'.- !E7YT9HV2UXMN8-"\NRI7>>9,O4<WQ$^KP@AZ
M\D'P66N8,ORX\HU"-]!3CD#N<N)%H,-^.<93!CH4@0E!_"GV/:7RLA#$2>LG
M2V;/<P!HN*!&J//%&7\9_I(R_I0-IT?TV\\!GRJ@9S;-C>< -@A&+.5PD,9V
M$O\SEW6!F]^1O]@=U'>6(G)I35C=DX/3+?[*:L:PGNX]F;?Q]B?V=$F/*%01
M3UTE!RZ+[+C@8Q P;*J\ZL;*[-TESXMNKZ(H2!"/?UG>$RVO?AI7=+$!FL8E
MBT>][68WMUHZ7'$2<#PPV*@VJ-^?W3[8=<^*J\[<AH0UO89XJYL<35O?MMQ*
MSB&\+#H'!/U.Z95+F]QR0&MV=I1S(*BWUW*XHI$U!O$X!]RM)!EG&3\ 0D1T
MO^&79'LL$)#FD,/5O0)5QU>WG$939")PE8^$QL]6V4R[Z1%JY(VF5N8.@Y:\
M2A9:>K(3;#MG;E-B_!NE:15!_E5)):LML2.L96AOTY8(%R$Q5@&^[C-^7+0^
M&P8C,0@IL=\03R98IT,<NF&"C0^"-9_/[;0MF2=T^2S>UC9LM4J**0XIN'NK
MM[MF%W(.,,Q-KJ\JDRDYY1% C7]$-K5LSM0WEP?*2@==O%\8U.M"U'<W(FT&
MYX#(@L#D<4)P#@%/2>"M@B-.][G*#/8@7]FSBP/CB0U_6)"S163!;2(+6G F
M[)5;A!6#[()_GTKKWU/YA2COCW\_TW9"/Q V?0[H"8Z$;=44Y'\%[2*A*ZA5
MS.<2<_ISP/OLXW- ,J^L+&MR>^76P?CR?CE_V6GZUCD <>7D0,Z%+=/Z\>_W
M')!&CX-9T)>+&(3#6O&KDK39<X!TMM54/NAU#NRA]PSBV8C;@(8E?^ZU;^RC
M-,X[P5R<2T4>^Y;L9YX,.XH:.WF..,'A%P=GH[\3DU0M^A/)A@MN%GS4T2<O
M*=7":1B$(';>X)I=AA*V:HC$L1VO03!Z^E:3V[8%"?OLV07_G/5S@"W>?P@?
M/P+YJ4<TD["E PI$Y5FJZ6_B_MSX_ \??V=AT?SYA_Y$SQ1\&R[K'[PR(.")
MR_?MIXYVRE>_=E=7,'GR:LE+RD1L[O;D.)F^%WM]L"&:.0;U/-H:QE^Y>PZ
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M.YQW^Q9*]%9=? OODG-N-OZL\P>XV:KZ@]K\A_8!G5#&U80JWT0GB&QQ<V!
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MJ<,'?1_H9N6%WFAJN<4*7Q?4^CAWS(Z)O"TA&?U,0$E^6KY+)+/C$K-?UCG
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MA7?@K<M'$/#)Y&)UTE7==)6F=!BOP V 6>SH,O;\71"$YU.FEGA#S[ _'PV
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M ^&.\F6GV];68RN6C2MS&7.+#OC=D+VJYI;U&,%WPW(]@*3;AO>T#8>D)#3
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MG82^KU"%D7!R:WMHG.7T2>I=]Y9P1=Q<"8:=4[(_." -!ESEQL(HXQHF>>;
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M1=Q3 I=R.O6NTC0K.VE']Q]")2UG]C8_K8 *Q2-Y"KJDJ;IP0Q3V^G?'BV\
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M1^^9F\H(ZQOQ_:Z/8V/Y4M.L#)>I5G,C;.JBPGZ,'U;0;36S_"&Q+JH\:U_
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M7[*\)K2FO)(RZ'E[6&#DE_D/IS.IUR^IG\?,R"4S-+^6_=1:Q.[V;?U^PP6
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M2237TA\GDB.X&:L^#^_.:;Q,?IQ##_":PBD[)6 C,H*<CEO@ME\]^E*Z@8"
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M>U=4?/N2!U!*4+G,W=:-#(X#<_!"FZ.X4.4^XKC\KG"MA5V\@-'.0._9=?(
MXL=&,V]L6_)?%XSE,1--P82,M^)7UJJ3N@"KP]AB=G<W]R^^#3I:5Y[<D@+_
MZ5J!Y8PSKQROIE1M#)RD9NF0)J$0%VB$98O,:M$;C5[!K\F;>U!Q%>F]_?W$
MZ0[""6\-Z*-W]",RVQP1ADW\J&SAM;AW@]BXF3$ROY7#7S-*5R&:37)D^_M$
M=/(-2^834X'V!(_3:&R18]T7AV=<E?.Z7)4T&0WF^68O[!)<)/1<0_X! /0
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M <C,M[2#E\WKYL@U3+B_*>TS)!BZBKFT:1<Y!%K,M8C5ZCX-K08GA9=9>E\
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M:95E9MU@I_LR _\1X*.YH4R/X+(I.*Y_B['X=&4":<#))UMEG]1-/_@GZ4^
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M67 LS2AIC_ZSR'.F="#OP%;SDFQ:30J=JTMOWV;3MPD/U4;[QS1L,.\;:L_
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MYQU\XF:307TB#WB$GA.L#3X^*Q0^5.&6,79FO3<PY_Y&3KN:=)(D)C3\Z%!
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M-X2-P:8A9TO0]PQ_H5/& ;F3SF]8_Q=4<Z3>K"@Y7'Y_;O*7R@Q:<.=F(^3
M$2-_0Y]^)D>PD XS =+V:WZ#ZO\R$_U':%.(+<SS)44VG,9-L<T.6F$=/70;
M:MDD'G,C3AX^\,_\9IBE_6S22%7118YL U/IGX<N3:$V!M3^   RZ@A8GV2R
M]"?[ '8)>-T\YR!A;\_?D7V8IQ<PW;$#2;_Q<Z3&AUOM\:JC3=[2XM-/EU.$
M$;F'0K#_]O*TZIH-;_Q&>Q^":E#_[GZ$9'GK4 (2D=W[]\+QSJ(Y/<GPP.VS
M_B2?7S;DM3M;)M@3\L_P@:>[_)>IGM/]W1ET";'RRQXH^"92VN&,%SZI_!E+
M2R!5-\U#\&2I\G=,VR9[F.&!(RSW6N^_!QUT0@ '@?%A+OU*U2B89%/VQB,W
MQVP5OWM/D@O] C7[WJ[W'ZT;]@P88G,_5O@LF4,GZ-BN. [!GUJ(P57&ZF-E
MZ%C])G<7-R<BVS/\M94]HKI.P#VGAYU]\KRL5_8H*?(=<GEGKZG9165R^?0^
MF)FN\6!^<4V]V]W%@2C%Y^F!K\3!),PK:B3^52$!6Z.AL[0;^C3> Y4<'+87
MU!K$%Y,\7H4AMD56#5:RX[9^(E8'U<X6PA(J,:>_SO#IYMK@ 4N$N# >*)]-
M!MQM>_5QWFP$"3G'\Z']&;"3-H^X7X\!I=N=J:!_D/X'&'"9,NV]<X\+6[%]
MDYS!2-TDNGBP&<HL:/2E$IN%6>,B:UH=M2>!M9Z]/5S\X4O%K0"7VXXKM9V+
MB*U92A'WYT^AO._88;_]CVER/OY@? ^$O[M\Q5O^:^8D;LC'B6BY]H$=^C &
MATK_%]&A$W9]O^5]R*Q?1O AF"(8&=&!/I#[:V'<P]]^KY7AUTA?R<J_:&G>
M_"E;O?(O80=^KY.X^\G-;$CI_7ZP4\10A32#MX+!1-RWE^=;+40['-L=^&$^
MW$/'O]C!T*<^8MO^-DQ=HF+TJY9'S('9TLV^DIG;\.\S5&4*T$'=L&PZKFR6
MDU7X?,!$2LE&'J"O>%_<*UD>OC@\FKME)$.\(F9WG$@W-9/-:#90^2-2 K G
M_>&22L7SER48_I06KO%;_#_T#NQ/_Z4C];_$#3[B^:4 N5^&^T6?AP?^.QEH
M_V) A3GWGZF@YTX90EAG<:M(@:V8.&I(]/AX^\=Q#B9,25C"AJV;:W6Y'WCI
M+75Z,%OAD340^O**^%UB8BE[<0=WZ4,;YKG3<$I2&9C,F$MC*M6]_VE1_C?1
ML]+=4Y4CDC1+NGQF :_X%R_F+OGQ9--,>H ^6*U<Y'L+*4,\*3,>6"4-7N?G
M2_-Y%,'YC7Z7SOX^T9H#54D75BSU/!Z(@^SR87-5LK?(NP5IF71+^HM/I),M
M162Q_1A"QU'XD"(MG)SM5]OM0K]8*;8X$@QP/<?-G5;BWEEQQ8&KI GN^/4F
MX/WK>!3KY7RB87_2!<XTWUL3>& :=$+(LB_"X-B!W[=&<])\*?[Q_9__!W,"
M__P1F1X52O7[=CEZ0/9.4<+.N7=O,:R_MVB<#M.M\8 3]-=6!6?NDB$AY?F!
M#X"_G2A<=@:"ND8HTOY^PO][B/.$PQ^'4HJMNO:0'?97;1[-F;U,2S))0^;O
MVU2@@_+S#?./5'L])"3(EY77U,[ZP*VG/G4:[AIXP!XZ^RB86]5NI^/7-I52
M ,&_8HWJK<"\G?;!JHIT'*"V&%0*SM>)<1"M0=#NXK"Z!EJ_-OO"[(GLUB0>
MB*_0J;^#!SHE<[VA>QM_O'-FOH;V5T'GP+NR6[,8+,'P >"S9_N91WB@(V=_
MZ=='&(TZ84P-%$6%N7)LA_,A5-1-,&S.2+C1(U^Y^PXR+&?7^E4:QM>#(UE]
M19DNN#,];#HZ3@N.)<L58W\UTVV>-MF-Z=7TRN.9F38J=;%S'18&<P",H(5^
M<'PQIJ'ZG()@)*5W(RZ9@! O./,LI7!'Z9#[Z\8NB!/YWWL<_P]ZR'^ ..)5
M;3<2ND)4@0=JP+_W12%GZ7]L?\HRAM0A=CEP+_]YZ1^C:-0[:PEES;G_ 4H-
M>T41]]<PW;__5S.[;-:GL"'%QM<&NA/QQR;9*&[M]U;ML+K.W\X&_!VC9_]_
MZ/^1H9J&[!,N?K65K#EBI)5J!T/1P4# #5P(P=W@*$W_Z93GO- 9)O ]9XSW
MGBP-4,M+=?D&T^X81Q53K:^EY)=?.V91A%S!KA7)>5[.?6,F(ZI?;)%F^^_R
M1=Z3\[HI=4L6+&8Q6/>TX-_Y!H0?_T]02P,$%     @ #4!T6@L 5<>Y>0(
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MYH!Z&CU#Y(BY #6R)K6F'%,WG!<*"P_.C<_**CYPCJM%2&&W(K$N#>&C\>U
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MXCV^-9\K EOMR?\+ H'\03O;"5BM/Q8C<%:8&:BC/_TV\[3;'7)&>JG)%/W
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M@DJ5^;6%>[<^]N%;"6-@$ZVW=>@F-[F#T9YN=[!.@M&T.X,7./KD\(H*U^9
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MD&/AGC$CWN9(2T%G_E6S@,GS)JUWY>4,G\BV/.A+R A6V(UGK)["1O$P&S<
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M5!H*NY@?V&;Q7/(_%E/GN)<OAF?DV<6!ZW/ $ WPC _38(IB6$.$ /_0H7^
M%]A[^^E]6<863 WI#,O'-HBT*+7C6V/>L&4H"B/$]6*G. 6-X03^37X&40-&
M__9DWF-?BGR-I7LO5^9XW-[M,[["XKG?\4IF1)?A \Z?%*4,,TT"!P;BL0@@
M XM/=,3#>EB_R4^&-=W_J"7A(:C/GWR0N&>)93B(]88J-R=) HOM3]*<92H>
MHD2JR8KJ2WZ@0IG](53XJ(>HUH@=_98@D;JWH ;;D0?9HPVRVK][E.TA8@(
MZB@KB)$17(Q2-[ZD73R.IU0F "")<#Z,LOC_'L,!_8U)0&3\7?=:K>O*9"VO
MCHX=/V9&\$?V*^7._XKP!6$'\75R<@+R4_+:&EG[QU 3(??^3.0\^R'[3P4
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MV=@:'#X>ZJ!X]QTR@./[0T*4.GT##[!)'<!,,4:"E0MD";B#"49M]PDOB/?
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MQ]05-:= HP7L1VYQ7:KTG6;Z'%\UO$Q=&6LS)>CC'ZDEF),O%-7]]MN;#73
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M<L+SW03$(\IJ^TN_)Z2!OX;K'/!CUV0W*ZIYJ[%J(]9ZS7JC4>=!+OYS%6K
M?WSL'"FUR)(%]1X0@:!\C, ,(G)B">A03?(VK.,)^1(C8#*_9=W7S5)<[6$2
M@S#UQ%9I^)THU84/FY256:O>]MWX^$7NGY;98P>%X/U]8[6#]@PMY@4>ZXW.
M7UYF%4)&76.#'K-HT8R:.;H16@4+-!E;IVJZF-!CQ[C#.20D8<D=G(D4C'7E
M+,O4K%5UL\)'[=UBT3+.#7W[3L_*WLSMO'%3->-+U(%]@^2^HOCX%5]'Q9U3
MMV,%KTUJ=(D/QB'HP%)(T:.L=YPNP6?K:<>>A]!062.:JVF![9J\X*(<\#$(
M&BU]W6WV7D_UX429G.Z=,.I_,*"!5YY0GX5&DPN;.!O?YY,M8@9++BA=['V\
M(%TW53+\1%)&@??F3\^M3_):X'Z!T/V4N)AA, Y,]YXX)/%PB<X7KS$V^TQ^
M:^L'4Y!#*@+!UB"_Z3)P8N96<(#DZ;F].#R2J#JA])B%FR8&;WDFUBT>-QK)
ME8[K!BAEL'E%R":V1H)2+*Z</3ZF0-4IL=2OQ?I6-Z2GJ!)N!@4%S>>\(AWY
MO;JE&DQ=;X^M063TML;)H,>!S*$AD;I8U?=%G-0G.L_UJZ3VPQI2C]AD;OO,
M"$[R"]H4JF]%U<(HN7A>\Q"S?E@<!WB]-^2PJ0YPT(P4IE3/]:WECJ[L,PRP
M$]A1MM -LT[@IV=_(') L*_?Q-](L)17X\/)^8"S]NP?(+'=DY@ A Z@5*CJ
M!R63%>:>?#>@(D H=648\B\JLEP#)$NK_$F?&$LC".</*>I5),;*F<=&'HMS
M/96F66O2/QR056]-6-AXO_3E4VI"3'E,;@WVL-/&9TXN)%#?-2A[PS7WMY.L
MI!I5!@_O1<6^EAGE 7II<#_AV#.ZU1X22!U_1<RQS51H3*N?_*$ \@FP9L69
M\VSGER[>A4"2N>J)F&" (Q4\[JLOMU@^_(!2X)$BY7U$EYV=NF8P_8?A-Y2.
M5Q?YBYQ"2RN:Q</&!;?&7!X!8$\)>J+8Q(3%O4E>Z=ZYIOD2IZ\VP;W)9)<*
MK"VT9N >95NJJPMD?%9*S]LI#\[5>UK&'OR2DDQ7_0M9'LN@U>.[_[SG?SOC
M:/<(.Y0VV8/<8C%0?BZ7NDZ6SIBG5R)L"';"+WG $RAK(G";*?-G:!=WJ.-0
M'9[&(B5@"PE*H7)R47S0/;1)G@RRN#U!J2&IUZ?+]&#.0<@6$'Q01VUVV_V4
M4L',ZJ,NOJ**^Z2Y1:%>89S;L?T0H^^K:*EFRMSDQ'0BSB5.6Q 2E]5=!WSY
M8<[[0T]=/Z/XXD!_@5C; 55#& Y.<UU*-YOPXUS2/0%6AB.NQL1"M)9+X5"F
M^LD'L9$>X\?LPK>/!]1?^4H9BPAOOE%S==R6$M66H:C;>['-?@,PO*(H+_TB
M$:_J8H^3EU]_:..5H5Z8LFD_O_.+6I6)\ZCN9#!;$2?>U>0?!&+E.P\;*ITB
MX(GZ.$Q"Q!.W0=(C?Z(P_V3H96-W"ON&G#6.;?1.\LL[#IRP(PI)7,G&N1M
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M4CB)7$3Q((XW@+J [BX*S-$Q4F4^@L6STD0S3O5H!3^>)L*LI<GO4=93^9J
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MGU/?U/OG=91>/::M5*/B&Z9<>_*H07S.) :Q\*$H_/NGI8/'"93R&[+'D+S
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M=N#:>+"'%%Z/#Z;<:=?#!S'Y-5U-#6=5K%B,B'>M3QV/^3EV-*V'A$@OO@)
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MH?UGTDV!$1T/D&=#B1;N"S/-/:?T,1-;55[8M.QQ/VT2QTN-T)">H3P]%34
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MP_W+#OUYMZ9;JA/CI).!5XW7DO1)-'1M[4F/!W<<&1)2^K["*>-V@;QHI^V
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M9(*,C A-"GA-\*T_4X;AG,AR+&9C_IEYWF6(Y=8Z^6">T/=_*\*,L>HI7CU
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MF^/:S )[SU2H#K<*%"9+JU%+W"K-Z[(Y"ZLOI)UG_4QT2[$8/(5[#\9??V8
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M^V$O\?+XV-?M&0PM+JR04R6)MY5"V45#7#G-RL'OFJ<_ZP2XLTY,T T+Q&8
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M&712/ERR$GBRUM!AO'LY,,/)<19<ZN,SQO7UG^H:(.H_?LQ#=L3M\OD6@.G
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MG7@=POM8H7=@N!OXSLK=KGOS1 WD)XMY>Y;Y(X4S[![A?=5//TBN:5/TP$K
MW.CPZ^EQR2.R)3L[X&MQ.?%SF5Z&A8X>.,5IDC&"V[6R9B]GEO3>!:TW S41
M*<FIXKZ95[&TV\S]PK5WZA?J0A6Y>XPQH'HW))RI]>?^M1?4BB.G^A,W;.F)
M^T*W>&^J7NX[IQ6?K^.T?JG\DR%;5X#9U$C#SB&QR!]TU_5?>0WQQ/VBOA4&
M"+SY=>B_(ATQ7*^(4\>OXWE7_'NS)?;70BG@^AK1]%?"B?71(ZO'7";WZ7@
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M0U+%6B! /)80Y>XNSGD8$S:-GHIHU#6K&&HT2UK&>#WFN]X[WA>-5 ;/-G;
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M2?&T';GSTE2Q)U$) ,#5QA<TA2<#>=;"8]GY6;&U44T^ .C=^3>:] 24S5R
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M[N-373:1&___*P<6;1;1Q!=7@)0#T<O-*\!$/R#XD[BS#-GH^J*)[_W6L"N
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M<IZ@A9/,+ =N8KH3(071FAX,,215PK<0K/>B*4XI"V.GP9,P)AM02[U,"!O
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M_PH6OM@6[_-S<F)^[GE@5WYX\"@ODK-W:V,'V25+<,+2#G1Q$U":_3Y,,A^
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M6_KM.SS1VQ"B'C>\U.=9[_[;6"ZY-NE%B73+42+DI]9]/Y]N;1K?H$YPW=S
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MP)F..NYP( (<"WF5NZ)9Y!O6+> M<W0@((^\@D%7[&IY*KBS?Q>'X1AJN'W
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M4LX2W^B?)R(P'[*9P\7%*0D9/8FJ,O\B53S0S4G.7YZ',K$GO:_<]$LLLU(
M,)!&F]VMF4B*^R?9Z>T']22^/T+_)%IFTR#/.TR1_M?VK2R@10AWZL"8M%=8
MZ'>Z+1'U!9N4-T4UY#]DJZ&IB9*)*<3UER<&+P9)G_ [_[?PMD0L_HKQ+SK;
MB \R^1?J%,%9[&Y.;@@+VG9._MP"GON"_G>UKN[?EJ>W ';G_Z]:EU2>89\M
MI+Q7?3^IC)A.;0W^AEE9!0_GK5L ;S%*W\TZ&V8J1[^]O:X^XN-79+R\0OE:
MD7W9;&%$F@TG.)+5S#W&L*.:;&AH)[[E",4R$J69CPZ]!<#LO%BL41WC_8GV
M?!(-_KN7V?<"*5^8<TG0TS5&Q',=[*:"G#X\ZC3U[Z@.R+O?R<*OE_>56.I[
M_*?I@HEW1-\3'=_QC%Y(>$O4ITGB 4AJETP75?AO1' J4&]:Z !SOQA4+@DP
ME#\*0F([-X-\&'=^;OS<G$+&5Z.#%(:^9V5<3SP$$=4%YT)0/^7& Z0/+C"!
M1=S_FMF[M8H<_W_S?> D,GX5="+2<&Z+^2]\_7<")_\;CO]'^_V/Q?K/I@1!
M!D&;_\L HF\!B]+_UB8%P@U-R,N@2KPKW7\&WY/1H'2NYO1$%HBAJJ\.VH()
MW875:4^F(TPZY;QMMGR^MK&^+?9-4YC1)"R5$^#W(DR@W?2^WA_<.>"[8 _M
MMG\)\C\GB]=W8V&;^N?+1 ,34Q"NI!<[6K]>N44E#A0:*3$2,/#=KX^34=*P
M=FYYJTHMGD(W]70$&)8D%&I(O2LF 37A+&P;O0789T]-O*BJK4X-Z$,/U#34
MQBUE]69;R:<<67MO\/KM=K-L96BG%3TY6VC"&%WLJ\B<8-JM:NH.X$N7X;W@
MFNWX#>4&>?[).Z(PSCE[WA)!:]FUX<0.XG^DW_VYD]'[7JV8:_#(-Z-;@-6N
M@0&I_4.V=,_=/(T6]H-2.MR5;9XW;W]_<WK[2#@!BZZR((2TT6B)F/AEA3:3
MEN\.&A9R^O6@Y_VA?L[U/G-61SEQOOI1BN"1ZVAF>44%Y%">N*\J#]-_/!E9
M1'$ID+<;B]_HO$X.M+12%1V8GWW.J:;W!5;.W=U2K#2U8+)+_WYEB#!-[?MO
M$_LA4=.!S5XF)WCN?6I0FNV2G"H'ML7U5L.%-D8Q?\3U, <=_JPDX"NX""TU
M09B\#JT#RJ2OF1^U_GCTG.@GURMJU@C\XO6G.,&_ASAJ_AL=S/!P8[L!DR]4
M&+W0_:)'*- _LX[GKT^5%/HUK+$2)!A_]G^7;ES_"Z/Z%.5:1G+I2E)YV8W_
M/VGA1\CXVL [R9I@>G5W?\ N\'IV":^LOGAAKQZ@6M&=7IO@@P=V'[\F@P?6
MEC9[*<NG::9OQG:#)0S]50-%Q@/D92'D]R,%#!Z_951]%KP&F.\+P-NBF$F,
MMP;MG(#"O?[#-I$R+;LG'?LE91*7-3L=J)<32-^R\:QOXC&<4;M'!;OPHE1O
M_B/.:.-,8_/?J=Y)7#:6QI'<XHPY#RXB7F1HAUG[!T3CG/YY;S:GDP?ZDJCT
MCC-Z@O'1I5<DDY4!YP><TS.5?XM6?8X/"<+)@V<6'V[P@LH?UDZ;5NZ?/]RG
M.5F<V_850O.UN8UP?-][/"4;UTE.ZM>T$A7-/!,1GS:L UP\@??;5Z,EH;+5
M5AE,F[%="H ?,:_O"!3O-1[C:Y\+UYJ.W%M >^JG!M^&^P9N\X.VND.;MP 1
M.=ZV@M9V^)UWH"UN"^0.ZIF<I[4@FW;Q+)>0T?B0^YG<_>L.7\S.HIS,ZXO.
M?=X'(6%=,3_@4C*?3Q/[L;AG=HI8%/1G&GR\G8GJI@TH=978@W]^5T1&5J2Q
M.(7A-<0^9#8V9GJ+ERWIT8;GA/45"C?T-WI+S.3!>.BBRO$Q+A_OE.N#O'X.
M$HS2\$',Z=WDGK<!569; _S6!5AZN#1MAA<P<B),? 8=LP:'/1,3\R[I1P7:
M(K)2^#'O.BN_M/^MZBXK2P%KXT-&!>"]FJ'IO074QN6X%^Y[H*(NSX.([9LU
M>]\7>.R9:&5Y3BZ:@GNH?TP]0ZA7*Z^K-_8[GDWH-\3A1'E&>@,'K1,@IT)?
M/M*,Q-X"?(1M6*D^PW4TB-WC\5$3B)R>' ":J<@WLZ_9(K_<Q*&==U*,B;='
MR6AK]E"<Z3U,%9Z8VY@]!>4XI5)\EG9/A,%E*O\#28HLSS4V6F12$$U0XNMJ
MB'#]Q'D,^O@:%0##7LN\+O:,CY!^$+9ZK21H]=.732.M(UC@#JB<K,FDZ_WZ
MG$TQ#^NNI1SLUQM=#?N0!AB*X^S8]0[<&D<:7<7UZP!NLP[H&5S3)8K=U%&C
MQ&*XV_IE%M*TV(6R$G*G[L*[/T^*74\\L,L61-A&5[@>BD5@*.T,Z/U1"$[_
MZ$BNUAQMZ=#V>.8LDJ3U0^#,:-=FJ#KY.)XQ"UQ_+5:QSX2[)W]=**(:E?QJ
MZFR"<GEQK,@N2I;G^Q[-]/SOH&[E\C)TQ 64HEOIJ\\$G<PQ[O139F&?6P#.
MRDVFP;4636JV\$S=[H&LH9]D5,7Y8NF8E2%4?-*6J[S,PN&(+&/U54-3+/<T
M83S_RML:VJ]4'.BF:Z6[./(7(N33UR+:"2'J,\G]%F0(S9S(5JL*U,WF;*6X
MGT"YJ[-G>AV(=-6BCZ^KT-XPM=F3GK"K;[B+JC.5#?_;C2JJ[<XD=;+@@7YJ
M1UBVSK6^VF#HX.[.)CYV&"A&A8.=Q=<UYG[6=60,]TN562!G7>DJOK$N];)X
MRX.?H=PW D #[131O?7-Q$6Y*EZRD5YY^]!?2L614#6=\N$!\6$-6:=,XQ<3
M]&L_A+'LL->"[C"J2P9#]7,: BY'3?15H1VGZ^Q:34L@+W]Y,53BFYLY&AXO
M[IH4(7W"RG>RS4'*,V)_3+I7:,]YV$4U^')M+%/2W]U-6=/-5XC:QBJ%[UP?
M?7@OT;M>#-L41/%-L9E#MF1[@)ZI$'GWY(K%(MU&DF_&HZ$D*7TI#BQ6(/!<
M?GQJQ6[;GE5Q!U(@S99HN5<E^KI^QM*<A@.('@D92A*@T Q3_:X1M-+-038\
M?L1J[-YFHFQY4 "X5T.:SPIX2(EUXM)T_1@M &UG1XLB,)5Y%44PDD_M='7'
M\6&XI>5 >[?=5$3G:Y%=BJ>3RTNU.D -P7/;A,%1 N&)\16^6T"P'1H;L=HK
MYPIC@N_$'?*W*L($-/HF?1TU$>*'B>OE('.H4_[4D9!GK."CS;HX*T<<-?Z?
M>34*M,ILRH[G@%UO?BN;C\9Y7\R POS/<XT5.)*,G"TEOG[LQU7BM:]W'Z(L
MH>X/)73GE>%E_QI,+<Z&U</\=$+NO0[>-CCJ%K"6P7(/H@@C<*68WV-^<GP1
M#9'+]]70/NZ(;I6!M4R6V:59$-=((*<^UZI6< 0)O_%AAKPX2+_RDI>\B90G
M]9T (YCS8<L^_3Z1&PQRN$*D]IJP_1;.6:$S.1JMR>1>26E%_FCW,DVJB&=F
MM4=$O45C"\:.9\]-3$-?&77#$]12.(3=?*PCNIRR59U"EO3$8_.'I^5J241)
M7U22RW[X^+$N74,0[P794Y8TY)V$?>$Z?P0?\8$$LFE^LS>$+C2$MW)@N#J<
M";HS?HP\2-WO67CWW'DMR3<_BL>F+H[:<] %"]NQ-^A8$SS?TS=MIE96%.WB
MD<V:0NIH^/#'\X53CK1L$R=[HZ3HA"<NK6\WSE(U'G$NMSY9_OE5=0T2V^:&
M!7@W![#-+:HK(TG23RH+_<B&[-!A).WYR8B(>X1]O(&\X\I@\ 3"WDD<'!PH
M,@,1A]F==Q L^88)41?D#>C&=V-8PA6FQ&G[ED<)6*NG!/@/"OF:+#PY!C_!
M*Z&5'U9HYB!4QP/=\I0(Y4KF#I@<@5+]]'FYRP+9_;C2@(>O+U+=RVH*W*II
M-UX:OZ6+21CX=OYI&JXK^S,TS9%[_ CH9$-LZ)_JW/)!:L(A@\^(]?4DZPME
M=OR"3P_*C #I"\1J'!\>[G[5P3G[6TGJ[V$XE$/=X:A]#\V.\(H/D]4N\LT_
M<*L&1:"-"XWF)];C"6I_2]2WLS<WMH0AJ9O#5"NL,.,UK0&%"EV"^4+K'7#K
M]?@(,+EX3IB$B4KT699#-U[K5"%"/"S3LIVW]M&6*T2BWG!.4_YK\!-.^\K\
MZK2W>NC0607 -7,4*F,.N8%2N04\S(F"D)1HEMM?A8>6H0TY#_/%ZW*GM]J.
M'_/!-!CTJ49KVGI%+1]1FWK&_KX%E&$G+J.I;_+%*N/IY2XB9(%YJ!"UXYO8
MF7I]!PM@</<*;,_3VRCS17#_R;D%G2YA>C/I8_WN-3>LLW.JKGG4UYL?&,UG
M5]U\YK*%;9,-*=_KZA._\JKP?P<]\2(W)X1>$_)0*'<_T]CHE>6[?ND+ZKL%
M4 O)D]DO&$8>G'\Q-<.,S8D[:C $$:,2?-\_;9XQH3Q>&0GB7WAC1[5PTC]%
M1P\32%(EH 1<541=$@LM['>.(-PQQ"OV&."T%Q@NY=D&ZGU?7IC5$2YN_LP4
MJ[BN@(;'^^*Y(B#K;?)!Q$=X@?DE7TL#BN%:%2U[\\T5PVZ*EI\Q-:A%^<!&
M*A^ '1**,6,S%0=P?L'"UFE.#@WQ>E<HX$2)YNC-Y_N\V*0DN?\I8OE#@./C
M<P&N(?-V8U)<_,(XZ35R/!RRU9#$B7$6NCO1OAI^!Y$0Q;\;RV4_;NMHF D$
MHL*TB7S?F_K;;9Z>\_F[^[!7V1A-B7\ZREK%&UJR)'KTDI5%:Q+,Z*N/[$?Y
M;X"B+H+P/?==R8P=O-,L^*?*T8K^CD65G[RR#+O?"=37.']?[O,7+ +:GU;S
M!SL^$-VN6%[ZM'66LUBTKH1I@(U)[.A :_>)< 6>^4'4O&S?RHI+_YG#UNH(
M4<C@V9QU<4F]9'Z"FU^TT%U=]J/:Z8$1]N$5WT[.QQQFL9PX#%D]HB%<[,94
M=;(HO;P\QR)JBDZ(7JZ@6:!P;*'$VNVW98X0!_$[>-""=[3K.P\O*8ZPV8I4
MF-';. 67-TZJ<:1?Q:L,# >Y0;[)R4\9/ T'P42W $=77(@J*K("S3]=FT-K
M_QZ38E6\3Z^)K"G:A2+;>:8\6W[7[E_#N0?;T\?:ZO,?UW'M$1B^#ITE5A#^
MC9D+I&A"I00<YVT\0PBF5':5[#4[6;!#G9V<(6P^[KF[5B:SR5JM<7>Y][9N
M*G''(*.;]92%3XH2"TE$=;+3S;+@WP5BKEVEV6,AS#2<*9-E@<VW4I4X4"QT
MD29=39WX,]QH:VL_:=V7,?PP6LGZ#%$=>)#T]"J0Y5S8>D%QZ[MY&-WXY.E/
M1ER7 F(L*49\0-+?\B,)"=()\D4LX_E$:4X2+^_Y;C+B[)YQG.V#9='N-P6M
MV,>,J*>^*QJHH'5)!#\SQ?'%/*N:7H##<1=3K8_6%'<R5M(>Z10?=<]C?%5
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M#"'(PSG3<L&U]=SGL(O@FT"UB/B+(-3Y(3_J%A";3]"!RW(#UT LGTYZ-G<
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M<3&BFWP-]RW-^^,[7LF/=H2"4BE +'<9O0.S*)D!23WS?U^/LFI,DA&7ENU
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MLJ6# CAC20U=T+QKC]A4M?HRSJ,W1VKT!)OB?<!G'_G:4[U^9'SN,'9_0,9
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MGWL!(6*AVD/'(&7K$NQW8TUQ/C'0*TBO;)/TQZT\[6/QCWKN7_G>J8O?%"#
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M-MBNN6%C<+\A]&#YEC_'N.<0ZH=>S5!^G:VKW?PIR^P?'9FG'[KRTM7A;I>
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MRHT;CEI>[#E;S@0T85MB0M6^_IT[M05V07>T,GX/P!V9-N"-\$!Y.F;7KN?
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MW%/:I4&@"M22RZ%8@P[#HH:7:JF79QK7XMVLM\:33EIC&=YV0)M+0.]CYDO
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M]:K>'JV:U[NAH'"DYR"6=GL$9V$U+G9+(%;K^TCT?:-WNA05:E'^C]B6C5A
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MY10*>I2BG5[KJ7[[%'<=-\B[#,A:&K<$/%3,MQ)":,U=6 'QU(5^5O@]DL7
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M2$;F!7C,F< \VJ!N'-B+<3][_9!DF'W:<[^AX6=#;.T7]O9,<@'?Z+$2?O]
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M'PL^>][V&CX0&?*YA8WI?7T4LYMV[7C<-W&3%8K%W6CWW1#^H!?MZ?3IQ7I
M \'73PJ_T)A7WG/[-)2E;>&@=NT%1<0A1?'U\HAPS2CNY:C\&XC/].51):XW
MM.:N&V<_ZQ1"GWDEX-=QUGB!G(ARGL!X49*'^W8-'FB@F>UG,_.\2 ZS,QYJ
M<*S48DZZ328PTOM&1J>Q"LJA8_'E^S/$5()X<C/Z;K.'-^7VDOZ])DK4[6@E
MA+(RDK9Z]^CX#JK_?N*T=4DL;_&X/_87"=C(W2TS(ZU+X^!1[VT3<R:RC%P/
M+I$P?)TTL.#LT%HN!&GY],36[T0TB?US-0>V^J%,,HOK=^(E:4$!SN?_7#A
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M@/'Z"K FZ7GVW*M-A:G7B[PK:B[2\NP#-"(AS-:01Q]!L!Z'%%JIH;'Y0K8
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M^0+%G_54@[_^/!!:R@IDYANC")RQ"#0NK9ANJ*1[L^K?"]C,90"[5\&=NF:
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MH7*9DB?5':LJ]@J*7Q=%)2)J>VC.S+.$CJ+IJELZPF\X6(J4:9[V:X@GE]U
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M6/^+%Z$4&['L:,]W<V:K.+FQ]K*ZSVK41Y3$AB>=W+$Q:$$EO[1Z5'"#_CI
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MV(H])\>\G&#P$&BLQ&WMJ34D*(<LWF^ZQ,G[1\K<.(U?JN\:265_B73[ST;
MP&FPMP EU9B4">O8,Z:,1FR4<P3B$&GA#I.(3_>G?\9+(Q,'%FW8F]*C\>EU
MEM^SJA)M '&A>!6*O'<*]9JO9MD;DE1L+I<'K.0NZ8J7S&PXT\&?^EWA1_PN
MWX;?331 .[T_8B*?15;)AVDQ>];-&%XY&REV&4H0V#G3)EKD!C.TA<):*5-(
M=JZ(JQ$^#TV?*,U[6H@)CX&'TLR^I=T8#)$)V.QG//O6WZZ2$:\*TQXJ/LI
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MP<W2R.2%B%?8X=<JS2+CG?<?*# 8?#@'G+%<JH'Y#1YN)J27L^J;52Q;U%-
M-^?_]EYWFS!,;H#U@:%P'MEVX >)_$F'KI2]$Y\>M6%>IL@;8Y)9??*_J;F5
MU*@37? Y0.AO[O/(?CX5C03^W)1SP&4?2A*TUJIZ6:X 8?"J ^''47(=O)T&
MS70ZV=89%^0\&-#Q$AGM;ZWMKX??F4/'$GL(%E2)XX?U&R7>J;J327\/V<RB
MWWD$2I%WH\-/(#^1UC?:W^1%,)<BI%I?=E\2R@[+VRPR0IV6)RZ#6KN)HQEH
M$$&<&Y9IVD8<R:UV#US6$!$Y%6W&Y$\:G+Z]\?)#3W)A-.U$LH.Z,U7S)(PR
M-.-$01'*!>"J<QJ3-#!QAY8I:9!W&W*K76W55:37XFZ*]=RR:&_3WIB\^4OU
MX:VMIS2)=GZ4J!,%\<3NTPX4L7HD#.R,DAXL#LEL'\_D(FAUHXC+^BY?4(>Q
MP?/WMW5JUQ(%6&Z,[W_:01@]F$PYDZ$T;.9FBDG,_-(W0\"M9C:F<)XA9B@;
MNV&P?P#$CV^[+%B,X-GY,2?PR\,5^A< RLF:]^;ZLO"R$X5Q,T28:C =T<2#
M4:>$8'%'SR)B,Q7]_!O Q7S/4<7.C1O6NBCR<SNV#0V9RZ/2'Q8^]3.= T(2
MN"G>@\5?6T@T"5SPVRTD@32X:@7, >AM.],.A4.*Z_[WE-H_$5/^E^10LRIL
M'/LOYZ.44)UL(!K+8,%RZ6\I@LIS#C!+_X4G"6"!%B.<-:Z!PG*EOJ'5>:+9
M=2E4<WT;-I5^YRY.IE>E3M&!=3*7LGZT?^OWLS$:*.=%&F6L,9)6OV8V0XK)
M+0A8H1Z"HVF[I#'02P(-6:(:U('Z:GCM-9PG@/4P3#)=VAUI$;O,('%42A>^
MGQ=6A\'-Y\KV%9P#6"XB(''D$4_N94ROW\U0S'X2:V"[K9?I I8K$]42JEF6
MW?QNHL8D5_'QHMED>+I[P&:P448<2$]3?$U?*O%_PX<N]B+.L\K(W+3(XZQO
M[IZ#LK^9FH0#@0Y6]Y;RA-Y$"THV&HJ7G'48,+J>/H-+$U8Y1@?79$F]5%VQ
M@O>PS'M33>VG5\ )#RZN,^,(*\!?)#SKGJ?=B$NI^ -LP(IAO&6"N6ABLN7)
M/$1TF40N]DR9Y =#8>>/8MKS[V@P_5W5.K&;;3?Z9<D+ECH[X H-9/VL0AW-
M#\BVKQ+\#0\C).SC"9YV RZZ+D_/1"@E5B3H0M*AOF/31+W%.^!H"@&YT*0Q
M6[@H:@L!I=4D;BNFL0K)7O^LQH=26**,DZ(V_?M'$4_7.>'J!$XA-Y@+MHQ^
M.L(F\L(!1CU77B/_!O7ZQ:TUGDEVMA=.KQI.\*__FEA^E]9@SI4N\6%]:7SK
M/\3>1Z^$036T#F(-E'F8B6LZRZRUJ,?6[J3>EFUGS3;]9/SH2T2*"MU#P<W+
MO,DF&*?'5N*WJ+=/"Y$)@N $ND9]29($1=R;HOD!M%O8O4$DP-*\AOW!<?=;
M5.,<;;52-CQ'M5]M?Q88G_S"8)$;M(XJ[,?;<4/*>%HI=@A8M@8S'!2T)M>9
M:XLJP5@1EZJ\!8)4^&JK"JUEK,)";G!]2 &/ 0!(4]>+_*:!%XKE&@@(>@H/
M1K?P68+6FPJP^_CH_;S!S?%]643%='+%+/O,$I/2/[ZN3HCS70T6KHS.(#9P
M^#F :\$M?DA,L,P2?9>@PKL,Z=-;$'#O) 5D(#T5A!Y%Z)4&W.F<YMZBZAC\
M^CBN%/\ *H+<5+-,,_[OTA7SK@M2GY[YMZ\^*,8[>Z8&JV_OIPURCT1!>'&W
MCO@Y'OU =?+',,=![Q-_(Y9,I)8:^YQ]6>H^7VK3R%TN'Q&V00VO>H]X,<PM
M8,]T*!'OUL!K#!]SK4MN]\X])!G6A "_NTROO?M6W@)*>?!FD\7WA@TFH&_6
M* 3Y1ZJ%>#AT>'G//:6$,3,B]XH%#RZN8"A]P]*GFR1LH[B;-JW$]/OI1^"
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M0QUG@JCI3=3'F8@&$%!K2?_VQZ:-#/DN8?B"0A6= JKSSZ)/QSD@Z1S@R\E
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M)KGD4JU)>O8+$?U<KD'./!-\;6#^%K!NEJ.9_AY;S*NAZ [B[6F3_QSJZ-T
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MIV8;\L/M27J08JT&PG-T>T_.S D__M$C%?]"%6#^]I.&K>Z-5%%&6\5?O@&
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M7Y=ZB0_=T6PY$L[ZJ1#Z2'\@NE?ZGT<2X&^0[O4' A7.23<$-1FWSC73%MP
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M1.F!.8+\B\?I +:EMDF;LRPUWQ?SA([#8[+&0HM7U6NC.;V/F\2L8U:^-Z'
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MKBA_ XCAI9&?I+/'.8WV%XC;F=1E[2WL^SXU7O)A]"@4WYK;IJTJ;QX[$1B
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M\>[GI*0:_L*2Q\BT30%FR=2,[&(* *K'KC-A#FP=G72K') W %?@P/J6.;Q
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M4_H[M^-HU1I9BW1,[8[J:(_GO>_F#DN[[_CCSW]5+!ZYLC]Y=&PN/IB3&M.
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M.)?:B4''F@10(0CDV$9/?IX>>>E!;T=&\DN"! W''_3P"-GDLI]EU.=/V9$
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MW7]#7OC!+2VN>)UWG2_<ZC#HW",R^.(SY 4C7C0/3F Y6H<-7NBLZ\1V"7Q
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M#7$'#3;>7.)>IN#AI%_/#A-:,$XD8@GP<]6[_>^W,EY:)!J_7(X._%]?(HL
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M(Y8B>3'#"!N102B"Y;)J761K:N!GAK>Q:TAHACQ_&E&BH:'@WMP+)XSA:D[
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MQ1Y&>P-Z[V"Q6QP;%T, ^Z&X'IWW%Y-W,M?)E@%F;(90O[/*'R&LG5+":PP
ME&3>/U3O$S2N*I5Y!!/#R<!E8UC[,W=/,K.8@=#:F?\L%5_^*XKS^*OT)WN&
M(VQ[;D%D[")Z6/H7FR/KG6=$-5>6Y<AM3DV!^:P*"^FC8[#<.%_QY]KBM8R4
M[?($^!<@?X#,#<!+_^(L%7<#X(M0\[E\0&!M6]Q87!L>4$SMH7XC%+!',/0_
MEY7M9$X:#T8\&_U..OU 4&'X[NUTQ8E<%1!\N* $ 0>6.65;TCSY(IWV16^0
M5::AT+E 4VM'M".%Y?K'."\*^>TV0N"LFOMZBJ)L#&J,C@V_</H<IBH3H6:"
M_=B=F]/NE=BHQ7>I/*O\P[9OFA OQ1=")$^\L1?<@:N_JFZ.)ZAMW@!HW7J\
M\/[AKO\TTP:Z3 W3M.%SS6?3:LV>SHV:UJ_F-.<O^;^H!YJQN)!\E5UT$J=*
ML=:,<*?-G&]#"JGSE02!=:L-#'")AO8.]?_UA51; B?.==<F*B8/<?-'_WAJ
M%:&'$I=2!^<6BHN)X13>4/WBYY&]=0="3(C8/&^OU&O[_// 1GU.MX_#1Z6:
M=_*B*.H-4#C-J^2 4@CM?JY%2JT5/A$;\'G&BZ#A\EA;LFX\CT8,E0D8OUO]
MFNP!,X\$#_5MJ&P6'#ZF!^?(05B4K6L)JMC5@BT<-PO>J3384P;8Z5C,>L_S
M[S"-V(<&VY601=7(,;WXXL3I+?$-SN"ZH1PL8W^DXH*JI.W>-=^<\KM_01]$
MS]",:,L;P!\;$^W:EUX2#V;)OCJ*_^?U]C?()?D-$\FO(>EP9BW.%7R[T&!/
M(/-K8X_#SUG:XW5%DD '[,) [4R%IMRBE=GR;,[112A/71.D5Q7BY)X7IEY)
M4.!Y/5O1JB^G6,PJFGM8:XM^)1OF.8+HD0[3 7#]K&1&:%RR$T@:XS1C#6G7
MEM0WCQ55*%W_SG*F]P9.YRU:6)FEK)G9Q1Z*;-\ EDY1EP7N ^S# \>)H845
M0=5KO27KP8ZFF,'NN++_%%NN!F#M_%TIHVOM*\KG)Q?BFLTT\;.W@>=D<ID#
M531T'/>_OGTX)$C41%3\A"-4,STCRO[\S &]*=Q9F.9O78OZRA["#E2&$3D^
M-M)1@,I@!OGM9_X-,)G9[OHFFV[KK=K-Z#>OYI\E9YH8@_>FJ?OL$KK=U\;E
M1X!NY^TO+\ETKSY"WK9J-81L'I."Y>B#O^V_V\\$B[C[<5=%SG8&L;#,V"ZG
MBXV7[KCN9OM.-$KGC38\JI<[I+J4 +DML!]58/Y-&F$IXV'[4]+T+;\#C9/T
MK+;S;=H$UM;D/6'2<=MI1*R(GFP0G;+])9# B+?_?L#-CN5N0HH8<N,[D+S[
MB,BJL@[]C10)$VSL=[[VE/R9KM\Y'WH?MT>3WA^A%Z&4-\QM][3%?;XJ#9=P
M1'+T? P=ZL#R]!GA2_HCV>W?0*AJ0V,_UAX4\BBV(,NBN_[K@*=B)<@*^*9)
M^@2F.QTU^YKM,JRJW<Z!;=KVW-=7)2[N8B'SZ%<A2;K_]K8E>NPC+7J0D45@
MGL:@GX:4!]QL\[723M/>TOJFDQB5C ,**AIM%NJ)^'MR7"?VF^;J%XT<BP?;
MB.GB2:_#<F)8J[%0T9BPQD?PW8)AREH.HLIA==#$1,&E]O5"H=P,00SJKLJP
M4 LE/$3Y8ZYBBNBDWYQPU"E>&BF>)6T]MHBVMIFSI?\U*L<&4#+\YE;$#@$7
M 1#!CB^PEFGBZ#-#[I6U=?<UY9ZI;[/;F+@<IQ!AV^6]<I  5L^ZGWX]P(NL
MT HZ,B[.$'=%8F)P=(#0<.^PKKH!B$'+C^U;<KY>]!!(]A;A!5TJ=&LQ)+F*
M3-D1L?SP1'G[GZ2/9EXG<GKV]E,[LOU2SOCZ\;T+?"N\QHN30Y#HJ#F.V_*+
MH=H3L58)/A1/Z@V +%*%8(9U.73"V@ZN<6,UAQ.538O#G[=@BN((.OYSUB#]
MMCF"'-BOKJS66_*MC9MEWFL@VYVT1\_TF+%H0^0ZFFZCB.E C:K3%DMEUX3W
M!CO>;^ 9?$Q0S&&OFR@^EBK_>I5[3OYCX 1AJ[DC=O&SS6,H\*-'2=]9:34\
MH8)UIGI/=I<GI++/;L1/T&G2R7W(ID5$3,Q9?-%R'K29LQ^)<@L=C$U3 NVS
M&);L+3@OB8L?'^O7YXZ'7MNH<[QT?)\H-]JJ,C0]RR$20M(;RZ'P8?HW;W?T
M*;=3+<P;9J&S0^8\PLOK+D*/2D]?1-)]C&3LO"KOONN:7<1<WS*"=ERLO]]O
M_*.G:\JK)8)#MW#!GL>H'=:8K0)]E[33WIQ!&(A&ST7ZAQMC)]'6F(Y^![ZY
M<![H?LHFE5I"PD:-BHA9HTO2<TQV5KT=V+!V)3C6.1LU&J' L&_ZJ/IY0]$:
M\TX%3;^5A[GNYRKD1O5S?: <,U-;&R^_@NZ3K,/5S/:N7*!(E3,#<&3=9<:R
M71\Q$N)O6);YY^JD;;[6<^;H'TY'>ME3)1S>V>T?/5+\A<6W47][,,J2./8G
MZMO@6W=N <Q".K'I?N2C:7^E$$*-E82,2(V>K7M#<)&KNL<LD-/$>\BLRF/C
M'_MU\/5#PAO\#0#%\R'T/$Y5)'C1&"->^(\4+A?=XDDYC,:I2K0)#QO$ZGOR
M-UZJ7HVP!H^/4%Y&H3PCM"_M\%36^"S,,L[MAV)1 KH93=2_QC$O,WE8)6%B
M;[&#Z+N#RVF#MZ8"9QE: YP#J#=I?8:R\-I4L364Y@W^<Q4*FB>C#$:Z8GTF
M.:J=Z,=+X6+UB<<I+H8@9%@USK^Z!KYG6(9N-Q@^E$DM*5]?@KB"FR(J#.=<
M-'"517X.Y+.CJZYF&1L7+MRVG!_E+WS='1Y2Z'Q%YJ[ZQ'M\)WY\T=X.'=4+
M>)A#7.B7JI97$(;[AO^[R16V*1ZSP8/7\:YKCGBU)_$ZHFS<TY.Y% P11!S9
M)_?MI<\S,@JPRNJ]I4:O1,ZO<WD%&-*J?P^WRC@=BA28.I8!T0=+VM__(_@!
MP9'WYP.]W<6)7O@1[!/, ;$:AR G$A9I+R(-D]<M$YYS,7#;-]#5Y\NO19M@
M] -"81>\GJ.Q05P5:'&$<9=P@GL7E!9M#]+XQS%',-U$"R-IU&P6I<7$CW":
MT3,S_XYFE)*J2#G5J7U'H:)1=P>-@49RCC'&P0D;A2,O,L8!++ .!DDDV\^V
M#U&R/Y)CDF,FM%5H14X6<<)39&B5C3P(#\&U$6MV+8:)2ZSGFQ4_<NZ9J1/X
MZHDN.361_J2IF%7X[)&P<?"K6T,2\$N\KAFNLZ#TY5M[<^KJV[YF5SA]=09>
M=)>,&DAS=>2^TZ3XY*>">LLXB<L8\UB8?Q,8'78JU[)04?:\FY?^<Y7&5^DV
MK[D ",IG;_U(J;4O?NHQHD.+[-NP;H09[/-5(<]3:[N!CS\OHCRHD\]WNX5.
M[4J?-B=S5O_MRTS>Y0QUJ5<,J-?I&))H-SP&7E<40YW&2QK;UR80!P>^@\PF
M>M\9AGEY0\38TE?NZF+([<)V^78K=#>.NQ\\TN3+=2A<7+/^?$\T=A7B/\@C
MUOA,]?4PE\+Q2PX]O^G_H'(=V,&KTAS@51I3\>I#GZW5ILXD/N-?RT8:!;\F
M3 'YJ'I?(;J4%I>P#_ IZCJJXNKF$ZV)>OILWA$/SQ4M)52=1A5SC]RH).2S
ME4!!B\U%V;_"3,V0$ORQT6D 1[ _16ENKUG4Y*-A$1:C#;7/P>9OE@"[K,>Y
M;L&GQ@6'F_"IWEP_7CO113J&7@;M'3:F+\#,DO!6!T O']9LFSUUND"I#B7\
MZ4/.;1O8!+=F0NO_ZP8JV2!N *&J1;]#/9EWZE %SSI_#)=H[C:,%P/]?PF\
M+,K5.H$$G409K@W7"\4-AWX:T-8 BI>D6K8F4I5GRR<[/GP1_3#C#R^).BOQ
MWPI!\A$M<]<JE1Q8Z0W@7/"3K]X8%)%F>!EV=#QUAA#Y/9PF49JZ)9!<Y4.$
M>&R;EQW-PO)X8DOW#>^Y%2"*5GUD6#<,OX\3^@PLU<8Y4R5D;!? /]TQBA:W
MC'S>?<@,0*7;7 KYGOI-P\YQ9X$W@-Z2K9QS".8QY$2[=-H!+)$J\QA.5+(<
MBW"0D4LY'?YT9S*#],20_ Y*4-F4%[M6)AT:/K5WO]!^N?$E?\_3,=KU)]N\
M)U9CGV*2H:)AM"%<H3YY%>/C_-[O%=.#_JN@=867KRP>?9(':G\]J41'!I^=
M[+3MS5E^@:8=C7?]'M9)5M1KG)%HAEU^N"#%D3[</@&];Z5OF^2C2$MI>8!)
M.\S3X.CCRV'9&F?,\E*&BO";1ZT-I-1D[[(6F^_U5HX5*$AGX *XH0;I3&]V
M\M)$&CO.BYMM$2<+:]JEQ@X.W8KS7\7MI6VMW\!-AI!4N.P_A9$:BOTM;W_U
M/I?*(&,;UU$."]ZAE_86'$]4RSUR@8&:=4M&-<7NK5*GG93^N<C9H0PU%VZ
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M=[H72@[?%\>8QB(B<S\VL(T3:N;#E>EPK:1Z+D7/7=!<D(-5Q&(>V5)7R]U
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M4O([Y.IR<U;LU:[._!_M[,6?X7?SYN=;?DMV9;S]90*[RX%_8<J4>K2ZRI0
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M:%H6?WA46SO*HYQ2Z_$&,$C'82/)Y,,4(75^R,L&/+A3H"..K[4IDR- [4^
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MT3T@.)'P?T=D!O[_(<*Q;QY\&%!%"UP!WVS9HIKS;C$0-.-#X,D7:/Z\^7]
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M11XG&Y\>@^>J:L\.9\E)P/IHD2O6KJE NW[;-MNI?C$P-]!RCZJY-'8$X'8
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M^)X:<%3K3:C]C9&MPZRF)CO1?@B]K2O;O'2YZ+1,TN#-8O;2K*\55QMTZ.X
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M%PUHA\8,@H4^5CK4Q@WR,K  ;O9V(6:F.D!4.7=#$T7HNR_#57%6!VC,I8[
MA!(6I$/YIIIO>NI7C!M%(K[\T(:7^26OS<>D]=L%4AI^7@I 5GAJ^"=M QOL
MOD'(5^#&MZ!-J\>_IEA[A)ZER/=]8R6JV\S&/>-;$UQJH?/72_OT@:'_:HHE
M6]+MNY[#]) '%-5*JG[CP)@8F<A<!6I%S*=T8VQ"T @&BFPOOA,'[@J?@&M[
M:@XUE:<U6W)8C-EKOLL:FI 4?H&^<%&I?<V5\EV+C=@S@S/IW*4CKO9@K!1V
M>8@>@UVO.?N5F/WC*%9,.V8>;<5,!O3\_M=X;+\->,V?SHP-DX!SF]?)"V2Y
M]6/63X,?15V6[SK<%I;[Q9Y!^R'RQ.]2J*Y*__J[)YF8O?O3_Z7@WS7PV/[9
M%A+EJA/U*V*1VYV!&#E!]?$XBTML^G2,K7162Z$F]'&$!!-KE*6K]8#7C)[C
MUG:^/121E!EKY%6J,-%B9M<\?!>J*L"<P9$HKE^?,KUHI"MPTM? <EDC+&VM
M2*YM#\@;,@RZW"I\;]F_%^L<5E,O8L"ZDJKS?:R2U4DH9+JLG,UT:+PJZ7:2
M_BM<:\*7;)'H4,--<VL;:2N]<X"!X8$JI1*TFC&+LD#WG0.HV-8NB'#6]-JS
M,VD[IMPFV@7+JZ?C>WZ6]K.I+K/'&-G/*P#"!6DOQ3E<;%9#_#$YVB+>6CU>
M!&U+(' 2AL[.1J!>"5>X<S3O\2.)A?8R_=MYEBL]:H[[D&8%RR=RA^L&-_-M
M/CW]%OTWK6(LO@SC%[15#2SM/2G\4IM.055$+F8OU(+(UYT70_7H>TRF8T!\
M?]-' X X"#/C2>ZJ%<4O1=U*(4C]#H^(Y)6^?!4 [?JF %7]0]M#T)GC5:Z(
MZSXR[.0;D[@.VTY<N3I)U#@!LL3H+?W9JJ<\&WGKM7S"Q.EQN4AI)]M<S=?W
M?5[_%D1HBEUYN6\FF-.$&B\VM D):1#]$A#.R% (&]:7X-=IPK!Y]V&J8FL6
MC7=V:K]L80-:551KL>1BDQANW>0I=KV[PCG0*]NNJ<5RT&+!J5Y2;6PA8WC!
MCPQJ3L3V;IO@@3BG^#C*-6+>8HNU^J9_\8^(,>O0@.68AP&.<7B3(IS!CI?$
M7T:;>FGSE[6Y8N[+(J-6<T_YE(5<^1OH->5S/Z[M.>- 9#9>:F4Q^G5:^6X7
M[HI'6M<G[^BLO?<UNFMR$]OZBI%W^_G69QU/Y$TN#D6:< @$N8MZCIZ96O3M
M:R8RD$R0[#-6?%9_M913QK:GE-!I:4RR?WEB./3UA(<OBXH;]'CE\%W?6<>)
ME]3.YJO<2U-^L\3[8/OF5I;[S%-?1Y)K[]Q*?'KTW%;UU!#F%-2J]0)@\ RP
M$00L*3K!;S.OBIGJT_"%ZMD&2^ ]P=!S /%6;]O9=_++LRQT0K7Z5=J%*++F
MT8F]?Q)Y7](ETU'TM=V&TKM$#_H2(B>%D0%/;YFL< Z(/A6-U^)TTXE3MF@5
M'BTO.U#7L[C%#W- U;<\6Q/I[)$-!.A*I/LXL>]H^2$RI!N/6^?UO_E62AC=
MZAF:\UN?^C8%&S]+<67577V6/YZ\GH1@U1^[_XT[YVYNI"9T%?;O62[G@#:3
MZ*,;QVVH:^3_2COZ4?TUX\NI(N\Z3(ZB)I*\(Z:SWW!Q:V&=O]G8B]O:E+><
M56<7G+XZ![AHYT8";]$\2]&GKWPFZW7DBTH. :^Z;XLA5,=/1CP86OS8YSE5
MU+WC%Q[B@=X/;;+\O'F&>-6RV9D80+:68/G+24,W\V[<WT[,O76O&WGBU"9<
M"4_O$TU1MQ87F;ZZSVXEP9B4'+K,%S^4=*='S;E";HQ;%X9Y<"TV4>*GJV_-
M$0PV5B(=2*J%YN\>\]J_0/B;O://&WKB$/>617]Q1V58GWM-P[>X;5JR8?CB
MT=(,/4I@;;X0YT+2'S&%[[D+;Y>G(E(<XK*")'PIE;,_G[Q,N9%B(#X0>U6D
M5R():%\ZQ<?:SR]^Z/PKSA3KWL<<)^O]@50F-[P#?.ASRN9=Y?RIG^#7OJE0
MI><KC.\4ZCA6RG.ZZ/*QM.MI 9?XQD";']]:MBA9:H'^'( >.@><_5M_3Y@
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M#TE7YLG^O;H5KS%TPYC/^!S0\&S^$;>U#'6BS*(D8.O%1>]("\MD$,S^^"0
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M!%VU) G2A3*QVP>&T!;=H&!#^Z;6FJ"LV"8:'Y\(ES:79#TF[[TP2)F4+.)
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M=?W=MJ641A]<.3W+7[^L%!+1DO-Q3>#]\?%2XBN$]7-14?R:J^IB8 AD+7>
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M;>8'W,'6V=]B0D8#S:"0@-KRR<F?*"/>/>#VY8V=%+O9H#?N<)1=XNI@USD
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MH04GN""76H^N+')52P- ,5A:H))QPEB:+5Z_9G+CD>5/1-./YD*H:)F# "Q
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MPJG77S_P]A^7_)12!HWB'N,BKO6DCCS8INFH]SF@_''@$[4_I;P>AMW*WLG
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M_Q(%&2N@#8!4J!F"=\.W,@+#H^WO<4 L<EQV[ZEG-_D^@]CJ.7O-[=E[>4X
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M$3F"DQ@_^&TSU5RQYF1,A%XAW>6Y/\)<D] ^OA9,>U.,3V\7L)1D[$/(2*Z
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M']6>C(C8.M7Q@L1;0/VQ>.N/>N) K5G+IGKC2B^Q%4%=N:3<K]"=,:QB,>=
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MG LX]65,+X.YM$#E@UBS/* AC;<,=<OKK9L,0U"ZS=B6;; N[E,^"]^%SVK
MUW+<B!6E((X4-^;'G+DV#'*FQ"3T-V:S(L\+=M C%;N)@Q5U8P]('-=HEUXF
M\ONHZ$J2QTY;19TKSALA)$./Y2B1C:N/DM?X&I#*C5^= @+%),G-YZP",WKX
MHA+?Z?7R/ZNTX=B*^_';/'RP?]*M0ES;1HM1&5_*DIH3Y9)0^QVHDR:C30=7
M\%7O1W:VJS=S!+XP..4>,N#0/!E>CM[TZVNH:.$SO6IWJIBQZ@RB#7B+H48M
M]#9:"B %&L.P1K^,5^ VY7NE'XLL=J\,1J*2A@_"(8(V&DG/#=74\(<_S+$(
M'AM73X@1\\EJE LPJ%:G:4^T#3O7S)GV>GYT.OT3FV@V0/2\RV IBN2>H \>
M8Q 1)@<MC;E&-O8R"V-8P/G+F(2U =BC!I0^C2799#U8\%0#Q>XU_4\K[040
M7-CF,BBS]"(L:_(RA*>?9C?.J"NG[A@K0AT1:HNDHO!99H@4R!X:AEERRH2V
ML+OU5"]:[JF\F4PZJZEI$QG]!R;RIN%L<7"9XM+ZN=XGDL(S&<I4K6E*&9LF
MJ]M7#%)6[NZ351>T ?L9 J.B7?4%Q&EJ&EI;365E+Z:7=*Y2XU8',]0=5WHE
M^I+M)PV'M22#SZ-HRCD_,-BF3E[JJK$$#9*9?VIR9G#HQ,>2HYGL^KR82:WE
M^Z.*[9,L=^EE'40&2_?(34S$LR93^[=L3HL3@*?W^K4M02C5U9F#F#L' YO/
M"DN#'3[HST%^F?>9Z*?_ZR<F<]0)HFZ^!83J9P$:\A_>-!2+$5:^=NBV;?9P
M*[1@,OE>57XM@H5DZB#'L4H87P09M4\>"S.&R_1?&^1I(X)\#?((\T 3I946
M="58"*8^;R^8#S4UIP]]/"-CL)']&5EKGARAN8?$480S=9[G9:WCZ]1;>>4*
M/,>U5U1D[#K9+"**8P>F819C7FZ&%WX6E8L>9I"L>D6+(+X 0PPQ4L^@$?)T
M)T.K$K'D8KZD6FP?1#,F)*?I6OPJSZXS>V4XW+.V+ORU*SJ1C2I6#8-GQ(6
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M=TLG%OR?IXVZ/PL]/?DD,IQ5LC)JEV1;"P/KY7VWI*EEU%4*9!W0?BNV&;>
M"/G$3?U[F;R%L(^9FQ8#B^M%OJ7I)NS<U]9T'Y+4%MB^Y1W9Q$5>_GB\R!Q"
M)P451';VYX0M*XQA-:!8>=1%.-;ZX^H^\:&V7AVR?FXRE,?.T=99;JF7*O$0
M\+2[:QW?A7HCYWZGX\J7SCJRL,+I-AX40X_$_%:6+==,A>5E?.$O)<<1]L9&
MKR1ECI:*+^KD!)\WU3X \,[Y.V634W*YAIT^?\],$#//]\C_6Y4RA:B;7;\:
MU2D^MJZ:KT*O9"S4S\"M]U(&WQ]>_WC[(C.J0TW'P)OI^!^%S./M(OO8J$^G
M^<\0K'5:Q7PRW(OP>_WL^K2VK%^H0B8138J$V \87]2C89UV)%G"&0LC<%Y&
MP[,*-)W\RM%CV/\A\.A=% EWIG6TY!_['_=6I/HM!OKA(=J?.UB;,%]7KT=D
MN(\W)L[UIVR#"3ZH#>\[_NME?"\U<8AM#!QK>OD80<-91N?E*RU5YMZBXR21
M)J9?;[[+N>Y9MJ4#MBB/F'8+7#)>Z)1(,Y65G=OS"TY"R0W%6L=YO[B7&$NA
MULUZV W_=T7O7U#])Q(E4U 6+AO<N7,PSFT3JSYP+-UM[HF/M[K>GXG^BF&2
M#"]"I73V=>)9^&B-K58G6VH:*C?X"O8^&Z_YS1X4N!:WIK+0;B))2,,Z0XX"
MH>MNLG!$/O=/!W#/,6EK6;+J">I-*)6L_(92L5,'KY:WMH8A?Y<1$D JB;G\
M>0L7?"40+]PBHU#/,/5W2;UW_61I46J"16J:-_#%OK3"\C0+AF+&#'C<FJ->
MZ_A^(J)>R*UAD+KK9"/)A*I&M$J-VVNCP6<5X-Z[$*#]7).ABT(' .R'90WY
MA@RY7_0OQK_<-/8:1.T+S;.L&4![(:18 U1GK)SXG:'JP7']CM$;$_3T;VZP
M5'4A?KE9];R9<.O98BOC1^V7A 7--[FX1PO:N?836$.DQU5Q-'O\:2]:8CY9
MV[O*-SU:JI(<L9;^6IC(NBMV/:YKFS^'4CO#D['Y:$EYF,_]6*QP*&_1U,'0
M3QP\H<X_%)O#SK2:E7ML(57Y_#"H-'#^L!Q-Y2SR)B9%U>7KG+Y@H ;E1(>V
M]G0F&Z!")C(KA'PHZX^.%S,V,=OGR/VGVJL_3H[/'=^@R[W!W/#1BJY'S-MX
M#_K)W C*HMUMTZ^7WYE%T?*__J9^L<Z40,OJ4:5R^7FW??KF9DDAJ'WTQV2Q
MCJ!^U7G+V,)5X+#B(UIB*\I70=@@CLGT=N'1+Q^N-NC1\\CC$/D LSO")+T%
MX.*HC\2&GB<?%X]KWSQJDT1_O04DL:&,<# R"L@N@U'S?__[P7>**([]*]@V
M[!9 AENV2E:4OP6L)K"<@$T[;^(56&\!$_U0*Z@&[C=DYMDM(-=H0PA+OH[3
M+#>Z!53?V;LKGZG]\UW(--G5AN(9KT_GNNI8D%(8AF/WZKDI=UZ-S'].*R"(
MY7;OWOXM5;(\3BA!H[ELYJREUOLA=O4)&3YC,.\(58;N6,&,;54G^5(5]!BR
M]1[WM^:FZX3FAK8Z)/5F[H/^>D[FLQ\!<_L'PNO%)C_^JN!QOTUJ^_+VVY#?
M=O"C1Z[]KAFMRN2Q'Q9_?6>?R@S6 5NBG22<X ;^<WN2//*,!3-VG#.6<0OE
MURMN><:F*I_YB$+8VN)]I7T?,9YH23XF8)+]</J6_S"XC"#-(:O+C\7*JK>8
MB7>*.N 4YWMVK;O;:!FC9'$!\=\_??;D#?4D=V^L\#DM&W)__H?CX1"_K4BU
ML<P7M6?A+FX$TGC;R8<3T;7*?*W+1Q?M1\=!N#P>Y6*3'C;C-0-R&I'8Y+K6
M%QVBZM*V_.Z)R5K10_-X(GW,,.E+)>MN:;DD;2XYC^Y^WB6JRX(SMV1+\$5G
MT-755YID%D6A]U0W]T854BSJ]B58?QA%F7X0?749"["=?SPN+%(7G/^;VBO:
M*'!E^1;PEP@U;P8;1?53%T@'4(:S-=/U!W;1'>M> F_&M/.^D9Q,7.=]@X62
MU[GCI$OOAB8@LK-5-9'FPL&!9^DNQEN \+.3Y[A#YC=62Z4E><>MURN77\GN
MGMO_IU53F>9_=4(0!/^O)D9XZ_7L98[W10W+<\6CR27NO/"%I0;2QE9'[KSH
M5_]_2RD@A  9SE]D-X_$A6X$FZ#&4"Z,ZBV 5?,UKO=_KI\PJM %RH\'E:V*
MY26IOU??T]XTF:\H!18OPC?D>L2&V94TPMAYON';F+\A3(R2)BJF<R2:J*AT
M(JL'TL<57;)=6Q2@\]1^,Y'^U22PX9*:MW+MX@*LVE&U9_$ I092=OD*G8SR
MV\_&S#EXN#O,&I(WS9;.#$\#R>BJ,9FK\GI&5@3 #L%Q0:P.P,M"@;H97[>G
MXV-3LP_YFT0J.SZ\;K='4E(*^.O'"RP].21!<AB65:WF(GAGWWO^EIS(]=1_
MNRU,N$)*U7R@;GK5PZXD"R7E$M%N3D07?V8S!<8([8V*3T,DD,XO:ZPQ.)-@
MM(ZV=4*,)Q"3-+ ,V,738Q+7)7-UOH5#%>/"@-XGF^B?W_BZ%-AO =V2'M"H
MJ\Z[_(UD%D%]S$041V-!'ZM\7L.X+UCF.FC_826AI-Z],KXQ@Y+/M_"%2-=[
MV+_.W", 9)RY_)"K%+LLG1/\%G<TKP-*\TA9T+;,9 XTG3WZ[MGH;';,)'C6
MT;EY9A?="<[YDOV@!>644^;3S#F%?1+P^J:T>%Z9K7ZD/VHK3FN4<L/7UIYY
M*5_9R("_RR9<9#J ^::@C065T#NSS#7.+UA7R3O4#S>K-YMS%-AJ;Y@$9YQ3
MKR5MO*!)L.?[;2W%;H>/R(3,TL N+(G:QLZA=$#P>N5KJYF UY[0N06+-J.8
MDL68X5R/DX4A.#5FL48%\*U<N"?9(JT7/JNRI6'Q6A>UW%ZT;*7],#6K2..3
M.+%Q)6(B%V1,_,KP1:,#3.7]!M%Y\9<_&[F\325ZKNK 6G!Y/<'0H3N/"?MX
M^T3U */*I\QZ'@$O'5=GE905@>RKCN5B7^0P>@.C@WK1+;-<[9"DCF AW>_@
M&XV";+X4?(:L:H84RF_^/F4+]A'XJY94)BL-O#<[)[70?E,#L8,_PO#U6_(B
MI_/!Y0GXP)6%H&?([8AUY1E!I\]/-'@FUM(_?"T,JXI]-T-1\7EC,TK/2FH?
M@M1J+5]Y@*'I:;%MS[,G765;WW5V(C$:ED>AK*)M9PZSV!M><7U[S?H>VLH5
M3,;9!&; $=:B> =@S%Q3X  ;)&)TQABYV,'8D;T\ &,SG!(XFN_?M)U^TWV8
M+=4Q]"W9F<21VGI -FJ_, VYF9DJK@(W\.8KKZNT ZGSE8/]Y9WT8%O@6\!C
M9PUG(<OATT#_'#\?=W03AJS2?,&T#]$NI#(EIU2D6@$'E:C+N9M*T#R%$<Q1
MN!(\A'V^OQ YZEL  1_/]1Q=2?&WV16;[Z6[VMA7_U688S:E;K(5!HP-"F)Z
MA]9$ 7@4A-C3CEM \.< .Q1+] 'T'!Z5C1<?*&08HQ_OSZ#I)]8T_KS&G](>
MXM$G^MG0?E$041!/-/-/4A&I/3L,%P\O73V4H5.@ 78\_(JHGGX@?E@<%5_G
M.4BLLA"ZT/$'SR>'E2+X14OEAS:9T&3?5 6=E*KOF]2:Y0U39:?#61V&.;U#
M!6EM ^<5(^52VIK'?V<*FTU/]OUGKY[#T=T8Z<*EH@2$,_GNO%$D5-QD8^*,
M%>K2WZ/VKV#[LYX2E;7C7\)T +?[UQ'O6P!R_!;PH)[LZ:P/AQRX4!G!Y#7$
M4RE L?JP,WB74>GQSO>R$6'=KRDIC<*])$;]'??O8H: +)E19%&"GK< "HRU
M(5BU6SMW3I6ZH>QC0WN*$!OP5,S2A;NVE"0!2TLG'Y#9K8C4N+'KN@4\D>-#
M-&/UUC3-7O];1VXNYV\-0#7*ADN!,Q @*%!!^3YWY7866Q1I3Q@![,^:$EN"
M<(_+]]R'R=;5!F6E@S-QOOK?#00-!H>*=:J<[9O]I-U-#@M:YI)-QYRG)1M5
M<$QR6'B#@E#0)#U7#ZF5,;+%Q]N@79MT#ICL8/0T9^Z0=QF49XP5R7MS8EYV
MDXW>>U37E*3;R*%@D_SWLCP3:71(4XX)1PS-K,-[RCO#,QQGZ"VA:V24^XD+
M$BF> MTT$A*)BV86RTL%Z3YZKG'WY&HOJO 1"0=]%9AMA!'L\,$!&/0+:S+1
M)E^UJ_!LDMWDTYW;B\("G.L#F4?7P!LO.K(]B9M^M6CXV'A_963_LE:>A8E#
MNJ/CFC':B&&A6$L^Y$IDE0?\_K+]"IF<++*_U[B^-L:L>CPN-:;4 =_"Q 84
MQ1E/N/2KZ<WC\2>E78P>2%^OGT>9SHBM3; E3S'5"M]%58:;8?W14;)\PT?G
MU4XLS38X<*JP?LQ3H0)5?&B&U.BA<<6 #%"C:27[IEEQ2^,+3ND]P#)43!P<
M2#9X_[+:U\G"G),XH&N:_Q;00-8E+_M^\HP+==Y><&506)#DT&'\],5-U?C\
MD;S"7S,SN=I%QZQ7$:%# :6$[-N*F4%/;V(Z7NRT#'2/,"C7([M;49(]4'J3
M #V48LRO22'FT5/+28_,+ EB[=^C3$Z_?B?9]_KJ\8IQ:(_,[)!RX0@7(*LK
M!+.0'DFHC[,9)O,.&G=7GL@I!B) @6^W>V=F_&Q2SA-FH;D-:LY6FA16A\(1
M)@1A!$Z/_2#5&*(,=%/L !.C?MZV*569EC!Z/& \5MJAS$4GR<6PSM?F[TQ+
MQ'ELOX:I:$U-;8B7AK^@P3+Z4G"@$U.,WL'0K=X":#&2O7X=91>_?4[?@-IE
MS6LB-8MWQP5_3<<X!U@$[#!K\Q1WA_XFD29Z"35INRG&X0\@^)R)E-<M1,UB
MAE^PGE1]DJB^=!WT0&IO"6XX"W(&<(^J]5H7]W80_R=C,#$JDP$Z"):GH&6Z
MZ7HARFZ.\_/8U)G#@AWO(R3,48S;PO"(W?Z?.1=<6/> [H*1C',2LII*WY!6
MM;?,UC 3P%,&I*\<+45H*HG[M"D)MEJ72"3*%Q8E%PTZ?&K0>-04/T/(.\B:
M9,?YLCBN= WSO")?%3]]W<;D5<%/OE'W0O;VK?DL=4$'D!HWU-_+6K=(FN_&
MA$>B_4A#++-V2DE6=J^J<GY@&??LIO468+="XF-GA"*AOP;%%#CX>25RAN2_
M&2E;U"QU,,QPI 0.B[DLP(G,+<L'V=ZIA4L3<#E$'Y\=S]>N5I570L,[UW@G
M*LYW/#(K'?9&<1^2=J?13]U7'-ZO\ FEH'\(@ L%&&U?TMH$W@)>X)X&P5@8
MY*R1*UU7T+B);N:'*)80,9 L"QF0F:5VBJTS ^2?+@%'<+6EHI=7"_3$XO^)
MBIS< KQ/B8*O<83^J+MZ)'L+"(WHSY9%LNN^['@V9?7^WV&;LK-"J2\4.&&J
M^KC Z0%_JNL0^68\E3H)F/5ULH7>$,9-)RE;W+^T(4-O<\P1RCTZ6$F1LM!0
M)3A;-HMI+3,,,I6 5I7QS.,@7\\/$[!49&NIG2A90XS_FEHB5K$0.*_0[(\X
M5 V@!YGMX0)B!'X)UM1]?CE"KA'8-/\^-OJ"B>RN!),B"-J4W3^NWU#X0XB5
MV!S(_]:^.AG&<TN]9C W4ZGY">MF;)8KW5&'PF,Z,5R0/@M_/=PLJC&Z@V[!
M=!9CU)6-/\'?QE:$B1\KG@AXGF2R>R'=OFQY="1-7;7T@^<#@3Z3OU64(E*S
M',Z,<9I0B>BGE\A"$U/'FO";!G/TJM*7$_<',XU_KJ+%EZN6!\%3*=F*I3_N
M7HL_' :J"*<L*=.)G8%J=.M\S9*\DFQK8+;FU4X_,V<,ETNM-.:/%CSGEQ)^
M"W4ZY "&P:M+_LH2'4)(:,SYM1691I6/DX'GV'G4D>5R_XS>];O?9.*A[H3W
M5;D5]+XO-G'M:1!TS$& KIX-2H(Y[-5]!'$'!=%&<6M)X#EWE\04@WZ]AS=Q
M00H89[3B#(X,P]7%@B_6)!;WZJ*ODUI.:-U"VPRY81KJ)QA7Y*.UAQY?/\S7
M^;8899N@HV[[))C^S;<21NOSTYZ&AFD=L[E>II886:G#5/O07Q:T!FRI]JF&
M_(E15*44O-5.^M1;;>^"B/&)JDM?U9HG.8F$U-D,7>H"Q1I;:HTN?+..T@]7
MBZ.SZ&3JOEL)7#8';J3I+SK5+1555HT &VDB/(P]I3U_G%W;3'$F#"5AGIW.
MLWR_5(IAJM[4__Z>DDW6V]V4U,9AW+?C+7X_\;U&EYW7X/Z#>%$W/S^#,KZ$
MN0FGHR?._DU%Q_O604!O?S/O1C":MS*E[%?<1R5:BURBX$RE/PQJ_?<V_+SZ
MWH@-DS?>,#T>I-<?-7.,B_V]J/VKYV9LUL\JKVRX9D+YUV4!%*AA<;-=A0MR
M/N:MS*KYUL-.0MRP^HMI//#TI]W6,5QL\G=]G E;E(%YM:,=>_-PP(H_?O:]
MKL/H9F7&ZH/ZDU=;::<:=U#Z(8?$_M'1^.59N;33 5M+]!#"WA HD-^>:-MB
M;/JR3VZ7W")Z]>@!GF'41,50S0\:4H8W ^PBJN"_K=VD==^D1H4!_0\M\KY;
MT_(I<5=64@]5[E2\#F5H#36S,->#^!OQD"J,?0:^857;8;-]V/Q2B3A8#4>>
M'/O3S6$(%JW^($D"QQC4YEG*791/M:#.>0%D7RG?;UV^3KG+PA:A-T8>^B<]
ML:1_(:CI6X"<4<;_M5U>XK_;2/^#.:KP%O!'9AC7GG<'8P\MG$)N-NYNIDN!
MD)/'-;< J'WGV3TCLU^W %_%,_%?C[GZ%4^X?2)P77Z-N!CQ]>Q'=W06JJ'1
M')G^L#,[>>&+HF\+0A4_23'"15&2COGG-<M_?3]TOGD*&@C H\7<U=$>J73!
MO,2Y[WQ+XK!PVDBN\,^+!I$/B./FJ$4+M>KS=?.+DK<T%2R!?(5,4Q=.,Y<B
M91Y[EN*\0[&ZSADO7,"55&:Z\?''*H<>=1-:G0&&M26G8;"3DD2!'XEXC/%,
M8Z_# (E9L)/V>+(MJTC%U9QY(5CG@MD 2YTVK%6Y';F \9*28U.</P:S:&7+
MQM@1$@%/NK>Y?G!:H\-2.MR[ ?<6<,LY#8:%UW0!BDC!^EP?W048CAOS%?$G
M0,#Y:2'0V[O(%.[^-)<?XFC&PY:^)C(;\9R0V*V F=0WH7<%PTO3(R#T<@RJ
M(+HWW: @,75L2LSTHB=#H=/5CO%^OT:4P:I$VNE7.O4H$LQ#UR17*^64M5,'
MXAR!?,-\C#7O6R>@Y,ULJ]BY+K#<+) LYR^SA7(GT%#<8.JFX'OG6:DB?"N@
M&=$Y&X'NFA87BL\A%GN&G LB#'#"M.4\$6K389W*L9@(D/TD)^O[(7$('9NX
M.%B*<:!-_Y:S-.2RN.J2S7NGJ1I8-Y1W=( .*E%!W &M2%F7P&0_G].;0+(P
M\%$PSGLUCL5BPI.8W#?0LVBXK(_J6U5!J))781>1.HG2M5Y?)](0/E?#$L8L
M@4E!GFA3^>QB'W*F@R'YQO.:3HV]1M,>AV1"SOXV0)<Q,X621@8:4 +[NA2?
MQ2U@0&@AYQ7F(U)R#0);>6R,<8>I]J-EWLP7AQ]ISF#936U2)KK +PB:&D\,
M>Q"&34W1^J*7KFJY)G-*5SXSZ_O](D-(=*7T*PK81Z!,O2_/J?149J&NX886
MKZ>OLPVQ19\"D<^[\#HV0^,_/7K1WW.)JJ-#P%4&U%*%-1>Z8^V5[G (*&=.
M;QW27^F,#L2DY\UBK/KIX5_.EBQ9(N\4E'2YVGG-?\GY_3BXDFWR%UB^\MCD
M\-B@RMHPY;D T?TPVE),[[H0EF(8G82)8XGW7&#24T.>'T># _"%L&P=3$VM
M./A)W<,6_RP9Q7K8Q4-=Z5#6=.+$P8"?,TNF0EAJME6GS%Q,8 ?7OH2P3X19
M6X>,4U;QKLSYR$\9SU"744^&6I"==!AKHVWZM(EULJ,J@6F[H"*&>^8@7S)!
MC@9YM(!@:A^(D?/WSH/G[LE8A-=<?:9P.'WID27C#9;&C5XEF[.37Q[2E^+[
MESQ,48%&TLJX:O!VMW@L1&N31I1\MQ++=/-(VHA.2?;KX^Y3,30L_>!&:#F+
MZ3<T+=L%^=NWY^W4SW0,;#3"CC$<WH?^".WP3C(YXER?B)<RJA$']>J"-#JM
MDPIS^2O+ZF 97UW5!S)-W]2&B)]( ![Q3>;@""U0>CH8'I3L.TV01BUF:IV%
M$BLS);9DX%0O;7;-TMU!GM/;.!VJE?2&K?V'*9R-H%&$Z#7/Z'&3(@B"X?8.
M5[2UBJ%/Z"G!,GA7[4]@!5':,*O&.EUU:_F!"+$%C05_SU0>MH2+_FO@PRXK
M!*]24<"=U0XN#1IE?H'Q#5R'4&%RWB-5Z@MV2-W+@-YH&N22F508N\\A%? D
M,S2P->\)7=2KYD^^TA7P!)!NH6&V4=HHI<=>]WCOQ^2D5M<6?5T7[XMUKY\&
M!5D5MB<'20+%/TP*)K0ZTAK0Z';<_MD_[,%=10PVP8W1T_0>$XHU6K*@5!HI
METR7,2P&G=,+ZG5U20CD2.GS7_&OW6QF=^A?TYJL$-T#!/K[7S_!&B>CGV",
MKJ46K79XUE<>.#3*=%3:D;=*C-AY>I:V>:V*/:PF[XS\TIOW.74G<'H=1^1Z
MS6F^TT$V+7;\%!-BU8H)*>>,R3/9G3<LFBDM"[IY0AN?^,/:HR;UTWA9$4)T
MCI5Z K):HEAC,%J\'@.4 Y;.[67CA3F+JQ^=W2C9MDTL@3]PT%SSO>"UL*B0
MCF*@>(;W@;YI7:JJ;DW.RW3-,$M-7[_D7RS0/Z[,3:>H68"#1[J>:BEOZ=+1
MSDKP3WMFQX<,;ZWSB;&%_-+VPX69TDN]-6<,A] A.6C]D#N+LM?4T=0;=H'Z
M@OEQ89H^2='G42[%5#<L#R]*>E@7G;>NS=A\]$AAZ:8"\B$G)EOFW\A%A)RS
MT$#<"S.493U4\XXA(I7Y#^HZ&X'HWP7S%O ( 8\;E8<-/F_^/)SGNV0V"U=Q
M"0I#1F"I\M'ZJ+"&3"I+J33U*/'K!1Y;E'AJ\:=E#S^[[&D4?XMG:Q]-ZIZN
M;]J@MUL,7\=[OW7<;.?]B;6^F3Y_9PH-\!U7OD.]LR*K\H16KUP*.^R[%_<D
M+G3.1IX4I1G711T-B=>R1UQT\:5L]]DQ:NO1A.62X,O[&H4Q\J8RI//6E*1(
M?$<<"MK@T]#UH+WK)^*;WD%9XXA&:?^\M1S5Y-(54#_9J1P] ]<=9<=/^[$D
M/E5$ODN8I]$<ZZ!<<6C,)D1)5*Z5LT0_,=Y- Y<_6*OD&K"DTB36&#\L"I_G
MV=#DO\PV6QP6JXRMB]?4';L%K"9;41[7W5BT:;KG[M&WV:V!C)?$CZIB'J:%
M.W&D68ROZ6P6+31)F/WI(\E\]3V1)>/F&0J.I29#O\2XE\\#6^#Q@D[GLG%.
MMX#>Z:1YX%7A5-[RF[&7'ZX#.U($8@1:WX4.)?_X[<T?:MLQ78OJ"*OPH2"+
M?+7JD$U_)^L.SK1F_!JLK:TU#;]E\BK ]6S?-.D1[,IVX.Z7BZZFZTTY"<+J
MJ_LV=*"?E<P!*F2$A]0'T!%>3_;LLOV,W17;>,_@H8FW+XK:$/F-697%6="\
MJ1<(LMEKM&3.ZDI($#N&;* %M(+Q[V/F'FO3_K7S]'38%?R1,X<S7ZZ2>$EC
M.Z%.W2_^]=!^5__#0/)5JSFC5<E>2"0-"Q66'(GH5<9\K5*GCL.U7??-3DRR
M4_;6'HJ:Y:EO]%@DL1[H,\U)0V.#&"#=YD$ GX;1!P@S;7*,GN5,&PB10.AC
MK046TFEIFKP%K-'/V/R[!8P9#O4?O#E:L6/I/.D"!H';$O=-C;!4M6CM#I10
MK)R ZSK=63NHVX]Z($J<6]Q?X X!6F5]["8%#9*U"%VFCV7XO[T<-_>-V[RT
M";EW.B4*I=Q'&#@8:YE*Q0,G"U5^4M,U2W77:\DENFX$5#;M#IV;5RID^,3F
M$-)H5;B<VRGZ4982N?^TID*,?_^>T=:^SYGLY;\7@$*%H%]@;K@.W1'.,;B'
MXUC"]3N\W-:?X*KO0-5O=21AY9,F5.LGEL'T MR]E,]2YX[HG*9W\<:3&_,2
MPA77IE;J&TK7.Z,5N%&241Y1VM%B0@=JNJ/[.NKBZ2SFOR?IU:@_Q%.K':R!
M//%@"\][W1;NW/<MH-M<[D6)3V._C%U(G8 "&9D/Q&CBC/0%C)ECO+X<I/TD
M3D,MQOA:("7J:4N2Q:AWG22EZ0!HLQ_6O!AZGD.@N%K.3("I50QSKO+8D7NX
M>F-NR?*$R7;\BN%&8D&[J3W8PDBK^=XAB2C<]O< ':4YI<AST<=[UPZT03)=
M:_F';@%EY6&RRS[\'*:5*J0[RTQ#[C4-\4>&M9.GKB+#U;IMO"5<' 6F.J9'
ME>Q)&N56$HE+08,KU8V1$+L5!JSS5.5VW026;3TGHA:C_;+:5^AS*"9O4U^C
MS)P]1G""HS7&F\"+^EW9YZU.A0#R6P!>X4U^8AZR*K_,1W%ML8.Y 44ZE1"#
MY?,M+YR)=3K7Y-WKD=7\*+B6M)2/QY;7[91ID\Q*$F)5;,B"U%><D[GH619"
M.7:(3XL-RS-],S?9-[7-ITI+K3$W,U$.+#:!6!=.]6B[BO;$4>DR#1G'1?=G
MW *0NK> .5&R"%&L2@[,.PGCKSU]A%4L[2O9;?G=6MWQN[&N.=6[7E/:*4\D
MIBDVBE\VN+3G#$K\( I!8%W6^.5GF4&"0-E[ _[5@M+K9/-HD:V4E(.%^@E9
M5V.21"URW)BKA@W](9^LE4.YV7GC<./H78_:5K.*B)R#RS7M6%,R6-:G)<].
M)HR1 ;(C['.:$?Q3VH@-Y%%N56FB7+?\HI%K:U5 [H;@G^2L%3&ENS>T=%-6
MW]HJSP6#KFGD$&+8E#'YQ?;5"WL9![H.*)_:MQH"@OXI>A3MW=>B:K,]?,T+
MW=17WD@^]/18D&* 8S/&<]7?'VS4I8BL;)-',;Q!Y0W(V9X,]VF4D547MO7S
M_<E0\YAZR56GU.)2L,'HG</4"5KYTEGK55FP8T5Q3J-IBA-OK9TXRY37.CD2
M$-5A3!!'F)DN$2!JOX8FJW/^F:+^(4*D!H6BG%BD^_B9[X>93.9J#L4%R/&^
M3J4V<\M7J50PKO<> 7(-79J!7CN7N!38\UB?,K[[<%0Z3!;U\W.A[<;6KH$N
M*'5:L]/?S"F(T?AN_G-"0*"58!J%ITTH=-;#,DS#L$X-,G-QC_C!+GHF372(
M(XG!2OY7720L2?CGG__!W'M%-?5%[Z)14!10I#<!E29=Z1T5Z0("4@-$Z2&$
MB+0 @2A(;P("2E6JE! ZTJ5+%T+O"4UZ0HT0PN%W[KV/__-T'N[#>ME[[#W6
MG&O.;W[?VF/MR=QBK"._27*\=%7Y>>XJ7C8[9V.2FY:P.AD5Q ''8%?PD).9
MLPU5YF8"<U>>F14J/NFNK\!FNXB/"XD@S;=2*7>]V61YDL220Q?>2J^L\0TA
MC$^NBV[BQ.[=Z"G9L&H ^W<60$&V&+5J4;$RRQ?:T GX@,FU6$[8' (;/DV6
M/&_8:^+!>RZ%=T:6*HOX+M-%IIV$>NTQN_CL][W&3Z3C^*0":ZI;:V-?ZC'7
M]MXP3>7_^A'ZJ6;/3HI;*98-]+ O535JZJ[PY\!))9WN^$9WH$W?D%G4> G>
MJ //621!-!_D=X<(QG55SV^G-H-,B_>@QU7*)<>_SN.0+A+1:E5T;=D?LF][
MSS-EW]B8T4Q8_II_P#+ZJJH*[OX@3ANE/_"VZ,:E%G]6+*G3JT8Q?>E>8:3K
MN2"0J% "][6MJIY$/):IGT!H%=HN6LO7AK^L_YJH7<.V&B7]2%+K"VJ\(OZ+
M0](ID  A4\>>J<)![4AF7OSM[\P7@$Z>\!;.^$[%B7"QN!+FVD) ;57B&N2F
M0VVP$(N0^RB=D+N5W70[PVW9)JX+P#6-\Z]EJER;/'=(CK@/6"C(,&[06^U&
MIIQE;7/T4$VPT^/9X<*FU/?_HOY5^@W=E%<R4%:P@^?4W!SI7'GU+6-3X97%
M0X%YW61!A2)AZI'U(@6-;OV'[[H5-:3*"H\=G'E*[ JW687S5DWK=1-U3#Q3
ME=XE!<=+^?>9^S=FYQT?)W7<0C4-L+ALBT%;)JD&F7\$4TK^TKOJ(=I[7RGD
MD13^R2]:7TG@3>4O2^91 G'RTQ$6_81&#[[']Q(E ^Q:J/%J.^-+K=$\["WL
M)%FBH? 6B([,#Q=2-O=$1Q0&ZPGQO!Q'/1>#^:2<1%EL&*%98N.EE%]/+LK1
M ")CFR0H#1(J<QOJSXC#?8/E=]_&AMU=,6]??L06)5]G6^VH;V5T[-\MU*]]
M5C939M[@=HI@';>AW#!=__$/NN<IQ[5"%JRJ[9_H4*4](L#.8^0N *?2YC\G
MPQ'L6[C%,S;8!>#0!>U1.I3S_]_^=?\WAW!FSVEC_(GY!>"):_VK7;7Q.61#
MZRG%2ZJO)-X+P">![Q> -[%Z%P ]=Y$)D5[R98WYS?CR E#>G7\!R*]CWF("
MF*H\T_Y>T9CF6<L&74W3:E-BX'-V_D6E=#6E^[;'^YM=UJ4[5M+I!HW!%MPX
M(2R</TR6>H=IN2_IVH>[O!4*5'%C8Z_28EK89=B! ;))M?,2X_Y)<C+LBC[K
M1NYWAT;6='[.;SD&V,P^1U1]0_B-U* 9@2XF4PM@%M8ZAEEB0&>5HDQKE%.D
ME5;PC1'*$1XQQ,#0CU8Y(Q!KT!^>.LTB/.:X&E_7,2_U<E2 ",Y1S]]84&/H
M4EJPW&J12M&_/M$Y7]KK5E+H2AWSJW,SW%/Z/=?1<7?X96;:JT]B)R1J4%JF
M(X?17Q?;%/D[1_N=L5OI$0,,DIVONOFT[PHWW(AP5,^*@HN9'\N?9QTU(KDM
MB84=,S[Y9<3%SM2@^Q--3\LT8![HX2)#O^,I@_@?P]2]=WW,GPP7SFJLJV3$
M\8CJ+D]W8"NCWAF8="GZZ/9]SDA?B]HRUV#VFM@UT],W%&X1E*MK^]@P>]*[
M ;D #&?NH9I]5#T(DR2F\!?X4_B9'KZG78W-9J.%N77B4(*66#P,^O,:H_P4
M9W,](%HOXNG/*[&9@RNRFS35'E]6+P V,94G%X"K%P"W6R)=5C9K:((P[JQ]
M)F]&/!,I%R:C<+O07\)]6[\M7+,>DYLV)O&EZT[)B]N\_S(<>)Z&'/,3)>C>
M,V*W:_VW3Y_-;W)$1)V91JY++38,P?@:$\>T;G5NY^CHA?H&_CHUUUKBF1;$
MRGT8W<C#9'>QLLH>&UG8$N,LCF@RK[B]>313%L^'SXT7L_0XADX_UC0G>F!L
M4V^/5\&DU^*R&SMT!W6-FC*R^$505K&91WHIFW/EG<Z2T-GKR3LH>%GLI2=B
MO1=S#E3?_*<I\A>H&D<0.KYJ[7LLUKW81?K^;RZR)T$/_C"^(G"7'BS0L-16
M>L?MCB!',NW2=BFC[BT'W/J52@PG4TM@D3>()J\(:A&J;,04-4:BG@6F^@+
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MG.H.1[VW?X4^&L+A&31N1;_FX^.*0._(EX#2]MU&#!4]6F6!E5#E5XP7@+'
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MJKM%D.#;W<H(_TRL[.E6!(6M P^XUL+58F1DQQG6#H8JY_#@ SMIBQ&VY\4
MP>N%Q+U+52H^WL1SIDZ4TR=*.'L2&+%=X1U[$4&\Q ]+_Z"%^,&NCPLWXU_(
MI5K9+)07P12MPIO!N-K:S#(+K=5R>;-IPJ4.V\(>)RP;7@'+7N)\C=PHPB\
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MLYON5ETDRHMUE/_.+*3*$@2V-[(Q6QC$LL(@/%_*:]J?VUO>C(?;1QW2Q5T
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MRT'"3VZLO/LIKZ;YG]\N)ZRW0?ZN1EQ3.KH 4+\EQ(>>;>YS-_U[J**V@;X
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MBK74B:T5O2F<7DR>Q$8ZACK5E#]7$SKH)M9+WE$MO SL_@Z>0[;4"\"5R0M
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ME+6IP3I>-F#-U)9GQO><,M<Z*]MQ65S$NW;)Z^L^DF-])%"RCHYI(SYI(W8
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M$,P-_ Z8XW ;WJR4?=DPM5,G)65=VUQF$Z[>7%J=@;M+H^SZ-K$\U?D!"30
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MVPU!6Q KSXDM'Q'MEL"LCB:!LKS0$R30.0D8T?86"?2BCP3Z_@2"OP@AU,4
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MN3V[#*6I25TLG_SQ>UX;V85B;KI3A%?$#EJ72[Q^9C?',WHA_X6=K*K[\?"
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MHWS^^7$"*A$6C)^"N/W+?TF.05RR&^L''\<&2>5+D:Z9B>3\F>4='NA:/+,
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ML\I\KJDJ9<&E8,)N^PPRYC'[SVE:2R^IW2SI(,-%5Q(!^!$M\.E_5;SXWXU
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M@UWAL/JTB'5L.MIAP(A3$BV,?_!74N&93E\4(_+-A#M%4=>= ]5%[F]EO\9
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M5 "RUER3_MXBSZ4M=$'T<[3VGR_ETC,)-$2T7P%V#Q0;S?W<?00;,B*3]6\
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MO [+?_-R_S:,#3K2_WTP@R%W/_;U\1URQ'7,L1!GU-S+\^Y?2^+Q?\26HT%
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MW#KU8.9SU\)N?D_C3+Z51@5S#3_LVZPF:VK2>]NL0!TN*=3]KVM&19R%\E7
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M45OGVMG7WA8-=QRGG-[+[%NH3,.U')_Z[I<>47;<7MFSA)\9[VJ[J'%D)4[
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M7W^WPDH'!/@N,3(:W.U+%DQO% ZX]RHZ_\/1(=:?*>I$!(0ZQ/%9W3^ RA5
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MX%EHVX%[Q\RA%:;#1&]B7<I#^1G\1]?'.<'/);O2+:L("A6YK6-@#96ZR<T
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M6'#S_J2S:>P_>-515,C7VZGV<\O.Y^#Z5$+"'9QD'@^,O3<PTBZM0QG!J,T
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M266Z]DM=F.J@I<L?*FAQ3S[>:1#(B^'Y].@#5EW)QKGFFJ[XCX0,3J\.8[.
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MH\Q\DZL!QN'WDZ)-O<"R_N_119CF=LOIMOX>^XDRD]!<DVHA%_!(*LBGI/'
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M0WZ^22RV97=.Q!N*MD_HB>Q0J 'KZIR1/#:K'?=\-QH:+21/OZ'A3GLQ6)H
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M%/#JK"#M_3QMNC7LK16S:UQ=OM6&J#65@<,2* 17*__JIGO4F4EM87^*:B+
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M1EW_\PGH_\?_VX!?3?\/4$L#!!0    (  U =%K*$\0/5<P  &37   0
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MHPMA'M-P1 F48OR  !36(.S9"ZJKBO,BOK)&) LQ^D=D"-5([YND_]U95(E
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M0L*!W0YN+$,@;V,-.A1.;0D-A7@Y1A<O]7^W7N80*E@N\G=,)Q.0VONHZO&
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MIU'#)N&%62/]Q<;JBPW;XD//V8>5]IZ,;\GF1MLH?DJ]23V./M9QYQG'O-\
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M]721L7]XS?*%\\]4\^)!)IGI1_UL%V77F;? F[5P>/U16'F[/H+#'L<?B+1
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MVIL^NW?= :&X?.;[1ECP6<Y:+YQ1*M;7I"^(OM6WHMB'6+6SNLGOR8&#^[V
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MS\61<A![M\H?!:"*>IJ5\K,>^6B19^OQI.,[A)0$FX"@O^JQ$%=<6DF\5\L
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M6I(SP_W4\["*M<#9Z8+%]H'+]-)\3=(OH!%BK=^2[#=OD[RDSQLR1)$-A.E
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M1A5J.M6A6D[0G&W@8.I9@L?Z#A5G(77:9T?0=Q<7,9LKK;IIJ8D9"+IQ&Y(
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M<U]E*86]@PD(&+^_;_OW]\WF2*DP3%O65IV2^;75T@?_SK/G5G/DH-;R--0
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MIB>K/VQ2YZ/>F"<1X%:S[>8QE#P:.JU9+!CP#- [C<3KH75+TZ=EYFR31IT
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MTQ3Q"/! D_"<'E^DLI$^19J.H@FCW<-BU_3A=0+"R&' R/\"$*/RDP[;0&+
M)V:2K_>N*HS*O]_XVLNB!P'\N\]9>CE-J,D_JY'-/P-\%$S5O*YT@T+I$'H
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M]$0,[/>.MMX[MHFL*:5Y5 /,N8HA@X#@]">WJ9J1XLS78$)4M/"A+=3QJ/Z
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MRN)'=/( :$]_-S1V?!-WFI"MT _FL3-OK_^0/,OFZJVY%^[4,.F-OUN0R43
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M_Z'"&9&]O@-0&4GVL)#^@^D#_TGGY?&J_^OYX?]!(@>3_P)02P,$%     @
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M6R<E FU]>A6@O&/.WX5"7</G+4NRJ#YI9S$(G0M>^.6@I^;O-X*SP+=KT.)
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MC15&>V4_"4(.Y;/!7<5,A3J5A"AVGMDU!C G&NWB%'P\ S3>=O F/_4_5Q+
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MPFBEQ+8[]-8:YK M;6U==2A?^=!51U;[TN\[9! ]4I81)"V[/L86Q8O^E8F
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MMX_ORL?6_PS$G@899HH,?SE\U:.!V!ZZ(O@1H.A C>+8SZ$_8X@ U@!GA2^
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MM4*R?YBP=VC6X&6UJNOI6UY$:LX+3.J6]D_Z0SMW9@7Y%T('H,9K241 6CO
MJ-B.FJHQ/*V-?#5K6[E?$7_;'?[?:3TPH+]);?S=7/H?'B0)+/R[0++/T65?
MXK7BUEI=A=+" S*'T* D_TNLAB7N0GPZTPQ$(##SVY@YY%I_^#%?0A]AL.4?
MQ8W^J[A):?'0FQ\*+W9AL7>NW7VG29YF&2^F\F2=,DWF\A4*<3%E,W_KL(?V
MOLJ4U_A;078OX_'I 7\H=;HS0OJ?^N.O;_\*3MY,3KK![48<MTOR#0.7?D-6
M&H;;9*O'HU +5IFM7O^O]*=2XE'K-YWYX&*P20X>,6.:S#X7(N!L0P3^9K]B
M[*55(O#%<>70AR"U$"FIS7./_6[-V3/I"N;<GUT^"*W1?.EG2JKFP6/Z%?[6
M="P]VAO4.^Q[MVP"I]LLR*FE!VQ6C[_]@1&"4BHL:&]6'L5"UTG&RR2M[=_4
ME'O6KJKO3I]C&OH@UJAV19"53DF0C_E.^/KS-P?S6?+NG)8:CDNR_=99.1L9
M8$'7=_1'75__K.;.Z->O)*^&D%QB*J,W+%!J2_-"A]5%"T-6:V5++K]/XI&^
MMWT3PA471K52'$=DY))V*&M;7^54+TD<#IJD^,MP4?#@Q)4;\AIUQ2MOT^HH
MGW[B5B9H0/KK W<UT!M&#9E8JZ5T+QEIY1'.V8:E#JB-0/OA-R91BHIKX.<?
MMKNE3^YRX1<@LY2B&UO?8.!+_'571Y^^N.I!P9_#T_]S]N#3Z)>!V$&UXTH2
M[(*SOD[TB%]!\3XT$/8G.R<6,2K&T"8H)C_+4N;IRJ\/5!T<?:%Y>K;7Q2T4
MPV=0^K*I>VS.)T-S-:V^9[B5-4=)")RF<-RE=I_Y3WX8"'.:^\/Q.S\2C#4O
MT LYLCO+58M@;[EQ2/(K.?.A(M\$YY,-B60^=7NY)_1BMC.O*\MR6"J'GJ\_
M,DU?,-HB,XWIFAYY^5_U6IG-6MDZ1/W%/R4A"@3K30K$(C.T&\;8 )H5[P4U
M5355(;0QR0@XX]=EO.&-%,U6M6!_JP7+RJKX;Q8#_FM^3):1"^H:.T'Q21X#
MC!_+H^*G\:DYY.D%U/J;YGR(6GB=)(P4ENN+.-N_+M]?(GJ3PO2F$!VM:FEJ
M\H&"[;*C8A.R9,_T\GFV_A_19>RSIK'@2T)".F^>2JGRT 6[N(BGI[6<AFPD
M.3C60_XRX[\$^A^Q,(YU7 &9DZ;$PS7<*$RRE!72AFO+1(4N:P9ZC444.5 ;
M=<5"'[SDH8S>8A^.X>4*!\S3&(#EB26G=;+X>ZE0%>=_B(9$4C1L_#V1 EYO
MGP^*%=TL=G!15@TEN^,D&#P !/+=MW2,/R=30E;JX)2E:=&67/$1!Q=U.SCG
MK_,DE&?Q'W#^-1/@PIMA&'[ ]@JOQI;!DT+W9TZW9*[+9IQKTH1(7^6(SD<&
M)#5"AE._)5&:N9%%?5G-=LL7.!_926[-O8434<LL_$O0A_Y+-(D?'/VCDNXZ
ME"Y&Q2>\\<W1\F2]B3U1@U0!GQR6O 0#[I9WN3A6L+$+4VN;Q0ER@JX(UJ;%
M*@G1J(>O_M4%H.JS)-#H?YS0L]*;=R18-U-R284:/^0RD_=\L&M:1< \6KE4
M^D.][-6W\O8YL@BV%/H/HLH @RN%QA(K*6_^;:GM]\\._YSR6H&)FPGRR4+G
MJ]K(S2ZUF+LZ^-/=:P@2]/LFG93PZ'OW0U??#%G=-8-,50Z3*V:FIG31=#8G
M%#R" NW?:MW?6[DW3YEX-*M^UVX@-UCBH,3C@K@WZ3;2 LQ^-V!'*@RM7P5Y
MIH._WQS-&)"H]0]HR] 'G_DEI;A1V-Q(N<W>RZ)=)RY]I=;2YA1,/JR9Y)PR
M39-Y;_CC54_Q>DJV4!2[B(Q:)+*'KYJ7S)C/M8#J(>S?9,8_K(+:FR<"2X%D
M%8U%2:$F7&JT;R@?W"AXZ/W*Y:Z,YDYN"ZU)^YM30__V-?O7I[_UP<XI3.(%
M?UUWPFOK/\P+>OEOO/]_*AOX-Z*5Y1(_;IN;?7I0F,,X3ZNT?40VMAJ&A6J\
M,*>IO%X^W?7HWOV6!P%/?,Y=FW]=]^UYCRHVME^9\FA3W&+SA >"4LP/&%]?
M(2E>Q)3[/\4D_XVBY_]&\.%+[BMX!R+PA B@?5 <0U\Y\,G'24[WW!U?>YN*
M;USN?B>=$?!->G! I&74DI,,2!Z=@M*<:(I4ZZSDKU2'?Z<\,M$&V/\ZY%]<
M$PN(EAZ@.3PIUQABFG_*&O=EH20:S!IK;CXX=)<[N86BP#\@3^X.E5(EHBF)
M=J3P:MO[X+E0&GI]OK=7?ET@ N1 <:1X4N-](O#LV>.#:MBR@%2^/^]N4W',
M]/D!H6GS,"+@!Y_W6?6,:20"&<^"B(#C+&PKZ#7P>.)/>OQGX^*FWQ0-QU=W
M+<6S+3#NA$=II?"2H)YZ//>98ZO9)C3NU%RQA&0D=#,1L"79Y*DIV7<=O9E7
MX- '=;>MP2?JJ*/W'NS8'2)@8WZ:D/NO'=%_,@1;>)KS,B#!N-2RPVJ8)F]@
M&_BN[X];^N ,VJXE]-8^IL#S#6FI3!3Q 3 \Y13D#6Q0H8?P:1173O'N/VS<
M/EG#GT/IZWY":KTC[I=H5=1SI!J%3V>@YFKOQU^,4-4+H]J?DG>U0"T^Q<DR
M!(1DVH\WR.4-2RN\#^!_#U.Y'WW9=F!#1F^8S=N?FRTJ4Y,_F:/7 \:"8RP9
M9:PN1E1Q]H?G5*TW6R=.IWWE'RM)DW/*Z+8HT3\?J3-UK\]\7 .,X;7Z["6K
MCW))+_<P^%)5-K/0)X%XZ1\I)WYXY1'G'5^#I2,UX/&1J8D!F"*:EELUEDF7
M,7V69FIJYRY%QI,4B":L"I!@-]'D(P+/0\:.R2%MS(2GQ67O5/D.O]K^&, 9
M5G%G&%KWI-W6[&:*:0H8K;%K^6!WD0BDF;TA_(:<L?[<!1&N9]D?[W,1(AO(
M2O_A4 4'7P8M^J'%OF^AZ+>Y:$/%MY$RQAY 1D(I&@MMN6S0:](YK/<0+-8_
MS]-Q+[US:U3-@DV(:^9QJ#/U@)*(FD!G$M_JRF*Z)NN/^^#V!&':V9AK+]/]
MOL33:@F)G$0N?#K&B3F_M/T%*-\W$TF*^'4*6[")Z&G2K0(,_ZR%GLYU'B$A
M'CZ6(_74SQ+L9,,ASU\VC@,BK^^.[_,52-XY"#\D!'P-"AK"I!+4 ^%8>BO8
MU@USRW_Z: ??7N6;1B/V:Y0483U":?<O"A7>6DGUF$Q.S:71M/R./T\-BE<>
M+5?Z+2Y.BJ:TZL0C.!'XX6N6#]O))K0:D3)# O#Y'X^BW*&PWU/$5N&2?8/A
M!W>JX;^M??"2]=4HP@JL=7%PBL:3"%RFWR'T-1&!L1T58+_\GSSBI_/OA-7]
M,46M(\APRV<1 J01?K9/!!HN%3$>_3VPWAAWP(_[8#GOR_^I/0S>U&,VV)0B
MJ3X;!9QQX6(>079(_>-PZ[E___-(%8__(%8AD@1%' NRNAGKCF-',>/$\1!K
M-K>.R^WPT+L6NR#;<;DJ_Q-]17._XDK5]=C!;&EEJCJ63S2K\-DI(TPS8AZV
M;(^[:G2NIX"ZM<F8:]K-SPWFCIK,E//=NH#+O6I^0KW8,Z +?\7ZZ^IN+U<%
M_ZR64DX&._38R"5S&!RD::X*\LCF4;__?*[%CHEV%-JX+J"!242N=+;6Q,K!
M>$**>^Q /]7NAP4NTO=5S5OU^;WWV,RP>9(U+TD&GM-B3Q<J K<YD&L#4%8<
MY(=\XN(,S;(VJ3A8>Z;26Q0^A7*.5^ZV>RYOM1LRM<B_JWGG7G_YV6IVD_@;
MN_E*8]^<6&2R^E,>GCF-8HP3LJQGD9D@19@6N/:]77*!2L4\04U*)+;=V'6Y
M?\([(H\(T&/<1H1?NIV@$QMK]EPS1_11+3D9W.GVY6>0!#6A&D^5A?AWVQ>,
MUFN7MR1V&[TNT565%.KG[LV(;\ZS/0AR?_IA)SDJ0W/)2?Y7'^6CIZ'.OR^7
MQ+I]/UUEO5/OA5__SOXFZ-'Y#T4,UX#BI=/U5N14W%ZU9&G'IT\_ K<V/G^*
MG#5^+->4M7_Y"WI=_Q;KM[62#)""L<2OS"]/VE)O?;;'+Y,\7.*2DV/:&_^*
M@ZA(&1IN/K_O8<%EW_]P=!H( G1*Y0':ZR$";R3L?A"!59Z'1, .!=L\9QJA
M100$J[3PT["CRQ4S$%S,5?C.@A2>S(W"($&TB/QOX\/<L-"O8>K3%(L51]&1
M0;K!BS3WMW_Q13)YF4E6UNY%K?T"^]&!W<"/1/N_2];&?*Z:+C==>9P32DD/
M8$;U\4T='!X:,IA7I3;:U5L%O!A]^?FX1*C@G+6F&HCOS"^].GT5>R==K=1,
M6(MK\'-=+S/T.T$A0F)2KH;!(RUDL<??$M/.]<,Y!0VVO55[/TEX@QO<?.M\
M0*2Q$FX$DX>EP]W O$:Y(D3B77RH(F20\/@C$)][!SA;_^G< $I@O_>.E7!F
M54CN+V\)%F^))+9XCJ1*JA'$]<GVGEX(\G9AD@HA?GE77FXQ=D8A@K<HQ,!>
M_6'68F=NRLOP]X:@>#50W?K<Y=TY\Q\-R[[7FU-/DAL<*- BO?:<.([E/"\[
MH9K-\9TSX=3'%84, ^'G/-AFK81/BQONSL;[K=70I5GZE\CK(Q411JE]1"!.
M (1Y^<["QCT,EK@[:];XL>UBM: ^7^_CC\#Y?DE@Z;QQ!/.0-1PC8MYG7<@W
M.#FS&./=,&OD?=+[/>)VRR%\669B3TKB4=7H4RFNW60BP!JH\/ EKM]^(7TU
M 7\3GTVXL%-(JT&/ 2UO//?16'R/"=<U#'_?)6 JTS!6;VE=K6\AR&NK[Y,S
M',)=Q/SFSXGKBHQT?E+0MY"!:L]O&I=#NG",R[/)7E?MCA)GSQF+#JU9*T]4
M+]==5ROE%OU2%EW&,RBD7,-:B(YU'C_Z&==#'\2[:^?%Z/7NIW9U^KJN]Y3$
MI?D\94[]A R&BV2=WQ!D1<QO(W1);&_&%?], G+T1KQB\'@_=6"L0Q_%W!_>
MYEZ-R.RNL]T*8\^56&@LUZV*EY3KG#(;OXV\>94N:TSTF_7)\RKN!R_G<\\>
MZ\,_3AS-&AD,GC8];JI=M,[0\)%TL%<ZN1J*WBB2(VO4EN?UC^U79%BIH2E;
M5R[[AZS_'PT:]0]$8-!<^\R>"&Q^$K\-.1XA)6]A4B[5=O& 'W#\@&83@3-)
M^O%4O#\1F-*''[%H<OW;FN")[R<"0?#T:J8I@@''%#[1BPB43@8M0.9\3JQ/
M+RSMPE;?V,*FFQ;/;%TU^8__R=I'.\_\G0B(K1\58@B31& '3OB>T/KOE1E3
MLH[")["=!"(@?<_TRLD4X5/-(8?\/T44M?P(;WW.UDD0Z:IA-T@EU"L.[U=X
M:H8?ZF7%%C/C H^/MFS0T7T-KR7OFSW,6M"]6ZQD23-L@^1**NRI"0.V13]4
M/;Z0],'PXER"F=)(W3[XX0O02].83P4Y@X/KI98QW/U#-#EM4>*1GY$;2F;*
MW/PDCI*5$%5&/QO18BRJ2#F,6TUIV?PTDA]1%!TVIAO 7O# ;+B_CX<(1'[L
MOU& H1&AH"@T &K_S;)1!V;:9(?<Z2\>/.1<2\M)?&7)$,*8<2/J1WUF03A4
M!?K+G@;FSIP,YSS&.W5"N<=+D*/=( 9WK@ZVEHF;\;#W(1TS9P-VH4<17\]G
MZ$2[/RH136UE =M<NPIY>$M[F!,@:PN$=0^ WX/#^!1KM^X71Z]%N=^Z_JI$
MZ)$#.Q6/$'A#LDN/@3MHU # Z<5UPAJYDG">91[9,[HI:LRN*R"!"-4)-:\G
MQ?IHU>G?<J.Q*O+O/M39&;J*Z;I*/9<H91&Z81!W7W(W8[$AU^M%KG<A1U1+
M2YLA96-C<]M$"1=7YON$RZ&2Z\D7]4O!A:^<4BDI&@)>4S7FR&0<R.J^7/Q\
MPX">OPH<3G?*'5ET38@LQL'!XB!'<M)$9*@-G/XJAI-G0/L;4T#7<6<G5=$U
M0%V3(FD%.21R",:.C5UQ+/I(]E$1\"?;(]N[\B_'@BD*210@NI'YY ')Z[-J
MW(C  4,=$:@)@1]1?=#XI]@HE?G+N!RR.^=A58*[.N '%J[Y#*XT(A]'.9!2
MNP%8RQ#XDE2R!A_&7!>YGNA9@ADVTL+J#A1<A6.EXN1*/F;T4265FPE.78AL
M2Z_:8T1<)9_41 X[GVJ<97&>)CE<B]A+CJ?_.N6GWLHTD!]8DPEQK_D%)3E^
M4GWJ]3;,LP\AC[O-FS+<%P21/QM+%#FM/B>M<V9^"1:7,Y?F]O-2D]%=BW\X
MQ]?Z$EBK(0+>]K]V>J!J$P1>3%S?F$7(N X2_:;" UWA[7UT6CS^(,6Z]F%Y
MK$50J!,K!6VT$I1 GY_%AWY%!*@X\3G'7EI8A:D^J_G&^:]K;WO8"P1:$ICK
MMWW "F&O>]I+:+W!39_TUJCNG#)1ZYU&D/CG4B:(B:O_+"Y10LVSVEI7OJ/1
MJ\R:[QLZN.!BRHR$SH^2]!.##UEWN/E>TF6=WK8PK]R&(4F=,-F\U<+%26\_
MJ4B<^%+_M1E=AEH0K9UG<Y;*TP#R@5VNNYYW*_>;51\DO9X^I\D:LH(^Q?![
ME86,&R!]XG/M>:>WH!=3KQN9&^8NZL,GVQ492YJM9 Q<-0]KT,_>>U5]BM<!
MU"86F6$^HS'[7-V+=+CK*)WD=SA+3$SQ9H;'!::$"]L+(V:3WN_JZAJS(,HS
M/^PL!N^GSQ7F>Z_('S[NEL((]U>5VWM.%7)$>%5(9C,GM#M!8G'B938]H9Y,
MV0C1AN>99D],K6^.A.V\$QMR^=YB]"%BO(UBZ@B.$3;N^<R+@#W5$'87$/S<
M#$?.J="VUTY(D*@Q=!X2Y^/:\3%+M4:&C$7&9AB,_S4XHQ*C"7I7.U]\2E]W
MM4K!%_5^MCN>2>?VXGR=@'ZG\M!@1>-KCN*;/[A?7J+UW\B2D;Z9_$U&(:.V
M>CQK=X#R]86_Y^A#J00->@$UY%R!@,S-=!N/ULO'B-9Z[^:Q8T/KY3'M[G5.
M25@\]8^&:,\N*8AKLAV=Q.Z1A+%NPK@!*AP3=ZMVXFC(I[)$_^BYE_/A6T.L
MJV/F:67.*U^.D$L=\%EQO=F7-S@?C@HV7&8'] B":\_1P$FY8\I#BZ<)E#%?
M@ HG\<]-,0?YSVY4366F*6V3'4">=]!C.M:Q=PI.^LYNABDFK(Y[16ASOBH>
M\0ST6LJB7>BYE6N(?=:8L"YW8/\E=NWC[^L4Y!T5/QI&O""W&FH;DU>:Z\81
MXU4K<S(22T;Q&0#U+=&12#*1B[K77R.4=%^^ZUTW>[X=[&VA1\UGJ[-=&KQ:
M[D"WD]XO_I[V?H?-(\%5US<B(A3?49J4FL\GV%X7NXF\IS>(?H*D?G)XUX0
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M+-82#%T/^2^(6+)?@[3-Q^#WG@8>N<M;IYD2 9>O@QL7ZP>X(2+\J4Z[7X'
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M%-ZH]S>_U4%_)6>!^G;&I*6MKJX@N0F-TPPE@T7(,0/F\1&7KA.P<UA,X2W
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M2P\&!"6$.=EN,M0,L[%<DOT=?@J$>W_)GB%REJ/!B35R2]@,A&?_F)MO?:Y
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M*7Z)?^5!BTUD7:\K:]$5OWE8^JUL6<_NP3'95Q[7^Y5;RT/'P74]1$3SC)Y
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M</"FC;QS^CA']RY.3O_]%QYQ@OZ/$<^(U$WD&+RL2RB92Z+\]=(C&@EW4&
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M.;=PWJ2?3\U;4TI,1 W>H==B$1A*I(XOWY8S"&.1>#;J'6!$(I$+VVCQS>^
M9N'' S1Q_@L'T;N@I-E-GN/2;5Y9L;V=SHU->!3X4W%29A!+.V;V'>H;K#!L
M?LO[\3.3X,;%ASD/ZGS;7J1<*\8:>;,P XCHY[JT:*2 YS6$V !D,G]J+W$L
M5D^.T.P*LR8,I_NS1LM)QDTY%-R(M[.>"TG2\'))"<40@K#)W1 66,!FPP.,
M52MIO1(-N_IX+G$!0WZZ;V@E<1C0WQIX?BO9IJZ^KB%N4<?6I3Z<T_9!E.;T
M!88P@(OKKOXJ99B65+L'EZ/+H^74%/VNU8"M7,WC/N JDROUPSD!H?.18,0Y
M+7'JFX@!"7PGM_361!RP2ORKFJ,%\K=JCHHJBUXD;N>,*GV_/7D*7.=H^?Q/
MJ^)OU$-^,VRBSC"0Q$,-'2 W(W>*EO[058S8D U:%,\@^10P[++W.:/+D#];
M&N1PZ7/_6#K!_->!SL9#M:ZY4V#(H.44J(&A?K:,M@Z<)))WD.*.0M7$E[+5
M)]QGX<>L8I.RXY\5N!8H^ -:<UQ,/P5 <TNDP%-@COV_V+&;_->]N4B]/V=D
MGXO\H.3_JI[Z7S0Z+_"4^1EI7SH%KJB-;4(.F3_^BSR1S*;"?_4&V/J@(@F"
MW@8L^\9^4.9A!S $]F+]ZVE7@9N7GNAO6[FL#S2$U-H='W^\ E=-;XI;U)PS
M?IW>H)9H^G(XZ98EFVW#.,609CY]29N)>+8=0] M<;/VU\:\)N2'[JF?WL<G
M9\V'T82B4O+JP'NB:-:D4&D<O!L<G1V&179#:!P^!5L1)KS4[;<:U;OMJG_^
M.+<3'!"HX3,GIVDY0QN\S<?+5F^,?T4JSL,X9J/.P)&*D %G"&:>*,Z>08/[
M6L'J7]T<#*YU\&*+#E/\20XV,1;4;=K:BS<^O0O=S3H/SG[JIZ=)*M -=,>Z
M+U='_'JO2U&8F.U69./LU":KI;1(&!X(W.=2V&]K2KO_;DR^_8C1_PH%1_X]
MEN@[N,PX/37$S,IQ9_+S7.Z6])6Q:.$IA$6W=4/A[M/$7Y6KGQP)PVBNGY85
MQPW'-APY6:+/XDVRJ1F*GO3@E_!VI"1= :S"B.Z=ZJY21":Z_UU!?3+G%2_Q
M^MK/&2?<J5YF\;)F[H'TP]<=%"; GVFA)\JAPXMLI+>ZY]V*H6Q]06CYVV"-
MOE#QEB2U*7B5T)TGMM>_EM5^BAVZ"@_?I[@W(#(S963XW$LHFE[P43G_VPKE
M  REO*@6M1X!([Y.$R;4(.M]J-)/*:I4X3DX(%^C'!H(4OBV_+90T*9SJ6%F
MKV_E8#;OVH2N4CYT#P..7]3./ %WYK+5<"R8ZA4KN#3R5]9_]!RL)'X)BKPA
M43:*2PI"S1?B5R90[HDRH*@EE@GP>6(0[K$ZWID)VU>G\F.8IO#]*$S^H)K_
MG$NCV476.;>DE4)YP6?Z?-62I%=@%S^"C63IB3WYVZ(\A)MH.5,7B..N\\?'
M0(5ICJZE&;*\3F>5&9^?+Y(86=>.EC-=7J8$XYU(R56JGGL6^ 927;T ,QQ=
M5<#<7^M)T[$=?!E[;&J;39Y?R[9,,7WTZ:-DD-6+R">4KF_&XB!LH9*A2[FR
M.<NGP.X>6F>)*I@:N[?6D8<9BV\8_]P0>@GQUDM-D=DC\])K6&@_GIF)>J\X
M]=C1-$L3O5B(!L7E86]!N!<1[ETH& %Y(KYI8XW7WF]_1M704MI+R#BT]3?7
M[M;".\[/M]<922MP+PVG*MS%!-SF1]T)Y0Z6PT:?N354CPHK&>V>3["YVGBB
MGEERA=^+N?WM@:(;VBR^['N>TH]XWFXI0T? -9B=((L](\?(<-6E<\&ZV+V\
M:#\' 1-TDWI-LL[=;^K1'=,*[CDC+1GHPY7BM]EV;Y^<S=BP0KW^C,V86W;1
M0W5:HJ_5!8[#WB0NUXA@*#]VK<:)5=F-P_L9RT0%I B6M; !D9\8X29N:0I.
MV%VJ-'U*J;+._IN:0SM]\G^WYG!W-77\C0L? X5P>:O6&0I9[79Q925Q77D0
M O!)8;GR)'"U0!'Q:WQ*P-MW(@5FW.*4?$.T*<V7WU,>3I(9HM'5;#N+3 3X
MB3;B=N]P.1&)@V4\]WTF8#+Q??.I57+%(]^>-38.\Q:/%W7=)N&M%\W[S)]M
M[,FN[&ETH6IH>^'TFQ_*BSV6Z!Z,_PS;X7\?U3TQR@EJ,9G\DD%GIM4)43(6
M,+'_33/@C"*5G )PI\ ^>_FB0Z(RZ95JI7'WU^VOU]._0XCZWWXQ2K0V-HIH
M-F73P=1BUDZT7![-%[XNQ)P1]N7WR$9PU_^\>F,IF7Q^=B= 6)20B3X%F']X
M9(1R?WSC9/%.#6ML!U^-7#4SO7_8]AZ=51AX^_HYBGS6%)2'Q=Q5ZQF4&VCV
M*EZ$<%'KFYXL\0G!!;MT948D;$2'8-%]Z*$=6AH2@GAL)U&?[2EPE<'4>XM7
M0^35 _WJJ>198S+]UQ,=\I=LC6C_R^#.EH!&S#"($:IM?AS;9H2:MW^?*E_9
M\963.=@]:DZS--):L=:0WK(L[8GLT0:9+OE$@!#=$\H"JL_KO^@Z'1R$$^BQ
M-TI?809;)TK"*+NUS2O;<]/5LYU,&WBXU1L2!$/64IZ'?2,QQ7Q2'CKZR-2;
MFT0#4!X.8<*4??79C5W@ M=P9<F?$S%W#>XB@QI].:D4#E[>>Z6YP?50\\5U
M3FX1F>HO3T(=#RV>^(Y"!VT_9 )*E-Y"%/A3X->$;BSO#_$/"C[-,912^4.8
M-Y;4[JDYJ_>;[9[XI/SX3I'T&^),DCUT(3.(5A/BT9FQ>G2A@WH\V6B^#BU"
M!N,!S^*LR;C39@?#^$9=M'5]D[^FF>>W;^='33-3S[VZ[/G3%WW<FTBY NI!
M<0=?P:F7NA=MY?*.[]=+M;2G<HBK2J/I7JI<S#"]X,K(&93:W*FI]OO.643X
M19#'P=$\B6JH>0C^.4YNKJ$5ISP![1 @W)N[_(&@V',&SAG9O.M,RPOTL( R
MG=<.:;2?OP,D,#+JSX7J[O+JR [NI(%KXQ+8XHW(W=Q9]5EHJH!'Y8JIF+O<
M%XJ7S2QAN4U5BG@K@I#B[@\L[<I!EV]9:<Q\U]-K]M<7"VQ=LQF]PS4D:A6^
M!RW5>P=6J2^?/YC)]+8MRK2/GY_=PF/'?/TE/@TPMWGR)O1(M,9H(=_4T(93
M7*;1NXGC20HVQ;7:Z=$27)[^@41]H\!I)%3>0C/M!ES.39=H/E\@2OZJ]O&5
MN)C(E^(9D?/!=PBIZ#&09R"(J8/%+*?<8XZ5 ]'-K;PU)W$[=/\^3!>VVDYJ
M*4IZ7N0O9[$?(W@*@%'86ZQTCVR0=? >"("XB3^^@XWN2@SLRI4@-%X>S4\;
MKO9<5)ORNC>YTIPF_R(G</RA#[SI%4?"\Q1/?"$^@_ +B\%+$@P5HW0EY:OT
MY G9$SL6!)^5ATDP,PC..-'KU;V)JOU*>;JVEH_9A]?.#\:EWLM;5$![KCBY
MX\T(M2O@V<S>/#:B.R]N8, B/H^72(G3Z4TSAND=L&[RAV LA*-]V)[@[*%#
M$H?,!XTJ33]2SD9F![N0=@IT@]_!,RA1II/1.4V\ZR"7L-!5T;,TU%U*]UBK
M3"W$]P:6E-A?6.[LL-42\D91;82T6L8D:L6C8_:2R?N2.DJ7U><('(_R0#$2
MP&8?L0>1*WK*N"_JZM:WMD)!X6CR],2N7;=$$E0^>+71=O5>Z\-4V_O/-2D%
MU2.Q.FC:?L88HC$NO5?C3VBZNF0CUNW-.\4+%T1+S!IN26*'USZ$/VEZ8&0.
M^&D?[]T,-M.=8^U*9H$06N]D^-[+WHR"^CW36A53:T)*@M^*/'"J42YS?*)9
M<9D2[S'3YEYQUC4WW"2D&<?5V^?6@"7EO*X[41YIOE4Y6R3WWKNB*,'/*]]F
MNH.9$+*21P%5VB1S3<#\6FU-OG\=X,OZ[CTF5QS88,+7Q3S *S'CP-6T)!$N
MSOGB<.VX(K=(5$)$]XU/0NI$F-8!$T*\1^]\;?ADS]S=W"PX/[4LC$K&;<!@
M[V.#E;?ZIZ,W$4[7#6I(7YXWO?%&2.D\"9)]DVNJ^V<20R5-!1.YE\0JDHOX
MM4.8W 0Z?PKZX?_&8BG3<2#BTRTDGK/N%)AX4?6I&<Q^"@Q499X"]\TL2-+7
M=_YI^4S*W&_(5=EW),53X*<C5RGHS]H9)4U';HK5JOVG%#Z?\=\IU60)%QZ]
M7]U&&?W:.?SUJ_HE62IT<I&9<!_GL#+3#3.[,>-O[HOF?C>=,:,=K+RPE<O?
M#-<8Y/\QQ:X]'_^5WY3*1KG_BX+8Q<.7$I3;Q_\9M=_Y:,K;>R6VT'=#]N+C
M%!N1CY>]>[UNO8D4)U/V%GX@ZOL/L00K7]*0.52HI-=Z[+YTF;!K"OR\+I.9
MO5A*)AN354D;)R.G0,@%P/[=AP/P(OQD"]R?^"_/I CCU!]DJHY(ZZ= 1SK1
M8Q'9MG0\@4S\[VAZ ;#SBMY$OO)]:D%$>B)_G>40'H8.+*L%OT?IR']8!W/;
MM0/_3 N__(Z:_NB85U>U.\S>Q6[8_VW97SSUUS(3X ?]U^IQ*Q;$[R0?TNH@
M?F]@,L[IOTG__G>8FOJ0WT'^*GG_W$QB)%]I /WJ1Z[9-RH$9RG;D>^<M _R
M.X._*;;B![0H&SQS)_;%/XT7HII?P2KE*Q4N>,;'%IC4$3AID74ZZMU6YT8A
MJ>&\$5.4D%M3\KL%&>C]^VY>&<<J%F4F.#J_7[%6-:D+O%,4*7Q1FET2#U""
M2.C87,Y=0G4)(:_;F7G&%1O8!:+;5ID--B74N/LR\<S]^/;134\(BW%;&/'N
M\&YYY@D;BC%)4^[16JJ'[]U;XMP+MEN&TQ%B@^6QQCTJ6611HIF&T>A)WSGN
MATC68.W#1<EOUG<CWV4\\VMW.A)17GZ TM$3)EQ%5^]58H1X5OY:M&):(,@N
MVT0I2F0O67J:H3X-IJO>,OVPLZ[&_;2DT3M593334_<K$/$ KA,FB6V(Q[G@
M2W#)+SHX@M6Q/Z*C]?BW;%@^0AMX4H=+$!9F-L\M$G5O/6E4&99$27@<?>\)
M\EY;"[_7\"7P(CGZ%'AX"LP.=")K R-$L#.1^;D8V^;F!$1F+X^TY)3:R2RW
MHC)N+4T]38>MV$I.END1Y3[MA0]GN<#!B29!"A^ #7B[ F* !AP$<M4AL:D[
M>U[E(6A/#*]5]OK6S(A' 5PIXT?>9XCJ7H+;\S\BJ1M \4*'Y0O;K/M4+(S2
M@\*%(CX)OP;/U5C)?OP]X<BM%)1S71IP3Z)9>"J8.[O,^J5Z'HE?_M;!L.B!
MI NEW71'&^]18-)428JFDRF.6V3.N'7#^@CG:=M/?4SGH*Y:J8/GOI(ACJAY
M6OSL-^)%C([B; [>?_(46%$BY;=9E9K+,O;CA6F2?O)&%;S_DF\L4(#4X$#]
MN)%"H16_#-J=P9[@9;#P!)1']9QXWS &'!?(S5I&J.XCBP2VPQ2N):&WG2A[
MAE64]82AW'2PU.\Z:S2VYRB,\0])KX)5L""C&204-%?=^\<XEJRRT[N3O1'?
M!O%+VW1F-(C;\<PO(CN]]&0XL/9(NRV0LA+E.=IV('P*=)FV!578SF[K72"$
MG$@BKO^N6]$6MWT$YJDW>_+^R+;-.W:I^\ONQZS[)[IR*6-9+/2<P;2%P9 S
M]IU &!WNR^/X"3/N!'V"1]<_RSF@0BBO,^ZIV.!JWQG!U(0>7.R5]RUNGQ"7
MKUR P91EC<2]>T'?EU@(-@;8I.1B K)G[D)&;/%F@*E+\1P4:V\W+W&KS%*\
MH=[D74(MQT$]$/C$]DV:ODH;\W(U"X*VA]_FA:Y2T?<M>^YX3W?/DJV&U->K
M1O5W$Q^^C967U>E;YTF-5S<)$(\[N&_>.G3/:=XOC$/_,448ZTU@D\8G]Y&P
M!GQ92_#CX7&(1@B:]DIV (:T3IPD>IS[QF431#Y"+IF25>%_@X@P^5MW _,.
M-$@_\S!&_X80_W>6YH&/1:V@UYOE@E<MY*^GN-Y/8:#\OK^1JP-8Z-V U:>:
M]-N1-QU7CA(V9)ONX=+'KO_.PQ<3EO*)E(2+&!1HYT]E1O*%JN?OOR.>:*V:
M'__IVY6'EQH#<KWG5>.LF!0%CYP&^O(2G"D(HLN5SP9. 7:B10G"I:=%CF/1
M\<=.)ML\J47:F/@4.MV'R=A&W[:6%G]^(3#@:OUAYRF@#>8,O;"-Q-I9)"[R
M$)RP(42+,T*'6M'JP$DEDB6<]6&CM=[8T=2MAH8[G0U5JL-O#32,<K]^'G!I
M^SB?#8Q@I?96"LG#H-K76&07BFDIV)Y40%:L:L=)H>7^J,J'%!$T+'&Z1]L:
M&OQU&^Q]SXH=/96OX503Q%*%KKEX,/[>P4+P-H36DT?V! S:JW$EY)GS>)M
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M75_1>,=I]&M?*;2,8?]AVFUKM4[1CZLO*=]X50] $E#UC;T6<\,#3S-WNTY
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M*(<HK-&_&?K"R]YX9C)Q:YG(!Z8!HF5[,$D:@! _'LST[C1@]5Y3H\7^<1Q
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M LN0.5L)?+/09Z;\^PSE=ASBR:V(JN-Q#]$ D>_/_"UM7Q?)X+[JDEG@GU+
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M!U%+%7]!CC2 FP9\D+]% X)!%%8O0CH-D!Q1_OTKF0;HVY6M@(Y.>('V^VA
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M*FY/XT?OU@9O(<\'B0V@A)5G5+,B6#_/N8Z]JQ <A,)*'WAW %/I.B\21SN
MI$NYVP7XB1&.\Z22[@V"4=]1;V4F-Q('BD[K_V*F\"G2]P..5?.)3[UM<7*M
MH8(S0%'YB8$W1@"YG"]2D[N]/X-6J,<%R%O;-$QX[(J/MVJZ?LBFQ7@\KC$<
M?BV6>FWG8@XT15T%&\+;?W&/.4)/F8;"- XWI/V5_F8Q: 1.GVJJ/M4N!?WR
MO1N7RS5W_FI !=,2H[SDTU//&'=QFAD*[R4!07$GG:I>NA,TYX']550%7A(=
MMSLTJ'TVIL-<XF!PMJYTP? K9'N?->#>*T+/<(U$A).H^G;3"/,/ZY#6)^3
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MOK\;N<12'?N+:-K,;;Q3\</>Z))4"NY<E/JJPMF'^U71"I2_IH-EJ0C%^BI
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M_=;'KWVF ?"7WCL_KAWU^C3D52IDJ\;G*#_F5ST$:6U8+FN2A]F6P3MO(D0
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M[^$*1HD)XQ9J"W!5 U%E$)?9\Y2T@@%1>T3'"8W9L8>D#FW*UCO()D%V^#&
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M]Y2CF0Q!-@PR Y4%9JIQIS3(<K9Y /0PR&R!^PSBA AW<Q6<DA_: &:'DA8
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M$A&-VU*;XX+(ZO.7M;CA:DZKR/*^5IQE34#(;V]]W)-F^4P1F;G $8P!V>Y
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M?QI_!_8J'T:4=>L%8#__ 5!+ P04    "  -0'1:'UK;SS,<  !/=@$ %0
M &YR>',M,C R-#$R,S%?8V%L+GAM;.5=;7/<-I+^?E7W'WC:JJU<U<FR[-BQ
MG>2V%+UX52=;*DE>[WU*021FAFN*4 !2TMRO/P D9TCBG4,2\.Y6-K$E=+.[
M'P#=:#2 7_[R?)]%CQ"3%.6_[AV^>+D7P3Q&29HO?]W[<K-_='-\?KX7D0+D
M"<A0#G_=R]'>7_[[W_\MHO_[Y3_V]Z.S%&;)A^@$Q?OG^0+]''T&]_!#]!'F
M$(,"X9^COX&L9#]!9VD&<72,[A\R6$#ZB^K#'Z(W+UZ]N8OV]RWX_@WF"<)?
MKL\W?%=%\4 ^'!P\/3V]R-$C>$+X&WD1HWL[AC<%*$JRX?;R^67]OXK\ERS-
MOWU@_[H#!$;47CGY\$S27_?8=^O//KU^@?#RX-7+EX<'?_]T<1.OX#W83W-F
MMQCN-52,BXSN\/W[]P?\MTU3H>7S'<Z:;[P^:,39<*:_337M6Y*0] /AXEV@
M&!0<=N-G(F4+]K?]IMD^^]'^X:O]UX<OGDFRUQB?6Q"C#%[#1<3^2]';?#6'
M)0;/*0?L@/WRX!C1#DDEY60K#!>TS^%G0KF_^O'P5<7[3YU&Q?J!=DR2LGZU
M%QT,_.YO(&,VNEE!6!#3]Z6-)Y#C"F"8%RM8I#'(G(224HXC(1LR\)YR)Y>+
MRP<VS&D_,II,3S6^9#<%BK^M4);06>;TCS(MUB=PD<9IX2*HD<GX<A\#LCK+
MT).3006B(7+QL4U@_&*)'@_B=5*/Q_4=51[&):;:7Z?DVR>0@R7_\%&>W!04
M2+A<GZ0DSA I,>R*W<S. F^F"OL#UZD:TP,_-)ZJG^@7< JRCB3G>9PF5(81
M-'3D/]9\0E+:0ZXP)/0K?-1=XB7(T__C?Z:FO:33!*:R4>$L)KXAW$8:)>7]
M/<!K.BK399[280AHSXAC5.8%#5BN4$8')C0/&R<NXTA^#3,*?4+GY&)]BT%.
M0&PU9YKHQI'N"B,Z'Q=K"AZ;XQ[8B#-)IJ,91ZISVKWR97J7P2-"+%RRJOTX
MTM >@DN8G#X_P)R8.YFB^3BR?$8%I/Y]#>XR:!)$UG8<*2X@L#!$M]4X7Z8K
MB'N4<]=,N]]7@.G(,/<//=58(PDN(,8PX9\QCR%9Z[$B"LIRGX7E"5MPT5[(
MYV=S3*$E&T>VVO87*;A+L[2PF+/5%.-(=$+=\B/5]!$Z"*4E&LMO%"GF$= 5
M#>W-WD+6>J3^!)>,,5LYXWN[KJ2D&&\62 L>_]+Q?(RX^X:Y30A@03J.C'^%
M("M6O\&<+AJL(%02C.53Z1_A+7@VVTC2=*PH[H[ /TIJ_--':#%OJ]K/&5..
M&UM.$V/:??N6!0(CZ='E-6VD;">W'?5T4;.=E&;*:2)H.^GT5)-$TW:":8G&
MC&GMQ)&UG3*^M9/*AG;2"--R@K$AGBK:M!/11#=AY&DGH 7I5+&?)<@&NM%C
M&ML)3D'@(]]V @N09N0SZVP,RG'S;RKN(_6+> 63,H.7BU-2I/?,\WXA<%%F
M%_13S;>-G<2%R=ARGX$4\XV_RT7E[*C]6H/I$YWB2[H^O\RO6;(6T]B'V]]9
MM7&^,[;V)VE6LE[1\ADL'GD$&8NSG95T8C>V+LQ>,;4J%P(FGV%Q@0BY@OAF
M!3!TUL6)W?BX$+!<8KBLAO?B&M*%3^FNA!V?L:4_+DE!YU=<KQ<([=*0=@(Z
MT3HK8,UJ*AU(_668U+9S'Q76K.9<!;IZG=VXCHV.:I7GC(TEHRGEOT#TLW5^
M_A;QV:7:;MY)&5NNTZ[977N9*Y^Q<9&MRYUAL& R7?[!U>(N/,:V=C_/X&QI
M X-I<BBN%K:E']NZO62)LW'U]./O8[K:U89V;)O654OYLDK].-M43S^VM'0)
MR.I+J%_N?K>U[G#6P)WGF'DYUSZBIQK;WG6^Z(CZK,>T6)\AW%H(.5O:A=OT
MFG1WJD=01LMP(GW(95GP2F;::YG#>X8XIBND(0L35XY3YH5=1X4;ERGJ(MRC
M%!OJ\6=[%GSN/V"ZMLF7GU "LZ]IL3I#68:>Z$^^PG2YHN'J/GBD4^&2^??R
M_F'80F2\;XUM!6[R2KQF^#IK9^8QZ8Z$\V+7C<WHN8<5#1@A.<_%#0CWY(,U
MKZGV6ER-;\]A,KM+]U6&F]Z&W81[2:X .#&9HLK)/6M@0SU^#B=&>9QFD+ Y
M N1K\AD6-X#^G6W!;()C1(9DI0:RGFJWSWD"M>8P>278D.#(D=5$E6*NDELS
M&#^/4V^G7F'TF)(MVBZ9' .+T??]8$*'4<;/_A4(KS<"7(,"LDA^L8 L4H&=
M7[AO^XWQF;%UIY/)21U/TP_*MB.=]71F.7Z42NUV3'OZFDXY3P G[CH868Q>
MK>">2C223E.AZ;Y;9$>ODS8&65QFW'E<T+]W*.!S ?,$)@T?)K3M@=(B+5CC
M^HSO8;3/#@27;,*G?ZQ;3B:)_-1H1Z)75(S-P3[ZYYHDJFEJR1K9,A1WY,G8
MH5[4.SW;.:"V .2.G]\MR?X2@(?JE!K,"M+\9'M<K?[![]6 /BXQ;AWRR< =
MS/@7?Z_;]9H=>)&5'81DGIO^IU5\<%3PD4U].:_"4.M@2=[7K=5'CG <(4SG
M_5_W#IOO !QW>H9XD+IN<4#81BO/!:2T"S3T"XSN=::NS8J&J-*&A$JQ%SWQ
M7 .7W@^$XFX_]2_FWJ>EL@/LE5? ;/0.":?SG,WN-*RA8JIQZ;:RP^&U5QQD
M>H5D]RL,'T#:;,TU%7^6D[05L1U*/WI%R<$*88%7[;BS%5K1WG;7#B(]56":
M?,2(D &ZU'2^?:L-0D)?M#%%2-V0^IKRON3E-B?P <,XK?,T[&J>JH[XZ![A
MHBXK5BJH]<<C?<&W[Q[0(<8VKZ3K[/OK.YWC]:IU@/^!W+L& %FX&*L1ZB=V
M=)UZ @U>NG4CUTR:R\474E5'J?N4@2R,L%(!D97*(6%TEN946W;^(NF7KVFC
M%!-=&&&E B4[I4."Z::^0(AZ%412#2Y"0SL@WO@!0J%62)9O);:-"RY96[]Y
ME;IJTCJCTF_OVZ^KK:](J,@5#JE#U=6V+OU*0^([8'$!2*]V2!BU*XYOT6\@
M_V;$2$/B.V*QQLBH=D@8R:N2UT:@3'2^(Q=KM.P,$!)DM9O7K">W+7S'+=8P
M])4:T>"2HQ#7?[_Y77U#5LN@K*6LH9U=WWJTJTKR\/IS2[S/*(\=PL-V\Z"F
M3QL]+$@#BAM%C>SF40E=F%W/JL,%!8D"B%UC0X^QKUFCL+N3>/>U)L4@:>MM
M=[1U6,10[B%M['M0J.TN;H&J5 VI'[4.')FJ;X26OH>S-18J)4,"XBA)4J8R
MR*Y FISGQ^ A+;:/ TAR#"H"WZM7:U@,*H>$SC6KDLQA<@IP3@,/TME#[+PY
M( )E0^M[#6N-F;TA0H*OY=;Y:P7VOM-,Z=LCV>JFCG1"1,SB%F"YBU(2^?96
M W&RO@YY6+ ]2Q+315]-0ZV:OQSTM;R@?Y^E6%S^FD^G<ORUMG(\^J'#XC\G
MK'(W//33$?K'GM!;V@@MHA:UEQF"EV]=8;30^=Y.(U^A []1[(R.#S9Z,8@+
M=GR\N7KL]#G.2GY' 2&0_L,.Z>ABB0',?'LH"5)"5#'81F$Y+5)<+CXBE/ I
M#^+'-(;DADYF.I^EIO'MLLS F34.JCINDSFLCFM=:&MAI8U]CR6-!CUH9. %
M-%9N8$;9+>L2<5U]3+>=[S%A#X!<PZ#&PS4DD(K"CB*=T"DX0[PZT8B)@<QW
MY&D/D97^02%6/=V:L1KEY#[-4U)4QS:-F!D)?:<@'&8V.QL$A1L_ /,9Y:BK
MI1$V$]V8V]1G:4X7)?0;QRN E\I-:K&9=Z=H9=SV=K5*U:#ZS'E>0 R)>3X6
M&GIWDDZ J+0($)+-7?%'R3_HXH1YB^V%<VJ #&3>'>80N*Q,$11XV]N3/H(T
M9P[FLG4!E+9ZWH+4N_\< J*U24):.K1/9UTNME,Y78L2_BP J4J+-7MGUAQ\
M5[4-0M750$&-4M81">N)D/;%TV>F<YF2536_G, [7;;/3.J[FFX0GM8F"6F4
M*C1U#G5M,?LI+,P,Z@>-E/NJQ#'R?!<X5B&'H-0IVV0O>\U\+]&D4JOJ.B4M
M@ZPGM%+*KD,&-!UTM#IZ!&E6'2]I55'5^[/\(2;++FC#**A.:J]Y_U".M%<$
M!'#ORN[T,4U@SC=PJFM:-NLY[44A]CR"&J:#876WFL%MS%NQT-[X%VLL^K5;
MG3J -]HZ@#:S/X,'1'Z.*I[1#S77N>H9V&UJ9QEZ4I0SO-6JP8BCBMK7K,M$
MX)>L4O5_6W\A[+#[QB?6E[-KZY]<> 3@6[ZGX,41F^_-)8274IG4'>R&Y@CI
M%9\G.HTW'NG2H#;4OM/9.P/L8J20P-W<T'V&\ DJ[XI%F37W+.A".1V5[[3V
MSF#:&"4D$#<W7'[%U# GZ$DS'F5M?6>L=P9,;8#I3VJS0W]4>'ZP5)T%8TVE
M+7UGEX?;7JE2> .D.BST/VF>-#O&FKE-TM9W.GGW&4UI@)!@X@_;_M9_J$D-
ME:J][XSRSG#I#1$29"%LO;T/%\A=MN$&[Q<H'-4Y(24[07*Y:&6Q:(13S^''
M*"=I4A_04'@P-Q:6:_"7 <+GKNQ<X<96JJ9P9BB$1GI+_$),HCAJ.A=X4Y=+
MAI@!<:R=_)<N]3H,.L,QO.[K7[/Z\C#@%,?04DR/.8X8LU7F":S^>YZ+[ZOH
MLAXVU):P!IT(L;=24.-4%+S)Z6BWKPQDEH"&F%VQ4_"[0+)^VJ5Y4E#ZQ(L+
MQ';\++$/.&FSFR4#[Q2]RYR'3-T;4DNH T[X6-LG>)?<NP#:$5>!VA+:@%-
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M+RKY& CG!/V9HR18B(,\2L363GCFP00&BUQU+ODFEUSS>)8%#Y2([42!=-
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M Z@ H4"DK/F';J?TP'R'R.P8$X*?J<$E<!]P&N\#5H!4(%C6W#YL 1 O>GL
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MO8^A(-E.,- :-CNSZESIK'*,6(EV*"CI"02ATS9^J(%.N1CH([-!-W14FL)
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MKDL.[>&/(I==YK9&6J\7,T]14-CP=\_X;HKSU&?W%2F/BW-J8PKO62E0VO+
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M!:SJ!%VZ _HWN@ZH3AY)-^X#UT(<YQS>L R%&L+=8-WN8\B8\F5QSHUQ37"
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M_9&E'&D#..XB,8AQ]UG4W:6[']FZG-P%EF(I0?Q:1U!4$WSU$GN7/%OR"QI
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M_R&%_Y#"?TCA/Z3PFT#:R1/?(87_D,)_2.$_I/ [A=XAA;^G%'X@$5E\S.3
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M'W+NB!_2@VE=+^O#3L4,^Y\'JB7ZF_\/4$L#!!0    (  U =%H\ESA$B:L
M %7X"0 5    ;G)X<RTR,#(T,3(S,5]L86(N>&ULY+U[<^0XDB?X_YG==\#5
MC.UVFRFK*C.[IRNK9W8M]*K6C5+22:JJV2M;*Z-(1(B3##(:9"@5\^D/ -_$
MFQ$!N/K&9J:407?GSXD?'&_'O_[/UW6&7C ITR+_MV_>?_O]-PCG<9&D^>K?
MOOGYX=WBX>SJZAM45E&>1%F1XW_[)B^^^9__X__\/Q#]GW_]O]Z]0Y<ISI(?
MT7D1O[O*E\5?T4VTQC^BGW".2505Y*_HERC;LE^*RS3#!)T5ZTV&*TP?U"_^
M$?WYVP]_?D+OWEG8_07G24%^OK_J[#Y7U:;\\;OOOG[]^FU>O$1?"_*E_#8N
MUG8&'ZJHVI:=M>]?OV_^IU;_URS-O_S(_M]35&)$OU=>_OA:IO_V#7MO\]JO
M'[\MR.J[#]]___Z[__A\_1 _XW7T+LW9=XOQ-ZT6LR+3>__ITZ?O^--65)!\
M?2)9^XZ/W[5P.LOT::J1'R ITQ]+#N^ZB*.*%[OQ-4@IP?[UKA5[QWYZ]_[#
MNX_OOWTMDV_:C\^_("DR?(^7B+OY8[7;4"J5*6/"-\UOSP0OY6 R0KYC^M_E
M>!55.&$O^L1>]/Y?V(O^J?GY.GK"V3>(25)^*/WZ-++5*'WG&^P=)FF17.3S
M4$^U \&G=8=4>S@PU/?NPF-11=DL\$--[[!O\+POWNOY_](TSN-Y7WJ@>138
ME0C9^?/*OVO&?KRF?XT@XM>*-F X:4$R$YH(S-_ &X;&=F>]B$=V,Q;-"R+Z
MSEI&;G,9E4_<\+9\MXJB#7W!AS]]A[.J;']YQW[A'Z'YX7?6-N(USJNS+"K+
MV^5#5<1?%J]IV;Z'._EOWUC(?S=U@&DN2.M%1&+#IV@DOHL+VI!MJG=9_=%K
M]24IUE8PFF]66 C_GCUU]NN/3"$H'!F)$5P66Q)CIS(>>F/[51N$ZXQJL X;
MSM_]_/#-_^!BJ%@B+HA^8Z+_^U^_ZTW/X5).7DM.D/<?ZN;]GV[N_^/A][,B
MI]W'*GW*\ ,-Z;@\O:/BF!"<\+=_QNLG3":..6GZ(,X,5QB%'-2"D\D=JT"K
M7AG5VN@4=?HMV6H3>]/M<*'KXN_;M-JQ00<=ON15:1.^Y#I!0I@.OC2,R12"
ML\\%Y91WM2CJ90\4T?:FF$6DTXOZ))0IENGDP-#'(5H=*S#9MH.+V>V@0C-<
M.ZAU1=T.2M6"4\D=JT4[N!BT@V40NCU@.J:>RSBU<CC2F1Q2\TZE"91Z!K@6
M[&,6X';$:+N]+G)S$RF1\]D^*F$.&T=!*#BG3,A$^C Y:!Q9)$G*YJ*C["Y*
MDZO\+-JD591I^6+0\<D=*_A#'FD5P'#*!N647[T.8DKOTAPU:G#8=H^K*,UQ
M<A&1/,U7I99F*F&?_-(#'A)++@F&45IX4RJUPJB5/C*#2E(-V$/_U3.'_H,U
MW&61I0F;EK[(*\IR+)M+T(OZ8(T-6,89G5QPQEB D_2,.G'4RA]W]G.1X=<H
M3S!I8MSUG;K7K9;UULDVP>WZU"K!X+2P02<T2:UXUQ)=W\%IC!ZV3V6:I!'9
M/409MEAB4<M[G9\TP1[-3:J$@_/)%N&44TSJT"LL>U/IZNY6VY49//=)%0'6
MD!K=0S!4F"*:%CU]#BAZ6*^Y66EXC2!V:VP6XF"HX[ZF!G\=[8JVG,LT3RM\
MG;Y@.@JL*'XV^[0H2UR5I[O/T7\6A"\Y:UHM9RM> ]0\%T=AS,T$&,;.PRV$
MQ,[*.VX&]790;0A*$_E(H@2O(_)%/^@7Q7SR405R2+BI#!A&*8!-*=.+P0EU
MC]3V[7)!" 7*%ZDU 4TAZY4F.K@CKL@$X1!&@TX<XF=4NR!11<,,&N@@.L ;
M_?NV>J8#ONHYRM%8Z:CS ==IC/,RS5>+%<$<B'H^0"WK;3[ !+>;#U )!B>1
M#;HIB3IQU,G#B4%7>5RL<;=-IMVDK^U::33\=J.,T,==)J5X<%K98Q0Z]*TL
MFQVHU5&K=H).HXP=PX#2&ZK/Z&2+/%DD:]I_*ZLZ2%Z\;F@-P=HNDJ6N3P(Z
MN3.DHI4B&%*ZH)W2L]&MF\N1-FK4X83".U)L,*EV=]2#BGK+]@%N6-4ZW;$^
M@R8D6FGZW7QG[<IX+YY1#0PK[;$*[7&1KYIQX^-HU @E3'Z.XN>4UIO=T"UM
M<-1J^"2>!?0AX33B8(AFQC@E6*?!PUZG$W8Y^9X-513KQX-GOA:,!3CM"G'W
M(#@!9&ADW2_:I*4Q;>,^XZC<DJ9_?\1(8BCHS[2176_7TG@A>>ZKP*6PVD(?
M/011\#)$0CVO9<+6Z\_1J[ZXQ\^]%;<,5E?<PX<PBEN"2 SKKQZ*VZ&?<+DE
M>5K1D$-;ILOTE?VEGV;6*?CL)9B!#SL):NG@U+&&..52I\"["*T*'&JQPT_;
M"A.[[J=2VO.&:AWDR;9JF2@8.NGQ2;98<VEO/4T''EW3/A%^+K+D:KTAQ0OO
M'.ECE%;#)Y\LH \YI1$'PRLS1F&LW&J@H0H<?EU&*>&)=$YW@^[W)<%_W^(\
MWFGF;*PTO3:*]JZ,6D>S&AC^V6,5^EZ#L54G#V6^IG-K@+*\Q_&6D#1?Z7MD
M5JI!:&CAC)2'&CUX1#2#%7IN5+7.W76".@U  3'-HSQ.H^PJ+RNR->PJ4$I[
M99P>\HAD<E$XO-+B$ZC42J->'$I,^S5BFQOTW?Z)C$_.2.$-F3(2 ,,/&:HI
M*QH90"&E;[6[/_^68D*_X?/N&K_00K;J9FF5 _6T+!Q2=+8TFF#HY@17W="A
M3H?/5MPL?H$2I3JOKG(Z!"ZY2^_M.EPRC2 D5$.7,D\4AT<W)49=9ZI6.D%<
M#;T'&/\&;GUP)MD'*"3[X$:R#V^ 9!]FDNP#;))]=";91R@D^^A&LH]O@&0?
M9Y+L(QR2+?(J3=)LR_9?/;"Q*S^R?/$:9]L$)Y>T5.NY9+Y[\';9GH._P^3A
M.2*T%R$WH.G^'?6-7E-N'/_3C1)V'.]U8"K9\7T43F8/%%"O :4W>[MAGFJ#
M_EC$9P60@1LR=O@<#,4DH*:<J$5*]#><)<?.HM8,[>4+8%();T<SY-"Z QGC
MQ\'+5XU),9L2.)=+MTO_)URL2+1Y9AO&%)OQ-+*^-N\8X;8;>92"P1EB@T[<
MK-Z+':--*''\[:IX^:ZL-J1F"_MKP!3ZK]_/%E-/VE^]E/X8 B_G^J?P)3K"
M(6R"6%Q?7=[>WUPM_!?9[=]D4-FOWHJLA] 5V>W?8!19AT-H>?]V=>N_L*ZN
M92#9K]X*JX?0%=;5-8S"ZG (1^ZOKZ]N;J\>_!?8KU<RH.Q7;P760^@*[-<K
M& 76X1 Z/E</9[<W#U<W_DOLL[0)^^RS"?LL-F&?@31AGU5-V.?%P\/B[&\_
M/UP\/@:H9Y?2P'CI,S!>BH'Q$DA@O%0%QLOKV_NK\[U['<J$?QG/+,"[LIIQ
MHUS.8Z(_-<Q!DC]1*'CAFI")R?TR5/!<#[5PZ,,?+%O.MJR*-2:J[* R(7_'
M0%0 ^[,@4XG@G-#"$@8>C<R1KSUJWK)0AP!!Q%\N?3FX/F/^^'GP\M6 4I;N
M LXJSADKCIP?HR_R^[3\<KH[Q7G\S+(;:99BS&I^3VO8.3$^MJ'7"4XL1Z"2
MA,*]&F)ZJ%.#LD:QB.-B6V^6Q>E+])3ILW:HQ;TNWAE CU;>%+)@R&4 *'18
M&G'4RX,.9894&UJ-P %,EUI#(PZ&66:,%A&+:4 )5FWK+3BF/\UHTO)*,SL7
M1E33J\"AFQ5.98],PKUC7X+5O/K4W D_#=8)/S5TPD^!L$ #2EGDI[Y*^,Q<
MPF?!2OC,4,)G$$OXS+)2^RKA<W,)GP<KX7-#"9]#+.%SNQ(^]U7"%^82O@A6
MPA>&$KZ 6,(7=B5\X:N$S04<K'P-Q0NQ=.T*%\S0D=V(0L? +SC?XANL/ZBH
MD/5Z^X0.[NC>"9E@<*;8H!/O4^-BPSDL*.2YQQF[M>LN(M7ND41Y&<5\%^CI
M;OA$,PWA8L#OS7VNCHUO\[/5!D-(9\@B2[E8?;*QR$GS3Z9V].O<^#YVEET%
MD_(V9\FC'K\6ZE9-*^ZMB;, W;5W&MG@#+($*&1\'&B@]YPV@(Z1#4FO;1)E
M@J$"E;HQ%*6"T\8(315@N.2QN\:?R:]1]27--5M%!!%OD4,!KHL6D^?!BUH#
M2MB[1;Y%C=SQB_@!1XIE-YF Q^*5 !L4[N IE*(5(8D%B[A0V'T^CVG%;HF\
MRI/T)4VVRK,C"CE?NWVT,-L-/U*AX(0P(1/NDV*RO/6_*TI^ WG(G,]GSRE>
M=NF$;I?+-%9,CQBEO=T8;8;<71JM%@7!&S,^83J%:: ^_U.C<^RF@_==_\;[
MKK2S:QAH"')^1Q@*F..AQ40H.!M,R#2#B0-F/#&7OGF8*<B%*'W#P'(B!*[T
M'8:2D,:0Y_BILLH>*!/T.894 QV.(46IX$0Q0ILRA0D>/DF@(D[PK?!G1?Z"
M2<4NQ]&,)96BWJ*% 6P7,!1RP:E@ 4XX-\F/'PS%X<2.Q=>()(8M?!,9KQM!
M9?!&NS^' L')H4,E[/-D,H?<?:>(#N<XYERCC=OC<[$M(S9E2F/2[C)]T70I
MK=2\10T')[H(8J$3G#".0,5FIM9$5!6UNJA61I?\-MOC=E&5T!_2UQG<&FB%
MIY;@@IE9G0IP8DUQ.O&**H>C%5NBGD.LH1X :HEN6)"K5X).+P&I&\&8>C"*
M7:2K9\VMW'9ZX2DF<<-,L8$2<(J)2)THQM6#4>PFU4WF6:F%)YCHA)E?O0YP
M>@E G=C%M(.1ZY$.-G&TK'3;+1V4PQ--Y9"9;E--X*13P'6B7F\#SAS#99JG
M%>87.%_E57.#,[_ N3S=U>?VLZC49:5ULN#Y*A17UR;7H]BJ!^?N?,R2:U2H
MA>9&[]Y&?:=WB9YVB)M!W,Z1-_05R^IK1/#5>I/QS(.1,J.KA;R_)1<+V/W2
MBT8X.*ML$0I+,8T*&NO "7IW466\.G$BXS-P2>$-0]-((#A-=*BFU&ADCMT!
MNTYCG)>ZQ9:IA+?P((?6!83QX^!EJ\8D7&[9"!VGEK=)UQ*<UA6<_M'7:_J/
MWZ_Q*LHN\BJ5'C602O@H<PTT5N:2Q\'+7(U)O-"42J%:[,@IFYZC/,<9V_:;
M8U*>19NTBC+-F36MO+\3;!:P^_-L&N'@I+!%*&[.XBJHU4&-TK%;@(O7F+YY
M1?O"997FJ^MKS2ETM:PWHIC@=B11"<(@B '=E!RM.&KD$54X-C'NZ$=/R[(@
MNYNBTLSTR>6\$4('LR.#3 @&$33(A"YA)XJ8[-$W[F'ZZ1-;%NBD_8THC9#[
M\:12% 8OC/B$L2170)Y)(D[_?2T&>X08!,W8PD7;&XG<7>I(9:\*@V3.>*>D
MHX3X,-P3QCEW]$'KX(6VX<FHXJ^G:P>^[^SJY6$0R0ZD)(];1QS/<6L1QP0G
M:<6F?U]P2=5T::[5POYR79L ]PFO59(PJ&*")\DDV<BC3L%_JT;%\3[MFDX_
M8,MF=DO3MJF583!M!F))^_;1?_OVD*[RJ-H2?!KE\J21:C%_?6TUR+Z3+<K
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MX+S$-,KS#9FC/H;BRUEI^N2?@RM#6EJH@6&K/59)JDBF67(>%GS3;=QT#B.
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MQ[@TA[>@'=DR']0*<1ZKR'^BG<T&VSDN8Y+RY73M@2P+)8^[Q"P=&&P4,VB
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M3KKP+ML?V#+ ']$&$\1-!F=@GY!G>!;WMKVUE<*F%84.;=B$CWZQ8)8EK[M
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M6GUP'MIAOS26@O.R15FR"[$&4^;4U[3\<KIC__\RBNF+;0.RDZ40P7B&J[)
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MWD E20H6X+%P$X^%'L'\\8(I!3,W?&#ZDHZ39,&$U&=JV90T3J/F5:PMCME
MCFA%=4$I9Y[I><X(^U=&N<# X T;X%6Q-V61;.. !Z%RX9DNR4Z?>$7S?L#.
MB$B4?G@5;PBFU77.ACF%^B:"33^1,;_+$]&4Y&H2Z:BGH)$%D>Q<D>K*") ^
M&497JNR;ACE4I54/0>$7D*]@$,I#I)=F:VG7%\@Z?2$R\C+/U)R?V9T;D=1F
M@)X*LFMB.,5XNFY(VIK'S%8VB]T=VZ"%>\C86@(&3[P08C],*B&.]LQYTJBC
M4MKS6T,D_0-T0FMO00O:EUCP<_>'IN&S\6D N$9MXR%K[71#82@7Z<2 99?A
MC%,G21TCEFG,BXTZ35%.B7GZC0$Z32W.@D44/Y5%Y68M.25F48P!.HF"LV 1
M!>Q)A-%NDVLXR45FPRPD UHGB77\?0H2+/+[1(T;MB$=9@D-X3F)!(HA%6N<
MDAGL_%T6G2DY3CEI41K%-3H$P; &=?L72YEH$SU" 1EANDL(R=+D*!OT4ME;
M'LS**:0Q_-4-^XG]NOT5^Q]XCL1^\W]02P,$%     @ #4!T6F@(ZI+J>P
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M><P-DK<T%ULR,N<VQUX37ON'']]_*.K^'P>%TLV:&V9"A5W]9?)]Q^^>>:'
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MZD) ;RL/A/UOF+#+]70 ^-PG<<&G%CCV%1$@_#^[ G]#6R0&[@BC<<"G= ;
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M@JHHE$-KC@88":!E01,2=/):M3/L<'"21N!04'(TXF$5Q"F<26O^AF'\>F^
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M/,)K0$]*W)5.4Y!&W:6%Q2;"9 DWVLM7@55&DV4Q>%V0)Y7G3"^*G@*YJPV
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M.F87<?:4SK-PZNOZO5H*.^[VB%Q#X$/G^#IZYEC$;/.5T91<Q"^*WMQ6%CN
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MWD$(5_7P&E/D1KT7;*A[S5F+%B+1@LYW !"%FH4UGZ(]LY#A-&IK@,,UQ.P
MMP]K+L?![,,<N;>WF-B=H0^PF%#6!34;^VD;>B\F )CA+R98[!,2)")/4VO
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MY:G0$_TP1=(Z_7I2*>8&?0"SA''ERGKP$XD(\T(^C$R#%;?&)"W<:)>O:SY
M:&]$ L71 FQ@)+029X0,^G@Y#</XQ8M\<A6SBSA[2N=9V+P\HUB& .61#U/Z
M^*_JJQ(CQ$9]L'+'XF>:<(:XJGFBR7/>>IH_PZC*ZZ@1PSY:&= 60 "A]_$+
MLHX3FBH8VY> 9N48 3EUM2U%CEY'SURMF&W* ;X-9E&PI1Q:9/. 8$M4<\3T
M=RV[]UX^\UF<42],;DDJ7LQ)"'M6#6,062"#UAXX&["[P*$:]9S&1P5&?)HS
MI!P0*Z4<=V :#HH-]=%[Z9VWR9T2C_'4_R.CC-0U5*PU]*+8;I<AUQM0H- I
MG:YBEM(_<Y"%SP+*ITX.?T<XW$8"!!$ZD\4>^-%[O7SU^'ZV# +ZG81T&<?!
M;/XEFGO/,1.;G@>2IF&^4]:Y:XRK _+^\PAX[P6HD^9P1R(O3$7<2R20(9P;
M$=/%,M6CD\85H:4&/8X) $!$)W\:\"5<2L4!0+G45XSD+67!6_\1<"C' ITF
MS4/V+<M=F0#>NS(6EKYJ5-!9:XO9OJ'>$PUINBECN^^)'R\B^J=J8#6M!\KQ
M&'P^W3#$I]Y+EE<7U^?7D0AE#OC*,%.MH23%\;(]6R!2A8@3?'V)*)RM1F$H
M5V/P'"G00&<J'^*7<<C13"[YECG=R(EJ*POE:0R^'SD6^#0M^5[XD;#56<Q8
M_"*><%?PU%882M08W#P*--"9$IU=/=9AYLFW,[A9/D'Z&K/?.<?GWIJF7GC!
M6^[3MOE$%):4A2+NM']$H9\4?[QLD/<D]%(2W'DLW52#YQ2Y(']2Y8(LZYOD
M%4ZJ-6)G@I1IJK^III?$OJ\F:^'9YN OT&MK1M6Y$9H&95=ZA\U(9_RK;)+F
M-D8EL#7?N'M%K8-U-^Z4ZW3&OY4&TU(= FQ2QS?#<JOVZ+?1JDW2!0>WE76#
M/G.C57!F-POFPY(K](]\WSB+Y*&]HFQ[4>R(/[G%5)>>*C4MK?PKGWQ\B:'(
M5HIBA^L9(]M0$WU#6U5!%[;>5A8[B$]/@:+QCG!P&Z?YN>=-S ?"?1#U)Q8G
MR7G&F#*B "2,''\.7736*#/ !9W#[9GUOIE:YA0B+DT9!H1I0; 6A%Q\MP@L
MT/2;(F17+N#2I +!7J>/(QVD>G%$TK&U/<:D#I<F)H,N9 Z3>3SR+X4S+R(+
MT<(^\<B2_EA5PF1@%,) 6>S0\RZ]U @62T-E6QN*4<.<EIH<=ISX4)2TPH'9
MRVPM,&])VG5Y617%CC ?=G79!&74%SZ:XXS)@A0_XGRPE:@+;(*6KR8K5],^
M:.T M/^BU6ZG<^.@-!]J[KR-L,?'./<+%0$IBE/3O\)/3?/J)^NB_DD:3Y+]
M%TZGJ/9.47<!*Q?D*04?EK9)N>V<!Y^)MJF&?_1YT*K&R*0(M*J5=X,DB/G)
M JMJ"N&?88H&74?<NC)]]K:VLJ.EI$T9]"/&PT9!LEK*)=Q@1FY?2CX&3$$I
M6?H5:3/B*+],P\U$GOA.%)>6QO87ZRRFNNS3J&S_K-'J*:XU[X8)Q&_X+-?:
M1K,CONZ=Z!XJ\ME+,T;3S05?T5V0Q&=TK<O] !)'/E%4K^64@[H&$<?XVSDR
M>&OS3&S!_F$+*(GJ.K#GCAY40L!!Y[.ZZ9<S=E@*^PS2B),V!2T?]$ZCX(&P
M9^J3*T+D=^VK7J9V$>Q30AC0>CT<L?5M(^\\JLQ]4"V%?9)G9.MM"H[<5:FY
MR:%\A.AO=><DX!H'^J-#;]D5>;K0<;K0<;K0<;K0<;K0<;K0X<2PZ^J%CC(1
MP"PB?$$-\EC))+#WSP:7$-1*H^\>3G<1;.V;/[.O7OH[5;RK(XHU2F%OS6"F
M+5'.&I0/Q O5)PBU,BX%R*E@;%',SIB0L+0R'O!_[<<"_H_?'L4.,W_J1>0L
MR[Q0LM;A925%W9@3!UG2R)6T\YJ7*3<BUUBNA-!G2=>/\6644L52IDTA727(
M?,HYT'.E4\W*4S8:$L^7E,RO:.1%/O7"V7Q.?<*D(QJ74 K@I;7L@G>#,0 8
MZ"NCTPW!]H74$6\(.G_5Q9G+@'VNNHPOP%Z"3I$(,)G-*[\S=M>T5X)].-BQ
MKW8 "GW<W;XXP*WXBB@??:H7=&DO:D"21&%T(K9/C)7'S.4 4CSCZ6NOC4*$
M7=KKFMP7A0,SZF$VS]YYG209"2XR1J/%'6$T#G*W5E+\GMML>3*N"NHVK <[
M[*^C672#"[V;2YK]JQ=FI#_)LFI<\L_TYU@-EE-)).]8O";B6" *1$;>M9AZ
M%%>A?E9=A=K6->&537:U85][VK;J+O3R47G7,'VP 4 4.]I VD1P@(&N!C<<
M>6 6I4$%.CWQXPBD+6P,0P:F>N-N+ ',=ILOGFH5Q0\@D+;R;//(/ZN.'  )
MOVTRJYJBAP?(5>,?U<4+@(3=(-/ :*$\5I7$?C'^L\?5CP@[6.OH#KF50MAN
M00/#K!$&P )])W*5L8BF?)G)VWA%7\5/\L/S4D@E@^T/ZLZ6'@ETLL[CU3I+
M"0-W+*D ]G:_.TT:#- YNB%>D@<@7:_6+'[.GW74]BBE$/:-P>Y< ;! YTNJ
M77ZXUF')4<HA'S3"MSG05<8!'J/VL4Y]/UMEN2^J^E V_SDD.3U14'VU5XJ(
MTA,_T!><7?T '/:#@MPW,=TC8<AF)U7QEG1QC^52V&>DPP\S%3 Z#S)IG'HA
M\G4SA<]7>=7LE[KS=^?P]5H=ONC7S-ZVZS<_23KCRYA +#Q)E)1=BWG1HEC/
MG&WV9<ICY>F+QP*#!%D]/^&X8\,@G59/(/"]RUH59!H O,]#U.V&J0S>O1H)
MP/HCA>_>+M34.K)KQ;X-AFM*HWNONVNYUR0*Q- )24-FYVMN6$ZKU9OV[T[Z
MV[F%=T'\W.'Q^!(_+N,L\<2---Z<S15?LBEOUX DL?VM-@V_&FAK *.E"&AI
M"Q[H:S<>*X+847GH-#9 /#J+Y)E$'7FLBF)[UO&9; )Y;"XOZ6(I/QM1MOY
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MR!% @EFZ)((A;@Q+;E/TF5Q'G%4B$B5KW"EFM;BQ=VGGJ7D/Q$ Q?!\,L+T
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ML6K/SYTR? K(?Z=Q/+6+H,?V&#NB5*H[F-:B2.8^FPN7][,7<D#V*5KTV2W
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MA%<UV=6U&VR1,H/NM#/) ZH40KJ?5[B>=BTK1XG28.6JZ.20PT4!]-2O[(&
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M);UR6E/J-DY)4J0H$7F?[CDK[%EV* Z6'M$2SDBOT7?N_(JYC1Y>5CR^%=Q
M6%J[(EY?8_E^G$5I<N=M)*]EMAIT0VQ$SGF80N,9<O>K!^(EQ)!(B?"(G/0F
M:KDZWIH.HV:CH[7[)T,L?26#WOC"VANJ:6*D9>6Q$VD,0*HL4GIL)^*]_)A#
M^B:M74\9@&R0OQ'(_"\%\Q%9>&E9UAGN;PD@X.6P-';*CP'8K6B-UY'U*Z&*
M(^]PZK^GBV4ZFW])2*Z/?ED$KPD]>TCW19(I7"ZMF"IMOV-D[=% G\$-*(Z>
M_:-7A]4#8W]3N6W#9KN?VCL]X%VO51@]*4C_WJ8 Q=$.!M^7-(70TXH,U9G>
MWA9EATQ%2SW+[5+HJ4K^__:NMB=A& C_%7Z"J GPD1"_&4W4Q/@1<$8TBHYA
M]-_;;LJZKO?2L7$'X8LQ>NUZSU-&G^NUUT(J;P"&PU M4?PV959#$(APY:"V
MRO-4H<HN(;(U/L"VQO.>>I6NCMO@+5TM#&[IW@&+H;^69$,=Y5WB/YND8ZY>
MTD;:I7];0 QQ3F,=Y#$G)YM QT'W @<9$LV<+&[!P2MF>F;[3(SGBI/Z(,P
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M%$))  #/?P( "@              @ $     97@Q.2TQ+FAT;5!+ 0(4 Q0
M   (  U =%IO#<&7W@(  ( -   *              "  6I)  !E>#(S+3$N
M:'1M4$L! A0#%     @ #4!T6CA#]9P7"   FT$   H              ( !
M<$P  &5X,S$M,2YH=&U02P$"% ,4    "  -0'1:_!7POB<(  #,00  "@
M            @ &O5   97@S,2TR+FAT;5!+ 0(4 Q0    (  U =%IPA;Q0
M"P8  ,,J   *              "  ?Y<  !E>#,R+3$N:'1M4$L! A0#%
M  @ #4!T6C/\/E@6"0  L2\   D              ( !,6,  &5X-"TQ+FAT
M;5!+ 0(4 Q0    (  U =%IE(>@W,><# -:?)0 ,              "  6YL
M  !F;W)M,3 M:RYH=&U02P$"% ,4    "  -0'1:*ICP0GBB 0"6I $ $
M            @ ')4P0 9F]R;3$P+6M?,# Q+FIP9U!+ 0(4 Q0    (  U
M=%K7-0O.Y%,! ,]F 0 0              "  6_V!0!F;W)M,3 M:U\P,#,N
M:G!G4$L! A0#%     @ #4!T6O=)!6YJ00, +<(# !               ( !
M@4H' &9O<FTQ,"UK7S P-2YJ<&=02P$"% ,4    "  -0'1:;"M0="7S P"G
M^0, $               @ $9C H 9F]R;3$P+6M?,# V+FIP9U!+ 0(4 Q0
M   (  U =%K'>\R1JFP  !%X   0              "  6Q_#@!F;W)M,3 M
M:U\P,#<N:G!G4$L! A0#%     @ #4!T6J!D_PG>L0$ Q\P! !
M     ( !1.P. &9O<FTQ,"UK7S P."YJ<&=02P$"% ,4    "  -0'1:#AY&
MQDIG  #==   $               @ %0GA  9F]R;3$P+6M?,# Y+FIP9U!+
M 0(4 Q0    (  U =%KV*(2NA%<  !EN   0              "  <@%$0!F
M;W)M,3 M:U\P,3 N:G!G4$L! A0#%     @ #4!T6M4'#(I4\@$ FA$" !
M             ( !>ET1 &9O<FTQ,"UK7S Q-"YJ<&=02P$"% ,4    "  -
M0'1:KV5(* Y5  #T7   $               @ '\3Q, 9F]R;3$P+6M?,#$U
M+FIP9U!+ 0(4 Q0    (  U =%K(Q//UJUD" "5P @ 0              "
M 3BE$P!F;W)M,3 M:U\P,C N:G!G4$L! A0#%     @ #4!T6D_7;;NWO0(
M<=L" !               ( !$?\5 &9O<FTQ,"UK7S R,2YJ<&=02P$"% ,4
M    "  -0'1:"P!5Q[EY @ &G0( $               @ 'VO!@ 9F]R;3$P
M+6M?,#(R+FIP9U!+ 0(4 Q0    (  U =%J3?XS.6ZX" %?# @ 0
M      "  =TV&P!F;W)M,3 M:U\P,C,N:G!G4$L! A0#%     @ #4!T6LH3
MQ ]5S   9-<  !               ( !9N4= &9O<FTQ,"UK7S R-"YJ<&=0
M2P$"% ,4    "  -0'1:G:)_WCHE 0!3;0$ $               @ 'IL1X
M9F]R;3$P+6M?,#(U+FIP9U!+ 0(4 Q0    (  U =%I?6GMG@!@  $,N 0 1
M              "  5'7'P!N<GAS+3(P,C0Q,C,Q+GAS9%!+ 0(4 Q0    (
M  U =%H?6MO/,QP  $]V 0 5              "  0#P'P!N<GAS+3(P,C0Q
M,C,Q7V-A;"YX;6Q02P$"% ,4    "  -0'1:Z5WJ:!]1  "*B 4 %0
M        @ %F#"  ;G)X<RTR,#(T,3(S,5]D968N>&UL4$L! A0#%     @
M#4!T6CR7.$2)JP  5?@) !4              ( !N%T@ &YR>',M,C R-#$R
M,S%?;&%B+GAM;%!+ 0(4 Q0    (  U =%IH".J2ZGL  +)E"  5
M      "  70)(0!N<GAS+3(P,C0Q,C,Q7W!R92YX;6Q02P4&     !P ' "T
)!@  D84A

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>124
<FILENAME>form10-k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:NRXS="http://neuraxis.com/20241231"
  xmlns:cyd="http://xbrl.sec.gov/cyd/2024"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2024"
  xmlns:stpr="http://xbrl.sec.gov/stpr/2024"
  xmlns:us-gaap="http://fasb.org/us-gaap/2024"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="nrxs-20241231.xsd" xlink:type="simple"/>
    <context id="From2024-01-01to2024-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2025-03-13">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
        </entity>
        <period>
            <instant>2025-03-13</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_ConvertibleSeriesBPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">NRXS:ConvertibleSeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_ConvertibleSeriesBPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">NRXS:ConvertibleSeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="From2023-01-012023-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_PreferredStockMember_custom_ConvertibleSeriesAPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">NRXS:ConvertibleSeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_PreferredStockMember_custom_ConvertibleSeriesSeedPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">NRXS:ConvertibleSeriesSeedPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_PreferredStockMember_custom_ConvertibleSeriesBPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">NRXS:ConvertibleSeriesBPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_PreferredStockMember_custom_ConvertibleSeriesAPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">NRXS:ConvertibleSeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_PreferredStockMember_custom_ConvertibleSeriesSeedPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">NRXS:ConvertibleSeriesSeedPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_PreferredStockMember_custom_ConvertibleSeriesBPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">NRXS:ConvertibleSeriesBPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_PreferredStockMember_custom_ConvertibleSeriesAPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">NRXS:ConvertibleSeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_PreferredStockMember_custom_ConvertibleSeriesSeedPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">NRXS:ConvertibleSeriesSeedPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_PreferredStockMember_custom_ConvertibleSeriesBPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">NRXS:ConvertibleSeriesBPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_PreferredStockMember_custom_ConvertibleSeriesAPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">NRXS:ConvertibleSeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_PreferredStockMember_custom_ConvertibleSeriesSeedPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">NRXS:ConvertibleSeriesSeedPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_PreferredStockMember_custom_ConvertibleSeriesBPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">NRXS:ConvertibleSeriesBPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_PreferredStockMember_custom_ConvertibleSeriesAPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">NRXS:ConvertibleSeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_PreferredStockMember_custom_ConvertibleSeriesSeedPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">NRXS:ConvertibleSeriesSeedPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_PreferredStockMember_custom_ConvertibleSeriesBPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">NRXS:ConvertibleSeriesBPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="From2023-01-102023-01-10">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
        </entity>
        <period>
            <startDate>2023-01-10</startDate>
            <endDate>2023-01-10</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_ConvertibleSeriesAPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">NRXS:ConvertibleSeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_ConvertibleSeriesSeedPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">NRXS:ConvertibleSeriesSeedPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="From2023-08-092023-08-09_us-gaap_CommonStockMember_custom_AlexanderCapitalLPMember_us-gaap_IPOMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">NRXS:AlexanderCapitalLPMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-08-09</startDate>
            <endDate>2023-08-09</endDate>
        </period>
    </context>
    <context id="AsOf2023-08-09_us-gaap_CommonStockMember_custom_AlexanderCapitalLPMember_us-gaap_IPOMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">NRXS:AlexanderCapitalLPMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-08-09</instant>
        </period>
    </context>
    <context id="From2023-08-092023-08-09_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-08-09</startDate>
            <endDate>2023-08-09</endDate>
        </period>
    </context>
    <context id="AsOf2024-08-15_us-gaap_SeriesBPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-08-15</instant>
        </period>
    </context>
    <context id="From2024-08-152024-08-15_us-gaap_SeriesBPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-08-15</startDate>
            <endDate>2024-08-15</endDate>
        </period>
    </context>
    <context id="From2024-08-152024-08-15_custom_ConvertibleSeriesAPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">NRXS:ConvertibleSeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-08-15</startDate>
            <endDate>2024-08-15</endDate>
        </period>
    </context>
    <context id="From2024-08-152024-08-15_custom_ConvertibleSeriesSeedPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">NRXS:ConvertibleSeriesSeedPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-08-15</startDate>
            <endDate>2024-08-15</endDate>
        </period>
    </context>
    <context id="AsOf2024-11-11_custom_ConvertibleSeriesBPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">NRXS:ConvertibleSeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-11-11</instant>
        </period>
    </context>
    <context id="From2024-11-112024-11-11_custom_ConvertibleSeriesBPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">NRXS:ConvertibleSeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-11-11</startDate>
            <endDate>2024-11-11</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_TrademarksMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_LicensingAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">NRXS:LicensingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_GeneralAndAdministrativeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_GeneralAndAdministrativeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_MachineryAndEquipmentMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_MachineryAndEquipmentMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_FurnitureAndFixturesMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_FurnitureAndFixturesMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_ComputerEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_LeaseholdImprovementsMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_LeaseholdImprovementsMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel2Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel2Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_OptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:OptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_OptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:OptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_CommonStockMember47706312">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_CommonStockMember47706312">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_WarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">NRXS:WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_WarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">NRXS:WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_SeriesBPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_SeriesBPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_stpr_CA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_stpr_CA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_stpr_OH">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:OH</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_stpr_OH">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:OH</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_stpr_IL">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:IL</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_stpr_IL">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:IL</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_stpr_WI">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:WI</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_stpr_WI">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:WI</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_stpr_MA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:MA</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_stpr_MA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:MA</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_stpr_FL">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:FL</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_stpr_FL">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:FL</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_AllOtherStatesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">NRXS:AllOtherStatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_AllOtherStatesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">NRXS:AllOtherStatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_CustomerAMember_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">NRXS:CustomerAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_CustomerAMember_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">NRXS:CustomerAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_CustomerAMember_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">NRXS:CustomerAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_CustomerAMember_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">NRXS:CustomerAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_CustomerBMember_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">NRXS:CustomerBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_CustomerBMember_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">NRXS:CustomerBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_CustomerBMember_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">NRXS:CustomerBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_CustomerBMember_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">NRXS:CustomerBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_CustomerCMember_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">NRXS:CustomerCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_CustomerCMember_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">NRXS:CustomerCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_CustomerCMember_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">NRXS:CustomerCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_CustomerCMember_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">NRXS:CustomerCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_CustomerDMember_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">NRXS:CustomerDMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_CustomerDMember_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">NRXS:CustomerDMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_CustomerDMember_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">NRXS:CustomerDMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_CustomerDMember_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">NRXS:CustomerDMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_CustomerEMember_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">NRXS:CustomerEMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_CustomerEMember_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">NRXS:CustomerEMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_CustomerEMember_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">NRXS:CustomerEMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_CustomerEMember_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">NRXS:CustomerEMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_CustomerMember_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">NRXS:CustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_CustomerMember_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">NRXS:CustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_CustomerMember_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">NRXS:CustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_CustomerMember_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">NRXS:CustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_CustomerAMember_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">NRXS:CustomerAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_CustomerAMember_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">NRXS:CustomerAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_CustomerBMember_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">NRXS:CustomerBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_CustomerBMember_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">NRXS:CustomerBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_CustomerCMember_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">NRXS:CustomerCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_CustomerCMember_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">NRXS:CustomerCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_CustomerMember_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">NRXS:CustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_CustomerMember_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">NRXS:CustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_ShareholdersOneAndTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">NRXS:ShareholdersOneAndTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_RelatedPartyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_MrWatkinsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">NRXS:MrWatkinsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_MrWatkinsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">NRXS:MrWatkinsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_MrSealeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">NRXS:MrSealeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_MrSealeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">NRXS:MrSealeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_MrSealeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">NRXS:MrSealeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_MrSealeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">NRXS:MrSealeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_srt_ChiefFinancialOfficerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefFinancialOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_ShareHolderOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">NRXS:ShareHolderOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_ShareHolderTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">NRXS:ShareHolderTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_RelatedPartyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_ShareHolderOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">NRXS:ShareHolderOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_ShareHolderTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">NRXS:ShareHolderTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_RelatedPartyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_OtherConvertiblesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">NRXS:OtherConvertiblesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_OtherConvertiblesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">NRXS:OtherConvertiblesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_ShareHolderOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">NRXS:ShareHolderOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_ShareHolderOneMember47707859">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">NRXS:ShareHolderOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_ShareHolderTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">NRXS:ShareHolderTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_ShareHolderTwoMember47707859">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">NRXS:ShareHolderTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_OtherConvertiblesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">NRXS:OtherConvertiblesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_OtherConvertiblesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">NRXS:OtherConvertiblesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_MachineryAndEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_MachineryAndEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_FurnitureAndFixturesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_FurnitureAndFixturesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_ComputerEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_LeaseholdImprovementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_LeaseholdImprovementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_DecemberTwoThousandTwentyFiveMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">NRXS:DecemberTwoThousandTwentyFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_DecemberTwoThousandTwentySixMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">NRXS:DecemberTwoThousandTwentySixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_DecemberTwoThousandTwentySevenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">NRXS:DecemberTwoThousandTwentySevenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_DecemberTwoThousandTwentyEightMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">NRXS:DecemberTwoThousandTwentyEightMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_DecemberTwoThousandTwentyNineMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">NRXS:DecemberTwoThousandTwentyNineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_DecemberTwoThousandTwentyThereafterMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">NRXS:DecemberTwoThousandTwentyThereafterMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_SoftwareImplementationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">NRXS:SoftwareImplementationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_SoftwareImplementationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">NRXS:SoftwareImplementationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_PatentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_PatentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_TrademarksMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_TrademarksMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_LicensesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">NRXS:LicensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_LicensesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">NRXS:LicensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-16_custom_ChannelPartnersCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">NRXS:ChannelPartnersCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-16</instant>
        </period>
    </context>
    <context id="From2023-03-162023-03-16_custom_ChannelPartnersCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">NRXS:ChannelPartnersCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-03-16</startDate>
            <endDate>2023-03-16</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-01-01_custom_ChannelPartnersCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">NRXS:ChannelPartnersCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-01-01</endDate>
        </period>
    </context>
    <context id="AsOf2022-09-16_custom_ChannelPartnersCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">NRXS:ChannelPartnersCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-16</instant>
        </period>
    </context>
    <context id="AsOf2023-05-24_custom_ChannelPartnersCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">NRXS:ChannelPartnersCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-05-24</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_ChannelPartnersCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">NRXS:ChannelPartnersCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_ChannelPartnersCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">NRXS:ChannelPartnersCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-02-15_custom_ExchangeListingLLCMember_custom_PromissoryNoteMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">NRXS:PromissoryNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">NRXS:ExchangeListingLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-02-15</instant>
        </period>
    </context>
    <context id="From2023-08-312023-08-31_custom_ExchangeListingLLCMember_custom_PromissoryNoteMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">NRXS:PromissoryNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">NRXS:ExchangeListingLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-08-31</startDate>
            <endDate>2023-08-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-08-09_custom_PromissoryNoteMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">NRXS:PromissoryNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-08-09</instant>
        </period>
    </context>
    <context id="From2024-08-092024-08-09_custom_PromissoryNoteMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">NRXS:PromissoryNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-08-09</startDate>
            <endDate>2024-08-09</endDate>
        </period>
    </context>
    <context id="AsOf2024-11-01_custom_SecondPromissoryNoteMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">NRXS:SecondPromissoryNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-11-01</instant>
        </period>
    </context>
    <context id="From2024-11-012024-11-01_custom_SecondPromissoryNoteMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">NRXS:SecondPromissoryNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-11-01</startDate>
            <endDate>2024-11-01</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_SecondPromissoryNoteMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">NRXS:SecondPromissoryNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_SecondPromissoryNoteMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">NRXS:SecondPromissoryNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-11-30_custom_TwoThousandTwentyTwoConvertibleNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">NRXS:TwoThousandTwentyTwoConvertibleNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-30</instant>
        </period>
    </context>
    <context id="From2022-11-302022-11-30_custom_TwoThousandTwentyTwoConvertibleNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">NRXS:TwoThousandTwentyTwoConvertibleNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-11-30</startDate>
            <endDate>2022-11-30</endDate>
        </period>
    </context>
    <context id="From2022-06-032022-11-30_custom_TwoThousandTwentyTwoConvertibleNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">NRXS:TwoThousandTwentyTwoConvertibleNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-03</startDate>
            <endDate>2022-11-30</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_TwoThousandTwentyTwoConvertibleNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">NRXS:TwoThousandTwentyTwoConvertibleNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-11-30_srt_MinimumMember_custom_TwoThousandTwentyTwoConvertibleNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">NRXS:TwoThousandTwentyTwoConvertibleNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-30</instant>
        </period>
    </context>
    <context id="AsOf2022-11-30_srt_MaximumMember_custom_TwoThousandTwentyTwoConvertibleNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">NRXS:TwoThousandTwentyTwoConvertibleNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-30</instant>
        </period>
    </context>
    <context id="AsOf2022-12-19_custom_TwoThousandTwentyTwoConvertibleNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">NRXS:TwoThousandTwentyTwoConvertibleNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-19</instant>
        </period>
    </context>
    <context id="From2022-12-192022-12-19_custom_TwoThousandTwentyTwoConvertibleNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">NRXS:TwoThousandTwentyTwoConvertibleNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-19</startDate>
            <endDate>2022-12-19</endDate>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_ConvertiblePromissoryNoteMember_custom_AccreditedInvestorsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">NRXS:AccreditedInvestorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">NRXS:ConvertiblePromissoryNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_AccreditedInvestorsMember_custom_ConvertiblePromissoryNoteMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">NRXS:AccreditedInvestorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">NRXS:ConvertiblePromissoryNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_ConvertiblePromissoryNoteMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">NRXS:ConvertiblePromissoryNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_TwoThousandTwentyThreeConvertibleNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">NRXS:TwoThousandTwentyThreeConvertibleNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_ConvertiblePromissoryNoteMember_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">NRXS:ConvertiblePromissoryNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_ConvertiblePromissoryNoteMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">NRXS:ConvertiblePromissoryNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_TwoThousandTwentyThreeConvertibleNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">NRXS:TwoThousandTwentyThreeConvertibleNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-08-09_custom_TwoThousandTwentyThreeConvertibleNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">NRXS:TwoThousandTwentyThreeConvertibleNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-08-09</instant>
        </period>
    </context>
    <context id="From2023-08-092023-08-09_custom_TwoThousandTwentyThreeConvertibleNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">NRXS:TwoThousandTwentyThreeConvertibleNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-08-09</startDate>
            <endDate>2023-08-09</endDate>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_SignatureBankMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">NRXS:SignatureBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_AlexanderCapitalLPMember_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">NRXS:AlexanderCapitalLPMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_AlexanderCapitalLPMember_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">NRXS:AlexanderCapitalLPMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-08-09_custom_ChannelPartnersCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">NRXS:ChannelPartnersCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-08-09</instant>
        </period>
    </context>
    <context id="From2023-08-092023-08-09_custom_ChannelPartnersCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">NRXS:ChannelPartnersCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-08-09</startDate>
            <endDate>2023-08-09</endDate>
        </period>
    </context>
    <context id="AsOf2023-11-08">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
        </entity>
        <period>
            <instant>2023-11-08</instant>
        </period>
    </context>
    <context id="From2023-11-082023-11-08">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
        </entity>
        <period>
            <startDate>2023-11-08</startDate>
            <endDate>2023-11-08</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_ConvertiblePromissoryNotesMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">NRXS:ConvertiblePromissoryNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_ConvertiblePromissoryNotesMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">NRXS:ConvertiblePromissoryNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_ConvertiblePromissoryNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">NRXS:ConvertiblePromissoryNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_ConvertiblePromissoryNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">NRXS:ConvertiblePromissoryNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_TwoThousandTwentyFourConvertiblePromissoryNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">NRXS:TwoThousandTwentyFourConvertiblePromissoryNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_SeriesBPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_SeriesBPreferredStockMember47710687">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-21_custom_TwoThousandTwentyFourConvertiblePromissoryNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">NRXS:TwoThousandTwentyFourConvertiblePromissoryNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-21</instant>
        </period>
    </context>
    <context id="AsOf2024-02-12_custom_TwoThousandTwentyFourConvertiblePromissoryNotesMember_us-gaap_SeriesBPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">NRXS:TwoThousandTwentyFourConvertiblePromissoryNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-12</instant>
        </period>
    </context>
    <context id="AsOf2024-12-12_us-gaap_SeriesBPreferredStockMember_custom_TwoThousandTwentyFourConvertiblePromissoryNotesMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">NRXS:TwoThousandTwentyFourConvertiblePromissoryNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-12</instant>
        </period>
    </context>
    <context id="AsOf2024-02-12_us-gaap_SeriesBPreferredStockMember_custom_TwoThousandTwentyFourConvertiblePromissoryNotesMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">NRXS:TwoThousandTwentyFourConvertiblePromissoryNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-12</instant>
        </period>
    </context>
    <context id="AsOf2024-02-12_us-gaap_SeriesBPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-12</instant>
        </period>
    </context>
    <context id="From2024-02-122024-02-12_us-gaap_SeriesBPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-12</startDate>
            <endDate>2024-02-12</endDate>
        </period>
    </context>
    <context id="From2024-08-152024-08-15_custom_TwoThousandTwentyFourConvertibleNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">NRXS:TwoThousandTwentyFourConvertibleNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-08-15</startDate>
            <endDate>2024-08-15</endDate>
        </period>
    </context>
    <context id="AsOf2024-09-15_custom_TwoThousandTwentyFourConvertiblePromissoryNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">NRXS:TwoThousandTwentyFourConvertiblePromissoryNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-15</instant>
        </period>
    </context>
    <context id="AsOf2024-08-15_custom_TwoThousandTwentyFourConvertiblePromissoryNotesMember_us-gaap_SeriesBPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">NRXS:TwoThousandTwentyFourConvertiblePromissoryNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-08-15</instant>
        </period>
    </context>
    <context id="From2024-08-152024-08-15_custom_TwoThousandTwentyFourConvertibleNotesMember_us-gaap_SeriesBPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">NRXS:TwoThousandTwentyFourConvertibleNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-08-15</startDate>
            <endDate>2024-08-15</endDate>
        </period>
    </context>
    <context id="From2024-08-152024-08-15_custom_TwoThousandTwentyFourConvertiblePromissoryNotesMember_us-gaap_SeriesBPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">NRXS:TwoThousandTwentyFourConvertiblePromissoryNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-08-15</startDate>
            <endDate>2024-08-15</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_TwoThousandTwentyFourConvertiblePromissoryNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">NRXS:TwoThousandTwentyFourConvertiblePromissoryNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="From2022-01-012022-01-01_custom_VersaillesIndianaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GeographicDistributionAxis">NRXS:VersaillesIndianaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-01-01</endDate>
        </period>
    </context>
    <context id="AsOf2022-01-01_custom_VersaillesIndianaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GeographicDistributionAxis">NRXS:VersaillesIndianaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-01</instant>
        </period>
    </context>
    <context id="From2024-01-012024-01-01_custom_CarmelIndianaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GeographicDistributionAxis">NRXS:CarmelIndianaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-01-01</endDate>
        </period>
    </context>
    <context id="AsOf2024-01-01_custom_CarmelIndianaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GeographicDistributionAxis">NRXS:CarmelIndianaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-01-01</instant>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_ConvertibleSeriesSeedPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">NRXS:ConvertibleSeriesSeedPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_VendorsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">NRXS:VendorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_VendorsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">NRXS:VendorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_EmployementAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">NRXS:EmployementAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_TwoThousandTwentyThreeConvertiblePromissoryNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">NRXS:TwoThousandTwentyThreeConvertiblePromissoryNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_TwoThousandTwentyTwoConvertibleNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">NRXS:TwoThousandTwentyTwoConvertibleNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_AdvisoryAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">NRXS:AdvisoryAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_UnderwritingAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">NRXS:UnderwritingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_TwoThousandTwentyFourConvertiblePromissoryNotesMember47712359">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">NRXS:TwoThousandTwentyFourConvertiblePromissoryNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_AdvisoryAgreementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">NRXS:AdvisoryAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_TwoThousandTwentyThreeConvertiblePromissoryNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">NRXS:TwoThousandTwentyThreeConvertiblePromissoryNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_PreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_PreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_PreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_PreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_InvestorWarrantOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">NRXS:InvestorWarrantOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_InvestorWarrantPSAOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">NRXS:InvestorWarrantPSAOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_InvestorWarrantPSAOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">NRXS:InvestorWarrantPSAOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_TwoThousandTwentyTwoConvertibleNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">NRXS:TwoThousandTwentyTwoConvertibleNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_TwoThousandTwentyTwoConvertibleNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">NRXS:TwoThousandTwentyTwoConvertibleNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_TwoThousandTwentyThreeConvertibleNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">NRXS:TwoThousandTwentyThreeConvertibleNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_TwoThousandTwentyThreeConvertibleNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">NRXS:TwoThousandTwentyThreeConvertibleNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_UnderwriterWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">NRXS:UnderwriterWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_AdvisoryAgreementWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">NRXS:AdvisoryAgreementWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_AdvisoryAgreementWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">NRXS:AdvisoryAgreementWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_SeriesAPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_SeriesSeedPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">NRXS:SeriesSeedPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_SeriesAPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-08-15_custom_AmendedTwoThousandTwentyFourConvertibleNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">NRXS:AmendedTwoThousandTwentyFourConvertibleNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-08-15</instant>
        </period>
    </context>
    <context id="From2024-08-152024-08-15_custom_AmendedTwoThousandTwentyFourConvertibleNotesMember_us-gaap_SeriesBPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">NRXS:AmendedTwoThousandTwentyFourConvertibleNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-08-15</startDate>
            <endDate>2024-08-15</endDate>
        </period>
    </context>
    <context id="AsOf2024-08-15_custom_AmendedTwoThousandTwentyFourConvertibleNotesMember_us-gaap_SeriesBPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">NRXS:AmendedTwoThousandTwentyFourConvertibleNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-08-15</instant>
        </period>
    </context>
    <context id="AsOf2024-11-11_us-gaap_SeriesBPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-11-11</instant>
        </period>
    </context>
    <context id="AsOf2024-11-13_us-gaap_SeriesBPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-11-13</instant>
        </period>
    </context>
    <context id="From2024-11-112024-11-11_us-gaap_SeriesBPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-11-11</startDate>
            <endDate>2024-11-11</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_PreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_PreferredStockMember47713734">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2017-10-12_custom_TwentySeventeenStockCompensationPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">NRXS:TwentySeventeenStockCompensationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-10-12</instant>
        </period>
    </context>
    <context id="AsOf2019-09-13_custom_TwentySeventeenStockCompensationPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">NRXS:TwentySeventeenStockCompensationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-13</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_srt_ChiefFinancialOfficerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefFinancialOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_TwentySeventeenStockCompensationPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">NRXS:TwentySeventeenStockCompensationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_TwentySeventeenStockCompensationPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">NRXS:TwentySeventeenStockCompensationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_MeasurementInputSharePriceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_MeasurementInputPriceVolatilityMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_MeasurementInputPriceVolatilityMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_MeasurementInputRiskFreeInterestRateMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_MeasurementInputRiskFreeInterestRateMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_MeasurementInputExpectedDividendRateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_FairValueInputsLevel1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_FairValueInputsLevel2Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_FairValueInputsLevel3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_FairValueInputsLevel1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_FairValueInputsLevel2Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_FairValueInputsLevel3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_FairValueInputsLevel1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_FairValueInputsLevel2Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_FairValueInputsLevel3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_FairValueInputsLevel1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_FairValueInputsLevel2Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_FairValueInputsLevel3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_FairValueInputsLevel1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_FairValueInputsLevel2Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_FairValueInputsLevel3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_MeasurementInputPriceVolatilityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_OperatingSegmentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_OperatingSegmentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2024-03-182024-03-18_custom_AdvisoryAgreementMember_us-gaap_PrivatePlacementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">NRXS:AdvisoryAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-03-18</startDate>
            <endDate>2024-03-18</endDate>
        </period>
    </context>
    <context id="From2024-03-182024-03-18_custom_AdvisoryAgreementMember_us-gaap_PrivatePlacementMember_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">NRXS:AdvisoryAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-03-18</startDate>
            <endDate>2024-03-18</endDate>
        </period>
    </context>
    <context id="AsOf2024-03-18_custom_AdvisoryAgreementMember_us-gaap_CommonStockMember_us-gaap_PrivatePlacementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">NRXS:AdvisoryAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-18</instant>
        </period>
    </context>
    <context id="From2025-03-262025-03-26_srt_ScenarioForecastMember_custom_AdvisoryAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">NRXS:AdvisoryAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-03-26</startDate>
            <endDate>2025-03-26</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_CommonStockMember_custom_SettlementAgreementMember_us-gaap_SeriesAPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">NRXS:SettlementAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_SeriesAPreferredStockMember_custom_SettlementAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">NRXS:SettlementAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_CommonStockMember_us-gaap_SeriesAPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_SeriesAPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2022-10-012022-10-01_srt_MinimumMember_custom_ExecutiveEmploymentAgreementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">NRXS:ExecutiveEmploymentAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2022-10-01</endDate>
        </period>
    </context>
    <context id="From2022-10-012022-10-01_srt_MaximumMember_custom_ExecutiveEmploymentAgreementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">NRXS:ExecutiveEmploymentAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2022-10-01</endDate>
        </period>
    </context>
    <context id="From2022-10-012022-10-01_custom_ExecutiveEmploymentAgreementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">NRXS:ExecutiveEmploymentAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2022-10-01</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_ExecutiveEmploymentAgreementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">NRXS:ExecutiveEmploymentAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_ExecutiveEmploymentAgreementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">NRXS:ExecutiveEmploymentAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="From2024-01-012024-06-30_custom_ExecutiveEmploymentAgreementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">NRXS:ExecutiveEmploymentAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2024-01-02_custom_ExecutiveEmploymentAgreementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">NRXS:ExecutiveEmploymentAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-01-02</instant>
        </period>
    </context>
    <context id="AsOf2024-01-02_custom_ExecutiveEmploymentAgreementsMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">NRXS:ExecutiveEmploymentAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-01-02</instant>
        </period>
    </context>
    <context id="AsOf2023-04-30_custom_ExecutiveEmploymentAgreementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">NRXS:ExecutiveEmploymentAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-30</instant>
        </period>
    </context>
    <context id="AsOf2023-04-30_custom_ExecutiveEmploymentAgreementsMember_us-gaap_IPOMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">NRXS:ExecutiveEmploymentAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-30</instant>
        </period>
    </context>
    <context id="From2024-04-102024-04-10_srt_ChiefOperatingOfficerMember_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefOperatingOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-10</startDate>
            <endDate>2024-04-10</endDate>
        </period>
    </context>
    <context id="From2024-04-102024-04-10_srt_ChiefOperatingOfficerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefOperatingOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-10</startDate>
            <endDate>2024-04-10</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-31_srt_ChiefOperatingOfficerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefOperatingOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="From2019-02-062019-02-06">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
        </entity>
        <period>
            <startDate>2019-02-06</startDate>
            <endDate>2019-02-06</endDate>
        </period>
    </context>
    <context id="From2022-07-142022-07-14">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
        </entity>
        <period>
            <startDate>2022-07-14</startDate>
            <endDate>2022-07-14</endDate>
        </period>
    </context>
    <context id="AsOf2024-01-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
        </entity>
        <period>
            <instant>2024-01-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_DomesticCountryMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_TaxYear2037Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">NRXS:TaxYear2037Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_TaxYear2038Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">NRXS:TaxYear2038Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_TaxYear2039Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">NRXS:TaxYear2039Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_TaxYear2040Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">NRXS:TaxYear2040Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_TaxYear2041Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">NRXS:TaxYear2041Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_TaxYearThereafterMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">NRXS:TaxYearThereafterMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_NoExpirationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">NRXS:NoExpirationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="From2025-01-032025-01-03_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-03</startDate>
            <endDate>2025-01-03</endDate>
        </period>
    </context>
    <context id="From2025-03-062025-03-06_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-03-06</startDate>
            <endDate>2025-03-06</endDate>
        </period>
    </context>
    <context id="From2025-01-172025-01-17_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-17</startDate>
            <endDate>2025-01-17</endDate>
        </period>
    </context>
    <context id="From2025-01-172025-01-17_us-gaap_SubsequentEventMember_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-17</startDate>
            <endDate>2025-01-17</endDate>
        </period>
    </context>
    <context id="From2025-01-172025-01-17_us-gaap_SubsequentEventMember_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-17</startDate>
            <endDate>2025-01-17</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Pure">
        <measure>pure</measure>
    </unit>
    <dei:AmendmentFlag contextRef="From2024-01-01to2024-12-31" id="Fact000003">false</dei:AmendmentFlag>
    <dei:DocumentFiscalPeriodFocus contextRef="From2024-01-01to2024-12-31" id="Fact000004">FY</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey contextRef="From2024-01-01to2024-12-31" id="Fact000005">0001933567</dei:EntityCentralIndexKey>
    <dei:AuditorFirmId contextRef="From2024-01-01to2024-12-31" id="xdx2ixbrl0058">89</dei:AuditorFirmId>
    <us-gaap:SecurityDeposit
      contextRef="AsOf2023-12-31"
      id="xdx2ixbrl0111"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="AsOf2024-12-31"
      id="xdx2ixbrl0155"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="AsOf2023-12-31"
      id="xdx2ixbrl0156"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2023-12-31"
      id="xdx2ixbrl0162"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="From2024-01-01to2024-12-31"
      id="xdx2ixbrl0244"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="From2024-01-01to2024-12-31"
      id="xdx2ixbrl0250"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockDividendsAndOtherAdjustments
      contextRef="From2023-01-012023-12-31"
      id="xdx2ixbrl0266"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_PreferredStockMember_custom_ConvertibleSeriesBPreferredStockMember"
      id="xdx2ixbrl0295"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2022-12-31_us-gaap_PreferredStockMember_custom_ConvertibleSeriesBPreferredStockMember"
      id="xdx2ixbrl0305"
      unitRef="Shares"
      xsi:nil="true"/>
    <NRXS:StockIssuedDuringPeriodValueCommonStockIssuedUponInitialPublicOffering
      contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember_custom_ConvertibleSeriesAPreferredStockMember"
      id="xdx2ixbrl0309"
      unitRef="USD"
      xsi:nil="true"/>
    <NRXS:StockIssuedDuringPeriodValueCommonStockIssuedUponInitialPublicOffering
      contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember_custom_ConvertibleSeriesSeedPreferredStockMember"
      id="xdx2ixbrl0310"
      unitRef="USD"
      xsi:nil="true"/>
    <NRXS:StockIssuedDuringPeriodValueCommonStockIssuedUponInitialPublicOffering
      contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember_custom_ConvertibleSeriesBPreferredStockMember"
      id="xdx2ixbrl0311"
      unitRef="USD"
      xsi:nil="true"/>
    <NRXS:StockIssuedDuringPeriodValueCommonStockIssuedUponInitialPublicOffering
      contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0314"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember_custom_ConvertibleSeriesBPreferredStockMember"
      id="xdx2ixbrl0321"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0324"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="From2023-01-012023-12-31"
      id="xdx2ixbrl0325"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfUnits
      contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember_custom_ConvertibleSeriesAPreferredStockMember"
      id="xdx2ixbrl0333"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfUnits
      contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember_custom_ConvertibleSeriesSeedPreferredStockMember"
      id="xdx2ixbrl0334"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfUnits
      contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember_custom_ConvertibleSeriesBPreferredStockMember"
      id="xdx2ixbrl0335"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfUnits
      contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0338"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember_custom_ConvertibleSeriesAPreferredStockMember"
      id="xdx2ixbrl0343"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember_custom_ConvertibleSeriesSeedPreferredStockMember"
      id="xdx2ixbrl0344"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember_custom_ConvertibleSeriesBPreferredStockMember"
      id="xdx2ixbrl0345"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0348"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember_custom_ConvertibleSeriesAPreferredStockMember"
      id="xdx2ixbrl0353"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember_custom_ConvertibleSeriesSeedPreferredStockMember"
      id="xdx2ixbrl0354"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember_custom_ConvertibleSeriesBPreferredStockMember"
      id="xdx2ixbrl0355"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0356"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0358"
      unitRef="USD"
      xsi:nil="true"/>
    <NRXS:StockIssuedDuringPeriodValueWarrantsExercised
      contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember_custom_ConvertibleSeriesAPreferredStockMember"
      id="xdx2ixbrl0361"
      unitRef="USD"
      xsi:nil="true"/>
    <NRXS:StockIssuedDuringPeriodValueWarrantsExercised
      contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember_custom_ConvertibleSeriesSeedPreferredStockMember"
      id="xdx2ixbrl0362"
      unitRef="USD"
      xsi:nil="true"/>
    <NRXS:StockIssuedDuringPeriodValueWarrantsExercised
      contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember_custom_ConvertibleSeriesBPreferredStockMember"
      id="xdx2ixbrl0363"
      unitRef="USD"
      xsi:nil="true"/>
    <NRXS:StockIssuedDuringPeriodValueWarrantsExercised
      contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0366"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember_custom_ConvertibleSeriesAPreferredStockMember"
      id="xdx2ixbrl0371"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember_custom_ConvertibleSeriesSeedPreferredStockMember"
      id="xdx2ixbrl0372"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember_custom_ConvertibleSeriesBPreferredStockMember"
      id="xdx2ixbrl0373"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0374"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0375"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_PreferredStockMember_custom_ConvertibleSeriesAPreferredStockMember"
      id="xdx2ixbrl0379"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_PreferredStockMember_custom_ConvertibleSeriesSeedPreferredStockMember"
      id="xdx2ixbrl0380"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_PreferredStockMember_custom_ConvertibleSeriesBPreferredStockMember"
      id="xdx2ixbrl0381"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2023-12-31_us-gaap_PreferredStockMember_custom_ConvertibleSeriesAPreferredStockMember"
      id="xdx2ixbrl0387"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2023-12-31_us-gaap_PreferredStockMember_custom_ConvertibleSeriesSeedPreferredStockMember"
      id="xdx2ixbrl0389"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2023-12-31_us-gaap_PreferredStockMember_custom_ConvertibleSeriesBPreferredStockMember"
      id="xdx2ixbrl0391"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_PreferredStockMember_custom_ConvertibleSeriesAPreferredStockMember"
      id="xdx2ixbrl0395"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_PreferredStockMember_custom_ConvertibleSeriesSeedPreferredStockMember"
      id="xdx2ixbrl0396"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_PreferredStockMember_custom_ConvertibleSeriesBPreferredStockMember"
      id="xdx2ixbrl0397"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2023-12-31_us-gaap_PreferredStockMember_custom_ConvertibleSeriesAPreferredStockMember"
      id="xdx2ixbrl0403"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2023-12-31_us-gaap_PreferredStockMember_custom_ConvertibleSeriesSeedPreferredStockMember"
      id="xdx2ixbrl0405"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2023-12-31_us-gaap_PreferredStockMember_custom_ConvertibleSeriesBPreferredStockMember"
      id="xdx2ixbrl0407"
      unitRef="Shares"
      xsi:nil="true"/>
    <NRXS:StockIssuedDuringPeriodValueWarrantsExercised
      contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember_custom_ConvertibleSeriesAPreferredStockMember"
      id="xdx2ixbrl0411"
      unitRef="USD"
      xsi:nil="true"/>
    <NRXS:StockIssuedDuringPeriodValueWarrantsExercised
      contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember_custom_ConvertibleSeriesSeedPreferredStockMember"
      id="xdx2ixbrl0412"
      unitRef="USD"
      xsi:nil="true"/>
    <NRXS:StockIssuedDuringPeriodValueWarrantsExercised
      contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember_custom_ConvertibleSeriesBPreferredStockMember"
      id="xdx2ixbrl0413"
      unitRef="USD"
      xsi:nil="true"/>
    <NRXS:StockIssuedDuringPeriodValueWarrantsExercised
      contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0416"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember_custom_ConvertibleSeriesAPreferredStockMember"
      id="xdx2ixbrl0421"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember_custom_ConvertibleSeriesSeedPreferredStockMember"
      id="xdx2ixbrl0422"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember_custom_ConvertibleSeriesBPreferredStockMember"
      id="xdx2ixbrl0423"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0424"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0426"
      unitRef="USD"
      xsi:nil="true"/>
    <NRXS:AdditionalPaidInCapitalFromWarrantsIssuedAsDebtDiscount
      contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember_custom_ConvertibleSeriesAPreferredStockMember"
      id="xdx2ixbrl0429"
      unitRef="USD"
      xsi:nil="true"/>
    <NRXS:AdditionalPaidInCapitalFromWarrantsIssuedAsDebtDiscount
      contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember_custom_ConvertibleSeriesSeedPreferredStockMember"
      id="xdx2ixbrl0430"
      unitRef="USD"
      xsi:nil="true"/>
    <NRXS:AdditionalPaidInCapitalFromWarrantsIssuedAsDebtDiscount
      contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember_custom_ConvertibleSeriesBPreferredStockMember"
      id="xdx2ixbrl0431"
      unitRef="USD"
      xsi:nil="true"/>
    <NRXS:AdditionalPaidInCapitalFromWarrantsIssuedAsDebtDiscount
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0432"
      unitRef="USD"
      xsi:nil="true"/>
    <NRXS:AdditionalPaidInCapitalFromWarrantsIssuedAsDebtDiscount
      contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0434"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember_custom_ConvertibleSeriesAPreferredStockMember"
      id="xdx2ixbrl0437"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember_custom_ConvertibleSeriesSeedPreferredStockMember"
      id="xdx2ixbrl0438"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember_custom_ConvertibleSeriesBPreferredStockMember"
      id="xdx2ixbrl0439"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0442"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature
      contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember_custom_ConvertibleSeriesAPreferredStockMember"
      id="xdx2ixbrl0447"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature
      contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember_custom_ConvertibleSeriesSeedPreferredStockMember"
      id="xdx2ixbrl0448"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature
      contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember_custom_ConvertibleSeriesBPreferredStockMember"
      id="xdx2ixbrl0449"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0450"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature
      contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0452"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember_custom_ConvertibleSeriesAPreferredStockMember"
      id="xdx2ixbrl0455"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember_custom_ConvertibleSeriesSeedPreferredStockMember"
      id="xdx2ixbrl0456"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0458"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0460"
      unitRef="USD"
      xsi:nil="true"/>
    <NRXS:StockIssuedDuringPeriodValuePreferredStock
      contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember_custom_ConvertibleSeriesAPreferredStockMember"
      id="xdx2ixbrl0465"
      unitRef="USD"
      xsi:nil="true"/>
    <NRXS:StockIssuedDuringPeriodValuePreferredStock
      contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember_custom_ConvertibleSeriesSeedPreferredStockMember"
      id="xdx2ixbrl0466"
      unitRef="USD"
      xsi:nil="true"/>
    <NRXS:StockIssuedDuringPeriodValuePreferredStock
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0468"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember_custom_ConvertibleSeriesAPreferredStockMember"
      id="xdx2ixbrl0475"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember_custom_ConvertibleSeriesSeedPreferredStockMember"
      id="xdx2ixbrl0476"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember_custom_ConvertibleSeriesBPreferredStockMember"
      id="xdx2ixbrl0477"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0478"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0479"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31_us-gaap_PreferredStockMember_custom_ConvertibleSeriesAPreferredStockMember"
      id="xdx2ixbrl0483"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31_us-gaap_PreferredStockMember_custom_ConvertibleSeriesSeedPreferredStockMember"
      id="xdx2ixbrl0484"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2024-12-31_us-gaap_PreferredStockMember_custom_ConvertibleSeriesAPreferredStockMember"
      id="xdx2ixbrl0491"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2024-12-31_us-gaap_PreferredStockMember_custom_ConvertibleSeriesSeedPreferredStockMember"
      id="xdx2ixbrl0493"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31_us-gaap_PreferredStockMember_custom_ConvertibleSeriesAPreferredStockMember"
      id="xdx2ixbrl0499"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31_us-gaap_PreferredStockMember_custom_ConvertibleSeriesSeedPreferredStockMember"
      id="xdx2ixbrl0500"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2024-12-31_us-gaap_PreferredStockMember_custom_ConvertibleSeriesAPreferredStockMember"
      id="xdx2ixbrl0507"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2024-12-31_us-gaap_PreferredStockMember_custom_ConvertibleSeriesSeedPreferredStockMember"
      id="xdx2ixbrl0509"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:InventoryWriteDown
      contextRef="From2023-01-012023-12-31"
      id="xdx2ixbrl0534"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PaidInKindInterest
      contextRef="From2024-01-01to2024-12-31"
      id="xdx2ixbrl0539"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensation
      contextRef="From2023-01-012023-12-31"
      id="xdx2ixbrl0543"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="From2024-01-01to2024-12-31"
      id="xdx2ixbrl0545"
      unitRef="USD"
      xsi:nil="true"/>
    <NRXS:IssuanceOfWarrantsForNoncashConsideration
      contextRef="From2023-01-012023-12-31"
      id="xdx2ixbrl0552"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="From2024-01-01to2024-12-31"
      id="xdx2ixbrl0557"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="From2024-01-01to2024-12-31"
      id="xdx2ixbrl0596"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2024-01-01to2024-12-31"
      id="xdx2ixbrl0605"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
      contextRef="From2023-01-012023-12-31"
      id="xdx2ixbrl0609"
      unitRef="USD"
      xsi:nil="true"/>
    <NRXS:DeferredOfferingCostsPaid
      contextRef="From2024-01-01to2024-12-31"
      id="xdx2ixbrl0611"
      unitRef="USD"
      xsi:nil="true"/>
    <NRXS:DeferredOfferingCostsPaid
      contextRef="From2023-01-012023-12-31"
      id="xdx2ixbrl0612"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromNotesPayable
      contextRef="From2024-01-01to2024-12-31"
      id="xdx2ixbrl0620"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="From2023-01-012023-12-31"
      id="xdx2ixbrl0648"
      unitRef="USD"
      xsi:nil="true"/>
    <NRXS:RecognitionOfRightOfUseAsset
      contextRef="From2023-01-012023-12-31"
      id="xdx2ixbrl0654"
      unitRef="USD"
      xsi:nil="true"/>
    <NRXS:ConversionOfConvertiblePromissoryNotesToSeriesBPreferredStock
      contextRef="From2023-01-012023-12-31"
      id="xdx2ixbrl0657"
      unitRef="USD"
      xsi:nil="true"/>
    <NRXS:FairValueOfWarrantsFromDebtDiscountInConvertibleNotesClassifiedOfAdditionalPaidInCapital
      contextRef="From2023-01-012023-12-31"
      id="xdx2ixbrl0660"
      unitRef="USD"
      xsi:nil="true"/>
    <NRXS:WriteoffOfDebtDiscountOnConvertibleNotesClassifiedAsAdditionalPaidInCapital
      contextRef="From2023-01-012023-12-31"
      id="xdx2ixbrl0663"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NotesIssued1
      contextRef="From2023-01-012023-12-31"
      id="xdx2ixbrl0666"
      unitRef="USD"
      xsi:nil="true"/>
    <NRXS:FairValueOfWarrantLiabilitiesOfWarrantsFromConvertibleNotes
      contextRef="From2024-01-01to2024-12-31"
      id="xdx2ixbrl0668"
      unitRef="USD"
      xsi:nil="true"/>
    <NRXS:FairValueOfDerivativeLiabilitiesOfConversionFeatureFromConvertibleNotes
      contextRef="From2024-01-01to2024-12-31"
      id="xdx2ixbrl0671"
      unitRef="USD"
      xsi:nil="true"/>
    <NRXS:ReclassificationOfWarrantLiabilityToEquity
      contextRef="From2024-01-01to2024-12-31"
      id="xdx2ixbrl0674"
      unitRef="USD"
      xsi:nil="true"/>
    <NRXS:ConversionOfPreferredStockToCommonStock
      contextRef="From2024-01-01to2024-12-31"
      id="xdx2ixbrl0677"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="AsOf2024-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel1Member"
      id="xdx2ixbrl0827"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="AsOf2024-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel2Member"
      id="xdx2ixbrl0828"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="AsOf2023-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel1Member"
      id="xdx2ixbrl0832"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="AsOf2023-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel2Member"
      id="xdx2ixbrl0833"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DividendsPreferredStock
      contextRef="From2023-01-012023-12-31"
      id="xdx2ixbrl0840"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember47706312"
      id="xdx2ixbrl0848"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2023-01-012023-12-31_us-gaap_SeriesBPreferredStockMember"
      id="xdx2ixbrl0854"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:DividendsPreferredStock
      contextRef="From2023-01-012023-12-31"
      id="xdx2ixbrl0865"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AccountsReceivableNet
      contextRef="AsOf2023-12-31_custom_CustomerAMember_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember"
      id="xdx2ixbrl0940"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AccountsReceivableNet
      contextRef="AsOf2024-12-31_custom_CustomerBMember_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember"
      id="xdx2ixbrl0944"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AccountsReceivableNet
      contextRef="AsOf2024-12-31_custom_CustomerDMember_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember"
      id="xdx2ixbrl0960"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AccountsReceivableNet
      contextRef="AsOf2024-12-31_custom_CustomerEMember_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember"
      id="xdx2ixbrl0968"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NotesAndLoansReceivableNetCurrent
      contextRef="AsOf2024-12-31_us-gaap_RelatedPartyMember"
      id="xdx2ixbrl1070"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:InterestReceivable
      contextRef="AsOf2024-12-31_us-gaap_RelatedPartyMember"
      id="xdx2ixbrl1072"
      unitRef="USD"
      xsi:nil="true"/>
    <NRXS:InterestIncomeCurrent
      contextRef="AsOf2024-12-31_us-gaap_RelatedPartyMember"
      id="xdx2ixbrl1074"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NotesAndLoansReceivableNetCurrent
      contextRef="AsOf2023-12-31_us-gaap_RelatedPartyMember"
      id="xdx2ixbrl1100"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:InterestReceivable
      contextRef="AsOf2023-12-31_us-gaap_RelatedPartyMember"
      id="xdx2ixbrl1102"
      unitRef="USD"
      xsi:nil="true"/>
    <NRXS:InterestIncomeCurrent
      contextRef="AsOf2023-12-31_us-gaap_RelatedPartyMember"
      id="xdx2ixbrl1104"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:LoansPayable
      contextRef="AsOf2024-12-31_custom_OtherConvertiblesMember"
      id="xdx2ixbrl1112"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:InterestPaid
      contextRef="From2024-01-012024-12-31_custom_OtherConvertiblesMember"
      id="xdx2ixbrl1116"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:LoansPayable
      contextRef="AsOf2024-12-31"
      id="xdx2ixbrl1118"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:InterestPaid
      contextRef="From2024-01-01to2024-12-31"
      id="xdx2ixbrl1122"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:LoansPayable
      contextRef="AsOf2023-12-31_custom_ShareHolderOneMember47707859"
      id="xdx2ixbrl1128"
      unitRef="USD"
      xsi:nil="true"/>
    <NRXS:InterestAndServiceFeeAccrued
      contextRef="AsOf2023-12-31_custom_ShareHolderOneMember47707859"
      id="xdx2ixbrl1130"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:LoansPayable
      contextRef="AsOf2023-12-31_custom_ShareHolderTwoMember47707859"
      id="xdx2ixbrl1138"
      unitRef="USD"
      xsi:nil="true"/>
    <NRXS:InterestAndServiceFeeAccrued
      contextRef="AsOf2023-12-31_custom_ShareHolderTwoMember47707859"
      id="xdx2ixbrl1140"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:LoansPayable
      contextRef="AsOf2023-12-31_custom_OtherConvertiblesMember"
      id="xdx2ixbrl1148"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:InterestPaid
      contextRef="From2023-01-012023-12-31_custom_OtherConvertiblesMember"
      id="xdx2ixbrl1152"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:LoansPayable
      contextRef="AsOf2023-12-31"
      id="xdx2ixbrl1154"
      unitRef="USD"
      xsi:nil="true"/>
    <NRXS:AdvisoryFees
      contextRef="AsOf2023-12-31"
      id="xdx2ixbrl1268"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="AsOf2023-12-31_custom_TwoThousandTwentyTwoConvertibleNotesMember"
      id="xdx2ixbrl1548">P5Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="AsOf2023-12-31_custom_AdvisoryAgreementMember"
      id="xdx2ixbrl1553">P5Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="AsOf2023-12-31_custom_UnderwritingAgreementMember"
      id="xdx2ixbrl1558">P5Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="AsOf2024-12-31_custom_TwoThousandTwentyFourConvertiblePromissoryNotesMember47712359"
      id="xdx2ixbrl1565">P5Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="AsOf2024-12-31_custom_AdvisoryAgreementsMember"
      id="xdx2ixbrl1570">P5Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl1607"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted
      contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember"
      id="xdx2ixbrl1645"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember"
      id="xdx2ixbrl1647"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations
      contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember"
      id="xdx2ixbrl1649"
      unitRef="Shares"
      xsi:nil="true"/>
    <NRXS:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsWeightedAverageExercisePriceCancelledExpiredNumber
      contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember"
      id="xdx2ixbrl1651"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="AsOf2023-12-31_us-gaap_PreferredStockMember"
      id="xdx2ixbrl1657"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2023-12-31_us-gaap_PreferredStockMember"
      id="xdx2ixbrl1659"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="AsOf2023-12-31"
      id="xdx2ixbrl1788"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="AsOf2024-12-31"
      id="xdx2ixbrl1796"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
      contextRef="AsOf2024-12-31"
      id="xdx2ixbrl1804"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensation
      contextRef="From2023-01-012023-12-31"
      id="xdx2ixbrl1808"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:WarrantsAndRightsOutstanding
      contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel1Member"
      id="xdx2ixbrl1830"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:WarrantsAndRightsOutstanding
      contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel2Member"
      id="xdx2ixbrl1832"
      unitRef="USD"
      xsi:nil="true"/>
    <NRXS:AdditionToWarrantLiabilities
      contextRef="From2023-01-012023-12-31_us-gaap_FairValueInputsLevel1Member"
      id="xdx2ixbrl1836"
      unitRef="USD"
      xsi:nil="true"/>
    <NRXS:AdditionToWarrantLiabilities
      contextRef="From2023-01-012023-12-31_us-gaap_FairValueInputsLevel2Member"
      id="xdx2ixbrl1838"
      unitRef="USD"
      xsi:nil="true"/>
    <NRXS:ReclassifiedToEquity
      contextRef="From2023-01-012023-12-31_us-gaap_FairValueInputsLevel1Member"
      id="xdx2ixbrl1842"
      unitRef="USD"
      xsi:nil="true"/>
    <NRXS:ReclassifiedToEquity
      contextRef="From2023-01-012023-12-31_us-gaap_FairValueInputsLevel2Member"
      id="xdx2ixbrl1844"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="From2023-01-012023-12-31_us-gaap_FairValueInputsLevel1Member"
      id="xdx2ixbrl1848"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="From2023-01-012023-12-31_us-gaap_FairValueInputsLevel2Member"
      id="xdx2ixbrl1850"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:WarrantsAndRightsOutstanding
      contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel1Member"
      id="xdx2ixbrl1854"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:WarrantsAndRightsOutstanding
      contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel2Member"
      id="xdx2ixbrl1856"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="From2024-01-012024-12-31_us-gaap_FairValueInputsLevel1Member"
      id="xdx2ixbrl1860"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="From2024-01-012024-12-31_us-gaap_FairValueInputsLevel2Member"
      id="xdx2ixbrl1862"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:WarrantsAndRightsOutstanding
      contextRef="AsOf2024-12-31_us-gaap_FairValueInputsLevel1Member"
      id="xdx2ixbrl1866"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:WarrantsAndRightsOutstanding
      contextRef="AsOf2024-12-31_us-gaap_FairValueInputsLevel2Member"
      id="xdx2ixbrl1868"
      unitRef="USD"
      xsi:nil="true"/>
    <NRXS:ChangesInDerivativeLiabilities
      contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel1Member"
      id="xdx2ixbrl1886"
      unitRef="USD"
      xsi:nil="true"/>
    <NRXS:ChangesInDerivativeLiabilities
      contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel2Member"
      id="xdx2ixbrl1888"
      unitRef="USD"
      xsi:nil="true"/>
    <NRXS:AdditionToDerivativeLiabilities
      contextRef="From2023-01-012023-12-31_us-gaap_FairValueInputsLevel1Member"
      id="xdx2ixbrl1892"
      unitRef="USD"
      xsi:nil="true"/>
    <NRXS:AdditionToDerivativeLiabilities
      contextRef="From2023-01-012023-12-31_us-gaap_FairValueInputsLevel2Member"
      id="xdx2ixbrl1894"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncreaseDecreaseInDerivativeLiabilities
      contextRef="From2023-01-012023-12-31_us-gaap_FairValueInputsLevel1Member"
      id="xdx2ixbrl1898"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncreaseDecreaseInDerivativeLiabilities
      contextRef="From2023-01-012023-12-31_us-gaap_FairValueInputsLevel2Member"
      id="xdx2ixbrl1900"
      unitRef="USD"
      xsi:nil="true"/>
    <NRXS:ExtinguishmentOfDerivativeLiabilities
      contextRef="From2023-01-012023-12-31_us-gaap_FairValueInputsLevel1Member"
      id="xdx2ixbrl1904"
      unitRef="USD"
      xsi:nil="true"/>
    <NRXS:ExtinguishmentOfDerivativeLiabilities
      contextRef="From2023-01-012023-12-31_us-gaap_FairValueInputsLevel2Member"
      id="xdx2ixbrl1906"
      unitRef="USD"
      xsi:nil="true"/>
    <NRXS:ChangesInDerivativeLiabilities
      contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel1Member"
      id="xdx2ixbrl1910"
      unitRef="USD"
      xsi:nil="true"/>
    <NRXS:ChangesInDerivativeLiabilities
      contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel2Member"
      id="xdx2ixbrl1912"
      unitRef="USD"
      xsi:nil="true"/>
    <NRXS:ChangesInDerivativeLiabilities
      contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel3Member"
      id="xdx2ixbrl1914"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="From2024-01-012024-12-31_us-gaap_OperatingSegmentsMember"
      id="xdx2ixbrl1967"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="From2024-01-012024-12-31_us-gaap_OperatingSegmentsMember"
      id="xdx2ixbrl1973"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensation
      contextRef="From2023-01-012023-12-31"
      id="xdx2ixbrl2008"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="From2024-01-01to2024-12-31"
      id="xdx2ixbrl2080"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="From2023-01-012023-12-31"
      id="xdx2ixbrl2081"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2024-01-01to2024-12-31"
      id="xdx2ixbrl2095"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2023-01-012023-12-31"
      id="xdx2ixbrl2096"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="From2024-01-01to2024-12-31"
      id="xdx2ixbrl2109"
      unitRef="Pure"
      xsi:nil="true"/>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="From2023-01-012023-12-31"
      id="xdx2ixbrl2110"
      unitRef="Pure"
      xsi:nil="true"/>
    <us-gaap:DeferredTaxLiabilities
      contextRef="AsOf2024-12-31"
      id="xdx2ixbrl2159"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DeferredTaxLiabilities
      contextRef="AsOf2023-12-31"
      id="xdx2ixbrl2160"
      unitRef="USD"
      xsi:nil="true"/>
    <dei:DocumentType contextRef="From2024-01-01to2024-12-31" id="Fact000011">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport contextRef="From2024-01-01to2024-12-31" id="Fact000012">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate contextRef="From2024-01-01to2024-12-31" id="Fact000013">2024-12-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate contextRef="From2024-01-01to2024-12-31" id="Fact000014">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus contextRef="From2024-01-01to2024-12-31" id="Fact000015">2024</dei:DocumentFiscalYearFocus>
    <dei:DocumentTransitionReport contextRef="From2024-01-01to2024-12-31" id="Fact000016">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="From2024-01-01to2024-12-31" id="Fact000017">001-41775</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="From2024-01-01to2024-12-31" id="Fact000018">Neuraxis, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="From2024-01-01to2024-12-31" id="Fact000019">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="From2024-01-01to2024-12-31" id="Fact000020">45-5079684</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="From2024-01-01to2024-12-31" id="Fact000021">11611     N Meridian St,</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="From2024-01-01to2024-12-31" id="Fact000022">Suite 330</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="From2024-01-01to2024-12-31" id="Fact000023">Carmel</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="From2024-01-01to2024-12-31" id="Fact000024">IN</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="From2024-01-01to2024-12-31" id="Fact000025">46032</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="From2024-01-01to2024-12-31" id="Fact000026">(812)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="From2024-01-01to2024-12-31" id="Fact000027">689-0791</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="From2024-01-01to2024-12-31" id="Fact000028">Common     Stock</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="From2024-01-01to2024-12-31" id="Fact000029">NRXS</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="From2024-01-01to2024-12-31" id="Fact000030">NYSEAMER</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer contextRef="From2024-01-01to2024-12-31" id="Fact000031">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers contextRef="From2024-01-01to2024-12-31" id="Fact000032">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus contextRef="From2024-01-01to2024-12-31" id="Fact000033">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="From2024-01-01to2024-12-31" id="Fact000034">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="From2024-01-01to2024-12-31" id="Fact000035">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="From2024-01-01to2024-12-31" id="Fact000036">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="From2024-01-01to2024-12-31" id="Fact000037">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod contextRef="From2024-01-01to2024-12-31" id="Fact000038">true</dei:EntityExTransitionPeriod>
    <dei:IcfrAuditorAttestationFlag contextRef="From2024-01-01to2024-12-31" id="Fact000039">false</dei:IcfrAuditorAttestationFlag>
    <dei:DocumentFinStmtErrorCorrectionFlag contextRef="From2024-01-01to2024-12-31" id="Fact000040">false</dei:DocumentFinStmtErrorCorrectionFlag>
    <dei:EntityShellCompany contextRef="From2024-01-01to2024-12-31" id="Fact000041">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat
      contextRef="AsOf2024-06-30"
      decimals="-5"
      id="Fact000042"
      unitRef="USD">16400000</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="AsOf2025-03-13"
      decimals="INF"
      id="Fact000043"
      unitRef="Shares">7215864</dei:EntityCommonStockSharesOutstanding>
    <dei:EntityListingParValuePerShare
      contextRef="From2024-01-01to2024-12-31"
      decimals="INF"
      id="Fact000044"
      unitRef="USDPShares">0.001</dei:EntityListingParValuePerShare>
    <cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000048">&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;CYBERSECURITY
RISK MANAGEMENT AND STRATEGY. &lt;/b&gt;NeurAxis has developed and implemented a cybersecurity framework intended to assess, identify and manage
risks from threats to the security of our information, systems, products and network using a risk-based approach. The framework is informed
in part by the National Institute of Standards and Technology (NIST) Cybersecurity Framework and International Organization for Standardization
27001 (ISO 27001) Framework, although this does not imply that we meet all technical standards, specifications, or requirements under
the NIST or ISO 27001.&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span&gt;Our
key cybersecurity processes include the following:&lt;/span&gt;&lt;/span&gt;&lt;div&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Risk-based
    controls for information systems and information on NeurAxis&#x2019; networks:&lt;/b&gt; We seek to maintain an information technology infrastructure
    that implements physical, administrative and technical controls that are calibrated based on risk and designed to protect &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_90E_ecyd--CybersecurityRiskManagementProcessesIntegratedFlag_dbT_c20240101__20241231_z5YO9ZFsajK9"&gt;the confidentiality,
    integrity and availability of our information systems&lt;/span&gt; and information stored on NeurAxis&#x2019; networks, including customer information,
    personal information, PHI/PII, intellectual property and proprietary information. NeurAxis added physical safeguards in the form
    of biometric entry systems to access server rooms and 24/7 surveillance at both NeurAxis locations.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Cybersecurity
    incident policies: &lt;/b&gt;We have cybersecurity incident policies, an incident response plan and a dedicated team to respond to cybersecurity
    incidents, including experienced counsel. When a cybersecurity incident occurs or we identify a vulnerability, the dedicated team
    is responsible for leading the initial assessment of priority and severity, including external experts that may also be engaged as
    appropriate. NeurAxis&#x2019; response to incidents depends on the severity level and seeks to improve its cybersecurity incident
    response plan. NeurAxis, through experienced cybersecurity and HIPAA/HITECH counsel, has developed a security manual and a privacy
    policy.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;



    &lt;div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"&gt;&lt;tr style="vertical-align: top; text-align: left"&gt;&lt;td style="text-align: center; width: 100%"&gt;61&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
    &lt;div style="break-before: page; margin-top: 6pt"&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"&gt;&lt;tr style="vertical-align: top; text-align: left"&gt;&lt;td style="width: 100%"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Training:
    &lt;/b&gt;We provide security awareness training to help our employees understand their information protection and cybersecurity responsibilities
    at NeurAxis. We also provide additional role-based training to some employees based on customer requirements, regulatory obligations,
    and industry risks.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Supplier
    risk assessments: &lt;/b&gt;We have participated in &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_90E_ecyd--CybersecurityRiskManagementThirdPartyEngagedFlag_dbT_c20240101__20241231_zAIa48IUx2j"&gt;several third-party risk assessment processes&lt;/span&gt; that include expectations regarding information
    and cybersecurity. NeurAxis also seeks contractual commitments from key suppliers to appropriately secure and maintain their information
    technology systems and protect NeurAxis information that is processed or stored on their systems. This may or may not include business
    associate agreements, downstream vendor agreements and vendor auditing in some cases.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Third-party
    assessments of NeurAxis: &lt;/b&gt;We have third-party cybersecurity companies engaged to assess NeurAxis&#x2019; cybersecurity readiness
    and to assist in identifying and remediating risks from cybersecurity threats. NeurAxis has a &#x201c;real time&#x201d; cybersecurity
    partner that monitors our servers 24/7/365 for any attempted intrusions.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;/div&gt;NeurAxis
routinely reviews the Office of Civil Right (OCR) audit requirements to assess any gaps within our cybersecurity, privacy and security
programs. We have not identified risks from known cybersecurity threats, that have materially affected us, including our operations,
business strategy, results of operations, cash flows or financial condition. We face certain ongoing risks from cybersecurity threats,
including active interactions with children&#x2019;s hospitals while assisting with insurance prior approvals, that, if realized, are
reasonably likely to materially affect us, including our operations, business strategy, results
of operations, cash flows or financial condition.</cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock>
    <cyd:CybersecurityRiskManagementProcessesIntegratedFlag contextRef="From2024-01-01to2024-12-31" id="Fact000049">true</cyd:CybersecurityRiskManagementProcessesIntegratedFlag>
    <cyd:CybersecurityRiskManagementThirdPartyEngagedFlag contextRef="From2024-01-01to2024-12-31" id="Fact000050">true</cyd:CybersecurityRiskManagementThirdPartyEngagedFlag>
    <cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000051">As of the fiscal year ended December 31, 2024, the
Company had &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_900_ecyd--CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag_dbF_c20240101__20241231_zgnGEIsUM3yj"&gt;not&lt;/span&gt; experienced any material cybersecurity incidents that have had a significant impact on our operations, data integrity,
results of operations, or financial performance.</cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock>
    <cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag contextRef="From2024-01-01to2024-12-31" id="Fact000052">false</cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag>
    <cyd:CybersecurityRiskBoardOfDirectorsOversightTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000054">&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;CYBERSECURITY
GOVERNANCE. &lt;/b&gt;NeurAxis&#x2019; Board of Directors is responsible for oversight of cybersecurity risk. The Board receives reporting about
NeurAxis&#x2019; practices, programs, notable threats or incidents and other developments related to cybersecurity throughout the year,
including through periodic updates from NeurAxis&#x2019; Chief Regulatory Officer/Privacy Officer and VP of IT/Security Officer.&lt;/span&gt;NeurAxis&#x2019;
Security Officer reports to NeurAxis&#x2019; &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_90B_ecyd--CybersecurityRiskRoleOfManagementTextBlock_c20240101__20241231_zVH6Wqj9tsI7"&gt;Chief Regulatory Officer and together, they lead the Company&#x2019;s overall cybersecurity
function&lt;/span&gt;. The Security Officer has over 13 years of experience in managing and leading IT or cybersecurity teams and participates in
various cyber security trainings frequently. The Security Officer collaborates with NeurAxis personnel and our outside IT vendors to
identify and analyze cybersecurity risks to NeurAxis, considers industry trends, implement controls, as appropriate and feasible, to
mitigate these risks and enables business leaders to make risk-based business decisions that impact cybersecurity considerations. The
Security Officer meets with senior leadership to review and discuss NeurAxis&#x2019; cybersecurity program, including emerging cyber risks,
threats, and industry trends. The Security Officer also supervises efforts to prevent, detect, mitigate, and remediate cybersecurity
risks and incidents through various means, including by collaborating with external security personnel and business stakeholders, and
incorporating threat intelligence and other information obtained from governmental, public, or private sources to strengthen our cybersecurity
technologies and processes.</cyd:CybersecurityRiskBoardOfDirectorsOversightTextBlock>
    <cyd:CybersecurityRiskRoleOfManagementTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000055">Chief Regulatory Officer and together, they lead the Company&#x2019;s overall cybersecurity
function</cyd:CybersecurityRiskRoleOfManagementTextBlock>
    <NRXS:NoInsiderTradingFlag contextRef="From2024-01-01to2024-12-31" id="Fact000057">true</NRXS:NoInsiderTradingFlag>
    <dei:AuditorOpinionTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000059">&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;We
have audited the accompanying balance sheets of Neuraxis, Inc. (the Company) as of December 31, 2024 and 2023, and the related
statements of operations, stockholders&#x2019; equity (deficit), and cash flows for each of the years in the two-year period ended
December 31, 2024, and the related notes (collectively referred to as the financial statements). In our opinion, the financial
statements present fairly, in all material respects, the financial position of the Company as of December 31, 2024 and 2023, and the
results of its operations and its cash flows for each of the years in the two-year period ended December 31, 2024, in conformity with
accounting principles generally accepted in the United States of America.&lt;/span&gt;</dei:AuditorOpinionTextBlock>
    <dei:AuditorName contextRef="From2024-01-01to2024-12-31" id="Fact000060">Rosenberg Rich Baker Berman, P.A.</dei:AuditorName>
    <dei:AuditorLocation contextRef="From2024-01-01to2024-12-31" id="Fact000061">Somerset, New Jersey</dei:AuditorLocation>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000069"
      unitRef="USD">3696870</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000070"
      unitRef="USD">78560</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000075"
      unitRef="USD">5000</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000077"
      unitRef="USD">11993</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000072"
      unitRef="USD">244618</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000073"
      unitRef="USD">73167</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:InventoryRawMaterialsNetOfReserves
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000082"
      unitRef="USD">4454</us-gaap:InventoryRawMaterialsNetOfReserves>
    <us-gaap:InventoryRawMaterialsNetOfReserves
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000084"
      unitRef="USD">0</us-gaap:InventoryRawMaterialsNetOfReserves>
    <us-gaap:InventoryNet
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000079"
      unitRef="USD">44328</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000080"
      unitRef="USD">21220</us-gaap:InventoryNet>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000086"
      unitRef="USD">280367</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000087"
      unitRef="USD">69663</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000089"
      unitRef="USD">4266183</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000090"
      unitRef="USD">242610</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000092"
      unitRef="USD">464402</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000093"
      unitRef="USD">436626</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000095"
      unitRef="USD">374420</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000096"
      unitRef="USD">348074</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000098"
      unitRef="USD">89982</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000099"
      unitRef="USD">88552</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000104"
      unitRef="USD">284656</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000105"
      unitRef="USD">70263</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000107"
      unitRef="USD">96588</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000108"
      unitRef="USD">108073</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:SecurityDeposit
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000110"
      unitRef="USD">20163</us-gaap:SecurityDeposit>
    <us-gaap:Assets
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000113"
      unitRef="USD">4757572</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000114"
      unitRef="USD">509498</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000122"
      unitRef="USD">596946</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000123"
      unitRef="USD">1204219</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000125"
      unitRef="USD">1577780</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000126"
      unitRef="USD">401088</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:NotesPayableToBankCurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000128"
      unitRef="USD">154152</us-gaap:NotesPayableToBankCurrent>
    <us-gaap:NotesPayableToBankCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000129"
      unitRef="USD">148062</us-gaap:NotesPayableToBankCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000131"
      unitRef="USD">62754</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000132"
      unitRef="USD">49127</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:Deposits
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000134"
      unitRef="USD">32527</us-gaap:Deposits>
    <us-gaap:Deposits
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000135"
      unitRef="USD">74947</us-gaap:Deposits>
    <NRXS:WarrantLiabilities
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000137"
      unitRef="USD">9166</NRXS:WarrantLiabilities>
    <NRXS:WarrantLiabilities
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000138"
      unitRef="USD">8225</NRXS:WarrantLiabilities>
    <us-gaap:LiabilitiesCurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000140"
      unitRef="USD">2433325</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000141"
      unitRef="USD">1885668</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000146"
      unitRef="USD">256499</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000147"
      unitRef="USD">27071</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:LiabilitiesNoncurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000149"
      unitRef="USD">256499</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:LiabilitiesNoncurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000150"
      unitRef="USD">27071</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000152"
      unitRef="USD">2689824</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000153"
      unitRef="USD">1912739</us-gaap:Liabilities>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2024-12-31_custom_ConvertibleSeriesBPreferredStockMember"
      decimals="INF"
      id="Fact000164"
      unitRef="USDPShares">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2023-12-31_custom_ConvertibleSeriesBPreferredStockMember"
      decimals="INF"
      id="Fact000166"
      unitRef="USDPShares">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2024-12-31_custom_ConvertibleSeriesBPreferredStockMember"
      decimals="INF"
      id="Fact000168"
      unitRef="Shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2023-12-31_custom_ConvertibleSeriesBPreferredStockMember"
      decimals="INF"
      id="Fact000170"
      unitRef="Shares">0</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="AsOf2024-12-31_custom_ConvertibleSeriesBPreferredStockMember"
      decimals="INF"
      id="Fact000172"
      unitRef="Shares">4280939</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2024-12-31_custom_ConvertibleSeriesBPreferredStockMember"
      decimals="INF"
      id="Fact000174"
      unitRef="Shares">4280939</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="AsOf2023-12-31_custom_ConvertibleSeriesBPreferredStockMember"
      decimals="INF"
      id="Fact000176"
      unitRef="Shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2023-12-31_custom_ConvertibleSeriesBPreferredStockMember"
      decimals="INF"
      id="Fact000178"
      unitRef="Shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000161"
      unitRef="USD">4281</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact000183"
      unitRef="USDPShares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact000185"
      unitRef="USDPShares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact000187"
      unitRef="Shares">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact000189"
      unitRef="Shares">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact000191"
      unitRef="Shares">6990227</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact000193"
      unitRef="Shares">6990227</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact000195"
      unitRef="Shares">6508897</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact000197"
      unitRef="Shares">6508897</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000180"
      unitRef="USD">6990</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000181"
      unitRef="USD">6509</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000199"
      unitRef="USD">58856089</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000200"
      unitRef="USD">47148361</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000202"
      unitRef="USD">-56799612</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000203"
      unitRef="USD">-48558111</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000205"
      unitRef="USD">2067748</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000206"
      unitRef="USD">-1403241</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000208"
      unitRef="USD">4757572</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000209"
      unitRef="USD">509498</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000211"
      unitRef="USD">2685925</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000212"
      unitRef="USD">2460049</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000214"
      unitRef="USD">362002</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000215"
      unitRef="USD">303345</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:GrossProfit
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000217"
      unitRef="USD">2323923</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000218"
      unitRef="USD">2156704</us-gaap:GrossProfit>
    <us-gaap:SellingExpense
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000220"
      unitRef="USD">324708</us-gaap:SellingExpense>
    <us-gaap:SellingExpense
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000221"
      unitRef="USD">323569</us-gaap:SellingExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000223"
      unitRef="USD">206107</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000224"
      unitRef="USD">169315</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000226"
      unitRef="USD">8949925</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000227"
      unitRef="USD">8328315</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000229"
      unitRef="USD">-7156817</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000230"
      unitRef="USD">-6664495</us-gaap:OperatingIncomeLoss>
    <NRXS:FinancingCharges
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000235"
      unitRef="USD">230824</NRXS:FinancingCharges>
    <NRXS:FinancingCharges
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000236"
      unitRef="USD">2772</NRXS:FinancingCharges>
    <us-gaap:InterestExpense
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000238"
      unitRef="USD">174328</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000239"
      unitRef="USD">476416</us-gaap:InterestExpense>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000241"
      unitRef="USD">941</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000242"
      unitRef="USD">-844854</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000245"
      unitRef="USD">198551</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000247"
      unitRef="USD">126387</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000248"
      unitRef="USD">4881622</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000251"
      unitRef="USD">-3649561</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:OtherNonoperatingIncome
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000253"
      unitRef="USD">33620</us-gaap:OtherNonoperatingIncome>
    <us-gaap:OtherNonoperatingIncome
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000254"
      unitRef="USD">15133</us-gaap:OtherNonoperatingIncome>
    <us-gaap:OtherNonoperatingExpense
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000256"
      unitRef="USD">585824</us-gaap:OtherNonoperatingExpense>
    <us-gaap:OtherNonoperatingExpense
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000257"
      unitRef="USD">10355</us-gaap:OtherNonoperatingExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000259"
      unitRef="USD">-1084684</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000260"
      unitRef="USD">-7962188</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000262"
      unitRef="USD">-8241501</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000263"
      unitRef="USD">-14626683</us-gaap:NetIncomeLoss>
    <us-gaap:PreferredStockDividendsAndOtherAdjustments
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000265"
      unitRef="USD">211268</us-gaap:PreferredStockDividendsAndOtherAdjustments>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000268"
      unitRef="USD">-8452769</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000269"
      unitRef="USD">-14626683</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2024-01-01to2024-12-31"
      decimals="INF"
      id="Fact000274"
      unitRef="USDPShares">-1.22</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2024-01-01to2024-12-31"
      decimals="INF"
      id="Fact000276"
      unitRef="USDPShares">-1.22</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2023-01-012023-12-31"
      decimals="INF"
      id="Fact000278"
      unitRef="USDPShares">-4.50</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2023-01-012023-12-31"
      decimals="INF"
      id="Fact000280"
      unitRef="USDPShares">-4.50</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2024-01-01to2024-12-31"
      decimals="INF"
      id="Fact000285"
      unitRef="Shares">6918887</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2024-01-01to2024-12-31"
      decimals="INF"
      id="Fact000287"
      unitRef="Shares">6918887</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2023-01-012023-12-31"
      decimals="INF"
      id="Fact000289"
      unitRef="Shares">3252328</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2023-01-012023-12-31"
      decimals="INF"
      id="Fact000291"
      unitRef="Shares">3252328</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2022-12-31_us-gaap_PreferredStockMember_custom_ConvertibleSeriesAPreferredStockMember"
      decimals="INF"
      id="Fact000301"
      unitRef="Shares">506637</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_PreferredStockMember_custom_ConvertibleSeriesAPreferredStockMember"
      decimals="0"
      id="Fact000293"
      unitRef="USD">507</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2022-12-31_us-gaap_PreferredStockMember_custom_ConvertibleSeriesSeedPreferredStockMember"
      decimals="INF"
      id="Fact000303"
      unitRef="Shares">115477</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_PreferredStockMember_custom_ConvertibleSeriesSeedPreferredStockMember"
      decimals="0"
      id="Fact000294"
      unitRef="USD">115</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2022-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000307"
      unitRef="Shares">1963322</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000296"
      unitRef="USD">1963</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000297"
      unitRef="USD">28355230</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000298"
      unitRef="USD">-33931428</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact000299"
      unitRef="USD">-5573613</us-gaap:StockholdersEquity>
    <NRXS:StockIssuedDuringPeriodSharesCommonStockIssuedUponInitialPublicOffering
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000317"
      unitRef="Shares">1098667</NRXS:StockIssuedDuringPeriodSharesCommonStockIssuedUponInitialPublicOffering>
    <NRXS:StockIssuedDuringPeriodValueCommonStockIssuedUponInitialPublicOffering
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000312"
      unitRef="USD">1099</NRXS:StockIssuedDuringPeriodValueCommonStockIssuedUponInitialPublicOffering>
    <NRXS:StockIssuedDuringPeriodValueCommonStockIssuedUponInitialPublicOffering
      contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000313"
      unitRef="USD">4109578</NRXS:StockIssuedDuringPeriodValueCommonStockIssuedUponInitialPublicOffering>
    <NRXS:StockIssuedDuringPeriodValueCommonStockIssuedUponInitialPublicOffering
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000315"
      unitRef="USD">4110677</NRXS:StockIssuedDuringPeriodValueCommonStockIssuedUponInitialPublicOffering>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember_custom_ConvertibleSeriesAPreferredStockMember"
      decimals="INF"
      id="Fact000327"
      unitRef="Shares">-506637</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember_custom_ConvertibleSeriesAPreferredStockMember"
      decimals="0"
      id="Fact000319"
      unitRef="USD">-507</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember_custom_ConvertibleSeriesSeedPreferredStockMember"
      decimals="INF"
      id="Fact000329"
      unitRef="Shares">-115477</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember_custom_ConvertibleSeriesSeedPreferredStockMember"
      decimals="0"
      id="Fact000320"
      unitRef="USD">-115</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000331"
      unitRef="Shares">1244228</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000322"
      unitRef="USD">1244</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000323"
      unitRef="USD">-622</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000341"
      unitRef="Shares">1649900</us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfUnits
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000336"
      unitRef="USD">1650</us-gaap:StockIssuedDuringPeriodValueConversionOfUnits>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfUnits
      contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000337"
      unitRef="USD">9897833</us-gaap:StockIssuedDuringPeriodValueConversionOfUnits>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfUnits
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000339"
      unitRef="USD">9899483</us-gaap:StockIssuedDuringPeriodValueConversionOfUnits>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000351"
      unitRef="Shares">425000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000346"
      unitRef="USD">425</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000347"
      unitRef="USD">749575</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000349"
      unitRef="USD">750000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000357"
      unitRef="USD">3720997</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000359"
      unitRef="USD">3720997</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <NRXS:StockIssuedDuringPeriodSharesWarrantsExercised
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000369"
      unitRef="Shares">127780</NRXS:StockIssuedDuringPeriodSharesWarrantsExercised>
    <NRXS:StockIssuedDuringPeriodValueWarrantsExercised
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000364"
      unitRef="USD">128</NRXS:StockIssuedDuringPeriodValueWarrantsExercised>
    <NRXS:StockIssuedDuringPeriodValueWarrantsExercised
      contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000365"
      unitRef="USD">315770</NRXS:StockIssuedDuringPeriodValueWarrantsExercised>
    <NRXS:StockIssuedDuringPeriodValueWarrantsExercised
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000367"
      unitRef="USD">315898</NRXS:StockIssuedDuringPeriodValueWarrantsExercised>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000376"
      unitRef="USD">-14626683</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000377"
      unitRef="USD">-14626683</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2023-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000393"
      unitRef="Shares">6508897</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000382"
      unitRef="USD">6509</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000383"
      unitRef="USD">47148361</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000384"
      unitRef="USD">-48558111</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000385"
      unitRef="USD">-1403241</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2023-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000409"
      unitRef="Shares">6508897</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000398"
      unitRef="USD">6509</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000399"
      unitRef="USD">47148361</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000400"
      unitRef="USD">-48558111</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000401"
      unitRef="USD">-1403241</us-gaap:StockholdersEquity>
    <NRXS:StockIssuedDuringPeriodSharesWarrantsExercised
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000419"
      unitRef="Shares">11000</NRXS:StockIssuedDuringPeriodSharesWarrantsExercised>
    <NRXS:StockIssuedDuringPeriodValueWarrantsExercised
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000414"
      unitRef="USD">11</NRXS:StockIssuedDuringPeriodValueWarrantsExercised>
    <NRXS:StockIssuedDuringPeriodValueWarrantsExercised
      contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000415"
      unitRef="USD">26169</NRXS:StockIssuedDuringPeriodValueWarrantsExercised>
    <NRXS:StockIssuedDuringPeriodValueWarrantsExercised
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000417"
      unitRef="USD">26180</NRXS:StockIssuedDuringPeriodValueWarrantsExercised>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000425"
      unitRef="USD">157745</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000427"
      unitRef="USD">157745</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <NRXS:AdditionalPaidInCapitalFromWarrantsIssuedAsDebtDiscount
      contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000433"
      unitRef="USD">97465</NRXS:AdditionalPaidInCapitalFromWarrantsIssuedAsDebtDiscount>
    <NRXS:AdditionalPaidInCapitalFromWarrantsIssuedAsDebtDiscount
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000435"
      unitRef="USD">97465</NRXS:AdditionalPaidInCapitalFromWarrantsIssuedAsDebtDiscount>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000445"
      unitRef="Shares">470330</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000440"
      unitRef="USD">470</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000441"
      unitRef="USD">1407541</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000443"
      unitRef="USD">1408011</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature
      contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000451"
      unitRef="USD">-165577</us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000453"
      unitRef="USD">-165577</us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature>
    <us-gaap:StockIssuedDuringPeriodSharesOther
      contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember_custom_ConvertibleSeriesBPreferredStockMember"
      decimals="INF"
      id="Fact000463"
      unitRef="Shares">2073524</us-gaap:StockIssuedDuringPeriodSharesOther>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember_custom_ConvertibleSeriesBPreferredStockMember"
      decimals="0"
      id="Fact000457"
      unitRef="USD">2074</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000459"
      unitRef="USD">4932929</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000461"
      unitRef="USD">4935003</us-gaap:StockIssuedDuringPeriodValueOther>
    <NRXS:StockIssuedDuringPeriodSharesPreferredStock
      contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember_custom_ConvertibleSeriesBPreferredStockMember"
      decimals="INF"
      id="Fact000473"
      unitRef="USD">2207415</NRXS:StockIssuedDuringPeriodSharesPreferredStock>
    <NRXS:StockIssuedDuringPeriodValuePreferredStock
      contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember_custom_ConvertibleSeriesBPreferredStockMember"
      decimals="0"
      id="Fact000467"
      unitRef="USD">2207</NRXS:StockIssuedDuringPeriodValuePreferredStock>
    <NRXS:StockIssuedDuringPeriodValuePreferredStock
      contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000469"
      unitRef="USD">5251456</NRXS:StockIssuedDuringPeriodValuePreferredStock>
    <NRXS:StockIssuedDuringPeriodValuePreferredStock
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000471"
      unitRef="USD">5253663</NRXS:StockIssuedDuringPeriodValuePreferredStock>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000480"
      unitRef="USD">-8241501</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000481"
      unitRef="USD">-8241501</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2024-12-31_us-gaap_PreferredStockMember_custom_ConvertibleSeriesBPreferredStockMember"
      decimals="INF"
      id="Fact000495"
      unitRef="Shares">4280939</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31_us-gaap_PreferredStockMember_custom_ConvertibleSeriesBPreferredStockMember"
      decimals="0"
      id="Fact000485"
      unitRef="USD">4281</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2024-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000497"
      unitRef="Shares">6990227</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000486"
      unitRef="USD">6990</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000487"
      unitRef="USD">58856089</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000488"
      unitRef="USD">-56799612</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000489"
      unitRef="USD">2067748</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2024-12-31_us-gaap_PreferredStockMember_custom_ConvertibleSeriesBPreferredStockMember"
      decimals="INF"
      id="Fact000511"
      unitRef="Shares">4280939</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31_us-gaap_PreferredStockMember_custom_ConvertibleSeriesBPreferredStockMember"
      decimals="0"
      id="Fact000501"
      unitRef="USD">4281</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2024-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000513"
      unitRef="Shares">6990227</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000502"
      unitRef="USD">6990</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000503"
      unitRef="USD">58856089</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000504"
      unitRef="USD">-56799612</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000505"
      unitRef="USD">2067748</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000518"
      unitRef="USD">-8241501</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000519"
      unitRef="USD">-14626683</us-gaap:NetIncomeLoss>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000524"
      unitRef="USD">126387</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000525"
      unitRef="USD">4881622</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000527"
      unitRef="USD">37831</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000528"
      unitRef="USD">40725</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:ProvisionForDoubtfulAccounts
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000530"
      unitRef="USD">7395</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:ProvisionForDoubtfulAccounts
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000531"
      unitRef="USD">25281</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:InventoryWriteDown
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000533"
      unitRef="USD">4454</us-gaap:InventoryWriteDown>
    <NRXS:NoncashLeaseExpense
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000536"
      unitRef="USD">32075</NRXS:NoncashLeaseExpense>
    <NRXS:NoncashLeaseExpense
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000537"
      unitRef="USD">31119</NRXS:NoncashLeaseExpense>
    <us-gaap:PaidInKindInterest
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000540"
      unitRef="USD">260777</us-gaap:PaidInKindInterest>
    <us-gaap:ShareBasedCompensation
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000542"
      unitRef="USD">227000</us-gaap:ShareBasedCompensation>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000546"
      unitRef="USD">-3649561</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <NRXS:IssuanceOfCommonStockForNoncashConsideration
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000548"
      unitRef="USD">1177187</NRXS:IssuanceOfCommonStockForNoncashConsideration>
    <NRXS:IssuanceOfCommonStockForNoncashConsideration
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000549"
      unitRef="USD">750000</NRXS:IssuanceOfCommonStockForNoncashConsideration>
    <NRXS:IssuanceOfWarrantsForNoncashConsideration
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000551"
      unitRef="USD">157745</NRXS:IssuanceOfWarrantsForNoncashConsideration>
    <NRXS:FinancingCharges
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000554"
      unitRef="USD">230824</NRXS:FinancingCharges>
    <NRXS:FinancingCharges
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000555"
      unitRef="USD">2772</NRXS:FinancingCharges>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000558"
      unitRef="USD">198551</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000560"
      unitRef="USD">941</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000561"
      unitRef="USD">-844854</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000566"
      unitRef="USD">178845</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000567"
      unitRef="USD">-75951</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000569"
      unitRef="USD">32500</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000570"
      unitRef="USD">-26913</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000572"
      unitRef="USD">-56157</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000573"
      unitRef="USD">68937</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000575"
      unitRef="USD">-607273</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000576"
      unitRef="USD">-387897</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000578"
      unitRef="USD">949693</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000579"
      unitRef="USD">-294154</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <NRXS:IncreaseDecreaseInCustomerDeposit
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000581"
      unitRef="USD">-42420</NRXS:IncreaseDecreaseInCustomerDeposit>
    <NRXS:IncreaseDecreaseInCustomerDeposit
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000582"
      unitRef="USD">15773</NRXS:IncreaseDecreaseInCustomerDeposit>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000584"
      unitRef="USD">-3414</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000585"
      unitRef="USD">-33396</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000587"
      unitRef="USD">-6098264</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000588"
      unitRef="USD">-6693978</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000593"
      unitRef="USD">27776</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000594"
      unitRef="USD">30781</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000597"
      unitRef="USD">41000</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000599"
      unitRef="USD">-27776</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000600"
      unitRef="USD">-71781</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000606"
      unitRef="USD">4847457</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000608"
      unitRef="USD">5253663</us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock>
    <us-gaap:ProceedsFromIssuanceOfWarrants
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000614"
      unitRef="USD">26180</us-gaap:ProceedsFromIssuanceOfWarrants>
    <us-gaap:ProceedsFromIssuanceOfWarrants
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000615"
      unitRef="USD">209097</us-gaap:ProceedsFromIssuanceOfWarrants>
    <us-gaap:RepaymentsOfNotesPayable
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000617"
      unitRef="USD">275994</us-gaap:RepaymentsOfNotesPayable>
    <us-gaap:RepaymentsOfNotesPayable
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000618"
      unitRef="USD">3553765</us-gaap:RepaymentsOfNotesPayable>
    <us-gaap:ProceedsFromNotesPayable
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000621"
      unitRef="USD">159831</us-gaap:ProceedsFromNotesPayable>
    <us-gaap:ProceedsFromConvertibleDebt
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000623"
      unitRef="USD">4935003</us-gaap:ProceedsFromConvertibleDebt>
    <us-gaap:ProceedsFromConvertibleDebt
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000624"
      unitRef="USD">5460000</us-gaap:ProceedsFromConvertibleDebt>
    <us-gaap:PaymentsOfFinancingCosts
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000626"
      unitRef="USD">194502</us-gaap:PaymentsOfFinancingCosts>
    <us-gaap:PaymentsOfFinancingCosts
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000627"
      unitRef="USD">552000</us-gaap:PaymentsOfFinancingCosts>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000629"
      unitRef="USD">9744350</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000630"
      unitRef="USD">6590620</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000632"
      unitRef="USD">3618310</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000633"
      unitRef="USD">-175139</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000635"
      unitRef="USD">78560</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact000636"
      unitRef="USD">253699</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000638"
      unitRef="USD">3696870</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000639"
      unitRef="USD">78560</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:InterestPaidNet
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000644"
      unitRef="USD">33830</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000645"
      unitRef="USD">214562</us-gaap:InterestPaidNet>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000647"
      unitRef="USD">10164</us-gaap:IncomeTaxesPaidNet>
    <NRXS:RecognitionOfRightOfUseAsset
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000653"
      unitRef="USD">284339</NRXS:RecognitionOfRightOfUseAsset>
    <NRXS:ConversionOfConvertiblePromissoryNotesToSeriesBPreferredStock
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000656"
      unitRef="USD">4935000</NRXS:ConversionOfConvertiblePromissoryNotesToSeriesBPreferredStock>
    <NRXS:FairValueOfWarrantsFromDebtDiscountInConvertibleNotesClassifiedOfAdditionalPaidInCapital
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000659"
      unitRef="USD">97465</NRXS:FairValueOfWarrantsFromDebtDiscountInConvertibleNotesClassifiedOfAdditionalPaidInCapital>
    <NRXS:WriteoffOfDebtDiscountOnConvertibleNotesClassifiedAsAdditionalPaidInCapital
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000662"
      unitRef="USD">165577</NRXS:WriteoffOfDebtDiscountOnConvertibleNotesClassifiedAsAdditionalPaidInCapital>
    <us-gaap:NotesIssued1
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000665"
      unitRef="USD">282086</us-gaap:NotesIssued1>
    <NRXS:FairValueOfWarrantLiabilitiesOfWarrantsFromConvertibleNotes
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000669"
      unitRef="USD">2446502</NRXS:FairValueOfWarrantLiabilitiesOfWarrantsFromConvertibleNotes>
    <NRXS:FairValueOfDerivativeLiabilitiesOfConversionFeatureFromConvertibleNotes
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000672"
      unitRef="USD">2375378</NRXS:FairValueOfDerivativeLiabilitiesOfConversionFeatureFromConvertibleNotes>
    <NRXS:ReclassificationOfWarrantLiabilityToEquity
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000675"
      unitRef="USD">3720997</NRXS:ReclassificationOfWarrantLiabilityToEquity>
    <NRXS:ConversionOfPreferredStockToCommonStock
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000678"
      unitRef="USD">1244</NRXS:ConversionOfPreferredStockToCommonStock>
    <us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000680">&lt;p id="xdx_800_eus-gaap--BusinessDescriptionAndBasisOfPresentationTextBlock_zhNYctRuImhg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;1.
&lt;span id="xdx_82C_zYzIq02BSlKk"&gt;Basis of Presentation, Organization and Other Matters&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Neuraxis,
Inc. (&#x201c;we,&#x201d; &#x201c;us,&#x201d; the &#x201c;Company,&#x201d; or &#x201c;Neuraxis&#x201d;) was established in 2011 and incorporated
in the state of Indiana on April 17, 2012, under the name of Innovative Health Solutions, Inc. In 2022, the name was changed to Neuraxis,
Inc. and the Company filed a Certificate of Conversion to become a Delaware corporation that increased the number of authorized shares
and established a par value.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company is headquartered in Carmel, Indiana, and specializes in the development, production, and sale of medical neuromodulation devices.
The Company has developed four FDA cleared products: (i) the IB-STIM (DEN180057, 2019), (ii) the Rectal Expulsion Device (&#x201c;RED&#x201d;)
(K242304, 2024), (iii) NSS-2 Bridge (DEN170018, 2017) and (iv) the original 510(K) clearance (K140530, 2014).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
    IB-STIM is a percutaneous electrical nerve field stimulator (PENFS) device that is indicated in patients 8-21 years of age with functional
    abdominal pain associated with irritable bowel syndrome. The IB-STIM currently is one of two products marketed and sold by the Company.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;RED
is indicated to evaluate the neuromuscular function of a patient&#x2019;s ability to expel its contents from the rectum and as a qualitative
test for rectal hypersensitivity patients who experience desire or urge to defecate at lower volumes of distention. RED is intended to
be used in a clinical setting by trained health care providers in adult populations. &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
    NSS-2 Bridge is a percutaneous nerve field stimulator (PNFS) device indicated for use in the reduction of the symptoms of opioid
    withdrawal. The NSS-2 Bridge device was licensed to Masimo Corporation in April 2020, and the Company received a one-time licensing
    fee of $250,000 from Masimo. Masimo markets and sells this product as its Masimo Bridge, and the Company will not receive any further
    licensing payments or other revenue from this product.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
    original 510(K) device was the EAD, an electroacupuncture device, now called NeuroStim. The EAD is no longer being manufactured,
    sold or distributed but reserved only for research purposes.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
January 10, 2023, the Company&#x2019;s board of directors authorized a &lt;span id="xdx_904_eus-gaap--StockholdersEquityNoteStockSplit_c20230110__20230110_zKlBv0h1ikB4" title="Description of stock split"&gt;1-for-2 reverse stock split&lt;/span&gt;. All per share information has been
adjusted for this reverse stock split. The reverse split became effective on January 12, 2023. All share and per share amounts for the
common stock have been retroactively restated to give effect to the splits.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
part of the conversion to a Delaware corporation, the total number of shares of all classes of stock which the Corporation had authority
to issue was (1) &lt;span id="xdx_907_eus-gaap--CommonStockSharesAuthorized_iI_c20241231_zOnIA2bk1eRl" title="Common stock, shares authorized"&gt;100,000,000&lt;/span&gt; shares of Common Stock, par value $&lt;span id="xdx_901_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20241231_z0t9slsGFmFb" title="Common stock, par value"&gt;0.001&lt;/span&gt; per share (&#x201c;Common Stock&#x201d;) and (ii) &lt;span id="xdx_904_eus-gaap--PreferredStockSharesAuthorized_iI_c20241231_zwgE6tZAogch" title="Preferred stock, shares authorized"&gt;1,120,000&lt;/span&gt; shares
of Preferred Stock, par value $&lt;span id="xdx_906_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20241231_zQd6K0WB8wQg" title="Preferred stock, par value"&gt;0.001&lt;/span&gt; per share (&#x201c;Preferred Stock&#x201d;), &lt;span id="xdx_901_eus-gaap--PreferredStockSharesAuthorized_iI_c20241231__us-gaap--StatementClassOfStockAxis__custom--ConvertibleSeriesAPreferredStockMember_zr5VCINVC3E8" title="Preferred stock, shares authorized"&gt;1,000,000&lt;/span&gt; shares of which was designated as &#x201c;Series
A Preferred Stock&#x201d; and &lt;span id="xdx_905_eus-gaap--PreferredStockSharesAuthorized_iI_c20241231__us-gaap--StatementClassOfStockAxis__custom--ConvertibleSeriesSeedPreferredStockMember_zDB5mk60DHTk" title="Preferred stock, shares authorized"&gt;120,000&lt;/span&gt; shares of which were designated as &#x201c;Series Seed Preferred Stock&#x201d; with the rights, preferences,
powers, privileges and restrictions, qualifications and limitations set forth in this Article IV of the Delaware Certificate of Incorporation.
All share amounts have been retroactively restated to give effect to these changes.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
August 9, 2023, the Company consummated an initial public offering (&#x201c;IPO&#x201d;), conducted on a firm commitment basis, pursuant
to which it sold &lt;span id="xdx_901_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20230809__20230809__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--ConsolidatedEntitiesAxis__custom--AlexanderCapitalLPMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zUDH8AN8ek9h" title="Sale of stock, number of shares issued in transaction"&gt;1,098,667&lt;/span&gt; shares of its common stock at a price of $&lt;span id="xdx_906_eus-gaap--SharesIssuedPricePerShare_iI_c20230809__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--ConsolidatedEntitiesAxis__custom--AlexanderCapitalLPMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zI9u57xXBAj6" title="Shares issued, price per share"&gt;6.00&lt;/span&gt; per share, resulting in gross proceeds to the Company of $&lt;span id="xdx_905_eus-gaap--ProceedsFromIssuanceOfCommonStock_c20230809__20230809__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--ConsolidatedEntitiesAxis__custom--AlexanderCapitalLPMember_zczW038XAupi" title="Proceeds from issuance of common stock"&gt;6,592,002&lt;/span&gt;.
Net proceeds to the Company, after deducting underwriting discounts and commissions and other offering expenses paid by the Company,
were $&lt;span id="xdx_90B_eus-gaap--DeferredOfferingCosts_iI_c20230809__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember__srt--ConsolidatedEntitiesAxis__custom--AlexanderCapitalLPMember_zGLTziJMzVdl" title="Deferred offering costs"&gt;4,110,721&lt;/span&gt;. All shares sold in our IPO were registered pursuant to a registration statement on Form S-1 (File No. 333- 269179),
as amended, declared effective by the SEC on August 9, 2023. Alexander Capital L.P. (&#x201c;Alexander&#x201d;) acted as sole book-running
manager for the offering and Spartan Capital Securities, LLC acted as co-manager for the offering. The underwriters did not exercise
their option to purchase up to an additional &lt;span id="xdx_906_ecustom--PurchaseOfAdditionalStockOnNumberOfOptionsNotExercised_c20230809__20230809__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zm8mbjoUdTSh" title="Purchase of additional stockon number of options not exercised"&gt;164,801&lt;/span&gt; shares of common stock. The Company paid the underwriters an underwriting discount
of seven percent (&lt;span id="xdx_90E_ecustom--UnderwritersDiscountPercentage_iI_pid_dp_uPure_c20230809__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember__srt--ConsolidatedEntitiesAxis__custom--AlexanderCapitalLPMember_zfRQJp40dYZa" title="Underwriters discount percentage"&gt;7&lt;/span&gt;%) of the amount raised in the offering. In addition, we also paid the underwriters a non-accountable expense allowance
in the amount of &lt;span id="xdx_90F_ecustom--NonaccountableExpenseAllowancePercentage_iI_pid_dp_uPure_c20230809__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember__srt--ConsolidatedEntitiesAxis__custom--AlexanderCapitalLPMember_zPCTDqW6Qvlc" title="Nonaccountable expense allowance percentage"&gt;1&lt;/span&gt;% (such &lt;span id="xdx_909_ecustom--CashFeePercentage_iI_pid_dp_uPure_c20230809__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember__srt--ConsolidatedEntitiesAxis__custom--AlexanderCapitalLPMember_zd5TUoVVCMSf" title="Cash fee percentage"&gt;8&lt;/span&gt;% in commissions and fees amounted to a total of $&lt;span id="xdx_907_eus-gaap--ProceedsFromIssuanceInitialPublicOffering_c20230809__20230809__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember__srt--ConsolidatedEntitiesAxis__custom--AlexanderCapitalLPMember_z27GlCZDvRrj" title="Proceeds from issuance initial public offering"&gt;527,000&lt;/span&gt;) at closing, as well as $&lt;span id="xdx_90B_ecustom--ReimbursementExpenses_c20230809__20230809__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember__srt--ConsolidatedEntitiesAxis__custom--AlexanderCapitalLPMember_zFn36kMnZ0w2" title="Reimbursement expenses"&gt;175,000&lt;/span&gt; for the reimbursement
of certain of the underwriters&#x2019; expenses. Additionally, as partial consideration for services rendered in connection with the offering,
the Company issued Alexander unregistered warrants to purchase an aggregate of &lt;span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20230809__20230809__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember__srt--ConsolidatedEntitiesAxis__custom--AlexanderCapitalLPMember_zfvPq9OomCPd" title="Warrants to purchase an aggregate common stock, shares"&gt;65,921&lt;/span&gt; shares of Company common stock, representing &lt;span id="xdx_90B_eus-gaap--SaleOfStockPercentageOfOwnershipAfterTransaction_pid_dp_c20230809__20230809__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember__srt--ConsolidatedEntitiesAxis__custom--AlexanderCapitalLPMember_zp4fZvG67qzk" title="Sale of stock, percentage of ownership after transaction"&gt;6.0&lt;/span&gt;%
of the aggregate shares sold in the offering. The warrants had an initial exercise price of $&lt;span id="xdx_901_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20230809__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember__srt--ConsolidatedEntitiesAxis__custom--AlexanderCapitalLPMember_zA7rR49oMrFg" title="Exercise price of warrants"&gt;7.20&lt;/span&gt; per share (equal to &lt;span id="xdx_90A_ecustom--OfferingPricePerPercentage_iI_pid_dp_c20230809__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember__srt--ConsolidatedEntitiesAxis__custom--AlexanderCapitalLPMember_z1Pdk2I5dVwf" title="Offering price per percentage"&gt;120&lt;/span&gt;% of the offering
price per share), a term of five years from the commencement of sales in the offering, and are exercisable at any time.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
August 15, 2024, the Company&#x2019;s shareholders (i) authorized &lt;span id="xdx_906_eus-gaap--PreferredStockSharesAuthorized_iI_c20240815__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zl89IR6FHHAl" title="Preferred stock, shares authorized"&gt;5,000,000&lt;/span&gt; shares of preferred stock of which &lt;span id="xdx_905_eus-gaap--TemporaryEquitySharesAuthorized_iI_pid_c20240815__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zESFK4ND2Is7" title="Temporary equity, shares authorized"&gt;4,000,000&lt;/span&gt; were designated
at $&lt;span id="xdx_90C_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20240815__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zbN3I9AT92J5" title="Preferred stock, par value"&gt;0.001&lt;/span&gt; par value &#x201c;Series B Preferred Stock&#x201d; inclusive of cumulative dividends, due and payable quarterly at the Company&#x2019;s
discretion either in cash or common stock when declared, &lt;span id="xdx_90E_eus-gaap--PreferredStockDividendPaymentTerms_c20240815__20240815__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zzdDgSZhsJR6" title="Cumulative dividend description"&gt;at a rate of 8.5% per annum through June 30, 2025&lt;/span&gt;, (ii) retired &lt;span id="xdx_906_eus-gaap--StockRepurchasedAndRetiredDuringPeriodShares_c20240815__20240815__us-gaap--StatementClassOfStockAxis__custom--ConvertibleSeriesAPreferredStockMember_zhR3u3LaTB8i" title="Stock repurchased and retired during period shares"&gt;1,000,000&lt;/span&gt; shares
of Series A Preferred Stock and (iii) retired &lt;span id="xdx_907_eus-gaap--StockRepurchasedAndRetiredDuringPeriodShares_c20240815__20240815__us-gaap--StatementClassOfStockAxis__custom--ConvertibleSeriesSeedPreferredStockMember_zcAg2O2sFNZ4" title="Stock repurchased and retired during period shares"&gt;120,000&lt;/span&gt; shares of Series Seed Preferred Stock. On November 11, 2024, the Company&#x2019;s
shareholders authorized (i) an increase in the number of designated Series B Preferred Stock to &lt;span id="xdx_909_eus-gaap--PreferredStockSharesAuthorized_iI_c20241111__us-gaap--StatementClassOfStockAxis__custom--ConvertibleSeriesBPreferredStockMember_z2SZx3kgdrUa" title="Preferred stock, shares authorized"&gt;5,000,000&lt;/span&gt; shares and (ii) an &lt;span id="xdx_902_eus-gaap--PreferredStockDividendPaymentTerms_c20241111__20241111__us-gaap--StatementClassOfStockAxis__custom--ConvertibleSeriesBPreferredStockMember_zAxo7p68lPQf" title="Cumulative dividend description"&gt;extension
of the 8.5% cumulative dividend period to December 31, 2026&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;






&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Neuraxis,
Inc.&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Notes
to Financial Statements&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock>
    <us-gaap:StockholdersEquityNoteStockSplit contextRef="From2023-01-102023-01-10" id="Fact000682">1-for-2 reverse stock split</us-gaap:StockholdersEquityNoteStockSplit>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact000684"
      unitRef="Shares">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact000686"
      unitRef="USDPShares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact000688"
      unitRef="Shares">1120000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact000690"
      unitRef="USDPShares">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2024-12-31_custom_ConvertibleSeriesAPreferredStockMember"
      decimals="INF"
      id="Fact000692"
      unitRef="Shares">1000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2024-12-31_custom_ConvertibleSeriesSeedPreferredStockMember"
      decimals="INF"
      id="Fact000694"
      unitRef="Shares">120000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="From2023-08-092023-08-09_us-gaap_CommonStockMember_custom_AlexanderCapitalLPMember_us-gaap_IPOMember"
      decimals="INF"
      id="Fact000696"
      unitRef="Shares">1098667</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="AsOf2023-08-09_us-gaap_CommonStockMember_custom_AlexanderCapitalLPMember_us-gaap_IPOMember"
      decimals="INF"
      id="Fact000698"
      unitRef="USDPShares">6.00</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2023-08-092023-08-09_us-gaap_CommonStockMember_custom_AlexanderCapitalLPMember_us-gaap_IPOMember"
      decimals="0"
      id="Fact000700"
      unitRef="USD">6592002</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:DeferredOfferingCosts
      contextRef="AsOf2023-08-09_us-gaap_CommonStockMember_custom_AlexanderCapitalLPMember_us-gaap_IPOMember"
      decimals="0"
      id="Fact000702"
      unitRef="USD">4110721</us-gaap:DeferredOfferingCosts>
    <NRXS:PurchaseOfAdditionalStockOnNumberOfOptionsNotExercised
      contextRef="From2023-08-092023-08-09_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000704"
      unitRef="Shares">164801</NRXS:PurchaseOfAdditionalStockOnNumberOfOptionsNotExercised>
    <NRXS:UnderwritersDiscountPercentage
      contextRef="AsOf2023-08-09_us-gaap_CommonStockMember_custom_AlexanderCapitalLPMember_us-gaap_IPOMember"
      decimals="INF"
      id="Fact000706"
      unitRef="Pure">0.07</NRXS:UnderwritersDiscountPercentage>
    <NRXS:NonaccountableExpenseAllowancePercentage
      contextRef="AsOf2023-08-09_us-gaap_CommonStockMember_custom_AlexanderCapitalLPMember_us-gaap_IPOMember"
      decimals="INF"
      id="Fact000708"
      unitRef="Pure">0.01</NRXS:NonaccountableExpenseAllowancePercentage>
    <NRXS:CashFeePercentage
      contextRef="AsOf2023-08-09_us-gaap_CommonStockMember_custom_AlexanderCapitalLPMember_us-gaap_IPOMember"
      decimals="INF"
      id="Fact000710"
      unitRef="Pure">0.08</NRXS:CashFeePercentage>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="From2023-08-092023-08-09_us-gaap_CommonStockMember_custom_AlexanderCapitalLPMember_us-gaap_IPOMember"
      decimals="0"
      id="Fact000712"
      unitRef="USD">527000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <NRXS:ReimbursementExpenses
      contextRef="From2023-08-092023-08-09_us-gaap_CommonStockMember_custom_AlexanderCapitalLPMember_us-gaap_IPOMember"
      decimals="0"
      id="Fact000714"
      unitRef="USD">175000</NRXS:ReimbursementExpenses>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted
      contextRef="From2023-08-092023-08-09_us-gaap_CommonStockMember_custom_AlexanderCapitalLPMember_us-gaap_IPOMember"
      decimals="INF"
      id="Fact000716"
      unitRef="Shares">65921</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted>
    <us-gaap:SaleOfStockPercentageOfOwnershipAfterTransaction
      contextRef="From2023-08-092023-08-09_us-gaap_CommonStockMember_custom_AlexanderCapitalLPMember_us-gaap_IPOMember"
      decimals="INF"
      id="Fact000718"
      unitRef="Pure">0.060</us-gaap:SaleOfStockPercentageOfOwnershipAfterTransaction>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2023-08-09_us-gaap_CommonStockMember_custom_AlexanderCapitalLPMember_us-gaap_IPOMember"
      decimals="INF"
      id="Fact000720"
      unitRef="USDPShares">7.20</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <NRXS:OfferingPricePerPercentage
      contextRef="AsOf2023-08-09_us-gaap_CommonStockMember_custom_AlexanderCapitalLPMember_us-gaap_IPOMember"
      decimals="INF"
      id="Fact000722"
      unitRef="Pure">1.20</NRXS:OfferingPricePerPercentage>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2024-08-15_us-gaap_SeriesBPreferredStockMember"
      decimals="INF"
      id="Fact000724"
      unitRef="Shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="AsOf2024-08-15_us-gaap_SeriesBPreferredStockMember"
      decimals="INF"
      id="Fact000726"
      unitRef="Shares">4000000</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2024-08-15_us-gaap_SeriesBPreferredStockMember"
      decimals="INF"
      id="Fact000728"
      unitRef="USDPShares">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockDividendPaymentTerms
      contextRef="From2024-08-152024-08-15_us-gaap_SeriesBPreferredStockMember"
      id="Fact000730">at a rate of 8.5% per annum through June 30, 2025</us-gaap:PreferredStockDividendPaymentTerms>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodShares
      contextRef="From2024-08-152024-08-15_custom_ConvertibleSeriesAPreferredStockMember"
      decimals="INF"
      id="Fact000732"
      unitRef="Shares">1000000</us-gaap:StockRepurchasedAndRetiredDuringPeriodShares>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodShares
      contextRef="From2024-08-152024-08-15_custom_ConvertibleSeriesSeedPreferredStockMember"
      decimals="INF"
      id="Fact000734"
      unitRef="Shares">120000</us-gaap:StockRepurchasedAndRetiredDuringPeriodShares>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2024-11-11_custom_ConvertibleSeriesBPreferredStockMember"
      decimals="INF"
      id="Fact000736"
      unitRef="Shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockDividendPaymentTerms
      contextRef="From2024-11-112024-11-11_custom_ConvertibleSeriesBPreferredStockMember"
      id="Fact000738">extension
of the 8.5% cumulative dividend period to December 31, 2026</us-gaap:PreferredStockDividendPaymentTerms>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000740">&lt;p id="xdx_80F_eus-gaap--SignificantAccountingPoliciesTextBlock_zlJdJYr3Cvnj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;2.
&lt;span id="xdx_828_zEQNQ1WBaVd4"&gt;Summary of Significant Accounting Policies&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
summary of significant accounting policies of Neuraxis, Inc. is presented to assist in understanding the Company&#x2019;s financial statements.
The financial statements and notes are representations of the Company&#x2019;s management, who are responsible for their integrity and
objectivity. These accounting policies conform to U.S. generally accepted accounting principles and have been consistently applied in
the preparation of the financial statements.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Preparing
the Company&#x2019;s financial statements in conformity with accounting principles generally accepted in the United States of America
(&#x201c;GAAP&#x201d;) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities
and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and
expenses during the reporting period.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_843_eus-gaap--UseOfEstimates_zCNBGrFAkxnd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_862_zCQCbX5hehLh"&gt;Use
of Estimates and Critical Accounting Estimates and Assumptions&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the
reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the dates of the financial statements
and the reported amounts of revenues and expenses during the reporting periods.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;These
significant accounting estimates or assumptions bear the risk of change due to the fact that there are uncertainties attached to these
estimates or assumptions, and certain estimates or assumptions are difficult to measure or value.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Management
bases its estimates on historical experience and on various assumptions that are believed to be reasonable in relation to the financial
statements taken as a whole under the circumstances, the results of which form the basis for making judgments about the carrying values
of assets and liabilities that are not readily apparent from other sources.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Management
regularly evaluates the key factors and assumptions used to develop the estimates utilizing currently available information, changes
in facts and circumstances, historical experience, and reasonable assumptions. After such evaluations, if deemed appropriate, those estimates
are adjusted accordingly. The Company uses estimates in accounting for, among other items, revenue recognition, allowance for credit
losses, stock-based compensation, income tax provisions, excess and obsolete inventory reserve, and impairment of property and equipment,
and intellectual property. Actual results could differ from those estimates.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84E_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_ztvqhicgjizf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_86B_zlm33AKL50gf"&gt;Cash
and Cash Equivalents&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company considers all highly liquid debt instruments purchased with a maturity of three months or less to be cash equivalents. The Company
did not hold any cash equivalents as of December 31, 2024 and 2023.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_846_eus-gaap--TradeAndOtherAccountsReceivablePolicy_zfROzNl3ffE" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_866_z8W5SJsnYNZ3"&gt;Trade
Accounts Receivable and Allowance for Credit Losses&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Trade
accounts receivable are stated at the amount management expects to collect from outstanding balances, net of an allowance for credit
losses. Management evaluates many factors when determining the collectability of specific customer accounts, including, but not
limited to, creditworthiness, past transaction and payment history, current economic industry trends and changes in payment terms.
Management used assumptions and judgment based on the best available facts and circumstances to estimate and record an allowance.
The allowance for credit losses was $&lt;span id="xdx_90F_eus-gaap--AllowanceForDoubtfulAccountsReceivable_iI_c20241231_zP8VFScW5y0c" title="Allowance for doubtful accounts"&gt;5,000&lt;/span&gt;
and $&lt;span id="xdx_903_eus-gaap--AllowanceForDoubtfulAccountsReceivable_iI_c20231231_ztE0yvQuOmXa" title="Allowance for doubtful accounts"&gt;11,993&lt;/span&gt;
as of December 31, 2024 and 2023, respectively. The Company recorded credit losses for the years ended December 31, 2024 and 2023 of
$&lt;span id="xdx_90D_eus-gaap--ProvisionForOtherCreditLosses_c20240101__20241231_z7Ql8mCSpFj8" title="Credit losses"&gt;7,395&lt;/span&gt; and $&lt;span id="xdx_904_eus-gaap--ProvisionForOtherCreditLosses_c20230101__20231231_zJyECgcqyDrd" title="Credit losses"&gt;25,281&lt;/span&gt;,
respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Neuraxis,
Inc.&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Notes
to Financial Statements&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_845_eus-gaap--DepositContractsPolicy_z0S65AE6qnwc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_86B_zs9KrkyOFyU1"&gt;Customer
Deposits&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Customer
deposits consists of  payments and returned devices from clients in advance of revenue recognition. The Company will recognize
the customer deposits over the next year. As of December 31, 2024, and 2023, the Company had customer deposits of $&lt;span id="xdx_904_eus-gaap--Deposits_iI_c20241231_zSmRjs0DXNzj" title="Customer deposits"&gt;32,527&lt;/span&gt; and $&lt;span id="xdx_902_eus-gaap--Deposits_iI_c20231231_zueWOiNKKjkg" title="Customer deposits"&gt;74,947&lt;/span&gt;,
respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_846_eus-gaap--InventoryPolicyTextBlock_zxmZEstGpDWd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_866_zKh9Gova5AU2"&gt;Inventories&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Inventories
are valued at the lower of cost or net realizable value. Cost is determined using the weighted average method. The inventory is comprised
of finished medical devices on hand. Certain components within the devices have an expiration date that are removed from current inventory
and expensed at the date of expiration. For the years ended December 31, 2024 and 2023, $&lt;span id="xdx_901_ecustom--InventoryExpenses_iI_c20241231_zZoDkfglZ1Ia" title="Inventory expenses"&gt;0&lt;/span&gt; and $&lt;span id="xdx_900_ecustom--InventoryExpenses_iI_c20231231_zEQ7Zl1KsBUg" title="Inventory expenses"&gt;25,008&lt;/span&gt; were expensed as expired inventory,
respectively. Inventory reserves totaled $&lt;span id="xdx_906_eus-gaap--InventoryRawMaterialsNetOfReserves_iI_c20241231_zgVGVW7KmyZ2" title="Inventory reserves"&gt;4,454&lt;/span&gt; and $&lt;span id="xdx_90C_eus-gaap--InventoryRawMaterialsNetOfReserves_iI_c20231231_zZjhKB4ngEMj" title="Inventory reserves"&gt;0&lt;/span&gt; as of December 31, 2024 and 2023, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_846_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zWScFqAl6Wg6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_860_zuZEawh0Gg39"&gt;Property
and Equipment&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Property
and equipment are recorded at cost less accumulated depreciation. Depreciation is computed using the straight-line method over the estimated
useful lives of the assets.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89D_ecustom--ScheduleOfPropertyPlantAndEquipmentUsefulLivesTableTextBlock_zA63jvQhipj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Depreciation
is calculated using the following estimated useful lives:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B1_zS3Vx59ipME8" style="display: none"&gt;Schedule of Estimated Useful Lives&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; width: 60%; border-collapse: collapse; margin-right: auto"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; width: 79%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Classification&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; width: 19%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Years&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Machinery
    and Equipment &lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_908_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--MachineryAndEquipmentMember__srt--RangeAxis__srt--MinimumMember_zBoCKBqUpo16" title="Property and equipment, estimated useful lives"&gt;7&lt;/span&gt;-&lt;span id="xdx_90B_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--MachineryAndEquipmentMember__srt--RangeAxis__srt--MaximumMember_zs1iIMSzTnZ" title="Property and equipment, estimated useful lives"&gt;10&lt;/span&gt;
    &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Furniture
    and Fixtures&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_906_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember__srt--RangeAxis__srt--MinimumMember_zmPdomKTkuj5" title="Property and equipment, estimated useful lives"&gt;3&lt;/span&gt;-&lt;span id="xdx_90D_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember__srt--RangeAxis__srt--MaximumMember_zMDjRUq42GH8" title="Property and equipment, estimated useful lives"&gt;10&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Computer
    Hardware&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_903_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_zay71H131WJ9" title="Property and equipment, estimated useful lives"&gt;5&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Leasehold
    Improvements&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90F_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember__srt--RangeAxis__srt--MinimumMember_zttmRcV3egyh" title="Property and equipment, estimated useful lives"&gt;10&lt;/span&gt;-&lt;span id="xdx_903_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember__srt--RangeAxis__srt--MaximumMember_zDksIX8dOpz9" title="Property and equipment, estimated useful lives"&gt;20&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p id="xdx_8A9_zz9GmOk7OY67" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Depreciation
expense was $&lt;span id="xdx_908_eus-gaap--Depreciation_c20240101__20241231_zCE9MU3CfcB" title="Depreciation expense"&gt;26,346&lt;/span&gt; and $&lt;span id="xdx_907_eus-gaap--Depreciation_c20230101__20231231_zg5lb62IyG23" title="Depreciation expense"&gt;30,240&lt;/span&gt; during the years ended December 31, 2024 and 2023, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_847_eus-gaap--ResearchAndDevelopmentExpensePolicy_zaqJbGezMLz8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_861_z6QRpnJ2AG38"&gt;Research
and Development&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Costs
for research and development are expensed as incurred. Research and development expenses consist primarily of clinical research studies
and new product development.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_843_eus-gaap--IntangibleAssetsFiniteLivedPolicy_zGVWfgMVm0Lf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_862_zLVPmPO16MM7"&gt;Intangible
Assets&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Intangible
assets consist of software, patents, a trademark and a license. Intangible assets are stated at their historical cost and amortized on
a straight-line basis over their expected useful lives. Capitalized patent costs, net of accumulated amortization, includes legal costs
incurred for patent applications. In accordance with ASC 350, once a patent is granted, we amortize the capitalized patent costs over
the remaining life of the patent using the straight-line method. If the patent is not granted, we write off any capitalized patent costs
at that time.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company purchased a trademark related to the Company&#x2019;s name for $&lt;span id="xdx_908_eus-gaap--PaymentsToAcquireIntangibleAssets_c20240101__20241231__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_zPy2rZ9bDnpa" title="Payment to acquire intangible assets"&gt;50,000&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;.
The trademark does not have a determinate life and therefore the cost is not being amortized.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company entered into an option agreement on April 12, 2023 to bring an optionor&#x2019;s invention to commercialization via a royalty-bearing
licensing agreement. The agreement required an initial payment of $&lt;span id="xdx_90D_eus-gaap--PaymentsToAcquireIntangibleAssets_c20240101__20241231__us-gaap--TypeOfArrangementAxis__custom--LicensingAgreementMember_zbq2IOfPbfml" title="Payment upon execution"&gt;1,000&lt;/span&gt; and was fully amortized in the year ended December 31, 2024.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Neuraxis,
Inc.&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Notes
to Financial Statements&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;We
review intangible assets for impairment annually or when events or circumstances indicate that their carrying amount may not be recoverable.
During the years ended December 31, 2024, and 2023, the Company recorded no impairment charges for intangible assets.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Amortization
expense was $&lt;span id="xdx_902_eus-gaap--AmortizationOfIntangibleAssets_c20240101__20241231_zHntBXDIkQQh" title="Amortization expense"&gt;11,485&lt;/span&gt; and $&lt;span id="xdx_909_eus-gaap--AmortizationOfIntangibleAssets_c20230101__20231231_z6VW5MqTev6c" title="Amortization expense"&gt;10,485&lt;/span&gt; during the years ended December 31, 2024 and 2023, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_844_eus-gaap--IncomeTaxPolicyTextBlock_zkgEMdBxd1ml" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_864_zSM75xOhiFEk"&gt;Income
Taxes&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company recognizes deferred tax assets and liabilities for the expected future tax consequences of events that have been included in
the Company&#x2019;s financial statements and tax returns. Deferred tax assets and liabilities are determined based upon the differences
between the financial statement carrying amounts, and the tax bases of existing assets and liabilities for the loss and credit carryforwards
using enacted tax rates expected to be in effect in the year in which the differences are expected to reverse. Deferred tax assets are
reduced by a valuation allowance if it is more likely than not that these assets may not be realized. The Company determines whether
a tax position will be sustained upon examination. If it is more likely than not that a position will be sustained, none of the benefit
attributable to the position is recognized. The tax benefit to be recognized for any tax position that meets the more likely than not
recognition threshold is calculated as &lt;span id="xdx_900_eus-gaap--IncomeTaxExaminationLikelihoodOfUnfavorableSettlement_c20240101__20241231_zhScl8zCptK8" title="Income tax examination, likelihood of unfavorable settlement"&gt;the largest amount that is more than 50% likely of being realized upon resolution of the contingency&lt;/span&gt;.
The Company accounts for interest and penalties related to uncertain tax positions as part of its provision for income taxes.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Management&#x2019;s
evaluation of the Company&#x2019;s deferred tax assets and liabilities did not have a material effect on the Company&#x2019;s financial
statements. Furthermore, &lt;span id="xdx_907_eus-gaap--IncomeTaxExaminationPenaltiesAndInterestAccrued_iI_do_c20241231_ztC0RV1l8oLb" title="Income tax interest or penalties accrued"&gt;&lt;span id="xdx_908_eus-gaap--IncomeTaxExaminationPenaltiesAndInterestAccrued_iI_do_c20231231_zhqBNkKSJdb6" title="Income tax interest or penalties accrued"&gt;no&lt;/span&gt;&lt;/span&gt; interest or penalties have been accrued or charged to expense as of December 31, 2024 and 2023 and for the
years then ended.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_847_eus-gaap--AdvertisingCostsPolicyTextBlock_zo5yvzL87Rx8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_867_zWUOXu7pc5n5"&gt;Advertising
Cost&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Advertising
costs are expensed as incurred and amounted to $&lt;span id="xdx_90F_eus-gaap--AdvertisingExpense_c20240101__20241231__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zHFN1G5pWFd9" title="Advertising cost"&gt;232,125&lt;/span&gt;
and $&lt;span id="xdx_900_eus-gaap--AdvertisingExpense_c20230101__20231231__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zIlntYARjZTf" title="Advertising cost"&gt;192,400&lt;/span&gt; for
the years ended December 31, 2024 and 2023, respectively, and are classified as general and administrative expenses in the
statements of operations.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Neuraxis,
Inc.&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Notes
to Financial Statements&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_848_ecustom--WarrantLiabilityPolicyTextBlock_zaVIsSf1c53d" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_86D_zrlgX8Mm8yia"&gt;Warrant
Liabilities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Management
evaluates all of the Company&#x2019;s financial instruments, including issued warrants to purchase its common stock, to determine if such
instruments are liabilities pursuant to ASC 480 and ASC 815-15. The classification
of derivative financial instruments, including whether such instruments should be recorded as liabilities or as equity, is reassessed
at the end of each reporting period.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company utilizes a Black-Scholes option-pricing model to compute the fair value of the derivative and to mark to market the fair value
of the derivative at each balance sheet date. The inputs utilized in the application of the Black-Scholes option-pricing model included
an exercise price, the stock price as of the valuation date, an expected remaining term of each warrant as of the valuation date, estimated
volatility, a dividend yield, and a risk-free rate. The Company records the change in the fair value of the warrant as other income or
expense in the statements of operations.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_846_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_zuoNDbkmfx99" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_867_zA6yTR80qBQ1"&gt;Fair
Value Measurements&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company accounts for financial instruments in accordance with ASC 820, Fair Value Measurements and Disclosures (&#x201c;ASC 820&#x201d;).
ASC 820 establishes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy
gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and
the lowest priority to unobservable inputs (Level 3 measurements). The three levels of the fair value hierarchy under ASC 820 are described
below:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
1 &#x2013; Quoted prices (unadjusted) for identical unrestricted assets or liabilities in active markets that the reporting entity has
the ability to access as of the measurement date.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
2 &#x2013; Significant other observable inputs other than Level 1 prices such as quoted prices for similar assets or liabilities: quoted
prices in markets that are not active; or financial instruments for which all significant inputs are observable or can be corroborated
by observable market date, either directly or indirectly.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
3 &#x2013; Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets
or liabilities. These unobservable inputs reflect that reporting entity&#x2019;s own assumptions about assumptions that market participants
would use in pricing the asset or liability. Level 3 assets and liabilities include financial instruments whose value is determined using
pricing models, discounted cash flow methodologies, or similar techniques, as well as instruments for which the determination of fair
value require significant management judgment or estimation.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s Level 1 assets/liabilities include cash, accounts receivable, accounts payable, prepaids, and other current assets. Management
believes the estimated fair value of these accounts on December 31, 2024 approximate their carrying value as reflected in the balance
sheets due to the short-term nature of these instruments or the use of market interest rates for debt instruments.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s Level 3 assets/liabilities include warrant liabilities. Inputs to determine fair value are generally unobservable
and typically reflect management&#x2019;s estimates of assumptions that market participants would use in pricing the asset or liability.
The fair values are therefore determined using model-based techniques, including option pricing models and discounted cash flow models.
The valuation techniques involve management&#x2019;s estimates and judgment based on unobservable inputs. The fair value estimates may
not be indicative of the amounts that would be realized in a market exchange. Additionally, there may be inherent uncertainties or changes
in the underlying assumptions used, which could significantly affect the current or future fair value estimates. Unobservable inputs
used in the models are significant to the fair values of the assets and liabilities.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Neuraxis,
Inc.&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Notes
to Financial Statements&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89E_eus-gaap--ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_zSRjCMWMj1w3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table provides a summary of the relevant assets and liabilities that are measured at fair value on a recurring
basis:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B3_z3g9hDaGrTA9" style="display: none"&gt;Schedule
of Fair Value of Assets and Liabilities  measured on Recurring Basis&lt;/span&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_4B9_us-gaap--FairValueByMeasurementFrequencyAxis_us-gaap--FairValueMeasurementsRecurringMember_us-gaap--FinancialInstrumentAxis_us-gaap--WarrantMember_zBZgAXCyF1Vk" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_4B0_us-gaap--FairValueByMeasurementFrequencyAxis_us-gaap--FairValueMeasurementsRecurringMember_us-gaap--FairValueByFairValueHierarchyLevelAxis_us-gaap--FairValueInputsLevel1Member_zDB43ntMIDc2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Level 1&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_4BA_us-gaap--FairValueByMeasurementFrequencyAxis_us-gaap--FairValueMeasurementsRecurringMember_us-gaap--FairValueByFairValueHierarchyLevelAxis_us-gaap--FairValueInputsLevel2Member_z9UbeIrsNMjf" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Level 2&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_4BC_us-gaap--FairValueByMeasurementFrequencyAxis_us-gaap--FairValueMeasurementsRecurringMember_us-gaap--FairValueByFairValueHierarchyLevelAxis_us-gaap--FairValueInputsLevel3Member_zWqguAEicMAk" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Level 3&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;Valuation Methodology&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;Unobservable&lt;br/&gt;
Inputs&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_439_c20241231_eus-gaap--LiabilitiesFairValueDisclosure_iI_z3pBMIl0Qkg3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 23%; text-align: left; padding-bottom: 1pt; padding-left: 0pt"&gt;Fair value of warrant  liabilities as of
    December 31, 2024&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; width: 7%; text-align: right"&gt;9,166&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; width: 7%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0827"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; width: 7%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0828"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; width: 7%; text-align: right"&gt;9,166&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; width: 12%"&gt;Black-Scholes model&lt;/td&gt;
    &lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; width: 17%"&gt;Project simulated cash flows&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_43C_c20231231_eus-gaap--LiabilitiesFairValueDisclosure_iI_z6bHNiK1NE4k" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt; padding-left: 0pt"&gt;Fair value of warrant  liabilities as of
    December 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;8,225&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0832"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0833"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;8,225&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;Black-Scholes model&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;Project simulated cash flows&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_8AF_zDV1NvmR9hqi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;There
were no transfers between any of the levels during the years ended December 31, 2024 and 2023. In addition to assets and liabilities
that are recorded at fair value on a recurring basis, the Company&#x2019;s assets and liabilities are also subject to recurring fair
value measurements. As of December 31, 2024 and 2023, the Company had no assets that were measured on a recurring basis.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_843_eus-gaap--EarningsPerSharePolicyTextBlock_z3Z5xHrFvPnb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_868_zRILTRgfzVRf"&gt;Basic
and Diluted Net Income (Loss) per Share&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Basic
earnings or loss per share (&#x201c;EPS&#x201d;) is computed by dividing net income (loss), net of preferred stock dividends, by the
weighted average number of common shares outstanding during the period. Diluted EPS is determined using the weighted average number
of common shares outstanding during the period, adjusted for the dilutive effect of common stock equivalents that were outstanding
for the periods presented. In periods when losses are reported, which is the case for December 31, 2024 and 2023 presented in these
financial statements, the weighted average number of common shares outstanding excludes common stock equivalents because their
inclusion would be anti-dilutive. Preferred stock dividends (neither declared nor paid) were $&lt;span id="xdx_90F_eus-gaap--DividendsPreferredStock_c20240101__20241231_zMa5zOaCz0dh" title="Preferred stock dividend"&gt;211,268&lt;/span&gt;
and $&lt;span id="xdx_906_eus-gaap--DividendsPreferredStock_dxL_c20230101__20231231_zCKOVIyQCu2e" title="Preferred stock dividend::XDX::-"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0840"&gt;0&lt;/span&gt;&lt;/span&gt;
as of December 31, 2024 and 2023, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Neuraxis,
Inc.&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Notes
to Financial Statements&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_894_eus-gaap--ScheduleOfEarningsPerShareDilutedByCommonClassTextBlock_zQrWqPsSpLsb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company had the following potentially dilutive common stock equivalents at December 31, 2024 and 2023:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8BC_zox9NmqQpub9" style="display: none"&gt;Schedule of Dilutive Common Stock Equivalents&lt;/span&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_494_20240101__20241231_zCfMhiwPQpEd" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49E_20230101__20231231_zb3LNMgKs5Qd" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--OptionMember_z2YvJ0OOXEw7" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%"&gt;Options&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;1,319,394&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;1,319,394&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--CommonStockMember_z4IBT9gvKFCb" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Pre-Funded Warrants for Common Stock&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;289,779&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0848"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--WarrantsMember_zm2CD0h3eBoj" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Warrants&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,352,751&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,822,358&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--SeriesBPreferredStockMember_zPVzzRS4kdql" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Series B Preferred Stock&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;4,280,939&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0854"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_zswUml38NNc9" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt; padding-left: 10pt"&gt;Totals&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;8,242,863&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;3,141,752&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AE_zZkRPjMKhCOg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89D_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_zX3d573GQcn8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table shows the calculation of the basic and diluted net loss per share and the effect of preferred stock dividends.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8BC_zXyehy2Q4OB7" style="display: none"&gt;Schedule of Basic and Diluted Net Loss Per Share&lt;/span&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49E_20240101__20241231_zkLWbBazjZl2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_493_20230101__20231231_zPg30jDzserk" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;For the Years Ended December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Numerator&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--NetIncomeLoss_iT_mtNILzQKI_zp3QgJK7iOg" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 60%; text-align: left; padding-left: 10pt"&gt;Net loss&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;(8,241,501&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;(14,626,683&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--DividendsPreferredStock_iN_di_zqUV04SEGgVl" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt; padding-left: 10pt"&gt;Preferred stock dividends&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(211,268&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0865"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_zqBPWqst7E72" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Net loss available to common stockholders&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(8,452,769&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(14,626,683&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Denominator&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt; padding-left: 20pt"&gt;Weighted-average shares of common stock outstanding - basic and diluted&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_903_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20240101__20241231_z6adsR0YsnZ9" title="Weighted average shares of common stock outstanding - basic"&gt;&lt;span id="xdx_901_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20240101__20241231_zco5F3MbpLAc" title="Weighted average shares of common stock outstanding - diluted"&gt;6,918,887&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_900_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20230101__20231231_zpa3Fn0QmNfb" title="Weighted average shares of common stock outstanding - basic"&gt;&lt;span id="xdx_903_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20230101__20231231_zRyq1dOtor4d" title="Weighted average shares of common stock outstanding - diluted"&gt;3,252,328&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Basic and diluted net loss per share&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_90E_eus-gaap--EarningsPerShareBasic_c20240101__20241231_zrz21PRWjGCl" title="Basic net loss per share"&gt;&lt;span id="xdx_90F_eus-gaap--EarningsPerShareDiluted_c20240101__20241231_zIgmac8dw9Ed" title="Diluted net loss per share"&gt;(1.22&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_908_eus-gaap--EarningsPerShareBasic_c20230101__20231231_z2hMbWcceUqg" title="Basic net loss per share"&gt;&lt;span id="xdx_905_eus-gaap--EarningsPerShareDiluted_c20230101__20231231_z96vWnNsnYxe" title="Diluted net loss per share"&gt;(4.50&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AF_z8OuXYGzkAE7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_848_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_zuHjXlK84ss5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_862_zfwsy8KpLtyk"&gt;Stock-Based
Compensation&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company accounts for all stock-based awards at fair value. The Company recognizes its stock-based compensation expense using the straight-line
method. Compensation cost is not adjusted for estimated forfeitures, but instead is adjusted upon an actual forfeiture.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company accounts for the granting of stock options and restricted stock units to employees and non-employees using the fair value method
whereby all awards are measured at fair value on the date of the grant. The fair value of all employee stock options and restricted stock
units is expensed over the requisite service period with a corresponding increase to additional paid-in capital. Upon exercise of stock
options, the consideration paid by the option holder is recorded in additional paid-in capital, while the par value of the shares received
is reclassified from additional paid-in-capital to common stock. Upon vesting of restricted stock units, the par value of the shares
issued are reclassified from additional paid-in-capital to common stock.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Stock-based
awards to non-employees are measured based on the fair value of the equity instrument issued. Compensation expense for non-employee stock
awards is recognized over the requisite service period following the measurement of the fair value on the grant date.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company uses the Black-Scholes option-pricing model to calculate the fair value of stock options. The use of the Black-Scholes option-pricing
model requires management to make assumptions with respect to the expected term of the option, the expected volatility of the common
stock consistent with the expected term of the option, risk-free interest rates, the value of the common stock and expected dividend
yield of the common stock. Changes in these assumptions can materially affect the fair value estimate.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Neuraxis,
Inc.&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Notes
to Financial Statements&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_843_eus-gaap--RevenueRecognitionPolicyTextBlock_zbJsYb6ra5wg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_862_zPNGdCffZD65"&gt;Revenue
Recognition&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
accordance with FASB&#x2019;s ASC 606, &lt;i&gt;Revenue from Contracts with Customers&lt;/i&gt;, (&#x201c;ASC 606&#x201d;), the Company recognizes revenue
when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the Company expects
to be entitled in exchange for those goods or services. To determine revenue recognition for arrangements that the Company determines
are within the scope of ASC 606, it performs the following five steps:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(i)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;identify
    the contract(s) with a customer&#x37e;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(ii)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;identify
    the performance obligations in the contract&#x37e;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(iii)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;determine
    the transaction price&#x37e;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(iv)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;allocate
    the transaction price to the performance obligations in the contract&#x37e; and&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(v)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;recognize
    revenue when (or as) the entity satisfies a performance obligation.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company applies the five-step model to contracts when it determines that it is probable it will collect substantially all the consideration
it is entitled to in exchange for the goods or services it transfers to the customer. At contract inception, once the contract is determined
to be within the scope of ASC 606, the Company assesses the goods or services promised within each contract and determines those that
are performance obligations and assesses whether each promised good or service is distinct. The Company then recognizes as revenue the
amount of the transaction price, after consideration of variability and constraints, if any, that is allocated to the respective performance
obligation when the performance obligation is satisfied.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company estimates credit losses on accounts receivable by utilizing an aging schedule.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company offers a Patient Assistance Program for patients without insurance coverage for IB-Stim. This program offers potential self-pay
discounts for IB-Stim devices, based upon household income and size.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Also,
the Company offers providers an opt-in program to address adequate insurance claim payments on IB-Stim devices. This program may extend
a rebate or invoice credit where the insurance payment and patient responsibility (i.e., deductible, co-payment, and/or co-insurance
amounts required by the Payer) are less than the acquisition cost of the IB-Stim device. The Company recognizes revenue at such a time
that collection of the amount due is assured.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89B_eus-gaap--DisaggregationOfRevenueTableTextBlock_z51iF5FwY8Ik" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table disaggregates the Company&#x2019;s revenue based on the customer&#x2019;s location by state for the years ended December
31:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B7_zFnT94CGa2N4" style="display: none"&gt;Schedule of Disaggregation of Revenue&lt;/span&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 60%; margin-right: auto"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 20%"&gt;California&lt;/td&gt;&lt;td style="width: 2%; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--Revenues_c20240101__20241231__srt--StatementGeographicalAxis__stpr--CA_ztWpMGR6FjK" style="width: 16%; font-weight: bold; text-align: right" title="Revenues"&gt;778,209&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--Revenues_c20230101__20231231__srt--StatementGeographicalAxis__stpr--CA_zhaa1ANY8XF7" style="width: 16%; text-align: right" title="Revenues"&gt;601,235&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Ohio&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--Revenues_c20240101__20241231__srt--StatementGeographicalAxis__stpr--OH_z8HHuDbKCMGd" style="font-weight: bold; text-align: right" title="Revenues"&gt;431,328&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--Revenues_c20230101__20231231__srt--StatementGeographicalAxis__stpr--OH_zzOMNsxW8pak" style="text-align: right" title="Revenues"&gt;407,632&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Illinois&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--Revenues_c20240101__20241231__srt--StatementGeographicalAxis__stpr--IL_zb6kZssrfWfe" style="font-weight: bold; text-align: right" title="Revenues"&gt;246,217&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--Revenues_c20230101__20231231__srt--StatementGeographicalAxis__stpr--IL_zWDTnM17q319" style="text-align: right" title="Revenues"&gt;117,963&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Wisconsin&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--Revenues_c20240101__20241231__srt--StatementGeographicalAxis__stpr--WI_z3428iyridQh" style="font-weight: bold; text-align: right" title="Revenues"&gt;157,786&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--Revenues_c20230101__20231231__srt--StatementGeographicalAxis__stpr--WI_zGxpKPV1TjK7" style="text-align: right" title="Revenues"&gt;292,601&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Massachusetts&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--Revenues_c20240101__20241231__srt--StatementGeographicalAxis__stpr--MA_zasnvjzBkL05" style="font-weight: bold; text-align: right" title="Revenues"&gt;154,407&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--Revenues_c20230101__20231231__srt--StatementGeographicalAxis__stpr--MA_zKTfMKrP2Fwk" style="text-align: right" title="Revenues"&gt;127,300&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Florida&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--Revenues_c20240101__20241231__srt--StatementGeographicalAxis__stpr--FL_zjSSE7PnWXPh" style="font-weight: bold; text-align: right" title="Revenues"&gt;149,985&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--Revenues_c20230101__20231231__srt--StatementGeographicalAxis__stpr--FL_z0AEkB7FcCsg" style="text-align: right" title="Revenues"&gt;186,840&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;All other states&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--Revenues_c20240101__20241231__srt--StatementGeographicalAxis__custom--AllOtherStatesMember_zhSbHj7bt2ag" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right" title="Revenues"&gt;767,993&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--Revenues_c20230101__20231231__srt--StatementGeographicalAxis__custom--AllOtherStatesMember_zVzeZm5mSkih" style="border-bottom: Black 1pt solid; text-align: right" title="Revenues"&gt;726,478&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--Revenues_c20240101__20241231_z8xgf1LC4xKf" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right" title="Revenues"&gt;2,685,925&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--Revenues_c20230101__20231231_zCiswA2OlDda" style="border-bottom: Black 1pt solid; text-align: right" title="Revenues"&gt;2,460,049&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A0_zvTYoR5sc9Ua" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Certain
economic factors affect the nature, amount, timing, and uncertainty of the Company&#x2019;s revenue and cash flows. All of the Company&#x2019;s
products are sold to healthcare customers including hospitals and clinics. Sales to healthcare customers lack seasonality and have a
mild correlation with economic cycles. All of the Company&#x2019;s sales are to customers located within the United States. Sales contracts
consist of purchase orders that are short-term (i.e., less than or equal to one year).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Neuraxis,
Inc.&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Notes
to Financial Statements&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company typically satisfies its performance obligations for goods at a point in time as they are received at the customer&#x2019;s
destination (rather than over time). Goods are shipped by common carrier to customers under FOB destination terms. As such,
ownership of goods in transit is transferred to the customer upon receipt as the Company bears the associated risks (e.g., loss,
damage, delay). Management typically relies on shipping information from common carriers to evaluate when the
customer has obtained control of the goods. Shipping and handling costs are recorded as Cost of Goods Sold in the Statements of
Operations.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s contracts with customers typically do not involve variable consideration. The information that the Company uses to determine
the transaction price for a contract is similar to the information that the Company&#x2019;s management uses in establishing the prices
of goods to be sold.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Orders
may not be cancelled after shipment. Customers may return devices within 10 days of delivery if the goods are found to be defective,
nonconforming, or otherwise do not meet the stated technical specifications. At the option of the customer, the Company shall either:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Refund
    the price paid for any defective or nonconforming products.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Supply
    and deliver to the customer replacement conforming products.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Reimburse
    the customer for the cost of repairing any defective or nonconforming products.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;At
the time revenue is recognized, the Company estimates expected returns and excludes those amounts from revenue. The Company also
maintains appropriate accounts to reflect the effects of expected returns on the Company&#x2019;s financial position and periodically
adjusts those accounts to reflect its actual return experience. Estimated returns totaled&lt;/span&gt; $&lt;span id="xdx_908_eus-gaap--ContractWithCustomerLiabilityRevenueRecognized_c20240101__20241231_zBqEO4HnlF7c" title="Estimated returns of revenue"&gt;5,000&lt;/span&gt; and $&lt;span id="xdx_90C_eus-gaap--ContractWithCustomerLiabilityRevenueRecognized_c20230101__20231231_zt5BroE5J4dl" title="Estimated returns of revenue"&gt;0&lt;/span&gt; as of December 31,
2024 and 2023, respectively.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Payment
for goods sold by the Company is typically due after an invoice is sent to the customer, within 30 days. The Company does not offer discounts
if the customer pays some or all of an invoiced amount prior to the due date. None of the Company&#x2019;s contracts have a significant
financing component.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Medical
devices that the Company contracts to sell and transfer to customers are manufactured by one specific third-party manufacturer located
within the state of Indiana. In no case does the Company act as an agent (i.e., the Company does not provide a service of arranging for
another party to transfer goods to the customer).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Neuraxis,
Inc.&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Notes
to Financial Statements&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_846_eus-gaap--LesseeLeasesPolicyTextBlock_zFGApbXnaIf2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_862_zlz6TSsaBUBh"&gt;Leases&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
accordance with Accounting Standards Updated (&#x201c;ASU&#x201d;) No. 2016-02, &lt;i&gt;Leases (Topic 842)&lt;/i&gt; (&#x201c;ASU 2016-02&#x201d; or
&#x201c;ASC 842&#x201d;), at the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based
on the unique facts and circumstances present in the arrangement. Leases with a term greater than one year are recognized on the balance
sheet as right-of-use assets and current and non-current lease liabilities, as applicable.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Operating
lease liabilities and their corresponding right-of-use assets are initially recorded based on the present value of lease payments over
the expected remaining lease term. Certain adjustments to the right-of-use asset may be required for items such as incentives received.
The interest rate implicit in lease contracts is typically not readily determinable. As a result, the Company utilizes its incremental
borrowing rate to discount lease payments, which reflects the fixed rate at which the Company could borrow on a collateralized basis
the amount of the lease payments in the same currency, for a similar term, in a similar economic environment. Prospectively, the Company
will adjust the right-of-use assets for straight-line rent expense, or any incentives received and remeasure the lease liability at the
net present value using the same incremental borrowing rate that was in effect as of the lease commencement or transition date. The Company
has elected not to recognize leases with an original term of one year or less on the balance sheet. The Company typically only includes
an initial lease term in its assessment of a lease arrangement. Options to renew a lease are not included in the Company&#x2019;s assessment
unless there is reasonable certainty that the Company will renew.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Assumptions
made by the Company at the commencement date are re-evaluated upon occurrence of certain events, including a lease modification. A lease
modification results in a separate contract when the modification grants the lessee an additional right of use not included in the original
lease and when lease payments increase commensurate with the standalone price for the additional right of use. When a lease modification
results in a separate contract, it is accounted for in the same manner as a new lease.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Entities
may elect not to separate lease and non-lease components. The Company has elected to account for lease and non-lease components together
as a single lease component for all underlying assets and allocate all the contract consideration to the lease component only.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Neuraxis,
Inc.&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Notes
to Financial Statements&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84C_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_zBrdlPiMtEtd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_864_z3HRppsuDOqc"&gt;Impairment
of Long-Lived Assets&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Long-lived
assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset group may
not be recoverable. If events or changes in circumstances indicate that the carrying amount of an asset group may not be recoverable,
we compare the carrying amount of the asset group to future undiscounted net cash flows, excluding interest costs, expected to be generated
by the asset group and their ultimate disposition. If the sum of the undiscounted cash flows is less than the carrying value, the impairment
to be recognized is measured by the amount by which the carrying amount of the asset group exceeds the fair value of the asset group.
Assets to be disposed of are reported at the lower of the carrying amount or fair value, less costs to sell.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84A_eus-gaap--ConcentrationRiskCreditRisk_znCEHkM7M1r6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_865_zp8VPiZFHkLc"&gt;Concentrations
of Credit Risk&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s business activity consists of the sale of medical neuromodulation devices to doctors, clinics, and hospitals across
the country. Receivables consist of unsecured amounts due from customers. The table below sets forth the Company&#x2019;s customers
that accounted for greater than 10% of its net accounts receivable for the years ended December 31, 2024 and 2023,
respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_898_eus-gaap--SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_zUwJC7G3vMd4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span id="xdx_8BF_ziuviCdUkIG6" style="display: none"&gt;Schedule of Customer Accounts Receivable&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Percentage
    of Net Accounts&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Percentage
    of Net Accounts&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Receivable&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt; Receivable&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 36%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Customer
    A&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--AccountsReceivableNet_iI_c20241231__srt--MajorCustomersAxis__custom--CustomerAMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zGVtJHY4ngni" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right" title="Net accounts receivable"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;119,616&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90A_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20240101__20241231__srt--MajorCustomersAxis__custom--CustomerAMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_ztfwx0Pn3dvb" title="Risk percentage"&gt;49&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--AccountsReceivableNet_iI_c20231231__srt--MajorCustomersAxis__custom--CustomerAMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zKXzKALlmJz7" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right" title="Net accounts receivable"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0940"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_901_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20231231__srt--MajorCustomersAxis__custom--CustomerAMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_z9o22JCbwIjb" title="Risk percentage"&gt;0&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Customer
    B&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--AccountsReceivableNet_iI_c20241231__srt--MajorCustomersAxis__custom--CustomerBMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zR77yBuhHffb" style="font: bold 10pt Times New Roman, Times, Serif; text-align: right" title="Net accounts receivable"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0944"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_905_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20240101__20241231__srt--MajorCustomersAxis__custom--CustomerBMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_z9SVmlN18mH9" title="Risk percentage"&gt;0&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--AccountsReceivableNet_iI_c20231231__srt--MajorCustomersAxis__custom--CustomerBMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zDCakzXb5lvc" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Net accounts receivable"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;23,900&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90A_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20231231__srt--MajorCustomersAxis__custom--CustomerBMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zYReW668WMIf" title="Risk percentage"&gt;28&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Customer
    C&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--AccountsReceivableNet_iI_c20241231__srt--MajorCustomersAxis__custom--CustomerCMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zECBJOkoPFzh" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Net accounts receivable"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;22,799&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_907_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20240101__20241231__srt--MajorCustomersAxis__custom--CustomerCMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zCoq7BCeaAUd" title="Risk percentage"&gt;9&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--AccountsReceivableNet_iI_c20231231__srt--MajorCustomersAxis__custom--CustomerCMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zSmayTQpiaTa" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Net accounts receivable"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;14,401&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90D_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20231231__srt--MajorCustomersAxis__custom--CustomerCMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_z058r726xm0j" title="Risk percentage"&gt;17&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Customer
    D&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--AccountsReceivableNet_iI_c20241231__srt--MajorCustomersAxis__custom--CustomerDMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_ziWgXs4rhsT5" style="font: bold 10pt Times New Roman, Times, Serif; text-align: right" title="Net accounts receivable"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0960"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_905_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20240101__20241231__srt--MajorCustomersAxis__custom--CustomerDMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zSEvYV8lKLbh" title="Risk percentage"&gt;0&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--AccountsReceivableNet_iI_c20231231__srt--MajorCustomersAxis__custom--CustomerDMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zgOcWsNkjKF1" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Net accounts receivable"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;23,982&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_909_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20231231__srt--MajorCustomersAxis__custom--CustomerDMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zlZgVpBjp056" title="Risk percentage"&gt;28&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;%&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Customer
    E&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--AccountsReceivableNet_iI_c20241231__srt--MajorCustomersAxis__custom--CustomerEMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zl2qNb56zJwh" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right" title="Net accounts receivable"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0968"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90F_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20240101__20241231__srt--MajorCustomersAxis__custom--CustomerEMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zqDT0bFj4H1k" title="Risk percentage"&gt;0&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--AccountsReceivableNet_iI_c20231231__srt--MajorCustomersAxis__custom--CustomerEMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zwaoP8QxF9Bf" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Net accounts receivable"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;9,599&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_901_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20231231__srt--MajorCustomersAxis__custom--CustomerEMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zyXKzz43jjZf" title="Risk percentage"&gt;11&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--AccountsReceivableNet_iI_c20241231__srt--MajorCustomersAxis__custom--CustomerMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_z1Hroo9j0F5k" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Net accounts receivable"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;142,415&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_902_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20240101__20241231__srt--MajorCustomersAxis__custom--CustomerMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zvYJPTm3tgrf" title="Risk percentage"&gt;58&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--AccountsReceivableNet_iI_c20231231__srt--MajorCustomersAxis__custom--CustomerMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_z3M4Bf5OFDta" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Net accounts receivable"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;71,882&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_906_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20231231__srt--MajorCustomersAxis__custom--CustomerMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zHYTFLfnmKr" title="Risk percentage"&gt;84&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p id="xdx_8AC_zCXEfpOPYya" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
table below sets forth the Company&#x2019;s customers that accounted for greater than 10% of its net sales for the years ended
December 31, 2024 and 2023, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_896_eus-gaap--ContractWithCustomerAssetAllowanceForCreditLossTableTextBlock_zkkwaR2En4R4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span id="xdx_8BA_z9EQpd6TmZ1d" style="display: none"&gt;Schedule of Customers Accounted Revenues&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Percentage of&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Percentage of&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Net Sales&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Net Sales&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 36%; text-align: left"&gt;Customer A&lt;/td&gt;&lt;td style="width: 2%; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20240101__20241231__srt--MajorCustomersAxis__custom--CustomerAMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zhKwbiXDFFs3" style="width: 12%; font-weight: bold; text-align: right" title="Revenue"&gt;521,810&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&lt;span id="xdx_903_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20240101__20241231__srt--MajorCustomersAxis__custom--CustomerAMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zklF9jeBuOtg" title="Risk percentage"&gt;20&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20230101__20231231__srt--MajorCustomersAxis__custom--CustomerAMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zHFwu8jqdfzh" style="width: 12%; text-align: right" title="Revenue"&gt;452,680&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&lt;span id="xdx_908_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20231231__srt--MajorCustomersAxis__custom--CustomerAMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zUGo6Jpa5fgl" title="Risk percentage"&gt;18&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Customer B&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20240101__20241231__srt--MajorCustomersAxis__custom--CustomerBMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zbvEOGjsePt8" style="font-weight: bold; text-align: right" title="Revenue"&gt;396,950&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90C_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20240101__20241231__srt--MajorCustomersAxis__custom--CustomerBMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_z6L6EIm7A9m7" title="Risk percentage"&gt;15&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20230101__20231231__srt--MajorCustomersAxis__custom--CustomerBMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zLhqQLg76db" style="text-align: right" title="Revenue"&gt;382,082&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20231231__srt--MajorCustomersAxis__custom--CustomerBMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zACbxoOC2pSe" title="Risk percentage"&gt;16&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Customer C&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20240101__20241231__srt--MajorCustomersAxis__custom--CustomerCMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zswU6SLkue39" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right" title="Revenue"&gt;142,270&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_904_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20240101__20241231__srt--MajorCustomersAxis__custom--CustomerCMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_z2crm1yRVs5d" title="Risk percentage"&gt;5&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;%&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20230101__20231231__srt--MajorCustomersAxis__custom--CustomerCMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zWVmxOqlJMFc" style="border-bottom: Black 1pt solid; text-align: right" title="Revenue"&gt;274,581&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_906_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20231231__srt--MajorCustomersAxis__custom--CustomerCMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zs8Tc7rodGKf" title="Risk percentage"&gt;11&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20240101__20241231__srt--MajorCustomersAxis__custom--CustomerMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zpQ98lLEyvZa" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right" title="Revenue"&gt;1,061,030&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_90E_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20240101__20241231__srt--MajorCustomersAxis__custom--CustomerMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zLqb9DZOwDyh" title="Risk percentage"&gt;40&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;%&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20230101__20231231__srt--MajorCustomersAxis__custom--CustomerMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zuCpenm53Myd" style="border-bottom: Black 1pt solid; text-align: right" title="Revenue"&gt;1,109,343&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20231231__srt--MajorCustomersAxis__custom--CustomerMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zV0CREuaTTec" title="Risk percentage"&gt;45&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A8_zQMCLDFvtWn5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;From
time to time, the Company&#x2019;s bank balances may exceed the FDIC limit of $&lt;span id="xdx_901_eus-gaap--CashFDICInsuredAmount_iI_c20241231_zo5mHRQzxyD1" title="Cash, FDIC insured amount"&gt;250,000&lt;/span&gt;.
As of December 31, 2024 and 2023, the Company had $&lt;span id="xdx_901_eus-gaap--CashUninsuredAmount_iI_c20241231_zJJUkOAzfSya" title="Cash uninsured"&gt;3,263,618&lt;/span&gt;
and $&lt;span id="xdx_909_eus-gaap--CashUninsuredAmount_iI_c20231231_zQEDtlFPjsD" title="Cash uninsured"&gt;0&lt;/span&gt; of its cash balance
uninsured, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84E_ecustom--GoingConcernPolicyTextBlock_zs8TSICVHdrc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_864_z7ogNBVMc5Kh"&gt;Going
Concern&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;We
have incurred losses since inception and have funded our operations primarily with a combination of sales, debt, and the sale of capital
stock. As of December 31, 2024, we had stockholders&#x2019; equity of $&lt;span id="xdx_908_eus-gaap--StockholdersEquity_iI_c20241231_zcrwDhOD4KL9" title="Stockholders' equity"&gt;2,067,748&lt;/span&gt;, short-term outstanding borrowings of $&lt;span id="xdx_901_eus-gaap--ShortTermBorrowings_iI_c20241231_zcj9tEASlJp6" title="Short term borrowings outstanding"&gt;154,152&lt;/span&gt;, cash
of $&lt;span id="xdx_909_eus-gaap--Cash_iI_c20241231_zqeGWmRH93nf" title="Cash"&gt;3,696,870&lt;/span&gt; and a working capital surplus of $&lt;span id="xdx_907_ecustom--WorkingCapitalDeficit_iI_c20241231_zeQGhPzPxHu3" title="Working capital surplus"&gt;1,832,858&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Neuraxis,
Inc.&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Notes
to Financial Statements&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Our
future capital requirements will depend upon many factors, including progress with developing, manufacturing, and marketing our technologies,
the time and costs involved in preparing, filing, prosecuting, maintaining, and enforcing patent claims and other proprietary rights,
our ability to establish collaborative arrangements, marketing activities and competing technological and market developments, including
regulatory changes and overall economic conditions in our target markets. Our ability to generate revenue and achieve profitability requires
us to successfully market and secure purchase orders for our products from customers currently identified in our sales pipeline and to
new customers as well. The primary activity that will drive all customers and revenues is the adoption of insurance coverage by commercial
insurance carriers nationally which is a top priority of the Company. These activities, including our planned research and development
efforts, will require significant uses of working capital through the rest of 2025 and beyond. Based on our current operating plans,
we believe that our existing cash at the time of this filing will only be sufficient to meet our anticipated operating needs before the
end of 2025.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Management
evaluates whether there are conditions or events that raise substantial doubt about the Company&#x2019;s ability to continue as a going
concern for a period of one year from the date the financial statements are issued.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;To
date, the Company has experienced operating losses and negative cash flows from operations. Management believes that increased sales
and acceptance of their product by insurance providers will allow the Company to achieve profitability in the future.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;While
the Company believes in the viability of its strategy to further implement its business plan and generate sufficient revenues and in
its ability to raise additional funds by way of a public or private offering of its debt or equity securities, there can be no assurance
that it will be able to do so on reasonable terms, or at all. The ability of the Company to continue as a going concern is dependent
upon its ability to further implement its business plan and generate sufficient revenues and its ability to raise additional funds by
way of a public or private offering. Neither future cash generated from operating activities, nor management&#x2019;s contingency plans
to mitigate the risk and extend cash resources through the evaluation period, are considered probable. As a result, substantial doubt
is deemed to exist about the Company&#x2019;s ability to continue as a going concern. As we continue to incur losses, our transition to
profitability is dependent upon achieving a level of revenues adequate to support its cost structure. We may never achieve profitability,
and unless and until doing so, we intend to fund future operations through additional dilutive or nondilutive financing. There can be
no assurances, however, that additional funding will be available on terms acceptable to us, if at all.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
financial statements do not include any adjustments related to the recoverability and classification of recorded asset amounts or the
amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84D_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zcEfnqT2G8F2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_862_zHoVgdNJrcdl"&gt;Recently
Adopted Accounting Pronouncements&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
November 2023, the FASB issued Accounting Standards Update (&#x201c;ASU&#x201d;) 2023-07, &lt;i&gt;Segment Reporting (Topic 280): Improvements
to Reportable Segment Disclosures&lt;/i&gt;, which requires disclosure of (i) significant segment expenses, (ii) other segment items and (iii)
the title and position of the Chief Operating Decision Maker (&#x201c;CODM&#x201d;) on an annual and interim basis. Additionally, ASU 2023-07
requires that a public entity that has a single reportable segment provide all the disclosures required by Topic 280. Public business
entities are required to adopt the standard for fiscal years beginning after December 15, 2023 and interim periods withing fiscal year
beginning after December 15, 2024. Disclosures are required for all prior periods presented in the financial statements. The Company
adopted the disclosure provisions of ASU 2023-07 as of December 31, 2024 as operations are managed through one reportable segment.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
June 2016, the FASB issued ASU 2016-13, &lt;i&gt;Financial Instruments &#x2013; Credit Losses (Topic 326): Measurement of Credit Losses on Financial
Instruments&lt;/i&gt;, which requires measurement and recognition of expected credit losses for financial assets held and enhanced disclosures
regarding significant estimates and judgments used in estimating credit losses. In November 2019, the FASB issued ASU 2019-10, Financial
Instruments &#x2013; Credit Losses (Topic 326), Derivatives and Hedging (Topic 815) and Leases (Topic 842): Effective Dates, which amended
the effective date of ASU 2016-13. Public business entities meeting the definition of an SEC filer, excluding entities eligible to be
a Smaller Reporting Company (&#x201c;SRC&#x201d;) as defined by the SEC, are required to adopt the standard for fiscal years beginning
after December 15, 2019, including interim periods within those fiscal years. All other entities are required to adopt the standard for
fiscal years beginning after December 15, 2022, including interim periods within those fiscal years. The Company meets the definition
of an SRC and therefore the standard was adopted as of January 1, 2023. The adoption of this guidance did not have a material impact
on the Company&#x2019;s financial statements.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_840_ecustom--RecentlyIssuedAccountingPronouncementsPolicyTextBlock_zjKjcdN7Te33" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_86A_zxIiHNzeegpc"&gt;Recently
Issued Accounting Pronouncements&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
November 2024, the FASB issued ASU 2024-03, &lt;i&gt;Income Statement&#x2014;Reporting Comprehensive Income&#x2014;Expense Disaggregation Disclosures
(Subtopic (220-40): Disaggregation of Income Statement Expenses&lt;/i&gt;, which requires disclosures that disaggregate, in a tabular presentation,
each relevant expense caption on the face of the income statement that includes inventory purchases, employee compensation, depreciation
and intangible amortization expense. Additional disclosures are also required to provide a qualitative description of the amounts in
an expense caption that are not separately disaggregated quantitatively and the total amount of selling expenses including a definition.
Public business entities are required to adopt the standard for fiscal years beginning after December 15, 2026 and interim periods within
fiscal years beginning after December 15, 2027. Disclosures are required for all prior periods presented in the financial statements.
Although the standard requires enhanced disclosures, the adoption is not expected to have a material impact on the Company&#x2019;s financial
statements.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
December 2023, the FASB issued ASU 2023-09, &lt;i&gt;Income Taxes (Topic 740): Improvements to Income Tax Disclosures&lt;/i&gt;, which requires the
enhancement of income tax disclosures to provide better insight into how an entity&#x2019;s operations and related tax risks, planning
and opportunities affect its tax rate and prospects for future cash flows. The enhanced disclosures require (i) specific categories in
a tabular rate reconciliation including both amounts and percentages and (ii) additional information for reconciling items and income
tax paid that meet a quantitative threshold. Public business entities are required to adopt the standard for annual periods beginning
after December 15, 2024. All other entities are required to adopt the standard for annual periods beginning after December 15, 2025.
The adoption of the standard is not expected to have a material impact on the Company&#x2019;s financial statements.&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_85C_zHvhrIrV3o8d" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Neuraxis,
Inc.&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Notes
to Financial Statements&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:UseOfEstimates contextRef="From2024-01-01to2024-12-31" id="Fact000742">&lt;p id="xdx_843_eus-gaap--UseOfEstimates_zCNBGrFAkxnd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_862_zCQCbX5hehLh"&gt;Use
of Estimates and Critical Accounting Estimates and Assumptions&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the
reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the dates of the financial statements
and the reported amounts of revenues and expenses during the reporting periods.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;These
significant accounting estimates or assumptions bear the risk of change due to the fact that there are uncertainties attached to these
estimates or assumptions, and certain estimates or assumptions are difficult to measure or value.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Management
bases its estimates on historical experience and on various assumptions that are believed to be reasonable in relation to the financial
statements taken as a whole under the circumstances, the results of which form the basis for making judgments about the carrying values
of assets and liabilities that are not readily apparent from other sources.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Management
regularly evaluates the key factors and assumptions used to develop the estimates utilizing currently available information, changes
in facts and circumstances, historical experience, and reasonable assumptions. After such evaluations, if deemed appropriate, those estimates
are adjusted accordingly. The Company uses estimates in accounting for, among other items, revenue recognition, allowance for credit
losses, stock-based compensation, income tax provisions, excess and obsolete inventory reserve, and impairment of property and equipment,
and intellectual property. Actual results could differ from those estimates.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:UseOfEstimates>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000744">&lt;p id="xdx_84E_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_ztvqhicgjizf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_86B_zlm33AKL50gf"&gt;Cash
and Cash Equivalents&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company considers all highly liquid debt instruments purchased with a maturity of three months or less to be cash equivalents. The Company
did not hold any cash equivalents as of December 31, 2024 and 2023.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:TradeAndOtherAccountsReceivablePolicy contextRef="From2024-01-01to2024-12-31" id="Fact000746">&lt;p id="xdx_846_eus-gaap--TradeAndOtherAccountsReceivablePolicy_zfROzNl3ffE" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_866_z8W5SJsnYNZ3"&gt;Trade
Accounts Receivable and Allowance for Credit Losses&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Trade
accounts receivable are stated at the amount management expects to collect from outstanding balances, net of an allowance for credit
losses. Management evaluates many factors when determining the collectability of specific customer accounts, including, but not
limited to, creditworthiness, past transaction and payment history, current economic industry trends and changes in payment terms.
Management used assumptions and judgment based on the best available facts and circumstances to estimate and record an allowance.
The allowance for credit losses was $&lt;span id="xdx_90F_eus-gaap--AllowanceForDoubtfulAccountsReceivable_iI_c20241231_zP8VFScW5y0c" title="Allowance for doubtful accounts"&gt;5,000&lt;/span&gt;
and $&lt;span id="xdx_903_eus-gaap--AllowanceForDoubtfulAccountsReceivable_iI_c20231231_ztE0yvQuOmXa" title="Allowance for doubtful accounts"&gt;11,993&lt;/span&gt;
as of December 31, 2024 and 2023, respectively. The Company recorded credit losses for the years ended December 31, 2024 and 2023 of
$&lt;span id="xdx_90D_eus-gaap--ProvisionForOtherCreditLosses_c20240101__20241231_z7Ql8mCSpFj8" title="Credit losses"&gt;7,395&lt;/span&gt; and $&lt;span id="xdx_904_eus-gaap--ProvisionForOtherCreditLosses_c20230101__20231231_zJyECgcqyDrd" title="Credit losses"&gt;25,281&lt;/span&gt;,
respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Neuraxis,
Inc.&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Notes
to Financial Statements&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:TradeAndOtherAccountsReceivablePolicy>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000748"
      unitRef="USD">5000</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000750"
      unitRef="USD">11993</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:ProvisionForOtherCreditLosses
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000752"
      unitRef="USD">7395</us-gaap:ProvisionForOtherCreditLosses>
    <us-gaap:ProvisionForOtherCreditLosses
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000754"
      unitRef="USD">25281</us-gaap:ProvisionForOtherCreditLosses>
    <us-gaap:DepositContractsPolicy contextRef="From2024-01-01to2024-12-31" id="Fact000756">&lt;p id="xdx_845_eus-gaap--DepositContractsPolicy_z0S65AE6qnwc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_86B_zs9KrkyOFyU1"&gt;Customer
Deposits&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Customer
deposits consists of  payments and returned devices from clients in advance of revenue recognition. The Company will recognize
the customer deposits over the next year. As of December 31, 2024, and 2023, the Company had customer deposits of $&lt;span id="xdx_904_eus-gaap--Deposits_iI_c20241231_zSmRjs0DXNzj" title="Customer deposits"&gt;32,527&lt;/span&gt; and $&lt;span id="xdx_902_eus-gaap--Deposits_iI_c20231231_zueWOiNKKjkg" title="Customer deposits"&gt;74,947&lt;/span&gt;,
respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:DepositContractsPolicy>
    <us-gaap:Deposits
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000758"
      unitRef="USD">32527</us-gaap:Deposits>
    <us-gaap:Deposits
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000760"
      unitRef="USD">74947</us-gaap:Deposits>
    <us-gaap:InventoryPolicyTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000762">&lt;p id="xdx_846_eus-gaap--InventoryPolicyTextBlock_zxmZEstGpDWd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_866_zKh9Gova5AU2"&gt;Inventories&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Inventories
are valued at the lower of cost or net realizable value. Cost is determined using the weighted average method. The inventory is comprised
of finished medical devices on hand. Certain components within the devices have an expiration date that are removed from current inventory
and expensed at the date of expiration. For the years ended December 31, 2024 and 2023, $&lt;span id="xdx_901_ecustom--InventoryExpenses_iI_c20241231_zZoDkfglZ1Ia" title="Inventory expenses"&gt;0&lt;/span&gt; and $&lt;span id="xdx_900_ecustom--InventoryExpenses_iI_c20231231_zEQ7Zl1KsBUg" title="Inventory expenses"&gt;25,008&lt;/span&gt; were expensed as expired inventory,
respectively. Inventory reserves totaled $&lt;span id="xdx_906_eus-gaap--InventoryRawMaterialsNetOfReserves_iI_c20241231_zgVGVW7KmyZ2" title="Inventory reserves"&gt;4,454&lt;/span&gt; and $&lt;span id="xdx_90C_eus-gaap--InventoryRawMaterialsNetOfReserves_iI_c20231231_zZjhKB4ngEMj" title="Inventory reserves"&gt;0&lt;/span&gt; as of December 31, 2024 and 2023, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:InventoryPolicyTextBlock>
    <NRXS:InventoryExpenses
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000764"
      unitRef="USD">0</NRXS:InventoryExpenses>
    <NRXS:InventoryExpenses
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000766"
      unitRef="USD">25008</NRXS:InventoryExpenses>
    <us-gaap:InventoryRawMaterialsNetOfReserves
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000768"
      unitRef="USD">4454</us-gaap:InventoryRawMaterialsNetOfReserves>
    <us-gaap:InventoryRawMaterialsNetOfReserves
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000770"
      unitRef="USD">0</us-gaap:InventoryRawMaterialsNetOfReserves>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000772">&lt;p id="xdx_846_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zWScFqAl6Wg6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_860_zuZEawh0Gg39"&gt;Property
and Equipment&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Property
and equipment are recorded at cost less accumulated depreciation. Depreciation is computed using the straight-line method over the estimated
useful lives of the assets.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89D_ecustom--ScheduleOfPropertyPlantAndEquipmentUsefulLivesTableTextBlock_zA63jvQhipj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Depreciation
is calculated using the following estimated useful lives:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B1_zS3Vx59ipME8" style="display: none"&gt;Schedule of Estimated Useful Lives&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; width: 60%; border-collapse: collapse; margin-right: auto"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; width: 79%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Classification&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; width: 19%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Years&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Machinery
    and Equipment &lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_908_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--MachineryAndEquipmentMember__srt--RangeAxis__srt--MinimumMember_zBoCKBqUpo16" title="Property and equipment, estimated useful lives"&gt;7&lt;/span&gt;-&lt;span id="xdx_90B_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--MachineryAndEquipmentMember__srt--RangeAxis__srt--MaximumMember_zs1iIMSzTnZ" title="Property and equipment, estimated useful lives"&gt;10&lt;/span&gt;
    &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Furniture
    and Fixtures&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_906_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember__srt--RangeAxis__srt--MinimumMember_zmPdomKTkuj5" title="Property and equipment, estimated useful lives"&gt;3&lt;/span&gt;-&lt;span id="xdx_90D_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember__srt--RangeAxis__srt--MaximumMember_zMDjRUq42GH8" title="Property and equipment, estimated useful lives"&gt;10&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Computer
    Hardware&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_903_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_zay71H131WJ9" title="Property and equipment, estimated useful lives"&gt;5&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Leasehold
    Improvements&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90F_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember__srt--RangeAxis__srt--MinimumMember_zttmRcV3egyh" title="Property and equipment, estimated useful lives"&gt;10&lt;/span&gt;-&lt;span id="xdx_903_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember__srt--RangeAxis__srt--MaximumMember_zDksIX8dOpz9" title="Property and equipment, estimated useful lives"&gt;20&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p id="xdx_8A9_zz9GmOk7OY67" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Depreciation
expense was $&lt;span id="xdx_908_eus-gaap--Depreciation_c20240101__20241231_zCE9MU3CfcB" title="Depreciation expense"&gt;26,346&lt;/span&gt; and $&lt;span id="xdx_907_eus-gaap--Depreciation_c20230101__20231231_zg5lb62IyG23" title="Depreciation expense"&gt;30,240&lt;/span&gt; during the years ended December 31, 2024 and 2023, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <NRXS:ScheduleOfPropertyPlantAndEquipmentUsefulLivesTableTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000774">&lt;p id="xdx_89D_ecustom--ScheduleOfPropertyPlantAndEquipmentUsefulLivesTableTextBlock_zA63jvQhipj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Depreciation
is calculated using the following estimated useful lives:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B1_zS3Vx59ipME8" style="display: none"&gt;Schedule of Estimated Useful Lives&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; width: 60%; border-collapse: collapse; margin-right: auto"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; width: 79%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Classification&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; width: 19%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Years&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Machinery
    and Equipment &lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_908_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--MachineryAndEquipmentMember__srt--RangeAxis__srt--MinimumMember_zBoCKBqUpo16" title="Property and equipment, estimated useful lives"&gt;7&lt;/span&gt;-&lt;span id="xdx_90B_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--MachineryAndEquipmentMember__srt--RangeAxis__srt--MaximumMember_zs1iIMSzTnZ" title="Property and equipment, estimated useful lives"&gt;10&lt;/span&gt;
    &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Furniture
    and Fixtures&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_906_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember__srt--RangeAxis__srt--MinimumMember_zmPdomKTkuj5" title="Property and equipment, estimated useful lives"&gt;3&lt;/span&gt;-&lt;span id="xdx_90D_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember__srt--RangeAxis__srt--MaximumMember_zMDjRUq42GH8" title="Property and equipment, estimated useful lives"&gt;10&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Computer
    Hardware&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_903_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_zay71H131WJ9" title="Property and equipment, estimated useful lives"&gt;5&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Leasehold
    Improvements&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90F_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember__srt--RangeAxis__srt--MinimumMember_zttmRcV3egyh" title="Property and equipment, estimated useful lives"&gt;10&lt;/span&gt;-&lt;span id="xdx_903_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember__srt--RangeAxis__srt--MaximumMember_zDksIX8dOpz9" title="Property and equipment, estimated useful lives"&gt;20&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
</NRXS:ScheduleOfPropertyPlantAndEquipmentUsefulLivesTableTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="AsOf2024-12-31_us-gaap_MachineryAndEquipmentMember_srt_MinimumMember"
      id="Fact000776">P7Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="AsOf2024-12-31_us-gaap_MachineryAndEquipmentMember_srt_MaximumMember"
      id="Fact000778">P10Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="AsOf2024-12-31_us-gaap_FurnitureAndFixturesMember_srt_MinimumMember"
      id="Fact000780">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="AsOf2024-12-31_us-gaap_FurnitureAndFixturesMember_srt_MaximumMember"
      id="Fact000782">P10Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="AsOf2024-12-31_us-gaap_ComputerEquipmentMember"
      id="Fact000784">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="AsOf2024-12-31_us-gaap_LeaseholdImprovementsMember_srt_MinimumMember"
      id="Fact000786">P10Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="AsOf2024-12-31_us-gaap_LeaseholdImprovementsMember_srt_MaximumMember"
      id="Fact000788">P20Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:Depreciation
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000790"
      unitRef="USD">26346</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000792"
      unitRef="USD">30240</us-gaap:Depreciation>
    <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="From2024-01-01to2024-12-31" id="Fact000794">&lt;p id="xdx_847_eus-gaap--ResearchAndDevelopmentExpensePolicy_zaqJbGezMLz8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_861_z6QRpnJ2AG38"&gt;Research
and Development&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Costs
for research and development are expensed as incurred. Research and development expenses consist primarily of clinical research studies
and new product development.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:IntangibleAssetsFiniteLivedPolicy contextRef="From2024-01-01to2024-12-31" id="Fact000796">&lt;p id="xdx_843_eus-gaap--IntangibleAssetsFiniteLivedPolicy_zGVWfgMVm0Lf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_862_zLVPmPO16MM7"&gt;Intangible
Assets&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Intangible
assets consist of software, patents, a trademark and a license. Intangible assets are stated at their historical cost and amortized on
a straight-line basis over their expected useful lives. Capitalized patent costs, net of accumulated amortization, includes legal costs
incurred for patent applications. In accordance with ASC 350, once a patent is granted, we amortize the capitalized patent costs over
the remaining life of the patent using the straight-line method. If the patent is not granted, we write off any capitalized patent costs
at that time.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company purchased a trademark related to the Company&#x2019;s name for $&lt;span id="xdx_908_eus-gaap--PaymentsToAcquireIntangibleAssets_c20240101__20241231__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_zPy2rZ9bDnpa" title="Payment to acquire intangible assets"&gt;50,000&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;.
The trademark does not have a determinate life and therefore the cost is not being amortized.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company entered into an option agreement on April 12, 2023 to bring an optionor&#x2019;s invention to commercialization via a royalty-bearing
licensing agreement. The agreement required an initial payment of $&lt;span id="xdx_90D_eus-gaap--PaymentsToAcquireIntangibleAssets_c20240101__20241231__us-gaap--TypeOfArrangementAxis__custom--LicensingAgreementMember_zbq2IOfPbfml" title="Payment upon execution"&gt;1,000&lt;/span&gt; and was fully amortized in the year ended December 31, 2024.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Neuraxis,
Inc.&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Notes
to Financial Statements&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;We
review intangible assets for impairment annually or when events or circumstances indicate that their carrying amount may not be recoverable.
During the years ended December 31, 2024, and 2023, the Company recorded no impairment charges for intangible assets.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Amortization
expense was $&lt;span id="xdx_902_eus-gaap--AmortizationOfIntangibleAssets_c20240101__20241231_zHntBXDIkQQh" title="Amortization expense"&gt;11,485&lt;/span&gt; and $&lt;span id="xdx_909_eus-gaap--AmortizationOfIntangibleAssets_c20230101__20231231_z6VW5MqTev6c" title="Amortization expense"&gt;10,485&lt;/span&gt; during the years ended December 31, 2024 and 2023, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:IntangibleAssetsFiniteLivedPolicy>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="From2024-01-012024-12-31_us-gaap_TrademarksMember"
      decimals="0"
      id="Fact000798"
      unitRef="USD">50000</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="From2024-01-012024-12-31_custom_LicensingAgreementMember"
      decimals="0"
      id="Fact000800"
      unitRef="USD">1000</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000802"
      unitRef="USD">11485</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000804"
      unitRef="USD">10485</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000806">&lt;p id="xdx_844_eus-gaap--IncomeTaxPolicyTextBlock_zkgEMdBxd1ml" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_864_zSM75xOhiFEk"&gt;Income
Taxes&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company recognizes deferred tax assets and liabilities for the expected future tax consequences of events that have been included in
the Company&#x2019;s financial statements and tax returns. Deferred tax assets and liabilities are determined based upon the differences
between the financial statement carrying amounts, and the tax bases of existing assets and liabilities for the loss and credit carryforwards
using enacted tax rates expected to be in effect in the year in which the differences are expected to reverse. Deferred tax assets are
reduced by a valuation allowance if it is more likely than not that these assets may not be realized. The Company determines whether
a tax position will be sustained upon examination. If it is more likely than not that a position will be sustained, none of the benefit
attributable to the position is recognized. The tax benefit to be recognized for any tax position that meets the more likely than not
recognition threshold is calculated as &lt;span id="xdx_900_eus-gaap--IncomeTaxExaminationLikelihoodOfUnfavorableSettlement_c20240101__20241231_zhScl8zCptK8" title="Income tax examination, likelihood of unfavorable settlement"&gt;the largest amount that is more than 50% likely of being realized upon resolution of the contingency&lt;/span&gt;.
The Company accounts for interest and penalties related to uncertain tax positions as part of its provision for income taxes.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Management&#x2019;s
evaluation of the Company&#x2019;s deferred tax assets and liabilities did not have a material effect on the Company&#x2019;s financial
statements. Furthermore, &lt;span id="xdx_907_eus-gaap--IncomeTaxExaminationPenaltiesAndInterestAccrued_iI_do_c20241231_ztC0RV1l8oLb" title="Income tax interest or penalties accrued"&gt;&lt;span id="xdx_908_eus-gaap--IncomeTaxExaminationPenaltiesAndInterestAccrued_iI_do_c20231231_zhqBNkKSJdb6" title="Income tax interest or penalties accrued"&gt;no&lt;/span&gt;&lt;/span&gt; interest or penalties have been accrued or charged to expense as of December 31, 2024 and 2023 and for the
years then ended.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:IncomeTaxExaminationLikelihoodOfUnfavorableSettlement contextRef="From2024-01-01to2024-12-31" id="Fact000808">the largest amount that is more than 50% likely of being realized upon resolution of the contingency</us-gaap:IncomeTaxExaminationLikelihoodOfUnfavorableSettlement>
    <us-gaap:IncomeTaxExaminationPenaltiesAndInterestAccrued
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000810"
      unitRef="USD">0</us-gaap:IncomeTaxExaminationPenaltiesAndInterestAccrued>
    <us-gaap:IncomeTaxExaminationPenaltiesAndInterestAccrued
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000812"
      unitRef="USD">0</us-gaap:IncomeTaxExaminationPenaltiesAndInterestAccrued>
    <us-gaap:AdvertisingCostsPolicyTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000814">&lt;p id="xdx_847_eus-gaap--AdvertisingCostsPolicyTextBlock_zo5yvzL87Rx8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_867_zWUOXu7pc5n5"&gt;Advertising
Cost&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Advertising
costs are expensed as incurred and amounted to $&lt;span id="xdx_90F_eus-gaap--AdvertisingExpense_c20240101__20241231__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zHFN1G5pWFd9" title="Advertising cost"&gt;232,125&lt;/span&gt;
and $&lt;span id="xdx_900_eus-gaap--AdvertisingExpense_c20230101__20231231__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zIlntYARjZTf" title="Advertising cost"&gt;192,400&lt;/span&gt; for
the years ended December 31, 2024 and 2023, respectively, and are classified as general and administrative expenses in the
statements of operations.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Neuraxis,
Inc.&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Notes
to Financial Statements&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:AdvertisingCostsPolicyTextBlock>
    <us-gaap:AdvertisingExpense
      contextRef="From2024-01-012024-12-31_us-gaap_GeneralAndAdministrativeExpenseMember"
      decimals="0"
      id="Fact000816"
      unitRef="USD">232125</us-gaap:AdvertisingExpense>
    <us-gaap:AdvertisingExpense
      contextRef="From2023-01-012023-12-31_us-gaap_GeneralAndAdministrativeExpenseMember"
      decimals="0"
      id="Fact000818"
      unitRef="USD">192400</us-gaap:AdvertisingExpense>
    <NRXS:WarrantLiabilityPolicyTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000820">&lt;p id="xdx_848_ecustom--WarrantLiabilityPolicyTextBlock_zaVIsSf1c53d" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_86D_zrlgX8Mm8yia"&gt;Warrant
Liabilities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Management
evaluates all of the Company&#x2019;s financial instruments, including issued warrants to purchase its common stock, to determine if such
instruments are liabilities pursuant to ASC 480 and ASC 815-15. The classification
of derivative financial instruments, including whether such instruments should be recorded as liabilities or as equity, is reassessed
at the end of each reporting period.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company utilizes a Black-Scholes option-pricing model to compute the fair value of the derivative and to mark to market the fair value
of the derivative at each balance sheet date. The inputs utilized in the application of the Black-Scholes option-pricing model included
an exercise price, the stock price as of the valuation date, an expected remaining term of each warrant as of the valuation date, estimated
volatility, a dividend yield, and a risk-free rate. The Company records the change in the fair value of the warrant as other income or
expense in the statements of operations.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</NRXS:WarrantLiabilityPolicyTextBlock>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000822">&lt;p id="xdx_846_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_zuoNDbkmfx99" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_867_zA6yTR80qBQ1"&gt;Fair
Value Measurements&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company accounts for financial instruments in accordance with ASC 820, Fair Value Measurements and Disclosures (&#x201c;ASC 820&#x201d;).
ASC 820 establishes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy
gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and
the lowest priority to unobservable inputs (Level 3 measurements). The three levels of the fair value hierarchy under ASC 820 are described
below:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
1 &#x2013; Quoted prices (unadjusted) for identical unrestricted assets or liabilities in active markets that the reporting entity has
the ability to access as of the measurement date.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
2 &#x2013; Significant other observable inputs other than Level 1 prices such as quoted prices for similar assets or liabilities: quoted
prices in markets that are not active; or financial instruments for which all significant inputs are observable or can be corroborated
by observable market date, either directly or indirectly.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
3 &#x2013; Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets
or liabilities. These unobservable inputs reflect that reporting entity&#x2019;s own assumptions about assumptions that market participants
would use in pricing the asset or liability. Level 3 assets and liabilities include financial instruments whose value is determined using
pricing models, discounted cash flow methodologies, or similar techniques, as well as instruments for which the determination of fair
value require significant management judgment or estimation.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s Level 1 assets/liabilities include cash, accounts receivable, accounts payable, prepaids, and other current assets. Management
believes the estimated fair value of these accounts on December 31, 2024 approximate their carrying value as reflected in the balance
sheets due to the short-term nature of these instruments or the use of market interest rates for debt instruments.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s Level 3 assets/liabilities include warrant liabilities. Inputs to determine fair value are generally unobservable
and typically reflect management&#x2019;s estimates of assumptions that market participants would use in pricing the asset or liability.
The fair values are therefore determined using model-based techniques, including option pricing models and discounted cash flow models.
The valuation techniques involve management&#x2019;s estimates and judgment based on unobservable inputs. The fair value estimates may
not be indicative of the amounts that would be realized in a market exchange. Additionally, there may be inherent uncertainties or changes
in the underlying assumptions used, which could significantly affect the current or future fair value estimates. Unobservable inputs
used in the models are significant to the fair values of the assets and liabilities.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Neuraxis,
Inc.&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Notes
to Financial Statements&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89E_eus-gaap--ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_zSRjCMWMj1w3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table provides a summary of the relevant assets and liabilities that are measured at fair value on a recurring
basis:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B3_z3g9hDaGrTA9" style="display: none"&gt;Schedule
of Fair Value of Assets and Liabilities  measured on Recurring Basis&lt;/span&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_4B9_us-gaap--FairValueByMeasurementFrequencyAxis_us-gaap--FairValueMeasurementsRecurringMember_us-gaap--FinancialInstrumentAxis_us-gaap--WarrantMember_zBZgAXCyF1Vk" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_4B0_us-gaap--FairValueByMeasurementFrequencyAxis_us-gaap--FairValueMeasurementsRecurringMember_us-gaap--FairValueByFairValueHierarchyLevelAxis_us-gaap--FairValueInputsLevel1Member_zDB43ntMIDc2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Level 1&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_4BA_us-gaap--FairValueByMeasurementFrequencyAxis_us-gaap--FairValueMeasurementsRecurringMember_us-gaap--FairValueByFairValueHierarchyLevelAxis_us-gaap--FairValueInputsLevel2Member_z9UbeIrsNMjf" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Level 2&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_4BC_us-gaap--FairValueByMeasurementFrequencyAxis_us-gaap--FairValueMeasurementsRecurringMember_us-gaap--FairValueByFairValueHierarchyLevelAxis_us-gaap--FairValueInputsLevel3Member_zWqguAEicMAk" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Level 3&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;Valuation Methodology&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;Unobservable&lt;br/&gt;
Inputs&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_439_c20241231_eus-gaap--LiabilitiesFairValueDisclosure_iI_z3pBMIl0Qkg3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 23%; text-align: left; padding-bottom: 1pt; padding-left: 0pt"&gt;Fair value of warrant  liabilities as of
    December 31, 2024&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; width: 7%; text-align: right"&gt;9,166&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; width: 7%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0827"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; width: 7%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0828"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; width: 7%; text-align: right"&gt;9,166&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; width: 12%"&gt;Black-Scholes model&lt;/td&gt;
    &lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; width: 17%"&gt;Project simulated cash flows&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_43C_c20231231_eus-gaap--LiabilitiesFairValueDisclosure_iI_z6bHNiK1NE4k" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt; padding-left: 0pt"&gt;Fair value of warrant  liabilities as of
    December 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;8,225&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0832"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0833"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;8,225&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;Black-Scholes model&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;Project simulated cash flows&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_8AF_zDV1NvmR9hqi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;There
were no transfers between any of the levels during the years ended December 31, 2024 and 2023. In addition to assets and liabilities
that are recorded at fair value on a recurring basis, the Company&#x2019;s assets and liabilities are also subject to recurring fair
value measurements. As of December 31, 2024 and 2023, the Company had no assets that were measured on a recurring basis.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000824">&lt;p id="xdx_89E_eus-gaap--ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_zSRjCMWMj1w3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table provides a summary of the relevant assets and liabilities that are measured at fair value on a recurring
basis:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B3_z3g9hDaGrTA9" style="display: none"&gt;Schedule
of Fair Value of Assets and Liabilities  measured on Recurring Basis&lt;/span&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_4B9_us-gaap--FairValueByMeasurementFrequencyAxis_us-gaap--FairValueMeasurementsRecurringMember_us-gaap--FinancialInstrumentAxis_us-gaap--WarrantMember_zBZgAXCyF1Vk" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_4B0_us-gaap--FairValueByMeasurementFrequencyAxis_us-gaap--FairValueMeasurementsRecurringMember_us-gaap--FairValueByFairValueHierarchyLevelAxis_us-gaap--FairValueInputsLevel1Member_zDB43ntMIDc2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Level 1&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_4BA_us-gaap--FairValueByMeasurementFrequencyAxis_us-gaap--FairValueMeasurementsRecurringMember_us-gaap--FairValueByFairValueHierarchyLevelAxis_us-gaap--FairValueInputsLevel2Member_z9UbeIrsNMjf" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Level 2&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_4BC_us-gaap--FairValueByMeasurementFrequencyAxis_us-gaap--FairValueMeasurementsRecurringMember_us-gaap--FairValueByFairValueHierarchyLevelAxis_us-gaap--FairValueInputsLevel3Member_zWqguAEicMAk" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Level 3&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;Valuation Methodology&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;Unobservable&lt;br/&gt;
Inputs&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_439_c20241231_eus-gaap--LiabilitiesFairValueDisclosure_iI_z3pBMIl0Qkg3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 23%; text-align: left; padding-bottom: 1pt; padding-left: 0pt"&gt;Fair value of warrant  liabilities as of
    December 31, 2024&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; width: 7%; text-align: right"&gt;9,166&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; width: 7%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0827"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; width: 7%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0828"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; width: 7%; text-align: right"&gt;9,166&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; width: 12%"&gt;Black-Scholes model&lt;/td&gt;
    &lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; width: 17%"&gt;Project simulated cash flows&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_43C_c20231231_eus-gaap--LiabilitiesFairValueDisclosure_iI_z6bHNiK1NE4k" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt; padding-left: 0pt"&gt;Fair value of warrant  liabilities as of
    December 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;8,225&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0832"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0833"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;8,225&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;Black-Scholes model&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;Project simulated cash flows&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="AsOf2024-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_WarrantMember"
      decimals="0"
      id="Fact000826"
      unitRef="USD">9166</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="AsOf2024-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel3Member"
      decimals="0"
      id="Fact000829"
      unitRef="USD">9166</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="AsOf2023-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_WarrantMember"
      decimals="0"
      id="Fact000831"
      unitRef="USD">8225</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="AsOf2023-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel3Member"
      decimals="0"
      id="Fact000834"
      unitRef="USD">8225</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000836">&lt;p id="xdx_843_eus-gaap--EarningsPerSharePolicyTextBlock_z3Z5xHrFvPnb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_868_zRILTRgfzVRf"&gt;Basic
and Diluted Net Income (Loss) per Share&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Basic
earnings or loss per share (&#x201c;EPS&#x201d;) is computed by dividing net income (loss), net of preferred stock dividends, by the
weighted average number of common shares outstanding during the period. Diluted EPS is determined using the weighted average number
of common shares outstanding during the period, adjusted for the dilutive effect of common stock equivalents that were outstanding
for the periods presented. In periods when losses are reported, which is the case for December 31, 2024 and 2023 presented in these
financial statements, the weighted average number of common shares outstanding excludes common stock equivalents because their
inclusion would be anti-dilutive. Preferred stock dividends (neither declared nor paid) were $&lt;span id="xdx_90F_eus-gaap--DividendsPreferredStock_c20240101__20241231_zMa5zOaCz0dh" title="Preferred stock dividend"&gt;211,268&lt;/span&gt;
and $&lt;span id="xdx_906_eus-gaap--DividendsPreferredStock_dxL_c20230101__20231231_zCKOVIyQCu2e" title="Preferred stock dividend::XDX::-"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0840"&gt;0&lt;/span&gt;&lt;/span&gt;
as of December 31, 2024 and 2023, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Neuraxis,
Inc.&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Notes
to Financial Statements&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_894_eus-gaap--ScheduleOfEarningsPerShareDilutedByCommonClassTextBlock_zQrWqPsSpLsb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company had the following potentially dilutive common stock equivalents at December 31, 2024 and 2023:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8BC_zox9NmqQpub9" style="display: none"&gt;Schedule of Dilutive Common Stock Equivalents&lt;/span&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_494_20240101__20241231_zCfMhiwPQpEd" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49E_20230101__20231231_zb3LNMgKs5Qd" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--OptionMember_z2YvJ0OOXEw7" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%"&gt;Options&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;1,319,394&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;1,319,394&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--CommonStockMember_z4IBT9gvKFCb" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Pre-Funded Warrants for Common Stock&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;289,779&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0848"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--WarrantsMember_zm2CD0h3eBoj" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Warrants&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,352,751&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,822,358&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--SeriesBPreferredStockMember_zPVzzRS4kdql" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Series B Preferred Stock&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;4,280,939&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0854"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_zswUml38NNc9" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt; padding-left: 10pt"&gt;Totals&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;8,242,863&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;3,141,752&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AE_zZkRPjMKhCOg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89D_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_zX3d573GQcn8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table shows the calculation of the basic and diluted net loss per share and the effect of preferred stock dividends.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8BC_zXyehy2Q4OB7" style="display: none"&gt;Schedule of Basic and Diluted Net Loss Per Share&lt;/span&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49E_20240101__20241231_zkLWbBazjZl2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_493_20230101__20231231_zPg30jDzserk" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;For the Years Ended December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Numerator&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--NetIncomeLoss_iT_mtNILzQKI_zp3QgJK7iOg" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 60%; text-align: left; padding-left: 10pt"&gt;Net loss&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;(8,241,501&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;(14,626,683&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--DividendsPreferredStock_iN_di_zqUV04SEGgVl" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt; padding-left: 10pt"&gt;Preferred stock dividends&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(211,268&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0865"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_zqBPWqst7E72" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Net loss available to common stockholders&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(8,452,769&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(14,626,683&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Denominator&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt; padding-left: 20pt"&gt;Weighted-average shares of common stock outstanding - basic and diluted&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_903_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20240101__20241231_z6adsR0YsnZ9" title="Weighted average shares of common stock outstanding - basic"&gt;&lt;span id="xdx_901_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20240101__20241231_zco5F3MbpLAc" title="Weighted average shares of common stock outstanding - diluted"&gt;6,918,887&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_900_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20230101__20231231_zpa3Fn0QmNfb" title="Weighted average shares of common stock outstanding - basic"&gt;&lt;span id="xdx_903_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20230101__20231231_zRyq1dOtor4d" title="Weighted average shares of common stock outstanding - diluted"&gt;3,252,328&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Basic and diluted net loss per share&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_90E_eus-gaap--EarningsPerShareBasic_c20240101__20241231_zrz21PRWjGCl" title="Basic net loss per share"&gt;&lt;span id="xdx_90F_eus-gaap--EarningsPerShareDiluted_c20240101__20241231_zIgmac8dw9Ed" title="Diluted net loss per share"&gt;(1.22&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_908_eus-gaap--EarningsPerShareBasic_c20230101__20231231_z2hMbWcceUqg" title="Basic net loss per share"&gt;&lt;span id="xdx_905_eus-gaap--EarningsPerShareDiluted_c20230101__20231231_z96vWnNsnYxe" title="Diluted net loss per share"&gt;(4.50&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AF_z8OuXYGzkAE7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:DividendsPreferredStock
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000838"
      unitRef="USD">211268</us-gaap:DividendsPreferredStock>
    <us-gaap:ScheduleOfEarningsPerShareDilutedByCommonClassTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000842">&lt;p id="xdx_894_eus-gaap--ScheduleOfEarningsPerShareDilutedByCommonClassTextBlock_zQrWqPsSpLsb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company had the following potentially dilutive common stock equivalents at December 31, 2024 and 2023:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8BC_zox9NmqQpub9" style="display: none"&gt;Schedule of Dilutive Common Stock Equivalents&lt;/span&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_494_20240101__20241231_zCfMhiwPQpEd" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49E_20230101__20231231_zb3LNMgKs5Qd" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--OptionMember_z2YvJ0OOXEw7" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%"&gt;Options&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;1,319,394&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;1,319,394&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--CommonStockMember_z4IBT9gvKFCb" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Pre-Funded Warrants for Common Stock&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;289,779&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0848"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--WarrantsMember_zm2CD0h3eBoj" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Warrants&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,352,751&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,822,358&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--SeriesBPreferredStockMember_zPVzzRS4kdql" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Series B Preferred Stock&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;4,280,939&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0854"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_zswUml38NNc9" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt; padding-left: 10pt"&gt;Totals&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;8,242,863&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;3,141,752&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfEarningsPerShareDilutedByCommonClassTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2024-01-012024-12-31_us-gaap_OptionMember"
      decimals="INF"
      id="Fact000844"
      unitRef="Shares">1319394</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2023-01-012023-12-31_us-gaap_OptionMember"
      decimals="INF"
      id="Fact000845"
      unitRef="Shares">1319394</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember47706312"
      decimals="INF"
      id="Fact000847"
      unitRef="Shares">289779</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2024-01-012024-12-31_custom_WarrantsMember"
      decimals="INF"
      id="Fact000850"
      unitRef="Shares">2352751</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2023-01-012023-12-31_custom_WarrantsMember"
      decimals="INF"
      id="Fact000851"
      unitRef="Shares">1822358</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2024-01-012024-12-31_us-gaap_SeriesBPreferredStockMember"
      decimals="INF"
      id="Fact000853"
      unitRef="Shares">4280939</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2024-01-01to2024-12-31"
      decimals="INF"
      id="Fact000856"
      unitRef="Shares">8242863</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2023-01-012023-12-31"
      decimals="INF"
      id="Fact000857"
      unitRef="Shares">3141752</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000859">&lt;p id="xdx_89D_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_zX3d573GQcn8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table shows the calculation of the basic and diluted net loss per share and the effect of preferred stock dividends.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8BC_zXyehy2Q4OB7" style="display: none"&gt;Schedule of Basic and Diluted Net Loss Per Share&lt;/span&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49E_20240101__20241231_zkLWbBazjZl2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_493_20230101__20231231_zPg30jDzserk" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;For the Years Ended December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Numerator&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--NetIncomeLoss_iT_mtNILzQKI_zp3QgJK7iOg" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 60%; text-align: left; padding-left: 10pt"&gt;Net loss&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;(8,241,501&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;(14,626,683&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--DividendsPreferredStock_iN_di_zqUV04SEGgVl" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt; padding-left: 10pt"&gt;Preferred stock dividends&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(211,268&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0865"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_zqBPWqst7E72" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Net loss available to common stockholders&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(8,452,769&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(14,626,683&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Denominator&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt; padding-left: 20pt"&gt;Weighted-average shares of common stock outstanding - basic and diluted&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_903_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20240101__20241231_z6adsR0YsnZ9" title="Weighted average shares of common stock outstanding - basic"&gt;&lt;span id="xdx_901_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20240101__20241231_zco5F3MbpLAc" title="Weighted average shares of common stock outstanding - diluted"&gt;6,918,887&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_900_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20230101__20231231_zpa3Fn0QmNfb" title="Weighted average shares of common stock outstanding - basic"&gt;&lt;span id="xdx_903_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20230101__20231231_zRyq1dOtor4d" title="Weighted average shares of common stock outstanding - diluted"&gt;3,252,328&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Basic and diluted net loss per share&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_90E_eus-gaap--EarningsPerShareBasic_c20240101__20241231_zrz21PRWjGCl" title="Basic net loss per share"&gt;&lt;span id="xdx_90F_eus-gaap--EarningsPerShareDiluted_c20240101__20241231_zIgmac8dw9Ed" title="Diluted net loss per share"&gt;(1.22&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_908_eus-gaap--EarningsPerShareBasic_c20230101__20231231_z2hMbWcceUqg" title="Basic net loss per share"&gt;&lt;span id="xdx_905_eus-gaap--EarningsPerShareDiluted_c20230101__20231231_z96vWnNsnYxe" title="Diluted net loss per share"&gt;(4.50&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000861"
      unitRef="USD">-8241501</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000862"
      unitRef="USD">-14626683</us-gaap:NetIncomeLoss>
    <us-gaap:DividendsPreferredStock
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000864"
      unitRef="USD">211268</us-gaap:DividendsPreferredStock>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000867"
      unitRef="USD">-8452769</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000868"
      unitRef="USD">-14626683</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2024-01-01to2024-12-31"
      decimals="INF"
      id="Fact000870"
      unitRef="Shares">6918887</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2024-01-01to2024-12-31"
      decimals="INF"
      id="Fact000872"
      unitRef="Shares">6918887</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2023-01-012023-12-31"
      decimals="INF"
      id="Fact000874"
      unitRef="Shares">3252328</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2023-01-012023-12-31"
      decimals="INF"
      id="Fact000876"
      unitRef="Shares">3252328</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2024-01-01to2024-12-31"
      decimals="INF"
      id="Fact000878"
      unitRef="USDPShares">-1.22</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2024-01-01to2024-12-31"
      decimals="INF"
      id="Fact000880"
      unitRef="USDPShares">-1.22</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2023-01-012023-12-31"
      decimals="INF"
      id="Fact000882"
      unitRef="USDPShares">-4.50</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2023-01-012023-12-31"
      decimals="INF"
      id="Fact000884"
      unitRef="USDPShares">-4.50</us-gaap:EarningsPerShareDiluted>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="From2024-01-01to2024-12-31" id="Fact000886">&lt;p id="xdx_848_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_zuHjXlK84ss5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_862_zfwsy8KpLtyk"&gt;Stock-Based
Compensation&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company accounts for all stock-based awards at fair value. The Company recognizes its stock-based compensation expense using the straight-line
method. Compensation cost is not adjusted for estimated forfeitures, but instead is adjusted upon an actual forfeiture.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company accounts for the granting of stock options and restricted stock units to employees and non-employees using the fair value method
whereby all awards are measured at fair value on the date of the grant. The fair value of all employee stock options and restricted stock
units is expensed over the requisite service period with a corresponding increase to additional paid-in capital. Upon exercise of stock
options, the consideration paid by the option holder is recorded in additional paid-in capital, while the par value of the shares received
is reclassified from additional paid-in-capital to common stock. Upon vesting of restricted stock units, the par value of the shares
issued are reclassified from additional paid-in-capital to common stock.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Stock-based
awards to non-employees are measured based on the fair value of the equity instrument issued. Compensation expense for non-employee stock
awards is recognized over the requisite service period following the measurement of the fair value on the grant date.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company uses the Black-Scholes option-pricing model to calculate the fair value of stock options. The use of the Black-Scholes option-pricing
model requires management to make assumptions with respect to the expected term of the option, the expected volatility of the common
stock consistent with the expected term of the option, risk-free interest rates, the value of the common stock and expected dividend
yield of the common stock. Changes in these assumptions can materially affect the fair value estimate.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Neuraxis,
Inc.&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Notes
to Financial Statements&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:RevenueRecognitionPolicyTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000888">&lt;p id="xdx_843_eus-gaap--RevenueRecognitionPolicyTextBlock_zbJsYb6ra5wg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_862_zPNGdCffZD65"&gt;Revenue
Recognition&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
accordance with FASB&#x2019;s ASC 606, &lt;i&gt;Revenue from Contracts with Customers&lt;/i&gt;, (&#x201c;ASC 606&#x201d;), the Company recognizes revenue
when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the Company expects
to be entitled in exchange for those goods or services. To determine revenue recognition for arrangements that the Company determines
are within the scope of ASC 606, it performs the following five steps:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(i)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;identify
    the contract(s) with a customer&#x37e;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(ii)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;identify
    the performance obligations in the contract&#x37e;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(iii)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;determine
    the transaction price&#x37e;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(iv)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;allocate
    the transaction price to the performance obligations in the contract&#x37e; and&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(v)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;recognize
    revenue when (or as) the entity satisfies a performance obligation.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company applies the five-step model to contracts when it determines that it is probable it will collect substantially all the consideration
it is entitled to in exchange for the goods or services it transfers to the customer. At contract inception, once the contract is determined
to be within the scope of ASC 606, the Company assesses the goods or services promised within each contract and determines those that
are performance obligations and assesses whether each promised good or service is distinct. The Company then recognizes as revenue the
amount of the transaction price, after consideration of variability and constraints, if any, that is allocated to the respective performance
obligation when the performance obligation is satisfied.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company estimates credit losses on accounts receivable by utilizing an aging schedule.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company offers a Patient Assistance Program for patients without insurance coverage for IB-Stim. This program offers potential self-pay
discounts for IB-Stim devices, based upon household income and size.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Also,
the Company offers providers an opt-in program to address adequate insurance claim payments on IB-Stim devices. This program may extend
a rebate or invoice credit where the insurance payment and patient responsibility (i.e., deductible, co-payment, and/or co-insurance
amounts required by the Payer) are less than the acquisition cost of the IB-Stim device. The Company recognizes revenue at such a time
that collection of the amount due is assured.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89B_eus-gaap--DisaggregationOfRevenueTableTextBlock_z51iF5FwY8Ik" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table disaggregates the Company&#x2019;s revenue based on the customer&#x2019;s location by state for the years ended December
31:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B7_zFnT94CGa2N4" style="display: none"&gt;Schedule of Disaggregation of Revenue&lt;/span&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 60%; margin-right: auto"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 20%"&gt;California&lt;/td&gt;&lt;td style="width: 2%; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--Revenues_c20240101__20241231__srt--StatementGeographicalAxis__stpr--CA_ztWpMGR6FjK" style="width: 16%; font-weight: bold; text-align: right" title="Revenues"&gt;778,209&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--Revenues_c20230101__20231231__srt--StatementGeographicalAxis__stpr--CA_zhaa1ANY8XF7" style="width: 16%; text-align: right" title="Revenues"&gt;601,235&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Ohio&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--Revenues_c20240101__20241231__srt--StatementGeographicalAxis__stpr--OH_z8HHuDbKCMGd" style="font-weight: bold; text-align: right" title="Revenues"&gt;431,328&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--Revenues_c20230101__20231231__srt--StatementGeographicalAxis__stpr--OH_zzOMNsxW8pak" style="text-align: right" title="Revenues"&gt;407,632&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Illinois&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--Revenues_c20240101__20241231__srt--StatementGeographicalAxis__stpr--IL_zb6kZssrfWfe" style="font-weight: bold; text-align: right" title="Revenues"&gt;246,217&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--Revenues_c20230101__20231231__srt--StatementGeographicalAxis__stpr--IL_zWDTnM17q319" style="text-align: right" title="Revenues"&gt;117,963&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Wisconsin&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--Revenues_c20240101__20241231__srt--StatementGeographicalAxis__stpr--WI_z3428iyridQh" style="font-weight: bold; text-align: right" title="Revenues"&gt;157,786&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--Revenues_c20230101__20231231__srt--StatementGeographicalAxis__stpr--WI_zGxpKPV1TjK7" style="text-align: right" title="Revenues"&gt;292,601&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Massachusetts&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--Revenues_c20240101__20241231__srt--StatementGeographicalAxis__stpr--MA_zasnvjzBkL05" style="font-weight: bold; text-align: right" title="Revenues"&gt;154,407&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--Revenues_c20230101__20231231__srt--StatementGeographicalAxis__stpr--MA_zKTfMKrP2Fwk" style="text-align: right" title="Revenues"&gt;127,300&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Florida&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--Revenues_c20240101__20241231__srt--StatementGeographicalAxis__stpr--FL_zjSSE7PnWXPh" style="font-weight: bold; text-align: right" title="Revenues"&gt;149,985&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--Revenues_c20230101__20231231__srt--StatementGeographicalAxis__stpr--FL_z0AEkB7FcCsg" style="text-align: right" title="Revenues"&gt;186,840&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;All other states&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--Revenues_c20240101__20241231__srt--StatementGeographicalAxis__custom--AllOtherStatesMember_zhSbHj7bt2ag" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right" title="Revenues"&gt;767,993&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--Revenues_c20230101__20231231__srt--StatementGeographicalAxis__custom--AllOtherStatesMember_zVzeZm5mSkih" style="border-bottom: Black 1pt solid; text-align: right" title="Revenues"&gt;726,478&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--Revenues_c20240101__20241231_z8xgf1LC4xKf" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right" title="Revenues"&gt;2,685,925&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--Revenues_c20230101__20231231_zCiswA2OlDda" style="border-bottom: Black 1pt solid; text-align: right" title="Revenues"&gt;2,460,049&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A0_zvTYoR5sc9Ua" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Certain
economic factors affect the nature, amount, timing, and uncertainty of the Company&#x2019;s revenue and cash flows. All of the Company&#x2019;s
products are sold to healthcare customers including hospitals and clinics. Sales to healthcare customers lack seasonality and have a
mild correlation with economic cycles. All of the Company&#x2019;s sales are to customers located within the United States. Sales contracts
consist of purchase orders that are short-term (i.e., less than or equal to one year).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Neuraxis,
Inc.&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Notes
to Financial Statements&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company typically satisfies its performance obligations for goods at a point in time as they are received at the customer&#x2019;s
destination (rather than over time). Goods are shipped by common carrier to customers under FOB destination terms. As such,
ownership of goods in transit is transferred to the customer upon receipt as the Company bears the associated risks (e.g., loss,
damage, delay). Management typically relies on shipping information from common carriers to evaluate when the
customer has obtained control of the goods. Shipping and handling costs are recorded as Cost of Goods Sold in the Statements of
Operations.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s contracts with customers typically do not involve variable consideration. The information that the Company uses to determine
the transaction price for a contract is similar to the information that the Company&#x2019;s management uses in establishing the prices
of goods to be sold.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Orders
may not be cancelled after shipment. Customers may return devices within 10 days of delivery if the goods are found to be defective,
nonconforming, or otherwise do not meet the stated technical specifications. At the option of the customer, the Company shall either:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Refund
    the price paid for any defective or nonconforming products.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Supply
    and deliver to the customer replacement conforming products.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Reimburse
    the customer for the cost of repairing any defective or nonconforming products.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;At
the time revenue is recognized, the Company estimates expected returns and excludes those amounts from revenue. The Company also
maintains appropriate accounts to reflect the effects of expected returns on the Company&#x2019;s financial position and periodically
adjusts those accounts to reflect its actual return experience. Estimated returns totaled&lt;/span&gt; $&lt;span id="xdx_908_eus-gaap--ContractWithCustomerLiabilityRevenueRecognized_c20240101__20241231_zBqEO4HnlF7c" title="Estimated returns of revenue"&gt;5,000&lt;/span&gt; and $&lt;span id="xdx_90C_eus-gaap--ContractWithCustomerLiabilityRevenueRecognized_c20230101__20231231_zt5BroE5J4dl" title="Estimated returns of revenue"&gt;0&lt;/span&gt; as of December 31,
2024 and 2023, respectively.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Payment
for goods sold by the Company is typically due after an invoice is sent to the customer, within 30 days. The Company does not offer discounts
if the customer pays some or all of an invoiced amount prior to the due date. None of the Company&#x2019;s contracts have a significant
financing component.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Medical
devices that the Company contracts to sell and transfer to customers are manufactured by one specific third-party manufacturer located
within the state of Indiana. In no case does the Company act as an agent (i.e., the Company does not provide a service of arranging for
another party to transfer goods to the customer).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Neuraxis,
Inc.&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Notes
to Financial Statements&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:RevenueRecognitionPolicyTextBlock>
    <us-gaap:DisaggregationOfRevenueTableTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000890">&lt;p id="xdx_89B_eus-gaap--DisaggregationOfRevenueTableTextBlock_z51iF5FwY8Ik" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table disaggregates the Company&#x2019;s revenue based on the customer&#x2019;s location by state for the years ended December
31:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B7_zFnT94CGa2N4" style="display: none"&gt;Schedule of Disaggregation of Revenue&lt;/span&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 60%; margin-right: auto"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 20%"&gt;California&lt;/td&gt;&lt;td style="width: 2%; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--Revenues_c20240101__20241231__srt--StatementGeographicalAxis__stpr--CA_ztWpMGR6FjK" style="width: 16%; font-weight: bold; text-align: right" title="Revenues"&gt;778,209&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--Revenues_c20230101__20231231__srt--StatementGeographicalAxis__stpr--CA_zhaa1ANY8XF7" style="width: 16%; text-align: right" title="Revenues"&gt;601,235&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Ohio&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--Revenues_c20240101__20241231__srt--StatementGeographicalAxis__stpr--OH_z8HHuDbKCMGd" style="font-weight: bold; text-align: right" title="Revenues"&gt;431,328&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--Revenues_c20230101__20231231__srt--StatementGeographicalAxis__stpr--OH_zzOMNsxW8pak" style="text-align: right" title="Revenues"&gt;407,632&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Illinois&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--Revenues_c20240101__20241231__srt--StatementGeographicalAxis__stpr--IL_zb6kZssrfWfe" style="font-weight: bold; text-align: right" title="Revenues"&gt;246,217&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--Revenues_c20230101__20231231__srt--StatementGeographicalAxis__stpr--IL_zWDTnM17q319" style="text-align: right" title="Revenues"&gt;117,963&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Wisconsin&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--Revenues_c20240101__20241231__srt--StatementGeographicalAxis__stpr--WI_z3428iyridQh" style="font-weight: bold; text-align: right" title="Revenues"&gt;157,786&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--Revenues_c20230101__20231231__srt--StatementGeographicalAxis__stpr--WI_zGxpKPV1TjK7" style="text-align: right" title="Revenues"&gt;292,601&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Massachusetts&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--Revenues_c20240101__20241231__srt--StatementGeographicalAxis__stpr--MA_zasnvjzBkL05" style="font-weight: bold; text-align: right" title="Revenues"&gt;154,407&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--Revenues_c20230101__20231231__srt--StatementGeographicalAxis__stpr--MA_zKTfMKrP2Fwk" style="text-align: right" title="Revenues"&gt;127,300&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Florida&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--Revenues_c20240101__20241231__srt--StatementGeographicalAxis__stpr--FL_zjSSE7PnWXPh" style="font-weight: bold; text-align: right" title="Revenues"&gt;149,985&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--Revenues_c20230101__20231231__srt--StatementGeographicalAxis__stpr--FL_z0AEkB7FcCsg" style="text-align: right" title="Revenues"&gt;186,840&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;All other states&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--Revenues_c20240101__20241231__srt--StatementGeographicalAxis__custom--AllOtherStatesMember_zhSbHj7bt2ag" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right" title="Revenues"&gt;767,993&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--Revenues_c20230101__20231231__srt--StatementGeographicalAxis__custom--AllOtherStatesMember_zVzeZm5mSkih" style="border-bottom: Black 1pt solid; text-align: right" title="Revenues"&gt;726,478&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--Revenues_c20240101__20241231_z8xgf1LC4xKf" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right" title="Revenues"&gt;2,685,925&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--Revenues_c20230101__20231231_zCiswA2OlDda" style="border-bottom: Black 1pt solid; text-align: right" title="Revenues"&gt;2,460,049&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:DisaggregationOfRevenueTableTextBlock>
    <us-gaap:Revenues
      contextRef="From2024-01-012024-12-31_stpr_CA"
      decimals="0"
      id="Fact000892"
      unitRef="USD">778209</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2023-01-012023-12-31_stpr_CA"
      decimals="0"
      id="Fact000894"
      unitRef="USD">601235</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2024-01-012024-12-31_stpr_OH"
      decimals="0"
      id="Fact000896"
      unitRef="USD">431328</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2023-01-012023-12-31_stpr_OH"
      decimals="0"
      id="Fact000898"
      unitRef="USD">407632</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2024-01-012024-12-31_stpr_IL"
      decimals="0"
      id="Fact000900"
      unitRef="USD">246217</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2023-01-012023-12-31_stpr_IL"
      decimals="0"
      id="Fact000902"
      unitRef="USD">117963</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2024-01-012024-12-31_stpr_WI"
      decimals="0"
      id="Fact000904"
      unitRef="USD">157786</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2023-01-012023-12-31_stpr_WI"
      decimals="0"
      id="Fact000906"
      unitRef="USD">292601</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2024-01-012024-12-31_stpr_MA"
      decimals="0"
      id="Fact000908"
      unitRef="USD">154407</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2023-01-012023-12-31_stpr_MA"
      decimals="0"
      id="Fact000910"
      unitRef="USD">127300</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2024-01-012024-12-31_stpr_FL"
      decimals="0"
      id="Fact000912"
      unitRef="USD">149985</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2023-01-012023-12-31_stpr_FL"
      decimals="0"
      id="Fact000914"
      unitRef="USD">186840</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2024-01-012024-12-31_custom_AllOtherStatesMember"
      decimals="0"
      id="Fact000916"
      unitRef="USD">767993</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2023-01-012023-12-31_custom_AllOtherStatesMember"
      decimals="0"
      id="Fact000918"
      unitRef="USD">726478</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000920"
      unitRef="USD">2685925</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000922"
      unitRef="USD">2460049</us-gaap:Revenues>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000924"
      unitRef="USD">5000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000926"
      unitRef="USD">0</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:LesseeLeasesPolicyTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000928">&lt;p id="xdx_846_eus-gaap--LesseeLeasesPolicyTextBlock_zFGApbXnaIf2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_862_zlz6TSsaBUBh"&gt;Leases&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
accordance with Accounting Standards Updated (&#x201c;ASU&#x201d;) No. 2016-02, &lt;i&gt;Leases (Topic 842)&lt;/i&gt; (&#x201c;ASU 2016-02&#x201d; or
&#x201c;ASC 842&#x201d;), at the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based
on the unique facts and circumstances present in the arrangement. Leases with a term greater than one year are recognized on the balance
sheet as right-of-use assets and current and non-current lease liabilities, as applicable.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Operating
lease liabilities and their corresponding right-of-use assets are initially recorded based on the present value of lease payments over
the expected remaining lease term. Certain adjustments to the right-of-use asset may be required for items such as incentives received.
The interest rate implicit in lease contracts is typically not readily determinable. As a result, the Company utilizes its incremental
borrowing rate to discount lease payments, which reflects the fixed rate at which the Company could borrow on a collateralized basis
the amount of the lease payments in the same currency, for a similar term, in a similar economic environment. Prospectively, the Company
will adjust the right-of-use assets for straight-line rent expense, or any incentives received and remeasure the lease liability at the
net present value using the same incremental borrowing rate that was in effect as of the lease commencement or transition date. The Company
has elected not to recognize leases with an original term of one year or less on the balance sheet. The Company typically only includes
an initial lease term in its assessment of a lease arrangement. Options to renew a lease are not included in the Company&#x2019;s assessment
unless there is reasonable certainty that the Company will renew.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Assumptions
made by the Company at the commencement date are re-evaluated upon occurrence of certain events, including a lease modification. A lease
modification results in a separate contract when the modification grants the lessee an additional right of use not included in the original
lease and when lease payments increase commensurate with the standalone price for the additional right of use. When a lease modification
results in a separate contract, it is accounted for in the same manner as a new lease.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Entities
may elect not to separate lease and non-lease components. The Company has elected to account for lease and non-lease components together
as a single lease component for all underlying assets and allocate all the contract consideration to the lease component only.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Neuraxis,
Inc.&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Notes
to Financial Statements&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000930">&lt;p id="xdx_84C_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_zBrdlPiMtEtd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_864_z3HRppsuDOqc"&gt;Impairment
of Long-Lived Assets&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Long-lived
assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset group may
not be recoverable. If events or changes in circumstances indicate that the carrying amount of an asset group may not be recoverable,
we compare the carrying amount of the asset group to future undiscounted net cash flows, excluding interest costs, expected to be generated
by the asset group and their ultimate disposition. If the sum of the undiscounted cash flows is less than the carrying value, the impairment
to be recognized is measured by the amount by which the carrying amount of the asset group exceeds the fair value of the asset group.
Assets to be disposed of are reported at the lower of the carrying amount or fair value, less costs to sell.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <us-gaap:ConcentrationRiskCreditRisk contextRef="From2024-01-01to2024-12-31" id="Fact000932">&lt;p id="xdx_84A_eus-gaap--ConcentrationRiskCreditRisk_znCEHkM7M1r6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_865_zp8VPiZFHkLc"&gt;Concentrations
of Credit Risk&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s business activity consists of the sale of medical neuromodulation devices to doctors, clinics, and hospitals across
the country. Receivables consist of unsecured amounts due from customers. The table below sets forth the Company&#x2019;s customers
that accounted for greater than 10% of its net accounts receivable for the years ended December 31, 2024 and 2023,
respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_898_eus-gaap--SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_zUwJC7G3vMd4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span id="xdx_8BF_ziuviCdUkIG6" style="display: none"&gt;Schedule of Customer Accounts Receivable&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Percentage
    of Net Accounts&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Percentage
    of Net Accounts&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Receivable&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt; Receivable&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 36%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Customer
    A&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--AccountsReceivableNet_iI_c20241231__srt--MajorCustomersAxis__custom--CustomerAMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zGVtJHY4ngni" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right" title="Net accounts receivable"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;119,616&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90A_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20240101__20241231__srt--MajorCustomersAxis__custom--CustomerAMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_ztfwx0Pn3dvb" title="Risk percentage"&gt;49&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--AccountsReceivableNet_iI_c20231231__srt--MajorCustomersAxis__custom--CustomerAMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zKXzKALlmJz7" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right" title="Net accounts receivable"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0940"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_901_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20231231__srt--MajorCustomersAxis__custom--CustomerAMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_z9o22JCbwIjb" title="Risk percentage"&gt;0&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Customer
    B&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--AccountsReceivableNet_iI_c20241231__srt--MajorCustomersAxis__custom--CustomerBMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zR77yBuhHffb" style="font: bold 10pt Times New Roman, Times, Serif; text-align: right" title="Net accounts receivable"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0944"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_905_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20240101__20241231__srt--MajorCustomersAxis__custom--CustomerBMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_z9SVmlN18mH9" title="Risk percentage"&gt;0&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--AccountsReceivableNet_iI_c20231231__srt--MajorCustomersAxis__custom--CustomerBMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zDCakzXb5lvc" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Net accounts receivable"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;23,900&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90A_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20231231__srt--MajorCustomersAxis__custom--CustomerBMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zYReW668WMIf" title="Risk percentage"&gt;28&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Customer
    C&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--AccountsReceivableNet_iI_c20241231__srt--MajorCustomersAxis__custom--CustomerCMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zECBJOkoPFzh" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Net accounts receivable"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;22,799&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_907_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20240101__20241231__srt--MajorCustomersAxis__custom--CustomerCMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zCoq7BCeaAUd" title="Risk percentage"&gt;9&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--AccountsReceivableNet_iI_c20231231__srt--MajorCustomersAxis__custom--CustomerCMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zSmayTQpiaTa" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Net accounts receivable"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;14,401&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90D_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20231231__srt--MajorCustomersAxis__custom--CustomerCMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_z058r726xm0j" title="Risk percentage"&gt;17&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Customer
    D&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--AccountsReceivableNet_iI_c20241231__srt--MajorCustomersAxis__custom--CustomerDMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_ziWgXs4rhsT5" style="font: bold 10pt Times New Roman, Times, Serif; text-align: right" title="Net accounts receivable"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0960"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_905_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20240101__20241231__srt--MajorCustomersAxis__custom--CustomerDMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zSEvYV8lKLbh" title="Risk percentage"&gt;0&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--AccountsReceivableNet_iI_c20231231__srt--MajorCustomersAxis__custom--CustomerDMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zgOcWsNkjKF1" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Net accounts receivable"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;23,982&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_909_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20231231__srt--MajorCustomersAxis__custom--CustomerDMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zlZgVpBjp056" title="Risk percentage"&gt;28&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;%&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Customer
    E&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--AccountsReceivableNet_iI_c20241231__srt--MajorCustomersAxis__custom--CustomerEMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zl2qNb56zJwh" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right" title="Net accounts receivable"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0968"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90F_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20240101__20241231__srt--MajorCustomersAxis__custom--CustomerEMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zqDT0bFj4H1k" title="Risk percentage"&gt;0&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--AccountsReceivableNet_iI_c20231231__srt--MajorCustomersAxis__custom--CustomerEMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zwaoP8QxF9Bf" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Net accounts receivable"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;9,599&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_901_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20231231__srt--MajorCustomersAxis__custom--CustomerEMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zyXKzz43jjZf" title="Risk percentage"&gt;11&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--AccountsReceivableNet_iI_c20241231__srt--MajorCustomersAxis__custom--CustomerMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_z1Hroo9j0F5k" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Net accounts receivable"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;142,415&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_902_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20240101__20241231__srt--MajorCustomersAxis__custom--CustomerMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zvYJPTm3tgrf" title="Risk percentage"&gt;58&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--AccountsReceivableNet_iI_c20231231__srt--MajorCustomersAxis__custom--CustomerMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_z3M4Bf5OFDta" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Net accounts receivable"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;71,882&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_906_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20231231__srt--MajorCustomersAxis__custom--CustomerMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zHYTFLfnmKr" title="Risk percentage"&gt;84&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p id="xdx_8AC_zCXEfpOPYya" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
table below sets forth the Company&#x2019;s customers that accounted for greater than 10% of its net sales for the years ended
December 31, 2024 and 2023, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_896_eus-gaap--ContractWithCustomerAssetAllowanceForCreditLossTableTextBlock_zkkwaR2En4R4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span id="xdx_8BA_z9EQpd6TmZ1d" style="display: none"&gt;Schedule of Customers Accounted Revenues&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Percentage of&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Percentage of&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Net Sales&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Net Sales&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 36%; text-align: left"&gt;Customer A&lt;/td&gt;&lt;td style="width: 2%; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20240101__20241231__srt--MajorCustomersAxis__custom--CustomerAMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zhKwbiXDFFs3" style="width: 12%; font-weight: bold; text-align: right" title="Revenue"&gt;521,810&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&lt;span id="xdx_903_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20240101__20241231__srt--MajorCustomersAxis__custom--CustomerAMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zklF9jeBuOtg" title="Risk percentage"&gt;20&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20230101__20231231__srt--MajorCustomersAxis__custom--CustomerAMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zHFwu8jqdfzh" style="width: 12%; text-align: right" title="Revenue"&gt;452,680&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&lt;span id="xdx_908_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20231231__srt--MajorCustomersAxis__custom--CustomerAMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zUGo6Jpa5fgl" title="Risk percentage"&gt;18&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Customer B&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20240101__20241231__srt--MajorCustomersAxis__custom--CustomerBMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zbvEOGjsePt8" style="font-weight: bold; text-align: right" title="Revenue"&gt;396,950&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90C_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20240101__20241231__srt--MajorCustomersAxis__custom--CustomerBMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_z6L6EIm7A9m7" title="Risk percentage"&gt;15&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20230101__20231231__srt--MajorCustomersAxis__custom--CustomerBMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zLhqQLg76db" style="text-align: right" title="Revenue"&gt;382,082&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20231231__srt--MajorCustomersAxis__custom--CustomerBMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zACbxoOC2pSe" title="Risk percentage"&gt;16&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Customer C&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20240101__20241231__srt--MajorCustomersAxis__custom--CustomerCMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zswU6SLkue39" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right" title="Revenue"&gt;142,270&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_904_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20240101__20241231__srt--MajorCustomersAxis__custom--CustomerCMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_z2crm1yRVs5d" title="Risk percentage"&gt;5&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;%&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20230101__20231231__srt--MajorCustomersAxis__custom--CustomerCMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zWVmxOqlJMFc" style="border-bottom: Black 1pt solid; text-align: right" title="Revenue"&gt;274,581&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_906_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20231231__srt--MajorCustomersAxis__custom--CustomerCMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zs8Tc7rodGKf" title="Risk percentage"&gt;11&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20240101__20241231__srt--MajorCustomersAxis__custom--CustomerMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zpQ98lLEyvZa" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right" title="Revenue"&gt;1,061,030&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_90E_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20240101__20241231__srt--MajorCustomersAxis__custom--CustomerMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zLqb9DZOwDyh" title="Risk percentage"&gt;40&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;%&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20230101__20231231__srt--MajorCustomersAxis__custom--CustomerMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zuCpenm53Myd" style="border-bottom: Black 1pt solid; text-align: right" title="Revenue"&gt;1,109,343&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20231231__srt--MajorCustomersAxis__custom--CustomerMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zV0CREuaTTec" title="Risk percentage"&gt;45&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A8_zQMCLDFvtWn5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;From
time to time, the Company&#x2019;s bank balances may exceed the FDIC limit of $&lt;span id="xdx_901_eus-gaap--CashFDICInsuredAmount_iI_c20241231_zo5mHRQzxyD1" title="Cash, FDIC insured amount"&gt;250,000&lt;/span&gt;.
As of December 31, 2024 and 2023, the Company had $&lt;span id="xdx_901_eus-gaap--CashUninsuredAmount_iI_c20241231_zJJUkOAzfSya" title="Cash uninsured"&gt;3,263,618&lt;/span&gt;
and $&lt;span id="xdx_909_eus-gaap--CashUninsuredAmount_iI_c20231231_zQEDtlFPjsD" title="Cash uninsured"&gt;0&lt;/span&gt; of its cash balance
uninsured, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000934">&lt;p id="xdx_898_eus-gaap--SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_zUwJC7G3vMd4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span id="xdx_8BF_ziuviCdUkIG6" style="display: none"&gt;Schedule of Customer Accounts Receivable&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Percentage
    of Net Accounts&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Percentage
    of Net Accounts&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Receivable&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt; Receivable&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 36%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Customer
    A&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--AccountsReceivableNet_iI_c20241231__srt--MajorCustomersAxis__custom--CustomerAMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zGVtJHY4ngni" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right" title="Net accounts receivable"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;119,616&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90A_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20240101__20241231__srt--MajorCustomersAxis__custom--CustomerAMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_ztfwx0Pn3dvb" title="Risk percentage"&gt;49&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--AccountsReceivableNet_iI_c20231231__srt--MajorCustomersAxis__custom--CustomerAMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zKXzKALlmJz7" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right" title="Net accounts receivable"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0940"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_901_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20231231__srt--MajorCustomersAxis__custom--CustomerAMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_z9o22JCbwIjb" title="Risk percentage"&gt;0&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Customer
    B&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--AccountsReceivableNet_iI_c20241231__srt--MajorCustomersAxis__custom--CustomerBMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zR77yBuhHffb" style="font: bold 10pt Times New Roman, Times, Serif; text-align: right" title="Net accounts receivable"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0944"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_905_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20240101__20241231__srt--MajorCustomersAxis__custom--CustomerBMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_z9SVmlN18mH9" title="Risk percentage"&gt;0&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--AccountsReceivableNet_iI_c20231231__srt--MajorCustomersAxis__custom--CustomerBMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zDCakzXb5lvc" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Net accounts receivable"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;23,900&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90A_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20231231__srt--MajorCustomersAxis__custom--CustomerBMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zYReW668WMIf" title="Risk percentage"&gt;28&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Customer
    C&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--AccountsReceivableNet_iI_c20241231__srt--MajorCustomersAxis__custom--CustomerCMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zECBJOkoPFzh" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Net accounts receivable"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;22,799&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_907_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20240101__20241231__srt--MajorCustomersAxis__custom--CustomerCMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zCoq7BCeaAUd" title="Risk percentage"&gt;9&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--AccountsReceivableNet_iI_c20231231__srt--MajorCustomersAxis__custom--CustomerCMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zSmayTQpiaTa" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Net accounts receivable"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;14,401&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90D_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20231231__srt--MajorCustomersAxis__custom--CustomerCMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_z058r726xm0j" title="Risk percentage"&gt;17&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Customer
    D&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--AccountsReceivableNet_iI_c20241231__srt--MajorCustomersAxis__custom--CustomerDMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_ziWgXs4rhsT5" style="font: bold 10pt Times New Roman, Times, Serif; text-align: right" title="Net accounts receivable"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0960"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_905_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20240101__20241231__srt--MajorCustomersAxis__custom--CustomerDMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zSEvYV8lKLbh" title="Risk percentage"&gt;0&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--AccountsReceivableNet_iI_c20231231__srt--MajorCustomersAxis__custom--CustomerDMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zgOcWsNkjKF1" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Net accounts receivable"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;23,982&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_909_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20231231__srt--MajorCustomersAxis__custom--CustomerDMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zlZgVpBjp056" title="Risk percentage"&gt;28&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;%&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Customer
    E&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--AccountsReceivableNet_iI_c20241231__srt--MajorCustomersAxis__custom--CustomerEMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zl2qNb56zJwh" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right" title="Net accounts receivable"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0968"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90F_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20240101__20241231__srt--MajorCustomersAxis__custom--CustomerEMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zqDT0bFj4H1k" title="Risk percentage"&gt;0&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--AccountsReceivableNet_iI_c20231231__srt--MajorCustomersAxis__custom--CustomerEMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zwaoP8QxF9Bf" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Net accounts receivable"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;9,599&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_901_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20231231__srt--MajorCustomersAxis__custom--CustomerEMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zyXKzz43jjZf" title="Risk percentage"&gt;11&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--AccountsReceivableNet_iI_c20241231__srt--MajorCustomersAxis__custom--CustomerMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_z1Hroo9j0F5k" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Net accounts receivable"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;142,415&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_902_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20240101__20241231__srt--MajorCustomersAxis__custom--CustomerMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zvYJPTm3tgrf" title="Risk percentage"&gt;58&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--AccountsReceivableNet_iI_c20231231__srt--MajorCustomersAxis__custom--CustomerMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_z3M4Bf5OFDta" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Net accounts receivable"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;71,882&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_906_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20231231__srt--MajorCustomersAxis__custom--CustomerMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zHYTFLfnmKr" title="Risk percentage"&gt;84&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
</us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock>
    <us-gaap:AccountsReceivableNet
      contextRef="AsOf2024-12-31_custom_CustomerAMember_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember"
      decimals="0"
      id="Fact000936"
      unitRef="USD">119616</us-gaap:AccountsReceivableNet>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2024-01-012024-12-31_custom_CustomerAMember_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember"
      decimals="INF"
      id="Fact000938"
      unitRef="Pure">0.49</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2023-01-012023-12-31_custom_CustomerAMember_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember"
      decimals="INF"
      id="Fact000942"
      unitRef="Pure">0</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2024-01-012024-12-31_custom_CustomerBMember_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember"
      decimals="INF"
      id="Fact000946"
      unitRef="Pure">0</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:AccountsReceivableNet
      contextRef="AsOf2023-12-31_custom_CustomerBMember_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember"
      decimals="0"
      id="Fact000948"
      unitRef="USD">23900</us-gaap:AccountsReceivableNet>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2023-01-012023-12-31_custom_CustomerBMember_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember"
      decimals="INF"
      id="Fact000950"
      unitRef="Pure">0.28</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:AccountsReceivableNet
      contextRef="AsOf2024-12-31_custom_CustomerCMember_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember"
      decimals="0"
      id="Fact000952"
      unitRef="USD">22799</us-gaap:AccountsReceivableNet>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2024-01-012024-12-31_custom_CustomerCMember_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember"
      decimals="INF"
      id="Fact000954"
      unitRef="Pure">0.09</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:AccountsReceivableNet
      contextRef="AsOf2023-12-31_custom_CustomerCMember_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember"
      decimals="0"
      id="Fact000956"
      unitRef="USD">14401</us-gaap:AccountsReceivableNet>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2023-01-012023-12-31_custom_CustomerCMember_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember"
      decimals="INF"
      id="Fact000958"
      unitRef="Pure">0.17</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2024-01-012024-12-31_custom_CustomerDMember_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember"
      decimals="INF"
      id="Fact000962"
      unitRef="Pure">0</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:AccountsReceivableNet
      contextRef="AsOf2023-12-31_custom_CustomerDMember_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember"
      decimals="0"
      id="Fact000964"
      unitRef="USD">23982</us-gaap:AccountsReceivableNet>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2023-01-012023-12-31_custom_CustomerDMember_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember"
      decimals="INF"
      id="Fact000966"
      unitRef="Pure">0.28</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2024-01-012024-12-31_custom_CustomerEMember_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember"
      decimals="INF"
      id="Fact000970"
      unitRef="Pure">0</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:AccountsReceivableNet
      contextRef="AsOf2023-12-31_custom_CustomerEMember_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember"
      decimals="0"
      id="Fact000972"
      unitRef="USD">9599</us-gaap:AccountsReceivableNet>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2023-01-012023-12-31_custom_CustomerEMember_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember"
      decimals="INF"
      id="Fact000974"
      unitRef="Pure">0.11</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:AccountsReceivableNet
      contextRef="AsOf2024-12-31_custom_CustomerMember_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember"
      decimals="0"
      id="Fact000976"
      unitRef="USD">142415</us-gaap:AccountsReceivableNet>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2024-01-012024-12-31_custom_CustomerMember_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember"
      decimals="INF"
      id="Fact000978"
      unitRef="Pure">0.58</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:AccountsReceivableNet
      contextRef="AsOf2023-12-31_custom_CustomerMember_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember"
      decimals="0"
      id="Fact000980"
      unitRef="USD">71882</us-gaap:AccountsReceivableNet>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2023-01-012023-12-31_custom_CustomerMember_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember"
      decimals="INF"
      id="Fact000982"
      unitRef="Pure">0.84</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ContractWithCustomerAssetAllowanceForCreditLossTableTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000984">&lt;p id="xdx_896_eus-gaap--ContractWithCustomerAssetAllowanceForCreditLossTableTextBlock_zkkwaR2En4R4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span id="xdx_8BA_z9EQpd6TmZ1d" style="display: none"&gt;Schedule of Customers Accounted Revenues&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Percentage of&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Percentage of&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Net Sales&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Net Sales&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 36%; text-align: left"&gt;Customer A&lt;/td&gt;&lt;td style="width: 2%; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20240101__20241231__srt--MajorCustomersAxis__custom--CustomerAMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zhKwbiXDFFs3" style="width: 12%; font-weight: bold; text-align: right" title="Revenue"&gt;521,810&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&lt;span id="xdx_903_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20240101__20241231__srt--MajorCustomersAxis__custom--CustomerAMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zklF9jeBuOtg" title="Risk percentage"&gt;20&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20230101__20231231__srt--MajorCustomersAxis__custom--CustomerAMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zHFwu8jqdfzh" style="width: 12%; text-align: right" title="Revenue"&gt;452,680&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&lt;span id="xdx_908_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20231231__srt--MajorCustomersAxis__custom--CustomerAMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zUGo6Jpa5fgl" title="Risk percentage"&gt;18&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Customer B&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20240101__20241231__srt--MajorCustomersAxis__custom--CustomerBMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zbvEOGjsePt8" style="font-weight: bold; text-align: right" title="Revenue"&gt;396,950&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90C_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20240101__20241231__srt--MajorCustomersAxis__custom--CustomerBMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_z6L6EIm7A9m7" title="Risk percentage"&gt;15&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20230101__20231231__srt--MajorCustomersAxis__custom--CustomerBMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zLhqQLg76db" style="text-align: right" title="Revenue"&gt;382,082&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20231231__srt--MajorCustomersAxis__custom--CustomerBMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zACbxoOC2pSe" title="Risk percentage"&gt;16&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Customer C&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20240101__20241231__srt--MajorCustomersAxis__custom--CustomerCMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zswU6SLkue39" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right" title="Revenue"&gt;142,270&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_904_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20240101__20241231__srt--MajorCustomersAxis__custom--CustomerCMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_z2crm1yRVs5d" title="Risk percentage"&gt;5&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;%&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20230101__20231231__srt--MajorCustomersAxis__custom--CustomerCMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zWVmxOqlJMFc" style="border-bottom: Black 1pt solid; text-align: right" title="Revenue"&gt;274,581&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_906_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20231231__srt--MajorCustomersAxis__custom--CustomerCMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zs8Tc7rodGKf" title="Risk percentage"&gt;11&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20240101__20241231__srt--MajorCustomersAxis__custom--CustomerMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zpQ98lLEyvZa" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right" title="Revenue"&gt;1,061,030&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_90E_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20240101__20241231__srt--MajorCustomersAxis__custom--CustomerMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zLqb9DZOwDyh" title="Risk percentage"&gt;40&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;%&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20230101__20231231__srt--MajorCustomersAxis__custom--CustomerMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zuCpenm53Myd" style="border-bottom: Black 1pt solid; text-align: right" title="Revenue"&gt;1,109,343&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20231231__srt--MajorCustomersAxis__custom--CustomerMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zV0CREuaTTec" title="Risk percentage"&gt;45&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ContractWithCustomerAssetAllowanceForCreditLossTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2024-01-012024-12-31_custom_CustomerAMember_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember"
      decimals="0"
      id="Fact000986"
      unitRef="USD">521810</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2024-01-012024-12-31_custom_CustomerAMember_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember"
      decimals="INF"
      id="Fact000988"
      unitRef="Pure">0.20</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2023-01-012023-12-31_custom_CustomerAMember_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember"
      decimals="0"
      id="Fact000990"
      unitRef="USD">452680</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2023-01-012023-12-31_custom_CustomerAMember_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember"
      decimals="INF"
      id="Fact000992"
      unitRef="Pure">0.18</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2024-01-012024-12-31_custom_CustomerBMember_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember"
      decimals="0"
      id="Fact000994"
      unitRef="USD">396950</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2024-01-012024-12-31_custom_CustomerBMember_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember"
      decimals="INF"
      id="Fact000996"
      unitRef="Pure">0.15</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2023-01-012023-12-31_custom_CustomerBMember_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember"
      decimals="0"
      id="Fact000998"
      unitRef="USD">382082</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2023-01-012023-12-31_custom_CustomerBMember_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember"
      decimals="INF"
      id="Fact001000"
      unitRef="Pure">0.16</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2024-01-012024-12-31_custom_CustomerCMember_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember"
      decimals="0"
      id="Fact001002"
      unitRef="USD">142270</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2024-01-012024-12-31_custom_CustomerCMember_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember"
      decimals="INF"
      id="Fact001004"
      unitRef="Pure">0.05</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2023-01-012023-12-31_custom_CustomerCMember_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember"
      decimals="0"
      id="Fact001006"
      unitRef="USD">274581</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2023-01-012023-12-31_custom_CustomerCMember_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember"
      decimals="INF"
      id="Fact001008"
      unitRef="Pure">0.11</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2024-01-012024-12-31_custom_CustomerMember_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember"
      decimals="0"
      id="Fact001010"
      unitRef="USD">1061030</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2024-01-012024-12-31_custom_CustomerMember_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember"
      decimals="INF"
      id="Fact001012"
      unitRef="Pure">0.40</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2023-01-012023-12-31_custom_CustomerMember_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember"
      decimals="0"
      id="Fact001014"
      unitRef="USD">1109343</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2023-01-012023-12-31_custom_CustomerMember_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember"
      decimals="INF"
      id="Fact001016"
      unitRef="Pure">0.45</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:CashFDICInsuredAmount
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact001018"
      unitRef="USD">250000</us-gaap:CashFDICInsuredAmount>
    <us-gaap:CashUninsuredAmount
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact001020"
      unitRef="USD">3263618</us-gaap:CashUninsuredAmount>
    <us-gaap:CashUninsuredAmount
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact001022"
      unitRef="USD">0</us-gaap:CashUninsuredAmount>
    <NRXS:GoingConcernPolicyTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact001024">&lt;p id="xdx_84E_ecustom--GoingConcernPolicyTextBlock_zs8TSICVHdrc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_864_z7ogNBVMc5Kh"&gt;Going
Concern&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;We
have incurred losses since inception and have funded our operations primarily with a combination of sales, debt, and the sale of capital
stock. As of December 31, 2024, we had stockholders&#x2019; equity of $&lt;span id="xdx_908_eus-gaap--StockholdersEquity_iI_c20241231_zcrwDhOD4KL9" title="Stockholders' equity"&gt;2,067,748&lt;/span&gt;, short-term outstanding borrowings of $&lt;span id="xdx_901_eus-gaap--ShortTermBorrowings_iI_c20241231_zcj9tEASlJp6" title="Short term borrowings outstanding"&gt;154,152&lt;/span&gt;, cash
of $&lt;span id="xdx_909_eus-gaap--Cash_iI_c20241231_zqeGWmRH93nf" title="Cash"&gt;3,696,870&lt;/span&gt; and a working capital surplus of $&lt;span id="xdx_907_ecustom--WorkingCapitalDeficit_iI_c20241231_zeQGhPzPxHu3" title="Working capital surplus"&gt;1,832,858&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Neuraxis,
Inc.&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Notes
to Financial Statements&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Our
future capital requirements will depend upon many factors, including progress with developing, manufacturing, and marketing our technologies,
the time and costs involved in preparing, filing, prosecuting, maintaining, and enforcing patent claims and other proprietary rights,
our ability to establish collaborative arrangements, marketing activities and competing technological and market developments, including
regulatory changes and overall economic conditions in our target markets. Our ability to generate revenue and achieve profitability requires
us to successfully market and secure purchase orders for our products from customers currently identified in our sales pipeline and to
new customers as well. The primary activity that will drive all customers and revenues is the adoption of insurance coverage by commercial
insurance carriers nationally which is a top priority of the Company. These activities, including our planned research and development
efforts, will require significant uses of working capital through the rest of 2025 and beyond. Based on our current operating plans,
we believe that our existing cash at the time of this filing will only be sufficient to meet our anticipated operating needs before the
end of 2025.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Management
evaluates whether there are conditions or events that raise substantial doubt about the Company&#x2019;s ability to continue as a going
concern for a period of one year from the date the financial statements are issued.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;To
date, the Company has experienced operating losses and negative cash flows from operations. Management believes that increased sales
and acceptance of their product by insurance providers will allow the Company to achieve profitability in the future.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;While
the Company believes in the viability of its strategy to further implement its business plan and generate sufficient revenues and in
its ability to raise additional funds by way of a public or private offering of its debt or equity securities, there can be no assurance
that it will be able to do so on reasonable terms, or at all. The ability of the Company to continue as a going concern is dependent
upon its ability to further implement its business plan and generate sufficient revenues and its ability to raise additional funds by
way of a public or private offering. Neither future cash generated from operating activities, nor management&#x2019;s contingency plans
to mitigate the risk and extend cash resources through the evaluation period, are considered probable. As a result, substantial doubt
is deemed to exist about the Company&#x2019;s ability to continue as a going concern. As we continue to incur losses, our transition to
profitability is dependent upon achieving a level of revenues adequate to support its cost structure. We may never achieve profitability,
and unless and until doing so, we intend to fund future operations through additional dilutive or nondilutive financing. There can be
no assurances, however, that additional funding will be available on terms acceptable to us, if at all.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
financial statements do not include any adjustments related to the recoverability and classification of recorded asset amounts or the
amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</NRXS:GoingConcernPolicyTextBlock>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact001026"
      unitRef="USD">2067748</us-gaap:StockholdersEquity>
    <us-gaap:ShortTermBorrowings
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact001028"
      unitRef="USD">154152</us-gaap:ShortTermBorrowings>
    <us-gaap:Cash
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact001030"
      unitRef="USD">3696870</us-gaap:Cash>
    <NRXS:WorkingCapitalDeficit
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact001032"
      unitRef="USD">1832858</NRXS:WorkingCapitalDeficit>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact001034">&lt;p id="xdx_84D_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zcEfnqT2G8F2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_862_zHoVgdNJrcdl"&gt;Recently
Adopted Accounting Pronouncements&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
November 2023, the FASB issued Accounting Standards Update (&#x201c;ASU&#x201d;) 2023-07, &lt;i&gt;Segment Reporting (Topic 280): Improvements
to Reportable Segment Disclosures&lt;/i&gt;, which requires disclosure of (i) significant segment expenses, (ii) other segment items and (iii)
the title and position of the Chief Operating Decision Maker (&#x201c;CODM&#x201d;) on an annual and interim basis. Additionally, ASU 2023-07
requires that a public entity that has a single reportable segment provide all the disclosures required by Topic 280. Public business
entities are required to adopt the standard for fiscal years beginning after December 15, 2023 and interim periods withing fiscal year
beginning after December 15, 2024. Disclosures are required for all prior periods presented in the financial statements. The Company
adopted the disclosure provisions of ASU 2023-07 as of December 31, 2024 as operations are managed through one reportable segment.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
June 2016, the FASB issued ASU 2016-13, &lt;i&gt;Financial Instruments &#x2013; Credit Losses (Topic 326): Measurement of Credit Losses on Financial
Instruments&lt;/i&gt;, which requires measurement and recognition of expected credit losses for financial assets held and enhanced disclosures
regarding significant estimates and judgments used in estimating credit losses. In November 2019, the FASB issued ASU 2019-10, Financial
Instruments &#x2013; Credit Losses (Topic 326), Derivatives and Hedging (Topic 815) and Leases (Topic 842): Effective Dates, which amended
the effective date of ASU 2016-13. Public business entities meeting the definition of an SEC filer, excluding entities eligible to be
a Smaller Reporting Company (&#x201c;SRC&#x201d;) as defined by the SEC, are required to adopt the standard for fiscal years beginning
after December 15, 2019, including interim periods within those fiscal years. All other entities are required to adopt the standard for
fiscal years beginning after December 15, 2022, including interim periods within those fiscal years. The Company meets the definition
of an SRC and therefore the standard was adopted as of January 1, 2023. The adoption of this guidance did not have a material impact
on the Company&#x2019;s financial statements.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <NRXS:RecentlyIssuedAccountingPronouncementsPolicyTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact001036">&lt;p id="xdx_840_ecustom--RecentlyIssuedAccountingPronouncementsPolicyTextBlock_zjKjcdN7Te33" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_86A_zxIiHNzeegpc"&gt;Recently
Issued Accounting Pronouncements&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
November 2024, the FASB issued ASU 2024-03, &lt;i&gt;Income Statement&#x2014;Reporting Comprehensive Income&#x2014;Expense Disaggregation Disclosures
(Subtopic (220-40): Disaggregation of Income Statement Expenses&lt;/i&gt;, which requires disclosures that disaggregate, in a tabular presentation,
each relevant expense caption on the face of the income statement that includes inventory purchases, employee compensation, depreciation
and intangible amortization expense. Additional disclosures are also required to provide a qualitative description of the amounts in
an expense caption that are not separately disaggregated quantitatively and the total amount of selling expenses including a definition.
Public business entities are required to adopt the standard for fiscal years beginning after December 15, 2026 and interim periods within
fiscal years beginning after December 15, 2027. Disclosures are required for all prior periods presented in the financial statements.
Although the standard requires enhanced disclosures, the adoption is not expected to have a material impact on the Company&#x2019;s financial
statements.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
December 2023, the FASB issued ASU 2023-09, &lt;i&gt;Income Taxes (Topic 740): Improvements to Income Tax Disclosures&lt;/i&gt;, which requires the
enhancement of income tax disclosures to provide better insight into how an entity&#x2019;s operations and related tax risks, planning
and opportunities affect its tax rate and prospects for future cash flows. The enhanced disclosures require (i) specific categories in
a tabular rate reconciliation including both amounts and percentages and (ii) additional information for reconciling items and income
tax paid that meet a quantitative threshold. Public business entities are required to adopt the standard for annual periods beginning
after December 15, 2024. All other entities are required to adopt the standard for annual periods beginning after December 15, 2025.
The adoption of the standard is not expected to have a material impact on the Company&#x2019;s financial statements.&lt;/span&gt;&lt;/p&gt;

</NRXS:RecentlyIssuedAccountingPronouncementsPolicyTextBlock>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact001038">&lt;p id="xdx_80E_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_zw3qdvYP29ce" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;3.
&lt;span id="xdx_823_zxseoGpv3kuf"&gt;Related Party Transactions&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company has two demand notes receivable from shareholders related to the sale of common stock on January 1, 2016. Both notes&#x2019; initial
balances were $&lt;span id="xdx_90D_eus-gaap--NotesAndLoansReceivableGrossCurrent_iI_c20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ShareholdersOneAndTwoMember_zYT7P04QrYh9" title="Loan Receivable"&gt;506,400&lt;/span&gt;, with interest calculated monthly based on applicable federal rates. No payments have been received on the notes.
Since repayment is not assured, the Company has fully reserved for the entire balance of principal and interest. The current allowance
is $&lt;span id="xdx_90D_ecustom--AllowanceForInterestReceivableCurrent_iI_c20241231_zKAxBF9ZSgWc" title="Allowance for interest receivable current"&gt;1,201,367&lt;/span&gt; as of December 31, 2024. The current loan balances are as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89C_eus-gaap--ScheduleOfRelatedPartyTransactionsTableTextBlock_zOv4aX3fMcwj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span&gt;&lt;span id="xdx_8B6_zby8DV48UlMe" style="display: none"&gt;Schedule of Related Party Transactions&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Loan&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Interest&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Interest&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold"&gt;December 31, 2024&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Receivable&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Receivable&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Income&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%"&gt;Shareholder 1&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--NotesAndLoansReceivableGrossCurrent_iI_c20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ShareHolderOneMember_zWFF6fDKgOOh" style="width: 12%; text-align: right" title="Loan Receivable"&gt;506,400&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--InterestReceivableCurrent_iI_c20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ShareHolderOneMember_zhO2kKTUPrH7" style="width: 12%; text-align: right" title="Interest Receivable"&gt;94,351&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_ecustom--InterestIncomeGrossCurrent_iI_c20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ShareHolderOneMember_zGv6Q28DbLFb" style="width: 12%; text-align: right" title="Interest Income"&gt;23,413&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;Shareholder 2&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--NotesAndLoansReceivableGrossCurrent_iI_c20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ShareHolderTwoMember_zk0nJ4TbCeT6" style="border-bottom: Black 1pt solid; text-align: right" title="Loan Receivable"&gt;506,400&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--InterestReceivableCurrent_iI_c20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ShareHolderTwoMember_zvYvtR6VyOQ5" style="border-bottom: Black 1pt solid; text-align: right" title="Interest Receivable"&gt;94,216&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_ecustom--InterestIncomeGrossCurrent_iI_c20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ShareHolderTwoMember_zDlrgzmboFb6" style="border-bottom: Black 1pt solid; text-align: right" title="Interest Income"&gt;23,413&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt"&gt;Principal Balance&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--NotesAndLoansReceivableGrossCurrent_iI_c20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_ztUVY7XqRxSd" style="text-align: right" title="Loan Receivable"&gt;1,012,800&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--InterestReceivableCurrent_iI_c20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zjTDLXBg8xha" style="text-align: right" title="Interest Receivable"&gt;188,567&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_ecustom--InterestIncomeGrossCurrent_iI_c20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zCgEEzRhYDy" style="text-align: right" title="Interest Income"&gt;46,826&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Allowance for Collection Risk&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--AllowanceForNotesAndLoansReceivableCurrent_iNI_di_c20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zfyohD0vh37l" style="border-bottom: Black 1pt solid; text-align: right" title="Allowance for collection risk, loan receivable"&gt;(1,012,800&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_ecustom--AllowanceForInterestReceivableCurrent_iI_c20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zVYzxHfKGjzl" style="border-bottom: Black 1pt solid; text-align: right" title="Allowance for collection risk, interest receivable"&gt;(188,567&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_ecustom--AllowanceForInterestIncomeCurrent_iNI_di_c20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zzOQmVoFft9" style="border-bottom: Black 1pt solid; text-align: right" title="Allowance for collection risk, interest income"&gt;(46,826&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt"&gt;Net Balance&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--NotesAndLoansReceivableNetCurrent_iI_c20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zWhNsIQX3dT1" style="border-bottom: Black 1pt solid; text-align: right" title="Loan Receivable"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1070"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--InterestReceivable_iI_c20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zYN9wmZutSp4" style="border-bottom: Black 1pt solid; text-align: right" title="Interest Receivable"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1072"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_ecustom--InterestIncomeCurrent_iI_c20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zJz5EcU2SFMh" style="border-bottom: Black 1pt solid; text-align: right" title="Interest Income"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1074"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Loan&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Interest&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Interest&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold"&gt;December 31, 2023&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Receivable&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Receivable&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Income&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%"&gt;Shareholder 1&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--NotesAndLoansReceivableGrossCurrent_iI_c20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ShareHolderOneMember_zWSabdjGXQL1" style="width: 12%; text-align: right" title="Loan Receivable"&gt;506,400&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--InterestReceivableCurrent_iI_c20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ShareHolderOneMember_zDPEXZk6ETm2" style="width: 12%; text-align: right" title="Interest Receivable"&gt;70,938&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_ecustom--InterestIncomeGrossCurrent_iI_c20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ShareHolderOneMember_zY8vYDQbfVG3" style="width: 12%; text-align: right" title="Interest Income"&gt;23,867&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;Shareholder 2&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--NotesAndLoansReceivableGrossCurrent_iI_c20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ShareHolderTwoMember_zeI6ZkI1sNy" style="border-bottom: Black 1pt solid; text-align: right" title="Loan Receivable"&gt;506,400&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--InterestReceivableCurrent_iI_c20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ShareHolderTwoMember_zGzV0Q4plaJ9" style="border-bottom: Black 1pt solid; text-align: right" title="Interest Receivable"&gt;70,803&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_ecustom--InterestIncomeGrossCurrent_iI_c20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ShareHolderTwoMember_zvRaHSTC4382" style="border-bottom: Black 1pt solid; text-align: right" title="Interest Income"&gt;23,867&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt"&gt;Principal Balance&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--NotesAndLoansReceivableGrossCurrent_iI_c20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zQi2kWkjffrh" style="text-align: right" title="Loan Receivable"&gt;1,012,800&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--InterestReceivableCurrent_iI_c20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zKHhhwuk6iJ8" style="text-align: right" title="Interest Receivable"&gt;141,741&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_ecustom--InterestIncomeGrossCurrent_iI_c20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zosHxJYGrgxj" style="text-align: right" title="Interest Income"&gt;47,734&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Allowance for Collection Risk&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--AllowanceForNotesAndLoansReceivableCurrent_iNI_di_c20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zfx5avVhZnK4" style="border-bottom: Black 1pt solid; text-align: right" title="Allowance for collection risk, loan receivable"&gt;(1,012,800&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_ecustom--AllowanceForInterestReceivableCurrent_iI_c20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_z3W1QciT6pS" style="border-bottom: Black 1pt solid; text-align: right" title="Allowance for collection risk, interest receivable"&gt;(141,741&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_ecustom--AllowanceForInterestIncomeCurrent_iNI_di_c20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zIEXyFnrGwx3" style="border-bottom: Black 1pt solid; text-align: right" title="Allowance for collection risk, interest income"&gt;(47,734&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt"&gt;Net Balance&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--NotesAndLoansReceivableNetCurrent_iI_c20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zhXSahQJ7MP1" style="border-bottom: Black 1pt solid; text-align: right" title="Loan Receivable"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1100"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--InterestReceivable_iI_c20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zuNWYHRuzlIg" style="border-bottom: Black 1pt solid; text-align: right" title="Interest Receivable"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1102"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_ecustom--InterestIncomeCurrent_iI_c20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_z4gJ4dE3iUN2" style="border-bottom: Black 1pt solid; text-align: right" title="Interest Income"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1104"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A4_zeWOMVKmkwK1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company has loans payable to shareholders related to funding needs for operations. The current loan details for all related party loans
are as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_891_ecustom--ScheduleOfRelatedPartyLoansTableTextBlock_zYPySHBVmcS7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B0_zf8TjuMlvU4c" style="display: none"&gt;Schedule of Related Party Loans payable to shareholder&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Interest &amp;amp;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Interest&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Loan&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Service Fee&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Interest&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold"&gt;December 31, 2024&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Due Date&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Rate&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Balance&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Accrued&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Paid&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 30%; text-align: left; padding-bottom: 1pt"&gt;Other Convertibles&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 12%; text-align: center; padding-bottom: 1pt"&gt;&lt;span id="xdx_90D_eus-gaap--DebtInstrumentMaturityDateDescription_c20240101__20241231__us-gaap--DebtInstrumentAxis__custom--OtherConvertiblesMember_ztlLQ0Sr0av9" title="Due date"&gt;Various&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; width: 10%; text-align: center"&gt;&lt;span id="xdx_908_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_dp_uPure_c20241231__us-gaap--DebtInstrumentAxis__custom--OtherConvertiblesMember_zqSoAz84D45j" title="Debt instrument percentage"&gt;5.0&lt;/span&gt;%&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--LoansPayable_iI_c20241231__us-gaap--DebtInstrumentAxis__custom--OtherConvertiblesMember_zWABE9Cu0pab" style="border-bottom: Black 1pt solid; width: 10%; text-align: right" title="Interest payable"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1112"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_ecustom--InterestAndServiceFeeAccrued_iI_c20241231__us-gaap--DebtInstrumentAxis__custom--OtherConvertiblesMember_zfhfCYXJY2w2" style="border-bottom: Black 1pt solid; width: 10%; text-align: right" title="Interest payable"&gt;66,648&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--InterestPaid_c20240101__20241231__us-gaap--DebtInstrumentAxis__custom--OtherConvertiblesMember_z57rRBACUFUg" style="border-bottom: Black 1pt solid; width: 10%; text-align: right" title="Interest payable"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1116"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--LoansPayable_iI_c20241231_zPLJkVYOokw9" style="border-bottom: Black 1pt solid; text-align: right" title="Loan payable"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1118"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_ecustom--InterestAndServiceFeeAccrued_iI_c20241231_zuHlAygaJSw6" style="border-bottom: Black 1pt solid; text-align: right" title="Interest payable"&gt;66,648&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--InterestPaid_c20240101__20241231_z8Wm1dCWuYgg" style="border-bottom: Black 1pt solid; text-align: right" title="Interest payable"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1122"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Interest &amp;amp;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Interest&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Loan&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Service Fee&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Interest&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold"&gt;December 31, 2023&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Due Date&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Rate&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Balance&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Accrued&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Paid&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 30%"&gt;Shareholder 1&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 12%; text-align: center"&gt;&lt;span id="xdx_90B_eus-gaap--DebtInstrumentMaturityDateDescription_c20230101__20231231__us-gaap--DebtInstrumentAxis__custom--ShareHolderOneMember_zD7Nd8CcgBnk" title="Due date"&gt;June, 2019&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: center"&gt;&lt;span id="xdx_90A_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_dp_uPure_c20231231__us-gaap--DebtInstrumentAxis__custom--ShareHolderOneMember_zLgE9AFgTgab" title="Debt instrument percentage"&gt;15.0&lt;/span&gt;%&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--LoansPayable_iI_c20231231__us-gaap--DebtInstrumentAxis__custom--ShareHolderOneMember_zN3dNK2VXGv6" style="width: 10%; text-align: right" title="Loan payable"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1128"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_ecustom--InterestAndServiceFeeAccrued_iI_c20231231__us-gaap--DebtInstrumentAxis__custom--ShareHolderOneMember_zFgriPhYsCj9" style="width: 10%; text-align: right" title="Interest payable"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1130"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--InterestPaid_c20230101__20231231__us-gaap--DebtInstrumentAxis__custom--ShareHolderOneMember_zQME5pjAHsJ8" style="width: 10%; text-align: right" title="Interest payable"&gt;10,047&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Shareholder 2&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span id="xdx_902_eus-gaap--DebtInstrumentMaturityDateDescription_c20230101__20231231__us-gaap--DebtInstrumentAxis__custom--ShareHolderTwoMember_zpH8ZXwFTij3" title="Due date"&gt;June, 2019&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&lt;span id="xdx_903_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_dp_uPure_c20231231__us-gaap--DebtInstrumentAxis__custom--ShareHolderTwoMember_zf0NRnHbYLxf" title="Debt instrument percentage"&gt;15.0&lt;/span&gt;%&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--LoansPayable_iI_c20231231__us-gaap--DebtInstrumentAxis__custom--ShareHolderTwoMember_zqeyWtHDawre" style="text-align: right" title="Loan payable"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1138"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_ecustom--InterestAndServiceFeeAccrued_iI_c20231231__us-gaap--DebtInstrumentAxis__custom--ShareHolderTwoMember_zwizrWGlHZB" style="text-align: right" title="Interest payable"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1140"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--InterestPaid_c20230101__20231231__us-gaap--DebtInstrumentAxis__custom--ShareHolderTwoMember_zqcl1NyjQVI5" style="text-align: right" title="Interest payable"&gt;27,056&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Other Convertibles&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; padding-bottom: 1pt"&gt;&lt;span id="xdx_90B_eus-gaap--DebtInstrumentMaturityDateDescription_c20230101__20231231__us-gaap--DebtInstrumentAxis__custom--OtherConvertiblesMember_zdURnn0ve00d" title="Due date"&gt;Various&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center"&gt;&lt;span id="xdx_90E_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_dp_uPure_c20231231__us-gaap--DebtInstrumentAxis__custom--OtherConvertiblesMember_zHHONbcvNHPk" title="Debt instrument percentage"&gt;5.0&lt;/span&gt;%&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--LoansPayable_iI_c20231231__us-gaap--DebtInstrumentAxis__custom--OtherConvertiblesMember_zsriqlzXJhOg" style="border-bottom: Black 1pt solid; text-align: right" title="Interest payable"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1148"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_ecustom--InterestAndServiceFeeAccrued_iI_c20231231__us-gaap--DebtInstrumentAxis__custom--OtherConvertiblesMember_zteqJglcLHv9" style="border-bottom: Black 1pt solid; text-align: right" title="Interest payable"&gt;66,648&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--InterestPaid_c20230101__20231231__us-gaap--DebtInstrumentAxis__custom--OtherConvertiblesMember_zdCzgHVG7OMf" style="border-bottom: Black 1pt solid; text-align: right" title="Interest payable"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1152"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--LoansPayable_iI_c20231231_z7ORZjjvl3zc" style="border-bottom: Black 1pt solid; text-align: right" title="Loan payable"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1154"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_ecustom--InterestAndServiceFeeAccrued_iI_c20231231_zk4ROeNOQu59" style="border-bottom: Black 1pt solid; text-align: right" title="Interest payable"&gt;66,648&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--InterestPaid_c20230101__20231231_zxw0Nw7EIlJ4" style="border-bottom: Black 1pt solid; text-align: right" title="Interest payable"&gt;37,103&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A2_zFWiTm1MloAl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company was granted an exclusive, worldwide non-transferable, royalty-free license for the auricular portion of certain patents owned
by a limited liability company in which the Company&#x2019;s President and Chief Executive Officer and Chief Regulatory, Compliance and
Privacy Officer both maintain an ownership interest. The license allows for the development, marketing and sales of electro-therapy treatments
by stimulation of cranial nerves, cranial nerve branches, auricular nerves, auricular nerve branches, auricular nerve bundles and auricular
anatomical structures in human patient. The exclusive license agreement expires on October 18, 2037, may be terminated by either party
upon 60 days prior written notice and requires the Company to pay costs associated with the maintenance, prosecution and continuation
of patent filings. For the year ended December 31, 2024, the Company paid the limited liability company $&lt;span id="xdx_90A_eus-gaap--RelatedPartyTransactionAmountsOfTransaction_c20240101__20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zYxMPwjCzXU6" title="Limited liability"&gt;4,973&lt;/span&gt;. No costs were incurred
during the year ended December 31, 2023. No amounts were owed to the limited liability company as of December 31, 2024 and 2023.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Mr.
Bradley Mitch Watkins, Director, provided certain sales, marketing and commercialization consulting services to the Company prior to
his appointment to the Board of Directors. For the years ended December 31, 2024 and 2023, the Company paid Mr. Watkins $&lt;span id="xdx_900_eus-gaap--RelatedPartyTransactionAmountsOfTransaction_c20240101__20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MrWatkinsMember_zEnDK5sjmQV3" title="Related party transaction amounts"&gt;0&lt;/span&gt; and $&lt;span id="xdx_907_eus-gaap--RelatedPartyTransactionAmountsOfTransaction_c20230101__20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MrWatkinsMember_zm5F2kSv1wZc" title="Related party transaction amounts"&gt;11,083&lt;/span&gt;,
respectively. No amounts were owed to Mr. Watkins as of December 31, 2024 and 2023.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s former Chief Financial Officer provides certain accounting and tax services on a continuous basis through a
third-party public accounting firm. He is the third-party public accounting firm&#x2019;s managing partner and majority shareholder.
Fees paid for services were $&lt;span id="xdx_907_eus-gaap--PaymentsForFees_c20240101__20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MrSealeMember_zMQRtP7A6AP5" title="Fees paid for services"&gt;207,103&lt;/span&gt;
and $&lt;span id="xdx_907_eus-gaap--PaymentsForFees_c20230101__20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MrSealeMember_zkxBH472uiVg" title="Fees paid for services"&gt;312,803&lt;/span&gt;
for the years ended December 31, 2024 and 2023, respectively. The Company owed the third-party accounting firm for open invoices of
$&lt;span id="xdx_903_eus-gaap--AccountsPayableCurrentAndNoncurrent_iI_c20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MrSealeMember_zTGy1xM9AsP" title="Accounts payable"&gt;4,173&lt;/span&gt;
and $&lt;span id="xdx_90A_eus-gaap--AccountsPayableCurrentAndNoncurrent_iI_c20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MrSealeMember_z0G24SXdEhAe" title="Accounts payable"&gt;84,279&lt;/span&gt;
that are included in accounts payable as of December 31, 2024 and 2023, respectively. On June 28, 2024, the Company also issued &lt;span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20240101__20241231__srt--TitleOfIndividualAxis__srt--ChiefFinancialOfficerMember_zQRfkfn74ZKb" title="Stock issued during period shares issued for services"&gt;20,000&lt;/span&gt;
common shares with a fair value $&lt;span id="xdx_904_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_c20240101__20241231__srt--TitleOfIndividualAxis__srt--ChiefFinancialOfficerMember_z2a6VJQXiZH8" title="Stock issued during period value  issued for services"&gt;55,600&lt;/span&gt;
to the former&lt;/span&gt; Chief Financial Officer for services rendered during the IPO process.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Neuraxis,
Inc.&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Notes
to Financial Statements&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:NotesAndLoansReceivableGrossCurrent
      contextRef="AsOf2024-12-31_custom_ShareholdersOneAndTwoMember"
      decimals="0"
      id="Fact001040"
      unitRef="USD">506400</us-gaap:NotesAndLoansReceivableGrossCurrent>
    <NRXS:AllowanceForInterestReceivableCurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact001042"
      unitRef="USD">1201367</NRXS:AllowanceForInterestReceivableCurrent>
    <us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact001044">&lt;p id="xdx_89C_eus-gaap--ScheduleOfRelatedPartyTransactionsTableTextBlock_zOv4aX3fMcwj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span&gt;&lt;span id="xdx_8B6_zby8DV48UlMe" style="display: none"&gt;Schedule of Related Party Transactions&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Loan&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Interest&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Interest&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold"&gt;December 31, 2024&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Receivable&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Receivable&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Income&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%"&gt;Shareholder 1&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--NotesAndLoansReceivableGrossCurrent_iI_c20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ShareHolderOneMember_zWFF6fDKgOOh" style="width: 12%; text-align: right" title="Loan Receivable"&gt;506,400&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--InterestReceivableCurrent_iI_c20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ShareHolderOneMember_zhO2kKTUPrH7" style="width: 12%; text-align: right" title="Interest Receivable"&gt;94,351&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_ecustom--InterestIncomeGrossCurrent_iI_c20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ShareHolderOneMember_zGv6Q28DbLFb" style="width: 12%; text-align: right" title="Interest Income"&gt;23,413&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;Shareholder 2&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--NotesAndLoansReceivableGrossCurrent_iI_c20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ShareHolderTwoMember_zk0nJ4TbCeT6" style="border-bottom: Black 1pt solid; text-align: right" title="Loan Receivable"&gt;506,400&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--InterestReceivableCurrent_iI_c20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ShareHolderTwoMember_zvYvtR6VyOQ5" style="border-bottom: Black 1pt solid; text-align: right" title="Interest Receivable"&gt;94,216&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_ecustom--InterestIncomeGrossCurrent_iI_c20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ShareHolderTwoMember_zDlrgzmboFb6" style="border-bottom: Black 1pt solid; text-align: right" title="Interest Income"&gt;23,413&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt"&gt;Principal Balance&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--NotesAndLoansReceivableGrossCurrent_iI_c20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_ztUVY7XqRxSd" style="text-align: right" title="Loan Receivable"&gt;1,012,800&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--InterestReceivableCurrent_iI_c20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zjTDLXBg8xha" style="text-align: right" title="Interest Receivable"&gt;188,567&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_ecustom--InterestIncomeGrossCurrent_iI_c20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zCgEEzRhYDy" style="text-align: right" title="Interest Income"&gt;46,826&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Allowance for Collection Risk&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--AllowanceForNotesAndLoansReceivableCurrent_iNI_di_c20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zfyohD0vh37l" style="border-bottom: Black 1pt solid; text-align: right" title="Allowance for collection risk, loan receivable"&gt;(1,012,800&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_ecustom--AllowanceForInterestReceivableCurrent_iI_c20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zVYzxHfKGjzl" style="border-bottom: Black 1pt solid; text-align: right" title="Allowance for collection risk, interest receivable"&gt;(188,567&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_ecustom--AllowanceForInterestIncomeCurrent_iNI_di_c20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zzOQmVoFft9" style="border-bottom: Black 1pt solid; text-align: right" title="Allowance for collection risk, interest income"&gt;(46,826&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt"&gt;Net Balance&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--NotesAndLoansReceivableNetCurrent_iI_c20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zWhNsIQX3dT1" style="border-bottom: Black 1pt solid; text-align: right" title="Loan Receivable"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1070"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--InterestReceivable_iI_c20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zYN9wmZutSp4" style="border-bottom: Black 1pt solid; text-align: right" title="Interest Receivable"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1072"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_ecustom--InterestIncomeCurrent_iI_c20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zJz5EcU2SFMh" style="border-bottom: Black 1pt solid; text-align: right" title="Interest Income"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1074"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Loan&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Interest&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Interest&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold"&gt;December 31, 2023&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Receivable&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Receivable&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Income&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%"&gt;Shareholder 1&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--NotesAndLoansReceivableGrossCurrent_iI_c20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ShareHolderOneMember_zWSabdjGXQL1" style="width: 12%; text-align: right" title="Loan Receivable"&gt;506,400&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--InterestReceivableCurrent_iI_c20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ShareHolderOneMember_zDPEXZk6ETm2" style="width: 12%; text-align: right" title="Interest Receivable"&gt;70,938&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_ecustom--InterestIncomeGrossCurrent_iI_c20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ShareHolderOneMember_zY8vYDQbfVG3" style="width: 12%; text-align: right" title="Interest Income"&gt;23,867&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;Shareholder 2&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--NotesAndLoansReceivableGrossCurrent_iI_c20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ShareHolderTwoMember_zeI6ZkI1sNy" style="border-bottom: Black 1pt solid; text-align: right" title="Loan Receivable"&gt;506,400&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--InterestReceivableCurrent_iI_c20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ShareHolderTwoMember_zGzV0Q4plaJ9" style="border-bottom: Black 1pt solid; text-align: right" title="Interest Receivable"&gt;70,803&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_ecustom--InterestIncomeGrossCurrent_iI_c20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ShareHolderTwoMember_zvRaHSTC4382" style="border-bottom: Black 1pt solid; text-align: right" title="Interest Income"&gt;23,867&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt"&gt;Principal Balance&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--NotesAndLoansReceivableGrossCurrent_iI_c20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zQi2kWkjffrh" style="text-align: right" title="Loan Receivable"&gt;1,012,800&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--InterestReceivableCurrent_iI_c20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zKHhhwuk6iJ8" style="text-align: right" title="Interest Receivable"&gt;141,741&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_ecustom--InterestIncomeGrossCurrent_iI_c20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zosHxJYGrgxj" style="text-align: right" title="Interest Income"&gt;47,734&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Allowance for Collection Risk&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--AllowanceForNotesAndLoansReceivableCurrent_iNI_di_c20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zfx5avVhZnK4" style="border-bottom: Black 1pt solid; text-align: right" title="Allowance for collection risk, loan receivable"&gt;(1,012,800&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_ecustom--AllowanceForInterestReceivableCurrent_iI_c20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_z3W1QciT6pS" style="border-bottom: Black 1pt solid; text-align: right" title="Allowance for collection risk, interest receivable"&gt;(141,741&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_ecustom--AllowanceForInterestIncomeCurrent_iNI_di_c20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zIEXyFnrGwx3" style="border-bottom: Black 1pt solid; text-align: right" title="Allowance for collection risk, interest income"&gt;(47,734&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt"&gt;Net Balance&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--NotesAndLoansReceivableNetCurrent_iI_c20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zhXSahQJ7MP1" style="border-bottom: Black 1pt solid; text-align: right" title="Loan Receivable"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1100"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--InterestReceivable_iI_c20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zuNWYHRuzlIg" style="border-bottom: Black 1pt solid; text-align: right" title="Interest Receivable"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1102"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_ecustom--InterestIncomeCurrent_iI_c20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_z4gJ4dE3iUN2" style="border-bottom: Black 1pt solid; text-align: right" title="Interest Income"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1104"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock>
    <us-gaap:NotesAndLoansReceivableGrossCurrent
      contextRef="AsOf2024-12-31_custom_ShareHolderOneMember"
      decimals="0"
      id="Fact001046"
      unitRef="USD">506400</us-gaap:NotesAndLoansReceivableGrossCurrent>
    <us-gaap:InterestReceivableCurrent
      contextRef="AsOf2024-12-31_custom_ShareHolderOneMember"
      decimals="0"
      id="Fact001048"
      unitRef="USD">94351</us-gaap:InterestReceivableCurrent>
    <NRXS:InterestIncomeGrossCurrent
      contextRef="AsOf2024-12-31_custom_ShareHolderOneMember"
      decimals="0"
      id="Fact001050"
      unitRef="USD">23413</NRXS:InterestIncomeGrossCurrent>
    <us-gaap:NotesAndLoansReceivableGrossCurrent
      contextRef="AsOf2024-12-31_custom_ShareHolderTwoMember"
      decimals="0"
      id="Fact001052"
      unitRef="USD">506400</us-gaap:NotesAndLoansReceivableGrossCurrent>
    <us-gaap:InterestReceivableCurrent
      contextRef="AsOf2024-12-31_custom_ShareHolderTwoMember"
      decimals="0"
      id="Fact001054"
      unitRef="USD">94216</us-gaap:InterestReceivableCurrent>
    <NRXS:InterestIncomeGrossCurrent
      contextRef="AsOf2024-12-31_custom_ShareHolderTwoMember"
      decimals="0"
      id="Fact001056"
      unitRef="USD">23413</NRXS:InterestIncomeGrossCurrent>
    <us-gaap:NotesAndLoansReceivableGrossCurrent
      contextRef="AsOf2024-12-31_us-gaap_RelatedPartyMember"
      decimals="0"
      id="Fact001058"
      unitRef="USD">1012800</us-gaap:NotesAndLoansReceivableGrossCurrent>
    <us-gaap:InterestReceivableCurrent
      contextRef="AsOf2024-12-31_us-gaap_RelatedPartyMember"
      decimals="0"
      id="Fact001060"
      unitRef="USD">188567</us-gaap:InterestReceivableCurrent>
    <NRXS:InterestIncomeGrossCurrent
      contextRef="AsOf2024-12-31_us-gaap_RelatedPartyMember"
      decimals="0"
      id="Fact001062"
      unitRef="USD">46826</NRXS:InterestIncomeGrossCurrent>
    <us-gaap:AllowanceForNotesAndLoansReceivableCurrent
      contextRef="AsOf2024-12-31_us-gaap_RelatedPartyMember"
      decimals="0"
      id="Fact001064"
      unitRef="USD">1012800</us-gaap:AllowanceForNotesAndLoansReceivableCurrent>
    <NRXS:AllowanceForInterestReceivableCurrent
      contextRef="AsOf2024-12-31_us-gaap_RelatedPartyMember"
      decimals="0"
      id="Fact001066"
      unitRef="USD">-188567</NRXS:AllowanceForInterestReceivableCurrent>
    <NRXS:AllowanceForInterestIncomeCurrent
      contextRef="AsOf2024-12-31_us-gaap_RelatedPartyMember"
      decimals="0"
      id="Fact001068"
      unitRef="USD">46826</NRXS:AllowanceForInterestIncomeCurrent>
    <us-gaap:NotesAndLoansReceivableGrossCurrent
      contextRef="AsOf2023-12-31_custom_ShareHolderOneMember"
      decimals="0"
      id="Fact001076"
      unitRef="USD">506400</us-gaap:NotesAndLoansReceivableGrossCurrent>
    <us-gaap:InterestReceivableCurrent
      contextRef="AsOf2023-12-31_custom_ShareHolderOneMember"
      decimals="0"
      id="Fact001078"
      unitRef="USD">70938</us-gaap:InterestReceivableCurrent>
    <NRXS:InterestIncomeGrossCurrent
      contextRef="AsOf2023-12-31_custom_ShareHolderOneMember"
      decimals="0"
      id="Fact001080"
      unitRef="USD">23867</NRXS:InterestIncomeGrossCurrent>
    <us-gaap:NotesAndLoansReceivableGrossCurrent
      contextRef="AsOf2023-12-31_custom_ShareHolderTwoMember"
      decimals="0"
      id="Fact001082"
      unitRef="USD">506400</us-gaap:NotesAndLoansReceivableGrossCurrent>
    <us-gaap:InterestReceivableCurrent
      contextRef="AsOf2023-12-31_custom_ShareHolderTwoMember"
      decimals="0"
      id="Fact001084"
      unitRef="USD">70803</us-gaap:InterestReceivableCurrent>
    <NRXS:InterestIncomeGrossCurrent
      contextRef="AsOf2023-12-31_custom_ShareHolderTwoMember"
      decimals="0"
      id="Fact001086"
      unitRef="USD">23867</NRXS:InterestIncomeGrossCurrent>
    <us-gaap:NotesAndLoansReceivableGrossCurrent
      contextRef="AsOf2023-12-31_us-gaap_RelatedPartyMember"
      decimals="0"
      id="Fact001088"
      unitRef="USD">1012800</us-gaap:NotesAndLoansReceivableGrossCurrent>
    <us-gaap:InterestReceivableCurrent
      contextRef="AsOf2023-12-31_us-gaap_RelatedPartyMember"
      decimals="0"
      id="Fact001090"
      unitRef="USD">141741</us-gaap:InterestReceivableCurrent>
    <NRXS:InterestIncomeGrossCurrent
      contextRef="AsOf2023-12-31_us-gaap_RelatedPartyMember"
      decimals="0"
      id="Fact001092"
      unitRef="USD">47734</NRXS:InterestIncomeGrossCurrent>
    <us-gaap:AllowanceForNotesAndLoansReceivableCurrent
      contextRef="AsOf2023-12-31_us-gaap_RelatedPartyMember"
      decimals="0"
      id="Fact001094"
      unitRef="USD">1012800</us-gaap:AllowanceForNotesAndLoansReceivableCurrent>
    <NRXS:AllowanceForInterestReceivableCurrent
      contextRef="AsOf2023-12-31_us-gaap_RelatedPartyMember"
      decimals="0"
      id="Fact001096"
      unitRef="USD">-141741</NRXS:AllowanceForInterestReceivableCurrent>
    <NRXS:AllowanceForInterestIncomeCurrent
      contextRef="AsOf2023-12-31_us-gaap_RelatedPartyMember"
      decimals="0"
      id="Fact001098"
      unitRef="USD">47734</NRXS:AllowanceForInterestIncomeCurrent>
    <NRXS:ScheduleOfRelatedPartyLoansTableTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact001106">&lt;p id="xdx_891_ecustom--ScheduleOfRelatedPartyLoansTableTextBlock_zYPySHBVmcS7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B0_zf8TjuMlvU4c" style="display: none"&gt;Schedule of Related Party Loans payable to shareholder&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Interest &amp;amp;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Interest&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Loan&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Service Fee&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Interest&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold"&gt;December 31, 2024&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Due Date&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Rate&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Balance&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Accrued&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Paid&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 30%; text-align: left; padding-bottom: 1pt"&gt;Other Convertibles&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 12%; text-align: center; padding-bottom: 1pt"&gt;&lt;span id="xdx_90D_eus-gaap--DebtInstrumentMaturityDateDescription_c20240101__20241231__us-gaap--DebtInstrumentAxis__custom--OtherConvertiblesMember_ztlLQ0Sr0av9" title="Due date"&gt;Various&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; width: 10%; text-align: center"&gt;&lt;span id="xdx_908_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_dp_uPure_c20241231__us-gaap--DebtInstrumentAxis__custom--OtherConvertiblesMember_zqSoAz84D45j" title="Debt instrument percentage"&gt;5.0&lt;/span&gt;%&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--LoansPayable_iI_c20241231__us-gaap--DebtInstrumentAxis__custom--OtherConvertiblesMember_zWABE9Cu0pab" style="border-bottom: Black 1pt solid; width: 10%; text-align: right" title="Interest payable"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1112"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_ecustom--InterestAndServiceFeeAccrued_iI_c20241231__us-gaap--DebtInstrumentAxis__custom--OtherConvertiblesMember_zfhfCYXJY2w2" style="border-bottom: Black 1pt solid; width: 10%; text-align: right" title="Interest payable"&gt;66,648&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--InterestPaid_c20240101__20241231__us-gaap--DebtInstrumentAxis__custom--OtherConvertiblesMember_z57rRBACUFUg" style="border-bottom: Black 1pt solid; width: 10%; text-align: right" title="Interest payable"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1116"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--LoansPayable_iI_c20241231_zPLJkVYOokw9" style="border-bottom: Black 1pt solid; text-align: right" title="Loan payable"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1118"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_ecustom--InterestAndServiceFeeAccrued_iI_c20241231_zuHlAygaJSw6" style="border-bottom: Black 1pt solid; text-align: right" title="Interest payable"&gt;66,648&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--InterestPaid_c20240101__20241231_z8Wm1dCWuYgg" style="border-bottom: Black 1pt solid; text-align: right" title="Interest payable"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1122"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Interest &amp;amp;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Interest&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Loan&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Service Fee&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Interest&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold"&gt;December 31, 2023&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Due Date&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Rate&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Balance&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Accrued&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Paid&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 30%"&gt;Shareholder 1&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 12%; text-align: center"&gt;&lt;span id="xdx_90B_eus-gaap--DebtInstrumentMaturityDateDescription_c20230101__20231231__us-gaap--DebtInstrumentAxis__custom--ShareHolderOneMember_zD7Nd8CcgBnk" title="Due date"&gt;June, 2019&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: center"&gt;&lt;span id="xdx_90A_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_dp_uPure_c20231231__us-gaap--DebtInstrumentAxis__custom--ShareHolderOneMember_zLgE9AFgTgab" title="Debt instrument percentage"&gt;15.0&lt;/span&gt;%&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--LoansPayable_iI_c20231231__us-gaap--DebtInstrumentAxis__custom--ShareHolderOneMember_zN3dNK2VXGv6" style="width: 10%; text-align: right" title="Loan payable"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1128"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_ecustom--InterestAndServiceFeeAccrued_iI_c20231231__us-gaap--DebtInstrumentAxis__custom--ShareHolderOneMember_zFgriPhYsCj9" style="width: 10%; text-align: right" title="Interest payable"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1130"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--InterestPaid_c20230101__20231231__us-gaap--DebtInstrumentAxis__custom--ShareHolderOneMember_zQME5pjAHsJ8" style="width: 10%; text-align: right" title="Interest payable"&gt;10,047&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Shareholder 2&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span id="xdx_902_eus-gaap--DebtInstrumentMaturityDateDescription_c20230101__20231231__us-gaap--DebtInstrumentAxis__custom--ShareHolderTwoMember_zpH8ZXwFTij3" title="Due date"&gt;June, 2019&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&lt;span id="xdx_903_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_dp_uPure_c20231231__us-gaap--DebtInstrumentAxis__custom--ShareHolderTwoMember_zf0NRnHbYLxf" title="Debt instrument percentage"&gt;15.0&lt;/span&gt;%&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--LoansPayable_iI_c20231231__us-gaap--DebtInstrumentAxis__custom--ShareHolderTwoMember_zqeyWtHDawre" style="text-align: right" title="Loan payable"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1138"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_ecustom--InterestAndServiceFeeAccrued_iI_c20231231__us-gaap--DebtInstrumentAxis__custom--ShareHolderTwoMember_zwizrWGlHZB" style="text-align: right" title="Interest payable"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1140"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--InterestPaid_c20230101__20231231__us-gaap--DebtInstrumentAxis__custom--ShareHolderTwoMember_zqcl1NyjQVI5" style="text-align: right" title="Interest payable"&gt;27,056&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Other Convertibles&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; padding-bottom: 1pt"&gt;&lt;span id="xdx_90B_eus-gaap--DebtInstrumentMaturityDateDescription_c20230101__20231231__us-gaap--DebtInstrumentAxis__custom--OtherConvertiblesMember_zdURnn0ve00d" title="Due date"&gt;Various&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center"&gt;&lt;span id="xdx_90E_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_dp_uPure_c20231231__us-gaap--DebtInstrumentAxis__custom--OtherConvertiblesMember_zHHONbcvNHPk" title="Debt instrument percentage"&gt;5.0&lt;/span&gt;%&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--LoansPayable_iI_c20231231__us-gaap--DebtInstrumentAxis__custom--OtherConvertiblesMember_zsriqlzXJhOg" style="border-bottom: Black 1pt solid; text-align: right" title="Interest payable"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1148"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_ecustom--InterestAndServiceFeeAccrued_iI_c20231231__us-gaap--DebtInstrumentAxis__custom--OtherConvertiblesMember_zteqJglcLHv9" style="border-bottom: Black 1pt solid; text-align: right" title="Interest payable"&gt;66,648&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--InterestPaid_c20230101__20231231__us-gaap--DebtInstrumentAxis__custom--OtherConvertiblesMember_zdCzgHVG7OMf" style="border-bottom: Black 1pt solid; text-align: right" title="Interest payable"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1152"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--LoansPayable_iI_c20231231_z7ORZjjvl3zc" style="border-bottom: Black 1pt solid; text-align: right" title="Loan payable"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1154"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_ecustom--InterestAndServiceFeeAccrued_iI_c20231231_zk4ROeNOQu59" style="border-bottom: Black 1pt solid; text-align: right" title="Interest payable"&gt;66,648&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--InterestPaid_c20230101__20231231_zxw0Nw7EIlJ4" style="border-bottom: Black 1pt solid; text-align: right" title="Interest payable"&gt;37,103&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</NRXS:ScheduleOfRelatedPartyLoansTableTextBlock>
    <us-gaap:DebtInstrumentMaturityDateDescription
      contextRef="From2024-01-012024-12-31_custom_OtherConvertiblesMember"
      id="Fact001108">Various</us-gaap:DebtInstrumentMaturityDateDescription>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="AsOf2024-12-31_custom_OtherConvertiblesMember"
      decimals="INF"
      id="Fact001110"
      unitRef="Pure">0.050</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <NRXS:InterestAndServiceFeeAccrued
      contextRef="AsOf2024-12-31_custom_OtherConvertiblesMember"
      decimals="0"
      id="Fact001114"
      unitRef="USD">66648</NRXS:InterestAndServiceFeeAccrued>
    <NRXS:InterestAndServiceFeeAccrued
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact001120"
      unitRef="USD">66648</NRXS:InterestAndServiceFeeAccrued>
    <us-gaap:DebtInstrumentMaturityDateDescription
      contextRef="From2023-01-012023-12-31_custom_ShareHolderOneMember"
      id="Fact001124">June, 2019</us-gaap:DebtInstrumentMaturityDateDescription>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="AsOf2023-12-31_custom_ShareHolderOneMember47707859"
      decimals="INF"
      id="Fact001126"
      unitRef="Pure">0.150</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:InterestPaid
      contextRef="From2023-01-012023-12-31_custom_ShareHolderOneMember"
      decimals="0"
      id="Fact001132"
      unitRef="USD">10047</us-gaap:InterestPaid>
    <us-gaap:DebtInstrumentMaturityDateDescription
      contextRef="From2023-01-012023-12-31_custom_ShareHolderTwoMember"
      id="Fact001134">June, 2019</us-gaap:DebtInstrumentMaturityDateDescription>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="AsOf2023-12-31_custom_ShareHolderTwoMember47707859"
      decimals="INF"
      id="Fact001136"
      unitRef="Pure">0.150</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:InterestPaid
      contextRef="From2023-01-012023-12-31_custom_ShareHolderTwoMember"
      decimals="0"
      id="Fact001142"
      unitRef="USD">27056</us-gaap:InterestPaid>
    <us-gaap:DebtInstrumentMaturityDateDescription
      contextRef="From2023-01-012023-12-31_custom_OtherConvertiblesMember"
      id="Fact001144">Various</us-gaap:DebtInstrumentMaturityDateDescription>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="AsOf2023-12-31_custom_OtherConvertiblesMember"
      decimals="INF"
      id="Fact001146"
      unitRef="Pure">0.050</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <NRXS:InterestAndServiceFeeAccrued
      contextRef="AsOf2023-12-31_custom_OtherConvertiblesMember"
      decimals="0"
      id="Fact001150"
      unitRef="USD">66648</NRXS:InterestAndServiceFeeAccrued>
    <NRXS:InterestAndServiceFeeAccrued
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact001156"
      unitRef="USD">66648</NRXS:InterestAndServiceFeeAccrued>
    <us-gaap:InterestPaid
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact001158"
      unitRef="USD">37103</us-gaap:InterestPaid>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction
      contextRef="From2024-01-012024-12-31_us-gaap_RelatedPartyMember"
      decimals="0"
      id="Fact001160"
      unitRef="USD">4973</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction
      contextRef="From2024-01-012024-12-31_custom_MrWatkinsMember"
      decimals="0"
      id="Fact001162"
      unitRef="USD">0</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction
      contextRef="From2023-01-012023-12-31_custom_MrWatkinsMember"
      decimals="0"
      id="Fact001164"
      unitRef="USD">11083</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
    <us-gaap:PaymentsForFees
      contextRef="From2024-01-012024-12-31_custom_MrSealeMember"
      decimals="0"
      id="Fact001166"
      unitRef="USD">207103</us-gaap:PaymentsForFees>
    <us-gaap:PaymentsForFees
      contextRef="From2023-01-012023-12-31_custom_MrSealeMember"
      decimals="0"
      id="Fact001168"
      unitRef="USD">312803</us-gaap:PaymentsForFees>
    <us-gaap:AccountsPayableCurrentAndNoncurrent
      contextRef="AsOf2024-12-31_custom_MrSealeMember"
      decimals="0"
      id="Fact001170"
      unitRef="USD">4173</us-gaap:AccountsPayableCurrentAndNoncurrent>
    <us-gaap:AccountsPayableCurrentAndNoncurrent
      contextRef="AsOf2023-12-31_custom_MrSealeMember"
      decimals="0"
      id="Fact001172"
      unitRef="USD">84279</us-gaap:AccountsPayableCurrentAndNoncurrent>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="From2024-01-012024-12-31_srt_ChiefFinancialOfficerMember"
      decimals="INF"
      id="Fact001174"
      unitRef="Shares">20000</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2024-01-012024-12-31_srt_ChiefFinancialOfficerMember"
      decimals="0"
      id="Fact001176"
      unitRef="USD">55600</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact001178">&lt;p id="xdx_80F_eus-gaap--PropertyPlantAndEquipmentDisclosureTextBlock_zUFxuIJo0Bz4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;4.
&lt;span id="xdx_82B_zGSUumEulbKl"&gt;Property and Equipment&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_898_eus-gaap--PropertyPlantAndEquipmentTextBlock_zZExnw39C8Mb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Property
and equipment, net consists of the following:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span id="xdx_8BD_zSpbTDAq6AI2" style="display: none"&gt;Schedule of Property And Equipment&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_492_20241231_z1L83aOgT7Ca" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;December 31, 2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49A_20231231_zX9lQ20XfjUh" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;December 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--MachineryAndEquipmentMember_zheELRMbM1pg" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;Machinery and equipment&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;282,181&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;282,181&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zgoPHiIyxVKh" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Furniture and fixtures&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;111,036&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;96,768&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_zQoYCrk5twy" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Computer hardware&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;50,121&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;36,613&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zidW0RfYiTCe" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Leasehold improvements&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;21,064&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;21,064&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--PropertyPlantAndEquipmentGross_iI_maPPAENzDOd_zAkjgdLgKp1c" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Total property and equipment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;464,402&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;436,626&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_di_msPPAENzDOd_zjVmdbF0MLib" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt"&gt;Less: accumulated depreciation&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(374,420&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(348,074&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--PropertyPlantAndEquipmentNet_iTI_mtPPAENzDOd_zctvrjFcVVIl" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 20pt; text-align: left; padding-bottom: 1pt"&gt;Property and equipment, net&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;89,982&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;88,552&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A8_z94iI4eYJHYa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Depreciation
expense was $&lt;span id="xdx_904_eus-gaap--Depreciation_c20240101__20241231_zsy0uhxgb9Ch" title="Depreciation"&gt;26,346&lt;/span&gt;&lt;/span&gt; &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;and
$&lt;span id="xdx_909_eus-gaap--Depreciation_c20230101__20231231_z1e82Ze8LH4j" title="Depreciation"&gt;30,240&lt;/span&gt;&lt;/span&gt; &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;for
the years ended December 31, 2024 and 2023, respectively. The Company expects to record future depreciation expense totaling $&lt;span id="xdx_90D_eus-gaap--Depreciation_c20240101__20241231__us-gaap--AwardTypeAxis__custom--DecemberTwoThousandTwentyFiveMember_zkjKxXzQIcy4" title="Depreciation"&gt;13,438&lt;/span&gt;,
$&lt;span id="xdx_903_eus-gaap--Depreciation_c20240101__20241231__us-gaap--AwardTypeAxis__custom--DecemberTwoThousandTwentySixMember_z3NxraUtaX4c" title="Depreciation"&gt;12,344&lt;/span&gt;, $&lt;span id="xdx_90B_eus-gaap--Depreciation_c20240101__20241231__us-gaap--AwardTypeAxis__custom--DecemberTwoThousandTwentySevenMember_zYV9ind1ph5d" title="Depreciation"&gt;11,977&lt;/span&gt;, $&lt;span id="xdx_907_eus-gaap--Depreciation_c20240101__20241231__us-gaap--AwardTypeAxis__custom--DecemberTwoThousandTwentyEightMember_zwE12gHhqe9a" title="Depreciation"&gt;9,753&lt;/span&gt;, $&lt;span id="xdx_907_eus-gaap--Depreciation_c20240101__20241231__us-gaap--AwardTypeAxis__custom--DecemberTwoThousandTwentyNineMember_ztixW5WddXW8" title="Depreciation"&gt;6,259&lt;/span&gt; and $&lt;span id="xdx_90D_eus-gaap--Depreciation_c20240101__20241231__us-gaap--AwardTypeAxis__custom--DecemberTwoThousandTwentyThereafterMember_zrjbQb1vUUYe" title="Depreciation"&gt;14,111&lt;/span&gt; for the years ending December 31, 2025, 2026, 2027, 2028, 2029 and thereafter, respectively.&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact001180">&lt;p id="xdx_898_eus-gaap--PropertyPlantAndEquipmentTextBlock_zZExnw39C8Mb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Property
and equipment, net consists of the following:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span id="xdx_8BD_zSpbTDAq6AI2" style="display: none"&gt;Schedule of Property And Equipment&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_492_20241231_z1L83aOgT7Ca" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;December 31, 2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49A_20231231_zX9lQ20XfjUh" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;December 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--MachineryAndEquipmentMember_zheELRMbM1pg" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;Machinery and equipment&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;282,181&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;282,181&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zgoPHiIyxVKh" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Furniture and fixtures&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;111,036&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;96,768&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_zQoYCrk5twy" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Computer hardware&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;50,121&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;36,613&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zidW0RfYiTCe" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Leasehold improvements&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;21,064&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;21,064&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--PropertyPlantAndEquipmentGross_iI_maPPAENzDOd_zAkjgdLgKp1c" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Total property and equipment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;464,402&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;436,626&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_di_msPPAENzDOd_zjVmdbF0MLib" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt"&gt;Less: accumulated depreciation&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(374,420&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(348,074&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--PropertyPlantAndEquipmentNet_iTI_mtPPAENzDOd_zctvrjFcVVIl" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 20pt; text-align: left; padding-bottom: 1pt"&gt;Property and equipment, net&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;89,982&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;88,552&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2024-12-31_us-gaap_MachineryAndEquipmentMember"
      decimals="0"
      id="Fact001182"
      unitRef="USD">282181</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2023-12-31_us-gaap_MachineryAndEquipmentMember"
      decimals="0"
      id="Fact001183"
      unitRef="USD">282181</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2024-12-31_us-gaap_FurnitureAndFixturesMember"
      decimals="0"
      id="Fact001185"
      unitRef="USD">111036</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2023-12-31_us-gaap_FurnitureAndFixturesMember"
      decimals="0"
      id="Fact001186"
      unitRef="USD">96768</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2024-12-31_us-gaap_ComputerEquipmentMember"
      decimals="0"
      id="Fact001188"
      unitRef="USD">50121</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2023-12-31_us-gaap_ComputerEquipmentMember"
      decimals="0"
      id="Fact001189"
      unitRef="USD">36613</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2024-12-31_us-gaap_LeaseholdImprovementsMember"
      decimals="0"
      id="Fact001191"
      unitRef="USD">21064</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2023-12-31_us-gaap_LeaseholdImprovementsMember"
      decimals="0"
      id="Fact001192"
      unitRef="USD">21064</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact001194"
      unitRef="USD">464402</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact001195"
      unitRef="USD">436626</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact001197"
      unitRef="USD">374420</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact001198"
      unitRef="USD">348074</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact001200"
      unitRef="USD">89982</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact001201"
      unitRef="USD">88552</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Depreciation
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact001203"
      unitRef="USD">26346</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact001205"
      unitRef="USD">30240</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="From2024-01-012024-12-31_custom_DecemberTwoThousandTwentyFiveMember"
      decimals="0"
      id="Fact001207"
      unitRef="USD">13438</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="From2024-01-012024-12-31_custom_DecemberTwoThousandTwentySixMember"
      decimals="0"
      id="Fact001209"
      unitRef="USD">12344</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="From2024-01-012024-12-31_custom_DecemberTwoThousandTwentySevenMember"
      decimals="0"
      id="Fact001211"
      unitRef="USD">11977</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="From2024-01-012024-12-31_custom_DecemberTwoThousandTwentyEightMember"
      decimals="0"
      id="Fact001213"
      unitRef="USD">9753</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="From2024-01-012024-12-31_custom_DecemberTwoThousandTwentyNineMember"
      decimals="0"
      id="Fact001215"
      unitRef="USD">6259</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="From2024-01-012024-12-31_custom_DecemberTwoThousandTwentyThereafterMember"
      decimals="0"
      id="Fact001217"
      unitRef="USD">14111</us-gaap:Depreciation>
    <us-gaap:IntangibleAssetsDisclosureTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact001219">&lt;p id="xdx_800_eus-gaap--IntangibleAssetsDisclosureTextBlock_zIGckrcXtkNe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;5.
&lt;span id="xdx_82C_zhiyZ8YSnib8"&gt;Intangible Assets&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89A_eus-gaap--ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_z7HEvAFzd705" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Intangible
assets, net consists of the following:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8BF_ztWJTbv4oTL3" style="display: none"&gt;Schedule of Intangible Assets&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_493_20241231_zffQXKuWcn2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;December 31, 2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_498_20231231_z33gPHqBRVv2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;December 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_hus-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--SoftwareImplementationMember_z91J2gu0Mtek" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;Software Implementation&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;49,815&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;49,815&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_hus-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zf6epMbZTE2h" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Patents&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;32,463&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;32,463&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_hus-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_z0qGsDlM50x4" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Trademark&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;50,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;50,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_hus-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LicensesMember_zPayp6miIW38" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;Licenses&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"&gt;1,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;1,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_maFLIANzh0b_ziGX9bS4QS2a" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Total intangible assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;133,278&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;133,278&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iNI_di_msFLIANzh0b_zI6Tp7ZxyOE7" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt"&gt;Less: accumulated amortization&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(36,690&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(25,205&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--FiniteLivedIntangibleAssetsNet_iTI_mtFLIANzh0b_zP3Z51RAYuo1" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 20pt; text-align: left; padding-bottom: 1pt"&gt;Intangible assets, net&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;96,588&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;108,073&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A1_zVo20MoPcPWd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Amortization
expense was $&lt;span id="xdx_907_eus-gaap--AmortizationOfIntangibleAssets_c20240101__20241231_zTMToDTzkRsf" title="Amortization expense"&gt;11,485&lt;/span&gt;
and $&lt;span id="xdx_907_eus-gaap--AmortizationOfIntangibleAssets_c20230101__20231231_zKXNJcVK7yUh" title="Amortization expense"&gt;10,485&lt;/span&gt;
for the years ended December 31, 2024 and 2023, respectively. The Company expect to record future amortization expense totaling $&lt;span id="xdx_90A_eus-gaap--AmortizationOfIntangibleAssets_c20240101__20241231__us-gaap--AwardTypeAxis__custom--DecemberTwoThousandTwentyFiveMember_z3T8gdPSqdxl" title="Amortization expense"&gt;10,485&lt;/span&gt;, $&lt;span id="xdx_909_eus-gaap--AmortizationOfIntangibleAssets_c20240101__20241231__us-gaap--AwardTypeAxis__custom--DecemberTwoThousandTwentySixMember_ztSoQDyy8PX5" title="Amortization expense"&gt;10,485&lt;/span&gt;, $&lt;span id="xdx_90F_eus-gaap--AmortizationOfIntangibleAssets_c20240101__20241231__us-gaap--AwardTypeAxis__custom--DecemberTwoThousandTwentySevenMember_z5FuQsYzAjXi" title="Amortization expense"&gt;10,485&lt;/span&gt;, $&lt;span id="xdx_90F_eus-gaap--AmortizationOfIntangibleAssets_c20240101__20241231__us-gaap--AwardTypeAxis__custom--DecemberTwoThousandTwentyEightMember_zjs5JWJzEcx8" title="Amortization expense"&gt;4,760&lt;/span&gt;, $&lt;span id="xdx_900_eus-gaap--AmortizationOfIntangibleAssets_c20240101__20241231__us-gaap--AwardTypeAxis__custom--DecemberTwoThousandTwentyNineMember_zruZIP5NfTPj" title="Amortization expense"&gt;1,941&lt;/span&gt; and $&lt;span id="xdx_90B_eus-gaap--AmortizationOfIntangibleAssets_c20240101__20241231__us-gaap--AwardTypeAxis__custom--DecemberTwoThousandTwentyThereafterMember_zJ6M35G3qjql" title="Amortization expense"&gt;8,432&lt;/span&gt; for the years
ending December 31, 2025, 2026, 2027, 2028, 2029 and thereafter, respectively. The Company&#x2019;s trademark does not have a determinate life
and therefore the cost is not being amortized.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:IntangibleAssetsDisclosureTextBlock>
    <us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact001221">&lt;p id="xdx_89A_eus-gaap--ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_z7HEvAFzd705" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Intangible
assets, net consists of the following:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8BF_ztWJTbv4oTL3" style="display: none"&gt;Schedule of Intangible Assets&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_493_20241231_zffQXKuWcn2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;December 31, 2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_498_20231231_z33gPHqBRVv2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;December 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_hus-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--SoftwareImplementationMember_z91J2gu0Mtek" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;Software Implementation&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;49,815&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;49,815&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_hus-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zf6epMbZTE2h" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Patents&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;32,463&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;32,463&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_hus-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_z0qGsDlM50x4" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Trademark&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;50,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;50,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_hus-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LicensesMember_zPayp6miIW38" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;Licenses&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"&gt;1,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;1,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_maFLIANzh0b_ziGX9bS4QS2a" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Total intangible assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;133,278&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;133,278&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iNI_di_msFLIANzh0b_zI6Tp7ZxyOE7" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt"&gt;Less: accumulated amortization&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(36,690&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(25,205&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--FiniteLivedIntangibleAssetsNet_iTI_mtFLIANzh0b_zP3Z51RAYuo1" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 20pt; text-align: left; padding-bottom: 1pt"&gt;Intangible assets, net&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;96,588&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;108,073&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="AsOf2024-12-31_custom_SoftwareImplementationMember"
      decimals="0"
      id="Fact001223"
      unitRef="USD">49815</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="AsOf2023-12-31_custom_SoftwareImplementationMember"
      decimals="0"
      id="Fact001224"
      unitRef="USD">49815</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="AsOf2024-12-31_us-gaap_PatentsMember"
      decimals="0"
      id="Fact001226"
      unitRef="USD">32463</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="AsOf2023-12-31_us-gaap_PatentsMember"
      decimals="0"
      id="Fact001227"
      unitRef="USD">32463</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="AsOf2024-12-31_us-gaap_TrademarksMember"
      decimals="0"
      id="Fact001229"
      unitRef="USD">50000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="AsOf2023-12-31_us-gaap_TrademarksMember"
      decimals="0"
      id="Fact001230"
      unitRef="USD">50000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="AsOf2024-12-31_custom_LicensesMember"
      decimals="0"
      id="Fact001232"
      unitRef="USD">1000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="AsOf2023-12-31_custom_LicensesMember"
      decimals="0"
      id="Fact001233"
      unitRef="USD">1000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact001235"
      unitRef="USD">133278</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact001236"
      unitRef="USD">133278</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact001238"
      unitRef="USD">36690</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact001239"
      unitRef="USD">25205</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact001241"
      unitRef="USD">96588</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact001242"
      unitRef="USD">108073</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact001244"
      unitRef="USD">11485</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact001246"
      unitRef="USD">10485</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="From2024-01-012024-12-31_custom_DecemberTwoThousandTwentyFiveMember"
      decimals="0"
      id="Fact001248"
      unitRef="USD">10485</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="From2024-01-012024-12-31_custom_DecemberTwoThousandTwentySixMember"
      decimals="0"
      id="Fact001250"
      unitRef="USD">10485</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="From2024-01-012024-12-31_custom_DecemberTwoThousandTwentySevenMember"
      decimals="0"
      id="Fact001252"
      unitRef="USD">10485</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="From2024-01-012024-12-31_custom_DecemberTwoThousandTwentyEightMember"
      decimals="0"
      id="Fact001254"
      unitRef="USD">4760</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="From2024-01-012024-12-31_custom_DecemberTwoThousandTwentyNineMember"
      decimals="0"
      id="Fact001256"
      unitRef="USD">1941</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="From2024-01-012024-12-31_custom_DecemberTwoThousandTwentyThereafterMember"
      decimals="0"
      id="Fact001258"
      unitRef="USD">8432</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact001260">&lt;p id="xdx_804_eus-gaap--AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_zNMRRyCHPx6h" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;6.
&lt;span id="xdx_820_zIWxJtFoBTZ6"&gt;Accrued Expenses&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_897_eus-gaap--ScheduleOfAccruedLiabilitiesTableTextBlock_zvUb0GeiOnXj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Accrued
expenses consisted of the following:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8BB_zpdknJa9shG3" style="display: none"&gt;Schedule of Accrued Expenses&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_499_20241231_zKsVdgUSQQmk" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;December 31, 2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_497_20231231_zTS4WmLwiwVl" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;December 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_ecustom--AccruedCompensationAndBenefitsCurrent_iI_maALCz94I_zfW9IkDNsimh" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;Compensation and benefits&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;1,261,317&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;333,477&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_ecustom--AdvisoryFees_iI_maALCz94I_zmfz7vtKw8Nj" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Advisory fees&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;176,750&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1268"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--InterestPayableCurrent_iI_maALCz94I_znHRDcQk5vL8" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Interest&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;66,648&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;66,648&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--AccrualForTaxesOtherThanIncomeTaxesCurrent_iI_maALCz94I_zEo4FtIWXx23" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;Other&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;73,065&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;963&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--AccruedLiabilitiesCurrent_iTI_mtALCz94I_zUvo3TiPrkFi" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt"&gt;Total accrued expenses&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;1,577,780&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;401,088&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AA_zWDzSdN9GyAg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact001262">&lt;p id="xdx_897_eus-gaap--ScheduleOfAccruedLiabilitiesTableTextBlock_zvUb0GeiOnXj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Accrued
expenses consisted of the following:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8BB_zpdknJa9shG3" style="display: none"&gt;Schedule of Accrued Expenses&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_499_20241231_zKsVdgUSQQmk" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;December 31, 2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_497_20231231_zTS4WmLwiwVl" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;December 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_ecustom--AccruedCompensationAndBenefitsCurrent_iI_maALCz94I_zfW9IkDNsimh" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;Compensation and benefits&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;1,261,317&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;333,477&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_ecustom--AdvisoryFees_iI_maALCz94I_zmfz7vtKw8Nj" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Advisory fees&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;176,750&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1268"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--InterestPayableCurrent_iI_maALCz94I_znHRDcQk5vL8" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Interest&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;66,648&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;66,648&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--AccrualForTaxesOtherThanIncomeTaxesCurrent_iI_maALCz94I_zEo4FtIWXx23" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;Other&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;73,065&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;963&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--AccruedLiabilitiesCurrent_iTI_mtALCz94I_zUvo3TiPrkFi" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt"&gt;Total accrued expenses&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;1,577,780&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;401,088&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <NRXS:AccruedCompensationAndBenefitsCurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact001264"
      unitRef="USD">1261317</NRXS:AccruedCompensationAndBenefitsCurrent>
    <NRXS:AccruedCompensationAndBenefitsCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact001265"
      unitRef="USD">333477</NRXS:AccruedCompensationAndBenefitsCurrent>
    <NRXS:AdvisoryFees
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact001267"
      unitRef="USD">176750</NRXS:AdvisoryFees>
    <us-gaap:InterestPayableCurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact001270"
      unitRef="USD">66648</us-gaap:InterestPayableCurrent>
    <us-gaap:InterestPayableCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact001271"
      unitRef="USD">66648</us-gaap:InterestPayableCurrent>
    <us-gaap:AccrualForTaxesOtherThanIncomeTaxesCurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact001273"
      unitRef="USD">73065</us-gaap:AccrualForTaxesOtherThanIncomeTaxesCurrent>
    <us-gaap:AccrualForTaxesOtherThanIncomeTaxesCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact001274"
      unitRef="USD">963</us-gaap:AccrualForTaxesOtherThanIncomeTaxesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact001276"
      unitRef="USD">1577780</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact001277"
      unitRef="USD">401088</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:DebtDisclosureTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact001279">&lt;p id="xdx_805_eus-gaap--DebtDisclosureTextBlock_zqDM9DydFvQj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;7.
&lt;span id="xdx_820_zrHP8dXRKMOk"&gt;Notes Payable&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Neuraxis,
Inc.&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Notes
to Financial Statements&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;Promissory
Notes&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company borrowed $&lt;span id="xdx_90E_eus-gaap--DebtInstrumentFaceAmount_iI_c20211216__dei--LegalEntityAxis__custom--ChannelPartnersCapitalMember_zEFgcCQS5p66"&gt;250,000 &lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;on
December 16, 2021, from Channel Partners Capital (the &#x201c;2021 Promissory Note&#x201d;). The 2021 Promissory Note called for 65
weekly payments of $&lt;span id="xdx_90D_eus-gaap--DebtInstrumentPeriodicPayment_pp2d_c20230316__20230316__dei--LegalEntityAxis__custom--ChannelPartnersCapitalMember_zIhJDUCy6u28"&gt;4,923 &lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;with
the final payment scheduled for March 16, 2023. The principal outstanding at January 1, 2022 was $&lt;span id="xdx_90B_eus-gaap--LongTermDebtAverageAmountOutstanding_c20220101__20220101__dei--LegalEntityAxis__custom--ChannelPartnersCapitalMember_zu7oEe0sn3j1"&gt;244,048&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;.
The Company borrowed $&lt;span id="xdx_905_eus-gaap--DebtInstrumentFaceAmount_iI_c20220916__dei--LegalEntityAxis__custom--ChannelPartnersCapitalMember_zDlf2W34cPyf"&gt;122,000 &lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;on
September 16, 2022, to bring the 2021 Promissory Note&#x2019;s principal balance back to $&lt;span id="xdx_902_eus-gaap--DebtInstrumentRepurchasedFaceAmount_iI_c20220916__dei--LegalEntityAxis__custom--ChannelPartnersCapitalMember_zu0onMRBFkE1"&gt;250,000&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;.
After making scheduled payments, the Company borrowed another $&lt;span id="xdx_90F_eus-gaap--DebtInstrumentFaceAmount_iI_c20230524__dei--LegalEntityAxis__custom--ChannelPartnersCapitalMember_zMDaPLFvDHL1"&gt;107,231 &lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;on
May 24, 2023, to bring the 2021 Promissory Note&#x2019;s principal balance back to $&lt;span id="xdx_908_eus-gaap--DebtInstrumentRepurchasedFaceAmount_iI_c20230524__dei--LegalEntityAxis__custom--ChannelPartnersCapitalMember_zoT6NPXmc5Ab"&gt;250,000 &lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;once
again. The terms of the incremental borrowings were the same as the 2021 Promissory Note with the final payment made on August 22,
2024. The principal outstanding as of December 31, 2024 and 2023 was $&lt;span id="xdx_90E_eus-gaap--NotesPayable_iI_c20241231__dei--LegalEntityAxis__custom--ChannelPartnersCapitalMember_z4GkskSuYK4d"&gt;0 &lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;and
$&lt;span id="xdx_90A_eus-gaap--NotesPayable_iI_c20231231__dei--LegalEntityAxis__custom--ChannelPartnersCapitalMember_zPcArPDgmb1"&gt;148,062&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;,
respectively, with an effective interest rate of &lt;span id="xdx_902_eus-gaap--DebtInstrumentInterestRateEffectivePercentage_iI_pid_dp_uPure_c20241231__dei--LegalEntityAxis__custom--ChannelPartnersCapitalMember_z0tGbscimUTh" title="Debt instrument interest rate effective percentage"&gt;&lt;span id="xdx_908_eus-gaap--DebtInstrumentInterestRateEffectivePercentage_iI_pid_dp_uPure_c20231231__dei--LegalEntityAxis__custom--ChannelPartnersCapitalMember_zNervzHDQ127" title="Debt instrument interest rate effective percentage"&gt;55.9&lt;/span&gt;&lt;/span&gt;%. The Company believes that the advancement of additional funds is a minor
modification to the terms of the existing promissory note since the difference in present value of the cash flows under the terms of
the new loan is less than 10% of the present value of the remaining cash flows under the terms of the original loan. As a result,
the modification was accounted for as a modification of debt.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
lender was granted and assigned a continuing security interest in all the Company&#x2019;s personal property assets including, but not
limited to, business equipment, inventory, accounts, accounts receivable, intellectual property, chattel paper, instruments, deposit
accounts, commercial tort claims, contract rights, licenses, claims, and general intangibles.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
February 15, 2023, The Company signed a note with Exchange Listing, LLC in the amount of $&lt;span id="xdx_901_eus-gaap--DebtInstrumentFaceAmount_iI_c20230215__dei--LegalEntityAxis__custom--ExchangeListingLLCMember__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember_zRMlWKPbwri7" title="Promissory note"&gt;52,600&lt;/span&gt; (the &#x201c;2023 Promissory Note&#x201d;).
The 2023 Promissory Note carried an interest rate of &lt;span id="xdx_90C_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_dp_uPure_c20230215__dei--LegalEntityAxis__custom--ExchangeListingLLCMember__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember_zql6zk4wtE0j" title="Interest rate"&gt;1&lt;/span&gt;% and was to be paid on the earlier of (i) three months or (ii) the Company receiving
financing at the minimum of $&lt;span id="xdx_905_eus-gaap--NotesPayable_iI_c20230215__dei--LegalEntityAxis__custom--ExchangeListingLLCMember__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember_zTzH4vK2X6Kf" title="Promissory note"&gt;3,000,000&lt;/span&gt;. In August 2023, the Company used proceeds from the IPO to pay the 2023 Promissory Note back in
full, including interest, in the amount of $&lt;span id="xdx_900_eus-gaap--ProceedsFromIssuanceInitialPublicOffering_pp2d_c20230831__20230831__dei--LegalEntityAxis__custom--ExchangeListingLLCMember__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember_zliXyL9i6Hg6" title="Proceeds from issuance of ipo"&gt;52,858&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
August 9, 2024, the Company entered into a $&lt;span id="xdx_90E_eus-gaap--NotesPayable_iI_c20240809__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember_zSLcTzH4lfH3" title="Promissory note"&gt;210,000&lt;/span&gt; promissory note to finance the premiums of its annual directors and officers insurance
policy, bearing interest at a rate of&#160;&lt;span id="xdx_903_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20240809__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember_zxUHjNWitNhc" title="Interest rate"&gt;7.40&lt;/span&gt;% per annum and maturing on &lt;span id="xdx_90E_eus-gaap--DebtInstrumentMaturityDate_pid_dp_uPure_c20240809__20240809__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember_z2OkaoitC9Bl" title="Maturity date"&gt;June 9, 2025&lt;/span&gt;. On November 1, 2024, the Company entered into
a second promissory note with a principal balance of $&lt;span id="xdx_90E_eus-gaap--DebtInstrumentFaceAmount_iI_c20241101__us-gaap--DebtInstrumentAxis__custom--SecondPromissoryNoteMember_zVxIbOe4nfM7" title="Face amount"&gt;64,328&lt;/span&gt; to finance premiums of its annual business insurance policies, bearing interest
at a rate of &lt;span id="xdx_908_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20241101__us-gaap--DebtInstrumentAxis__custom--SecondPromissoryNoteMember_zT8azvnZtHBk"&gt;7.65&lt;/span&gt;% per annum and maturing on &lt;span id="xdx_902_eus-gaap--DebtInstrumentMaturityDate_pid_dp_uPure_c20241101__20241101__us-gaap--DebtInstrumentAxis__custom--SecondPromissoryNoteMember_z3FbP6YiSzJi" title="Maturity date"&gt;September 1, 2025&lt;/span&gt; (collectively referred to as the &#x201c;2024 Promissory Notes&#x201d;).
The principal outstanding on 2024 Promissory Notes was $&lt;span id="xdx_90A_eus-gaap--DebtInstrumentFaceAmount_iI_c20241231__us-gaap--DebtInstrumentAxis__custom--SecondPromissoryNoteMember_zKmFOTDHcsNh" title="Outstanding promissory notes"&gt;154,152&lt;/span&gt; and $&lt;span id="xdx_904_eus-gaap--DebtInstrumentFaceAmount_iI_c20231231__us-gaap--DebtInstrumentAxis__custom--SecondPromissoryNoteMember_zIKBHYh1IO6j" title="Outstanding promissory notes"&gt;0&lt;/span&gt; as of December 31, 2024 and 2023, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;2022
Convertible Notes&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
2022, the Company issued multiple convertible notes with aggregate gross principal amounts totaling $&lt;span id="xdx_908_eus-gaap--DebtInstrumentCarryingAmount_iI_c20221130__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyTwoConvertibleNotesMember_zqQaw6ZIDRqc" title="Debt instrument gross"&gt;3,333,333&lt;/span&gt;
and net proceeds of $&lt;span id="xdx_906_eus-gaap--ProceedsFromIssuanceOfDebt_c20221130__20221130__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyTwoConvertibleNotesMember_zjgkQLG15Kl7" title="Net proceeds of debt"&gt;2,870,000&lt;/span&gt;
(the &#x201c;2022 Convertible Notes&#x201d;). The 2022 Convertible Notes consisted of an &lt;span id="xdx_90F_eus-gaap--DebtInstrumentDescriptionOfVariableRateBasis_c20220603__20221130__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyTwoConvertibleNotesMember_zvDbyVtXaXMi" title="Debt instrument description"&gt;original
issue discount of 10% with an interest rate of the greater of (i) Prime rate plus 8.5% or (ii) 12% resulting in an effective
interest rate of &lt;span id="xdx_90F_eus-gaap--DebtInstrumentInterestRateEffectivePercentage_iI_pid_dp_uPure_c20221231__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyTwoConvertibleNotesMember_zmFpWDLEwHX8" title="Debt instrument interest rate effective percentage"&gt;24.2&lt;/span&gt;%.&lt;/span&gt; The 2022 Convertible Notes converted into common shares at the lower of (i) $&lt;span id="xdx_900_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_c20221130__srt--RangeAxis__srt--MinimumMember__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyTwoConvertibleNotesMember_zvQKZ0utCRB1"&gt;9.44&lt;/span&gt;
or (ii) a &lt;span id="xdx_900_ecustom--DebtInstrumentDiscountRate_iI_dp_uPure_c20221130__srt--RangeAxis__srt--MaximumMember__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyTwoConvertibleNotesMember_z50OMeun7FZd"&gt;30&lt;/span&gt;%
discount to the price per share of any subsequent offering. The 2022 Convertible Notes matured on the one-year anniversary date from
issuance and contained &lt;span id="xdx_900_ecustom--DebtWarrantConversionDescription_c20221130__20221130__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyTwoConvertibleNotesMember_zeHL1W9gR2jk" title="Debt warrant conversion, description"&gt;a
five-year warrant to purchase common stock equal to one hundred percent (100%) of the shares into which the 2022 Convertible Notes
could be converted into at issuance. &lt;/span&gt;The warrants had an exercise price at the lower of (i) $&lt;span id="xdx_902_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20221130__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyTwoConvertibleNotesMember_zD15DYCBQuc3" title="Exercise price"&gt;11.80&lt;/span&gt;
per share or (ii) a &lt;span id="xdx_908_ecustom--ClassOfWarrantDiscountRate_iI_dp_uPure_c20221130__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyTwoConvertibleNotesMember_zpyyX39zWKL1" title="Class of warrant discount rate"&gt;12.5&lt;/span&gt;%
discount to the price per share of any subsequent offering.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
convertible notes signed on December 19, 2022 had aggregate gross principal amounts totaling $&lt;span id="xdx_902_eus-gaap--DebtInstrumentCarryingAmount_iI_c20221219__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyTwoConvertibleNotesMember_zY4AipqPlXjh" title="Debt instrument gross"&gt;222,222&lt;/span&gt; and net proceeds of $&lt;span id="xdx_90A_eus-gaap--ProceedsFromIssuanceOfDebt_c20221219__20221219__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyTwoConvertibleNotesMember_zzQRSmAAdBD6" title="Net proceeds of debt"&gt;200,000&lt;/span&gt; and
consisted of an original issue discount of &lt;span id="xdx_902_ecustom--DebtInstrumentDiscountRate_iI_dp_uPure_c20221219__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyTwoConvertibleNotesMember_z7hWSk50ycQj" title="Debt instrument discount rate"&gt;10&lt;/span&gt;% of the principal amount with an interest rate of &lt;span id="xdx_901_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_dp_uPure_c20221219__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyTwoConvertibleNotesMember_zOVeh7LRY85" title="Accrued interest"&gt;12&lt;/span&gt;% per annum. The notes matured at the
earlier of (i) twelve (12) months from the issue date or (ii) the date upon which the Company completes a registered public offering
of shares of the Company, which encompasses the closing of the IPO. The notes are convertible into shares of common stock at the higher
of (i) $&lt;span id="xdx_901_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_c20221219__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyTwoConvertibleNotesMember_zPaI12QxapN9" title="Conversion price"&gt;9.44&lt;/span&gt; per share or (ii) the price per share of common stock issued pursuant to the next registered public offering of shares of
the Company made prior to the conversion of any portion of the note. Interest accrues on the aggregate principal amount (which includes
original issue discount) and is payable on the maturity date, at the Company&#x2019;s election, in cash or in-kind. The holders of the
notes are entitled to piggyback registration rights on any registration statement filed by the Company, other than any registration statement
filed on Form S-4 or Form S-8. The warrants and conversion shares are subject to anti-dilution provisions.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
investors of the notes signed on December 19, 2022 above did not convert their notes and, as such the Company used proceeds from the
initial public offering to pay the remaining promissory notes back in full, including interest in the amount of $&lt;span id="xdx_906_eus-gaap--ProceedsFromIssuanceInitialPublicOffering_c20221219__20221219__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyTwoConvertibleNotesMember_zO90UJ5v8AA4" title="Proceeds from issuance of ipo"&gt;239,104&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;2023
Convertible Notes&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
2023, the Company conducted multiple closings of a private placement offering to accredited investors for aggregate gross principal
amounts of $&lt;span id="xdx_90E_eus-gaap--DebtInstrumentCarryingAmount_iI_c20231231__us-gaap--DebtInstrumentAxis__custom--ConvertiblePromissoryNoteMember__srt--TitleOfIndividualAxis__custom--AccreditedInvestorsMember_zpDMokGIBjK3" title="Debt instrument gross"&gt;6,066,667&lt;/span&gt;
and net proceeds of $&lt;span id="xdx_902_eus-gaap--ProceedsFromIssuanceOfDebt_c20230101__20231231__srt--TitleOfIndividualAxis__custom--AccreditedInvestorsMember__us-gaap--DebtInstrumentAxis__custom--ConvertiblePromissoryNoteMember_znCDb3Ms1PEg" title="Net proceeds of debt"&gt;4,908,000&lt;/span&gt;
(the &#x201c;2023 Convertible Notes&#x201d;). The offering consisted of a convertible promissory note that accrued interest at &lt;span id="xdx_90E_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_dp_uPure_c20231231__us-gaap--DebtInstrumentAxis__custom--ConvertiblePromissoryNoteMember_zUaQiNCsuCb6" title="Debt instrument interest rate"&gt;12&lt;/span&gt;%
that could be paid in cash or PIK and had an original issue discount of &lt;span id="xdx_90B_ecustom--DebtInstrumentDiscountRate_iI_pid_dp_uPure_c20231231__us-gaap--DebtInstrumentAxis__custom--ConvertiblePromissoryNoteMember_z9UC19ga76na" title="Debt instrument discount rate"&gt;10&lt;/span&gt;%
resulting in an effective interest rate of &lt;span id="xdx_909_eus-gaap--DebtInstrumentInterestRateEffectivePercentage_iI_pid_dp_uPure_c20231231__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeConvertibleNotesMember_zDQzuqODLQR1" title="Debt instrument interest rate effective percentage"&gt;27.5&lt;/span&gt;%. The 2023 Convertible Notes automatically converted into common shares at a &lt;span id="xdx_90C_ecustom--DebtInstrumentDiscountRate_iI_dp_uPure_c20231231__us-gaap--DebtInstrumentAxis__custom--ConvertiblePromissoryNoteMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z5r3vk1LAJxh" title="Discount rate"&gt;30&lt;/span&gt;%
discount to the IPO. The 2023 Convertible Notes matured on the sooner of the six-month anniversary date from issuance or a
successful IPO on primary exchange in the U.S. and included &lt;span id="xdx_90B_ecustom--DebtWarrantConversionDescription_c20230101__20231231__us-gaap--DebtInstrumentAxis__custom--ConvertiblePromissoryNoteMember_z3Ni11xEdEwf" title="Debt warrant conversion, description"&gt;a
five-year warrant to purchase common stock equal to fifty percent (50%) of the shares into which the 2032 Convertible Notes could be
converted into at issuance. &lt;/span&gt;The warrants had a strike price at a &lt;span id="xdx_903_eus-gaap--DebtInstrumentConvertibleConversionRatio1_dp_uPure_c20230101__20231231__us-gaap--DebtInstrumentAxis__custom--ConvertiblePromissoryNoteMember_zfRoCwQIV1jc" title="Strilke price"&gt;25&lt;/span&gt;%
premium to the conversion price subject to anti-dilution, issuable on a pro rata basis at each funding.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company used proceeds from the 2023 Convertible Notes to pay a portion of the principal balance of the 2022 Convertible Notes totaling
$&lt;span id="xdx_90C_eus-gaap--NotesPayable_iI_c20231231__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeConvertibleNotesMember_zoEzkqhpEx76"&gt;2,650,000&lt;/span&gt; which resulted in a $&lt;span id="xdx_908_eus-gaap--GainsLossesOnExtinguishmentOfDebt_c20230101__20231231__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeConvertibleNotesMember_zovuuAZwlnyg" title="Gain on extinguishment of debt liabilities"&gt;1,129,653&lt;/span&gt; gain recorded as a benefit to Extinguishment of Debt Liabilities in the Statements of Operations.
Upon partial repayment, the terms of the remaining 2022 Convertible Notes were amended to accrue interest at &lt;span id="xdx_904_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_dp_uPure_c20231231__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeConvertibleNotesMember_zDkNUsQQ8Xh6"&gt;8&lt;/span&gt;% per annum without maturity
or default rights. The remaining principal balance also automatically converted into shares of common stock at a &lt;span id="xdx_903_ecustom--DebtInstrumentDiscountRate_iI_dp_uPure_c20231231__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeConvertibleNotesMember_zIQaTlFHT68b"&gt;27.5&lt;/span&gt;% discount to the
per share offering price in the Company&#x2019;s IPO, or $&lt;span id="xdx_904_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_c20231231__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeConvertibleNotesMember_zU3VLYdijpM1"&gt;4.35&lt;/span&gt; per share. After the closing of the IPO on August 9, 2023, the Company
converted some of the remaining balance of the 2022 Convertible Notes and $&lt;span id="xdx_90D_eus-gaap--NotesPayable_iI_c20230809__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeConvertibleNotesMember_zpxhJO0tYrzd"&gt;173,205&lt;/span&gt; of accrued interest into &lt;span id="xdx_905_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230809__20230809__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeConvertibleNotesMember_zaVdBFCEvqsa"&gt;107,509&lt;/span&gt; shares of common
stock. The shares were issued at a discounted price of $&lt;span id="xdx_907_eus-gaap--SharesIssuedPricePerShare_iI_c20230809__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeConvertibleNotesMember_zFKBNQfNmFg5"&gt;4.35&lt;/span&gt; per share resulting in a $&lt;span id="xdx_90B_eus-gaap--GainsLossesOnExtinguishmentOfDebt_c20230809__20230809__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeConvertibleNotesMember_z3wlc7JBI3Z4" title="Extinguishment of debt"&gt;663,991&lt;/span&gt; loss to the Company recorded as a charge
to Extinguishment of Debt Liabilities in the Statements of Operations. As the remaining holders of the 2022 Convertible Notes did not
convert, the Company used proceeds from the IPO to pay the remaining balance in full, including interest in the amount of $&lt;span id="xdx_90E_eus-gaap--ProceedsFromIssuanceInitialPublicOffering_c20230809__20230809__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeConvertibleNotesMember_zLhLTcObjsG2" title="Proceeds from issuance of ipo"&gt;445,544&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
facilitators to the 2023 Convertible Notes, Signature Bank received a $&lt;span id="xdx_903_eus-gaap--EscrowDeposit_iI_c20231231__dei--LegalEntityAxis__custom--SignatureBankMember_zoSjuS5jBFCa" title="Escrow deposit"&gt;6,000&lt;/span&gt; escrow fee and Alexander Capital, L.P. received (i) a $&lt;span id="xdx_90B_eus-gaap--ProceedsFromFeesReceived_c20230101__20231231__dei--LegalEntityAxis__custom--AlexanderCapitalLPMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z1ehwztzuPv8" title="Deferred financing fees"&gt;546,000&lt;/span&gt;
cash commission representing nine percent (9%) of the proceeds raised in the offering from investors introduced to the Company and (ii)
&lt;span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20231231__dei--LegalEntityAxis__custom--AlexanderCapitalLPMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zFOaTIC7d4T3" title="Number of warrants received"&gt;120,235&lt;/span&gt; warrants for the purchase of a number of shares of Common Stock equal to 6% of the number of underlying securities.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;After
the closing of the IPO on August 9, 2023, the Company converted the 2023 Convertible Notes and $&lt;span id="xdx_90F_eus-gaap--NotesPayable_iI_c20230809__dei--LegalEntityAxis__custom--ChannelPartnersCapitalMember_zwuNrF6R97Ah"&gt;226,391&lt;/span&gt; of accrued interest into &lt;span id="xdx_906_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230809__20230809__dei--LegalEntityAxis__custom--ChannelPartnersCapitalMember_zlTXDEX9FLD6"&gt;1,498,332&lt;/span&gt;
shares of common stock. The shares were issued at a discounted price of $&lt;span id="xdx_908_eus-gaap--SharesIssuedPricePerShare_iI_c20230809__dei--LegalEntityAxis__custom--ChannelPartnersCapitalMember_znT55MEeIB31"&gt;4.20&lt;/span&gt; per share that resulted in a $&lt;span id="xdx_907_eus-gaap--GainsLossesOnExtinguishmentOfDebt_c20230809__20230809__dei--LegalEntityAxis__custom--ChannelPartnersCapitalMember_zOlt4qwjAyi"&gt;4,115,223&lt;/span&gt; loss to the Company
which was recorded as a charge to Extinguishment of Debt Liabilities in the Statements of Operations.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;2024
Convertible Notes&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
November 8, 2023, the Company entered into a Securities Purchase Agreement (&#x201c;SPA&#x201d;) with a shareholder for the
issuance&#160;&lt;span id="xdx_90F_eus-gaap--ConvertiblePreferredStockSharesIssuedUponConversion_iI_c20231108_zSpU5amBgfOd"&gt;1,260,504&lt;/span&gt;&#160;shares
of Series B Convertible Preferred Stock, par value $&lt;span id="xdx_900_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_c20231108_z4JXZysGzjk8"&gt;0.001&lt;/span&gt;&#160;per
share (the &#x201c;Series B Preferred Stock&#x201d;), for an aggregate purchase price of $&lt;span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20231108__20231108_zganK9PRuxs7"&gt;3,000,000&lt;/span&gt;&#160;paid
in 15 monthly installments of $&lt;span id="xdx_90F_eus-gaap--DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid_iI_c20231108_zK3TtlgteSQe"&gt;200,000&lt;/span&gt;&#160;each,
commencing on the later of January 10, 2024 or a date after stockholder approval of an amendment to the Company&#x2019;s Certificate
of Incorporation to authorize the creation of the Series B Preferred Stock. The Series B Preferred Stock was convertible at any time
into shares of common stock of the Company without any further consideration. Following the issuance of the Series B Preferred
Stock, it would rank senior to the common stock with respect to payments upon the liquidation, dissolution and winding up of the
Company. Due to a delay in the stockholder approval, the Company amended the SPA on February 12, 2024 to issue a promissory note,
due and payable on the earlier of 15 months or 12 months if the Series B Preferred Stock has not been authorized, convertible into
Series B Convertible Preferred Stock with identical funding amounts and terms (the &#x201c;$&lt;span id="xdx_903_eus-gaap--ConvertibleDebt_iI_c20241231_zgzI8itrNQO5" title="Convertible debt"&gt;3,000,000&lt;/span&gt;
Convertible Promissory Note&#x201d;). The shareholder funded $&lt;span id="xdx_905_eus-gaap--ProceedsFromContributedCapital_c20240101__20241231__us-gaap--DebtInstrumentAxis__custom--ConvertiblePromissoryNotesMember__srt--RangeAxis__srt--MaximumMember_zjteYQfZeOV3" title="Shareholder funded"&gt;800,000&lt;/span&gt;
of the $&lt;span id="xdx_900_eus-gaap--ProceedsFromContributedCapital_c20240101__20241231__us-gaap--DebtInstrumentAxis__custom--ConvertiblePromissoryNotesMember__srt--RangeAxis__srt--MinimumMember_zubQQQVByqo4" title="Shareholder funded"&gt;3,000,000&lt;/span&gt;
commitment in 2024.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company then proceeded to enter into a series of incremental convertible promissory notes with other investors totaling $&lt;span id="xdx_902_eus-gaap--DebtInstrumentAnnualPrincipalPayment_iI_c20241231__us-gaap--DebtInstrumentAxis__custom--ConvertiblePromissoryNotesMember_zqMtxGlPF6ui" title="Total principal amount"&gt;1,135,000&lt;/span&gt;&#160;with
terms identical to the $&lt;span id="xdx_907_eus-gaap--ConvertibleDebt_iI_c20241231__us-gaap--DebtInstrumentAxis__custom--ConvertiblePromissoryNotesMember_zcyNEtVNxe14" title="Convertible debt"&gt;3,000,000&lt;/span&gt;&#160;Convertible Promissory Note (collectively referred to as the &#x201c;Original 2024 Convertible
Promissory Notes&#x201d;) for an aggregate principal amount of $&lt;span id="xdx_90C_eus-gaap--DebtInstrumentPeriodicPayment_c20240101__20241231__us-gaap--DebtInstrumentAxis__custom--ConvertiblePromissoryNotesMember_zTtOsplvGC0b" title="Principal amount due in monthly installments"&gt;1,935,000&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
2024 Original Convertible Promissory Notes earned interest at&#160;&lt;span id="xdx_907_eus-gaap--DebtConversionOriginalDebtInterestRateOfDebt_dp_uPure_c20240101__20241231__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyFourConvertiblePromissoryNotesMember_zFrMXutDFmci" title="Debt conversion, original debt, interest rate of debt"&gt;8.5&lt;/span&gt;% per annum payable quarterly in either cash or common stock at the
election of the Company. At any time following the date of shareholder approval to authorize the creation of Series B Preferred Stock
prior to the maturity date, the investor may elect to convert all or part of the principal into the Company&#x2019;s Series B Preferred
Stock at a conversion price per share equal to $&lt;span id="xdx_906_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pid_c20241231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zgG3yQ2gkZ47" title="Preferred stock, par value"&gt;2.38&lt;/span&gt;. Without limiting the forgoing, all principal amounts outstanding on the maturity
date will automatically convert into the Company&#x2019;s Series B Preferred Stock. The Series B Preferred Stock is entitled to cumulative
dividends at&lt;span id="xdx_905_ecustom--CumulativeDividendsPercent_iI_pid_dp_uPure_c20241231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zX9iursTBdyl" title="Cumulative dividends percent"&gt;&#160;8.5&lt;/span&gt;% per annum (whether or not declared) payable quarterly in either cash or common stock at the $&lt;span id="xdx_903_eus-gaap--CommonStockConvertibleConversionPriceDecrease_pid_c20240101__20241231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zEmJMQVEvfoe" title="Common stock conversion price"&gt;2.38&lt;/span&gt;&#160;conversion
price at the election of the Company. Upon conversion to Series B Preferred Stock, the investor may elect, at its option at any time,
to convert all or part of the Series B Preferred Stock plus accrued but unpaid dividends into an equivalent amount of common stock at
the $&lt;span id="xdx_907_eus-gaap--CommonStockConvertibleConversionPriceDecrease_pid_c20240101__20241231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zYUMz2kUlIAf" title="Common stock conversion price"&gt;2.38&lt;/span&gt;&#160;conversion price.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Subsequently,
the Company entered into three convertible promissory notes with related institutional accredited investors with terms similar to
the Original 2024 Convertible Promissory Notes (collectively referred to as the &#x201c;Amended 2024 Convertible Promissory
Notes&#x201d;) for an additional principal amount of $&lt;span id="xdx_904_eus-gaap--ConvertibleDebt_iI_c20241221__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyFourConvertiblePromissoryNotesMember_zxzVGfogPE5"&gt;3,000,000&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;.
Certain provisions to the SPA and Certificate of Designation previously issued on February 12, 2024 changed, including (i) the
number of shares of preferred stock to be designated as Series B Preferred Stock was increased &#160;to&#160;&lt;span id="xdx_906_eus-gaap--PreferredStockSharesAuthorized_iI_c20240212__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyFourConvertiblePromissoryNotesMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_z29Cg7GrSyLe"&gt;4,000,000 &lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;shares,
(ii) the stated value of the Series B Preferred Stock was changed to $&lt;span id="xdx_907_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pid_c20240212__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyFourConvertiblePromissoryNotesMember_zKe3cDwiWKWa"&gt;2.38&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;per
share, (iii) the right to receive dividends will expire automatically on June 30, 2025, (iv) the liquidation rights will
automatically expire on June 30, 2025, and (v) the number of shares of the common stock that a holder of Series B preferred stock is
entitled to receive shall not exceed the maximum percentage chosen by the holder, which is initially set at between&lt;span id="xdx_90A_ecustom--DebtInstrumentDiscountRate_iI_dp_uPure_c20241212__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyFourConvertiblePromissoryNotesMember__srt--RangeAxis__srt--MinimumMember_zk5Yi6FLQSx4"&gt;&#160;4.99&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%
and&#160;&lt;span id="xdx_906_ecustom--DebtInstrumentDiscountRate_iI_dp_uPure_c20240212__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyFourConvertiblePromissoryNotesMember__srt--RangeAxis__srt--MaximumMember_zCior02h0463"&gt;19.99&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%
until shareholder approval is obtained, of the number of outstanding shares of the common stock at the time of the conversion of the
Series B Preferred Stock shares.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
maturity date was on the earlier of (i) June 21, 2025, (ii) upon written demand occurring on or after March 21, 2025 in the event that
the Series B Preferred Stock has not been duly authorized on or before such date, or (iii) immediately upon the occurrence of an event
of default. Automatic conversion into shares of Series B preferred stock (at a conversion price of $&lt;span id="xdx_901_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pid_c20240212__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_z38FWDM4Q7k2" title="Preferred stock, par value"&gt;2.38&lt;/span&gt;&#160;per share) would occur
following the date of shareholder approval. In the event the Company failed to obtain shareholder approval before August 15, 2024, rights
existed to convert the outstanding amount into shares of the common stock, at a price per share of $&lt;span id="xdx_907_eus-gaap--CommonStockConvertibleConversionPriceDecrease_pid_c20240212__20240212__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zFq5z6Zgut6d" title="Common stock conversion price"&gt;2.38&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of August 15, 2024, the Company received $&lt;span id="xdx_90E_eus-gaap--DebtInstrumentPeriodicPayment_c20240815__20240815__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyFourConvertibleNotesMember_zXnYu9tKPJV1" title="Principal amount due in monthly installments"&gt;4,935,000&lt;/span&gt;&#160;of
the principal amount of the Amended 2024 Convertible Notes with the remainder due in monthly installments through March of 2025
resulting in an effective interest rate of &lt;span id="xdx_904_eus-gaap--DebtInstrumentInterestRateEffectivePercentage_iI_pid_dp_uPure_c20240915__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyFourConvertiblePromissoryNotesMember_zRmMIGMhojjd" title="Debt instrument interest rate effective percentage"&gt;12.5&lt;/span&gt;%. On August 15, 2024, the Company&#x2019;s shareholders authorized&#160;&lt;span id="xdx_903_eus-gaap--PreferredStockSharesAuthorized_iI_c20240815__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyFourConvertiblePromissoryNotesMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zrwbtgBVzqU4" title="Preferred stock, shares authorized"&gt;5,000,000&lt;/span&gt;&#160;shares
of preferred stock of which&#160;&lt;span id="xdx_909_eus-gaap--TemporaryEquitySharesAuthorized_iI_pid_c20240815__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyFourConvertiblePromissoryNotesMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zWIBgMWt78qi" title="Temporary equity, shares authorized"&gt;4,000,000&lt;/span&gt;&#160;shares
were designated as $&lt;span id="xdx_902_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20240815__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyFourConvertiblePromissoryNotesMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zFlL4jy3qIjk" title="Common stock, par value"&gt;0.001&lt;/span&gt;&#160;par
value Series B preferred stock. Pursuant to the terms of the Amended 2024 Convertible Promissory Notes, the outstanding principal
balance of $&lt;span id="xdx_902_eus-gaap--DebtInstrumentPeriodicPayment_c20240815__20240815__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyFourConvertibleNotesMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zZt5xsKjsRT1" title="Principal amount due in monthly installments"&gt;4,935,000&lt;/span&gt;&#160;was
mandatorily converted into &lt;span id="xdx_90B_eus-gaap--ConversionOfStockSharesConverted1_c20240815__20240815__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyFourConvertiblePromissoryNotesMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zZ33ZmUS0hka" title="Number of shares converted"&gt;2,073,524&lt;/span&gt;&#160;Series
B Preferred Shares at a conversion price of $&lt;span id="xdx_907_ecustom--CommonStockConvertibleConversionPrice_pid_c20240815__20240815__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyFourConvertiblePromissoryNotesMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zPYYVSWxi6ve" title="Common stock conversion price"&gt;2.38&lt;/span&gt;.
Upon the mandatory conversion, the unamortized debt discount of $&lt;span id="xdx_902_eus-gaap--UnamortizedDebtIssuanceExpense_iI_c20241231__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyFourConvertiblePromissoryNotesMember_zWlZydP0zQ8i"&gt;165,577&lt;/span&gt;
was reclassified to Additional Paid-In-Capital in the Statements of Stockholders&#x2019; Equity (Deficit).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Interest
expense totaled $&lt;span id="xdx_90D_eus-gaap--InterestExpense_c20240101__20241231_zjJ8eRLATKW8" title="Interest expense"&gt;174,328&lt;/span&gt; and $&lt;span id="xdx_904_eus-gaap--InterestExpense_c20230101__20231231_zgAjaQYk3xmc" title="Interest expense"&gt;476,416&lt;/span&gt; for the years ended December 31, 2024 and 2023, respectively. The Company&#x2019;s accrued interest
total $&lt;span id="xdx_908_eus-gaap--AccruedLiabilitiesCurrentAndNoncurrent_iI_c20241231_zyK2e3l3mMzf"&gt;&lt;span id="xdx_902_eus-gaap--AccruedLiabilitiesCurrentAndNoncurrent_iI_c20231231_z78hv9D4gJpc"&gt;66,648&lt;/span&gt;&lt;/span&gt; as of December 31, 2024 and 2023.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Neuraxis,
Inc.&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Notes
to Financial Statements&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2021-12-16_custom_ChannelPartnersCapitalMember"
      decimals="0"
      id="Fact001280"
      unitRef="USD">250000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentPeriodicPayment
      contextRef="From2023-03-162023-03-16_custom_ChannelPartnersCapitalMember"
      decimals="2"
      id="Fact001281"
      unitRef="USD">4923</us-gaap:DebtInstrumentPeriodicPayment>
    <us-gaap:LongTermDebtAverageAmountOutstanding
      contextRef="From2022-01-012022-01-01_custom_ChannelPartnersCapitalMember"
      decimals="0"
      id="Fact001282"
      unitRef="USD">244048</us-gaap:LongTermDebtAverageAmountOutstanding>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2022-09-16_custom_ChannelPartnersCapitalMember"
      decimals="0"
      id="Fact001283"
      unitRef="USD">122000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentRepurchasedFaceAmount
      contextRef="AsOf2022-09-16_custom_ChannelPartnersCapitalMember"
      decimals="0"
      id="Fact001284"
      unitRef="USD">250000</us-gaap:DebtInstrumentRepurchasedFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2023-05-24_custom_ChannelPartnersCapitalMember"
      decimals="0"
      id="Fact001285"
      unitRef="USD">107231</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentRepurchasedFaceAmount
      contextRef="AsOf2023-05-24_custom_ChannelPartnersCapitalMember"
      decimals="0"
      id="Fact001286"
      unitRef="USD">250000</us-gaap:DebtInstrumentRepurchasedFaceAmount>
    <us-gaap:NotesPayable
      contextRef="AsOf2024-12-31_custom_ChannelPartnersCapitalMember"
      decimals="0"
      id="Fact001287"
      unitRef="USD">0</us-gaap:NotesPayable>
    <us-gaap:NotesPayable
      contextRef="AsOf2023-12-31_custom_ChannelPartnersCapitalMember"
      decimals="0"
      id="Fact001288"
      unitRef="USD">148062</us-gaap:NotesPayable>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="AsOf2024-12-31_custom_ChannelPartnersCapitalMember"
      decimals="INF"
      id="Fact001290"
      unitRef="Pure">0.559</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="AsOf2023-12-31_custom_ChannelPartnersCapitalMember"
      decimals="INF"
      id="Fact001292"
      unitRef="Pure">0.559</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2023-02-15_custom_ExchangeListingLLCMember_custom_PromissoryNoteMember"
      decimals="0"
      id="Fact001294"
      unitRef="USD">52600</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="AsOf2023-02-15_custom_ExchangeListingLLCMember_custom_PromissoryNoteMember"
      decimals="INF"
      id="Fact001296"
      unitRef="Pure">0.01</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:NotesPayable
      contextRef="AsOf2023-02-15_custom_ExchangeListingLLCMember_custom_PromissoryNoteMember"
      decimals="0"
      id="Fact001298"
      unitRef="USD">3000000</us-gaap:NotesPayable>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="From2023-08-312023-08-31_custom_ExchangeListingLLCMember_custom_PromissoryNoteMember"
      decimals="2"
      id="Fact001300"
      unitRef="USD">52858</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <us-gaap:NotesPayable
      contextRef="AsOf2024-08-09_custom_PromissoryNoteMember"
      decimals="0"
      id="Fact001302"
      unitRef="USD">210000</us-gaap:NotesPayable>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="AsOf2024-08-09_custom_PromissoryNoteMember"
      decimals="INF"
      id="Fact001304"
      unitRef="Pure">0.0740</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentMaturityDate
      contextRef="From2024-08-092024-08-09_custom_PromissoryNoteMember"
      id="Fact001306">2025-06-09</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2024-11-01_custom_SecondPromissoryNoteMember"
      decimals="0"
      id="Fact001308"
      unitRef="USD">64328</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="AsOf2024-11-01_custom_SecondPromissoryNoteMember"
      decimals="INF"
      id="Fact001309"
      unitRef="Pure">0.0765</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentMaturityDate
      contextRef="From2024-11-012024-11-01_custom_SecondPromissoryNoteMember"
      id="Fact001311">2025-09-01</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2024-12-31_custom_SecondPromissoryNoteMember"
      decimals="0"
      id="Fact001313"
      unitRef="USD">154152</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2023-12-31_custom_SecondPromissoryNoteMember"
      decimals="0"
      id="Fact001315"
      unitRef="USD">0</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="AsOf2022-11-30_custom_TwoThousandTwentyTwoConvertibleNotesMember"
      decimals="0"
      id="Fact001317"
      unitRef="USD">3333333</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:ProceedsFromIssuanceOfDebt
      contextRef="From2022-11-302022-11-30_custom_TwoThousandTwentyTwoConvertibleNotesMember"
      decimals="0"
      id="Fact001319"
      unitRef="USD">2870000</us-gaap:ProceedsFromIssuanceOfDebt>
    <us-gaap:DebtInstrumentDescriptionOfVariableRateBasis
      contextRef="From2022-06-032022-11-30_custom_TwoThousandTwentyTwoConvertibleNotesMember"
      id="Fact001321">original
issue discount of 10% with an interest rate of the greater of (i) Prime rate plus 8.5% or (ii) 12% resulting in an effective
interest rate of 24.2%.</us-gaap:DebtInstrumentDescriptionOfVariableRateBasis>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="AsOf2022-12-31_custom_TwoThousandTwentyTwoConvertibleNotesMember"
      decimals="INF"
      id="Fact001323"
      unitRef="Pure">0.242</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="AsOf2022-11-30_srt_MinimumMember_custom_TwoThousandTwentyTwoConvertibleNotesMember"
      decimals="INF"
      id="Fact001324"
      unitRef="USDPShares">9.44</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <NRXS:DebtInstrumentDiscountRate
      contextRef="AsOf2022-11-30_srt_MaximumMember_custom_TwoThousandTwentyTwoConvertibleNotesMember"
      decimals="INF"
      id="Fact001325"
      unitRef="Pure">0.30</NRXS:DebtInstrumentDiscountRate>
    <NRXS:DebtWarrantConversionDescription
      contextRef="From2022-11-302022-11-30_custom_TwoThousandTwentyTwoConvertibleNotesMember"
      id="Fact001327">a
five-year warrant to purchase common stock equal to one hundred percent (100%) of the shares into which the 2022 Convertible Notes
could be converted into at issuance.</NRXS:DebtWarrantConversionDescription>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2022-11-30_custom_TwoThousandTwentyTwoConvertibleNotesMember"
      decimals="INF"
      id="Fact001329"
      unitRef="USDPShares">11.80</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <NRXS:ClassOfWarrantDiscountRate
      contextRef="AsOf2022-11-30_custom_TwoThousandTwentyTwoConvertibleNotesMember"
      decimals="INF"
      id="Fact001331"
      unitRef="Pure">0.125</NRXS:ClassOfWarrantDiscountRate>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="AsOf2022-12-19_custom_TwoThousandTwentyTwoConvertibleNotesMember"
      decimals="0"
      id="Fact001333"
      unitRef="USD">222222</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:ProceedsFromIssuanceOfDebt
      contextRef="From2022-12-192022-12-19_custom_TwoThousandTwentyTwoConvertibleNotesMember"
      decimals="0"
      id="Fact001335"
      unitRef="USD">200000</us-gaap:ProceedsFromIssuanceOfDebt>
    <NRXS:DebtInstrumentDiscountRate
      contextRef="AsOf2022-12-19_custom_TwoThousandTwentyTwoConvertibleNotesMember"
      decimals="INF"
      id="Fact001337"
      unitRef="Pure">0.10</NRXS:DebtInstrumentDiscountRate>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="AsOf2022-12-19_custom_TwoThousandTwentyTwoConvertibleNotesMember"
      decimals="INF"
      id="Fact001339"
      unitRef="Pure">0.12</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="AsOf2022-12-19_custom_TwoThousandTwentyTwoConvertibleNotesMember"
      decimals="INF"
      id="Fact001341"
      unitRef="USDPShares">9.44</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="From2022-12-192022-12-19_custom_TwoThousandTwentyTwoConvertibleNotesMember"
      decimals="0"
      id="Fact001343"
      unitRef="USD">239104</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="AsOf2023-12-31_custom_ConvertiblePromissoryNoteMember_custom_AccreditedInvestorsMember"
      decimals="0"
      id="Fact001345"
      unitRef="USD">6066667</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:ProceedsFromIssuanceOfDebt
      contextRef="From2023-01-012023-12-31_custom_AccreditedInvestorsMember_custom_ConvertiblePromissoryNoteMember"
      decimals="0"
      id="Fact001347"
      unitRef="USD">4908000</us-gaap:ProceedsFromIssuanceOfDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="AsOf2023-12-31_custom_ConvertiblePromissoryNoteMember"
      decimals="INF"
      id="Fact001349"
      unitRef="Pure">0.12</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <NRXS:DebtInstrumentDiscountRate
      contextRef="AsOf2023-12-31_custom_ConvertiblePromissoryNoteMember"
      decimals="INF"
      id="Fact001351"
      unitRef="Pure">0.10</NRXS:DebtInstrumentDiscountRate>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="AsOf2023-12-31_custom_TwoThousandTwentyThreeConvertibleNotesMember"
      decimals="INF"
      id="Fact001353"
      unitRef="Pure">0.275</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <NRXS:DebtInstrumentDiscountRate
      contextRef="AsOf2023-12-31_custom_ConvertiblePromissoryNoteMember_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact001355"
      unitRef="Pure">0.30</NRXS:DebtInstrumentDiscountRate>
    <NRXS:DebtWarrantConversionDescription
      contextRef="From2023-01-012023-12-31_custom_ConvertiblePromissoryNoteMember"
      id="Fact001357">a
five-year warrant to purchase common stock equal to fifty percent (50%) of the shares into which the 2032 Convertible Notes could be
converted into at issuance.</NRXS:DebtWarrantConversionDescription>
    <us-gaap:DebtInstrumentConvertibleConversionRatio1
      contextRef="From2023-01-012023-12-31_custom_ConvertiblePromissoryNoteMember"
      decimals="INF"
      id="Fact001359"
      unitRef="Pure">0.25</us-gaap:DebtInstrumentConvertibleConversionRatio1>
    <us-gaap:NotesPayable
      contextRef="AsOf2023-12-31_custom_TwoThousandTwentyThreeConvertibleNotesMember"
      decimals="0"
      id="Fact001360"
      unitRef="USD">2650000</us-gaap:NotesPayable>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="From2023-01-012023-12-31_custom_TwoThousandTwentyThreeConvertibleNotesMember"
      decimals="0"
      id="Fact001362"
      unitRef="USD">1129653</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="AsOf2023-12-31_custom_TwoThousandTwentyThreeConvertibleNotesMember"
      decimals="INF"
      id="Fact001363"
      unitRef="Pure">0.08</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <NRXS:DebtInstrumentDiscountRate
      contextRef="AsOf2023-12-31_custom_TwoThousandTwentyThreeConvertibleNotesMember"
      decimals="INF"
      id="Fact001364"
      unitRef="Pure">0.275</NRXS:DebtInstrumentDiscountRate>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="AsOf2023-12-31_custom_TwoThousandTwentyThreeConvertibleNotesMember"
      decimals="INF"
      id="Fact001365"
      unitRef="USDPShares">4.35</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:NotesPayable
      contextRef="AsOf2023-08-09_custom_TwoThousandTwentyThreeConvertibleNotesMember"
      decimals="0"
      id="Fact001366"
      unitRef="USD">173205</us-gaap:NotesPayable>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2023-08-092023-08-09_custom_TwoThousandTwentyThreeConvertibleNotesMember"
      decimals="INF"
      id="Fact001367"
      unitRef="Shares">107509</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="AsOf2023-08-09_custom_TwoThousandTwentyThreeConvertibleNotesMember"
      decimals="INF"
      id="Fact001368"
      unitRef="USDPShares">4.35</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="From2023-08-092023-08-09_custom_TwoThousandTwentyThreeConvertibleNotesMember"
      decimals="0"
      id="Fact001370"
      unitRef="USD">663991</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="From2023-08-092023-08-09_custom_TwoThousandTwentyThreeConvertibleNotesMember"
      decimals="0"
      id="Fact001372"
      unitRef="USD">445544</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <us-gaap:EscrowDeposit
      contextRef="AsOf2023-12-31_custom_SignatureBankMember"
      decimals="0"
      id="Fact001374"
      unitRef="USD">6000</us-gaap:EscrowDeposit>
    <us-gaap:ProceedsFromFeesReceived
      contextRef="From2023-01-012023-12-31_custom_AlexanderCapitalLPMember_us-gaap_WarrantMember"
      decimals="0"
      id="Fact001376"
      unitRef="USD">546000</us-gaap:ProceedsFromFeesReceived>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2023-12-31_custom_AlexanderCapitalLPMember_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact001378"
      unitRef="Shares">120235</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:NotesPayable
      contextRef="AsOf2023-08-09_custom_ChannelPartnersCapitalMember"
      decimals="0"
      id="Fact001379"
      unitRef="USD">226391</us-gaap:NotesPayable>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2023-08-092023-08-09_custom_ChannelPartnersCapitalMember"
      decimals="INF"
      id="Fact001380"
      unitRef="Shares">1498332</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="AsOf2023-08-09_custom_ChannelPartnersCapitalMember"
      decimals="INF"
      id="Fact001381"
      unitRef="USDPShares">4.20</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="From2023-08-092023-08-09_custom_ChannelPartnersCapitalMember"
      decimals="0"
      id="Fact001382"
      unitRef="USD">4115223</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion
      contextRef="AsOf2023-11-08"
      decimals="INF"
      id="Fact001383"
      unitRef="Shares">1260504</us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="AsOf2023-11-08"
      decimals="INF"
      id="Fact001384"
      unitRef="USDPShares">0.001</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2023-11-082023-11-08"
      decimals="0"
      id="Fact001385"
      unitRef="USD">3000000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid
      contextRef="AsOf2023-11-08"
      decimals="0"
      id="Fact001386"
      unitRef="USD">200000</us-gaap:DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid>
    <us-gaap:ConvertibleDebt
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact001388"
      unitRef="USD">3000000</us-gaap:ConvertibleDebt>
    <us-gaap:ProceedsFromContributedCapital
      contextRef="From2024-01-012024-12-31_custom_ConvertiblePromissoryNotesMember_srt_MaximumMember"
      decimals="0"
      id="Fact001390"
      unitRef="USD">800000</us-gaap:ProceedsFromContributedCapital>
    <us-gaap:ProceedsFromContributedCapital
      contextRef="From2024-01-012024-12-31_custom_ConvertiblePromissoryNotesMember_srt_MinimumMember"
      decimals="0"
      id="Fact001392"
      unitRef="USD">3000000</us-gaap:ProceedsFromContributedCapital>
    <us-gaap:DebtInstrumentAnnualPrincipalPayment
      contextRef="AsOf2024-12-31_custom_ConvertiblePromissoryNotesMember"
      decimals="0"
      id="Fact001394"
      unitRef="USD">1135000</us-gaap:DebtInstrumentAnnualPrincipalPayment>
    <us-gaap:ConvertibleDebt
      contextRef="AsOf2024-12-31_custom_ConvertiblePromissoryNotesMember"
      decimals="0"
      id="Fact001396"
      unitRef="USD">3000000</us-gaap:ConvertibleDebt>
    <us-gaap:DebtInstrumentPeriodicPayment
      contextRef="From2024-01-012024-12-31_custom_ConvertiblePromissoryNotesMember"
      decimals="0"
      id="Fact001398"
      unitRef="USD">1935000</us-gaap:DebtInstrumentPeriodicPayment>
    <us-gaap:DebtConversionOriginalDebtInterestRateOfDebt
      contextRef="From2024-01-012024-12-31_custom_TwoThousandTwentyFourConvertiblePromissoryNotesMember"
      decimals="INF"
      id="Fact001400"
      unitRef="Pure">0.085</us-gaap:DebtConversionOriginalDebtInterestRateOfDebt>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2024-12-31_us-gaap_SeriesBPreferredStockMember"
      decimals="INF"
      id="Fact001402"
      unitRef="USDPShares">2.38</us-gaap:PreferredStockParOrStatedValuePerShare>
    <NRXS:CumulativeDividendsPercent
      contextRef="AsOf2024-12-31_us-gaap_SeriesBPreferredStockMember"
      decimals="INF"
      id="Fact001404"
      unitRef="Pure">0.085</NRXS:CumulativeDividendsPercent>
    <us-gaap:CommonStockConvertibleConversionPriceDecrease
      contextRef="From2024-01-012024-12-31_us-gaap_SeriesBPreferredStockMember47710687"
      decimals="INF"
      id="Fact001406"
      unitRef="USDPShares">2.38</us-gaap:CommonStockConvertibleConversionPriceDecrease>
    <us-gaap:CommonStockConvertibleConversionPriceDecrease
      contextRef="From2024-01-012024-12-31_us-gaap_SeriesBPreferredStockMember47710687"
      decimals="INF"
      id="Fact001408"
      unitRef="USDPShares">2.38</us-gaap:CommonStockConvertibleConversionPriceDecrease>
    <us-gaap:ConvertibleDebt
      contextRef="AsOf2024-12-21_custom_TwoThousandTwentyFourConvertiblePromissoryNotesMember"
      decimals="0"
      id="Fact001409"
      unitRef="USD">3000000</us-gaap:ConvertibleDebt>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2024-02-12_custom_TwoThousandTwentyFourConvertiblePromissoryNotesMember_us-gaap_SeriesBPreferredStockMember"
      decimals="INF"
      id="Fact001410"
      unitRef="Shares">4000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2024-02-12_custom_TwoThousandTwentyFourConvertiblePromissoryNotesMember_us-gaap_SeriesBPreferredStockMember"
      decimals="INF"
      id="Fact001411"
      unitRef="USDPShares">2.38</us-gaap:PreferredStockParOrStatedValuePerShare>
    <NRXS:DebtInstrumentDiscountRate
      contextRef="AsOf2024-12-12_us-gaap_SeriesBPreferredStockMember_custom_TwoThousandTwentyFourConvertiblePromissoryNotesMember_srt_MinimumMember"
      decimals="INF"
      id="Fact001412"
      unitRef="Pure">0.0499</NRXS:DebtInstrumentDiscountRate>
    <NRXS:DebtInstrumentDiscountRate
      contextRef="AsOf2024-02-12_us-gaap_SeriesBPreferredStockMember_custom_TwoThousandTwentyFourConvertiblePromissoryNotesMember_srt_MaximumMember"
      decimals="INF"
      id="Fact001413"
      unitRef="Pure">0.1999</NRXS:DebtInstrumentDiscountRate>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2024-02-12_us-gaap_SeriesBPreferredStockMember"
      decimals="INF"
      id="Fact001415"
      unitRef="USDPShares">2.38</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:CommonStockConvertibleConversionPriceDecrease
      contextRef="From2024-02-122024-02-12_us-gaap_SeriesBPreferredStockMember"
      decimals="INF"
      id="Fact001417"
      unitRef="USDPShares">2.38</us-gaap:CommonStockConvertibleConversionPriceDecrease>
    <us-gaap:DebtInstrumentPeriodicPayment
      contextRef="From2024-08-152024-08-15_custom_TwoThousandTwentyFourConvertibleNotesMember"
      decimals="0"
      id="Fact001419"
      unitRef="USD">4935000</us-gaap:DebtInstrumentPeriodicPayment>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="AsOf2024-09-15_custom_TwoThousandTwentyFourConvertiblePromissoryNotesMember"
      decimals="INF"
      id="Fact001421"
      unitRef="Pure">0.125</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2024-08-15_custom_TwoThousandTwentyFourConvertiblePromissoryNotesMember_us-gaap_SeriesBPreferredStockMember"
      decimals="INF"
      id="Fact001423"
      unitRef="Shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="AsOf2024-08-15_custom_TwoThousandTwentyFourConvertiblePromissoryNotesMember_us-gaap_SeriesBPreferredStockMember"
      decimals="INF"
      id="Fact001425"
      unitRef="Shares">4000000</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2024-08-15_custom_TwoThousandTwentyFourConvertiblePromissoryNotesMember_us-gaap_SeriesBPreferredStockMember"
      decimals="INF"
      id="Fact001427"
      unitRef="USDPShares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:DebtInstrumentPeriodicPayment
      contextRef="From2024-08-152024-08-15_custom_TwoThousandTwentyFourConvertibleNotesMember_us-gaap_SeriesBPreferredStockMember"
      decimals="0"
      id="Fact001429"
      unitRef="USD">4935000</us-gaap:DebtInstrumentPeriodicPayment>
    <us-gaap:ConversionOfStockSharesConverted1
      contextRef="From2024-08-152024-08-15_custom_TwoThousandTwentyFourConvertiblePromissoryNotesMember_us-gaap_SeriesBPreferredStockMember"
      decimals="INF"
      id="Fact001431"
      unitRef="Shares">2073524</us-gaap:ConversionOfStockSharesConverted1>
    <NRXS:CommonStockConvertibleConversionPrice
      contextRef="From2024-08-152024-08-15_custom_TwoThousandTwentyFourConvertiblePromissoryNotesMember_us-gaap_SeriesBPreferredStockMember"
      decimals="INF"
      id="Fact001433"
      unitRef="USDPShares">2.38</NRXS:CommonStockConvertibleConversionPrice>
    <us-gaap:UnamortizedDebtIssuanceExpense
      contextRef="AsOf2024-12-31_custom_TwoThousandTwentyFourConvertiblePromissoryNotesMember"
      decimals="0"
      id="Fact001434"
      unitRef="USD">165577</us-gaap:UnamortizedDebtIssuanceExpense>
    <us-gaap:InterestExpense
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact001436"
      unitRef="USD">174328</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact001438"
      unitRef="USD">476416</us-gaap:InterestExpense>
    <us-gaap:AccruedLiabilitiesCurrentAndNoncurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact001439"
      unitRef="USD">66648</us-gaap:AccruedLiabilitiesCurrentAndNoncurrent>
    <us-gaap:AccruedLiabilitiesCurrentAndNoncurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact001440"
      unitRef="USD">66648</us-gaap:AccruedLiabilitiesCurrentAndNoncurrent>
    <us-gaap:LesseeOperatingLeasesTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact001442">&lt;p id="xdx_802_eus-gaap--LesseeOperatingLeasesTextBlock_zDaqugDXqxi6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;8.
&lt;span id="xdx_82C_zWExa9FWg8Q5"&gt;Leases&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s leases are comprised of operating leases for office space. At the inception of the lease, the Company determines whether
the lease contract conveys the right to control the use of identified property for a period of time in exchange for consideration. Leases
are classified as operating or finance leases at the commencement date of the lease. Operating leases are recorded as operating lease
right-of-use assets, other current liabilities, and operating lease liabilities in the Balance Sheets. The Company did not have any finance
leases at December 31, 2024 and 2023.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company has two leases primarily consisting of office space in Versailles and Carmel, Indiana.&#160;&lt;span id="xdx_90E_eus-gaap--LesseeOperatingLeaseDescription_c20240101__20241231_zzNggvW090B1" title="Operating lease description"&gt;The lease in Versailles, Indiana
started January 1, 2022 and had a term of one year, with automatic one year renewal options, unless 60 day notice of vacating is given.
The current monthly lease payment for this lease is $&lt;span id="xdx_90B_eus-gaap--OperatingLeasePayments_c20220101__20220101__us-gaap--GeographicDistributionAxis__custom--VersaillesIndianaMember_zXtKFmAmcJGd" title="Operating lease payment"&gt;1,800&lt;/span&gt;&#160;with a&#160;&lt;span id="xdx_90B_eus-gaap--LesseeOperatingLeaseDiscountRate_iI_dp_uPure_c20220101__us-gaap--GeographicDistributionAxis__custom--VersaillesIndianaMember_zsOtgeDtJ2x2" title="Discount rate"&gt;4&lt;/span&gt;% per annum increase. A new lease in Carmel, Indiana commenced
January 1, 2024. The initial term is five years and five months. The monthly lease payment started at $&lt;span id="xdx_900_eus-gaap--OperatingLeasePayments_c20240101__20240101__us-gaap--GeographicDistributionAxis__custom--CarmelIndianaMember_zEzmFZPahbfg" title="Operating lease payment"&gt;6,721&lt;/span&gt;&#160;with an annual increase
of&#160;&lt;span id="xdx_90E_eus-gaap--LesseeOperatingLeaseDiscountRate_iI_pid_dp_uPure_c20240101__us-gaap--GeographicDistributionAxis__custom--CarmelIndianaMember_zefaptoL8Nvb" title="Operating lease payment rate"&gt;2.5&lt;/span&gt;%. As long as the Company is not in default, it is only obligated to pay an amount equal to 50% of the monthly base rent for
months 1-10&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Operating
lease right-of-use assets and liabilities are recognized at the commencement date based on the present value of lease payments over the
lease term. As the implicit interest rate is generally not readily determinable, the Company uses an incremental borrowing rate based
on the information available at the commencement date in determining the present value of lease payments. The incremental borrowing rate
reflects the estimated rate of interest that the Company would pay to borrow on a collateralized basis over a similar economic environment.
Lease expense for the operating lease is recognized on a straight-line basis over the lease term.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Leases
may include renewal options, and the renewal option is included in the lease term if the Company concludes that it is reasonably certain
that the option will be exercised. Certain leases may contain rent escalation clauses, either fixed or adjusted periodically for inflation
of market rates, that are factored into the calculation of lease payments to the extent they are fixed and determinable at lease inception.
The Company also has variable lease payments that do not depend on a rate or index, primarily for items such as common area maintenance
and real estate taxes, which are recorded as expenses when incurred.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;For
the years ended December 31, 2024 and 2023, the Company recognized $&lt;span id="xdx_90B_eus-gaap--OperatingLeaseExpense_c20240101__20241231_zzEan1koYyq8" title="Operating lease expense"&gt;96,177&lt;/span&gt; and $&lt;span id="xdx_907_eus-gaap--OperatingLeaseExpense_c20230101__20231231_zTeBySBAQXg2" title="Operating lease expense"&gt;49,051&lt;/span&gt; of operating lease expense, including short-term
lease expense and variable lease costs, which are immaterial.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89C_eus-gaap--LeaseCostTableTextBlock_zFztbrypnsXg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table presents information related to the Company&#x2019;s operating leases:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span id="xdx_8B7_zfHapyJiPMx" style="display: none"&gt;Schedule of Operating Leases&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_495_20241231_zcoyBtzitmTd" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;December 31, 2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49B_20231231_z7nQi5gKvHf4" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;December 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--OperatingLeaseRightOfUseAsset_iI_z3IUYNRAlpId" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left; padding-bottom: 1pt"&gt;Operating lease right-of-use assets&lt;/td&gt;&lt;td style="width: 2%; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;284,656&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; width: 16%; text-align: right"&gt;70,263&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--OperatingLeaseLiabilityCurrent_iI_maOLLz38G_zLVvb7Ghl128" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Other current liabilities&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;62,754&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;49,127&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_maOLLz38G_zUI2yxIjMR36" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Operating lease liabilities&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;256,499&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;27,071&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--OperatingLeaseLiability_iTI_mtOLLz38G_zKDhLqa2gJd" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;Total&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;319,253&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;76,198&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Weighted-average remaining lease term (in years)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_907_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20241231_zQIProZFW8bc" title="Weighted average remaining lease term (in years)"&gt;2.75&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20231231_zhbewRy86dwf" title="Weighted average remaining lease term (in years)"&gt;3.75&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Weighted-average discount rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_900_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_dp_uPure_c20241231_z5BSj9aa6XE4" title="Weighted average discount rate"&gt;15.0&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_dp_uPure_c20231231_z940P4nqH1Ke" title="Weighted average discount rate"&gt;15.0&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A1_z7jIB6o5sUmf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89C_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zHwzvxcPJMja" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of December 31, 2024, the maturities of the Company&#x2019;s operating lease liabilities were as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B6_zTIR3865vQEf" style="display: none"&gt;Schedule of Maturities Operating Lease Liabilities&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"&gt;
  &lt;tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;td id="xdx_49E_20241231_zE69sUSivHee" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_maLOLLPzyNu_zAnUqfeRV5mj" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 80%; text-align: left"&gt;2025&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;105,130&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_maLOLLPzyNu_z8Q5BQvx38Mf" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;2026&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;108,106&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_maLOLLPzyNu_z1wKRjz18iIb" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;2027&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;86,856&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFour_iI_maLOLLPzyNu_ztch8OL13t4l" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;2028&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;89,027&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFive_iI_maLOLLPzyNu_z3Yt9rhqjbL" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;2029&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;38,025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_mtLOLLPzyNu_z63kL7uUXONc" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Total lease payments&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;427,144&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_di_zDr3iSUhUu2l" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Less: imputed interest&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(107,891&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--OperatingLeaseLiability_iI_zMTx5ZJu3jC8" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Total present value of lease payments&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;319,253&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:LesseeOperatingLeasesTextBlock>
    <us-gaap:LesseeOperatingLeaseDescription contextRef="From2024-01-01to2024-12-31" id="Fact001444">The lease in Versailles, Indiana
started January 1, 2022 and had a term of one year, with automatic one year renewal options, unless 60 day notice of vacating is given.
The current monthly lease payment for this lease is $1,800&#160;with a&#160;4% per annum increase. A new lease in Carmel, Indiana commenced
January 1, 2024. The initial term is five years and five months. The monthly lease payment started at $6,721&#160;with an annual increase
of&#160;2.5%. As long as the Company is not in default, it is only obligated to pay an amount equal to 50% of the monthly base rent for
months 1-10</us-gaap:LesseeOperatingLeaseDescription>
    <us-gaap:OperatingLeasePayments
      contextRef="From2022-01-012022-01-01_custom_VersaillesIndianaMember"
      decimals="0"
      id="Fact001446"
      unitRef="USD">1800</us-gaap:OperatingLeasePayments>
    <us-gaap:LesseeOperatingLeaseDiscountRate
      contextRef="AsOf2022-01-01_custom_VersaillesIndianaMember"
      decimals="INF"
      id="Fact001448"
      unitRef="Pure">0.04</us-gaap:LesseeOperatingLeaseDiscountRate>
    <us-gaap:OperatingLeasePayments
      contextRef="From2024-01-012024-01-01_custom_CarmelIndianaMember"
      decimals="0"
      id="Fact001450"
      unitRef="USD">6721</us-gaap:OperatingLeasePayments>
    <us-gaap:LesseeOperatingLeaseDiscountRate
      contextRef="AsOf2024-01-01_custom_CarmelIndianaMember"
      decimals="INF"
      id="Fact001452"
      unitRef="Pure">0.025</us-gaap:LesseeOperatingLeaseDiscountRate>
    <us-gaap:OperatingLeaseExpense
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact001454"
      unitRef="USD">96177</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact001456"
      unitRef="USD">49051</us-gaap:OperatingLeaseExpense>
    <us-gaap:LeaseCostTableTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact001458">&lt;p id="xdx_89C_eus-gaap--LeaseCostTableTextBlock_zFztbrypnsXg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table presents information related to the Company&#x2019;s operating leases:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span id="xdx_8B7_zfHapyJiPMx" style="display: none"&gt;Schedule of Operating Leases&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_495_20241231_zcoyBtzitmTd" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;December 31, 2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49B_20231231_z7nQi5gKvHf4" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;December 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--OperatingLeaseRightOfUseAsset_iI_z3IUYNRAlpId" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left; padding-bottom: 1pt"&gt;Operating lease right-of-use assets&lt;/td&gt;&lt;td style="width: 2%; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;284,656&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; width: 16%; text-align: right"&gt;70,263&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--OperatingLeaseLiabilityCurrent_iI_maOLLz38G_zLVvb7Ghl128" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Other current liabilities&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;62,754&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;49,127&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_maOLLz38G_zUI2yxIjMR36" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Operating lease liabilities&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;256,499&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;27,071&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--OperatingLeaseLiability_iTI_mtOLLz38G_zKDhLqa2gJd" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;Total&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;319,253&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;76,198&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Weighted-average remaining lease term (in years)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_907_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20241231_zQIProZFW8bc" title="Weighted average remaining lease term (in years)"&gt;2.75&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20231231_zhbewRy86dwf" title="Weighted average remaining lease term (in years)"&gt;3.75&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Weighted-average discount rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_900_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_dp_uPure_c20241231_z5BSj9aa6XE4" title="Weighted average discount rate"&gt;15.0&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_dp_uPure_c20231231_z940P4nqH1Ke" title="Weighted average discount rate"&gt;15.0&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact001460"
      unitRef="USD">284656</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact001461"
      unitRef="USD">70263</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact001463"
      unitRef="USD">62754</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact001464"
      unitRef="USD">49127</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact001466"
      unitRef="USD">256499</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact001467"
      unitRef="USD">27071</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiability
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact001469"
      unitRef="USD">319253</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiability
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact001470"
      unitRef="USD">76198</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="AsOf2024-12-31" id="Fact001472">P2Y9M</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="AsOf2023-12-31" id="Fact001474">P3Y9M</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact001476"
      unitRef="Pure">0.150</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact001478"
      unitRef="Pure">0.150</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact001480">&lt;p id="xdx_89C_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zHwzvxcPJMja" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of December 31, 2024, the maturities of the Company&#x2019;s operating lease liabilities were as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B6_zTIR3865vQEf" style="display: none"&gt;Schedule of Maturities Operating Lease Liabilities&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"&gt;
  &lt;tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;td id="xdx_49E_20241231_zE69sUSivHee" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_maLOLLPzyNu_zAnUqfeRV5mj" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 80%; text-align: left"&gt;2025&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;105,130&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_maLOLLPzyNu_z8Q5BQvx38Mf" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;2026&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;108,106&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_maLOLLPzyNu_z1wKRjz18iIb" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;2027&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;86,856&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFour_iI_maLOLLPzyNu_ztch8OL13t4l" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;2028&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;89,027&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFive_iI_maLOLLPzyNu_z3Yt9rhqjbL" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;2029&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;38,025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_mtLOLLPzyNu_z63kL7uUXONc" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Total lease payments&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;427,144&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_di_zDr3iSUhUu2l" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Less: imputed interest&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(107,891&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--OperatingLeaseLiability_iI_zMTx5ZJu3jC8" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Total present value of lease payments&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;319,253&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact001482"
      unitRef="USD">105130</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact001484"
      unitRef="USD">108106</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact001486"
      unitRef="USD">86856</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact001488"
      unitRef="USD">89027</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact001490"
      unitRef="USD">38025</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact001492"
      unitRef="USD">427144</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact001494"
      unitRef="USD">107891</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact001496"
      unitRef="USD">319253</us-gaap:OperatingLeaseLiability>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact001498">&lt;p id="xdx_80B_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zyRGFQBtZSU1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;9.
&lt;span id="xdx_827_zOYBYQ9MVzY8"&gt;Common Stock and Warrants&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company authorized &lt;span id="xdx_90E_eus-gaap--CommonStockSharesAuthorized_iI_c20241231_zx0NR2fOdFD9" title="Common stock, shares authorized"&gt;&lt;span id="xdx_909_eus-gaap--CommonStockSharesAuthorized_iI_c20231231_z9bAu6A7b1S3" title="Common stock, shares authorized"&gt;100,000,000&lt;/span&gt;&lt;/span&gt; shares of common stock, of which &lt;span id="xdx_907_eus-gaap--CommonStockSharesIssued_iI_c20241231_zWqLP4IufL74" title="Common stock, shares issued"&gt;&lt;span id="xdx_90C_eus-gaap--CommonStockSharesOutstanding_iI_c20241231_zw3AtzhhAce4" title="Common stock, shares outstanding"&gt;6,990,227&lt;/span&gt;&lt;/span&gt; and &lt;span id="xdx_90B_eus-gaap--CommonStockSharesIssued_iI_c20231231_zQNWweik0yQc" title="Common stock, shares, issued"&gt;&lt;span id="xdx_900_eus-gaap--CommonStockSharesOutstanding_iI_c20231231_zKgmFzJ3Robd" title="Common stock, shares, outstanding"&gt;6,508,897&lt;/span&gt;&lt;/span&gt; shares were issued and outstanding as of December
31, 2024 and 2023, respectively. On January 10, 2023, the Company&#x2019;s board of directors authorized a &lt;span id="xdx_909_eus-gaap--StockholdersEquityReverseStockSplit_c20230110__20230110_z3gbNKCeDgo4" title="Reverse stock split"&gt;2-for-1 reverse stock split.&lt;/span&gt;
All share information in these financial statements has been adjusted for this reverse stock split.&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
the year ended December 31, 2023, the Company issued (i) &lt;span id="xdx_90E_ecustom--StockIssuedDuringPeriodSharesCommonStockIssuedUponInitialPublicOffering_c20230101__20231231_zX9UpQi4jOn4" title="Common shares, issued upon initial public offering, shares"&gt;1,098,667&lt;/span&gt; common shares issued upon the completion of the IPO on August 9, 2023
at a price of $&lt;span id="xdx_909_eus-gaap--SharePrice_iI_c20231231_zYvgEdpVO7C4" title="Common shares, per share"&gt;6.00&lt;/span&gt; per share resulting in net proceeds of $&lt;span id="xdx_90B_eus-gaap--ProceedsFromIssuanceInitialPublicOffering_c20230101__20231231_zyooScp2GJO8" title="Net proceeds"&gt;4,110,677&lt;/span&gt;, (ii) &lt;span id="xdx_907_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_c20230101__20231231_zD5lTo3DroD3" title="Conversion shares"&gt;1,244,228&lt;/span&gt; common shares upon conversion of &lt;span id="xdx_902_eus-gaap--ConvertiblePreferredStockSharesIssuedUponConversion_iI_c20231231_zMptYG4BMD5f" title="Shares issued upon conversion"&gt;506,637&lt;/span&gt; shares
of Convertible Series A Preferred Stock and &lt;span id="xdx_90B_eus-gaap--ConversionOfStockSharesConverted1_c20230101__20231231__us-gaap--StatementClassOfStockAxis__custom--ConvertibleSeriesSeedPreferredStockMember_zRnID9P3FCBf" title="Stock value converted"&gt;115,477&lt;/span&gt; shares of Convertible Series Seed Preferred Stock, (iii) &lt;span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodSharesConversionOfUnits_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zR4zARwjwVI4" title="Common stock issued upon debt conversion, shares"&gt;&lt;span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodSharesConversionOfUnits_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z7Cg7pRur7Nj" title="Common stock issued upon debt conversion, shares"&gt;1,649,900&lt;/span&gt;&lt;/span&gt; common shares
upon conversion of the 2022 and 2023 Convertible Notes, (iv) &lt;span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20230101__20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--VendorsMember_zmVZK67FzrC8" title="Service for payments"&gt;425,000&lt;/span&gt; common shares as payment to vendors for services and (v) &lt;span id="xdx_902_eus-gaap--ConversionOfStockSharesIssued1_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z6oOmHqPdwNc" title="Exercise of warrants"&gt;127,780&lt;/span&gt;
common shares upon the exercise of warrants.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
the year ended December 31, 2024, the Company issued (i) &lt;span id="xdx_901_ecustom--StockIssuedDuringPeriodSharesCommonStockIssuedUponInitialPublicOffering_c20240101__20241231_zsxKga9uUwme" title="Common shares, issued upon initial public offering, shares"&gt;245,955&lt;/span&gt; common shares to settle 2022 Convertible Note and Series A Preferred
Stock holder disputes, (ii) &lt;span id="xdx_901_eus-gaap--ConversionOfStockSharesIssued1_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zLweVUlZfsu8" title="Exercise of warrants"&gt;11,000&lt;/span&gt; common shares upon the exercise of warrants, (iii) &lt;span id="xdx_900_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20240101__20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--VendorsMember_zCE1ZtZ3VkJ9" title="Service for payments"&gt;115,145&lt;/span&gt; common shares as payment to vendors for
services, (iv) &lt;span id="xdx_904_eus-gaap--ConversionOfStockSharesConverted1_c20240101__20241231_zhgdD00kyqH7" title="Conversion, interest"&gt;59,055&lt;/span&gt; common shares in lieu of interest on the 2024 Convertible Notes, (v) &lt;span id="xdx_904_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20240101__20241231__us-gaap--TypeOfArrangementAxis__custom--EmployementAgreementMember_zZZUyryZreT9" title="Service for payments"&gt;25,832&lt;/span&gt; shares pursuant to the severance provisions
of an employment agreement and (vi) &lt;span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20240101__20241231_zRr3DNtdTN9a" title="Service for payments"&gt;24,343&lt;/span&gt; common shares for board service.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Neuraxis,
Inc.&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Notes
to Financial Statements&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
the year ended December 31, 2023, the Company issued (i) &lt;span id="xdx_903_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20231231__us-gaap--TypeOfArrangementAxis__custom--TwoThousandTwentyThreeConvertiblePromissoryNotesMember_zVKjb30hmoFh" title="Number of Warrants"&gt;505,570&lt;/span&gt; &lt;span id="xdx_907_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dxL_c20231231__us-gaap--TypeOfArrangementAxis__custom--TwoThousandTwentyTwoConvertibleNotesMember_zosR6VaCDMLc" title="Warrants, term::XDX::P5Y"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1548"&gt;five-year&lt;/span&gt;&lt;/span&gt; warrants to purchase common stock equal to fifty percent (50%)
of the shares into which the 2023 Convertible Promissory Notes could be converted at issuance at an exercise price of $&lt;span id="xdx_90D_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20231231__us-gaap--TypeOfArrangementAxis__custom--TwoThousandTwentyThreeConvertiblePromissoryNotesMember_zR4x9Sat3sV3"&gt;5.25&lt;/span&gt; per share,
(ii) &lt;span id="xdx_905_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20231231__us-gaap--TypeOfArrangementAxis__custom--AdvisoryAgreementMember_zVQ7JmajdSq6" title="Number of Warrants"&gt;122,202&lt;/span&gt; &lt;span id="xdx_906_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dxL_c20231231__us-gaap--TypeOfArrangementAxis__custom--AdvisoryAgreementMember_zeMxjMDhpCM7" title="Warrants, term::XDX::P5Y"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1553"&gt;five year&lt;/span&gt;&lt;/span&gt; warrants to purchase common stock pursuant an advisory agreement with a consulting firm upon closing of the Company&#x2019;s
IPO at an exercise price of $&lt;span id="xdx_904_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20231231__us-gaap--TypeOfArrangementAxis__custom--AdvisoryAgreementMember_zzJImS8mABYg"&gt;5.25&lt;/span&gt; per share and (iii) &lt;span id="xdx_901_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20231231__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementMember_zFd7uBVvCi7" title="Number of Warrants"&gt;186,156&lt;/span&gt; &lt;span id="xdx_90C_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dxL_c20231231__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementMember_zLXlqvyUvWO6" title="Warrants, term::XDX::P5Y"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1558"&gt;five-year&lt;/span&gt;&lt;/span&gt; warrants to purchase common stock pursuant to an underwriting
agreement upon closing of the Company&#x2019;s IPO at an exercise price of $&lt;span id="xdx_908_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20231231__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementMember_z32lFDpFX2ed"&gt;5.25&lt;/span&gt; per share. Additionally, &lt;span id="xdx_904_ecustom--NumberOfEquivalentOfWarrantsDescription_c20230101__20231231_zZ30RcjUsfNl" title="Number of equivalent of warrants, description"&gt;investors converted (i) 87,856
warrants into an equivalent number of common shares at an exercise price of $2.38 in exchange for $209,097 in cash proceeds and (ii)
40,000 warrants into 39,924 common shares in a cashless exercise transaction.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
the year ended December 31, 2024, the Company issued (i) &lt;span id="xdx_901_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20241231__us-gaap--TypeOfArrangementAxis__custom--TwoThousandTwentyFourConvertiblePromissoryNotesMember_zNMBz3dhtKck" title="Number of Warrants"&gt;38,697&lt;/span&gt; &lt;span id="xdx_905_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dxL_c20241231__us-gaap--TypeOfArrangementAxis__custom--TwoThousandTwentyFourConvertiblePromissoryNotesMember_z93VtfAJbd4j" title="Warrants, term::XDX::P5Y"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1565"&gt;five-year&lt;/span&gt;&lt;/span&gt; warrants to purchase common stock equal to six percent (6%)
of the aggregate number of Original 2024 Convertible Promissory Note common stock equivalents pursuant to an underwriting agreement at
an exercise price of $&lt;span id="xdx_90D_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20241231__us-gaap--TypeOfArrangementAxis__custom--TwoThousandTwentyFourConvertiblePromissoryNotesMember_z0WCE7f0jCYl"&gt;2.38&lt;/span&gt; per share, (ii) &lt;span id="xdx_903_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20241231__us-gaap--TypeOfArrangementAxis__custom--AdvisoryAgreementsMember_zaTjwtuUgC58" title="Number of Warrants"&gt;68,067&lt;/span&gt; &lt;span id="xdx_904_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dxL_c20241231__us-gaap--TypeOfArrangementAxis__custom--AdvisoryAgreementsMember_z6uin94lQ6Ke" title="Warrants, term::XDX::P5Y"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1570"&gt;five-year&lt;/span&gt;&lt;/span&gt; warrants to purchase common stock pursuant to an advisory agreement at an
exercise price of $&lt;span id="xdx_906_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20241231__us-gaap--TypeOfArrangementAxis__custom--AdvisoryAgreementsMember_zbo3yjrjVAY1"&gt;2.38&lt;/span&gt; per share. The Common Stock Purchase Warrant Agreements attached to the 2023 Convertible Promissory Notes contained
anti-dilution provisions on both the exercise price and the number of warrants. These anti-dilution features were triggered when the
Company issued the Original 2024 Convertible Promissory Notes that contained a conversion price of $&lt;span id="xdx_907_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20241231__us-gaap--TypeOfArrangementAxis__custom--TwoThousandTwentyFourConvertiblePromissoryNotesMember_zgL4MnU5TVJ8"&gt;2.38&lt;/span&gt; per share as compared to the
$&lt;span id="xdx_900_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20241231__us-gaap--TypeOfArrangementAxis__custom--TwoThousandTwentyThreeConvertiblePromissoryNotesMember_zgoFI7KbFvnb"&gt;5.25&lt;/span&gt; per share exercise price in the 2023 Convertible Promissory Note Common Stock Purchase Warrant Agreements. As a result, the Company
issued &lt;span id="xdx_90B_ecustom--ClassOfWarrantOrRightAdditional_iI_pid_c20241231__us-gaap--TypeOfArrangementAxis__custom--TwoThousandTwentyFourConvertiblePromissoryNotesMember_zw314jkXahv6" title="Number of Warrants, additional"&gt;754,660&lt;/span&gt; additional warrants in 2024 to the holders of the 2023 Convertible Promissory Note Common Stock Purchase Warrant Agreements.
Additionally, &lt;span id="xdx_904_ecustom--NumberOfEquivalentOfWarrantsDescription_c20240101__20241231_z4crh28Pft94" title="Number of equivalent of warrants, description"&gt;investors converted  11,000 warrants into an equivalent number of common shares at an exercise price of $2.38 in exchange
for $26,180 in cash proceeds.&lt;/span&gt;  The Company also
canceled &lt;span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z7adNtyrgzn3" title="Warrants, canceled"&gt;30,252&lt;/span&gt; warrants for no consideration in conjunction with an amendment to an advisory agreement.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89D_ecustom--ScheduleOfWarrantActivityForCommonStockTableTextBlock_hus-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zLrw0eGMZ8Fh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following is a summary of warrant activity for common stock during the years ended December 31, 2024 and 2023:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;span id="xdx_8B4_zF19HNxPm3Bk" style="display: none"&gt;Schedule of Warrant Activity for Common Stock&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Number of Warrants for Common Stock&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Weighted-Avg. Exercise Price&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Weighted-Avg. Remaining Contractual Life&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 40%; font-weight: bold"&gt;Outstanding as of January 1, 2023&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zqCUE1twemab" style="width: 16%; text-align: right" title="Number of Warrants, Outstanding at beginning of period"&gt;846,507&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zhr3vJ6fezYi" style="width: 16%; text-align: right" title="Weighted Average Exercise Price, Outstanding at beginning of period"&gt;5.06&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z1Jwb8Y6z7F4" title="Weighted Average Remaining Contractual Life - Warrants"&gt;4.72&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zvCO7feZJtO3" style="text-align: right" title="Number of Warrants, Granted"&gt;813,928&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zJhAxuudUgBe" style="text-align: right" title="Weighted Average Exercise Price, granted"&gt;5.81&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsWeightedAverageRemainingContracualLifeOutstandingNumberGranted_dtY_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zdueqO08qFP" title="Weighted Average Remaining Contractual Life - Warrants Granted"&gt;4.38&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Converted Prefunded Warrants&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsConvertedPrefundedWarrants_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z1T7to5A8GSd" style="text-align: right" title="Number of Warrants, Converted Prefunded Warrants"&gt;289,779&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsConvertedPrefundedWarrantsInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zY56eTAD5bmg" style="text-align: right" title="Weighted Average Exercise Price, Converted Prefunded Warrants"&gt;0.01&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Cancelled&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zYXpsY5K2eyh" style="text-align: right" title="Number of Warrants, Granted"&gt;(30,252&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsWeightedAverageExercisePriceCancelledExpiredNumber_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zftXG45d9Fcg" style="text-align: right" title="Weighted Average Exercise Price, Cancelled Expired"&gt;2.38&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90B_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsCancelledWeightedAverageRemainingContractualTerm1_dtY_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z3ExdXdKOUI4" title="Weighted Average Remaining Contractual Life - Warrants Cancelled"&gt;4.79&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;Exercised&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zJwgA5K3QICa" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Warrants, Exercised"&gt;(127,856&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_ztaF8wIpjGHb" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price, Excercised"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1607"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;Outstanding as of December 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zyC3xdrUua51" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Warrants, Outstanding at beginning of period"&gt;1,822,358&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zk5KvZkRA7S6" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price, Outstanding at beginning of period"&gt;4.69&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zpHWNBLzvNfe" title="Weighted Average Remaining Contractual Life - Warrants"&gt;3.05&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zyDwKGvOqya4" style="text-align: right" title="Number of Warrants, Granted"&gt;861,424&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zP5e8TEsARIl" style="text-align: right" title="Weighted Average Exercise Price, granted"&gt;2.38&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z9qIs9iz7aje" title="Weighted Average Remaining Contractual Life - Warrants Granted"&gt;3.49&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Cancelled&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_iN_pid_di_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z0JtbrAmw6L9" style="text-align: right" title="Number of Warrants, Granted"&gt;(30,252&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsWeightedAverageExercisePriceCancelledExpiredNumber_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z0fBvAhyc7fe" style="text-align: right" title="Weighted Average Exercise Price, Cancelled Expired"&gt;2.38&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90E_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsCancelledWeightedAverageRemainingContractualTerm1_dtY_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zgIGKKCyLomf" title="Weighted Average Remaining Contractual Life - Warrants Cancelled"&gt;4.79&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;Exercised&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zfwcoWXVFRFd" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Warrants, Exercised"&gt;(11,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zbTO4y9uPVR2" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price, Excercised"&gt;2.38&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_90A_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisedWeightedAverageRemainingContractualTerm1_dtY_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zcjv1U3Qle25" title="Weighted Average Remaining Contractual Life - Warrants Granted"&gt;3.61&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;Outstanding as of December 31, 2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zgqcy9ma0rvk" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Warrants, Outstanding at Ending of period"&gt;2,642,530&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_znzR0pZ73WD1" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price, Outstanding at Ending of period"&gt;2.41&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zti3Xue9xa3i" title="Weighted Average Remaining Contractual Life - Warrants"&gt;2.93&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A6_zEQVibhbHKD5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Neuraxis,
Inc.&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Notes
to Financial Statements&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_891_ecustom--ScheduleOfWarrantActivityForPreferredStockTableTextBlock_hus-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zNT710L4p2uf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following is a summary of warrant activity for preferred stock during the year ended December 31, 2023:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8BD_zdZp51J3cWs2" style="display: none"&gt;Schedule of Warrant Activity for Preferred Stock&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Number of&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Weighted-Avg.&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Warrants for&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Exercise&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Preferred Stock&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Price&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; font-weight: bold; padding-bottom: 1pt"&gt;Outstanding as of December 31, 2022&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zfcGzLOG3dr1" style="border-bottom: Black 1pt solid; width: 16%; text-align: right" title="Number of Warrants, Outstanding at beginning of period"&gt;144,890&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zN0O4Rsc9wJ" style="border-bottom: Black 1pt solid; width: 16%; text-align: right" title="Weighted Average Exercise Price, Outstanding at beginning of period"&gt;0.01&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_z2Va9eQzser" style="text-align: right" title="Number of Warrants, Granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1645"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_uUSDPShares_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zOMOCQMMk1bg" style="text-align: right" title="Weighted Average Exercise Price, granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1647"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Cancelled/Expired&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zF9FzeR5PABe" style="text-align: right" title="Number of Warrants, Cancelled Expired"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1649"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsWeightedAverageExercisePriceCancelledExpiredNumber_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_z14hGJgeTKV6" style="text-align: right" title="Weighted Average Exercise Price, Cancelled Expired"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1651"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Converted to Common Stock Warrant&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsCommonStockWarrant_iN_pid_di_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_znHVx7Qc6Qmb" style="border-bottom: Black 1pt solid; text-align: right" title="Converted to Common Stock Warrant"&gt;(144,890&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsWeightedAverageExercisePriceCommonStockWarrant_iN_pid_di_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zxR5E0bIf4hl" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price, Converted to Common Stock Warrant"&gt;(0.01&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;Outstanding as of December 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zMic3aPT4rBb" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Warrants, Outstanding at Ending of period"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1657"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_z8VxpLHbvBK4" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price, Outstanding at Ending of period"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1659"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AC_zyLc5OvCht5e" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;There
was no preferred stock warrant activity during the year ended December 31, 2024.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_898_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_z9igFQMpLx0d" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table summarizes the Company&#x2019;s warrants outstanding and exercisable as of December 31, 2024:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8BC_zvxaUvkopMl5" style="display: none"&gt;Schedule of Warrants outstanding and Exercisable&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Number of&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Warrants&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Exercise&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: center"&gt;Expiration&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Outstanding&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Price&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Date&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 40%; text-align: left"&gt;Investor Warrant&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--InvestorWarrantOneMember_zCwbBa9nn5Ti" style="width: 16%; text-align: right" title="Number of Warrants"&gt;12,852&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--InvestorWarrantOneMember_zzr2tmz9546e" style="width: 16%; text-align: right" title="Exercise Price"&gt;8.76&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 18%; text-align: center"&gt;&lt;span id="xdx_90E_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--InvestorWarrantOneMember_zYJKbGJUSZKb" title="Expiration Date"&gt;September 18, 2028&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Investor Warrant&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--InvestorWarrantPSAOneMember_zcLpYDWZaeAl" style="text-align: right" title="Number of Warrants"&gt;289,779&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--InvestorWarrantPSAOneMember_zmzsgDqFYzq6" style="text-align: right" title="Exercise Price"&gt;0.01&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span id="xdx_90C_ecustom--WarrantExpirationDateDescription_c20240101__20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--InvestorWarrantPSAOneMember_zhIdSpG22uz" title="Expiration Date"&gt;None&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;2022 Convertible Notes&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--TwoThousandTwentyTwoConvertibleNotesMember_zoK0YKQK2Zlc" style="text-align: right" title="Number of Warrants"&gt;782,655&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--TwoThousandTwentyTwoConvertibleNotesMember_zvl7qbY1ug3e" style="text-align: right" title="Exercise Price"&gt;2.38&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span id="xdx_90B_ecustom--WarrantExpirationDateDescription_c20240101__20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--TwoThousandTwentyTwoConvertibleNotesMember_zvM5SIXYBBo6" title="Expiration Date"&gt;Various in 2027&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;2023 Convertible Notes&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--TwoThousandTwentyThreeConvertibleNotesMember_z9Htp0tD3X5g" style="text-align: right" title="Number of Warrants"&gt;1,149,586&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--TwoThousandTwentyThreeConvertibleNotesMember_zfgkRFQC2Yj5" style="text-align: right" title="Exercise Price"&gt;2.38&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span id="xdx_90E_ecustom--WarrantExpirationDateDescription_c20240101__20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--TwoThousandTwentyThreeConvertibleNotesMember_znoFVfcfoDo7" title="Expiration Date"&gt;Various in 2028&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Underwriter Warrants&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--UnderwriterWarrantsMember_zZO43U71DrG2" style="text-align: right" title="Number of Warrants"&gt;331,146&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--UnderwriterWarrantsMember_zUZ13v9jeyFj" style="text-align: right" title="Exercise Price"&gt;2.38&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span id="xdx_903_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--UnderwriterWarrantsMember_zwBgUbqUDd2i" title="Expiration Date"&gt;August 8, 2028&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Advisory Agreement Warrants&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--AdvisoryAgreementWarrantsMember_zeWU4i89Vkd2" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Warrants"&gt;76,512&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--AdvisoryAgreementWarrantsMember_zuEVWVpc4Ix3" style="padding-bottom: 1pt; text-align: right" title="Exercise Price"&gt;2.38&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; padding-bottom: 1pt"&gt;&lt;span id="xdx_90E_ecustom--WarrantExpirationDateDescription_c20240101__20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--AdvisoryAgreementWarrantsMember_zns5lNIaieig" title="Expiration Date"&gt;Various in 2029&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20241231_zCUeLXbdEkB4" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Warrants"&gt;2,642,530&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p id="xdx_8AC_zLQMJ8gCt1T4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact001500"
      unitRef="Shares">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact001502"
      unitRef="Shares">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact001504"
      unitRef="Shares">6990227</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact001506"
      unitRef="Shares">6990227</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact001508"
      unitRef="Shares">6508897</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact001510"
      unitRef="Shares">6508897</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityReverseStockSplit contextRef="From2023-01-102023-01-10" id="Fact001512">2-for-1 reverse stock split.</us-gaap:StockholdersEquityReverseStockSplit>
    <NRXS:StockIssuedDuringPeriodSharesCommonStockIssuedUponInitialPublicOffering
      contextRef="From2023-01-012023-12-31"
      decimals="INF"
      id="Fact001514"
      unitRef="Shares">1098667</NRXS:StockIssuedDuringPeriodSharesCommonStockIssuedUponInitialPublicOffering>
    <us-gaap:SharePrice
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact001516"
      unitRef="USDPShares">6.00</us-gaap:SharePrice>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact001518"
      unitRef="USD">4110677</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <us-gaap:DebtConversionConvertedInstrumentSharesIssued1
      contextRef="From2023-01-012023-12-31"
      decimals="INF"
      id="Fact001520"
      unitRef="Shares">1244228</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
    <us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact001522"
      unitRef="Shares">506637</us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion>
    <us-gaap:ConversionOfStockSharesConverted1
      contextRef="From2023-01-012023-12-31_custom_ConvertibleSeriesSeedPreferredStockMember"
      decimals="INF"
      id="Fact001524"
      unitRef="Shares">115477</us-gaap:ConversionOfStockSharesConverted1>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact001526"
      unitRef="Shares">1649900</us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits
      contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact001528"
      unitRef="Shares">1649900</us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="From2023-01-012023-12-31_custom_VendorsMember"
      decimals="INF"
      id="Fact001530"
      unitRef="Shares">425000</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:ConversionOfStockSharesIssued1
      contextRef="From2023-01-012023-12-31_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact001532"
      unitRef="Shares">127780</us-gaap:ConversionOfStockSharesIssued1>
    <NRXS:StockIssuedDuringPeriodSharesCommonStockIssuedUponInitialPublicOffering
      contextRef="From2024-01-01to2024-12-31"
      decimals="INF"
      id="Fact001534"
      unitRef="Shares">245955</NRXS:StockIssuedDuringPeriodSharesCommonStockIssuedUponInitialPublicOffering>
    <us-gaap:ConversionOfStockSharesIssued1
      contextRef="From2024-01-012024-12-31_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact001536"
      unitRef="Shares">11000</us-gaap:ConversionOfStockSharesIssued1>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="From2024-01-012024-12-31_custom_VendorsMember"
      decimals="INF"
      id="Fact001538"
      unitRef="Shares">115145</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:ConversionOfStockSharesConverted1
      contextRef="From2024-01-01to2024-12-31"
      decimals="INF"
      id="Fact001540"
      unitRef="Shares">59055</us-gaap:ConversionOfStockSharesConverted1>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="From2024-01-012024-12-31_custom_EmployementAgreementMember"
      decimals="INF"
      id="Fact001542"
      unitRef="Shares">25832</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="From2024-01-01to2024-12-31"
      decimals="INF"
      id="Fact001544"
      unitRef="Shares">24343</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2023-12-31_custom_TwoThousandTwentyThreeConvertiblePromissoryNotesMember"
      decimals="INF"
      id="Fact001546"
      unitRef="Shares">505570</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="AsOf2023-12-31_custom_TwoThousandTwentyThreeConvertiblePromissoryNotesMember"
      decimals="INF"
      id="Fact001549"
      unitRef="USDPShares">5.25</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2023-12-31_custom_AdvisoryAgreementMember"
      decimals="INF"
      id="Fact001551"
      unitRef="Shares">122202</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="AsOf2023-12-31_custom_AdvisoryAgreementMember"
      decimals="INF"
      id="Fact001554"
      unitRef="USDPShares">5.25</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2023-12-31_custom_UnderwritingAgreementMember"
      decimals="INF"
      id="Fact001556"
      unitRef="Shares">186156</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="AsOf2023-12-31_custom_UnderwritingAgreementMember"
      decimals="INF"
      id="Fact001559"
      unitRef="USDPShares">5.25</us-gaap:SharesIssuedPricePerShare>
    <NRXS:NumberOfEquivalentOfWarrantsDescription contextRef="From2023-01-012023-12-31" id="Fact001561">investors converted (i) 87,856
warrants into an equivalent number of common shares at an exercise price of $2.38 in exchange for $209,097 in cash proceeds and (ii)
40,000 warrants into 39,924 common shares in a cashless exercise transaction.</NRXS:NumberOfEquivalentOfWarrantsDescription>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2024-12-31_custom_TwoThousandTwentyFourConvertiblePromissoryNotesMember47712359"
      decimals="INF"
      id="Fact001563"
      unitRef="Shares">38697</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="AsOf2024-12-31_custom_TwoThousandTwentyFourConvertiblePromissoryNotesMember47712359"
      decimals="INF"
      id="Fact001566"
      unitRef="USDPShares">2.38</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2024-12-31_custom_AdvisoryAgreementsMember"
      decimals="INF"
      id="Fact001568"
      unitRef="Shares">68067</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="AsOf2024-12-31_custom_AdvisoryAgreementsMember"
      decimals="INF"
      id="Fact001571"
      unitRef="USDPShares">2.38</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="AsOf2024-12-31_custom_TwoThousandTwentyFourConvertiblePromissoryNotesMember47712359"
      decimals="INF"
      id="Fact001572"
      unitRef="USDPShares">2.38</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="AsOf2024-12-31_custom_TwoThousandTwentyThreeConvertiblePromissoryNotesMember"
      decimals="INF"
      id="Fact001573"
      unitRef="USDPShares">5.25</us-gaap:SharesIssuedPricePerShare>
    <NRXS:ClassOfWarrantOrRightAdditional
      contextRef="AsOf2024-12-31_custom_TwoThousandTwentyFourConvertiblePromissoryNotesMember47712359"
      decimals="INF"
      id="Fact001575"
      unitRef="Shares">754660</NRXS:ClassOfWarrantOrRightAdditional>
    <NRXS:NumberOfEquivalentOfWarrantsDescription contextRef="From2024-01-01to2024-12-31" id="Fact001577">investors converted  11,000 warrants into an equivalent number of common shares at an exercise price of $2.38 in exchange
for $26,180 in cash proceeds.</NRXS:NumberOfEquivalentOfWarrantsDescription>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact001579"
      unitRef="Shares">30252</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations>
    <NRXS:ScheduleOfWarrantActivityForCommonStockTableTextBlock
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      id="Fact001581">&lt;p id="xdx_89D_ecustom--ScheduleOfWarrantActivityForCommonStockTableTextBlock_hus-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zLrw0eGMZ8Fh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following is a summary of warrant activity for common stock during the years ended December 31, 2024 and 2023:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;span id="xdx_8B4_zF19HNxPm3Bk" style="display: none"&gt;Schedule of Warrant Activity for Common Stock&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Number of Warrants for Common Stock&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Weighted-Avg. Exercise Price&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Weighted-Avg. Remaining Contractual Life&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 40%; font-weight: bold"&gt;Outstanding as of January 1, 2023&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zqCUE1twemab" style="width: 16%; text-align: right" title="Number of Warrants, Outstanding at beginning of period"&gt;846,507&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zhr3vJ6fezYi" style="width: 16%; text-align: right" title="Weighted Average Exercise Price, Outstanding at beginning of period"&gt;5.06&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z1Jwb8Y6z7F4" title="Weighted Average Remaining Contractual Life - Warrants"&gt;4.72&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zvCO7feZJtO3" style="text-align: right" title="Number of Warrants, Granted"&gt;813,928&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zJhAxuudUgBe" style="text-align: right" title="Weighted Average Exercise Price, granted"&gt;5.81&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsWeightedAverageRemainingContracualLifeOutstandingNumberGranted_dtY_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zdueqO08qFP" title="Weighted Average Remaining Contractual Life - Warrants Granted"&gt;4.38&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Converted Prefunded Warrants&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsConvertedPrefundedWarrants_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z1T7to5A8GSd" style="text-align: right" title="Number of Warrants, Converted Prefunded Warrants"&gt;289,779&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsConvertedPrefundedWarrantsInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zY56eTAD5bmg" style="text-align: right" title="Weighted Average Exercise Price, Converted Prefunded Warrants"&gt;0.01&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Cancelled&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zYXpsY5K2eyh" style="text-align: right" title="Number of Warrants, Granted"&gt;(30,252&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsWeightedAverageExercisePriceCancelledExpiredNumber_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zftXG45d9Fcg" style="text-align: right" title="Weighted Average Exercise Price, Cancelled Expired"&gt;2.38&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90B_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsCancelledWeightedAverageRemainingContractualTerm1_dtY_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z3ExdXdKOUI4" title="Weighted Average Remaining Contractual Life - Warrants Cancelled"&gt;4.79&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;Exercised&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zJwgA5K3QICa" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Warrants, Exercised"&gt;(127,856&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_ztaF8wIpjGHb" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price, Excercised"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1607"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;Outstanding as of December 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zyC3xdrUua51" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Warrants, Outstanding at beginning of period"&gt;1,822,358&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zk5KvZkRA7S6" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price, Outstanding at beginning of period"&gt;4.69&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zpHWNBLzvNfe" title="Weighted Average Remaining Contractual Life - Warrants"&gt;3.05&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zyDwKGvOqya4" style="text-align: right" title="Number of Warrants, Granted"&gt;861,424&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zP5e8TEsARIl" style="text-align: right" title="Weighted Average Exercise Price, granted"&gt;2.38&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z9qIs9iz7aje" title="Weighted Average Remaining Contractual Life - Warrants Granted"&gt;3.49&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Cancelled&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_iN_pid_di_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z0JtbrAmw6L9" style="text-align: right" title="Number of Warrants, Granted"&gt;(30,252&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsWeightedAverageExercisePriceCancelledExpiredNumber_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z0fBvAhyc7fe" style="text-align: right" title="Weighted Average Exercise Price, Cancelled Expired"&gt;2.38&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90E_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsCancelledWeightedAverageRemainingContractualTerm1_dtY_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zgIGKKCyLomf" title="Weighted Average Remaining Contractual Life - Warrants Cancelled"&gt;4.79&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;Exercised&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zfwcoWXVFRFd" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Warrants, Exercised"&gt;(11,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zbTO4y9uPVR2" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price, Excercised"&gt;2.38&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_90A_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisedWeightedAverageRemainingContractualTerm1_dtY_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zcjv1U3Qle25" title="Weighted Average Remaining Contractual Life - Warrants Granted"&gt;3.61&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;Outstanding as of December 31, 2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zgqcy9ma0rvk" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Warrants, Outstanding at Ending of period"&gt;2,642,530&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_znzR0pZ73WD1" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price, Outstanding at Ending of period"&gt;2.41&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zti3Xue9xa3i" title="Weighted Average Remaining Contractual Life - Warrants"&gt;2.93&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</NRXS:ScheduleOfWarrantActivityForCommonStockTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="AsOf2022-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact001583"
      unitRef="Shares">846507</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2022-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact001585"
      unitRef="USDPShares">5.06</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember"
      id="Fact001587">P4Y8M19D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact001589"
      unitRef="Shares">813928</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact001591"
      unitRef="USDPShares">5.81</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <NRXS:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsWeightedAverageRemainingContracualLifeOutstandingNumberGranted
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      id="Fact001593">P4Y4M17D</NRXS:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsWeightedAverageRemainingContracualLifeOutstandingNumberGranted>
    <NRXS:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsConvertedPrefundedWarrants
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact001595"
      unitRef="Shares">289779</NRXS:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsConvertedPrefundedWarrants>
    <NRXS:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsConvertedPrefundedWarrantsInPeriodWeightedAverageExercisePrice
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact001597"
      unitRef="USDPShares">0.01</NRXS:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsConvertedPrefundedWarrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact001599"
      unitRef="Shares">-30252</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations>
    <NRXS:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsWeightedAverageExercisePriceCancelledExpiredNumber
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact001601"
      unitRef="Shares">2.38</NRXS:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsWeightedAverageExercisePriceCancelledExpiredNumber>
    <NRXS:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsCancelledWeightedAverageRemainingContractualTerm1
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      id="Fact001603">P4Y9M14D</NRXS:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsCancelledWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact001605"
      unitRef="Shares">-127856</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="AsOf2023-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact001609"
      unitRef="Shares">1822358</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2023-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact001611"
      unitRef="USDPShares">4.69</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      id="Fact001613">P3Y18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact001615"
      unitRef="Shares">861424</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact001617"
      unitRef="USDPShares">2.38</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      id="Fact001619">P3Y5M26D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact001621"
      unitRef="Shares">30252</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations>
    <NRXS:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsWeightedAverageExercisePriceCancelledExpiredNumber
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact001623"
      unitRef="Shares">2.38</NRXS:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsWeightedAverageExercisePriceCancelledExpiredNumber>
    <NRXS:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsCancelledWeightedAverageRemainingContractualTerm1
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      id="Fact001625">P4Y9M14D</NRXS:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsCancelledWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact001627"
      unitRef="Shares">-11000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact001629"
      unitRef="USDPShares">2.38</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <NRXS:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisedWeightedAverageRemainingContractualTerm1
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      id="Fact001631">P3Y7M9D</NRXS:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisedWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="AsOf2024-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact001633"
      unitRef="Shares">2642530</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2024-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact001635"
      unitRef="USDPShares">2.41</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      id="Fact001637">P2Y11M4D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <NRXS:ScheduleOfWarrantActivityForPreferredStockTableTextBlock
      contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember"
      id="Fact001639">&lt;p id="xdx_891_ecustom--ScheduleOfWarrantActivityForPreferredStockTableTextBlock_hus-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zNT710L4p2uf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following is a summary of warrant activity for preferred stock during the year ended December 31, 2023:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8BD_zdZp51J3cWs2" style="display: none"&gt;Schedule of Warrant Activity for Preferred Stock&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Number of&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Weighted-Avg.&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Warrants for&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Exercise&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Preferred Stock&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Price&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; font-weight: bold; padding-bottom: 1pt"&gt;Outstanding as of December 31, 2022&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zfcGzLOG3dr1" style="border-bottom: Black 1pt solid; width: 16%; text-align: right" title="Number of Warrants, Outstanding at beginning of period"&gt;144,890&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zN0O4Rsc9wJ" style="border-bottom: Black 1pt solid; width: 16%; text-align: right" title="Weighted Average Exercise Price, Outstanding at beginning of period"&gt;0.01&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_z2Va9eQzser" style="text-align: right" title="Number of Warrants, Granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1645"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_uUSDPShares_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zOMOCQMMk1bg" style="text-align: right" title="Weighted Average Exercise Price, granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1647"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Cancelled/Expired&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zF9FzeR5PABe" style="text-align: right" title="Number of Warrants, Cancelled Expired"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1649"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsWeightedAverageExercisePriceCancelledExpiredNumber_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_z14hGJgeTKV6" style="text-align: right" title="Weighted Average Exercise Price, Cancelled Expired"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1651"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Converted to Common Stock Warrant&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsCommonStockWarrant_iN_pid_di_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_znHVx7Qc6Qmb" style="border-bottom: Black 1pt solid; text-align: right" title="Converted to Common Stock Warrant"&gt;(144,890&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsWeightedAverageExercisePriceCommonStockWarrant_iN_pid_di_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zxR5E0bIf4hl" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price, Converted to Common Stock Warrant"&gt;(0.01&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;Outstanding as of December 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zMic3aPT4rBb" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Warrants, Outstanding at Ending of period"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1657"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_z8VxpLHbvBK4" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price, Outstanding at Ending of period"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1659"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</NRXS:ScheduleOfWarrantActivityForPreferredStockTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="AsOf2022-12-31_us-gaap_PreferredStockMember"
      decimals="INF"
      id="Fact001641"
      unitRef="Shares">144890</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2022-12-31_us-gaap_PreferredStockMember"
      decimals="INF"
      id="Fact001643"
      unitRef="USDPShares">0.01</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <NRXS:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsCommonStockWarrant
      contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember"
      decimals="INF"
      id="Fact001653"
      unitRef="Shares">144890</NRXS:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsCommonStockWarrant>
    <NRXS:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsWeightedAverageExercisePriceCommonStockWarrant
      contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember"
      decimals="INF"
      id="Fact001655"
      unitRef="Shares">0.01</NRXS:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsWeightedAverageExercisePriceCommonStockWarrant>
    <us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact001661">&lt;p id="xdx_898_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_z9igFQMpLx0d" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table summarizes the Company&#x2019;s warrants outstanding and exercisable as of December 31, 2024:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8BC_zvxaUvkopMl5" style="display: none"&gt;Schedule of Warrants outstanding and Exercisable&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Number of&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Warrants&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Exercise&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: center"&gt;Expiration&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Outstanding&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Price&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Date&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 40%; text-align: left"&gt;Investor Warrant&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--InvestorWarrantOneMember_zCwbBa9nn5Ti" style="width: 16%; text-align: right" title="Number of Warrants"&gt;12,852&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--InvestorWarrantOneMember_zzr2tmz9546e" style="width: 16%; text-align: right" title="Exercise Price"&gt;8.76&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 18%; text-align: center"&gt;&lt;span id="xdx_90E_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--InvestorWarrantOneMember_zYJKbGJUSZKb" title="Expiration Date"&gt;September 18, 2028&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Investor Warrant&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--InvestorWarrantPSAOneMember_zcLpYDWZaeAl" style="text-align: right" title="Number of Warrants"&gt;289,779&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--InvestorWarrantPSAOneMember_zmzsgDqFYzq6" style="text-align: right" title="Exercise Price"&gt;0.01&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span id="xdx_90C_ecustom--WarrantExpirationDateDescription_c20240101__20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--InvestorWarrantPSAOneMember_zhIdSpG22uz" title="Expiration Date"&gt;None&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;2022 Convertible Notes&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--TwoThousandTwentyTwoConvertibleNotesMember_zoK0YKQK2Zlc" style="text-align: right" title="Number of Warrants"&gt;782,655&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--TwoThousandTwentyTwoConvertibleNotesMember_zvl7qbY1ug3e" style="text-align: right" title="Exercise Price"&gt;2.38&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span id="xdx_90B_ecustom--WarrantExpirationDateDescription_c20240101__20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--TwoThousandTwentyTwoConvertibleNotesMember_zvM5SIXYBBo6" title="Expiration Date"&gt;Various in 2027&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;2023 Convertible Notes&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--TwoThousandTwentyThreeConvertibleNotesMember_z9Htp0tD3X5g" style="text-align: right" title="Number of Warrants"&gt;1,149,586&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--TwoThousandTwentyThreeConvertibleNotesMember_zfgkRFQC2Yj5" style="text-align: right" title="Exercise Price"&gt;2.38&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span id="xdx_90E_ecustom--WarrantExpirationDateDescription_c20240101__20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--TwoThousandTwentyThreeConvertibleNotesMember_znoFVfcfoDo7" title="Expiration Date"&gt;Various in 2028&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Underwriter Warrants&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--UnderwriterWarrantsMember_zZO43U71DrG2" style="text-align: right" title="Number of Warrants"&gt;331,146&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--UnderwriterWarrantsMember_zUZ13v9jeyFj" style="text-align: right" title="Exercise Price"&gt;2.38&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span id="xdx_903_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--UnderwriterWarrantsMember_zwBgUbqUDd2i" title="Expiration Date"&gt;August 8, 2028&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Advisory Agreement Warrants&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--AdvisoryAgreementWarrantsMember_zeWU4i89Vkd2" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Warrants"&gt;76,512&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--AdvisoryAgreementWarrantsMember_zuEVWVpc4Ix3" style="padding-bottom: 1pt; text-align: right" title="Exercise Price"&gt;2.38&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; padding-bottom: 1pt"&gt;&lt;span id="xdx_90E_ecustom--WarrantExpirationDateDescription_c20240101__20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--AdvisoryAgreementWarrantsMember_zns5lNIaieig" title="Expiration Date"&gt;Various in 2029&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20241231_zCUeLXbdEkB4" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Warrants"&gt;2,642,530&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


</us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2024-12-31_custom_InvestorWarrantOneMember"
      decimals="INF"
      id="Fact001663"
      unitRef="Shares">12852</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2024-12-31_custom_InvestorWarrantOneMember"
      decimals="INF"
      id="Fact001665"
      unitRef="USDPShares">8.76</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingMaturityDate
      contextRef="AsOf2024-12-31_custom_InvestorWarrantOneMember"
      id="Fact001667">2028-09-18</us-gaap:WarrantsAndRightsOutstandingMaturityDate>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2024-12-31_custom_InvestorWarrantPSAOneMember"
      decimals="INF"
      id="Fact001669"
      unitRef="Shares">289779</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2024-12-31_custom_InvestorWarrantPSAOneMember"
      decimals="INF"
      id="Fact001671"
      unitRef="USDPShares">0.01</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <NRXS:WarrantExpirationDateDescription
      contextRef="From2024-01-012024-12-31_custom_InvestorWarrantPSAOneMember"
      id="Fact001673">None</NRXS:WarrantExpirationDateDescription>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2024-12-31_custom_TwoThousandTwentyTwoConvertibleNotesMember"
      decimals="INF"
      id="Fact001675"
      unitRef="Shares">782655</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2024-12-31_custom_TwoThousandTwentyTwoConvertibleNotesMember"
      decimals="INF"
      id="Fact001677"
      unitRef="USDPShares">2.38</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <NRXS:WarrantExpirationDateDescription
      contextRef="From2024-01-012024-12-31_custom_TwoThousandTwentyTwoConvertibleNotesMember"
      id="Fact001679">Various in 2027</NRXS:WarrantExpirationDateDescription>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2024-12-31_custom_TwoThousandTwentyThreeConvertibleNotesMember"
      decimals="INF"
      id="Fact001681"
      unitRef="Shares">1149586</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2024-12-31_custom_TwoThousandTwentyThreeConvertibleNotesMember"
      decimals="INF"
      id="Fact001683"
      unitRef="USDPShares">2.38</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <NRXS:WarrantExpirationDateDescription
      contextRef="From2024-01-012024-12-31_custom_TwoThousandTwentyThreeConvertibleNotesMember"
      id="Fact001685">Various in 2028</NRXS:WarrantExpirationDateDescription>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2024-12-31_custom_UnderwriterWarrantsMember"
      decimals="INF"
      id="Fact001687"
      unitRef="Shares">331146</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2024-12-31_custom_UnderwriterWarrantsMember"
      decimals="INF"
      id="Fact001689"
      unitRef="USDPShares">2.38</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingMaturityDate
      contextRef="AsOf2024-12-31_custom_UnderwriterWarrantsMember"
      id="Fact001691">2028-08-08</us-gaap:WarrantsAndRightsOutstandingMaturityDate>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2024-12-31_custom_AdvisoryAgreementWarrantsMember"
      decimals="INF"
      id="Fact001693"
      unitRef="Shares">76512</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2024-12-31_custom_AdvisoryAgreementWarrantsMember"
      decimals="INF"
      id="Fact001695"
      unitRef="USDPShares">2.38</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <NRXS:WarrantExpirationDateDescription
      contextRef="From2024-01-012024-12-31_custom_AdvisoryAgreementWarrantsMember"
      id="Fact001697">Various in 2029</NRXS:WarrantExpirationDateDescription>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact001699"
      unitRef="Shares">2642530</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:PreferredStockTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact001701">&lt;p id="xdx_805_eus-gaap--PreferredStockTextBlock_zZYzrZvyML03" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;10.
&lt;span id="xdx_826_zCSBQTL0v5Ba"&gt;Preferred Stock&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of December 31, 2023, the Company had&#160;&lt;span id="xdx_907_eus-gaap--PreferredStockSharesAuthorized_iI_c20231231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zp47lXYOLbfj" title="Preferred stock, shares authorized"&gt;1,000,000&lt;/span&gt;&#160;and&#160;&lt;span id="xdx_905_eus-gaap--PreferredStockSharesAuthorized_iI_c20231231__us-gaap--StatementClassOfStockAxis__custom--SeriesSeedPreferredStockMember_zAWxjg4zLpJi" title="Preferred stock, shares authorized"&gt;120,000&lt;/span&gt;&#160;shares authorized as Series A and Series Seed Preferred
Stock, respectively, of which&#160;&lt;span id="xdx_901_eus-gaap--PreferredStockSharesIssued_iI_dc_c20231231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zTdXQaXAUy61" title="Preferred stock, shares issued"&gt;&lt;span id="xdx_906_eus-gaap--PreferredStockSharesOutstanding_iI_dc_c20231231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zSodCfpNEsh3" title="Preferred stock, shares outstanding"&gt;&lt;span id="xdx_900_eus-gaap--PreferredStockSharesIssued_iI_dc_c20231231__us-gaap--StatementClassOfStockAxis__custom--SeriesSeedPreferredStockMember_zjoOeCO9i7ng" title="Preferred stock, shares issued"&gt;&lt;span id="xdx_909_eus-gaap--PreferredStockSharesOutstanding_iI_dc_c20231231__us-gaap--StatementClassOfStockAxis__custom--SeriesSeedPreferredStockMember_ziLCyiFQcgbc" title="Preferred stock, shares outstanding"&gt;zero&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&#160;shares are issued and outstanding for both classes of preferred stock. The Series A and
Series Seed Preferred Stock (i) voted together with common stock on an as-converted basis, and not as separate classes and (ii) converted
1:1 to common stock at any time at option of holder, subject to adjustments for stock dividends, splits, combinations, and similar events.
The Series A Preferred Stock carried an annual&#160;&lt;span id="xdx_90C_eus-gaap--PreferredStockDividendRatePercentage_dp_uPure_c20230101__20231231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zMQGLxpbUZs8" title="Preferred stock dividend rate percentage"&gt;8&lt;/span&gt;% cumulative dividend, payable upon any liquidation, dissolution or winding up of
the Company. For any other dividends or distributions, the Series A Preferred Stock participated with common stock on an as-converted
basis. &lt;span id="xdx_90F_ecustom--PreferredStockSharesRetiredDescription_iI_c20231231__us-gaap--StatementClassOfStockAxis__custom--SeriesSeedPreferredStockMember_zoZlUtluCbr8" title="Preferred stock, retired description"&gt;The Company&#x2019;s&#160;1,000,000&#160;shares of Series A Preferred Stock and&#160;120,000&#160;shares of Series Seed Preferred
Stock were retired on August 15, 2024.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
August 15, 2024, the Company&#x2019;s shareholders authorized&#160;&lt;span id="xdx_90E_eus-gaap--PreferredStockSharesAuthorized_iI_c20240815__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zgA7sLfI2vkj" title="Preferred stock, shares authorized"&gt;5,000,000&lt;/span&gt;&#160;shares of preferred stock of which&#160;&lt;span id="xdx_909_eus-gaap--TemporaryEquitySharesAuthorized_iI_pid_c20240815__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zqZFtyvS61i2" title="Temporary equity, shares authorized"&gt;4,000,000&lt;/span&gt;&#160;shares
were designated as $&lt;span id="xdx_909_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20240815__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zUiJ7TNL8Jr7" title="Preferred stock, par value"&gt;0.001&lt;/span&gt;&#160;par value Series B Preferred Stock. Series B Preferred Stock shareholders vote with Common Stock shareholders
on an as-converted basis and not as a separate class. Cumulative dividends accrue at&#160;&lt;span id="xdx_906_eus-gaap--PreferredStockDividendRatePercentage_dp_uPure_c20240815__20240815__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zaTB22F8i2Oi" title="Preferred stock dividend rate percentage"&gt;8.5&lt;/span&gt;% per annum and are due and payable in either
cash for common shares as the Company&#x2019;s discretion on a quarterly basis through June 30, 2025. Series B Preferred Stock converts
to common stock on a 1:1 basis, subject to adjustments for stock dividends, splits, combinations and similar events as well as unpaid
dividends thereon, solely at the election of the holder at any time.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Pursuant
to the terms of the Amended 2024 Convertible Notes, the principal balance of $&lt;span id="xdx_90C_eus-gaap--DebtInstrumentFaceAmount_iI_c20240815__us-gaap--ShortTermDebtTypeAxis__custom--AmendedTwoThousandTwentyFourConvertibleNotesMember_zYHpg4Zafdq2" title="Borrowed amount"&gt;4,935,000&lt;/span&gt; on August 15, 2024 was mandatorily converted
into &lt;span id="xdx_90E_eus-gaap--ConversionOfStockSharesConverted1_c20240815__20240815__us-gaap--ShortTermDebtTypeAxis__custom--AmendedTwoThousandTwentyFourConvertibleNotesMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zIYWn3b9oGh6" title="Shares converted"&gt;2,073,524&lt;/span&gt; Series B Preferred Shares at a conversion price of $&lt;span id="xdx_90B_eus-gaap--SharesIssuedPricePerShare_iI_c20240815__us-gaap--ShortTermDebtTypeAxis__custom--AmendedTwoThousandTwentyFourConvertibleNotesMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zjAj2KsuJf55" title="Conversion per shares"&gt;2.38&lt;/span&gt;. Subsequently, the Company then proceeded to issue &lt;span id="xdx_90A_ecustom--ProceedsFromIssuanceOfStock_c20240815__20240815__us-gaap--ShortTermDebtTypeAxis__custom--AmendedTwoThousandTwentyFourConvertibleNotesMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zCyF4tansIoh" title="Issuance of debt, shares"&gt;64,913&lt;/span&gt; shares
of Series B Preferred Stock to various investors for $&lt;span id="xdx_90E_eus-gaap--ProceedsFromIssuanceOfDebt_c20240815__20240815__us-gaap--ShortTermDebtTypeAxis__custom--AmendedTwoThousandTwentyFourConvertibleNotesMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zv8WWQCZm0Ug" title="Issuance of debt"&gt;154,500&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
November 11, 2024, the Company&#x2019;s shareholders authorized (i) an increase in the number of designated Series B Preferred Stock
to &lt;span id="xdx_905_eus-gaap--PreferredStockSharesAuthorized_iI_c20241111__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_z6g2JyMHGWMa" title="Preferred stock, shares authorized"&gt;5,000,000&lt;/span&gt;
shares and (ii) an extension of the &lt;span id="xdx_902_ecustom--CumulativeDividendsPercent_iI_pid_dp_uPure_c20241111__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zf3nOa6DXTx5" title="Cumulative dividends percent"&gt;8.5&lt;/span&gt;%
per annum cumulative dividend period to December 31, 2026. Subsequently, the Company issued &lt;span id="xdx_900_eus-gaap--SharesIssued_iI_c20241113__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zJ2jGjVeNYii" title="Preferred stock, shares issued"&gt;2,100,840&lt;/span&gt;
shares of Series B Preferred Stock to a dedicated life sciences fund for $&lt;span id="xdx_904_eus-gaap--PreferredStockSharesAuthorized_iI_c20241113__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zmmXdHHuihg6" title="Preferred stock, shares authorized"&gt;5,000,000&lt;/span&gt;
and &lt;span id="xdx_900_ecustom--ProceedsFromIssuanceOfStock_c20241111__20241111__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zZqFfsYMI1ng" title="Issuance of debt, shares"&gt;41,662&lt;/span&gt; shares of Series B Preferred Stock to various investors for $&lt;span id="xdx_90F_eus-gaap--ProceedsFromIssuanceOfDebt_c20241111__20241111__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zGXcN9H8Pjn6" title="Issuance of debt"&gt;99,164&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Upon
any liquidation, dissolution or winding up of the Company, whether voluntary or involuntary, the Series B Preferred Stock
shareholders maintain priority preference over all other classes of capital stock. A merger or consolidation (other than one in
which stockholders of the Company own a majority by voting power of the outstanding shares of the surviving or acquiring
corporation) and a sale, lease, transfer, exclusive license or other disposition of all or substantially all of the assets of the
Company will be treated as a liquidation event, thereby triggering payment of the liquidation preferences.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of December 31, 2024, there were &lt;span id="xdx_90D_eus-gaap--PreferredStockSharesOutstanding_iI_c20241231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zBbg0B4WYbb8"&gt;4,280,939 &lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;shares
of Series B Preferred Stock issued and outstanding. As of December 31, 2024 and 2023, there were&#160;&lt;span id="xdx_907_eus-gaap--DividendsPayableCurrentAndNoncurrent_iI_do_c20241231__us-gaap--StatementClassOfStockAxis__us-gaap--PreferredStockMember_z7lAlJ6WX1Jg" title="Dividends declared"&gt;&lt;span id="xdx_90F_eus-gaap--DividendsPayableCurrentAndNoncurrent_iI_do_c20231231__us-gaap--StatementClassOfStockAxis__us-gaap--PreferredStockMember_z1oUoRfkOZK3" title="Dividends declared"&gt;no&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;preferred
stock dividends declared or paid. Series B Preferred Stock undeclared cumulative dividends totaled $&lt;span id="xdx_902_eus-gaap--DividendsPreferredStock_c20240101__20241231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zwgSShbrbgD1" title="Dividends"&gt;211,268&lt;/span&gt;,
or $&lt;span id="xdx_900_eus-gaap--PreferredStockDividendRatePerDollarAmount_uUSDPShares_c20240101__20241231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zFsHY00Iz4bc" title="Dividends, preferred stock per share"&gt;0.05&lt;/span&gt; per share, as of December 31, 2024. Series B Preferred Stock did not exist during the year ended December 31, 2023.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:PreferredStockTextBlock>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2023-12-31_us-gaap_SeriesAPreferredStockMember"
      decimals="INF"
      id="Fact001703"
      unitRef="Shares">1000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2023-12-31_custom_SeriesSeedPreferredStockMember"
      decimals="INF"
      id="Fact001705"
      unitRef="Shares">120000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="AsOf2023-12-31_us-gaap_SeriesAPreferredStockMember"
      decimals="INF"
      id="Fact001707"
      unitRef="Shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2023-12-31_us-gaap_SeriesAPreferredStockMember"
      decimals="INF"
      id="Fact001709"
      unitRef="Shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="AsOf2023-12-31_custom_SeriesSeedPreferredStockMember"
      decimals="INF"
      id="Fact001711"
      unitRef="Shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2023-12-31_custom_SeriesSeedPreferredStockMember"
      decimals="INF"
      id="Fact001713"
      unitRef="Shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockDividendRatePercentage
      contextRef="From2023-01-012023-12-31_us-gaap_SeriesAPreferredStockMember"
      decimals="INF"
      id="Fact001715"
      unitRef="Pure">0.08</us-gaap:PreferredStockDividendRatePercentage>
    <NRXS:PreferredStockSharesRetiredDescription
      contextRef="AsOf2023-12-31_custom_SeriesSeedPreferredStockMember"
      decimals="INF"
      id="Fact001717"
      unitRef="Shares">1000000</NRXS:PreferredStockSharesRetiredDescription>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2024-08-15_us-gaap_SeriesBPreferredStockMember"
      decimals="INF"
      id="Fact001719"
      unitRef="Shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="AsOf2024-08-15_us-gaap_SeriesBPreferredStockMember"
      decimals="INF"
      id="Fact001721"
      unitRef="Shares">4000000</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2024-08-15_us-gaap_SeriesBPreferredStockMember"
      decimals="INF"
      id="Fact001723"
      unitRef="USDPShares">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockDividendRatePercentage
      contextRef="From2024-08-152024-08-15_us-gaap_SeriesBPreferredStockMember"
      decimals="INF"
      id="Fact001725"
      unitRef="Pure">0.085</us-gaap:PreferredStockDividendRatePercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2024-08-15_custom_AmendedTwoThousandTwentyFourConvertibleNotesMember"
      decimals="0"
      id="Fact001727"
      unitRef="USD">4935000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:ConversionOfStockSharesConverted1
      contextRef="From2024-08-152024-08-15_custom_AmendedTwoThousandTwentyFourConvertibleNotesMember_us-gaap_SeriesBPreferredStockMember"
      decimals="INF"
      id="Fact001729"
      unitRef="Shares">2073524</us-gaap:ConversionOfStockSharesConverted1>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="AsOf2024-08-15_custom_AmendedTwoThousandTwentyFourConvertibleNotesMember_us-gaap_SeriesBPreferredStockMember"
      decimals="INF"
      id="Fact001731"
      unitRef="USDPShares">2.38</us-gaap:SharesIssuedPricePerShare>
    <NRXS:ProceedsFromIssuanceOfStock
      contextRef="From2024-08-152024-08-15_custom_AmendedTwoThousandTwentyFourConvertibleNotesMember_us-gaap_SeriesBPreferredStockMember"
      decimals="INF"
      id="Fact001733"
      unitRef="Shares">64913</NRXS:ProceedsFromIssuanceOfStock>
    <us-gaap:ProceedsFromIssuanceOfDebt
      contextRef="From2024-08-152024-08-15_custom_AmendedTwoThousandTwentyFourConvertibleNotesMember_us-gaap_SeriesBPreferredStockMember"
      decimals="0"
      id="Fact001735"
      unitRef="USD">154500</us-gaap:ProceedsFromIssuanceOfDebt>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2024-11-11_us-gaap_SeriesBPreferredStockMember"
      decimals="INF"
      id="Fact001737"
      unitRef="Shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <NRXS:CumulativeDividendsPercent
      contextRef="AsOf2024-11-11_us-gaap_SeriesBPreferredStockMember"
      decimals="INF"
      id="Fact001739"
      unitRef="Pure">0.085</NRXS:CumulativeDividendsPercent>
    <us-gaap:SharesIssued
      contextRef="AsOf2024-11-13_us-gaap_SeriesBPreferredStockMember"
      decimals="INF"
      id="Fact001741"
      unitRef="Shares">2100840</us-gaap:SharesIssued>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2024-11-13_us-gaap_SeriesBPreferredStockMember"
      decimals="INF"
      id="Fact001743"
      unitRef="Shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <NRXS:ProceedsFromIssuanceOfStock
      contextRef="From2024-11-112024-11-11_us-gaap_SeriesBPreferredStockMember"
      decimals="INF"
      id="Fact001745"
      unitRef="Shares">41662</NRXS:ProceedsFromIssuanceOfStock>
    <us-gaap:ProceedsFromIssuanceOfDebt
      contextRef="From2024-11-112024-11-11_us-gaap_SeriesBPreferredStockMember"
      decimals="0"
      id="Fact001747"
      unitRef="USD">99164</us-gaap:ProceedsFromIssuanceOfDebt>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2024-12-31_us-gaap_SeriesBPreferredStockMember"
      decimals="INF"
      id="Fact001748"
      unitRef="Shares">4280939</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:DividendsPayableCurrentAndNoncurrent
      contextRef="AsOf2024-12-31_us-gaap_PreferredStockMember"
      decimals="0"
      id="Fact001750"
      unitRef="USD">0</us-gaap:DividendsPayableCurrentAndNoncurrent>
    <us-gaap:DividendsPayableCurrentAndNoncurrent
      contextRef="AsOf2023-12-31_us-gaap_PreferredStockMember47713734"
      decimals="0"
      id="Fact001752"
      unitRef="USD">0</us-gaap:DividendsPayableCurrentAndNoncurrent>
    <us-gaap:DividendsPreferredStock
      contextRef="From2024-01-012024-12-31_us-gaap_SeriesBPreferredStockMember47710687"
      decimals="0"
      id="Fact001754"
      unitRef="USD">211268</us-gaap:DividendsPreferredStock>
    <us-gaap:PreferredStockDividendRatePerDollarAmount
      contextRef="From2024-01-012024-12-31_us-gaap_SeriesBPreferredStockMember47710687"
      decimals="INF"
      id="Fact001756"
      unitRef="USDPShares">0.05</us-gaap:PreferredStockDividendRatePerDollarAmount>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact001758">&lt;p id="xdx_806_eus-gaap--DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_z582ETxRitH3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;11.
&lt;span id="xdx_82F_zoqOnkd3y7Th"&gt;Stock-Based Compensation&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
October 12, 2017, the Company adopted the 2017 Stock Compensation Plan authorizing the issuance of &lt;span id="xdx_90F_eus-gaap--CommonStockSharesAuthorized_iI_pid_c20171012__us-gaap--PlanNameAxis__custom--TwentySeventeenStockCompensationPlanMember_zfNNVZCieyQ1" title="Common stock, shares authorized"&gt;1,435,652&lt;/span&gt; shares of common stock.
On September 13, 2019 the Company entered into a Stock Option Cancellation agreement with all holders of these stock options effective
on that date.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;This
plan was then amended on September 13, 2019, to increase the share amount to &lt;span id="xdx_901_eus-gaap--SharesIssued_iI_pid_c20190913__us-gaap--PlanNameAxis__custom--TwentySeventeenStockCompensationPlanMember_zB1TMvrsYdXl" title="Shares issued"&gt;2,638,788&lt;/span&gt;. This plan was enacted to enable the Company to
retain the services of certain key employees, officers, and directors of the Company. The Plan provides for the grant of stock options,
including incentive stock options, or ISOs, and nonqualified stock options, or NSOs and restricted stock, and they were estimated using
the Black-Scholes option-pricing model with the following weighted-average assumptions:&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_892_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zG5Qp2V0YQjd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B2_zGOV7bG7BGUc" style="display: none"&gt;Schedule of Option-pricing Model with Following Weighted-average Assumptions&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 60%; margin-right: auto"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;Assumptions as of December 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;Fully Vested&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 40%"&gt;Number of Shares&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_c20231231__us-gaap--PlanNameAxis__custom--TwentySeventeenStockCompensationPlanMember_znhL7DOHtJSf" style="width: 16%; text-align: right" title="Number of Shares"&gt;1,319,394&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Stock price&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--SharePrice_iI_c20231231__us-gaap--PlanNameAxis__custom--TwentySeventeenStockCompensationPlanMember_z35t4olRGgj2" style="text-align: right" title="Stock price"&gt;2.67&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Exercise price&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_c20231231__us-gaap--PlanNameAxis__custom--TwentySeventeenStockCompensationPlanMember_zAUbudleH1La" style="text-align: right" title="Exercise price"&gt;6.94&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Expected term&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230101__20231231__us-gaap--PlanNameAxis__custom--TwentySeventeenStockCompensationPlanMember_z14VKcAWI4G3" title="Expected term"&gt;5.75&lt;/span&gt; years&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Expected volatility&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20230101__20231231__us-gaap--PlanNameAxis__custom--TwentySeventeenStockCompensationPlanMember_zQeLhyj1Eqy1" style="text-align: right" title="Expected volatility"&gt;31.90&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Risk-free interest rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20230101__20231231__us-gaap--PlanNameAxis__custom--TwentySeventeenStockCompensationPlanMember_zNjBU10Mq145" style="text-align: right" title="Risk-free interest rate"&gt;3.84&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Dividend rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20230101__20231231__us-gaap--PlanNameAxis__custom--TwentySeventeenStockCompensationPlanMember_zUZLFZTEndI5" style="text-align: right" title="Dividend rate"&gt;0&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A1_zrs24MhAL5Ji" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Neuraxis,
Inc.&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Notes
to Financial Statements&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89E_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zN7Dhk6r2Y0a" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following is a summary of the outstanding stock options as of December 31, 2024 and 2023:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8BB_zZTUR7enWRSi" style="display: none"&gt;Schedule of Stock Option Activity&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Number of Options&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Weighted Avg. Remaining Contractual Life (in years)&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Weighted Avg. Exercise Price&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Aggregate Intrinsic Value&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 36%; font-weight: bold; padding-bottom: 1pt"&gt;Outstanding as of December 31, 2023&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20240101__20241231_zbdgYc0k0tj6" style="border-bottom: Black 1pt solid; width: 12%; text-align: right" title="Number of Options, Outstanding, Beginning balance"&gt;1,319,394&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; width: 12%; text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230101__20231231_z39nUXErIBH7" title="Weighted Average Remaining Contractual Life (in years), Outstanding"&gt;5.69&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_uUSDPShares_c20240101__20241231_zRBnsQjAVTg3" style="border-bottom: Black 1pt solid; width: 12%; text-align: right" title="Weighted Average Exercise Price, Outstanding, Beginning balance"&gt;6.94&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_c20240101__20241231_zo0CKJ6eWyza" style="border-bottom: Black 1pt solid; width: 12%; text-align: right" title="Aggregate Intrinsic Value, Outstanding, Beginning balance"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1788"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;Outstanding as of December 31, 2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20240101__20241231_z55EeHnyKinh" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Options, Outstanding, Ending balance"&gt;1,319,394&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231_zxR1WpQg0Oz2" title="Weighted Average Remaining Contractual Life (in years), Outstanding"&gt;4.69&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_uUSDPShares_c20240101__20241231_zvtuUdJvgcr" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price, Outstanding, Ending balance"&gt;6.94&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_c20240101__20241231_zwttZBExv1sa" style="border-bottom: Black 1pt solid; text-align: right" title="Aggregate Intrinsic Value, Outstanding, Ending balance"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1796"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;Vested and Exercisable as of December 31, 2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_iE_pid_c20240101__20241231_zj5LvhhpSMce" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Options, Vested and Exercisable, Ending balance"&gt;1,319,394&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_dtY_c20240101__20241231_zg10RHlZAHDg" title="Weighted Average Remaining Contractual Life (in years), Vested and Exercisable"&gt;4.69&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iE_pid_uUSDPShares_c20240101__20241231_zHcu58EvmXoj" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price, Vested and Exercisable, Ending balance"&gt;6.94&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_iE_c20240101__20241231_zURCbanmCr4e" style="border-bottom: Black 1pt solid; text-align: right" title="Aggregate Intrinsic Value, Vested and Exercisable, Ending balance"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1804"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AD_zZE9c8ADNSw4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;Total stock-based compensation
expense is classified in the Company&#x2019;s statements of operations as general and administrative expense totaling $&lt;span id="xdx_90C_eus-gaap--ShareBasedCompensation_c20240101__20241231_zI8x5UZ9IfJk" title="Share based compensation"&gt;227,000&lt;/span&gt;
and $&lt;span id="xdx_90E_eus-gaap--ShareBasedCompensation_dxL_c20230101__20231231_zx6I8yThynj1" title="Share based compensation::XDX::-"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1808"&gt;0&lt;/span&gt;&lt;/span&gt;
for the years ended December 31, 2024 and 2023, respectively. The stock compensation incurred during the year ended December 31,
2024 related to a hiring grant of &lt;span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20240101__20241231__srt--TitleOfIndividualAxis__srt--ChiefFinancialOfficerMember_z4ZqWM8HhEI9" title="Granted"&gt;100,000&lt;/span&gt; common
shares to the Company&#x2019;s Chief Financial Officer at a fair value of $&lt;span id="xdx_902_eus-gaap--SharePrice_iI_c20241231__srt--TitleOfIndividualAxis__srt--ChiefFinancialOfficerMember_zUe2s28C9Eul" title="Share price"&gt;2.27&lt;/span&gt; per share.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2017-10-12_custom_TwentySeventeenStockCompensationPlanMember"
      decimals="INF"
      id="Fact001760"
      unitRef="Shares">1435652</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:SharesIssued
      contextRef="AsOf2019-09-13_custom_TwentySeventeenStockCompensationPlanMember"
      decimals="INF"
      id="Fact001762"
      unitRef="Shares">2638788</us-gaap:SharesIssued>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact001764">&lt;p id="xdx_892_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zG5Qp2V0YQjd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B2_zGOV7bG7BGUc" style="display: none"&gt;Schedule of Option-pricing Model with Following Weighted-average Assumptions&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 60%; margin-right: auto"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;Assumptions as of December 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;Fully Vested&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 40%"&gt;Number of Shares&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_c20231231__us-gaap--PlanNameAxis__custom--TwentySeventeenStockCompensationPlanMember_znhL7DOHtJSf" style="width: 16%; text-align: right" title="Number of Shares"&gt;1,319,394&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Stock price&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--SharePrice_iI_c20231231__us-gaap--PlanNameAxis__custom--TwentySeventeenStockCompensationPlanMember_z35t4olRGgj2" style="text-align: right" title="Stock price"&gt;2.67&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Exercise price&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_c20231231__us-gaap--PlanNameAxis__custom--TwentySeventeenStockCompensationPlanMember_zAUbudleH1La" style="text-align: right" title="Exercise price"&gt;6.94&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Expected term&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230101__20231231__us-gaap--PlanNameAxis__custom--TwentySeventeenStockCompensationPlanMember_z14VKcAWI4G3" title="Expected term"&gt;5.75&lt;/span&gt; years&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Expected volatility&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20230101__20231231__us-gaap--PlanNameAxis__custom--TwentySeventeenStockCompensationPlanMember_zQeLhyj1Eqy1" style="text-align: right" title="Expected volatility"&gt;31.90&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Risk-free interest rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20230101__20231231__us-gaap--PlanNameAxis__custom--TwentySeventeenStockCompensationPlanMember_zNjBU10Mq145" style="text-align: right" title="Risk-free interest rate"&gt;3.84&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Dividend rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20230101__20231231__us-gaap--PlanNameAxis__custom--TwentySeventeenStockCompensationPlanMember_zUZLFZTEndI5" style="text-align: right" title="Dividend rate"&gt;0&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="AsOf2023-12-31_custom_TwentySeventeenStockCompensationPlanMember"
      decimals="INF"
      id="Fact001766"
      unitRef="Shares">1319394</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <us-gaap:SharePrice
      contextRef="AsOf2023-12-31_custom_TwentySeventeenStockCompensationPlanMember"
      decimals="INF"
      id="Fact001768"
      unitRef="USDPShares">2.67</us-gaap:SharePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="AsOf2023-12-31_custom_TwentySeventeenStockCompensationPlanMember"
      decimals="INF"
      id="Fact001770"
      unitRef="USDPShares">6.94</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="From2023-01-012023-12-31_custom_TwentySeventeenStockCompensationPlanMember"
      id="Fact001772">P5Y9M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="From2023-01-012023-12-31_custom_TwentySeventeenStockCompensationPlanMember"
      decimals="INF"
      id="Fact001774"
      unitRef="Pure">0.3190</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="From2023-01-012023-12-31_custom_TwentySeventeenStockCompensationPlanMember"
      decimals="INF"
      id="Fact001776"
      unitRef="Pure">0.0384</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="From2023-01-012023-12-31_custom_TwentySeventeenStockCompensationPlanMember"
      decimals="INF"
      id="Fact001778"
      unitRef="Pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact001780">&lt;p id="xdx_89E_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zN7Dhk6r2Y0a" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following is a summary of the outstanding stock options as of December 31, 2024 and 2023:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8BB_zZTUR7enWRSi" style="display: none"&gt;Schedule of Stock Option Activity&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Number of Options&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Weighted Avg. Remaining Contractual Life (in years)&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Weighted Avg. Exercise Price&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Aggregate Intrinsic Value&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 36%; font-weight: bold; padding-bottom: 1pt"&gt;Outstanding as of December 31, 2023&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20240101__20241231_zbdgYc0k0tj6" style="border-bottom: Black 1pt solid; width: 12%; text-align: right" title="Number of Options, Outstanding, Beginning balance"&gt;1,319,394&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; width: 12%; text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230101__20231231_z39nUXErIBH7" title="Weighted Average Remaining Contractual Life (in years), Outstanding"&gt;5.69&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_uUSDPShares_c20240101__20241231_zRBnsQjAVTg3" style="border-bottom: Black 1pt solid; width: 12%; text-align: right" title="Weighted Average Exercise Price, Outstanding, Beginning balance"&gt;6.94&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_c20240101__20241231_zo0CKJ6eWyza" style="border-bottom: Black 1pt solid; width: 12%; text-align: right" title="Aggregate Intrinsic Value, Outstanding, Beginning balance"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1788"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;Outstanding as of December 31, 2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20240101__20241231_z55EeHnyKinh" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Options, Outstanding, Ending balance"&gt;1,319,394&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231_zxR1WpQg0Oz2" title="Weighted Average Remaining Contractual Life (in years), Outstanding"&gt;4.69&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_uUSDPShares_c20240101__20241231_zvtuUdJvgcr" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price, Outstanding, Ending balance"&gt;6.94&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_c20240101__20241231_zwttZBExv1sa" style="border-bottom: Black 1pt solid; text-align: right" title="Aggregate Intrinsic Value, Outstanding, Ending balance"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1796"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;Vested and Exercisable as of December 31, 2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_iE_pid_c20240101__20241231_zj5LvhhpSMce" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Options, Vested and Exercisable, Ending balance"&gt;1,319,394&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_dtY_c20240101__20241231_zg10RHlZAHDg" title="Weighted Average Remaining Contractual Life (in years), Vested and Exercisable"&gt;4.69&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iE_pid_uUSDPShares_c20240101__20241231_zHcu58EvmXoj" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price, Vested and Exercisable, Ending balance"&gt;6.94&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_iE_c20240101__20241231_zURCbanmCr4e" style="border-bottom: Black 1pt solid; text-align: right" title="Aggregate Intrinsic Value, Vested and Exercisable, Ending balance"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1804"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact001782"
      unitRef="Shares">1319394</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="From2023-01-012023-12-31" id="Fact001784">P5Y8M8D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact001786"
      unitRef="USDPShares">6.94</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact001790"
      unitRef="Shares">1319394</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="From2024-01-01to2024-12-31" id="Fact001792">P4Y8M8D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact001794"
      unitRef="USDPShares">6.94</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact001798"
      unitRef="Shares">1319394</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1 contextRef="From2024-01-01to2024-12-31" id="Fact001800">P4Y8M8D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact001802"
      unitRef="USDPShares">6.94</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensation
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact001806"
      unitRef="USD">227000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted
      contextRef="From2024-01-012024-12-31_srt_ChiefFinancialOfficerMember"
      decimals="INF"
      id="Fact001810"
      unitRef="Shares">100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted>
    <us-gaap:SharePrice
      contextRef="AsOf2024-12-31_srt_ChiefFinancialOfficerMember"
      decimals="INF"
      id="Fact001812"
      unitRef="USDPShares">2.27</us-gaap:SharePrice>
    <NRXS:WarrantLiabilitiesDisclosureTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact001814">&lt;p id="xdx_802_ecustom--WarrantLiabilitiesDisclosureTextBlock_zLJ9px8k3Syi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;12.
&lt;span id="xdx_824_z6GXrWDDRILk"&gt;Warrant Liabilities&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company has evaluated financial instruments arising from warrants that are issued and outstanding as of December 31, 2024 and 2023. The
Company utilizes a Black-Scholes option-pricing model to compute the fair value of the liability and to mark to market the fair value
of the warrant at each balance sheet date. The inputs utilized in the application of the Black-Scholes option-pricing model included
(i) an exercise price of $&lt;span id="xdx_902_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uUSDPShares_c20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember_zrjptfCvcQz8" title="Warrants and rights outstanding, measurement input"&gt;8.76&lt;/span&gt; per share, (ii) an expected remaining term of each warrant based on the remaining contractual maturity
of the each warrant, (iii) estimated volatility ranging from &lt;span id="xdx_901_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__srt--RangeAxis__srt--MinimumMember_zmSn9NaiSFL2" title="Warrants and rights outstanding, measurement input"&gt;75.0&lt;/span&gt;% to &lt;span id="xdx_902_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__srt--RangeAxis__srt--MaximumMember_zf5dKmajsiZ6" title="Warrants and rights outstanding, measurement input"&gt;84.5&lt;/span&gt;% based on historical stock prices of comparable companies
with a look back period commensurate with the period to maturity, (iv) a risk-free interest rate ranging from &lt;span id="xdx_90C_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MinimumMember_zQ203NSiNd12" title="Warrants and rights outstanding, measurement input"&gt;3.84&lt;/span&gt;% to &lt;span id="xdx_90E_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MaximumMember_zThTTGydVYB5" title="Warrants and rights outstanding, measurement input"&gt;4.38&lt;/span&gt;% based on
the interest rates of U.S. Treasury Notes consistent with the expected remaining contract term and (v) a &lt;span id="xdx_908_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zB9nQtROHcvl" title="Warrants and rights outstanding, measurement input"&gt;0&lt;/span&gt;% expected dividend yield as
the Company has not paid dividends to date and does not anticipate declaring dividends in the near future.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Neuraxis,
Inc.&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Notes
to Financial Statements&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_897_ecustom--ScheduleOfChangesInWarrantLiabilitiesTableTextBlock_zhnajgsOSnk5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following are the changes in the warrant liabilities during the years ended December 31, 2024 and 2023.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8BD_ziPvejQmf2bf" style="display: none"&gt;Schedule of Changes in Warrant Liabilities&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Level 1&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Level 2&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Level 3&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%; font-weight: bold"&gt;Warrant liabilities as of January 1, 2023&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--WarrantsAndRightsOutstanding_iS_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zT88wBP0RRP8" style="width: 12%; text-align: right" title="Warrant liabilities, Beginning balance"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1830"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--WarrantsAndRightsOutstanding_iS_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zdwd7tq2Q0bl" style="width: 12%; text-align: right" title="Warrant liabilities, Beginning balance"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1832"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--WarrantsAndRightsOutstanding_iS_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zx9tsgBNOnD4" style="width: 12%; text-align: right" title="Warrant liabilities, Beginning balance"&gt;2,234,384&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt"&gt;Addition&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_ecustom--AdditionToWarrantLiabilities_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zee6DAMsbl2j" style="text-align: right" title="Addition"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1836"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_ecustom--AdditionToWarrantLiabilities_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zSD8bz35u2Id" style="text-align: right" title="Addition"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1838"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_ecustom--AdditionToWarrantLiabilities_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zA7l7yecfaIh" style="text-align: right" title="Addition"&gt;2,446,502&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Reclassified to equity&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_ecustom--ReclassifiedToEquity_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zvOYF9TMRBFg" style="text-align: right" title="Reclassified to equity"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1842"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_ecustom--ReclassifiedToEquity_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zw1ZC82J6fde" style="text-align: right" title="Reclassified to equity"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1844"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_ecustom--ReclassifiedToEquity_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z4zv76UCtXHk" style="text-align: right" title="Reclassified to equity"&gt;(3,827,807&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt"&gt;Changes in fair value of warrant liabilities&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--FairValueAdjustmentOfWarrants_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zHU0YUGcnGE5" style="border-bottom: Black 1pt solid; text-align: right" title="Changes in fair value of warrant liabilities"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1848"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--FairValueAdjustmentOfWarrants_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zaBHCB3F95se" style="border-bottom: Black 1pt solid; text-align: right" title="Changes in fair value of warrant liabilities"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1850"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--FairValueAdjustmentOfWarrants_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zvYO3V51Q4Q8" style="border-bottom: Black 1pt solid; text-align: right" title="Changes in fair value of warrant liabilities"&gt;(844,854&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold"&gt;Warrant liabilities as of December 31, 2023&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--WarrantsAndRightsOutstanding_iS_c20240101__20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zAQCcSYfDdUi" style="text-align: right" title="Warrant liabilities, Beginning balance"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1854"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--WarrantsAndRightsOutstanding_iS_c20240101__20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zl5xaH5D1Jo8" style="text-align: right" title="Warrant liabilities, Beginning balance"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1856"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--WarrantsAndRightsOutstanding_iS_c20240101__20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zbrQ6KXGpJW7" style="text-align: right" title="Warrant liabilities, Beginning balance"&gt;8,225&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt"&gt;Changes in fair value of warrant liabilities&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--FairValueAdjustmentOfWarrants_c20240101__20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zf8FawArezfl" style="border-bottom: Black 1pt solid; text-align: right" title="Changes in fair value of warrant liabilities"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1860"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--FairValueAdjustmentOfWarrants_c20240101__20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zZrLRI2XKRp8" style="border-bottom: Black 1pt solid; text-align: right" title="Changes in fair value of warrant liabilities"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1862"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--FairValueAdjustmentOfWarrants_c20240101__20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zXJzf1PfozVa" style="border-bottom: Black 1pt solid; text-align: right" title="Changes in fair value of warrant liabilities"&gt;941&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;Warrant liabilities as of December 31, 2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--WarrantsAndRightsOutstanding_iE_c20240101__20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zkMY2pnoFcq3" style="border-bottom: Black 1pt solid; text-align: right" title="Warrant liabilities, Ending balance"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1866"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--WarrantsAndRightsOutstanding_iE_c20240101__20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zdADnq4PbFzl" style="border-bottom: Black 1pt solid; text-align: right" title="Warrant liabilities, Ending balance"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1868"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--WarrantsAndRightsOutstanding_iE_c20240101__20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zDMfqGcS94G1" style="border-bottom: Black 1pt solid; text-align: right" title="Warrant liabilities, Ending balance"&gt;9,166&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AF_zxrrg3ZKTql1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</NRXS:WarrantLiabilitiesDisclosureTextBlock>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2024-12-31_us-gaap_MeasurementInputSharePriceMember"
      decimals="INF"
      id="Fact001816"
      unitRef="USDPShares">8.76</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2024-12-31_us-gaap_MeasurementInputPriceVolatilityMember_srt_MinimumMember"
      decimals="INF"
      id="Fact001818"
      unitRef="Pure">75.0</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2024-12-31_us-gaap_MeasurementInputPriceVolatilityMember_srt_MaximumMember"
      decimals="INF"
      id="Fact001820"
      unitRef="Pure">84.5</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2024-12-31_us-gaap_MeasurementInputRiskFreeInterestRateMember_srt_MinimumMember"
      decimals="INF"
      id="Fact001822"
      unitRef="Pure">3.84</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2024-12-31_us-gaap_MeasurementInputRiskFreeInterestRateMember_srt_MaximumMember"
      decimals="INF"
      id="Fact001824"
      unitRef="Pure">4.38</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2024-12-31_us-gaap_MeasurementInputExpectedDividendRateMember"
      decimals="INF"
      id="Fact001826"
      unitRef="Pure">0</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <NRXS:ScheduleOfChangesInWarrantLiabilitiesTableTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact001828">&lt;p id="xdx_897_ecustom--ScheduleOfChangesInWarrantLiabilitiesTableTextBlock_zhnajgsOSnk5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following are the changes in the warrant liabilities during the years ended December 31, 2024 and 2023.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8BD_ziPvejQmf2bf" style="display: none"&gt;Schedule of Changes in Warrant Liabilities&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Level 1&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Level 2&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Level 3&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%; font-weight: bold"&gt;Warrant liabilities as of January 1, 2023&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--WarrantsAndRightsOutstanding_iS_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zT88wBP0RRP8" style="width: 12%; text-align: right" title="Warrant liabilities, Beginning balance"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1830"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--WarrantsAndRightsOutstanding_iS_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zdwd7tq2Q0bl" style="width: 12%; text-align: right" title="Warrant liabilities, Beginning balance"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1832"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--WarrantsAndRightsOutstanding_iS_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zx9tsgBNOnD4" style="width: 12%; text-align: right" title="Warrant liabilities, Beginning balance"&gt;2,234,384&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt"&gt;Addition&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_ecustom--AdditionToWarrantLiabilities_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zee6DAMsbl2j" style="text-align: right" title="Addition"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1836"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_ecustom--AdditionToWarrantLiabilities_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zSD8bz35u2Id" style="text-align: right" title="Addition"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1838"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_ecustom--AdditionToWarrantLiabilities_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zA7l7yecfaIh" style="text-align: right" title="Addition"&gt;2,446,502&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Reclassified to equity&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_ecustom--ReclassifiedToEquity_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zvOYF9TMRBFg" style="text-align: right" title="Reclassified to equity"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1842"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_ecustom--ReclassifiedToEquity_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zw1ZC82J6fde" style="text-align: right" title="Reclassified to equity"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1844"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_ecustom--ReclassifiedToEquity_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z4zv76UCtXHk" style="text-align: right" title="Reclassified to equity"&gt;(3,827,807&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt"&gt;Changes in fair value of warrant liabilities&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--FairValueAdjustmentOfWarrants_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zHU0YUGcnGE5" style="border-bottom: Black 1pt solid; text-align: right" title="Changes in fair value of warrant liabilities"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1848"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--FairValueAdjustmentOfWarrants_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zaBHCB3F95se" style="border-bottom: Black 1pt solid; text-align: right" title="Changes in fair value of warrant liabilities"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1850"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--FairValueAdjustmentOfWarrants_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zvYO3V51Q4Q8" style="border-bottom: Black 1pt solid; text-align: right" title="Changes in fair value of warrant liabilities"&gt;(844,854&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold"&gt;Warrant liabilities as of December 31, 2023&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--WarrantsAndRightsOutstanding_iS_c20240101__20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zAQCcSYfDdUi" style="text-align: right" title="Warrant liabilities, Beginning balance"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1854"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--WarrantsAndRightsOutstanding_iS_c20240101__20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zl5xaH5D1Jo8" style="text-align: right" title="Warrant liabilities, Beginning balance"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1856"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--WarrantsAndRightsOutstanding_iS_c20240101__20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zbrQ6KXGpJW7" style="text-align: right" title="Warrant liabilities, Beginning balance"&gt;8,225&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt"&gt;Changes in fair value of warrant liabilities&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--FairValueAdjustmentOfWarrants_c20240101__20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zf8FawArezfl" style="border-bottom: Black 1pt solid; text-align: right" title="Changes in fair value of warrant liabilities"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1860"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--FairValueAdjustmentOfWarrants_c20240101__20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zZrLRI2XKRp8" style="border-bottom: Black 1pt solid; text-align: right" title="Changes in fair value of warrant liabilities"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1862"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--FairValueAdjustmentOfWarrants_c20240101__20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zXJzf1PfozVa" style="border-bottom: Black 1pt solid; text-align: right" title="Changes in fair value of warrant liabilities"&gt;941&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;Warrant liabilities as of December 31, 2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--WarrantsAndRightsOutstanding_iE_c20240101__20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zkMY2pnoFcq3" style="border-bottom: Black 1pt solid; text-align: right" title="Warrant liabilities, Ending balance"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1866"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--WarrantsAndRightsOutstanding_iE_c20240101__20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zdADnq4PbFzl" style="border-bottom: Black 1pt solid; text-align: right" title="Warrant liabilities, Ending balance"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1868"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--WarrantsAndRightsOutstanding_iE_c20240101__20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zDMfqGcS94G1" style="border-bottom: Black 1pt solid; text-align: right" title="Warrant liabilities, Ending balance"&gt;9,166&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</NRXS:ScheduleOfChangesInWarrantLiabilitiesTableTextBlock>
    <us-gaap:WarrantsAndRightsOutstanding
      contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel3Member"
      decimals="0"
      id="Fact001834"
      unitRef="USD">2234384</us-gaap:WarrantsAndRightsOutstanding>
    <NRXS:AdditionToWarrantLiabilities
      contextRef="From2023-01-012023-12-31_us-gaap_FairValueInputsLevel3Member"
      decimals="0"
      id="Fact001840"
      unitRef="USD">2446502</NRXS:AdditionToWarrantLiabilities>
    <NRXS:ReclassifiedToEquity
      contextRef="From2023-01-012023-12-31_us-gaap_FairValueInputsLevel3Member"
      decimals="0"
      id="Fact001846"
      unitRef="USD">-3827807</NRXS:ReclassifiedToEquity>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="From2023-01-012023-12-31_us-gaap_FairValueInputsLevel3Member"
      decimals="0"
      id="Fact001852"
      unitRef="USD">-844854</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:WarrantsAndRightsOutstanding
      contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel3Member"
      decimals="0"
      id="Fact001858"
      unitRef="USD">8225</us-gaap:WarrantsAndRightsOutstanding>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="From2024-01-012024-12-31_us-gaap_FairValueInputsLevel3Member"
      decimals="0"
      id="Fact001864"
      unitRef="USD">941</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:WarrantsAndRightsOutstanding
      contextRef="AsOf2024-12-31_us-gaap_FairValueInputsLevel3Member"
      decimals="0"
      id="Fact001870"
      unitRef="USD">9166</us-gaap:WarrantsAndRightsOutstanding>
    <us-gaap:DerivativesAndFairValueTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact001872">&lt;p id="xdx_805_eus-gaap--DerivativesAndFairValueTextBlock_zu2vEO7IMDw7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;13.
&lt;span id="xdx_827_zVORf07c8s3c"&gt;Derivative Liabilities&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company has evaluated derivatives arising from convertible financial instruments as of December 31, 2024 and 2023. The Company utilized
a Monte Carlo simulation model for commitment shares that have an option to convert at a variable number of shares to compute the fair
value of the derivative and to mark to market the fair value of the derivative at each balance sheet date. The inputs utilized in the
application of the Monte Carlo model included a starting stock price of $&lt;span id="xdx_905_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember_zKzjUyOljpae" title="Derivative liability, measurement input"&gt;7.91&lt;/span&gt; per share, (ii) an expected remaining term of each derivative
based on the remaining contractual maturity of the each derivative, (iii) estimated volatility of &lt;span id="xdx_90B_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zkpiEtIGim5e" title="Derivative liability, measurement input"&gt;70.0&lt;/span&gt;% based on historical stock prices
of comparable companies with a look back period commensurate with the period to maturity, (iv) a risk-free interest rate ranging from
&lt;span id="xdx_902_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MinimumMember_zfRiq3dgO9ai" title="Derivative liability, measurement input"&gt;3.46&lt;/span&gt;% to &lt;span id="xdx_903_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MaximumMember_zf7y7oyPPPa7" title="Derivative liability, measurement input"&gt;5.47&lt;/span&gt;% based on the interest rates of U.S. Treasury Notes consistent with the expected remaining contract term and (v) a &lt;span id="xdx_901_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zVhPZeP70wph" title="Derivative liability, measurement input"&gt;0&lt;/span&gt;% expected
dividend yield as the Company has not paid dividends to date and does not anticipate declaring dividends in the near future and (vi)
drift.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89F_eus-gaap--ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock_zfXEuYd43pb8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following are the changes in the derivative liabilities during the year ended December 31, 2023:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B4_zD5ZA7TNqMEk" style="display: none"&gt;Schedule of Changes in Derivative Liabilities&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Level 1&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Level 2&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Level 3&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%; font-weight: bold"&gt;Derivative liabilities as of December 31, 2022&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_ecustom--ChangesInDerivativeLiabilities_iS_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zP8tnL9A2rg8" style="width: 12%; text-align: right" title="Derivative liabilities, Beginning balance"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1886"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_ecustom--ChangesInDerivativeLiabilities_iS_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zeqmf28McAp2" style="width: 12%; text-align: right" title="Derivative liabilities, Beginning balance"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1888"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_ecustom--ChangesInDerivativeLiabilities_iS_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zCuIuUgQiaw2" style="width: 12%; text-align: right" title="Derivative liabilities, Beginning balance"&gt;1,735,700&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt"&gt;Addition&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_ecustom--AdditionToDerivativeLiabilities_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zbSf9gQIUbWc" style="text-align: right" title="Addition"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1892"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_ecustom--AdditionToDerivativeLiabilities_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zUnRulXJI57e" style="text-align: right" title="Addition"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1894"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_ecustom--AdditionToDerivativeLiabilities_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z6VRuutgHygf" style="text-align: right" title="Addition"&gt;2,375,378&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Changes in fair value of derivative liabilities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--IncreaseDecreaseInDerivativeLiabilities_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zPG3xHL5PHK6" style="text-align: right" title="Changes in fair value of Derivative liabilities"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1898"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--IncreaseDecreaseInDerivativeLiabilities_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_z7iD4PCJp5qi" style="text-align: right" title="Changes in fair value of Derivative liabilities"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1900"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--IncreaseDecreaseInDerivativeLiabilities_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z0aCo4QrZhql" style="text-align: right" title="Changes in fair value of Derivative liabilities"&gt;(198,551&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt"&gt;Extinguishment of derivative liabilities&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_ecustom--ExtinguishmentOfDerivativeLiabilities_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_z2tptvDslgV6" style="border-bottom: Black 1pt solid; text-align: right" title="Extinguishment of Derivative liabilities"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1904"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_ecustom--ExtinguishmentOfDerivativeLiabilities_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zG9Bj6nOkTKj" style="border-bottom: Black 1pt solid; text-align: right" title="Extinguishment of Derivative liabilities"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1906"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_ecustom--ExtinguishmentOfDerivativeLiabilities_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zcshAjGpFsW9" style="border-bottom: Black 1pt solid; text-align: right" title="Extinguishment of Derivative liabilities"&gt;(3,912,527&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;Derivative liabilities as of December 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_ecustom--ChangesInDerivativeLiabilities_iE_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zpfbG6B2XGSk" style="border-bottom: Black 1pt solid; text-align: right" title="Derivative liabilities, Ending balance"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1910"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_ecustom--ChangesInDerivativeLiabilities_iE_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zdxl4nMNr2uh" style="border-bottom: Black 1pt solid; text-align: right" title="Derivative liabilities, Ending balance"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1912"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_ecustom--ChangesInDerivativeLiabilities_iE_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zHFXPAjluqB6" style="border-bottom: Black 1pt solid; text-align: right" title="Derivative liabilities, Ending balance"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1914"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AC_z3wz7LuPHqBe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;There
were no derivatives identified during the year ended December 31, 2024.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Neuraxis,
Inc.&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Notes
to Financial Statements&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:DerivativesAndFairValueTextBlock>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="AsOf2024-12-31_us-gaap_MeasurementInputSharePriceMember"
      decimals="INF"
      id="Fact001874"
      unitRef="Pure">7.91</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="AsOf2024-12-31_us-gaap_MeasurementInputPriceVolatilityMember"
      decimals="INF"
      id="Fact001876"
      unitRef="Pure">70.0</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="AsOf2024-12-31_us-gaap_MeasurementInputRiskFreeInterestRateMember_srt_MinimumMember"
      decimals="INF"
      id="Fact001878"
      unitRef="Pure">3.46</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="AsOf2024-12-31_us-gaap_MeasurementInputRiskFreeInterestRateMember_srt_MaximumMember"
      decimals="INF"
      id="Fact001880"
      unitRef="Pure">5.47</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="AsOf2024-12-31_us-gaap_MeasurementInputExpectedDividendRateMember"
      decimals="INF"
      id="Fact001882"
      unitRef="Pure">0</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact001884">&lt;p id="xdx_89F_eus-gaap--ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock_zfXEuYd43pb8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following are the changes in the derivative liabilities during the year ended December 31, 2023:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B4_zD5ZA7TNqMEk" style="display: none"&gt;Schedule of Changes in Derivative Liabilities&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Level 1&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Level 2&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Level 3&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%; font-weight: bold"&gt;Derivative liabilities as of December 31, 2022&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_ecustom--ChangesInDerivativeLiabilities_iS_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zP8tnL9A2rg8" style="width: 12%; text-align: right" title="Derivative liabilities, Beginning balance"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1886"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_ecustom--ChangesInDerivativeLiabilities_iS_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zeqmf28McAp2" style="width: 12%; text-align: right" title="Derivative liabilities, Beginning balance"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1888"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_ecustom--ChangesInDerivativeLiabilities_iS_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zCuIuUgQiaw2" style="width: 12%; text-align: right" title="Derivative liabilities, Beginning balance"&gt;1,735,700&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt"&gt;Addition&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_ecustom--AdditionToDerivativeLiabilities_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zbSf9gQIUbWc" style="text-align: right" title="Addition"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1892"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_ecustom--AdditionToDerivativeLiabilities_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zUnRulXJI57e" style="text-align: right" title="Addition"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1894"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_ecustom--AdditionToDerivativeLiabilities_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z6VRuutgHygf" style="text-align: right" title="Addition"&gt;2,375,378&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Changes in fair value of derivative liabilities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--IncreaseDecreaseInDerivativeLiabilities_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zPG3xHL5PHK6" style="text-align: right" title="Changes in fair value of Derivative liabilities"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1898"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--IncreaseDecreaseInDerivativeLiabilities_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_z7iD4PCJp5qi" style="text-align: right" title="Changes in fair value of Derivative liabilities"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1900"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--IncreaseDecreaseInDerivativeLiabilities_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z0aCo4QrZhql" style="text-align: right" title="Changes in fair value of Derivative liabilities"&gt;(198,551&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt"&gt;Extinguishment of derivative liabilities&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_ecustom--ExtinguishmentOfDerivativeLiabilities_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_z2tptvDslgV6" style="border-bottom: Black 1pt solid; text-align: right" title="Extinguishment of Derivative liabilities"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1904"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_ecustom--ExtinguishmentOfDerivativeLiabilities_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zG9Bj6nOkTKj" style="border-bottom: Black 1pt solid; text-align: right" title="Extinguishment of Derivative liabilities"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1906"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_ecustom--ExtinguishmentOfDerivativeLiabilities_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zcshAjGpFsW9" style="border-bottom: Black 1pt solid; text-align: right" title="Extinguishment of Derivative liabilities"&gt;(3,912,527&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;Derivative liabilities as of December 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_ecustom--ChangesInDerivativeLiabilities_iE_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zpfbG6B2XGSk" style="border-bottom: Black 1pt solid; text-align: right" title="Derivative liabilities, Ending balance"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1910"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_ecustom--ChangesInDerivativeLiabilities_iE_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zdxl4nMNr2uh" style="border-bottom: Black 1pt solid; text-align: right" title="Derivative liabilities, Ending balance"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1912"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_ecustom--ChangesInDerivativeLiabilities_iE_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zHFXPAjluqB6" style="border-bottom: Black 1pt solid; text-align: right" title="Derivative liabilities, Ending balance"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1914"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock>
    <NRXS:ChangesInDerivativeLiabilities
      contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel3Member"
      decimals="0"
      id="Fact001890"
      unitRef="USD">1735700</NRXS:ChangesInDerivativeLiabilities>
    <NRXS:AdditionToDerivativeLiabilities
      contextRef="From2023-01-012023-12-31_us-gaap_FairValueInputsLevel3Member"
      decimals="0"
      id="Fact001896"
      unitRef="USD">2375378</NRXS:AdditionToDerivativeLiabilities>
    <us-gaap:IncreaseDecreaseInDerivativeLiabilities
      contextRef="From2023-01-012023-12-31_us-gaap_FairValueInputsLevel3Member"
      decimals="0"
      id="Fact001902"
      unitRef="USD">-198551</us-gaap:IncreaseDecreaseInDerivativeLiabilities>
    <NRXS:ExtinguishmentOfDerivativeLiabilities
      contextRef="From2023-01-012023-12-31_us-gaap_FairValueInputsLevel3Member"
      decimals="0"
      id="Fact001908"
      unitRef="USD">-3912527</NRXS:ExtinguishmentOfDerivativeLiabilities>
    <us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact001916">&lt;p id="xdx_801_eus-gaap--PensionAndOtherPostretirementBenefitsDisclosureTextBlock_zjerfXftDTjh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;14.
&lt;span id="xdx_82F_z78zqGuKdltg"&gt;Retirement Plan&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company sponsors a 401(k)-retirement plan for its employees. Employees are eligible to participate in the elective deferral portion of
the plan after twelve months and 1,000 hours of service. The Company can also make a &lt;span id="xdx_901_eus-gaap--DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_dp_uPure_c20240101__20241231_z2NE3ADGeJXk" title="Employee contribution percentage"&gt;3&lt;/span&gt;% discretionary profit-sharing contribution on
an annual basis to employees with earnings under a certain threshold. Profit sharing expense totaled $&lt;span id="xdx_902_eus-gaap--DefinedContributionPlanAdministrativeExpenses_c20240101__20241231_zOF0Tk3wGnW8" title="Profit sharing contribution expenses"&gt;20,868&lt;/span&gt; and $&lt;span id="xdx_903_eus-gaap--DefinedContributionPlanAdministrativeExpenses_c20230101__20231231_zuptPMhsu8b9" title="Profit sharing contribution expenses"&gt;6,980&lt;/span&gt; for years ended
December 31, 2024 and 2023, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock>
    <us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent
      contextRef="From2024-01-01to2024-12-31"
      decimals="INF"
      id="Fact001918"
      unitRef="Pure">0.03</us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent>
    <us-gaap:DefinedContributionPlanAdministrativeExpenses
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact001920"
      unitRef="USD">20868</us-gaap:DefinedContributionPlanAdministrativeExpenses>
    <us-gaap:DefinedContributionPlanAdministrativeExpenses
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact001922"
      unitRef="USD">6980</us-gaap:DefinedContributionPlanAdministrativeExpenses>
    <us-gaap:SegmentReportingDisclosureTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact001924">&lt;p id="xdx_80A_eus-gaap--SegmentReportingDisclosureTextBlock_zzwg7jbYz5R7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;15.
&lt;span id="xdx_820_zr9ex6xRUP24"&gt;Segment Information&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The Company evaluates the following factors to identify its reportable segments: (i) nature of products and services, (ii) type of customer
for the products and services, (iii) sales, production and distribution methods of the products and services and (iv) the nature of the
regulatory environment, if applicable. Based on an evaluation of these factors, management concluded that the Company&#x2019;s operations are managed through one reportable segment, IB-STIM, that derives its revenues in the United States from a
PENFS device that is used to treat patients 8-21 years of age with functional abdominal pain associated with irritable bowel syndrome.
IB-STIM currently is the only product marketed and sold by the Company. The accounting policies of the IB-STIM segment are the same as
those described in the Summary of Significant Accounting Policies (see Footnote 2). The CODM regularly evaluates the performance of the
IB-STIM segment for the purpose of allocating resources based on net sales and operating loss, both of which are reported in the Statements
of Operations. The CODM uses net sales to evaluate IB-STIM&#x2019;s adoption and utilization by insurance carriers and physicians. As
Neuraxis is an emerging growth company, operating loss is used to monitor the Company&#x2019;s cost structure in order to achieve future
segment profitability. Both net sales and operating loss are measured against the budget on a periodic basis to assess achievement toward
annual compensation incentive targets. The Company&#x2019;s CODM is its Chief Executive Officer.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89D_eus-gaap--ScheduleOfSegmentReportingInformationBySegmentTextBlock_zxiAZRRNNNX4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following reconciles the reportable segment net sales and operating loss to the Company&#x2019;s reported net loss:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B3_zIRrk2PmXsYd"&gt;Schedule
of Reconciles the Company&#x2019;s Net Sales and Operating Loss&lt;/span&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="display: none; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="display: none; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_496_20240101__20241231__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_zQVzSUxLXCS8" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="display: none; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="display: none; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_492_20230101__20231231__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_zS6R7VBfCF2f" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="display: none; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;For the Years Ended December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_maCzEo3_zCN9uWPcUpNh" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; width: 60%; font-weight: bold; text-align: left"&gt;Net Sales&lt;/td&gt;&lt;td style="width: 2%; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; font-weight: bold; text-align: right"&gt;2,685,925&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;2,460,049&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--CostOfGoodsAndServicesSold_msCzEo3_zdJ2IIL909ld" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Cost of Goods Sold&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"&gt;362,002&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;303,345&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--GrossProfit_iT_mtCzEo3_maOILz3im_zHXktUBsxMc" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; font-weight: bold; text-align: left"&gt;Gross Profit&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;2,323,923&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,156,704&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--SellingExpense_i01_msOILz3im_zYmpOrmV48va" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Selling Expenses &lt;span id="xdx_F44_ztbxsniXabr"&gt;(a)&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;324,708&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;323,569&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--ResearchAndDevelopmentExpense_i01_msOILz3im_zhthLcmgssrj" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Research and Development &lt;span id="xdx_F4B_zOI0PHE1bj1j"&gt;(a)&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;206,107&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;169,315&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--LaborAndRelatedExpense_i01_msOILz3im_zF297Hh5Tt95" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Wages and Benefits &lt;span id="xdx_F41_zAwA6AQear57"&gt;(a)&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;5,378,952&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4,367,486&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--ProfessionalAndContractServicesExpense_i01_msOILz3im_zCoI4NrOzSv2" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Professional Services &lt;span id="xdx_F4D_z7AiQB8GNFef"&gt;(a)&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;1,945,331&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,721,461&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--OtherCostAndExpenseOperating_i01_msOILz3im_zoEc5bAAdv51" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Other Operating Expenses &lt;span id="xdx_F4C_zrk53HU68AZ1"&gt;(a)&lt;/span&gt; &lt;span id="xdx_F4B_zK9RzMvJ25Ee"&gt;(b)&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"&gt;1,625,642&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;1,239,368&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--OperatingIncomeLoss_iT_maCz7fC_mtOILz3im_zxdpcZ5o8Qyf" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-weight: bold; text-align: left; padding-bottom: 1pt"&gt;Segment Operating Loss&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"&gt;(7,156,817&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(6,664,495&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--NonoperatingIncomeExpenseAbstract_iB_zbAcjN2ODiE7" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Other (Expense) Income:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_ecustom--FinancingCharges_i01N_di_msONIEz60J_z2B0GCtuEkt6" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 20pt; text-align: left"&gt;Financing charges&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;(230,824&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(2,772&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--InterestExpense_i01N_di_msONIEz60J_zztXzQpOihe6" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 20pt; text-align: left"&gt;Interest expense&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;(174,328&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(476,416&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--FairValueAdjustmentOfWarrants_i01N_di_msONIEz60J_zNFSq4n7haY6" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 20pt; text-align: left"&gt;Change in fair value of warrant liability&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;(941&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;844,854&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--DerivativeGainLossOnDerivativeNet_i01_maONIEz60J_z1Q0FrtYcXu5" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 20pt; text-align: left"&gt;Change in fair value of derivative liability&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1967"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;198,551&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--AmortizationOfFinancingCostsAndDiscounts_i01N_di_msONIEz60J_ztXLMWhzcoo6" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 20pt; text-align: left"&gt;Amortization of debt discount and issuance cost&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;(126,387&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(4,881,622&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--GainsLossesOnExtinguishmentOfDebt_i01_maONIEz60J_zG8IEht4gaie" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 20pt; text-align: left"&gt;Extinguishment of debt liabilities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1973"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(3,649,561&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--OtherNonoperatingIncome_i01_maONIEz60J_zCzqQ1YCpcMj" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 20pt; text-align: left"&gt;Other income&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;33,620&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;15,133&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--OtherNonoperatingExpense_i01N_di_msONIEz60J_zdZ31bllWTOa" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 20pt; text-align: left; padding-bottom: 1pt"&gt;Other expense&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"&gt;(585,824&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(10,355&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--OtherNonoperatingIncomeExpense_i01T_maCz7fC_mtONIEz60J_znSMZiHMxXVk" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 30pt; text-align: left; padding-bottom: 1pt"&gt;Total other (expense) income, net&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"&gt;(1,084,684&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(7,962,188&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--NetIncomeLoss_iT_mtCz7fC_zCVtniRT8qb4" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left; padding-bottom: 1pt"&gt;Net Loss&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"&gt;(8,241,501&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(14,626,683&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span id="xdx_F0A_zSHbxJTS4XIa" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(a)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span id="xdx_F1B_zCM34Oh92oT7" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
                                            significant expense categories and amounts align with the segment-level information provided
                                            on a regular basis to the CODM.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_F0D_zmCzF8AwSMi2" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(b)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span id="xdx_F12_zBTE0DIvtEci" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Other
                                            operating expenses include advertising, rent and utilities, insurance, depreciation and
                                            amortization, travel, software subscription fees, board fees and bad debt expense.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p id="xdx_8A8_zThmupzGkeR1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Total
segment assets for IB-STIM amounted to $&lt;span id="xdx_909_eus-gaap--Assets_iI_c20241231_zdWgAYvatPX4" title="Assets"&gt;4,757,572&lt;/span&gt;
and $&lt;span id="xdx_90B_eus-gaap--Assets_iI_c20231231_z0XPgYkRHAof" title="Assets"&gt;509,498&lt;/span&gt; as of December 31, 2024 and 2023,
respectively. Total segment capital expenditures for IB-STIM amounted to $&lt;span id="xdx_904_eus-gaap--NetCashProvidedByUsedInInvestingActivities_iN_di_c20240101__20241231_z5UjbH8Wd5ek" title="Net cash used by investing activities"&gt;27,776&lt;/span&gt;
and $&lt;span id="xdx_905_eus-gaap--NetCashProvidedByUsedInInvestingActivities_iN_di_c20230101__20231231_zy3dON3rH4Rf" title="Net cash used by investing activities"&gt;71,781&lt;/span&gt;
for the years ended December 31, 2024 and 2023, respectively. Total segment depreciation and amortization amounted to $&lt;span id="xdx_901_eus-gaap--DepreciationAndAmortization_c20240101__20241231_z4TCnRFV1smd" title="Depreciation and amortization"&gt;37,831&lt;/span&gt; and $&lt;span id="xdx_906_eus-gaap--DepreciationAndAmortization_c20230101__20231231_zWCRrQ7y47z9" title="Depreciation and amortization"&gt;40,725&lt;/span&gt; for the years ended December 31, 2024 and 2023, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;Significant segment non-cash charges settled in common stock
include (i) consulting and advisory fees totaling $&lt;span id="xdx_90E_ecustom--ConsultingAndAdvisoryFees_c20240101__20241231_z1JustoTJCo7" title="Consulting and advisory fees"&gt;754,685&lt;/span&gt; and $&lt;span id="xdx_90A_ecustom--ConsultingAndAdvisoryFees_c20230101__20231231_z4M3Sf3Wnc1h" title="Consulting and advisory fees"&gt;750,000&lt;/span&gt; for the years ended December 31, 2024 and 2023, respectively,
and (ii) hiring grants totaling $&lt;span id="xdx_907_eus-gaap--ShareBasedCompensation_c20240101__20241231_zXkZInxUm2k4" title="Stock based compensation"&gt;227,000&lt;/span&gt; and $&lt;span id="xdx_90D_eus-gaap--ShareBasedCompensation_dxL_c20230101__20231231_zkdR0OGsfFM" title="Stock based compensation::XDX::-"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2008"&gt;0&lt;/span&gt;&lt;/span&gt; for the years ended December 31, 2024 and 2023, respectively.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:SegmentReportingDisclosureTextBlock>
    <us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact001926">&lt;p id="xdx_89D_eus-gaap--ScheduleOfSegmentReportingInformationBySegmentTextBlock_zxiAZRRNNNX4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following reconciles the reportable segment net sales and operating loss to the Company&#x2019;s reported net loss:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B3_zIRrk2PmXsYd"&gt;Schedule
of Reconciles the Company&#x2019;s Net Sales and Operating Loss&lt;/span&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="display: none; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="display: none; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_496_20240101__20241231__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_zQVzSUxLXCS8" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="display: none; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="display: none; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_492_20230101__20231231__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_zS6R7VBfCF2f" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="display: none; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;For the Years Ended December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_maCzEo3_zCN9uWPcUpNh" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; width: 60%; font-weight: bold; text-align: left"&gt;Net Sales&lt;/td&gt;&lt;td style="width: 2%; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; font-weight: bold; text-align: right"&gt;2,685,925&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;2,460,049&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--CostOfGoodsAndServicesSold_msCzEo3_zdJ2IIL909ld" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Cost of Goods Sold&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"&gt;362,002&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;303,345&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--GrossProfit_iT_mtCzEo3_maOILz3im_zHXktUBsxMc" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; font-weight: bold; text-align: left"&gt;Gross Profit&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;2,323,923&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,156,704&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--SellingExpense_i01_msOILz3im_zYmpOrmV48va" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Selling Expenses &lt;span id="xdx_F44_ztbxsniXabr"&gt;(a)&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;324,708&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;323,569&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--ResearchAndDevelopmentExpense_i01_msOILz3im_zhthLcmgssrj" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Research and Development &lt;span id="xdx_F4B_zOI0PHE1bj1j"&gt;(a)&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;206,107&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;169,315&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--LaborAndRelatedExpense_i01_msOILz3im_zF297Hh5Tt95" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Wages and Benefits &lt;span id="xdx_F41_zAwA6AQear57"&gt;(a)&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;5,378,952&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4,367,486&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--ProfessionalAndContractServicesExpense_i01_msOILz3im_zCoI4NrOzSv2" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Professional Services &lt;span id="xdx_F4D_z7AiQB8GNFef"&gt;(a)&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;1,945,331&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,721,461&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--OtherCostAndExpenseOperating_i01_msOILz3im_zoEc5bAAdv51" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Other Operating Expenses &lt;span id="xdx_F4C_zrk53HU68AZ1"&gt;(a)&lt;/span&gt; &lt;span id="xdx_F4B_zK9RzMvJ25Ee"&gt;(b)&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"&gt;1,625,642&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;1,239,368&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--OperatingIncomeLoss_iT_maCz7fC_mtOILz3im_zxdpcZ5o8Qyf" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-weight: bold; text-align: left; padding-bottom: 1pt"&gt;Segment Operating Loss&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"&gt;(7,156,817&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(6,664,495&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--NonoperatingIncomeExpenseAbstract_iB_zbAcjN2ODiE7" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Other (Expense) Income:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_ecustom--FinancingCharges_i01N_di_msONIEz60J_z2B0GCtuEkt6" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 20pt; text-align: left"&gt;Financing charges&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;(230,824&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(2,772&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--InterestExpense_i01N_di_msONIEz60J_zztXzQpOihe6" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 20pt; text-align: left"&gt;Interest expense&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;(174,328&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(476,416&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--FairValueAdjustmentOfWarrants_i01N_di_msONIEz60J_zNFSq4n7haY6" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 20pt; text-align: left"&gt;Change in fair value of warrant liability&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;(941&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;844,854&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--DerivativeGainLossOnDerivativeNet_i01_maONIEz60J_z1Q0FrtYcXu5" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 20pt; text-align: left"&gt;Change in fair value of derivative liability&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1967"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;198,551&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--AmortizationOfFinancingCostsAndDiscounts_i01N_di_msONIEz60J_ztXLMWhzcoo6" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 20pt; text-align: left"&gt;Amortization of debt discount and issuance cost&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;(126,387&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(4,881,622&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--GainsLossesOnExtinguishmentOfDebt_i01_maONIEz60J_zG8IEht4gaie" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 20pt; text-align: left"&gt;Extinguishment of debt liabilities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1973"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(3,649,561&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--OtherNonoperatingIncome_i01_maONIEz60J_zCzqQ1YCpcMj" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 20pt; text-align: left"&gt;Other income&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;33,620&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;15,133&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--OtherNonoperatingExpense_i01N_di_msONIEz60J_zdZ31bllWTOa" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 20pt; text-align: left; padding-bottom: 1pt"&gt;Other expense&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"&gt;(585,824&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(10,355&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--OtherNonoperatingIncomeExpense_i01T_maCz7fC_mtONIEz60J_znSMZiHMxXVk" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 30pt; text-align: left; padding-bottom: 1pt"&gt;Total other (expense) income, net&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"&gt;(1,084,684&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(7,962,188&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--NetIncomeLoss_iT_mtCz7fC_zCVtniRT8qb4" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left; padding-bottom: 1pt"&gt;Net Loss&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"&gt;(8,241,501&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(14,626,683&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span id="xdx_F0A_zSHbxJTS4XIa" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(a)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span id="xdx_F1B_zCM34Oh92oT7" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
                                            significant expense categories and amounts align with the segment-level information provided
                                            on a regular basis to the CODM.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_F0D_zmCzF8AwSMi2" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(b)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span id="xdx_F12_zBTE0DIvtEci" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Other
                                            operating expenses include advertising, rent and utilities, insurance, depreciation and
                                            amortization, travel, software subscription fees, board fees and bad debt expense.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

</us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2024-01-012024-12-31_us-gaap_OperatingSegmentsMember"
      decimals="0"
      id="Fact001928"
      unitRef="USD">2685925</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2023-01-012023-12-31_us-gaap_OperatingSegmentsMember"
      decimals="0"
      id="Fact001929"
      unitRef="USD">2460049</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="From2024-01-012024-12-31_us-gaap_OperatingSegmentsMember"
      decimals="0"
      id="Fact001931"
      unitRef="USD">362002</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="From2023-01-012023-12-31_us-gaap_OperatingSegmentsMember"
      decimals="0"
      id="Fact001932"
      unitRef="USD">303345</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:GrossProfit
      contextRef="From2024-01-012024-12-31_us-gaap_OperatingSegmentsMember"
      decimals="0"
      id="Fact001934"
      unitRef="USD">2323923</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="From2023-01-012023-12-31_us-gaap_OperatingSegmentsMember"
      decimals="0"
      id="Fact001935"
      unitRef="USD">2156704</us-gaap:GrossProfit>
    <us-gaap:SellingExpense
      contextRef="From2024-01-012024-12-31_us-gaap_OperatingSegmentsMember"
      decimals="0"
      id="Fact001937"
      unitRef="USD">324708</us-gaap:SellingExpense>
    <us-gaap:SellingExpense
      contextRef="From2023-01-012023-12-31_us-gaap_OperatingSegmentsMember"
      decimals="0"
      id="Fact001938"
      unitRef="USD">323569</us-gaap:SellingExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2024-01-012024-12-31_us-gaap_OperatingSegmentsMember"
      decimals="0"
      id="Fact001940"
      unitRef="USD">206107</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2023-01-012023-12-31_us-gaap_OperatingSegmentsMember"
      decimals="0"
      id="Fact001941"
      unitRef="USD">169315</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:LaborAndRelatedExpense
      contextRef="From2024-01-012024-12-31_us-gaap_OperatingSegmentsMember"
      decimals="0"
      id="Fact001943"
      unitRef="USD">5378952</us-gaap:LaborAndRelatedExpense>
    <us-gaap:LaborAndRelatedExpense
      contextRef="From2023-01-012023-12-31_us-gaap_OperatingSegmentsMember"
      decimals="0"
      id="Fact001944"
      unitRef="USD">4367486</us-gaap:LaborAndRelatedExpense>
    <us-gaap:ProfessionalAndContractServicesExpense
      contextRef="From2024-01-012024-12-31_us-gaap_OperatingSegmentsMember"
      decimals="0"
      id="Fact001946"
      unitRef="USD">1945331</us-gaap:ProfessionalAndContractServicesExpense>
    <us-gaap:ProfessionalAndContractServicesExpense
      contextRef="From2023-01-012023-12-31_us-gaap_OperatingSegmentsMember"
      decimals="0"
      id="Fact001947"
      unitRef="USD">2721461</us-gaap:ProfessionalAndContractServicesExpense>
    <us-gaap:OtherCostAndExpenseOperating
      contextRef="From2024-01-012024-12-31_us-gaap_OperatingSegmentsMember"
      decimals="0"
      id="Fact001949"
      unitRef="USD">1625642</us-gaap:OtherCostAndExpenseOperating>
    <us-gaap:OtherCostAndExpenseOperating
      contextRef="From2023-01-012023-12-31_us-gaap_OperatingSegmentsMember"
      decimals="0"
      id="Fact001950"
      unitRef="USD">1239368</us-gaap:OtherCostAndExpenseOperating>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2024-01-012024-12-31_us-gaap_OperatingSegmentsMember"
      decimals="0"
      id="Fact001952"
      unitRef="USD">-7156817</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2023-01-012023-12-31_us-gaap_OperatingSegmentsMember"
      decimals="0"
      id="Fact001953"
      unitRef="USD">-6664495</us-gaap:OperatingIncomeLoss>
    <NRXS:FinancingCharges
      contextRef="From2024-01-012024-12-31_us-gaap_OperatingSegmentsMember"
      decimals="0"
      id="Fact001958"
      unitRef="USD">230824</NRXS:FinancingCharges>
    <NRXS:FinancingCharges
      contextRef="From2023-01-012023-12-31_us-gaap_OperatingSegmentsMember"
      decimals="0"
      id="Fact001959"
      unitRef="USD">2772</NRXS:FinancingCharges>
    <us-gaap:InterestExpense
      contextRef="From2024-01-012024-12-31_us-gaap_OperatingSegmentsMember"
      decimals="0"
      id="Fact001961"
      unitRef="USD">174328</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="From2023-01-012023-12-31_us-gaap_OperatingSegmentsMember"
      decimals="0"
      id="Fact001962"
      unitRef="USD">476416</us-gaap:InterestExpense>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="From2024-01-012024-12-31_us-gaap_OperatingSegmentsMember"
      decimals="0"
      id="Fact001964"
      unitRef="USD">941</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="From2023-01-012023-12-31_us-gaap_OperatingSegmentsMember"
      decimals="0"
      id="Fact001965"
      unitRef="USD">-844854</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="From2023-01-012023-12-31_us-gaap_OperatingSegmentsMember"
      decimals="0"
      id="Fact001968"
      unitRef="USD">198551</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="From2024-01-012024-12-31_us-gaap_OperatingSegmentsMember"
      decimals="0"
      id="Fact001970"
      unitRef="USD">126387</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="From2023-01-012023-12-31_us-gaap_OperatingSegmentsMember"
      decimals="0"
      id="Fact001971"
      unitRef="USD">4881622</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="From2023-01-012023-12-31_us-gaap_OperatingSegmentsMember"
      decimals="0"
      id="Fact001974"
      unitRef="USD">-3649561</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:OtherNonoperatingIncome
      contextRef="From2024-01-012024-12-31_us-gaap_OperatingSegmentsMember"
      decimals="0"
      id="Fact001976"
      unitRef="USD">33620</us-gaap:OtherNonoperatingIncome>
    <us-gaap:OtherNonoperatingIncome
      contextRef="From2023-01-012023-12-31_us-gaap_OperatingSegmentsMember"
      decimals="0"
      id="Fact001977"
      unitRef="USD">15133</us-gaap:OtherNonoperatingIncome>
    <us-gaap:OtherNonoperatingExpense
      contextRef="From2024-01-012024-12-31_us-gaap_OperatingSegmentsMember"
      decimals="0"
      id="Fact001979"
      unitRef="USD">585824</us-gaap:OtherNonoperatingExpense>
    <us-gaap:OtherNonoperatingExpense
      contextRef="From2023-01-012023-12-31_us-gaap_OperatingSegmentsMember"
      decimals="0"
      id="Fact001980"
      unitRef="USD">10355</us-gaap:OtherNonoperatingExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="From2024-01-012024-12-31_us-gaap_OperatingSegmentsMember"
      decimals="0"
      id="Fact001982"
      unitRef="USD">-1084684</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="From2023-01-012023-12-31_us-gaap_OperatingSegmentsMember"
      decimals="0"
      id="Fact001983"
      unitRef="USD">-7962188</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-012024-12-31_us-gaap_OperatingSegmentsMember"
      decimals="0"
      id="Fact001985"
      unitRef="USD">-8241501</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-12-31_us-gaap_OperatingSegmentsMember"
      decimals="0"
      id="Fact001986"
      unitRef="USD">-14626683</us-gaap:NetIncomeLoss>
    <us-gaap:Assets
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact001990"
      unitRef="USD">4757572</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact001992"
      unitRef="USD">509498</us-gaap:Assets>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact001994"
      unitRef="USD">-27776</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact001996"
      unitRef="USD">-71781</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:DepreciationAndAmortization
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact001998"
      unitRef="USD">37831</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact002000"
      unitRef="USD">40725</us-gaap:DepreciationAndAmortization>
    <NRXS:ConsultingAndAdvisoryFees
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact002002"
      unitRef="USD">754685</NRXS:ConsultingAndAdvisoryFees>
    <NRXS:ConsultingAndAdvisoryFees
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact002004"
      unitRef="USD">750000</NRXS:ConsultingAndAdvisoryFees>
    <us-gaap:ShareBasedCompensation
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact002006"
      unitRef="USD">227000</us-gaap:ShareBasedCompensation>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact002010">&lt;p id="xdx_802_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_z9MraOrNsOl4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;16&lt;/b&gt;.
&lt;b&gt;&lt;span id="xdx_82A_ze7exhKFYWQ5"&gt;Commitments and Contingencies&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Manufacturing
Services Agreement&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company is party to a manufacturing services agreement for the manufacture and supply of the Company&#x2019;s IB-STIM device based on
the Company&#x2019;s product specifications that automatically renews annually unless either party provides a written termination notice
to the other party within 180 days prior to the end of the then-current term. The Company provides the necessary equipment to the manufacturer
and retains ownership. The manufacturer bears the risk of loss of and damage to the equipment and consigned materials. Performance under
the agreement is initiated by orders issued by the Company and accepted by the manufacturer.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Advisory
Agreement&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
March 18, 2024, the Company terminated its private placement services agreement and entered into an advisory agreement with a financial
advisor for debt, equity and public securities market services for one year. The advisory agreement included a monthly fee of $&lt;span id="xdx_90E_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_c20240318__20240318__us-gaap--TypeOfArrangementAxis__custom--AdvisoryAgreementMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zjfu9PspRz64" title="Monthly advisory fee"&gt;30,000&lt;/span&gt;
and &lt;span id="xdx_90D_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_c20240318__20240318__us-gaap--TypeOfArrangementAxis__custom--AdvisoryAgreementMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zNXrgHi5fopl" title="Monthly advisory fee"&gt;7,563&lt;/span&gt; common stock warrants to be issued monthly at an exercise price of $&lt;span id="xdx_902_eus-gaap--SaleOfStockPricePerShare_iI_pid_c20240318__us-gaap--TypeOfArrangementAxis__custom--AdvisoryAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zxKzUidIR55l" title="Monthly exercise price"&gt;2.38&lt;/span&gt; with a term of five years. On December 31, 2024, the
Company and the financial advisor terminated the advisory agreement subject to the cancelation of all common stock warrants issued after
July 2024 and the payment for services rendered in three equal installments of $&lt;span id="xdx_900_eus-gaap--IssuanceOfStockAndWarrantsForServicesOrClaims_c20250326__20250326__srt--StatementScenarioAxis__srt--ScenarioForecastMember__us-gaap--TypeOfArrangementAxis__custom--AdvisoryAgreementMember_zGZcEnjrkRab" title="Payment for services"&gt;60,000&lt;/span&gt; by March 26, 2025.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Settlement
Agreements&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company issued &lt;span id="xdx_909_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--SettlementAgreementMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_z87GpsPnaq4j" title="Number of shares new issuance"&gt;245,955&lt;/span&gt; shares of common stock to various pre-IPO 2022 Convertible Note and Series A Preferred Stock holders to settle
certain claims. The Company recorded the fair value of the settlements as $&lt;span id="xdx_902_ecustom--FinanceCharges_c20240101__20241231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember__us-gaap--TypeOfArrangementAxis__custom--SettlementAgreementMember_z3dFFcYQGAWa" title="Finance Charges"&gt;230,824&lt;/span&gt; of Finance Charges and $&lt;span id="xdx_902_eus-gaap--OtherExpenses_c20240101__20241231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember__us-gaap--TypeOfArrangementAxis__custom--SettlementAgreementMember_zSpbD2ayjoja" title="Other expense"&gt;580,250&lt;/span&gt; of Other Expense in
the Statements of Operations.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Furthermore,
the Company authorized the issuance of &lt;span id="xdx_909_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zLY0XIiDMZ6h" title="New issuance, shares"&gt;1,518&lt;/span&gt; shares of its common stock to settle remaining claims with one pre-IPO Series A Preferred
Stock shareholder classified as $&lt;span id="xdx_905_eus-gaap--OtherExpenses_c20240101__20241231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zmOQVLFTy9ee" title="Other expenses"&gt;4,220&lt;/span&gt; of Other Expense for the year ended December 31, 2024 in the Statements of Operations and accrued
expenses in the Balance Sheets as of December 31, 2024. These common shares have not yet been issued as of the reporting date as the
Company awaits execution of the settlement agreements by the counterparties.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Executive
Employment Agreements&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company, as authorized by the board of directors, entered into employment agreements with nine key employees to provide incentives to
improve shareholder value and to contribute to the growth and financial success of the Company. The agreements had an employment start
date of October 1, 2022, with initial terms from &lt;span id="xdx_904_ecustom--ExecutiveEmploymentAgreementsTerms_dtY_c20221001__20221001__srt--RangeAxis__srt--MinimumMember__us-gaap--TypeOfArrangementAxis__custom--ExecutiveEmploymentAgreementsMember_zAkLqA3S85r6" title="Executive employment agreements renewals"&gt;2&lt;/span&gt; to &lt;span id="xdx_90A_ecustom--ExecutiveEmploymentAgreementsTerms_dtY_c20221001__20221001__srt--RangeAxis__srt--MaximumMember__us-gaap--TypeOfArrangementAxis__custom--ExecutiveEmploymentAgreementsMember_z5nCL1ZDLvd2" title="Executive employment agreements renewals"&gt;5&lt;/span&gt; years and &lt;span id="xdx_900_ecustom--DescriptionOfExecutiveEmploymentAgreementsRenewals_dtY_c20221001__20221001__us-gaap--TypeOfArrangementAxis__custom--ExecutiveEmploymentAgreementsMember_znpA4eJ42zlb" title="Description of Executive employment agreements renewals"&gt;optional one-year renewals&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
total base salaries for the nine key employees in the agreements are $&lt;span id="xdx_902_eus-gaap--SalariesAndWages_c20240101__20241231__us-gaap--TypeOfArrangementAxis__custom--ExecutiveEmploymentAgreementsMember_zaUJD6RObTX" title="Base salaries for nine key employees"&gt;1,920,000&lt;/span&gt; per year with various provisions for annual increases.
In addition to base salaries, eight of the employees have a provision for a special one-time incentive payment to be paid in a lump sum
after the start date. The total amount of these special incentive payments is $&lt;span id="xdx_909_eus-gaap--IncentiveFeeExpense_c20240101__20241231__us-gaap--TypeOfArrangementAxis__custom--ExecutiveEmploymentAgreementsMember_z4oweevxVPzc" title="Incentive payments"&gt;1,100,000&lt;/span&gt;. The special incentive payment amount includes
any accrued backpay wages for the employee. The amount for backpay of $&lt;span id="xdx_90E_eus-gaap--AccruedLiabilitiesCurrent_iI_c20231231__us-gaap--TypeOfArrangementAxis__custom--ExecutiveEmploymentAgreementsMember_zwz8Yxj2KZZ1" title="Accrued amount for backpay"&gt;417,390&lt;/span&gt; was paid in the year ended December 31, 2023.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;There
are seven key employees that have stock options of the Company totaling &lt;span id="xdx_900_eus-gaap--StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan_pid_uShares_c20240101__20240630__us-gaap--TypeOfArrangementAxis__custom--ExecutiveEmploymentAgreementsMember_z30oTuhjpm95" title="Seven key employees stock options"&gt;1,238,712&lt;/span&gt; shares. These key employees have a provision in their
agreements whereas the Company will pay a special bonus equal to the aggregate of the strike price or exercise price of all their stock
options plus a tax gross-up payment. The special bonus shall be paid in twenty percent (&lt;span id="xdx_900_ecustom--SpecialBonusPercentage_iI_pid_dp_uPure_c20240102__us-gaap--TypeOfArrangementAxis__custom--ExecutiveEmploymentAgreementsMember_zEThdkppPw7j" title="Special bonus percentage"&gt;20&lt;/span&gt;%) installments starting January 2, 2024, and
the same date each of the next four years. As a condition of the payment, the key employee must exercise at least &lt;span id="xdx_901_ecustom--KeyEmployeeExercisePercentage_iI_pid_dp_uPure_c20240102__us-gaap--TypeOfArrangementAxis__custom--ExecutiveEmploymentAgreementsMember__srt--RangeAxis__srt--MinimumMember_zyz75b434FS5" title="Key employee exercise percentage"&gt;20&lt;/span&gt;% of their stated
number of stock options. There are additional provisions to cover termination and change of control events. None of the key employees
exercised any of options as of January 2, 2025.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
April 2023, the Company amended the employee agreements to, among other things, clarify that the special one-time incentive payment and
the deferred bonus are contingent upon the effective date of the planned initial public offering. The amendment also sets forth a process
for executives to exercise the stock options in accordance with the terms of the stock option agreement in effect as of the date of the
employment agreement and to clarify that there is no modification to the stock option agreements.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Neuraxis,
Inc.&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Notes
to Financial Statements&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company recorded the backpay portion of the incentive bonus notes above. The balance of the incentive bonuses of $&lt;span id="xdx_90C_eus-gaap--AccruedBonusesCurrent_iI_c20230430__us-gaap--TypeOfArrangementAxis__custom--ExecutiveEmploymentAgreementsMember_zuWouEEq34kg" title="Incentive bonus"&gt;694,056&lt;/span&gt; and the special
options bonuses of $&lt;span id="xdx_900_eus-gaap--AccruedBonusesCurrent_iI_c20230430__us-gaap--TypeOfArrangementAxis__custom--ExecutiveEmploymentAgreementsMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_z3lp8dxKDAtf" title="Incentive bonus"&gt;14,821,830&lt;/span&gt; were contingent upon a successful IPO. The incentive bonuses have been paid in full while the special
options bonuses will be recorded when paid.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
April 10, 2024, the Company terminated the employment of the Company&#x2019;s Chief Operating Officer. Pursuant to the employment agreement,
the Company made (i) make salary continuation payments for six months during the year ended December 31, 2024, (ii) issued &lt;span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20240410__20240410__srt--TitleOfIndividualAxis__srt--ChiefOperatingOfficerMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zrAsVhH5OgGi" title="Common stock shares issue"&gt;25,832&lt;/span&gt; shares
of common stock at a fair value of $&lt;span id="xdx_901_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20240410__20240410__srt--TitleOfIndividualAxis__srt--ChiefOperatingOfficerMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zRHnOyE1Lek4" title="Common stock with a fair value"&gt;78,788&lt;/span&gt; and (iii) made a $&lt;span id="xdx_903_eus-gaap--PaymentsToAcquireEquitySecuritiesFvNi_c20240410__20240410__srt--TitleOfIndividualAxis__srt--ChiefOperatingOfficerMember_zeNAE0Wt252k" title="One time payment"&gt;41,980&lt;/span&gt; one-time payment in lieu of the exercise of &lt;span id="xdx_905_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20240410__20240410__srt--TitleOfIndividualAxis__srt--ChiefOperatingOfficerMember_za3qfLRP1EBe" title="Stock option, exercise"&gt;13,764&lt;/span&gt; stock options
that expired on January 2, 2024. The Company is obligated to provide health care coverage through October 2025 and has accrued for that
obligation totaling $&lt;span id="xdx_908_eus-gaap--AccruedLiabilitiesFairValueDisclosure_iI_c20241231__srt--TitleOfIndividualAxis__srt--ChiefOperatingOfficerMember_zKSSNoKQNmqd" title="Accrued expenses"&gt;21,418&lt;/span&gt; classified as Accrued Expenses in the Balance Sheets as of December 31, 2024.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Litigation&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;From
time to time, the Company may be involved in litigation relating to claims arising out of operations in the normal course of business.
As of the date of issuance, other than those described below, there were no pending or threatened legal proceedings that could reasonably
be expected to have a material effect on the results of the Company&#x2019;s operations. There are also no proceedings in which any of
the Company&#x2019;s directors, officers or affiliates is an adverse party to the Company or has a material interest adverse to the Company&#x2019;s
interest. Legal fees are expensed as incurred.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
February 6, 2019, plaintiff Ritu Bhambhani, M.D., initiated a lawsuit against Innovative Health Solutions, Inc. and others in the United
States District Court for the District of Maryland. Plaintiffs Bhambhani and Sudhir Rao subsequently amended the complaint, with the
Third Amended Complaint (&#x201c;Complaint&#x201d;) containing the most recent set of allegations. The Complaint asserted claims under
the RICO Act, as well as of fraudulent misrepresentation, intentional misrepresentation by concealment, and civil conspiracy and sought
compensatory damages in excess of $&lt;span id="xdx_900_eus-gaap--LossContingencyDamagesSoughtValue_pn6n6_c20190206__20190206_zSpe14Of6Bn4" title="Sought compensatory damages"&gt;5&lt;/span&gt; million, pre-judgment interest, punitive damages, attorney&#x2019;s fees, court costs and designation
of the case as a class action. The Complaint stated that the Company, distributors of the Company&#x2019;s product, and medical billing
and coding consultants allegedly made misrepresentations to the plaintiffs that the Company&#x2019;s NeuroStim device and related procedures
could be billed to, and reimbursed by, Medicare and other insurance payors as a surgically implantable neurostimulator. Plaintiffs claim
to have suffered damages when Medicare administrative contractors declined to pay plaintiffs for their use of the device.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
February 11, 2022, the Company filed a motion for summary judgment based upon the plaintiffs not being proper parties to assert claims
against the Company. On June 14, 2022, the Court granted the Company&#x2019;s motion for summary judgment and dismissed the Complaint.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
July 14, 2022, plaintiffs Ritu Bhambhani and Sudhir Rao filed a notice of appeal with the Fourth Circuit Court of Appeals. On June 3,
2024, the Fourth Circuit denied the plaintiff&#x2019;s appeal and entered judgment against the plaintiffs. On June 25, 2024, the Fourth
Circuit entered its mandate declaring that its judgment against the plaintiffs took effect that day. The plaintiffs did not seek any
further review or appeal of that judgment.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Also
on July 14, 2022, plaintiffs Ritu Bhambhani, LLC; Box Hill Surgery Center, LLC; Pain and Spine Specialists of Maryland, LLC; and SimCare
ASC, LLC initiated a lawsuit against the Company and others in the United States District Court for the District of Maryland. The plaintiffs
in this lawsuit are business entities owned or partially owned by the plaintiffs that initiated the litigation described above. The Complaint
asserted claims under the RICO Act, as well as fraudulent misrepresentation, intentional misrepresentation by concealment, and civil
conspiracy and seeks compensatory damages in excess of $&lt;span id="xdx_90E_eus-gaap--LossContingencyDamagesSoughtValue_c20220714__20220714_zh22x5PD1Rth" title="Sought compensatory damages"&gt;75,000&lt;/span&gt;, pre-judgment interest, punitive damages, attorney&#x2019;s fees, and court
costs. The Complaint states that the Company, distributors of the Company&#x2019;s product, and medical billing and coding consultants
allegedly made misrepresentations to the plaintiffs that the Company&#x2019;s NeuroStim device and related procedures could be billed
to, and reimbursed by, Medicare and other insurance payors as a surgically implantable neurostimulator. Plaintiffs claim to have suffered
damages when Medicare administrative contractors declined to pay plaintiffs for their use of the device.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
September 28, 2022, the Company filed a motion to dismiss all claims. On May 25, 2023, the Court issued an Order and a Memorandum
Opinion which dismissed the plaintiffs&#x2019; claims related to the RICO Act. The remaining claims are still pending, and no trial
date has been set for the case. &lt;/span&gt;The Court has vacated its Scheduling Order at the parties&#x2019; request so that the parties
could try to resolve the disputes in both cases through an independent third-party mediator. Mediation has not yet resulted in a
resolution of the case.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Neuraxis,
Inc.&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Notes
to Financial Statements&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In January 2024, Dr. Arturo Taca served notice to the Company that asserted
an interest in its U.S. Patent No. 10,413,719 valued at $&lt;span id="xdx_904_eus-gaap--FiniteLivedPatentsGross_iI_c20240131_zhTQ8gMuj3Y2" title="Patent value"&gt;2,000,000&lt;/span&gt; based on his own work in neurostimulation.&#160; The Company denied
both the neurostimulation patent and compensation claims.&#160; The case remains unresolved.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;While it is too early to predict
the ultimate outcome of these matters, we believe the Company has meritorious defenses and intends to defend these matters vigorously.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="From2024-03-182024-03-18_custom_AdvisoryAgreementMember_us-gaap_PrivatePlacementMember"
      decimals="0"
      id="Fact002012"
      unitRef="USD">30000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="From2024-03-182024-03-18_custom_AdvisoryAgreementMember_us-gaap_PrivatePlacementMember_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact002014"
      unitRef="USD">7563</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="AsOf2024-03-18_custom_AdvisoryAgreementMember_us-gaap_CommonStockMember_us-gaap_PrivatePlacementMember"
      decimals="INF"
      id="Fact002016"
      unitRef="USDPShares">2.38</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims
      contextRef="From2025-03-262025-03-26_srt_ScenarioForecastMember_custom_AdvisoryAgreementMember"
      decimals="0"
      id="Fact002018"
      unitRef="USD">60000</us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember_custom_SettlementAgreementMember_us-gaap_SeriesAPreferredStockMember"
      decimals="INF"
      id="Fact002020"
      unitRef="Shares">245955</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <NRXS:FinanceCharges
      contextRef="From2024-01-012024-12-31_us-gaap_SeriesAPreferredStockMember_custom_SettlementAgreementMember"
      decimals="0"
      id="Fact002022"
      unitRef="USD">230824</NRXS:FinanceCharges>
    <us-gaap:OtherExpenses
      contextRef="From2024-01-012024-12-31_us-gaap_SeriesAPreferredStockMember_custom_SettlementAgreementMember"
      decimals="0"
      id="Fact002024"
      unitRef="USD">580250</us-gaap:OtherExpenses>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember_us-gaap_SeriesAPreferredStockMember"
      decimals="INF"
      id="Fact002026"
      unitRef="Shares">1518</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:OtherExpenses
      contextRef="From2024-01-012024-12-31_us-gaap_SeriesAPreferredStockMember"
      decimals="0"
      id="Fact002028"
      unitRef="USD">4220</us-gaap:OtherExpenses>
    <NRXS:ExecutiveEmploymentAgreementsTerms
      contextRef="From2022-10-012022-10-01_srt_MinimumMember_custom_ExecutiveEmploymentAgreementsMember"
      id="Fact002030">P2Y</NRXS:ExecutiveEmploymentAgreementsTerms>
    <NRXS:ExecutiveEmploymentAgreementsTerms
      contextRef="From2022-10-012022-10-01_srt_MaximumMember_custom_ExecutiveEmploymentAgreementsMember"
      id="Fact002032">P5Y</NRXS:ExecutiveEmploymentAgreementsTerms>
    <NRXS:DescriptionOfExecutiveEmploymentAgreementsRenewals
      contextRef="From2022-10-012022-10-01_custom_ExecutiveEmploymentAgreementsMember"
      id="Fact002034">optional one-year renewals</NRXS:DescriptionOfExecutiveEmploymentAgreementsRenewals>
    <us-gaap:SalariesAndWages
      contextRef="From2024-01-012024-12-31_custom_ExecutiveEmploymentAgreementsMember"
      decimals="0"
      id="Fact002036"
      unitRef="USD">1920000</us-gaap:SalariesAndWages>
    <us-gaap:IncentiveFeeExpense
      contextRef="From2024-01-012024-12-31_custom_ExecutiveEmploymentAgreementsMember"
      decimals="0"
      id="Fact002038"
      unitRef="USD">1100000</us-gaap:IncentiveFeeExpense>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="AsOf2023-12-31_custom_ExecutiveEmploymentAgreementsMember"
      decimals="0"
      id="Fact002040"
      unitRef="USD">417390</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan
      contextRef="From2024-01-012024-06-30_custom_ExecutiveEmploymentAgreementsMember"
      decimals="INF"
      id="Fact002042"
      unitRef="Shares">1238712</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan>
    <NRXS:SpecialBonusPercentage
      contextRef="AsOf2024-01-02_custom_ExecutiveEmploymentAgreementsMember"
      decimals="INF"
      id="Fact002044"
      unitRef="Pure">0.20</NRXS:SpecialBonusPercentage>
    <NRXS:KeyEmployeeExercisePercentage
      contextRef="AsOf2024-01-02_custom_ExecutiveEmploymentAgreementsMember_srt_MinimumMember"
      decimals="INF"
      id="Fact002046"
      unitRef="Pure">0.20</NRXS:KeyEmployeeExercisePercentage>
    <us-gaap:AccruedBonusesCurrent
      contextRef="AsOf2023-04-30_custom_ExecutiveEmploymentAgreementsMember"
      decimals="0"
      id="Fact002048"
      unitRef="USD">694056</us-gaap:AccruedBonusesCurrent>
    <us-gaap:AccruedBonusesCurrent
      contextRef="AsOf2023-04-30_custom_ExecutiveEmploymentAgreementsMember_us-gaap_IPOMember"
      decimals="0"
      id="Fact002050"
      unitRef="USD">14821830</us-gaap:AccruedBonusesCurrent>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2024-04-102024-04-10_srt_ChiefOperatingOfficerMember_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact002052"
      unitRef="Shares">25832</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2024-04-102024-04-10_srt_ChiefOperatingOfficerMember_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact002054"
      unitRef="USD">78788</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:PaymentsToAcquireEquitySecuritiesFvNi
      contextRef="From2024-04-102024-04-10_srt_ChiefOperatingOfficerMember"
      decimals="0"
      id="Fact002056"
      unitRef="USD">41980</us-gaap:PaymentsToAcquireEquitySecuritiesFvNi>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="From2024-04-102024-04-10_srt_ChiefOperatingOfficerMember"
      decimals="INF"
      id="Fact002058"
      unitRef="Shares">13764</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:AccruedLiabilitiesFairValueDisclosure
      contextRef="AsOf2024-12-31_srt_ChiefOperatingOfficerMember"
      decimals="0"
      id="Fact002060"
      unitRef="USD">21418</us-gaap:AccruedLiabilitiesFairValueDisclosure>
    <us-gaap:LossContingencyDamagesSoughtValue
      contextRef="From2019-02-062019-02-06"
      decimals="-6"
      id="Fact002062"
      unitRef="USD">5000000</us-gaap:LossContingencyDamagesSoughtValue>
    <us-gaap:LossContingencyDamagesSoughtValue
      contextRef="From2022-07-142022-07-14"
      decimals="0"
      id="Fact002064"
      unitRef="USD">75000</us-gaap:LossContingencyDamagesSoughtValue>
    <us-gaap:FiniteLivedPatentsGross
      contextRef="AsOf2024-01-31"
      decimals="0"
      id="Fact002066"
      unitRef="USD">2000000</us-gaap:FiniteLivedPatentsGross>
    <NRXS:HealthBenefitPlanDisclosureTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact002068">&lt;p id="xdx_801_ecustom--HealthBenefitPlanDisclosureTextBlock_zOGtIJTwkHU8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;17.
&lt;span id="xdx_827_zpEbH2V3LJbi"&gt;Health Benefit Plan&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company participates in a self-funded employer program in conjunction with a group health plan for the benefit of eligible employees.
This plan is a level funded plan, and the services and products include:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A
    self-funded employer health benefit plan.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Stop
    loss insurance purchased from a stop loss insurance company.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Third
    party administrator to provide administrative services with regard to the plan.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company maintains a stop loss contract that reimburses the Company for claims paid under the plan if they exceed a predetermined level.
The Company makes contributions for health care costs and associated expenses that are expected during the plan year. The amount of contributions
is determined annually based on the Company&#x2019;s maximum liability for expected claims, administrative expenses, and premiums for
the stop loss policy. The Company paid premiums of $&lt;span id="xdx_90B_eus-gaap--HealthCareOrganizationStopLossInsurancePremiumExpense_c20240101__20241231_zl9uSPmhw03l" title="Stop loss insurance premium expense"&gt;257,642&lt;/span&gt; and $&lt;span id="xdx_90E_eus-gaap--HealthCareOrganizationStopLossInsurancePremiumExpense_c20230101__20231231_zenk5ce2Vlr2" title="Stop loss insurance premium expense"&gt;255,715&lt;/span&gt; for the years ended December 31, 2024 and 2023, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company is responsible for the monthly premiums, as established, and nothing further. The stop loss policy covers the claims if they
exceed the claims funds. After a certain time, and if there is a surplus in the claims fund, the Company may be entitled to receive a
&lt;span id="xdx_90E_ecustom--HealthCareOrganizationStopLossInsurancePremiumPercentage_pid_dp_uPure_c20240101__20241231_zs7tu9UUY2Cg" title="Stop loss insurance premium percentage"&gt;48.5&lt;/span&gt;% refund from the fund. This amount is recognized by the Company when received.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</NRXS:HealthBenefitPlanDisclosureTextBlock>
    <us-gaap:HealthCareOrganizationStopLossInsurancePremiumExpense
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact002070"
      unitRef="USD">257642</us-gaap:HealthCareOrganizationStopLossInsurancePremiumExpense>
    <us-gaap:HealthCareOrganizationStopLossInsurancePremiumExpense
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact002072"
      unitRef="USD">255715</us-gaap:HealthCareOrganizationStopLossInsurancePremiumExpense>
    <NRXS:HealthCareOrganizationStopLossInsurancePremiumPercentage
      contextRef="From2024-01-01to2024-12-31"
      decimals="INF"
      id="Fact002074"
      unitRef="Pure">0.485</NRXS:HealthCareOrganizationStopLossInsurancePremiumPercentage>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact002076">&lt;p id="xdx_802_eus-gaap--IncomeTaxDisclosureTextBlock_zqVtiVAgaN9h" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;18.
&lt;span id="xdx_823_zmuUDI73bEIh"&gt;Income Taxes&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_890_eus-gaap--ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_zDb3lcW75Ijk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
income tax provision consists of:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B5_zNP32LdYNA2g"&gt;Schedule
of Income Tax Provision&lt;/span&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="display: none"&gt;&#160;&lt;/td&gt;&lt;td style="display: none; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49F_20240101__20241231_zGKRhM3a4gI" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="display: none; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="display: none; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49A_20230101__20231231_zoONEQJVCXxg" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="display: none; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;For the Years Ended December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--CurrentIncomeTaxExpenseBenefit_maDITEBzp9r_zgzdKTwjUnl5" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0pt; text-align: left"&gt;Total current provision&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2080"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2081"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 0pt"&gt;Deferred:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--DeferredFederalIncomeTaxExpenseBenefit_maDITEBzp9r_z4B2XbNXY3Se" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; width: 60%"&gt;Federal&lt;/td&gt;&lt;td style="width: 2%; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; font-weight: bold; text-align: right"&gt;(1,721,242&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;(3,067,056&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--DeferredStateAndLocalIncomeTaxExpenseBenefit_maDITEBzp9r_zfUDQpdKPKFd" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; padding-bottom: 1pt"&gt;State&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"&gt;124,823&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(154,060&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--DeferredIncomeTaxExpenseBenefit_iT_mtDITEBzp9r_maITEBzTsP_z0FkcE7aj5Sb" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0pt; text-align: left"&gt;Total deferred benefit&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;(1,596,419&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(3,221,116&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_maITEBzTsP_zfcx9bJKyV79" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Valuation allowance&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"&gt;1,596,419&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;3,221,116&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--IncomeTaxExpenseBenefit_iT_mtITEBzTsP_zIsWExreKkA6" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Total income tax provision&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2095"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2096"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A0_zDSa6BtIEhIa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_892_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_z1gVIsJ6URf6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A
reconciliation of the U.S. federal statutory income tax rate to the effective income tax rate is as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B0_zTBhoPXev1aj" style="display: none"&gt;Schedule of Federal Statutory Income Tax Rate and Effective Income Tax Rate&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="display: none"&gt;&#160;&lt;/td&gt;&lt;td style="display: none; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_490_20240101__20241231_zdvSC8iN66j" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="display: none; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="display: none; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49C_20230101__20231231_z0XKOJgDOSWc" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="display: none; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;For the Years Ended December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_uPure_maEIT001_z1qbu3Hil3a6" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; width: 60%; text-align: left"&gt;Federal statutory income tax rate&lt;/td&gt;&lt;td style="width: 2%; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; font-weight: bold; text-align: right"&gt;21.0&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;%&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;21.0&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_pid_dp_uPure_maEIT001_zIZ8oRAWthS2" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;State tax rate, net of federal benefit&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;5.3&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4.9&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_pid_dp_uPure_maEIT001_zZTKo9bs0Sp9" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0pt; text-align: left; padding-bottom: 1pt"&gt;Change in valuation allowance&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"&gt;(26.3&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(25.9&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_iT_pid_dp_uPure_mtEIT001_zLvS1c6f5o88" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Effective income tax rate&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2109"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold; text-align: left"&gt;%&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2110"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AF_znd1p4cCyBn1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company did not recognize an income tax provision for the years ended December 31, 2024 and 2023 due to net operating losses reported
in both years.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_898_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zVope19dWKwe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Deferred
income taxes are provided for temporary differences between the financial and tax bases of the Company&#x2019;s assets and liabilities.
The temporary differences that give rise to net deferred tax assets and liabilities were as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B9_zndQqMtgcaHi"&gt;Schedule
of Net Deferred Tax Assets and Liabilities&lt;/span&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="display: none"&gt;&#160;&lt;/td&gt;&lt;td style="display: none; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49F_20241231_zhXUsZI3niV4" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="display: none; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="display: none; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_490_20231231_z7C0J1onSSN7" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="display: none; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Deferred tax assets:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_maDTAGzJbV_zNoECr7RCSAh" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; width: 60%; text-align: left"&gt;Net operating losses&lt;/td&gt;&lt;td style="width: 2%; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; font-weight: bold; text-align: right"&gt;8,019,218&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;6,573,406&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_iI_maDTAGzJbV_za6weCmEW96f" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Stock based compensation&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;1,447,339&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,366,391&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_ecustom--DeferredTaxAssetsNotesReceivableReserve_iI_maDTAGzJbV_zP9Xtj47KL35" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Notes receivable reserve&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;266,816&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;251,893&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsOther_iI_maDTAGzJbV_zsPbpUzTJcX4" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Accrued compensation&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;296,297&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;57,763&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_ecustom--DeferredTaxAssetsAccountsPayable_iI_maDTAGzJbV_zZVAIHIlDJl8" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Accounts payable&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;143,484&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;257,391&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_ecustom--DeferredTaxAssetsOperatingLeasePayable_iI_maDTAGzJbV_zIk3RIZ85ade" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Operating lease payable&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;84,105&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;18,951&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--DeferredTaxAssetsOther_iI_maDTAGzJbV_zwDLA3KP1g6i" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; padding-bottom: 1pt"&gt;Other&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"&gt;206,468&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;175,904&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--DeferredTaxAssetsGross_iTI_mtDTAGzJbV_maDTANz8qu_zSMHce1zy2w4" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0pt; text-align: left"&gt;Total gross deferred tax assets&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;10,463,727&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;8,701,699&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_di_msDTANz8qu_zAcJuJYdrqti" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 0pt; text-align: left; padding-bottom: 1pt"&gt;Valuation allowance&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"&gt;(10,225,739&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(8,629,320&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--DeferredTaxAssetsNet_iTI_mtDTANz8qu_msDTLzJxU_zZCRtEmahuWk" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0pt; text-align: left; padding-bottom: 1pt"&gt;Total deferred tax assets&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"&gt;237,988&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;72,379&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0pt; text-align: left"&gt;Deferred tax liabilities:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_ecustom--DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset_iI_maDITLzRLP_zZrYdGsyoYyj" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Operating lease right of use asset&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;74,991&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;17,475&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--DeferredTaxLiabilitiesPrepaidExpenses_iI_maDITLzRLP_zpaquPF7s5Bg" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Prepaid expenses&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;72,560&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7,337&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_ecustom--DeferredTaxLiabilityAccountsReceivable_iI_maDITLzRLP_zjaKtI9Ap3i3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Accounts receivable&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;64,443&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;18,197&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--DeferredTaxLiabilitiesOther_iI_maDITLzRLP_zlQ4mlye7Uv1" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; padding-bottom: 1pt"&gt;Other&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"&gt;25,994&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;29,370&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--DeferredIncomeTaxLiabilities_iTI_mtDITLzRLP_maDTLzJxU_zHtpCPEkSRbj" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Total deferred tax liabilities&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"&gt;237,988&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;72,379&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--DeferredTaxLiabilities_iTI_mtDTLzJxU_zlE7IC9Wb103" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Deferred tax assets, net&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2159"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2160"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AA_zScLxdMbkknb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Neuraxis,
Inc.&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Notes
to Financial Statements&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Management
assessed the realizability of its deferred tax assets and determined that it is more likely than not that the Company will not recognize
the benefits of the net deferred tax assets due to a history of operating losses. As a result, the Company maintained a full valuation
allowance and does not reflect any deferred taxes in its Balance Sheets as of December 31, 2024 and 2023.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
December 31, 2024, the Company&#x2019;s federal and state net operating loss (NOL) carryforwards totaled $&lt;span id="xdx_901_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_iI_c20241231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--DomesticCountryMember_zAJh4uZZVVpk"&gt;36,202,858
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;and $34&lt;/span&gt;,748,524 respectively. These NOL carryforwards
may be offset against future taxable income. There is no limitation on the number of years to utilize the federal NOLs. The federal deduction
will be limited to 80% of modified taxable income. The state NOLs are allowed up to &lt;span id="xdx_90E_eus-gaap--EffectiveIncomeTaxRateReconciliationOtherAdjustments_pid_dp_c20240101__20241231_zRpt4R9WCYJd"&gt;100&lt;/span&gt;%
of taxable income and generally can be carried forward no longer than 20 years after the year of the taxable loss.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Federal
and state tax laws impose limitations on the utilization of NOLs and credit carryforwards in the event of an ownership change for tax
purposes, as defined in Section 382 of the Internal Revenue Code. Accordingly, the Company&#x2019;s ability to utilize these carryforwards
may be limited as a result of an ownership change. Such an ownership change could result in a limitation in the use of the NOLs in future
years and possibly a reduction of the net operating losses available.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89B_eus-gaap--SummaryOfOperatingLossCarryforwardsTextBlock_z8KsPtHCLbOb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;If
not used, the state NOL carryforwards will expire as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8BF_zsQ5DJSkDt42" style="display: none"&gt;Schedule of State Carryforwards&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 60%; margin-right: auto"&gt;
  &lt;tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="display: none; text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="display: none"&gt;&#160;&lt;/td&gt;
    &lt;td style="display: none; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_49B_20241231_zIjmiiM9ZDLj" style="display: none; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="display: none; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40F_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_iI_hus-gaap--TaxPeriodAxis__custom--TaxYear2037Member_zjxftYeYpkz4" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 78%; text-align: justify"&gt;2037&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 18%; text-align: right"&gt;72,216&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_iI_hus-gaap--TaxPeriodAxis__custom--TaxYear2038Member_zrilnWyMrWh3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;2038&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,039,986&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_iI_hus-gaap--TaxPeriodAxis__custom--TaxYear2039Member_zYpBSeKjSPo4" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;2039&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,033,565&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_iI_hus-gaap--TaxPeriodAxis__custom--TaxYear2040Member_zzAYhiafCmD1" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;2040&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4,457,495&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_iI_hus-gaap--TaxPeriodAxis__custom--TaxYear2041Member_zG5919ryuNS6" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;2041&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,406,225&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_iI_hus-gaap--TaxPeriodAxis__custom--TaxYearThereafterMember_zwC79DGKyVgc" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Thereafter&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;24,671,088&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_iI_hus-gaap--TaxPeriodAxis__custom--NoExpirationMember_zia4lqC4qMhe" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1pt; text-align: justify"&gt;No expiration&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;67,949&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_iI_z9mLazXw2Q1a" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: justify"&gt;Total state NOL carryforwards&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;34,748,524&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AD_zSMz5TaeJgIh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company believes it has made adequate provision for all income tax uncertainties. The assessment is subject to change based on the completion
of audits or statute of limitation expirations.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
federal and state income tax returns have a three-year statute of limitations once filed with the appropriate jurisdiction. The Company&#x2019;s
income tax returns are subject to examination by the federal and state taxing authorities in the United States for the years ended 2021
through 2024 and 2021 through 2024, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact002078">&lt;p id="xdx_890_eus-gaap--ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_zDb3lcW75Ijk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
income tax provision consists of:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B5_zNP32LdYNA2g"&gt;Schedule
of Income Tax Provision&lt;/span&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="display: none"&gt;&#160;&lt;/td&gt;&lt;td style="display: none; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49F_20240101__20241231_zGKRhM3a4gI" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="display: none; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="display: none; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49A_20230101__20231231_zoONEQJVCXxg" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="display: none; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;For the Years Ended December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--CurrentIncomeTaxExpenseBenefit_maDITEBzp9r_zgzdKTwjUnl5" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0pt; text-align: left"&gt;Total current provision&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2080"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2081"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 0pt"&gt;Deferred:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--DeferredFederalIncomeTaxExpenseBenefit_maDITEBzp9r_z4B2XbNXY3Se" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; width: 60%"&gt;Federal&lt;/td&gt;&lt;td style="width: 2%; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; font-weight: bold; text-align: right"&gt;(1,721,242&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;(3,067,056&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--DeferredStateAndLocalIncomeTaxExpenseBenefit_maDITEBzp9r_zfUDQpdKPKFd" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; padding-bottom: 1pt"&gt;State&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"&gt;124,823&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(154,060&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--DeferredIncomeTaxExpenseBenefit_iT_mtDITEBzp9r_maITEBzTsP_z0FkcE7aj5Sb" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0pt; text-align: left"&gt;Total deferred benefit&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;(1,596,419&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(3,221,116&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_maITEBzTsP_zfcx9bJKyV79" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Valuation allowance&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"&gt;1,596,419&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;3,221,116&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--IncomeTaxExpenseBenefit_iT_mtITEBzTsP_zIsWExreKkA6" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Total income tax provision&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2095"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2096"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact002083"
      unitRef="USD">-1721242</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact002084"
      unitRef="USD">-3067056</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact002086"
      unitRef="USD">124823</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact002087"
      unitRef="USD">-154060</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact002089"
      unitRef="USD">-1596419</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact002090"
      unitRef="USD">-3221116</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact002092"
      unitRef="USD">1596419</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact002093"
      unitRef="USD">3221116</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact002098">&lt;p id="xdx_892_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_z1gVIsJ6URf6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A
reconciliation of the U.S. federal statutory income tax rate to the effective income tax rate is as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B0_zTBhoPXev1aj" style="display: none"&gt;Schedule of Federal Statutory Income Tax Rate and Effective Income Tax Rate&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="display: none"&gt;&#160;&lt;/td&gt;&lt;td style="display: none; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_490_20240101__20241231_zdvSC8iN66j" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="display: none; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="display: none; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49C_20230101__20231231_z0XKOJgDOSWc" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="display: none; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;For the Years Ended December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_uPure_maEIT001_z1qbu3Hil3a6" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; width: 60%; text-align: left"&gt;Federal statutory income tax rate&lt;/td&gt;&lt;td style="width: 2%; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; font-weight: bold; text-align: right"&gt;21.0&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;%&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;21.0&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_pid_dp_uPure_maEIT001_zIZ8oRAWthS2" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;State tax rate, net of federal benefit&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;5.3&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4.9&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_pid_dp_uPure_maEIT001_zZTKo9bs0Sp9" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0pt; text-align: left; padding-bottom: 1pt"&gt;Change in valuation allowance&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"&gt;(26.3&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(25.9&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_iT_pid_dp_uPure_mtEIT001_zLvS1c6f5o88" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Effective income tax rate&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2109"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold; text-align: left"&gt;%&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2110"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="From2024-01-01to2024-12-31"
      decimals="INF"
      id="Fact002100"
      unitRef="Pure">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="From2023-01-012023-12-31"
      decimals="INF"
      id="Fact002101"
      unitRef="Pure">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="From2024-01-01to2024-12-31"
      decimals="INF"
      id="Fact002103"
      unitRef="Pure">0.053</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="From2023-01-012023-12-31"
      decimals="INF"
      id="Fact002104"
      unitRef="Pure">0.049</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="From2024-01-01to2024-12-31"
      decimals="INF"
      id="Fact002106"
      unitRef="Pure">-0.263</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="From2023-01-012023-12-31"
      decimals="INF"
      id="Fact002107"
      unitRef="Pure">-0.259</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact002112">&lt;p id="xdx_898_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zVope19dWKwe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Deferred
income taxes are provided for temporary differences between the financial and tax bases of the Company&#x2019;s assets and liabilities.
The temporary differences that give rise to net deferred tax assets and liabilities were as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B9_zndQqMtgcaHi"&gt;Schedule
of Net Deferred Tax Assets and Liabilities&lt;/span&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="display: none"&gt;&#160;&lt;/td&gt;&lt;td style="display: none; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49F_20241231_zhXUsZI3niV4" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="display: none; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="display: none; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_490_20231231_z7C0J1onSSN7" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="display: none; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Deferred tax assets:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_maDTAGzJbV_zNoECr7RCSAh" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; width: 60%; text-align: left"&gt;Net operating losses&lt;/td&gt;&lt;td style="width: 2%; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; font-weight: bold; text-align: right"&gt;8,019,218&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;6,573,406&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_iI_maDTAGzJbV_za6weCmEW96f" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Stock based compensation&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;1,447,339&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,366,391&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_ecustom--DeferredTaxAssetsNotesReceivableReserve_iI_maDTAGzJbV_zP9Xtj47KL35" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Notes receivable reserve&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;266,816&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;251,893&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsOther_iI_maDTAGzJbV_zsPbpUzTJcX4" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Accrued compensation&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;296,297&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;57,763&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_ecustom--DeferredTaxAssetsAccountsPayable_iI_maDTAGzJbV_zZVAIHIlDJl8" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Accounts payable&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;143,484&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;257,391&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_ecustom--DeferredTaxAssetsOperatingLeasePayable_iI_maDTAGzJbV_zIk3RIZ85ade" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Operating lease payable&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;84,105&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;18,951&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--DeferredTaxAssetsOther_iI_maDTAGzJbV_zwDLA3KP1g6i" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; padding-bottom: 1pt"&gt;Other&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"&gt;206,468&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;175,904&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--DeferredTaxAssetsGross_iTI_mtDTAGzJbV_maDTANz8qu_zSMHce1zy2w4" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0pt; text-align: left"&gt;Total gross deferred tax assets&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;10,463,727&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;8,701,699&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_di_msDTANz8qu_zAcJuJYdrqti" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 0pt; text-align: left; padding-bottom: 1pt"&gt;Valuation allowance&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"&gt;(10,225,739&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(8,629,320&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--DeferredTaxAssetsNet_iTI_mtDTANz8qu_msDTLzJxU_zZCRtEmahuWk" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0pt; text-align: left; padding-bottom: 1pt"&gt;Total deferred tax assets&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"&gt;237,988&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;72,379&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0pt; text-align: left"&gt;Deferred tax liabilities:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_ecustom--DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset_iI_maDITLzRLP_zZrYdGsyoYyj" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Operating lease right of use asset&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;74,991&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;17,475&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--DeferredTaxLiabilitiesPrepaidExpenses_iI_maDITLzRLP_zpaquPF7s5Bg" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Prepaid expenses&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;72,560&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7,337&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_ecustom--DeferredTaxLiabilityAccountsReceivable_iI_maDITLzRLP_zjaKtI9Ap3i3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Accounts receivable&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;64,443&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;18,197&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--DeferredTaxLiabilitiesOther_iI_maDITLzRLP_zlQ4mlye7Uv1" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; padding-bottom: 1pt"&gt;Other&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"&gt;25,994&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;29,370&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--DeferredIncomeTaxLiabilities_iTI_mtDITLzRLP_maDTLzJxU_zHtpCPEkSRbj" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Total deferred tax liabilities&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"&gt;237,988&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;72,379&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--DeferredTaxLiabilities_iTI_mtDTLzJxU_zlE7IC9Wb103" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Deferred tax assets, net&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2159"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2160"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact002114"
      unitRef="USD">8019218</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact002115"
      unitRef="USD">6573406</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact002117"
      unitRef="USD">1447339</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact002118"
      unitRef="USD">1366391</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits>
    <NRXS:DeferredTaxAssetsNotesReceivableReserve
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact002120"
      unitRef="USD">266816</NRXS:DeferredTaxAssetsNotesReceivableReserve>
    <NRXS:DeferredTaxAssetsNotesReceivableReserve
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact002121"
      unitRef="USD">251893</NRXS:DeferredTaxAssetsNotesReceivableReserve>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsOther
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact002123"
      unitRef="USD">296297</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsOther>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsOther
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact002124"
      unitRef="USD">57763</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsOther>
    <NRXS:DeferredTaxAssetsAccountsPayable
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact002126"
      unitRef="USD">143484</NRXS:DeferredTaxAssetsAccountsPayable>
    <NRXS:DeferredTaxAssetsAccountsPayable
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact002127"
      unitRef="USD">257391</NRXS:DeferredTaxAssetsAccountsPayable>
    <NRXS:DeferredTaxAssetsOperatingLeasePayable
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact002129"
      unitRef="USD">84105</NRXS:DeferredTaxAssetsOperatingLeasePayable>
    <NRXS:DeferredTaxAssetsOperatingLeasePayable
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact002130"
      unitRef="USD">18951</NRXS:DeferredTaxAssetsOperatingLeasePayable>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact002132"
      unitRef="USD">206468</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact002133"
      unitRef="USD">175904</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact002135"
      unitRef="USD">10463727</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact002136"
      unitRef="USD">8701699</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact002138"
      unitRef="USD">10225739</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact002139"
      unitRef="USD">8629320</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact002141"
      unitRef="USD">237988</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact002142"
      unitRef="USD">72379</us-gaap:DeferredTaxAssetsNet>
    <NRXS:DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact002144"
      unitRef="USD">74991</NRXS:DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset>
    <NRXS:DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact002145"
      unitRef="USD">17475</NRXS:DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset>
    <us-gaap:DeferredTaxLiabilitiesPrepaidExpenses
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact002147"
      unitRef="USD">72560</us-gaap:DeferredTaxLiabilitiesPrepaidExpenses>
    <us-gaap:DeferredTaxLiabilitiesPrepaidExpenses
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact002148"
      unitRef="USD">7337</us-gaap:DeferredTaxLiabilitiesPrepaidExpenses>
    <NRXS:DeferredTaxLiabilityAccountsReceivable
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact002150"
      unitRef="USD">64443</NRXS:DeferredTaxLiabilityAccountsReceivable>
    <NRXS:DeferredTaxLiabilityAccountsReceivable
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact002151"
      unitRef="USD">18197</NRXS:DeferredTaxLiabilityAccountsReceivable>
    <us-gaap:DeferredTaxLiabilitiesOther
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact002153"
      unitRef="USD">25994</us-gaap:DeferredTaxLiabilitiesOther>
    <us-gaap:DeferredTaxLiabilitiesOther
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact002154"
      unitRef="USD">29370</us-gaap:DeferredTaxLiabilitiesOther>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact002156"
      unitRef="USD">237988</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact002157"
      unitRef="USD">72379</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal
      contextRef="AsOf2024-12-31_us-gaap_DomesticCountryMember"
      decimals="0"
      id="Fact002161"
      unitRef="USD">36202858</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="From2024-01-01to2024-12-31"
      decimals="INF"
      id="Fact002162"
      unitRef="Pure">1</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:SummaryOfOperatingLossCarryforwardsTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact002164">&lt;p id="xdx_89B_eus-gaap--SummaryOfOperatingLossCarryforwardsTextBlock_z8KsPtHCLbOb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;If
not used, the state NOL carryforwards will expire as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8BF_zsQ5DJSkDt42" style="display: none"&gt;Schedule of State Carryforwards&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 60%; margin-right: auto"&gt;
  &lt;tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="display: none; text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="display: none"&gt;&#160;&lt;/td&gt;
    &lt;td style="display: none; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_49B_20241231_zIjmiiM9ZDLj" style="display: none; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="display: none; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40F_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_iI_hus-gaap--TaxPeriodAxis__custom--TaxYear2037Member_zjxftYeYpkz4" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 78%; text-align: justify"&gt;2037&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 18%; text-align: right"&gt;72,216&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_iI_hus-gaap--TaxPeriodAxis__custom--TaxYear2038Member_zrilnWyMrWh3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;2038&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,039,986&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_iI_hus-gaap--TaxPeriodAxis__custom--TaxYear2039Member_zYpBSeKjSPo4" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;2039&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,033,565&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_iI_hus-gaap--TaxPeriodAxis__custom--TaxYear2040Member_zzAYhiafCmD1" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;2040&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4,457,495&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_iI_hus-gaap--TaxPeriodAxis__custom--TaxYear2041Member_zG5919ryuNS6" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;2041&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,406,225&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_iI_hus-gaap--TaxPeriodAxis__custom--TaxYearThereafterMember_zwC79DGKyVgc" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Thereafter&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;24,671,088&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_iI_hus-gaap--TaxPeriodAxis__custom--NoExpirationMember_zia4lqC4qMhe" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1pt; text-align: justify"&gt;No expiration&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;67,949&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_iI_z9mLazXw2Q1a" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: justify"&gt;Total state NOL carryforwards&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;34,748,524&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:SummaryOfOperatingLossCarryforwardsTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal
      contextRef="AsOf2024-12-31_custom_TaxYear2037Member"
      decimals="0"
      id="Fact002166"
      unitRef="USD">72216</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal
      contextRef="AsOf2024-12-31_custom_TaxYear2038Member"
      decimals="0"
      id="Fact002168"
      unitRef="USD">1039986</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal
      contextRef="AsOf2024-12-31_custom_TaxYear2039Member"
      decimals="0"
      id="Fact002170"
      unitRef="USD">2033565</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal
      contextRef="AsOf2024-12-31_custom_TaxYear2040Member"
      decimals="0"
      id="Fact002172"
      unitRef="USD">4457495</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal
      contextRef="AsOf2024-12-31_custom_TaxYear2041Member"
      decimals="0"
      id="Fact002174"
      unitRef="USD">2406225</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal
      contextRef="AsOf2024-12-31_custom_TaxYearThereafterMember"
      decimals="0"
      id="Fact002176"
      unitRef="USD">24671088</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal
      contextRef="AsOf2024-12-31_custom_NoExpirationMember"
      decimals="0"
      id="Fact002178"
      unitRef="USD">67949</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact002180"
      unitRef="USD">34748524</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal>
    <us-gaap:SubsequentEventsTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact002182">&lt;p id="xdx_806_eus-gaap--SubsequentEventsTextBlock_zYQ16dqfOpui" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;19.
&lt;span id="xdx_824_zlexf9AyuLj3"&gt;Subsequent Events&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;On January 3, 2025 and March 6, 2025,
the Company granted &lt;span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_c20250103__20250103__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_znHlIcZjDMU3" title="Restricted stock, granted"&gt;360,902
&lt;/span&gt;and &lt;span id="xdx_909_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_c20250306__20250306__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zrRZ7byrH4Xh" title="Restricted stock, granted"&gt;373,275&lt;/span&gt; restricted stock units (&#x201c;RSUs&#x201d;), respectively, pursuant to the Neuraxis, Inc. 2022 Omnibus Securities and Incentive
Plan as amended on August 15, 2024. The RSUs cliff-vest at the end of a three year period and are payable in shares of the Company&#x2019;s
common stock. The RSUs fully vest upon (i) death or disability or (ii) change of control. Dividend equivalents accrue on RSUs and are
paid upon vesting; there were no accrued dividends on unvested RSUs as of the report date.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
January 17, 2025, the Company issued &lt;span id="xdx_906_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20250117__20250117__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zQ5n3hCkO3Oe" title="Issued common shares"&gt;39,471 &lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;common
shares to its independent board members for their service from April 1, 2024 through December 31, 2024 and an investor converted
&lt;span id="xdx_904_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_c20250117__20250117__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zkPLlHLmw2dk" title="Investor converted warrant"&gt;502,647&lt;/span&gt; warrants into &lt;span id="xdx_909_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_c20250117__20250117__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zHoyPGV7ySJa" title="Investor converted warrants into common shares"&gt;186,166&lt;/span&gt; common shares in a cashless exercise transaction.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company has evaluated subsequent events through the filing of this Annual Report on Form 10-K and determined that there have been no
other events that have occurred that would require adjustments to our disclosures in the financial statements.&lt;/span&gt;&lt;/p&gt;

</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="From2025-01-032025-01-03_us-gaap_SubsequentEventMember"
      decimals="INF"
      id="Fact002184"
      unitRef="Shares">360902</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="From2025-03-062025-03-06_us-gaap_SubsequentEventMember"
      decimals="INF"
      id="Fact002186"
      unitRef="Shares">373275</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2025-01-172025-01-17_us-gaap_SubsequentEventMember"
      decimals="INF"
      id="Fact002188"
      unitRef="Shares">39471</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="From2025-01-172025-01-17_us-gaap_SubsequentEventMember_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact002190"
      unitRef="Shares">502647</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="From2025-01-172025-01-17_us-gaap_SubsequentEventMember_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact002192"
      unitRef="Shares">186166</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <link:footnoteLink
      xlink:role="http://www.xbrl.org/2003/role/link"
      xlink:type="extended">
        <link:loc
          xlink:href="#Fact001937"
          xlink:label="Fact001937"
          xlink:type="locator"/>
        <link:footnote id="Footnote001987" xlink:label="Footnote001987" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">The
                                            significant expense categories and amounts align with the segment-level information provided
                                            on a regular basis to the CODM.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001937"
          xlink:to="Footnote001987"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001938"
          xlink:label="Fact001938"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001938"
          xlink:to="Footnote001987"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001940"
          xlink:label="Fact001940"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001940"
          xlink:to="Footnote001987"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001941"
          xlink:label="Fact001941"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001941"
          xlink:to="Footnote001987"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001943"
          xlink:label="Fact001943"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001943"
          xlink:to="Footnote001987"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001944"
          xlink:label="Fact001944"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001944"
          xlink:to="Footnote001987"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001946"
          xlink:label="Fact001946"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001946"
          xlink:to="Footnote001987"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001947"
          xlink:label="Fact001947"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001947"
          xlink:to="Footnote001987"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001949"
          xlink:label="Fact001949"
          xlink:type="locator"/>
        <link:footnote id="Footnote001988" xlink:label="Footnote001988" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Other
                                            operating expenses include advertising, rent and utilities, insurance, depreciation and
                                            amortization, travel, software subscription fees, board fees and bad debt expense.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001949"
          xlink:to="Footnote001988"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001950"
          xlink:label="Fact001950"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001950"
          xlink:to="Footnote001988"
          xlink:type="arc"/>
    </link:footnoteLink>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
